<SEC-DOCUMENT>0001055726-21-000018.txt : 20210301
<SEC-HEADER>0001055726-21-000018.hdr.sgml : 20210301
<ACCEPTANCE-DATETIME>20210301155342
ACCESSION NUMBER:		0001055726-21-000018
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		114
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210301
DATE AS OF CHANGE:		20210301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		21697536

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ino-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:457132bc-9fa0-4eb7-b7bc-387259668e99,g:003ddec6-0acb-4351-b822-2fdc6632a099,d:06d07667d4974765a8282374d1211e66--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ino="http://www.inovio.com/20201231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ino-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl80L2ZyYWc6ODcyMTRlNGMwOGQ3NGZmN2FkYjZiZTUzNjZiMDliYjMvdGFibGU6NzkzODFmNGEwZmM1NGUzYzgxNWViMzRhOTVmOTc4ZDQvdGFibGVyYW5nZTo3OTM4MWY0YTBmYzU0ZTNjODE1ZWIzNGE5NWY5NzhkNF80LTEtMS0xLTA_cdfd8476-7ee5-42a9-aca8-8db042aaff82">false</ix:nonNumeric><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl80L2ZyYWc6ODcyMTRlNGMwOGQ3NGZmN2FkYjZiZTUzNjZiMDliYjMvdGFibGU6NzkzODFmNGEwZmM1NGUzYzgxNWViMzRhOTVmOTc4ZDQvdGFibGVyYW5nZTo3OTM4MWY0YTBmYzU0ZTNjODE1ZWIzNGE5NWY5NzhkNF82LTEtMS0xLTA_2a522920-3ead-4d3b-846b-2ce3562d8e4a">2020</ix:nonNumeric><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl80L2ZyYWc6ODcyMTRlNGMwOGQ3NGZmN2FkYjZiZTUzNjZiMDliYjMvdGFibGU6NzkzODFmNGEwZmM1NGUzYzgxNWViMzRhOTVmOTc4ZDQvdGFibGVyYW5nZTo3OTM4MWY0YTBmYzU0ZTNjODE1ZWIzNGE5NWY5NzhkNF83LTEtMS0xLTA_17dda1f8-c179-475f-99a2-64dcf4c9b5b5">FY</ix:nonNumeric><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl80L2ZyYWc6ODcyMTRlNGMwOGQ3NGZmN2FkYjZiZTUzNjZiMDliYjMvdGFibGU6NzkzODFmNGEwZmM1NGUzYzgxNWViMzRhOTVmOTc4ZDQvdGFibGVyYW5nZTo3OTM4MWY0YTBmYzU0ZTNjODE1ZWIzNGE5NWY5NzhkNF85LTEtMS0xLTA_8289fa02-f035-483f-a69e-c2473854371f">0001055726</ix:nonNumeric><ix:nonNumeric contextRef="iee35bc1d9e0c43538284362e3939b7f2_D20170101-20171231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTAtMS0xLTMxNDc_6c803ced-512a-40ed-a3f9-5c37b9e3854b">us-gaap:AccountingStandardsUpdate201601Member</ix:nonNumeric><ix:nonNumeric contextRef="i83b2ddee9dbd4ad99f2320f64af7b7d5_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzg3MzY_3ade6400-d079-4bc2-a028-5e2e5c6e9030">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i83b2ddee9dbd4ad99f2320f64af7b7d5_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzk2MDM_9dbc4512-b92b-4a6e-ae6e-052ec9675f3d">P2Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="iaa895d662b3145c5a41a31d0ed8415b0_D20190219-20190301" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzgvZnJhZzo0YzViYmRmZWY0MDA0YThkYWU0N2QwODBjMzk0NmY4ZS90YWJsZTpiNjNhMzdkMDQ1OTI0NzFhYmM5YWQ5ZWI5N2E4MjMyMy90YWJsZXJhbmdlOmI2M2EzN2QwNDU5MjQ3MWFiYzlhZDllYjk3YTgyMzIzXzItMS0xLTEtMA_57abfa90-4c48-462b-aee2-23ff321af171">0.1858045</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i8951003210074b36b9dda9db0f8457f5_D20200803-20200803" decimals="10" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzgvZnJhZzo0YzViYmRmZWY0MDA0YThkYWU0N2QwODBjMzk0NmY4ZS90YWJsZTpiNjNhMzdkMDQ1OTI0NzFhYmM5YWQ5ZWI5N2E4MjMyMy90YWJsZXJhbmdlOmI2M2EzN2QwNDU5MjQ3MWFiYzlhZDllYjk3YTgyMzIzXzUtMi0xLTEtMA_f8072c97-bf03-4b53-9390-31ffb5ad365e">0.0002110595</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i71b20462bd004edbab068b83724e067a_D20200803-20200803" decimals="10" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzgvZnJhZzo0YzViYmRmZWY0MDA0YThkYWU0N2QwODBjMzk0NmY4ZS90YWJsZTpiNjNhMzdkMDQ1OTI0NzFhYmM5YWQ5ZWI5N2E4MjMyMy90YWJsZXJhbmdlOmI2M2EzN2QwNDU5MjQ3MWFiYzlhZDllYjk3YTgyMzIzXzYtMi0xLTEtMA_28b0ddae-8bfd-4094-ad1f-b25e79a7426c">0.0002756873</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i5ab9e4f47cb2474880c78cd6c2a71a3f_D20191226-20191226" decimals="10" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzgvZnJhZzo0YzViYmRmZWY0MDA0YThkYWU0N2QwODBjMzk0NmY4ZS90YWJsZTpiNjNhMzdkMDQ1OTI0NzFhYmM5YWQ5ZWI5N2E4MjMyMy90YWJsZXJhbmdlOmI2M2EzN2QwNDU5MjQ3MWFiYzlhZDllYjk3YTgyMzIzXzktMi0xLTEtMA_66d6e9a6-5728-4a38-b543-e14d5c2053a5">0.0002147766</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i42d318dbd29f463e80af152ae64602b6_D20191226-20191226" decimals="10" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzgvZnJhZzo0YzViYmRmZWY0MDA0YThkYWU0N2QwODBjMzk0NmY4ZS90YWJsZTpiNjNhMzdkMDQ1OTI0NzFhYmM5YWQ5ZWI5N2E4MjMyMy90YWJsZXJhbmdlOmI2M2EzN2QwNDU5MjQ3MWFiYzlhZDllYjk3YTgyMzIzXzEwLTItMS0xLTA_74dce970-7639-4e00-8055-cb6331e0f53c">0.0003579611</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ino-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ib419158dcd6f4738afa4cc04916d0e83_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8cea5729188744ba8f522ce4fcb02501_I20210226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i461a06745d764430b3e72d9b80f2433e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if06f128df0d4400ebe7bd1d7e8943618_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a2b66e18d454ede830f8d1d4aada02f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fcbfe891e274002a1ffb387d3ce3a69_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0158aa5ba6a546b99ab881b2e80f21f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63bf584a99b7490ca78c1a42bda4e636_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iffddb18409714a948fe63c504296aa8c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dc6151b860b45f89bb347c96f739dc4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30743f88af6d4d7884fdb78b4e04be01_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2ddf6e556714a9194d76e2fc479466d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d14809ed4f847dfa70ec56139f770f3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba3bf773708b42baa53946d5d820581b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a9e17b526b04b5ba4c3e10ea48bf9be_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ef7cd7ce94c488a826cce5fbf50a188_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i278953abb6d94a6bbe934e65ea84cbfe_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9103f0c23474b5c8e125a115c2724a8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33e4ffc6b1db495eb2fe9e7c8433e217_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic393612319cb4ba8af0f0b3942e04555_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6014b9675e54093ba947147d012abd7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67b9315f7b704679b653ff7f7615cf07_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3981f22251049ee93fbe814da0d83e3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i505e79e18d4842ec9b1a16442f4c83ba_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaf5815034574ba68cf12263477730bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3888369ceb0d47fd91589b1bd565e24b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0398c951aeaa42e8a809af10d39ca6e8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37ba42be07e34414bfad4d78f2cdd2c1_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28bc6b87217f4ff59425a80bbd1e2ad1_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2d253912b0f4408b7670b8cbf6b0149_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic56fe18af934493fa8353bf3feefd308_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75e4a748c91441108389565fa9192239_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8049e1241294c54aa32f8547e18a755_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i098d7fa0e69c497394a273e6da442d60_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee35bc1d9e0c43538284362e3939b7f2_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7aba2cb555e4b1ba182fde50316d33e_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9955fcfc3e2c4e3b81ca03f6caf2daa2_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb4f83564ad0407e9192905a852387c8_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia18d7a4702454a37944331f885cfb8b1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib44b98a091634594bb6b156389961e55_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i287bb517d7014611b68f17996d1f4e9c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86080f7508e64793a3517dba947f4e05_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f0daeaeee744d499efc2b85f77f9d54_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a3a60879f794353a9d97762ab033aa3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i740feef31f3f47f0ba79a75a7d90f120_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67fdcc0b65fc4a0089a046845912b455_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife9269e896424523ab66d904e94b790c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia497f4c2f35943b49482c9b5840af9b9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc185e611aa641b780dc3634c14f4ee0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cbd0517be1f4ad2b1e368f3d2f228a3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7825d9df4ecd47ff89c494932b5e4951_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if885952e35d34a77981589fd208c6f6e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bb1fb8250b642e28bbf60ee14bb5157_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87950b9f2a414087a42b5de774c7f46d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2a2c6f594ba44cea4528ac7e5994bbe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e3418a8da5543a1b4777a24eeab51bd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i005f7fef38fe454d8d059b0ff21bb4cc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i107de4cc8049489c90dcdc7df31185d7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3627569429294e4ca52aea6769a42428_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf69dcb513af441394c278e7178dd8e1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23a4b782e98343ba867b1942902cd9c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia154d39818f845b8b99981331588d907_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab9cb5c1258e4438bb749f1d6a97298c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7793a330338242b48cd682861d2c7f7b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i360f12716f38470bbf4ae171a15c2372_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71043bc300f54b1da5f262214bdd0d8f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cd6d538b5cf46eea148f05fc8d3313e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic03220c5093b43cfac7c2b6ee8ed0184_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51877c6afa3e4a95a48234a7814aa510_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa46d2918b494bf6b84cf170d1bd45b3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib11feb96d4f04657b2246c8fc89ee878_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cf0fd331c9340aab8d9ff4bdb145e55_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4b271c4ed074580b9dd08164751212e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cbd1b6109f04daeb2321b67b43c7080_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7451d3a8f3541b6bfb4ad50349ef17c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f72e3ff2fe94fd3bd217b59590c7d5e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe28f3a96c8b4546bb455081a9f12d46_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b8aa89313b84034867fdb688e65bfdd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc5e017651494a17b39d87c26345b84c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6150a0ddcd004d80a33e1a8697c53f20_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if84110be1e7d414fba59970232a6a0c4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie36d4982a87c49f39d1d799e83d16f3d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i537cf66d5bd342bc8318a0e2943c17c8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i340206d59d1a4f37a0d265ecd256f49a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="krw"><xbrli:measure>iso4217:KRW</xbrli:measure></xbrli:unit><xbrli:context id="i9e8658006af5464d94cdc5612be9184f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b92526d2c7d46a19cf0c21a5393e2ca_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b080f596f2e47f7a9e4906d33a20b22_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ino:segment</xbrli:measure></xbrli:unit><xbrli:context id="i83b2ddee9dbd4ad99f2320f64af7b7d5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ea16c625aa4430da8652fcd9977062c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2f035d8d1f74d318e1f75455e89e2e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba72fa0012f445dd820803f63d0f038a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i656dfbe21acc42619acc008ddb6d5362_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9025cc3fe1a74a43b1903d7fbd5b140e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9609d90a67ee46b7abceb06d1fcaa5b7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c0e39c482da423594a8b74a964a6471_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3dffc4892f444aea3b32fa15bd0cbca_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf6b492d876f45ff96cd2a77765bdef8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3e05652c96d47cbb27fabd2cf99fc32_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2128ce96ca6b41749cc080d568dfb0af_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i922f47d757b34b2d903a5c97adad9e66_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd0b936b6baf4cd39d116548a1ec5f65_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0491bd11569e4c70be12a68e3eb1cbf2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f8129c3d125441a91d09e391d9c6e73_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89954e650abd432f915000cefb94d545_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icecba79931fe4bc5a892cd67d1db6a6c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82c6c3c2c1c34abca8e04f10eaa8f2fc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09fb87c71e9d48c9b0018f20e4d467a7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c09b6ea337f41979072422f8aba29f1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdabd2e1d4a641529a738e6e5213335b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27178e3407dc46aeabb6e03458be5284_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i833eed11e677427591fa49c0a58a8d3f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1f13165d5d6482590debad2f6e92178_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb0e0943a16c445bbe684491faf920a8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddced08b347f44f785f1537e866c5bf5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2d6cd258bb84425bbbfe977d3faefb6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c09bb9e28c146a2a7d84bd07c5eb551_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i020096d75bda46dcb066c2fd6645c02b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58fdd3cd014b4e69a232a56367655377_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59d8b0164c8b45a394697662732fe279_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36022e8256554cf79c99deed72b40319_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1340701a627440abb646d47f8dd59a0_D20210301-20210301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i613bf85d5ad641aeb9777c902ee5e720_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1629a50f2cbd40418d7f6000e5d7136c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07a67056b0694c8eb1abe2d9df8f95cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0580e1e8b8464f7daadfc64c85589325_D20171229-20171229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-29</xbrli:startDate><xbrli:endDate>2017-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic70aad9f1bbb46c7aef9aac80dd8d982_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccbc152ca5c64a51b143e8f925a6386c_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d23e87ce6a14739b73a33d11363becf_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i198477edba824f6ea373e4e1b0ef0825_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d79fdc0914349cba02f4425251657ee_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida214446db3b464690a216afd28cd2bd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5415ff5fd21249ac9bb9bf4e91ebb967_D20150901-20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a96b2b8330c413eac49b9d0b68a5735_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecbf562e66684d72bb93637a9483430f_D20171231-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-31</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icde7df1aa421475ebcaddca0a5faed9e_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ba7d9f763e04c32b364239929d24393_D20190302-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-02</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f7ef79982d84ebd9bc2953403b7e029_D20180411-20180411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-11</xbrli:startDate><xbrli:endDate>2018-04-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea76d18ca06a49d7851b0c0ff3a34c6d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85493c81c5114a8795086a2445f83c41_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id233e1d41be44b12951cb39c380c2e4c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62896ff9dfdf42f19fd838c00bab3f1d_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6e5de1ef1e64ba791fd38a6b29b9cc9_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d96c9c2aee04b989b045f3a11979c60_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d1c029556354cc880be0619e862bd95_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e7308dee93f48cb8fc7b11c2b76aaad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b4cb28aa5624d32a8dd171551850f0e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56edaab4f0df412ba9168d447a83002d_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i234be8858e5244cdbdbccb259435578a_D20190801-20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6257d5c8c1b740bea21e2623fc3ce7b3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic708a39c59804e988fb7464a0d0169de_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if593976c97db405798c736bb8b0cda97_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8903d8385b2841c5b9653a466d3c1db9_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i915d8cff852f486180f3c82d2ebda044_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief209891b012422a8c1dc68518ef3bc4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87746e71a46a454787656a4370821f51_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ea2ecae9adf4b6a887dee064675992e_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bd9953ed4844195ad1d5a16e1dba0ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99bceb219d684923a420db226755fc2f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>ino:investment</xbrli:measure></xbrli:unit><xbrli:context id="id0595f6d10944686ae57a515abd3ec36_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id170cedd88294bc89c6f402a37e123d7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if06443a97a314fdb92d5c69b9c9a3577_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9de27164b224d649a37a0d1268584c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id26a1e4045ce4ee0b3633de9cb1dac61_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id77b897f2b2646018276c3a658805161_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68422a65e88b40e79296e5aa6b8060db_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic061ab952f6e49ceb26243c60817cee2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17c551a0610440a7b6f0abe61e8c82f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacece918c44e4d6ca768677f180897d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94dda5a90e794d048dc952d0627fdba7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddeab32014174a6eb2d035b28d1446b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ca9c371fd4d4ea3be2f6127b2b2dffa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbdeb8f70e6a44778a3ea02aaaeb1562_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e8472dc355b42e086aa634156b612b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if851e1354ade45b6a4ac89925d9a4403_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62adc1206c1a4893b5f3e46ab68ec7dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ca4e3a2cfb347d1961b839895da975d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if81c022e21c148fcbb11892de0c3ae71_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99fa94fde4e748cfab7a583ebf129abd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1a574e3690b4028a3943434014b9a30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0710bc234ed846439f5d59a967a8aa8b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76a5e1669e794e9db24a12f605d4c94b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1005ed8e84ab4360b9311d1c584538bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13d84d47d468404abefbd435934323d5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e2afcee19774482b251567dfd704749_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2913e54184ff437ea27bd0066e1dafd0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia26736c769c2420f9ca66117d30c734a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0ea3dd77c114edaa793e22ac478cf97_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66b39d6da16f4eb380e2a990dfff1f36_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i096fa31c0c464101ae5cf90270267cde_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idce13f5e5f4c4fc5af43c4edef726f4a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd3a02a734354ed7820d83f40571c7d6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8add3b9ca8da438b900d8ea5ac0b076c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie64a636ae54645beb9d8ee43e42dcc10_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86bce27cb66c4603aa2e7c5f6f92d9d6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7004a0f54b4e4ac8adfa3750ee6ccf4e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d23fef8ecff4bdebfef8e1a463d13e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i221a334cfa384bf7bff65c8d98c24f2e_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i627a611d119640b18733b47fcdec6850_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib52bd61505e648f7bd380109eafb2944_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7a4e61e0eaa451ca758740df043909a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c79379a56b342509ef8394d089e5206_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib09ce28847f9441691e291976b0a485e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc1ad91fea794c9590f178cc0037615c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e8cb281f8e84403b97d0d2fecd0b80c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4ea9cc86768413da095a70b56c90878_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16a1aae8996946329e172cd6fe4f18be_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71a6c7568e7c4d8d9bfa945381152967_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic13e135184a4471d939ad3f817c42607_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i786830bb15014490bcfe93e2c9d6a1e0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86bef865624946d194ded3a39b0a65c9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id292a9ccf0334d99847358e5a3ab1c42_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifab0a228644849cbb1110e99d5c4def2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34104c83002345e7a7bc49036cda039d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i281ff24884ff458b8adb28cb18217a61_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c4dc4da8dca44c2a1fe44b672260615_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85bcd3d07a5448baa7741c3754cf1afb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8cfb53cdc7e41538de275f318de41dc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60903cdb147d440493201f13edec1181_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdff2f0208d44cfe89bc5c92c6d26e82_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e37913d1c5547849d25527ab47a8354_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia92449862a9b4330882477084d9c358a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6147c70afd684bf981a1e0b1202b8058_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica6d55dbeb8f4cc3a279ee53cb51b7f6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf1bd4850cb8489ea58ab4b2fda5a1a9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1e50a9cd8294f3fa132e51c85220781_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06dcac265f274ebb9813e7af23d4696d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69dd35be2ade4fb39a51b18d53c5b8ac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i608cd9009af344c89aa12e0f7b311227_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i823cb278de9e47d192778260c3f6db48_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc88be27567345b7a63177cf8f6f0a99_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic35720e7a755474fbed63e8de7d3a5c2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93819976a973446ea1061a1f37473186_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4efea026d744acf8d1ff320d47ea351_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i488395dd3cfd4a979f4c1b6dc93cab19_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74e4216a6494415aa925b9f9484b6be5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia060b83189564cb68c4c124f57185051_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d4ece7344ab45b3a9385623a0a4e13d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8525ad5935324dd89b3d251246713420_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:MCDCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4b3aa0a98414a8abe5a915a77d31a03_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:MCDCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife05d4e1d47d421fb4f563cd562c6a2c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f2dd21c2fb446e1ae44bb46996bcb90_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37c81a59aea34482aaa080e093a3867a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1ab2e4de0604a18954781289db76d63_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c19b53631bf4b87bd6a70572b19cb99_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33214248981d4bc3b9306852d8766f9d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a2f30004a6f4760aa2daadba4a229e7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i142b64fd7b4e4c77ab64ed7e235de34e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5d0edfd70ad4cd9b77378f5caf6c6fb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i331d2b93d53845bbbec83894edc52039_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i714873ccaa6945ed8fddc9ca8b4a2ba9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78dee1adddd343d99fde448fd85a0794_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i898390694847439889865bfd898b6744_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b01ba2e220c4965b4bea51288906959_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c086571fe9d4f12adaba3aba2947770_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0d8a0c7b06b44b58e6943d769503627_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i564bfb8806cf4e91b81d269583a69770_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3873b02397f24b078c0992e44ff9bc6b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18f5246a5fd14efc8c588f0e34623d44_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic368e3ff4b6c43beb3e373aaad80cfaf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ab95ac0698643e2a24b4f704858ab14_I20190301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa895d662b3145c5a41a31d0ed8415b0_D20190219-20190301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-19</xbrli:startDate><xbrli:endDate>2019-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1fd9f19434d481d9950a24dc8314104_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>ino:day</xbrli:measure></xbrli:unit><xbrli:context id="i1ef0a0da5279497abe1189b528c9b923_I20190801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie42755ee382b4362b35b654a372750a0_D20190801-20190801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9081e6bad5e84753997332afda1396e2_D20200803-20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b97fc9dbea24d1a8c1cc2caf0be1794_I20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e5cc4151269456bb11f37ef3096b655_I20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b884d1d8cee4549b13c04c430171c0d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68fab246bae941029c1bb3eb8d3d4400_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b9a6b9c0fba4da0a1e8ad1ae9afb802_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01aabdcf7e1946cfad86edb560658159_I20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icec95e1e34f940efa96dfde18a03f4f4_D20191226-20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-26</xbrli:startDate><xbrli:endDate>2019-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i700bda11831d4df3889dde4f49d91305_I20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b023471d6394305b1996c77b2d112da_I20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJuly22020ConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90a70ccee3354926b91c35b43f4f36de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbed9e38f9f44e17bc3443f38555ff5b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d6e94e1cacc426ebf7ec4cb5e51ff53_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic594f80a76ff4858a3452511b0ae1fad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i450df2d2eb374134a57819c4d3d41137_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8951003210074b36b9dda9db0f8457f5_D20200803-20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71b20462bd004edbab068b83724e067a_D20200803-20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJanuary22020ConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ab9e4f47cb2474880c78cd6c2a71a3f_D20191226-20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-26</xbrli:startDate><xbrli:endDate>2019-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42d318dbd29f463e80af152ae64602b6_D20191226-20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJuly22020ConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-26</xbrli:startDate><xbrli:endDate>2019-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43ff85947d654cd3b9d8600362c08d4e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d422727fda34bcea389c96828efbd6f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf338a94fd4b4eceba8d37e44eab78f0_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ea987ce83ae454ba3d280374d688b3a_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8846f56dce3d432d966649b28efa7c9a_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia01d038a4d224f74b7cec88d7ab01932_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02e208f208514fac82fa7b99a461039a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ae124c42b254d14b9b5f269fd7419ce_D20200403-20200512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-03</xbrli:startDate><xbrli:endDate>2020-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b37597d28484e31879b4ec99d19767b_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64aec48d41f548978f711e0981b117a9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a9f7074a224430daf98266033b9e313_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00014904fa624256a7ae429094225ce3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie326789176224a66adc6eb18840f7e83_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i868ece5d5ec040e5bc282761eb8ff2b3_I20160513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d250281b0084a9c9e85c87f5e174e6c_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5aa6e62b90746e2a0e7a79dcda10743_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i336b7f2097e04fa9946695e9082976b1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ddcf49caf034014b934f70e033c7381_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9a611d11b194c04a97196e8637d3ea5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d376d80def94aaeaa2d3d07b689dd72_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b2e5387ae774d5b966fe4cfedf17ca3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3f04bc964bc4062b85a1da80bfd3649_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i495966b5ff4e4727a8837c97fa4bd60a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60c500e2193a495a8e8d53e8bda2c96e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5686e8d556c34f1287b6ab813a0dfe50_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcfb3bb7cf6d4f7f907cc373a9f10860_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f0bd5564d5d480c930234de144bd099_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bd082535e33430d840b84b42712a05a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic358738bd92c4585907376620670c7fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6335ae27741400684bafee789c7d140_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadcbc296b043424a97f9d0cbf4b4f313_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8447cd2594e94149a11ee2086d36b99a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d936012135e4af182293a6bbca9297d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2a529a3bc394bac9063df42512b5b9c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f5ffa0e16ec4dcca0f2275c5832f658_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a196d09ea024f9f8f82d3947718333d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieac0bc60961d47e7ab6e7a227877260b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a4f019880eb4d7e9f92a9fef1fc03ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb1a3d043e3142e993801b0549b85c79_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i424ca8a2ddb04b9d9993270673bfb2b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0529e897544648afb4f8c8facb9c526d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b636fe087494ecaa5b251e1c14a1e4b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0898c082ec1c41a5a28d7feae8fd298d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8ba04b2fc50444a883de5f9c28c9da1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a8b1922df074f8d881dc9835917dfc0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1329f8962cf44001a77927afa8dd9600_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d1018668fb54f4a8f27dc2bbbebbc43_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c519ce051934157ac2a92180ffe1298_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01d41a23f9d7414e9ca33540626eb820_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3b43b488fbc4c9bb91dea3e06d1edd9_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i091f59652b674cbba9a610be2bac6d93_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice5bec7f1fe94cf09064dbef4b963a15_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i1795839f068f4fc6864f4b49d44926c3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8df0be21b6144949f383e03e347241b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49fe24c3cf784f4aad4300bb064363bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71066e05ce5044f48965c132ee5b5187_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>ino:lease</xbrli:measure></xbrli:unit><xbrli:context id="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id04015c2a4c74d3f9bda78d8a29a1f31_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d75b37d31b1415baa94fe75e2eced26_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2747486006c46f3999136afeba9ca67_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5382c3775034bdc84ed280f6032b6c1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ef5e314188044e59bf80890444a8798_D20200827-20200827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-27</xbrli:startDate><xbrli:endDate>2020-08-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dcec29e7a224ece9361e16b87782889_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib776ba015a6a43aea6946a399cff7c5d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:CaliforniaIncomeTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6a7c79dd6fb44fea2add2a158468fae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:PennsylvaniaStateIncomeTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id072f2455d4849af90468cc0d319cb25_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41c87ddc992c48b1acc2970661bb9d63_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id820841c83d4427ca89b1647c1b78ca7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1a1fd05e61e4d45b37b83d2c13345a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52f711d0981940219b0fb0f426d25c3d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc506eb64eb44797985abc96b9c8f82f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9f188d112294323bf3087ef33c420b6_I20200827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39837d9d2abd48a3aca884118a65d728_D20200827-20200827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-27</xbrli:startDate><xbrli:endDate>2020-08-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbd8535467dc4b5eae52e74f3983bcef_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec6e16acd2c14a4e90471eef35722254_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31ce6dcaa01b46eeab8e3956ce276921_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if81fb01786fc4764ac42fbc00018292e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i741b2d70a16540e4849e177841399ef2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9933acb5084469ba365e771ad142f6f_I20200220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fa046515d344201b301dfcac426f1d7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12e6aa36d34c4fed9f215ef703733288_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i584919522b8946388cc46b11e1b6c134_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i850db8c1404e41ef8a3f4e2c5d6497c9_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib07cb6287f3248b5b722d555d87a2523_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i510403322bee48dd9b1d7fa361079cf8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bc8a5ec417940d080468c000bb0c684_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i329099e1a64e4114916fa70aa8f77967_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1344066b478244ff886e0ea7d3f13c3c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3278752f623242159a014d02f29d289b_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie036575d65ff4badb43323c689c9ffe6_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f560f41562c4fc9a3ad15d9c446af7c_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie331329335874c70bd80518d6ff9c532_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fae662cff7740e8b862767817b4873b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if720e223acd541dc9a923f12ccafdf0a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6ef275f991c4ded9ea7eddc6b7b1498_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bc7852775b6421ca17e8e3e194bab5c_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eaf8e38eb024ee5bd2c0e686600ecd3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75e5c84b89524b7285a0f1fd58ce7d28_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica4b744c22f9404fa2cb9f77877257ff_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3d03457e0864bfc8b1b8bfd7dfc1ec0_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c0fc01307c94a3f818e05fa200f315f_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a56ec56c1704c999304cafdca127971_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d304f7e01154532bc01359f95252e17_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic121c422f0fe4bf881984c703f46d52f_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i684fbe7297024813bfc8e35aab204865_D20200601-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefe35c0283fe4a69ae2e6dd8855e61f9_D20200601-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i760444398ee74fd3afd5baf01b8fc34e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide3b32650b4e4f67aa4cae4aa5642502_D20200601-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i294f24f4c95d4f61a311238a03b975ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dc3ada5f7d04ae89165c132fbfcfc62_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0f4d31539a04f7f8e95ff7d666d0c49_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if88d7d6e81274ed0ba37814cb46d85e5_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i573ba12b81674a4e8f8ea7ef32efdbe8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i795cb1a151064426a4dfe996df0c38c4_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13703c117a254b43812c022797496182_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67fe64f9d9cc4e94987901784abf46ab_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i070e992116654fa581ad7cf2f0c976f3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife87feec4ca84488991ff60a2283130f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d9cc3f0455f498ab2daa193d5030329_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6d2e46c031143829dacb9e46e09d8e3_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i590abc5d2cd1439bb9b334157e97cf1c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10e7342c08644032af98955a95c3f840_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63f67afbae934928a16259c4523b7b46_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b066217c7b540b2bc2fabd939e07804_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b1addc1c587493fa83cae1c6f2f7fc9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica64d2e3910943c8a4e37fa1fe5e8214_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e09b6ad2e474af5bfdec3ff92271d9f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdb7d9b899e44f18bf0403f267912de3_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib072c12c52ab4aeda860c97446fc70b6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie49e671657294b3c8baefe0969b6bae7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a5a1a01c5584587899e703311afd962_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1af80391a9d7498d9623d41397672588_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97adc1d442cd448fb9146600ab5d2804_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i270677398e2d488297835140b7cd4b5e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab53db1ca1924309875498ea3f081da6_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if64f1e0018c643a58e89139a5f4c240e_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c9ec00a3c0e4514abe1f49e7c8af240_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fdefad67e8242bda643664dba8120e2_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb1b5faf5d454621b7facd84a26755bc_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedf7ee151bb8419a90965b37855024f2_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie53b02189840498b87e2fd8412e3a928_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i606478849fd3433da994e2810ba1aab2_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie60fc32c63d143b0a967a81f8d4d95a9_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i748a768d51414cce859cb0837e99006b_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c6db7698a064eee933877749271a1c0_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if258c2eac36b42adb8115f070d01b735_D20210125-20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-25</xbrli:startDate><xbrli:endDate>2021-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6888c79a29d34124835456052fe2309e_I20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-25</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTE3LTEtMS0w_cc5c860d-7f6b-4e8e-b5ce-8cd85ed11ea6 id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTExLTEtMS0w_bdc02a01-e7e8-4a2a-9036-379da004ddf3 id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTEzLTEtMS0w_3be9cd88-22ff-4670-9e3c-923cb963bbe8" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90ZXh0cmVnaW9uOmRlZGFlNzNlM2MyMTRiYjJhYWY1NGIxZTdiM2FiNzMzXzExNDY_195c7e0a-b8ba-4aef-9e33-54bfb12e8a43" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i06d07667d4974765a8282374d1211e66_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODc1_0d2fa81f-48d2-4a94-ab91-4ddfc6769027">10-K</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6ZDZjODJlNDc5Mzk4NGY0Nzg0OTUxNTg2ZGYzODJmNTcvdGFibGVyYW5nZTpkNmM4MmU0NzkzOTg0ZjQ3ODQ5NTE1ODZkZjM4MmY1N18wLTAtMS0xLTMwOTc_29065eed-2045-406f-a950-d72c1a2b6b8d">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> FOR THE FISCAL YEAR ENDED <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5OTE2_e211a8bb-aa48-4b17-9049-bc151893a919"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5OTE2_de891eec-78db-48a7-a549-8b3531a0014c">DECEMBER 31</ix:nonNumeric>, 2020</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.465%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6ODA2NjU4YTM4MmY2NGFlY2FiOTZjNmIzYzgxNWE0Y2YvdGFibGVyYW5nZTo4MDY2NThhMzgyZjY0YWVjYWI5NmM2YjNjODE1YTRjZl8wLTAtMS0xLTMxMDc_9251fa2e-c261-4923-b979-826ec18cbed4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">       </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COMMISSION FILE NO.&#160;<ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODk2_5e06afd0-6ea5-417e-9491-37ecc0fead7e">001-14888</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img src="ino-20201231_g1.jpg" alt="ino-20201231_g1.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:204px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODc2_e3a1e873-08e6-448d-9062-d95aededa447">INOVIO PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NzQyYjg2NThjODY2NDRmNTg5YjlhODk1ZTJhZDQzMGYvdGFibGVyYW5nZTo3NDJiODY1OGM4NjY0NGY1ODliOWE4OTVlMmFkNDMwZl8wLTAtMS0xLTMxMTI_b0eb10b5-7b3d-4d64-81f7-385e064f932f">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NzQyYjg2NThjODY2NDRmNTg5YjlhODk1ZTJhZDQzMGYvdGFibGVyYW5nZTo3NDJiODY1OGM4NjY0NGY1ODliOWE4OTVlMmFkNDMwZl8wLTItMS0xLTMxMTQ_f50fd6f5-d210-411a-acf0-2ebc8ed8c0b2">33-0969592</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NzQyYjg2NThjODY2NDRmNTg5YjlhODk1ZTJhZDQzMGYvdGFibGVyYW5nZTo3NDJiODY1OGM4NjY0NGY1ODliOWE4OTVlMmFkNDMwZl8zLTAtMS0xLTY0NTIvdGV4dHJlZ2lvbjo2MTc2NDYwY2FhN2Y0ZGUyYjM1ZmJiOGRkZTc4ZDVlMV82NTk3MDY5NzY2NzQ2_cf4dd8e9-d578-4eee-9d82-96dd3df66b92">660 W. Germantown Pike</ix:nonNumeric>, <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NzQyYjg2NThjODY2NDRmNTg5YjlhODk1ZTJhZDQzMGYvdGFibGVyYW5nZTo3NDJiODY1OGM4NjY0NGY1ODliOWE4OTVlMmFkNDMwZl8zLTAtMS0xLTY0NTIvdGV4dHJlZ2lvbjo2MTc2NDYwY2FhN2Y0ZGUyYjM1ZmJiOGRkZTc4ZDVlMV82NTk3MDY5NzY2NzU4_3bd1265c-b0e2-452e-852d-5951b078b708">Suite 110</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NzQyYjg2NThjODY2NDRmNTg5YjlhODk1ZTJhZDQzMGYvdGFibGVyYW5nZTo3NDJiODY1OGM4NjY0NGY1ODliOWE4OTVlMmFkNDMwZl8zLTAtMS0xLTY0NTIvdGV4dHJlZ2lvbjo2MTc2NDYwY2FhN2Y0ZGUyYjM1ZmJiOGRkZTc4ZDVlMV82NTk3MDY5NzY2Nzc3_654e0f3f-51c6-4517-a0d5-c14655438ad7">Plymouth Meeting</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NzQyYjg2NThjODY2NDRmNTg5YjlhODk1ZTJhZDQzMGYvdGFibGVyYW5nZTo3NDJiODY1OGM4NjY0NGY1ODliOWE4OTVlMmFkNDMwZl8zLTAtMS0xLTY0NTIvdGV4dHJlZ2lvbjo2MTc2NDYwY2FhN2Y0ZGUyYjM1ZmJiOGRkZTc4ZDVlMV82NTk3MDY5NzY2Nzky_732d4bbe-4eb8-4a9f-a88e-c143295c7330">Pennsylvania</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NzQyYjg2NThjODY2NDRmNTg5YjlhODk1ZTJhZDQzMGYvdGFibGVyYW5nZTo3NDJiODY1OGM4NjY0NGY1ODliOWE4OTVlMmFkNDMwZl8zLTItMS0xLTMxMTc_66d3c7c8-3e0f-4a46-98c7-4c90be8523be">19462</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">REGISTRANT&#8217;S TELEPHONE NUMBER, INCLUDING AREA CODE: (<ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODc4_5d954b8c-eba5-4184-aa66-8a68d9ad53ca">267</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODgy_fe7d3673-365e-4db5-8b78-761011f0e626">440-4200</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(B) OF THE ACT:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NDc1YzU3M2FkNTkzNGE2ZmI0ZTdjZDZiYjg1MDgxOTgvdGFibGVyYW5nZTo0NzVjNTczYWQ1OTM0YTZmYjRlN2NkNmJiODUwODE5OF8xLTAtMS0xLTMxMjI_887df21b-d032-4d68-a2dc-7afef0e83892">COMMON STOCK, $0.001 PAR VALUE</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NDc1YzU3M2FkNTkzNGE2ZmI0ZTdjZDZiYjg1MDgxOTgvdGFibGVyYW5nZTo0NzVjNTczYWQ1OTM0YTZmYjRlN2NkNmJiODUwODE5OF8xLTEtMS0xLTMxMjI_119c15ba-c7d3-49ef-8ceb-575fd0b8d18c">INO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NDc1YzU3M2FkNTkzNGE2ZmI0ZTdjZDZiYjg1MDgxOTgvdGFibGVyYW5nZTo0NzVjNTczYWQ1OTM0YTZmYjRlN2NkNmJiODUwODE5OF8xLTItMS0xLTMxMjI_cc06896c-bff1-4cf7-b2bc-7f0f6db68ad4">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT: NONE</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzcxMDE4_93ab7fed-7ae0-48e1-b104-8825a0c46217">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODg5_66336ba2-e718-46d7-a488-ecfe255302e3">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODkw_373887b2-ce49-4ce2-8cb4-6946135b805c">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODkx_80182e0f-8203-4915-ac82-81ce75801173">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6MzBkZTc5YmEyZjQwNDZkNzk3MTZjMGMwMjBhYjcwZjkvdGFibGVyYW5nZTozMGRlNzliYTJmNDA0NmQ3OTcxNmMwYzAyMGFiNzBmOV8wLTAtMS0xLTMxMjk_950e5d97-2d48-4969-b8ab-b7688da4c7a2">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6MzBkZTc5YmEyZjQwNDZkNzk3MTZjMGMwMjBhYjcwZjkvdGFibGVyYW5nZTozMGRlNzliYTJmNDA0NmQ3OTcxNmMwYzAyMGFiNzBmOV8yLTQtMS0xLTA_99d88b98-f59c-4781-a8d3-6184ae70a06c">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6MzBkZTc5YmEyZjQwNDZkNzk3MTZjMGMwMjBhYjcwZjkvdGFibGVyYW5nZTozMGRlNzliYTJmNDA0NmQ3OTcxNmMwYzAyMGFiNzBmOV8zLTQtMS0xLTA_4a7b4a35-d72e-49f0-b957-1c4eb23389b1">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzcxMDE2_b41e4f9b-c8ed-4ca1-a236-1ec69f66d2c6">&#9746;</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODk0_4fc2257b-9b87-4096-9639-438821455881">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity (which consists solely of shares of Common Stock) held by non-affiliates of the Registrant as of June&#160;30, 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="ib419158dcd6f4738afa4cc04916d0e83_I20200630" decimals="-8" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5OTM1_0e79bb32-09b1-4ce7-8f3b-0d003c33c4b7">4.2</ix:nonFraction> billion based on $26.95 per share, the closing price on that date of the Registrant&#8217;s Common Stock on the Nasdaq Global Select Market.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares outstanding of the Registrant&#8217;s Common Stock, $0.001 par value, was <ix:nonFraction unitRef="shares" contextRef="i8cea5729188744ba8f522ce4fcb02501_I20210226" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM18yNjI1_53abc506-ce1b-4c3a-83ce-1cc832f41141">207,632,584</ix:nonFraction> as of February&#160;26, 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODk1_8252de07-0a05-470f-b28e-c800dd239203" escape="true"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive proxy statement to be filed with the Commission pursuant to Regulation&#160;14A in connection with the registrant&#8217;s 2021 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8217;) are incorporated by reference into Part&#160;III of this Report. Such Proxy Statement will be filed with the Commission not later than 120&#160;days after the conclusion of the registrant&#8217;s fiscal year ended December&#160;31, 2020.</span></div></ix:nonNumeric><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i06d07667d4974765a8282374d1211e66_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:81.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_10">PART I</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_10">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_13">ITEM&#160;1. BUSINESS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_13">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_16">ITEM&#160;1A. RISK FACTORS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_16">41</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_19">ITEM&#160;1B. UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_19">61</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_22">ITEM&#160;2. PROPERTIES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_22">61</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_25">ITEM&#160;3. LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_25">62</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_28">ITEM&#160;4. MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_28">63</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_31">PART II</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_31">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_34">ITEM&#160;5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_34">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_37">ITEM&#160;6. SELECTED FINANCIAL DATA</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_37">65</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_40">ITEM&#160;7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_40">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_58">ITEM&#160;7A. QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_58">78</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_61">ITEM&#160;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_61">79</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_64">ITEM&#160;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_64">79</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_67">ITEM&#160;9A. CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_67">79</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_73">ITEM 9B. OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_73">76</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_76">PART III</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_76">82</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_79">ITEM&#160;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_79">82</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_82">ITEM&#160;11. EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_82">82</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_85">ITEM&#160;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_85">82</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_88">ITEM&#160;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_88">82</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_91">ITEM&#160;14. PRINCIPAL ACCOUNTING FEES AND SERVICES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_91">82</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_94">PART IV</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_94">83</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_97">ITEM&#160;15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_97">83</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_100">ITEM 16. FORM 10-K SUMMARY</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_100">87</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_103">SIGNATURES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_103">88</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_106">CONSOLIDATED FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_106">1</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless stated to the contrary, or unless the context otherwise requires, references to &#8220;INOVIO,&#8221; &#8220;the company,&#8221; &#8220;our company,&#8221; &#8220;our,&#8221; or &#8220;we&#8221; in this report include Inovio Pharmaceuticals, Inc. and its subsidiaries.</span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i06d07667d4974765a8282374d1211e66_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i06d07667d4974765a8282374d1211e66_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K (including the following section regarding Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations), or this Annual Report, contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates&#8221; and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this Annual Report. Additionally, statements concerning future matters, including statements regarding our business, our financial position, the research and development of our products and other statements regarding matters that are not historical are forward-looking statements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Although forward-looking statements in this Annual Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include without limitation those discussed under the heading &#8220;Risk Factors&#8221; below, as well as those discussed elsewhere in this Annual Report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Annual Report. Readers are urged to carefully review and consider the various disclosures made in this Annual Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report includes trademarks and registered trademarks of Inovio Pharmaceuticals, Inc. Products or service names of other companies mentioned in this Annual Report may be trademarks or registered trademarks of their respective owners. References herein to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;INOVIO&#8221; or the &#8220;Company&#8221; refer to Inovio Pharmaceuticals, Inc. and its subsidiaries. References herein to &#8220;DNA medicines&#8221; refers to INOVIO&#8217;s product candidates for cancer and infectious diseases in development.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Company Overview</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus (HPV). Our DNA medicines pipeline is comprised of three types of product candidates: DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies (dMAbs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In clinical trials, we have demonstrated that DNA medicines can be delivered directly into cells in the body through our proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted pathogens and cancers. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate strategy is to advance, protect and, once approved, commercialize our novel DNA medicines to meet urgent and emerging global health needs. We continue to advance and clinically validate an array of DNA medicine candidates that target HPV-associated diseases, cancer, and infectious diseases, such as COVID-19 (SARS-CoV-2). We aim to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our novel DNA medicine candidates are made using our proprietary SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology that uses a computer algorithm to identify and optimize the DNA sequence of the target antigen (proteins associated with a cancer or infectious disease that the body will recognize as foreign or not normal). INOVIO then creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce the target antigen to help the person&#8217;s immune system recognize and destroy cancerous or virally infected cells.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patented CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery devices provide optimized uptake, or absorption, of our DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trial data to date has shown a favorable safety profile of our DNA medicines in more than 7,000 administrations across more than 3,000 patients.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, our lead product candidate VGX-3100, currently in Phase 3 trials for precancerous cervical high-grade squamous intraepithelial lesions (HSIL), cleared high-risk HPV-16 and/or HPV-18 in a Phase 2b clinical trial. Also in clinical development are programs targeting HPV-associated cancers and a rare HPV-associated disease, recurrent respiratory papillomatosis (RRP); non-HPV-associated cancers glioblastoma multiforme (GBM) and prostate cancer; as well as externally funded infectious disease DNA vaccine development programs in Zika, Lassa fever, Ebola, HIV, and coronaviruses associated with MERS and COVID-19 diseases. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our COVID-19 vaccine program, INO-4800, we published Phase 1 clinical data from the first cohort of 40 participants in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EClinicalMedicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an open access clinical journal published by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Lancet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in December 2020. The paper, titled </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, Phase 1 clinical trial," found that INO-4800 was immunogenic in all vaccinated subjects, effectively generating an immune response of humoral (including neutralizing antibodies) and/or cellular responses (both CD4 and CD8 T cells). Furthermore, the 1.0 mg and 2.0 mg dose groups both demonstrated seroconversion in 95% of subjects, respectively, with 78% demonstrating neutralizing antibodies in the 1.0 mg dose group and 84% demonstrating neutralizing antibodies in the 2.0 mg dose group. Cellular (T cell) response were observed to multiple regions of the spike protein, including the receptor binding domain region. 74% had measurable cellular responses at the 1.0 mg dose group and 100% of the subjects in the 2.0 mg dose group demonstrated cellular responses.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently conducting the Phase 2 segment of our planned Phase 2/3 clinical trial for INO-4800, called INNOVATE (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OVIO I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-4800 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Va</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ccine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rial for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fficacy). INNOVATE is a randomized, blinded, placebo-controlled safety and efficacy trial of INO-4800 conducted in adults in the U.S. It is being funded by the U.S. Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD (HA)) and the Defense Health Agency (DHA).</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DoD agreed to provide funding for both the Phase 2 and Phase 3 segments of the INNOVATE clinical trial, in addition to the $71.1 million of funding previously announced in June 2020 for the large-scale manufacture of the company's proprietary smart device, CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP, production of doses and the procurement of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2000 devices.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co., Ltd. (Advaccine), ApolloBio Corporation, AstraZeneca, the Bill &amp; Melinda Gates Foundation, CEPI, DARPA/JPEO-CBRND)/DoD, HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects. These risks are discussed more fully in Item 1A. Risk Factors herein. These risk factors include, but are not limited to, the following:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business could be adversely affected by the effects of health epidemics, including the global COVID-19 pandemic.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our planned clinical development of INO-4800 as a potential COVID-19 vaccine has been placed on partial clinical hold by the FDA, which may cause delays in the commencement of our planned Phase 3 clinical trial or completion of clinical testing, both of which could result in increased costs to us and delay or limit our ability to proceed to commercialization and generate revenues.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There can be no assurance that the product we are developing for COVID-19 would be granted an Emergency Use Authorization by the FDA or similar authorization by regulatory authorities outside of the United States if we were to decide to apply for such an authorization. If we do not apply for such an authorization or, if we do apply and no authorization is granted or, once granted, it is terminated, we will be unable to sell our product in the near future and instead, will be required to pursue the biologic licensure process in order to sell our product, which is lengthy and expensive.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delays in the commencement or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">None of our human vaccine candidates, including INO-4800, or our immunotherapy and DNA encoded monoclonal antibody product candidates have been approved for sale, and we may never develop commercially successful vaccine, immunotherapy or monoclonal antibody products.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional capital to develop our DNA vaccines, DNA immunotherapies and dMAb programs and electroporation delivery technology.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">A small number of licensing partners and government contracts account for a substantial portion of our revenue.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have agreements with government agencies, which are subject to termination and uncertain future funding. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face intense and increasing competition and many of our competitors have significantly greater resources and experience.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we and the contract manufacturers upon whom we rely fail to produce our electroporation devices and product candidates in the volumes that we require on a timely basis, or at all, or fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our electroporation equipment and product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Differentiated DNA Medicines Platform </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview of Our Platform </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DNA medicines platform uses precisely designed DNA plasmids, which are circular strands of DNA that contain an optimized genetic sequence of an antigen (protein) or monoclonal antibody specific to a targeted disease to be produced inside a patient's own body. Our proprietary design and optimization process for our DNA plasmids is called SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These plasmids are delivered directly into cells in the body intramuscularly or intradermally via our proprietary CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart devices, which use brief electrical pulses to reversibly open small pores in the cell, enabling DNA plasmids to enter. Once inside the cell, the plasmids instruct the body&#8217;s cellular machinery to temporarily produce the target antigen or monoclonal antibody. We believe our DNA medicines platform offers versatile capabilities, both in terms of addressing a number of disease targets as well as providing us with several product development opportunities. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The characteristics and core components of our DNA medicines platform include: </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Design Process:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> optimized plasmids have shown the ability to help break the immune system&#8217;s tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Smart Device:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Once our DNA medicines are injected into the cells of the body using our proprietary smart device, the DNA plasmids instruct the cell to temporarily produce the target antigen or monoclonal antibody. The antigen is processed naturally in the cell and induces the immune system to generate antibodies and/or T cells that perform preventive or therapeutic functions. Similarly, dMAbs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> generated in this manner can also trigger desired immune system functions.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Our DNA medicines have generated best-in-class </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(within the body) immune responses: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With our core platform technology, we have developed a pipeline of clinical-stage product candidates that have generated best-in-class in vivo immune responses, in particular CD4+ and CD8+ T cells that are fundamental in eliminating cancerous or infected cells. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. Our DNA medicines work naturally with the immune system: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared to other technologies, our DNA medicines are designed to work more naturally with the immune system to reduce or minimize the risk of unwanted inflammatory responses. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mechanism of action for our DNA medicines and the process for administration of our DNA medicines are summarized in the following graphic:</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-indent:22.5pt"><img src="ino-20201231_g2.jpg" alt="ino-20201231_g2.jpg" style="height:776px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><img src="ino-20201231_g3.jpg" alt="ino-20201231_g3.jpg" style="height:384px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nucleic Acid Vaccines: Similarities and Differences between DNA and mRNA-based Approaches</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of nucleic acid-based vectors (DNA or RNA) as an alternative to traditional immunization is a strategy that has been under development for many years. We believe that the approval for emergency use authorization of two mRNA-based vaccines for COVID-19 in 2020 proves the power of nucleic acids, which are also core to DNA-based vaccines. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA-based vaccines are composed of purified, closed-circular plasmid DNA containing genes that encode target antigens. Historical studies have shown the ability for DNA-based vaccines to generate immune responses against various pathogens in diverse animal species. Immunization with DNA-based plasmids has also been successfully attempted in several tissues by various routes of administration, with most experiments being conducted with DNA delivered to skeletal muscle or the skin. Past experimental studies involving nucleic acid vaccines targeted a broad range of infectious diseases which included leishmaniasis, tuberculosis, malaria, and hepatitis.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past decade, the scientific community and the vaccine industry have been asked to respond urgently to various epidemics, including but not limited to: H1N1 influenza, Ebola, Zika and, most recently, SARS-CoV-2, the virus that causes COVID-19. Today, multiple platforms are under development in the fight against COVID-19. Among those are DNA- and RNA-based platforms, along with those for developing viral vectors and recombinant-subunit vaccines. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO&#8217;s efforts to develop a DNA vaccine candidate for COVID-19 is based on the suitability and scalability of our DNA medicines platform, as well as our track record of rapidly generating promising countermeasures against previous pandemic threats. INOVIO was the first company to advance a vaccine against MERS-CoV, a related coronavirus, into clinical evaluation in humans. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INOVIO&#8217;s DNA Medicines&#8217; Differentiation from mRNA</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While DNA and RNA both use fragments of genetic materials that, once injected, instruct the body to fight pathogens, cancer and infectious disease, there are unique advantages to DNA vaccines compared to RNA vaccines. While it has been demonstrated that DNA vaccines allow for the option of repeated administration, RNA vaccines specific nanolipidic formulation may impair re-administration, and, on balance, they have resulted in weaker CD8 T cell responses, require colder storage temperature than Antarctica for transportation, require complex lipid nano particle (LNP) formulations for scaling, and are on average more expensive when considering manufacturing and distribution. INOVIO&#8217;s DNA vaccines offer several key potential advantages:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt">Well-tolerated:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our DNA vaccines appear to be well-tolerated when evaluated against multiple disease targets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Stability of Product:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our DNA vaccines are stable for more than a year at room temperature or for more than a month at 37&#186; C, have a five-year projected shelf life at normal refrigeration temperature and do not require frozen cold storage or shipping.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt">Rapid Design and Manufacture:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Similar to mRNA vaccines, our DNA vaccines can be rapidly designed and scaled, which are critical aspects in addressing global pandemics like COVID-19.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:10.5pt">T Cell Responses: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our DNA vaccines have demonstrated ability to generate high levels of T cell (CD4+ and CD8+) responses along with antibody responses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The CD8+ T cell responses in particular are regarded to be very important in their ability to clear tumor cells in the body as well as to fight off infections. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:11.07pt">Ability to Safely Readminister DNA Vaccines:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Our DNA vaccines have been used to boost our vaccines&#8217; immunity profile with repeat administration with our DNA vaccines. Our DNA vaccines could be safely readministered if immunity weans, offering the possibility for seasonal boosting usage without any concerns of generating an anti-vector response.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our DNA Medicines Platform in Detail: Delivery Science  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goal of our DNA medicines platform is to generate and deliver safe and effective therapeutics and vaccines. Our technologies allows us to enable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> generation of functional immune responses to achieve desired therapeutic and preventive outcomes. Historically, we have focused primarily on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> production of disease-specific antigens directly in the body to stimulate prophylactic or therapeutic immune responses. More recently, we have explored an additional new application for the platform: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> generation of monoclonal antibodies to achieve preventive and therapeutic outcomes complementary to our antigen-generating immunotherapies. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With these core technologies, we have developed a robust pipeline of 15 clinical-stage programs that have generated robust </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> immune responses, in particular CD4+ and CD8+ T cell responses, which are fundamental in eliminating cancerous or infected cells.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are two components to our DNA medicines platform. The first is a biological component, by which we encode proteins (antigens, monoclonal antibodies, interleukins i.e.IL-12) into closed-circular DNA plasmids. These DNA plasmids encode highly optimized antigens or transgene proteins that drive increased expression intracellularly while also driving immune responses. The second component is our proprietary CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart devices technology, which facilitates delivery of the DNA plasmids.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The resulting immune responses from DNA medicine administration then neutralize or eliminate infectious agents, such as&#160;viruses, bacteria, and other microorganisms, or abnormal cells, such as&#160;malignant tumor or infected cells. T cells can be immediately &#8220;trafficked&#8221; to parts of the body where cells are displaying the target antigen. Memory cells are also created for durable effects.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> DNA medicines are designed to generate antigen-specific antibody and T cell responses. First, we identify one or more antigens that we believe are the best targets, based on extensive due diligence, pre-clinical and clinical data that we have evaluated to direct the immune system toward a particular cancer or infectious disease. We then apply our SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> design process, which uses the genetic make-up of the selected antigens from multiple variants of a cancer or strains of a virus.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each antigen, we create a new genetic sequence that represents a nucleotide consensus sequence of the targeted antigen from multiple virus variants or strains. We can create a differentiated SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> variant to help the immune system better recognize a cancer self-antigen (from a cancerous cell grown in the body) and &#8220;break the tolerance&#8221; of those cancer cells within the body. In human clinical trials, we have generated immune responses with SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> DNA medicines that were not matched to different strains of an infectious disease, such as influenza or HIV, indicating that such immunotherapies may have more universal protective capabilities against unmatched strains of a circulating virus. As a result, these SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> constructs may provide a solution to broadly cover the genetic &#8220;shift&#8221; and &#8220;drift&#8221; that is typical of many infectious diseases. Since the new engineered Syncon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sequence is closely similar to the originating sequences but does not match any, so we believe it is patentable. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sequence is then inserted into a circular DNA plasmid with its own promoter. The plasmid is optimized at the DNA level for codon usage, improved stability of mRNA, and provided with enhanced and proprietary leader sequences for ribosome loading; it is optimized at the genetic level to enable high expression in human cells. We believe these design capabilities allow us to better target appropriate immune system mechanisms and produce a higher level of the coded antigen to enhance the overall ability of the immunotherapy to induce the desired immune response.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plasmids are then manufactured in a bacterial fermentation process using scalable technology. These manufactured DNA medicines can be stable under normal environmental conditions for extended periods of time.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DNA medicines platform also allows for rapid design, pre-clinical testing, manufacturing at scale, and clinical development of both our DNA vaccine and DNA immunotherapy product candidates. Speed is an important feature, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">particularly as it relates to developing a response to globally emerging infectious diseases such as COVID-19. Responses to emerging infectious diseases that we have been involved in are described in more detail below. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Delivery Technology</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DNA medicines are delivered directly into cells of the body intramuscularly or intradermally in a small local area of tissue using our proprietary CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart devices. CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart devices use brief electrical pulses to reversibly open small pores in the cell, enabling DNA plasmids to enter. Through this process, the cellular uptake of the DNA plasmids increases by more than 1,000 fold compared to the injection of a DNA plasmid alone without other delivery mechanisms. This improved cellular uptake has enabled the immune responses observed in our clinical trials along with the efficacy results generated by these immune responses.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alternative delivery approaches based on the use of virus-based vectors, bacteria, nanoparticles and lipids are complex and expensive and have generated safety concerns. Because those alternative delivery vectors themselves possess many additional antigens specific to the vector, they can attract unwanted immune responses that are believed to compromise the vectors&#8217; ability to deliver their genetic &#8220;payload&#8221; and produce the desired immune response. In contrast, a DNA plasmid vector possesses no antigens of its own, the plasmid results in production of only the target antigen.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have published preclinical data in which we observed improved immune responses generated by our SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> DNA medicines delivered using CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart devices compared to a leading viral vector-based approach (Adenovirus type 5). The delivery of DNA medicines using CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart devices to date has shown a favorable safety profile in clinical trials, without serious adverse events and only transient and mild local injection-related side effects such as redness and swelling. Our delivery system based approach is designed to be tolerable without the need for an anesthetic, and because it does not induce side effects, it can be repeatedly administered for booster/maintenance vaccinations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart devices provide a straightforward, cost-effective method for delivering our DNA medicines into cells with high efficiency, minimal complications and the ability to enable what we believe to be clinically relevant levels of gene expression, immune responses, and efficacy.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Choice of Tissue for DNA Medicine Delivery</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Skeletal muscle has been a core focus for delivery of DNA medicines via CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> because it is mainly composed of large, elongated cells that are non short-term dividing, meaning that longer-term expression can be obtained without integration of the gene of interest into the genome. We have generated pre-clinical and clinical evidence that muscle cells may have a capacity for secretion of proteins into the bloodstream. Secreted therapeutic proteins may therefore act systemically and produce therapeutic effects in distant tissues of the body. In this respect, the muscle functions as a production factory for the biopharmaceutical needed by the body. We envision that CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-delivered DNA medicines to muscle cells will circumvent the costly and complicated production procedures of viral based delivery vectors, bacterial based delivery vectors, protein-based drugs, conventional vaccines and recombinant monoclonal antibodies. This approach may provide long-term stable expression of a therapeutic protein or monoclonal antibody at a sustained level.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to generating pre-clinical and clinical evidence that intramuscular DNA delivery can be effective for a number of immunotherapies, we are also exploring delivery to the skin as an optimal route of administration for DNA vaccines. Skin, or intradermal, administration is an attractive site for immunization given its high density of antigen presenting cells. Unlike muscle, skin is the first line of defense against most pathogens and is therefore rich in immune cells and molecules that may generate a robust immune response. With intradermal delivery, we may be able to demonstrate a comparable cellular immune response to muscle delivery. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Smart Delivery Systems</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are several configurations in the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart device family. The first configuration covers intramuscular (IM) delivery, while the second covers intradermal/subcutaneous delivery (ID). Smart devices with these configurations have been validated, manufactured under Current Good Manufacturing Practices (cGMP) and are being used in human clinical trials. We have filed device master files with the U.S. Food and Drug Administration (FDA) covering the use of the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart devices in human clinical trials. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SP smart devices combine the functionality of our current generation of skin and intramuscular devices in clinical testing with enhanced form, design and portability. All components of the pulse generator and applicator are integrated into a cordless, rechargeable device. The rechargeable battery can enable immunization of several hundred subjects, making the device useful for mass vaccinations. The devices are designed to accommodate different electrode arrays to meet the requirements of the particular DNA medicine and targeted tissue for delivery.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Next-Generation Smart Device Development</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also advancing a new generation of ID delivery devices called CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-3P. Currently used ID devices penetrate no more than 3 mm into the target tissue, compared to IM devices that go deeper. All of our current vaccine clinical studies are using these CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-3P smart devices.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical arm of the U.S. Defense Threat Reduction Agency (DTRA) has agreed to fund the further development of our commercial ID delivery device or CELLECTRA 3PSP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. DTRA provided $8.14 million of grant funding to support us in developing a small, portable, battery-powered ID device to be branded as CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-3PSP, which will be used in the administration of our vaccines and therapies, including DTRA-developed products. In addition to the development of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; _</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3PSP, this award will fund the investigation of DNA vaccines developed by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) using the new device.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we were awarded $71.1 million in funding from the U.S. Department of Defense (DoD) to support the large-scale manufacture of the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP smart device, production of doses and the procurement of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2000 devices. The DoD contract, from the JPEO-CRBND-EB through funding provided by the Defense Health Program, builds upon two separate prior $5 million grants from the Bill &amp; Melinda Gates Foundation and CEPI, to accelerate the testing of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background on DNA Medicines and Immuno-Oncology </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple technology advancements and product approvals have highlighted the potential of immunotherapies to usher in a new era of cancer therapeutics. Monoclonal antibodies (mAbs) such as Herceptin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and dendritic cell therapy Provenge</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for prostate cancer have had varying degrees of success. While a significant step forward, suitable monoclonal antibodies with desired characteristics have been difficult to design or identify and expensive to produce, and the technology does not lend itself to designing mAbs for many diseases. Dendritic, or other cell-based therapy, is a highly personalized medicine involving removing cells from the patient, modifying, multiplying, and then returning them to the body. In addition to the high-cost and complex processes to manufacture products, a weakness of this approach is that it has not been shown to generate high levels of cancer-specific T cells.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress in the field of immune checkpoint inhibitors (CIs) has resulted in optimism regarding the potential for new immunotherapies against a spectrum of cancers. The immune system relies on a safeguard system of checkpoint mechanisms to prevent excessive or incorrectly directed immune responses. Many cancer cells can &#8220;hijack&#8221; these checkpoints and neutralize T cells sent by the immune system to eliminate them. CIs prevent cancer cells&#8217; from interfering with these checkpoints and enable T cells (especially CD8+ killer T cells) to complete their killing function against cancer cells. Clinical trials of CIs have shown notable therapeutic impact against melanoma and other cancers, but with response rates in the 15-20% range (and only in the case of melanoma going up to the 40% range or higher), there remains a significant opportunity. Observations suggest CIs may be less effective if there is not a high enough pre-existing level of antigen-specific CD8+ T cells in the tumor micro-environment, meaning that the tumor is &#8220;cold&#8221; rather than &#8220;hot&#8221; (with a significant level of CD8+ T cells). More recently, scientists have recognized that a strong CD8+ T cell generating &#8220;active&#8221; immunotherapy may be able to transform a "cold" tumor into a "hot" tumor and in combination with CIs may possess significant therapeutic potential to fight cancers.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More recently, a new category of immunotherapies called adoptive cell transfer, for example CAR-T technology, has provided further evidence of the merit of providing an enhanced T cell presence to fight cancer. CAR-T therapies have achieved dramatic results, most notably in B cell cancers. Unfortunately, they have also been associated with significant side effects. When this technology has been applied to solid tumors, it has generated significant cytokine storms that have resulted in severe side effects, including deaths. Moreover, adoptive cell transfer such as CAR-T, like dendritic cell therapy, involves removing T cells from a patient, modifying them to better target a cancer cell, multiplying the T cells, then returning them to the patient. These complex therapeutic products need to be manufactured and released for each patient, leading to expensive and timely manufacturing, as well as increased supply chain complexity.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To summarize, while there have been promising  advancements in recent years that better harness or activate capable killer T cells, we believe there is still significant untapped potential to develop &#8220;ideal&#8221; immunotherapies to fight cancers and infectious diseases.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to advance product candidates that:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">Target disease-specific antigens or proteins unique to a cancer or infectious disease;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">Do not depend on complex manufacturing processes;</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Activate functional</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">killer T cells;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">Generate robust T cell responses or a significant number of T cells that are persistent and durable over time (memory response);</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Do not induce toxic inflammatory responses; and</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Are capable of &#8220;breaking tolerance&#8221; of cancer cells grown in the body.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Data from our Phase 2b data of VGX-3100, discussed below, lead us to believe our approach to activating significant antigen-targeted T cells may achieve these characteristics. Accordingly, we are advancing a pipeline of pre-clinical and clinical immunotherapy product candidates.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our DNA Medicines in Development</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The chart below summarizes the status of our active DNA medicines development programs, each of which is described in more detail following the chart. </span></div><div style="margin-top:5pt;text-align:center"><img src="ino-20201231_g4.jpg" alt="ino-20201231_g4.jpg" style="height:298px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VGX-3100 for the Treatment of HPV-associated Precancerous Lesions</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview and Background</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HPV is a sexually-transmitted, persistent infection with one or more high-risk (HR) genotypes of that virus can lead to, and thus are the causative agents responsible for, cervical pre-cancers (cervical dysplasia), cervical cancer, other anogenital cancers, and head &amp; neck cancer, which is one of the most rapidly growing cancers in men. Scientific literature estimates that, at any given time, approximately 43% of the U.S. adult population is infected with HPV, and about 25% of adult men and 20% of adult women in the U.S. have a genital infection with one or more HR-HPV genotypes. Worldwide, the prevalence of cervical HPV infection in women overall (all ages combined) averages about 12%. However, this varies widely by age and geography -- in some regions of the world, e.g. Africa, the cervical HPV prevalence by age reaches about 45%. The lifetime risk for acquiring an HPV infection of any genotype is about 80% for people worldwide. In a recently published analysis, U.S. Centers for Disease Control and Prevention (CDC) estimates that 13 million new urogenital HPV infections occurred in year 2018 in persons aged 15 to 59 years alone in the United States., with about 42.5 million persons in that age group being HPV infected at any time during that year. That study also estimates that HPV comprised 50% of all incident infections and 63% of all prevalent sexually transmitted incident infections due to any agent. Nearly half of HPV infections are in the age group 15 to 24 years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HPV is the most common viral infection of the reproductive tract and is the major cause of cervical cancers. Almost 300 million women globally are estimated to be infected with HPV, with another 30 million additional cases that have progressed to the pre-cancerous stage. In the United States, an estimated 14,480 new cases of cervical cancer will occur in 2021, and an estimated 4,290 women will die of cervical cancer that year. Worldwide, the International Agency for Research on Cancer (IARC) estimates that more than 604,000 new cases of cervical cancer occurred in 2020 and nearly 342,000 deaths. IARC predicts that nearly 850,000 new cases of cervical cancer and more than 524,000 deaths will occur worldwide in 2040. Virtually all cases are linked with persistent infection with HPV.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Challenges with acceptance, accessibility and compliance of vaccines to prevent HPV infection and their resulting pre-cancers and cancers have been substantial since such vaccination availability began in 2006 in the U.S. These challenges have resulted in many vaccine-eligible girls and women remaining unvaccinated and at risk. In 2017, a U.S. national survey found that only 57% of girls aged 13-17 years were up to date with the HPV vaccine series. However, we believe such surveys yield overestimates. One recently published US national assessment found that only about 46% of females age 15 had been vaccinated with two or more doses of the HPV vaccine.  Even lower proportions have been vaccinated in some of the other countries around the world which have access to HPV vaccines.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While approximately 90% of genital HPV infections in women are ultimately cleared naturally by the body's own immune system within three years of incident infection, persistent cervical infection with one or more HR-HPV genotypes can lead to cervical HSILs and, if untreated, eventually invasive cervical cancer. Researchers have estimated the global prevalence of clinically pre-cancerous cervical HSILs at between 28 and 40 million. HPV-16 and HPV-18 are the two most prevalent high-risk types of HPV worldwide, causing the majority of HPV-associated cancers. In the United States, 43% of all cervical HSIL cases were attributable to HPV-16/18 in 2016, and about 70% of invasive cervical cancers are attributable to HPV-16/18 worldwide.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated annual incidence of diagnosed cervical HSIL is up to 195,000 cases in the United States (including those uninsured, partially insured, and publicly insured) and approximately 263,000 to 503,000 cases in Europe. Patients with this condition represent a significant market opportunity for our product candidates. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To prevent HPV infection and the precancers and cancers it causes, there is currently one FDA-approved preventive vaccine available in the United States, called Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9. That vaccine protects against infection by nine total HPV genotypes, consisting of seven genotypes that confer high-risk for cancer and two that confer risk for RRP and genital warts. However, preventive HPV vaccines cannot treat or protect those already infected with the same HPV genotypes, which is a large population. Currently there is no viable immunotherapy or drug to fight incident, prevalent, or persistent HPV infection or treat cervical HSIL.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current management options for cervical HSIL are unappealing. The &#8220;watch-and-wait&#8221; process associated with low grade squamous intraepithelial lesions (LSIL, formerly called low-grade dysplasia or CIN 1) and in some young women with higher grade lesions (though only for the CIN 2 level of cervical HSIL) is a stressful approach. The only available treatment option for cervical HSIL is surgery, which involves ablating or cutting a women&#8217;s cervix to remove the pre-cancerous lesions. While surgical procedures are generally initially effective in removing lesions, they can lead to short-term adverse effects including cervical scarring, excess bleeding and infection, and to longer-term reproductive risks such as pre-term birth, miscarriage, and perhaps infertility. Current excisional and ablative procedures nearly double the overall risk of pre-term births from approximately 5% to 10%. Anticipation of these procedures produces significant anxiety for patients, despite their doctor&#8217;s reassurances, and full recovery from surgery can take up to several weeks. Because surgery does not clear the underlying HPV infection, there is a 10-16% chance of high-grade pre-cancer lesion recurrence after surgery as a result of persistent HPV infection and/or incomplete removal of the lesion, with the persistent HPV infection being the better predictor of recurrence.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our therapeutic vaccine candidate VGX-3100 is designed to significantly increase T cell immune responses against the E6 and E7 oncogenic proteins of high-risk HPV types 16 and 18 that are present in both precancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into precancerous and cancerous cells, thus making them appealing targets for T cell directed immunotherapy. The goal of VGX-3100 is to stimulate the body's immune system to mount a T cell response strong enough to kill the cells producing the E6/E7 protein. The potential of such an immunotherapy would be to treat precancerous dysplasias caused by these HPV types.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGX-3100 for the Treatment of Cervical HSIL</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2b</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Study Results</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In  2015, we published clinical data from our randomized, placebo-controlled, double-blind Phase 2b study of VGX-3100. We initiated this study in 2011 using our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> device in women with HPV type 16 or 18 and diagnosed with, but not yet treated for, cervical HSIL (also called high grade cervical intraepithelial neoplasia (CIN 2/3)).</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analyses of patient immune responses showed that overall antigen-specific T cell levels in women treated with VGX-3100 were greater than those treated by placebo at all observation periods. At week 14, levels of CD8+ T cells specific to the E6 and E7 HPV antigens in women treated with VGX-3100 were ten times greater than those in the placebo group. This response increased with each of the three immunizations, then declined modestly to a sustained and durable level of T cells (memory T cells) measured through 36 weeks (24 weeks post-treatment).</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients whose lesions regressed had higher frequencies of HPV-specific CD8+ T cells which co-expressed key molecules important in the T cell killing cascade and directly correlated with clinical efficacy. Specifically, higher levels of CD8+ killer T cells co-expressing checkpoint molecule CD137 on their surface, as well as the cytolytic protein perforin, were observed to be a predictive tool for efficacy. As a strong activation marker for CD8+ T cells, stimulation through CD137 has been shown in some systems to confer resistance of CD8+ T cells to the suppressive activity of regulatory T cells, indicating that its presence can identify tumor reactive T cells. Perforin is a pore-forming protein deployed by killer T cells to bore holes into the target cell's plasma membrane and destroy the cell. The difference in frequencies of CD8+ T cells expressing CD137 and perforin was greatest in patients who had both regressed their lesions and cleared HPV as compared to patients who did not.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To our knowledge, this was the first published study from which a direct correlation between antigen-specific CD8+ T cells generated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and clinical efficacy was observed. We have identified several potential key biomarkers of killer T cells </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that we believe can be used to predict the clinical efficacy of VGX-3100, as well as other immunotherapies, which we are seeking to confirm in our ongoing Phase 3 trial, described below.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2b</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trial Design </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The women in the Phase 2b study received either 6 mg of VGX-3100 or a placebo. VGX-3100 and placebo were administered using the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> device at months 0, 1 and 3. The study assessed efficacy by measuring regression of cervical lesions from high-grade to low-grade or normal in the treated versus control subjects. Immunological responses were also measured in this clinical study to assess the ability of this therapy to generate strong T cell responses in a larger, controlled study. Safety was also assessed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoint of the trial, histologic regression, was evaluated 36 weeks after the first treatment. In the per protocol analysis of this three-immunization regimen, cervical HSIL resolved to LSIL or no disease in 53 of 107 (49.5%) women treated with VGX-3100, compared to 11 of 36 (30.6%) who received placebo. This difference was statistically significant (p=0.017). Intent to treat results were also similar and statistically significant.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was also a high level of complete clearance of cervical HSIL when compared to that of a normal cervix. In a post-hoc analysis, cervical HSIL resolved to no disease in 43 of 107 (40.2%) women treated with VGX-3100, compared to 6 of 36 (16.7%) who received placebo (p=0.006).</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A secondary endpoint of the trial was virological clearance of HPV 16 or 18 from the cervix in conjunction with histopathological regression of cervical HSIL to low-grade or no disease. This endpoint was achieved in 43 of 107 (40.2%) VGX-3100 recipients, compared to 5 of 35 (14.3%) placebo recipients (p=0.001). We believe this is an important outcome, as persistence of the HPV virus is associated with recurrence of cervical HSIL.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Phase 2b patients were monitored for an additional 52 weeks for a safety follow up. No significant safety issues were observed through week 88 following treatment.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 Trial (REVEAL)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparation for pivotal Phase 3 development and commercialization, we completed a manufacturing technology-transfer to a commercial manufacturing facility and scaled up manufacturing of VGX-3100.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also designed and manufactured a new smart delivery device, CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-5PSP, which is being used in our global Phase 3 clinical trial of VGX-3100. This smart device is a fully automated, smaller and user-friendly hand-held device. The new CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-5PSP smart device is being used in our ongoing VGX-3100 Phase 3 trial, which started in June 2017, and is being developed for potential commercial use.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted additional market research with physicians and patients to better understand the unmet medical needs relating to cervical HSIL. These include a preference for a non-invasive, non-surgical procedure for removing cervical lesions; a treatment that can clear HPV, the cause of the pre-cancer, throughout the body and not just in the limited area of the lesion; and a treatment that does not result in pre-term births or infertility. We believe that cervical HSIL represents a unique market opportunity for a novel therapy capable of providing a first-line alternative to surgery and in some cases even an alternative to watchful waiting. This market research will help guide our communication and interaction with the physician, patient and support communities.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Phase 3 program, named REVEAL, consists of a primary study (REVEAL 1) and confirmatory study (REVEAL 2), being conducted in parallel. The REVEAL1 study enrolled 201 subjects while enrollment of REVEAL 2 is ongoing.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The REVEAL studies are prospective, randomized (2:1), double-blind, placebo-controlled trials evaluating adult women with HPV 16/18 positive biopsy-proven cervical&#160;HSIL (CIN 2/3). The primary endpoint is regression of cervical HSIL and virologic clearance of HPV-16 and/or HPV-18 in the cervix, which was a secondary endpoint that was achieved in our Phase 2b trial described above. Overall, the Phase 3 studies are evaluating cervical tissue changes at approximately 9 months after beginning a three-dose regimen of VGX-3100 administered at months 0, 1 and 3. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, VGX-3100 was granted an Advanced Therapy Medicinal Product Certificate by the European Medicines Agency (EMA), for quality and non-clinical data. The procedure of certification of quality and non-clinical data involves an assessment of the available data in view of future registration and the related European Scientific Data Requirements, not including any clinical data or benefit-risk assessment. The granted EMA's certificate confirms that our chemistry, manufacturing and controls (CMC) data and nonclinical results available to date overall comply with the scientific and technical standards for evaluating an EU Marketing Authorization.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we announced that VGX-3100 had achieved the primary and secondary endpoints among all evaluable subjects (modified intention to treat (mITT) population) for the REVEAL 1 trial.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial protocol-defined mITT population (N=193) includes all subjects with endpoint data. For the primary endpoint of histopathological regression of HSIL combined with virologic clearance of HPV-16 and/or HPV-18 at week 36, the percentage of responders was 23.7% (31/131) in the treatment group, versus 11.3% (7/62) in the placebo group (p=0.022; 95%CI: 0.4,22.5), thus achieving statistical significance. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All secondary efficacy endpoints were achieved. These endpoints were: a) regression of cervical HSIL to normal tissue combined with HPV16/18 viral clearance, b) regression of cervical HSIL alone, c) regression of cervical HSIL to normal tissue, and d) HPV 16/18 viral clearance alone. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial protocol-defined intention to treat (ITT) population (N=201) includes all randomized subjects regardless of availability of endpoint data, and defines those without endpoint data as non-responders. There were eight such subjects (seven in the treatment group, one in the placebo group). Including subjects with missing endpoint data, the percentage of subjects meeting the primary endpoint was 22.5% (31/138) in the treatment group, versus 11.1% (7/63) in the placebo group (p=0.029; 95%CI: -0.4,21.2), which was not statistically significant. All secondary endpoints were achieved except for regression of cervical HSIL alone (95%CI: -0.6,24.5). The reasons for missing endpoint data were: one subject was randomized but was never dosed, one withdrawal due to pregnancy, one withdrawal due to administration error, one withdrawal due to post-administration pain, one loss of follow-up due to COVID19-related travel restrictions, and three losses to follow up due to undetermined reasons. A pre-specified per-protocol (PP) analysis will also be performed upon trial completion.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no treatment-related serious adverse events and most adverse events were self-resolving and were considered to be mild to moderate, consistent with earlier clinical trials.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to follow subjects in the REVEAL1 trial for safety and durability of response for 18 months following the last administration. We expect to present full data from REVEAL 1 at an upcoming scientific meeting.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enrollment for the confirmatory REVEAL 2 trial is ongoing.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGX-3100 for the Treatment of Vulvar HSIL</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precancerous lesions of the vulva, or vulvar HSIL, has less than a 5% rate of spontaneous or natural regression and there are no&#160;FDA-approved non-surgical treatments. Surgery, the most common treatment, is associated with high rates of disease recurrence and can cause disfigurement, long-term pain, and psychological distress for the women who undergo the procedure. Vulvar HSIL recurs in approximately one of every two patients who undergo surgical treatment.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2017, we commenced an open label Phase 2 trial to evaluate the efficacy of VGX-3100 in patients with vulvar HSIL. This randomized, open-label Phase 2 clinical trial will assess the efficacy of VGX-3100 in 33 women with vulvar HSIL. VGX-3100 is administered with our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;intramuscular delivery smart device. The primary endpoint of the study is histologic clearance of high-grade lesions and virologic clearance of the HPV virus in vulvar tissue samples. The study will also evaluate the safety and tolerability of VGX-3100.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we announced positive efficacy results for the Phase 2 trial. A 25% or more reduction in HPV-16/18-associated vulvar HSIL was observed for 63% of trial participants (12 of 19) treated with VGX-3100 at six months post-treatment. Three out of the 20 participants with histology data (15%) resolved their vulvar HSIL and had no HPV-16/18 virus detectable in the healed area. By comparison, the spontaneous resolution of vulvar HSIL caused by HPV-16/18 is estimated to be only 2%. VGX-3100 was well-tolerated in the Phase 2 trial.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to pursue a registrational Phase 3 clinical trial for HPV-16/18-associated vulvar dysplasia as well as to apply for rare and orphan disease designation for this indication.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGX-3100 for the Treatment of Anal or Perianal HSIL</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Left untreated, anal HSIL may progress to cancer. Spontaneous regression of anal HSIL may occur, but only in the range of 20% to 29% of patients after one year of follow-up. Persistent infection with a high-risk HPV genotype is responsible for a large portion of anal cancer. In the United States, about 55% to 80% of anal HSIL cases are associated with HPV-16/18, and worldwide about 80% of anal HSIL cases are associated with HPV-16/18. In the United States, over 90% of anal cancer is attributable to HPV, and about 87% of those HPV anal cancers are attributable to HPV-16/18 specifically.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no validated screening tests or a general screening recommendation consensus for anal HSIL. Treatment usually consists of repeated ablation, most commonly radiofrequency ablation (RFA), resections or laser therapy. However, treatment of anal HSIL represents a significant unmet medical need due primarily to the high recurrence rates up to 49% one year after treatment.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we commenced a Phase 2 clinical trial to evaluate VGX-3100 in patients who are HIV-negative with histologically confirmed anal or perianal HSIL, or anal intraepithelial neoplasia (AIN), associated with HPV-16 and/or HPV-18. The open-label trial enrolled 24 patients who received 3 doses of VGX-3100 delivered by our intramuscular CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> device. The primary endpoint of the study was histologic clearance of the high-grade lesions and virologic clearance of the HPV-16/18 virus in anal/perianal tissue samples.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, in partnership with the AIDS Malignancy Consortium (AMC), we commenced a Phase 2 clinical trial to evaluate VGX-3100 in patients who are HIV-positive with histologically confirmed anal or perianal HSIL associated with HPV-16 and/or HPV-18. The open-label single-arm trial will enroll approximately 75 patients who will receive 4 doses of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VGX-3100 delivered by our intramuscular CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart device. The primary endpoint of the study was histological regression of high-grade anal lesions to low-grade or normal. The trial was fully funded by AMC.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced positive Phase 2 efficacy results demonstrating that VGX-3100 showed resolution of HPV-16/18-associated precancerous anal lesions (HSIL) in 50% (11 of 22) of subjects six months following the start of treatment. VGX-3100 was well-tolerated in this trial</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO plans to pursue a registrational Phase 3 clinical trial for HPV-16-/18-associated anal dysplasia as well as to apply for rare and orphan disease designation for this indication.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGX-3100 Immune Correlates and Biomarker Signatures</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, we announced that a post-hoc analysis of data generated from our Phase 2b trial of VGX-3100 identified immune correlates and biomarker signatures that were predictive of potential treatment success.&#160;Details of the new biomarker and immunologic data are highlighted in the peer-reviewed journal&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Cancer Research&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the article, &#8220;Clinical and Immunologic Biomarkers for Histologic Regression of High-grade Cervical Dysplasia and Clearance of HPV-16 and HPV-18 after Immunotherapy,&#8221; by us and our academic collaborators.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into a collaboration with QIAGEN N.V. to co-develop a liquid biopsy-based companion diagnostic for the related immune correlates and biomarker signatures to identify patients most likely to respond to VGX-3100.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we announced an extension of our partnership with QIAGEN with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing technology to complement INOVIO&#8217;s therapies. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial project in this expanded collaboration focuses on the co-development of a diagnostic test that identifies women who are most likely to benefit from clinical use of VGX-3100. QIAGEN&#8217;s bioinformatic expertise will further increase the predictive power of INOVIO&#8217;s preliminary biomarker signature &#8211; and the assay will now be developed for use on the Illumina NextSeq&#8482; 550Dx platform, the first development based on a partnership QIAGEN and Illumina signed in October 2019.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Collaboration Agreement for VGX-3100 within Greater China</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into an amended agreement providing&#160;ApolloBio Corporation with the exclusive right to develop and commercialize VGX-3100 within&#160;Greater China&#160;(defined as China,&#160;Hong Kong,&#160;Macao and&#160;Taiwan). Additional details on the ApolloBio Agreement are provided below under "Business-License, Collaboration and Supply Agreements." </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the transaction in March 2018, we received proceeds of $19.4 million which comprised the upfront payment of $23.0 million less $2.2 million in foreign income taxes and $1.4 million in certain foreign non-income taxes. We may also receive potential milestone payments of up to $20 million in the aggregate. In addition, we are entitled to receive double-digit tiered royalty payments on sales. This collaboration of VGX-3100 encompasses the treatment and/or prevention of precancerous HPV infections and HPV-driven dysplasias (including cervical, vulvar and anal precancers) and excludes HPV-driven cancers and all combinations of VGX-3100 with other immunostimulants. The agreement also provides for potential inclusion of the Republic of Korea during the first three years of the term of the agreement.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis (RRP)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RRP is a rare disease (estimated at 15,000 active cases in the United States, including both juvenile and adult cases) that is characterized by the growth of tumors in the respiratory tract primarily caused by HPV-6 and/or HPV-11 genotypes. Although limited, the published epidemiologic data on RRP suggest this disease occurs worldwide. Although benign, papillomas can cause severe, sometimes life-threatening airway obstruction and respiratory complications. A distinguishing aspect of this disease is the tendency for the papilloma to recur after surgical procedures to remove them. If RRP develops in the lungs, affected individuals can potentially experience recurrent pneumonia, chronic lung disease (bronchiectasis) and, ultimately, progressive pulmonary failure. In extremely rare cases (less than 1%), RRP can develop into squamous cell carcinoma. Additional symptoms of RRP can include hoarse voice, difficulty in sleeping and swallowing, and chronic coughing. RRP symptoms are usually more severe in children than in adults. In children, the disorder is most often diagnosed at or around the age of four years. In adults, the disorder occurs most often in the third or fourth decade, though evidence exists for some incidence of new diagnoses in the sixth decade.</span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we announced the publication of clinical data from a pilot clinical study of a DNA medicine candidate (INO-3107) targeting HPV 6-associated RRP in the scientific journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaccines (MDPI)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Study results demonstrated that the candidate generated immunogenicity and engagement and expansion of an HPV 6-specific cellular response, including cytotoxic T cells. Two out of two patients receiving treatment who previously required approximately two surgeries per year for several years to manage this disease delayed their need for surgery, with one patient able to delay surgery for over a year and a half (584 days surgery-free) and the second remaining surgery-free for over two and a half years (915 days surgery-free).</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we commenced an open-label, multicenter Phase 1/2 trial that plans to enroll up to approximately 63 subjects in the United States and will evaluate the efficacy, safety, tolerability and immunogenicity of INO-3107 in subjects </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with HPV-6 and/or HPV-11-associated RRP who have required at least two surgical interventions per year for the past three years for the removal of associated papilloma(s). For this study, adult subjects will first undergo surgical removal of their papilloma(s) and then receive four doses of INO-3107, one every three weeks. The primary efficacy endpoint will be a doubling or more in the time between surgical interventions following the first dose of INO-3107 relative to the frequency prior to study therapy. If we obtain sufficient safety and potential efficacy data in adults, we plan to expand the trial to include pediatric patients as well as a potential booster regimen. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we announced that the FDA granted orphan drug designation for INO-3107. Orphan drug designation is intended to advance drug development for rare diseases. FDA grants orphan drug status to medicines intended for the prevention, diagnosis, and treatment of rare diseases or conditions. In the United States, an orphan disease is defined as a disease or condition with a prevalence of less than 200,000 patients in the United States annually. This orphan drug designation from the FDA qualifies INO-3107 for various development incentives, including a tax credit on expenditures incurred in clinical studies, a waiver of the New Drug Application (NDA) fee, research grant awarded by the FDA, and potentially up to seven years of U.S. market exclusivity upon approval for the treatment of RRP.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we announced the dosing of the first subject with INO-3107 in a Phase 1/2 clinical trial for the treatment of RRP. Patient recruitment is ongoing.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MEDI0457 (VGX-3100 + INO-9012) for the Treatment of HPV-Associated Cancers</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview and Background</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HPV is also associated with some head and neck cancers, especially those in the oropharynx and perhaps to some extent the larynx and oral cavity. The incidence of HPV-caused oropharyngeal squamous cell cancer (OPSCC) has increased significantly within the last 30 years in the United States, including a 225% increase from 1988 to 2004, an average annual increase of 14%. More recently, from 1999 to 2015, HPV-associated OPSCC incidence in the United States increased among men at an annual average rate of 2.7% and among women at an annual average rate of 0.8%, and by approximately 2009 the incidence of these HPV-associated mouth and throat cancers in men exceeded that of cervical cancers in women. Oropharyngeal cancer is the fastest-rising cancer among young white men in the United States, and U.S. men in general are about four times more likely than women to be diagnosed with HPV-associated oropharynx cancer. Increasing trends of the cancer in the United States are projected to continue at least through the year 2030. The estimated U.S. prevalence of HPV-caused oral cavity and pharynx cancer was approximately 108,000 cases in 2015.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPSCC is the most common HPV-attributable cancer in the United States. An estimated 14,000 new cases were diagnosed annually from 2013 to 2017 on average, with about 75% of those cases being among men. Worldwide, an estimated 98,412 new cases of oropharyngeal cancer overall occurred in 2020, and about 21% of those cases per year of this cancer are HPV- attributable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scientists have estimated that by 2030 OPSCC will constitute the majority of all head &amp; neck cancers.  In the U.S., about 70% of cancers of the oropharynx are now caused by HPV, with HPV-16 being the most prevalent genotype and causing about 86% of those HPV-caused cancers.  The U.S. incidence rate of this cancer is projected to continue its exponential growth and reach 31,000 new annual cases by 2029.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Improvements in primary treatment modalities (surgery and radiation) have produced significant improvements in morbidity, but intensive radiation has a profound long-term impact on mortality and quality of life. Based on these factors, we believe there is a significant opportunity for an effective immunotherapy.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Considering the several known cancers caused by HPV, the relative and total burden of those in terms of the annual U.S. average annual incidence rates and portions attributable to the HPV-16/18 genotypes for the period from 2013 to 2017 (the latest time period for which such HPV association and attribution data are available) are shown in the following figure. In total for that period, an average of nearly 36,000 cases of HPV-attributable cancers per year were diagnosed in the United States, and 80% of those per year were specifically due to HPV-16/18 genotypes.</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Incidence of HPV-Attributable Invasive Cancers by Site in the United States, 2013 - 2017</span></div><div style="margin-top:5pt;text-align:center"><img src="ino-20201231_g5.jpg" alt="ino-20201231_g5.jpg" style="height:467px;margin-bottom:5pt;vertical-align:text-bottom;width:666px"/></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide data estimates of the HPV-attributable fractions of HPV-associated cancers are shown in the following table.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Incidence of HPV-Attributable Cancers by Site Worldwide</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><img src="ino-20201231_g6.jpg" alt="ino-20201231_g6.jpg" style="height:323px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MEDI0457 for the Treatment of Head &amp; Neck Cancer</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, we initiated a Phase 1 clinical trial assessing the immunogenicity and safety of our product candidate INO-3112 (consisting of a combination of VGX-3100 and our product candidate INO-9012) in head &amp; neck cancer patients. INO-3112 is now called MEDI0457, following our collaboration with AstraZeneca, described below. We added INO-9012, a DNA-based IL-12 immune activator, to VGX-3100 for this cancer study because our prior HIV vaccine clinical study had indicated that the addition of IL-12 to our DNA medicine could enhance the activation of CD8+ T cells.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enrolled 22 adults with HPV16 and/or HPV18-positive HNSCC in this open-label Phase 1 trial. Patients were treated with four doses of MEDI0457 and then followed for safety, immune and clinical responses. In one part of the study, six patients were treated once with MEDI0457 before and after resection of their tumor. These patients received three additional doses subsequent to surgery and chemoradiation therapies. In the second part of the study, 16 patients were recruited into the study after their surgery and completion of chemotherapy and radiation therapy. These patients were treated with four doses of MEDI0457 and followed. Each MEDI0457 treatment was administered using our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery system.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, at the Annual Meeting of the&#160;Society for Immunotherapy of Cancer&#160;(SITC), we reported interim immunology results showing that in the group of six patients treated before resection (one dose averaging 14 days and ranging 7 to 28 days prior to definitive surgery) and post-surgery (three additional doses), MEDI0457 generated robust HPV16/18 specific CD8+ T cell responses in peripheral blood in four of five subjects who also showed increased T cell activation in resected tumor tissue samples. One subject withdrew consent after surgery, leaving five evaluable subjects in this group.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we announced a paper published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Cancer Research</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a major cancer journal, detailing results of a patient with head and neck cancer treated with MEDI0457 who achieved a sustained complete response (full remission) on treatment with a subsequent PD-1 checkpoint inhibitor. In our sponsored study of 22 patients with head and neck squamous cell carcinoma we reported 91% (20/22) showed T cell activity in the blood or tissue.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, we announced that a second patient with HPV-associated head and neck cancer treated with MEDI0457 in the Phase 1 trial achieved a sustained complete response (full remission) after subsequent treatment with a PD-1 checkpoint inhibitor.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both patients who achieved full cancer remission were treated with four doses of MEDI0457. This response indicates that MEDI0457 generated robust HPV-16/18 specific CD8+ T cell responses in peripheral blood and increased CD8+ T cell infiltration in resected tumor tissue samples.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the four patients who developed progressive disease and were subsequently administered a PD-1 checkpoint inhibitor, two patients rapidly exhibited a complete response. The most recent patient for which data was presented in January 2019 received pembrolizumab (KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), while the previously reported complete responder was treated with nivolumab (OPDIVO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The patients moved from metastatic head and neck cancer to no evidence of disease and they remain alive two years after treatment.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasing evidence suggests that response rates from checkpoint inhibitors can be enhanced when used in combination with cancer vaccines like MEDI0457 that generate tumor-specific T cells. Interim data from a MEDI0457 monotherapy study of head and neck cancer patients demonstrated that MEDI0457 generated robust HPV-16/18 specific CD8+ T cell responses in peripheral blood and increased CD8+ T cell infiltration in resected tumor tissue samples.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration with AstraZeneca</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we formed a strategic collaboration with AstraZeneca focused on cancer immunotherapies. Under this agreement AstraZeneca licensed INO-3112 (renamed MEDI0457), to be studied in combination with selected immunotherapy molecules within its pipeline in HPV-associated cancers. See &#8220;Business- License, Collaboration and Supply Agreements&#8221; for additional information about the collaboration agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we announced that AstraZeneca will conduct a Phase 1/2 clinical trial investigating the combination of MEDI0457 and durvalumab, a PD-L1 checkpoint inhibitor. The combination trial will enroll patients with metastatic HPV-associated HNSCC with persistent or recurrent disease after chemotherapy treatment.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The open-label clinical trial is evaluating the safety and efficacy of the combination therapy in 35 subjects with metastatic head and neck cancer at multiple U.S. sites. Subjects will receive multiple doses of MEDI0457 and durvalumab. The primary endpoints of the trial are safety and objective response rate. The trial will also evaluate immunological impact, progression-free survival and overall survival. The Phase 2 portion of this study was initiated in December 2017, and this initiation triggered a $7 million milestone payment from AstraZeneca to us.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we announced the dosing of the first patient in an open-label, Phase 2 combination trial to evaluate MEDI0457, in combination with durvalumab, in patients with HPV-associated cervical, anal, penile and vulvar cancers. This trial, which is being funded by AstraZeneca, has an estimated total enrollment of 77 patients.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first dosing of a cervical cancer patient in this trial resulted in an additional $2.0 million milestone payment from AstraZeneca to us in 2018. A first dosing of a patient with a third distinct HPV-associated cancers other than H&amp;N or cervical triggered another $2.0 million milestone payment in April 2019.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration agreement, AstraZeneca will fund all of the costs of developing MEDI0457.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-5151 (INO-5150 + INO-9012) for the Treatment of Prostate Cancer</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States in 2021, there will be an estimated 248,530 new cases of prostate cancer and more than 34,000 deaths due to this cancer. Worldwide in 2020, an estimated 1.41 million new cases of and nearly 375,000 deaths occurred due to this cancer.  IARC projects that in year 2040, about 2.24 million new cases will occur.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we initiated a Phase 1 trial to evaluate our DNA immunotherapy for prostate cancer, INO-5150, in men with biochemically relapsed prostate cancer. This study is evaluating the safety, tolerability and immunogenicity of INO-5150 alone or in combination with INO-9012 (DNA vector expressing interleukin 12). The multi-centered study is also evaluating changes in prostate specific antigen, or PSA, levels, an important biomarker in prostate cancer. We have fully enrolled 62 patients in the trial across four dose cohorts.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An interim data analysis presented in 2017 at the European Society of Medical Oncology (ESMO) meeting in Madrid, Spain showed that INO-5150 had generated antigen-specific CD8+ killer T cell responses measured in peripheral blood from subjects with biochemically recurrent prostate cancer. Treatment with INO-5150 as a monotherapy generated PSA and prostate specific membrane antigen, or PSMA, specific T cell responses in peripheral blood in 60% (35/58) of the subjects. Patients with specific CD8+ T cell responses experienced dampening in the rise of PSA and significant increases in Prostate Specfic Antigen Doubling Times (PSADT).</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, additional prostate cancer data from the trial was presented at the American Society of Clinical Oncology (ASCO) annual meeting. The additional data showed clinically meaningful PSA stabilization after administration of INO-5150 in patients, with no documented disease progression during the study. Of note, this effect was also observed in the patients with the fastest PSADT at the time of study entry.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we announced new data from the trial in which a slowing of PSADT was observed in men with prostate cancer. Eighty-six percent (86%) of patients remained progression-free at Week 72 of the study, and immunogenicity was observed in 77% (47/61) of patients by multiple immunologic assessments. These data were presented at the 2018 European Society for Medical Oncology (ESMO) congress.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we announced a clinical collaboration agreement with Parker Institute for Cancer Immunotherapy (PICI) and the Cancer Research Institute (CRI) in which INO-5151 will be combined with an immune modulator (CDX-301, FLT3 ligand, a dendritic cell mobilizer) and a PD-1 checkpoint inhibitor (nivolumab) targeting metastatic castration resistant prostate cancer (mCRPC) in a PICI sponsored platform study. INO-5151 is a combined formulation of INO-5150 (with SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> antigens encoding for PSA and PSMA) and INO-9012.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This combination trial is an open-label, non-randomized, exploratory platform study designed to assess the safety and antitumor activity of multiple immunotherapy based combinations in participants with mCRPC who have received prior secondary androgen inhibition. This study will evaluate biomarkers of immune activity and clinical outcomes using a multi-omic, multi-parameter approach. Our immunotherapy is one arm (Cohort C) of this broad PICI-supported study, which is a multi-arm, multi-stage platform design.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, PICI will design and execute the clinical study, working in collaboration with its established network of the most pre-eminent clinical academic and industry cancer centers, and with funding support from CRI. Based on PICI's novel approach to accelerating studies of cancer immunotherapies, we will provide financial contributions based on the actual costs of the study, if our product(s) studied under the collaboration reaches the initiation of a Phase 3 study.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical trial is currently enrolling.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-5401 for the Treatment of Glioblastoma Multiforme (GBM)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Glioblastoma (GBM) is the most common and aggressive type of brain cancer.  The median age at diagnosis is 65 years, and the incidence rate increases with age to the maximum being in the group age 75-84 years.  Its prognosis is extremely poor, despite a limited number of new therapies approved over the last 10 years. From 2013 to 2017 the median overall survival for patients receiving standard of care therapy was approximately 8 months and the five-year survival was 7.2%.  3-year survival has recently been estimated to be 10.5% from data of the 2004 to 2013 period.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, a recently published analysis of data from the 2013 &#8211; 2017 period found an estimated annual GBM incidence of 12,000 cases and projected incidence of 12,800 cases for the year 2020 and nearly 13,000 cases for the year 2021.  </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate INO-5401 is an immunotherapy consisting of three tumor-associated antigens: hTERT, Wilms' tumor gene (WT1) and PSMA. The National Cancer Institute previously highlighted WT1, hTERT and PSMA among a list of attractive cancer antigens, designating them as high priorities for cancer immunotherapy development. WT1 was at the top of the list. The hTERT antigen relates to 85% of cancers and WT1 and PSMA antigens are also widely prevalent in many cancers.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we reported data indicating that our SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> WT1 cancer antigen was capable of breaking immune tolerance, a major challenge to researchers striving to develop potent cancer therapies, and induced neo-antigen-like T cell responses to cause tumor regression in pre-clinical studies. The results were published in the scientific journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Molecular Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While mice in the preclinical study did not mount an immune response to native mouse WT1 antigens, mice immunized with our SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> WT1 antigen broke tolerance and generated robust neo-antigen-like T cells. The immunized mice also exhibited smaller tumors and prolonged survival in a tumor challenge study. SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> WT1 DNA vaccination also broke tolerance and generated neo-antigen-like T cell immune responses in Rhesus monkeys, a species whose immune system closely resembles that of humans. The ability to overcome the immune system&#8217;s usual tolerance of WT1 antigen suggests the potential of our SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> WT1 antigen to tackle any WT1-expressing cancer in humans, including pancreatic, brain, lung, thyroid, breast, testicular, ovarian, and melanoma.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously reported similar results for our SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hTERT and PSMA cancer antigens.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These attributes of breaking tolerance and having broader prevalence across different cancers create the potential for INO-5401 to be an effective universal cancer immunotherapy in combination with different checkpoint inhibitors.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, we dosed the first patient as part of a Phase 1/2 immuno-oncology trial in patients with newly diagnosed GBM. The trial is designed to evaluate INO-5401 and INO-9012, in combination with cemiplimab (Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), a PD-1 inhibitor developed jointly by Regeneron Pharmaceuticals and Sanofi.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The open-label Phase 2 trial of 50 newly diagnosed GBM patients is being conducted at approximately 25 U.S. sites, and the primary endpoint is safety and tolerability. The study will also evaluate immunological impact, progression-free survival and overall survival.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we provided interim results from the Phase 2 study. Key interim data from the 52-patient clinical trial showed that 80% (16 of 20) of MGMT gene promoter methylated patients and 75% (24 of 32) of unmethylated patients were progression-free at six months (PFS6) measured from the time of their first dose, substantially exceeding historical standard-of-care data.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This immunotherapy combination with a PD-1 checkpoint inhibitor also exhibited supportive safety, tolerability, and immunogenicity data and suggested a safety profile consistent with that of Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> as well as our other product candidates. Most patients tested had a T cell immune response to one or more tumor-associated antigens encoded by INO-5401. Immune responses to all three tumor-associated antigens were demonstrated in this study.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we announced that 85% (44 out of 52) of the patients in the Phase 1/2 trial were alive for at least 12 months or more following treatment. The Phase 1/2 clinical trial demonstrated that 84.4% percent (27 of 32) of patients with MGMT promoter unmethylated tumors, and 85% (17 of 20) of patients with MGMT promoter methylated tumors were alive at 12 months. Activated, killer T cells directed towards all three cancer antigens in INO-5401 were detected in all patients tested to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date. INO-5401 + INO-9012 was well-tolerated when given not only with radiation and temozolomide, but also with PD-1 inhibition with Libtayo.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, additional data from the Phase 1/2 study were presented at the Society for Neuro-Oncology (SNO) 2020 Annual Meeting. Survival data at 18 months showed that 70% (14/20) of MGMT promoter methylated GBM patients were alive, and 50% (16/32) of MGMT promoter unmethylated patients, which are the more difficult to treat group, were alive after 18 months. Median overall survival in the unmethylated GBM patients was 17.9 months, which compares favorably to historical controls. Median overall survival for methylated patients has not yet been reached and the study is ongoing.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim data demonstrated that in the MGMT promoter unmethylated cohort, 19/22 (86%) subjects had an IFN-gamma T cell response that increased over baseline to one or more of the antigens encoded by INO-5401. In the MGMT promoter methylated cohort, 16/17 (94%) subjects had an IFN-gamma response that increased over baseline to one or more of the antigens encoded by INO-5401. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Infectious Disease Product Candidates</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development platform also allows for rapid design, pre-clinical testing, manufacturing and clinical development of our vaccine and immunotherapy product candidates. In 2016, we were the first entity able to advance a Zika vaccine into human clinical trials, just 4.5 months after the World Health Organization, or WHO, declared the emerging Zika infections to be a Pandemic Health Emergency of International Concern. Previously, we led the development of the first MERS vaccine in human clinical trials. More recently, our DNA medicines platform and SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sequencing capabilities allowed us to rapidly respond to the coronavirus outbreak of 2020. We believe that our development platform is well positioned to support global health agencies in order to develop preparedness countermeasures against bioterrorism and/or emerging pandemic agents.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-4800 for COVID-19 </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background on COVID-19</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A novel strain of coronavirus emerged in the human population in Wuhan City, China in November-December 2019. On December 31, 2019 the World Health Organization (WHO) China Office was informed of a number of pneumonia cases of unknown etiology appearing in the previous few days in Wuhan, China. On January 8, 2020, Chinese scientists announced the identification of a new Coronavirus associated with this pneumonia outbreak, and on January 11, they publicly shared the genetic sequence of that new virus. The new virus was temporarily referred to as &#8220;2019-nCoV&#8221; and &#8220;2019 novel coronavirus,&#8221; among other names, but subsequently was named SARS-CoV-2 due to the large similarity of its genetic sequence with that of the original severe acute respiratory syndrome coronavirus (SARS coronavirus or SARS-CoV). The new virus is a member of the genus of Coronaviruses, which is comprised of seven known viruses that can infect and make humans ill, including Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). This novel coronavirus is part of the Coronaviridae family of viruses that include the high risk viruses MERS-CoV and SARS-CoV, and four other lower risk coronaviruses which can cause the common cold. The disease caused by the SARS-CoV-2 novel coronavirus was subsequently named &#8220;COVID-19&#8221;.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During this emergence, on January 30, 2020 the WHO declared a Public Health Emergency of International Concern (PHEIC), and on March 11, 2020 the WHO declared this to be a pandemic.  In the continued evolution of the pandemic since then, it has become clear that this is already one of the worst pandemics in recorded history, using the metric of the absolute number of caused deaths.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The virus quickly spread throughout China, Asia, and worldwide. As of February 2021, every country on earth has reported confirmed cases. A total of more than 100 million confirmed cases had been reported worldwide, with a total of nearly  2,300,000 reported deaths due to this disease, although the actual number of cases is far higher than the reported number.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The case-fatality ratio (aka case-fatality rate) for COVID-19 in the U.S. to date is about  0.60% in the United States, which is significantly lower than that of SARS (10%) and MERS (about 34%) but significantly higher than for seasonal influenza (0.1%). Estimates of the reproductive number (R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), or the average number of persons one infected person in turn infects, of SARS-CoV-2 in populations largely before significant community, travel, and business restrictions (aka &#8220;lockdowns&#8221;) were implemented ranged from 2.2 to somewhat above 4.0, with an average of about 3.8. The R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for this novel coronavirus then appeared to be significantly higher than that of MERS-CoV (&lt; 1.0) and the original SARS-CoV (about 2.0). It is the combination of the significant R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the significant case-fatality ratio, and the primary airborne transmission route of this respiratory disease that led to this new coronavirus and disease to become one of the most serious pandemics in modern history.  Presently, several major variants of SARS-CoV-2 have evolved and spread significantly from several portions of the globe and quickly to many countries.  Each of these major variants have the characteristics of at least having a significantly increased transmission rate with respect to the original/main SARS-CoV-2 strain.  However, some also have or appear to be likely developing significantly diminished susceptibility to one or more of the emergency-use authorized vaccines.  Further, evidence is emerging that at least one of the variants has possibly increased pathogenicity as measured by case-fatality.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Development</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded us a grant of up to $9 million to develop a vaccine against COVID-19. Our candidate, INO-4800 targets the major surface antigen Spike protein of SARS-CoV-2 virus, which causes COVID-19 disease.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we announced the publication of preclinical study data demonstrating robust neutralizing antibody and T cell immune responses against coronavirus SARS-CoV-2 in the peer-reviewed journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature Communications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the preclinical studies, INO-4800 demonstrated virus neutralizing activity using three separate neutralization assays testing the vaccine's ability to generate antibodies which can block virus infection by: 1) an assay using live SARS-CoV-2 viruses; 2) an assay using a pseudo-virus assay, where another virus displays the SARS-CoV-2 Spike protein; and, 3) a novel high-throughput surrogate neutralization assay measuring the ability of INO-4800-induced antibodies to block SARS-CoV-2 Spike binding to the host ACE2 receptor. Researchers also detected these antibodies in the lungs of the vaccinated animals which could be important in providing protection from SARS-CoV-2. In addition, high levels of Spike-specific T cell responses were observed with INO-4800 vaccination, which could be important in mediating protection from the virus infection. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we announced that INO-4800 was effective in protecting non-human primates (NHPs), specifically rhesus macaques, from live virus challenge 13 weeks after the last vaccination. These protective results were mediated by memory T and B cell immune responses from INO-4800 vaccination.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In these studies, INO-4800 reduced viral load in both the lower lungs and nasal passages in macaques that received two doses of INO-4800 (1 mg) four weeks apart and then were challenged with live virus 13 weeks after the second dose (study week 17). The reduced viral loads following exposure to SARS-CoV-2 infection at this timeframe demonstrated an important durable impact mediated by INO-4800.  This is the first time a vaccine protection in non-human primates was reported from memory immune responses as previously reported monkey vaccine challenge studies were conducted at the time near their peak immune responses (1-4 weeks from their last vaccination).</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INO-4800-treated animals demonstrated seroconversion after a single vaccination, with protective neutralizing antibodies and T cells lasting in their blood more than four months after the initial dose. The antibody levels were similar to or greater than those seen in patients who have recovered from COVID-19, and the T cell responses were significantly higher than those from convalescent patients.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1 Clinical Trial</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced the publication of peer-reviewed Phase 1 clinical data from the first cohort of 40 participants for INO-4800. In this trial, INO-4800 was immunogenic in all vaccinated subjects, generating an immune response of humoral (including neutralizing antibodies) and/or cellular responses (both CD4+ and CD8+ T cells).</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Phase 1 clinical data found INO-4800 to have a favorable safety and tolerability profile with no serious adverse events reported. Only six Grade 1 adverse events (AEs) were observed, primarily minor injection site reactions. Notably, these only occurred on the day of the first or second dosing, and the AEs did not increase in frequency with the second administration. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Phase 2/3 Clinical Trial &#8211; INNOVATE</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced the dosing of the first subject in our Phase 2 clinical trial evaluating INO-4800, as part of our Phase 2/3 clinical trial, called INNOVATE (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OVIO I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-4800 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Va</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ccine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rial for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fficacy). The Phase 2 segment of the trial has enrolled approximately 400 participants who are 18 years or older at up to 17 U.S. sites to evaluate safety and immunogenicity in order to confirm the dose(s) for the subsequent efficacy evaluation as part of the Phase 3 segment of the trial. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 2 segment of the trial is designed to evaluate safety, tolerability and immunogenicity of INO-4800 in a 2-dose regimen (1.0 mg or 2.0 mg), in a three-to-one randomization to receive either INO-4800 or placebo to confirm the more appropriate dosing level(s) for each of three age groups (18-50 years, 51-64 years and 65 years and older) at high risk of SARS-CoV-2 exposure for the subsequent Phase 3 efficacy evaluation.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The INNOVATE Phase 3 segment is planned as a randomized, blinded, placebo-controlled safety and efficacy evaluation of INO-4800 being conducted in adults 18 years and older. The INNOVATE trial is funded by the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD (HA)) and the Defense Health Agency (DHA). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DoD has agreed to provide funding for both the Phase 2 and Phase 3 segments of INNOVATE, in addition to the $71.1 million of funding previously announced in June for the large-scale manufacture of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP, production of doses and the procurement of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2000 devices.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">INO-4800 in China</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced the dosing of the first subject in our Phase 2 clinical trial of INO-4800 in China. The Phase 2 clinical trial being conducted in China is independent of the INNOVATE Phase 2/3 clinical trial of INO-4800 and will enroll approximately 640 participants who are 18 years or older. Our collaborator Advaccine is conducting and funding the Phase 2 trial in China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Phase 2 clinical trial of INO-4800 in China has enrolled both 18-59 years old adults and older adults (60 years and older) with the primary endpoints of evaluating safety and immunogenicity within the Chinese population. The dosing regimen involves two vaccinations at 0 and 28 days with either 1.0 mg or 2.0 mg dosing levels and is similar to the Phase 2 segment of the INNOVATE trial. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">INO-4800 in South Korea</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   In June 2020, we announced a partnership with the International Vaccine Institute (IVI), and Seoul National University Hospital to start a Phase 1/2 clinical trial of  INO-4800 in South Korea. The two-stage trial of INO-4800, the first clinical study of COVID-19 vaccine in Korea, will assess the safety, tolerability, and immunogenicity of INO-4800 in 40 healthy adults aged 19-50 years, and will further expand to enroll an additional 120 people aged 19-64 years. The trial is funded by CEPI through us and is supported by the Korea Center for Disease Control and Prevention/Korea National Institute of Health.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 dMAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced that we along with a team of scientists from The Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University received a $37.6 million grant from the U.S. Defense Advanced Research Projects Agency (DARPA), a research and development agency of the DoD and the JPEO-CBRND, to use our dMAb technology to develop anti-SARS-CoV-2-specific dMAbs that function as both a therapeutic and preventive treatment for COVID-19. See &#8220;Synthetic DNA-based Monoclonal Antibodies Program&#8221; below for more information about our dMAb technology.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of DARPA's two-year grant, our and Wistar teams will construct COVID-19 dMAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> candidates mirroring AstraZeneca's traditional recombinant monoclonal antibody candidates currently being tested in clinical trials to treat COVID-19. These dMAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> candidates can be quickly developed and produced </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, offering a cost-effective and scalable therapeutic and preventive option for treatment of SARS-CoV-2 virus infection. The dMAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> candidates will then be advanced into preclinical studies and then into human clinical trials.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global Manufacturing Consortium for INO-4800</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we announced with Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), that the DoD awarded Ology Bioservices with a contract valued at $11.9 million to work with us on rapid manufacture DNA vaccines. This work is supported by the Office of the Assistant Secretary of Defense for Health Affairs with funding from the Defense Health Agency. Under this program, Ology Bioservices will work with us to manufacture INO-4800.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we received a $5 million grant from the Bill &amp; Melinda Gates Foundation to accelerate the testing and scale up of CELLECTRA&#174; 3PSP proprietary smart devices for the intradermal delivery of INO-4800.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we announced an agreement to expand our manufacturing partnership with the German contract manufacturer Richter-Helm BioLogics GmbH &amp; Co. KG, to support large-scale manufacturing of INO-4800.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we announced that Thermo Fisher Scientific signed a letter of intent to manufacture INO-4800. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thermo Fisher plans to manufacture INO-4800 drug substance as well as perform fill and finish of INO-4800 drug product at its commercial facilities in the United States.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced the execution of an agreement with Kaneka Eurogentec S.A., an affiliate of Kaneka Corporation, for Eurogentec to manufacture INO-4800 at their GMP plasmid production scales. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Variants of Concern (VOC) </span></div><div style="margin-top:5pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been closely monitoring the development and evolution of SARS-CoV-2, with a particular focus on the UK, South African and Brazilian variants of the virus. We are currently evaluating the impact of newly circulating strains of the SARS-CoV-2 virus on the immune profile of INO-4800 through an assessment of binding antibodies, neutralizing antibodies in both live and pseudo assays as well as assessing the impact of the INO-4800-generated T cell responses on these variants. </span></div><div style="margin-top:5pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also developing next-generation, pan-COVID vaccine candidates, that could be tailored to the known and potentially the unknown SARS-CoV-2 variants. Using our SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene optimization algorithm to analyze the available sequence data from all existing circulating variants, we are seeking to create a synthetic SAR-CoV-2 spike protein gene design intended to protect against the known VOC as well the future unknown strains. Our DNA vaccines generate a balanced immune response, including T cell responses,which we believe could make our pan-COVID vaccine candidates less susceptible to changes in the genetic sequence of the virus. DNA vaccines can also be used for multiple boosts without being impacted by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anti-vector immunity or an increase in reactogenicity. Moreover, pre-clinical studies and clinical trials have shown that DNA vaccines could also be used to boost the initial immune responses generated by multiple other vaccine platforms.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-4700 for Middle East Respiratory Syndrome (MERS)</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background on MERS</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Middle East Respiratory Syndrome or MERS is a viral respiratory illness first reported in Saudi Arabia in 2012. MERS appears to have been transmitted from an animal reservoir to humans but human to human transmission has been confirmed. The virus for this disease belongs to the Coronaviradea family (or a coronavirus &#8211; MERS-CoV), and was not shown to be a communicable virus spreading in a sustained way in communities, but rather via rapid spread in the nosocomial setting, such as emergency rooms and/or hospitals without adherence to state-of-the-art infection control practices, which can result in outbreaks with many cases, including super-spreading events. Like the severe acute respiratory syndrome (SARS) outbreak in 2003 linked to another coronavirus (SARS-CoV-1), which made approximately 8,000 people ill and was fatal in nearly 10% of those cases, MERS-CoV appears to cause severe lung infections. However, the case-fatality rate (death rate) of MERS has typically been between 30% and 40%, which is significantly higher than that of SARS. While the SARS epidemic in 2003 killed 10% of those who became ill from the SARS virus, MERS has killed approximately 34% of people who people who became ill from the MERS virus from 2012 to January 2020. MERS differs in that it also causes rapid kidney failure. Its high death rate has caused serious concern among global health officials.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the continuing threat of MERS outbreaks, there are no licensed vaccines or treatments for MERS. Since the virus was first identified in Saudi Arabia in 2012, the World Health Organization reports 2,519 laboratory-confirmed cases of MERS and 866 deaths from MERS worldwide as of January 2020. Twenty-seven countries have reported cases, including Korea where an outbreak in the summer of 2015 resulted in 186 cases and 38 deaths. The majority of MERS cases reported in the world by country have been reported from the Kingdom of Saudi Arabia, with a total of 2,121 cases, 788 associated deaths, and a case-fatality rate of 37% from 2012 through January 2020. Of those cases to date in Saudi Arabia, nearly 20% have been in healthcare workers.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Development &#8211; MERS </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, we announced that preclinical testing of our SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> MERS vaccine candidate, INO-4700 (also known as GLS-5300), had induced robust and durable immune responses in mice, demonstrating the potential for such a vaccine to prevent and treat this deadly virus. DNA medicine constructs targeting multiple MERS antigens were designed using our SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine platform with the goal to universally protect against multiple strains of MERS, which has been shown to have diverse genetic variants. These SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> constructs were administered via our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery technology.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A consensus MERS "spike" protein vaccine construct was created based on multiple strains of the MERS virus.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we announced that our MERS vaccine had induced 100% protection from a live virus challenge in a preclinical study in mice, camels and monkeys, or non-human primates. In all three species, the vaccine induced robust immune responses capable of preventing the virus from infecting cells. We believe the data from camels is an important finding because camels represent not only a host reservoir of the disease, but also act as a mode of transmission to humans. In monkeys, all vaccinated animals in the study were protected from symptoms of MERS disease when challenged with a live MERS virus.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preclinical results appeared in the peer-reviewed journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Science Translational Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development &#8211; MERS </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we and our collaborator GeneOne commenced a Phase 1, dose-escalation clinical trial of INO-4700 in 75 healthy volunteers at the Walter Reed Army Institute of Research (WRAIR) in Maryland. The primary and secondary goals of this Phase 1 trial are to obtain safety and immunogenicity data. This trial represents the first MERS vaccine to be tested in humans for this disease that has no approved vaccines or treatments.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we announced that the International Vaccine Institute (IVI) will provide new funding and support to further advance the clinical development of INO-4700. IVI will add technical, laboratory and financial support for INO-4700 clinical trials in Korea with the goal to advance clinical testing toward emergency use authorization by the Korean government as well as authorities of other countries. This collaborative funding is part of a grant from the Samsung Foundation to IVI to support the development of a MERS vaccine for emergency use in Korea and internationally.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, we announced a collaboration with CEPI under which we will develop vaccine candidates against MERS. CEPI will fund up to $56 million of costs to support our pre-clinical and clinical advancement through Phase 2 of INO-4700. The goal of the collaboration is for the MERS vaccine to be available as soon as possible for emergency use.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, we announced positive results from the Phase 1 trial of INO-4700 for MERS. In the trial, treatment with INO-4700 was well tolerated and resulted in overall high levels of antibody responses in roughly 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants. Antibody responses were observed in 94% of subjects at week 14 (two weeks after the third dose). Additionally, there were no statistically significant dose-dependent </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">differences in antibody response rates (91%, 95%, and 95% at doses of 0.67, 2, and 6 mg, respectively). Durable antibody responses were also maintained through 60 weeks following dosing. These results were published in The Lancet Infectious Diseases in a peer-reviewed article entitled, "Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: A phase 1, open-label, single-arm, dose-escalation trial." </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we announced the dosing of the first subject in a Phase 1/2a study of INO-4700 for MERS in South Korea funded by IVI.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we announced interim data through week 16 from a Phase 1/2a trial of DNA vaccine INO-4700. Vaccine recipients demonstrated strong antibody and T cell immune responses after 2 or 3 doses with 0.6 mg, delivered intradermally with our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> device. The vaccination regimen was well-tolerated with no vaccine-associated severe adverse events (SAEs). The researchers at the Wistar Institute, Seoul National University Hospital, and the International Vaccine Institute (IVI) collaborated on this study.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For those receiving 0.6 mg of INO-4700, 88% demonstrated seroconversion after a 2 dose regimen at 0 and 8 weeks, while for those receiving a 3 dose regimen given at 0, 4 and 12 weeks, 84% seroconverted after 2 doses and 100% after 3 doses, as measured by a binding antibody assay against the full-length S protein (ELISA). Additionally, 92% of the vaccine recipients in both groups displayed the ability to neutralize the virus using a pseudotype-based neutralization assay. Robust T cell responses were observed in 60% of vaccine recipients after the 2 dose regimen and 84% of those in the 3 dose group (ELISpot assay). A single dose of 0.6 mg of INO-4700 intradermal vaccination resulted in 74% binding antibody response rate and 48% neutralization antibody response rate.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-4212 for Ebola Virus Disease</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background on Ebola</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ebola virus causes one of the most virulent viral diseases, with case fatality rates averaging 50% but approaching up to 90% in past outbreaks in areas with no or under-developed health care. Ebola can spread through human-to-human transmission by direct contact with the blood, secretions, organs or bodily fluids of an infected individual and with surfaces or materials that contain the contaminated fluids of an infected person, such as bedding and clothing. It is capable of causing death within two to twenty-one days of exposure. In November 2019, the first conditional approval was issued for a preventive vaccine against Ebola virus. This approval was from the EMA for the vaccine ERVEBO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. That same month, the WHO pre-qualified that vaccine for use in high-risk countries. In the next month, the FDA approved that vaccine. However, there are no proven effective therapeutic treatments for Ebola. In addition, various experimental approaches have already been associated with undesirable side effects and limited ability to scale manufacturing.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the CDC, the 2014 West Africa Ebola epidemic was the largest Ebola outbreak in world history, resulting in 28,610 suspected and confirmed cases and 11,308 deaths as of June 2016, when it was declared over.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, two Ebola outbreaks occurred, both in the Democratic Republic of Congo (DRC). The second Ebola outbreak of 2018 in the DRC became the second largest Ebola outbreak in world history. This particular outbreak had a 66% case-fatality ratio (aka case-fatality rate) as of February 2020. On June 1, 2020 an additional Ebola outbreak was declared in the DRC, before the outbreak was declared over on November 18, 2020.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical and Clinical Development - Ebola</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, we entered into a collaboration with GeneOne to advance a DNA immunotherapy for Ebola into clinical development. The decision to advance our Ebola immunotherapy was based on positive results observed in preclinical studies, in which 100% of immunized guinea pigs and mice were protected from death after being exposed to the Ebola virus. Unlike the non-immunized animals, immunized animals were also protected from weight loss, a measure of morbidity. Researchers found significant increases in neutralizing antibody titers and strong and broad levels of immunotherapy-induced T cells, including "killer" T cells, suggesting that DNA immunotherapy could provide both preventive and treatment benefits. This data was published in 2013 in the peer-reviewed journal Molecular Therapy.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we received a contract from DARPA to lead a consortium to develop multiple treatment and prevention approaches against Ebola. Other collaborators include AstraZeneca, GeneOne and David B. Weiner, Ph.D., a director of our company, who also serves as executive vice president at the Wistar Institute. A previous collaboration agreement with GeneOne for Ebola was incorporated into this consortium funded by DARPA.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are taking a multi-faceted approach to develop products to prevent and treat Ebola infection. These programs include development and early clinical testing of:</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">A therapeutic DNA-based monoclonal antibody product against the Ebola virus infection, which we believe has properties that best fit a response to the outbreak in that they could be designed and manufactured expediently on a large scale using common fermentation technology, are thermal-stable, and may provide more rapid therapeutic benefit;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">A highly potent conventional protein-based therapeutic monoclonal antibody (mAb) product against Ebola virus infection; and</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">A DNA-based vaccine against Ebola.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract with DARPA covers the pre-clinical development costs for the dMAb products and protein mAb candidates, as well as GMP manufacturing costs and the Phase 1 clinical trial costs for the three product candidates described above.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we and our collaborators initiated a Phase 1 clinical trial of INO-4212, an Ebola DNA vaccine to evaluate its safety, tolerability and immune responses in 75 healthy subjects divided into five study arms. INO-4212 consists of two optimized SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> DNA plasmids coding for the Ebola glycoprotein antigen from circulating Ebola strains from 1975-2014. The study was designed to evaluate INO-4212 and its components, alone or in combination with our product candidate INO-9012, delivered into muscle or skin using our proprietary DNA smart delivery technology.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we reported initial results from the trial. Of 69 evaluated subjects, 64 (92.8%) seroconverted and mounted a strong antibody response to the Ebola glycoprotein antigen following the three dose immunization regimen; 48 subjects (69.6%) seroconverted after only two doses.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the study arm using intradermal (skin) administration, 13 of 13 evaluable subjects (100%) generated antigen-specific antibody responses after only two doses, and all remained seropositive after three immunizations. Similarly, in the study arm receiving the vaccine with intramuscular administration in combination with plasmid IL-12, 13 of 13 evaluable subjects (100%) produced strong antibody responses after three immunizations, and 12 of 13 (92.3%) achieved strong antibody responses after only two immunizations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ebola glycoprotein specific geometric mean antibody titers measured in the five cohorts ranged from over 2,000 to greater than 46,000. Significantly, a majority of vaccinated subjects in each of the five cohorts produced strong Ebola antigen specific T cell responses as measured by interferon gamma ELISpot analysis.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INO-4212 was well tolerated, with no systemic serious adverse effects observed. Side effects, such as fever, joint pain, and low white blood cell counts have previously been reported following treatment with some viral vector based Ebola vaccines currently in development. Moreover, unlike the viral vectored vaccines which must be kept frozen, the INO-4212 formulation used in the trial was kept in a solution which was refrigerated at 2-8 degrees Celsius.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we announced that enrollment of this study was being expanded to up to 200 subjects to further characterize and identify in humans the most optimal immunization regimen using intradermal (skin) delivery of the Ebola DNA vaccine.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we reported preliminary results from the expanded Phase 1 trial. Across both stages of the trial, including both intramuscular and intradermal delivery, 95% (170/179) of evaluable subjects generated an Ebola-specific antibody immune response, with the mean antibody titer comparable or superior to those reported from viral vector-based Ebola vaccines. Our Ebola vaccine was also well tolerated in the second stages of the trial, with a favorable safety profile compared to viral vector-based Ebola vaccines, some of which have been associated with serious adverse events including myalgia, arthralgia, fever, and rash.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we announced that INO-4212 provided 100% protection following a challenge with a lethal dose of the Ebola virus in a preclinical study. An article in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of Infectious Diseases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">highlighted that regimens of the INO-4212 vaccine delivered by intramuscular administration provided 100% protection against a lethal Ebola challenge in all preclinical animals. In a separate study, two injections by intradermal administration generated strong immunogenicity and provided 100% protection against a lethal Ebola challenge. In the study, scientists observed that vaccination induced long-term immune responses in monkeys that were detectable for at least one year after the final vaccination.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Phase 1 clinical data of our Ebola vaccine candidate INO-4201 was published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Journal of Infectious Diseases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe that this study, which is being fully funded by DARPA, further supports the advancement of the intradermal delivery platform for emerging infectious diseases. Significantly, intradermal (skin) administration with our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery device resulted in 100% of evaluable subjects in the study generating antigen-specific antibody responses that persisted for more than one year in most subjects and generated T cell responses equivalent to or better than the group that received intramuscular delivery. We believe these published data further validate the tolerability, potency, and product stability advantages of our vaccine and immunotherapy platform.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Ebola vaccine candidate was evaluated in five groups of healthy subjects. Of 70 evaluated subjects, 67 (96%) seroconverted and mounted a strong antibody response to the Ebola glycoprotein antigen following the three dose immunization regimen; 52 subjects (74%) seroconverted after only two doses.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the study arm using intradermal (skin) administration, 13 of 13 evaluable subjects (100%) generated antigen-specific antibody responses after only two doses and all remained seropositive after three immunizations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date INO-4201 has been well-tolerated and has not demonstrated systemic serious adverse effects, such as fever, joint pain, and low white blood cell counts, reported in association with some viral vector-based Ebola vaccines currently in development.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-4500 for Lassa Fever</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background on Lassa Fever</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lassa fever, also known as Lassa hemorrhagic fever, is an acute viral disease which occurs mostly in West Africa. The disease can cause a range of outcomes including fever, vomiting, diarrhea, cough, and swelling of the face, pain in the muscles, chest, back and abdomen, bleeding of various parts of the body including the eyes and nose, vagina, and gastrointestinal tract, and death. Of the survivors of Lassa fever, about one-third have sudden-onset hearing loss, with more than half of those cases resulting in permanent hearing loss. This infection is spread through contact with infected rodents. Person to person transmission is also possible, via bodily fluids, albeit less common. Lassa virus infection in West Africa is estimated to affect 100,000 to 300,000 people annually, resulting in approximately 5,000 deaths, as disease and infection surveillance has been poor. Because of difficulties in diagnosing Lassa fever and the remoteness of many areas in which the disease occurs, the numbers of cases and deaths are likely significantly under-reported. Though the majority (about 80%) of Lassa virus-infected persons are asymptomatic or have mild symptoms, the infection can be quite serious to fatal in others. There are no licensed vaccines or treatments specifically for Lassa. The case-fatality ratio (aka case-fatality rate) (CFR) among patients hospitalized for Lassa fever is about 15% to 20%, and in some epidemics the CFR has reached 50% in hospitalized patients, such as in the 2015-2016 Nigeria portion of the West Africa outbreak. In lab confirmed cases in Nigeria from 2019 through 2020, the CFR was 21%. The CFR among pregnant women is particularly high, and in pregnant women infected with Lassa virus the fetal death rate due to spontaneous abortion rate is estimated to be about 95%.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trials</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we dosed our first patient in our Phase 1, first-in-human clinical trial to evaluate INO-4500, a DNA candidate vaccine to prevent infection from the Lassa virus. In 2019, we fully enrolled 60 volunteers in this placebo controlled, blinded, dose escalation study evaluating INO-4500 for safety, tolerability and immune responses. This trial represents the first Lassa candidate vaccine to enter the clinic. Our sponsored trial, as well as our INO-4500 program, is fully funded through the global partnership with CEPI that we entered into in April 2018.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the results of this study are positive, we expect to advance INO-4500 into both Phase 1b and Phase 2 field trials in endemic countries of West Africa. If satisfactory Phase 2 data are achieved, CEPI, in cooperation with local regulatory authorities and the WHO, could elect to stockpile the vaccine for future use throughout the region. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Development Candidates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-1800 for the Treatment of Hepatitis B Virus</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although an effective preventive vaccine against hepatitis B virus, or HBV, infection has existed for over three decades, HBV remains a major epidemic, especially among people of Asian and African descent. The World Health Organization estimates that 2 billion people globally are or have been infected with HBV, with over 257 million people chronically infected with the virus and at risk of developing the major complications of cirrhosis or liver cancer. It is estimated that over two million people in the United States are chronically infected with the virus, including those who were foreign-born. Currently, the only therapies available for chronically infected individuals are interferon-alpha and nucleoside analog treatments, which function by controlling viral replication, but they do not clear infection. Interferon can prevent viral replication in only 30% of patients and does so with undesirable side effects.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liver cancer is the fourth most common cause of death from cancer worldwide, and it kills the vast majority of patients within five years of diagnosis in the U.S. Approximately 900,000 new cases arose in 2020 worldwide. Liver cancer is estimated to have 42,230 new cases occur and kill more than 30,000 U.S. persons in 2021. One of the major causes and risk factors for liver cancer is infection by hepatitis B. Chronically infected individuals may develop a permanent scarring of the liver, a condition called cirrhosis. Liver cirrhosis can evolve into hepatocellular carcinoma, which claimed an estimated 830,000 lives worldwide in 2020.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INO-1800 is encoded for the HBcAg antigen and represents a consensus of the unique HBcAg DNA sequences of all major HBV genotypes (A through E). When delivered by CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in a preclinical study, INO-1800 elicited strong HBcAg-specific T cell and antibody responses in the periphery (outside of the liver) as measured by ELISpot, ICS and cell proliferation assays. Researchers observed that the immunization could also induce antigen-specific CD8+ and CD4+ T cells that produced both IFN-y and TNF-a in the liver, indicating that a strong immunotherapy-induced T cell response was also present in the liver.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the preclinical study, the antigen-specific T cells exhibited a killing function and were able to migrate to and stay in the liver and cause clearance of target cells without any evidence of liver injury. This was the first study to provide evidence that intramuscular immunization could induce killer T cells that can migrate to the liver and eliminate target cells.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we initiated a Phase 1 trial to evaluate INO-1800 in patients chronically infected with HBV. This randomized, open-label, active-controlled, dose escalation study was designed to evaluate the safety, tolerability and immunogenicity of INO-1800 alone or in combination with INO-9012. This international study enrolled patients in the United States and Asia Pacific region with a primary endpoint of safety and tolerability of the therapy. Secondary endpoints are evaluating the cellular and humoral immune response to INO-1800 and its effect on several viral and antiviral parameters. All trial subjects are also medicated with standard-of-care antiviral therapies.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we announced interim results from the trial, in which INO-1800 was well-tolerated and generated virus-specific T cells, including CD8+ killer T cells, meeting the objectives of the clinical study. Preliminary immunology data from the trial revealed that treatment of patients with INO-1800 resulted in the generation of T cells that recognized key components of the hepatitis B virus and reacted by making antiviral cytokines such as Interferon gamma, a protein believed to be linked to clearance of HBV from the liver. In the trial, INO-1800 was also able to activate and expand CD8+ killer T cells that displayed markers believed to be important for retention in the liver as well as multiple potential mechanisms for killing virally infected cells.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently seeking a collaboration partner in order to further advance the clinical development of INO-1800.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Synthetic DNA-based Monoclonal Antibody Programs</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background on recombinant Monoclonal Antibodies (mAbs)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recombinant mAbs have become one of the most valuable therapeutic technologies of recent years. In 2020, global sales of mAbs exceeded $100 billion.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mAbs are designed to bind to a very specific epitope (area) of an antigen or cell surface target and can bind to almost any selected target. They have the ability to alert the immune system to attack and kill specific cancer cells (as in the case of Yervoy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) or block certain biochemical pathways (such as those leading to rheumatoid arthritis, as in the case of Humira</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). However, mAb technology has limitations. mAbs are manufactured outside the body and require costly large-scale laboratory development and production. Additional limitations include high cost to develop and manufacture, their limited duration of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> potency, and a pharmacokinetic profile that can result in toxicity. We have created DNA encoded monoclonal antibodies that we believe may overcome many of the limitations associated with conventional mAb technology.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using our core platform technology, we insert the DNA sequence for a specific monoclonal antibody in a DNA plasmid. We deliver the plasmid directly into cells of the body using our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery system, enabling the electroporated cells to manufacture those mAbs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, - unlike conventional mAb technology that requires manufacture outside of the body. We believe this approach provides potentially significant advantages in terms of design simplicity, rapidity of execution and lower production costs.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to design dMAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates not only for new disease targets not currently addressable with conventional recombinant mAbs, but also targets of existing, commercially available mAb products. We have already designed and produced dMAb product candidates targeting cancer mechanisms including checkpoint inhibition, anti-cancer pathways and anti-Tregs, as well as prophylactic and therapeutic dMAb product candidates for infectious diseases including Ebola, influenza, antibiotic resistant bacteria, dengue and Chikungunya.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proof of Concept</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first published research on a DNA-based monoclonal antibody was presented in October 2013 in the journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Human Vaccines &amp; Immunotherapeutics.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In a preclinical study, a single administration in mice of a highly optimized dMAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;HIV immunotherapy generated antibody molecules in the bloodstream that possessed desirable functional activity, including high antigen-binding and HIV-neutralization capabilities, against diverse strains of HIV viruses. In the study, this delivery strategy resulted in an increase in Fab levels in as little as 48 hours, when compared with protein-based immunization.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A second paper was published in July 2015 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Scientific Reports,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a&#160;Nature Publishing Group&#160;journal. In this study, a single intramuscular injection of a DNA plasmid encoding a monoclonal antibody targeting dengue protected mice subsequently exposed to the dengue virus. The protection conferred by the monoclonal antibodies expressed by these dMAb product candidates was very rapid, with 100% survival in mice challenged with lethal enhanced dengue disease less than a week after dMAb administration. While conventional vaccine and monoclonal antibody technologies have shown limited ability to provide an effective solution to dengue to date, the unique attributes and data generated by dMAb immunotherapies show their potential to provide a needed solution. Furthermore, this short time frame to achieve full protection is significantly more rapid than vaccine-driven protection, which can take weeks to months to reach peak efficacy levels.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A paper published in March 2016 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Journal of Infectious Diseases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;discussed the results of our preclinical study in which animals transfected with our DNA-based mAb targeting Chikungunya virus (CHIKV) exhibited the specific ability to bind to the CHIKV envelope antigen, and this serum possessed CHIKV-neutralizing activity. CHIKV is a serious mosquito-borne alpha-virus responsible for several recent epidemics in tropical Africa and Asia. In mid-2015, the CDC reported that suspected or confirmed cases of Chikungunya had reached 1.74&#160;million in 45 countries or territories in the Americas. There is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">currently no vaccine or therapeutic against this virus. In the study, the treatment of the animals with anti-CHIKV mAb plasmids protected 100% of the treated animals from a lethal injection of CHIKV virus while 100% of the control animals died. The treated animals were also spared virus-related morbidity, as measured by dramatic weight loss and lethargy.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Next Steps</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2014, DARPA awarded a $12.2 million grant to our scientists and those from the Perelman School of Medicine at the University of Pennsylvania and AstraZeneca in order to develop and assess dMAb product candidates in preclinical studies.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This collaboration aims to demonstrate that DNA plasmids can activate sufficient quantities of disease-specific monoclonal antibodies in the body to be protective against a pathogen challenge. Using the capabilities and advantages of DNA plasmids delivered using CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the team is constructing and evaluating multiple dMAb product candidates focused on influenza virus and antibiotic resistant bacteria, such as Pseudomonas aeruginosa and Staphylococcus aureus.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we expanded the collaboration to include The Wistar Institute after the collaborating investigator, Dr. David Weiner, a member of our board of directors, moved to the Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the outcome of the preclinical studies, we and our collaborators may seek to advance a dMAb product candidate into clinical trials, if we are able to obtain additional governmental or non-governmental funding to do so.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, in April 2015, we received a grant from DARPA to lead a consortium to develop multiple treatment and prevention approaches against Ebola. The aim of the research funded by this grant is to compare combinations of a DNA vaccine with conventional or DNA-based monoclonal antibodies.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, we announced that our DNA-based monoclonal antibody technology will be deployed to develop product candidates which could be used alone and in combination with other immunotherapies in the pursuit of new ways to treat and potentially cure infection from HIV. Funding for this research is part of a&#160;$23 million&#160;grant from the&#160;National Institutes of Health&#160;to&#160;our collaborator, The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, we have also received a&#160;sub-grant through&#160;The Wistar Institute&#160;to develop a DNA-based monoclonal antibody designed to provide a fast-acting treatment against Zika infection and its debilitating effects.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we announced that in collaboration with The Wistar Institute and the University of Pennsylvania, the first subject was dosed as part of the first-ever human study of our dMAb technology. Funded fully by the Bill &amp; Melinda Gates Foundation, this trial's focus is on the safety and tolerability of DNA plasmid encoding for a human anti-Zika antibody. This open-label trial is a single center, dose escalation trial that enrolled 24 healthy volunteers who received from one to four doses of INO-A002, inovio&#8217;s DNA plasmid encoding for a human anti-Zika antibody. Doses ranges from 0.5 mg to 4 mg of plasmids injected per subjects, independent of their body weight.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, we have received grant funding to develop anti-SARS-CoV-2-specific dMAbs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to function as both a therapeutic and preventive treatment for COVID-19.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License, Collaboration, Supply and Other Agreements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various arrangements with corporate, academic, and government collaborators, licensors, licensees and others. These arrangements are summarized below.</span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into a Collaboration and License Agreement (the &#8220;Agreement&#8221;) with Advaccine. Under the terms of the Agreement, we have granted to Advaccine the exclusive right to develop, manufacture and commercialize our vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;). Advaccine will not have the right to grant sublicenses, other than to affiliated entities, without our express prior written consent. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Agreement, Advaccine has made an upfront payment to us of $3.0&#160;million.  In addition to the upfront payment, we are entitled to receive up to an aggregate of $108.0&#160;million, payable upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China, if approved. As of December 31, 2020, we have earned a $2.0&#160;million milestone payment based on the enrollment of the first subject in the Phase 2 clinical trial for the product in the Advaccine territory. We are also entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within Greater China, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#8217;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Agreement, Advaccine will be responsible for the development and commercialization of the licensed products at its own cost and expense and shall use commercially reasonable efforts to develop, obtain and maintain regulatory approval of INO-4800, as well as our CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> device and arrays for use in connection with the administration of INO-4800, in each region in Greater China. In the event that we have not initiated the planned Phase 3 segment of our ongoing clinical trial of INO-4800 in the United States within one year after entering into the Agreement, Advaccine may elect to conduct a Phase 3 clinical trial outside of Greater China at its own cost and expense for the purposes of obtaining regulatory approval in China, subject to our right to review and approve the protocols and design of such a trial.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2015, we entered into a strategic cancer vaccine collaboration and license agreement with AstraZeneca. Under the agreement, AstraZeneca acquired exclusive rights to our immunotherapy candidate INO-3112 (renamed MEDI0457), which targets cancers caused by human papillomavirus (HPV) types 16 and 18.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, AstraZeneca made an upfront payment of $27.5 million to us in the third quarter of 2015. AstraZeneca will fund all development costs. The agreement also calls for potential future payments totaling up to $700 million upon reaching specified development and commercial milestones. We are entitled to receive up to double-digit tiered royalties on MEDI0457 product sales.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AstraZeneca is studying MEDI0457 in combination with its PD-L1 checkpoint inhibitor, durvalumab, in a Phase 1/2 clinical trial in patients with recurrent or metastatic head and neck squamous cancer associated with HPV. On December 28, 2017, we received a $7.0 million milestone payment from AstraZeneca, which was triggered by the initiation of the Phase 2 portion of this ongoing clinical trial. In December 2018, we received a $2.0 million milestone payment upon the dosing of the first cervical cancer patient in the trial. In January 2019, we received a $2.0 million milestone payment upon the initiation of a Phase 2 combination trial to evaluate MEDI0457 in combination with durvalumab targeting a broad array of cancers associated with HPV.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into an Amended and Restated License and Collaboration Agreement with Beijing Apollo Saturn Biological Technology Limited, a corporation organized under the laws of China, or ApolloBio. Under the terms of this License and Collaboration Agreement, which became effective in March 2018, we granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, our DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the territories of China, Hong Kong, Macao and Taiwan. The territory may be expanded to include Korea in the event that no patent covering&#160;VGX-3100&#160;issues in China within the first three years of the term of the agreement.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the License and Collaboration Agreement, we have granted to ApolloBio an option to negotiate an exclusive license to research, develop and commercialize MEDI0457 in the event of termination of our current collaboration with AstraZeneca for the development of&#160;MEDI0457 in the territory covered by the License and Collaboration Agreement. As part of the collaboration, ApolloBio will fund all clinical development costs within the licensed territory, and the parties will discuss in good faith the inclusion of clinical trial sites in China as part of our ongoing Phase 3 clinical development program for&#160;VGX-3100.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the License and Collaboration Agreement, we received proceeds of $19.4 million in March 2018, which comprised an upfront payment of $23.0 million less $2.2 million in foreign income taxes and $1.4 million in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the consolidated statement of operations during the year ended December 31, 2018.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the upfront payment, we are entitled to receive up to an aggregate of $20.0&#160;million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in the United States, China and Korea. In the event that&#160;VGX-3100&#160;is approved for marketing in these territories, we will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. The License and Collaboration Agreement, once effective, will continue in force until ApolloBio has no remaining royalty obligations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we develop and seek to ultimately commercialize our product candidates, we face and will continue to encounter competition with an array of existing or development-stage drug and immunotherapy approaches targeting diseases we are pursuing. We are aware of various established enterprises, including major pharmaceutical companies, broadly engaged in vaccine/immunotherapy research and development. These include Janssen Pharmaceuticals (part of J&amp;J), Sanofi-Aventis, GlaxoSmithKline&#160;plc, Merck, Pfizer, and our collaborator AstraZeneca. There are also various development-stage biotechnology companies involved in different vaccine and immunotherapy technologies including but not limited to Advaxis, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bavarian Nordic, BioNTech, CureVac, Dynavax, Hookipa, Iovance, Moderna, Nektar, Novavax, Translate Bio and Vir Biotechnology. If these companies are successful in developing their technologies, it could materially and adversely affect our business and our future growth prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck and GlaxoSmithKline have commercialized preventive vaccines against HPV to protect against cervical cancer. Some companies are seeking to treat early HPV infections or low grade cervical dysplasia. Loop Electrosurgical Excision Procedure, commonly known as LEEP, is the current standard of care for treating high-grade cervical dysplasia. Advaxis and Gilead Sciences have therapeutic cervical cancer product candidates under development. Many companies are pursuing different approaches to GBM, prostate, breast, lung and other cancers we are targeting.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A large number of companies are actively advancing COVID-19 vaccines through the clinic. Pfizer and BioNtech, Moderna Therapeutics, Janssen (J&amp;J) and AstraZeneca have received approval for their COVID-19 vaccines from either the U.S. or European regulatory authorities. Additionally, several companies such as CanSino Biologics, SinoVAc, Bharat Biotech and Novavax are currently developing vaccine candidates into Phase 2 and Phase 3 clinical stage of development.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also compete more specifically with companies seeking to utilize antigen-encoding DNA delivered with electroporation or other DNA delivery technologies such as viral vectors or lipid vectors to induce </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> generated antigen production and immune responses to prevent or treat various diseases. These competitive technologies have shown promise, but they each also have their unique obstacles to overcome.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Viral Vaccine Delivery</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This technology utilizes a virus as a carrier to deliver genetic material into target cells. The method is efficient for delivering immunotherapy antigens and has the advantage of mimicking real viral infection so that the recipient will mount a broad immune response against the immunotherapy. The greatest limitation of the technology stems from problems with unwanted immune responses against the viral vector, limiting its use to patients who have not been previously exposed to the viral vector and making repeated administration difficult. In addition, complexity and safety concerns increase their cost and complicate regulatory approval.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lipid DNA/RNA Delivery</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of lipid formulations have been developed that increase the effect of DNA/RNA immunotherapies. These work by either increasing uptake of the DNA/RNA into cells or by acting as an adjuvant, alerting the immune system. While there has been significant progress in this field, including emergency approval of COVID-19 mRNA vaccines in 2020, lipid nanoparticle delivery of mRNA has thermal stability issues as well as the potential of adverse events from the lipid nanoparticle formulations. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DNA Immunotherapy Delivery with Electroporation</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are other companies with electroporation intellectual property and devices. We believe we have significant competitive advantages over other companies focused on electroporation for multiple reasons:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">We have an extensive history and experience in developing the methods and devices that optimize the use of electroporation in conjunction with DNA-based agents. This experience has been validated with multiple sets of interim data from multiple clinical studies assessing DNA-based immunotherapies and vaccines against cancers and infectious disease. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">We have a broad product line of electroporation instruments designed to enable DNA delivery in tumors, muscle, and skin.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">We have been proactive in filing for patents, as well as acquiring and licensing additional patents, to expand our global patent estate.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our competitors develop products with efficacy or safety profiles significantly better than our product candidates, we may not be able to commercialize our products, and sales of any of our commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or products obsolete or noncompetitive, or result in treatments or cures superior to ours.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitive position will be affected by the disease indications addressed by our product candidates and those of our competitors, the timing of market introduction for these products and the stage of development of other technologies to address these disease indications. For us and our competitors, proprietary technologies, the ability to complete clinical trials on a timely basis and with the desired results, and the ability to obtain timely regulatory approvals to market these product candidates are likely to be significant competitive factors. Other important competitive factors will include the efficacy, safety, ease of use, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reliability, availability and price of products and the ability to fund operations during the period between technological conception and commercial sales.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory agencies may expand current requirements for public disclosure of DNA-based product development data, which may harm our competitive position with foreign and United States companies developing DNA-based products for similar indications.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization and Manufacturing</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the broad potential applications of our technologies, we intend to develop and commercialize products both on our own and through our collaborators and licensees. We intend to develop and commercialize products in well-defined specialty markets, such as infectious diseases and cancer. Where appropriate, we intend to rely on strategic marketing and distribution alliances.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our plasmids can be produced in commercial quantities through uniform methods of fermentation and processing that are applicable to all plasmids. We believe we will be able to obtain sufficient supplies of plasmids for all foreseeable clinical investigations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other proprietary rights are essential to our business. We file patent applications to protect our technologies, inventions and improvements to our inventions that we consider important to the development of our business. We file for patent registration extensively in the United States and in key foreign markets. Although our patent filings include claims covering various features of our products and product candidates, including composition, methods of manufacture and use, our patents do not provide us with complete protection, or guarantee, against the development of competing products. In addition, some of our know-how and technology are not patentable. We thus also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position. We also require employees, consultants, advisors and collaborators to enter into confidentiality agreements, but such agreements may provide limited protection for our trade secrets, know-how or other proprietary information.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intellectual property portfolio covers our proprietary technologies, including CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delivery systems as well as immunotherapy and vaccine construct related technologies. As of December 31, 2020, our patent portfolio included 84 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued United States patents and over 500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued foreign counterpart patents. We also have a number of patent applications pending in the United States and various foreign jurisdictions.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to protect our intellectual property rights adequately our competitors might gain access to our technology and our business would thus be harmed. In addition, defending our intellectual property rights might entail significant expense. Any of our intellectual property rights may be challenged by others or invalidated through administrative processes or litigation through the courts. In addition, our patents, or any other patents that may be issued to us in the future, may not provide us with any competitive advantages, or may be challenged by third parties. Furthermore, legal standards relating to the validity, enforceability and scope of protection of intellectual property rights are uncertain. Effective patent, trademark, copyright and trade secret protection may not be available to us in each country where we operate. The laws of some foreign countries may not be as protective of intellectual property rights as those in the United States, and domestic and international mechanisms for enforcement of intellectual property rights in those countries may be inadequate. Accordingly, despite our efforts, we may be unable to prevent third parties from infringing upon or misappropriating our intellectual property or otherwise gaining access to our technology. We may be required to expend significant resources to monitor and protect our intellectual property rights. We may initiate claims or litigation against third parties for infringement of our proprietary rights or to establish the validity of our proprietary rights. Any such litigation, whether or not it is ultimately resolved in our favor, would result in significant expense to us and divert the efforts of our technical and management personnel.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be rights we are not aware of, including applications that have been filed but not published that, when issued, could be asserted against us. These third-parties could bring claims against us, and that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or biologic drug candidate that is the subject of the suit. As a result of patent infringement claims, or in order to avoid potential claims, we may choose or be required to seek a license from the third-party. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be non-exclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. All of the issues described above could also impact our collaborators, which would also impact the success of the collaboration and therefore us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Important legal issues remain to be resolved as to the extent and scope of available patent protection for biologic products, including vaccines, and processes in the United States and other important markets outside the United States, such as Europe and Japan. Foreign markets may not provide the same level of patent protection as provided under the United States patent system. We recognize that litigation or administrative proceedings may be necessary to determine the validity and scope of certain of our and others&#8217; proprietary rights. Any such litigation or proceeding may result in a significant commitment of resources in the future and could force us to interrupt our operations, redesign our products or processes, or negotiate a license agreement, all of which would adversely affect our revenue. Furthermore, changes in, or different interpretations of, patent laws in the United States and other countries may result in patent laws that allow others to use our discoveries or develop and commercialize our products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that the patents we obtain or the unpatented technology we hold will afford us significant commercial protection.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States at the federal, state and local level and in other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biological products, or biologics, and medical devices, such as our product candidates. Generally, before a new biologic or medical device can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific to each regulatory authority, submitted for review and approved by the regulatory authority.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review and Approval of Combination Products in the United States</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain products may be comprised of components that would normally be regulated under different types of regulatory authorities, and frequently by different centers at the FDA. These products are known as combination products. Specifically, under regulations issued by the FDA, a combination product may be:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A product comprised of two or more regulated components that are physically, chemically, or otherwise combined or mixed and produced as a single entity;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Two or more separate products packaged together in a single package or as a unit and comprised of drug and device products;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device or biological where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any investigational drug, device, or biological packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are combination products comprising an electroporation device for delivery of a biologic. Under the Federal Food, Drug, and Cosmetic Act, or FDCA, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. That determination is based on the &#8220;primary mode of action&#8221; of the combination product, which means the mode of action expected to make the greatest contribution to the overall intended therapeutic effects. Thus, if the primary mode of action of a device-biologic combination product is attributable to the biologic product, that is, if it acts by means of a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product, the FDA center responsible for premarket review of the biologic product would have primary jurisdiction for the combination product. We believe that all of our product candidates will have a biologic primary mode of action, with the device component reviewed under a Device Master File.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Biological Product Development</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates biologics under FDCA, and the Public Health Service Act, or PHSA, and their implementing regulations. Biologics are also subject to other federal, state, and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates must be approved by the FDA through the Biologics License Application, or BLA, process before they may be legally marketed in the United States. The process required by the FDA before a biologic may be marketed in the United States generally involves the following:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Completion of extensive nonclinical, sometimes referred to as pre-clinical laboratory tests, pre-clinical animal studies and formulation studies in accordance with applicable regulations, including the FDA&#8217;s Good Laboratory Practice, or GLP, regulations;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Performance of adequate and well-controlled human clinical trials in accordance with applicable IND and other clinical trial-related regulations, sometimes referred to as good clinical practices, or GCPs, to establish the safety and efficacy of the proposed product candidate for its proposed indication;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Submission to the FDA of a BLA;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the product is produced to assess compliance with the FDA&#8217;s current good manufacturing practice, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality, purity and potency;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potential FDA audit of the pre-clinical and/or clinical trial sites that generated the data in support of the BLA; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of the BLA prior to any commercial marketing or sale of the product in the United States. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The data required to support a BLA is generated in two distinct development stages: pre-clinical and clinical. The pre-clinical development stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The conduct of the pre-clinical studies must comply with federal regulations, including GLPs. The sponsor must submit the results of the pre-clinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human trials. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a product candidate at any time before or during clinical trials due to safety concerns or non-compliance. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that could cause the trial to be suspended or terminated.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical stage of development involves the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products, including biologics, are required to register and disclose specified clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are generally conducted in three sequential phases that may overlap, known as Phase 1, Phase 2 and Phase 3 clinical trials. Phase 1 clinical trials generally involve a small number of healthy volunteers who are initially exposed to a product candidate. The primary purpose of these clinical trials is to assess the action, side effect tolerability and safety of the product candidate and, if possible, to gain early evidence on effectiveness. Phase 2 clinical trials typically involve studies in patients to determine the dose required to produce the desired benefits. At the same time, safety and preliminary evaluation of efficacy is assessed. Phase 3 clinical trials generally involve large numbers of patients at multiple sites, in multiple countries (from several hundred to several thousand subjects) and are designed to provide the data necessary to demonstrate the efficacy of the product for its intended use, its safety in use, and to establish the overall benefit/risk relationship of the product and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provide an adequate basis for product approval. Phase 3 clinical trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of a BLA.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, FDA may grant conditional approval of a BLA on the sponsor&#8217;s agreement to conduct additional clinical trials, such as these post-approval trials, to further assess the biologic&#8217;s safety and effectiveness after BLA approval.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse, findings from other studies suggesting a significant risk to humans exposed to the drug, findings from animal or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing suggesting a significant risk to humans, and any clinically important rate increase of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated intervals based on access to certain data from the trial. We may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate. Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BLA and FDA Review Process</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following trial completion, trial data is analyzed to assess safety and efficacy. The results of pre-clinical studies and clinical trials are then submitted to the FDA as part of a BLA, along with proposed labeling for the product and information about the manufacturing process and facilities that will be used to ensure product quality, results of analytical testing conducted on the chemistry of the product candidate, and other relevant information. The BLA is a request for approval to market the biologic for one or more specified indications and must contain proof of safety, purity, potency and efficacy, which is demonstrated by extensive pre-clinical and clinical testing. The application includes positive findings from pre-clinical and clinical trials as well as ambiguous or negative results. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee, which is adjusted on an annual basis. PDUFA also imposes an annual program fee for approved products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a BLA has been accepted for filing, which occurs, if at all, sixty days after the BLA&#8217;s submission, the FDA&#8217;s goal is to review BLAs within ten months of the filing date for standard review or six months of the filing date for priority review, if the application is for a product intended for a serious or life-threatening condition and the product, if approved, would provide a significant improvement in safety or effectiveness. The review process is often significantly extended by FDA requests for additional information or clarification. If not accepted for filing, the sponsor must resubmit the BLA and begin the FDA&#8217;s review process again, including the initial sixty day review to determine if the application is sufficiently complete to permit substantive review.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the BLA submission is accepted for filing, the FDA reviews the BLA to determine, among other things, whether the proposed product candidate is safe and effective for its intended use, and whether the product candidate is being manufactured in accordance with cGMP to assure and preserve the product candidate&#8217;s identity, strength, quality, purity and potency. The FDA may refer applications for novel drug product candidates or drug product candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA will likely re-analyze the clinical trial data, which could result in extensive discussions between the FDA and us during </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the review process. The review and evaluation of a BLA by the FDA is extensive and time consuming and may take longer than originally planned to complete, and we may not receive a timely approval, if at all.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. In addition, before approving a BLA, the FDA may also audit data from clinical trials to ensure compliance with GCP requirements. After the FDA evaluates the application, manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the BLA identified by the FDA. The Complete Response Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, pre-clinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information is submitted, the FDA may ultimately decide that the BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that the FDA will ultimately approve a product for marketing in the United States and we may encounter significant difficulties or costs during the review process. If a product receives marketing approval, the approval may be significantly limited to specific populations, severities of allergies, and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval of the BLA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct post-market testing or clinical trials and surveillance to monitor the effects of approved products. For example, the FDA may require Phase 4 testing which involves clinical trials designed to further assess the product&#8217;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve the BLA without an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Marketing Requirements</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval of a new product, a manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities with updated safety and efficacy information, product sampling and distribution requirements, and complying with promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling, also known as off-label use, limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although physicians may prescribe legally available drugs and biologics for off-label uses, manufacturers may not market or promote such off-label uses. Modifications or enhancements to the product or its labeling or changes of the site of manufacture are often subject to the approval of the FDA and other regulators, which may or may not be received or may result in a lengthy review process. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Any distribution of prescription drug products and pharmaceutical samples must comply with the U.S. Prescription Drug Marketing Act, or the PDMA, a part of the FDCA.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, once a product is approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. The FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP. Moreover, the constituent parts of a combination product retain their regulatory status, for example, as a biologic or device, and as such, we may be subject to additional requirements in the Quality System Regulation, or QSR, applicable to medical devices, such as design controls, purchasing controls, and corrective and preventive action. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. cGMP regulations require, among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. These regulations also impose certain organizational, procedural and documentation requirements with respect to manufacturing and quality assurance activities. BLA holders using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable, their suppliers are subject to inspections by the FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such facilities or the ability to distribute products manufactured, processed or tested by them. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may require post-approval testing, sometimes referred to as Phase 4 testing, REMS and post-marketing surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coverage and Reimbursement</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs. Accordingly, a pharmaceutical company&#8217;s ability to commercialize its products successfully depends in part on the extent to which private health insurers, other third-party payors, and governmental authorities, including Medicare and Medicaid, establish appropriate coverage and reimbursement levels for its product candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors generally require that products be approved for marketing by the FDA.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are available. The process for obtaining coverage for a product or service is separate from the process to obtain the associated reimbursement. Reimbursement levels can affect the adoption of products and services by physicians and patients. Additionally, products used in connection with medical procedures may not be reimbursed separately, but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for a product or the treatment or procedure in which the product is used may not be available.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time consuming and costly which may require the provision of scientific and clinical support for the use of the product to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Reform</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the United States and certain foreign jurisdictions there have been, and continue to be, a number of legislative and regulatory changes to the healthcare system that impact the ability to sell pharmaceutical products profitably.&#160;In the United States, the federal government enacted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA. Among the ACA&#8217;s provisions of importance to the pharmaceutical industry are that it:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Created new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expanded the entities eligible for discounts under the Public Health program;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Established a Center for Medicare &amp; Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending that began on January 1, 2011; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Created a licensure framework for follow on biologic products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain judicial and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry qualifying health insurance coverage for all or part of a year. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax, and, effective January 1, 2021, also eliminated the health insurer tax. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing the case, although it is unknown when a decision will be made. Further, although the U.S. Supreme Court has not yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden administration will impact the ACA and our business. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect through 2030 with the exception of a temporary suspension from May 1, 2020 through March 31, 2021 unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">until March 22, 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2020, CMS issued an interim final rule implementing the Trump administration&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. It is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, at the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. It is also possible that additional governmental action is taken in response to the COVID-19 pandemic.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Laws</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to the business of a pharmaceutical company. The laws that may affect a pharmaceutical company&#8217;s ability to operate include:</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">The federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or the purchasing, ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid;</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">Federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities; </span></div><div style="padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members, and which, beginning in 2022, will require applicable manufacturers to report information regarding payments and other transfers of value provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants, and certified nurse-midwives;</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">The Federal Food, Drug, and Cosmetic Act, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; </span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">The U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; and</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">State law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div><div style="margin-top:5pt;padding-left:47.25pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">Additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A pharmaceutical company will need to spend substantial time and money to ensure that its business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that its business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If a pharmaceutical company&#8217;s operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to it, it may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm and the curtailment or restructuring of operations.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Regulations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are subject to various federal, state and local laws, regulations, and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our research. The extent of government regulation that might result from any future legislation or administrative action cannot be accurately predicted.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Customers and Research and Development</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we derived 68% of our revenue from Advaccine and 18% of our revenue from Plumbline Life Sciences. During the year ended December 31, 2019, we derived 78% of our revenue from AstraZeneca. During the year ended December 31, 2018, we derived 75% of our revenue from ApolloBio and 23% of our revenue from AstraZeneca. Since our inception, virtually all of our activities have consisted of research and development efforts related to developing our electroporation technologies and immunotherapies. Research and development expense consists of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Our research and development expense was $94.2 million in 2020, $88.0 million in 2019 and $95.3 million in 2018. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our revenue for the years ended December&#160;31, 2020, 2019 and 2018 was earned in the United States. All of our long-lived assets are located in the United States.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, our former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and our former majority -owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located at 660 W. Germantown Pike, Suite 110, Plymouth Meeting, Pennsylvania 19462, and our main telephone number is (267) 440-4200. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Internet website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.inovio.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition to the information contained in this Annual Report, information about us can be found on our website. Our website and information included in or linked to our website are not part of this Annual Report.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make our annual report on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, or the Exchange Act, available free of charge on our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or the SEC. The SEC maintains an Internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding our corporate governance, including the charters of our audit committee, our nomination and corporate governance committee and our compensation committee, our Code of Business Conduct and Ethics, our Corporate Governance Guidelines, our Corporate Governance Policy and information for contacting our board of directors is available on our website.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Code of Business Conduct and Ethics includes our Code of Ethics applicable to our Chief Executive Officer and Chief Financial Officer, who also serves as our principal accounting officer. Any amendments to or waivers of the Code of Ethics will be promptly posted on our website or in a report on Form 8-K, as required by applicable law.</span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Human Capital Resources</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 12, 2021, we employed 262 people on a full-time basis. Of the combined total, 210 were in product research, which includes research and development, quality assurance, clinical, engineering and manufacturing, and 52 were in general and administrative functions, which includes corporate development, information technology, legal, investor relations, finance and corporate administration. About 50% of our workforce is comprised of women and approximately 50% is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">comprised of individuals with ethnically diverse backgrounds.  In addition, three of the seven members of our board of directors are women. None of our employees are subject to collective bargaining agreements. We con</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sider our relationship with our employees to be good. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete in the highly competitive biotechnology industry. Attracting, developing and retaining talented people in research, quality assurance, clinical, engineering, manufacturing and other positions is crucial to executing our strategy and our ability to compete effectively. Our ability to recruit and retain such talent depends on several factors, including compensation and benefits, talent development and career opportunities, and work environment. To that end, we invest in our employees to be an employer of choice.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Engagement</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we work to make an impact on how healthcare is delivered, we believe it is critical that our employees are informed and engaged. We communicate frequently and transparently with our employees through a variety of communication methods, including video and written communications, town hall meetings, employee surveys and our company intranet, and acknowledge individual contributions to INOVIO through several rewards and recognition award programs. We believe these engagement efforts keep employees informed about our strategy, culture and purpose and motivated to do their best work. As a result of the COVID-19 pandemic, we also further strengthened our digital communication platform. Our employee communications during the pandemic have kept our employees informed on critical priorities, important actions being taken by management in response to the pandemic.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health, Safety and Wellness</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The physical health, financial wellbeing, life balance and mental health of our employees is vital to our success.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The environmental, health and safety team stays abreast of local, regional and global concerns and trends and ensures safety procedures are in place to mitigate workplace injuries and safety risks. Employees are required to complete training in various safety procedures for the laboratories and manufacturing facilities and specialized safety training based on particular job duties. Designated Safety Officers and response teams oversee safety-related initiatives and a safety committee that provides input on safety procedures, practices, and policies. Employees are required to wear personal protective equipment relevant for their particular job duties. Occupational injuries at the workplace are extremely low and are always investigated to determine if any environmental or other changes need to be implemented.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the onset of the COVID-19 pandemic, strict safety protocols have been put in place for employees working on-site, including following federal and local guidelines and mandates to ensure the safety of the workforce. In addition to providing the necessary personal protective equipment, special engineering controls have been installed at the facilities to further protect workers. Regular communication and training about the virus and how individuals can protect themselves and others is ongoing with employees. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i06d07667d4974765a8282374d1211e66_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the following factors regarding information included in this Annual Report. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. If any of the following risks actually occur, our business, financial condition and operating results could be materially adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant operating losses over the last several years. As of December 31, 2020 our accumulated deficit was $906.2 million. We have generated limited revenues, primarily consisting of license revenue, grant funding and interest income. We expect to continue to incur substantial additional operating losses for at least the next several years as we advance our clinical trials and research and development activities. We may never successfully commercialize our DNA vaccine and DNA immunotherapy product candidates or electroporation-based synthetic vaccine delivery technology and thus may never have any significant future revenues or achieve and sustain profitability.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited sources of revenue and our success is dependent on our ability to develop our DNA vaccines, DNA immunotherapies, dMAbs and electroporation equipment. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not sell any products and may not have any other products commercially available for several years, if at all. Our ability to generate future revenues depends heavily on our success in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and securing United States and/or foreign regulatory approvals for our product candidates, including securing regulatory approval for conducting clinical trials with product candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing our electroporation-based DNA delivery technology; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercializing any products for which we receive approval from the FDA and foreign regulatory authorities. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our electroporation equipment and product candidates will require extensive additional clinical study and evaluation, regulatory approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote our electroporation equipment and product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities. If we do not receive regulatory approval for and successfully commercialize any products, we will not generate any revenues from sales of electroporation equipment and products, and we may not be able to continue our operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional capital to develop our DNA vaccines, DNA immunotherapies and dMAb programs and electroporation delivery technology.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting the costly and time-consuming research, pre-clinical studies and clinical testing necessary to obtain regulatory approvals and bring our product candidates and delivery technology to market will require a commitment of substantial funds in excess of our current capital. Our future capital requirements will depend on many factors, including, among others:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress of our current and new product development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, scope and results of our pre-clinical and clinical testing; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost involved in obtaining regulatory approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our products and product candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of prosecuting, enforcing and defending against patent infringement claims and other intellectual property rights; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">debt service obligations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and costs to establish and maintain collaborative and other arrangements with third parties to assist in potentially bringing our products to market. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional financing may not be available on acceptable terms, or at all. Domestic and international capital markets have from time to time experienced heightened volatility and turmoil, particularly in light of the COVID-19 pandemic, making it more difficult in many cases to raise capital through the issuance of equity securities. Volatility in the capital markets can also negatively impact the cost and availability of credit, creating illiquid credit markets and wider credit spreads. Concern about the stability of the markets generally and the strength of counterparties specifically has led many lenders and institutional investors to reduce, and in some cases cease to provide, funding to borrowers. To the extent we are able to raise additional capital through </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sale of equity securities, or we issue securities in connection with another transaction in the future, the ownership position of existing stockholders could be substantially diluted. If additional funds are raised through the issuance of preferred stock or debt securities, these securities are likely to have rights, preferences and privileges senior to our common stock and may involve significant fees, interest expense, restrictive covenants and the granting of security interests in our assets. Fluctuating interest rates could also increase the costs of any debt financing we may obtain. Raising capital through a licensing or other transaction involving our intellectual property could require us to relinquish valuable intellectual property rights and thereby sacrifice long-term value for short-term liquidity.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to successfully address ongoing liquidity requirements would have a substantially negative impact on our business. If we are unable to obtain additional capital on acceptable terms when needed, we may need to take actions that adversely affect our business, our stock price and our ability to achieve cash flow in the future, including possibly surrendering our rights to some technologies or product opportunities, delaying our clinical trials or curtailing or ceasing operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Product Development, Manufacturing and Regulatory Approval</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain FDA approval of our products, we will not be able to commercialize them in the United States.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need FDA approval prior to marketing our electroporation equipment and product candidates in the United States. If we fail to obtain FDA approval to market our electroporation equipment and product candidates, we will be unable to sell our products in the United States, which will significantly impair our ability to generate any revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This regulatory review and approval process, which includes evaluation of preclinical studies and clinical trials of our products as well as the evaluation of our manufacturing processes and our third-party contract manufacturers' facilities, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials that our electroporation equipment and product candidates are both safe and effective for each indication for which approval is sought. To the extent that our product candidates are manufactured at multiple sites or using different processes, we will also need to demonstrate comparability across the manufacturing batches in order to obtain regulatory approval. Satisfaction of the approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the product. We do not know if or when we might receive regulatory approvals for our electroporation equipment and any of our product candidates currently under development. Moreover, any approvals that we obtain may not cover all of the clinical indications for which we are seeking approval, or could contain significant limitations in the form of narrow indications, warnings, precautions or contra-indications with respect to conditions of use. In such event, our ability to generate revenues from such products would be greatly reduced and our business would be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has substantial discretion in the approval process and may either refuse to consider our application for substantive review or may form the opinion after review of our data that our application is insufficient to allow approval of our electroporation equipment and product candidates. If the FDA does not consider or approve our application, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our application. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our applications for approval, which might significantly harm our business and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that none of our products or any product we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us or our collaborators to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our products, generating revenues and achieving and sustaining profitability. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our products may not be predictive of the results of later-stage clinical trials. Results from one study may not be reflected or supported by the results of similar studies. Results of an animal study may not be indicative of results achievable in human studies. Human-use equipment and product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical testing. The time required to obtain approval by the FDA and similar foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials, depending upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change. We have not obtained regulatory approval for any human-use products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products could fail to complete the clinical trial process for many reasons, including the following:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our electroporation equipment or product candidate is safe and effective for any indication; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be successful in enrolling a sufficient number of participants in clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our electroporation equipment or product candidate's clinical and other benefits outweigh its safety risks; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our electroporation equipment or product candidate presents an advantage over existing therapies, or over placebo in any indications for which the FDA requires a placebo-controlled trial; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a new drug application or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of us or third-party manufacturers with which we or our collaborators contract for clinical and commercial supplies; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are combination products regulated under both the biologic and device regulations of the Public Health Service Act and Federal Food, Drug, and Cosmetic Act. Third-party manufacturers may not be able to comply with cGMP regulations, regulations applicable to biologic/device combination products, including applicable provisions of the FDA&#8217;s drug cGMP regulations, device cGMP requirements embodied in the QSR or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of our product candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our electroporation equipment and our product candidates may be harmed and our ability to generate product revenues will be delayed. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement or completion of clinical trials may adversely affect the trading price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Delays in the commencement or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delays in the commencement or completion of clinical testing could significantly affect our product development costs. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. In addition, ongoing clinical trials may not be completed on schedule, or at all, and could be placed on a hold by the regulators for various reasons. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining regulatory approval to commence a clinical trial;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">adverse results from third party clinical trials involving gene-based therapies and the regulatory response thereto;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reaching agreement on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">future bans or stricter standards imposed on clinical trials of gene-based therapy;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">manufacturing sufficient quantities of our electroporation equipment and product candidates for use in clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining institutional review board, or IRB, approval to conduct a clinical trial at a prospective site;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">slower than expected recruitment and enrollment of patients to participate in clinical trials for a variety of reasons, including competition from other clinical trial programs for similar indications;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conducting clinical trials with sites internationally due to regulatory approvals and meeting international standards;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">retaining patients who have initiated a clinical trial but may be prone to withdraw due to side effects from the therapy, lack of efficacy or personal issues, or who are lost to further follow-up;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">collecting, reviewing and analyzing our clinical trial data; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">global unrest, global pathogen outbreaks or pandemics, terrorist activities, and economic and other external factors.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">unforeseen safety issues; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial.</span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our electroporation equipment and our product candidates may be harmed and our ability to generate product revenues will be delayed. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement or completion of clinical trials may adversely affect the trading price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">None of our human vaccine candidates, including INO-4800, or our immunotherapy and DNA encoded monoclonal antibody product candidates have been approved for sale, and we may never develop commercially successful vaccine, immunotherapy or DNA encoded monoclonal antibody products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our human vaccine programs, which includes our COVID-19 vaccine candidate INO-4800, our immunotherapy programs and our DNA encoded monoclonal antibodies program are in various stages of research and development, and currently include product candidates in discovery, preclinical studies and Phase 1, 2 and 3 clinical trials. There are limited data regarding the efficacy of synthetic vaccine candidates and immunotherapy candidates compared with conventional vaccines, and we must conduct a substantial amount of additional research and development before the FDA or any comparable foreign regulatory authority will approve any of our vaccine product candidates, including INO-4800. The success of our efforts to develop and commercialize our product candidates, including INO-4800, could be delayed or fail for a number of reasons. For example, we could experience delays in product development and clinical trials. Our product candidates could be found to be ineffective or unsafe, or otherwise fail to receive necessary regulatory clearances to proceed with further clinical development or to be approved for marketing. Our products, even if they are deemed to be safe and effective by regulatory authorities, could be difficult to manufacture on a large scale or uneconomical to market, or our competitors could develop superior products more quickly and efficiently or more effectively market their competing products. The ability to manufacture sufficient quantities of INO-4800 on a large scale is particularly challenging and will require substantial resources and the engagement of third parties, which we may not be able to obtain on a timely basis, or at all.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, adverse events, or the perception of adverse events, relating to vaccine and immunotherapy candidates and delivery technologies may negatively impact our ability to develop commercially successful products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism. These and other claims may influence public perception of the use of vaccine and immunotherapy products and could result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approval of our potential products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our planned clinical development of INO-4800 as a potential COVID-19 vaccine has been placed on partial clinical hold by the FDA, which may cause delays in the commencement of our planned Phase 3 clinical trial or completion of clinical testing, both of which could result in increased costs to us and delay or limit our ability to proceed to commercialization and generate revenues.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our planned clinical development of INO-4800 as a potential COVID-19 vaccine has been placed on partial clinical hold by the FDA. We may not commence our planned Phase 3 clinical trial of INO-4800 until we satisfactorily resolve the FDA&#8217;s remaining questions relating to our CELLECTRA 2000 delivery device to be used in connection with INO-4800 in our Phase 3 clinical trials and commercial product, if authorized or licensed by FDA. We are actively working to address the FDA&#8217;s questions and plan to respond in May 2021, after which the FDA will have up to 30 days to notify us of its decision as to whether our Phase 3 trial may proceed. However, there can be no assurance regarding the timing of the FDA&#8217;s agreement to lift the partial clinical hold or that we will ultimately be successful in obtaining any such determination from the FDA to do so.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays in the commencement of our Phase 3 trial or completion of ongoing clinical testing for INO-4800 could significantly affect our product development costs. We do not know whether our planned Phase 3 clinical trial will begin on time or be completed on schedule, if at all. In addition, our ongoing clinical trials for INO-4800 may not be completed on schedule, or at all, and could be placed on additional holds by regulators for reasons unrelated to our current hold. Our Phase 3 trial for INO-4800 will require interim data results at various points throughout the trial. Our clinical trials may therefore also be delayed as a result of ambiguous or negative interim results. Even if our interim results related to our INO-4800 are positive, there can be no assurance that our topline results will be consistent with the interim results. If we experience delays in completion of, or if we terminate, any of our clinical trials relating to INO-4800, the commercial prospects for our product candidate may be harmed and our ability to generate product revenues will be delayed. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement or completion of clinical trials may adversely affect the trading price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Newly emerging SARS-CoV-2 variants could reduce the immunogenicity and effectiveness of INO-4800 as a potential COVID-19 vaccine.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Multiple variants of the virus that causes COVID-19 have been documented in the United States and globally during this pandemic. The new SARS-CoV-2 variants could be less affected by the immune responses generated by INO-4800 in the vaccine recipients and therefore could reduce the overall efficacy of the vaccine in controlling severe COVID-19 disease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">There can be no assurance that the product we are developing for COVID-19 would be granted an Emergency Use Authorization by the FDA or similar authorization by regulatory authorities outside of the United States if we were to decide to apply for such an authorization. If we do not apply for such an authorization or, if we do apply and no authorization is granted or, once granted, it is terminated, we will be unable to sell our product in the near future and instead, will be required to pursue the biologic licensure process in order to sell our product, which is lengthy and expensive.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek an Emergency Use Authorization, or EUA, from the FDA or similar authorization from regulatory authorities outside of the United States, such as conditional marketing authorization from the EMA. If we apply for an EUA and it is granted, an EUA will authorize us to market and sell our COVID-19 vaccine under certain conditions of authorization as long as the public health emergency exists. The FDA expects that companies which receive an EUA for COVID-19 vaccines will proceed to licensure of their vaccine products under a full Biologics License Application. The FDA may issue an EUA during a Public Health Emergency if the agency determines that the potential benefits of a product outweigh the potential risks and if other regulatory criteria are met. There is no guarantee that we will apply for an EUA or other similar authorization or, if we do apply, that we will be able to obtain such authorization. If an EUA or other authorization is granted, we will rely on the FDA or other applicable regulatory authority policies and guidance governing vaccines authorized in this manner in connection with the marketing and sale of our product. If these policies and guidance change unexpectedly and/or materially or if we misinterpret them, potential sales of our product could be adversely impacted. An EUA authorizing the marketing and sale of our product will terminate upon expiration of the Public Health Emergency, which is a determination made by the Secretary of Health and Human Services. The FDA may also terminate an EUA if safety issues or other concerns about our product arise or if we fail to comply with the conditions of authorization. If we apply for an EUA or similar authorization from regulatory authorities outside of the United States, the failure to obtain such authorization or the termination of such an authorization, if obtained, would adversely impact our ability to market and sell our COVID-19 vaccine, which could adversely impact our business, financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we and the contract manufacturers upon whom we rely fail to produce our electroporation devices and product candidates in the volumes that we require on a timely basis, or at all, or fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our electroporation equipment and product candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture some components of our electroporation devices and utilize the services of contract manufacturers to manufacture the remaining components of these devices. We also rely on third party contract manufacturers to produce our product candidates for use in our clinical trials and potentially for commercial distribution, if any product candidate is approved by regulatory authorities. The manufacture of these devices and our product candidates requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers often encounter difficulties in production, particularly in scaling up for commercial production. These problems include difficulties with production costs and yields, quality control, including stability of the equipment and product candidates and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our manufacturers were to encounter any of these difficulties or our manufacturers otherwise fail to comply with their obligations to us, our ability to provide our electroporation equipment to our partners and to supply product candidates for clinical trials or to commercially launch a product would be jeopardized. For example, we previously relied on VGXI to manufacture DNA plasmids for our product candidates, including INO-4800. In 2020, VGXI notified us that they would be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unable to produce the necessary plasmids to meet this timeline due to a lack of manufacturing capacity. As a result, we have engaged several additional third-party contract manufacturers to support the planned large-scale manufacturing of INO-4800. However, there can be no assurance that we will be able to secure adequate additional manufacturing capacity on commercially reasonable terms. Our inability to secured sufficient manufacturing capacity, or our inability to transfer necessary manufacturing know-how to third parties, would adversely affect our commercialization plans and could also harm our reputation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, any delay or interruption in the supply of clinical trial supplies for INO-4800 or any of our other product candidates could delay the completion of our clinical trials, increase the costs associated with maintaining our clinical trial program and, depending upon the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all manufacturers of our products must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the generation and maintenance of records and documentation. Manufacturers of our products may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. We have little control over our manufacturers' compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any product is compromised due to our or our manufacturers' failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our products, entail higher costs or result in our being unable to effectively commercialize our products. Furthermore, if our manufacturers fail to deliver the required commercial quantities on a timely basis, pursuant to provided specifications and at commercially reasonable prices, we may be unable to meet demand for our products and would lose potential revenues.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval, they may still face future development and regulatory difficulties.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if United States regulatory approval is obtained, the FDA may still impose significant restrictions on a product's indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. This governmental oversight may be particularly strict with respect to gene-based therapies. Our products will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, advertising, promotion, record keeping and submission of safety and other post-market information. For example, the FDA strictly regulates the promotional claims that may be made about medical products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may in certain circumstances share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue Warning Letters or untitled letters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose civil or criminal penalties; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend regulatory approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements to applications filed by us; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose restrictions on operations, including costly new manufacturing requirements; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products or require us to initiate a product recall. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any electroporation equipment and product candidates outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">time required to obtain approval in other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects detailed above regarding FDA approval in the United States. Such effects include the risks that our product candidates may not be approved for all indications requested, which could limit the uses of our product candidates and have an adverse effect on their commercial potential or require costly, post-marketing follow-up studies. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have obtained Orphan Drug Designation for one of our product candidates. As part of our business strategy, we may continue to seek Orphan Drug Designation for additional product candidates, and we may be unsuccessful in obtaining new designations or may be unable to obtain or maintain the benefits associated with Orphan Drug Designation, including the potential for orphan drug exclusivity.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained Orphan Drug Designation from the FDA for INO-3107 for the treatment of for the treatment of recurrent respiratory papillomatosis. We have sought and may continue to seek Orphan Drug Designation for one or more of our other product candidates, including but not limited to VGX-3100 for the treatment of HPV-16-/18-associated anal dysplasia, although we may be unsuccessful in doing so. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as tax advantages and user fee waivers. Opportunities for grant funding toward clinical trial costs may also be available for clinical trials of drugs for rare diseases, regardless of whether the drugs are designated for the orphan use. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years, except in limited circumstances. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have obtained Orphan Drug Designation for INO-3107 for the treatment of for the treatment of recurrent respiratory papillomatosis, and even if we obtain Orphan Drug Designation for our other product candidates in specific indications, we may not be the first to obtain marketing approval of these product candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. If a competitor with a product that is determined by the FDA to be the same as one of our product candidates obtains marketing approval before us for the same indication we are pursuing and obtains orphan drug exclusivity, our product candidate may not be approved until the period of exclusivity ends unless we are able to demonstrate that our product candidate is clinically superior. Even after obtaining approval, we may be limited in our ability to market our product. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different principal molecular structural features can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same principal molecular structural features for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for some of our product candidates, we may never receive such designations. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax reform legislation enacted in 2017 reduced the amount of the qualified clinical research costs for a designated orphan product that a sponsor may claim as a credit from 50% to 25%. This reduction could further limit the advantage of, and may impact our future business strategy with respect to, seeking the Orphan Drug Designation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, and may continue to enter into, distribution, co-promotion, partnership, sponsored research and other arrangements for development, manufacturing, sales, marketing and other commercialization activities relating to our products. For example, in the past we have entered into license and collaboration agreements to develop, obtain regulatory approval for and commercialize our product candidates for specified indications, including in jurisdictions outside of the United States. The amount and timing of resources applied by our collaborators are largely outside of our control. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our current or future collaborators breaches or terminates our agreements, or fails to conduct our collaborative activities in a timely manner, our commercialization of products could be diminished or blocked completely. We may not receive any event-based payments, milestone payments or royalty payments under our collaborative agreements if our collaborative partners fail to develop products in a timely manner or at all. It is possible that collaborators will change their strategic focus, pursue alternative technologies or develop alternative products, either on their own or in collaboration with others. Further, we may be forced to fund programs that were previously funded by our collaborators, and we may not have, or be able to access, the necessary funding. The effectiveness of our partners, if any, in marketing our products will also affect our revenues and earnings.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We desire to enter into new collaborative agreements. However, we may not be able to successfully negotiate any additional collaborative arrangements and, if established, these relationships may not be scientifically or commercially successful. Our success in the future depends in part on our ability to enter into agreements with other highly-regarded organizations. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate and implement a collaboration. Once news of discussions regarding possible collaborations are known in the medical community, regardless of whether the news is accurate, failure to announce a collaborative agreement or the entity's announcement of a collaboration with another entity may result in adverse speculation about us, resulting in harm to our reputation and our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes could also arise between us and our existing or future collaborators, as to a variety of matters, including financial and intellectual property matters or other obligations under our agreements. These disputes could be both expensive and time-consuming and may result in delays in the development and commercialization of our products or could damage our relationship with a collaborator. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A small number of licensing partners and government contracts account for a substantial portion of our revenue. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive, and in the past we have derived, a significant portion of our revenue from a limited number of licensing partners and government grants and contracts. Revenue can fluctuate significantly depending on the timing of upfront and event-based payments and work performed. If we fail to sign additional future contracts with major licensing partners and the government, if a contract is delayed or deferred, or if an existing contract expires or is canceled and we fail to replace the contract with new business, our revenue would be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have agreements with government agencies, which are subject to termination and uncertain future funding. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with government agencies, such as the NIAID, DARPA and the DoD, and we intend to continue entering into these types of agreements in the future. Our business is partially dependent on the continued performance by these government agencies of their responsibilities under these agreements, including adequate continued funding of the agencies and their programs. We have no control over the resources and funding that government agencies may devote to these agreements, which may be subject to annual renewal and which generally may be terminated by the government agencies at any time. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government agencies may fail to perform their responsibilities under these agreements, which may cause them to be terminated by the government agencies. In addition, we may fail to perform our responsibilities under these agreements. Many of our government agreements are subject to audits, which may occur several years after the period to which the audit relates. If an audit identifies significant unallowable costs, we could incur a material charge to our earnings or reduction in our cash position. As a result, we may be unsuccessful entering, or ineligible to enter, into future government agreements. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we and our collaborators may not be able to obtain regulatory approval for or commercialize our product candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators have entered into agreements with CROs to provide monitors for and to manage data for our on-going clinical programs. We and the CROs conducting clinical trials for our electroporation equipment and product candidates are required to comply with current good clinical practices, or GCPs, regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or the CROs conducting clinical trials of our product candidates fail to comply with applicable GCPs, the clinical data generated in the clinical trials may be deemed unreliable and the FDA may require additional clinical trials before approving any marketing applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any relationships with CROs terminate, we or our collaborators may not be able to enter into arrangements with alternative CROs. In addition, these third-party CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our on-going clinical programs or perform trials efficiently. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could harm our competitive position. If CROs do not successfully carry out their </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. Cost overruns by or disputes with our CROs may significantly increase our expenses.   </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no marketing and sales organization. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not have a sales organization for the marketing, sales and distribution of our electroporation equipment and product candidates. In order to commercialize any products, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We contemplate establishing our own sales force or seeking third-party partners to sell our products. The establishment and development of our own sales force to market any products we may develop will be expensive and time consuming and could delay any product launch, and we may not be able to successfully develop this capability. We will also have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. To the extent we rely on third parties to commercialize our approved products, if any, we will receive lower revenues than if we commercialized these products ourselves. In addition, we may have little or no control over the sales efforts of third parties involved in our commercialization efforts. In the event we are unable to develop our own marketing and sales force or collaborate with a third-party marketing and sales organization, we would not be able to commercialize our product candidates which would negatively impact our ability to generate product revenues. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If products for which we receive regulatory approval do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our electroporation equipment and product candidates for which we obtain marketing approval from the FDA or other regulatory authorities will depend upon the acceptance of these products by both the medical community and patient population. Coverage and reimbursement of our product candidates by third-party payors, including government payors, generally is also necessary for optimal commercial success. The degree of market acceptance of any of our approved products will depend on a number of factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to provide acceptable evidence of safety and efficacy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative convenience and ease of administration; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any actual or perceived adverse side effects; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in a product's FDA-approved labeling, including, for example, potential &#8220;black box&#8221; warnings </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of alternative treatments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and cost effectiveness; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our or any future collaborators' sales and marketing strategies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the public perception of new therapies and the reputational challenges that the vaccine industry is facing related to the growing momentum of the anti-vaccine movement;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain sufficient third-party coverage and adequate reimbursement; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out of pocket in the absence of third-party coverage. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our electroporation equipment and product candidates are approved but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to uncertainty relating to coverage and reimbursement policies which, if not favorable to our product candidates, could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and medical treatments. Accordingly, our ability to commercialize our electroporation equipment and product candidates successfully will depend in part on the extent to which governmental authorities, including Medicare and Medicaid, private health insurers and other third-party payors establish appropriate coverage and reimbursement levels for our product candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors generally require that drug products have been approved for marketing by the FDA. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are already available. Even if we obtain coverage for a given product, the associated reimbursement rate may not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and distribution expenses, or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless reimbursement is adequate to cover all or a significant portion of the cost of our drug products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some of our products, if approved, will be provided under the supervision of a physician. When used in connection with medical procedures, our product candidates may not be reimbursed separately but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our product candidates or procedures using our product candidates, could reduce physician utilization of our products once approved.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs. We may not be able to obtain third-party payor coverage or reimbursement for our products in whole or in part.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Managing Our Growth and Employee and Operational Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have actions brought against us by stockholders relating to past transactions, changes in our stock price or other matters. For example, during 2020, numerous purported shareholder class action complaints have been filed against us, naming us and our directors and executive officers as defendants, and alleging that we made materially false and misleading statements regarding the development of our INO-4800 vaccine candidate against COVID-19 in violation of certain federal securities laws. We may also become party to litigation with third parties as a result of our business activities. In 2020, we filed a lawsuit against one of our contract manufacturers, who then filed a counterclaim against us alleging that we had breached our contract with them, among other claims. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These litigation matters, described in this report, are ongoing, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">even though we intend to vigorously defend ourselves in these actions, there can be no assurance that we will ultimately prevail. These and any potential future actions against us could give rise to substantial damages, which could have a material adverse effect on our financial position, liquidity or results of operations. Even if an action is not resolved against us, the uncertainty and expense associated with litigation could harm our business, financial condition and reputation, as litigation is often costly, time-consuming and disruptive to business operations. The defense of our existing and potential future lawsuits could also result in diversion of our management's time and attention away from business operations, which could harm our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the global COVID-19 pandemic.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus, since named SARS-CoV-2, causing the disease known as COVID-19, was reported in China. Since then, COVID-19 has spread globally, resulting in the World Health Organization (WHO) declaring the outbreak of COVID-19 as a &#8220;pandemic&#8221; in March 2020 and United States also declaring a national emergency. In response to the COVID-19 pandemic, a number of governmental orders and other public health guidance measures were implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. As a result, our expected clinical development timelines could be negatively affected by COVID-19, which could then materially and adversely affect our business, financial condition and results of operations. Further, we have implemented a work from home policy allowing employees who can work from home to do so, while those needing to work in laboratory facilities work in shifts to reduce the number of people gathered together at one time. Business travel has been suspended and online and teleconference technology is used to meet virtually rather than in person. We have taken measures to secure our research and development project activities, while work in laboratories has been organized to reduce risk of COVID-19 transmission. Our increased reliance on personnel working from home may negatively impact our productivity, or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could disrupt, delay or otherwise adversely impact our business. For example, with our personnel working from home, some of our research activities that require our personnel to be in our laboratories could be delayed.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as local jurisdictions continue to put restrictions in place, our ability to continue to conduct and enroll patients in our clinical trials, manufacture our product candidates and pursue collaborations may also be limited. Such events may result in business and manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19, which has caused a broad impact globally, could also affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, it has resulted in significant disruption of global financial markets, which could reduce our ability to access capital. Although we have raised significant funds from the sale of our common stock in the public markets during the pandemic, there can be no guarantee that we will be able to continue to so, which could negative affect our future liquidity. In addition, if a global economic recession results following the spread of COVID-19, its impact could materially affect our business and the value of our common stock.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continued spread of COVID-19 globally has and could continue to adversely affect our clinical trial operations, including our ability to initiate and conduct our planned trials on their expected timelines and to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. For example, COVID-19 has adversely impacted the timeline for data collection for our VGX-3100 program. An increasing number of trial participants are either not able or do not feel safe going into healthcare facilities, which is necessary for the collection and completion of data samples for this trial. These concerns are magnified by increasing COVID-19 infection rates, surges in cases globally, and lockdowns now occurring in Europe. As a result, it is taking longer than anticipated to complete the data collection process. Further, the COVID-19 outbreak could result in delays in our clinical trials due to prioritization of hospital resources toward the outbreak, restrictions in travel, potential unwillingness of patients to enroll in trials, patients withdrawing from trials following enrollment as a result of contracting COVID-19 or other health conditions, or the inability of patients to comply with clinical trial protocols as quarantines and travel restrictions impede patient movement or interrupt healthcare services. In addition, we rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us. These restrictions may delay the conduct of multiple clinical trials including our Phase 1 through 3 clinical trials.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, COVID-19 may also result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with local and foreign regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees, and refusals to accept data from clinical trials conducted in these affected geographies.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global outbreak of COVID-19 continues to rapidly evolve. The extent to which COVID-19 may impact our business, operations and clinical trials will depend on future developments, including the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, the effectiveness of actions taken in the United States and other countries to contain and treat the disease and whether the United States and additional countries are required to move to complete lock-down status. The ultimate long-term impact of COVID-19 is highly uncertain.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense and increasing competition and many of our competitors have significantly greater resources and experience. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our competitors develop products with efficacy or safety profiles significantly better than our products, we may not be able to commercialize our products, and sales of any of our commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or products obsolete or noncompetitive, or result in treatments or cures superior to ours.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many other companies are pursuing other forms of treatment or prevention for diseases that we target. For example, many of our competitors are working on developing and testing COVID-19 vaccines, cancer vaccines and immunotherapies, and several products such as the CAR-Ts developed by our competitors have been approved for human use. Some of our competitors have already received regulatory approval for their COVID-19 vaccines and have begun distribution in our target markets. The earlier market entry of these other vaccines, and their actual or perceived efficacious or success relative to our own, may lead to diversion of funding away from us, decreased demand for INO-4800, if approved, and difficulty in finding participants for our clinical trials. All of these factors could substantially impact our ability to complete the development of, commercialize and generate revenues from INO-4800. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our competitors and potential competitors include large pharmaceutical and more established biotechnology companies. These companies have significantly greater financial and other resources and greater expertise than us in research and development, securing government contracts and grants to support research and development efforts, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing. This may make it easier for them to respond more quickly than us to new or changing opportunities, technologies or market needs. Many of these competitors operate large, well-funded research and development programs and have significant products approved or in development. Small companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical companies or through acquisition or development of intellectual property rights. Our potential competitors also include academic institutions, governmental agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for product and clinical development and marketing. Research and development by others may seek to render our technologies or products obsolete or noncompetitive.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to successfully acquire, develop and market additional product candidates or approved products would impair our ability to grow.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire, in-license, develop and/or market additional products and product candidates. The success of these actions depends partly upon our ability to identify, select and acquire promising product candidates and products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, future acquisitions may entail numerous operational and financial risks, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to unknown liabilities; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption of our business and diversion of our management's time and attention to develop acquired products or technologies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher than expected acquisition and integration costs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased amortization expenses; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to retain key employees of any acquired businesses. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend upon key personnel who may terminate their employment with us at any time and we may need to hire additional qualified personnel in order to obtain financing, pursue collaborations or develop or market our product candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business strategy will depend to a significant degree upon the continued services of key management, technical and scientific personnel and our ability to attract and retain additional qualified personnel and managers, including personnel with expertise in clinical trials, government regulation, manufacturing, marketing and other areas. Competition for qualified personnel is intense among companies, academic institutions and other organizations. If we are unable to attract and retain key personnel and advisors, it may negatively affect our ability to successfully develop, test, commercialize and market our products and product candidates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the FDA and other government agencies could hinder our ability to hire and retain key leadership and other personnel, or otherwise prevent new products from being developed or commercialized in a timely manner, which could negatively impact our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days from December 2018 to January 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on information technology and our systems and infrastructure face certain risks, including from cybersecurity breaches and data leakage.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely to a large extent upon sophisticated information technology systems to operate our businesses, some of which are managed, hosted provided and/or used for third-parties or their vendors. We collect, store and transmit large amounts of confidential information (including personal information and pseudonymized information), and we deploy and operate an array of technical and procedural controls to maintain the confidentiality and integrity of such confidential information. A significant breakdown, invasion, corruption, destruction, interruption, or unavailability of critical information technology systems or infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations. Hardware, software, or applications we develop or obtain from third parties may contain defects in design or manufacture or other supply chain problems that could unexpectedly compromise our information and network security. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our or our third-party providers' systems, portable media or storage devices. We could also experience a business interruption, theft of confidential information or reputational damage from industrial espionage attacks, malware or other cyber-attacks (including ransomware), which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. While we have invested in the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us. In addition, as the regulatory environment related to information security, data collection and use, and privacy becomes increasingly rigorous, with new and constantly changing requirements applicable to our business, compliance with those requirements could also result in additional costs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure and, if successful claims are brought against us, we may incur substantial liability.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of our electroporation equipment and DNA vaccine, DNA immunotherapy and dMAb candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism, and these companies have incurred material costs to defend these claims. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our product candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of related litigation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management's attention from our primary business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenues; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to commercialize our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained product liability insurance coverage for our clinical trials, but our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform measures could hinder or prevent our products' commercial success. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the United States and certain foreign jurisdictions there have been, and we anticipate there will continue to be, a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell any of our products profitably. In the United States, the federal government enacted healthcare reform legislation, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA.   Among the ACA&#8217;s provisions of importance to the pharmaceutical industry are that it:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposed an annual excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United States, with limited exceptions, although the effective rate paid may be lower. However, the 2020 federal spending package permanently eliminated, effective January 1, 2020, this ACA-mandated medical device tax;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded the entities eligible for discounts under the Public Health program;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">established a Center for Medicare &amp; Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending that began on January 1, 2011; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created a licensure framework for follow on biologic products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain judicial and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry qualifying health insurance coverage for all or part of a year. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage, and, effective January 1, 2021, also eliminated the health insurer tax. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing the case, although it is unknown when a decision will be made. Further, although the U.S. Supreme Court has not yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden administration will impact the ACA and our business.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect through 2030 with the exception of a temporary suspension from May 1, 2020 through March 31, 2021 unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">methodologies for products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. The Department of Health and Human Services, or HHS, has solicited feedback on some of these measures and implemented others under its existing authority. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until March 22, 2021.  On November 20, 2020, CMS issued an interim final rule implementing the Trump administration&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. It is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives.  Further, at the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. It is also possible that additional governmental action is taken in response to the COVID-19 pandemic. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to make and implement healthcare reforms may adversely affect: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price we believe is fair for our products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenues and achieve or maintain profitability; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain timely approval of our products. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to our business. The laws that may affect our ability to operate include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid. The intent standard under the federal healthcare program Anti-Kickback Statute was amended by the ACA to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the ACA codified case law that a claim including items or services resulting from a violation of the federal healthcare program Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal healthcare program Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, as well as ownership and investment </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interests held by physicians and their immediate family members, and which, beginning in 2022, will require applicable manufacturers to report information regarding payments and other transfers of value provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants, and certified nurse-midwives;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Federal Food, Drug, and Cosmetic Act, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may run afoul of one or more laws.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm, and the curtailment or restructuring of our operations. Any such penalties could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our third-party manufacturers' activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In the event of an accident, state or federal authorities may curtail the use of these materials and interrupt our business operations. If we are subject to any liability as a result of our or our third-party manufacturers' activities involving hazardous materials, our business and financial condition may be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have entered into collaborations with Chinese companies and conduct certain research and development activities in China. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war or political unrest in China could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct research and development activities in China through our collaboration with Advaccine, which is conducting and funding the Phase 2 trial of INO-4800 in China. In addition, we are party to a license and collaboration agreement with China-based company ApolloBio, pursuant to which ApolloBio has the exclusive right to develop and commercialize VGX-3100 in China, Hong Kong, Macao and Taiwan. The Chinese legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions may be cited for reference but have limited precedential value. In addition, the Chinese legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or at all, and which may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until after the occurrence of the violation. Any administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. Since Chinese administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. Furthermore, we are exposed to the possibility of disruption of our research and development activities in the event of changes in the policies of the United States or Chinese governments, political unrest or unstable </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">economic conditions in China. For example, a trade war could lead to increased costs for clinical materials that are manufactured in China. These interruptions or failures could also impede commercialization of our product candidates and impair our competitive position. Further, we may be exposed to fluctuations in the value of the local currency in China. These uncertainties may impede our ability to enforce the contracts we have entered into and our ability to continue our research and development activities and could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in part on obtaining and maintaining patent, trademark, trade secret, and other intellectual property protection relating to our electroporation equipment and product candidates, as well as successfully defending these intellectual property rights against third-party challenges. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. The laws and regulations regarding the breadth of claims allowed in biotechnology patents have evolved over recent years and continues to undergo review and revision, both in the United States and abroad. The biotechnology patent situation outside the United States can be even more uncertain depending on the country. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our licensed patents, our patents or in third-party patents, nor can we predict the likelihood of our patents surviving a patent validity challenge. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our intellectual property rights is uncertain, because legal decision-making can be unpredictable, thereby often times resulting in limited protection, which may not adequately protect our rights or permit us to gain or keep our competitive advantage, or resulting in an invalid or unenforceable patent. For example: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or the parties from whom we have acquired or licensed patent rights, may not have been the first to file the underlying patent applications or the first to make the inventions covered by such patents; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the named inventors or co-inventors of patents or patent applications that we have licensed or acquired may be incorrect, which may give rise to inventorship and ownership challenges; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may develop similar or alternative technologies, or duplicate any of our products or technologies that may not be covered by our patents, including design-arounds; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pending patent applications may not result in issued patents; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents covering our products and technologies may not provide us with any competitive advantages or have any commercial value; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be challenged and invalidated, or rendered unenforceable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be subject to reexamination, which could result in a narrowing of the scope of claims or cancellation of claims found unpatentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop or acquire additional proprietary technologies that are patentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our trademarks may be invalid or subject to a third party's prior use; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enforce our patent rights will depend on our ability to detect infringement, and litigation to enforce patent rights may not be pursued due to significant financial costs, diversion of resources, and unpredictability of a favorable result or ruling. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend, in part, on our licensors and collaborators to protect a portion of our intellectual property rights. In such cases, our licensors and collaborators may be primarily or wholly responsible for the maintenance of patents and prosecution of patent applications relating to important areas of our business. If any of these parties fail to adequately protect these products with issued patents, our business and prospects would be harmed significantly. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our trade secrets to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our licensors fail to obtain or maintain patent protection or trade secret protection for our product candidates or our technologies, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and attain profitability. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, U.S. and other policymakers have proposed reforming the patent laws and regulations of their countries. In September 2011 the America Invents Act (the Act) was signed into law. The Act changed the current &#8220;first-to-invent&#8221; system to a system that awards a patent to the &#8220;first-inventor-to-file&#8221; for an application for a patentable invention. The Act also created a procedure to challenge newly issued patents in the patent office via post-grant proceedings and new inter parties reexamination proceedings. These changes may make it easier for competitors to challenge our patents, which could result in increased competition and have a material adverse effect on our product sales, business and results of operations. The changes may also make it harder to challenge third-party patents and place greater importance on being the first inventor to file a patent application on an invention. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other companies may have or may acquire intellectual property rights that could be enforced against us. If they do so, we may be required to alter our technologies, pay licensing fees or cease activities. If our products or technologies infringe the intellectual property rights of others, they could bring legal action against us or our licensors or collaborators claiming damages and seeking to enjoin any activities that they believe infringe their intellectual property rights. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications can take many years to issue, and there is a period when the application remains undisclosed to the public, there may be currently pending applications unknown to us or reissue applications that may later result in issued patents upon which our products or technologies may infringe. There could also be existing patents of which we are unaware that our products or technologies may infringe. In addition, if third parties file patent applications or obtain patents claiming products or technologies also claimed by us in pending applications or issued patents, we may have to participate in interference or derivation proceedings in the United States Patent and Trademark Office to determine priority or derivation of the invention. If third parties file oppositions in foreign countries, we may also have to participate in opposition proceedings in foreign tribunals to defend the patentability of our filed foreign patent applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a third party claims that we infringe its intellectual property rights, it could cause our business to suffer in a number of ways, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become involved in time-consuming and expensive litigation, even if the claim is without merit, the third party's patent is invalid or we have not infringed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become liable for substantial damages for past infringement if a court decides that our technologies infringe upon a third party's patent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be enjoined by a court to stop making, selling or licensing our products or technologies without a license from a patent holder, which may not be available on commercially acceptable terms, if at all, or which may require us to pay substantial royalties or grant cross-licenses to our patents; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to redesign our products so that they do not infringe upon others' patent rights, which may not be possible or could require substantial investment or time. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, our business could suffer and the market price of our common stock may decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to an Investment in Our Common Stock</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not be sustained.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed on the Nasdaq Global Select Market, we cannot assure you that an active trading market for our shares will continue to be sustained. If an active market for our common stock is not sustained, it may be difficult for investors in our common stock to sell shares without depressing the market price for the shares or to sell the shares at all.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has been and may continue to be volatile, and an investment in our common stock could decline substantially in value. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of our small size and limited resources, as well as the uncertainties and risks that can affect our business and industry, our stock price has been and may continue to be highly volatile and has been and may in the future be subject to substantial drops, with or even in the absence of news affecting our business. Period to period comparisons are not indicative of future performance. The following factors, in addition to the other risk factors described in this report, and the potentially low volume of trades in our common stock, may have a significant impact on the market price of our common stock, some of which are beyond our control: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning any research and development, clinical trials, manufacturing, and marketing efforts or collaborations, particularly developments concerning the prospects of INO-4800 as a potential vaccine candidate against COVID-19;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuating public or scientific interest in the potential for COVID-19 and other pandemic or other applications for our vaccine or other product candidates; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our announcement of significant acquisitions, strategic collaborations, joint ventures or capital commitments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our operating results; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new products or services that we or our competitors offer; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, conduct and/or outcome of intellectual property and/or litigation matters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial or other estimates by securities analysts or other reviewers or evaluators of our business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions or trends in bio-pharmaceutical or other healthcare industries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and other countries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative perception of gene-based therapy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the economic performance and/or market valuations of other biotechnology and medical device companies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our capital structure;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions by executive officers or directors involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting principles; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">global unrest, terrorist activities, and economic and other external factors; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">catastrophic weather and/or global disease pandemics, including COVID-19. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock market in general has recently experienced relatively large price and volume fluctuations, particularly in response to the COVID-19 outbreak. In particular, the market prices of securities of smaller biotechnology and medical device companies have experienced dramatic fluctuations that often have been unrelated or disproportionate to the operating results of these companies. Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. In addition, price volatility may increase if the trading volume of our common stock remains limited or declines.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation contains provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authority of our board of directors to issue shares of undesignated preferred stock and to determine the rights, preferences and privileges of these shares, without stockholder approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all stockholder actions must be effected at a duly called meeting of stockholders and not by written consent; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the elimination of cumulative voting. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors, including to delay or impede a merger, tender offer or proxy contest involving our company. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid cash dividends on our common stock and we do not anticipate paying dividends in the foreseeable future. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid no cash dividends on our common stock to date, and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any future debt or credit facility may preclude or limit our ability to pay any dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of potential gain for the foreseeable future. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expenses related to our electroporation equipment, product candidates or future development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses related to corporate transactions, including ones not fully completed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addition or termination of clinical trials or funding support; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit in which we may become involved; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any legal claims that may be asserted against us or any of our officers; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our electroporation equipment and product candidates or those of our competitors; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations on the Notes and the December 2019 Bonds;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the fair value of our investments, including investments in affiliated entities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if any of our products receives regulatory approval, the levels of underlying demand for our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and liquidity needs could be materially affected by market fluctuations and general economic conditions. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be materially affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, global pathogen outbreaks or pandemics, including COVID-19, and the availability and cost of credit have in the past and may continue to contribute to increased volatility and diminished expectations for the economy and the markets going forward. Market upheavals may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected. Our future cost of equity or debt capital and access to the capital markets could be adversely affected, and our stock price could decline. There may be disruption in or delay in the performance of our third-party contractors and suppliers. If our contractors, suppliers and partners are unable to satisfy their contractual commitments, our business could suffer. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits, and we may experience losses on these deposits. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business, and we have limited research coverage by equity research analysts. Equity research analysts may elect not to initiate or continue to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. Even if we have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation authorizes us to issue up to 600,000,000 shares of common stock and up to 10,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plans or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs and demands upon management as a result of being a public company.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company listed in the United States, we incur significant legal, accounting and other costs that could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and stock exchanges, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws could adversely affect our business and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Tax Cuts and Jobs Act of 2017 was enacted, which significantly revised the Internal Revenue Code of 1986, as amended, or the Code. The new federal income tax law, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35 percent to a flat rate of 21 percent, limitation of the tax deduction for interest expense to 30 percent of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80 percent of current-year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions). Notwithstanding the reduction in the corporate income tax rate, the overall impact of the federal tax law is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the federal tax law.</span></div><div><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_19"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i06d07667d4974765a8282374d1211e66_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own no real property and have no plans to acquire any real property in the future. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">San Diego Leases</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2013, we entered into a lease, or the First San Diego Lease, for office space in San Diego, California. The term of the First San Diego Lease commenced on December 1, 2013. The initial term of the First San Diego Lease is ten years, with an option to extend the term by five years, subject to specified conditions. In June 2015, we amended the First San Diego Lease to increase the total leased space to 31,207 square feet and occupy the entire building. The commencement of the amended First San Diego Lease was in January 2016. As of December 31, 2020, rent payments under the First San Diego Lease include base rent with an annual increase of approximately 3 percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. We had an option to terminate the First San Diego Lease on December 1, 2019, which we did not exercise.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016, we entered into an office lease, or the Second San Diego Lease, for a second property in San Diego, California. The total space under the Second San Diego Lease is approximately 51,000 square feet. We are using the facility for office, manufacturing and research and development purposes. The term of the Second San Diego Lease commenced on June&#160;1, 2017. The initial term of the Second San Diego Lease is ten years, with a right to terminate on November&#160;30, 2023, subject to specified conditions.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base rent adjusts periodically throughout the term of the Second San Diego Lease. As of December 31, 2020, rent payments under the Second San Diego Lease include base rent with an annual increase of approximately 3 percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. In addition, we have paid a security deposit of $95,000. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plymouth Meeting Lease </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, we entered into a lease, or the Plymouth Meeting Lease, for our corporate headquarters in Plymouth Meeting, Pennsylvania. We occupied the space in June 2014. The initial term of the Plymouth Meeting Lease was 11.5 years, with a right to extend the term by five years, subject to specified conditions. We use the space for office purposes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base rent adjusts periodically throughout the term of the Plymouth Meeting Lease. As of December 31, 2020, rent payments under the Plymouth Meeting Lease include base rent with an annual increase of approximately 2 percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. In addition, we have paid a security deposit of $49,000. In July 2015, we amended the Plymouth Meeting Lease to increase the total leased space to 27,583 square feet. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, we entered into another amendment to the Plymouth Meeting Lease to increase the total leased space to 57,361 square feet and extend the lease term through December 31, 2029. In connection with this amendment, we paid the landlord an additional security deposit of $75,000.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, we entered into two agreements to sublease a total of approximately 13,500 square feet in our Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our current and future planned facilities will be adequate to meet our operating needs for the foreseeable future. Should we need additional space, we believe we will be able to secure additional space at commercially reasonable rates.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_25"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Securities Litigation</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;12, 2020, a purported shareholder class action complaint,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed in the United States District Court for the Eastern District of Pennsylvania, naming us and J. Joseph Kim, our Chief Executive Officer, as defendants. The lawsuit alleges that we made materially false and misleading statements regarding our development of a vaccine for&#160;COVID-19 in our public disclosures in violation of certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. On June 18, 2020, the court appointed Manuel Williams to serve as lead plaintiff.&#160;On August 3, 2020, Mr. Williams filed a consolidated complaint, naming us and three of our officers as defendants. On September 21, 2020, Mr. Williams and another purported stockholder, Andrew Zenoff filed a first amended complaint, naming us and three of our officers as defendants. Defendants filed a motion to dismiss plaintiff&#8217;s first amended complaint on November 5, 2020. On February 16, 2021, the court issued an order granting in part, and denying in part, Defendants&#8217; motion to dismiss.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The court granted Defendants&#8217; motion to dismiss, and dismissed with prejudice, the claims premised on the April 30 and June 30, 2020 statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The court denied Defendants&#8217; motion to dismiss as to the remaining statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defendants&#8217; deadline to file their answer to the complaint is March 2, 2021.</span></div><div style="margin-top:5.2pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, a purported shareholder derivative complaint, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Behesti v. Kim, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class action complaint. The lawsuit accuses our board of directors of failing to exercise reasonable and prudent supervision over our management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of us as well as governance reforms. On June 5, 2020, the court stayed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Beheshti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay.</span></div><div style="margin-top:5pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 12 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Isman v. Benito</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Devarakonda et al. v Kim, et. al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160; The complaints assert substantially similar claims as the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Beheshti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action and name our current directors as defendants.&#160;The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Devarakonda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint also names one of our former directors as a defendant.&#160; On July 21, 2020, the court consolidated the three derivative cases under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Inovio Pharmaceuticals, Inc. Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160; The consolidated action is stayed pending resolution of a forthcoming motion to dismiss the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">McDermid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> securities class action or until any party provides notice that they no longer consent to the stay.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 7, 2020, a fourth shareholder derivative complaint, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Fettig v. Kim et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The complaint asserts substantially similar claims as those in the consolidated derivative action.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to defend these actions vigorously.</span></div><div style="margin-top:5pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">VGXI Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"> </span></div><div style="margin-top:5pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On June 3, 2020, we filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached our supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI.  On June 3, 2020, we filed a petition for preliminary injunction, which was denied on June 25, 2020.  On June 26, 2020, we filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> On July 7, 2020, VGXI filed an answer, new matter and counterclaims against us, alleging that we had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment.  The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from us.  Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that we had engaged to provide services similar to those </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">that were being provided by VGXI. On July 27, 2020, we filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. On October 1, 2020, we filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.  </span></div><div style="margin-top:5pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We intend to aggressively prosecute the claims set forth in our complaint against VGXI and to vigorously defend ourselves against VGXI&#8217;s counterclaims. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against us, alleging that we had breached the CELLECTRA Device License Agreement, or the Agreement, between us and GeneOne. We terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from us. We intend to vigorously defend ourselves against GeneOne&#8217;s claims. On January 29, 2021, we filed preliminary objections to the complaint.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div id="i06d07667d4974765a8282374d1211e66_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i06d07667d4974765a8282374d1211e66_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i06d07667d4974765a8282374d1211e66_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock, par value $0.001 per share, began trading on the Nasdaq Global Select Market on September 15, 2014 under the symbol "INO," having previously traded on the NYSE MKT exchange. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 11, 2021, we had approximately 457 common stockholders of record. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The closing price per share of our common stock on February 11, 2021 was $13.00, as reported on the Nasdaq Global Select Market.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payment of any dividends on our common stock is within the discretion of our board of directors. We have never paid cash dividends on our common stock and the board of directors does not expect to declare cash dividends on the common stock in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below compares the performance of our common stock with the performance of the NYSE American Index, the S&amp;P SuperCap Biotechnology index and the Nasdaq Composite Index for the five years ended December 31, 2020. The graph assumes a $100 investment on December 31, 2015 in our common stock and in each index, with the reinvestment of all dividends, if any.</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><img src="ino-20201231_g7.jpg" alt="ino-20201231_g7.jpg" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:558px"/></div><div style="padding-left:108pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*$100 invested on 12/31/15 in stock or index, including reinvestment of dividends.<br/>Fiscal year ended December 31.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:15pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/20</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inovio Pharmaceuticals, Inc.&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NYSE American</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nasdaq Composite</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P SuperCap Biotechnology Index</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The stock price performance included in this graph is not necessarily indicative of future stock price performance. The performance graph is furnished solely to accompany this Form 10-K annual report and shall not be deemed to be incorporated by reference by means of any general statement incorporating by reference this Form 10-K into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate such information by reference, and shall not otherwise be deemed filed under such acts.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we issued 5,147 shares of common stock upon the conversion of preferred stock and a total of 16,498,024 shares of common stock upon the conversion of convertible debt instruments.  The foregoing shares of common stock were issued in reliance upon the exemption set forth in Section 3(a)(9) of the Securities Act of 1933, as amended, for securities exchanged by us and existing security holders where no commission or other remuneration is paid or given directly or indirectly by us for soliciting such exchange.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Parties </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;SELECTED FINANCIAL DATA</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following selected consolidated financial data should be read together with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our consolidated financial statements and related notes included elsewhere in this report. The selected consolidated balance sheet data at December 31, 2020 and 2019 and the selected consolidated statements of operations data for the years ended December 31, 2020, 2019 and 2018 have been derived from our audited consolidated financial statements that are included elsewhere in this report. The selected consolidated balance sheet data at December 31, 2018, 2017, and 2016 and the selected consolidated statements of operations data for the years ended December&#160;31, 2017 and 2016 have been derived from our audited consolidated financial statements not included in this report. Historical results are not necessarily indicative of the results to be expected in the future.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/>2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/>2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/>2016</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Statement of Operations Data:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research&#160;and development arrangements, including from affiliated entity</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,624,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,872,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,310,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,173,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,891,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grants&#160;and miscellaneous revenue, including from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,046,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,477,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,411,220&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,111,930&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,481,897&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,220,086&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,368,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,082,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,108,545)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,091,138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,642,901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,235,937)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,095,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,846,358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,612,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,670,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,763,652)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on investment in affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,556,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,090,557)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,988,567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,982,664)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,121,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,177,043)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,762,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,584,610)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Provision for) benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,169,811)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167,474,914)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,551,777)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,967,830)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,205,772)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,740,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,063,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,192,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166,411,157)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,359,219)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,967,830)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,205,772)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,740,339)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share attributable to common stockholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.07)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.05)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.08)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.07)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.21)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.05)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.09)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.01)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2016</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Data:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,728,118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,196,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,693,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,786,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,136,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,914,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,338,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,538,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,638,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,629,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,772,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,951,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,113,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,239,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,707,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,705,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,989,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,299,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,405,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,823,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,925,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,557,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,781,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,345,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,505,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(906,196,812)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(739,785,655)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(620,426,436)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(523,356,317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(434,838,235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,140,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,404,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,032,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,488,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,378,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i06d07667d4974765a8282374d1211e66_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This report contains forward-looking statements, as defined in Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements are reasonable based on our current expectations and projections, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We are under no obligation to update any of the forward-looking statements after the filing of this Annual Report to conform such statements to actual results or to changes in our expectations.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes and other financial information appearing elsewhere in this Annual Report. Readers are also urged to carefully review and consider the various disclosures made by us which attempt to advise interested parties of the factors which affect our business, including without limitation the disclosures made in Item&#160;1A of Part&#160;I of this Annual Report under the Caption &#8220;Risk Factors.&#8221;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk factors that could cause actual results to differ from those contained in the forward-looking statements include but are not limited to: our history of losses; our lack of products that have received regulatory approval; uncertainties inherent in clinical trials and product development programs, including but not limited to the fact that pre-clinical and clinical results may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve desired results, that preclinical studies and clinical trials may not commence, have sufficient enrollment or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our electroporation technology and DNA vaccines may fail to show the desired safety and efficacy traits in clinical trials; the availability of funding; the ability to manufacture vaccine candidates; the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; our ability to receive development, regulatory and commercialization event-based payments under our collaborative agreements; whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity; and the impact of government healthcare laws and proposals.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_43"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus (HPV). Our DNA medicines pipeline is comprised of three types of product candidates: DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies (dMAbs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In clinical trials, we have demonstrated that DNA medicines can be delivered directly into cells in the body through our proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted pathogens and cancers. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our novel DNA medicine candidates are made using our proprietary SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology that uses a computer algorithm designed to identify and optimize the DNA sequence of the target antigen (be it virus or a tumor). INOVIO then creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce antigens to help the person&#8217;s immune system recognize and destroy cancerous or virally infected cells.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patented CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery devices provide optimized uptake of our DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches, namely cellular uptake. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trial data to date has shown a favorable safety profile of our DNA medicines delivered directly into cells in the body using the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart device in more than 7,000 administrations across more than 3,000 patients.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate strategy is to advance, protect and, once approved, commercialize our novel DNA medicines to meet urgent and emerging global health needs. We continue to advance and clinically validate an array of DNA medicine candidates that target HPV-associated diseases, cancer, and infectious diseases, such as COVID-19 (SARS-CoV-2). We aim to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners and collaborators include ApolloBio Corp., AstraZeneca, Advaccine, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium (MCDC), International Vaccine Institute (IVI), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators are currently conducting or planning clinical studies of our DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis, or RRP; glioblastoma multiforme, or GBM; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome, or MERS; Lassa fever; Zika virus; and the COVID-19 virus.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are in the research and development phase. We have not generated any revenues from the sale of any products, and we do not expect to generate any such revenues for at least the next several years. We earn revenue from license fees and milestone revenue and collaborative research and development agreements. Our product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that we advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had an accumulated deficit of $906.2 million. We expect to continue to incur substantial operating losses in the future due to our commitment to our research and development programs, the funding of preclinical studies, clinical trials and regulatory activities and the costs of general and administrative activities. </span></div><div style="margin-top:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impacts of COVID-19 on Our Business </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has had a number of significant impacts on our business during 2020. Most notably, in the United States, South Korea and China, we have accelerated the clinical development of INO-4800, our DNA vaccine candidate matched to the outbreak strain of SARS-CoV-2, the virus that causes COVID-19. In January, we received initial grant funding from CEPI to advance INO-4800 into preclinical studies and clinical development through Phase 1 human testing. We had previously been awarded grants from CEPI for the development of other DNA vaccines against Lassa fever and Middle East Respiratory Syndrome, MERS, which is also caused by a coronavirus like COVID-19. We commenced a Phase 1 clinical trial in the United States in April, and in June we reported positive interim data from the first two cohorts of the trial. In December 2020, we dosed the first subject in the Phase 2 segment of our Phase 2/3 clinical trial called INNOVATE (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IN</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ovio</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> INO</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-4800 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Va</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ccine </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rial for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fficacy).  We have fully enrolled approximately 400 participants in the Phase 2 segment who are 18 years or older at 17 U.S. sites to evaluate safety and immunogenicity in order to confirm the dose(s) for the subsequent efficacy evaluation as part of the Phase 3 segment of the trial, once the FDA allows us to proceed.  The Phase 3 segment of the INNOVATE remains on partial clinical hold until we satisfactorily resolve the FDA's remaining questions related to the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2000 device that will be used to deliver INO-4800 into the cells of the skin. We plan to satisfy the remaining device questions during the conduct of Phase 2 segment and prior to the start of the Phase 3 segment of INNOVATE. In the Phase 3 segment of the trial, we intend to enroll healthy men and non-pregnant women 18 years and older, to evaluate the efficacy of the proposed dosing level(s) for each age group based on the data from the Phase 2 evaluation. Participants will be enrolled in a one-to-one randomization to receive either INO-4800 or a placebo. The Phase 3 segment will be case-driven with the final number of enrollees to be determined by the incidence of COVID-19 during the Phase 3 segment. The primary endpoint of the Phase 3 segment will be virologically-confirmed COVID-19 disease.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also initiated clinical trials of INO-4800 in South Korea and China. In April, CEPI awarded us a grant of $6.9 million to work with International Vaccine Institute and the Korea National Institute of Health to conduct a Phase 1/2 trial, which was the first COVID-19 vaccine clinical trial approved in South Korea. In China, we are collaborating with Advaccine and have dosed 640 subjects with the first vaccination in a Phase 2 clinical trial in China. The Phase 2 clinical trial of INO-4800 in China has enrolled both adults who are 18-59 years old and older adults (60 years and older) with the primary endpoints of evaluating safety and immunogenicity within the Chinese population. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In parallel with our accelerated clinical development efforts, we have engaged a network of partners for the planned large-scale manufacturing of INO-4800 if it achieves regulatory approval. In March, the U.S. Department of Defense, or DoD, awarded Ology Bioservices Inc. a contract to manufacture INO-4800 for the DoD to be used in upcoming clinical trials. In April, we entered into an agreement with the German contract manufacturer Richter-Helm BioLogics GmbH &amp; Co. KG and expanded our preexisting manufacturing partnership to support large-scale manufacturing of INO-4800. In March, we also received a grant from the Bill and Melinda Gates Foundation for accelerated testing and scale up of our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP proprietary smart device for the intradermal delivery of INO-4800. In June, the DoD awarded us $71.1 million to support the large-scale manufacture of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP, production of doses and the procurement of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2000 devices that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are used to deliver INO-4800 intradermally. In the second half of 2020, we added Thermo Fisher Scientific and Kaneka Eurogentec S.A., an affiliate of Kaneka Corporation, to our manufacturing consortium.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operationally, we have not experienced significant disruptions to date as a result of the COVID-19 pandemic.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the outbreak, a number of governmental orders and other public health guidance measures were implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. We have implemented a work from home policy allowing employees who can work from home to do so, while those needing to work in laboratory facilities work in shifts to reduce the number of people gathered together at one time. Business travel has been suspended, and online and teleconference technology is used to meet virtually rather than in person. We have taken measures to secure our research and development project activities, while work in laboratories has been organized to reduce risk of COVID-19 transmission.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, our liquidity has also not been negatively impacted by the pandemic. During the year ended December 31, 2020, we raised </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$454.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in net proceeds from the sale of shares of our common stock through our "at-the-market" equity offering program, which further enhanced our liquidity and capital resources. As of December 31, 2020, our cash and cash equivalents and short-term investments were $411.6 million, compared to $89.5 million as of December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in January 2021, we closed an underwritten public offering with net proceeds to us of $162.1&#160;million. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are closely monitoring the impact of the COVID-19 pandemic on our employees, collaborators and service providers. The extent to which the pandemic will impact our business and operations will depend on future developments, including the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, that are highly uncertain. For additional information on the potential effects of the COVID-19 pandemic on our business, financial condition and results of operations, see the &#8220;Risk Factors&#8221; section above in Part I, Item 1A of this Form 10-K.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC defines critical accounting policies as those that are, in management&#8217;s view, important to the portrayal of our financial condition and results of operations and require management&#8217;s judgment. Our discussion and analysis of our financial condition and results of operations are based on our audited consolidated financial statements, which have been prepared in accordance with U.S.&#160;GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses. We base our estimates on experience and on various assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates. Our critical accounting policies include:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether our collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, we assesses whether the payments between us and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to us represent consideration from a customer, then we account for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Topic 606&#8221;). However, if we concludes that our collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, we present such payments as a reduction of research and development expense.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy our performance obligations. At contract inception, we assess the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. We evaluate whether we are the principal or agent in the arrangement. We have determined that we are the principal in current arrangements as we control the product supply before it is transferred to the customer. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or our collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our collaborative arrangements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grants</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is outside the scope of Topic 606, as the government agencies granting us funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our long-term operating leases, we recognized an operating lease right-of-use asset and an operating lease liability on our consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that we would pay to borrow equivalent funds on a collateralized basis at the lease commencement </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. We determined the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for our operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Liabilities</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in our financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our activities have largely consisted of research and development efforts related to developing electroporation delivery technologies and DNA immunotherapies and vaccines. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from our independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. We review and accrue clinical trial expense based on work performed, relying on estimates of total trial management costs, sites activated, patients enrolled, and number of patient visits. We follow this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to our results of operations.</span></div><div><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding recent accounting pronouncements is contained in Note&#160;2 to the consolidated financial statements, included elsewhere in this report.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial data for the years ended December&#160;31, 2020, 2019 and 2018 is presented in the following table and the results of these periods are used in the discussion thereafter.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:21.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.112%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,  </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)          2020 vs. 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)          2019 vs. 2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements, including from affiliated entities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,624,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,872,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,310,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,751,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,437,715)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenue, including from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">786,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">547,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,411,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,111,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,481,897&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,299,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,369,967)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,245,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,017,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,257,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,228,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,240,557)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,247,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,203,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,315,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,044,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,112,003)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,493,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,220,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,573,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,272,789&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,352,560)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124,082,044)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(111,108,545)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(94,091,138)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,973,499)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,017,407)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,311,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,605,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,264,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">705,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,702,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,948,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(753,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,948,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(360,795)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75,670,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,763,652)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,907,325)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,763,652)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) on investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,556,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,090,557)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,988,567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,647,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,101,990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,695,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,695,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(704,896)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,343,856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,201,096)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,840,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,121,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,121,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,177,043)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,177,043)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,762,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,762,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss before income tax benefit/(provision for income tax) </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(162,890,304)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120,809,112)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(94,798,019)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42,081,192)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,011,093)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit/(provision for income taxes)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,169,811)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(257,335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,427,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share in net loss of Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,584,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,584,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(167,474,914)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120,551,777)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96,967,830)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,923,137)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,583,947)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,063,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,192,558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128,801)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,192,558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributed to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(166,411,157)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119,359,219)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96,967,830)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,051,938)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,391,389)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Not meaningful</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December&#160;31, 2020 and 2019 </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consisted of revenues under collaborative research and development arrangements, including arrangements with affiliated entities for the years ended December 31, 2020 and 2019. Our year over year total revenue increased $3.3 million, or 80%. The increase</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was primarily due to revenue earned from Advaccine a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd the milestone revenue earned from our affiliated entity Plumbline Life Sciences, Inc., or PLS, offset by a decrease in revenue recognized from our collaboration with AstraZeneca. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $6.2 million increase in research and development expenses for the year ended December&#160;31, 2020 as compared to 2019 was primarily due to higher drug manufacturing expenses and outside services related to our INO-4800 clinical trials of $17.1 million,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> an increase in engineering services related to our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device development and array automation project of $12.4 million, higher expensed device materials of $5.0 million, higher contract labor expense of $2.4 million, higher employee stock-based compensation expense of $2.1 million, higher drug manufacturing expenses related to our Wistar IPCAVD grant of $1.2 million and an increase in patent maintenance and milestone fees to Wistar of $1.1 millio</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n. These increases were offset by an increase in contra-research and development expense recorded from grant agreements of $33.5 million, am</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ong other variances.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions received from current grant agreements and recorded as contra-research and development expense were $45.4 million and $11.9 million for the years ended December&#160;31, 2020 and 2019, respectively. The increase year over year was primarily due to increases of $21.2 million, $10.0 million and $4.1 million earned under grants from the DoD, CEPI and Gates, respectively, related to INO-4800 and device development activities, partially offset by a decrease of $2.4 million earned from the Gates grant and Wistar sub-grant related to our dMAb technology, among other variances. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The $10.0 million increase in general and administrative expenses for the year ended December&#160;31, 2020 as compared to 2019 was primarily related to an increase in legal expenses of $5.2 million, an increase in expenses for work performed related to corporate marketing and communications of $3.1 million and higher employee and consultant stock-based compensation expense of $3.0 million, partially offset by a gain on foreign exchange of $2.2 million recorded as contra-general and administrative expense, among other variances.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the employee&#8217;s requisite service period. Total employee stock-based compensation cost for the years ended December&#160;31, 2020 and 2019 was $14.5 million and $9.8 million, of which $8.0 million and $5.9 million was included in research and development expenses and $6.5 million and $3.9 million was included in general and administrative expenses, respectively. The increase for 2020 compared to 2019 was primarily due to a higher weighted average grant date fair value for the awards granted in 2020, offset in part by the reversal of previously recorded stock option expense due to a reduction in force in the third quarter of 2019 and an option modification expense recorded in the second quarter of 2019. At December&#160;31, 2020, there was $4.4 million of total unrecognized compensation cost related to unvested stock options, which we expect to recognize over a weighted-average period of 1.4 years, as compared to $3.4 million for the year ended December&#160;31, 2019 expected to be recognized over a weighted-average period of 1.7 years. At December&#160;31, 2020, there was $10.9 million of total unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 1.9 years, as compared to $4.3 million for the year ended December&#160;31, 2019 expected to be recognized over a weighted-average period of 1.6 years. Total stock-based compensation for options granted to non-employees for the years ended December&#160;31, 2020 and 2019 was $1.2 million and $970,000, respectively.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $706,000 increase in interest income for the year ended December&#160;31, 2020 as compared to 2019 was primarily due to more interest earned on our higher balance of short-term investment holdings.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $754,000 increase in interest expense for the year ended December&#160;31, 2020 as compared to 2019 was primarily due to higher interest expense recorded from our August 2019 Bonds and December 2019 Bonds, which were issued during the third and fourth quarters of 2019, respectively. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Derivative Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of derivative liability for the year ended December&#160;31, 2020 and 2019 was $75.7 million and $1.8 million, respectively. We determined that our August 2019 Bonds included an embedded conversion feature that was considered to be a derivative liability requiring bifurcation from the debt instrument and separate recognition in our financial statements. The conversion feature was revalued at the end of each reporting period and immediately prior to the conversion of the August 2019 Bonds in August 2020, with the resulting changes in fair value reflected in the consolidated statements of operations. The derivative liability was derecognized upon the conversion in full of the August 2019 Bonds.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain (Loss) on Investment in Affiliated Entity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain (loss) on investment in affiliated entity for the years ended December&#160;31, 2020 and 2019 was $36.6 million and $(3.1) million, respectively, resulting from the change in the fair market value of our investments in GeneOne and PLS.  During the third quarter of 2020, we sold our full equity interest in GeneOne. We record our investment in PLS at its market value </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on the closing price of the shares on the Korea New Exchange Market at each balance sheet date, with changes in fair value reflected in the consolidated statements of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Unrealized Gain on Available-for-Sale Equity Securities </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gain on available-for-sale equity securities for the year ended December&#160;31, 2020 of $1.7 million resulted from a change in the fair market value of our equity investments as of December&#160;31, 2020.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain on Deconsolidation of Geneos </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain recorded represents the excess of the fair value of our retained noncontrolling investment in Geneos and the carrying amount of the non-controlling interest over the carrying amount of Geneos's assets and liabilities as of June 1, 2020, the date of deconsolidation. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Extinguishment of Convertible Bonds </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the full conversion of our August 2019 Bonds, a loss of $8.2 million was recorded for the difference between the fair value of the derivative liability immediately prior to its derecognition plus the carrying amount of the debt component, and the fair value of our common stock issued upon conversion.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain on Extinguishment of Convertible Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the partial conversions of the Notes during the third and fourth quarters of 2020, we recorded an $8.8 million gain on extinguishment calculated as the difference between the estimated fair value of the debt and the carrying value of the Notes as of the conversion dates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share in Net Loss of Geneos</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The share in net loss of Geneos represents our share of Geneos's losses during the period after deconsolidation. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Benefit/Provision for Income Taxes</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax benefit of $257,000 for the year ended December 31, 2019 reflected our application of the intraperiod tax allocation rules under which we are required to record a tax benefit in continuing operations to offset the tax provision we recorded directly to other comprehensive income (loss) related to unrealized gains on our short-term investments. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred operating losses and accordingly have not recorded a provision for U.S. income taxes for any of the periods presented. Utilization of net operating losses and tax credits are subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code of 1986, as amended, or IRC. As of December&#160;31, 2020, we had net operating loss carry forwards for U.S. federal, California and Pennsylvania income tax purposes of $566.2 million, $68.6 million and $75.3 million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. We also had U.S. federal and state research and development tax credits of $19.8 million and $3.2 million, respectively, net of the federal research and development credits that will expire due to IRC Section&#160;383 limitations. The net operating losses and credits began to expire during 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December&#160;31, 2019 and 2018</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:0.730%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consisted of revenues under collaborative research and development arrangements, including arrangements with affiliated entities for the years ended December 31, 2019 and 2018. Our year over year total revenue decreased $26.4 million, or 87%. The decrease was primarily due to the recognition of a one-time upfront payment of $23.0 million from ApolloBio during the second quarter of 2018.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $7.2 million decrease in research and development expenses for the year ended December 31, 2019 as compared to 2018 was primarily due to a decrease in expenses related to our collaboration with AstraZeneca of $2.9 million, a decrease in employee compensation expense of $2.6 million due to lower employee headcount and an increase in contra-research and development expense recorded from grant agreements of $2.4 million, as well as no sub-license fee expense in 2019 as compared to $1.9 million recorded in 2018 related to the ApolloBio collaboration. These decreases were offset by an increase in clinical trial related expenses of $3.5 million and the one-time personnel-related restructuring charge of approximately $1.9 million in connection with the employee termination costs incurred during the third quarter of 2019, among other variances.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions received from current grant agreements and recorded as contra-research and development expense were $11.9 million and $9.5 million for the years ended December 31, 2019 and 2018, respectively. The increase year over year was primarily due to an increase of $1.9 million earned from the CEPI grant, an increase of $1.9 million from the Bill &amp; Melinda </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gates Foundation grant and an increase of $890,000 from the MCDC grant, offset in part by decreases of $1.1 million and $963,000 from various Wistar sub-grants and the DARPA Ebola grant, respectively, among other variances.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $2.1 million decrease in general and administrative expenses for the year ended December 31, 2019 as compared to 2018 was primarily related to the $1.4 million of foreign non-income taxes withheld from the ApolloBio upfront payment we received in 2018 and the associated advisory fees of $960,000, among other variances.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the employee&#8217;s requisite service period. Total employee stock-based compensation cost for the years ended December 31, 2019 and 2018 was $9.8 million and $10.2 million, of which $5.9 million and $5.9 million was included in research and development expenses and $3.9 million and $4.3 million was included in general and administrative expenses, respectively. The slight decrease for 2019 compared to 2018 was primarily due to the reversal of previously recognized stock-based compensation expense due to the reduction in our workforce in July 2019 and a lower weighted average grant date fair value for the awards granted in 2019, offset by an option modification expense recorded in the second quarter of 2019. At December 31, 2019, there was $3.4 million of total unrecognized compensation cost related to unvested stock options, which we expect to recognize over a weighted-average period of 1.7 years, as compared to $5.2 million for the year ended December 31, 2018 expected to be recognized over a weighted-average period of 1.7 years. At December 31, 2019, there was $4.3 million of total unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 1.6 years, as compared to $5.1 million for the year ended December 31, 2018 expected to be recognized over a weighted-average period of 1.7 years. Total stock-based compensation for options granted to non-employees for the years ended December 31, 2019 and 2018 was $970,000 and $302,000, respectively.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $341,000 increase in interest income for the year ended December 31, 2019 as compared to 2018 was primarily related to the interest earned on our higher short-term investments holdings in 2019.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest expense for the year ended December 31, 2019 of $7.9 million primarily relates to our 6.5% convertible senior notes due 2024, or the Notes, which were issued during the first quarter of 2019, as well as our 1.0% convertible bonds due August 2024, or the August 2019 Bonds, which were issued during the third quarter of 2019.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Common Stock Warrants</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of common stock warrants for the year ended December 31, 2018 was $361,000. The warrants were exercised during the quarter ended September 30, 2018, eliminating the associated fair value re-measurement in subsequent periods.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Derivative Liability</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of derivative liability for the year ended December 31, 2019 was $1.8 million. We determined that our August 2019 Bonds included an embedded conversion feature that is considered to be a derivative liability requiring bifurcation from the debt instrument and separate recognition in our financial statements. The conversion option is revalued at each reporting period with the resulting changes in fair value reflected in the consolidated statements of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Investment in Affiliated Entity</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss on investment in affiliated entity for the years ended December 31, 2019 and 2018 was $3.1 million and $2.0 million, respectively, resulting from the change in the fair market value of our investments in GeneOne and PLS. We record our investments in GeneOne and PLS at their market values based on the closing prices of those securities on the applicable stock exchange at each balance sheet date, with changes in fair value reflected in the consolidated statements of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Benefit/Provision for Income Taxes</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax benefit of $257,000 for the year ended December 31, 2019 reflected our application of the intraperiod tax allocation rules under which we are required to record a tax benefit in continuing operations to offset the tax provision we recorded directly to other comprehensive income (loss) related to unrealized gains on our short-term investments. The provision for income taxes of $2.2 million for the year ended December 31, 2018 was related to foreign income taxes on the upfront payment received from ApolloBio in 2018.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred operating losses and accordingly have not recorded a provision for U.S. income taxes for any of the periods presented. Utilization of net operating losses and tax credits are subject to a substantial annual limitation due to ownership change limitations provided by the IRC. As of December 31, 2019, we had net operating loss carry forwards for U.S. federal, California and Pennsylvania income tax purposes of $483.3 million, $68.6 million and $80.5 million, respectively, net of the net operating losses that will expire due to IRC Section 382 limitations. We also had U.S. federal and state research and development tax credits of $17.3 million and $3.2 million, respectively, net of the federal research and development credits that will expire due to IRC Section 383 limitations. The net operating losses and credits began to expire during 2020.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our primary uses of cash have been to finance research and development activities including clinical trial activities in the oncology, DNA vaccines and other immunotherapy areas of our business. Since inception, we have satisfied our cash requirements principally from proceeds from the sale of equity securities, indebtedness and grants and government contracts.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working Capital and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had cash and short-term investments of $411.6 million and working capital of $429.5 million, as compared to $89.5 million and $62.2 million as of December&#160;31, 2019, respectively. The increase in cash and short-term investments during the year ended December 31, 2020 was primarily due to the net proceeds from the sale of our common stock under at-the-market, or ATM, sales agreements, offset by expenditures related to our research and development activities, clinical trials and various general and administrative expenses related to legal, consultants, accounting and audit, and corporate development.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December 31, 2020 of $178.0 million consisted of net loss of&#160;$167.5 million&#160;less use of net cash in operating assets and liabilities of&#160;$71.1 million, partially offset by net non-cash adjustments of&#160;$60.6 million. The net cash used in operating activities included a $62.1 million increase in prepaid expenses and other assets, primarily comprising prepayments for facilities, equipment and manufacturing related to INO-4800 and a $17.9 million increase in accounts receivable primarily from the DoD. The primary non-cash adjustments to net loss included the increase in fair value of derivative liability of $75.7 million prior to its derecognition, stock-based compensation of&#160;$15.6 million, share of net loss in Geneos of $4.6 million, interest expense of $4.1 million and depreciation and amortization of&#160;$3.6 million, offset by gain on investment in affiliated entities of $36.6 million and gain on deconsolidation of Geneos of $4.1 million, among other items. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December 31, 2019 of $97.9 million consisted of net loss of&#160;$120.6 million&#160;less use of net cash in operating assets and liabilities of&#160;$3.5 million, partially offset by net non-cash adjustments of&#160;$26.2 million. The primary non-cash expenses added back to net loss included stock-based compensation of&#160;$10.9 million, interest expense of $5.2 million, depreciation and amortization of&#160;$4.7 million and loss on investment in affiliated entities of&#160;$3.1 million and change in fair value of derivative liability of $1.8 million.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $58.8 million and $9.0 million for the years ended December&#160;31, 2020 and 2019, respectively. The variance was primarily the result of timing differences in short-term investment purchases, sales and maturities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, offs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">et by the proceeds from the sale of our investment in GeneOne of $40.1 million.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $465.3 million and $105.4 million for the years ended December&#160;31, 2020 and 2019, respectively. The variance was primarily due to the significantly higher net proceeds from the sale of common stock under the ATM sales agreement as well as proceeds from stock option exercises in 2020, offset by the net proceeds received in 2019 from the issuance of Notes and August 2019 and December 2019 Bonds.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuances of Notes and Bonds</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we completed a private placement of our 1.0% convertible bonds due December 2024, or the December 2019 Bonds, to an institutional investor in Korea for an aggregate principal amount of 4.7 billion Korean Won (KRW) (approximately USD $4.1 million based on the exchange rate on the date of issuance). Net proceeds from the offering were $4.0 million, after deducting the offering expenses payable by us. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we completed a private placement of aggregate principal amount of 18 billion Korean Won (KRW) (approximately USD $15.0 million based on the exchange rate on the date of issuance) of August 2019 Bonds issued to institutional investors led by Korea Investment Partners. Net proceeds from the offering were $14.5 million, after deducting the offering expenses payable by us. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the August 2019 Bonds were fully converted into 4,692,364 shares of our common stock. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2019, we completed a private placement of $78.5 million aggregate principal amount of Notes, sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offering were $75.7 million, after deducting the initial p</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">urchasers' discount and offering expenses payable by us. During 2020, certain holders of the Notes converted principal amount of $62.1 million into an aggregate of 11,535,660 shares of our common stock. As of December 31, 2020, $16.4 million aggregate principal amount of Notes remains outstanding. See Note 11 to the consolidated financial statements included in this report for further discussion.</span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Issuances of Common Stock</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we entered into an At-the-Market Equity Offering Sales Agreement, or the Sales Agreement, with an outside placement agent, or the Placement Agent, to sell shares of our common stock with aggregate gross proceeds of up to $100.0 million, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent would act as sales agent. During the year ended December&#160;31, 2019, we sold 3,340,678 shares of common stock under the Sales Agreement for aggregate net proceeds of $9.1 million. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, we entered into amendments to the&#160;Sales Agreement to increase the amount of our common stock that could be sold through the Placement Agent under the Sales Agreement to an aggregate offering price of up to $250.0 million. During the three months ended March 31, 2020, we sold 43,148,952 shares of common stock under the Sales Agreement for aggregate net proceeds of $208.2 million. Following these sales, there was no remaining capacity under this Sales Agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2020, we entered into a new sales agreement, or the New Sales Agreement, with the same Placement Agent to sell shares of our common stock. On that same day, we filed a prospectus supplement pursuant to the New Sales Agreement for the offer and sale of our common stock for aggregate gross proceeds of up to $150.0 million. On May 12, 2020 we filed an additional prospectus supplement pursuant to the New Sales Agreement for the offer and sale of our common stock for an additional $100.0 million of gross proceeds, bringing the maximum gross proceeds of sales under the New Sales Agreement to $250.0 million. Through December 31, 2020, w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e sold 22,915,934 shares of common stock under the New Sales Agreement for aggregate net proceeds of $246.2 million. As of December&#160;31, 2020, there was no remaining capacity under the New Sales Agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, we closed an underwritten public offering of 20,355,000 shares of our common stock at a public offering price of $8.50 per share. The net proceeds, after deducting the underwriters' discounts and commissions and other estimated offering expenses payable by us, were $162.1&#160;million. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, stock options to purchase 2,178,252 shares of common stock were exercised for aggregate net proceeds of $12.3 million, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $4.0 million. During the year ended December&#160;31, 2019, stock options to purchase 42,969 shares of common stock were exercised for aggregate net proceeds of $113,000, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $893,000. During the year ended December&#160;31, 2018, stock options and warrants to purchase 756,853 shares of common stock were exercised for aggregate net proceeds of $2.4 million, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $612,000.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had an accumulated deficit of $906.2 million and we expect to continue to operate at a loss for some time. The amount of the accumulated deficit will continue to increase, as it will be expensive to continue research and development efforts. These activities will require additional financing. If these activities are successful and if we receive approval from the FDA to market our DNA vaccine and DNA immunotherapy product candidates, then we will need to raise additional funding to market and sell the approved products and equipment. We cannot predict the outcome of the above matters at this time. We are evaluating potential collaborations as an additional way to fund operations. We believe that our current cash and short-term investments are sufficient to meet our planned working capital requirements for at least the next twelve months.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, future minimum payments due under our contractual obligations are as follows:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than<br/>1&#160;year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1&#160;&#8211;&#160;3&#160;years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,149,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,134,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible bonds (2)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,701,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,571,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations (3)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,988,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,968,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,068,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,064,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,888,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts represent remaining contractual amounts due under our Notes, including interest based on the fixed rate of 6.5% per year. Although these Notes mature in March 2024, they may be converted into shares of our common stock prior to maturity if certain conditions are met. Any conversion prior to maturity would result in repayments of the principal amounts sooner than the scheduled repayments as indicated in the table.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During 2020, certain holders of the Notes converted principal amount of $62.1 million into an aggregate of 11,535,660 shares of our common stock. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ee Note 11, "Convertible Debt&#8221; in the Consolidated Financial Statements section of this report for further discussion.</span></div><div style="margin-top:5pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Amounts represent contractual amounts due under our December 2019 Bonds, including interest based on the fixed rate of 1% per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of 6% at maturity. Although these bonds mature in December 2024, they may be converted into equity securities prior to maturity if certain conditions are met. Any conversion prior to maturity can result in repayments of the principal amounts sooner than the scheduled repayments as indicated in the table. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, our August 2019 Bonds were fully converted into 4,962,364 shares of our common stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 11, "Convertible Debt&#8221; in the Consolidated Financial Statements section of this report for further discussion.</span></div><div style="margin-top:5pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) We have entered into operating leases for our facilities, which expire from 2023 to 2029, and operating leases for office equipment, which expire in 2021 and 2022. In the fourth quarter of 2019, we entered into two subleases for a portion of our Plymouth Meeting corporate headquarters facility through December 31, 2022 and March 31, 2025. As of December&#160;31, 2020, we expect to receive aggregate future minimum lease payments totaling $1.2 million (non-discounted) over the duration of the sublease agreements, which expected payments are not included in the table above.&#160;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we are a party to a variety of agreements pursuant to which we may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by us under these types of agreements have not had a material effect on our business, consolidated results of operations or financial condition.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i06d07667d4974765a8282374d1211e66_58"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.&#160;&#160;&#160;&#160;QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk represents the risk of loss that may impact our consolidated financial position, results of operations or cash flows due to adverse changes in financial and commodity market prices and rates. We are exposed to market risk primarily in the area of changes in United States interest rates and conditions in the credit markets, and the recent fluctuations in interest rates and availability of funding in the credit markets primarily impact the performance of our investments. We do not have any material foreign currency or other derivative financial instruments. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to increase the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in investment grade securities. Due to the short-term maturities of our cash equivalents and the low risk profile of our investments at December&#160;31, 2020, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on our indebtedness, consisting exclusively of the Notes and Bonds, is fixed and not subject to fluctuations in interest rates.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investment in affiliated entity at December 31, 2020 represents our ownership interest in the Korean-based company PLS. We report this investment at fair value on the consolidated balance sheet using the closing price of PLS shares of common stock as reported on the date of determination on the Korea New Exchange Market.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operated primarily in the United States and most transactions during the year ended December&#160;31, 2020 were made in United States dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations, with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the exception of the sale of our investment in GeneOne, which was denominated in South Korean Won, the issuance of the August 2019 and December 2019 Bonds, which were and are denominated in South Korean Won, and the valuation of our equity investment in PLS, which is denominated in South Korean Won and then translated into United States dollars. We do not have any foreign currency hedging instruments in place.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain transactions are denominated primarily in foreign currencies, including South Korean Won, Euros, British Pounds and Canadian Dollars. These transactions give rise to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. The value of these monetary assets and liabilities are subject to changes in currency exchange rates from the time the transactions are originated until settlement in cash. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets where we conduct business.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use derivative financial instruments for speculative purposes and do not engage in exchange rate hedging or hold or issue foreign exchange contracts for trading purposes. </span></div><div><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;8 is incorporated by reference to our Consolidated Financial Statements and the Report of Independent Registered Public Accounting Firm beginning at page&#160;F-1 of this report.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i06d07667d4974765a8282374d1211e66_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i06d07667d4974765a8282374d1211e66_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules&#160;and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, as appropriate to allow timely decisions regarding required disclosures. </span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an evaluation carried out as of the end of the period covered by this Annual Report, under the supervision and with the participation of our management, including our CEO and CFO, our CEO and CFO have concluded that, as of the end of such period, our disclosure controls and procedures (as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934) were effective as of December&#160;31, 2020 at the reasonable assurance level.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internal Control Over Financial Reporting</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules&#160;13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is a process designed under the supervision of our Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external purposes in accordance with United States generally accepted accounting principles.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, management, with the participation of the Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in &#8220;Internal Control&#8212;Integrated Framework,&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on the assessment, management determined that we maintained effective internal control over financial reporting as of December&#160;31, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have not been any changes in our internal control over financial reporting that occurred during the fourth quarter of our fiscal year ended December&#160;31, 2020, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Attestation Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The independent registered public accounting firm that audited the consolidated financial statements that are included in this Annual Report on Form 10-K has issued an audit report on the effectiveness of our internal control over financial reporting as of December&#160;31, 2020. The report appears below.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i06d07667d4974765a8282374d1211e66_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors and Stockholders of Inovio Pharmaceuticals,&#160;Inc.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Inovio Pharmaceuticals, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission 2013 framework (the COSO criteria). In our opinion, Inovio Pharmaceuticals, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2020, based on the COSO criteria.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2020 and 2019, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows, for each of the three years in the period ended December&#160;31, 2020 and related notes and our report dated March&#160;1, 2021 expressed an unqualified opinion thereon.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for designing, implementing, and maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A company&#8217;s internal control over financial reporting is a process effected by those charged with governance, management, and other personnel, designed to provide reasonable assurance regarding the preparation of reliable financial statements in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and those charged with governance; and (3) provide reasonable assurance regarding prevention, or timely detection and correction of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of its inherent limitations, internal control over financial reporting may not prevent, or detect and correct, misstatements. Also, projections of any assessment of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.220%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Diego, California</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i06d07667d4974765a8282374d1211e66_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. &#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i06d07667d4974765a8282374d1211e66_76"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i06d07667d4974765a8282374d1211e66_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;10 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2020 fiscal year, under the captions &#8220;Election of Directors&#8221; and &#8220;Executive Officers and Other Information.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i06d07667d4974765a8282374d1211e66_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;11 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2020 fiscal year, under the captions &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Executive Compensation,&#8221; &#8220;Compensation of Directors&#8221; and &#8220;Director Compensation Table.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i06d07667d4974765a8282374d1211e66_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;12 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2020 fiscal year, under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i06d07667d4974765a8282374d1211e66_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director independence and other information required by this Item&#160;13 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2020 fiscal year, under the captions &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Election of Directors.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i06d07667d4974765a8282374d1211e66_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;14 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2020 fiscal year, under the caption &#8220;Ratification of Appointment of Registered Public Accounting Firm.&#8221;</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i06d07667d4974765a8282374d1211e66_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i06d07667d4974765a8282374d1211e66_97"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.&#160;&#160;&#160;&#160;EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Financial Statements</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated financial statements required to be filed hereunder are indexed on Page&#160;F-1 hereof.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Financial Statement Schedules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedules not listed herein have been omitted because the information required to be set forth therein is not applicable or is included in the Financial Statements or notes thereto.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Exhibits</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed as part of this annual report on Form&#160;10-K:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">Certificate of Incorporation with all amendments (incorporated by reference to Exhibit&#160;3.1 of the registrant&#8217;s Form S-3 registration statement, filed on July 23, 2014).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">Amended and Restated Bylaws of Inovio Pharmaceuticals, Inc. dated August&#160;10, 2011 (incorporated by reference to Exhibit&#160;3.2 to the registrant&#8217;s Form&#160;8-K current report filed on August&#160;12, 2011).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm">Indenture, dated as of February 19, 2019, by and between the registrant and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.1 to the registrant&#8217;s current report on Form 8-K filed with the SEC on February 20, 2019).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm">4.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm">Form of Note representing the registrant&#8217;s 6.50% Convertible Senior Notes due 2024 (included as Exhibit A to the Indenture filed as Exhibit 4.1).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519214088/d595826dex41.htm">4.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519214088/d595826dex41.htm">Convertible Bonds Subscription Agreement, dated July 31, 2019, by and among the registrant and the Purchasers named therein (incorporated by reference to Exhibit 4.1 to the registrant&#8217;s current report on Form 8-K filed with the SEC on August 6, 2019).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519214088/d595826dex41.htm">4.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519214088/d595826dex41.htm">Form of Bond representing the registrant&#8217;s 1% Convertible Bonds due 2024 (included as Exhibit A to the Convertible Bonds Subscription Agreement filed as Exhibit 4.3).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519214088/d595826dex991.htm">4.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519214088/d595826dex991.htm">Registration Rights Agreement, dated July 31, 2019, by and among the registrant and the Purchasers named therein (incorporated by reference to Exhibit 99.1 to the registrant&#8217;s current report on Form 8-K filed with the SEC on August 6, 2019).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312520000651/d863139dex41.htm">4.6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312520000651/d863139dex41.htm">Convertible Bonds Subscription Agreement, dated December 26, 2019, by and between the registrant and the Purchaser named therein (incorporated by reference to Exhibit 4.1 to the registrant&#8217;s current report on Form 8-K filed with the SEC on January 2, 2020).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312520000651/d863139dex41.htm">4.7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312520000651/d863139dex41.htm">Form of Bond representing the registrant&#8217;s 1% Convertible Bonds due 2024 (included as Exhibit A to the Convertible Bonds Subscription Agreement filed as Exhibit 4.6).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312520000651/d863139dex101.htm">4.8</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312520000651/d863139dex101.htm">Registration Rights Agreement, dated December 26, 2019, by and between the registrant and the Purchaser named therein (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s current report on Form 8-K filed with the SEC on January 2, 2020).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-12312019x10xkex49.htm">4.9</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-12312019x10xkex49.htm">Description of the Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-12312019x10xkex49.htm">(incorporated by reference to Exhibit 4.9 to the registrant&#8217;s annual report on Form 10-K filed with the SEC on March 12, 2020)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_31.htm">10.1&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_31.htm">R&amp;D Alliance Agreement dated December&#160;19, 2005 by and between Ganial Immunotherapeutics,&#160;Inc. and VGX Pharmaceuticals,&#160;Inc., as amended by Novation and Amendment Agreement by and between VGX Pharmaceuticals, Inc., Ganial Immunotherapeutics, Inc., and Onconox (incorporated by reference to Exhibit&#160;10.31 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.370%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_39.htm">10.2&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_39.htm">R&amp;D Collaboration and License Agreement dated December&#160;18, 2006 by and between VGX International,&#160;Inc. and VGX Pharmaceuticals,&#160;Inc., as amended by First Amendment dated October&#160;31, 2007 and as amended by Second Amendment dated August&#160;4, 2008 (incorporated by reference to Exhibit&#160;10.39 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_50.htm">10.3&#8224;&#160;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_50.htm">Patent License Agreement dated April&#160;27, 2007 by and between The Trustees of the University of Pennsylvania and VGX Pharmaceuticals,&#160;Inc., as amended by First Amendment dated June&#160;12, 2008 (incorporated by reference to Exhibit&#160;10.50 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_34.htm">10.4&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_34.htm">License Agreement dated May&#160;9, 2007 by and between Baylor University and VGX Pharmaceuticals,&#160;Inc. (incorporated by reference to Exhibit&#160;10.34 as filed with the registrant&#8217;s registration statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312518175305/d593417d8k.htm">10.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312518175305/d593417d8k.htm">At-the-Market Equity Offering Sales Agreement dated May 25, 2018 between Inovio Pharmaceuticals, Inc. and Stifel, Nicolaus &amp; Company, Incorporated (incorporated by reference to Exhibit 1.1 of the registrant's Form 8-K filed on May 25, 2018).</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312510122273/dex102.htm">10.6&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312510122273/dex102.htm">License and Collaboration Agreement dated March&#160;24, 2010 between Inovio Pharmaceuticals, Inc. and VGX International, Inc. (incorporated by reference to Exhibit 10.2 as filed with the registrant&#8217;s Form 10-Q quarterly report for the quarter ended March&#160;31, 2010 filed on May&#160;17, 2010).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511298587/d237108dex101.htm">10.7&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511298587/d237108dex101.htm">Collaborative Development and License Agreement dated October 7, 2011 between VGX International, Inc. and Inovio Pharmaceuticals, Inc., as amended by First Amendment dated August 21, 2013, and Second Amendment dated October 7, 2013 (incorporated by reference to Exhibit 10.1 as filed with the registrant&#8217;s Form 10-Q quarterly report for the quarter ended September&#160;30, 2011 filed on November&#160;7, 2011).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572615000015/ino-9302015x10qex101.htm">10.8&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572615000015/ino-9302015x10qex101.htm">DNA Cancer Vaccine Collaboration and License Agreement dated August 7, 2015 by and between MedImmune, Limited and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 of the registrant's Form 10-Q quarterly report for the quarter ended September 30, 2015 filed on November 9, 2015).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016x10qexhibit101.htm">10.9</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016x10qexhibit101.htm">Collaborative Research Agreement dated March 14, 2016 by and between The Wistar Institute of Anatomy and Biology, a Commonwealth of Pennsylvania nonprofit corporation, and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 as filed with the registrant's Form 10-Q quarterly report for the quarter ended March 31, 2016 filed on May 9, 2016).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016xexhibit102.htm">10.10</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016xexhibit102.htm">Collaborative Research Agreement dated March 14, 2016 by and between The Wistar Institute of Anatomy and Biology, a Commonwealth of Pennsylvania nonprofit corporation, and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 as filed with the registrant's Form 10-Q quarterly report for the quarter ended March 31, 2016 filed on May 9, 2016).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572618000014/ino-12312017x10kex1012.htm">10.11&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572618000014/ino-12312017x10kex1012.htm">Amended and Restated License and Collaboration Agreement, dated December 29, 2017, by and between Inovio Pharmaceuticals, Inc. and Beijing Apollo Saturn Biological Technology Limited (incorporated by reference to Exhibit 10.12 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2017 filed on March 14, 2018).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000048/a200622dodnatickotaagr.htm">10.12</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572618000014/ino-12312017x10kex1012.htm">&#8224;&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000048/a200622dodnatickotaagr.htm">Other Transaction Authority For Prototype Agreement dated June 22, 2020 between Inovio Pharmaceuticals, Inc. and Natick Contracting Division (incorporated by reference to Exhibit 10.1 as filed with the registrant's Form 10-Q quarterly report for the quarter ended June 30, 2020 filed on August 10, 2020).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000048/a200618dodnatickawarde.htm">10.13</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572618000014/ino-12312017x10kex1012.htm">&#8224;&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000048/a200618dodnatickawarde.htm">Award Agreement dated June 18, 2020 between Inovio Pharmaceuticals, Inc. and Natick Contracting Division (incorporated by reference to Exhibit 10.2 as filed with the registrant's Form 10-Q quarterly report for the quarter ended June 30, 2020 filed on August 10, 2020).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312020x10kex1014.htm">10.14</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312020x10kex1014.htm">&#8224;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312020x10kex1014.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312020x10kex1014.htm">Collaboration and License Agreement dated December 31, 2020 between Inovio Pharmaceuticals, Inc. and Advaccine Biopharmaceuticals Suzhou Co., Ltd. (filed herewith).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572613000005/ino-3312013x10qex101.htm">10.15</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572613000005/ino-3312013x10qex101.htm">Lease dated April 9, 2013 by and between BMR-Wateridge LP and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to registrant's quarterly report for the quarter ended March 31, 2013, filed on May 10, 2013).</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.370%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000067/ino-9302016x10qex101.htm">10.16</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000003/ino-12312013x10kex1036.htm">Lease Agreement dated as of March 5, 2014 between Brandywine Operating Partnership L.P. and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.36 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2014 filed on March 17, 2014).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000003/ino-12312013x10kex1036.htm">10.17</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000067/ino-9302016x10qex101.htm">Office Lease Agreement dated October 10, 2016 by and between 6759 Mesa Ridge Road Holdings, LLC and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 as filed with the registrant's Form 10-Q quarterly report for the quarter ended September 30, 2016 filed on November 9, 2016).</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex101.htm">10.18</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex102.htm">Sublease dated June 21, 2017 between Accolade, Inc. and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 as filed with the registrant's Form 10-Q quarterly report for the quarter ended June 30, 2017 filed on August 8, 2017).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex102.htm">10.19</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex101.htm">Second Amendment to the Lease Agreement dated June 22, 2017 between Brandywine Operating Partnership, L.P. and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 as filed with the registrant's Form 10-Q quarterly report for the quarter ended June 30, 2017 filed on August 8, 2017).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_43.htm">10.20+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_43.htm">Employment Agreement dated March&#160;31, 2008 by and between J. Joseph Kim, Ph.D. and VGX Pharmaceuticals,&#160;Inc., as amended by First Amendment of Employment Agreement dated March&#160;31, 2008 (incorporated by reference to Exhibit&#160;10.43 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1041.htm">10.21+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1041.htm">First Amendment to Employment Agreement dated as of December&#160;31, 2012 between Inovio Pharmaceuticals, Inc. and J. Joseph Kim, PhD. (incorporated by reference to Exhibit&#160;10.41 of the registrant&#8217;s Form 10-K annual report for the year ended December&#160;31, 2012 filed on March&#160;18, 2013).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511068803/dex105.htm">10.23+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511068803/dex105.htm">Employment Agreement dated as of December&#160;27, 2010 between Inovio Pharmaceuticals, Inc. and Peter Kies (incorporated by reference to Exhibit 10.5 to the registrant&#8217;s Form 10-K report for the year ended December&#160;31, 2010 filed on March&#160;16, 2011).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1042.htm">10.24+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1042.htm">First Amendment to Employment Agreement dated as of December&#160;31, 2012 between Inovio Pharmaceuticals, Inc. and Peter Kies (incorporated by reference to Exhibit&#160;10.42 of the registrant&#8217;s Form 10-K annual report for the year ended December&#160;31, 2012 filed on March&#160;18, 2013).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000013/ino930201410qex102.htm">10.25+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000013/ino930201410qex102.htm">Second Amendment to Employment Agreement dated November 7, 2014 by and between Inovio Pharmaceuticals, Inc. and Peter Kies (incorporated by reference to Exhibit 10.2 of the registrant's Form 10-Q quarterly report for the quarter ended September 30, 2014 filed on November 10, 2014).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino1231209x10kex1026.htm">10.26+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino1231209x10kex1026.htm">Employment Agreement dated March 8, 2019 between Inovio Pharmaceuticals, Inc. and Jacqueline E. Shea (</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino1231209x10kex1026.htm">incorporated by reference to Exhibit 10.26 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino1231209x10kex1026.htm">of the registrant's Form 10-K annual report for the year ended December 31, 2019 filed on March 12, 2020)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino1231209x10kex1026.htm">.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino12312019x10kex1027.htm">10.27+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino12312019x10kex1027.htm">Employment Agreement dated as of March 4, 2019 between Inovio Pharmaceuticals, Inc. and Laurent M. Humeau </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino12312019x10kex1027.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino12312019x10kex1027.htm">incorporated by reference to Exhibit 10.27 of the registrant's Form 10-K annual report for the year ended December 31, 2019 filed on March 12, 2020)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino12312019x10kex1027.htm">.</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465909050590/a09-18452_1ex10d1.htm">10.28</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465909050590/a09-18452_1ex10d1.htm">Form of Indemnification Agreement for Directors and Officers of Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit&#160;10.1 to the registrant&#8217;s Form&#160;10-Q quarterly report for the quarterly period ended June&#160;30, 2009, filed on August&#160;19, 2009).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000033/ino-12312015x10kex1012.htm">10.29+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000033/ino-12312015x10kex1012.htm">Amended and Restated 2007 Omnibus Incentive Plan, as amended (incorporated by reference to Exhibit 10.12 to the registrant's Form 10-K report for the year ended December 31, 2015 filed on March 14, 2016).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465907039528/a07-14196_1ex4d4.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465907039528/a07-14196_1ex4d4.htm">0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465907039528/a07-14196_1ex4d4.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465907039528/a07-14196_1ex4d4.htm">Form of Incentive and Non-Qualified Stock Option Grants under the 2007 Omnibus Stock Incentive Plan (incorporated by reference to Exhibit&#160;4.4 to the registrant&#8217;s Registration Statement on Form&#160;S-8 filed on May&#160;14, 2007).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000036/ino-2016xproxy.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000036/ino-2016xproxy.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000036/ino-2016xproxy.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000036/ino-2016xproxy.htm">Inovio Pharmaceuticals, Inc. 2016 Omnibus Incentive Plan, as amended to date (incorporated by reference to Exhibit 10.1 to the registrant's Form 8-K filed on May 10, 2019).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1055.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1055.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1055.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1055.htm">Form of Incentive Stock Option Agreement under 2016 Omnibus Incentive Plan. (incorporated by reference to Exhibit 10.55 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2016 filed on March 15, 2017.)</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1056.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1056.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1056.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1056.htm">Form of Nonqualified Stock Option Agreement under 2016 Omnibus Incentive Plan. (incorporated by reference to Exhibit 10.56 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2016 filed on March 15, 2017.)</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1054.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1054.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1054.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1054.htm">Form of Restricted Stock Units Award Agreement under 2016 Omnibus Incentive Plan. (incorporated by reference to Exhibit 10.54 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2016 filed on March 15, 2017.)</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312020x10kex211.htm">21.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312020x10kex211.htm">Subsidiaries of the registrant (filed herewith).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312020x10kex231.htm">23.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312020x10kex231.htm">Consent of Independent Registered Public Accounting Firm (filed herewith).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_103">24.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_103">Power of Attorney (included on signature page).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312020x10kex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312020x10kex311.htm">Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312020x10kex312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312020x10kex312.htm">Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312020x10kex321.htm">32.1&#94;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312020x10kex321.htm">Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designates management contract, compensatory plan or arrangement.</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been granted for certain portions omitted from this exhibit (indicated by asterisks) pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The confidential portions of this exhibit have been separately filed with the Securities and Exchange Commission.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain confidential portions of this exhibit (indicated by asterisks) were omitted pursuant to applicable regulations. </span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:4.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#94;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">These certifications are being furnished solely to accompany this Annual Report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i06d07667d4974765a8282374d1211e66_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i06d07667d4974765a8282374d1211e66_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on March&#160;1, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inovio Pharmaceuticals, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;J. J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OSEPH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">J. Joseph Kim</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">President and Chief Executive Officer</span></div></td></tr></table></div><div style="margin-top:14pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints J. Joseph Kim and Peter Kies, and each of them severally, his or her true and lawful attorney-in-fact with power of substitution and resubstitution to sign in his or her name, place and stead, in any and all capacities, to do any and all things and execute any and all instruments that such attorney may deem necessary or advisable under the Securities Exchange Act of 1934 and any rules, regulations and requirements of the United States Securities and Exchange Commission in connection with the Annual Report on Form&#160;10-K and any and all amendments hereto, as fully for all intents and purposes as he or she might or could do in person, and hereby ratifies and confirms all said attorneys-in-fact and agents, each acting alone, and his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:29.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;J. JOSEPH KIM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">J. Joseph Kim</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;SIMON X. BENITO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Simon X. Benito</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;PETER KIES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peter Kies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/    ANN MILLER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ann Miller</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JAY SHEPARD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jay Shepard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;DAVID WEINER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">David Weiner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;WENDY YARNO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wendy Yarno</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;LOTA ZOTH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lota Zoth</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="i06d07667d4974765a8282374d1211e66_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div id="i06d07667d4974765a8282374d1211e66_109"></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:89.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_112">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_112">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_115">Consolidated Balance Sheets </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_115">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_121">Consolidated Statements of Operations </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_121">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_124">Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_124">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_127">Consolidated Statements of Stockholders' Equity </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_127">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_133">Consolidated Statements of Cash Flows </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_133">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_136">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i06d07667d4974765a8282374d1211e66_136">9</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i06d07667d4974765a8282374d1211e66_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors and Stockholders of Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2020 and 2019, the related consolidated statements of operations, comprehensive loss, stockholders' equity, and cash flows, for each of the three years in the period ended December&#160;31, 2020, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2020, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) and our report dated March&#160;1, 2021 expressed an unqualified opinion thereon.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the US federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Critical Audit Matters</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Valuation of Debt Instruments</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Description of the Matter</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As described in Note 11 to the consolidated financial statements, for the year ended December 31, 2020, the Company recorded $75.7 million related to the change in the fair value of the August 2019 Convertible Bond embedded derivative liability. Management measured the fair value of the embedded derivative liability using the Monte Carlo simulation model and techniques that require management to make several assumptions.                                       Auditing management&#8217;s valuations of the derivative liability was especially challenging due to the complexity of valuation model and the inputs that are highly sensitive to changes such as volatility, risk free rates, conversion rate and yield.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">How We Addressed the Matter in our Audit</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls relating to management&#8217;s valuation of the August 2019 Convertible Bond embedded derivative liability. These procedures also included, among others, the involvement of professionals with specialized skill and knowledge to assist in developing an independent estimate of the valuation to compare to management&#8217;s assumptions. Additionally, we tested the mathematical accuracy of the valuation model and agreed certain inputs to underlying source information.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrual of Clinical Trial Expenses</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Description of the Matter</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2020, the Company incurred $94.2 million for research and development expenses and as of December 31, 2020 accrued $10.0 million for clinical study costs. A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers, including clinical research organizations (&#8220;CROs&#8221;). External costs to be paid to CROs are accrued and expensed based upon actual work completed in accordance with signed agreements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Auditing management&#8217;s accounting for accrued clinical study costs is especially challenging because the evaluation is dependent upon a high-volume of data and input exchanged between clinical personnel and third-party service providers, such as the number of sites activated, the number of patients enrolled, and the number of patient visits, which is tracked in spreadsheets and other end user computing programs.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">How We Addressed the Matter in our Audit</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the accounting for accrued clinical trial expenses. For example, we tested controls over management&#8217;s assessment and measurement of estimated accrued clinical study costs, including patient enrollment and total cost incurred to date from third-parties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To test the completeness of the Company&#8217;s accrued clinical trial expenses, we obtained from third-parties confirmation of patient enrollment and direct service cost to date for significant clinical trials. We attended internal clinical trial and project status meetings with accounting personnel and the clinical project manager to understand the status of significant clinical trial activities. To assess the appropriate measurement of accrued clinical trial expenses, we inspected key terms, timelines of completion, activities and costs for a sample of vendor contracts, including amendments, and compared these to management&#8217;s analyses used in tracking the progress of service agreements. We also tested a sample of subsequent payments by agreeing the invoice to the original accrual and the invoice payments to bank statements.</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ernst&#160;&amp; Young&#160;LLP</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company's auditor since 2002.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Diego, California</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i06d07667d4974765a8282374d1211e66_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQtMS0xLTEtMA_d21e037b-f11c-4810-8d2e-fcaddce6474d">250,728,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQtMy0xLTEtMA_b89d6a91-8741-43ad-8b81-5f4252b49968">22,196,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUtMS0xLTEtMA_1bc7c0aa-1564-4894-9fc9-fd0178db9a71">160,914,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUtMy0xLTEtMA_9db420ea-43f6-4015-be67-cfdf98150a20">67,338,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzYtMS0xLTEtMA_59ce6ed8-ba94-4a2d-b868-edbedd13c43f">18,559,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzYtMy0xLTEtMA_642db9d8-a367-4570-8afd-3adcf4b90b2e">700,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzctMS0xLTEtMA_c1c31720-dd5a-4d22-b6eb-c93ac85396fe">503,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzctMy0xLTEtMA_0d2456a5-db13-4fee-8b5e-31db92c680f1">1,332,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzgtMS0xLTEtMA_978e557e-93ca-4a8f-a7f8-0ccbf9b08d15">40,357,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzgtMy0xLTEtMA_d1e59aeb-2e47-4441-ac76-4c00a487d18f">1,584,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzktMS0xLTEtMA_3136d693-a357-4807-9801-760a173c3f89">106,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzktMy0xLTEtMA_27a42f2a-8a9e-4b25-a444-1f2a8cf0abe0">1,050,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzExLTEtMS0xLTA_795ac727-891d-4c45-8b43-674c6ec091a3">471,170,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzExLTMtMS0xLTA_a8002e20-c853-44cd-8ff1-60f64e492ecc">94,200,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzEzLTEtMS0xLTA_6cb60291-1aa3-4efb-ba3b-c13e6b0c4fbe">11,348,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzEzLTMtMS0xLTA_c704e07c-a10a-4ca2-a735-53f5098b44e0">12,773,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in affiliated entities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE0LTEtMS0xLTA_8fed0780-3637-49d4-a50f-3836e09a24ba">4,460,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE0LTMtMS0xLTA_b78d5191-c6ca-4cda-a651-f75748bb312f">6,315,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE1LTEtMS0xLTA_2fc4a2f9-0953-4ac8-afd5-cab173128be0">434,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE1LTMtMS0xLTA_ce6d8f32-8ba6-48c9-8d6b-5e5e70f1f6e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE2LTEtMS0xLTA_83771023-04ed-42d4-b2f1-2a1a8bdd7a99">3,146,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE2LTMtMS0xLTA_e3da2d6a-1138-4fc9-87de-89c8960c4e49">3,693,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE3LTEtMS0xLTA_bc302da5-1b36-4637-b43b-033e548c8e18">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE3LTMtMS0xLTA_891acbe6-61ee-4039-bfcb-c3a25a92fedf">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE4LTEtMS0xLTA_b4f33359-eb2e-4bf9-a1b0-7d52520532a9">12,741,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE4LTMtMS0xLTA_9bd05156-0400-4ef3-8975-ad10be0d8c50">13,783,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE5LTEtMS0xLTA_23512443-1ebd-4932-9d53-8237deae63c8">25,957,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE5LTMtMS0xLTA_184f989a-2a27-4d8f-b3b4-b27090eeaf6e">2,672,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzIwLTEtMS0xLTA_96bcb389-c531-4789-b5cc-333da3ff0082">539,772,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzIwLTMtMS0xLTA_abf6ccdf-5a61-4158-8ef8-5ec8c3910476">143,951,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzIzLTEtMS0xLTA_b9d83fd0-bf6b-4aad-be60-bcc725bfcd92">21,203,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzIzLTMtMS0xLTA_a05a56fa-c405-4954-80cc-724c5edbe351">18,237,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses due to affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI0LTEtMS0xLTA_ad817782-ac69-4d30-a554-731427bda6d3">642,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI0LTMtMS0xLTA_b487acc3-b39e-4478-b4f4-8e11b25cd7b0">729,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:AccruedClinicalTrialExpenseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI1LTEtMS0xLTA_e5a8a9b6-1c6f-4090-9628-8dadb616f76b">9,950,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="ino:AccruedClinicalTrialExpenseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI1LTMtMS0xLTA_d1d19913-9da5-489b-b2bc-954fca2135ed">4,049,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI2LTEtMS0xLTA_296bd7f5-a7c0-443b-901b-69ce4d419192">46,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI2LTMtMS0xLTA_14cceecb-84df-41cb-a722-b24e89865aff">92,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:zerodash" name="ino:DeferredRevenueFromAffiliatedEntityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI3LTEtMS0xLTA_2f9b1711-defa-4f47-8abe-ccc21f82dac5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredRevenueFromAffiliatedEntityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI3LTMtMS0xLTA_7b94dfa3-7adb-4e92-a3e1-97eb0b7f89a5">31,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI5LTEtMS0xLTA_a7203d2b-b0df-4f18-926f-5ccc597ce010">2,329,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI5LTMtMS0xLTA_cae3c4a2-549c-466b-a5fb-484bd7c4f09f">2,074,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzMwLTEtMS0xLTA_7adcc721-b7d8-48ab-a6f7-0db48a030ef3">7,474,310</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzMwLTMtMS0xLTA_4d8f0b06-f240-4064-850d-0e4f2ded79d6">6,065,212</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingFromAffiliateCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzMxLTEtMS0xLTA_ed9146d9-f69d-417f-b4ea-ef618d72ea22">58,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingFromAffiliateCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzMxLTMtMS0xLTA_7de3e229-5c21-4508-8803-b2a4c8724ca7">708,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzMyLTEtMS0xLTA_a25cca64-a70b-431e-af3b-219ee2e408d5">41,705,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzMyLTMtMS0xLTA_5e6ad976-0b12-40cb-a78e-15338a181585">31,989,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzMzLTEtMS0xLTA_2670923b-1c39-445d-80cf-5a0696b628de">79,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzMzLTMtMS0xLTA_c9340584-34e3-441a-b506-bb652ae5c551">101,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a2b66e18d454ede830f8d1d4aada02f_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzM1LTEtMS0xLTA_41648d86-b8a3-47dd-a64c-fa1d25a4d5d7">14,139,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcbfe891e274002a1ffb387d3ce3a69_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzM1LTMtMS0xLTA_74126820-82b7-4099-85da-8d0b60693bcb">64,180,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0158aa5ba6a546b99ab881b2e80f21f8_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzM2LTEtMS0xLTA_02929256-8777-495f-816f-12af2fd2cf35">4,515,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63bf584a99b7490ca78c1a42bda4e636_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzM2LTMtMS0xLTA_adbeaf4d-2fd4-4024-ae3c-6a67fb133ca1">12,842,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzM4LTEtMS0xLTA_a5b85fa4-5a22-45a0-aafc-aaa6ebf6cc80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzM4LTMtMS0xLTA_bfd4e914-481c-411a-ad96-f8a743e354c1">8,819,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQwLTEtMS0xLTA_9c477b78-d3a1-4eed-96e2-2df5934bebf5">18,063,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQwLTMtMS0xLTA_aba83fe3-7f68-4223-9154-4d4fdc214671">20,409,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQxLTEtMS0xLTA_521ca78c-4b1c-424a-98b5-2fb69c8e8253">32,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQxLTMtMS0xLTA_82d52c3f-908f-489e-b1da-399ef79dc76e">32,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entity, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingFromAffiliateNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQyLTEtMS0xLTA_ca357c25-d7c4-4834-80d2-599450634c8e">37,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingFromAffiliateNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQyLTMtMS0xLTA_03df10c5-0933-4075-b6f2-1ed41785a9f5">135,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQzLTEtMS0xLTA_4111742c-21ec-48b8-97df-3277545628fe">57,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQzLTMtMS0xLTA_c43df967-ca50-420c-9daa-33b8a0fb2e85">36,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ0LTEtMS0xLTA_038034ac-cb5f-4cd4-9df9-7cf5ef6012c3">78,631,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ0LTMtMS0xLTA_feb7cdf9-5220-40fa-84d0-b4c92a8a04be">138,546,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ1LTEtMS0xLTA_a3d80409-c3ef-484b-9e25-ad52ed8fabc3"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ1LTMtMS0xLTA_b530cebf-e8ef-4ef7-a3eb-ee8fbad00554"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inovio Pharmaceuticals, Inc. stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock&#8212;par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3ZmYxMGQ4NWVjMzg0Mzk0YTMxYmFlMDE2ZTk3OWIzZF82NTk3MDY5NzY2ODEy_6fd541a8-41bc-49fc-b2b5-a3fadf73c019"><ix:nonFraction unitRef="usdPerShare" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3ZmYxMGQ4NWVjMzg0Mzk0YTMxYmFlMDE2ZTk3OWIzZF82NTk3MDY5NzY2ODEy_8d057eec-b97a-41fc-9415-3fcc6dbe6907">0.001</ix:nonFraction></ix:nonFraction>; Authorized shares: <ix:nonFraction unitRef="shares" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3ZmYxMGQ4NWVjMzg0Mzk0YTMxYmFlMDE2ZTk3OWIzZF82NTk3MDY5NzY2ODI1_0873bfde-6cf6-41ca-906c-f9c4a03790c4"><ix:nonFraction unitRef="shares" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3ZmYxMGQ4NWVjMzg0Mzk0YTMxYmFlMDE2ZTk3OWIzZF82NTk3MDY5NzY2ODI1_4c333985-aa90-4ce9-a173-1f973e4cf4da">10,000,000</ix:nonFraction></ix:nonFraction>, issued and outstanding shares: <ix:nonFraction unitRef="shares" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3ZmYxMGQ4NWVjMzg0Mzk0YTMxYmFlMDE2ZTk3OWIzZF82NTk3MDY5NzY2ODI5_8abf60bf-a415-4f98-873d-17d9bda1f766"><ix:nonFraction unitRef="shares" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3ZmYxMGQ4NWVjMzg0Mzk0YTMxYmFlMDE2ZTk3OWIzZF82NTk3MDY5NzY2ODI5_9e11c9a2-a40e-4c7b-a4f5-e79a01c6570e">9</ix:nonFraction></ix:nonFraction> at December&#160;31, 2020 and <ix:nonFraction unitRef="shares" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3ZmYxMGQ4NWVjMzg0Mzk0YTMxYmFlMDE2ZTk3OWIzZF82NTk3MDY5NzY2ODM0_4d377c01-bfcb-4097-93af-73c3e9534480"><ix:nonFraction unitRef="shares" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3ZmYxMGQ4NWVjMzg0Mzk0YTMxYmFlMDE2ZTk3OWIzZF82NTk3MDY5NzY2ODM0_86640b10-97d2-49c0-82f7-6c5e0c83d278">23</ix:nonFraction></ix:nonFraction> at December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTEtMS0xLTA_3a4bead6-3f95-43d4-aecc-a71312bf65c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTMtMS0xLTA_3f46d666-2b3f-4da0-afed-c39d753cc2b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock&#8212;par value $<ix:nonFraction unitRef="usdPerShare" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NThhM2YxM2FiM2I0OWE1ODA5MDNmY2UxMzA4MzgxNl82NTk3MDY5NzY2ODY1_2e296d44-52dc-49a2-afd6-dfb25cf39dd8"><ix:nonFraction unitRef="usdPerShare" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NThhM2YxM2FiM2I0OWE1ODA5MDNmY2UxMzA4MzgxNl82NTk3MDY5NzY2ODY1_3d626885-ffb6-44c9-ad78-bd476c7aa6be">0.001</ix:nonFraction></ix:nonFraction>; Authorized shares: <ix:nonFraction unitRef="shares" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NThhM2YxM2FiM2I0OWE1ODA5MDNmY2UxMzA4MzgxNl82NTk3MDY5NzY2ODc5_1686c912-4be2-4d2e-a650-9f6dabd1be4b"><ix:nonFraction unitRef="shares" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NThhM2YxM2FiM2I0OWE1ODA5MDNmY2UxMzA4MzgxNl82NTk3MDY5NzY2ODc5_ca78b21f-395a-43ff-8171-a1b411b06a8c">600,000,000</ix:nonFraction></ix:nonFraction> at December 31, 2020 and December 31, 2019, issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NThhM2YxM2FiM2I0OWE1ODA5MDNmY2UxMzA4MzgxNl82NTk3MDY5NzY2ODkz_56d18637-64f2-4db9-bafc-d5e57fa81e21"><ix:nonFraction unitRef="shares" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NThhM2YxM2FiM2I0OWE1ODA5MDNmY2UxMzA4MzgxNl82NTk3MDY5NzY2ODkz_d3160517-baf4-4660-9b5b-d03592f8d32e">186,851,493</ix:nonFraction></ix:nonFraction> at December&#160;31, 2020 and <ix:nonFraction unitRef="shares" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NThhM2YxM2FiM2I0OWE1ODA5MDNmY2UxMzA4MzgxNl82NTk3MDY5NzY2OTA3_5ce41c88-815d-4222-bbd9-c937f36fa314"><ix:nonFraction unitRef="shares" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NThhM2YxM2FiM2I0OWE1ODA5MDNmY2UxMzA4MzgxNl82NTk3MDY5NzY2OTA3_fe0c75b7-522f-4fae-a604-937239295a06">101,361,034</ix:nonFraction></ix:nonFraction> at December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTEtMS0xLTA_953c23b3-fb6f-4366-8d71-ab8089848028">186,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTMtMS0xLTA_aa5b6d23-fb94-4e66-86d0-beefbd66b7aa">101,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ5LTEtMS0xLTA_47eae51f-2485-40eb-bc14-2f4374a14f35">1,367,406,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ5LTMtMS0xLTA_a3f69366-3cd6-4816-a778-c03e9f585b99">742,646,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUwLTEtMS0xLTA_db2e5eab-6e3c-4832-932d-7a9cf1eccfc6">906,196,812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUwLTMtMS0xLTA_c0e5dfe0-5051-42e4-a070-067af6fc505b">739,785,655</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUxLTEtMS0xLTA_b33017f5-6a60-4687-a84a-4201823aefce">256,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUxLTMtMS0xLTA_1031b87d-f62a-420b-a3e4-7b56373671cd">472,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUyLTEtMS0xLTA_ba315b26-683b-4a05-9b85-e00e74fab486">461,140,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUyLTMtMS0xLTA_8e1a003d-7233-49ec-b735-a1986ebf6e59">3,435,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUzLTEtMS0xLTA_23559e4b-9b7b-4df7-80d2-20f81a7f9410">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUzLTMtMS0xLTA_2f6bfd3c-542b-4cb2-9fdd-c0761f5844a6">1,969,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzU0LTEtMS0xLTA_2e3fbc38-2e49-4e38-9edd-f16f662d2fc8">461,140,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzU0LTMtMS0xLTA_a4cb595f-d388-4072-8577-2607fa2276df">5,404,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzU1LTEtMS0xLTA_f90f7232-89e6-4365-b1b6-4504754a8926">539,772,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzU1LTMtMS0xLTA_4ab2a391-ca3f-4df5-8814-4351f3d20fd9">143,951,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i06d07667d4974765a8282374d1211e66_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:55.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffddb18409714a948fe63c504296aa8c_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzUtMS0xLTEtMA_db31fa9c-7b28-4ce3-961f-f6381ebe15b6">5,170,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc6151b860b45f89bb347c96f739dc4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzUtMy0xLTEtMA_722454b1-52c0-4a38-b482-8b376e49908a">3,636,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30743f88af6d4d7884fdb78b4e04be01_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzUtNS0xLTEtMA_511b821a-13ce-4c3b-92ef-a90e5d7537ea">29,860,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ddf6e556714a9194d76e2fc479466d_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzYtMS0xLTEtMA_fdb3434f-88fe-42de-bdc7-bc54265d9612">1,453,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d14809ed4f847dfa70ec56139f770f3_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzYtMy0xLTEtMA_522e90c6-5ff9-4301-b06c-7bf2e6eff143">235,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3bf773708b42baa53946d5d820581b_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzYtNS0xLTEtMA_a74880d1-a9fb-44f1-8cd7-7e05d6cf83fd">449,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a9e17b526b04b5ba4c3e10ea48bf9be_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzctMS0xLTEtMA_b5b25b4b-beb0-43a6-b352-2c244b92c8ac">786,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef7cd7ce94c488a826cce5fbf50a188_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzctMy0xLTEtMA_bca132cf-2d7b-44ad-a21e-0127536ec879">237,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i278953abb6d94a6bbe934e65ea84cbfe_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzctNS0xLTEtMA_f8b58bf5-66ba-44b7-b551-933b234623e2">171,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9103f0c23474b5c8e125a115c2724a8_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzgtMS0xLTEtMA_35ea0748-d117-4bb4-b023-6db8fc2d7c55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33e4ffc6b1db495eb2fe9e7c8433e217_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzgtMy0xLTEtMA_4d726eec-e7da-4506-b021-9d12a7e66bb9">1,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic393612319cb4ba8af0f0b3942e04555_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzgtNS0xLTEtMA_aedd3ca0-bd6e-4170-800d-0c1784db65cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzktMS0xLTEtMA_fce24118-40d9-4fcb-83f8-c05d0bbab828">7,411,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzktMy0xLTEtMA_9a54e815-8ad1-420d-bfe5-c4b563a0b04b">4,111,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzktNS0xLTEtMA_f55633be-0924-4cab-9d82-f33511a699f2">30,481,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzExLTEtMS0xLTA_2a0387c8-c0a3-44e4-a8a4-3069dc8d67c8">94,245,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzExLTMtMS0xLTA_75ebbecf-7e61-4d44-88dc-55a7176f796e">88,017,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzExLTUtMS0xLTA_ef7a0171-068f-4ac9-89bc-60993428aede">95,257,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzEyLTEtMS0xLTA_3510c084-c0bb-4a69-8f5f-41395f7301bf">37,247,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzEyLTMtMS0xLTA_599c79aa-8456-4918-a34f-1483d21949cb">27,203,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzEyLTUtMS0xLTA_c59008fe-7973-4d9e-ab93-707ac1f11e87">29,315,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE1LTEtMS0xLTA_d7f7baa5-ac46-46d5-a9f1-ab1cbb131662">131,493,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE1LTMtMS0xLTA_2837c947-b5e1-459b-a3fe-36decb8912cf">115,220,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE1LTUtMS0xLTA_ffd5a8f0-114a-4efe-93c8-c85e58412c67">124,573,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE2LTEtMS0xLTA_b6765976-97f6-49a4-9a4e-8bfca11d724a">124,082,044</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE2LTMtMS0xLTA_e99c540d-8fd2-4cc3-a23f-558d379045cf">111,108,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE2LTUtMS0xLTA_a55ab1bc-ea92-4f07-a4ea-207ea7c6afa1">94,091,138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE4LTEtMS0xLTA_4af75335-a1ad-4db8-98f4-3460bae9fabc">3,311,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE4LTMtMS0xLTA_36d0e300-0654-406f-a3b4-394ddec4fec6">2,605,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE4LTUtMS0xLTA_02182145-9917-4504-b5b7-9ba1885483ec">2,264,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE5LTEtMS0xLTA_ac7aeb17-2e52-40da-8744-5e9fc36af761">8,702,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE5LTMtMS0xLTA_10ecad19-afae-4f70-8c15-deb5b9fdc57c">7,948,539</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE5LTUtMS0xLTA_047cc297-0f27-4909-bc0a-f1f2614284b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ino:ChangeInFairValueOfCommonStockWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIwLTEtMS0xLTA_f1aa8ac6-9cca-4d11-9cfc-cbab86fc62f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ino:ChangeInFairValueOfCommonStockWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIwLTMtMS0xLTA_b9e1d194-7183-43fb-bd9e-d8c4c9f06506">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ino:ChangeInFairValueOfCommonStockWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIwLTUtMS0xLTA_32946c11-3060-4a05-ad58-dbeac2f6994b">360,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIxLTEtMS0xLTA_534b3c5c-f405-44dd-aad9-c67489c4870d">75,670,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIxLTMtMS0xLTA_13d658f0-0a82-4533-8c0b-a84d4141b69b">1,763,652</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIxLTUtMS0xLTA_a9da3926-5def-43ae-90d3-c0e8a5b0dbb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on investment in affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIyLTEtMS0xLTA_d4bbce08-3db5-4445-adf3-6ce6b675207c">36,556,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIyLTMtMS0xLTA_a74dedb8-badc-4d22-bbfe-d24b10850139">3,090,557</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIyLTUtMS0xLTA_1c3d389b-2360-4ecb-9ac9-48f31c1b05d6">1,988,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIzLTEtMS0xLTI0NzY_15c1b55e-c33f-45c7-b8a4-349935297e24">1,695,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIzLTMtMS0xLTI0NzY_48214e22-a40d-4080-86a4-f10471d87a4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIzLTUtMS0xLTI0NzY_7e8bb0e2-a411-4a00-85e1-622521a2b424">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIzLTEtMS0xLTA_0812bed5-1a58-40bc-bfa1-e0e0d4e0d87c">704,896</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIzLTMtMS0xLTA_e4aeed6c-854b-4bc9-86b0-d886b4cdc588">496,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIzLTUtMS0xLTA_d1f4dd6d-c1df-4042-bf15-6b0a00056ea8">1,343,856</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI1LTEtMS0xLTI0Nzk_7b7cdc6d-f2ba-4e0a-b4f5-15f5a333f810">4,121,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI1LTMtMS0xLTI0Nzk_3451744c-3119-4b14-95f0-507b36cf7412">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI1LTUtMS0xLTI0Nzk_6b8f848c-3001-4a2f-97de-2f49c041ac59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67b9315f7b704679b653ff7f7615cf07_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI2LTEtMS0xLTI0Nzk_2ab763e0-cd05-4c10-99bd-fdd954c667c5">8,177,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3981f22251049ee93fbe814da0d83e3_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI2LTMtMS0xLTI0Nzk_3233eb61-623a-4591-b318-69c055122612">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505e79e18d4842ec9b1a16442f4c83ba_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI2LTUtMS0xLTI0Nzk_beb4bb35-0ac1-48fa-9d37-87e9fc73f547">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaf5815034574ba68cf12263477730bb_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI3LTEtMS0xLTI0Nzk_292c2461-7272-43c6-bb87-247fe2b008d6">8,762,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3888369ceb0d47fd91589b1bd565e24b_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI3LTMtMS0xLTI0Nzk_3b9a2cab-250f-4fab-a5dc-2dd8c995198d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0398c951aeaa42e8a809af10d39ca6e8_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI3LTUtMS0xLTI0Nzk_79def4f1-6f8c-4336-9894-2d249ff5d99d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss before income tax benefit/(provision for income tax)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI0LTEtMS0xLTA_16cac49e-cf50-4ee3-92cc-be3ac7d9c460">162,890,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI0LTMtMS0xLTA_bb94bbcc-3a23-41d6-af45-7213f6e67143">120,809,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI0LTUtMS0xLTA_e26c1737-a660-4fd8-bc49-1eb5fc073445">94,798,019</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (provision for income taxes)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI1LTEtMS0xLTA_8ef56ac6-cd1b-40c7-8690-ff30851aeff1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI1LTMtMS0xLTA_80823c48-1bb7-470b-8ea8-85135d9fc3fe">257,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI1LTUtMS0xLTA_68ef1871-35dd-413a-9438-fa59e01a25dd">2,169,811</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzMwLTEtMS0xLTQ0NjI_70990ada-f25a-49f7-aa40-3c34bd8ae468">4,584,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzMwLTMtMS0xLTQ0NjI_e7c88595-c18d-434f-840d-f0875e4597fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzMwLTUtMS0xLTQ0NjI_ff209079-5cb1-4388-9516-f1d12b660d95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI2LTEtMS0xLTA_8b975bda-bdc4-4c53-b828-f22f5485e041">167,474,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI2LTMtMS0xLTA_19f461fa-7353-4b1f-99cc-6f87bfb88719">120,551,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI2LTUtMS0xLTA_df92955b-9b3d-496b-b13e-b129d08c4656">96,967,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI3LTEtMS0xLTA_4dda885c-2666-4467-98ca-53d969579ef6">1,063,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI3LTMtMS0xLTA_1d6a69a4-c7e0-46c1-a3ff-057f9e939a77">1,192,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI3LTUtMS0xLTA_641ad0ea-0ffb-4e32-bde5-b975ebec7f3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI4LTEtMS0xLTA_caa725d0-805a-40bb-889e-eb11dc6ecfb4">166,411,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI4LTMtMS0xLTA_b297604c-7836-462f-b4d1-0a8f02b32661">119,359,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI4LTUtMS0xLTA_93dec403-47d0-4b44-9803-21e9bc8f6f93">96,967,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzMwLTEtMS0xLTA_67917961-b49d-4b32-b48e-c3c727b69693">1.07</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzMwLTMtMS0xLTA_80f0dbac-80e6-4d52-b336-dd27df5e2886">1.21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzMwLTUtMS0xLTA_4b3ced07-791c-4993-b19c-96006261148d">1.05</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of common shares outstanding </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzMzLTEtMS0xLTA_34fa5607-c11c-4f8a-832b-784fe36b2627">155,126,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzMzLTMtMS0xLTA_468a6123-d91b-4161-8755-4b1f405075b1">98,717,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzMzLTUtMS0xLTA_69b66e72-d440-4c18-9b0f-e5b13c1cba30">92,539,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i06d07667d4974765a8282374d1211e66_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzItMS0xLTEtMA_562b1eb8-e032-4d68-b11a-0b585609416e">167,474,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzItMy0xLTEtMA_e3b4f661-7614-4f99-af64-45126fcf60a1">120,551,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzItNS0xLTEtMA_6a4dbbaa-f281-4057-8835-a0cd8d169e79">96,967,830</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzUtMS0xLTEtMA_8db35047-fb0b-4e6b-a3bf-1401818ecafc">27,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzUtMy0xLTEtMA_ee7b58c9-eb54-41d2-aee2-1566c31a0ce2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzUtNS0xLTEtMA_829cb21a-3c63-4c09-b37d-e4e81f0808d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Unrealized gain (loss) on short-term investments, net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzYtMS0xLTEtMA_2119fdcf-c098-43d4-85d0-d1eeeef6b718">755,963</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzYtMy0xLTEtMA_870a2377-8d47-49ca-82b6-0d6a4c7166b9">1,001,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzYtNS0xLTEtMA_1663996b-9d85-44a6-9349-6b34dacda6fa">180,496</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzctMS0xLTEtMA_5993747f-2707-4fbc-977d-55a9a85e67de">168,203,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzctMy0xLTEtMA_b76584a1-1b41-4709-a5b8-cd785c8968ea">119,550,302</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzctNS0xLTEtMA_e798e93c-7064-44f6-9ecc-eaac79616de6">97,148,326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Comprehensive loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzgtMS0xLTEtMA_d5c098df-b891-4da9-9da6-716bc9fa17a4">1,063,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzgtMy0xLTEtMA_cbf95981-56e8-43c2-abeb-9787b21141e5">1,192,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzgtNS0xLTEtMA_1065af87-523d-4fee-a85d-62407eb60621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzktMS0xLTEtMA_2852ba23-d4cd-4c4f-8280-15172079ba0b">167,139,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzktMy0xLTEtMA_f0eb22ba-adc4-47fc-bf11-3f25b2691e40">118,357,744</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzktNS0xLTEtMA_550cdf62-ed9b-4f05-aa3f-58405976a444">97,148,326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i06d07667d4974765a8282374d1211e66_127"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:25.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.292%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.576%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>interest</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2017</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37ba42be07e34414bfad4d78f2cdd2c1_I20171231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc2LTEtMS0xLTA_9497b97c-c000-43dc-b9a0-dfb6781d3d54">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37ba42be07e34414bfad4d78f2cdd2c1_I20171231" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc2LTMtMS0xLTA_e916898c-e714-4984-91cf-92353edff5a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28bc6b87217f4ff59425a80bbd1e2ad1_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc2LTUtMS0xLTA_3c487198-af22-4e2b-9d77-a07263430e87">90,357,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28bc6b87217f4ff59425a80bbd1e2ad1_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc2LTctMS0xLTA_1cedefd6-14fc-43ac-ac89-abebf4ccc708">90,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2d253912b0f4408b7670b8cbf6b0149_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc2LTktMS0xLTA_b8c3703d-9ac1-4069-88d7-8b0dfe2060db">665,775,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic56fe18af934493fa8353bf3feefd308_I20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc2LTExLTEtMS0w_e2f164f7-2382-4c20-93ab-ba746db760e8">523,356,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75e4a748c91441108389565fa9192239_I20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc2LTEzLTEtMS0w_51a740ff-5131-4faf-8292-366d9ac65353">117,005</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8049e1241294c54aa32f8547e18a755_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc2LTE1LTEtMS0w_033e4444-7073-44eb-9126-952793e2d8ee">96,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i098d7fa0e69c497394a273e6da442d60_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc2LTE3LTEtMS0w_a6cf37d5-8fe3-44ab-97de-7c091a9e993c">142,488,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTAtMS0xLTMxNDc_6c803ced-512a-40ed-a3f9-5c37b9e3854b">Cumulative effect of accounting change (1)</span></span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7aba2cb555e4b1ba182fde50316d33e_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTExLTEtMS0w_bdc02a01-e7e8-4a2a-9036-379da004ddf3">231,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9955fcfc3e2c4e3b81ca03f6caf2daa2_I20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTEzLTEtMS0w_3be9cd88-22ff-4670-9e3c-923cb963bbe8">231,366</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb4f83564ad0407e9192905a852387c8_I20171231" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTE3LTEtMS0w_cc5c860d-7f6b-4e8e-b5ce-8cd85ed11ea6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia18d7a4702454a37944331f885cfb8b1_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc4LTUtMS0xLTA_f7de6b20-3f60-46c6-b81f-7704b3157fa1">5,669,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia18d7a4702454a37944331f885cfb8b1_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc4LTctMS0xLTA_21462bf7-c9ac-45cf-aa77-318fff083469">5,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib44b98a091634594bb6b156389961e55_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc4LTktMS0xLTA_3e132892-b969-4204-bb29-3c47b2f1d4fe">29,222,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc4LTE3LTEtMS0w_de460d59-dee2-4be9-bb8f-77f24727af64">29,227,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia18d7a4702454a37944331f885cfb8b1_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc5LTUtMS0xLTA_45652b8a-88b9-4d1a-b227-3c4c5df769ed">1,199,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia18d7a4702454a37944331f885cfb8b1_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc5LTctMS0xLTA_d95a940b-f8cc-4cf0-b1be-1f9edf5038df">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib44b98a091634594bb6b156389961e55_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc5LTktMS0xLTA_37970517-73f5-4405-af27-7354bf034ab5">1,808,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc5LTE3LTEtMS0w_731a4104-feb9-4704-913d-cfb888859762">1,809,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib44b98a091634594bb6b156389961e55_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgwLTktMS0xLTA_5c3f51b9-1f6e-4433-9b2b-920035262f96">10,988,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i287bb517d7014611b68f17996d1f4e9c_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgwLTExLTEtMS0w_7f8e044d-94d1-40b1-8505-1cc170237e39">333,655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgwLTE3LTEtMS0w_c893bd36-73f0-40fd-a4c2-0dfec966cfd7">10,654,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i287bb517d7014611b68f17996d1f4e9c_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgxLTExLTEtMS0w_426ea1de-91ad-4526-97bc-815f858d2245">96,967,830</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgxLTE3LTEtMS0w_5fd26aaa-96bb-4068-9478-a9d08ebf10ce">96,967,830</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86080f7508e64793a3517dba947f4e05_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgyLTEzLTEtMS0w_b50ce14f-c6bb-447b-b2f2-897504759a0e">180,496</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgyLTE3LTEtMS0w_283d5d3b-c4f3-426c-a7d7-2cb864a8a016">180,496</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f0daeaeee744d499efc2b85f77f9d54_I20181231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgzLTEtMS0xLTA_1f14bfd9-c831-4c23-a184-996bac26371e">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f0daeaeee744d499efc2b85f77f9d54_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgzLTMtMS0xLTA_efb101f4-708b-439d-a584-5412a1fb6495">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a3a60879f794353a9d97762ab033aa3_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgzLTUtMS0xLTA_ad591c3a-1b2d-452d-916f-928e48a62a54">97,225,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a3a60879f794353a9d97762ab033aa3_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgzLTctMS0xLTA_a86f3a5c-99c1-4fe0-8d4b-82aa135075cb">97,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i740feef31f3f47f0ba79a75a7d90f120_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgzLTktMS0xLTA_79135f6a-4071-4e4d-a79a-3f9a5ffc7f86">707,794,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67fdcc0b65fc4a0089a046845912b455_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgzLTExLTEtMS0w_f926ffdf-db0f-47ef-8c6d-f25546113cbb">620,426,436</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife9269e896424523ab66d904e94b790c_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgzLTEzLTEtMS0w_ad0737df-42f3-4ce4-a386-3e06c4e1604a">528,867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia497f4c2f35943b49482c9b5840af9b9_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgzLTE1LTEtMS0w_ca69b5db-b93f-498e-8e3f-2a6ee4cf4215">96,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc185e611aa641b780dc3634c14f4ee0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgzLTE3LTEtMS0w_74489f4d-1b6e-49a6-b25b-8371e67b55be">87,032,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cbd0517be1f4ad2b1e368f3d2f228a3_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg0LTUtMS0xLTA_c7a2d6e8-bb45-445e-8dfe-cd78983dfb33">3,340,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cbd0517be1f4ad2b1e368f3d2f228a3_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg0LTctMS0xLTA_4901e8b8-1876-42a7-a8df-1839690bbddc">3,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7825d9df4ecd47ff89c494932b5e4951_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg0LTktMS0xLTA_12047a9a-28ec-4513-876c-88d683c67480">9,085,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg0LTE3LTEtMS0w_0c92b50b-ba4a-41c2-ba01-faf8f8fca2db">9,089,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cbd0517be1f4ad2b1e368f3d2f228a3_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg1LTUtMS0xLTA_160ffe1e-299c-4faf-a9b7-73f7ecf9c45a">794,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cbd0517be1f4ad2b1e368f3d2f228a3_D20190101-20191231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg1LTctMS0xLTA_aeeee462-f750-4ed9-80eb-da8596cb62d2">795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7825d9df4ecd47ff89c494932b5e4951_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg1LTktMS0xLTA_ff51fd6d-6681-4b9e-a561-3844f35ac8fa">781,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg1LTE3LTEtMS0w_c93e16ff-ac73-40c8-b95b-bfb56146edfd">780,405</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity component of issuance of convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7825d9df4ecd47ff89c494932b5e4951_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg2LTktMS0xLTA_57f195e7-7a95-4644-88c0-2f3b5a514029">15,752,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg2LTE3LTEtMS0w_71acc1ac-af9b-40d0-8906-b880322d5651">15,752,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7825d9df4ecd47ff89c494932b5e4951_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg3LTktMS0xLTA_16cc3a0e-f349-4760-93ad-5dcd38bc0fdc">10,795,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if885952e35d34a77981589fd208c6f6e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg3LTE1LTEtMS0w_ccdf3a13-acac-486b-afad-1ef9e187882b">105,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg3LTE3LTEtMS0w_4a014f47-fcfb-40b6-939e-1f07e7d474a2">10,901,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of non-controlling interest in Geneos, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if885952e35d34a77981589fd208c6f6e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg4LTE1LTEtMS0w_32e9f801-5a25-494e-9313-9778e4d8a759">2,960,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg4LTE3LTEtMS0w_acb75c9c-9b9b-4610-b12d-2e5bacd6b9f8">2,960,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bb1fb8250b642e28bbf60ee14bb5157_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg5LTExLTEtMS0w_465071e0-6865-40b2-aad9-e5ac135c9689">119,359,219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if885952e35d34a77981589fd208c6f6e_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg5LTE1LTEtMS0w_169c101e-606b-4d8c-94a0-74044fc07cee">1,192,558</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg5LTE3LTEtMS0w_dcb7861c-f9c7-4230-9114-1829f1415e6f">120,551,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87950b9f2a414087a42b5de774c7f46d_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkwLTEzLTEtMS0w_d72d9869-76bb-456c-aead-42cc58148e6a">1,001,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkwLTE3LTEtMS0w_750b3fa4-dcb1-451b-8dcf-25405406fe1a">1,001,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2a2c6f594ba44cea4528ac7e5994bbe_I20191231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkxLTEtMS0xLTA_bed2c998-1989-4504-9fcc-4657b3fce26e">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2a2c6f594ba44cea4528ac7e5994bbe_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkxLTMtMS0xLTA_5362f722-3891-4296-8496-f87e35d99b72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e3418a8da5543a1b4777a24eeab51bd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkxLTUtMS0xLTA_4953b6ab-7f94-44d3-b264-e50534c4f5be">101,361,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e3418a8da5543a1b4777a24eeab51bd_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkxLTctMS0xLTA_32c4298f-68c3-408d-87ab-868eeb511c48">101,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i005f7fef38fe454d8d059b0ff21bb4cc_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkxLTktMS0xLTA_fd26b824-b350-41b8-8df6-b3a584ccb205">742,646,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i107de4cc8049489c90dcdc7df31185d7_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkxLTExLTEtMS0w_3effe74b-4af7-41df-b0f2-244d58211bb1">739,785,655</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3627569429294e4ca52aea6769a42428_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkxLTEzLTEtMS0w_c331bcd3-fbe6-441d-a5f9-c44e3b18e0b2">472,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf69dcb513af441394c278e7178dd8e1_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkxLTE1LTEtMS0w_d42925dd-6acb-4e3a-a38c-4bf2c202e136">1,969,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkxLTE3LTEtMS0w_0f0b9581-e8b7-46d7-aa79-ee1e1273026a">5,404,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i23a4b782e98343ba867b1942902cd9c0_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkyLTUtMS0xLTQyMg_ec78a746-8cac-4315-9fee-6d7739a7c8a4">66,064,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23a4b782e98343ba867b1942902cd9c0_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkyLTctMS0xLTQyMg_674af010-2735-4a49-9d29-769045c1a1ca">66,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia154d39818f845b8b99981331588d907_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkyLTktMS0xLTQyMg_47c61e90-4831-46eb-b08a-93b80f216c16">454,420,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkyLTE3LTEtMS00MjI_5796318e-0e6d-4fa8-a416-81b18014b152">454,486,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of preferred stock to common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iab9cb5c1258e4438bb749f1d6a97298c_D20200101-20201231" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkzLTEtMS0xLTQyMg_5f4205a4-914f-4b20-9fe6-9747faec8457">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i23a4b782e98343ba867b1942902cd9c0_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkzLTUtMS0xLTQyMg_29e86ff9-09b2-4a0b-98c8-53654e08b7c2">5,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23a4b782e98343ba867b1942902cd9c0_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkzLTctMS0xLTQyMg_5d140314-9286-43aa-a393-505ad9fdfe20">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia154d39818f845b8b99981331588d907_D20200101-20201231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkzLTktMS0xLTQyMg_08802ba5-07ac-43f0-a753-54a545feaf9e">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkzLTE3LTEtMS00MjI_09a715e7-8893-42fd-9ec8-bc6875ffd0f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of senior notes to common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7793a330338242b48cd682861d2c7f7b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk0LTUtMS0xLTQyMg_0ff6257a-5ad4-4b83-a70a-c4020d26717b">11,535,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7793a330338242b48cd682861d2c7f7b_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk0LTctMS0xLTQyMg_ba5f5f65-a3a2-4369-a161-50cbdd47cd0a">11,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i360f12716f38470bbf4ae171a15c2372_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk0LTktMS0xLTQyMg_9312ca07-10b5-4873-b596-da66ec6d59e4">43,682,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaf5815034574ba68cf12263477730bb_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk0LTE3LTEtMS00MjI_c6fe08f9-0d62-4d15-b557-8f898644d7fa">43,694,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of August 2019 Bonds to common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i71043bc300f54b1da5f262214bdd0d8f_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk1LTUtMS0xLTQyMg_53b012cb-d3f5-43c9-a64d-f0ceb69eb55c">4,962,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71043bc300f54b1da5f262214bdd0d8f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk1LTctMS0xLTQyMg_38c4af13-50e3-45da-9220-1a7295ce2cb5">4,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cd6d538b5cf46eea148f05fc8d3313e_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk1LTktMS0xLTQyMg_e1ea6f03-1799-4156-9251-53a8116e5d70">102,666,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic03220c5093b43cfac7c2b6ee8ed0184_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk1LTE3LTEtMS00MjI_8a5179f0-24b4-478f-8963-35c5a7951d34">102,671,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i23a4b782e98343ba867b1942902cd9c0_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk2LTUtMS0xLTQyMg_0f21f805-53a4-4369-8184-24651d01b024">2,922,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23a4b782e98343ba867b1942902cd9c0_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk2LTctMS0xLTQyMg_8913f0d4-d730-4898-8a59-f2c4de91f48f">2,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia154d39818f845b8b99981331588d907_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk2LTktMS0xLTQyMg_b3cb408e-16a8-4717-8c35-0f84024b7c66">8,238,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk2LTE3LTEtMS00MjI_907e843d-7f10-44d5-af19-71396a9c98bc">8,241,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia154d39818f845b8b99981331588d907_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk3LTktMS0xLTQyMg_fdc7ed19-2e4d-4d48-8faa-57a83c816c48">15,655,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51877c6afa3e4a95a48234a7814aa510_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk3LTE1LTEtMS00MjI_465e27a1-6fe0-4bab-a21e-e82dce549a24">8,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk3LTE3LTEtMS00MjI_cf0b7453-1cf6-4ce2-a7ba-4c795f4a17a2">15,647,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of non-controlling interest in Geneos, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51877c6afa3e4a95a48234a7814aa510_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk4LTE1LTEtMS00MjI_05b714a2-5098-4e87-a741-285359222c6f">2,379,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk4LTE3LTEtMS00MjI_65c21e54-7688-441c-a521-6f6190456400">2,379,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51877c6afa3e4a95a48234a7814aa510_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk5LTE1LTEtMS00MjI_b7f8c06f-7637-468b-8e72-05b972f812eb">3,181,640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk5LTE3LTEtMS00MjI_5bed2ade-f2e9-4801-a8f1-746fa770f6f1">3,181,640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa46d2918b494bf6b84cf170d1bd45b3_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMC0xMS0xLTEtNDIy_eb42939a-d845-4bfe-ba74-0465367900c5">166,411,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51877c6afa3e4a95a48234a7814aa510_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMC0xNS0xLTEtNDIy_c77bd460-e924-40b9-b554-ef91212d094a">1,063,757</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMC0xNy0xLTEtNDIy_4a2f76af-b6f3-46df-94db-62955e92286d">167,474,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dissolution of majority-owned subsidiary VGX Animal Health, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia154d39818f845b8b99981331588d907_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMS05LTEtMS05MDYx_ee473969-8d47-48c5-923b-f615e29a10e5">96,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51877c6afa3e4a95a48234a7814aa510_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMS0xNS0xLTEtOTA2MQ_93fc479a-7942-457c-8797-2ed14b970e6b">96,269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMS0xNy0xLTEtOTA2Nw_f13ae7b3-fc41-4d4c-b8db-c1bc2a696236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib11feb96d4f04657b2246c8fc89ee878_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMS0xMy0xLTEtNDIy_ef04125c-bbd1-42e1-8422-8da83d206ce2">755,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMS0xNy0xLTEtNDIy_f8eaea1d-6a87-4ab2-b345-485161c84382">755,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib11feb96d4f04657b2246c8fc89ee878_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMi0xMy0xLTEtNDIy_106de8b2-d97b-4010-814c-2b72ada15678">27,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMi0xNy0xLTEtNDIy_52909d28-596a-4e91-a073-f8de000261d4">27,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1cf0fd331c9340aab8d9ff4bdb145e55_I20201231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMy0xLTEtMS00MjI_4c6ed4b8-d27a-42e1-9b27-86e05c86333f">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cf0fd331c9340aab8d9ff4bdb145e55_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMy0zLTEtMS00MjI_7391db9d-6ae1-46b2-b1fa-15a22dab2460">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4b271c4ed074580b9dd08164751212e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMy01LTEtMS00MjI_f6e55737-45bd-453e-b50f-b77457c8a197">186,851,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4b271c4ed074580b9dd08164751212e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMy03LTEtMS00MjI_91e9fafc-d4e8-4a9c-a7b2-cff2a580474b">186,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cbd1b6109f04daeb2321b67b43c7080_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMy05LTEtMS00MjI_7bf1ee4f-de3d-4848-95ad-87b6a32f91d8">1,367,406,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7451d3a8f3541b6bfb4ad50349ef17c_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMy0xMS0xLTEtNDIy_8b821d70-ce30-4ed4-9d24-6cd0d701d998">906,196,812</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f72e3ff2fe94fd3bd217b59590c7d5e_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMy0xMy0xLTEtNDIy_8e0c0ddf-5872-43a9-b678-25428ceedcee">256,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe28f3a96c8b4546bb455081a9f12d46_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMy0xNS0xLTEtNDIy_d71115b0-90c1-4693-b728-dd084544c395">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMy0xNy0xLTEtNDIy_05359a16-0a71-4354-aef8-8c0169c717d1">461,140,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90ZXh0cmVnaW9uOmRlZGFlNzNlM2MyMTRiYjJhYWY1NGIxZTdiM2FiNzMzXzExNDY_195c7e0a-b8ba-4aef-9e33-54bfb12e8a43" footnoteRole="http://www.xbrl.org/2003/role/footnote">Upon adoption of ASU 2016-01 on January 1, 2018, the Company began to measure and record equity investments, except those accounted for under the equity method of accounting that have a readily determinable fair value, at fair value and began to recognize the changes in fair value in its consolidated statements of operations, instead of recognizing unrealized gains and losses through accumulated other comprehensive income (loss), as done under the previous guidance. The Company recorded a $<ix:nonFraction unitRef="usd" contextRef="ib7aba2cb555e4b1ba182fde50316d33e_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90ZXh0cmVnaW9uOmRlZGFlNzNlM2MyMTRiYjJhYWY1NGIxZTdiM2FiNzMzXzg2OQ_4b00f765-c300-4d57-b01f-4b2603f7afe6"><ix:nonFraction unitRef="usd" contextRef="i9955fcfc3e2c4e3b81ca03f6caf2daa2_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90ZXh0cmVnaW9uOmRlZGFlNzNlM2MyMTRiYjJhYWY1NGIxZTdiM2FiNzMzXzg2OQ_abedb938-2214-484f-a63d-f5e670a01056">231,000</ix:nonFraction></ix:nonFraction> cumulative effect adjustment to reclassify the cumulative unrealized gain, net of tax effect, from its investment in an affiliated entity, PLS, from accumulated other comprehensive loss to accumulated deficit.</ix:footnote></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i06d07667d4974765a8282374d1211e66_133"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:61.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMtMS0xLTEtMA_00fa0a08-5c88-4aef-a7bb-4f9955e56edd">167,474,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMtMy0xLTEtMA_954e0e77-9bde-4658-a041-d604c0431684">120,551,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMtNS0xLTEtMA_7313a76d-0e0b-4f4c-a104-8fbaf69b1014">96,967,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUtMS0xLTEtMA_87b6dbbf-b69f-4818-9aa9-b4ebe334d8db">3,038,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUtMy0xLTEtMA_3a656761-5fc7-4db9-91dd-b64967259999">3,598,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUtNS0xLTEtMA_69b09d97-e179-4ce1-8417-feec1a9014fc">3,747,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYtMS0xLTEtMA_32b84d72-d62e-4ec6-bf4d-3a7b6befb2e0">547,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYtMy0xLTEtMA_dc4eb53b-8c00-45fa-a5ed-9fc8e3c0abef">1,066,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYtNS0xLTEtMA_77088892-43a2-47ec-9066-bddd7b1c7f66">1,249,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ino:AmortizationOfOperatingLeaseRightOfUseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzctMS0xLTEtMA_953685b1-9764-4baf-9988-9b0f2a12d5e5">1,041,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ino:AmortizationOfOperatingLeaseRightOfUseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzctMy0xLTEtMA_5e3b3fd9-84f6-40bc-bfef-f3e93f048a64">851,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ino:ChangeInValueOfCommonStockWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzgtMS0xLTEtMA_d46f60cd-4faa-47c0-8b72-0bb9fbb33426">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ino:ChangeInValueOfCommonStockWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzgtMy0xLTEtMA_adf748e5-8c21-43e1-9642-427281eee549">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ChangeInValueOfCommonStockWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzgtNS0xLTEtMA_101722d6-c0a9-4648-8632-60b25485dfe2">360,795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzktMS0xLTEtMA_acdfbe9c-0a51-41a8-801c-2ce936604c78">75,670,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzktMy0xLTEtMA_a5161aeb-bf9b-4624-bb4c-28d4238ad3c1">1,763,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzktNS0xLTEtMA_30be6ed9-0bf6-4db5-a37a-e621636bcfdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzExLTEtMS0xLTA_689c6c53-e9f1-45a4-a8bd-18ea029fa633">15,647,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzExLTMtMS0xLTA_4ca5e5f1-0f88-4c28-844c-d7281577ca75">10,901,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzExLTUtMS0xLTA_81f9308f-3aaf-4767-affb-6a4eaac98753">10,654,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ino:NonCashInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzEyLTEtMS0xLTA_e0ffebe6-c75b-4bfb-a868-348dcf00e6d3">4,077,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ino:NonCashInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzEyLTMtMS0xLTA_1fb20137-2d8c-480f-96bc-8d99f534c8ff">5,230,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ino:NonCashInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzEyLTUtMS0xLTA_6245de95-a838-4d8c-a913-85ca3528209c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of premiums on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:InvestmentIncomeAmortizationOfPremium" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzEzLTEtMS0xLTA_0f7256cc-fe39-4d38-ab31-ba6b6302ff1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeAmortizationOfPremium" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzEzLTMtMS0xLTA_14a7372a-50a2-4de3-97ad-2cb237b283f6">1,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeAmortizationOfPremium" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzEzLTUtMS0xLTA_723c5c6f-5c16-41b3-9793-70317f16f1b2">72,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE1LTEtMS0xLTA_380528fa-b81b-4f54-a020-e51a0f4cb0b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE1LTMtMS0xLTA_636ca916-587c-4dbc-a4a9-97eed3bc3adb">5,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE1LTUtMS0xLTA_5455e4b5-37a7-4714-b525-b5700fa79d07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) on short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE4LTEtMS0xLTA_79052109-823b-43f3-a071-91a478ce638b">588,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE4LTMtMS0xLTA_a39c77db-9fc4-44c1-bb93-c35018f3924b">476,368</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE4LTUtMS0xLTA_96eac4ca-0ad6-4705-be81-c48bc4583f62">1,342,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of receivable with shares of common stock from affiliated entity (PLS)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE5LTEtMS0xLTQ0Njk_6198b20f-34ab-43ce-804f-d1b1515b9cce">1,713,770</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE5LTMtMS0xLTQ0Njk_f99d0ece-4759-4f30-9f91-b2d077a209ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE5LTUtMS0xLTQ0Njk_95426c10-b915-4405-af57-169db79dfa04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIwLTEtMS0xLTQ0NzU_2c45fe54-92cb-4a0e-869b-35ec240b113e">4,121,075</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIwLTMtMS0xLTQ0NzU_d68a5886-57b6-4e97-b75a-6ac305c09249">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIwLTUtMS0xLTQ0NzU_c5fa3899-5940-44a6-8b0f-c9ed457e0f11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on disposal of fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE5LTEtMS0xLTA_a1ffb1f2-47bc-4836-a12a-57cd62832f3b">26,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE5LTMtMS0xLTA_bdec8722-7922-46e2-b1a7-9d00d4122913">5,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE5LTUtMS0xLTA_0d92c45e-7580-4a0c-9c70-79272e1eecf1">14,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on equity investment in affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIwLTEtMS0xLTA_4ca353f7-56b9-4afd-89f0-1b27c87f5ff8">36,556,658</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIwLTMtMS0xLTA_584bfc43-5205-4b84-83a1-2d23010038c3">3,090,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIwLTUtMS0xLTA_ff6d28cb-0548-4519-8c82-450de89cbf76">1,988,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share of net loss in Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIxLTEtMS0xLTA_10226b80-6fed-4a9f-adf6-501c2363bb35">4,584,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIxLTMtMS0xLTA_79ea8cf0-b149-4ffe-b851-5fe8c0e108a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIxLTUtMS0xLTA_d28c98fa-15e8-4de2-8cc3-3d4073f1d96c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible August 2019 bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic03220c5093b43cfac7c2b6ee8ed0184_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI0LTEtMS0xLTQ0ODY_4fe6a796-be4e-43cd-94b4-20d40e8af426">8,177,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b8aa89313b84034867fdb688e65bfdd_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI0LTMtMS0xLTQ0ODY_562dc32f-b3f1-4410-9d19-bea57a02ca17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc5e017651494a17b39d87c26345b84c_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI0LTUtMS0xLTQ0ODY_75952463-cf58-4c96-9d26-d76bd5a26959">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaaf5815034574ba68cf12263477730bb_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI1LTEtMS0xLTQ0ODY_fc6d7727-e91a-434f-a0d9-37893bafc98f">8,762,030</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3888369ceb0d47fd91589b1bd565e24b_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI1LTMtMS0xLTQ0ODY_e05fe868-7c2d-450a-af94-0c5be9b93896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0398c951aeaa42e8a809af10d39ca6e8_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI1LTUtMS0xLTQ0ODY_63ac558f-d40c-465c-af42-44f7e2fe9b35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI2LTEtMS0xLTQ0OTI_b4ce7fa5-ad1e-4326-8cd7-f41e41957eb2">1,695,497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI2LTMtMS0xLTQ0OTI_f9d1d44f-ad1c-41af-8635-613a65a368a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI2LTUtMS0xLTQ0OTI_d4151708-b529-4dcd-961b-6961c71cc9b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit from other unrealized gains on short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIyLTEtMS0xLTA_d62cc118-8c93-4f0f-ad4c-2cbbd6c6985b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIyLTMtMS0xLTA_bc322159-b2ff-4344-805d-fd376c507e29">266,215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIyLTUtMS0xLTA_8c9f28c9-61da-4169-acba-4afd5fb1bae8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized transaction loss on foreign-currency denominated debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIzLTEtMS0xLTA_a9c64b72-83d9-4564-a4f2-fe89b9eda107">15,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIzLTMtMS0xLTA_14c60c36-63b1-4359-b8dd-512cf289dbbd">471,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIzLTUtMS0xLTA_27bc7b01-7ef2-48ae-b2cc-1471d2fdaa48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI1LTEtMS0xLTA_12931f91-8b4f-4288-af84-f969e20f1c9d">17,859,894</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI1LTMtMS0xLTA_133bd261-b8af-462d-b093-f213f861c097">2,616,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI1LTUtMS0xLTA_ccb679e7-e691-44f2-b05b-df682142c8dd">2,686,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI2LTEtMS0xLTA_b61b2077-ed09-403d-912c-47e3040c5293">844,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI2LTMtMS0xLTA_78c086bf-5793-4ca7-9da2-3773d4475a2f">593,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI2LTUtMS0xLTA_93a54646-3cb9-4fc6-adf5-16950cfa3bb2">251,964</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI3LTEtMS0xLTA_6bdc8120-9f93-491e-800f-a97c25c5f946">38,849,572</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI3LTMtMS0xLTA_ae65e3a9-db5e-4fde-b12d-f76f713dcc6c">178,008</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI3LTUtMS0xLTA_1744af7e-770b-4fd1-8d09-fd88218b5c75">1,194,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI4LTEtMS0xLTA_dae67bc4-3bff-4c82-894f-ee716060fde5">374,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI4LTMtMS0xLTA_a1f6c126-5f20-45e5-adda-dcfd9d6fd71d">70,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI4LTUtMS0xLTA_c3348853-1c65-4b81-bdaa-3fad4f536659">725,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMwLTEtMS0xLTA_18294eda-d16d-4fda-9e71-1eb634240065">23,285,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMwLTMtMS0xLTA_544980ee-74c1-426d-9b90-3ee4e1bf69bd">2,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMwLTUtMS0xLTA_e22264c1-5ad9-4100-9799-56129df2dc6c">30,644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMxLTEtMS0xLTA_37c15ee7-f1dd-4232-963f-3847b3412128">3,115,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMxLTMtMS0xLTA_7367d483-abb8-4983-97e0-aac37c16c456">4,337,829</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMxLTUtMS0xLTA_5898065c-6ef0-404d-b043-e63c59644128">550,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMyLTEtMS0xLTA_ddac1ae6-8f90-4348-baef-a37ca20a24b2">5,962,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMyLTMtMS0xLTA_4a0e4aac-c2e9-4275-b363-08ca811b008b">1,622,037</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMyLTUtMS0xLTA_ee0c6311-bb74-40e4-8adc-c42fa3548727">2,940,128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses due to affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMzLTEtMS0xLTA_a5c78e1f-8d94-4327-b81e-f713bf2974f2">135,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMzLTMtMS0xLTA_913c1eef-efa8-4e51-ac43-903b1a7a7f64">248,063</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMzLTUtMS0xLTA_00db7a57-f054-49da-ade8-c0c37bf53329">50,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM0LTEtMS0xLTA_5602aa61-2f2a-49e8-ba3c-9cc5c3e91e0e">68,078</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM0LTMtMS0xLTA_ee0cee17-218f-45fa-b0b5-33d8c9184078">180,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM0LTUtMS0xLTA_00278614-8a0e-4172-a095-7ef73e1f2a47">1,016,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM1LTEtMS0xLTA_9ad9bea2-5b4b-4101-892f-0f9af76e5830">5,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM1LTMtMS0xLTA_bc7e414e-355d-4eda-9a58-05009c2aa610">1,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM1LTUtMS0xLTA_d1d3b453-8297-42c2-a3ef-7d97845fd509">140,535</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred rent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:StraightLineRent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM2LTEtMS0xLTA_3767006d-0394-4ea0-b022-a418336d882f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:StraightLineRent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM2LTMtMS0xLTA_30a07016-fa40-41b4-98e8-2a731e7e8388">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StraightLineRent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM2LTUtMS0xLTA_21b283a6-afab-42cc-ba0e-b4dbc0e51417">398,357</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM3LTEtMS0xLTA_2115350e-c63d-40c5-b9b2-916df506dfc3">2,091,855</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM3LTMtMS0xLTA_ec4ca243-6220-4e01-8eaa-522168cfa54a">1,733,599</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Grant funding liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM4LTEtMS0xLTA_0720515f-1498-4f3b-82ed-dbffaace3e5e">1,409,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM4LTMtMS0xLTA_481a2fbf-3107-48a1-a819-bf085991bc11">1,899,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM4LTUtMS0xLTA_0944dcbf-46f1-4c99-a7a3-9414d2461b3e">4,165,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM5LTEtMS0xLTA_552955ab-5556-4e54-a373-ee8810d41391">784,925</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM5LTMtMS0xLTA_abd955f9-1dfa-4dbc-9634-ec061da9d9e1">816,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM5LTUtMS0xLTA_33023851-0cda-41a0-84aa-bb4423d6e625">27,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQwLTEtMS0xLTA_1e0e7894-3640-473e-9abd-0d2071bcf058">20,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQwLTMtMS0xLTA_36197582-7c47-47f1-86b0-f6671693e200">48,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQwLTUtMS0xLTA_224d2d1b-9c40-45e8-99d9-9430d4e34324">87,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQxLTEtMS0xLTA_173cfd91-8e89-4e3d-8a9d-0b1e41866c8d">177,979,046</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQxLTMtMS0xLTA_5f1eb86d-f284-46b2-9395-a130d8a813d8">97,850,136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQxLTUtMS0xLTA_d8bab279-e183-484b-9e85-5a392367bb57">73,550,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQzLTEtMS0xLTA_4067e1bb-aafa-4d66-a8e2-20a5cfff2e55">156,216,677</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQzLTMtMS0xLTA_65463a0a-6094-48b7-8d4e-7cf38de71f6c">100,950,301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQzLTUtMS0xLTA_158caa3e-94af-480a-aa10-b3b0810331e1">88,155,046</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of or maturity of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ0LTEtMS0xLTA_bc607f1d-c13c-426e-94fb-b32bb99d2d53">62,991,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ0LTMtMS0xLTA_953abbdd-d9de-416a-9fda-43bde503baf1">92,893,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ0LTUtMS0xLTA_4ef4cf80-18ca-4e18-a15f-5dee99702555">132,659,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of capital assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ1LTEtMS0xLTA_4d4edacd-7897-410a-a18f-ee6508e67481">1,520,665</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ1LTMtMS0xLTA_43574da4-9ae1-438b-8ebb-11b3cd758855">987,926</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ1LTUtMS0xLTA_61d3a699-e4da-4de0-9ef0-2eff10aa1cfd">2,085,022</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of investment of GeneOne</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ino:ProceedsFromSaleOfEquitySecuritiesFVNI" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ2LTEtMS0xLTA_66b65ad8-de79-4f24-ad9d-64d528a26b17">40,125,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="ino:ProceedsFromSaleOfEquitySecuritiesFVNI" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ2LTMtMS0xLTA_8a494891-9268-4df0-976b-88c3627fbbca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ino:ProceedsFromSaleOfEquitySecuritiesFVNI" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ2LTUtMS0xLTA_76d50283-ba48-4ba8-ad11-abd893fd9355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decrease of cash resulting from the deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashDivestedFromDeconsolidation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ3LTEtMS0xLTA_a4bc1fee-060b-4720-9df7-e24d1c7900fb">2,774,851</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:CashDivestedFromDeconsolidation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ3LTMtMS0xLTA_37524fac-bc1f-413f-84cd-8f246e72a675">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:CashDivestedFromDeconsolidation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ3LTUtMS0xLTA_c0d54c1b-af9c-483f-8c09-f9d3503d763a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment in Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ4LTEtMS0xLTA_824fa8f0-f02c-4ce2-b655-7dbfc1875e0a">1,399,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ4LTMtMS0xLTA_41da1a66-7200-4f0d-afa6-154b258f936f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ4LTUtMS0xLTA_bfcb6a2c-df06-42cf-823d-cb2ca0d3c768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUwLTEtMS0xLTA_f868ca9d-1c19-41fe-ae53-84db26cb6a21">58,795,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUwLTMtMS0xLTA_b6cb28a7-141a-4025-a2a3-60e1edb4ff8d">9,044,995</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUwLTUtMS0xLTA_2fa5105f-8bfd-4d4f-8dda-6b09183bc4c3">42,419,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuances of convertible senior notes and convertible bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUyLTEtMS0xLTA_b1be8de7-26b1-4c19-b650-b6017f983d6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUyLTMtMS0xLTA_27ba758d-a86d-47c6-8234-9836b80da534">97,443,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUyLTUtMS0xLTA_3b620de6-0fe9-4db8-adbf-cb3c5493ad33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs related to issuances of convertible senior notes and convertible bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUzLTEtMS0xLTA_5b57e100-3bc7-483f-a60c-c2e3c179c1ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUzLTMtMS0xLTA_fae70432-b55d-42ae-bf43-65b5548e5f29">3,314,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUzLTUtMS0xLTA_d1ba88c8-1845-430c-b7cc-af3357db629b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU0LTEtMS0xLTA_0af2338e-279f-41e3-b14b-1fc331ac7945">454,486,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU0LTMtMS0xLTA_e624cd80-4413-4c90-a792-475051fae6e2">9,089,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU0LTUtMS0xLTA_f51f96a0-f632-4644-8318-e30eca9b2332">29,227,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from stock option and warrant exercises, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ino:ProceedsfromStockOptionandWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU1LTEtMS0xLTA_acd5fbe0-e6f5-4145-9ea3-8ae9a88924a2">12,269,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ino:ProceedsfromStockOptionandWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU1LTMtMS0xLTA_caa0fcb8-19c5-444b-9c02-65dfeae87e19">112,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="ino:ProceedsfromStockOptionandWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU1LTUtMS0xLTA_20510e5c-45c6-4d01-9f3b-4c7fe4f726c0">2,421,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards, net of proceeds from option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU2LTEtMS0xLTA_e5cbec6e-0a8d-4e8f-be2c-c856e32e2258">4,028,177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU2LTMtMS0xLTA_2609591d-7b01-4a44-bee9-9d8c879d2406">892,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU2LTUtMS0xLTA_75d568de-674c-4e33-8df4-7633a79ee5b8">611,610</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMinorityShareholders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU3LTEtMS0xLTA_5bc14825-2c02-4df1-ab86-26ace0cb2693">2,379,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMinorityShareholders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU3LTMtMS0xLTA_62a6bd81-3d7d-4ebc-b48b-f7f13db39f47">2,960,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromMinorityShareholders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU3LTUtMS0xLTA_9a8556d2-7b7c-438c-8433-0a280a455460">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from Geneos issuance of note payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYzLTEtMS0xLTQ1MDY_c50a3cdd-24ea-478f-ada8-406310a9f223">171,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYzLTMtMS0xLTQ1MDY_8707b6b4-2b60-4446-9843-145a0db65fe0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYzLTUtMS0xLTQ1MDY_c0d1ba7f-2c77-4942-acae-ecfcfd849112">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU4LTEtMS0xLTA_901e32ed-bf33-45f3-b695-183eef004a8c">465,279,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU4LTMtMS0xLTA_94471088-7998-400c-9bf8-88c40a24f635">105,397,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU4LTUtMS0xLTA_6ab7952a-ee9f-4dd5-8ffd-8165b25d6b03">31,037,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU5LTEtMS0xLTA_feedca0d-6b78-40d3-9dc4-7fa9fccff0b4">27,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU5LTMtMS0xLTA_97e1e7bd-38b8-4180-91ea-7abca7eb6dd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU5LTUtMS0xLTA_945005b3-b378-4bf4-9ffb-040072b35bad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYwLTEtMS0xLTA_5abd258d-73e9-4f3e-9c51-c8b68e4fa4e6">228,532,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYwLTMtMS0xLTA_ac841557-9269-4009-b9bf-8a82d83ed692">1,497,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYwLTUtMS0xLTA_2c2b59df-7948-4704-9d39-51be4adabd56">92,946</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYxLTEtMS0xLTA_fd2316f5-bd8b-4537-bafd-5830c8cfa9e4">22,196,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc185e611aa641b780dc3634c14f4ee0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYxLTMtMS0xLTA_9bfb9338-cb04-49eb-93a0-a364232ded6f">23,693,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i098d7fa0e69c497394a273e6da442d60_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYxLTUtMS0xLTA_be305565-d325-4bb2-b9c2-c44580cdafad">23,786,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYyLTEtMS0xLTA_bfe81c7f-a5fa-4524-97be-742d431c7b7d">250,728,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYyLTMtMS0xLTA_51e4a7b5-394c-4955-8573-0c095d317a45">22,196,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc185e611aa641b780dc3634c14f4ee0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYyLTUtMS0xLTA_007bf029-713c-43d9-9cc7-2177c6b71d12">23,693,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts accrued for purchases of property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY2LTEtMS0xLTA_f7be0c90-e329-4489-9d64-bdcf0ed84db1">136,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY2LTMtMS0xLTA_ef60456b-f035-4a02-aa53-500d3d3bdf5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY2LTUtMS0xLTA_5982ad84-c574-4756-bb63-94bd68f3d56e">559,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY3LTEtMS0xLTA_3a319326-3344-4e98-92c5-bca1b63b9e44">4,624,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY3LTMtMS0xLTA_6f1a1112-8e29-4cc7-b146-93078b28c560">2,717,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY3LTUtMS0xLTA_27bcaebf-daec-4d29-9b89-137475a9b50f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity component of issuance of convertible notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:zerodash" name="ino:EquityComponentOfConvertibleDebtIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY4LTEtMS0xLTA_8c715997-de77-45e7-8035-470484d42954">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="ino:EquityComponentOfConvertibleDebtIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY4LTMtMS0xLTA_38dd4647-2b2a-40fc-8a91-8d381aa3e435">15,752,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="ino:EquityComponentOfConvertibleDebtIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY4LTUtMS0xLTA_5a7fd887-389f-4165-97d6-c4bbdc327c5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY5LTEtMS0xLTA_781f0ce5-c656-4361-a3d0-ccca6134a205">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY5LTMtMS0xLTA_9384a0c4-b25f-428d-9d64-b6982a1fedf8">14,634,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="i06d07667d4974765a8282374d1211e66_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i06d07667d4974765a8282374d1211e66_139"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzkvZnJhZzoyZWZiZGIwNGE2MDA0MjFjYWNhYzc3MWE5YTJmMTMxMS90ZXh0cmVnaW9uOjJlZmJkYjA0YTYwMDQyMWNhY2FjNzcxYTlhMmYxMzExXzMyNTg_a0c34572-0549-421a-9a6d-e6c88855a0be" continuedAt="id9e2b6917bed46279a37085e10716bb3" escape="true">The Company</ix:nonNumeric></span></div><ix:continuation id="id9e2b6917bed46279a37085e10716bb3"><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;), is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus (HPV). INOVIO's DNA medicines pipeline is comprised of three types of product candidates: DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies (dMAbs</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In clinical trials, INOVIO has demonstrated that DNA medicines can be delivered directly into cells in the body through its proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted pathogens and cancers. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's novel DNA medicine candidates are made using its proprietary SynCon</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology that uses a computer algorithm designed to identify and optimize the DNA sequence of the target antigen (be it virus or a tumor). INOVIO then creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce antigens to help the person&#8217;s immune system recognize and destroy cancerous or virally infected cells.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's patented CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery devices provide optimized uptake of its DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trial data to date has shown a favorable safety profile of INOVIO's DNA medicines delivered directly into cells in the body using the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart device in more than 7,000 administrations across more than 3,000 patients.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> INOVIO's corporate strategy is to advance, protect and, once approved, commercialize its novel DNA medicines to meet urgent and emerging global health needs. The Company continues to advance and clinically validate an array of DNA medicine candidates that target HPV-associated diseases, cancer, and infectious diseases, such as COVID-19 (SARS-CoV-2). The Company aims to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's partners and collaborators include ApolloBio Corporation.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> AstraZeneca, Beijing Advaccine, The Bill &amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), The U.S. Department of Defense (DoD), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium (MCDC), International Vaccine Institute (IVI), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators are currently conducting or planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis (RRP); glioblastoma multiforme (GBM); prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus).  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div></ix:continuation><div><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_142"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   2. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzIw_ce16bcfc-0f0d-4e88-bd7a-ba4ffcf704aa" continuedAt="ide1e23ed586f4a46936e76512cadd68a" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ide1e23ed586f4a46936e76512cadd68a" continuedAt="i9cf698497b954734b8a901e24a481f69"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzIx_99d50a97-b634-4278-b42a-c9916fde8791" continuedAt="i674dce9235ff41bd8f9b9a1cdded929c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO incurred a net loss attributable to common stockholders of $<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjU2MTQ_e0831233-14e5-49c7-af7a-acbed3e86cbc">166.4</ix:nonFraction> million for the year ended December&#160;31, 2020. INOVIO had working capital of $<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:WorkingCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzIwOQ_b6d73d0f-7d9e-4dbc-9035-70a4b8eef82f">429.5</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjU1ODE_62588a88-1264-4c7b-9b11-c11093bad219">906.2</ix:nonFraction> million as of December&#160;31, 2020. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MTIwMzk_49545ef8-4b5f-4031-9464-592b664b075e">411.6</ix:nonFraction> million as of December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of potential future At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds under past Sales </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9cf698497b954734b8a901e24a481f69" continuedAt="ic5e5c7b25f1b4f0d897b94cc64d68e51"><ix:continuation id="i674dce9235ff41bd8f9b9a1cdded929c"><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreements of $<ix:nonFraction unitRef="usd" contextRef="i6150a0ddcd004d80a33e1a8697c53f20_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzEwOTk1MTE2MzkwMjcz_a27dacc0-061a-4eeb-b197-194fa869ee69">454.5</ix:nonFraction>&#160;million during the year ended December 31, 2020, and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="if84110be1e7d414fba59970232a6a0c4_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjM0Nzk_1d36c8fe-22fb-4ea2-8d38-5093908a0ee2">9.1</ix:nonFraction>&#160;million under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ie36d4982a87c49f39d1d799e83d16f3d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjM0OTU_b11b2f37-247c-4704-bbaf-23caccded925">75.7</ix:nonFraction>&#160;million from a private placement of <ix:nonFraction unitRef="number" contextRef="i537cf66d5bd342bc8318a0e2943c17c8_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjM1MTA_529f344f-a87c-4629-9a51-4b7ca19b8bf6">6.50</ix:nonFraction>% convertible senior notes due 2024 (the &#8220;Notes&#8221;), net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i340206d59d1a4f37a0d265ecd256f49a_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjM1MTc_4a26a7e3-0681-43b4-ba66-e0773ad0f190">14.5</ix:nonFraction>&#160;million from the private placement of <ix:nonFraction unitRef="krw" contextRef="i9e8658006af5464d94cdc5612be9184f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzEwOTk1MTE2MzkwMjk2_71a8fdbd-2c49-416d-9165-44e519ecbd15">18</ix:nonFraction>&#160;billion Korean Won (KRW) (approximately USD $<ix:nonFraction unitRef="usd" contextRef="i9e8658006af5464d94cdc5612be9184f_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjM1MzU_34178899-83f1-4f7e-9b2e-6bd2c6265d78">15.0</ix:nonFraction>&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i9e8658006af5464d94cdc5612be9184f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjM1NDk_e8ed2a93-a997-44ce-bab3-4d2a6659af70">1.0</ix:nonFraction>% convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i7b92526d2c7d46a19cf0c21a5393e2ca_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzEwOTk1MTE2MzkwMzQ2_925a6213-9f15-435a-ad47-4919b82f2654">4.0</ix:nonFraction>&#160;million from the private placement of <ix:nonFraction unitRef="krw" contextRef="i0b080f596f2e47f7a9e4906d33a20b22_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzEwOTk1MTE2MzkwMzYw_85020b86-4703-4160-b664-94f4231a79e8">4.7</ix:nonFraction>&#160;billion KRW (approximately USD $<ix:nonFraction unitRef="usd" contextRef="i0b080f596f2e47f7a9e4906d33a20b22_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzEwOTk1MTE2MzkwNDQ0_f7c232c1-a2a0-4e94-aa2f-eba0bfaabef9">4.1</ix:nonFraction>&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i0b080f596f2e47f7a9e4906d33a20b22_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjM1NTQ_1553a3b9-509c-48a8-87f4-ddc4f9ad7b44">1.0</ix:nonFraction>% convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#8220;Bonds&#8221;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company&#160;may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is closely monitoring the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will impact the Company's business and operations will depend on future developments, including the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, that are highly uncertain.</span></div></ix:continuation><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzEwNDQ1MzYwNTc2MzY2_ea453cfc-0f4d-4222-8211-5e555a2984f8" continuedAt="i01c1f97ffeff4a88a1a940ca7eed9b41" escape="true">Consolidation</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i01c1f97ffeff4a88a1a940ca7eed9b41">The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. As of December 31, 2020 the Company consolidated its wholly-owned subsidiary Inovio Asia LLC.  On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority -owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions have been eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.</ix:continuation>  Refer to Footnote 19 for further discussion of Geneos.</span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2Nzcx_8c6bbc91-b723-4f00-92c8-143a8a6d6053" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as <ix:nonFraction unitRef="segment" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQ5Njc_054eaa18-1290-4394-8bdd-584fe2afc981">one</ix:nonFraction> segment operating primarily within the United States.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzEy_19110707-d8ae-4f09-bd3a-8d98e4541c25" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzYw_06c98f11-2762-4581-a164-8a6865519f65" continuedAt="ia12ccfdf91164b65b4e3e4d8038f3b24" escape="true">Concentration of Credit Risk</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic5e5c7b25f1b4f0d897b94cc64d68e51" continuedAt="id924cd922e7845eb8d1530ee59a72913"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia12ccfdf91164b65b4e3e4d8038f3b24">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracts with certain of its customers that have represented more than 10% of the Company's total revenues, as discussed in Note 7.</span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODUz_ba67406b-1744-4384-b0ae-05d20b98708d" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist principally of cash equivalents, short-term investments and investments in affiliated entities. The carrying amounts of cash equivalents approximate the related fair values due to the short-term maturities of these instruments. Investments are recorded at fair value, based on current market valuations. The Company carries convertible notes and bonds at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.</span></div></ix:nonNumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2Nzc3_f5733b1a-0426-4650-80b1-4d68515a6401" continuedAt="i3c739449adf8460e8b30daffb9bb4199" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3c739449adf8460e8b30daffb9bb4199">Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December&#160;31, 2020 and money market accounts at December 31, 2019.</ix:continuation>  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODQ3_c8ce7c2f-4306-4d68-a3e2-19ebdafe25d9" continuedAt="i3f7d98fdeaf246d7bfab1b3dc5d87ae5" escape="true">Investments</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3f7d98fdeaf246d7bfab1b3dc5d87ae5">The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#8217;s affiliated entity, PLS, at December 31, 2020. Investments included mutual funds and an equity investment in the Company's affiliated entities, PLS and GeneOne, at December 31, 2019.</ix:continuation> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODYx_42ddcefd-943c-4251-9188-a9816b1b2248" continuedAt="i1db01eb8218c419ba82259518a8905b9" escape="true">Accounts Receivable</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1db01eb8218c419ba82259518a8905b9">Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers.</ix:continuation> <ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzg0OTU_208adcf7-151b-4df7-b4b6-5765112e44b7"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzg0OTU_bfdd599d-e925-401d-b091-96b9f1f5b9f0">No</ix:nonFraction></ix:nonFraction> allowance for doubtful accounts was deemed necessary at December&#160;31, 2020 and 2019.</span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODgz_48894f70-de1b-4f23-8df5-e0d30917a8a7" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzg3MzY_3ade6400-d079-4bc2-a028-5e2e5c6e9030">three</span> to <ix:nonNumeric contextRef="i1ea16c625aa4430da8652fcd9977062c_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzEwOTk1MTE2MzkwNDg1_97535446-badb-41ff-9e49-da6a0133fad0">five years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</span></div></ix:nonNumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODEx_2317c4d8-5fb4-435b-b229-d3ebb500920f" continuedAt="i7dd5679a7ee243329dea3bd7fd531d0f" escape="true">Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7dd5679a7ee243329dea3bd7fd531d0f">All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets.</ix:continuation> The Company has not recognized any losses on long-lived assets through December&#160;31, 2020.</span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2Nzcy_6e948db8-86ac-4c25-b3b6-ff27bdb05811" continuedAt="i1d4b5ccf861d4bb69d84d8cafddae0b0" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Valuation of Intangible Assets and Goodwill</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzk2MDM_9dbc4512-b92b-4a6e-ae6e-052ec9675f3d">two</span> to <ix:nonNumeric contextRef="i1ea16c625aa4430da8652fcd9977062c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzk2MDk_7103a456-ab24-4a7c-87a6-c7727549d473">18</ix:nonNumeric> years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the Company has recorded patents at cost and amortized these costs using the straight-line method over the expected useful lives of the patents or <ix:nonNumeric contextRef="if2f035d8d1f74d318e1f75455e89e2e6_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzEwMTA0_5a3f8dbb-8650-4cbc-a3b0-0e2fb1db33e0">17</ix:nonNumeric> years, whichever is less. Patent cost consists of the consideration paid for patents and related legal costs. New patent costs are expensed as incurred, with patent costs capitalized as of that date continuing to be amortized over the expected life of the patent. License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&#160;31, 2019 and 2018, the Company&#8217;s intangible assets resulting from acquisitions and additional intangibles including previously capitalized patent costs and license costs, net of accumulated amortization, totaled $<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzExMDY0_2e16879e-f8c3-422d-9b7f-9ab2826c796b">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzExMDcx_5b810b83-cb13-4ff3-afc2-a0c87fc2df78">3.7</ix:nonFraction> million, respectively.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id924cd922e7845eb8d1530ee59a72913" continuedAt="i6ae5aa052efd4910b91ffea1a876f03f"><ix:continuation id="i1d4b5ccf861d4bb69d84d8cafddae0b0" continuedAt="i06f55d3b9ae845eab72fbf1ec2395dc5"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through December&#160;31, 2020.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment as of November 30, 2020, identifying no impairment.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i06f55d3b9ae845eab72fbf1ec2395dc5">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations.</ix:continuation> See Note&#160;10 for further discussion of the Company&#8217;s goodwill and intangible assets.</span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2Nzky_2aec2067-b65f-4d25-92c8-01109579aaf9" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances against the Company&#8217;s deferred tax assets were $<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjU1OTU_614cb767-e9af-4800-9f81-3e96207b841f">159.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjU2MDQ_b3750a5f-3b8e-4d2d-b56a-f4f5a24e1523">137.2</ix:nonFraction> million at December&#160;31, 2020 and 2019, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODQx_3b0583c6-611f-449f-9f1d-aafeeb408867" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;Topic 606&#8221;). However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.</span></div></ix:nonNumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzY1_a1e27db2-cb80-4334-a443-8e4679cbe24a" continuedAt="i4ccaa27c2cb24542bf6895f97eed98fc" escape="true">Revenue Recognition</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6ae5aa052efd4910b91ffea1a876f03f" continuedAt="ibbd650184942434ca7ed117bba1c398b"><ix:continuation id="i4ccaa27c2cb24542bf6895f97eed98fc"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibbd650184942434ca7ed117bba1c398b" continuedAt="i7cf66e6b4a7345dcb6d96db7139ab7dc"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="ino:GrantRevenuePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzI0_e3f246b1-0788-43d4-8b95-d91314eda863" continuedAt="ib9d5ccb7d54d47d0aaaf547ee3509238" escape="true">Grants</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="ib9d5ccb7d54d47d0aaaf547ee3509238" continuedAt="ibb9a9aeb0f2b46ccb3d952312dab0513"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibb9a9aeb0f2b46ccb3d952312dab0513">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzU2_b302d48f-afd1-47ce-a5dd-24d8aeef3754" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Liabilities</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company's financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzA5_c53509e8-d24e-4b33-9018-c709c67cf414" continuedAt="ia1dd8ef9b6ad4706804c19d099c6dbaf" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are remeasured at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Investments</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="ia1dd8ef9b6ad4706804c19d099c6dbaf" continuedAt="i63b45d6a08bf4594bc6cb483e33dd43e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i63b45d6a08bf4594bc6cb483e33dd43e"> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</ix:continuation>&#160;</span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODU2_97d169f4-2800-48af-83a2-054aec02f06d" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMAbs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total trial management costs, sites activated, patients enrolled, and number of patient visits. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7cf66e6b4a7345dcb6d96db7139ab7dc" continuedAt="i51b6869f9ac44efda112641314c7e027"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2Nzk1_ec4c2717-cb83-44b5-bf2e-098b23f6b14d" continuedAt="ica280a13224f46508d8c15a1d2bf214f" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="margin-top:4.5pt;text-indent:27pt"><ix:continuation id="ica280a13224f46508d8c15a1d2bf214f" continuedAt="i18f409c67aa94122a88a10f354d6501c"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 11) has been considered using the "if-converted" method. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i18f409c67aa94122a88a10f354d6501c">For the years ended December 31, 2020, 2019 and 2018, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive.</ix:continuation> </span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODA4_1c3e0292-62d2-49eb-a3ca-c6a9d290818e" escape="true"><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba72fa0012f445dd820803f63d0f038a_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzItMS0xLTEtMA_6d08f939-9957-4dd9-81c1-fb19bdf5f2cf">8,906,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i656dfbe21acc42619acc008ddb6d5362_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzItMy0xLTEtMA_8046309c-5ff5-421e-97b3-84dc4afd2383">9,265,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9025cc3fe1a74a43b1903d7fbd5b140e_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzItNS0xLTEtMA_3f299963-720d-436c-bcae-37545bcf98ba">8,752,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9609d90a67ee46b7abceb06d1fcaa5b7_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzQtMS0xLTEtMA_910fdb40-64f4-4584-809b-90b47070a226">2,558,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c0e39c482da423594a8b74a964a6471_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzQtMy0xLTEtMA_fd6e40e2-2dfc-4d72-b073-306af265a3ed">2,069,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3dffc4892f444aea3b32fa15bd0cbca_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzQtNS0xLTEtMA_2d7f9e76-2606-4e43-bd42-f21a79fda647">1,688,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf6b492d876f45ff96cd2a77765bdef8_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzUtMS0xLTEtMzg1Mg_847dd7f0-d3b9-4136-9dea-594266652044">663,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3e05652c96d47cbb27fabd2cf99fc32_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzUtMy0xLTEtMzg1Mg_d695bef9-d2be-4ff8-bd15-882d3fef2c7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2128ce96ca6b41749cc080d568dfb0af_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzUtNS0xLTEtMzg1Mg_2fcb9063-4015-449d-a6e5-f1c004ff6711">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i922f47d757b34b2d903a5c97adad9e66_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzUtMS0xLTEtMA_0942e2a3-ae81-4da0-a8d5-039fd2a6e351">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd0b936b6baf4cd39d116548a1ec5f65_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzUtMy0xLTEtMA_09246a8d-4b75-4ec0-8fb2-f7f56dfb60e2">8,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0491bd11569e4c70be12a68e3eb1cbf2_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzUtNS0xLTEtMA_c0020c05-e6f7-4f8e-93cc-e8eea2044b32">8,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f8129c3d125441a91d09e391d9c6e73_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzYtMS0xLTEtMA_ebbf078c-4fab-4bc0-be13-80935c186158">3,049,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89954e650abd432f915000cefb94d545_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzYtMy0xLTEtMA_576c773d-da7e-4dc6-ae1a-e5208c5b9d8b">14,585,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icecba79931fe4bc5a892cd67d1db6a6c_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzYtNS0xLTEtMA_2d6ac513-15ba-475e-871e-560bceb15e0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82c6c3c2c1c34abca8e04f10eaa8f2fc_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzctMS0xLTEtMA_5b71c1d6-caab-45bc-8354-c2a341870ca0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09fb87c71e9d48c9b0018f20e4d467a7_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzctMy0xLTEtMA_82d9c657-0bf0-422b-bdaf-2ec2574803aa">3,799,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c09b6ea337f41979072422f8aba29f1_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzctNS0xLTEtMA_444ed911-fea8-45f0-929b-3b21ab5c06c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdabd2e1d4a641529a738e6e5213335b_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzgtMS0xLTEtMA_03e4ba74-65f9-417b-bf19-66d0a5435ad6">1,009,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27178e3407dc46aeabb6e03458be5284_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzgtMy0xLTEtMA_70dbde31-0ed6-4140-b830-4f215b7d12d3">1,009,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i833eed11e677427591fa49c0a58a8d3f_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzgtNS0xLTEtMA_3db742ce-7029-4812-8a0b-ceeed609000b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzktMS0xLTEtMA_227b7158-6a73-41b6-b3aa-66e2ffb8824c">16,190,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzktMy0xLTEtMA_2cfff47e-0aaa-4bf1-a797-916094d4ef7b">30,737,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzktNS0xLTEtMA_48894f7e-10b0-4ac7-a7fc-c653dcf1cf5d">10,449,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzE4_b77cd367-9893-4a92-8d63-73d8544d57eb" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div></ix:nonNumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODAz_eedeb390-ef79-4b08-a25d-28f07eb12511" continuedAt="i6217591f3f42483ea6a38c81e260975e" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6217591f3f42483ea6a38c81e260975e" continuedAt="i7b694b71f86344198a9f2a98d9b559b8">The Company incurs stock-based compensation expense related to restricted stock units and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. </ix:continuation></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7b694b71f86344198a9f2a98d9b559b8">The Company recognizes forfeitures as they occur.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODQz_90eb9462-b8ac-4070-9735-f0819e827ed7" continuedAt="icdeb4f59b466469899ea14080bb61ec0" escape="true">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i51b6869f9ac44efda112641314c7e027" continuedAt="i1d83a52601004aa8951f7c8d1bcdf811"><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="icdeb4f59b466469899ea14080bb61ec0" continuedAt="i5fbdcb5fdee74fd2a0033516675df09a"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1f13165d5d6482590debad2f6e92178_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzItMS0xLTEtMA_7b934863-e1d2-4ea0-9a19-e52d0da5f31c">0.63</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb0e0943a16c445bbe684491faf920a8_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzItMy0xLTEtMA_60d00ac3-a339-4991-b20a-cf3f8d37250a">2.42</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iddced08b347f44f785f1537e866c5bf5_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzItNS0xLTEtMA_95e50acf-16f9-40e3-adee-36dd3b6cb5f7">2.73</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1f13165d5d6482590debad2f6e92178_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzMtMS0xLTEtMA_922ead6e-6339-4e13-ac1e-e590a6dedee7">78</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb0e0943a16c445bbe684491faf920a8_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzMtMy0xLTEtMA_8a438044-df6b-46b6-bee9-c12fd23a05f6">70</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iddced08b347f44f785f1537e866c5bf5_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzMtNS0xLTEtMA_b84d506f-4fd0-4e29-8a77-0feab0c8d4b8">72</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if1f13165d5d6482590debad2f6e92178_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzQtMS0xLTEtMA_fe25a221-a815-4d30-965d-920426ba1050">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb0e0943a16c445bbe684491faf920a8_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzQtMy0xLTEtMA_71ddbd0c-1aaf-4e06-9e67-1e1886a726a1">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iddced08b347f44f785f1537e866c5bf5_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzQtNS0xLTEtMA_37a5ea8e-48ab-43e9-8068-c9f87dcaf05b">6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if1f13165d5d6482590debad2f6e92178_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzUtMS0xLTEtMA_548504cf-f22f-43bf-bfbc-eb3bee1ad2c0">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb0e0943a16c445bbe684491faf920a8_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzUtMy0xLTEtMA_d43d788e-1120-4aa3-85c5-a652b7a3464e">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iddced08b347f44f785f1537e866c5bf5_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzUtNS0xLTEtMA_c8799c99-fdd1-4277-baae-9baefc4d3e85">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU 2018-07 on January 1, 2019, which generally aligned the accounting for stock-based compensation for non-employees with that of employees. The fair value of the stock options granted to non-employees was estimated using the Black-Scholes pricing model.</span></div><ix:continuation id="i5fbdcb5fdee74fd2a0033516675df09a"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2d6cd258bb84425bbbfe977d3faefb6_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzItMS0xLTEtMA_502999ff-025f-4983-b0cc-144e48ee2232">0.82</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c09bb9e28c146a2a7d84bd07c5eb551_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzItMy0xLTEtMA_f8be9a24-5e6e-4cf8-a084-6b0200880d9e">2.45</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i020096d75bda46dcb066c2fd6645c02b_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzItNS0xLTEtMA_4e757583-133d-4c11-8249-b19efc2365f0">2.71</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2d6cd258bb84425bbbfe977d3faefb6_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzMtMS0xLTEtMA_db960c38-0898-4dcc-bc43-4548c6894594">76</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c09bb9e28c146a2a7d84bd07c5eb551_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzMtMy0xLTEtMA_2b57d360-2897-4890-835b-a5db405b58ec">88</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i020096d75bda46dcb066c2fd6645c02b_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzMtNS0xLTEtMA_c5c636a6-7d76-4302-82f2-55fcb4bfb2d6">78</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id2d6cd258bb84425bbbfe977d3faefb6_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzQtMS0xLTEtMA_d0f35612-a4d5-4087-8ce5-d686c8ae130d">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1c09bb9e28c146a2a7d84bd07c5eb551_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzQtMy0xLTEtMA_37c07b44-bde3-4fa2-b576-1cc72bfaf39e">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i020096d75bda46dcb066c2fd6645c02b_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzQtNS0xLTEtMA_91d203fa-9e7c-4bc2-b8eb-52d7344aeb51">9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2d6cd258bb84425bbbfe977d3faefb6_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzUtMS0xLTEtMA_dcde901f-bbc4-4312-8191-f172eaf92285">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c09bb9e28c146a2a7d84bd07c5eb551_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzUtMy0xLTEtMA_b5b8cef8-4e62-4f5c-963d-62f43beda1ad">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i020096d75bda46dcb066c2fd6645c02b_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzUtNS0xLTEtMA_6f0b33db-3f83-4862-aa6a-9e8c028239f0">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzE5_63304561-9c50-4265-b34e-dccf6ad2c51c" continuedAt="i9ebb27fc179b4b958dcb1930f08c27bf" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Recently Adopted</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2019-12. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. FASB issued this Update as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 became effective as of the beginning of 2020; however, there was no cumulative effect to be recognized with the early adoption. As of December 31, 2020, there was a loss from continuing operations and a cumulative loss in other comprehensive income and there was therefore no effect on the tax provision for the period ended December 31, 2020. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2016-13</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonably supportable forecast information. The Company adopted ASU 2016-13 on January 1, 2020, and there was no material impact to its consolidated financial statements. The Company will continue to monitor the impact of the coronavirus, SARS-CoV-2 (&#8220;COVID-19&#8221;) outbreak on expected credit losses.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2018-13</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In August 2018, the FASB issued ASU 2018-13, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends certain disclosure requirements over fair value measurements. Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this guidance on January 1, 2020, and there was no material impact to its consolidated financial statement disclosures (see Note 6 for more information about the Company&#8217;s fair value classifications).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2018-18</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In November 2018, the FASB issued ASU 2018-18, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which clarified the interaction between Topic 808, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i1d83a52601004aa8951f7c8d1bcdf811" continuedAt="i53741383fd744f7a9c9755931fe655af"><ix:continuation id="i9ebb27fc179b4b958dcb1930f08c27bf" continuedAt="i203564daa49f43d49b59ec674e9e9fc7"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Topic 606, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company adopted this guidance on January 1, 2020, and there was no material impact to its consolidated financial statements.</span></ix:continuation></ix:continuation></div><div style="text-indent:27pt"><ix:continuation id="i53741383fd744f7a9c9755931fe655af" continuedAt="i937b3ea5035a4d549c21bebd1d0ee662"><ix:continuation id="i203564daa49f43d49b59ec674e9e9fc7" continuedAt="ia244c7fde69d43d5a925386024bb096a"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2017-04.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In January 2017, the FASB issued ASU 2017-04,&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#160;</span></ix:continuation></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i937b3ea5035a4d549c21bebd1d0ee662"><ix:continuation id="ia244c7fde69d43d5a925386024bb096a">("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and there was no material impact to its consolidated financial statements.</ix:continuation></ix:continuation> </span></div><div style="text-indent:27pt"><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_148"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDgvZnJhZzplMTRlNjc3YTgzYjI0NGQ1YmJkNDE3ZGEyMDYxNDg0Zi90ZXh0cmVnaW9uOmUxNGU2NzdhODNiMjQ0ZDViYmQ0MTdkYTIwNjE0ODRmXzc3MQ_5ec11372-9d79-49e5-80cd-144fb54eb721" continuedAt="i39983b64799a4599ba9d8d9c1d93d161" escape="true">Revenue Recognition  </ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i39983b64799a4599ba9d8d9c1d93d161">During the year ended December&#160;31, 2020, the Company recognized total revenue under license and other agreements of $<ix:nonFraction unitRef="usd" contextRef="i58fdd3cd014b4e69a232a56367655377_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDgvZnJhZzplMTRlNjc3YTgzYjI0NGQ1YmJkNDE3ZGEyMDYxNDg0Zi90ZXh0cmVnaW9uOmUxNGU2NzdhODNiMjQ0ZDViYmQ0MTdkYTIwNjE0ODRmXzQzOTgwNDY1MTIyNjY_b7efee4e-61ba-4381-a8d8-a753da7cd3ea">5.0</ix:nonFraction> million from Advaccine, $<ix:nonFraction unitRef="usd" contextRef="i59d8b0164c8b45a394697662732fe279_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDgvZnJhZzplMTRlNjc3YTgzYjI0NGQ1YmJkNDE3ZGEyMDYxNDg0Zi90ZXh0cmVnaW9uOmUxNGU2NzdhODNiMjQ0ZDViYmQ0MTdkYTIwNjE0ODRmXzQzOTgwNDY1MTIyODU_b93dd908-b469-436f-9727-d48ef0b2b6ea">1.4</ix:nonFraction> million from its affiliated entity Plumbline Life Sciences, Inc. ("PLS"), and $<ix:nonFraction unitRef="usd" contextRef="i36022e8256554cf79c99deed72b40319_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDgvZnJhZzplMTRlNjc3YTgzYjI0NGQ1YmJkNDE3ZGEyMDYxNDg0Zi90ZXh0cmVnaW9uOmUxNGU2NzdhODNiMjQ0ZDViYmQ0MTdkYTIwNjE0ODRmXzQzOTgwNDY1MTIzNTE_9bde42dd-0241-4860-856a-5aa85b7c9626">1.0</ix:nonFraction> million from various other contracts. Of the total revenue recognized during the year ended December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDgvZnJhZzplMTRlNjc3YTgzYjI0NGQ1YmJkNDE3ZGEyMDYxNDg0Zi90ZXh0cmVnaW9uOmUxNGU2NzdhODNiMjQ0ZDViYmQ0MTdkYTIwNjE0ODRmXzQ5MQ_bbb2e9ef-f2ef-4572-97d0-8ca830a44c23">127,000</ix:nonFraction> was in deferred revenue as of December 31, 2019. During the year ended December 31, 2019, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDgvZnJhZzplMTRlNjc3YTgzYjI0NGQ1YmJkNDE3ZGEyMDYxNDg0Zi90ZXh0cmVnaW9uOmUxNGU2NzdhODNiMjQ0ZDViYmQ0MTdkYTIwNjE0ODRmXzYxNA_91b3b251-f240-4d27-bf1c-f12a879a9b29">293,000</ix:nonFraction> that was included in deferred revenue at December 31, 2018. Performance obligations are generally satisfied within 12 months of the initial contract date.</ix:continuation> </span></div><div><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzEwOTk1MTE2MzI1MTc2_e861d772-8e2f-4ec2-87f4-c59f92a3686d" continuedAt="ic7f9fefea200489181734f8737532465" escape="true">Collaborative Agreements </ix:nonNumeric></span></div><ix:continuation id="ic7f9fefea200489181734f8737532465" continuedAt="i7b6db53507774637904610813bbf1656"><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. (Advaccine)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a Collaboration and License Agreement (the &#8220;Agreement&#8221;) with Advaccine. Under the terms of the Agreement, the Company has granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;). Advaccine will not have the right to grant sublicenses, other than to affiliated entities, without the Company&#8217;s express prior written consent. As part of the collaboration, Advaccine has also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Advaccine have collaborated since January 2020 to leverage Advaccine&#8217;s clinical development expertise to conduct an early-stage clinical trial in China in parallel with the Company&#8217;s clinical development efforts in the United States and South Korea. In December 2020, the Company and Advaccine announced that they had dosed the first subject in a Phase 2 clinical trial of INO-4800 in China. This trial is independent of the Company&#8217;s ongoing clinical trial of INO-4800, called INNOVATE, being conducted in the United States.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Agreement, Advaccine made an upfront payment to the Company of $<ix:nonFraction unitRef="usd" contextRef="ie1340701a627440abb646d47f8dd59a0_D20210301-20210301" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzMyOTg1MzQ5MjgwNTc_e646af0f-9087-455a-8570-4256224eb109">3.0</ix:nonFraction>&#160;million subsequent to December 31, 2020. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i613bf85d5ad641aeb9777c902ee5e720_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzEwOTk1MTE2MzI1MTc4_bbbdc963-c4f2-40a8-bec5-b98e769c07f3">108.0</ix:nonFraction>&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China, if approved. As of December 31, 2020 the Company had earned a $<ix:nonFraction unitRef="usd" contextRef="i613bf85d5ad641aeb9777c902ee5e720_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborationAgreementPaymentEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzMyOTg1MzQ5MzM2NDA_09b95815-30e5-41a7-bb61-4210b6aca1fb">2.0</ix:nonFraction>&#160;million milestone payment based on the enrollment of the first subject in the Phase 2 clinical trial for the product in the Advaccine territory. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within Greater China, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#8217;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for <ix:nonNumeric contextRef="i613bf85d5ad641aeb9777c902ee5e720_D20200101-20201231" format="ixt-sec:durwordsen" name="ino:CollaborationAgreementRoyaltyPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzEwOTk1MTE2MzI1MjA5_931e66a0-b54d-4aad-bbc3-215f540b8a6c">ten years</ix:nonNumeric> after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Agreement, Advaccine will be responsible for the development and commercialization of the licensed products at its own cost and expense and shall use commercially reasonable efforts to develop, obtain and maintain regulatory approval of INO-4800, as well as the Company&#8217;s CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> device and arrays for use in connection with the administration of INO-4800, in each region in Greater China. In the event that the Company has not initiated the planned Phase 3 segment of its ongoing clinical trial of INO-4800 in the United States within <ix:nonNumeric contextRef="i613bf85d5ad641aeb9777c902ee5e720_D20200101-20201231" format="ixt-sec:durwordsen" name="ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzEwOTk1MTE2MzI1MjI3_7a582422-0197-4bf0-b456-b63f51843d03">one year</ix:nonNumeric> after entering into the Agreement, Advaccine may elect to conduct a Phase 3 clinical trial outside of Greater China at its own cost and expense for the purposes of obtaining regulatory approval in China, subject to the Company&#8217;s right to review and approve the protocols and design of such a trial.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Agreement, the Company will supply Advaccine&#8217;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#8217;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808, and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606.  The license to INO-4800 in the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7b6db53507774637904610813bbf1656" continuedAt="ia8fdbe3b18b84fcca8a4cd4f58c5e8d5"><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the $<ix:nonFraction unitRef="usd" contextRef="i613bf85d5ad641aeb9777c902ee5e720_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzMyOTg1MzQ5MzQyNTY_d27cc633-eec9-492d-be89-dd15cd2b4c7f">3.0</ix:nonFraction>&#160;million upfront payment plus the initial $<ix:nonFraction unitRef="usd" contextRef="i613bf85d5ad641aeb9777c902ee5e720_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborationAgreementPaymentEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzMyOTg1MzQ5MzE5MDM_03b43e05-303b-42a3-a744-642327acbb63">2.0</ix:nonFraction>&#160;million milestone payment which was achieved upon contract signing.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Agreement, subject to certain conditions. Advaccine may terminate the Agreement at any time for convenience upon nine months&#8217; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in Greater China, or 18 months&#8217; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $<ix:nonFraction unitRef="usd" contextRef="i613bf85d5ad641aeb9777c902ee5e720_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzEwOTk1MTE2MzI1MjMz_971ecee1-e900-4a4a-b8cf-dad9ce87fb9b">5.0</ix:nonFraction>&#160;million was allocated to the license performance obligation. The Company determined that as of December 31, 2020, the transfer of technology has occurred for the use and benefit of the license and accordingly, the performance obligation was fully satisfied.  The Company accordingly has recognized $<ix:nonFraction unitRef="usd" contextRef="i1629a50f2cbd40418d7f6000e5d7136c_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzMyOTg1MzQ5MzQ4MzA_daee5085-b2fb-452e-ad20-1cc502f0f330">5.0</ix:nonFraction>&#160;million in revenue under collaborative research and development arrangements on the consolidated statement of operations during the year ended December 31, 2020. As of December&#160;31, 2020, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="i07a67056b0694c8eb1abe2d9df8f95cc_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1NzAzOTM_a4f48401-9188-4fc3-a5e2-6931ee2ec47c">7.1</ix:nonFraction> million from Advaccine.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the territories of China, Hong Kong, Macao, Taiwan, and may include Korea in the event that no patent covering&#160;VGX-3100&#160;is issued in China within the <ix:nonNumeric contextRef="i0580e1e8b8464f7daadfc64c85589325_D20171229-20171229" format="ixt-sec:durwordsen" name="ino:CollaborationAgreementTerritoryExpansionOptionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzEwOTk1MTE2MzI1MjQ2_776db8cb-d49a-4268-8708-cd7d91d70e0d">three years</ix:nonNumeric> following the effective date of the ApolloBio Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ApolloBio Agreement, the Company received proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic70aad9f1bbb46c7aef9aac80dd8d982_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="ino:ProceedsFromCollaborativeAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzc3NQ_6758a8d1-fc85-44b8-9967-c89546d85bf4">19.4</ix:nonFraction> million in March 2018, which comprised the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ic70aad9f1bbb46c7aef9aac80dd8d982_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzgzMg_f4a9e89f-0817-4173-9b1d-2d7fc1d3a484">23.0</ix:nonFraction> million less $<ix:nonFraction unitRef="usd" contextRef="iccbc152ca5c64a51b143e8f925a6386c_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementCorporateIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzg0MA_a6646928-6bea-4bbc-9ba6-443f50661829">2.2</ix:nonFraction> million in foreign income taxes and $<ix:nonFraction unitRef="usd" contextRef="iccbc152ca5c64a51b143e8f925a6386c_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementForeignNonIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzg3MQ_bdc8b969-62b8-48f3-817e-40a0a07ad63e">1.4</ix:nonFraction> million in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the consolidated statement of operations. The Company also incurred advisory fees of $<ix:nonFraction unitRef="usd" contextRef="i0d23e87ce6a14739b73a33d11363becf_I20180331" decimals="-3" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementAdvisoryFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzExOTg_1b9d3a17-3db3-44ec-899b-c75fb46d91fd">960,000</ix:nonFraction> in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i198477edba824f6ea373e4e1b0ef0825_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzE3ODY_15bfc2b8-d88f-42f9-a3c4-ec305a2d708e">20.0</ix:nonFraction> million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in the United States, China and Korea. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for <ix:nonNumeric contextRef="i198477edba824f6ea373e4e1b0ef0825_D20200101-20201231" format="ixt-sec:duryear" name="ino:CollaborationAgreementRoyaltyPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzIzMjc_b85eb3f3-b753-4a79-80b8-f07bcb7976a9">10</ix:nonNumeric> years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the ApolloBio Agreement under ASC Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the $<ix:nonFraction unitRef="usd" contextRef="i198477edba824f6ea373e4e1b0ef0825_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzI5NjE_1fb991c2-60db-480e-aa0f-0812d8905611">23.0</ix:nonFraction> million upfront payment.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia8fdbe3b18b84fcca8a4cd4f58c5e8d5" continuedAt="i08c0e22cbf0946f692348b2a1942485b"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, 2020 there have been no significant reimbursable program costs under the ApolloBio Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning <ix:nonNumeric contextRef="i198477edba824f6ea373e4e1b0ef0825_D20200101-20201231" format="ixt-sec:durwordsen" name="ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzgyNDYzMzcyNTk2ODU_8ea215b5-f304-44d1-85e7-aa62ec2e09c8">one year</ix:nonNumeric> after the effective date for any reason upon <ix:nonNumeric contextRef="i198477edba824f6ea373e4e1b0ef0825_D20200101-20201231" format="ixt-sec:durday" name="ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQyNDU_f7790453-b851-47cb-890a-1f27ae9a69fe">90</ix:nonNumeric> days written notice to the Company.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $<ix:nonFraction unitRef="usd" contextRef="i9d79fdc0914349cba02f4425251657ee_D20180401-20180630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzMzM_11dc8e2c-c7fb-498f-8b84-d5d9a7d16c3a">23.0</ix:nonFraction> million was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. The Company has recorded the gross upfront payment received from ApolloBio of $<ix:nonFraction unitRef="usd" contextRef="ida214446db3b464690a216afd28cd2bd_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQ2MzY_fe513f3b-a749-447e-9f52-c7f755026d34">23.0</ix:nonFraction> million as license revenue on the consolidated statement of operations during the year ended December 31, 2018.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i5415ff5fd21249ac9bb9bf4e91ebb967_D20150901-20150930" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzUyNzQ_13aab287-e65f-44fd-864f-4661e95514c8">27.5</ix:nonFraction> million to the Company in September 2015. AstraZeneca may be obligated to make potential future development and regulatory event-based payments to the Company totaling up to $<ix:nonFraction unitRef="usd" contextRef="i0a96b2b8330c413eac49b9d0b68a5735_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="ino:CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzU0NDM_36b46dae-8442-45dd-8705-fa593b0e5e27">125</ix:nonFraction> million and potential future commercial event-based payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="i0a96b2b8330c413eac49b9d0b68a5735_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="ino:CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzU1MTQ_fd764019-7943-42c2-a1ca-b9f206267d26">115</ix:nonFraction> million, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca will fund all development costs associated with MEDI0457 immunotherapy. The Company is entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca can also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2017, the Company had recognized all of the $<ix:nonFraction unitRef="usd" contextRef="iecbf562e66684d72bb93637a9483430f_D20171231-20171231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzY1NDQ_3d667d7d-140e-4e89-b65d-bfc36b8c6406">27.5</ix:nonFraction> million upfront payment as revenue, as all identified materia</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l performance obligations had been met with respect to that payment.&#160;In both December 2018 and March 2019, the Company recognized as revenue $<ix:nonFraction unitRef="usd" contextRef="icde7df1aa421475ebcaddca0a5faed9e_D20181201-20181231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementMilestonePaymentRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzY3NDE_692ed506-f721-4c89-8dd5-3318ebaedbff"><ix:nonFraction unitRef="usd" contextRef="i1ba7d9f763e04c32b364239929d24393_D20190302-20190331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementMilestonePaymentRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzY3NDE_8bda92bb-d193-4a6b-824b-15be4a0fd2f5">2.0</ix:nonFraction></ix:nonFraction> million in milestone payments from AstraZeneca triggered by AstraZeneca&#8217;s initiation of the Phase 2 portion of ongoing clinical trials in the second and third major indication, respectively, under the agreement. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;11, 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate&#160;preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i9f7ef79982d84ebd9bc2953403b7e029_D20180411-20180411" decimals="-6" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzgwODM_4f5bcb66-b821-4e95-a1dc-159d9bfb1a14">56</ix:nonFraction> million of costs over a <ix:nonNumeric contextRef="i9f7ef79982d84ebd9bc2953403b7e029_D20180411-20180411" format="ixt-sec:durwordsen" name="ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzEwOTk1MTE2MzI1MjQ3_1378ae08-dcca-462e-8a2e-b3a697c6bd1d">five-year</ix:nonNumeric> period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the years ended December&#160;31, 2020 and 2019, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="iea76d18ca06a49d7851b0c0ff3a34c6d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjYzOTY_93ac2659-f3bc-4c1a-b13d-9c89ab9223ce">6.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i85493c81c5114a8795086a2445f83c41_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzgzOTU_d51d3648-6eef-4d93-8b17-27679792d00c">6.3</ix:nonFraction> million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of December&#160;31, 2020, the Company had a grant funding liability balance related to the CEPI grant of $<ix:nonFraction unitRef="usd" contextRef="id233e1d41be44b12951cb39c380c2e4c_I20201231" decimals="-5" name="ino:DeferredGrantFundingCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzg2MDA_dcacab4d-0e55-4bca-a68a-d23e28a5a9c2">2.6</ix:nonFraction> million recorded as grant funding liability on the consolidated balance sheet related to the CEPI grant. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $<ix:nonFraction unitRef="usd" contextRef="i62896ff9dfdf42f19fd838c00bab3f1d_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjU0NzU_6463c653-91e7-46b9-b195-0f47f1ef2c85">9.0</ix:nonFraction>&#160;million to develop a vaccine against COVID-19. This initial CEPI funding is intended to support preclinical and clinical development through Phase 1 human testing in the United States of INO-4800, the Company's COVID-19 vaccine candidate against COVID-19. In April 2020, CEPI awarded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="id6e5de1ef1e64ba791fd38a6b29b9cc9_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjU0ODk_badd1abb-1afa-49f3-a212-d84b1dbe3ed6">6.9</ix:nonFraction>&#160;million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $<ix:nonFraction unitRef="usd" contextRef="i3d96c9c2aee04b989b045f3a11979c60_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjU1MTc_8300fb2d-4daf-4f98-8616-ef07cfcec9c9">5.0</ix:nonFraction>&#160;million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP, for the intradermal delivery of INO-4800, and a grant of $<ix:nonFraction unitRef="usd" contextRef="i3d1c029556354cc880be0619e862bd95_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjU1MDM_af8649d3-23e9-43cd-9b9d-b31279b1ddc2">1.3</ix:nonFraction>&#160;million to support large-scale manufacturing of INO-4800. During the year ended December&#160;31, 2020, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="i0e7308dee93f48cb8fc7b11c2b76aaad_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjYzNjM_44a47760-7200-431d-acb6-d7ceb2f85683">10.0</ix:nonFraction> million from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of December&#160;31, 2020 the Company had $<ix:nonFraction unitRef="usd" contextRef="i8b4cb28aa5624d32a8dd171551850f0e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzEwOTk1MTE2MzI1Mjk3_0843d7ab-c1b4-4efb-b3bf-3a6b109ed5b2">3.4</ix:nonFraction>&#160;million recorded as deferred grant funding on the consolidated balance sheet related to the CEPI grants related to INO-4800.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i08c0e22cbf0946f692348b2a1942485b"><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Bill &amp; Melinda Gates Foundation (&#8220;Gates&#8221;) awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="i56edaab4f0df412ba9168d447a83002d_D20181001-20181031" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjU2ODI_afc3f59d-9a78-4e74-9e95-029131051857">2.2</ix:nonFraction>&#160;million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $<ix:nonFraction unitRef="usd" contextRef="i234be8858e5244cdbdbccb259435578a_D20190801-20190830" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjU2OTY_2ba2c3eb-deaf-419f-aa10-cfdf1dba0fb3">1.1</ix:nonFraction>&#160;million for the project. During the years ended December&#160;31, 2020 and 2019, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i6257d5c8c1b740bea21e2623fc3ce7b3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjY0MDU_82876a6e-5776-4ab9-ac16-17505e422c8f">463,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic708a39c59804e988fb7464a0d0169de_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjY0MTA_431a7ec0-903d-4334-8751-045e72134a2e">2.1</ix:nonFraction> million, respectively, as contra-research and development expense related to the Gates dMAb grant. As of December&#160;31, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="if593976c97db405798c736bb8b0cda97_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjU5NjQ_a56f7c21-e207-425f-9099-71b429461844">575,000</ix:nonFraction> recorded as deferred grant funding on the consolidated balance sheet related to the grant.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Gates awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="i8903d8385b2841c5b9653a466d3c1db9_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjU5OTA_b3f09032-6a43-455d-ad58-4d6596a41c7d">5.0</ix:nonFraction>&#160;million to accelerate the development of the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device for the intradermal delivery of INO-4800. During the year ended December&#160;31, 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i915d8cff852f486180f3c82d2ebda044_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjY0MzQ_8c2bb1a4-6e7e-4acb-bcec-b6328c1c834c">4.1</ix:nonFraction> million as contra-research and development expense and had $<ix:nonFraction unitRef="usd" contextRef="ief209891b012422a8c1dc68518ef3bc4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjYxMjU_48b50d90-533c-4283-991a-00c691f08eec">884,000</ix:nonFraction> recorded as deferred grant funding on the consolidated balance sheet related to this Gates grant. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Defense (DoD) </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the DoD to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is approximately $<ix:nonFraction unitRef="usd" contextRef="i87746e71a46a454787656a4370821f51_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjYxNjk_08803adc-4269-455d-b8cb-b48dccfd7cbe">54.5</ix:nonFraction>&#160;million. The Company has determined that the OTA Agreement should be considered under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Not-for-Profit Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which is outside the scope of Topic 606, as the government agency granting the Company funds is not receiving reciprocal value for their contributions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company will record contra-research development expense on the consolidated statement of operations in the same period that the underlying expenses are incurred. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 device and accessories. The CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2000 devices will be used to inject&#160;INO-4800&#160;in the Company&#8217;s planned later-stage clinical trials. The total purchase price under the Procurement Contract is approximately $<ix:nonFraction unitRef="usd" contextRef="i6ea2ecae9adf4b6a887dee064675992e_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeArrangementFixedPriceContractAmountAwarded" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjYyNjY_6225cd39-02fb-4a5c-a2ae-6bb8f8439916">16.6</ix:nonFraction>&#160;million. The Company has determined that the Procurement Contract does not currently fall under the scope of ASC Topic 606 as contingencies remain regarding INO-4800 which does not give the Company the ability to satisfy its obligations under the arrangement. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i7bd9953ed4844195ad1d5a16e1dba0ee_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:GrantProceedsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjY0NjI_55485df5-2bb4-4b3c-80bf-12d7908629e2">21.2</ix:nonFraction> million as contra-research and development expense related to these agreements with the DoD. As of December&#160;31, 2020, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="i99bceb219d684923a420db226755fc2f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjYzMzc_087073ba-e240-4988-8b64-49b45207b70c">11.4</ix:nonFraction>&#160;million on the consolidated balance sheet from the DoD.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company announced that the DoD has also agreed to provide funding for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 2/3 clinical trial for INO-4800, called INNOVATE (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OVIO I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-4800 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Va</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ccine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rial for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fficacy)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These expenses will be paid directly by the DoD.</span></div></ix:continuation><div style="margin-top:5pt"><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_154"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90ZXh0cmVnaW9uOmRjYjdkMWIxMjQ1YTRhMWNhZDk3NjZkMmYyYzBhNTk0XzE0NTA_b84a5188-7145-4752-99e7-b9d46dc7977b" continuedAt="id4fbef811951419ab701d37d1f669169" escape="true">Short-term Investments</ix:nonNumeric></span></div><ix:continuation id="id4fbef811951419ab701d37d1f669169" continuedAt="i983607ea4bc240fb954d227c313e31a8"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments at December&#160;31, 2020 consisted of mutual funds, certificates of deposit and U.S. agency mortgage-backed securities. Short-term investments at December&#160;31, 2019 consisted of mutual funds. Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's debt securities are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the consolidated statements of operations and are derived using the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specific identification method for determining the cost of the securities sold.&#160;During the years ended December&#160;31, 2020 and 2019, the Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross realized ga</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in on investments of $<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90ZXh0cmVnaW9uOmRjYjdkMWIxMjQ1YTRhMWNhZDk3NjZkMmYyYzBhNTk0Xzc1OA_2d31a88b-5ec0-4581-99e4-c355293bf266">744,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90ZXh0cmVnaW9uOmRjYjdkMWIxMjQ1YTRhMWNhZDk3NjZkMmYyYzBhNTk0Xzc2NQ_1a0ce313-6026-41d5-bd88-b4fb744510a4">594,000</ix:nonFraction>, respectively, and gross realized loss on investments of $<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90ZXh0cmVnaW9uOmRjYjdkMWIxMjQ1YTRhMWNhZDk3NjZkMmYyYzBhNTk0XzgyNQ_aa6b2205-801c-4d18-a2db-dae76e4eac2b">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90ZXh0cmVnaW9uOmRjYjdkMWIxMjQ1YTRhMWNhZDk3NjZkMmYyYzBhNTk0XzgzMg_53925e68-31c6-49c0-a571-78ee0104e2c6">118,000</ix:nonFraction>, respectively. During the year ended December&#160;31, 2020, the Company recorded net unrealized gain on available for sale equity securities of $<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90ZXh0cmVnaW9uOmRjYjdkMWIxMjQ1YTRhMWNhZDk3NjZkMmYyYzBhNTk0XzQzOTgwNDY1MTMxNjQ_9ad8c252-43af-420e-802a-7f565a0a6029">1.7</ix:nonFraction>&#160;million. There was no material unrealized gain or loss on available-for-sale equity securities recorded during the year ended December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the years ended&#160;December&#160;31, 2020,&#160;2019&#160;and&#160;2018. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2020, the Company had&#160;<ix:nonFraction unitRef="investment" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90ZXh0cmVnaW9uOmRjYjdkMWIxMjQ1YTRhMWNhZDk3NjZkMmYyYzBhNTk0XzExODU_3f53008d-1d33-439c-87f2-f67b936b092d">12</ix:nonFraction>&#160;available-for-sale securities in a gross unrealized loss position, of which <ix:nonFraction unitRef="investment" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90ZXh0cmVnaW9uOmRjYjdkMWIxMjQ1YTRhMWNhZDk3NjZkMmYyYzBhNTk0XzEyNjQ_8acf375f-9785-49f3-9441-9cc3853353de">none</ix:nonFraction> were in such position for longer than 12 months. </span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90ZXh0cmVnaW9uOmRjYjdkMWIxMjQ1YTRhMWNhZDk3NjZkMmYyYzBhNTk0XzE0NTg_7043411c-164a-41a5-9578-ebdf75db7706" continuedAt="i7e8e0b81d2274cb0a72d0c1fae53984b" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December&#160;31, 2020 and 2019:   </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i983607ea4bc240fb954d227c313e31a8"><ix:continuation id="i7e8e0b81d2274cb0a72d0c1fae53984b"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0595f6d10944686ae57a515abd3ec36_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzItMy0xLTEtMA_4b702403-6dd6-4a53-90d2-0b72758baafe">153,177,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0595f6d10944686ae57a515abd3ec36_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzItNS0xLTEtMA_3b7eaba8-2b4a-4ba4-bb8b-5e64bd56d963">2,339,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0595f6d10944686ae57a515abd3ec36_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzItNy0xLTEtMA_8a4eccb9-241a-4ebc-b0f9-41a90380be1a">644,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0595f6d10944686ae57a515abd3ec36_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzItOS0xLTEtMA_a39fef65-33c8-419d-af05-183d1f7d8ec8">154,873,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="id170cedd88294bc89c6f402a37e123d7_D20200101-20201231" format="ixt-sec:duryear" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzQtMS0xLTEtNjY3NC90ZXh0cmVnaW9uOjU0MmI1OGNkZTc5OTQ2YjE5NDQ3MTFiZDk5MGJjZDczXzY1OTcwNjk3NjY2NzI_a40f3169-d492-416e-a9a1-fd211a61c1ba">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06443a97a314fdb92d5c69b9c9a3577_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzQtMy0xLTEtMA_75f8e688-eadc-49c1-8f8a-536aa147ff1d">3,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06443a97a314fdb92d5c69b9c9a3577_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzQtNS0xLTEtMA_9e9d7171-f3e6-4216-9cd0-e19d48aaf323">26,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if06443a97a314fdb92d5c69b9c9a3577_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzQtNy0xLTEtMA_04d20363-ca2a-4b0f-a958-7a6b43f70da7">10,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06443a97a314fdb92d5c69b9c9a3577_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzQtOS0xLTEtMA_3bea03e4-1d4d-4dd5-8a8c-27c807fcdfac">3,016,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9de27164b224d649a37a0d1268584c1_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzUtMy0xLTEtMA_3168bcd8-d179-4948-b8dc-22c46af34f12">3,062,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9de27164b224d649a37a0d1268584c1_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzUtNS0xLTEtMA_a41edef5-8435-4dde-979d-0cee14e4cefb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9de27164b224d649a37a0d1268584c1_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzUtNy0xLTEtMA_75dc810c-7592-49f2-ba4d-c0509c071d2d">36,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9de27164b224d649a37a0d1268584c1_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzUtOS0xLTEtMA_aeb38262-e38d-4125-a71b-222f5afb0909">3,025,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzctMy0xLTEtMA_95e7b7bb-627a-45eb-b80f-fb4457e60dff">159,239,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzctNS0xLTEtMA_f7b89e13-b657-4d55-bf89-1f4ae9fa03dd">2,365,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzctNy0xLTEtMA_d15e458c-c0e5-457e-b768-c7d4bbf6fe7d">690,895</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzctOS0xLTEtMA_b30fd314-44f5-4d48-a142-6cfeb50e8545">160,914,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id26a1e4045ce4ee0b3633de9cb1dac61_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYTk2NDI2NTMwYmU0MjAwYmRiOTUwY2RjODk1MDBiOC90YWJsZXJhbmdlOmRhOTY0MjY1MzBiZTQyMDBiZGI5NTBjZGM4OTUwMGI4XzItMy0xLTEtMA_7b019027-6e18-4a2b-99f6-03609c23d840">66,599,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id26a1e4045ce4ee0b3633de9cb1dac61_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYTk2NDI2NTMwYmU0MjAwYmRiOTUwY2RjODk1MDBiOC90YWJsZXJhbmdlOmRhOTY0MjY1MzBiZTQyMDBiZGI5NTBjZGM4OTUwMGI4XzItNS0xLTEtMA_1b4da174-65ad-438b-98ae-e479f06019ab">754,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id26a1e4045ce4ee0b3633de9cb1dac61_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYTk2NDI2NTMwYmU0MjAwYmRiOTUwY2RjODk1MDBiOC90YWJsZXJhbmdlOmRhOTY0MjY1MzBiZTQyMDBiZGI5NTBjZGM4OTUwMGI4XzItNy0xLTEtMA_03f51571-1c22-4003-b7c8-fde9257760dd">15,911</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id26a1e4045ce4ee0b3633de9cb1dac61_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYTk2NDI2NTMwYmU0MjAwYmRiOTUwY2RjODk1MDBiOC90YWJsZXJhbmdlOmRhOTY0MjY1MzBiZTQyMDBiZGI5NTBjZGM4OTUwMGI4XzItOS0xLTEtMA_1a38cbdf-2b8b-45f2-8e9a-991db16dbd64">67,338,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div></ix:continuation><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2020&#160;were primarily due to changes in interest rates, including credit spreads from perceived increased credit risks as a result of the COVID-19 global pandemic, and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at December&#160;31, 2020, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div></ix:continuation><div><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_160"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzU4Njg_a81503cd-cf77-4328-87b9-756f3f7b44cd" continuedAt="i75048c8ef2764f5db866c4dd97dc84a5" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i75048c8ef2764f5db866c4dd97dc84a5" continuedAt="i291a181b4ff34e28b0f1bfb92ab7c6a2"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level&#160;1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets are, and prior to September 30, 2020 liabilities were, classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company did not have any transfer of assets and liabilities between Level 1, Level 2 and Level 3 of the fair value hierarchy during the years ended December&#160;31, 2020 and 2019. All liabilities in the fair value hierarchy were extinguished as of September 30, 2020 as described below.</span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzU4NzY_2f85eb7d-e8e8-4c62-aa61-c534554b0756" continuedAt="i4334f7ac71864cdca146320390d8c0ee" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i291a181b4ff34e28b0f1bfb92ab7c6a2" continuedAt="i07407e5fc7df4691a4a636d165c3b0cf"><ix:continuation id="i4334f7ac71864cdca146320390d8c0ee"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:38.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id77b897f2b2646018276c3a658805161_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzUtMS0xLTEtMA_62d3e9e1-ec00-4e65-b23b-a5eb8dac51ea">59,996,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68422a65e88b40e79296e5aa6b8060db_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzUtMy0xLTEtMA_ecc07c29-5dd0-495b-b25c-4f5e06d83609">59,996,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic061ab952f6e49ceb26243c60817cee2_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzUtNS0xLTEtMA_4631aebd-062b-4ff3-9446-2e3dd21207c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c551a0610440a7b6f0abe61e8c82f8_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzUtNy0xLTEtMA_5baba00c-0d33-477a-8945-8d7fa3570931">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacece918c44e4d6ca768677f180897d7_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzgtMS0xLTEtMA_88832884-c5e6-472a-a3ff-7aae5f77462f">154,873,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94dda5a90e794d048dc952d0627fdba7_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzgtMy0xLTEtMA_bef3b4ff-5e7c-465a-b6a3-75f68fcef990">154,873,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddeab32014174a6eb2d035b28d1446b8_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzgtNS0xLTEtMA_256dae0a-16ea-4e33-a631-fcfeed947a1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca9c371fd4d4ea3be2f6127b2b2dffa_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzgtNy0xLTEtMA_82e00c8c-feab-4e55-9c13-2151c324a196">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbdeb8f70e6a44778a3ea02aaaeb1562_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzEwLTEtMS0xLTA_c0cf2fad-85c3-4e5f-a0c0-439265793f44">3,016,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e8472dc355b42e086aa634156b612b7_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzEwLTMtMS0xLTA_7e914c5c-5110-4c75-b324-c1ff80bb2090">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if851e1354ade45b6a4ac89925d9a4403_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzEwLTUtMS0xLTA_e891c5f1-2fd9-491f-bfe1-9cd7f59f4736">3,016,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62adc1206c1a4893b5f3e46ab68ec7dd_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzEwLTctMS0xLTA_ba3c48ca-8b11-4704-88cb-45e6c55bea63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ca4e3a2cfb347d1961b839895da975d_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzExLTEtMS0xLTEyODQ_8bfd2679-dd29-4093-97a3-833869d2332c">3,025,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if81c022e21c148fcbb11892de0c3ae71_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzExLTMtMS0xLTEyODQ_83b09f99-7341-49da-8def-98ea6795e324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99fa94fde4e748cfab7a583ebf129abd_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzExLTUtMS0xLTEyODQ_28b14f91-8ace-40a0-95db-958e662b2daf">3,025,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1a574e3690b4028a3943434014b9a30_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzExLTctMS0xLTEyODQ_a2730601-437a-48a8-a529-a00871a35561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0710bc234ed846439f5d59a967a8aa8b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzEzLTEtMS0xLTA_be633323-219f-4cb1-9fe1-7dad7afe2eb1">160,914,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a5e1669e794e9db24a12f605d4c94b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzEzLTMtMS0xLTA_b6a2e516-a0fa-45ca-b907-3d568ac14eef">154,873,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1005ed8e84ab4360b9311d1c584538bd_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzEzLTUtMS0xLTA_29d72bfe-38e3-451f-85ef-7f5ef10c0f00">6,041,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13d84d47d468404abefbd435934323d5_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzEzLTctMS0xLTA_ea62c138-b69f-448f-81ec-44175551879d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0710bc234ed846439f5d59a967a8aa8b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzE1LTEtMS0xLTEyOTc_8aa44efd-b2b7-47f8-970e-b1bb70cd0d79">4,460,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a5e1669e794e9db24a12f605d4c94b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzE1LTMtMS0xLTEyOTc_7b9a6adf-5fc7-4006-a8a0-9bff3937d5c8">4,460,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1005ed8e84ab4360b9311d1c584538bd_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzE1LTUtMS0xLTEyOTc_38af9aaa-8dc7-4e6c-9a16-adf0840f8460">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13d84d47d468404abefbd435934323d5_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzE1LTctMS0xLTEyOTc_b74eb6dd-cc9a-4202-9d19-18b898e5bc94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0710bc234ed846439f5d59a967a8aa8b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzE2LTEtMS0xLTYwODI_d537ea3d-7c96-416f-92b3-05bfd1049780">225,372,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a5e1669e794e9db24a12f605d4c94b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzE2LTMtMS0xLTYwODI_ee5263ba-8ce2-4786-bd2f-0ef73fb39b9a">219,330,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1005ed8e84ab4360b9311d1c584538bd_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzE2LTUtMS0xLTYwODI_ebe4b98f-c6dc-41d2-945c-79c16e928ae9">6,041,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13d84d47d468404abefbd435934323d5_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzE2LTctMS0xLTYwODI_cd7c8eb0-0657-4ec9-ad09-618f35389eac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, 2019:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e2afcee19774482b251567dfd704749_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzUtMS0xLTEtNDA1Mg_2c2b71b8-ba51-4e80-a4c4-da8922d516c3">2,349,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2913e54184ff437ea27bd0066e1dafd0_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzUtMy0xLTEtNDA1Mg_09a04f30-79ef-43e4-b2d3-b417b2ab2527">2,349,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia26736c769c2420f9ca66117d30c734a_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzUtNS0xLTEtNDA1Mg_2fc73a98-dda4-473e-ae91-511d4d35802a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0ea3dd77c114edaa793e22ac478cf97_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzUtNy0xLTEtNDA1Mg_006148d5-d793-421a-99e7-b2c4a434a857">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b39d6da16f4eb380e2a990dfff1f36_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzUtMS0xLTEtMA_4868797a-23f9-4bf6-9fe4-fd593dcd2a2e">67,338,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i096fa31c0c464101ae5cf90270267cde_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzUtMy0xLTEtMA_e202f848-abdd-46db-8164-0eca8dd57cb5">67,338,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idce13f5e5f4c4fc5af43c4edef726f4a_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzUtNS0xLTEtMA_99005701-4b17-4c66-9e14-77685aeeea42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd3a02a734354ed7820d83f40571c7d6_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzUtNy0xLTEtMA_f1020094-6841-404e-9661-a0440999e717">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8add3b9ca8da438b900d8ea5ac0b076c_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzgtMS0xLTEtMA_815bd8c9-ccdc-4d38-996d-8ba1d8da9d2c">6,315,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie64a636ae54645beb9d8ee43e42dcc10_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzgtMy0xLTEtMA_4c2f02e3-8522-49c2-84e2-0d83ab952f03">6,315,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bce27cb66c4603aa2e7c5f6f92d9d6_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzgtNS0xLTEtMA_2ddf5f58-3d7f-4bda-9fe0-b7cf6b431ea6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7004a0f54b4e4ac8adfa3750ee6ccf4e_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzgtNy0xLTEtMA_c9f90f7d-5340-4bb3-b3e5-b99c4e502c93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8add3b9ca8da438b900d8ea5ac0b076c_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEwLTEtMS0xLTA_6bf6753c-96f1-4595-8c85-c0e3c7bd2526">76,003,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie64a636ae54645beb9d8ee43e42dcc10_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEwLTMtMS0xLTA_00a9d344-fe67-411e-bb3c-c1eef10216b1">76,003,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bce27cb66c4603aa2e7c5f6f92d9d6_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEwLTUtMS0xLTA_5b586d7e-3ee6-4091-a857-65e787da6a0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7004a0f54b4e4ac8adfa3750ee6ccf4e_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEwLTctMS0xLTA_b5481edf-f900-4018-9984-6c5152086bd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Derivative liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8add3b9ca8da438b900d8ea5ac0b076c_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEyLTEtMS0xLTA_dab05ae2-bed7-4fc4-b457-1b853e894671">8,819,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie64a636ae54645beb9d8ee43e42dcc10_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEyLTMtMS0xLTA_02f6f5d9-38db-413a-9355-cbb18121847d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bce27cb66c4603aa2e7c5f6f92d9d6_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEyLTUtMS0xLTA_13539484-db17-4588-80ce-a31d5cb21aed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7004a0f54b4e4ac8adfa3750ee6ccf4e_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEyLTctMS0xLTA_9a494971-34be-4e51-ada2-8b9e4aae1469">8,819,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8add3b9ca8da438b900d8ea5ac0b076c_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEzLTEtMS0xLTA_68c70561-94c5-4052-946a-81c6810dc90c">8,819,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie64a636ae54645beb9d8ee43e42dcc10_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEzLTMtMS0xLTA_6c4d90ff-6341-4a98-a5d9-9416fe7d71e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bce27cb66c4603aa2e7c5f6f92d9d6_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEzLTUtMS0xLTA_7116086d-9139-4a4d-b628-58b765389641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7004a0f54b4e4ac8adfa3750ee6ccf4e_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEzLTctMS0xLTA_cae3dfed-4107-4429-b707-c5754fb116e3">8,819,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 assets at December&#160;31, 2020 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. Level 1 assets at December&#160;31, 2019 consisted of money market funds and mutual funds held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investments in its affiliates, GeneOne and PLS. The Company accounts for its investment in <ix:nonFraction unitRef="shares" contextRef="i7d23fef8ecff4bdebfef8e1a463d13e3_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzE5MjA_e15eff0b-d87a-4e17-b372-358602ef0f91">597,808</ix:nonFraction> common shares of PLS as an equity investment with a fair value based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of operations as unrealized gain (loss) on available-for-sale equity securities or as a gain (loss) on investment in affiliated entities. In August 2020, the Company sold its investment in <ix:nonFraction unitRef="shares" contextRef="i221a334cfa384bf7bff65c8d98c24f2e_I20200831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzQzOTgwNDY1MTc1MDE_225c7d06-9b47-4862-baca-d9aa64e21559">1,644,155</ix:nonFraction> common shares of its affiliated entity GeneOne for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i627a611d119640b18733b47fcdec6850_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="ino:ProceedsFromSaleOfEquitySecuritiesFVNI" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzQzOTgwNDY1MjAyNTY_00650595-e1b7-49da-bb57-1fd6d1dc04e6">40.1</ix:nonFraction>&#160;million, resulting in a gain on investment in affiliated entity of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i07407e5fc7df4691a4a636d165c3b0cf"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i627a611d119640b18733b47fcdec6850_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzQzOTgwNDY1MjAyNzE_cf9ce8ee-6725-447c-98f5-601c8806751b">36.7</ix:nonFraction>&#160;million. Previously, the Company accounted for its investment in GeneOne based on the closing price of the shares on the KOSDAQ Market of the Korea Exchange (KOSDAQ) on the applicable balance sheet date. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at December&#160;31, 2020 consisted of certificates of deposit and U.S. agency mortgage-backed securities. Level 2 assets held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="ib52bd61505e648f7bd380109eafb2944_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzU4Nzc_b3381296-e691-4e4d-a2df-5d03db3bde3e"><ix:nonFraction unitRef="usd" contextRef="if7a4e61e0eaa451ca758740df043909a_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzU4Nzc_cf18fb81-2dd8-4182-8c65-c4046ec233e3">no</ix:nonFraction></ix:nonFraction> Level 3 assets held as of December&#160;31, 2020 and 2019. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="ib52bd61505e648f7bd380109eafb2944_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzQzOTgwNDY1MTgxNjQ_f5fa7a95-5b89-4770-96a7-c3ffb14b0454">no</ix:nonFraction> Level 3 liabilities held at December&#160;31, 2020 due to the full conversion of the August 2019 Bonds into shares of the Company's common stock. Level 3 liabilities held as of December 31, 2019 consisted of the embedded conversion option contained in the August 2019 Bonds that met the criteria to be bifurcated and accounted for separately from the August 2019 Bonds (the "derivative liability") (see Note 11 below for more information). The derivative liability was recorded at fair value of $<ix:nonFraction unitRef="usd" contextRef="i6c79379a56b342509ef8394d089e5206_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzQzMDk_b02b5e43-c8a5-4002-9ca2-f6de96def0f1">7.1</ix:nonFraction> million upon the issuance of the August 2019 Bonds, and is subsequently remeasured to fair value at each reporting period. The derivative liability was initially valued and remeasured using a "with-and-without" method. The "with-and-without" methodology involves valuing the whole instrument on an as-is basis and then valuing the instrument without the embedded conversion option. The difference between the entire instrument with the embedded conversion option compared to the instrument without the embedded conversion option is the fair value of the derivative, recorded as the derivative liability. There was no derivative liability associated with the issuance of the December 2019 Bonds.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the August 2019 Bonds with the conversion option is estimated using a Monte Carlo simulation approach. The key inputs to valuing the August 2019 Bonds with the conversion option on the date of issuance and as of August 3, 2020 conversion date included the Company&#8217;s stock price on the valuation date; the expected annual volatility of the Company&#8217;s common stock, and the discount yield, which was derived by making the fair value of the August 2019 Bonds equal to the face value on the issuance date. Fair value measurements are highly sensitive to changes in these inputs and significant changes in these inputs could result in a significantly higher or lower fair value. </span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzU4NjY_16c4cbc7-87d1-4a0c-a8ee-9ce32c7e27df" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair value of the derivative liability for the year ended December&#160;31, 2020: </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTpmNTFhYWEyMTZmYzY0ODZiYjRiZTE4NzExM2Q5Nzg3My90YWJsZXJhbmdlOmY1MWFhYTIxNmZjNjQ4NmJiNGJlMTg3MTEzZDk3ODczXzAtMS0xLTEtMA_587ba43e-0f4c-4c2a-a287-e6ffceef51d0">8,819,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTpmNTFhYWEyMTZmYzY0ODZiYjRiZTE4NzExM2Q5Nzg3My90YWJsZXJhbmdlOmY1MWFhYTIxNmZjNjQ4NmJiNGJlMTg3MTEzZDk3ODczXzEtMS0xLTEtMA_253d894f-8e31-45bd-817a-9f1f4e561bf7">75,670,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Derecognition of the derivative liability upon conversion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTpmNTFhYWEyMTZmYzY0ODZiYjRiZTE4NzExM2Q5Nzg3My90YWJsZXJhbmdlOmY1MWFhYTIxNmZjNjQ4NmJiNGJlMTg3MTEzZDk3ODczXzItMS0xLTEtMA_a6221f57-198c-4c63-8b69-2990307130dc">84,490,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTpmNTFhYWEyMTZmYzY0ODZiYjRiZTE4NzExM2Q5Nzg3My90YWJsZXJhbmdlOmY1MWFhYTIxNmZjNjQ4NmJiNGJlMTg3MTEzZDk3ODczXzMtMS0xLTEtMA_630497d1-3a75-47bf-bdd0-2f082039110d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_163"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzEzNzA_9aea6a42-c2db-4b04-9266-17c4f630544b" continuedAt="i3836e02dae654250829b4a05a169b597" escape="true">Major Customers and Concentration of Credit Risk</ix:nonNumeric></span></div><ix:continuation id="i3836e02dae654250829b4a05a169b597" continuedAt="ia0d9182acaa842ec9a71f9d52692ec00"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzEzNjA_a00b857a-28bd-452c-ad99-e6b8f0d05e54" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Customer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018 Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ApolloBio</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib09ce28847f9441691e291976b0a485e_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzEtMS0xLTEtMA_277655ee-2b65-438a-90cb-a5e98f1530bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icc1ad91fea794c9590f178cc0037615c_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzEtMy0xLTEtMA_216c93f2-a159-4736-bdc1-5908a287d6fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e8cb281f8e84403b97d0d2fecd0b80c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzEtNS0xLTEtMA_f87c338f-8fcd-4abd-abf2-3c737d509c1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic4ea9cc86768413da095a70b56c90878_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzEtNy0xLTEtMA_8629fe63-44c5-43aa-bcc6-d32149e78c64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16a1aae8996946329e172cd6fe4f18be_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzEtOS0xLTEtMA_31ec1126-a005-42de-bfef-e1ca4b9b10d0">23,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i71a6c7568e7c4d8d9bfa945381152967_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzEtMTEtMS0xLTA_689a58f5-f564-4cb5-8b1f-6b2b0d3b64d4">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic13e135184a4471d939ad3f817c42607_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzItMS0xLTEtMA_9d0490e2-103d-4281-b3a0-ffd46d5dc8de">170,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i786830bb15014490bcfe93e2c9d6a1e0_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzItMy0xLTEtMA_97d36307-f415-4e5e-937e-a20d145479de">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bef865624946d194ded3a39b0a65c9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzItNS0xLTEtMA_5ce3f7e4-fbf2-471c-b194-643906da1b51">3,194,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id292a9ccf0334d99847358e5a3ab1c42_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzItNy0xLTEtMA_5b95fbb4-fdf6-4d42-ab24-f465fdb9ec93">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab0a228644849cbb1110e99d5c4def2_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzItOS0xLTEtMA_ae8c808b-2a67-438a-a236-3b73a803f3c2">6,850,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34104c83002345e7a7bc49036cda039d_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzItMTEtMS0xLTA_d3c6b0ac-a59c-4196-bba1-3c0c3ae5111c">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advaccine</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i281ff24884ff458b8adb28cb18217a61_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzMtMS0xLTEtMA_dc2cabdd-434f-451a-b54f-6392e773ab28">5,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c4dc4da8dca44c2a1fe44b672260615_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzMtMy0xLTEtMA_710a9967-7fbd-4293-b73b-cee984f199a9">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85bcd3d07a5448baa7741c3754cf1afb_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzMtNS0xLTEtMA_898ac156-8dd1-45e8-96fb-4ffe3aabad76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8cfb53cdc7e41538de275f318de41dc_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzMtNy0xLTEtMA_f2442823-69fc-44de-b2ca-7bec3778b43e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60903cdb147d440493201f13edec1181_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzMtOS0xLTEtMA_5032dd66-1c94-490e-9867-53f2a90a8da7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibdff2f0208d44cfe89bc5c92c6d26e82_D20180101-20181231" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzMtMTEtMS0xLTA_acba2797-59de-4b45-8047-887bbe41903a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plumbline Life Sciences, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e37913d1c5547849d25527ab47a8354_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzQtMS0xLTEtMA_d85e71b7-711d-481f-95f5-fb9a64ed4863">1,370,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia92449862a9b4330882477084d9c358a_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzQtMy0xLTEtMA_2b790dc4-9176-415f-ad85-18dfe641e574">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6147c70afd684bf981a1e0b1202b8058_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzQtNS0xLTEtMA_8f818790-0035-4d68-aeae-6dcb937d5a47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica6d55dbeb8f4cc3a279ee53cb51b7f6_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzQtNy0xLTEtMA_e5f56b49-c474-4d75-9d31-011117ffd32f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf1bd4850cb8489ea58ab4b2fda5a1a9_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzQtOS0xLTEtMA_498ddd2a-571b-4de8-831f-f0d330550924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1e50a9cd8294f3fa132e51c85220781_D20180101-20181231" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzQtMTEtMS0xLTA_bc1b0a24-69a3-4b34-81bb-fa47b3e1548f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other, including affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06dcac265f274ebb9813e7af23d4696d_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzUtMS0xLTEtMA_1a27ac02-5dad-44b4-abc1-516586013526">870,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69dd35be2ade4fb39a51b18d53c5b8ac_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzUtMy0xLTEtMA_e1cc76e1-304c-4187-9164-5f2ac22763c4">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608cd9009af344c89aa12e0f7b311227_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzUtNS0xLTEtMA_437577f3-8426-4ed1-9aad-85d79c229315">917,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i823cb278de9e47d192778260c3f6db48_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzUtNy0xLTEtMA_e0f24c01-6940-435b-83f6-11a677f97926">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc88be27567345b7a63177cf8f6f0a99_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzUtOS0xLTEtMA_22024d30-7ecd-4769-b75f-e82cc4cb1a19">631,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic35720e7a755474fbed63e8de7d3a5c2_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzUtMTEtMS0xLTA_f94bd630-e5b1-4c06-88f4-2e4b6ec97a19">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzYtMS0xLTEtMA_d3f6b9b8-19fc-46e8-b3ae-01bb79dd58ad">7,411,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i93819976a973446ea1061a1f37473186_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzYtMy0xLTEtMA_fcc7a3d1-8328-40ca-9556-cc1dd40f4401">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzYtNS0xLTEtMA_6d113549-29ce-4dca-9c01-3e91770ef443">4,111,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4efea026d744acf8d1ff320d47ea351_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzYtNy0xLTEtMA_8414806e-86ba-4dd2-b836-e177c40c99ef">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzYtOS0xLTEtMA_536cef07-ac2a-4cb2-b4ef-303f1770b6f0">30,481,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i488395dd3cfd4a979f4c1b6dc93cab19_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzYtMTEtMS0xLTA_cb360321-d9d6-4a73-9fb2-a8c8a3030e4c">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020, 2019 and 2018, the Company recognized revenue from various license and other agreements. As of December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i74e4216a6494415aa925b9f9484b6be5_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzQzOTgwNDY1MTM2OTY_0de5bcf8-44af-49d4-b829-69a286ad5917">11.4</ix:nonFraction> million, or <ix:nonFraction unitRef="number" contextRef="ia060b83189564cb68c4c124f57185051_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzQzOTgwNDY1MTM3MTA_67343eb8-1207-44f1-9e5d-ce44983e0471">62</ix:nonFraction>%, and $<ix:nonFraction unitRef="usd" contextRef="i07a67056b0694c8eb1abe2d9df8f95cc_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzQzOTgwNDY1MTM3MTU_a4f48401-9188-4fc3-a5e2-6931ee2ec47c">7.1</ix:nonFraction> million, or <ix:nonFraction unitRef="number" contextRef="i6d4ece7344ab45b3a9385623a0a4e13d_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzQzOTgwNDY1MTM3Mjk_ef351c38-2902-46ed-9358-7b5a266db48e">38</ix:nonFraction>%, of the Company's accounts receivable was attributable to the DoD and Advaccine, respectively. As of December&#160;31, 2019, $<ix:nonFraction unitRef="usd" contextRef="i8525ad5935324dd89b3d251246713420_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzQzOTgwNDY1MTMxNDk_ddc5640c-2547-4ca1-85f4-f43be471c5a2">469,000</ix:nonFraction>, or <ix:nonFraction unitRef="number" contextRef="ic4b3aa0a98414a8abe5a915a77d31a03_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzQzOTgwNDY1MTMxNTk_6e301255-5cb1-4601-b55c-55f99563fa85">67</ix:nonFraction>%, and $<ix:nonFraction unitRef="usd" contextRef="ife05d4e1d47d421fb4f563cd562c6a2c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzEwNDU_03f57dd4-f5f6-4e61-a57d-02ad3617e4eb">161,000</ix:nonFraction>, or <ix:nonFraction unitRef="number" contextRef="i3f2dd21c2fb446e1ae44bb46996bcb90_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzEwNTI_f9ae4776-0c24-451b-a2eb-50e1298d7392">23</ix:nonFraction>%, of the Company's accounts receivable was attributable to MCDC and AstraZeneca, respectively. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia0d9182acaa842ec9a71f9d52692ec00">There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.</ix:continuation></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_1858"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:OtherCurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODU4L2ZyYWc6NzRjMDI1ZTNhNjg1NDQzOWI5NTVlYWE2Y2Q4NTM3ZjUvdGV4dHJlZ2lvbjo3NGMwMjVlM2E2ODU0NDM5Yjk1NWVhYTZjZDg1MzdmNV84MjQ2MzM3MjA5OTA2_55f9b5d7-42f5-4772-863b-edf8b837f775" continuedAt="ie0d77c58a704458e922ceaac47d05711" escape="true">Prepaid Expenses and Other Current Assets</ix:nonNumeric></span></div><ix:continuation id="ie0d77c58a704458e922ceaac47d05711"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODU4L2ZyYWc6NzRjMDI1ZTNhNjg1NDQzOWI5NTVlYWE2Y2Q4NTM3ZjUvdGV4dHJlZ2lvbjo3NGMwMjVlM2E2ODU0NDM5Yjk1NWVhYTZjZDg1MzdmNV84MjQ2MzM3MjA5OTA3_9cec650d-2c87-4384-b23f-0a468e56362c" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets at December&#160;31, 2020 and 2019 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:PrepaidManufacturingExpensesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODU4L2ZyYWc6NzRjMDI1ZTNhNjg1NDQzOWI5NTVlYWE2Y2Q4NTM3ZjUvdGFibGU6ODZlZjFmYmRkYTY4NDc3ZmI0OTVhZjcyNTQzZWI0ZGMvdGFibGVyYW5nZTo4NmVmMWZiZGRhNjg0NzdmYjQ5NWFmNzI1NDNlYjRkY18yLTEtMS0xLTY4Mzk_b6e37173-4d4c-4c88-976a-8b3e47d8ec7a">35,661,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:zerodash" name="ino:PrepaidManufacturingExpensesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODU4L2ZyYWc6NzRjMDI1ZTNhNjg1NDQzOWI5NTVlYWE2Y2Q4NTM3ZjUvdGFibGU6ODZlZjFmYmRkYTY4NDc3ZmI0OTVhZjcyNTQzZWI0ZGMvdGFibGVyYW5nZTo4NmVmMWZiZGRhNjg0NzdmYjQ5NWFmNzI1NDNlYjRkY18yLTMtMS0xLTY4Mzk_eaff564e-a198-4a31-ab96-91988a29c16d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODU4L2ZyYWc6NzRjMDI1ZTNhNjg1NDQzOWI5NTVlYWE2Y2Q4NTM3ZjUvdGFibGU6ODZlZjFmYmRkYTY4NDc3ZmI0OTVhZjcyNTQzZWI0ZGMvdGFibGVyYW5nZTo4NmVmMWZiZGRhNjg0NzdmYjQ5NWFmNzI1NDNlYjRkY18zLTEtMS0xLTY4Mzk_77b0e3bd-895d-4fa5-aae0-b196eb9b1f49">4,695,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODU4L2ZyYWc6NzRjMDI1ZTNhNjg1NDQzOWI5NTVlYWE2Y2Q4NTM3ZjUvdGFibGU6ODZlZjFmYmRkYTY4NDc3ZmI0OTVhZjcyNTQzZWI0ZGMvdGFibGVyYW5nZTo4NmVmMWZiZGRhNjg0NzdmYjQ5NWFmNzI1NDNlYjRkY18zLTMtMS0xLTY4Mzk_89fa4953-65ed-4b66-a6fe-2bc80dc3db7a">1,584,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODU4L2ZyYWc6NzRjMDI1ZTNhNjg1NDQzOWI5NTVlYWE2Y2Q4NTM3ZjUvdGFibGU6ODZlZjFmYmRkYTY4NDc3ZmI0OTVhZjcyNTQzZWI0ZGMvdGFibGVyYW5nZTo4NmVmMWZiZGRhNjg0NzdmYjQ5NWFmNzI1NDNlYjRkY18xMS0xLTEtMS02ODM5_f106cdc6-2a9b-47c7-b31b-41b1801f1a2a">40,357,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODU4L2ZyYWc6NzRjMDI1ZTNhNjg1NDQzOWI5NTVlYWE2Y2Q4NTM3ZjUvdGFibGU6ODZlZjFmYmRkYTY4NDc3ZmI0OTVhZjcyNTQzZWI0ZGMvdGFibGVyYW5nZTo4NmVmMWZiZGRhNjg0NzdmYjQ5NWFmNzI1NDNlYjRkY18xMS0zLTEtMS02ODM5_82b7ada8-0bc9-422b-86d4-e6ab9f580311">1,584,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:24.91pt">Prepaid manufacturing expenses related to deposits made to reserve capacity for the manufacturing of INO-4800 expected in 2021. In the event that the manufacturing does not occur in 2021 the deposits will be forfeited.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_166"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90ZXh0cmVnaW9uOmIyY2E1OTk3OTJjMzRlOTA5NDRlMGI1YmQxODI2OTU3XzQ2MQ_1f2c06c7-358e-460f-9041-69c08c137b3b" continuedAt="i1621cd4143874a4cb96e0ecc2e35d472" escape="true">Fixed Assets</ix:nonNumeric></span></div><ix:continuation id="i1621cd4143874a4cb96e0ecc2e35d472"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90ZXh0cmVnaW9uOmIyY2E1OTk3OTJjMzRlOTA5NDRlMGI1YmQxODI2OTU3XzQ2OA_a16aea13-7b2e-4395-9f72-376c718b4adc" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets at December&#160;31, 2020 and 2019 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Depreciation<br/>and<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c81a59aea34482aaa080e093a3867a_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzItMS0xLTEtMA_854cc153-7218-4b3f-ac8b-1215783c9967">15,179,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37c81a59aea34482aaa080e093a3867a_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzItMy0xLTEtMA_72e117cd-c680-46e1-8451-2aa7f8f19308">6,549,418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c81a59aea34482aaa080e093a3867a_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzItNS0xLTEtMA_5c39a5ed-6c55-485a-91f5-67f91bbcb534">8,630,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ab2e4de0604a18954781289db76d63_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzMtMS0xLTEtMA_12e08a9f-2422-4664-b922-98062cf468ea">4,788,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1ab2e4de0604a18954781289db76d63_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzMtMy0xLTEtMA_eb295e1e-e0d8-4197-a298-a36a642ae635">3,727,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ab2e4de0604a18954781289db76d63_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzMtNS0xLTEtMA_27bfa889-7ef6-4933-bf8a-e36202ea70e9">1,061,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c19b53631bf4b87bd6a70572b19cb99_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzQtMS0xLTEtMA_9e07e18c-39a3-4466-878e-6139a1d519de">2,828,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c19b53631bf4b87bd6a70572b19cb99_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzQtMy0xLTEtMA_e4c4fdeb-b381-4f72-b8d5-9199e3180033">2,296,942</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c19b53631bf4b87bd6a70572b19cb99_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzQtNS0xLTEtMA_f082cfcc-74dd-48ae-a811-81d9cb37f0d9">531,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33214248981d4bc3b9306852d8766f9d_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzUtMS0xLTEtMA_508de953-fdee-4123-9e04-634a9846728b">4,544,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33214248981d4bc3b9306852d8766f9d_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzUtMy0xLTEtMA_5919fe9c-e993-45ee-9dad-f9d99edba749">3,419,703</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33214248981d4bc3b9306852d8766f9d_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzUtNS0xLTEtMA_54b7c81b-a51c-4005-96d2-b4553b904790">1,125,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzYtMS0xLTEtMA_dede9fca-47f4-4f60-bd38-650c8bde4632">27,341,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzYtMy0xLTEtMA_907c2389-fcd3-44ac-96a4-9e2e20c5042a">15,993,571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzYtNS0xLTEtMA_77679efe-1109-4d4e-9f98-6cb4eb606e09">11,348,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a2f30004a6f4760aa2daadba4a229e7_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzgtMS0xLTEtMA_9cd3a56c-7ce3-4dfb-9ef0-1e971bd21499">15,007,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a2f30004a6f4760aa2daadba4a229e7_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzgtMy0xLTEtMA_c23b320b-a85c-421e-88e3-7fe9a208fb7e">4,996,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a2f30004a6f4760aa2daadba4a229e7_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzgtNS0xLTEtMA_c4e26af7-f491-4b66-8aa9-4ea4daf7c75b">10,011,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i142b64fd7b4e4c77ab64ed7e235de34e_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzktMS0xLTEtMA_d874d9e1-54d1-42a1-9d21-0bab94cd5663">4,102,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i142b64fd7b4e4c77ab64ed7e235de34e_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzktMy0xLTEtMA_8c385d46-8a0a-45d7-a1e8-78de03b36d72">3,229,357</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i142b64fd7b4e4c77ab64ed7e235de34e_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzktNS0xLTEtMA_1513b2a9-4134-4a9f-b5b4-41ab52878c36">873,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d0edfd70ad4cd9b77378f5caf6c6fb_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzEwLTEtMS0xLTA_b3d53f92-ee8f-4d83-b1f1-dc435e6b0226">3,048,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5d0edfd70ad4cd9b77378f5caf6c6fb_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzEwLTMtMS0xLTA_c79582f2-7d6e-4c4e-9798-1312ed0e4d74">1,944,293</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d0edfd70ad4cd9b77378f5caf6c6fb_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzEwLTUtMS0xLTA_9f7c8e19-ad50-4fa5-9864-b043681fc3d9">1,103,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i331d2b93d53845bbbec83894edc52039_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzExLTEtMS0xLTA_011b7486-a95e-48de-9f96-8221e415bfcd">3,781,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i331d2b93d53845bbbec83894edc52039_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzExLTMtMS0xLTA_716447e2-8245-4778-bb04-19872441429a">2,996,031</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i331d2b93d53845bbbec83894edc52039_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzExLTUtMS0xLTA_d3d32e5b-9812-4ceb-91fa-45e653d7e169">784,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzEyLTEtMS0xLTA_10093a77-d94d-45e1-a02c-4285e325f45c">25,939,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzEyLTMtMS0xLTA_f1b7630c-031f-45e2-ad6f-7e642d689035">13,166,458</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzEyLTUtMS0xLTA_eae46eb6-6665-45e0-82dc-ae2b5842ca1a">12,773,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90ZXh0cmVnaW9uOmIyY2E1OTk3OTJjMzRlOTA5NDRlMGI1YmQxODI2OTU3XzQzOTgwNDY1MTE2MjI_3471d691-0576-43a5-9989-339d6b4bfe3b">3.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90ZXh0cmVnaW9uOmIyY2E1OTk3OTJjMzRlOTA5NDRlMGI1YmQxODI2OTU3XzQzOTgwNDY1MTE2MzA_2c5ae3b5-44cc-4bf3-877b-cd8004c2f73b">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90ZXh0cmVnaW9uOmIyY2E1OTk3OTJjMzRlOTA5NDRlMGI1YmQxODI2OTU3XzQzOTgwNDY1MTE2Mzg_a7909996-863f-45ff-9fd4-ae4f4e459529">3.7</ix:nonFraction> million, respectively. The Company determined that the carrying value of these long-lived assets was not impaired during the periods presented.  During the year ended December 31, 2020 the Company disposed of fixed assets with a net book value of $<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentDisposals" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90ZXh0cmVnaW9uOmIyY2E1OTk3OTJjMzRlOTA5NDRlMGI1YmQxODI2OTU3XzQxNw_3ca257a8-3845-4a8c-bf43-e9fb983c5646">227,000</ix:nonFraction> and accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90ZXh0cmVnaW9uOmIyY2E1OTk3OTJjMzRlOTA5NDRlMGI1YmQxODI2OTU3XzQ1Mg_c6e213e4-206b-4675-ab3e-2d891857bd97">200,000</ix:nonFraction>.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_169"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90ZXh0cmVnaW9uOmNkMTQ3YTE4ZTI4ZjRhMzRiNzBlMmQxMjhlYTcyN2ZkXzEwNzU_cdd74ea1-cbdb-473b-a15d-44dc9bccf2f8" continuedAt="i54ba98f042eb402f810435b456331711" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="i54ba98f042eb402f810435b456331711" continuedAt="iad1a26a63f1a423e851f133144e19288"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90ZXh0cmVnaW9uOmNkMTQ3YTE4ZTI4ZjRhMzRiNzBlMmQxMjhlYTcyN2ZkXzEwNzI_eb331e25-14d2-4ebc-b1c9-f0ccc7b4bcfb" continuedAt="i8ebcb03e685a486bb8da81c17b664515" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iad1a26a63f1a423e851f133144e19288"><ix:continuation id="i8ebcb03e685a486bb8da81c17b664515"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.874%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:53pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzMtMy0xLTEtMA_ca116398-7a9f-4c94-8c83-a5a3de869c50">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzMtNy0xLTEtMA_01440f95-caf7-47df-8abc-a9d16104bf53">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzMtOS0xLTEtMA_8ae2c1ee-7c98-43b2-976a-e40064b15cb8">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzMtMTMtMS0xLTA_5a775dad-ffac-4b6c-a392-597e489d09c9">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i714873ccaa6945ed8fddc9ca8b4a2ba9_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzYtMS0xLTEtMA_a957e3ef-bef3-4ba6-b1f9-6e69a53e8f8f">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78dee1adddd343d99fde448fd85a0794_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzYtMy0xLTEtMA_e554f469-6741-476a-bb0e-c147a9ffd384">1,323,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78dee1adddd343d99fde448fd85a0794_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzYtNS0xLTEtMA_16255b62-45f8-44aa-ab6d-251b81b75bd7">1,276,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78dee1adddd343d99fde448fd85a0794_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzYtNy0xLTEtMA_728fa7b8-86ee-4378-a307-c0e7727ac89e">46,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i898390694847439889865bfd898b6744_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzYtOS0xLTEtMA_6bb40ddb-cc70-4759-b554-fa4bc519ae67">1,323,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i898390694847439889865bfd898b6744_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzYtMTEtMS0xLTA_59dda494-683f-4c6c-98c8-5389473a76e9">1,248,104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i898390694847439889865bfd898b6744_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzYtMTMtMS0xLTA_458980ed-ae73-47a8-bfa4-06d52b599f0b">75,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5b01ba2e220c4965b4bea51288906959_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzktMS0xLTEtMA_dd89def0-4862-4d7d-bf75-a47189273be4">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c086571fe9d4f12adaba3aba2947770_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzktMy0xLTEtMA_449121a0-9e76-4466-a0d9-7702300944a4">5,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c086571fe9d4f12adaba3aba2947770_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzktNS0xLTEtMA_0e1608cc-94d2-48e5-bb5a-882aded6d94c">2,468,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c086571fe9d4f12adaba3aba2947770_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzktNy0xLTEtMA_84f77d3a-e939-4a04-b74a-f3022d845949">2,631,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0d8a0c7b06b44b58e6943d769503627_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzktOS0xLTEtMA_12be2736-63c0-4b08-a644-393d25f3045a">5,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0d8a0c7b06b44b58e6943d769503627_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzktMTEtMS0xLTA_25ee0b8b-4a7a-4cf5-a641-75bd507c1472">2,175,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0d8a0c7b06b44b58e6943d769503627_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzktMTMtMS0xLTA_5005fdd0-4e4a-47b0-80b0-c0e8d90a3037">2,924,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (c)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i564bfb8806cf4e91b81d269583a69770_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEwLTEtMS0xLTA_a565dc60-8660-48d9-a477-62b1ac876b33">18</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3873b02397f24b078c0992e44ff9bc6b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEwLTMtMS0xLTA_41ba8905-f9d0-40e6-8962-2da3be35ad43">4,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3873b02397f24b078c0992e44ff9bc6b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEwLTUtMS0xLTA_ebd134eb-5091-4935-8ed6-b2aaaa25a3c3">3,581,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3873b02397f24b078c0992e44ff9bc6b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEwLTctMS0xLTA_ceeaf2d3-d72f-4ed7-8034-9fc4fbcffb41">468,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f5246a5fd14efc8c588f0e34623d44_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEwLTktMS0xLTA_3aa59e53-3ce4-4b93-a9a8-2b353d7afc32">4,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f5246a5fd14efc8c588f0e34623d44_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEwLTExLTEtMS0w_25f563f9-b756-4ad0-881c-a8d18cd43f99">3,356,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f5246a5fd14efc8c588f0e34623d44_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEwLTEzLTEtMS0w_71df64c4-b745-4842-a678-4270ac343082">693,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic368e3ff4b6c43beb3e373aaad80cfaf_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzExLTEtMS0xLTA_7891ddae-5bb6-41d1-bccf-9e5dddd8155b">11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzExLTMtMS0xLTA_f7f068d5-3c35-4345-9429-4a9e25f512b0">10,473,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzExLTUtMS0xLTA_0380b7f8-56f0-4652-995f-348ab34a42ac">7,326,991</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzExLTctMS0xLTA_95d904cd-f19b-4b8b-a98f-cbf07d294f7d">3,146,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzExLTktMS0xLTA_057e0d0d-f123-4c05-b300-782f7ae70f94">10,473,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzExLTExLTEtMS0w_f6a35f6a-259e-43f5-9e76-ab7b8cd608b8">6,779,910</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzExLTEzLTEtMS0w_3b922f58-8a70-4df8-a488-69f766c37655">3,693,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:GoodwillAndIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEyLTMtMS0xLTA_2c47e214-b2c4-4986-b302-01fda4ba998c">20,987,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEyLTUtMS0xLTA_914e37bb-25aa-41f4-995d-6285c5c019ef">7,326,991</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:GoodwillAndIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEyLTctMS0xLTA_5e9e3863-d581-43b3-ab24-0fb34134fc2c">13,660,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="ino:GoodwillAndIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEyLTktMS0xLTA_c4001d3e-2d1a-4d2e-a79c-f60c27e2c005">20,987,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEyLTExLTEtMS0w_3a1cd45c-066d-4e38-ad3e-f8ac0a636e71">6,779,910</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="ino:GoodwillAndIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEyLTEzLTEtMS0w_df62a5b3-7a93-4a44-97f4-e651f4c88e2a">14,207,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Goodwill was recorded from the acquisition of other companies and assets.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Other intangible assets represent the estimated fair value of acquired intellectual property.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense on intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90ZXh0cmVnaW9uOmNkMTQ3YTE4ZTI4ZjRhMzRiNzBlMmQxMjhlYTcyN2ZkXzQzOTgwNDY1MTI1OTU_e6a1bc48-919c-41f9-af07-77437f4548a6">547,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90ZXh0cmVnaW9uOmNkMTQ3YTE4ZTI4ZjRhMzRiNzBlMmQxMjhlYTcyN2ZkXzQzOTgwNDY1MTI2MDA_b7680399-38db-4231-ac44-44175faa354b">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90ZXh0cmVnaW9uOmNkMTQ3YTE4ZTI4ZjRhMzRiNzBlMmQxMjhlYTcyN2ZkXzQzOTgwNDY1MTI2MDg_4a316714-977c-4f3b-850e-ed350a034aaa">1.2</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90ZXh0cmVnaW9uOmNkMTQ3YTE4ZTI4ZjRhMzRiNzBlMmQxMjhlYTcyN2ZkXzEwNzA_6bf78696-829d-45fe-aeb5-89f82e859ee6" continuedAt="ic914f35a39c440aba7137702bf154925" escape="true">Amortization expense related to intangible assets at December&#160;31, 2020 is expected to be incurred as follows: </ix:nonNumeric></span></div><ix:continuation id="ic914f35a39c440aba7137702bf154925"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:86.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZToxNTc1ZmI1NjlkOGI0MDM2OGMzNGJmNGQ1NDVlODkyOS90YWJsZXJhbmdlOjE1NzVmYjU2OWQ4YjQwMzY4YzM0YmY0ZDU0NWU4OTI5XzEtMS0xLTEtMA_8106ffc6-43ff-4175-ac6e-ce9a862b3895">521,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZToxNTc1ZmI1NjlkOGI0MDM2OGMzNGJmNGQ1NDVlODkyOS90YWJsZXJhbmdlOjE1NzVmYjU2OWQ4YjQwMzY4YzM0YmY0ZDU0NWU4OTI5XzItMS0xLTEtMA_9b1b50eb-9d9c-4224-9675-ef923bd4f611">493,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZToxNTc1ZmI1NjlkOGI0MDM2OGMzNGJmNGQ1NDVlODkyOS90YWJsZXJhbmdlOjE1NzVmYjU2OWQ4YjQwMzY4YzM0YmY0ZDU0NWU4OTI5XzMtMS0xLTEtMA_fb84838d-b74d-4bf4-9a30-d68dcee388c9">276,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZToxNTc1ZmI1NjlkOGI0MDM2OGMzNGJmNGQ1NDVlODkyOS90YWJsZXJhbmdlOjE1NzVmYjU2OWQ4YjQwMzY4YzM0YmY0ZDU0NWU4OTI5XzQtMS0xLTEtMA_7cbea71d-4c8b-4bc2-9206-f2fce0f612e0">253,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZToxNTc1ZmI1NjlkOGI0MDM2OGMzNGJmNGQ1NDVlODkyOS90YWJsZXJhbmdlOjE1NzVmYjU2OWQ4YjQwMzY4YzM0YmY0ZDU0NWU4OTI5XzUtMS0xLTEtMA_8abd8ac9-5d06-4b07-9dba-9def76d78be7">253,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZToxNTc1ZmI1NjlkOGI0MDM2OGMzNGJmNGQ1NDVlODkyOS90YWJsZXJhbmdlOjE1NzVmYjU2OWQ4YjQwMzY4YzM0YmY0ZDU0NWU4OTI5XzYtMS0xLTEtMA_aec9ef94-fcf8-4717-9291-6b43d51f2ac1">1,351,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZToxNTc1ZmI1NjlkOGI0MDM2OGMzNGJmNGQ1NDVlODkyOS90YWJsZXJhbmdlOjE1NzVmYjU2OWQ4YjQwMzY4YzM0YmY0ZDU0NWU4OTI5XzctMS0xLTEtMA_b5a376be-a10e-4efc-86d2-722debb64a0e">3,147,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90ZXh0cmVnaW9uOmNkMTQ3YTE4ZTI4ZjRhMzRiNzBlMmQxMjhlYTcyN2ZkXzkyOA_3242a3fc-1a1e-41fc-aeaf-247eb8b67b12"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90ZXh0cmVnaW9uOmNkMTQ3YTE4ZTI4ZjRhMzRiNzBlMmQxMjhlYTcyN2ZkXzkyOA_6a4e7e3e-63e1-4d7c-97c1-c6eabd562991"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90ZXh0cmVnaW9uOmNkMTQ3YTE4ZTI4ZjRhMzRiNzBlMmQxMjhlYTcyN2ZkXzkyOA_fa2f692c-2e8e-40cd-87a5-f5fe8bf3987e">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment or impairment indicators present and no losses were recorded during the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_175"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE1NTQw_bb99a0c7-eb7c-40e7-bd86-72567108d0d1" continuedAt="icbf396396be3471dae2183a28c2a69a5" escape="true">Convertible Debt</ix:nonNumeric></span></div><div style="text-indent:27pt"><span><br/></span></div><ix:continuation id="icbf396396be3471dae2183a28c2a69a5" continuedAt="ifb10e8c5bcdd497e8c594007d58cda35"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="i7ab95ac0698643e2a24b4f704858ab14_I20190301" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzEzOA_ccf073d8-db67-4f6b-b8b9-e27856b6e6eb">78.5</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i7ab95ac0698643e2a24b4f704858ab14_I20190301" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE3NQ_d7f29f48-80b9-4e26-822f-584ae6e7d84c">6.50</ix:nonFraction>% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="iaa895d662b3145c5a41a31d0ed8415b0_D20190219-20190301" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQyMQ_56d1ca42-734e-4236-b43d-2d394e82360b">75.7</ix:nonFraction> million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of <ix:nonFraction unitRef="number" contextRef="i7ab95ac0698643e2a24b4f704858ab14_I20190301" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzYzMA_102a9ee9-1e98-46c1-855f-3b9df1702f98">6.50</ix:nonFraction>% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifb10e8c5bcdd497e8c594007d58cda35" continuedAt="id4a522250758424cb531764bfe51518a"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate will be 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE0MzI_7a91c3e9-5194-41d6-a367-ad7a72bc107b">5.38</ix:nonFraction> per share), subject to adjustment upon the occurrence of specified events.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the Notes prior to March 1, 2022. On or after March 1, 2022, the Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds <ix:nonFraction unitRef="number" contextRef="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE3NDQ_24feeb97-3cef-48d7-9ccb-0dc178b7f642">130</ix:nonFraction>% of the conversion price on (i) each of at least <ix:nonFraction unitRef="day" contextRef="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE3OTU_9dfdabb6-7bb8-47b7-8453-e30492f2cecf">20</ix:nonFraction> trading days (whether or not consecutive) during the <ix:nonFraction unitRef="day" contextRef="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE4NTE_eb480205-4a25-4704-b085-bb707067c497">30</ix:nonFraction> consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to <ix:nonFraction unitRef="number" contextRef="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzIxMjI_88778a6c-f03d-4d19-80a4-358bc4fccd60">100</ix:nonFraction>% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet, and that the cash conversion guidance applies. Therefore, the Notes issuance proceeds of $<ix:nonFraction unitRef="usd" contextRef="i7ab95ac0698643e2a24b4f704858ab14_I20190301" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzI2NTE_36bafe7f-288c-4560-bd9d-0cc4cd74228e">78.5</ix:nonFraction> million are allocated first to the liability component based on the fair value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion features. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was $<ix:nonFraction unitRef="usd" contextRef="i7ab95ac0698643e2a24b4f704858ab14_I20190301" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzI5Njc_cc025620-2ea9-459f-b8d5-1422a5a02a2a">62.2</ix:nonFraction> million and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of $<ix:nonFraction unitRef="usd" contextRef="i7ab95ac0698643e2a24b4f704858ab14_I20190301" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzMxNzk_51bb2e85-c7ab-4cf5-abdb-714ba66eb71e">2.8</ix:nonFraction> million are allocated to the liability and equity component in the same proportion as the issuance proceeds. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $<ix:nonFraction unitRef="usd" contextRef="i7ab95ac0698643e2a24b4f704858ab14_I20190301" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1Mjc0Mzc_b96bb55b-3be4-48e6-b3bc-60a744fef2d2">18.6</ix:nonFraction> million, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is <ix:nonFraction unitRef="number" contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1Mjc2Njg_87c0b85e-33b0-446f-9e00-24be4c4a1eb5">13.1</ix:nonFraction>%.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2020, the Company received notices for the conversion of $<ix:nonFraction unitRef="usd" contextRef="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzMyOTg1MzQ5MDkzNzI_0ffc4a75-32b8-401b-ac45-85ea974259b6">62.1</ix:nonFraction>&#160;million of principal amount of the Notes, which were settled into an aggregate of <ix:nonFraction unitRef="shares" contextRef="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzMyOTg1MzQ5MDkzODk_ca9c0819-8cd9-431d-956b-978a26daa3f0">11,535,660</ix:nonFraction> shares of the Company's common stock. The fair value of the Notes at the date of conversion was $<ix:nonFraction unitRef="usd" contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzcxODU_ed4a3fc6-0e86-4c0f-b730-286d7acfa318">43.7</ix:nonFraction>&#160;million compared to the carrying value of $<ix:nonFraction unitRef="usd" contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzczMjg_aee2a2f7-4084-4c66-8b83-bb818ab790d0">52.5</ix:nonFraction>&#160;million, resulting in a $<ix:nonFraction unitRef="usd" contextRef="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzcyNTQ_e1c7cdbd-6991-4ee2-b894-30ec5a78fe63">8.8</ix:nonFraction>&#160;million gain on extinguishment of debt. Thi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">s gain was recorded in the consolidated statement of operations. To measure the fair value of the converted Notes as of the conversion dates, the Company engaged a third-party valuation expert and utilized a binomial lattice model.</span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE1NTQx_48a5f88c-a1b8-4df2-972e-82830cb37865" continuedAt="i67efeb9b91b14db992253a6aeb3c61e5" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at December&#160;31, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a2b66e18d454ede830f8d1d4aada02f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo0NmFjNjBkMzcwNjU0MTM2YTU4OTJlMDQxOTVlYTI2NC90YWJsZXJhbmdlOjQ2YWM2MGQzNzA2NTQxMzZhNTg5MmUwNDE5NWVhMjY0XzAtMS0xLTEtMA_d3b6757e-01ea-4643-8c49-c604b6378823">78,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a2b66e18d454ede830f8d1d4aada02f_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:DebtInstrumentConvertibleDebtConvertedAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo0NmFjNjBkMzcwNjU0MTM2YTU4OTJlMDQxOTVlYTI2NC90YWJsZXJhbmdlOjQ2YWM2MGQzNzA2NTQxMzZhNTg5MmUwNDE5NWVhMjY0XzEtMS0xLTEtMzY0OA_4efb5cb1-21fc-4ba3-a3fa-61ccbbe984eb">62,085,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount on the liability component</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a2b66e18d454ede830f8d1d4aada02f_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo0NmFjNjBkMzcwNjU0MTM2YTU4OTJlMDQxOTVlYTI2NC90YWJsZXJhbmdlOjQ2YWM2MGQzNzA2NTQxMzZhNTg5MmUwNDE5NWVhMjY0XzEtMS0xLTEtMA_f29f4212-966a-46d2-aad5-0b3837ae8b86">2,312,404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a2b66e18d454ede830f8d1d4aada02f_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo0NmFjNjBkMzcwNjU0MTM2YTU4OTJlMDQxOTVlYTI2NC90YWJsZXJhbmdlOjQ2YWM2MGQzNzA2NTQxMzZhNTg5MmUwNDE5NWVhMjY0XzItMS0xLTEtMA_6c1e0f75-17f9-4311-a533-31a7d2e18a13">318,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a2b66e18d454ede830f8d1d4aada02f_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:DebtinstrumentAccruedInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo0NmFjNjBkMzcwNjU0MTM2YTU4OTJlMDQxOTVlYTI2NC90YWJsZXJhbmdlOjQ2YWM2MGQzNzA2NTQxMzZhNTg5MmUwNDE5NWVhMjY0XzMtMS0xLTEtMA_9fe3944f-8e32-495a-84f7-8d4044afc341">355,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a2b66e18d454ede830f8d1d4aada02f_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo0NmFjNjBkMzcwNjU0MTM2YTU4OTJlMDQxOTVlYTI2NC90YWJsZXJhbmdlOjQ2YWM2MGQzNzA2NTQxMzZhNTg5MmUwNDE5NWVhMjY0XzQtMS0xLTEtMA_d1d05db1-2f2f-456a-a083-ba19c403543b">14,139,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020 and 2019,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQxNjM_68408ea3-3215-4ddd-9230-1fbc42c0cafe">6.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie36d4982a87c49f39d1d799e83d16f3d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MjkzMjM_0509dc4e-c0ca-4181-9b61-abfa161c1d2a">7.0</ix:nonFraction>&#160;million, respectively, of interest expense related to the Notes, of which $<ix:nonFraction unitRef="usd" contextRef="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQyMTc_71497464-2732-469f-9c70-137722f400f7">4.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie36d4982a87c49f39d1d799e83d16f3d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MjkyNjg_d1e298f3-c8aa-42df-b2fb-f5458eb13b0e">4.4</ix:nonFraction>&#160;million, respectively, related to the contractual interest coupon. </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">August 2019 Convertible Bonds </span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2019, the Company closed a private placement of the August 2019 Bonds with an aggregate principal amount of <ix:nonFraction unitRef="krw" contextRef="i1ef0a0da5279497abe1189b528c9b923_I20190801" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQ0OTI_7e624bab-cead-4bae-800f-6c8978398eab">18</ix:nonFraction> billion KRW (approximately USD $<ix:nonFraction unitRef="usd" contextRef="i1ef0a0da5279497abe1189b528c9b923_I20190801" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQ1MzE_e6bf8401-882f-44b8-a49b-0244e5ab7840">15.0</ix:nonFraction> million based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="ie42755ee382b4362b35b654a372750a0_D20190801-20190801" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQ3ODI_f8057fed-f63c-46ac-8bea-ad971ea3d94e">14.5</ix:nonFraction> million. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2019 Bonds, which are unsecured obligations of the Company, were issued on August 1, 2019 and accrued interest at a coupon rate of <ix:nonFraction unitRef="number" contextRef="i1ef0a0da5279497abe1189b528c9b923_I20190801" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzUxNDc_790da17e-78cd-48a1-b000-d7de273e6df5">1.00</ix:nonFraction>% per annum, payable quarterly. The August 2019 Bonds were scheduled to mature on July 31, 2024, unless earlier converted or repurchased. On August 3, 2020 the August 2019 Bonds were converted in full into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i9081e6bad5e84753997332afda1396e2_D20200803-20200803" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzAyMzc_287ae931-d955-4f59-9323-bd562783e5bd">4,962,364</ix:nonFraction> shares of the Company's common stock, leaving no further August 2019 Bonds outstanding. The initial </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id4a522250758424cb531764bfe51518a" continuedAt="i2c999b78301343838b46bc19e8a81953"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conversion rate was 211.0595 shares per KRW1,000,000 in principal amount (equivalent to an initial conversion price of approximately USD $<ix:nonFraction unitRef="usdPerShare" contextRef="i1b97fc9dbea24d1a8c1cc2caf0be1794_I20200803" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzYwNDY_d31cbe2b-d32d-4f0b-8b3e-28f9f0d81c06">4.00</ix:nonFraction> per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate was reset on January 2, 2020 and was subject to reset quarterly thereafter if the current market price was lower than the conversion price then in effect. The conversion rate as of the date of conversion on August 1, 2020 was 275.6873 shares per KRW1,000,000 in principal amount (equivalent to a conversion price of approximately USD $<ix:nonFraction unitRef="usdPerShare" contextRef="i3e5cc4151269456bb11f37ef3096b655_I20200803" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzEwMzg_26bbdeac-69f7-4fd1-97f7-f92990adca8f">3.14</ix:nonFraction> per share). </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature was considered a derivative requiring bifurcation from the August 2019 Bonds as it did not meet the equity scope exception due to the fact that it was denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was $<ix:nonFraction unitRef="usd" contextRef="i1ef0a0da5279497abe1189b528c9b923_I20190801" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzgwOTg_f3401595-98ce-4955-8c06-853d335aa683">7.1</ix:nonFraction> million, which was recorded as a reduction to the carrying value of the debt. This debt discount was being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option was accounted for as a derivative liability, which was revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the consolidated&#160;statements of operations.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At their issuance, the Company determined that the expected life of the August 2019 Bonds was equal to the period through August 1, 2022 as this represented the point at which the August 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $<ix:nonFraction unitRef="usd" contextRef="i1ef0a0da5279497abe1189b528c9b923_I20190801" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzkxNzM_67afd868-8499-4151-b372-c8eaadeeae79">7.3</ix:nonFraction> million, inclusive of the fair value of the embedded conversion feature derivative at issuance, was being amortized using the effective interest method through August 1, 2022. For the years ended December&#160;31, 2020 and 2019,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i4b884d1d8cee4549b13c04c430171c0d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzk0NDk_98139c41-841d-4c06-a536-6793c6a2bca4">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i340206d59d1a4f37a0d265ecd256f49a_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzgyNDYzMzcyMzQ2MTI_51bbd66e-685d-410b-b0aa-41a55ed74642">982,000</ix:nonFraction>, respectively, of interest expense related to the August 2019 Bonds, of which $<ix:nonFraction unitRef="usd" contextRef="i4b884d1d8cee4549b13c04c430171c0d_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzk1MTU_3bd79d22-2f78-4e59-ac1f-91ba93b5d142">87,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i340206d59d1a4f37a0d265ecd256f49a_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzIyNzg_f133954a-e896-4c7c-8ab8-35405540294f">65,000</ix:nonFraction>, respectively, related to the contractual interest coupon. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, all outstanding August 2019 Bonds were converted into common stock. Immediately prior to the conversion, the derivative liability was revalued at $<ix:nonFraction unitRef="usd" contextRef="i68fab246bae941029c1bb3eb8d3d4400_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzQ4MDc_691612e4-033f-4508-9561-746e21685212">84.5</ix:nonFraction>&#160;million. The change in fair value of the derivative liability was an increase of $<ix:nonFraction unitRef="usd" contextRef="i8b9a6b9c0fba4da0a1e8ad1ae9afb802_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzQ4MjI_5f0d628b-8913-43c7-abc2-dc27ee44b68e">75.7</ix:nonFraction>&#160;million, which was recorded on the consolidated statement of operations. To measure the fair value of the derivative liability as of the conversion date, the Company engaged a third-party valuation expert.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, a loss on extinguishment of $<ix:nonFraction unitRef="usd" contextRef="i8b9a6b9c0fba4da0a1e8ad1ae9afb802_D20200801-20200831" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzQ4Mzc_2d66d928-9a27-46ab-bddf-770c7329df31">8.2</ix:nonFraction>&#160;million was recorded on the consolidated statement of operations. This loss represents the difference between (a) the calculated fair value of the derivative liability immediately prior to its derecognition plus the carrying amount of the debt component including any unamortized debt discount and issuance costs and (b) the fair value of the <ix:nonFraction unitRef="shares" contextRef="i8b9a6b9c0fba4da0a1e8ad1ae9afb802_D20200801-20200831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzQ4NTE_0a5f61f5-5a85-4c37-aa73-5d76d12a3dcc">4,692,364</ix:nonFraction> shares of the Company's common stock issued upon conversion.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Convertible Bonds </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#8220;December 2019 Bonds&#8221;) with an aggregate principal amount of <ix:nonFraction unitRef="krw" contextRef="i01aabdcf7e1946cfad86edb560658159_I20191226" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzk5Nzk_6ecae8c1-57b9-4232-83c9-bc9ab1e4995f">4.7</ix:nonFraction> billion KRW (approximately USD $<ix:nonFraction unitRef="usd" contextRef="i01aabdcf7e1946cfad86edb560658159_I20191226" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzEwMDA1_bac0e217-9b9f-4b3c-a990-29fff8370b32">4.1</ix:nonFraction> million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="icec95e1e34f940efa96dfde18a03f4f4_D20191226-20191226" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzEwMTU4_2128c2b7-2ddc-4c9e-950d-6a046c64b679">4.0</ix:nonFraction> million.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Bonds, which are unsecured obligations of the Company, were issued on December&#160;31, 2019 and will accrue interest at a coupon rate of <ix:nonFraction unitRef="number" contextRef="i01aabdcf7e1946cfad86edb560658159_I20191226" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzEwMzE1_1cb1f8fe-d75a-41f8-9993-72ab25f31d03">1.00</ix:nonFraction>% per annum, payable quarterly. The December 2019 Bonds will mature on December&#160;31, 2024, unless earlier converted or repurchased. The outstanding December 2019 Bonds will be repaid at maturity at a price equal to the principal of the outstanding bonds to be repaid plus a premium on such bonds to provide an internal rate of return with respect to such bonds of <ix:nonFraction unitRef="number" contextRef="i01aabdcf7e1946cfad86edb560658159_I20191226" decimals="INF" name="ino:DebtInstrumentConvertibleInternalRateOfReturn" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzEwNjc5_9df13a45-16e4-4a2a-af50-5ef663040fc1">6.00</ix:nonFraction>%. Commencing on December&#160;31, 2020, the December 2019 Bonds are convertible until the date that is one month prior to maturity date. Upon conversion, the Company will deliver shares of common stock of the Company. The initial conversion rate was 214.7766 shares per KRW1,000,000 principal amount of Bonds (equivalent to an initial conversion price of approximately USD $<ix:nonFraction unitRef="usdPerShare" contextRef="i700bda11831d4df3889dde4f49d91305_I20191226" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzExMTM3_fba6ae12-6ad8-4e33-816d-bdcddf5d334a">4.00</ix:nonFraction> per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. The conversion rate was subject to reset on July&#160;2, 2020 and on each three month anniversary thereafter until the maturity date to the then current market price if the current market price is lower than the conversion price then in effect; provided that the conversion rate will not exceed 357.9611 shares per KRW1,000,000 (equivalent to a conversion price of approximately USD $<ix:nonFraction unitRef="usdPerShare" contextRef="i8b023471d6394305b1996c77b2d112da_I20191226" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzExNjM2_4baa958d-1de5-4001-bb99-a4ef480e974b">2.40</ix:nonFraction> per share based on the exchange rate as of December&#160;19, 2019). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion rate has not been reset as of December&#160;31, 2020 from the initial conversion rate.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Bonds will be subject to repurchase by the Company at the option of the bondholders from and including December&#160;31, 2022 up to the date that is one month prior to the maturity date at a repurchase price equal to the principal of the December 2019 Bonds to be repurchased plus a premium on the Bonds in order to ensure an internal rate of return with respect to the Bonds equal to <ix:nonFraction unitRef="number" contextRef="i01aabdcf7e1946cfad86edb560658159_I20191226" decimals="INF" name="ino:DebtInstrumentConvertibleInternalRateOfReturn" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzEyMTAw_9d1e2404-900d-48eb-a8a9-d450d0e091cf">6.00</ix:nonFraction>%. In addition, upon the occurrence of a fundamental change (as defined in the Subscription Agreement) the Company will be required to offer to repurchase the Bonds at a repurchase price equal to the principal amount thereof plus accrued and unpaid interest thereon to but excluding the applicable repurchase date. If certain </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2c999b78301343838b46bc19e8a81953" continuedAt="i112b99766cc244a8942d12047e997236"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bankruptcy and insolvency-related events of default occur, the principal of, and accrued and unpaid interest on, all of the then outstanding December 2019 Bonds shall automatically become due and payable. If any other event of default occurs and is continuing, the holders of at least <ix:nonFraction unitRef="number" contextRef="icec95e1e34f940efa96dfde18a03f4f4_D20191226-20191226" decimals="INF" name="ino:DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzEyNzEy_310a6e52-2ec5-48fe-86b5-7c2a3fb50fa4">25</ix:nonFraction>% of the in aggregate principal amount of the December 2019 Bonds by notice to the Company may declare the principal of, and accrued and unpaid interest on, all of the then-outstanding December 2019 Bonds to be due and payable.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature does not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature meets the definition of a derivative, it qualifies for the equity scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet. The December 2019 Bonds are denominated in a foreign currency other than the Company&#8217;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#8217;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario is fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency does not impact the settlement of the conversion option. Further, as there is no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.</span></div><ix:continuation id="i67efeb9b91b14db992253a6aeb3c61e5"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the December 2019 Bonds at December&#160;31, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90a70ccee3354926b91c35b43f4f36de_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo4MTFhOTFjYTliMjY0YzE5OGIwNmQ5NmIxOTU3NDVjMi90YWJsZXJhbmdlOjgxMWE5MWNhOWIyNjRjMTk4YjA2ZDk2YjE5NTc0NWMyXzAtMS0xLTEtMA_4e57cf54-a89e-435f-be1f-966e881e0500">4,327,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90a70ccee3354926b91c35b43f4f36de_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo4MTFhOTFjYTliMjY0YzE5OGIwNmQ5NmIxOTU3NDVjMi90YWJsZXJhbmdlOjgxMWE5MWNhOWIyNjRjMTk4YjA2ZDk2YjE5NTc0NWMyXzItMS0xLTEtMA_db9a6d03-f6a3-4778-9916-155c42867071">36,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of premium associated with the December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90a70ccee3354926b91c35b43f4f36de_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:DebtInstrumentAccretionOfPremium" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo4MTFhOTFjYTliMjY0YzE5OGIwNmQ5NmIxOTU3NDVjMi90YWJsZXJhbmdlOjgxMWE5MWNhOWIyNjRjMTk4YjA2ZDk2YjE5NTc0NWMyXzMtMS0xLTEtMA_c9150370-f641-4de8-8185-8b4dff907a03">214,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90a70ccee3354926b91c35b43f4f36de_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:DebtinstrumentAccruedInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo4MTFhOTFjYTliMjY0YzE5OGIwNmQ5NmIxOTU3NDVjMi90YWJsZXJhbmdlOjgxMWE5MWNhOWIyNjRjMTk4YjA2ZDk2YjE5NTc0NWMyXzQtMS0xLTEtMA_bd08af65-8c8e-41ee-ae41-1774f329d853">10,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90a70ccee3354926b91c35b43f4f36de_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo4MTFhOTFjYTliMjY0YzE5OGIwNmQ5NmIxOTU3NDVjMi90YWJsZXJhbmdlOjgxMWE5MWNhOWIyNjRjMTk4YjA2ZDk2YjE5NTc0NWMyXzUtMS0xLTEtMA_61e68721-5dcd-4895-b975-9e03ac6765c8">4,515,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the expected life of the December 2019 Bonds was equal to the period through December 31, 2022 as this represents the point at which the December 2019 Bonds are initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds is <ix:nonFraction unitRef="number" contextRef="ifbed9e38f9f44e17bc3443f38555ff5b_I20201231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE0ODIz_1a86e559-c3af-4b69-a8e9-de12a44e7a25">6.2</ix:nonFraction>%. For the year ended December&#160;31, 2020,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i4d6e94e1cacc426ebf7ec4cb5e51ff53_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzUxMDM_55b306b3-52b6-4b73-8b50-48421e28f374">253,000</ix:nonFraction> of interest expense related to the December 2019 Bonds, of which $<ix:nonFraction unitRef="usd" contextRef="i4d6e94e1cacc426ebf7ec4cb5e51ff53_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzUxMDc_6efbf5b1-f45d-4e42-b151-dbc79e639f6b">40,000</ix:nonFraction> related to the contractual interest coupon. As of December&#160;31, 2020, there have not been any conversions or redemptions of the December 2019 Bonds.</span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE1NTQ0_71041647-1fb6-419e-9efc-0c82c5d926b2" continuedAt="i8749687890a14ebca2178fc47f780282" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, future minimum payments due under the Company's convertible debt instruments are as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible Notes (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 2019 Bonds (2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzItMi0xLTEtMA_3756bb63-5fe2-4aca-9759-47097b3f1090">1,067,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbed9e38f9f44e17bc3443f38555ff5b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzItNi0xLTEtMA_d52a5ce8-4d2b-4f75-ba9e-97bc0ffdb976">43,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic594f80a76ff4858a3452511b0ae1fad_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzItOC0xLTEtMA_3b2a1343-7a33-4891-8219-6a30e14ad6e9">1,110,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzMtMi0xLTEtMA_19856807-95df-45ab-a682-a24485fa55d1">1,067,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbed9e38f9f44e17bc3443f38555ff5b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzMtNi0xLTEtMA_427b7057-2b3a-4326-822e-66162cb06fff">43,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic594f80a76ff4858a3452511b0ae1fad_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzMtOC0xLTEtMA_eaf3dee7-b764-4fe8-aa48-1ff7aee8da3d">1,110,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzQtMi0xLTEtMA_8dfdc255-5ec9-46fb-a282-b360af1e928a">1,067,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbed9e38f9f44e17bc3443f38555ff5b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzQtNi0xLTEtMA_ddbb4315-0133-4790-8dfe-f92ef40d85c9">44,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic594f80a76ff4858a3452511b0ae1fad_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzQtOC0xLTEtMA_ad40ff88-edb3-4815-8d53-1bf23c885e49">1,111,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzUtMi0xLTEtMA_993e8b8a-68f4-4b8c-b132-08111946a330">16,948,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbed9e38f9f44e17bc3443f38555ff5b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzUtNi0xLTEtMA_8481eeea-54ee-4d23-b6b9-dd6e15ed2597">5,571,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic594f80a76ff4858a3452511b0ae1fad_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzUtOC0xLTEtMA_341ed811-2912-4e45-b401-591cc7764be0">22,519,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzctMi0xLTEtMA_3c1ecde7-fc42-4bf4-9c16-f36b7a1b5204">20,149,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbed9e38f9f44e17bc3443f38555ff5b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzctNi0xLTEtMA_6bab3dbb-34ec-4b7c-bd40-3a67e780e5b3">5,701,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic594f80a76ff4858a3452511b0ae1fad_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzctOC0xLTEtMA_5ce15392-0d29-4243-aebd-b37d955d8722">25,850,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of <ix:nonFraction unitRef="number" contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE1MjYy_33feab5d-442b-4681-a963-133b751b8a43">6.5</ix:nonFraction>% per year. </span></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i112b99766cc244a8942d12047e997236"><ix:continuation id="i8749687890a14ebca2178fc47f780282">(2) Amounts represent amounts due under the December 2019 Bonds, including interest based on the fixed rate of <ix:nonFraction unitRef="number" contextRef="i450df2d2eb374134a57819c4d3d41137_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE1NDE1_876f9f3d-d3b5-493a-8370-c7922fdeb791">1</ix:nonFraction>% per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of <ix:nonFraction unitRef="number" contextRef="i450df2d2eb374134a57819c4d3d41137_I20201231" decimals="INF" name="ino:DebtInstrumentConvertibleInternalRateOfReturn" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE1NTI0_9d03d473-537a-496b-a0bb-4a85591e403c">6</ix:nonFraction>% at maturity.</ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_181"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90ZXh0cmVnaW9uOmZjODNiOWQ0OTgzMDRiYzRhOGRkODVlNzgyY2E4NTk1XzE1MQ_f7f84081-ef60-4c00-9a58-96485e96c298" continuedAt="id27cf226843d48db90a0c8bfd1ecfff0" escape="true">Accounts Payable and Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="id27cf226843d48db90a0c8bfd1ecfff0" continuedAt="i1c0debeabecd4e51a216565a990c6014"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90ZXh0cmVnaW9uOmZjODNiOWQ0OTgzMDRiYzRhOGRkODVlNzgyY2E4NTk1XzE1Mw_ed531f08-b28b-4db4-b98a-07b33417c1f3" continuedAt="ia5e58d1e84f742b4bef64f0a415bb7c0" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses at December&#160;31, 2020 and 2019 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i1c0debeabecd4e51a216565a990c6014"><ix:continuation id="ia5e58d1e84f742b4bef64f0a415bb7c0"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzItMS0xLTEtMA_a6a06c93-8a5c-47c1-9a5b-4ca315e1d76d">825,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzItMy0xLTEtMA_a636a469-db4e-4b6c-9ef7-dfe271283e9f">6,919,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzMtMS0xLTEtMA_ec116b5f-a381-40ce-aba5-0481209f1fcc">13,127,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzMtMy0xLTEtMA_07230dfa-f450-4ff4-a491-08abec062a88">8,967,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued subcontract costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:AccruedSubcontractExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzQtMS0xLTEtMA_e2b4cd40-aad7-4247-a103-9b8e1e9a680e">247,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="ino:AccruedSubcontractExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzQtMy0xLTEtMA_902b91c4-0eeb-4a41-a8b9-26c8b6717c12">273,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzYtMS0xLTEtMA_d6cd0c12-a719-4da1-bb6c-5f530836a3ab">7,003,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzYtMy0xLTEtMA_c27a06ab-6ed7-40da-934e-d12bb7878a80">2,076,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzExLTEtMS0xLTA_13152d70-fc63-40ce-b0ce-0a5d90027ce6">21,203,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzExLTMtMS0xLTA_88df34d0-0719-475c-8369-e2c70c167c1b">18,237,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_184"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzNTY2_a72eff60-8af9-41c7-be19-8dac394520f9" continuedAt="i7541060f69f64440930e3a9c1f8b04ee" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><div style="margin-top:3pt"><span><br/></span></div><ix:continuation id="i7541060f69f64440930e3a9c1f8b04ee" continuedAt="i6396b96a926d4f9fbf7a20e5830a728f"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzNTc5_4165421f-0750-4007-bf03-d29974c93a0c" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:47.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Outstanding as of<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par $<ix:nonFraction unitRef="usdPerShare" contextRef="i43ff85947d654cd3b9d8600362c08d4e_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTphMWE1NjkyZjliMDc0YzQ3YTExM2M0ZjJkNTdhMTQwNy90YWJsZXJhbmdlOmExYTU2OTJmOWIwNzRjNDdhMTEzYzRmMmQ1N2ExNDA3XzQtMC0xLTEtNjY4MC90ZXh0cmVnaW9uOmM2ZGQ5NDMzYTAzMzQ3MjFhMTk3YTE1MjhmMTlmYzVhXzY1OTcwNjk3NjY3MDI_63e5982f-e633-430e-a1da-8a4773339730">0.001</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43ff85947d654cd3b9d8600362c08d4e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTphMWE1NjkyZjliMDc0YzQ3YTExM2M0ZjJkNTdhMTQwNy90YWJsZXJhbmdlOmExYTU2OTJmOWIwNzRjNDdhMTEzYzRmMmQ1N2ExNDA3XzQtMS0xLTEtMA_eda4772a-0b59-490e-8637-57a81601f4e6">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43ff85947d654cd3b9d8600362c08d4e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTphMWE1NjkyZjliMDc0YzQ3YTExM2M0ZjJkNTdhMTQwNy90YWJsZXJhbmdlOmExYTU2OTJmOWIwNzRjNDdhMTEzYzRmMmQ1N2ExNDA3XzQtMy0xLTEtMA_47ae25b1-404b-43e2-8c61-7a20d0ddba21">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43ff85947d654cd3b9d8600362c08d4e_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTphMWE1NjkyZjliMDc0YzQ3YTExM2M0ZjJkNTdhMTQwNy90YWJsZXJhbmdlOmExYTU2OTJmOWIwNzRjNDdhMTEzYzRmMmQ1N2ExNDA3XzQtNS0xLTEtMA_873cbfaf-f8d5-4b72-82e2-b5ce23041002">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d422727fda34bcea389c96828efbd6f_I20191231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTphMWE1NjkyZjliMDc0YzQ3YTExM2M0ZjJkNTdhMTQwNy90YWJsZXJhbmdlOmExYTU2OTJmOWIwNzRjNDdhMTEzYzRmMmQ1N2ExNDA3XzQtNy0xLTEtMA_317b02f8-f9a3-44b7-8aa8-129021b29ea3">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, <ix:nonFraction unitRef="shares" contextRef="idf338a94fd4b4eceba8d37e44eab78f0_D20200601-20200630" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1MjQ4ODU_74a362e6-ebf1-476b-8daa-fb62a10b8433">14</ix:nonFraction> shares of the Company&#8217;s Series&#160;C preferred stock were converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i9ea987ce83ae454ba3d280374d688b3a_D20200601-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1MjQ4ODk_a264c4e4-6110-4268-a51d-36a687823ee6">5,147</ix:nonFraction> shares of the Company&#8217;s common stock.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The holder of any share or shares of Series C Preferred Stock has the right at any time, at such holder&#8217;s option, to convert all or any lesser portion of such holder&#8217;s shares of the Preferred Stock into fully paid and non-assessable shares of Common Stock. As of December 31, 2020, the Conversion Value w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as $<ix:nonFraction unitRef="usdPerShare" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="2" name="ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzMyOTg1MzQ5MDk2Mzg_dbf28b6f-fb99-4b55-a76a-7a7d123bf61b">27.20</ix:nonFraction> per share, such</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> that the outstanding shares of Series C Preferred Stock were convertible into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i43ff85947d654cd3b9d8600362c08d4e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzMyOTg1MzQ5MDk2NDY_54da81c4-757c-4f5b-8810-8e7ddc465e86">3,309</ix:nonFraction> shares of common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company entered into the Sales Agreement with an outside placement agent (the &#8220;Placement Agent&#8221;) to sell shares of its common stock w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ith aggregate gross proceeds of up to $<ix:nonFraction unitRef="usd" contextRef="i8846f56dce3d432d966649b28efa7c9a_D20180501-20180531" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSalesAgreementMaximumAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzUxNjg_abc4c7ae-048f-4cd4-9058-f0bc8e1478bb">100.0</ix:nonFraction> million, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent will act as sales agent. During the first quarter of 2020, the Company and the Placement Agent entered into a first and second amendment to the Sales Agreement (the "Prior Sales Agreement") to increase the amount of common stock that may be sold under the Sales Agreement from $<ix:nonFraction unitRef="usd" contextRef="i8846f56dce3d432d966649b28efa7c9a_D20180501-20180531" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSalesAgreementMaximumAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1MjU4NzE_15046048-4ecf-4bd3-a61b-e4325f1b0901">100.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="ia01d038a4d224f74b7cec88d7ab01932_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSalesAgreementMaximumAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1MjU4ODc_58487ff6-eeb8-4b66-90e5-c6df83e20631">250.0</ix:nonFraction>&#160;million. As of March 31, 2020, there was <ix:nonFraction unitRef="usd" contextRef="i02e208f208514fac82fa7b99a461039a_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="ino:StockSalesAgreementRemainingAuthorizedAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzgyNDYzMzcyMzQwMjc_dbec97cd-f8f1-4899-9481-5ef5265c8d9c">no</ix:nonFraction> remaining capacity under the Prior Sales Agreement. On April 3, 2020, the Company and the Placement Agent entered into a new Sales Agreement (the "New Sales Agreement") to sell shares of its common stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2020 and May 12, 2020, the Company filed prospectus supplements pursuant to the New Sales Agreement for the offer and sale of its Common Stock for aggregate gross proceeds of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i5ae124c42b254d14b9b5f269fd7419ce_D20200403-20200512" decimals="-5" format="ixt:numdotdecimal" name="ino:StockSalesAgreementMaximumAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzgyNDYzMzcyMzQwNDU_68f79fda-87e5-4168-8b83-130083c15d45">250.0</ix:nonFraction>&#160;million. Under the New Sales Agreement, the Company will set the parameters for the sale of shares, inclu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ding the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The New Sales Agreement provides that the Placement Agent will be entitled to compensation for its services in an amount equal to up to <ix:nonFraction unitRef="number" contextRef="i2b37597d28484e31879b4ec99d19767b_D20180501-20180531" decimals="3" name="ino:StockSalesAgreementAgentFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzU3NTY_cb5cd605-48ab-4d3f-a14d-7feaff618e98">3.0</ix:nonFraction>% of the gross proceeds from the sales of shares sold through the Placement Agent under the New Sales Agreement. The Company has no obligation to sell any shares under the New Sales Agreement, and could at any time suspend solicitation and offers under the New Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i64aec48d41f548978f711e0981b117a9_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1Mjc3MjQ_eb73d5da-f67a-4c83-b5b6-553aba7a87da">43,148,952</ix:nonFraction> shares of its common stock under the Prior Sales Agreement. The sales were made at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i02e208f208514fac82fa7b99a461039a_I20200331" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1Mjc3MzY_48373b92-c75c-4d30-8052-2e84b3efa88d">4.92</ix:nonFraction> per share, resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i64aec48d41f548978f711e0981b117a9_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1Mjc3NDM_435d3e94-ff38-4b63-ab63-0cc463aafdb2">208.2</ix:nonFraction>&#160;million. As of March 31, 2020, there was <ix:nonFraction unitRef="usd" contextRef="i0a9f7074a224430daf98266033b9e313_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="ino:StockSalesAgreementRemainingAuthorizedAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1Mjc3NTg_c4522acb-1bf7-4170-b9ba-395420b0e047">no</ix:nonFraction> remaining capacity under the Prior Sales Agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company sold a total of <ix:nonFraction unitRef="shares" contextRef="i00014904fa624256a7ae429094225ce3_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzYwNzU_b167682e-803e-45a8-812b-7c36ae9a8759">22,915,934</ix:nonFraction> shares of common stock under the New</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement. The sales were made at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie326789176224a66adc6eb18840f7e83_I20201231" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzYxNzk_0f4afd2b-b915-4f74-8761-9539df98c6a5">10.91</ix:nonFraction> per share resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i00014904fa624256a7ae429094225ce3_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzYyMzE_1da7661c-58af-4093-b49a-e3c93dcc425e">246.2</ix:nonFraction> million. As of December&#160;31, 2020, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie326789176224a66adc6eb18840f7e83_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="ino:StockSalesAgreementRemainingAuthorizedAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzY1OTcwNjk3OTI0OTQ_2bcb97c1-0b16-4746-ba2d-f51c5cf5d6be">no</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> remaining capacity under the New Sales Agreement.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. The maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the 2016 Incentive Plan </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6396b96a926d4f9fbf7a20e5830a728f" continuedAt="i12787b16146544a097ee6793fafdfe1a"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may not exceed <ix:nonFraction unitRef="shares" contextRef="i868ece5d5ec040e5bc282761eb8ff2b3_I20160513" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0Xzg4MDU_1430953d-48b1-4a4a-8e76-ad6e2fa3e726">18,000,000</ix:nonFraction> shares, provided that commencing with the first business day of each calendar year beginning January&#160;1, 2020, such maximum number of shares shall be increased by&#160;<ix:nonFraction unitRef="shares" contextRef="i868ece5d5ec040e5bc282761eb8ff2b3_I20160513" decimals="INF" format="ixt:numdotdecimal" name="ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0Xzg5NzA_6fe8e3c1-3b45-4e16-9c16-653ea160edfc">2,000,000</ix:nonFraction> shares of common stock unless the Board determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2021, the maximum number of shares to be issued increased by <ix:nonFraction unitRef="shares" contextRef="i1d250281b0084a9c9e85c87f5e174e6c_I20200101" decimals="INF" format="ixt:numdotdecimal" name="ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzkyNzE_2538bd3d-3cbe-4361-b469-b336ac278c02">2,000,000</ix:nonFraction>. At December&#160;31, 2020, there were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="if5aa6e62b90746e2a0e7a79dcda10743_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzkyOTM_65a42dee-bf44-4358-9d0f-3ae25917612f">18,000,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of common stock reserved for issuance upon exercise of incentive awards granted and to be granted at future dates under the 2016 Incentive Plan. At December&#160;31, 2020, the Company had <ix:nonFraction unitRef="shares" contextRef="if5aa6e62b90746e2a0e7a79dcda10743_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0Xzk0NzE_e2e8d124-37e2-4588-b4d0-771e265052dd">6,739,577</ix:nonFraction> shares of common stock available for future grant under the 2016 Incentive Plan, <ix:nonFraction unitRef="shares" contextRef="i336b7f2097e04fa9946695e9082976b1_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="ino:NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0Xzk1NTU_965eb398-1de1-4cf0-8ee5-5fac02dfae29">2,558,052</ix:nonFraction> shares underlying outstanding but unvested restricted stock units and options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="if5aa6e62b90746e2a0e7a79dcda10743_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0Xzk2NjA_d5ac3f88-b5d3-4e7d-9571-3b73c4be67b7">5,742,109</ix:nonFraction> shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over <ix:nonNumeric contextRef="i336b7f2097e04fa9946695e9082976b1_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzgyNDYzMzcyMzQwNzM_38d1ac9b-fc16-4f41-ae20-6d3805e1d68d">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="i336b7f2097e04fa9946695e9082976b1_D20200101-20201231" format="ixt-sec:durwordsen" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzgyNDYzMzcyMzQwOTU_b466a6d0-446c-46d6-b79b-b747a7ca407f">ten years</ix:nonNumeric>. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At December&#160;31, 2020, the Company had options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="i7ddcf49caf034014b934f70e033c7381_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwMTU0_e4eca104-a871-4bc4-83e2-11c9ad7a216d">3,164,515</ix:nonFraction> shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over <ix:nonNumeric contextRef="ia9a611d11b194c04a97196e8637d3ea5_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzgyNDYzMzcyMzQxMTc_8ab3b3f4-6f4d-44e6-98f1-35778a5c363c">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="ia9a611d11b194c04a97196e8637d3ea5_D20200101-20201231" format="ixt-sec:durwordsen" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzgyNDYzMzcyMzQxMzk_de28ef2b-2076-4868-b30a-c7407cda9910">ten years</ix:nonNumeric>. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December&#160;31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i3d376d80def94aaeaa2d3d07b689dd72_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNTA3_ade6d6bb-3398-4610-9644-b15deea51c01">14.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7b2e5387ae774d5b966fe4cfedf17ca3_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNTEx_2ed605ab-1d7f-4dff-b307-942847b05595">9.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib3f04bc964bc4062b85a1da80bfd3649_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNTE4_7bb3cc28-0495-40cf-bf41-cc30d87ff125">10.2</ix:nonFraction> million, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="i495966b5ff4e4727a8837c97fa4bd60a_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNTQ1_69dc416c-6d4b-4393-93f1-f748418efc36">8.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i60c500e2193a495a8e8d53e8bda2c96e_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNTQ5_fc0e57f6-5bdf-4894-a10f-ea1cbb4470b1">5.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5686e8d556c34f1287b6ab813a0dfe50_D20180101-20181231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNTU2_743db82a-2c29-4a4b-9776-5142fc380d5d">5.9</ix:nonFraction> million was included in research and development expenses and $<ix:nonFraction unitRef="usd" contextRef="ifcfb3bb7cf6d4f7f907cc373a9f10860_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNjIx_0e3ff4ac-8d73-4444-b44b-77a72d15ad2f">6.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i4f0bd5564d5d480c930234de144bd099_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNjI1_0aba075b-ff82-4732-b4e1-a9fe4888e4df">3.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9bd082535e33430d840b84b42712a05a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNjMy_bd451fd6-ffa6-42d5-ae3f-32ff59e46acf">4.3</ix:nonFraction> million was included in general and administrative expenses, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, there was $<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNzM5_5ab2314f-a2c1-4c56-bac4-42da23822ea5">4.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNzQ2_0a816f31-77e6-4ea8-9bea-8a9c0a7c32a5">3.4</ix:nonFraction> million, respectively, of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwOTE3_b981cde1-747c-4964-b6fd-253647bfb073">1.4</ix:nonNumeric> years and <ix:nonNumeric contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1MzY3MTA_7db0f2ea-7e67-4e80-9558-fa2d97a3930e">1.7</ix:nonNumeric> years, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020 and 2019, there was $<ix:nonFraction unitRef="usd" contextRef="ic358738bd92c4585907376620670c7fb_I20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwOTY0_09cf1422-bf56-46f5-b1c8-362e03a914ab">10.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia6335ae27741400684bafee789c7d140_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwOTc5_4402f5ed-fc9a-41aa-8e02-f6e775a03ba1">4.3</ix:nonFraction> million, respectively, of total unrecognized compensation expense related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="iadcbc296b043424a97f9d0cbf4b4f313_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzExMTUz_39de6724-957d-443b-8976-72c60ca99385">1.9</ix:nonNumeric> years and <ix:nonNumeric contextRef="i8447cd2594e94149a11ee2086d36b99a_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzExMTY2_feca6cc2-425d-4089-b2af-cf5fcb8585c0">1.6</ix:nonNumeric> years, respectively.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and restricted stock units granted to non-employees for the years ended December&#160;31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i9d936012135e4af182293a6bbca9297d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzExNjI0_3f194134-d95b-4cbe-8682-d9c8c2372f00">1.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia2a529a3bc394bac9063df42512b5b9c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzExNjI4_59e33c21-3f7b-4073-91ed-7a0d349b68f9">970,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0f5ffa0e16ec4dcca0f2275c5832f658_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzExNjM1_2aa4f4f5-aae3-4ecc-b9b7-3e20af5e4259">302,000</ix:nonFraction>, respectively. As of December&#160;31, 2020, options to purchase <ix:nonFraction unitRef="shares" contextRef="i6a196d09ea024f9f8f82d3947718333d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzExNjk2_2f26eaec-7d4a-496d-8aca-10009a3e2649">845,375</ix:nonFraction> shares of common stock granted to non-employees remained outstanding.</span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzNTY4_f337bad5-9c3d-4c11-b726-08bf6e58fd39" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock options outstanding at December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:26.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted    Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ieac0bc60961d47e7ab6e7a227877260b_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzItMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTgzM2FmZjQxMTRiYjFiNTFiZmEzYjg5OTJjNzkzXzY1OTcwNjk3NjY2NzY_3831e5c4-85de-49ff-87b9-41ed04250fec">1.48</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="ieac0bc60961d47e7ab6e7a227877260b_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzItMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTgzM2FmZjQxMTRiYjFiNTFiZmEzYjg5OTJjNzkzXzY1OTcwNjk3NjY2ODQ_4c185fbb-82cc-463f-855b-6af0ca31422b">3.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a4f019880eb4d7e9f92a9fef1fc03ba_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzItMi0xLTEtMA_4075d85a-4fcc-4f95-b2e1-8af20d324b73">452,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieac0bc60961d47e7ab6e7a227877260b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzItNC0xLTEtMA_c5dd7bb1-be68-4aa8-be07-ad5f5037a182">2.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a4f019880eb4d7e9f92a9fef1fc03ba_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzItNi0xLTEtMA_bdbae6a2-5c0a-48e0-9c3c-faa69fcb4c32">2.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a4f019880eb4d7e9f92a9fef1fc03ba_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzItOC0xLTEtMA_0efdc8f2-2959-40ef-8774-f6a93fc21684">428,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a4f019880eb4d7e9f92a9fef1fc03ba_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzItMTAtMS0xLTA_d16131f7-01ae-4d20-8e58-095284c17428">2.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ieb1a3d043e3142e993801b0549b85c79_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjQyMTlmYTQ4MmZkNTRmMDBiODNlYmU0MDJjYmQ3NjI1XzY1OTcwNjk3NjY2NzY_c521cac6-4273-4c96-9b3c-be255cc67581">3.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="ieb1a3d043e3142e993801b0549b85c79_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjQyMTlmYTQ4MmZkNTRmMDBiODNlYmU0MDJjYmQ3NjI1XzY1OTcwNjk3NjY2ODQ_dd08c88f-c6c7-4f14-b9cd-e32cf89fe0e1">6.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i424ca8a2ddb04b9d9993270673bfb2b7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzMtMi0xLTEtMA_ccc8efd4-b4f0-4d09-a32c-66b18e2777a2">3,261,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieb1a3d043e3142e993801b0549b85c79_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzMtNC0xLTEtMA_1f6f575c-2632-4589-8236-bc3f3d241e04">7.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i424ca8a2ddb04b9d9993270673bfb2b7_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzMtNi0xLTEtMA_5827b11a-ea06-428d-817d-dab6cf97331d">3.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i424ca8a2ddb04b9d9993270673bfb2b7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzMtOC0xLTEtMA_8b989b18-2eec-4708-b4a4-882e9e903d03">1,975,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i424ca8a2ddb04b9d9993270673bfb2b7_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzMtMTAtMS0xLTA_ccca4ff0-7074-4555-889b-5aa44133a156">3.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i0529e897544648afb4f8c8facb9c526d_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjJjNDhiMGRiYmE4YzQ5M2FiZmYzYzMyMmMyNjRiMjc3XzY1OTcwNjk3NjY2NzY_ea86f776-f6ec-4e0b-b46a-34a2d7b3ce3d">6.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i0529e897544648afb4f8c8facb9c526d_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjJjNDhiMGRiYmE4YzQ5M2FiZmYzYzMyMmMyNjRiMjc3XzY1OTcwNjk3NjY2ODQ_fb5619b7-c8d5-49da-9703-45f871f5bbb2">9.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b636fe087494ecaa5b251e1c14a1e4b_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzQtMi0xLTEtMA_fbc5c823-6021-4153-bcad-fda943e59987">3,879,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0529e897544648afb4f8c8facb9c526d_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzQtNC0xLTEtMA_ae951b20-6eba-4d6e-be1c-2e35ce0efcb8">6.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b636fe087494ecaa5b251e1c14a1e4b_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzQtNi0xLTEtMA_bad7be69-5c54-4b89-b209-312f80eb5ed8">7.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b636fe087494ecaa5b251e1c14a1e4b_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzQtOC0xLTEtMA_ebd47740-a488-40ad-9aca-19fafab86801">2,864,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b636fe087494ecaa5b251e1c14a1e4b_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzQtMTAtMS0xLTA_be19331c-d28d-4e4f-b79a-7bc366e12eb2">7.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i0898c082ec1c41a5a28d7feae8fd298d_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjgxMmY2YWEwMWZhZDQzYjZhOTA3ODI3ZmY4YWIyMDY3XzY1OTcwNjk3NjY2Nzc_8cc7e58d-036c-4be0-9980-fd75859b4aa3">9.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i0898c082ec1c41a5a28d7feae8fd298d_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjgxMmY2YWEwMWZhZDQzYjZhOTA3ODI3ZmY4YWIyMDY3XzY1OTcwNjk3NjY2ODY_f8c658e0-5cf0-4c81-a8dd-b86650243282">12.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8ba04b2fc50444a883de5f9c28c9da1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzUtMi0xLTEtMA_0f256dd2-eb09-4ca8-a737-70301d1d71c3">365,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0898c082ec1c41a5a28d7feae8fd298d_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzUtNC0xLTEtMA_61856f66-9f85-4492-8bb5-d138b217f8ed">7.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib8ba04b2fc50444a883de5f9c28c9da1_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzUtNi0xLTEtMA_d77d8820-883a-4bbc-8d95-315e37a68c6e">10.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8ba04b2fc50444a883de5f9c28c9da1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzUtOC0xLTEtMA_f7726354-489c-44d7-853e-e73fd3ea5850">233,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib8ba04b2fc50444a883de5f9c28c9da1_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzUtMTAtMS0xLTA_e15d9151-38c6-451d-be57-f6e4b512faad">10.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i2a8b1922df074f8d881dc9835917dfc0_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtMC0xLTEtMzMyMy90ZXh0cmVnaW9uOjVhZWE5NTQxNDc2ZTQ5ZDc4OGVkZjM4ZjAzZTkwMmM2XzY1OTcwNjk3NjY2Nzk_ab8f949b-93d5-4cee-a4c5-20338de00c9f">12.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i2a8b1922df074f8d881dc9835917dfc0_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtMC0xLTEtMzMyMy90ZXh0cmVnaW9uOjVhZWE5NTQxNDc2ZTQ5ZDc4OGVkZjM4ZjAzZTkwMmM2XzY1OTcwNjk3NjY2ODg_9a982226-42ab-4d76-978a-0f211fcd795b">15.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1329f8962cf44001a77927afa8dd9600_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtMi0xLTEtMzMyMw_f1ccf6d2-936d-435e-9236-227e1a81ec2b">833,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a8b1922df074f8d881dc9835917dfc0_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtNC0xLTEtMzMyMw_a2cbc8eb-1565-47d3-bdf4-420e8a178fe3">5.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1329f8962cf44001a77927afa8dd9600_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtNi0xLTEtMzMyMw_ff4f172f-f0c2-479e-a110-d6e1efa9c07e">13.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1329f8962cf44001a77927afa8dd9600_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtOC0xLTEtMzMyMw_c7606a95-1730-4135-9ac8-f5ef4f5b4e69">546,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1329f8962cf44001a77927afa8dd9600_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtMTAtMS0xLTMzMjM_b5508c3e-b400-4852-a723-e8311aaab7c6">13.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5d1018668fb54f4a8f27dc2bbbebbc43_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjY5NGU4ZTBjZjIyZjRkMDhhMjU0YjgwNjAyZWFkYjE2XzY1OTcwNjk3NjY2Nzk_1c01d9bb-0c3a-42b2-ab20-553882102110">15.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i5d1018668fb54f4a8f27dc2bbbebbc43_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjY5NGU4ZTBjZjIyZjRkMDhhMjU0YjgwNjAyZWFkYjE2XzY1OTcwNjk3NjY2ODg_fc248ff5-dcd6-4f7a-8d7a-59aff5ace278">25.62</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c519ce051934157ac2a92180ffe1298_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtMi0xLTEtMA_fc18c035-f81d-49b0-8fd2-65296d5dd489">114,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5d1018668fb54f4a8f27dc2bbbebbc43_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtNC0xLTEtMA_925818de-c82e-40a0-97ee-3b42b912a5d2">9.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c519ce051934157ac2a92180ffe1298_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtNi0xLTEtMA_e467628e-439a-43e9-9e7e-59060db38ce9">20.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c519ce051934157ac2a92180ffe1298_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtOC0xLTEtMA_4fea72ea-91ae-41f5-978a-b4c448cf4ad4">31,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c519ce051934157ac2a92180ffe1298_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtMTAtMS0xLTA_6e2f89bd-c66b-42fa-89ab-2c1684b05664">20.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzctMi0xLTEtMA_b8fcc9b7-d89f-4424-a724-45385c6ececf">8,906,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzctNC0xLTEtMA_f74a77d2-8af0-4c35-ad9a-1660fdd93692">6.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzctNi0xLTEtMA_ed173937-b42a-46c1-874b-8ad7dda67fbd">6.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzctOC0xLTEtMA_4d1f17e9-dd04-43b2-bf7e-fae62acda4cf">6,079,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzctMTAtMS0xLTA_82dd2c12-96ea-4c8c-bb98-26cec2634e3a">6.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the aggregate intrinsic value of options outstanding was $<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzExOTM1_dc5aa4a6-dcfa-478a-81dc-5a2c8c194250">24.2</ix:nonFraction> million, the aggregate intrinsic value of options exercisable was $<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzExOTk2_41baa088-56a0-4232-a6ff-ac35d0d7ae4c">16.8</ix:nonFraction> million, and the weighted average remaining contractual term of options exercisable was <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" format="ixt-sec:duryear" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyMDc5_8e349701-309e-4176-9fa4-02ecf47b0569">5.7</ix:nonNumeric> years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, the aggregate intrinsic value of unvested restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="ic358738bd92c4585907376620670c7fb_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyMTc4_d0c52796-894e-4b37-a540-d3d2f6d27bf9">22.6</ix:nonFraction> million and the aggregate intrinsic value of restricted stock units which vested during the year ended December 31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="iadcbc296b043424a97f9d0cbf4b4f313_D20200101-20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyMjk2_750f05a8-b87c-4976-8e0a-723c9de2f780">13.5</ix:nonFraction> million.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, options to purchase <ix:nonFraction unitRef="shares" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyMzQ4_8bc53dd2-45a7-4488-a280-0216f3beada8">8,906,624</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="ic358738bd92c4585907376620670c7fb_I20201231" decimals="INF" format="ixt:numdotdecimal" name="ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyMzc4_3f91c480-2f8b-4db9-bef0-d0d0896a552e">2,558,052</ix:nonFraction> restricted stock units were expected to vest.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i12787b16146544a097ee6793fafdfe1a"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzNTcy_9d6c6e60-8fe2-467d-996e-3e4c2e56388c" escape="true"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2020 was as follows: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:70.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzktMS0xLTEtMA_9ad2e208-ed15-43db-8e86-f1e7d913eb7c">9,265,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzktMy0xLTEtMA_a436f1c0-7d0b-4ca5-9938-f8ff5fe25e5d">5.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzEwLTEtMS0xLTA_123d7705-0b12-474d-95ef-656038221a5b">2,126,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzEwLTMtMS0xLTA_bb44b571-d6a0-432e-9bcb-6d309fdd2a25">10.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzExLTEtMS0xLTA_a4e77d2e-d537-4392-a309-d37f78f74b7a">2,178,252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzExLTMtMS0xLTA_83238fd5-09e8-4c0d-a4f0-b2bbcbf53253">5.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzEyLTEtMS0xLTA_7762738a-be6f-4ab2-a2e7-1984552508bb">306,696</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzEyLTMtMS0xLTA_315509ae-0170-495c-9e96-a30ede9b6db8">6.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzEzLTEtMS0xLTA_4d83999c-7198-4be2-b313-28c515be2f9c">8,906,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzEzLTMtMS0xLTA_368c0dda-47e8-4709-8d39-026a4274a3c9">6.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzNTUx_5e17779c-4b4d-4d9d-a0a3-59e86770b1a0" escape="true"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2020 was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:84.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6335ae27741400684bafee789c7d140_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZToyMzQ3ODI2YzU2NTM0ZGY1Yjc4MDFmNDQwNWYzYTdjMy90YWJsZXJhbmdlOjIzNDc4MjZjNTY1MzRkZjViNzgwMWY0NDA1ZjNhN2MzXzktMS0xLTEtMA_fccfb449-7779-47e0-95dd-365eedc38151">2,069,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iadcbc296b043424a97f9d0cbf4b4f313_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZToyMzQ3ODI2YzU2NTM0ZGY1Yjc4MDFmNDQwNWYzYTdjMy90YWJsZXJhbmdlOjIzNDc4MjZjNTY1MzRkZjViNzgwMWY0NDA1ZjNhN2MzXzEwLTEtMS0xLTA_bb4b99b5-2d68-4b19-95d0-09e4027a4115">1,586,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iadcbc296b043424a97f9d0cbf4b4f313_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZToyMzQ3ODI2YzU2NTM0ZGY1Yjc4MDFmNDQwNWYzYTdjMy90YWJsZXJhbmdlOjIzNDc4MjZjNTY1MzRkZjViNzgwMWY0NDA1ZjNhN2MzXzExLTEtMS0xLTA_9d3568d6-befe-4df9-b5a9-badc1da46e2e">1,040,628</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iadcbc296b043424a97f9d0cbf4b4f313_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZToyMzQ3ODI2YzU2NTM0ZGY1Yjc4MDFmNDQwNWYzYTdjMy90YWJsZXJhbmdlOjIzNDc4MjZjNTY1MzRkZjViNzgwMWY0NDA1ZjNhN2MzXzEyLTEtMS0xLTA_6a6a78d7-3889-429c-9112-1e3cb3513610">57,536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic358738bd92c4585907376620670c7fb_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZToyMzQ3ODI2YzU2NTM0ZGY1Yjc4MDFmNDQwNWYzYTdjMy90YWJsZXJhbmdlOjIzNDc4MjZjNTY1MzRkZjViNzgwMWY0NDA1ZjNhN2MzXzEzLTEtMS0xLTA_1cdf0c50-af63-41cd-8686-d9cf869453a0">2,558,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price per share was $<ix:nonFraction unitRef="usdPerShare" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyNzA3_2786140f-bec5-456c-932c-ad74a14e70ed">4.44</ix:nonFraction> for the <ix:nonFraction unitRef="shares" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyNzE4_ad3829f0-cdb6-44cb-b85a-1141f5dcc026">78,750</ix:nonFraction> options which expired during the year ended December&#160;31, 2020, $<ix:nonFraction unitRef="usdPerShare" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyNzgy_7681159a-e81c-4948-8c0c-54cddcfce58d">6.27</ix:nonFraction> for the <ix:nonFraction unitRef="shares" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyNzkz_69e1d241-6762-4c97-b9fa-c10a0020f7e3">324,502</ix:nonFraction> options which expired during the year ended December&#160;31, 2019 and $<ix:nonFraction unitRef="usdPerShare" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyODYw_a06238f3-8daa-4c5d-a4c1-ebff485238fa">5.17</ix:nonFraction> for the <ix:nonFraction unitRef="shares" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyODcx_6d130a98-535b-4b8f-93bc-001580306a1c">119,091</ix:nonFraction> options which expired during the year ended December&#160;31, 2018.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $<ix:nonFraction unitRef="usdPerShare" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyOTky_231c439b-ce64-4ec9-a7cd-34a44fe8fd88">6.87</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyOTk2_08c766cb-81ac-4787-8261-4eb172193f06">2.19</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzMDAz_f246fe1a-1a6c-40a5-aa63-2fdd6342832d">2.86</ix:nonFraction> for options granted during the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value was $<ix:nonFraction unitRef="usdPerShare" contextRef="iadcbc296b043424a97f9d0cbf4b4f313_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzMTM4_ae67b4b9-9a34-479e-927a-bbee9772c380">9.12</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8447cd2594e94149a11ee2086d36b99a_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzMTQy_2c533b79-926b-4976-8f42-7543fd307814">3.09</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i01d41a23f9d7414e9ca33540626eb820_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzMTQ5_5a10cc2a-d94f-4478-be1e-4fac43f7b804">4.31</ix:nonFraction> per share for restricted stock units granted during the years ended December&#160;31, 2020, 2019 and 2018, respectively. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received $<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzMjg0_df4a65a1-a7e9-4a79-9428-64e3f75076bc">12.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzMjg4_c2a9a9d7-7225-40a8-926c-6bc57b8c9dc1">113,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzMjk1_db7a31db-f4b3-49ee-8c85-cb631db3c64b">1.5</ix:nonFraction> million in proceeds from the exercise of stock options during the years ended December&#160;31, 2020, 2019 and 2018, respectively. The aggregate intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzNDY1_21323c69-49ae-4131-a3f9-b74e05e2fc8c">14.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzNDY5_67fecd79-4432-4857-9aea-32a0f0c026f2">25,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzNDc2_1cbb8920-1312-4096-ab67-d196ab0d10f0">910,000</ix:nonFraction> during the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 28, 2020, the Company granted <ix:nonFraction unitRef="shares" contextRef="ie3b43b488fbc4c9bb91dea3e06d1edd9_D20200828-20200828" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1Mjk5ODU_041c747e-26ab-4b3e-ae12-5cbd22b70613">663,353</ix:nonFraction> performance-based RSUs to key employees under the 2016 Incentive Plan. The RSUs will vest in two tranches as follows: <ix:nonFraction unitRef="number" contextRef="i091f59652b674cbba9a610be2bac6d93_D20200828-20200828" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1Mjk5OTQ_4318e85e-12b1-4151-a9a3-f0868d9847a1">50</ix:nonFraction>% of the shares in each tranche will vest upon achievement of the predetermined performance milestones and the remaining <ix:nonFraction unitRef="number" contextRef="ice5bec7f1fe94cf09064dbef4b963a15_D20200828-20200828" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1Mjk5OTk_cff01c79-b877-4c21-837a-733c3787512b">50</ix:nonFraction>% of the shares in each tranche will vest upon subsequent completion of a <ix:nonNumeric contextRef="ice5bec7f1fe94cf09064dbef4b963a15_D20200828-20200828" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzgyNDYzMzcyMzQwNjE_967cfbe2-5682-4093-8a00-ed2aa4e83c6d">one-year</ix:nonNumeric> service period. The grant date fair value of the performance-based RSUs was $<ix:nonFraction unitRef="usd" contextRef="ie3b43b488fbc4c9bb91dea3e06d1edd9_D20200828-20200828" decimals="-5" format="ixt:numdotdecimal" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1MzAwMDU_696465c3-54b8-452a-8e42-5744a135da25">8.0</ix:nonFraction>&#160;million based on the grant date closing price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie3b43b488fbc4c9bb91dea3e06d1edd9_D20200828-20200828" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1MzAwMTk_c4646cbc-a7aa-4d0a-96e5-9eac00af6025">12.06</ix:nonFraction>. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December&#160;31, 2020</span><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, the underlying performance milestones of the RSUs were not probable of achievement, and no stock-based compensation expense was recognized for the performance-based RSUs for the year then ended.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_190"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzMzMTY_893e30d4-c065-42b0-8271-18f75977bcb7" continuedAt="iea2cf9863d904d71bd7ea2a4d589d303" escape="true">Leases </ix:nonNumeric></span></div><ix:continuation id="iea2cf9863d904d71bd7ea2a4d589d303" continuedAt="if2e8b1b360604f93a10c73d1ca8809a4"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i1795839f068f4fc6864f4b49d44926c3_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzUw_1dcb1360-9ed0-4a9d-95cf-74f3fce7a56b">82,200</ix:nonFraction> square feet of office, laboratory, and manufacturing space in San Diego, California and <ix:nonFraction unitRef="sqft" contextRef="id8df0be21b6144949f383e03e347241b_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzE0MQ_4a509d57-2998-432e-9779-42be91e9d475">57,360</ix:nonFraction> square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms of <ix:nonNumeric contextRef="i49fe24c3cf784f4aad4300bb064363bb_I20201231" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzgyNDYzMzcyMTMxNTQ_64567f40-b412-4da4-a628-1651c988ca42">2.9</ix:nonNumeric> years to <ix:nonNumeric contextRef="i71066e05ce5044f48965c132ee5b5187_I20201231" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzgyNDYzMzcyMTMxMzM_8b861751-757a-4a82-a5d0-547d09c2f787">9.0</ix:nonNumeric> years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if2e8b1b360604f93a10c73d1ca8809a4"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzMzMDQ_c5b842cc-6123-49f3-958d-deb3daf434d6" escape="true"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of December&#160;31, 2020, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzEtMS0xLTEtMA_23490e5c-28b5-44c5-a8b0-d7a70e2fccea">3,968,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzItMS0xLTEtMA_2245d471-7650-4e16-96d2-a06368470e15">4,045,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzMtMS0xLTEtMA_e15a6fef-170a-4449-907f-b9a06043fa45">4,023,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzQtMS0xLTEtMA_c71d7087-8087-4ce5-b03d-2bddbb6548a3">3,001,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzUtMS0xLTEtMA_b69cb50f-ff40-4a1a-afb6-2c21f0172806">3,063,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzYtMS0xLTEtMA_b225ad62-d4e0-4551-9f29-c2d0eb096566">9,888,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzctMS0xLTEtMA_d2f33029-7457-417d-a75a-c3ac97c1fb33">27,988,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzgtMS0xLTEtMA_fe7c8f30-8cd7-4997-8007-ab45909daf57">7,595,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzktMS0xLTEtMA_93ceeb61-8b29-4cb4-b706-eafc8eec6ad7">20,393,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzEwLTEtMS0xLTA_4abca6b3-affd-4e98-b9a0-b9b56db8cf0b">2,329,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzExLTEtMS0xLTA_39313ca3-9941-4e54-ab18-836ab834ea58">18,064,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzEzLTEtMS0xLTA_f8ec3937-d25f-49f0-a4d7-68486c17f278">7.4</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzE0LTEtMS0xLTA_57e3b5e4-6cc5-4feb-a86d-76e3577e7091">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the consolidated statements of operations for the years ended December&#160;31, 2020, 2019 and 2018 were $<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzIxMTA_1ef91bdb-07fb-4a03-92a9-46066767fce4">3.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzIxMTQ_326f82b4-2feb-427f-bff8-84c9882ad527">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzIxMjE_aa016570-2103-4382-b2d8-05c5209a0f2c">3.4</ix:nonFraction> million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, the Company entered into <ix:nonFraction unitRef="lease" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="INF" format="ixt-sec:numwordsen" name="ino:LesseeNumberOfLeaseAgreementsEnteredInto" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzI0MDM_453733e8-dba5-42ff-8992-aa3ad61170c1">two</ix:nonFraction> agreements to sublease a total of approximately <ix:nonFraction unitRef="sqft" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="0" format="ixt:numdotdecimal" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzI0NTQ_7ab73600-d06e-497b-b6d2-2f38824fbad3">13,500</ix:nonFraction> square feet in its Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_193"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTMvZnJhZzplNDY1OWIyYmNiYzA0ODFiYjFmMzM5YmVmNWU0OTI0MS90ZXh0cmVnaW9uOmU0NjU5YjJiY2JjMDQ4MWJiMWYzMzliZWY1ZTQ5MjQxXzM2Ng_83825b46-05a3-4d19-9ce0-b313bc54c7c2" continuedAt="i6c267d57dfb845edaae95eea7538d630" escape="true">Investment in Affiliated Entity</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="i6c267d57dfb845edaae95eea7538d630"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, the Company held <ix:nonFraction unitRef="shares" contextRef="id04015c2a4c74d3f9bda78d8a29a1f31_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTMvZnJhZzplNDY1OWIyYmNiYzA0ODFiYjFmMzM5YmVmNWU0OTI0MS90ZXh0cmVnaW9uOmU0NjU5YjJiY2JjMDQ4MWJiMWYzMzliZWY1ZTQ5MjQxXzQ5NDc4MDIzMjU0ODc_8ebcd083-8956-4156-b1d2-46e4c036831a">597,808</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5d75b37d31b1415baa94fe75e2eced26_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTMvZnJhZzplNDY1OWIyYmNiYzA0ODFiYjFmMzM5YmVmNWU0OTI0MS90ZXh0cmVnaW9uOmU0NjU5YjJiY2JjMDQ4MWJiMWYzMzliZWY1ZTQ5MjQxXzE4Mg_a35e4109-5488-48ab-bc26-934168362ac7">395,758</ix:nonFraction> common shares in PLS, representing a <ix:nonFraction unitRef="number" contextRef="if2747486006c46f3999136afeba9ca67_I20201231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTMvZnJhZzplNDY1OWIyYmNiYzA0ODFiYjFmMzM5YmVmNWU0OTI0MS90ZXh0cmVnaW9uOmU0NjU5YjJiY2JjMDQ4MWJiMWYzMzliZWY1ZTQ5MjQxXzIxNQ_399ba5b4-4511-4d7c-a531-4e4787b424c2">19.7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ie5382c3775034bdc84ed280f6032b6c1_I20191231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTMvZnJhZzplNDY1OWIyYmNiYzA0ODFiYjFmMzM5YmVmNWU0OTI0MS90ZXh0cmVnaW9uOmU0NjU5YjJiY2JjMDQ4MWJiMWYzMzliZWY1ZTQ5MjQxXzIyMg_f160cf12-5a21-4554-959d-0b1e696a0ad5">15.0</ix:nonFraction>% ownership interest, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 27, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i2ef5e314188044e59bf80890444a8798_D20200827-20200827" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTMvZnJhZzplNDY1OWIyYmNiYzA0ODFiYjFmMzM5YmVmNWU0OTI0MS90ZXh0cmVnaW9uOmU0NjU5YjJiY2JjMDQ4MWJiMWYzMzliZWY1ZTQ5MjQxXzQ5NDc4MDIzMjYxOTI_bc1718ab-fd7e-48a9-a580-dfb38f75fce6">1,644,155</ix:nonFraction> shares of common stock in GeneOne for net proceeds of approximately <ix:nonFraction unitRef="krw" contextRef="i2ef5e314188044e59bf80890444a8798_D20200827-20200827" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTMvZnJhZzplNDY1OWIyYmNiYzA0ODFiYjFmMzM5YmVmNWU0OTI0MS90ZXh0cmVnaW9uOmU0NjU5YjJiY2JjMDQ4MWJiMWYzMzliZWY1ZTQ5MjQxXzgyNDYzMzcyMTA0MjY_0c0e7710-699e-41f3-bac5-45a56523d9d2">47.4</ix:nonFraction>&#160;billion KRW (approximately USD $<ix:nonFraction unitRef="usd" contextRef="i2ef5e314188044e59bf80890444a8798_D20200827-20200827" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTMvZnJhZzplNDY1OWIyYmNiYzA0ODFiYjFmMzM5YmVmNWU0OTI0MS90ZXh0cmVnaW9uOmU0NjU5YjJiY2JjMDQ4MWJiMWYzMzliZWY1ZTQ5MjQxXzQ5NDc4MDIzMjYyMDQ_f6133456-c2d1-48f3-8b54-911857e66e31">40.1</ix:nonFraction>&#160;million based on the exchange rate on the date of sale). The Company no longer holds an investment in GeneOne shares and GeneOne is no longer considered a related party to the Company under ASC Topic 850.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Please see further information as discussed in Note 2 and Note 6.</span></ix:continuation></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_199"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzQ5NTA_8fdb126d-6404-4bcc-8b21-efa4dcd3bf5f" continuedAt="ifd5a13e4d66f4b35bf9298f5250738e5" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="ifd5a13e4d66f4b35bf9298f5250738e5" continuedAt="i247ad7f466f24a6f8cacf5cddbe068f5"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.</span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzgyNDYzMzcyMTY1MDc_834e2b7a-7a44-4c52-8ebe-d12e8670d52a" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of pretax loss from operations are as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYzU0ZDFiNWQ3NWM0YmMwYmFjYjJmMDdhNmI5MDIzZi90YWJsZXJhbmdlOmVjNTRkMWI1ZDc1YzRiYzBiYWNiMmYwN2E2YjkwMjNmXzItMS0xLTEtNjk3Nw_11f670b4-7cb3-41e5-b279-1b2d73823267">162,664,355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYzU0ZDFiNWQ3NWM0YmMwYmFjYjJmMDdhNmI5MDIzZi90YWJsZXJhbmdlOmVjNTRkMWI1ZDc1YzRiYzBiYWNiMmYwN2E2YjkwMjNmXzItMy0xLTEtNjk3Nw_c21fbbc5-d319-4915-a7ac-873ac87ef0c8">120,809,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYzU0ZDFiNWQ3NWM0YmMwYmFjYjJmMDdhNmI5MDIzZi90YWJsZXJhbmdlOmVjNTRkMWI1ZDc1YzRiYzBiYWNiMmYwN2E2YjkwMjNmXzItNS0xLTEtNjk3Nw_a957f7f0-5d5f-4c0e-bb49-bfe4d68aded6">94,798,019</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYzU0ZDFiNWQ3NWM0YmMwYmFjYjJmMDdhNmI5MDIzZi90YWJsZXJhbmdlOmVjNTRkMWI1ZDc1YzRiYzBiYWNiMmYwN2E2YjkwMjNmXzMtMS0xLTEtNjk3Nw_251eadeb-032f-4abb-a14e-21822af29aaa">225,949</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYzU0ZDFiNWQ3NWM0YmMwYmFjYjJmMDdhNmI5MDIzZi90YWJsZXJhbmdlOmVjNTRkMWI1ZDc1YzRiYzBiYWNiMmYwN2E2YjkwMjNmXzMtMy0xLTEtNjk3Nw_edde4279-2b30-4470-a15f-466b2fc87adf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYzU0ZDFiNWQ3NWM0YmMwYmFjYjJmMDdhNmI5MDIzZi90YWJsZXJhbmdlOmVjNTRkMWI1ZDc1YzRiYzBiYWNiMmYwN2E2YjkwMjNmXzMtNS0xLTEtNjk3Nw_b6d98754-be98-4b96-87a4-fb883e882844">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax loss from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYzU0ZDFiNWQ3NWM0YmMwYmFjYjJmMDdhNmI5MDIzZi90YWJsZXJhbmdlOmVjNTRkMWI1ZDc1YzRiYzBiYWNiMmYwN2E2YjkwMjNmXzQtMS0xLTEtODg2Mg_2ad6a92f-d063-492f-9f90-3da2bdbedfa3">162,890,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYzU0ZDFiNWQ3NWM0YmMwYmFjYjJmMDdhNmI5MDIzZi90YWJsZXJhbmdlOmVjNTRkMWI1ZDc1YzRiYzBiYWNiMmYwN2E2YjkwMjNmXzQtMy0xLTEtODg2Mg_1e217899-0ad7-457e-8d93-b17271bfc924">120,809,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYzU0ZDFiNWQ3NWM0YmMwYmFjYjJmMDdhNmI5MDIzZi90YWJsZXJhbmdlOmVjNTRkMWI1ZDc1YzRiYzBiYWNiMmYwN2E2YjkwMjNmXzQtNS0xLTEtODg2Mg_f7b68442-f9a8-48ae-a3fc-2ec34edcdfbb">94,798,019</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><ix:continuation id="i247ad7f466f24a6f8cacf5cddbe068f5" continuedAt="i1cc83bef860f4e2ead84cc87f3041be3"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzQ5MjU_bbda0a79-0eb2-404d-8314-cb5680f3b571" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the provision for (benefit from) income taxes are presented in the following table: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzMtMS0xLTEtMA_598910a7-80e7-4ca2-8b65-dcfd87b799f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzMtMy0xLTEtMA_8f6d6ffc-0e03-4729-b258-dfc5e43a0a6d">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzMtNS0xLTEtMA_fe674bb5-6ed7-4ee0-b643-0cc6df7c3ade">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzQtMS0xLTEtMA_70be785d-de07-4b42-88c2-485921b3ca22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzQtMy0xLTEtMA_95d6fa26-efc6-4a68-85e1-7df9c41b4df0">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzQtNS0xLTEtMA_7ae729c1-36f5-4277-8fab-81abf3b072dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzUtMS0xLTEtMA_2e82bc05-e140-4209-abe5-b9a45d62c8b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzUtMy0xLTEtMA_dc6ab88a-b3d3-40b7-a794-2869a9d65963">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzUtNS0xLTEtMA_f7f6c4b0-4ee4-4834-9937-bbcf25d60907">2,170,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzYtMS0xLTEtMA_bc99d4fb-cc2f-437a-b2d0-1dab6215d0cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzYtMy0xLTEtMA_a11868d2-cd35-48ea-b56d-62e0b6934bbc">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzYtNS0xLTEtMA_e9af4849-75ed-48b4-b60c-ce682774e992">2,170,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzgtMS0xLTEtMA_4c22de25-7d05-4774-ad18-fceaf397ffcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzgtMy0xLTEtMA_53325691-16ec-4606-a5dc-b120e923368e">263,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" xsi:nil="true" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzgtNS0xLTEtMA_5a051495-82a1-4377-bf14-9fc5e62fb87b"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzktMS0xLTEtMA_04bbbbf1-c93e-4fa9-b9b4-1fdc381fade6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzktMy0xLTEtMA_ebeb6785-65e7-43cb-801a-492d6ea72001">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzktNS0xLTEtMA_3069f38e-10f7-474b-a1f0-1e0faaf10045">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzEwLTEtMS0xLTA_fca881d7-a951-4158-9961-13eb884bbc34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzEwLTMtMS0xLTA_b7b10dff-a2be-439d-8852-7c7988e20c58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzEwLTUtMS0xLTA_eb9edcb0-30a6-495b-a40b-51d42af4083c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzExLTEtMS0xLTA_a0b92cd4-84be-409f-9091-764cea0c8e00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzExLTMtMS0xLTA_0dd66a15-fe62-46ad-ae0c-0bb276af259f">263,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzExLTUtMS0xLTA_f3d18f52-2f06-4599-8383-2e1fc67ba1a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzEyLTEtMS0xLTA_1f5e1a74-f49f-4607-b45e-90642a13b4c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzEyLTMtMS0xLTA_5a99cf25-d0c7-44de-a682-f73c81f53858">257,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzEyLTUtMS0xLTA_615354c9-e7a6-467d-a3f0-0413f8c343f7">2,170,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzQ5MjY_a5a82dbe-3282-4cd9-aa28-6be8588531dd" escape="true"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax expense (benefit), using a 21% statutory tax rate for December 31, 2020, 2019 and 2018, is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (benefit) taxes at statutory rates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzItMS0xLTEtMA_97764c9f-d6fb-477d-a827-f52efde89a5e">34,207,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzItMy0xLTEtMA_c2b53651-cecc-4476-91af-6be7b61f5ad2">25,370,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzItNS0xLTEtMA_7e9d6c6b-30ee-487b-9150-b8cd9de1b99f">19,908,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzMtMS0xLTEtMA_000ee685-e169-4b75-9f40-0a80d4163da1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzMtMy0xLTEtMA_ed82520d-bbe4-4deb-bec9-c0544c5abddb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzMtNS0xLTEtMA_23661aef-6bab-48c2-839d-0c1d12e81e17">4,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ino:EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzQtMS0xLTEtMA_286e43c8-6283-4d43-b57c-10c717d7e18d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="ino:EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzQtMy0xLTEtMA_35b06efd-5ac0-4104-811c-d166b6618c1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="ino:EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzQtNS0xLTEtMA_4acbf3d9-d342-4e5b-80a0-c95f17a94799">2,170,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzUtMS0xLTEtMA_a8c75a1a-e1f9-4c08-a175-a6896c2fa634">21,428,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzUtMy0xLTEtMA_f30564d2-d731-4e37-b2d3-b7a296aa5e69">25,457,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzUtNS0xLTEtMA_5a73c6b9-0ed9-474a-9240-5ab8832a5f54">20,898,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzYtMS0xLTEtNjk5OQ_f5cf9688-e951-4d29-b019-f4f7b9d8e429">14,450,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzYtMy0xLTEtNjk5OQ_dd3ec3ec-bbf8-4805-8f6f-b10c40c8b4bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzYtNS0xLTEtNjk5OQ_9d821819-c926-4451-8fe1-848ad4747d6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ino:IncomeTaxReconciliationStatuteLimitations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzYtMS0xLTEtMA_7068465a-d348-49f5-ab12-a9cc7df94fcf">2,650,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ino:IncomeTaxReconciliationStatuteLimitations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzYtMy0xLTEtMA_2b4b23b1-bd40-4568-a45d-a30b41632e53">3,838,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ino:IncomeTaxReconciliationStatuteLimitations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzYtNS0xLTEtMA_f1c4e5aa-14dc-4722-b341-928f0fe35fff">3,170,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ino:IncomeTaxReconciliationFairValueWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzctMS0xLTEtMA_7b08b832-57b7-406b-88b4-2f61956ef70c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="ino:IncomeTaxReconciliationFairValueWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzctMy0xLTEtMA_92a68b0a-da81-4840-8ea3-db7ecf1a3e59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ino:IncomeTaxReconciliationFairValueWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzctNS0xLTEtMA_7c4b0c01-9351-4196-a1b2-0bfad464c29b">76,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzgtMS0xLTEtMA_af4ca1f8-7ab6-4ba8-9b83-fc62611f5ea1">1,953,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzgtMy0xLTEtMA_92aaa5b2-257b-4142-a946-7c9e758c3f69">1,114,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzgtNS0xLTEtMA_46700f22-3ed4-4385-870b-8622f8fb1154">1,094,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzktMS0xLTEtMA_c3046505-3938-435c-b229-895e3e4ccd09">1,068,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzktMy0xLTEtMA_279f74da-32a6-4457-a725-b673ffcfea1b">1,537,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzktNS0xLTEtMA_578ace8d-af35-4803-8b79-66a1752765ad">1,268,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deconsolidation of subsidiary</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzExLTEtMS0xLTcwMDM_964a60df-04d1-4e0e-b341-04c08eaea569">853,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzExLTMtMS0xLTcwMDM_6ccb6702-d136-4a91-8494-7c82a9be6c46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzExLTUtMS0xLTcwMDM_524162b3-909b-449d-b979-99d74ad93592">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzEwLTEtMS0xLTA_dba7dce6-861a-4e7e-91d7-938dee58f495">468,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzEwLTMtMS0xLTA_46dd4824-ac0a-4a53-ac78-a7eef51bf678">616,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzEwLTUtMS0xLTA_3bbb2f89-87db-4147-9ec7-f64c68db5b70">2,176,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited NOLs and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzExLTEtMS0xLTA_c431da66-b942-47ff-a79a-2e532eda49cb">368,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzExLTMtMS0xLTA_5dc443ee-24d2-44bf-9577-94dc0a8e47fd">616,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzExLTUtMS0xLTA_be57edff-1b93-468f-9a69-eeb4bdcde438">2,176,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzEyLTEtMS0xLTA_a68480bd-d705-4a4c-84e2-85db9a37dabb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzEyLTMtMS0xLTA_eadd4720-3061-499c-bc36-2a1d38c891f3">12,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzEyLTUtMS0xLTA_11e09431-5382-4394-ba3a-94e4ec6c0b9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzE1LTEtMS0xLTcwMDc_5507d9bc-3eb9-4487-a87b-022eae769373">9,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzE1LTMtMS0xLTcwMDc_029d2918-c0b2-4589-bb3c-0fb13194c52f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzE1LTUtMS0xLTcwMDc_329cec0d-f6da-425f-9118-53ba58738a65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzEzLTEtMS0xLTA_c74c41b1-bf6c-454b-bf75-19f736776b0d">920,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzEzLTMtMS0xLTA_c17e1c5d-620a-46a3-8202-e162fda5e0a7">831,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzEzLTUtMS0xLTA_70c56a8b-49fb-4c7e-84bc-70b488a4cd8e">102,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="ino:ComprehensiveIncomeLossTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzE0LTEtMS0xLTA_ce09bf5b-525e-49c3-9181-ee5cc005edde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ino:ComprehensiveIncomeLossTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzE0LTMtMS0xLTA_6579d517-4219-4177-b7f9-7ec3b744440f">257,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="ino:ComprehensiveIncomeLossTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzE0LTUtMS0xLTA_4d098637-09b7-436f-bf6d-7c271b4af746">2,170,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax benefit recorded during the year ended December 31, 2019 of  $<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzk1OA_1ca5b0fd-eb6d-46b2-9905-4422a456dd96">257,000</ix:nonFraction> was principally due to a requirement under ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that a company must consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations. As a result of the requirement under ASC 740-20-45-7, the pretax income which the Company generated from other comprehensive income was a source of income which resulted in the partial realization of the current year loss from continuing operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adoption of ASU 2019-12</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company early adopted ASU No. 2019-12 as of January 1, 2020.  Among other provisions, ASU 2019-12 eliminated the requirement under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzQ5MTE_5b8f77e1-4b4f-4869-9d55-2f78e2dcee95" continuedAt="i29109d7d084a429997ddb9678fedb5be" escape="true">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2020 and 2019 are shown below:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1cc83bef860f4e2ead84cc87f3041be3" continuedAt="iad2e105b93de4899b1094f9a52d16b49"><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i29109d7d084a429997ddb9678fedb5be"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzMtMS0xLTEtMA_3499bf8b-816d-4992-966e-091406c6633a">5,250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzMtMy0xLTEtMA_b94dd7f2-73a1-4001-bcf5-d32a8686f822">6,300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzQtMS0xLTEtMA_1d212dc6-4edd-4944-af34-6d4078f39390">127,835,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzQtMy0xLTEtMA_8ee6dee6-e3ae-41a8-ad32-e39ec63675b4">110,788,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOtherTaxCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzUtMS0xLTEtMA_2a2d7edc-d5e7-4b3e-b6a9-e8f25d5b4305">13,242,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOtherTaxCarryforwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzUtMy0xLTEtMA_7c329d47-b30f-4995-9094-3cdd4dd1763a">11,737,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzYtMS0xLTEtMA_c730aa91-9207-48fa-91bd-f5763dcd4607">1,628,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzYtMy0xLTEtMA_ad883e60-9336-4b26-aca9-4b0c3f03dd5f">1,506,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzgtMS0xLTEtMA_22947114-d905-454d-88e5-56b1d945781e">3,256,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzgtMy0xLTEtMA_a27d4473-4a38-4c97-a745-6a5d2eb95363">3,255,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredTaxAssetsIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzktMS0xLTEtMA_b0355a5a-d1ab-4d42-afdd-7244fc3172ea">757,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredTaxAssetsIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzktMy0xLTEtMA_abc4739f-9282-4e7d-90b2-3a516cded5c9">889,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzEwLTEtMS0xLTA_0b84eae1-0e6c-4e3c-b9fa-4f2f4078375f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzEwLTMtMS0xLTA_1bd6ccba-39a6-4e88-bf50-323c121567d2">1,852,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredTaxAssetInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzExLTEtMS0xLTA_9882de1d-14d7-425a-a343-c4ec6ac37c8b">564,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredTaxAssetInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzExLTMtMS0xLTA_04e35656-0fb1-45d7-a3f9-3ca5cc0beb1c">1,122,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzEyLTEtMS0xLTA_3f4ebcf4-2d01-4a4c-995f-5898cb42f3b1">542,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzEyLTMtMS0xLTA_bc2837b4-a347-461b-87d2-9bc25aa8af57">645,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredTaxAssetsOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzEzLTEtMS0xLTA_39877d89-1e9a-4b8a-9698-bee9a7b14c84">4,283,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredTaxAssetsOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzEzLTMtMS0xLTA_f31d0f34-e6f7-43b6-9f57-e50f66a1943e">4,722,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE0LTEtMS0xLTA_c3e6125d-6f22-4afd-92a3-d4619d85b392">6,127,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE0LTMtMS0xLTA_20c52d93-8468-463e-b124-eda59665fe03">2,413,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE1LTEtMS0xLTA_5c49a096-9c54-4876-95fb-1d3b9eaa07b2">163,484,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE1LTMtMS0xLTA_49e3b544-e6b6-4cd8-be32-54f586692bbd">145,229,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE2LTEtMS0xLTA_823ccf3c-3202-48c5-84e7-b9cbab3cd0bb">159,705,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE2LTMtMS0xLTA_2dfa6d85-42ad-4531-af5f-a10a9f2396f7">137,159,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE3LTEtMS0xLTA_27208165-48e0-48f7-a8d7-702665de6680">3,779,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE3LTMtMS0xLTA_bd265456-73c9-40ca-a346-b01f42931f34">8,070,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE5LTEtMS0xLTA_79a15424-d5cf-4333-9e1f-e30c3f0de107">179,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE5LTMtMS0xLTA_cdcd0690-5030-404d-84e8-0861c2fd6d73">160,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzIxLTEtMS0xLTA_0dd9bc41-7707-4bf7-9bb4-02fc8ccd55e0">2,676,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzIxLTMtMS0xLTA_8612c90f-6749-426f-887c-73e5d85a9534">2,894,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredTaxLiabilitiesFinancingArrangementDiscount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzIyLTEtMS0xLTA_57584b6a-ccce-458b-ae7b-498e7b322e31">469,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredTaxLiabilitiesFinancingArrangementDiscount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzIyLTMtMS0xLTA_6777f354-0e3c-44e4-8549-0d2530ba2753">2,862,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzIzLTEtMS0xLTA_2508719f-0782-43ef-97e2-e9cc37db1a95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzIzLTMtMS0xLTA_208d57ee-3a3b-41f1-b4b5-b5aee0aa1ae8">1,381,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzI0LTEtMS0xLTA_08e23996-b693-4a5c-9cf4-66cf435320af">487,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzI0LTMtMS0xLTA_3de8863e-48a6-4189-b372-7affef4bda15">805,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzI1LTEtMS0xLTA_3c1f34e3-5db8-4546-bb23-a5c29aac698e">32,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzI1LTMtMS0xLTA_d5e90980-b448-4a8d-8a28-4f0e3b9907cb">32,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2020, the Company had federal, California and Pennsylvania tax net operating loss (NOL) carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i2dcec29e7a224ece9361e16b87782889_I20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzE3MTY_92d92ad3-b7f4-462c-a90a-b089097044ca">566.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ib776ba015a6a43aea6946a399cff7c5d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzE3MjA_ce5cf50b-7be6-4d5b-a7cb-572d37d8a2d5">68.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if6a7c79dd6fb44fea2add2a158468fae_I20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzE3Mjc_74aace1a-97c9-43e8-aadf-fa4605607f5d">75.3</ix:nonFraction> million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. The aggregate federal net operating losses generated in 2018 and after for the amount of $<ix:nonFraction unitRef="usd" contextRef="id072f2455d4849af90468cc0d319cb25_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzE4OTE_70f7cfa9-07d9-44e8-be18-e67ff6324c4f">270.3</ix:nonFraction> million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year, subject to certain modifications made by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) enacted in 2020. The federal NOL carryforward began to expire in 2021, and the California and Pennsylvania NOL carryforwards will begin and have begun to expire in 2028 and 2020, respectively, unless previously utilized. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December 31, 2020, the Company had federal and state research and development (R&amp;D) tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i41c87ddc992c48b1acc2970661bb9d63_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzIzMTQ_f82248c7-c67c-48bf-99e0-22f322be0c67">19.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id820841c83d4427ca89b1647c1b78ca7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzIzMjE_0e3d97dc-5cd1-4fca-bee3-4264b47a566c">3.2</ix:nonFraction> million, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.</span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzQ5NDY_42413872-0b99-44d7-b6f0-25e03bca75f2" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal R&amp;D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State R&amp;D</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1a1fd05e61e4d45b37b83d2c13345a4_I20201231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringintheNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzItMS0xLTEtMA_5063d0f6-ec16-4dd9-b464-3fe9e97df26c">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f711d0981940219b0fb0f426d25c3d_I20201231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringintheNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzItMy0xLTEtMA_43bee9e5-850a-49ab-94cd-717027ccc894">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc506eb64eb44797985abc96b9c8f82f_I20201231" decimals="-5" format="ixt:zerodash" name="ino:TaxCreditCarryforwardExpiringintheNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzItNS0xLTEtMA_56d8404e-9c0d-42a1-84e2-f3ef5bdc69cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id820841c83d4427ca89b1647c1b78ca7_I20201231" decimals="-5" format="ixt:zerodash" name="ino:TaxCreditCarryforwardExpiringintheNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzItNy0xLTEtMA_3cb505b9-1aaf-4d9c-ae8f-06c9442731c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1a1fd05e61e4d45b37b83d2c13345a4_I20201231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinTwoYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzMtMS0xLTEtMA_7c01b23f-1fac-4cc5-b27f-f251782eb9ce">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f711d0981940219b0fb0f426d25c3d_I20201231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinTwoYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzMtMy0xLTEtMA_cb372ff2-990c-43d3-894b-717b49d25e8a">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc506eb64eb44797985abc96b9c8f82f_I20201231" decimals="-5" format="ixt:zerodash" name="ino:TaxCreditCarryforwardExpiringinTwoYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzMtNS0xLTEtMA_99a0b150-630b-485e-a68f-9168dc5ead84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id820841c83d4427ca89b1647c1b78ca7_I20201231" decimals="-5" format="ixt:zerodash" name="ino:TaxCreditCarryforwardExpiringinTwoYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzMtNy0xLTEtMA_f311cf3c-4aba-4df8-b2fb-1af68f779123">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1a1fd05e61e4d45b37b83d2c13345a4_I20201231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinThreeYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzQtMS0xLTEtMA_14f09f0b-c254-4d3e-8b2f-0fe9e51397ab">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f711d0981940219b0fb0f426d25c3d_I20201231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinThreeYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzQtMy0xLTEtMA_2cdf8775-9101-41b2-b127-161709f09a13">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc506eb64eb44797985abc96b9c8f82f_I20201231" decimals="-5" format="ixt:zerodash" name="ino:TaxCreditCarryforwardExpiringinThreeMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzQtNS0xLTEtMA_0140f5de-af26-42a4-9f38-84c297e2faad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id820841c83d4427ca89b1647c1b78ca7_I20201231" decimals="-5" format="ixt:zerodash" name="ino:TaxCreditCarryforwardExpiringinThreeMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzQtNy0xLTEtMA_86a78adc-8cbd-412e-bd72-b4c79ec4c587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1a1fd05e61e4d45b37b83d2c13345a4_I20201231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFourYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzUtMS0xLTEtMA_eda5525e-d327-4417-9195-7173274dc07d">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f711d0981940219b0fb0f426d25c3d_I20201231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFourYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzUtMy0xLTEtMA_ed84f0f5-233a-499b-8ad1-66af9116fb74">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc506eb64eb44797985abc96b9c8f82f_I20201231" decimals="-5" format="ixt:zerodash" name="ino:TaxCreditCarryforwardExpiringinFourMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzUtNS0xLTEtMA_85ed22f1-1683-4d66-8b8a-57067e59e619">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id820841c83d4427ca89b1647c1b78ca7_I20201231" decimals="-5" format="ixt:zerodash" name="ino:TaxCreditCarryforwardExpiringinFourMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzUtNy0xLTEtMA_6b489e2b-f7d3-4d7d-8b99-8cb39674b22a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1a1fd05e61e4d45b37b83d2c13345a4_I20201231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFiveYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzYtMS0xLTEtMA_9ed6e2d8-e337-46ee-8f47-42cbec0a5222">267.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f711d0981940219b0fb0f426d25c3d_I20201231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFiveYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzYtMy0xLTEtMA_c9eaa206-5d5c-4832-b8f2-e2d3329acbac">132.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc506eb64eb44797985abc96b9c8f82f_I20201231" decimals="-5" name="ino:TaxCreditCarryforwardExpiringinFiveYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzYtNS0xLTEtMA_dc67a55d-64f1-4e3d-8b40-53a4b4ffa564">19.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id820841c83d4427ca89b1647c1b78ca7_I20201231" decimals="-5" format="ixt:zerodash" name="ino:TaxCreditCarryforwardExpiringinFiveYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzYtNy0xLTEtMA_fda087be-4a4f-4a96-9893-49e710443a23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1a1fd05e61e4d45b37b83d2c13345a4_I20201231" decimals="-5" name="ino:OperatingLossCarryforwardsIndefinitelyCarryforward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzctMS0xLTEtMA_a70fd64c-2d9a-43d8-994b-004d5fd3ca20">270.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f711d0981940219b0fb0f426d25c3d_I20201231" decimals="-5" format="ixt:zerodash" name="ino:OperatingLossCarryforwardsIndefinitelyCarryforward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzctMy0xLTEtMA_3670633f-c49c-4d4f-81af-9db1db7d2244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc506eb64eb44797985abc96b9c8f82f_I20201231" decimals="-5" format="ixt:zerodash" name="ino:TaxCreditCarryforwardCarryforwardIndefinitely" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzctNS0xLTEtMA_caa4f817-e7a9-4e26-911c-d9514cc06019">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id820841c83d4427ca89b1647c1b78ca7_I20201231" decimals="-5" name="ino:TaxCreditCarryforwardCarryforwardIndefinitely" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzctNy0xLTEtMA_c25c3d2c-f744-4dc6-a2f8-c20346881f71">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1a1fd05e61e4d45b37b83d2c13345a4_I20201231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzgtMS0xLTEtMA_ed3fff44-6a02-4ccd-b1ca-8f99e0fc8942">566.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f711d0981940219b0fb0f426d25c3d_I20201231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzgtMy0xLTEtMA_6b3a4e79-d5c0-4110-bf58-25318a87fed8">143.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc506eb64eb44797985abc96b9c8f82f_I20201231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzgtNS0xLTEtMA_1a029742-8e8c-4f10-839f-0eadae286604">19.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id820841c83d4427ca89b1647c1b78ca7_I20201231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzgtNy0xLTEtMA_02adb8b9-a4f1-4efa-bd4e-698c0b21cd99">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#8217;s NOL and R&amp;D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section&#160;382/383 analysis regarding the limitation of NOL and R&amp;D credit </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iad2e105b93de4899b1094f9a52d16b49"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carryforwards as of December&#160;31, 2020. As a result of the analysis, the Company estimates that approximately $<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:TaxBenefitsExpired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzMwMjM_5b8455bb-73d0-48af-8395-8cf06c106e47">10.2</ix:nonFraction> million of tax benefits related to NOL and R&amp;D carryforwards will expire unused. Accordingly, the related NOL and R&amp;D credit carryforwards have been removed from deferred tax assets, accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes may further limit the ability to use the NOL and R&amp;D carryforwards.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act of 2017 subjects a U.S. stockholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.  The Company has elected to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. For 2020, the Company did not generate any GILTI due to losses earned by its foreign subsidiary.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On March 27, 2020, the CARES Act was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits federal NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows federal NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. Due to the Company's history of net operating losses, the CARES Act is not expected to have a material impact on the Company's financial statements.</span></div><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzQ5MTY_f1e62647-bfea-45e4-83a3-c8922f075f67" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company's unrecognized tax benefits:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzItMS0xLTEtMA_b872d82b-e153-4828-b47a-9c194026a707">11,204,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc185e611aa641b780dc3634c14f4ee0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzItMy0xLTEtMA_bcf38ad3-6c00-47b7-8789-c115f7466057">9,632,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i098d7fa0e69c497394a273e6da442d60_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzItNS0xLTEtMA_d80c5429-10d8-4aac-afa9-3deb6482d0f2">8,313,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzMtMS0xLTEtMA_f16fa9e1-d37b-46ca-a55e-89c8a1e659cf">1,043,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzMtMy0xLTEtMA_d1ca805b-f13c-447e-90b9-477a909e0557">1,575,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzMtNS0xLTEtMA_47e01221-94e6-4676-a904-8036a5e16206">1,319,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzQtMS0xLTEtMA_45c4e6cd-da22-46c4-8d06-3b106092175b">27,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzQtMy0xLTEtMA_364a588b-e9fb-4b63-bf3a-6a580285416a">3,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzQtNS0xLTEtMA_43ec8cc5-8ffc-475a-8f8e-291cf8b30b56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzUtMS0xLTEtNzExNA_bb99866a-c2db-4a30-9bf2-8edfb33f22ad">64,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzUtMy0xLTEtNzExNA_dac36a5a-839d-4332-b962-274ed428a716">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzUtNS0xLTEtNzExNA_927fd4fa-5ecd-49d7-8fd5-6bc303f59392">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzUtMS0xLTEtMA_7146d214-4135-4b92-bb5f-5be1576e3d17">12,210,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzUtMy0xLTEtMA_a31a6e2b-342c-4059-abd4-9ad976abbaaa">11,204,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc185e611aa641b780dc3634c14f4ee0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzUtNS0xLTEtMA_0f9ba524-98cb-406f-9559-b0c20c504621">9,632,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was $<ix:nonFraction unitRef="usd" contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzM4MDA_e6fda5f1-b1cd-41ae-a4d2-c6c77f1b1ea2">10.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzM4MDQ_68be8aeb-0a55-4cfb-b055-684744759a1e">9.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifc185e611aa641b780dc3634c14f4ee0_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzM4MTE_fd1f04c6-6928-4dcb-8d17-113ba9c6f059">8.3</ix:nonFraction> million as of December&#160;31, 2020, 2019 and 2018, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve&#160;months of the reporting date.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2017 and state and local income tax examinations before 2016. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not currently under Internal Revenue Service (&#8220;IRS&#8221;), state or local tax examination.</span></div></ix:continuation><div><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_202"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDIvZnJhZzo2MzYzNGQyYTQ0OTQ0Y2E2OWU4N2I4MDhjZDlmYTAxNS90ZXh0cmVnaW9uOjYzNjM0ZDJhNDQ5NDRjYTY5ZTg3YjgwOGNkOWZhMDE1XzU0NA_b8b96fea-88a1-41a5-97cb-43bae37dc27c" continuedAt="i7d9a48eee0bc49e59d54177a0e6a659d" escape="true">401(k) Plan</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7d9a48eee0bc49e59d54177a0e6a659d">The Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches <ix:nonFraction unitRef="number" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDIvZnJhZzo2MzYzNGQyYTQ0OTQ0Y2E2OWU4N2I4MDhjZDlmYTAxNS90ZXh0cmVnaW9uOjYzNjM0ZDJhNDQ5NDRjYTY5ZTg3YjgwOGNkOWZhMDE1XzI2MA_20fccc40-212e-4f8c-b555-9f7495ae49ab">50</ix:nonFraction>% of its employees&#8217; contributions, up to <ix:nonFraction unitRef="number" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDIvZnJhZzo2MzYzNGQyYTQ0OTQ0Y2E2OWU4N2I4MDhjZDlmYTAxNS90ZXh0cmVnaW9uOjYzNjM0ZDJhNDQ5NDRjYTY5ZTg3YjgwOGNkOWZhMDE1XzMwMg_24abaa55-0e4d-4a03-8232-3ebefcc6c1a3">6</ix:nonFraction>% of their annual compensation. The Company&#8217;s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled $<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDIvZnJhZzo2MzYzNGQyYTQ0OTQ0Y2E2OWU4N2I4MDhjZDlmYTAxNS90ZXh0cmVnaW9uOjYzNjM0ZDJhNDQ5NDRjYTY5ZTg3YjgwOGNkOWZhMDE1XzQ1Nw_0455a452-ac18-4c62-a9cd-5f135b2b8d5d">1.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDIvZnJhZzo2MzYzNGQyYTQ0OTQ0Y2E2OWU4N2I4MDhjZDlmYTAxNS90ZXh0cmVnaW9uOjYzNjM0ZDJhNDQ5NDRjYTY5ZTg3YjgwOGNkOWZhMDE1XzQ2MQ_79cbc12c-f9a6-4846-954b-1b7269b4ddf6">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDIvZnJhZzo2MzYzNGQyYTQ0OTQ0Y2E2OWU4N2I4MDhjZDlmYTAxNS90ZXh0cmVnaW9uOjYzNjM0ZDJhNDQ5NDRjYTY5ZTg3YjgwOGNkOWZhMDE1XzQ3Ng_4bca90ed-d267-4c98-9b8e-b4b921c41530">1.2</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</ix:continuation></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_205"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzc2ODY_7000d883-ebf4-4524-9c4f-22a4a2870c28" continuedAt="ia9398975c4e844a299e3bb6f35c368c8" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="ia9398975c4e844a299e3bb6f35c368c8" continuedAt="iaef20fd2c45a48249d729bf200da39f1"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Life Sciences </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 27, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="ie9f188d112294323bf3087ef33c420b6_I20200827" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzc3_4f93d108-32b6-4c53-87f8-6713359aad63">1,644,155</ix:nonFraction> shares of common stock in GeneOne for net proceeds of approximately <ix:nonFraction unitRef="krw" contextRef="i39837d9d2abd48a3aca884118a65d728_D20200827-20200827" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzgyNDYzMzcyMjQyMTY_d6035cf3-232e-467a-9a6c-0d69abe3edae">47.4</ix:nonFraction>&#160;billion KRW (approximately USD $<ix:nonFraction unitRef="usd" contextRef="i39837d9d2abd48a3aca884118a65d728_D20200827-20200827" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQ5NDc4MDIzMzM3NDg_db0679a0-14ab-4017-b114-ff16d4a65cc8">40.1</ix:nonFraction>&#160;million based on the exchange rate on the date of sale). The Company no longer holds an investment in GeneOne shares and GeneOne is no longer considered a related party to the Company under ASC 850. The Company's consolidated balance sheet as of December 31, 2020 no longer reflects GeneOne&#8217;s portion in accounts receivable and accounts payable and accrued expenses with affiliated entities, whereas the Company&#8217;s balance sheet as of December 31, 2019 reflects $<ix:nonFraction unitRef="usd" contextRef="idbd8535467dc4b5eae52e74f3983bcef_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQ5NDc4MDIzMzQ4OTc_1e4af4f2-f223-4f6d-8f5d-1f6ba1aab915">128,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="idbd8535467dc4b5eae52e74f3983bcef_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQ5NDc4MDIzMzM4MDU_b1380b8e-13e1-440f-ab8f-7f2f1509cc4e">511,000</ix:nonFraction> in accounts receivable and accounts payable and accrued expenses with </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iaef20fd2c45a48249d729bf200da39f1"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">affiliated entities, respectively, related to GeneOne. Revenues recognized from GeneOne will no longer be presented as revenue with affiliated entity on the consolidated statement of operations after the change in related party designation in August 2020. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from GeneOne for the years ended December&#160;31, 2020, 2019 and 2018 consisting of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patent, device maintenance and licensing fees was $<ix:nonFraction unitRef="usd" contextRef="iec6e16acd2c14a4e90471eef35722254_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQzMjk_4010c8ea-32de-4a2f-833b-fafb3a98abc7">125,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i31ce6dcaa01b46eeab8e3956ce276921_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQzMzM_157d731f-b09a-476f-8ebc-d035a20a7c9c">127,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if81fb01786fc4764ac42fbc00018292e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQzNDA_fbc1be5c-9336-4cb1-ac7b-fbcadeca2772">342,000</ix:nonFraction>, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses recorded from transactions with GeneOne related primarily to biologics manufacturing and were $<ix:nonFraction unitRef="usd" contextRef="iec6e16acd2c14a4e90471eef35722254_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQ0NzA_6aff6026-6733-4df3-bce5-79af796834d3">4.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i31ce6dcaa01b46eeab8e3956ce276921_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQ0NzQ_4ce775b2-9430-42f8-bf85-f5b78598ca8e">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if81fb01786fc4764ac42fbc00018292e_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQ0ODE_f515f41f-7eec-48d6-935b-2525973dd5d0">7.0</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owned <ix:nonFraction unitRef="shares" contextRef="i741b2d70a16540e4849e177841399ef2_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQ5ODI_0cbee8b8-1c6d-4aca-9fb2-37e155a2e85d">597,808</ix:nonFraction> shares of common stock in Plumbline Life Sciences, Inc. ("PLS") as of December 31, 2020 and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, the Company entered into a Debt and Share Subscription Agreement with PLS under which the Company received <ix:nonFraction unitRef="shares" contextRef="if9933acb5084469ba365e771ad142f6f_I20200220" decimals="INF" format="ixt:numdotdecimal" name="ino:InvestmentOwnedAdditionalSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQ5NDc4MDIzMzU1NDc_7f429409-9ee7-47ce-9ed2-40332b122e4c">202,050</ix:nonFraction> shares of PLS common stock in exchange for a portion of the outstanding accounts receivable balance due from PLS. Following the issuance of these shares and as of December 31, 2020, the Company held a <ix:nonFraction unitRef="number" contextRef="i741b2d70a16540e4849e177841399ef2_I20201231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzMyOTg1MzQ4OTY2MDY_9afcccb3-bc20-4739-8acc-4d97629f4467">19.7</ix:nonFraction>% ownership interest in PLS.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from PLS consists of milestone, license and patent fees. For the years ended December&#160;31, 2020 and 2019, the Company recognized revenue from PLS of $<ix:nonFraction unitRef="usd" contextRef="i8fa046515d344201b301dfcac426f1d7_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzUyOTg_14f10b0e-e684-44ff-be08-5c8bfef0c4bd">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i12e6aa36d34c4fed9f215ef703733288_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzUzMDU_67bffadc-5c57-4407-9814-a88b6ecac207">111,000</ix:nonFraction>, respectively. At December 31, 2020 and 2019, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="i741b2d70a16540e4849e177841399ef2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzU0MDA_9e3aa9aa-6c7d-4013-9a9f-d32a75885b94">67,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i584919522b8946388cc46b11e1b6c134_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzU0MDc_73a21572-98c0-4e78-9566-c64c4c094e8e">589,000</ix:nonFraction>, respectively, related to PLS.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company will reimburse Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $<ix:nonFraction unitRef="usd" contextRef="i850db8c1404e41ef8a3f4e2c5d6497c9_D20160301-20160331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementExpensesToReimburse" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzYyMDg_64efd19c-bab9-4ba7-bc35-5b47cafdd1f9">3.1</ix:nonFraction> million during the <ix:nonNumeric contextRef="i850db8c1404e41ef8a3f4e2c5d6497c9_D20160301-20160331" format="ixt-sec:durwordsen" name="ino:CollaborativeArrangementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzgyNDYzMzcyMjQyNTg_5a99dcec-987e-4271-a122-11a061ceb50e">five-year</ix:nonNumeric> term of the agreement. The Company will have the exclusive right to in-license new intellectual property developed in this agreement.  </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company rece</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ived a&#160;$<ix:nonFraction unitRef="usd" contextRef="ib07cb6287f3248b5b722d555d87a2523_D20161101-20161130" decimals="-5" format="ixt:numdotdecimal" name="ino:ProceedsFromSubGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzY0MDc_6888d02e-fb95-476e-a30c-c2649d86eab5">6.1</ix:nonFraction> million&#160;sub-grant through Wistar to develop a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DMAb</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against the Zika infection, with fun</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ding through December 2020. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $<ix:nonFraction unitRef="usd" contextRef="i510403322bee48dd9b1d7fa361079cf8_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementAwardedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzgyNDYzMzcyMjQyMzA_a18b809d-8a67-4234-862f-6362436caea1">10.7</ix:nonFraction>&#160;million sub-grant through Wistar for the preclinical development and translational studies of DMAbs as countermeasures for COVID-19, with funding through September 2022. The sub-grant also includes an option for an additional $<ix:nonFraction unitRef="usd" contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementAwardedOptionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzgyNDYzMzcyMjQyNDU_72ffa380-bdf3-40d4-996c-f7bf8ca44a4f">6.0</ix:nonFraction>&#160;million in funding through September 2024. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended December&#160;31, 2020 and 2019, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i510403322bee48dd9b1d7fa361079cf8_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:GrantProceedsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzY5NDk_eeb9a005-3ca7-4020-b7a5-e0dfe9ce9fbc">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4bc8a5ec417940d080468c000bb0c684_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="ino:GrantProceedsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzY5NTY_3bb9751e-39e9-47e5-a45b-6952b6d7d858">2.2</ix:nonFraction> million, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 4). Research and development expenses recorded from Wistar for the years ended December&#160;31, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="i510403322bee48dd9b1d7fa361079cf8_D20200101-20201231" decimals="-5" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzczMzQ_5e68a6b0-8ad5-4ff2-9f3b-594c7bfc0598">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4bc8a5ec417940d080468c000bb0c684_D20190101-20191231" decimals="-5" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzczNDk_da7bcc0a-b6ea-4f4b-8016-93c255b4a429">1.5</ix:nonFraction> million, respectively. At December&#160;31, 2020 and 2019, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="i329099e1a64e4114916fa70aa8f77967_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzc0Mzk_649c35bd-5c1c-43de-ba5b-76eefe8ed93b">425,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1344066b478244ff886e0ea7d3f13c3c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzc0NDY_5497b022-2f85-4a6a-aebc-60e7f351b042">616,000</ix:nonFraction>, respectively, and an accounts payable and accrued liability balance of $<ix:nonFraction unitRef="usd" contextRef="i329099e1a64e4114916fa70aa8f77967_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzc1MjE_12981947-673f-48a9-9162-1e6ae17183b4">643,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1344066b478244ff886e0ea7d3f13c3c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzc1Mjg_1e7ccf7a-3b2e-42e8-957e-434143cf7ff8">219,000</ix:nonFraction>, respectively, related to Wistar. As of December&#160;31, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="i329099e1a64e4114916fa70aa8f77967_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingFromAffiliate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzc1OTE_fe6b483d-5993-4cb4-9da1-537e3c364718">96,000</ix:nonFraction> recorded as grant funding liability on its consolidated balance sheet related to Wistar.</span></div></ix:continuation><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_1844"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl84MjQ2MzM3MjIzNzg4_b593797e-df3a-40c4-a8f1-cb56139208c0" continuedAt="ib4ce2a2d94914ef8ba348b613ef31094" escape="true">Geneos Therapeutics, Inc. </ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><ix:continuation id="ib4ce2a2d94914ef8ba348b613ef31094" continuedAt="i7f3c8d430c3c487f9e40599eebd6a8b3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In February 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested&#160;$<ix:nonFraction unitRef="usd" contextRef="i3278752f623242159a014d02f29d289b_D20190201-20190228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4ODY1_1f08473b-8f6d-43f6-bf42-fdf46bfa56e9">1.2</ix:nonFraction>&#160;million&#160;in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;<ix:nonFraction unitRef="number" contextRef="ie036575d65ff4badb43323c689c9ffe6_I20190228" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4ODc5_967e47f5-4771-4d67-9e25-af361a61635c">61</ix:nonFraction>%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7f3c8d430c3c487f9e40599eebd6a8b3" continuedAt="i4fefed6a510b4f4c82c42944c7efd339"><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $<ix:nonFraction unitRef="usd" contextRef="i9f560f41562c4fc9a3ad15d9c446af7c_I20200101" decimals="-3" format="ixt:numdotdecimal" name="ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4ODg5_7000606f-ff56-4319-a85b-fdb1552bdae6">800,000</ix:nonFraction>. Following this transaction, as of March 31, 2020, the Company held&#160;<ix:nonFraction unitRef="number" contextRef="ie331329335874c70bd80518d6ff9c532_I20200331" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4ODg0_4ac26abc-3f7e-4760-81de-406aeac67272">52</ix:nonFraction>%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $<ix:nonFraction unitRef="usd" contextRef="i5fae662cff7740e8b862767817b4873b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4ODk5_92cf8e15-6a29-44ed-a1ff-ae129fb80f4b">800,000</ix:nonFraction>.  Following this transaction, the Company owned <ix:nonFraction unitRef="number" contextRef="if720e223acd541dc9a923f12ccafdf0a_I20200630" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4OTA5_fc6aa071-f012-430e-97e5-6f5c149f1d5f">47</ix:nonFraction>% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support.  However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $<ix:nonFraction unitRef="usd" contextRef="id6ef275f991c4ded9ea7eddc6b7b1498_D20200601-20200601" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationGainOrLossAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4OTE0_310d34ae-06b7-4f25-80a1-ae012a631ebb">4.1</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="id6ef275f991c4ded9ea7eddc6b7b1498_D20200601-20200601" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4OTI4_9be78adf-79eb-444f-8c55-eb1ae60489a8">2.4</ix:nonFraction>&#160;million related to the remeasurement of the retained noncontrolling interest investment to fair value.  The gain has been recorded separately on the Company's consolidated statement of operations.  <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl84MjQ2MzM3MjIzNzg5_4b649067-24b6-4d5d-9dc9-fb781be0e1fb" continuedAt="i0eb52dc2d8ca48e5ba5452125cc6a9c5" escape="true">The following table shows the amounts related to the deconsolidation accounting: </ix:nonNumeric></span></div><ix:continuation id="i0eb52dc2d8ca48e5ba5452125cc6a9c5" continuedAt="iaf5efb2182eb455f89c25240ade7d236"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (excluding cash) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bc7852775b6421ca17e8e3e194bab5c_I20200601" decimals="0" format="ixt:numdotdecimal" name="ino:WorkingCapitalExcludingCash" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6ZTA1ODM2NjY0Y2Q0NDgyZGFkNjg0Y2ExOTA1OTIzN2YvdGFibGVyYW5nZTplMDU4MzY2NjRjZDQ0ODJkYWQ2ODRjYTE5MDU5MjM3Zl8wLTEtMS0xLTU3Ng_6c37622b-3403-48cb-8531-7b3a14a849c3">59,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bc7852775b6421ca17e8e3e194bab5c_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6ZTA1ODM2NjY0Y2Q0NDgyZGFkNjg0Y2ExOTA1OTIzN2YvdGFibGVyYW5nZTplMDU4MzY2NjRjZDQ0ODJkYWQ2ODRjYTE5MDU5MjM3Zl8xLTEtMS0xLTU3Ng_ebd756e7-c8d8-4db2-a1a7-cdd24c59630f">171,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net of accumulated depreciation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bc7852775b6421ca17e8e3e194bab5c_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6ZTA1ODM2NjY0Y2Q0NDgyZGFkNjg0Y2ExOTA1OTIzN2YvdGFibGVyYW5nZTplMDU4MzY2NjRjZDQ0ODJkYWQ2ODRjYTE5MDU5MjM3Zl8yLTEtMS0xLTU3Ng_4340ce3c-3e2a-4899-902f-d8aa29f6cc70">16,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of noncontrolling interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bc7852775b6421ca17e8e3e194bab5c_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6ZTA1ODM2NjY0Y2Q0NDgyZGFkNjg0Y2ExOTA1OTIzN2YvdGFibGVyYW5nZTplMDU4MzY2NjRjZDQ0ODJkYWQ2ODRjYTE5MDU5MjM3Zl8zLTEtMS0xLTU3Ng_ae37d5c5-d7af-4d62-a7c8-4012273e8fa3">3,181,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of investment in Geneos retained</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bc7852775b6421ca17e8e3e194bab5c_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedInterestFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6ZTA1ODM2NjY0Y2Q0NDgyZGFkNjg0Y2ExOTA1OTIzN2YvdGFibGVyYW5nZTplMDU4MzY2NjRjZDQ0ODJkYWQ2ODRjYTE5MDU5MjM3Zl80LTEtMS0xLTU3Ng_ad1b9445-dba8-4834-bb63-714ded2697bf">3,618,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6ef275f991c4ded9ea7eddc6b7b1498_D20200601-20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6ZTA1ODM2NjY0Y2Q0NDgyZGFkNjg0Y2ExOTA1OTIzN2YvdGFibGVyYW5nZTplMDU4MzY2NjRjZDQ0ODJkYWQ2ODRjYTE5MDU5MjM3Zl81LTEtMS0xLTU3Ng_6e70103d-87c1-4979-8b26-4cfad8352dde">4,121,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash resulting from the deconsolidation of Geneos</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ef275f991c4ded9ea7eddc6b7b1498_D20200601-20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashDivestedFromDeconsolidation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6ZTA1ODM2NjY0Y2Q0NDgyZGFkNjg0Y2ExOTA1OTIzN2YvdGFibGVyYW5nZTplMDU4MzY2NjRjZDQ0ODJkYWQ2ODRjYTE5MDU5MjM3Zl82LTEtMS0xLTU3NDU_c6011bc1-c840-438d-85f9-1de7ec565122">2,774,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The details of the Company&#8217;s <ix:nonFraction unitRef="number" contextRef="i4eaf8e38eb024ee5bd2c0e686600ecd3_I20201231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4OTQy_d3f1b1a2-12e0-4df1-b63a-01d7b4157744">47</ix:nonFraction>% retained equity investment in Geneos are shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:54.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Geneos Share Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i75e5c84b89524b7285a0f1fd58ce7d28_I20200601" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6MTQ5NDhjYTNkMmJhNDdjY2I2ZjRiNTdjMDkzNDEwYWMvdGFibGVyYW5nZToxNDk0OGNhM2QyYmE0N2NjYjZmNGI1N2MwOTM0MTBhY18xLTEtMS0xLTU3Ng_2c851935-7266-4af4-be8e-12749289a807">3,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i75e5c84b89524b7285a0f1fd58ce7d28_I20200601" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6MTQ5NDhjYTNkMmJhNDdjY2I2ZjRiNTdjMDkzNDEwYWMvdGFibGVyYW5nZToxNDk0OGNhM2QyYmE0N2NjYjZmNGI1N2MwOTM0MTBhY18xLTMtMS0xLTU3Ng_5a16071c-e26a-492b-9759-f2c6549c341b">0.273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e5c84b89524b7285a0f1fd58ce7d28_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6MTQ5NDhjYTNkMmJhNDdjY2I2ZjRiNTdjMDkzNDEwYWMvdGFibGVyYW5nZToxNDk0OGNhM2QyYmE0N2NjYjZmNGI1N2MwOTM0MTBhY18xLTUtMS0xLTU3Ng_2169165e-fc76-4e5a-b03b-d445da374e97">819,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica4b744c22f9404fa2cb9f77877257ff_I20200601" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6MTQ5NDhjYTNkMmJhNDdjY2I2ZjRiNTdjMDkzNDEwYWMvdGFibGVyYW5nZToxNDk0OGNhM2QyYmE0N2NjYjZmNGI1N2MwOTM0MTBhY18yLTEtMS0xLTU3Ng_b635afae-9f04-4b83-9298-0085f46a63e1">2,113,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica4b744c22f9404fa2cb9f77877257ff_I20200601" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6MTQ5NDhjYTNkMmJhNDdjY2I2ZjRiNTdjMDkzNDEwYWMvdGFibGVyYW5nZToxNDk0OGNhM2QyYmE0N2NjYjZmNGI1N2MwOTM0MTBhY18yLTMtMS0xLTU3Ng_ff2706ba-123c-4d83-b2ff-9af8536b2146">1.325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica4b744c22f9404fa2cb9f77877257ff_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6MTQ5NDhjYTNkMmJhNDdjY2I2ZjRiNTdjMDkzNDEwYWMvdGFibGVyYW5nZToxNDk0OGNhM2QyYmE0N2NjYjZmNGI1N2MwOTM0MTBhY18yLTUtMS0xLTU3Ng_8a0bed50-247a-4288-b07e-fad55a7681e6">2,799,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bc7852775b6421ca17e8e3e194bab5c_I20200601" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6MTQ5NDhjYTNkMmJhNDdjY2I2ZjRiNTdjMDkzNDEwYWMvdGFibGVyYW5nZToxNDk0OGNhM2QyYmE0N2NjYjZmNGI1N2MwOTM0MTBhY18zLTEtMS0xLTU3Ng_da5f83e0-d807-47f4-b43b-ebb202f7494d">5,113,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bc7852775b6421ca17e8e3e194bab5c_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6MTQ5NDhjYTNkMmJhNDdjY2I2ZjRiNTdjMDkzNDEwYWMvdGFibGVyYW5nZToxNDk0OGNhM2QyYmE0N2NjYjZmNGI1N2MwOTM0MTBhY18zLTUtMS0xLTU3Ng_87e05848-105b-4018-a36d-48a54e1fbe8e">3,618,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos Series A preferred stock was based on the per share price paid by third-party investors in connection with the most recent closing of the Series A preferred stock financing for Geneos on June 1, 2020. The fair value of Geneos common stock was determined by a third-party valuation, as there is no public market for such stock. Geneos&#8217;s enterprise value, which was estimated using a market approach that derived an implied total equity value from a transaction involving its own securities, was allocated to all classes of equity using the option pricing method. Under the option pricing method, each equity class was modeled as having a call option with a distinct claim on the total value of Geneos. Each option&#8217;s exercise price was based on the total value available for each participating security holder. The characteristics of each class of ownership determined the claim on the total value for that class of ownership.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated value allocated to common stock included assumptions related to the fair value of the enterprise, expected volatility, expected term, and risk-free interest rate. Expected volatility was based on historical asset volatilities derived from daily stock price changes of guideline public companies. The estimated expected term was based on a weighted average of the estimated time to Geneos's next financing and successful exit timing assumption.  The risk-free interest rate was based on the yield of U.S. Treasury with a comparable term. Geneos&#8217;s common stock is classified as a Level 3 financial instrument. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl84MjQ2MzM3MjIzNzkz_c4bcc1a3-6fe3-49d2-9dc3-da4274a9cdc9" continuedAt="ia2492328cffa49e5ad6758d42528e505" escape="true">The assumptions used in the fair value calculation as of June 1, 2020 are presented below:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:center"><ix:continuation id="ia2492328cffa49e5ad6758d42528e505"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id3d03457e0864bfc8b1b8bfd7dfc1ec0_D20200601-20200601" format="ixt-sec:duryear" name="ino:AlternativeInvestmentMeasurementInputTerm" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6NjU1ZDM2MjBlZThlNDEyZjgzMmM2M2UwN2E2YTAwYjgvdGFibGVyYW5nZTo2NTVkMzYyMGVlOGU0MTJmODMyYzYzZTA3YTZhMDBiOF8wLTEtMS0xLTU3Ng_b8bfd5be-f148-4e7c-b4d1-910e5a09c417">2.92</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c0fc01307c94a3f818e05fa200f315f_I20200601" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6NjU1ZDM2MjBlZThlNDEyZjgzMmM2M2UwN2E2YTAwYjgvdGFibGVyYW5nZTo2NTVkMzYyMGVlOGU0MTJmODMyYzYzZTA3YTZhMDBiOF8xLTEtMS0xLTU3Ng_04cc4c88-c7a5-406a-9c8a-4cc682c4cd28">70</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a56ec56c1704c999304cafdca127971_I20200601" decimals="4" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6NjU1ZDM2MjBlZThlNDEyZjgzMmM2M2UwN2E2YTAwYjgvdGFibGVyYW5nZTo2NTVkMzYyMGVlOGU0MTJmODMyYzYzZTA3YTZhMDBiOF8yLTEtMS0xLTU3Ng_84f69037-9289-4836-8b88-f4c25985e0f2">2.46</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geneos enterprise value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i9bc7852775b6421ca17e8e3e194bab5c_I20200601" decimals="0" format="ixt:numdotdecimal" name="ino:EquityMethodInvestmentEnterpriseValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6NjU1ZDM2MjBlZThlNDEyZjgzMmM2M2UwN2E2YTAwYjgvdGFibGVyYW5nZTo2NTVkMzYyMGVlOGU0MTJmODMyYzYzZTA3YTZhMDBiOF8zLTEtMS0xLTU3Ng_b6ab909d-c139-4abd-a4e5-2f29c87fc38c">4,966,531</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock.  Since the Company&#8217;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#8217;s common stock investment and will therefore be recorded as an equity security under ASC 321.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4fefed6a510b4f4c82c42944c7efd339"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 1, 2020, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217;s net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the Series A preferred stock financing on June 1, 2020. The Company has determined that its Series A preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $<ix:nonFraction unitRef="usd" contextRef="i1d304f7e01154532bc01359f95252e17_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl8zMjk4NTM0ODk4NTIx_3a73d42a-88d8-45aa-8b8a-91211572f5a0">1.4</ix:nonFraction>&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continues to be a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continues to not be the primary beneficiary of Geneos, as it does not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="ic121c422f0fe4bf881984c703f46d52f_I20201130" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl8zMjk4NTM0ODk4NTM1_9780205e-f4ed-48d2-a80f-da9fab301814">36</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos&#8217;s Series A-1 preferred stock was based on the per share price paid by third-party investors in connection with the closing on November 12, 2020.  The Company has concluded that its Series A-1 preferred stock investment is not similar to its prior Series A preferred stock investment due to certain material rights held solely by Series A preferred stockholders. Therefore, the Company will continue to record its Series A preferred stock investment in Geneos at cost, as there have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos for the period from June 1, 2020 through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as $<ix:nonFraction unitRef="usd" contextRef="i684fbe7297024813bfc8e35aab204865_D20200601-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4OTU3_c03adae5-204e-42a5-b358-e4b77f9bb797">4.6</ix:nonFraction>&#160;million. O</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f this amount, $<ix:nonFraction unitRef="usd" contextRef="iefe35c0283fe4a69ae2e6dd8855e61f9_D20200601-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE5MDM4_22aa8517-7a27-48d9-9453-55df9446bd37">819,000</ix:nonFraction> has been allocated to the equity method investment, thereby reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="i760444398ee74fd3afd5baf01b8fc34e_I20201231" decimals="0" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE5MDQ4_765c9b95-3230-4544-8bb1-d289c145d122">0</ix:nonFraction> as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. <ix:continuation id="iaf5efb2182eb455f89c25240ade7d236" continuedAt="i41ce2932c60b49d18df9ebe6b4a3fa82">The remaining </ix:continuation></span><ix:continuation id="i41ce2932c60b49d18df9ebe6b4a3fa82" continuedAt="i1f2170e0b9fb4cdeb62fab5660c27042"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ide3b32650b4e4f67aa4cae4aa5642502_D20200601-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE5MDUy_0f51a11c-ec97-4b68-9b79-f339a8263690">3.8</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> loss has been allocated to the Company&#8217;s Series A and Series A-1 preferred stock investments in Geneos, on a ratable basis, thereby reducing the investment balance t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o $<ix:nonFraction unitRef="usd" contextRef="i294f24f4c95d4f61a311238a03b975ba_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl84MjQ2MzM3MjIzNzk1_6d73dd39-d5fc-48d2-909e-fa1a3fb6884d">434,000</ix:nonFraction> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as shown in the table below:</span></ix:continuation></div><div style="margin-bottom:6pt;margin-top:5pt"><ix:continuation id="i1f2170e0b9fb4cdeb62fab5660c27042"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos upon deconsolidation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bc7852775b6421ca17e8e3e194bab5c_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6NGFkNTc4ZWRiNGMwNDUwZmJiMzQ1N2EzYmEyNTVjYmUvdGFibGVyYW5nZTo0YWQ1NzhlZGI0YzA0NTBmYmIzNDU3YTNiYTI1NWNiZV8xLTItMS0xLTU3Njc_620b3a42-75bb-488f-adab-3f27c7db718e">3,618,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dc3ada5f7d04ae89165c132fbfcfc62_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6NGFkNTc4ZWRiNGMwNDUwZmJiMzQ1N2EzYmEyNTVjYmUvdGFibGVyYW5nZTo0YWQ1NzhlZGI0YzA0NTBmYmIzNDU3YTNiYTI1NWNiZV8yLTItMS0xLTU3Njc_c100f066-d9f3-417c-9408-0fd25098d5fa">1,399,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i684fbe7297024813bfc8e35aab204865_D20200601-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6NGFkNTc4ZWRiNGMwNDUwZmJiMzQ1N2EzYmEyNTVjYmUvdGFibGVyYW5nZTo0YWQ1NzhlZGI0YzA0NTBmYmIzNDU3YTNiYTI1NWNiZV8zLTItMS0xLTU3Njc_f1bde3c6-3971-4ad1-a74e-49321b7b7a6f">4,584,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f4d31539a04f7f8e95ff7d666d0c49_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6NGFkNTc4ZWRiNGMwNDUwZmJiMzQ1N2EzYmEyNTVjYmUvdGFibGVyYW5nZTo0YWQ1NzhlZGI0YzA0NTBmYmIzNDU3YTNiYTI1NWNiZV80LTItMS0xLTU3Njc_406b3064-f5f5-470a-bc8c-9f1d7c6aece1">434,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</span></div></ix:continuation><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_208"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90ZXh0cmVnaW9uOjcxNDI2MDdjNjE1YjQ3MDE5MWViY2ZkNGMzNDAxNzQ1XzIwOQ_7c80affc-28dc-48e1-bab9-9394d5045abe" continuedAt="i317b2126c9ef4af08e253af85d598867" escape="true">Quarterly Financial Information (Unaudited)</ix:nonNumeric></span></div><ix:continuation id="i317b2126c9ef4af08e253af85d598867" continuedAt="i89c8e2adeb8f427b81a213ddae95356a"><ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90ZXh0cmVnaW9uOjcxNDI2MDdjNjE1YjQ3MDE5MWViY2ZkNGMzNDAxNzQ1XzIxMw_966faa59-fa6e-44df-97aa-43eee3367cb6" continuedAt="i86cd579b8a6e4fc8bb8cbcb119ae6cd7" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the quarterly results of operations of the Company for the years ended December&#160;31, 2020 and 2019 (unaudited):</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i89c8e2adeb8f427b81a213ddae95356a" continuedAt="i69c1e9d9384b436eb257fd8bd52359ea"><ix:continuation id="i86cd579b8a6e4fc8bb8cbcb119ae6cd7" continuedAt="i16b1b482522146989bad00b73d360916"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Consolidated Statements of Operations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if88d7d6e81274ed0ba37814cb46d85e5_D20201001-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzQtMS0xLTEtMA_d38db849-d36c-425b-b0ae-3dd1b7b2f431">5,003,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i573ba12b81674a4e8f8ea7ef32efdbe8_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzQtMy0xLTEtMA_7d380d00-e9d4-476b-a7a8-21f95220ba14">21,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i795cb1a151064426a4dfe996df0c38c4_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzQtNS0xLTEtMA_6792cae5-e487-4c44-a880-345eb29fae93">74,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13703c117a254b43812c022797496182_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzQtNy0xLTEtMA_b72d5a4a-7a77-4370-873b-9503fd79c166">71,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67fe64f9d9cc4e94987901784abf46ab_D20201001-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzUtMS0xLTEtMA_7fe93294-c0c6-4777-a9f9-df178051679c">82,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i070e992116654fa581ad7cf2f0c976f3_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzUtMy0xLTEtMA_8ecbd83f-9dfb-401a-bf5b-d366fb63be1c">103,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife87feec4ca84488991ff60a2283130f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzUtNS0xLTEtMA_98016138-d559-4890-8ff7-955fbe3f2577">95,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d9cc3f0455f498ab2daa193d5030329_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzUtNy0xLTEtMA_335c3211-4a09-4d33-8b28-ef6567ecd056">1,172,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue, including from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6d2e46c031143829dacb9e46e09d8e3_D20201001-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzYtMS0xLTEtMA_51237bc4-3fa2-4fe4-a88d-7524849b9a4e">494,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590abc5d2cd1439bb9b334157e97cf1c_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzYtMy0xLTEtMA_20f37ce8-ad04-41eb-90cc-0d57e8d7bc94">111,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10e7342c08644032af98955a95c3f840_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzYtNS0xLTEtMA_c23fd3c4-8466-4332-ad79-b5ba59f4be08">97,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63f67afbae934928a16259c4523b7b46_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzYtNy0xLTEtMA_11df2260-093b-4d48-98be-6eee5d8b6657">83,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzgtMS0xLTEtMA_83332acc-1152-41e7-8fc2-111b49c97f56">5,580,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzgtMy0xLTEtMA_79ff660f-8622-4c9b-b210-41bd0114ad1e">236,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzgtNS0xLTEtMA_758de3ac-48f0-46c6-b3cc-4e2a90330584">267,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzgtNy0xLTEtMA_73a96b0d-4a94-4bce-b591-dacbaceb6d38">1,327,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzEwLTEtMS0xLTA_e08837d7-a31e-420d-80c8-af5eb388dad0">26,302,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzEwLTMtMS0xLTA_04105173-b494-4502-be64-3fe8cc186a58">26,455,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzEwLTUtMS0xLTA_c4a9424c-bceb-4526-b52c-8d640ae3d8fc">22,376,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzEwLTctMS0xLTA_2f14955f-5e16-4eb2-9ed6-ce11c849e221">19,111,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzExLTEtMS0xLTA_f8aa8069-f21a-44d1-8b0c-1acc4ec98310">8,617,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzExLTMtMS0xLTA_cc2e6266-5375-4bb4-bdad-dd47273ecabb">10,110,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzExLTUtMS0xLTA_4aa8d60d-611a-4365-9618-817464236d0b">11,071,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzExLTctMS0xLTA_654cc10e-415e-461f-8d4b-8f6da54d992f">7,448,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzEzLTEtMS0xLTA_8ea16746-22a5-4076-b8f2-12443ac0aa79">34,920,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzEzLTMtMS0xLTA_f8211860-765c-4ea8-bc6b-4651fe73f79d">36,565,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzEzLTUtMS0xLTA_ff107002-387c-4b22-80e8-9571d6849725">33,448,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzEzLTctMS0xLTA_06185599-93a2-41c8-8793-ae1f561b345c">26,559,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE0LTEtMS0xLTA_a98b87c0-d05e-435f-8826-e04f7dda85a9">29,339,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE0LTMtMS0xLTA_9aa64360-4953-4e38-8692-998ac1c73288">36,329,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE0LTUtMS0xLTA_716f7fd4-d68f-4de9-b474-7c9d7ec54cc2">33,180,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE0LTctMS0xLTA_2a735ff1-159e-4c33-84b1-e22f76266c66">25,232,268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE1LTEtMS0xLTA_0c0835fa-aeda-4f51-b0e7-030b64b3789e">931,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE1LTMtMS0xLTA_62a2d57f-f34c-49ba-bb43-7d8c83f721f3">896,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE1LTUtMS0xLTA_5bd50360-25a0-4e82-a8fb-00ac9f1d01b6">1,067,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE1LTctMS0xLTA_f143bb62-b0d1-49df-ae04-4fe34af1ee84">416,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE2LTEtMS0xLTA_b1c13bb2-0617-4df4-8277-c222a2b44ee8">1,068,008</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE2LTMtMS0xLTA_20951723-b6b3-4e6c-8cb8-25db20485f5a">1,984,046</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE2LTUtMS0xLTA_a1c0e6f2-54a6-4c36-a155-7cf23750a28b">2,846,641</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE2LTctMS0xLTA_23e9eadf-706c-452b-a927-807afd4d5f27">2,803,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE4LTEtMS0xLTA_45601d42-3835-4a11-951c-8b8678103c42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE4LTMtMS0xLTA_ed84de9a-dfc9-4d44-a785-0c35d0015a02">35,306,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE4LTUtMS0xLTA_1188624a-0fe2-44fb-8e61-9c00b4bee37a">97,755,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE4LTctMS0xLTA_6516b6fe-4e4f-4ac8-be79-90b56ee38225">13,221,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on investment in affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="0" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE5LTEtMS0xLTA_0b1efe38-2524-48cd-892e-0dbc393b9727">306,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE5LTMtMS0xLTA_f2c8457f-d0ac-4077-a813-eac5251ca861">26,951,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE5LTUtMS0xLTA_e224f1f1-103a-4ac8-8290-f3face94a68c">3,883,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE5LTctMS0xLTA_525514e5-53a0-4925-9890-836d4dd850ad">13,181,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE5LTEtMS0xLTEwNjk_a55772d8-4dd9-45ea-a44a-1f3c96d328ac">1,070,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE5LTMtMS0xLTEwNjk_9003095a-622e-4311-b579-08f528b5ed37">1,315,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE5LTUtMS0xLTEwNzg_6ba044c5-5dc5-4bfa-a62f-add0c7545482">4,358,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE5LTctMS0xLTEwNzg_9574bc5c-869c-461c-b05b-589a9f4cf266">5,050,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIwLTEtMS0xLTA_1875043a-f698-47ab-aa1d-6a4eaeb8ed8d">9,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIwLTMtMS0xLTA_48216014-0d90-4be2-b5f2-734a9b369326">136,644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIwLTUtMS0xLTA_63ed8856-5cb3-4b7b-ac13-56fdc16a5285">152,102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIwLTctMS0xLTA_24c36919-2171-43f7-a2e6-ebaad0fb4917">425,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIxLTEtMS0xLTEwNjk_c86a62f3-549a-4f43-801e-682551e523b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIxLTMtMS0xLTEwNjk_5833dc7e-f2cf-48fb-9d65-2e19b22234f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIxLTUtMS0xLTEwNzg_0396b8b7-c0f8-4eae-b3bb-9d391cc1849e">4,121,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIxLTctMS0xLTEwNzg_b46acd9a-4d66-4bf7-97ab-14e62d430f1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b066217c7b540b2bc2fabd939e07804_D20201001-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIyLTEtMS0xLTEwNjk_b7f72600-e3a5-4c51-85fe-b335e84c149d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b1addc1c587493fa83cae1c6f2f7fc9_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIyLTMtMS0xLTEwNjk_da3b0a85-b863-4261-b8d6-13798739d67d">8,177,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica64d2e3910943c8a4e37fa1fe5e8214_D20200401-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIyLTUtMS0xLTEwNzg_0ff193f9-5e84-459a-8b9c-36c2f2636a77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e09b6ad2e474af5bfdec3ff92271d9f_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIyLTctMS0xLTEwNzg_a6b412d7-83b7-4045-a95e-2b5c993e078c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb7d9b899e44f18bf0403f267912de3_D20201001-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIzLTEtMS0xLTEwNjk_fc1b0129-fc4a-4453-996e-5dda8ea2057b">5,674,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib072c12c52ab4aeda860c97446fc70b6_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIzLTMtMS0xLTEwNjk_3d74727e-2ed9-4c7a-b864-71546b111f25">3,087,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie49e671657294b3c8baefe0969b6bae7_D20200401-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIzLTUtMS0xLTEwNzg_27bf8532-fad1-423f-b508-8476d0e39efd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a5a1a01c5584587899e703311afd962_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIzLTctMS0xLTEwNzg_75365766-468e-4283-86f2-ea674fd2d6d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) before income tax benefit and share in net loss of Geneos</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIxLTEtMS0xLTA_e48e44f6-bb96-4e45-b4f5-edecd0ef6b8d">22,415,201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIxLTMtMS0xLTA_2418b106-2e83-4a6b-a86a-b0ebe76ff8a7">20,931,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIxLTUtMS0xLTA_2aa6d0a1-6b14-40ba-ac4e-e6f50d352722">128,270,709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIxLTctMS0xLTA_1ab44cd1-6d8f-46e2-bdd5-c70566544e6c">33,135,404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI2LTEtMS0xLTEwNzM_50a58d19-9ce7-4985-867d-cb022b9dddc5">1,923,179</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI2LTMtMS0xLTEwNzM_90692c91-6aae-44a8-97f9-4b4d293964e6">1,759,674</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI2LTUtMS0xLTEwODI_8f947552-4c9c-45a4-9fea-6ab2e8b9f1e9">901,757</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI2LTctMS0xLTEwODI_d5768e31-bc10-42aa-9f7c-949c705c728b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIzLTEtMS0xLTA_dc76362f-d1a2-4b6b-9cd9-b28a85134645">24,338,380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIzLTMtMS0xLTA_4adc9d9a-03ff-431d-bb2d-b239a5e0a959">19,171,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIzLTUtMS0xLTA_a1107ab3-9a94-4de0-ad5b-e044cdd1f518">129,172,466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIzLTctMS0xLTA_0d671b4a-ca9a-478b-a931-d9e00a8cdfb4">33,135,404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI0LTEtMS0xLTA_1b93a588-8d5c-4fc1-8047-fd69035ada67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI0LTMtMS0xLTA_eabd6eb1-0276-4226-b447-23552c96ad2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI0LTUtMS0xLTA_5229cca3-68f1-43d3-91b3-4e0ab191cca8">469,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI0LTctMS0xLTA_5cb7c81c-f815-400d-a9d5-0ca8aa5b945a">594,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI1LTEtMS0xLTA_cdd952e8-39d4-4f5e-8808-2e974ab8dc95">24,338,380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI1LTMtMS0xLTA_8a935c5a-8bbf-4357-8e90-48f56de2b57f">19,171,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI1LTUtMS0xLTA_ce83103f-0831-4cf6-a60b-9f981bbb0984">128,703,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI1LTctMS0xLTA_424e20d6-7b01-4a07-90a0-0e8a7aeb36f1">32,541,054</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI3LTEtMS0xLTA_f1b0b8ea-925a-4a41-999f-1ff8a741a245">0.14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI3LTMtMS0xLTA_8aa79df2-3983-413f-8adf-94e6efe401d6">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI3LTUtMS0xLTA_3acf9682-dd05-49bb-bf76-0d392a3fe65f">0.83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI3LTctMS0xLTA_6c427db8-cb23-46a1-8f68-5e0edf4649c0">0.26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI4LTEtMS0xLTA_3e0fc8f6-c29b-4224-950a-564b327144ce">0.14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI4LTMtMS0xLTA_f43dab25-7ee8-4ecb-ad12-e929252b2c5e">0.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI4LTUtMS0xLTA_72839f37-af65-45b6-a9e3-0f71cf003d1b">0.83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI4LTctMS0xLTA_5e7d47e4-19ec-4e0a-b062-f8dc2b91d363">0.26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i69c1e9d9384b436eb257fd8bd52359ea"><ix:continuation id="i16b1b482522146989bad00b73d360916"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Consolidated Statements of Operations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af80391a9d7498d9623d41397672588_D20191001-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzQtMS0xLTEtMA_71e73d37-6bde-4759-8c56-7b487e0b9898">184,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97adc1d442cd448fb9146600ab5d2804_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzQtMy0xLTEtMA_44f5165b-e73e-4c2e-aa22-378a88b550ff">617,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i270677398e2d488297835140b7cd4b5e_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzQtNS0xLTEtMA_110c3c9c-5d61-4cf6-9ff1-f145ec5b9780">64,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab53db1ca1924309875498ea3f081da6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzQtNy0xLTEtMA_4e6d0d6b-4f43-4b51-819f-dcc322774744">2,770,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if64f1e0018c643a58e89139a5f4c240e_D20191001-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzUtMS0xLTEtMA_e3ca3cdb-4051-47bb-8514-ae1d60097814">55,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9ec00a3c0e4514abe1f49e7c8af240_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzUtMy0xLTEtMA_0804316c-1ed0-477c-be91-170f20f580ca">53,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fdefad67e8242bda643664dba8120e2_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzUtNS0xLTEtMA_be622ce7-4607-406d-a80f-0f89a18befb8">71,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb1b5faf5d454621b7facd84a26755bc_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzUtNy0xLTEtMA_1fddf463-d6ad-4d2e-a241-acd27f78b6ad">55,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue, including from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedf7ee151bb8419a90965b37855024f2_D20191001-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzYtMS0xLTEtMA_011e707c-dd4c-41ff-9da3-33f02d8d86ec">39,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie53b02189840498b87e2fd8412e3a928_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzYtMy0xLTEtMA_65091932-3e14-4c5c-94fe-d9f43757710d">196,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i606478849fd3433da994e2810ba1aab2_D20190401-20190630" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzYtNS0xLTEtMA_89e8369f-8050-4b94-8f3f-61ac01e90092">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie60fc32c63d143b0a967a81f8d4d95a9_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzYtNy0xLTEtMA_288157fc-65ab-468a-b37f-09c711bfa528">3,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzgtMS0xLTEtMA_b40d5a47-3262-4693-b055-e07e6c3b4132">279,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzgtMy0xLTEtMA_230836c9-1189-4cd8-828e-6049da390d47">866,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzgtNS0xLTEtMA_4ad2a1e5-4e19-41ac-95ef-0cec3d928c61">135,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzgtNy0xLTEtMA_13e808a8-9358-4329-b883-6e35f772dca4">2,829,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzEwLTEtMS0xLTA_f05cff3c-f59a-438e-9086-10213937fd81">22,003,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzEwLTMtMS0xLTA_71f38aa1-4e02-43b7-a0f0-5e7212190f98">19,137,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzEwLTUtMS0xLTA_92bb04bc-7a9a-4a3c-aa59-32f8ef975b07">22,486,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzEwLTctMS0xLTA_00bedacd-7e77-4608-9f0b-810c67fdcdcb">24,389,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzExLTEtMS0xLTA_b415a22c-001c-4b46-936c-97a2efb59550">8,696,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzExLTMtMS0xLTA_40b4e658-8d7d-4bb4-b795-8a23c190c1fe">5,681,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzExLTUtMS0xLTA_1a393c34-afdd-4eef-809d-e0298713a505">5,850,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzExLTctMS0xLTA_75db5e8f-a04d-44ba-968f-f1fca57ac333">6,975,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzEzLTEtMS0xLTA_cdc4ba0d-9704-402a-a4b2-1ff33ccf64db">30,700,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzEzLTMtMS0xLTA_88670209-4566-47db-9513-6c3c67a41ce1">24,818,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzEzLTUtMS0xLTA_06aaf0fe-5232-404c-b5db-0e255801e984">28,336,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzEzLTctMS0xLTA_f86825c8-18dc-456e-86d0-dc493bc0eeda">31,364,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE0LTEtMS0xLTA_3e2033c7-dda9-4a26-a260-e1b2c691d2b1">30,421,053</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE0LTMtMS0xLTA_2f6d4dd1-c59e-448e-9e30-581fe2e2cd2b">23,951,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE0LTUtMS0xLTA_dd594e6a-6ad5-4323-9630-9a50d5796e64">28,200,694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE0LTctMS0xLTA_3fa30ccc-3edd-42ac-89f0-c7490fd01b4e">28,535,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE1LTEtMS0xLTA_575808d5-99bd-47ea-b116-cd8c4aaa5bb1">587,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE1LTMtMS0xLTA_94bfb88a-ba05-4a01-b158-55ca735a0e96">637,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE1LTUtMS0xLTA_112e80fa-afcb-4c75-8835-cd8a4c9a0ffb">755,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE1LTctMS0xLTA_8206785e-4e00-4b51-ab7a-a8f22e3ce8f2">625,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE2LTEtMS0xLTEwNTI_4bfb7b9e-070e-4d7e-b4a1-fff67b47351b">2,668,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE2LTMtMS0xLTEwNTI_002d1437-19d5-488d-9ec2-200e4b28ffa2">2,428,671</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE2LTUtMS0xLTEwNTI_018f76a2-fe56-4e22-9942-ba2992c3e3d1">2,194,783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE2LTctMS0xLTEwNTI_406fd3c0-75f7-4460-b21b-16aef7787c34">656,248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE2LTEtMS0xLTA_412c6d5e-ef6d-4526-a916-a9ceadcb7f5b">4,315,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE2LTMtMS0xLTA_9248ed33-44c9-41fa-8c28-42d52879b1a1">2,551,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630" decimals="0" format="ixt:zerodash" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE2LTUtMS0xLTA_66a8eef9-7782-48f8-8009-8fc3772ffb51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331" decimals="0" format="ixt:zerodash" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE2LTctMS0xLTA_706d8203-e910-4225-a976-4938d8edf85f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from investment in affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE4LTEtMS0xLTEwNTI_4a7c4587-22b0-4171-8a57-fe311c01a5b4">1,681,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE4LTMtMS0xLTEwNTI_5fd66cec-6b5e-4a43-b103-3661b4c5b694">485,841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE4LTUtMS0xLTEwNTI_6b8b85c3-5ae1-4785-bea0-a0ac3438825f">173,212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE4LTctMS0xLTEwNTI_c3b49976-a0c9-4b2c-8cf7-59395521dfef">750,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE3LTEtMS0xLTA_0280c597-23df-4e56-b066-c4fe35bfa766">263,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE3LTMtMS0xLTA_9f10c5a2-41a5-48b3-aadb-5be35dc926d6">140,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE3LTUtMS0xLTA_350e5b87-9fcb-462b-9777-4f45392899a7">127,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE3LTctMS0xLTA_a708515d-fdfe-482a-a100-93dc8aa1b0c0">35,839</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss before income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE4LTEtMS0xLTA_8f2d216e-b422-469b-a562-ce2410aa8783">38,235,146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE4LTMtMS0xLTA_5d1bce2b-08dd-416f-8a9e-5b8f2c9c9d7f">23,536,452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE4LTUtMS0xLTA_5df6de44-a968-4aa4-9859-055d48f4ab0d">29,685,847</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE4LTctMS0xLTA_0f52f81d-8d64-4f1e-af60-d2fb98282d8e">29,351,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE5LTEtMS0xLTA_936db1ae-ebe4-4d69-9e8f-3de6ab8659e6">87,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE5LTMtMS0xLTA_048dd203-cb36-47f4-b1d3-1e3035abc049">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE5LTUtMS0xLTA_2f0fff01-c3d9-4862-bcb6-4f4c90500ae4">106,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE5LTctMS0xLTA_d4ad3ed0-97e4-470d-9a26-f6923c14004b">62,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIwLTEtMS0xLTA_10470330-8046-4a70-be5a-92d13b1af901">38,147,382</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIwLTMtMS0xLTA_b62b0425-f0bd-4aa5-9b0e-f4400d36fbb0">23,536,452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIwLTUtMS0xLTA_da773161-1156-46fa-88ce-61dad51117f8">29,579,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIwLTctMS0xLTA_f562996e-866f-41e4-a848-0065b536c846">29,288,867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIxLTEtMS0xLTA_991d15df-be02-4cdc-ba25-5167137fdc74">485,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIxLTMtMS0xLTA_dba4beeb-a7d4-4878-b4a7-1231a4b13938">445,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIxLTUtMS0xLTA_108a8666-a8d5-45e3-b980-112fd18a4066">191,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIxLTctMS0xLTA_c7773e12-f895-4868-8eb3-4bd93a686c88">69,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIyLTEtMS0xLTA_c6f86a39-f9e7-433a-ba8b-6344c91f6bbe">37,662,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIyLTMtMS0xLTA_c0ea27d7-d09b-4626-b822-b90f1519c3e4">23,090,693</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIyLTUtMS0xLTA_3ae1d623-64f9-4475-81f6-26cb09aa0c55">29,387,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIyLTctMS0xLTA_301670da-0c8b-4f7f-8ffa-8a47f57afe37">29,219,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzI0LTEtMS0xLTA_7974b278-eec8-48ab-b98a-735b75b3db5f">0.38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzI0LTMtMS0xLTA_8b86d6db-2a2c-4eae-9128-8f704e71fa8e">0.23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzI0LTUtMS0xLTA_e0940dce-08da-43f8-8862-b80afaa25de7">0.30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzI0LTctMS0xLTA_58be537c-cb3f-4bc0-b1b2-9cf6f43444c3">0.30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzI1LTEtMS0xLTA_c1b9f407-30f3-4694-a47c-8ddc77441e94">0.38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzI1LTMtMS0xLTA_a3401424-2162-4b2f-8b84-5c24cee14244">0.25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzI1LTUtMS0xLTA_ae38914d-64a0-401f-aa22-3e3f86536cb9">0.30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzI1LTctMS0xLTA_e90b1e26-e4d3-405d-8e98-0dba50fd4012">0.30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div id="i06d07667d4974765a8282374d1211e66_211"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21. <ix:nonNumeric contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMTEvZnJhZzo0YjQyMTlmM2QzZDU0NTkwOTc5ZjcxNGVkODNjMDgzNC90ZXh0cmVnaW9uOjRiNDIxOWYzZDNkNTQ1OTA5NzlmNzE0ZWQ4M2MwODM0XzE4NDU_a01803bf-b9df-4faf-86fb-ea86cee74bf9" continuedAt="i9ba1e1721a464411b77a8409e8161626" escape="true">Subsequent Events</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9ba1e1721a464411b77a8409e8161626">On January 25, 2021, the Company closed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="if258c2eac36b42adb8115f070d01b735_D20210125-20210125" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMTEvZnJhZzo0YjQyMTlmM2QzZDU0NTkwOTc5ZjcxNGVkODNjMDgzNC90ZXh0cmVnaW9uOjRiNDIxOWYzZDNkNTQ1OTA5NzlmNzE0ZWQ4M2MwODM0XzMyOTg1MzQ4ODgzMTY_4a15f295-e485-4ab1-93e1-8191f01ffd49">20,355,000</ix:nonFraction> shares of the Company's common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6888c79a29d34124835456052fe2309e_I20210125" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMTEvZnJhZzo0YjQyMTlmM2QzZDU0NTkwOTc5ZjcxNGVkODNjMDgzNC90ZXh0cmVnaW9uOjRiNDIxOWYzZDNkNTQ1OTA5NzlmNzE0ZWQ4M2MwODM0XzMyOTg1MzQ4ODgzMjg_dd05b611-1ff1-4abc-a235-b9c1f6c84321">8.50</ix:nonFraction> per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other estimated offering expenses, were $<ix:nonFraction unitRef="usd" contextRef="i6888c79a29d34124835456052fe2309e_I20210125" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMTEvZnJhZzo0YjQyMTlmM2QzZDU0NTkwOTc5ZjcxNGVkODNjMDgzNC90ZXh0cmVnaW9uOjRiNDIxOWYzZDNkNTQ1OTA5NzlmNzE0ZWQ4M2MwODM0XzMyOTg1MzQ4ODgzMzU_2fdf1e68-78f4-49e4-9637-5aa419200248">162.1</ix:nonFraction>&#160;million.</ix:continuation> </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>2
<FILENAME>ino-12312020x10kex1014.htm
<DESCRIPTION>EX-10.14
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i412cef2899bc4cd386fa14bf1a8043af_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 10.14</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTION COPY</font></div></div><div style="margin-bottom:12pt;text-align:center;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaboration and License Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into as of December 31, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a corporation organized and existing under the laws of Delaware and having a place of business at 60 W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462 USA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a corporation having a place of business at B1-308, No. 218 Xinghu Street, Suzhou 214002, Jiangsu Province, China (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Inovio and Advaccine are sometimes referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Inovio is currently conducting research and development of the Vaccine (as defined below) and the Product (as defined below)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Advaccine is a pharmaceutical company with experience in developing pharmaceutical products in, among other regions, the Advaccine Territory (as defined below)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties have been collaborating in co-development of Vaccine since January 2020, including conducting preclinical studies, early stage clinical trials and other development activities in connection with the Product, and desire to continue the collaboration for the Development, Manufacturing and Commercialization of the Product (with each capitalized term as respectively defined below). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in furtherance of such collaboration, Advaccine desires to obtain from Inovio an exclusive license subject to the limitations set forth below to  Develop, Manufacture and Commercialize the Product in the Advaccine Territory (with each capitalized term as respectively defined below), and Inovio is willing to grant such license to Advaccine, all under the terms and conditions hereof&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Advaccine and Inovio are concurrently entering into that certain Non-exclusive License Agreement, dated as of the date hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Non-Exclusive License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), pursuant to which Advaccine grants Inovio a non-exclusive license to certain DNA vaccine manufacturing processes for use in the Advaccine Territory and Inovio Territory (each as defined below).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Now, Therefore</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement, the Parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 1.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Definitions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accounting Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i) for Inovio, the U.S. generally accepted accounting principles (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and (ii) for Advaccine, the International Financial Reporting </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">1</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Standards (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IFRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) or any other accounting standards it is required to adopt under the applicable Laws, in either case consistently applied.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, as applicable, the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. &#167;&#167;301 et seq., and&#47;or the Public Health Service Act, 42 U.S.C. &#167;&#167;262 et seq., as such may be amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Patents that claim Advaccine Inventions. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, collectively, mainland China, Taiwan, Hong Kong and Macau (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Region</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Adverse Risk</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any risk of an adverse effect on the Development, procurement or maintenance of Regulatory Approval, Manufacture or Commercialization of the Products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party.  For the purposes of this definition, the word &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under common control with&#8221;) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, or by contract or otherwise.  For clarity, once a Person ceases to be an Affiliate of a Party, then, without any further action, such Person shall cease to have any rights, including license and sublicense rights, under this Agreement by reason of being an Affiliate of such Party. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Anti-Corruption Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means laws, regulations, or orders prohibiting the provision of a financial or other advantage for a corrupt purpose or otherwise in connection with the improper performance of a relevant function, including without limitation, to the extent applicable, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Corruption of Foreign Public Officials Act (CFPOA)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">US Foreign Corrupt Practices Act (FCPA)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">UK Bribery Act 2010</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and similar laws governing corruption and bribery, whether public, commercial or both, to the extent applicable. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Array</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means device arrays used in combination with the Inovio Device.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biosimilar Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a particular Product that has received Regulatory Approval for a particular indication in a particular Region and is being marketed and sold by Advaccine or any of its Affiliates or Sublicensees in the applicable Region, a biologic product that (a) is sold in such region by a Third Party that is not a sublicensee of Advaccine or its Affiliate, and where such Third Party did not purchase or acquire such product in a chain of distribution that included any of Advaccine or its Affiliates or sublicensees, and (b) has received Regulatory Approval (with all references in the definitions for Biosimilar Product and Regulatory Approval to the &#8220;Product&#8221; to be deemed references to such biologic product) in such Region for the same indication as the applicable Product as a &#8220;bioequivalent,&#8221; &#8220;biosimilar&#8221; or similar designation of interchangeability by the applicable Regulatory Authority in such Region pursuant to an expedited or abbreviated approval process, where (i) such Product is the reference product in such Region, and (ii) such Regulatory Approval referred to or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">relied on the approved Marketing Authorization Application for such Product held by Advaccine or its Affiliate or Sublicensee in such Region or the data contained or incorporated by reference in such approved Marketing Authorization Application for such Product in such Region. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a day other than Saturday, Sunday or any day that banks in Suzhou, China&#59; Plymouth Meeting, PA&#59; or New York City, New York, are required or permitted to be closed. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means each successive period of three (3) consecutive calendar months ending on March 31, June 30, September 30, or December 31.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means with respect to either Party&#58; (a) the sale of all or substantially all of such Party&#8217;s assets or business relating to this Agreement (other than to an Affiliate of such Party)&#59; (b) a merger, reorganization or consolidation involving such Party in which the voting securities of such Party outstanding immediately prior thereto cease to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization or consolidation&#59; or (c) a Person, or group of Persons, acting in concert acquire more than fifty percent (50%) of the voting equity securities or management control of such Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any clinical testing of a pharmaceutical or biologic product in human subjects.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CMC Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Information related to the chemistry, manufacturing and controls of the Product, as specified by the FDA, NMPA and other applicable Regulatory Authorities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all activities undertaken before and after obtaining Regulatory Approvals relating specifically to the pre-launch, launch, promotion, detailing, medical education and medical liaison activities, marketing, pricing, reimbursement, sale, and distribution of the Products, including strategic marketing, sales force detailing, advertising, market the Product support, all customer support, the Product distribution and invoicing and sales activities&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall exclude any activities relating to the Manufacture of the Product.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercializing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the correlative meanings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to either Party&#8217;s obligations under this Agreement, the carrying out of such obligations with a level of efforts and resources consistent with the commercially reasonable practices of a similarly situated company in the pharmaceutical industry for the active and diligent commercialization of a similarly situated branded pharmaceutical product as the Product at a similar stage of commercialization, taking into account efficacy, safety, patent and regulatory exclusivity, anticipated or approved labeling, present and future market potential, competitive market conditions, the profitability of the product in light of pricing and reimbursement issues, and all other relevant factors.  It is understood that in fulfilling any obligation to use Commercially Reasonable Efforts in this Agreement, a Party shall not take into account (i) any other pharmaceutical product such Party is then researching, developing, manufacturing or commercializing outside the scope of this Agreement, (ii) the payments required to be made by such Party to the other Party under this Agreement, (iii) such Party&#8217;s access to sufficient personnel, capital or resources to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">conduct its responsibilities hereunder in accordance with the foregoing standards or (iv) political considerations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Common Technical Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CTD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a set of specifications for application dossier adopted by the ICH for organizing applications of pharmaceuticals for human use to regulatory authorities. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Competing Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any biological or pharmaceutical product, other than the Vaccine or the Product, that is intended for the prevention or treatment of the disease caused by SARS-CoV-2. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of a Party means any and all Information of such Party or its Affiliates that is disclosed to the other Party or its Affiliates under this Agreement, whether in oral, written, graphic, or electronic form.  In addition, all Information disclosed by a Party or its Affiliates pursuant to the mutual non-disclosure agreement between Beijing Advaccine Biotechnology Co., Ltd. and Inovio dated January 27, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be deemed to be Confidential Information of such Party disclosed hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that any use or disclosure of any such Information that is authorized under Article 12 shall not be restricted by, or be deemed a violation of, the Confidentiality Agreement.  For clarity, Inovio Licensed Know-How shall be deemed Confidential Information of Inovio. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to any material, Information, Patent or other intellectual property right, possession of the right, whether directly or indirectly, and whether by ownership, license, or otherwise, to grant a license, sublicense, or other right to or under, such material, Information, Patent, or intellectual property right without violating the terms of any existing agreement or other arrangement with any Third Party&#59; provided that, with respect to any material, Information, Patent or other intellectual property right obtained by Inovio after the Effective Date from a Third Party, Inovio shall be deemed to Control such material, Information, Patent or other intellectual property right only if it possesses the right to grant such license, sublicense, or other right thereto without being obligated to pay any royalties or other consideration therefor, unless Advaccine agrees in advance of any grant of rights thereto to pay such royalties or other consideration. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Patent and a Product, that the Manufacture, use, offer for sale, sale or import of such Product by an unlicensed Third Party would infringe a Valid Claim in such Patent&#59; provided, however, that in determining whether a claim of a pending Patent application would be infringed, it shall be treated as if issued in the form then currently being prosecuted.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Covered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Covering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the correlative meanings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CTA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Clinical Trial Application which provides comprehensive information about the investigational medicinal product(s) and planned trial, enabling Regulatory Authorities to assess the acceptability of conducting the applicable study.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all data, including CMC Information, non-clinical data, preclinical data and clinical data, generated by or on behalf of a Party or its Affiliates or their respective Sublicensees (in the case of Advaccine) or licensees, including Inovio Partners (in the case of Inovio), pursuant to activities conducted under this Agreement.  For clarity, Data does not include any patentable Inventions. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all activities conducted after the Effective Date relating to preclinical and clinical trials, toxicology testing, statistical analysis, publication and presentation of study results with respect to the Products, and the reporting, preparation and submission of regulatory applications (including any CMC Information) for obtaining, registering and maintaining Regulatory Approval of the Products&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall exclude any activities relating to the Manufacture of the Product.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Developing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the correlative meanings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Drug Substance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means bulk drug substance that is represented for use in a drug that, when used in the Manufacturing of a drug, becomes an active pharmaceutical ingredient.   </font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the European Medicines Agency or any successor entity. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S. Food and Drug Administration or any successor entity. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all prophylactic and therapeutic use in humans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means with respect to a Region, the first sale of a Product in such Region to a Third Party by or on behalf of Advaccine, its Affiliates or Sublicensees after Regulatory Approval has been obtained in such Region. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fiscal Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Advaccine&#8217;s fiscal year that starts on January 1 and ends on December 31.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Good Clinical Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the then-current standards, practices and procedures promulgated or endorsed by the FDA as set forth in the guidelines entitled &#8220;Guidance for Industry E6 Good Clinical Practice&#58; Consolidated Guidance,&#8221; including related regulatory requirements imposed by the FDA, and comparable regulatory standards, practices and procedures promulgated by the NMPA or other Regulatory Authority applicable in the Advaccine Territory, as they may be updated from time to time, including applicable quality guidelines promulgated under the ICH.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Good Laboratory Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, and comparable regulatory standards promulgated by NMPA or other Regulatory Authority applicable to the Advaccine Territory, as may be updated from time to time, including applicable quality guidelines promulgated under the ICH.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) the good manufacturing practices required by the FDA and set forth in the FDCA or FDA regulations (including without limitation 21 CFR 210 and 211), policies, guidances or guidelines, or any applicable equivalent within a regulatory jurisdiction, including, without limitation, any applicable current good manufacturing practices requirements and pharmaceutical industry standards for the manufacture and testing of investigational pharmaceutical materials in force from time-to-time in the European Union (including, without limitation, Directive 2003&#47;94&#47;EC laying down the principles and guidelines of good manufacturing practice), the relevant national implementations of these rules and any relevant national and European Commission and Committee on Proprietary Medicinal Products guidance and, in particular, Annex 13 of the Guide to Good Manufacturing Practice entitled &#8220;Manufacture of investigational medicinal products&#8221;, as updated and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">amended from time-to-time, in each case in effect at any time during the term of this Agreement, for the manufacture, handling and testing of investigational pharmaceutical products&#59; (b) the corresponding requirements of each applicable Regulatory Agency or other governmental authority, and (c) any other guidances, procedures, practices, arrangements, additions or clarifications, as the Parties may agree in writing from time-to-time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Government Official</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) any official or employee of any Governmental Authority, or any department, agency, or instrumentality thereof (including without limitation commercial entities owned or controlled, directly or indirectly, by a Governmental Authority), (b) any political party or official thereof, or any candidate for political office, or (c) any official or employee of any public international organization. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any multi-national, national, federal, state, local, municipal, provincial or other governmental authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ICH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Data, results, technology, business or financial information or information of any type whatsoever, in any tangible or intangible form, including know-how, copyrights, trade secrets, practices, techniques, methods, processes, inventions, developments, specifications, formulae, software, algorithms, marketing reports, expertise, technology, test data (including pharmacological, biological, chemical, biochemical, clinical test data and data resulting from non-clinical studies), CMC Information, stability data and other study data and procedures.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Clinical Trial, enrollment of the first patient in such Clinical Trial.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initiate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initiating</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the correlative meanings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Device</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Inovio&#8217;s proprietary electroporation device CELLECTRA&#174; 2000 and CELLECTRA&#174; 3PSP, including any improvements and variants thereof Controlled by Inovio, and the associated Arrays, applicators and components. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Licensed Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all Information (including Data and Regulatory Materials) that (a)(i) is Controlled by Inovio or its Affiliates as of the Effective Date or (ii) becomes Controlled by Inovio or its Affiliates during the Term, and (b) is necessary for the Development, Manufacture, or Commercialization of the Vaccine and&#47; or the Product in the Field in the Advaccine Territory.  For clarity, Inovio Licensed Know-How shall include Inovio&#8217;s interest in any Information included in Inovio Inventions and Joint Inventions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all Patents that (a)(i) are Controlled by Inovio or its Affiliates as of the Effective Date or (ii) become Controlled by Inovio or its Affiliates during the Term, and (b) Cover the Vaccine and&#47;or the Product in the Field in the Advaccine Territory.  Inovio Licensed Patents include the Patents listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and Inovio&#8217;s interest in any Joint Patents that may be filed during the Term.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Product-Specific Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Inovio Licensed Patents specifically claiming the composition of matter of, or the method of making or using, the Vaccine and&#47;the Product in the Field in the Advaccine Territory.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Parties acknowledge and agree that the Patents listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are Inovio Product-Specific Licensed Patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Inovio Licensed Know-How and Inovio Licensed Patents. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the world except for the Advaccine Territory. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio US Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Phase 3 Clinical Trial or any other trials that are equivalent or similar to a Pivotal Clinical Trial, as requested by the FDA or at its own initiative, designed or intended to ascertain efficacy of the Product in a larger population, to be conducted by Inovio, itself or by its Affiliate or a Third Party in the U.S. or any other jurisdictions in the Inovio Territory. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any inventions and&#47;or discoveries, including processes, manufacture, composition of matter, Information, methods, assays, designs, protocols, and formulas, and improvements or modifications thereof, patentable or otherwise, that are generated, developed, conceived or reduced to practice (constructively or actually) by or on behalf of a Party or its Affiliates or their respective Sublicensees (in the case of Advaccine) or licensees, including Inovio Partners (in the case of Inovio) (a) pursuant to activities conducted under this Agreement, or (b) in connection with the Development, Manufacture, and Commercialization of the Product, in each case of (a) and (b), including all rights, title and interest in and to the intellectual property rights therein and thereto&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that Inventions shall exclude Data.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Patents that claim Joint Inventions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, municipal, city or other political subdivision, domestic or foreign.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; mean activities directed to manufacturing, processing, filling, finishing, packaging, labeling, quality control, quality assurance testing and release, post-marketing validation testing, inventory control and management, storing and transporting the Vaccine or the Product (as well as the Array), including oversight and management of vendors therefor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing Cost</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a particular drug product supplied by Inovio pursuant to Section 7.1&#58; (a) if Inovio or its Affiliate Manufactures the applicable drug product, the actual manufacturing cost of such drug product (as determined in accordance with U.S. GAAP consistently applied with its other products)&#59; or (b) if a Third Party Manufactures such drug product, the actual transfer price paid by Inovio or its Affiliate to such Third Party for the Manufacture of such drug product without any additional mark-up&#59; in each case of (a) and (b), excluding the external costs of insurance and transportation, import and export taxes and fees, and similar charges, for such drug product. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Marketing Authorization Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means new drug application, biologics license application, or other marketing authorization application to the appropriate Regulatory Authority for approval to market a Product, but excluding pricing approvals.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.52&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the gross amounts billed or invoiced by Advaccine, its Affiliates and their respective Sublicensees for sales of the Products to Third Parties, less the following deductions to the extent reasonable, customary, and actually allowed and taken with respect to such sales&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;trade, cash or quantity discounts not already reflected in the amount invoiced, to the extent related to the gross amount billed or invoiced&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;price reductions, rebates and administrative fees (including those paid or credited to pharmacy benefit managers, governmental authorities or otherwise) (provided that, such administrative fees shall not be in excess, in the aggregate of &#91;***&#93; of Net Sales with respect to any given Calendar Quarter)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;shipping costs, including freight, insurance and other transportation charges or costs incurred in shipping of the Products to Third Parties (provided that, such shipping costs shall not be in excess of &#91;***&#93; of Net Sales with respect to any given Calendar Quarter)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;sales, use, excise, value-added or similar taxes, customs duties and other governmental fees, charges and surcharges imposed on the sale of the Products&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;amounts repaid or credited by reason of rejections, defects, recalls or returns&#59;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;amounts paid or credited for wholesaler chargebacks&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;any receivables that have been included in gross sales and are deemed to be uncollectible according to Accounting Standards (any such bad debt deductions shall be applied to Net Sales in the period in which such receivables are written off) (provided that, the amount of such receivables shall not be in excess of &#91;***&#93; of Net Sales with respect to any given Calendar Quarter).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, amounts received or invoiced by Advaccine, its Affiliates, or their respective Sublicensees for the sale of the Product among Advaccine, its Affiliates or their respective Sublicensees shall not be included in the computation of Net Sales hereunder unless the purchasing entity is the end-user.  For purposes of determining Net Sales, the Product shall be deemed to be sold when billed or invoiced.  Net Sales shall be accounted for in accordance with standard Advaccine practices for operation by Advaccine, its Affiliates or their respective Sublicensees, as practiced in the Advaccine Territory, but in any event in accordance with Accounting Standards consistently applied in the Advaccine Territory.  For clarity, a particular item may only be deducted once in the calculation of Net Sales.  Notwithstanding anything to the contrary in the foregoing, to the extent any amounts deducted pursuant to subsections (d) or (g) above are subsequently recovered by Advaccine, its Affiliates, or their respective Sublicensees during the Term, such recovered amounts shall be deemed &#8220;Net Sales&#8221; for the subsequent Calendar Quarter&#59; provided that, if no royalties are owed by Advaccine </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">for such subsequent Calendar Quarter pursuant to Section 8.4, Advaccine shall promptly refund such recovered amounts to Inovio.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The transfer of any Product to an Affiliate, Sublicensee, or other Third Party (x) in connection with the research, development or testing of a Product (including, without limitation, the conduct of Clinical Trials), (y) for purposes of distribution as promotional samples, or (z) at nominal cost for indigent or similar public support or compassionate use programs, will not, in any case, be considered a Net Sale of a Product under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">With respect to any transfer of any Product in the Advaccine Territory for any substantive consideration other than monetary consideration on arm&#8217;s length terms, for the purposes of calculating the Net Sales under this Agreement, such Product shall be deemed to be sold exclusively for money at the average Net Sales price charged to Third Parties for cash sales in the Advaccine Territory during the applicable reporting period (or if there were only de minimus cash sales in the Advaccine Territory, at the fair market value as determined by comparable markets).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advaccine, its Affiliates, and their respective Sublicensees shall sell the Product as a standalone product and will not sell the Product as a part of a bundle with other products or offer packaged arrangements to customers that include the Product, except with Inovio&#8217;s prior written consent.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event that a Product is sold by Advaccine, its Affiliates or their respective Sublicensees in a relevant Region as part of a Combination Product, where &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any unified dose (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">., not a kit of two separate and distinct drug dosage forms that are priced and sold separately) of pharmaceutical product which is comprised of (x) a Product and (y) other therapeutically active compound(s) not licensed by Inovio to Advaccine hereunder (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Net Sales of such Product, for the purposes of determining royalty payments, shall be determined by the subsections below&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NMPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the National Medical Products Administration of the People&#8217;s Republic of China, formerly known as the China Food and Drug Administration, or any successor agency or authority thereto. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) pending patent applications, issued patents, utility models and designs&#59; (b) reissues, substitutions, confirmations, registrations, validations, re-examinations, additions, continuations, continued prosecution applications, continuations-in-part, or divisions of or to any of the foregoing&#59; and (c) extensions, renewals or restorations of any of the foregoing by existing or future extension, renewal or restoration mechanisms, including supplementary protection certificate, patent term additions, patent term extensions or the equivalent thereof. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means an individual, corporation, partnership, limited liability company, limited partnership, trust, business trust, association, joint stock company, joint venture, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">pool, syndicate, sole proprietorship, unincorporated organization, Governmental Authority or any other form of entity not specifically listed herein. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Phase&#8239;2 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any human clinical trial of a Vaccine conducted mainly to test the effectiveness of chemical or biologic agents or other types of interventions for purposes of identifying the appropriate dose for a Phase 3 Clinical Trial for a particular indication or indications that would satisfy the requirements of 21&#8239;CFR &#167;&#8239;312.21(b) or its non-United States equivalents. A &#8220;Phase 2&#47;3 Clinical Trial&#8221; shall be deemed to be a Phase 2 Clinical Trial with respect to the portion of that clinical trial that is regarded as its Phase 2 component, in accordance with the applicable protocol. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Phase&#8239;3 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any human clinical trial of a Vaccine designed to&#58; (i) establish that such Product is safe and efficacious for its intended use&#59; (ii) define warnings, precautions and adverse reactions that are associated with the Product in the dosage range to be prescribed&#59; and (iii) support regulatory approval of such Product, that would satisfy the requirements of 21&#8239;CFR &#167;&#8239;312.21(c) or its non-United States equivalents.&#160; A &#8220;Phase 2&#47;3 Clinical Trial&#8221; shall be deemed to be a Phase 3 Clinical Trial with respect to the portion of that clinical trial that is regarded as its Phase 3 component, in accordance with the applicable protocol. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.58&#160;&#160;&#160;&#160;&#8220;Pivotal Clinical Trial&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means a pivotal study in human patients with a defined dose or a set of defined doses of the Product designed or intended to ascertain efficacy and safety of the Product for the purpose of enabling the preparation and forming the primary basis for submission of a Marketing Authorization Application for the Product to the competent Regulatory Authority in a Region of the Advaccine Territory, which may be a Phase 2 Clinical Trial or a Phase 3 Clinical Trial. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any pharmaceutical&#47;biological product in any form comprising the Vaccine, with or without an Inovio Device.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proper Conduct Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, Advaccine, its Affiliates and Sublicensees, and each of their Representatives not, directly or indirectly, (a) making, offering, authorizing, providing or paying anything of value in any form, whether in money, property, services or otherwise to any Government Official, or other Person charged with similar public or quasi-public duties, or to any customer, supplier, or any other Person, or to any employee thereof, or failing to disclose fully any such payments in violation of the laws of any relevant jurisdiction to (i) obtain favorable treatment in obtaining or retaining business for it or any of its Affiliates, (ii) pay for favorable treatment for business secured, (iii) obtain special concessions or for special concessions already obtained, for or in respect of it or any of its Affiliates, in each case which would have been in violation of any applicable Laws, (iv) influence an act or decision of the recipient (including a decision not to act) in connection with the Person&#8217;s or its Affiliate&#8217;s business, (v) induce the recipient to use his or her influence to affect any government act or decision in connection with the Person&#8217;s or its Affiliate&#8217;s business or (vi) induce the recipient to violate his or her duty of loyalty to his or her organization, or as a reward for having done so&#59; (b) engaging in any transactions, establishing or maintaining any fund or assets in which it or any of its Affiliates shall have proprietary rights that have not been recorded in the books and records of it or any of its Affiliates&#59; (c) making any unlawful payment to any agent, employee, officer or director of any Person with which it or any of its Affiliates does business for the purpose of influencing such agent, employee, officer or director to do business with it or any of its Affiliates&#59; (d) violating any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provision of applicable Anti-Corruption Laws&#59; (e) making any payment in the nature of bribery, fraud, or any other unlawful payment under the applicable Laws of any jurisdiction where it or any of its Affiliates conducts business or is registered&#59; or, (f) if such Person or any of its Representatives is a Government Official, improperly using his or her position as a Government Official to influence the award of business or regulatory approvals to or for the benefit of such Person, its Representatives or any of their business operations, or failing to recuse himself or herself from any participation as a Government Official in decisions relating to such Person, its Representatives or any of their business operations. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all approvals (including marketing authorization approvals, supplements, amendments, pre- and post-approvals, and pricing and reimbursement approvals), licenses, registrations or authorizations of any national, supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, that are necessary for the Manufacture, distribution, marketing, importation, exportation, use or commercial sale of a Product in a given country or regulatory jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, in a particular country or jurisdiction, any applicable Governmental Authority involved in granting Regulatory Approval in such country or jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means regulatory applications (including CTA and MAA), submissions, notifications, communications, correspondence, registrations, Regulatory Approvals and&#47;or other filings made to, received from or otherwise conducted with a Regulatory Authority in order to Develop, Manufacture, market, sell or otherwise Commercialize the Products in a particular country or jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, as to any Person, such Person&#8217;s Affiliates and its and their successors, controlling Persons, directors, officers and employees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Third Party that has received a license or other right under the Inovio Technology in accordance with Section 2.1(c), but shall not include (i) any Third Party wholesaler or distributor engaged for the sale of the Product (even if such wholesaler or distributor is granted a right or license to sell Product) provided that such wholesaler or distributor does not make any royalty, milestone, profit share or other payment to Advaccine or its Affiliate based on such wholesaler&#8217;s or distributor&#8217;s sale of the Product&#59; or (ii) any Third Party contract research organization or manufacturer providing services to Advaccine or its Affiliate (even if such contract research organization or manufacturer is granted a right or license to make the Vaccine or the Product). For clarity, the gross invoiced price for sale of the Product to any wholesaler, distributor, contract research organization or manufacturer described above shall be included in Net Sales.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Person other than a Party or an Affiliate of a Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.67</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">U.S. Dollar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a U.S. dollar, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">US$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall be interpreted accordingly. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">USA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the United States of America, including all possessions and territories thereof. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vaccine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means INO-4800, which includes the DNA plasmid identified as pGX9501, encoding the Spike protein of SARS-CoV-2. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means a claim (including a process, use, or composition of matter claim) of (a) an issued and unexpired patent that has not (i) irretrievably lapsed or been revoked, dedicated to the public or disclaimed or (ii) been held invalid, unenforceable or not patentable by a court, governmental agency, national or regional patent office or other appropriate body that has competent jurisdiction, which holding, finding or decision is final and unappealable or unappealed within the time allowed for appeal, or (b) a pending patent application that has been prosecuted in good faith pending for no more than seven (7) years since its priority date and has not been abandoned or finally disallowed without the possibility of appeal. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.71</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any period of twelve (12) consecutive months.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.72&#160;&#160;&#160;&#160;Additional Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; The following table identifies the location of definitions set forth in various Sections of the Agreement&#58;  </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:75.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.267%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Defined Terms</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Accused Party</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.5</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advaccine</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advaccine Housemarks</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.6(b)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advaccine Indemnitees</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advaccine Inventions</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1(d)(ii)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advaccine Product Mark</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.6(a)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advaccine Sublicense Agreement</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1(c)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Agreement</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Alliance Manager</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Bankruptcy Laws</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.13</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Claims</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Clinical Manufacturing Technology Transfer Agreement</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1(c)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Clinical Supply Agreement</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1(a)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Combination Product</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.52</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Commercialization Plan</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2(a)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Confidentiality Agreement</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.19</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Development Plan</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Divestiture</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Effective Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Enforcing Party</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.4(c)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive Officer</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">First Supplemental Development Plan</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">GAAP</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IFRS</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:75.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.267%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indemnified Party</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indemnifying Party</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Infringement</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.4(a)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Infringement Action</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.5</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Initial Development Plan</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inovio</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inovio Device Commercial Supply Agreement</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2(a)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inovio Indemnitees</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inovio Inventions</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1(d)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inovio Partner</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insolvency Event</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.5</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insolvent Party</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.13</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Joint Inventions</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1(d)(iii)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Joint Steering Committee</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2(a)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Losses</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Non-Exclusive License Agreement</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Recitals</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Non-Insolvent Party</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.13</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Other Products</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.52</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Party</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PDF</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.12</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pharmacovigilance Agreement</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.8</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Product Materials</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.7</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Region</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.4</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Remedial Action</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.9</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Royalty Term</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4(b)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SEC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.3(c)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Securities Regulators</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2(c)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SIAC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SIAC Rules</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Step-In Rights</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2(d)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tax Withholding</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.9(b)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Term</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">VAT</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.9(c)</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Working Group</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 2.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">License</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.1&#160;&#160;&#160;&#160;License to Advaccine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions of this Agreement, Inovio hereby grants Advaccine an exclusive (even as to Inovio except as provided in Section 2.1(b) below) license, with the right to sublicense (solely as provided in Section 2.1(c)), under the Inovio Technology, to Develop, Manufacture and have Manufactured (solely in accordance with Section 7.2), distribute, market, promote, sell, have sold, offer for sale, import, label, package and otherwise Commercialize the Products in the Field in the Advaccine Territory.  For clarity, no rights shall be granted to Advaccine under this Section 2.1(a), with respect to the Development, Manufacture or Commercialization of any product containing or using for administration an Inovio Device without the Vaccine.  For further clarity and unless otherwise agreed in Section 2.1(d), no rights shall be granted to Advaccine under this Section 2.1(a) with respect to the Manufacture of the Inovio Device other than the right to Manufacture the Arrays in the Advaccine Territory.  As consideration for the foregoing license and access to and transfers of know-how under this Agreement, Advaccine will make certain payments to Inovio as set out in, and subject to the terms and conditions of, Article 8. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Inovio Retained Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding the exclusive rights granted to Advaccine in Section 2.1(a), Inovio and its Affiliates shall retain the following&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:101.67pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i. the right to practice the Inovio Technology within the scope of the license granted to Advaccine under Section 2.1(a) in order to perform, or have performed by a Third Party contractor, Inovio&#8217;s obligations under this Agreement&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:98.34pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii. the right to Manufacture or have Manufactured the Products anywhere in the world for sale and use in the Inovio Territory, provided that Inovio shall obtain prior written consent, not to be unreasonably withheld, from Advaccine before Manufacturing or having Manufactured the Products in the Advaccine Territory using any rights granted to Inovio under the Non-Exclusive License Agreement for sale and use in the Inovio Territory&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:95.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii. the right to practice and license the Inovio Technology outside the scope of the license granted to Advaccine under Section 2.1(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Sublicense Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall not have the right to grant sublicenses of the license granted in Section 2.1(a) without Inovio&#8217;s express prior written consent, except that Advaccine may grant such sublicense without Inovio&#8217;s consent to its Affiliates.  Upon receiving approval from Inovio for the grant of a sublicense to a Third Party, Advaccine shall, within thirty (30) days after granting any such sublicense, notify Inovio of the grant of such sublicense and provide Inovio with a true and complete copy of the sublicense agreement (which may have financial information and other confidential information redacted, provided that such redacted information is not reasonably necessary for Inovio to assess compliance of the sublicense agreement with this Section 2.1(c)) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine Sublicense Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Each Advaccine Sublicense Agreement shall be consistent with the terms and conditions of this Agreement, and Advaccine shall be solely responsible for all of its Sublicensees&#8217; activities and any and all failures by its Sublicensees to comply with the applicable terms of this Agreement.  Without limiting the foregoing, each Advaccine Sublicense Agreement shall include the following additional terms and conditions&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.67pt">the Sublicensee shall be bound by non-use and non-disclosure obligations no less stringent than those set forth in this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii. the Sublicensee shall not have any right to grant further sublicenses to the Inovio Technology (excluding sublicenses to Third Party contractors, including distributors and wholesalers)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii. the Sublicensee shall not have any right to prosecute or maintain or enforce any Inovio Licensed Patents&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv. the Sublicensee shall assign or license to Advaccine all Data and Inventions generated by such Sublicensee, and shall grant Advaccine all of the rights necessary for Advaccine to fulfill its obligations under Sections 9.1(a) and 9.1(d).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Additional License. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inovio hereby agrees to expand the license granted to Advaccine under Section 2.1 for Advaccine, by itself or through any ofits Affiliates or a Third Party, to conduct the Phase 3 Clinical Trial in the Inovio Territory at Advaccine&#8217;s own cost and expense for the purpose of obtaining the Regulatory Approval of the Product in the Advaccine Territory,  in the event of (i) unless a Phase 3 Clinical Trial in the Inovio Territory has already been completed, a Change of Control of Inovio, where the acquirer of Inovio, by itself or through any of its Affiliates or a Third Party, is developing, manufacturing or commercializing any Competing Product for the Advaccine Territory&#59; (ii) an official request by any Regulatory Authority in the Advaccine Territory&#59; (iii) the occurrence of such circumstances as described in Section 4.2&#59; or (iv) otherwise upon mutual agreement of the Parties&#59; provided, however, that Inovio shall have the right to review and approve the protocols and design of such Phase 3 Clinical Trial.  Inovio hereby agrees to expand the license granted to Advaccine under Section 2.1 for Advaccine to have the Inovio Device Manufactured in the U.S. or any other mutually agreed upon country by a Third Party contract manufacturer for use with the Product in the Advaccine Territory in the event of the occurrence of an Insolvency Event of Inovio.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.1&#160;&#160;&#160;&#160;Inovio Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inovio has the right, in its sole discretion, to enter into one or more agreements with Third Parties and grant such Third Parties the right to Develop, Manufacture and&#47;or Commercialize the Products in one or more countries in the Inovio Territory (each such Third Party, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; provided that (a) Inovio shall remain solely responsible for any Inovio Partner&#8217;s activities, and (b) the grant of such rights to such Inovio Partner shall not affect Inovio&#8217;s obligations under the Agreement.  So long as such Inovio Partner(s) is not actively developing or commercializing any Competing Product in the Advaccine Territory, (i) Inovio shall have the right (but not the obligation) to fulfill any of its obligations under this Agreement through Inovio Partner(s), including Inovio&#8217;s obligations under Article 3, and (ii) Inovio shall have the right to disclose to Inovio Partner(s) all Information solely regarding the Products, including all Regulatory Materials relating thereto, disclosed by Advaccine to Inovio under this Agreement, for use by Inovio Partner(s) in their Development, Manufacture and Commercialization of the Product in the Inovio Territory&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that (A) all such Information disclosed to Inovio Partner(s) by Inovio shall be deemed the Confidential Information of Advaccine, and (B) any Inovio Partner(s) that receive such information shall be obligated to abide by restrictions on disclosure and use substantially similar to the provisions set forth in Section 12.1 and Inovio shall remain responsible for the Inovio Partner(s)&#8217; performance of such obligations and compliance with such restrictions. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.3&#160;&#160;&#160;&#160;Negative Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine covenants that, except as explicitly set forth in this Agreement, it will not, and will not permit any of its Affiliates or Sublicensees to, use or practice any Inovio Technology outside the scope of the license granted to it under Section 2.1(a). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.4&#160;&#160;&#160;&#160;No Implied Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as explicitly set forth in this Agreement, neither Party shall be deemed by estoppel or implication to have granted the other Party any license or other right to any intellectual property of such Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.5&#160;&#160;&#160;&#160;Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Exclusivity Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term, Advaccine hereby covenants not to, itself or through any Affiliate or Third Party, Develop, Manufacture or Commercialize any Competing Product in the Field in the Advaccine Territory.  For clarity, the foregoing restrictions shall not apply to (i) internal research and internal non good laboratory practices preclinical work by either Party&#59; and (ii) any Development, Manufacture and Commercialization of any Combination Product by Advaccine in the Advaccine Territory upon mutual agreement of the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Advaccine Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that, in connection with an Advaccine Change of Control, Advaccine or any of its Affiliates obtains or holds the rights to a Competing Product that would cause Advaccine to be in breach of Section 2.5(a), then upon written notice to Inovio within thirty (30) days after such rights are first obtained, Advaccine shall elect one of the following&#58; (A) to terminate this Agreement pursuant to Section 13.2, in which case such notice will serve as notice of termination under Section 13.2&#59; or (B) to (or have its Affiliate) sell, exclusively license or transfer rights to the Competing Product to a Third Party without Advaccine or any of its Affiliates receiving a continuing share of profit, royalty payments, or other economic interest in the success of such Competing Product in the Advaccine Territory (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Divestiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in which case Advaccine or any of its Affiliates shall, or shall cause the applicable entity to, complete the Divestiture of such Competing Product within twelve (12) months from the date of such Advaccine Change of Control, in which case the conduct of activities with respect to such Competing Product by Advaccine or any of its Affiliates during such 12-month period shall not be deemed a breach of Advaccine&#8217;s exclusivity obligations under Section 2.5, provided that such activities with respect to such Competing Product during such 12-month period are conducted independently of the activities conducted under this Agreement and no Inovio Technology or Advaccine Inventions is used in the conduct of such activities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:60.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.6&#160;&#160;&#160;&#160;Transfer of Inovio Licensed Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inovio shall provide Advaccine with complete and accurate copies of the Inovio Licensed Know-How directly applicable to the Vaccine, the Product and the Arrays to the extent expressly provided for in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and in accordance with the timeline specified therein.  The JSC shall establish a reasonable process and schedule for the transfer of additional Inovio Licensed Know-How related to the Vaccine, the Product and the Array as required for the filing of an MAA in the Advaccine Territory and any other necessary Inovio Licensed Know-How that subsequently comes into existence and becomes Controlled by Inovio or its Affiliates during the Term.  Inovio shall reasonably cooperate with Advaccine in providing Advaccine only with copies of such Inovio Licensed Know-How directly applicable to the Vaccine, the Product and the Array (but not the Inovio Device) in accordance with the process and schedule agreed upon through the JSC.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 3.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Governance</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.1&#160;&#160;&#160;&#160;Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within thirty (30) days after the Effective Date, each Party shall appoint and notify the other Party of the identity of a representative having the appropriate qualifications, including a general understanding of pharmaceutical development, manufacturing, and commercialization issues, to act as its alliance manager under this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Alliance Managers shall serve as the primary contact points between the Parties for the purpose of providing each Party with information on the progress and results of Advaccine&#8217;s Development, Manufacturing, and Commercialization of the Products.  The Alliance Managers shall also be primarily responsible for facilitating the flow of information and otherwise promoting communication, coordination and collaboration between the Parties with respect to the Products.  Each Party may replace its Alliance Manager at any time upon written notice to the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.2&#160;&#160;&#160;&#160;Joint Steering Committees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Formation&#59; Purpose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within thirty (30) days after the Effective Date, the Parties shall establish a joint steering committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the overall coordination and oversight of the Parties&#8217; activities under this Agreement.  The role of the JSC shall be&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:101.67pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i. to review, discuss and coordinate the overall strategy for the Development, Manufacturing, and Commercialization of the Products and the Modified Products in the Field in the Advaccine Territory, including related regulatory activities&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:98.34pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii. to review, discuss and approve the Initial Development Plan and any proposed amendments or revisions to the Development Plan, including the First Supplemental Development Plan and those with respect to clinical Development activities set forth in Section 4.4(b)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:95.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii. to review and discuss (but not approve) the Commercialization Plan and any proposed amendments or revisions to such plan, and review and discuss (but not approve) the Commercialization of the Products in the Field in the Advaccine Territory (including any pricing strategy with respect to the Products)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:95.67pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv. to coordinate the Commercialization of the Products in the Advaccine Territory and Inovio Territory to ensure consistent global marketing of the Products in the Field&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:99pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">v. to perform such other functions as appropriate to further the purposes of this Agreement, as expressly set forth in this Agreement or as determined by the Parties in writing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Members</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The JSC shall be comprised of an equal number of representatives from each Party.  Each Party&#8217;s representatives shall be an officer or employee of such Party or its Affiliate having sufficient seniority within the applicable Party to make decisions arising within the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">scope of the JSC&#8217;s responsibilities.  In addition, at least one of Advaccine&#8217;s JSC representatives must be someone whose job responsibilities within Advaccine include active involvement in the development and implementation of Advaccine&#8217;s Development (including regulatory) strategy with respect to the Products in the Field in the Advaccine Territory (at all times that Advaccine or its Affiliate or sublicensee is conducting such Development) or Advaccine&#8217;s Commercialization strategy with respect to the Products in the Field in the Advaccine Territory (at all times that Advaccine or its Affiliate or sublicensee is conducting such Commercialization), and each of Advaccine&#8217;s JSC representatives must have up-to-date knowledge of Advaccine&#8217;s ongoing and planned Development (including regulatory) and Commercialization activities with respect to the Products in the Field in the Advaccine Territory (at all times that Advaccine is conducting such activities).  Each Party shall initially appoint two (2) representatives to the JSC.  The JSC may change its size from time to time by unanimous consent of its representatives, and each Party may replace its representatives at any time upon written notice to the other Party.  Each Party shall appoint one (1) of its representatives on the JSC to act as the co-chairperson.  The role of the co-chairpersons shall be to convene and preside at the JSC meetings and to ensure the circulation of meeting agendas at least five (5) Business Days in advance of JSC meetings and the preparation of meeting minutes and any pre-read materials in accordance with Section 3.2(c), but the co-chairpersons shall have no additional powers or rights beyond those held by other JSC representatives.  Employees or consultants of either Party that are not representatives of the Parties on the JSC may attend meetings of the JSC, provided that such attendees shall not vote or otherwise participate in the decision-making process of the JSC and are subject to obligations of confidentiality substantially similar to the provisions set forth in Section&#160;12.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JSC shall meet at least once per Calendar Quarter during the Term, unless the Parties mutually agree in writing to a different frequency for such meetings.  Either Party may also call a special JSC meeting (by videoconference or teleconference) by at least ten (10) Business Days prior written notice to the other Party in the event such Party reasonably believes that a significant matter must be addressed prior to the next regularly scheduled meeting, and such Party shall provide the JSC no later than ten (10) Business Days prior to the special meeting with materials reasonably adequate to enable an informed decision.  The JSC may meet in person, by videoconference or by teleconference.  All JSC meetings shall be conducted in English, and all communications, reports and records by and between the Parties under this Agreement shall be in English.  The co-chairpersons shall alternate responsibility for preparing reasonably detailed written minutes of the JSC meetings that reflect, without limitation, all material decisions made at such meetings.  The co-chairpersons (or their designees) shall send draft meeting minutes to each representative of the JSC for review and approval within ten (10) Business Days after the JSC meeting.  Such minutes shall be deemed approved unless one or more JSC representatives object to the accuracy of such minutes within ten (10) Business Days of receipt.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Decision Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JSC shall strive to seek consensus in its actions and decision making process and all decisions by the JSC shall be made by consensus, with each Party having collectively one (1) vote in all decisions.  If after reasonable discussion and good faith consideration of each Party&#8217;s view on a particular matter before the JSC, the representatives of the Parties cannot reach an agreement as to such matter (to the extent that such matter requires the agreement of the Parties hereunder) within ten (10) Business Days after such matter was brought to the JSC for resolution or after such matter has been referred to the JSC, then, Advaccine&#8217;s Executive Officer </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall have the final decision making authority with respect to such matter within the JSC&#8217;s authority&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that Inovio&#8217;s Executive Officer shall have the right in their sole discretion to veto any decision by Advaccine reasonably likely to result in Adverse Risk on the Inovio Technology, or the safety or efficacy of the Product, or the Development or Commercialization of the Product in the Inovio Territory, including any global Clinical Trial of Product or Regulatory Approval of any Product in the Inovio Territory, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that (i) any decision to Develop, Manufacture or Commercialize the Product as a Combination Product in the Advaccine Territory will require the mutual agreement of the Parties, and (ii) Advaccine shall not have the right, by virtue of its decision-making authority, to cause Inovio to violate the terms of any agreement with a Third Party, or cause Inovio to violate any applicable Laws, ethical requirement, or intellectual property right of any Third Party, and Advaccine&#8217;s exercise of its decision-making authority shall be subject to the limitations set forth in Section 3.3&#59; provided, that Inovio shall provide Advaccine with an explanation as to why any such decision of Advaccine would cause Inovio to violate the terms of any agreement with a Third Party, or cause Inovio to violate any applicable Laws, ethical requirement, or intellectual property right of any Third Party. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For clarity, the JSC shall be a forum for discussing, but shall not have any decision-making authority with respect to, Inovio&#8217;s Development of the Product in the Inovio Territory, and Inovio shall have full control and authority over the Development, Commercialization of the Product in the Inovio Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.3&#160;&#160;&#160;&#160;Limitation of JSC Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JSC shall only have the powers expressly assigned to it in this Article 3 and elsewhere in this Agreement and shall not have the authority to&#58; (a) modify or amend the terms and conditions of this Agreement&#59; (b) waive or determine either Party&#8217;s compliance with the terms and conditions of under this Agreement&#59; or (c) decide any issue in a manner that would conflict with the express terms and conditions of this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.4&#160;&#160;&#160;&#160;Discontinuation of the JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The activities to be performed by the JSC shall solely relate to governance under this Agreement, and are not intended to be or involve the delivery of services.  The JSC shall continue to exist until the first to occur of&#58; (a) the Parties mutually agree to disband the JSC&#59; or (b) Inovio provides written notice to Advaccine of its intention to disband and no longer participate in the JSC.  Thereafter, the JSC shall have no further obligations under this Agreement and each Party shall designate a contact person for the exchange of information relevant to activities that would have been performed by the JSC under this Agreement and decisions of the JSC shall be decisions as between the Parties, subject to the other terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.5&#160;&#160;&#160;&#160;Working Groups</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  From time to time, the JSC may establish and delegate duties of the JSC to sub-committees or directed teams (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Working Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) on an &#8220;as-needed&#8221; basis to oversee particular projects or activities&#59; provided that in any case neither Party shall be required by the Working Group to assume any responsibility, financial or otherwise, beyond those agreed to in writing by such Party, in particular pursuant to each Party&#8217;s respective obligations under this Agreement.  Each such Working Group shall be constituted and shall operate as the JSC determines.  Working Groups may be established on an ad hoc basis for purposes of a specific project or on such other basis as the JSC may determine.  Each Working Group and its activities shall be subject to the oversight, review and approval of, and shall report to, the JSC.  In no event shall the authority of the Working Group exceed that of the JSC.  All decisions of a Working Group shall be by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">consensus.  Any disagreement between the members of a Working Group shall be referred to the JSC for resolution.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 4.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DEVELOPMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.1&#160;&#160;&#160;&#160;Overview&#59; Diligence of Advaccine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions of this Agreement (including the diligence obligations set forth below), Advaccine shall be solely responsible for the Development of the Products in the Field in the Advaccine Territory, at its own cost and expense (except as otherwise expressly set forth herein), including (except as set forth in Section 4.7) all non-clinical and clinical studies and collection of CMC Information, as necessary to obtain the Regulatory Approval for the Products in any Region in the Advaccine Territory.  Advaccine shall maintain adequate funding and use Commercially Reasonable Efforts to Develop and obtain the Regulatory Approval for the Products in the Field in each Region in the Advaccine Territory.  Without limiting the generality of the foregoing, Advaccine shall use Commercially Reasonable Efforts to conduct its Development activities under and in accordance with the Development Plan, as well as Manufacturing activities related to such Development, as set forth in the Initial Development Plan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.2&#160;&#160;&#160;&#160;Diligence of Inovio. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inovio shall use Commercially Reasonable Efforts to Develop and obtain the Regulatory Approval for the Products in the Field in the United States, and shall provide all reasonable assistance and cooperation to assist and support Advaccine, at Advaccine&#8217;s sole cost and expense, as specified in this Agreement, the Development Plan or as reasonably requested by Advaccine from time to time, in obtaining the Regulatory Approval for the Products (as well as the Inovio Device and the Array for use in connection with the Products) in the Advaccine Territory.  Except for circumstances provided in Section 2.1 (d) (i), (ii) and (iv), in the event that, within twelve (12) months from the Effective Date, the Inovio US Trial is not Initiated or Inovio decides not to conduct or is not required to conduct the Inovio US Trial, Inovio shall inform Advaccine thereof in writing.  In such an event, Advaccine may elect to conduct a Phase 3 Clinical Trial in the Inovio Territory at its own cost and expense for the purpose of obtaining Regulatory Approval of the Product in the Advaccine Territory, subject to Section 2.1(d)&#59; provided, however, that Inovio shall have the right to review and approve the protocols and design of such Phase 3 Clinical Trial.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.3&#160;&#160;&#160;&#160;Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Without limiting the generality of the other provisions in this Article 4, within thirty (30) days after the Effective Date, Advaccine (in conjunction with assistance from Inovio) will prepare and submit to the JSC an initial, summary plan and budget for research and Development of the Vaccine and the Products in the Field in the Advaccine Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which Initial Development Plan shall be mutually agreed upon by the Parties.  Within ninety (90) days after the Effective Date, Advaccine (in conjunction with assistance from Inovio) will prepare and submit to the JSC a detailed plan containing the strategy, activities, study designs, timeline, study material needs (including Inovio Devices and the Vaccine) and budget for research and Development of the Vaccine and the Products in the Field in the Advaccine Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Supplemental</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; and together with the Initial Development Plan and any subsequent updates pursuant to this Section 4.3, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The First Supplemental Development Plan shall include among other things, all material non-clinical and clinical studies, CMC Information collection activities and regulatory activities with respect to the Vaccine and the Products to be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">conducted by or on behalf of Advaccine or its Affiliates or their respective Sublicensees in the Advaccine Territory.  From time to time during the Term (but at least once per Fiscal Year), Advaccine shall prepare amendments and updates, as appropriate, to the then-current Development Plan, and shall submit such amendments and updates to the JSC in accordance with Section 4.4. For further clarity, if there are no amendments or updates to the then-current Development Plan that are applicable in a Fiscal Year, Advaccine&#8217;s sole responsibility under this Section 4.3 during such Fiscal Year shall be to inform Inovio that the then-current Development Plan is up to date.  Advaccine shall be solely responsible for all decisions regarding the day-to-day conduct of Development within the Advaccine Territory. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.4&#160;&#160;&#160;&#160;Other Development Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Pre-Clinical Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon prior written consent from Inovio, Advaccine may conduct pre-clinical studies to generate and obtain Data that is reasonably useful for the Development of any Product in the Field in the Advaccine Territory, provided that Advaccine shall promptly amend the Development Plan to include such pre-clinical studies and submit such amendment to the JSC for review. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Clinical Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If Advaccine wishes to conduct any Clinical Trials for the Development of any Product in the Field other than as set forth in the First Supplemental Development Plan in the Advaccine Territory, Advaccine may propose an amendment to the Development Plan to include such Clinical Trials and submit such amendment to the JSC for review and approval.  If and upon receipt of such proposal, the JSC shall promptly (but in any event within thirty (30) days) review and decide on whether to approve such proposal.  Upon the JSC&#8217;s approval of such amendment, such Clinical Trials shall be included in the amended Development Plan and Advaccine may conduct such Clinical Trials at its own cost.  Advaccine shall ensure that any Clinical Trials conducted in the Advaccine Territory, whether by itself or through a subcontractor pursuant to Section&#160;4.9, are conducted only at medical facilities that are qualified and registered with the NMPA or any other applicable Regulatory Authority. For clarity, Advaccine shall not conduct any Clinical Trials of any Product outside of the Field.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As agreed to between the Parties, Inovio may provide such technical assistance and cooperation to Advaccine as Advaccine may reasonably request, at Advaccine&#8217;s sole cost and expense, as necessary or reasonably useful for Advaccine to Develop or Commercialize the Products in the Field in the Advaccine Territory.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.5&#160;&#160;&#160;&#160;Development Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall maintain complete, current and accurate records of all activities (and all Data and other Information resulting from such activities) conducted with respect to Products by Advaccine, its Affiliates and their respective Sublicensees in the Advaccine Territory.  Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes.  Advaccine shall document all non-clinical studies and Clinical Trials for the Products in formal written study records according to applicable Laws, including applicable national and international guidelines such as ICH, GCP and GLP, and shall, at Inovio&#8217;s reasonable request, provide Inovio English translations thereof (to the extent prepared and originated in a language other than English) at Inovio&#8217;s sole cost and expense.  Subject to provisions in Section 4.8, Inovio shall have the right to review and copy such records at reasonable times and to obtain access to the original to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">extent necessary or useful for regulatory or patent purposes and for legal proceedings in accordance with this Agreement.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.6&#160;&#160;&#160;&#160;Development Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall keep Inovio reasonably informed as to the progress and results of Advaccine&#8217;s, its Affiliates&#8217; and their respective Sublicensees&#8217; Development activities (including prompt reporting of available clinical Data).  Without limiting the foregoing, at each regularly scheduled JSC meeting, Advaccine shall provide Inovio with a reasonably detailed written report summarizing its Development activities performed since the last JSC meeting and the results thereof, as reasonably sufficient to enable Inovio to determine Advaccine&#8217;s compliance with its diligence obligations under Section 4.1&#59; provided that, even if the JSC does not hold a meeting in one or more Calendar Quarters, Advaccine shall provide such written report to Inovio at least once every Calendar Quarter.  At such JSC meeting, the Parties shall discuss the status, progress and results of Advaccine&#8217;s, its Affiliates&#8217; and their respective Sublicensees&#8217; Development activities.  Advaccine shall promptly respond to Inovio&#8217;s reasonable questions or requests for additional information relating to such Development activities.  In addition, within thirty (30) days after the end of each Fiscal Year, Advaccine shall provide Inovio with a detailed written annual report regarding the progress of its Development activities and any results therefrom.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.7&#160;&#160;&#160;&#160;Data Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In addition to Inovio&#8217;s obligation with respect to the transfer of Inovio Licensed Know-How set forth under Section 2.6 and each Party&#8217;s adverse event and safety Data reporting obligations pursuant to Section 5.8, but subject to the remainder of this Section 4.7 and Section 4.8, each Party shall, at its sole cost and expense, promptly provide the other Party with copies of any Data and Regulatory Materials related to the Vaccine or the Products generated by or on behalf of such Party or its Affiliates or Sublicensees in the performance of Development activities hereunder that would be reasonably necessary for the Development, Manufacture and Commercialization of the Vaccine or the Products in the Field in the other Party&#8217;s respective territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The JSC may establish reasonable policies to effectuate the exchange of additional Product Materials between the Parties.  Advaccine shall have the right to use the data provided by Inovio hereunder for the purpose of obtaining and maintaining Regulatory Approval for and Commercializing the Product in the Field in the Advaccine Territory.  Inovio shall have the right to use the data provided by Advaccine hereunder for the purpose of obtaining and maintaining Regulatory Approval for and Commercializing the Product in the Inovio Territory.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.8&#160;&#160;&#160;&#160;Clinical Trial Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties acknowledge and agree that certain government approval or filing may be required in the Advaccine Territory before certain Data generated from the Clinical Trials in the Advaccine Territory may be provided to or otherwise made available to Inovio or its designee.  The Parties agree to use their Commercially Reasonable Efforts to collaborate with each other and with Third Parties in obtaining such approval or filing in the most efficient manner as permitted by the applicable Laws.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.9&#160;&#160;&#160;&#160;Subcontractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Advaccine, upon prior express written consent from Inovio, shall have the right to engage subcontractors to conduct any activities necessary for Development or Manufacturing (subject to the terms of Article 7) of the Products, including but not limited to non-clinical studies, Clinical Trials, CMC activities, and regulatory services for the Products, under this Agreement, provided that such subcontractors (a) are bound by written obligations of confidentiality, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">non-use and compliance with applicable Laws, including Proper Conduct Practices, consistent with this Agreement and have agreed in writing to assign to Advaccine all Data, Information, inventions or other intellectual property generated by such subcontractor in the course of performing such subcontracted work, (b) are capable of producing Data (including non-clinical Data, clinical Data and CMC Information, as applicable) acceptable to the NMPA, the FDA and the EMA (and other applicable Regulatory Authorities in the Advaccine Territory, the United States or the European Union) and (c) as applicable, with respect to matters covered by Article 7, meet the specifications and requirements thereunder. Advaccine shall remain responsible for any obligations that have been delegated or subcontracted to any subcontractor, and shall be responsible for the performance of its subcontractors.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 5.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Matters</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.1&#160;&#160;&#160;&#160;Regulatory Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, Advaccine will be responsible, at its sole cost and expense, for the conduct of all regulatory activities required to obtain and maintain Regulatory Approval of the Products (including the Inovio Device and the Arrays for use in connection with the Products) in the Field in the Advaccine Territory, including the preparation and submission of all Regulatory Materials and all communications and interactions with Regulatory Authorities, as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">necessary to obtain Regulatory Approval for the Products in any Region in the Field in the Advaccine Territory.  Advaccine shall be responsible for filing each CTA in the Field in the Advaccine Territory for each Product.  Advaccine shall be responsible for filing each MAA in the Field in the Advaccine Territory for each Product in Advaccine&#8217;s name.  The Development Plan shall include the regulatory strategy for obtaining Regulatory Approval of the Products in the Field in the Advaccine Territory.  Advaccine shall use Commercially Reasonable Efforts to carry out its regulatory obligations for the Products pursuant to such strategy. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Inovio shall provide all reasonable assistance and cooperation to Advaccine as Advaccine may reasonably request, at Advaccine&#8217;s sole cost and expense, during the Term of this Agreement, with respect to the satisfaction of its obligations under Section 5.1(a), including (i) in connection with the preparation of Regulatory Materials, (ii) (A) making available competent personnel to attend regulatory meetings or join such meetings by teleconference and (B) providing documentation within Inovio&#8217;s possession and control, in each case as requested by Regulatory Authorities at Advaccine&#8217;s cost, and (iii) providing Advaccine with additional Product Materials in the Inovio Territory as requested by Regulatory Authorities in the Advaccine Territory within a reasonable timeframe commensurate with the volume of Advaccine&#8217;s reasonable request.  In the event that Inovio believes that such requests are not reasonable or are otherwise burdensome to Inovio, then such matter shall be promptly submitted to the JSC for review and discussion. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.2&#160;&#160;&#160;&#160;Regulatory Information Sharing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall (a) provide Inovio with the original documents (in the electronic format in which it has been prepared by Advaccine) of draft package inserts, CTA and CTD, and, at Inovio&#8217;s request, together with English translations (to the extent originated by Advaccine in Chinese), for Inovio&#8217;s review and comment, in connection with obtaining or maintaining any MAA approval for the Products in the Field in the Advaccine Territory, prior to the submission of such documents to the Regulatory Authority in the Advaccine Territory&#59; and (b) shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">keep Inovio informed of any material verbal or written communication or question relating to the Products received by Advaccine from the Regulatory Authority in the Advaccine Territory.  Except as required by applicable Law, (i) Advaccine, its Affiliates and Sublicensees shall not submit any Regulatory Materials to, or communicate with, any Regulatory Authority in the Inovio Territory regarding any Products.  If such submission or communication is required by applicable Law, Advaccine shall, if legally permitted, promptly notify Inovio in writing of such requirement and the content of such submission or communication&#59; (ii) except to the extent in connection with the exercise of its retained rights under Section 2.1(b), Inovio, its Affiliate and Sublicensees shall not submit any Regulatory Materials to, or communicate with, any Regulatory Authority in the Advaccine Territory regarding any Products.  If such submission or communication is required by applicable Law, Inovio shall, if legally permitted, promptly notify Advaccine in writing of such requirements and the content of such submission or communication. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.3&#160;&#160;&#160;&#160;Meetings with Regulatory Authorities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall lead all interactions with Regulatory Authorities in the Advaccine Territory with respect to the Products for use in the Field.  Advaccine shall keep Inovio reasonably informed of any material regulatory developments related to the Products in the Field in the Advaccine Territory.  At each regularly scheduled JSC meeting, Advaccine shall provide Inovio with a list and schedule of any in-person meeting or teleconference with the applicable Regulatory Authorities (or related advisory committees) in the Advaccine Territory planned for the next Calendar Quarter that relates to any Product in the Field.  In addition, Advaccine shall notify Inovio as soon as reasonably possible (but in no event later than two (2) Business Days if possible) after Advaccine becomes aware of any additional such meetings or teleconferences that become scheduled for such Calendar Quarter.  Inovio shall provide all assistance and documentation reasonably requested by Advaccine to prepare for any such meeting or teleconference, including making available competent personnel to attend any such meeting or teleconference at Advaccine&#8217;s reasonable request (subject to reimbursement by Advaccine of Inovio&#8217;s costs and expenses with respect thereto).  To the extent permitted by applicable Laws and by the Regulatory Authorities (as reasonably determined by Advaccine), Inovio shall have the right to participate (whether directly or through a representative) in all such meetings and teleconferences, at Inovio&#8217;s cost.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.4&#160;&#160;&#160;&#160;Regulatory Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Unless otherwise provided in this Agreement, Advaccine shall be responsible for the costs and expenses incurred in connection with the preparation and filing of any and all Regulatory Materials and the maintenance of any and all Regulatory Approvals (including MAA approvals) for the Products in the Field in the Advaccine Territory.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.5&#160;&#160;&#160;&#160;Right of Reference to Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party hereby grants to the other Party the right of reference to all Regulatory Materials pertaining to the Products submitted by or on behalf of such Party, subject to provisions in Section 4.8.  The receiving Party may use such right of reference solely for the purpose of seeking, obtaining and maintaining Regulatory Approval of the Products in its respective territory.  Each Party shall support the other Party, as reasonably requested by such other Party and at such other Party&#8217;s expense, in obtaining Regulatory Approvals in such other Party&#8217;s territory, including providing necessary documents or other materials required by applicable Laws to obtain Regulatory Approval in such territory, all in accordance with the terms and conditions of this Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.6&#160;&#160;&#160;&#160;No Harmful Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If either Party believes that the other Party is taking or intends to take any action with respect to any Product that could reasonably be expected to have an Adverse Risk, whether in the Inovio Territory or in the Advaccine Territory, such Party may bring the matter to the attention of the JSC and the Parties shall discuss in good faith to promptly resolve such concern.  Without limiting the foregoing, unless the Parties otherwise agree&#58; (a) (i) Advaccine shall not communicate with any Regulatory Authority having jurisdiction outside the Advaccine Territory, unless so ordered by such Regulatory Authority, in which case Advaccine shall immediately notify Inovio of such order&#59; and (ii) Advaccine shall not submit any Regulatory Materials or seek Regulatory Approvals for the Vaccine or the Product in the Inovio Territory&#59; and (b) (i) except to the extent in connection with the exercise of its retained rights under Section 2.1(b), Inovio shall not communicate with any Regulatory Authority having jurisdiction outside the Inovio Territory, unless so ordered by such Regulatory Authority, in which case Inovio shall immediately notify Advaccine of such order&#59; (ii) except to the extent in connection with the exercise of its retained rights under Section 2.1(b), Inovio shall not submit any Regulatory Materials or seek Regulatory Approvals for the Vaccine or the Product in the Advaccine Territory.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.7&#160;&#160;&#160;&#160;Notification of Threatened Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall immediately notify the other Party (including by providing notice to the other Party&#8217;s Alliance Manager) of any information it receives regarding any threatened or pending action, inspection or communication by or from any Third Party, including without limitation a Regulatory Authority, which may affect the Development, Manufacture, Commercialization or regulatory status of any Product.  Upon receipt of such information, the Parties shall consult with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate action.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.8&#160;&#160;&#160;&#160;Adverse Event Reporting and Safety Data Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No later than ninety (90) days before the Initiation of a Clinical Trial with respect to the Development of any Product in the Advaccine Territory, the Parties shall define and finalize the actions that the Parties shall employ with respect to such Product to protect patients and promote their well-being in a written pharmacovigilance agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the Development of the Product globally.  Further, no later than one hundred and eighty (180) days before the anticipated launch date of any Product in the Advaccine Territory, the Parties shall enter into a separate Pharmacovigilance Agreement for the Commercialization of the Product.  Each of the Pharmacovigilance Agreements shall include mutually acceptable guidelines and procedures for the receipt, investigation, recording, communication, and exchange (as between the Parties) of adverse event reports, pregnancy reports, and any other information concerning the safety of the Product, and other routine pharmacovigilance reporting requirements.  Such guidelines and procedures shall be in accordance with, and enable the Parties to fulfill, local and national regulatory reporting obligations under applicable Laws.  Furthermore, such agreed procedure shall be consistent with relevant ICH guidelines, except where said guidelines may conflict with existing local regulatory reporting safety reporting requirement, in which case local reporting requirement shall prevail.  The Pharmacovigilance Agreement shall provide for an adverse event database for the Products in the Field in the Advaccine Territory to be maintained by Advaccine at Advaccine&#8217;s expense, and a global safety database for the Products to be maintained by Inovio at Inovio&#8217;s expense.  As between the Parties, Advaccine shall be responsible for preparing all adverse event reports and responses to safety issues and requests of Regulatory Authorities relating to the Products in the Field in the Advaccine Territory, and Advaccine shall be responsible for filing such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">reports and responses with Regulatory Authorities in the Advaccine Territory.  As between the Parties, Advaccine shall also be responsible for reporting any quality complaints, adverse events and safety data related to the Products in the Field in the Advaccine Territory to Inovio for inclusion in the global safety database.  Each Party hereby agrees to comply with its respective obligations under such Pharmacovigilance Agreement and to cause its Affiliates and permitted Sublicensees to comply with such obligations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.9&#160;&#160;&#160;&#160;Remedial Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party will notify the other Party immediately, and promptly confirm such notice in writing, if it obtains information indicating that any Product may be subject to any recall, corrective action or other regulatory action taken by virtue of applicable Laws (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Remedial Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Parties will assist each other in gathering and evaluating such information as is necessary to determine the necessity of conducting a Remedial Action.  Advaccine shall, and shall ensure that its Affiliates and Sublicensees will, maintain adequate records to permit the Parties to trace the packaging, labeling, distribution, sale and use (to the extent possible) of the Product in the Advaccine Territory.  Advaccine shall have sole discretion with respect to any matters relating to any Remedial Action in the Advaccine Territory, including the decision to commence such Remedial Action and the control over such Remedial Action in its territory, at its cost and expense.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 6.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.1&#160;&#160;&#160;&#160;Overview&#59; Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions of this Agreement (including the diligence obligations set forth below), Advaccine shall have the sole right and responsibility for and have operational control over all aspects of the Commercialization of the Products in the Field in the Advaccine Territory, including&#58;  (a) developing and executing a commercial launch and pre-launch plan, (b)&#160;negotiating with applicable Governmental Authorities regarding the price and reimbursement status of the Products&#59; (c) marketing, advertising and promotion&#59; (d) booking sales and distribution and performance of related services&#59; (e) handling all aspects of order processing, invoicing and collection, inventory and receivables&#59; (f) providing customer support, including handling medical queries, and performing other related functions&#59; and (g) conforming its practices and procedures to applicable Laws relating to the marketing, detailing and promotion of the Products in the Field in the Advaccine Territory.  Advaccine shall bear all of the costs and expenses incurred in connection with such Commercialization activities.  Advaccine shall use Commercially Reasonable Efforts to Commercialize the Products in the Advaccine Territory and to actively market and sell the Products in the Advaccine Territory and to expand annual Net Sales of the Products in the Advaccine Territory.  Without limiting the generality of the foregoing, Advaccine shall use Commercially Reasonable Efforts to conduct its Commercialization activities under and in accordance with the Commercialization Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.2&#160;&#160;&#160;&#160;Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall Commercialize the Products in the Field in the Advaccine Territory pursuant to a commercialization plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Commercialization Plan shall include (i) a detailed description of all key strategic decisions (including messaging, branding, marketing, advertising, sales force positioning, number of representatives and details, pricing strategy, etc.), implementation tactics and pre-launch and post-launch activities&#59; (ii) a reasonably detailed description and timeline of Advaccine&#8217;s, its Affiliates&#8217; and their respective </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sublicensees&#8217; Commercialization activities for the Products in the Advaccine Territory for the next Fiscal Year, including medical marketing activities, sales forecasts and projections, pricing, reimbursement, market research, sales training, distribution channels, customer service and sales force matters related to the launch and sale of the Products in the Advaccine Territory, and (iii) a strategic plan for Commercialization of the Products in the Advaccine Territory for the following two (2) Fiscal Years.  In the event that Advaccine&#8217;s Commercialization Plan requires the use of Inovio internal resources to conduct additional activities, the extent of such need shall be clearly specified in the Commercialization Plan and will require the prior written approval of Inovio.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Initial Plan and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within a reasonable time (but no less than six (6) months) prior to the anticipated Regulatory Approval of each Product in the Advaccine Territory, Advaccine shall prepare and present to the JSC an initial Commercialization Plan for review and discussion (but not approval) by the JSC.  From time to time (but at least on an annual basis) during the Term, Advaccine shall prepare updates and amendments, as appropriate, to the then-current Commercialization Plan (including to take into account changed circumstances that are material to the Commercialization of Product, including changes in the marketplace, relative success of the Product, and other relevant factors influencing such plan and activities), and shall submit all updates and amendments to the Commercialization Plan to the JSC for review and discussion (but not approval).  Notwithstanding anything to the contrary contained in this Agreement, the Commercialization Plan, and any updates and amendments thereto, shall not require the approval of the JSC or Inovio.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.3&#160;&#160;&#160;&#160;Data Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall keep Inovio reasonably informed of Advaccine&#8217;s, its Affiliates&#8217; and their respective Sublicensees&#8217; Commercialization activities with respect to the Products in the Field in the Advaccine Territory.  Inovio shall provide to Advaccine, upon Advaccine&#8217;s request, and no more than once every six (6) months, at Inovio&#8217;s cost, copies of any materials prepared by or on behalf of Inovio that are necessary or reasonably useful in connection with Advaccine&#8217;s Commercialization of the Products in the Field in the Advaccine Territory (including relevant training materials, global brand and global market research, in each case, with respect to the Products), and, to the extent elected by Advaccine, Advaccine shall have the right to use such materials in connection with the Commercialization of the Products in the Field in the Advaccine Territory in accordance with the Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.4&#160;&#160;&#160;&#160;No Diversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party hereby covenants and agrees that it shall not, and shall ensure that its Affiliates and Sublicensees (in the case of Advaccine) or licensees, including Inovio Partners (in the case of Inovio) will not, directly or indirectly, promote, market, distribute, import, sell or have sold the Products, including via internet or mail order, in the other Party&#8217;s territory.  With respect to any country in the other Party&#8217;s territory, a Party shall not, and shall ensure that its Affiliates and their respective Sublicensees (in the case of Advaccine) or licensees, including Inovio Partners (in the case of Inovio) will not&#58; (a) establish or maintain any branch, warehouse or distribution facility for the Products in such countries, (b) knowingly engage in any advertising or promotional activities relating to the  Products that are directed primarily to customers or other purchaser or users of the  Products located in such countries, (c) actively solicit orders for the  Products from any prospective purchaser located in such countries, or (d) knowingly sell or distribute the Products to any person in such Party&#8217;s territory who intends to sell or has in the past sold the Products in such countries.  If either Party receives any order for any Product from a prospective purchaser reasonably believed to be located in a country in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">other Party&#8217;s territory, such Party shall immediately refer that order to the other Party and such Party shall not accept any such orders.  Each Party shall not deliver or tender (or cause to be delivered or tendered) the Products into a country in the other Party&#8217;s territory.  Each Party shall not, and shall ensure that its Affiliates and their respective Sublicensees (in the case of Advaccine) or licensees, including Inovio Partners (in the case of Inovio) will not, knowingly restrict or impede in any manner the other Party&#8217;s exercise of its retained exclusive rights in the other Party&#8217;s territory. For the avoidance of doubt, nothing in this Section 6.4 shall limit Inovio&#8217;s retained rights under Section 2.1(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.5&#160;&#160;&#160;&#160;Field Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine hereby covenants that it shall not, and shall cause its Affiliates and Sublicensees not to, promote or encourage the use of the Products in the Advaccine Territory for any use outside the Field.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 7.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MANUFACTURE AND SUPPLY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.1&#160;&#160;&#160;&#160;Clinical Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Clinical Inovio Device</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term, Inovio will supply Advaccine&#8217;s clinical requirements of the applicable Inovio Device for clinical use in the Advaccine Territory, at Inovio&#8217;s fully burdened manufacturing cost plus an agreed-to profit margin to support preclinical development and clinical studies in the Field in the Advaccine Territory.  Upon Advaccine&#8217;s reasonable request, the Parties agree to negotiate in good faith the terms and conditions of a supply of Inovio Device manufactured by or on behalf of Inovio under a separate agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Clinical Supply Agreement shall contain commercially reasonable terms as may be agreed upon in good faith by the Parties.  Notwithstanding the foregoing, Advaccine shall have the right to Manufacture in the Advaccine Territory any Arrays used with the Inovio Device for use in the Field in the Advaccine Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Vaccine Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term, Inovio will supply Advaccine&#8217;s clinical requirements of the Vaccine for clinical use in the Advaccine Territory, at Inovio&#8217;s fully burdened manufacturing cost plus an agreed-to profit margin to support preclinical development and clinical studies in the Field in the Advaccine Territory.  Upon Advaccine&#8217;s reasonable request, the Parties agree to negotiate in good faith the terms and conditions of a supply of the Vaccine manufactured by or on behalf of Inovio under a separate agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Vaccine Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall have the right to appoint additional or alternative suppliers (or conduct its own Manufacturing) of the applicable Vaccine for clinical use in the Advaccine Territory.  Additionally, Inovio may elect to transfer Manufacturing responsibility for the Vaccine to Advaccine.  Upon either Party&#8217;s request, the Parties shall enter into a manufacturing technology transfer agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical Manufacturing Technology Transfer Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) as more fully detailed below.  Under such Clinical Manufacturing Technology Transfer Agreement, Inovio shall transfer to Advaccine (or its designee) such documents and information, and provide such technical assistance and support, necessary or reasonably useful for Advaccine to Manufacture or have Manufactured the Vaccine or the Products, to the extent Controlled by Inovio as of such date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that (i) Advaccine shall notify Inovio of any such Third Party </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">contractor and shall not engage with such Third Party contractor if Inovio believes in good faith that such Third Party contractor is not capable of manufacturing the applicable Vaccine with sufficient quality to satisfy GMP requirements, and (ii) any such Third Party contractor shall (A) be bound by written obligations of confidentiality, non-use and compliance with applicable Laws (including Proper Conduct Practices, GMP and any regulations required by the NMPA, the FDA and the EMA), consistent with this Agreement and have agreed in writing to assign to Advaccine all Data, Information, inventions or other intellectual property generated by such subcontractor in the course of performing such subcontracted work, and (B) upon reasonable prior written notice given by Inovio to Advaccine, shall permit Inovio or its representatives to audit, during such subcontractor&#8217;s normal business hours and without additional charge, the performance of Manufacturing activities hereunder, the facilities used and relevant processes, systems, books, documents and records, in order to determine Advaccine&#8217;s compliance with this Agreement. Advaccine shall pay Inovio&#8217;s reasonable external costs (including FTEs) incurred in connection with providing such information or assistance pursuant to this Section 7.1(c).   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.2&#160;&#160;&#160;&#160;Commercial Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Commercial Inovio Device</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. During the Term, Inovio will supply Advaccine&#8217;s commercial requirements of the applicable Inovio Device for commercial use in the Field in the Advaccine Territory, at Inovio&#8217;s fully burdened manufacturing cost plus an agreed-to profit margin.  Upon Advaccine&#8217;s reasonable request, the Parties agree to negotiate in good faith the terms and conditions of a supply of Inovio Device manufactured by or on behalf of Inovio under a separate agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Device</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercial Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Inovio Device Commercial Supply Agreement shall contain commercially reasonable terms as may be agreed upon in good faith by the Parties.  Notwithstanding the foregoing, Advaccine shall have the right to Manufacture Arrays used with the Inovio Device for use in the Field in the Advaccine Territory.  Notwithstanding the foregoing, in the event that Inovio is unable to supply sufficient quantity of the Inovio Device pursuant to the Inovio Device Commercial Supply Agreement to meet at least eighty-five percent (85%) of Advaccine forecasted requirements of the Products in the Advaccine Territory for a period of six (6) consecutive months, then Inovio shall establish a second source supplier for the Inovio Device in order to Manufacture the Inovio Device for use in the Advaccine Territory for use with the Products. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Manufacture and Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine assumes responsibility for the manufacture and supply of the Vaccine itself or through a contract manufacturer, for commercial use in the Field in the Advaccine Territory.  Advaccine assumes responsibility for the manufacture and supply of any Arrays itself or through a contract manufacturer for use in the Field in the Advaccine Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event that neither Party has already initiated a technology transfer in accordance with Section 7.1(c), then, upon either Party&#8217;s request, the Parties shall enter into a manufacturing technology transfer agreement for the applicable Vaccine in the manner set forth in Section 7.1(c).  Advaccine shall pay Inovio&#8217;s reasonable external costs incurred in connection with providing such information or assistance pursuant to this Section 7.2(c).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.3&#160;&#160;&#160;&#160;Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine will be solely responsible for the distribution of the Products in the Field in the Advaccine Territory.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.4&#160;&#160;&#160;&#160;Brand Security and Anti-Counterfeiting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties will establish contacts for communication regarding brand security issues, and each Party shall reasonably cooperate with the other Party with respect thereto.  Practices around these incidents will comply with Inovio&#8217;s then-current standards, where such standards define product security features, warehouse&#47;cargo protection requirements, and response and communication process for such incidents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 8.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Compensation</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.1&#160;&#160;&#160;&#160;Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within thirty (30) calendar days after the Effective Date, Advaccine shall pay to Inovio a one-time, non-refundable, non-creditable upfront payment of three million U.S. Dollars (US$3,000,000). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.2&#160;&#160;&#160;&#160;Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall pay to Inovio the one-time, non-refundable, non-creditable payments set forth in the table below. Advaccine shall notify Inovio in writing within ten (10) days of achievement by a Product of a regulatory milestone event (except for milestone No. 3, which Inovio shall notify Advaccine upon achievement) and Advaccine shall pay to Inovio the required milestone payment within thirty (30) Business Days of the achievement by a Product of the applicable milestone event.  </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:5.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bdd6ee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:12.55pt;padding-right:3.75pt;text-indent:-16.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">No.</font></div></td><td colspan="3" style="background-color:#bdd6ee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:24.3pt;padding-right:24.3pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone Event</font></div></td><td colspan="3" style="background-color:#bdd6ee;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone Payment</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Enrollment of first subject in first Phase 2 Clinical Trial or Pivotal Clinical Trial for  the Product in the Advaccine Territory</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Enrollment of first subject in first Phase 3 Clinical Trial or Pivotal Clinical Trial for the Product in the Advaccine Territory</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Marketing Authorization for a Product in the Field in the U.S. by the FDA</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Marketing Authorization for a Product in the Field by the NMPA</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">First Commercial Sale of a Product in the Advaccine Territory</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If any development milestone event set forth above is achieved before any prior development milestone event, then such prior development milestone event(s) shall then also be due and payable together with the achieved development milestone event. For the avoidance of doubt, two or more development milestones may be achieved concurrently. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.3&#160;&#160;&#160;&#160;Commercial Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall pay to Inovio the additional one-time, non-refundable, non-creditable payments set forth in the table below within forty-five (45) Business Days after the Calendar Quarter in which the aggregate Net Sales of the Products sold in the Advaccine Territory in a Calendar Year of the corresponding threshold value indicated below is first achieved.  For clarity, each of the following milestone payments shall be payable only once regardless of the number of times such milestone is achieved.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.756%"><tr><td style="width:1.0%"></td><td style="width:65.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercial Milestone Event</font></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone Payment</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The aggregate Net Sales of the Products in the Advaccine Territory in a given Calendar Year first reaches &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The aggregate Net Sales of the Products in the Advaccine Territory in a given Calendar Year first reaches &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The aggregate Net Sales of the Products in the Advaccine Territory in a given Calendar Year first reaches &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The aggregate Net Sales of the Products in the Advaccine Territory in a given Calendar Year first reaches &#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.4&#160;&#160;&#160;&#160;Royalties on Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Royalty Rates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions of this Section 8.4, Advaccine shall pay to Inovio non-creditable, non-refundable royalties equal to &#91;***&#93; Net Sales of all Products in the Advaccine Territory on a Product-by- Product and Region-by-Region basis during the applicable Royalty Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Royalties payable under Section 8.4(a) shall be paid by Advaccine (on a Product-by-Product and Region-by-Region basis) from the period beginning on the date of the First Commercial Sale of each Product in a Region in the Advaccine Territory and continuing until the later of&#58; (i) ten (10) years from the date of First Commercial Sale of such Product in such Region, and (ii) expiration of the last Valid Claim of an Inovio Licensed Patent Covering such Product in such Region (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  For clarity, if a Valid Claim of an Inovio Licensed Patent Covers the Manufacture of such Product in such Region, then regardless of whether such Product is actually Manufactured in such Region, such Product shall be deemed to be Covered by a Valid Claim of an Inovio Licensed Patent in such Region.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Royalty Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:29.67pt">Biosimilar Entry</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If a Product is generating Net Sales in a Region during the applicable Royalty Term at a time when a Biosimilar Product with respect to such Product is being sold in such Region, and such Biosimilar Product(s) obtain (x) a market share of at least &#91;***&#93; in such Region on a volume basis, then, subject to Section 8.4(c)(iv), the royalty rates applicable to Net Sales of such Product in such Region shall be reduced to &#91;***&#93; of the royalty rate set forth in Section 8.4(a), or (y) a market share of at least &#91;***&#93; in such Region on a volume basis, then, subject to Section 8.4(c)(iv), the royalty rates applicable to Net Sales of such Product in such Region shall be reduced to &#91;***&#93; of the royalty rate set forth in Section 8.4(a), but in each case of (x) and (y) only for so long as the Biosimilar Product with respect to such Product is being sold in such Region with such market share.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.&#160;&#160;&#160;&#160;Third Party Royalty Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If Advaccine determines (based on advice of outside Patent counsel) that it is necessary to obtain a license to any Patent owned by a Third Party that contains claims that cover the Vaccine in a Region in the Advaccine Territory (i.e., but for such license, the making, having made, using, selling, offering for sale, or importing of the Vaccine, as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">31</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">contained in or comprising a Product, would infringe such Patent owned by such Third Party in such Region) and Advaccine obtains such a license, then, subject to Section 8.4(c)(iv), Advaccine shall have the right to deduct, from the royalty payment that would otherwise be payable to Inovio pursuant to Section 8.4(a) with respect to Net Sales of such Product in such Region in a particular Calendar Quarter, an amount equal to &#91;***&#93; of the payments by Advaccine to such Third Party pursuant to such license on account of the sale of such Product in such Region during such Calendar Quarter&#59; provided that (i) in no event will the royalty payment that would otherwise be payable to Inovio pursuant to this Section 8.4 with respect to Net Sales of such Product in such Region in such particular Calendar Quarter (without regard to any other reductions) be reduced by more than &#91;***&#93; in any given Calendar Quarter as a result of any deduction under this Section 8.4(c)(ii) and (ii) Advaccine will be entitled to carry forward to subsequent Calendar Quarters any amounts with respect to which Advaccine would have been entitled to take a deduction pursuant to this Section 8.4(c)(ii) but is unable to take such deduction pursuant to the foregoing sub-clause (i).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">No Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For each Product and for any period during the Royalty Term in which the sale of such Product in a given country is neither&#58; (i) Covered by any Valid Claim of an Inovio Licensed Patent or Joint Patent nor (ii) protected by any data exclusivity right applicable to such Product in such country, then the Royalty rate applicable to Net Sales of such Product in such country during such period shall be equal to &#91;***&#93; of the applicable Royalty rate set forth in this Section 8.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv. Notwithstanding the foregoing, in no event shall the operation of Section 8.4(c)(i), Section 8.4(c)(ii) or Section 8.4(c)(iii)), individually or in combination, reduce the royalties paid to Inovio with respect to the Net Sales of any Product in any Region in the Advaccine Territory in any Calendar Quarter to less than &#91;***&#93; of the amount that would otherwise have been payable to Inovio pursuant to Section 8.4(a) with respect to such Net Sales.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.5&#160;&#160;&#160;&#160;Royalty Payments&#59; Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Royalties under Section 8.4 shall be calculated and reported for each Calendar Quarter during the Royalty Term and shall be paid within thirty&#160;(30) Business Day after the end of the applicable Calendar Quarter, commencing with the Calendar Quarter in which the First Commercial Sale of a Product occurs.  Each payment of royalties shall be accompanied by a report of Net Sales of the Products by Advaccine, its Affiliates and their respective Sublicensees in sufficient detail to permit confirmation of the accuracy of the royalty payment made, including&#58; (a) the amount of gross sales and Net Sales of the Products in the Advaccine Territory on a Product-by-Product and Region-by-Region basis, (b) an itemized calculation showing the deductions from gross sales (by major category as set forth in the definition of Net Sales) to determine Net Sales, and (c) a calculation of the amount of royalties due to Inovio in U.S. Dollars, including the application of any exchange rate used. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.6&#160;&#160;&#160;&#160;Payment Method&#59; Foreign Exchange&#59; Blocked Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All payments owed by Advaccine under this Agreement shall be made by wire transfer in immediately available funds to a bank and account designated in writing by Inovio.  For clarity, all payments by Advaccine to Inovio pursuant to Sections 8.1, 8.2, 8.3 and 8.4 shall be in U.S. Dollars.  The rate of exchange to be used in computing the amount of currency equivalent in U.S. Dollars of any amounts payable in U.S. Dollars by Advaccine to Inovio under this Agreement shall be determined and calculated (i) with respect to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">32</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chinese Yuan, using the middle rate published by the Bank of China for exchange of US dollars with the Chinese Yuan on the date of transfer of the payment, and (ii) with respect to any other currency, the average rate of exchange based on OANDA rates for the Calendar Quarter in which the applicable payment is due.  In the event that, by reason of applicable Laws in the Advaccine Territory, it becomes impossible or illegal for Advaccine or its Affiliate to transfer, or have transferred on its behalf, payments to Inovio, Advaccine shall promptly notify Inovio of the conditions preventing such transfer and such payments shall be deposited in local currency in the relevant country to the credit of Inovio in a recognized banking institution designated by Inovio. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.7&#160;&#160;&#160;&#160;Interest on Late Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If Inovio does not receive payment of any sum due to it on or before the due date, interest shall thereafter accrue on the sum due to Inovio until the date of payment at the per annum rate of &#91;***&#93; over the then-current prime rate reported in The Wall Street Journal or the maximum rate allowable by applicable Laws, whichever is lower, with such interest compounded quarterly. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.8&#160;&#160;&#160;&#160;Records&#59; Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Advaccine shall, and shall cause its Affiliates and their respective Sublicensees to, maintain in accordance with Accounting Standards, reasonably complete and accurate records in sufficient detail to permit Inovio to confirm the accuracy of the calculation of royalty payments and the achievement of the milestone events.  All payments and other relevant amounts under this Agreement shall be accounted for in accordance with Accounting Standards.  Upon reasonable prior written notice, in any event no less than thirty (30) days prior written notice, such records shall be available for examination during regular business hours and in a manner that does not interfere with Advaccine&#8217;s business activities for a period of three (3) years from the end of the Fiscal Year to which they pertain, and not more often than once each Fiscal Year, by an independent certified public accountant selected by Inovio and reasonably acceptable to Advaccine, for the sole purpose of verifying the accuracy of the financial reports furnished by Advaccine pursuant to this Agreement and any payments with respect thereto.  Any such auditor shall not disclose Advaccine&#8217;s Confidential Information, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by Advaccine or the amount of payments due under this Agreement.  Any amounts shown to be owed but unpaid shall be paid within thirty (30) days from the accountant&#8217;s report, plus interest (as set forth in Section 8.7) from the original due date.  Inovio shall bear the full cost of such audit unless such audit discloses an underpayment by Advaccine of more than &#91;***&#93; of the amount due for the audited period, in which case Advaccine shall bear the full cost of such audit.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Inovio shall, and shall ensure that its Affiliates and its and their respective employees, agents and contractors, maintain complete and accurate records with respect to Inovio&#8217;s pharmacovigilance-related obligations set forth in Section 5.8.  Upon reasonable prior notice, such records shall be available for examination during regular business hours for a period of three (3) years from the end of the Fiscal Year to which they pertain, and not more often than once each Fiscal Year, by Advaccine or its designee that is reasonably acceptable to Inovio, for the sole purpose of ensuring compliance with NMPA and other Regulatory Authority regulations.  Any such records shall be deemed Confidential Information of Inovio.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.9&#160;&#160;&#160;&#160;Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">33</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Taxes on Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as set forth in this Section 8.9, each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the efforts of the Parties under this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to Section 8.9(d), if Advaccine is required by applicable Laws to make any tax deduction, tax withholding or similar payment (other than value-added tax, any goods and services tax, harmonized sales tax and any similar provincial sales tax) from any amount paid or payable by Advaccine to Inovio (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) under this Agreement, then in the case of any payments to be made by Advaccine to Inovio under this Agreement (including pursuant to Sections 8.1, 8.2, 8.3, and 8.4), Advaccine will (A) deduct and withhold the amount of such Tax Withholding for the account of Inovio to the extent required by applicable Laws (such amounts payable to Inovio shall be reduced by the amount of Tax Withholding deducted and withheld) and (B) pay any such Tax Withholding (including any additional Tax Withholding required with respect to Advaccine&#8217;s additional payments under this Section 8.9) directly to the proper Governmental Authority. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;VAT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All payments due to Inovio from Advaccine pursuant to this Agreement shall be paid exclusive of, and without reduction for, any value-added tax (including, for greater certainty, any goods and services tax, harmonized sales tax and any similar taxes) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VAT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (which, if applicable, shall be payable by Advaccine). Advaccine shall be responsible for the payment of all VAT applicable to the payments made by Advaccine to Inovio under this Agreement in the Advaccine Territory and shall file all applicable VAT tax returns or seek any exemption or reduction of such VAT pursuant to any applicable Laws.  Inovio shall cooperate, to the extent reasonably required, with the filing of any such VAT tax returns or any application of reduction or exemption of such VAT with the proper Government Authority in the Advaccine Territory. Advaccine shall indemnify Inovio for any VAT imposed on Inovio in the Advaccine Territory with respect to the payments made to it by Advaccine under this Agreement and if Inovio directly pays any such VAT, Advaccine shall promptly reimburse Inovio for such VAT including all reasonable related costs.  If Inovio determines that it is required to report any such tax, Advaccine shall promptly provide Inovio with applicable receipts and other documentation necessary or appropriate for such report.  For clarity, this Section 8.9(c) is not intended to limit Advaccine&#8217;s right to deduct VAT in determining Net Sales.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Tax Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Without limiting Section 8.9(b) and 8.9(c), the Parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate Tax Withholding or similar obligations in respect of payments made by Advaccine to Inovio under this Agreement (including pursuant to Sections 8.1, 8.2, 8.3 and 8.4).  To the extent Advaccine is required to make any Tax Withholdings for any payment to Inovio, Advaccine shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Inovio an official tax certificate or other evidence of such withholding sufficient to enable Inovio to claim such payment of taxes from any applicable Government Authority.  Inovio shall provide Advaccine any tax forms or other similar documentation that may be reasonably necessary in order for Advaccine not to make any Tax Withholdings or to make Tax Withholdings at a reduced rate under an applicable bilateral income tax treaty, and shall update such forms and documentation from time to time as necessary to reflect changes in facts.  Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by applicable Laws, of Tax Withholdings, VAT or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">34</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">withholding tax or VAT.  Specifically, in the event that any tax has been withheld upon a payment made under this Agreement or has otherwise been remitted to a Governmental Authority, if requested by either Party, and if, and for so long as, the Parties acting in good faith mutually agree that there is a reasonable prospect of successfully obtaining a refund of such tax, then the other Party shall, at the requesting Party&#8217;s sole cost and expense, seek a refund of such tax from the proper Governmental Authority. In the event that any taxes withheld or reimbursed by Advaccine under Section 8.9(a) are subsequently refunded to Advaccine by the appropriate Governmental Authority, Advaccine shall pay over the amount of such refund, less any cash Taxes attributable to the receipt thereof and any reasonable expenses incurred by Advaccine in obtaining such refund. Advaccine agrees to reasonably cooperate with Inovio and its Affiliates in the pursuit of such tax refund (including, if required by applicable Laws or by the applicable Governmental Authority, permitting Inovio to seek such tax refund in Advaccine&#8217;s name and participating in any application or appeal that requires that Advaccine be the party applying for such tax refund, solely with Advaccine&#8217;s prior written consent)&#59; provided that, Inovio agrees to assume responsibility for direct payment of lawyers&#8217; and other advisors&#8217; fees and any other costs associated with seeking such refund.  Notwithstanding anything contained in the Agreement to the contrary, in the event that Inovio is unable to utilize any portion of a Tax Withholding as tax credit to effectively lower its income tax for the applicable tax year during which the applicable payment is received, Advaccine shall reimburse Inovio for any such portion thereof within forty-five (45) days after receipt of an invoice from Inovio (and shall gross-up Inovio for any Tax Withholding on such payment). </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 9.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual Property Matters</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.1&#160;&#160;&#160;&#160;Ownership&#59; License Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Data Generated by Inovio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inovio shall solely own all Data generated by Inovio.  For clarity, all Data solely directed to the Vaccine and the Array Controlled by Inovio are included in the Inovio Licensed Know-How and licensed to Advaccine under Section 2.1(a). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Data Generated by Advaccine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Advaccine shall solely own all Data generated by Advaccine in the Development of the Vaccine and the Products in the Field in the Advaccine Territory.  Advaccine hereby grants to Inovio (i) an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license, with the right to grant sublicenses, to use such Data generated and owned by Advaccine for the purpose of seeking and maintaining any Regulatory Approval for the Vaccine or the Product in the Inovio Territory, and (ii) upon expiration or termination of the Agreement (other than termination of the Agreement by Advaccine pursuant to Sections 13.4 or 13.5), an irrevocable, perpetual, royalty-free, fully paid-up, non-exclusive license, with the right to grant sublicenses, to use such Data generated and owned by Advaccine for the Development, Manufacture and Commercialization of the Vaccine or the Product in the Field in the Advaccine Territory.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Product Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions of this Agreement, each Party hereby grants to the other Party a fully-paid up, royalty-free exclusive license, with the right to grant sublicenses under multiple tiers, to use Product Materials generated and owned by such Party, solely to the extent reasonably necessary for the Development, Manufacture (with respect to Advaccine, solely to the extent applicable under Section 7.2) and Commercialization of the Vaccine and the Product in the Field in the other Party&#8217;s respective territory during the Term of this Agreement. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">35</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inventorship of any Invention will be determined in accordance with the standards of inventorship and conception under U.S. patent laws.  </font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:29.67pt">Inovio Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any Invention generated, developed, conceived or reduced to practice (constructively or actually) solely by or on behalf of Inovio, its Affiliates and their respective licensees (including Inovio Partners), including their employees, agents and contractors (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be solely and exclusively owned by Inovio. For clarity, any and all Inovio Inventions that are Controlled by Inovio and reasonably necessary for the Development, Manufacture and Commercialization of the Vaccine and the Product in the Field in the Advaccine Territory shall be included in the Inovio Technology licensed to Advaccine under Section 2.1(a), including any Patent rights therein. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Advaccine Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any Inventions generated, developed, conceived or reduced to practice (constructively or actually) solely by or on behalf of Advaccine, its Affiliates and their respective Sublicensees, including their employees, agents and contractors (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be solely and exclusively owned by Advaccine.  Advaccine shall disclose in writing to Inovio all Advaccine Inventions promptly following the generation, development, conception or reduction to practice thereof.  Advaccine hereby grants Inovio (A) an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license, with the right to grant sublicenses, under the Advaccine Inventions in the Inovio Territory, and (B) upon expiration or termination of this Agreement (other than termination of this Agreement by Advaccine pursuant to Sections 13.4 or 13.5) an irrevocable, perpetual, royalty-free, fully paid-up, non-exclusive license, with the right to grant sublicenses, under the Advaccine Inventions in the Advaccine Territory, in each case of (A) and (B), solely for the Development, Manufacture and Commercialization of the Vaccine or the Products in the Field.   </font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Joint Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any Invention generated, developed, conceived or reduced to practice (constructively or actually) jointly by or on behalf of Advaccine and Inovio, their Affiliates and respective Sublicensees, including their employees, agents and contractors (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be jointly owned by the Parties, and, subject to the licenses set forth in this Agreement, each Party may freely exploit such Joint Inventions without any duty to account to the other Party.  Each Party shall disclose in writing to the other Party all Joint Inventions promptly following the generation, development, conception or reduction to practice thereof.  Advaccine hereby grants Inovio an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license, with the right to grant sublicenses, under its rights in such Joint Inventions (i) in the Inovio Territory, and (ii) upon termination of the Agreement (other than termination of the Agreement by Advaccine pursuant to Sections 13.4 or 13.5), in the Advaccine Territory, in each case of (i) and (ii), solely for the Development, Manufacture and Commercialization of the Vaccine or the Product in the Field.  Inovio hereby grants Advaccine an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license, with the right to grant sublicenses, under its rights in such Joint Inventions in the Advaccine Territory solely for the Development, Manufacture and Commercialization of the Vaccine or the Product in the Field. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Affiliates, Sublicensees and Subcontractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party  shall ensure that each of its Affiliates, Sublicensees and subcontractors under this Agreement has a contractual obligation to disclose to it all Data, Product Materials and Inventions generated, invented, discovered, developed, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">36</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">made or otherwise created by them or their employees, agents or independent contractors, and to provide sufficient rights with respect thereto, so that each Party  can comply with its obligations to the other Party under this Section 9.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.2&#160;&#160;&#160;&#160;Patent Prosecution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Definition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For the purpose of this Article 9, &#8220;prosecution&#8221; of Patents shall include, without limitation, all communication and other interaction with any patent office or patent authority having jurisdiction over a Patent application throughout the world in connection with any pre-grant proceedings and post-grant proceeding, including opposition proceedings. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Inovio Licensed Patents&#59; Joint Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as set forth in Section 9.2(d), as between the Parties, Inovio shall have the sole right to prepare, file, prosecute and maintain or abandon the Inovio Licensed Patents on a worldwide basis.  Except as set forth in Section 9.2(d), as between the Parties, Inovio shall have the sole right to prepare, file, prosecute and maintain or abandon the Joint Patents on a worldwide basis.  Inovio shall provide Advaccine with a copy of the draft prepared for the filing of a Joint Patent, before the filing of such Joint Patent and will consider in good faith comments thereto provided by Advaccine in connection with the filing thereof.  Inovio shall, at the request of Advaccine, provide Advaccine with regular updates on the prosecution of the Inovio Product-Specific Licensed Patents and Joint Patents in the Field in the Advaccine Territory.  For clarity, Advaccine shall not have any rights pursuant to this Agreement with respect to any Inovio Licensed Patents in the Inovio Territory (including any Step-In Rights relating thereto).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Advaccine Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as set forth in Section 9.2(d), as between the Parties, Advaccine shall have the sole right to prepare, file, prosecute and maintain or abandon the Advaccine Patents.  Advaccine shall provide Inovio with a copy of the draft prepared for the filing of a Advaccine Patent, before the filing of such Advaccine Patent and will consider in good faith comments thereto provided by Inovio in connection with the filing thereof.  Advaccine shall provide Inovio with regular updates on the prosecution of the Advaccine Patents in the Field in the Advaccine Territory.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Step-In Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Either Party may cease prosecution and&#47;or maintenance of any Patent that such Party is responsible for prosecuting and maintain pursuant to this Section 9.2 on a country-by-country basis by providing the other Party written notice reasonably in advance of such due date.  If the responsible Party elects to cease prosecution or maintenance of the relevant Patent in a country, the other Party, shall have the right, but not the obligation, at its sole discretion and cost, to continue prosecution or maintenance of such Patent and in such country (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Step-In Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), provided that Advaccine may only exercise its Step-In Rights with respect to Joint Patents and Inovio Product-Specific Licensed Patents in the Advaccine Territory.  If the other Party elects to continue prosecution or maintenance or elects to file additional applications following the responsible Party&#8217;s election to cease prosecution or maintenance pursuant to this Section 9.2(d), the responsible Party shall transfer the applicable patent files to such other Party or its designee and execute such documents and perform such acts at the responsible Party&#8217;s expense as may be reasonably necessary to allow the other Party to initiate or continue such filing, prosecution or maintenance at the other Party&#8217;s sole expense.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall provide the other Party with all reasonable assistance and cooperation in the patent prosecution efforts set forth in this Section 9.2, including </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">37</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">providing any necessary powers of attorney and executing any other required documents or instruments for such prosecution.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.3&#160;&#160;&#160;&#160;Patent Term Extensions in the Advaccine Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JSC will discuss and recommend for which, if any, of the Patents within the Inovio Licensed Patents, Advaccine Patents and Joint Patents in the Advaccine Territory the Parties should seek patent term extensions.   If after reasonable discussion and good faith consideration of each Party&#8217;s view on a particular matter before the JSC, the representatives of the Parties cannot reach an agreement as which Patents such extensions should be sought for, (a) Inovio, in the case of Inovio Licensed Patents and Joint Patents, and (b) Advaccine, in the case of Advaccine Patents, shall have the final decision-making authority with respect to applying for any such patent term extension in the Advaccine Territory, and will act with reasonable promptness in light of the development stage of the Products to apply for any such patent term extension, where it so elects&#59; provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that if only one such Patent can obtain a patent term extension, the Parties will consult in good faith to determine which such Patent should be the subject of efforts to obtain a patent term extension, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">further provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that, if an Inovio Licensed Patent is the only Patent that is eligible for a patent term extension with respect to a Product in the Advaccine Territory, then (i) Advaccine shall have the right, but not the obligation, to request Inovio to apply for such patent term extension at Advaccine&#8217;s sole discretion and cost, and (ii) upon Inovio&#8217;s receipt of such request, Inovio shall use Commercially Reasonable Efforts to apply for such patent term extension.  Each Party will cooperate fully with the other Party in making such filings or actions, for example and without limitation, making available all required regulatory Data and Information and executing any required authorizations to apply for such patent term extension.  All expenses incurred in connection with activities of each Party with respect to the Patent(s) for which such Party seeks patent term extensions pursuant to this Section 9.3 shall be borne by such Party. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.4&#160;&#160;&#160;&#160;Patent Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Notification&#59; Information Sharing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If either Party becomes aware of any existing or threatened infringement of any Inovio Licensed Patent, Advaccine Patent or Joint Patent (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), it shall promptly notify the other Party in writing to that effect and the Parties will consult with each other regarding any actions to be taken with respect to such Infringement.  Each Party shall share with the other Party all Information available to it regarding such alleged Infringement, pursuant to a mutually agreeable &#8220;common interest agreement&#8221; executed by the Parties under which the Parties agree to their shared, mutual interest in the outcome of any suit or other action to enforce the Inovio Licensed Patents, Advaccine Patent and Joint Patent against such Infringement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Enforcement Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:101.67pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Inovio Product-Specific Licensed Patents&#59; Joint Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Inovio shall have the first right, but not the obligation, to bring an appropriate suit or other action against any Person engaged in the Infringement of any Inovio Product-Specific Licensed Patent or Joint Patent in the Advaccine Territory, at Inovio&#8217;s cost and expense.  If Inovio elects to commence a suit or other action to enforce the applicable Inovio Product-Specific Licensed Patent or Joint Patent against such Infringement in the Advaccine Territory, then Advaccine shall have the right to join such enforcement action upon written notice to Inovio, and the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">38</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Parties shall share the cost and expense of such enforcement action equally.  If Inovio notifies Advaccine in writing that it does not intend to commence a suit or other action to enforce the applicable Inovio Product-Specific Licensed Patent or Joint Patent against such Infringement or to take other action to secure the abatement of such Infringement, or fails to take any such action after a period of forty-five (45) Business Days following either Party&#8217;s receipt of the notice of Infringement pursuant to Section 9.4(a), then, to the extent that such Infringement is resulting from a Third Party&#8217;s use or sale of a product that competes with a Product in the Field in the Advaccine Territory, Advaccine shall have the right, but not the obligation, to commence such a suit or take such action, at Advaccine&#8217;s sole cost and expense&#59; provided that, in the event the Person engaged in the Infringement of any Inovio Product-Specific Licensed Patent or Joint Patent in the Advaccine Territory is also engaged in such Infringement in the Inovio Territory, and Inovio has commenced a suit to secure the abatement of such Infringement in the Inovio Territory, then Inovio shall promptly notify Advaccine thereof and Advaccine shall not have the right to commence such suit or action without the prior written consent of Inovio, not to be unreasonably withheld. In such case, Inovio shall take appropriate actions in order to enable Advaccine to commence a suit or take the actions set forth in the preceding sentence.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Neither Party shall settle any such suit or action under Section 9.4(b)(i)(1) in any manner that would negatively impact the Inovio Product-Specific Licensed Patents or Joint Patents or that would limit or restrict the ability of Advaccine to sell the Products in the Advaccine Territory, without the prior written consent of the other Party.  For clarity, Advaccine shall not have the right to commence any such suit or action against any existing or threatened infringement of the Inovio Product-Specific Licensed Patents or Joint Patents outside the Advaccine Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:98.34pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Advaccine Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall have the first right, but not the obligation, to bring an appropriate suit or other action against any Person engaged in the Infringement of any Advaccine Patent, at Advaccine&#8217;s cost and expense.  If Advaccine elects to commence a suit to enforce the applicable Advaccine Patent against such Infringement, where such Infringement relates to the Commercialization in the Advaccine Territory of unauthorized products containing the Vaccine, then Inovio shall have the right to join such enforcement action upon notice to Advaccine, and in this case the Parties shall share the cost and expense of such enforcement action equally.  If Advaccine notifies Inovio that it does not intend to commence a suit to enforce the applicable Advaccine Patent against such Infringement or to take other action to secure the abatement of such Infringement, or fails to take any such action after a period of ninety (90) days, then Inovio shall have the right, but not the obligation, to commence such a suit or take such action, at Inovio&#8217;s cost and expense.  In such case, Advaccine shall take appropriate actions in order to enable Inovio to commence a suit or take the actions set forth in the preceding sentence.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Collaboration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall provide to the Party bringing a claim, suit or action under Section 9.4(b) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Enforcing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) with reasonable assistance in such enforcement, including joining such action as a party plaintiff if required by applicable Laws to pursue such action.  The Enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts, and shall reasonably consider the other Party&#8217;s comments on any such efforts.  The non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the Enforcing Party. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">39</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Expenses and Recoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Enforcing Party shall be solely responsible for any expenses it incurs as a result of such enforcement action, except that the Parties shall share equally the cost and expense of the enforcement action when Inovio is the Enforcing Party and Advaccine elects to join the enforcement action.  If the Enforcing Party recovers monetary damages in such claim, suit or action brought under Section 9.4(b), such recovery shall be allocated first to the reimbursement of any documented expenses incurred by the Parties in such enforcement action, and any remaining amounts shall be shared by the Parties as follows&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.67pt">if (A) Inovio is the Enforcing Party under Section 9.4(b)(i)(1) and Advaccine elects to join the enforcement action and share the cost and expenses related thereto, or (B) Advaccine is the Enforcing Party under Section 9.4(b)(ii) and Inovio elects to join the enforcement action and share the cost and expenses related thereto&#58; &#91;***&#93; of the remaining amounts shall be retained by Inovio, and &#91;***&#93; of the remaining amounts shall be paid to Advaccine&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.&#160;&#160;&#160;&#160;if Inovio is the Enforcing Party (A) under Section 9.4(b)(i)(1) and Advaccine does not elect to join the enforcement action and share the cost and expenses related thereto, or (B) under Section 9.4(b)(ii)&#58; &#91;***&#93; of the remaining amounts shall be retained by Inovio, and &#91;***&#93; of the remaining amounts shall be paid to Advaccine&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.&#160;&#160;&#160;&#160;if Advaccine is the Enforcing Party (A) under Section 9.4(b)(ii) and Inovio does not elect to join the enforcement action and share the cost and expenses related thereto, or (B) under Section 9.4(b)(i)(1)&#58; &#91;***&#93; of the remaining amounts shall be retained by Advaccine, and &#91;***&#93; of the remaining amounts shall be paid to Inovio. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Sections 9.4(c) and 9.4(d) shall survive the termination of this Agreement solely with respect to any pending enforcement action initiated during the Term under this Section 9.4.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.5&#160;&#160;&#160;&#160;Third Party Infringement Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If the Manufacture, use or sale of the Products in the Field in the Advaccine Territory pursuant to this Agreement results in a claim, suit or proceeding alleging patent infringement against Inovio or Advaccine (or their respective Affiliates, licensees or Sublicensees) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Infringement Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), such Party shall promptly notify the other Party hereto in writing.  Subject to Article 11, the Party for which the Infringement Action is brought against (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accused Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall have the right to direct and control the defense of such Infringement Action, at its own expense with counsel of its choice&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the other Party may participate in the defense and&#47;or settlement thereof, at its own expense with counsel of its choice.  In any event, the Accused Party agrees to keep the other Party reasonably informed of all material developments in connection with any such Infringement Action for which the Accused Party exercises its right to direct and control the defense.  The Accused Party agrees not to settle such Infringement Action, or make any admissions or assert any position in such Infringement Action, in a manner that would adversely affect the rights or interests of the other Party, without the prior written consent of the other Party, which shall not be unreasonably withheld or delayed.  Subject to Article 11, if the Accused Party does not exercise its right to direct and control the defense of an Infringement Action that is brought against the other Party, then the other Party shall have such right and it shall agree to keep  the Accused Party reasonably informed of all material developments in connection with such Infringement Action and it shall not settle such Infringement Action, or make any admissions or assert </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">40</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any position in such Infringement Action, in a manner that would materially adversely affect the rights or interests of the Accused Party, without the prior written consent of the Accused Party, which shall not be unreasonably withheld or delayed. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.6&#160;&#160;&#160;&#160;Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Subject to Section 9.6(c) below, Advaccine shall Commercialize the Products in the Field in the Advaccine Territory under any trademark owned or Controlled by Advaccine (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine Product Mark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; provided that, prior to finalizing any Advaccine Product Mark, Advaccine shall provide Inovio with such proposed trademark and related trade dress and shall reasonably consider in good faith Inovio&#8217;s comments with respect thereto.  Advaccine shall, and shall cause its Affiliates and Sublicensees to, use the Advaccine Product Mark solely in connection with the Development, Manufacturing, and Commercialization of the Products in the Field in the Advaccine Territory.  Advaccine shall own all rights in the Advaccine Product Mark, and all goodwill in the Advaccine Product Mark shall accrue to Advaccine.  Advaccine shall register and maintain, at Advaccine&#8217;s cost and expense, the Advaccine Product Marks in the Advaccine Territory.    </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Subject to Section 9.6(c) below, Advaccine shall have the right to brand the Products in the Field in the Advaccine Territory with those trademarks of Advaccine that are associated with Advaccine&#8217;s name or identity (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine Housemarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Advaccine shall own all rights in the Advaccine Housemarks, and all goodwill in the Advaccine Housemarks shall accrue to Advaccine.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In connection with Advaccine&#8217;s use of any Advaccine Product Mark or Advaccine Housemark, subject to Section 9.6(d), Advaccine shall not, and shall cause its Affiliates and their respective Sublicensees to not make any use of trademarks that are confusingly similar to any trademarks or housemarks of Inovio or its Affiliates (including the corporate name of Inovio or any of its Affiliates), without the prior written consent of Inovio. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary, to the extent required by applicable Laws, (i) Advaccine may include Inovio&#8217;s name and corporate logo on the Product label, packaging, promotional&#47;marketing materials to indicate that the Product is in-licensed from Inovio, and shall display Inovio&#8217;s name and corporate logo with equal prominence and comparable size, resolution, print quality, and location, as instructed by Inovio from time to time, as Advaccine&#8217;s name and corporate logo is displayed, and (ii) Inovio hereby grants to Advaccine a non-exclusive, fully paid-up, royalty free, sublicensable license to use Inovio&#8217;s name and corporate logo solely for the Commercialization of the Product in the Field in the Advaccine Territory, to the extent consistent with the foregoing.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 10.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Representations And Warranties&#59; covenants</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.1&#160;&#160;&#160;&#160;Mutual Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party hereby represents and warrants to the other Party, as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Corporate Existence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As of the Effective Date, it is a company or corporation duly organized, validly existing, and in good standing under the Laws of the jurisdiction in which it is incorporated&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">41</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Corporate Power, Authority and Binding Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As of the Effective Date, (i) it has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder&#59; (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder&#59; and (iii) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and similar Laws affecting creditors&#8217; rights and remedies generally&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;No Conflict</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The execution and delivery of this Agreement, the performance of such Party&#8217;s obligations in the conduct of the Development Plan and the license to be granted pursuant to this Agreement (i) do not and will not conflict with or violate any requirement of applicable Laws existing as of the Effective Date&#59; (ii) do not and will not conflict with or violate the certificate of incorporation or by-laws (or other constating documents) of such Party&#59; and (iii) do not and will not conflict with, violate, breach or constitute a material default under any contractual obligations of such Party or any of its Affiliates existing as of the Effective Date&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;No Violation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither such Party nor any of its Affiliates is under any obligation to any Person, contractual or otherwise, that is in violation of the terms of this Agreement or that would impede the fulfillment of such Party&#8217;s obligations hereunder&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;No Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither such Party nor any of its Affiliates is debarred or disqualified under the Act or comparable applicable Laws outside the U.S.&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;No Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No authorization, consent, approval of a Third Party, nor to such Party&#8217;s knowledge, any license, permit, exemption of or filing or registration with or notification to any court or Governmental Authority is or will be necessary for the (i) valid execution and delivery of this Agreement by such Party&#59; or (ii) the consummation by such Party of the transactions contemplated hereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.2&#160;&#160;&#160;&#160;Additional Representations and Warranties of Inovio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inovio represents and warrants to Advaccine, as of the Effective Date, as follows&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inovio (i) has the right to grant the license that it grants in Section 2.1(a)&#59; and (ii) has not granted, and will not grant during the Term,  any right to any Third Party that would conflict with the License that it grants in Section 2.1(a) or rights granted to Advaccine hereunder&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Notice of Infringement or Misappropriation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  It has not received any written notice from any Third Party asserting or alleging that (i) any research, development, manufacture, or commercialization of a Product by Inovio prior to the Effective Date infringed or misappropriated the intellectual property rights of such Third Party, or (ii) the Development, Manufacture, or Commercialization of the Vaccine and the Products in the Advaccine Territory would infringe or misappropriate the intellectual property rights of such Third Party&#59; to Inovio&#8217;s actual knowledge, except as otherwise disclosed to Advaccine prior to the Effective Date, the Development, Manufacture or Commercialization of the Vaccine and theProducts does not infringe or misappropriate any intellectual property rights of any Third Party&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">42</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Non-Infringement of Rights by Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To Inovio&#8217;s actual knowledge, no Third Party is infringing or has infringed the Inovio Product-Specific Licensed Patents as of the Effective Date&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Non-Assertion by Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To Inovio&#8217;s actual knowledge, no Third Party has asserted in writing that the issued patents within the Inovio Licensed Patents set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are invalid or unenforceable&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;No Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  There is no pending, and to Inovio&#8217;s actual knowledge, no threatened, adverse action, suit or proceeding against Inovio involving any Inovio Technology or the safety (including any product liability claim) of a Product&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;Prosecution of Inovio Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except with respect to any Inovio Product-Specific Licensed Patents for which Inovio has ceased prosecution and&#47;or maintenance and granted Advaccine Step-In Rights therewith pursuant to Section 9.2(d), all maintenance fees, annuity payments, and similar payments relating to the Inovio Product-Specific Licensed Patents in the Advaccine Territory have been made, and during the Term will be made, in a timely manner.  To Inovio&#8217;s actual knowledge, prior to the Effective Date, Inovio has not taken action or failed to undertake an action, in connection with filing, prosecuting and maintaining the Inovio Product-Specific Licensed Patents set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in the Advaccine Territory in violation of any applicable Laws&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(g)&#160;&#160;&#160;&#160;Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To Inovio&#8217;s actual knowledge, Inovio has complied with all applicable Laws in connection with the prosecution of the Inovio Product-Specific Licensed Patents, including the duty of candor owed to any patent office pursuant to such Laws&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(h)&#160;&#160;&#160;&#160;Inovio Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inovio does not have actual knowledge of any Information which leads it to believe that any issued patents included in the Inovio Licensed Patents set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are invalid or unenforceable&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inovio has not entered, and shall not enter, into any agreement with any Third Party that is in conflict with the rights granted to Advaccine under this Agreement, and has not taken and shall not take any action that would in any way prevent it from granting the rights granted to Advaccine under this Agreement, or that would otherwise materially conflict with or adversely affect Advaccine&#8217;s rights under this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.3&#160;&#160;&#160;&#160;Additional Representations and Warranties of Advaccine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine represents and warrants to Inovio that, to Advaccine&#8217;s knowledge as of the Effective Date Advaccine does not Control any Patent that is necessary to make, use, import, offer for sale or sell the Products in the Field.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.4&#160;&#160;&#160;&#160;Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Each Party shall, and shall ensure that its Affiliates and their respective Sublicensees will, comply in all respects with Proper Conduct Practices, and all applicable Laws (including all applicable Laws regarding data privacy) in the Development, Manufacturing, and Commercialization of the Products and performance of its obligations under this Agreement, including </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">43</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the ICH, GCP, GLP and any Regulatory Authority and Governmental Authority health care programs having jurisdiction in such Party&#8217;s respective territory, each as may be amended from time to time.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each Party shall immediately notify the other Party if it has any information or suspicion that there may be a violation of any applicable Laws (including Anti-Corruption Laws) in connection with its performance under this Agreement or the Development or Commercialization of any Product hereunder.  In the event that either Party has violated or been suspected of violating any of its obligations, representations, warranties or covenants in Section 10.4(a), such Party will take reasonable actions to remedy such breach and to prevent further such breaches from occurring.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, each Party will have the right, upon reasonable prior written notice and during the other Party&#8217;s regular business hours, to audit the other Party&#8217;s books and records in the event that a suspected violation of any Anti-Corruption Law needs to be investigated (in such Party&#8217;s reasonable, good-faith discretion).  Such audit shall be conducted by such Party&#8217;s audit team comprised of qualified auditors who have received anticorruption training. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For clarity, a credible finding, after a reasonable investigation, of any breach of Section 10.4(a) or 10.4(b) with respect to any Anti-Corruption Law, shall be deemed a material breach of this Agreement and allow the non-breaching Party to terminate this Agreement in accordance with Section 13.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.5&#160;&#160;&#160;&#160;Additional Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In addition to any covenants made by Advaccine elsewhere in this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Advaccine hereby covenants to Inovio that neither Advaccine nor any of its Affiliates or Sublicensees, will employ or use the services of any Person who is debarred or disqualified under the Act, or comparable applicable Laws outside the U.S., in connection with activities relating to any Product&#59; and in the event that Advaccine becomes aware of the debarment or disqualification or threatened debarment or disqualification of any Person providing services to Advaccine or any of its Affiliates with respect to any activities relating to any Product, Advaccine will immediately notify Inovio in writing and Advaccine will cease, or cause its Affiliate to cease (as applicable), employing, contracting with, or retaining any such Person to perform any services relating to any Product&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each Party hereby covenants to the other Party that neither such Party nor any of its Affiliates, nor any of their respective employees shall use any confidential information obtained from any Third Party (including any prior employer) to which such Party or any of its Affiliates, or any of their respective employees has a duty to keep in confidence such information, directly or indirectly, whether obtained prior to the Effective Date or during the Term, in connection with activities performed under this Agreement, unless consented to in writing by such Third party, and such Party shall be solely responsible and liable for, and shall indemnify the other Party pursuant to Article 11 in connection with, any breach of this covenant by such Party, any of its Affiliates, or their respective employees.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.6&#160;&#160;&#160;&#160;No Other Representations or Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, ARE MADE OR GIVEN BY OR ON BEHALF OF A PARTY OR ITS AFFILIATES, AND ALL </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">44</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED.  FOR CLARITY AND WITHOUT LIMITING THE FOREGOING, INOVIO MAKES NO REPRESENTATION OR WARRANTY CONCERNING THE PRODUCTS OR INOVIO TECHNOLOGY EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 10. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 11.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnification</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.1&#160;&#160;&#160;&#160;Indemnification by Inovio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inovio shall defend, indemnify, and hold Advaccine and its Affiliates and their respective officers, directors, employees, and agents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) harmless from and against any and all losses, damages, liabilities, actually incurred expenses and costs, including reasonable legal expense and attorneys&#8217; fees (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to which any Advaccine Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">arising out of, based on, or resulting from (a) the Development, Manufacture, or Commercialization of the Products in the Field in the Advaccine Territory by or on behalf of Inovio or its Affiliates prior to the Effective Date, (b) the Development, Manufacture, or Commercialization of the Products in the Inovio Territory, (c) the breach of any of Inovio&#8217;s obligations under this Agreement, including Inovio&#8217;s representations, warranties or covenants set forth herein, (d) the conduct of any pharmacovigilance-related activities set forth in Section 5.8 by or on behalf of Inovio (except to the extent that such Claim arises from Advaccine&#8217;s provision of false, misleading, inaccurate or incomplete information to Inovio under Section 5.8 or Advaccine&#8217;s breach of its obligations under the Pharmacovigilance Agreement) or (e) the willful misconduct or negligent acts of any Inovio Indemnitee.  The foregoing indemnity obligation shall not apply to the extent that (i) the Advaccine Indemnitees fail to comply with the indemnification procedures set forth in Section 11.3 and Inovio&#8217;s defense of the relevant Claim is materially prejudiced by such failure, or (ii) any Claim arises from, is based on, or results from any activity or occurrence for which Advaccine is obligated to indemnify the Inovio Indemnitees under Section 11.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.2&#160;&#160;&#160;&#160;Indemnification by Advaccine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall defend, indemnify, and hold Inovio and its Affiliates and their respective officers, directors, employees, and agents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) harmless from and against any and all Losses to which any Inovio Indemnitee may become subject as a result of any Claims arising out of, based on, or resulting from (a) the Development, Manufacture, or Commercialization of the Products by or on behalf of Advaccine or its Affiliates or Sublicensees on or after the Effective Date (except to the extent that any such activities are conducted by or on behalf of Inovio or its Affiliates) (including any Infringement Actions), (b) the breach of any of Advaccine&#8217;s obligations under this Agreement, including Advaccine&#8217;s representations, warranties, or covenants set forth herein, or (c) the willful misconduct or negligent acts of any Advaccine Indemnitee.  The foregoing indemnity obligation shall not apply to the extent that (i) the Inovio Indemnitees fail to comply with the indemnification procedures set forth in Section 11.3 and Advaccine&#8217;s defense of the relevant Claim is materially prejudiced by such failure, or (ii) any Claim arises from, is based on, or results from any activity or occurrence for which Inovio is obligated to indemnify the Advaccine Indemnitees under Section 11.1.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">45</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.3&#160;&#160;&#160;&#160;Indemnification Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Party claiming indemnity under this Article 11 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall give written notice to the Party from whom indemnity is being sought (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) promptly after learning of such Claim and shall offer control of the defense of such Claim to the Indemnifying Party.  The Indemnified Party shall provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party&#8217;s expense, in connection with the defense of the Claim for which indemnity is being sought.  The Indemnified Party may participate in and monitor such defense with counsel of its own choosing at its sole expense&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the Indemnifying Party shall have the right to assume and conduct the defense of the Claim with counsel of its choice.  The Indemnifying Party shall not settle any Claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld, unless the settlement involves only the payment of money.  So long as the Indemnifying Party is actively defending the Claim in good faith, the Indemnified Party shall not settle or compromise any such Claim without the prior written consent of the Indemnifying Party.  If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (a) the Indemnified Party may defend against, consent to the entry of any judgment, or enter into any settlement with respect to such Claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith), and (b) the Indemnifying Party shall remain responsible to indemnify the Indemnified Party as provided in this Article 11.  Notwithstanding anything contained in this Section 11.3, the provisions of Section 9.5 shall govern the defense of any Infringement Actions.  Additionally, in the event that Inovio has elected to defend any such Infringement Action, then Advaccine shall not be obligated to indemnify Inovio for any Claims related to such Infringement Action&#59; rather, the Parties shall share equal responsibility for any Losses resulting therefrom. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.4&#160;&#160;&#160;&#160;Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.  NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 11.4 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 11.1 OR 11.2, OR DAMAGES AVAILABLE FOR A PARTY&#8217;S BREACH OF ITS EXCLUSIVITY OBLIGATIONS IN SECTION 2.5 OR ITS CONFIDENTIALITY OBLIGATIONS IN ARTICLE 12.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.5&#160;&#160;&#160;&#160;Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall procure and maintain insurance, including product liability insurance, adequate to cover its obligations hereunder and consistent with normal business practices of prudent companies similarly situated.  It is understood that such insurance shall not be construed to create a limit of either Party&#8217;s liability with respect to its indemnification obligations under this Article 11.  Each Party shall provide the other Party with written evidence of such insurance upon request.  Each Party shall provide the other Party with written notice at least thirty (30) days prior to the cancellation, nonrenewal or material change in such insurance.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 12.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidentiality</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">46</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.1&#160;&#160;&#160;&#160;Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party agrees that, during the Term and for a period of ten (10) years thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder or thereunder) any Confidential Information of the other Party, except to the extent expressly agreed in writing by the Parties.  The foregoing confidentiality and non-use obligations shall not apply to any portion of the other Party&#8217;s Confidential Information that the receiving Party can demonstrate by competent written proof&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;was already known to the receiving Party or its Affiliate, other than under an obligation of confidentiality, at the time of disclosure by the other Party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party or its Affiliate in breach of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;was disclosed to the receiving Party or its Affiliate without any confidentiality obligations by a Third Party who, to the Party&#8217;s knowledge, had a legal right to make such disclosure and who did not obtain such information directly or indirectly from the other Party&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;was independently discovered or developed by the receiving Party or its Affiliate without use of or reference to the other Party&#8217;s Confidential Information, as evidenced by a contemporaneous writing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.2&#160;&#160;&#160;&#160;Authorized Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding the obligations set forth in Section 12.1, a Party may disclose the other Party&#8217;s Confidential Information and the terms of this Agreement to the extent&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;such disclosure is reasonably necessary (i) for the filing or prosecuting of Patent rights as contemplated herein&#59; (ii) to comply with the requirements of Regulatory Authorities with respect to obtaining and maintaining Regulatory Approval of the Product&#59; or (iii) for the prosecuting or defending litigation as contemplated herein&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;such disclosure is reasonably necessary to its or its Affiliate&#8217;s employees, agents, consultants, contractors, licensees or Sublicensees, (including Inovio Partners) on a need-to-know basis for the sole purpose of performing its obligations or exercising its rights hereunder&#59; provided that in each case, the disclosees are bound by written obligations of confidentiality consistent with those contained in this Agreement&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;such disclosure is (i) reasonably necessary to comply with applicable Laws, including regulations or rules promulgated by applicable securities commissions (or other securities regulatory authorities), security exchanges (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Regulators</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, including without limitation to, the Securities and Futures Commission of Hong Kong, The Stock Exchange of Hong Kong Limited, the China Securities Regulatory Commission, the Shanghai Stock Exchange or the U.S. Securities and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">47</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exchange Commission), court order, administrative subpoena or order&#59; or (ii) at the request of applicable Securities Regulators, or reasonably anticipated by one Party that such disclosure will be required by applicable Laws or applicable Securities Regulators&#59;  and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;solely with respect to the terms of this Agreement and excluding disclosure of any other Confidential Information, such disclosure is reasonably necessary to any bona fide potential or actual investor, acquiror, merger partner, or other financial or commercial partner for the sole purpose of evaluating or carrying out an actual or potential investment, acquisition or other business relationship&#59; provided that in connection with such disclosure, such Party shall inform each disclosee of the confidential nature of such Confidential Information and require each disclosee to treat such Confidential Information as confidential.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party&#8217;s Confidential Information pursuant to Section 12.2(a), 12.2(c) or 12.2(d), such Party shall promptly notify the other Party of such required disclosure, to the extent that it is legally authorized or permitted to so, and shall use reasonable efforts to obtain, or to assist the other Party in obtaining, a protective order preventing or limiting the required disclosure.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.3&#160;&#160;&#160;&#160;Publicity&#59; Terms of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Parties agree that the existence or terms of this Agreement are the Confidential Information of both Parties, subject to the special authorized disclosure provisions set forth in this Section 12.3.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If either Party desires to make a public disclosure concerning the existence or terms of this Agreement, such Party shall give the proposed text of such disclosure to the other Party reasonably in advance (but in any case no less than three (3) Business Days prior to the disclosure) for its prior review and approval (except as otherwise provided herein), which approval shall not be unreasonably withheld or delayed.  A Party commenting on such a proposed disclosure shall provide its comments, if any, within three (3) Business Days after receiving the proposed disclosure for review (or such shorter period of time as necessitated by regulatory requirements).  In addition, where required by applicable Laws, including regulations promulgated by applicable security exchanges, either Party shall have the right to make a press release or other public disclosure regarding the achievement of each milestone under this Agreement as it is achieved, the achievements of Regulatory Approval in the Advaccine Territory as they occur, or the occurrence of other events that affect either Party&#8217;s rights or obligations under this Agreement, including the results of any Clinical Trial of the Products, whether in the Advaccine Territory or the Inovio Territory&#59; provided that such Party shall provide the proposed text of such disclosure to the other Party at least one (1) Business Day in advance, and the other Party shall provide its comments thereto within such one (1) Business Day.  In relation to the other Party&#8217;s review of such an announcement, such other Party may make specific, reasonable comments on such proposed press release within the prescribed time for commentary.  Neither Party shall be required to seek the permission of the other Party to repeat any information regarding the terms of this Agreement that has already been publicly disclosed by such Party, or by the other Party, in accordance with this Section 12.3.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">48</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Parties acknowledge that either or both Parties or their Affiliates may be obligated to file under applicable Laws a copy of this Agreement with Governmental Authorities, including, without limitation, the U.S. Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Each Party and its Affiliates shall be entitled to make such a required filing, provided that it requests confidential treatment of the commercial terms and sensitive technical terms hereof to the extent such confidential treatment is reasonably available.  In the event of any such filing, each Party will provide the other Party with a copy of this Agreement marked to show provisions for which such Party or its Affiliate intends to seek confidential treatment and shall reasonably consider and incorporate the other Party&#8217;s timely comments thereon to the extent consistent with the legal requirements, with respect to the filing Party or Affiliate, governing disclosure of material agreements and material information that must be publicly filed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.4&#160;&#160;&#160;&#160;Technical Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither Party may publish peer reviewed manuscripts, or give other forms of public disclosure such as abstracts and presentations, of results of studies carried out under this Agreement or otherwise pertaining to the Development of the Vaccine or the Products in the Advaccine Territory, without the opportunity for prior review and comment by the other Party in accordance with this Section 12.4, except to the extent required by applicable Laws.  A Party seeking publication shall provide the other Party the opportunity to review and comment on any such proposed publication at least five (5) calendar days for abstracts ten (10) calendar days for manuscripts prior to its intended submission for publication.  The other Party shall provide the Party seeking publication with its comments in writing, if any, within three (3) calendar days for abstracts and seven (7) calendar days for manuscripts after receipt of such proposed publication.  The Party seeking publication shall consider in good faith any comments thereto provided by the other Party and shall comply with the other Party&#8217;s request to remove any and all of such other Party&#8217;s Confidential Information from the proposed publication. Further, if Inovio reasonably determines and notifies Advaccine that a proposed publication is reasonably likely to result in Adverse Risk in the Inovio Territory, Advaccine shall not submit such publication unless and until the Parties agree to a proposal to mitigate such Adverse Risk. In addition, the Party seeking publication shall delay the submission for a period up to thirty (30) calendar days in the event that the other Party can demonstrate reasonable need for such delay for the preparation and filing of a patent application.  If the other Party fails to provide its comments to the Party seeking publication within the specified time frame, such other Party shall be deemed to not have any comments, and the Party seeking publication shall be free to publish in accordance with this Section 12.4.  The Party seeking publication shall provide the other Party a copy of the manuscript at the time of the submission.  Each Party agrees to acknowledge the contributions of the other Party and its employees in all publications in accordance with scientific practices.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.5&#160;&#160;&#160;&#160;Equitable Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party acknowledges that its breach of this Article 12 will cause irreparable harm to the other Party, which cannot be reasonably or adequately compensated in damages in an action at law.  By reasons thereof, each Party agrees that the other Party shall be entitled, in addition to any other remedies it may have under this Agreement or otherwise, to preliminary and permanent injunctive and other equitable relief to prevent or curtail any actual or threatened breach of the obligations relating to Confidential Information set forth in this Article 12 by the other Party.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 13.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">49</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Term And Termination</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.1&#160;&#160;&#160;&#160;Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The term of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall commence upon the Effective Date and, unless earlier terminated pursuant to this Article 13, shall remain in effect until the expiration of the Royalty Term on a Region-by-Region basis.  Upon the expiration (but not early termination) of this Agreement, on a Region-by-Region basis, the licenses granted hereunder by Inovio to Advaccine shall become fully paid-up and royalty free&#59; provided that such licenses shall thereafter be granted on a non-exclusive basis.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.2&#160;&#160;&#160;&#160;Termination by Advaccine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine may terminate this Agreement in its entirety for convenience upon (i) nine (9) months prior written notice to Inovio (if such notice is provided before the First Commercial Sale in any Region) or (ii) eighteen (18) months prior written notice to Inovio (if such notice is provided following the First Commercial Sale in any Region)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that in each case under (i) and (ii) Inovio may, in its discretion, upon prior written notice to Advaccine accelerate the effectiveness of such termination to the extent permitted by Law in the Advaccine Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.3&#160;&#160;&#160;&#160;Termination by Inovio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Inovio may terminate this Agreement upon written notice to Advaccine, if Advaccine ceases all Development (including all regulatory activities) or all Commercialization of the Products (including through Sublicensees and contractors) in the Advaccine Territory for a period of nine (9) or more consecutive months, unless Development or Commercialization of the Products was prevented throughout such period by a force majeure for which Advaccine provided notice pursuant to Section 15.2 prior to or at the start of such period and that persisted throughout such period despite Advaccine&#8217;s Commercially Reasonable Efforts to remove or mitigate it. Such termination shall go into effect on the date specified in the applicable termination notice. For clarity, a delay by Regulatory Authorities and&#47;or a decision by Regulatory Authorities to suspend a Clinical Trial (e.g., a &#8220;regulatory hold&#8221;) shall not give Inovio the right to terminate this Agreement under this Section 13.3(a), so long as Advaccine continues to use Commercially Reasonable Efforts to remove such regulatory hold.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Inovio may terminate this Agreement in its entirety upon thirty (30) days&#8217; prior written notice to Advaccine, if Advaccine or its Affiliates or their respective Sublicensees (directly or indirectly, individually or in association with any other Person) challenges the validity, enforceability or scope of any Inovio Licensed Patent, unless during such thirty (30)-day period the subject challenge is permanently dismissed or withdrawn and is not thereafter reinstituted or continued&#59; provided that in the event a Sublicensee of Advaccine initiates such challenge, Inovio may not terminate this Agreement if (i) Advaccine successfully causes such Sublicensee to abort such challenge within such thirty (30)-day period, or (ii) Advaccine (A) provides Inovio a written notice of its intent to terminate its sublicense with such Sublicensee within such thirty (30)-day period, and (B) successfully terminates such sublicense within such thirty (30)-day period.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Inovio may terminate this Agreement in its entirety upon thirty (30) days&#8217; prior written notice to Advaccine, if the Ringpu License Agreement (as defined in the Non-exclusive License Agreement) is not executed in a form reasonably satisfactory to Inovio within thirty (30) days after the Effective Date. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">50</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.4&#160;&#160;&#160;&#160;Termination for Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall have the right to terminate this Agreement in its entirety immediately upon written notice to the other Party if the other Party materially breaches its obligations under this Agreement and, after receiving written notice identifying such material breach in reasonable detail, fails to cure such material breach within ninety (90) (or thirty (30) days in case of failure to make a payment due under this Agreement for reasons other than that set forth in Section 8.6) days from the date of such notice&#59; provided that, if either Party disputes (a) whether such material breach has occurred, or (b) whether the defaulting Party has cured such material breach, the Parties agree to resolve the dispute as expeditiously as possible under Article 14.  It is understood and acknowledged that during the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.5&#160;&#160;&#160;&#160;Termination Due to Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Either Party may terminate this Agreement if, at any time, the other Party files in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of that Party or of its assets, or if the other Party proposes a written agreement of composition or extension of its debts, or if the other Party is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition is not dismissed within sixty (60) days after the filing thereof, or if the other Party proposes or becomes a Party to any dissolution or liquidation, or if the other Party makes an assignment for the benefit of its creditors (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Insolvency Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.6&#160;&#160;&#160;&#160;Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon any termination of this Agreement, the following shall apply (in addition to any other rights and obligations under this Agreement with respect to such termination)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All licenses and other rights granted by Inovio to Advaccine under this Agreement shall terminate.  Inovio shall have a reversion of all rights previously licensed to Advaccine hereunder for which the relevant licenses have terminated on a fully paid-up and royalty-free basis, itself or with or through an Affiliate or Third Party, to Develop and Commercialize the Products in the Field in the Advaccine Territory at Inovio&#8217;s discretion. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Wind-Down</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine will (i) responsibly wind-down, in accordance with accepted pharmaceutical industry norms and ethical practices, any on-going Clinical Trials for which it has responsibility hereunder in which patient dosing has commenced or, (ii) unless if this Agreement is terminated by Advaccine pursuant to Sections 13.4 or 13.5, at Inovio&#8217;s reasonable request, (A) transfer to Inovio of its designee such Clinical Trial to the extent permitted under applicable Laws and accepted pharmaceutical industry norms and ethical practices, or (B) if reasonably practicable and not adverse to patient safety, complete such Clinical Trials and Inovio shall reimburse Advaccine its reasonable, out-of-pocket costs associated therewith.  For clarity, except as provided for above, Advaccine may transfer to Inovio or its designee or wind-down any ongoing Clinical Trials prior to the date of termination in accordance with accepted pharmaceutical industry norms and ethical practices and Advaccine will be responsible for any costs associated with such transfer or wind-down.  Notwithstanding the foregoing, if this Agreement is terminated by Advaccine pursuant to Sections 13.4 or 13.5, then Inovio will be responsible for any costs associated with such wind-down.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">51</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Regulatory Materials&#59; Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   Except if this Agreement is terminated by Advaccine pursuant to Sections 13.4 or 13.5, Advaccine shall (i) provide and assign to Inovio or its designee all Regulatory Materials, including Regulatory Approvals, for the Products to the extent possible under applicable Laws in the Advaccine Territory, (ii) promptly provide to Inovio all Data (to the extent not already provided to Inovio), including pharmacovigilance data, generated by or on behalf of Advaccine, and (iii) promptly return or destroy, at Inovio&#8217;s election, all Confidential Information of Inovio.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except if this Agreement is terminated by Advaccine pursuant to Sections 13.4 or 13.5, upon Inovio&#8217;s written request, Advaccine shall grant to Inovio, effective as of the date of such request, an exclusive, transferable, fully paid-up, royalty free, sublicensable license to use Advaccine Product Marks in connection with the Commercialization of the Products in the Advaccine Territory (and excluding, for clarity, any Advaccine Housemarks). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Transition Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon Inovio&#8217;s reasonable request, (i) Advaccine shall provide such assistance as may be reasonably necessary or useful for Inovio to continue the Development and Commercialization of the Products in the Advaccine Territory, to the extent Advaccine or its Affiliate is then performing or having performed such activities, including upon the reasonable request of Inovio, assigning (to the extent Advaccine has rights to assign) or using Commercially Reasonable Efforts to amend as appropriate any agreements or arrangements Advaccine or its Affiliate have with any Third Party for the Development, distribution, sale or otherwise Commercialization of the Products&#59; and (ii) Advaccine shall provide Inovio with copies of any promotional and marketing materials generated by or on behalf of Advaccine with respect to the Products prior to the effective date of termination. If this Agreement is terminated by Advaccine pursuant to Sections 13.4 or 13.5, Inovio shall bear all costs arising out of any of the transition assistance activities set forth in clause (i) or (ii) performed by Advaccine. If this Agreement is terminated by Advaccine pursuant to Section 13.2 or by Inovio pursuant to Sections 13.3, 13.4, or 13.5, Advaccine shall bear all costs arising out of any of the transition assistance activities set forth in clause (i) or (ii) performed by Advaccine. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;Inventory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that this Agreement is terminated in its entirety, Inovio shall have the right, but not the obligation, to purchase any and all of the inventory of the Products held by Advaccine or its Affiliates as of the date of termination, at a price equal to the transfer price paid by Advaccine to Inovio for such inventory.  Notwithstanding the foregoing, if this Agreement is terminated by Advaccine pursuant to Sections 13.4 or 13.5, upon Advaccine&#8217;s request, at its sole discretion, Inovio shall re-purchase any and&#47;or all of its inventory of the Products, at a price equal to the transfer price paid by Advaccine to Inovio (if supplied by Inovio) or Advaccine&#8217;s manufacturing cost (if manufactured by Advaccine or its subcontractor) therefor.  Advaccine shall also have the right to continue to be permitted to sell such inventory for up to at least twelve (12) months after the effective date of termination of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.7&#160;&#160;&#160;&#160;Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any expiration or termination of this Agreement shall not affect rights or obligations of the Parties under this Agreement that have accrued prior to the date of expiration or termination (including with respect to any payments that have accrued prior to the effective date of expiration or termination of this Agreement).  Notwithstanding anything to the contrary, the following </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">52</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provisions shall survive any expiration or termination of this Agreement&#58; Sections 2.4, 4.5, 8.5 through 8.9 (inclusive), 9.1(a), 9.1(b), 9.1(d), 10.6, 13.6, 13.7 and 13.8 and Articles 1, 11, 12, 14 and 15.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.8&#160;&#160;&#160;&#160;Termination Not Sole Remedy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Termination is not the sole remedy under this Agreement and, whether or not termination is effected and notwithstanding anything contained in this Agreement to the contrary, all other remedies shall remain available except as agreed to otherwise herein.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 14.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dispute Resolution</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.1&#160;&#160;&#160;&#160;Disputes&#59; Internal Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties recognize that disputes as to certain matters may from time to time arise that relate to either Party&#8217;s rights and&#47;or obligations hereunder.  It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation.  To accomplish this objective, the Parties agree that, except as otherwise provided in Section 3.2(d), if a dispute arises under or relates to this Agreement, including, without limitation, any alleged breach under this Agreement or any issue relating to the interpretation or application of this Agreement, and the Parties are unable to resolve such dispute within thirty (30) days after such dispute is first identified by either Party in writing to the other, the Parties shall refer such dispute to a senior executive of each of Inovio (or one of its Affiliates) and Advaccine (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for attempted resolution by good faith negotiations within thirty (30) days after notice referring to the dispute is received.  If the dispute is not resolved within such thirty (30) days, then the dispute shall be resolved by arbitration in accordance with Section 14.2 and thereafter neither Party shall have any further obligation under this Section 14.1.  Notwithstanding the foregoing, and without waiting for the expiration of any such thirty (30)-day periods, each Party shall each have the right to apply to any court of competent jurisdiction for appropriate interim or provisional relief, as necessary to protect the rights or property of such Party. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.2&#160;&#160;&#160;&#160;Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All disputes arising out of or in connection with this Agreement, including any questions regarding its formation, existence, validity or termination, or the scope or applicability of this agreement to arbitrate, shall be referred to and finally resolved by arbitration administered by the Singapore International Arbitration Centre (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) under the Arbitration Rules of the Singapore International Arbitration Centre (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIAC Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the time being in force and as may be amended by the rest of this clause. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The seat, or legal place, of arbitration shall be the Republic of Singapore.  There shall be three (3) arbitrators, with two (2) arbitrators to be respectively nominated by each Party and the third (presiding) arbitrator to be appointed by SIAC.  The language of the arbitration shall be English.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any decision or arbitral award of SIAC shall be final and binding on each Party.  If any Party fails to implement the final arbitral award, the other Party may file an application for the enforcement of the arbitral award to a court with competent jurisdiction.  The costs of arbitration shall be borne by the losing Party or as otherwise determined by the arbitral tribunal.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">53</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;In the course of arbitration, the Parties shall make Commercially Reasonable Efforts to continue to implement the Agreement except for those matters subject to arbitration.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Each Party retains the right to apply to any court of competent jurisdiction for interim and&#47;or conservatory measures, including pre-arbitral attachments or preliminary injunctions, and any such request shall not be deemed incompatible with, or a waiver of, this agreement to arbitrate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The existence and content of the arbitral proceedings and any rulings or awards shall be kept confidential by the Parties and members of the arbitral tribunal except (i) to the extent that disclosure may be required of a Party to fulfill a legal duty, protect or pursue a legal right, or enforce or challenge an award in bona fide legal proceedings before a state court or other judicial authority, (ii) with the consent of all Parties, (iii) where needed for the preparation or presentation of a claim or defense in this arbitration, (iv) where such information is already in the public domain other than as a result of a breach of this clause, or (v) by order of the arbitral tribunal upon application of a Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;For avoidance of doubt, nothing contained in this Section 14.2 shall operate as a restriction on a Party's rights to terminate this Agreement pursuant to Article 13. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.3&#160;&#160;&#160;&#160;Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall be governed by and construed under, and all disputes arising under or in connection with this Agreement shall be resolved in accordance with, the laws of the State of New York, U.S., without regard to the conflicts of law provisions thereof.  The United Nations Convention on International Contracts on the Sale of Goods does not apply to this Agreement and is expressly and entirely excluded.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 15.</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Miscellaneous</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.1&#160;&#160;&#160;&#160;Entire Agreement&#59; Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement, including the Exhibits hereto, sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof and supersedes, as of the Effective Date, all prior and contemporaneous agreements and understandings between the Parties with respect to the subject matter hereof (other than the Non-Exclusive License Agreement, and that certain Research Service Contract dated December 30, 2020)&#59; provided, however, that, Advaccine shall pay to Inovio all amounts invoiced under the Research Service Contract dated December 30, 2020 within thirty (30) days after the Effective Date.  The foregoing shall not be interpreted as a waiver of any remedies available to either Party as a result of any breach, prior to the Effective Date, by the other Party of its obligations under the Confidentiality Agreement.  There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth in this Agreement.  No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.2&#160;&#160;&#160;&#160;Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Both Parties shall be excused from the performance of their obligations under this Agreement to the extent that such performance is prevented by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party.  Such excuse </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">54</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall be continued only for so long as (a) the condition constituting force majeure continues and (b) the nonperforming Party takes all reasonable efforts to remove the condition.  For purposes of this Agreement, force majeure shall include conditions beyond the reasonable control of the applicable Party, which may include an act of God, war, civil commotion, terrorist act, labor strike or lock-out, epidemic, pandemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe, action or inaction of any Governmental Authority, and failure of plant or machinery.  Notwithstanding the foregoing, a Party shall not be excused from making payments owed hereunder because of a force majeure affecting such Party.  If a force majeure persists for more than ninety (90) days, then the Parties will discuss in good faith the modification of the Parties&#8217; obligations under this Agreement in order to mitigate the delays caused by such force majeure.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.3&#160;&#160;&#160;&#160;Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice required or permitted to be given under this Agreement shall be in writing, shall specifically refer to this Agreement, and shall be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section 15.3, and shall be deemed to have been given for all purposes (a) when received, if hand-delivered or sent by a reputable courier service, (b) five (5) Business Days after mailing, if mailed by first class certified or registered airmail, postage prepaid, return receipt requested, or (c) if sent by electronic mail, upon electronic confirmation of receipt.</font></div><div style="padding-left:172.1pt;text-indent:-136.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to Inovio&#58;  &#160;&#160;&#160;&#160;Inovio Pharmaceuticals, Inc. </font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">600 W. Germantown Pike, Suite 110</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Plymouth Meeting, PA 19462</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58; Joseph Kim, President and CEO</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#160;&#58; joseph.kim&#64;inovio.com</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-136.1pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;with copies to (which shall not constitute notice)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:172.1pt;text-indent:-136.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Inovio Pharmaceuticals, Inc. </font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">600 W. Germantown Pike, Suite 110</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Plymouth Meeting, PA 19462</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58; Tom Mancini, Vice President, Intellectual Property</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#160;&#58; Thomas.Mancini&#64;inovio.com</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font><br></font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font><br></font></div><div style="padding-left:180pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cooley LLP</font></div><div style="padding-left:180pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">500 Boylston Street</font></div><div style="padding-left:180pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Boston, MA 02116-3737</font></div><div style="padding-left:180pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">USA</font></div><div style="padding-left:171.35pt;text-indent:-171.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Attn&#58; Geoffrey Spolyar</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#160;&#58; gspolyar&#64;cooley.com</font></div><div style="padding-left:171.35pt;text-align:justify;text-indent:-171.35pt"><font><br></font></div><div style="padding-left:171pt;text-align:justify;text-indent:-136.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to Advaccine&#58;  &#160;&#160;&#160;&#160;         Advaccine Biopharmaceuticals Suzhou Co., Ltd.</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-136.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;        18 Qingqiu Road</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">55</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-136.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;         Suzhou, China</font></div><div style="padding-left:171pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58;  Alliance Manager</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#160;&#58; partner&#64;advaccine.com</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:172.1pt;text-indent:-136.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with copies to (which shall not constitute notice)&#58;</font></div><div style="padding-left:172.1pt;text-indent:-136.1pt"><font><br></font></div><div style="padding-left:172.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Mengyu LU</font></div><div style="padding-left:172.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Partner </font></div><div style="padding-left:172.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sidley Austin LLP </font></div><div style="padding-left:172.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">39&#47;F, Two International Finance Center </font></div><div style="padding-left:172.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Central, Hong Kong</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </font></div><div style="padding-left:136.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58; Mengyu.lu&#64;Sidley.com</font></div><div style="padding-left:172.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:172.1pt;text-indent:-136.1pt"><font><br></font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-136.1pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.4&#160;&#160;&#160;&#160;No Strict Construction&#59; Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement has been prepared jointly by the Parties and shall not be strictly construed against either Party.  Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.  The headings of each Article and Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section.  Except where the context otherwise requires, the use of any gender shall be applicable to all genders, and the word &#8220;or&#8221; is used in the inclusive sense (and&#47;or).  The term &#8220;including&#8221; as used herein means including, without limiting the generality of any description preceding such term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.5&#160;&#160;&#160;&#160;Assignment&#59; Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Except as provided in Section 15.5(b), this Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the prior written consent of the other Party.  Any attempted assignment not in accordance with the foregoing shall be null and void and of no legal effect.  Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement.  The terms and conditions of this Agreement shall be binding upon, and shall inure to the benefit of, the Parties and their respected successors and permitted assigns.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, Inovio may, without the consent of Advaccine, (i) assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate of Inovio, or in whole to its successor-in-interest in connection with the sale of all or substantially all of its stock or its assets to which this Agreement relates, or in connection with a merger, acquisition or similar transaction&#59; (ii)&#160;sell or otherwise assign to any Third Party Inovio&#8217;s right to receive any payment (or portion thereof) from Advaccine under this Agreement, and&#47;or (iii) grant a security interest in its rights, title and interest in, to and under this Agreement.  If Inovio sells or assigns to any Third Party a right to receive a portion or all of its payments under this Agreement, such Third Party shall also have the right to receive the information received by Inovio pursuant to this Agreement and to conduct audits in accordance with Section 8.8 and Advaccine shall, at Inovio&#8217;s request, cooperate to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">56</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">facilitate the provision of any such information and the payment of any such amounts directly to such Third Party.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, Advaccine may without consent of Inovio, assign this Agreement or delegate its rights and obligations hereunder in whole or in part to an Affiliate of Advaccine (provided that in such case, Advaccine shall inform Inovio of such assignment or delegation and remain responsible for the performance of its Affiliate under this Agreement), or in whole to its successor-in-interest in connection with the sale of all or substantially all of its stock or its assets to which this Agreement relates, or in connection with a merger, acquisition or similar transaction.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.6&#160;&#160;&#160;&#160;Performance by Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party may discharge any obligations and exercise any right hereunder through any of its Affiliates.  Each Party hereby guarantees the performance by its Affiliates of such Party&#8217;s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance.  Any breach by a Party&#8217;s Affiliate of any of such Party&#8217;s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party&#8217;s Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.7&#160;&#160;&#160;&#160;Further Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.8&#160;&#160;&#160;&#160;Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by an arbitral tribunal constituted in accordance with Section 14.2, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof.  The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.9&#160;&#160;&#160;&#160;No Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any delay in enforcing a Party&#8217;s rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such Party&#8217;s rights to the future enforcement of its rights under this Agreement, except with respect to an express written and signed waiver relating to a particular matter for a particular period of time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.10&#160;&#160;&#160;&#160;Independent Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give either Party the power or authority to act for, bind, or commit the other Party in any way.  Nothing herein shall be construed to create the relationship of partners, principal and agent, or joint-venture partners between the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.11&#160;&#160;&#160;&#160;English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement was prepared in the English language, which language shall govern the interpretation of, and any dispute regarding, the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.12&#160;&#160;&#160;&#160;Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be executed in one (1) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement may be executed via electronic signature or via the exchange </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">57</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of signed portable document format (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PDF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) versions of this Agreement.  Such electronic signatures, and signatures on PDF versions of this Agreement, will be considered the legally binding equivalent of wet-ink, original, hand-written signatures.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.13&#160;&#160;&#160;&#160;Rights in Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All rights and licenses granted under or pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11 of the U.S. Code and other similar laws in any jurisdiction outside the U.S. (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Bankruptcy Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), licenses of rights to &#8220;intellectual property&#8221; as defined under the Bankruptcy Laws.  Upon the occurrence of any Insolvency Event with respect to a Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Insolvent Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Insolvent Party agrees that the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Non-Insolvent Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Laws.  Each Party shall, during the Term, create and maintain current copies or, if not amenable to copying, detailed descriptions or other appropriate embodiments, to the extent feasible, of all such intellectual property.  Each Party agrees and acknowledges that &#8220;embodiments&#8221; of intellectual property within the meaning of Section 365(n) include, without limitation, laboratory notebooks, cell lines, product samples and inventory, research studies and data, Regulatory Approvals and Regulatory Materials, in each case to the extent related to the Products.  If (i) a case is commenced during the Term by or against a Party under the Bankruptcy Laws, (ii) this Agreement is rejected as provided for under the Bankruptcy Laws, and (iii) the Non-Insolvent Party elects to retain its rights hereunder as provided for under the Bankruptcy Laws, then the Insolvent Party (in any capacity, including debtor-in-possession) and its successors and assigns (including a Title 11 trustee), shall (x) provide to the Non-Insolvent Party immediately upon the Non-Insolvent Party&#8217;s written request copies of all such intellectual property (including embodiments thereof) held by the Insolvent Party and such successors and assigns, or otherwise available to them, and (y) not interfere with the Non-Insolvent Party&#8217;s rights under this Agreement, or any related agreements between the Parties, to such intellectual property (including such embodiments), including any right to obtain such intellectual property (or such embodiments) from another entity, to the extent provided in the Bankruptcy Laws.  Whenever the Insolvent Party or any of its successors or assigns provides to the Non-Insolvent Party any of the intellectual property licensed hereunder (or any embodiment thereof) pursuant to this Section 15.13, the Non-Insolvent Party shall have the right to perform the Insolvent Party&#8217;s obligations hereunder with respect to such intellectual property, but neither such provision nor such performance by the Non-Insolvent Party shall release the Insolvent Party from liability resulting from rejection of the license or the failure to perform such obligations.  All rights, powers and remedies of the Non-Insolvent Party as provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including the Bankruptcy Laws) in the event of the commencement of a case by or against a Party under the Bankruptcy Laws.  In particular, it is the intention and understanding of the Parties  that the rights granted to the Parties under this Section 15.13 are essential to the Parties&#8217; respective businesses and the Parties acknowledge that damages are not an adequate remedy.  The Parties agree that they intend the following rights to extend to the maximum extent permitted by applicable Laws, and to be enforceable under Section 365(n) of Title 11 of the U.S. Code&#58; (A) the right of access to any intellectual property (including embodiments thereof) of the Insolvent Party, or any Third Party with whom the Insolvent Party contracts to perform an obligation of the Insolvent Party under this Agreement, and, in the case of the Third Party, which is necessary for the Development, Manufacture and Commercialization of Products&#59; and (B) the right to contract directly with any Third </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">58</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Party to complete the contracted work upon failure of the Insolvent Party to comply with its applicable obligations.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#123;Signature Page Follows&#125;</font></div><div><font><br></font></div><div id="i412cef2899bc4cd386fa14bf1a8043af_4"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">In Witness Whereof, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Parties have executed this Collaboration and License Agreement in duplicate originals by their duly authorized officers as of the Effective Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">59</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</font></div><div style="margin-bottom:18pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; J. Joseph Kim&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; J. Joseph Kim, PhD</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; President &#38; CEO</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd.</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jane Yu&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;  Jane Yu</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;  President</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">60</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><div id="i412cef2899bc4cd386fa14bf1a8043af_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">List of Exhibits</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A&#58;&#160;&#160;&#160;&#160;Inovio Licensed Patents</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit B&#58;&#160;&#160;&#160;&#160;Inovio Licensed Know-How </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Licensed Patents</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Licensed Know-How</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To be mutually agreed upon within thirty (30) days after the Effective Date.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall only include a requirement to provide Licensed Know-How not previously provided to Advaccine.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ino-12312020x10kex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie89581381d5f46b1bc549e0f430e5d12_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Subsidiary Name(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inovio Asia, LLC</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ino-12312020x10kex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i53d00642393e4e799bfeeadca7f9ec57_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No. 333- 236202) of Inovio Pharmaceuticals, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No. 333- 237172) of Inovio Pharmaceuticals, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No. 333- 252256) of Inovio Pharmaceuticals, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No.333-161559) pertaining to Inovio Biomedical Corporation 2007 Omnibus Incentive Plan,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 Nos. 333-166906, 333-174353, 333-181532, 333-192318, 333-196325, 333-209155, and 333-216061) pertaining to Inovio Pharmaceuticals, Inc&#8217;s 2007 Omnibus Incentive Plan, </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 Nos. 333-216059, 333-223776, 333-230337, and 333-231872) Inovio Pharmaceutical, Inc.&#8217;s 2016 Omnibus Incentive Plan, and </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-236201) Inovio Pharmaceutical, Inc.&#8217;s 2016 Omnibus Incentive Plan, as amended</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of our reports dated March&#160;1, 2021, with respect to the consolidated financial statements and the effectiveness of internal control over financial reporting of Inovio Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Inovio Pharmaceuticals, Inc. for the year ended December 31, 2020.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">March&#160;1, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ino-12312020x10kex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i0f674cdae337443ab36ed84ba0451b02_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CEO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, J. Joseph Kim, certify that&#58; </font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form&#160;10-K of Inovio Pharmaceuticals, Inc.</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15(d)-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;J. J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OSEPH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">J. Joseph Kim</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ino-12312020x10kex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i02fc7104aaab47959d4f45c129bf0ca3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CFO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter Kies, certify that&#58; </font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form&#160;10-K of Inovio Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15(d)-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ino-12312020x10kex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i23fb122423834f018c6404db75150a25_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section&#160;1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the year ending December&#160;31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge&#58; </font></div><div style="margin-top:9pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;J. J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OSEPH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">J. Joseph Kim</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Executive Officer)</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>ino-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:457132bc-9fa0-4eb7-b7bc-387259668e99,g:003ddec6-0acb-4351-b822-2fdc6632a099-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://www.inovio.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.inovio.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.inovio.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompany" roleURI="http://www.inovio.com/role/TheCompany">
        <link:definition>2101101 - Disclosure - The Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2102102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2405401 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.inovio.com/role/RevenueRecognition">
        <link:definition>2108103 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDetails" roleURI="http://www.inovio.com/role/RevenueRecognitionDetails">
        <link:definition>2409404 - Disclosure - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.inovio.com/role/CollaborativeAgreements">
        <link:definition>2110104 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsDetails" roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails">
        <link:definition>2411405 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestments" roleURI="http://www.inovio.com/role/ShorttermInvestments">
        <link:definition>2112105 - Disclosure - Short-term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsTables" roleURI="http://www.inovio.com/role/ShorttermInvestmentsTables">
        <link:definition>2313302 - Disclosure - Short-term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsNarrativeDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails">
        <link:definition>2414406 - Disclosure - Short-term Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails">
        <link:definition>2415407 - Disclosure - Short-term Investments - Summary of Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.inovio.com/role/FairValueMeasurements">
        <link:definition>2116106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.inovio.com/role/FairValueMeasurementsTables">
        <link:definition>2317303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2418408 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2419409 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails" roleURI="http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails">
        <link:definition>2420410 - Disclosure - Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersandConcentrationofCreditRisk" roleURI="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRisk">
        <link:definition>2121107 - Disclosure - Major Customers and Concentration of Credit Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersandConcentrationofCreditRiskTables" roleURI="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskTables">
        <link:definition>2322304 - Disclosure - Major Customers and Concentration of Credit Risk (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersandConcentrationofCreditRiskDetails" roleURI="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails">
        <link:definition>2423411 - Disclosure - Major Customers and Concentration of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssets" roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssets">
        <link:definition>2124108 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>2325305 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>2426412 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssets" roleURI="http://www.inovio.com/role/FixedAssets">
        <link:definition>2127109 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsTables" roleURI="http://www.inovio.com/role/FixedAssetsTables">
        <link:definition>2328306 - Disclosure - Fixed Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsDetails" roleURI="http://www.inovio.com/role/FixedAssetsDetails">
        <link:definition>2429413 - Disclosure - Fixed Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets">
        <link:definition>2130110 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2331307 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails">
        <link:definition>2432414 - Disclosure - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1">
        <link:definition>2432414 - Disclosure - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>2433415 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails">
        <link:definition>2434416 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebt" roleURI="http://www.inovio.com/role/ConvertibleDebt">
        <link:definition>2135111 - Disclosure - Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtTables" roleURI="http://www.inovio.com/role/ConvertibleDebtTables">
        <link:definition>2336308 - Disclosure - Convertible Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtNarrativeDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails">
        <link:definition>2437417 - Disclosure - Convertible Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtBalanceOfConvertibleDebtDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails">
        <link:definition>2438418 - Disclosure - Convertible Debt - Balance Of Convertible Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtScheduleofMaturitiesDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails">
        <link:definition>2439419 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpenses" roleURI="http://www.inovio.com/role/AccountsPayableandAccruedExpenses">
        <link:definition>2140112 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesTables" roleURI="http://www.inovio.com/role/AccountsPayableandAccruedExpensesTables">
        <link:definition>2341309 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesDetails" roleURI="http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails">
        <link:definition>2442420 - Disclosure - Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.inovio.com/role/StockholdersEquity">
        <link:definition>2143113 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.inovio.com/role/StockholdersEquityTables">
        <link:definition>2344310 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofPreferredStockDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails">
        <link:definition>2445421 - Disclosure - Stockholders' Equity - Summary of Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2446422 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofStockOptionsOutstandingDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails">
        <link:definition>2447423 - Disclosure - Stockholders' Equity - Summary of Stock Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails">
        <link:definition>2448424 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails">
        <link:definition>2449425 - Disclosure - Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.inovio.com/role/Leases">
        <link:definition>2150114 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.inovio.com/role/LeasesTables">
        <link:definition>2351311 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.inovio.com/role/LeasesNarrativeDetails">
        <link:definition>2452426 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails" roleURI="http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails">
        <link:definition>2453427 - Disclosure - Leases - Summary of Maturities of Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" roleURI="http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1">
        <link:definition>2453427 - Disclosure - Leases - Summary of Maturities of Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentinAffiliatedEntity" roleURI="http://www.inovio.com/role/InvestmentinAffiliatedEntity">
        <link:definition>2154115 - Disclosure - Investment in Affiliated Entity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentinAffiliatedEntityDetails" roleURI="http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails">
        <link:definition>2455428 - Disclosure - Investment in Affiliated Entity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.inovio.com/role/IncomeTaxes">
        <link:definition>2156116 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.inovio.com/role/IncomeTaxesTables">
        <link:definition>2357312 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofPretaxLossfromOperationsDetails" roleURI="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails">
        <link:definition>2458429 - Disclosure - Income Taxes - Components of Pretax Loss from Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails" roleURI="http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails">
        <link:definition>2459430 - Disclosure - Income Taxes - Summary of the Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofIncomeTaxesDetails" roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails">
        <link:definition>2460431 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2461432 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2462433 - Disclosure - Income Taxes Significant Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails">
        <link:definition>2463434 - Disclosure - Income Taxes Expected Expirations of Federal and State Losses and Credits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" roleURI="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails">
        <link:definition>2464435 - Disclosure - Income Taxes Unrecognized Tax Benefits Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlan" roleURI="http://www.inovio.com/role/A401kPlan">
        <link:definition>2165117 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlanDetails" roleURI="http://www.inovio.com/role/A401kPlanDetails">
        <link:definition>2466436 - Disclosure - 401(k) Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.inovio.com/role/RelatedPartyTransactions">
        <link:definition>2167118 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2468437 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsInc" roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc">
        <link:definition>2169119 - Disclosure - Geneos Therapeutics, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncTables" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables">
        <link:definition>2370313 - Disclosure - Geneos Therapeutics, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncNarrativeDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails">
        <link:definition>2471438 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncDeconsolidationAccountingDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails">
        <link:definition>2472439 - Disclosure - Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncInvestmentinGeneosDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails">
        <link:definition>2473440 - Disclosure - Geneos Therapeutics, Inc. - Investment in Geneos (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncFairValueAssumptionsDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails">
        <link:definition>2474441 - Disclosure - Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncPreferredStockInvestmentDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails">
        <link:definition>2475442 - Disclosure - Geneos Therapeutics, Inc. - Preferred Stock Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnaudited" roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited">
        <link:definition>2176120 - Disclosure - Quarterly Financial Information (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnauditedTables" roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables">
        <link:definition>2377314 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnauditedDetails" roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails">
        <link:definition>2478443 - Disclosure - Quarterly Financial Information (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.inovio.com/role/SubsequentEvents">
        <link:definition>2179121 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.inovio.com/role/SubsequentEventsDetails">
        <link:definition>2480444 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ino_LesseeOperatingLeaseAreaofLandUnderLease" abstract="false" name="LesseeOperatingLeaseAreaofLandUnderLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="ino_ServiceBasedRestrictedStockUnitsMember" abstract="true" name="ServiceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_ChangeInValueOfCommonStockWarrants" abstract="false" name="ChangeInValueOfCommonStockWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" abstract="false" name="StockSaleAgreementAggregateProceedsFromIssuanceOfStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringinFiveYears" abstract="false" name="TaxCreditCarryforwardExpiringinFiveYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" abstract="false" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ino_AfterJuly22020ConversionPriceMember" abstract="true" name="AfterJuly22020ConversionPriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingToBeReceived" abstract="false" name="CollaborativeAgreementFundingToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringinThreeMonths" abstract="false" name="TaxCreditCarryforwardExpiringinThreeMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementPaymentEarned" abstract="false" name="CollaborationAgreementPaymentEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" abstract="false" name="NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_GrantRevenuePolicyTextBlock" abstract="false" name="GrantRevenuePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedAmount" abstract="false" name="CollaborativeAgreementAwardedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliateNoncurrent" abstract="false" name="DeferredGrantFundingFromAffiliateNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ApolloBioMember" abstract="true" name="ApolloBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementMilestonePaymentRevenueRecognized" abstract="false" name="CollaborativeAgreementMilestonePaymentRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" abstract="false" name="CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A2016IncentivePlanMember" abstract="true" name="A2016IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_A2007IncentivePlanMember" abstract="true" name="A2007IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_GeneOneLifeSciencesMember" abstract="true" name="GeneOneLifeSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" abstract="false" name="NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_CollaborativeAgreementForeignNonIncomeTaxes" abstract="false" name="CollaborativeAgreementForeignNonIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" abstract="false" name="EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" abstract="false" name="StockPurchaseAgreementCommitmentOfAdditionalInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseinDeferredGrantFundingCurrent" abstract="false" name="IncreaseDecreaseinDeferredGrantFundingCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_EquityComponentOfConvertibleDebtIssued" abstract="false" name="EquityComponentOfConvertibleDebtIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" abstract="false" name="IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_EquityMethodInvestmentEnterpriseValue" abstract="false" name="EquityMethodInvestmentEnterpriseValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringinFourMonths" abstract="false" name="TaxCreditCarryforwardExpiringinFourMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ConvertibleBondsMember" abstract="true" name="ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_EmployeesAndDirectorsMember" abstract="true" name="EmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_DeferredTaxAssetInterestExpense" abstract="false" name="DeferredTaxAssetInterestExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_August2019ConvertibleBondsMember" abstract="true" name="August2019ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_NewSalesAgreementMember" abstract="true" name="NewSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringinTwoYears" abstract="false" name="TaxCreditCarryforwardExpiringinTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringinFourYears" abstract="false" name="OperatingLossCarryforwardsExpiringinFourYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OtherRevenueMember" abstract="true" name="OtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_IncomeTaxReconciliationFairValueWarrant" abstract="false" name="IncomeTaxReconciliationFairValueWarrant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_TaxBenefitsExpired" abstract="false" name="TaxBenefitsExpired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedOptionAmount" abstract="false" name="CollaborativeAgreementAwardedOptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" abstract="false" name="SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CoalitionforEpidemicPreparednessInnovationsMember" abstract="true" name="CoalitionforEpidemicPreparednessInnovationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringinThreeYears" abstract="false" name="OperatingLossCarryforwardsExpiringinThreeYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DepartmentOfDefenceMember" abstract="true" name="DepartmentOfDefenceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_AdvaccineMember" abstract="true" name="AdvaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_SeriesAOnePreferredStockMember" abstract="true" name="SeriesAOnePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_BillAndMelindaGatesFoundationMember" abstract="true" name="BillAndMelindaGatesFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_PlymouthMeetingPennsylvaniaMember" abstract="true" name="PlymouthMeetingPennsylvaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_DeferredGrantFundingCurrent" abstract="false" name="DeferredGrantFundingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" abstract="false" name="DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ino_ChangeInValueOfInvestmentsInAffiliatedCompany" abstract="false" name="ChangeInValueOfInvestmentsInAffiliatedCompany" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" abstract="false" name="CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_RangeOfExercisePricesFourMember" abstract="true" name="RangeOfExercisePricesFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_DNAEncodedMonoclonalAntibodyTechnologyMember" abstract="true" name="DNAEncodedMonoclonalAntibodyTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" abstract="false" name="ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" abstract="false" name="CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" abstract="false" name="CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_OtherCounterpartyMember" abstract="true" name="OtherCounterpartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborativeArrangementFixedPriceContractAmountAwarded" abstract="false" name="CollaborativeArrangementFixedPriceContractAmountAwarded" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_INO4800Member" abstract="true" name="INO4800Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_ChangeInFairValueOfCommonStockWarrants" abstract="false" name="ChangeInFairValueOfCommonStockWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsIndefinitelyCarryforward" abstract="false" name="OperatingLossCarryforwardsIndefinitelyCarryforward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_RangeOfExercisePricesFiveMember" abstract="true" name="RangeOfExercisePricesFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_DebtInstrumentConvertibleInternalRateOfReturn" abstract="false" name="DebtInstrumentConvertibleInternalRateOfReturn" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ino_SalesAgreementMember" abstract="true" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_AllOtherCustomersMember" abstract="true" name="AllOtherCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_GoodwillAndIntangibleAssetsNet" abstract="false" name="GoodwillAndIntangibleAssetsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_NonCashInterestExpense" abstract="false" name="NonCashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CommonStockEquivalentsAbstract" abstract="true" name="CommonStockEquivalentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_CaliforniaIncomeTaxAuthorityMember" abstract="true" name="CaliforniaIncomeTaxAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringinFiveYears" abstract="false" name="OperatingLossCarryforwardsExpiringinFiveYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths" abstract="false" name="TaxCreditCarryforwardExpiringintheNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardCarryforwardIndefinitely" abstract="false" name="TaxCreditCarryforwardCarryforwardIndefinitely" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TheWistarInstituteMember" abstract="true" name="TheWistarInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_PlumblineLifeSciencesMember" abstract="true" name="PlumblineLifeSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliate" abstract="false" name="DeferredGrantFundingFromAffiliate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_WorkingCapitalExcludingCash" abstract="false" name="WorkingCapitalExcludingCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DebtInstrumentAccretionOfPremium" abstract="false" name="DebtInstrumentAccretionOfPremium" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GoodwillAndIntangibleAssetsGross" abstract="false" name="GoodwillAndIntangibleAssetsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" abstract="false" name="OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_InitialConversionPriceMember" abstract="true" name="InitialConversionPriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_EmployeeMember" abstract="true" name="EmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_WorkingCapital" abstract="false" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LicensewithAffiliatedEntitiesMember" abstract="true" name="LicensewithAffiliatedEntitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths" abstract="false" name="OperatingLossCarryforwardsExpiringintheNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CELLECTRA3PSPProprietarySmartDeviceMember" abstract="true" name="CELLECTRA3PSPProprietarySmartDeviceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" abstract="true" name="AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_DebtSecuritiesAvailableforSaleContractualMaturity" abstract="false" name="DebtSecuritiesAvailableforSaleContractualMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount" abstract="false" name="EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" abstract="false" name="IncreaseDecreaseInDeferredRevenueFromRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_December2019ConvertibleBondsMember" abstract="true" name="December2019ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_DebtInstrumentConvertibleDebtConvertedAmount" abstract="false" name="DebtInstrumentConvertibleDebtConvertedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AlternativeInvestmentMeasurementInputTerm" abstract="false" name="AlternativeInvestmentMeasurementInputTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CollaborationAgreementRoyaltyPeriod" abstract="false" name="CollaborationAgreementRoyaltyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringinTwoYears" abstract="false" name="OperatingLossCarryforwardsExpiringinTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ProceedsFromSubGrant" abstract="false" name="ProceedsFromSubGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ComprehensiveIncomeLossTaxExpenseBenefit" abstract="false" name="ComprehensiveIncomeLossTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PennsylvaniaStateIncomeTaxAuthorityMember" abstract="true" name="PennsylvaniaStateIncomeTaxAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_OtherRevenueAffiliatedEntityMember" abstract="true" name="OtherRevenueAffiliatedEntityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_SARSCoV2COVID19VaccineMember" abstract="true" name="SARSCoV2COVID19VaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliateCurrent" abstract="false" name="DeferredGrantFundingFromAffiliateCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PLSaffiliatedentityMember" abstract="true" name="PLSaffiliatedentityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_BiojectMember" abstract="true" name="BiojectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_MutualFundsMember" abstract="true" name="MutualFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_PrepaidManufacturingExpensesCurrent" abstract="false" name="PrepaidManufacturingExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AmortizationOfOperatingLeaseRightOfUseAssets" abstract="false" name="AmortizationOfOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ProceedsFromSaleOfEquitySecuritiesFVNI" abstract="false" name="ProceedsFromSaleOfEquitySecuritiesFVNI" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PriorSalesAgreementMember" abstract="true" name="PriorSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_ProceedsfromStockOptionandWarrantExercises" abstract="false" name="ProceedsfromStockOptionandWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" abstract="false" name="ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ino_StockSalesAgreementRemainingAuthorizedAmount" abstract="false" name="StockSalesAgreementRemainingAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_RangeOfExercisePricesSixMember" abstract="true" name="RangeOfExercisePricesSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_InvestmentOwnedAdditionalSharesAcquired" abstract="false" name="InvestmentOwnedAdditionalSharesAcquired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_ProceedsFromCollaborativeAgreement" abstract="false" name="ProceedsFromCollaborativeAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncomeTaxReconciliationStatuteLimitations" abstract="false" name="IncomeTaxReconciliationStatuteLimitations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementCorporateIncomeTax" abstract="false" name="CollaborativeAgreementCorporateIncomeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DoDMember" abstract="true" name="DoDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborationAgreementTerritoryExpansionOptionPeriod" abstract="false" name="CollaborationAgreementTerritoryExpansionOptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_DebtinstrumentAccruedInterest" abstract="false" name="DebtinstrumentAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A6.50ConvertibleSeniorNotesDue2024Member" abstract="true" name="A6.50ConvertibleSeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" abstract="false" name="CollaborativeAgreementPeriodFromEffectiveDateForTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" abstract="false" name="ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SanDiegoCaliforniaMember" abstract="true" name="SanDiegoCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_RangeOfExercisePricesOneMember" abstract="true" name="RangeOfExercisePricesOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_GrantProceedsReceived" abstract="false" name="GrantProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementExpensesToReimburse" abstract="false" name="CollaborativeAgreementExpensesToReimburse" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AfterJanuary22020ConversionPriceMember" abstract="true" name="AfterJanuary22020ConversionPriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_DeferredRevenueFromAffiliatedEntityCurrent" abstract="false" name="DeferredRevenueFromAffiliatedEntityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LesseeNumberOfLeaseAgreementsEnteredInto" abstract="false" name="LesseeNumberOfLeaseAgreementsEnteredInto" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" abstract="false" name="EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAdvisoryFees" abstract="false" name="CollaborativeAgreementAdvisoryFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AccruedClinicalTrialExpenseCurrent" abstract="false" name="AccruedClinicalTrialExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSalesAgreementAgentFee" abstract="false" name="StockSalesAgreementAgentFee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" abstract="false" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredTaxAssetsIntangibleAssets" abstract="false" name="DeferredTaxAssetsIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateNumberofSharesIssued" abstract="false" name="StockSaleAgreementAggregateNumberofSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_MCDCMember" abstract="true" name="MCDCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_AccruedSubcontractExpenses" abstract="false" name="AccruedSubcontractExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GeneosTherapeuticsInc.Member" abstract="true" name="GeneosTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_RangeOfExercisePricesTwoMember" abstract="true" name="RangeOfExercisePricesTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborationAgreementAdditionalRevenueToBeAchieved" abstract="false" name="CollaborationAgreementAdditionalRevenueToBeAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSalesAgreementMaximumAuthorizedAmount" abstract="false" name="StockSalesAgreementMaximumAuthorizedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" abstract="false" name="DeferredTaxLiabilitiesFinancingArrangementDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInAccruedClinicalTrialExpense" abstract="false" name="IncreaseDecreaseInAccruedClinicalTrialExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PlumblineLifeSciencesIncMember" abstract="true" name="PlumblineLifeSciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_RangeOfExercisePricesThreeMember" abstract="true" name="RangeOfExercisePricesThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_NonEmployeeMember" abstract="true" name="NonEmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementsUpfrontPaymentReceived" abstract="false" name="CollaborativeAgreementsUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" abstract="false" name="UnrecognizedTaxBenefitsIncreaseDecreaseInOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>ino-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:457132bc-9fa0-4eb7-b7bc-387259668e99,g:003ddec6-0acb-4351-b822-2fdc6632a099-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/CoverPage" xlink:type="simple" xlink:href="ino-20201231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a077326c-05a5-4391-81e1-d3c92041eabd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_50323f10-0033-4d10-8235-749bd8525f33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a077326c-05a5-4391-81e1-d3c92041eabd" xlink:to="loc_us-gaap_MinorityInterest_50323f10-0033-4d10-8235-749bd8525f33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0a6236ab-dfae-489b-aa07-455051445fae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a077326c-05a5-4391-81e1-d3c92041eabd" xlink:to="loc_us-gaap_StockholdersEquity_0a6236ab-dfae-489b-aa07-455051445fae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7608abb8-4b3b-48dd-9fde-8cba2fb658c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3a8c2b47-50cc-4583-a79d-4cd4208accbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7608abb8-4b3b-48dd-9fde-8cba2fb658c7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3a8c2b47-50cc-4583-a79d-4cd4208accbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5b6569d8-d5b0-4d98-b2cf-877d2dcffb04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7608abb8-4b3b-48dd-9fde-8cba2fb658c7" xlink:to="loc_us-gaap_Liabilities_5b6569d8-d5b0-4d98-b2cf-877d2dcffb04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_70eff5ca-1748-49a1-9be0-749126bcd4c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7608abb8-4b3b-48dd-9fde-8cba2fb658c7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_70eff5ca-1748-49a1-9be0-749126bcd4c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8113adfd-5c64-4c38-a3c7-62d10d095e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_f4c4b4d7-5a7d-4abf-8016-238b97569f12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8113adfd-5c64-4c38-a3c7-62d10d095e61" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_f4c4b4d7-5a7d-4abf-8016-238b97569f12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0e4d4f28-f370-494c-8ad2-088b6025267d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8113adfd-5c64-4c38-a3c7-62d10d095e61" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0e4d4f28-f370-494c-8ad2-088b6025267d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_936daa33-280f-4cd9-b0ee-5a80fe73b51c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8113adfd-5c64-4c38-a3c7-62d10d095e61" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_936daa33-280f-4cd9-b0ee-5a80fe73b51c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_3b585cc9-d46f-4d51-9596-ee8845f27e65" xlink:href="ino-20201231.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8113adfd-5c64-4c38-a3c7-62d10d095e61" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_3b585cc9-d46f-4d51-9596-ee8845f27e65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f89526f0-ab6c-4a5b-aab7-e3fc1d99c168" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8113adfd-5c64-4c38-a3c7-62d10d095e61" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f89526f0-ab6c-4a5b-aab7-e3fc1d99c168" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c184e889-9da8-43a5-ba7e-d17a065cfa39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8113adfd-5c64-4c38-a3c7-62d10d095e61" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c184e889-9da8-43a5-ba7e-d17a065cfa39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_b09d1b55-dd30-401c-9267-28884e0cb13f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8113adfd-5c64-4c38-a3c7-62d10d095e61" xlink:to="loc_us-gaap_ConvertibleDebt_b09d1b55-dd30-401c-9267-28884e0cb13f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2a0aac15-d378-477f-947b-95b125e8bc3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8113adfd-5c64-4c38-a3c7-62d10d095e61" xlink:to="loc_us-gaap_LiabilitiesCurrent_2a0aac15-d378-477f-947b-95b125e8bc3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f378e23a-9e34-4149-bb23-aae7ce185615" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0ec14b89-852d-4f98-a4fb-5d7ffcc282f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f378e23a-9e34-4149-bb23-aae7ce185615" xlink:to="loc_us-gaap_AssetsCurrent_0ec14b89-852d-4f98-a4fb-5d7ffcc282f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8625685b-cc4b-47e7-ae79-4441d961bc65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f378e23a-9e34-4149-bb23-aae7ce185615" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8625685b-cc4b-47e7-ae79-4441d961bc65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_1aa35955-0024-4872-bfb1-1b70d3c5990b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f378e23a-9e34-4149-bb23-aae7ce185615" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_1aa35955-0024-4872-bfb1-1b70d3c5990b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bfd41c10-3936-42bb-8ce6-7700eb3aad4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f378e23a-9e34-4149-bb23-aae7ce185615" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bfd41c10-3936-42bb-8ce6-7700eb3aad4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d5a37405-7342-4d3a-98c9-c1dd5fdda9ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f378e23a-9e34-4149-bb23-aae7ce185615" xlink:to="loc_us-gaap_Goodwill_d5a37405-7342-4d3a-98c9-c1dd5fdda9ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9c530f31-8833-427d-84b3-5be96c5e5e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f378e23a-9e34-4149-bb23-aae7ce185615" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9c530f31-8833-427d-84b3-5be96c5e5e39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5e1a22d9-c120-4a8e-a31b-67e375d55151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f378e23a-9e34-4149-bb23-aae7ce185615" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5e1a22d9-c120-4a8e-a31b-67e375d55151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_103a15d6-e15a-45d2-80dc-e509a0e9fd8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f378e23a-9e34-4149-bb23-aae7ce185615" xlink:to="loc_us-gaap_EquityMethodInvestments_103a15d6-e15a-45d2-80dc-e509a0e9fd8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_595c839d-56f5-4297-8f32-b3f2118bbd2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0b85ffae-342e-4527-ab2d-2504a8ef6a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_595c839d-56f5-4297-8f32-b3f2118bbd2f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0b85ffae-342e-4527-ab2d-2504a8ef6a5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_18d46421-4540-4f7e-974a-dbbc2aa2ba71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_595c839d-56f5-4297-8f32-b3f2118bbd2f" xlink:to="loc_us-gaap_ShortTermInvestments_18d46421-4540-4f7e-974a-dbbc2aa2ba71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b2fb3a55-665f-4ede-820e-073405ec1cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_595c839d-56f5-4297-8f32-b3f2118bbd2f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b2fb3a55-665f-4ede-820e-073405ec1cfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b27aba20-8e34-46c1-8dcf-f0fd77289fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_595c839d-56f5-4297-8f32-b3f2118bbd2f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b27aba20-8e34-46c1-8dcf-f0fd77289fca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_634c07dc-280a-4eb7-bc32-fbbea8120c14" xlink:href="ino-20201231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_595c839d-56f5-4297-8f32-b3f2118bbd2f" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_634c07dc-280a-4eb7-bc32-fbbea8120c14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_56e23f05-d939-4d98-87d6-5483559706b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_595c839d-56f5-4297-8f32-b3f2118bbd2f" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_56e23f05-d939-4d98-87d6-5483559706b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_012367ed-ac32-4588-848b-de4dfff54c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6f5eeeba-a5fa-4e73-b3d8-de22d940f298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_012367ed-ac32-4588-848b-de4dfff54c90" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6f5eeeba-a5fa-4e73-b3d8-de22d940f298" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_888f65f8-22f9-45d3-af7a-8c404133d505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_012367ed-ac32-4588-848b-de4dfff54c90" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_888f65f8-22f9-45d3-af7a-8c404133d505" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2bad248f-fefb-4d3e-a6c5-3efd84e672a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_012367ed-ac32-4588-848b-de4dfff54c90" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2bad248f-fefb-4d3e-a6c5-3efd84e672a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3bf72e29-9dd2-4ef1-810b-9c18879684ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_012367ed-ac32-4588-848b-de4dfff54c90" xlink:to="loc_us-gaap_CommonStockValue_3bf72e29-9dd2-4ef1-810b-9c18879684ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7dd7703e-1733-4613-ac84-4b4f5dc19a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_012367ed-ac32-4588-848b-de4dfff54c90" xlink:to="loc_us-gaap_PreferredStockValue_7dd7703e-1733-4613-ac84-4b4f5dc19a4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c26d0359-c874-4458-868e-4262a7e20aec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredRevenueFromAffiliatedEntityCurrent_7ac6be1e-3418-482d-99bb-e39fa6be1d5d" xlink:href="ino-20201231.xsd#ino_DeferredRevenueFromAffiliatedEntityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c26d0359-c874-4458-868e-4262a7e20aec" xlink:to="loc_ino_DeferredRevenueFromAffiliatedEntityCurrent_7ac6be1e-3418-482d-99bb-e39fa6be1d5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2ae0bc2f-8695-4292-b271-9b6e3fbac373" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c26d0359-c874-4458-868e-4262a7e20aec" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2ae0bc2f-8695-4292-b271-9b6e3fbac373" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_0ccf1074-337e-4f02-852d-b0d8515643f0" xlink:href="ino-20201231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c26d0359-c874-4458-868e-4262a7e20aec" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_0ccf1074-337e-4f02-852d-b0d8515643f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_c570544f-f79c-4f81-aae2-052e9132be30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c26d0359-c874-4458-868e-4262a7e20aec" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_c570544f-f79c-4f81-aae2-052e9132be30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7b8acbce-1052-4119-a468-cb90a1c436e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c26d0359-c874-4458-868e-4262a7e20aec" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7b8acbce-1052-4119-a468-cb90a1c436e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_1e338f49-69a6-45bd-827e-708818098b8f" xlink:href="ino-20201231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c26d0359-c874-4458-868e-4262a7e20aec" xlink:to="loc_ino_DeferredGrantFundingCurrent_1e338f49-69a6-45bd-827e-708818098b8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_85f8f5c9-88d0-4bf4-aa1b-dce8b78008fd" xlink:href="ino-20201231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c26d0359-c874-4458-868e-4262a7e20aec" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_85f8f5c9-88d0-4bf4-aa1b-dce8b78008fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b30638ff-0e79-48a7-a2dc-15b40544e158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c26d0359-c874-4458-868e-4262a7e20aec" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b30638ff-0e79-48a7-a2dc-15b40544e158" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ino-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432f902f-01e8-45b4-bcac-209f9d9e7dae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_22283042-8190-48c3-9f64-7033a18ae62e" xlink:href="ino-20201231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432f902f-01e8-45b4-bcac-209f9d9e7dae" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_22283042-8190-48c3-9f64-7033a18ae62e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f4302f5c-d4a0-49ec-bf3f-90553b1c44da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432f902f-01e8-45b4-bcac-209f9d9e7dae" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f4302f5c-d4a0-49ec-bf3f-90553b1c44da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_49da3565-29ad-4839-98df-ae283c0a9be7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432f902f-01e8-45b4-bcac-209f9d9e7dae" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_49da3565-29ad-4839-98df-ae283c0a9be7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4d36dd86-0422-488f-a3a6-dd1920ebb1f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432f902f-01e8-45b4-bcac-209f9d9e7dae" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4d36dd86-0422-488f-a3a6-dd1920ebb1f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_b73eef23-8484-40b5-96cd-6723517fa2f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432f902f-01e8-45b4-bcac-209f9d9e7dae" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_b73eef23-8484-40b5-96cd-6723517fa2f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_67475574-7cb4-4ae9-9f32-588557c35190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432f902f-01e8-45b4-bcac-209f9d9e7dae" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_67475574-7cb4-4ae9-9f32-588557c35190" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInFairValueOfCommonStockWarrants_0790980b-b6e4-4910-96a5-479771d04986" xlink:href="ino-20201231.xsd#ino_ChangeInFairValueOfCommonStockWarrants"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432f902f-01e8-45b4-bcac-209f9d9e7dae" xlink:to="loc_ino_ChangeInFairValueOfCommonStockWarrants_0790980b-b6e4-4910-96a5-479771d04986" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9e85a16e-72b7-4fb9-877a-fe773ab779dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432f902f-01e8-45b4-bcac-209f9d9e7dae" xlink:to="loc_us-gaap_InterestExpense_9e85a16e-72b7-4fb9-877a-fe773ab779dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_636df9a6-b41b-4722-9bce-b568d99daae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432f902f-01e8-45b4-bcac-209f9d9e7dae" xlink:to="loc_us-gaap_OperatingIncomeLoss_636df9a6-b41b-4722-9bce-b568d99daae4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_82a4ae11-e8dc-4acd-88d1-d141490d483d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_432f902f-01e8-45b4-bcac-209f9d9e7dae" xlink:to="loc_us-gaap_InterestIncomeOperating_82a4ae11-e8dc-4acd-88d1-d141490d483d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_880c8105-d9f7-4e51-8e0d-c0dc23880eac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_4a0777b0-f508-4b12-97d9-cd0c47378fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_880c8105-d9f7-4e51-8e0d-c0dc23880eac" xlink:to="loc_us-gaap_OperatingExpenses_4a0777b0-f508-4b12-97d9-cd0c47378fbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bb5b2abf-9615-4281-8c4e-4e07e92985d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_880c8105-d9f7-4e51-8e0d-c0dc23880eac" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bb5b2abf-9615-4281-8c4e-4e07e92985d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ee2edbf6-a54e-4c9b-bb24-9fcc13949b43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_684e1d3e-076a-4a01-b4f9-b450aef9b6ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ee2edbf6-a54e-4c9b-bb24-9fcc13949b43" xlink:to="loc_us-gaap_ProfitLoss_684e1d3e-076a-4a01-b4f9-b450aef9b6ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7dee68bb-0bc9-4dcc-868d-12ba00c923f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ee2edbf6-a54e-4c9b-bb24-9fcc13949b43" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7dee68bb-0bc9-4dcc-868d-12ba00c923f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0cb52d8e-e3ab-4545-b4ff-dc1bcdf0b238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_84313b04-3df4-4fda-ac27-012ab1c70a71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_0cb52d8e-e3ab-4545-b4ff-dc1bcdf0b238" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_84313b04-3df4-4fda-ac27-012ab1c70a71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6f823470-8ac1-490f-850c-abe1444a876d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_0cb52d8e-e3ab-4545-b4ff-dc1bcdf0b238" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6f823470-8ac1-490f-850c-abe1444a876d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f5ab1d27-7554-40eb-98fc-5e9ac775ea0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_0cb52d8e-e3ab-4545-b4ff-dc1bcdf0b238" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f5ab1d27-7554-40eb-98fc-5e9ac775ea0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_08b338f8-132b-4156-aba5-4a4bfa55d431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7f5c2174-f0f2-405d-8f9a-a0cea0b4c1b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_08b338f8-132b-4156-aba5-4a4bfa55d431" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7f5c2174-f0f2-405d-8f9a-a0cea0b4c1b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5404a444-087a-46d6-98f5-3b42157b8b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_08b338f8-132b-4156-aba5-4a4bfa55d431" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5404a444-087a-46d6-98f5-3b42157b8b3b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20201231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9096cb09-202c-4066-b61e-7fa9922b2102" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7e338e07-cdd2-4014-8869-7a638ea750c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9096cb09-202c-4066-b61e-7fa9922b2102" xlink:to="loc_us-gaap_ProfitLoss_7e338e07-cdd2-4014-8869-7a638ea750c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_92264adf-8b3f-47fe-9c52-2562577b075f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9096cb09-202c-4066-b61e-7fa9922b2102" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_92264adf-8b3f-47fe-9c52-2562577b075f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_202a59ab-b627-4023-920a-8acb3adf90d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9096cb09-202c-4066-b61e-7fa9922b2102" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_202a59ab-b627-4023-920a-8acb3adf90d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b3ed8db7-7ffb-4e10-9bac-19c91a138415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_650f0d83-2643-44c0-a4cf-7edf20273402" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b3ed8db7-7ffb-4e10-9bac-19c91a138415" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_650f0d83-2643-44c0-a4cf-7edf20273402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_9c098af6-6305-4c4c-ad7a-49859c2d9fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b3ed8db7-7ffb-4e10-9bac-19c91a138415" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_9c098af6-6305-4c4c-ad7a-49859c2d9fcd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d44b3405-fc43-4b85-8264-9f94e9d5571e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_3a69080f-6ff4-46da-829f-55535092780e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d44b3405-fc43-4b85-8264-9f94e9d5571e" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_3a69080f-6ff4-46da-829f-55535092780e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromSaleOfEquitySecuritiesFVNI_6d088fdf-92b9-435d-9eed-a945d9c5dd79" xlink:href="ino-20201231.xsd#ino_ProceedsFromSaleOfEquitySecuritiesFVNI"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d44b3405-fc43-4b85-8264-9f94e9d5571e" xlink:to="loc_ino_ProceedsFromSaleOfEquitySecuritiesFVNI_6d088fdf-92b9-435d-9eed-a945d9c5dd79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_627993d0-4169-432b-b889-a853800e4234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d44b3405-fc43-4b85-8264-9f94e9d5571e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_627993d0-4169-432b-b889-a853800e4234" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_51e3b2ed-b7f8-432a-8a7e-5bc02bc6e9c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d44b3405-fc43-4b85-8264-9f94e9d5571e" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_51e3b2ed-b7f8-432a-8a7e-5bc02bc6e9c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_cd682aef-b86b-4ccb-bf1b-6db36fab68e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d44b3405-fc43-4b85-8264-9f94e9d5571e" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_cd682aef-b86b-4ccb-bf1b-6db36fab68e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_adb194ca-a8f1-4355-9027-0bedce7fd970" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d44b3405-fc43-4b85-8264-9f94e9d5571e" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_adb194ca-a8f1-4355-9027-0bedce7fd970" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_259e0d74-a88d-4831-985a-94dafe655cda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2e2b77ff-bf73-45b9-8ee7-3e6ec7ae07e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_259e0d74-a88d-4831-985a-94dafe655cda" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2e2b77ff-bf73-45b9-8ee7-3e6ec7ae07e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b1d594d7-8f83-48c2-b7a0-883b1a5c1d16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_259e0d74-a88d-4831-985a-94dafe655cda" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b1d594d7-8f83-48c2-b7a0-883b1a5c1d16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a999c4ac-9b12-4c92-ab50-d6e939f4153e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_259e0d74-a88d-4831-985a-94dafe655cda" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a999c4ac-9b12-4c92-ab50-d6e939f4153e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsfromStockOptionandWarrantExercises_fe8fea3b-4cbb-47d0-84e1-f1501b7cf16a" xlink:href="ino-20201231.xsd#ino_ProceedsfromStockOptionandWarrantExercises"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_259e0d74-a88d-4831-985a-94dafe655cda" xlink:to="loc_ino_ProceedsfromStockOptionandWarrantExercises_fe8fea3b-4cbb-47d0-84e1-f1501b7cf16a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_31844668-07fc-46da-be74-fc467c015a2c" xlink:href="ino-20201231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_259e0d74-a88d-4831-985a-94dafe655cda" xlink:to="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_31844668-07fc-46da-be74-fc467c015a2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_52f479d0-2e68-4dae-a09e-373513f669af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_259e0d74-a88d-4831-985a-94dafe655cda" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_52f479d0-2e68-4dae-a09e-373513f669af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_da15047d-6528-4858-95d2-041565155c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_259e0d74-a88d-4831-985a-94dafe655cda" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_da15047d-6528-4858-95d2-041565155c6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f4d7109e-8568-4328-b765-c17d730757d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa782440-f7f4-4e16-8c3b-129e6dc67b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f4d7109e-8568-4328-b765-c17d730757d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa782440-f7f4-4e16-8c3b-129e6dc67b15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58b75e35-7bf5-47ec-afef-d08cf874f765" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f4d7109e-8568-4328-b765-c17d730757d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_58b75e35-7bf5-47ec-afef-d08cf874f765" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_415a78e3-d522-4286-a63a-506424f9576e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f4d7109e-8568-4328-b765-c17d730757d8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_415a78e3-d522-4286-a63a-506424f9576e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d45a84f5-5c77-4000-8f7a-ab3894611c43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f4d7109e-8568-4328-b765-c17d730757d8" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d45a84f5-5c77-4000-8f7a-ab3894611c43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ed67ff77-5538-456e-855c-ad4ac834e30b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ed67ff77-5538-456e-855c-ad4ac834e30b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d5f35494-6c8e-4494-b269-b0336de4dca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d5f35494-6c8e-4494-b269-b0336de4dca7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_ade4a657-f3f5-44e0-a09a-bf4e5ae2f1e2" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_ade4a657-f3f5-44e0-a09a-bf4e5ae2f1e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_57f853dd-5610-47ac-bfae-d2967cc76f46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_57f853dd-5610-47ac-bfae-d2967cc76f46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_b114ef56-ed53-49f1-a72f-1e66a12b3b90" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_b114ef56-ed53-49f1-a72f-1e66a12b3b90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2dcfefdc-ea05-41a5-a05e-ec26197aa13c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2dcfefdc-ea05-41a5-a05e-ec26197aa13c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_3f646cb2-ffe0-4f30-aba7-db62dbcd27c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_GainLossOnInvestments_3f646cb2-ffe0-4f30-aba7-db62dbcd27c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7d53f617-261b-4ec5-99e7-ff23d5cf6a65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_7d53f617-261b-4ec5-99e7-ff23d5cf6a65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3d13abbe-a5e6-43b5-9817-8ddceee90076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3d13abbe-a5e6-43b5-9817-8ddceee90076" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_0d234f4b-da22-4479-9b20-2a1d9d15d620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_0d234f4b-da22-4479-9b20-2a1d9d15d620" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_6b42f683-fd1c-436c-9a7c-224d6cda7a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_6b42f683-fd1c-436c-9a7c-224d6cda7a1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_5dc88c19-cb17-4aef-8239-75706e6e3fa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_5dc88c19-cb17-4aef-8239-75706e6e3fa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_951a2151-f081-4134-a933-e89baf7d866f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_951a2151-f081-4134-a933-e89baf7d866f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_7ea46f0f-3860-4703-be0a-a262b5435213" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_7ea46f0f-3860-4703-be0a-a262b5435213" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_97aaca82-8d0f-4ff9-a45a-8bc97fa94274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_97aaca82-8d0f-4ff9-a45a-8bc97fa94274" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_810e827b-c9ba-485d-a7ad-27a51af51ae4" xlink:href="ino-20201231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_810e827b-c9ba-485d-a7ad-27a51af51ae4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c88e049e-dad7-4297-9d05-19fd9d5916a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c88e049e-dad7-4297-9d05-19fd9d5916a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_01b1dd4b-dc8c-479e-9c83-12d88e8207e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_01b1dd4b-dc8c-479e-9c83-12d88e8207e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_140ca66b-f9e3-49e6-8a46-c4bfe62fafb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_140ca66b-f9e3-49e6-8a46-c4bfe62fafb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestExpense_7c6d33a2-0235-436e-9021-0a915baf3118" xlink:href="ino-20201231.xsd#ino_NonCashInterestExpense"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_ino_NonCashInterestExpense_7c6d33a2-0235-436e-9021-0a915baf3118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_7b286019-d556-4757-ba60-f4104f1acab5" xlink:href="ino-20201231.xsd#ino_AmortizationOfOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_7b286019-d556-4757-ba60-f4104f1acab5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1069d005-b7d1-4d9b-b1b6-63d6fd9adfad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_Depreciation_1069d005-b7d1-4d9b-b1b6-63d6fd9adfad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_36e7a333-6c77-44ca-a1c4-af42f9e0d80f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="23" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_36e7a333-6c77-44ca-a1c4-af42f9e0d80f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfCommonStockWarrants_5f4cfbbf-708a-4e3a-bb74-c9672e47e662" xlink:href="ino-20201231.xsd#ino_ChangeInValueOfCommonStockWarrants"/>
    <link:calculationArc order="24" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_ino_ChangeInValueOfCommonStockWarrants_5f4cfbbf-708a-4e3a-bb74-c9672e47e662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_455e2fb0-b9bf-4676-9d90-cbb1da590658" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:calculationArc order="25" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_455e2fb0-b9bf-4676-9d90-cbb1da590658" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_587d98e4-3269-4ff0-be9e-ea3317c6efb3" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:calculationArc order="26" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_587d98e4-3269-4ff0-be9e-ea3317c6efb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1ae443a5-1342-46eb-9cc7-3c8f91e39847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="27" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1ae443a5-1342-46eb-9cc7-3c8f91e39847" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_dce2ad5b-3316-4e32-a9fe-e94b963b29ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="28" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_ShareBasedCompensation_dce2ad5b-3316-4e32-a9fe-e94b963b29ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_987d2ece-35de-4b6d-8774-4d51815dcfe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:calculationArc order="29" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_987d2ece-35de-4b6d-8774-4d51815dcfe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_370763c3-05a3-4daf-957b-a498e235fd2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="30" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_ProfitLoss_370763c3-05a3-4daf-957b-a498e235fd2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2194aec0-7143-4e2f-9c91-081a8fcf982f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="31" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2194aec0-7143-4e2f-9c91-081a8fcf982f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_23bd40f7-6a3d-4d97-911c-dea06d53fd3a" xlink:href="ino-20201231.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:calculationArc order="32" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_23bd40f7-6a3d-4d97-911c-dea06d53fd3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StraightLineRent_e12aa99b-ac37-485d-81ca-b2cf7a692439" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StraightLineRent"/>
    <link:calculationArc order="33" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_StraightLineRent_e12aa99b-ac37-485d-81ca-b2cf7a692439" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_f0a21490-f82b-4892-b23e-a21a4c9930cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:calculationArc order="34" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_f0a21490-f82b-4892-b23e-a21a4c9930cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_85b7b90f-e94f-4670-b6c0-545e5c83027e" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:calculationArc order="35" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aef49efd-d05a-46fb-b2a6-f09763790ea5" xlink:to="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_85b7b90f-e94f-4670-b6c0-545e5c83027e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/TheCompany" xlink:type="simple" xlink:href="ino-20201231.xsd#TheCompany"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/TheCompany" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ino-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ino-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ino-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognition" xlink:type="simple" xlink:href="ino-20201231.xsd#RevenueRecognition"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/RevenueRecognition" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#RevenueRecognitionDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="ino-20201231.xsd#CollaborativeAgreements"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#CollaborativeAgreementsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestments" xlink:type="simple" xlink:href="ino-20201231.xsd#ShorttermInvestments"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="simple" xlink:href="ino-20201231.xsd#ShorttermInvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#ShorttermInvestmentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0a458109-b1a9-46aa-9715-efcbcc509413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7314c898-f93b-42f1-ac27-3c0f858e4fab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0a458109-b1a9-46aa-9715-efcbcc509413" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7314c898-f93b-42f1-ac27-3c0f858e4fab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_16ad20b7-564b-4f4c-b014-53362637d187" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0a458109-b1a9-46aa-9715-efcbcc509413" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_16ad20b7-564b-4f4c-b014-53362637d187" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_408f57ca-f84f-4583-a227-043a93187b47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0a458109-b1a9-46aa-9715-efcbcc509413" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_408f57ca-f84f-4583-a227-043a93187b47" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ino-20201231.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ino-20201231.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_c68bb261-4e2f-4abb-8680-c020565ed511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_6fe07560-93c7-4079-a6b9-c00d7720ae0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_c68bb261-4e2f-4abb-8680-c020565ed511" xlink:to="loc_us-gaap_DerivativeLiabilities_6fe07560-93c7-4079-a6b9-c00d7720ae0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4b89c905-bed9-4e0b-9d95-36edb3141120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c0e93f43-667e-4bd0-afd5-927039e0227e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4b89c905-bed9-4e0b-9d95-36edb3141120" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c0e93f43-667e-4bd0-afd5-927039e0227e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_6e58aa17-48f5-4876-8cc6-1e2515b47e29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4b89c905-bed9-4e0b-9d95-36edb3141120" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_6e58aa17-48f5-4876-8cc6-1e2515b47e29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_08b87f32-e0a3-465b-ad44-545348a9f794" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4b89c905-bed9-4e0b-9d95-36edb3141120" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_08b87f32-e0a3-465b-ad44-545348a9f794" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRisk" xlink:type="simple" xlink:href="ino-20201231.xsd#MajorCustomersandConcentrationofCreditRisk"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRisk" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskTables" xlink:type="simple" xlink:href="ino-20201231.xsd#MajorCustomersandConcentrationofCreditRiskTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#MajorCustomersandConcentrationofCreditRiskDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="simple" xlink:href="ino-20201231.xsd#PrepaidExpensesandOtherCurrentAssets"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="simple" xlink:href="ino-20201231.xsd#PrepaidExpensesandOtherCurrentAssetsTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#PrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_db57cbf9-d5af-405b-a617-85ea39a47a36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpensesCurrent_fe31379e-db24-4db9-b675-9cfba3096d70" xlink:href="ino-20201231.xsd#ino_PrepaidManufacturingExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_db57cbf9-d5af-405b-a617-85ea39a47a36" xlink:to="loc_ino_PrepaidManufacturingExpensesCurrent_fe31379e-db24-4db9-b675-9cfba3096d70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_6f39c966-9a23-447a-9ef9-01a3fa0b72ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_db57cbf9-d5af-405b-a617-85ea39a47a36" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_6f39c966-9a23-447a-9ef9-01a3fa0b72ec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssets" xlink:type="simple" xlink:href="ino-20201231.xsd#FixedAssets"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FixedAssets" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsTables" xlink:type="simple" xlink:href="ino-20201231.xsd#FixedAssetsTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FixedAssetsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#FixedAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8b005c71-0de9-4e13-a62e-154752501ed9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fa80afa0-e1a7-4da8-a43e-d112410f497b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8b005c71-0de9-4e13-a62e-154752501ed9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fa80afa0-e1a7-4da8-a43e-d112410f497b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d158c29b-d4e1-4f1b-8600-746424ddc26a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8b005c71-0de9-4e13-a62e-154752501ed9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d158c29b-d4e1-4f1b-8600-746424ddc26a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="ino-20201231.xsd#GoodwillandIntangibleAssets"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="ino-20201231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6f16bd15-f1b0-4367-a451-e2070bbfdb01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_11aa6d7e-dc5e-4fa7-9552-fd8b0d0c4567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6f16bd15-f1b0-4367-a451-e2070bbfdb01" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_11aa6d7e-dc5e-4fa7-9552-fd8b0d0c4567" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5e5ba38f-6e3e-4bc7-aa0f-28e1b92612d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6f16bd15-f1b0-4367-a451-e2070bbfdb01" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5e5ba38f-6e3e-4bc7-aa0f-28e1b92612d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_e3eb478a-c3dd-47c7-90c3-38a55a995e0a" xlink:href="ino-20201231.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c99d765f-50e5-4da0-bdc0-41f48596f9e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_e3eb478a-c3dd-47c7-90c3-38a55a995e0a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c99d765f-50e5-4da0-bdc0-41f48596f9e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_75826430-c23e-4832-866b-50ca557e0557" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_e3eb478a-c3dd-47c7-90c3-38a55a995e0a" xlink:to="loc_us-gaap_Goodwill_75826430-c23e-4832-866b-50ca557e0557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_3810b37e-afb2-4c0f-9718-8d7d7af78f73" xlink:href="ino-20201231.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_eaa4ebb2-1cf0-4b4f-8183-6566ee7c5e7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_3810b37e-afb2-4c0f-9718-8d7d7af78f73" xlink:to="loc_us-gaap_Goodwill_eaa4ebb2-1cf0-4b4f-8183-6566ee7c5e7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e2a8af69-bc60-4224-b180-842a3236244c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_3810b37e-afb2-4c0f-9718-8d7d7af78f73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e2a8af69-bc60-4224-b180-842a3236244c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ino-20201231.xsd#GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_a11c6aef-cbbc-4318-a38d-57ab2ef14334" xlink:href="ino-20201231.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_eb1749af-78d0-4d28-8dfd-540576a37725" xlink:href="ino-20201231.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_a11c6aef-cbbc-4318-a38d-57ab2ef14334" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_eb1749af-78d0-4d28-8dfd-540576a37725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_aee8eb29-7406-40ad-aa2e-35aae832d5c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_a11c6aef-cbbc-4318-a38d-57ab2ef14334" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_aee8eb29-7406-40ad-aa2e-35aae832d5c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bcc3856b-2118-40db-ac7e-12e88334f0d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ecc96b57-5c6e-46d3-9ed3-2e9ded333c39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bcc3856b-2118-40db-ac7e-12e88334f0d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ecc96b57-5c6e-46d3-9ed3-2e9ded333c39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6b6c8ae4-7843-4cf0-bec1-a18151fcff92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bcc3856b-2118-40db-ac7e-12e88334f0d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6b6c8ae4-7843-4cf0-bec1-a18151fcff92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0b4d0768-ba83-4379-ad25-676078e01207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bcc3856b-2118-40db-ac7e-12e88334f0d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0b4d0768-ba83-4379-ad25-676078e01207" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_266dee32-bb79-4f84-86c6-3d159d254e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bcc3856b-2118-40db-ac7e-12e88334f0d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_266dee32-bb79-4f84-86c6-3d159d254e4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_de6a9fe0-cc42-47f0-b7df-83f17e33466b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bcc3856b-2118-40db-ac7e-12e88334f0d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_de6a9fe0-cc42-47f0-b7df-83f17e33466b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_e355ea20-6ba2-489d-aa74-3218ca933ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bcc3856b-2118-40db-ac7e-12e88334f0d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_e355ea20-6ba2-489d-aa74-3218ca933ce1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:type="simple" xlink:href="ino-20201231.xsd#ConvertibleDebt"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="simple" xlink:href="ino-20201231.xsd#ConvertibleDebtTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#ConvertibleDebtBalanceOfConvertibleDebtDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_28adfeb8-f346-49cd-8339-e0a1dc104ee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_df6dbc7c-e684-404e-8c2e-429fbb452076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_28adfeb8-f346-49cd-8339-e0a1dc104ee2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_df6dbc7c-e684-404e-8c2e-429fbb452076" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_25f9c65d-7372-416c-8d57-15f562481321" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_28adfeb8-f346-49cd-8339-e0a1dc104ee2" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_25f9c65d-7372-416c-8d57-15f562481321" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_8eca2a95-3d9b-4c26-bab5-93381f175370" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_28adfeb8-f346-49cd-8339-e0a1dc104ee2" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_8eca2a95-3d9b-4c26-bab5-93381f175370" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccretionOfPremium_a1e0620d-a501-4dca-b27e-bf4b184bfc73" xlink:href="ino-20201231.xsd#ino_DebtInstrumentAccretionOfPremium"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_28adfeb8-f346-49cd-8339-e0a1dc104ee2" xlink:to="loc_ino_DebtInstrumentAccretionOfPremium_a1e0620d-a501-4dca-b27e-bf4b184bfc73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtinstrumentAccruedInterest_d317eb05-0a22-41c3-b2b7-2be8db844359" xlink:href="ino-20201231.xsd#ino_DebtinstrumentAccruedInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_28adfeb8-f346-49cd-8339-e0a1dc104ee2" xlink:to="loc_ino_DebtinstrumentAccruedInterest_d317eb05-0a22-41c3-b2b7-2be8db844359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_85d2156d-7057-496c-ae5e-37a8f42610e7" xlink:href="ino-20201231.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_28adfeb8-f346-49cd-8339-e0a1dc104ee2" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_85d2156d-7057-496c-ae5e-37a8f42610e7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2333b72d-d7b7-4c84-9cc6-4abd786321ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_c5211e19-96be-41e3-aef2-943c426f97e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2333b72d-d7b7-4c84-9cc6-4abd786321ac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_c5211e19-96be-41e3-aef2-943c426f97e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_37fec841-f798-42c7-924a-dc4eb2433e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2333b72d-d7b7-4c84-9cc6-4abd786321ac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_37fec841-f798-42c7-924a-dc4eb2433e1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d198e9e9-4b53-4e65-a570-7320aae1b1ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2333b72d-d7b7-4c84-9cc6-4abd786321ac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d198e9e9-4b53-4e65-a570-7320aae1b1ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_589a6cef-81cf-44af-b07f-adfede8b6655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2333b72d-d7b7-4c84-9cc6-4abd786321ac" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_589a6cef-81cf-44af-b07f-adfede8b6655" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableandAccruedExpenses" xlink:type="simple" xlink:href="ino-20201231.xsd#AccountsPayableandAccruedExpenses"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/AccountsPayableandAccruedExpenses" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableandAccruedExpensesTables" xlink:type="simple" xlink:href="ino-20201231.xsd#AccountsPayableandAccruedExpensesTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#AccountsPayableandAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2c6b39f1-3d94-40a7-ae7c-783651fe3467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_16b04edf-fd15-4ef5-bb96-08b49a4b673e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2c6b39f1-3d94-40a7-ae7c-783651fe3467" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_16b04edf-fd15-4ef5-bb96-08b49a4b673e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_2425d187-71bb-4598-b2f8-1f2f2d7a73e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2c6b39f1-3d94-40a7-ae7c-783651fe3467" xlink:to="loc_us-gaap_AccruedSalariesCurrent_2425d187-71bb-4598-b2f8-1f2f2d7a73e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_3fe1e1ba-07c9-44a3-9554-113b1e14109a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2c6b39f1-3d94-40a7-ae7c-783651fe3467" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_3fe1e1ba-07c9-44a3-9554-113b1e14109a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedSubcontractExpenses_dd681603-fbe9-48b2-a88c-3f531a4187d1" xlink:href="ino-20201231.xsd#ino_AccruedSubcontractExpenses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2c6b39f1-3d94-40a7-ae7c-783651fe3467" xlink:to="loc_ino_AccruedSubcontractExpenses_dd681603-fbe9-48b2-a88c-3f531a4187d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquitySummaryofPreferredStockDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquitySummaryofStockOptionsOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/Leases" xlink:type="simple" xlink:href="ino-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesTables" xlink:type="simple" xlink:href="ino-20201231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36c23d6e-6044-4e39-85f5-6bd74dde4c1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_69db7779-40db-4c9e-8c83-0db90dd25b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36c23d6e-6044-4e39-85f5-6bd74dde4c1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_69db7779-40db-4c9e-8c83-0db90dd25b1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ae60ae2c-1ff9-49ba-a5c4-a66fc53cd67e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36c23d6e-6044-4e39-85f5-6bd74dde4c1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ae60ae2c-1ff9-49ba-a5c4-a66fc53cd67e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_595372c4-5cd7-4ac6-bca1-710e5d2720aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36c23d6e-6044-4e39-85f5-6bd74dde4c1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_595372c4-5cd7-4ac6-bca1-710e5d2720aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_03226122-2838-441c-be5f-a0d00b2da4f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36c23d6e-6044-4e39-85f5-6bd74dde4c1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_03226122-2838-441c-be5f-a0d00b2da4f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_11837798-991b-4d74-8429-3b5e2cfa6214" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36c23d6e-6044-4e39-85f5-6bd74dde4c1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_11837798-991b-4d74-8429-3b5e2cfa6214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_7105eb88-1cdb-4285-90d6-e2681f9abf99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36c23d6e-6044-4e39-85f5-6bd74dde4c1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_7105eb88-1cdb-4285-90d6-e2681f9abf99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d1fa1b2c-56be-4d15-9253-56eb7723628b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5c7062e8-41bb-493b-97b7-a852cdff0913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_d1fa1b2c-56be-4d15-9253-56eb7723628b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5c7062e8-41bb-493b-97b7-a852cdff0913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_463cedf8-8881-4885-a6ee-a69c3d4d45e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_d1fa1b2c-56be-4d15-9253-56eb7723628b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_463cedf8-8881-4885-a6ee-a69c3d4d45e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" xlink:type="simple" xlink:href="ino-20201231.xsd#LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3bb05c7c-f7c5-4dbf-9692-6e1324a65a71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e5812d29-1974-4b42-8581-fe0c5e1b6573" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3bb05c7c-f7c5-4dbf-9692-6e1324a65a71" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e5812d29-1974-4b42-8581-fe0c5e1b6573" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a861bd64-37c9-4a6c-ac20-d4fbce3b2aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3bb05c7c-f7c5-4dbf-9692-6e1324a65a71" xlink:to="loc_us-gaap_OperatingLeaseLiability_a861bd64-37c9-4a6c-ac20-d4fbce3b2aab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/InvestmentinAffiliatedEntity" xlink:type="simple" xlink:href="ino-20201231.xsd#InvestmentinAffiliatedEntity"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/InvestmentinAffiliatedEntity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#InvestmentinAffiliatedEntityDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesComponentsofPretaxLossfromOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6d66a1b5-6539-4966-92e9-d4124f273c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_f5075157-e1eb-4684-8be3-a3a649ac997d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6d66a1b5-6539-4966-92e9-d4124f273c2d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_f5075157-e1eb-4684-8be3-a3a649ac997d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2918bb2a-1c9f-4bbf-9f0e-11bcccbca5b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6d66a1b5-6539-4966-92e9-d4124f273c2d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2918bb2a-1c9f-4bbf-9f0e-11bcccbca5b3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c0bbb3d6-42df-42f8-b8a4-aae14653d06d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_66202a62-6d95-4c9d-8baa-c8808ba7c72d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c0bbb3d6-42df-42f8-b8a4-aae14653d06d" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_66202a62-6d95-4c9d-8baa-c8808ba7c72d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_153d8b50-9862-445d-a45f-3363123ec937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c0bbb3d6-42df-42f8-b8a4-aae14653d06d" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_153d8b50-9862-445d-a45f-3363123ec937" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_0d771d07-091e-4b45-9f02-5644edd4ff61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c0bbb3d6-42df-42f8-b8a4-aae14653d06d" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_0d771d07-091e-4b45-9f02-5644edd4ff61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_de1974ca-7793-432c-a216-ca9834e075f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4cb611d2-78af-4f50-9a18-d1db0825a675" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_de1974ca-7793-432c-a216-ca9834e075f0" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4cb611d2-78af-4f50-9a18-d1db0825a675" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_51f5d9a5-00fd-473a-8204-ed73d5ec1f85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_de1974ca-7793-432c-a216-ca9834e075f0" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_51f5d9a5-00fd-473a-8204-ed73d5ec1f85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b9d163fa-7b41-4864-8135-f7f91ae615f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_de1974ca-7793-432c-a216-ca9834e075f0" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b9d163fa-7b41-4864-8135-f7f91ae615f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_48732373-9274-46ad-a7e1-5ba7fc157738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c3939518-4409-4b05-a039-d28fac53e301" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_48732373-9274-46ad-a7e1-5ba7fc157738" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c3939518-4409-4b05-a039-d28fac53e301" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_56129112-9e32-498e-b63e-c168e11b0993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_48732373-9274-46ad-a7e1-5ba7fc157738" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_56129112-9e32-498e-b63e-c168e11b0993" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesReconciliationofIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_c1bae217-068a-46c4-aa05-127adea6734e" xlink:href="ino-20201231.xsd#ino_ComprehensiveIncomeLossTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_618983f6-a42a-479c-8308-de7375941458" xlink:href="ino-20201231.xsd#ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_c1bae217-068a-46c4-aa05-127adea6734e" xlink:to="loc_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_618983f6-a42a-479c-8308-de7375941458" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_e639fcff-f8f4-480b-8fb6-20d2e7d6bd2d" xlink:href="ino-20201231.xsd#ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_c1bae217-068a-46c4-aa05-127adea6734e" xlink:to="loc_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_e639fcff-f8f4-480b-8fb6-20d2e7d6bd2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_ef7a14ab-e385-4186-905b-4372a95acd93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_c1bae217-068a-46c4-aa05-127adea6734e" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_ef7a14ab-e385-4186-905b-4372a95acd93" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_37877ce6-4ba9-4898-8207-bf3bf753d34a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_d2d0728e-11ec-437f-9a65-66e2a95edee8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_37877ce6-4ba9-4898-8207-bf3bf753d34a" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_d2d0728e-11ec-437f-9a65-66e2a95edee8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_733e098b-685b-49e0-95e6-479a42ab1bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_37877ce6-4ba9-4898-8207-bf3bf753d34a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_733e098b-685b-49e0-95e6-479a42ab1bcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_f4b5b48d-217d-47f2-a79e-31369ac912ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_37877ce6-4ba9-4898-8207-bf3bf753d34a" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_f4b5b48d-217d-47f2-a79e-31369ac912ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_338ba913-2fc8-43a3-84d2-4517714d0888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_37877ce6-4ba9-4898-8207-bf3bf753d34a" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_338ba913-2fc8-43a3-84d2-4517714d0888" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0eaf2d0c-7560-4fe1-8b1a-14a9da9f3318" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_37877ce6-4ba9-4898-8207-bf3bf753d34a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0eaf2d0c-7560-4fe1-8b1a-14a9da9f3318" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsIntangibleAssets_ef649f78-be90-481e-9231-e8c0260c9420" xlink:href="ino-20201231.xsd#ino_DeferredTaxAssetsIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_37877ce6-4ba9-4898-8207-bf3bf753d34a" xlink:to="loc_ino_DeferredTaxAssetsIntangibleAssets_ef649f78-be90-481e-9231-e8c0260c9420" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_5eb6e519-1af5-42fb-997f-a31d7ae687ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_37877ce6-4ba9-4898-8207-bf3bf753d34a" xlink:to="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_5eb6e519-1af5-42fb-997f-a31d7ae687ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetInterestExpense_2a79ad62-07af-42d1-a85d-374fb81d64ae" xlink:href="ino-20201231.xsd#ino_DeferredTaxAssetInterestExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_37877ce6-4ba9-4898-8207-bf3bf753d34a" xlink:to="loc_ino_DeferredTaxAssetInterestExpense_2a79ad62-07af-42d1-a85d-374fb81d64ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_a5586547-9fc2-4346-9999-0701d5994e3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_37877ce6-4ba9-4898-8207-bf3bf753d34a" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_a5586547-9fc2-4346-9999-0701d5994e3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_f26a1ad8-2e5f-4316-8800-41e57db387d8" xlink:href="ino-20201231.xsd#ino_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_37877ce6-4ba9-4898-8207-bf3bf753d34a" xlink:to="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_f26a1ad8-2e5f-4316-8800-41e57db387d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_f61b06ce-df43-496e-8ed1-204079e97fec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_37877ce6-4ba9-4898-8207-bf3bf753d34a" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_f61b06ce-df43-496e-8ed1-204079e97fec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_390734dc-98c3-4181-b3fe-b6fa0f858cd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2304f79a-5b34-44f5-b44d-e9b7c33e07ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_390734dc-98c3-4181-b3fe-b6fa0f858cd5" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_2304f79a-5b34-44f5-b44d-e9b7c33e07ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_364cf7ba-a019-4b03-99f2-43c51e63d82e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_390734dc-98c3-4181-b3fe-b6fa0f858cd5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_364cf7ba-a019-4b03-99f2-43c51e63d82e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_9721507e-1d51-4c0a-9216-38d72305d8a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_e28139f2-83d1-4a4b-942a-8705b067a3de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_9721507e-1d51-4c0a-9216-38d72305d8a2" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_e28139f2-83d1-4a4b-942a-8705b067a3de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_72be69a2-c497-4f9c-ae8c-73fbf5ab7155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_9721507e-1d51-4c0a-9216-38d72305d8a2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_72be69a2-c497-4f9c-ae8c-73fbf5ab7155" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_d667554b-9d35-4ee6-b0e9-aaa7352bd8ea" xlink:href="ino-20201231.xsd#ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_9721507e-1d51-4c0a-9216-38d72305d8a2" xlink:to="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_d667554b-9d35-4ee6-b0e9-aaa7352bd8ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_7ea6e262-979d-48f1-b1d2-2f23d8ba1f26" xlink:href="ino-20201231.xsd#ino_DeferredTaxLiabilitiesFinancingArrangementDiscount"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_9721507e-1d51-4c0a-9216-38d72305d8a2" xlink:to="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_7ea6e262-979d-48f1-b1d2-2f23d8ba1f26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_b54a1312-2d1f-4130-abfa-71ebea9faa73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_9721507e-1d51-4c0a-9216-38d72305d8a2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_b54a1312-2d1f-4130-abfa-71ebea9faa73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cb613802-e173-40a0-84b0-0de552f687d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_9721507e-1d51-4c0a-9216-38d72305d8a2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cb613802-e173-40a0-84b0-0de552f687d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_d516fdaa-0508-43d7-aa50-c52caa2c9d8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_fa0ce286-32f2-4bb1-8a21-cb17a6717e76" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_d516fdaa-0508-43d7-aa50-c52caa2c9d8f" xlink:to="loc_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_fa0ce286-32f2-4bb1-8a21-cb17a6717e76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_b6176ede-d723-48b1-9187-1e9bd60e3510" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_d516fdaa-0508-43d7-aa50-c52caa2c9d8f" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_b6176ede-d723-48b1-9187-1e9bd60e3510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_0e995c43-510c-40ac-ae56-d0db364b080d" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringinThreeMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_d516fdaa-0508-43d7-aa50-c52caa2c9d8f" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_0e995c43-510c-40ac-ae56-d0db364b080d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_ce0af4b8-f812-4ec3-8f41-6f6d888ecb2d" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringinFourMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_d516fdaa-0508-43d7-aa50-c52caa2c9d8f" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_ce0af4b8-f812-4ec3-8f41-6f6d888ecb2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_3260cd94-4824-4c11-b258-eda32f782d69" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringinFiveYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_d516fdaa-0508-43d7-aa50-c52caa2c9d8f" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_3260cd94-4824-4c11-b258-eda32f782d69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_db04bb82-ef51-435c-b7f3-419ef77f6035" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_d516fdaa-0508-43d7-aa50-c52caa2c9d8f" xlink:to="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_db04bb82-ef51-435c-b7f3-419ef77f6035" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1d2c7ede-7cb1-4cf6-85a8-4ed9c8d27097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_328cd84e-c042-4325-8dd0-fa49c5eadf6d" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_1d2c7ede-7cb1-4cf6-85a8-4ed9c8d27097" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_328cd84e-c042-4325-8dd0-fa49c5eadf6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_fe8bec0a-cb02-47e2-b0f0-8939e50de4d0" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_1d2c7ede-7cb1-4cf6-85a8-4ed9c8d27097" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_fe8bec0a-cb02-47e2-b0f0-8939e50de4d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_65efd171-723b-47a1-8f14-533f2f19cd9b" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_1d2c7ede-7cb1-4cf6-85a8-4ed9c8d27097" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_65efd171-723b-47a1-8f14-533f2f19cd9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_694e0a23-ea66-4aa8-a5cc-160d8ae3c580" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_1d2c7ede-7cb1-4cf6-85a8-4ed9c8d27097" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_694e0a23-ea66-4aa8-a5cc-160d8ae3c580" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_96fa0982-2de6-44ad-a450-68d4e6f2b71a" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringinFiveYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_1d2c7ede-7cb1-4cf6-85a8-4ed9c8d27097" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_96fa0982-2de6-44ad-a450-68d4e6f2b71a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_f65b7511-cb04-4a4c-8478-4bd6ec4010f3" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_1d2c7ede-7cb1-4cf6-85a8-4ed9c8d27097" xlink:to="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_f65b7511-cb04-4a4c-8478-4bd6ec4010f3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/A401kPlan" xlink:type="simple" xlink:href="ino-20201231.xsd#A401kPlan"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/A401kPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#A401kPlanDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/A401kPlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ino-20201231.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#RelatedPartyTransactionsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsInc"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsIncTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsIncDeconsolidationAccountingDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsIncInvestmentinGeneosDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsIncFairValueAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsIncPreferredStockInvestmentDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="ino-20201231.xsd#QuarterlyFinancialInformationUnaudited"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="ino-20201231.xsd#QuarterlyFinancialInformationUnauditedTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#QuarterlyFinancialInformationUnauditedDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ino-20201231.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>ino-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:457132bc-9fa0-4eb7-b7bc-387259668e99,g:003ddec6-0acb-4351-b822-2fdc6632a099-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CoverPage" xlink:type="simple" xlink:href="ino-20201231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CoverPage" xlink:type="extended" id="i300b2be0c564479cbca4a36a191f227f_CoverPage"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i766e34dc54604565860a095227a7d376_ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2262ac26-d147-42f9-94ca-cad6e6dafe0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2262ac26-d147-42f9-94ca-cad6e6dafe0a" xlink:to="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_a9510222-27bd-4529-90d4-47b3bb1a9f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_a9510222-27bd-4529-90d4-47b3bb1a9f58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a37de319-be51-489f-a72b-615937f6fe3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a9510222-27bd-4529-90d4-47b3bb1a9f58" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a37de319-be51-489f-a72b-615937f6fe3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_ef8515cf-82a1-40e8-99a0-da4bdc119aa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a9510222-27bd-4529-90d4-47b3bb1a9f58" xlink:to="loc_us-gaap_ShortTermInvestments_ef8515cf-82a1-40e8-99a0-da4bdc119aa2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_eea50259-0ec3-49e8-a45d-2f2092622667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a9510222-27bd-4529-90d4-47b3bb1a9f58" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_eea50259-0ec3-49e8-a45d-2f2092622667" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_f303d670-b689-46a2-966b-fd04d278870b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a9510222-27bd-4529-90d4-47b3bb1a9f58" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_f303d670-b689-46a2-966b-fd04d278870b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b1f40e73-1a55-4344-bf1d-cabc629059ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a9510222-27bd-4529-90d4-47b3bb1a9f58" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b1f40e73-1a55-4344-bf1d-cabc629059ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_d45c3b06-078e-4399-a0d2-e7713a529b36" xlink:href="ino-20201231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a9510222-27bd-4529-90d4-47b3bb1a9f58" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_d45c3b06-078e-4399-a0d2-e7713a529b36" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_49bd1024-02c4-4d55-aaff-37602717d4e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a9510222-27bd-4529-90d4-47b3bb1a9f58" xlink:to="loc_us-gaap_AssetsCurrent_49bd1024-02c4-4d55-aaff-37602717d4e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dae31c6d-5990-4e72-980b-eed76c84608e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_dae31c6d-5990-4e72-980b-eed76c84608e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_642323fc-fb95-4f03-91dc-dc9a4d73ae70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_642323fc-fb95-4f03-91dc-dc9a4d73ae70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_4b203831-9a75-49ac-af69-f7c7b68b3786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:to="loc_us-gaap_EquityMethodInvestments_4b203831-9a75-49ac-af69-f7c7b68b3786" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_465986b8-3763-44ee-8503-7e89f423a3ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_465986b8-3763-44ee-8503-7e89f423a3ba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3defaefb-69c5-4670-ba98-557abdcdd958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:to="loc_us-gaap_Goodwill_3defaefb-69c5-4670-ba98-557abdcdd958" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a2edfa20-c9bc-4107-9b6b-3b10b5490807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a2edfa20-c9bc-4107-9b6b-3b10b5490807" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_814fe59a-abfb-4c24-9bd6-9d6f445d56b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_814fe59a-abfb-4c24-9bd6-9d6f445d56b8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_775cd706-f20b-4494-bf2f-001cb9d5fb75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:to="loc_us-gaap_Assets_775cd706-f20b-4494-bf2f-001cb9d5fb75" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2262ac26-d147-42f9-94ca-cad6e6dafe0a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cbf37fe6-5928-447f-ad55-bc57dd760745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cbf37fe6-5928-447f-ad55-bc57dd760745" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_03a53731-254c-464f-b713-25bfedb5d054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_03a53731-254c-464f-b713-25bfedb5d054" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_f5402c48-761f-4fe1-b6ab-7f2472b484e2" xlink:href="ino-20201231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_f5402c48-761f-4fe1-b6ab-7f2472b484e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e2bd86cd-0768-4e1f-a304-8bb2e6c41bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e2bd86cd-0768-4e1f-a304-8bb2e6c41bd5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredRevenueFromAffiliatedEntityCurrent_3ac895b8-3948-4233-8241-6b2abc340ff4" xlink:href="ino-20201231.xsd#ino_DeferredRevenueFromAffiliatedEntityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:to="loc_ino_DeferredRevenueFromAffiliatedEntityCurrent_3ac895b8-3948-4233-8241-6b2abc340ff4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_de441cd2-9a23-4583-bfb3-ae4b994b69f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_de441cd2-9a23-4583-bfb3-ae4b994b69f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_d29d5b95-60a8-4d3c-a9c2-22075a42f3e4" xlink:href="ino-20201231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:to="loc_ino_DeferredGrantFundingCurrent_d29d5b95-60a8-4d3c-a9c2-22075a42f3e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_701a98c0-de98-4dd6-92e6-600d1c0840ee" xlink:href="ino-20201231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_701a98c0-de98-4dd6-92e6-600d1c0840ee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4ef28b21-e6fc-4c58-84a9-d90702d6d648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:to="loc_us-gaap_LiabilitiesCurrent_4ef28b21-e6fc-4c58-84a9-d90702d6d648" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1350b5c5-acd0-4322-bc9b-a0aa8dbe4249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1350b5c5-acd0-4322-bc9b-a0aa8dbe4249" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_54805bd9-3635-44ee-bb15-522fe25f8172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_ConvertibleDebt_54805bd9-3635-44ee-bb15-522fe25f8172" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_6c537efe-45cb-4daa-8010-424e8e9eb3ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_6c537efe-45cb-4daa-8010-424e8e9eb3ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_35d91f38-9bad-4524-a762-2f137417a288" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_35d91f38-9bad-4524-a762-2f137417a288" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5b0b164f-0268-4645-9208-263e1bdf2208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5b0b164f-0268-4645-9208-263e1bdf2208" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_033dbbd4-4f46-4276-9325-0cca11a5f724" xlink:href="ino-20201231.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_033dbbd4-4f46-4276-9325-0cca11a5f724" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_62c68279-e1fc-4301-a9ba-abfb31af4ab2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_62c68279-e1fc-4301-a9ba-abfb31af4ab2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7b9dbed0-1132-4e4a-8d99-62ac8fc6d68d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_Liabilities_7b9dbed0-1132-4e4a-8d99-62ac8fc6d68d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c7d83699-fa79-499f-87bf-d52ddff4de5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c7d83699-fa79-499f-87bf-d52ddff4de5f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b33a15fb-b244-4244-a294-bb1b3eb9dcd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:to="loc_us-gaap_PreferredStockValue_b33a15fb-b244-4244-a294-bb1b3eb9dcd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9e93c433-a2d8-446c-ad8d-01eec7254c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:to="loc_us-gaap_CommonStockValue_9e93c433-a2d8-446c-ad8d-01eec7254c9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9e09644d-fc11-4445-861a-ba154168639a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9e09644d-fc11-4445-861a-ba154168639a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_320d5a70-cc78-4d46-a452-92ac7bda4cf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_320d5a70-cc78-4d46-a452-92ac7bda4cf7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_203117f7-e37f-4d70-be0b-d7a4ae48bffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_203117f7-e37f-4d70-be0b-d7a4ae48bffd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d4935baf-e7bf-4150-87a7-1cebb653240e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:to="loc_us-gaap_StockholdersEquity_d4935baf-e7bf-4150-87a7-1cebb653240e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_f0e9cbb4-f024-4e5c-8c4b-361dd8333aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:to="loc_us-gaap_MinorityInterest_f0e9cbb4-f024-4e5c-8c4b-361dd8333aa0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a839b1d4-960b-44bc-96f8-df7463e74d12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a839b1d4-960b-44bc-96f8-df7463e74d12" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_256e8c22-f08b-4a8a-87e8-df7ccc5904c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_256e8c22-f08b-4a8a-87e8-df7ccc5904c2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_db99f619-f021-4dc6-ac5d-2ff16d4f8c5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2262ac26-d147-42f9-94ca-cad6e6dafe0a" xlink:to="loc_us-gaap_StatementTable_db99f619-f021-4dc6-ac5d-2ff16d4f8c5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_33557433-680f-4591-9985-efb506a8ee06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_db99f619-f021-4dc6-ac5d-2ff16d4f8c5e" xlink:to="loc_us-gaap_DebtInstrumentAxis_33557433-680f-4591-9985-efb506a8ee06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_33557433-680f-4591-9985-efb506a8ee06_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_33557433-680f-4591-9985-efb506a8ee06" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_33557433-680f-4591-9985-efb506a8ee06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3f2d0622-c96a-41ee-b009-6168f074636b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_33557433-680f-4591-9985-efb506a8ee06" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3f2d0622-c96a-41ee-b009-6168f074636b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_52197ef8-3b70-417d-a50d-367142f27c9e" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3f2d0622-c96a-41ee-b009-6168f074636b" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_52197ef8-3b70-417d-a50d-367142f27c9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_f3a2271f-604b-460d-8d99-c51f97ed13c4" xlink:href="ino-20201231.xsd#ino_ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3f2d0622-c96a-41ee-b009-6168f074636b" xlink:to="loc_ino_ConvertibleBondsMember_f3a2271f-604b-460d-8d99-c51f97ed13c4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ino-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ie72b5f2c67d84e9a8a1c6063b722d175_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="i684e706a4a3148d3bb997168fbd5833a_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_3f5b05ba-b834-46fc-8bba-c29375b5b06d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_RevenuesAbstract_3f5b05ba-b834-46fc-8bba-c29375b5b06d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_948a0c8b-cbd5-4108-9558-527c6806a1db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_3f5b05ba-b834-46fc-8bba-c29375b5b06d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_948a0c8b-cbd5-4108-9558-527c6806a1db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2dad4692-7e0d-46c6-8b1e-47fb1118d15f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2dad4692-7e0d-46c6-8b1e-47fb1118d15f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0f86584a-7a6b-45d4-a51e-f84f203b1461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2dad4692-7e0d-46c6-8b1e-47fb1118d15f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0f86584a-7a6b-45d4-a51e-f84f203b1461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9d6a0067-d95d-422c-b963-061d19307e06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2dad4692-7e0d-46c6-8b1e-47fb1118d15f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9d6a0067-d95d-422c-b963-061d19307e06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e0c51348-069f-4339-ad17-450a6713a69e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2dad4692-7e0d-46c6-8b1e-47fb1118d15f" xlink:to="loc_us-gaap_OperatingExpenses_e0c51348-069f-4339-ad17-450a6713a69e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_eddcb30d-39b5-4a1b-9151-c0cec8421ba4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_OperatingIncomeLoss_eddcb30d-39b5-4a1b-9151-c0cec8421ba4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_7e9f1435-3342-46e0-b2f6-a66ebfd9cbd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:to="loc_us-gaap_InterestIncomeOperating_7e9f1435-3342-46e0-b2f6-a66ebfd9cbd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_68e7f46c-033b-4f5a-a7bc-3ea5637a6796" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:to="loc_us-gaap_InterestExpense_68e7f46c-033b-4f5a-a7bc-3ea5637a6796" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInFairValueOfCommonStockWarrants_625889d4-394a-485d-95b8-cbee7095c70f" xlink:href="ino-20201231.xsd#ino_ChangeInFairValueOfCommonStockWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:to="loc_ino_ChangeInFairValueOfCommonStockWarrants_625889d4-394a-485d-95b8-cbee7095c70f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1a26a056-b6c9-4580-97ca-cc691a5bdc77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1a26a056-b6c9-4580-97ca-cc691a5bdc77" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_3e2330f4-e9eb-40ed-af96-f91aed1e9f17" xlink:href="ino-20201231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_3e2330f4-e9eb-40ed-af96-f91aed1e9f17" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d64c9f54-2f90-42fd-8a33-a303696625e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d64c9f54-2f90-42fd-8a33-a303696625e8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e20d2d25-5fe0-46d7-99ee-c94e55cf4ff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e20d2d25-5fe0-46d7-99ee-c94e55cf4ff3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_014cd792-0290-47cc-92f4-21d794f86b12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_014cd792-0290-47cc-92f4-21d794f86b12" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4b57370a-9ad1-4552-bc8b-73d77540c4b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4b57370a-9ad1-4552-bc8b-73d77540c4b6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fe7a179c-5455-427d-90d3-e90bf8fd6cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fe7a179c-5455-427d-90d3-e90bf8fd6cd7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_013cc8eb-a772-4223-a05f-d697de5c6356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_013cc8eb-a772-4223-a05f-d697de5c6356" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cbc9e170-9734-4cc7-bf6c-c0c4d12ab047" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cbc9e170-9734-4cc7-bf6c-c0c4d12ab047" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a4218d8d-4731-4853-9aee-d37f99816a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_ProfitLoss_a4218d8d-4731-4853-9aee-d37f99816a54" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_12d96fe4-964f-4f3e-aa9e-509ce3116884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_12d96fe4-964f-4f3e-aa9e-509ce3116884" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ae713411-7f4b-494a-a5ba-9d51682bfa44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_NetIncomeLoss_ae713411-7f4b-494a-a5ba-9d51682bfa44" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_193ab1b6-489b-43b0-b24a-42aee6500b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_EarningsPerShareAbstract_193ab1b6-489b-43b0-b24a-42aee6500b9b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_f7bc77ef-07e1-444d-bd0e-624625ea1d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_193ab1b6-489b-43b0-b24a-42aee6500b9b" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_f7bc77ef-07e1-444d-bd0e-624625ea1d83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_528e43bf-2b31-48b6-ac36-e5b9a24ecc75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_528e43bf-2b31-48b6-ac36-e5b9a24ecc75" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_15f833f1-c610-4f74-bf3f-4076c477ba55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_528e43bf-2b31-48b6-ac36-e5b9a24ecc75" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_15f833f1-c610-4f74-bf3f-4076c477ba55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_42bd9fa1-08f1-4d5d-a473-11df7aa7c4d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_StatementTable_42bd9fa1-08f1-4d5d-a473-11df7aa7c4d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_411f0be2-ad15-4bc6-9919-24e3bbe826fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_42bd9fa1-08f1-4d5d-a473-11df7aa7c4d9" xlink:to="loc_srt_ProductOrServiceAxis_411f0be2-ad15-4bc6-9919-24e3bbe826fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_411f0be2-ad15-4bc6-9919-24e3bbe826fa_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_411f0be2-ad15-4bc6-9919-24e3bbe826fa" xlink:to="loc_srt_ProductsAndServicesDomain_411f0be2-ad15-4bc6-9919-24e3bbe826fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4a719b8b-46ee-4ea2-8db8-41768faf42ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_411f0be2-ad15-4bc6-9919-24e3bbe826fa" xlink:to="loc_srt_ProductsAndServicesDomain_4a719b8b-46ee-4ea2-8db8-41768faf42ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_2e50c83a-d46d-42ee-ab74-e5043190cfd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4a719b8b-46ee-4ea2-8db8-41768faf42ae" xlink:to="loc_us-gaap_LicenseMember_2e50c83a-d46d-42ee-ab74-e5043190cfd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_1ad4e591-c7b4-4bba-b4b8-967290634bf4" xlink:href="ino-20201231.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4a719b8b-46ee-4ea2-8db8-41768faf42ae" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_1ad4e591-c7b4-4bba-b4b8-967290634bf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherRevenueMember_7df9cf90-86a1-4637-8e29-4a706186037b" xlink:href="ino-20201231.xsd#ino_OtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4a719b8b-46ee-4ea2-8db8-41768faf42ae" xlink:to="loc_ino_OtherRevenueMember_7df9cf90-86a1-4637-8e29-4a706186037b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherRevenueAffiliatedEntityMember_7f13463e-a956-4724-a2af-6c761d6b3eab" xlink:href="ino-20201231.xsd#ino_OtherRevenueAffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4a719b8b-46ee-4ea2-8db8-41768faf42ae" xlink:to="loc_ino_OtherRevenueAffiliatedEntityMember_7f13463e-a956-4724-a2af-6c761d6b3eab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2d0c8c70-ab44-4299-bbda-924db4cd6906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_42bd9fa1-08f1-4d5d-a473-11df7aa7c4d9" xlink:to="loc_us-gaap_DebtInstrumentAxis_2d0c8c70-ab44-4299-bbda-924db4cd6906" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2d0c8c70-ab44-4299-bbda-924db4cd6906_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2d0c8c70-ab44-4299-bbda-924db4cd6906" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2d0c8c70-ab44-4299-bbda-924db4cd6906_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_57633e30-3c2c-4d5c-963a-19ba554b369d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2d0c8c70-ab44-4299-bbda-924db4cd6906" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_57633e30-3c2c-4d5c-963a-19ba554b369d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_6ed17063-cccc-4f1e-9a02-1cecd6b25e0e" xlink:href="ino-20201231.xsd#ino_ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_57633e30-3c2c-4d5c-963a-19ba554b369d" xlink:to="loc_ino_ConvertibleBondsMember_6ed17063-cccc-4f1e-9a02-1cecd6b25e0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_8b46490e-079b-4065-95e6-20c7ef136067" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_57633e30-3c2c-4d5c-963a-19ba554b369d" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_8b46490e-079b-4065-95e6-20c7ef136067" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20201231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="i7ba41d8c136f49a98a5af7799317dad6_ConsolidatedStatementsofComprehensiveLoss"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ibb175b47060a48319fc8a2914c68c44b_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c53ddc81-278e-48fd-8cb5-4c2dd88857a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c53ddc81-278e-48fd-8cb5-4c2dd88857a9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_21b49280-fd49-44dd-bd60-fd46b5370342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_SharesIssued_21b49280-fd49-44dd-bd60-fd46b5370342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_abd8698d-f55a-4552-b75c-4a5bef1db64f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_abd8698d-f55a-4552-b75c-4a5bef1db64f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_308ecf46-67a7-4b1c-998b-be2b28e377d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_308ecf46-67a7-4b1c-998b-be2b28e377d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_59d0cf93-8cc3-49c1-b7f2-4000ef2c6af4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_59d0cf93-8cc3-49c1-b7f2-4000ef2c6af4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2cd8c032-e29f-4f52-8f72-c290a0ef9ac2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2cd8c032-e29f-4f52-8f72-c290a0ef9ac2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3963a022-6716-447b-8ea7-1fde9d884d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3963a022-6716-447b-8ea7-1fde9d884d82" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d334fa2c-74b6-435b-b8b5-1ed0755443ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d334fa2c-74b6-435b-b8b5-1ed0755443ae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a45bf37e-2d17-4275-adcc-b85edee81040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a45bf37e-2d17-4275-adcc-b85edee81040" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_87332ecb-e387-4c27-b7e1-ce6c24a50295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_87332ecb-e387-4c27-b7e1-ce6c24a50295" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_59ffb7d2-ce98-4f89-ad89-c33c8cef928e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_59ffb7d2-ce98-4f89-ad89-c33c8cef928e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_2dc7a96b-14ac-41a7-ad38-a6122b52bb3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_2dc7a96b-14ac-41a7-ad38-a6122b52bb3d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_0542968b-230f-42dd-9805-aa239ffc8c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_0542968b-230f-42dd-9805-aa239ffc8c72" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4f00407c-bf8d-4f42-8c26-888aaa99533c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_ProfitLoss_4f00407c-bf8d-4f42-8c26-888aaa99533c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_498bd9ec-f17d-40bf-8015-4601227e8bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_498bd9ec-f17d-40bf-8015-4601227e8bdb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2237b373-030e-4a3d-85f7-b47df17d8f53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2237b373-030e-4a3d-85f7-b47df17d8f53" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cea18d62-5a4e-4965-a445-96f5533129ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cea18d62-5a4e-4965-a445-96f5533129ae" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_f6ead124-b846-4b85-9325-41d4592553e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7b0658d4-b87c-4246-b24c-322034fe0bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_80fef50a-8f98-4962-9b49-4ec47fecfd4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_80fef50a-8f98-4962-9b49-4ec47fecfd4b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e4a42ec1-fd74-41c0-b312-97228c8df522" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c53ddc81-278e-48fd-8cb5-4c2dd88857a9" xlink:to="loc_us-gaap_StatementTable_e4a42ec1-fd74-41c0-b312-97228c8df522" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8087a847-af72-4ac4-ad00-b2d38cad7832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e4a42ec1-fd74-41c0-b312-97228c8df522" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8087a847-af72-4ac4-ad00-b2d38cad7832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8087a847-af72-4ac4-ad00-b2d38cad7832_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8087a847-af72-4ac4-ad00-b2d38cad7832" xlink:to="loc_us-gaap_EquityComponentDomain_8087a847-af72-4ac4-ad00-b2d38cad7832_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6ab5880b-78a1-43d0-b730-afb5bc805bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8087a847-af72-4ac4-ad00-b2d38cad7832" xlink:to="loc_us-gaap_EquityComponentDomain_6ab5880b-78a1-43d0-b730-afb5bc805bf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_b96b1e22-077f-4edd-9809-810dddb6ccb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6ab5880b-78a1-43d0-b730-afb5bc805bf2" xlink:to="loc_us-gaap_PreferredStockMember_b96b1e22-077f-4edd-9809-810dddb6ccb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0ceaf1e5-c092-45b3-a5d2-192cfcdc7c83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6ab5880b-78a1-43d0-b730-afb5bc805bf2" xlink:to="loc_us-gaap_CommonStockMember_0ceaf1e5-c092-45b3-a5d2-192cfcdc7c83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_eba7e2b8-abf9-489c-a520-64935e112c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6ab5880b-78a1-43d0-b730-afb5bc805bf2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_eba7e2b8-abf9-489c-a520-64935e112c54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ba896275-2ada-44fd-9cff-26a13cfbf03b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6ab5880b-78a1-43d0-b730-afb5bc805bf2" xlink:to="loc_us-gaap_RetainedEarningsMember_ba896275-2ada-44fd-9cff-26a13cfbf03b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c7ccc9af-4dc6-40d2-807f-3480f01d0af2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6ab5880b-78a1-43d0-b730-afb5bc805bf2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c7ccc9af-4dc6-40d2-807f-3480f01d0af2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9af2c7f9-9395-4621-b713-11a0244eddcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6ab5880b-78a1-43d0-b730-afb5bc805bf2" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9af2c7f9-9395-4621-b713-11a0244eddcc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9429e747-5f3d-4e54-8c97-814c0f37aa0b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e4a42ec1-fd74-41c0-b312-97228c8df522" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9429e747-5f3d-4e54-8c97-814c0f37aa0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9429e747-5f3d-4e54-8c97-814c0f37aa0b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9429e747-5f3d-4e54-8c97-814c0f37aa0b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9429e747-5f3d-4e54-8c97-814c0f37aa0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c4b2d9a3-eed5-4581-8aab-7677e07d66dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9429e747-5f3d-4e54-8c97-814c0f37aa0b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c4b2d9a3-eed5-4581-8aab-7677e07d66dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_11200aa7-f12b-4116-afe9-1572760947a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c4b2d9a3-eed5-4581-8aab-7677e07d66dc" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_11200aa7-f12b-4116-afe9-1572760947a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b717ffa0-8e50-4d7e-87b4-201ffe35a24e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e4a42ec1-fd74-41c0-b312-97228c8df522" xlink:to="loc_us-gaap_DebtInstrumentAxis_b717ffa0-8e50-4d7e-87b4-201ffe35a24e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b717ffa0-8e50-4d7e-87b4-201ffe35a24e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b717ffa0-8e50-4d7e-87b4-201ffe35a24e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b717ffa0-8e50-4d7e-87b4-201ffe35a24e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b46c2795-527c-488a-88d2-09a9018e0870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b717ffa0-8e50-4d7e-87b4-201ffe35a24e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b46c2795-527c-488a-88d2-09a9018e0870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_95ebfbcf-4842-4e07-be51-964c5aa8fa6f" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b46c2795-527c-488a-88d2-09a9018e0870" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_95ebfbcf-4842-4e07-be51-964c5aa8fa6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_9f7e8c7b-b9c4-4d12-9fe7-d3b1318da862" xlink:href="ino-20201231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b46c2795-527c-488a-88d2-09a9018e0870" xlink:to="loc_ino_August2019ConvertibleBondsMember_9f7e8c7b-b9c4-4d12-9fe7-d3b1318da862" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i6ed321a15b1b44d88a99eecf50adebee_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_97931f62-9f20-4a41-9606-b88d1df64a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6762ca56-c842-4aae-856e-3473dd01ec23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_97931f62-9f20-4a41-9606-b88d1df64a1c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6762ca56-c842-4aae-856e-3473dd01ec23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_76c27fa9-610d-46eb-b12c-2c4547174008" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6762ca56-c842-4aae-856e-3473dd01ec23" xlink:to="loc_us-gaap_ProfitLoss_76c27fa9-610d-46eb-b12c-2c4547174008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6762ca56-c842-4aae-856e-3473dd01ec23" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ec07b791-5cea-42ad-b3db-12782cdbaca5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_Depreciation_ec07b791-5cea-42ad-b3db-12782cdbaca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b90b5b43-ec4e-419a-87eb-f2cf4014b4c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b90b5b43-ec4e-419a-87eb-f2cf4014b4c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_76f14004-c65d-4788-86de-6b31abae8aef" xlink:href="ino-20201231.xsd#ino_AmortizationOfOperatingLeaseRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_76f14004-c65d-4788-86de-6b31abae8aef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfCommonStockWarrants_4dbf650d-f641-409c-8da1-82924aed95f4" xlink:href="ino-20201231.xsd#ino_ChangeInValueOfCommonStockWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_ino_ChangeInValueOfCommonStockWarrants_4dbf650d-f641-409c-8da1-82924aed95f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_e8670d81-785c-4396-9aec-bccad0530feb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_e8670d81-785c-4396-9aec-bccad0530feb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6c0a8380-7b88-482b-89ad-64efffdd01cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_ShareBasedCompensation_6c0a8380-7b88-482b-89ad-64efffdd01cf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestExpense_d322df78-9e44-45cf-90e2-de3c16c32ee2" xlink:href="ino-20201231.xsd#ino_NonCashInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_ino_NonCashInterestExpense_d322df78-9e44-45cf-90e2-de3c16c32ee2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_98a3d85c-d767-4541-bb93-2c9981863b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_98a3d85c-d767-4541-bb93-2c9981863b1d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_221f5572-bc16-449d-b5d8-b7493623bd8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_221f5572-bc16-449d-b5d8-b7493623bd8a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_2deb2fb1-e464-4321-b44e-a27ad5ed59a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_GainLossOnInvestments_2deb2fb1-e464-4321-b44e-a27ad5ed59a8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_a7a303bf-0bba-4493-a493-29c936c29598" xlink:href="ino-20201231.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_a7a303bf-0bba-4493-a493-29c936c29598" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_b03b4911-8bd5-4c3c-8192-a5b784cb12be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_b03b4911-8bd5-4c3c-8192-a5b784cb12be" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_d102794b-2c34-4d69-84a1-b7bd2742548d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_d102794b-2c34-4d69-84a1-b7bd2742548d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_4b993072-0787-4d3d-8786-90e03808935b" xlink:href="ino-20201231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_4b993072-0787-4d3d-8786-90e03808935b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_58e243d7-ce77-47e4-af85-7f396b551c71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_58e243d7-ce77-47e4-af85-7f396b551c71" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_efa93a4d-6720-491c-a21b-f9d754c8606f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_efa93a4d-6720-491c-a21b-f9d754c8606f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_67776607-796a-46e4-a1ba-7ee6a7565dbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_67776607-796a-46e4-a1ba-7ee6a7565dbd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_35c5b1d3-f547-4312-b2de-5d756e5eeea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_35c5b1d3-f547-4312-b2de-5d756e5eeea1" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5e8c37c0-cf16-459b-9cb8-2a39c3476684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5e8c37c0-cf16-459b-9cb8-2a39c3476684" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6762ca56-c842-4aae-856e-3473dd01ec23" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_478ee985-9f8b-470a-9301-240cc3ae1446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_478ee985-9f8b-470a-9301-240cc3ae1446" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9f041739-767d-4e79-bac6-f004c0890bd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9f041739-767d-4e79-bac6-f004c0890bd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_999a5178-b245-44a9-aba2-f989439fc915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_999a5178-b245-44a9-aba2-f989439fc915" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_2a43455b-3c0a-4efa-88ae-f2ec43e5ae4b" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_2a43455b-3c0a-4efa-88ae-f2ec43e5ae4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6c074cbd-294f-469d-89f6-7529c0036173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6c074cbd-294f-469d-89f6-7529c0036173" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_28ac6a66-baa1-4246-9276-acca08a0c4ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_28ac6a66-baa1-4246-9276-acca08a0c4ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_5914116c-afe6-4fd7-a9ca-625d7a67fc65" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_5914116c-afe6-4fd7-a9ca-625d7a67fc65" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_82d9d5ee-bd65-4758-9ae9-9164c4d7a0f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_82d9d5ee-bd65-4758-9ae9-9164c4d7a0f0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c9eb9839-1835-4063-ad6e-996a747f9610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c9eb9839-1835-4063-ad6e-996a747f9610" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_257e8f59-fe53-4f69-ab85-9d6c41ecca63" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_257e8f59-fe53-4f69-ab85-9d6c41ecca63" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StraightLineRent_e4d41b1a-e73c-4bc2-a930-3df7347da021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StraightLineRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_us-gaap_StraightLineRent_e4d41b1a-e73c-4bc2-a930-3df7347da021" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_5810179a-6b3a-494e-97a5-a0225de900c0" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_5810179a-6b3a-494e-97a5-a0225de900c0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_6e3ab90d-af74-4956-ade8-7c286114a6e4" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_6e3ab90d-af74-4956-ade8-7c286114a6e4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_887036b9-9c45-434d-82fe-c0f97a2667a3" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_887036b9-9c45-434d-82fe-c0f97a2667a3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_084afc7f-16af-44e9-b064-d0fed9081289" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_084afc7f-16af-44e9-b064-d0fed9081289" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b726b422-6360-4505-b57e-dd0c5fba86f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6762ca56-c842-4aae-856e-3473dd01ec23" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b726b422-6360-4505-b57e-dd0c5fba86f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11fca4d0-b713-4e7c-9644-d05441f4dded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_97931f62-9f20-4a41-9606-b88d1df64a1c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11fca4d0-b713-4e7c-9644-d05441f4dded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_6798fc16-5fe7-4d57-8455-791ee10548b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11fca4d0-b713-4e7c-9644-d05441f4dded" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_6798fc16-5fe7-4d57-8455-791ee10548b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_92abdfe3-a7e9-461a-80b9-0fc24c35ab97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11fca4d0-b713-4e7c-9644-d05441f4dded" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_92abdfe3-a7e9-461a-80b9-0fc24c35ab97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_eb227b57-96d0-4f09-ab61-b06989f98aca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11fca4d0-b713-4e7c-9644-d05441f4dded" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_eb227b57-96d0-4f09-ab61-b06989f98aca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromSaleOfEquitySecuritiesFVNI_ca52b456-ed25-48c3-9a0b-16f67b9e1432" xlink:href="ino-20201231.xsd#ino_ProceedsFromSaleOfEquitySecuritiesFVNI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11fca4d0-b713-4e7c-9644-d05441f4dded" xlink:to="loc_ino_ProceedsFromSaleOfEquitySecuritiesFVNI_ca52b456-ed25-48c3-9a0b-16f67b9e1432" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_38bd72f8-5447-4bdb-87ab-829f822bf3c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11fca4d0-b713-4e7c-9644-d05441f4dded" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_38bd72f8-5447-4bdb-87ab-829f822bf3c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ec447e6c-1eb3-4970-bbbc-bef71231b0e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11fca4d0-b713-4e7c-9644-d05441f4dded" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ec447e6c-1eb3-4970-bbbc-bef71231b0e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a3d0f4b-14f9-41d1-bbdc-7a6a3b7ca441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11fca4d0-b713-4e7c-9644-d05441f4dded" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a3d0f4b-14f9-41d1-bbdc-7a6a3b7ca441" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_97931f62-9f20-4a41-9606-b88d1df64a1c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1248de8b-ffd7-45b0-8bfc-c52a0e9adee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1248de8b-ffd7-45b0-8bfc-c52a0e9adee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_08a9ad57-09bc-4adc-a82f-c3bfefb8f27b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_08a9ad57-09bc-4adc-a82f-c3bfefb8f27b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a2cdccad-ca50-4937-80f4-42c77292e3e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a2cdccad-ca50-4937-80f4-42c77292e3e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsfromStockOptionandWarrantExercises_b3c11b60-0978-4243-9a7c-54b9d37142b4" xlink:href="ino-20201231.xsd#ino_ProceedsfromStockOptionandWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:to="loc_ino_ProceedsfromStockOptionandWarrantExercises_b3c11b60-0978-4243-9a7c-54b9d37142b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_e3ff9161-b2d4-4831-a287-97aba40ed94c" xlink:href="ino-20201231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:to="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_e3ff9161-b2d4-4831-a287-97aba40ed94c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_1e5fcb14-fcbb-4287-803b-593b50120403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_1e5fcb14-fcbb-4287-803b-593b50120403" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_c4ce64cf-af0f-4236-93ee-08af40bb894a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_c4ce64cf-af0f-4236-93ee-08af40bb894a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b4dea8a4-b24c-4dcb-936f-4550c34ec8b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b4dea8a4-b24c-4dcb-936f-4550c34ec8b0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_71ba9c12-c404-45d2-8787-5d34b27b74be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_97931f62-9f20-4a41-9606-b88d1df64a1c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_71ba9c12-c404-45d2-8787-5d34b27b74be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7518d2bd-60ee-483f-903b-98ee9733df91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_97931f62-9f20-4a41-9606-b88d1df64a1c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7518d2bd-60ee-483f-903b-98ee9733df91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d0e1ddcb-3dcd-4bbc-bf46-d7bfc82d7c5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_97931f62-9f20-4a41-9606-b88d1df64a1c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d0e1ddcb-3dcd-4bbc-bf46-d7bfc82d7c5a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_834c5f2a-d361-4ddb-965c-e6e98237212b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3ac040a5-7d14-4140-9c88-3434ba4e75bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_97931f62-9f20-4a41-9606-b88d1df64a1c" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3ac040a5-7d14-4140-9c88-3434ba4e75bb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_bc427a76-92c7-440d-a57a-4d959366c295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3ac040a5-7d14-4140-9c88-3434ba4e75bb" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_bc427a76-92c7-440d-a57a-4d959366c295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_5fe6e2d9-baa0-4f2d-8a4f-aa4d5bc50337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3ac040a5-7d14-4140-9c88-3434ba4e75bb" xlink:to="loc_us-gaap_InterestPaidNet_5fe6e2d9-baa0-4f2d-8a4f-aa4d5bc50337" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityComponentOfConvertibleDebtIssued_659b969e-c184-4120-bcff-94ae5b42049e" xlink:href="ino-20201231.xsd#ino_EquityComponentOfConvertibleDebtIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3ac040a5-7d14-4140-9c88-3434ba4e75bb" xlink:to="loc_ino_EquityComponentOfConvertibleDebtIssued_659b969e-c184-4120-bcff-94ae5b42049e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_06d32d92-1881-48f0-a4f1-a00ea8433a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3ac040a5-7d14-4140-9c88-3434ba4e75bb" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_06d32d92-1881-48f0-a4f1-a00ea8433a1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c07ac6c5-9c3d-4f66-8062-c12d382d2a65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_97931f62-9f20-4a41-9606-b88d1df64a1c" xlink:to="loc_us-gaap_StatementTable_c07ac6c5-9c3d-4f66-8062-c12d382d2a65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d0a406df-9bd9-4bc1-a91a-77d116e31afc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c07ac6c5-9c3d-4f66-8062-c12d382d2a65" xlink:to="loc_us-gaap_DebtInstrumentAxis_d0a406df-9bd9-4bc1-a91a-77d116e31afc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d0a406df-9bd9-4bc1-a91a-77d116e31afc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d0a406df-9bd9-4bc1-a91a-77d116e31afc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d0a406df-9bd9-4bc1-a91a-77d116e31afc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a0cf8143-970c-4b46-b011-476ccd9664f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d0a406df-9bd9-4bc1-a91a-77d116e31afc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a0cf8143-970c-4b46-b011-476ccd9664f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_7dcaaba4-8398-4cc9-a797-e41fa64d1819" xlink:href="ino-20201231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a0cf8143-970c-4b46-b011-476ccd9664f9" xlink:to="loc_ino_August2019ConvertibleBondsMember_7dcaaba4-8398-4cc9-a797-e41fa64d1819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_bab7899b-efba-46fb-a917-986411d04a83" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a0cf8143-970c-4b46-b011-476ccd9664f9" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_bab7899b-efba-46fb-a917-986411d04a83" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/TheCompany" xlink:type="simple" xlink:href="ino-20201231.xsd#TheCompany"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/TheCompany" xlink:type="extended" id="i15f4c931db0944038341af3cecb055da_TheCompany"/>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ino-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i89b816b5b69c42bd888a59f0ac1ee518_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ino-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="iba7773c3ebf74323890d1224f5316801_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ino-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i705b37c415574f5d8aed0d8d78d5ea17_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="ibded3619fbb94eb9a0248e34796ec3e3_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f7193f87-dc82-4788-a644-a76718e4c5ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_NetIncomeLoss_f7193f87-dc82-4788-a644-a76718e4c5ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital_2d69b435-8684-4cd1-abc3-a8dc53813a1b" xlink:href="ino-20201231.xsd#ino_WorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_ino_WorkingCapital_2d69b435-8684-4cd1-abc3-a8dc53813a1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1b5ff6bc-815c-48e0-a5b3-b11f9577111e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1b5ff6bc-815c-48e0-a5b3-b11f9577111e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_9fc1d074-76ed-4e02-884b-c9518715cdc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_9fc1d074-76ed-4e02-884b-c9518715cdc6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e653eb27-441a-47a3-b0fb-6cdc6ea73e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e653eb27-441a-47a3-b0fb-6cdc6ea73e90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_954b40b0-015f-46e8-a01a-fdc5fa85fa25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_954b40b0-015f-46e8-a01a-fdc5fa85fa25" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_76aef761-a15a-4a4a-9acb-7178484867df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_76aef761-a15a-4a4a-9acb-7178484867df" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ea140698-c51a-4a77-a0bd-1700f15d5089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ea140698-c51a-4a77-a0bd-1700f15d5089" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_95c908a8-e558-4d04-9885-3110d8165546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_NumberOfOperatingSegments_95c908a8-e558-4d04-9885-3110d8165546" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d0fa4747-bde8-4038-8f43-f290cdb9a4aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d0fa4747-bde8-4038-8f43-f290cdb9a4aa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_cc995c8d-04e3-4af9-b2b0-afc12d5d588b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_cc995c8d-04e3-4af9-b2b0-afc12d5d588b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c32844da-5f41-4e93-8131-88bd7edc799d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c32844da-5f41-4e93-8131-88bd7edc799d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_263ce13e-e283-4485-bf95-246cfeeba72b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_263ce13e-e283-4485-bf95-246cfeeba72b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_32c0e44a-7fd1-4a7d-a59b-1919f4a75a79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_32c0e44a-7fd1-4a7d-a59b-1919f4a75a79" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_439422f7-c51a-42f1-ba6e-544155d7ceda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_439422f7-c51a-42f1-ba6e-544155d7ceda" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59845912-33c5-4e27-a022-02e44148f895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_439422f7-c51a-42f1-ba6e-544155d7ceda" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59845912-33c5-4e27-a022-02e44148f895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59845912-33c5-4e27-a022-02e44148f895_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59845912-33c5-4e27-a022-02e44148f895" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59845912-33c5-4e27-a022-02e44148f895_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a37e2a4b-0a48-4d16-bf7c-cdc7371e9d80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59845912-33c5-4e27-a022-02e44148f895" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a37e2a4b-0a48-4d16-bf7c-cdc7371e9d80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_2e5e8a19-5bef-4bb3-a927-4ee6c091978d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a37e2a4b-0a48-4d16-bf7c-cdc7371e9d80" xlink:to="loc_us-gaap_PatentsMember_2e5e8a19-5bef-4bb3-a927-4ee6c091978d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cf63323d-6b0e-4a79-86a2-69dab6d290f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_439422f7-c51a-42f1-ba6e-544155d7ceda" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cf63323d-6b0e-4a79-86a2-69dab6d290f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cf63323d-6b0e-4a79-86a2-69dab6d290f0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cf63323d-6b0e-4a79-86a2-69dab6d290f0" xlink:to="loc_us-gaap_ClassOfStockDomain_cf63323d-6b0e-4a79-86a2-69dab6d290f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e77dcb76-65d5-4293-87ae-3af49f90348d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cf63323d-6b0e-4a79-86a2-69dab6d290f0" xlink:to="loc_us-gaap_ClassOfStockDomain_e77dcb76-65d5-4293-87ae-3af49f90348d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c5d2bf4b-05fd-41f9-8ee1-30f76634e68c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e77dcb76-65d5-4293-87ae-3af49f90348d" xlink:to="loc_us-gaap_CommonStockMember_c5d2bf4b-05fd-41f9-8ee1-30f76634e68c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8c843f72-0fee-4580-8808-966d97ed2d10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_439422f7-c51a-42f1-ba6e-544155d7ceda" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8c843f72-0fee-4580-8808-966d97ed2d10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8c843f72-0fee-4580-8808-966d97ed2d10_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8c843f72-0fee-4580-8808-966d97ed2d10" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8c843f72-0fee-4580-8808-966d97ed2d10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a8d86416-e6c5-4cf5-b453-cc9048d7c20c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8c843f72-0fee-4580-8808-966d97ed2d10" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a8d86416-e6c5-4cf5-b453-cc9048d7c20c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_0b3a5a1b-c2d9-4a34-be3f-106ebf8a9d8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a8d86416-e6c5-4cf5-b453-cc9048d7c20c" xlink:to="loc_us-gaap_ConvertibleDebtMember_0b3a5a1b-c2d9-4a34-be3f-106ebf8a9d8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fc783554-8a1d-4ddf-afeb-a26b58325937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_439422f7-c51a-42f1-ba6e-544155d7ceda" xlink:to="loc_us-gaap_DebtInstrumentAxis_fc783554-8a1d-4ddf-afeb-a26b58325937" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fc783554-8a1d-4ddf-afeb-a26b58325937_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fc783554-8a1d-4ddf-afeb-a26b58325937" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fc783554-8a1d-4ddf-afeb-a26b58325937_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5cb17677-d940-43d7-a29f-cb5652320f91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fc783554-8a1d-4ddf-afeb-a26b58325937" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5cb17677-d940-43d7-a29f-cb5652320f91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_a68158f4-86db-40ac-8c55-c212a626abcb" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5cb17677-d940-43d7-a29f-cb5652320f91" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_a68158f4-86db-40ac-8c55-c212a626abcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_7f5fa5cd-60e5-4c68-a011-4f6f4e49345b" xlink:href="ino-20201231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5cb17677-d940-43d7-a29f-cb5652320f91" xlink:to="loc_ino_August2019ConvertibleBondsMember_7f5fa5cd-60e5-4c68-a011-4f6f4e49345b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_a851cf43-f7f4-4caa-9283-d287797e8fa6" xlink:href="ino-20201231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5cb17677-d940-43d7-a29f-cb5652320f91" xlink:to="loc_ino_December2019ConvertibleBondsMember_a851cf43-f7f4-4caa-9283-d287797e8fa6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_895a5654-7a3b-440a-bf56-79f6418a9a9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_439422f7-c51a-42f1-ba6e-544155d7ceda" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_895a5654-7a3b-440a-bf56-79f6418a9a9c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_895a5654-7a3b-440a-bf56-79f6418a9a9c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_895a5654-7a3b-440a-bf56-79f6418a9a9c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_895a5654-7a3b-440a-bf56-79f6418a9a9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9cce10b8-7cdb-4e02-833b-5f63a3d81ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_895a5654-7a3b-440a-bf56-79f6418a9a9c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9cce10b8-7cdb-4e02-833b-5f63a3d81ed6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_fc5fad5c-a359-4251-ba25-9ce5044c3e73" xlink:href="ino-20201231.xsd#ino_SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9cce10b8-7cdb-4e02-833b-5f63a3d81ed6" xlink:to="loc_ino_SalesAgreementMember_fc5fad5c-a359-4251-ba25-9ce5044c3e73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_20f968ab-3efe-406b-9626-283bd26ccf0c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_439422f7-c51a-42f1-ba6e-544155d7ceda" xlink:to="loc_srt_RangeAxis_20f968ab-3efe-406b-9626-283bd26ccf0c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_20f968ab-3efe-406b-9626-283bd26ccf0c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_20f968ab-3efe-406b-9626-283bd26ccf0c" xlink:to="loc_srt_RangeMember_20f968ab-3efe-406b-9626-283bd26ccf0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3cc6f634-f473-43bb-868f-152128e7703d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_20f968ab-3efe-406b-9626-283bd26ccf0c" xlink:to="loc_srt_RangeMember_3cc6f634-f473-43bb-868f-152128e7703d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3961c89a-854c-4778-8326-bb958ad02190" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3cc6f634-f473-43bb-868f-152128e7703d" xlink:to="loc_srt_MinimumMember_3961c89a-854c-4778-8326-bb958ad02190" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12742e30-8a0e-4e05-a1d7-573c5b6f2643" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3cc6f634-f473-43bb-868f-152128e7703d" xlink:to="loc_srt_MaximumMember_12742e30-8a0e-4e05-a1d7-573c5b6f2643" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="extended" id="i451b1f6ff3d84946ad5bc2e8d99d02bf_SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_603ad068-9802-4467-ba61-668a69b05993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CommonStockEquivalentsAbstract_32ec8ced-2df0-445a-a2dd-13350dc32671" xlink:href="ino-20201231.xsd#ino_CommonStockEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_603ad068-9802-4467-ba61-668a69b05993" xlink:to="loc_ino_CommonStockEquivalentsAbstract_32ec8ced-2df0-445a-a2dd-13350dc32671" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0015d650-df0b-4396-8a11-9d2921919e09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_CommonStockEquivalentsAbstract_32ec8ced-2df0-445a-a2dd-13350dc32671" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0015d650-df0b-4396-8a11-9d2921919e09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ae6389b9-61ed-4c73-985f-d1f2a9e0aae8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_603ad068-9802-4467-ba61-668a69b05993" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ae6389b9-61ed-4c73-985f-d1f2a9e0aae8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f0f95786-947b-46e4-a361-41ac0679d11e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ae6389b9-61ed-4c73-985f-d1f2a9e0aae8" xlink:to="loc_us-gaap_DebtInstrumentAxis_f0f95786-947b-46e4-a361-41ac0679d11e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f0f95786-947b-46e4-a361-41ac0679d11e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f0f95786-947b-46e4-a361-41ac0679d11e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f0f95786-947b-46e4-a361-41ac0679d11e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a89dbecc-f89a-4e01-a65d-0387a80ee3e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f0f95786-947b-46e4-a361-41ac0679d11e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a89dbecc-f89a-4e01-a65d-0387a80ee3e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_79440068-978c-43ee-8cab-1c99e10973aa" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a89dbecc-f89a-4e01-a65d-0387a80ee3e3" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_79440068-978c-43ee-8cab-1c99e10973aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_02fce4d0-d3a7-4a82-bf7c-fe0fc19bb9da" xlink:href="ino-20201231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a89dbecc-f89a-4e01-a65d-0387a80ee3e3" xlink:to="loc_ino_August2019ConvertibleBondsMember_02fce4d0-d3a7-4a82-bf7c-fe0fc19bb9da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_825d62c8-4851-48e9-ae59-568cefc1c454" xlink:href="ino-20201231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a89dbecc-f89a-4e01-a65d-0387a80ee3e3" xlink:to="loc_ino_December2019ConvertibleBondsMember_825d62c8-4851-48e9-ae59-568cefc1c454" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_19b10955-d6b5-492f-9f94-999dcf22094f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ae6389b9-61ed-4c73-985f-d1f2a9e0aae8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_19b10955-d6b5-492f-9f94-999dcf22094f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_19b10955-d6b5-492f-9f94-999dcf22094f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_19b10955-d6b5-492f-9f94-999dcf22094f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_19b10955-d6b5-492f-9f94-999dcf22094f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_645cc3cc-7942-44c2-be6e-2bd5847c34e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_19b10955-d6b5-492f-9f94-999dcf22094f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_645cc3cc-7942-44c2-be6e-2bd5847c34e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9a98e7d3-7c3c-432e-a61d-9846c2e78e4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_645cc3cc-7942-44c2-be6e-2bd5847c34e6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9a98e7d3-7c3c-432e-a61d-9846c2e78e4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_7b5b2679-b321-4ba8-8ee6-fa305c21ee53" xlink:href="ino-20201231.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_645cc3cc-7942-44c2-be6e-2bd5847c34e6" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_7b5b2679-b321-4ba8-8ee6-fa305c21ee53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bfd70979-2557-43e0-9534-2f79847e92d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_645cc3cc-7942-44c2-be6e-2bd5847c34e6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bfd70979-2557-43e0-9534-2f79847e92d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_39a0e520-9d6a-49b4-9c28-21ae7924c013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_645cc3cc-7942-44c2-be6e-2bd5847c34e6" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_39a0e520-9d6a-49b4-9c28-21ae7924c013" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_7fce5a0d-bc90-40fe-bbfd-fa443294985c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_645cc3cc-7942-44c2-be6e-2bd5847c34e6" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_7fce5a0d-bc90-40fe-bbfd-fa443294985c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="extended" id="i3d4e0cf9e1e5445197101e050f1bd35c_SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b7decd7f-c89c-4443-a979-7984abdb4430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_f20bc6f7-e40f-4bed-97a5-e8c40e8668a5" xlink:href="ino-20201231.xsd#ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b7decd7f-c89c-4443-a979-7984abdb4430" xlink:to="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_f20bc6f7-e40f-4bed-97a5-e8c40e8668a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_290d2425-e516-41c6-8be4-94f9dfa799c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_f20bc6f7-e40f-4bed-97a5-e8c40e8668a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_290d2425-e516-41c6-8be4-94f9dfa799c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f41f6384-a61c-48d2-adce-d7736a23ee7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_f20bc6f7-e40f-4bed-97a5-e8c40e8668a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f41f6384-a61c-48d2-adce-d7736a23ee7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d8cc54b6-de2c-4633-8c84-c7604dc428d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_f20bc6f7-e40f-4bed-97a5-e8c40e8668a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d8cc54b6-de2c-4633-8c84-c7604dc428d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b6328591-1961-4df9-a958-9f7c8ba8ca5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_f20bc6f7-e40f-4bed-97a5-e8c40e8668a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b6328591-1961-4df9-a958-9f7c8ba8ca5a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f487e599-da2b-41af-91b3-c743ef1cd98c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b7decd7f-c89c-4443-a979-7984abdb4430" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f487e599-da2b-41af-91b3-c743ef1cd98c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_d3ed401b-c067-4c78-a053-c3d737fa6beb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f487e599-da2b-41af-91b3-c743ef1cd98c" xlink:to="loc_srt_TitleOfIndividualAxis_d3ed401b-c067-4c78-a053-c3d737fa6beb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d3ed401b-c067-4c78-a053-c3d737fa6beb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_d3ed401b-c067-4c78-a053-c3d737fa6beb" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d3ed401b-c067-4c78-a053-c3d737fa6beb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_189ddfc7-30df-4c91-980a-46e076f8cb93" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_d3ed401b-c067-4c78-a053-c3d737fa6beb" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_189ddfc7-30df-4c91-980a-46e076f8cb93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_f64fae16-c58f-4dae-b654-a9c877d32760" xlink:href="ino-20201231.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_189ddfc7-30df-4c91-980a-46e076f8cb93" xlink:to="loc_ino_EmployeesAndDirectorsMember_f64fae16-c58f-4dae-b654-a9c877d32760" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_eed9c1e5-ee56-42aa-ae7e-f709eb78df40" xlink:href="ino-20201231.xsd#ino_NonEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_189ddfc7-30df-4c91-980a-46e076f8cb93" xlink:to="loc_ino_NonEmployeeMember_eed9c1e5-ee56-42aa-ae7e-f709eb78df40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b3fb5e7f-b8b1-410f-9cd1-d6624dd48176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f487e599-da2b-41af-91b3-c743ef1cd98c" xlink:to="loc_us-gaap_AwardTypeAxis_b3fb5e7f-b8b1-410f-9cd1-d6624dd48176" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3fb5e7f-b8b1-410f-9cd1-d6624dd48176_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b3fb5e7f-b8b1-410f-9cd1-d6624dd48176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3fb5e7f-b8b1-410f-9cd1-d6624dd48176_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9ab9a903-f5da-4bd4-b54d-e23070c9457e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b3fb5e7f-b8b1-410f-9cd1-d6624dd48176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9ab9a903-f5da-4bd4-b54d-e23070c9457e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3b5a8c92-2dde-4134-b240-4a416b084ef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9ab9a903-f5da-4bd4-b54d-e23070c9457e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3b5a8c92-2dde-4134-b240-4a416b084ef0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognition" xlink:type="simple" xlink:href="ino-20201231.xsd#RevenueRecognition"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RevenueRecognition" xlink:type="extended" id="i5adec70e890f407e8b585f3fa0eca451_RevenueRecognition"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#RevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="extended" id="i1daf43f3280449a892302215b50bb24f_RevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_fa76a66f-3b0e-4f36-87d3-a27c6ce0f394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4844f6a7-938f-460e-ada2-307e74532566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fa76a66f-3b0e-4f36-87d3-a27c6ce0f394" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4844f6a7-938f-460e-ada2-307e74532566" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0eac0ab0-7bda-4482-90c6-0efa67d9d12a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fa76a66f-3b0e-4f36-87d3-a27c6ce0f394" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0eac0ab0-7bda-4482-90c6-0efa67d9d12a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a561a5a9-391e-47f8-a96e-23c2651d618e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fa76a66f-3b0e-4f36-87d3-a27c6ce0f394" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a561a5a9-391e-47f8-a96e-23c2651d618e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c914009d-d905-4f28-b452-182cb734f3bc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a561a5a9-391e-47f8-a96e-23c2651d618e" xlink:to="loc_srt_CounterpartyNameAxis_c914009d-d905-4f28-b452-182cb734f3bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c914009d-d905-4f28-b452-182cb734f3bc_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c914009d-d905-4f28-b452-182cb734f3bc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c914009d-d905-4f28-b452-182cb734f3bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f82b365-d43d-4c13-a2c9-ce13023b6cad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c914009d-d905-4f28-b452-182cb734f3bc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f82b365-d43d-4c13-a2c9-ce13023b6cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_dbe54c54-81a4-496b-9309-387e5d2f36f1" xlink:href="ino-20201231.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f82b365-d43d-4c13-a2c9-ce13023b6cad" xlink:to="loc_ino_AdvaccineMember_dbe54c54-81a4-496b-9309-387e5d2f36f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_04ba61e9-243f-4d28-b60c-479c6ffe7117" xlink:href="ino-20201231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f82b365-d43d-4c13-a2c9-ce13023b6cad" xlink:to="loc_ino_PlumblineLifeSciencesMember_04ba61e9-243f-4d28-b60c-479c6ffe7117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherCounterpartyMember_4c9d2149-201a-4852-9dba-c22a5a9ffa70" xlink:href="ino-20201231.xsd#ino_OtherCounterpartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f82b365-d43d-4c13-a2c9-ce13023b6cad" xlink:to="loc_ino_OtherCounterpartyMember_4c9d2149-201a-4852-9dba-c22a5a9ffa70" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="ino-20201231.xsd#CollaborativeAgreements"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended" id="i807183383e3b476680561c8c3dc861ae_CollaborativeAgreements"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#CollaborativeAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended" id="i895adace732f4eef973a72c0395cc199_CollaborativeAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_ad4b8982-6e03-41a1-9d03-cbdc8fe2cc36" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_ad4b8982-6e03-41a1-9d03-cbdc8fe2cc36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_38348373-7796-4386-bea3-6e4e073bb107" xlink:href="ino-20201231.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_38348373-7796-4386-bea3-6e4e073bb107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned_6b715063-f9e9-48af-b117-03209e5253c0" xlink:href="ino-20201231.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborationAgreementPaymentEarned_6b715063-f9e9-48af-b117-03209e5253c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_1473ff03-e8a6-400a-aa0f-2376b3dc9130" xlink:href="ino-20201231.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_1473ff03-e8a6-400a-aa0f-2376b3dc9130" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_3bd93765-7d8c-47cf-8ea5-da0ecde166c2" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_3bd93765-7d8c-47cf-8ea5-da0ecde166c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_36ba590b-bb72-4fd3-aa8d-65326f6ed58d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_36ba590b-bb72-4fd3-aa8d-65326f6ed58d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_aea14300-272d-4f39-8726-1630dd30fac6" xlink:href="ino-20201231.xsd#ino_CollaborationAgreementTerritoryExpansionOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_aea14300-272d-4f39-8726-1630dd30fac6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement_0a78c755-fea0-4b58-b3a7-4cd48412adeb" xlink:href="ino-20201231.xsd#ino_ProceedsFromCollaborativeAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_ProceedsFromCollaborativeAgreement_0a78c755-fea0-4b58-b3a7-4cd48412adeb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax_a9719f36-c1b8-4999-a644-d99bc27e2119" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementCorporateIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeAgreementCorporateIncomeTax_a9719f36-c1b8-4999-a644-d99bc27e2119" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_6212c2c0-a66c-4da1-a065-6739d8a3d105" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_6212c2c0-a66c-4da1-a065-6739d8a3d105" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees_ee9e0c21-5da5-42c1-9468-7e2a4c45a1e1" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementAdvisoryFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeAgreementAdvisoryFees_ee9e0c21-5da5-42c1-9468-7e2a4c45a1e1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_538cef53-5bfd-4f85-8b54-39a50a0b4ad7" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_538cef53-5bfd-4f85-8b54-39a50a0b4ad7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_32cfb055-3f45-41a4-a344-d8878e14c6ff" xlink:href="ino-20201231.xsd#ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_32cfb055-3f45-41a4-a344-d8878e14c6ff" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_324e2a71-c037-4d1c-a7a0-705e222d8821" xlink:href="ino-20201231.xsd#ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_324e2a71-c037-4d1c-a7a0-705e222d8821" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_f442fd7f-c325-4003-af05-8248280ca978" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementMilestonePaymentRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_f442fd7f-c325-4003-af05-8248280ca978" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_178902d1-6727-41ba-8f0e-0cd5c178eee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_f6933649-4e4d-4680-af44-1753fadf4130" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_f6933649-4e4d-4680-af44-1753fadf4130" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_5a16ed0e-7347-4332-95b5-dfe8c54c5969" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_5a16ed0e-7347-4332-95b5-dfe8c54c5969" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_c414ea0d-99be-4a98-8dc4-dfa30c8522c0" xlink:href="ino-20201231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_DeferredGrantFundingCurrent_c414ea0d-99be-4a98-8dc4-dfa30c8522c0" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_13a0c9c9-8c48-48eb-8667-8c2de26bc915" xlink:href="ino-20201231.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_13a0c9c9-8c48-48eb-8667-8c2de26bc915" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_1354cd6f-3be1-4b05-8555-43931ee2d490" xlink:href="ino-20201231.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_GrantProceedsReceived_1354cd6f-3be1-4b05-8555-43931ee2d490" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_2d4cb6a1-5a56-4898-9a4a-86def41b0af6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_2d4cb6a1-5a56-4898-9a4a-86def41b0af6" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8420ef7-9238-463d-b2d2-1c95e91c368e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8420ef7-9238-463d-b2d2-1c95e91c368e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_93b9b905-1851-4638-80f0-ff279e8ec97e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8420ef7-9238-463d-b2d2-1c95e91c368e" xlink:to="loc_srt_CounterpartyNameAxis_93b9b905-1851-4638-80f0-ff279e8ec97e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93b9b905-1851-4638-80f0-ff279e8ec97e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_93b9b905-1851-4638-80f0-ff279e8ec97e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93b9b905-1851-4638-80f0-ff279e8ec97e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_753c030f-5632-4193-9630-7c0f1fd71e99" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_93b9b905-1851-4638-80f0-ff279e8ec97e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_753c030f-5632-4193-9630-7c0f1fd71e99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_a73ee4ce-3fcb-4c7e-af2a-1a65f973c810" xlink:href="ino-20201231.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_753c030f-5632-4193-9630-7c0f1fd71e99" xlink:to="loc_ino_AdvaccineMember_a73ee4ce-3fcb-4c7e-af2a-1a65f973c810" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_894aebcf-6ab3-40b4-8523-ce70435ca8f9" xlink:href="ino-20201231.xsd#ino_ApolloBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_753c030f-5632-4193-9630-7c0f1fd71e99" xlink:to="loc_ino_ApolloBioMember_894aebcf-6ab3-40b4-8523-ce70435ca8f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember_efd00b6a-d552-44e4-8ca2-612478f66a36" xlink:href="ino-20201231.xsd#ino_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_753c030f-5632-4193-9630-7c0f1fd71e99" xlink:to="loc_ino_AstraZenecaMember_efd00b6a-d552-44e4-8ca2-612478f66a36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_210955ba-704d-4ebf-af50-d5475f1e3d6b" xlink:href="ino-20201231.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_753c030f-5632-4193-9630-7c0f1fd71e99" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_210955ba-704d-4ebf-af50-d5475f1e3d6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_5eb1553c-953f-455f-897d-ed8bbb471a05" xlink:href="ino-20201231.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_753c030f-5632-4193-9630-7c0f1fd71e99" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_5eb1553c-953f-455f-897d-ed8bbb471a05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember_9b97205f-dcdb-490b-a595-19f5f54f2f96" xlink:href="ino-20201231.xsd#ino_DepartmentOfDefenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_753c030f-5632-4193-9630-7c0f1fd71e99" xlink:to="loc_ino_DepartmentOfDefenceMember_9b97205f-dcdb-490b-a595-19f5f54f2f96" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4f09bb4d-a7d8-4472-909b-2adc1eb95f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8420ef7-9238-463d-b2d2-1c95e91c368e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4f09bb4d-a7d8-4472-909b-2adc1eb95f3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f09bb4d-a7d8-4472-909b-2adc1eb95f3f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f09bb4d-a7d8-4472-909b-2adc1eb95f3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f09bb4d-a7d8-4472-909b-2adc1eb95f3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_062a2b51-0d5f-4635-a447-b05aa86d07d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f09bb4d-a7d8-4472-909b-2adc1eb95f3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_062a2b51-0d5f-4635-a447-b05aa86d07d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_47f1e92f-e97b-4442-9a0e-4046acd01b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_062a2b51-0d5f-4635-a447-b05aa86d07d4" xlink:to="loc_us-gaap_CollaborativeArrangementMember_47f1e92f-e97b-4442-9a0e-4046acd01b4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b821f6e9-66b3-49c2-a51b-076321c3268a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8420ef7-9238-463d-b2d2-1c95e91c368e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b821f6e9-66b3-49c2-a51b-076321c3268a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b821f6e9-66b3-49c2-a51b-076321c3268a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b821f6e9-66b3-49c2-a51b-076321c3268a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b821f6e9-66b3-49c2-a51b-076321c3268a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cd1eab6a-b498-417e-8f99-888e982b8ed7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b821f6e9-66b3-49c2-a51b-076321c3268a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cd1eab6a-b498-417e-8f99-888e982b8ed7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bfb4c6f1-2d28-4a4e-9aaf-187824991f32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_cd1eab6a-b498-417e-8f99-888e982b8ed7" xlink:to="loc_us-gaap_SubsequentEventMember_bfb4c6f1-2d28-4a4e-9aaf-187824991f32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_43ccf103-4f33-4a71-8928-bc70fb6e060f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8420ef7-9238-463d-b2d2-1c95e91c368e" xlink:to="loc_srt_ProductOrServiceAxis_43ccf103-4f33-4a71-8928-bc70fb6e060f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_43ccf103-4f33-4a71-8928-bc70fb6e060f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_43ccf103-4f33-4a71-8928-bc70fb6e060f" xlink:to="loc_srt_ProductsAndServicesDomain_43ccf103-4f33-4a71-8928-bc70fb6e060f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7e6daa94-85a7-4427-a2fa-24640728a0a8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_43ccf103-4f33-4a71-8928-bc70fb6e060f" xlink:to="loc_srt_ProductsAndServicesDomain_7e6daa94-85a7-4427-a2fa-24640728a0a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_7face40d-77e6-404f-8314-cf65bb6edf8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7e6daa94-85a7-4427-a2fa-24640728a0a8" xlink:to="loc_us-gaap_LicenseMember_7face40d-77e6-404f-8314-cf65bb6edf8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember_c35845f9-8e17-4a60-bd1a-09cb5744bb8f" xlink:href="ino-20201231.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7e6daa94-85a7-4427-a2fa-24640728a0a8" xlink:to="loc_ino_SARSCoV2COVID19VaccineMember_c35845f9-8e17-4a60-bd1a-09cb5744bb8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_d8109309-803c-4a00-8f8f-91349bc6cf4d" xlink:href="ino-20201231.xsd#ino_INO4800Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7e6daa94-85a7-4427-a2fa-24640728a0a8" xlink:to="loc_ino_INO4800Member_d8109309-803c-4a00-8f8f-91349bc6cf4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_739af8a3-45e6-4c3d-b66d-fdc412de8595" xlink:href="ino-20201231.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7e6daa94-85a7-4427-a2fa-24640728a0a8" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_739af8a3-45e6-4c3d-b66d-fdc412de8595" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_f76011a2-c3e3-4439-89eb-4e54573e6118" xlink:href="ino-20201231.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7e6daa94-85a7-4427-a2fa-24640728a0a8" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_f76011a2-c3e3-4439-89eb-4e54573e6118" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_9b3e7d81-370a-4974-a79a-dd8be50a1cc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8420ef7-9238-463d-b2d2-1c95e91c368e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_9b3e7d81-370a-4974-a79a-dd8be50a1cc1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9b3e7d81-370a-4974-a79a-dd8be50a1cc1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_9b3e7d81-370a-4974-a79a-dd8be50a1cc1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9b3e7d81-370a-4974-a79a-dd8be50a1cc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0e0c600e-9a5c-4d5b-b938-c5123dadcefd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_9b3e7d81-370a-4974-a79a-dd8be50a1cc1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0e0c600e-9a5c-4d5b-b938-c5123dadcefd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_0e6f5eb9-724b-4675-8a08-820ee147b371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0e0c600e-9a5c-4d5b-b938-c5123dadcefd" xlink:to="loc_us-gaap_ForeignCountryMember_0e6f5eb9-724b-4675-8a08-820ee147b371" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestments" xlink:type="simple" xlink:href="ino-20201231.xsd#ShorttermInvestments"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestments" xlink:type="extended" id="i2a6cafcac31e4bd4a0a301c8988f66c4_ShorttermInvestments"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="simple" xlink:href="ino-20201231.xsd#ShorttermInvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="extended" id="i23bea75225644096a9aab2f5a12144b4_ShorttermInvestmentsTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#ShorttermInvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="extended" id="i339251106e644245bd88663d13176d57_ShorttermInvestmentsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended" id="i4851b076b036496592503e137946f716_ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_83451222-4068-4d33-bae9-5361b1d2056f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_0a1ff24a-1be4-4c80-a72b-3c331d9fd461" xlink:href="ino-20201231.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_83451222-4068-4d33-bae9-5361b1d2056f" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_0a1ff24a-1be4-4c80-a72b-3c331d9fd461" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_07b31dbf-ab8c-4158-9767-82d3e5070c5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_83451222-4068-4d33-bae9-5361b1d2056f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_07b31dbf-ab8c-4158-9767-82d3e5070c5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a0686de1-e9fd-493c-9d8f-8bc307cdb848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_07b31dbf-ab8c-4158-9767-82d3e5070c5f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a0686de1-e9fd-493c-9d8f-8bc307cdb848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_928e488c-776b-4677-ad6d-bc96bfaf49f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_07b31dbf-ab8c-4158-9767-82d3e5070c5f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_928e488c-776b-4677-ad6d-bc96bfaf49f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cc3bae30-c330-4d03-86ab-ace3d47f16d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_07b31dbf-ab8c-4158-9767-82d3e5070c5f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cc3bae30-c330-4d03-86ab-ace3d47f16d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_39afb47e-3482-4775-b3c5-927c2731bcbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_07b31dbf-ab8c-4158-9767-82d3e5070c5f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_39afb47e-3482-4775-b3c5-927c2731bcbd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_75d26f83-8e75-45ca-8e28-4632639434c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_83451222-4068-4d33-bae9-5361b1d2056f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_75d26f83-8e75-45ca-8e28-4632639434c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9710192e-074f-48e6-9137-9ac1ccf18f13" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_75d26f83-8e75-45ca-8e28-4632639434c7" xlink:to="loc_srt_RangeAxis_9710192e-074f-48e6-9137-9ac1ccf18f13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9710192e-074f-48e6-9137-9ac1ccf18f13_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9710192e-074f-48e6-9137-9ac1ccf18f13" xlink:to="loc_srt_RangeMember_9710192e-074f-48e6-9137-9ac1ccf18f13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8a2bcef3-d4c5-48f2-bbd9-b1432b8bd673" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9710192e-074f-48e6-9137-9ac1ccf18f13" xlink:to="loc_srt_RangeMember_8a2bcef3-d4c5-48f2-bbd9-b1432b8bd673" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6743099c-b4b4-4b67-adcf-b6314036bc18" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8a2bcef3-d4c5-48f2-bbd9-b1432b8bd673" xlink:to="loc_srt_MaximumMember_6743099c-b4b4-4b67-adcf-b6314036bc18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e0cea5ec-b4a4-4074-aa1d-b9c2584c2b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_75d26f83-8e75-45ca-8e28-4632639434c7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e0cea5ec-b4a4-4074-aa1d-b9c2584c2b67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0cea5ec-b4a4-4074-aa1d-b9c2584c2b67_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e0cea5ec-b4a4-4074-aa1d-b9c2584c2b67" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0cea5ec-b4a4-4074-aa1d-b9c2584c2b67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a8c0683b-7d2e-471e-a7fa-48dcb13bb3aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e0cea5ec-b4a4-4074-aa1d-b9c2584c2b67" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a8c0683b-7d2e-471e-a7fa-48dcb13bb3aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_1ebd84f4-0076-44c3-adba-48fdf3933d0e" xlink:href="ino-20201231.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a8c0683b-7d2e-471e-a7fa-48dcb13bb3aa" xlink:to="loc_ino_MutualFundsMember_1ebd84f4-0076-44c3-adba-48fdf3933d0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_5f00daf6-1f6c-4c0f-a4f9-88de365fa052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a8c0683b-7d2e-471e-a7fa-48dcb13bb3aa" xlink:to="loc_us-gaap_CertificatesOfDepositMember_5f00daf6-1f6c-4c0f-a4f9-88de365fa052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_0ba9473a-17f5-4ce4-9bde-15a5b5936b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a8c0683b-7d2e-471e-a7fa-48dcb13bb3aa" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_0ba9473a-17f5-4ce4-9bde-15a5b5936b02" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ino-20201231.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurements" xlink:type="extended" id="ifbba092a3e5f411fb6891d7071f31fce_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ino-20201231.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="extended" id="ib00f9a3380b84619b60f9dd601fc1e4c_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i9d317f7d980f4ba595dc22933d4009bf_FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ca5e0c1a-2c5b-4687-8c33-b05bd55da328" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1479a904-0d7f-4611-afb8-d1858f964c27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ca5e0c1a-2c5b-4687-8c33-b05bd55da328" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1479a904-0d7f-4611-afb8-d1858f964c27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9884ff63-2449-49ae-a4e5-60c7f38fde0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1479a904-0d7f-4611-afb8-d1858f964c27" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9884ff63-2449-49ae-a4e5-60c7f38fde0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6350025e-3dbf-4806-af84-f9820240728c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1479a904-0d7f-4611-afb8-d1858f964c27" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6350025e-3dbf-4806-af84-f9820240728c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_6d66b103-27e7-4b7d-9b56-7972f41207c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1479a904-0d7f-4611-afb8-d1858f964c27" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_6d66b103-27e7-4b7d-9b56-7972f41207c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ecf44d9b-13c8-4567-a47b-e75d820b81e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1479a904-0d7f-4611-afb8-d1858f964c27" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ecf44d9b-13c8-4567-a47b-e75d820b81e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_85bc99c4-44d5-40c8-a296-61dfdc36dfbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1479a904-0d7f-4611-afb8-d1858f964c27" xlink:to="loc_us-gaap_DerivativeLiabilities_85bc99c4-44d5-40c8-a296-61dfdc36dfbd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_fe5e386a-1a7c-43ca-b742-304acc0cc083" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1479a904-0d7f-4611-afb8-d1858f964c27" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_fe5e386a-1a7c-43ca-b742-304acc0cc083" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db816c55-f451-493e-8f52-eb2a4f93464b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ca5e0c1a-2c5b-4687-8c33-b05bd55da328" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db816c55-f451-493e-8f52-eb2a4f93464b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c1b6ba0a-e91b-445f-b805-bd20fb26d33b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db816c55-f451-493e-8f52-eb2a4f93464b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c1b6ba0a-e91b-445f-b805-bd20fb26d33b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c1b6ba0a-e91b-445f-b805-bd20fb26d33b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c1b6ba0a-e91b-445f-b805-bd20fb26d33b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c1b6ba0a-e91b-445f-b805-bd20fb26d33b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b275515d-0e05-4d06-8ff5-cbcb81e08c55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c1b6ba0a-e91b-445f-b805-bd20fb26d33b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b275515d-0e05-4d06-8ff5-cbcb81e08c55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ec8ef262-13d6-4464-b2c8-04fd15ce3e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b275515d-0e05-4d06-8ff5-cbcb81e08c55" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ec8ef262-13d6-4464-b2c8-04fd15ce3e7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5488994e-5566-4e13-aa0b-a0445542b876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db816c55-f451-493e-8f52-eb2a4f93464b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5488994e-5566-4e13-aa0b-a0445542b876" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5488994e-5566-4e13-aa0b-a0445542b876_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5488994e-5566-4e13-aa0b-a0445542b876" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5488994e-5566-4e13-aa0b-a0445542b876_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_950a9f23-a43d-459a-9bc6-162c22ca45bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5488994e-5566-4e13-aa0b-a0445542b876" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_950a9f23-a43d-459a-9bc6-162c22ca45bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_96fec26b-27cf-4385-b4d6-c6b70752f71d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_950a9f23-a43d-459a-9bc6-162c22ca45bd" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_96fec26b-27cf-4385-b4d6-c6b70752f71d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1c0ed67d-8600-430f-98a5-c30fb40470b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_950a9f23-a43d-459a-9bc6-162c22ca45bd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1c0ed67d-8600-430f-98a5-c30fb40470b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_1a40eae1-3aa0-48bf-a27c-9b34899a369e" xlink:href="ino-20201231.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_950a9f23-a43d-459a-9bc6-162c22ca45bd" xlink:to="loc_ino_MutualFundsMember_1a40eae1-3aa0-48bf-a27c-9b34899a369e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_674db3ba-d66b-4b17-8bc1-78398e17a630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_950a9f23-a43d-459a-9bc6-162c22ca45bd" xlink:to="loc_us-gaap_CertificatesOfDepositMember_674db3ba-d66b-4b17-8bc1-78398e17a630" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_244d9a82-e12a-44f3-8873-79d7403774e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_950a9f23-a43d-459a-9bc6-162c22ca45bd" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_244d9a82-e12a-44f3-8873-79d7403774e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86a2a202-fb47-46d2-a100-384c97306aac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db816c55-f451-493e-8f52-eb2a4f93464b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86a2a202-fb47-46d2-a100-384c97306aac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86a2a202-fb47-46d2-a100-384c97306aac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86a2a202-fb47-46d2-a100-384c97306aac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86a2a202-fb47-46d2-a100-384c97306aac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_954e119d-ab3f-47d7-9742-cb6105b0e10d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86a2a202-fb47-46d2-a100-384c97306aac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_954e119d-ab3f-47d7-9742-cb6105b0e10d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6c76579e-1d53-49aa-bf1e-b5a9a78f6b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_954e119d-ab3f-47d7-9742-cb6105b0e10d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6c76579e-1d53-49aa-bf1e-b5a9a78f6b0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9a9e304c-fdb3-4cc5-88cf-447bc45788ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_954e119d-ab3f-47d7-9742-cb6105b0e10d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9a9e304c-fdb3-4cc5-88cf-447bc45788ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_80ad8699-803b-4200-9139-8278b5e1b8ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_954e119d-ab3f-47d7-9742-cb6105b0e10d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_80ad8699-803b-4200-9139-8278b5e1b8ea" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i327f53fcfd7e4231b42fa241c1698076_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_eb35ec04-0422-45e3-b385-b8d02b8210f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_eb35ec04-0422-45e3-b385-b8d02b8210f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_ca3de9b9-5aec-4b3c-910f-a944f79614de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:to="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_ca3de9b9-5aec-4b3c-910f-a944f79614de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromSaleOfEquitySecuritiesFVNI_13338d6f-5c07-43dd-8c64-6791009d2713" xlink:href="ino-20201231.xsd#ino_ProceedsFromSaleOfEquitySecuritiesFVNI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:to="loc_ino_ProceedsFromSaleOfEquitySecuritiesFVNI_13338d6f-5c07-43dd-8c64-6791009d2713" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGain_bc122219-0ee4-4db9-b080-3af6ffe133d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGain_bc122219-0ee4-4db9-b080-3af6ffe133d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_ea189ba3-6621-4677-94b2-c1ad1c7f9792" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:to="loc_us-gaap_GainLossOnInvestments_ea189ba3-6621-4677-94b2-c1ad1c7f9792" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2ac7c842-cc1b-42a7-8b16-803c78ec2068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2ac7c842-cc1b-42a7-8b16-803c78ec2068" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_98c00878-2c25-4267-be11-59e2658b8279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_98c00878-2c25-4267-be11-59e2658b8279" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_11d2b5c8-81c0-4988-9755-eddf873b35ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:to="loc_us-gaap_DerivativeLiabilities_11d2b5c8-81c0-4988-9755-eddf873b35ae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d5a2ac80-a333-45d8-b584-7221d0775b16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d5a2ac80-a333-45d8-b584-7221d0775b16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_2e82bc64-609a-4b1d-a774-26e3590262cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d5a2ac80-a333-45d8-b584-7221d0775b16" xlink:to="loc_us-gaap_InvestmentTypeAxis_2e82bc64-609a-4b1d-a774-26e3590262cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2e82bc64-609a-4b1d-a774-26e3590262cb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_2e82bc64-609a-4b1d-a774-26e3590262cb" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2e82bc64-609a-4b1d-a774-26e3590262cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_8504ffe5-4dad-4344-aca0-f9f4cad69dfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_2e82bc64-609a-4b1d-a774-26e3590262cb" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_8504ffe5-4dad-4344-aca0-f9f4cad69dfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f43bade6-955c-486c-a101-221ea21e3ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_8504ffe5-4dad-4344-aca0-f9f4cad69dfd" xlink:to="loc_us-gaap_CommonStockMember_f43bade6-955c-486c-a101-221ea21e3ed5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f03b651d-1795-4081-a57d-1e97fb2dd4b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d5a2ac80-a333-45d8-b584-7221d0775b16" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f03b651d-1795-4081-a57d-1e97fb2dd4b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f03b651d-1795-4081-a57d-1e97fb2dd4b1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f03b651d-1795-4081-a57d-1e97fb2dd4b1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f03b651d-1795-4081-a57d-1e97fb2dd4b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6fb3880-7b6a-4862-aa60-84849ccd5f67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f03b651d-1795-4081-a57d-1e97fb2dd4b1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6fb3880-7b6a-4862-aa60-84849ccd5f67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3aec28ff-06a0-4d1c-871a-9eef205bb0f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6fb3880-7b6a-4862-aa60-84849ccd5f67" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3aec28ff-06a0-4d1c-871a-9eef205bb0f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8e84e657-756b-48ef-bb41-f70baeb358d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6fb3880-7b6a-4862-aa60-84849ccd5f67" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8e84e657-756b-48ef-bb41-f70baeb358d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ff3124d4-4280-4703-bd92-ccd4ebc006c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d5a2ac80-a333-45d8-b584-7221d0775b16" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ff3124d4-4280-4703-bd92-ccd4ebc006c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ff3124d4-4280-4703-bd92-ccd4ebc006c4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ff3124d4-4280-4703-bd92-ccd4ebc006c4" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ff3124d4-4280-4703-bd92-ccd4ebc006c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2d4cf549-d3bd-4d4c-81d4-d878ae16c23b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ff3124d4-4280-4703-bd92-ccd4ebc006c4" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2d4cf549-d3bd-4d4c-81d4-d878ae16c23b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneOneLifeSciencesMember_00ac9243-8beb-4bbb-a22d-5579b1458618" xlink:href="ino-20201231.xsd#ino_GeneOneLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2d4cf549-d3bd-4d4c-81d4-d878ae16c23b" xlink:to="loc_ino_GeneOneLifeSciencesMember_00ac9243-8beb-4bbb-a22d-5579b1458618" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails" xlink:type="extended" id="ie3d53ba5c3cb4609853a6b701e1ed304_FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRisk" xlink:type="simple" xlink:href="ino-20201231.xsd#MajorCustomersandConcentrationofCreditRisk"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRisk" xlink:type="extended" id="i49f4cadb5bea4204a2ea877e46c1426c_MajorCustomersandConcentrationofCreditRisk"/>
  <link:roleRef roleURI="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskTables" xlink:type="simple" xlink:href="ino-20201231.xsd#MajorCustomersandConcentrationofCreditRiskTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskTables" xlink:type="extended" id="i92986873bc23477d962a12089735791f_MajorCustomersandConcentrationofCreditRiskTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#MajorCustomersandConcentrationofCreditRiskDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails" xlink:type="extended" id="i11bcbe52d001444aa027d8d499d999ef_MajorCustomersandConcentrationofCreditRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_5e787b3f-9681-4401-bcec-1b23aa9773d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fab95d47-4915-45d2-b75a-d64dee5cb3ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5e787b3f-9681-4401-bcec-1b23aa9773d4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fab95d47-4915-45d2-b75a-d64dee5cb3ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_622cc6fe-2f40-4245-a36a-5b46b2bf869e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5e787b3f-9681-4401-bcec-1b23aa9773d4" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_622cc6fe-2f40-4245-a36a-5b46b2bf869e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_62b73295-d0bd-42e7-9cc5-9e538f92a2e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5e787b3f-9681-4401-bcec-1b23aa9773d4" xlink:to="loc_us-gaap_AccountsReceivableNet_62b73295-d0bd-42e7-9cc5-9e538f92a2e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_38a6915d-a417-42df-ac4f-e85fdc9e7981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5e787b3f-9681-4401-bcec-1b23aa9773d4" xlink:to="loc_us-gaap_ConcentrationRiskTable_38a6915d-a417-42df-ac4f-e85fdc9e7981" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ec87fdf6-de96-4a1d-8c09-bc1af8eb9629" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_38a6915d-a417-42df-ac4f-e85fdc9e7981" xlink:to="loc_srt_MajorCustomersAxis_ec87fdf6-de96-4a1d-8c09-bc1af8eb9629" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ec87fdf6-de96-4a1d-8c09-bc1af8eb9629_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_ec87fdf6-de96-4a1d-8c09-bc1af8eb9629" xlink:to="loc_srt_NameOfMajorCustomerDomain_ec87fdf6-de96-4a1d-8c09-bc1af8eb9629_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c5f93851-5cf4-47fe-876d-384fe3fec91b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_ec87fdf6-de96-4a1d-8c09-bc1af8eb9629" xlink:to="loc_srt_NameOfMajorCustomerDomain_c5f93851-5cf4-47fe-876d-384fe3fec91b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_544a34b8-a2b3-47c2-8916-e9c8645d4101" xlink:href="ino-20201231.xsd#ino_ApolloBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c5f93851-5cf4-47fe-876d-384fe3fec91b" xlink:to="loc_ino_ApolloBioMember_544a34b8-a2b3-47c2-8916-e9c8645d4101" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember_aff37763-4604-48c1-9dae-a1d73647aa6c" xlink:href="ino-20201231.xsd#ino_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c5f93851-5cf4-47fe-876d-384fe3fec91b" xlink:to="loc_ino_AstraZenecaMember_aff37763-4604-48c1-9dae-a1d73647aa6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_36d66ec9-b7b0-4d0c-b4f5-87a34e7f0bbf" xlink:href="ino-20201231.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c5f93851-5cf4-47fe-876d-384fe3fec91b" xlink:to="loc_ino_AdvaccineMember_36d66ec9-b7b0-4d0c-b4f5-87a34e7f0bbf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesIncMember_cee060d9-c35a-4436-8b1b-84dec6f320e0" xlink:href="ino-20201231.xsd#ino_PlumblineLifeSciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c5f93851-5cf4-47fe-876d-384fe3fec91b" xlink:to="loc_ino_PlumblineLifeSciencesIncMember_cee060d9-c35a-4436-8b1b-84dec6f320e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AllOtherCustomersMember_1a207d8b-2ed0-42f6-81bf-5c4634567e20" xlink:href="ino-20201231.xsd#ino_AllOtherCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c5f93851-5cf4-47fe-876d-384fe3fec91b" xlink:to="loc_ino_AllOtherCustomersMember_1a207d8b-2ed0-42f6-81bf-5c4634567e20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DoDMember_8293c355-6f2a-41fa-bb16-20db5ee23db8" xlink:href="ino-20201231.xsd#ino_DoDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c5f93851-5cf4-47fe-876d-384fe3fec91b" xlink:to="loc_ino_DoDMember_8293c355-6f2a-41fa-bb16-20db5ee23db8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MCDCMember_d45b2742-6519-47fb-8aa7-752fe965a9ea" xlink:href="ino-20201231.xsd#ino_MCDCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c5f93851-5cf4-47fe-876d-384fe3fec91b" xlink:to="loc_ino_MCDCMember_d45b2742-6519-47fb-8aa7-752fe965a9ea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_25f99ddf-4b10-4133-ad60-534c65f2cb4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_38a6915d-a417-42df-ac4f-e85fdc9e7981" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_25f99ddf-4b10-4133-ad60-534c65f2cb4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_25f99ddf-4b10-4133-ad60-534c65f2cb4d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_25f99ddf-4b10-4133-ad60-534c65f2cb4d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_25f99ddf-4b10-4133-ad60-534c65f2cb4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dc5c16ba-1f17-4623-ad2f-0eee09e982b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_25f99ddf-4b10-4133-ad60-534c65f2cb4d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dc5c16ba-1f17-4623-ad2f-0eee09e982b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_b4c4045b-99ca-4eeb-ab51-9441f542a8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dc5c16ba-1f17-4623-ad2f-0eee09e982b0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_b4c4045b-99ca-4eeb-ab51-9441f542a8f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_fbff6651-d857-49ab-b9eb-fad7bb365ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dc5c16ba-1f17-4623-ad2f-0eee09e982b0" xlink:to="loc_us-gaap_AccountsReceivableMember_fbff6651-d857-49ab-b9eb-fad7bb365ea1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1d352166-4c84-4a70-8bf8-ab5eb1a418a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_38a6915d-a417-42df-ac4f-e85fdc9e7981" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1d352166-4c84-4a70-8bf8-ab5eb1a418a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1d352166-4c84-4a70-8bf8-ab5eb1a418a0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1d352166-4c84-4a70-8bf8-ab5eb1a418a0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1d352166-4c84-4a70-8bf8-ab5eb1a418a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fe363ab9-8bdb-4991-8a73-15b03d0b6430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1d352166-4c84-4a70-8bf8-ab5eb1a418a0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fe363ab9-8bdb-4991-8a73-15b03d0b6430" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e0fef072-7de9-464f-b972-ae75b0f5ce21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_fe363ab9-8bdb-4991-8a73-15b03d0b6430" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e0fef072-7de9-464f-b972-ae75b0f5ce21" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="simple" xlink:href="ino-20201231.xsd#PrepaidExpensesandOtherCurrentAssets"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="extended" id="ic4dc2e3a2bad47579bb9e79d9745c923_PrepaidExpensesandOtherCurrentAssets"/>
  <link:roleRef roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="simple" xlink:href="ino-20201231.xsd#PrepaidExpensesandOtherCurrentAssetsTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="extended" id="i3b42107ce82a4842ba0db5b303f1aa54_PrepaidExpensesandOtherCurrentAssetsTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#PrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended" id="i6cf184d1024a45e6bb6d1f1177fbcc54_PrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssets" xlink:type="simple" xlink:href="ino-20201231.xsd#FixedAssets"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FixedAssets" xlink:type="extended" id="i2e9910d1b0cb4a619e7de023f8e6dfc8_FixedAssets"/>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsTables" xlink:type="simple" xlink:href="ino-20201231.xsd#FixedAssetsTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FixedAssetsTables" xlink:type="extended" id="i9591e030760b42ad9af92c1e966d1a91_FixedAssetsTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#FixedAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="extended" id="ib528a3e3587344cab321cb5b8ab81948_FixedAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4dbef8aa-554d-4bed-8fce-397f71b32d7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_25515352-017e-4413-8042-af101f9d2744" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4dbef8aa-554d-4bed-8fce-397f71b32d7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_25515352-017e-4413-8042-af101f9d2744" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_044c7ab0-1af6-46e8-bc24-acef24c05b48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4dbef8aa-554d-4bed-8fce-397f71b32d7c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_044c7ab0-1af6-46e8-bc24-acef24c05b48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e3187ad1-fec3-49d1-a21e-3b6943ec86da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4dbef8aa-554d-4bed-8fce-397f71b32d7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e3187ad1-fec3-49d1-a21e-3b6943ec86da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_38b2561a-0bfd-474b-94fe-9a63c45f170f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4dbef8aa-554d-4bed-8fce-397f71b32d7c" xlink:to="loc_us-gaap_Depreciation_38b2561a-0bfd-474b-94fe-9a63c45f170f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_6589a7a8-873d-4da6-9c88-e693da508d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4dbef8aa-554d-4bed-8fce-397f71b32d7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_6589a7a8-873d-4da6-9c88-e693da508d8c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_2537dd50-7b3f-44c1-80c3-29b5d7a20389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4dbef8aa-554d-4bed-8fce-397f71b32d7c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_2537dd50-7b3f-44c1-80c3-29b5d7a20389" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_93c7d793-4914-4b36-ba1a-f100a4f36cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4dbef8aa-554d-4bed-8fce-397f71b32d7c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_93c7d793-4914-4b36-ba1a-f100a4f36cd0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_efeb3bfa-1f5c-4d46-a298-fefeb9987376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_93c7d793-4914-4b36-ba1a-f100a4f36cd0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_efeb3bfa-1f5c-4d46-a298-fefeb9987376" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_efeb3bfa-1f5c-4d46-a298-fefeb9987376_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_efeb3bfa-1f5c-4d46-a298-fefeb9987376" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_efeb3bfa-1f5c-4d46-a298-fefeb9987376_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_610885c4-b223-43fa-9ab3-fe47ac2bace5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_efeb3bfa-1f5c-4d46-a298-fefeb9987376" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_610885c4-b223-43fa-9ab3-fe47ac2bace5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_37cd6fe4-42ae-4000-8696-9be9721f64fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_610885c4-b223-43fa-9ab3-fe47ac2bace5" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_37cd6fe4-42ae-4000-8696-9be9721f64fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_c7d574ef-45e8-4285-b856-58fd05fe3140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_610885c4-b223-43fa-9ab3-fe47ac2bace5" xlink:to="loc_us-gaap_OfficeEquipmentMember_c7d574ef-45e8-4285-b856-58fd05fe3140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3b1658bd-0626-49c4-9fe2-c239ad58382d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_610885c4-b223-43fa-9ab3-fe47ac2bace5" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3b1658bd-0626-49c4-9fe2-c239ad58382d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_14af96a3-cf32-4897-ba16-df563fec05e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_610885c4-b223-43fa-9ab3-fe47ac2bace5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_14af96a3-cf32-4897-ba16-df563fec05e5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="ino-20201231.xsd#GoodwillandIntangibleAssets"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="extended" id="ie67a8c758fae4d78b7459e740f4cf7c1_GoodwillandIntangibleAssets"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="ino-20201231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended" id="iaf9ecd3063074765867dfcd6afae2dd2_GoodwillandIntangibleAssetsTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" xlink:type="extended" id="idf566660ba974ae0bb414dc4e66f2550_GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5678115e-23ce-4368-99bd-6e23a5076c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4b1fea36-7a1b-46f8-9329-eb0376af19c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5678115e-23ce-4368-99bd-6e23a5076c38" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4b1fea36-7a1b-46f8-9329-eb0376af19c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f535af2b-dc55-4b65-8be1-034719ef575f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4b1fea36-7a1b-46f8-9329-eb0376af19c0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f535af2b-dc55-4b65-8be1-034719ef575f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c8e6cea0-f8ed-4be9-b7b4-d54848b1f94d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4b1fea36-7a1b-46f8-9329-eb0376af19c0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c8e6cea0-f8ed-4be9-b7b4-d54848b1f94d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f11cac19-9903-462a-baa5-490ac435d1f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c8e6cea0-f8ed-4be9-b7b4-d54848b1f94d" xlink:to="loc_us-gaap_Goodwill_f11cac19-9903-462a-baa5-490ac435d1f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d445bc62-d2bc-48f4-abd4-e60cb0594749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4b1fea36-7a1b-46f8-9329-eb0376af19c0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d445bc62-d2bc-48f4-abd4-e60cb0594749" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9a5299f7-33c8-46e3-986e-36981d88e5ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d445bc62-d2bc-48f4-abd4-e60cb0594749" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9a5299f7-33c8-46e3-986e-36981d88e5ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_05cfb2ab-7cd9-4f1d-8d4a-603e4b828b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d445bc62-d2bc-48f4-abd4-e60cb0594749" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_05cfb2ab-7cd9-4f1d-8d4a-603e4b828b2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6dbb46fd-13f4-474e-81b8-39eace6e6a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d445bc62-d2bc-48f4-abd4-e60cb0594749" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6dbb46fd-13f4-474e-81b8-39eace6e6a05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_a5a4f353-39eb-4c18-8c8a-ced8a82571a7" xlink:href="ino-20201231.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4b1fea36-7a1b-46f8-9329-eb0376af19c0" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_a5a4f353-39eb-4c18-8c8a-ced8a82571a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_a101b3e9-dc37-4690-ad8a-0fede3b97946" xlink:href="ino-20201231.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4b1fea36-7a1b-46f8-9329-eb0376af19c0" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_a101b3e9-dc37-4690-ad8a-0fede3b97946" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_944cfcdb-801d-413d-b536-2ebe29207a25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5678115e-23ce-4368-99bd-6e23a5076c38" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_944cfcdb-801d-413d-b536-2ebe29207a25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50a27cc4-bd02-47f4-8192-1e917099bde8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_944cfcdb-801d-413d-b536-2ebe29207a25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50a27cc4-bd02-47f4-8192-1e917099bde8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_50a27cc4-bd02-47f4-8192-1e917099bde8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50a27cc4-bd02-47f4-8192-1e917099bde8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_50a27cc4-bd02-47f4-8192-1e917099bde8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5375a52f-69ec-4964-80e3-1269f8583d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50a27cc4-bd02-47f4-8192-1e917099bde8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5375a52f-69ec-4964-80e3-1269f8583d6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b133c39d-3035-43d1-a99b-660150927847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5375a52f-69ec-4964-80e3-1269f8583d6a" xlink:to="loc_us-gaap_LicensingAgreementsMember_b133c39d-3035-43d1-a99b-660150927847" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_851dadb2-21d9-46bb-ae30-7ca26dd96ee6" xlink:href="ino-20201231.xsd#ino_BiojectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5375a52f-69ec-4964-80e3-1269f8583d6a" xlink:to="loc_ino_BiojectMember_851dadb2-21d9-46bb-ae30-7ca26dd96ee6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_3834ce21-51f6-4143-b587-3c71c16f534a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5375a52f-69ec-4964-80e3-1269f8583d6a" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_3834ce21-51f6-4143-b587-3c71c16f534a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ab522534-dfc0-4223-9cb1-e758a6206741" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_944cfcdb-801d-413d-b536-2ebe29207a25" xlink:to="loc_srt_RangeAxis_ab522534-dfc0-4223-9cb1-e758a6206741" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ab522534-dfc0-4223-9cb1-e758a6206741_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ab522534-dfc0-4223-9cb1-e758a6206741" xlink:to="loc_srt_RangeMember_ab522534-dfc0-4223-9cb1-e758a6206741_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0bdeee09-48d8-4323-9af0-0b69ea136445" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ab522534-dfc0-4223-9cb1-e758a6206741" xlink:to="loc_srt_RangeMember_0bdeee09-48d8-4323-9af0-0b69ea136445" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_3cfde46b-62c8-43b9-9612-a6c48930e324" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0bdeee09-48d8-4323-9af0-0b69ea136445" xlink:to="loc_srt_WeightedAverageMember_3cfde46b-62c8-43b9-9612-a6c48930e324" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b318ccb8-34fb-4392-a5a6-5616d6bc88e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_944cfcdb-801d-413d-b536-2ebe29207a25" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b318ccb8-34fb-4392-a5a6-5616d6bc88e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b318ccb8-34fb-4392-a5a6-5616d6bc88e8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b318ccb8-34fb-4392-a5a6-5616d6bc88e8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b318ccb8-34fb-4392-a5a6-5616d6bc88e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d3506df6-61aa-4b5b-a474-da0bdd9fd3ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b318ccb8-34fb-4392-a5a6-5616d6bc88e8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d3506df6-61aa-4b5b-a474-da0bdd9fd3ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_033beb81-338c-4b35-b027-391b1575829b" xlink:href="ino-20201231.xsd#ino_BiojectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d3506df6-61aa-4b5b-a474-da0bdd9fd3ea" xlink:to="loc_ino_BiojectMember_033beb81-338c-4b35-b027-391b1575829b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended" id="i36a7834c10154bb3ad2764f49e565daf_GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="extended" id="i48ac7bd9ce964fd8b8c114afd21e4cfd_GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:type="simple" xlink:href="ino-20201231.xsd#ConvertibleDebt"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended" id="if098f648f58a43c0b7276d19ca9f3bfc_ConvertibleDebt"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="simple" xlink:href="ino-20201231.xsd#ConvertibleDebtTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended" id="i3fcbe5e85516439ba884c836d42320e2_ConvertibleDebtTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended" id="i7b2c05552c0c49d1940691cd1f331380_ConvertibleDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_98f361a7-063d-4697-80bf-c32728fd4f01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_98f361a7-063d-4697-80bf-c32728fd4f01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_49d44d73-a7cc-4be0-8dd1-613e4a88acd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_49d44d73-a7cc-4be0-8dd1-613e4a88acd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_d5175e75-22b4-424a-8994-0e8bc0279894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_d5175e75-22b4-424a-8994-0e8bc0279894" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_64df274b-e2b3-4e25-bf65-225a20e54e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_64df274b-e2b3-4e25-bf65-225a20e54e7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_59e7760a-fb9c-4eac-a881-45be3ec18b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_59e7760a-fb9c-4eac-a881-45be3ec18b3b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_86c72cda-e57a-401a-ad2b-0380eb37194e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_86c72cda-e57a-401a-ad2b-0380eb37194e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_77ee6d22-de35-49f4-8c38-e4ce86dc5659" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_77ee6d22-de35-49f4-8c38-e4ce86dc5659" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2db71f52-4e1a-42c3-b8e4-edba40111bff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2db71f52-4e1a-42c3-b8e4-edba40111bff" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_40b33847-130a-44d4-8e6e-cb2bf5338578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_40b33847-130a-44d4-8e6e-cb2bf5338578" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_880a1faf-ed22-42de-919c-4e07f297f951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_LongTermDebtFairValue_880a1faf-ed22-42de-919c-4e07f297f951" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_256adef1-30aa-4554-a3fc-1b1026c30365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_256adef1-30aa-4554-a3fc-1b1026c30365" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_938cacb2-8785-4560-a6f7-3bc67d77a9e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_938cacb2-8785-4560-a6f7-3bc67d77a9e4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_25846e42-18cd-4e1a-820b-c4c1e2943404" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_25846e42-18cd-4e1a-820b-c4c1e2943404" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4d3b6366-c582-46bf-b087-1805ed74304f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4d3b6366-c582-46bf-b087-1805ed74304f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_bd459e0a-eaf0-413e-acb8-54ef06430a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_bd459e0a-eaf0-413e-acb8-54ef06430a0e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_7d27e6e1-62f8-4eb3-964f-b4cb334decf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentFairValue_7d27e6e1-62f8-4eb3-964f-b4cb334decf5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_0e52dcb7-a93f-484b-b8bf-06a937144038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_0e52dcb7-a93f-484b-b8bf-06a937144038" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3fecffab-3f8e-4ec6-9828-65a042811390" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3fecffab-3f8e-4ec6-9828-65a042811390" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ea44add7-563f-4e97-a262-5984afb61356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_InterestExpense_ea44add7-563f-4e97-a262-5984afb61356" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_334d229e-3079-48f1-90d9-e7a2cf60a46f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_InterestExpenseDebt_334d229e-3079-48f1-90d9-e7a2cf60a46f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_9a396004-f8ee-4b07-80cd-4c83a7f03a88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_9a396004-f8ee-4b07-80cd-4c83a7f03a88" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_426d647f-733f-416a-a417-ba4f0779bff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_426d647f-733f-416a-a417-ba4f0779bff7" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_d878b1d9-e865-468b-8476-5d3667368a3f" xlink:href="ino-20201231.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_d878b1d9-e865-468b-8476-5d3667368a3f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_82d6d2d4-3ab2-44cd-a886-0c39465fa5f6" xlink:href="ino-20201231.xsd#ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_82d6d2d4-3ab2-44cd-a886-0c39465fa5f6" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cc7b4fdc-fdf0-4c84-bad2-6be87aa52327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentTable_cc7b4fdc-fdf0-4c84-bad2-6be87aa52327" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c8f6daa6-f415-4454-bc54-8743c169f9ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cc7b4fdc-fdf0-4c84-bad2-6be87aa52327" xlink:to="loc_us-gaap_DebtInstrumentAxis_c8f6daa6-f415-4454-bc54-8743c169f9ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c8f6daa6-f415-4454-bc54-8743c169f9ee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c8f6daa6-f415-4454-bc54-8743c169f9ee" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c8f6daa6-f415-4454-bc54-8743c169f9ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f17e3ff3-26c2-430e-a794-e064138c8ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c8f6daa6-f415-4454-bc54-8743c169f9ee" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f17e3ff3-26c2-430e-a794-e064138c8ff5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_c8d1571f-c533-4a8c-9189-675a4edae676" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f17e3ff3-26c2-430e-a794-e064138c8ff5" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_c8d1571f-c533-4a8c-9189-675a4edae676" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_92909ca7-5776-41d4-b1e1-6cf68f2cf9a8" xlink:href="ino-20201231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f17e3ff3-26c2-430e-a794-e064138c8ff5" xlink:to="loc_ino_August2019ConvertibleBondsMember_92909ca7-5776-41d4-b1e1-6cf68f2cf9a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_1e94e427-f3c7-465f-b363-afe21f0abbcd" xlink:href="ino-20201231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f17e3ff3-26c2-430e-a794-e064138c8ff5" xlink:to="loc_ino_December2019ConvertibleBondsMember_1e94e427-f3c7-465f-b363-afe21f0abbcd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0186c36b-aa7e-485e-91aa-40db9767134e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cc7b4fdc-fdf0-4c84-bad2-6be87aa52327" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0186c36b-aa7e-485e-91aa-40db9767134e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0186c36b-aa7e-485e-91aa-40db9767134e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0186c36b-aa7e-485e-91aa-40db9767134e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0186c36b-aa7e-485e-91aa-40db9767134e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b4562cf8-ce9c-4cc3-9b50-43e5d5785166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0186c36b-aa7e-485e-91aa-40db9767134e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b4562cf8-ce9c-4cc3-9b50-43e5d5785166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_9d0f2675-76ab-45f1-a0c3-92ff0d9d6925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b4562cf8-ce9c-4cc3-9b50-43e5d5785166" xlink:to="loc_us-gaap_ConvertibleDebtMember_9d0f2675-76ab-45f1-a0c3-92ff0d9d6925" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_02af9a07-6f5c-4a2a-8509-3c800045a279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cc7b4fdc-fdf0-4c84-bad2-6be87aa52327" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_02af9a07-6f5c-4a2a-8509-3c800045a279" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_02af9a07-6f5c-4a2a-8509-3c800045a279_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_02af9a07-6f5c-4a2a-8509-3c800045a279" xlink:to="loc_us-gaap_DebtConversionNameDomain_02af9a07-6f5c-4a2a-8509-3c800045a279_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_fc73def8-9e4e-4307-98a9-a1e601c1c2dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_02af9a07-6f5c-4a2a-8509-3c800045a279" xlink:to="loc_us-gaap_DebtConversionNameDomain_fc73def8-9e4e-4307-98a9-a1e601c1c2dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InitialConversionPriceMember_5f28cdb2-dbcf-40a9-a7cc-b1014bf87c9f" xlink:href="ino-20201231.xsd#ino_InitialConversionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_fc73def8-9e4e-4307-98a9-a1e601c1c2dd" xlink:to="loc_ino_InitialConversionPriceMember_5f28cdb2-dbcf-40a9-a7cc-b1014bf87c9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AfterJanuary22020ConversionPriceMember_bcac6122-e974-47c6-87df-ca497bea0008" xlink:href="ino-20201231.xsd#ino_AfterJanuary22020ConversionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_fc73def8-9e4e-4307-98a9-a1e601c1c2dd" xlink:to="loc_ino_AfterJanuary22020ConversionPriceMember_bcac6122-e974-47c6-87df-ca497bea0008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AfterJuly22020ConversionPriceMember_09831c1a-19c1-4335-8f08-815b94c4151b" xlink:href="ino-20201231.xsd#ino_AfterJuly22020ConversionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_fc73def8-9e4e-4307-98a9-a1e601c1c2dd" xlink:to="loc_ino_AfterJuly22020ConversionPriceMember_09831c1a-19c1-4335-8f08-815b94c4151b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_20140f44-0adb-4e40-8fe7-0c4fdaa74a4b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cc7b4fdc-fdf0-4c84-bad2-6be87aa52327" xlink:to="loc_srt_RangeAxis_20140f44-0adb-4e40-8fe7-0c4fdaa74a4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_20140f44-0adb-4e40-8fe7-0c4fdaa74a4b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_20140f44-0adb-4e40-8fe7-0c4fdaa74a4b" xlink:to="loc_srt_RangeMember_20140f44-0adb-4e40-8fe7-0c4fdaa74a4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_94fc1a1f-96bc-462f-adeb-5d2f6679fdbe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_20140f44-0adb-4e40-8fe7-0c4fdaa74a4b" xlink:to="loc_srt_RangeMember_94fc1a1f-96bc-462f-adeb-5d2f6679fdbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e7822426-e56a-4a6c-9dfe-ad7544e4af73" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_94fc1a1f-96bc-462f-adeb-5d2f6679fdbe" xlink:to="loc_srt_MaximumMember_e7822426-e56a-4a6c-9dfe-ad7544e4af73" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#ConvertibleDebtBalanceOfConvertibleDebtDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="extended" id="i0aa80c4c94b94ef381fd91c6775c0d1e_ConvertibleDebtBalanceOfConvertibleDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e0da9fd0-afc7-435d-ab9b-1fdc55f71215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a041e799-3d99-4bc5-9dfb-cfeb6239ef7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0da9fd0-afc7-435d-ab9b-1fdc55f71215" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a041e799-3d99-4bc5-9dfb-cfeb6239ef7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_1e7c5284-5a60-4fb8-9328-d289f8093c88" xlink:href="ino-20201231.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0da9fd0-afc7-435d-ab9b-1fdc55f71215" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_1e7c5284-5a60-4fb8-9328-d289f8093c88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_22a978a6-b5ef-4b05-a394-049bc55e3d69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0da9fd0-afc7-435d-ab9b-1fdc55f71215" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_22a978a6-b5ef-4b05-a394-049bc55e3d69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_fc832b3a-dd29-4d05-a620-77cbc17f09cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0da9fd0-afc7-435d-ab9b-1fdc55f71215" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_fc832b3a-dd29-4d05-a620-77cbc17f09cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccretionOfPremium_a168ba4b-ac97-4d7c-b082-1ee8ccae6a6d" xlink:href="ino-20201231.xsd#ino_DebtInstrumentAccretionOfPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0da9fd0-afc7-435d-ab9b-1fdc55f71215" xlink:to="loc_ino_DebtInstrumentAccretionOfPremium_a168ba4b-ac97-4d7c-b082-1ee8ccae6a6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtinstrumentAccruedInterest_d9801568-dc43-4ead-b6cd-d7344b6888ec" xlink:href="ino-20201231.xsd#ino_DebtinstrumentAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0da9fd0-afc7-435d-ab9b-1fdc55f71215" xlink:to="loc_ino_DebtinstrumentAccruedInterest_d9801568-dc43-4ead-b6cd-d7344b6888ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_41af9216-ca8e-4223-a3d4-3320a514c42d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0da9fd0-afc7-435d-ab9b-1fdc55f71215" xlink:to="loc_us-gaap_LongTermDebt_41af9216-ca8e-4223-a3d4-3320a514c42d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_897c89ff-9ee6-490f-aef9-f62a749b356c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0da9fd0-afc7-435d-ab9b-1fdc55f71215" xlink:to="loc_us-gaap_DebtInstrumentTable_897c89ff-9ee6-490f-aef9-f62a749b356c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c449c5fe-02fb-4258-a9b8-99c9a2ca7417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_897c89ff-9ee6-490f-aef9-f62a749b356c" xlink:to="loc_us-gaap_DebtInstrumentAxis_c449c5fe-02fb-4258-a9b8-99c9a2ca7417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c449c5fe-02fb-4258-a9b8-99c9a2ca7417_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c449c5fe-02fb-4258-a9b8-99c9a2ca7417" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c449c5fe-02fb-4258-a9b8-99c9a2ca7417_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c7c4bcc4-1b80-4b07-850a-60fa109dc029" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c449c5fe-02fb-4258-a9b8-99c9a2ca7417" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c7c4bcc4-1b80-4b07-850a-60fa109dc029" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_187323c8-e7a6-4ddf-b89f-8676d7df8f26" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7c4bcc4-1b80-4b07-850a-60fa109dc029" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_187323c8-e7a6-4ddf-b89f-8676d7df8f26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_c0b86d44-dfa9-462e-98c0-7730ae739e84" xlink:href="ino-20201231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7c4bcc4-1b80-4b07-850a-60fa109dc029" xlink:to="loc_ino_December2019ConvertibleBondsMember_c0b86d44-dfa9-462e-98c0-7730ae739e84" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended" id="i464cda970a6d4e28b1ff2aaf64968746_ConvertibleDebtScheduleofMaturitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9ff5dfbe-c9e1-4926-8ce9-0a0d44061fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d3a04899-1f8c-4d37-b856-97e8a997cebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ff5dfbe-c9e1-4926-8ce9-0a0d44061fca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d3a04899-1f8c-4d37-b856-97e8a997cebf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_64fb2bea-a73b-43e1-b51c-62854ac6f9e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ff5dfbe-c9e1-4926-8ce9-0a0d44061fca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_64fb2bea-a73b-43e1-b51c-62854ac6f9e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_dea14040-6904-4c69-b3ef-0cdc154ecd75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ff5dfbe-c9e1-4926-8ce9-0a0d44061fca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_dea14040-6904-4c69-b3ef-0cdc154ecd75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_b01228b3-d328-4952-be83-07381c06a802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ff5dfbe-c9e1-4926-8ce9-0a0d44061fca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_b01228b3-d328-4952-be83-07381c06a802" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f9613119-5e9e-42ac-a9c8-ad441d9af2f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ff5dfbe-c9e1-4926-8ce9-0a0d44061fca" xlink:to="loc_us-gaap_LongTermDebt_f9613119-5e9e-42ac-a9c8-ad441d9af2f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_061ca5fb-1fdc-43be-9206-f8982b7c6ac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ff5dfbe-c9e1-4926-8ce9-0a0d44061fca" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_061ca5fb-1fdc-43be-9206-f8982b7c6ac1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_97e04374-6f09-4ab8-81d2-ed0a9cff9308" xlink:href="ino-20201231.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ff5dfbe-c9e1-4926-8ce9-0a0d44061fca" xlink:to="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_97e04374-6f09-4ab8-81d2-ed0a9cff9308" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ef70f8f8-dfcb-4894-9e08-8c8031e265fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ff5dfbe-c9e1-4926-8ce9-0a0d44061fca" xlink:to="loc_us-gaap_DebtInstrumentTable_ef70f8f8-dfcb-4894-9e08-8c8031e265fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_910bbe96-234f-4049-8a9d-9ef862e27b28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ef70f8f8-dfcb-4894-9e08-8c8031e265fc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_910bbe96-234f-4049-8a9d-9ef862e27b28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_910bbe96-234f-4049-8a9d-9ef862e27b28_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_910bbe96-234f-4049-8a9d-9ef862e27b28" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_910bbe96-234f-4049-8a9d-9ef862e27b28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cdbb8c75-9783-4082-b362-a8e98aaf7efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_910bbe96-234f-4049-8a9d-9ef862e27b28" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cdbb8c75-9783-4082-b362-a8e98aaf7efd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_9a56e67e-2807-4986-b40b-bb24b745d2d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cdbb8c75-9783-4082-b362-a8e98aaf7efd" xlink:to="loc_us-gaap_ConvertibleDebtMember_9a56e67e-2807-4986-b40b-bb24b745d2d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e9f8f8e5-84cd-4263-b6b5-0e53de2e56d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ef70f8f8-dfcb-4894-9e08-8c8031e265fc" xlink:to="loc_us-gaap_DebtInstrumentAxis_e9f8f8e5-84cd-4263-b6b5-0e53de2e56d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e9f8f8e5-84cd-4263-b6b5-0e53de2e56d3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e9f8f8e5-84cd-4263-b6b5-0e53de2e56d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e9f8f8e5-84cd-4263-b6b5-0e53de2e56d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_99c002ca-1c20-4625-94eb-1a0ad42ade7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e9f8f8e5-84cd-4263-b6b5-0e53de2e56d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_99c002ca-1c20-4625-94eb-1a0ad42ade7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_66579fc5-0d81-4f7c-8ff4-3c04fbe274d2" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_99c002ca-1c20-4625-94eb-1a0ad42ade7a" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_66579fc5-0d81-4f7c-8ff4-3c04fbe274d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_41487b46-0f9b-4ac8-a70c-0c86ab086557" xlink:href="ino-20201231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_99c002ca-1c20-4625-94eb-1a0ad42ade7a" xlink:to="loc_ino_December2019ConvertibleBondsMember_41487b46-0f9b-4ac8-a70c-0c86ab086557" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableandAccruedExpenses" xlink:type="simple" xlink:href="ino-20201231.xsd#AccountsPayableandAccruedExpenses"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/AccountsPayableandAccruedExpenses" xlink:type="extended" id="id9b49b02f5344f2c96a308a09b3133bc_AccountsPayableandAccruedExpenses"/>
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableandAccruedExpensesTables" xlink:type="simple" xlink:href="ino-20201231.xsd#AccountsPayableandAccruedExpensesTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended" id="ib5a8c82eaee14fcfb0fa79ad75364db6_AccountsPayableandAccruedExpensesTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#AccountsPayableandAccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails" xlink:type="extended" id="ic997cd91edca463db59a66b9d95d7ddc_AccountsPayableandAccruedExpensesDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended" id="i002ca0a0487441b69b3b9ef77d22748a_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended" id="ib1f77ccadf0e407485889fa39ce153d7_StockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquitySummaryofPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="extended" id="i29bdfdb8d4e54afb83585ef5d292e05f_StockholdersEquitySummaryofPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_26eadc8b-ff83-4a91-b71f-a0e491adf944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_442c0e84-c2f1-4dc2-994f-6afc3da87827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_26eadc8b-ff83-4a91-b71f-a0e491adf944" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_442c0e84-c2f1-4dc2-994f-6afc3da87827" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_db063d08-3923-4f9d-b0cb-2d1ee6c6525f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_442c0e84-c2f1-4dc2-994f-6afc3da87827" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_db063d08-3923-4f9d-b0cb-2d1ee6c6525f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b25f1e97-a95a-47fe-b5e8-3f3ae01718a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_442c0e84-c2f1-4dc2-994f-6afc3da87827" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b25f1e97-a95a-47fe-b5e8-3f3ae01718a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_41cd84f5-cfb5-456d-b9c9-140b93844f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_442c0e84-c2f1-4dc2-994f-6afc3da87827" xlink:to="loc_us-gaap_PreferredStockSharesIssued_41cd84f5-cfb5-456d-b9c9-140b93844f7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_28f841eb-a4b2-4f61-b690-ab7726d7a190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_442c0e84-c2f1-4dc2-994f-6afc3da87827" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_28f841eb-a4b2-4f61-b690-ab7726d7a190" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_14a84d2b-c486-4109-b1a7-7c0dea0b8443" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_26eadc8b-ff83-4a91-b71f-a0e491adf944" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_14a84d2b-c486-4109-b1a7-7c0dea0b8443" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_163809b9-aa0c-49bb-a07f-54ae00279e1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_14a84d2b-c486-4109-b1a7-7c0dea0b8443" xlink:to="loc_us-gaap_StatementClassOfStockAxis_163809b9-aa0c-49bb-a07f-54ae00279e1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_163809b9-aa0c-49bb-a07f-54ae00279e1f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_163809b9-aa0c-49bb-a07f-54ae00279e1f" xlink:to="loc_us-gaap_ClassOfStockDomain_163809b9-aa0c-49bb-a07f-54ae00279e1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d8bb9b4a-91ca-4544-8468-b723f48df8db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_163809b9-aa0c-49bb-a07f-54ae00279e1f" xlink:to="loc_us-gaap_ClassOfStockDomain_d8bb9b4a-91ca-4544-8468-b723f48df8db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_b0cccd12-d4ab-47f3-b36a-3bd591b45e88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d8bb9b4a-91ca-4544-8468-b723f48df8db" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_b0cccd12-d4ab-47f3-b36a-3bd591b45e88" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="ice7fc35477c4465eb9fc54553b51cbbe_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_20ab4f29-201a-468f-b806-c119ddd6ac27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_20ab4f29-201a-468f-b806-c119ddd6ac27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_4086ded1-5de1-439a-b853-164c87fc90ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_4086ded1-5de1-439a-b853-164c87fc90ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_fa051375-df6b-4c0a-88bc-4d83ca08fe23" xlink:href="ino-20201231.xsd#ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_fa051375-df6b-4c0a-88bc-4d83ca08fe23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_078f7b86-07f0-40d2-bfdd-e1f481327a88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_078f7b86-07f0-40d2-bfdd-e1f481327a88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_a2466c18-82cc-4fcd-8ca6-74b15c560367" xlink:href="ino-20201231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_a2466c18-82cc-4fcd-8ca6-74b15c560367" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_8c15db9a-dd46-4465-a21e-9591dc84ba11" xlink:href="ino-20201231.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_8c15db9a-dd46-4465-a21e-9591dc84ba11" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementAgentFee_a05bf359-2ec5-4dec-ab09-8afc4076a086" xlink:href="ino-20201231.xsd#ino_StockSalesAgreementAgentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_StockSalesAgreementAgentFee_a05bf359-2ec5-4dec-ab09-8afc4076a086" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_b2204978-a7d2-4c06-bcaa-4e3c7c0b778e" xlink:href="ino-20201231.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_b2204978-a7d2-4c06-bcaa-4e3c7c0b778e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_21f36472-0ba0-4304-9bdb-f9be8e852d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_21f36472-0ba0-4304-9bdb-f9be8e852d7e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_743492d0-31cf-4aa2-8b18-d7d9632d8089" xlink:href="ino-20201231.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_743492d0-31cf-4aa2-8b18-d7d9632d8089" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d8e61556-29e9-461f-b3a6-f8aaac8f8095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d8e61556-29e9-461f-b3a6-f8aaac8f8095" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_d0815c7b-e92f-47db-84d9-9e3d653a6bc7" xlink:href="ino-20201231.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_d0815c7b-e92f-47db-84d9-9e3d653a6bc7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_742f9d58-5a2e-42f1-b5d7-608a0934f72c" xlink:href="ino-20201231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_742f9d58-5a2e-42f1-b5d7-608a0934f72c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_15760307-3727-4af6-9385-ed579b16cce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_15760307-3727-4af6-9385-ed579b16cce4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_a7451dcf-de2d-4fb4-a23a-25a6278a2715" xlink:href="ino-20201231.xsd#ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_a7451dcf-de2d-4fb4-a23a-25a6278a2715" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_da0f7cac-ec27-413c-b17f-b74e296ef10b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_da0f7cac-ec27-413c-b17f-b74e296ef10b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fee91e9c-382f-4e5f-812d-aaf79bbf1f95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fee91e9c-382f-4e5f-812d-aaf79bbf1f95" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_a473defe-5874-4858-a744-6fa574c46821" xlink:href="ino-20201231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_a473defe-5874-4858-a744-6fa574c46821" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_660524d9-6d74-4e6e-9d34-170bf84f4490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensation_660524d9-6d74-4e6e-9d34-170bf84f4490" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_939f47f3-842b-4957-8cd7-5d8f580de868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_939f47f3-842b-4957-8cd7-5d8f580de868" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0d6f3d41-f59e-4e5a-9407-c7e3129f7d69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0d6f3d41-f59e-4e5a-9407-c7e3129f7d69" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ea3a2c9b-2e2b-410f-9ab6-79dde5078cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ea3a2c9b-2e2b-410f-9ab6-79dde5078cb4" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3ab8b0ec-bd0a-41b5-bb72-d09d01948396" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3ab8b0ec-bd0a-41b5-bb72-d09d01948396" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_d83c3142-fc5a-43a4-ac11-25927db45270" xlink:href="ino-20201231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_d83c3142-fc5a-43a4-ac11-25927db45270" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a6bbc332-3237-42c8-bcc8-0a75d80f8a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a6bbc332-3237-42c8-bcc8-0a75d80f8a0d" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_8a80062d-3dc5-4695-adb1-b1f3d04c4db9" xlink:href="ino-20201231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_8a80062d-3dc5-4695-adb1-b1f3d04c4db9" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_4cc13eab-5ae2-4b47-8193-2b922f6300b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_4cc13eab-5ae2-4b47-8193-2b922f6300b3" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c8991361-ae74-4f8c-80dd-a523f70441c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c8991361-ae74-4f8c-80dd-a523f70441c7" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_d092adcb-8a06-475e-86ff-4086be826dd7" xlink:href="ino-20201231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_d092adcb-8a06-475e-86ff-4086be826dd7" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_a8f7f024-2f20-4db6-9a4c-332804756764" xlink:href="ino-20201231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_a8f7f024-2f20-4db6-9a4c-332804756764" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_29dd0712-db62-4378-8787-58599aab640d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_29dd0712-db62-4378-8787-58599aab640d" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_125ecbc0-462c-4733-9c06-c7f9c8f5c18c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_125ecbc0-462c-4733-9c06-c7f9c8f5c18c" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cfdc25b1-0781-48d0-892e-73fe16792b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cfdc25b1-0781-48d0-892e-73fe16792b2c" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c9d7789a-561f-4eae-ba26-f2eabe0e06b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c9d7789a-561f-4eae-ba26-f2eabe0e06b2" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d938a9e5-9ac4-4872-8d90-a21f655ece75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d938a9e5-9ac4-4872-8d90-a21f655ece75" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_44b0f9eb-9b08-4e2c-825b-bcc83330c36d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_44b0f9eb-9b08-4e2c-825b-bcc83330c36d" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0a2c8efe-f6cb-4797-ad3e-aa45cab0ee34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0a2c8efe-f6cb-4797-ad3e-aa45cab0ee34" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dc96bf86-ec45-4e0e-a4cb-e8b504ae6b4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dc96bf86-ec45-4e0e-a4cb-e8b504ae6b4b" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_99323855-3423-4de3-b598-5263e18d7c50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_1ba435d6-8fab-4d31-a5fa-6b4492e47540" xlink:href="ino-20201231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_1ba435d6-8fab-4d31-a5fa-6b4492e47540" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a5b0391d-1661-4f59-a6c1-524ba64a9c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a5b0391d-1661-4f59-a6c1-524ba64a9c24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3967766a-6601-4e70-8c5f-2b208d946244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a5b0391d-1661-4f59-a6c1-524ba64a9c24" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3967766a-6601-4e70-8c5f-2b208d946244" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3967766a-6601-4e70-8c5f-2b208d946244_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3967766a-6601-4e70-8c5f-2b208d946244" xlink:to="loc_us-gaap_ClassOfStockDomain_3967766a-6601-4e70-8c5f-2b208d946244_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_86cbd085-ed43-46b0-b1e4-82a1283945ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3967766a-6601-4e70-8c5f-2b208d946244" xlink:to="loc_us-gaap_ClassOfStockDomain_86cbd085-ed43-46b0-b1e4-82a1283945ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_7d1a1130-aa2e-48b3-bdd8-c58a68658e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_86cbd085-ed43-46b0-b1e4-82a1283945ec" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_7d1a1130-aa2e-48b3-bdd8-c58a68658e0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f984634c-088a-4721-9b74-bebbec56dbe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_86cbd085-ed43-46b0-b1e4-82a1283945ec" xlink:to="loc_us-gaap_CommonStockMember_f984634c-088a-4721-9b74-bebbec56dbe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_86ad86df-f944-44e0-a3e0-2614841f2814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a5b0391d-1661-4f59-a6c1-524ba64a9c24" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_86ad86df-f944-44e0-a3e0-2614841f2814" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86ad86df-f944-44e0-a3e0-2614841f2814_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_86ad86df-f944-44e0-a3e0-2614841f2814" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86ad86df-f944-44e0-a3e0-2614841f2814_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b6315a05-2ede-4930-93a6-b567593ff254" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_86ad86df-f944-44e0-a3e0-2614841f2814" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b6315a05-2ede-4930-93a6-b567593ff254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_ae4e7fe1-11be-4ee5-89e0-bfb6ccc1a2c5" xlink:href="ino-20201231.xsd#ino_SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b6315a05-2ede-4930-93a6-b567593ff254" xlink:to="loc_ino_SalesAgreementMember_ae4e7fe1-11be-4ee5-89e0-bfb6ccc1a2c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PriorSalesAgreementMember_9499b054-fc15-40f5-b2ee-476f122b4b86" xlink:href="ino-20201231.xsd#ino_PriorSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b6315a05-2ede-4930-93a6-b567593ff254" xlink:to="loc_ino_PriorSalesAgreementMember_9499b054-fc15-40f5-b2ee-476f122b4b86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NewSalesAgreementMember_a38a07bb-1e2b-4396-8a68-ee8fdaf1fa1c" xlink:href="ino-20201231.xsd#ino_NewSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b6315a05-2ede-4930-93a6-b567593ff254" xlink:to="loc_ino_NewSalesAgreementMember_a38a07bb-1e2b-4396-8a68-ee8fdaf1fa1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ca3f757e-c1f0-47c9-8e49-e02a647d8956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a5b0391d-1661-4f59-a6c1-524ba64a9c24" xlink:to="loc_us-gaap_PlanNameAxis_ca3f757e-c1f0-47c9-8e49-e02a647d8956" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ca3f757e-c1f0-47c9-8e49-e02a647d8956_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ca3f757e-c1f0-47c9-8e49-e02a647d8956" xlink:to="loc_us-gaap_PlanNameDomain_ca3f757e-c1f0-47c9-8e49-e02a647d8956_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ac2dd9d3-4483-4e9e-b3a6-6bf84fab265f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ca3f757e-c1f0-47c9-8e49-e02a647d8956" xlink:to="loc_us-gaap_PlanNameDomain_ac2dd9d3-4483-4e9e-b3a6-6bf84fab265f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_4a3fb8f7-43d3-45ed-a9b1-e4522ca42a28" xlink:href="ino-20201231.xsd#ino_A2016IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ac2dd9d3-4483-4e9e-b3a6-6bf84fab265f" xlink:to="loc_ino_A2016IncentivePlanMember_4a3fb8f7-43d3-45ed-a9b1-e4522ca42a28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_39aca558-ac5f-406d-9389-800200ed2106" xlink:href="ino-20201231.xsd#ino_A2007IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ac2dd9d3-4483-4e9e-b3a6-6bf84fab265f" xlink:to="loc_ino_A2007IncentivePlanMember_39aca558-ac5f-406d-9389-800200ed2106" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_743f8dd5-8827-4703-a11f-032db18ac88a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a5b0391d-1661-4f59-a6c1-524ba64a9c24" xlink:to="loc_us-gaap_AwardTypeAxis_743f8dd5-8827-4703-a11f-032db18ac88a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_743f8dd5-8827-4703-a11f-032db18ac88a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_743f8dd5-8827-4703-a11f-032db18ac88a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_743f8dd5-8827-4703-a11f-032db18ac88a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b2c91a26-bfd3-4eae-9300-2e8c70ef4578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_743f8dd5-8827-4703-a11f-032db18ac88a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b2c91a26-bfd3-4eae-9300-2e8c70ef4578" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_45609ae4-ade7-40b4-9ca4-f996a8e15218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b2c91a26-bfd3-4eae-9300-2e8c70ef4578" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_45609ae4-ade7-40b4-9ca4-f996a8e15218" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_da5845eb-e747-4f31-aa2d-ec0e9637a9c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a5b0391d-1661-4f59-a6c1-524ba64a9c24" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_da5845eb-e747-4f31-aa2d-ec0e9637a9c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_da5845eb-e747-4f31-aa2d-ec0e9637a9c6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_da5845eb-e747-4f31-aa2d-ec0e9637a9c6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_da5845eb-e747-4f31-aa2d-ec0e9637a9c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_155ba4f6-a191-422e-8da9-241acb93404a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_da5845eb-e747-4f31-aa2d-ec0e9637a9c6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_155ba4f6-a191-422e-8da9-241acb93404a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeeMember_c2df13b6-1e55-4236-98f1-f905bf4c69fa" xlink:href="ino-20201231.xsd#ino_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_155ba4f6-a191-422e-8da9-241acb93404a" xlink:to="loc_ino_EmployeeMember_c2df13b6-1e55-4236-98f1-f905bf4c69fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a31fed57-eb66-494c-9c96-26c7b3aec3c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_155ba4f6-a191-422e-8da9-241acb93404a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a31fed57-eb66-494c-9c96-26c7b3aec3c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7fc49a77-c677-4b25-83cb-3ad3a0ee06ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_155ba4f6-a191-422e-8da9-241acb93404a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7fc49a77-c677-4b25-83cb-3ad3a0ee06ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_ff146a1b-80e0-4204-a522-e44d81ae1749" xlink:href="ino-20201231.xsd#ino_NonEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_155ba4f6-a191-422e-8da9-241acb93404a" xlink:to="loc_ino_NonEmployeeMember_ff146a1b-80e0-4204-a522-e44d81ae1749" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7bd2c1e7-7423-4c69-a103-87ab8d67c3ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a5b0391d-1661-4f59-a6c1-524ba64a9c24" xlink:to="loc_us-gaap_VestingAxis_7bd2c1e7-7423-4c69-a103-87ab8d67c3ea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7bd2c1e7-7423-4c69-a103-87ab8d67c3ea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_7bd2c1e7-7423-4c69-a103-87ab8d67c3ea" xlink:to="loc_us-gaap_VestingDomain_7bd2c1e7-7423-4c69-a103-87ab8d67c3ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_89042022-d897-4b39-8654-18c6112d5e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_7bd2c1e7-7423-4c69-a103-87ab8d67c3ea" xlink:to="loc_us-gaap_VestingDomain_89042022-d897-4b39-8654-18c6112d5e18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e8527f8e-81d0-47a5-825d-7ca6d50c847e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_89042022-d897-4b39-8654-18c6112d5e18" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e8527f8e-81d0-47a5-825d-7ca6d50c847e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_3b4e4c02-82e5-4514-8356-8937be313482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_89042022-d897-4b39-8654-18c6112d5e18" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_3b4e4c02-82e5-4514-8356-8937be313482" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquitySummaryofStockOptionsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" xlink:type="extended" id="i8a73f2c5dadf4d2eb29ec3299e545343_StockholdersEquitySummaryofStockOptionsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_fe02fba8-8c72-4bbf-968f-8d8fb8af1e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_bb6be56d-d7ef-4462-a907-19829104e83f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_fe02fba8-8c72-4bbf-968f-8d8fb8af1e71" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_bb6be56d-d7ef-4462-a907-19829104e83f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_bb37474c-ba22-43b3-addc-c8e0e53a0f85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_fe02fba8-8c72-4bbf-968f-8d8fb8af1e71" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_bb37474c-ba22-43b3-addc-c8e0e53a0f85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_a5bc1bfd-e395-4bd9-853c-a5a7383c0346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_fe02fba8-8c72-4bbf-968f-8d8fb8af1e71" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_a5bc1bfd-e395-4bd9-853c-a5a7383c0346" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_4c0748fb-136c-4578-b97e-eb3ec3c13678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_fe02fba8-8c72-4bbf-968f-8d8fb8af1e71" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_4c0748fb-136c-4578-b97e-eb3ec3c13678" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c83a2171-44b9-49a1-a167-259bbc100948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_fe02fba8-8c72-4bbf-968f-8d8fb8af1e71" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c83a2171-44b9-49a1-a167-259bbc100948" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_dc4ca2b8-3811-4d29-8391-780272b491d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_fe02fba8-8c72-4bbf-968f-8d8fb8af1e71" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_dc4ca2b8-3811-4d29-8391-780272b491d4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_9ce9d665-813d-47d6-a0c6-54c3312a755c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_fe02fba8-8c72-4bbf-968f-8d8fb8af1e71" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_9ce9d665-813d-47d6-a0c6-54c3312a755c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_258ddd8e-114f-4702-b570-58696154c23f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_fe02fba8-8c72-4bbf-968f-8d8fb8af1e71" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_258ddd8e-114f-4702-b570-58696154c23f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0957990b-f628-4478-a627-fb814d611626" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_258ddd8e-114f-4702-b570-58696154c23f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0957990b-f628-4478-a627-fb814d611626" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0957990b-f628-4478-a627-fb814d611626_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0957990b-f628-4478-a627-fb814d611626" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0957990b-f628-4478-a627-fb814d611626_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b2bebffb-c16c-42c4-bd09-bad0b0e007e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0957990b-f628-4478-a627-fb814d611626" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b2bebffb-c16c-42c4-bd09-bad0b0e007e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesOneMember_e27a06a0-fa95-4fa0-b6b9-1283b28dc621" xlink:href="ino-20201231.xsd#ino_RangeOfExercisePricesOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b2bebffb-c16c-42c4-bd09-bad0b0e007e6" xlink:to="loc_ino_RangeOfExercisePricesOneMember_e27a06a0-fa95-4fa0-b6b9-1283b28dc621" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesTwoMember_4761a222-97a1-4b6f-9089-a6053c2da8cc" xlink:href="ino-20201231.xsd#ino_RangeOfExercisePricesTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b2bebffb-c16c-42c4-bd09-bad0b0e007e6" xlink:to="loc_ino_RangeOfExercisePricesTwoMember_4761a222-97a1-4b6f-9089-a6053c2da8cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesThreeMember_048b1c7c-ba26-4986-b2a7-808ac5f36c5c" xlink:href="ino-20201231.xsd#ino_RangeOfExercisePricesThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b2bebffb-c16c-42c4-bd09-bad0b0e007e6" xlink:to="loc_ino_RangeOfExercisePricesThreeMember_048b1c7c-ba26-4986-b2a7-808ac5f36c5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFourMember_667ecb1d-9ab4-47de-91db-813aa4952ccd" xlink:href="ino-20201231.xsd#ino_RangeOfExercisePricesFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b2bebffb-c16c-42c4-bd09-bad0b0e007e6" xlink:to="loc_ino_RangeOfExercisePricesFourMember_667ecb1d-9ab4-47de-91db-813aa4952ccd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFiveMember_8ff08243-af5e-48f3-bdff-fbc5d4e05d75" xlink:href="ino-20201231.xsd#ino_RangeOfExercisePricesFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b2bebffb-c16c-42c4-bd09-bad0b0e007e6" xlink:to="loc_ino_RangeOfExercisePricesFiveMember_8ff08243-af5e-48f3-bdff-fbc5d4e05d75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesSixMember_8be93dbd-a05c-42de-96d5-93dd2b02a261" xlink:href="ino-20201231.xsd#ino_RangeOfExercisePricesSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b2bebffb-c16c-42c4-bd09-bad0b0e007e6" xlink:to="loc_ino_RangeOfExercisePricesSixMember_8be93dbd-a05c-42de-96d5-93dd2b02a261" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="extended" id="i2480df49c328438dbf571f9d0478004b_StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="extended" id="if8d11669251c4d64b915a4d7c9e4e7ee_StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3936c9e2-04f4-4388-96a0-a12d818fb2b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c76f4bcd-7e91-43fe-ba28-46ac8e5d2a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3936c9e2-04f4-4388-96a0-a12d818fb2b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c76f4bcd-7e91-43fe-ba28-46ac8e5d2a9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e7813529-21a3-44b2-85c3-46365180b547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c76f4bcd-7e91-43fe-ba28-46ac8e5d2a9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e7813529-21a3-44b2-85c3-46365180b547" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_54238789-32e5-4ce9-8ee4-2dd8d19cbec8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c76f4bcd-7e91-43fe-ba28-46ac8e5d2a9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_54238789-32e5-4ce9-8ee4-2dd8d19cbec8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_018e92d1-00ab-40b5-8c96-fad7f53f9cbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c76f4bcd-7e91-43fe-ba28-46ac8e5d2a9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_018e92d1-00ab-40b5-8c96-fad7f53f9cbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_41e5feb0-40d7-4362-8a05-44da4179e70c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c76f4bcd-7e91-43fe-ba28-46ac8e5d2a9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_41e5feb0-40d7-4362-8a05-44da4179e70c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dc46fa8a-7459-458a-ad21-a34f31628880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11162237-497d-42d6-8f0f-27107b57f41e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3936c9e2-04f4-4388-96a0-a12d818fb2b2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11162237-497d-42d6-8f0f-27107b57f41e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_674f0f35-ceee-435b-8d4a-d04206c4b7d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11162237-497d-42d6-8f0f-27107b57f41e" xlink:to="loc_us-gaap_AwardTypeAxis_674f0f35-ceee-435b-8d4a-d04206c4b7d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_674f0f35-ceee-435b-8d4a-d04206c4b7d0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_674f0f35-ceee-435b-8d4a-d04206c4b7d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_674f0f35-ceee-435b-8d4a-d04206c4b7d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba16ceac-4855-4031-8517-ad363c95d448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_674f0f35-ceee-435b-8d4a-d04206c4b7d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba16ceac-4855-4031-8517-ad363c95d448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5a4e7f02-94a1-4b0e-9aef-a85391027b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba16ceac-4855-4031-8517-ad363c95d448" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5a4e7f02-94a1-4b0e-9aef-a85391027b2d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/Leases" xlink:type="simple" xlink:href="ino-20201231.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/Leases" xlink:type="extended" id="i89216dae1e8444d1afb7995fef5ad54b_Leases"/>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesTables" xlink:type="simple" xlink:href="ino-20201231.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/LeasesTables" xlink:type="extended" id="iea8c20d548074b268ffcc12820d4728e_LeasesTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ib984e827cc474fcba3fe4e132583aa71_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_ea779802-b67b-4f9c-a554-4470b7f9c6f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_5c4fcd15-7175-4789-af2c-b021b39b03cf" xlink:href="ino-20201231.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ea779802-b67b-4f9c-a554-4470b7f9c6f0" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_5c4fcd15-7175-4789-af2c-b021b39b03cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_fb31401c-4848-43d5-b792-fc1ba9f7f12e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ea779802-b67b-4f9c-a554-4470b7f9c6f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_fb31401c-4848-43d5-b792-fc1ba9f7f12e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_fd404f1d-9364-456b-964c-c508124e55d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ea779802-b67b-4f9c-a554-4470b7f9c6f0" xlink:to="loc_us-gaap_LeaseCost_fd404f1d-9364-456b-964c-c508124e55d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto_b5e02dc9-95c5-4b6b-b2ec-17f9f5fdb1dc" xlink:href="ino-20201231.xsd#ino_LesseeNumberOfLeaseAgreementsEnteredInto"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ea779802-b67b-4f9c-a554-4470b7f9c6f0" xlink:to="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto_b5e02dc9-95c5-4b6b-b2ec-17f9f5fdb1dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b762b746-b913-4edc-830a-bf165a15bff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ea779802-b67b-4f9c-a554-4470b7f9c6f0" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b762b746-b913-4edc-830a-bf165a15bff4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_52129b12-1f32-41fa-a526-6a1e66085b5f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b762b746-b913-4edc-830a-bf165a15bff4" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_52129b12-1f32-41fa-a526-6a1e66085b5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_52129b12-1f32-41fa-a526-6a1e66085b5f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_52129b12-1f32-41fa-a526-6a1e66085b5f" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_52129b12-1f32-41fa-a526-6a1e66085b5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_83083aa2-4f56-41c8-9d61-97792350c2b1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_52129b12-1f32-41fa-a526-6a1e66085b5f" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_83083aa2-4f56-41c8-9d61-97792350c2b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember_abb623e4-8c3d-49b4-b8ab-56375f0651cd" xlink:href="ino-20201231.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_83083aa2-4f56-41c8-9d61-97792350c2b1" xlink:to="loc_ino_SanDiegoCaliforniaMember_abb623e4-8c3d-49b4-b8ab-56375f0651cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_bf64b980-d2a3-496b-81ab-2593cf89eaf2" xlink:href="ino-20201231.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_83083aa2-4f56-41c8-9d61-97792350c2b1" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_bf64b980-d2a3-496b-81ab-2593cf89eaf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_99bf8a46-70b9-4f52-a9a2-1a335e9b4452" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b762b746-b913-4edc-830a-bf165a15bff4" xlink:to="loc_srt_RangeAxis_99bf8a46-70b9-4f52-a9a2-1a335e9b4452" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_99bf8a46-70b9-4f52-a9a2-1a335e9b4452_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_99bf8a46-70b9-4f52-a9a2-1a335e9b4452" xlink:to="loc_srt_RangeMember_99bf8a46-70b9-4f52-a9a2-1a335e9b4452_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a3cca864-0748-4952-aa21-bfc889c8f0db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_99bf8a46-70b9-4f52-a9a2-1a335e9b4452" xlink:to="loc_srt_RangeMember_a3cca864-0748-4952-aa21-bfc889c8f0db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1cb49e4b-13ef-4f7b-aa55-c6ddbaa42808" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a3cca864-0748-4952-aa21-bfc889c8f0db" xlink:to="loc_srt_MinimumMember_1cb49e4b-13ef-4f7b-aa55-c6ddbaa42808" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8b339419-c3fe-411a-91a3-90a2a672f612" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a3cca864-0748-4952-aa21-bfc889c8f0db" xlink:to="loc_srt_MaximumMember_8b339419-c3fe-411a-91a3-90a2a672f612" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="extended" id="i2640e94827ed40c2a06874088dc4f8b9_LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/InvestmentinAffiliatedEntity" xlink:type="simple" xlink:href="ino-20201231.xsd#InvestmentinAffiliatedEntity"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/InvestmentinAffiliatedEntity" xlink:type="extended" id="i32981081cec34f0b840e45fbe8e285b6_InvestmentinAffiliatedEntity"/>
  <link:roleRef roleURI="http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#InvestmentinAffiliatedEntityDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails" xlink:type="extended" id="i49e4e6cc22744af4948418e18a68d674_InvestmentinAffiliatedEntityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_8b6e2658-517b-4904-a28c-878200bb7787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_580d3729-37cb-4c37-8972-44f54b88821b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8b6e2658-517b-4904-a28c-878200bb7787" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_580d3729-37cb-4c37-8972-44f54b88821b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_581293f9-b580-4e31-953c-457d703438c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8b6e2658-517b-4904-a28c-878200bb7787" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_581293f9-b580-4e31-953c-457d703438c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c1aac1e7-9ca4-4fa3-82a5-5fd33b471844" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8b6e2658-517b-4904-a28c-878200bb7787" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c1aac1e7-9ca4-4fa3-82a5-5fd33b471844" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f5113d66-f9e7-4148-abfd-3bd632a5e9bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8b6e2658-517b-4904-a28c-878200bb7787" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f5113d66-f9e7-4148-abfd-3bd632a5e9bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_39551b57-5079-4059-af22-e40a46f6b0e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8b6e2658-517b-4904-a28c-878200bb7787" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_39551b57-5079-4059-af22-e40a46f6b0e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8d5fd5be-52dd-4c0e-918b-4856e5f7350a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_39551b57-5079-4059-af22-e40a46f6b0e4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8d5fd5be-52dd-4c0e-918b-4856e5f7350a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8d5fd5be-52dd-4c0e-918b-4856e5f7350a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8d5fd5be-52dd-4c0e-918b-4856e5f7350a" xlink:to="loc_us-gaap_RelatedPartyDomain_8d5fd5be-52dd-4c0e-918b-4856e5f7350a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_abdf5df0-f4ce-464b-badc-debe7aea38be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8d5fd5be-52dd-4c0e-918b-4856e5f7350a" xlink:to="loc_us-gaap_RelatedPartyDomain_abdf5df0-f4ce-464b-badc-debe7aea38be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_f0b47dfe-3edb-4bde-ada6-3e9870aaa5c8" xlink:href="ino-20201231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_abdf5df0-f4ce-464b-badc-debe7aea38be" xlink:to="loc_ino_PlumblineLifeSciencesMember_f0b47dfe-3edb-4bde-ada6-3e9870aaa5c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneOneLifeSciencesMember_4aeb61cf-8b1e-4965-bf8c-683972e32c68" xlink:href="ino-20201231.xsd#ino_GeneOneLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_abdf5df0-f4ce-464b-badc-debe7aea38be" xlink:to="loc_ino_GeneOneLifeSciencesMember_4aeb61cf-8b1e-4965-bf8c-683972e32c68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_5e866ba9-5b34-4563-baf5-661931fed55c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_39551b57-5079-4059-af22-e40a46f6b0e4" xlink:to="loc_us-gaap_InvestmentTypeAxis_5e866ba9-5b34-4563-baf5-661931fed55c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5e866ba9-5b34-4563-baf5-661931fed55c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_5e866ba9-5b34-4563-baf5-661931fed55c" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5e866ba9-5b34-4563-baf5-661931fed55c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4d37016c-f82f-41f1-b1ae-794141ff6fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_5e866ba9-5b34-4563-baf5-661931fed55c" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4d37016c-f82f-41f1-b1ae-794141ff6fca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0f51380d-1ab3-4f84-869d-6842f6248e13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4d37016c-f82f-41f1-b1ae-794141ff6fca" xlink:to="loc_us-gaap_CommonStockMember_0f51380d-1ab3-4f84-869d-6842f6248e13" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended" id="i3f149822d0eb44669c499a6703176048_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesTables" xlink:type="extended" id="ic429cfecb4c44bfe9e1b223f86162c7e_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesComponentsofPretaxLossfromOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="extended" id="ifd45defef3bd4deda97aa3fe2c8f21d5_IncomeTaxesComponentsofPretaxLossfromOperationsDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails" xlink:type="extended" id="i047be10e5a114bf8bfc17b4b239eb815_IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesReconciliationofIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="extended" id="ib58b52deca034a3f8aec2a4e8707b65f_IncomeTaxesReconciliationofIncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i8a68eb111e0646ea83b828dd99ec0172_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_6216398e-417c-4039-a8e5-5c29419afaa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a43048a6-290c-4559-b81d-ea10cfb373f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6216398e-417c-4039-a8e5-5c29419afaa5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a43048a6-290c-4559-b81d-ea10cfb373f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_cab28675-5a1a-4138-b98c-56708df5cba5" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6216398e-417c-4039-a8e5-5c29419afaa5" xlink:to="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_cab28675-5a1a-4138-b98c-56708df5cba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_8efd9eee-839f-439d-aa5b-46ab7788136a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6216398e-417c-4039-a8e5-5c29419afaa5" xlink:to="loc_us-gaap_OperatingLossCarryforwards_8efd9eee-839f-439d-aa5b-46ab7788136a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_a3e46b03-aeea-4a55-b80c-f2d81f35ad01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6216398e-417c-4039-a8e5-5c29419afaa5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_a3e46b03-aeea-4a55-b80c-f2d81f35ad01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxBenefitsExpired_da32a5fe-a355-4a1b-85ef-2039eeb5a2cb" xlink:href="ino-20201231.xsd#ino_TaxBenefitsExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6216398e-417c-4039-a8e5-5c29419afaa5" xlink:to="loc_ino_TaxBenefitsExpired_da32a5fe-a355-4a1b-85ef-2039eeb5a2cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_123c415d-7401-4e74-b418-8a09cd7da695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6216398e-417c-4039-a8e5-5c29419afaa5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_123c415d-7401-4e74-b418-8a09cd7da695" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_a69ca7d8-34e0-4ad8-b792-8cad307162c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6216398e-417c-4039-a8e5-5c29419afaa5" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_a69ca7d8-34e0-4ad8-b792-8cad307162c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_a735108e-3088-4ed2-b8ed-9cbc9a61592d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a69ca7d8-34e0-4ad8-b792-8cad307162c8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_a735108e-3088-4ed2-b8ed-9cbc9a61592d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a735108e-3088-4ed2-b8ed-9cbc9a61592d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a735108e-3088-4ed2-b8ed-9cbc9a61592d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a735108e-3088-4ed2-b8ed-9cbc9a61592d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_38c6db7c-55bf-404f-9f58-a0fbb99455f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a735108e-3088-4ed2-b8ed-9cbc9a61592d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_38c6db7c-55bf-404f-9f58-a0fbb99455f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_408988aa-0617-4576-afe8-923d9d4512b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_38c6db7c-55bf-404f-9f58-a0fbb99455f9" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_408988aa-0617-4576-afe8-923d9d4512b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CaliforniaIncomeTaxAuthorityMember_80ed4433-de07-425c-9405-baaee6f10cab" xlink:href="ino-20201231.xsd#ino_CaliforniaIncomeTaxAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_38c6db7c-55bf-404f-9f58-a0fbb99455f9" xlink:to="loc_ino_CaliforniaIncomeTaxAuthorityMember_80ed4433-de07-425c-9405-baaee6f10cab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_7a502c2d-66ee-4902-8abd-b789811f7762" xlink:href="ino-20201231.xsd#ino_PennsylvaniaStateIncomeTaxAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_38c6db7c-55bf-404f-9f58-a0fbb99455f9" xlink:to="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_7a502c2d-66ee-4902-8abd-b789811f7762" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_c1f83c75-4cd1-430c-81fc-fa85625e35e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_38c6db7c-55bf-404f-9f58-a0fbb99455f9" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_c1f83c75-4cd1-430c-81fc-fa85625e35e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_f1fbf019-c9e3-4703-be93-e2843738ae14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a69ca7d8-34e0-4ad8-b792-8cad307162c8" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_f1fbf019-c9e3-4703-be93-e2843738ae14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f1fbf019-c9e3-4703-be93-e2843738ae14_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_f1fbf019-c9e3-4703-be93-e2843738ae14" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f1fbf019-c9e3-4703-be93-e2843738ae14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7cf56c8c-5e0b-4c96-85b0-06451602477d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_f1fbf019-c9e3-4703-be93-e2843738ae14" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_7cf56c8c-5e0b-4c96-85b0-06451602477d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_0ee58530-2613-4237-8e5d-55eba7e3ec5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7cf56c8c-5e0b-4c96-85b0-06451602477d" xlink:to="loc_us-gaap_ResearchMember_0ee58530-2613-4237-8e5d-55eba7e3ec5a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended" id="i53f3fe5fb561464cb0358cc00962ec14_IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="extended" id="i1124620322ec4d058db66b28e9325b1e_IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_9b0e9e25-9bd0-4120-98d0-5f1ce1ff57f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_8cc95774-ac01-4ca8-96de-aa9892e0743a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9b0e9e25-9bd0-4120-98d0-5f1ce1ff57f4" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_8cc95774-ac01-4ca8-96de-aa9892e0743a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_943331ed-90aa-427e-8e58-f215d733fff6" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_8cc95774-ac01-4ca8-96de-aa9892e0743a" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_943331ed-90aa-427e-8e58-f215d733fff6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_358a2c6d-8fa0-44ad-b7f7-6b0aec3804e1" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_8cc95774-ac01-4ca8-96de-aa9892e0743a" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_358a2c6d-8fa0-44ad-b7f7-6b0aec3804e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_d226465a-b915-4958-b75d-7329d404de68" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_8cc95774-ac01-4ca8-96de-aa9892e0743a" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_d226465a-b915-4958-b75d-7329d404de68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_a9099da4-9814-4aed-a5f2-2bbe87dca987" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_8cc95774-ac01-4ca8-96de-aa9892e0743a" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_a9099da4-9814-4aed-a5f2-2bbe87dca987" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_9f540300-91ab-428a-be63-8770abfe2031" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringinFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_8cc95774-ac01-4ca8-96de-aa9892e0743a" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_9f540300-91ab-428a-be63-8770abfe2031" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_a367facc-4511-4015-99c0-6e34025465f5" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_8cc95774-ac01-4ca8-96de-aa9892e0743a" xlink:to="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_a367facc-4511-4015-99c0-6e34025465f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_f6e9ce39-42a4-4b53-b591-e2c770164d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_8cc95774-ac01-4ca8-96de-aa9892e0743a" xlink:to="loc_us-gaap_OperatingLossCarryforwards_f6e9ce39-42a4-4b53-b591-e2c770164d0d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_5d00e8f5-4865-47ab-a4a3-0597f82e35f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9b0e9e25-9bd0-4120-98d0-5f1ce1ff57f4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_5d00e8f5-4865-47ab-a4a3-0597f82e35f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_1f77f781-f79a-4cb4-a848-c0b297f38b90" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_5d00e8f5-4865-47ab-a4a3-0597f82e35f1" xlink:to="loc_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_1f77f781-f79a-4cb4-a848-c0b297f38b90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_cf49c41d-a8b7-4db3-a669-a264ad59eecb" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_5d00e8f5-4865-47ab-a4a3-0597f82e35f1" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_cf49c41d-a8b7-4db3-a669-a264ad59eecb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_a51d6ddd-4bb3-41db-938c-5bdccf8e405a" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringinThreeMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_5d00e8f5-4865-47ab-a4a3-0597f82e35f1" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_a51d6ddd-4bb3-41db-938c-5bdccf8e405a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_b2cd0fdc-4b95-4e89-8a1f-aba709688ad3" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringinFourMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_5d00e8f5-4865-47ab-a4a3-0597f82e35f1" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_b2cd0fdc-4b95-4e89-8a1f-aba709688ad3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_c8404678-52c9-4302-8a76-e0d22cfd9da6" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringinFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_5d00e8f5-4865-47ab-a4a3-0597f82e35f1" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_c8404678-52c9-4302-8a76-e0d22cfd9da6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_e0b03023-ed46-4dc6-acc4-297402077281" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_5d00e8f5-4865-47ab-a4a3-0597f82e35f1" xlink:to="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_e0b03023-ed46-4dc6-acc4-297402077281" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_7e77dae9-6f30-4797-bea7-b8db543c7881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_5d00e8f5-4865-47ab-a4a3-0597f82e35f1" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_7e77dae9-6f30-4797-bea7-b8db543c7881" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_e2da1e0d-e479-4bfb-8828-53599314de2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9b0e9e25-9bd0-4120-98d0-5f1ce1ff57f4" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_e2da1e0d-e479-4bfb-8828-53599314de2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_021377d1-06c4-435b-9091-81378a76d206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e2da1e0d-e479-4bfb-8828-53599314de2d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_021377d1-06c4-435b-9091-81378a76d206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_021377d1-06c4-435b-9091-81378a76d206_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_021377d1-06c4-435b-9091-81378a76d206" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_021377d1-06c4-435b-9091-81378a76d206_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_833afb57-024d-4a94-9261-0d4daf9bd9cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_021377d1-06c4-435b-9091-81378a76d206" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_833afb57-024d-4a94-9261-0d4daf9bd9cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_2eff5874-80e9-4001-aa8c-1f6a5d10c66e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_833afb57-024d-4a94-9261-0d4daf9bd9cd" xlink:to="loc_us-gaap_ResearchMember_2eff5874-80e9-4001-aa8c-1f6a5d10c66e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6d9f317a-2fd0-4078-800c-fe9db786d81a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e2da1e0d-e479-4bfb-8828-53599314de2d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6d9f317a-2fd0-4078-800c-fe9db786d81a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6d9f317a-2fd0-4078-800c-fe9db786d81a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6d9f317a-2fd0-4078-800c-fe9db786d81a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6d9f317a-2fd0-4078-800c-fe9db786d81a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e7111249-2122-4fc1-8e32-8048c6102c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6d9f317a-2fd0-4078-800c-fe9db786d81a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e7111249-2122-4fc1-8e32-8048c6102c24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_8c35e50d-ddc3-40e5-9fa3-b9b6bbda6de4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e7111249-2122-4fc1-8e32-8048c6102c24" xlink:to="loc_us-gaap_DomesticCountryMember_8c35e50d-ddc3-40e5-9fa3-b9b6bbda6de4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_4ff587a5-ee85-4e1f-a0b0-0956c7e5b71b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e7111249-2122-4fc1-8e32-8048c6102c24" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_4ff587a5-ee85-4e1f-a0b0-0956c7e5b71b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="extended" id="ib4e9cba32d874b6aa570a9c36cb8df33_IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/A401kPlan" xlink:type="simple" xlink:href="ino-20201231.xsd#A401kPlan"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/A401kPlan" xlink:type="extended" id="i3902a2fd60b64f12b6b7fa4f419534b1_A401kPlan"/>
  <link:roleRef roleURI="http://www.inovio.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#A401kPlanDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/A401kPlanDetails" xlink:type="extended" id="i47b0b77a716c44dbb60fe77879e081f9_A401kPlanDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ino-20201231.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended" id="icb4c7f2fa32f4b30985466546cacae55_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i3a99cfd5780a479c85f7c70065bf6bb7_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_9d25aaf4-4361-450b-ab98-e13819cf0534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_9d25aaf4-4361-450b-ab98-e13819cf0534" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c4a936ba-97c0-43f7-adcb-77aec5b3691a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c4a936ba-97c0-43f7-adcb-77aec5b3691a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_eeef6a8b-1e3c-4ac9-a9f9-029b388ea856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_eeef6a8b-1e3c-4ac9-a9f9-029b388ea856" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_809ec63d-8974-4f3e-ac03-ecdab9584dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_809ec63d-8974-4f3e-ac03-ecdab9584dfc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_a9821ec3-e5a4-41d8-bf83-5210fe0ea95c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_us-gaap_RevenueFromRelatedParties_a9821ec3-e5a4-41d8-bf83-5210fe0ea95c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_738f289f-f96c-4721-88b2-a8434166c007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_738f289f-f96c-4721-88b2-a8434166c007" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InvestmentOwnedAdditionalSharesAcquired_d37bd38e-699c-4534-a854-2cc729b16a24" xlink:href="ino-20201231.xsd#ino_InvestmentOwnedAdditionalSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_ino_InvestmentOwnedAdditionalSharesAcquired_d37bd38e-699c-4534-a854-2cc729b16a24" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_bb42a43b-784d-43ad-ae81-9675ba067b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_bb42a43b-784d-43ad-ae81-9675ba067b79" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_af9a78ec-c427-4a09-a512-6a418dd3e9de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_220f9682-53f2-4341-8ff7-e02ff7f21da8" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_220f9682-53f2-4341-8ff7-e02ff7f21da8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_0d9fde28-0b31-4801-9894-315d9dc3313d" xlink:href="ino-20201231.xsd#ino_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_ino_CollaborativeArrangementTerm_0d9fde28-0b31-4801-9894-315d9dc3313d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromSubGrant_32e32672-c9d9-4934-a7ab-551ce3493f90" xlink:href="ino-20201231.xsd#ino_ProceedsFromSubGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_ino_ProceedsFromSubGrant_32e32672-c9d9-4934-a7ab-551ce3493f90" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_70bca6fb-6981-4d06-bb0e-46c544221c25" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_70bca6fb-6981-4d06-bb0e-46c544221c25" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_1d774e73-b7ff-45f3-aa3a-7d9e27dbb329" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_1d774e73-b7ff-45f3-aa3a-7d9e27dbb329" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_f07624e4-155e-451f-b389-50c8eb0c5876" xlink:href="ino-20201231.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_ino_GrantProceedsReceived_f07624e4-155e-451f-b389-50c8eb0c5876" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_3182e2b0-98aa-4f0e-ac17-6ca615d365b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_1713dbd2-fcf3-4f77-8365-a9362768de69" xlink:href="ino-20201231.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_1713dbd2-fcf3-4f77-8365-a9362768de69" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5d60b588-c51b-44b5-ab61-2a569ae47beb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5d60b588-c51b-44b5-ab61-2a569ae47beb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4d4982cb-70da-4d44-9d97-753af8c83720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5d60b588-c51b-44b5-ab61-2a569ae47beb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4d4982cb-70da-4d44-9d97-753af8c83720" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4d4982cb-70da-4d44-9d97-753af8c83720_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4d4982cb-70da-4d44-9d97-753af8c83720" xlink:to="loc_us-gaap_RelatedPartyDomain_4d4982cb-70da-4d44-9d97-753af8c83720_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_248dcb91-7f1e-45c9-bebe-c3b114004393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4d4982cb-70da-4d44-9d97-753af8c83720" xlink:to="loc_us-gaap_RelatedPartyDomain_248dcb91-7f1e-45c9-bebe-c3b114004393" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneOneLifeSciencesMember_f61d5c65-98c5-4960-8668-46600f4f98da" xlink:href="ino-20201231.xsd#ino_GeneOneLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_248dcb91-7f1e-45c9-bebe-c3b114004393" xlink:to="loc_ino_GeneOneLifeSciencesMember_f61d5c65-98c5-4960-8668-46600f4f98da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PLSaffiliatedentityMember_95c0fbbb-21e6-4d12-b0ab-489035188224" xlink:href="ino-20201231.xsd#ino_PLSaffiliatedentityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_248dcb91-7f1e-45c9-bebe-c3b114004393" xlink:to="loc_ino_PLSaffiliatedentityMember_95c0fbbb-21e6-4d12-b0ab-489035188224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_43f028e4-727e-4423-8594-b9dcda75d3b2" xlink:href="ino-20201231.xsd#ino_TheWistarInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_248dcb91-7f1e-45c9-bebe-c3b114004393" xlink:to="loc_ino_TheWistarInstituteMember_43f028e4-727e-4423-8594-b9dcda75d3b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9d2611f1-69d4-4e69-842f-d44625d0aae8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5d60b588-c51b-44b5-ab61-2a569ae47beb" xlink:to="loc_srt_CounterpartyNameAxis_9d2611f1-69d4-4e69-842f-d44625d0aae8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d2611f1-69d4-4e69-842f-d44625d0aae8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9d2611f1-69d4-4e69-842f-d44625d0aae8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d2611f1-69d4-4e69-842f-d44625d0aae8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc7ea041-245d-4b14-96d5-cae172a64126" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9d2611f1-69d4-4e69-842f-d44625d0aae8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc7ea041-245d-4b14-96d5-cae172a64126" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneOneLifeSciencesMember_ab83324a-754b-4ddf-988a-62f831ff2997" xlink:href="ino-20201231.xsd#ino_GeneOneLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc7ea041-245d-4b14-96d5-cae172a64126" xlink:to="loc_ino_GeneOneLifeSciencesMember_ab83324a-754b-4ddf-988a-62f831ff2997" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_0232ee80-bc18-4d44-a19a-7f04eaac10b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5d60b588-c51b-44b5-ab61-2a569ae47beb" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_0232ee80-bc18-4d44-a19a-7f04eaac10b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_0232ee80-bc18-4d44-a19a-7f04eaac10b1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_0232ee80-bc18-4d44-a19a-7f04eaac10b1" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_0232ee80-bc18-4d44-a19a-7f04eaac10b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_bb0ef73a-117d-4462-8c35-35b77b52670a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_0232ee80-bc18-4d44-a19a-7f04eaac10b1" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_bb0ef73a-117d-4462-8c35-35b77b52670a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_979e5f30-3288-42fb-a9e8-0e23b84bb44f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_bb0ef73a-117d-4462-8c35-35b77b52670a" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_979e5f30-3288-42fb-a9e8-0e23b84bb44f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsInc"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended" id="ica670dbbe1f9402c88a98a477f3388bb_GeneosTherapeuticsInc"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsIncTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="extended" id="i30118f50153b4058aeb183503b61bade_GeneosTherapeuticsIncTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended" id="i4c0cd439bdf144349ae62d62a03c75a6_GeneosTherapeuticsIncNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_a72e8107-dc04-42c9-9f05-4f488cf6161c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_a72e8107-dc04-42c9-9f05-4f488cf6161c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_7832ae07-0954-42aa-9e1b-bf2beed94345" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_7832ae07-0954-42aa-9e1b-bf2beed94345" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_672a7c55-4397-4342-be00-d81e8da2674f" xlink:href="ino-20201231.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:to="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_672a7c55-4397-4342-be00-d81e8da2674f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_ed908fc3-9e91-4001-a1e1-018d84ad3c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_ed908fc3-9e91-4001-a1e1-018d84ad3c7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_05c3bffd-2d92-46e4-852d-a16d8910beac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_05c3bffd-2d92-46e4-852d-a16d8910beac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3f6364f3-c7ad-4ffd-a5c6-de48d229fe28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3f6364f3-c7ad-4ffd-a5c6-de48d229fe28" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0ed97827-d3e8-4ece-bcd6-25203025e233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0ed97827-d3e8-4ece-bcd6-25203025e233" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_25fdf840-6c55-4ec1-bafe-d81e90880a29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:to="loc_us-gaap_EquityMethodInvestments_25fdf840-6c55-4ec1-bafe-d81e90880a29" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_b5a6a6da-13d4-4b0d-a27f-85e341ab6222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:to="loc_us-gaap_MinorityInterestTable_b5a6a6da-13d4-4b0d-a27f-85e341ab6222" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3d067daa-3533-4c18-856c-d084b871412b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_b5a6a6da-13d4-4b0d-a27f-85e341ab6222" xlink:to="loc_srt_CounterpartyNameAxis_3d067daa-3533-4c18-856c-d084b871412b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d067daa-3533-4c18-856c-d084b871412b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3d067daa-3533-4c18-856c-d084b871412b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d067daa-3533-4c18-856c-d084b871412b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1956c3ff-c533-401e-b425-ca555f323f6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3d067daa-3533-4c18-856c-d084b871412b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1956c3ff-c533-401e-b425-ca555f323f6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_1e6598f4-f0a6-4df7-8da3-8cbe5dca7ffe" xlink:href="ino-20201231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1956c3ff-c533-401e-b425-ca555f323f6e" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_1e6598f4-f0a6-4df7-8da3-8cbe5dca7ffe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5d74c468-8601-404e-9560-e9d751af3db6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_b5a6a6da-13d4-4b0d-a27f-85e341ab6222" xlink:to="loc_srt_OwnershipAxis_5d74c468-8601-404e-9560-e9d751af3db6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_5d74c468-8601-404e-9560-e9d751af3db6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_5d74c468-8601-404e-9560-e9d751af3db6" xlink:to="loc_srt_OwnershipDomain_5d74c468-8601-404e-9560-e9d751af3db6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_91168122-d965-4401-8c5d-f0b50d9bd637" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_5d74c468-8601-404e-9560-e9d751af3db6" xlink:to="loc_srt_OwnershipDomain_91168122-d965-4401-8c5d-f0b50d9bd637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_875c1255-85c8-4f8b-a123-eb7f057a69ad" xlink:href="ino-20201231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_91168122-d965-4401-8c5d-f0b50d9bd637" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_875c1255-85c8-4f8b-a123-eb7f057a69ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_49251507-a2b9-45eb-b683-d023efa4ad9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_b5a6a6da-13d4-4b0d-a27f-85e341ab6222" xlink:to="loc_us-gaap_StatementClassOfStockAxis_49251507-a2b9-45eb-b683-d023efa4ad9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_49251507-a2b9-45eb-b683-d023efa4ad9d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_49251507-a2b9-45eb-b683-d023efa4ad9d" xlink:to="loc_us-gaap_ClassOfStockDomain_49251507-a2b9-45eb-b683-d023efa4ad9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8dd79fdf-e140-4ded-9630-9b21d87b6b58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_49251507-a2b9-45eb-b683-d023efa4ad9d" xlink:to="loc_us-gaap_ClassOfStockDomain_8dd79fdf-e140-4ded-9630-9b21d87b6b58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f583c0f0-96ee-4599-bff8-150af3951531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8dd79fdf-e140-4ded-9630-9b21d87b6b58" xlink:to="loc_us-gaap_CommonStockMember_f583c0f0-96ee-4599-bff8-150af3951531" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_2e8ae78a-c946-44e8-a789-abb35ddf4258" xlink:href="ino-20201231.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8dd79fdf-e140-4ded-9630-9b21d87b6b58" xlink:to="loc_ino_SeriesAOnePreferredStockMember_2e8ae78a-c946-44e8-a789-abb35ddf4258" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsIncDeconsolidationAccountingDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="extended" id="if21b7a0a96e84c188e007e9cd104b4e9_GeneosTherapeuticsIncDeconsolidationAccountingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_94519fe4-4777-4cfe-bbe0-578a2aa1808a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapitalExcludingCash_f1392801-01ea-45b3-b58c-a4326daf5275" xlink:href="ino-20201231.xsd#ino_WorkingCapitalExcludingCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_94519fe4-4777-4cfe-bbe0-578a2aa1808a" xlink:to="loc_ino_WorkingCapitalExcludingCash_f1392801-01ea-45b3-b58c-a4326daf5275" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_2fa24451-726e-47bd-a03b-a0b387475312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_94519fe4-4777-4cfe-bbe0-578a2aa1808a" xlink:to="loc_us-gaap_NotesPayable_2fa24451-726e-47bd-a03b-a0b387475312" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_615df396-1477-47cd-8bee-b2787a6d7b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_94519fe4-4777-4cfe-bbe0-578a2aa1808a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_615df396-1477-47cd-8bee-b2787a6d7b2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_094debc4-c2e4-41b6-bcd2-c97612b8d916" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_94519fe4-4777-4cfe-bbe0-578a2aa1808a" xlink:to="loc_us-gaap_MinorityInterest_094debc4-c2e4-41b6-bcd2-c97612b8d916" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedInterestFairValueDisclosure_c2168995-0dcd-4779-83d9-8306fefaa22b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedInterestFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_94519fe4-4777-4cfe-bbe0-578a2aa1808a" xlink:to="loc_us-gaap_RetainedInterestFairValueDisclosure_c2168995-0dcd-4779-83d9-8306fefaa22b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_04de8fa6-4e62-4475-94fc-9adbe7207a21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_94519fe4-4777-4cfe-bbe0-578a2aa1808a" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_04de8fa6-4e62-4475-94fc-9adbe7207a21" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_fed2dc14-9296-498b-b7ac-308ad67d57f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_94519fe4-4777-4cfe-bbe0-578a2aa1808a" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_fed2dc14-9296-498b-b7ac-308ad67d57f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_022b4c65-d863-402f-92f7-102eefecdafb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_94519fe4-4777-4cfe-bbe0-578a2aa1808a" xlink:to="loc_us-gaap_MinorityInterestTable_022b4c65-d863-402f-92f7-102eefecdafb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9e1397f2-2222-481c-8860-1ae348673e8b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_022b4c65-d863-402f-92f7-102eefecdafb" xlink:to="loc_srt_CounterpartyNameAxis_9e1397f2-2222-481c-8860-1ae348673e8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e1397f2-2222-481c-8860-1ae348673e8b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9e1397f2-2222-481c-8860-1ae348673e8b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e1397f2-2222-481c-8860-1ae348673e8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9feb636c-afca-4527-ac11-743ae6c364a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9e1397f2-2222-481c-8860-1ae348673e8b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9feb636c-afca-4527-ac11-743ae6c364a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_7caaf195-42f2-450e-bb90-100691669e42" xlink:href="ino-20201231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9feb636c-afca-4527-ac11-743ae6c364a4" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_7caaf195-42f2-450e-bb90-100691669e42" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsIncInvestmentinGeneosDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails" xlink:type="extended" id="i2bedea56a6ef475dbe766e419383d37b_GeneosTherapeuticsIncInvestmentinGeneosDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_0515f2a2-78e5-402c-bb16-c6a462a5e607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_41fbd022-f623-42de-8fb4-b2dd5b3e1ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_0515f2a2-78e5-402c-bb16-c6a462a5e607" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_41fbd022-f623-42de-8fb4-b2dd5b3e1ef7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_68b7da7f-0d3c-4376-a603-00916462f08d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_0515f2a2-78e5-402c-bb16-c6a462a5e607" xlink:to="loc_us-gaap_SharePrice_68b7da7f-0d3c-4376-a603-00916462f08d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_3bec42aa-1eff-4052-a154-f37876f874f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_0515f2a2-78e5-402c-bb16-c6a462a5e607" xlink:to="loc_us-gaap_EquityMethodInvestments_3bec42aa-1eff-4052-a154-f37876f874f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_d237f3e2-fd16-4a25-9ead-7a4c1ad3eb25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_0515f2a2-78e5-402c-bb16-c6a462a5e607" xlink:to="loc_us-gaap_MinorityInterestTable_d237f3e2-fd16-4a25-9ead-7a4c1ad3eb25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1eb3ae0f-9af5-4694-be0e-6a0d8dbfb238" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_d237f3e2-fd16-4a25-9ead-7a4c1ad3eb25" xlink:to="loc_srt_CounterpartyNameAxis_1eb3ae0f-9af5-4694-be0e-6a0d8dbfb238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1eb3ae0f-9af5-4694-be0e-6a0d8dbfb238_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1eb3ae0f-9af5-4694-be0e-6a0d8dbfb238" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1eb3ae0f-9af5-4694-be0e-6a0d8dbfb238_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13e056f3-e772-460d-b2cf-e24bf23a328d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1eb3ae0f-9af5-4694-be0e-6a0d8dbfb238" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13e056f3-e772-460d-b2cf-e24bf23a328d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_4b1b152c-9238-458e-bc5b-54912b379d45" xlink:href="ino-20201231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13e056f3-e772-460d-b2cf-e24bf23a328d" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_4b1b152c-9238-458e-bc5b-54912b379d45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7a7f7aa0-e1c0-4ee4-93ba-4bf596cf5a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_d237f3e2-fd16-4a25-9ead-7a4c1ad3eb25" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7a7f7aa0-e1c0-4ee4-93ba-4bf596cf5a5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7a7f7aa0-e1c0-4ee4-93ba-4bf596cf5a5e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7a7f7aa0-e1c0-4ee4-93ba-4bf596cf5a5e" xlink:to="loc_us-gaap_ClassOfStockDomain_7a7f7aa0-e1c0-4ee4-93ba-4bf596cf5a5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f2921a50-f607-4137-8ab2-f9904948fb24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7a7f7aa0-e1c0-4ee4-93ba-4bf596cf5a5e" xlink:to="loc_us-gaap_ClassOfStockDomain_f2921a50-f607-4137-8ab2-f9904948fb24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_507fa006-52eb-4727-be4d-1158d41c5853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f2921a50-f607-4137-8ab2-f9904948fb24" xlink:to="loc_us-gaap_CommonStockMember_507fa006-52eb-4727-be4d-1158d41c5853" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredClassAMember_5eebaa56-83e3-4b71-b518-113cf5ed906a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f2921a50-f607-4137-8ab2-f9904948fb24" xlink:to="loc_us-gaap_PreferredClassAMember_5eebaa56-83e3-4b71-b518-113cf5ed906a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsIncFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="extended" id="i8ddb2bed79a0407dac4abb515634aa68_GeneosTherapeuticsIncFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_7addb918-e2a0-4191-8b7e-58a0abb4069a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AlternativeInvestmentMeasurementInputTerm_a12b77b6-ba0d-46cd-b677-b81a81bb563f" xlink:href="ino-20201231.xsd#ino_AlternativeInvestmentMeasurementInputTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_7addb918-e2a0-4191-8b7e-58a0abb4069a" xlink:to="loc_ino_AlternativeInvestmentMeasurementInputTerm_a12b77b6-ba0d-46cd-b677-b81a81bb563f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_f2b2912c-3f67-4e35-9254-b400196332ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_7addb918-e2a0-4191-8b7e-58a0abb4069a" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_f2b2912c-3f67-4e35-9254-b400196332ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentEnterpriseValue_9a2c27f0-b778-469e-92bf-a4245133638e" xlink:href="ino-20201231.xsd#ino_EquityMethodInvestmentEnterpriseValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_7addb918-e2a0-4191-8b7e-58a0abb4069a" xlink:to="loc_ino_EquityMethodInvestmentEnterpriseValue_9a2c27f0-b778-469e-92bf-a4245133638e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_1ce20ccc-5001-4df4-90dc-6afe3e664722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_7addb918-e2a0-4191-8b7e-58a0abb4069a" xlink:to="loc_us-gaap_MinorityInterestTable_1ce20ccc-5001-4df4-90dc-6afe3e664722" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_aa5d2cb0-2c6f-42cd-91f5-2e23654d613b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_1ce20ccc-5001-4df4-90dc-6afe3e664722" xlink:to="loc_srt_CounterpartyNameAxis_aa5d2cb0-2c6f-42cd-91f5-2e23654d613b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa5d2cb0-2c6f-42cd-91f5-2e23654d613b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_aa5d2cb0-2c6f-42cd-91f5-2e23654d613b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa5d2cb0-2c6f-42cd-91f5-2e23654d613b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0387a79-6c53-433e-b0e5-cbe2362341e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_aa5d2cb0-2c6f-42cd-91f5-2e23654d613b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0387a79-6c53-433e-b0e5-cbe2362341e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_0b4841ac-cb66-4178-8d2d-a6a27f62bd70" xlink:href="ino-20201231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0387a79-6c53-433e-b0e5-cbe2362341e0" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_0b4841ac-cb66-4178-8d2d-a6a27f62bd70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_be2b7aa4-3fc1-47b6-ba6f-1b93940d79dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_1ce20ccc-5001-4df4-90dc-6afe3e664722" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_be2b7aa4-3fc1-47b6-ba6f-1b93940d79dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_be2b7aa4-3fc1-47b6-ba6f-1b93940d79dc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_be2b7aa4-3fc1-47b6-ba6f-1b93940d79dc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_be2b7aa4-3fc1-47b6-ba6f-1b93940d79dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_501c6bce-b483-4e90-9d6c-05add922637d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_be2b7aa4-3fc1-47b6-ba6f-1b93940d79dc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_501c6bce-b483-4e90-9d6c-05add922637d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_318fc4c6-faee-4d7f-9fdd-d9d4c54fa3e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_501c6bce-b483-4e90-9d6c-05add922637d" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_318fc4c6-faee-4d7f-9fdd-d9d4c54fa3e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_666e8b45-1f4f-4d3f-ab4d-88dbcfba087f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_501c6bce-b483-4e90-9d6c-05add922637d" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_666e8b45-1f4f-4d3f-ab4d-88dbcfba087f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_de78d2eb-bf22-47ca-a3c8-234401951ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_501c6bce-b483-4e90-9d6c-05add922637d" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_de78d2eb-bf22-47ca-a3c8-234401951ef3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsIncPreferredStockInvestmentDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" xlink:type="extended" id="i003b20dcb337418b84ca97fbf22bcdf7_GeneosTherapeuticsIncPreferredStockInvestmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_202e898c-6a65-4fae-9430-99b87165d9c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_36cf44f7-b633-4492-adaf-172a6a04b82f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_202e898c-6a65-4fae-9430-99b87165d9c3" xlink:to="loc_us-gaap_EquityMethodInvestments_36cf44f7-b633-4492-adaf-172a6a04b82f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_611f0f47-55b7-4252-a497-8bd570c093f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_202e898c-6a65-4fae-9430-99b87165d9c3" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_611f0f47-55b7-4252-a497-8bd570c093f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_99f4e22d-e5bd-41e3-bd35-71e8f5c0d42a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_6ff10dea-6dbc-46e7-8fd4-635760e8f319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_202e898c-6a65-4fae-9430-99b87165d9c3" xlink:to="loc_us-gaap_MinorityInterestTable_6ff10dea-6dbc-46e7-8fd4-635760e8f319" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_267d9bb2-948a-45f9-b338-22d17a8c7daf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_6ff10dea-6dbc-46e7-8fd4-635760e8f319" xlink:to="loc_srt_CounterpartyNameAxis_267d9bb2-948a-45f9-b338-22d17a8c7daf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_267d9bb2-948a-45f9-b338-22d17a8c7daf_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_267d9bb2-948a-45f9-b338-22d17a8c7daf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_267d9bb2-948a-45f9-b338-22d17a8c7daf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e44c8ca-a858-4289-b513-847dfd31b5cc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_267d9bb2-948a-45f9-b338-22d17a8c7daf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e44c8ca-a858-4289-b513-847dfd31b5cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_a1c58840-44f3-497b-b46d-483c70d8fb66" xlink:href="ino-20201231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e44c8ca-a858-4289-b513-847dfd31b5cc" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_a1c58840-44f3-497b-b46d-483c70d8fb66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_655b776c-b30a-4abc-a1a2-1cf8090b5d47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_6ff10dea-6dbc-46e7-8fd4-635760e8f319" xlink:to="loc_us-gaap_StatementClassOfStockAxis_655b776c-b30a-4abc-a1a2-1cf8090b5d47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_655b776c-b30a-4abc-a1a2-1cf8090b5d47_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_655b776c-b30a-4abc-a1a2-1cf8090b5d47" xlink:to="loc_us-gaap_ClassOfStockDomain_655b776c-b30a-4abc-a1a2-1cf8090b5d47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3c298e63-e0fc-4c3c-ae5d-0772253c723d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_655b776c-b30a-4abc-a1a2-1cf8090b5d47" xlink:to="loc_us-gaap_ClassOfStockDomain_3c298e63-e0fc-4c3c-ae5d-0772253c723d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_50fafdd3-739c-46eb-89a1-ad4501ec6435" xlink:href="ino-20201231.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3c298e63-e0fc-4c3c-ae5d-0772253c723d" xlink:to="loc_ino_SeriesAOnePreferredStockMember_50fafdd3-739c-46eb-89a1-ad4501ec6435" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="ino-20201231.xsd#QuarterlyFinancialInformationUnaudited"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended" id="i72295f6d34804686bb9cd120c95e3bda_QuarterlyFinancialInformationUnaudited"/>
  <link:roleRef roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="ino-20201231.xsd#QuarterlyFinancialInformationUnauditedTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended" id="i639b57535ece493a86df70ab81cddd39_QuarterlyFinancialInformationUnauditedTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#QuarterlyFinancialInformationUnauditedDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="extended" id="i6f747c43d05247cabf0676a7f3db21a5_QuarterlyFinancialInformationUnauditedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2d8044d0-bfa1-476d-b7eb-1a55ec52bf51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2d8044d0-bfa1-476d-b7eb-1a55ec52bf51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4feb0cf7-75bc-47b1-ae79-ce16333b158c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4feb0cf7-75bc-47b1-ae79-ce16333b158c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a8f9027b-0234-4c6f-b541-1db5ab8b41f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a8f9027b-0234-4c6f-b541-1db5ab8b41f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_93ca316c-fc6a-4d45-9a0a-f98373109e41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_OperatingExpenses_93ca316c-fc6a-4d45-9a0a-f98373109e41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f5d696b1-5bf2-4431-b94a-bfd2cfcf9322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_OperatingIncomeLoss_f5d696b1-5bf2-4431-b94a-bfd2cfcf9322" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_aed9281f-0728-4491-ac91-65afc1943259" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_InterestIncomeOperating_aed9281f-0728-4491-ac91-65afc1943259" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6ff22941-ed86-45b2-9602-f04f66e763c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_InterestExpense_6ff22941-ed86-45b2-9602-f04f66e763c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_28a1e8e0-c1da-4512-a610-fa5fc70d2672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_28a1e8e0-c1da-4512-a610-fa5fc70d2672" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_e93f8f4b-7bb3-4892-a100-a7e94ee3552f" xlink:href="ino-20201231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_e93f8f4b-7bb3-4892-a100-a7e94ee3552f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7649ff54-8d9b-43ac-994e-0a2d01c92d23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7649ff54-8d9b-43ac-994e-0a2d01c92d23" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_682d7435-2318-421b-8b97-d2e2a4cef59d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_682d7435-2318-421b-8b97-d2e2a4cef59d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_912c612f-f2c0-4a2f-a779-f05b4a3a2efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_912c612f-f2c0-4a2f-a779-f05b4a3a2efd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_14ac310c-b405-45de-9c5e-7359c1a7d13f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_14ac310c-b405-45de-9c5e-7359c1a7d13f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19cdb827-0bd6-41c5-9b8f-18ac8c42dcaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19cdb827-0bd6-41c5-9b8f-18ac8c42dcaa" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dff49986-7f1a-4781-9398-7f9ecea27580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dff49986-7f1a-4781-9398-7f9ecea27580" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4292d096-c44d-4041-b979-17951bfd07d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4292d096-c44d-4041-b979-17951bfd07d1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d7cbae13-f464-4c42-9d76-22406d5575c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_ProfitLoss_d7cbae13-f464-4c42-9d76-22406d5575c7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_059a08d0-4e53-463d-874b-5c532bc6b1ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_059a08d0-4e53-463d-874b-5c532bc6b1ae" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_76c32f65-ea1c-4649-87cb-ba2e739d1474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_NetIncomeLoss_76c32f65-ea1c-4649-87cb-ba2e739d1474" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3453af46-6299-48c1-8c7d-fa23428163e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3453af46-6299-48c1-8c7d-fa23428163e0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cc600f73-7790-4b1d-848c-3a856ecc91c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3453af46-6299-48c1-8c7d-fa23428163e0" xlink:to="loc_us-gaap_EarningsPerShareBasic_cc600f73-7790-4b1d-848c-3a856ecc91c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_cc683596-6c31-4759-981d-341a21ec300c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3453af46-6299-48c1-8c7d-fa23428163e0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_cc683596-6c31-4759-981d-341a21ec300c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_64a727ac-5296-41f4-af26-070e0f3ac7ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_64a727ac-5296-41f4-af26-070e0f3ac7ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_508adc9b-dd8c-4f5d-9447-56eb3a8cbcd4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_64a727ac-5296-41f4-af26-070e0f3ac7ce" xlink:to="loc_srt_ProductOrServiceAxis_508adc9b-dd8c-4f5d-9447-56eb3a8cbcd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_508adc9b-dd8c-4f5d-9447-56eb3a8cbcd4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_508adc9b-dd8c-4f5d-9447-56eb3a8cbcd4" xlink:to="loc_srt_ProductsAndServicesDomain_508adc9b-dd8c-4f5d-9447-56eb3a8cbcd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_297da84a-5fe4-4bdd-a54f-7e2f868cd1d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_508adc9b-dd8c-4f5d-9447-56eb3a8cbcd4" xlink:to="loc_srt_ProductsAndServicesDomain_297da84a-5fe4-4bdd-a54f-7e2f868cd1d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_357bff14-7a0e-4b55-a7a1-a25c2f968635" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_297da84a-5fe4-4bdd-a54f-7e2f868cd1d5" xlink:to="loc_us-gaap_LicenseMember_357bff14-7a0e-4b55-a7a1-a25c2f968635" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_cfe1a1f1-2fb9-45c8-9f1c-5395051b6f8e" xlink:href="ino-20201231.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_297da84a-5fe4-4bdd-a54f-7e2f868cd1d5" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_cfe1a1f1-2fb9-45c8-9f1c-5395051b6f8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherRevenueAffiliatedEntityMember_434ddcc1-7b7d-43f6-8889-e29f55613822" xlink:href="ino-20201231.xsd#ino_OtherRevenueAffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_297da84a-5fe4-4bdd-a54f-7e2f868cd1d5" xlink:to="loc_ino_OtherRevenueAffiliatedEntityMember_434ddcc1-7b7d-43f6-8889-e29f55613822" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_108e3ce0-db40-424a-81ab-b584b04393d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_64a727ac-5296-41f4-af26-070e0f3ac7ce" xlink:to="loc_us-gaap_DebtInstrumentAxis_108e3ce0-db40-424a-81ab-b584b04393d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_108e3ce0-db40-424a-81ab-b584b04393d2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_108e3ce0-db40-424a-81ab-b584b04393d2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_108e3ce0-db40-424a-81ab-b584b04393d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7d8382c5-0d0f-46f3-bfcf-b252eb927711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_108e3ce0-db40-424a-81ab-b584b04393d2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7d8382c5-0d0f-46f3-bfcf-b252eb927711" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_30c916f5-11e2-4729-b5d9-c5810d4d2d6e" xlink:href="ino-20201231.xsd#ino_ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d8382c5-0d0f-46f3-bfcf-b252eb927711" xlink:to="loc_ino_ConvertibleBondsMember_30c916f5-11e2-4729-b5d9-c5810d4d2d6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_49ce6b64-c35b-474e-999d-510407e29592" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d8382c5-0d0f-46f3-bfcf-b252eb927711" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_49ce6b64-c35b-474e-999d-510407e29592" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ino-20201231.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SubsequentEvents" xlink:type="extended" id="icbfc83ccc84142c487ecc8d8a88fda7c_SubsequentEvents"/>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended" id="ie864fb40d23e429283e2b2ab68646cec_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_12c6e236-691c-4b58-9087-f3ecfb2425b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_329cb27d-db6e-418c-abd3-4aa93b2dc821" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_12c6e236-691c-4b58-9087-f3ecfb2425b2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_329cb27d-db6e-418c-abd3-4aa93b2dc821" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4f24099a-923c-4f9a-8d16-0fdb5ee0d0ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_12c6e236-691c-4b58-9087-f3ecfb2425b2" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4f24099a-923c-4f9a-8d16-0fdb5ee0d0ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_fe9bdb40-df99-45e7-af62-ab930388dc55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_12c6e236-691c-4b58-9087-f3ecfb2425b2" xlink:to="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_fe9bdb40-df99-45e7-af62-ab930388dc55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_cbf8501b-ace1-4a81-b114-520a16253015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_12c6e236-691c-4b58-9087-f3ecfb2425b2" xlink:to="loc_us-gaap_SubsequentEventTable_cbf8501b-ace1-4a81-b114-520a16253015" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ea70ed77-c361-4d09-a349-f1520c23d6a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_cbf8501b-ace1-4a81-b114-520a16253015" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ea70ed77-c361-4d09-a349-f1520c23d6a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ea70ed77-c361-4d09-a349-f1520c23d6a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ea70ed77-c361-4d09-a349-f1520c23d6a9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ea70ed77-c361-4d09-a349-f1520c23d6a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2984e41f-e637-4379-a3a4-cbdedd73b338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ea70ed77-c361-4d09-a349-f1520c23d6a9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2984e41f-e637-4379-a3a4-cbdedd73b338" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6d4ffdbe-5ea2-41db-96fd-ba010ffb2510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2984e41f-e637-4379-a3a4-cbdedd73b338" xlink:to="loc_us-gaap_SubsequentEventMember_6d4ffdbe-5ea2-41db-96fd-ba010ffb2510" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>ino-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:457132bc-9fa0-4eb7-b7bc-387259668e99,g:003ddec6-0acb-4351-b822-2fdc6632a099-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ead3ef36-daf5-4294-a65d-5eeddffdaa3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_87d8e38b-153f-45fa-b981-4ab2cc3637d0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OtherRevenueAffiliatedEntityMember_71734a5e-f96b-47f4-a1b3-8db04d6c8830_terseLabel_en-US" xlink:label="lab_ino_OtherRevenueAffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue from affiliated entities</link:label>
    <link:label id="lab_ino_OtherRevenueAffiliatedEntityMember_cdf1f0d3-9b96-44e7-a88b-ea2d951c1edf_verboseLabel_en-US" xlink:label="lab_ino_OtherRevenueAffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue, including from affiliated entities</link:label>
    <link:label id="lab_ino_OtherRevenueAffiliatedEntityMember_label_en-US" xlink:label="lab_ino_OtherRevenueAffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenue Affiliated Entity [Member]</link:label>
    <link:label id="lab_ino_OtherRevenueAffiliatedEntityMember_documentation_en-US" xlink:label="lab_ino_OtherRevenueAffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenue Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherRevenueAffiliatedEntityMember" xlink:href="ino-20201231.xsd#ino_OtherRevenueAffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OtherRevenueAffiliatedEntityMember" xlink:to="lab_ino_OtherRevenueAffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_033a4c17-b49a-4e5c-ba78-5f87c7696697_negatedLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease in Prepaid Expenses and Other Current Assets from Affiliated Entity</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:to="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_56fe05d2-8071-4e1f-8b9d-be903ac0479b_negatedNetLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derecognition of the derivative liability upon conversion</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c1b99341-c938-4c5c-9cfd-5c003b649c67_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b90be209-bc12-41b8-a590-e2ff1ae51e88_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_86c7ae08-288b-4866-a36a-9fd45875fb02_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_c8202f57-f5e2-418a-aa98-7337cdaaef21_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Fair Value of Embedded Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_34a91028-ca3e-4098-afca-80c1e5d08cdb_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability from affiliated entity, net of current portion</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Noncurrent</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:href="ino-20201231.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:to="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_06dedd4d-cb89-4380-9cfa-a1bb273292af_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in tax rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesTwoMember_b525a5a8-bd06-4873-afe8-36c96c2df8fb_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1.48-$3.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesTwoMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Two [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesTwoMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesTwoMember" xlink:href="ino-20201231.xsd#ino_RangeOfExercisePricesTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesTwoMember" xlink:to="lab_ino_RangeOfExercisePricesTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_49bd4e97-7ca3-4a38-a143-68b946a6fcfc_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU's expected to vest (in shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:href="ino-20201231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_e996131c-6220-4b86-8f0c-097aa4e575a4_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definite lived:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_27910d5d-c31c-44e9-83da-387c6e985424_verboseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_5a79effa-acf0-4ecd-b81f-9f0ddab5d8d5_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8303b592-de29-4be6-a670-a9a00b14d042_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_d4d0163b-754c-47a9-8764-a5b0ef49e801_terseLabel_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a1969b03-9d1a-47c1-bc41-3335c9bbb9b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EquityComponentOfConvertibleDebtIssued_ebad23ae-8b90-4373-8926-192d824ef46d_terseLabel_en-US" xlink:label="lab_ino_EquityComponentOfConvertibleDebtIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of issuance of convertible notes</link:label>
    <link:label id="lab_ino_EquityComponentOfConvertibleDebtIssued_label_en-US" xlink:label="lab_ino_EquityComponentOfConvertibleDebtIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component Of Convertible Debt Issued</link:label>
    <link:label id="lab_ino_EquityComponentOfConvertibleDebtIssued_documentation_en-US" xlink:label="lab_ino_EquityComponentOfConvertibleDebtIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component Of Convertible Debt Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityComponentOfConvertibleDebtIssued" xlink:href="ino-20201231.xsd#ino_EquityComponentOfConvertibleDebtIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EquityComponentOfConvertibleDebtIssued" xlink:to="lab_ino_EquityComponentOfConvertibleDebtIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_8618e3a8-1884-47d3-8f23-32b28d57406a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of issuance of convertible notes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_c42f1823-a5d4-4a6f-9524-9c77e8e79794_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1bfb1b70-b6dd-4870-9cbc-05fc4c896cce_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_7f7473fd-9140-49a6-af98-21467ca8cfa5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2007IncentivePlanMember_91d07d47-27d9-462f-8e1c-902015860164_terseLabel_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember" xlink:href="ino-20201231.xsd#ino_A2007IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2007IncentivePlanMember" xlink:to="lab_ino_A2007IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0265647c-648c-4308-8262-8bd05515cc47_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuances of convertible senior notes and convertible bonds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_31a5135a-07c2-42cc-8e82-44b3b88f545d_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, payment earned</link:label>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_label_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Payment Earned</link:label>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Payment Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned" xlink:href="ino-20201231.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementPaymentEarned" xlink:to="lab_ino_CollaborationAgreementPaymentEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_b42daf85-fd53-4a59-9f76-8b45160bf9b4_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, corporate income tax</link:label>
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_label_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Corporate Income Tax</link:label>
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Corporate Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementCorporateIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementCorporateIncomeTax" xlink:to="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_62f01e46-e23d-457b-817b-8693135a6fe6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_0c32dfdd-0b0e-4a10-b2bd-b7eea6897b8f_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets_cdf194f4-08ff-4b2a-a0ae-6637669f4e44_terseLabel_en-US" xlink:label="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Operating Lease Right-Of-Use Assets</link:label>
    <link:label id="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Operating Lease Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:href="ino-20201231.xsd#ino_AmortizationOfOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:to="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_695d9602-fc83-4b4c-91a7-35e285d2f3d9_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_266ef270-cd26-4558-8741-ecb650713c22_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_2eeee87b-9e21-43c0-bb04-6a7ec4b0ccf1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, realized gain</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_be4fdd79-f032-4198-9860-ef905e80b729_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and intangible assets, Net Book Value</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Net</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet" xlink:href="ino-20201231.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet" xlink:to="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_fa3b50d1-8eae-451a-b8a7-be055c266bcf_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ba3c02eb-4cbb-44c2-a7ef-d28fac414a06_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52e12e80-895d-450a-b383-351e107ccf68_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_c1765b74-187d-4bc7-aaf0-abd6b09cdeb3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_d28d8766-0742-47df-a654-ee3cb8e03b79_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Two Years</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:to="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_89b717a2-7159-4eb3-8c0f-db1a4cf3bf7b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_f1bb3acb-4763-48c7-ba32-e1daaf7644a5_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9e33398d-e846-4fe0-9cb1-7fded2de9ad7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto_0c8c0f8c-9571-49ac-97b1-d728d02f7798_terseLabel_en-US" xlink:label="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lease agreements entered into</link:label>
    <link:label id="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto_label_en-US" xlink:label="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Number Of Lease Agreements Entered Into</link:label>
    <link:label id="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto_documentation_en-US" xlink:label="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Number Of Lease Agreements Entered Into</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:href="ino-20201231.xsd#ino_LesseeNumberOfLeaseAgreementsEnteredInto"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:to="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7081dda1-d0b4-4ea6-b0bc-a5c8689ba02f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6be69f9d-e7e2-4acc-a97f-eee6b306ef86_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AlternativeInvestmentMeasurementInputTerm_07004721-18ce-43e5-8025-602f350698c5_terseLabel_en-US" xlink:label="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, measurement input, expected term</link:label>
    <link:label id="lab_ino_AlternativeInvestmentMeasurementInputTerm_label_en-US" xlink:label="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input, Term</link:label>
    <link:label id="lab_ino_AlternativeInvestmentMeasurementInputTerm_documentation_en-US" xlink:label="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AlternativeInvestmentMeasurementInputTerm" xlink:href="ino-20201231.xsd#ino_AlternativeInvestmentMeasurementInputTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AlternativeInvestmentMeasurementInputTerm" xlink:to="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_32fe811e-3659-45c9-8a97-f51e16744013_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Territory expansion option period</link:label>
    <link:label id="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_label_en-US" xlink:label="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Territory Expansion Option Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Territory Expansion Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:href="ino-20201231.xsd#ino_CollaborationAgreementTerritoryExpansionOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:to="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsfromStockOptionandWarrantExercises_34bcc6c9-2d52-44c9-98cd-a4428f2982dc_verboseLabel_en-US" xlink:label="lab_ino_ProceedsfromStockOptionandWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option and warrant exercises, net of tax payments</link:label>
    <link:label id="lab_ino_ProceedsfromStockOptionandWarrantExercises_label_en-US" xlink:label="lab_ino_ProceedsfromStockOptionandWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Option and Warrant Exercises</link:label>
    <link:label id="lab_ino_ProceedsfromStockOptionandWarrantExercises_documentation_en-US" xlink:label="lab_ino_ProceedsfromStockOptionandWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Option and Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsfromStockOptionandWarrantExercises" xlink:href="ino-20201231.xsd#ino_ProceedsfromStockOptionandWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsfromStockOptionandWarrantExercises" xlink:to="lab_ino_ProceedsfromStockOptionandWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a2a207ef-e779-4ef2-950e-bb3b7ec47afb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options outstanding to purchase common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_33a8e3f6-f160-4c30-a355-ac537f474687_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_46b9c70b-ceab-4071-967b-2f662b44773d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DepartmentOfDefenceMember_4cfa1861-5ded-409e-b308-ae6b15feb31c_terseLabel_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defence</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_label_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defence [Member]</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_documentation_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defence</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember" xlink:href="ino-20201231.xsd#ino_DepartmentOfDefenceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DepartmentOfDefenceMember" xlink:to="lab_ino_DepartmentOfDefenceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9b81b2fb-d1c1-47a0-93f1-c0d8a1cd7182_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_63bf0aa7-d058-4905-a9fc-1d9256118c24_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_f24bb433-86ac-4456-a085-58e468c48104_terseLabel_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Bonds</link:label>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_label_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_documentation_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Convertible Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember" xlink:href="ino-20201231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_December2019ConvertibleBondsMember" xlink:to="lab_ino_December2019ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c63c12c8-0426-4ef3-914d-5fcefeeb951b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a0a73fe3-7014-409c-81c3-5e19442f1f7a_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_06124ed4-5c74-4f56-90f8-9d6a8eb49a36_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_926c1729-b264-4c01-b0cc-6550d8c53a90_totalLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_43a09219-9d35-4e5c-8c1d-7985614e27c7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock&#8212;par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December&#160;31, 2020 and 23 at December&#160;31, 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_bc564b4c-87c2-4bed-8973-4fd5a4c1787b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price, lower range limit (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_bdcdb28d-ab51-41ce-a34f-9cc807f0852b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4b537d1f-fddd-4daf-bf08-b081f83d7d16_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_463bd81a-bace-4caa-8774-5e6fb02bf062_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_MutualFundsMember_66c0d35a-0060-4c46-9a09-d02b7253d41f_terseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_10909d57-3614-401f-90e7-172600c7224e_verboseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_label_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Funds [Member]</link:label>
    <link:label id="lab_ino_MutualFundsMember_documentation_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember" xlink:href="ino-20201231.xsd#ino_MutualFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MutualFundsMember" xlink:to="lab_ino_MutualFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_146ac4d5-2a8e-4493-8541-2fdf28749b1e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1f16d0c8-801b-411e-a652-024693c0fe5d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c3136493-bf0a-438b-b4a4-3d7731b8db66_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_343a1254-67c0-4622-af5d-5c52245f72ea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_cc6d5a72-dddd-40dd-afea-ad5c860ae7f5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BiojectMember_2c75690c-0978-4e29-b346-77003e722f08_terseLabel_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject</link:label>
    <link:label id="lab_ino_BiojectMember_label_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject [Member]</link:label>
    <link:label id="lab_ino_BiojectMember_documentation_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember" xlink:href="ino-20201231.xsd#ino_BiojectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BiojectMember" xlink:to="lab_ino_BiojectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_87ba17af-40f6-46f6-b3d5-0614e27019cb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_db255328-1b17-45d9-a4db-0ea64f697d04_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:to="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_58ea3a08-5665-4148-b472-39e7ec1b6061_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_46aaf5fa-81c6-4357-ad54-14d490638df9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_853a5a24-0f19-4e7f-a099-b0f09a2882f9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_c5eb46f7-174e-45a3-bff8-ef8e2dcf86ff_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from collaborative agreement</link:label>
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_label_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Collaborative Agreement</link:label>
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_documentation_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Collaborative Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement" xlink:href="ino-20201231.xsd#ino_ProceedsFromCollaborativeAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromCollaborativeAgreement" xlink:to="lab_ino_ProceedsFromCollaborativeAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b0ee1b34-cf23-4b41-86f4-2388ff767283_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_af7f5467-726d-46a5-8374-c7e9b4aedc6a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GeneOneLifeSciencesMember_ce802096-149a-43f6-9add-bbe1fde9c4b9_terseLabel_en-US" xlink:label="lab_ino_GeneOneLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GeneOne (affiliated entity)</link:label>
    <link:label id="lab_ino_GeneOneLifeSciencesMember_0f740d82-2a02-4116-a81d-844fed76c216_verboseLabel_en-US" xlink:label="lab_ino_GeneOneLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GeneOne Life Sciences</link:label>
    <link:label id="lab_ino_GeneOneLifeSciencesMember_label_en-US" xlink:label="lab_ino_GeneOneLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GeneOne Life Sciences [Member]</link:label>
    <link:label id="lab_ino_GeneOneLifeSciencesMember_documentation_en-US" xlink:label="lab_ino_GeneOneLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GeneOne Life Sciences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneOneLifeSciencesMember" xlink:href="ino-20201231.xsd#ino_GeneOneLifeSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GeneOneLifeSciencesMember" xlink:to="lab_ino_GeneOneLifeSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_19b8b317-1415-466c-b90e-9766cf1a5d24_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_9bd412e1-9ca2-4e2a-84a4-faf87976f189_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_47f7a86e-71fb-4301-84c0-486d2c44ad3b_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:href="ino-20201231.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_623a6373-5866-46f4-987a-4917d301502b_terseLabel_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-based restricted stock units</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:href="ino-20201231.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:to="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_921e7a1e-dc6f-4bf4-bd0f-65e146f0247b_negatedTerseLabel_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note discount</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_label_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangement, Discount</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_documentation_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangement, Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:href="ino-20201231.xsd#ino_DeferredTaxLiabilitiesFinancingArrangementDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:to="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_WorkingCapitalExcludingCash_6a4b8e8b-042a-4ba6-9788-ac162bf26f3a_negatedTerseLabel_en-US" xlink:label="lab_ino_WorkingCapitalExcludingCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital (excluding cash)</link:label>
    <link:label id="lab_ino_WorkingCapitalExcludingCash_label_en-US" xlink:label="lab_ino_WorkingCapitalExcludingCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital, Excluding Cash</link:label>
    <link:label id="lab_ino_WorkingCapitalExcludingCash_documentation_en-US" xlink:label="lab_ino_WorkingCapitalExcludingCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital, Excluding Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapitalExcludingCash" xlink:href="ino-20201231.xsd#ino_WorkingCapitalExcludingCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WorkingCapitalExcludingCash" xlink:to="lab_ino_WorkingCapitalExcludingCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_e53ce5dc-0e7a-495c-a011-25c6454ba774_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_17ac386b-45e5-49ef-83a3-6bbf212b8011_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire additional interest in subsidiaries</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_8d2fc6c7-1666-4716-8304-3da60e6b4181_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_ab463192-957c-4f7d-afed-05a32d5acc82_terseLabel_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_label_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_documentation_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember" xlink:href="ino-20201231.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BillAndMelindaGatesFoundationMember" xlink:to="lab_ino_BillAndMelindaGatesFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_6ea6da72-cb22-4d2b-bcea-ad82f41e25c0_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_e7b5a08f-3fd5-4e35-9034-ceae35970c5d_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesSixMember_7671e9f3-b8f7-4b99-a052-3b2b77aacb55_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$15.01-$25.62</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesSixMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Six [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesSixMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesSixMember" xlink:href="ino-20201231.xsd#ino_RangeOfExercisePricesSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesSixMember" xlink:to="lab_ino_RangeOfExercisePricesSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b33c9848-77bb-445d-9a27-d22a5e58b0b6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_5c69899a-8906-44c8-9ec6-abd8960cdfa6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_210800d4-1841-425b-b8ee-d88d4ce94e90_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_e42fce23-56c2-4a11-9540-460e5a257f93_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:href="ino-20201231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_2bc1a3be-890c-4404-9e3a-d4db512cd223_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b41d0377-f6a9-4813-8b67-292c125095ee_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_99a2358d-40f5-4d4d-9f6a-3f0d0802eca8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_30822c71-378d-4169-b21a-ad35b141cb5e_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of year</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3cec6855-9245-4ffb-b9dd-4016d5f62306_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of year</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ed6c81e4-bda0-4475-bce1-b13c0a31616c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserved number of shares under the Incentive Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e156ef6d-9008-4cf2-943f-601f7793e015_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grants under the Incentive Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_3b25b086-705a-47c4-aa1f-2ab51d7238a6_negatedTerseLabel_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of receivable with shares of common stock from affiliated entity (PLS)</link:label>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_label_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Of Receivable With Shares Of Common Stock From Equity Security</link:label>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_documentation_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Of Receivable With Shares Of Common Stock From Equity Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:href="ino-20201231.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:to="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_21752b5e-e8c0-418d-a68a-d3b62b317b7e_verboseLabel_en-US" xlink:label="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assumptions used to estimate the fair value of stock options</link:label>
    <link:label id="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_label_en-US" xlink:label="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used In Estimation Of Fair Value Of Stock Options [Abstract]</link:label>
    <link:label id="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_documentation_en-US" xlink:label="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions used in estimation of fair value of stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:href="ino-20201231.xsd#ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:to="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_ba74ab4f-b1e4-48db-a383-1d200837deca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_d63e89c8-44d8-4373-b7f5-2ff25fe48cb4_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77cd909c-cda9-4495-9325-8cec83792e45_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f83a6328-4ab3-40e6-bc14-5ea1ae76075e_verboseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_607b23a3-a543-4aa8-8278-d2ca4c53bfa5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2a14cdf4-2941-42cb-be80-04be64b414cc_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts accrued for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_1037bd91-6dbf-43c6-a2db-826c60b39842_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_41a0b3f4-6257-4743-b34a-bfbb622ae753_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and intangible assets, Gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross" xlink:href="ino-20201231.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross" xlink:to="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_2e8811f4-bd0b-4f9f-a967-769b4c9a00d6_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears_7739e596-81f3-4cbc-ac60-d218ca887287_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 and thereafter</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Five Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringinFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_7fcbaeb2-8c4a-41b7-b78d-41d3b40c6c60_terseLabel_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_label_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_documentation_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember" xlink:href="ino-20201231.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EmployeesAndDirectorsMember" xlink:to="lab_ino_EmployeesAndDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_61305c56-4794-45d8-867a-e7231e992b74_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value</link:label>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_40634ce3-de13-4c85-8829-372b3aa7bf29_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_d6475a94-e6bb-429d-8c77-5db4423d8f3b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CommonStockEquivalentsAbstract_54744ba8-18ba-4652-b56a-f0bf1c23f90a_verboseLabel_en-US" xlink:label="lab_ino_CommonStockEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</link:label>
    <link:label id="lab_ino_CommonStockEquivalentsAbstract_label_en-US" xlink:label="lab_ino_CommonStockEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Equivalents [Abstract]</link:label>
    <link:label id="lab_ino_CommonStockEquivalentsAbstract_documentation_en-US" xlink:label="lab_ino_CommonStockEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CommonStockEquivalentsAbstract" xlink:href="ino-20201231.xsd#ino_CommonStockEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CommonStockEquivalentsAbstract" xlink:to="lab_ino_CommonStockEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_b8518dea-1521-4dc9-9af2-c4d6dbfa6c62_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_894d25e3-801f-4c50-9527-e03c3fbbe02b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_0c7f68ee-dc4b-49e2-a544-d2455aa28951_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited NOLs and credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:href="ino-20201231.xsd#ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:to="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3f42b2b9-1982-495c-9520-85f2bd36c90d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_6b3244d8-81e2-4b64-b30f-6791993bbc15_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_94292501-6ee1-4dd1-bbf3-fd63736c843c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_347929f9-4651-4933-b602-c62d7ee91c65_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0a947672-4a57-41bf-8052-91e745474d2f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c3cf9470-5a63-4b70-8ea2-ab36495164c0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_e7e29ace-b5fc-41b1-81f0-922200d2fdb0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_d1259f84-f274-4b9a-8c24-61628d4af028_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument principal amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_776bee3f-ff49-4112-b702-7e1f0a3ab0c2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_201cd497-5896-42fe-a008-01821ecbf8b6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c9620552-031f-44a0-98f3-3adf373bff50_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_b299d211-f20b-4748-95c4-3a84e5ec30ab_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_420ce742-dc81-4587-884d-55e9e879a68a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_4bf49286-27d9-40df-a4a3-91de7df7eae0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ed004269-1e89-4dd0-bb82-38aed1b2a7a0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9c173f90-95fe-4815-8bf5-d00c24c77234_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_2f11b75b-427d-4ea9-987b-922252f28b0f_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock sale agreement, aggregate number of shares issued (in shares)</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:href="ino-20201231.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:to="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_54f0db89-89a7-4d69-b1d6-07f836b6e99d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_ef18111d-4e92-4eed-bafd-5a9a6c8858fe_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2631cd6d-4116-447f-af9c-4d98a9de05c0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_d9c8d0bd-82b0-44c1-8b70-a9d3a242117e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:to="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AdvaccineMember_6bb90b61-8b57-4f84-85d8-a18cf017aab3_terseLabel_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine</link:label>
    <link:label id="lab_ino_AdvaccineMember_label_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine [Member]</link:label>
    <link:label id="lab_ino_AdvaccineMember_documentation_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember" xlink:href="ino-20201231.xsd#ino_AdvaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AdvaccineMember" xlink:to="lab_ino_AdvaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_cbd41005-a203-4f6c-bbbd-3d6f537e6eaf_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded option amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fd236238-1ebe-43dd-9e7c-3f74ae6d94ad_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9decd04a-e320-4261-9158-2dcb6ef1f71c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_3f45f147-1114-4e17-963a-c17553222530_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_a1322403-08e6-4531-bd77-34103e3393df_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_b7715ce2-8358-49bf-b458-5e9b4bda8298_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding from affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate" xlink:href="ino-20201231.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliate" xlink:to="lab_ino_DeferredGrantFundingFromAffiliate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_c413d4aa-d4ba-4583-af33-32c6ffe21093_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_589fdb5f-df43-445c-8f0b-189d9a665331_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4a492750-334f-4e40-8e63-a99bbc149d80_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_6fa31f21-abc9-43b1-9917-9f78b4d08f2b_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Three Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a5e9469c-3c39-4f2b-9064-dffaf8d32937_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TheWistarInstituteMember_79343adc-4d08-433f-af8f-99ecacaa4b11_terseLabel_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_label_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_documentation_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember" xlink:href="ino-20201231.xsd#ino_TheWistarInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TheWistarInstituteMember" xlink:to="lab_ino_TheWistarInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_862c3bb6-3df0-4f06-b0d7-02e0c9e04ac8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5087e586-b831-4105-82cf-7914eaa3fb96_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_57e1cb32-0406-4783-99c0-dcfd9a26a8d5_terseLabel_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]</link:label>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:href="ino-20201231.xsd#ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_60fa74c7-2880-4f8f-82fb-929cd0106e89_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_c0b58e57-09ff-44cf-b079-811dfcc72261_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of preferred stock authorized, issued and outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AfterJanuary22020ConversionPriceMember_a3a00ec7-d2e8-4681-bce9-25d1bddee635_terseLabel_en-US" xlink:label="lab_ino_AfterJanuary22020ConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After January 2, 2020 Conversion Price</link:label>
    <link:label id="lab_ino_AfterJanuary22020ConversionPriceMember_label_en-US" xlink:label="lab_ino_AfterJanuary22020ConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After January 2, 2020 Conversion Price [Member]</link:label>
    <link:label id="lab_ino_AfterJanuary22020ConversionPriceMember_documentation_en-US" xlink:label="lab_ino_AfterJanuary22020ConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After January 2, 2020 Conversion Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AfterJanuary22020ConversionPriceMember" xlink:href="ino-20201231.xsd#ino_AfterJanuary22020ConversionPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AfterJanuary22020ConversionPriceMember" xlink:to="lab_ino_AfterJanuary22020ConversionPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f72f7019-44e5-41a3-85e7-766c107f2967_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_53d34626-6556-4671-aeb3-b6b86cac0a38_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_1b4162d2-fadf-4f0d-bc8f-b7bd847892ac_terseLabel_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_label_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:to="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daaf3d72-0cce-428e-a405-3e3c7850d2f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_0a36a5e1-7f05-4903-8f55-61b026f0e14f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_5ff52655-447b-439e-af3b-e8a44b3c73fb_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities that are measured at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_f0d90761-2816-491e-9ee4-697e2b42793a_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AfterJuly22020ConversionPriceMember_ab53ce30-b6ca-4f4b-ba6c-94982f654fd9_terseLabel_en-US" xlink:label="lab_ino_AfterJuly22020ConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After July 2, 2020 Conversion Price</link:label>
    <link:label id="lab_ino_AfterJuly22020ConversionPriceMember_label_en-US" xlink:label="lab_ino_AfterJuly22020ConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After July 2, 2020 Conversion Price [Member]</link:label>
    <link:label id="lab_ino_AfterJuly22020ConversionPriceMember_documentation_en-US" xlink:label="lab_ino_AfterJuly22020ConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After July 2, 2020 Conversion Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AfterJuly22020ConversionPriceMember" xlink:href="ino-20201231.xsd#ino_AfterJuly22020ConversionPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AfterJuly22020ConversionPriceMember" xlink:to="lab_ino_AfterJuly22020ConversionPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_fc7b5f1e-23ff-4d2a-a73a-0da965ae7cc1_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_44e37bd8-d9d8-460b-a2b6-71941032131e_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_75ba0cd9-d7b7-4f43-9216-8eb179e50fe1_terseLabel_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_label_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_documentation_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:href="ino-20201231.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:to="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_af219a3a-3f54-4739-9e29-3ab856eba296_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in a gross unrealized loss position for more than twelve months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_818b4922-5184-44f4-ae35-f818e660c5b7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_b13cece4-5240-4ed6-aac1-916998c6c393_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dissolution of majority-owned subsidiary VGX Animal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a6357be5-9eb7-4eec-b321-4917f512fe2a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_3b4c3839-0179-4879-a627-4c21c3bc2d75_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_fb2728dc-ada9-4939-a8df-dd787b8f4db4_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_f53614a3-0989-49e8-bad3-ad58468f9d40_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos upon deconsolidation</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_dfaf64c2-4dfc-40d0-9419-b34a03ff6e6b_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos as of December 31, 2020</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_4d0ecddc-61e9-4e3c-bbf4-140e854d3a40_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_dffa49ef-b22f-4ab6-8b12-145696c72bbd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_e684a1dd-d8aa-4ac4-80b6-526925edc7e0_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability from affiliated entities</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:href="ino-20201231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:to="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_d0b5bd35-3de9-4bd9-a350-c1f398df205e_terseLabel_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID19 Vaccine</link:label>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_label_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S A R S Co V2 C O V I D19 Vaccine [Member]</link:label>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_documentation_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S A R S Co V2 C O V I D19 Vaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember" xlink:href="ino-20201231.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SARSCoV2COVID19VaccineMember" xlink:to="lab_ino_SARSCoV2COVID19VaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_670c79d9-51d3-4290-8e72-8030d21e4cc3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_51e17f9f-d3c6-4417-88fb-b1d35f0bb7f6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before income tax benefit/(provision for income tax)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5932c335-0d3a-4a1e-8bb6-38b145c31324_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50725db2-0994-46a3-bb25-f15968ed8cb5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_6fc8c0da-90ee-4d10-b912-20156d477dde_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_c8235c0a-85fc-4326-bc81-d0c4db2bf206_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restricted stock unit activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_92ea2917-e48a-4c44-891d-12c6b1d31cca_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_c840a951-a3ed-4e98-b5fc-b29f12978548_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_9e920844-00b1-459d-b0c8-a593d1756873_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonEmployeeMember_c40d6a5d-0b46-449b-b659-cba3374c4793_terseLabel_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee</link:label>
    <link:label id="lab_ino_NonEmployeeMember_label_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee [Member]</link:label>
    <link:label id="lab_ino_NonEmployeeMember_documentation_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non employee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember" xlink:href="ino-20201231.xsd#ino_NonEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonEmployeeMember" xlink:to="lab_ino_NonEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_50a92d67-4f03-4ecd-a69b-f5c94853ee8e_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nondeductible loss on extinguishment of debt</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible, Loss on Extinguishment of Debt</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible, Loss on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" xlink:href="ino-20201231.xsd#ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" xlink:to="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2397301c-83ac-4f7a-ae57-0b21c09c7b3c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_c5944a06-f26f-454f-b203-7780be030a48_terseLabel_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_label_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale Contractual Maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_documentation_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale contractual maturity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:href="ino-20201231.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:to="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_bb8c1044-27d5-4062-b513-040b4d111e9c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_497e3e34-50a2-4780-8f9d-ccd51c441720_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_725bf7ef-c7c3-4702-9a5d-a4e4d7194e15_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_d79591ad-d954-4eb9-92cd-77f32e9a7373_terseLabel_en-US" xlink:label="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="ino-20201231.xsd#ino_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_45aa353d-536f-4785-a199-e73050370828_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_eca289a5-0a69-4a14-a790-ae4909f2699d_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccruedSubcontractExpenses_d673d888-676c-4985-a257-3baa7654350f_terseLabel_en-US" xlink:label="lab_ino_AccruedSubcontractExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued subcontract costs</link:label>
    <link:label id="lab_ino_AccruedSubcontractExpenses_label_en-US" xlink:label="lab_ino_AccruedSubcontractExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Subcontract Expenses</link:label>
    <link:label id="lab_ino_AccruedSubcontractExpenses_documentation_en-US" xlink:label="lab_ino_AccruedSubcontractExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Subcontract Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedSubcontractExpenses" xlink:href="ino-20201231.xsd#ino_AccruedSubcontractExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccruedSubcontractExpenses" xlink:to="lab_ino_AccruedSubcontractExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionNameDomain_d9690fe7-b660-4500-bf13-df47bcc6de92_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtConversionNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionNameDomain" xlink:to="lab_us-gaap_DebtConversionNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_0a39fc68-a88c-45a5-960e-5ca16eb89968_terseLabel_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_label_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_85208d7d-2809-4e33-b011-36be6d3b6ebe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_5e54e991-9753-472b-8dc2-b6ea3399b744_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired NOLs and credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:href="ino-20201231.xsd#ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:to="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_64f95450-0420-4dfa-9806-9411e2e20701_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue under collaborative research and development arrangements</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_32ff2fbc-0819-4017-a208-6a200dd50117_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_54b342d9-5801-4a2d-966f-8c144673fe26_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of capital assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonCashInterestExpense_257063b6-37b8-4eda-b6b7-68b50e3243c1_terseLabel_en-US" xlink:label="lab_ino_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_ino_NonCashInterestExpense_label_en-US" xlink:label="lab_ino_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense</link:label>
    <link:label id="lab_ino_NonCashInterestExpense_documentation_en-US" xlink:label="lab_ino_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestExpense" xlink:href="ino-20201231.xsd#ino_NonCashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonCashInterestExpense" xlink:to="lab_ino_NonCashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8a6c42a7-391a-4056-9991-572a80195c81_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_1365e435-1b5b-492f-989c-e76c84d17a10_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_e0b16a04-65e0-4eea-9e0a-2e7261523143_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_e19df0df-4b80-49cf-8d4f-d8ea4b93ce9c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_f83cbb35-0cde-4809-b348-392bfbae958f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_ebf7c1d3-7b58-473f-93f2-11371f97a54e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_b110db64-d7a8-48df-83c4-cd7962679aeb_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_b362a9a8-0547-4f62-ab36-173cb44d6205_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in affiliated entities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_b7def8a1-7c88-451e-a2a2-a3b922dd27e9_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in affiliated entities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_82848694-f132-4a17-953d-12152a35ecd3_terseLabel_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-1 Preferred Stock</link:label>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_label_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_documentation_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember" xlink:href="ino-20201231.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SeriesAOnePreferredStockMember" xlink:to="lab_ino_SeriesAOnePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_dee1b8d6-adb7-4ab4-be98-e6e86930281b_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_c5d245dc-3ec9-4ee5-8717-09b986336737_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development and other tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other Tax Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain_be8d7be5-53cf-4c06-b698-01a12307aa86_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_42cb41e1-6396-4921-a0aa-5865baacbc61_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_7e6bbd7e-696b-4d65-8805-675137722047_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_952adcab-a7ce-4f9a-a775-0699bb643d83_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_85fedafd-084d-4160-ba26-28a5e93d2ef1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair&#160;Market&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3c452131-9ce3-4189-b8ab-be7a61124944_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_0566be77-5f56-4e09-8cb1-f0df18d39504_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_4b1b7b2f-7dc8-4d88-94d3-f1c304bc487f_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, remaining contractual term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:href="ino-20201231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_6fc83032-099a-45f4-b7c5-9322b35a3ae3_terseLabel_en-US" xlink:label="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued upon conversion, conversion price (in USD per share)</link:label>
    <link:label id="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_label_en-US" xlink:label="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share</link:label>
    <link:label id="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_documentation_en-US" xlink:label="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:href="ino-20201231.xsd#ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:to="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_WorkingCapital_90d5b222-bdc9-4bdb-b842-d3723664e0f6_verboseLabel_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_ino_WorkingCapital_label_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital</link:label>
    <link:label id="lab_ino_WorkingCapital_documentation_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount of current assets and current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital" xlink:href="ino-20201231.xsd#ino_WorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WorkingCapital" xlink:to="lab_ino_WorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_bc662b7f-5c10-4ee0-aff0-19b67aac9790_terseLabel_en-US" xlink:label="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pennsylvania</link:label>
    <link:label id="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_label_en-US" xlink:label="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pennsylvania State Income Tax Authority [Member]</link:label>
    <link:label id="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_documentation_en-US" xlink:label="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pennsylvania State Income Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:href="ino-20201231.xsd#ino_PennsylvaniaStateIncomeTaxAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:to="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_005835e3-1439-4c7e-a723-2e02027efd05_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. agency mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed Securities, Issued by US Government Sponsored Enterprises [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_16e7e45f-9ea9-4905-a8b1-dbae82e36d0f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_998be63b-c157-42fe-937e-43b6f367700e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_72c59d1d-d80f-4c71-8e56-8091d68fed31_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement anticipated development and regulatory event based payment receivable milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_label_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:href="ino-20201231.xsd#ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:to="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8006b0f0-cce7-45e9-9f46-aedaab3e99f5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assumptions used to estimate the fair value of stock options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_de9df79e-ad0f-4448-9116-1ae415438332_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_a401dde3-288b-4753-912b-37fd40ca1e41_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesFiveMember_6eb56fee-9e96-453c-aadd-00ce14343418_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$12.01-$15.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFiveMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Five [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFiveMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFiveMember" xlink:href="ino-20201231.xsd#ino_RangeOfExercisePricesFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesFiveMember" xlink:to="lab_ino_RangeOfExercisePricesFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_bfb08523-382d-436c-9549-375dea02aa35_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_c67915d3-d9b8-45a1-929f-58ae30483ab9_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_bac3adf9-9756-4c8d-b8e1-66c705ab154c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_dfbff243-54db-405d-b7e9-d80fa6acf1e6_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsFromSubGrant_9b285015-7e6b-4117-ae76-0d03756c43ee_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromSubGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sub-grant</link:label>
    <link:label id="lab_ino_ProceedsFromSubGrant_label_en-US" xlink:label="lab_ino_ProceedsFromSubGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sub-Grant</link:label>
    <link:label id="lab_ino_ProceedsFromSubGrant_documentation_en-US" xlink:label="lab_ino_ProceedsFromSubGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sub-Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromSubGrant" xlink:href="ino-20201231.xsd#ino_ProceedsFromSubGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromSubGrant" xlink:to="lab_ino_ProceedsFromSubGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PriorSalesAgreementMember_390a03aa-b57a-4008-a605-fc6e89a9b29d_terseLabel_en-US" xlink:label="lab_ino_PriorSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Sales Agreement</link:label>
    <link:label id="lab_ino_PriorSalesAgreementMember_label_en-US" xlink:label="lab_ino_PriorSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_PriorSalesAgreementMember_documentation_en-US" xlink:label="lab_ino_PriorSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Sales Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PriorSalesAgreementMember" xlink:href="ino-20201231.xsd#ino_PriorSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PriorSalesAgreementMember" xlink:to="lab_ino_PriorSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit_de3aacad-ae0c-4f4b-9010-6b1d0ec35f51_totalLabel_en-US" xlink:label="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit_label_en-US" xlink:label="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Tax Expense (Benefit)</link:label>
    <link:label id="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit_documentation_en-US" xlink:label="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:href="ino-20201231.xsd#ino_ComprehensiveIncomeLossTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:to="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b398f170-366d-45d3-b5e8-51c8bb137447_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_e295fdf6-789d-4178-95c1-8f194775483c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9fdbbdaa-d4df-4394-8725-81e94886fb4e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_23308838-8bff-4415-ab74-14e4b003efe5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_241f91c5-8f01-429c-8436-52ec4be673f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AstraZenecaMember_b63e8571-2612-4bf3-b80d-7faf04ccd42b_terseLabel_en-US" xlink:label="lab_ino_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_ino_AstraZenecaMember_label_en-US" xlink:label="lab_ino_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_ino_AstraZenecaMember_documentation_en-US" xlink:label="lab_ino_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember" xlink:href="ino-20201231.xsd#ino_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AstraZenecaMember" xlink:to="lab_ino_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_ea8b63d2-d93b-41d0-9785-bb72ffa1c065_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_1de8429d-4faf-431d-8af1-4b91ac2d5375_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_567c4154-2664-46e5-99f3-082f627475fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_be5cb0bd-5520-4002-a04d-5f83ee48b98e_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Indefinitely Carryforward</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Indefinitely Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:to="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_a7751e92-9c9f-4dcf-acb1-f0988d657d46_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options expected to vest (in shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:href="ino-20201231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_08ea6f96-8d15-44b4-b486-920d6906fbaf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation written off due to disposal of property plant and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Sale or Disposal of Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_8fb3ab1a-6350-42f1-af5a-41680773f8a4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock/senior notes to common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_13da4894-d30d-4624-a42c-ea6276fd97a0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_6442ab09-f78e-4b28-96d0-f8d6a11ffd51_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expirations of Operating Loss Carryforwards, Components [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_061cd02d-908f-4cd6-a39d-79897b4d0801_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:to="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5d223cfd-4cee-4375-a19f-5624a2c83825_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_63d6aac0-35e8-4213-a489-e29c35f0188e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_fcc4470c-2d3a-444a-9c3f-0e30ddae7a9e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_3e4232f4-9468-46eb-9656-1bb35618dd63_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1524dd7f-e393-4e61-9d5e-8c668227173e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CaliforniaIncomeTaxAuthorityMember_b923e475-2062-40d8-b85f-b5c1cd1000ba_terseLabel_en-US" xlink:label="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_ino_CaliforniaIncomeTaxAuthorityMember_label_en-US" xlink:label="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Income Tax Authority [Member]</link:label>
    <link:label id="lab_ino_CaliforniaIncomeTaxAuthorityMember_documentation_en-US" xlink:label="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Income Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CaliforniaIncomeTaxAuthorityMember" xlink:href="ino-20201231.xsd#ino_CaliforniaIncomeTaxAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CaliforniaIncomeTaxAuthorityMember" xlink:to="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredRevenueFromAffiliatedEntityCurrent_71f873ba-7a64-47b8-bbc3-f1355fef3a2f_verboseLabel_en-US" xlink:label="lab_ino_DeferredRevenueFromAffiliatedEntityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue from affiliated entities</link:label>
    <link:label id="lab_ino_DeferredRevenueFromAffiliatedEntityCurrent_label_en-US" xlink:label="lab_ino_DeferredRevenueFromAffiliatedEntityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue from Affiliated Entity, Current</link:label>
    <link:label id="lab_ino_DeferredRevenueFromAffiliatedEntityCurrent_documentation_en-US" xlink:label="lab_ino_DeferredRevenueFromAffiliatedEntityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The carrying amount of consideration received or receivable from related parties as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredRevenueFromAffiliatedEntityCurrent" xlink:href="ino-20201231.xsd#ino_DeferredRevenueFromAffiliatedEntityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredRevenueFromAffiliatedEntityCurrent" xlink:to="lab_ino_DeferredRevenueFromAffiliatedEntityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_a81376e1-acb4-4e63-8d43-7beedcd7ed22_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_b030bdc7-d2ff-4459-b957-de15806e8f3c_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_20631d17-3d09-470f-9b47-ce5699632d55_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d3d8b27-2c4d-4bab-8f9c-a3a91aabfd7c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_3a1e6754-5db1-4a0a-9aca-831fac6a9f80_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value measurement inputs and valuation techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_86ddf159-b693-4ce7-9cba-f7848aa09145_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_41369d97-7702-4d92-826b-5562eae3ee05_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_c9666070-f207-46bc-b940-9cc964a06cd0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_6ec388c1-7704-42d2-b4f3-e2dd70041762_netLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxBenefitsExpired_94effaa2-e894-4446-a5cc-9547717ef926_terseLabel_en-US" xlink:label="lab_ino_TaxBenefitsExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits expired</link:label>
    <link:label id="lab_ino_TaxBenefitsExpired_label_en-US" xlink:label="lab_ino_TaxBenefitsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Benefits Expired</link:label>
    <link:label id="lab_ino_TaxBenefitsExpired_documentation_en-US" xlink:label="lab_ino_TaxBenefitsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Benefits Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxBenefitsExpired" xlink:href="ino-20201231.xsd#ino_TaxBenefitsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxBenefitsExpired" xlink:to="lab_ino_TaxBenefitsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_3a46e593-6734-4a78-b7b7-146f224a1461_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_36429321-b0d6-48f5-a7c7-dc770c3a7fad_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held-in-trust</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_841f3310-5452-4ff5-9be7-80430006902d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_842f1da6-4a34-4d39-b50f-333801ddcff0_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_cbe705ac-383f-469b-a644-7936af86db9d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of intangible assets by major asset class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_dbdc3fdd-8040-4e3e-9cc2-fd7ea864d828_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_40730e6a-fe9c-441b-8c4b-fa217708023e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b146b9ae-7f23-43ef-930a-793287843814_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_37e55c21-9a31-469b-9dff-e91cd13b6af8_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_6612cc13-0cc1-4316-8b15-1d66e7cc9d87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of finite-lived intangible assets, future amortization expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_MCDCMember_5b1066d9-8df2-47e1-943a-e2bd590564c0_terseLabel_en-US" xlink:label="lab_ino_MCDCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MCDC</link:label>
    <link:label id="lab_ino_MCDCMember_label_en-US" xlink:label="lab_ino_MCDCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MCDC [Member]</link:label>
    <link:label id="lab_ino_MCDCMember_documentation_en-US" xlink:label="lab_ino_MCDCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MCDC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MCDCMember" xlink:href="ino-20201231.xsd#ino_MCDCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MCDCMember" xlink:to="lab_ino_MCDCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_66901c6f-3c4f-418d-b460-2640bf296664_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Carryforward Indefinitely</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Carryforward Indefinitely</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:to="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths_22dff54c-01c0-4c88-a353-2c19cd21a764_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Three Months</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Three Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringinThreeMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths" xlink:to="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_dee5e9b5-9926-455b-b08d-b753048a9c91_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_924d827c-91e5-4960-b4f1-3d5017e5ac1c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3362e536-b221-443f-ab3e-85c5edf84cbd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_fbfef957-2ade-4e95-8bbf-f38744255872_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2fa0dc55-3349-466e-86e6-f71aa66270f0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_7fd64e2d-dd28-4bd8-ae71-464ad54b27e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of shares authorized under stock option plans, by exercise price range</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_524ecbb7-113e-47c1-9302-9368a4316897_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_94e1c8e2-6dfa-409e-8ff5-ff44b90170ac_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_647c6baa-d74c-4610-81b8-daab273a53f4_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f791658e-2220-4680-b494-7639120970d9_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a68648ac-2a27-4d49-8692-7df8864d3c10_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;par value $0.001; Authorized shares: 600,000,000 at December 31, 2020 and December 31, 2019, issued and outstanding: 186,851,493 at December&#160;31, 2020 and 101,361,034 at December&#160;31, 2019</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_5953317b-b791-412b-b7dd-d531680b9595_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9480b1ca-17a4-4c1c-b409-1ada0554acd0_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_13ea152d-cd97-4844-abe8-ebf1e668a5d0_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_adc01086-67cd-4004-af82-829e8cdf7dc0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_44425940-5a04-421e-9378-d2a4592a65d3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c26d4ff6-6182-4535-b6fe-5bc863a851a2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_a6752a01-4d19-481f-8c18-13f82179c708_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets and liabilities, net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:to="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_9cea45d4-5e93-4782-a67b-99ac08e5e9bc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther_4973db68-bd78-4bf3-8214-334936733470_terseLabel_en-US" xlink:label="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther_label_en-US" xlink:label="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) In Other</link:label>
    <link:label id="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther_documentation_en-US" xlink:label="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) In Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" xlink:href="ino-20201231.xsd#ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" xlink:to="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_93710321-b5f6-4c2e-b957-8623ad29267f_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7436b6f2-b655-4cbb-961b-97aeb9c6e583_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_a6ae710d-e523-4177-bd66-379bd5c95f17_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_1a697484-a290-48f7-836b-b3726ffa7217_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_38676904-6e7c-4c26-aa59-7be8ec95f910_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ba65b502-d21f-4028-9653-ce60fec9beb0_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_20c19f8c-f2a9-4c85-878f-462c7d0df10f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_957e7434-eebc-408f-95a8-53a026862a28_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_b923f6e2-f6a9-48b7-b4f7-7030484c06b6_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_410f2f81-b844-4611-9c43-a613e80a0ed5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_07eed197-b22f-4cff-b7b9-86835ba162aa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_cebf0b00-6e5e-45ca-9c4c-7c6cefef3991_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_47c7422d-8819-4cff-bb38-e81c2ca0ef49_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Company</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_7c169af1-b5a1-43a3-abb8-0227b94a7bb4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax rate differential</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_e39bc01a-421a-43aa-9432-aaec4dec91ba_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, measurement input</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_949b0a33-16f8-4e25-9279-52c3184fbc26_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_56c2a8cc-90a8-4302-80d3-12bad21b6d51_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_a377f722-4b3a-49eb-b39b-f872b90a64e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_aab54d25-75d1-4ef6-995e-a9a999893af5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_5d1a3151-268b-4011-8f7f-d120ca317a0c_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d45ff6e6-ef49-456f-93fa-9d10dc3e63c8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_949e5558-bf49-4a36-87f7-9661fc21c3f3_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_446fa395-71ea-4257-a8b1-9a4bed74465a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_05886da8-e856-430c-bb8a-633a2028978b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_667dedd5-bf31-402f-bcba-df37c1ff4100_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Item or Group for Fair Value Option [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_fa6a66ad-aae2-4886-8f65-73e62668ceb6_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_65286903-dc84-4aa5-9fdd-53ad4cc74362_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_60017d52-b2dd-4643-a585-2f3ecb470eb8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8d7ebf7c-74e4-407a-b13f-44e363d0a660_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGain_798b7323-f5b6-438f-b446-3869c98cdfb6_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain on sale of investment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGain_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1429b3b7-7766-4aba-89a7-e056d87a2c30_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_7010d7c4-4103-40a7-a1e5-b0f77b571b2d_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_8cb16ecc-2cf1-4e50-97d2-6b5498fe932b_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_5a5c4a9f-15a2-49d1-ab65-23e3bb6960d9_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_81504fcb-ecb1-400c-a5b8-6cf2f1e1b0e0_verboseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent" xlink:href="ino-20201231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingCurrent" xlink:to="lab_ino_DeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_640d56e1-77e2-43c9-ab74-c77fff852d5f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_3edec04a-570c-4264-9e29-62db875c44af_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_e2018cba-5e3b-42fe-be23-f5005514adf7_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_7dd9a365-4891-4f46-be69-2f6dc346c417_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_6641ca03-5407-4aa6-826a-689796566541_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_5afcd801-e365-4755-be27-e25d43d99434_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_87600326-5613-4954-9b24-6d0b1992b38f_negatedTerseLabel_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount converted into common shares</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_label_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Converted Amount</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_documentation_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Converted Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:href="ino-20201231.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:to="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_315dbc91-211e-4aec-829c-0abf9fad907c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e4b882c8-9b24-41e1-8448-4e13f6a84e1d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_6f79bca8-ce52-4d15-a1a5-965a2be993b8_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of non-controlling interest in Geneos, net</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8c845309-581a-46bd-8a57-8122aecb7b67_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inovio Pharmaceuticals, Inc. stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2be0c154-4e40-4e25-9527-7467d94f5b3f_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_46ce4f5f-a56a-48fe-9cc4-f948b2ef5151_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_34d55b62-e61b-407a-a135-ba1cfd2083e1_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_756ab837-80ac-4683-bb1c-37f4164f7fa5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_2d6dbf3f-7d2c-4ab5-9aed-c50671118366_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_d610243b-65b3-4bed-b4ed-430aaa3b9a89_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_6e8cf8f8-fc8a-46c0-a498-6e415be6c018_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ffdeee59-f52f-4e48-8374-cecf17fac654_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_872acd57-9a89-4c53-b36b-c6d49825595a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_4308f858-00e8-4c7a-a7da-a7cdc6bd0bee_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's contribution to 401(k) plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_7229e0e1-c6de-413f-bb9c-7a5fc75abd7b_verboseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual year term of incentive plan</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award maximum contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:href="ino-20201231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_0372abe1-0e2a-4da7-8fe3-c444b0bef96d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_243f98c0-6f00-4adc-8308-400c80172d97_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredClassAMember_f71328ce-2c73-4c4c-ac4e-2d0997682d13_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred</link:label>
    <link:label id="lab_us-gaap_PreferredClassAMember_label_en-US" xlink:label="lab_us-gaap_PreferredClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredClassAMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredClassAMember" xlink:to="lab_us-gaap_PreferredClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_331a451a-fb92-4b06-9ca3-66d9f16f53ae_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_d0fdf956-46ed-4d96-b132-66d874ba8811_terseLabel_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_label_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_documentation_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:href="ino-20201231.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:to="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a848abe7-f5e4-4150-a2fb-8d6029a2cc24_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f22466b6-a484-4f47-804d-2c173c866bab_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_c1229151-43e8-40a9-bff6-c9af1359ddc9_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_52e1c981-5050-4f4f-9b47-90f150c9bc72_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_63eb0eb9-4432-47ef-8be1-30a190ce1db1_terseLabel_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue under collaborative research and development arrangements from affiliated entities</link:label>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_label_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License with Affiliated Entities [Member]</link:label>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_documentation_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License with Affiliated Entities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember" xlink:href="ino-20201231.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LicensewithAffiliatedEntitiesMember" xlink:to="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_6f41e517-5c76-4746-a8d0-ca310d0d5958_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_cb465df3-140d-44b4-b294-71929256827b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in a gross unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_19e3c399-4125-4eaa-8924-88411531f81a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d39f0ef5-f39d-40e8-a759-1b0b5feab891_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_2caca8c8-3f3a-4f89-a4b9-62581d819206_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_e9b5df9d-5ad6-4b2b-9269-edb3ea4e7f68_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ae2d4692-039c-4379-99a9-3b9de125e168_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_0f74fb34-8013-44cd-aa5a-826e7d2260b4_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_607bc49f-b5f3-432a-bd58-de35079a40ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_f99d7c5b-857b-45e2-a9bf-17b906066baf_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_d96b1c3c-cd5e-4910-a4ef-f73d3eef5bca_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of net loss in Geneos</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_01dab2c2-3e42-41da-b486-6beaf13ceccb_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_19bf61c3-fba7-4107-a85c-c25373a34caf_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6f97a668-5bdc-4a64-a36d-7813afaa1025_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0e7603cb-42c1-4b5f-8534-6033439455c6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_4fbfffae-9bef-474c-9023-2ca7af8aafd8_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2bf03bee-68e2-4c92-ad18-a5bbd726a245_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_94c32846-2460-4fb2-ac16-f3ab092d2828_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_bddbc090-eac1-4913-ab4f-b235c48d5e1e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFourMonths_fc724d8f-5577-4ac1-b6e5-9a5b4910d2c2_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFourMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFourMonths_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFourMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Four Months</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFourMonths_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFourMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Four Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFourMonths" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringinFourMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringinFourMonths" xlink:to="lab_ino_TaxCreditCarryforwardExpiringinFourMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxAssetsIntangibleAssets_17fc9066-a268-4562-940e-1ab7ba5175df_terseLabel_en-US" xlink:label="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intangibles</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsIntangibleAssets_label_en-US" xlink:label="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Intangible Assets</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsIntangibleAssets_documentation_en-US" xlink:label="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsIntangibleAssets" xlink:href="ino-20201231.xsd#ino_DeferredTaxAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxAssetsIntangibleAssets" xlink:to="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_80ece0c4-5af1-4cc5-b0cd-6ab6547a9174_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_4671d1d9-c630-4992-8519-228ff1a55966_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities held</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_00fbd7be-2544-4a8c-8988-686e14487e96_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_6696646e-2a5e-4713-a4c6-544c9d4a8f1d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of unrecognized tax benefits rollforward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_93be7c1c-b26c-412c-a635-2bd854205424_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_018621fb-43db-4e0e-a989-e7ab003d859b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_63dd96d5-b799-4571-8bd3-e5670fa1b84f_terseLabel_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, required bondholder approval, percentage</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_label_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Required Bondholder Approval, Percentage</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_documentation_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Required Bondholder Approval, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" xlink:href="ino-20201231.xsd#ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" xlink:to="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_1175af3c-bb93-41f4-9775-08b5f4dd9a71_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_4e9b1672-7b38-47bd-bcd5-d52547d99d56_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_9c162789-fa89-4c96-895b-27483368b487_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_b285991f-ef54-4309-8b2e-c142c366320e_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_46c82004-fcce-4b03-8b6b-c3b1576a6546_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_5bc62500-8e9b-4eac-8404-11dd54b8dfb5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_5fd65a8b-d7aa-46bd-9ac4-3928347848db_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment disposed of</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Disposals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f71dc7d4-6988-42fe-a7a7-3f32d0b3d5ed_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_44faf46d-5f25-46d2-9b9a-d5bacafb4a42_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_39d1e613-a5d9-408b-87a8-4a70ecfdd7b9_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DoDMember_d40531f9-e6b3-4465-9af2-d4462661570e_terseLabel_en-US" xlink:label="lab_ino_DoDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DoD</link:label>
    <link:label id="lab_ino_DoDMember_label_en-US" xlink:label="lab_ino_DoDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DoD [Member]</link:label>
    <link:label id="lab_ino_DoDMember_documentation_en-US" xlink:label="lab_ino_DoDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DoD [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DoDMember" xlink:href="ino-20201231.xsd#ino_DoDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DoDMember" xlink:to="lab_ino_DoDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ApolloBioMember_52f46a6e-6a60-4aab-bd87-47feeb2a6821_terseLabel_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio</link:label>
    <link:label id="lab_ino_ApolloBioMember_label_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:label id="lab_ino_ApolloBioMember_documentation_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember" xlink:href="ino-20201231.xsd#ino_ApolloBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ApolloBioMember" xlink:to="lab_ino_ApolloBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_InitialConversionPriceMember_9626c865-e7d8-4796-93cb-34cede79a6ef_terseLabel_en-US" xlink:label="lab_ino_InitialConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Conversion Price</link:label>
    <link:label id="lab_ino_InitialConversionPriceMember_label_en-US" xlink:label="lab_ino_InitialConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Conversion Price [Member]</link:label>
    <link:label id="lab_ino_InitialConversionPriceMember_documentation_en-US" xlink:label="lab_ino_InitialConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Conversion Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InitialConversionPriceMember" xlink:href="ino-20201231.xsd#ino_InitialConversionPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_InitialConversionPriceMember" xlink:to="lab_ino_InitialConversionPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0eb3f74d-8b48-4fed-84cc-dcd82f65b78a_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_1014cf3d-8b49-4739-afe6-a98ce1a04e6c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_55561d86-63f8-46be-9660-977549e6b251_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_1d496b1c-c8c1-4352-a0be-6bff5366570b_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_803dde6e-8e83-42d4-a583-cdcfc48e8044_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_a7361551-04a9-450f-bc17-cf87a960bebd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on short-term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_c3a8c355-2b04-4c70-932a-d9be73421134_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_cb978411-d9eb-4a8f-87a7-50637dfb9957_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_2e5d87d1-d1f9-4edf-8055-b7823a896549_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers and Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2d775f6-48ec-41f7-ba5e-13b785377733_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_dafaaf47-d674-4a28-be10-cdecef0d17c2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_233962c5-27e6-44c9-bcc5-511cbf3e21d3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ec797975-7b16-4939-98ec-fb1cf1d45b7b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_e4557b05-826d-4a23-9e89-0e713996341c_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtinstrumentAccruedInterest_dca99d3e-8fb6-4d00-8958-bbd28b6180d4_terseLabel_en-US" xlink:label="lab_ino_DebtinstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_ino_DebtinstrumentAccruedInterest_label_en-US" xlink:label="lab_ino_DebtinstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Accrued Interest</link:label>
    <link:label id="lab_ino_DebtinstrumentAccruedInterest_documentation_en-US" xlink:label="lab_ino_DebtinstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtinstrumentAccruedInterest" xlink:href="ino-20201231.xsd#ino_DebtinstrumentAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtinstrumentAccruedInterest" xlink:to="lab_ino_DebtinstrumentAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_01e91303-07c0-47c7-9e78-b42be1ae08a8_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_34b4920d-09d3-48d6-8b62-7b5403fd35d7_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e3cf038a-d752-42ba-bbcb-73d8ae153490_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4f9ecd6a-7dfa-439b-81f4-0f90a7003dd4_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_139b4c81-f2f9-49d9-bd7e-88d910645fd2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_eb67a308-ad13-4f67-a93d-43c6d5c91cb8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_b08a710a-98c7-4f00-952c-f763a2ae2b66_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, expirations in period, weighted average exercise price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_9784b5d0-f981-4105-af32-180fdc2b0558_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d5fd447d-8212-4ced-96d6-39870fb05b77_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_084f1719-2e1c-433c-a587-0942854e174c_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Two Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_137fba9e-e8ea-43d4-b794-c3549407636e_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_74895369-d347-4ff3-a63e-48f436e428ee_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_40bc332e-8f34-4d57-bf86-82f7d8d1066e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fe05cef4-4f6e-4ba0-a4ce-b1a6340e7c27_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of common and preferred stock authorized, issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7bcd0c18-2676-426d-b636-f13617399230_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a457af68-86da-49d4-9579-9a33c43cc6b5_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_3dc5159a-882e-4a80-9ef6-6a6fd4afc82f_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_874f23df-09c4-4f3a-bd7c-abc45c076256_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(k) Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesFourMember_5e1d3e44-7555-482c-9fc5-ac3e79d17bab_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$9.01-$12.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFourMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Four [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFourMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFourMember" xlink:href="ino-20201231.xsd#ino_RangeOfExercisePricesFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesFourMember" xlink:to="lab_ino_RangeOfExercisePricesFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_2d4897ae-9c4c-465b-ab0f-0f45523b5078_verboseLabel_en-US" xlink:label="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of vested restricted stock outstanding under the plan (in shares)</link:label>
    <link:label id="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_label_en-US" xlink:label="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares of Vested Restricted Stock Outstanding Under Plan</link:label>
    <link:label id="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_documentation_en-US" xlink:label="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of vested restricted stock outstanding under the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:href="ino-20201231.xsd#ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:to="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f1988f6c-e030-47b8-a2f8-b23aa33b46bb_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_d866bce1-d585-4396-95a9-2b496cab7dd1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_6cf2471d-b263-454a-95bc-e9e59defa979_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_9c80f464-51a9-44c3-9f53-ba615f9d8ee3_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses related to affiliated entity</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_f55b33e6-1c3e-4ded-a76b-8e3201c45c5c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_93803995-37d8-4b23-87da-db2a324f967c_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_93046ed0-c2d1-49e4-a0fd-2eeffcdeadf8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_7855e923-0526-4824-91c0-d4dcb9959c32_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ChangeInValueOfCommonStockWarrants_b0fd9f3b-2604-4b7b-b826-0c69a29745c8_verboseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfCommonStockWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of common stock warrants</link:label>
    <link:label id="lab_ino_ChangeInValueOfCommonStockWarrants_label_en-US" xlink:label="lab_ino_ChangeInValueOfCommonStockWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Value of Common Stock Warrants</link:label>
    <link:label id="lab_ino_ChangeInValueOfCommonStockWarrants_documentation_en-US" xlink:label="lab_ino_ChangeInValueOfCommonStockWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net change during the reporting period in the fair value of common stock warrants, which are revalued at each balance sheet date subsequent to initial receipt or issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfCommonStockWarrants" xlink:href="ino-20201231.xsd#ino_ChangeInValueOfCommonStockWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInValueOfCommonStockWarrants" xlink:to="lab_ino_ChangeInValueOfCommonStockWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_7dcd1239-727d-4273-807f-565f3fbc9192_verboseLabel_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential shares authorized for issuance under a share-based compensation plan (in shares)</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_label_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_documentation_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential shares authorized for issuance under a share-based compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:href="ino-20201231.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:to="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a3cb5da7-1227-4709-90d4-216433031320_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a9497445-fabb-4f44-9e1e-afee768a7c8a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_8c6ec391-d11b-45b6-874f-3dd190b6360f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs related to issuances of convertible senior notes and convertible bonds</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_a6025a9b-dae1-4cfc-8e87-c6791c2ae840_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise&#160;price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantProceedsReceived_aaa9d7e9-b578-4ecc-bf03-cbdf18818a64_terseLabel_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant proceeds received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_label_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_documentation_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived" xlink:href="ino-20201231.xsd#ino_GrantProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantProceedsReceived" xlink:to="lab_ino_GrantProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d5a4f0f8-d898-4b7f-a2f0-3c48fe8cac49_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e83a3eff-f1ea-49b2-9d64-a0867b70ee2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_907d371a-d422-4792-a9fe-8c2ac1313a17_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period of incentive plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_568aaf7a-0cd0-4bd9-83c4-e5967a58ec55_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c8b886c8-6273-46d5-bafd-b75f9ea970c3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_f9e3f649-6843-40d4-9bd6-eaa0c46b032c_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_45fc0f32-ea79-4725-89a4-6078c8ec6b16_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_adaed2e1-6b1b-4868-bf79-0017962b0b88_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_300a302c-f04e-4d91-b2d6-a21e9e5b0111_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (benefit) taxes at statutory rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5aaf494b-6be5-41a6-98c4-7e235f8cd88d_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_72e865b5-7c78-41e8-bfad-b633e591c17e_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_3e2a341b-af87-4812-911a-1bdb7edbbfe8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_d8be3c41-6448-421e-85cd-ff0ea00a9d52_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_053e5c87-6fd1-460c-af9d-d474684f38f6_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount on the liability component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_9469d483-03f7-411d-a1c1-e6daa7d0a35b_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_1d06d707-cb42-4941-9bce-b06c5bf6dbf1_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_43c364f7-3609-4f4e-be35-9e0da6576c13_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_46a12cfe-42ea-40c5-b75c-651f2d481f71_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFiveYears_e2f371b1-1bb9-4bfb-bdda-3a2c10d0d00f_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 and thereafter</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFiveYears_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Five Years</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFiveYears_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringinFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:to="lab_ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_9bd04b48-5837-4f02-abed-847ada60a07d_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_e0ae1e9a-38b9-4b6f-8171-9c443371c2e7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_5245d4fa-83a4-40f1-b6ad-e7cd119665ae_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_b032524c-a0e0-4006-ae51-251d2bff3f69_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:to="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_d9c9611d-65f5-4721-9cb5-a04ea0e0a5bd_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_INO4800Member_6c7676b4-09f4-4ce5-83c5-790ab6a67ad1_terseLabel_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IN O4800</link:label>
    <link:label id="lab_ino_INO4800Member_label_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I N O4800 [Member]</link:label>
    <link:label id="lab_ino_INO4800Member_documentation_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I N O4800</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member" xlink:href="ino-20201231.xsd#ino_INO4800Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_INO4800Member" xlink:to="lab_ino_INO4800Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ff6dc417-fbb6-4304-be61-b93314956127_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_6435e690-e7b7-4a2b-b06b-d6da5b768502_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e62c84a2-18ec-48d6-b78d-91320f00bd5b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b3c3525f-d392-4331-9b91-d16a0780c9e6_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f6f905d7-d50b-4489-9a5d-68ec492d5582_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_eced7c2f-5ef8-4335-9c5c-6b8b380bb2e2_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per Share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_2fdc6b77-f550-4c6c-aca2-85ffa1c393de_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_2a243810-bd1f-43da-8482-15d0d8296b79_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_758bd735-6c61-4b0b-8a2a-7d73a50bf9a3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_6d116677-4947-47f3-9d33-2d20dddffc6d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3a636285-72d1-4fe3-a3fc-dabcfe1ed6d0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_f5a7fb60-3dfc-4a40-9463-52657aa6007f_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_6ab269c5-c817-49e9-b374-8359ec2e0a86_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_718a51f2-1b41-4bfe-8437-12db3bdad7a9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_907321f9-3cd0-4c95-8f3c-3e172f2fe292_terseLabel_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase agreement, commitment of additional investment</link:label>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_label_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Commitment Of Additional Investment</link:label>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_documentation_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Commitment Of Additional Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:href="ino-20201231.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:to="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_51a59093-9351-4c50-9f21-5f552defa3ca_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedInterestFairValueDisclosure_87945cce-0988-4942-b91d-8216629be094_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedInterestFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of investment in Geneos retained</link:label>
    <link:label id="lab_us-gaap_RetainedInterestFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_RetainedInterestFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Interest, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedInterestFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedInterestFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedInterestFairValueDisclosure" xlink:to="lab_us-gaap_RetainedInterestFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_ba466ed8-5ae8-4fbd-bf8b-8561ce15dcf7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of date conversion</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_c8f599e3-e087-4d61-a70e-fd04f4918379_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards, net of proceeds from option exercises</link:label>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_label_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</link:label>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_documentation_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:href="ino-20201231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:to="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6a833c86-8a7f-4cee-bac9-3e40f2be8ac7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantRevenuePolicyTextBlock_9e8639f3-e9d5-4c0f-a9a7-ac54dd64fbf4_terseLabel_en-US" xlink:label="lab_ino_GrantRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants</link:label>
    <link:label id="lab_ino_GrantRevenuePolicyTextBlock_label_en-US" xlink:label="lab_ino_GrantRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Revenue [Policy Text Block]</link:label>
    <link:label id="lab_ino_GrantRevenuePolicyTextBlock_documentation_en-US" xlink:label="lab_ino_GrantRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantRevenuePolicyTextBlock" xlink:href="ino-20201231.xsd#ino_GrantRevenuePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantRevenuePolicyTextBlock" xlink:to="lab_ino_GrantRevenuePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_dfa13f7e-0f3c-4b9c-8654-22ceb0abcb04_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_63ced84a-ebf2-4705-9c25-161f084cbe4c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_04663202-1ab1-495c-b79f-c53749d56079_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_94f677bf-bc3c-41b8-8a6f-0016776076fc_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation of subsidiary</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deconsolidation of Subsidiary</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deconsolidation of Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" xlink:href="ino-20201231.xsd#ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" xlink:to="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7073fea3-0e87-4935-9f7a-521de14bc2e8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_053a8276-fcc9-4dcc-af34-c0a5b5153a72_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advisory fees</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Advisory Fees</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Advisory Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementAdvisoryFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAdvisoryFees" xlink:to="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_f766d949-cb8b-4261-bc70-e6a39f9579f6_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2d819831-abc8-47eb-a1d3-ee2a78848f37_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncomeTaxReconciliationFairValueWarrant_c539169a-e128-4b82-ab96-cd56e5557587_terseLabel_en-US" xlink:label="lab_ino_IncomeTaxReconciliationFairValueWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrants</link:label>
    <link:label id="lab_ino_IncomeTaxReconciliationFairValueWarrant_label_en-US" xlink:label="lab_ino_IncomeTaxReconciliationFairValueWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Fair Value Warrant</link:label>
    <link:label id="lab_ino_IncomeTaxReconciliationFairValueWarrant_documentation_en-US" xlink:label="lab_ino_IncomeTaxReconciliationFairValueWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Fair Value Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeTaxReconciliationFairValueWarrant" xlink:href="ino-20201231.xsd#ino_IncomeTaxReconciliationFairValueWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncomeTaxReconciliationFairValueWarrant" xlink:to="lab_ino_IncomeTaxReconciliationFairValueWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_cc10694f-84f7-480c-802b-f543cacaea65_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_d3904492-4b4b-4d96-98cc-d73b36a98d56_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ca1e5a2d-e5cc-44e5-ba67-c7b1e8d94be9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_2a340542-4a90-4194-b719-5fbb6fb2c5c8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions and other estimated offering expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities for Commissions, Expense and Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:to="lab_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_92642951-073e-4bff-82cd-a1300cf0d8fc_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_dddb0a90-04b3-4579-83ee-492288530c51_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SalesAgreementMember_2182732b-b03f-43a0-a8e3-4703c78094ba_terseLabel_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement</link:label>
    <link:label id="lab_ino_SalesAgreementMember_label_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_SalesAgreementMember_documentation_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember" xlink:href="ino-20201231.xsd#ino_SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SalesAgreementMember" xlink:to="lab_ino_SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_04173555-290c-47ba-a516-6687e71e5082_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e0971f2a-00ee-4ec2-a3a0-c6560c32e88d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AllOtherCustomersMember_fed4c9c3-cf29-45d2-a368-7ece2ef39b12_terseLabel_en-US" xlink:label="lab_ino_AllOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other, including affiliated entities</link:label>
    <link:label id="lab_ino_AllOtherCustomersMember_label_en-US" xlink:label="lab_ino_AllOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Customers [Member]</link:label>
    <link:label id="lab_ino_AllOtherCustomersMember_documentation_en-US" xlink:label="lab_ino_AllOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Customers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AllOtherCustomersMember" xlink:href="ino-20201231.xsd#ino_AllOtherCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AllOtherCustomersMember" xlink:to="lab_ino_AllOtherCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a82d1952-b0f1-448e-9c23-e998f6998f42_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments_626a5388-8f71-4237-a8c5-1931226a12d1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:to="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_56c6cb7a-4ee4-41a2-987a-9d5b1946639e_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bbf44cd4-2a2f-40dc-877c-39377b4d396b_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_36e72be4-2c02-49a2-b1ab-8e42c141fcca_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1d660a12-f9af-4209-ae2b-7ef2d6575c33_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6339b2be-e6cf-4050-ba68-80d2fe357209_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_9bf0f54e-4f31-4099-9da4-a348d7150a24_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (in Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3eb7564a-3711-40e1-9d50-7258c065711c_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_c617cf7b-3b98-481c-b30c-4067c31cceb9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_7e756e11-23cb-458b-a746-fd8bef4a0c51_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_2c5a12ea-e232-408a-84c9-d6936b9bc496_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_19322ac2-df2c-478f-8ad1-de11b18a9015_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares held in an affiliated entity (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advances to Affiliates, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:to="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_cbd69ec1-0830-4af6-b075-0e69debca1c8_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_6a6534e9-0775-4a95-8ad0-ba66191752de_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EquityMethodInvestmentEnterpriseValue_a7e20811-8417-4439-9f06-d3f716b26e71_terseLabel_en-US" xlink:label="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos enterprise value</link:label>
    <link:label id="lab_ino_EquityMethodInvestmentEnterpriseValue_label_en-US" xlink:label="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Enterprise Value</link:label>
    <link:label id="lab_ino_EquityMethodInvestmentEnterpriseValue_documentation_en-US" xlink:label="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Enterprise Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentEnterpriseValue" xlink:href="ino-20201231.xsd#ino_EquityMethodInvestmentEnterpriseValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EquityMethodInvestmentEnterpriseValue" xlink:to="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_5cd44883-6191-446a-a58e-947ca53c3f66_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Affiliated Entity</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_85303b83-7dd3-416e-9986-3e32c8ed83e9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_64e87e48-d5f7-4847-95b1-a98837688607_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1a3ec50b-ed1d-49e8-9eb5-13a62ff1da97_verboseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investment in affiliated entities</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_5ffb429e-3b70-49d0-b9d9-1c9e5bf900ba_negatedLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity investment in affiliated entities</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_a7be098e-594b-425d-b9b4-bbf0e71dc775_terseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investment in affiliated entities</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_label_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Value of Investments in Affiliated Company</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_documentation_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:href="ino-20201231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:to="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_fb1f9e36-e3f1-480c-9860-76ffb75f60c3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1e42982a-9e6c-4371-8c6f-52889ed9be55_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_f9f86a80-e469-45c6-81ad-505b26728daf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_42c10f9c-d944-41dc-af2e-c0136f2ed6e1_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, Net Book Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cec547b9-b7ab-4635-ad86-6d954040ddf0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, grants in period, weighted average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_bd24c63e-ed00-4285-ba1c-a626291c54a9_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement, milestone payment, revenue recognized</link:label>
    <link:label id="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_label_en-US" xlink:label="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Milestone Payment, Revenue Recognized</link:label>
    <link:label id="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Milestone Payment, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementMilestonePaymentRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized" xlink:to="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlumblineLifeSciencesIncMember_7951fb77-be24-4acd-9114-614ed605d784_terseLabel_en-US" xlink:label="lab_ino_PlumblineLifeSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences, Inc.</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesIncMember_label_en-US" xlink:label="lab_ino_PlumblineLifeSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences, Inc. [Member]</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesIncMember_documentation_en-US" xlink:label="lab_ino_PlumblineLifeSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesIncMember" xlink:href="ino-20201231.xsd#ino_PlumblineLifeSciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlumblineLifeSciencesIncMember" xlink:to="lab_ino_PlumblineLifeSciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_abb4c4a2-13f0-44d2-a946-3a5958e8603c_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9be6918a-f588-4bbf-9d27-a13d0fe687c8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on short-term investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_3755bb61-c343-4110-b25e-309689f7d93b_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_68b33f6d-2138-440d-a556-0eb7a963aef9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_1b4fb623-0604-49f9-93b1-12c8d7384f92_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8def2e0c-7cb4-43bc-8986-134d8dd68c46_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_3226900b-44a1-44df-adc1-0610f16ed4e3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1d0b4e71-59ff-4d30-ba75-327104e27777_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_08418800-c08a-420b-be1b-c327894f888f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_2fb8c26f-c02e-4e7f-901f-c27562970726_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0b0e07a3-9235-4e55-9271-6fb95373d4b7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_3bce6872-8b02-473c-9d5f-9b7df1603ed5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Geneos issuance of note payable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b7011ad1-ddf6-4a09-9b5b-6f9d338e24ae_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8206f881-e61c-408d-b3e9-950c09ad89ac_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from deferred revenue beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_f72298c0-696b-4e3f-a63a-f9061920488a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock shares outstanding under the Incentive Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Other Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:to="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_99cdf9fe-c81d-4804-8d0d-8aaed6f3a416_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, realized gain</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesThreeMember_1b82bd72-d89f-4d48-89a8-696ff1fd4570_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$6.01-$9.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesThreeMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Three [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesThreeMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesThreeMember" xlink:href="ino-20201231.xsd#ino_RangeOfExercisePricesThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesThreeMember" xlink:to="lab_ino_RangeOfExercisePricesThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_03a9361a-2456-4c18-9eb9-10ed6e4ab7fb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0d154d59-29be-48c7-bfa2-f0d00995fb0b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_ea7b8a19-e782-4265-a108-db05a87a1dcb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of quarterly financial information (unaudited)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ConvertibleBondsMember_61e3d3cf-c768-43f8-a8b4-9bd5d30a9944_terseLabel_en-US" xlink:label="lab_ino_ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Bonds</link:label>
    <link:label id="lab_ino_ConvertibleBondsMember_label_en-US" xlink:label="lab_ino_ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_ConvertibleBondsMember_documentation_en-US" xlink:label="lab_ino_ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember" xlink:href="ino-20201231.xsd#ino_ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ConvertibleBondsMember" xlink:to="lab_ino_ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_8c0d62aa-8480-4d11-b6c9-4ffcf036e919_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_df06c791-4def-40e2-a508-4386e8c61ae7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_b37aed7e-2ded-43bc-8a18-e368b7a91d98_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_f42e2b06-e9ce-49ea-b72f-098626d1e0ce_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6accac46-c5d0-4ca3-882c-70dd3201e2b7_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_1066b3a6-c079-49ba-b8ef-9bac2624c069_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_5c7c8d1d-5b5f-431b-bd6f-c152649fe39c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_0b7695a8-a879-402e-9910-841dfadb4d2b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_845dff88-f53b-43a0-beda-5875be523c5a_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1360c2d7-2259-4250-ab33-a71958481764_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_95870477-464a-4354-b8c9-d8d0e8968951_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_bddceeaf-2072-44d7-ab2d-7abf9e4adf04_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_a91a290a-1648-420f-880b-90d74d2508e9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_c65fec90-a819-42bf-a795-9e4626f40d66_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_fde71c61-dc28-43e7-94bf-085907f613e5_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_3deec33e-7b41-41ae-8bfd-9554c166b159_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_eace3941-fefe-4ec1-9349-f6b215bdf80c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b26e4a27-a33c-4d7e-bb6a-9887a3463fa5_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7e4f8bc5-fd07-4948-9b34-082855514313_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8a3c9054-e0fb-48ca-85fa-fa61caaf3d00_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentAccretionOfPremium_8863222b-04e8-4565-859e-125d29f28506_terseLabel_en-US" xlink:label="lab_ino_DebtInstrumentAccretionOfPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of premium associated with the bonds</link:label>
    <link:label id="lab_ino_DebtInstrumentAccretionOfPremium_label_en-US" xlink:label="lab_ino_DebtInstrumentAccretionOfPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accretion Of Premium</link:label>
    <link:label id="lab_ino_DebtInstrumentAccretionOfPremium_documentation_en-US" xlink:label="lab_ino_DebtInstrumentAccretionOfPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accretion Of Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccretionOfPremium" xlink:href="ino-20201231.xsd#ino_DebtInstrumentAccretionOfPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentAccretionOfPremium" xlink:to="lab_ino_DebtInstrumentAccretionOfPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9a03194d-5121-4bf7-920f-fa2ebdf5e8c2_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ca35f995-c720-47dc-9e1f-e0e0b5a3b0b3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_9479d0f5-df46-4cbd-93f7-8cbe38597f57_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_ad8ee22d-5ef0-4437-889f-75a5f887a2b9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_251ee939-0a50-46c8-a3ec-613906856eda_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_40d965da-c8be-41ef-a361-1005f8d30835_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_eeb3d788-7bc6-40ef-b0c8-55cad75b400c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effective income tax rate reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_8c24906b-0110-4fed-b97a-2279b740c129_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EmployeeMember_e1230dc8-cb99-4d9b-aa57-593a1734c3e5_terseLabel_en-US" xlink:label="lab_ino_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_ino_EmployeeMember_label_en-US" xlink:label="lab_ino_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_ino_EmployeeMember_documentation_en-US" xlink:label="lab_ino_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeeMember" xlink:href="ino-20201231.xsd#ino_EmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EmployeeMember" xlink:to="lab_ino_EmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_75845021-bc00-474b-b2ca-f6f5d18f378e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_3069b1f5-540e-4afa-9c56-8d52c6a4b3d0_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_cb23b160-4bf8-4bfd-8ca0-e8a1079fee41_verboseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_ca0a710e-dc9a-4d7f-bfec-e260594902fd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_be9a0089-0c8a-4bdc-a40b-ec621c08ee73_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_9f469bd5-51c6-495a-a455-eddc93a71dc8_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses to reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_label_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:to="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_baeca626-0975-4560-ace2-6daa9c026614_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_b49a653d-9295-4051-b7f7-b5df6c8d7644_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_9351c60e-c01d-4b16-8844-a90c0838a553_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_45b469df-547e-4242-aab2-b0921b36b33d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from affiliated entities</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_e1924b4f-296b-46b2-9c52-d83c7e9e7b99_terseLabel_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_label_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member" xlink:href="ino-20201231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GeneosTherapeuticsInc.Member" xlink:to="lab_ino_GeneosTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1a1444f9-1e8c-4316-adf0-40fec8a96c9a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_658598c7-f969-4d03-9a32-101e1ab4b54e_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_ad9797c0-b2ca-4f11-995d-dfe5a9c851c8_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_30da0906-1366-454c-9d09-c397fcf3723b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_8402a76f-9a18-4894-a811-10247ee7d4e6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_467c90d1-acdb-4526-9446-73f281815105_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, funding to be received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding To Be Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:to="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_80f20c9a-3d2f-4887-aa18-271513f2244c_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets by major asset class</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_fca042bc-1d1e-4157-ae39-7e6645542b84_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1a7467d3-e8c2-4364-9180-a6fd9f312e96_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contribution per employee, percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_3db4b998-9348-4c53-915b-ad77d393961b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of pretax loss from operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_ae0efa71-7b8c-4a09-ac4b-4805dc09a38f_verboseLabel_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_label_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_documentation_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:href="ino-20201231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:to="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_3323b62a-91f7-4c0e-9e40-b5c9f51dab61_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_04a85754-e02e-4e5e-8c3d-0e9a0ed58d15_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_51fb3913-90fe-4e1a-98b3-bca8f965e1cd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_afb98afc-ea4b-402d-be3b-5bdefb8ffffe_terseLabel_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California</link:label>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_label_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California [Member]</link:label>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_documentation_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember" xlink:href="ino-20201231.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SanDiegoCaliforniaMember" xlink:to="lab_ino_SanDiegoCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_b12e3554-fb5d-4f20-b953-ebbe646411ac_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_233a75ea-abdb-481d-8f1f-7326df55d607_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_9e459460-a6f7-40fd-814b-d93e550925de_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_d57adcd1-425a-447b-bc74-c3fe9ef94627_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_e915ddec-66e6-4048-9869-472029035bdd_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_2922ab6f-dc0a-4196-9f4b-51b32a449597_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncomeTaxReconciliationStatuteLimitations_642c056d-6741-4a70-bbd4-c2f5fceda890_terseLabel_en-US" xlink:label="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_ino_IncomeTaxReconciliationStatuteLimitations_label_en-US" xlink:label="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Statute Limitations</link:label>
    <link:label id="lab_ino_IncomeTaxReconciliationStatuteLimitations_documentation_en-US" xlink:label="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Statute Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeTaxReconciliationStatuteLimitations" xlink:href="ino-20201231.xsd#ino_IncomeTaxReconciliationStatuteLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncomeTaxReconciliationStatuteLimitations" xlink:to="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8696a1d6-85ae-462e-b224-db2f9f1e4155_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ChangeInFairValueOfCommonStockWarrants_85585ba5-66d4-43eb-b9fa-bb155f7ed6b1_verboseLabel_en-US" xlink:label="lab_ino_ChangeInFairValueOfCommonStockWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of common stock warrants</link:label>
    <link:label id="lab_ino_ChangeInFairValueOfCommonStockWarrants_label_en-US" xlink:label="lab_ino_ChangeInFairValueOfCommonStockWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Fair Value of Common Stock Warrants</link:label>
    <link:label id="lab_ino_ChangeInFairValueOfCommonStockWarrants_documentation_en-US" xlink:label="lab_ino_ChangeInFairValueOfCommonStockWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net result for the period of the change in fair value of common stock warrants which are measured at fair value on a recurring basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInFairValueOfCommonStockWarrants" xlink:href="ino-20201231.xsd#ino_ChangeInFairValueOfCommonStockWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInFairValueOfCommonStockWarrants" xlink:to="lab_ino_ChangeInFairValueOfCommonStockWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_0f04d993-a512-4de9-804f-87f18be88368_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_af958574-a66e-4e2a-83e8-e5f1668b5ab5_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_66a3cd44-a207-45bb-bb39-1edec73b2167_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_352d2c0d-52c5-4f2e-9172-be7cbdc3a919_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_22f5a7d7-b30c-4de2-a4e8-288f566d9d67_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d03a8de4-2202-4991-8818-2f735c976b46_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fb093e7c-8b70-43f9-9949-a5d21c453a74_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock options, activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_a1d3dc4f-a5fb-4650-8190-e5013241cdfd_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_efbb7d74-b176-411d-b772-82ed9114ac23_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, area of land under lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:href="ino-20201231.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:to="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_a8f97738-9ada-4baa-803e-fe17b786222a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_def9ada3-99d1-4b79-bc61-739eb77db5f7_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:href="ino-20201231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_667b2aff-c636-458a-b15a-671a372f232d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_4c137e5b-80de-463f-8437-4316e6ee6aa0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and other</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Other Types [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_1e6f69ee-996c-4af1-9910-3ee13740ffeb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_e4604015-de1a-4171-b80a-68e33eba95bf_negatedTerseLabel_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:href="ino-20201231.xsd#ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a2005406-17ec-4566-a0cc-fd86fa5421bf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4bcadf06-2a4b-422f-996c-0b324c9e211d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OtherCounterpartyMember_05796ecf-870b-46b9-ab0b-f085c389a567_terseLabel_en-US" xlink:label="lab_ino_OtherCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Counterparty</link:label>
    <link:label id="lab_ino_OtherCounterpartyMember_label_en-US" xlink:label="lab_ino_OtherCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Counterparty [Member]</link:label>
    <link:label id="lab_ino_OtherCounterpartyMember_documentation_en-US" xlink:label="lab_ino_OtherCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Counterparty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherCounterpartyMember" xlink:href="ino-20201231.xsd#ino_OtherCounterpartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OtherCounterpartyMember" xlink:to="lab_ino_OtherCounterpartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_8a74f5b1-88b8-422c-b9f3-c4b126c219b4_terseLabel_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2019 Bonds</link:label>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_label_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2019 Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_documentation_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2019 Convertible Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember" xlink:href="ino-20201231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_August2019ConvertibleBondsMember" xlink:to="lab_ino_August2019ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_958f682f-d629-45b6-8c53-920cfef59397_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_4ea8a64c-6a54-4d8a-b987-972b426b301a_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fa2f28d5-9488-4f94-a6d1-63521b71cae1_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total remaining lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_561e8cd0-bdc9-40c1-bc0f-45ea365f412d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_fcbf9e95-6090-44af-84b6-5a465794df65_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price, procurement contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_label_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:href="ino-20201231.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:to="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_8f2ae3a4-f9d2-4ada-a93f-de30b457addc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_ca8854e2-dd88-4097-a9ee-423a8c10fe12_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_7001ffd7-ae81-429d-9700-c15c7d1d168f_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StraightLineRent_915bc2e5-e01b-4860-86c5-d95be02b5c14_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StraightLineRent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_StraightLineRent_label_en-US" xlink:label="lab_us-gaap_StraightLineRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Straight Line Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StraightLineRent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StraightLineRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StraightLineRent" xlink:to="lab_us-gaap_StraightLineRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_c8dc097e-9d7d-4a96-9b52-15612210d5fe_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_388cad29-0192-46a5-a9ff-206a9f580763_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement period from effective date for termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:to="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0a25de97-05ab-4939-a999-5595ef932182_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_32f69420-3a86-4ecf-8787-2e2e98481051_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesOneMember_15237ee1-2964-41ca-868c-8614a9417020_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1.48-$3.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesOneMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices One [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesOneMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesOneMember" xlink:href="ino-20201231.xsd#ino_RangeOfExercisePricesOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesOneMember" xlink:to="lab_ino_RangeOfExercisePricesOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_55446550-c1d9-4dd8-a559-8a377cbe91a6_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_3fffaf1b-26f1-487f-b8a0-d4d6427afdb7_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_d0620151-bbf7-4a40-ae4f-3f9b6354ca44_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_5565cf61-a574-488b-aa43-12d168d89b83_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock sale agreement, aggregate proceeds from issuance of stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:href="ino-20201231.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:to="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_ee4ebafd-3da8-4254-8960-a24ed25f72a5_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_28ee2943-1ada-45d9-b07b-0989c807a1c6_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Unobservable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_5078a8d0-8d23-4ecb-a2b3-b8ab82411b09_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expirations of Tax Credit Carryforwards [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_5a14dfd5-a366-4059-acc5-b4db4646c798_terseLabel_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_label_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C E L L E C T R A3 P S P Proprietary Smart Device [Member]</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_documentation_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C E L L E C T R A3 P S P Proprietary Smart Device</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:href="ino-20201231.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:to="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_ae355c04-de3c-4f5d-82f5-d3fba2095ed3_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_325a00ae-4e87-4d12-9b07-f15d165ec48f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_0f6cf3c4-5116-45dd-be28-3ed3ed08c434_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PLSaffiliatedentityMember_78b1126f-6162-4e4d-9751-fbb097846552_terseLabel_en-US" xlink:label="lab_ino_PLSaffiliatedentityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PLS (affiliated entity)</link:label>
    <link:label id="lab_ino_PLSaffiliatedentityMember_label_en-US" xlink:label="lab_ino_PLSaffiliatedentityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PLS (affiliated entity) [Member]</link:label>
    <link:label id="lab_ino_PLSaffiliatedentityMember_documentation_en-US" xlink:label="lab_ino_PLSaffiliatedentityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PLS (affiliated entity) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PLSaffiliatedentityMember" xlink:href="ino-20201231.xsd#ino_PLSaffiliatedentityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PLSaffiliatedentityMember" xlink:to="lab_ino_PLSaffiliatedentityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_e9a6ee2a-df22-4b22-b688-f39c3a79bb7f_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of stock, shares converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_51e2f844-a0e2-4c46-8b33-b1c4c8afa44a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_0c8dfdb9-30a3-473c-8c7c-1768b2713d68_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedParties" xlink:to="lab_us-gaap_AccountsReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_b87fbfcc-4d09-4ab2-a308-b18509c70519_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_16a27236-4e2f-46f4-99e8-77714e25e0c2_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_3a8bc3ed-fb0e-4c9f-bde1-ebb71ff65c33_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_448a87a0-36e9-4c60-85df-467061f55e43_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_edbb8d72-12b6-495c-9f0c-913e81c4d86e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ff1b0d53-fa76-4ffd-9296-61f521299c7e_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_1bb3364c-1db2-464d-aa00-3702e6142a9e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit from other unrealized gains on short-term investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_86d79576-69c0-4ad4-8af4-534cbbdc08d6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_41c4e551-83b4-42dd-b36d-8e449f0ed57f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, expirations in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_22148663-1d86-4a99-a586-61991dab40b3_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_fc9dc795-89aa-4b52-a86b-286cbe7f2d28_verboseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease in Deferred Revenue From Related Parties</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:to="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0faa3840-01ee-4e37-b57a-eda097ace004_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_f993f7d8-7696-48c9-8ff3-50c64311f7b3_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares authorized (in shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:href="ino-20201231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_9c3b9c4a-bfff-43ff-b4e5-c9e1cb3f08a8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_0812df46-b92d-4f53-b49f-076a31dc82ba_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_3b666083-a9d9-45e1-b7e2-1060b87efe7b_terseLabel_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, internal rate of return</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_label_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Internal Rate Of Return</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_documentation_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Internal Rate Of Return</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:href="ino-20201231.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:to="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_cd213efd-46fa-4bc9-93bc-b2a65aa294b3_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_0ba27732-7090-4e1f-8178-c3565da9e30f_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in the Next Twelve Months</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in the Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths" xlink:to="lab_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_2c5d3e4b-625b-4393-833a-32577806b9ae_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b21abe35-6724-47c1-ac12-c40aac8b9f98_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_8d505937-3969-4292-b5f1-72ee72d7b754_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ce2ba0f9-92a3-43fa-8777-632e18524667_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value for options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_7d207596-d189-4e3e-984c-251ab16eadc4_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_73e79e00-af35-48cb-88d9-aaf87e219359_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_9ef0e54a-7a9c-4c0c-9d1c-50308aaefad1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_bfdbf38a-3205-437f-b23a-f8a0ebee3e07_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_202c5fd0-8858-40c6-b6ee-af588d31ca8e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_85880d4e-387c-427e-b40d-3fd3827a574d_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_e0795f96-230a-4b17-bd51-0124242c7903_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_493d1ddd-ae19-4ed8-b487-0f16d990a728_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_844b64f1-a01c-43d1-a828-7c98d92f4d5c_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2cf93882-522a-4f0e-b0df-a2d46bb79da9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_224d71ba-d59d-4440-8a2a-c08042d50d1d_terseLabel_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">D N A Encoded Monoclonal Antibody Technology</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_label_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">D N A Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_documentation_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">D N A Encoded Monoclonal Antibody Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:href="ino-20201231.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:to="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_a17fc563-d8bd-4150-b988-543a48a7837c_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_f78eafb8-90dd-473b-b35a-5e09939209e9_negatedLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_11554650-0976-4f61-81c5-f76f37d1cd11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_5ec9752a-5f85-47ba-9c5d-f959cde2da41_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_a832dc82-e1e0-4ccf-b66d-0f078719eef1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares owned (shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_21748bac-caa2-4f97-b487-da40614fe7bf_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NewSalesAgreementMember_8b18a969-0d2d-4691-adcf-7db257a91694_terseLabel_en-US" xlink:label="lab_ino_NewSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Sales Agreement</link:label>
    <link:label id="lab_ino_NewSalesAgreementMember_label_en-US" xlink:label="lab_ino_NewSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_NewSalesAgreementMember_documentation_en-US" xlink:label="lab_ino_NewSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Sales Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NewSalesAgreementMember" xlink:href="ino-20201231.xsd#ino_NewSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NewSalesAgreementMember" xlink:to="lab_ino_NewSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_e3f0cb12-09b9-43a7-a48e-5ef2dbb48a0f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidManufacturingExpensesCurrent_3e7edcc2-8230-46a1-98c9-cef21cde78cf_terseLabel_en-US" xlink:label="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid manufacturing expenses</link:label>
    <link:label id="lab_ino_PrepaidManufacturingExpensesCurrent_label_en-US" xlink:label="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Manufacturing Expenses, Current</link:label>
    <link:label id="lab_ino_PrepaidManufacturingExpensesCurrent_documentation_en-US" xlink:label="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Manufacturing Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpensesCurrent" xlink:href="ino-20201231.xsd#ino_PrepaidManufacturingExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidManufacturingExpensesCurrent" xlink:to="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_e97dddd6-1e7a-47d0-b81c-f050ff40f280_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0adaf05b-91dc-4b9b-a9d2-3bee691f6e51_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_c76ab9a7-ecdd-4af6-8a4c-c3de3ea32af3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_5ca3ac4c-abca-471e-acba-764aeaf8c97c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8a769c05-36ce-4770-814e-e15eae420ff1_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ed836d3f-71f4-4404-a12a-66637b1ba89a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_ea053e12-eece-496a-92fa-7e510d92e6e3_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of major customers and concentration risks</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_a0b3e2dd-2931-4bdb-85bd-bf71ca31c1b5_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, foreign non-income Taxes</link:label>
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_label_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Foreign Non-Income Taxes</link:label>
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Non-Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:to="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_24d81418-0e13-4d51-988a-22e8b045c47e_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_e8666109-193d-4f76-8b2a-8244bd869db3_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_e9912947-520a-47e1-af4b-154ff04c3917_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series&#160;C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_ce7c6f32-4ffb-4692-9e03-2b9f344eaada_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_462e5b19-61f0-437f-a219-6838f7a89604_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total antidilutive securities (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_InvestmentOwnedAdditionalSharesAcquired_4555dedb-9e20-443a-b511-e94fe2fa4b47_terseLabel_en-US" xlink:label="lab_ino_InvestmentOwnedAdditionalSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment owned, additional shares acquired (in shares)</link:label>
    <link:label id="lab_ino_InvestmentOwnedAdditionalSharesAcquired_label_en-US" xlink:label="lab_ino_InvestmentOwnedAdditionalSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Additional Shares Acquired</link:label>
    <link:label id="lab_ino_InvestmentOwnedAdditionalSharesAcquired_documentation_en-US" xlink:label="lab_ino_InvestmentOwnedAdditionalSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Additional Shares Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InvestmentOwnedAdditionalSharesAcquired" xlink:href="ino-20201231.xsd#ino_InvestmentOwnedAdditionalSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_InvestmentOwnedAdditionalSharesAcquired" xlink:to="lab_ino_InvestmentOwnedAdditionalSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_1abd1bf4-1fb7-46dc-9b81-7bd12bf98b32_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_72a6fe49-e942-41ac-8070-8c39869c7b7a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases (decreases) related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_2fe7ae56-b944-44d1-aade-c4a47440ad53_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e993c094-b549-4e08-a407-14a02736f978_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b951e4f3-a5dd-4fe8-920d-6d4762ae20ad_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_efd0d337-bfc9-4634-80ef-84a14b028c30_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1abf25f5-31e5-49da-88eb-92de9ad98db2_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7ec5f3a9-82c6-4cb4-b170-68ffbd7bd009_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Book Value</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1d51428e-f819-45c3-91b7-d9092d2075ca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6449c5a3-4e98-424c-bb4c-0a3a3769e6fc_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_58747432-69d3-455f-8d0e-046efa1b1428_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Inovio Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_61402df1-61c9-4a17-8817-ac10e787a995_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from operations</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_95bdcf80-d408-45c2-89a4-12f7a209d506_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement, anticipated commercial event based payment receivable milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_label_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:href="ino-20201231.xsd#ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:to="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5bbc8c38-67ad-4a48-89db-8215a33d2133_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_bea2f026-c72f-47ff-b8dc-690cf70d295a_verboseLabel_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets from affiliated entities</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_label_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets from Affiliated Entity</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_documentation_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:href="ino-20201231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:to="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_3a3cc51e-a4cc-4a1f-b06e-b6fa64ae1e2c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, carrying amount of equity component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_5ec1754c-a6ba-4310-ad3f-0c252d541f65_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_d66e7820-7c74-4238-bc8c-f00819155b8e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeAmortizationOfPremium_f59631f2-9817-4e5c-ad8b-7a355e43b412_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums on investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeAmortizationOfPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Amortization of Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:to="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementTerm_0181bca6-1dc2-4b4f-93f0-3e7055568916_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm" xlink:href="ino-20201231.xsd#ino_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementTerm" xlink:to="lab_ino_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2817434a-4b17-4c99-a6bb-0fc877302d80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_0c39bcf5-4738-4f4e-a091-d39f26d66a3e_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of or maturity of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_284199f4-7066-45aa-8dd3-6a06b0fce0b3_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_8abcf309-e30c-4fff-83b4-44b7f01af212_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_8fbeb32b-bb7e-4cde-8ab6-41605ecfebd4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_86724f3c-71be-420c-9886-4539af131a90_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in affiliated entity</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_6f3622ce-74e5-4f72-a2f4-761fabdda960_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_225aea8f-6a1e-4b0d-a5fa-d60617c7eeda_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_e9e14b98-8d63-4649-830b-13aef31ff569_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_832c9b53-4761-4579-a9e3-575e2ea578b5_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_778289d5-1ce8-4832-b9e0-b4d2f8b9d26a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fixed assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6a8d06c7-2a09-48cd-81cc-6bb74812da4a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b8e20058-0714-4aa8-bd6b-447777bf943c_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten public offering, common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_4f88a5a4-b56d-4616-b18a-afbc44f3ee5f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_700d0a5d-5b04-4c0d-a23f-ee8535a3709d_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_63d291b0-289f-4c65-b38e-15fa8261b03b_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, period to receive funding for research and development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:to="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_603c86d1-371c-4266-a847-911b5e27aacc_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_972a7c3a-cb11-422e-b2fb-67b0eb79a654_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock/senior notes to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_908fd93f-5b7b-49cf-a226-14fa3364ff2a_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_05f1401d-14c3-41e7-993b-d942a3dd7a29_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation and Amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_4c05e479-800b-4c24-a07d-6f2e504be606_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in the Next Twelve Months</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in the Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_ce95437f-dcf6-40de-a31e-8cb469e49091_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ba8e4bce-5c5f-4a81-9d5f-470270ce0a72_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_5f285106-9ac8-4d41-8f72-ee451ef9c190_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d61d8571-c05f-4c5c-81f4-45c7a3ba092f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Liquidity</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_429908a6-9606-44fc-8b86-566f96c84408_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount_a5ff6400-9d50-46b3-85ba-c877aec1e03f_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign income taxes</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Foreign Withholding Taxes, Amount</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Foreign Withholding Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount" xlink:href="ino-20201231.xsd#ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount" xlink:to="lab_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b62d9df7-d635-4eb0-b1ef-4b5043b06ff9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_13311ca8-a4f3-4f48-843b-306774dde1ad_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_e969799e-2e20-4c65-a77f-6666bce94fe9_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_d5b27fce-b134-4b3d-a743-9ef4b0afd232_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_e7abec64-4aeb-4776-b9b8-8ba2e17db187_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of ownership</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_c4fb3b7b-ad59-44a2-9e3e-d435585043cc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_a494db75-9a2c-46b9-b3d2-d3719d53c229_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Four Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_cfca521c-546d-43d9-a287-9932e9d95a42_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional revenue to be achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_label_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:href="ino-20201231.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:to="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1a51d36f-b425-48cf-b6f3-550c4d375e8c_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_f4d7260f-afbd-4a91-974f-7cc721ee49d6_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement, number of days written notice before termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_label_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:to="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_0308aeb6-ea5c-4083-9620-74a6b6f7a1b9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6bbaeee8-e87b-4bbb-b39f-6b34fbb8e830_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_f4dbfe00-6f4e-49d6-b4c0-d12518be0df7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized transaction loss on foreign-currency denominated debt</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_af54ab56-feee-4c32-95b6-f747e2a7efe7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (provision for income taxes)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a0cc2933-3646-44ed-bcfa-d284b70feceb_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4aed247c-369d-4b9b-b456-0f85c5e75be6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ec0a2dd5-2c74-48af-97d9-06a0d87f2d6b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bd5dc253-e4ab-47d6-8544-d31b7167891c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dacc6ec4-42a9-4c3b-9b52-1165fba44193_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementAgentFee_a926957f-c658-4027-9191-0c5877b0b43a_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementAgentFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agent fee</link:label>
    <link:label id="lab_ino_StockSalesAgreementAgentFee_label_en-US" xlink:label="lab_ino_StockSalesAgreementAgentFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Agent Fee</link:label>
    <link:label id="lab_ino_StockSalesAgreementAgentFee_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementAgentFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Agent Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementAgentFee" xlink:href="ino-20201231.xsd#ino_StockSalesAgreementAgentFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementAgentFee" xlink:to="lab_ino_StockSalesAgreementAgentFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7bf83d34-9729-4728-97d5-1c4133c46e15_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7dce238b-f564-4242-a20c-70468c3c611a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of maturities of long-term debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_7f329e1f-7549-460f-b6fa-ea51c3a84b74_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_a5128286-bfda-440e-bc14-de2d7d321022_verboseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5a6a9554-813a-4487-9199-09bafe61b197_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsFromSaleOfEquitySecuritiesFVNI_f52163ef-17dc-401c-962c-de52c550f5b4_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromSaleOfEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of investment</link:label>
    <link:label id="lab_ino_ProceedsFromSaleOfEquitySecuritiesFVNI_label_en-US" xlink:label="lab_ino_ProceedsFromSaleOfEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Equity Securities, FV-NI</link:label>
    <link:label id="lab_ino_ProceedsFromSaleOfEquitySecuritiesFVNI_documentation_en-US" xlink:label="lab_ino_ProceedsFromSaleOfEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromSaleOfEquitySecuritiesFVNI" xlink:href="ino-20201231.xsd#ino_ProceedsFromSaleOfEquitySecuritiesFVNI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromSaleOfEquitySecuritiesFVNI" xlink:to="lab_ino_ProceedsFromSaleOfEquitySecuritiesFVNI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_955de0e1-b135-4312-8ada-97ae23c052d8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_4f30b569-bbb8-41a0-8462-779f204052d1_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options outstanding</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:href="ino-20201231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_1adaf67e-ea59-4a44-89e5-b2cab2cd9e62_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a4ae8b78-dbc9-4779-8f19-99e5c0af174a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_131d1ca9-cacf-46c5-8b41-a86aa5e7d303_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercises in period, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2016IncentivePlanMember_3ea12ef1-6395-4130-9c3d-b4358fd48766_terseLabel_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember" xlink:href="ino-20201231.xsd#ino_A2016IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2016IncentivePlanMember" xlink:to="lab_ino_A2016IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_59a0da8f-1bdd-4551-90ef-8fe33e9c624c_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value of the financial liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_bab36b33-e849-4763-80fa-a89886d6d0a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price, upper range limit (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_1deb6d16-092e-46a1-8445-9feeb6910eba_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligation period to pay royalties</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_label_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:href="ino-20201231.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:to="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_cec60b90-39a4-40e9-aa64-4e082e640ebb_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases (decreases) related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_1439c5d4-1571-45d2-a4d0-07c9be7f1326_terseLabel_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_label_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_documentation_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember" xlink:href="ino-20201231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlumblineLifeSciencesMember" xlink:to="lab_ino_PlumblineLifeSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_72114a8b-9df1-49b7-8260-16884c48b1cd_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_d2ffd8b3-4f88-4f6a-8946-315e33dce920_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_a154f2d3-8dd6-48db-af6f-3fd208c35b28_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_9cf7062d-d36b-4e24-a80a-a3227e72ee1d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_1294e0f4-69f2-47de-9ace-6e55cd021e1e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of unvested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_8a126954-1d6b-4633-9566-1004d5e59520_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_5ea040a9-4f2c-4eb5-a9e4-64b52d634925_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_d1f77d8b-3e7e-4024-ba91-2a943efeb598_terseLabel_en-US" xlink:label="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of operating loss and tax credit carryforward expirations</link:label>
    <link:label id="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_label_en-US" xlink:label="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]</link:label>
    <link:label id="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_documentation_en-US" xlink:label="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:href="ino-20201231.xsd#ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:to="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1c50a0a6-c340-4ac1-893e-0ae92ef90c40_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9affa34a-6da6-4f95-80a6-cba0bdcd2d74_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbd3afa6-1c14-455d-a3c3-140093502b25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7f9a8cd-dd06-4891-a75b-80369e800061_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_d668d9fc-aef7-43c1-8f8c-4f9102d57e70_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_e7c72042-be7b-4e57-a641-3c9826c314b4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease of cash resulting from the deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_69da8076-f63d-4f59-bba9-938222d4a4b2_terseLabel_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in cash resulting from the deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Divested from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:to="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8f7f1db9-8c4f-4029-b6af-242c30b4525d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OtherRevenueMember_8ce93668-c89d-4225-8eef-f12013725d67_terseLabel_en-US" xlink:label="lab_ino_OtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_ino_OtherRevenueMember_label_en-US" xlink:label="lab_ino_OtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenue [Member]</link:label>
    <link:label id="lab_ino_OtherRevenueMember_documentation_en-US" xlink:label="lab_ino_OtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherRevenueMember" xlink:href="ino-20201231.xsd#ino_OtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OtherRevenueMember" xlink:to="lab_ino_OtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_623bcf06-164b-4a9a-8427-98c1bc7e8951_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_c0b646c1-44b6-450c-aa00-63fc2a4941dc_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxAssetInterestExpense_1a3ad03d-c70e-4c92-81df-7f561cd5124e_terseLabel_en-US" xlink:label="lab_ino_DeferredTaxAssetInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_ino_DeferredTaxAssetInterestExpense_label_en-US" xlink:label="lab_ino_DeferredTaxAssetInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Interest Expense</link:label>
    <link:label id="lab_ino_DeferredTaxAssetInterestExpense_documentation_en-US" xlink:label="lab_ino_DeferredTaxAssetInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetInterestExpense" xlink:href="ino-20201231.xsd#ino_DeferredTaxAssetInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxAssetInterestExpense" xlink:to="lab_ino_DeferredTaxAssetInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d3882b68-521a-4115-85b5-dfc09662d6e6_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5a8c6bb3-b548-4dde-8368-2a5c39f93f4b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements - Recently Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_f0c2db3a-05cc-47eb-b14a-be6874571a4a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_5432dc3e-ee9b-4008-bca8-027bd59d4e24_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>ino-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:457132bc-9fa0-4eb7-b7bc-387259668e99,g:003ddec6-0acb-4351-b822-2fdc6632a099-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/CoverPage" xlink:type="simple" xlink:href="ino-20201231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1936fd00-bad9-4c9f-869c-dab5f323f222" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_DocumentType_1936fd00-bad9-4c9f-869c-dab5f323f222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_9976c25f-34c7-4805-9ee5-6e8c17b68e35" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_DocumentAnnualReport_9976c25f-34c7-4805-9ee5-6e8c17b68e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_07e19010-d646-41f5-906c-5b5132a0d647" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_DocumentPeriodEndDate_07e19010-d646-41f5-906c-5b5132a0d647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a289d093-bde4-4d1e-a36e-f51c88937193" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_CurrentFiscalYearEndDate_a289d093-bde4-4d1e-a36e-f51c88937193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ce664124-bcf3-4550-b601-6456edba9b65" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_DocumentTransitionReport_ce664124-bcf3-4550-b601-6456edba9b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_dfdb6879-eddf-44d3-bf75-ff51ce287576" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntityFileNumber_dfdb6879-eddf-44d3-bf75-ff51ce287576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_207f4f88-69c7-4d30-bf65-c273c7e01a8f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntityRegistrantName_207f4f88-69c7-4d30-bf65-c273c7e01a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0996e9a6-b277-4abf-ae1b-5e138a620865" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0996e9a6-b277-4abf-ae1b-5e138a620865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_13cd31f9-d10c-4472-899e-e07be2afcb17" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntityTaxIdentificationNumber_13cd31f9-d10c-4472-899e-e07be2afcb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_bfc6658b-46e2-4fac-9115-3f6b0f956825" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntityAddressAddressLine1_bfc6658b-46e2-4fac-9115-3f6b0f956825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_35333e28-f5bf-4255-b66f-6833667e7ba0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntityAddressAddressLine2_35333e28-f5bf-4255-b66f-6833667e7ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_efd754ba-aad9-4569-8679-e9f6d1cee758" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntityAddressCityOrTown_efd754ba-aad9-4569-8679-e9f6d1cee758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_bfe01106-3624-4558-b6b9-623fd7346a65" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntityAddressStateOrProvince_bfe01106-3624-4558-b6b9-623fd7346a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bfa0ca1c-e98f-4551-baf0-7959a9871f01" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntityAddressPostalZipCode_bfa0ca1c-e98f-4551-baf0-7959a9871f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0fe0ee01-358c-4eb4-862f-113e5cd0131d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_CityAreaCode_0fe0ee01-358c-4eb4-862f-113e5cd0131d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_680c0de0-232c-46a6-a73c-fe444e0b4738" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_LocalPhoneNumber_680c0de0-232c-46a6-a73c-fe444e0b4738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9879a40d-5173-49a5-9024-6e0f0e4304db" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_Security12bTitle_9879a40d-5173-49a5-9024-6e0f0e4304db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1bd37f77-8e53-45cc-af09-8da2c1c52dc6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_TradingSymbol_1bd37f77-8e53-45cc-af09-8da2c1c52dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3c0e5785-ddc1-4a6f-9cbd-e1fbc537b19c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_SecurityExchangeName_3c0e5785-ddc1-4a6f-9cbd-e1fbc537b19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_821f938d-863e-4a26-8cf3-96baac04b093" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_821f938d-863e-4a26-8cf3-96baac04b093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_1f6c68d3-2d2f-4747-8ada-1e58d1e951f5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntityVoluntaryFilers_1f6c68d3-2d2f-4747-8ada-1e58d1e951f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_e0b5e12a-0157-4fc0-a43f-cbc9ff039d94" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntityCurrentReportingStatus_e0b5e12a-0157-4fc0-a43f-cbc9ff039d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_3d7b6e7b-01bd-49df-928c-b0ab0b23da6c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntityInteractiveDataCurrent_3d7b6e7b-01bd-49df-928c-b0ab0b23da6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_de09d115-bdb0-4fd7-93a4-ca3de727237e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntityFilerCategory_de09d115-bdb0-4fd7-93a4-ca3de727237e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d897e386-03a3-4fd5-beab-fa40dafcacc7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntitySmallBusiness_d897e386-03a3-4fd5-beab-fa40dafcacc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c35c6a8d-0174-4d81-86a4-adabdf71d166" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntityEmergingGrowthCompany_c35c6a8d-0174-4d81-86a4-adabdf71d166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_02b643f2-db9a-4391-9863-daef9045d0a5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_IcfrAuditorAttestationFlag_02b643f2-db9a-4391-9863-daef9045d0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1e451132-9e26-49d1-b282-ed592f1d3c93" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntityShellCompany_1e451132-9e26-49d1-b282-ed592f1d3c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_6171a2f1-ba23-48d6-9f50-83563be6e4aa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntityPublicFloat_6171a2f1-ba23-48d6-9f50-83563be6e4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_002b9628-cae9-4e72-9ee3-8c0beeed7aed" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_002b9628-cae9-4e72-9ee3-8c0beeed7aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_afc8f608-7dc8-4d67-9ac0-18f4c4f57571" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_afc8f608-7dc8-4d67-9ac0-18f4c4f57571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2f4adeb6-06b2-497d-892c-931ec941c3fc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_AmendmentFlag_2f4adeb6-06b2-497d-892c-931ec941c3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d7451067-eede-44e5-ae2f-79dc25cf706c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_DocumentFiscalYearFocus_d7451067-eede-44e5-ae2f-79dc25cf706c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_706cccc0-e9c5-4653-9e47-39dc3b82ef36" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_DocumentFiscalPeriodFocus_706cccc0-e9c5-4653-9e47-39dc3b82ef36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0589ed01-e7bd-4ad8-892c-fe1c44a9edc5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d9703dbf-2e00-4a6c-9c99-6b3e8bc44ddb" xlink:to="loc_dei_EntityCentralIndexKey_0589ed01-e7bd-4ad8-892c-fe1c44a9edc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c77e47e0-7378-4944-98c0-54e4aaeacfc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_db99f619-f021-4dc6-ac5d-2ff16d4f8c5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c77e47e0-7378-4944-98c0-54e4aaeacfc8" xlink:to="loc_us-gaap_StatementTable_db99f619-f021-4dc6-ac5d-2ff16d4f8c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_33557433-680f-4591-9985-efb506a8ee06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_db99f619-f021-4dc6-ac5d-2ff16d4f8c5e" xlink:to="loc_us-gaap_DebtInstrumentAxis_33557433-680f-4591-9985-efb506a8ee06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3f2d0622-c96a-41ee-b009-6168f074636b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_33557433-680f-4591-9985-efb506a8ee06" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3f2d0622-c96a-41ee-b009-6168f074636b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_52197ef8-3b70-417d-a50d-367142f27c9e" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3f2d0622-c96a-41ee-b009-6168f074636b" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_52197ef8-3b70-417d-a50d-367142f27c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_f3a2271f-604b-460d-8d99-c51f97ed13c4" xlink:href="ino-20201231.xsd#ino_ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3f2d0622-c96a-41ee-b009-6168f074636b" xlink:to="loc_ino_ConvertibleBondsMember_f3a2271f-604b-460d-8d99-c51f97ed13c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2262ac26-d147-42f9-94ca-cad6e6dafe0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_db99f619-f021-4dc6-ac5d-2ff16d4f8c5e" xlink:to="loc_us-gaap_StatementLineItems_2262ac26-d147-42f9-94ca-cad6e6dafe0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2262ac26-d147-42f9-94ca-cad6e6dafe0a" xlink:to="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_a9510222-27bd-4529-90d4-47b3bb1a9f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_a9510222-27bd-4529-90d4-47b3bb1a9f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a37de319-be51-489f-a72b-615937f6fe3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a9510222-27bd-4529-90d4-47b3bb1a9f58" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a37de319-be51-489f-a72b-615937f6fe3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_ef8515cf-82a1-40e8-99a0-da4bdc119aa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a9510222-27bd-4529-90d4-47b3bb1a9f58" xlink:to="loc_us-gaap_ShortTermInvestments_ef8515cf-82a1-40e8-99a0-da4bdc119aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_eea50259-0ec3-49e8-a45d-2f2092622667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a9510222-27bd-4529-90d4-47b3bb1a9f58" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_eea50259-0ec3-49e8-a45d-2f2092622667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_f303d670-b689-46a2-966b-fd04d278870b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a9510222-27bd-4529-90d4-47b3bb1a9f58" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_f303d670-b689-46a2-966b-fd04d278870b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b1f40e73-1a55-4344-bf1d-cabc629059ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a9510222-27bd-4529-90d4-47b3bb1a9f58" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b1f40e73-1a55-4344-bf1d-cabc629059ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_d45c3b06-078e-4399-a0d2-e7713a529b36" xlink:href="ino-20201231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a9510222-27bd-4529-90d4-47b3bb1a9f58" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_d45c3b06-078e-4399-a0d2-e7713a529b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_49bd1024-02c4-4d55-aaff-37602717d4e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a9510222-27bd-4529-90d4-47b3bb1a9f58" xlink:to="loc_us-gaap_AssetsCurrent_49bd1024-02c4-4d55-aaff-37602717d4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dae31c6d-5990-4e72-980b-eed76c84608e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_dae31c6d-5990-4e72-980b-eed76c84608e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_642323fc-fb95-4f03-91dc-dc9a4d73ae70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_642323fc-fb95-4f03-91dc-dc9a4d73ae70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_4b203831-9a75-49ac-af69-f7c7b68b3786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:to="loc_us-gaap_EquityMethodInvestments_4b203831-9a75-49ac-af69-f7c7b68b3786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_465986b8-3763-44ee-8503-7e89f423a3ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_465986b8-3763-44ee-8503-7e89f423a3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3defaefb-69c5-4670-ba98-557abdcdd958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:to="loc_us-gaap_Goodwill_3defaefb-69c5-4670-ba98-557abdcdd958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a2edfa20-c9bc-4107-9b6b-3b10b5490807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a2edfa20-c9bc-4107-9b6b-3b10b5490807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_814fe59a-abfb-4c24-9bd6-9d6f445d56b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_814fe59a-abfb-4c24-9bd6-9d6f445d56b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_775cd706-f20b-4494-bf2f-001cb9d5fb75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4c7ee14f-35c4-48cf-8f5d-64fbc645f80b" xlink:to="loc_us-gaap_Assets_775cd706-f20b-4494-bf2f-001cb9d5fb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2262ac26-d147-42f9-94ca-cad6e6dafe0a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cbf37fe6-5928-447f-ad55-bc57dd760745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cbf37fe6-5928-447f-ad55-bc57dd760745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_03a53731-254c-464f-b713-25bfedb5d054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_03a53731-254c-464f-b713-25bfedb5d054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_f5402c48-761f-4fe1-b6ab-7f2472b484e2" xlink:href="ino-20201231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_f5402c48-761f-4fe1-b6ab-7f2472b484e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e2bd86cd-0768-4e1f-a304-8bb2e6c41bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e2bd86cd-0768-4e1f-a304-8bb2e6c41bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredRevenueFromAffiliatedEntityCurrent_3ac895b8-3948-4233-8241-6b2abc340ff4" xlink:href="ino-20201231.xsd#ino_DeferredRevenueFromAffiliatedEntityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:to="loc_ino_DeferredRevenueFromAffiliatedEntityCurrent_3ac895b8-3948-4233-8241-6b2abc340ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_de441cd2-9a23-4583-bfb3-ae4b994b69f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_de441cd2-9a23-4583-bfb3-ae4b994b69f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_d29d5b95-60a8-4d3c-a9c2-22075a42f3e4" xlink:href="ino-20201231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:to="loc_ino_DeferredGrantFundingCurrent_d29d5b95-60a8-4d3c-a9c2-22075a42f3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_701a98c0-de98-4dd6-92e6-600d1c0840ee" xlink:href="ino-20201231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_701a98c0-de98-4dd6-92e6-600d1c0840ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4ef28b21-e6fc-4c58-84a9-d90702d6d648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cffad0c4-fc86-4926-997f-778a244e8ef8" xlink:to="loc_us-gaap_LiabilitiesCurrent_4ef28b21-e6fc-4c58-84a9-d90702d6d648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1350b5c5-acd0-4322-bc9b-a0aa8dbe4249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1350b5c5-acd0-4322-bc9b-a0aa8dbe4249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_54805bd9-3635-44ee-bb15-522fe25f8172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_ConvertibleDebt_54805bd9-3635-44ee-bb15-522fe25f8172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_6c537efe-45cb-4daa-8010-424e8e9eb3ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_6c537efe-45cb-4daa-8010-424e8e9eb3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_35d91f38-9bad-4524-a762-2f137417a288" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_35d91f38-9bad-4524-a762-2f137417a288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5b0b164f-0268-4645-9208-263e1bdf2208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5b0b164f-0268-4645-9208-263e1bdf2208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_033dbbd4-4f46-4276-9325-0cca11a5f724" xlink:href="ino-20201231.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_033dbbd4-4f46-4276-9325-0cca11a5f724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_62c68279-e1fc-4301-a9ba-abfb31af4ab2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_62c68279-e1fc-4301-a9ba-abfb31af4ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7b9dbed0-1132-4e4a-8d99-62ac8fc6d68d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_Liabilities_7b9dbed0-1132-4e4a-8d99-62ac8fc6d68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c7d83699-fa79-499f-87bf-d52ddff4de5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c7d83699-fa79-499f-87bf-d52ddff4de5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b33a15fb-b244-4244-a294-bb1b3eb9dcd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:to="loc_us-gaap_PreferredStockValue_b33a15fb-b244-4244-a294-bb1b3eb9dcd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9e93c433-a2d8-446c-ad8d-01eec7254c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:to="loc_us-gaap_CommonStockValue_9e93c433-a2d8-446c-ad8d-01eec7254c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9e09644d-fc11-4445-861a-ba154168639a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9e09644d-fc11-4445-861a-ba154168639a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_320d5a70-cc78-4d46-a452-92ac7bda4cf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_320d5a70-cc78-4d46-a452-92ac7bda4cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_203117f7-e37f-4d70-be0b-d7a4ae48bffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_203117f7-e37f-4d70-be0b-d7a4ae48bffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d4935baf-e7bf-4150-87a7-1cebb653240e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:to="loc_us-gaap_StockholdersEquity_d4935baf-e7bf-4150-87a7-1cebb653240e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_f0e9cbb4-f024-4e5c-8c4b-361dd8333aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:to="loc_us-gaap_MinorityInterest_f0e9cbb4-f024-4e5c-8c4b-361dd8333aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a839b1d4-960b-44bc-96f8-df7463e74d12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a7ba5069-dcf4-45f5-9208-dacf01aaa811" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a839b1d4-960b-44bc-96f8-df7463e74d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_256e8c22-f08b-4a8a-87e8-df7ccc5904c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2981686c-bb60-490e-8c13-c694ba98f3ea" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_256e8c22-f08b-4a8a-87e8-df7ccc5904c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ino-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_56411125-4c69-4a02-ac23-7034d87fcf9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9f370666-8bc6-4029-949c-8e3d969a6596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_56411125-4c69-4a02-ac23-7034d87fcf9d" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9f370666-8bc6-4029-949c-8e3d969a6596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_13dc1bd0-1d56-4d3f-ab83-e6cfd50ecf8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_56411125-4c69-4a02-ac23-7034d87fcf9d" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_13dc1bd0-1d56-4d3f-ab83-e6cfd50ecf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b443fb23-195d-467d-ace6-94910aff9112" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_56411125-4c69-4a02-ac23-7034d87fcf9d" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b443fb23-195d-467d-ace6-94910aff9112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ba6b59c6-91c1-46c8-9f35-6d500132a092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_56411125-4c69-4a02-ac23-7034d87fcf9d" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ba6b59c6-91c1-46c8-9f35-6d500132a092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_63097ab6-91a8-4a47-9f8b-36e4b3929d24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_56411125-4c69-4a02-ac23-7034d87fcf9d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_63097ab6-91a8-4a47-9f8b-36e4b3929d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b2d92f1b-6962-4728-8090-ebf6656bc4ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_56411125-4c69-4a02-ac23-7034d87fcf9d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b2d92f1b-6962-4728-8090-ebf6656bc4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_52d78f4e-b5e3-4e10-b20f-89f7ff0aeca9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_56411125-4c69-4a02-ac23-7034d87fcf9d" xlink:to="loc_us-gaap_CommonStockSharesIssued_52d78f4e-b5e3-4e10-b20f-89f7ff0aeca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7b2b3011-642e-423d-88aa-4885452257bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_56411125-4c69-4a02-ac23-7034d87fcf9d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7b2b3011-642e-423d-88aa-4885452257bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_9c40751d-566c-446e-bf05-fdfad2904dd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_42bd9fa1-08f1-4d5d-a473-11df7aa7c4d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9c40751d-566c-446e-bf05-fdfad2904dd9" xlink:to="loc_us-gaap_StatementTable_42bd9fa1-08f1-4d5d-a473-11df7aa7c4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_411f0be2-ad15-4bc6-9919-24e3bbe826fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42bd9fa1-08f1-4d5d-a473-11df7aa7c4d9" xlink:to="loc_srt_ProductOrServiceAxis_411f0be2-ad15-4bc6-9919-24e3bbe826fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4a719b8b-46ee-4ea2-8db8-41768faf42ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_411f0be2-ad15-4bc6-9919-24e3bbe826fa" xlink:to="loc_srt_ProductsAndServicesDomain_4a719b8b-46ee-4ea2-8db8-41768faf42ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_2e50c83a-d46d-42ee-ab74-e5043190cfd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4a719b8b-46ee-4ea2-8db8-41768faf42ae" xlink:to="loc_us-gaap_LicenseMember_2e50c83a-d46d-42ee-ab74-e5043190cfd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_1ad4e591-c7b4-4bba-b4b8-967290634bf4" xlink:href="ino-20201231.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4a719b8b-46ee-4ea2-8db8-41768faf42ae" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_1ad4e591-c7b4-4bba-b4b8-967290634bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherRevenueMember_7df9cf90-86a1-4637-8e29-4a706186037b" xlink:href="ino-20201231.xsd#ino_OtherRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4a719b8b-46ee-4ea2-8db8-41768faf42ae" xlink:to="loc_ino_OtherRevenueMember_7df9cf90-86a1-4637-8e29-4a706186037b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherRevenueAffiliatedEntityMember_7f13463e-a956-4724-a2af-6c761d6b3eab" xlink:href="ino-20201231.xsd#ino_OtherRevenueAffiliatedEntityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4a719b8b-46ee-4ea2-8db8-41768faf42ae" xlink:to="loc_ino_OtherRevenueAffiliatedEntityMember_7f13463e-a956-4724-a2af-6c761d6b3eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2d0c8c70-ab44-4299-bbda-924db4cd6906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42bd9fa1-08f1-4d5d-a473-11df7aa7c4d9" xlink:to="loc_us-gaap_DebtInstrumentAxis_2d0c8c70-ab44-4299-bbda-924db4cd6906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_57633e30-3c2c-4d5c-963a-19ba554b369d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2d0c8c70-ab44-4299-bbda-924db4cd6906" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_57633e30-3c2c-4d5c-963a-19ba554b369d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_6ed17063-cccc-4f1e-9a02-1cecd6b25e0e" xlink:href="ino-20201231.xsd#ino_ConvertibleBondsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_57633e30-3c2c-4d5c-963a-19ba554b369d" xlink:to="loc_ino_ConvertibleBondsMember_6ed17063-cccc-4f1e-9a02-1cecd6b25e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_8b46490e-079b-4065-95e6-20c7ef136067" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_57633e30-3c2c-4d5c-963a-19ba554b369d" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_8b46490e-079b-4065-95e6-20c7ef136067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42bd9fa1-08f1-4d5d-a473-11df7aa7c4d9" xlink:to="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_3f5b05ba-b834-46fc-8bba-c29375b5b06d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_RevenuesAbstract_3f5b05ba-b834-46fc-8bba-c29375b5b06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_948a0c8b-cbd5-4108-9558-527c6806a1db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3f5b05ba-b834-46fc-8bba-c29375b5b06d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_948a0c8b-cbd5-4108-9558-527c6806a1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2dad4692-7e0d-46c6-8b1e-47fb1118d15f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2dad4692-7e0d-46c6-8b1e-47fb1118d15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0f86584a-7a6b-45d4-a51e-f84f203b1461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2dad4692-7e0d-46c6-8b1e-47fb1118d15f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0f86584a-7a6b-45d4-a51e-f84f203b1461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9d6a0067-d95d-422c-b963-061d19307e06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2dad4692-7e0d-46c6-8b1e-47fb1118d15f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9d6a0067-d95d-422c-b963-061d19307e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e0c51348-069f-4339-ad17-450a6713a69e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2dad4692-7e0d-46c6-8b1e-47fb1118d15f" xlink:to="loc_us-gaap_OperatingExpenses_e0c51348-069f-4339-ad17-450a6713a69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_eddcb30d-39b5-4a1b-9151-c0cec8421ba4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_OperatingIncomeLoss_eddcb30d-39b5-4a1b-9151-c0cec8421ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_7e9f1435-3342-46e0-b2f6-a66ebfd9cbd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:to="loc_us-gaap_InterestIncomeOperating_7e9f1435-3342-46e0-b2f6-a66ebfd9cbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_68e7f46c-033b-4f5a-a7bc-3ea5637a6796" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:to="loc_us-gaap_InterestExpense_68e7f46c-033b-4f5a-a7bc-3ea5637a6796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInFairValueOfCommonStockWarrants_625889d4-394a-485d-95b8-cbee7095c70f" xlink:href="ino-20201231.xsd#ino_ChangeInFairValueOfCommonStockWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:to="loc_ino_ChangeInFairValueOfCommonStockWarrants_625889d4-394a-485d-95b8-cbee7095c70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1a26a056-b6c9-4580-97ca-cc691a5bdc77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_1a26a056-b6c9-4580-97ca-cc691a5bdc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_3e2330f4-e9eb-40ed-af96-f91aed1e9f17" xlink:href="ino-20201231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_3e2330f4-e9eb-40ed-af96-f91aed1e9f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d64c9f54-2f90-42fd-8a33-a303696625e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d64c9f54-2f90-42fd-8a33-a303696625e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e20d2d25-5fe0-46d7-99ee-c94e55cf4ff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e20d2d25-5fe0-46d7-99ee-c94e55cf4ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_014cd792-0290-47cc-92f4-21d794f86b12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_014cd792-0290-47cc-92f4-21d794f86b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4b57370a-9ad1-4552-bc8b-73d77540c4b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_aec2db38-8a85-4357-896c-5ab5b5ddcb0f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4b57370a-9ad1-4552-bc8b-73d77540c4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fe7a179c-5455-427d-90d3-e90bf8fd6cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fe7a179c-5455-427d-90d3-e90bf8fd6cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_013cc8eb-a772-4223-a05f-d697de5c6356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_013cc8eb-a772-4223-a05f-d697de5c6356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cbc9e170-9734-4cc7-bf6c-c0c4d12ab047" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cbc9e170-9734-4cc7-bf6c-c0c4d12ab047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a4218d8d-4731-4853-9aee-d37f99816a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_ProfitLoss_a4218d8d-4731-4853-9aee-d37f99816a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_12d96fe4-964f-4f3e-aa9e-509ce3116884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_12d96fe4-964f-4f3e-aa9e-509ce3116884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ae713411-7f4b-494a-a5ba-9d51682bfa44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_NetIncomeLoss_ae713411-7f4b-494a-a5ba-9d51682bfa44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_193ab1b6-489b-43b0-b24a-42aee6500b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_EarningsPerShareAbstract_193ab1b6-489b-43b0-b24a-42aee6500b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_f7bc77ef-07e1-444d-bd0e-624625ea1d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_193ab1b6-489b-43b0-b24a-42aee6500b9b" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_f7bc77ef-07e1-444d-bd0e-624625ea1d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_528e43bf-2b31-48b6-ac36-e5b9a24ecc75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ffe08d27-f3e1-4082-9bab-fb334f5cd391" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_528e43bf-2b31-48b6-ac36-e5b9a24ecc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_15f833f1-c610-4f74-bf3f-4076c477ba55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_528e43bf-2b31-48b6-ac36-e5b9a24ecc75" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_15f833f1-c610-4f74-bf3f-4076c477ba55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20201231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cb40d532-ad4e-4e85-8cfc-180ac955eb64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_72a18139-83f4-4be9-8d60-07b362cb9eba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cb40d532-ad4e-4e85-8cfc-180ac955eb64" xlink:to="loc_us-gaap_ProfitLoss_72a18139-83f4-4be9-8d60-07b362cb9eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_30d9c40f-726a-407f-abb4-57e5d75b9a25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cb40d532-ad4e-4e85-8cfc-180ac955eb64" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_30d9c40f-726a-407f-abb4-57e5d75b9a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2258df16-c046-4eb6-9b31-66f081461e68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_30d9c40f-726a-407f-abb4-57e5d75b9a25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2258df16-c046-4eb6-9b31-66f081461e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f9947f61-e826-4b58-90fd-e2bbdac592b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_30d9c40f-726a-407f-abb4-57e5d75b9a25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f9947f61-e826-4b58-90fd-e2bbdac592b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b3370fb5-b3e8-49e9-babf-e9f109588240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cb40d532-ad4e-4e85-8cfc-180ac955eb64" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b3370fb5-b3e8-49e9-babf-e9f109588240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_9ee85d54-ad4d-4262-a5c0-0aad4d560d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cb40d532-ad4e-4e85-8cfc-180ac955eb64" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_9ee85d54-ad4d-4262-a5c0-0aad4d560d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_96b22373-789b-40a2-9aea-0d5af5c72687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cb40d532-ad4e-4e85-8cfc-180ac955eb64" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_96b22373-789b-40a2-9aea-0d5af5c72687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_aecbd6d0-376e-4f37-a435-d8d78f2f6e08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e4a42ec1-fd74-41c0-b312-97228c8df522" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_aecbd6d0-376e-4f37-a435-d8d78f2f6e08" xlink:to="loc_us-gaap_StatementTable_e4a42ec1-fd74-41c0-b312-97228c8df522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8087a847-af72-4ac4-ad00-b2d38cad7832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e4a42ec1-fd74-41c0-b312-97228c8df522" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8087a847-af72-4ac4-ad00-b2d38cad7832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6ab5880b-78a1-43d0-b730-afb5bc805bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8087a847-af72-4ac4-ad00-b2d38cad7832" xlink:to="loc_us-gaap_EquityComponentDomain_6ab5880b-78a1-43d0-b730-afb5bc805bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_b96b1e22-077f-4edd-9809-810dddb6ccb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6ab5880b-78a1-43d0-b730-afb5bc805bf2" xlink:to="loc_us-gaap_PreferredStockMember_b96b1e22-077f-4edd-9809-810dddb6ccb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0ceaf1e5-c092-45b3-a5d2-192cfcdc7c83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6ab5880b-78a1-43d0-b730-afb5bc805bf2" xlink:to="loc_us-gaap_CommonStockMember_0ceaf1e5-c092-45b3-a5d2-192cfcdc7c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_eba7e2b8-abf9-489c-a520-64935e112c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6ab5880b-78a1-43d0-b730-afb5bc805bf2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_eba7e2b8-abf9-489c-a520-64935e112c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ba896275-2ada-44fd-9cff-26a13cfbf03b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6ab5880b-78a1-43d0-b730-afb5bc805bf2" xlink:to="loc_us-gaap_RetainedEarningsMember_ba896275-2ada-44fd-9cff-26a13cfbf03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c7ccc9af-4dc6-40d2-807f-3480f01d0af2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6ab5880b-78a1-43d0-b730-afb5bc805bf2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c7ccc9af-4dc6-40d2-807f-3480f01d0af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9af2c7f9-9395-4621-b713-11a0244eddcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6ab5880b-78a1-43d0-b730-afb5bc805bf2" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9af2c7f9-9395-4621-b713-11a0244eddcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9429e747-5f3d-4e54-8c97-814c0f37aa0b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e4a42ec1-fd74-41c0-b312-97228c8df522" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9429e747-5f3d-4e54-8c97-814c0f37aa0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c4b2d9a3-eed5-4581-8aab-7677e07d66dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9429e747-5f3d-4e54-8c97-814c0f37aa0b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c4b2d9a3-eed5-4581-8aab-7677e07d66dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_11200aa7-f12b-4116-afe9-1572760947a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c4b2d9a3-eed5-4581-8aab-7677e07d66dc" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_11200aa7-f12b-4116-afe9-1572760947a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b717ffa0-8e50-4d7e-87b4-201ffe35a24e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e4a42ec1-fd74-41c0-b312-97228c8df522" xlink:to="loc_us-gaap_DebtInstrumentAxis_b717ffa0-8e50-4d7e-87b4-201ffe35a24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b46c2795-527c-488a-88d2-09a9018e0870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b717ffa0-8e50-4d7e-87b4-201ffe35a24e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b46c2795-527c-488a-88d2-09a9018e0870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_95ebfbcf-4842-4e07-be51-964c5aa8fa6f" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b46c2795-527c-488a-88d2-09a9018e0870" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_95ebfbcf-4842-4e07-be51-964c5aa8fa6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_9f7e8c7b-b9c4-4d12-9fe7-d3b1318da862" xlink:href="ino-20201231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b46c2795-527c-488a-88d2-09a9018e0870" xlink:to="loc_ino_August2019ConvertibleBondsMember_9f7e8c7b-b9c4-4d12-9fe7-d3b1318da862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c53ddc81-278e-48fd-8cb5-4c2dd88857a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e4a42ec1-fd74-41c0-b312-97228c8df522" xlink:to="loc_us-gaap_StatementLineItems_c53ddc81-278e-48fd-8cb5-4c2dd88857a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c53ddc81-278e-48fd-8cb5-4c2dd88857a9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_21b49280-fd49-44dd-bd60-fd46b5370342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_SharesIssued_21b49280-fd49-44dd-bd60-fd46b5370342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_abd8698d-f55a-4552-b75c-4a5bef1db64f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_abd8698d-f55a-4552-b75c-4a5bef1db64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_308ecf46-67a7-4b1c-998b-be2b28e377d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_308ecf46-67a7-4b1c-998b-be2b28e377d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_59d0cf93-8cc3-49c1-b7f2-4000ef2c6af4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_59d0cf93-8cc3-49c1-b7f2-4000ef2c6af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2cd8c032-e29f-4f52-8f72-c290a0ef9ac2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2cd8c032-e29f-4f52-8f72-c290a0ef9ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3963a022-6716-447b-8ea7-1fde9d884d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3963a022-6716-447b-8ea7-1fde9d884d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d334fa2c-74b6-435b-b8b5-1ed0755443ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d334fa2c-74b6-435b-b8b5-1ed0755443ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a45bf37e-2d17-4275-adcc-b85edee81040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a45bf37e-2d17-4275-adcc-b85edee81040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_87332ecb-e387-4c27-b7e1-ce6c24a50295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_87332ecb-e387-4c27-b7e1-ce6c24a50295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_59ffb7d2-ce98-4f89-ad89-c33c8cef928e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_59ffb7d2-ce98-4f89-ad89-c33c8cef928e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_2dc7a96b-14ac-41a7-ad38-a6122b52bb3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_2dc7a96b-14ac-41a7-ad38-a6122b52bb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_0542968b-230f-42dd-9805-aa239ffc8c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_0542968b-230f-42dd-9805-aa239ffc8c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4f00407c-bf8d-4f42-8c26-888aaa99533c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_ProfitLoss_4f00407c-bf8d-4f42-8c26-888aaa99533c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_498bd9ec-f17d-40bf-8015-4601227e8bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_498bd9ec-f17d-40bf-8015-4601227e8bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2237b373-030e-4a3d-85f7-b47df17d8f53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2237b373-030e-4a3d-85f7-b47df17d8f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cea18d62-5a4e-4965-a445-96f5533129ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cea18d62-5a4e-4965-a445-96f5533129ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_f6ead124-b846-4b85-9325-41d4592553e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_SharesIssued_f6ead124-b846-4b85-9325-41d4592553e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7b0658d4-b87c-4246-b24c-322034fe0bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7b0658d4-b87c-4246-b24c-322034fe0bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_80fef50a-8f98-4962-9b49-4ec47fecfd4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_986004e1-fa79-4f42-9d66-884ea1377f1f" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_80fef50a-8f98-4962-9b49-4ec47fecfd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b099ed97-149e-4c24-98fc-7cc064b8b419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c07ac6c5-9c3d-4f66-8062-c12d382d2a65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b099ed97-149e-4c24-98fc-7cc064b8b419" xlink:to="loc_us-gaap_StatementTable_c07ac6c5-9c3d-4f66-8062-c12d382d2a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d0a406df-9bd9-4bc1-a91a-77d116e31afc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c07ac6c5-9c3d-4f66-8062-c12d382d2a65" xlink:to="loc_us-gaap_DebtInstrumentAxis_d0a406df-9bd9-4bc1-a91a-77d116e31afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a0cf8143-970c-4b46-b011-476ccd9664f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d0a406df-9bd9-4bc1-a91a-77d116e31afc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a0cf8143-970c-4b46-b011-476ccd9664f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_7dcaaba4-8398-4cc9-a797-e41fa64d1819" xlink:href="ino-20201231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a0cf8143-970c-4b46-b011-476ccd9664f9" xlink:to="loc_ino_August2019ConvertibleBondsMember_7dcaaba4-8398-4cc9-a797-e41fa64d1819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_bab7899b-efba-46fb-a917-986411d04a83" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a0cf8143-970c-4b46-b011-476ccd9664f9" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_bab7899b-efba-46fb-a917-986411d04a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_97931f62-9f20-4a41-9606-b88d1df64a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c07ac6c5-9c3d-4f66-8062-c12d382d2a65" xlink:to="loc_us-gaap_StatementLineItems_97931f62-9f20-4a41-9606-b88d1df64a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6762ca56-c842-4aae-856e-3473dd01ec23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_97931f62-9f20-4a41-9606-b88d1df64a1c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6762ca56-c842-4aae-856e-3473dd01ec23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_76c27fa9-610d-46eb-b12c-2c4547174008" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6762ca56-c842-4aae-856e-3473dd01ec23" xlink:to="loc_us-gaap_ProfitLoss_76c27fa9-610d-46eb-b12c-2c4547174008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6762ca56-c842-4aae-856e-3473dd01ec23" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ec07b791-5cea-42ad-b3db-12782cdbaca5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_Depreciation_ec07b791-5cea-42ad-b3db-12782cdbaca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b90b5b43-ec4e-419a-87eb-f2cf4014b4c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b90b5b43-ec4e-419a-87eb-f2cf4014b4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_76f14004-c65d-4788-86de-6b31abae8aef" xlink:href="ino-20201231.xsd#ino_AmortizationOfOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_76f14004-c65d-4788-86de-6b31abae8aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfCommonStockWarrants_4dbf650d-f641-409c-8da1-82924aed95f4" xlink:href="ino-20201231.xsd#ino_ChangeInValueOfCommonStockWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_ino_ChangeInValueOfCommonStockWarrants_4dbf650d-f641-409c-8da1-82924aed95f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_e8670d81-785c-4396-9aec-bccad0530feb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_e8670d81-785c-4396-9aec-bccad0530feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6c0a8380-7b88-482b-89ad-64efffdd01cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_ShareBasedCompensation_6c0a8380-7b88-482b-89ad-64efffdd01cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestExpense_d322df78-9e44-45cf-90e2-de3c16c32ee2" xlink:href="ino-20201231.xsd#ino_NonCashInterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_ino_NonCashInterestExpense_d322df78-9e44-45cf-90e2-de3c16c32ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_98a3d85c-d767-4541-bb93-2c9981863b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_98a3d85c-d767-4541-bb93-2c9981863b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_221f5572-bc16-449d-b5d8-b7493623bd8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_221f5572-bc16-449d-b5d8-b7493623bd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_2deb2fb1-e464-4321-b44e-a27ad5ed59a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_GainLossOnInvestments_2deb2fb1-e464-4321-b44e-a27ad5ed59a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_a7a303bf-0bba-4493-a493-29c936c29598" xlink:href="ino-20201231.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_a7a303bf-0bba-4493-a493-29c936c29598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_b03b4911-8bd5-4c3c-8192-a5b784cb12be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_b03b4911-8bd5-4c3c-8192-a5b784cb12be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_d102794b-2c34-4d69-84a1-b7bd2742548d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_d102794b-2c34-4d69-84a1-b7bd2742548d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_4b993072-0787-4d3d-8786-90e03808935b" xlink:href="ino-20201231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_4b993072-0787-4d3d-8786-90e03808935b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_58e243d7-ce77-47e4-af85-7f396b551c71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_58e243d7-ce77-47e4-af85-7f396b551c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_efa93a4d-6720-491c-a21b-f9d754c8606f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_efa93a4d-6720-491c-a21b-f9d754c8606f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_67776607-796a-46e4-a1ba-7ee6a7565dbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_67776607-796a-46e4-a1ba-7ee6a7565dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_35c5b1d3-f547-4312-b2de-5d756e5eeea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_35c5b1d3-f547-4312-b2de-5d756e5eeea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5e8c37c0-cf16-459b-9cb8-2a39c3476684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a2654bc5-6116-4321-8e27-57a607d5865e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5e8c37c0-cf16-459b-9cb8-2a39c3476684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6762ca56-c842-4aae-856e-3473dd01ec23" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_478ee985-9f8b-470a-9301-240cc3ae1446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_478ee985-9f8b-470a-9301-240cc3ae1446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9f041739-767d-4e79-bac6-f004c0890bd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9f041739-767d-4e79-bac6-f004c0890bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_999a5178-b245-44a9-aba2-f989439fc915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_999a5178-b245-44a9-aba2-f989439fc915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_2a43455b-3c0a-4efa-88ae-f2ec43e5ae4b" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_2a43455b-3c0a-4efa-88ae-f2ec43e5ae4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6c074cbd-294f-469d-89f6-7529c0036173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6c074cbd-294f-469d-89f6-7529c0036173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_28ac6a66-baa1-4246-9276-acca08a0c4ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_28ac6a66-baa1-4246-9276-acca08a0c4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_5914116c-afe6-4fd7-a9ca-625d7a67fc65" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_5914116c-afe6-4fd7-a9ca-625d7a67fc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_82d9d5ee-bd65-4758-9ae9-9164c4d7a0f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_82d9d5ee-bd65-4758-9ae9-9164c4d7a0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c9eb9839-1835-4063-ad6e-996a747f9610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c9eb9839-1835-4063-ad6e-996a747f9610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_257e8f59-fe53-4f69-ab85-9d6c41ecca63" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_257e8f59-fe53-4f69-ab85-9d6c41ecca63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StraightLineRent_e4d41b1a-e73c-4bc2-a930-3df7347da021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StraightLineRent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_us-gaap_StraightLineRent_e4d41b1a-e73c-4bc2-a930-3df7347da021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_5810179a-6b3a-494e-97a5-a0225de900c0" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_5810179a-6b3a-494e-97a5-a0225de900c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_6e3ab90d-af74-4956-ade8-7c286114a6e4" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_6e3ab90d-af74-4956-ade8-7c286114a6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_887036b9-9c45-434d-82fe-c0f97a2667a3" xlink:href="ino-20201231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_887036b9-9c45-434d-82fe-c0f97a2667a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_084afc7f-16af-44e9-b064-d0fed9081289" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f2f6049a-5ad6-411e-84a6-f206ffc1cf41" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_084afc7f-16af-44e9-b064-d0fed9081289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b726b422-6360-4505-b57e-dd0c5fba86f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6762ca56-c842-4aae-856e-3473dd01ec23" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b726b422-6360-4505-b57e-dd0c5fba86f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11fca4d0-b713-4e7c-9644-d05441f4dded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_97931f62-9f20-4a41-9606-b88d1df64a1c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11fca4d0-b713-4e7c-9644-d05441f4dded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_6798fc16-5fe7-4d57-8455-791ee10548b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11fca4d0-b713-4e7c-9644-d05441f4dded" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_6798fc16-5fe7-4d57-8455-791ee10548b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_92abdfe3-a7e9-461a-80b9-0fc24c35ab97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11fca4d0-b713-4e7c-9644-d05441f4dded" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_92abdfe3-a7e9-461a-80b9-0fc24c35ab97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_eb227b57-96d0-4f09-ab61-b06989f98aca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11fca4d0-b713-4e7c-9644-d05441f4dded" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_eb227b57-96d0-4f09-ab61-b06989f98aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromSaleOfEquitySecuritiesFVNI_ca52b456-ed25-48c3-9a0b-16f67b9e1432" xlink:href="ino-20201231.xsd#ino_ProceedsFromSaleOfEquitySecuritiesFVNI"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11fca4d0-b713-4e7c-9644-d05441f4dded" xlink:to="loc_ino_ProceedsFromSaleOfEquitySecuritiesFVNI_ca52b456-ed25-48c3-9a0b-16f67b9e1432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_38bd72f8-5447-4bdb-87ab-829f822bf3c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11fca4d0-b713-4e7c-9644-d05441f4dded" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_38bd72f8-5447-4bdb-87ab-829f822bf3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ec447e6c-1eb3-4970-bbbc-bef71231b0e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11fca4d0-b713-4e7c-9644-d05441f4dded" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ec447e6c-1eb3-4970-bbbc-bef71231b0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a3d0f4b-14f9-41d1-bbdc-7a6a3b7ca441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11fca4d0-b713-4e7c-9644-d05441f4dded" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a3d0f4b-14f9-41d1-bbdc-7a6a3b7ca441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_97931f62-9f20-4a41-9606-b88d1df64a1c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1248de8b-ffd7-45b0-8bfc-c52a0e9adee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1248de8b-ffd7-45b0-8bfc-c52a0e9adee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_08a9ad57-09bc-4adc-a82f-c3bfefb8f27b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_08a9ad57-09bc-4adc-a82f-c3bfefb8f27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a2cdccad-ca50-4937-80f4-42c77292e3e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a2cdccad-ca50-4937-80f4-42c77292e3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsfromStockOptionandWarrantExercises_b3c11b60-0978-4243-9a7c-54b9d37142b4" xlink:href="ino-20201231.xsd#ino_ProceedsfromStockOptionandWarrantExercises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:to="loc_ino_ProceedsfromStockOptionandWarrantExercises_b3c11b60-0978-4243-9a7c-54b9d37142b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_e3ff9161-b2d4-4831-a287-97aba40ed94c" xlink:href="ino-20201231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:to="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_e3ff9161-b2d4-4831-a287-97aba40ed94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_1e5fcb14-fcbb-4287-803b-593b50120403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_1e5fcb14-fcbb-4287-803b-593b50120403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_c4ce64cf-af0f-4236-93ee-08af40bb894a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_c4ce64cf-af0f-4236-93ee-08af40bb894a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b4dea8a4-b24c-4dcb-936f-4550c34ec8b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0d6c6fa-f571-4c15-8092-69bc3cb9048a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b4dea8a4-b24c-4dcb-936f-4550c34ec8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_71ba9c12-c404-45d2-8787-5d34b27b74be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_97931f62-9f20-4a41-9606-b88d1df64a1c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_71ba9c12-c404-45d2-8787-5d34b27b74be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7518d2bd-60ee-483f-903b-98ee9733df91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_97931f62-9f20-4a41-9606-b88d1df64a1c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7518d2bd-60ee-483f-903b-98ee9733df91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d0e1ddcb-3dcd-4bbc-bf46-d7bfc82d7c5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_97931f62-9f20-4a41-9606-b88d1df64a1c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d0e1ddcb-3dcd-4bbc-bf46-d7bfc82d7c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_834c5f2a-d361-4ddb-965c-e6e98237212b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_97931f62-9f20-4a41-9606-b88d1df64a1c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_834c5f2a-d361-4ddb-965c-e6e98237212b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3ac040a5-7d14-4140-9c88-3434ba4e75bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_97931f62-9f20-4a41-9606-b88d1df64a1c" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3ac040a5-7d14-4140-9c88-3434ba4e75bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_bc427a76-92c7-440d-a57a-4d959366c295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3ac040a5-7d14-4140-9c88-3434ba4e75bb" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_bc427a76-92c7-440d-a57a-4d959366c295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_5fe6e2d9-baa0-4f2d-8a4f-aa4d5bc50337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3ac040a5-7d14-4140-9c88-3434ba4e75bb" xlink:to="loc_us-gaap_InterestPaidNet_5fe6e2d9-baa0-4f2d-8a4f-aa4d5bc50337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityComponentOfConvertibleDebtIssued_659b969e-c184-4120-bcff-94ae5b42049e" xlink:href="ino-20201231.xsd#ino_EquityComponentOfConvertibleDebtIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3ac040a5-7d14-4140-9c88-3434ba4e75bb" xlink:to="loc_ino_EquityComponentOfConvertibleDebtIssued_659b969e-c184-4120-bcff-94ae5b42049e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_06d32d92-1881-48f0-a4f1-a00ea8433a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3ac040a5-7d14-4140-9c88-3434ba4e75bb" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_06d32d92-1881-48f0-a4f1-a00ea8433a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/TheCompany" xlink:type="simple" xlink:href="ino-20201231.xsd#TheCompany"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/TheCompany" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_74d2c698-b4ff-4ff4-92ed-554447f261b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_c68d8ae5-438c-4848-829a-90c83dba7c45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_74d2c698-b4ff-4ff4-92ed-554447f261b0" xlink:to="loc_us-gaap_NatureOfOperations_c68d8ae5-438c-4848-829a-90c83dba7c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ino-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bdb8fd1b-9545-4c76-b915-c30c9ebc13fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9153dba6-b2d5-4b20-abd4-988683e6c3dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bdb8fd1b-9545-4c76-b915-c30c9ebc13fb" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9153dba6-b2d5-4b20-abd4-988683e6c3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ino-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3b1a45e4-f0f9-49e0-b03f-4006ae062733" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3b1a45e4-f0f9-49e0-b03f-4006ae062733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_0c4d58a5-0943-4fc7-b430-4cc4773683dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_0c4d58a5-0943-4fc7-b430-4cc4773683dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_e26b6f57-c0ca-40bc-8100-6d4c10bbe0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_e26b6f57-c0ca-40bc-8100-6d4c10bbe0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b1feefa1-3317-454e-97d2-5e22f19dc576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_UseOfEstimates_b1feefa1-3317-454e-97d2-5e22f19dc576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_b6237d5b-8ef0-462a-adef-6a3e5f141b27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_b6237d5b-8ef0-462a-adef-6a3e5f141b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_42b1e07f-aeb3-4804-8acf-e86b27d34c67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_42b1e07f-aeb3-4804-8acf-e86b27d34c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0d7280d1-c076-4e52-a63d-fe4e1c41ef2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0d7280d1-c076-4e52-a63d-fe4e1c41ef2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_b71fcbb2-4ca8-4ab8-9320-886842cbc0f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_b71fcbb2-4ca8-4ab8-9320-886842cbc0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_fe8090c7-7e7d-4e62-b131-4643a0b3d341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_fe8090c7-7e7d-4e62-b131-4643a0b3d341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_742d35b0-15a9-4563-bc32-8ed24e469732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_742d35b0-15a9-4563-bc32-8ed24e469732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a873038b-6851-4575-a9d9-18dadaa6c6e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a873038b-6851-4575-a9d9-18dadaa6c6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_d31c4224-85ce-462a-b601-79ee023be58c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_d31c4224-85ce-462a-b601-79ee023be58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_f53ae368-ee5c-4823-96a1-7e0cde03b540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_f53ae368-ee5c-4823-96a1-7e0cde03b540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_2a8c4802-dabd-4709-8e4d-6e74d3d57e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_2a8c4802-dabd-4709-8e4d-6e74d3d57e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_15010a39-10a1-4867-980f-504d76c78193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_15010a39-10a1-4867-980f-504d76c78193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantRevenuePolicyTextBlock_b5b53651-9fde-4971-abc2-026988e3596e" xlink:href="ino-20201231.xsd#ino_GrantRevenuePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_ino_GrantRevenuePolicyTextBlock_b5b53651-9fde-4971-abc2-026988e3596e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_d7610426-79b9-4efd-bc7d-1952359e63a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_d7610426-79b9-4efd-bc7d-1952359e63a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3fd0bd6d-5448-4e57-b82b-8c16c7c95588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3fd0bd6d-5448-4e57-b82b-8c16c7c95588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_eb91c00e-6150-4d90-92ef-302fa4c34f32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_eb91c00e-6150-4d90-92ef-302fa4c34f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_61a20cf7-f299-4c6b-a9b3-dd5c71d23d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_61a20cf7-f299-4c6b-a9b3-dd5c71d23d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_e5180fc3-2014-42f4-ac1b-76f3883bdfa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_e5180fc3-2014-42f4-ac1b-76f3883bdfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_691df2b3-ba0d-4033-bcef-b8426911ccb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_691df2b3-ba0d-4033-bcef-b8426911ccb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_eb3caeea-c786-4d66-8f23-362c100a7e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4cea64c8-633e-4e14-b8ad-93d10e1b0320" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_eb3caeea-c786-4d66-8f23-362c100a7e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ino-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9bc606f7-108f-419e-aaa7-2719c4806e25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_11ab6fed-47fd-4db3-bcf7-bb6299ad5ed8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9bc606f7-108f-419e-aaa7-2719c4806e25" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_11ab6fed-47fd-4db3-bcf7-bb6299ad5ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0253645c-1af8-4f11-8c36-a3758ab07d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9bc606f7-108f-419e-aaa7-2719c4806e25" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0253645c-1af8-4f11-8c36-a3758ab07d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cef27b20-5d54-4a05-a974-aae4eefc2c93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_439422f7-c51a-42f1-ba6e-544155d7ceda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cef27b20-5d54-4a05-a974-aae4eefc2c93" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_439422f7-c51a-42f1-ba6e-544155d7ceda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59845912-33c5-4e27-a022-02e44148f895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_439422f7-c51a-42f1-ba6e-544155d7ceda" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59845912-33c5-4e27-a022-02e44148f895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a37e2a4b-0a48-4d16-bf7c-cdc7371e9d80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59845912-33c5-4e27-a022-02e44148f895" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a37e2a4b-0a48-4d16-bf7c-cdc7371e9d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_2e5e8a19-5bef-4bb3-a927-4ee6c091978d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a37e2a4b-0a48-4d16-bf7c-cdc7371e9d80" xlink:to="loc_us-gaap_PatentsMember_2e5e8a19-5bef-4bb3-a927-4ee6c091978d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cf63323d-6b0e-4a79-86a2-69dab6d290f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_439422f7-c51a-42f1-ba6e-544155d7ceda" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cf63323d-6b0e-4a79-86a2-69dab6d290f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e77dcb76-65d5-4293-87ae-3af49f90348d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cf63323d-6b0e-4a79-86a2-69dab6d290f0" xlink:to="loc_us-gaap_ClassOfStockDomain_e77dcb76-65d5-4293-87ae-3af49f90348d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c5d2bf4b-05fd-41f9-8ee1-30f76634e68c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e77dcb76-65d5-4293-87ae-3af49f90348d" xlink:to="loc_us-gaap_CommonStockMember_c5d2bf4b-05fd-41f9-8ee1-30f76634e68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8c843f72-0fee-4580-8808-966d97ed2d10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_439422f7-c51a-42f1-ba6e-544155d7ceda" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8c843f72-0fee-4580-8808-966d97ed2d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a8d86416-e6c5-4cf5-b453-cc9048d7c20c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8c843f72-0fee-4580-8808-966d97ed2d10" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a8d86416-e6c5-4cf5-b453-cc9048d7c20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_0b3a5a1b-c2d9-4a34-be3f-106ebf8a9d8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a8d86416-e6c5-4cf5-b453-cc9048d7c20c" xlink:to="loc_us-gaap_ConvertibleDebtMember_0b3a5a1b-c2d9-4a34-be3f-106ebf8a9d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fc783554-8a1d-4ddf-afeb-a26b58325937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_439422f7-c51a-42f1-ba6e-544155d7ceda" xlink:to="loc_us-gaap_DebtInstrumentAxis_fc783554-8a1d-4ddf-afeb-a26b58325937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5cb17677-d940-43d7-a29f-cb5652320f91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fc783554-8a1d-4ddf-afeb-a26b58325937" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5cb17677-d940-43d7-a29f-cb5652320f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_a68158f4-86db-40ac-8c55-c212a626abcb" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5cb17677-d940-43d7-a29f-cb5652320f91" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_a68158f4-86db-40ac-8c55-c212a626abcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_7f5fa5cd-60e5-4c68-a011-4f6f4e49345b" xlink:href="ino-20201231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5cb17677-d940-43d7-a29f-cb5652320f91" xlink:to="loc_ino_August2019ConvertibleBondsMember_7f5fa5cd-60e5-4c68-a011-4f6f4e49345b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_a851cf43-f7f4-4caa-9283-d287797e8fa6" xlink:href="ino-20201231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5cb17677-d940-43d7-a29f-cb5652320f91" xlink:to="loc_ino_December2019ConvertibleBondsMember_a851cf43-f7f4-4caa-9283-d287797e8fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_895a5654-7a3b-440a-bf56-79f6418a9a9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_439422f7-c51a-42f1-ba6e-544155d7ceda" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_895a5654-7a3b-440a-bf56-79f6418a9a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9cce10b8-7cdb-4e02-833b-5f63a3d81ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_895a5654-7a3b-440a-bf56-79f6418a9a9c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9cce10b8-7cdb-4e02-833b-5f63a3d81ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_fc5fad5c-a359-4251-ba25-9ce5044c3e73" xlink:href="ino-20201231.xsd#ino_SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9cce10b8-7cdb-4e02-833b-5f63a3d81ed6" xlink:to="loc_ino_SalesAgreementMember_fc5fad5c-a359-4251-ba25-9ce5044c3e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_20f968ab-3efe-406b-9626-283bd26ccf0c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_439422f7-c51a-42f1-ba6e-544155d7ceda" xlink:to="loc_srt_RangeAxis_20f968ab-3efe-406b-9626-283bd26ccf0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3cc6f634-f473-43bb-868f-152128e7703d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_20f968ab-3efe-406b-9626-283bd26ccf0c" xlink:to="loc_srt_RangeMember_3cc6f634-f473-43bb-868f-152128e7703d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3961c89a-854c-4778-8326-bb958ad02190" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3cc6f634-f473-43bb-868f-152128e7703d" xlink:to="loc_srt_MinimumMember_3961c89a-854c-4778-8326-bb958ad02190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12742e30-8a0e-4e05-a1d7-573c5b6f2643" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3cc6f634-f473-43bb-868f-152128e7703d" xlink:to="loc_srt_MaximumMember_12742e30-8a0e-4e05-a1d7-573c5b6f2643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_439422f7-c51a-42f1-ba6e-544155d7ceda" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f7193f87-dc82-4788-a644-a76718e4c5ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_NetIncomeLoss_f7193f87-dc82-4788-a644-a76718e4c5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital_2d69b435-8684-4cd1-abc3-a8dc53813a1b" xlink:href="ino-20201231.xsd#ino_WorkingCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_ino_WorkingCapital_2d69b435-8684-4cd1-abc3-a8dc53813a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1b5ff6bc-815c-48e0-a5b3-b11f9577111e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1b5ff6bc-815c-48e0-a5b3-b11f9577111e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_9fc1d074-76ed-4e02-884b-c9518715cdc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_9fc1d074-76ed-4e02-884b-c9518715cdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e653eb27-441a-47a3-b0fb-6cdc6ea73e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e653eb27-441a-47a3-b0fb-6cdc6ea73e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_954b40b0-015f-46e8-a01a-fdc5fa85fa25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_954b40b0-015f-46e8-a01a-fdc5fa85fa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_76aef761-a15a-4a4a-9acb-7178484867df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_76aef761-a15a-4a4a-9acb-7178484867df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ea140698-c51a-4a77-a0bd-1700f15d5089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ea140698-c51a-4a77-a0bd-1700f15d5089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_95c908a8-e558-4d04-9885-3110d8165546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_NumberOfOperatingSegments_95c908a8-e558-4d04-9885-3110d8165546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d0fa4747-bde8-4038-8f43-f290cdb9a4aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d0fa4747-bde8-4038-8f43-f290cdb9a4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_cc995c8d-04e3-4af9-b2b0-afc12d5d588b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_cc995c8d-04e3-4af9-b2b0-afc12d5d588b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c32844da-5f41-4e93-8131-88bd7edc799d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c32844da-5f41-4e93-8131-88bd7edc799d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_263ce13e-e283-4485-bf95-246cfeeba72b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_263ce13e-e283-4485-bf95-246cfeeba72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_32c0e44a-7fd1-4a7d-a59b-1919f4a75a79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0cc53b01-c7cf-40d2-b863-90811953cb28" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_32c0e44a-7fd1-4a7d-a59b-1919f4a75a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8e08a73c-d556-4c17-88b1-d137b540f5e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ae6389b9-61ed-4c73-985f-d1f2a9e0aae8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e08a73c-d556-4c17-88b1-d137b540f5e8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ae6389b9-61ed-4c73-985f-d1f2a9e0aae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f0f95786-947b-46e4-a361-41ac0679d11e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ae6389b9-61ed-4c73-985f-d1f2a9e0aae8" xlink:to="loc_us-gaap_DebtInstrumentAxis_f0f95786-947b-46e4-a361-41ac0679d11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a89dbecc-f89a-4e01-a65d-0387a80ee3e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f0f95786-947b-46e4-a361-41ac0679d11e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a89dbecc-f89a-4e01-a65d-0387a80ee3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_79440068-978c-43ee-8cab-1c99e10973aa" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a89dbecc-f89a-4e01-a65d-0387a80ee3e3" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_79440068-978c-43ee-8cab-1c99e10973aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_02fce4d0-d3a7-4a82-bf7c-fe0fc19bb9da" xlink:href="ino-20201231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a89dbecc-f89a-4e01-a65d-0387a80ee3e3" xlink:to="loc_ino_August2019ConvertibleBondsMember_02fce4d0-d3a7-4a82-bf7c-fe0fc19bb9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_825d62c8-4851-48e9-ae59-568cefc1c454" xlink:href="ino-20201231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a89dbecc-f89a-4e01-a65d-0387a80ee3e3" xlink:to="loc_ino_December2019ConvertibleBondsMember_825d62c8-4851-48e9-ae59-568cefc1c454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_19b10955-d6b5-492f-9f94-999dcf22094f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ae6389b9-61ed-4c73-985f-d1f2a9e0aae8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_19b10955-d6b5-492f-9f94-999dcf22094f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_645cc3cc-7942-44c2-be6e-2bd5847c34e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_19b10955-d6b5-492f-9f94-999dcf22094f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_645cc3cc-7942-44c2-be6e-2bd5847c34e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9a98e7d3-7c3c-432e-a61d-9846c2e78e4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_645cc3cc-7942-44c2-be6e-2bd5847c34e6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9a98e7d3-7c3c-432e-a61d-9846c2e78e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_7b5b2679-b321-4ba8-8ee6-fa305c21ee53" xlink:href="ino-20201231.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_645cc3cc-7942-44c2-be6e-2bd5847c34e6" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_7b5b2679-b321-4ba8-8ee6-fa305c21ee53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bfd70979-2557-43e0-9534-2f79847e92d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_645cc3cc-7942-44c2-be6e-2bd5847c34e6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bfd70979-2557-43e0-9534-2f79847e92d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_39a0e520-9d6a-49b4-9c28-21ae7924c013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_645cc3cc-7942-44c2-be6e-2bd5847c34e6" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_39a0e520-9d6a-49b4-9c28-21ae7924c013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_7fce5a0d-bc90-40fe-bbfd-fa443294985c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_645cc3cc-7942-44c2-be6e-2bd5847c34e6" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_7fce5a0d-bc90-40fe-bbfd-fa443294985c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_603ad068-9802-4467-ba61-668a69b05993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ae6389b9-61ed-4c73-985f-d1f2a9e0aae8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_603ad068-9802-4467-ba61-668a69b05993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CommonStockEquivalentsAbstract_32ec8ced-2df0-445a-a2dd-13350dc32671" xlink:href="ino-20201231.xsd#ino_CommonStockEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_603ad068-9802-4467-ba61-668a69b05993" xlink:to="loc_ino_CommonStockEquivalentsAbstract_32ec8ced-2df0-445a-a2dd-13350dc32671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0015d650-df0b-4396-8a11-9d2921919e09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CommonStockEquivalentsAbstract_32ec8ced-2df0-445a-a2dd-13350dc32671" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0015d650-df0b-4396-8a11-9d2921919e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_af58f624-c6be-4a2b-b682-247492b1f02a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f487e599-da2b-41af-91b3-c743ef1cd98c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af58f624-c6be-4a2b-b682-247492b1f02a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f487e599-da2b-41af-91b3-c743ef1cd98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_d3ed401b-c067-4c78-a053-c3d737fa6beb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f487e599-da2b-41af-91b3-c743ef1cd98c" xlink:to="loc_srt_TitleOfIndividualAxis_d3ed401b-c067-4c78-a053-c3d737fa6beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_189ddfc7-30df-4c91-980a-46e076f8cb93" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_d3ed401b-c067-4c78-a053-c3d737fa6beb" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_189ddfc7-30df-4c91-980a-46e076f8cb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_f64fae16-c58f-4dae-b654-a9c877d32760" xlink:href="ino-20201231.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_189ddfc7-30df-4c91-980a-46e076f8cb93" xlink:to="loc_ino_EmployeesAndDirectorsMember_f64fae16-c58f-4dae-b654-a9c877d32760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_eed9c1e5-ee56-42aa-ae7e-f709eb78df40" xlink:href="ino-20201231.xsd#ino_NonEmployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_189ddfc7-30df-4c91-980a-46e076f8cb93" xlink:to="loc_ino_NonEmployeeMember_eed9c1e5-ee56-42aa-ae7e-f709eb78df40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b3fb5e7f-b8b1-410f-9cd1-d6624dd48176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f487e599-da2b-41af-91b3-c743ef1cd98c" xlink:to="loc_us-gaap_AwardTypeAxis_b3fb5e7f-b8b1-410f-9cd1-d6624dd48176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9ab9a903-f5da-4bd4-b54d-e23070c9457e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b3fb5e7f-b8b1-410f-9cd1-d6624dd48176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9ab9a903-f5da-4bd4-b54d-e23070c9457e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3b5a8c92-2dde-4134-b240-4a416b084ef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9ab9a903-f5da-4bd4-b54d-e23070c9457e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3b5a8c92-2dde-4134-b240-4a416b084ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b7decd7f-c89c-4443-a979-7984abdb4430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f487e599-da2b-41af-91b3-c743ef1cd98c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b7decd7f-c89c-4443-a979-7984abdb4430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_f20bc6f7-e40f-4bed-97a5-e8c40e8668a5" xlink:href="ino-20201231.xsd#ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b7decd7f-c89c-4443-a979-7984abdb4430" xlink:to="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_f20bc6f7-e40f-4bed-97a5-e8c40e8668a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_290d2425-e516-41c6-8be4-94f9dfa799c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_f20bc6f7-e40f-4bed-97a5-e8c40e8668a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_290d2425-e516-41c6-8be4-94f9dfa799c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f41f6384-a61c-48d2-adce-d7736a23ee7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_f20bc6f7-e40f-4bed-97a5-e8c40e8668a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f41f6384-a61c-48d2-adce-d7736a23ee7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d8cc54b6-de2c-4633-8c84-c7604dc428d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_f20bc6f7-e40f-4bed-97a5-e8c40e8668a5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d8cc54b6-de2c-4633-8c84-c7604dc428d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b6328591-1961-4df9-a958-9f7c8ba8ca5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_f20bc6f7-e40f-4bed-97a5-e8c40e8668a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b6328591-1961-4df9-a958-9f7c8ba8ca5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognition" xlink:type="simple" xlink:href="ino-20201231.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8131ad9d-39e0-4742-bd53-2a1bcc6f1efe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_65b8711a-05e2-4519-ac76-628225c5eaf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8131ad9d-39e0-4742-bd53-2a1bcc6f1efe" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_65b8711a-05e2-4519-ac76-628225c5eaf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#RevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_905e478e-ab3d-48a6-9784-3bb3b8a69cf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a561a5a9-391e-47f8-a96e-23c2651d618e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_905e478e-ab3d-48a6-9784-3bb3b8a69cf0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a561a5a9-391e-47f8-a96e-23c2651d618e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c914009d-d905-4f28-b452-182cb734f3bc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a561a5a9-391e-47f8-a96e-23c2651d618e" xlink:to="loc_srt_CounterpartyNameAxis_c914009d-d905-4f28-b452-182cb734f3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f82b365-d43d-4c13-a2c9-ce13023b6cad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c914009d-d905-4f28-b452-182cb734f3bc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f82b365-d43d-4c13-a2c9-ce13023b6cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_dbe54c54-81a4-496b-9309-387e5d2f36f1" xlink:href="ino-20201231.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f82b365-d43d-4c13-a2c9-ce13023b6cad" xlink:to="loc_ino_AdvaccineMember_dbe54c54-81a4-496b-9309-387e5d2f36f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_04ba61e9-243f-4d28-b60c-479c6ffe7117" xlink:href="ino-20201231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f82b365-d43d-4c13-a2c9-ce13023b6cad" xlink:to="loc_ino_PlumblineLifeSciencesMember_04ba61e9-243f-4d28-b60c-479c6ffe7117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherCounterpartyMember_4c9d2149-201a-4852-9dba-c22a5a9ffa70" xlink:href="ino-20201231.xsd#ino_OtherCounterpartyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f82b365-d43d-4c13-a2c9-ce13023b6cad" xlink:to="loc_ino_OtherCounterpartyMember_4c9d2149-201a-4852-9dba-c22a5a9ffa70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_fa76a66f-3b0e-4f36-87d3-a27c6ce0f394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a561a5a9-391e-47f8-a96e-23c2651d618e" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_fa76a66f-3b0e-4f36-87d3-a27c6ce0f394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4844f6a7-938f-460e-ada2-307e74532566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fa76a66f-3b0e-4f36-87d3-a27c6ce0f394" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4844f6a7-938f-460e-ada2-307e74532566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0eac0ab0-7bda-4482-90c6-0efa67d9d12a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fa76a66f-3b0e-4f36-87d3-a27c6ce0f394" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0eac0ab0-7bda-4482-90c6-0efa67d9d12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="ino-20201231.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_563c3fa8-a4f5-40cc-b9d8-0dd62de435df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_9aa2919f-6c76-426f-a044-ddb17022ef47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_563c3fa8-a4f5-40cc-b9d8-0dd62de435df" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_9aa2919f-6c76-426f-a044-ddb17022ef47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#CollaborativeAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4ead76b9-ddfb-4b09-8347-7e1b475b0844" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8420ef7-9238-463d-b2d2-1c95e91c368e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4ead76b9-ddfb-4b09-8347-7e1b475b0844" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8420ef7-9238-463d-b2d2-1c95e91c368e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_93b9b905-1851-4638-80f0-ff279e8ec97e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8420ef7-9238-463d-b2d2-1c95e91c368e" xlink:to="loc_srt_CounterpartyNameAxis_93b9b905-1851-4638-80f0-ff279e8ec97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_753c030f-5632-4193-9630-7c0f1fd71e99" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_93b9b905-1851-4638-80f0-ff279e8ec97e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_753c030f-5632-4193-9630-7c0f1fd71e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_a73ee4ce-3fcb-4c7e-af2a-1a65f973c810" xlink:href="ino-20201231.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_753c030f-5632-4193-9630-7c0f1fd71e99" xlink:to="loc_ino_AdvaccineMember_a73ee4ce-3fcb-4c7e-af2a-1a65f973c810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_894aebcf-6ab3-40b4-8523-ce70435ca8f9" xlink:href="ino-20201231.xsd#ino_ApolloBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_753c030f-5632-4193-9630-7c0f1fd71e99" xlink:to="loc_ino_ApolloBioMember_894aebcf-6ab3-40b4-8523-ce70435ca8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember_efd00b6a-d552-44e4-8ca2-612478f66a36" xlink:href="ino-20201231.xsd#ino_AstraZenecaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_753c030f-5632-4193-9630-7c0f1fd71e99" xlink:to="loc_ino_AstraZenecaMember_efd00b6a-d552-44e4-8ca2-612478f66a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_210955ba-704d-4ebf-af50-d5475f1e3d6b" xlink:href="ino-20201231.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_753c030f-5632-4193-9630-7c0f1fd71e99" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_210955ba-704d-4ebf-af50-d5475f1e3d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_5eb1553c-953f-455f-897d-ed8bbb471a05" xlink:href="ino-20201231.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_753c030f-5632-4193-9630-7c0f1fd71e99" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_5eb1553c-953f-455f-897d-ed8bbb471a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember_9b97205f-dcdb-490b-a595-19f5f54f2f96" xlink:href="ino-20201231.xsd#ino_DepartmentOfDefenceMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_753c030f-5632-4193-9630-7c0f1fd71e99" xlink:to="loc_ino_DepartmentOfDefenceMember_9b97205f-dcdb-490b-a595-19f5f54f2f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4f09bb4d-a7d8-4472-909b-2adc1eb95f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8420ef7-9238-463d-b2d2-1c95e91c368e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4f09bb4d-a7d8-4472-909b-2adc1eb95f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_062a2b51-0d5f-4635-a447-b05aa86d07d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f09bb4d-a7d8-4472-909b-2adc1eb95f3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_062a2b51-0d5f-4635-a447-b05aa86d07d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_47f1e92f-e97b-4442-9a0e-4046acd01b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_062a2b51-0d5f-4635-a447-b05aa86d07d4" xlink:to="loc_us-gaap_CollaborativeArrangementMember_47f1e92f-e97b-4442-9a0e-4046acd01b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b821f6e9-66b3-49c2-a51b-076321c3268a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8420ef7-9238-463d-b2d2-1c95e91c368e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b821f6e9-66b3-49c2-a51b-076321c3268a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cd1eab6a-b498-417e-8f99-888e982b8ed7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b821f6e9-66b3-49c2-a51b-076321c3268a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cd1eab6a-b498-417e-8f99-888e982b8ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bfb4c6f1-2d28-4a4e-9aaf-187824991f32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_cd1eab6a-b498-417e-8f99-888e982b8ed7" xlink:to="loc_us-gaap_SubsequentEventMember_bfb4c6f1-2d28-4a4e-9aaf-187824991f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_43ccf103-4f33-4a71-8928-bc70fb6e060f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8420ef7-9238-463d-b2d2-1c95e91c368e" xlink:to="loc_srt_ProductOrServiceAxis_43ccf103-4f33-4a71-8928-bc70fb6e060f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7e6daa94-85a7-4427-a2fa-24640728a0a8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_43ccf103-4f33-4a71-8928-bc70fb6e060f" xlink:to="loc_srt_ProductsAndServicesDomain_7e6daa94-85a7-4427-a2fa-24640728a0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_7face40d-77e6-404f-8314-cf65bb6edf8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7e6daa94-85a7-4427-a2fa-24640728a0a8" xlink:to="loc_us-gaap_LicenseMember_7face40d-77e6-404f-8314-cf65bb6edf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember_c35845f9-8e17-4a60-bd1a-09cb5744bb8f" xlink:href="ino-20201231.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7e6daa94-85a7-4427-a2fa-24640728a0a8" xlink:to="loc_ino_SARSCoV2COVID19VaccineMember_c35845f9-8e17-4a60-bd1a-09cb5744bb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_d8109309-803c-4a00-8f8f-91349bc6cf4d" xlink:href="ino-20201231.xsd#ino_INO4800Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7e6daa94-85a7-4427-a2fa-24640728a0a8" xlink:to="loc_ino_INO4800Member_d8109309-803c-4a00-8f8f-91349bc6cf4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_739af8a3-45e6-4c3d-b66d-fdc412de8595" xlink:href="ino-20201231.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7e6daa94-85a7-4427-a2fa-24640728a0a8" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_739af8a3-45e6-4c3d-b66d-fdc412de8595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_f76011a2-c3e3-4439-89eb-4e54573e6118" xlink:href="ino-20201231.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7e6daa94-85a7-4427-a2fa-24640728a0a8" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_f76011a2-c3e3-4439-89eb-4e54573e6118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_9b3e7d81-370a-4974-a79a-dd8be50a1cc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8420ef7-9238-463d-b2d2-1c95e91c368e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_9b3e7d81-370a-4974-a79a-dd8be50a1cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0e0c600e-9a5c-4d5b-b938-c5123dadcefd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_9b3e7d81-370a-4974-a79a-dd8be50a1cc1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0e0c600e-9a5c-4d5b-b938-c5123dadcefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_0e6f5eb9-724b-4675-8a08-820ee147b371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0e0c600e-9a5c-4d5b-b938-c5123dadcefd" xlink:to="loc_us-gaap_ForeignCountryMember_0e6f5eb9-724b-4675-8a08-820ee147b371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8420ef7-9238-463d-b2d2-1c95e91c368e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_ad4b8982-6e03-41a1-9d03-cbdc8fe2cc36" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_ad4b8982-6e03-41a1-9d03-cbdc8fe2cc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_38348373-7796-4386-bea3-6e4e073bb107" xlink:href="ino-20201231.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_38348373-7796-4386-bea3-6e4e073bb107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned_6b715063-f9e9-48af-b117-03209e5253c0" xlink:href="ino-20201231.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborationAgreementPaymentEarned_6b715063-f9e9-48af-b117-03209e5253c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_1473ff03-e8a6-400a-aa0f-2376b3dc9130" xlink:href="ino-20201231.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_1473ff03-e8a6-400a-aa0f-2376b3dc9130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_3bd93765-7d8c-47cf-8ea5-da0ecde166c2" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_3bd93765-7d8c-47cf-8ea5-da0ecde166c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_36ba590b-bb72-4fd3-aa8d-65326f6ed58d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_36ba590b-bb72-4fd3-aa8d-65326f6ed58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_aea14300-272d-4f39-8726-1630dd30fac6" xlink:href="ino-20201231.xsd#ino_CollaborationAgreementTerritoryExpansionOptionPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_aea14300-272d-4f39-8726-1630dd30fac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement_0a78c755-fea0-4b58-b3a7-4cd48412adeb" xlink:href="ino-20201231.xsd#ino_ProceedsFromCollaborativeAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_ProceedsFromCollaborativeAgreement_0a78c755-fea0-4b58-b3a7-4cd48412adeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax_a9719f36-c1b8-4999-a644-d99bc27e2119" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementCorporateIncomeTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeAgreementCorporateIncomeTax_a9719f36-c1b8-4999-a644-d99bc27e2119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_6212c2c0-a66c-4da1-a065-6739d8a3d105" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_6212c2c0-a66c-4da1-a065-6739d8a3d105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees_ee9e0c21-5da5-42c1-9468-7e2a4c45a1e1" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementAdvisoryFees"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeAgreementAdvisoryFees_ee9e0c21-5da5-42c1-9468-7e2a4c45a1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_538cef53-5bfd-4f85-8b54-39a50a0b4ad7" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_538cef53-5bfd-4f85-8b54-39a50a0b4ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_32cfb055-3f45-41a4-a344-d8878e14c6ff" xlink:href="ino-20201231.xsd#ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_32cfb055-3f45-41a4-a344-d8878e14c6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_324e2a71-c037-4d1c-a7a0-705e222d8821" xlink:href="ino-20201231.xsd#ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_324e2a71-c037-4d1c-a7a0-705e222d8821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_f442fd7f-c325-4003-af05-8248280ca978" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementMilestonePaymentRevenueRecognized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_f442fd7f-c325-4003-af05-8248280ca978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_178902d1-6727-41ba-8f0e-0cd5c178eee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_178902d1-6727-41ba-8f0e-0cd5c178eee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_f6933649-4e4d-4680-af44-1753fadf4130" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_f6933649-4e4d-4680-af44-1753fadf4130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_5a16ed0e-7347-4332-95b5-dfe8c54c5969" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_5a16ed0e-7347-4332-95b5-dfe8c54c5969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_c414ea0d-99be-4a98-8dc4-dfa30c8522c0" xlink:href="ino-20201231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_DeferredGrantFundingCurrent_c414ea0d-99be-4a98-8dc4-dfa30c8522c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_13a0c9c9-8c48-48eb-8667-8c2de26bc915" xlink:href="ino-20201231.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_13a0c9c9-8c48-48eb-8667-8c2de26bc915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_1354cd6f-3be1-4b05-8555-43931ee2d490" xlink:href="ino-20201231.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_ino_GrantProceedsReceived_1354cd6f-3be1-4b05-8555-43931ee2d490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_2d4cb6a1-5a56-4898-9a4a-86def41b0af6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_efa5ae99-5c0f-4f67-8bcf-d8bf0f0cbb3b" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_2d4cb6a1-5a56-4898-9a4a-86def41b0af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestments" xlink:type="simple" xlink:href="ino-20201231.xsd#ShorttermInvestments"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ae64fbb7-98b5-4922-a79d-1c11ed7b554e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_100de5dd-bb94-4ce3-a58b-9025cbdf5cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ae64fbb7-98b5-4922-a79d-1c11ed7b554e" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_100de5dd-bb94-4ce3-a58b-9025cbdf5cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="simple" xlink:href="ino-20201231.xsd#ShorttermInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4f78a5d8-67ce-404c-9c88-cd068dcdb395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_8e5a0ae1-c67d-4ca8-b210-ca15d05cfba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4f78a5d8-67ce-404c-9c88-cd068dcdb395" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_8e5a0ae1-c67d-4ca8-b210-ca15d05cfba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#ShorttermInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c4c1fb31-9dec-48d9-92ee-6598dc07a2d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_3b1e5ced-3a82-4bad-9edf-57781be70a7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c4c1fb31-9dec-48d9-92ee-6598dc07a2d5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_3b1e5ced-3a82-4bad-9edf-57781be70a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_3d57bb77-f025-490d-bb1c-13e4aed2f0ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c4c1fb31-9dec-48d9-92ee-6598dc07a2d5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_3d57bb77-f025-490d-bb1c-13e4aed2f0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9ef3e16a-2cf4-4eeb-b787-dba8695c3a31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c4c1fb31-9dec-48d9-92ee-6598dc07a2d5" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9ef3e16a-2cf4-4eeb-b787-dba8695c3a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_f1cbedb2-e429-4afa-bd58-a0e46cf0244b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c4c1fb31-9dec-48d9-92ee-6598dc07a2d5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_f1cbedb2-e429-4afa-bd58-a0e46cf0244b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_10a6da38-fb4d-4dbd-8371-f8565727e8df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c4c1fb31-9dec-48d9-92ee-6598dc07a2d5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_10a6da38-fb4d-4dbd-8371-f8565727e8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fd5bc06c-4c54-466e-9aca-617f729b659b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_75d26f83-8e75-45ca-8e28-4632639434c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fd5bc06c-4c54-466e-9aca-617f729b659b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_75d26f83-8e75-45ca-8e28-4632639434c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9710192e-074f-48e6-9137-9ac1ccf18f13" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_75d26f83-8e75-45ca-8e28-4632639434c7" xlink:to="loc_srt_RangeAxis_9710192e-074f-48e6-9137-9ac1ccf18f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8a2bcef3-d4c5-48f2-bbd9-b1432b8bd673" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9710192e-074f-48e6-9137-9ac1ccf18f13" xlink:to="loc_srt_RangeMember_8a2bcef3-d4c5-48f2-bbd9-b1432b8bd673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6743099c-b4b4-4b67-adcf-b6314036bc18" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8a2bcef3-d4c5-48f2-bbd9-b1432b8bd673" xlink:to="loc_srt_MaximumMember_6743099c-b4b4-4b67-adcf-b6314036bc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e0cea5ec-b4a4-4074-aa1d-b9c2584c2b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_75d26f83-8e75-45ca-8e28-4632639434c7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e0cea5ec-b4a4-4074-aa1d-b9c2584c2b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a8c0683b-7d2e-471e-a7fa-48dcb13bb3aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e0cea5ec-b4a4-4074-aa1d-b9c2584c2b67" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a8c0683b-7d2e-471e-a7fa-48dcb13bb3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_1ebd84f4-0076-44c3-adba-48fdf3933d0e" xlink:href="ino-20201231.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a8c0683b-7d2e-471e-a7fa-48dcb13bb3aa" xlink:to="loc_ino_MutualFundsMember_1ebd84f4-0076-44c3-adba-48fdf3933d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_5f00daf6-1f6c-4c0f-a4f9-88de365fa052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a8c0683b-7d2e-471e-a7fa-48dcb13bb3aa" xlink:to="loc_us-gaap_CertificatesOfDepositMember_5f00daf6-1f6c-4c0f-a4f9-88de365fa052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_0ba9473a-17f5-4ce4-9bde-15a5b5936b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a8c0683b-7d2e-471e-a7fa-48dcb13bb3aa" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_0ba9473a-17f5-4ce4-9bde-15a5b5936b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_83451222-4068-4d33-bae9-5361b1d2056f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_75d26f83-8e75-45ca-8e28-4632639434c7" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_83451222-4068-4d33-bae9-5361b1d2056f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_0a1ff24a-1be4-4c80-a72b-3c331d9fd461" xlink:href="ino-20201231.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_83451222-4068-4d33-bae9-5361b1d2056f" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_0a1ff24a-1be4-4c80-a72b-3c331d9fd461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_07b31dbf-ab8c-4158-9767-82d3e5070c5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_83451222-4068-4d33-bae9-5361b1d2056f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_07b31dbf-ab8c-4158-9767-82d3e5070c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a0686de1-e9fd-493c-9d8f-8bc307cdb848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_07b31dbf-ab8c-4158-9767-82d3e5070c5f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a0686de1-e9fd-493c-9d8f-8bc307cdb848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_928e488c-776b-4677-ad6d-bc96bfaf49f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_07b31dbf-ab8c-4158-9767-82d3e5070c5f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_928e488c-776b-4677-ad6d-bc96bfaf49f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cc3bae30-c330-4d03-86ab-ace3d47f16d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_07b31dbf-ab8c-4158-9767-82d3e5070c5f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cc3bae30-c330-4d03-86ab-ace3d47f16d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_39afb47e-3482-4775-b3c5-927c2731bcbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract_07b31dbf-ab8c-4158-9767-82d3e5070c5f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_39afb47e-3482-4775-b3c5-927c2731bcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ino-20201231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_58bc0157-3e2f-4151-8e9b-e60bbfd627cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_40f845df-2b32-431e-bcf5-90de6226ea9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_58bc0157-3e2f-4151-8e9b-e60bbfd627cc" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_40f845df-2b32-431e-bcf5-90de6226ea9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ino-20201231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_39f9bf03-da3d-4a24-88eb-2ad5688560c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a3f5f8cf-2ab2-4bd9-b43b-2ba9025dd96a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_39f9bf03-da3d-4a24-88eb-2ad5688560c9" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a3f5f8cf-2ab2-4bd9-b43b-2ba9025dd96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6669606b-df65-4991-9e49-9f351e99c7b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_39f9bf03-da3d-4a24-88eb-2ad5688560c9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6669606b-df65-4991-9e49-9f351e99c7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_63779ff7-75da-4162-9352-3c19cc013c46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db816c55-f451-493e-8f52-eb2a4f93464b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_63779ff7-75da-4162-9352-3c19cc013c46" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db816c55-f451-493e-8f52-eb2a4f93464b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c1b6ba0a-e91b-445f-b805-bd20fb26d33b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db816c55-f451-493e-8f52-eb2a4f93464b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c1b6ba0a-e91b-445f-b805-bd20fb26d33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b275515d-0e05-4d06-8ff5-cbcb81e08c55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c1b6ba0a-e91b-445f-b805-bd20fb26d33b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b275515d-0e05-4d06-8ff5-cbcb81e08c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ec8ef262-13d6-4464-b2c8-04fd15ce3e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b275515d-0e05-4d06-8ff5-cbcb81e08c55" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ec8ef262-13d6-4464-b2c8-04fd15ce3e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5488994e-5566-4e13-aa0b-a0445542b876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db816c55-f451-493e-8f52-eb2a4f93464b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5488994e-5566-4e13-aa0b-a0445542b876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_950a9f23-a43d-459a-9bc6-162c22ca45bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5488994e-5566-4e13-aa0b-a0445542b876" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_950a9f23-a43d-459a-9bc6-162c22ca45bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_96fec26b-27cf-4385-b4d6-c6b70752f71d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_950a9f23-a43d-459a-9bc6-162c22ca45bd" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_96fec26b-27cf-4385-b4d6-c6b70752f71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1c0ed67d-8600-430f-98a5-c30fb40470b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_950a9f23-a43d-459a-9bc6-162c22ca45bd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1c0ed67d-8600-430f-98a5-c30fb40470b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_1a40eae1-3aa0-48bf-a27c-9b34899a369e" xlink:href="ino-20201231.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_950a9f23-a43d-459a-9bc6-162c22ca45bd" xlink:to="loc_ino_MutualFundsMember_1a40eae1-3aa0-48bf-a27c-9b34899a369e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_674db3ba-d66b-4b17-8bc1-78398e17a630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_950a9f23-a43d-459a-9bc6-162c22ca45bd" xlink:to="loc_us-gaap_CertificatesOfDepositMember_674db3ba-d66b-4b17-8bc1-78398e17a630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_244d9a82-e12a-44f3-8873-79d7403774e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_950a9f23-a43d-459a-9bc6-162c22ca45bd" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_244d9a82-e12a-44f3-8873-79d7403774e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86a2a202-fb47-46d2-a100-384c97306aac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db816c55-f451-493e-8f52-eb2a4f93464b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86a2a202-fb47-46d2-a100-384c97306aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_954e119d-ab3f-47d7-9742-cb6105b0e10d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_86a2a202-fb47-46d2-a100-384c97306aac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_954e119d-ab3f-47d7-9742-cb6105b0e10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6c76579e-1d53-49aa-bf1e-b5a9a78f6b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_954e119d-ab3f-47d7-9742-cb6105b0e10d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6c76579e-1d53-49aa-bf1e-b5a9a78f6b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9a9e304c-fdb3-4cc5-88cf-447bc45788ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_954e119d-ab3f-47d7-9742-cb6105b0e10d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9a9e304c-fdb3-4cc5-88cf-447bc45788ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_80ad8699-803b-4200-9139-8278b5e1b8ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_954e119d-ab3f-47d7-9742-cb6105b0e10d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_80ad8699-803b-4200-9139-8278b5e1b8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ca5e0c1a-2c5b-4687-8c33-b05bd55da328" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_db816c55-f451-493e-8f52-eb2a4f93464b" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ca5e0c1a-2c5b-4687-8c33-b05bd55da328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1479a904-0d7f-4611-afb8-d1858f964c27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ca5e0c1a-2c5b-4687-8c33-b05bd55da328" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1479a904-0d7f-4611-afb8-d1858f964c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9884ff63-2449-49ae-a4e5-60c7f38fde0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1479a904-0d7f-4611-afb8-d1858f964c27" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9884ff63-2449-49ae-a4e5-60c7f38fde0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6350025e-3dbf-4806-af84-f9820240728c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1479a904-0d7f-4611-afb8-d1858f964c27" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6350025e-3dbf-4806-af84-f9820240728c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_6d66b103-27e7-4b7d-9b56-7972f41207c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1479a904-0d7f-4611-afb8-d1858f964c27" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_6d66b103-27e7-4b7d-9b56-7972f41207c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ecf44d9b-13c8-4567-a47b-e75d820b81e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1479a904-0d7f-4611-afb8-d1858f964c27" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ecf44d9b-13c8-4567-a47b-e75d820b81e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_85bc99c4-44d5-40c8-a296-61dfdc36dfbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1479a904-0d7f-4611-afb8-d1858f964c27" xlink:to="loc_us-gaap_DerivativeLiabilities_85bc99c4-44d5-40c8-a296-61dfdc36dfbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_fe5e386a-1a7c-43ca-b742-304acc0cc083" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1479a904-0d7f-4611-afb8-d1858f964c27" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_fe5e386a-1a7c-43ca-b742-304acc0cc083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4a73fb9d-6af9-4452-867e-22b04f170df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d5a2ac80-a333-45d8-b584-7221d0775b16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4a73fb9d-6af9-4452-867e-22b04f170df3" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d5a2ac80-a333-45d8-b584-7221d0775b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_2e82bc64-609a-4b1d-a774-26e3590262cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d5a2ac80-a333-45d8-b584-7221d0775b16" xlink:to="loc_us-gaap_InvestmentTypeAxis_2e82bc64-609a-4b1d-a774-26e3590262cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_8504ffe5-4dad-4344-aca0-f9f4cad69dfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_2e82bc64-609a-4b1d-a774-26e3590262cb" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_8504ffe5-4dad-4344-aca0-f9f4cad69dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f43bade6-955c-486c-a101-221ea21e3ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_8504ffe5-4dad-4344-aca0-f9f4cad69dfd" xlink:to="loc_us-gaap_CommonStockMember_f43bade6-955c-486c-a101-221ea21e3ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f03b651d-1795-4081-a57d-1e97fb2dd4b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d5a2ac80-a333-45d8-b584-7221d0775b16" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f03b651d-1795-4081-a57d-1e97fb2dd4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6fb3880-7b6a-4862-aa60-84849ccd5f67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f03b651d-1795-4081-a57d-1e97fb2dd4b1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6fb3880-7b6a-4862-aa60-84849ccd5f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3aec28ff-06a0-4d1c-871a-9eef205bb0f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6fb3880-7b6a-4862-aa60-84849ccd5f67" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3aec28ff-06a0-4d1c-871a-9eef205bb0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8e84e657-756b-48ef-bb41-f70baeb358d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6fb3880-7b6a-4862-aa60-84849ccd5f67" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8e84e657-756b-48ef-bb41-f70baeb358d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ff3124d4-4280-4703-bd92-ccd4ebc006c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d5a2ac80-a333-45d8-b584-7221d0775b16" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ff3124d4-4280-4703-bd92-ccd4ebc006c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2d4cf549-d3bd-4d4c-81d4-d878ae16c23b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ff3124d4-4280-4703-bd92-ccd4ebc006c4" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2d4cf549-d3bd-4d4c-81d4-d878ae16c23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneOneLifeSciencesMember_00ac9243-8beb-4bbb-a22d-5579b1458618" xlink:href="ino-20201231.xsd#ino_GeneOneLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2d4cf549-d3bd-4d4c-81d4-d878ae16c23b" xlink:to="loc_ino_GeneOneLifeSciencesMember_00ac9243-8beb-4bbb-a22d-5579b1458618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d5a2ac80-a333-45d8-b584-7221d0775b16" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_eb35ec04-0422-45e3-b385-b8d02b8210f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_eb35ec04-0422-45e3-b385-b8d02b8210f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_ca3de9b9-5aec-4b3c-910f-a944f79614de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:to="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_ca3de9b9-5aec-4b3c-910f-a944f79614de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromSaleOfEquitySecuritiesFVNI_13338d6f-5c07-43dd-8c64-6791009d2713" xlink:href="ino-20201231.xsd#ino_ProceedsFromSaleOfEquitySecuritiesFVNI"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:to="loc_ino_ProceedsFromSaleOfEquitySecuritiesFVNI_13338d6f-5c07-43dd-8c64-6791009d2713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGain_bc122219-0ee4-4db9-b080-3af6ffe133d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGain"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGain_bc122219-0ee4-4db9-b080-3af6ffe133d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_ea189ba3-6621-4677-94b2-c1ad1c7f9792" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:to="loc_us-gaap_GainLossOnInvestments_ea189ba3-6621-4677-94b2-c1ad1c7f9792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2ac7c842-cc1b-42a7-8b16-803c78ec2068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2ac7c842-cc1b-42a7-8b16-803c78ec2068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_98c00878-2c25-4267-be11-59e2658b8279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_98c00878-2c25-4267-be11-59e2658b8279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_11d2b5c8-81c0-4988-9755-eddf873b35ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4914b68a-f35c-4139-a529-cc1387d1eb6a" xlink:to="loc_us-gaap_DerivativeLiabilities_11d2b5c8-81c0-4988-9755-eddf873b35ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e0190513-c194-4bf6-a87c-cdca83728240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_c6bc6478-0610-4e51-946b-73f236a9146b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e0190513-c194-4bf6-a87c-cdca83728240" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_c6bc6478-0610-4e51-946b-73f236a9146b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8e57a264-fbd9-45cc-b295-9af634819579" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_c6bc6478-0610-4e51-946b-73f236a9146b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8e57a264-fbd9-45cc-b295-9af634819579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f8780fe1-c1b6-40b3-82d1-e70f30880676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_c6bc6478-0610-4e51-946b-73f236a9146b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f8780fe1-c1b6-40b3-82d1-e70f30880676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_4bb770ee-8d18-42b8-909c-e4f94e323bd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_c6bc6478-0610-4e51-946b-73f236a9146b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_4bb770ee-8d18-42b8-909c-e4f94e323bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_039b23bd-2ca9-4b50-b6ab-acc9795e35d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_c6bc6478-0610-4e51-946b-73f236a9146b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_039b23bd-2ca9-4b50-b6ab-acc9795e35d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRisk" xlink:type="simple" xlink:href="ino-20201231.xsd#MajorCustomersandConcentrationofCreditRisk"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRisk" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_d296a471-fdb1-4efc-8322-f2f075ecd7b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_27bfafbd-ea2b-4cc4-8dd0-3fcdcf9d0383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_d296a471-fdb1-4efc-8322-f2f075ecd7b7" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_27bfafbd-ea2b-4cc4-8dd0-3fcdcf9d0383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskTables" xlink:type="simple" xlink:href="ino-20201231.xsd#MajorCustomersandConcentrationofCreditRiskTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_f442e77c-fa69-40ad-9aa3-a2457e805ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_b3d36a4d-688e-40f1-a883-78e6f39fc6fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_f442e77c-fa69-40ad-9aa3-a2457e805ca1" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_b3d36a4d-688e-40f1-a883-78e6f39fc6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#MajorCustomersandConcentrationofCreditRiskDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_898e46f5-0058-48f7-99f5-28a5013246c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_38a6915d-a417-42df-ac4f-e85fdc9e7981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_898e46f5-0058-48f7-99f5-28a5013246c7" xlink:to="loc_us-gaap_ConcentrationRiskTable_38a6915d-a417-42df-ac4f-e85fdc9e7981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ec87fdf6-de96-4a1d-8c09-bc1af8eb9629" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_38a6915d-a417-42df-ac4f-e85fdc9e7981" xlink:to="loc_srt_MajorCustomersAxis_ec87fdf6-de96-4a1d-8c09-bc1af8eb9629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c5f93851-5cf4-47fe-876d-384fe3fec91b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_ec87fdf6-de96-4a1d-8c09-bc1af8eb9629" xlink:to="loc_srt_NameOfMajorCustomerDomain_c5f93851-5cf4-47fe-876d-384fe3fec91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_544a34b8-a2b3-47c2-8916-e9c8645d4101" xlink:href="ino-20201231.xsd#ino_ApolloBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c5f93851-5cf4-47fe-876d-384fe3fec91b" xlink:to="loc_ino_ApolloBioMember_544a34b8-a2b3-47c2-8916-e9c8645d4101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember_aff37763-4604-48c1-9dae-a1d73647aa6c" xlink:href="ino-20201231.xsd#ino_AstraZenecaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c5f93851-5cf4-47fe-876d-384fe3fec91b" xlink:to="loc_ino_AstraZenecaMember_aff37763-4604-48c1-9dae-a1d73647aa6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_36d66ec9-b7b0-4d0c-b4f5-87a34e7f0bbf" xlink:href="ino-20201231.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c5f93851-5cf4-47fe-876d-384fe3fec91b" xlink:to="loc_ino_AdvaccineMember_36d66ec9-b7b0-4d0c-b4f5-87a34e7f0bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesIncMember_cee060d9-c35a-4436-8b1b-84dec6f320e0" xlink:href="ino-20201231.xsd#ino_PlumblineLifeSciencesIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c5f93851-5cf4-47fe-876d-384fe3fec91b" xlink:to="loc_ino_PlumblineLifeSciencesIncMember_cee060d9-c35a-4436-8b1b-84dec6f320e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AllOtherCustomersMember_1a207d8b-2ed0-42f6-81bf-5c4634567e20" xlink:href="ino-20201231.xsd#ino_AllOtherCustomersMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c5f93851-5cf4-47fe-876d-384fe3fec91b" xlink:to="loc_ino_AllOtherCustomersMember_1a207d8b-2ed0-42f6-81bf-5c4634567e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DoDMember_8293c355-6f2a-41fa-bb16-20db5ee23db8" xlink:href="ino-20201231.xsd#ino_DoDMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c5f93851-5cf4-47fe-876d-384fe3fec91b" xlink:to="loc_ino_DoDMember_8293c355-6f2a-41fa-bb16-20db5ee23db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MCDCMember_d45b2742-6519-47fb-8aa7-752fe965a9ea" xlink:href="ino-20201231.xsd#ino_MCDCMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c5f93851-5cf4-47fe-876d-384fe3fec91b" xlink:to="loc_ino_MCDCMember_d45b2742-6519-47fb-8aa7-752fe965a9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_25f99ddf-4b10-4133-ad60-534c65f2cb4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_38a6915d-a417-42df-ac4f-e85fdc9e7981" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_25f99ddf-4b10-4133-ad60-534c65f2cb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dc5c16ba-1f17-4623-ad2f-0eee09e982b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_25f99ddf-4b10-4133-ad60-534c65f2cb4d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dc5c16ba-1f17-4623-ad2f-0eee09e982b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_b4c4045b-99ca-4eeb-ab51-9441f542a8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dc5c16ba-1f17-4623-ad2f-0eee09e982b0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_b4c4045b-99ca-4eeb-ab51-9441f542a8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_fbff6651-d857-49ab-b9eb-fad7bb365ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dc5c16ba-1f17-4623-ad2f-0eee09e982b0" xlink:to="loc_us-gaap_AccountsReceivableMember_fbff6651-d857-49ab-b9eb-fad7bb365ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1d352166-4c84-4a70-8bf8-ab5eb1a418a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_38a6915d-a417-42df-ac4f-e85fdc9e7981" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1d352166-4c84-4a70-8bf8-ab5eb1a418a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fe363ab9-8bdb-4991-8a73-15b03d0b6430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1d352166-4c84-4a70-8bf8-ab5eb1a418a0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fe363ab9-8bdb-4991-8a73-15b03d0b6430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e0fef072-7de9-464f-b972-ae75b0f5ce21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_fe363ab9-8bdb-4991-8a73-15b03d0b6430" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e0fef072-7de9-464f-b972-ae75b0f5ce21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_5e787b3f-9681-4401-bcec-1b23aa9773d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_38a6915d-a417-42df-ac4f-e85fdc9e7981" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_5e787b3f-9681-4401-bcec-1b23aa9773d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fab95d47-4915-45d2-b75a-d64dee5cb3ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5e787b3f-9681-4401-bcec-1b23aa9773d4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fab95d47-4915-45d2-b75a-d64dee5cb3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_622cc6fe-2f40-4245-a36a-5b46b2bf869e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5e787b3f-9681-4401-bcec-1b23aa9773d4" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_622cc6fe-2f40-4245-a36a-5b46b2bf869e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_62b73295-d0bd-42e7-9cc5-9e538f92a2e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5e787b3f-9681-4401-bcec-1b23aa9773d4" xlink:to="loc_us-gaap_AccountsReceivableNet_62b73295-d0bd-42e7-9cc5-9e538f92a2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="simple" xlink:href="ino-20201231.xsd#PrepaidExpensesandOtherCurrentAssets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0f445fc0-702c-4f97-ba6f-56c7423024d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_55a5b8f5-04e9-4b58-ab48-3866b4874a72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0f445fc0-702c-4f97-ba6f-56c7423024d4" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_55a5b8f5-04e9-4b58-ab48-3866b4874a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="simple" xlink:href="ino-20201231.xsd#PrepaidExpensesandOtherCurrentAssetsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_36d53dc3-8b03-4a18-a075-3ef64f976b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_cdbb79c6-c017-44dc-a98d-bd90df4351e5" xlink:href="ino-20201231.xsd#ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_36d53dc3-8b03-4a18-a075-3ef64f976b7f" xlink:to="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_cdbb79c6-c017-44dc-a98d-bd90df4351e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#PrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_3fc650be-32de-4be5-bdb6-4f17767907c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpensesCurrent_52c8c805-2d6a-49d0-9f59-3570a2b4918c" xlink:href="ino-20201231.xsd#ino_PrepaidManufacturingExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_3fc650be-32de-4be5-bdb6-4f17767907c7" xlink:to="loc_ino_PrepaidManufacturingExpensesCurrent_52c8c805-2d6a-49d0-9f59-3570a2b4918c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_6ad4a1b0-19da-4bcc-9289-851961eb7c0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_3fc650be-32de-4be5-bdb6-4f17767907c7" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_6ad4a1b0-19da-4bcc-9289-851961eb7c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5073806e-77fa-442f-a639-f14a4e15450a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_3fc650be-32de-4be5-bdb6-4f17767907c7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5073806e-77fa-442f-a639-f14a4e15450a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssets" xlink:type="simple" xlink:href="ino-20201231.xsd#FixedAssets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FixedAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f227e7b6-0815-41ea-8e8b-fc69b7ea8766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_dfe16d34-5854-4be2-9f63-7c616726f888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f227e7b6-0815-41ea-8e8b-fc69b7ea8766" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_dfe16d34-5854-4be2-9f63-7c616726f888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsTables" xlink:type="simple" xlink:href="ino-20201231.xsd#FixedAssetsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FixedAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4d8825c7-9e16-4fe0-8999-68b39b151e6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f53cb7ee-3415-4609-9514-7a715ba2cb62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4d8825c7-9e16-4fe0-8999-68b39b151e6b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f53cb7ee-3415-4609-9514-7a715ba2cb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#FixedAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d7250f96-94d6-45a6-b744-ae0eda594d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_93c7d793-4914-4b36-ba1a-f100a4f36cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d7250f96-94d6-45a6-b744-ae0eda594d48" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_93c7d793-4914-4b36-ba1a-f100a4f36cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_efeb3bfa-1f5c-4d46-a298-fefeb9987376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_93c7d793-4914-4b36-ba1a-f100a4f36cd0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_efeb3bfa-1f5c-4d46-a298-fefeb9987376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_610885c4-b223-43fa-9ab3-fe47ac2bace5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_efeb3bfa-1f5c-4d46-a298-fefeb9987376" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_610885c4-b223-43fa-9ab3-fe47ac2bace5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_37cd6fe4-42ae-4000-8696-9be9721f64fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_610885c4-b223-43fa-9ab3-fe47ac2bace5" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_37cd6fe4-42ae-4000-8696-9be9721f64fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_c7d574ef-45e8-4285-b856-58fd05fe3140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_610885c4-b223-43fa-9ab3-fe47ac2bace5" xlink:to="loc_us-gaap_OfficeEquipmentMember_c7d574ef-45e8-4285-b856-58fd05fe3140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3b1658bd-0626-49c4-9fe2-c239ad58382d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_610885c4-b223-43fa-9ab3-fe47ac2bace5" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3b1658bd-0626-49c4-9fe2-c239ad58382d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_14af96a3-cf32-4897-ba16-df563fec05e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_610885c4-b223-43fa-9ab3-fe47ac2bace5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_14af96a3-cf32-4897-ba16-df563fec05e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4dbef8aa-554d-4bed-8fce-397f71b32d7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_93c7d793-4914-4b36-ba1a-f100a4f36cd0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4dbef8aa-554d-4bed-8fce-397f71b32d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_25515352-017e-4413-8042-af101f9d2744" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4dbef8aa-554d-4bed-8fce-397f71b32d7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_25515352-017e-4413-8042-af101f9d2744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_044c7ab0-1af6-46e8-bc24-acef24c05b48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4dbef8aa-554d-4bed-8fce-397f71b32d7c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_044c7ab0-1af6-46e8-bc24-acef24c05b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e3187ad1-fec3-49d1-a21e-3b6943ec86da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4dbef8aa-554d-4bed-8fce-397f71b32d7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e3187ad1-fec3-49d1-a21e-3b6943ec86da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_38b2561a-0bfd-474b-94fe-9a63c45f170f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4dbef8aa-554d-4bed-8fce-397f71b32d7c" xlink:to="loc_us-gaap_Depreciation_38b2561a-0bfd-474b-94fe-9a63c45f170f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_6589a7a8-873d-4da6-9c88-e693da508d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4dbef8aa-554d-4bed-8fce-397f71b32d7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_6589a7a8-873d-4da6-9c88-e693da508d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_2537dd50-7b3f-44c1-80c3-29b5d7a20389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4dbef8aa-554d-4bed-8fce-397f71b32d7c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_2537dd50-7b3f-44c1-80c3-29b5d7a20389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="ino-20201231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4e2c667c-bd3d-4b94-a3d4-49e6f1ddd798" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_27358057-a4ae-4c06-8090-1cb3d41ea5e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4e2c667c-bd3d-4b94-a3d4-49e6f1ddd798" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_27358057-a4ae-4c06-8090-1cb3d41ea5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="ino-20201231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_88bf8391-4bb9-4a18-aef0-48fbe6e3fbcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_aca2f3a5-85ce-438a-9c73-420331646728" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_88bf8391-4bb9-4a18-aef0-48fbe6e3fbcf" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_aca2f3a5-85ce-438a-9c73-420331646728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_85215beb-b1d7-46cc-9033-e8eeeedd3de4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_88bf8391-4bb9-4a18-aef0-48fbe6e3fbcf" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_85215beb-b1d7-46cc-9033-e8eeeedd3de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cea55fa9-9595-4be7-89ca-8d1996891ad8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_944cfcdb-801d-413d-b536-2ebe29207a25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cea55fa9-9595-4be7-89ca-8d1996891ad8" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_944cfcdb-801d-413d-b536-2ebe29207a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50a27cc4-bd02-47f4-8192-1e917099bde8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_944cfcdb-801d-413d-b536-2ebe29207a25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50a27cc4-bd02-47f4-8192-1e917099bde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5375a52f-69ec-4964-80e3-1269f8583d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50a27cc4-bd02-47f4-8192-1e917099bde8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5375a52f-69ec-4964-80e3-1269f8583d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b133c39d-3035-43d1-a99b-660150927847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5375a52f-69ec-4964-80e3-1269f8583d6a" xlink:to="loc_us-gaap_LicensingAgreementsMember_b133c39d-3035-43d1-a99b-660150927847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_851dadb2-21d9-46bb-ae30-7ca26dd96ee6" xlink:href="ino-20201231.xsd#ino_BiojectMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5375a52f-69ec-4964-80e3-1269f8583d6a" xlink:to="loc_ino_BiojectMember_851dadb2-21d9-46bb-ae30-7ca26dd96ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_3834ce21-51f6-4143-b587-3c71c16f534a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5375a52f-69ec-4964-80e3-1269f8583d6a" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_3834ce21-51f6-4143-b587-3c71c16f534a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ab522534-dfc0-4223-9cb1-e758a6206741" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_944cfcdb-801d-413d-b536-2ebe29207a25" xlink:to="loc_srt_RangeAxis_ab522534-dfc0-4223-9cb1-e758a6206741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0bdeee09-48d8-4323-9af0-0b69ea136445" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ab522534-dfc0-4223-9cb1-e758a6206741" xlink:to="loc_srt_RangeMember_0bdeee09-48d8-4323-9af0-0b69ea136445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_3cfde46b-62c8-43b9-9612-a6c48930e324" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0bdeee09-48d8-4323-9af0-0b69ea136445" xlink:to="loc_srt_WeightedAverageMember_3cfde46b-62c8-43b9-9612-a6c48930e324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b318ccb8-34fb-4392-a5a6-5616d6bc88e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_944cfcdb-801d-413d-b536-2ebe29207a25" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b318ccb8-34fb-4392-a5a6-5616d6bc88e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d3506df6-61aa-4b5b-a474-da0bdd9fd3ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b318ccb8-34fb-4392-a5a6-5616d6bc88e8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d3506df6-61aa-4b5b-a474-da0bdd9fd3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_033beb81-338c-4b35-b027-391b1575829b" xlink:href="ino-20201231.xsd#ino_BiojectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d3506df6-61aa-4b5b-a474-da0bdd9fd3ea" xlink:to="loc_ino_BiojectMember_033beb81-338c-4b35-b027-391b1575829b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5678115e-23ce-4368-99bd-6e23a5076c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_944cfcdb-801d-413d-b536-2ebe29207a25" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5678115e-23ce-4368-99bd-6e23a5076c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4b1fea36-7a1b-46f8-9329-eb0376af19c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5678115e-23ce-4368-99bd-6e23a5076c38" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4b1fea36-7a1b-46f8-9329-eb0376af19c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f535af2b-dc55-4b65-8be1-034719ef575f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4b1fea36-7a1b-46f8-9329-eb0376af19c0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f535af2b-dc55-4b65-8be1-034719ef575f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c8e6cea0-f8ed-4be9-b7b4-d54848b1f94d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4b1fea36-7a1b-46f8-9329-eb0376af19c0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c8e6cea0-f8ed-4be9-b7b4-d54848b1f94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f11cac19-9903-462a-baa5-490ac435d1f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c8e6cea0-f8ed-4be9-b7b4-d54848b1f94d" xlink:to="loc_us-gaap_Goodwill_f11cac19-9903-462a-baa5-490ac435d1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d445bc62-d2bc-48f4-abd4-e60cb0594749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4b1fea36-7a1b-46f8-9329-eb0376af19c0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d445bc62-d2bc-48f4-abd4-e60cb0594749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9a5299f7-33c8-46e3-986e-36981d88e5ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d445bc62-d2bc-48f4-abd4-e60cb0594749" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9a5299f7-33c8-46e3-986e-36981d88e5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_05cfb2ab-7cd9-4f1d-8d4a-603e4b828b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d445bc62-d2bc-48f4-abd4-e60cb0594749" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_05cfb2ab-7cd9-4f1d-8d4a-603e4b828b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6dbb46fd-13f4-474e-81b8-39eace6e6a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_d445bc62-d2bc-48f4-abd4-e60cb0594749" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6dbb46fd-13f4-474e-81b8-39eace6e6a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_a5a4f353-39eb-4c18-8c8a-ced8a82571a7" xlink:href="ino-20201231.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4b1fea36-7a1b-46f8-9329-eb0376af19c0" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_a5a4f353-39eb-4c18-8c8a-ced8a82571a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_a101b3e9-dc37-4690-ad8a-0fede3b97946" xlink:href="ino-20201231.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4b1fea36-7a1b-46f8-9329-eb0376af19c0" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_a101b3e9-dc37-4690-ad8a-0fede3b97946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ino-20201231.xsd#GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2816000c-2188-45f5-baad-11261648aa04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_a44e2039-afd3-4fad-bff2-5196a627d8b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2816000c-2188-45f5-baad-11261648aa04" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_a44e2039-afd3-4fad-bff2-5196a627d8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e074c321-39fd-4b25-8784-1efcfe056d84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2816000c-2188-45f5-baad-11261648aa04" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e074c321-39fd-4b25-8784-1efcfe056d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_59e6b659-c680-4487-b15f-9402cce5f8ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f3a3e218-f456-49f9-ac77-da65cdd68915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_59e6b659-c680-4487-b15f-9402cce5f8ea" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f3a3e218-f456-49f9-ac77-da65cdd68915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d74e740a-de1d-43ac-87a6-259b46e68f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_59e6b659-c680-4487-b15f-9402cce5f8ea" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d74e740a-de1d-43ac-87a6-259b46e68f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f11b92f0-88bc-4fe2-a3f3-c53911ac7b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_59e6b659-c680-4487-b15f-9402cce5f8ea" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f11b92f0-88bc-4fe2-a3f3-c53911ac7b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_eda4c52e-3e32-48be-9a5e-542583489732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_59e6b659-c680-4487-b15f-9402cce5f8ea" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_eda4c52e-3e32-48be-9a5e-542583489732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_7f611f2f-04a7-48c9-b560-beec131dac5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_59e6b659-c680-4487-b15f-9402cce5f8ea" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_7f611f2f-04a7-48c9-b560-beec131dac5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_b6c2e547-965d-4bbc-9de0-ca5d054b1fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_59e6b659-c680-4487-b15f-9402cce5f8ea" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_b6c2e547-965d-4bbc-9de0-ca5d054b1fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c46cf5db-44c2-4fa9-babf-4d63d7d9e140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_59e6b659-c680-4487-b15f-9402cce5f8ea" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c46cf5db-44c2-4fa9-babf-4d63d7d9e140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:type="simple" xlink:href="ino-20201231.xsd#ConvertibleDebt"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5af201ac-3d77-4392-bc06-9258a0d89fe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_134a671d-d18d-422e-b10b-74bea8d099e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5af201ac-3d77-4392-bc06-9258a0d89fe8" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_134a671d-d18d-422e-b10b-74bea8d099e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="simple" xlink:href="ino-20201231.xsd#ConvertibleDebtTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3c490d39-4b20-4afa-bd03-3626f4f342e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_b4214dcf-e689-44b4-af76-b854a68e78e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3c490d39-4b20-4afa-bd03-3626f4f342e3" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_b4214dcf-e689-44b4-af76-b854a68e78e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1baab10a-858e-442b-adf2-71136eff0e24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3c490d39-4b20-4afa-bd03-3626f4f342e3" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1baab10a-858e-442b-adf2-71136eff0e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d5f494f8-3a59-4022-83a6-9faa23f7f39b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cc7b4fdc-fdf0-4c84-bad2-6be87aa52327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d5f494f8-3a59-4022-83a6-9faa23f7f39b" xlink:to="loc_us-gaap_DebtInstrumentTable_cc7b4fdc-fdf0-4c84-bad2-6be87aa52327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c8f6daa6-f415-4454-bc54-8743c169f9ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cc7b4fdc-fdf0-4c84-bad2-6be87aa52327" xlink:to="loc_us-gaap_DebtInstrumentAxis_c8f6daa6-f415-4454-bc54-8743c169f9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f17e3ff3-26c2-430e-a794-e064138c8ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c8f6daa6-f415-4454-bc54-8743c169f9ee" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f17e3ff3-26c2-430e-a794-e064138c8ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_c8d1571f-c533-4a8c-9189-675a4edae676" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f17e3ff3-26c2-430e-a794-e064138c8ff5" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_c8d1571f-c533-4a8c-9189-675a4edae676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_92909ca7-5776-41d4-b1e1-6cf68f2cf9a8" xlink:href="ino-20201231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f17e3ff3-26c2-430e-a794-e064138c8ff5" xlink:to="loc_ino_August2019ConvertibleBondsMember_92909ca7-5776-41d4-b1e1-6cf68f2cf9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_1e94e427-f3c7-465f-b363-afe21f0abbcd" xlink:href="ino-20201231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f17e3ff3-26c2-430e-a794-e064138c8ff5" xlink:to="loc_ino_December2019ConvertibleBondsMember_1e94e427-f3c7-465f-b363-afe21f0abbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0186c36b-aa7e-485e-91aa-40db9767134e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cc7b4fdc-fdf0-4c84-bad2-6be87aa52327" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0186c36b-aa7e-485e-91aa-40db9767134e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b4562cf8-ce9c-4cc3-9b50-43e5d5785166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0186c36b-aa7e-485e-91aa-40db9767134e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b4562cf8-ce9c-4cc3-9b50-43e5d5785166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_9d0f2675-76ab-45f1-a0c3-92ff0d9d6925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b4562cf8-ce9c-4cc3-9b50-43e5d5785166" xlink:to="loc_us-gaap_ConvertibleDebtMember_9d0f2675-76ab-45f1-a0c3-92ff0d9d6925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_02af9a07-6f5c-4a2a-8509-3c800045a279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cc7b4fdc-fdf0-4c84-bad2-6be87aa52327" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_02af9a07-6f5c-4a2a-8509-3c800045a279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_fc73def8-9e4e-4307-98a9-a1e601c1c2dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_02af9a07-6f5c-4a2a-8509-3c800045a279" xlink:to="loc_us-gaap_DebtConversionNameDomain_fc73def8-9e4e-4307-98a9-a1e601c1c2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InitialConversionPriceMember_5f28cdb2-dbcf-40a9-a7cc-b1014bf87c9f" xlink:href="ino-20201231.xsd#ino_InitialConversionPriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_fc73def8-9e4e-4307-98a9-a1e601c1c2dd" xlink:to="loc_ino_InitialConversionPriceMember_5f28cdb2-dbcf-40a9-a7cc-b1014bf87c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AfterJanuary22020ConversionPriceMember_bcac6122-e974-47c6-87df-ca497bea0008" xlink:href="ino-20201231.xsd#ino_AfterJanuary22020ConversionPriceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_fc73def8-9e4e-4307-98a9-a1e601c1c2dd" xlink:to="loc_ino_AfterJanuary22020ConversionPriceMember_bcac6122-e974-47c6-87df-ca497bea0008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AfterJuly22020ConversionPriceMember_09831c1a-19c1-4335-8f08-815b94c4151b" xlink:href="ino-20201231.xsd#ino_AfterJuly22020ConversionPriceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_fc73def8-9e4e-4307-98a9-a1e601c1c2dd" xlink:to="loc_ino_AfterJuly22020ConversionPriceMember_09831c1a-19c1-4335-8f08-815b94c4151b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_20140f44-0adb-4e40-8fe7-0c4fdaa74a4b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cc7b4fdc-fdf0-4c84-bad2-6be87aa52327" xlink:to="loc_srt_RangeAxis_20140f44-0adb-4e40-8fe7-0c4fdaa74a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_94fc1a1f-96bc-462f-adeb-5d2f6679fdbe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_20140f44-0adb-4e40-8fe7-0c4fdaa74a4b" xlink:to="loc_srt_RangeMember_94fc1a1f-96bc-462f-adeb-5d2f6679fdbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e7822426-e56a-4a6c-9dfe-ad7544e4af73" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_94fc1a1f-96bc-462f-adeb-5d2f6679fdbe" xlink:to="loc_srt_MaximumMember_e7822426-e56a-4a6c-9dfe-ad7544e4af73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cc7b4fdc-fdf0-4c84-bad2-6be87aa52327" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_98f361a7-063d-4697-80bf-c32728fd4f01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_98f361a7-063d-4697-80bf-c32728fd4f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_49d44d73-a7cc-4be0-8dd1-613e4a88acd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_49d44d73-a7cc-4be0-8dd1-613e4a88acd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_d5175e75-22b4-424a-8994-0e8bc0279894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_d5175e75-22b4-424a-8994-0e8bc0279894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_64df274b-e2b3-4e25-bf65-225a20e54e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_64df274b-e2b3-4e25-bf65-225a20e54e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_59e7760a-fb9c-4eac-a881-45be3ec18b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_59e7760a-fb9c-4eac-a881-45be3ec18b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_86c72cda-e57a-401a-ad2b-0380eb37194e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_86c72cda-e57a-401a-ad2b-0380eb37194e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_77ee6d22-de35-49f4-8c38-e4ce86dc5659" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_77ee6d22-de35-49f4-8c38-e4ce86dc5659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2db71f52-4e1a-42c3-b8e4-edba40111bff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2db71f52-4e1a-42c3-b8e4-edba40111bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_40b33847-130a-44d4-8e6e-cb2bf5338578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_40b33847-130a-44d4-8e6e-cb2bf5338578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_880a1faf-ed22-42de-919c-4e07f297f951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_LongTermDebtFairValue_880a1faf-ed22-42de-919c-4e07f297f951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_256adef1-30aa-4554-a3fc-1b1026c30365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_256adef1-30aa-4554-a3fc-1b1026c30365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_938cacb2-8785-4560-a6f7-3bc67d77a9e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_938cacb2-8785-4560-a6f7-3bc67d77a9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_25846e42-18cd-4e1a-820b-c4c1e2943404" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_25846e42-18cd-4e1a-820b-c4c1e2943404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4d3b6366-c582-46bf-b087-1805ed74304f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_4d3b6366-c582-46bf-b087-1805ed74304f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_bd459e0a-eaf0-413e-acb8-54ef06430a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_bd459e0a-eaf0-413e-acb8-54ef06430a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_7d27e6e1-62f8-4eb3-964f-b4cb334decf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentFairValue_7d27e6e1-62f8-4eb3-964f-b4cb334decf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_0e52dcb7-a93f-484b-b8bf-06a937144038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_0e52dcb7-a93f-484b-b8bf-06a937144038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3fecffab-3f8e-4ec6-9828-65a042811390" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3fecffab-3f8e-4ec6-9828-65a042811390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ea44add7-563f-4e97-a262-5984afb61356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_InterestExpense_ea44add7-563f-4e97-a262-5984afb61356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_334d229e-3079-48f1-90d9-e7a2cf60a46f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_InterestExpenseDebt_334d229e-3079-48f1-90d9-e7a2cf60a46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_9a396004-f8ee-4b07-80cd-4c83a7f03a88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_9a396004-f8ee-4b07-80cd-4c83a7f03a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_426d647f-733f-416a-a417-ba4f0779bff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_426d647f-733f-416a-a417-ba4f0779bff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_d878b1d9-e865-468b-8476-5d3667368a3f" xlink:href="ino-20201231.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_d878b1d9-e865-468b-8476-5d3667368a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_82d6d2d4-3ab2-44cd-a886-0c39465fa5f6" xlink:href="ino-20201231.xsd#ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b1122114-7c17-4cee-bb9f-a44bb0d0e32a" xlink:to="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_82d6d2d4-3ab2-44cd-a886-0c39465fa5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#ConvertibleDebtBalanceOfConvertibleDebtDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_43d64047-54d7-4636-86df-2c8b022b5193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_897c89ff-9ee6-490f-aef9-f62a749b356c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_43d64047-54d7-4636-86df-2c8b022b5193" xlink:to="loc_us-gaap_DebtInstrumentTable_897c89ff-9ee6-490f-aef9-f62a749b356c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c449c5fe-02fb-4258-a9b8-99c9a2ca7417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_897c89ff-9ee6-490f-aef9-f62a749b356c" xlink:to="loc_us-gaap_DebtInstrumentAxis_c449c5fe-02fb-4258-a9b8-99c9a2ca7417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c7c4bcc4-1b80-4b07-850a-60fa109dc029" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c449c5fe-02fb-4258-a9b8-99c9a2ca7417" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c7c4bcc4-1b80-4b07-850a-60fa109dc029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_187323c8-e7a6-4ddf-b89f-8676d7df8f26" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7c4bcc4-1b80-4b07-850a-60fa109dc029" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_187323c8-e7a6-4ddf-b89f-8676d7df8f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_c0b86d44-dfa9-462e-98c0-7730ae739e84" xlink:href="ino-20201231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7c4bcc4-1b80-4b07-850a-60fa109dc029" xlink:to="loc_ino_December2019ConvertibleBondsMember_c0b86d44-dfa9-462e-98c0-7730ae739e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e0da9fd0-afc7-435d-ab9b-1fdc55f71215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_897c89ff-9ee6-490f-aef9-f62a749b356c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e0da9fd0-afc7-435d-ab9b-1fdc55f71215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a041e799-3d99-4bc5-9dfb-cfeb6239ef7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0da9fd0-afc7-435d-ab9b-1fdc55f71215" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a041e799-3d99-4bc5-9dfb-cfeb6239ef7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_1e7c5284-5a60-4fb8-9328-d289f8093c88" xlink:href="ino-20201231.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0da9fd0-afc7-435d-ab9b-1fdc55f71215" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_1e7c5284-5a60-4fb8-9328-d289f8093c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_22a978a6-b5ef-4b05-a394-049bc55e3d69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0da9fd0-afc7-435d-ab9b-1fdc55f71215" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_22a978a6-b5ef-4b05-a394-049bc55e3d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_fc832b3a-dd29-4d05-a620-77cbc17f09cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0da9fd0-afc7-435d-ab9b-1fdc55f71215" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_fc832b3a-dd29-4d05-a620-77cbc17f09cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccretionOfPremium_a168ba4b-ac97-4d7c-b082-1ee8ccae6a6d" xlink:href="ino-20201231.xsd#ino_DebtInstrumentAccretionOfPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0da9fd0-afc7-435d-ab9b-1fdc55f71215" xlink:to="loc_ino_DebtInstrumentAccretionOfPremium_a168ba4b-ac97-4d7c-b082-1ee8ccae6a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtinstrumentAccruedInterest_d9801568-dc43-4ead-b6cd-d7344b6888ec" xlink:href="ino-20201231.xsd#ino_DebtinstrumentAccruedInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0da9fd0-afc7-435d-ab9b-1fdc55f71215" xlink:to="loc_ino_DebtinstrumentAccruedInterest_d9801568-dc43-4ead-b6cd-d7344b6888ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_41af9216-ca8e-4223-a3d4-3320a514c42d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0da9fd0-afc7-435d-ab9b-1fdc55f71215" xlink:to="loc_us-gaap_LongTermDebt_41af9216-ca8e-4223-a3d4-3320a514c42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a7e14648-125d-40da-9858-29909deea9ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ef70f8f8-dfcb-4894-9e08-8c8031e265fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a7e14648-125d-40da-9858-29909deea9ed" xlink:to="loc_us-gaap_DebtInstrumentTable_ef70f8f8-dfcb-4894-9e08-8c8031e265fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_910bbe96-234f-4049-8a9d-9ef862e27b28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ef70f8f8-dfcb-4894-9e08-8c8031e265fc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_910bbe96-234f-4049-8a9d-9ef862e27b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cdbb8c75-9783-4082-b362-a8e98aaf7efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_910bbe96-234f-4049-8a9d-9ef862e27b28" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cdbb8c75-9783-4082-b362-a8e98aaf7efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_9a56e67e-2807-4986-b40b-bb24b745d2d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cdbb8c75-9783-4082-b362-a8e98aaf7efd" xlink:to="loc_us-gaap_ConvertibleDebtMember_9a56e67e-2807-4986-b40b-bb24b745d2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e9f8f8e5-84cd-4263-b6b5-0e53de2e56d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ef70f8f8-dfcb-4894-9e08-8c8031e265fc" xlink:to="loc_us-gaap_DebtInstrumentAxis_e9f8f8e5-84cd-4263-b6b5-0e53de2e56d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_99c002ca-1c20-4625-94eb-1a0ad42ade7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e9f8f8e5-84cd-4263-b6b5-0e53de2e56d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_99c002ca-1c20-4625-94eb-1a0ad42ade7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_66579fc5-0d81-4f7c-8ff4-3c04fbe274d2" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_99c002ca-1c20-4625-94eb-1a0ad42ade7a" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_66579fc5-0d81-4f7c-8ff4-3c04fbe274d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_41487b46-0f9b-4ac8-a70c-0c86ab086557" xlink:href="ino-20201231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_99c002ca-1c20-4625-94eb-1a0ad42ade7a" xlink:to="loc_ino_December2019ConvertibleBondsMember_41487b46-0f9b-4ac8-a70c-0c86ab086557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9ff5dfbe-c9e1-4926-8ce9-0a0d44061fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ef70f8f8-dfcb-4894-9e08-8c8031e265fc" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9ff5dfbe-c9e1-4926-8ce9-0a0d44061fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d3a04899-1f8c-4d37-b856-97e8a997cebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ff5dfbe-c9e1-4926-8ce9-0a0d44061fca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d3a04899-1f8c-4d37-b856-97e8a997cebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_64fb2bea-a73b-43e1-b51c-62854ac6f9e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ff5dfbe-c9e1-4926-8ce9-0a0d44061fca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_64fb2bea-a73b-43e1-b51c-62854ac6f9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_dea14040-6904-4c69-b3ef-0cdc154ecd75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ff5dfbe-c9e1-4926-8ce9-0a0d44061fca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_dea14040-6904-4c69-b3ef-0cdc154ecd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_b01228b3-d328-4952-be83-07381c06a802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ff5dfbe-c9e1-4926-8ce9-0a0d44061fca" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_b01228b3-d328-4952-be83-07381c06a802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f9613119-5e9e-42ac-a9c8-ad441d9af2f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ff5dfbe-c9e1-4926-8ce9-0a0d44061fca" xlink:to="loc_us-gaap_LongTermDebt_f9613119-5e9e-42ac-a9c8-ad441d9af2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_061ca5fb-1fdc-43be-9206-f8982b7c6ac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ff5dfbe-c9e1-4926-8ce9-0a0d44061fca" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_061ca5fb-1fdc-43be-9206-f8982b7c6ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_97e04374-6f09-4ab8-81d2-ed0a9cff9308" xlink:href="ino-20201231.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9ff5dfbe-c9e1-4926-8ce9-0a0d44061fca" xlink:to="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_97e04374-6f09-4ab8-81d2-ed0a9cff9308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableandAccruedExpenses" xlink:type="simple" xlink:href="ino-20201231.xsd#AccountsPayableandAccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/AccountsPayableandAccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_fe12a73b-bf73-4d4b-9331-5a06156fee24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_96d665f4-1fa3-4345-9505-ca8e48d0ae0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fe12a73b-bf73-4d4b-9331-5a06156fee24" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_96d665f4-1fa3-4345-9505-ca8e48d0ae0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableandAccruedExpensesTables" xlink:type="simple" xlink:href="ino-20201231.xsd#AccountsPayableandAccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_c13ea5c6-7d50-4094-a4c3-77a7836f13fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_19b31d69-c4c7-4c87-b94e-b4efc66cbd95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c13ea5c6-7d50-4094-a4c3-77a7836f13fa" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_19b31d69-c4c7-4c87-b94e-b4efc66cbd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#AccountsPayableandAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_4a4ee498-a217-4ea5-8278-d02847b2c2b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_ec0f2b6c-a811-4f65-87cf-853f443ae6a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4a4ee498-a217-4ea5-8278-d02847b2c2b5" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_ec0f2b6c-a811-4f65-87cf-853f443ae6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_c72a0529-92ff-4b12-83e2-96338e41e596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4a4ee498-a217-4ea5-8278-d02847b2c2b5" xlink:to="loc_us-gaap_AccruedSalariesCurrent_c72a0529-92ff-4b12-83e2-96338e41e596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedSubcontractExpenses_e21f074a-dab2-4027-886f-6f924dcf6d37" xlink:href="ino-20201231.xsd#ino_AccruedSubcontractExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4a4ee498-a217-4ea5-8278-d02847b2c2b5" xlink:to="loc_ino_AccruedSubcontractExpenses_e21f074a-dab2-4027-886f-6f924dcf6d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_53cbf7d0-1934-42ef-87bc-a3dbcf16b442" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4a4ee498-a217-4ea5-8278-d02847b2c2b5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_53cbf7d0-1934-42ef-87bc-a3dbcf16b442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_dfaaaab3-9447-4f93-b3dc-e1824902cad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4a4ee498-a217-4ea5-8278-d02847b2c2b5" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_dfaaaab3-9447-4f93-b3dc-e1824902cad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_2a40ec91-4df4-4ac6-8049-2a80e9dbeb15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ccccf4e6-1c3d-4c2d-adfd-220af485e214" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_2a40ec91-4df4-4ac6-8049-2a80e9dbeb15" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ccccf4e6-1c3d-4c2d-adfd-220af485e214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_8a4de71f-c847-466a-ad8d-d1634fba1839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_f9a45122-751e-4615-8154-c74a4704336c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8a4de71f-c847-466a-ad8d-d1634fba1839" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_f9a45122-751e-4615-8154-c74a4704336c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_3c20bb5a-976f-4b6f-be5e-8e627aea9e2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8a4de71f-c847-466a-ad8d-d1634fba1839" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_3c20bb5a-976f-4b6f-be5e-8e627aea9e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6d9bcfb4-2c70-46ec-b4bc-8a3e2738ff78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8a4de71f-c847-466a-ad8d-d1634fba1839" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6d9bcfb4-2c70-46ec-b4bc-8a3e2738ff78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_da5e034d-dbf1-4f2d-8f06-2799b8062088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8a4de71f-c847-466a-ad8d-d1634fba1839" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_da5e034d-dbf1-4f2d-8f06-2799b8062088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquitySummaryofPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_2de191a7-d2b0-4496-9600-2c3b8b12493b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_14a84d2b-c486-4109-b1a7-7c0dea0b8443" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_2de191a7-d2b0-4496-9600-2c3b8b12493b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_14a84d2b-c486-4109-b1a7-7c0dea0b8443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_163809b9-aa0c-49bb-a07f-54ae00279e1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_14a84d2b-c486-4109-b1a7-7c0dea0b8443" xlink:to="loc_us-gaap_StatementClassOfStockAxis_163809b9-aa0c-49bb-a07f-54ae00279e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d8bb9b4a-91ca-4544-8468-b723f48df8db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_163809b9-aa0c-49bb-a07f-54ae00279e1f" xlink:to="loc_us-gaap_ClassOfStockDomain_d8bb9b4a-91ca-4544-8468-b723f48df8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_b0cccd12-d4ab-47f3-b36a-3bd591b45e88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d8bb9b4a-91ca-4544-8468-b723f48df8db" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_b0cccd12-d4ab-47f3-b36a-3bd591b45e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_26eadc8b-ff83-4a91-b71f-a0e491adf944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_14a84d2b-c486-4109-b1a7-7c0dea0b8443" xlink:to="loc_us-gaap_ClassOfStockLineItems_26eadc8b-ff83-4a91-b71f-a0e491adf944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_442c0e84-c2f1-4dc2-994f-6afc3da87827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_26eadc8b-ff83-4a91-b71f-a0e491adf944" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_442c0e84-c2f1-4dc2-994f-6afc3da87827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_db063d08-3923-4f9d-b0cb-2d1ee6c6525f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_442c0e84-c2f1-4dc2-994f-6afc3da87827" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_db063d08-3923-4f9d-b0cb-2d1ee6c6525f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b25f1e97-a95a-47fe-b5e8-3f3ae01718a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_442c0e84-c2f1-4dc2-994f-6afc3da87827" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b25f1e97-a95a-47fe-b5e8-3f3ae01718a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_41cd84f5-cfb5-456d-b9c9-140b93844f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_442c0e84-c2f1-4dc2-994f-6afc3da87827" xlink:to="loc_us-gaap_PreferredStockSharesIssued_41cd84f5-cfb5-456d-b9c9-140b93844f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_28f841eb-a4b2-4f61-b690-ab7726d7a190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_442c0e84-c2f1-4dc2-994f-6afc3da87827" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_28f841eb-a4b2-4f61-b690-ab7726d7a190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_70089172-ab76-4b0a-80e4-c73bd592d2a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a5b0391d-1661-4f59-a6c1-524ba64a9c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_70089172-ab76-4b0a-80e4-c73bd592d2a6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a5b0391d-1661-4f59-a6c1-524ba64a9c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3967766a-6601-4e70-8c5f-2b208d946244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a5b0391d-1661-4f59-a6c1-524ba64a9c24" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3967766a-6601-4e70-8c5f-2b208d946244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_86cbd085-ed43-46b0-b1e4-82a1283945ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3967766a-6601-4e70-8c5f-2b208d946244" xlink:to="loc_us-gaap_ClassOfStockDomain_86cbd085-ed43-46b0-b1e4-82a1283945ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_7d1a1130-aa2e-48b3-bdd8-c58a68658e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_86cbd085-ed43-46b0-b1e4-82a1283945ec" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_7d1a1130-aa2e-48b3-bdd8-c58a68658e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f984634c-088a-4721-9b74-bebbec56dbe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_86cbd085-ed43-46b0-b1e4-82a1283945ec" xlink:to="loc_us-gaap_CommonStockMember_f984634c-088a-4721-9b74-bebbec56dbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_86ad86df-f944-44e0-a3e0-2614841f2814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a5b0391d-1661-4f59-a6c1-524ba64a9c24" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_86ad86df-f944-44e0-a3e0-2614841f2814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b6315a05-2ede-4930-93a6-b567593ff254" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_86ad86df-f944-44e0-a3e0-2614841f2814" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b6315a05-2ede-4930-93a6-b567593ff254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_ae4e7fe1-11be-4ee5-89e0-bfb6ccc1a2c5" xlink:href="ino-20201231.xsd#ino_SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b6315a05-2ede-4930-93a6-b567593ff254" xlink:to="loc_ino_SalesAgreementMember_ae4e7fe1-11be-4ee5-89e0-bfb6ccc1a2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PriorSalesAgreementMember_9499b054-fc15-40f5-b2ee-476f122b4b86" xlink:href="ino-20201231.xsd#ino_PriorSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b6315a05-2ede-4930-93a6-b567593ff254" xlink:to="loc_ino_PriorSalesAgreementMember_9499b054-fc15-40f5-b2ee-476f122b4b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NewSalesAgreementMember_a38a07bb-1e2b-4396-8a68-ee8fdaf1fa1c" xlink:href="ino-20201231.xsd#ino_NewSalesAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b6315a05-2ede-4930-93a6-b567593ff254" xlink:to="loc_ino_NewSalesAgreementMember_a38a07bb-1e2b-4396-8a68-ee8fdaf1fa1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ca3f757e-c1f0-47c9-8e49-e02a647d8956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a5b0391d-1661-4f59-a6c1-524ba64a9c24" xlink:to="loc_us-gaap_PlanNameAxis_ca3f757e-c1f0-47c9-8e49-e02a647d8956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ac2dd9d3-4483-4e9e-b3a6-6bf84fab265f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ca3f757e-c1f0-47c9-8e49-e02a647d8956" xlink:to="loc_us-gaap_PlanNameDomain_ac2dd9d3-4483-4e9e-b3a6-6bf84fab265f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_4a3fb8f7-43d3-45ed-a9b1-e4522ca42a28" xlink:href="ino-20201231.xsd#ino_A2016IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ac2dd9d3-4483-4e9e-b3a6-6bf84fab265f" xlink:to="loc_ino_A2016IncentivePlanMember_4a3fb8f7-43d3-45ed-a9b1-e4522ca42a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_39aca558-ac5f-406d-9389-800200ed2106" xlink:href="ino-20201231.xsd#ino_A2007IncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ac2dd9d3-4483-4e9e-b3a6-6bf84fab265f" xlink:to="loc_ino_A2007IncentivePlanMember_39aca558-ac5f-406d-9389-800200ed2106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_743f8dd5-8827-4703-a11f-032db18ac88a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a5b0391d-1661-4f59-a6c1-524ba64a9c24" xlink:to="loc_us-gaap_AwardTypeAxis_743f8dd5-8827-4703-a11f-032db18ac88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b2c91a26-bfd3-4eae-9300-2e8c70ef4578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_743f8dd5-8827-4703-a11f-032db18ac88a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b2c91a26-bfd3-4eae-9300-2e8c70ef4578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_45609ae4-ade7-40b4-9ca4-f996a8e15218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b2c91a26-bfd3-4eae-9300-2e8c70ef4578" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_45609ae4-ade7-40b4-9ca4-f996a8e15218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_da5845eb-e747-4f31-aa2d-ec0e9637a9c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a5b0391d-1661-4f59-a6c1-524ba64a9c24" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_da5845eb-e747-4f31-aa2d-ec0e9637a9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_155ba4f6-a191-422e-8da9-241acb93404a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_da5845eb-e747-4f31-aa2d-ec0e9637a9c6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_155ba4f6-a191-422e-8da9-241acb93404a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeeMember_c2df13b6-1e55-4236-98f1-f905bf4c69fa" xlink:href="ino-20201231.xsd#ino_EmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_155ba4f6-a191-422e-8da9-241acb93404a" xlink:to="loc_ino_EmployeeMember_c2df13b6-1e55-4236-98f1-f905bf4c69fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a31fed57-eb66-494c-9c96-26c7b3aec3c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_155ba4f6-a191-422e-8da9-241acb93404a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a31fed57-eb66-494c-9c96-26c7b3aec3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7fc49a77-c677-4b25-83cb-3ad3a0ee06ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_155ba4f6-a191-422e-8da9-241acb93404a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7fc49a77-c677-4b25-83cb-3ad3a0ee06ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_ff146a1b-80e0-4204-a522-e44d81ae1749" xlink:href="ino-20201231.xsd#ino_NonEmployeeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_155ba4f6-a191-422e-8da9-241acb93404a" xlink:to="loc_ino_NonEmployeeMember_ff146a1b-80e0-4204-a522-e44d81ae1749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7bd2c1e7-7423-4c69-a103-87ab8d67c3ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a5b0391d-1661-4f59-a6c1-524ba64a9c24" xlink:to="loc_us-gaap_VestingAxis_7bd2c1e7-7423-4c69-a103-87ab8d67c3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_89042022-d897-4b39-8654-18c6112d5e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_7bd2c1e7-7423-4c69-a103-87ab8d67c3ea" xlink:to="loc_us-gaap_VestingDomain_89042022-d897-4b39-8654-18c6112d5e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e8527f8e-81d0-47a5-825d-7ca6d50c847e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_89042022-d897-4b39-8654-18c6112d5e18" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e8527f8e-81d0-47a5-825d-7ca6d50c847e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_3b4e4c02-82e5-4514-8356-8937be313482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_89042022-d897-4b39-8654-18c6112d5e18" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_3b4e4c02-82e5-4514-8356-8937be313482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a5b0391d-1661-4f59-a6c1-524ba64a9c24" xlink:to="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_20ab4f29-201a-468f-b806-c119ddd6ac27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_20ab4f29-201a-468f-b806-c119ddd6ac27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_4086ded1-5de1-439a-b853-164c87fc90ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_4086ded1-5de1-439a-b853-164c87fc90ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_fa051375-df6b-4c0a-88bc-4d83ca08fe23" xlink:href="ino-20201231.xsd#ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_fa051375-df6b-4c0a-88bc-4d83ca08fe23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_078f7b86-07f0-40d2-bfdd-e1f481327a88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_078f7b86-07f0-40d2-bfdd-e1f481327a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_a2466c18-82cc-4fcd-8ca6-74b15c560367" xlink:href="ino-20201231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_a2466c18-82cc-4fcd-8ca6-74b15c560367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_8c15db9a-dd46-4465-a21e-9591dc84ba11" xlink:href="ino-20201231.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_8c15db9a-dd46-4465-a21e-9591dc84ba11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementAgentFee_a05bf359-2ec5-4dec-ab09-8afc4076a086" xlink:href="ino-20201231.xsd#ino_StockSalesAgreementAgentFee"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_StockSalesAgreementAgentFee_a05bf359-2ec5-4dec-ab09-8afc4076a086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_b2204978-a7d2-4c06-bcaa-4e3c7c0b778e" xlink:href="ino-20201231.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_b2204978-a7d2-4c06-bcaa-4e3c7c0b778e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_21f36472-0ba0-4304-9bdb-f9be8e852d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_21f36472-0ba0-4304-9bdb-f9be8e852d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_743492d0-31cf-4aa2-8b18-d7d9632d8089" xlink:href="ino-20201231.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_743492d0-31cf-4aa2-8b18-d7d9632d8089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d8e61556-29e9-461f-b3a6-f8aaac8f8095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d8e61556-29e9-461f-b3a6-f8aaac8f8095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_d0815c7b-e92f-47db-84d9-9e3d653a6bc7" xlink:href="ino-20201231.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_d0815c7b-e92f-47db-84d9-9e3d653a6bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_742f9d58-5a2e-42f1-b5d7-608a0934f72c" xlink:href="ino-20201231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_742f9d58-5a2e-42f1-b5d7-608a0934f72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_15760307-3727-4af6-9385-ed579b16cce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_15760307-3727-4af6-9385-ed579b16cce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_a7451dcf-de2d-4fb4-a23a-25a6278a2715" xlink:href="ino-20201231.xsd#ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_a7451dcf-de2d-4fb4-a23a-25a6278a2715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_da0f7cac-ec27-413c-b17f-b74e296ef10b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_da0f7cac-ec27-413c-b17f-b74e296ef10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fee91e9c-382f-4e5f-812d-aaf79bbf1f95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fee91e9c-382f-4e5f-812d-aaf79bbf1f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_a473defe-5874-4858-a744-6fa574c46821" xlink:href="ino-20201231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_a473defe-5874-4858-a744-6fa574c46821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_660524d9-6d74-4e6e-9d34-170bf84f4490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensation_660524d9-6d74-4e6e-9d34-170bf84f4490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_939f47f3-842b-4957-8cd7-5d8f580de868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_939f47f3-842b-4957-8cd7-5d8f580de868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0d6f3d41-f59e-4e5a-9407-c7e3129f7d69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0d6f3d41-f59e-4e5a-9407-c7e3129f7d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ea3a2c9b-2e2b-410f-9ab6-79dde5078cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ea3a2c9b-2e2b-410f-9ab6-79dde5078cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3ab8b0ec-bd0a-41b5-bb72-d09d01948396" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3ab8b0ec-bd0a-41b5-bb72-d09d01948396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_d83c3142-fc5a-43a4-ac11-25927db45270" xlink:href="ino-20201231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_d83c3142-fc5a-43a4-ac11-25927db45270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a6bbc332-3237-42c8-bcc8-0a75d80f8a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a6bbc332-3237-42c8-bcc8-0a75d80f8a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_8a80062d-3dc5-4695-adb1-b1f3d04c4db9" xlink:href="ino-20201231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_8a80062d-3dc5-4695-adb1-b1f3d04c4db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_4cc13eab-5ae2-4b47-8193-2b922f6300b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_4cc13eab-5ae2-4b47-8193-2b922f6300b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c8991361-ae74-4f8c-80dd-a523f70441c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c8991361-ae74-4f8c-80dd-a523f70441c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_d092adcb-8a06-475e-86ff-4086be826dd7" xlink:href="ino-20201231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_d092adcb-8a06-475e-86ff-4086be826dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_a8f7f024-2f20-4db6-9a4c-332804756764" xlink:href="ino-20201231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_a8f7f024-2f20-4db6-9a4c-332804756764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_29dd0712-db62-4378-8787-58599aab640d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_29dd0712-db62-4378-8787-58599aab640d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_125ecbc0-462c-4733-9c06-c7f9c8f5c18c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_125ecbc0-462c-4733-9c06-c7f9c8f5c18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cfdc25b1-0781-48d0-892e-73fe16792b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cfdc25b1-0781-48d0-892e-73fe16792b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c9d7789a-561f-4eae-ba26-f2eabe0e06b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c9d7789a-561f-4eae-ba26-f2eabe0e06b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d938a9e5-9ac4-4872-8d90-a21f655ece75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d938a9e5-9ac4-4872-8d90-a21f655ece75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_44b0f9eb-9b08-4e2c-825b-bcc83330c36d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_44b0f9eb-9b08-4e2c-825b-bcc83330c36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0a2c8efe-f6cb-4797-ad3e-aa45cab0ee34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0a2c8efe-f6cb-4797-ad3e-aa45cab0ee34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dc96bf86-ec45-4e0e-a4cb-e8b504ae6b4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dc96bf86-ec45-4e0e-a4cb-e8b504ae6b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_99323855-3423-4de3-b598-5263e18d7c50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_99323855-3423-4de3-b598-5263e18d7c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_1ba435d6-8fab-4d31-a5fa-6b4492e47540" xlink:href="ino-20201231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a0b45d7c-3553-43e3-81a9-fac7289a742c" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_1ba435d6-8fab-4d31-a5fa-6b4492e47540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquitySummaryofStockOptionsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_a2ee1f22-5572-4c03-bcec-fcbe8bdb6c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_258ddd8e-114f-4702-b570-58696154c23f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a2ee1f22-5572-4c03-bcec-fcbe8bdb6c1a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_258ddd8e-114f-4702-b570-58696154c23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0957990b-f628-4478-a627-fb814d611626" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_258ddd8e-114f-4702-b570-58696154c23f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0957990b-f628-4478-a627-fb814d611626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b2bebffb-c16c-42c4-bd09-bad0b0e007e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0957990b-f628-4478-a627-fb814d611626" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b2bebffb-c16c-42c4-bd09-bad0b0e007e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesOneMember_e27a06a0-fa95-4fa0-b6b9-1283b28dc621" xlink:href="ino-20201231.xsd#ino_RangeOfExercisePricesOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b2bebffb-c16c-42c4-bd09-bad0b0e007e6" xlink:to="loc_ino_RangeOfExercisePricesOneMember_e27a06a0-fa95-4fa0-b6b9-1283b28dc621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesTwoMember_4761a222-97a1-4b6f-9089-a6053c2da8cc" xlink:href="ino-20201231.xsd#ino_RangeOfExercisePricesTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b2bebffb-c16c-42c4-bd09-bad0b0e007e6" xlink:to="loc_ino_RangeOfExercisePricesTwoMember_4761a222-97a1-4b6f-9089-a6053c2da8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesThreeMember_048b1c7c-ba26-4986-b2a7-808ac5f36c5c" xlink:href="ino-20201231.xsd#ino_RangeOfExercisePricesThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b2bebffb-c16c-42c4-bd09-bad0b0e007e6" xlink:to="loc_ino_RangeOfExercisePricesThreeMember_048b1c7c-ba26-4986-b2a7-808ac5f36c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFourMember_667ecb1d-9ab4-47de-91db-813aa4952ccd" xlink:href="ino-20201231.xsd#ino_RangeOfExercisePricesFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b2bebffb-c16c-42c4-bd09-bad0b0e007e6" xlink:to="loc_ino_RangeOfExercisePricesFourMember_667ecb1d-9ab4-47de-91db-813aa4952ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFiveMember_8ff08243-af5e-48f3-bdff-fbc5d4e05d75" xlink:href="ino-20201231.xsd#ino_RangeOfExercisePricesFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b2bebffb-c16c-42c4-bd09-bad0b0e007e6" xlink:to="loc_ino_RangeOfExercisePricesFiveMember_8ff08243-af5e-48f3-bdff-fbc5d4e05d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesSixMember_8be93dbd-a05c-42de-96d5-93dd2b02a261" xlink:href="ino-20201231.xsd#ino_RangeOfExercisePricesSixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b2bebffb-c16c-42c4-bd09-bad0b0e007e6" xlink:to="loc_ino_RangeOfExercisePricesSixMember_8be93dbd-a05c-42de-96d5-93dd2b02a261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_fe02fba8-8c72-4bbf-968f-8d8fb8af1e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_258ddd8e-114f-4702-b570-58696154c23f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_fe02fba8-8c72-4bbf-968f-8d8fb8af1e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_bb6be56d-d7ef-4462-a907-19829104e83f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_fe02fba8-8c72-4bbf-968f-8d8fb8af1e71" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_bb6be56d-d7ef-4462-a907-19829104e83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_bb37474c-ba22-43b3-addc-c8e0e53a0f85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_fe02fba8-8c72-4bbf-968f-8d8fb8af1e71" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_bb37474c-ba22-43b3-addc-c8e0e53a0f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_a5bc1bfd-e395-4bd9-853c-a5a7383c0346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_fe02fba8-8c72-4bbf-968f-8d8fb8af1e71" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_a5bc1bfd-e395-4bd9-853c-a5a7383c0346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_4c0748fb-136c-4578-b97e-eb3ec3c13678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_fe02fba8-8c72-4bbf-968f-8d8fb8af1e71" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_4c0748fb-136c-4578-b97e-eb3ec3c13678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c83a2171-44b9-49a1-a167-259bbc100948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_fe02fba8-8c72-4bbf-968f-8d8fb8af1e71" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c83a2171-44b9-49a1-a167-259bbc100948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_dc4ca2b8-3811-4d29-8391-780272b491d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_fe02fba8-8c72-4bbf-968f-8d8fb8af1e71" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_dc4ca2b8-3811-4d29-8391-780272b491d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_9ce9d665-813d-47d6-a0c6-54c3312a755c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_fe02fba8-8c72-4bbf-968f-8d8fb8af1e71" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_9ce9d665-813d-47d6-a0c6-54c3312a755c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_de6317bc-9e25-4550-a75a-8445b1737a42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_83655964-f582-4195-9e50-448eb91f0954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_de6317bc-9e25-4550-a75a-8445b1737a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_83655964-f582-4195-9e50-448eb91f0954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_399b555f-6ed6-4159-bb7d-2962fe3a06b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_83655964-f582-4195-9e50-448eb91f0954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_399b555f-6ed6-4159-bb7d-2962fe3a06b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bb294ce4-2667-45f8-bf5e-2553e5f72001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_83655964-f582-4195-9e50-448eb91f0954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bb294ce4-2667-45f8-bf5e-2553e5f72001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f13b6ad9-17e1-441b-83e1-c62ad01c9d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_83655964-f582-4195-9e50-448eb91f0954" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f13b6ad9-17e1-441b-83e1-c62ad01c9d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_4fefd2ee-3fbb-43a6-8b62-91e6ee3e65f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_83655964-f582-4195-9e50-448eb91f0954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_4fefd2ee-3fbb-43a6-8b62-91e6ee3e65f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1c44b7a6-49ac-48fa-b846-9fb92dccbab3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_83655964-f582-4195-9e50-448eb91f0954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1c44b7a6-49ac-48fa-b846-9fb92dccbab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_485d6fbd-b546-42b3-897c-6e6b04843828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_de6317bc-9e25-4550-a75a-8445b1737a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_485d6fbd-b546-42b3-897c-6e6b04843828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8e1b5e70-5e44-43f2-9b24-c192996c4c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_485d6fbd-b546-42b3-897c-6e6b04843828" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8e1b5e70-5e44-43f2-9b24-c192996c4c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2b30a8f8-a760-47e6-9d57-ecebc20ac1fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_485d6fbd-b546-42b3-897c-6e6b04843828" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2b30a8f8-a760-47e6-9d57-ecebc20ac1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_980c35a1-a735-414b-97e5-99cce0d199d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_485d6fbd-b546-42b3-897c-6e6b04843828" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_980c35a1-a735-414b-97e5-99cce0d199d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_438280af-b212-418b-a6ef-2707696c5971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_485d6fbd-b546-42b3-897c-6e6b04843828" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_438280af-b212-418b-a6ef-2707696c5971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_43ad0c22-649d-4df8-927b-29d7e829ef71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_485d6fbd-b546-42b3-897c-6e6b04843828" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_43ad0c22-649d-4df8-927b-29d7e829ef71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_e7514d51-2de4-4f42-83c4-df6f5da08369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11162237-497d-42d6-8f0f-27107b57f41e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e7514d51-2de4-4f42-83c4-df6f5da08369" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11162237-497d-42d6-8f0f-27107b57f41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_674f0f35-ceee-435b-8d4a-d04206c4b7d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11162237-497d-42d6-8f0f-27107b57f41e" xlink:to="loc_us-gaap_AwardTypeAxis_674f0f35-ceee-435b-8d4a-d04206c4b7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba16ceac-4855-4031-8517-ad363c95d448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_674f0f35-ceee-435b-8d4a-d04206c4b7d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba16ceac-4855-4031-8517-ad363c95d448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5a4e7f02-94a1-4b0e-9aef-a85391027b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba16ceac-4855-4031-8517-ad363c95d448" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5a4e7f02-94a1-4b0e-9aef-a85391027b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3936c9e2-04f4-4388-96a0-a12d818fb2b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11162237-497d-42d6-8f0f-27107b57f41e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3936c9e2-04f4-4388-96a0-a12d818fb2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c76f4bcd-7e91-43fe-ba28-46ac8e5d2a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3936c9e2-04f4-4388-96a0-a12d818fb2b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c76f4bcd-7e91-43fe-ba28-46ac8e5d2a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e7813529-21a3-44b2-85c3-46365180b547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c76f4bcd-7e91-43fe-ba28-46ac8e5d2a9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e7813529-21a3-44b2-85c3-46365180b547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_54238789-32e5-4ce9-8ee4-2dd8d19cbec8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c76f4bcd-7e91-43fe-ba28-46ac8e5d2a9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_54238789-32e5-4ce9-8ee4-2dd8d19cbec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_018e92d1-00ab-40b5-8c96-fad7f53f9cbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c76f4bcd-7e91-43fe-ba28-46ac8e5d2a9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_018e92d1-00ab-40b5-8c96-fad7f53f9cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_41e5feb0-40d7-4362-8a05-44da4179e70c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c76f4bcd-7e91-43fe-ba28-46ac8e5d2a9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_41e5feb0-40d7-4362-8a05-44da4179e70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dc46fa8a-7459-458a-ad21-a34f31628880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c76f4bcd-7e91-43fe-ba28-46ac8e5d2a9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dc46fa8a-7459-458a-ad21-a34f31628880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/Leases" xlink:type="simple" xlink:href="ino-20201231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cf930a9c-854c-4fa4-9b5a-82f2e18d2624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_a08230b9-fa68-48e6-ad60-77b40d1e44db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cf930a9c-854c-4fa4-9b5a-82f2e18d2624" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_a08230b9-fa68-48e6-ad60-77b40d1e44db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesTables" xlink:type="simple" xlink:href="ino-20201231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4479ba4d-c3a4-42e8-a3da-112a9b9117d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b3adf6b1-efea-4193-9a49-0942659ce2c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4479ba4d-c3a4-42e8-a3da-112a9b9117d5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b3adf6b1-efea-4193-9a49-0942659ce2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5d9aef8b-fcde-4318-905c-af50389d4e53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b762b746-b913-4edc-830a-bf165a15bff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5d9aef8b-fcde-4318-905c-af50389d4e53" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b762b746-b913-4edc-830a-bf165a15bff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_52129b12-1f32-41fa-a526-6a1e66085b5f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b762b746-b913-4edc-830a-bf165a15bff4" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_52129b12-1f32-41fa-a526-6a1e66085b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_83083aa2-4f56-41c8-9d61-97792350c2b1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_52129b12-1f32-41fa-a526-6a1e66085b5f" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_83083aa2-4f56-41c8-9d61-97792350c2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember_abb623e4-8c3d-49b4-b8ab-56375f0651cd" xlink:href="ino-20201231.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_83083aa2-4f56-41c8-9d61-97792350c2b1" xlink:to="loc_ino_SanDiegoCaliforniaMember_abb623e4-8c3d-49b4-b8ab-56375f0651cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_bf64b980-d2a3-496b-81ab-2593cf89eaf2" xlink:href="ino-20201231.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_83083aa2-4f56-41c8-9d61-97792350c2b1" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_bf64b980-d2a3-496b-81ab-2593cf89eaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_99bf8a46-70b9-4f52-a9a2-1a335e9b4452" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b762b746-b913-4edc-830a-bf165a15bff4" xlink:to="loc_srt_RangeAxis_99bf8a46-70b9-4f52-a9a2-1a335e9b4452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a3cca864-0748-4952-aa21-bfc889c8f0db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_99bf8a46-70b9-4f52-a9a2-1a335e9b4452" xlink:to="loc_srt_RangeMember_a3cca864-0748-4952-aa21-bfc889c8f0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1cb49e4b-13ef-4f7b-aa55-c6ddbaa42808" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a3cca864-0748-4952-aa21-bfc889c8f0db" xlink:to="loc_srt_MinimumMember_1cb49e4b-13ef-4f7b-aa55-c6ddbaa42808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8b339419-c3fe-411a-91a3-90a2a672f612" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a3cca864-0748-4952-aa21-bfc889c8f0db" xlink:to="loc_srt_MaximumMember_8b339419-c3fe-411a-91a3-90a2a672f612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_ea779802-b67b-4f9c-a554-4470b7f9c6f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b762b746-b913-4edc-830a-bf165a15bff4" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_ea779802-b67b-4f9c-a554-4470b7f9c6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_5c4fcd15-7175-4789-af2c-b021b39b03cf" xlink:href="ino-20201231.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ea779802-b67b-4f9c-a554-4470b7f9c6f0" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_5c4fcd15-7175-4789-af2c-b021b39b03cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_fb31401c-4848-43d5-b792-fc1ba9f7f12e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ea779802-b67b-4f9c-a554-4470b7f9c6f0" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_fb31401c-4848-43d5-b792-fc1ba9f7f12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_fd404f1d-9364-456b-964c-c508124e55d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ea779802-b67b-4f9c-a554-4470b7f9c6f0" xlink:to="loc_us-gaap_LeaseCost_fd404f1d-9364-456b-964c-c508124e55d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto_b5e02dc9-95c5-4b6b-b2ec-17f9f5fdb1dc" xlink:href="ino-20201231.xsd#ino_LesseeNumberOfLeaseAgreementsEnteredInto"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_ea779802-b67b-4f9c-a554-4470b7f9c6f0" xlink:to="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto_b5e02dc9-95c5-4b6b-b2ec-17f9f5fdb1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ec4f2f5f-37d8-4635-b17e-c508774a5432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_db6a346f-bbc5-4b63-b09f-811d0e5c99bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ec4f2f5f-37d8-4635-b17e-c508774a5432" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_db6a346f-bbc5-4b63-b09f-811d0e5c99bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cffb8702-11af-4336-9d2d-3b0eecbd98d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ec4f2f5f-37d8-4635-b17e-c508774a5432" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cffb8702-11af-4336-9d2d-3b0eecbd98d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_38f56ca0-2130-4192-9c9b-b779a8d45929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ec4f2f5f-37d8-4635-b17e-c508774a5432" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_38f56ca0-2130-4192-9c9b-b779a8d45929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_15282acc-4975-498a-85bd-917390403b2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ec4f2f5f-37d8-4635-b17e-c508774a5432" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_15282acc-4975-498a-85bd-917390403b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_893642ce-449a-4df1-9b1d-193b5164c129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ec4f2f5f-37d8-4635-b17e-c508774a5432" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_893642ce-449a-4df1-9b1d-193b5164c129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b79ad0b2-5eba-4ad3-8d33-66c4967c6148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ec4f2f5f-37d8-4635-b17e-c508774a5432" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b79ad0b2-5eba-4ad3-8d33-66c4967c6148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bbb5887e-e78b-40d9-97a0-4a8f7ddbce07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ec4f2f5f-37d8-4635-b17e-c508774a5432" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bbb5887e-e78b-40d9-97a0-4a8f7ddbce07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_eaa4fe2e-2660-463c-9967-b72e4c3762d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ec4f2f5f-37d8-4635-b17e-c508774a5432" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_eaa4fe2e-2660-463c-9967-b72e4c3762d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e548a700-705e-4d5b-a8c6-97b691fb2160" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ec4f2f5f-37d8-4635-b17e-c508774a5432" xlink:to="loc_us-gaap_OperatingLeaseLiability_e548a700-705e-4d5b-a8c6-97b691fb2160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ef46839e-9eda-42c3-90c5-97c3b0601ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ec4f2f5f-37d8-4635-b17e-c508774a5432" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ef46839e-9eda-42c3-90c5-97c3b0601ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_770730ba-6a5b-4083-bada-ec4c5d5773ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ec4f2f5f-37d8-4635-b17e-c508774a5432" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_770730ba-6a5b-4083-bada-ec4c5d5773ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fc92e559-1206-4507-9d38-1fecb2197943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ec4f2f5f-37d8-4635-b17e-c508774a5432" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fc92e559-1206-4507-9d38-1fecb2197943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a93b522e-6e01-4bc4-b213-956ef8021e8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ec4f2f5f-37d8-4635-b17e-c508774a5432" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a93b522e-6e01-4bc4-b213-956ef8021e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" xlink:type="simple" xlink:href="ino-20201231.xsd#LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/InvestmentinAffiliatedEntity" xlink:type="simple" xlink:href="ino-20201231.xsd#InvestmentinAffiliatedEntity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/InvestmentinAffiliatedEntity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_4e1611de-baaf-4ef9-8bad-e2640b346738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_1ef519e8-1703-4900-8f0d-208dc68c9e13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_4e1611de-baaf-4ef9-8bad-e2640b346738" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_1ef519e8-1703-4900-8f0d-208dc68c9e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#InvestmentinAffiliatedEntityDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_be619452-ebe6-465b-a76e-0baeb9a8d13f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_39551b57-5079-4059-af22-e40a46f6b0e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_be619452-ebe6-465b-a76e-0baeb9a8d13f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_39551b57-5079-4059-af22-e40a46f6b0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8d5fd5be-52dd-4c0e-918b-4856e5f7350a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_39551b57-5079-4059-af22-e40a46f6b0e4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8d5fd5be-52dd-4c0e-918b-4856e5f7350a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_abdf5df0-f4ce-464b-badc-debe7aea38be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8d5fd5be-52dd-4c0e-918b-4856e5f7350a" xlink:to="loc_us-gaap_RelatedPartyDomain_abdf5df0-f4ce-464b-badc-debe7aea38be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_f0b47dfe-3edb-4bde-ada6-3e9870aaa5c8" xlink:href="ino-20201231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_abdf5df0-f4ce-464b-badc-debe7aea38be" xlink:to="loc_ino_PlumblineLifeSciencesMember_f0b47dfe-3edb-4bde-ada6-3e9870aaa5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneOneLifeSciencesMember_4aeb61cf-8b1e-4965-bf8c-683972e32c68" xlink:href="ino-20201231.xsd#ino_GeneOneLifeSciencesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_abdf5df0-f4ce-464b-badc-debe7aea38be" xlink:to="loc_ino_GeneOneLifeSciencesMember_4aeb61cf-8b1e-4965-bf8c-683972e32c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_5e866ba9-5b34-4563-baf5-661931fed55c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_39551b57-5079-4059-af22-e40a46f6b0e4" xlink:to="loc_us-gaap_InvestmentTypeAxis_5e866ba9-5b34-4563-baf5-661931fed55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4d37016c-f82f-41f1-b1ae-794141ff6fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_5e866ba9-5b34-4563-baf5-661931fed55c" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4d37016c-f82f-41f1-b1ae-794141ff6fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0f51380d-1ab3-4f84-869d-6842f6248e13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4d37016c-f82f-41f1-b1ae-794141ff6fca" xlink:to="loc_us-gaap_CommonStockMember_0f51380d-1ab3-4f84-869d-6842f6248e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_8b6e2658-517b-4904-a28c-878200bb7787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_39551b57-5079-4059-af22-e40a46f6b0e4" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_8b6e2658-517b-4904-a28c-878200bb7787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_580d3729-37cb-4c37-8972-44f54b88821b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8b6e2658-517b-4904-a28c-878200bb7787" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_580d3729-37cb-4c37-8972-44f54b88821b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_581293f9-b580-4e31-953c-457d703438c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8b6e2658-517b-4904-a28c-878200bb7787" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_581293f9-b580-4e31-953c-457d703438c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c1aac1e7-9ca4-4fa3-82a5-5fd33b471844" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8b6e2658-517b-4904-a28c-878200bb7787" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c1aac1e7-9ca4-4fa3-82a5-5fd33b471844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f5113d66-f9e7-4148-abfd-3bd632a5e9bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8b6e2658-517b-4904-a28c-878200bb7787" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f5113d66-f9e7-4148-abfd-3bd632a5e9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_93acb7b8-a05f-4545-aa10-1aad1dd503e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4210b2c4-2bfd-42db-9814-c4d08175e90e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93acb7b8-a05f-4545-aa10-1aad1dd503e4" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4210b2c4-2bfd-42db-9814-c4d08175e90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2891b810-4c8f-4c1a-8bc9-5e6a8f0fde3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_c24f82a7-52be-4a76-9b97-89a3e039b338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2891b810-4c8f-4c1a-8bc9-5e6a8f0fde3d" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_c24f82a7-52be-4a76-9b97-89a3e039b338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_c8e73b29-12d7-42a6-909b-ac9474aebcc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2891b810-4c8f-4c1a-8bc9-5e6a8f0fde3d" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_c8e73b29-12d7-42a6-909b-ac9474aebcc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0d9d72f2-26fc-4272-b1ec-4fc15c424210" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2891b810-4c8f-4c1a-8bc9-5e6a8f0fde3d" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0d9d72f2-26fc-4272-b1ec-4fc15c424210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2e3e543f-1cd7-482f-acd5-e048995ed52d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2891b810-4c8f-4c1a-8bc9-5e6a8f0fde3d" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2e3e543f-1cd7-482f-acd5-e048995ed52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_cce63877-7e3f-4358-8c04-17f63f26efe1" xlink:href="ino-20201231.xsd#ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2891b810-4c8f-4c1a-8bc9-5e6a8f0fde3d" xlink:to="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_cce63877-7e3f-4358-8c04-17f63f26efe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_6621753f-7701-4674-9c3a-4a8ebe87fe2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2891b810-4c8f-4c1a-8bc9-5e6a8f0fde3d" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_6621753f-7701-4674-9c3a-4a8ebe87fe2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesComponentsofPretaxLossfromOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_149dbe9c-24a6-4c6d-821f-5322e7af4004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_40737725-fb77-48bc-a957-b6f1c6e9d1b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_149dbe9c-24a6-4c6d-821f-5322e7af4004" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_40737725-fb77-48bc-a957-b6f1c6e9d1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8eb3461e-2940-4a87-b718-e06128253b43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_149dbe9c-24a6-4c6d-821f-5322e7af4004" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8eb3461e-2940-4a87-b718-e06128253b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15ef4684-67e1-4615-a740-19973c4cc7d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_149dbe9c-24a6-4c6d-821f-5322e7af4004" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15ef4684-67e1-4615-a740-19973c4cc7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fc54c7ec-d898-452d-bb54-e3370ddef2a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d6e7593e-66fa-4701-aa4e-7bfac1f2e7e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fc54c7ec-d898-452d-bb54-e3370ddef2a4" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d6e7593e-66fa-4701-aa4e-7bfac1f2e7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_4d474597-a78b-43bb-91fe-3657708b757d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d6e7593e-66fa-4701-aa4e-7bfac1f2e7e5" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_4d474597-a78b-43bb-91fe-3657708b757d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_bf5f5c68-b5f3-4406-b206-9b3208393176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d6e7593e-66fa-4701-aa4e-7bfac1f2e7e5" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_bf5f5c68-b5f3-4406-b206-9b3208393176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_876d28de-9d20-4014-9d00-5a030c210c1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d6e7593e-66fa-4701-aa4e-7bfac1f2e7e5" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_876d28de-9d20-4014-9d00-5a030c210c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8c851680-c7c2-4b73-8c7d-4fc976a95f2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d6e7593e-66fa-4701-aa4e-7bfac1f2e7e5" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8c851680-c7c2-4b73-8c7d-4fc976a95f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_4c8e170c-f860-44d6-abbc-5694026b20b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fc54c7ec-d898-452d-bb54-e3370ddef2a4" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_4c8e170c-f860-44d6-abbc-5694026b20b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_de402ecc-fe8b-4937-a623-62d5ab2f0a57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_4c8e170c-f860-44d6-abbc-5694026b20b2" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_de402ecc-fe8b-4937-a623-62d5ab2f0a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9fde81c1-d793-4234-9d8f-b037d02b5e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_4c8e170c-f860-44d6-abbc-5694026b20b2" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9fde81c1-d793-4234-9d8f-b037d02b5e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_74c56233-0b1d-4612-817c-71375fb4b7c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_4c8e170c-f860-44d6-abbc-5694026b20b2" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_74c56233-0b1d-4612-817c-71375fb4b7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cba36e30-e5bd-497d-883a-2e7616b520c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_4c8e170c-f860-44d6-abbc-5694026b20b2" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cba36e30-e5bd-497d-883a-2e7616b520c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_589f6cba-60a7-4b25-af16-06d0b520b7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fc54c7ec-d898-452d-bb54-e3370ddef2a4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_589f6cba-60a7-4b25-af16-06d0b520b7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesReconciliationofIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9f49d58f-4d63-47ce-a40e-4f3075762dcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4097c333-e710-4eeb-9527-923f233a0cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9f49d58f-4d63-47ce-a40e-4f3075762dcb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4097c333-e710-4eeb-9527-923f233a0cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2542d353-befe-497b-8040-39ed0ad7d5ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4097c333-e710-4eeb-9527-923f233a0cd2" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2542d353-befe-497b-8040-39ed0ad7d5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_fdab10c1-5161-4790-bcfd-683c7922d34c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4097c333-e710-4eeb-9527-923f233a0cd2" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_fdab10c1-5161-4790-bcfd-683c7922d34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount_d49721f4-2a51-46d1-ab88-9979516090f9" xlink:href="ino-20201231.xsd#ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4097c333-e710-4eeb-9527-923f233a0cd2" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount_d49721f4-2a51-46d1-ab88-9979516090f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_13912b6b-fa08-464e-96da-73e609788d28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4097c333-e710-4eeb-9527-923f233a0cd2" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_13912b6b-fa08-464e-96da-73e609788d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_21b5717b-2046-4b78-9d1c-2a6f2d1dc061" xlink:href="ino-20201231.xsd#ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4097c333-e710-4eeb-9527-923f233a0cd2" xlink:to="loc_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_21b5717b-2046-4b78-9d1c-2a6f2d1dc061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeTaxReconciliationStatuteLimitations_f58fd7b8-3e0b-42c8-832f-c11dcdc83017" xlink:href="ino-20201231.xsd#ino_IncomeTaxReconciliationStatuteLimitations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4097c333-e710-4eeb-9527-923f233a0cd2" xlink:to="loc_ino_IncomeTaxReconciliationStatuteLimitations_f58fd7b8-3e0b-42c8-832f-c11dcdc83017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeTaxReconciliationFairValueWarrant_012098a9-b0bd-426d-b88b-865390441698" xlink:href="ino-20201231.xsd#ino_IncomeTaxReconciliationFairValueWarrant"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4097c333-e710-4eeb-9527-923f233a0cd2" xlink:to="loc_ino_IncomeTaxReconciliationFairValueWarrant_012098a9-b0bd-426d-b88b-865390441698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_5493cc8c-b5ad-4db7-9ae1-4c01ff98d6c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4097c333-e710-4eeb-9527-923f233a0cd2" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_5493cc8c-b5ad-4db7-9ae1-4c01ff98d6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_5f5293b9-9e70-4b6a-b420-67b3d6f0bfeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4097c333-e710-4eeb-9527-923f233a0cd2" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_5f5293b9-9e70-4b6a-b420-67b3d6f0bfeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_f65d1248-5339-45bc-8cbf-09296a76ec64" xlink:href="ino-20201231.xsd#ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4097c333-e710-4eeb-9527-923f233a0cd2" xlink:to="loc_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_f65d1248-5339-45bc-8cbf-09296a76ec64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_632d54f1-709d-4078-8e95-bd07ba15721d" xlink:href="ino-20201231.xsd#ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4097c333-e710-4eeb-9527-923f233a0cd2" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_632d54f1-709d-4078-8e95-bd07ba15721d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_ebead063-2a29-4d0e-8ca9-af426b1ba824" xlink:href="ino-20201231.xsd#ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4097c333-e710-4eeb-9527-923f233a0cd2" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_ebead063-2a29-4d0e-8ca9-af426b1ba824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_b10a4a97-4626-429d-b49e-78bdb70622ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4097c333-e710-4eeb-9527-923f233a0cd2" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_b10a4a97-4626-429d-b49e-78bdb70622ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8e5ef305-8ff9-421c-9d8f-3b9bc6726d75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4097c333-e710-4eeb-9527-923f233a0cd2" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8e5ef305-8ff9-421c-9d8f-3b9bc6726d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_2b4c9f1b-6065-45fa-8273-fb39312e12d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4097c333-e710-4eeb-9527-923f233a0cd2" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_2b4c9f1b-6065-45fa-8273-fb39312e12d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_ae5d41a9-30e2-4b8f-af25-ebdc5015adef" xlink:href="ino-20201231.xsd#ino_ComprehensiveIncomeLossTaxExpenseBenefit"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4097c333-e710-4eeb-9527-923f233a0cd2" xlink:to="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_ae5d41a9-30e2-4b8f-af25-ebdc5015adef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_141657ed-1826-4caf-89e6-44c3505a0b56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_a69ca7d8-34e0-4ad8-b792-8cad307162c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_141657ed-1826-4caf-89e6-44c3505a0b56" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_a69ca7d8-34e0-4ad8-b792-8cad307162c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_a735108e-3088-4ed2-b8ed-9cbc9a61592d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a69ca7d8-34e0-4ad8-b792-8cad307162c8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_a735108e-3088-4ed2-b8ed-9cbc9a61592d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_38c6db7c-55bf-404f-9f58-a0fbb99455f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a735108e-3088-4ed2-b8ed-9cbc9a61592d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_38c6db7c-55bf-404f-9f58-a0fbb99455f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_408988aa-0617-4576-afe8-923d9d4512b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_38c6db7c-55bf-404f-9f58-a0fbb99455f9" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_408988aa-0617-4576-afe8-923d9d4512b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CaliforniaIncomeTaxAuthorityMember_80ed4433-de07-425c-9405-baaee6f10cab" xlink:href="ino-20201231.xsd#ino_CaliforniaIncomeTaxAuthorityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_38c6db7c-55bf-404f-9f58-a0fbb99455f9" xlink:to="loc_ino_CaliforniaIncomeTaxAuthorityMember_80ed4433-de07-425c-9405-baaee6f10cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_7a502c2d-66ee-4902-8abd-b789811f7762" xlink:href="ino-20201231.xsd#ino_PennsylvaniaStateIncomeTaxAuthorityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_38c6db7c-55bf-404f-9f58-a0fbb99455f9" xlink:to="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_7a502c2d-66ee-4902-8abd-b789811f7762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_c1f83c75-4cd1-430c-81fc-fa85625e35e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_38c6db7c-55bf-404f-9f58-a0fbb99455f9" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_c1f83c75-4cd1-430c-81fc-fa85625e35e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_f1fbf019-c9e3-4703-be93-e2843738ae14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a69ca7d8-34e0-4ad8-b792-8cad307162c8" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_f1fbf019-c9e3-4703-be93-e2843738ae14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7cf56c8c-5e0b-4c96-85b0-06451602477d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_f1fbf019-c9e3-4703-be93-e2843738ae14" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_7cf56c8c-5e0b-4c96-85b0-06451602477d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_0ee58530-2613-4237-8e5d-55eba7e3ec5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7cf56c8c-5e0b-4c96-85b0-06451602477d" xlink:to="loc_us-gaap_ResearchMember_0ee58530-2613-4237-8e5d-55eba7e3ec5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_6216398e-417c-4039-a8e5-5c29419afaa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a69ca7d8-34e0-4ad8-b792-8cad307162c8" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_6216398e-417c-4039-a8e5-5c29419afaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a43048a6-290c-4559-b81d-ea10cfb373f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6216398e-417c-4039-a8e5-5c29419afaa5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a43048a6-290c-4559-b81d-ea10cfb373f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_cab28675-5a1a-4138-b98c-56708df5cba5" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6216398e-417c-4039-a8e5-5c29419afaa5" xlink:to="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_cab28675-5a1a-4138-b98c-56708df5cba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_8efd9eee-839f-439d-aa5b-46ab7788136a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6216398e-417c-4039-a8e5-5c29419afaa5" xlink:to="loc_us-gaap_OperatingLossCarryforwards_8efd9eee-839f-439d-aa5b-46ab7788136a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_a3e46b03-aeea-4a55-b80c-f2d81f35ad01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6216398e-417c-4039-a8e5-5c29419afaa5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_a3e46b03-aeea-4a55-b80c-f2d81f35ad01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxBenefitsExpired_da32a5fe-a355-4a1b-85ef-2039eeb5a2cb" xlink:href="ino-20201231.xsd#ino_TaxBenefitsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6216398e-417c-4039-a8e5-5c29419afaa5" xlink:to="loc_ino_TaxBenefitsExpired_da32a5fe-a355-4a1b-85ef-2039eeb5a2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_123c415d-7401-4e74-b418-8a09cd7da695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6216398e-417c-4039-a8e5-5c29419afaa5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_123c415d-7401-4e74-b418-8a09cd7da695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_03c88808-0a48-4299-a372-f91604341bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_771a628a-75e7-47c3-a0fb-4bcbe9e7bf78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_03c88808-0a48-4299-a372-f91604341bf4" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_771a628a-75e7-47c3-a0fb-4bcbe9e7bf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3faf237e-92c4-4051-8f77-c6a3d733ffae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_771a628a-75e7-47c3-a0fb-4bcbe9e7bf78" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3faf237e-92c4-4051-8f77-c6a3d733ffae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e3abd705-a6ab-400c-bc99-53a0263cc0bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_771a628a-75e7-47c3-a0fb-4bcbe9e7bf78" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e3abd705-a6ab-400c-bc99-53a0263cc0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_5423b491-e386-4b27-be35-f31149a9a42b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_771a628a-75e7-47c3-a0fb-4bcbe9e7bf78" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_5423b491-e386-4b27-be35-f31149a9a42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_d2994dd4-d371-4874-93fc-2d325ef169cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_771a628a-75e7-47c3-a0fb-4bcbe9e7bf78" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_d2994dd4-d371-4874-93fc-2d325ef169cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7d0edcd8-88f8-493e-b4cb-bafb6094e802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_771a628a-75e7-47c3-a0fb-4bcbe9e7bf78" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7d0edcd8-88f8-493e-b4cb-bafb6094e802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsIntangibleAssets_9378d5a6-5b85-4373-89b2-6139e79c40a1" xlink:href="ino-20201231.xsd#ino_DeferredTaxAssetsIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_771a628a-75e7-47c3-a0fb-4bcbe9e7bf78" xlink:to="loc_ino_DeferredTaxAssetsIntangibleAssets_9378d5a6-5b85-4373-89b2-6139e79c40a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_33b0a5f4-9102-479e-a150-e8e6fd51f5d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_771a628a-75e7-47c3-a0fb-4bcbe9e7bf78" xlink:to="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_33b0a5f4-9102-479e-a150-e8e6fd51f5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetInterestExpense_be5937fd-aaad-4de4-8d16-eb3645e5f243" xlink:href="ino-20201231.xsd#ino_DeferredTaxAssetInterestExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_771a628a-75e7-47c3-a0fb-4bcbe9e7bf78" xlink:to="loc_ino_DeferredTaxAssetInterestExpense_be5937fd-aaad-4de4-8d16-eb3645e5f243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_6ca36625-2595-4fb0-9783-a14ac28b8f09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_771a628a-75e7-47c3-a0fb-4bcbe9e7bf78" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_6ca36625-2595-4fb0-9783-a14ac28b8f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_4539bca8-a872-4ee8-a5e9-4a9e429ab815" xlink:href="ino-20201231.xsd#ino_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_771a628a-75e7-47c3-a0fb-4bcbe9e7bf78" xlink:to="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_4539bca8-a872-4ee8-a5e9-4a9e429ab815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_be476edb-6c5a-4c78-90ae-500aaaef84f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_771a628a-75e7-47c3-a0fb-4bcbe9e7bf78" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_be476edb-6c5a-4c78-90ae-500aaaef84f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_37740742-bdca-4e2b-8319-8e2e3b5bed10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_771a628a-75e7-47c3-a0fb-4bcbe9e7bf78" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_37740742-bdca-4e2b-8319-8e2e3b5bed10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b725db82-1aa4-43d9-8812-694529e03740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_771a628a-75e7-47c3-a0fb-4bcbe9e7bf78" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b725db82-1aa4-43d9-8812-694529e03740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7878334e-1d1f-48e2-8a3d-f47dd136c078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_771a628a-75e7-47c3-a0fb-4bcbe9e7bf78" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7878334e-1d1f-48e2-8a3d-f47dd136c078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_26062acc-b3bb-4448-be57-82efa6118304" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_03c88808-0a48-4299-a372-f91604341bf4" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_26062acc-b3bb-4448-be57-82efa6118304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9d8d39d2-ba4e-4905-913c-b14362236e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_26062acc-b3bb-4448-be57-82efa6118304" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9d8d39d2-ba4e-4905-913c-b14362236e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_d1688159-f438-4cb0-a982-fdff5cdf17eb" xlink:href="ino-20201231.xsd#ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_26062acc-b3bb-4448-be57-82efa6118304" xlink:to="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_d1688159-f438-4cb0-a982-fdff5cdf17eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_0ef610b2-8914-448f-a1f9-c145cb167b59" xlink:href="ino-20201231.xsd#ino_DeferredTaxLiabilitiesFinancingArrangementDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_26062acc-b3bb-4448-be57-82efa6118304" xlink:to="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_0ef610b2-8914-448f-a1f9-c145cb167b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_a2f02486-c210-46cf-a238-30a3cc3e7c86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_26062acc-b3bb-4448-be57-82efa6118304" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_a2f02486-c210-46cf-a238-30a3cc3e7c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_9b6372c2-a7db-44fe-97a7-c359c8b48d70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_26062acc-b3bb-4448-be57-82efa6118304" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_9b6372c2-a7db-44fe-97a7-c359c8b48d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_3134d343-4121-44dd-a45d-9b031ddae32b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_03c88808-0a48-4299-a372-f91604341bf4" xlink:to="loc_us-gaap_DeferredTaxLiabilities_3134d343-4121-44dd-a45d-9b031ddae32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f1a5fda1-4362-444a-ae9d-8acaf5e728d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_e2da1e0d-e479-4bfb-8828-53599314de2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f1a5fda1-4362-444a-ae9d-8acaf5e728d7" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_e2da1e0d-e479-4bfb-8828-53599314de2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_021377d1-06c4-435b-9091-81378a76d206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e2da1e0d-e479-4bfb-8828-53599314de2d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_021377d1-06c4-435b-9091-81378a76d206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_833afb57-024d-4a94-9261-0d4daf9bd9cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_021377d1-06c4-435b-9091-81378a76d206" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_833afb57-024d-4a94-9261-0d4daf9bd9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_2eff5874-80e9-4001-aa8c-1f6a5d10c66e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_833afb57-024d-4a94-9261-0d4daf9bd9cd" xlink:to="loc_us-gaap_ResearchMember_2eff5874-80e9-4001-aa8c-1f6a5d10c66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6d9f317a-2fd0-4078-800c-fe9db786d81a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e2da1e0d-e479-4bfb-8828-53599314de2d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6d9f317a-2fd0-4078-800c-fe9db786d81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e7111249-2122-4fc1-8e32-8048c6102c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6d9f317a-2fd0-4078-800c-fe9db786d81a" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e7111249-2122-4fc1-8e32-8048c6102c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_8c35e50d-ddc3-40e5-9fa3-b9b6bbda6de4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e7111249-2122-4fc1-8e32-8048c6102c24" xlink:to="loc_us-gaap_DomesticCountryMember_8c35e50d-ddc3-40e5-9fa3-b9b6bbda6de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_4ff587a5-ee85-4e1f-a0b0-0956c7e5b71b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e7111249-2122-4fc1-8e32-8048c6102c24" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_4ff587a5-ee85-4e1f-a0b0-0956c7e5b71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_9b0e9e25-9bd0-4120-98d0-5f1ce1ff57f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e2da1e0d-e479-4bfb-8828-53599314de2d" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_9b0e9e25-9bd0-4120-98d0-5f1ce1ff57f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_8cc95774-ac01-4ca8-96de-aa9892e0743a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9b0e9e25-9bd0-4120-98d0-5f1ce1ff57f4" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_8cc95774-ac01-4ca8-96de-aa9892e0743a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_943331ed-90aa-427e-8e58-f215d733fff6" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_8cc95774-ac01-4ca8-96de-aa9892e0743a" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_943331ed-90aa-427e-8e58-f215d733fff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_358a2c6d-8fa0-44ad-b7f7-6b0aec3804e1" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_8cc95774-ac01-4ca8-96de-aa9892e0743a" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_358a2c6d-8fa0-44ad-b7f7-6b0aec3804e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_d226465a-b915-4958-b75d-7329d404de68" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_8cc95774-ac01-4ca8-96de-aa9892e0743a" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_d226465a-b915-4958-b75d-7329d404de68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_a9099da4-9814-4aed-a5f2-2bbe87dca987" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_8cc95774-ac01-4ca8-96de-aa9892e0743a" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_a9099da4-9814-4aed-a5f2-2bbe87dca987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_9f540300-91ab-428a-be63-8770abfe2031" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsExpiringinFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_8cc95774-ac01-4ca8-96de-aa9892e0743a" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_9f540300-91ab-428a-be63-8770abfe2031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_a367facc-4511-4015-99c0-6e34025465f5" xlink:href="ino-20201231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_8cc95774-ac01-4ca8-96de-aa9892e0743a" xlink:to="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_a367facc-4511-4015-99c0-6e34025465f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_f6e9ce39-42a4-4b53-b591-e2c770164d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_8cc95774-ac01-4ca8-96de-aa9892e0743a" xlink:to="loc_us-gaap_OperatingLossCarryforwards_f6e9ce39-42a4-4b53-b591-e2c770164d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_5d00e8f5-4865-47ab-a4a3-0597f82e35f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_9b0e9e25-9bd0-4120-98d0-5f1ce1ff57f4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_5d00e8f5-4865-47ab-a4a3-0597f82e35f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_1f77f781-f79a-4cb4-a848-c0b297f38b90" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_5d00e8f5-4865-47ab-a4a3-0597f82e35f1" xlink:to="loc_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_1f77f781-f79a-4cb4-a848-c0b297f38b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_cf49c41d-a8b7-4db3-a669-a264ad59eecb" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_5d00e8f5-4865-47ab-a4a3-0597f82e35f1" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_cf49c41d-a8b7-4db3-a669-a264ad59eecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_a51d6ddd-4bb3-41db-938c-5bdccf8e405a" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringinThreeMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_5d00e8f5-4865-47ab-a4a3-0597f82e35f1" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_a51d6ddd-4bb3-41db-938c-5bdccf8e405a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_b2cd0fdc-4b95-4e89-8a1f-aba709688ad3" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringinFourMonths"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_5d00e8f5-4865-47ab-a4a3-0597f82e35f1" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_b2cd0fdc-4b95-4e89-8a1f-aba709688ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_c8404678-52c9-4302-8a76-e0d22cfd9da6" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardExpiringinFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_5d00e8f5-4865-47ab-a4a3-0597f82e35f1" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_c8404678-52c9-4302-8a76-e0d22cfd9da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_e0b03023-ed46-4dc6-acc4-297402077281" xlink:href="ino-20201231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_5d00e8f5-4865-47ab-a4a3-0597f82e35f1" xlink:to="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_e0b03023-ed46-4dc6-acc4-297402077281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_7e77dae9-6f30-4797-bea7-b8db543c7881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_5d00e8f5-4865-47ab-a4a3-0597f82e35f1" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_7e77dae9-6f30-4797-bea7-b8db543c7881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_91fd8215-6cdb-48a4-ad2e-96f6abd3fde4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8f660f6-5ff3-49c6-9b35-d38934093c64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_91fd8215-6cdb-48a4-ad2e-96f6abd3fde4" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8f660f6-5ff3-49c6-9b35-d38934093c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_77729f1f-5131-4d20-bd5f-16bfd1c6509e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8f660f6-5ff3-49c6-9b35-d38934093c64" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_77729f1f-5131-4d20-bd5f-16bfd1c6509e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_afc235f9-f09d-49c0-b47b-3e1ac03040c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8f660f6-5ff3-49c6-9b35-d38934093c64" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_afc235f9-f09d-49c0-b47b-3e1ac03040c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_67efc429-3768-4676-9796-cb750691c634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8f660f6-5ff3-49c6-9b35-d38934093c64" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_67efc429-3768-4676-9796-cb750691c634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_57fa9948-7db1-4cae-a28e-833b72eff542" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8f660f6-5ff3-49c6-9b35-d38934093c64" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_57fa9948-7db1-4cae-a28e-833b72eff542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther_686abb86-1d3e-4cd1-998c-e84b5d4af321" xlink:href="ino-20201231.xsd#ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8f660f6-5ff3-49c6-9b35-d38934093c64" xlink:to="loc_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther_686abb86-1d3e-4cd1-998c-e84b5d4af321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c780a4c5-6e75-4692-a31e-6695df22cb1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8f660f6-5ff3-49c6-9b35-d38934093c64" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_c780a4c5-6e75-4692-a31e-6695df22cb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/A401kPlan" xlink:type="simple" xlink:href="ino-20201231.xsd#A401kPlan"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/A401kPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80db3640-6088-464a-a72b-529a06ceea5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5a5e1432-bfed-443e-bda9-994245d2ed97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80db3640-6088-464a-a72b-529a06ceea5f" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5a5e1432-bfed-443e-bda9-994245d2ed97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#A401kPlanDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/A401kPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d4445fbb-eb0b-4089-a14e-1de28454dcea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_560ebef2-a110-4934-a1e5-6698e3819f5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d4445fbb-eb0b-4089-a14e-1de28454dcea" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_560ebef2-a110-4934-a1e5-6698e3819f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_dc9fa985-9c3d-463a-aadf-8990f80d7a50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d4445fbb-eb0b-4089-a14e-1de28454dcea" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_dc9fa985-9c3d-463a-aadf-8990f80d7a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_960cc4d7-402b-4148-9229-7edb7d7cb1ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d4445fbb-eb0b-4089-a14e-1de28454dcea" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_960cc4d7-402b-4148-9229-7edb7d7cb1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ino-20201231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_7d57c263-adbb-44c8-ae98-9760923395c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_3f3e16d1-b1b1-45e9-bc29-90c42d46a981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_7d57c263-adbb-44c8-ae98-9760923395c2" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_3f3e16d1-b1b1-45e9-bc29-90c42d46a981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_50ad3a1e-1e45-428b-a58d-5722408e6ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5d60b588-c51b-44b5-ab61-2a569ae47beb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_50ad3a1e-1e45-428b-a58d-5722408e6ce1" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5d60b588-c51b-44b5-ab61-2a569ae47beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4d4982cb-70da-4d44-9d97-753af8c83720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5d60b588-c51b-44b5-ab61-2a569ae47beb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4d4982cb-70da-4d44-9d97-753af8c83720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_248dcb91-7f1e-45c9-bebe-c3b114004393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4d4982cb-70da-4d44-9d97-753af8c83720" xlink:to="loc_us-gaap_RelatedPartyDomain_248dcb91-7f1e-45c9-bebe-c3b114004393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneOneLifeSciencesMember_f61d5c65-98c5-4960-8668-46600f4f98da" xlink:href="ino-20201231.xsd#ino_GeneOneLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_248dcb91-7f1e-45c9-bebe-c3b114004393" xlink:to="loc_ino_GeneOneLifeSciencesMember_f61d5c65-98c5-4960-8668-46600f4f98da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PLSaffiliatedentityMember_95c0fbbb-21e6-4d12-b0ab-489035188224" xlink:href="ino-20201231.xsd#ino_PLSaffiliatedentityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_248dcb91-7f1e-45c9-bebe-c3b114004393" xlink:to="loc_ino_PLSaffiliatedentityMember_95c0fbbb-21e6-4d12-b0ab-489035188224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_43f028e4-727e-4423-8594-b9dcda75d3b2" xlink:href="ino-20201231.xsd#ino_TheWistarInstituteMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_248dcb91-7f1e-45c9-bebe-c3b114004393" xlink:to="loc_ino_TheWistarInstituteMember_43f028e4-727e-4423-8594-b9dcda75d3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9d2611f1-69d4-4e69-842f-d44625d0aae8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5d60b588-c51b-44b5-ab61-2a569ae47beb" xlink:to="loc_srt_CounterpartyNameAxis_9d2611f1-69d4-4e69-842f-d44625d0aae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc7ea041-245d-4b14-96d5-cae172a64126" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9d2611f1-69d4-4e69-842f-d44625d0aae8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc7ea041-245d-4b14-96d5-cae172a64126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneOneLifeSciencesMember_ab83324a-754b-4ddf-988a-62f831ff2997" xlink:href="ino-20201231.xsd#ino_GeneOneLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cc7ea041-245d-4b14-96d5-cae172a64126" xlink:to="loc_ino_GeneOneLifeSciencesMember_ab83324a-754b-4ddf-988a-62f831ff2997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_0232ee80-bc18-4d44-a19a-7f04eaac10b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5d60b588-c51b-44b5-ab61-2a569ae47beb" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_0232ee80-bc18-4d44-a19a-7f04eaac10b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_bb0ef73a-117d-4462-8c35-35b77b52670a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_0232ee80-bc18-4d44-a19a-7f04eaac10b1" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_bb0ef73a-117d-4462-8c35-35b77b52670a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_979e5f30-3288-42fb-a9e8-0e23b84bb44f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_bb0ef73a-117d-4462-8c35-35b77b52670a" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_979e5f30-3288-42fb-a9e8-0e23b84bb44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5d60b588-c51b-44b5-ab61-2a569ae47beb" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_9d25aaf4-4361-450b-ab98-e13819cf0534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_9d25aaf4-4361-450b-ab98-e13819cf0534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c4a936ba-97c0-43f7-adcb-77aec5b3691a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c4a936ba-97c0-43f7-adcb-77aec5b3691a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_eeef6a8b-1e3c-4ac9-a9f9-029b388ea856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_eeef6a8b-1e3c-4ac9-a9f9-029b388ea856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_809ec63d-8974-4f3e-ac03-ecdab9584dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_809ec63d-8974-4f3e-ac03-ecdab9584dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_a9821ec3-e5a4-41d8-bf83-5210fe0ea95c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_us-gaap_RevenueFromRelatedParties_a9821ec3-e5a4-41d8-bf83-5210fe0ea95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_738f289f-f96c-4721-88b2-a8434166c007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_738f289f-f96c-4721-88b2-a8434166c007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InvestmentOwnedAdditionalSharesAcquired_d37bd38e-699c-4534-a854-2cc729b16a24" xlink:href="ino-20201231.xsd#ino_InvestmentOwnedAdditionalSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_ino_InvestmentOwnedAdditionalSharesAcquired_d37bd38e-699c-4534-a854-2cc729b16a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_bb42a43b-784d-43ad-ae81-9675ba067b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_bb42a43b-784d-43ad-ae81-9675ba067b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_af9a78ec-c427-4a09-a512-6a418dd3e9de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_220f9682-53f2-4341-8ff7-e02ff7f21da8" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_220f9682-53f2-4341-8ff7-e02ff7f21da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_0d9fde28-0b31-4801-9894-315d9dc3313d" xlink:href="ino-20201231.xsd#ino_CollaborativeArrangementTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_ino_CollaborativeArrangementTerm_0d9fde28-0b31-4801-9894-315d9dc3313d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromSubGrant_32e32672-c9d9-4934-a7ab-551ce3493f90" xlink:href="ino-20201231.xsd#ino_ProceedsFromSubGrant"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_ino_ProceedsFromSubGrant_32e32672-c9d9-4934-a7ab-551ce3493f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_70bca6fb-6981-4d06-bb0e-46c544221c25" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_70bca6fb-6981-4d06-bb0e-46c544221c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_1d774e73-b7ff-45f3-aa3a-7d9e27dbb329" xlink:href="ino-20201231.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_1d774e73-b7ff-45f3-aa3a-7d9e27dbb329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_f07624e4-155e-451f-b389-50c8eb0c5876" xlink:href="ino-20201231.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_ino_GrantProceedsReceived_f07624e4-155e-451f-b389-50c8eb0c5876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_3182e2b0-98aa-4f0e-ac17-6ca615d365b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_1713dbd2-fcf3-4f77-8365-a9362768de69" xlink:href="ino-20201231.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4ae559e2-aa02-42d2-bb65-61ee2606d842" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_1713dbd2-fcf3-4f77-8365-a9362768de69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsInc"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_a38b6a56-f0ec-4e1c-9ef8-67078041e395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_bbd45399-bf0c-44c9-b8d6-392bcab2ba2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_a38b6a56-f0ec-4e1c-9ef8-67078041e395" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_bbd45399-bf0c-44c9-b8d6-392bcab2ba2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsIncTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_27f7d3b2-ad60-4f67-a626-0bc53128610e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_58d70f19-3518-458f-bc7f-e427311fc2e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_27f7d3b2-ad60-4f67-a626-0bc53128610e" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_58d70f19-3518-458f-bc7f-e427311fc2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_3d9927ea-719b-4698-898f-949719c17454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_27f7d3b2-ad60-4f67-a626-0bc53128610e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_3d9927ea-719b-4698-898f-949719c17454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_ef87ae84-dfaa-433e-ba95-bafe2105e329" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_b5a6a6da-13d4-4b0d-a27f-85e341ab6222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_ef87ae84-dfaa-433e-ba95-bafe2105e329" xlink:to="loc_us-gaap_MinorityInterestTable_b5a6a6da-13d4-4b0d-a27f-85e341ab6222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3d067daa-3533-4c18-856c-d084b871412b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_b5a6a6da-13d4-4b0d-a27f-85e341ab6222" xlink:to="loc_srt_CounterpartyNameAxis_3d067daa-3533-4c18-856c-d084b871412b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1956c3ff-c533-401e-b425-ca555f323f6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3d067daa-3533-4c18-856c-d084b871412b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1956c3ff-c533-401e-b425-ca555f323f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_1e6598f4-f0a6-4df7-8da3-8cbe5dca7ffe" xlink:href="ino-20201231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1956c3ff-c533-401e-b425-ca555f323f6e" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_1e6598f4-f0a6-4df7-8da3-8cbe5dca7ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5d74c468-8601-404e-9560-e9d751af3db6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_b5a6a6da-13d4-4b0d-a27f-85e341ab6222" xlink:to="loc_srt_OwnershipAxis_5d74c468-8601-404e-9560-e9d751af3db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_91168122-d965-4401-8c5d-f0b50d9bd637" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_5d74c468-8601-404e-9560-e9d751af3db6" xlink:to="loc_srt_OwnershipDomain_91168122-d965-4401-8c5d-f0b50d9bd637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_875c1255-85c8-4f8b-a123-eb7f057a69ad" xlink:href="ino-20201231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_91168122-d965-4401-8c5d-f0b50d9bd637" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_875c1255-85c8-4f8b-a123-eb7f057a69ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_49251507-a2b9-45eb-b683-d023efa4ad9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_b5a6a6da-13d4-4b0d-a27f-85e341ab6222" xlink:to="loc_us-gaap_StatementClassOfStockAxis_49251507-a2b9-45eb-b683-d023efa4ad9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8dd79fdf-e140-4ded-9630-9b21d87b6b58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_49251507-a2b9-45eb-b683-d023efa4ad9d" xlink:to="loc_us-gaap_ClassOfStockDomain_8dd79fdf-e140-4ded-9630-9b21d87b6b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f583c0f0-96ee-4599-bff8-150af3951531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8dd79fdf-e140-4ded-9630-9b21d87b6b58" xlink:to="loc_us-gaap_CommonStockMember_f583c0f0-96ee-4599-bff8-150af3951531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_2e8ae78a-c946-44e8-a789-abb35ddf4258" xlink:href="ino-20201231.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8dd79fdf-e140-4ded-9630-9b21d87b6b58" xlink:to="loc_ino_SeriesAOnePreferredStockMember_2e8ae78a-c946-44e8-a789-abb35ddf4258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_b5a6a6da-13d4-4b0d-a27f-85e341ab6222" xlink:to="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_a72e8107-dc04-42c9-9f05-4f488cf6161c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_a72e8107-dc04-42c9-9f05-4f488cf6161c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_7832ae07-0954-42aa-9e1b-bf2beed94345" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_7832ae07-0954-42aa-9e1b-bf2beed94345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_672a7c55-4397-4342-be00-d81e8da2674f" xlink:href="ino-20201231.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:to="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_672a7c55-4397-4342-be00-d81e8da2674f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_ed908fc3-9e91-4001-a1e1-018d84ad3c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_ed908fc3-9e91-4001-a1e1-018d84ad3c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_05c3bffd-2d92-46e4-852d-a16d8910beac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_05c3bffd-2d92-46e4-852d-a16d8910beac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3f6364f3-c7ad-4ffd-a5c6-de48d229fe28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3f6364f3-c7ad-4ffd-a5c6-de48d229fe28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0ed97827-d3e8-4ece-bcd6-25203025e233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0ed97827-d3e8-4ece-bcd6-25203025e233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_25fdf840-6c55-4ec1-bafe-d81e90880a29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_ae54e30a-b2b2-43e8-b1dd-70918b932395" xlink:to="loc_us-gaap_EquityMethodInvestments_25fdf840-6c55-4ec1-bafe-d81e90880a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsIncDeconsolidationAccountingDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_69655210-a70e-4418-bb65-cde3c0248668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_022b4c65-d863-402f-92f7-102eefecdafb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_69655210-a70e-4418-bb65-cde3c0248668" xlink:to="loc_us-gaap_MinorityInterestTable_022b4c65-d863-402f-92f7-102eefecdafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9e1397f2-2222-481c-8860-1ae348673e8b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_022b4c65-d863-402f-92f7-102eefecdafb" xlink:to="loc_srt_CounterpartyNameAxis_9e1397f2-2222-481c-8860-1ae348673e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9feb636c-afca-4527-ac11-743ae6c364a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9e1397f2-2222-481c-8860-1ae348673e8b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9feb636c-afca-4527-ac11-743ae6c364a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_7caaf195-42f2-450e-bb90-100691669e42" xlink:href="ino-20201231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9feb636c-afca-4527-ac11-743ae6c364a4" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_7caaf195-42f2-450e-bb90-100691669e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_94519fe4-4777-4cfe-bbe0-578a2aa1808a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_022b4c65-d863-402f-92f7-102eefecdafb" xlink:to="loc_us-gaap_MinorityInterestLineItems_94519fe4-4777-4cfe-bbe0-578a2aa1808a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapitalExcludingCash_f1392801-01ea-45b3-b58c-a4326daf5275" xlink:href="ino-20201231.xsd#ino_WorkingCapitalExcludingCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_94519fe4-4777-4cfe-bbe0-578a2aa1808a" xlink:to="loc_ino_WorkingCapitalExcludingCash_f1392801-01ea-45b3-b58c-a4326daf5275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_2fa24451-726e-47bd-a03b-a0b387475312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_94519fe4-4777-4cfe-bbe0-578a2aa1808a" xlink:to="loc_us-gaap_NotesPayable_2fa24451-726e-47bd-a03b-a0b387475312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_615df396-1477-47cd-8bee-b2787a6d7b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_94519fe4-4777-4cfe-bbe0-578a2aa1808a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_615df396-1477-47cd-8bee-b2787a6d7b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_094debc4-c2e4-41b6-bcd2-c97612b8d916" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_94519fe4-4777-4cfe-bbe0-578a2aa1808a" xlink:to="loc_us-gaap_MinorityInterest_094debc4-c2e4-41b6-bcd2-c97612b8d916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedInterestFairValueDisclosure_c2168995-0dcd-4779-83d9-8306fefaa22b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedInterestFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_94519fe4-4777-4cfe-bbe0-578a2aa1808a" xlink:to="loc_us-gaap_RetainedInterestFairValueDisclosure_c2168995-0dcd-4779-83d9-8306fefaa22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_04de8fa6-4e62-4475-94fc-9adbe7207a21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_94519fe4-4777-4cfe-bbe0-578a2aa1808a" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_04de8fa6-4e62-4475-94fc-9adbe7207a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_fed2dc14-9296-498b-b7ac-308ad67d57f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_94519fe4-4777-4cfe-bbe0-578a2aa1808a" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_fed2dc14-9296-498b-b7ac-308ad67d57f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsIncInvestmentinGeneosDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_937be1aa-c50a-4902-a613-7cf090d3b9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_d237f3e2-fd16-4a25-9ead-7a4c1ad3eb25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_937be1aa-c50a-4902-a613-7cf090d3b9e1" xlink:to="loc_us-gaap_MinorityInterestTable_d237f3e2-fd16-4a25-9ead-7a4c1ad3eb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1eb3ae0f-9af5-4694-be0e-6a0d8dbfb238" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_d237f3e2-fd16-4a25-9ead-7a4c1ad3eb25" xlink:to="loc_srt_CounterpartyNameAxis_1eb3ae0f-9af5-4694-be0e-6a0d8dbfb238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13e056f3-e772-460d-b2cf-e24bf23a328d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1eb3ae0f-9af5-4694-be0e-6a0d8dbfb238" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13e056f3-e772-460d-b2cf-e24bf23a328d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_4b1b152c-9238-458e-bc5b-54912b379d45" xlink:href="ino-20201231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13e056f3-e772-460d-b2cf-e24bf23a328d" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_4b1b152c-9238-458e-bc5b-54912b379d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7a7f7aa0-e1c0-4ee4-93ba-4bf596cf5a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_d237f3e2-fd16-4a25-9ead-7a4c1ad3eb25" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7a7f7aa0-e1c0-4ee4-93ba-4bf596cf5a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f2921a50-f607-4137-8ab2-f9904948fb24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7a7f7aa0-e1c0-4ee4-93ba-4bf596cf5a5e" xlink:to="loc_us-gaap_ClassOfStockDomain_f2921a50-f607-4137-8ab2-f9904948fb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_507fa006-52eb-4727-be4d-1158d41c5853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f2921a50-f607-4137-8ab2-f9904948fb24" xlink:to="loc_us-gaap_CommonStockMember_507fa006-52eb-4727-be4d-1158d41c5853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredClassAMember_5eebaa56-83e3-4b71-b518-113cf5ed906a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f2921a50-f607-4137-8ab2-f9904948fb24" xlink:to="loc_us-gaap_PreferredClassAMember_5eebaa56-83e3-4b71-b518-113cf5ed906a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_0515f2a2-78e5-402c-bb16-c6a462a5e607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_d237f3e2-fd16-4a25-9ead-7a4c1ad3eb25" xlink:to="loc_us-gaap_MinorityInterestLineItems_0515f2a2-78e5-402c-bb16-c6a462a5e607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_41fbd022-f623-42de-8fb4-b2dd5b3e1ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_0515f2a2-78e5-402c-bb16-c6a462a5e607" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_41fbd022-f623-42de-8fb4-b2dd5b3e1ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_68b7da7f-0d3c-4376-a603-00916462f08d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_0515f2a2-78e5-402c-bb16-c6a462a5e607" xlink:to="loc_us-gaap_SharePrice_68b7da7f-0d3c-4376-a603-00916462f08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_3bec42aa-1eff-4052-a154-f37876f874f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_0515f2a2-78e5-402c-bb16-c6a462a5e607" xlink:to="loc_us-gaap_EquityMethodInvestments_3bec42aa-1eff-4052-a154-f37876f874f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsIncFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_c751eeb7-246d-4af2-8411-2cb0af186d87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_1ce20ccc-5001-4df4-90dc-6afe3e664722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_c751eeb7-246d-4af2-8411-2cb0af186d87" xlink:to="loc_us-gaap_MinorityInterestTable_1ce20ccc-5001-4df4-90dc-6afe3e664722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_aa5d2cb0-2c6f-42cd-91f5-2e23654d613b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_1ce20ccc-5001-4df4-90dc-6afe3e664722" xlink:to="loc_srt_CounterpartyNameAxis_aa5d2cb0-2c6f-42cd-91f5-2e23654d613b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0387a79-6c53-433e-b0e5-cbe2362341e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_aa5d2cb0-2c6f-42cd-91f5-2e23654d613b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0387a79-6c53-433e-b0e5-cbe2362341e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_0b4841ac-cb66-4178-8d2d-a6a27f62bd70" xlink:href="ino-20201231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0387a79-6c53-433e-b0e5-cbe2362341e0" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_0b4841ac-cb66-4178-8d2d-a6a27f62bd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_be2b7aa4-3fc1-47b6-ba6f-1b93940d79dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_1ce20ccc-5001-4df4-90dc-6afe3e664722" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_be2b7aa4-3fc1-47b6-ba6f-1b93940d79dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_501c6bce-b483-4e90-9d6c-05add922637d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_be2b7aa4-3fc1-47b6-ba6f-1b93940d79dc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_501c6bce-b483-4e90-9d6c-05add922637d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_318fc4c6-faee-4d7f-9fdd-d9d4c54fa3e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_501c6bce-b483-4e90-9d6c-05add922637d" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_318fc4c6-faee-4d7f-9fdd-d9d4c54fa3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_666e8b45-1f4f-4d3f-ab4d-88dbcfba087f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_501c6bce-b483-4e90-9d6c-05add922637d" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_666e8b45-1f4f-4d3f-ab4d-88dbcfba087f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_de78d2eb-bf22-47ca-a3c8-234401951ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_501c6bce-b483-4e90-9d6c-05add922637d" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_de78d2eb-bf22-47ca-a3c8-234401951ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_7addb918-e2a0-4191-8b7e-58a0abb4069a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_1ce20ccc-5001-4df4-90dc-6afe3e664722" xlink:to="loc_us-gaap_MinorityInterestLineItems_7addb918-e2a0-4191-8b7e-58a0abb4069a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AlternativeInvestmentMeasurementInputTerm_a12b77b6-ba0d-46cd-b677-b81a81bb563f" xlink:href="ino-20201231.xsd#ino_AlternativeInvestmentMeasurementInputTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_7addb918-e2a0-4191-8b7e-58a0abb4069a" xlink:to="loc_ino_AlternativeInvestmentMeasurementInputTerm_a12b77b6-ba0d-46cd-b677-b81a81bb563f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_f2b2912c-3f67-4e35-9254-b400196332ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_7addb918-e2a0-4191-8b7e-58a0abb4069a" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_f2b2912c-3f67-4e35-9254-b400196332ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentEnterpriseValue_9a2c27f0-b778-469e-92bf-a4245133638e" xlink:href="ino-20201231.xsd#ino_EquityMethodInvestmentEnterpriseValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_7addb918-e2a0-4191-8b7e-58a0abb4069a" xlink:to="loc_ino_EquityMethodInvestmentEnterpriseValue_9a2c27f0-b778-469e-92bf-a4245133638e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#GeneosTherapeuticsIncPreferredStockInvestmentDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_8779bef7-1229-4fc5-81ae-61e326a0383b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_6ff10dea-6dbc-46e7-8fd4-635760e8f319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_8779bef7-1229-4fc5-81ae-61e326a0383b" xlink:to="loc_us-gaap_MinorityInterestTable_6ff10dea-6dbc-46e7-8fd4-635760e8f319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_267d9bb2-948a-45f9-b338-22d17a8c7daf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_6ff10dea-6dbc-46e7-8fd4-635760e8f319" xlink:to="loc_srt_CounterpartyNameAxis_267d9bb2-948a-45f9-b338-22d17a8c7daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e44c8ca-a858-4289-b513-847dfd31b5cc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_267d9bb2-948a-45f9-b338-22d17a8c7daf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e44c8ca-a858-4289-b513-847dfd31b5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_a1c58840-44f3-497b-b46d-483c70d8fb66" xlink:href="ino-20201231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e44c8ca-a858-4289-b513-847dfd31b5cc" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_a1c58840-44f3-497b-b46d-483c70d8fb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_655b776c-b30a-4abc-a1a2-1cf8090b5d47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_6ff10dea-6dbc-46e7-8fd4-635760e8f319" xlink:to="loc_us-gaap_StatementClassOfStockAxis_655b776c-b30a-4abc-a1a2-1cf8090b5d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3c298e63-e0fc-4c3c-ae5d-0772253c723d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_655b776c-b30a-4abc-a1a2-1cf8090b5d47" xlink:to="loc_us-gaap_ClassOfStockDomain_3c298e63-e0fc-4c3c-ae5d-0772253c723d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_50fafdd3-739c-46eb-89a1-ad4501ec6435" xlink:href="ino-20201231.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3c298e63-e0fc-4c3c-ae5d-0772253c723d" xlink:to="loc_ino_SeriesAOnePreferredStockMember_50fafdd3-739c-46eb-89a1-ad4501ec6435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_202e898c-6a65-4fae-9430-99b87165d9c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_6ff10dea-6dbc-46e7-8fd4-635760e8f319" xlink:to="loc_us-gaap_MinorityInterestLineItems_202e898c-6a65-4fae-9430-99b87165d9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_36cf44f7-b633-4492-adaf-172a6a04b82f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_202e898c-6a65-4fae-9430-99b87165d9c3" xlink:to="loc_us-gaap_EquityMethodInvestments_36cf44f7-b633-4492-adaf-172a6a04b82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_611f0f47-55b7-4252-a497-8bd570c093f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_202e898c-6a65-4fae-9430-99b87165d9c3" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_611f0f47-55b7-4252-a497-8bd570c093f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_99f4e22d-e5bd-41e3-bd35-71e8f5c0d42a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_202e898c-6a65-4fae-9430-99b87165d9c3" xlink:to="loc_us-gaap_EquityMethodInvestments_99f4e22d-e5bd-41e3-bd35-71e8f5c0d42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="ino-20201231.xsd#QuarterlyFinancialInformationUnaudited"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_11ae3255-e9c5-4a7f-befe-ad5341e41497" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_393475b4-217e-453b-af73-0cb781c2d9c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_11ae3255-e9c5-4a7f-befe-ad5341e41497" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_393475b4-217e-453b-af73-0cb781c2d9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="ino-20201231.xsd#QuarterlyFinancialInformationUnauditedTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_eda3c0db-f812-4497-a832-b549be779ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_b6ad9706-e1fd-46e5-b022-1bc866d7cc70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_eda3c0db-f812-4497-a832-b549be779ce1" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_b6ad9706-e1fd-46e5-b022-1bc866d7cc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#QuarterlyFinancialInformationUnauditedDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9701d56d-4e93-49d2-b81d-746e4de97aba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_64a727ac-5296-41f4-af26-070e0f3ac7ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9701d56d-4e93-49d2-b81d-746e4de97aba" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_64a727ac-5296-41f4-af26-070e0f3ac7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_508adc9b-dd8c-4f5d-9447-56eb3a8cbcd4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_64a727ac-5296-41f4-af26-070e0f3ac7ce" xlink:to="loc_srt_ProductOrServiceAxis_508adc9b-dd8c-4f5d-9447-56eb3a8cbcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_297da84a-5fe4-4bdd-a54f-7e2f868cd1d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_508adc9b-dd8c-4f5d-9447-56eb3a8cbcd4" xlink:to="loc_srt_ProductsAndServicesDomain_297da84a-5fe4-4bdd-a54f-7e2f868cd1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_357bff14-7a0e-4b55-a7a1-a25c2f968635" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_297da84a-5fe4-4bdd-a54f-7e2f868cd1d5" xlink:to="loc_us-gaap_LicenseMember_357bff14-7a0e-4b55-a7a1-a25c2f968635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_cfe1a1f1-2fb9-45c8-9f1c-5395051b6f8e" xlink:href="ino-20201231.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_297da84a-5fe4-4bdd-a54f-7e2f868cd1d5" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_cfe1a1f1-2fb9-45c8-9f1c-5395051b6f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherRevenueAffiliatedEntityMember_434ddcc1-7b7d-43f6-8889-e29f55613822" xlink:href="ino-20201231.xsd#ino_OtherRevenueAffiliatedEntityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_297da84a-5fe4-4bdd-a54f-7e2f868cd1d5" xlink:to="loc_ino_OtherRevenueAffiliatedEntityMember_434ddcc1-7b7d-43f6-8889-e29f55613822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_108e3ce0-db40-424a-81ab-b584b04393d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_64a727ac-5296-41f4-af26-070e0f3ac7ce" xlink:to="loc_us-gaap_DebtInstrumentAxis_108e3ce0-db40-424a-81ab-b584b04393d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7d8382c5-0d0f-46f3-bfcf-b252eb927711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_108e3ce0-db40-424a-81ab-b584b04393d2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7d8382c5-0d0f-46f3-bfcf-b252eb927711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_30c916f5-11e2-4729-b5d9-c5810d4d2d6e" xlink:href="ino-20201231.xsd#ino_ConvertibleBondsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d8382c5-0d0f-46f3-bfcf-b252eb927711" xlink:to="loc_ino_ConvertibleBondsMember_30c916f5-11e2-4729-b5d9-c5810d4d2d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_49ce6b64-c35b-474e-999d-510407e29592" xlink:href="ino-20201231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d8382c5-0d0f-46f3-bfcf-b252eb927711" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_49ce6b64-c35b-474e-999d-510407e29592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_64a727ac-5296-41f4-af26-070e0f3ac7ce" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2d8044d0-bfa1-476d-b7eb-1a55ec52bf51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2d8044d0-bfa1-476d-b7eb-1a55ec52bf51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4feb0cf7-75bc-47b1-ae79-ce16333b158c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4feb0cf7-75bc-47b1-ae79-ce16333b158c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a8f9027b-0234-4c6f-b541-1db5ab8b41f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a8f9027b-0234-4c6f-b541-1db5ab8b41f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_93ca316c-fc6a-4d45-9a0a-f98373109e41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_OperatingExpenses_93ca316c-fc6a-4d45-9a0a-f98373109e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f5d696b1-5bf2-4431-b94a-bfd2cfcf9322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_OperatingIncomeLoss_f5d696b1-5bf2-4431-b94a-bfd2cfcf9322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_aed9281f-0728-4491-ac91-65afc1943259" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_InterestIncomeOperating_aed9281f-0728-4491-ac91-65afc1943259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6ff22941-ed86-45b2-9602-f04f66e763c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_InterestExpense_6ff22941-ed86-45b2-9602-f04f66e763c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_28a1e8e0-c1da-4512-a610-fa5fc70d2672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_28a1e8e0-c1da-4512-a610-fa5fc70d2672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_e93f8f4b-7bb3-4892-a100-a7e94ee3552f" xlink:href="ino-20201231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_e93f8f4b-7bb3-4892-a100-a7e94ee3552f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7649ff54-8d9b-43ac-994e-0a2d01c92d23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7649ff54-8d9b-43ac-994e-0a2d01c92d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_682d7435-2318-421b-8b97-d2e2a4cef59d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_682d7435-2318-421b-8b97-d2e2a4cef59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_912c612f-f2c0-4a2f-a779-f05b4a3a2efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_912c612f-f2c0-4a2f-a779-f05b4a3a2efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_14ac310c-b405-45de-9c5e-7359c1a7d13f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_14ac310c-b405-45de-9c5e-7359c1a7d13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19cdb827-0bd6-41c5-9b8f-18ac8c42dcaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_19cdb827-0bd6-41c5-9b8f-18ac8c42dcaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dff49986-7f1a-4781-9398-7f9ecea27580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dff49986-7f1a-4781-9398-7f9ecea27580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4292d096-c44d-4041-b979-17951bfd07d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4292d096-c44d-4041-b979-17951bfd07d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d7cbae13-f464-4c42-9d76-22406d5575c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_ProfitLoss_d7cbae13-f464-4c42-9d76-22406d5575c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_059a08d0-4e53-463d-874b-5c532bc6b1ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_059a08d0-4e53-463d-874b-5c532bc6b1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_76c32f65-ea1c-4649-87cb-ba2e739d1474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_NetIncomeLoss_76c32f65-ea1c-4649-87cb-ba2e739d1474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3453af46-6299-48c1-8c7d-fa23428163e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e8411248-650b-4ea5-b531-5b9def6dcc46" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3453af46-6299-48c1-8c7d-fa23428163e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cc600f73-7790-4b1d-848c-3a856ecc91c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3453af46-6299-48c1-8c7d-fa23428163e0" xlink:to="loc_us-gaap_EarningsPerShareBasic_cc600f73-7790-4b1d-848c-3a856ecc91c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_cc683596-6c31-4759-981d-341a21ec300c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3453af46-6299-48c1-8c7d-fa23428163e0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_cc683596-6c31-4759-981d-341a21ec300c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ino-20201231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_71c578ac-28fa-48ba-ab37-fea7ca9c2b3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_7607a223-df17-4d85-9e12-ccac12f94c2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_71c578ac-28fa-48ba-ab37-fea7ca9c2b3d" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_7607a223-df17-4d85-9e12-ccac12f94c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ino-20201231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_fd631498-013a-436e-9997-e37bf1892c39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_cbf8501b-ace1-4a81-b114-520a16253015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_fd631498-013a-436e-9997-e37bf1892c39" xlink:to="loc_us-gaap_SubsequentEventTable_cbf8501b-ace1-4a81-b114-520a16253015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ea70ed77-c361-4d09-a349-f1520c23d6a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_cbf8501b-ace1-4a81-b114-520a16253015" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ea70ed77-c361-4d09-a349-f1520c23d6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2984e41f-e637-4379-a3a4-cbdedd73b338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ea70ed77-c361-4d09-a349-f1520c23d6a9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2984e41f-e637-4379-a3a4-cbdedd73b338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6d4ffdbe-5ea2-41db-96fd-ba010ffb2510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2984e41f-e637-4379-a3a4-cbdedd73b338" xlink:to="loc_us-gaap_SubsequentEventMember_6d4ffdbe-5ea2-41db-96fd-ba010ffb2510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_12c6e236-691c-4b58-9087-f3ecfb2425b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_cbf8501b-ace1-4a81-b114-520a16253015" xlink:to="loc_us-gaap_SubsequentEventLineItems_12c6e236-691c-4b58-9087-f3ecfb2425b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_329cb27d-db6e-418c-abd3-4aa93b2dc821" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_12c6e236-691c-4b58-9087-f3ecfb2425b2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_329cb27d-db6e-418c-abd3-4aa93b2dc821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4f24099a-923c-4f9a-8d16-0fdb5ee0d0ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_12c6e236-691c-4b58-9087-f3ecfb2425b2" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4f24099a-923c-4f9a-8d16-0fdb5ee0d0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_fe9bdb40-df99-45e7-af62-ab930388dc55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_12c6e236-691c-4b58-9087-f3ecfb2425b2" xlink:to="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_fe9bdb40-df99-45e7-af62-ab930388dc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ino-20201231_g1.jpg
<TEXT>
begin 644 ino-20201231_g1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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MX5.2T_$F1&."E:+"18,H1F2EQ"='9H2C_\0 '@$!  (# 0 # 0
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (G*\,Z \
MHB\<H#RB\<KR@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(O'* \HB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M20"N8;*1@+W,5>$/)IZTA<#(S-'9@**U!S#-&ZR#0!$1 $1$ 1$0!$1 $1$
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M_AM'>QMH'<2*-I!Z@(2%PGKR-T2,SA(/RM#CNAM)D]*9.3'9*+D7<CIVP9_
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/B
M:EU#3Q&.OY;(SQU<?C*5K(7K,I,$5>G2@.S:GD(G81"&"(Y#)W9A$7=W9F5*
MO=3O4-Y<OJ7.Y/!:ZS.#PEW*6Y\1B*L.-:#'XQY2&C7%K&/EGZAKC&4KRR&;
MS%([NW+"TXW?:]I1M*[=5M$4+'1E]P)I:UD8C9I(=-XXH)<H4C-R01WYI:F.
M;EQ:Q#+= >L(YQ:HP@,X_P DMWZ_LGZ@_P %A_\ =:?DEN_7]D_4'^"P_P#N
MM8.(@,X_R2W?K^R?J#_!8?\ W6GY);OU_9/U!_@L/_NM8.(@,X_R2W?K^R?J
M#_!8?_=:?DEN_7]D_4/^"P_^ZU@XN6:#T1D=39O$:=Q$/CY3.9&IBZ$7!.Q6
MKLP01.?2SDT8.?B2N+.XQ 9,S\<("V/W.VLMTM:8#46N-PM6YC.XRY;BPVEJ
M5\:$<'%!SDS&58:M."21Y+)U\?5<S9HWIY!WC-IHC"9U=2[#[18_06C=-Z.Q
M;-ZGI[$T\<TO2P%;GAB;UR]*+.[-/?ME/<GX?CQ9SZ>!X9NVD 1$0!$1 %AS
MW@6O\SI;9O7NH-/9"?$YK%XB*QC\C6:)YZLSY&E$\D;31RQ.[QR&#L<9CP3^
M2S&6!7>@?$'N9]@X?PKCT!5'_)+=^O[)^H/\%A_]UI^26[]?V3]0?X+#_P"Z
MU@XB SC_ "2W?K^R?J#_  6'_P!UI^26[]?V3]0?X+#_ .ZU@XB SC_)+=^O
M[)^H/\%A_P#=:?DEN_7]D_4'^"P_^ZU@XB NF=T7O1JK7>U,^<UAF[>?RPZL
MS5$;]T:XS-4KUL8<$#-6@KQ=$932N/SOJY-^2?RXE$4-O<8_$I8^W?4'[TPZ
MF20!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1%XY0'E%A'V@^\0VEVU>:OGM55+>6AZA/ X%QS.8&06
M?YS8KU#**A([\-QD)ZG'6)/P#]30@;[]_)JK)^/4V]TO3TU6)G"+*Y^0,QEW
M%^KYZ-"#P\73DZ7'B(YLJ &+EXL@ET,!:+RF6JT8)+5VS7IUHFZI;%J:.O!&
M+>;E)+*01@S-[W(F91P[U][7LGHPYJH:E?563A=Q*CI. LM&)LS^4F69XL*+
ML3>')''D);$1^4D#>?%03=OM%Z\UY8.SK'5N=U 1D1>!>OR_!\/6[.0U<5!X
M.+IQN[,_A5*<$7+<]'/+KIAD!/GO+W]>L+[RU]"Z1P^G:Y,0CD<_+-G<IQSR
M,L52L=#&U)6;@7"=\M&7M/Y.X],5^\';5W5UWXH:FUSG[=.9RZ\95N'B\20G
MYO%)CL9ZI5GB_I0LQSL/R<<+%Q$!_ QB/N%F_69F_P!"_M$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'\D+/[V9_UVY7=&U'
M:*UYH4V/2&KL_I\&+K>KC\C.&.D/EW<IL9(4F.F)^7Y*6J9<$3<^T_/3*(":
M_9[OS]T<(\,&JL3I_6=$/*25XI<#FB%FZ1Z;U+UC&ET^1.TN&*25V=BL!RYC
M+-LSWU>SFI/!@SUC*:(O2O''TYNE)9QOB'PW_.N+&W##$)<\SWXZ4(1\'(8<
MDP4ZD0&Q@T7N#@=24H\CI[,XO.4)18X[F)OULA6,2YZ7::K+*'GP_'M-[N%S
M!:Z/0FY&HM+7!R&FL[F-/WA?EK>&R5O&SN_RL9U)HGD$F;I,).L#'V3$A=V4
MMNPW??;GZ;\"KJ^GC=>8\'83GL-'A,YX;-QY7Z%8J$IMPSL4^+(S]II)'(FD
M "W>BC&[/O>V[.Z[:"M8S1Z-R\K1B6-U;X&/A>8N&<*^7":7$S Y\M$1VJ\I
MCT.=>(R\)I,JUF.:,)89 EBD%CCEB(9(Y )N1,#!W$A)O-B%W9V\V= ?NB(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"HM=YM\?>YOV<J_@/$J]*J+7>;?'WN;]
MG*OX#Q* P41$0!$1 %(KW2OTQ>V?]OU=_![JY1U*17NE?IB]L_[?J[^#W5R
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M#K/_ .(9/^\98W@C_ ^F?ZEC?[J(1%X6BFTE [M%9-KV\VZMEG%V_FA:O@Y
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MO$W#&>.MWL+9=N?,^9@R]<B9O-@&")BXX<AY<FVW1O;AX'R6ED6:IIN_=Y>
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M!+)XNU1LV:-ZO+4NTK$U2Y5F'IFJVZTA0V*\H_H9(9@.,Q^0A=O/WN!Z*(B
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MBO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_ +?J[^#W5R N]HB( B(@"(B (B(
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MFFLSJ;(NXB5;#T9K?@N3.XO:F 6KTXW82+Q;<T$3"+DYLS.[3;=G;T>+<S4
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M2]R(JV3B;R8J]Z$V$&+I8#,I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 5-7OB^TH6N-U;& I3
MN>!T%"6#K"),\5C-2$TV=NMTN[.XS-!C(^7+I''F8]/K!BUH/MI]H:':[;74
M^KR.)K]2B=3!Q2L[A8SU]GJXF(@'ASC"T8V)P8@ZJT$S-(#\$U!VU<FL2RV+
M$LD]BQ+)8L3RDYRSV)C*6:>4W\SEFE,Y)#?S(R<G\W0'X(B( B(@"(O!$S,[
MOY,S<N_U&0$JW<^]FUM>;L5<M>KM-@]!10:DN^(+E#)EO&>/3U5_9<7D>Y%-
MD@$N&<,5(_//2)7.U&?W4/9K+;K:7$27JQ5\_J_IU1F0D%FE@&]$/P31D9O,
M2JXIJQ31'[<-N>U&7F+NI,$ 1$0!$1 $1$ 6!7>@?$'N9]@X?PKCUGJL"N]
M^(/<S[!P_A7'H"C(B(@"(B (B("W]W&/Q*6/MWU!^],.IDE#;W&/Q*6/MWU!
M^],.IDD 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 %^4TH )&9"  +F9D[" B+=1$1/P(B(L[N3NS,S/R[-RL,>UGV]
MMO=GJ?\ ]D62]<SLT1'C]+XKIM9FV_3U <T8OX6,J%RWYMR,E>$FY&OZQ+Q$
M54WM@=Y7N)NZ5K'6[;:=TA(?$6EL/)+'!8A%WZ/AN\[C8R\I-P\D1^!CF)A\
M.@)#XA@3U]KOOF-#:&*UA=%1AKO4L?BQ%8JSC'I?&S@[AQ:R<9%)D91/_P"U
M\5'+"0L?BWZQ, R5G^T7VO=PMU+Q6]9ZAM7JPRO)3PM;BE@L>W/L!4QE?IA(
MXV\O6[?K5Z3WRVI/+C&AFX\EY0!$1 $1$ 1$0!$1 $1$ 1?8P&GK^5MQT,51
MN9.]+_0J6/JSW;4GUPKUHY)79OE?IX9O-W9F=2+[.=T=OAJYXY9=,Q:3QTG2
M_P (:KO04#<7X<O#Q-9[F:ZV%V(6LT*D$G/2-AG8^D"-!>')F\W=F;Z[\*S_
M +4]P/IR!HIM;ZYS63E9F>2EIJK3Q%5S9V?I*YD8<M:DA=N1)HH:DWN<)@?R
M4F^U?=R[*Z.\(\1H#"S68O,;N:"7/W.>..7GS,MUV\_:9@81$GY 1X9F I%[
M?;2ZJU9+X&E]-9[44C$P'\#8F]D8XB?CRGGJP205F\VY*Q)&+<MR[+/G;WN?
MM]L^P%)IFCIZ(_?+J/,5*CASQQUUJ+9*XWOY]FL7''!,Q>R]TVG3AKQ1P5XH
MH((@:.*&&,8HH@%N!".,&$  6\F$19F;R9F7LH"L;M[Z/_FY/#DU9N+C*?T'
MBU-.8>UD/J]?A9+*3XYFX?R!SQ3]7O=AXZ7S1T3W%^T&/$7R][5FH)!XY\?*
MPXZ$_)^>J+&U8)&Y?AVZ; \<<>?+J:%$!@=HWNQMAL'TO4VSP%HAX=BS;W]1
MOU-^BXS]S) +\^? "PL_'2+,(LV4NFMF-(86,8L1I73N,C#IZ0H87'51'HXZ
M.&@K!QT<>SQ[ODX79B(#\XHA 6 !$!'R819A%F^HS,S,W[3+]$1 $1$ 1$0!
M$1 $1$ 1$0'AVY\G]RX;G-N=/9,#CR6"P^0"1G8PNXRE:$V?S=B::$V?E_/S
M^5<S1 88ZR[N_9#/,?PAMCI,3D^CFQF/;!V3?EBY*UA#Q]ERY;CK>7JZ>1YZ
M7=GQ0UIW(VR628WQM;4FG3+GH;'Y^S=@CYZ?^KS39*4^.'XYL?HGZG?R9I?4
M0%;G7_H_8.TAZ5W(D!V;F.KJ+!!.QOS]"5_&6ZSPLW].V.L._#-T>;DV#NX/
M<K;X81CDITM-ZGB#DN<#G'&5Q^1O5LU2P\KF_DQ!%XK"_/!D+=3W*$0&O=W.
M[-.X6B_$+56BM2X.&)^#N7,3;^#A?ZGPI#'+CG?Y>!M._'R+H\3$OH79_P!9
MV?\ T+9)+%_=+L6;4ZS:7YHM!Z<NS2L77<BQT5#(=1>^1K^/:K;:7_[IXW7Q
MY=7" H'HK7NZ_<.;<Y)Y9](ZCU)I:<NMXZ=N2OJ#$@_OCC ;4=?+@W/LD<V6
MMOT\<!U,_7%MO+W*V\NF_$FP5;$ZYI [OSA;\&/R0QL+D\DF,S4M(3XXZ1BH
MW;UB0O(('Y0$1:+G&O=LM2:5M^HZFP&8T_;ZG!H,QCK6/,R'Z(8O68HQE<?T
M7A$?'RK@Z (B( B(@"(B (B( NS-I]YM5Z%RH9O2&?R6G\F#AU6,=/X8V C+
MJ&&[6-I*E^OSSU5KL$]<A(A*,F)V?K-$!9T[(_?DXV^]3";MX\<3;+B(=7X>
M CQ$A]7 GEL6QR6L;R+\%9I>NUNMG*2"G"[D$_NE]4XW-T*N5P]^GE,9=B::
MI?H6(K=2S$[NW7#/"9QFS$SB_23N)"X%P0NS:XY9/]F7MB:^VCR/KNC<P]>K
M-,,^0P-X3MX#*$PL#O=Q[2P\2E&S1O;IS5;K",;#9%HP9@+^**+#L8]ZYH+=
M)JF&RTL>CM:RB(_ V1F?X.R<O'!O@\L8QU[!.7#CC[;ULDXES#!:"*:4)3N4
M!Y1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 5%KO-OC[W-^SE7\!XE7I51:[S;X^]S?LY5_ >)0&"
MB(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%WM$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD^S.DOQDQ
MRIC( B(@"(B (B( B(@"(B +GFV.YN<T=G\7J;3E^;&YG$6H[=.U"1-[0/\
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M-F$;T?/W?R_S+^'I+F94_P"7\F7Y%2^L_P#+^\JUK*^9RDAJ_IN^WR,-MS<
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M'4R2 (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M4TDAU9"DZ:&0=H6C]7NE)4M1H#RB(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M[3W1WQ":*_NQ^&;R CD[X?N[G/U[=_1-%RE_H^N\16%N"C"-A?5%.$1Y>0&
M1S<4?]$#C*,#F%^22MBSK9%SP!*!QR ,D<@D$D9BQ 8&SB0&),XD)"[B0NSL
M[.[.SLJ>?>I=WH6UN;+5^E*9?S/L[99GKPQ_.]*Y>P9<XLNGD8\5;+@\1([
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M"(B (B( B(@(GN^J^(3.?9[2GX<JJF@KE_?5?$)G/L]I3\.55300!$1 $1$
M5X;NI_I?MN/L?E_QDS*H\J\-W4_TOVW'V/R_XR9E 2%(B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B\.@(/>_;[9TFVNU;:3PEOU?56Y$EC"P
MG&7$U#344;/J+(!P[$,L\4L&'K$W#B>1EL@7748#I-[>:6/*WH:PL[0#Q)9,
M?T$(^3LS_P!,;\ #?5?GAV%UFYWNG:BDW3WVU;?@M>-I_2TWS&Z<C&1S@"E@
MCDBR-J/R$'/(YLLC:*1AZG@*K7(Y JQFNO=J-.1XG&0-89X[>3%YI'?V3 &
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MTK$5FK,<-B NN.4/HA+W.W'T+B[<B0DSB0NXDSB_#Y[[-[Q4]11M4L=%7+Q
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B+^3-A9R)V869W=W?AF9O-W=W\F
M9F\W=_)F0$,/?9=I-])[;P:,QTXQYC7UHJ5EA?B6OIJBS3Y:4>'Y$KL[TL8/
M4'25>U>(3&6$.:AZSL[Q_M'EN;NUJ3+U[+S8+$RMIS38B?5".,Q3E%-:CZ>
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M-F5PDK9+5KA(_P ]O,1#)5PIL('6Q11Q3S,[RY3ERCI5(=T1 $1$ 1$0!$1
M%_)&PL[D[,S-R[N_#,S>]W=_)F7;6S&QVJ]PLY6T[I#"W,SD[!!UC7C=JU*
MBX*YDKA<5L?3C\W.Q9DC%W;PXFDF*.([5/8?[H326W?JFH=:^IZRUD'1-$$]
M=CT[@IV=C#X.I6&+U^["3,XY.\'(&S'3JU#%I" AG[%_=(:YW+]6S>I1GT5H
MV3ID&W<A9L]EHG\_^2<7,/,$),[<9')#%"[.SU:UUF/HM-]G/LHZ%VJQ0XO1
MF#@H=<<87LG-^:LSE3#AWFR61D;QIB,^9/!#P:<)/TU:L$0A&.1;,O* (B(
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MV[CK836A-+9O8=GAK874\SLYF3\L$>+S,Q>37>L*-HR_-\<9D5T*I>KM(Y7
M9.[A<WCK>)RV.G*M?QUZ$H+=2<>'>.6,O=R+B8&+E'+&02Q&<9B3@<=1$0!$
M1 $1$!DGV5^U1JG:+5,&IM,6.6+PX,QB)R+X.SN-8^LZ-T&YZ2;DCJ7(V:Q2
MG?Q(G<"EAENX=ESM1:7W;TI5U5IB<_",O5LEC+/0.1PN2  .?'7X@(A:0&,3
MAFC<H+4!QSP&XGP.O\64G9&[6>I=GM5U]28"4IJLKQU\[A))"&EG,:Q.YUIQ
M\VCLP]12T+C"\E6QP_MP23PR@7[$72/9Y[06F]S=*X[5NE[C6<?>C89H#<6N
M8R\  ]O%Y&%G?P+M,RZ) Y<)!Z)X#EKRQ2GW<@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B *BUWFWQ][F_9RK^ \2KTJHM
M=YM\?>YOV<J_@/$H#!1$1 $1$ 4BO=*_3%[9_P!OU=_![JY1U*17NE?IB]L_
M[?J[^#W5R N]HB( B(@"(B (B( B(@"(B (B( B(@(J.^B^('4GV9TE^,F.5
M,97.>^B^('4GV9TE^,F.5,9 $1$ 1$0!7:>Z.^(317]V/PS>5)97:>Z.^(31
M7]V/PS>0$DZ(B *.KO&.PE0WHTJWJ35J6ML$$L^F\K( #X[.SG-@K\W#'\'9
M F9P-R=J5QHK8LX-8BFD51 :XG4>F\AA\A>Q.5IV,=D\;;GHY"A;C>*S4MUI
M'BG@FC?S$XS%V^42;@P<@(2?XJMA=[CW=_S:XZQN7HRESJ[#4^<]C*PLQZEQ
M%4>?6(8A9O$S6,AZBC\VDOT0>HWBV(*415/?Y?K?K_7^1V^1 $1$ 1$0!$1
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MC=@?R<H9QXZ@+CD)8RZ989&\XY0 V\Q95$MR=L,GMUK#-:+S/)OC[)-3M.W
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MK@W)S6)GBKPQB4LTL<8$33H]GKN/[DG@7MS=0QUH_(SP&F)'FFZ?)_"MYJS
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M;S$XS$3 F\Q)F=O-E?'[!G:-#=':[3&IY) ++-3'%:AC N7BSN,8:M\^GEW
M+I .1@!W=QKVXA(B(2=4,U.7W&_:2?3^N,KM[D+#MB]:UVN8H"=NB#4F*AD-
MQC]SC\)XII@E]_5+CJ;,P\F1 6Q41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MFL:!U!.9X&V[G*6*M.Q2S:>OR%R7BUQ8I<?.9%ZY2;S)[->RS1G( B(@"(B
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MMVY AP)LF4 P4*$,UJY9DCKP5JL1SV;5F8ACAK5H(1*6::60PCBAB$CDD(0
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M?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MTM!.3%)A")V<;!GC!<VFH11V9UK=:]B2&2.:&22&:(PEBEB,HY8I8R8XY8I
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M?\9,RJ/*O#=U/]+]MQ]C\O\ C)F4!(4B(@"(B (B( B(@"(B (B( B(@"(B
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MEM"S@]!I#YDL::R9R25' 2?J=L9>&U2D86Z(8),<W5U3=(@3?(B( B(@"(B
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M&B(@"(B +MG8W>G.[>:JP^L--V/5\IA[(S )]3U[E<O9MXZZ D+RT[T#G7L
MQ"3";21&$T<<@]3(@-@UV;.T'@=T-'8C66GI'>GDHB&Q5D?\TXS(UW\*_C+8
M\"[6*=AB#JZ6">)XK4/5!/$9=[*EUW6';?+:?6@XG-V^C0VK9H:F8>>4A@PN
M1?B*AJ .7\...-^FGE'?I%Z$C63/JH1@=T*.02%B$F(29B$A=B$A)N6)G;R=
MG;S9V\G;W(#^T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MPG%[QE%]FG_6NZ?1[-%?3O(^Q86F[=K<W1U3IPUF5IM5XFJ#\8RU*;L6<J1
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M;V2R-R4I9I781=R,S)V".(1CAB$8HHXX8P 9U-8T:&3C. @\2*>,HYP(&Z"
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MC",4DDDDD6WQ<6JBN%--<*JJHJ%==<5"$(16RC&*22279)!$1>X] 1$0!$1
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M.[.6G=S=.3:>U!"0^93XW)P,#7\1>Z'".Y3D)G;Y>FQ7/YS:AYBE;Z @J/\
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M"VEQ5:_9]8U!HTFTSEW(W*:>"H'.%O2=7).5G%/7BFD<B\6Y5M2\BQL R=H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M%FM/&[C)#/!*(2Q2 [.Q 8B3?473FJMO&-RLXX>#=^J2KRS"3^;N4+_H2_\
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MI8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MNP+.5I8X':)A<F;Z)V;RX^5F_P#-OD6(>Z/:BITRDKT'^$+;.X\1DWJL1?\
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M&9+=_2<2,8QG)^M^/TJM6_64HJNZ3;WM[(V[#U>VK9-\\.GNRZ[+Y/NOXI?
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M.<A=I(-,8UWBJ>;LSL^1R'KMTNEW ZHX]_(QD9 3<PPA& QQB(1@(@ "S"(
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M1R%'&4</B&T;.@.^41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM(=HPB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M#<N#SU)2B>6%W87.O8%AL5I'9O%KRQ2<,Q+A*GT[]3LU/B=3X3<S'0,-#4L
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M16)A;\]Y&P9V\I==^D'=[F0GLV.7%G9I&'AN&9N^$ 1$0!$1 $1$ 1$0!$1
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M#JG?C6?P1I^QX9]-F^[4H7YX<!-G*S+_ /HZXFPNWND.-W\N5;%[LK8QMO\
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M=.34E&#PL)N%'/FXF'^AQ9ZN\,>H(1\FX>Q--6RA-R7SW(R]+B+" @1&(B(
MB(@"\$S.SL_FSMP[?59>40%U[NG^TLVXNTV*BN6'FS^CGCTMF6D)GGD"E7B?
M$7R]Q&%W&%"+SDW,MRK=%SDDBD-Y,E3&[G[M*-H/=>GA[UCP<#KT(M.W7(G:
M*#+=9R:>M&WT+,]V0\:YO_0QR;R$0Q@?-SE $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!1Z]YWVE'VTVESUVG9]7S^H8STSIXQ(6FANY2&6.Q?A9_?)C*
M#6KL;\$(V(H.L7!W92%*G;WSW:3;6>Z'S+T;/BX7;Z&?$L(._A2:AME#+G9G
MX]F0ZSP4\9SR_@R4[("P$<W4!$"S<-Q_[_YW\W_;1$0!$1 $1$!^L$$DIA%%
M&<LLIC'%%&+G)++(3!''&#<N1R&[  LW)$[,WFZOD=@[LYQ[7;7Z8TQ)%&&6
M>F&4U$<;-\]SV3 +.0%S]\H5#(<?#([-UP5(B8(V?H&K[W1/9K?7V[..R=V#
MQ=/Z' =1Y%S'F.?(QD4>!I>8N+N60XR$@NS]5?'2QOTO*!-=$9 >41$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 %@5WH'Q![F?8.'\*X]9ZK KO0/B#W,^P</X
M5QZ HR(B( B(@"(B M_=QC\2EC[=]0?O3#J9)0V]QC\2EC[=]0?O3#J9) $1
M$ 1$0!$1 $1$ 1$0!$1 $1$!@+WF7:"_F<[/:GRE>;PLOF(@TQ@NEV:3X1S3
M20231]3.W51QH7\A\CNU3I%V,@5&@6X9F^HIXN_<WZ^%M;8#;ZI-U5=)XX<M
ME0%_)LUG08ZT)MY/UU</'7L>;$W1E!Z78NME \@"(B (B( IM.Y![-_S3;@W
M]=9"LQXK0E8&H'(#O'-J7*A+'6\)W9A(\;CAM6IN"<H9+6/+IXE8AA*=_K._
MUF9W=_K,S>]W]S-[W]S<J]-W<'9V_F:[2:8P]F 8<WDZS:AU"WDYCE<P 62J
MR$W/46-JO6QSNQ$#G5,XWZ39 9UHB( B(@"(B (B( B(@"(B (B( B(@"(B
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M>;Z:]:P7OZ6I95L?;,^ER]7BL1CQXKJ\N@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( J+7>;?'WN;]G*OX#Q*O2JBUWFWQ][F_9RK^ \2@,%$1$
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0'AU4_[P;,O:WGUR7+N,5O$519_+I:IIW#UR9N>>&*2*0_J.1.3,S$S*V
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M>@*,B(B (B( B(@+?W<8_$I8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1
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M;A8;&I,G\!X@R;VO@?"</;G'^E&UEY[%=Q?VO^2V-O8D%3]( B(@"(B (B(
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M3;RU*[GB[%75.(C)Q\Z>0?U#+A&+>UTUKL-"8R?EG+)"S.W#L@+$J(B (B(
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M>,V?GV"8?[W#^3J^GOAV/]L]QXW'66B\%F;'0X1Y0Z85<W7;EWXK9JGZOE(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MC'XE+'V[Z@_>F'4R2AM[C'XE+'V[Z@_>F'4R2 (B( B(@"(B (B( B(@"(B
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M^MT..!PM*C/)&W SW0B8[]EO)GXL73GF;JY)A-F=W=N7[J1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0'Y3PA*!QR ,D<@D$D9BQ@8&SB8&),XD)"[
ML0NSL[.[.SMY*@!VN-E9-O-RM9:0<3&MBLY<?%D?T4N%N2/=P\CEPS&?P=8K
MQS$+,/K$<S,S<<-L!%5O[^W9=Z.J-':\K1-X&?QMK3V3,1XZ,CA3&WCCD+]$
M=W'W;,0-^A#$ES]$R K_ *(B (B( L_>["WD;16]>C+DTK14<Y<?2E\G=V'P
MM0.%.HY\>72.4^#RY+@09GD)^!6 2_>K<EKRQ6(#**>O+'/!*#N)QS0F,D4@
M$/F)!((D),[.+LSL[.R V1*+I_L_;H1:UT/I35D3L[9_ XW)2=+,S#8L5HRM
M1LS>0^'9\6/IX9QZ>'$79V;N! $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 5%KO-OC[W-^SE7\!XE7I51:[S;X^]S?LY5_ >)0&"B(B (B( I%>Z5^F+
MVS_M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%WM$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD^S.DOQDQRIC( B(@"(B *[3W
M1WQ":*_NQ^&;RI+*[3W1WQ":*_NQ^&;R DG1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!8']OWL18G>K2)8XG@HZJQ'BV]+9J1B%JUP@XDQ]XHQ.23$Y%
MF&.U'T2/!(,-V&,IJX@>>"(#7*:ST;E=.Y;(X+.4+&+S&)M2TLCC[(B,]2U"
M_!Q'TD0&WN*.6,SBFB()83.,Q)^-*WEWL7=Z-N/AY-=Z2IL^N\#2Z;-. !$]
M4X>L[F]0N.&DRU",I),;(7)V8V?&D7#U7AJ(21D!$!B0&!$!@8N!@8NXD!@3
M,0F),XD),Q"3.SLSL@/X1$0!$1 $1$!*CW87> 6-HM1-@L_8DDV]U%<#X4!^
MN5]/Y&1AACSU0&=W:#@8XLQ7C%WFJB-J,#LU0CFN9X[(P7*\%NK-%8JVH8K%
M:Q"8R0SP3@,L,T4@.XR12QD)QF+N)"3$SNSLM;VK"W<^=X@V(FI;2:VOB&*L
MFT&B,Q;F=FH7)I/9TU:EDY$:=LS_ .1I"(!K6><=P4=FH-<"STB(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@(GN^J^(3.?9[2GX<JJF@KE_?5?$)G/L]I3\.55300!$1 $1$ 5
MX;NI_I?MN/L?E_QDS*H\J\-W4_TOVW'V/R_XR9E 2%(B( B(@"(B (B( B(@
M*WO?VYTGN;;8W]!'6U%>^I[<LF+K/Y]7OXA;RZ?_ +Y_<O7[A'<*FV1W*TH7
M#7I*>FM01/SPYUHY<OCIA9N.2\*0X"X9_9:;EV]OE<-[^Q^-8;>M\GS-9G\*
M5E%KW;^__P#,^[1>C;]FPT.'SS/H[-N<GAQ^IZ@B**C*9/R(M4SP8FT1./+P
M1S1 X/,Y*W^D:"\W@!8]:WL>)D9,$N\K,?-MR>1+U<_*<$O5R1!>5GJCBB5L
MOLJVJIM_=C;C5U;OX*//N_DB^,B(J@$Z!$1 $1$!XX6&._?=\;0[D-))J71F
M-^$9&?IS>'\7!9J.1^7:3U_%G6.SP3]3PWAMUI"9O&@D9N%F>B]^G:IDX=BN
MQ,B[&MCVLHMG5-?[4'%[?%;[/U/+F8-.1!U7TUW5OO"V$;(O_9DFBLUOAW#&
M7I^-<VQUM%<$>HXL)K('KS./+N,4><Q=:2(I&%F$/6,3$$AE[<U<&<E$1O/V
M;MS]MGD^;K166QE*(G$LL$(9+".S<<'\,8X[5*,2Y;I\::%W=V!Q:3D6OM\+
M^)8A,7$Q8Q)G8A)F(29VX=G%^6=G;WL[.ILX;]H;6L/EAF1IU*I=_-2HR-O@
MKZH\C_G64V2?JR(>)/ K1<[FE5">%:^SJ?/6G\77-\R_"%E:^1KKGM8RX .+
MB R#^@\Q<FX9^7XY?GV2]Y?1,_UF]2CIZSC[<63PMZUCLA7=RKW\9;GI78'?
MAW\*U5DBL1L7#=3"8L3-P7+,KI>_7=8;+Z_:>:UI:+3>4FZR^%]'O%@+;3$W
MYXDK00GBK<S%U$[W<?8:0B(Y6,GY:&+>[N+MP<#XUO;W4^/UA4#J*+%Y@0P&
M;\-F(FB&UXDV(N3<,(-(9XN.0R<G" &X4^<.^/&@:@E7DSEI]LERRAF07DRW
M[I7PYJN79[-W>3O\"%-8\$M>TYNW3[_I<(^\E7)\ZV[?5R<;-^G:MS,9]D.]
MUWTT(<5?)Y.GKW#QNPG2U37_ .41C;WM5SU%J]X)'X9F+(AE8Q%G8(1=^MIF
M=A^_2VHU&4%+6-7,;?Y*3H!Y\C 65T^<I<"[#EL8$L]4.KJ(I<GCZ56*/IZ[
M;ERS5EMS-O\ 6>AK3T->:1SFFYV?I8LOCY8:TWM.'55R0-)C[L;FS@,U.W/"
M;L[!(2Z]*OC;C>R0@3M[G9G;E_KM[O\ R;WK(ZWX0\-ZQ#SJJ:J96+>.5ILX
M51E^THP4\6S=]7+RG)_K=F>;3/%OB'2)^3G5VVQ@]I0R83L:VZ;;OEOAVZ+F
MY5\.YL*-";C8#5&/CRNF\SC,[CI6;P[N)O5[]9W=N>'EKR2")<>?23B3?*S+
MFC+7;:.NZDTG?#+Z0S^9T[D0XZ;N!R=K'2F/4Q/'.5.6,;$!.+>)7L-+!(+,
M,D1CRRE/V0[[[=W2CP5=98O$;@8T' 99Y6^9_4#1MRQ&-^A7FQTTC,[FX3XA
MGD<1!K%<7<V@?B3V;]2HYIZ;DTYT.K55NV-D?**<I2HF]N\G;5OZ1)IX;\>-
M*S-HY*EBSZ;R3\VO?UWV2LC^')+\2WTJLOI*6I.B/:?%]1?/9-4Y'H]GIXKQ
MXBJY?TW5^:F8?T/#O\O"D]V&[Y;9/6?@5LEFYM"96;H%Z6L8PQ]-I2?I\,,[
M$<V&]_'!6+E;JZF81<N6:!3TB'<Z#4.ZVA<%B+5?)UL;H."[!+1L!9@DN:CS
MN2$HPDB<H7YJ8?'S>(!D)1SAR[,/G2?VC]!U'3^'LO$RL+*HR,N_#Q:*Y43W
MNLEETRY*6DXW<\82C'RW+F;26^YC?'[7L7)X0SHXM]=_TJ[ HAY4U-\SS*;7
M%Q7O1;KIL]V23W6VWH0Y;%X-[-VSDC'YW4%H(2=FX>Q.SO([?+S'"S,[^[B9
MF;GEV:5_NF<H63[7&C<1"_5'IK0^M]071'AV"6Y0JX>!S\GX<(\I$[<]+MZR
M#L_$G!8&X2G5TU@N;!B$./IRVKTWN9S 'FLR?*[\DQ#&WF3MT"S.3\/GCZ,O
MIFQJ??7=?<:S&;_!>@PP8D3NX1GJ_4F,NPQ!R724E>GHEH&(1(H83<'*,+##
M+=KPN\+H\$>&%NG7I1S'IU^3J<EM[VIZKR5RK;727T964X49)[2CCPG]YIZ7
MX&<)_1'BQE':5+\VQ].N18MY+IT?EU)PZ?JP?J7=T1%6TMR$1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 5;SONM$/6U3HS4HQNP9/"W</-+\CS8
MNVUN$&?ZK19*4N/K\JR&HJN^$VH/4.TDN7K1N=O1V9HY[V&9S+'2!/BLG'U/
M]#%'#?BR$O'F_P '@S/YNSP/[3'"\M6X)URB$'.W'QX9]22WEO@VPR;.7YNB
M%T4EU?-LNK(Z\5]+>7H.?&*WG37'*AMU?][3C;/9=VW5&Q;+J]]EWV*ME.[T
MMU/YL+.7[3-S^UY?*L"]O,]5JZOPV4O^=&MJG&9*][/B.].OF8+5OV'X8^8
ME]E_HOH7?S69H6?G4OG_ -5)_J%Q_G4=E6/Q&,?>Y]0\?5<O+_.[_P"=?;^X
MU:+#D\1<F7VK/_1O$36W-&&VN62Y7MTYG*._7JX1W70JSP!+;Z3/]7R=M_\
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MY<!HXCJTF?WE#/G;U4+U@'XZ3*KC\;)TD0Q2QD(RJQQ#"$8#'& A& L(  L
M"(MP(B(LPL+-Y,S,S,WN;A?JJ[\4>T#K6=S0Q/+TRE]O)^MR.7X/(LBMFO25
M-5,E\2=>&?!/1M/4965O,M7=W)1JW^*JCW_"R=B?P,?]C^ROMYMO4&IHG2>(
MP(L/2=J" K&3G\NERMY:Z=G*6S)O(CLVY2)N&=W9F9=_\+RBA++S+LBR5M]M
MEULWO.RV<K+)/XRG-N3?XLENC'KJ@JZH0KA'I&%<8PA%?!1BDE^2"(B\Q^P1
M%X=^//W?70'E%B/OAV[MH]NF./5>N\#3O@'6V&J6QRN=-N'Z.,/BVMWP&1_9
M"::"&NQ?1S"+$[1"[U^D XN+QJFVV@[V9E^ABS.JK7P3CQ\GXE#$TAM9&XW/
M O#-<Q+\/U-*_3TENO#_ (=ZUJG*\/3LB=<NUUD511MZM77.NN6WPC*4O@FS
M6]7XOTS 3^E9E-<H]ZU+GLW^'EPYIKX;M)?%HL8\J*?OA.U;@-O]A]SZGS0X
MRIJO.Z3R>FL'BVO0-EY+>I:_P,]BO3$WLB5.K?FO!,4;1@\ D[^YGKC[Q]XW
MOUN"TT-[65S3F-G\BQFCA/3L71U.3 ^0JROFB'SZ#ZLGTRQLP3"8\\PM=JVW
MZO)2QY3G9NV'FR61GEE*>P9$3A!X\TA')))*969I'D-R<N@G=W)W4]\'^SID
M4WX^7J>93'R+JKGBX]<K?,\N<9^79=9Y<8J3CRR4*[$T^DB-5XS8>;EQT_3Z
M9VSM4U*Z<E!5PC"4IS4(\[?1;1<I0]YQ374^#W?.;/&;\[-VXF=BCW(TE /0
M["[-<RU>B7#NSLS-'9+EN/,>6Y9WY;:J+4\=CVK/-O-M"%<W"7^:MMV;$QE&
M_AQ:PPTLX]0>?MP!(#C[I&)XR]DW6V'6,]IN"^FZ5/IS2Q;XOX[1NBU^6\Y;
M?F21PR_J[%^U%_FT]_ZD$1%6(V8(B( B(@"(B (B( B(@"(B *O'W[O9J]=Q
M6GMTL;!^:,.;:=U*X-YRXR[-XF&NFS-[Z.0.Q3,W9W./)0L9L%6,7L.+K'>C
M:O&ZXTGJ+2.6!CQ^H<1=Q<[\,Y0O9A((;</+.PV:5CPK=65FZHK$$4H\$#.@
M-=ZBYMN5M_D=)ZAS>F<O&\63P.3N8JZ+BX,\U.8HGE 7=^(YQ89XGY)GBD!V
M(F=G?A* (B( B(@.].S-OA<VWU[IC6M+K(L%DHY[4,?/-O&3@=3+4^&=NKUG
M'6+,0B[M\\("9Q(1)K_^E]24LSC,=E\;.%K'96C4R5"S&_,=BE>KQVJLX/\
M*$T$H2"_RB3+7&*W%W(W:5;5.WEO0U^?JR^@9HH:HF7)SZ;R93RXTX^KAR&A
M9BN8^00<FKPQT6/H:Q"+@37(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MXG;G_E7-''A<5RWO<6R&0KN?'F,;&?+,+NU"-FX9FY=_KN_+O]=W^5W][O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MP.0 >2LUA'(,W+6_#FH6N3T=K#)Z?RN/SF%NSX[+8JW#>Q]ZL?1/5M0$QQR
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M+HO*AY-'X.ZY1E^#A39'Y]M\[I'@'J^8U/4LI8\'U<'/GGU^%=3Y7_M6Q?\
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M1$1 $1$ 4BO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B
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M(=FJ&<Q(R/QSX>0Q7-IX1;E_%M8NF[\.S1^;<UA-:T\QIBVV.U?I[*Z>ND1
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MNY.7#F%Y.-%M;3M]^7QV?V%_1Z[>CDT$1%#9G@B(@"(B (B( B(@"(B (B(
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M:G ?<-C,VQGR<H=7)^$5IX1,B((Q<G62J(H@S<^_)L=N1=;?;+[5EUD[9O\
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MFM-9G'UP?GA[5BA.%1WX9W]FUX1>3/[O<ZUYM:5CC V]Q@)-^L0L[(#]D1$
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MQ1P0011PP0Q ,<4,,0,$<48"S"$<8"(  LPB+,S,S,O91%S_ &R80B(@"(B
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MM6@!N AKUXQBAB!O/@(XP$1;E_)F7OHBYO-[]7U;[LF$(B+X 1$0!$1 $1$
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MVMR\CK/5&H-69:0I,CJ++WLM9Y)R:%[<Y20U(N7=QKTJ[Q4ZL?+M%6KQ1,_
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MG49Q1<E\&W)I9</=L&+?T*KDI)*/47NDRE<6\G\@*R*(B (B( B(@+,_</\
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M$5JO7Y NJHOG8G+5;]6O>I6(+E.Y!%9J6JTH35[-><!DAG@FC(HY8I8R$XY
M)P,28A=V?E?10!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:" (B(
M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MLJPW)^5"QIV./H[''IWZJ"<N5;)RG)<QZ9_+^VO2/WKW3^7]M>D?O60K]/\
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MVL=>NUVEP&B(QU+DW,>8IKT4GAX*CY\LYRY#B\8NSB];'3@3B4D;O=.0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MC&^/79617O1_\2^3_@^GP;[,1$46&3"(B (B( B(@"(B (B( B(@"(B (B(
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M8Z[?@>+4&M9&U-E&,>F6O5L1C'A,>_N=AKXT8[,@ORXW+UMF)P:/IE%7XUX
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MU1$0!$1 %9R]'W_YBW.^S.F_WADE6-5G+T?C_F+<W[,Z;_>&20%AY$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %&9WQ'TNFX']OT3_"%I
M129J,7OC; AV=]= _/,UO1<8<-Y=0Z[TS._5YMPW1"?FW/M<-QP_+ 4J41$
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M<>>\+O'7(GE/#UZ]60R;%Y&;*%52HMELE5<JH5UJB;^S9RKR9/WVZFW5O$^
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M_20]RS]\HMKY,(B+3#.!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M B(@"D5[I7Z8O;/^WZN_@]U<HZE(KW2OTQ>V?]OU=_![JY 7>T1$ 1$0!$1
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M9RED(M)Y.T8C'I_)VI'9\59GD(>C#Y&<Q>J9OTX^\9"Y#5M?F8"U:B(@"(B
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M=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B (B( B(@"(B
M(B( B(@"(B BH[Z+X@=2?9G27XR8Y4QE<Y[Z+X@=2?9G27XR8Y4QD 1$0!$1
M %=I[H[XA-%?W8_#-Y4EE=I[H[XA-%?W8_#-Y 23HB( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"KB=\-W
M=KSC?W?T31YFC"2UKS$50!O&AC%B/5%6(&%RFA%B?. +&<T3#D6%CBN'+8[7
MY3P!*!QR ,D<@$$D9BQ@8$SB0&!,XD)"[B0DSL3.[.W" UNB*8?O6.[T/;'-
M'K32E,OF U!=83IUH"\+265G%R?'F\?4,>(O2C))BYC&**M+(V)?VAI%9AX0
M!$1 $1$ 1_J(B M:]T5WB+:PH5ML-:7NK5F*JDVG,G9=V/46(J WYBGF)^F3
M-8N'R\^B3(8^-I^F6Q5O3R3MK7#8#4%_$WJ>3Q=RSCLEC[,-RA?IRE#:IVZY
MC)!8@E'S"2,Q$F?S9^.DF(7<7NM=W#V\:.\^EGCR#UJ6N,!'##J+&QD(#<!V
M8(<]CX7=B]1NDSM/&+$U"YU5C+PSK',!(^B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1
M$0!$1 %>&[J?Z7[;C['Y?\9,RJ/*O#=U/]+]MQ]C\O\ C)F4!(4B(@"(B (B
M( B(@"(O#H"M3Z2.#_,KM47#NS:HSPN7'LL18>%V%R]S.3"3LS^;L).WT+JJ
M-<EX"*-OT3N;M^LW#?6^7_,K=_I'>'(]K]OLBW4XUMRHJ)\<=+>OZ3U/.Q&W
M3RW#XWI$N6%NOI+DC#BG_,?,O'R"(LW[7+_Z7?W*_7@/8GPSB+]6[,B_Q>39
M+^J2( X]A_ZUFW^I7+_LXK^LLU^CH;)-9S&O]Q+4+/'BZF-TEAI2!G9[=]SR
MF<(2?V@DKU(<+&SC]%'?F%_H>%:V41_<B[<!@.SYIBWX;#/J>_F]0S%T=!R#
M/D9J-5SY9G)FJ4(?"-_)XG!Q=Q<5+@JE^+.LO-XAU*S?>%5[Q*UZ*&(E0]OE
M*<)V/YS?X$N\*8:HT_&CMUG#S9?%NWW^OX1:C^"01$4<FQ!$1 $1?$U!J7'8
MFI-D,K?I8RA6C*6S=R%J"E4KQ W)R36;,D4,48-YD<AB(MYN[+[1BY-**;;>
MR26[;?9)+JV?#:2W?1+NWT2/MKQRHHM\N^;V0T=XT&.SEC761BZQ&IHV&/(U
M3D%W;I^&YI:V%('?AVE@NV!('YC\1VZ7ATWG[]7=74?C5M$Z=PNA*A\@%N>0
MM3YIAXX\09[52ABX9'XZQC^"[#1<N#RV&9C4F</>#VOZCRRKP9XU+V^NS7]&
MAL^S4)KSYQ_:KIFOF:5K7B)I& GYV97.:_Q='ULOPWC]7%_*4XLMH9_4>/Q5
M66]E+U3'4H6ZIK=ZS#4K1,S._)SSG'&/DSOYDW/#\*+S>_OFMC=(%/4H9^UK
M7+0.0O0TC1GOU&-AY;KS\XUL 0]3>&;5,C;L0GRTE<>'XJ3:_P!:ZYUU8/(Z
MVU9J+4TYD?1\-9:W:J5^LNN4*>/.5L=CX.2;BM1K5:S=;L$3>;+B<&G\?4'F
M0X^6;W#Q\GU^?_-3OP[[-.+#:>IYUN1+HW5BQ5%2?JI66*RVR/\ -C1+YHA+
MB#VB8INO3\9.7;FLWMG\MH0Y8P?\Z5B)@M[>_9W1U 4M306GL)HK'GR(W[X'
MJ+4+MSRQQ%*5;"TG<7<3B/&Y,F^CBM1OPS16;G;@:ZW#L-:USJK.ZF()/%BA
MRM^66A7DYYZZN.9PQ]4F;RZX*L9](BSD["W'RL"]K*6@QVG<-D<WD#=ABHX?
M'6\M>D-V\ACIT()[!D[-Y"$3N_G\G"D9V<[I7?36HQ6<CC*6A,;,P$TVJ;)!
MD&B+SZAPE ;%V.1AY_,]]Z$S'TA*,7)&,K5:;POPS!3Y=/T]Q7NV62C+*GTZ
M\L['9E6;[]H.6WP2V(XLUGBSB*3A37DSKD^J2<:8K?IO&/+3#\9-?CON1EU]
M.4*C-XA@W'Z$?/ZGN\N&_O\ _@OI8JV]RW'CL+CK63R$O]!IT*D]^Y+P[#S'
M5JQR2DW+MR31\-SYNRM#;(=Q/MUAFBL:YSV:UW?'I*2 .K3>"ZF?GI"A2M6L
MB8\<B?K&9F8VX,8XG\FEMVHV!T1H6GZCHW2> TU6?I>5L/BZE*:R8CT--<LQ
M1-9NV'%NDK%N:><V^BD=1[Q#[2&E8_-#3L:_.FNBLE_>M#_:3LC*]K]ET5[]
MMUW-NT7V>L_(<;-4S54GLY50?FS7QBU!QJ7X^9-+X/L5$]G>ZOWYUR\<\^GJ
M^BL3(S$V0U;<CIS&#\<^!A*;W,QXC,3&/KM3'P2#RX67+R7L=M3L"P;&UM*1
M3ZJL:ES>I!RDEUFH14,;4@QKTQ'U.)YK%J0BDM^W)/,S<,(C$S\D5T#A58N^
MZUNU_<[ 8.,V./3^D:\DK,_/A7LUD;L\\3M[F)Z-+&2\LS.0RCSY"RU/@?Q9
MUK7];IQ[94X^%&N^ZW&QZME*,*I1KY[;79:]K9UM\LX1;^YMT-ZUWPST?1-,
MLMQZI3RG.JNN^V6\DY33GRQ@H06]<;%UBVEZ^I6I[7,XO4PE?Y3L7K'U^((J
M\?/UN?6?V_/R?A6;_1?-X'O;>;A:%EFZI-+ZJJ9RI#YOX=#5%%Q(N?T(R9##
M778&=VZF,^&<R<JLO:?R'K&9K5F?D:5$6=F]S26)"E/]9^AHF=O^RWUE+=Z-
M3N'+B-^\_IXCZ*>J]N<LSQ\NWBY7 9G!W\>_#/TEX6-LY_CJ'EFD=P(6ZQ.6
M/%S2%E<+Y\=O?HA#,AOZ.BV,YO\ Z!VI?SO@93@"WR7BQ?W^:+^?FN3C_%P9
M>Q1$7/HFX(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( NN-X-<CI
MC2FIM2&X\8' 9?+\'] 18ZA8M@!>;<]9Q,''+<N[-RW*['4>7>NZO^!>SUNC
M:8N@[&GGQ41=3"[2YBY5Q@<.[MR[O:X$6Y<G=F9G]SY;0<'Z5G86-MNLC+QZ
M'^%MT(/^$CR9]_E476_Y.JR?]"#E_8:_AYY9@!I#*223Y]8D-W*224_:(S)_
M-R,W(R=_>3\NN5Z9S4&.M#*;\2B/SOEGX%R\G=WX]DNGR;GW<\\KX=2!A%S+
MW"W+\_49O_9<?,GD(C?Y2YX^HWR-^LS<<+J%*?7=>GP_AL52R,6%E,Z)[\DX
MN,]GLWS=))OX->ZUZKH98T-?UIF%I?#/J]W/')=/'/#MYOT\LY?4Y;GCEE]:
M2GC+C>3L+O[^>';S_:_E_>5CWN.^SUI'56P.6BU?I;!:DI9;7^<F"#.8BGD8
M_#IXW"T(I('N5Y'CE@GAM/#9K$TD$CEX4D<P'QW;O=W%NU>?&:?1^1S6@,B;
MF4;5)2SN$$R^A:3$9*P%EX0]KIBIY>@3\MS([-P\-Y7CSI6+J.5IV=3D4?1K
MYT?2815],N39.4HPVNAL]TXPKM?3OUV7@L\!,JS&JS--R8[VUJQ4N7E26^[4
M5S;U2].LI5]_EUK#;::LUAH2V>0T)JC,Z;L&3'+\#9"6M7LDW#=5RBSO3MNS
M-PSVZ\SBWD/#.I1]F._&W<TY)'6UMA<#KG&B[,=J&$M.Z@ >&'EK5/Q<19$&
M'D8CP]>:0R)Y+_''3P3>'N<-\=(--8P<6*U[0A?D3P-IJ.5./S?K?#Y4X?;8
M6Y*&M>N&SNP1/.3MS&MJ1\O@;98W5.!R^!R .P24<_BKV'O 7GQS6R->M.W4
MW+B_1P0MU"[CYK9YXG"_$T'+;3]0DX[2G!QCEP6W3>4/+RZOES./;;;NC7(Y
MG%W#DDI+(C5%[J+W=4NO79/GHF^O7;X_'8ML[)]]7LEJLX*F8RF0T)DYN@6@
MU51DBQOB$_!"V?H^N8F$ ?CF7)6,<)<^PQ,SNTJ&F-78K-U([^'R5#*T9A$H
MK>.MP7:QB3,0N,U>22-^6?GZ+E:\,H<9<;RZ0=_^Z3>?]YV_]^%R+0^:U1I&
MV.1T7JG.Z;M@7/C:?R][&/(W/4\=B*I/%%:A)_.2O:CF@E]TD9L[LHMXA]FG
M"LWGIF;=C2ZOR<F*R*M_11G'R[81^<O/EZ_(W_0_:,E%JO4\-)]%SU[U2_%J
M7/7-_P UUHV':*H%L[WVN\NEO!@U9C<)N!2BZ ,[,?S.9F0!YZG^$L95GH-*
M?+<D>#D'R9N@7?J4N>R/?=;.:G&&#4,N5T!D#X"6+457Q\8,O#<M'F<;ZS7:
M%RY:*:Y%1(A9SDBA8288*XA\&.(-.WE+">74O\;@R^D+\?*2CD16W7>5*C\R
M;="\3=&U!+RLR%<VE]7?]4^OIS-NIOY*QOY$Q2+AVB=PL#J6C#E-.9O$9_&S
ML[PY#"Y*GE*4K"_#O%:HS3P&S/Y%TF_#^3\/[N8J+K*Y0DXSC*$HMJ49)QE%
MKNFGLTUZIF^0FI)2BU*+6Z::::^*:Z-!$1?0^P1$0'A8U;M]CC:W73R'JK0F
MF\M8E<G.])C8:^1<R;AY/A&HT%WQ&]XR>/U"_N=9+(O5AYU^/-68]UM%B[64
MV3JFOPE!QDOWGX9&-7;%PMKA9!]XV1C.+_%23132[[WL.:3V TGIO7VW53+Q
MTLGJ@<!FL/DLM-D,;3CM8ZY;HSXZQ9@FR<,\EBH<<@6\A<@.)V:&* @=RJ0:
MVUA:SV2LY.YTM+.XL,8<N$,,8L$40N_F70+>T3\=9N1,(L_2VPK])(TW'<[*
M.KL@;,Y:?U3MWDHW=F=QDOZUPNE^1=WY%WCU"8NXL3])$+LPN1#KJ%?;P-U_
M*U'05=EW69%U.;D8KNMDYV35<*+HJ<Y;RDXQR(K=MO9+=MD;YW#F#AYDK<;%
MJHG.I)NN/*N64GNHQ7NQ3E!-J*7;X$M_<5YSU#M4;4GXC1^LWLW0Y<7+K:YI
MO+1/&S,S]+G[F-^&'Y79O-;,E:R;N/,.5WM3[2"+2/ZOE\K==H@<W8:NGLM(
M3GPS],;-_1#\F ?-W9;-E0/[2BC^FL/;O^C*^;_\UE;&X\/?R,O](_\ NQ"(
MBKN9X(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"_B0&)G$F8A)G8A
M=F<29VX=B9_)V=O)V?R=E_:("BGWB_9N/;#=;4>&@B>/"92<M1:<+A^CX*RT
MLDSU!?C_ /-EWUK'-R[D\->"4WZI>&P;5NCOM>S5\U>W5;6V/@ZLQH&>2S9>
M.)CELZ:R#QQ9.(R'@W:A8"IDHR?Q AABO,P#ZS)(-1= $1$ 1$0!3Y]Q3VDV
MQ&I\YMED+##3U2!9O A(Y=(YW&U>G(UXGYZ1._B( G(7;VGQ(]+B9$TL!BYQ
MMGN%D=):BP>I\3(462P&4I9:F0FX=4M.<)O!,FY^=60$Z\XNQ#)!+)&8&!$+
M@;%A%UGLUNEC=;:4T]JW$2#)C]0XFGE*_!,11>LPB<M67I=V&Q3G\6K9C?VX
MK$,L1LQB3-V8@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(N
M$[DZ_P =I73^9U+EYF@QF"QMS*792=AX@IPG,8L[^76?0T<;?HC(6^5 5O\
MOW^TF]S+:=VNQMC\S8J/YI-2B#E\\R%D7AP=(^.!XIU/7+TH/XC')=HDSQG6
M=CKRKLO>7=/(ZXU9J+5^6-RR&HLM<RDPN1$-<+$K^JTHG)W=J^/J#!1K"[^Q
M7KQ!^A76B (B( B(@"S [!W9S/=+=+3.EY(2EQ+6"R^HC9N0AP6*Z;%L97Z2
M9AO3>K8J-NE^9K\7/2'68X?JV%W&_9L?3^ALEN%DJS1Y/6MEX,2\D?$L6F<6
M91PRB1/RPY/(^MV&86Z9*L%&=C)I>  G)@A", CC%@ !$  6X$0%F$1%OD81
M9F9OD9E^J(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"P*[T#X@]S/L'#^%<>L]5@5WH'Q![F?8.'\*X] 49$1$ 1$0!$1 6_
MNXQ^)2Q]N^H/WIAU,DH;>XQ^)2Q]N^H/WIAU,D@"(B (B( B(@"(B (B( L/
M^W[H)]2[,[C8L0:25],9"_ WERT^)C;*1$//O(2J<BWO=_)O/A9@+T,KC(+M
M:Q3M1C-6MP35;$1?0RP3QE%-&7_9.,R$OK.@-;Z+\LS_ %69>5R?6VC;.G,U
MF-/7.I[>!RN1PMDB'I<Y\5<FHRGQ[N)#@<Q<7<7$F<7<79WXP@"(B (B("VS
MW$FX0Y+:K-8 C'Q],ZKN ,?GUM2S%6MD8)7Y=V8#M/?BCXX\ZY^7RO-NJK?<
M%[A-2UOKG3)R,(:@T[C<G$#OYE9T[>LQ< /R.5;.V"D)G;EH8V)BZ1Z;4B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M0G<=+Y:?I <M$Q/P&.LD(1Y>,'%HQZ<B E)!-'8B+3A ;(JO8CFC"6(PEBE
M9(Y(R$XY(S9B P,7<3 Q=B$A=Q)G9V=V\U^RK7=SOWB'AO0V?UM=]EWAIZ!R
ML[OY>3B&EK4K\LS>0M@C)V;WXOGJ]1 K** (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1
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MYV<W,>&KB-50XC-R]+%IW4\?P%E6D)OZ'7>T7P?DG9_)RQ5^\(NXB;@9,"D
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M=G;EG;S9V?W.WUG7E $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1%X=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M:PQV=>X>QT/@9#=G4TF<L=3')IS2\UJAAQ;_ .#8S<L=;+W6=_,SJ08AV9W
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M4I3KR8^I8?.2D[ACZU_DW?(]]_B=F:V0VXVVL5\UNQ;JS0W<A&T%O$[?#,#
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M=XL-N'%6PAL3LT4>?K'-)IZ5^2;I.Q+8MXH..IY)LC #@7 G'<90!$1 $1$
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MT>"I>YV>2?)]-SI+@2K8VWY]72)76$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MMG0.]&#^%]'949+=80',Z?NMZKG<'9(6ZH+U(^".'JY&#(57GQ]KA_ LF0R
M&6ZUI&CM<:BTEEZFI](YG):?SN/-C@R&)M25;+"W#$!/&_38KR#R%FG8&:K;
MA(HK$$L9$!3V[4^D&ZU@TJ]+4&@<9J#5<0!%3S\&4DQ&+MM[0G9RF'BHV9&G
MC=A=X\?;KP6^HF;U#H9Y?RXP]G[-INYM&:S,>R72BVRNO(QTWZSL<*[:X_KI
MQL2Z.N6SF_STGQ,Q?*_]8-8\X1ZVQC*55FWPC%2G";V^SLXOTDND2V-+*("1
MF0@ "Y&1$PB(BW)$1.[,(LS.[N[\,S.[J,CM*][?LYMQ)9QWPX6K]15V,2P6
MDA')/#,/EX-_+B0X:A)U>102W3N@W!O4<'8E5KW^[;6\6[4L@:GU7>JX:3R'
M3.GRFPN 8.KJ$;-6I*TV4<>!=CRMBZT9#U0C#U$SXT4M*4J8MXKQCT_H69N6
MX^3CW-_+R6V<)^S7!<MNL9;D^C^BX;Y8?':S)LCS27I*-=4/V;=MFXZXJ]H.
MBERJTZGS)]E9:N9OYQJA+I\4YR:^,"3?M"]\GO)KT[%+3/JFW> D=QBCPK';
MU'+$XN!>N9ZTW0'7RY .+QV..!WZ7LV7 )GC";2LMFS8R65M6+=ZY*\]R_?L
M2V[MR8N'.>U:L')9LRD[>U++(9EY<EY<OS71^)R^H<A'A=(Z?RNH<K-PT='"
MX^UD[?3R(O(<=6*5X(0<A\6Q-X<$(^U+* <DTP79][C_ %_J4J^0W(SU?16-
M)VDEPN,\'-:CG#AG\$[0S-A\4?+^<S%F';I(/5?;&<)EMS.&>%*.1O$T].*V
MK@N?*O2[;QBK,J_K]^?-%-^].*(HA'BGBBW>$;W5O]NQ\M5>[Z[;N-%?3[L?
M>V72+[$+7K]&J4<, ///(8Q0QB#R22RF["$<40,YR2&3LP +$1$_##SPRD&[
M/W=B;T[E%!:+"?,3IV7@FS6JF*G+)&_F[T,"!/F;!<.)#)9K4*9B_P [MR$)
M K0_9S[O_:G:X8IM,Z5HGF CZ#U)EP'+:@/GS/P\C<&0Z02/P\D&.&G ;B#G
M&3@+MF8H+XK]I2V?-5HV(JH]4LK,2E9_.KQX2\N+7H[9VIKO4B6N%_9YQ:G&
M[5,B65:MFZJFU7OWVE9)*37Q5<:VMNDV1#]F[N8]J=$G!D=11V]PL[&\<OK&
MHAA'"U9@=B_,&GZPC5<.IA+G*S969B%WCEBC)XE+7C<=7J5X:M2"&K5KQA#7
MK5XHX(((8Q88XH88A".*,!9A",!$0%F9F9F7O(JY:[Q+GZG;YV?EW94_3S)[
MPAOZ5UK:NM?LUQBOD3]I.B8F#7Y6)CU8\/55Q2<OG.7VIOYR;81>.5'[VJ.\
MRVGVG&S4S&>#-:DKL8MI331P93-M,(\C#>$)@J8AR]G_ )ULU"Z28Q V7ETK
M1\K.NCCX>/;DW2[5TPE.6W;F>RVC%>LI-1CW;2/3FY]&-6[<BVNFN/>=DE%?
M@M^[^"6[?HC)+M)[RUMOM#:EU?:<'^!L9--5CDY<;&1F<:V,JNS.+EZS?FKP
M]+.//7]$/T3:]'=S5UG+Y6U-9G*Q-):LV[DYNY'9R5R8[%VQ(3_12'-(74[^
M?6\COYDZE"[:?>EZQW@Q-C'38FEI72,%^&SCL+6GDO9*[=@"<*T^6RA!7"<8
M!G*<:5:G!5CF".0WL2UX9FAWE9W=W=W=R=W=W?EW)_-W=_E=W?E^?>ZN1X4<
M"WZ)BW?3(PAFY5D960C*-GE4UQ^JJE.+<7/FG;*?)*4>L5NW$KCQ[Q95J614
ML:3GC40DH2:<599-^_-)[/EVC",>9)^[)^J/BRA^TO0D!?9E!>A*'\O\ZF.J
M9IU4_P#CY'/-D-I;FN]::4T7CP,K>I]08O"BX,[O#!=M1QW+A=+.XPX^CZS>
MLFS/X=>M+)P_1PME1I33-3"XO&XBA'X5'%4:F.IQ,PMX=:E!'6@'@1$>6BC%
MGX%FYY=F95&_1]>SE\.:^U'N-=KN]'1./CQ6)EDCYCDU!GXIQL% ;LXO-C</
M#(T_#L<89FMY.,S\7!%4'V@N(UD:E1@0>\,"KFL_UC)4+)+X>[3&G\)2FNA8
M'PST[R\2>3)>]DSVC_HZFXI_G-S^6RBT$1% !)(1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!1X=ZAMF^I]D=71QQ]=K"#1U)4X;DQ/#VHYK+@W
M#\D>..["_N]F4N'9U(>N/ZKTU5S.+R.(O!XE+*T;>.MQ^7)UKM>2M.+<L[,[
MQR%P_#\/PZRV@ZF\+-Q,N.^^-DTW[+U5=D9./^TDTUZI['AU/#61C7T/M=39
M7U]'.#BG^3:?Y&L_R%7PK-B/Y FD9F_[/6_3_FX=?W5J'*;11MR9,3LWEY,+
M<O\ Z%V=OAM_<TKJK.8#(CTWL1D+>.M>RXB<]"Q+2EDC8N7\*62N4L3\EU1F
M),[L[._6> SHTK\%@V9P8G&1G;EO#D9Q?GR=O9Y8OJ\,NC5$H6.#4N:N;C)2
MB^DH2V::^3333^!3'.\V,;5&&]M<9[5OHW.">T'\'S+8^-EL;8C8F.-W;AV?
MY>6?R]WO]W/^=7Y.ZIWQ;7NQ.@\E)-XU_#XP=*91W?F0;VFN,6SS<NY^+/3A
MJ6B*3@I?':;S&07>EFXXZ^/N",B;ZSL__C^M[UVQLKO=N+M;=+(;?ZKR>%CD
MF&Q<QD4WK6"R1@+!SDL+9\7'V9'B;P6LO -V*-W&O:A?@FU?Q1\,GKF#"G&M
MKJR*+O-IE;S.MIPE"=4I14IP4]X/F49[."W6W5>GP^\6*-.RI?3*;:XVU^79
M%;=U).,X\S49<NTEMS+I)O==GL!$5;OLZ=_=#UP8S=G2<M N!C+5.E6.W3<_
M)G._@+#^N50X8G*7'W,B1&[ -*(&*1IW]F>T+HC<+'_">B]3XC4-5NGQFQ]R
M.2U4(QZQCOT2<;M"4@X,8K=>$RC<9 $HR$GI1Q/P#JVCR:SL*VNO?97P2MQY
M;]MKJ^:";_4FXV+U@F6QT+BS3]2@I8>57:]MW7ORVK\:Y;2V7ZR3C\&SN5?G
M+&)B0$+$),XD)-U"0NW!"3.SL[.WDXOY.W++^^5Y6G&Q$9_:,[IC9O<3QK18
M$](9N3J(<WHTJV(F>5W<NJUCBK6,/=$B_HOCX]YW!R:*Q!([2#!YO]W)^[&D
M?'O:'NT=PL7$Y&-2$X,+J2.$6=^7I7K XZZ0BSN05,B-F1^D*U.:0NAK>:*3
M>%_%[7=*Y8U9;R*(_P#NV9OD5<OZL9.2NKC\(U6PC\C1>(O#C2-34O/Q80LE
MWNH2JLW^+23KF_BYPDW^1KN=3AE]/WSP^J<+D<)DX^>NAF:%G'VV$7Z7(8K4
M<1F#$SMX@,<?4SLQ.[.R^+8Q.-OB_#B+DWF)<.S\_)SQ[OUVX6P-W6V0T?KK
M'EBM8Z9PFI:!?0P9C'5KO@&WF,M66:,IJE@']J.Q5DAGB+VHY!+S4*?:"[A?
M2F2\>_MGJ:]I"Z_688;,C+G,!*3N[C#'8\:++XP?/I:=Y<J$8,S-2,N35C>%
M_:-TS)Y:]3ILT^Q]';%/(QF_CO"*OKW?HZK(Q];-NI '$/L^9=#E;I.3YB75
M5-JJSUZ<LGY,_P >:#?I'T((-B^U/NSM1X46A]79"KBH6XCT_><<MIUA=^7&
M+%7'D@IB3]3O\'E4-R(CZNM^IIK.S[W^>.E:&CNOI&;"V.KIES^D1L9#$NW'
M]&EPEN:;+TQ8GX>*M;S)] ];$1$T+1!;\=AK>;:TI9=0Z1OY##1%P^H=.1S9
MW#,'F[26Y*<)6L9&[,S/+DZE2%C(8AE*0Q%\ M=[Y:<Q%<WO-ZQ=Z7>.A5Z7
ML&7R>+S[%<'=O,Y>GR^A _H7WG5.">&N)*GDJO%O=G7Z;A60A=S/UG;2VIS7
MZN1"S9]X[KIKFB\4<6Z+D0PW3D7]5&./97*46ETWY+-N2'9N=<X12Z\VV[-A
M#MGVN-LM88.SJ/3FN-.Y'#4*LEW)6WR$-,\55B!Y)I<O4O\ JMW$M#&SG,.1
MK53B;SD$551[U;TBT[P7] =G>\\=0_&IYS=%X9HY90Y**2MH:*;PCB$B9^K4
MUJ$PDA?JPD!>)!E8ZLFYF[N4SLTS=3T*,C%%\'TY9 BD@=V?PKACT/=9^D7<
M9A\'J;J"$'Y765+%22MU/S''_3E\O_=;Y?U_=]=:GPQ[/^E:?F2RK[;-0A!I
MXV/D5P5=;_6O4?=R9)[<B<*ZUWE5-[<MF:.(\NW%K>177C72C]:JK'-)_JQ?
MW7^LHRGUZ1FUU?I-XD\LAD1S3SRRV)YI#*266>>0IIY[$LA$<LLTLAS332$<
MDLIG)(1F;N_TN@*X.3NW+,[D;\,S,S<O^L+>]_J_Z/IF(0CT@S-]5_+EW^J[
M_P#A[F^HI\.XB[KD]Y]9AN)K7%M+M;HF\$@5KU?Q*>L]453CEKX9HI1\*YA<
M8_YJSSNTM>>4:V'DCE"S>&O+O$O$6-I6%?GY<^6FB.^RVY[)OI736GWLLEM&
M*[+K*348R:\F-3*^<807?^I=W+X)?\=2P!Z/AW=D^T^W4VX6JZ+U]>;E0UK@
M5IP<;& T< C/AL7(Q"QQWLD9EF<FWDP--0HN#'0DEGL,KPS>[CRX^1O=^TO*
MYL\3\19&JYV1GY+^MR)\W*M^6N"2C75#?KR55J,([]6EO+>3;<CXV/&J$:X]
MHK;\7ZM_-OJ$1%@3]PB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B *-CO5NS3_-(VFRS4X'ES^DC?5.#\-F>64J%>8,E0;RZC"[C)++#
M$+MU6X:<G!%" O).O#MS[_-G^1 :V\29V9V\V=F=G^L_FR\K-_O$>S:.UNZN
MH-/U(/ PE]PU#IP1C\.$,-EI9W"K![A>/'7(+F-$0X8 J W''#OA @"(B (B
M(#W<9DK%*S6NU)2@MT[$%NK.#\'#9K2A/7F!_D**6,#%VX=G%N'97YNQQV@Z
MVZ&V^E]90N#6<C1\#+P#PSU,WCY#HY:N0?1 +7()):_4PO+3EKV!;PY@=Z!B
MG[[BGM+/B]29O;')3]-'44$F>P#R2\!%F\>$<>0HQ@7+=>2QO%L.EP9BQ,HN
MTASAT@6E41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!T%VHM]:6VN@M3:T
MN^$387'224X)7=AN92=QJXNEPQ"1>MWYJ\+L)"709.SMQRU '.YRYE+U[)Y"
M<[60R=RUD+]J1^9+-V]/):MV)'^4YK$LDA/_ $Q.K!G?O]I4;>2T_M7CK'5'
MB_"U/J08I/)KUF":'"49V']%#2FL9$HC=FZ;E&=P=_!,:[R (B( B(@"\._'
MF_DS>;_6;Y77E9>]A/LY2;I;H:9TN<9EBAMAEM12"Q<!@,7)'9OQ.8\>&60X
MCQD4G+.$MP9!8G#I<"T)W0W9K+0&T]#(Y"N4.?UO*VI,B,@LTE:C*'AX*D_D
MSMT8UH[LH%[<=J_8B?D8QXE/7XUJT<,<<,,8111 $<448B$<<8"PA& "S"
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M?K M-:4EMXZM9KR<MX&5R'C/D<J)1^Q/%+-#0L<F[X\!<8PPTP^F*F.=I)7
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M?VOR5CJLX.<]0:=:0W<WP]\XX\G1C9W\XZ&3=K8<<NS960'Z8X8V5A! $1$
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MF/TYA<1I_%0#6QF$QM'$X^N#<##2Q]:.K6C;_NPQ SN_+N_+N[N[N@.5(B(
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MKAR27:U%I?=_ODMK\"4E73<&6UM>!W%CQL0X[#,3.[.QY7(],IL[<.!T<=>
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M$OSW?4(B+0S(!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MW=+F;(72;@7ZKEZ6Q9?J;J;Q."=W9W?NQ $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MR[.SNQ,0DSNQ"0N)"[/PXD+\.),_DXOYL_+/[EX0!$1 %X=N?)>40%S'N?\
MM/OK_:ZMALE9\;4>A9 P-WK)GFM8E@Z\%D';ER+FFSXZ4W\RLX^60N&F#F5]
M48>[@[4;[4;HXC+V[/@:<S7_ -C^J1)W\$<9=D#P+YMSTB6)OC7N>*[.XU1N
MQ,X#8,FO-12B8B8$)@8L0&+L0D)-R)"[<LXDSL[.SNSL_+(#]$1$ 1$0!$1
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M!$1 $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:"
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MR(>T-&I;F=Q"(C'*14Z>^#[7_P#-!U^6D\18\32N@YYZ,1QD)09/49"T>6R
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M;7] ;B[$+D)"[$)"3B0D+\B0D+L0D+LSB0NSB[,[.SL@-D<BAG[J/O#FW*Q
M:(U=<9]>8*HWJURQ*WBZKQ%<!'U_DN"DR](68,J')G8#HR?412VAKS,( B(@
M"(B (B( B(@"(B B>[ZKXA,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$
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MV?VM<%LSH?(:MS#C8M<^HZ?PS2,%C.9N>,RJT(/>0Q"P'8NV&%QJTX9IB\V
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MDW][]1_>^R]Y;;V8T1%5DWD(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M$$D4L9$$D9BXF!.),[.[+VT0%+OO.>[^GV@U$V9T_7EEV]U!8+X+EZCF+ Y
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M,DTTIG-/*1S32'(9$_".S[L%IO;/2N,T?I6FU3%XT'<C+H>WD+LO!6\GD9@
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M5VE;TN,SF%M1WL?=KEP<$X,XD!LW#25[$125[,$G,=FM+-!*)!(3/='C'A;
MXNTBNRBRMSE6[]/RTOL3DNL)].=5S<57?4US0E%-Q\RM(J1PCQ%F\(ZM/$RH
MS^BSL55U4GZ;]'%OIS13YZ9[[2B]M^26YL.T6"W8%[;F%WLT='E8/ HZHQ(U
MZ>KM/A(Y'C<B<9=%JL!\2GB,IX,T^-G+JX8)Z<DAVJ=CC.AG7/W5M*R,')NQ
M,JJ5.11-UV5R[J2]4^THR34H2BW&<'&46XM,N[@9U6337D43C95;%3A.+Z-/
M^II]))]8R332::,?.TYV9]+[L:1R&D-55/%J6Q>2E>A81R.&R4;/ZIE<9.0E
MX5NL;L[B[%!:A>2I;BGJ3S0G28[2?9IU=LGJV72NJH?%K6"GET_G( +X.U%B
M@D80M57+SAM1#)%'DL>;O/1LET<S5Y*UJQ?J=8T]JSLIZ5W?TG:TMJ>N[,3'
M-B<O7&/X3P62Z'&'(X^4Q=F,7=AL5SYKW8.J"P! [.,G^%/BG=H.0J;G*W3+
MY[W5+K*B;V7TBA?K))>;#M;%;=)J,EH'B-X=X^N8S]V,,RN#5-G1*:7556/X
M;[\DN\)/?K%M.AUEL;( 27,?-+6GFKVJAG"91R>J7:\U.]7)V_ZNU!++7F!^
M.J(I(R%Q-V4/6ZFUUG3=OH?JEH2D_JMAV\VX?^@3.S,S2BS>3_0R#YCYL0C/
M)V@-@M5;-ZPN:-U; Y$',V+R\<,L>,U!BS?B'(XZ0^L7%_.*U6\4YJ%H9*T[
MN0@9XZ[@Z!I9BE,!Q!/7G!V,'9G<7][.SMYB8OY@;<.+MU,ZOO@9=&557E8T
MZ[:KZXSA;7LU9#JX-/;?9;R]U]8MR32>Z*L<,<29G#N;+3\^-GD<[@XS[Q>^
MVZWZ*:79KW9Q277HU">Z_@VY%V^JSM_?9=H[G;96].7"CD$CI2F7JEGCR)OH
MO!EX\AG!O)V]QLW6/EU,/6"]19K%RJ[ZX74S4ZYI2C*+[K^QKLT^J:V?5&R=
M[B?<(LYL5CX9#ZY,5DY(B?RY8<GC<;FA;@7<6'G(%T]+"/O86=FY>9M5K/1O
M=2E)HG4>(<OG=?!;;9*(>7=GDMX;*TK3LWN8A;&5!+EV)^6;CV'XLIKG%XKX
M*Q^(M4K2V4LB-W_YBJN]_P ;'^'8W+@^[GT[&_85M/\ T%UE*_A!?D$1%'AL
MH1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!?Q)&)B0&+&),XD),SB0DW!"3/RSL[.[.S^3MY/
MY+^T0%$SO$.S>>U^ZVI,%#"\>$R$[Z@TV?GT/A\J1S-69W]Q8RYZWC79W<GC
MJPSNPC. MA$K</?<]FKYJ=O*>N,=!U9C0=DI;C@ N=G3.1Z8LC&3MP;OC[8T
MLA&[N01P!D!:-SG8QJ/( B(@"(B *P)W$G:2^#=09_;#(67:KJ$"U#IZ(W;I
MCS&/KM'EZ\3N[/U7L7#7M>&W4S?!<L@ +G.95^US_:G<C(Z.U-@-5XDR#(Z>
MRU++5>DG#Q#ISA*=8W;Z*&W"TE2Q&7(2UYI8I!.,R%P-BBBZ[VEW,QNLM,X'
M5>'E&;&:@Q=/*5"$F)Q"U",A02>3.,U:1SKV(R$9(IXI(Y  Q(1[$0!$1 $1
M$ 1$0!$1 $1</W!USCM,8/+ZBR\S5\9A,=;R=Z9^/8K4X3GEXY=F<R$.D!Y;
MJ-Q'GS0%<KOX.TH\][3NUF-GYBI@.IM3,!>16IF.#!4#^O!!ZWD)A?RYL8\A
M?D)!:NHNT][]V\EKS5^HM8Y8G]=U#E;61.+J<@J02R.U.C"Y>?@4*8P4X>>'
M>. 2+VG)WZL0!$1 $1$ 67'87[.Q[H[H:8TH<)2XLK+Y74),S]$6 Q?38OM*
M3,_0-PO Q@/Y<SWH0ZA<NIL1U:Y[C3LUO@=%93<7(UO#R.LK#T\0\@,TD>F\
M7*4;3 [^V 9/)C9EZ>!:6M4I6!<PDC=@)T:U>.&..*(!CBB 8XXP%A (P%A
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M'!93(X7+U):.4Q-VQC\A3F%QDK7*DI0SQ$SLW/28OTDWLF#B8\B3.@./HB(
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MR>\-UM=>?R'G[K_WW:1O]#+VQ]F_.VZZEA)^OU=[7[^7^Q'DGXJXR[8F0_\
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M8RUB_A&2S&%$(G*P4S]/@.#?/(Y1?S:0?-F9N>M^/"ZF,>J*77NHFR^8RN3
M2$;UVQ/$!-[;1&;M ),WEUM$P,3,_#%RS>2NH^O5>OH0[X2U:A1=G863&?D8
MZARRFFDK92:Y.OWN2,G+;TY&^Z+M'HX\Q0OEJG#L,NW.CIS8N6(9(2;V7'R;
MWW)&]INH.&%G\R5J=5<^X!Q_JFHM35/ZET)@ZWUOG%R"+ZK_ -)]5U:,7/CQ
MOV_](\Q[=Z\5_P#P]:_J2+#^'UG-IL)>CORFOP>18_[0B(HD-V"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MF\@))T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M7!?/E@HK=]V]MVVVV13J6M])WY-SZ)N=ELI2>WXO=OX)+\$CX99TF^AB%O\
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MW'V/R_XR9E4>5>&[J?Z7[;C['Y?\9,R@)"D1$ 1$0!$1 $1$ 1$0!$1 $1$
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M#5RH^'#GZ3.WL\G=XR@"SCTAD_! &C@9W BF1$0!$1 %X)N6=OJ_R\G;W/\
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MSE!CZY=#/U3W3ACM7;/.;: (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MZ%E\7(PC]1C+];RZ>?\ \;]I9VT/G>*-V?WB+?\ XK_RX6PZ?6DI/U_LV_\
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MRW1$5'B>@B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M2Q]N^H/WIAU,DH;>XQ^)2Q]N^H/WIAU,D@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( L->V_V.,)O/HZ? WW"GFJ+3W-,9OHZI,5E#B86:1F]N7'
M77CBAR5879YH0"0.+%> PS*1 :[+=?:K.Z(U%E=*ZEH28[-8>R5:Y6/@@?R8
MX;-:4?8LT[4)!/5LQ.\<T)B0OSRS=>*Z]WCO=\XW>; ->Q;5L=K["P&6%R9
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MCD=R#-VH96:K5DCBDP\764S/?GZ:$_C,@/*(B (B( B(@"(B (B( B(@"(B
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M5[>Q^YE[3@^(>F,N\V9T=;D<B\7"RV'$L=+*3,TMW"2F-"T_M$<7J=N3I]=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M+%7LZ=+R;AWKYJ<1+@2=G=F>0/1G;6V?U#$,V%W/T%D8RXZ7KZKPK]74XLW
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M;OWIHZU2K$ ,Y$<L\H1LW'DY=3\,W+7>^PAV2Z.SFWN+TO'X-C-6.K*:HR@
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M1'KXE\S,UC2[I;SCD^2HR?7=U0KIY7^W%*'-\=TWUW+^>.I!6KP5H_H*\,4
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MQCX9G/3SV2=@<.7MY"[9Y=G\W?B5O:_1<=3>3LL^53_C:[S-9U:?ZVI9K_\
MB;-BU/#5?)IV!']7#QE_V, H3._IY_F+XUF^77>!Y=WXX_,F5=OU^7X;]OS\
ME-FH3._J^)?&_;U@/WKE%E?"[_VAT?\ UVK^MGAXW_P1J/\ JMO_ '2JJ;/\
M$NWN?E_?\G ^?/U./KJ[[W:_Q#[6_:I1_P!>7S_;]ZI!RF[XCA_JNWUW\O+G
MZO''E_\ 5Q=\[M?XA]K?M3H_ZTJLI[3/^"]/_P!?_P#EKBN7LX_\MU3^8_\
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M$)<2U\<8M)GK@LSL3=..8Z,1L[/'9OPRMSX3L],9F9O)O)F]S?60!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M*..IQ5&C.'PVE>>/I<9S/VI)G(>6?J=WXX?@181;R9F;[>^>YM?!8R:;J%R
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M--B\"B6\7<]GESB^G1K>%&Z_5=DT]G&V.Q*NG\)2>T\^Y7/O]'I3KQE\IO\
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M:G,[,[^!:CBF9F?D&X797* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M=C\,WD!).B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M$]?6^E6ADY%B?H:UDJT[=+NX%XD$?M"71U!TF6Q,X7E;A1[1?$$%M*&G6O\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M4D?1-%BGAZ-/TGY]KPXZ4AWQ9_=-D[#\-U*5Y $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M 1$0!$1 %@5WH'Q![F?8.'\*X]9ZK KO0/B#W,^P</X5QZ HR(B( B(@"(B
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M/4FDX9JV;&U@;///#MX>7KU.>'\G<2(?<[$XNSO1>7AV9_?YH#8YZ>U5B\O
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M_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN,?B4L?;OJ#]Z8=3)(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MB (B( B(@"(B (B( B(@"(B (B( B(@"(O#(#RB(@"(B (B( B(@"(B (B(
MB(@"+PO* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (O'*\H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MOT^]ERG">EP=D.V3#/;W,QC.Y,YWMOKT@BS-RSNV-N9 ^"?V1Z1)^?HF$?-
M6=44'^W'I'_8LU//'5J[X8G$V9./8U7IS6ND*X.3DS,62U+IO%XEWX'J)X[Y
MB#./6XN3,I/MH>UEM?N!7AM:'W$T5JV"P[#7DT[J;#Y9IW+Z%HFI7)BDZOT/
M0S]7R<H#()$1 $1$ 1$0!$1 $1$ 1%XY0'E$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $18[[P=KK:O;Z&6QKK<;1&D(8'XG/46J,-B/!=G$7:4
M;MR$H^"(6?K9N')F][H#(A%!MN)Z23V+--335I][<=E[,75\[TKI?7&JX)"!
MQ9QCR> TSD,/R_5U"YY$!,6=P(N%BCFO2XNR)5)Q@L[FY)F<68Z6W]R,79QZ
MG)FR-Z@? O[!<@Q=7F(D'M("SNBJPEZ7[V4?&$&QV[CPN!.4_P P]5NF1G9A
MC\%\_P"(3$/)>(WLB[,+^;^7W<5Z75V1K!]$Q;I41Z@;Q;6@)C!F)^'+BCD[
MDG3&WM'Q'U.W]#$W\D!:!10(:$])P[%6<*&(MWI<%8G+I&+4FA=PL1#'Y#P\
M^4ETN>%@%W+H9Y<F')"_Z'I)Y*]EN\)V*W&'JT+N_MSJEV:/KBP^K\):L1%*
M(&$4U4;C68)W&0.JO-$$X.3"<8EY(#,1%_(&)"Q"[$),Q"0NSL0NW+.SMY.S
MMYL[>3M[E_2 (B( B(@"(B (B( B(@"+PG* \HB( B(@"+PSKR@"(B (B( B
M(@"(B (B( M39VG>_$[7&'W-W*PV*WYUG0Q6&W#UQB,71A@TV4-/&XO5.5H4
M*L93X&:8@KU:\40E++(;L#.1.ZVR:TB_; ^-_=S[JNY'XZ9Q 9R_D\W;'_5"
M:W_Q;2W\74_)YNV/^J$UO_BVEOXNJ))$!+;^3S=L?]4)K?\ Q;2W\74_)YNV
M/^J$UO\ XMI;^+JB21 2V_D\W;'_ %0FM_\ %M+?Q=3\GF[8_P"J$UO_ (MI
M;^+JB21 2V_D\W;'_5":W_Q;2W\74_)YNV/^J$UO_BVEOXNJ))$!+;^3S=L?
M]4)K?_%M+?Q=3\GF[8_ZH36_^+:6_BZHDD0$MOY/-VQ_U0FN/\6TM_%U<NQ'
MI#G;2I1Q11[]Z@FCA)G8;FF-O;AR-U=;C-8L:/.W*)>8OU6.M@]D#%F'B&1$
M!8^VO]*N[7V *(<GGM$ZPK@8/*&>T;6K6I@ >'#UO!7,4$3R/YF8TR9GYZ '
MRXE][-WIH(':K4]W]DRIU)#<;&H=NM2/D#KL_#"1:4U#2I221 _4<\L&J);#
M!Y08^>1F$Z(B(#<I=BKO:^S[V@6"OMIN1@LEGWKO:FT;DIQP>M*\ N RREIG
M*/7R<\$!20C8MT8;=. YH(Y; '-&)2/+1/XC+W,=<JY''7+F.R-"<+5#(X^U
M8HY"C:B?F*S2NU)(;56Q&_G'-!+'(+^XF5Q3N?\ TI_56C+>,T!VE[UO5^C9
M9(J>.W.:O#)JK2X$(10#JB"K' .H\'"8L\^6&(M04HI))[+Y>*(1C V)B+BV
MB-;X?4N'QFH-/Y.EF<)F:5;)8K*XVQ';H9"A;B&:M:J682*.:&:,A(# G9V?
MCR=G9N4H B(@"(B (B( OX.1A9R)V$19R(B=F$19N7<G?R9F;S=W\F91>]Y=
MWN^SW9;P W]>Y:3(:GR->:336@, \%O56?DCZ0&0:TDL4.*Q(3'&-K-926O3
MA%S:#UNT(5)-<_WE?I N_7:+L9##_#<^W.VE@WCKZ"TA:.H=VJW#,^J=2Q##
MF,[--TL4U.*6AA %V@;&3.TEJP!?$[=OI&79GV.*[BGU8.Y6L:9%#)I+;>6E
MGYZUL"Z"K9;.-:CT]B)8CZFLP6LD]^OX4L;TCL,$$E23M7>EU]H36@V:6VVG
MM*[0XZ7Q BN1?_9OJB.(G;H,<CF:%#"0V8V;EB;3LT/).)1R,S$]4B.,0%A
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M6TM<8MN=UN@ +1.>N5Y*N?D&+KFLZ+S(D$6:@$F-CQ]F&AG*[MR>.DK/#;F
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M 3"K1M3W].R122028N&3U2[1 VSZ+!_L!]X5MGVD]"5]>[9Y<[=-I IYS"9
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MP<6+P0V]0:2M/I+5$,+$ 36VQ-J/(8#+V A9Y&I^M:>"Q.1/Z]6CZ0:G+RB
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M!]SS;[][91 85_D\W;'_ %0FM_\ %M+?Q=3\GF[8_P"J$UO_ (MI;^+JB21
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M(R>=RDT4NAIY8L=B*4^0NR10AIWKFD"M7E((@]J0F8!\W96;UB]VW_B6W?\
MN7Z__%/+("NIV;MVNV5NQB[^8T7KP[M'&WFQUL[D6B:!C:>".RPA%-I[J,?"
ME!W-O)G?CWK(O^9CV_/TX5_\:T)_%U=O]P7\7NL_MP#\#TE/$@(D>SA!VAM,
M:"W=R>\.>&YE:>FK&0T9:A/3]@J$]#"Y^Q=F8,5C*D#D-D<9((W8K &\7 BP
M>*)P?]G?O;]W,3J_3N2UOK"_J'2 WXZ^?Q\^+P-:,Z-J,H)[(3XW#5;36,<,
MK9"**.9O%>NT1 82.+VPNTM\7&O_ +2=5?@*^JGW8Y[*?\U/87=:&A%UZETO
MJ/$:BT\XM\\L2UL%.U_%.[,Y$&2HO($0-[KT5,_<),0%R''Y""W7@M59H[%:
MS#%8KV(3&2&>"8!DBFBD!W&2.6,A,#%W$Q)B9W9U[BA=[EKM7/K/0,NA\K,1
M9_0(5JM9Y"9SN:8GZ@Q4@\^TYXR2*7%V&X=HX0QY=7-CH":) %X=^/-_)F][
M_47E1I]ZCVKVVNVQOAC[/@:GU>-G3VGWC)FGJ^-7=LIF(V\W'X*IR]44S"XQ
MW[% 2_H@LX$*7;D[UK<F7<?4-/;;5MC!:0P,XX*H]"AA;T64N4WE:]E9;&2Q
M=XQ>U;&S!3BBF&(J5*&9A>4YG:QWV+M<Y;4VU.@L_GKIY+,9;3E&[D;TD=>&
M2U:E$GDF.*K%!7!R=O,888XV_0@RJQ[M]E8]!]EC36I\I6:'4.O]R]/Y203Y
M>>II^'2FMO@*G)U"SA)/'--E)P9_)[L44CO) [-9Q[O3XD=L?M3QO^H2 S)1
M$0!$1 $1$ 1$0!$1 %I%^V!\;^[GW5=R/QTSBW="TB_; ^-_=S[JNY'XZ9Q
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M,?G2U^QY_P!R)?17SLQ^=+7['G_<B0&][K_T./\ [@_ZK+]E^-?^AQ_]P?\
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M;9F>"/$#-)U2WMO\]/;GPIP\@)$.!R,60P4T?7.]6H&'<CCCN5X([:: (B(
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M):[W4R7@3V\%B98-,XN>5H6SFKLBST]-8<2Z9"8+>4E@>W($<IUZ$=NUX9M
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M1 $1$ 7!-SMS=/:,T]F-5ZLS%#3^F]/T+&4S6:REB.I0QU"J#R3V;$\CL(B
MMP(MU22R.$40'(8 7,+U^&K#-9LS15ZU>*2>Q8GD"*&""$'DEFFE-Q".**,2
M.20R80 2(G9FY6KP](6[[FYVC=6V-M]OLC+#L=H[*OZM8K3F#;D9^BSQ'J.Z
M,;B$FG:-@K$>F*4A3Q6P"+44HQSSTX*0'S^^[](+U9VDK^3T!M]-D-);%03-
M ]%QDI9_<0JM@C#)ZG<96*K@)2CKV,=I7H$A>(+.:DL6#"C0K<,S,S,S<,WD
MS-[F;ZC+RO8ITYK,\%6M#-:MVYX:M2I6ADL6K=JQ(,->K5K0B<UFS8F,(:]>
M$#EFE(8XP,R$4!ZZSV[$/=B;Y]HF_P"J[4Z#R.9QL4XU\AJW(F&$T9B2ZW&1
M[NHK_17GEAZ9'.AB(\IE'>*0 H&8D+6KNYW]%3&Y!B]Q^U'5D$)@BN8C9N.2
M:N0 3=<4VO\ (U9XI7F<7'G2] ABA]H<K>L&Y48+SF@MO<#I7#X_3NF,)B=.
M8#$U8:6*PF"QU3$XG&TZX#%!5HXZA#!4J5X8Q&..&"&., %A$69F0%,SL<^A
MN:*QPTLIOKN/G-5718);&D]!L&F=/>)RQ%6O9ZU!<U'?@9B>,WQ9Z<F(XPD"
MQX1G ]E3LZ]TUV;]J8H!T1LYH7&V:[ X92WA*N:S12 +"U@\OFAOY%[+L+=5
MAK#2GYN1NY%S(>B _@ 81819A$69A%F9F$6\F%F;R9F;R9F;R;W+^N%Y1 %X
MX7E$!^-BN$H'%* 2Q2 X21R")QR 3.)@8$SB0$+N)"3.SL[L[>:C;[2/<\]F
M;=B&<=:;-:)LV[ 2B68Q&)BTUG8SF+KEGAS.GO@S(!:,FY>SX[S\LSM)RS.T
ME2("C_VP_0U]-V@N9/8G<W+82T3R2U])[B1PYO#\NQF-2GJ3%5*69IPL31PQ
M'DJF>L #E)/9G(6$J=G;0[N#>WL^9-L=NSH#+:;@GG.#':AA>#+Z2S#B?1&6
M-U+BY+.-(YV<)(J%V6CEP"0!M8ZO-U1#NDUP3<O:_3>L\'D=,ZNP.(U-IW+U
MI*>4PF=Q]7*8N_6E%PDAM4KD4U>4'9_+J!W%^"%V)F=@-&4BNT]\KZ+%8TS5
MS&YO9CJW,GAJP6\EG=H9#L7LMCZ\8E/+/M_:D>>WE88V:1FTO=,[PQC%'A[=
MI^F@U)5BYY\B%Q(@(2%P,# G$XS F$PDC-B P,1,"%Q)F)G%@)U^YA[\C7'9
M4SE; W_6]5;*Y7(-)J'1CF4MO3Y63?UK4&B'DD&*C?$S:UD<,_3CLVP2>53)
M3>OOM.=@=_=([HZ.P&OM"9NGJ+2FIL?%D<1E:,G5'-#(SL<4P/Q+5NU)ADJW
MZ-@([5&Y#-5LQ13Q2 .CP5BST>WOF+G9MU_'HS6N3E+9/7-^.'-!:E,JVA<_
M:DBBK:SI,_7ZMCI/.MJBO&#12UBBR[O'-CIWL@;41%^%:S'-''-#($L4H#)%
M+&0G')&8L021F+N)@8NQ"0NXD+L[.[.SK]T 1$0!:@7O[_IQ^T!]N53\6, M
MOTM0+W]_TX_: ^W*I^+& 0$1*O!^A3?](^TA]A=I?W]N2J/BO!^A3?\ 2/M(
M?87:7]_;DH"_:B(@"X;N+_T>SOV&RG[QG7,EPW<7_H]G?L-E/WC.@-%AA_SI
M5_8\'[D*^BOG8?\ .E7]CP?N0KZ* (L[==]WQK;#[":$[1=07S6@-7YO46F\
MQ)2H3#+HC-87+R8O'QYN=IYPFQ^I/!E+'9,8:D%>\#8JT/K%FC):P20%J7T;
M3OL'V,U-6V5W(R!#M'K3,N^#R]J0BCV]U;E9!!C-S+IATKJ&XX#DQ!NC%Y>=
MLNXM7N92:/9CQ2B8B8$)@8L0&+L0D)-R)"3.[$),[.+L[L[.SLM$B8,0N),Q
M"3.)"[<L[.W#L[/Y.SMY.S^3_*M@5Z,)WWQZFJ8OLT;LY<Y-28JF]?:G565N
M-)-J3$TQ(FT1?GGXDDS>"IBSX"222>3*86M+4(ALXL/7 +M"(B (B( B(@"(
MB (B( B(@->CZ:1\9NP_VBZU_#^#5+U70O32/C-V'^T76OX?P:I>H";'T<GZ
M=G87[*ZX_@JUXMM^M2!Z.3].SL+]E=<?P5:\6V_0!$1 %JT/2NOIQ]0?<\V^
M_>V46TO6K0]*Z^G'U!]SS;[][91 5OE-WW!W=NZ#[46\>H-O]P\AJG&X7%[?
M9/55:?2.1QN,R19*EGM.XR**:?)X?-P'3>OE;)'$%6.5Y1A)IA$" X1%:\]#
MO^F<UC]QC/\ XWZ*0$_/Y3L[+GZ;-[_ONTA_P^3\IV=ES]-F]_WW:0_X?*UV
MB JB?E.SLN?ILWO^^[2'_#Y/RG9V7/TV;W_?=I#_ (?*UVB JB?E.SLN?ILW
MO^^[2'_#Y/RG9V7/TV;W_?=I#_A\K7:("J)^4[.RY^FS>_[[M(?\/D_*=G9<
M_39O?]]VD/\ A\K7:("J)^4[.RY^FS>_[[M(?\/D_*=G9<_39O?]]VD/^'RM
M=H@*HGY3L[+GZ;-[_ONTA_P^3\IV=ES]-F]_WW:0_P"'RM=H@*HGY3L[+GZ;
M-[_ONTA_P^3\IV=ES]-F]_WW:0_X?*UVB JA'Z'3V7"9Q?5F^'#L[/QJ[2+>
M3^7O_F?JRSV>=C\1MIH;2>W^ FR%C":.P6.T]BY\K-!8R4U+&5PK5Y+T]:M2
MKRV2C!GEDAJ5XR/EPA!N!;N1$ 1$0$-_?:]ZSBNRKM)9U!6:CD=Q]5>MX/;3
M3USQ#AMYMJ[%/G,G! 03%@-,Q2Q9#*,,M;UR0J6'BMUK63KRAJ6MT=T-1:WU
M)G-8:NR]S4&J-2Y&QEL[FLA(TMS(W[)<R32DS,(  L$->"(0@JUHH:U>.."&
M.,95._<[P"?M"]HK6&<IV3ET9HJY>T!H.%IO$K'A]/Y"Q5R&=KB)$ _-/EXK
M.5 AX,L=\%QSB,L! ,.'* +E6A="9S5.9QVG-,X;*:BU!E[ U,5A,)1L9+*Y
M"R;L+15*54))I79R9Y"8?#A#F28XXQ(VYMV?]AM5;I:WTQMUH?&'F-6ZORD>
M)PN/$GC YGBEM6;5N9@D]6QV-H5[62R=L@(:F/J6;)"31]!;7;NBNY:VV[*V
MF()*-2GJ3=++8^M'K#<2Y58KUB?HZK&)TV$[RG@--13&8QTJAQSY%@AM9B6W
M8CA]7 JD=@+T0C<#5U6GG]_]5R;98ZQT3#HS298K-ZT>N72[!E,S8#(Z:P=J
M0')WKUJVHBKNT33DTQ35J]M/LL]P[V5=HHJQ:>VEP&:RM=FYU%KB+YL\Y,?0
M G(5G.M:KP=9 TW@4JE2I%,[E7KPLPB,OO"\H#YV(Q%3'UH*5"K7I4ZT8Q5J
ME2"*M6KQ#]#%!!"(111BWD(1@(M\C+Z"\H@"\+RB \+$/M!=@'9+=6*Q'N'M
M7H75DEEW*:YE=.8V7)F;\^W\*A7CR+&+OUB36F<9&$V]L1=LO40%.SMH^A\;
M2ZECM979+5^?VSS)#UQ:=SDIZNT3-)R[N,;VW#5&)>3K=W>/-Y&E'X<4=;&5
MQ>0BI'=NGNU-Y^S?G PN[&CY\17MSR0X;5.-E^%M':A\-_HL/GH(PC\8P<9/
M@S*08S-1 7,V-C%NI]T(NH=]=A=&[FZ6R^B=?:<Q6JM+9RL=7)X;,58[568"
M;V)H^IO$JW*Y\3TK]62&[2LA':J3PV(@D$#1VK^3!B9Q)F(29V(29G9V?R=G
M9_)V=O)V?R=3X]^KW*.8[*6K:V;T])<S>S&L<C+6TIFK3R37]-Y8HI;?S&ZC
MLNW3-::O#9GP.4(F+,8^I8&P 7Z-@K,"" OG>C#=^%;R4N*[,V[N:>Q;CK04
M=G=49&8SLW(*D1!_,_RMN8R:>S3J1POI*<W::Q3AGQ$SG-6H%8O1+128'/W\
M3?Q^6Q-VQC,MB;]+*XK)4Y'AMX[)XVS%=Q]^K*/#QV*5R"&S ;?0R1"_R>>X
M7[G/M_P=I+8/1NXLK1P:F"*?3FN* ./YCU=@)/4<G* CY!4S #7SV.'WC0RE
M>*1@GCFC "41$1 %B]VW_B6W?^Y?K_\ %/++*%8O=M_XEMW_ +E^O_Q3RR B
M^[@OXO=9_;@'X'I*>)0.]P7\7NL_MP#\#TE/$@.D^TM\7&O_ +2=5?@*^H6?
M1]?^BFXWVPX3\$R*:;M+?%QK_P"TG57X"OJ%GT?7_HIN-]L.$_!,B Q>[0^)
MN=ESM+8W6^)K21Z)U=9LY*6L N-23%92P$6K</"T?LM-B+4\67Q\+-Q"QXT.
MDH'.,K4&%S-7(TZF0HSQV:5ZM!<J6(B8HIZUF(9H)HR;Z()8C$Q?Y6=E@3WF
MG9;;=/:W+TJ5<9M2:>&346FGZ6\66[1A,K6-C+]"^6H^/2#EV!K159)'Z(G6
M(_<E]JM]4:,M;<9:<GSFA(Q?&C.3M8M:7L3D$ ])\2/\!VS;&2"[?F:K+C(B
MXZA9 3?D3,SN[LS,SN[N_#,S>;N[O[F957=:36.U7VG*^*K.<^WF@[,D$L\3
M_.)=/8;( ^4LB[^3%JS*QA1K2BWB/C2K3.+%7< E?[V?M6EMIMA<IXNRT&I]
M9/)@<.8FS2TJ9BSYO*"/D3/5QY%6K2-PT=^[4E=C&,XRX]W/_93_ )GNVD.?
MR51X-3:^&GF[WC XV:N&&*0M/XV5B9CC*.M:GR$T1\2!9R,L<S"<70 '47?S
M5HX=G-+11 $<46Y&%CBC 6$(XPTGK(0  %F$0 681$69F%F9EGUW>GQ([8_:
MGC?]0E@9W]_Q0:9^Z7A_Q5UFL\^[T^)';'[4\;_J$@,R41$ 1$0!$1 $1$ 1
M$0!:1?M@?&_NY]U7<C\=,XMW0M(OVP/C?W<^ZKN1^.F<0&.ZV/?H:_Q ;D?=
M=O?BEI9:X1;'OT-?X@-R/NNWOQ2TL@+>J(B (B( B(@"(B (B( B(@.B^TUV
M>M.[L;?ZOVWU95]:T_K/ 9' 9(&Z?&ABOUSBCN53(2:*[0G>.[2FZ2\*U!%)
MTOT\/I6-]=E\UMQK;5NWVHA9LYHK466TUDS$'C"Q8Q-N2L-V*,O;C@R, PY"
MN!^V,%F)B\^5O&G6J2])\VDATIVR=P)JT(P5]88'1FM $69NNQ?P_P #9"8N
M/HBFR. MRN3LS\GT\.PL1 5_5:V]$([2%K2_:.U'M]+9Z<+N=M_?/U4G9A+4
M^B[U7)X:P)$_ \87(ZJK'&+.4YSU'ZF:NPG5)4GW<K;E'I/M9; Y<2(0EW#Q
MF"G$2D%I(=3UKFG&CD:/S,'GRD!]!,X,8 9,S!U,!N,67E$0!1C=[AWC^$[,
M&S.>W"O!!?U'8_Y"T)I^65HWSNK;\4C4(9.&(VQV. )<KEY0$BCQM.=@YFDA
M$I.5J??2*N\D+M![^Y2C@LB]O;C:J2_HS1XP67FQV3R=>T46K-5U^D0B-\MD
M:X8VG9#Q0FQ&'HSUIS@MN1@0H[L;JZBUUJC4&M-796QG-4:IRUS-YW+6B=YK
MF0O2O+*3,[NT5>(>BM3K _A4Z4%>I"PPP S=?HN<;9;:Y[6>H\#I#2N,L9K4
MNI\M1P>"Q547*>]D\C.->M"W#.T43$3RV;!\15*L<UJ<@@AD-@,NN[E[N_7W
M::W*QVW>A:S0QMX-_5FI[0.^(T=IOQO#LYC(.W!6+,C#)7PV*B?UC+9'H@8J
M]0+MZGMF.[Z[O3;CLU[?8_0&W6,\&&,8[&?U#=&&34.KLUT<6,WJ"]'''ZQ:
ME=R"M7C&.CBZ;18[&UZU*"*(>F>Z([L73/9:VEQFC,:%6]JW*A5R^XFJ(H6"
M;4.IRKL,PQR%U3MAL1XDM#!5))'&O48YN@+%RRYRF( B(@"(B (B( B(@"(B
M (B(#J3?38C1^YFE<QHC7FG\=J?2N>JG3RN&RD/C5K$1-Y&)"X35K,)<2U;E
M62&W4G$)ZTT4H";:JKOL.Y;U/V3M80V*$E_4FT&J+,@Z-U=88);F.M^W(>DM
M5G!'#'%FZL(M+1R+004L[2?Q*_1D*V0J0;;!8Y]K/LKZ-WKV]U+MGK[%QY73
M.IZ+U+41-TV*=F,PL8_*XZ=OGE/*8J]%!?Q]N)QD@LP1DSN/4) :1M>';W<.
M0NSB0D!.!@8$Q!)&8NQ!)&;"<<@.Q@8B8NQ,SMF=W@/8AU7V=]V-5;5ZM I;
M&$ME8P>8:-XZVIM*W99BP.H*C](A^;:D?AWX \J.5@OT7Y:N)GAD@-H_Z-WW
MNLG:'VSFT-K;(^L;N;84\?2S-F=A&;5VF)!*KA=6"XB 37^:TF.U$,8L89"*
M&](+1Y6 BLHK2R]W;VUL[V>MX]%;KX([!C@,B$&HL7!+)&&H-(9$HZ^I,'.(
M=33-9H\VJ(R1RC!F*6-NC&\M6/C<O;7;EX36>FL!J[3=^#*:?U/AL;G\)D:Q
MA+!>Q66IPWJ-J*2,B @FK3QFSB3MY\<OP@.>(B("C_Z9CV4VM:9VHWLH5.J?
M!YJUMWJ*S& \AB\_6M9G!367%NOP8,MB[5..4W>.*?*Q0,W7;%4#UN<N]*[)
ML6^'9_W2VT>!IKV?TO<EP?SOQ3BU)ARCS.G9X Y;F>+,T*91<.WM\-[N5IB(
M",@%Y(RBDX;Q(C9V**3W'$;$S$)QDS@3$+$SL[.S.SLP'Z.<H\'!(\4\;C)!
M*W#O%,#L<4K,_D[QR")M]<5NAN[+[5L&]VPFUVY\4S36-3:5I'E^#8RAU%C"
MDPVHZLI,S-X]7.X_(5YV9F898S%O<M+TM@[Z&MVJ1R>@-SMF;UWKMZ0U)!K7
M 5)#Y./ :M@&MDXZ_7([O!!J#&6;4D4(=$$V5>25P>U%X@%U-$1 $1$ 1$0!
M$1 ?G+(("1F[" "Y$3OPPB+<D3O\C,S<N_U%IK>]R[5A;U=I+=S<*.R5K%WM
M438/3A.3%%'IG2<$.FL.U7H(XFKVHL8>38HG8+$^0GN$+2V9.=G!WZ_:V?9K
MLM;L:FIWBQ^H,OIVSHK2EB*0HK4.HM9 6 HW*9QNTH6L6%V?*P2@Q##)1&68
M?!"0FU ,,0Q@,8-P("("W+OP(LS,W+\N_#,WF[\H#]%<=]#I[(AZ@W2W"WGR
M-/JQ>W^ KZ/T_9D;V)-4:L)KF5>#GJ8I,5I^A7&=W8'C^:"J\9ES,(TX#-A$
MB)V$19R(G?AF9O-W=W\F9F\W=;;7T>#LAGM!V4]MJ5^C)0U'K6@^XVI8;$+P
M7(KNKV#)8^G<CDCBL16,;@BQ-&:M9!IZD\$M<V%X^E@*67I6?9!/;OM-3:VH
MUGCT_O'I^IJB.46^=#JK"M'@M4U.>IW\0X8<%F'(N&,\O,$;=-=^*S*V@/I7
M'9!+</LQW-;8VGZQGMG<Y0UD+QQ]5@M,62^!-6@+LXOX5'&WPS\_41"U?"S.
M$4D[Q,M7\@.Y>SKO_FMJ-?:,W-TZ3MF=!ZCQ>IZ47B%"%QL98&6YC)I 8B"M
ME\>]O%6B$2(:UR4@;K87;=M;>:\QFJ<!A-2X6=K6(U#B<?FL799F;QZ&4J17
M:DCBSETD<$P.0<NX%R+^;.M& MHQZ*MVORW*[,%'2N1L-+G]GL_<T%9$Y1DG
MFT\5>MF])7W!O;"#X,R,F"C*1^N6UI^[(WL.'(%EA$1 $1$ 1$0!$1 <8UMK
M'':=PN7U!E[,=/$X+%W\QE+<K\15<=C*DMV[9D=F?B."M!+*;\/P(OY+27=J
M3M"Y#=K<K7>Y^48PNZ[U3EM2/%(0D=6G>L/\%43<.0<Z&*CI4B<'<"*NY"[L
M_+[-WTGKM9-MAV4M5XRK8>'-[J7Z6VF+&.0@G]6S,-J[J*<'C)C (--XW*"4
MKMX3RS5ZTCL5J)BU5+-Q[O)F\F0'E79_0UNR&]_5NZ&^>1K?F?3^*K[;Z5D/
MAQ/(YJ6IG=57  @Y8ZE&A@<?6L1R.SCD<O6,!=F<J2<\PQ@<AOP("1D_OX$6
MY?R][^3>YO-_<RV^O</]CR39+LM[7Z5R%<Z^H\OB3UOJP)08)HM0:SF+.V*$
MHB[MUX6I:I8-G8B8QQK2=1.9$X$P"(B +2M]X]],9VA/N[[Q_P (^I5NI%I6
M^\>^F,[0GW=]X_X1]2H##-;";T+7XL-\?NDX/\4J2U[*V$WH6OQ8;X_=)P?X
MI4D!=*1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!3L],Z^(W:/[L8?B'K):Z)
M;%WTSKXC=H_NQA^(>LEKHD!E'V&_CMV;^ZKMY^-N(6[-6DR[#?QV[-_=5V\_
M&W$+=FH B(@"(B (B( B(@"(B (B(#^3!B9Q)F(29V(79G9V?R=G9_)V=O)V
M?WLM0YW\_8<K[!=IK7>F,/3&GH_4_J>X.BHHW^=08;4_C%DL< LW$ XG5-34
M%"O68B\/&18V5FB"Q'#'MY50R]--VN@"UL)K<0%K$WS9Z1E(6!CDB:/$YN+Q
M'X\0VA**5HN7<0\:7AN3=T!1<6:/=Q]H:?:G?W9W<&*P5:#3NX>F2RQ@+&YZ
M<RN2APFIX>AW$7*;3V2R01.3],<_@S$Q-'TOA<OPM7#KQG8CX\2NSV(^?-O$
M@^>ARW+.[,0,[LSMRWRL@-[NBZJV)U#)EM$:-RLQ=4V3TKI[(2EQQU2W<13L
MR%QR_')2N_'+\<\<NNU4 59?TM?Z4#)_=&V]_"TJLT*LOZ6O]*!D_NC;>_A:
M5 :O=?.S'YTM?L>?]R)?17SLQ^=+7['G_<B0&][K_P!#C_[@_P"JR_9?C7_H
M<?\ W!_U67[( B(@-?%Z:9\86P7VFZ^_#>F%2L5U/TTSXPM@OM-U]^&],*E8
M@)L/1T/IS]D/LGJC\1]2JXQZ2%W(O\W73<F\&V>,!]X='XU@R.+K"$9[AZ6I
M"9EBR?@1DU)AXG.;3\\I,]J$9<++( STY:M.?T=#Z<_9#[)ZH_$?4JVX" T1
M_FSNQ"0$)$!A()1R1R 3A)')&;"<<D9B021F(G&8D!BQ"[,5W#TGGN/QT_9R
M_:9VDPXAA+LLM_=_2V+IQQQ8J]/,\EC</'PUA%O5<A+*<FL(GC;P+3/J!Y3:
MUD6CI'H">_N%.^0O]EG< L1J:Q8L[+ZYR4'S:T!&6<]-Y0J\=&KKC$UX^KF:
MM'#3JZAK #ED,+7"2/\ -6-JC+M8M*ZHQV<QF.S6'O5LGB<O1J9+%Y&E*%BG
M?Q]Z".S3N59XW()J]FO+'-#*#N)QF),[L[+17*Y9Z,7WW9:$RN/[..[.;8=$
M9NU#6VKU'D[#M%I+.W9Y&+1E^U.3A%I[.V9HBT\<A118;+E-CG(ZF5IAC@-B
M(B(@"(B (B( B(@"(B QV[7WQ2[H_<[UM^+636D'P_YTJ_L>#]R%;OCM??%+
MNC]SO6WXM9-:0?#_ )TJ_L>#]R% ?16V#]&)^D?V6_9&Z?\ #-N&M3XML'Z,
M3](_LM^R-T_X9MPT!/:B(@"(O@:JU1C\)B\EFLM;KX_%8>A<RF3OVI0@JT<?
MCZ\EN[;LS2$,<,%:M#+--+(0A'&!$1,S.[ 0+>D,][.79GVGCQFE+0#NQN0]
MS"Z-87$CT]CXH'^&]:3@3.W1B!DKU,9&_!6<U?I<-ZO6N2PZIR>Q++))--+-
M8GGEDGGL6)#FL6)YC*6>Q8FD(I)IYY2*6::0BDEE,I#(C)W>1#O6.WSDNTIO
MCK#<ZQ-.V GLMA-!XV5Y&##Z)Q#E!AX8HI!C.*;*EX^H,EXD<<SY'+6 ,(XX
M88(8ZD 5IKT=KN)Q[0.4@W?W3H&^R^G\G8KXG!RO)"^Y6>Q<SPV:TKCTG\R&
M(NQG7RY1DSYJ_!-AQ(:L&1\6)/NEN[ES/:@WGP&W50K5+35;HU!N!G:T9.6&
MT?1LPC>""1O8ARN;D,<-ASD=ABMV2NN,P4I()-P/MAME@-%Z=PFDM+8JG@].
M:<QE/#83$8^$:]/'XVA %>K5KQ S"(1Q +<^9&7)FY&1$X')\)A:>-I5,=CZ
MM>C0H5H*=*E4ACKU*E2M$,->M6KQ",4%>"$ BABC$0CC$0$6%F9?41$ 1$0!
M$1 $1$ 1$0!$1 %5K](M[CFGOQI>[NYMKC @WITABI)+%"F,, ;DZ?HL,TN&
MO,X-XNI,95CLEI:[XD1V))"PUZ26M/2DQ]I1$!HDY8CC,XY8Y(I8I#AFAFC.
M*:&:(RCEAFBD89(IH9!..:*01DBD$@,1(79OS5J'TJ'NS:^T6[-'=W2=!J>A
MMXK=LLE4JUVCH8/<2I7:UE(8O";PX(=4T@EST%<QCYR-7/20%)&3Q5:KR MG
M^BF=YQ+MMNC-L3JK)FVB=V+D/S)#:EXJX#<8!D&&"JYNS01ZUKN&/E@_H<V;
MHXAJXA;OV/6]E"M%'@\]?Q5^AEL5;EH97$WJ65Q=^ R">CDL;:BNX^Y"8N)#
M+5MP0SQNQ,['&WFMS5W8O;%K;^;#;:[JP^&%O4VGXQSU6-R=J&J</8GP>J*#
M=<<1N%7/8W(1P2O%&-FLT%N$? GB)P,\D1$ 1$0!$1 $1$ 1$0!$1 8W=LGX
MH-U?N;ZY_%C*+2'X?\Z5?V/!^Y"MWAVR?B@W5^YOKG\6,HM(?A_SI5_8\'[D
M* ^BMLQZ-)])-LG^Q]<?PD:P6IG6V8]&D^DFV3_8^N/X2-8("=A$1 $1$ 1$
M0!$1 $1$ 1$0'#-Q-N\%J[!973.IL31SNG\[1GQN7Q&2@"U1R%&R#QSU[,$C
M.)@8OY/Y&!,)@0F(DVJ@[]WN;+_92U]6NZ=]<R6SFN;=HM$9.U(=JWI_(1"5
MFUHC-6S;KFM4J[%9PF0F=Y<KB(S:>2;(X[(32[9)8=]OCL8:7[0.TVL=JM61
MB-'4N,EBQ^2&();6G\]79Y\'J+'];/T7,/D0@M@PN+3Q!-4E=X+$H$!I4U]_
M2FJ\I@<KC,YA+]G%9G#9"GE<3E*4GA6\?DL?8CM4KE8^'89:]B*.06(2C+IZ
M) .,C!^;;Z[+:@VWUIJK0&JZKTM1Z-SV1T]F(.DA#UO'SE$UB!C]IZEZ#P;]
M(W=WDIV8).?:752 W$/<W=XA3[3&Q.E-?22U&U=2ACTUN)CZ8O%%C];8FK6;
M+%#6(Y)*U'+#-!F\9#(<A1X_)5X_&G\/QY)3UK#?13>W7_,P[04FVV7O>KZ7
MWMIU\'&$\S!5@USA1N6]+S ,A!&%G+5Y\G@F)B\2W8L8NFP32M4&/9Y( B(@
M"U<GI97TX62^YEH#]TU MHVM7)Z65].%DON9: _=-0("M4K5GH?7TT.I_N.Z
MC_&?1ZJIJU9Z'U]-#J;[CNH_QGT>@)'O2@.Y#*T.8[3VT^*%[->&?(;QZ9HQ
M<%<K01L9[@XV&-F8[E.$)/FL@87ENTQCS$9/8IW([E#,29V9V=G9V9V=O-G9
M_<[/\K.M[7:JQ3Q20S1A-#,!Q2Q2@,D4L4@N$D<D9LXF!B[B8$SB0N[.SL_"
MUA_I&/<EGV?-52;I[;XPFV6UGE!"7&TJK!7VVU->=W^!'&!O"ATOEYQ.33TI
M!7CQ]F5M/^WTX\YP*PRMG^C3]]LVS>>I[$[GY48MJM4Y*1M(9NY(?AZ"U9EK
MC2/2GE?F.#2NH[MB:2P9^''B,U,UMR]4R%MZU3!?R8"0N),Q"3.Q"[,[.S^3
ML[/Y.SMRW" WN+$SLSMYL_FWU_UEY5+ST8OOOGUKCL=V<=V\X4NML/6.';#4
MV5LN4VK]/T:S&VD[]J<G.SJ?3]:&8\?++*4^:P40CTR7L5:GN70T 1$0!$1
M$1$ 1$0!0Q>D-_27=H#[3ZWXQ813.J&+TAOZ2[M ?:?6_&+"(#46+P_N=>5X
M?W.@-SEW3OTK'9I^X!LW_!UIQ9_K #NG?I6.S3]P#9O^#K3BS_0!$1 $1$ 1
M$0!$4&?I#';_ 'V"[.&IKF)M-#K?< WV_P!%B,@A/!=S5>?X8S8"XF3A@,#%
MD+XNP=)7_@ZJ<D/K8R@!K[._E[>@]H+M(ZPU#C+7K6CM'D>WVAS G>O/A=/7
M;0W\O W+_.\]FY<A?BD9_GU#U B8'9HPAN7YPQ#& @//2 L(\OR_ MPW+OYN
M_E[W\W]Z\FY,WL <IOPP11"YRRR$_2$48-YG)(;L$8,W)&3"S<N@+7GHEW8*
M+<+>[);QYJIXFF-FJI#AWD;F&YN#J"E-5H\-[C;3^!GO9$A)N OW\/8C+Q*I
M,VRW43O<H=@>+LZ=GC16A;-88M59&*35^O)GB&.>QK#44<-B_!8X "-L+3CQ
M^G*GBL\HT</5"0CD$C*6) :Q#TJ_L%OMAV@/YIV(KO'I3>VN^9D$1XAQ^N<+
M4IX_4M0'\(6:/,5H\?J,&*6>4K]S-/\ .*H4X1J_+;G]_CV!V[079PU=@,?4
M:QK'2#-K[0I!'U3EG]/5+;S8R-QXD>/.X:SD\.<0]?5);@F"&2Q7K].HJKSC
M+&$@?0R )C^L3=3<_4?A_-OD= 2G=S-V[).SOVA]":\LV)(M+7KH:/UX =9"
M^D-26JM6]>*(!-Y3P-L*6> & C./'35XNB2P,@[B&K:BGCCFAD":&4 EBEB,
M9(Y8Y!8XY(S!W$P,'8@,7<2%V=G=G9:).2,3$@)F(29Q)G]SB[<.S_6=O)UM
M5O1GNWY+O9V<,1A\[>];UQM/:^8+4)RRF=K(8NI"%C2.;E\1R-RMX"6MC[<K
MR'XV4Q60G88(YHH(P+#J(B (B( B(@"(B (B( B(@"(B (B( J_GI0_TDF[/
MV3VO_A8T2K :K^>E#_22;L_9/:_^%C1* U22^;F?SI:_8\W[F2^DOFYG\Z6O
MV/-^YD@-IEWR_=RR=H/L<:<^ *0V=PMM]'::UQHIFZ1FR)8_3=1M0:;&0G8&
M?/83UJ&GU](#EX,8<DD4+3$M6\)<LS\.W/O8A<2%_E$A)F(29_)Q)F(79V)F
M=G9;PGLW_%WH+[2]+?@.BM6CZ1#W=S=G[M#YPL-3>MH+=(LAK[1@QP^'4Q\U
MRZQ:KTY6(.8FCPN;MM9JUQ:,JF)S&+K>#X<4<\X$$9@Q"XDS$),XD+MRSL[<
M.SL_D[.WD[?46SZ]%H[Q0MWMBWVZU%>]8USLQ)4TW(\TO7:RVB)JXEI+,%UO
MXDDE4([>GKI-UCXN(@LD8O?&"+6#J3GN>^WM:[.._P#HC<,[,L6EI[?S,;@5
M =O!NZ-SKM4NSV!?WOI^X=/4U4Q<9 FQ+P]3U[5J&<#<;HOF8;,5,C3J9"A8
MAMT;U:"Y3MUS&6"U4M1#/7L02@[C)#-$82QR"[B8$),[L_*^F@"(B (B( B(
M@"(B (B( B(@([^]2[=V*[..QVM=S[QPEDZ%-L5I''2N/5F=99GJJ:>QT<9,
M_B#ZT[WKOLDT.+I7K4C>%7D=M-MJ+4>1S.1R.9S%R;(Y?,Y&]E\OD;)E)8R&
M5REN:_D;TYDY$4UN[8GL2.[N[G([\JTAZ5OWB8;H;STMG].7QLZ-V9>0,K)7
MD8ZV4W%RM2-\H;$/D8Z9Q<\>$!V?ALC:SD9,[0PR*JP@/#OQYOY,RV3_ *)O
MW=$VV^T>3WHU/0"OJW> X),#'(Q/:QNV^.?_ )%&429F@GU%D7NYZ2(6(O@V
M3"#.0V FKP4;^ZM[!.0[2>^&CMKX!LQX.U8?-ZYR%9GZ\9H;#S5I,],,O(C7
ML9 9J^#H3D7,.0RM:88YGB\$]R3IW3U'$8^CBL95AHXW&4ZV/Q]*L#1UZ=*G
M"%>K5@C'RCA@@CCBC!O(0 6;W(#2 ;_?&!N!]ONM?QGRJZG7;&_WQ@;@?;[K
M7\9\JNIT!LE?0U?I:-QON_ZD_@SVF5MM5)/0U?I:-QON_P"I/X,]IE;;0!$1
M 8O]M[XEMWON7Z__ !4RRTCV'_.E7]CP?N0K=P]M[XEMWON7Z_\ Q4RRTCV'
M_.E7]CP?N0H#Z*VT/HU?TDNQW[#UO_"9K-:EY;:'T:OZ278[]AZW_A,UF@)S
MT1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 :'S"_G.K_:(O]05]-?,POYSJ_VB
M+_4%?30&SC]$+^E*F^ZQKW_5PBM&JKEZ(7]*5-]UC7O^KA%:-0!$1 $1$ 1$
M0!$1 $1$ 7S<QAZF0J6J%^M!=HW:\U2Y3M0QV*UJK8C**>O8@E$HYH9HC*.6
M*02 P(A)G9W9?21 :P'TB;N0&[.FHX]S=M,?+_,5U=D'@FQX&\S;=:FM2=46
M%Y/YXVFLPY&^G9"*5\?8BGP\\@1OBO&K&K>!]I'L^:7W6T'JS;G6F/CRFF-8
MX2[@\M4D;@F@N1. 6JTC.TE:_0G\*]C[D)!/3O5Z]J"2.:$#'33]N'LDY_8G
M=K7.TVI/$EOZ/S4E2K?.)X1S6"M1A>T]GH!X87ARV(L5+).#,$=I[-;@3KF
M 8KQRG&021')%+%($T,L,AQ30S1$,D4T,L;C)%-%((R12QD,D4@B8$)"+MMA
MO1Y^\W_GC]C*$>H,B%S<[;4,=I3<!C(6N9 O5Y@T[JV>(6$6'5-"A8GFEC%H
M#S-#-0PM'ZL4,6IV4Y?H[_;P/8OM,:1?(6WKZ-W.GI[;:M$Y1BJ5SSE^&+2^
M;LN;C&(8?4,M>*>>0@"IC,GD[1DXQ.! ;:5$1 $1$!44],E^EYV\^[#B_P 4
M=7+6]+9"^F2_2\[>?=AQ?XHZN6MZ0'?G9/\ C7VJ^Z?MY^..%6[T6D+[)_QK
M[5?=/V\_''"K=Z( B(@"(L9>V7VIM.;)[7:VW4U7,,6%T9A)\G+&\@QR9"Z9
MQTL/AZQ%Y/=S>9M4,11C9B*6Y=@C$2(F%P*K'I7W>Q3:0TY%V:M"Y  U!KG$
MR6MT+\$G,^'T1<;P:NF8G ^8[FL>+(Y%S%GAT]7FA%GDR\4M;7GLW'DS<,WD
MS-\B[A[06^NHMS]=ZOW&U;:DN:CUMJ')ZCRLDDQSM!+D+!25\=6.1W<<?AZ;
M5L1BZXL$-7&T:M6"*&&((@Z?0']1@1D  !R22&$4440%++++*31Q10Q1L4DL
MTLA#'%%&)')(0@ D9"S[(GT=?N#:FT>*Q6^&\.(CL[LYJE';TMIN^P3U]ML1
M;89H)YJS@\3ZWOP^#)=L&4Q:?A=L91*"X63FFA<]%;[IZ#=#6MG?W76+:SH;
M;?*M1T7C[L'72U)KZ"&.Q+DSCD;HM8[1T<]:2+V9()M0SQ"7$V&FC6R(0!$1
M $1$ 1$0!$1 $1$ 1$0'AU2$])D[B>OEZ.:[2>SN&*/4%"(;NZFCL5!$,&<Q
M=<#]:UQB*,$0F^H,?'X1Z@KP.7PMBZYWXJY9.K,]^[XO7M58IXI()XXYH9HS
MBFAE 9(I8I!<)(Y(S8@.,P=Q,"9Q(7<29V=V0&B5 Q)F(78A)F<29V=B9VY9
MV=O)V=O-G;R^HA@),XDS$),XD+MRSL[<.SL_D[.WD[?44YGI!'=IQ=F[?G(5
M=/U3K[<[CQWM9Z#C&)PK8H2M@&H]*5Y&Y XM/9*U!)2CY&6MA<MB8) +PAL3
MP:H#9@>BI=Y3:W7VBO;1ZNR3W-;;/>IT<79L2%)=S6W=N-@T_:G,^7FM8&S%
M:T]8D<G.2E5Q%B5Y+$]@U:P6G4[E[MBR[%]I?:_7$ELJN"M9GYCM8!XG1!9T
MKJ]AQ%MK7+B+PXS)R8G4 =9QA':PU>20VB&02W%$<@F(F!"0$S$)"[$)"3<B
M0NW+.SL[.SL_#MYL@/[1$0!:@7O[_IQ^T!]N53\6, MOTM0+W]_TX_: ^W*I
M^+& 0$1*O!^A3?\ 2/M(?87:7]_;DJCXKP?H4W_2/M(?87:7]_;DH"_:B(@"
MX;N+_P!'L[]ALI^\9US)<-W%_P"CV=^PV4_>,Z T6&'_ #I5_8\'[D*^BOG8
M?\Z5?V/!^Y"OHH#9^^C:[3Z=UWV#L-HS5N)J9S3.ILGN7ALWB;T;2U;V.OZF
MR<-B&07\Q+I+JBE!QE@F$)X3CEC QH^=\MW3FI.REN=-@S:YE=M]2RV+^V^K
M)W:4KV/!ADLX#,2@ !%J/ D?@V1<6')4/5<M [O/:@J7R/16OI-=$?;/K_\
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M_MP#\#T5/$L#^P-V)6V.T]FL"VIGU1\+YALMZV^&;"^K\4X*GJ_@-E<KXO\
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M-6"'X1TKJ6M&#WL7;!B+Q*\G4-S%7HR."_CIX)A,9FL002$H B(@"(B (B(
MH8O2&_I+NT!]I];\8L(IG5#%Z0W])=V@/M/K?C%A$!J+%X?W.O*\/[G0&YR[
MIWZ5CLT_< V;_@ZTXL_U@!W3OTK'9I^X!LW_  =:<6?Z (B( B(@"(B \.M6
MCZ4#V]I=WNT9?T7BK92Z+V7A/2>-".0"K9#5EH(;>L,PS1\B;P6'JZ=K$9&4
M0XB[)'X8WY0?8!=[SVYH.SOV?MPMR(YJX:BK8B;"Z'@L@4L5O6^=C/'::"2
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M]5JPW;,T76;POFJ4U#4$0NXB4&5B., C(1:7% $1$ 1$0!$1 $1$ 1$0!$1
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M4,OBK<-_&92G6R&/NUS:2O;I7(0L5;,)M]%%-#($@/Y<B3<LSH#[B(B (B(
MB(@"(B (B( HRN][[?%/LW["ZUW&>6O\T34CP&A*4[@[9'6^:@G@P,/@D_58
M@IRC)E[\0-Y8W'7#,HXP.4)-5K!?2FN\2@W?WSAVWTYD!N:+V3?)X.26M*3T
M\EK^^5:/5D_ DX6"T\]*'344[CS7N09V&#B.8Y;(%9G+YB[DKES)9*W/?R62
MN6LCDK]J1Y;-[(7[$EN]=LR/YR6+=J:6Q,;_ $4DA%Y<KY[OQ[_)D4F7="=@
MF[VC]_-$;>>JSRZ7BO!J3<&['X;18_1>#,;>1BE.7D?%SU@:NG*<8!-*4^5]
M8> JM2W+"!>-]%#[O&/;7927>+.T/!UCO5'4R-"2<3]8H;=T))RTO7A8^&@C
MSY33ZFE>(6*Y5N8=YY)1IU0KVL5\_$8JM0J5:-.".M3I5X:E2O$/3%7K5HQA
M@AB%O(8XH@$ %O<(LR^@@-'/O]\8&X'V^ZU_&?*KJ==L;_?&!N!]ONM?QGRJ
MZG0&R5]#5^EHW&^[_J3^#/:96VU4D]#5^EHW&^[_ *D_@SVF5MM $1$!B_VW
MOB6W>^Y?K_\ %3++2/8?\Z5?V/!^Y"MW#VWOB6W>^Y?K_P#%3++2/8?\Z5?V
M/!^Y"@/HK;0^C5_22['?L/6_\)FLUJ7EMH?1J_I)=COV'K?^$S6: G/1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!H?,+^<ZO]HB_U!7TU\S"_G.K_:(O]05]
M- ;./T0OZ4J;[K&O?]7"*T:JN7HA?TI4WW6->_ZN$5HU $1$ 1$0!$1 $1$
M1$0!$1 %1:],D[%L)8_;7M 8FDWK-6\6VNL[$(^T=&_%<R^D;MOI%^8J=^KE
M\6,QF QS9FI S&5@>B]*HTN^([-8;M=F;>3130-8NVM%Y/+X<'%Y"'.::!M1
M88X@9GZK Y'&5WKMY?/O#X('9C8#3>+^H[$T)A-6F*O9@DCGK6 _HE>S 8RU
M[$?N^>03 $H/RW20,_++UJTS2QQRMRS21A(S/\C&+$W^9_Y?)^Z W./=9=K&
M/?#L][4[G,_YLU%I6M%FP<G)X-2X*>QIW4]?J)W.08=08K(A',?25B)HY_#C
M:5A'/]4\_0WM^RS&RFX>W=B82ET+KX\G0A=S>0,5K#'PWR+E_9&%\O3R?0 M
MPTCRD[D1NPW#$ 1$0%13TR7Z7G;S[L.+_%'5RUO2V0OIDOTO.WGW8<7^*.KE
MK>D!WYV3_C7VJ^Z?MY^..%6[T6D+[)_QK[5?=/V\_''"K=Z( B(@"HG>F.]N
M8XH] =G7#VC%[L5?<S7(Q%Q&5&"Y>QFC,7,0B_6<V3H9C,SU_$ H&QN*FEBD
MCO5S"]BM-'WM7:N;>SM&[L;AP6&M8F_J>UA=-S"_5')IC2_& PLT!](N5>[7
MH/DH'(1/P[S,3,3<,!'6N=;7;8YS6VI].Z,TS5:[J/5N<QFG,%5?J:.7*9BW
M%2J/.8B;Q5(9)FL7;'00UJ<4]DVZ(B7!5:.]$I[)[:Z[2>0U[D*?CX3:#2%O
M+P3%X3@&L=4SM@M.Q]!?/'<,.&K;WBP\>!-4J!([C9Z7 V(78N[*VGMDMK=%
M;6Z8C%L5H_!U,9ZPT;1R9*^PO-E<O9'DG>UE<E):OSN9R%XEAQ>0^GE90(B
M(B( B(@"(B (B( B(@"(B (B("M[Z4KV/Z^Y?9<S^JZ],9M1;.W(=?XRP(.5
MF/#0]-'5]:-Q'EX)<%-+>LQF8P<XR"R;%-4KN.K16\FWFVXHZQT?JO2.4KC;
MQFJM-9W3>1JFPN%FCG,7:QENN;&Q!TS5[4D9,8D/!/U,[<LM2Q>]'][8U*>>
MG'L/J^_'4FEJQWX;NE1BNQUY"BCN1C+J1I1"R -.(R-UBQLQ<NSN@(>K$(R
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M\O>WD_N?S;Y?-?J@-JKZ+KOU3UKV0-#XZ*;Q,CMWEM1[?YB'@!>M-C,@^5Q
MMTOR8SZ9S6#M/(8 [RS3 W6T?B'8;6K ]' [V2CV<-U;FF-<WPH[3[HE3HY[
M(RA*<>E=55?S/I_4TOAGQ'B9PEDP^H92AE>M6EH93K@K8RXT^TSQ^0@MUX+5
M6>&S5LPQV*UFO*$T%BO, R0SP31D4<L,L9#)%)&1 8$)"3B[.@/<1$0!$1 $
M1$ 1$0!$1 %7*](C[H[7_:KTOMK4VTLZ0IZAT7J3+7;D^K\MD\34DPN5Q)59
M:]6;%X+.RR6'O0TIBCE@AC\.(B\1R815C5$!K(_RH'VL?Z][(_?KJ[_ATN^.
MRQZ*=VHM%;H;:ZRRN;V=^"M(;@Z+U1E&QVK]46+YXS3^I,;E<A%2@L:!JP36
MY:52>*O%-:KQ'*8B<T0NYCL9$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!:1?M@?&_NY]U7<C\=,XMW0M(OVP/C?W<^ZKN1^.F<0&.ZV/?H
M:_Q ;D?==O?BEI9:X1;'OT-?X@-R/NNWOQ2TL@+>J(B (B( B(@"(B (B( B
M(@/3R%^"I!-:M315ZU:*2Q8GG,8H8((0*26:60W$(XXHQ(Y#-V$ %R)V9G=:
M7CO)^U''O5OUNKN?6DDEQ>J=6W9<"4A2$[Z<QD<.&P!AXHC)''8Q>.K6PA,!
M*!K'@N+/&ZO!^D]]\_BM"Z0S'9SVYRXVMP]9X^7'[@9''6!<=$Z/OP=%S%32
MQ\D.HM45)BIPUHS"7'8D[EVR\<LU"*?7.B+"S"S,S#Y,S-PS,WN9F^1F9 ?T
MK$GHM.Q9ZS[7VE\B=<I:6WFE-5:XLRL+N%:P$-/3.,<C^A&26WJ-QC!_:DC"
M<@9VA,@KMK9&^B*=AN?0VS6H-X\U3*OF=X\A V$\83":/0NEIK]+$RM$;NT<
M>8R]C,Y6*81![N/DQDQ>)!'4D<"W&B+Y^6NM6JV;#NS-!7FF=R=F%FBC(W<G
M?R9FZ>7=_)F0&G][]#>4M>]KK?;/M9>U6@U?#IG'&Q$\4>/T?A,5IF** '\H
MH_'QEF:0 $6*W/:G)GEFE,XH5S;<S7LNJ]3ZGU5,[O+JG4NH-2R\^3]>H,O<
MRY,[/P_+/<X?R9^6\V;W+A* FC]'J[.\.Y/:\VDQ]N$)\?I3(7MQ;T4@]<9M
MHVLUW%N3.[")0Z@FP]J,G8V\2N L+&0&.W-6NN]#'VL]?WAWCUD<8F&E]NL#
M@(B(6=X;.LM13W6,'<'Z3*OHRQ%U,8%X9R@PF)DX;%% $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!:XCTQ?LXQ8'>W;[<RG T<.X.ASP>7..(0"3.:*OFU:S-*W
MG+:N8/-5:C,7+C5P43#PPNMCNJ@WIDVVH7]@MN=5\,\NF-UZ5'EOHFKZETWG
MZYN[]+^QZQCZHNW6/MG'[)>\0-<0N5:#W%R6C\_@-88:5X<OI'.X;5.)F8G%
MXLGIS)U<S0-B'VAZ;=*)W<>";CEGY9EQ5?E/$T@'&7T)@0/^L3.+_P"9T!O3
M=$:MJ9_"XC/4"<J.:Q>/R](G]Y5,E4AN5R?ZY0S [_77*%&OW.FYLNL.RUL-
MJ&Q-X]F[MGI>.U)U$7%FACXL?/$Y'P3^#)5*+GW>QY>7"DH0!1U][-V28]\.
MSMNMMP,<9Y/+Z6N7M-R2"S^KZJP#AG=-S,709QB67QU6O9*(?$*G/9A9B:4A
M*11$!HD'"0'<)HI()HR*.:O,!1S5YXR>.:O/&;,<<\$HE%-&;,82 0FS$SLO
M"EH[\OLEOLQVI=U]+5ZS5L'FLT^OM+"+<1O@-;/)F/!B;J,FCQN;/-84?$=I
M";&-*[.,@D42Z V+GH=7:W+4FT>OMG\C88\AMAJ:OF\()F+2'I/70W+00Q@[
MO)-\&:DQ6=::0?G=>KDL36>./V#GN*+5'>C.=K@-K.U=H_'W[95<#NK6L;:9
M%G-@@++Y>2.UHXYFX=S.745:OAZP,XMX^;$RYZ!XVN* (B( B(@"A7](*[8D
MVR_96W(S>,LO6U-JBK5V^TL82O#-#E-86!Q=S(0FPR.TN%P)YC-0BX/'-8Q\
M%64H@L/*$U"UY/ICO; +,[B[=;'XZ=BH:+P3Z]U(P.W#ZAU.=S&8.D?DQM)C
ML#0M7Y1?F(X]043!WEAE8 *8,,0Q@$8-P("("WOX$69F;E_/R9OE7\V)ACC.
M0N>F,",N/?TB+D_'U^&7[*2?N@>Q['OMVC]KMN[M4+N L9P=1:MK3")03Z3T
ML+9G,5+(FXA)6R;5Z^(L1=0G-!D)(XG:4@=@-G+W'_8^_F(=F3;#1UFJ-7.W
ML,.K]5"T;QREJ35KMFL@%CJCCE>:D%FOC&:9GDAAHPU6?PX $99%X9>4 5?_
M -)?[(H[J=E+7%^K5:QGMKFCW.PY!!XU@:^FXYCU+%"_6#Q--I>;+O(3-([C
M"PM$9./%@!?)SV$JY.C=QMV$;%+(5+%&W ;,035;<)U[$1B3.)#)%(8$SL[.
MSNSL[>2 T4K.S^;>[ZWN?GSY_;_^KR19;=O7LNV-E-Z=S=J9XY(X]$ZMOXW&
M>(\A%)I^V$.8TQ.QROXLHV-.9+%3#/+Q).Q^,;,1NL24!LX_1-.V''N!V;Y-
MO;ED9,]LOFSTW) 4XR6/F5SA6LSI*YX7+SQU'!LOAJTDSNTD^!NQ0<15Q ;1
MJU=?HJ7:Y_F==IVOHV[9\'";QX&QI.4#?YT6I,*UG/:7,N98XPD(1S>/A,AD
M,Y,B%:('DL-SM%$ 1$0!$1 % GZ2EVKY-K.R9N &.N>J:@W"]0VWPI!,T5@8
MM3V!@U%8K\?/7DKZ6CS1 <3B<$QPS=8,'*GL6NH],:[6)Y_=C;O9NC/)\';?
MZ8EUCG(Q-VAFU-K&:2GC898W]\V(T]BCGBD%^D@U+*!,1Q-X8%.01869F9F9
MF9F9FX9F;R9F;Y&9O<R_B>88P.0O(8P(R?W\"+.3^3>?N;Y%^JD1[IGLGCO=
MVC=I]N;-;UK$9/4T.7U)"XL<9Z8TO%+J'-Q6!)Q8JURMCFQLX]0/(-WP@,99
M(W0&ST[C?LB#LMV7]J]*6*7J6=R6!@UCJN(@<)_FDU>(YR_#:8P&5IZ VH,:
M<<CD\#4FKQDT,48#+6OY 6%F%FX869F;ZC,W#-_>7]( B(@"TK?>/?3&=H3[
MN^\?\(^I5NI%I6^\>^F,[0GW=]X_X1]2H##-;";T+7XL-\?NDX/\4J2U[*OU
M^AR[I:8T]MIO7#G]1X'!RV=Q<++7BS&7Q^,DGB'2E,"EACNV(3EC8V<',&<>
MMG'GJ9V8"\*BZ4_GE=N?T_Z*^^K!?^O3^>5VY_3_ **^^K!?^O0'=:+I3^>5
MVY_3_HK[ZL%_Z]/YY7;G]/\ HK[ZL%_Z] =UHNE/YY7;G]/^BOOJP7_KT_GE
M=N?T_P"BOOJP7_KT!W6BZ4_GE=N?T_Z*^^K!?^O3^>5VY_3_ **^^K!?^O0'
M=:+I3^>5VY_3_HK[ZL%_Z]/YY7;G]/\ HK[ZL%_Z] =UHNE/YY7;G]/^BOOJ
MP7_KT_GE=N?T_P"BOOJP7_KT!W6BZ4_GE=N?T_Z*^^K!?^O3^>5VY_3_ **^
M^K!?^O0'=:+BFDM=X3/P26L%F<5FJT4CPRV,1D*F2@CF86-XI)J<TT82,!"7
MAD3%TD+\<.W/*T 1$0%.STSKXC=H_NQA^(>LEKHEL7?3.OB-VC^[&'XAZR6N
MB0&4?8;^.W9O[JNWGXVXA;LU:3+L-_';LW]U7;S\;<0MV:@"(B (B( B(@"(
MB (B( B+BNM]<X73.)OY[465QV#PF*KE;R66RUR"ACJ-8'9BFM7+1QP01]1"
M+%(8]1D(#R1"S@?AN%K_  VE,!F]4:BR-7#Z?TYB<CG<WE;THP4\;B<34FO9
M&]:F-V"*O4J033S&3LP@!._N6F@[R?MBV=_M]-R-VI@F@IZISK!I^G.1/)1T
MKA*=;!::K.!!%X!R8G'5[UJNT4?1D+MPI&.Q)--+/5Z07Z08.^@W-F=F;ENM
MM'7M$&K-3E#ZM8W*M4YP.M5QH&[V:NB:T\366*:.O<U%8&O++%7Q4 Q9*IJ@
M"M1>B9=B.SN!O]>W5R-(STOLWB3L5;<L)>K6-<ZE@L8_#U:\SD,9V<9AFS&2
MM +3O4:QBSF"$KM.0JV&QVR>J-R=8Z;T!HK%39O5>K<I!A\'C(.>9[4PG+)-
M/(PGZO1H58K&0R=PA>.ECJMFW+[$)+<$=UAW?6"[,^S&E]L<5)%?RE:%\KK'
M/QQE$6HM7Y(0ES638#.0H:@S"-+%UNMVJXRI4A?F09)# D51$0!5E_2U_I0,
MG]T;;W\+2JS0JR_I:_TH&3^Z-M[^%I4!J]U\[,?G2U^QY_W(E]%?.S'YTM?L
M>?\ <B0&][K_ -#C_P"X/^JR_9?C7_H<?_<'_59?L@"(B U\7IIGQA;!?:;K
M[\-Z85*Q74_33/C"V"^TW7WX;TPJ5B FP]'0^G/V0^R>J/Q'U*MN M1_Z.A]
M.?LA]D]4?B/J5;<! $1$!'CWG'=R:+[3VUN5V\U7''4OMSD=(:ICK1S9/2.I
M(0=JF5H$7!%!,+E2RU'K&+)8R>Q5EX)XI(M1#VJNRWK39;<#4FVFO\6>+U-I
MF])5G'I/U/)TG,_@[/8>8V9K>%S-41N8ZR#N_AF5>PT5VO:KP[NQ5_\ O[.Y
MCQ?:CT&.<TU7KTMY]"X^_+HG)%,U2#45.3P[5S16;E?YR=7)25P?#7K;?\B9
M4O%">O0O98; &J/65?8G[96MM@MRM-[H:"OR5LQ@;3>N8X[$\.+U-A)_8RFF
ML[%"_3:Q>2@=V;Q(Y2H7HZ>6J UZA6,<;]3:9R6$R>1PN9H6\5F,/>M8O+8N
M_"5>[CLC1F.O<I6X#]J*>O.!QF/FSNW4!$!"3_$0&Z:[OSMW:)[1FV& W-T/
M:YIY2%H,OAISC?*:8U!7$1RNG\M'&1,%NA8=Q"4>8+M4H+U4Y*UB,WS66H)[
MFKO9=2=E'<R+. ][+;;ZEDK4-Q])0%XGKF/ V&'46(KR&$0ZEP0.9U"8X?A&
MD5C%V9'"2L4&VTVGW6T[KK36#UCI++4\[IG4F-JY?"9>A)XM2_C[D;2P3Q%P
MQ#R+],D4@A-#*)PS1QRQF @=A(B( B(@"(B QV[7WQ2[H_<[UM^+636D'P_Y
MTJ_L>#]R%;OCM??%+NC]SO6WXM9-:0?#_G2K^QX/W(4!]%;8/T8GZ1_9;]D;
MI_PS;AK4^+;!^C$_2/[+?LC=/^&;<- 3VHB(#TLED8:E>>W9D&*O5AEL3RES
MTQ0P 4DLA<,[]( )$_#._#>Y:13M4;N6M?[I;F:[N$1V=9;@ZSU,;E(4O3'F
M=19&]5@ R=W:"K4EKU:L;/T0U888(Q&*,!;<5=XQN>>BM@]Y]61\]>GML=:Y
M4>D1,N:>G[\G(B0D).W'+,XNSO\ (M*G1@>*"&)_-XXHP=_JN ,+O^V[(#VE
M;B]#P[/T&?WZUUN%;@:0=OM!?!^+.2+J"++:TR#59K$,O3\[MP8C$W:OD;<U
M,K9$@+K$AJ.K8>>A?;=#7VBWFU=TBYYG=.EIMBY9R8-,Z,P.3<>.>1%RU;R_
MD+&[>\G#@0+FB(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MDJ]RO7N5)XK52U#%9JV:\@306*\\8RPSP2QN02PRQD,D<@$X&!,0NXNSKW4
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M,MD];S\OYNS-+J A$'\X@$8O+HX8"85$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MI *3PP .KI$68#>3(M(1_/6;K?V5=SO\H6L/]\I_/6;K?V5=SO\ *%K#_?*
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M*G]55_\ #Q?[2 \? U3^I:_^!C_V4^!JG]2U_P# Q_[*\_#%3^JJ_P#AXO\
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M?*Z?U-B,=GL)DZDL<U:_BLK4BO4;<$L1'')'/6GCD$@,A=G\G= <X1$0!$1
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M[?=:_C/E5U.@-DKZ&K]+1N-]W_4G\&>TRMMJI)Z&K]+1N-]W_4G\&>TRMMH
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MP-4_J6O_ (&/_97GX8J?U57_ ,/%_M)\,5/ZJK_X>+_:0'CX&J?U+7_P,?\
MLI\#5/ZEK_X&/_97GX8J?U57_P /%_M)\,5/ZJK_ .'B_P!I >/@:I_4M?\
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M=G;F/+$WEY^8EDW$F^JSL[/[G9V7:6CNY=[)>"D&6AV<]GRD NH"R>AL%G'
MF=W8P^&ZF082%WY F9B!V%Q=ND7$#3P:-TWD]1W0QFG,7D]19*5N8\=I_'7<
MWD#;EAZAI8N"W9<>HA'J:+IZB$>>29GF)[,OH]O:XW2GK/CMJ;FC\19%C?4>
MX^0J:2Q4$9?02%1,KVJ+#%_2T-.6R!V=IFB=;9#0FU6E]+5 H:9TW@-.48WY
MCI8+#X[$5(W^J%?'UZ\(OYOYB#>]<^0%/SL$>B(;5Z+GQ^H-\-27-V,Y5DKV
MFTM1B/3^WT=B,O%\.]4$Y<YJ*$#:,'AO9*IC+@A*UW$SP6/5H+;NCM&8C3N+
MHX/ 8RAA<-C*X5<=B\74@HX^E6#GIAJU*P1P0QL[N73& LY$1/R1.[\F1 $1
M$ 70_:FT>^HML=QM/C&TQ9S0>K\.,+L;M*^3T_D:31NT?SQV-Y^EVC]MV?@?
M:X7?"]6]6::":%WX:6*2)W^HT@.'/^= :(G$/S4K?5>O"[_KO&/F_P!=U]!=
MK[];;EHW7FN=($#QMI76>J=.QBX/'Q7PV=OX^J[ _/ '6KQ&'R.!"[<L[._5
M" OO^A5:P\3 ]H73SD[O1S^@,]T=(,PAFL5J#&B?6S>([F6G)&Z2=P%HV<."
M.17D5K?/0WMV@Q6_FY.CYIPC#6.V,60K1._MV,CH_450HP!N'YZ<=J+)RD_(
ML+1<<$Y-T[(- $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!5P?2M-9CB^QIK&B\C
M ^H]8;;X81=HW>8H-98O4+QMUMU,[#@2EYBXDXC=G^=/(SV/E3;],SW7"ELY
MM1HH)(GEU%N7)G9H.IO&:MIG367A"9AZ7+PFLYL(R?J$?$(.>IQ%F UV:(O7
MMSM%%)([<M'&<CM]5@%R_P#! ;:#T:C2YXKL6;,12!T/=J:KS0L_6SO'GM;:
MCS$9/U^?)1W1)^GYWR_SKYWTJ=A1_P#=4;5R:)[-FQNEYA89L3MCI"*;@8Q<
MI9\/6MR&;1NX>(93N<KL[N\CDY>T[J0! $1$!X=:>SOO^R>VS/:BW7TE6JO5
MPN3S?S;Z;!F=HGPFM&+,B,#M'%'X57+29;'C'"/A5_4GKB_SKAMPHJ,GIF'9
M(";&;5;Z4*K>L8VU8VSU-9CB%G/&Y%[F>TN5J;JZR"EE(\W7J1]#B$F:L.YL
M4@BX%"I61/17.U.6WG:JQFF[=QX,)NUIG*Z*M5S(_ ESU(HM1:8M= NP-:A/
M'9;'02R/T#!F;@,Q2R0\5NUS';K<O-:+U#@-9:<L>JZ@TEFL7J7"6.DB:/*X
M.[!DJ/B !QE) <]8(K$3&/C5SEA<F&1W0&\_1=3;#;Q8G<+16D]=8*09</J_
M3V)U%CB"49F&MEJ4-P(GE!F$Y(/%>"5Q9F\2,FX;W+ME $1<?U7J>EA,7DLS
MDYXZN-Q%"YD\A9E,(XJU*A7DM6IY#D((P"*"*20SD, $1=R(69W8#79^F&]K
MJ/4N[^AMG,=9:6IME@)-0Y^,"!QAU/K6*O+1JR]+];6:NF:M2X44K=(5LW5E
MA)WGE$:?:R:[:/:1M;P[N;D;I6SD(M<ZOR^=J#*YN<&(DF:K@:G3([G&%/!U
M<;4CA=_G 0#"W+ RQE0$NO<4=CTMZ^U'M=IRS"\NG]-9F#<757(@4<F&T1:J
MYB''2C()1G%FLW'B<1:B?HD+'6[\D!C/"#K;]JDYZ&OV0Y,5HW<[?#)5^F36
M>3HZ%TJ9Q.)CA-)RV[.H+D,KOP<63U!?AH&'2WAR:9ZF=VF\KL: (B( B(@/
MY(6)G9V9V=G9V=N6=G\G9V?R=G;R=G6F?[U_L>-L/VA=SMM:U9ZN$QN>ER^D
MXN2<0TCJ/G+X&")R<B>+'UK)8D"(G,FQ_47M/PMS$J&OIE/8T8;.V._^,K2<
ME"6UVL)(XY'@:$)LCG]'7IS%O!AE"S:U#C#DD^?W6N8Z'K:/'Q X%%E6)O1>
M>UM_,Q[56!P=ZYZMI_=G!Y+0.0CD(F@?-,\><TI:<>1C:>+(8ZSBXII"88X,
MW<%F(Y 9J[*^_I/6&4T[EL3J+!V"IYS3V5QN?PML69RJ9C"W8,EB[(L_(N]>
M]5@EX=G8NGI=N'= ;U%%CQV2NT/C-VML=![EX9A''ZWTMA]10P@;R-5ER-..
M:W1>1Q#Q#H7'GI&?2/4<!$S,RR'0!$7X6;,<,<DTIC'%$!R2&3\"$8"Y&1/\
MC"+.[O\ (S(#7S>F3]J\<KKC:_96C88H-*8FSN%J"$'9V#*Z@>UA-/Q2.).W
MBPXNIF+!1&(R117ZTK?.[3.=*]9T=YMVH?YM':"W;W-"89Z.IM87 PLH3#/$
M6G<!7JZ8TZ4$P,(2UY<+A:,T$@"PG'*Q^TY.98+H"2#NA^R26]_:0VHV_EKG
M8PTVIJ>H]5L+.XCI+2<L>=S<4KB0D 9(*D.$:07<H9,K'-T$$1\;D]F9O)FX
M9O)F;R;ZW]Y4*/0S^R2\V0W9WRR55O"JPX[;;24LL0NY3R$V=UA<@,X^1$ ;
M3>.BGKR.QG\+59>EX7$K[" (B( B(@"TK?>/?3&=H3[N^\?\(^I5NI%I6^\>
M^F,[0GW=]X_X1]2H##-7W_0[MG=(:HVUWIGU+I73>HIZFXF%@JS9S!XO+35H
M"TK4D*&"6_5L'#$4A%(\<9"#F1'T]1.[T(%L)O0M?BPWQ^Z3@_Q2I("V3_.F
M;5_V,]O_ +S-.?[M3^=,VK_L9[?_ 'F:<_W:L@40&/W\Z9M7_8SV_P#O,TY_
MNU/YTS:O^QGM_P#>9IS_ ':L@40&/W\Z9M7_ &,]O_O,TY_NU/YTS:O^QGM_
M]YFG/]VK(%$!C]_.F;5_V,]O_O,TY_NU/YTS:O\ L9[?_>9IS_=JR!1 8_?S
MIFU?]C/;_P"\S3G^[4_G3-J_[&>W_P!YFG/]VK(%$!C]_.F;5_V,]O\ [S-.
M?[M3^=,VK_L9[?\ WF:<_P!VK(%$!C]_.F;5_P!C/;_[S-.?[M3^=,VK_L9[
M?_>9IS_=JR!1 <+T3MOIW3->6IIO X73]2>7QYJN$Q='%5YIW$0\:6&A!!')
M+T"(>(8N?2(CU<,S+FB(@"(B IV>F=?$;M']V,/Q#UDM=$MB[Z9U\1NT?W8P
M_$/62UT2 ^]I72^1SF4QN$P].;(Y?,Y"GBL5CZ["]B]DLA8CJ4:<#&0 \UFS
M-%#$QF N9CU$+<NTGK]Q=VP_U/&X'_R8+_?2Q'[#?QV[-_=5V\_&W$+=FH#3
MT_D%W;#_ %/&X'_R8+_?2?D%W;#_ %/&X'_R8+_?2W"R(#3T_D%W;#_4\;@?
M_)@O]])^07=L/]3QN!_\F"_WTMPLB T]/Y!=VP_U/&X'_P F"_WTGY!=VP_U
M/&X'_P F"_WTMPLB T]/Y!=VP_U/&X'_ ,F"_P!])^07=L/]3QN!_P#)@O\
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MPNIL!?K97 ZBQ&-SN$RE*:.Q3R6(R].'(8V_4L0D<,]:Y3L0V()HC..6*0#
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MM3^=,VK_ +&>W_WF:<_W:L@40&/W\Z9M7_8SV_\ O,TY_NU/YTS:O^QGM_\
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MQQ&XXNO6D:1JD<A 0.+YV8_.EK]CS_N1+Z*^=F/SI:_8\_[D2 WP*(B (B(
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MV@/MRJ?BQ@$!$2KP?H4W_2/M(?87:7]_;DJCXKP?H4W_ $C[2'V%VE_?VY*
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M;!?:;K[\-Z85*Q 38>CH?3G[(?9/5'XCZE6W 6H_]'0^G/V0^R>J/Q'U*MN
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M<=D:L]'(XVY;QV1H60\.S1R%"Q+4O4[ /]!/5M0RP2CYLQQOP[MYK>P+6/\
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M5</N!IWUK*;=:ME$V^"LP<+C)B\H<,<LUC3>;88ZV7JC',<3A7R5./UZC6=
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MJ%OA^B0L3B;6=RM=G^A<X6SV(D)F\P:87=^#9FO&H B(@"(B (B( B(@"(B
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M6PF]"U^+#?'[I.#_ !2I+7LK83>A:_%AOC]TG!_BE20%TI$1 $1$ 1$0!$1
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M!2<*,>GLZ^4RDT0OE-4:BRF+EAR>H<P8ES/?OR-& 1^+X5.E#4QM1XZE.N
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MG5@$YK-NU.<<%:M"!S3S&$48$9,+@=X]ESLU:KWBW#TEMCHBGZ]J?6.5CQM
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M (B( B(@"(B JX>D;]R0&_NEY=V-M<7%_-GT;BQ";'UAAKEN'IFD12R82P?
MC+J#%P'//INU.3%.X_ <L\5:Q!)5UD<\$D4DD,T4L$T,DD$\$\9PSP3PF44T
M$\,HA+#/#*!Q30R ,D4H'&8B8NS;VM4&_2>^X]#%'F.TWM'A8X\?,=O)[SZ9
MQT9 U:>0@EEW%Q=.,'B:*4GL2:VCC*)VE>+4 12R2YF9@*.:LB>CS=]19[-V
MM0V_UW?<MD=<Y4"RDUF24PV^U%9!J\6JZ0,QM'B+YC6K:KKBP@$$<.;#Y[3M
MA<K=L_\ >7AVY\G]R N:^F:Y.O=W$V N4YX;52WM]J^S5M5Y FKV:\^;P4L$
M\$T;E'+#-$0212 1 8$)"[B[.J9:[[W5[36LM;Z6VYTAJ?)_"N)VJP^6T]HH
MYP(LAC\!EKU>^6'GME*3VJ6.EK108B,HP*A1$:8F<,<3#T(@)L?1R?IV=A?L
MKKC^"K7BVWZU('HY/T[.POV5UQ_!5KQ;;] $1$ 6K0]*Z^G'U!]SS;[][91;
M2]:M#TKKZ<?4'W/-OOWME$!6^5KST._Z9S6/W&,_^-^BE5#5KST._P"F<UC]
MQC/_ (WZ*0&RT1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %7$]*#[#=G=[LUY+4.
M"IR7-6;0Y$-?8RM!&<EF_A(8):&KL=!'&SG+-\!V)LK7A$2*>UB8*X,QSL36
M.UZ>0Q\%NO/5M0Q6:MF&6O9KSQC+!/!,!1S0S1&Q!)%+&1!)&8N)@3B3.SNR
M T3(&Q"Q"[$),SB0OR+L[<L[.WD[.WFS_*WN0Q8F<29B$F=B%VY9V?R=G9_>
MSMY.WU'=3-]^AW8=KLP;UY#"XZO(VV^N),GJC;2X[D<<&+*X)932AS.S=5O2
M5FY7J").\AX>UB+$A'++*;PS(#9">BU][C5W)T)7[/\ KO+!_-%V]HO'H^Q=
MG?UG6&@:<4?JP!),9'<S>E&ZZ%^,'*63#!C,@XD37I MU\K1C[:;F:AT9J'#
M:LTEFLAIW4VG<A!E,'G,5.];(8V_7=_#GKR,Q"3$!'#8KS!+6MU99ZEN&>K/
M-">RR[F3TD70F^M/$[?[KVL?H'>.*O2HQS7)J]'2>X5QV>#UK3-N69AQ^:M2
M1C-;TQ>\(QFM1QX.SE86E&J!:'1$0!$1 $1$ 1$0!$1 %3V]+:[QS':2VNK]
MGG 9$#UAN<6-R6K(:E@PLX/;_%Y2.^PVWA<2B^:S+8L,2%:20?7</!FXI89J
MDAL4D'?!]_3MKV7L58P6/DJ:[W@NQE%BM"8R]7<,$4M>26#,ZXM1R$6$Q,;M
M%X=( FS>3.: :=$:96<E2U;7: W_ -7[IZSU!N!KW-6,_JS4]TKV6R4[, N7
M#1P4Z5</G5'&T*XQU<?1@9H:M:,(QZCZY# Z=7\22" D9/P("Y$_U!%N7?\
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MWXI:66N$6Q[]#7^(#<C[KM[\4M+("WJB(@"(B (B( B(@"(B (B( B(@"(B
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M,3F)*[-7''Y.]&T]X"HLLS>QMWA>\W9_R,M_:37F7TI%:L!;R.$#P<AIC+V
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M,[,(LP&\X7P\SJ;&XX>O(9"C0#AGZKEN"J/#]7#]4\@-P_0?#\^?07]*_&D
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ML,3-&#%6*$V !%@8NCI#IZ6P@S'YTM?L>?\ <B0&^!1$0!$1 $1$ 1$0!$1
M$1$!C=VR?B@W5^YOKG\6,HM(?A_SI5_8\'[D*W>';)^*#=7[F^N?Q8RBTA^'
M_.E7]CP?N0H#Z*M;]VWZ4%=[/&RVB]GH=F*^JX]'QYN,<^>N3PY7_AG4>7U
M[OCFTQD6KO7?+/5X:Y+XC0-+['B= U2$0%YO\NJY']3M5_RER?Q+3\NJY']3
MM5_RER?Q+5&1$!>;_+JN1_4[5?\ *7)_$M/RZKD?U.U7_*7)_$M49$0%YO\
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MD\K%TSX31E2UTR6-/Z1:6&.8C?@(,OJ"9AM98HNBM#0Q_%4K&2(@"(B (B(
MM7)Z65].%DON9: _=-0+:-K5R>EE?3A9+[F6@/W34" K5*U9Z'U]-#J;[CNH
M_P 9]'JJFK5GH?7TT.ION.ZC_&?1Z V8B(B (B( B(@"(B (B( B(@"JL^DA
M]R'_ #=]-EO#MECN=XM%8J0,AB*K5XFW&TK49ISQDO7&QRZGP<<<TVF)6L1-
M;BFNX6P-@[&+DH6IEXX0&B3DC,#..0#BDB,XI8I0.*6&6(WCEAFBD$9(IHI!
M*.6*01DCD$@,1,79OX5WGTGSN0AP<^6[36TN&D?%W;$=C=S2F*J%(&.M3.,!
M;@XRI7%WAI3%X(:NKPQ>#7D?YHR\&-\S,](5G9V9V\V?S0'E>']SKRO#^YT!
MN<NZ=^E8[-/W -F_X.M.+/\ 6 '=._2L=FG[@&S?\'6G%G^@,8^V=VHL%LKM
M7KK=/4DC#BM%:>O9@XNERDOW0%H,3BJX,0==K+Y:>EC*HN<8O8MQ]<L0=4@:
M6_=[=7-:[U;JC7&HY_6=0:QU#E]3YJ?J<V/)9J]-?LB!%[3PPG-ZO79_H*\4
M0>3"S-=Q],2[?+<:*[-V"M\O,-7<7<+P96<6KQ3V*VC,%8%A?VY[E>]J&Q&\
M@20A1PLA1R0WA)J)2 *^=Z'5V#Y*]+7?:+SM)A?*.6WVWYR@WB/CZ,PVM8YB
M%W;J:"YDQQV$@=G'J/"Y%R$HRK2*CMM!M)G]?:LTUH?2M1[NI-7YO':>PE;I
MD(3R&3L!6BDF\())1JU6,K=R0(S>&G!/-TDT;LMTMV.NS%@MF-KM"[7:<%O@
MK1.F\7@H[#QC'+D;52L W\M:$.6];RMY[&0M.SNWCV38>!860&2J(B (B( B
M(@"(B (B( B(@"(B +6V^ES]AD=#[QZ<WFPU HL%N[0DH:AGACXJP:[TO4J0
M,4SMRT5G/:<]6L1]3BUH\'D91!Y([$DFR245??2=A<>T)V==P-"5*D-G5-;&
MR:HT(4H@Q1ZRT[%+?P]>.<N"K?"SA-A)YA,1&MDIO&:2#Q(9 -/&N4Z&UQEM
M,9S"ZFP-LJ.<TYE\9GL-=!R9ZN5P]V'(4)_8(2<8[5>)Y!$A<X^H.6ZEQ@XY
M (HYH9:\\1G%/7G HIZ\\1/'-7GB-F.*>"43BFB-F..4" V8A=F_E ;J#N\>
MV%B-^]F-O]UL1TQCJK 5I\K19^3Q.HZ;EC]28>5ND'YQN;JWJT4C@ V:P07(
M6>O8B(LT%K]?0]>WS)B]3:T[.N?NM\&Z@JRZ]T ,\ILU;-T'AJZNPU<"<HG'
M*T9<?FZT<?@N$^-S$A^LG=#P-@4@"(B (B( B(@"(B *OYZ4/]))NS]D]K_X
M6-$JP&J_GI0_TDF[/V3VO_A8T2@-4DOFYG\Z6OV/-^YDOI+YN9_.EK]CS?N9
M(#>-=F_XN]!?:7I;\!T5W0NE^S?\7>@OM+TM^ Z*[H0!$1 $1$ 1$0$=G>L]
MA/']H[8G7.UMEP@RF3HQY3262(8G+$ZQP<C9'3UUGE=@:"2["V/R(N<3SXF]
M?K--!XWC!IO-2Z:R.$R>3PF8IRX[,87)7\-E\?.SC-0RN*MS8_(T9F=FXEJ7
M:\]>3R^BC?CRX6]66M>]+/[O*/;G=S$;V:=QW@:7WB*Q7U(]6N\=/'[C8BK"
M<LDY!S%'9U=A@/)APT;V[V$SEN03LR333 5,$1$!YZ3=V&.,YI#<0BAB%SEF
ME-V&.&(&\SEE-QCC!O,S)A;S=EMV.XC[N<>S9V?]/::RE< UWJJ0M:;A3LS=
M0ZART$ P8<"<1D]6T[B8*&'C$O([5:[=8(CNR1C1;]&6[N<M[=_J>L<[CGL[
M?[,G0U9EBL1-)0R>KRF<]&X&039X[#Q6:]C45J#@ACCQ--K/$=V&.QM.T 1$
M0!$1 $1$ 1$0&CGW^^,#<#[?=:_C/E5U.NV-_OC W ^WW6OXSY5=3H#9*^AJ
M_2T;C?=_U)_!GM,K;:J2>AJ_2T;C?=_U)_!GM,K;: (B(#%_MO?$MN]]R_7_
M .*F66D>P_YTJ_L>#]R%;N'MO?$MN]]R_7_XJ99:1[#_ )TJ_L>#]R% ?15K
MONW_ $H:[V>ME=$;/1;+U]5QZ,AS<(Y\]<GB#R'PSJ7,ZB<GQS:8R#5O5WR[
MU.&N3>(T'C>QXGAA5$1 7F_RZKD?U.U7_*7)_$M/RZKD?U.U7_*7)_$M49$0
M%YO\NJY']3M5_P I<G\2T_+JN1_4[5?\I<G\2U1D1 7F_P NJY']3M5_RER?
MQ+3\NJY']3M5_P I<G\2U1D1 7F_RZKD?U.U7_*7)_$M/RZKD?U.U7_*7)_$
MM49$0%YO\NJY']3M5_RER?Q+3\NJY']3M5_RER?Q+5&1$!>;_+JN1_4[5?\
M*7)_$M/RZKD?U.U7_*7)_$M49$0%YO\ +JN1_4[5?\I<G\2T_+JN1_4[5?\
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MJ[4<1='E[/,>3%^GR;V?=Y-Y>2]RUOMKR<'BGU[KJ:,N'>.76>II =Q=G%W
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M_P"N>R_W[ZF_B GY4,[6?]<]E_OWU-_$!;.9$!K&?RH9VL_ZY[+_ '[ZF_B
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M4TUJ;6M[.31Y'3>8Q$'J%7*;<86A,8VK\!2C8RE01KM-(!G( 0RWID1 $1$
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M  \C3HO=S]KPV-@DR&I<M)?U#DYV8S9[&0R=F<F)V*1V6:2( B(@"(B (B(
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MDN8;3V%Q-N2J<DE8[..QM:G.=>26*"4X"EA-XCD@AD*-Q<XHR=P;L)$0!$1
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MGLO]^^IOX@+9S(@-8S^5#.UG_7/9?[]]3?Q 3\J&=K/^N>R_W[ZF_B MG,B
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MS'Z'J8<-#9C4F6.L>F;&K)KQ9+X?TAI<81F'/U6J>JO<<WBL>,T##&\MGM$
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M 681%F869F9E["( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
J (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ino-20201231_g2.jpg
<TEXT>
begin 644 ino-20201231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" -U JP# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ_9:\?1^$=9GDF^&^MS,VC:E,<_V?,QR89&[*2?Y-W;'TR#GD<B@#P;]K/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=QW.H9BK@G DP"10![5XN^'OAOQW%"FOZ/;:F(6#1M,IW*0<C!&#UYKB==^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV>].O/AM;:;K,\EU,%=X=13Y9&F=MTDXS_"3@*IXVJ#WXV? VDRW=OIGA:;
MM;&V5))P<>?#& NT#LQ.,]L$XZU[$JK&H55"JHP% P *^BI8=PJ>TG)R>R\O
MN[GP&(S"-3#K#4*2IQO=VNVVMKMMZ*[LEZN[/B#QMX!\0?"7Q! TSR1!9-]E
MJEJ2JN1Z'^%O53^HKWSX,_'J#QD(=&UUH[77<;8IONQW?T_NO_L]^WI7JGB#
MP_I_BC29]-U2U2[LYAAHW'Y$'L1V(Z5\@_%GX0ZA\,=16XA:2[T25_\ 1[T<
M-$W4(Y'1O1N^/7BN_?<\<^SJ6O"_@7\=/^$@\CP[XBG U4#;:WKG NO]EO\
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MQU816_BW2U7[6D0VI<QGA9T';)X9>QQV(KVWQ!_R =2_Z]I/_0#7YL^#5?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9+OREW2",?Q;5()]JY_PI\7OA[XBUZ'1?#WB#2[S5+K[48[:R()D^S2".XY
MP?+=@IYX)KQ7]OK4/^%>>%?A_P#%J.%II? 7B6&]F"#DVL\;V\J_0EX_RKY@
MO[SQ3\&?A+X0TVQUO4-'O)O@[XA\37*V=R\7^GS3Q7 G.TC]XIF(#=10,_42
ML;1?&FA^(M:UO2-,U2VO=3T26.#4K6%]TEI(Z!T60=B5(8>QK\X?VC_%M]\,
MO!>G:9IWC[Q?_P )3:^"4\5QZEK'BB6W26ZGN$W-;QQKNNIQ@J(G/E1QG..:
M^G?V8+AKKX^?M%SY5Y9=2T60GL6;2HCG\2:!'N7P_M9[2SUH3PR0F36+V1/,
M4KN0S,0PSU!'0UU-?E#I/QB\<6.GK=Z/XX\67WQ#?PMXQO?$.C7-Y<2)9:C#
M*!;^7;O\J.D7S*BC  4XYYZKPOXJ\07UCX>TK3/B??7^@:MX]\,:?,= U^^N
MWMOM-G.;J(7\RJ6,OR.\2$B)^.#B@=C]%O%7AC_A((X9(;C[)>P;O+EV[E(.
M,JPR,@X'TQ63X<\ RZ?J<=_J-U'<20DM%%"I"AB,;B2<DX)P.V>]?FMJOQ*\
M6KX>TK0=3^(5_HOAG3I/&4-IK&KZ_>6K"YM+T1VH,\*M+<S0QG=' V?,Y'/%
M>H:7\1M=TS]IKPFNN>.]5\37EYJ>BZ<^GZ5J=Q875A))IZM(DNE3(([BRE8F
M5YU =&."5*D4"L?H;1110 5S'Q$\!V/Q$\,W&EW@"2??M[C&6AE X8?R([@F
MNGIKNL:,[$*JC))Z 4 ?#.BZMK7P?\>&5HS#J&GRF&YMR?EFC.-RY[JPP0?H
M:^S](\7:5K/AFWUZ*[BCTR:(2^=,X0(.X8GH0<@^XKYF_:*\7>$O%VK6<VAS
M-=ZI;YAN+N%?W$D?9=W\3 ]".,$\UY)-J5TVEBQ:YF:QC9I5M2Y\L,>K!>F3
MBKM<D_073[^WU2R@O+659[:=!)%*O1U(R"/8BK%87@.'[/X(\/Q_W=/MQ_Y#
M6MVH*"O/]-^/WPYUCXA3>!;+QGH]SXNA=XWTF.Y!F\Q!ET'8NHY*@Y'<5Z!7
MYJ>$_&VF>"?C-I^B^"9[#QSI^I>-M6DC\'>(=*5/$/A;5&69I;V&16)-N6'W
MI ,JX .>@!^B/B_QGH?@'09M:\1ZI;:-I,+QQR7EV^R-6=PB GU+,H'N16S7
MY"-XR\1>*O@3K=SJWCHZ[-?:)I%[KNCR:E>7\L%^=;A433>8@BLI?OQFV1ON
MJIQ@9KUC5OB5\0E^/'CBYT_QJ]OXNT_Q+KEE9>&I+^\GGNM.ATYY+>-=.6,P
M1Q [)5N6(W.,9YP0=C]$/$GBC1_!NCS:MKNIVFCZ9"R+)>7TRQ1(78(H+,0!
MEF4#U)%:=?ECXXU#P[XL_9/\436'Q(\6>,+F'0O#.N:];WFI37-G8ZA+<HMP
MYG+$K(0SE[;A8_+1\ @8[30?'WB:]_:1N8M-^(#BYLO%D6G:)I5QK-[=S:GH
MHTWS(U6S56B>&0?O3>2-G>.6YH _0&X\::':^+K3PM-JEM'XBN[22^@TUG_?
M20(P5Y O=0S*"?>MJOS8_8K\20^*OVA_AAJ<_BO4O%'B:Z\!ZI-X@74[Y[E[
M&_:^C\R$!S^YZ#]T,  *<#/.G\3OB)KMC^TYJ]I?>,_$FE^(%^)7AS3=.T&&
M^GALIM!D2(R'R1^[9'D+!G/)/R]\4"/T4HK\KK/XI^.I?#_Q%UN;XB7%KXI3
M0/%TNK:+'J][->0-;RE;61H-@AT\P801E6!D5R1DUI>*/''C/P;=>)M"L_&F
MNRZ'>MX(NM5O-8UVX46T=ZDOVMFNAN>UAD98U=H\;0>,4#/T_HKPK]C/4]1U
M7X+B2^\3KXN@CU?4(;#4HY;B=3:K<,(XUGG19)U3!19B"'50037NM @HHHH
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M"@$_WJTIY;EN$?M<7B8S2^S'6_\ 7],SJ9EF6,C[+"8:4&_M3TMYV_KT,/\
M8+^#]_X@\6WOQ0UQ)'MX#+'I\TXYNKF3(FG&>H4%ESW9S_=K[EU__D ZC_U[
M2?\ H!J32=*L]#TVVT_3[6*RL;:,10V\"!$C0<!0!T%&KV[W6DWL$0W220.B
MC.,DJ0*\7,,?+,<4Z\E9;)=DCVLNR^.6X14(N[U;?=O<_/\ _P"";?\ R4[Q
M-_V!%_\ 1Z5^A=?'O[%?[._COX-^.-<U+Q7I<%A9W6F"VB>*\CF)D$JMC"$X
MX!YK["KOXBK4\1F$ZE*2DK+5:K8X.'*-7#Y="G6BXRN]&K/<*\8_:;_9[L?C
MOX-V0+':^*-/5I-,O6&,GJ87/]QOT.#Z@^ST5X6'Q%3"U8UJ3M)'OXC#T\52
ME1K*\9'YK? WX^:C\)]$\8?"_P 9K-::=-9WMK;K<@[]-O#&X,1'_/-V/T#$
M'HQ-=M_P34!'B#QR#U^QV?\ Z'+7JG[77[*,GQ<2+Q/X3@A3Q?"%BN('<1)?
MQ=!ECP'3L3U&0>@K/_8I^ ?C7X-ZUXKN/%FF0V$-_;V\=NT5W',69&<L#L)Q
M]X=:^^Q6.P6*RRO6IM1J5.7FC?JFM4O/^M;GY]A<#CL+FE"C43E2I\W+*W1I
MV3?EM_P+&-_P40^*W]E>'-*\!64V+C4F%]J 4\BW1OW:'_>D!/\ VS]Z]B_9
M+^%)^$_P:TFTN8?*UC4Q_:5_D?,)) -J'_=0*OU!KPG_ (9E^(GQ0_:7_P"$
MQ\=:1;V7A@ZA]I,?VV*8_9X?]1!M4D\[5W?5J^W*\+,*]+#X&C@*$E+[4VG?
M7M\O\CWLNH5<1CZV88B+C]F":MHNOS_S"BBBOECZLXCXT?#FW^+'PSU[PQ/M
M62\MS]GD;_EG.OS1/^# ?AFOB[]@GXE7'@GXEZMX U@M;1:L6\N&7CRKZ'(9
M/8LJL/JBU^@Y&:^(?V@?V4?'MS\=&\;_  WL;>5)Y8=3W-=QP&"\1OFX8C(8
MJ&X_O-7U>3XBE4H5LOQ,E&,U=-Z)27]?@?)9UAZU.O0S'"Q<I0=FENXO^OQ/
MM^BJ.BW%Y=Z/8SZC:?8+^2!'N+4.'$4A4;D# X(!R,CKBKU?*M6=CZQ.ZN%%
M%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 1W%O%=PM%/$DT3=4D4,I_ U')I]K-CS
M+:&3Y#'\T8/RGJOT]JL44 4[C2+"[DBDGLK>:2)&CC:2)6**1@J"1P".HJ>*
MUA@9VBACC9\;BJ@%L# SZ\5+10!Y5X)_9N\*^!_'2^+(;S7=7U2WBN;>P76M
M5EO(].BN)!).D <Y4,RKDL6.% ! &*](M=%T^R@2&WL;:"%)/-6.*%557_O
M <'WJ[10!2GT73[J)(YK"UEC27SE22%6 DZ[P"/O>_6GMI=FVH+?&T@-ZJ>6
M+DQKY@7^[NQG'M5JB@ HHHH **** /*/B9^S[HWC;S;[3=FC:RW)DC7]S,?^
MFB#O_M#GUS7RYXR\%ZSX'OGL=9LGM9"#Y<G6.4>J-T/\QW%??59VO>'=-\4:
M;+I^JV<5]9R#YHY5R/J#U!]QS5)B#P[%Y'A_3(_[EK$OY(*T:9%&L,:1H,*@
M"@>PIU2,6JD>DV,6H27R6=NE[(NU[E8E$C#T+8R14D][;VK 33QPD]!(X7/Y
MU)'-',NZ-U=?[RG(I75[!<JQZ+I\/VC986J?:'\R;;"H\UO[S<<GW-2+IMHM
M\U\+6$7K)Y;7(C'F%?[I;&<>U6:R?%'B.V\*Z+<:C<J\HCPL<$0S)/*Q"QQ(
M.[,Q"@>II@9%Y=V&G^(+3PUI>D6DLE]OO-018U2.&WY!ED 'S,[X50?O8<]$
M-=%'I%C%=QW265NES''Y*3+$H=8Q_ &QD+[=*Q? _ARYT:RN+W5&277]4D%S
MJ$L?*JV,+"A_YYQKA5]<%CRQKI: *EMI5E9R-);V=O!(S,S/'$JDECEB2!U)
MZ^M>:Z]^S?X5\3?$2#Q=J=YKMY)#?V^K)H\NJRMIHO(%*PSB G 9<Y !"YY*
MYYKU6B@"F-'L%FN9A96XEN@!/)Y2[I0.@<X^;\:=+I=E-'-')9V\B3((Y%:)
M2'4=%88Y'L:M44 1V]O%:0QPP1)#%&H5(XU"JH'0 #H*DHHH **** "BBO$_
MCU^U/HGP!UW2]+U71=1U.74+9KE)+(QA5"MMP=S#FNG#X>KBJBI48WD^AS8C
M$TL)3=6O+EBNI[917E?P&_:&T#X_:7JESI%M=:=<Z=,L4]E>E/,"L,I(-I(*
MG##ZJ:]4J:U&IAZCI58VDMT50KT\3356C*\7LPHHHK W"BBO*_CU^T-H'P T
MO3+G5[:ZU&YU&9HX+*R*>8549>0[B!M&5'U85O1HU,145*E&\GLC"O7IX:FZ
MM:5HK=GJE%>+_ /]J#1?V@-4UBQTK1M0TM]-ACFD:],9#AV( &UCS\O>O:*>
M(P]7"U'2K1M)="</B:6+IJM0ES1?4****YSI"BBB@ HHHH **** "BHYI/)A
MD?&0JEORKP+X _M<6?QY\:7_ (>M_#-QHSVEF]V;B:[64,%D5-N H_O9_"NJ
MEA:U:G.K3C>,-_*YR5<51H5(4JDK2GLM=;'T#17C_P"T5^T1;_L]Z;HEY<Z'
M-K:ZG/) J0W"PF/8H;)RISG-=U\-/&R?$CP#H7B>*T:PCU6U2Z6V=P[1AOX2
MP S^5$L+6A0CB91]R3LGYK\0CBJ,Z\L-&7OQ5VO)_@=-1117*=84444 %%%?
M/7B/]KRS\/?'J+X8MX8N)[B2_MK'^TENU" S*C!MFW.!OZ9[5U8?"UL4Y1HQ
MNTKOT1R8C%4<(HRK2LI.R]6?0M%%%<IUA1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !116+XN\46_A'0YM0G4RL"(X8%.&ED/W4'U[GL 3
MVH LZYX@T[PU8F\U.[CM( 0H9^2S'HJJ.68]@ 2:CO/$UAI>EQW^I3#3(7&0
MMU\C_3;US[#FO"+/Q)=WOB2XUS4/+U36[<[+.!P?L]FQ&6?;V"@@*.K$DD\
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M0RLH8@;C),&  [\*:^F:ZLADY8&/9-I>E]#?+G?#KLKV]+BT445]">F%%%%
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M<L6>RH"!CUR>]>TU\/:7^Q!X\U+3+2[@^+UP(+B%)8]OVG&UE!&/WWH:M?\
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MP_#WQ!J'[%_[1FH:;KD4TFAOFTN61<F:R9MT-R@_B*X!('^VO6OTQKSCXT?
M7PM\<M$CLM?MGCO+<-]DU.U(6XMB>N"1@J>,J<@_7FN'*\PIX9U*.)5Z516E
M;IV:]#MS;+JF*5.MA7:K3=XWV?=/U.U\.^)-+\6:/;:KHU_;ZGIMR@>*YMI
MZ,#[CO[=16C7P9)^Q3\7OACJ$TWP]\<1M;NV?W%Y+82L.V]!N0G\:F;]GO\
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MS/G?]:,L_G?_ ("_\C[]HKX"_P"'C7C+_H2=*_[^S_X4?\/&O&7_ $).E?\
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MA^?GP4_Y/XO_ /L,ZO\ ^@S5]'?M\?\ )N]__P!A&S_]&5\X_!3_ )/XO_\
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MR.]?-G_!.'QE<P:YXN\'SR;H'A34HH]V0DBL(I<?4&/_ +YKO/\ AW#\//\
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M$^Q/R]_;>^&-I\-_C'=3:;"MMINO6W]I1PQC"QREBLJ@=AN&['^W7Z6^$_\
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M>TS3W*76HVMLR]5FG5"/S-3V>H6NH1^9:W$-RG]Z&0./S%?G-\*/V:=(UO\
M:6UOP#XKO)=?M='T\W%U<P.T)EF*PG&<EMH,I'7)Q47Q7^$.J?#G]I >%/A3
M+?:/=2:<FH6,$%\Z.[+&[.H<GDGRVPK<$\5R?V)AI5?80Q'O<O/=QM&WKS77
MW';_ &YBHTO;SP_N\W)92O*_IRV?WGZ17$\=K#)--(L44:EWD<X55 R23V %
M?F]\>?VD)_C5XRCMYAJ,/PBTW488+M=/RC72%CF21L8W,JN40] ,_>YK0US]
MM#Q)K/P7\3>"/$UG+!XPD06"ZE''Y):,L!,LT?&R0)N' P<]!W]H_9M^ .D^
M(OV3YM'U>%4E\7![]YMOSPG.+9Q_N!%8?[Q]:Z\+@XY'%XK&QO+F48V[/5R7
MRV./%8V6>R6$P,K)1<I7[K11?SW\A/CQ^RQI'BCP9HGBKX4V=II^M:/;1S6,
M%DB^5J%N!O08/#28.0S9W9(;.1C3_9YU[X;?M"^%9;?6/!'A^S\7V">5J=@V
MFQ1L?X?.0;<[2<@]U;CT)S?V-?B#J/AN]UKX,^+)/+\0>'9)#8[NDEN#ED4G
MJ%W!U_V'']VD_:8^">L>$_$\?QD^&>ZU\1Z<?/U6Q@7*W<8'SR;1]X[>'7^(
M<_>'.,I3YWEV(J6:UISOWU2;[2[]&;QC!068X:G=/2I"W;1M+^:/;JCSO]BG
MPIINE?&SXB^%-7TJQU)]-W"WEO+9)7B:&X:/*E@=N0RYQZ"OO!8U1555"JHP
M% P!7QA^PW'>>/?BE\2?B5/:"TMM0<PJBDE!++)YSJI[A0$_[Z%?:%>;Q!*4
ML<U)ZI1OZ\JN>EP]&,<!%Q6C<K>G,["T445\X?2A1110 4444 %?%G_!2S_D
M"^ /^OF\_P#0(J^TZ\G^/G[.^D?M VNB0:MJM_IBZ5)+)&;$)ES(%!W;E/3:
M.GK7L9/B:>#QU.O5=HJ]_N:/&SG"U,9@*E"BKRE:WWIG(_ GX^_#CP]\&?!>
MF:EXUT:RO[72K>*>WFNU5XW" %6'8@UW?_#2WPK_ .A^T'_P,6O$/^';_@W_
M *&O7_R@_P#C='_#M[P;_P!#7K_Y0?\ QNO7J4LDJSE4=>>KO\/?Y'CTJN>T
MJ<::P\-$E\7;YGM__#2WPK_Z'[0?_ Q:/^&EOA7_ -#]H/\ X&+7B'_#M[P;
M_P!#7K_Y0?\ QNC_ (=O>#?^AKU_\H/_ (W6?U?(_P#G_/\ \!_X!I]9SW_H
M'A_X%_P3Z=\)^.- \=:7)J?A[5[36-/CD:%[FTE#HKJ 2I([@$'\:^%_VKOV
MC-1^,WB2/X:^ ?-OM':Y%O,]GRVJW&>(U_Z9*>_1B,] ,_2OA[]EJR\)_!_4
M_AYI'BW6K'3]2O'N;J^B$0N71T56B!V852$&2!G!(S@T_P"!O[)GA'X%ZQ=:
MOI\]WK&K2IY45UJ 0FVC/WEC"J "W<]<#'3.9P5;+L!4J8F[G*/P)K\7_7XE
M8ZCF684J>&:5.,OC:?X(3]F#]G&Q^!/A<RW8BO/%NH(#J%XHR(QU$$9_N*>I
M_B//H!/^TQ^SKIWQX\*CR1'9^*;!&;3K]AP>YAD/>-O_ !T\CN#[/17C_P!H
M8EXKZYS^_>]_T].ENQ[/]G8987ZER?N[6M^OKUOW/SV_9;_:*U/X&>*)OAM\
M0%FL=&2Y,"-=?>TJ<GE3_P!,6)SGH,[AP37W%\29%D^&?BET8.C:1=$,IR"/
M);D5Y[\=/V4_"7QVU*SU349;K2-7@3RGO=/V!KB/LD@92#@]#U&2.E:-G\.I
M/A7\!_$?AT:_J'B"TM=*NUM9=2"&6&/R6Q&&4#*CMGD#CH!7K8[$8/'3IXJE
M[M5M<T;:7[I_U]YY& P^-P,*F%K>]22?+*^MNS7]?=M^<WP%O/%7@S4+SXA^
M%H!>GPHL,NHV?.9;68LCY _A^7D_PY#?PU^D7PG_ &C/ WQ>TJ"?2-9M[;4&
M4&;2;V18KF%NXVD_,/\ :7(-?*__  37C6;7O'4;JKHUC:*RL,@@M)D$5ZO\
M4?V!?!'C;4)=1\/7=QX/O96+O#;1B:U+>HC)!3G^ZP'M7NYW4P6(QTZ&,;@X
MVM)*^C2=I+KKLT>!D-/&X? 0Q&#2FI7O!NVJ;5XOIINF?2][J-KIMLUQ=W,-
MK;J,M+-(J(/J2<5\<_M:?MA:,WAK4/!?@6_74[V^1K>_U:U;,,$1X>.)A]]V
M&5R. ">2>F-'_P $X=9NI5CO_B'&]H#T6PD<X]@TN*]J^$/[%O@+X5WUOJDT
M<WB;6H"&BNM3"F.%AT9(@-H([$[B.QKR:,,HR^2KRK.M);146E?SO_7J>Q7G
MG&80="-%48O1R<E)VZVM_7H<_P#L-? R[^&?@J\\2:W:M:ZYKZH4MY%P]O:K
MDHK#LS$EB.PVCJ#7F/\ P4N_Y"7@/_KWOOYPU]UUX[\?OV9M%_:"N-&EU?5]
M0TPZ6DR1BQ$>'\PH3NW*>FP=/6L,%FB>:K'XIV6M_+1I(WQV4M92\OPBN]+7
MZZIMF9XP\*WWC;]C4:-ID;37]QX6M6AA7[TC)#')L'N=N/QKP7_@GS\6O#_A
MF/7_  AK-[#I=]J%TMY9273"-)SL"/%N/ <;00#UR<=*^W/#&@Q>%_#6DZ-!
M+)-#IUI%:)))C<ZQH%!..,D#M7A'QA_8@\$?%#5+G6+"6X\*ZQ<,7GDL45[>
M9R<EVA/&X]RI7/4Y-/!X["RI5L%BFU";NI+6S\UV)QF Q4:U#&X5)S@N5Q>E
MUY/N?108, 1R.V*X[XB?%[PA\*]-DO/$NNVNG;5RML7#7$IQP$B'S,3]*^5X
M?V!?&MBOV:U^+-Q!9#@)'%<)Q_NB;%=7X'_X)Z>$-)U%+_Q7KFH^+9E(8P,/
ML\+GT?!+L/\ @0K/ZGE=)\U3%.2[1BTW\WHC;ZYFE5<M/"J+[RFFE\EJSY2_
M:2^(6O\ QNU=?'UQILVG>%I9)-(T9)CR5C&]_JQ+98C@'Y<G;7Z8_#GQ3I.O
M^"_#LVGZC:W:7%A"T8BF5B?W8R, YR.X[8K ^*/P \)?%3P#:^$KVT.F:?8L
MKV#Z:%B:S905&P8(Q@D%2,'/XUY[\%?V*_#_ ,&?'EKXJM?$&I:I?6T<L<4,
MT4:1_O%*DG R3@^HKLQF.P./P4*=W3E3ORQM>ZZ:]^[.+!8#'9?C9U=*D:EN
M:5[-/KIV[+T/G+X)_P#)_%__ -AG5_\ T&:OH[]OC_DW>^_["-G_ .C*U?"7
M[).@>$/C/-\1[?6]4GU.6[NKLV<HB\@-.'##A=V!O..>PKO/C1\)=/\ C7X'
MF\,:G>W6GVLL\4YFL]OF HV0/F!&#]*6)S'#U,?AL1%^[!13T[/4,+EF)I9?
MBL/)>]-S:U[K0\H_8!_Y-\A_["EW_P"A"OI&N"^"OPAT_P""/@E/#.F7UUJ%
MJMQ)<^=>;=^7()'R@#''I7>UX&85H8C%U:U/:3;1]#EU&>'P=*C4^*,4G\D)
M7YZ?\%'?^2L>&/\ L"#_ -*)*_0RO#_CO^RCH/Q\\2:?K.JZUJ>F3V=I]C2.
MR$>UEWL^3N4G.6_2N[(\92P.-C7KNT4G^*.#/<'6QV!E0H*\FU^#/7]+MX[K
MP_:0RHLD4EJB.C=&4H 0?PK\Z+Q-?_8=_:&DNXK26\\,7A=85'"WEBS [ W0
M2Q''7NH[-7Z16=N+.UA@4EEB14!/4X&*PO'?P]\/?$S09=&\2Z7#JNGR<^7*
M,,C=G1ARK#U!!J<MS".#G.%6/-2FK27ZKS1>9Y=+&PA.C+EJTW>+_1^3,KX<
M_&OP7\5M-BN_#NO6MT[ %[.201W,1_NO$3N!_3T)KL;R^MM/A::ZN(K:)>3)
M,X11^)KXZ\5_\$W])N;Q[CPSXPO-+7.4@U"V6XV>PD5D/Y@UBVO_  3AU:\F
M5=5^(BR6PZB*Q=V_#?+BNR6"RB;YX8MQ79P;?X:'%''9Q!<D\&I/NII+\=3K
M?VLOVM-"L?">H>#?!6IIK&OZFIM+B\T]]\5I&W#A77AI&'R@+G&2>H /;?L:
M_!?4OA7\/)=0U_SD\1:XRSS6\[EFM85!\J(@]&Y9F]VQVK3^#O[('@+X/WD.
MIP6TVN:[#S'J.J%7,3>L<8 5#[X)]Z]OK'%XW#4\-]1P*?*W>4GO)_HOZ]=\
M'@<34Q/U['-<R5HQ6T5^K_KT^3_V]/@9>>.O#-CXST2U:[U+1(GBO;>)<O+:
M$[MR@=3&V3CT9O2H_P!E3]L+0O$'AG3O"WC74X=*U^RC6WM]0NW"07T:@!"7
M/"R8P"#C=C(/) ^M*^=OBQ^PYX!^)%]/J=A]H\*:I.Q>63354V\C'JS0GC)_
MV2M;87'86OA5@<PNE'6,ENO)^1AB\OQ6'Q;Q^7V;EI*+VEYI]SZ$M[R"\@$\
M$T<T+#(DC<,I'KD5Y;\7OVF? WP?TN>34-6@U'5E4F'2+"59)Y&[!L<1KGJS
M8_'I7S<__!.+7+=C%:?$2%;0_P )L9%./]T2XKTOX5?L$>"? NH0ZEK]U/XO
MOX6$B1742Q6BL.A,0)WG/]YB/:E]5RFA^\GB747\JBTW\WHA_6\WKKV<,,J;
M_F<DTODM6?$?QRD\5>(M8MO&_BV/[->>+(9+^UM<$&*V1O+C !Z+@?+W(&3]
MZOUE\)_\BOH__7G#_P"BUKR7X\?LI:!\?-:TS4=4UC4=*>PM#:1QV BVE2V[
M)W*>?I7LVFV*Z9IUK9HS.EO$L2LW4A0 "?RJLVS*CC\-AX4U9QYKKHEI9+Y(
MG)\KK9?BL1.H[QGRV?5O6[?;5EFBBBOECZL**** "BBB@#RK0]/32M*L[*,E
MH[>)85)Z[5&!^@J_4$##;@U/5D!1110 44>]% %>&S2&\N;GJ\VT?0 =/SS7
M-?$3]_'H-GU^T:DC%?4)&[?SQ76UROB9?M/C#PM!U"&XG(^BHH/_ (\: *WB
MC2M=T*!KWPD+>63:/-TB[?9;RMQ\Z'^!L9S@@'@UR,VJ:_J%A-<Z]IEMHK("
M5M;>X\]FP#RS8  ]AFO5-3F"1GGBO-/%%PMU-#:YSY\H4_[B_,WZ#'XT 94=
MJ(+>'/WROS#W_P _RKN/A?X<MO%.K>([&_C\RRFL%A<*<$%I6*L#V(*9![$"
MN0:=)KQ8P<^6VU@.QZD5Z[\#-+:'2=4U)@1]KN!$GNL0P2/^!M)^5)C1S7AZ
MS\2_!SQ%>?:-'O-?T6\"B6ZTN+S7;;D++Y8Y5]IPR]#@%3Q@^UV=TE]:0W"+
M(B2J'"S1M&XSV*L 0?8U/14E!1110 4444 %<U\1/A[HGQ2\(W_ASQ!:_:=.
MNUP=IP\;#E9$;^%E/(/]*Z6BKA.5.2G!V:(G"-2+A-73/F?5OBG\2?V==*;2
M?$7A*Z^(&A6</E:=XFTG/FNJKA%NXL':PX!<'!Z\FOEOX/\ Q[O_  +XH\3^
M+)/"=[XN^(NN2L([B57$-LC$%@$52Y).!@8PJ* >M?IY56[B\M&EC4*XY8J,
M$BOHL/FU"E3G&IATW.UVFU>WETOU2LGV/G,3E%>M4A.GB&E"]DXJ5KZ;^71N
M[7<_.?XB?"[XX?&CPWJ_C[QG!);6VE6S7%II$RF)_+R"XAMQDKA1N+/\S;>]
M?0W["7C_ $'Q%\)8] L;:UT_6M'D*WT,*A6N0Y)2Y/=BP^4GL5],5] FX#9S
MAL\'/.:^.OB9^SUXL^#7Q"'Q'^#Z-<0*[2W.A0C+Q!CF1%3_ ):0M_='S+QC
MH".^./IYM0E@:UJ;6L+:1_POU[]SSIY?4R?$1QU#FJIZ3OK+_$O3LNATG[-K
M+K7[6/QMUE27$4C6JMCC'G[>/PAH^.A31/VU/@_JH)7[9"MJ3V/[R5.O_;45
MQG[&_P 3O#WAOQ)\1[KQ?K%GX9UO6;Y+E;75)#;_ "[I7< OCHSXP>>*J_M5
M?%+2/'GQ'^'EQ\-[]/%?B70YY)!%IL#W";M\;QC(&&^93D XQU-=WU:K_:LJ
M?*^7DY;VT_AVWVM<XOK-'^R8U.9<WM.:W7^)?;>]BK^VII^G>/OCYX;\)>&-
M-MSXIGC2"_NH5PTLDI'EI)CKL0%B>H#>U6M)^*7QU_99ABT/Q'X</B7PQ:#R
MK:<HTD2QCH([B,$J,=%D&1Z"O5OV:OV?-0\%ZQ?^/_'<XO\ Q[JI>38S!Q9"
M0Y<ENAD;H<<*ORCO7T2+K (W<'J*X<1FM'#PA@5!5J<%9MWU?5Q?1=$=N&RF
MOB)SQ[FZ-2;NDK:1Z*2ZOJS\XOBU^T=I_C_XA^%O'GA30M0\/>-]*=5N%9UF
MBND7[H.T!B<%D.5Y5L=A7U-<>)?B)^TMX9_L?2/#M]\-/#=^@34=<U<C[7+"
M1\\5K",'YN1YC$#'2O=;*SMWN@\5M!')U,B1*&_,"MRN#$9M0J1IJC0Y7#9N
M3E;KY7MTO>QZ.&RFO3G4E6K\RGNE%1OT[NU^MK7.9^'/P[T3X5^$;#PWX?MO
MLVG6BX&XY>1SRTCGNS'DG^F!73445\[.<JDG.;NV?1PA&G%0@K);!1114%A1
M110 4444 %%%% !1110 4444 %%%% !1110 5S/Q._Y)MXL_[!-W_P"B7KIJ
MCN+>*[MY8)XTFAE4H\<BAE92,$$'J"*N$N62EV(G'FBX]SX-_P"":+!O$7CC
M!!_T*T_]#DK[VK%T'P7X?\*R2OHNA:;I#S +(UA:1P%P.@;:!D#)Z^M;5>EF
MF,688N6)C&R=M/1)'F95@7EV$AAI2NU?7U=PHHHKRCU@HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKL"RXQOCP4*$Y&!@8->@:E\>/AOHNM3:1?\ CWPW9:K"TJ2V<^JP)+&T2[I
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M "BBB@ HHHH **** "BBB@ HHHH \M\S:O%8NN:M#IUG-<W#^7#$NYFQD^P
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M1OYD-Q ^R6%\8RK?3((((/<5E_#?X/:)\,S<36#7%YJ%PH26\NV!?8#G8H
M5<\\#D]>@KNJPP.%G3POL<3K>^F^G8[<VS"E5S#ZU@+QM;79MKK_ %OUW/-/
MA]\!= ^'^K?VK'-=ZIJ*AEBFO&7$((P2JJH&2.,G)QZ9->E5E:UXGL=!9%N7
M8R/RL<:[FQZ^PJ?2=<LM:B9[282;?O*>&7Z@UWT:-/#QY*4;(\+$X^ICJW/B
M*G-/S,WQU>7=EX?EDM&9&WJKR+P40GD@]NW/O7#>&])@U"1C*_3G;W->@^)O
M$FE^&]/\W59=L4Q\M(50R/,<?=5 "6.,]OK7G6B:MH/BJ_N4\+WDD&I6Z^9)
MI-Y&T4FW^\@;J.@X) ]J;K4XS5-R7,^G4\^OE^)JKZU"FY4X[Z.R.FV65K\B
M6H)']^F7#0S+C[-&!]*J6>L?;U,,Z^7.N1R,'(Z@U+N]ZV//4DUH8.J6_P!A
MN(IH,QNIWK@_=(.>*Z'4?%U[?A1;G['$1GY3\Q_'_"J6H6PNH<#[XY%9"SRV
MHV,F\#H#P?I0<W-*DVHNR9NZ?XDO]/F5I9VN(=PW+(V[CO@]J]$5@R@CD$9%
M>-374TBX2-%'ODUTMC\0[JWC1+FRCD55"YC<J>/KF@Z</BHPNIO0]!HK+T;Q
M)9:XO^CR;91]Z&3AQ^'?\*U*#UXR4E>+N@HHHH*"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#YPUK5IIKA;.S42WDH^53]U%[NW^
MR/U/%;?AOPZFFP@ M+(YWR3/]Z1N['_#L.*A\->'?L,;22-YUU,=TTV,;CV
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M(RQCYR$'^T<5Y>-/\?>+AON[Y= M&Z0Q_(^/H/F_,BG+\%;:;YKW6[ZY?J2
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M'OGIWK[2T&UN+'0]/MKN3SKJ&VCCFDSG<X4!C^)!JQ'8VT5P\Z6\23O]^54
M9OJ>IJ>O,P& >#E.<Y\SEY6V/>S?.(9E3I4:5+DC"_6^KMY+30\<^,GB"VB\
M4V.CZL\BZ0UDUUY*N56XEW[?F_O!  =O3+@GH*\X^"_B:?3?B];Z5I3N=&U
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M@Z<'=5&EM8V:***#V HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \RMK<1J.!4]%%60%4=0NA&IP:M3R>6E<GX@U(QQD*<LW"B@#$
MUV_-U<&,'**>?KZ5E;/:K'EY[$GO4L=OG&!_P*@"HL/J,>U.\GK\@'ZUHI:=
MZD^RCT_2@#)\D <K^(J*93"OF 9,9W#'<#J/RS6N]MQTJLT.#@]#VH V]%N
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MX#UJ6.,OUZTVUM4MXTC3.U?4Y)/4DGN2:T;>#O5D#K>'':K\<5)#%^%6E6@
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M4]#VJM)<6_VI;5Y8_M#J76$L-S*#@D#N*\O_ .%0ZUHS$Z%XMN;9.T<VY?\
MT$D?I7&^,-%\8IXDTRUO+N35M42(O:R69.]%W8R2 ,<CJ:+%1IQF])'T%Y,?
M]T?E2^4%SA<>O%<3_:/B30_ MQ/KEQ;_ &]3&@GMQEXD9U4NY^Z64$G(XXKB
M_'6I:5IK0W6A2O9WL0WBY60F3<.I9B<MGOGK7D8W,(8-V:OUW_JY]%D_#U7-
MXN4)\JO9:75TD]=59:KOZ'IGB+4C#>Z=IZW36"77F/+<IC>J(%RJD]"2PY[
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ML=8M)Q_RRFC?\F&?TKGG2]I3E%]47&7+)-'T0D/K4RK4<-U;W%Q+!%/')+&
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M KE4"JV75 Q%<#I/[*?Q$O="\5^&YO#6OQ^(K32?%D%OK5Q>6<.ES/?R$PI
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MZ=;^(M?L_#CDAM#ANP( I.3&K;=ZH?[H-==';V^F0PV=K"EM:6Z"**&,85$
MP !Z8KJE[*G15*G*]GIILO\ @]>A-^5:&M&K3<YJ*ZC:,>E/L[M47/6H[ZZ#
MJ<5RENW+<S6OV@;[QJ]:WRW*_P"U6#>3#)Q3]&=FN!^-!QQJ/FL;=S<>5Y0'
MWI'"#\B2?R%1RW:QLQ& 2,$]R/2JFM2&);:7LDHW?0@K_6M*SM4CA5F4-(PR
M6(Z>U!O=RDXHSIKFWO[>6"94G@D4QR1N,JRD8((KD+7X2^'(KY9V%W<1*0RV
MDT^Z+Z'C<P]B?KFO3+&UBOM3M8)E#1O( P(ZCKC]*ZNZ\":1<$LD+6S'O"Y
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?%^GV\\IT='8,\D4)F:$2;=GF!,,4!+ ')&*!'IM>%2?\G9)COI_/_?DU!\
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MB[+=G;4445\.?7A1110 4444 %%%%)B8^BBBMB0HHHH **** "BBB@ HHHH
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M445 F/HHHKH)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1CEVY9V/)8GU)R:O5]:?DYY<?A]'\.8Y+?PGI(AT:X/F/:VF6,4N,%L$Y((
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MD)I":2HYAV#-+FDHJ.898HHHKN,@HHHH **** "BBB@ HHHH **** "BBB@
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M>SD=M%GBU6SSE;>Z8),H],GY6^O%?MN4YC05)4:SLUWV9\#F.#K<[JTE=/\
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M[5?,*QC>&?V?_!GAMDD_LW^T[A>?.U!O-Y_W?N_I7H<,$=M$L4,:Q1*,*B*
M /8"I**@85SGBSXA:%X+C']IWJI.PREK&-\S_11V]S@5+XZ\1'PGX1U/554/
M+;Q?NE/0R$A4'_?1%>(V^DQZ>@GNQ]LUBZ43W5Y/\SEFYP*]+"86-;WZFWEU
M//Q.(E3?)3W\^AT=[\?M2NF8Z1X7D:'/RRWLVS</7:!Q^=06WQ^UNVDSJ/AB
M-X>_V6X.X?@1S7/W$PZ#I67<7"="P'XU[L<)AFK>S_%_YGC2Q&(3O[1_<O\
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MD^57&E=V/.?B/81?$/XY>%?!FI-CPWINGR:_>VI;:EQ(K;8U?_97&?Q->?\
MQ3\ +I'Q[\*^(O"=F+75K^W*620QF-FC@W-(3MQ^[*DA=W/7MBJWQ&^-5K-X
M_P!&^(.A^&]0O]"TM_[+N]3GMRMK>P%B2J-G&[=DKD8X%>K>+O$$K?$#P?\
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M*TON>C?_ (!Z'JULA4_>P\M_N_K[SW+5-:L=%A\V^NH[9.WF-R?H.I_"O/\
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M&)$D?W$5?]T8I]%%=*26B,PHHHI@%%%% !1110 4444 %%%% !1110 4444
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MN6(]< #I74?#G3?[-\*69(Q)<9N&_P"!=/\ QW%=,0&!!Y'I2*JQJJJ JJ,
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MF:5;S>7!:Q$[8U.&(&23R23U[U]95\V_&/36T+XE3W)7$&I0I,C=BR@*P^O
M/XU[V7XFI7K3C4E>ZVZ:6Z;;'AXW"TL/2A*E%*SWZZWZ[[G'WNM-)>-$C[8U
M./K6G8J)E&6Y^M</JEP]CJ3L?N,=P:M&S\0;%&'KZ3V;<?=/"]JE/WCHKRX-
MG)][*^E5M0N5FL9.<JRUSFI:]YJDEN:EM[QVT<$\DY 'XU2I-6;)=92ND?4_
MP9D>7X8^'V<Y/D%?P#L!^@%=I6#X$T=O#_@W1M/8;7@M45QZ-C+?J36]7Y[7
MDI59R6S;/NJ$7&E"+Z)?D%%%%8&P4444 %%%% !1110 4444 %%%% !1110
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MW=.KK^=*FO:<]Q>0?;8!+9[1<*9 /+W#*YSZ@B@#0HJ*2ZAAA$KS1I%C.]F
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M"WB2"",;4CC4*JCT '2LL7F\9P<:-[OJS3"Y4X34JMK+HB6BBBOECZ4****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
; "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ino-20201231_g3.jpg
<TEXT>
begin 644 ino-20201231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 0X!X # 2(  A$! Q$!_\0
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M54L<#K72=@5)';M)@G@4]8TAY<Y:F-<LP^7Y164JB1:BNI-^[@]S3&N2W"C
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M/VB6;,K3SH6W2,Q^ZBC&<<?6O$?#?AO5/&&O66BZ+92ZCJE[((H+:$99V/\
M( 9))X !)( KZ9_X*/?\EPT/_L78/_2FZKT?_@G-\*[:'1=:\?WEONOIIFTV
MP=Q_JXE"M*Z_[S$+GMY9'<TW3YZKBAU,"L5FL\-37+&_3HCJO@W^P'X0\*Z;
M;7GC;=XGUQE5Y+82-'9P-UVJ%(:3'3+'!Q]T5[E!\!_AM;QA$\ >&2H_OZ1;
ML?S*$UY7^V1^T=>_!7P]8:1X>*+XGUA7:.X8!A9PK@&3:>"Q)PN1CACVP?SM
MU3Q5K7B34!J.K:O?:E?@[A=7=R\L@.<Y#,21S7JZ(^AQ6-P6526'I45)K?\
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MB^G.(X\]@.K-CG ]LD9S71_M ?"O2?A4/#=GISS7$]Q#,]S=3-S*P9<?*.%
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M19'@Z6+Q#]JKJ*O;N1Z7\$_ >DVR00^$M)D1!@-=6JSN?JT@8D_4U'K'P-\
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M?CUIMMX>OAJ.AQ^(8!97*JZ[X?/4IPP!R!@'(Y(K]9)IDMX9)96"Q(I9F/0
M#)-?D!\.89(/BAX7BE1HI8]8M5='!#*1,H(([&OUF\>,5\#^(F4D,-.N"".H
M_=-7J86/)!GT'#\K4ZTK6UV^\^#O&W[=7C[5?%,L_AR:UT70XICY%HUI'*\T
M8/'FLX)R1UV%<9Q[U]K_  5^(3_%3X7Z!XHF@2VN+Z%A/%'G:LJ.T;[<DD L
MA(R>A%?DO&M?IC^QD,?L[^&_^NEW_P"E,E71E*4G<Y\CQN(Q&*G&K-M-7_%;
M=CXB_:LTBW\/_'SQA9VL0@B:Y2X\M>FZ6))6/XLY/XU]\?LN_P#)O_@G_KQ_
M]G:OA;]LK+?M*>+A_P!>?_I'!7W5^R]_R0'P5_UX_P#L[5G3G^_E!&N4I1S+
M$17][_TH\2_:F_:PU[X=^,I_!W@S[-83V<:O>ZA) )'$L@W[$5AL^ZRDL0<E
MB.,'/=?L@_'S6OC-H>M6?B,1S:MI#0DWD,8C$\<@8 LHX# HV< #!'%?'O[5
MA+_M">,\G)^TQCG_ *XQU[1_P3M_Y#WC7_KVM?\ T.2N"E7J2Q?*WI=JQAA<
M=B*F;.G*3Y;R5NEE>WY%[_@HEH,8D\%:U'"@E87-G-+QN8#RWC'N!F7\_>I/
MV!_A/:S6^I>/M0@$MS',UAIOF)_J\*#+*I/<[@@(Z8<=ZU?^"AW_ "*G@_\
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MK5K0E&%&7*K=#'/<77P]6%*C)Q5KZ:=3]5/A/\0K7XI^!=-\2VUO]E:Z4I-
M3N,4B,59<]QG)!]".!TKXZ_;DDFA^-&G302-%+'I-NZ2(2K*PFF(((Z$5[C^
MPY9W5O\ !>::XSY5UJL\MOR3^["1H?I\Z/7AW[<S!?C'9 G_ )@\/_HV:GCI
MSJ9?&<MW8WS&K.ME4*D]WRGV)\)?&\?Q,^&NAZ^0IDO+8"YC ^43+E)5P>V]
M6Q[8K\W/C5X%;X<_%+Q%H2Q>7;073/;#!QY#_/'CUPK ?4&OI/\ 8.^( WZ[
MX-N)>N-2LU8GV24#_P AG'^\:W?VLO@S+XY^('@*^LHFSJ=RNCWLD9^9$R9%
M< \<)YY)_P!D=:SQ*ECL#"JE>2_X9_YDXJ^99?3KQUDO^&?XV9W/[(/@?_A#
M?@GI<TJ;+O66;4Y><_*^!%_Y#5#CU)KY-_:X\>_\)Q\9=2AAE\RPT91IL&UB
M5+(296QTSYA9<CJ$6ONSXD>*K3X5?#'5M7C2.*+2[+9:P]%,F D*?0L5%?EG
M<7$MY<2SSNTLTK%WD<Y+,3DDGU)K/-)>PHT\+#Y_UYLRSF:P^'I8./S^7^;(
M:Z7P%\.?$/Q.UB;2_#6G_P!I7\,#7+P^='%B,,JELR,HZNHQG/-<WL8]!7MW
M[)/Q T#X8_$?4M5\2ZA_9MC-I,ELDODR2YD,T+!<(K'HC<XQQ7@X>C&I5C&H
M[1>Y\SAJ=*I6C"K*T7N]BE_PR1\6A_S*7_E2M/\ X[36_9)^+K?\RI@?]A*T
M_P#CM?8O_#6GPH_Z&K_RG7?_ ,:H_P"&M/A3_P!#5_Y3KO\ ^-5]%_9V7K_E
M[_Y-'_(^J6796O\ E_\ ^31_R/CV/]D'XJ\%_"VX_P#81M/_ ([7,^/OA)XJ
M^%OV >)M*_LP7WF?9_\ 2(I=^S;N_P!6[8QO7KCK7W3_ ,-9?"G_ *&K_P I
MUW_\:KYT_:]^+/A3XH?\(G_PC&J_VG]A^U_:/]'EBV;_ "=G^L1<YV-TSTK#
M$X7"4:3E2J7DNEUW.#'8+ 4:$JE&MS25K+FB^O9(^=*W_!<G_%2:4A/_ "]P
MX_[[%8*CO6MX58KXHT?'_/Y#_P"ABO!<5*Q\G*"J67F?JY7RC_PPG_U._P#Y
M2?\ [?7U=7Q-_P -M>.?^@5X?_\  >?_ ./5]CFDL%'D^N1OO;?ROL_0_1LZ
MEEL?9_VA%O>UK^5]FO(]^^$O[-OAWX4:L^K0W%QJVK;#''<704+"IR&V*!P2
M."23QG&,G./^UM\2;3PC\-;O0XY5?5]:7R$A&"4AS^\=AV& 5'NWL:\-U/\
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MW'7\*_.S7M%N?#FM7^EWB[;JSF>"0<XRI(R/8]1[&OF\^PWLZRKQVE^:_P"
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MN_'31-2N%1)[S53<2+&"%#.S,0,DG&3ZU]A?&C_DD_BO_L'R_P#H-?&'P/\
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M7,ZT71]GU/>J9I1GEBP23YE;M;>_?]#[I_X)P_\ )#]<_P"QBG_])K6OGO\
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MZTW5K5K>]LWY,;,NV6%Q[9(]Q@C@U^0^!77_  W^+'BOX3ZI)?>%]8FTV24
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MI9EO(G92R%6QN1AZ<#GM^-?#[5Z;X4_:,\:>%+-+1;R'5+:, (FHQF0J!VW
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MQ;_R*NL_]>4W_HMJ_/"QO)M-O+>[MW\NXMY%EC? .UE.0<'@\CO7?7G[0WQ
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M4HM0TJ]GT^]B.4FMW*M]..H/<'@UV8'&/!U.:UT]T=N69A++ZKE:\7NC[/\
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MPRI59:N+^XU^HXOK1E_X"_\ (\5I:[3QQ\%_''PWA\[Q'X9O],ML@?:FC$D
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M39Z_I>P3(1D B1?O '.4;(SG(!Z7R>9[DLBWC3K)S73^G^A^4-/C8C(%=/\
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M5I))&D;:/[H+D#V%?G[^V5XRL_&7QXUAK!TFMM-BBT[SHVR'>,$O^3LR_P#
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MVH^^?>K(YJ0VH4'9QGG%-VE>#P?2NE;%,*=31]:?0Q#EXI1S24^D 8[4D?\
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M)6FFDU:X0,V,B-)"D:_1455_"OM#_@G??RS_  HU^U=V>.WUAC&&8D*&AC)
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M4*2N"I<P+P,ONY&0#TYJ).\4DCR,QKPG@84:=.:5URMI6^^_8_0SP;XN\/\
MQD\!1ZA:&'4-*U.W:&ZM9,-MW+B2&1?7D@CO]#7AOB_]@'P+K,DLVA:EJ?AV
M5EPD.\74"'UVO\Y_[[_*N/T7]C/Q_P##6QU#6_#/Q#>SUN&W:6.RTVW<+=NB
MDI$Q:0*03Q\RD#/2N%\,_MW?$7PW,+37[#3]<,!,<PN;<VUSN!P02F%!'(/R
M5G6JTXI*LMSOKXNCR0CFE&S?7?UVU7H=YXZ^&_[0OPO\)PVGASQ@WB#P[IEN
ML44.F01PW44*+@#84W,  !\KLWM7QE>7EQJ-Y/=7<\ES=3R-++/,Y=Y'8Y9F
M8\DDDDD]<U^MGPG\??\ "T/A[H_B?^S9M(.H1L_V2<[BN&*Y!P-RG;D' R"#
MBOSE_:HT>RT3]H#QC:Z?&D5M]HCFV1C #R0QR2<?[[M7F8VBHPC4C)M/N>1G
M.#A3HT\12FW%[)MO=75KGZ<>'O\ D :9_P!>T7_H K\G_BSXDN_%_P 3/$^K
M7LKRS3ZA-C>?NH'*H@]E4*!]*_6#P_\ \@'3?^O:+_T 5^7/Q_\ AWJ'PU^*
MFO6%Y;O':W%U+=64Q!V30.Y92">I .T^A!KHS%2]G%K8]#B*,WAZ36R>OW:?
MJ>U_\$^?%EU;>-_$7ALNS6-W8?;@I<[4ECD1,A>@+++R?]A:]#_X*#:3!-\.
M/#>IM$IN;?5OLR28Y"R0R,P^A,2_D*XS_@G[X OQKNO>,KBWDBT\6G]G6LCK
MA9G:17D*^NWRU&>GSX[''4_\%"/$$$/@OPOH>_\ TJYU!KT(.R1QLA)_&88^
MAJ(W6!?-_6IG2O'(Y>TVZ??I^)[#^S'X=@\,_ GP?!!S]ILEOI&[L\Q,AS]-
MP'T KX3_ &I/&UWXT^-WB9IY7:VTRZ?3+:)ND2PDHP'U<.W_  *ON']E/Q7!
MXL^!/AAXG4RV$']G3H#DHT1V@'TRFQOHPKXR_:X^&=_X%^+VL:BUJXTC7)VO
M[6Y )1G?YI4)Z!@Y8X]"#WI8R[PL'#;3\AYM>66T72^'2_W:?UW.6_9]\77O
M@KXQ>%KZSF:)9KZ*SN%!(62&5PCJP'48.1GNJGM7Z,?'3PW%XL^#_B_3I(5F
M9M-FEA5NGFQJ9(S[8=5YK\_/V9?AOJ/Q$^+6A?9H'.GZ7=17]]<;<I''&X8*
M3TRY7:!UZGH#7WI^T9XLA\&_!7Q9>2RF*6>RDL;<HV'\V8&-=ON-V[Z*32P-
MUAYN6W_ #);QP%9U/@U_+4^1?V"_^2T7_P#V!9__ $;#7T'^W!XBGT'X'2V\
M#R1G5-0@L7:,X^3#RD$^A\K!]<X[U\^_L&G_ (O3?#_J"S_^C8:]K_;\_P"2
M.Z-_V'H?_2>XK;"7CA7\PP+<<FJ->9\*:#JLF@ZYIVIPAC+9W,=R@5MIW(P8
M8/;IUK]>=242:==*PRK1,"/48-?CRHK]B+[_ (\;C_KFW\C71A7\0^'7=5EZ
M?J?F5^SGXZM?AQ\7=#UG4'\K3=SV]U)C.Q)$*[OHK%6..P-?HIXT\#>&OBUX
M733=;M8M7TF9DN86CE(PP!VR(ZD$'#'D'D$CH:_.'X-_">[^,/BM]"LM2M=-
MG6V>Y\RZW$,JE00H Y;Y@<<< ^E>[^*/A1\3?V8_ [:]X7\=76I6=O,HNM,B
ML\P0Q'),NUV=<;L X4'YLYXJ:<W3IMM71RY36JT<-/VE+GI:M[?/1[G4:I^P
MAIFG:E;:IX0\6ZAH^H6EPMS;_;H$N51U;<N"NPC! Y(;IWKS3X_6OQW\(:/=
M+XH\0SZIX:N/W$MWI91(&5CC9*J(C*&Z<C:<XR<XK1\%_MZ^)TOK>TU[PW9Z
MRLDJQAM-WPSG) X4E@S>@&W)XXK[/U[2[/7_  _?V&HQ*]C=V[Q3QRC(V,I!
MR/H:Z.6%6-X.QZ-'#X''TIK R<'UM=+RNMON/B;]@GP^E[\1M<U:0!C8:=Y:
M @<-*X^8?\!1A_P*OI#]I3X6^)/B]X(M-!\/7]E8_P"F+<77VZ62-)456POR
M(V?F(.",?*#VKYH_82\31:7\4-3TB:18QJFGMY09L%Y8V#!0.YV&0_\  :^C
MOVI/$7C?P=\/X==\$WDEK+9W(-_Y=M%.?LY4_.0Z-PK!<D= 23P.(I6]CJ/+
M_9?V5+G3:UO;?^K'A'@[]BWXB^$_%6D:Q#K?AZ.2PNXK@-'=7&[Y6!(_U(SD
M C'?-?6_Q(T*/Q-\/_$FE2$!;S3YX@Q_A8QG#?@<'\*^&_!?[17QK\?>*--T
M#2?$ZR7]]*(DWZ=:A$[EV(A)"J 23@\ UZCXXA_:3\'>'-1U6^\4:7>Z?:0-
M+<&UAM,B,#YCAX%SQG@<G'&3BN53I48R<(2:>_\ 5R,'B<+2HU/J]*;B]]$^
MGJ<'^Q3\1=-\'^/-2TC5)TM(]<BCC@GD;"^>C'8A/;<'8#W '4BOKKXG_!?P
MM\7K6WC\0V<DD]J&6WNK>4QRQ;L9QV/0<,".*^%O@;^SS??&ZUU*>TUVQTQ+
M&1(Y8I5:2;Y@2&VC VG! .>H/I7I_P 09/BE^RI;Z)]A\83^(M!N R$7EGO@
MA=>D669F4%>1M9>C<<&N+"U94\-:M"\.^GY>IS9?B)T<%;$TN:EWT?7MZG9P
M_L=ZIX#UI=<^'OCB?2]3BC=(UU&V20,&7!#,!C&#WC.#@]0*\*^/4GQ:T6:/
M2O'^IWEU83/OA:-U^R3D=QL !(ST8 CTZ5[?\$/VP-8^('C'2O#.L^';=KB^
M9D%YIKLH3"EMQC;=Q@<G=[^U>I?M0:-8:Q\#_$XOMJ_985N8)& )257&W'H6
M^[]&-7.C0KX>4\-)I+IK;[CHJ87"XK"3J8*3BE?2[M>U]4S\W%Z4Y>M)3@*^
M5/A1:5:2G+4@+3J:*=28#EIR]:2E6I*'4JTE.[4#%'6G4BTX5#8"TY:2G"I
M<K$'BIEDW=>*A4=Z<O6L94XRW&3T5$*?N-<DJ#7PLHE67:<'D5.I21?\:J"C
MG/H:$YQW M?9ACC@T@A:HUN67@C(J=;A&XS@^XK3F;'H,,9%,;=V!JW^M.4>
M]2TWU#E\S.:.5^B-4]K:2J?F  ^M7!GUI=X').:GEON6((1CGFGJJJ. %IC3
M#^$4PL3WIJ*0B5I O3DTPL6ZTT?2G4"'+TI124N*3&.7UIRT#CBE%24.IRTV
MGT *M.I%IRU+*0M/IH&:<*S8#@*<M)3A4@*!FG4BTY:EC%I:*0TA#:*** 8-
M3*<U-JR1&-)110 4AI:1JJ(D-HHHJR0IM*U-JD 4444"8C4E%% @I&I::U,!
M****" IM*33:I %-W4ZFTQ,2FTYC3:H04444"$8TVBB@ H-%(U4D2)1116@!
M36I:;0)A11102(U-I6I*H HHI&H)$-(:6FM3$)112-5 -HHHIH3"D:EIM6A!
M1113 *93FIM @HHHJR1&IM*:2@04A-+3:/(DD6;'#?G3]PZ@U!1TKFG1C+8"
M4U'L7.<4N_UI":Y'3E'<I"EOEP*J3OP:L$U&V",$9JHRL-+6YG2-GWI%'M5Q
MK6-N<8^E1M;CLU;*2-^9$%%2- R]Q1Y;+VIA="44NQO2DH$%%%&<4!8<M+BH
MFD-,W,QP"3]*=@Y>Y9\Q5ZFHWO /NKFDCLW?EOE'ZU:BMXXN0,GUK:--=27*
M,2M'#+<X+DJE6HH4A7"#'OWI]%:I6V,I3;"K<;;U!JI4ULV&QVK.M'FC<XJ\
M.:-^Q:YHSS1Z45YUSR HHH-.+L[FM.7+),J3Q[']CTJ.KDT?F+[BJ=>I%W1[
M>C2:$HHHJ@"BBB@ I&I:1NU9U':(T.A^]5AN]0P=:F?I7G+<);%.XIEM_%[T
MMQ]ZEMU_=CWKLI[FFT22BBBNDR"BBB@ HHHH &Z4L/WJ0TL/WJXJ^Y<2PU4Y
MZN-5.>LHBC\1#;_ZYOI5FJMO_KOPJU7=#X2I[A1116AF%%%% !5>Y?D#TJ=F
MVKD]*I.VYB:RJ/H:TXZW$)IE!-)FL3J1Y1M*]1SZ45:D4-4#1[?\:^XISA66
MFC.6,E/491110XN.C'9K<****D0Z+B05>A.&K/7[PJ]&WS UZ&'EI8T6Q'>+
M\QJK5Z\&035&NTWAL?9_[$W[0OP_^$7PWUK2_%NO_P!DW]QJS7,4/V*XFW1F
M&)0V8XV Y5A@G/%<=^W'\9O!WQAUKPG/X0UC^UXK&WN$N&^RS0[&9D*C]XBY
MS@],]*^8:*Y<3)J"B>G6S.M+"+!M+E^=]'?O^A]Y_LE_M.?#3X9_!/2] \2^
M)?[-U:&XN'DM_L%S+A6E9E.Z.-EY!'>OG3]KKXA>'_BA\:+W7?#.H?VGI4EI
M;Q+<>3)%EE3##;(JMP?:O%Z*XI592@H/9&%?,ZV(PL<))+EC;O?33O\ H?5?
M["_QN\%?!S_A-O\ A,-:_LC^TOL/V7_19Y_,\O[1O_U2-C'F)UQG/'>H?VY/
MC3X,^,5YX.D\(:S_ &NFGQW:W)^RS0>67,.W_6HN<[&Z9Z5\M4ZDZTO9^SZ"
M_M*M]3^HV7+\[[W[VW\CW/\ 8Y^)7ASX5_%Y];\4ZC_9>F'39K?S_(DF^=F0
M@;8U9OX3SC'%>Z?M@?M*?#CXI?!V70_#'B/^T]4:_@F$'V&YB^1=VX[I(U7C
M([U\,440K2C#DZ%4<SK4<++"12Y7?O?7Y_H?4O[#'QH\&_""\\8OXNUC^R5U
M!+1;8_99IO,*&;=_JT;&-Z]<=:TOVW/C3X-^+Z>#3X1UC^UO[/\ MOVG_19H
M?+\SR-G^L1<YV-TSTY[5\F0_>K07_5&O63]VQI+,:OU/ZE9<OSOO?O\ H>N?
MLF?$#0/AC\9;+7?$M_\ V;I4=I<1M<>3)+AF3"C;&K-R?:OH3]K+]ICX;?$O
MX*ZIH'AOQ)_:6K37%N\=O]AN8LJLJLQW/&J\ 'O7PNU1-]ZA2Z%X?,:M##2P
ML4N65^]]?F='\--6M/#WQ&\*:I?R^186.K6MS<2[2VR-)D9FP 2< $X )K]
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M6BS,>N24.XFO%OVAOVPM'OO#][X:\#7#WT]XC076J[&CCBC.598LX)8C^+&
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M3$HHHH)"FTK4VJ0!111G%!(C4E%(U,0AI***H!&IM%%- %!Z44C51(E%%%4
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MK3_[EN__ ,35J'PQ\0)\;-'\0/\ [MM+_A2_U#J?]!42O[-J?TCO*=VKC(_
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M"FTK4E @HHHH ::2BBJ&AM)2TE,@**** "BBB@ HHHH **** "BBB@ HHHH
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MP3;_ .K\):(O_;A%_P#$UUM%1[:IUD_O'R1['/0_#_PM#_J_#>D)_NV,0_\
M9:MQ^$]#AQLT;3T_W;6,?TK6HJ.:7<KE78HIHNGQ?<L+5/\ =A4?TJ=+2"/[
MD$:_[J@5/12YGW 0#'3BC'O2T4AC?QHIU% #>:7FEHH 2C'M2T4 )BD_"G44
M -HIU)0 GX4=:=10 W:?6C;3J* &_E2TM% "?A12T4 -VT>U.HH 2DQ3J* $
MHQ2T4 )BBEHH 3%'X4M% "?A12T4 )12T4 -VXHIU% #?K1QZ4ZB@!M+2T4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF:W=F%5NM0U&W6>663'S,K,"8P3G 3&./K7S]_P4,\'ZC8^)O"?CFTB9K6*
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M-NR1.>>^:]MT/6;7Q%HFGZM9/YEE?6\=U Y_BC=0RG\B*^2?^"D'_(I^"_\
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M<]-O-6_9;^-=M8HTMRT<;!$^\RJA9@/7Y0W'>J_[+/PKUOXF>#M3.A_&35/
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M#]CMD1$:."8AMZRR9XD/''XUB_\ !-]1_P (KXU; W&]MP3CG_5M_B: .O\
MV<?VK-8^*'CK4O!/C#0;?1/$5JLK*;0.B;XFVR1/&Y8JPY/WCT/3O\N:MKWQ
M.D_:S34[GP[IL?Q+^T0D:,LB_9=XM%"#=YQ&#%M;_6=3VZ5Z3\&/^3^O%?\
MU^:I_-J/$S!/^"CT)8A1]MM!R>YTZ,"D(]@^)WPK\;?&^S\ 6FN^&] TF?;'
M<Z]K "/<V3(^YK: [F;:^>H<C(.2.][]HG]IJ^^%OBK1O!OA31(]?\7:H(W2
M*X8^5&'<I&N%(+.Q!XRN!@\YKW^&:.XC62)UEC895T(((]C7RO\ M7?#_P"&
M7Q&\9Z5;:KXZM_"/CE(X[6%6C,JR*S%HQ*!C9RQPY88#<YXIE%&?]J#XQ?#?
MQ1I-E\1_AM:QV.H.0G]AAY)2HP&*%9959ER#LX)]LYKZVBD$T22*&"L P#*5
M//J#R#[&O@#Q;KGQG_9#FTB:Z\;6/B;1KQR(+*>Y>Z#H.>4D =%]T;'/7FON
MGP7XA_X2[P?H6N_9VM/[3L(+W[.YR8O,C5]I]QNQ^% CR7]K'XZ:]\"?"NBZ
MGH%IIUW/>WIMI%U**1U"B,MD!'0YR.Y-<[\:OVEO$_PX^"/P\\8Z;8:3/J?B
M*"VENHKJ&5H4,EL)6\L+(K ;C@98\?G7.?\ !1O_ ))WX5_["K?^B6KB/VJ?
M^34/@I_UYV/_ *0+0!T7B+]KWXM0>#[;QMIWP\L+7P23'&VH:@'=I6)"EU"R
MJ40OD E6'(&XGK>F_:^^)'CCPK<^(/A[\.H9M)TJW\S5KW4W,J)(%#2+$JR1
ME@HYXR<<E16S\7D6/_@GW8!5"C_A']#. ,<F2U)/YTO[*L*1_L=ZHRKAI(M3
M9SZG:PS^0'Y4 =A\$?VDG^,'PG\1^(/[.AT_7M#BE-Q; L\#,(F>-UYSM.""
M,Y&#ST->/_#G]L;XK_%&PO=.\-> ]+UOQ)"WG-+ 'BM(+<+QO#S<N6SCYUZ<
M!CTQ/V'?^25?&+_KS3_T1<5T'_!-I1_97CTXY\ZR&?\ @,U #_ _[<'C/Q7]
MI\-1> 8M2^(#S^3:6UFS16WR[O,,JNQ9=FW^]@\Y*XYZ;X1_M7>+=0^,7_"N
M?B3X:L="UB5S#&^GAU$<NS>JN"\@977HRMCE>H.1YE^QW:Q7'[6?CUY$W/!;
M:C)&?[K?;8ES^3,/QJ3XC?\ *0S1O^OS3_\ TG2@#UKX@?M+>)_"G[3FB?#F
MTL-)DT2^N+**2XFAE-R!,1NPPD"Y&>,J?QK;_:T^/?B#X#Z'X?O- L]-O)=0
MN9891J44CJ J@C;LD3GGOFO!?CU>0Z-^W5X6O;Z1;2T2YTN1IY3M0(& +$^@
M(//L:Z#_ (*->(--N=*\':7#>P3:@D\UR]O&X9DC*(%9@.@.>,]<''2@#T?X
M\?M'^)?A?\'_  +XKTJQTJXU'74@:YBO(96B3?;B0[ LBD?-ZD\?G7$:Y^UA
M\7[CP</&NA?#JQB\&0HOFZCJ =VEY"M(J+*K*F[=@X8#C+5@?M@?\FS?"+_K
ME:?^D0KV#Q!&D7["\2HJH/\ A"[9L*,<FVC)/XDD_C0!TOPG_:,TCX@?!B\\
M?ZE!_8T&E^;'J4(;S!')&JL=AX+;E="!URV.>I\=TG]J3XS_ !(AO]<\ _#2
MQO?"UK*R;[O>\[@8R%Q*F]L=0BMC/>O.?A7876I?L"_$Z&S1GF76_-(3.?+3
M["\A^@16/TIO[-?PEUWXA_#>6_T?XW:IX,@L9Y5N=&M'E5+89!\P[;F, ,#G
M=M SGDX- 'U9^SI^T)I_Q\\.WDZV?]E:UISK'?6!DW@;A\LB' .UB&&#R"I!
M[$^G>(-;M?#.@ZEK%\YCLM/MI+N=E&2(XT+,?R!KP#]ES]GZP^%NOZQXBTOX
MAVOC>WU*V\B7[) @7?O#B0R+-)D\-]=Q.:]V\82:/'X5U?\ X2":&#0VM9$O
M9+A]D8A92K[CV&"1^-,9\J:#^U)\:/BN-4U7X<_#O2KSP]93-$6OI"\V0H;;
MGSX]S;2#M53U Y[^B_!#]H3Q+\9/"/B:,^&/[$\7:7 [6WGP2M8W,N&"KR5(
M(< ,F[.#D'KCP+PS^SD=1OM2UKX%_%Z&2*TE99()Y9K2:(  @,Z#]XN#]XH%
M/([&O1_V3?VB/&/C+X@:OX \82V^M7&GPRM'JUJ$)W0R+&P9T^5T.>' R3Z[
MLA".U_91_:,U7XYVWB*T\16=AI^N:5,A$-C')&K0L",E7=CN#*P//\2\>N;I
M/[2'BCQ=^U'>?#G0;#27\-Z?*Z7E[/#*URHB0>=@K(%'[WY!E3U&:\6\:ZZ_
M[)O[66NZS# ?[#URQGNTMU7Y7\U68)@<#%S&!QT4]LUZ#_P3]\#S+X?\2^/=
M1'F7VM71MH)GSN,:$M*WIAI&Q]8Z +.L?M7>/O'7Q&U?PO\ "+P=I^NII3.L
MUUJ<F/-"-M:0?O8E1=W RQ)Z\9P.C^!_[27C#Q9\1KOP-X\\%/H>LPJ?])L(
M9#!&X3?MD!+!0R\JX8@Y'J#7D/B'X$>#?B-\4-6O?A%\4[;3/$TDKW;Z:ID1
M49FRYAG3!QN_A4-C/4 "K_PM^.?Q-^&GQUT_X8^-M5M?%T-Q=)9R3PR":2!G
M'RNLN QP<%ED&0,]* /+_CCK'Q!F_:JT>[U'0["W\5V]_9C1K&-P8;E5N#]E
M,A\T@;SC=EUZ_P -?4GC[]I;7O@U\)] O?&N@6J_$;5GFC70[&4>0FV5@KEE
M>3Y=AB. Q)9L<<X\6_:.D2']N+P%)(RHBW>CLS,<  77))J/_@H-:S_\+,\%
MZE]HDMM->S:W2]BRPBECG8R$8/WE#+P#GCVH [74_P!J;XR_#2*PUKXA?#2R
ML_#%W(J"2S+1S)NR0&S+)M; /RNJYQVKNOVB_P!I:_\ AO\ #/PGXN\&1:;J
MEMKLR[&U&.1U\IHBXP$D4ALC!!/'(KS3Q)^S#?:]X=LO^$A_:2NK[0M396M5
MU5F>WNF'S#8)+S:Q'7CD5A?M9^ ?^%7_ +-OPX\,?VL-=6QU&8)J"PB(2JXE
MD7"AFP ' ^\<XSWH Z'Q%^U[\6H/!]MXVT[X>6%KX))CC;4-0#NTK$A2ZA95
M*(7R 2K#D#<3UO3?M??$CQQX5N?$'P]^'4,VDZ5;^9JU[J;F5$D"AI%B59(R
MP4<\9..2HK9^+R+'_P $^[ *H4?\(_H9P!CDR6I)_.E_95A2/]CO5&5<-)%J
M;.?4[6&?R _*@#T3]F?X_+\?/!]W?3V"Z;J^GSB"\@B8M$=PRCH3S@C/!Y!4
M]>*] ^(%[XBT_P &ZK<^$K"WU3Q''%FRL[M@L4KY'#$NG&,_Q"OE#_@FW_R"
M?'O_ %WL_P#T&:OM"@9^9/[,NN?$K2_BSXBG\$>']-UC7)HI%U*VO9%6.&(S
MH79"9DR0^ /F;@]#UKZG^.'[6%WX+\=P^ O OA]?%/BYRJR*Y8Q1.PW"/:N"
M[;<,>0%'4]<>-?L/74-K\?O'[32I"OV*Y.Z1@HXNX\]:C^'.I6O@']O#Q0WB
MB9;#[9>WZVL]W\BCSFWP'<>@9"%!_P!H#O2)._7]KKX@_"[Q1I^G_&#P);Z+
MI]]_J[W2BV$'&6_UDBR;<\J&##/X'ZRLKR#4;."[M95GMIXUEBE0Y5T89# ^
MA!%?(W_!1+Q5HLW@;P[X?2Y@FUXZFMZ(8RK21P"&123W4,SQX]=OM7T1\#]'
MO] ^#O@S3M4#K?V^DVR2QR9W1GRQ\AST*C"X[8IC.;_:/_: L_@%X5M+QK/^
MTM7U"1HK&S9]BMM +NQ_NKN7IR2P^H\7F_:K^,7A'P<_BCQ=\.+*VT&]MG_L
M^_M5=1%,R$P&>,RLWELQ0'/ED@\'.!7._P#!133[FW\6^!=5FB:32O(EA/&1
MO61692/4JPZ]<'TKV[]IKXB>%[C]FG6[V/4K2YM-:LEBTU8Y 3.[%2NP#J5X
M8CMMYH 3X'_M'3^,/@;K7Q!\:1V6G1:7=31RC38G53&B1E0%=V)=F? YP21T
MKS72_P!J3XU^/M-OO$O@WX::?=>$K61AYEP7>=U!YVXE3>1WV(V#7FW@_3KW
M4OV ?%ZV89Q#KOGSHA/,2M;%LCN!PW_ <]JN?L\?"37?'WPIAU72OCMJW@^S
ML7F2ZT>W>58K#$C-DXN4 5@0^=H&6/7!- 'TO\(OVD+/XP?"O7_$5A9K8:WH
MMO(UWITK&1$D$;.C C!*-M/H?E8=LGQ;X;_MC?%3XI6-UIGASP)IFN>*(Y/,
M+P!X+.WM\  R;YN6+9_C48'?MU7P;^ %C\(_"/Q UC2O'UKXTL]4T::)_L=N
MBH&5'8.76:3)Y;TZURW_  3:4?V7X^; W&:R!..?NS?XF@#M?V>_VKM=^(7Q
M&O/ ?C7P];:+X@B$NQK,.BB2+EXG1V8@X!.0Q^[T[U+\4_VIO$4/Q/?X>_"[
MPS#XH\0VQ*W<UWN\F-QC<H 9,!<@,[, #Q[UY-\.?^4AFL_]?FH?^D[UY_X0
M\%ZOK'[47C'P\_CN^^'>LW-Y?!=2MF?S+IC.'$1*RQDAQ\XRQR57C)&$!]+?
M#7]JCQ+'\4+;X??%/PM!X7UV]*I:7%HQ\EW;(12"SY#D;5=7(SQ[C*^.W[7/
MBCX2_&I_"ECHFFZKI8MXG1#%+]JEEDC)50PDV@;RH^X3C/4UA?\ #)$FJ?$+
M3)]7^/!U_P 2Z3-#+':W\/GW<81]ZJ ]VS*,Y/3N3BN:^-4:R?M\>$PRAA]M
MTHX/J&4@_F*8'N_AGXL?%7P]X%\4>*/B3X(M+**PACDT[3=$W27-TSG&&"R2
M[ ,KDD C)..*\HD_:H^.DO@N7QS#\/-%C\'1L=US*LAD"AMI.//#$ \;O+QP
M:]\_:6^,%U\$OA?<:_86<=YJ,MQ'9VRSY\M)'#'>P&"0 IX!&3BOE/Q?=_%+
MXD? F^\=>*/BAIMEX<NK9_*T.R"QO<,&VBW8(J\DXX+.<$9]* /<+CXY^)/C
M!^S+J7B?P9X?MI-:S+8:G87<H,<,8C)FD1BZ9PC*PR<\XPV.? _V%M8^(.GZ
M]?VWA70[#4O#=S?6:Z[>73A9;6++@-&#*F3M+GA7Z#CU])_8O_Y-5^('_7]J
M'_I#!6?_ ,$W[J&'2_':R2I&S7%D &8 DD3  ?C0!UOBK]JWQGXJ^(^H^$/A
M!X1M?$TNF%DN;Z_8^4Q5MK$8DC55#9 9G^;L*W/@G^U%JOBKXA3_  ^^('AQ
M/"OB]%9HEB9A%,0H?9M8D@E,L#N8,/PS\F_LV_#K6_%GQ!\0>&[?XBZA\.==
MA4AQ:M()+QTD*O&=LT9)4G.,D\DXX-?0/@7]EE+?XPZ7XCN?C5'XN\0Z-=QR
M7%K/")KIE3K$[&Y=E^7CD' /2@#Z\HHHIC"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110!Y+K7[-/AC7?C);?$NXO\
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MVG@GC.5'/7/HU% ',_#?X>Z5\*_!>F^&-%\XZ?8JP1[AE:5RS%F9R  22QZ
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M@#%;OB;]FGPQXK^+VG_$:[O]6CUNQEMY8[>&:(6Q,.-N5,9;!QSAA^%>M44
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M0P1$121VW XZ]<5[!XQ\*V'CGPKJWA_4U<V&I6SVTWED!PK#&Y200&'4'!Y
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MB@".>&.ZADAFC66&12CQR*&5E(P00>H(KYSOOV!OA?>:])J"_P!M6UN\A?\
MLV"\46XR<[1F,N!_P.OI"B@#Q_X??LN^$/A=\1;GQ?X<N-4L+B>)X&TU9HS9
MB-MN4"^7OP"JL,N>0*]@HHH _._PKX#T3XE_MH^./#_B"T^V:9=7FI[D#%65
M@S%65AR&!Y_GD9%?3'PY_8M^'7PW\2P:[;)J6KWULXEMAJLZ21PN#D,JHBY(
M[;LXKUJR\ ^&--U^77;3PYI-KK<S,TFI0V,27+EOO$R!=Q)[Y/-;U(1Y1\9?
MV9O!?QQO+6]UV*\M-3MX_)6^TV58Y6CSD(VY65@"3C(R,FN'N/V"?AA-X=AT
MM#K,$R3^<^IQW49NI/E*[&+1E O.<*HYQS7T?13&<#XZ^"OA[XD?#JR\&Z^;
MR]L+-8?)N_-"W*R1IL67<%V[RI8'Y<'<>*X7PU^QKX*\*^#?%/AJSU+7FL?$
M<<,=[)+=1&0"*3>A3$04')(R5/!->\44 <%\,?@OX?\ A9X"F\'V)N=4T::2
M5Y4U8QRM()  RMM15*X'3%>3ZM_P3_\ ACJ6IR7<,^O:9$[[OL=I>1F)><X'
MF1,V/^!5]*T4 >?>$?@3X1\"^ =5\):%8O8:?JD$D%Y<*^ZYFWH4+EV!Y )P
M,;1V'6JWP3^ GA_X#Z?J=GH%YJ5Y%J$J32G4I8W8%00-NR-..>^:]*HH \E\
M,_LT^&/"GQ>U#XC6E_JTFMWTMQ+);S31&V!FSNPHC#8&>,L?QJA\7OV2O _Q
MF\2C7]7?5-/U1HUBEFTR=$\X*,+O#HXR!@9&. *]IHH P_!'A"Q\ ^$]+\.Z
M:\\EAIT(@A:Y</(5'3) &?RKD/B]^SOX+^-GV>7Q%8RKJ%NOEQ:A92>5.J<G
M83@AER2<,#CMC)KTNB@#YQ\,_L$_##P]JD-[.=8UQ8F#"UU.ZC,)(Z;A'&A(
M]B<'O7T7%$D$211(L<: *J*,!0.  .PI]% 'G7QJ^!>@_';1=/TS7[O4;2"R
MN#<QMILD:,6*E<$NCC&#V K*^('[-/ACXC_#WPOX.U*_U:#3/#L<45K+:S1+
M,XCB$2^86C92=HR<*.?RKUJB@#@?$GP8T3Q1\'H?AO=76H1Z'%9VEB+B&1!<
M[+<QE"6*%=Q\I<_+CDX [+X!^#.B_#GX:S>"--NK^?294G1IKJ1&GQ-G=@JB
MKQN./E_.N]HH \E^%?[-/ACX0^'_ !+H^C7^K7-MK\0BNFOIHG= $=?D*QJ
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M<D*)(W('L#@=J^D** .$^%'P3\)?!?2YK/PSIY@>X(-S>3N9)YR,XW,>PR<
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M]>I44 <#XD^#&B>*/@]#\-[JZU"/0XK.TL1<0R(+G9;F,H2Q0KN/E+GY<<G
M'9? /P9T7X<_#6;P1IMU?SZ3*DZ--=2(T^)L[L%45>-QQ\OYUWM% 'F/P1_9
M]\._ 6WU>'P_>ZI>+J;Q/,=2EC<J8PP&W9&F/OG.<]J].HHH ^>_%7[#OPY\
M5^+KOQ"\NLZ;<74[7,MK874:0>8QRQ :-F7)R<!@!GC%=O\ %S]G7P3\:C%-
MX@T^2/4HEV)J5C)Y5P%_NDX(8<]&!QVQ7IM% '@WPZ_8K^&_PYUV#5XH-0UR
M]MV$ENVL3I(D3@Y#!$1%)';<#CKUQ7O-%% '@'[8GBK0/#W@G3+7Q;X.NO$_
MAN^N&2:[L[CRI-/F4#RF4[?O,#)CD#Y<'.:^4->C_9YT'X<ZO>^&+_7-8\6W
MUH8K.PUF(M]A=R S$K&D9*KNP=SX.".>1^D]Y96^I6LMM=V\5U;2C;)#,@='
M'H0>"*Y>V^#O@*RO%N[?P1X<@NE;<)X])MU<'.<[@F<TA'E/[$W@J[T/]GV&
M#6K+;'K%U/=BUN8_O0.JH RGJ&"$\]0P]:HZW^P%\,=7U26\@EUS28Y'+_8[
M&[C\E<G.!YD;L!_P*OI.BF,\]\"? GPC\-O!NI^'/#]E)9VVIQ-%>71DWW,V
MY2NYG(Z@,<#&!D\<G-/X(_L^^'?@+;ZO#X?O=4O%U-XGF.I2QN5,88#;LC3'
MWSG.>U>G44 >2Z+^S3X8T+XR7/Q+M[_5GUVXEFE:WDFB-J#(A1L*(PV,$X^:
MD^,'[+W@;XU:C'J6M6UU9:LJ"-M0TR58I9%'0/N5E;'0$C..,X KUNB@#PWX
M9_L;_#KX7Z_;:W:07^L:G:L)+:;5IUD$+@Y#JJ(B[AV)!QU'/-;'B;]FGPQX
MK^+VG_$:[O\ 5H];L9;>6.WAFB%L3#C;E3&6P<<X8?A7K5% '/\ CSP'HGQ*
M\+WGA_Q!9K>Z;= ;DR59&!RKJPY5@>01_+(KQ+0?V"OAAHEY+<2_VQJP=&5(
M;^Z0QQE@1N 2-<D9R-V1D#K7T;10!YO\&O@3H7P1T'4]&T:^U/4=.U";SY(-
M5DCE56*!&VA(T'S*%!SG.T5PWA_]B+X>^%_'5AXHTVXUNVN;&\2]M[,7:&W1
MT<.JX,>\KD8P6Z5] T4 >*?%;]D/X?\ Q<UZ36M1@OM*U6;'GW.DS+$9R/XG
M5D92WN ">^:L?"?]D_P!\']775]*M;O4=7C!$-]JDPE>'((.P*JJ"0>NW/H>
M37L=% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% ";112T4 )MH-+10 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9^N^(M*\+Z<^H:SJ
M=GI%@C!6NKZX2"($G !9B!DFM"N>\=> =!^)?AV70O$EA_:6E2NDCV_G2199
M3E3N1E;@^] 'P'\*?'/C3X]>-]6EUGXU77@)U*26ML;XPQ7#NY"PQ1>;&O'
MX#'D<'-??UCX]\+ZAKTF@V?B/2;K6X2R2:;#?Q27*%/O!HPQ8$=\CCO7P-^P
MK\,/#/Q&\7:]-XATW^T)-(CMKJR;SY8O*E\QCN^1EW?='#9'%=1\&/\ D_KQ
M7_U^:I_-JD1]I:[X^\,>%]0M[#6?$>DZ1?7"AH;6^OHH)9 3M!568$@D$<=Q
M3]:\<>'/#>H6EAJ_B#2]*OKO'V>UO;V.&6;)VC8K,"W/''>OBK]NC_DX+P#_
M ->=O_Z5R4W_ (*%-.OQ0\$&VE:WN18DQ3(Q4HWGG# CD$'!I@?9UU\2_"%C
MK']D7/BK1+?5=VS[#+J,*S[LXQL+;LY[8KI*^%/VJ/V7O!?PF^#-GK6BQ7?]
MN6]Y#!<7T]P[F[WAMQ9"2JG(R-H'?.:U_&?Q5U[P[^P=X1O;>_F74]6==':\
M5SYJQ!I^C9SDI $SZ$T ?5-U\6/!%CJ1T^X\9>'[>_5MAM9=4@64-Z;2^<_A
M3?B?\1-/^&O@'5O$5U=V4;6]I-)917=RL*WDZQ/)'"A)^9GV' 7)/. :^8?A
M-^Q?X)\?? 72-1NVNH/$^L6HNUU99786Y8DJHBW!67&,YY/."*]!\;?L^Z/X
M5_9;\0>&M8O[SQ5#H-E>:OIL][(T1M9X[:3R]@1A\BDL0K%A\Q[8  (?V5?V
ME)OBY!K/_"6:SH]CK,M^(M-TB.5(9#%Y88B-&;?)SGGGI6Q\"_#/]C_$#7[G
M_A=G_"QO-AD']A?;?.^PYE4[]OVB3&W[GW1][MTKQ;_@G_\ ##PSXBT[4O%>
MHZ;]HU_2-3"65YY\J^4#$,C8K!6^\?O ]:ROV);R/3_CI\1KJ7/E0:?=2OM&
M3A;I"?Y4 ?<'B'Q;H?A&W2XUW6=/T6"0D)+J%U' K$=0"Y /4?G3O#_BK1?%
MEJUSH>L6&LVZG#3:?<I.@/H2A(KX._9^\#0_M>?%;Q=XJ\>3W%]86'E.NGI.
MT:_O6?RH@5.5C58V&%())!SURWXW>&HOV._C9X;U_P "W-S::9?QF:73'E:1
M2BN!)"2QRZ,",;B2#SG(!H ^[=2\;>'='URTT6_U[2['6+P*;;3[F\CCN)@S
M%5*1E@S98$# Y((JHOQ,\(/K/]D+XKT1M6W^7]@&HPF?=TV^7NW9]L5\4_MR
M6<^H_M+>#+.VNI+*>ZTJS@2XC)#1E[RX7<".XS3_ -L+]FOP7\'?AOH.M>&+
M>ZM;TZDEA</-<O*;@-%*^]LG 8&+^$ ?,>* /O2>>.UADFFD6*&-2[R2,%55
M R22>@ KE8?C!X#N;P6D/C;P[+=$[1 FK6Y?/IM#YS7C6N:78_%+]D7PH?&'
MC23PI:2V-K+=ZFS*1<,J%520,<ON.&P""2M?*?QBM_@5I?@"RTOP+<:CJWB^
MV:,3:SY<R077'[PLDK +[;%[#D]: /M_]KC7-2\-_L]^*]2TC4+K2M0A^R>5
M=V4S0RQYNX5.UU((R"0<'H2*SOV,_$6J^*/@3IFH:SJ=YJ]^]W<JUU?7#SRD
M"0@ LQ)P!7D>LZU=Z]_P3=%W?3R7%P(88/,D8LVV+55C09/HJ*/PKTO]A7_D
MW?2O^ORZ_P#1IH ^@JY&Z^+W@2QO#:7/C7P[;W:G:8)=5@60'TVE\YJ7XHZ/
M;:_\/=>T^]UV3PU97%JR3ZK%(L9MX_XSN;@ C(/L3TKX!\6Z'^SSX/\ AQJ>
MDV.MZAXN\;>7*;;6+.&:*-9<GRU*,PCV?=#$;CU([* 9^CK:K9)IK:BUY;KI
MZQ&=KLRKY0C R7+YQM YSG&*PXOB=X.GT2368O%FAR:1'*8'U!=2A-NL@ )0
MR;MH;# XSG!'K7RE^R9KUWJ7[*/Q-T^XE:6&PBOA;[V)V(]GDH/0;@Q^K&N&
M_8O^ _ASXR:;X@N?%@N=1TW3)T2VTU+F2*(2R(=\IV$'.$C'!_AYS@4"/OG0
M/%&C>++,W>B:M8ZQ:JVTSZ?<I.@/IN0D9KY@\1?M@R-^T?IGA+3M7T&W\"0S
MQBZUQ;B.1+A6MQ(?WQ;RT4.=O'.5Z]J\V_9=T\_#O]L+Q-X3TJYF&CQM?V9C
MD;)>.)B8]W8L-HYQW/K7,ZU\'_"-G^VO'X"BTG9X3-S;QG3_ +3,?E:R25AY
MA??RY)^][=.* /J#XX:;9^-M;\-ZII_QW@^']D]L&AM;;452/45+Y$BE;F,.
M/X<@-]>U>7_M^^/O$_@WQ%X0BT#Q'JVAQSVMPTJ:;?2VXD(= "P1ADC)ZUQW
M[;_AO3O!_C;X;Z+I%O\ 9-,L=-6"W@WL^Q!.<#<Q+'\2:T_^"D/_ ",_@G_K
MSN?_ $-* /LV]^(_A+3=8&D7?BC1;752VT6,VH0I/D]O++;L_A715\;_ !I_
M8X\'>$_@;JVM6SWC^+-+M?MMSJTUR\GVR08,H9"=H!^;& "#C)/-<?H_[0'B
M;2_V(YIEOYO[576SX9M]0+$S1P& 39#=<A-R ]0,8Y - 'VCJGQ0\&Z'J1T_
M4O%NA:??JVTVMUJ4,4H/IM9@<_A71P3QW4,<T,BRPR*'22-@RLI&001U!%?'
MWP%_8W\#>-/@YINM^)$O+_6]<MS="\CNGC^RAB=NQ0=K'&"2X;))KE/V7?B1
MK7PD\9?$KP!=W;ZMIF@6NI7-JCY*)/:.0VT$@JC@$D#N!TR30!]H:]\0O"WA
M6\CM-:\2Z/H]U( 4@O[^*!VSTPKL":^2O&WQ%\1K^W)HVC67B?5%\.3W-B1I
M]OJ$GV21'MT8_NPVPALYZ<YS7'_LF_!G1_VB]9\7>*_'\MSKDL<ZKY)G>/S)
M9 S,[,A#<8&U00/P&*S(?AO;_"G]MKPUX=L;F>YTV'4+62T-R^]TB= P0GT4
MD@>P% 'U!XT\,_:_CYI.I?\ "[/[ \N:U/\ P@_VW9]JQCY/+^T+GS/^N9SG
MO7M6L:YIWAVQ:]U74+73+-3AKB\F6*,?5F(%?#OQG_Y/Z\*?]?FE_P UKG/V
MI_B1I_B;]I8Z/XQDU63P+X?=86L=,V><Q,(=V4,RKEG(4L3D(..>* /OCP[X
MX\.>,/,_L'Q!I>M^6,O_ &=>QW&WZ[&.*N:WX@TOPS8M>ZOJ5II5DI"FXOIT
MAC!/0;F(&>*_+WQI\1O 7AGQMX?\3_!NQU[PQ=V,A>XMM38-$V"NT*?.D8AA
MN#*QP01BO4_VSKC4[_XE>$/$^N:9?:O\.Y;"WGAMH)&BC^8[I8S( 0DC97G&
M2-H[< 'VYX?^(WA/Q9<FVT/Q/HVLW !)AT_4(IWP.O",3715^>/A;2_@-X^\
M9:!?>%_$6L?";5+:0/\ 9;HM(LDH8;#'</(PC(.?O'!R.!@Y_0U054 DL<=3
MWH&07U_;:79RW5Y<0VEK$-TDT[A$0>I8\ 5SFF_%GP/K%\EE8>,O#]]>NVU;
M>VU2"20GT"AR<UYO^UMX)\.>-? MC%XI\=-X)TRWN#(&*K)'<R;?E!CR&<J-
MQ 4]R?I\4_'J3X*0:3I5O\+AJ;:O;S!;F]F\[RKB,*?G/FD$/N"_=11@GI@4
M"/TV\0>*-&\(V(O=<U:QT6R9Q$+C4+E((RY!(7<Y R0#Q[&LW4OB;X/T6&RF
MU#Q7H=C%>Q+/:R7.HPQK/&PRKH68;E((((X-?*'[1VMW7B/]B3X?ZC>R--=S
M2:?YLK'+2,+>52Q/J<9/N:H^!_V8/"/B;]EVY\9ZT;V_\3S:-/>V]\UTX%J(
M4<0QJF=I4+&@(8'C@8XH ^V[.]M]2M8KJTGBNK:50\<T+AT=3T((X(K$U7XC
M^$M"U0:9J7BC1=/U)B +.ZU"&*8YZ?(S _I7QE^RK\2-6\&?LR_%*_MYV=]&
M/FV"O\PAEECVY /8-M;'U]:;^R-^S;X6^,_@[6_%OC7[7K-Y<7\EI$ANI(RA
M"(S3,RD%G+2=\CY>0<\ &]X ^('B:^_;HU30IO$FK7&@+=7H33)+Z5K4*L#E
M0(BVW ."..*^TZ_/7X"^#_\ A /VX&\.BZFO(]/DO(8I[AMTC1"V<Q[CZA"H
M_"OT*H0'Q=K_ (^\3P_M]Q>'H_$>K)H!N[93I2WTHM<&P1R/*W;<%B6Z=3FO
MJW6OB5X1\-ZH-,U?Q3HNEZD0I%G>ZC##,0WW3L9@>>W'-? /[1'CF?X:_MG:
M]XFM8$N;K3FMI(8I,["YT^)5W8[ L"1W KO/V(?"&D_%+QIXB^(/BC4CK?BZ
MRNEDCM;CK$S#(N3_ 'N054#A-G^[@ ]N^(GAG[=\=/#^H?\ "[/^$6\J:S/_
M  A?VWR_MVV7.SR_M"Y\W[G^K.?]KI7DW[6/C[Q/X<_:9\":7I/B/5M+TRYM
M;!I[*ROI8892U[,K%D5@K$J #D<@ 5@_M%?\GS> /^OS1O\ TJ%'[97_ "=?
M\//^O/3O_2^>@#=_;+\?>)_"_P <?!-AHWB/5M(L;BT@::UL;Z6"*0FY=265
M6 )( '/85]DZAJ5II-G+>7UU#96D0W27%Q((XT'3)8G KX8_;H_Y."\ _P#7
MG;_^E<E0?MR?$0:E\9-#\(ZQ/?0^#M,2"XOK>P*F69I#EW4,0I81X5=QP#N/
M<T ?:_A_XA>%O%MP]OH?B71]9G09:+3[^*=E'J0C$BIO$GC;P[X-2W?Q!KVE
MZ$MP6$+:E>1VXD(QD+O89QD9QZBOS&^)7C#X6VK:)JOPET_Q-X5\0Z?<*[RW
MSJ490IQ(K>=(P<,!P %(8],8/KW[;'BL^.?A+\'?$#[1+J5K+<RJJD!9&B@+
M@ ]@V1^%%PN?:\/C[PQ<:^VAQ>(])EUM6*-IJ7T1N0PZ@Q[MV1]*U-5MY[K2
M[R&VD\FYDA=(I-Q7:Q4@'(Y&#Z5XM^S[^SGX/\"Z+X;\6+8R7OC&:Q6XGU>X
MN978R31@R80ML'WB,XS@GGDU[G3&?GW\3_A'\??A/X&U+Q5J_P 5+JYT_3_*
M\V.R\1:@TIWRI&-H9%'WG&<D<9J#X3_"_P"/7QB\&V_B;1OBG>6UA/+)$L=]
MXAOTE!1MIR%5AC/O7T[^VE_R;/XQ_P"W/_TM@K+_ &%?^3=]*_Z_+K_T::0C
MW+P[9W>G^'],M;Z?[3?06L44\V\OYDBH S;CR<D$Y//-2:MK%AH-C)>ZG?6V
MG6<?W[B[E6*-?JS$ 5<KX4_:'N+GXR?M>:'\-M2O+B#PY9RV\+6\+[0Q>$3R
M..HWE6" XXP/>F,^R_#WQ#\*^+KAH-"\3:/K4ZC+1Z??Q3L!ZD(QK7U#4K32
M;.6\OKJ&RM(ANDN+B01QH.F2Q.!7SG?_ +#'A2S\9:/KWA+6M2\'?V>5<Q6;
MM,[R*1AUDD8E>,@C!!ST X/CO[<GQ$&I?&30_".L3WT/@[3$@N+ZWL"IEF:0
MY=U#$*6$>%7<< [CW-(1]K^'_B%X6\6W#V^A^)='UF=!EHM/OXIV4>I",2*^
M:?\ @H!XV\1>#=+\%/X?U[5-":XFNQ,VFWDEN9 %BP&V,,XR<9]37S%\2O&'
MPMM6T35?A+I_B;PKXAT^X5WEOG4HRA3B16\Z1@X8#@ *0QZ8P?7OVV/%9\<_
M"7X.^('VB74K66YE55("R-% 7 ![!LC\* .M_;"\>>)?#/PA^&-YH_B'5M)O
M+R)3<W%C>RPR3'[/&?G96!;DD\]S7TU\/];2+X4^&-5U>_5 ='M)[F]O9L9)
MA0L[NQZDG))/>ODG]M[_ )(I\)O^N*_^DT=,_:RTOQ/?? 7X33V$-S<^%[;2
MX'U*.U#$+)Y$/EO+C("@;P"1P6/J* /K[2?BMX)UZ_2QTSQAH&HWKMM2VM-3
M@ED8^@56))KJ:_-2U7]GKXB6.EV=O_;'PKUB.1?.O)VDOX)ACD%BYVG.#NVH
M!Z>GZ)>#;6.R\)Z/;PZO)K\,5I&B:I+(LC72A0!(67ALCG(Z^_6@9LU\U?"C
M1?$^N_M":]XC?XJ:3XC\+H]S+!X=T?Q%+=^0CDI")+< (H53[X8#'K7M'Q:\
M5?\ "$_##Q3KHD,4MCIL\L3+U\W81'C_ (&5%?)?[%$:^ ?@C\3?'\JJCQJZ
M0R. 3_H\#28'L6E4>Y ]* /KW3_B5X0U9KY;+Q5HEXUBN^[%OJ,+FW4';F3#
M?*,\<XYJQX<\<^&_&!F&@^(-+ULP_P"M&FWL=QY?^]L8X_&O@?\ 8Y_9WM/C
M)%K>L^)YKN3PS;W*0FQAF:-;ZX4;CYC*<X17'0@YDZC'.C^S;H-KHO[:>LZ;
MX5>2/P_ICZA$R>87#0(#& 6_B42%"">N :!'Z!UA:+X\\,^)-4N=-TGQ%I.J
M:C:AC/9V5]%--$%8*Q=%8E<,0#D=3BMVOAOP"5^&O[?WB2PFD2SM=6-VS,S!
M4V30B[&3TQN4?B*8S[)\2^./#G@Q;<^(-?TO0A<;A"=2O8[?S=N-VW>PSC(S
MCID5X[^U-=:IX@\+^'K+PM\2]!\"S7$_VW[9?:\VG-=PA"%$3QY+H2^3VX4U
MX5I-H_[9/[4%QJ,ZM+X#\.D!5.0DL",=B?69\L>^W(["I/VCD'Q,_;-\(>$=
MH-IIYLK6:-1_"6^T2G'_ %S8?D*0CZU\ >(='T/3]%\%7OC#3M8\86-G'!>6
M\FIK/>33+&&E<JS>8<_,W(SBNE\1>*M%\(V*WNNZO8:+9M((EN-1N4MXRY!(
M4,Y R0"<>QKXR^,$9^'_ .WKX0UK(@BUA[)C)G:,2 VCY/T7GV-5OC1?7?[5
MG[26F_#_ $>X;_A&- D9;NZAY4;2/M$OH2"!&O;/LU 'VU8^(M*U+1DU>SU.
MSNM)=#(M_!<(\!4$@L) =N!@\Y[5D:5\4?!FO:BNGZ;XNT+4;]CM%K:ZE#+*
M3Z;58G-?'?[3]_J7C;XQ>%/@=X=D.C^&[5;2V-M#G82RA@[#^)8XL8![@GKT
MO_M.?LJ^!/A7\&&\0^'ENK#6M+FMU^T2W3NUYOD"'()VJPW;AL"_=- 'VY7B
MW[4'Q]_X4?X+6?2Y-,NO$MS*D<&GWDXWK$P?,_E AF4%,=AD]>U:W[+_ (OU
M'QU\!O"6LZM,USJ$L$L,LSG+2>5-)$&)[DB,$GU)KQ[_ (*%>"]&F^'NG>*W
ML\Z_#>PZ<EWYK\6Y69RFS=M^]SG&?>@#V']G?XL6_P 4/ASHMS=Z[INI>*&M
MC/J%I:S1>;"2[ ;XE.4&,#D5V&O?$CPEX6OA9ZUXIT72+PX(M[_4(8).>GRL
MP/<5\H^$;31?@7^R$_Q%\-Z>;+QCK&FI:2:@)I'R\D^P/L9BBE1\PPHY45!^
MR[^RKX2^*'PQ7QEXU2[UO4=:EN#"QO)(_)59&C+Y4@M(61SEB1R.* /M"QO[
M;5+.*ZL[B&[M91NCF@<.CCU##@BI99D@B>65UCC0%F=C@*!R23V%?#/[-NJ:
MG\%_VIM8^%-OJ,VH>'+J:XC2.8Y".D+3I*!T5]B[6QP<].!C[DNK6*^M9K>9
M=\,R-&ZY(RI&",CVIC/@KXW?&K6_'W[1B^%M"^*"^%O!BM!#%K.EZ@$M5#0+
M))(\D<BAR'++@O@$ <<UZCJW@.=8_!"W'[2S:?)#;!MS:EM_MI6N9'64#[6N
MX%66+^/[G4UX/K7P?\(V?[:\?@*+2=GA,W-O&=/^TS'Y6LDE8>87W\N2?O>W
M3BM_]L/PWIW@_P",7PRT72+?[)IECIMK!;P;V?8@NY,#<Q+'\2:0C[WU35K+
M1+&6]U&\M["SB&9+BZE6.-![LQ %8=O\4/!MYH]WJT'BW0I]+LRHN;Z/4H6@
MA+,%7>X;:N20!D\D@5\??M@:GJ'Q-_:*\(?#/[9)9:/OM8G"G@RSO\TN.Y"%
M0 >X/K3_ -K#]F'PI\*?A:OB#P>MYI;Q2Q6>H0M=/*EY$S AG#'[P=8S@87C
MID T >S_ +6GCN6W_9WO/$'A'Q"\8DNK<0:IHMZ1N7S=K;)8VY'!!P>Q%2?L
MU?%+3[/]GGP?J?C7Q?;07]Y]KS>:]J:K+-MNYE'SRMEL *.O  %>*^+/^4=.
M@?\ 76/_ -+9*/@%^R[X1\??LZMXH\1+=WVJW<%XUC*EU(@L4BDD4!$!VDET
M=CN!'S=* /M"3Q1HT.@G7)-7L4T54\PZDUR@M@N<;O,SMQGC.:^8_@G^U_+\
M0/BYX@L?$VJ:'X;\,6UK(+!);A(EFE$R*I\V1AO8KN("X&#TXS7&?L#Z?!\0
M/ OQ'\':^KZAX<9K-S8M*Z*#)YV_!4@KGRH^A'W:X3]DOX2^%/B'\9O%>D>(
M-*_M#3M-MY9K6'[1+'Y;I<HJG*."<*2.2: /T>JAK6OZ9X;L6O=7U&TTJS4[
M3<7LZPQ@^FYB!V/Y5?KX,^(,+_M%?MH)X)UR[N8_#.F2R6Z6D4A'RQ0%Y"/0
MNZX+=0N!V%,9]K>'?'GAKQ@TBZ#XATK6VC&YUTZ]BN"H]3L8XZC\ZN:YXBTK
MPS9_;-8U.STFTSCS[ZX2&//IN8@5X)9_L3^&O#?Q,TKQ7X3UO4O"L%BR2#3[
M1C*6<,=W[V5F.UE^4J0P//KBLG]JSP#\.M;\:>'];^(7Q"FT2TMHE4:#Y9E\
M^(.2Q18QYB[CP7PW3 Z# !] >'_B-X3\67)MM#\3Z-K-P 28=/U"*=\#KPC$
MU/KWCCPYX5NK6UUKQ!I>CW-U_P >\-_>QP/-R!\@=@6Y(''K7YC?$+Q'X T?
MXM>'M7^$4>I:596CPNXG>0 3+)UC+NSX*X!#>_8U[1_P4:FDMO%W@6:)VBEC
MM;AT=3@JPD0@@^M(1]D7WQ+\(:7JW]E7OBK1+35-VW[%/J,*39]-A;=G\*Z2
MOAC]IC]EGP?\+?@6NNV"74GB:UG@6ZU&6Y>3[6TA"R;E)V@;B6& #ZYK4OOB
MKKOAG]@'PYJ-M?3+JM^[:.EX'/F11+<3H-K9R"(H=@],\=* /JF^^*W@G2]2
M;3[SQCH%IJ"MM-K/J<"2@^A0MG/X5T\4R3Q)+$ZR1N RNIR&!Y!![BOC+X)?
ML<^"OB)\!=/U;4S=+XFUF"2>/5%F<BU;<RH!%D*ZC"DAN3S@CMW7CC2-0_91
M_99UVSTGQ'J&KWJ.L%C=W"JOV3SG5&$8'*@ NPY.&/:@9[AJ?Q/\':+J1T[4
M?%FAV&H!MIM+K4H8Y0?38S Y_"M][ZWCLVO'N(EM%C\TW#.!&$QG=NZ8QSGI
MBORW^'NO?!"#P1/!XYT;Q9JOBZ[:1I-2L63R[<ECM,8,Z[R1@L9%/)('K7LO
M[&?Q$O\ 4OAG\2_!]W<R75EI^ES7EAYO6)&CD611UP,["%SP2WK0(^O!\7O
MC:<=0'C7PZ; 2>2;K^U8/*$F,[-V_&[!!QUYKIM/U"UU:SAO+&YAO+29=T=Q
M;R"2-QZJP."/I7YX_L5? OPY\9)O$ESXLAFU+3-)\E;?3UN)(D,LP;<Y*,I!
M B4<'GOT%?H3HNBV7AS1[+2M-MDM-/LH4M[>"/.V.-0 JC/H!WH&&L:WIWA^
MR:\U2_M=-M%.&N+R98HP?0LQ K'T+XF^#_%%X+31O%>AZO=GI!8ZC#,Y_P"
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MGMBOCCPO\4M<\+_L$W-S:WLRWWV]]&M;D,=\$+N"0#U&%+J".F1CI6M^S?\
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M*L3T]^'?MSZJFN^.OAKJ4<;1)>:5'<+&QR5#RA@#^= 'W9K_ (ETCPIIYO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ^+OV O /B?P;XB\7RZ_X<U;0XY[6W6)]2L9;<2$.Y(4NHR1D=*Q
MO&W@?XB_ _\ :@U+Q_X>\'7WC#2[^>:Y1;"&28,LRG?&WEJS1LK$X)!' ZY(
MK[JHI6$?G?\ &30?BU\6OB;X7\6ZQ\/M4TVT:2."UL+.UEN6M((Y0VZ9E7@D
MNQ^8+PO0"N^_;D\ ^)_%OQ*\&76A^'-6UJVM[3;--I]C+.D9\[.&9%(!QSS7
MVE10!X'^VSX;U?Q7\$9+#1-*O=8OCJ-N_P!FT^W>>3:-V3M0$X'K7(Z?\!]6
M^)7[%WA[PC<VLVC^)+(/>6UMJ,30LLZS381U8 KN1V&2.-P/2OJJB@9\/>#?
MBO\ '+X9_#>+P%;?"G5KC5K&-K6RUQ;666.%26VD@(T;E<\'>%P%R#SGWGPI
MHGQ+\:? 'Q-IGCTV4?BC6-.N[6U@AC6,Q+) 402E3MW%B2<8P#S[>T44P/B+
M]C^X^(?PEUJ7P;J7PUUF.PU34EEN=9G@ECAM5$>T\[-CC(7D/Z]:M?L;_#WQ
M+X;^-WCB\USPUJNEZ==6=PD5QJ%A+#%-FY0@*SJ V5!.!VK[3HI"/AG1?A[\
M3OV0_B5K&H^%?"MQXX\(:F=GD6(9Y&C#;D#! S)(FXC=M*G)_"Q)\-/B-^UE
M\6-+U[QKX9N/!/@_2]JK9WBE93&&W&-0X#,[G@N5"@#IP ?MZB@#XN_:Q\ ^
M)_$?[3/@35-)\.:MJFF6UK8+/>V5C+-#$5O9F8,ZJ54A2"<G@$&O0?V\/"NM
M^,/A#I%GH.CZAK=Y'KL,SV^G6KW$BH+>X!8J@) RRC/3)'K7TA10,^)OC'\%
M/&OC+]E[X7P:5I5Y+?Z%; WVBM&R7/S(%#>6<$LN"-N-WSG ZUR7B33_ (C?
M$#X,_P#"+:1\$_\ A$K?3X(9+^]6Q:*YOS%C CC,:NS,<,0-Y)!YK]!J*+"/
MCBV\)>([G_@GY=^&!X:UJ/Q%;RB(Z7)I\JW,F=36;<D6W<R[&SD#^%O2O5OV
M,_#NJ^%_@3IFGZSIEYI%^EW<LUK?6[P2@&0D$JP!P17N-%,9Y!^U9\/==^)G
MP7U71O#O[S41+%<BUW[?M*HVXQ@YQGN >"5%?+?P_P!-^)"?"V\^'>E?!-=.
MUBZ@N+6Z\5:C9FW9X9-V[+/&-S[25!#G^'"]*_0.B@#XR_94\&^)- ^ GQ6T
M;5?#6M:7J5S;SO;6][I\L+7&^U=%$8907.Y<8&>J^M=#^P'X,\0>#?#'BV+7
M]"U+0Y9[R%HDU*SDMVD 1@2H<#('M7U912 ^+?A+X!\3Z;^VUXFUV[\.:M:Z
M)-=ZDT>I36,J6SABVTB0KM(/;!YK/^.7@OQUX'_:TC^)&C>#-2\6Z8SV]S%'
MIL+R!BELL+(S(KE#E2<E<<CK7W%10(^#_P!J?P]XY^*FL_#;7HO VMI=/IH:
M^M+6QFG^QR>>24<JO!QSS@XKI?V\/ASXG\?>+O!*:!H.I:K$L$T4UQ9V<LT<
M!:1,&1D4[1U//8&OLNB@#XC^(_Q$^.OBKX>R?#>[^%^HC5)T6RO=>MTDFAN8
MUP"0VWRU+XY8N1R< 9X[:P_9"NF_99;P'<7<$?B>2[_MKS,_N4O,!1&2 <CR
MQL+#OR..*^IJ*!GQ-\/_ (H?'#X*^#5\#3_"C4=>N; -!I^I0Q2R11*6) <Q
MJRR*,G&&7C&>E=?^R_\ LTZUH\WBGQ?\0TQKOB:WGMGLRRM(D<[;YG<C(#N<
M<#H,YY.!]544"/@[X=:3\6?V1/&6O:78>!;[QUX>U)E,<FG1R,C[=PCD#HC^
M6<-AE9><?0U0T3P;\4O$/[5GA?QEXL\(:C9_;+V"[E>VLY'MK*$ HD;R*"JE
M55<Y.>><$D5^@%% 'Q;\6O /B?4OVVO#.NVGAS5KK1(;O36DU*&QE>V0*5W$
MR!=H [Y/%7_C]\'?&W@;X[6'Q>^'^DMK[%UDN]/MT+R)((O*?Y!\S))'D97)
M!)XZ9^PZ*!GS%X9_: ^-?C7Q796EC\')-$TML+<2:XT\&SU?S71 !C^$(Q],
MUI_M!>(OC9X2\76M]X0TBV\3^"V5?/TNWLQ+._&)(Y0<L5;DAD'&<$<<_15%
M,#\[?B+X%\8_M#Z[I%OH/P-/PZEC+?:KZ:W:V2;/\4CM%$N!S_"S'ID]*^__
M  OH[>'?#6DZ4]PUV]C:0VIN'^](40+N/N<9_&M.B@#Y%_;L^$'B_P =7/AG
M7?#NFW&OV>G1R03Z=:JTDB,S!@XC'+!@-IV\C:/P\R^+FF_$?XM?#6VM-*^"
MK>"=$TF>*XEM+*Q875U-AHE,<(C5]@#N2-IP#DL<"OT'HI"/C+XL>#?$FO?L
M4^!-&LO#6M3ZU:W%LD^F+I\INHO+29&+1!=P&<<D=&![UZW\.?#NJV/[($>C
M7.F7EOK'_".7D']GRV[K<>8R2A4\LC=N.1@8SR*]RHH ^-/V0O@[J][\(OB3
MX7\5:)J>@+K16"/^T;.2W;F)@)%#@;MK8/U%<]\)=2^,G[+DNM>$!\-K_P 8
M:=/<-/;7%BDK0+*5"^8LJ(PV,%0E&VD8['-?=E% SX1^!/P]^(]C^UQ%XB\9
M>&[^VENA<W5W?QVCFR1YK9F""8 I\N\)@,<$$9)%?=U%%,#XD\8?"[7->_;P
M35[KPGJ5]X7:\M)&U"33Y'LCLLH^3)MV$!UQUZC%2>(OA_XJ_9U_:@B\5>$/
M#>K:WX0UDF2]M](LI;A8HY&_?1$1J<%6Q(@Z?='8U]KT4A'Q9\=? ?B;7/VQ
M_ VNZ?X;UB]T6"ZTEYM0@L)7@B5+@,Y=PN%VCDY(QWIW[6/@'Q/XC_:9\":I
MI/AS5M4TRVM;!9[VRL99H8BM[,S!G52JD*03D\ @U]HT4#/BW]LOP#XG\4?'
M'P3?Z-X<U;5[&WM(%FNK&QEGBC(N78AF52 0"#SV-=!^U=\#?%MU\0M!^*/@
M.S_M/5],,)N+! &D+1/NCD53]\=%91S@# /./K*B@#Y6T_\ :.^-WBC5].L]
M*^"ESIHX6ZDUA9XHW;^\LCK&L:]>#O/3\<W]O7P7XI\::#X$&D^'M0UF[@>Y
M:[CT>UENUA9DA[JF<9#8) SCI7UW10(P_ MO+9^"/#T$\3P3Q:=;I)'(I5D8
M1*""#T(/:MRBBF,\?_:XT/4O$G[/?BO3=(T^ZU74)OLGE6EE"TTLF+N%CM10
M2< $G Z FL[]C/P[JOA?X$Z9I^LZ9>:1?I=W+-:WUN\$H!D)!*L <$5[C10
M5\A_M+?!CQGHOQETCXN> ]-;7+J!X7O-/B4M)YD0" [!RR/& I"\C!]>/KRB
M@#Y%_P"%S?M"?$KQ5I-MX;^'\_@>Q3Y;M];M&:)\XR[/*B$!0#A4&3D\MQB;
M]JGX&^,+CQ[X>^*/@>U75=;TSR#=V4*?.TD3[DE2,GYE/W2H). .O)'UI12
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M&XJ((M[ $\LW>@1G7WAW5?%'_!/OP[I^C:9>:O?O(K+:V-N\\I O)"2%4$X
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M#XGTW]MKQ-KMWX<U:UT2:[U)H]2FL94MG#%MI$A7:0>V#S7VE12L(^+?VR_
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ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***XWQ@;C0M9L==B9Y+=?W,
M\><@*?0>_P#,"L*U7V,.=JZZ^G<F4N57.RHID,R7$*2Q,'CD4,K#H0>AI];[
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4==;ZGG$OC*ZUSX[>/;OQ5X1ETNXTWX9S0ZAHKWPD2X07$DA$=Q&!E'1P-X
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M:]JG[*VB:>-/;4_%B:G%XLU337D>"2^N'D:6> OD,C[9"@((.8Q@Y.:J>$?
M.A^(OB;X.?PO\)_$VB6VFW0U'4M4\:7&I1I:&,?(MNDER5EEW<9PR@=B,XA4
M,(X2:UM=7]%H_B6[UV=]E8T>)QRJ03=K\KMWNW=:1?PK3=6W=SO_  5^TIKG
MC)M>U)/ #6OA+0+R]M=3UIM71FC^SAF9HX/+#2955XR,%P,G!(O>"_CQXL\4
M_P#",ZG<?#"]M_"?B"6-+75K#4X[Z6%) 3'+<0(@,:=-S;B$SSSP:7P \/\
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MHW/]K1VLIFV;RD,)1FD('')7)X&:]:\.ZQ_PD&@Z?J?V.[TXW<"3&SOX3%/
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M>FS?L_NM&]]+FE\5_C)KGCT? [Q%X2T%[G2-5U:.[A@N=3%L;BZ42J;610C
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M\:/B!\?;2UT*]T.^U3PK:P6%CJJ"*XDPL@C,B$_NR[#@,<@$$U9\>^*/$_Q
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M2&T"%Y(TQEA+*\C\#G;FNC\;Z7KP\2^#K3Q9HOC;4_A]'X8M8TT[P@EQG[>
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M"_Q0\*?$;XP^ =5L/#TLFHZQX7N;RTUB:[='M81,%DMV@'R,=X/SYXV\9!K
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXWXK_$_3_A/X4_MB]MKC4;B>YBL;#3K-09KRZE.(X4SP"<$Y/0 ]3@'BM/\
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M9M7N;/&4TI*FKN*>EG;3=)VLV>TT5S_P^\70>/O N@>)+==D6JV,-X(_[A=
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M"X_X1.PN'@U&^&LQ[XMLNPM#&8PTJ@%"3\F"6 SM)KKM(_:%U9O&7A/3-?\
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M[2\^A[S17E=E\;KG1?"?BW6?'OA+4/!9\-JDEP/,%W;W:.N4^S3@*LK$X4C
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M$H9K20C^\DH8;NNV0CTKTOQMXRTSX?>$]5\1ZS*T.F:; T\[(NYB!T51W8G
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M4O&Z^&-8\.^'])\,7.DV:ZU:-;W=_<2G<Q6$_,JJ!C)')Z=>.\_9>T>_\/\
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M=#=Q0R_9#)&Y!BCD?.[  X+%L8SZUI_ 70=3T?QO\7Y[_3KNQ@OO$S3VDES
MT:W$?DH-\9(&Y<@C(R.*]EHKSYXJ4U)-;I+[K'J4\%&FXM/X6W]]_P#,\/\
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MH4W&%+;776_Q->FUN@8&IB:L9U*[UT]VR27NQ;Z7W;ZGA+?M5:H_AU_&MO\
M#F_G^&B7'EGQ!_:$8N6A$GEFX6SV[C'N_P!H''.*[/Q)\4_&'_"17FF^#OAO
M<^)K2TABE?5;[44TVUG,B[@MNSQOYV!C)& #P3TSY?\ #WQWX[^%WPGT[X>V
MGPXUR\\=:4O]G6=RUB6T:8>8=D[W2LJB/:<D9#9'OFL?Q5I>LZA\3O%<?Q,\
M+>.O%]IF'^P;+PL;E=':/RAN#&.10CEQR96^O%=WU>ESOW%97MJW=75G:Z^^
MZ7EH>9];K^SC[\KNU_=2Y79W5^5_=RM^>IWNH_M80V_PS\.>*K3PC?7M[JGB
M(>&IM$%PJW$%UB7*JVTK(=T84#Y0=XY&*Z'PK\<-7F^(D7@_QKX./@W4+O3Y
M-2L9UU2.]@FBC($BLZJNQU!R1R,#KTSX3X!^'/B;2/ASX TNY\)ZAIUWIOQ7
M6\N;&.UD=+6V"S?O0V,- -R@2@E3QS7KWQ0\%ZCXH_:&\&O'97G]D/X>U:RN
M=2BMV:&W:5%50S@;0QR< D9Q2JT<+&3II*WO:W?3;K;\[E4<1C)PC5E)W]Q6
MLM;[WTO^5C.;]JK5'\.OXUM_AS?S_#1+CRSX@_M",7+0B3RS<+9[=QCW?[0.
M.<5TVM_'35[[QEJ7ASP!X,;QO-I,,4FI7C:I'8VT#2+OCB5V5M[E2#@  9Y(
MKSSX>^._'?PN^$^G?#VT^'&N7GCK2E_LZSN6L2VC3#S#LG>Z5E41[3DC(;(]
M\US>O?"FR\(?%?QEJ/CGP)XH\8V&O21:C9:GX/:]*QRF,":"2&"92OS_ '6;
M.1U(J_J^'YY)Q6E^6SOS:K6W,NEWHU?MH9_6L5[.#C-ZVYKJW*[.ZOROK9:Q
M=N^J/3]?_:H@T_X>:!XBTSPK>ZEJ>H>(U\+7.@33K!<V=]B3=$3M968-&H'0
M$2 DC!%>L>"=6U_6M#6Y\2>'X_#6I^8RFQBOUO5"CHWF*JCGTQQ7S+I'PSUG
M2_ OPU>#P/-X>>X^)5MKEQI=J]S>36EKY4J":Z>221E?:L>]LJH)'"DFOKFN
M#&1HTTHTEU>M]=]M[?UN>I@)XBJW*O+9+2UEJM]4G^7H%%%%>6>R%%%% !6?
MKVD1ZYI<]G)QO'R-_=8=#^=:%%3**G%QELQ-75F<MX#U>2XL9=-NLK>V)\ME
M;J5Z#\NGY5U-<3XLA?PYKUIX@MU)B8^5=*O<>OXC]0*[.&9+B%)8V#QNH96'
M0@\@UQ863BG0GO'\5T9G3?V7T'T445WFIQWQ7^)VG_";PB^MWUM<7\LD\=G9
M:?:#,UY<R';'$F> 2>YZ 'KT/FNL?&;7KJ+6O"/C3P/+X.U+5- O[O3)HM22
M_@N1%"3+&71%V2*&!QR,=^1GH?VDO".M^)/"?A_4_#UC_:NJ>%_$%GX@3300
M'NU@+!XTSQNVN2/=>.<5AZI\4/%?Q*_M#2]"\":YI/AT:-?_ -IW?B/3)+2X
M>9H"((;5"V78N?F.&&.!S7K8>G#V:ERIO6[O:UMOZL[[*QX6*JU%6E#F:6ED
ME=2O>_3IY-6W=SSWX0_'S7?AU^SWX.UB]^'UW)X%T^TM[2[U[^THEF52XB:9
M+7!9HPYQDL"1S@#FO8?%WQJU6W\?7?@SP3X0D\9:YIMM'=:HTFH)86UDLG,2
M-(RMND8#<%"]"#GKCS+Q-X-UZ;]@.'P[%H>HR:^-%M(CI26DANMXGC++Y0&[
M( )(QG@UTE[J&L_!GXZ>./$%SX5USQ)X:\706,\-WX=L6O);2XMX?):*6)?F
M 8 ,& QR!ZXZZD*-64YJ*YKRLKO6SC;KV;>EKV.&E4Q%&%.G*;4;0N[+W;J5
M[:=U%:IVN79/VJ+"/P#<ZN_AR^A\36^M1^')?#5Q/''(E^Y^1&F/RB,C)$G3
M Z5U'A3XJ>()-1U>T\;^![GP9'I^GG4_[3CO!?V#PJ2''GJB[9% SL(R0">F
M,^)2>"O%>H>"?'?BG5OARNM6OBSQ+;WEUX1OE)OH]+C7RS)'M==MSP&"YXP>
MN:@\#_#/5M=UCQ-H'@NS\9>%OAUJGAN^L+NS\:+*D27DR&.(VT4N9!M!RS="
M!C)XIRPV&Y)6LK=;WMMHM?5*Z=^X1Q>,YXWN[]+6OO9M<O56;M)6['H#?M/:
MW;^&HO&UY\-K^U^&\C*ZZY_:,378MF<*ERUF%W!#D'[Y.#G!'-:FN_M :W_P
MM35? OA3P,?%5]9V-OJ*7@U:.VMVBD&269D.W&5"[=Q;/0 $U\^6OPQLX_ .
MG^%/^%+>*KKXA*L>FW#WU]J2Z$Q4A'N#.ER(_**@MM7')P!@#/OGPT\'ZAX=
M_:,\:3OI=Q;Z1_PC^E6=K>>1(MM(T:LK)&[9W;<#(W$CC-.M1PM-2DH[)V5]
M]8V>DF^K[)]M!4,1C:KC&4[)M7:6JTDVM8)+9=VNKU.W^#WQ27XK>';^]ETB
MXT'5-,U&?2=2TVXD$AM[F+:64.  XPRD-@=:Q/&WQFU?3/B(W@GPAX1_X2W7
M;?3UU.]6?4X]/B@A9]B ,R,78D= ,#(Y](/V>M#U'1;GXIG4=/NK 7GCC4+N
MV-U"T?GPM' %E3<!N0E3AAP<'TKA_P!H+PS9ZY\2(9/%_P .]6\0^'TTY1I7
MB+P?;W$FJ6EQO)>*7RG!V8^9?E(!8]R<<<*5%XF46O=MHOZ:;^^YWU*V(6#A
M/FM*^KMZ^32OWY;>FZR?VBOB7XLU_P"$OA"^MO!^H:#+<^([:#4++4KPVLL4
ML<ZB.'&P^;%*<GS!P H.#G [>[_: \7R?$6Z\$:3\-DU37K+3+74KU?[>CAA
M@\U 9(][1?,5<A01]_D_*!7F6K>$_B!-^SK:C5--\1:R^G^,H-1TZQOE^U:O
M'I$<RF,3*OS/*/F.!D@$= ./3_AI:ZCJ7[1GC;Q,^C:IIVD:IH&E-;3:A926
M^6VL6C.X#$BY 9>JGK79.%&-)IQ3Y>;J][QMU[?D>?3GB)UTU.47/DOHMK2O
MT[I??\C5U[XM>/8]6UJ'PY\)[W6=/TJ5H'O+_5$T\W3*H+&VC>-C*G. _ ;'
M%8EG\5?#'Q(\6? S7HO#LMS<Z^-4DTR^GNVB?2V2U;SP8URLNX*T?S'C[PKR
M_4-!U36O$WC*#X@^"/'7C;Q(^IW"Z+;6LES'X?\ LQ/^CXD21(T4 G=OR<'H
M3Q5[X->"?$6E6W[-45YH&J6C:*^OIJ7GV4J"S+PS+&925&P.2-I/#9&,YH>'
MHPI\RT=GLWK[DG_,[ZI=$NFHOK6(J55%W<6UHTM+5(+^56T;ZR:WT.PTW]J+
MQ5XCT?Q-J^A?"R;4M*\.7EU:W]TVMQQ;A 26,*F+=(VP!BN!C( +&NBU;]HT
MWTG@RR\%>&I/%.L>*-,.L6UK<WR6$<-L ,EY&5OG!)&U0?NGMS6'\%_"^L:5
M\#?B-87NDWUG?7>J:W)!:SVSI+,LA;RV12,L&XP1U[5YY)X*E_X5C\)]/\;?
M##5/$7AVTT$Q3SZ3:W UO2;[*[?D1U<1E1RNT_, 3P,%>QPTJC2BK)VW>NC[
MM7U[-%_6,9&E&3F[R5]4M/>2Z1=M'NT[;GNO_"Y+^T^%/B[Q1X@\+WOA#4_#
M\5SYMCJ!\R.5XTW(T,P 66-R0H88YR/0GGO@7X@G\!7WA[X3:MIAM+^/PW'K
M::B\XS>322DW2>7M&UUE=C]XD@YP*\Q\+^$_&^K>&1X2N++Q4W@G6O%5DMC%
MXDC:2^M-+@7S[DSO@^4CO%&B*Y!^; '//I_[4&C^(M,M/#/Q \&Z7<:OXG\+
MW4BK9V<!FEGM;B,Q2J$ )?#&-N <!2>V1G*E2C+ZOI[[=M=G;W?QNG>YK&O6
ME%8II^XE?35IOWNG9)JR5_*YHP_'R_U33?%=[HO@K4/$$>E:_P#\(]8)ILPD
M:_F7 EE?Y L$*,<&0EAQGBI?#'QJ\0-\1M*\'>-/ S>$[W6+:>XTRYM]52_@
MN/) :5&*HA1@K ]#U'K7GOC'X?\ BWX;_L^> ?#VAIK=Q!;WL,GBH>&L_P!J
M30R;Y+GR=O)S(YS@[L8QQFN=\"^"8;?]HSX?:[X;^'GBK0/#L,&H0W>L>($N
MGN;B=[<X,HE=VB0=%9M@9G8 <"J6'P\H3DDK>]9Z]%IUZ[VL]^A$L5BXU*<9
M-WO&ZLK>\]?LO9.U^:.W7KU>F_M!ZM\6/A/XMUJ^^&/_ !0\6E:K'?S2:^%:
M?R89=T**L0?:X 7S!@J6. =N3VL/Q*U?1_"?@2P\%?#J^ULZEHL%U%";WR+'
M3X1$FV*2[=&R^" !C<VTFN.^'?A36[']A_6]!N='U"WUR31]>B33);5UN6>2
M6[,:B(C<2P92HQSN&.M<UXLTGQ!#-\,K'Q)HOC:^^'T/A*UBN=-\)I.LPU-0
MH9+M(2LFSRP !D8;/O5.E1G4E"*22E+2[ULO75_-$*MB*=.%2<FY2C%MV2LV
M]5?ET2\TST&7]IF[TOP;\1;[6O!LND^)O!*02WNBMJ*2Q2I.,PM'<*F"& 8_
M<XQ[\.T_]HS7H=0\(3^(/AU=:#X8\57D-AI^JG4XIY5EF&8!- J@QA_]XD=P
M#Q7A</P[U>W\'_M"VVD?#W7O#MEKFFZ6^BZ7/!-<W%PL9E#Y?+[I26#LFXLN
M_!Z$U[O\9/#NJ:EX0^$,%EIEY=RV/BS0[BZCM[=W:WBC)\R1P!\BKW8X [T5
M*&&A)145J^[T]V+TU?5OOVU"EB,94@YN3]U;66OOR6MXI_"ELEWLCA_!GQ6\
M1>$_C#\<M;\3^'?LNBZ7#97%[Y.JBY:R6.S+0QQ)L ?SL[C@J$9SG/)KTCP9
M\9O&&NZIX=_MGX8WFE:%KR![75M/U)-16$,F]&N$1!Y2L,#=D@$@9KC;N#Q/
MHOQ:^.-MI_A&YU2X\2V5E-I$VH6#R:3>>38>7)#-*"%4L<H%)&2?3FN&\!^#
M[G3O'/@N;X<>#?'7@&\_M"!_$MCJ:S1:(+0 _:47S682,3PA0G&<\<8J=*C6
MBY.*3Y8]7;X%_>TUTV>UM]YA6Q%"2@I-KFE=65W[[_NZZ:VO&U[WMHOJOX@>
M.M*^&G@W5O$^MRO%IFFP^=*8UW.W("HHXRS,549(&2,D=:\MA_:'\0Z'=^'K
MCQM\.;KPEX>URYCM+;5/[4CNFMY)?]4+F)44Q;N.[8/!Z5U/[1O@74_B3\%_
M$N@:*(VU:>.&>UCE.%DDAGCG$>>V[R]O.!EN2.M>5_$;Q-XD_:$T7P[X.L/
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MJFE^$?B]#>:9>6<U]XMURYM8Y[=T:XBD(\N1 1\ZMV89![5X;:_!?4;?P/\
M!CQ'K_@W7M=TW2=*N-+UK0M/\^VU*UWR,\<RHCI(V"3N3/3'!SQ$:.%G-II*
MS[O7W6^K[KHUV+EB,;3@I*3?,KO1>[[R6EHOHWNGM>Q]":-^T)#9-XIL?'6@
MS>"]<\/:=_;%Q9FY6\BN++) F@E4+O\ F4H5*@AB!SSCQCX_?%CQ1XV^$VCS
MZO\ #VZ\-Z'JVJZ;/IVH-J,5R[#ST=!/$J@PEDR1RPR,'!(IVD_ ^+XA6?Q'
M'AGP'J/@O3+WP^VDZ;?>)KB]_M&\N#(DS*8KB=A'!NCC&2H;/(/5:7XK^-O%
MOQ"^$_AOPC!\+_%UKK=K?:<VJ/+ICFU@6&1-S12#/F@L ?E!PN2<8K>C1H0K
M1E3CK=7N[<NG3WGU[MVV.?$5\34P\XU9.S3M97YM6K/W5TMLE??8^L?$FL?\
M(_X=U35/*^T?8;66Y\K=MW[$+;<X.,XQG!KY_P!+_:UURY\"Z=X\OOAA?6/@
M28QBZU5-3CEFMP6"M*MOY89XE8XWY4G&<8KV[XD?\D[\4?\ 8*NO_1+5\G^%
M?%WB3QM^RCHOPWTCP#X@EUO5-*BT^+4GM<:6+=S_ ,?!N<[>$Y*?>#<8KS\'
M1IU*;E.*?O).[M9:W>Z/4S#$5:550IS:]UM)).\DU9;/]#T_PSKD-A^TW\5M
M7BAN-1@A\-:;=)#81&::=0CL%C0?>9AT'<D5<U#]HCQ;X5M]'UCQ9\+KCP_X
M6U&Z@MC??VQ%-=6IF($9FMA&"O)&1N)7H1GBN3O/!/C;POXV^*Y\)6=Y_:">
M#]-L=(U.2W*1W$T4;*PC<C:9 !P,G#$9KRKQEX%;Q)X)T>?1_AS\1=1\66MW
M976KZUXH6[>2,"6/S1#$[D2L6)/[J/A Q)P*[X4*%:47.S5HKS7NKS5OQUTL
M>94Q.(H0DJ=T[S>VC]YZ?"[_ "MIK<^D]<^.WB"X\9>)]"\%^ G\7)X9,<>I
MW#:M'9L)73>(X8V1FD.WN=H)! SUIGC+]HC4/#MU\.;'3O >J:EJWC2&Z>'2
M[J865S9R0I&Q2574@#]XQ9LC:J$@-TKS;XM^$[+5/B=XCN_%OPX\42:AF+^P
MO%7P]AN/M$\/E@;+AE<JLJMA=SJ!@#L!G7\&^&/'I\5_L\7GC"TOK[6--L==
M&K7S1F46WF1QBW6>11M#E JY)^9E;J<UA[##J$9N*V?5ZOD;Z/:Z\K;'3]9Q
M3G.FI/=:V6BYTMG'1\KZN2:UN;^E_M%>,];\0:WX5LOA3-+XRT4K)?6#:["E
MI'"ZAHG%R8_F+Y.%"?PG)%5+SXP^&?B5IGP8\2W/A:2[FUC7V@LUFOVB?2KI
M!(CN0@Q+@HP"M@$$'CI75?#G0]1L?VA_C#J5SI]U;Z=?0:(+2[EA98;@QV\P
MD$;D8?:2 <$X)&:\'^&7@#Q18>"_@Q!=>&]7MIK#QQ=W=W'-8RJUM"QEVRR
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M -"\=>%? JV]T==T[Q8LL5IN* 6ZVT<Q+%PYR6!(VC&>N: \#^(A_P $\?\
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M:W\*/&'B?QA8RSPZ=J&CW5^-*U%'<M#([Q3K'",,-ZD+T]2<>L_$'X=Z_P"
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M_@WHFJ^%_ $OE:QXOGT&+18=5:1S<223GS5DD0Y+O']PX W]>.?1M%^,FO\
M_"P?"_A#Q)X-CT#4];M;R[/E:LMVL"P;<<K$H;?N]1C'>NB>#JPOIHK]5?3?
M2YRT\PH5%&[U=ME*WO;:V6_G8]9HKR/Q1^T-8^#_ !-\0-.U+2919>$=)M]4
MDNX9M[W/FY C$>T;3D 9+'KVI_@OXN>,-:U[1+77_AI=Z)I6LQ-+:ZM8:DFI
M1183>HN B+Y08<!LD9(&>I&?U6KR\[6GJNU]-==.QK]=H<_(GKML^]M=--=-
M3UFBN8^)7Q"TKX5^"M3\3ZTTGV"Q0$QP*&DE=F"I&@)&69B .>_I7G5I\?\
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M7HC]A^?'XBO.J?[/657[,M'Z]'^AC+W9<W1G<T445Z)L%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 <!\0/@SIOC[7+'7%UG7/#.O6<#6B
M:GH%X()G@9MQB?<K*R[N<%>":N?#7X4Z/\+[74AI\]_J-_J<_P!IU#5-5N//
MN[N0# +O@# '    ]*[.BMW7J.'LW+0YEAZ2J>U4?>[A1116!TA1110 4444
M %%%% !1110 4444 %%%% !1110 5Q'BJ)_#/B"UU^!3Y$A\JZ5>_O\ B!^8
M'K7;U5U33XM6T^>TF&8Y5VGV]#^!YKEQ%)UJ=H_$M5ZHB<>9:$\4J31I)&P=
M' 96'0@]#3ZX_P !ZA+;FZT*\.+FS8[,_P 29[?3^1%=A5T*JK4U/[_)]1QE
MS*X5R_CSX>Z=\0X]!349KJ$:+K%KK=O]E=5W30,617W*<H2>0,'T(KJ**Z8R
M<'S1>HIPC4BXR5T%%%%26%%%% !1110 4444 <(OP>TE_B?_ ,)S>:EK&IW\
M*,MCI]]>&2QTYG0)(]O%CY&<#DDG[QP!QCNZ**TE4E.W,[VT,X4X4[\BM=W?
MJ%%%%9F@4444 <[X^\!Z3\2O"MYH&M1R/97&UO,MY#'+%(K!DDC<<JRL 0?Y
M@D5R7A;X Z7H'BNP\1:GXC\2^,-3TU'33V\17ZW"61<;7:-$1!N*\%FR<=Z]
M/HK>->I"+A&6C_I_><T\/2J3524;M?IM]W3L%%%%8'2%%%% %+6])AU[1K_3
M+AG2"]MY+:1HR P5U*DC((S@^E9O@/P99?#OP;H_AK39;B>PTNW6VADNF5I6
M5>A8J "?H!6_15\TN7DOH1R1Y^>VNP4445!84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !2,H92",@\$&EHH X;1"?"/BR?
M2G.+&]/F6Y/0-V']/P%=S7.^-]#.L:09(01>6I\V)EZ\=0/\]0*M>%=<&OZ-
M#<$CSU^251V8=?SZ_C7G8?\ <5'AWMO'TZKY/\#&/NOD^XV****]$V"BBB@
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M;BYF=BSRROCYG8G)/]!73444Y2E.3E)W;%"$:<5""LD%%%%26%%%% !1110
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M*VBCB!\DN &#!G*L."4(!S@5];T5E'&RA+F2Z)?=_F;3R^%2/*Y/>3_\"U_
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M=S7-A:DI1=.?Q1T?Z/YHB#=K/=!1117::!1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME;HSJJ***]$V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:!XFTR*;@7$VCRR1+[L\0=0/<G%>M>&_B1X>\51*^E:Q97X9=P^SW"2<9QG
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MDTG_ 'T:6HGH5A!]JG_Y[R?]]FC[5/\ \]I/^^S3-M'"C)X'O5:$W)/M4_\
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M$WQ.\(8_Y&[0?_!I!_\ %U\H>);[5M#\/ZGJ,.IZ;++9VTEPD<F@::58HI8
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M_:@^)FD_"CQ#XL\0>)_@QXP:UU73[&VF^'=_=7UK DK,)_M3/+\K[?+*8/\
M>)!XKA?$O[!OQ-D\ ^"]/TT?#G7]4T#QCK7B*73_ !;]JN=)NH+QCY4<D:P;
MG90<E2  0,,:[/1_V6_BGK7PP\1^$/$/AGX*^#K:\U'3[VVA^'-C=V$,_ENQ
MG^TAH_F;9Y80J/[V2.*\+%>T]A/V7Q6T]3Z[(OJG]J8;Z_;V//'GOMRWU_ ]
M,\,_M$:W\3M0\<:WX.BT?_A7WA:SN%^W7RO)>:E>I"SKY:+(OE0#Y26=26 P
MO)8Q\#\&?VO_ !MXJ\9_ JW\7:7H5KX;^*/A>YNK>[TZWFBD@UB F1X=SS.O
ME-"!M4C<7;[QQ@^B^)/V?=8TGXB:QK'@-](TKP_XCT&31]:T>9GMXO,6)H[:
M>%(XV7*@[2#C"[L<MQYGXS_8N\7Z]^Q;\//AQI>NZ7I/Q0\#R6=]I.N17$RV
MD5U$[!R)!%YFPQR/_P L^6"Y'&1.%]JHM5OBN_3RMY6_KJ=&?/ RKTYY;94G
M"-E]I.UI*;ZRYKN^S35DE[JSK']MKQQKUUX>US3=)\/_ /"$>)/BS#X$T:>6
MWG:>YTP"19KP.)MI=I$(0[0 $8%6X->Y?M4?&?6_@=X)\-ZQH5KI]W<ZEXHT
MS1)EU&-W18;F;9(RA'4AP.A)(SU!KROXJ?L@>*[/X%_!#P;\)[OPY!K'PUUV
MQUN.3Q.\\=I=2012EV801LQ,DTF\@;>&;D'%4/BE\&/VG/CC\+I]'\777PEM
M/$.FZ_I.MZ&VBR:FEHWV9Y7F6Z,B,YR?(VA ./,R1\M=A\T>M_MG?&[7OV=_
MV=_$?COPU;:9=:SI\UG%#'K"2/:XFNHH6+B-T;A9">&'('7I7*_LU_&WX@>-
M]0\37OCOQU\$/$GAO2+#[1++\,-6N;R>T?)(>Y\QV5(RB2X[DK[&N-^+/P1_
M:6_:(^"'C+P)\0;GX3VKZ@UA+ILGAU]31-\-Y%-*)S,C_*8XR%VJ?F/.!S7H
M_P ;?V7[2^^!OC3P7\&/#O@WX=ZSXL@BTW4-0M=.2PC:S+XF#?9XLR-Y32JJ
MM@?O#R* .._8Z_;"\4?'SQMKFB>-- T_PVNH:8OB?P@EK'(DUYH[74UOOGWN
MP,BE(CE, B3.!7,_#?\ ;:\>:S8_!/Q%XETGP[;^$?&_B74_"FJ7-G!/%)9W
MB32QV'EL\S+B3RB&# \JQ!' K2\*?L#ZG\&/BY\,/&?@+XC>)O$EMX;9M+OM
M+\>ZS]IBAT=X3&8;(1VX\MD(1EC.U#L7E<<RZ;^Q3XAD_8BU/X0:CJNE1>,4
MU"ZUC2-6LYY3;VMY]M>ZMG\PQAUQD*Q"$@,V,\4 >J_!'XX:[\8_B_\ %VPM
MK335^'W@[4H= T_4(DD-U>:BD8:]#MOV;(V95 "Y.X$GM7M]?/WPQ^"_CWX"
M?LMVOA7P/>>&]3^*?%_>:EXD:X;3;O4)[A9;V21H565EVM*L9"@G;'N YKTN
M^_X6-_PF'B#['_PB_P#PBW]D#^QO/^T_;O[3RV?M./D^SXV_<^?K[4 >6?MI
M?M'Z[^SKX2\)2^'8= M]3\2Z[%HT>M^+FG31M-W(S^9<M#\X!"$#D ?,Y.$(
M.'X-_:4^(5Y\/?AKJGB'2O"7]I>(O&2^'9]0\.Z@NHZ5J%F7=1>64D<S% Q4
MJ%E)92C;E&<#HOC1\-_C-\2?@_X9LK/4/A])XLB*-XD\-Z]I;WWAC6NA,9\R
M-YT5'59$*X)*X;L1Y#\-_P!B?XB_#GX8V$%AJ'@NV\7#QZ_C9M)LOM<6@Z?^
M[V);6P*M*4^1&.0F VP?<#-RXIU%1;I;Z;>I[^11PL\QIQQK2IOFOS;?"[7^
M=C[AHK@_A=_PL[_B9_\ "Q_^$2_Y9?8/^$7^U?[?F^;Y_P#VSV[?]K/:N\K:
MG/GBI6:]3R\5A_JM:5'GC.W6+NGI?1_UJ?GU>?\ 'W/_ +[?SK5\'Z[_ &#K
M,<CG_1I?W<P[;3W_  //YUE7G_'W/_OM_.H:^JK488BE*E-:-6/Q2%25.:G'
M='V7\.-8^W:-]A=]TMD BG.=T1^X?P *_P# <]ZZ]:^;O@QXU-O);B9R9+3]
MU+W+P-CG\"!T_NCUKZ15@P!!R#R"*^5HRG'FHU?CAH_/L_FC].P->.(HJ4?Z
M_K86EV_*:04ZND[RA<<$56JS<]JK=:UZ$"J>:=3*?3)'5&XJ3TJ.>00QO(W"
M*-Q/L*G97%HE=G+?$'XA:/\ #?16U#5KA85)VQQY^:1CP% [DFO-=)\2>-OB
MCI\^I:=I<=AIP+"%=1=D\W'HB\_F:\QUSPGJW[0WQQLI;^62+PSI\GFVL:MP
MP1N7^N1@5]1:+)_84\NFW+)';I\UO(QQE>X/O7!&HZ[;;M$^#C76<U.>NVL.
MVXJSLF_[WK]U]#SOX=_V]XD\/R74]OI-I>12/!/;O P:)U.""<\U1U;5K_R]
M0LM4T1F6%U"S6;8%PC#*B,<9;@@CM5W7M62/QQ=#0[AIX;U%6YMH>=\BG@K]
M1P37=>&_#=RMPNI:NXEO NV&!>4MU[@>K'N?PK.$?::(\BC@:.857A,+#W8:
M2E>\7KT\[?U8^?\ 3?VA-$^'ER?[3L#8*K;-DT#AT7ZX_6O4/!7QT\$>.-36
M[T[6;4321;&1Y@#P<@8->A:OX2T7Q!&4U'3+6\5NOFQ!JX]?V>?A_#="XB\-
MVD$V<[HEVG]*Z(4:E/1._J?48;)J^!BJ="K>,7=)K]49GB7X@01>--,N;)!>
M6UO;S*[=!O)3 R?;/Y5@^(==G\2:UI%WILT/VV"1WG@M8C(S#:0BG''WCDD^
ME>H0_#?PW @4:5"0/[P)_G6W8Z59Z;&([2UAMT':- O\J2HSE?G>YQU<EQ^,
MF_K6(2@W?EBNOJ_^"?/,FNPZCJ]SIUW'+IUVQ*W"2?=0\9; Z=>O>MZX^"5K
MI-O#>VNK"U#LN'B:0E\GH"7[UK_'+X07?C2Q.K>&YUL?$5NF!GA+E?[C?T->
M0?!3XW7VF>*8O!'Q#M)--O+:8?9O/7Y=V>.3U&>A%8*DX2:J*Z[GCQR9X"I.
ME7ASQE;EGVUZ^B/;+&'Q/X%MY9M1NX]2TI6W+(J'S(%/]\?Q =R.?K78:'XB
MM]:1E4B.X49:/.<@]&![@^M4/%VI-?W4'A^RDVW%TN^:3'$</<_4]JY>^\/R
M>%;I([.;:UMA[1G;[R$X,9]L\?1AZ5NIN$K0U2/6K8B>5U.?#WE1C92N[V?E
MZ?=T.SU3'/:L0]:T?[0CU33[>[C&!*H;;W![@_0UFL#O(/2O7IM.-T?5<RFE
M*.S'JV*GC8@]>*@7FI4[ U3'$N0M[U=CDS@5G0]:NQM6,C57+L;8Z&I-YVU6
M1J?NKFJ(Z(!-,R].E0?;]I]J)FR.M95VQ4G!XKQ,14=/5'MX:FIZ,TVOP3D&
ML;QE\1+#P-H,^I7T@"QJ=J=V/H*9;R/))L')KS#XE>$;SQCKEM#<L1802!=G
MN>K?@*^>Q683C#]WN]#Z/"8"G.=I[(O>#;CQ7\8IGU"ZO!H^C;0T*Q@/(P/3
M@\#BMOPOX9U'1_&NH:-JOB"_,$BB;3YA(JAUQ\R$8ZC^M:%K>:;X,:S-M<QP
MVT,8B> $<@#K]:R/&'BVQ\<:IIEMI"2W-U;2^8DT(PW(P5^A[UPQEAZ4.::Y
MJJ?JY'9.G6JSY8^[3:]$C1\06>K:3J(ELM5%]I4BM#)]H4,XDR-HC ^]N)(_
M"N \47'Q&\'WDU_!X;9X-NZ)=/96"]^1Z^M>W^#?!#6<R7^J$2W:#]U"#E(/
MIZM[UV5PH;@CBO2PN5*O'VV(7++HD]CQ,1F;H2]G2M)=6UN?+'A_]JQIKN&S
M\3>&]3T^:.0'>UL2!CKS74^./B;;^++&QBT=F5([B*Y,KJPSM8';C%>U7&FV
MDS?O+:%R>NY :A73;2'.RVA7Z(*].I@:W)*$*S][=VNSCHXVBJBJ2H[;6>GW
M'BFI7FH^.=)FT^2VU"[>8C,D<?E1H P.,MZX]S7-^,+C5O"-Y9Q:G;1&TF;$
M4VXML/\ =+'OC\Z^B)]JD@ #V KE?&&@V/BC29]/U"(2P2C'N#V(/8UX>(R.
MG*F^:HY3[MGT6#S-QJ+]VE#LCS+2=,\.ZYH+7 9W>-<RJK8;/KQZT6OA%+:.
M*\TZYFM9-@Q"Q.P@#C</7WZUYM>>%O$?PA\0&>!I-5T*0X++DE5ST8?UKU"3
MQ1#J6E6LUM(J-<C&,C*>I/TKP:EJ2M6BDTK>OF?50]YWI2;3_#R)M+\32LVR
MY^Z#L9NZ,.Q]1[UT*7(P&!-9&G^'8+A8S;X<,,-WS[UKKH\MC#L<-\O0GN*>
M&KUK6EJNYG6]BY>[HRY;W)ZD\596XSBLE"1D'CVJQ!(<XZU[^&KW9Y6)HJUS
MHK23=@UKV[^GK7/V+'I6W:YXKZBC,^1Q%.S-2$U?M?\ 6'Z50AQQ6A:_>/TK
MTH.YX=16,/Q5;RV%Q:ZU:C$UNPWX[KGC/\OQKO-.OHM4L8+J$YBE4,/;V^HK
M%FA2XA>*1=T;@JRGN#61X'O7T?5+K0;ALKDR6S'N.I'XCG\#7!-?5\1S?9G^
M$O\ @K\3E7NR\F=U1117:= 4444 %%%% "49HJKJ%_'I\+22,  ">32;25V-
M)MV17UO6(=)MV9WVN1Q[<=:\KT>.?X@^(WF?<ND6[?,V>'-97C;Q@=;98YIF
MAC8[7V_W03T_"NC\,_$#POI>EK:1R&WCA_A(P7/K7%[:,I\O0]&-&5.'-;4^
M5OVJ_ 9UCXN:9I]K ?(F97? Z**]A\(V<>CZ=%;Q#8(D"*O; I?B'JECXD\8
M1ZM8IOB2/9YC"L:XO;J8 0OY8Z9Q7CRFHU'8^CISE4I1B^AE_$*UGNM42.QC
MW75P-FWMSWKOOA7X"T'X5VKWEQ/"^LW8W339!(!["N-AMM8:[1VCR%_Y:#KB
MK\RR(IE>VDE '.>:=.I[.7,8U8\ZY;GL5OX[\/V*LTEZF6[9YJ:'XC:'):S/
M',T_E@GRE'+5\S:MXCMH[I0T!C.<?,.E=+X;\::9IKMO:/YADGBNZGF,I2LS
MB_LV,H[F;\2M>^(WQ0U@>99R^'_ \!^Y'Q)<?7VK>\,6<>FV21PQ^7&HP%K6
MN/BS;:G;M:AU<,-H08/%5[-A)'CH#S2G4]HSI5%4H\MC17+IUXJ.-BK<<<U-
M%CR?]VF*V#TH))]H8$D*<]<CK7.^(OAWHGBFS9;RPB.[CS(QAA70[N,TX-N(
M[#^[03<\L\.R>-OV>;[[5I-S-XE\'LV9]/F8L\*^J_2OJ[X=^.-)\?:!!K&B
MW*S6DN-T?\43=U->2^9Y:N@P4;ALCMZ5P>CZS-\%O'D6LZ:"OA:_DV7]FOW8
MF)^^!VITY\DM3EKT?;+FBM3[&W4M4]/OH=0MXKBWD66"91(CKT*D<&KE>JGS
M*Z/#VT"BBBJ$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %)2T4 -;G@]*^/OVM/AQ'/XHM;RTF2$7B$S0C_9!YK[!->6_&3X-#XE+
M#<P77V6\A4J&(R"/2N>M6Q&'C[3"I.?FKV\R)X7#XR/L\2WR>6E_+YGP_P#9
M]86QNHU5)$BCVP39Z\=,5\W7ELT-]<QSH$FWMN'H2:^A]1;Q%X7U34_#?V5S
M>),R*)1T(/4>QKQ;Q5I%W;ZA/]KB9;AFR_O[BO5R/)ZE"OB88EQ;J)-<N[/G
M\SSZ#IX6IAE)>S=GS;(I?"S0]#C\27)U^WS92(?)E880-[FL+Q[I>G_\)5>1
M^&EFFTM>3MY16[U[%K&L>#M0\ +I41"W0A^5<?-YG?FJ_P )]?TS3_#M[ISZ
M3]JO%W$D+G>/2OS;$9?B:<JN/=)I1ERV>UNY^WX3BK#.-+"^T3DXWT_(S?"_
MA.7P/X;T[7+^Y\_3-XDDL?X>>A^M=5<>+?#E]J$6M6$+"]B&V.V;A7![XKS_
M $&QO/%&O?V9J%U+:63RL5@=N%&>%Q7HMGX TWP?>)<WDGVE<X@0>_K7U=')
M\%A9QCC9.5>2NHQT33Z'YCCL_P =F+G5P<5&C%V<I:V?<[SX575[\0/&%AIJ
M6";+B=2^P<JH/)]J_1>TMUM+6&!/NQH%'T Q7RM^SG\'[^:^A\6JK:3&&!@1
ME_UJXY.*^KA[]:]BHJ%-*GAZ?(ENO/J>9@8UY<U;$3YY/9^7044M)16!ZH4F
M/SI:6@!M'6E[4G-( &:7FBAJ *&N7<]CI-W<6\7G311EU3^\1VK\XO&3:KX_
M^(^LR3WYL()G)N&ST_V17Z5,NY2#TKX\^/OPZU3P9K"ZO!IT5_IMY,X?R5P4
M9NF[VJ5*I3<G25Y-6UV7F?(\18>=6E":VB[L^+[J3P'H]Y.FHO<WT:AXW]I
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MBT:RU*SE$MM=PK-&P.1@@5Z>$J<T;,\;'4>2?.MF:E%%%>@>8%%%% !1110
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M9UKG]>\>:3X?NUL'EDO=789CTK3XS/=..Q\M?NK_ +3[5]31N!TNY44LS!5
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M&W*L.K8KNOCWX?;Q#\-]0B5/,>$I.$]=K9(_+->61^+I_AK\/6M$M)+>?4)
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M9(8PV(V+,-JH5)V@U]'^#?"5AX%\-V>B:8)?LEMO.^=]\DCN[/)(Y[LSLS'
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MZAJ7FVMYJ4,,J9O[AAN1F!&001D="#7NM+2>]P/(/#<DOCSQMX@\<P6EU::
MFAKI.F2W<#0O?*S--)<*C@,L?,:J2/FPQ'&*P/A_\.6\:? /X=ZCI5V-(\6:
M3IT<^E:H!GRW*X:*0?Q1./E9?3GM7OU%*P'SG\/?'.J_#SX7?$+7->T?[#XG
MD\372PZ+NW>;>S+#Y,2'(+JS.I!'5,L,CFMS3OV<[NY^&<OAG5O&^MDZBK7.
MI1Q0V)CDO)'\V23<;8RG][R"9-V  ",#'M[4VG;N!PGP;\97'BSP@+?5"J^(
M]&F?2M7BW9(N8CM+_P"ZX <'N&KNZ*C:J &D!!IC.%ILC=JAD:G:YFRK>-NK
MQ3XS_##0[Z-M?*1VM^K*LAQA9^> WN.S=17M%R>:^??VBOB NAZII>G^6MPD
M8^T20-T<GA1_.O>R:G5J8R"I.UM?D>)FTXT\)-R5[Z+U9SWA/Q1IUOXXAU%;
MKS[:WC\MH64_NU("[U[$ +S[$GM7T-&JS1JZ$,C#((KP2_TK2/#_ (=TW4_.
MMEU*0#[?;1$' ;D8'^QQ^&:]=^'-V9O#Z6[/YAM7,0;.<IU7GO\ *17H9M3C
M4C'$0OV//RN4J,I86?JOU-\1'-/\LU-MI:^6N?1$6W')I=O<]*EP*R/%VK#1
M?#.I7I./(@9Q]<55.+J24([O04I*"<GT.$\;>-YF:XCLK=[NVMW$.U!Q))[_
M .R/U/%<?X+M[#4O$EEJNJ0SS:C#>".9;R/:J[U^5E!]#@>V:P_@UXKAGU:X
MU35_M<]O"Q6UMX87=#)_%(2!C/8?C78ZYX@M-0\62SVT,UO'<1I(?/C,>9(V
M!R,]>!^E?9/#Q@Y86FO=2W[L^2A4J<L<74?O-K3LCWRV^7;C@5IQ_=S659MN
MC0YSD"M.-N!7PDHGVT9%F/M3ZA5JD%8\I5ROK'_()O?^N#_^@FO$_@?\7? O
MA[X(^%(-3\8Z%9W5GI:>?:R:C%YZ%5R5\O=NW?[(&?:O=E-6HJAJQ1\_ZAI=
M_J7A/XT^,;O3[C2[75](EM+"WO8FBG:WMK:=1,\; ,F]I'(5@&VA<@9K8O\
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MG'.K30*XRA= <J&'(R.>U+I&NZ;X@MY9]+U"UU*&*5H))+.995213AD)4G#
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M@\ D^U-<!\+25U0C]_KY^3^YDOC[BN+L\1+[O3R\U]Z/7_['^#__ #\>-/\
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M_P#S\>-/^^;2OFCXA?M"6OPM\3:II?B+1Y;>%; 7ND74$QD_M1]P1H NP;)
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MSPI )',>+/B5I.L>"?&%KJ0\2>$[_2K!KN\M8-EOJ4< )Q+;R!FB<'8P#([
M'@D&J.C>(++X6_$3QL/%4Z:58Z]?PW^GZ]?-Y=M,/LR1FV:8_(CQF%MJ,064
MY&<'%7XJ_$C1_''PF^(MKHAN-1LK71+ACK$,1-A*Y5P8XINDC+@$[<J-P&<@
M@,#;D^,6D>&=0T'PI'::]KNM7>D6][9QI''+/=HQ*9=RZJ' 1G=G*IQ][) /
M2^&_'EIXBFU6TGL[O1-2TK8U[8ZD(Q)"CJ6CDW1N\;(P5OF5S@JP.""*\Y\$
MJO\ PO#2G(!8> +0!L<@&Y;C]!^51^.-%N_$_P 4O'.C6,ODW>H> 8[:%LX
MD>XNU7)[<GK[FG=@=6?C!;W5H^IV7AKQ!J/AQ2#_ &Y:VT1@>/C=*D1E%Q)&
M,GYDB.X*2NX8)ZW2=7LO$&EVNI:=<QWEC=1B6&>(Y5U(R"#7A&@ZW\/--\&V
MB:CJOB33O$%I!';3>%H_$NI#41<!540Q6HN S9)&W:-I4@Y R1ZY\.=)C\/^
M!]'LHM)?00L&]M-DNVNFMG<EW0RL27PS'D_I519FS:G:OE'XC0VGBS]J#3]
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M>A?$#2M8TG5[ZX$NBOHSNFJ6NJ!8Y;$J@D)D(9EVE"'#JS*5(()KD_ ,:?\
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MXAT<>(;?5&OT6,&/;-"H5&DD/E!2.N#T->,?%SX/_$#]LB]^$?\ PM+X+_\
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M117UQ\H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWK\?AGPQ*7E$,MPK%G)QLC RS?E_.OF77I/AOXCU*2^N?B%<1R. !&NBS%4
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M5M]0T?6_$JZ]'K U.%"8S)$QB6)B&W#;R6('RMC/RY^]/^$0^''_ $4"Y_\
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M/^$L^(7_ $(5O_X.(O\ "C_A+/B%_P!"%;_^#B+_  H]E+NOO0?6X?RR_P#
M9?Y'H=%>>?\ "6?$+_H0K?\ \'$7^%'_  EGQ"_Z$*W_ /!Q%_A1[*7=?>@^
MMP_EE_X#+_(]#HKSS_A+/B%_T(5O_P"#B+_"C_A+/B%_T(5O_P"#B+_"CV4N
MZ^]!];A_++_P&7^1Z'17GG_"6?$+_H0K?_P<1?X4?\)9\0O^A"M__!Q%_A1[
M*7=?>@^MP_EE_P" R_R/0Z*\\_X2SXA?]"%;_P#@XB_PH_X2SXA?]"%;_P#@
MXB_PH]E+NOO0?6X?RR_\!E_D>AT5YY_PEGQ"_P"A"M__  <1?X4?\)9\0O\
MH0K?_P '$7^%'LI=U]Z#ZW#^67_@,O\ (]#HKSS_ (2SXA?]"%;_ /@XB_PH
M_P"$L^(7_0A6_P#X.(O\*/92[K[T'UN'\LO_  &7^1Z'17GG_"6?$+_H0K?_
M ,'$7^%'_"6?$+_H0K?_ ,'$7^%'LI=U]Z#ZW#^67_@,O\CT.BO//^$L^(7_
M $(5O_X.(O\ "C_A+/B%_P!"%;_^#B+_  H]E+NOO0?6X?RR_P# 9?Y'Q[>?
M\?<_^^W\ZAJ2Y):XE+#:V\Y&<XYJ.OIS\H>X5;TK39=6U""TA^_*VW/H.Y_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M SY;@<+,%P<#Y77#ID$A?>@F[@BO-OBE\&[/QO ]Y:A++653:EP5)60 Y5)
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MXJ>%JQFGHGJO+J<F)P]/$TW":_X!\F> =4U?QQ?7::.8TU*;)!W$8P -QP<
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M[AU"XD2W^:>&[U 2Q[1_I'S-, JCS'SM&!4.@? OQNW_  3]TF[L/#6K:?\
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MBO(S2C0SBA]6QM-2A>]KM:_)HWP^=9MA:RKTL4U)7M[M/KO]@^%/^&:_'?\
MT!I?^^X__BZ/^&:_'?\ T!I?^^X__BZ^ZZ*^3_U/R'_H&_\ )I__ "1[/^N/
M$?\ T&O_ , I?_('PI_PS7X[_P"@-+_WW'_\71_PS7X[_P"@-+_WW'_\77W7
M11_J?D/_ $#?^33_ /D@_P!<>(_^@U_^ 4O_ ) ^%/\ AFOQW_T!I?\ ON/_
M .+KK_#/PE\<>'_!'BC0&\-33MK+6K+.)XE$7DN6Y&[G.?48KZ\HKT<NX?RK
M*L5#&X2ARU(;/FF_+9R:/-S+B#.LVPD\%C,4Y4Y[KEIJ^M]U!,^)?^% >.O^
M@#+_ -_8O_BZ/^% >.O^@#+_ -_8O_BZ^VJ*^_\ [<Q?=?<?GO\ 8.'_ )Y?
MA_D?$O\ PH#QU_T 9?\ O[%_\71_PH#QU_T 9?\ O[%_\77VU11_;F+[K[@_
ML'#_ ,\OP_R/B9?@#XZ# _V#+_W]B_\ BZ][\%^(/&/A;PKIFDMX!N[DVD(C
M\W[?$F[WP>E>O45Q8C,*N+259)V.G#Y5#"R<Z522;]/\CSS_ (6!XP_Z)U=_
M^#&'_"C_ (6!XP_Z)U=_^#&'_"O0Z*XN>/\ *OQ_S._V%7_G\_NC_P#(GGG_
M  L#QA_T3J[_ /!C#_A1_P + \8?]$ZN_P#P8P_X5Z'11SQ_E7X_YA["K_S^
M?W1_^1///^%@>,/^B=7?_@QA_P */^%@>,/^B=7?_@QA_P *]#HHYX_RK\?\
MP]A5_P"?S^Z/_P B>>?\+ \8?]$ZN_\ P8P_X4?\+ \8?]$ZN_\ P8P_X5Z'
M11SQ_E7X_P"8>PJ_\_G]T?\ Y$\\_P"%@>,/^B=7?_@QA_PH_P"%@>,/^B=7
M?_@QA_PKT.BCGC_*OQ_S#V%7_G\_NC_\B>>?\+ \8?\ 1.KO_P &,/\ A1_P
ML#QA_P!$ZN__  8P_P"%>AT4<\?Y5^/^8>PJ_P#/Y_='_P"1///^%@>,/^B=
M7?\ X,8?\*/^%@>,/^B=7?\ X,8?\*]#HHYX_P J_'_,/85?^?S^Z/\ \B>>
M?\+ \8?]$ZN__!C#_A1_PL#QA_T3J[_\&,/^%>AT4<\?Y5^/^8>PJ_\ /Y_=
M'_Y$\B_X7=XB_P"B9Z__ -^Y/_C5'_"[O$7_ $3/7_\ OW)_\:KUVBJ]I3_D
M_%F7U?$_\_W_ . Q_P CR+_A=WB+_HF>O_\ ?N3_ .-4?\+N\1?]$SU__OW)
M_P#&J]=HH]I3_D_%A]7Q/_/]_P#@,?\ (^)--^'NM3ZU$=4T;4--LWD+O)=6
MSQ CKM!8#DU]0_#_ ,-OI.AO=7$+075TPQ&Z[6CC7(52.Q/+?B!VI2W_  F/
MC3;][3=,.?9WS_4C\EKN&4-P0#]:X/K$L97==_#'2/ZO]/D<^!R^GA;N+N9P
M7 I*T/+3^XOY4OEI_<7\JZN8]A1*-(WW35_RT_NK^5'EI_=7\J.8=CF-07FJ
M.VNR:UA;K#&?JHIOV&W_ .?>+_O@5JJJ[&3A<Y +3@N:ZW[#;_\ /O%_WP*7
M[';_ //"/_O@4_:KL'LV<GMHVUUGV.W_ .>$?_? H^QV_P#SPC_[X%+VJ[![
M-G*JM!KJOL=O_P \(_\ O@4?8X/^>$?_ 'P*/:KL'LV<GLI1'BNK^QP?\\(_
M^^!1]C@_YX1_]\"CVJ[![-G+A<TNRNG^R0?\\8_^^!1]D@_YXQ_]\"CV@<C.
M:5<<4NVNE^RP_P#/&/\ [Y%'V6'_ )XQ_P#?(I>T78?(<Z%IP&370?98?^>,
M?_?(H^S0_P#/)/\ OD4O:#Y#!V4_;QZ5N?9XO^>2?]\BCR(_^>:_]\BCV@<I
MP^K5AM]^O4&T^UD^];0M]8P:9_9-C_SY6_\ WZ7_  K6-91Z&3I-]3S-1TJ1
M>U>D?V38_P#/E;_]^E_PH_LFR_Y\[?\ []+_ (57UA=A>Q?<\[4U(IKT'^R[
M+_GS@_[]+_A1_9=G_P ^D'_?M?\ "E[==A^R?<X*,U+G KN?[-L_^?2#_OV/
M\*/[.M/^?6'_ +]C_"I]LNP_9,XM*E7FNP_L^U_Y]H?^_8I?L-M_S[Q?]\"E
M[5=A^S9R<?6K"]172?8;?_GWB_[X%+]C@_YXQ_\ ? I>U78?LV<Z.M/KH/LL
M/_/&/_OD4?98?^>,?_?(I>T0^0Y^HV&:Z3[+#_SQC_[Y%'V6'_GC'_WR*7M
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MFM2.WBB<ND2(QX+*H!KTL+AU033U9P8C$NML24445V'"%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %)2T4 )BC I:* $Q12T4 )M%
M+110 F**6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKC/&]U+JU]9^'[5OGG823L/X5'(S_/\  5U6I7T6EV,]U,<1Q*6/O[?C7,>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB,/5J9;B59QU7EW^3NFB<)*<9.C/H=G1117WQZ84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^_,7_P <H_X:;\+_ //AJ_\ WYB_^.4?VWEW_/Y!]8I?S'KM%>1_\-->%_\
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M_P".4?VWEW_/Y!]8I?S'JE%>5_\ #1GAO_GQU7_OU%_\<I?^&B_#?_/EJO\
MWZB_^.4?VWEW_/Y!]8I?S'J=%>6?\-%^&_\ GRU7_OU%_P#'*7_AHGPW_P ^
M6J?]^H__ (Y1_;>7?\_D'UBE_,>I45Y;_P -$^&_^?+5/^_4?_QRC_AHCPY_
MSY:I_P!^H_\ XY1_;>7?\_D'UBE_,>I45Y=_PT1X<_Y\M4_[]1__ !RC_AH?
MPY_SY:I_WZC_ /CE']MY=_S^0?6*7\QZC17E_P#PT-X<_P"?+5/^_4?_ ,<H
M_P"&AO#G_/EJG_?J/_XY1_;>7?\ /Y!]8I?S'J%%>8?\-">'?^?+5/\ OU'_
M /'*/^&A/#O_ #Y:I_WZC_\ CE']MY=_S^0?6*7\QZ?17F'_  T'X=_Y\M4_
M[]1__'*7_AH+P[_SY:I_WZC_ /CE']MY=_S^0?6*7\QZ=17F/_#07AW_ )\M
M4_[]1_\ QRE_X:!\/?\ /GJ?_?J/_P".4?VWEW_/Y!]8I?S'IM%>9?\ #0/A
M[_GSU/\ []1__'*7_AH#P]_SYZG_ -^H_P#XY1_;>7?\_D'UBE_,>F45YG_P
MO_P]_P ^>I_]^H__ (Y1_P +^\/?\^>I_P#?J/\ ^.4?VWEW_/Y!]8I?S'IE
M%>:?\+^\/?\ /GJ?_?J/_P".4?\ "_?#W_/GJ?\ WZC_ /CE']MY=_S^0?6*
M7\QZ717FO_"_/#__ #YZE_WZC_\ CE'_  OSP_\ \^>I?]^H_P#XY1_;>7?\
M_D'UBE_,>E45YK_POKP__P ^>I?]^H__ (Y2_P#"^O#_ /SYZE_WZC_^.4?V
MWEW_ #^0?6*7\QZ317FW_"^O#_\ SYZE_P!^H_\ XNE_X7QH'_/GJ7_?J/\
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M%Y:#_P ^FH_]^X__ (NC^V\N_P"?R#ZQ2_F/1**\[_X7CH7_ #Z:C_W[C_\
MBZ7_ (7AH7_/IJ/_ '[C_P#BZ/[;R[_G\@^L4OYCT.BO//\ A>&A?\^FH_\
M?N/_ .+I?^%W:%_SZ:A_W[C_ /BZ/[;R[_G\@^L4OYCT*BO/?^%W:%_SZ:A_
MW[C_ /BZ7_A=NA_\^FH?]^X__BZ/[;R[_G\@^L4OYCT&BO/O^%VZ'_SZ:A_W
M[C_^+H_X79H?_/KJ'_?N/_XNC^V\N_Y_(/K%+^8]!HKS_P#X77H?_/KJ'_?N
M/_XNC_A=>A_\^NH?]^X__BZ/[;R[_G\@^L4OYCT"BN _X75HG_/KJ'_?M/\
MXNC_ (75HG_/KJ'_ '[3_P"+H_MO+O\ G\@^L4OYCOZ*X#_A=&B?\^NH?]^T
M_P#BZ7_A=&B?\^NH?]^T_P#BZ/[;R[_G\@^L4OYCOJ*X'_A<^B?\^NH?]^T_
M^+I?^%S:)_SZW_\ W[3_ .+H_MO+O^?R#ZQ2_F.]HK@O^%S:+_SZW_\ W[3_
M .+H_P"%RZ+_ ,^M_P#]^T_^+H_MO+O^?R#ZQ2_F.]HK@O\ A<VB?\^M_P#]
M^T_^+H_X7+HO_/K?_P#?M/\ XNC^V\N_Y_(/K%+^8[VBN#_X7)HO_/K?_P#?
MM/\ XNC_ (7)HO\ SZW_ /W[3_XNC^V\N_Y_(/K%+^8[RBN$_P"%Q:+_ ,^M
M_P#]^T_^+H_X7%HO_/K?_P#?M/\ XNC^V\N_Y_(/K%+^8[NBN%_X7#HW_/M?
M?]^T_P#BZ/\ A<.C?\^U]_W[3_XNC^V\N_Y_(/K%+^8[JBN%_P"%P:-_S[7W
M_?M/_BZ7_A<&C?\ /M??]^T_^+H_MO+O^?R#ZQ2_F.YHKAO^%OZ-_P ^U]_W
M[3_XNE_X6]H__/M??]^T_P#BZ/[;R[_G\@^L4OYCN**X?_A;VC_\^U]_W[3_
M .+I?^%N:/\ \^U]_P!^T_\ BZ/[;R[_ )_(/K%+^8[>BN'_ .%O:/\ \^U]
M_P!^T_\ BZ/^%N:/_P ^U]_W[3_XNC^V\N_Y_(/K%+^8[BBN(_X6YH__ #[7
MW_?M/_BZ/^%N:/\ \^U]_P!^T_\ BZ/[;R[_ )_(/K%+^8[>BN)_X6UI'_/M
M??\ ?M/_ (NC_A;6D?\ /M??]^T_^+H_MO+O^?R#ZQ2_F.VHKBO^%L:1_P ^
MU[_WPG_Q='_"V-(_Y]KW_OA/_BZ/[;R[_G\@^L4OYCM:*XK_ (6QI'_/M>_]
M\)_\72_\+7TC_GWO?^^$_P#BZ/[;R[_G\@^L4OYCM**XK_A;&D?\^U[_ -\)
M_P#%TO\ PM?2/^?>]_[X3_XNC^VLN_Y_(/K%+^8[2BN+_P"%KZ1_S[WO_?"?
M_%TO_"UM)_Y][W_OA/\ XJG_ &UEW_/Y!]8I?S'9T5QG_"UM)_Y][W_OA/\
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M_A9VE_\ /O>?]\)_\51_;67?\_D'UBE_,=?17(_\+-TO_GA>?]\)_P#%4?\
M"S-+_P">%Y_WPG_Q5']M9=_S^0?6*7\QUU%<E_PLS2_^>%W_ -\+_P#%4?\
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M_P#"PM._YXW7_?"__%4_[8P'_/Y![>E_,=/17,?\+!T[_GC=?]\+_P#%4?\
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MF>K_ .!\K'K4<-2HZQ6H4445] =04444 %%%% !1110 4444 %%%% !1110
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M-3@^TV,^WS(M[)NVL&'*D'J!WK0HKV91C.+C)73-VDU9GG__  H7P)_T O\
MR;G_ /CE+_PH?P+_ - /_P FY_\ XNN_HKS_ .S,#_SXA_X"O\C+V-/^5?<<
M!_PH?P+_ - /_P FY_\ XNE_X4/X&_Z ?_DW/_\ %UWU%']F8'_GQ#_P%?Y!
M[&G_ "K[C@?^%$>!O^@'_P"3<_\ \71_PHGP-_T _P#R;G_^+KOJ*/[,P/\
MSXA_X"O\@]C3_E7W' _\*)\#?] /_P FY_\ XNC_ (43X&_Z ?\ Y-S_ /Q=
M=]11_9F!_P"?$/\ P%?Y![&G_*ON."_X47X'_P"@)_Y-S_\ Q='_  HOP/\
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M?_%T?\*:\'?] ?\ \F9O_BZ[6BC^S,#_ ,^(?^ K_(/8T_Y5]QQ7_"F_!_\
MT!__ "9F_P#BZ7_A3?@__H$?^3,W_P 77:44?V9@?^?$/_ 5_D'L:?\ *ON.
M+_X4WX/_ .@1_P"3,W_Q='_"G?"'_0(_\F9O_BZ[2BC^S,#_ ,^(?^ K_(/8
MT_Y5]QQ?_"G?"'_0(_\ )F;_ .+I?^%.^$/^@1_Y,S?_ !==G11_9F!_Y\0_
M\!7^0>QI_P J^XXS_A3OA#_H$?\ DS-_\71_PI_PC_T"/_)F;_XNNSHH_LS
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M./\ ^%1^$_\ H$_^3,W_ ,71_P *D\)_] K_ ,F9?_BZ["BC^S,#_P ^(?\
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M>7_XJC_A5_AG_H&?^1Y?_BJZJBC^S,#_ ,^(?^ K_(/8T_Y5]QRW_"L/#/\
MT#?_ "/+_P#%4?\ "L?#/_0-_P#(\O\ \574T4?V9@?^?$/_  %?Y![&G_*O
MN.6_X5CX:_Z!O_D>7_XJC_A6/AK_ *!O_D>7_P"*KJ:*/[,P/_/B'_@*_P @
M]C3_ )5]QRW_  K'PS_T#?\ R/+_ /%4O_"LO#7_ $#?_(\O_P 57444?V9@
M?^?$/_ 5_D+V-/\ E7W'+_\ "LO#7_0-_P#(\O\ \51_PK/PU_T#?_(\O_Q5
M=111_9F!_P"?$/\ P%?Y#]C3_E7W'+_\*S\-_P#0-_\ (\O_ ,51_P *S\-_
M] W_ ,CR_P#Q5=111_9F!_Y\0_\  5_D'L:?\J^XYC_A6OAO_H'?^1Y/_BJ/
M^%:^&_\ H'?^1Y/_ (JNGHH_LS _\^(?^ K_ "#V-/\ E7W',?\ "M?#G_0.
M_P#(\G_Q5+_PK;PY_P! [_R/)_\ %5TU%']F8'_GQ#_P%?Y![&G_ "K[CF?^
M%;^'/^@=_P"1Y/\ XJC_ (5OX=_Z!W_D>3_XJNFHH_LS _\ /B'_ ("O\@]C
M3_E7W',_\*W\._\ 0._\CR?_ !5+_P *Y\._] [_ ,CR?_%5TM%']F8'_GQ#
M_P !7^0>QI_RK[CF?^%;^'?^@=_Y'D_^*I?^%<>'?^@=_P"1Y/\ XJNEHH_L
MS _\^(?^ K_(/8T_Y5]QS7_"N?#O_0._\CR?_%4?\*Y\._\ 0/\ _(\G_P 5
M72T4?V9@?^?$/_ 5_D'L:?\ *ON.;_X5UX>_Z!__ )&D_P#BJ/\ A77A[_H'
M_P#D:3_XJNDHH_LS _\ /B'_ ("O\@]C3_E7W'-_\*[\/?\ 0/\ _(TG_P 5
M1_PKOP]_T#__ "-)_P#%5TE%']F8'_GQ#_P%?Y![&G_*ON.<_P"%>>'_ /H'
M_P#D:3_XJC_A7OA__H'_ /D:3_XJNCHH_LS _P#/B'_@*_R#V-/^5?<<Y_PK
MSP__ - __P C2?\ Q5'_  KWP_\ ] __ ,C2?_%5T=%']FX'_GQ#_P !7^0>
MQI_RK[CG/^%>^'_^@?\ ^1I/_BJ7_A7N@?\ /A_Y&D_^*KHJ*/[-P/\ SXA_
MX"O\@]C3_E7W'._\*]T#_GP_\C2?_%4?\*_T#_GP_P#(TG_Q5=%11_9N!_Y\
M0_\  5_D'L:?\J^XYW_A7^@?\^'_ )&D_P#BJ7_A7^@?\^'_ )&D_P#BJZ&B
MC^S<#_SXA_X"O\@]C3_E7W'/?\(!H/\ SX?^1I/_ (JC_A7^@_\ /A_Y&D_^
M*KH:*/[-P/\ SXA_X"O\@]C3_E7W'/?\(!H/_/A_Y&D_^*H_X0#0?^?#_P C
M2?\ Q5=#11_9N!_Y\0_\!7^0>QI_RK[CGO\ A =!_P"?#_R-)_\ %4O_  @.
M@_\ /C_Y&D_^*KH**/[-P/\ SXA_X"O\@]C3_E7W'/\ _"!:%_SX_P#D:3_X
MJC_A ]"_Y\?_ "-)_P#%5T%%']FX'_GQ#_P%?Y![&G_*ON.?_P"$#T+_ )\?
M_(TG_P 52_\ "":'_P ^/_D:3_XJM^BC^S<#_P ^(?\ @*_R#V-/^5?<8'_"
M!Z%_SX_^1I/_ (JC_A ]"_Y\?_(TG_Q5;]%']FX'_GQ#_P !7^0>QI_RK[C
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M!7^0>SA_*C(_X132O^?7_P B/_C2_P#"*Z7_ ,^O_D1_\:UJ*/J.$_Y]1_\
M 5_D'LX?RHR?^$5TO_GU_P#(C_XT?\(MI?\ SZ_^1&_QK6HI_4<+_P ^H_\
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M]AV7_/'_ ,?;_&E_L2R_YX_^/M_C5ZBCZM0_D7W(.2/8H_V+9?\ /'_QYO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBB@ HHJ"]O8--LY[NZFCMK6WC:66:5@J1HHRS$GH  3F@">BO._ O[07P_\
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MG]B[_D\2[_[B7_LU'[:/_)XEI_W#?_9:I_L*Z@-6_:M2^ VBY@OY@/3<I/\
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M^S3KW[/>F>(1XCU2SU"]U&6,0Q:;<2R6\42 DG#HGSLS'/R]%'/)%?1M%%?
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M*X!'2O:=!TN#0]#T[3K5VEMK.WCMXGD(+,B*%!)  )P!T%>;?M5?\F]>-_\
MKQ_]J)7YG*UW8_6HWLKGG'[,?CX>$?@S'J7B3P9'X2\/:/I,<R>(_.20ZDK-
MR0BH&!)V\$G)(%6X/VLO%6JZ6^OZ1\&M?U#PD 9%U0W021XAG,BPB,[ACN&(
MZ\\5YS\9/M7_  P/X(^S[O*Q8?:-O3R]KXS[;]GXXK[)\/?V?_8&F?V1L_LK
M[+%]C\O.WR=@\O&>VW%2!P^C_'30_%7P;U?XA>'U;4+/3K"YNY+*5O*D66&(
MR- YPVUN!R,C# C(K@? ?[4OB#XE3://X?\ A=J=]HEU+#;WFK+>JL5K,VW>
M%!C'F+'N^9OEZ'CU\O\ A+Y'_" ?M4?V;M_L+?J?V'RO]5M\JZQM]MGE_ABO
M>OV3;>.U_9V\$I&NU3:.Y'NTSL3^9- 'KE%%%,84444 %%%% !7YO?\ !33_
M )*]X8_[ 2_^E$U?I#7YO?\ !33_ )*]X8_[ 2_^E$U?2</_ ._Q]'^1\KQ-
M_P BZ7JOS/HW]JOXH^)_A'^SIX=UOPGJ?]DZH]Q96S3_ &>*;,;0.2NV167J
MJ\XSQ7@?@?\ :6_:0^,7@ZWL_ VF?;[[2TD_M3Q +6U#7$A=G15$@6%2L91=
MBJ6.,]Z]2_;S_P"35/#7_80L/_2>6NI_X)ZV<5K^S?821KM>XU&[ED..K!PF
M?R1?RKKI.CA\M^L2I1E+G:U7Y]_0X:L:^)S7ZM&M*$.1-V?Y=GY[GF/[)O[8
MWC/Q;\4H_ /Q#:&\N;PRPV]Z;9+:>&XC5F,4BH I!",/N@AL=<\>(_MU?\+$
M_P"%K2?\)K_R!?M%U_PCG_'O_P >?F#'^J^;^Y_K/F_6MGP>H7_@HM. ,#_A
M*KX\?]M:['_@I_\ \C5X#_Z\KK_T8E>Q1C2HYG2=*"2J0OMMOMV/$KSK8C**
MWMJCDZ<[;[JZW[]T=O\  _7?CQX7^#7C+6?%\_V;P_IW@N2\\,3[+!_+>.W+
MPMMC!8X0*<2@YQR,UX3X8_;;^.?B"PN-"TJ\E\0>(KR9'M[BUTB"6>&-5;<D
M<,<6&+$@DLK8"\=37VUK7_)E=_\ ]D^D_P#3::^6_P#@F+I]O-XZ\:7KQ*US
M!IT,4<A'*J\A+ ?78OY5PT*E"=#$XJK1BW%JRMIV_P"'[GH8BEB(8C"X.C7F
ME).[O=]_+T78]:M?CY\5_AK^S#'XJ\8Z#=ZOXWOK^2WL[6?2GMS;0@8$MTD:
MKM&4<@80MN7MDCQZ#XO?M;ZUX-D\=6:S1^%UC:Y+QZ=8 >4O+,(G4S%, _,
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M@^+NA726%S8^ ]0O2TI_L0&PBMERSJ+DH&+;5*@[^6(X[5P7_!2__DNVA?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML/VKS-RA<8\Q,8Q[U[915/,,2ZD*W-[T%9:+1?<0LMPBI3H*'NS=VKO5_?\
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M:$$\<$<9S7S_ .$_V<_VEO%'ANU^'WB+6F\-^ X\0R+->V\Q\@8^1?)+2.N
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M5KQ=FUV9\M?L<_LBW7P.FO/$_BF:WN?%-Y#]GBM[<^9'91$@M\Y'S2,0 2.
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MO6.GX[_,YL-/GI*^ZT^X****]\Z@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=[*"07+Y!Q\N>N &4 9W&D!]<T5\N>"_&OB/X-_&[0_ >L^,I/'OA7Q)$_\
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MRI0JZ4:_O)]%)[_>]'\CR5/ZMB'&7PRU^9ZY1117Z.>L%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^.GB>Z;Q9%J,BOI6HWDMO#%&H& BI@\'>NU3P ./7] (XTAC6.-51% 5548
M Z "N<UCX9^$/$.I?VCJOA31-3U#(/VJ\TZ&67CI\[*3V'>D(^0O@/?^$)/V
MOT_X0C2GTKPM)HLT.GLT4B"[VGYYAYA+%2R. 3S\G0=*]4_9O_Y+]^T!_P!A
M.R_]N:]X/A'0CK%EJQT73SJEC#]GM;[[+'Y]O%@C9&^-RKAF& 0.3ZU)IOAO
M2-&U#4+_ $_2K*QOM097O;FVMTCDN67.TR, "Y&YL%L]3ZT ?-_QM_Y/&^#G
M_7"7^<E9NF^)-/\ V>OVK/&]QXOE;3="\7PQW6GZM(C&'>""R,0#MPQ<>V%)
MP&S7U!?>%=%U/6+/5[S1["[U:R!%K?3VJ// #G(20C<O4]#WI^N>'-)\461L
M]9TNSU:T)R;>^MTFCSZ[6!% SQ:X_:67QA\7/"_A#X<"R\3V4Q:;7=1V2-':
M0 KRC@JN[ ?KD99 .<BOG?P/\._A5X)^(_C+PE\9-*^RWJWSW.D:K=75S!!<
M6S$X :-P.F&!/JP)R,5]V>'?".A>$;=[?0M%T_18)#N>+3K6.W5CSR0@ /4_
MG1XB\(Z%XNMXX-=T73]:@C)9(M1M8[A5)ZD!P0.E CY.\ Z3\%+[X[:)HWPW
M\!2:]+8$7T_B2WU>\%OI[H<J=KLPDY '. 20.><=S\-?^3UOB]_V#-/_ /1%
MO7O7A_PKHOA.U:VT/1[#1K=CEH=/M4@0GU(0 4ZV\-Z19:W>:S;Z590:O>*J
M7.H1VZ+<3JH 4/(!N8 *  3Q@>E SQK]H;XC>$= \2>'O#'Q$\)1ZAX/U92W
M]OW&7BM)QN^3:J%E. GS*P.'/8&OG7QYHOP]\&^,O"EU\!_$M]+XMOM4BB.E
MZ9=O/;^2<YW,><9P"K,05+9&!FOO75M&T_7K%[+4[&VU&SDQOM[N%98VQTRK
M @UE^'?A[X6\(SO-H7AK1]%F<8:33K"*!B/0E%% CH****8PHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9-#
M'<0O%*BRQ2*5=' *L",$$'J*^(]$^(4O[-?A?XU> 9)6CN=,E^U>'MV=S1W6
M(U(Y_@#1/]=U?;]>4_$;]FOPA\4/'VC^+M9-\NH::(D\BVD18+I8Y#(JS*4)
M89..&''% %O]G'X;_P#"K/@[X>T26+RM0,/VJ^!!!\^3YF!SW7(3_@ KQ_PA
M\0?BI^TCK_B:3PEXIT_P%X8TJ]^P*#8+=7D@Y^<AQP<#/!7&<=LU]5UX7XC_
M &/?!6M^*-0UVPU+Q#X7NM0<R7<6@Z@+>*9B<L2I1L9))P"!R< 4@/(?"NBW
M7AC]MCPII6I^.+OQUJT.EW'VJ[N@$%NYAG(@5 S;<+AB,_QUVG[.\T6B?M,_
M''2=1(AU:]O(;RUCEX=[?=*Q*YYQMEA/';'I7<^&?V4? _@SQ;X<\1Z'_:6G
M:GHIE8.EPK_;&D4J[3ET9F)#,/E*XSQ6M\5/V=?"/Q<U2TU;4EOM+UVU79%J
MVCW'V>Y"C. 6P0<9."1D9H$:GBKXR:!X1^(7AKP7<K=W6NZ]N,$=I&KK"JD?
M-+E@5!^8@@'B-NG&?'/V%9HM-\/>/?#UV1%X@L?$D\EW;R<2A"D:*3GDC?'(
M/_UUZ9\+?V<?"7PIUJYUNR;4=9UZ=/+;5M;N1<7"J>H4A5 ST) SCC.*I?$3
M]EOP=\0O%#^)#/JWAS7I%VS:AH%V+:2;@#YLJP)P ,@ GO0,Z1?C)H$OQ</P
MZ@6[N=>2R^VS20QJUO O/RNV[(;&WC;C]XO/7'RM\#_^3#_B-_UUOO\ T3#7
MU%\)_@5X5^#<5ZVAPW%QJ%\0;K4]0E\ZZFQS@O@ #/. !D\FLOPK^SCX:\(?
M"76OAY9WVJRZ+JS2M///-$;E?,55;:PC"CA!C*GO0!8_9EB2'X ^!50;0=,C
M;\3DG]2:^:OA?8W^K_"']I.RL"[3M?W3I&O)('F%P!ZE5(K['\#^$+/P#X1T
MGP[I\L\UEIMNMM#)<LK2,J]"Q4 $_0"N>^%WP9T7X2W/B.?2+J_N7UV]-]<B
M^D1PDA+'";47"_,>N3[T ?.'[.OPU\<^-/A'H=[X9^-EQHVG(C1'28-&BE^Q
M.'.Z,L902<G=D@9# ]ZZ?X*^$]$\)_&+Q_K6I_%)?'6M6^E/!KMN=%:$1*AB
M.]I S(Y58RFU<DY/=2*Z[7/V-? VI:S>:CI5_P"(/")O#NN+;P_J MX)#W^1
MD; YZ# ] *] ^%GP;\+?!W0Y],\.6+1+<MONKFX?S)[EAG!=CUP"<   9/')
MR"/GWPS^SV=1T^7Q1\!_BO?:-HUW.[)I\@=[3S%8@J0<$8(XWQL<$<D')]#_
M &8OBQXL\=7GC;PUXS-C=:UX5O([234-/7$=SN,H/ P,@Q'D!>&' (J'4OV+
M_!$^J7=YI&J^)?"L5VY>:QT/4A#;L3U^5D8@>P.!G P*],^&'PG\-_"#P^VD
M>&[(VT$DGFSS2N9)IY,8W.YZG';@#L!0!V%%%%,84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+S75'K0KTZDN2+-.BBBO:.@**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HIDTT=NNZ1UC7U8XKG[OX@:'9R"-KMG<G $4+OS^ X^IXH Z.BL)?&VC,<
M?:P/^ G_  K4LM2M=14M;7$<X'78V<4 6:*** "BBB@ HHHH **** "BBB@
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MXNKX=^(FJWVM6$,L::A9ZE<&[)A8#$T,I);.T[AS@\AAGIZ#\#_V]/ ?PO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "JUU?1VJN2065=Q7<!@?B:LUAZN(X9DDD@1D=62
M65MN0HY P>2#Z"@# OOB8(9&2.S(93@AVS^-9$/C[5=TI*[XI.AR R?2JNI1
M1WU]/.H 5VR!C'%8MTN)"%&5''6@"UJ6L3ZA)(ZW,A92 \;GYEXX(/I5&*,W
M#,9&9O;/6J6G023:Q.5R8Q'AOSXK0EC,3>AH &\N%>%4'Z<UH^&]8_L_5H95
MR >>#CZC\JQVQ)GL:BM9/+O(U/8F@#Z"5@ZA@<@C(-+5#0;K[9H]I-_>C&?P
MX_I5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M88.5:G@^5PJ-O6]XM[^IYW_P3+^']]:6?BSQE<PO#978CTZS9E($NTEI6'J
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M,5ZO]I8*.-GBHM^_%IZ;/2WY'C_V5CY8"&#E&/N236NZ]Z_YJQX%_P %2/\
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M?/W!C&.]*&98>-7"3;=J<;/3RL54RG$RHXV"2O5DG'7IS7/%_%W_ "C:@_[
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MZ>V89"H_NYX/X5REUH4%S=&[MI'T^_Z&YML O[.OW7'U'XTP:U>:.H76+<-
M/^8C:*3'_P #3[R?7D>]7S&?H>M:;XF@NL)-^YD]?X3_ (5LYSR.17E%M?1S
M1)+%*LL3KN61&!5AZ@UM:5XJETU@C'S8/[F>GT-8RBNAO&H]I'?456L-0@U*
MW$UNX=#U]0?0U9K,Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.:".X
MC*2QK(A_A89%244 8=QX/TZX)PCQ9_N-_C7F_BCP+JVG7^+6]A^Q/R&DA+.H
M_/&:]DJIJEF+VS=",D<B@#S?1]!AL;3RTR[-R\C=7/J:KZEI93)QQ73VL!1B
M "1UZ5;U+2?,M?,53T]* /+;B(HQJG(W^E0M]0:W]6M#&YXKGYE_>.!U4#%
M'L?@"]^UZ%M[Q2%3^(!_K72UYO\ "[5,74]JQXFCW#_>7_ZQ_2O2* "BBB@
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M/EICKC&#6KP==4Y5G'W8NSU6YBL=AY584%+WI+F2L]5WV/9J***XSN"BBB@
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M'O\ _7JY?0>6N.X%?F..=&6)F\.O<OH?O&4QQ4<#26,=ZEM;[^5_.VY)X9U
MZ;J\,H./+D#=?X>A_0FO=$82*K#D,,BOGF.3R[B-^QX->V^#]0_M'08&)R\?
M[MOP[_E7 >N;=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHS%MHW%G<;"<#<'.TD;@.H],_:0_:*TS]GWPQ9W,EFVL:]J<C0:;I4;[3*P
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M@O!^NZKXBL],LKBQOQ:Q+I<4D:%3&K98/(YSD]B*]\DD2&-Y)'6.- 69F.
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MZ#=65CJ)LX&TNYU(;K=+LW,N"PVMW2+^$\XKT;_A!_VM_P#HH7@C_P !S_\
M(=<U+#T*.'ISER-S5WSM[7V5OS.JMBL1B,35A'VBC!V7(H[VO=W_ "['LGP+
M^-^A_'KP1'K^CJUK-&_D7NGS,#):S  E2>X(.0V.1Z$$#T6OFS]DO]GOQS\$
M?$'C2_\ %>JZ+>P>(&BN/)T>20JLRO(S-M:) HQ(1A?RX%?2=>%C84:=>4:#
MO'I_7D?0X"I7JX:,L3&T^O\ G\]SYE^)'[3OC.\^*^H?#KX2>#K;Q/K>EINU
M&^U*0I;0M@$K]Y!QD DN,G( .,UD:'^U=\0/A_\ $71/"OQG\$67AZ+6I%AM
M-6TB0M &+!03F20, 64-AP5SG!!J/XJ_LT_$OPW\6M7^)?P=\26]GJ.K#-]I
M5X5'F,<;@N]6C=20#AMI4YP>E<;J7[3'C?P#J^BVO[0'PET^ZL([DI;:VEHC
MF!\C=)&29(W8 9PC(2![5]#2P^'K4XQH0C-<NJNU4O;7=VW/F:V)Q-"K*6(J
M2@U+1V3I\M]$[*^JZMGL?Q8_:$\2?"?]H;P1X7U"RTIO WB79"M^T<B7,4Q8
MQD&3?LPKM$Q^3[K]1UKVCQQXML_ ?@_6O$6H$"STNTDNY!G&X(I.T'U)P![F
MO"?VZOAZOQ"^ LVN:=^\U#P](FK6TT1.XPXQ+@CML(?_ +9BO,/CY\;+OXP?
MLW_#+P_HDGF>(OB!<0VES%&V2#"ZI,#CD S[/^ AJXJ6#ABX4)05M7&7RUO_
M . W^X[ZV.J8*IB(3=]%*'STM_X%;[STCP'^U5K-K^S9??%?X@:98P+)=-#I
M>GZ1%)$;E=PC3+2._)<2<\ *F<'I7-V_QV_:9U;P['XJL/A3H7_".RP_:HK5
MY7:]>'&00OGAB2.0/+R>PY%>O_$C]G/2?'7P%M_AG;71TRWL;:WCL;M8P=DD
M( 5W4$;MW.[G)W$]:\#T]/VK?@+96VGP6.G?$7P]8*(8=@69Q$!A5&#'.2!Z
MAL=.1BMZ'U6LIRI1AS.3TDVER]+=+G-B/KE!PC5E/D45K!)OFZN6C=NUCV3X
M;?M$:E\=/@IK'B'P+HUNGC:P/V8Z+J4F85N/E(R^Y,H5)(.5.01VY^9OV-=;
M^+%K\2O&,>@^']%N].NO$-N/%4MS(0]F#-+YAM_WRYPIFQP_W5Z]_H[]DOXW
M>&?BOINOV6F>#K7P+X@TV9#JFF6L"1I(S;AYF5123N5P0PRIQR<YK@OV#?\
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MEA+OE;OTOOS=N_D%%%%>8>L%%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<]:\YN?&XF8QVJF1NF[! KKOACX%G^(WBC3K*\DD:WGG57"< +GG],U2NW9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(]JQ_$4.5W"M'37^4CVIFL0^9"?I0!Y?K$7WN*Y6\7K7<ZQ#][BN.OH]K,*
M,B3YHSZJ:]-^$>L;I;NQ8\2*)T'OT8?RKS1N'(]:U/!NK?V/KUI<$[524*_N
MC<&@#Z$HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "O#/VQ=8NM,^$?DV\C1)>WT4$S*2"4P
MS8^A*BO<ZX3XV_#S_A9_PXU30XRJW;*)K9FZ>:ARH/L>1^- 'YV^'_%EQH.H
M0/YK1EF(\O=G('_UN:]G@\1"\M(I85^9E!/H#CM7@NH>&;SPQKEY:W>GR:??
MQE(IXKC(/R]MOJ!W[UTWAK4+RZM1IM@+FZN7DPMM:1%Y&^F*N,^4Y:M/FU2U
M.YUOQ)9Z2C2W]TJG^[G+'VQ7!:UX\U;4 4TVW32[4C_C[O.7/^['U_/%>N^"
M_P!E'QEXN9;O4XX?#-LQSOO/WMR1[(#Q^)%?07@?]EOP/X/9)[BS;Q!?@<W&
MID2+GU$?W1^1I.;>P1HVW/S:N;&.[\4:>KW-WJ^L&57,T[']VF>2$'"YZ#N<
MU]7^#_@;XQ\>207*V']@V+1A3>:B"K.H[K%]X_CBOJW0?A?X0\+7TU[I'AG2
M].NYFW//;VB*['USC-=16#AS/WF=L9*"M%'D?@;]F?PIX4:.YU!'\1:BIW>=
M? >6I_V8QQ^>37K4<:0QJD:*B*,!5& !["G45HHJ.Q+;>X4444Q!7#_'"P.I
M_"#Q?;@;F;39B![A2P_E7<5F^)K'^T_#FJV>-WVBUEBQ_O(1_6@:W/R_M?FA
M0YS5R%<,*JV$9C@$;\.GRGZCBKT8P:XI'>=3H$FUUKVWX=Z@4N(E.=NX'VKP
MG1Y-C*:]8\"W?EW$?UHI.TCFK1NC["T^;S[&!_[R"K%8?@VZ^U:%"<Y*Y']:
MW*[GN<T=D%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "H[A?,A=?45)10!EV<FV;\?YU=O$WPFJ&WRYL#Z?E_\ 6Q6G
M_K(_J* . UJ#:S\5Q.I0[7->D:[;_,QQ7":M#R: .4N%VMFJ^X+,ISA6XS5Z
M\2L^1<H1W% 'T)X+U;^V?#=E.QS*J>6_^\O!K<KRSX,ZWN:]TUVY($\8_1OZ
M5ZC0 N:,TW-&Z@!]%(#D4M !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% ''>.OA'X3^([1R:]I$5W<1C"W
M"DQR@>FY2"1[&M'PG\/_  YX%M?L^@Z/::8A^\T,8WM]6/)_$UT%% !1110
M4444 %%%% !1110 4AYXI:* /S1\9:3_ ,(_XZ\1:;MV"VU"=%7T7>2/T(K*
M4_-7H_[2NCMHGQPU_P"7:EX(;Q/?<@!/_?2M7F_\5<<MSOCJD;&FR?,,5Z7X
M0N/+FCY[UY;IIVM7?>%[K;)'S6<=S.IL?7_POO/M&E,G4  YKMJ\F^#NIAF$
M);[R],UZS7HOHSAAM8****184444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2&EI&Z4
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M(H 6DR*&Z5&#SC- $F:,U MU"SE%E1G'50PS^52!J2:>PKH?2TT4ZF,****
M"BDR*,B@!:*2C.: %HI,CUHH 6BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1Z***L84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS5NP^21A_>%2K9CN?RJ9(5CZ#F@!]%%% !1110 4444 %%%% !1110 4444
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MA0Q@E5'89KK_ (1^ H/AG\/-&\/Q8,EM"#<2#_EI,WS2-GO\Q/X 5Y_\"?\
MDJ?Q@]?[8B_]%"F!V7Q:^+%G\,=,M MK)JVNZC)]GTW2;?\ UES(?Y*.,FN*
MT_X2^//B#&E]X\\97FDI+\PT/PZ_D1P@_P +2_>8X]*C^%=NOQ(^-?C;QM>
M3P:+/_86D*_(B"#,LB^A8GK[FO=U  XH \;D_9?T*)"]CXE\66-U_#.FL2.0
M?7!X-8FH>(/'O[/\T=SXBO6\<> ]X2;41"%OK!2<;Y .'4=S7T!5:_L8-2M)
M[6YB2>VG0Q2Q2#*NI&"#^!I -TG5+36M-MK^QG2ZL[F-9H9HSE75AD$5;KP[
M]G.23PGK/C7X=32-)#X>OO-T_P PY(M)AO1?P_K7N% "T444 %%%% !1110
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MT5RGH#514^Z *=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!XI^U__ ,D3O_\ K\M?_1HKN?'W_)(O$/\ V!)__1#5PW[7_/P3OO\
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M:7T"SQX.>&&<?4'C\*\6;_B[W[2P&?-\/> XL^J27\@_FN/S4>M<MX.^(Q^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !5'_#>GP]_Y]-9_\!1_\51_96._Y],7U[#?SH^DZ*^;?^&\OA]_SZ:S_P"
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M[_17@/\ PV=X(_Y]=4_\!Q_C2_\ #9G@C_GVU3_P''^-']E8W_GTP_M; _\
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M:/[*QO\ SZ8_[7P/_/U'O=%>"?\ #9'@K_GUU3_P''^-'_#9/@K_ )]M4_\
M <?XTO[+QO\ SZ8O[7P/_/U'O=%>!_\ #9/@G_GUU3_P''^-'_#97@G_ )]M
M4_\  <?XT?V7C?\ GTQ_VM@?^?J/?**\";]LSP0O_+KJG_@./\:3_ALWP/\
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M\!?\^FK_ /@,/_BJ/[-QG_/MC_M/!_\ /Q'T/17SQ_PW%X"_Y]-7_P# 8?\
MQ5)_PW'X"_Y]-6_\!A_\51_9N,_Y]L/[3P?_ #\1]$T5\[?\-R> O^?75O\
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MVP_M'"?\_$?1])^%?.'_  W=\/O^?76/_ 8?XTO_  W9\/CS]EUC_P !A_\
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MQH_X:P\)?\^^H_\ ?@?XTO[;R[_G\@_M3!?\_$>V4<UXI_PUAX2_Y]]1'_;
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M ,!Q_C1_;F7?\_D']J8+_GZCW^EKY]_X;6\#_P#/KJG_ (#C_&D_X;8\#_\
M/IJI_P"W<?XT_P"W,N_Y_(/[4P7_ #]1]!<^E%?/G_#;7@;_ )]=5_\  <?X
MTT_MN>!A_P NFJ_^ X_QH_MO+O\ G\@_M3!_\_4?0M%?//\ PV]X%_Y]-5_\
M!Q_C2?\ #<'@3_GUU;_P''^-/^VLN_Y_(/[3P?\ S]1]#\T5\[_\-Q> _P#G
MUU;_ ,!A_C33^W)X#'_+IJW_ (##_P"*H_MK+_\ G\A_VG@_^?J/HK-'-?.;
M?MT> A_RZ:M_X##_ .*IO_#=7@+_ )]=6_\  8?XT_[:P'_/Y"_M3!_\_4?1
MW-'-?./_  W9X!_Y]=7_ / 8?XTW_AN[P!_SZZO_ . H_P :/[9P'_/U!_:>
M#_Y^(^D*6OFP_MY?#\?\NNK_ /@,/\:3_AO+X?\ _/KK'_@*/\:?]L8#_GZ@
M_M/!_P#/Q'TI25\U']O7X?C_ )<]8_\  8?XTG_#?'P^_P"?36/_  %'_P 5
M1_;& _Y^H?\ :>#_ .?B/I:BOFC_ (;X^'H_Y=-8_P# 4?XTA_;\^'@ZVFL_
M^ H_^*I_VQ@?^?J#^T\'_P _$?3%%?,I_;^^'8_Y<]:_\!1_\52'_@H!\._^
M?/6?_ 4?_%4?VO@?^?J#^T\'_P _$?3?-'-?,9_X*!?#K_GSUG_P%'_Q5-;_
M (*"_#E?^736?_ 4?_%4?VO@?^?J#^T\'_S\1]/45\P?\/"/AP/^736O_ 0?
M_%4W_AX5\./^?/6O_ 0?_%4_[6P/_/U!_:>#_P"?B/J&EKY</_!0SX;C_ERU
MO_P$'_Q5)_P\.^&W_/EK?_@(/_BJ?]K8'_GZA_VE@_\ GXCZCHYKY;/_  40
M^&O_ #YZW_X"#_XJF_\ #Q+X:?\ /GKG_@(/_BJ/[6P/_/U!_:6#_P"?B/J;
M\*/PKY8_X>*?#3_GSUS_ ,!!_P#%4W_AXQ\,Q_RYZY_X"#_XJG_:N"_Y^H/[
M2P?_ #\1]545\J?\/&OAG_SYZY_X"#_XJD/_  4<^&8_Y<]<_P# 0?\ Q5']
MJX+_ )^(/[2P?_/Q'U717RG_ ,/'OAE_SY:Y_P" @_\ BJ:?^"D7PQ'_ "Y:
M[_X"#_XJG_:F#_Y^(/[2PG_/Q'YZK3EHHK^B3Y5CUI_:BB@D<O>I***3(8JU
M(***9FQPYIZT44C-CZ<N.***"624Y:**$9L?3EX%%%,S9)3J**"21:<***#-
MCQ3N]%%!#)%I:**9FQXZU(M%%(E[#EIZT44&3'#K3UHHH(8Y>M2+1109L>*<
MM%%'4DD_AI5HHJC,D6G+112ZF;'CI3Z**"!PJ2BBF0Q5H:BB@D;33VHHI (>
ME-HHI#%IK445#*$IE%%'0H0]J0]:**DL2D;M114@-I&HHI#0E-HHJ2A#T--H
MHH*04444AC::W2BBD,;2-113&)36HHK,:$HHHH*$I***0T(:;114C$;I3:**
M $/2FT44%(*6BBI*0C=*9112*%IE%% PIE%% T+36HHI#$HHHIC04445+V*N
M-I***3V$!Z4RBBI-$+36HHH0A****0"-TIM%%, HHHJ "BBBGT*"BBB@84X=
M!1168"T[VHHK%DA3ATHHK!B%IRT45A(!:<O2BBLV M*O2BBN=B%IR]***PD
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ino-20201231_g4.jpg
<TEXT>
begin 644 ino-20201231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,@!R@# 2(  A$! Q$!_\0
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M -C1_P +$_ZA_P#Y&_\ L:XRB@#L_P#A8G_4/_\ (W_V-'_"Q/\ J'_^1O\
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MA_\ Y&_^QH_X6)_U#_\ R-_]C7&44 =G_P +$_ZA_P#Y&_\ L:/^%B?]0_\
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M$_ZA_P#Y&_\ L:\4\'?&[P1\0/%VM>%] UZ/4==T<N+VU6&5/+V/Y;$,RA7
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M(?-CC!+MO"[!@ \$@^E3RR[#YEW/5?\ A8G_ %#_ /R-_P#8T?\ "Q/^H?\
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M!V?_  L3_J'_ /D;_P"QH_X6)_U#_P#R-_\ 8UQE% '9_P#"Q/\ J'_^1O\
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M %#_ /R-_P#8T?\ "Q/^H?\ ^1O_ +&N,HH [/\ X6)_U#__ "-_]C6GX?\
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M;5P&M?\ (9O_ /KXD_\ 0C0!TW_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\
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M\?C>-9)G6-6FTZ\C0$G W.T(51ZDD =2:?L:FW*_N%[2'\R/J7_A8G_4/_\
M(W_V-'_"Q/\ J'_^1O\ [&O,M0\::-I>N:#H]Q?*NHZ[YQTZ%$=Q.(H_,D.Y
M054!<'+$ Y &20*\\O\ ]K;X0Z7XK?PY<^.+&+4XYA;N?+E-NCG'!N GE #.
M"2^%(()!!J8PE+97*<HQW9](?\+$_P"H?_Y&_P#L:/\ A8G_ %#_ /R-_P#8
MUXS\2/C)X+^$6EVFH>+M?MM'M[MBML&5Y9)L8R4CC5G8#<N2!@;ADC(JOX-^
M.G@3XA>%=5\1>'O$5OJ>DZ5&\M])''(LMNBJS%GB91( 0K$?+\VTXSBCDE;F
MMH'-&]KZGMW_  L3_J'_ /D;_P"QH_X6)_U#_P#R-_\ 8UYMX2\6:5XZ\-Z?
MKVAW7VW2;^/SK:X\MX]ZY(SM<!AT[@53\(_$+P_X[N-<@T._^W2Z)?R:7J"^
M3)'Y-S&</'\ZC=@]UR/0TN5ZZ;#NCU7_ (6)_P!0_P#\C?\ V-'_  L3_J'_
M /D;_P"QKR;XB?$OPU\)_#IUWQ7J:Z3I0E6#SVBDE)=L[5"QJS$\'H.QJ&^^
M*WA73?AROCRXU95\)M;1W@U%(9''E2%0K;%4OG+ %=N0>H&#1RR>J0N9;7/7
M_P#A8G_4/_\ (W_V-'_"Q/\ J'_^1O\ [&OF?PS^V)\'O%VO66C:9XTADU"]
MD\J".XLKFW1W/1=\D2J">@R1DD <D"NE^)WQ^^'_ ,'+FTMO%_B6WTF[ND\R
M*U$4L\Q3)&\I$K,JDA@&( )4@'(-5[.:?+RN_H+VD;7OH>Y_\+$_ZA__ )&_
M^QH_X6)_U#__ "-_]C7B-O\ '3P)>?#>Y\>VWB*WN?"=KCS[^".20PG*C:\:
MJ9%;+K\I7(# XQ7*>&_VQ?@]XLUZQT?3/&<,FH7LHA@CGL;J!7<]%WR1*H)/
M R1DD#J10J<W>T7H'/%=3Z9_X6)_U#__ "-_]C1_PL3_ *A__D;_ .QKQ?XG
M_&CP9\&K.QNO&.M+H\-](T5N?L\TQD90"V%C1C@ CDC'(]:O>.OB9X:^&OA4
M^)?$6J+8:&&C7[8D4DZDN<)@1JQ(/J!BIY9.VFX^9:Z['K7_  L3_J'_ /D;
M_P"QH_X6)_U#_P#R-_\ 8U\T^%OVO_A'XT\1:?H6C>+?MFJZA,L%M;_V;=Q^
M8YZ#<T04?B0*?<?M>_!ZT\3'09?'5BNH+,+<MY4QM@Y];@)Y0'JV_ YR>*OV
M52]N5_<3[2&]T?2?_"Q/^H?_ .1O_L:/^%B?]0__ ,C?_8UX/\3/VA?A_P#!
M^\L+3Q=X@&E3WT1GMU%G<3B1 <%LQ1L!SZU9^&/QU\"?&3[:/!_B&'6)++:9
MX?)E@D0'HVR558KVW 8SQFI]G/EYK:%<\;\M]3V__A8G_4/_ /(W_P!C1_PL
M3_J'_P#D;_[&OG#Q#^UE\*O"MK87.J>*?LMO?F<6TG]G7;B7R96BD(VQ'@2(
MRYZ''&14VD_M3_"_7?#[ZY8^)_/TM+^'2VG_ +/NEQ<R@F./:8@W(4\XP,<D
M57LJEK\K^X7M(;7/HG_A8G_4/_\ (W_V-'_"Q/\ J'_^1O\ [&O*O$GQ"T#P
MCKGA_1]6O_LFHZ].UMIL/DR/Y\B@%EW*I"X!'+$"J'@_XP>$/'TGB%-!UE+^
M3P_,UOJ<8ADC:V<;L@JZ@D?(^&7(.TX)Q4<LK7MH/F5[7/9/^%B?]0__ ,C?
M_8T?\+$_ZA__ )&_^QKYVU;]J;X7Z'X.T'Q5?>)_(T'7&F33[O\ L^Z;SS"Y
M20;!$67# CY@,]LUJ?#O]H'X??%B/47\*^)8-4;3XS-<P^3+#*D8ZOY<B*S+
MVW $9('6J]G-*[B["YXWM<]U_P"%B?\ 4/\ _(W_ -C1_P +$_ZA_P#Y&_\
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M<910![-1110 F!Z4M%% "44M% !1110 4444 %%%% !1110 4444 >9^,/\
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M .,GD\GN:U]+^ 7@#1?AW?>!;#PW!:>&+[/VJSBEE#SDMNR\V[S&.0 "6R
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M0P>)E1PISO;YL;AD8(P,"K04>6S_ .#<;I2;YKF-^S'_ ,F]_#W_ + UO_Z
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M(Y+N>@RQ.  !P !TU35DIS<D.G%QBDPHHHK(T"BBB@#TSP?_ ,BY:?\  _\
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M.25E;Z$$5U7Q-^ ?@#XQ7%K<>+_#5OJUU:KY<5T))()@F20ADB96*@LQ"DD
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M)ZJ2.U<_XL_9^\ ^-O$6HZ[K&@?:-5U*S6PO9X;RX@^U0*RL$E6.15<91/O
MG"*.@ JGB(2T:_J]_N)]C);/^K'RT?"?BSP/\1_V?]&\%KHZ>*(/"=R^/$ F
M^R^9(C23[_*^?.7?&.^,UV?[3DGC:W^!NA77Q%;P['J=MXPL9FE\.F<6D=J
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M-DL=P4$EF.?F.>JKEJR4YN2-Z<7&-F%%%%9&@4444 %%%% 'LU%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!A:EX/L]4O9+J66=9),9",H'  [CV
MJM_PK_3_ /GM=?\ ?2__ !-;W]H6VXC[3#E3@C>.#Z4OVZV_Y^(O^^Q0!@?\
M*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$UO_;K;_GXB_[[%'VZV_Y^
M(O\ OL4 8'_"O]/_ .>UU_WTO_Q-'_"O]/\ ^>UU_P!]+_\ $UO_ &ZV_P"?
MB+_OL4?;K;_GXB_[[% &!_PK_3_^>UU_WTO_ ,31_P *_P!/_P">UU_WTO\
M\36_]NMO^?B+_OL4?;K;_GXB_P"^Q0!@?\*_T_\ Y[77_?2__$T?\*_T_P#Y
M[77_ 'TO_P 36_\ ;K;_ )^(O^^Q1]NMO^?B+_OL4 8'_"O]/_Y[77_?2_\
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M 'TO_P 31_PK_3_^>UU_WTO_ ,36_P#;K;_GXB_[[%'VZV_Y^(O^^Q0!@?\
M"O\ 3_\ GM=?]]+_ /$T?\*_T_\ Y[77_?2__$UO_;K;_GXB_P"^Q1]NMO\
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M //:Z_[Z7_XFM_[=;?\ /Q%_WV*/MUM_S\1?]]B@# _X5_I__/:Z_P"^E_\
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MM_S\1?\ ?8H P/\ A7^G_P#/:Z_[Z7_XFC_A7^G_ //:Z_[Z7_XFM_[=;?\
M/Q%_WV*/MUM_S\1?]]B@# _X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\
MXFM_[=;?\_$7_?8H^W6W_/Q%_P!]B@# _P"%?Z?_ ,]KK_OI?_B:/^%?Z?\
M\]KK_OI?_B:W_MUM_P _$7_?8H^W6W_/Q%_WV* ,#_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:W_MUM_S\1?]]BC[=;?\_$7_ 'V* ,#_ (5_I_\
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MC=W4T[RW >5RY"LN,DYX^6MIM1M%(!NH03TS(.?UI?MUM_S\1?\ ?8H P/\
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M)K?^W6W_ #\1?]]BC[=;?\_$7_?8H P/^%?Z?_SVNO\ OI?_ (FC_A7^G_\
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MO(J*/['R_P#Y\1^Y!_;V:_\ 03/_ ,"9Z[_PU-X]_P"?NS_\!%H_X:F\>_\
M/W9_^ BUY%11_8^7_P#/B/W(/[>S7_H)G_X$SUW_ (:F\>_\_=G_ . BT?\
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M_=G_ . BT?\ #4WCW_G[L_\ P$6O-++PSK&I:X=%M-*OKK60[Q'3X;9WN-Z
MEU\L#=E0K9&.,'/2BX\-ZO9ZZ-$N-*O8-9:5(1ITENZW!D;&U/+(W;CD8&,G
M(H_LO++V]C"^^RV[A_;6<6YO;U+7MN]^WJ>E_P##4WCW_G[L_P#P$6C_ (:F
M\>_\_=G_ . BUYIKWAO5_"M\++6M*O='O"@D%O?V[P2%22 VUP#@X//L:S:J
M.4Y;)<T:$6O1$RSS-X-QEB)IK^\SUW_AJ;Q[_P _=G_X"+1_PU-X]_Y^[/\
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MD7XF>+_^AKUO_P &,W_Q5<G^O&'_ .?,OO1T?Z@XG_G_ !^YGV__ ,(/I?\
MSSD_[^&C_A!]+_YYR?\ ?PU\1K\2O%__ $-6M_\ @QF_^*IR_$KQ=_T-6M?^
M#&;_ .*J/]>L-_SXE]Z%_J'B?^?\?N9]M?\ "#Z7_P \Y/\ OX:/^$'TO_GG
M)_W\-?%"_$GQ=_T-.M?^#";_ .*J0?$CQ;G_ )&G6O\ P83?_%5+X\PR_P"7
M$OO1/^HF)_Y_Q^YGVG_P@^E_\\Y/^_AH_P"$'TO_ )YR?]_#7Q<OQ(\6_P#0
MT:U_X,)O_BJ>OQ&\6?\ 0T:U_P"#";_XJI_U^PW_ #XE]Z(_U&Q/_/Z/W,^S
MO^$'TO\ YYR?]_#1_P (/I?_ #SD_P"_AKXU_P"%C>+/^AGUG_P82_\ Q5.'
MQ$\5Y_Y&?6?_  /E_P#BJC_7_#?\^)?>A?ZCXC_G]'[F?9'_  @^E_\ /.3_
M +^&C_A!]+_YYR?]_#7QW_PL3Q5_T,VL?^!\O_Q5._X6'XJ_Z&;6/_ ^7_XJ
MI_XB#A?^?$OO1/\ J3B/^?T?N9]A?\(/I?\ SSD_[^&C_A!]+_YYR?\ ?PU\
M@?\ "PO%/_0RZQ_X'R__ !52+\0?%/\ T,NK_P#@?+_\54_\1#PO_/B7WHG_
M %*Q'_/Y?<SZ[_X0?2_^><G_ '\-'_"#Z7_SSD_[^&OD9?B!XH_Z&35__ Z7
M_P"*J1?'_BC_ *&35_\ P.E_^*J/^(B87_H'E]Z%_J7B/^?R^YGUK_P@^E_\
M\Y/^_AH_X0?2_P#GG)_W\-?)J^/O$_\ T,>K?^!TO_Q5.7Q]XG_Z&/5O_ Z7
M_P"*J?\ B(V%_P"@>7WHC_4W$?\ /Y?<SZ5U/P[96NO:?:1JXAF!W@L<UM_\
M(/I?_/.3_OX:^3CXR\02S)*^NZD\J?==KN0LOT.>*L+X\\2_]#%JW_@;+_\
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M .?J^YGTE_P@^E_\\Y/^_AH_X0?2_P#GG)_W\-?-_P#PFGB'_H.ZG_X&2?\
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M_&G#QAKV/^0WJ/\ X%R?XTO^(IX/_H&E]Z)_U8K?\_%]S/H/_A!]+_YYR?\
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M_AH_X0?2_P#GG)_W\-;]% &!_P (/I?_ #SD_P"_AH_X0?2_^><G_?PUOT4
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MLW=4VLH&..,=JYJV"E0I^T<D];:.YUX?,(8BK[*,)+2^JL;_ /PA&E_W)/\
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M28Z'_P!>"_\ H9KW.OYSQ_\ O=;_ !2_-G]997_N%#_!'\D%%%%<!Z84444
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M<\-:'J'BG31I6MZAJ^AZ_9>&4T^TAA\W4;^Z@CGACMR\JH%V2Y9YFC5=CY.
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MX?S P9F23(X/+MNZ$YSFLW6O$4OB;PKK.E:=9RZ7>ZAK%SHROI\B"4["?-N
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MPG1HF6*_@M]S'.4*B4KCN?GZ8%<?U=SDO]F2;=OB6^_Y:'>L4H1?^UN22O\
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M&D,=NP7"@GHI/X5])^$?VSO@MXZ\3:;X>T'QU8ZCK.I3""UM8X9E:60] "4
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MM1]<S#_H%_\ )XA]0RK_ *#?_*<O\SPVBO<O^&G_ /J1]#_[X_\ K4?\-/\
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MG_\ 7H_X0G_J)7/Y_P#UZ .GHKF/^$)_ZB5S^?\ ]>C_ (0G_J)7/Y__ %Z
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MO_DF.A_]>"_^AFO<Z_G/'_[W6_Q2_-G]997_ +A0_P $?R04445P'IA1110
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M^ K_ ".R_P"%M>*_^@K_ .2\7_Q%*/BSXK_Z"O\ Y+Q?_$5Q].7I4/B'.?\
MH,J_^#)_YD/+\'_SYC_X"O\ (Z]?BQXJ_P"@K_Y+Q?\ Q%5[3XB^(;&6>2#4
M-CSMND/DQG<>3W7CJ:YI:6H_UBSG_H-J_P#@R?\ F2\!A/\ GS'_ ,!7^1V
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <SXH_Y#F@_]=O\
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M2UO_ ) U_P#]<)/_ $$T 4_!_P#R+EI_P/\ ]#:MFL;P?_R+EI_P/_T-JV:
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M*3XC:+XDT?1;7Q?X=N]6O='MTL;;4--U,64DEJA/EQ3*T,JMLR0&4(VW ).
M:AU[XT^*-0U[^T=)U&Y\*PQ6D6GVUGH=S+;I#:Q9\N+(;<^"68EB22Q/M7!T
M5HL'03ORWWWNUKV3T7R,I8_$R5N>VVJLF[:*[6K^;/3/AW^T#XO\#^*M-U.Z
MUW6]9TZUN'N)M*FU:98;DL6+;LEADLQ8DJ<G)K/T'XL7FEZEXRU*_BN-8U'Q
M'I4^EFZNKMB\(E*9<LRDOA4V@9'!_"N#HI/!8=RE+D5W9/IL[_G]_4:S#%*,
M8>T;46VKZV;5GOY?=T.M\"^.H_"MKKFEZAIYU?P_K=LMO?64<_V>7<C!X98Y
M=K;'1P#RK*06!7G(Z6/XX/9:[I7V+1(XO"ECI4FAG0I;DL;BTER;C?,JKB61
MF9_,55 8+\I P?+:*=3!T*DG*<;M^;[6O;O;2^]NHJ>/Q%&*A"5DO)=[VO:]
MKZVVOT.R\7>/+76/#.C^&M$TJ31M!T^6:Z,=Q="YN+FYDP&EED6.-3A%1% 0
M8"\DDUQM%%;TZ<:4>6"T_P SFK5IUY<]1ZZ+MHM%HM HHHK4Q"BBB@ HHHH
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MX6IZ]:^YO^%=>%/^A8T;_P %\7_Q-+_PKOPI_P!"QHW_ (+XO_B:C_4#%?\
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M"]_W/ZBM2LOQ1_R +W_<_J* '>&_^0%9?]<Q6E6;X;_Y 5E_US%:5 !1110
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M-Z9^]C:&X_A=37W%7SU^T;^QKX7^/NIV7B*'4;_P=XYL% M?$FCMMFP/NK(
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M (+A_D>Y_P#"T?A+_P!$YD_[^#_XJC_A:/PE_P"B<R?]_!_\57AE%']C8?\
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M_K5TU% ',_V'KO\ T&!^7_UJ/[#UW_H,#\O_ *U=-10!S/\ 8>N_]!@?E_\
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MZQ/&7_(NW7U3_P!#% &98:/K4EC;/%JHCC:-2J8^Z,# Z58_L/7?^@P/R_\
MK5X9\0?VCO$O@/Q7<:%I]CI4UI:06VQ[F&5I#N@C<Y(D ZL>W2L ?M<^,/\
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M_P N&D?]^9?_ (Y4/CC)U]J7_@)/^J69]E]Y[M_8>N_]!@?E_P#6H_L/7?\
MH,#\O_K5X:O[3/BAO^7#2/\ OS+_ /'*>O[2OB<_\N.D_P#?F7_XY4OCO)E]
MJ7_@)/\ JIF2Z+[SV_\ L/7?^@P/R_\ K4?V'KO_ $&!^7_UJ\47]I+Q,?\
MEQTG_OS+_P#'*>/VCO$O'^@Z5_WYE_\ CE1_K]DJ^U+_ ,!(_P!5LR[+[SVC
M^P]=_P"@P/R_^M1_8>N_]!@?E_\ 6KQL?M%>)#_RY:7_ -^I?_CE/'[1'B/_
M )\M+_[]2?\ QRH_XB!DG\TO_ 2?]6,Q[+[SV'^P]=_Z# _+_P"M1_8>N_\
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M !=.'QLUS_GUT_\ []R?_%U/_$2<@_FE_P" L7]@8WLOO/1O[#UW_H,#\O\
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M_K5TU% ',_V'KO\ T&!^7_UJ/[#UW_H,#\O_ *U=-10!S/\ 8>N_]!@?E_\
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M_K5TU% ',_V'KO\ T&!^7_UJ/[#UW_H,#\O_ *U=-10!S/\ 8>N_]!@?E_\
M6H_L/7?^@P/R_P#K5TU% ',_V'KO_08'Y?\ UJI:QI.L0:9<27&IB:%5RT>.
MHS79UE^*/^0!>_[G]10!@Z3I.L3:;;R0:F(860%8\=!Z5<_L/7?^@P/R_P#K
M5J>&_P#D!67_ %S%:5 ',_V'KO\ T&!^7_UJ/[#UW_H,#\O_ *U=-10!S/\
M8>N_]!@?E_\ 6H_L/7?^@P/R_P#K5TU% ',_V'KO_08'Y?\ UJ/[#UW_ *#
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MJ/[#UW_H,#\O_K5TU% ',_V'KO\ T&!^7_UJ/[#UW_H,#\O_ *U=-10!S/\
M8>N_]!@?E_\ 6H_L/7?^@P/R_P#K5TU% ',_V'KO_08'Y?\ UJ/[#UW_ *#
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M-?6UK=17EO%<02+-!*H=)$.592,@@]P15U*4Z3M-6)C4A/X7<P/[#UW_ *#
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MOB'Q!^U!\>M*U37M3U+2]-O]EC8WEY)+!:KY\HQ$C,508 &% Z"OJG5/L?\
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M]UNUK^!\NH))4_;IJ2BOA>T7IKTN^O4^\Z***^0/O#\]/VT_^1QT7_KWF_\
M1E?.E?9?[0\/P\E\16!\;3ZA#=^7)Y L@Q4KOYS@'O7D_P!C^ __ #^ZY_WR
M_P#\37[%DF8JCE]*G[&;LGJHW6[ZGX%Q%E+Q&:UJOUBG&[6DIV:T6Z/#**]S
M^Q_ ?_G]US_OE_\ XFC['\!_^?W7/^^7_P#B:]S^UE_T#U/_   ^<_L-_P#0
M51_\#7^1X917N?V/X#_\_NN?]\O_ /$T?8_@/_S^ZY_WR_\ \31_:R_Z!ZG_
M ( ']AO_ *"J/_@:_P CPRBO<_L?P'_Y_=<_[Y?_ .)H^Q_ ?_G]US_OE_\
MXFC^UE_T#U/_   /[#?_ $%4?_ U_D>&45[G]C^ _P#S^ZY_WR__ ,31]C^
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MI_X ']AO_H*H_P#@:_R/#**]S^Q_ ?\ Y_=<_P"^7_\ B:/L?P'_ .?W7/\
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M\<IW_#/G@#_H ?\ DY<?_'*WO,\4?\\K7\Q_C1YGBC_GE:_F/\:7]CY;_P!
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M\%_] ;_R:G_^+K3\SQ1_SRM?S'^-'F>*/^>5K^8_QI?V%E/_ $"4_P#P"/\
MD+^T\?\ \_Y_^!/_ #,[_A2O@S_H#?\ DU-_\72_\*7\&_\ 0'_\FIO_ (NM
M#S/%'_/*U_,?XT>9XH_YY6OYC_&E_8.4?] E/_P"/^0O[2QW_/\ G_X$_P#,
MH?\ "F?!W_0'_P#)J;_XNE_X4WX/_P"@1_Y,S?\ Q=7O,\4?\\K7\Q_C1YGB
MC_GE:_F/\:7]@91_T!T__ (_Y"_M+&_\_P"?_@3_ ,RE_P *=\(?] C_ ,F9
MO_BZ7_A3_A'_ *!/_DS-_P#%U<\SQ1_SRM?S'^-'F>*/^>5K^8_QH_U?R?\
MZ Z7_@N/^0O[1QO_ #^E_P"!/_,Y?5/AGX:MO$6FVT>F[8)@=Z^?*<]>^ZMW
M_A47A+_H$_\ DS-_\75+46UG^W+ SI"+S_EB%QM_'FMCS/%'_/*U_,?XTO\
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MSRM?S'^-'F>*/^>5K^8_QH Z:BN9\SQ1_P \K7\Q_C1YGBC_ )Y6OYC_ !H
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M?<^?';B#RFW[<9VX.<<^E &KX/\ ^1<M/^!_^AM6S6-X/_Y%RT_X'_Z&U;-
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MKMH5HXBE&K%:/N>?B</+"UI4)M-Q=M-@HHHK<Y@HHHH **** "BBB@ HHHH
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M^-YAQ1F.'Q=6C3:M&4DM.B;1^YY?PCE>)P5&O44N:48MZ]6DV?77_#7'@_\
MZ!NN?]^(?_CM._X:T\(?] [6_P#OQ#_\=KY&6IEKS'QAFO>/W':^"\I_EE_X
M$?6G_#67A'_H':U_WXA_^.T[_AJ_PE_T#M:_[\0__':^3%J5:R?&6:_S1_\
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M_P##(O\ U-G_ )3?_MM.'[(__4U_^4[_ .VUD^$LZ_Y\?^30_P#DC-\59/\
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M>??] _\ Y-#_ .2,WQ+E7_/[_P EE_D>'+3UZ5[@O[,6/^9E_P#)#_[93O\
MAF7_ *F3_P D/_ME9/@K/_\ H'_\FA_\D9/B3*O^?W_DLO\ (\26I%[5[8/V
M:,?\S'_Y(_\ VRG#]FO'_,Q_^2/_ -LK)\$<0?\ 0-_Y/#_Y(A\197_S]_\
M)9?Y'BB]:D7I7JM[\!_L6K6=E_;F_P"T?\M/LF-OX;^:U?\ AF__ *F+_P D
M?_ME9O@?B#_H&_\ )X?_ "1G_K%EG_/W_P EE_D>,+3EKV8?LX_]3#_Y)?\
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M[,M=-7,^*/\ D.:#_P!=O_9EKIJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH _)G]KGX,ZE\*_B]?ZKY$DFA:I="]@N4!*
MJ2P)4GUS_*N-D\;V5CX^O_& NVGU!U9H[:.)AAC'L!<]L ?RK];O'OP[T3XD
M:#/I&NV:7=K(#M9@-T;=-RGL:^%/BM_P3UUS1[Z6\\%7'VVTR66W;&Y>O&"<
M_ED>PK[/!9I1K0C2Q$N7E5KGQV+RVK1E*KAX\W,[V/GW2/BI9^'(?#D"Z6M_
M)I<9ECOG9E:.20EI"OJ<]<_G6?<_$Z_\.Z)/IWAS5;G3S)JD]V6MVVDQNH(!
MXZ9Q^52Z]\'?%?AB>2WU3P]<1O&V"JC;M/KM;!'L.AK%;P+XAO HBTNX9T;:
M0L6T$'IU].G&>*]V%'!.W+-?>>+.MC;:TSKO^%O-97^O:K97<D&J:CI\$)GB
M0;C.@P6Z<GD=?2L[1?BA?QWVH:KK%Y/KNHW-H;&WANB0IB9OWB_*/E!'7 Y_
M48D?@W5G95?2I944;51E$9SW)8D=>3^%=IX+_9I\=^.IGCT[2+CR&Y>6.,N3
MD="_RI^&X"IE' TX23J+4U4L9*49*&W0Y3Q?XDA\7:/H=M::=':S6#O:Q6MK
MF1-C$,%7C^]G /-?=?\ P3W^$NH^$=&U+Q%J$9A6[C-O#R?WA+JTA]"%V1J#
MZA\57^!G[!=EX<GAU+Q;-YDHY-C"^YW&?NO(,!5.!E4Y/=J^PM-TVVTNUAM[
M2)+>WAC$44,2A4C4<!5 Z 8KY;,,RIU:7U6AK%=3Z++\OG3J_6J^DGT+E%%%
M?-'T@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+6_^0-?_P#7
M"3_T$U=JEK?_ "!K_P#ZX2?^@F@"GX/_ .1<M/\ @?\ Z&U;-8W@_P#Y%RT_
MX'_Z&U;- !1110 4444 %%%% 'S!^W!_PI_^S?"/_"V_[:^S^=<_V=_8^<[M
ML?F;\>VS'XU\G?\ &&G_ %.W_CU?I]K'AO2?$2Q+JNEV6IK$28Q>6Z2A,XSC
M<#C.!^59G_"L_"'_ $*FB?\ @NA_^)KUL/C(T::@^;Y2LOR/#Q67RKU742AK
MWC=_?<^;OV(?^%(_VYXJ_P"%2_V]]K^SP?VA_;&=NS<^S;GOG=7UM67H_A;1
M?#LDCZ5I%AICR@"1K.V2(N!T!V@9K4KAQ%15JCFK_-W9Z6%HNA25-VT[*R^X
M****YSJ"BBB@#XT_:'\#^&/%WB*PF\0>+8?#<T4<BQPRA29%+Y)Y8=#Q7DW_
M  IGX<?]%1M/^^(__BZV?VT_^1QT7_KWF_\ 1E?.E?L628/$5,OI3AB9133T
M2CIJ^ZN?@7$6/PE'-:T*F$C-IK5N=WHNTDCW+_A3/PX_Z*C:?]\1_P#Q='_"
MF?AQ_P!%1M/^^(__ (NO#:*]SZAB_P#H+E]T/_D3YS^U,#_T P_\"G_\D>Y?
M\*9^''_14;3_ +XC_P#BZ/\ A3/PX_Z*C:?]\1__ !=>&T4?4,7_ -!<ONA_
M\B']J8'_ * 8?^!3_P#DCW+_ (4S\./^BHVG_?$?_P 71_PIGX<?]%1M/^^(
M_P#XNO#:*/J&+_Z"Y?=#_P"1#^U,#_T P_\  I__ "1[E_PIGX<?]%1M/^^(
M_P#XNC_A3/PX_P"BHVG_ 'Q'_P#%UX;11]0Q?_07+[H?_(A_:F!_Z 8?^!3_
M /DCW+_A3/PX_P"BHVG_ 'Q'_P#%T?\ "F?AQ_T5&T_[XC_^+KPVBCZAB_\
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M3/PX_P"BHVG_ 'Q'_P#%T?\ "F?AQ_T5&T_[XC_^+KPVBCZAB_\ H+E]T/\
MY$/[4P/_ $ P_P# I_\ R1[E_P *9^''_14;3_OB/_XNC_A3/PX_Z*C:?]\1
M_P#Q=>&T4?4,7_T%R^Z'_P B']J8'_H!A_X%/_Y(]R_X4S\./^BHVG_?$?\
M\71_PIGX<?\ 14;3_OB/_P"+KPVBCZAB_P#H+E]T/_D0_M3 _P#0##_P*?\
M\D?I1\#XT\+^#M-L]#D_X2"SBM@D=U'P)%W$[N,UZ1_PD6L?] 23\S_A7F7[
M)?\ R3'0_P#KP7_T,U[G7X;C(N.)JQ;NU)Z]]3^D<ODI8.C**LG&.G;1:',_
M\)%K'_0$D_,_X4?\)%K'_0$D_,_X5TU%<9WG,_\ "1:Q_P! 23\S_A1_PD6L
M?] 23\S_ (5TU% ',_\ "1:Q_P! 23\S_A1_PD6L?] 23\S_ (5TU% ',_\
M"1:Q_P! 23\S_A1_PD6L?] 23\S_ (5TU% ',_\ "1:Q_P! 23\S_A1_PD6L
M?] 23\S_ (5TU% ',_\ "1:Q_P! 23\S_A1_PD6L?] 23\S_ (5TU% ',_\
M"1:Q_P! 23\S_A1_PD6L?] 23\S_ (5TU% ',_\ "1:Q_P! 23\S_A1_PD6L
M?] 23\S_ (5TU% ',_\ "1:Q_P! 23\S_A1_PD6L?] 23\S_ (5TU% ',_\
M"1:Q_P! 23\S_A1_PD6L?] 23\S_ (5TU% ',_\ "1:Q_P! 23\S_A1_PD6L
M?] 23\S_ (5TU% ',_\ "1:Q_P! 23\S_A1_PD6L?] 23\S_ (5TU% ',_\
M"1:Q_P! 23\S_A1_PD6L?] 23\S_ (5TU% ',_\ "1:Q_P! 23\S_A1_PD6L
M?] 23\S_ (5TU% ',_\ "1:Q_P! 23\S_A1_PD6L?] 23\S_ (5TU% ',_\
M"1:Q_P! 23\S_A1_PD6L?] 23\S_ (5TU% ',_\ "1:Q_P! 23\S_A1_PD6L
M?] 23\S_ (5TU% ',_\ "1:Q_P! 23\S_A1_PD6L?] 23\S_ (5TU% ',_\
M"1:Q_P! 23\S_A1_PD6L?] 23\S_ (5TU% ',_\ "1:Q_P! 23\S_A1_PD6L
M?] 23\S_ (5TU% ',_\ "1:Q_P! 23\S_A1_PD6L?] 23\S_ (5TU% ',_\
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M?F?\*/\ A(M8_P"@))^9_P *^=5_:P\7'_F':+_WXF_^.T\?M7>+?^@=HO\
MWXF_^.U/^N64_P TO_ 2?]3<U_EC_P"!'T/_ ,)%K'_0$D_,_P"%'_"1:Q_T
M!)/S/^%?/0_:L\6_] [1?^_$W_QVG#]JKQ9_T#]&_P"_$W_QVI_UTRG^:7_@
M(O\ 4_->T?O/H/\ X2+6/^@))^9_PH_X2+6/^@))^9_PKY^_X:G\6?\ 0/T;
M_OQ+_P#':</VIO%?_0/T;_OS+_\ ':7^NV4?S2_\!%_J?FG:/WGO_P#PD6L?
M] 23\S_A1_PD6L?] 23\S_A7@?\ PU%XJ_Z!^C_]^9?_ ([2_P##4/BK_H'Z
M/_WYE_\ CM3_ *[Y/_-+_P !)_U1S3M'[SWO_A(M8_Z DGYG_"C_ (2+6/\
MH"2?F?\ "O!_^&G_ !3_ ,^&C_\ ?F7_ ..TX?M.>*?^?#2/^_,O_P <J?\
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M);1F^:&2/(P5=<CG'S#%73I2JR4([LBI4C3BYRV1]+?\)%K'_0$D_,_X4?\
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MH JHHP !T %/K@K5/;3<SKP.$C@<-##Q=^7^F%%%%8G>%%%% !1110 4444
M%%%% !1110 4444 %4M;_P"0-?\ _7"3_P!!-7:I:W_R!K__ *X2?^@F@"GX
M/_Y%RT_X'_Z&U;-8W@__ )%RT_X'_P"AM6S0 4444 %%%% !1110 4444 %%
M%% !1110 4444 ?GI^VG_P CCHO_ %[S?^C*^=*^TOV@/@=K'Q8\065YIMY:
MVB6J21.MR'R27SQM4UY9_P ,;>*?^@MIGY2__$5^PY+G& PV7TJ56JE))W6O
M=GX)Q%D.9XO-*U>A1<HMJST[+S/ **]__P"&-O%/_06TS\I?_B*/^&-O%/\
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M^@MIGY2__$4?\,;>*?\ H+:9^4O_ ,11_;^6?\_E^/\ D'^K&<?] [_#_,\
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M17,_\)U;?\^=U_WR/\:/^$ZMO^?.Z_[Y'^- '345S/\ PG5M_P ^=U_WR/\
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M_D7_ &QF7_034_\  Y?YG._\,Z_#W_H7_P#R=N/_ (Y2_P##._P]_P"A?_\
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M_ Y?YF%_PS_X!_Z /_DY<?\ QRE_X4#X"_Z /_DY<?\ QRMS_A.K;_GSNO\
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M8[_G_/\ \"?^91_X4WX/_P"@1_Y,S?\ Q='_  IOP?\ ] C_ ,F9O_BZO?\
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MR?\ Z Z7_@N/^0?VAC/^?TO_  )_YE7_ (5'X3_Z!7_DS-_\71_PJ3PG_P!
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M J7_ (+A_D'U_%_\_I?^!/\ S-'_ (53X6_Z!?\ Y,2__%4O_"J_"W_0+_\
M)B7_ .*J;_A.K;_GSNO^^1_C1_PG5M_SYW7_ 'R/\:7^KN2_] 5+_P %P_R%
M]?Q?_/Z7_@3_ ,R'_A5?A?\ Z!?_ ),2_P#Q5+_PJWPO_P! S_R8E_\ BJE_
MX3JV_P"?.Z_[Y'^-'_"=6W_/G=?]\C_&C_5W)?\ H"I?^"X?Y!]>Q?\ S]E_
MX$_\R+_A5OAC_H&?^3$O_P 52_\ "KO#'_0,_P#)B7_XJI/^$ZMO^?.Z_P"^
M1_C1_P )U;?\^=U_WR/\:/\ 5S)?^@*E_P""X?Y"^O8K_G[+_P "?^9'_P *
MO\,_] S_ ,CR_P#Q5+_PK'PS_P! W_R/+_\ %4__ (3JV_Y\[K_OD?XT?\)U
M;?\ /G=?]\C_ !I?ZN9)_P! 5+_P7#_(/KV*_P"?LOO?^80_#?PW"X9=,4D?
MWI9&'Y%JZ*WMXK2%8H(DAB485(U"@?0"N=_X3JV_Y\[K_OD?XT?\)U;?\^=U
M_P!\C_&O0PF6X' 7>$H0IWWY8J-_N2,:E>K6_B3;]6V=-17,_P#"=6W_ #YW
M7_?(_P :/^$ZMO\ GSNO^^1_C7I&!TU%<S_PG5M_SYW7_?(_QH_X3JV_Y\[K
M_OD?XT =-17,_P#"=6W_ #YW7_?(_P :/^$ZMO\ GSNO^^1_C0!TU%<S_P )
MU;?\^=U_WR/\:/\ A.K;_GSNO^^1_C0!TU9?BC_D 7O^Y_45F_\ "=6W_/G=
M?]\C_&J6L>+H-0TRXMUM;A&D7 9E&!S]: .A\-_\@*R_ZYBM*N.TGQA!8Z;;
MV[6MP[1H%+*HP?UJW_PG5M_SYW7_ 'R/\: .FHKF?^$ZMO\ GSNO^^1_C1_P
MG5M_SYW7_?(_QH Z:BN9_P"$ZMO^?.Z_[Y'^-'_"=6W_ #YW7_?(_P : .FH
MKF?^$ZMO^?.Z_P"^1_C1_P )U;?\^=U_WR/\: .FHKF?^$ZMO^?.Z_[Y'^-'
M_"=6W_/G=?\ ?(_QH Z:BN9_X3JV_P"?.Z_[Y'^-'_"=6W_/G=?]\C_&@#IJ
M*YG_ (3JV_Y\[K_OD?XT?\)U;?\ /G=?]\C_ !H Z:BN9_X3JV_Y\[K_ +Y'
M^-'_  G5M_SYW7_?(_QH Z:BN9_X3JV_Y\[K_OD?XT?\)U;?\^=U_P!\C_&@
M#IJ*YG_A.K;_ )\[K_OD?XT?\)U;?\^=U_WR/\: #Q1_R'-!_P"NW_LRUTU<
M#K'B2+4-2TVX6WF1;:3<RL!EN5/'Y5L?\)U;?\^=U_WR/\: .FHKF?\ A.K;
M_GSNO^^1_C1_PG5M_P ^=U_WR/\ &@#IJ*YG_A.K;_GSNO\ OD?XT?\ "=6W
M_/G=?]\C_&@#IJ*YG_A.K;_GSNO^^1_C1_PG5M_SYW7_ 'R/\: .FHKF?^$Z
MMO\ GSNO^^1_C1_PG5M_SYW7_?(_QH Z:BN9_P"$ZMO^?.Z_[Y'^-'_"=6W_
M #YW7_?(_P : .FHKF?^$ZMO^?.Z_P"^1_C1_P )U;?\^=U_WR/\: .FHKF?
M^$ZMO^?.Z_[Y'^-'_"=6W_/G=?\ ?(_QH Z:OFG]N;P+K_C7P3X=;0=*N-6:
MROV>>*U3>ZJT94-M';/\Z]P_X3JV_P"?.Z_[Y'^-'_"=6W_/G=?]\C_&F!^7
MW_"D_'RK@>"]: /_ $YM_A2+\$?'JXQX*UD;>G^AMQ^E?J%_PG5M_P ^=U_W
MR/\ &C_A.K;_ )\[K_OD?XT^85C\OA\$_'RC \%ZT!_UYM7I&B_!_P <^$_A
M/-::1X6U)_%GC.8Z><0%?[/TY&'F;V_@,KX'/\"GUK[Y_P"$ZMO^?.Z_[Y'^
M-'_"=6W_ #YW7_?(_P :UI5?9S4[7L95*?M(.%[7,WX,_#.R^$?PYT;PQ:!6
M-I%FXF48,T[<R.?J?T KN*YC_A.K;_GSN?\ OD?XTO\ PG5M_P ^=U_WR/\
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M '345S/_  G5M_SYW7_?(_QH_P"$ZMO^?.Z_[Y'^- '345S/_"=6W_/G=?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*@#GO^$\TW^[<?\ ? _QH_X3S3?[MQ_WP/\ &NA\E/[B_E1Y*?W%_*@#GO\
MA/--_NW'_? _QH_X3S3?[MQ_WP/\:Z'R4_N+^5'DI_<7\J .>_X3S3?[MQ_W
MP/\ &C_A/--_NW'_ 'P/\:Z'R4_N+^5'DI_<7\J .>_X3S3?[MQ_WP/\:/\
MA/--_NW'_? _QKH?)3^XOY4>2G]Q?RH Y[_A/--_NW'_ 'P/\:/^$\TW^[<?
M]\#_ !KH?)3^XOY4>2G]Q?RH Y[_ (3S3?[MQ_WP/\:/^$\TW^[<?]\#_&NA
M\E/[B_E1Y*?W%_*@#GO^$\TW^[<?]\#_ !H_X3S3?[MQ_P!\#_&NA\E/[B_E
M1Y*?W%_*@#GO^$\TW^[<?]\#_&C_ (3S3?[MQ_WP/\:Z'R4_N+^5'DI_<7\J
M .>_X3S3?[MQ_P!\#_&C_A/--_NW'_? _P :Z'R4_N+^5'DI_<7\J .>_P"$
M\TW^[<?]\#_&C_A/--_NW'_? _QKH?)3^XOY4>2G]Q?RH Y[_A/--_NW'_?
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MR_\ PO7PY_SX:A_WYC_^+I/^%[^&_P#GPU#_ +\Q_P#Q=5]3Q'\C(_M7!?\
M/U'4_P#">:;_ ';C_O@?XT?\)YIO]VX_[X'^-<I_POGPW_SX:C_WYB_^+I/^
M%^>&O^@?J/\ WYB_^.4?4\1_(P_M7!?\_4=9_P )YIO]VX_[X'^-'_">:;_=
MN/\ O@?XUR/_  O[PS_T#]2_[\Q?_'*3_AH#PS_T#]2_[\Q?_'*?U/$?R,/[
M5P7_ #]1U_\ PGFF_P!VX_[X'^-'_">:;_=N/^^!_C7'_P##07A@?\P_4O\
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MPGFF_P!VX_[X'^->;?\ #5G@W_H%ZQ_X#P__ !VD_P"&KO!O_0*UG_P'A_\
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M_/U'KG_">:;_ ';C_O@?XT'Q]IO'R7!_X /\:\B_X;.\"_\ 0'U[_P !H/\
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MM? ?\_4?17_">:;_ ';C_O@?XT?\)YIO]VX_[X'^-?.G_#QOX8?] #Q3_P"
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MFF_W;C_O@?XT?\)YIO\ =N/^^!_C70^2G]Q?RH\E/[B_E0!SW_">:;_=N/\
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MFF_W;C_O@?XUT/DI_<7\J/)3^XOY4 <]_P )YIO]VX_[X'^-'_">:;_=N/\
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MA74_!VEZ=9ZC'/&RS3Q75Y*ZA0V[ 2:,[B-IW<$X. #RZX_:GU?5+[]HG6/
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M[6)AV95G52.N0:]GH **** "L7QA_P BY=_\ _\ 0UK:K%\8?\BY=_\  /\
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MPB^E?\^4?Z_XU_.6/_WNM_BE^;/ZSRS_ '&A_@C^2'?\))IG_/[#_P!]4?\
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M/3+R%K>YLKR-9H9XV&&1T8%64@D$$8(-6+?7-'M8(X(+FWAAC4(D<>%55 P
M .@ [4[_ (1?2O\ GRC_ %_QH_X1?2O^?*/]?\: '?\ "2:9_P _L/\ WU1_
MPDFF?\_L/_?5-_X1?2O^?*/]?\:/^$7TK_GRC_7_ !H =_PDFF?\_L/_ 'U1
M_P ))IG_ #^P_P#?5-_X1?2O^?*/]?\ &C_A%]*_Y\H_U_QH 277M(GB>*6Z
M@DC<%61N0P/!!'<56T>Z\.>'=)L]+TH6.F:99PK;VUE9QK##!&HPJ(B@*J@
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MFJV$RB524JKCS-N_O]>O4X__ (4_IG_0V0_^ G_VRD_X4YIG_0VP_P#@)_\
M;*[#_A-_A[_S\Q_^ T__ ,32?\)S\//^?J/_ ,!I_P#XFK]OC^S_ / ?^ 9?
M4\E[Q_\  _\ [8XX_!G3/^ANA_\  3_[933\%],_Z&Z'_P  _P#[978_\)W\
M._\ GZC_ / :?_XFD_X3[X=?\_<?_@-/_P#$T_;YAV?_ (#_ , /J>2=X_\
M@?\ ]L<:?@KIA_YF^'_P#_\ ME-_X4EIG_0WP_\ @'_]LKL_^%@?#G_G[C_\
M!9__ (FD_P"%A?#@?\OD?_@+/_\ $4>WS#L__ ?^ 'U/).\?_ __ +8XP_!#
M3#_S.$/_ (!__;*:?@;IA_YG"'_P"_\ ME=I_P +$^&__/Y'_P" L_\ \12?
M\+&^&W_/['_X"S__ !%/ZQF'9_\ @/\ P!?4\D[Q_P# _P#[8XG_ (45IG_0
MXP_^ 7_VRD/P(TP_\SE#_P" 7_VRNV_X61\-?^?V/_P%N/\ XBD_X65\-/\
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M_P#@O_\ MM,_X9ITS_H>8?\ P7__ &VO0/\ A</PI_Z"<?\ X!7/_P 13?\
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M?_;J](_X:!^#0_YC4?\ X+[O_P"-TG_#0GP8'_,;C_\ !?=__&Z?UK->TO\
MP'_@!]1R'O'_ ,#_ /MCS9OV1-,/_-0H?_!9_P#;J:?V0=,_Z*%#_P""O_[=
M7I7_  T-\%_^@Y'_ ."^[_\ C=-_X:(^"W_0<C_\%]W_ /&J/K.:]I?^ _\
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MW$DC<O*[22,S'J7:O#_%=UJ.G^'/CWX*\4^-?#.@^(?$?B34KA/#,WA2>_\
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M+_:P^(7Q<U;2I8;WP#JG@JW\&6'B*$%[>_O%N+N:6>VE'$L<#RQ+YB97S%<
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M\)PZ9J6@7VF^(;6:\M;C^UU$]U$L:.DEG$J,+F,K(&9PZA%*$;MW'PC\!IM
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M7,:[_P C7H_^>]=/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;<C(.\9SGVKI-&_;#^'VMZQIUO$=8ATC4[\Z7I_B.XTYTTN\N@2/*CG/<D$
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MG_\ /:Z_[Z7_ .)H Z:BN9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\
MXF@#IJ*YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B: .FHKF?^%?Z
M?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)H Z:BN9_X5_I__/:Z_P"^E_\
MB:/^%?Z?_P ]KK_OI?\ XF@#IJ*YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VN
MO^^E_P#B: .FHKF?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)H Z:B
MN9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XF@#IJ*YG_A7^G_\]KK_
M +Z7_P")H_X5_I__ #VNO^^E_P#B: .FHKF?^%?Z?_SVNO\ OI?_ (FC_A7^
MG_\ /:Z_[Z7_ .)H Z:BN9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\
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MKK_OI?\ XFC_ (5_I_\ SVNO^^E_^)H Z:L7QA_R+EW_ , _]#6J?_"O]/\
M^>UU_P!]+_\ $UGZ]X/L]+TF>ZBEG:2/;@.RD<L!V'O0!R&O_"?5_$U^NI6M
MS91P300;5F=PPVQ(ISA".H/>LP_ ?7S_ ,OFF_\ ?V3_ .(KN(M,\-16\'VW
M6HK6Z:)'DADNHD*EE#=",CK3OL/@_P#Z&*W_ / Z&O5AC,3&*C%:+R/FJV59
M?4J2G.6K;;][J<$?@)X@_P"?S3?^_LG_ ,;IC? 'Q"?^7S3/^_LG_P ;KO\
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M]AWQV?\ F+>'?_ F?_XS3&_89\>'_F+>'?\ P)G_ /C%?27]O?#3_H>]'_\
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M?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\
M"O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?
M]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-1
M7,_\*_T__GM=?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=
M?]]+_P#$T?\ "O\ 3_\ GM=?]]+_ /$T =-17,_\*_T__GM=?]]+_P#$T?\
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MTWV^]A[*'809QSUI:**\XU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "J6M_\@:__ .N$G_H)J[5+6_\ D#7_ /UPD_\ 030!3\'_ /(N
M6G_ _P#T-JV:QO!__(N6G_ __0VK9H **** "BBB@ HHHH **** /@I3X_\
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M2OWGA[_D5T?1_FS^9>*O^1SB/5?^DH****^B/E HHHH **** "BBB@ HHHH
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M#_Y(^<_LO!_]!T/NG_\ (GAM%>Y?\+>^&/\ T3*'_OM/\*/^%O?#'_HF4/\
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M$RA_[[3_  H_X6]\,?\ HF4/_?:?X4?VAB?^@2?WP_\ D@_LO!_]!T/NG_\
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M4=M%>Z<VD6YM[I+942V66/9M<1+%&J!@=@C4+@**M_V!K7_09;\C1_8&M?\
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M3_M:OV7X_P"8?ZMX3^:7WK_(^=V^"'C4_P#,%_\ )J#_ .+IC? WQM_T!/\
MR;@_^+KZ+_L#6O\ H,M^1H_L#6O^@RWY&G_:U?LOQ_S%_JWA/YI?>O\ (^<&
M^!?CCG_B2?\ DW!_\73&^!/CC_H"?^3<'_Q=?27]@:U_T&6_(T?V!K7_ $&6
M_(T_[7K]E^/^8?ZM83^:7WK_ "/FIO@/XZ_Z ?\ Y-P?_%U&WP%\=\_\2+_R
M;@_^.5],_P!@:U_T&6_(T?V!K7_09;\C1_;%?^5?C_F'^K6$_FE]Z_R/F-O@
M'X\_Z 7_ ).0?_'*8WP!\>_] +_R<M__ (Y7T_\ V!K7_09;\C1_8&M?]!EO
MR-/^V*_\J_'_ ##_ %:PG\TOO7^1\NM^S_X^Y_XD/_DY;_\ QRHV_9]\?_\
M0!_\G+?_ ..5]3?V!K7_ $&6_(T?V!K7_09;\C1_;&(_E7X_YB_U9P?\TOO7
M^1\FZC\#?&^EP"6YT3RHRVT-]K@/.#Z/[5,?V>?B W30/_)VW_\ CE?2OB?2
M]1L]/22[U W49D "8/7!Y_G6LN@ZU@?\3EOR-/\ MG$?RK\?\P_U9P?\TOO7
M^1\HM^SO\0O^A?\ _)VW_P#CE1M^SI\0_P#H7_\ R=M__CE?6?\ 8&M?]!EO
MR-']@:U_T&6_(T?VSB/Y5^/^8O\ 5G!_S2^]?_(GR2W[.7Q$Y_XI[_R=M_\
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M )5;+_X]7Z9?V!K7_09;\C1_8&M?]!EOR-']O8K^6/W/_,/]6<'_ #2^]?\
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M:U_T&6_(T?V!K7_09;\C0!TU%<S_ &!K7_09;\C1_8&M?]!EOR- '345S/\
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MU&-2:U>ORZ?.V_;8\[&T:>'Q$J5-W4=/FM_E>]GU6H4445UG$%%%% !1110
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M55W,"V%50,\ #BO']3MO&OQV_9K\(_#_ $[X8>(/#S7UCH^SQ5K5[I7V.P6
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M#\2M6^%>HW^JZ EL=>O?AQ\/M&L);R,R0037EW/;":10065!*7V@C<5 R,Y
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M_P#LU=-7,ZM_R.6E?]<S_P"S5TU !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% ',:[_P C7H_^>]=/7,:[_P C7H_^>]=/0 4444 %%%%
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M_P",T?V)\!_^A@US_OV__P 9I_VM'_GQ4_\  &+^PY?]!-'_ ,&(\,HKW/\
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M:RW]K92@*UDWFV[PSP!5C"K-$[+Y:$,&4&O2/M/BC_GUM?S'_P 51]I\4?\
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MKP1=1Z/;V2W^C:?I'A6_\'V=E8SKY<=E=K$)&)D5W:4>2I#LQR2Q8.3FJO\
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M_F/_ (JC[3XH_P"?6U_,?_%4 =-6+XP_Y%R[_P" ?^AK5/[3XH_Y];7\Q_\
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MJ;X0^._^A*\1?^"J?_XBH6^$'CS_ *$GQ%_X*9__ (BOT;^T^*/^?6U_,?\
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MO_!/<?\ Q%5;CX.^/K=D67P1XCC:0X0/I-P"Q]!\G-?J5]I\4?\ /K:_F/\
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M !5?.XC$5,34=2J[L^JPV&I82DJ5%62.FHKF?M/BC_GUM?S'_P 51]I\4?\
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M!TU%<S]I\4?\^MK^8_\ BJ/M/BC_ )];7\Q_\50!TU%<S]I\4?\ /K:_F/\
MXJC[3XH_Y];7\Q_\50!TU%<S]I\4?\^MK^8_^*H^T^*/^?6U_,?_ !5 ":[_
M ,C7H_\ GO73UP.I3:RVM6#7$,*W8_U*J1M//?FMC[3XH_Y];7\Q_P#%4 =-
M17,_:?%'_/K:_F/_ (JC[3XH_P"?6U_,?_%4 =-17,_:?%'_ #ZVOYC_ .*H
M^T^*/^?6U_,?_%4 =-17,_:?%'_/K:_F/_BJ/M/BC_GUM?S'_P 50!TU%<S]
MI\4?\^MK^8_^*H^T^*/^?6U_,?\ Q5 '345S/VGQ1_SZVOYC_P"*H^T^*/\
MGUM?S'_Q5 '345S/VGQ1_P ^MK^8_P#BJ/M/BC_GUM?S'_Q5 '345S/VGQ1_
MSZVOYC_XJC[3XH_Y];7\Q_\ %4 =-17,_:?%'_/K:_F/_BJ/M/BC_GUM?S'_
M ,50!TU%<S]I\4?\^MK^8_\ BJ/M/BC_ )];7\Q_\50!TU%<S]I\4?\ /K:_
MF/\ XJC[3XH_Y];7\Q_\50!TU%<S]I\4?\^MK^8_^*H^T^*/^?6U_,?_ !5
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MB-M/N1/;6ZP&)MY4C(7!SCYO2@#5\'_\BY:?\#_]#:MFL;P?_P BY:?\#_\
M0VK9H **** "BBB@ HHHH **** /E[]H7]F/]GZZMY];\5RV'P^OY2THU/3[
MQ+&21R<[A$<H[9YX0L>>:^2=-_:B\:?!WQC!H'PO^(FI?%W0MVV*RUK2)7R
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M<?\ (=U/_P #)/\ XJG+XT\0_P#0=U/_ ,#)/\:Q%Z4Y:G^T,9_S^E_X$_\
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MQO\ S^E_X$_\R/J]'^1?<C7'B[7<_P#(:U#_ ,"I/\:=_P );KG_ $&=0_\
M J3_ !K'7K3JC^T<;_S^E_X$_P#,CV%+^1?<C8'BS7,?\AG4/_ J3_&E7Q9K
MG_09U#_P*D_QK(7I3EJ/[2QO_/\ E_X$_P#,AT*7\B^Y&O\ \)9K?_09U#_P
M*?\ QIX\5ZWG_D,:A_X%/_C6/3UZUF\RQO\ S_G_ .!/_,ET*7\B^Y&M_P )
M5K?_ $&+_P#\"G_QJS:>-M>LY Z:K=,1SB60R#\FS6%3J<<US"G)2AB)IKM*
M7^9E+#T9:."^Y'MO@+X@#Q,QL[M%AOT7<"OW90.I ['VKM*^>?!<DL?BS23"
M2'^T(#C^Z3AOT)KZ&K^K?#[/L5GF62^N/FG3ER\W=6NK^:V?R>Y^?9QA*>%K
MKV6BDKV[!1117Z@>$%%%% !1110 4444 <SJW_(Y:5_US/\ [-735S.K?\CE
MI7_7,_\ LU=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!S&N_\ (UZ/_GO73US&N_\ (UZ/_GO73T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45!<,-P&><
M$@>M>8?%3XD?\(O9O9V/_(4F'RD<^4O +$=^O2O*S+,:.5X:>)K;1^]OLO,W
MHT9XB?)3/5J*^9_ACJ6I:/\ $2"&_:1);V/]X)>6?.2K$^AP>.U?1\;;EW9
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M^)H_X2^Z_P"@+=?K_P#$T =-17,_\)?=?] 6Z_7_ .)H_P"$ONO^@+=?K_\
M$T =-17,_P#"7W7_ $!;K]?_ (FC_A+[K_H"W7Z__$T =-17,_\ "7W7_0%N
MOU_^)H_X2^Z_Z MU^O\ \30!TU%<S_PE]U_T!;K]?_B:/^$ONO\ H"W7Z_\
MQ- '345S/_"7W7_0%NOU_P#B:/\ A+[K_H"W7Z__ !- '35B^,/^1<N_^ ?^
MAK5/_A+[K_H"W7Z__$UGZ]XCGO\ 29X'TR>W5]N9'S@88'T]J /D;X[?\E0U
M/_KWL_\ TDAKA5K[[T_Q3<6^GVT2Z1<2+'$JAUSAL #(^6K'_"7W7_0%NOU_
M^)K\VQ?!OUK$5*_UBW-)NW+M=W_F/U3!\<_5,-2P_P!6OR14;\^]E:_PGY_K
MTIZ]J^_?^$ONO^@+=?K_ /$T?\)?=?\ 0%NOU_\ B:XO]1?^HG_R3_[8ZO\
MB('_ %"_^3__ &A\#+3UK[V_X2^Z_P"@+=?K_P#$T?\ "7W7_0%NOU_^)J/]
M0_\ J)_\D_\ MB?]?_\ J%_\G_\ M3X,6I*^[_\ A+[K_H"W7Z__ !-'_"7W
M7_0%NOU_^)J7P#?_ )BO_)/_ +8G_7W_ *A?_)__ +4^$UZTY>M?=7_"7W7_
M $!;K]?_ (FC_A+[K_H"W7Z__$U'_$/_ /J*_P#)/_MR?]?/^H;_ ,G_ /M3
MX:I]?<7_  E]U_T!;K]?_B:/^$ONO^@+=?K_ /$U'_$/?^HK_P D_P#MR?\
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MW)_UO_Z<?^3?_:GRFM.KZJ_X2^Z_Z MU^O\ \31_PE]U_P! 6Z_7_P")J?\
MB%W_ %&_^4__ +<7^MW_ $X_\F_^U/E>G+7U-_PE]U_T!;K]?_B:/^$ONO\
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MW7_0%NOU_P#B: $UW_D:]'_SWKIZX>;5I=3\2Z6\EG):E6VA9,Y.3UZ"NXH
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MJO7]M@_9>R:E:]^G:QX+H8_V_MTX7M;[6U[GKVG:A;ZMI]K?6D@FM;F)9H9
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M(1% 55'   '%=O\ &SXF0?!WX3^*?&<\)NCI%B\\%J 2;FX/RP0@#DF25D0
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M"65(X<6TI\T^4P ;"8Y9TX! /H"BOD#X[?M"6_B#P'XGOO"JZUI=UJOP9O\
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MC9),]OYK(Z@+@$_0= !1110 4444 %8OC#_D7+O_ (!_Z&M;58OC#_D7+O\
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MC_\ Z#__ ))V_P#\;IP_:"\?_P#0?_\ ).W_ /C=><KUIR]:R><9E_T$S_\
M Y?YF3RC+O\ H&A_X!'_ "/1_P#AH#Q]_P!![_R3M_\ XW3_ /A?_CW_ *#W
M_DG;_P#QNO.J?63SG,_^@FI_X'+_ #)>4Y=_T#P_\ C_ )'HJ_'WQY_T'?\
MR3M__C=.'Q\\=_\ 0=_\DX/_ (W7GBT]>E9O.LS_ .@JI_X'+_,R>4Y?_P!
M\/\ P&/^1Z$/CUX[_P"@[_Y*0?\ QNGK\>/'7_0<_P#)2#_XBO/5Z5(M9/.L
MT_Z"JG_@<O\ ,S>59?\ ] \/_ 8_Y'H"_';QS_T'/_)2#_XBGK\=?'!_YC?_
M )*0?_$5Y^M/6LGG>:_]!53_ ,#E_F1_967_ /0/#_P&/^1Z!_PO/QO_ -!O
M_P E(/\ XBG#XY>-_P#H-_\ DI!_\17 T]>M9O/,U_Z"JG_@<O\ ,AY7@/\
MH'A_X#'_ ".TOOB]XMU2$0W6K>;&&W!?LT(YP?1/>K@^-WC7 _XG7_DK!_\
M$5P2]:DK)YYFW_074_\  Y?YF;RO ?\ /B'_ ("O\CO/^%V^-/\ H,_^2L'_
M ,13U^-?C/\ Z#/_ )*P_P#Q%<'4BUD\]S;_ *"ZG_@<O\S-Y9@?^?$/_ 5_
MD=TOQJ\9_P#09_\ )6'_ .(IR_&CQE_T&/\ R5A_^(KAEIZUF\^S?_H+J?\
M@<O\R'EN!_Y\0_\  5_D=NOQH\9?]!C_ ,E8?_B*>/C-XQ_Z#'_DK#_\17#K
M3UZ5#S[-_P#H+J?^!R_S,_[-P/\ SXA_X"O\CME^,GC#_H,?^2T/_P 13O\
MA<GC#_H+_P#DM#_\17$K3JS_ +?S?_H,J?\ @<O\R/[-P7_/B'_@*_R.V_X7
M%XO_ .@O_P"2T/\ \12K\8O%_P#T%_\ R6A_^(KBJ<M1_;^<?]!E3_P9+_,G
M^SL%_P ^(_\ @*_R.U'Q@\7?]!?_ ,EH?_B*<OQ@\7?]!;_R6A_^(KBUZ4Y:
MG_6#./\ H,J_^#)?YD/+L%_SYC_X"O\ ([/_ (6_XN_Z"W_DM#_\13O^%O>+
M?^@M_P"2T/\ \17%T^L_]8,X_P"@RK_X,E_F2\OP?_/F/_@*_P CLE^+GBW_
M *"W_DM#_P#$4[_A;?BSC_B:_P#DM#_\17&K3^XJ7Q!G/_095_\ !D_\R/[/
MP?\ SYC_ . K_([%?BUXK_Z"O_DO%_\ $4O_  MKQ7_T%?\ R7B_^(KCUI:C
M_6'.?^@RK_X,G_F3_9^#_P"?,?\ P%?Y'8_\+8\5_P#05_\ )>+_ .(JO=?$
M7Q#J#P23ZAYCPMNC/DQC!X]%]A7,TY>E0^(LY_Z#:O\ X,G_ )D?4,)_SYC_
M . K_(ZX?%?Q5_T%/_)>+_XBGK\5?%/_ $%/_)>+_P")KCUZU(M0^(LZ_P"@
MVK_X,G_F1]0PG_/F/_@*_P CK1\5/%/_ $%/_)>+_P")IW_"U/%'_04_\EXO
M_B:Y%>M.J?\ 6+.O^@VK_P"#)_YD?4<)_P ^H_\ @*_R.M'Q2\4?]!/_ ,EX
MO_B:5?BEXG_Z"?\ Y+Q?_$UR:]*<M1_K'G7_ $&U?_!D_P#,EX'"?\^H_P#@
M*_R.L_X6AXG_ .@G_P"2\7_Q-.'Q/\3?]!/_ ,@1?_$UR=/7K6;XCSO_ *#:
MO_@R?^9#P.%_Y]1_\!7^1U?_  L[Q-_T$O\ R!%_\35BT^*OB&WD#27$5RO=
M9(5 /_?(%<=3J<>)L\IR4EC:OSG)_@W8SE@<*]/91^Y'O?@WQS:^+(F0)]GO
M8QEX2<@C^\I[C^5=-7SWX(NY;/Q9I;Q$AFG6,^ZL=I_0U]"5_4? ?$6(XARZ
M4\7_ !*;Y6]N;2Z?KW^_J?!9M@X8.NE3^%Z^@4445^DGB!1110 4444 %%%%
M ',ZM_R.6E?]<S_[-735S.K?\CEI7_7,_P#LU=-0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!S&N_P#(UZ/_ )[UT]<QKO\ R->C_P">
M]=/0 4444 %%%% !1110 4444 %%%% !1110 4444 ?/_P"VY\2O^%<_ ?6_
M(N/L^I:T8]%M&V[B&N&\MF ')VH7;C^[7SS\%_B/X(\(_M'^!-.\%:BTVC:W
MX='AR^C>"2!?M-N-T$F7'S,RJZ^IQFOI[XK?!/5OB?\ &CX?:[=W&GMX-\,I
M/=RV$KN9[B]8;8VV;-I15R<ELY/2C]H3X$W?Q-\&V4?A=M-TGQ1I>I6NJ:=<
MW0,<*212@D,R(S %-R\#O75&<8QLSW*%>C3I*BW\6K\GT/E?XB6>@Z!\4O']
MQ\;_  OXFU&&[OGN-#\4:8T\D-G8E0L8C6)QY10Y);OGFKGQP\$>"?'&L?L]
MW6EZK?\ B72M3OCI)U)]1F,ES;I"Q&2&!5\]6&&[9KZ&USPE\>;?6==BTR_\
M#:]X?OVS:0ZTUS!+9*4"M&1'"XF7(SR5)R1D8%>>3?L:>+?"WP\^&%AX4UK0
M[OQ)X1UJ?6IVU7S8;2Y>8-N1?+1V55R ..@K3FBNIJJL(RC/F5]C.UCX1OX_
M_:5U_P %KKNKZ5X,T[PSIOGZ=I]])#).09%C4R [@ %;)!R<\YK,^*,/P0OO
M'&N6NH6WB?QQXEA1;<1:.UQ<C2BD9"K&RNJQD;<DCG)YZU]"^!_A1XCTWXO:
M]XTUVYTPKJVB6-C);Z?)(VV>+>92-R#Y/F&TYSUR!7F'A']GOXP?#-_%FA>%
M=9\()X:U[4I[U=7O#<?VG:K*26'EK%LD9<G;EP!QG/2ES1;M<RA.G*27,E;^
MF7?V9?C)#I?[(]CXP\::F_V?2X9XYKNZ)\Z2*)V6,-DG=(0 /J:I_ WPGJVL
M0>(OCQXULQ_PD6I64DFDZ>PRNG:<BEHT [,X 9CUYKB=6_8N^*<7PU\"^$=,
MUSPI>V6@ZE<:C>6NJ37*V]\YE+P[U2(Y !R5X&>A->MZ3H/[2#7%G9:N?A?)
MH#.L5[%:R7PE:W(VNB Q;<[3QGBDU'XDT54C3BG.E46K[]#Y8\&WOAGXE_#^
M\\4>+O#7CO7/B#JS3W5OKVGVTIBLGRWDK;LLH547"\ <]Z[+P+H?B?XZ?$;P
M)I?C?4=8TG=X.DDUG38YVMGORER%4N%(*;A@G:0:]9\)?!/XU_"'PYJ7@[P/
MK/A"Z\+F>5]*O=9FN4O+")V)$9C2%ED"Y./G7WKO?#/P;\2:;\:-,\9ZIJEA
MJ,4'AD:/=2H&CGFN?-#LX3;M"=?XL^U#G%=1U*].,7RM/L?)/Q*\4:I^R_JG
MQ3\&>#M6U6+2+K3K&YTZ*:Y>X?3Y;B;RW,)<ENF>_7%.U:WTOPK8Z%K7PM\(
M>/+#QU:W=NUS?75M-Y>IH659Q.7E8'(+$''':OH3XH?LF7OQ2^)?C;5[[4K.
MTT76]"M].M&B9VNK:ZBDWK*5VA< XZ-GVK5\->$?V@RWAS3=:UOP58Z782)_
M:&I:<]U<7=_$@P%\J2)$0L ,G><'/6JYX6T-95J#A&4+7MK<\W^&/PYT7]J7
MQE\1?$WCZ*XUJRT_6&T?1])FN)$AL(HT4NP5"!O9B3N/(P.:Z+XN^#_AO\,?
MAGH/A;QUXOU^XTA-2,]GIHOYI+O4%W?+;$*=\D2@C/(Z<FM>+X(_$WX5_$3Q
M;K7PPOO#%WX?\3S"]NM%\1S7%O\ 9;K;M:2)XHI,ANI! Y K$\4?L[?%S5/$
MW@CQTOB'PKK'C;0_M<5U:ZA'/#I[PSX^6)E1W!4 @,1SP<<5%XN5[Z'-+V=2
MIS*:4>APG[-?B;1])_:@O/#G@K3M<\/>"]0\/?;3H^L1O$J7*S%?-BC=F*AE
M/8@<=*^KOB-J6B:1HRW>J*I8-B'8=LI8GHI'/.![<<UY'\/_ -G_ .(MO^T%
M#\3?&FN:%>-)I$NG2Z?I;3;+7]YNC6(O&-ZX^\S%3GH*] ^*7PJUCQQJMI/9
MW=G';0Q&,Q7,CKR2#D *?SKYCB*KB:.#E/ T?:U-DB^6A4Q4.>:MU9Y5<2ZY
M\0IIQ%$ZV<>?,<+R%Z?.>KMCMWKV7X;>#-#T.Q%S8.M[,X4/<'J,#IC^'Z5R
MFC_!3Q=9XC;Q';V4*C %J68_JH_K7HW@GP#;^"[.XCBN9KJ>Y<2332M]YAGD
M#MUK\WX:R7$4L2L1C,,[N]W/H_[JZ'9F6*IV]E0J7CY'5T445^R'RH4444 %
M%%% !1110 4444 %%%% !1110 4444 %4M;_ .0-?_\ 7"3_ -!-7:I:W_R!
MK_\ ZX2?^@F@"GX/_P"1<M/^!_\ H;5LUC>#_P#D7+3_ ('_ .AM6S0 4444
M %%%% !1110 4444 %%%% !1110 4444 ?GI^VG_ ,CCHO\ U[S?^C*^=*^O
MOVEOA)XB^)/B33KK0X(9H;>*2.0RS+&<E\CK[5XY_P ,M^/O^?*T_P# M*_9
M\CS+!4<NI4ZM:*DD]&UW9_/G$F3YAB,VKU:-"4HMJS2=MD>245ZW_P ,M^/O
M^?*T_P# M*/^&6_'W_/E:?\ @6E>[_;&7_\ /^/WH^:_L'-?^@:?_@+/)**]
M;_X9;\??\^5I_P"!:4?\,M^/O^?*T_\  M*/[8R__G_'[T']@YK_ - T_P#P
M%GDE%>M_\,M^/O\ GRM/_ M*/^&6_'W_ #Y6G_@6E']L9?\ \_X_>@_L'-?^
M@:?_ ("SR2BO6_\ AEOQ]_SY6G_@6E'_  RWX^_Y\K3_ ,"TH_MC+_\ G_'[
MT']@YK_T#3_\!9Y)17K?_#+?C[_GRM/_  +2C_AEOQ]_SY6G_@6E']L9?_S_
M (_>@_L'-?\ H&G_ . L\DHKUO\ X9;\??\ /E:?^!:4?\,M^/O^?*T_\"TH
M_MC+_P#G_'[T']@YK_T#3_\  6>245ZW_P ,M^/O^?*T_P# M*/^&6_'W_/E
M:?\ @6E']L9?_P _X_>@_L'-?^@:?_@+/)**];_X9;\??\^5I_X%I1_PRWX^
M_P"?*T_\"TH_MC+_ /G_ !^]!_8.:_\ 0-/_ ,!9Y)17K?\ PRWX^_Y\K3_P
M+2C_ (9;\??\^5I_X%I1_;&7_P#/^/WH/[!S7_H&G_X"SR2BO6_^&6_'W_/E
M:?\ @6E'_#+?C[_GRM/_  +2C^V,O_Y_Q^]!_8.:_P#0-/\ \!9Y)17K?_#+
M?C[_ )\K3_P+2C_AEOQ]_P ^5I_X%I1_;&7_ //^/WH/[!S7_H&G_P" L\DH
MKUO_ (9;\??\^5I_X%I1_P ,M^/O^?*T_P# M*/[8R__ )_Q^]!_8.:_] T_
M_ 6>245ZW_PRWX^_Y\K3_P "TH_X9;\??\^5I_X%I1_;&7_\_P"/WH/[!S7_
M *!I_P#@+/)**];_ .&6_'W_ #Y6G_@6E'_#+?C[_GRM/_ M*/[8R_\ Y_Q^
M]!_8.:_] T__  %GDE%>M_\ #+?C[_GRM/\ P+2C_AEOQ]_SY6G_ (%I1_;&
M7_\ /^/WH/[!S7_H&G_X"S[(_9+_ .28Z'_UX+_Z&:]SKQ#X P/\/O!&EZ9K
M \J[M[58G6/YP&#$]1]:]0_X3?2O^>DG_?LU^#XV49XJK*+NG)_F?TQE\)4\
M'1A-6:C%/[D;]%8'_";Z5_STD_[]FC_A-]*_YZ2?]^S7&>@;]%8'_";Z5_ST
MD_[]FC_A-]*_YZ2?]^S0!OUY%XT^''BO1?BLGQ%^'JZ)>:GJ&G1Z1KVB:_<S
M6D-_!$TCVLT5S%%,T,L3RR@@PNLB28^0HK5WW_";Z5_STD_[]FC_ (3?2O\
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M1RKM,9'< RQA2S?5W_";Z5_STD_[]FC_ (3?2O\ GI)_W[- 'D_PI\/Z_P#
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M?)E/7K7UA]G\!_\ 0 TW_P %L?\ \31Y/@3_ * &F_\ @MC_ /B:E^'.+?\
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MO^>DG_?LT ;]%8'_  F^E?\ /23_ +]FC_A-]*_YZ2?]^S0!!JW_ ".6E?\
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M^S0!OT5@?\)OI7_/23_OV:/^$WTK_GI)_P!^S0!OT5@?\)OI7_/23_OV:/\
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M)_W[-'_";Z5_STD_[]F@#?HK _X3?2O^>DG_ '[-'_";Z5_STD_[]F@#?HK
M_P"$WTK_ )Z2?]^S1_PF^E?\])/^_9H WZ*P/^$WTK_GI)_W[-'_  F^E?\
M/23_ +]F@#?HK _X3?2O^>DG_?LT?\)OI7_/23_OV: -^BL#_A-]*_YZ2?\
M?LT?\)OI7_/23_OV: -^BL#_ (3?2O\ GI)_W[-'_";Z5_STD_[]F@#?HK _
MX3?2O^>DG_?LT?\ ";Z5_P ])/\ OV: -^BL#_A-]*_YZ2?]^S1_PF^E?\])
M/^_9H WZ*P/^$WTK_GI)_P!^S1_PF^E?\])/^_9H WZ*P/\ A-]*_P">DG_?
MLT?\)OI7_/23_OV: -^BL#_A-]*_YZ2?]^S1_P )OI7_ #TD_P"_9H WZ*P/
M^$WTK_GI)_W[-'_";Z5_STD_[]F@#?HK _X3?2O^>DG_ '[-'_";Z5_STD_[
M]F@#?HK _P"$WTK_ )Z2?]^S1_PF^E?\])/^_9H WZ*P/^$WTK_GI)_W[-'_
M  F^E?\ /23_ +]F@#?HK _X3?2O^>DG_?LT?\)OI7_/23_OV: -^BL#_A-]
M*_YZ2?\ ?LT?\)OI7_/23_OV: -^J6M_\@:__P"N$G_H)K-_X3?2O^>DG_?L
MU6U+QAIMUIMU#')(7DB9%RAZD$"@"_X/_P"1<M/^!_\ H;5LUC>#_P#D7+3_
M ('_ .AM6S0 4444 %%%% !1110 4444 %%>>_'?QYXB^&?PXO?$?AGPX_BJ
M_LI8GETN,.7D@+@2E=N2"%R<X.,9(-8WP)_:@\#?'_3_ /B0ZA]DUN-<W.AW
MY$=W">Y"Y_>*/[RY'3.#Q6RHU'3]JEH<[Q%.-7V,G:3_ !]#UNBBBL3H"BBB
M@"O_ &?:[B?LT.6.2?+')H^P6O\ S[0_]\"K%% %?[!:_P#/M#_WP*/L%K_S
M[0_]\"K%% %?[!:_\^T/_? H^P6O_/M#_P!\"K%% %?[!:_\^T/_ 'P*/L%K
M_P ^T/\ WP*L44 5_L%K_P ^T/\ WP*/L%K_ ,^T/_? JQ10!7^P6O\ S[0_
M]\"C[!:_\^T/_? JQ10!7^P6O_/M#_WP*/L%K_S[0_\ ? JQ10!7^P6O_/M#
M_P!\"C[!:_\ /M#_ -\"K%% %?[!:_\ /M#_ -\"C[!:_P#/M#_WP*L44 5_
ML%K_ ,^T/_? H^P6O_/M#_WP*L44 5_L%K_S[0_]\"C[!:_\^T/_ 'P*L44
M5_L%K_S[0_\ ? H^P6O_ #[0_P#? JQ10!7^P6O_ #[0_P#? H^P6O\ S[0_
M]\"K%% %?[!:_P#/M#_WP*/L%K_S[0_]\"K%% %?[!:_\^T/_? H^P6O_/M#
M_P!\"K%% %?[!:_\^T/_ 'P*/L%K_P ^T/\ WP*L44 5O[.M 21:P@GJ?+'^
M%+]@M?\ GVA_[X%6** *_P!@M?\ GVA_[X%'V"U_Y]H?^^!5BB@"O]@M?^?:
M'_O@4?8+7_GVA_[X%6** *_V"U_Y]H?^^!1]@M?^?:'_ +X%6** *_V"U_Y]
MH?\ O@4?8+7_ )]H?^^!5BB@"O\ 8+7_ )]H?^^!1]@M?^?:'_O@58HH K_8
M+7_GVA_[X%'V"U_Y]H?^^!5BB@"O]@M?^?:'_O@4?8+7_GVA_P"^!5BB@"O]
M@M?^?:'_ +X%'V"U_P"?:'_O@58HH K_ &"U_P"?:'_O@4?8+7_GVA_[X%6*
M* *_V"U_Y]H?^^!1]@M?^?:'_O@58HH K_8+7_GVA_[X%'V"U_Y]H?\ O@58
MHH K_8+7_GVA_P"^!1]@M?\ GVA_[X%6** *_P!@M?\ GVA_[X%'V"U_Y]H?
M^^!5BB@"O]@M?^?:'_O@4?8+7_GVA_[X%6** *_V"U_Y]H?^^!1]@M?^?:'_
M +X%6** *_V"U_Y]H?\ O@4?8+7_ )]H?^^!5BB@"O\ 8+7_ )]H?^^!1]@M
M?^?:'_O@58HH K_8+7_GVA_[X%'V"U_Y]H?^^!5BB@"O]@M?^?:'_O@4?8+7
M_GVA_P"^!5BB@"O]@M?^?:'_ +X%'V"U_P"?:'_O@58HH K_ &"U_P"?:'_O
M@4?8+7_GVA_[X%6** *_V"U_Y]H?^^!1]@M?^?:'_O@58HH K_8+7_GVA_[X
M%#:?:,,&UA(]XQ_A5BB@"N-/M1P+:$#_ *YBC[!:_P#/M#_WP*L44 5_L%K_
M ,^T/_? H^P6O_/M#_WP*L44 5_L%K_S[0_]\"C[!:_\^T/_ 'P*L44 5_L%
MK_S[0_\ ? H^P6O_ #[0_P#? JQ10!7^P6O_ #[0_P#? H^P6O\ S[0_]\"K
M%% %?[!:_P#/M#_WP*/L%K_S[0_]\"K%% %?[!:_\^T/_? H^P6O_/M#_P!\
M"K%% %?[!:_\^T/_ 'P*/L%K_P ^T/\ WP*L44 5_L%K_P ^T/\ WP*/L%K_
M ,^T/_? JQ10!7^P6O\ S[0_]\"C[!:_\^T/_? JQ10!6;3;1N&M82/>,?X4
MOV"U_P"?:'_O@58HH K_ &"U_P"?:'_O@4?8+7_GVA_[X%6** *_V"U_Y]H?
M^^!1]@M?^?:'_O@58HH K_8+7_GVA_[X%'V"U_Y]H?\ O@58HH K_8+7_GVA
M_P"^!1]@M?\ GVA_[X%6** *_P!@M?\ GVA_[X%'V"U_Y]H?^^!5BB@"O]@M
M?^?:'_O@4?8+7_GVA_[X%6** *_V"U_Y]H?^^!1]@M?^?:'_ +X%6** *_V"
MU_Y]H?\ O@4?8+7_ )]H?^^!5BB@"O\ 8+7_ )]H?^^!1]@M?^?:'_O@58HH
M K_8+7_GVA_[X%(=-M&P3:PDCI^['^%6:* *_P!@M?\ GVA_[X%'V"U_Y]H?
M^^!5BB@"O]@M?^?:'_O@4?8+7_GVA_[X%6** *_V"U_Y]H?^^!1]@M?^?:'_
M +X%6** *_V"U_Y]H?\ O@4?8+7_ )]H?^^!5BB@"O\ 8+7_ )]H?^^!1]@M
M?^?:'_O@58HH K_8+7_GVA_[X%'V"U_Y]H?^^!5BB@"O]@M?^?:'_O@4?8+7
M_GVA_P"^!5BB@"O]@M?^?:'_ +X%'V"U_P"?:'_O@58HH K_ &"U_P"?:'_O
M@4?8+7_GVA_[X%6** *_V"U_Y]H?^^!1]@M?^?:'_O@58HH K?V;:;@?LL.1
MW\L?X4OV"U_Y]H?^^!5BB@"O]@M?^?:'_O@4?8+7_GVA_P"^!5BB@"O]@M?^
M?:'_ +X%'V"U_P"?:'_O@58HH K_ &"U_P"?:'_O@4?8+7_GVA_[X%6** *_
MV"U_Y]H?^^!1]@M?^?:'_O@58HH K_8+7_GVA_[X%'V"U_Y]H?\ O@58HH K
M_8+7_GVA_P"^!1]@M?\ GVA_[X%6** *_P!@M?\ GVA_[X%'V"U_Y]H?^^!5
MBB@"O]@M?^?:'_O@4?8+7_GVA_[X%6** *_V"U_Y]H?^^!1]@M?^?:'_ +X%
M6** *QTVT)!-K"2.A\L?X4OV"U_Y]H?^^!5BB@"O]@M?^?:'_O@4?8+7_GVA
M_P"^!5BB@"O]@M?^?:'_ +X%'V"U_P"?:'_O@58HH K_ &"U_P"?:'_O@4?8
M+7_GVA_[X%6** *_V"U_Y]H?^^!1]@M?^?:'_O@58HH K_8+7_GVA_[X%'V"
MU_Y]H?\ O@58HH K_8+7_GVA_P"^!1]@M?\ GVA_[X%6** *_P!@M?\ GVA_
M[X%'V"U_Y]H?^^!5BB@"O]@M?^?:'_O@4?8+7_GVA_[X%6** *_V"U_Y]H?^
M^!1]@M?^?:'_ +X%6** *_V"U_Y]H?\ O@4?8+7_ )]H?^^!5BB@"O\ 8+7_
M )]H?^^!1]@M?^?:'_O@58HH K_8+7_GVA_[X%'V"U_Y]H?^^!5BB@"O]@M?
M^?:'_O@4?8+7_GVA_P"^!5BB@"O]@M?^?:'_ +X%'V"U_P"?:'_O@58HH K_
M &"U_P"?:'_O@4?8+7_GVA_[X%6** *_V"U_Y]H?^^!1]@M?^?:'_O@58HH
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MJC_A:7C/_H;-;_\ !C-_\51_J;B/^?R^YA_Q$#"_\^)?>C]5?^$PTC_G\_\
M(;_X4?\ "8:1_P _G_D-_P#"ORJ_X6EXS_Z&S6__  8S?_%4?\+2\9_]#9K?
M_@QF_P#BJ/\ 4W$?\_E]S#_B(&%_Y\2^]'ZJ_P#"8:1_S^?^0W_PH_X3#2/^
M?S_R&_\ A7Y5?\+2\9_]#9K?_@QF_P#BJ/\ A:7C/_H;-;_\&,W_ ,51_J;B
M/^?R^YA_Q$#"_P#/B7WH_57_ (3#2/\ G\_\AO\ X4?\)AI'_/Y_Y#?_  K\
MJO\ A:7C/_H;-;_\&,W_ ,51_P +2\9_]#9K?_@QF_\ BJ/]3<1_S^7W,/\
MB(&%_P"?$OO1^JO_  F&D?\ /Y_Y#?\ PH_X3#2/^?S_ ,AO_A7Y5?\ "TO&
M?_0V:W_X,9O_ (JC_A:7C/\ Z&S6_P#P8S?_ !5'^IN(_P"?R^YA_P 1 PO_
M #XE]Z/U5_X3#2/^?S_R&_\ A1_PF&D?\_G_ )#?_"ORJ_X6EXS_ .ALUO\
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MOO1^JO\ PF&D?\_G_D-_\*/^$PTC_G\_\AO_ (5^57_"TO&?_0V:W_X,9O\
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MY#?_  H_X3#2/^?S_P AO_A5O^P]._Y\+;_OTO\ A1_8>G?\^%M_WZ7_  H
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M^0W_ ,*/^$PTC_G\_P#(;_X5;_L/3O\ GPMO^_2_X4?V'IW_ #X6W_?I?\*
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M_P!^E_PH J?\)AI'_/Y_Y#?_  H_X3#2/^?S_P AO_A5O^P]._Y\+;_OTO\
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M#2/^?S_R&_\ A5O^P]._Y\+;_OTO^%']AZ=_SX6W_?I?\* *G_"8:1_S^?\
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M#2/^?S_R&_\ A5O^P]._Y\+;_OTO^%']AZ=_SX6W_?I?\* *G_"8:1_S^?\
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MY#?_  H_X3#2/^?S_P AO_A5O^P]._Y\+;_OTO\ A1_8>G?\^%M_WZ7_  H
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M^0W_ ,*/^$PTC_G\_P#(;_X5;_L/3O\ GPMO^_2_X4?V'IW_ #X6W_?I?\*
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M_P!^E_PH J?\)AI'_/Y_Y#?_  H_X3#2/^?S_P AO_A5O^P]._Y\+;_OTO\
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M3@X[5BS0R6\SQ2HT<J,5='!#*1P01V--3C)N*>J"5.<8J<HM)[/N,HK?\/\
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M[7'Q9'_,U_\ E.M/_C51-^UW\6A_S-G_ )3;3_XU3_L+$_S1^]_Y#_UGP?\
M)+[E_P#)'Z2T5^:S?M??%L?\S;_Y3;3_ .-5$W[87Q=Y_P"*M_\ *;9__&:/
M["Q/\T?O?^0?ZSX/^27W+_Y(_2ZN9\2?\C!H?_73^JU^>3?MB?%X?\S=_P"4
MVS_^,U1N_P!K7XKW=Q!/+XJWRP',;?V=:#!_"+VH_L+$_P T?O?^0?ZS8/\
MEE]R_P#DC]0:*_,-OVROC"/^9O\ _*99_P#QFHF_;.^,8_YG#_RF6?\ \9I_
MV#B?YH_>_P#(/]9L'_++[E_\D?J#17Y<M^VA\9!_S./_ )2[+_XS43?MJ?&;
M_H<O_*79?_&:/[!Q/\T?O?\ D'^LV#_EE]R_^2/U+HK\L6_;6^,X_P"9R_\
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M5*=*K&[51V7KKOKTMJ?5=%%%>2>N%%%% !1110 4444 %%%% !1110 4444
M%4M;_P"0-?\ _7"3_P!!-7:I:W_R!K__ *X2?^@F@"GX/_Y%RT_X'_Z&U;-8
MW@__ )%RT_X'_P"AM6S0 4444 %%%% !7R[^T]^UAX?^&/B:X\!^(?AU>>,[
M"YLH[B; 1[>17+?(493DC;G\J^HJ^5OVN/VWH/V>]3_X1;1M$;5O%DULMRLU
MX=MG;HQ(5B%.Z0_*?E&T=#N[5VX.FZE514.;YV^=SSL?45*@Y.?)YVO\K'SI
MIO[3WP)\'ZI#J]O^SNUE=1OF*:X\ME5^H*JZE01CC R,<5]Q_LZ?'BR_:(\
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MP _R)M926SQV@?%'XQZI\+/A7XX_X69(-0\5^-Y/"UQI<NBV+6$=F]U>VRS
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M=ZA>IF[U"]4,A>H&[U.]0-WH&0O4+5,]0M3 @;O4+U,W>H7J@('J%JF>H6H
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M3>WWD3 DRPP#C!)J]^VI;ZGX\_:=\$>!/"OD+?Z;8V\-G%*^(HIF9I!D,-H
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M.W\8:/X_^-6HZ]=:MX],-W!()8!&EFYBW[EY(?*A0, !0"N*M_\ !,/2[1M
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M "BBB@ HHHH **** "J6M_\ (&O_ /KA)_Z":NU2UO\ Y U__P!<)/\ T$T
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M4^-/$?QH_;I\-^.+SP%KGA+3X])GLG74()"BE8)L$R&-0,EP,5]_U\J?LO\
M[27C;6_B1K/PE^+6G16/CG383<07D"*BW: *2&"?)NVL'5DPI7/ (Y^JZQQS
M?M%%QLDDE9W5N]S?+5'V4I*3DW)MW5FGU304445YQZQ^>G[:?_(XZ+_U[S?^
MC*^=*^H/VNO">N>)/%FD2Z3HVH:I%'!*KO96KS*I,F0"5!Q7@O\ PK#QE_T*
M6N?^"V;_ .)K]QR#$48991C*:3L^J[L_F_BC"XBIG%>4*;:NMD_Y4<S173?\
M*P\9?]"EKG_@MF_^)H_X5AXR_P"A2US_ ,%LW_Q-?0?6L/\ \_%]Z/EOJ6*_
MY]2^YG,T5TW_  K#QE_T*6N?^"V;_P")H_X5AXR_Z%+7/_!;-_\ $T?6L/\
M\_%]Z#ZEBO\ GU+[F<S173?\*P\9?]"EKG_@MF_^)H_X5AXR_P"A2US_ ,%L
MW_Q-'UK#_P#/Q?>@^I8K_GU+[F<S173?\*P\9?\ 0I:Y_P""V;_XFC_A6'C+
M_H4M<_\ !;-_\31]:P__ #\7WH/J6*_Y]2^YG,T5TW_"L/&7_0I:Y_X+9O\
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M)H_X5AXR_P"A2US_ ,%LW_Q-'UK#_P#/Q?>@^I8K_GU+[F<S173?\*P\9?\
M0I:Y_P""V;_XFC_A6'C+_H4M<_\ !;-_\31]:P__ #\7WH/J6*_Y]2^YG,T5
MTW_"L/&7_0I:Y_X+9O\ XFC_ (5AXR_Z%+7/_!;-_P#$T?6L/_S\7WH/J6*_
MY]2^YG,T5TW_  K#QE_T*6N?^"V;_P")H_X5AXR_Z%+7/_!;-_\ $T?6L/\
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M +7_ +_+_C1_;6G_ //_ &O_ '^7_&@"[15+^VM/_P"?^U_[_+_C1_;6G_\
M/_:_]_E_QH NT52_MK3_ /G_ +7_ +_+_C1_;6G_ //_ &O_ '^7_&@"[15+
M^VM/_P"?^U_[_+_C1_;6G_\ /_:_]_E_QH NT52_MK3_ /G_ +7_ +_+_C1_
M;6G_ //_ &O_ '^7_&@"[15+^VM/_P"?^U_[_+_C1_;6G_\ /_:_]_E_QH N
MT52_MK3_ /G_ +7_ +_+_C1_;6G_ //_ &O_ '^7_&@"[15+^VM/_P"?^U_[
M_+_C1_;6G_\ /_:_]_E_QH NT52_MK3_ /G_ +7_ +_+_C1_;6G_ //_ &O_
M '^7_&@"[15+^VM/_P"?^U_[_+_C1_;6G_\ /_:_]_E_QH NT52_MK3_ /G_
M +7_ +_+_C1_;6G_ //_ &O_ '^7_&@"[15+^VM/_P"?^U_[_+_C1_;6G_\
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M7_O\O^-'M)_S,7L*7\B^Y%+_ (0GP[_T -+_ / ./_XFD_X0?PY_T -+_P#
M*/\ ^)J]_;6G_P#/_:_]_E_QH_MK3_\ G_M?^_R_XT>TG_,P]A2_D7W(H?\
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M\+?]"UH__@!%_P#$T?\ "O?"O_0LZ/\ ^ $7_P 36G_;6G_\_P#:_P#?Y?\
M&C^VM/\ ^?\ M?\ O\O^-'M:G\S^\/J]'^1?<C+_ .%=^%?^A9T?_P  (O\
MXFC_ (5UX4_Z%C1O_!?%_P#$UJ?VUI__ #_VO_?Y?\:/[:T__G_M?^_R_P"-
M'M:G\S^\/J]'^1?<C*_X5SX3_P"A7T;_ ,%\/_Q-)_PK?PE_T*VB_P#@OA_^
M)K6_MK3_ /G_ +7_ +_+_C1_;6G_ //_ &O_ '^7_&CVM3^9_>'U>C_(ON1D
M_P#"MO"/_0K:+_X+H?\ XFD_X5KX0_Z%71/_  70_P#Q-:_]M:?_ ,_]K_W^
M7_&C^VM/_P"?^U_[_+_C1[6I_,_O%]7H_P B^Y'#>+OA[X6MO[/\GPUH\6Z?
M#;+"(9'H<+70_P#"LO!__0IZ'_X+8?\ XFJWB[4+6Y_L_P FYAEVSY;9(#@>
MIQ70_P!M:?\ \_\ :_\ ?Y?\:/;5/YG]X?5Z/\B^Y&-_PK'P=_T*>A_^"V'_
M .)I/^%7^#?^A2T+_P %L/\ \36U_;6G_P#/_:_]_E_QH_MK3_\ G_M?^_R_
MXT>VJ?S/[P^KT?Y%]R,7_A5W@S_H4="_\%L/_P 32?\ "K?!?_0H:#_X+(?_
M (FMO^VM/_Y_[7_O\O\ C1_;6G_\_P#:_P#?Y?\ &CVU3^9_>'U>C_(ON1A_
M\*K\%?\ 0H:#_P""R#_XFC_A57@G_H3] _\ !9!_\36Y_;6G_P#/_:_]_E_Q
MH_MK3_\ G_M?^_R_XT>VJ?S/[P^KT?Y%]R,+_A5'@C_H3M _\%<'_P 12?\
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MG_\ /_:_]_E_QH]M5_F?WA]7H_R+[D<I_P *+^&W_1/?"O\ X);;_P"(I/\
MA17PU_Z)[X5_\$EM_P#$5UG]M:?_ ,_]K_W^7_&C^VM/_P"?^U_[_+_C1[:K
M_,_O#ZO1_D7W(Y/_ (41\-/^B>>%/_!);?\ Q%)_PH?X9_\ 1._"?_@DMO\
MXBNM_MK3_P#G_M?^_P O^-']M:?_ ,_]K_W^7_&CVU7^9_>'U>C_ "+[D<C_
M ,*%^&7_ $3KPG_X([7_ .-UH:'\)_!'AF\6[T?P;X?TFZ7I/8Z7!"X_X$J
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M=;F%H5A(:02#:#A^"?Q'YUT/]M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\
MO\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__ )_[7_O\O^-']M:?_P _]K_W
M^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\: +M%4O[:T__
M )_[7_O\O^-']M:?_P _]K_W^7_&@"[15+^VM/\ ^?\ M?\ O\O^-']M:?\
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M^-']M:?_ ,_]K_W^7_&@"[15+^VM/_Y_[7_O\O\ C1_;6G_\_P#:_P#?Y?\
M&@"[15+^VM/_ .?^U_[_ "_XT?VUI_\ S_VO_?Y?\: +M%4O[:T__G_M?^_R
M_P"-']M:?_S_ -K_ -_E_P : +M%4O[:T_\ Y_[7_O\ +_C1_;6G_P#/_:_]
M_E_QH NT52_MK3_^?^U_[_+_ (T?VUI__/\ VO\ W^7_ !H NU2UO_D#7_\
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M%=6JD8(BVC82K"1<<,K9XQS]!5GC)2=1)QLDE;KIZFV7QC&E)J7,VW=[:]=
MHHHK@/3/A_\ :@^*/B?X>^)M,MM U/[!!/%(\B_9XI-Q#X!RZG''I7BW_#27
MQ&_Z&+_R1MO_ (W7??MI_P#(XZ+_ ->\W_HROG2OVK(LOP=;+J4ZE&+;3U<4
MWN_(_GCB7-,?0S:O3HXB<8IJR4I)+1=$STW_ (:2^(W_ $,7_DC;?_&Z/^&D
MOB-_T,7_ )(VW_QNO,J*]W^R\!_T#P_\!C_D?-?VUF?_ $%5/_ Y?YGIO_#2
M7Q&_Z&+_ ,D;;_XW1_PTE\1O^AB_\D;;_P"-UYE11_9> _Z!X?\ @,?\@_MK
M,_\ H*J?^!R_S/3?^&DOB-_T,7_DC;?_ !NC_AI+XC?]#%_Y(VW_ ,;KS*BC
M^R\!_P! \/\ P&/^0?VUF?\ T%5/_ Y?YGIO_#27Q&_Z&+_R1MO_ (W1_P -
M)?$;_H8O_)&V_P#C=>944?V7@/\ H'A_X#'_ "#^VLS_ .@JI_X'+_,]-_X:
M2^(W_0Q?^2-M_P#&Z/\ AI+XC?\ 0Q?^2-M_\;KS*BC^R\!_T#P_\!C_ )!_
M;69_]!53_P #E_F>F_\ #27Q&_Z&+_R1MO\ XW1_PTE\1O\ H8O_ "1MO_C=
M>944?V7@/^@>'_@,?\@_MK,_^@JI_P"!R_S/3?\ AI+XC?\ 0Q?^2-M_\;H_
MX:2^(W_0Q?\ DC;?_&Z\RHH_LO ?] \/_ 8_Y!_;69_]!53_ ,#E_F>F_P##
M27Q&_P"AB_\ )&V_^-T?\-)?$;_H8O\ R1MO_C=>944?V7@/^@>'_@,?\@_M
MK,_^@JI_X'+_ #/3?^&DOB-_T,7_ )(VW_QNC_AI+XC?]#%_Y(VW_P ;KS*B
MC^R\!_T#P_\  8_Y!_;69_\ 054_\#E_F>F_\-)?$;_H8O\ R1MO_C='_#27
MQ&_Z&+_R1MO_ (W7F5%']EX#_H'A_P" Q_R#^VLS_P"@JI_X'+_,]-_X:2^(
MW_0Q?^2-M_\ &Z/^&DOB-_T,7_DC;?\ QNO,J*/[+P'_ $#P_P# 8_Y!_;69
M_P#054_\#E_F>F_\-)?$;_H8O_)&V_\ C='_  TE\1O^AB_\D;;_ .-UYE11
M_9> _P"@>'_@,?\ (/[:S/\ Z"JG_@<O\STW_AI+XC?]#%_Y(VW_ ,;H_P"&
MDOB-_P!#%_Y(VW_QNO,J*/[+P'_0/#_P&/\ D']M9G_T%5/_  .7^9Z;_P -
M)?$;_H8O_)&V_P#C='_#27Q&_P"AB_\ )&V_^-UYE11_9> _Z!X?^ Q_R#^V
MLS_Z"JG_ ('+_,]-_P"&DOB-_P!#%_Y(VW_QNC_AI+XC?]#%_P"2-M_\;KS*
MBC^R\!_T#P_\!C_D']M9G_T%5/\ P.7^9^DW[/$S^.O NE:CKA^VWD]HLLDF
M/+RQ8C.$P/TKU;_A#](_Y]/_ "*_^->3?LE_\DQT/_KP7_T,U[G7X+C8J&*J
MQBK)2?YL_IS+I2G@J,YN[<8W?R1B_P#"'Z1_SZ?^17_QH_X0_2/^?3_R*_\
MC6U17$>@8O\ PA^D?\^G_D5_\:/^$/TC_GT_\BO_ (UM44 8O_"'Z1_SZ?\
MD5_\:/\ A#](_P"?3_R*_P#C6U10!B_\(?I'_/I_Y%?_ !H_X0_2/^?3_P B
MO_C6U10!B_\ "'Z1_P ^G_D5_P#&C_A#](_Y]/\ R*_^-;5% &+_ ,(?I'_/
MI_Y%?_&C_A#](_Y]/_(K_P"-;5% &+_PA^D?\^G_ )%?_&C_ (0_2/\ GT_\
MBO\ XUM44 8O_"'Z1_SZ?^17_P :/^$/TC_GT_\ (K_XUM44 8O_  A^D?\
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MI'_/I_Y%?_&C_A#](_Y]/_(K_P"-;5% &+_PA^D?\^G_ )%?_&C_ (0_2/\
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M )%?_&N3_P"&A_A\?^9@_P#)*X_^-T?\-"_#_P#Z#_\ Y)7'_P ;I?VQEO\
MT$P_\#C_ )A_9&9?] T__ )?Y'6?\(?I'_/I_P"17_QH_P"$/TC_ )]/_(K_
M .-<I_PT)X _Z#__ ))W'_QNE_X:"\ ?]!__ ,D[C_XW1_;&6_\ 03#_ ,#C
M_F+^R,Q_Z!I_^ 2_R.J_X0_2/^?3_P BO_C1_P (?I'_ #Z?^17_ ,:Y;_AH
M#P#_ -![_P D[C_XW2_\+_\  7_0>_\ ).X_^-TO[9RS_H)I_P#@<?\ ,/[)
MS'_H'G_X!+_(ZC_A#](_Y]/_ "*_^-'_  A^D?\ /I_Y%?\ QKF/^%^^ _\
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M .2TW_Q%'_"X/"/_ $%O_):;_P"(H_U@R?\ Z#*7_@R/^8O[.QO_ #YE_P"
MO_(V/^$/TC_GT_\ (K_XT?\ "'Z1_P ^G_D5_P#&L?\ X6_X1_Z"W_DM-_\
M$4O_  M[PE_T%O\ R6F_^(I?ZP9/_P!!E+_P9'_,/[/QG_/F7_@+_P C7_X0
M_2/^?3_R*_\ C1_PA^D?\^G_ )%?_&LC_A;GA+_H+?\ DM-_\12_\+;\)_\
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M_D5_\:/^$/TC_GT_\BO_ (UF?\+7\*_]!3_R7E_^(H_X6KX6_P"@I_Y+R_\
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M .-'_"'Z1_SZ?^17_P :VJ* ,7_A#](_Y]/_ "*_^-'_  A^D?\ /I_Y%?\
MQK:HH Q?^$/TC_GT_P#(K_XT?\(?I'_/I_Y%?_&MJB@#%_X0_2/^?3_R*_\
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MV&F68#7%Y.02(T!('0%BQ(554L2 * +O_"'Z1_SZ?^17_P :/^$/TC_GT_\
M(K_XU^<O[8?[8WQ@^'?Q*?PCIVKV/AJ6WMH;B[@TNW6;RVD7>L?GR ER%*Y9
M509) '&3]"_LI>,O%GQT^#MKXQTOQKJFGZW#<RV5[I^M117]C)-& <C")*JL
MK*>),KDCG'/9/"SITE6ELS"-:,I."W/I7_A#](_Y]/\ R*_^-'_"'Z1_SZ?^
M17_QKG_ _P 0I]8U.Y\.^(--&A^*[.+SI+1)?-@NH<X%Q;2$#?'G@@@,A(#
M9!.!\2M:\5ZE\0-,\)>%=9MO#]Q)HE[JQN[BT6X$LL4L,<43!ONQDRDL5^;
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M\:V$^[3JR+,7_A#](_Y]/_(K_P"-'_"'Z1_SZ?\ D5_\:VJ* ,7_ (0_2/\
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M\8/C!^UE9^"?%'B&"^\/LUZ'MX[-$)\O.WY@,\8H _3_ /X0_1_^?3_R*_\
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M'B&'QD;B.:TFMA;0WB()MKVZ2,^]"59&9CCG(Y!P10!ZC_PA^D?\^G_D5_\
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M@DX"NO)QU^E0>"?AKK/Q&\:KX:\-K'JUPTC#[9$'6W6)6P9V+*&2/D'+*&Y
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MKLP=6=;#PJ5-VM3@S"C##XNI2I?"GI<****[3SPHHHH **** "BBB@ HHHH
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M,O;3P:+;2/#6BZP_A_P?IWV;2-)U-HY_-:&)W;$X2.(-,%B:38C&-#\H]O\
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M84444 %%%% !1110!S.H_P#(\Z9_UQ/\GKIJYG4?^1YTS_KB?Y/734 %%%%
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M]-Y8^RD]JX_XZ?!FS^(&J)/>SZ?%;V?A;4;"T>\N6A:&ZD> PS\8^12GS$Y
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MX?\ Q=US4-!\9RWLVC:O=Z3H5KK,&H:3"T=N6FBG<6S@NV3&81T(.V1<@'J
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M$G_H)J[5+6_^0-?_ /7"3_T$T 4_!_\ R+EI_P #_P#0VK9K&\'_ /(N6G_
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M5K[3]48L6O;6Y>.8[OO9=2&Y[\\U!JVL7^O:A-?ZG>W&HWTQ!ENKN5I97(
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MH>K?#[PMJFB:0K+INFWNBVTUM9 XR(8V0K&#@9V@=!7;T4 ,BB2")(HD6.-
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M%% !1110 4444 %%%% !1110!S/B?_D/:%_UV_\ 9EKIJYGQ/_R'M"_Z[?\
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MMMY:VRI(-WWN1ZT ?EM_P6XP?B[\.!GG^PIO_2@UT_['O_!4"_FO?A=\'AX
MMU@)M]&.K'5"6QT\SR_*X/MN_&OTL\;?"'P5\2+RVN_%'AC3==N;:,Q0RWT
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M;7+R/-$J@+(SDER1W+9.:BB\,Z5#YGEZ?;IYEN+1\(/FA ($9_V<$\4 ?/\
MX/\ B')8_L[>)O&__".>'K<#3UO4TNRTY;>)SL!"RJ&;>/FX/&?2NC^%_P :
MAJ?PO\7>,M:T^STV+2)Y1/<V\)@^TF.)&)>)LNC#(7#$D@ C@BO3-'^''AG0
M=+N]-T_1K:VL+L 3VR@E) .@()Z5?F\*Z1<6UY;R:=;O!>2"6YB:,;9G  W,
M.YPHZ^@H \1L/VE+_4/V;M:\>BPLX?$>D;H;S3OWABAG!4@8(5R-CHV, DY
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M ,%T7^%>E44>WK?SO[V'U:A_(ON1YK_PH/PO_P! S3?_  71?X4?\*#\+_\
M0,TW_P %T7^%>E44>WK?SO[V'U:A_(ON1YK_ ,*#\+_] S3?_!=%_A1_PH/P
MO_T#--_\%T7^%>E44>WK?SO[V'U:A_(ON1YK_P *#\+_ /0,TW_P71?X4?\
M"@_"_P#T#--_\%T7^%>E44>WK?SO[V'U:A_(ON1YK_PH/PO_ - S3?\ P71?
MX4?\*#\+_P#0,TW_ ,%T7^%>E44>WK?SO[V'U:A_(ON1YK_PH/PO_P! S3?_
M  71?X4?\*#\+_\ 0,TW_P %T7^%>E44>WK?SO[V'U:A_(ON1YK_ ,*#\+_]
M S3?_!=%_A1_PH/PO_T#--_\%T7^%>E44>WK?SO[V'U:A_(ON1YK_P *#\+_
M /0,TW_P71?X4?\ "@_"_P#T#--_\%T7^%>E44>WK?SO[V'U:A_(ON1YK_PH
M/PO_ - S3?\ P71?X4?\*#\+_P#0,TW_ ,%T7^%>E44>WK?SO[V'U:A_(ON1
MYK_PH/PO_P! S3?_  71?X4?\*#\+_\ 0,TW_P %T7^%>E44>WK?SO[V'U:A
M_(ON1YK_ ,*#\+_] S3?_!=%_A1_PH/PO_T#--_\%T7^%>E44>WK?SO[V'U:
MA_(ON1YK_P *#\+_ /0,TW_P71?X4?\ "@_"_P#T#--_\%T7^%>E44>WK?SO
M[V'U:A_(ON1QVG_#F+285ALKTV<"C:L=O$(U4>F <5;_ .$/G_Z#%U^O^-=-
M16+;;NSH225D<S_PA\__ $&+K]?\:/\ A#Y_^@Q=?K_C7344AG,_\(?/_P!!
MBZ_7_&C_ (0^?_H,77Z_XUTU% ',_P#"'S_]!BZ_7_&C_A#Y_P#H,77Z_P"-
M=-10!S/_  A\_P#T&+K]?\:/^$/G_P"@Q=?K_C7344 <S_PA\_\ T&+K]?\
M&C_A#Y_^@Q=?K_C7344 <S_PA\__ $&+K]?\:/\ A#Y_^@Q=?K_C7344 <S_
M ,(?/_T&+K]?\:/^$/G_ .@Q=?K_ (UTU% ',_\ "'S_ /08NOU_QH_X0^?_
M *#%U^O^-=-10!S/_"'S_P#08NOU_P :/^$/G_Z#%U^O^-=-10!S/_"'S_\
M08NOU_QH_P"$/G_Z#%U^O^-=-10!S/\ PA\__08NOU_QH_X0^?\ Z#%U^O\
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M,AR"RDD?0[N*E_X0^?\ Z#%U^O\ C7344 <S_P (?/\ ]!BZ_7_&C_A#Y_\
MH,77Z_XUTU% ',_\(?/_ -!BZ_7_ !H_X0^?_H,77Z_XUTU% ',_\(?/_P!!
MBZ_7_&C_ (0^?_H,77Z_XUTU% ',_P#"'S_]!BZ_7_&C_A#Y_P#H,77Z_P"-
M=-10!S/_  A\_P#T&+K]?\:/^$/G_P"@Q=?K_C7344 <S_PA\_\ T&+K]?\
M&C_A#Y_^@Q=?K_C7344 <S_PA\__ $&+K]?\:/\ A#Y_^@Q=?K_C7344 <S_
M ,(?/_T&+K]?\:/^$/G_ .@Q=?K_ (UTU% ',_\ "'S_ /08NOU_QH_X0^?_
M *#%U^O^-=-10!S/_"'S_P#08NOU_P :/^$/G_Z#%U^O^-=-10!S/_"'S_\
M08NOU_QH_P"$/G_Z#%U^O^-=-10!S/\ PA\__08NOU_QH_X0^?\ Z#%U^O\
MC7344 <S_P (?/\ ]!BZ_7_&C_A#Y_\ H,77Z_XUTU% ',_\(?/_ -!BZ_7_
M !H_X0^?_H,77Z_XUTU% ',_\(?/_P!!BZ_7_&C_ (0^?_H,77Z_XUTU% ',
M_P#"'S_]!BZ_7_&C_A#Y_P#H,77Z_P"-=-10!S/_  A\_P#T&+K]?\:/^$/G
M_P"@Q=?K_C7344 <S_PA\_\ T&+K]?\ &C_A#Y_^@Q=?K_C7344 <S_PA\__
M $&+K]?\:/\ A#Y_^@Q=?K_C7344 <S_ ,(?/_T&+K]?\:/^$/G_ .@Q=?K_
M (UTU% ',_\ "'S_ /08NOU_QH_X0^?_ *#%U^O^-=-10!S/_"'S_P#08NOU
M_P :/^$/G_Z#%U^O^-=-10!S/_"'S_\ 08NOU_QH_P"$/G_Z#%U^O^-=-10!
MS/\ PA\__08NOU_QH_X0^?\ Z#%U^O\ C7344 <S_P (?/\ ]!BZ_7_&FOX,
MFD1E.KW!##!#9(/ZUU%% %+1]._LG3H;3S/-\O/SXQG))Z?C5VBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **^6OC1^T;>?"'6K2R>UN]3^U(\@9
M;TQ!<-C&-IKSO_ANJY_Z 5[_ .#/_P"UU[N'R/,,52C6HTKQ>SNOU9\UBN),
MJP5:6'Q%:TX[JTOT1]TT5\+?\-U7/_0"O?\ P9__ &NC_ANJY_Z 5[_X,_\
M[771_JWFO_/G\8_YG+_K=DG_ $$?^2R_^1/NFBOA;_ANJY_Z 5[_ .#/_P"U
MT?\ #=5S_P! *]_\&?\ ]KH_U;S7_GS^,?\ ,/\ 6[)/^@C_ ,EE_P#(GW31
M7PM_PW5<_P#0"O?_  9__:Z/^&ZKG_H!7O\ X,__ +71_JWFO_/G\8_YA_K=
MDG_01_Y++_Y$^Z:*^%O^&ZKG_H!7O_@S_P#M='_#=5S_ - *]_\ !G_]KH_U
M;S7_ )\_C'_,/];LD_Z"/_)9?_(GW317PM_PW5<_] *]_P#!G_\ :Z/^&ZKG
M_H!7O_@S_P#M='^K>:_\^?QC_F'^MV2?]!'_ )++_P"1/NFBOA;_ (;JN?\
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M5S_T KW_ ,&?_P!KH_X;JN?^@%>_^#/_ .UT?ZMYK_SY_&/^8?ZW9)_T$?\
MDLO_ )$^Z:*^%O\ ANJY_P"@%>_^#/\ ^UT?\-U7/_0"O?\ P9__ &NC_5O-
M?^?/XQ_S#_6[)/\ H(_\EE_\B?=-%?"W_#=5S_T KW_P9_\ VNC_ (;JN?\
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M%<S_ ,(SJG_0=F_)O_BJ/^$9U3_H.S?DW_Q5 '345S/_  C.J?\ 0=F_)O\
MXJC_ (1G5/\ H.S?DW_Q5 '345S/_",ZI_T'9OR;_P"*H_X1G5/^@[-^3?\
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M_H.S?DW_ ,50!TU%<S_PC.J?]!V;\F_^*H_X1G5/^@[-^3?_ !5 '345S/\
MPC.J?]!V;\F_^*H_X1G5/^@[-^3?_%4 =-17,_\ ",ZI_P!!V;\F_P#BJ/\
MA&=4_P"@[-^3?_%4 =-17#:I8ZGI]]86YUBXD-R^T,&8;>0.F>>M:?\ PC.J
M?]!V;\F_^*H Z:BN9_X1G5/^@[-^3?\ Q5'_  C.J?\ 0=F_)O\ XJ@#IJ*Y
MG_A&=4_Z#LWY-_\ %4?\(SJG_0=F_)O_ (J@#IJ*YG_A&=4_Z#LWY-_\51_P
MC.J?]!V;\F_^*H Z:BN9_P"$9U3_ *#LWY-_\51_PC.J?]!V;\F_^*H Z:BN
M9_X1G5/^@[-^3?\ Q5'_  C.J?\ 0=F_)O\ XJ@#IJ*YG_A&=4_Z#LWY-_\
M%4?\(SJG_0=F_)O_ (J@#IJ*YG_A&=4_Z#LWY-_\51_PC.J?]!V;\F_^*H Z
M:BN9_P"$9U3_ *#LWY-_\51_PC.J?]!V;\F_^*H Z:BN9_X1G5/^@[-^3?\
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M9SSG6YV$4;/M^89P,X^]0!UM%9/A6:2XT&UDED:61MV6<DD_.>]:U !1110
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M^CV=IXI\1'6M4N99Y(&<^=]JNMEK$D&V./S?OS3-Y:9)?Z=H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K%\8?\BY=_\  /\ T-:VJQ?&'_(N
M7?\ P#_T-: /.=:_:,\-^!;]=!O['59KRTMX-[VT431G=$CC!,@/1AVZU57]
MK+PB_33M:_[\0_\ QVOG[XX_\E1U/_KA9_\ I)#7'P_>K\6S+BK,L+BZU&FU
M:,I):=$['[A@.$LLQ&"HUYI\THQ;UZM)L^ME_:H\)OTT_6?^_$/_ ,=J5?VH
M/"S]+#6/^_,7_P =KY2AJ_#7@U.-LWCM*/\ X":3X0RN.RE]Y]2+^TMX8;I8
M:M_WYB_^.5,O[1GAMNECJO\ WZB_^.5\R0]*OPUY]3CW.H[2C_X"<<^%<MCL
MG]Y](+^T+X<;_ERU3_OU'_\ '*D7X_\ AYNEGJ?_ 'ZC_P#CE?.\=68ZXI>(
M6>+[4?\ P$XY<-9>NC^\^@E^/.@-_P N>I?]^H__ (NI%^.>@M_RZ:C_ -^X
M_P#XNO XZLQ]JY9>(V?+[4?_  %'-+AW KH_O/>(_C9H4C*#;WZ G[S1)@?D
M]=3H?BO2O$8;[!=K,ZC+1D%7'O@\X]Z^:(^U7].O)]/NHKFVD:&>-MR.O4&N
MK ^*&:4*R^NPC4I];*TK>3O;[U\T>?B.'\.XOV3:?WH^GZ*S/#>KC7M#L[_&
MTS1Y8=@P.&Q[9!K3K^G,/B*>*HPQ%)WC-)I^35U^!^?S@Z<G"6ZT"BBBN@@*
M*** "BBB@#FO'W_(%B_Z[K_Z"U=(OW1]*YOQ]_R!8O\ KNO_ *"U=(OW1]*
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M2<]\HP_ 5\_F>61PU.&(I/W9=.Q[^6YE+$5)8>LO>CU[GOM%%%?.GT84444
M(3@9/2HX[J&9@$EC<XSA6!I9O+=3%(5(<$;6/45\Y'X?WGA_4/&]SH&@_P!B
MWLOC/2VT^ZMK(Q@Z?LL%N-NPJ6A_=3[E! .&]>=(14KW=B6['TC7Y2?M/_";
MX?7WQSNO$?B!-22R\0>*Y?#6M7<=T$&F710&"\48QY;*R$HV<^3+@CBOMGPK
MI_C"'Q]H3ZM_:TEFFH:X9Y#%<_9V#7T)M#M$F$7RO,*;RRA=PQR*^1?CYX'^
M-UQ\>OB,=/\ A#-XX\"ZGJMI>P6UTA^SS2VQ5XIU97#9.7C8=&1B/>O:RU>R
MJNT[:=[=;?\ !.6O[T5='B7PH^ OA^S^)FL:3KUGJ!O_  #Y=[JD]M<;1<W/
MVA88;8*1A0TK1MQR4W=QS^TT*NL2AV#N!AF QD]SCM7Y01^'?VD]=\10RS_!
MJ;0Y-8UW3=2\0ZE9P%6O_LP$:;P93L503(=O)?YNM?K"*,VG*I*$I23]'?M?
M\;_(,,E%.R%HHHKP3L"BBB@ HHHH *I:W_R!K_\ ZX2?^@FKM4M;_P"0-?\
M_7"3_P!!- %/P?\ \BY:?\#_ /0VK9K&\'_\BY:?\#_]#:MF@ HHHH ****
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M6]NRE=L;AI!(6?<=NQ&7Y&W%?ESH5^?$W@:^\!-\-;?6E4>)M4^&_C?7-<<
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MU[0G[+NS_F9L_P#;A_\ ;:L)^S/L_P"9DS_VX_\ VRO.J<%9]+;#_P#DT/\
MY(X9\294]JW_ )++_(\;CJS'7L*_LW[?^9B_\D?_ +94B_LZ[?\ F8,_]N7_
M -LKAEP-Q"]L-_Y/#_Y(XY<098]JOX2_R/)(ZLQ]J]77]GS;_P Q_P#\D_\
M[94J_ /;_P QW_R3_P#ME<<N N(WMAO_ ">G_P#)'++/<N?_ "]_"7^1Y;'V
MJW;QO-(J(I=V("JHR2?2O38_@2JLN[6RRYY"VN#^>^NN\,_#O2O#,HGC5[JZ
M'2:?!*_[H' _G73@?#;/,564<5!4H=6Y1>GDHMW?K8\W$9[@XQ;IOF?HU^9H
M>$=)?0_#=A92?ZV-,N/1F)8C\S6Q117]5X3#4\'AZ>&I?#"*BO1*R/SJI-U)
MN<MV[A111749A1110 4444 <UX^_Y L7_7=?_06KI%^Z/I7-^/O^0+%_UW7_
M -!:ND7[H^E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5S/B[_D(:+_ -?']5KIJYGQ=_R$-%_Z^/ZK0!TU%%% !1110 4444 %%%%
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M^);+1(;R_M8X1(\UK)-&WG6CLR^=&T)E=8B0?,C9"<CGT:;DZ7+;_@=OQO\
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M/ _] ,/_  *?_P D>Y?\*3^'O_14[#_OB/\ ^.4?\*3^'O\ T5.P_P"^(_\
MXY7AM%'U#%_]!<O_  &'_P B']IX'_H!A_X%/_Y(]R_X4G\/?^BIV'_?$?\
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M_P" P_\ D0_M/ _] ,/_  *?_P D>Y?\*3^'O_14[#_OB/\ ^.4?\*3^'O\
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MW_0#E_,_X5TU% ',_P#"2:M_T Y?S/\ A6?KVMZC>:3/#/I4EM$VW,K$X'S
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MX/'3_.*UE\2:M@?\2.7\S_A3O'W_ "!8O^NZ_P#H+5TB_='TH YK_A)-6_Z
M<OYG_"C_ (235O\ H!R_F?\ "NFHH YG_A)-6_Z <OYG_"C_ (235O\ H!R_
MF?\ "NFHH YG_A)-6_Z <OYG_"C_ (235O\ H!R_F?\ "NFHH YG_A)-6_Z
M<OYG_"C_ (235O\ H!R_F?\ "NFHH YG_A)-6_Z <OYG_"C_ (235O\ H!R_
MF?\ "NFHH YG_A)-6_Z <OYG_"C_ (235O\ H!R_F?\ "NFHH YG_A)-6_Z
M<OYG_"C_ (235O\ H!R_F?\ "NFHH YG_A)-6_Z <OYG_"C_ (235O\ H!R_
MF?\ "NFHH YG_A)-6_Z <OYG_"C_ (235O\ H!R_F?\ "NFHH YG_A)-6_Z
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M 2<OUYZ?YQ6Q_P ))JW_ $ Y?S/^%&K?\CEI7_7,_P#LU=-0!S/_  DFK?\
M0#E_,_X4?\))JW_0#E_,_P"%=-10!S/_  DFK?\ 0#E_,_X4?\))JW_0#E_,
M_P"%=-10!S/_  DFK?\ 0#E_,_X4?\))JW_0#E_,_P"%=-10!S/_  DFK?\
M0#E_,_X4?\))JW_0#E_,_P"%=-10!S/_  DFK?\ 0#E_,_X4?\))JW_0#E_,
M_P"%=-10!S/_  DFK?\ 0#E_,_X4?\))JW_0#E_,_P"%=-10!S/_  DFK?\
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M@ERARA;Y>=IZ9Z=J;<8O+>X@G\'V\\-Q+Y\T<D 99)!CYV!7EN!R>>!7<44
M<5<R->>9]H\)0S^9!]F?S(0VZ'KY9RO*?[/2I['5;W2[6.UL_#?V2VC&$A@7
M8BCV 7 KKJ* .9_X235O^@'+^9_PH_X235O^@'+^9_PKIJ* .9_X235O^@'+
M^9_PH_X235O^@'+^9_PKIJ* .9_X235O^@'+^9_PH_X235O^@'+^9_PKIJ*
M.9_X235O^@'+^9_PJOJ/B#4YM/N8Y-'DBC:)E:0D_*"#D]*ZZJ6M_P#(&O\
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M^?T?_ E_F?,?V5F'_0//_P !E_D<#17??\*%\?\ _0LW7_?2?_%4?\*%\?\
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M@L.GVR06B/G?Y< C\M"VXY8+DYZU+_PH7Q__ -"S=?\ ?2?_ !5'_"A?'_\
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M_L?Y'_"C_A*-*_Y_8_R/^% &K165_P )1I7_ #^Q_D?\*/\ A*-*_P"?V/\
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M4:5M'^FQ_D?\*A^%^#?_ #$R^Y$_ZU5O^?2^]GS:O@W7\?\ (#U+_P !)/\
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M_"C_ (2C2O\ G]C_ "/^% &K165_PE&E?\_L?Y'_  H_X2C2O^?V/\C_ (4
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M ,_J?D?\*/\ A)]*_P"?U/R/^%!/.[6-:BLK_A*-*_Y_8_R/^%'_  E&E?\
M/['^1_PH,S5HK*_X2C2O^?V/\C_A1_PE&E?\_L?Y'_"@#5HK*_X2C2O^?V/\
MC_A1_P )1I7_ #^Q_D?\* -6BLK_ (2C2O\ G]C_ "/^%'_"4:5_S^Q_D?\
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M?^^:TJ* ,W_A'=,_Y\8?^^:/^$=TS_GQA_[YK2HH S?^$=TS_GQA_P"^:/\
MA'=,_P"?&'_OFM*B@#-_X1W3/^?&'_OFC_A'=,_Y\8?^^:TJ* ,W_A&]+R3]
MBAY]J/\ A'=,_P"?&'_OFM*B@#-_X1W3/^?&'_OFC_A'=,_Y\8?^^:TJ* ,W
M_A'=,_Y\8?\ OFC_ (1W3/\ GQA_[YK2HH S?^$=TS_GQA_[YH_X1W3/^?&'
M_OFM*B@#-_X1W3/^?&'_ +YH_P"$=TS_ )\8?^^:TJ* ,W_A'=,_Y\8?^^:/
M^$=TS_GQA_[YK2HH S?^$=TS_GQA_P"^:/\ A'=,_P"?&'_OFM*B@#-_X1W3
M/^?&'_OFC_A'=,_Y\8?^^:TJ* ,W_A'=,_Y\8?\ OFC_ (1W3/\ GQA_[YK2
MHH S?^$=TS_GQA_[YH_X1W3/^?&'_OFM*B@#-_X1W3/^?&'_ +YH_P"$=TS_
M )\8?^^:TJ* ,W_A'=,_Y\8?^^:/^$=TS_GQA_[YK2HH S?^$=TS_GQA_P"^
M:/\ A'=,_P"?&'_OFM*B@#-_X1W3/^?&'_OFC_A'=,_Y\8?^^:TJ* ,W_A'=
M,_Y\8?\ OFC_ (1W3/\ GQA_[YK2HH S?^$=TS_GQA_[YH_X1W3/^?&'_OFM
M*B@#-_X1W3/^?&'_ +YH_P"$=TS_ )\8?^^:TJ* ,W_A'=,_Y\8?^^:/^$=T
MS_GQA_[YK2HH S?^$=TS_GQA_P"^:/\ A'=,_P"?&'_OFM*B@#-_X1W3/^?&
M'_OFC_A'=,_Y\8?^^:TJ* ,W_A'=,_Y\8?\ OFC_ (1W3/\ GQA_[YK2HH S
M?^$=TS_GQA_[YH_X1W3/^?&'_OFM*B@#-_X1W3/^?&'_ +YH_P"$=TS_ )\8
M?^^:TJ* ,W_A'=,_Y\8?^^:&\-Z6PP;*'\!BM*B@#-'AO3!Q]AA_[YH_X1W3
M/^?&'_OFM*B@#-_X1W3/^?&'_OFC_A'=,_Y\8?\ OFM*B@#-_P"$=TS_ )\8
M?^^:/^$=TS_GQA_[YK2HH S?^$=TS_GQA_[YH_X1W3/^?&'_ +YK2HH S?\
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M'=,_Y\8?^^:TJ* ,W_A'=,_Y\8?^^:/^$=TS_GQA_P"^:TJ* ,W_ (1W3/\
MGQA_[YH_X1W3/^?&'_OFM*B@#-_X1W3/^?&'_OFC_A'=,_Y\8?\ OFM*B@#-
M_P"$=TS_ )\8?^^:/^$=TS_GQA_[YK2HH S?^$=TS_GQA_[YH_X1W3/^?&'_
M +YK2HH S?\ A'=,_P"?&'_OFD/AO2VQ_H47'M6G10!F_P#".Z9_SXP_]\T?
M\([IG_/C#_WS6E10!F_\([IG_/C#_P!\T?\ ".Z9_P ^,/\ WS6E10!F_P#"
M.Z9_SXP_]\T?\([IG_/C#_WS6E10!F_\([IG_/C#_P!\T?\ ".Z9_P ^,/\
MWS6E10!F_P#".Z9_SXP_]\T?\([IG_/C#_WS6E10!F_\([IG_/C#_P!\T?\
M".Z9_P ^,/\ WS6E10!F_P#".Z9_SXP_]\T?\([IG_/C#_WS6E10!F_\([IG
M_/C#_P!\T?\ ".Z9_P ^,/\ WS6E10!F_P#".Z9_SXP_]\T?\([IG_/C#_WS
M6E10!F_\([IG_/C#_P!\T?\ ".Z9_P ^,/\ WS6E10!F?\(WI>X'[%%Q[4O_
M  CNF?\ /C#_ -\UI44 9O\ PCNF?\^,/_?-'_".Z9_SXP_]\UI44 9O_".Z
M9_SXP_\ ?-'_  CNF?\ /C#_ -\UI44 9O\ PCNF?\^,/_?-'_".Z9_SXP_]
M\UI44 9O_".Z9_SXP_\ ?-'_  CNF?\ /C#_ -\UI44 9O\ PCNF?\^,/_?-
M'_".Z9_SXP_]\UI44 9O_".Z9_SXP_\ ?-'_  CNF?\ /C#_ -\UI44 9O\
MPCNF?\^,/_?-'_".Z9_SXP_]\UI44 9O_".Z9_SXP_\ ?-'_  CNF?\ /C#_
M -\UI44 9O\ PCNF?\^,/_?-'_".Z9_SXP_]\UI44 9A\-Z62#]BBX]J7_A'
M=,_Y\8?^^:TJ* ,W_A'=,_Y\8?\ OFC_ (1W3/\ GQA_[YK2HH S?^$=TS_G
MQA_[YH_X1W3/^?&'_OFM*B@#-_X1W3/^?&'_ +YH_P"$=TS_ )\8?^^:TJ*
M,W_A'=,_Y\8?^^:/^$=TS_GQA_[YK2HH S?^$=TS_GQA_P"^:/\ A'=,_P"?
M&'_OFM*B@#-_X1W3/^?&'_OFC_A'=,_Y\8?^^:TJ* ,W_A'=,_Y\8?\ OFC_
M (1W3/\ GQA_[YK2HH S?^$=TS_GQA_[YH_X1W3/^?&'_OFM*B@#-_X1W3/^
M?&'_ +YH_P"$=TS_ )\8?^^:TJ* ,W_A'=,_Y\8?^^:/^$=TS_GQA_[YK2HH
M S?^$=TS_GQA_P"^:/\ A'=,_P"?&'_OFM*B@#-_X1W3/^?&'_OFC_A'=,_Y
M\8?^^:TJ* ,W_A'=,_Y\8?\ OFC_ (1W3/\ GQA_[YK2HH S?^$=TS_GQA_[
MYH_X1W3/^?&'_OFM*B@#-_X1W3/^?&'_ +YH_P"$=TS_ )\8?^^:TJ* ,W_A
M'=,_Y\8?^^:/^$=TS_GQA_[YK2HH S?^$=TS_GQA_P"^:/\ A'=,_P"?&'_O
MFM*B@#-_X1W3/^?&'_OFC_A'=,_Y\8?^^:TJ* ,W_A'=,_Y\8?\ OFC_ (1W
M3/\ GQA_[YK2HH S?^$=TS_GQA_[YH_X1W3/^?&'_OFM*B@#-_X1W3/^?&'_
M +YH_P"$=TS_ )\8?^^:T6;;2;@:5P,__A'=,_Y\8?\ OFC_ (1W3/\ GQA_
M[YK1W4;J+@9W_".Z9_SXP_\ ?-'_  CNF?\ /C#_ -\UHTM,#-_X1W3/^?&'
M_OFC_A'=,_Y\8?\ OFM*B@#-_P"$=TS_ )\8?^^:#X;TP\?88?\ OFM*B@"*
MUM8K.!88$$<2]%'09.:EHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBJDVKV-O]J\V]MXOLJAKC?*H\
MD$9!?GY00.] %NBJTVI6EO9?;);J&*TVAOM#R 1X.,'=G&#D?G6?=>,_#]E<
M207&NZ;!/&VUXI;R-64CL03D&@#9HK&?QEX?CMXKA]=TU8)2RQRM=QA7*XW
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M)#V(^5NF <;N3$Y-B,/!U$U)+MN>A@\_PV*J*DTXM[7V/L&BBBO!/I@HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/^3EOA2/^F%[_P"@&E_:W_Y$GPQ_V,MC_P"A/0!VWQ<^%>G_ !2\*R:==O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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1%'; [45T?DKNSSGZT4 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ino-20201231_g5.jpg
<TEXT>
begin 644 ino-20201231_g5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '3 IH# 2(  A$! Q$!_\0
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MB:0@1\ G(W9S\V.*T>#J17O2UUT]$G^H1K4)/W8*VG1=7;]#O_\ AG'X7_\
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MD)DJ% /S$GDG@#%8WC+XS>-VUSXB?\(AIV@G2/ ,:-J/]LM-Y]_(8?.=(BA
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M;YDAXX!SC-5=/^/'C/QQ>_#BQ\+Z7H=E=^+?#L^KRMJS2O':21LH.-A!=>2
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M.=0D[73>]]$K_H6ZE#D<XPO:RVZMI+\UZ'4M^S?\,5.#X%TD'WC;_P"*I/\
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MU52C*FZD()J\5LOM<OY7^_0[G_AG'X7_ /0CZ3_W[;_XJC_AG'X8?]"-I/\
MW[;_ .*KSGP?^U#J=Z?!FH^)-/T_2M U.;4](U2XA+G[/J5IN*E')QY4BHV
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M-QJ<^KD7'Q)DAO+>VN97NC";A]]NK(VYCC*A5/) QVK2G@IU%%\V_+^/E?\
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M%R7=1NJ+=1NH"Y+NHW5%NHW4!<EW5ROQ81YOA=XOCB1Y)&TFZ54C4EF)B;@
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MU'%6=_UI/6W]=+!?^OG<^.?AC^S_ *WXNU#PO#K-O#H5AIO@[PTMU<WFAYU
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M?^&?^P7:_P#HI:TC\)Y=;_>/^W?U9ZA^R5_R;[X5_P"WC_THDKUB5OFKR?\
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M#_PM+Q]_T,MM_P""F+_&C_A:7C[_ *&6V_\ !3%_C7/45[/U##?R'D_6J_\
M._O.A_X6EX^_Z&6V_P#!3%_C1_PM+Q]_T,MM_P""F+_&N>HH^H8;^0/K5?\
MG?WG0_\ "TO'W_0RVW_@IB_QH_X6EX^_Z&6V_P#!3%_C7/44?4,-_('UJO\
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MFT8*]ZV/,,0:X6+#$,"F=Q VASO #*JY:H> PD=XO_P*7^9K'&8R6U1GHO\
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M ">OH&OGL5A:=/$2A&Z5EU?^9]/EM:I7HN523;O_ )'&_P#"*^+_ /H?6_\
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MO]Y?S%&]?[R_F*]-_P"&:?!W_0/B_P"_8H_X9I\'?] ^+_OV*/[87_/O\?\
M@!_9DOYD>9;U_O+^8HWK_>7\Q7IO_#-/@[_H'Q?]^Q1_PS3X._Z!\7_?L4?V
MPO\ GW^/_ #^S)?S(\RWK_>7\Q1O7^\OYBO3?^&:?!W_ $#XO^_8H_X9I\'?
M] ^+_OV*/[87_/O\?^ ']F2_F1YEO7^\OYBH;JUM+Z-4N8;>Y16#A9T5P&'0
M@'//O7J?_#-/@[_H'Q?]^Q1_PS3X._Z!\7_?L4?VPO\ GW^/_ #^S9_SH\EM
M]'TVU;?':V_F>>]T)'56<3.<LX8\ACZCL *>VEZ<\,L365DT4LGFR1F%"KO_
M 'V&,%O<\UZO_P ,T^#O^@?%_P!^Q1_PS3X._P"@?%_W[%+^UU_S[_'_ ( _
M[-G_ #GF7F+_ 'U_[Z%&]?[R_F*]-_X9I\'?] ^+_OV*/^&:?!W_ $#XO^_8
MI_VPO^??X_\  %_9DOYD>9;U_O+^8HWK_>7\Q7IO_#-/@[_H'Q?]^Q1_PS3X
M._Z!\7_?L4?VPO\ GW^/_ #^S)?S(\RWK_>7\Q1O7^\OYBO3?^&:?!W_ $#X
MO^_8H_X9I\'?] ^+_OV*/[87_/O\?^ ']F2_F1YEO7^\OYBC>O\ >7\Q7IO_
M  S3X._Z!\7_ '[%'_#-/@[_ *!\7_?L4?VPO^??X_\  #^S)?S(\RWK_>7\
MQ1O7^\OYBO3?^&:?!W_0/B_[]BC_ (9I\'?] ^+_ +]BC^V%_P ^_P ?^ ']
MF2_F1YEO7^\OYBC>O]Y?S%>F_P##-/@[_H'Q?]^Q1_PS3X._Z!\7_?L4?VPO
M^??X_P# #^S)?S(\RWK_ 'E_,4;U_O+^8KTW_AFGP=_T#XO^_8H_X9I\'?\
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MY^'_  2MO3^^O_?0HWI_?7_OH59_X9I\'_\ /A'_ -\"C_AFGP?_ ,^$?_?
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MO1N]Z N3;J-U0[O>C=[T!<FW4;JAW>]&[WH"Y-NHW5#N]Z-WO0%SS']J)L_
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M_DG_ (9_[!=K_P"BEKMOVFFS\#?$_P#NP?\ H^.N)^'?_)/_  S_ -@NU_\
M12UHOA.&7\?Y?J>H?LE?\F^^%?\ MX_]*)*[_6C_ *<?]U:X#]DK_DWWPK_V
M\?\ I1)7>:Z?^)@?]Q:B7Q,[*?\  AZ+\CQ/XL>!O'NN^(-7N/"4^DK9:MH(
MT>=M0O)H9+=A*[^;$$4C=A@,GTKN/ <WC)K&9/&5OHUO<1>6ELVCW$LP= N&
M,AD48.0.GO72;J-U;RK.5-4VEIUZG.J24W43?Z$F[WHW>]1[J-U8&]R3=[T;
MO>H]U&Z@+DF[WHW>]1[J-U 7)-PYYZ=>:1I55"[.JH!N+$X 'KGTKQ/XRP:K
MH_BHIH\-P_\ PGNG+X8EDMT9A;72R$QW#D?< MI;KYC@9B0=Q7.^(/B)J^FZ
MUJ/@.V-ZA@URZL8[)=,<QKH?]D2-;_O1'LVF50 V[<6!7VI=+_U_6S]"U&[_
M *_KNO4^C8YDFC22.19(W 971MRL#R"".H/K3MWO7SGX5\8>,/#]GX?\,QPZ
MA);P^'K3Q!#);6"NXL8=."26(W+M,INU0!6.XJY["M?]EGXA^*O'FF^+/^$E
MNI=1AL[RW.G7TT6UI(I8 [H6^S6X<H^Y3B/Y3E=SXS5M6;7;_AB.B9Z]XP19
MO"NJQODJULX."0<8]1R*^=1X?L,?ZN;_ ,"YO_BZ^B?%3?\ %-ZG_P!>[_RK
MP>OH<JA&4)<ROJ>+F#=XF=_PC]A_SSF_\"IO_BZ/^$?L/^><W_@5-_\ %UHT
M5[GL:?\ *ON1Y/,^YG?\(_8?\\YO_ J;_P"+H_X1^P_YYS?^!4W_ ,76D.HK
MS[3_ !).M[XFDANM0*R2"RTNSU*&7<UV%D^==R "-V   .,1[C@-S$H4H_97
MW(N*E+J=?_PC]A_SSF_\"IO_ (NC_A'[#_GG-_X%3?\ Q=>7R:EXH,)\JYUP
MV#6I:VF:*3SVU'R(R(GRN1%YN\8(V9!&< 5T_@B[\07&NR#5#=;O(N/M\,RL
M+>&<3@0"#(P5,63\I(/!/-)1I-VY%]R+<9)7N=3_ ,(_8?\ /.;_ ,"IO_BZ
M/^$?L/\ GG-_X%3?_%UHT5I[&G_*ON1CS/N9W_"/V'_/.;_P*F_^+JGJFB6D
M*6903KOO;:-L7<W*M,BL/O\ <$C\:W:H:Q_J[#_L(V?_ */2N7%T:?U>I[JV
M?3R'S/N=JW@70@Q'V%O_  *F_P#BZ/\ A!="_P"?%O\ P*F_^+JC\3+O5K31
M+8Z5(\ DO8X[RXBCE=X;<A]S 1?O/O! 2G(#$\=:\_U+6O'DUO/-9VVK6>L[
M%8:<0TL,=F;-2SAB-KSB?<!D[\C!&*Y)8;"Q;7LH_P#@*_R.&/M9)/G_ !/4
M(_ N@M(H-@V"0/\ CZF_^+KL/A'\*_"NN?#?0K_4-(%Y>W$3M+-+<S%F(E<#
M/S^@%<3\/IKR:SO#<2W=Q9C491ITU_N^T26GR[&?> WWMX!89P!FO4/A3#JM
MQ\&_"ZZ1>6EE<^6Y:2\MFG0KYLF0%5T(.<<Y_"O&S##4%.ERTTKI]%_=/:RE
MRE4FIN]D9WP]ACTV;Q3I=N&2RL-<N8+:)G9_+CPA"@L2< D_G77[O>O,?"5G
MXI.M>,1#J^DHZZY<"8OILC!WVIEE'G#:.G'/UKT+2TO8[2)+^>"YN\G?+!$8
MHVYXPI9L<8[UY-))4U9GT29<W>]&[WKPYO$6KWVJ:K-!J/B:#PP=62WG1K>X
M%]!&D,X::,^7N6*2<0J%3.%0,=HD-7?AWJ?CBY\2:4GB$Z@E]F1=3M9(RMFE
MK]DC,,B8&SS3/N!VG=G>", 5LE<IZ'LF[WHW>]1[J-U(5R3=[T;O>H]U&Z@+
MDF[WHW>]1[J-U 7)-WO1N]ZCW4;J N2;O>C=[U'NHW4!<DW>]&[WJ/=1NH"Y
M)N]Z-WO4>ZC=0%R3=[T;O>H]U&Z@+DF[WHW>]1[J-U 7)-WO1N]ZCW4;J N2
M;O>C=[U'NHW4!<DW>]&[WJ/=1NH"Y)N]Z-WO4>ZC=0%R3=[T;O>H]U&Z@+DF
M[WHW>]1[J-U 7)-WO1N]ZCW4;J N2;O>C=[U'NHW4!<DW>]&[WJ/=1NH"Y)N
M]Z-WO4>ZC=0%R3=[T;O>H]U&Z@+DF[WHW>]1[J-U 7)-WO1N]ZCW4;J N2;O
M>C=[U'NHW4!<DW>]&[WJ/=1NH"YYK^TNW_%C_$_^Y!_Z41UQOP[_ .2?^&?^
MP7:_^BEKL/VE3_Q8_P 3_P"Y!_Z/CKC_ (=_\D_\,_\ 8+M?_12U:^$XY?Q_
ME^IZA^R5_P F^^%?^WC_ -*)*[G7S_Q,F_W%KAOV2O\ DWWPK_V\?^E$E=KX
MB;;JC?[B_P JE_$SKA_ AZ+\BED49%1;O>C=[T$DN11D5%N]Z-WO0!+D49%1
M;O>C=[T 2Y%&146[WHW>] $P<KD D9&#[TOG.%VAVV_W<G%0;O>C=[T 3>82
M"-QP3GKW]:5YFD.7=G/^T<U!N]Z-WO0!F^+IX[?POJLLC;(X[:1F;!X 4DFO
MG+_A.-!_Z"<7_?#_ /Q-?3-VJ3V[QR8,;#:P/3!ZUB_\(CH/_/O;_F*[\+C)
MX5.,5>YR5\.J]FW:QX#_ ,)QH/\ T$XO^^'_ /B:/^$XT'_H)Q?]\/\ _$U[
M]_PB.@_\^]O^8H_X1'0?^?>W_,5V_P!K5?Y4<OU"/\WX'@/_  G&@_\ 03B_
M[X?_ .)I&\;: Y4MJ4+%>5+1N=O&./EXXKW_ /X1'0?^?>W_ #%'_"(Z#_S[
MV_YBC^UJO\J#ZA'^;\#P'_A.="_Z"D?_ 'R__P 31_PG&@_]!2/_ +X?_P")
MKW[_ (1'0?\ GWM_S%'_  B.@_\ /O;_ )BC^UJO\J#ZA'^;\#P'_A.-!_Z"
M<7_?#_\ Q-'_  G&@_\ 03B_[X?_ .)KW[_A$=!_Y][?\Q1_PB.@_P#/O;_F
M*/[6J_RH/J$?YOP/ ?\ A.-!_P"@G%_WP_\ \35+5/&6B2QV>S48VV7MM(WR
M/PJS(S'[O8 G\*^B_P#A$=!_Y][?\Q39/!OA^08:VMS^(K*KF56K3E3Y5JK!
M]0C_ #?@>=?\+2\)[B1KUM_WR_\ \31_PM+PG_T'K?\ [Y?_ .)KT8>$= ''
MV>W_ #%+_P (CH/_ #[V_P"8K'^T<3_=^Y__ "1S?V32_G?X'G,?Q2\)"16.
MO6W7).U__B:[#X1_&KP+H?PVT*PO_$UG:7MO$ZRPR!]RDRN1GY?0BM4^$- 8
M8-M;_F*1/!OA^,8%M;C\17%B*U?$.,I-*U^CZV_O>1WX3"1PC;A*]^Y3^'6J
M6NM7?BS4K&7[187FMW$]O.H(66,A &&1TR#^5=GD5GV,-GIT(BMVBCC'8,*L
M?:8O^>T?_?0K"G#DBHG?<L^8>/F/YTF[C&>*K_:8O^>T?_?0H^TQ?\]H_P#O
MH587+&11D57^TQ?\]H_^^A1]IB_YZQ_]]"@+EC(HR*K_ &F+_GM'_P!]"C[3
M%_SVC_[Z%&@7+&11D57^TQ?\]H_^^A3]_O0%R7(HR*BW>]&[WH ER*,BHMWO
M1N]Z )<BC(J+=[T;O>@"7(HR*BW>]&[WH ER*,BHMWO1N]Z )<BC(J+=[T;O
M>@"7(HR*BW>]&[WH ER*,BHMWO1N]Z )<BC(J+=[T;O>@"7(HR*BW>]&[WH
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ML_\ OPO^%'_"*Z+_ - FS_[\+_A6I11[.'9 9?\ PBNB_P#0)L_^_"_X4?\
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M_H'ZK_X!'_&C_A-[3_H'ZK_X!'_&O7O^$M\!?]!S1/\ P*C_ ,:/^$M\!?\
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M<Y-NHW5#NHW4 4_$GB;3?".BW&K:Q=I8Z?;[=\S*S'+$*JJJ@LS,Q "J"22
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MI_<7_OD5Z[K#9TB__P"O>3_T$UY)7T>4_!/U/*QOV1/+3^XO_?(H\M/[B_\
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M[J-U $VZC=4.ZC=0!P?[01_XLUXF_P"N</\ Z/CK%^'?_)/_  S_ -@NU_\
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M>6?2N*_X6J/^A9U;_OJW_P#CM'_"U1_T+.K?]]6__P =H^K5_P"1_<'M:?\
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M1_<'M:?\QVOEGTH\L^E<5_PM4?\ 0LZM_P!]6_\ \=H_X6J/^A9U;_OJW_\
MCM'U:O\ R/[@]K3_ )CM?+/I1Y9]*XK_ (6J/^A9U;_OJW_^.T?\+5'_ $+.
MK?\ ?5O_ /':/JU?^1_<'M:?\QVOEGTH\L^E<5_PM4?]"SJW_?5O_P#':/\
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MB_X16S_OS?F/\*/^$5L_[\WYC_"CZY7_ )V'U&G_ "GR[_PK/QO_ -!>V_\
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M +\WYC_"D_X16S_YZ2G_ ($/\*/KE?\ G8?4:?\ *?+W_"L_&_\ T%[;_P
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MS'^%'_"*V?\ ?F_,?X4?7*_\[#ZC3_E/EW_A6?C?_H+VW_@&G^-'_"L_&_\
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M5>T?\(K9_P!^;\Q_A2?\(K9_\])<_P"\/\*R]G#S^]_YG3[.?],\8_MSXO\
M_0=TO_P5)_\ %5%):?$#Q5=:=#XEUFSGTVUNX[WR;:P2)G>,DJ"P/ YKVW_A
M%;/^_-^8_P */^$5L_[\WYC_  H]E#S^]_YB]G/^F<?Y=&RNP_X16S_OS?F/
M\*/^$5L_[\WYC_"MN9"]E(\*_:(7'P7\3?\ 7.'_ -'QUS_P[_Y)_P"&?^P7
M:_\ HI:] _:CT*WT_P" _BB:)I"X%NOS$8YN(_:O/_AW_P D_P##/_8+M?\
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M\5NBRG[.&4,0[-*0=HP1DU] ^(?#VE^+-#OM%U?3X-0TB]B,%Q93INCDC/\
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M7^'_ (Z>.?[7TE?$/AG0+;26\4/X.OY].U":29KP!MMS"C( (,J 4<[^2<X
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M-\3O%\OBJ\\+R^$;*WN-/T2'5=9U*UUHF*S$WVE5CMMT ::0& ,"RHN"<\@
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MVY?FO2V_9Y\+7'@KQ5X9O[K7-7M_$YC?4[_4=4DFO9)(T18Y$F/,;*(T(V@
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MKA]8^+UWX1\2>*+=;'6/%D[^)++0=/TB 6T(@DEL%G&R0[<QDY9FD)*DG'
MKKM"\):]I'BRPFF\2WE_X>L-(>T%O=,C37UW)*':XFV(JKY:(%0( /WCY P*
M;<?"?2+GQ)-K;W%X+J37+?7R@==@N(;3[*JXVYV%.2,YW=\<4]+^7_!7Z$?U
M^!RG_#05Q<Z?I-GI_@G4KWQM?WM[IY\-&\@C%O)9[3<N]T3Y?E@/'M8 EO,4
M8'.,RS^,FH>'_B=XHM=:M;Y[:ZU7P[I-GI331G^S9;VW8R9(R& <9;:3G'%=
M1KGP'TO5+Q-1L=>USP]KL.JW>JV^K:9+%YT+72JMQ#MDC>-HF"+PRD@JI!!
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M^6P;!&*X7P_^SOK>C?!?Q9I-K'=V.N:WXI@N[.-9XC<:;I=OJ,9M8D<Y0^5
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M"'XJ:UXD^,_B7PI+XLT[QGI-AIWVN>XATDZ;+IUV+CR_LRJS$SQE0QWX.TH
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M&,L)%(&5P:T_%O[5GA3P)JBZ=K^G:EIE[;6T%WK$$T]EOT>.8GR_.7[1F5L
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M^\+>,K>TD\UKF)M!E\VPCC^_+<+G"(!\P()+#) .#6;XM_9_M]<FOY=)U?\
ML!UMM%CTCRK42KI\VFS2RP.5+ 2(?,"E/E^4'!R01S?Q2_9GUOXP6>GGQ-XP
MTG5;Y+&[L+F.^\-B>QC$[*1/:6S3XBGC"[5DD:0X)IOR!6OKY?\ !._\!^.[
MKQ9\1O'FF"X@N=$TM-+ETV2),$I<VQE=BW\0)P1Z"HI/CIX>M-6UG3]1L->T
M5]-LKK45FU32Y+>*]M[8 SO;EO\ 6; 5." 2&!&1S5OX<?#$?#[7-<U$:E]O
M&IVVF6WEF'9Y?V2V\C.<G._[W;'3FO*= _8__L;6=6OY?$MC=3WFF:MI8U!=
M$":E<+?8_>7ET92UP\9&% "+@= :J=N9\NW_  - T:5]]/\ @G?Z;^TAX*OM
M'UK5+E]5T6RTJQBU1FU?2YK9[FSD.V*>!&&Z16?Y  -VX@8^89A^$_Q>N_B5
M\2O'&E&PO])TW1K/3)(;#6-.:SO(99Q<&3S WW@1'&01D=>>N%\=? >+QU8S
M6TVNS6!;P];Z+%/! K/#-!<I<17(#'!Q)&F4/4 \UJ?#GX=:[X7\8>)?%/B3
MQ-;^(M7UVVLK>5;/3OL5O;BV\[ C4R2-AO.S\S$Y!YQ@!.U]/ZW)Z#(_CIX>
MCU+6[&_L=>T272["YU3=JVE26RWEK;X\^2WW<N%W+P0"=P(!!S3/#?QZ\.^*
M[;5)+#3O$7G65E%J4=G/HL\=S?6DAVQSVT1&Z1&8%>@([@#!KS?PK^Q__P (
M[J6KWDOB/3[F>]T75-$^W1:&(M0N5O"I\^]N3*S7,J%<=%4CH!7;?$'X$2>.
M=-FMH_$,FFR/X?MM#$BVY=6\FY2?=( ZEHY-GEO&",H[#<,T:67]=_\ @?>5
MI?3^MO\ @A)\:E\0S>"FT&*ZT_[;XJ_L'6-/UBR,-W;8LYIS&R$_(QVPL&!(
M*M[UT?BSXN:-X3\56?AQK'6=9UF>%+J6VT339+PV=N[E%GG*\1H65@.I.UB!
M@$UQ'P]_9K3P+!IJIJFF1&U\5?\ "4/:Z-HRZ?9JWV(VIMX85D;8O._<2Q/.
M<DYKJ-?^&>NO\2I/%_ACQ7%X?DU&QMM.U>VN=,6\\^*"21XG@8R+Y4@\Z126
M#J0P.W(HTT_KHOU%_7XO]"Q)\:-#M?%EUX?OK#7-*N(H;F:WNM0TR2&VOEMU
MWS"WD/WRJ@MT 8#*DBLK0/VD_!&O:;J6I/+JFC:;9Z2-=%YK.F36L=U88&;B
M#<,R*"RJ0!NRRX!# GC-+_9+_L_X@77B67Q#87+N=5V7)T4?VI.M\DB[;J\,
MI,JP^9A%547:H!&1FNK\2?L^VOBSPK8:#?:S,EO;>%&\,F>"$"3=NMW2Y7)(
M!5K93L.0<X)I=-?ZW_X!?N_U\O\ @ER;]H#1+71[6ZN/#_BRUU"]N7MK'0I]
M$D34;PH@D>2*$GF-4.2Y( Z'#$"I(_V@_"-Y=>&[;3?[5UF;7[5KZT73]-ED
M\NW280RR3\#R1$[8??@C!&">*Y7QY^SMK7Q2L=#N_%_B+P[XD\1Z+<3R6G]I
M>%EFTDPRQK&\<EHTY8L2BR>8)00P( "G%=CX*^$:>#-8TC4+:[L;8:?H,FBB
MTTO3$LK8,]P)_-CB5B$ ((V<YSDGK1U_KM_F3I;^N_\ D:_PZ^)6F?%#2Y=3
MT>SU6'305-M>:C8O;Q7T3#*30,WWXR._!Z9 R*Y_X]_$"]^&OA%=8M?%?A3P
MDJF3]_XJADE2ZD"%D@B5)8SN;:W(+'T4US_AOX3^,OANU_<:%JNDW&I:]JMB
M+J/3]+^PZ996L<C/<W/V8S/FXEC)0LA +&,[?E)KO_B+X<\3>)+..W\.:[I&
MCQ.LD5U%K.B_VE'*C#&57S8]K 9'.Y3GD5,KVT'&W-KL>77_ ,9/B'X@LYSX
M;T;1=%U'1/"=GXFUK3]<26=I+BXCE==/B:-T\O @?,S!\%D&P\UE>&?VJ-6U
M;Q)>2SZ(KZ/<V:RZ9I$5E/%?"61(&LU:X<^3+]I\V0@(!Y:PNS$A6QL6_P"R
M[>>%]$M=(\&^-YM%LYO#5OX5U:2_T];R:ZMH?-\N>%@Z"&<">502'0!E&WY1
M77:W\#+'7-+GTF34YX-)MO#S>'=$MXDS_9D;PF&6?)/[R5EVKDXP@*C[[$V[
M7;7G^O\ P+"5K)/^MO\ @W.ITGQ5!9_#Z+Q'KVLZ3);V]BUYJ&J:=)FQ0(I:
M5D;+91<$9SD[?7BO)OB#^U=IVC_#/QCJ^A:)K\?B32]).IV&FZOHLL+W,#,(
MTNUC8@O KLN_D,H(W 9%=3X;^ ]I8_"'Q1X%UB]MYX?$GVHWLFB6*Z?;P>?&
ML9%M!N<1A0H;!)RQ8GKBL'6?V=]?\;:7KJ^+_',&KZO=^'Y/#=A>66CBTBMK
M>22.2262/S7,DSM%'DAE4;?E49-3+6]OZ_IV$M%Y_P##?\$[6Q\>)X+^%&E>
M(/&5[?RW+1PQR&?2OLU]<W$KA8H19QEL2LS*HC4GG\:QY/VE/"4&B_;)[3Q!
M;ZBNIQZ,^@2:1+_:<=Y)"T\41@'/[R-2RL"5/]X8..E^*/P_/Q&\-VMC;ZF^
MBZII]_:ZKIVHK")A!=6[AXR\9(#H>59<@D,<$'!KE-!^!M];^)H/%.N>)(M4
M\3R:Y!K-]<6FG_9K:1(+*:TAMH8C(Y1569F+,SDDGMC%:-N_];?\$-++^M?Z
ML7=0_:*\):7K7V"ZBUJ*&&:"TO\ 5/[+E-CI=S,(S';W4P^6.0^;$".0I=0Q
M&:EM_P!H3PC-XPCT IK,9;5Y- ;5)-+E73TU!6*_9C<8V[V(^7'!) R"0*Y_
MQ%^SS?:YJ'B33HO%BVO@/Q-J\>M:OHC::'NFG4Q-)'#=>8 D4C0(6!C9AEMK
M#(QF^%_@WXIUS7+]M>U]K'PG!XXNO$D.AG3E%S.\=R9;8BY$F! SA92ICWDC
M&X+Q1&SM?^MO^#8<K*]OZW_X%S1^"O[1%IXZT;1K36K?4XM?O+>[E6Z&DRQ6
M5ZUO*XECMGQB1T502HZX.TM@XVO^&BO"EKH?B+4]6M==\/+H*V\M[9ZMI,L-
MUY,\OE0S)%RSHSAAQ\P*G(!J"W^!#0^#?"F@#Q'<P'0H-2@%_:1>7,WVN&:(
M/&=Q\MX_.W \\J.E<;X+_9''A32]?MSK>CPSZM;Z7;.VB: +"/\ T*Z,XED'
MG.TLLF<,[-G/(XXIJU]=@E:UT>@I\?/#,>D^([W4+;6=$DT"S@O[W3]4T]H+
MORIV=82D627+O&R #G=@=31IWQ^\+:IXP7P[%%K,<QU*;13J$VF2I8"_CR3:
M^>1M\PA6(QD'&,@\5S_Q<^%EUX[^.?PVU2W@N(](M1/+X@F51Y%S!;R1W%E;
MN3SN%UMD4 ?=23/6NA;X2R0:6(8M3\Z6'Q7-XK13%MWLTDD@M\Y^7E\;_;.V
MITM=_P!:_P"5P?9?UI_G^9CZ7^U-X)U/5;JW:#7=/TV#2Y]:77;_ $IX=/GL
MHF57GBE)RZEF4+A<MN7 Y&=C2?CMHFM:7K$]MHWB8ZEI0A>?07T:4:DT<I80
MRI#WC?8^'R -K;MN*^:_@G^S_KNIZ+K7@O7O#5YI.D:]H<UAXAU/4]$@M+BU
MN 4:%+6=9G%VGF;V;Y%1M@8X+8KU5?V4/^*'U'18[KP?I%W<WUI=L=!\(K8V
M-ZENS$07T"S[KF-]YW+O0 @8'4$_K\?\AZ?UZ'76OQE'BCQI\.(-!:2+2-<D
MU>WU*UU"T,5U!-:1 ^4RGF-TDW!ASGUQS7>>)_&6F^#YM#34VFC76-1CTJVD
MCC+(MQ(K&,2'^ ,4V@G^)E'>O)O"W[/ES\+]+T*\T>]MM2OO#<VMZA:Z98:;
M'8P7,U\AVPQIOV0HC8 Y(QU]:[?Q/\/]7^('P<3PUKVKPVOBJ6RMY'UJPM_W
M=MJ<125+F*,G[J3H&"Y&0,9YJI6TMY?\'^O06FB]?^ 5-<^/?A_0]/OM072_
M$6JZ=I]]=6-Y>:7I$EQ#;FV(%Q*[CCRT)(R,DE'P#M-5/%?[27A/PKKEMIJV
M6O:\99;*"2\T32WN;:WDO"HM4EER K2!T('/#+G&17$>-/V/X?%7A/PWH2>(
M+*6WTW2+G2[I=<T8:C#+-<,))M0AB:55BNC)O(=MX <C'>N!\0_"GQEX?^.W
M]KZ1X7N-;O[(Z5;Z/<7VCPW6F7$,%O#%)/+=^<K6K*1,0I1F5E#*6WXI1M>S
M_KO_ %_D#[K^NQ[9;?'RRT73+1=92]\0:SJ5_JT.GV?A?1IY9)8K*Z,3J8R2
M0R KN<D*Q!*XR!6OKOQZ\,Z#X?T;Q";;6]0\.:E:K??VSI^E2RVMI;M_RTN'
MP/+ [K@L,'(IW@_X0CPCXBT74UU<W2Z9)K;>5Y&WS1J%VMQC.XX\O9M_VLYX
MZ5Y=XX_8V_X331=)TN7Q+I\MM::)_8S?VKH8OOLY\V23[59AI0MO.WF!6<AR
M51<8(I=%?^M_^ &EV>O?#WQ;J'B3Q3\1K&]>)[70]<CL+'RXPI$+6-M,=Q_B
M.^5^?0@=J?\ $3XJV'PU6.74-%\1:C:")KBXO-'TJ2Z@M(5SNDF<8"@ $D#+
M8&<5C0>"O$WA3QA<W.@7D$UGXD\1QZKK,UQ N+6SBL(X# F6RTDCPQD,!\H+
M9Z<\Y\=?V:S\:/$#7\FKZ4MK-I+:2]EKNBC5$M,L[?:;-6E18ISOP697R$3I
MCDELK>7Y?YC5KZ_UJ=#KG[1G@W0=<FTV5M6NEM19R7NHV6F2S65E%=*&MY9I
M@-JHV1SR1U( !-<[\6/VC;7PYJ46B>'(K^XU*'Q+I>AWFI_V7)+IL4D]U L]
MJ9_NB80RY]%) SN^6MH_ C_BFO&.D#7#CQ%8:=9><;?/V?[+ L.[&[YM^W..
M,9[UDZY^SQJVH:QJ<5CXS6P\)ZAXGM?%LNDMI8DN/MD<\,TD8N/,'[EVA#8V
M;@S'YBORU?NJ:[7_ %7Z7)TY+];?I_F>D:Y\1M!\.>([[1M1N)+.YL]'EUZ2
M22(B(V<3E)65^A9#MW+U =3WK!M_CQX5G\-ZOKC'4(+/29["VO$FLV2:.2\2
MW> ;.OW;J+=_=)8'I5;XX?!.'XSC0<ZO)HK6%RZWC10B0WVG3!1=6+<C:LNR
M/YN<;.AK \>?L]ZOXKUSQ0VF^,H]%\/>)+_3M4U#36TH3S&XM# %6.8R +$Z
M6\89=A8$9# $BHCY_P!:_P"7XH':SM_7]?J:GP\^,L>K>*_$7A[7[E(+^+6M
M7ATV00>7";.R: ,K/G!D43!CGDKD]C5P_M >'%M?#E^^F^(H]%UR*WF@UJ32
M)%LH%G8)!YTG\!<LN, XWKNVYKE_&W[,(\7>'-6L(/$\NDZA?>)KO74U*"T#
M/%;W<?DW5G@MR)(6D3?D8)5L?+5;XB_LIP>.O'2:W#J^G6NGQC3?LUI?:,+R
MXTT6<BLD=C.9 +=) H#X0L3R&[56FE_+\M?Z]2I6O+E\_P ]#TSX@_%+2?AS
M<:;9WEGJVKZOJ1D-II.AV+WEW*D>WS9-B]$3>N6)'+*!DD"JLWQBT>U\8:9X
M?N],U^P;4WC@M-4O-*EAL9;AXS(L E;_ ):%0>,8R"N<C%1?$3X<ZQXD\7:'
MXK\+^(X/#7B+3+:ZT\R7NG?;K>>UN&C9U,?F1D.KPQLK!L9!!!!K@Y/V6Y+C
MXN6?C>\\26>I36VLPZTMQ>:*KZIN2$1-;+=^9B.V/+B-(Q@L0214QW5_Z_I"
M=K.QUWAO]HKP=XHUB.RMSJUG;RK=^1JFHZ;+;V,[VI?[3&DS#:S1B-V/8A6(
M)P<1V?[17A>\\-2Z\=/\1VNFO)!%IKW6C31/K#3Y\@62GF4O@D#@@?,0!S3(
M?@-:R>#_  WX;OM5>ZL=+DU,SE(MC7,=[%<QL@^8["HN3SSG;T&:YW6?V;]8
M\8?#?3_"7BOQ?IOB&'1)[.;1?M'AV,VR_9E9%^V0M*PN"Z.5?:8UX!4*:7_
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M-Z5_PD-G"+:UU8VB&Z@A *B-),;@N&88![GUKH*IVZ&84444@/(_VLO^3?\
MQ3_V[?\ I1'7EOP[_P"2?^&?^P7:_P#HI:]2_:R_Y-_\4_\ ;M_Z41UY;\._
M^2?^&?\ L%VO_HI:UC\)Y=;_ 'C_ +=_5GJ'[)7_ ";[X5_[>/\ THDKI?'7
MQM\&?#;5ETSQ!JLUKJ!M/[0-O;V-Q=,EKO*-</Y2-LB4J=SM@+U)&:YK]DK_
M )-]\*_]O'_I1)72>(OAU<ZWXH\2ZJE[#%'JWA?_ (1](G0DQR>9,WF$]UQ,
M!CKP:SG\3^9W8:WLH7[+]"36?C-X.T'7H-(O-7;[3(("\]O:336EMYQ @^T7
M"(8H/,R-GF,N[(QU%45^/_@B3QQ#X2CU"^FU>:>XMHWATF[>S:6W4M<(+H1>
M26CVD, _RD8//%>67W[(8N/'D&LR0^&==L;R/35U)-;CO?,ADM;>*#,"Q3+'
M(K"%&"RK\K9.6' XOX9>%/%4?Q7U$+I>J6^J:EJFM1RSWVCW\+>&X;EKAEOH
M+EYC82R,?)X@B5G#C)R&RNMEY_\  .A)6N_+_@GM_BK]I[P=X;\%Z]XAC@UR
M_P#['$#S:;_8MY;W<D<TGEQS)'+$&:(D-B4 K\I&<XK4@^,^FKXJ%M>SPV.B
MW5OI@L?M-K=0WXNKR6>.-+B&2("%&,("EB&W9#!<KGRCPM^R7K^FZ#XSAU#7
M='35M>T6VTT7=FEY/YEQ!.TRW5PUQ,[,9&(W*A7'.,]:] \1_!G6?'5GXOGU
MW4]/MM8\0:#I]DDFFQR>59:A:2SS1W";SN*++)$P!Y_=GUIZ*P]+-?UT_P""
M=+K7QL\'Z#/=V\^H75U>6M\^FO9Z;IMS>W#3QQI+*J10QLSK&DJ%W4%5W8)!
MXKK=%UJP\2:/9:MI5W%?Z;>PK<6UU VY)8V&0P-?.OB;]DN]UGP[X+N)+W1M
M=\6Z.E^^IMJZW4-EJ%Q?3)/=3*;>19(V$J#8#N&SY2. 1[/X \):CX'L=*T.
M!-#L_"^GZ5%;16.EVTT;1W8=C(R%Y&Q"5(PIR^[)+'-'34EVZ'84444A!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'D?[67_)O_BG_MV_]*(Z\M^'?_)/_#/_ &"[7_T4M>I?M9?\F_\
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MOA2V A YN6/Q!U3X:ZMX$^'>K)<^,?$U]9">^UNYO8+19/WFUS$)"IG92?\
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M]B@!U%-\Q/\ GHG_ 'V*/,3_ )Z)_P!]B@!U%-\Q/^>B?]]BCS$_YZ)_WV*
M'44WS$_YZ)_WV*/,3_GHG_?8H =13?,3_GHG_?8H\Q/^>B?]]B@!U%-\Q/\
MGHG_ 'V*/,3_ )Z)_P!]B@!U%-\Q/^>B?]]BCS$_YZ)_WV* '44WS$_YZ)_W
MV*/,3_GHG_?8H =13?,3_GHG_?8H\Q/^>B?]]B@!U%-\Q/\ GHG_ 'V*/,3_
M )Z)_P!]B@!U%-\Q/^>B?]]BCS$_YZ)_WV* '44WS$_YZ)_WV*/,3_GHG_?8
MH =13?,3_GHG_?8H\Q/^>B?]]B@!U%-\Q/\ GHG_ 'V*/,3_ )Z)_P!]B@!U
M%-\Q/^>B?]]BCS$_YZ)_WV* '44WS$_YZ)_WV*/,3_GHG_?8H =13?,3_GHG
M_?8H\Q/^>B?]]B@!U%-\Q/\ GHG_ 'V*/,3_ )Z)_P!]B@!U%-\Q/^>B?]]B
MCS$_YZ)_WV* '44WS$_YZ)_WV*/,3_GHG_?8H =13?,3_GHG_?8H\Q/^>B?]
M]B@!U%-\Q/\ GHG_ 'V*/,3_ )Z)_P!]B@!U%-\Q/^>B?]]BCS$_YZ)_WV*
M'44WS$_YZ)_WV*/,3_GHG_?8H =13?,3_GHG_?8H\Q/^>B?]]B@!U%-\Q/\
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M_OHT44 'FR?\]'_[Z-'FR?\ /1_^^C110 >;)_ST?_OHT>;)_P ]'_[Z-%%
M!YLG_/1_^^C1YLG_ #T?_OHT44 'FR?\]'_[Z-'FR?\ /1_^^C110 >;)_ST
M?_OHT>;)_P ]'_[Z-%% !YLG_/1_^^C1YLG_ #T?_OHT44 'FR?\]'_[Z-'F
MR?\ /1_^^C110 >;)_ST?_OHT>;)_P ]'_[Z-%% !YLG_/1_^^C1YLG_ #T?
M_OHT44 'FR?\]'_[Z-'FR?\ /1_^^C110 >;)_ST?_OHT>;)_P ]'_[Z-%%
M!YLG_/1_^^C1YLG_ #T?_OHT44 'FR?\]'_[Z-'FR?\ /1_^^C110 >;)_ST
M?_OHT>;)_P ]'_[Z-%% !YLG_/1_^^C1YLG_ #T?_OHT44 'FR?\]'_[Z-'F
MR?\ /1_^^C110 >;)_ST?_OHT>;)_P ]'_[Z-%% !YLG_/1_^^C1YLG_ #T?
M_OHT44 'FR?\]'_[Z-'FR?\ /1_^^C110 >;)_ST?_OHT>;)_P ]'_[Z-%%
M!YLG_/1_^^C1YLG_ #T?_OHT44 'FR?\]'_[Z-'FR?\ /1_^^C110 >;)_ST
M?_OHT>;)_P ]'_[Z-%% !YLG_/1_^^C1YLG_ #T?_OHT44 'FR?\]'_[Z-'F
MR?\ /1_^^C110 >;)_ST?_OHT>;)_P ]'_[Z-%% !YLG_/1_^^C1YLG_ #T?
M_OHT44 'FR?\]'_[Z-'FR?\ /1_^^C110 >;)_ST?_OHT>;)_P ]'_[Z-%%
M!YLG_/1_^^C1YLG_ #T?_OHT44 'FR?\]'_[Z-'FR?\ /1_^^C110 >;)_ST
M?_OHT>;)_P ]'_[Z-%% !YLG_/1_^^C1YLG_ #T?_OHT44 (TCE3EV(]V)K]
H)OA7X!T&?X7^#Y'T\,[Z/9LQ\U^28$)_BHHK"KLCV\KBI3E==#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ino-20201231_g6.jpg
<TEXT>
begin 644 ino-20201231_g6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %# JP# 2(  A$! Q$!_\0
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MXA^(-]KGA[2[F62'2])BL+RWU".W(GAU-IIQ@R*<>0[#YAAMQ7O7,^)/A/\
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M4$J :7*M%?>PK[GOF#Z48/I7S)%\&_B!IU[INF+<:K<>%)+RYEM(;77$BN]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH AN+.WNVC,\$4YC;<AD0-M;U&>AJ1E612K
M*&5A@JPR"/2G44P(K>UALX5BMX8X(EZ1Q*%4?@*EHHH ****0!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !4-U9V]]&$N8(KA%.X+*@8
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MZ5_W]/\ A7H^X^I]:-S#N:/=[ ><?\-%?#/_ *'72O\ OZ?\*/\ AHKX9_\
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M-:74*7$,FUE+(PRIP0",@]" :M;F]32T[ ><?\-%?#/_ *'72O\ OZ?\*/\
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MK8\?FQ-T;:P##Z$ T66]@.3_ .&BOAG_ -#KI7_?T_X4?\-%?#/_ *'72O\
MOZ?\*[I=<L9-8FTI;Z%M3A@6YELQ(#*D3,55V7J%)5@">NT^E9MGX\T:_P#&
MNJ^$H+MW\0:79P:A=6?DN-D$S2+$X8C:VYHI!@$D%3G%.R[ <O\ \-%?#/\
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M.F_LS>(-$_9J\#?#:QU_38M1\,7EK/*PMI%L-7AAE8M;W" [@LJ$;L9PP'!
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MRF,0_+Y<BR>9C  E7=L(P%]^_L_Q'_T'+'_P6'_X]1_9_B/_ *#EC_X+#_\
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MZ;#=Z>VG*+5X)OL,HM])N-.FF*AMRRSFX65@./W$8))^:OJ?^S_$?_0<L?\
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MS?!V^OOV<=0^&VJZ]_:^L:AX=ET:\UZY@!,\\EL83<-'GGG!QGHHYKM/[/\
M$?\ T'+'_P %A_\ CU']G^(_^@Y8_P#@L/\ \>J)-RO=[E=4SYBU3]GN[TOP
MU\0Y;+3KB2[A\!C1)]+MM/(M]3UB"Q>.WO;$DEL^7.\)P!E@N>4S5;P#^R1X
MDF\-^&;QO$4VB:=<RVE[J'A/=/;I"ITJ"UE97!WQW8FC:;<!C<QYR=]?4W]G
M^(_^@Y8_^"P__'J/[/\ $?\ T'+'_P %A_\ CU:>T;OY_P##DVV\O^ >;?#O
MX9>-OA?XBN4LM8L=:\-ZOK4M[>6^HB1[FQMVB=BL,^0SYN&!"R!]J$J&P!BY
MX\^ EGXCU+7]4T&2U\+ZWJ5C(HU:T@)N/MI $<[<XPFQ&PN"SJC$YC2N]_L_
MQ'_T'+'_ ,%A_P#CU']G^(_^@Y8_^"P__'JSN44OA?X7U;P;X&T[2-<UE]>U
M.!IFDO7+'Y7F=TB!8EF6-&6,,QR0@)Y-<SK7PEOD^/=E\4M%OK=KT^'G\-7V
MF7X81R0?:!<1RQ.N2CJ^X$%2&##E2H)[/^S_ !'_ -!RQ_\ !8?_ (]1_9_B
M/_H.6/\ X+#_ /'J+Z\PNECQ/QQ^S?XJ\;_%R7Q1/XFLK719;:YLY=/LC=6\
M\L4^G?9G!D$AV$2@2+LP!@'&_+'-TO\ 93\3_P!I6[:]XWDUZR30SIH6.26P
ME@F#7:[U: J&$D5V%DX3+PI(%^ZJ^_?V?XC_ .@Y8_\ @L/_ ,>H_L_Q'_T'
M+'_P6'_X]3YF,\EU[X"^*]6^!.B> SXIL[O4[2[9KG5KVV=?-MB9@%VQ%%:4
M+(@+,NUBI;8"1MX%_P!BW6YK=Y+K7]&U'4I+;P@TMU>6<DC2W.C2 REV)+,D
MZCJ3N!ZY%?3']G^(_P#H.6/_ (+#_P#'JQ_[;U/_ (2C^P?^$@L?M_D^=_R#
M/E]=G^OSNV_-C'3FJBY-Z>OW$NUK?+[SQ.']D?5;34%U6WU+2TUK_A8LGBQK
MS,X)TQIGE%B!V(+]AMX/K6!X9_8>USPEX5T&RL/$^FK>Z/)H;B#R)EL[U[![
MDRSRJ&RLDZ7(C.,C;"@);/R_4?\ 9_B/_H.6/_@L/_QZC^S_ !'_ -!RQ_\
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M2[V/S,R@$!2C!]C)DAT+ ]B/)/B[^QSXJ^(^M^*KJUU_2+2UU;5;S4;:*4W
M-OYVA_V<H^4=5F"W''!(]?FKZ<_L_P 1_P#0<L?_  6'_P"/4?V?XC_Z#EC_
M ."P_P#QZA,=]4SS3X4?!'7O!/Q$U;Q-KOB)M<-U!&EMMGF#0YMK:*6!E)VR
M1A[;S(V/S+YKC )8MYQI/[(OB33?$6E:R=3T5[JS^)5[X[=A)<#?;SI,HM0-
MNT.OG$[\<[1QR:][UC6M2T'4-.L[OQ#8I-?2&./_ (EG"\$[FS/P"0%XS\S*
M.]:_]G^(_P#H.6/_ (+#_P#'JTYI1:E_6_\ P";*W+_78\D^"O[+FD^!_ ^L
MZ5XLL=,UW5M5.K6EQ?P^8^=/OKN6X>U7S/N+F7#!<!BH8\].J^'OP=N/"'P'
M@^'FIZXVOW:Z2^E3:Q<0C=,OE&&-F3/.V,1KR>=F3R378_V?XC_Z#EC_ ."P
M_P#QZC^S_$?_ $'+'_P6'_X]6;?,G%[%7UYNI\W>#_V<Y_!]O%;&WDDF\/\
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M]'XLM_#/BR>+XA:Q,;*]6UL+D6&G^=-.$"&(#[/LV-/(J_=+9C/S<G+?B?\
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M7T&UNK.WO&NM/FN$AD9;NW,?V=)I3#;M-G_5B60%5SSD<@5B2?!^75/A7?\
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M3P>@89&!FN?E_9IM;FXU&635!"FLDIJEK;PD0B'[2ESY=L"W[H;U<'KGSG.
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MR-+\7:-K6K7NF6.I075_9 &XMXV^9 69<^XW(RY&0"I'45KU(PHHHI %%%%
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M "KK R F(Y($H9E)4C@TTFU=!L=Q1114 %%%% !1110 4444 %%%% !1110
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MRA#,TP VH&^5G8+DG"D+T KMZ**EMO<=K!1112 **** "BBB@ HHHH ****
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MWFHOV>UBM08O-<QLT40$:2%"I<( NXM@ <5U5%%2W=W&%%%%( HHHH ****
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MT?XX>&M>8+9IJS;[:VO8/,TR:,W,$\@CCDB#*"ZY(SC[HP3C(J,? 7PE]O\
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MK>VFC3WMR^I%R9+[[1;00K&5SD;3$Q.>,)%C/.-.6.NI/1'N]%%%9#"BBB@
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M'!6&)II6) PJJB,26P.,=:>O094U3X5^#=<L+"RU#POI-]9V!)M8+BT1T@)
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M (W1RL#>HK!_X3?2?6^_\%MS_P#&Z/\ A-])];[_ ,%MS_\ &Z.5@;U%8/\
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M44@#<?6C<?6BBF ;CZT;CZT44 &X^M&X^M%% !N/K1N/K110 ;CZT;CZT44
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M25I49I&/RLIPIZACEN]7)_V=S->ZW=MKL#W6H7D-Y'<RZ6K3V^+J"ZFA$GF
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MDM(+%WB9SF"$$0Q\D_*@9@H[9/K7*>+H)?AWI/@/2M"L$NX;:\D@#SV<]WY
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M!P,J+CG (8'+*VX^NI]$Z?H]EI)NFL;.&T-U.UU<&",)YLS !I&QU8@#)//
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M!!1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ino-20201231_g7.jpg
<TEXT>
begin 644 ino-20201231_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYE^(W_!5[]F
MKPS^TI>_L=?"#P[XS^+WQ0T>#SO$GA'X5Z)'?-H,>0-U_=W$T%G:'<0I22<.
M"0"H+#/K'[6WCKQO\+_V4_B;\2_AG9FX\2>'?A[K6I^'[<1AS+?6]C-+ NT\
M',B(,=\U^5G_  9:V&@Z[^Q'\8_B_JMZU]XU\0_&F:+Q)JEU*9+JZ@CTVRG@
M>5VRSYFN[ULDDEG<]Z /TD^$/_!0'X*?%S]HUOV0QX:\9^&?B9;^#[KQ/J7A
M+Q=X5FLI+338+JTM?.%Q\UM<J\MXBH]M+,A,4H+*R$5BC_@IQ\ ?%W[0/B?]
ME[]G7PQXL^+OC3P.BGQS8?#NQM9+3P\[,RK!=7]]<6UFLY*2#R%F:7,;@H"C
M ;/[>NAW'@K]G?XF_M5_##0-WQ0\#_ WQA;>!]5@!\^)IK2.\\E0/O;KK3K)
MAG)!BXQDY_.[_@RUTC0G_P"";/Q%\;*PGUS5?CA?Q:Q>R'=-(L6E:8\2NQY8
M S2N">\K>] 'Z,?LK_\ !0']FG]L'7/%G@+X3^)KZW\:> KTV?CCX?>)--?3
MM;T28$@":VFQN1B/EFC9X6R,.:\N\,?\%MOV)]:_;LMO^"</B5_%_A;XJWFH
M2V5OI/B7P[Y-K).D+S!%NHY'A<.L;!&5BKMA02Q K\Z/V@M=\4?#+_@]!^'\
MOP7ED6Z\8^%+&U\;VMIE5N[5M&N5F$X'WPD%K;3#/1H(SU4&JO\ P<1_LJ>-
M;;X=:M_P50^ (>R\>_L__M&-+>:E:QYD3398=*>WG;'+?9[Y8"%Z!;N9CP*
M/US_ &\OV_OV<O\ @G!\$D^/W[3FMZE9Z#+JT6FP+H^F/>7$L\B.X"Q)SM"1
MNS,<  >I /&V'_!5K]G[4_V%'_X*/V/@'QY)\*$T]]1.LC1K;[3]@25HGN_L
MOVGSO*612I^7?CYPI3+5^>'_  59_:7\-?\ !3?_ ((G_%W]OKPO9M%X7T;X
M8^&=%\-V;Y(@UR_UG1;W7<$C$GD;+"Q60?=DAOTS\S"NM^&G_*FW<_\ 9O\
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MAEX6@LYM5^Q6X'GW4\DUU%9VL",RQ^;-<HCN=J%R"!=^!'[9GPN^/GQ4\4_
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M[4WPY\7_ !;_ &?_ (;?%OQ3X>\ L!XPO])\ /*^F91Y,M )?.DPD;L?+1R
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M_1CI'PZ^&.F:B1H_AG34NK/7I]<"H@9[?4+F.6.6Z Y*22)-.I88W"5_[QH
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MP&%8D,!^,'_!03]H#Q;_ ,%$/A]^Q_\ \$*_'G@.U^":ZOH?@[Q!;?%3QSJ
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MFT_3/&^@:WJ%]?\ B7PM:!5TF743>R2>1=)&SQO%#MB_=IM4 "OKJ@ HHHH
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M+[7["/1O \ND/IPN2G^C,SZA="=4"8#X0G//I7!?!;_@F'\%/V=_^"BGC_\
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M<[KB7^UK<,F^UC 5$0X+?,<@CV#XT_LC?MP?M">(? =C\1/VV/!&G>#?"OQ
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M>%-1TNQ\7BT?9<?V=<W<$<5RR'!V*VYU960,I#5^)_[!_@OQW^TW_P $]?\
M@J'\&?V9=736/&&O_$!M2T72=%NEENM4T^/4;F>=8$0EIA/;QRQ+M!#F0*,E
M@#TGQ0M]1_:K_9@_X)1_L^_LF:Q#J_C_ ,/ZO;W^LVNAS++<^&H]-?3TOKN\
M5"6M4AECD+&0+DPL!EAB@#]=?B9_P6=_X)S_  C^.OC']F#QO\;M5@^(O@72
MWU#7_!D'P\UV:],"QQ2EK8)9%;S,4T<H\AI,Q;I?]7&[KT_P_P#^"H?["'Q*
M_8PN?^"@WAW]H;2H_A)81RG4O%6HV\]L+.2.41/!)!)&)A-YC*BQ!"\A=-@?
M>A/Y@^$_B/\ #;3/^#L+]JG6=6\=Z)!:I^S=<6@N[C4X5C2Y@TK0FGBWEL"2
M-(9RZYRHBDSC:<?+W[$'@W]FWXQ_\&F?Q@\+_'3XUS^$X/"WQK?4X+S2[07L
M\6I,FFI902VWF1[XYVD,>YG55R9-V(F% '[>>'O^"Q'[!^N_%/P?\#KOQUXL
MTGQA\0-+L=4\&>'=7^&&O0W&JZ=>/LMKY/\ 0BJ6[-D&21D$>UO,V8->N?M<
M0WI_9B\?:EI/B'5=)OM-\'ZE?:=J6BZG+:7%M<PVLLD4BO$P)VNH.ULJV,,I
M'%?FW^R?X/\ @?\ M@_\%0?@+^UOXT_;\_9RNO$GP4^$"^%O#7PX^#_Q8BUV
M]\1:B]I=0W-U(98+62.W2.YD*P1QRD% S2 %E/Z,?MK^+?"O@K]D3XFZ]XR\
M2Z?I-BG@+6$:\U.\2"(,;*; WN0,GL,\T ?G/_P;+?MM_%[XW?\ !-_XI?MP
M?MU?M#>-?&-WX1^(6IZ;<ZA?R7=^EAH]II6F7C&.QLT8R.&N9F++$\FT # !
M!^DK;_@X=_X)$ZAX9\,^.]*_:FFN/#OBKQ%_85CXD_X076X=/M-0)X@NYYK-
M$LW(!<"8H3&#)CRP7'Y\_P#!KM\4OAIX8_X(1?M*:!XC\?Z-8W]AXK\5ZG>V
M%UJ423PV;^&=+C2X:,MN$;21N@?&"RE0<\5\.?$KQ9X0/_!IA\//":>(]..K
M']J^Y?\ LU;M#<873]09F,>=V LD1)QP)$_O#(!_35^T+^VE^SU^S'XN\(_#
M;XG>++I_%OCZ\FMO!7@W0-'N=3U;67AC,L[0VMLCOY448+O*P6- .6!(!XK4
M/^"L'[!.F?LIZI^VO=?&^=_AQH&M-H_B;6++PEJUW<:#?K((WMK^R@M7NK)T
M=D5O.B0*9(\G$B%O@G]HK3M6\"?\'+G[*_[8WQ-\56W_  J;Q3\&;S1/!WC:
MXU!1I-MJ8TS56:U-R6\I9)1<*Z9/[WSP%W%3BG_P0-_9:N_VD7_X* ^)/BAH
M<]]\$?V@/BYJVG>$)VXM]7M#=:PMY>VA.59&CO+15G3*EX" <Q' !^CWAK_@
MHG^R7XS^"_P__:$\)>.-=U/PC\4M;ATGP+JMC\/M<E;4KN5G6-3 MF9H$8QR
M$2S(D>$+;L#-?.?_  3X^.6G?$/_ (*D_M/Z9!_P4JUWXAV>F"U*_!37/ NK
M:3'X $3^6Y$M]#'"1D%,P<2JWFODX->$_P#!M]\#OVL?A[!XR_9"_:>TMG\*
M?LF_%37M'\!ZE,& U+4K^%6$L2G[L<%I<W<J$D[T\0J,#R@3\[_ +3M9^/W_
M  5!_P""IWP@_9_\;:?<>+_'?PNUC3/!,=EJD6_4;PPM$8H'#<G>?++J?W9;
M)QB@#]8? W_!7O\ 8"^(GB'PYI7AKXTSG2_&?BNX\,>"_&-YX;O[?0/$&LPM
MLDL;/4Y(5MIY"X9$P^V9D98FD*D5](ZC80:II\^F7+S+'<PM%(UM<O#(%8$$
MK)&5=&P>&4A@>001FOYIOB]H>L_'7_@W)_8[_8'^ T4EQ\<8_P!I&_LG\!VT
MGEZSI-Y!=>(_/>X@SYUJL37EK*[NJB-9%9BHK^E1[R#0M#.H>(=6ACBL[3S+
MZ^N'6*-51<O(Q. B@ DD\ 4 ?AK^Q-\?_P!L+]H[]KO]O_X.>._^"A/Q3\.Z
M'\ ;[Q$?AKJ4'B.(KHD=EJ>I10M<_:(G6ZB6*UB#B7)90QW!CN'-1_\ !8'_
M (*'?M!?\&U'C7]MCQ7\3=9\+_%#X??%:Q\/Z+\0O#:+IYU^S>:Q6226"-1"
M[ 7DL3;8PFZ)2 '#U1_X(J_"O]CK]K/_ (+3_MW^#?CW8>%O&.C^(/B1K=YX
M9TG4M6$EIK4+>(]0=GCB60)>Q[7B;D.N&5AUS7V-_P '1GA;X2_!+_@A-XI^
M$OP]\.^'O">D1:]X?L_#7AK1[2"QMT":G#*T5M;QA5&%5W*HO #-ZF@#V_\
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MO2HOAGX:NIK3Q)KVJ6MQ9R:5>1% ]G/;31K.EQF2(+#Y9>0RQ[ ^]<Z7@O\
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M_P""_P 2/CC\*Y?^#8/PC^S+#XOA?Q[H/[4$U[KWA=(I#=:7;FRU ))<KMQ
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MX5ZG=^-]%6"T^!T]I-<2:E$$@N6L-7=8F8MA)#'(K!3@E7!Z,,@'Z4_LH?\
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M?$V\^(WPD_;%UCXJ_L]^*O 0C\(8\8QZBVB:DMT//6/5(G%[=B6)D*//+-+
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MA_\ %CP]K'AW5/B['KEMJ=KJ<30OIC7ND?Z4QS\D7RL"S8 *.#@JP&C^S_\
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MD^_QKXLN_"_@_P 2/X>OET+6]:M7CCFL+74S#]EFD#RI&&60QNYV([."HO\
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M^.'C[PM\/OAW\6I;F7Q[-JD7P]U>[T"]MM,\62:<^R^73;V:%8+LPMG.QSO
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M,;WXBZSKK^'C<6.FR7=[XLUR>^F6"/3[&S1Y'\X%&CBC3;%&RJ0@7 M_!O\
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MO'/CCP=\,_!FJ_$3XA^)['1-!T/3YK_6=8U.Y6&WLK:)"\DTDC$!$50223@
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M)::C93 >=9WULLT4F#D;D<$'D \BI[2TM+"UCL;&VCA@AC"0PPH%1% P% '
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YM_\
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MX+_M01^%KZ^\%+X9\7^&M0\'+J+7%L$6/S;*<W$:VTI1(P#+%.JNFXI(&,8
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MG5\._P!G2X@F&MQ:8=5\537402=]2NV\Z5) "0&B5H[<8) 6W49.,T >8?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/V
MY_\ DT?Q[_V 7_\ 0UH [KX7?\DS\._]@*T_]$I6[6%\+O\ DF?AW_L!6G_H
ME*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *\H_;G_Y-'\>_P#8!?\ ]#6O5Z\H_;G_ .31_'O_ & 7_P#0UH [
MKX7?\DS\._\ 8"M/_1*5NUA?"[_DF?AW_L!6G_HE*W: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9/:W<*R1R+Z,K @CV-6** *NBZ'HOAS3(M%\/:1:V%G NV"TLK=8HHQZ*J@
M#Z"F2^'/#UQKL7BB?0;)]3@@:"#47M4,\<1.2BR8W!2>2 <5=HH **** "O*
M/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-: .Z^%W_),_#O_
M & K3_T2E;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\ ]#6@#NOA=_R3/P[_ -@*T_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M7 ?$#XY0:1K9^'WPVT5O$GBEQ@V%L^(;/MON).B ?W<YZ#C(->;FN;Y?DN&]
MOBY\J;LDDW*4GM&$5>4I/I&*;?8Z\'@<3CZOLZ,;O=O9)=7)O1)=6VD=/XX\
M>^$OASH4GB/QCK,5G;)PI<Y>5NR(HY=CZ#^5>=#1OB9^T6PN/%*7?A7P6_,>
MDHVR_P!53L9F'^JC/]P<GWX:MCP/\#K@Z]'\1OC%K2^(?$8YMPR8L]-'79!&
M>,C^^1GC. <D^BU\W_9V:\4>_FB='"O:@G[\U_T_E%Z)_P#/J#MTG.2;@O4^
MM8/*-,&U4K=:C7NQ_P"O:?7^_)7_ )4MW1\.>&M \(:-#X?\,Z3!965NNV&W
MMTVJ/?W)[D\D\FKU%%?94:-+#THTJ45&,59)*R26R26B2['A3G.K-SF[MZMO
M5L****T)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *\H_;G_Y-'\>_]@%__0UKU>O*/VY_^31_'O\ V 7_ /0UH [KX7?\
MDS\._P#8"M/_ $2E;M87PN_Y)GX=_P"P%:?^B4K=H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "J7B'Q'H/A/2)M>\2ZM!96=NN9;BXD"JOM[D]@.3V
MKE/B/\<=%\&ZFO@WPUIDWB#Q/<+_ *-H>G'+)_M3/TB3H23SCG&.:R/#WP0U
MSQGJ\/CC]H+5(M7O8FWV'A^WS_9VG_\  #_KG]6;(_WL U\IC>(ZM;%2P&3T
MU7KQ=I2;M2I/_IY-;R_Z=PO-Z<W(GS'LX?*X4Z*Q..E[.F]4OMS_ ,,>W]^5
MH]N9Z%-_$_Q._:#<V?@ W7A?PBQ(F\0SQ[;W4$[BV0\QJ?\ GH>?3D%:[[X?
M_#;P=\,=$&A>#M(2VC)W3S$[I;A_[\CGEC]>G; XK<5510B* H&  . *6NC*
MN':>#Q/U[&5'7Q35O:25N5/>-*.JIP\E>4M.>4WJ98S,YUZ7U>A'V=%?975]
MYO>4O-Z+[*2T"BBBOHSRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@"MK6M:/X;T:[\1>(M6MK#3["VDN;Z^O)UBAMX44L\DCL0J(J@DL2
M  "37RW#_P %F_V(#JC75[J_C.T\)'2M'U&W^)%U\/\ 4E\/S6VJ7=[:6,WV
MD0EHH)I["=$NIHX[>3Y"DKAP:]Q_:E^ NA_M3_LU>/\ ]FGQ+KEWIFG^/_!V
MI>'[S4K#_76L=W;20&5 2 Q4/NVGAL8/!-?@M\&_VFOVC_\ @@Q^TGK7[ O_
M  5^\!)\5/@AXN^'_A_P98>/]%8RQZ1X8CN]=.F[@JARA:YU13;RLMQ&EH3
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+V%.*ITEM".WK)[REYR;MTLM HHHKZ(\P**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M*/VY_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'\>_]@%__ $-: .Z^%W_),_#O
M_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H
M:UZO7E'[<_\ R:/X]_[ +_\ H:T =U\+O^29^'?^P%:?^B4K=K"^%W_),_#O
M_8"M/_1*5NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MID2.AW+R&"Y!KV^O*/VY_P#DT?Q[_P!@%_\ T-: .Y^%B)'\,?#B(H55T&S
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M_P#(1N-8L_7[3H5P,?DA_P FC_7O@Y?%CJ<?\4E'_P!*L'^KN>/X</)^BO\
ME<],HKSBV_:W_9YNCA/B+&AZ$2Z?<I@_\"C%:-K^TA\"KO\ U7Q1TD?]=9]G
M_H0%=%'C+A#$?PLQH2]*U-_E(RGD6>4OCPM1>L)?Y';45S=K\9?A%>\6OQ2\
M.N3_  C6H,_ENS6C:^-?!M]C[%XMTR;/3RK^-L_DU>I1S;*L1_"Q$)>DXO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O*/VY_^31_'O_8!?_T-:]7KRC]N?_DT?Q[_ -@%_P#T-: .Z^%W_),_#O\
MV K3_P!$I6[6%\+O^29^'?\ L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BN4\=?&[X8?#ES;>)O%=NMWG":=;9FN68]!Y:989]3@>]<S_
M ,+(^/'Q"^7X:_"V/0K%_N:QXOD*.1ZK;)E@<<@DD&OF\;Q7DN#Q#PL)NM66
M].E%U)K_ !*-U#UFXKS/5P^38^O25:45"F_M3:C%^C?Q>D4WY'J#LJ*7=@%
MR23P!7#^*OVC_A!X4N_[+?Q4FI7Y.U-/T6,W<K-_=Q'D ^Q(K)3]G&?Q6XN_
MC3\3-8\3,3EM/CE^QV(]O*B()^N1FNY\*> _!?@:T^Q>#_"UCIT>,-]EME5G
M_P!YL98^Y)KE^L\99E_!HT\)!]:K]K4_\%TY1@GY^VGYQ[[>RR+"?Q*DJTNT
M%R1_\"DG)_\ @"]3AO\ A:7QT\9?+\._@DVFP/\ <U'Q?=B #ZVZ9D_(TO\
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M_.)UPS?-:7P8B:])R7ZGFTW[(O[/4K^8OP_$3]FAU.Z0C\I<4S_AD[X51?\
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M5F]T<]/%8>K7G1A*\H6NNU[V_(****],Z HHHH **** "BBB@ HHHH ****
M"O*/VY_^31_'O_8!?_T-:]7KRC]N?_DT?Q[_ -@%_P#T-: .Z^%W_),_#O\
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M_P#B:/\ AXE^Q)_T<AX<_P"_[_\ Q-3_ *K<3?\ 0#6_\%3_ /D2O]:^%O\
MH/H_^#8?_)'M%%>+_P##Q+]B3_HY#PY_W_?_ .)H_P"'B7[$G_1R'AS_ +_O
M_P#$T?ZK<3?] -;_ ,%3_P#D0_UKX6_Z#Z/_ (-A_P#)'M%%>+_\/$OV)/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH=XYY\=?MM:-X9@;F6Q\%>!XI,^RSW#"1?K^E;+AF%'_ 'O'4*7_ &^ZK_\
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MO[CZPHKX"G_X+M:7XYD:#]F[]B[XC>-RQQ"T%DZDGI]VWBGS],_C4#?MI?\
M!9[XL?N_A+_P3XM?#T$OW)O%!%K-&/4_:[B(<>GED^U>HN#\TIZXF=*BN\ZL
M/RBY2_ IUL7+2GA:K?:4/9?C7=*/XGZ"45^?J?![_@OC\5SGQ+\?O /@>U?[
MUM"Z--'G^Z;6U;)^LE36_P#P25_;/\>M]H^./_!4GQC<H_\ K=.T>SN&C'J%
M>6ZPH]O+I/(LEP_^\9E3_P"X<9S_ #4!I9I4VI0A_P!?*BO\O8QK+\4?>6K:
MYHN@V_VO7-7M;*+_ )ZW=PL:_FQ KC/$7[5/[,/A#(\5_M&^!--*@Y6^\76<
M1XZ\-(":^6="_P"""/[*IN1J?Q)^+GQ.\5W38\[^T?$D443_ (10AQ_WV:])
M\'?\$=/^"</@IUN+/]FJQOYQ]Z;6]7O;W>?4I-,R?DHKGG0X6HJRKU:C\H1@
MOQG(Z(4JC=ZM6,?*,7/\92I6_P# 6;?BK_@J?_P3T\&R&/6/VK_"LI'7^RYY
M+[_TF22N$\0_\%QO^"<^D(?["^*VL:_(!_J=&\(7^XGT!GBC7/XXKW#PW^QG
M^R'X/"?\(O\ LM_#RP9!Q+;>#+%7_%A%N)]R:[_2=!T+08%M=#T6TLHE&%CM
M+98U ] % %<_M>'86:I59>LXK\H,Z.;#137*Y=G>W_DMG_Z4CX@UO_@O'\%&
MBW^ _P!EWXN:P#G9-/H-O:PO]&\]SC_@-<EJG_!<;XW:FWE>"_\ @GUJ\,;C
M,=]K?B60+CWCALV)_!J_1>BO1H9GPG3_ (F73E_W':_*D>=B)YM?_9W17^.G
M5E_Z3B(+\#\T+K_@K%^WKXA/_$D^'/PM\.HQY_MC0/$U[(@]O(@52?KQ4(_;
M=_;0\4C&O?MFZ7X5W=3X9^ -]?;?I]LQG\:_36BNY<0\*07N98U_W%@__2J#
M.!OC&_N8K#Q_[E6__2L1(_,I?BOXG\2$)\2/^"IGQQN Y_>GPU\&TT?ZX\J-
M]OX9ITVF_L+:G(4^)W[=G[5/B5_^6UMJ^LZHD/T$<=HNT>V>]?IG11_K+D"?
MNX.I'_#6IQ_+#![7CY+W<PHKTPMO_2:Z/S0L/AI_P0N%R-0\7^#?&.M3IDF^
M\2?\)+/CUR%8*<^ZUVWA?QA_P0C\+.BZ9\&_"C8(^?4_AE?WF/<^?;.37WS1
M43XAR*JK3HXE_P#<W'_YG9G.IXASTEF=)^M"I_\ -2/DCP[^W)_P2+\#OL\)
M:AX3T=H_E T[X8WEN5QV^2Q&*[./_@J=^P)'&L<7Q_ME50 JC0-1  ],?9^*
M^A*@DTO3)7,DNG0,S'+,T*DD_E7%+'<(5'>>%Q'_ (4TW_[JG++#\<2=Y8W#
MO_N6J_\ S6SPN/\ X*?_ +!\L8D7]H;3P". VEWJG\C!D5<C_P""D?[#DL@C
M7]HS0P2>"R3J/S,>!7K\GA/PK,YEE\,Z>S,<LS62$G]*JO\ #;X=2 B3P#HK
M;OO;M*A.?_':GV_!C_YAL0O^XU-_^ZZ)^K\;+_F)P[_[@5%_[L,\T@_X*%_L
M3W#E(_VDO#((&?WEV5'YLHJU!^WG^QE<J6C_ &F/!XP>?,UF-/\ T(BNVF^#
M'P>N8S%<?"CPU(AZJ^A6Y'Y%*J7'[/7P"N\?:O@?X/EV_=\SPS:MC\XZ/:<&
M/_EUB%_W$IO_ -QH/9\;+_E[AW_W#J+_ -R,Y^#]MK]CZX021_M/>! #TW^*
M+93^1<&KL'[7/[*-R_EVW[3OP\D;&=J>-+$G]):L3_LN?LRW+F6Y_9U\"2,>
MK/X1LB3^<54I_P!CC]D:X3RY/V7?AX!G/R>#+%3^8B!HOP8^F(7SIO\ 1"MQ
MLNN'?RJ+]6:,'[3/[-]TGF6O[07@B1<XW1^*[,C/X25>@^./P5NG\NU^+_A:
M1L9VQ^(+8G'X/7*3_L.?L=7+^9)^S'X(!QC]WX<MT'Y*H%49_P#@GU^Q5<)L
MD_9K\+ 9S^[L-I_-2*.3@Q_\O,0O^W*;_P#;T/VG&R_Y=X=_]OU%_P"XV>C6
MWQ-^&UX UI\0M#E#'"F/5H6R?3AJOV_B7PY=DBTU^REV_>\NZ1L?D:\=N?\
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M&)KI=%^*G[<VB 3>'?V.]&L/[OV?X?S1L/Q+[OSK+_B,.;XCX<$Z?I2KUO\
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M3=?_ *^T:527_@;DJGW31\]_J5PC1UP4JV&?_3F3A'_P6JGLW\X,S+?]N/\
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M6+_@?I!17YGW7_!'#]K:P.=-^,'AS4%'47GCOQ+ Q'MLD89J+_AU/^UC:?\
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M=+$9C4^+#TZ?_<2=7\J= ^-;#_@J-^U]\0F"?!?_ ()2_$&_BE_U-_XAU?\
MLZ'ZY:V*'Z;Q6K8_$W_@MS\1[EHM&_9R^#?P^M94^2;Q;K]QJ$L>1US93,,_
M6/ZBOL>BN">:Y=#_ '?!07G*4YO\XK_R4[Z>(JKXH0_[=C+\>><_PL?',7[*
M'_!6;XC6<UO\5/\ @I-HOA6*4\V?@3X?038'HMQ(()4^H)JM<?\ !&?PSX_B
M0_M%?MK?&WQVX(,MM>>+!#:/[>4R2,H]@XQ7V?14KB+-*3_<25/_  1C'\4K
M_B4Z\I+6,?7DA?[^6Y\M^"_^",7_  3D\&2)=']GY=7N5ZW.O:]?76[ZQM-Y
M?_CE>Q>!?V2OV6_ACL;X>_LY^!]&DC^[/I_A:TCE)]3((]Q/N3FO0J*X:^99
MCBG^^K2EZR;_ %+GC<94CRRJ2:[7=ON$1$C01QJ%51A5 P *6BBN(Y@HHHH
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M2J5*.T5]PR&VM[?/V>W1,]=B 9_*GT45T))*R- HHHI@%%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y;^U!^U
M5X$_9G\*_;=7=;[7+N,_V3H<4F))CT\QS_!$#U8]<8&3TP/VN_VT_"7[..EO
MX=T3R=5\77,.;73-V4M 1Q+/CD#N$^\WL/FKRK]F+]C+QA\7/%1_:/\ VM7N
M+ZZOI1<V.A7X^:;^X\Z=$C QMA  P!D!1M/YAQ/QCF&)S)\/<,153&O^)4>M
M/#Q?VIO5.?\ +#77=/X7\_F&:5ZE=X++US5>K^S!=WY]E_PQD?L^?LT?$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ2OTQ--71[^X4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBB@ HHHH **** "BBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\
MDT?Q[_V 7_\ 0UH [KX7?\DS\._]@*T_]$I6[6%\+O\ DF?AW_L!6G_HE*W:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXJ_#?XIZ=_:OP[\;Z;K$(4%_L5TK/'GLZ?>0^S &N@KX_P#'W_!+BYT34O\
MA*?V=/BW>Z1?0L7MK;5)64H?]BY@ =/;*,?>L7_A/O\ @IS^SS\OB;PO+XNT
MR'_EK)9KJ"E>[&2W(G'UDZ>E6O$'B/(_<XCRBK!+_E[A_P!]2]6E[T%Y.['_
M &UCL)ICL-)?WH>]'U[KYGVU17R/X*_X*P^#F;^S_BM\*-6TNYC;9+)I4R7"
MAN^4E\MD^F6->J>$OV_/V4_%VV.+XH1:?,W6'5K.:WV_5V79_P"/5[^5^)G
M>;I>PS"FF^DW[.7I:?*[G;A\_P GQ/P5X^C?*_N=CV2BL#1/BO\ "[Q+&LOA
MWXD:#?JXRK6>L0RY_P"^6-;T<D<J"2)PRD<,IR#7V=#$X;$QYJ,U)=TT_P C
MU(5*=17BT_06BBBMRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*M98K,9>TJ+9?8AZ+J_-_P#!"BBBOU ^@"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_^31_'O\ V 7_ /0U
MKU>O*/VY_P#DT?Q[_P!@%_\ T-: .Z^%W_),_#O_ & K3_T2E;M87PN_Y)GX
M=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGV-_\&1_^1#^P<1_T&5?_ E_D?%O_"\O^"HMI\TWP>\T'H/^$?5L?]\O2_\
M#0'_  4]_P"B(C_PFV_^.5]HT4?\0WS=;9_C/_ X_P#R(?V%B?\ H,J_>O\
M(^+?^&AO^"G4'[V3X&[PO5?^$9<Y_!9,TO\ PTU_P4O_ .C?!_X2ES_\=K[1
MHH_XASGBVS_%_P#@47_[:']AXM;8VI]Z_P CXM_X:I_X*3V?RS?LX>:6Y!_X
M0^];'_?$M'_#7W_!1NT_>3?LO>:#QM_X0G4V_'Y9<U]I44?\0\XB7P\08KY\
MC_0/[$QW3&U/P/BW_AM?_@H+;?/??LI84\#_ (HK5DY^IE- _;Q_;<MODO\
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MP#0!_1A^S=\:M#_:2_9X\!_M$>&+5H-.\=^#=,\0V-N[[FABO+6.X5">Y42
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M9@ #  \A*WJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[<
M_P#R:/X]_P"P"_\ Z&M>KUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6
MG_HE*W:POA=_R3/P[_V K3_T2E;M !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^
MW/\ \FC^/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K
M3_T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP35_9^\4^.I9I-8U'X*^%[C4IKC/F2S/I5LS2/GG<Q.X^Y->ZT %>4?MS_\
M)H_CW_L O_Z&M=)\9M$^.6MZ991? [QOHNAW:3L;Z76M,:Y66/;PJ@$;3GG-
M?/O[57@[]M+3?V=_%M]\0OC)X.U+18M*9M1L;+P[)%+-'N7*J^[Y3TYH ^F/
MA=_R3/P[_P!@*T_]$I6[7Q;X5^$'_!8J[\,:;=>%?VN/AC:Z7+80OIMM<>$R
MTD-N4!C1CY!RP7 )R>1UJ_\ \*8_X+4?]'C?"S_PD#_\CT ?8=%?'G_"F/\
M@M1_T>-\+/\ PD#_ /(]'_"F/^"U'_1XWPL_\) __(] 'V'17QY_PIC_ (+4
M?]'C?"S_ ,) _P#R/1_PIC_@M1_T>-\+/_"0/_R/0!]AT5\>?\*8_P""U'_1
MXWPL_P#"0/\ \CT?\*8_X+4?]'C?"S_PD#_\CT ?8=%?'G_"F/\ @M1_T>-\
M+/\ PD#_ /(]'_"F/^"U'_1XWPL_\) __(] 'V'17QY_PIC_ (+4?]'C?"S_
M ,) _P#R/1_PIC_@M1_T>-\+/_"0/_R/0!]AT5\>?\*8_P""U'_1XWPL_P#"
M0/\ \CT?\*8_X+4?]'C?"S_PD#_\CT ?8=%?'G_"F/\ @M1_T>-\+/\ PD#_
M /(]'_"F/^"U'_1XWPL_\) __(] 'V'17QY_PIC_ (+4?]'C?"S_ ,) _P#R
M/1_PIC_@M1_T>-\+/_"0/_R/0!]AT5\>?\*8_P""U'_1XWPL_P#"0/\ \CT?
M\*8_X+4?]'C?"S_PD#_\CT ?8=%?'G_"F/\ @M1_T>-\+/\ PD#_ /(]'_"F
M/^"U'_1XWPL_\) __(] 'V'17QY_PIC_ (+4?]'C?"S_ ,) _P#R/1_PIC_@
MM1_T>-\+/_"0/_R/0!]AT5\+_&+0?^"RGP?^&.M?$S6OVN_AM/:Z-9FXGALO
M!Z^:Z@@87?;A<\]ZV?#OPP_X+0^(?#]AK]M^V%\+TCOK.*XC63PA\P5T# '%
MOC.#VH ^SZ*^//\ A3'_  6H_P"CQOA9_P"$@?\ Y'H_X4Q_P6H_Z/&^%G_A
M('_Y'H ^PZ*^//\ A3'_  6H_P"CQOA9_P"$@?\ Y'H_X4Q_P6H_Z/&^%G_A
M('_Y'H ^PZ*^//\ A3'_  6H_P"CQOA9_P"$@?\ Y'H_X4Q_P6H_Z/&^%G_A
M('_Y'H ^PZ*^//\ A3'_  6H_P"CQOA9_P"$@?\ Y'H_X4Q_P6H_Z/&^%G_A
M('_Y'H ^PZ*^//\ A3'_  6H_P"CQOA9_P"$@?\ Y'H_X4Q_P6H_Z/&^%G_A
M('_Y'H ^PZ*^//\ A3'_  6H_P"CQOA9_P"$@?\ Y'H_X4Q_P6H_Z/&^%G_A
M('_Y'H ^PZ*^//\ A3'_  6H_P"CQOA9_P"$@?\ Y'H_X4Q_P6H_Z/&^%G_A
M('_Y'H ^PZ*^//\ A3'_  6H_P"CQOA9_P"$@?\ Y'H_X4Q_P6H_Z/&^%G_A
M('_Y'H ^PZ*^//\ A3'_  6H_P"CQOA9_P"$@?\ Y'H_X4Q_P6H_Z/&^%G_A
M('_Y'H ^PZ*^//\ A3'_  6H_P"CQOA9_P"$@?\ Y'H_X4Q_P6H_Z/&^%G_A
M('_Y'H ^PZ*^//\ A3'_  6H_P"CQOA9_P"$@?\ Y'H_X4Q_P6H_Z/&^%G_A
M('_Y'H ^PZ*^//\ A3'_  6H_P"CQOA9_P"$@?\ Y'KFOC%H/_!93X/_  QU
MKXF:U^UW\-I[71K,W$\-EX/7S74$#"[[<+GGO0!]T45\8>'?AA_P6A\0^'[#
M7[;]L+X7I'?6<5Q&LGA#Y@KH& .+?&<'M5S_ (4Q_P %J/\ H\;X6?\ A('_
M .1Z /L.BOCS_A3'_!:C_H\;X6?^$@?_ )'H_P"%,?\ !:C_ */&^%G_ (2!
M_P#D>@#[#HKX\_X4Q_P6H_Z/&^%G_A('_P"1Z/\ A3'_  6H_P"CQOA9_P"$
M@?\ Y'H ^PZ*^//^%,?\%J/^CQOA9_X2!_\ D>C_ (4Q_P %J/\ H\;X6?\
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MQOA9_P"$@?\ Y'H ^PZ*^//^%,?\%J/^CQOA9_X2!_\ D>C_ (4Q_P %J/\
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M /@C5X/_ &N/VO/B[<ZWK$C^*-3\5^+-:904MK;5[_+L$4*D<4,0 5%"JB
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M7ERJX$TH0!W P,9;)_&K= !1110 4444 %%%% !1110 4444 %%%% !1110
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MX5TVWU2[7;=ZE#8QI<3#T>0#<P^IK2HH **** "BBB@ HHHH **** "BBB@
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M4=%@GE90, %W0D@#IS70T4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNI0D4$,:EGD=CPJJH))/  H M45G>$/%OAGQ_P"$]+\=^"M<MM4T;6].@O\
M2=2LY0\-W:S1K)%-&PX9&1E8'N"*T: "BBB@ HHHH **\Y^/7[6O[._[,6N^
M!O#7QV^)MKX>OOB5XOM_"_@BWN+6>4ZGJT_^JMP8HW$>XX'F2;8P64%@6 /H
MU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >:WW[87[,FFWLVG7_QFT:*>WE:.:)I6RCJ<$'Y>Q%1_\-G_ ++7_1;=
M$_[^M_\ $UR6K_\ !-S]F36]6NM:O]*U@SWEP\\Q75V +NQ8X&..35?_ (=D
M_LL_] G6O_!PW^%?EM3%^,BF^3#8.U]+SJWM]Q\]*IQ1S.U.E;UD=K_PV?\
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MM+_L7:_\*[_QWX9O]<^%^NZAXNT_55UV&R^:YM[B*S++97"1?O#&)9EP/O\
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M;7I]+^*$VG:=X%\'0V\3:QJ^N7TYMH-(B0R"(SF=)%+%Q&JQ/(6"*35'1?\
M@HK\0_!7[<_@C]A+]J7]F-?"6M?$_P .W^J^ /$OA+Q9)K^EW364;RW-G=O)
M8V;6EPD2;_E66([U DRPS^3/PU\>^*'_ ."!?[&_[5OP"\+:MXXB_91^,UGX
MK^*/AW2-/F)6PCU'4OM'EL5"22PQR1%PI;R8[H2OM3D_K+^S+_P5_P#V0OV[
M?&_A_P !?L,^,KGXAW-Z@O?%MY;:'>VMMX4TX1,_F7LL\*(D\D@2".W#&1G=
MGQY<4C  9\6_^"B_Q1L?AC\0_C[^R[^RO!\2O ?PMO=4M/$FL7'CM=(NM5ET
MQF74O[(M_L<ZWJV[Q3Q%II;822P2+%Y@VNW,:S_P6>^'5YX"_9I^/'PI^$UQ
MXG^&_P"TQX[TOPAH'B :ZMK?:)JEW--$\5W9M"RL(6MYT8QSMF2%U QM=OA7
M_@GE^U=_P3?_ ."?:_$#_@G1_P %??@WX3\+?$GP)X_URYT'Q3XQ^&7]J+XT
MT6^OY[NWNX;A+6:29F,SA58?-&8@FY@Z)[/_ ,%9/$W@[X;?LF_L=_M-K\!$
M^%OPV\#?M@>&?%&NZ+9: MDGAKP\UQJ'E7]U:PQK]E:2.6":6+:&CFN3$V7Z
M@'V-\4/^"@&I?"+_ (*.?"[]@'Q7\%/,B^+NCZSJ'A;QI8>) ZQ+IEFUS<1W
M-HT"M&^5"KLD=2'5L@[D'SY^Q%^W'^W5\;?^"MO[4'P7\=? /2U\.?#L^!M$
M72[7QVNSPY93PZK>"^VF K>W-REP&D5/+""WBBW/L#GS']IW]M+]FWXO_P#!
M>']B3XK?"_XCPZ_X/MO#_C^P@\8:1:RW&F7]W-I8B6&TGC4BZ(D:.-GBW1B2
M01[MZNJ=3^Q;\:OAO\ _^#@C]MOX4?%;7FTKQ)\4[CX:7'P]T9K.62?7H(-&
MN(KB:W5%.^*%IE,LGW8U21F($;E0#Z2_8H_;\\$?M,?M.?M%_!]OV:+WX9:M
M\&M4T6W\7ZMXBO=/-SJ\EU:W,B33&S>2-4C@MD*N9Y,I( ?+VD5PWQ=_X+%^
M(O /[)EY_P %&/ W[)%[XI_9_P!/OXU?Q-#XL^S>(;_36OELCJ]GHYM&26S\
MQMZ&:[@E:+]Z8D7FOG']C>_\$?M,_M[_ /!4GX$_"SXN:!)K?Q$TS1-*\+S6
M>LPN9I#X=U"RDFBVL?,6">15D9<A&P&P2*E_X) _\%K/V6O@)^Q#X-_85_:E
MC\2^%/C[\);0>"KSX0)X2OKG6-9N[4F*T2QCBB99GFC$:\LH5]S,5BVR, ?:
MWQ,_X*'6UO\ M&?#S]DK]GGX6KXO\<_$3X?S^.+,>(]8FT/3--T&-D03W%P+
M2YF$TDDBHL"6[$$$R&,8W:?[ '[=^E_MT>&/B!;ZE\*KWP7XL^%OQ'U+P/X[
M\,WFH)?0P:E9["[VUTBH+FW=9%*R%(V.#E ,$_+?[7?_  4%NO!W_!2[X;_L
M<_MJ_$I_@?\ #C6O@?\ \)-J&MZ+JDMI+XI\2O=K#)X?BUB$":""%5>3;:O#
M/-((E+A9$CDY+_@@Y\?/V=_AW\:/VTOAI'JT_A:WL/V@]6\21V?B33KJP_LW
M0WM[>.*YO&NU4VFXH?EN2DC'=P2K[0"G_P $'/VJ/ '[%O\ P;:_#W]H?XDP
M2SZ=I.KZO:06D,T<37-Y>>*KFRM83)(0D2M<7$2M*YVQJ6<\*:^\_AO^T/\
MM"7?[2-E^SQ\<_V:=+\.)JG@?4/$>F>+?"_CI]9TV8VEW86TEDWG6%I+'/\
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MS+LFB8.!@A\<$,  >M4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOQM::C>3?VG=6;7'FK:22>1:(;."XFG=<)':MMRS!' /K"OEW_@J!;:K\<_
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M^,_'.K?$3P/>^(O VLZ5KFFQ6NOK%$7B2V)F8)&V,R371MQ$F7"R#:&^//\
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M<6MW"LD<J'JK*P(8'T-6** *5CX<\/:8]M)IN@V5NUG:&ULV@M40P0$J?*3
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M/?CMK>J"X\5V-B?#WCT,V9%UFQ"Q32/Z-,GE7('9;E:[W]AS]F?P?\+/V3/
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M *)]\5?_  VU[_A1_P /@?V8O^B??%7_ ,-M>_X5]545?M\K_P"?$O\ P/\
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ME:6*2QTV.9)+BX$SM-%NN!*(84M78P"(S 2F1'_LM_M*_MK?!_\ X*_>*O\
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MQ:\!6'@SXB_#?7-7@CU7P9))+IT]JK+Y]PWVAGO3'@21Q1-9JY^5VP-QR_\
M@HI\ ?VR?BW_ ,%<?V3_ -I;X1?L@>)/$7@+X)7OB!O%NO6WB?P_;&4:G;Q6
MZ-;P7.I1S2"/RM[;D0D'"@GBNB^/?P,_:J\8_P#!;_X&_M<>&?V6O$5W\-_
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MZ.^8T<'UKX5_'_\ ;X\+?\%%=#_9\BU#XI_%'X%>/O"%XT_Q*\7?!H^'M1\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*OB)XN\0WD=[XR^(?CB]6XU36[F.%((MY4!8H8HHUCCA0;4&2=SO([^PT44
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>ino-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:ino="http://www.inovio.com/20201231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ino-20201231.xsd" xlink:type="simple"/>
    <context id="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib419158dcd6f4738afa4cc04916d0e83_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8cea5729188744ba8f522ce4fcb02501_I20210226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2021-02-26</instant>
        </period>
    </context>
    <context id="i461a06745d764430b3e72d9b80f2433e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if06f128df0d4400ebe7bd1d7e8943618_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4a2b66e18d454ede830f8d1d4aada02f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3fcbfe891e274002a1ffb387d3ce3a69_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0158aa5ba6a546b99ab881b2e80f21f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i63bf584a99b7490ca78c1a42bda4e636_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iffddb18409714a948fe63c504296aa8c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0dc6151b860b45f89bb347c96f739dc4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i30743f88af6d4d7884fdb78b4e04be01_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie2ddf6e556714a9194d76e2fc479466d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5d14809ed4f847dfa70ec56139f770f3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iba3bf773708b42baa53946d5d820581b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7a9e17b526b04b5ba4c3e10ea48bf9be_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ef7cd7ce94c488a826cce5fbf50a188_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i278953abb6d94a6bbe934e65ea84cbfe_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie9103f0c23474b5c8e125a115c2724a8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i33e4ffc6b1db495eb2fe9e7c8433e217_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic393612319cb4ba8af0f0b3942e04555_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idb7e049ad2784543b766df1154e2599c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id6014b9675e54093ba947147d012abd7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i67b9315f7b704679b653ff7f7615cf07_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib3981f22251049ee93fbe814da0d83e3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i505e79e18d4842ec9b1a16442f4c83ba_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iaaf5815034574ba68cf12263477730bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3888369ceb0d47fd91589b1bd565e24b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0398c951aeaa42e8a809af10d39ca6e8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i37ba42be07e34414bfad4d78f2cdd2c1_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i28bc6b87217f4ff59425a80bbd1e2ad1_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic2d253912b0f4408b7670b8cbf6b0149_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic56fe18af934493fa8353bf3feefd308_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i75e4a748c91441108389565fa9192239_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic8049e1241294c54aa32f8547e18a755_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i098d7fa0e69c497394a273e6da442d60_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iee35bc1d9e0c43538284362e3939b7f2_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ib7aba2cb555e4b1ba182fde50316d33e_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i9955fcfc3e2c4e3b81ca03f6caf2daa2_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="icb4f83564ad0407e9192905a852387c8_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ia18d7a4702454a37944331f885cfb8b1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib44b98a091634594bb6b156389961e55_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i287bb517d7014611b68f17996d1f4e9c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i86080f7508e64793a3517dba947f4e05_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4f0daeaeee744d499efc2b85f77f9d54_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7a3a60879f794353a9d97762ab033aa3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i740feef31f3f47f0ba79a75a7d90f120_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i67fdcc0b65fc4a0089a046845912b455_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ife9269e896424523ab66d904e94b790c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia497f4c2f35943b49482c9b5840af9b9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifc185e611aa641b780dc3634c14f4ee0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5cbd0517be1f4ad2b1e368f3d2f228a3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7825d9df4ecd47ff89c494932b5e4951_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if885952e35d34a77981589fd208c6f6e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4bb1fb8250b642e28bbf60ee14bb5157_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i87950b9f2a414087a42b5de774c7f46d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib2a2c6f594ba44cea4528ac7e5994bbe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7e3418a8da5543a1b4777a24eeab51bd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i005f7fef38fe454d8d059b0ff21bb4cc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i107de4cc8049489c90dcdc7df31185d7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3627569429294e4ca52aea6769a42428_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icf69dcb513af441394c278e7178dd8e1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i23a4b782e98343ba867b1942902cd9c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia154d39818f845b8b99981331588d907_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iab9cb5c1258e4438bb749f1d6a97298c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7793a330338242b48cd682861d2c7f7b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i360f12716f38470bbf4ae171a15c2372_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i71043bc300f54b1da5f262214bdd0d8f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2cd6d538b5cf46eea148f05fc8d3313e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic03220c5093b43cfac7c2b6ee8ed0184_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i51877c6afa3e4a95a48234a7814aa510_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifa46d2918b494bf6b84cf170d1bd45b3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib11feb96d4f04657b2246c8fc89ee878_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1cf0fd331c9340aab8d9ff4bdb145e55_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4b271c4ed074580b9dd08164751212e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5cbd1b6109f04daeb2321b67b43c7080_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie7451d3a8f3541b6bfb4ad50349ef17c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f72e3ff2fe94fd3bd217b59590c7d5e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe28f3a96c8b4546bb455081a9f12d46_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b8aa89313b84034867fdb688e65bfdd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibc5e017651494a17b39d87c26345b84c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6150a0ddcd004d80a33e1a8697c53f20_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if84110be1e7d414fba59970232a6a0c4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie36d4982a87c49f39d1d799e83d16f3d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i537cf66d5bd342bc8318a0e2943c17c8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i340206d59d1a4f37a0d265ecd256f49a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9e8658006af5464d94cdc5612be9184f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7b92526d2c7d46a19cf0c21a5393e2ca_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0b080f596f2e47f7a9e4906d33a20b22_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i83b2ddee9dbd4ad99f2320f64af7b7d5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ea16c625aa4430da8652fcd9977062c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if2f035d8d1f74d318e1f75455e89e2e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iba72fa0012f445dd820803f63d0f038a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i656dfbe21acc42619acc008ddb6d5362_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9025cc3fe1a74a43b1903d7fbd5b140e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9609d90a67ee46b7abceb06d1fcaa5b7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9c0e39c482da423594a8b74a964a6471_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie3dffc4892f444aea3b32fa15bd0cbca_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibf6b492d876f45ff96cd2a77765bdef8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id3e05652c96d47cbb27fabd2cf99fc32_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2128ce96ca6b41749cc080d568dfb0af_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i922f47d757b34b2d903a5c97adad9e66_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icd0b936b6baf4cd39d116548a1ec5f65_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0491bd11569e4c70be12a68e3eb1cbf2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8f8129c3d125441a91d09e391d9c6e73_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i89954e650abd432f915000cefb94d545_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icecba79931fe4bc5a892cd67d1db6a6c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i82c6c3c2c1c34abca8e04f10eaa8f2fc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i09fb87c71e9d48c9b0018f20e4d467a7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1c09b6ea337f41979072422f8aba29f1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifdabd2e1d4a641529a738e6e5213335b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i27178e3407dc46aeabb6e03458be5284_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i833eed11e677427591fa49c0a58a8d3f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if1f13165d5d6482590debad2f6e92178_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idb0e0943a16c445bbe684491faf920a8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iddced08b347f44f785f1537e866c5bf5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id2d6cd258bb84425bbbfe977d3faefb6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1c09bb9e28c146a2a7d84bd07c5eb551_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i020096d75bda46dcb066c2fd6645c02b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i58fdd3cd014b4e69a232a56367655377_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i59d8b0164c8b45a394697662732fe279_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36022e8256554cf79c99deed72b40319_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie1340701a627440abb646d47f8dd59a0_D20210301-20210301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="i613bf85d5ad641aeb9777c902ee5e720_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1629a50f2cbd40418d7f6000e5d7136c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i07a67056b0694c8eb1abe2d9df8f95cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0580e1e8b8464f7daadfc64c85589325_D20171229-20171229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-29</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="ic70aad9f1bbb46c7aef9aac80dd8d982_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="iccbc152ca5c64a51b143e8f925a6386c_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i0d23e87ce6a14739b73a33d11363becf_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i198477edba824f6ea373e4e1b0ef0825_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d79fdc0914349cba02f4425251657ee_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ida214446db3b464690a216afd28cd2bd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5415ff5fd21249ac9bb9bf4e91ebb967_D20150901-20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="i0a96b2b8330c413eac49b9d0b68a5735_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iecbf562e66684d72bb93637a9483430f_D20171231-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-31</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="icde7df1aa421475ebcaddca0a5faed9e_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1ba7d9f763e04c32b364239929d24393_D20190302-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-02</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i9f7ef79982d84ebd9bc2953403b7e029_D20180411-20180411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-11</startDate>
            <endDate>2018-04-11</endDate>
        </period>
    </context>
    <context id="iea76d18ca06a49d7851b0c0ff3a34c6d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i85493c81c5114a8795086a2445f83c41_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id233e1d41be44b12951cb39c380c2e4c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62896ff9dfdf42f19fd838c00bab3f1d_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="id6e5de1ef1e64ba791fd38a6b29b9cc9_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i3d96c9c2aee04b989b045f3a11979c60_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i3d1c029556354cc880be0619e862bd95_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i0e7308dee93f48cb8fc7b11c2b76aaad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8b4cb28aa5624d32a8dd171551850f0e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i56edaab4f0df412ba9168d447a83002d_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i234be8858e5244cdbdbccb259435578a_D20190801-20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="i6257d5c8c1b740bea21e2623fc3ce7b3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic708a39c59804e988fb7464a0d0169de_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if593976c97db405798c736bb8b0cda97_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8903d8385b2841c5b9653a466d3c1db9_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i915d8cff852f486180f3c82d2ebda044_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ief209891b012422a8c1dc68518ef3bc4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i87746e71a46a454787656a4370821f51_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6ea2ecae9adf4b6a887dee064675992e_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7bd9953ed4844195ad1d5a16e1dba0ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99bceb219d684923a420db226755fc2f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id0595f6d10944686ae57a515abd3ec36_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id170cedd88294bc89c6f402a37e123d7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if06443a97a314fdb92d5c69b9c9a3577_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie9de27164b224d649a37a0d1268584c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id26a1e4045ce4ee0b3633de9cb1dac61_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id77b897f2b2646018276c3a658805161_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i68422a65e88b40e79296e5aa6b8060db_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic061ab952f6e49ceb26243c60817cee2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i17c551a0610440a7b6f0abe61e8c82f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iacece918c44e4d6ca768677f180897d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i94dda5a90e794d048dc952d0627fdba7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iddeab32014174a6eb2d035b28d1446b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ca9c371fd4d4ea3be2f6127b2b2dffa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibbdeb8f70e6a44778a3ea02aaaeb1562_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9e8472dc355b42e086aa634156b612b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if851e1354ade45b6a4ac89925d9a4403_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62adc1206c1a4893b5f3e46ab68ec7dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ca4e3a2cfb347d1961b839895da975d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if81c022e21c148fcbb11892de0c3ae71_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99fa94fde4e748cfab7a583ebf129abd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1a574e3690b4028a3943434014b9a30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0710bc234ed846439f5d59a967a8aa8b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76a5e1669e794e9db24a12f605d4c94b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1005ed8e84ab4360b9311d1c584538bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i13d84d47d468404abefbd435934323d5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e2afcee19774482b251567dfd704749_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2913e54184ff437ea27bd0066e1dafd0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia26736c769c2420f9ca66117d30c734a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic0ea3dd77c114edaa793e22ac478cf97_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i66b39d6da16f4eb380e2a990dfff1f36_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i096fa31c0c464101ae5cf90270267cde_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idce13f5e5f4c4fc5af43c4edef726f4a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icd3a02a734354ed7820d83f40571c7d6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8add3b9ca8da438b900d8ea5ac0b076c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie64a636ae54645beb9d8ee43e42dcc10_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i86bce27cb66c4603aa2e7c5f6f92d9d6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7004a0f54b4e4ac8adfa3750ee6ccf4e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7d23fef8ecff4bdebfef8e1a463d13e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i221a334cfa384bf7bff65c8d98c24f2e_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i627a611d119640b18733b47fcdec6850_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ib52bd61505e648f7bd380109eafb2944_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if7a4e61e0eaa451ca758740df043909a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6c79379a56b342509ef8394d089e5206_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib09ce28847f9441691e291976b0a485e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icc1ad91fea794c9590f178cc0037615c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e8cb281f8e84403b97d0d2fecd0b80c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic4ea9cc86768413da095a70b56c90878_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i16a1aae8996946329e172cd6fe4f18be_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i71a6c7568e7c4d8d9bfa945381152967_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic13e135184a4471d939ad3f817c42607_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i786830bb15014490bcfe93e2c9d6a1e0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i86bef865624946d194ded3a39b0a65c9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id292a9ccf0334d99847358e5a3ab1c42_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifab0a228644849cbb1110e99d5c4def2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i34104c83002345e7a7bc49036cda039d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i281ff24884ff458b8adb28cb18217a61_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1c4dc4da8dca44c2a1fe44b672260615_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i85bcd3d07a5448baa7741c3754cf1afb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic8cfb53cdc7e41538de275f318de41dc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i60903cdb147d440493201f13edec1181_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibdff2f0208d44cfe89bc5c92c6d26e82_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8e37913d1c5547849d25527ab47a8354_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia92449862a9b4330882477084d9c358a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6147c70afd684bf981a1e0b1202b8058_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ica6d55dbeb8f4cc3a279ee53cb51b7f6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idf1bd4850cb8489ea58ab4b2fda5a1a9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia1e50a9cd8294f3fa132e51c85220781_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i06dcac265f274ebb9813e7af23d4696d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i69dd35be2ade4fb39a51b18d53c5b8ac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i608cd9009af344c89aa12e0f7b311227_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i823cb278de9e47d192778260c3f6db48_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idc88be27567345b7a63177cf8f6f0a99_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic35720e7a755474fbed63e8de7d3a5c2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i93819976a973446ea1061a1f37473186_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib4efea026d744acf8d1ff320d47ea351_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i488395dd3cfd4a979f4c1b6dc93cab19_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i74e4216a6494415aa925b9f9484b6be5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia060b83189564cb68c4c124f57185051_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6d4ece7344ab45b3a9385623a0a4e13d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8525ad5935324dd89b3d251246713420_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:MCDCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic4b3aa0a98414a8abe5a915a77d31a03_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:MCDCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ife05d4e1d47d421fb4f563cd562c6a2c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3f2dd21c2fb446e1ae44bb46996bcb90_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i37c81a59aea34482aaa080e093a3867a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1ab2e4de0604a18954781289db76d63_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c19b53631bf4b87bd6a70572b19cb99_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i33214248981d4bc3b9306852d8766f9d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a2f30004a6f4760aa2daadba4a229e7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i142b64fd7b4e4c77ab64ed7e235de34e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie5d0edfd70ad4cd9b77378f5caf6c6fb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i331d2b93d53845bbbec83894edc52039_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i714873ccaa6945ed8fddc9ca8b4a2ba9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i78dee1adddd343d99fde448fd85a0794_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i898390694847439889865bfd898b6744_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5b01ba2e220c4965b4bea51288906959_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3c086571fe9d4f12adaba3aba2947770_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie0d8a0c7b06b44b58e6943d769503627_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i564bfb8806cf4e91b81d269583a69770_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3873b02397f24b078c0992e44ff9bc6b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i18f5246a5fd14efc8c588f0e34623d44_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic368e3ff4b6c43beb3e373aaad80cfaf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ab95ac0698643e2a24b4f704858ab14_I20190301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-01</instant>
        </period>
    </context>
    <context id="iaa895d662b3145c5a41a31d0ed8415b0_D20190219-20190301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-19</startDate>
            <endDate>2019-03-01</endDate>
        </period>
    </context>
    <context id="ib1fd9f19434d481d9950a24dc8314104_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ef0a0da5279497abe1189b528c9b923_I20190801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="ie42755ee382b4362b35b654a372750a0_D20190801-20190801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-01</endDate>
        </period>
    </context>
    <context id="i9081e6bad5e84753997332afda1396e2_D20200803-20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="i1b97fc9dbea24d1a8c1cc2caf0be1794_I20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="i3e5cc4151269456bb11f37ef3096b655_I20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="i4b884d1d8cee4549b13c04c430171c0d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i68fab246bae941029c1bb3eb8d3d4400_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i8b9a6b9c0fba4da0a1e8ad1ae9afb802_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i01aabdcf7e1946cfad86edb560658159_I20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-26</instant>
        </period>
    </context>
    <context id="icec95e1e34f940efa96dfde18a03f4f4_D20191226-20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-26</startDate>
            <endDate>2019-12-26</endDate>
        </period>
    </context>
    <context id="i700bda11831d4df3889dde4f49d91305_I20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-26</instant>
        </period>
    </context>
    <context id="i8b023471d6394305b1996c77b2d112da_I20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJuly22020ConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-26</instant>
        </period>
    </context>
    <context id="i90a70ccee3354926b91c35b43f4f36de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifbed9e38f9f44e17bc3443f38555ff5b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d6e94e1cacc426ebf7ec4cb5e51ff53_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic594f80a76ff4858a3452511b0ae1fad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i450df2d2eb374134a57819c4d3d41137_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8951003210074b36b9dda9db0f8457f5_D20200803-20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="i71b20462bd004edbab068b83724e067a_D20200803-20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJanuary22020ConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="i5ab9e4f47cb2474880c78cd6c2a71a3f_D20191226-20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-26</startDate>
            <endDate>2019-12-26</endDate>
        </period>
    </context>
    <context id="i42d318dbd29f463e80af152ae64602b6_D20191226-20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJuly22020ConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-26</startDate>
            <endDate>2019-12-26</endDate>
        </period>
    </context>
    <context id="i43ff85947d654cd3b9d8600362c08d4e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d422727fda34bcea389c96828efbd6f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idf338a94fd4b4eceba8d37e44eab78f0_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9ea987ce83ae454ba3d280374d688b3a_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8846f56dce3d432d966649b28efa7c9a_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="ia01d038a4d224f74b7cec88d7ab01932_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i02e208f208514fac82fa7b99a461039a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5ae124c42b254d14b9b5f269fd7419ce_D20200403-20200512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-03</startDate>
            <endDate>2020-05-12</endDate>
        </period>
    </context>
    <context id="i2b37597d28484e31879b4ec99d19767b_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i64aec48d41f548978f711e0981b117a9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0a9f7074a224430daf98266033b9e313_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00014904fa624256a7ae429094225ce3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie326789176224a66adc6eb18840f7e83_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i868ece5d5ec040e5bc282761eb8ff2b3_I20160513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-13</instant>
        </period>
    </context>
    <context id="i1d250281b0084a9c9e85c87f5e174e6c_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="if5aa6e62b90746e2a0e7a79dcda10743_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i336b7f2097e04fa9946695e9082976b1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ddcf49caf034014b934f70e033c7381_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9a611d11b194c04a97196e8637d3ea5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3d376d80def94aaeaa2d3d07b689dd72_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7b2e5387ae774d5b966fe4cfedf17ca3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib3f04bc964bc4062b85a1da80bfd3649_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i495966b5ff4e4727a8837c97fa4bd60a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i60c500e2193a495a8e8d53e8bda2c96e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5686e8d556c34f1287b6ab813a0dfe50_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifcfb3bb7cf6d4f7f907cc373a9f10860_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f0bd5564d5d480c930234de144bd099_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9bd082535e33430d840b84b42712a05a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic358738bd92c4585907376620670c7fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia6335ae27741400684bafee789c7d140_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iadcbc296b043424a97f9d0cbf4b4f313_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8447cd2594e94149a11ee2086d36b99a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9d936012135e4af182293a6bbca9297d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia2a529a3bc394bac9063df42512b5b9c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0f5ffa0e16ec4dcca0f2275c5832f658_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6a196d09ea024f9f8f82d3947718333d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieac0bc60961d47e7ab6e7a227877260b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6a4f019880eb4d7e9f92a9fef1fc03ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb1a3d043e3142e993801b0549b85c79_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i424ca8a2ddb04b9d9993270673bfb2b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0529e897544648afb4f8c8facb9c526d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7b636fe087494ecaa5b251e1c14a1e4b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0898c082ec1c41a5a28d7feae8fd298d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib8ba04b2fc50444a883de5f9c28c9da1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a8b1922df074f8d881dc9835917dfc0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1329f8962cf44001a77927afa8dd9600_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5d1018668fb54f4a8f27dc2bbbebbc43_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5c519ce051934157ac2a92180ffe1298_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01d41a23f9d7414e9ca33540626eb820_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie3b43b488fbc4c9bb91dea3e06d1edd9_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i091f59652b674cbba9a610be2bac6d93_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="ice5bec7f1fe94cf09064dbef4b963a15_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i1795839f068f4fc6864f4b49d44926c3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id8df0be21b6144949f383e03e347241b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i49fe24c3cf784f4aad4300bb064363bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71066e05ce5044f48965c132ee5b5187_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id04015c2a4c74d3f9bda78d8a29a1f31_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5d75b37d31b1415baa94fe75e2eced26_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if2747486006c46f3999136afeba9ca67_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie5382c3775034bdc84ed280f6032b6c1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2ef5e314188044e59bf80890444a8798_D20200827-20200827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-27</startDate>
            <endDate>2020-08-27</endDate>
        </period>
    </context>
    <context id="i2dcec29e7a224ece9361e16b87782889_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib776ba015a6a43aea6946a399cff7c5d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:CaliforniaIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6a7c79dd6fb44fea2add2a158468fae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:PennsylvaniaStateIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id072f2455d4849af90468cc0d319cb25_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i41c87ddc992c48b1acc2970661bb9d63_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id820841c83d4427ca89b1647c1b78ca7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie1a1fd05e61e4d45b37b83d2c13345a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i52f711d0981940219b0fb0f426d25c3d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc506eb64eb44797985abc96b9c8f82f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie9f188d112294323bf3087ef33c420b6_I20200827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-27</instant>
        </period>
    </context>
    <context id="i39837d9d2abd48a3aca884118a65d728_D20200827-20200827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-27</startDate>
            <endDate>2020-08-27</endDate>
        </period>
    </context>
    <context id="idbd8535467dc4b5eae52e74f3983bcef_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iec6e16acd2c14a4e90471eef35722254_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i31ce6dcaa01b46eeab8e3956ce276921_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if81fb01786fc4764ac42fbc00018292e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i741b2d70a16540e4849e177841399ef2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if9933acb5084469ba365e771ad142f6f_I20200220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-20</instant>
        </period>
    </context>
    <context id="i8fa046515d344201b301dfcac426f1d7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i12e6aa36d34c4fed9f215ef703733288_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i584919522b8946388cc46b11e1b6c134_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i850db8c1404e41ef8a3f4e2c5d6497c9_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="ib07cb6287f3248b5b722d555d87a2523_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i510403322bee48dd9b1d7fa361079cf8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4bc8a5ec417940d080468c000bb0c684_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i329099e1a64e4114916fa70aa8f77967_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1344066b478244ff886e0ea7d3f13c3c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3278752f623242159a014d02f29d289b_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="ie036575d65ff4badb43323c689c9ffe6_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i9f560f41562c4fc9a3ad15d9c446af7c_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="ie331329335874c70bd80518d6ff9c532_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5fae662cff7740e8b862767817b4873b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if720e223acd541dc9a923f12ccafdf0a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id6ef275f991c4ded9ea7eddc6b7b1498_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i9bc7852775b6421ca17e8e3e194bab5c_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i4eaf8e38eb024ee5bd2c0e686600ecd3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i75e5c84b89524b7285a0f1fd58ce7d28_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="ica4b744c22f9404fa2cb9f77877257ff_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="id3d03457e0864bfc8b1b8bfd7dfc1ec0_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i3c0fc01307c94a3f818e05fa200f315f_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i9a56ec56c1704c999304cafdca127971_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i1d304f7e01154532bc01359f95252e17_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="ic121c422f0fe4bf881984c703f46d52f_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i684fbe7297024813bfc8e35aab204865_D20200601-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iefe35c0283fe4a69ae2e6dd8855e61f9_D20200601-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i760444398ee74fd3afd5baf01b8fc34e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ide3b32650b4e4f67aa4cae4aa5642502_D20200601-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i294f24f4c95d4f61a311238a03b975ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4dc3ada5f7d04ae89165c132fbfcfc62_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="ic0f4d31539a04f7f8e95ff7d666d0c49_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if88d7d6e81274ed0ba37814cb46d85e5_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i573ba12b81674a4e8f8ea7ef32efdbe8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i795cb1a151064426a4dfe996df0c38c4_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i13703c117a254b43812c022797496182_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i67fe64f9d9cc4e94987901784abf46ab_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i070e992116654fa581ad7cf2f0c976f3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ife87feec4ca84488991ff60a2283130f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0d9cc3f0455f498ab2daa193d5030329_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib6d2e46c031143829dacb9e46e09d8e3_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i590abc5d2cd1439bb9b334157e97cf1c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i10e7342c08644032af98955a95c3f840_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i63f67afbae934928a16259c4523b7b46_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6b066217c7b540b2bc2fabd939e07804_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8b1addc1c587493fa83cae1c6f2f7fc9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ica64d2e3910943c8a4e37fa1fe5e8214_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6e09b6ad2e474af5bfdec3ff92271d9f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ifdb7d9b899e44f18bf0403f267912de3_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib072c12c52ab4aeda860c97446fc70b6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie49e671657294b3c8baefe0969b6bae7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9a5a1a01c5584587899e703311afd962_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1af80391a9d7498d9623d41397672588_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i97adc1d442cd448fb9146600ab5d2804_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i270677398e2d488297835140b7cd4b5e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iab53db1ca1924309875498ea3f081da6_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="if64f1e0018c643a58e89139a5f4c240e_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9c9ec00a3c0e4514abe1f49e7c8af240_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1fdefad67e8242bda643664dba8120e2_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ieb1b5faf5d454621b7facd84a26755bc_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="iedf7ee151bb8419a90965b37855024f2_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie53b02189840498b87e2fd8412e3a928_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i606478849fd3433da994e2810ba1aab2_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie60fc32c63d143b0a967a81f8d4d95a9_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:OtherRevenueAffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i748a768d51414cce859cb0837e99006b_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7c6db7698a064eee933877749271a1c0_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="if258c2eac36b42adb8115f070d01b735_D20210125-20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-25</startDate>
            <endDate>2021-01-25</endDate>
        </period>
    </context>
    <context id="i6888c79a29d34124835456052fe2309e_I20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-25</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="krw">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="segment">
        <measure>ino:segment</measure>
    </unit>
    <unit id="investment">
        <measure>ino:investment</measure>
    </unit>
    <unit id="day">
        <measure>ino:day</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="lease">
        <measure>ino:lease</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl80L2ZyYWc6ODcyMTRlNGMwOGQ3NGZmN2FkYjZiZTUzNjZiMDliYjMvdGFibGU6NzkzODFmNGEwZmM1NGUzYzgxNWViMzRhOTVmOTc4ZDQvdGFibGVyYW5nZTo3OTM4MWY0YTBmYzU0ZTNjODE1ZWIzNGE5NWY5NzhkNF80LTEtMS0xLTA_cdfd8476-7ee5-42a9-aca8-8db042aaff82">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl80L2ZyYWc6ODcyMTRlNGMwOGQ3NGZmN2FkYjZiZTUzNjZiMDliYjMvdGFibGU6NzkzODFmNGEwZmM1NGUzYzgxNWViMzRhOTVmOTc4ZDQvdGFibGVyYW5nZTo3OTM4MWY0YTBmYzU0ZTNjODE1ZWIzNGE5NWY5NzhkNF82LTEtMS0xLTA_2a522920-3ead-4d3b-846b-2ce3562d8e4a">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl80L2ZyYWc6ODcyMTRlNGMwOGQ3NGZmN2FkYjZiZTUzNjZiMDliYjMvdGFibGU6NzkzODFmNGEwZmM1NGUzYzgxNWViMzRhOTVmOTc4ZDQvdGFibGVyYW5nZTo3OTM4MWY0YTBmYzU0ZTNjODE1ZWIzNGE5NWY5NzhkNF83LTEtMS0xLTA_17dda1f8-c179-475f-99a2-64dcf4c9b5b5">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl80L2ZyYWc6ODcyMTRlNGMwOGQ3NGZmN2FkYjZiZTUzNjZiMDliYjMvdGFibGU6NzkzODFmNGEwZmM1NGUzYzgxNWViMzRhOTVmOTc4ZDQvdGFibGVyYW5nZTo3OTM4MWY0YTBmYzU0ZTNjODE1ZWIzNGE5NWY5NzhkNF85LTEtMS0xLTA_8289fa02-f035-483f-a69e-c2473854371f">0001055726</dei:EntityCentralIndexKey>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="iee35bc1d9e0c43538284362e3939b7f2_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTAtMS0xLTMxNDc_6c803ced-512a-40ed-a3f9-5c37b9e3854b">us-gaap:AccountingStandardsUpdate201601Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i83b2ddee9dbd4ad99f2320f64af7b7d5_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzg3MzY_3ade6400-d079-4bc2-a028-5e2e5c6e9030">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i83b2ddee9dbd4ad99f2320f64af7b7d5_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzk2MDM_9dbc4512-b92b-4a6e-ae6e-052ec9675f3d">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="iaa895d662b3145c5a41a31d0ed8415b0_D20190219-20190301"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzgvZnJhZzo0YzViYmRmZWY0MDA0YThkYWU0N2QwODBjMzk0NmY4ZS90YWJsZTpiNjNhMzdkMDQ1OTI0NzFhYmM5YWQ5ZWI5N2E4MjMyMy90YWJsZXJhbmdlOmI2M2EzN2QwNDU5MjQ3MWFiYzlhZDllYjk3YTgyMzIzXzItMS0xLTEtMA_57abfa90-4c48-462b-aee2-23ff321af171"
      unitRef="number">0.1858045</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i8951003210074b36b9dda9db0f8457f5_D20200803-20200803"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzgvZnJhZzo0YzViYmRmZWY0MDA0YThkYWU0N2QwODBjMzk0NmY4ZS90YWJsZTpiNjNhMzdkMDQ1OTI0NzFhYmM5YWQ5ZWI5N2E4MjMyMy90YWJsZXJhbmdlOmI2M2EzN2QwNDU5MjQ3MWFiYzlhZDllYjk3YTgyMzIzXzUtMi0xLTEtMA_f8072c97-bf03-4b53-9390-31ffb5ad365e"
      unitRef="number">0.0002110595</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i71b20462bd004edbab068b83724e067a_D20200803-20200803"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzgvZnJhZzo0YzViYmRmZWY0MDA0YThkYWU0N2QwODBjMzk0NmY4ZS90YWJsZTpiNjNhMzdkMDQ1OTI0NzFhYmM5YWQ5ZWI5N2E4MjMyMy90YWJsZXJhbmdlOmI2M2EzN2QwNDU5MjQ3MWFiYzlhZDllYjk3YTgyMzIzXzYtMi0xLTEtMA_28b0ddae-8bfd-4094-ad1f-b25e79a7426c"
      unitRef="number">0.0002756873</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i5ab9e4f47cb2474880c78cd6c2a71a3f_D20191226-20191226"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzgvZnJhZzo0YzViYmRmZWY0MDA0YThkYWU0N2QwODBjMzk0NmY4ZS90YWJsZTpiNjNhMzdkMDQ1OTI0NzFhYmM5YWQ5ZWI5N2E4MjMyMy90YWJsZXJhbmdlOmI2M2EzN2QwNDU5MjQ3MWFiYzlhZDllYjk3YTgyMzIzXzktMi0xLTEtMA_66d6e9a6-5728-4a38-b543-e14d5c2053a5"
      unitRef="number">0.0002147766</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i42d318dbd29f463e80af152ae64602b6_D20191226-20191226"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzgvZnJhZzo0YzViYmRmZWY0MDA0YThkYWU0N2QwODBjMzk0NmY4ZS90YWJsZTpiNjNhMzdkMDQ1OTI0NzFhYmM5YWQ5ZWI5N2E4MjMyMy90YWJsZXJhbmdlOmI2M2EzN2QwNDU5MjQ3MWFiYzlhZDllYjk3YTgyMzIzXzEwLTItMS0xLTA_74dce970-7639-4e00-8055-cb6331e0f53c"
      unitRef="number">0.0003579611</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODc1_0d2fa81f-48d2-4a94-ab91-4ddfc6769027">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6ZDZjODJlNDc5Mzk4NGY0Nzg0OTUxNTg2ZGYzODJmNTcvdGFibGVyYW5nZTpkNmM4MmU0NzkzOTg0ZjQ3ODQ5NTE1ODZkZjM4MmY1N18wLTAtMS0xLTMwOTc_29065eed-2045-406f-a950-d72c1a2b6b8d">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5OTE2_e211a8bb-aa48-4b17-9049-bc151893a919">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5OTE2_de891eec-78db-48a7-a549-8b3531a0014c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6ODA2NjU4YTM4MmY2NGFlY2FiOTZjNmIzYzgxNWE0Y2YvdGFibGVyYW5nZTo4MDY2NThhMzgyZjY0YWVjYWI5NmM2YjNjODE1YTRjZl8wLTAtMS0xLTMxMDc_9251fa2e-c261-4923-b979-826ec18cbed4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODk2_5e06afd0-6ea5-417e-9491-37ecc0fead7e">001-14888</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODc2_e3a1e873-08e6-448d-9062-d95aededa447">INOVIO PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NzQyYjg2NThjODY2NDRmNTg5YjlhODk1ZTJhZDQzMGYvdGFibGVyYW5nZTo3NDJiODY1OGM4NjY0NGY1ODliOWE4OTVlMmFkNDMwZl8wLTAtMS0xLTMxMTI_b0eb10b5-7b3d-4d64-81f7-385e064f932f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NzQyYjg2NThjODY2NDRmNTg5YjlhODk1ZTJhZDQzMGYvdGFibGVyYW5nZTo3NDJiODY1OGM4NjY0NGY1ODliOWE4OTVlMmFkNDMwZl8wLTItMS0xLTMxMTQ_f50fd6f5-d210-411a-acf0-2ebc8ed8c0b2">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NzQyYjg2NThjODY2NDRmNTg5YjlhODk1ZTJhZDQzMGYvdGFibGVyYW5nZTo3NDJiODY1OGM4NjY0NGY1ODliOWE4OTVlMmFkNDMwZl8zLTAtMS0xLTY0NTIvdGV4dHJlZ2lvbjo2MTc2NDYwY2FhN2Y0ZGUyYjM1ZmJiOGRkZTc4ZDVlMV82NTk3MDY5NzY2NzQ2_cf4dd8e9-d578-4eee-9d82-96dd3df66b92">660 W. Germantown Pike</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NzQyYjg2NThjODY2NDRmNTg5YjlhODk1ZTJhZDQzMGYvdGFibGVyYW5nZTo3NDJiODY1OGM4NjY0NGY1ODliOWE4OTVlMmFkNDMwZl8zLTAtMS0xLTY0NTIvdGV4dHJlZ2lvbjo2MTc2NDYwY2FhN2Y0ZGUyYjM1ZmJiOGRkZTc4ZDVlMV82NTk3MDY5NzY2NzU4_3bd1265c-b0e2-452e-852d-5951b078b708">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NzQyYjg2NThjODY2NDRmNTg5YjlhODk1ZTJhZDQzMGYvdGFibGVyYW5nZTo3NDJiODY1OGM4NjY0NGY1ODliOWE4OTVlMmFkNDMwZl8zLTAtMS0xLTY0NTIvdGV4dHJlZ2lvbjo2MTc2NDYwY2FhN2Y0ZGUyYjM1ZmJiOGRkZTc4ZDVlMV82NTk3MDY5NzY2Nzc3_654e0f3f-51c6-4517-a0d5-c14655438ad7">Plymouth Meeting</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NzQyYjg2NThjODY2NDRmNTg5YjlhODk1ZTJhZDQzMGYvdGFibGVyYW5nZTo3NDJiODY1OGM4NjY0NGY1ODliOWE4OTVlMmFkNDMwZl8zLTAtMS0xLTY0NTIvdGV4dHJlZ2lvbjo2MTc2NDYwY2FhN2Y0ZGUyYjM1ZmJiOGRkZTc4ZDVlMV82NTk3MDY5NzY2Nzky_732d4bbe-4eb8-4a9f-a88e-c143295c7330">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NzQyYjg2NThjODY2NDRmNTg5YjlhODk1ZTJhZDQzMGYvdGFibGVyYW5nZTo3NDJiODY1OGM4NjY0NGY1ODliOWE4OTVlMmFkNDMwZl8zLTItMS0xLTMxMTc_66d3c7c8-3e0f-4a46-98c7-4c90be8523be">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODc4_5d954b8c-eba5-4184-aa66-8a68d9ad53ca">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODgy_fe7d3673-365e-4db5-8b78-761011f0e626">440-4200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NDc1YzU3M2FkNTkzNGE2ZmI0ZTdjZDZiYjg1MDgxOTgvdGFibGVyYW5nZTo0NzVjNTczYWQ1OTM0YTZmYjRlN2NkNmJiODUwODE5OF8xLTAtMS0xLTMxMjI_887df21b-d032-4d68-a2dc-7afef0e83892">COMMON STOCK, $0.001 PAR VALUE</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NDc1YzU3M2FkNTkzNGE2ZmI0ZTdjZDZiYjg1MDgxOTgvdGFibGVyYW5nZTo0NzVjNTczYWQ1OTM0YTZmYjRlN2NkNmJiODUwODE5OF8xLTEtMS0xLTMxMjI_119c15ba-c7d3-49ef-8ceb-575fd0b8d18c">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6NDc1YzU3M2FkNTkzNGE2ZmI0ZTdjZDZiYjg1MDgxOTgvdGFibGVyYW5nZTo0NzVjNTczYWQ1OTM0YTZmYjRlN2NkNmJiODUwODE5OF8xLTItMS0xLTMxMjI_cc06896c-bff1-4cf7-b2bc-7f0f6db68ad4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzcxMDE4_93ab7fed-7ae0-48e1-b104-8825a0c46217">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODg5_66336ba2-e718-46d7-a488-ecfe255302e3">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODkw_373887b2-ce49-4ce2-8cb4-6946135b805c">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODkx_80182e0f-8203-4915-ac82-81ce75801173">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6MzBkZTc5YmEyZjQwNDZkNzk3MTZjMGMwMjBhYjcwZjkvdGFibGVyYW5nZTozMGRlNzliYTJmNDA0NmQ3OTcxNmMwYzAyMGFiNzBmOV8wLTAtMS0xLTMxMjk_950e5d97-2d48-4969-b8ab-b7688da4c7a2">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6MzBkZTc5YmEyZjQwNDZkNzk3MTZjMGMwMjBhYjcwZjkvdGFibGVyYW5nZTozMGRlNzliYTJmNDA0NmQ3OTcxNmMwYzAyMGFiNzBmOV8yLTQtMS0xLTA_99d88b98-f59c-4781-a8d3-6184ae70a06c">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGFibGU6MzBkZTc5YmEyZjQwNDZkNzk3MTZjMGMwMjBhYjcwZjkvdGFibGVyYW5nZTozMGRlNzliYTJmNDA0NmQ3OTcxNmMwYzAyMGFiNzBmOV8zLTQtMS0xLTA_4a7b4a35-d72e-49f0-b957-1c4eb23389b1">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzcxMDE2_b41e4f9b-c8ed-4ca1-a236-1ec69f66d2c6">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODk0_4fc2257b-9b87-4096-9639-438821455881">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ib419158dcd6f4738afa4cc04916d0e83_I20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5OTM1_0e79bb32-09b1-4ce7-8f3b-0d003c33c4b7"
      unitRef="usd">4200000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i8cea5729188744ba8f522ce4fcb02501_I20210226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM18yNjI1_53abc506-ce1b-4c3a-83ce-1cc832f41141"
      unitRef="shares">207632584</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xL2ZyYWc6OGFhNGJmMzJjYjgxNDExZjkyNGJhNmZjNjBiZDdlMDMvdGV4dHJlZ2lvbjo4YWE0YmYzMmNiODE0MTFmOTI0YmE2ZmM2MGJkN2UwM182NTk3MDY5NzY5ODk1_8252de07-0a05-470f-b28e-c800dd239203">&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Portions of the registrant&#x2019;s definitive proxy statement to be filed with the Commission pursuant to Regulation&#160;14A in connection with the registrant&#x2019;s 2021 Annual Meeting of Stockholders (the &#x201c;Proxy Statement&#x2019;) are incorporated by reference into Part&#160;III of this Report. Such Proxy Statement will be filed with the Commission not later than 120&#160;days after the conclusion of the registrant&#x2019;s fiscal year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQtMS0xLTEtMA_d21e037b-f11c-4810-8d2e-fcaddce6474d"
      unitRef="usd">250728118</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQtMy0xLTEtMA_b89d6a91-8741-43ad-8b81-5f4252b49968"
      unitRef="usd">22196097</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUtMS0xLTEtMA_1bc7c0aa-1564-4894-9fc9-fd0178db9a71"
      unitRef="usd">160914935</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUtMy0xLTEtMA_9db420ea-43f6-4015-be67-cfdf98150a20"
      unitRef="usd">67338017</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzYtMS0xLTEtMA_59ce6ed8-ba94-4a2d-b868-edbedd13c43f"
      unitRef="usd">18559967</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzYtMy0xLTEtMA_642db9d8-a367-4570-8afd-3adcf4b90b2e"
      unitRef="usd">700073</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzctMS0xLTEtMA_c1c31720-dd5a-4d22-b6eb-c93ac85396fe"
      unitRef="usd">503782</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzctMy0xLTEtMA_0d2456a5-db13-4fee-8b5e-31db92c680f1"
      unitRef="usd">1332044</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzgtMS0xLTEtMA_978e557e-93ca-4a8f-a7f8-0ccbf9b08d15"
      unitRef="usd">40357456</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzgtMy0xLTEtMA_d1e59aeb-2e47-4441-ac76-4c00a487d18f"
      unitRef="usd">1584598</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzktMS0xLTEtMA_3136d693-a357-4807-9801-760a173c3f89"
      unitRef="usd">106432</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzktMy0xLTEtMA_27a42f2a-8a9e-4b25-a444-1f2a8cf0abe0"
      unitRef="usd">1050140</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <us-gaap:AssetsCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzExLTEtMS0xLTA_795ac727-891d-4c45-8b43-674c6ec091a3"
      unitRef="usd">471170690</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzExLTMtMS0xLTA_a8002e20-c853-44cd-8ff1-60f64e492ecc"
      unitRef="usd">94200969</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzEzLTEtMS0xLTA_6cb60291-1aa3-4efb-ba3b-c13e6b0c4fbe"
      unitRef="usd">11348144</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzEzLTMtMS0xLTA_c704e07c-a10a-4ca2-a735-53f5098b44e0"
      unitRef="usd">12773017</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE0LTEtMS0xLTA_8fed0780-3637-49d4-a50f-3836e09a24ba"
      unitRef="usd">4460366</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE0LTMtMS0xLTA_b78d5191-c6ca-4cda-a651-f75748bb312f"
      unitRef="usd">6315356</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquityMethodInvestments
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE1LTEtMS0xLTA_2fc4a2f9-0953-4ac8-afd5-cab173128be0"
      unitRef="usd">434387</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE1LTMtMS0xLTA_ce6d8f32-8ba6-48c9-8d6b-5e5e70f1f6e6"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE2LTEtMS0xLTA_83771023-04ed-42d4-b2f1-2a1a8bdd7a99"
      unitRef="usd">3146770</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE2LTMtMS0xLTA_e3da2d6a-1138-4fc9-87de-89c8960c4e49"
      unitRef="usd">3693851</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE3LTEtMS0xLTA_bc302da5-1b36-4637-b43b-033e548c8e18"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE3LTMtMS0xLTA_891acbe6-61ee-4039-bfcb-c3a25a92fedf"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE4LTEtMS0xLTA_b4f33359-eb2e-4bf9-a1b0-7d52520532a9"
      unitRef="usd">12741296</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE4LTMtMS0xLTA_9bd05156-0400-4ef3-8975-ad10be0d8c50"
      unitRef="usd">13783009</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE5LTEtMS0xLTA_23512443-1ebd-4932-9d53-8237deae63c8"
      unitRef="usd">25957448</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzE5LTMtMS0xLTA_184f989a-2a27-4d8f-b3b4-b27090eeaf6e"
      unitRef="usd">2672024</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzIwLTEtMS0xLTA_96bcb389-c531-4789-b5cc-333da3ff0082"
      unitRef="usd">539772472</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzIwLTMtMS0xLTA_abf6ccdf-5a61-4158-8ef8-5ec8c3910476"
      unitRef="usd">143951597</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzIzLTEtMS0xLTA_b9d83fd0-bf6b-4aad-be60-bcc725bfcd92"
      unitRef="usd">21203808</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzIzLTMtMS0xLTA_a05a56fa-c405-4954-80cc-724c5edbe351"
      unitRef="usd">18237258</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI0LTEtMS0xLTA_ad817782-ac69-4d30-a554-731427bda6d3"
      unitRef="usd">642969</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI0LTMtMS0xLTA_b487acc3-b39e-4478-b4f4-8e11b25cd7b0"
      unitRef="usd">729729</us-gaap:DueToRelatedPartiesCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI1LTEtMS0xLTA_e5a8a9b6-1c6f-4090-9628-8dadb616f76b"
      unitRef="usd">9950345</ino:AccruedClinicalTrialExpenseCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI1LTMtMS0xLTA_d1d19913-9da5-489b-b2bc-954fca2135ed"
      unitRef="usd">4049727</ino:AccruedClinicalTrialExpenseCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI2LTEtMS0xLTA_296bd7f5-a7c0-443b-901b-69ce4d419192"
      unitRef="usd">46628</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI2LTMtMS0xLTA_14cceecb-84df-41cb-a722-b24e89865aff"
      unitRef="usd">92353</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ino:DeferredRevenueFromAffiliatedEntityCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI3LTEtMS0xLTA_2f9b1711-defa-4f47-8abe-ccc21f82dac5"
      unitRef="usd">0</ino:DeferredRevenueFromAffiliatedEntityCurrent>
    <ino:DeferredRevenueFromAffiliatedEntityCurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI3LTMtMS0xLTA_7b94dfa3-7adb-4e92-a3e1-97eb0b7f89a5"
      unitRef="usd">31775</ino:DeferredRevenueFromAffiliatedEntityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI5LTEtMS0xLTA_a7203d2b-b0df-4f18-926f-5ccc597ce010"
      unitRef="usd">2329394</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzI5LTMtMS0xLTA_cae3c4a2-549c-466b-a5fb-484bd7c4f09f"
      unitRef="usd">2074842</us-gaap:OperatingLeaseLiabilityCurrent>
    <ino:DeferredGrantFundingCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzMwLTEtMS0xLTA_7adcc721-b7d8-48ab-a6f7-0db48a030ef3"
      unitRef="usd">7474310</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingCurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzMwLTMtMS0xLTA_4d8f0b06-f240-4064-850d-0e4f2ded79d6"
      unitRef="usd">6065212</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzMxLTEtMS0xLTA_ed9146d9-f69d-417f-b4ea-ef618d72ea22"
      unitRef="usd">58500</ino:DeferredGrantFundingFromAffiliateCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzMxLTMtMS0xLTA_7de3e229-5c21-4508-8803-b2a4c8724ca7"
      unitRef="usd">708425</ino:DeferredGrantFundingFromAffiliateCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzMyLTEtMS0xLTA_a25cca64-a70b-431e-af3b-219ee2e408d5"
      unitRef="usd">41705954</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzMyLTMtMS0xLTA_5e6ad976-0b12-40cb-a78e-15338a181585"
      unitRef="usd">31989321</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzMzLTEtMS0xLTA_2670923b-1c39-445d-80cf-5a0696b628de"
      unitRef="usd">79214</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzMzLTMtMS0xLTA_c9340584-34e3-441a-b506-bb652ae5c551"
      unitRef="usd">101567</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ConvertibleDebt
      contextRef="i4a2b66e18d454ede830f8d1d4aada02f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzM1LTEtMS0xLTA_41648d86-b8a3-47dd-a64c-fa1d25a4d5d7"
      unitRef="usd">14139988</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i3fcbfe891e274002a1ffb387d3ce3a69_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzM1LTMtMS0xLTA_74126820-82b7-4099-85da-8d0b60693bcb"
      unitRef="usd">64180325</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i0158aa5ba6a546b99ab881b2e80f21f8_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzM2LTEtMS0xLTA_02929256-8777-495f-816f-12af2fd2cf35"
      unitRef="usd">4515834</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i63bf584a99b7490ca78c1a42bda4e636_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzM2LTMtMS0xLTA_adbeaf4d-2fd4-4024-ae3c-6a67fb133ca1"
      unitRef="usd">12842592</us-gaap:ConvertibleDebt>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzM4LTEtMS0xLTA_a5b85fa4-5a22-45a0-aafc-aaa6ebf6cc80"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzM4LTMtMS0xLTA_bfd4e914-481c-411a-ad96-f8a743e354c1"
      unitRef="usd">8819023</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQwLTEtMS0xLTA_9c477b78-d3a1-4eed-96e2-2df5934bebf5"
      unitRef="usd">18063515</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQwLTMtMS0xLTA_aba83fe3-7f68-4223-9154-4d4fdc214671"
      unitRef="usd">20409922</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQxLTEtMS0xLTA_521ca78c-4b1c-424a-98b5-2fb69c8e8253"
      unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQxLTMtMS0xLTA_82d52c3f-908f-489e-b1da-399ef79dc76e"
      unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <ino:DeferredGrantFundingFromAffiliateNoncurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQyLTEtMS0xLTA_ca357c25-d7c4-4834-80d2-599450634c8e"
      unitRef="usd">37500</ino:DeferredGrantFundingFromAffiliateNoncurrent>
    <ino:DeferredGrantFundingFromAffiliateNoncurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQyLTMtMS0xLTA_03df10c5-0933-4075-b6f2-1ed41785a9f5"
      unitRef="usd">135000</ino:DeferredGrantFundingFromAffiliateNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQzLTEtMS0xLTA_4111742c-21ec-48b8-97df-3277545628fe"
      unitRef="usd">57663</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQzLTMtMS0xLTA_c43df967-ca50-420c-9daa-33b8a0fb2e85"
      unitRef="usd">36943</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ0LTEtMS0xLTA_038034ac-cb5f-4cd4-9df9-7cf5ef6012c3"
      unitRef="usd">78631714</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ0LTMtMS0xLTA_feb7cdf9-5220-40fa-84d0-b4c92a8a04be"
      unitRef="usd">138546739</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ1LTEtMS0xLTA_a3d80409-c3ef-484b-9e25-ad52ed8fabc3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ1LTMtMS0xLTA_b530cebf-e8ef-4ef7-a3eb-ee8fbad00554"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3ZmYxMGQ4NWVjMzg0Mzk0YTMxYmFlMDE2ZTk3OWIzZF82NTk3MDY5NzY2ODEy_6fd541a8-41bc-49fc-b2b5-a3fadf73c019"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3ZmYxMGQ4NWVjMzg0Mzk0YTMxYmFlMDE2ZTk3OWIzZF82NTk3MDY5NzY2ODEy_8d057eec-b97a-41fc-9415-3fcc6dbe6907"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3ZmYxMGQ4NWVjMzg0Mzk0YTMxYmFlMDE2ZTk3OWIzZF82NTk3MDY5NzY2ODI1_0873bfde-6cf6-41ca-906c-f9c4a03790c4"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3ZmYxMGQ4NWVjMzg0Mzk0YTMxYmFlMDE2ZTk3OWIzZF82NTk3MDY5NzY2ODI1_4c333985-aa90-4ce9-a173-1f973e4cf4da"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3ZmYxMGQ4NWVjMzg0Mzk0YTMxYmFlMDE2ZTk3OWIzZF82NTk3MDY5NzY2ODI5_8abf60bf-a415-4f98-873d-17d9bda1f766"
      unitRef="shares">9</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3ZmYxMGQ4NWVjMzg0Mzk0YTMxYmFlMDE2ZTk3OWIzZF82NTk3MDY5NzY2ODI5_9e11c9a2-a40e-4c7b-a4f5-e79a01c6570e"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3ZmYxMGQ4NWVjMzg0Mzk0YTMxYmFlMDE2ZTk3OWIzZF82NTk3MDY5NzY2ODM0_4d377c01-bfcb-4097-93af-73c3e9534480"
      unitRef="shares">23</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTAtMS0xLTAvdGV4dHJlZ2lvbjo3ZmYxMGQ4NWVjMzg0Mzk0YTMxYmFlMDE2ZTk3OWIzZF82NTk3MDY5NzY2ODM0_86640b10-97d2-49c0-82f7-6c5e0c83d278"
      unitRef="shares">23</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTEtMS0xLTA_3a4bead6-3f95-43d4-aecc-a71312bf65c2"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ3LTMtMS0xLTA_3f46d666-2b3f-4da0-afed-c39d753cc2b9"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NThhM2YxM2FiM2I0OWE1ODA5MDNmY2UxMzA4MzgxNl82NTk3MDY5NzY2ODY1_2e296d44-52dc-49a2-afd6-dfb25cf39dd8"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NThhM2YxM2FiM2I0OWE1ODA5MDNmY2UxMzA4MzgxNl82NTk3MDY5NzY2ODY1_3d626885-ffb6-44c9-ad78-bd476c7aa6be"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NThhM2YxM2FiM2I0OWE1ODA5MDNmY2UxMzA4MzgxNl82NTk3MDY5NzY2ODc5_1686c912-4be2-4d2e-a650-9f6dabd1be4b"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NThhM2YxM2FiM2I0OWE1ODA5MDNmY2UxMzA4MzgxNl82NTk3MDY5NzY2ODc5_ca78b21f-395a-43ff-8171-a1b411b06a8c"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NThhM2YxM2FiM2I0OWE1ODA5MDNmY2UxMzA4MzgxNl82NTk3MDY5NzY2ODkz_56d18637-64f2-4db9-bafc-d5e57fa81e21"
      unitRef="shares">186851493</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NThhM2YxM2FiM2I0OWE1ODA5MDNmY2UxMzA4MzgxNl82NTk3MDY5NzY2ODkz_d3160517-baf4-4660-9b5b-d03592f8d32e"
      unitRef="shares">186851493</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NThhM2YxM2FiM2I0OWE1ODA5MDNmY2UxMzA4MzgxNl82NTk3MDY5NzY2OTA3_5ce41c88-815d-4222-bbd9-c937f36fa314"
      unitRef="shares">101361034</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTAtMS0xLTAvdGV4dHJlZ2lvbjo3NThhM2YxM2FiM2I0OWE1ODA5MDNmY2UxMzA4MzgxNl82NTk3MDY5NzY2OTA3_fe0c75b7-522f-4fae-a604-937239295a06"
      unitRef="shares">101361034</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTEtMS0xLTA_953c23b3-fb6f-4366-8d71-ab8089848028"
      unitRef="usd">186851</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ4LTMtMS0xLTA_aa5b6d23-fb94-4e66-86d0-beefbd66b7aa"
      unitRef="usd">101361</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ5LTEtMS0xLTA_47eae51f-2485-40eb-bc14-2f4374a14f35"
      unitRef="usd">1367406869</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzQ5LTMtMS0xLTA_a3f69366-3cd6-4816-a778-c03e9f585b99"
      unitRef="usd">742646785</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUwLTEtMS0xLTA_db2e5eab-6e3c-4832-932d-7a9cf1eccfc6"
      unitRef="usd">-906196812</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUwLTMtMS0xLTA_c0e5dfe0-5051-42e4-a070-067af6fc505b"
      unitRef="usd">-739785655</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUxLTEtMS0xLTA_b33017f5-6a60-4687-a84a-4201823aefce"
      unitRef="usd">-256150</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUxLTMtMS0xLTA_1031b87d-f62a-420b-a3e4-7b56373671cd"
      unitRef="usd">472608</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUyLTEtMS0xLTA_ba315b26-683b-4a05-9b85-e00e74fab486"
      unitRef="usd">461140758</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUyLTMtMS0xLTA_8e1a003d-7233-49ec-b735-a1986ebf6e59"
      unitRef="usd">3435099</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUzLTEtMS0xLTA_23559e4b-9b7b-4df7-80d2-20f81a7f9410"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzUzLTMtMS0xLTA_2f6bfd3c-542b-4cb2-9fdd-c0761f5844a6"
      unitRef="usd">1969759</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzU0LTEtMS0xLTA_2e3fbc38-2e49-4e38-9edd-f16f662d2fc8"
      unitRef="usd">461140758</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzU0LTMtMS0xLTA_a4cb595f-d388-4072-8577-2607fa2276df"
      unitRef="usd">5404858</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzU1LTEtMS0xLTA_f90f7232-89e6-4365-b1b6-4504754a8926"
      unitRef="usd">539772472</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMTUvZnJhZzo3YmM2ZmEyNmZlNjA0MWFjYTNiNDE0YmJmY2VhZmIzYS90YWJsZTowMWNkMDE4YTZkOGQ0MGZjYmQwNjBkNmFmMWQ3ZWFkOS90YWJsZXJhbmdlOjAxY2QwMThhNmQ4ZDQwZmNiZDA2MGQ2YWYxZDdlYWQ5XzU1LTMtMS0xLTA_4ab2a391-ca3f-4df5-8814-4351f3d20fd9"
      unitRef="usd">143951597</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffddb18409714a948fe63c504296aa8c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzUtMS0xLTEtMA_db31fa9c-7b28-4ce3-961f-f6381ebe15b6"
      unitRef="usd">5170586</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dc6151b860b45f89bb347c96f739dc4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzUtMy0xLTEtMA_722454b1-52c0-4a38-b482-8b376e49908a"
      unitRef="usd">3636945</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30743f88af6d4d7884fdb78b4e04be01_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzUtNS0xLTEtMA_511b821a-13ce-4c3b-92ef-a90e5d7537ea"
      unitRef="usd">29860785</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2ddf6e556714a9194d76e2fc479466d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzYtMS0xLTEtMA_fdb3434f-88fe-42de-bdc7-bc54265d9612"
      unitRef="usd">1453730</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d14809ed4f847dfa70ec56139f770f3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzYtMy0xLTEtMA_522e90c6-5ff9-4301-b06c-7bf2e6eff143"
      unitRef="usd">235649</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba3bf773708b42baa53946d5d820581b_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzYtNS0xLTEtMA_a74880d1-a9fb-44f1-8cd7-7e05d6cf83fd"
      unitRef="usd">449524</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a9e17b526b04b5ba4c3e10ea48bf9be_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzctMS0xLTEtMA_b5b25b4b-beb0-43a6-b352-2c244b92c8ac"
      unitRef="usd">786904</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ef7cd7ce94c488a826cce5fbf50a188_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzctMy0xLTEtMA_bca132cf-2d7b-44ad-a21e-0127536ec879"
      unitRef="usd">237536</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i278953abb6d94a6bbe934e65ea84cbfe_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzctNS0xLTEtMA_f8b58bf5-66ba-44b7-b551-933b234623e2"
      unitRef="usd">171588</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9103f0c23474b5c8e125a115c2724a8_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzgtMS0xLTEtMA_35ea0748-d117-4bb4-b023-6db8fc2d7c55"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33e4ffc6b1db495eb2fe9e7c8433e217_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzgtMy0xLTEtMA_4d726eec-e7da-4506-b021-9d12a7e66bb9"
      unitRef="usd">1800</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic393612319cb4ba8af0f0b3942e04555_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzgtNS0xLTEtMA_aedd3ca0-bd6e-4170-800d-0c1784db65cc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzktMS0xLTEtMA_fce24118-40d9-4fcb-83f8-c05d0bbab828"
      unitRef="usd">7411220</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzktMy0xLTEtMA_9a54e815-8ad1-420d-bfe5-c4b563a0b04b"
      unitRef="usd">4111930</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzktNS0xLTEtMA_f55633be-0924-4cab-9d82-f33511a699f2"
      unitRef="usd">30481897</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzExLTEtMS0xLTA_2a0387c8-c0a3-44e4-a8a4-3069dc8d67c8"
      unitRef="usd">94245436</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzExLTMtMS0xLTA_75ebbecf-7e61-4d44-88dc-55a7176f796e"
      unitRef="usd">88017319</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzExLTUtMS0xLTA_ef7a0171-068f-4ac9-89bc-60993428aede"
      unitRef="usd">95257876</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzEyLTEtMS0xLTA_3510c084-c0bb-4a69-8f5f-41395f7301bf"
      unitRef="usd">37247828</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzEyLTMtMS0xLTA_599c79aa-8456-4918-a34f-1483d21949cb"
      unitRef="usd">27203156</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzEyLTUtMS0xLTA_c59008fe-7973-4d9e-ab93-707ac1f11e87"
      unitRef="usd">29315159</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE1LTEtMS0xLTA_d7f7baa5-ac46-46d5-a9f1-ab1cbb131662"
      unitRef="usd">131493264</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE1LTMtMS0xLTA_2837c947-b5e1-459b-a3fe-36decb8912cf"
      unitRef="usd">115220475</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE1LTUtMS0xLTA_ffd5a8f0-114a-4efe-93c8-c85e58412c67"
      unitRef="usd">124573035</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE2LTEtMS0xLTA_b6765976-97f6-49a4-9a4e-8bfca11d724a"
      unitRef="usd">-124082044</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE2LTMtMS0xLTA_e99c540d-8fd2-4cc3-a23f-558d379045cf"
      unitRef="usd">-111108545</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE2LTUtMS0xLTA_a55ab1bc-ea92-4f07-a4ea-207ea7c6afa1"
      unitRef="usd">-94091138</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE4LTEtMS0xLTA_4af75335-a1ad-4db8-98f4-3460bae9fabc"
      unitRef="usd">3311846</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE4LTMtMS0xLTA_36d0e300-0654-406f-a3b4-394ddec4fec6"
      unitRef="usd">2605981</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE4LTUtMS0xLTA_02182145-9917-4504-b5b7-9ba1885483ec"
      unitRef="usd">2264747</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE5LTEtMS0xLTA_ac7aeb17-2e52-40da-8744-5e9fc36af761"
      unitRef="usd">8702450</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE5LTMtMS0xLTA_10ecad19-afae-4f70-8c15-deb5b9fdc57c"
      unitRef="usd">7948539</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzE5LTUtMS0xLTA_047cc297-0f27-4909-bc0a-f1f2614284b2"
      unitRef="usd">0</us-gaap:InterestExpense>
    <ino:ChangeInFairValueOfCommonStockWarrants
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIwLTEtMS0xLTA_f1aa8ac6-9cca-4d11-9cfc-cbab86fc62f0"
      unitRef="usd">0</ino:ChangeInFairValueOfCommonStockWarrants>
    <ino:ChangeInFairValueOfCommonStockWarrants
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIwLTMtMS0xLTA_b9e1d194-7183-43fb-bd9e-d8c4c9f06506"
      unitRef="usd">0</ino:ChangeInFairValueOfCommonStockWarrants>
    <ino:ChangeInFairValueOfCommonStockWarrants
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIwLTUtMS0xLTA_32946c11-3060-4a05-ad58-dbeac2f6994b"
      unitRef="usd">360795</ino:ChangeInFairValueOfCommonStockWarrants>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIxLTEtMS0xLTA_534b3c5c-f405-44dd-aad9-c67489c4870d"
      unitRef="usd">-75670977</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIxLTMtMS0xLTA_13d658f0-0a82-4533-8c0b-a84d4141b69b"
      unitRef="usd">-1763652</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIxLTUtMS0xLTA_a9da3926-5def-43ae-90d3-c0e8a5b0dbb5"
      unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIyLTEtMS0xLTA_d4bbce08-3db5-4445-adf3-6ce6b675207c"
      unitRef="usd">36556658</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIyLTMtMS0xLTA_a74dedb8-badc-4d22-bbfe-d24b10850139"
      unitRef="usd">-3090557</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIyLTUtMS0xLTA_1c3d389b-2360-4ecb-9ac9-48f31c1b05d6"
      unitRef="usd">-1988567</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIzLTEtMS0xLTI0NzY_15c1b55e-c33f-45c7-b8a4-349935297e24"
      unitRef="usd">1695497</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIzLTMtMS0xLTI0NzY_48214e22-a40d-4080-86a4-f10471d87a4b"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIzLTUtMS0xLTI0NzY_7e8bb0e2-a411-4a00-85e1-622521a2b424"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIzLTEtMS0xLTA_0812bed5-1a58-40bc-bfa1-e0e0d4e0d87c"
      unitRef="usd">-704896</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIzLTMtMS0xLTA_e4aeed6c-854b-4bc9-86b0-d886b4cdc588"
      unitRef="usd">496200</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzIzLTUtMS0xLTA_d1f4dd6d-c1df-4042-bf15-6b0a00056ea8"
      unitRef="usd">-1343856</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI1LTEtMS0xLTI0Nzk_7b7cdc6d-f2ba-4e0a-b4f5-15f5a333f810"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI1LTMtMS0xLTI0Nzk_3451744c-3119-4b14-95f0-507b36cf7412"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI1LTUtMS0xLTI0Nzk_6b8f848c-3001-4a2f-97de-2f49c041ac59"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i67b9315f7b704679b653ff7f7615cf07_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI2LTEtMS0xLTI0Nzk_2ab763e0-cd05-4c10-99bd-fdd954c667c5"
      unitRef="usd">-8177043</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib3981f22251049ee93fbe814da0d83e3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI2LTMtMS0xLTI0Nzk_3233eb61-623a-4591-b318-69c055122612"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i505e79e18d4842ec9b1a16442f4c83ba_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI2LTUtMS0xLTI0Nzk_beb4bb35-0ac1-48fa-9d37-87e9fc73f547"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="iaaf5815034574ba68cf12263477730bb_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI3LTEtMS0xLTI0Nzk_292c2461-7272-43c6-bb87-247fe2b008d6"
      unitRef="usd">8762030</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i3888369ceb0d47fd91589b1bd565e24b_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI3LTMtMS0xLTI0Nzk_3b9a2cab-250f-4fab-a5dc-2dd8c995198d"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0398c951aeaa42e8a809af10d39ca6e8_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI3LTUtMS0xLTI0Nzk_79def4f1-6f8c-4336-9894-2d249ff5d99d"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI0LTEtMS0xLTA_16cac49e-cf50-4ee3-92cc-be3ac7d9c460"
      unitRef="usd">-162890304</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI0LTMtMS0xLTA_bb94bbcc-3a23-41d6-af45-7213f6e67143"
      unitRef="usd">-120809112</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI0LTUtMS0xLTA_e26c1737-a660-4fd8-bc49-1eb5fc073445"
      unitRef="usd">-94798019</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI1LTEtMS0xLTA_8ef56ac6-cd1b-40c7-8690-ff30851aeff1"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI1LTMtMS0xLTA_80823c48-1bb7-470b-8ea8-85135d9fc3fe"
      unitRef="usd">-257335</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI1LTUtMS0xLTA_68ef1871-35dd-413a-9438-fa59e01a25dd"
      unitRef="usd">2169811</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzMwLTEtMS0xLTQ0NjI_70990ada-f25a-49f7-aa40-3c34bd8ae468"
      unitRef="usd">-4584610</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzMwLTMtMS0xLTQ0NjI_e7c88595-c18d-434f-840d-f0875e4597fb"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzMwLTUtMS0xLTQ0NjI_ff209079-5cb1-4388-9516-f1d12b660d95"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI2LTEtMS0xLTA_8b975bda-bdc4-4c53-b828-f22f5485e041"
      unitRef="usd">-167474914</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI2LTMtMS0xLTA_19f461fa-7353-4b1f-99cc-6f87bfb88719"
      unitRef="usd">-120551777</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI2LTUtMS0xLTA_df92955b-9b3d-496b-b13e-b129d08c4656"
      unitRef="usd">-96967830</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI3LTEtMS0xLTA_4dda885c-2666-4467-98ca-53d969579ef6"
      unitRef="usd">-1063757</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI3LTMtMS0xLTA_1d6a69a4-c7e0-46c1-a3ff-057f9e939a77"
      unitRef="usd">-1192558</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI3LTUtMS0xLTA_641ad0ea-0ffb-4e32-bde5-b975ebec7f3f"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI4LTEtMS0xLTA_caa725d0-805a-40bb-889e-eb11dc6ecfb4"
      unitRef="usd">-166411157</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI4LTMtMS0xLTA_b297604c-7836-462f-b4d1-0a8f02b32661"
      unitRef="usd">-119359219</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzI4LTUtMS0xLTA_93dec403-47d0-4b44-9803-21e9bc8f6f93"
      unitRef="usd">-96967830</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzMwLTEtMS0xLTA_67917961-b49d-4b32-b48e-c3c727b69693"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzMwLTMtMS0xLTA_80f0dbac-80e6-4d52-b336-dd27df5e2886"
      unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzMwLTUtMS0xLTA_4b3ced07-791c-4993-b19c-96006261148d"
      unitRef="usdPerShare">-1.05</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzMzLTEtMS0xLTA_34fa5607-c11c-4f8a-832b-784fe36b2627"
      unitRef="shares">155126857</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzMzLTMtMS0xLTA_468a6123-d91b-4161-8755-4b1f405075b1"
      unitRef="shares">98717999</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjEvZnJhZzpmYzYxMWQ1YTgwNjQ0YzhiOTE3N2EwZGQ3YmRhYTU3NC90YWJsZTo3MWQ3YmU4MGViYjE0MjcxYjc0ZWVlMzg2Y2Y3YWJhYy90YWJsZXJhbmdlOjcxZDdiZTgwZWJiMTQyNzFiNzRlZWUzODZjZjdhYmFjXzMzLTUtMS0xLTA_69b66e72-d440-4c18-9b0f-e5b13c1cba30"
      unitRef="shares">92539997</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzItMS0xLTEtMA_562b1eb8-e032-4d68-b11a-0b585609416e"
      unitRef="usd">-167474914</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzItMy0xLTEtMA_e3b4f661-7614-4f99-af64-45126fcf60a1"
      unitRef="usd">-120551777</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzItNS0xLTEtMA_6a4dbbaa-f281-4057-8835-a0cd8d169e79"
      unitRef="usd">-96967830</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzUtMS0xLTEtMA_8db35047-fb0b-4e6b-a3bf-1401818ecafc"
      unitRef="usd">27205</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzUtMy0xLTEtMA_ee7b58c9-eb54-41d2-aee2-1566c31a0ce2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzUtNS0xLTEtMA_829cb21a-3c63-4c09-b37d-e4e81f0808d4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzYtMS0xLTEtMA_2119fdcf-c098-43d4-85d0-d1eeeef6b718"
      unitRef="usd">-755963</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzYtMy0xLTEtMA_870a2377-8d47-49ca-82b6-0d6a4c7166b9"
      unitRef="usd">1001475</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzYtNS0xLTEtMA_1663996b-9d85-44a6-9349-6b34dacda6fa"
      unitRef="usd">-180496</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzctMS0xLTEtMA_5993747f-2707-4fbc-977d-55a9a85e67de"
      unitRef="usd">-168203672</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzctMy0xLTEtMA_b76584a1-1b41-4709-a5b8-cd785c8968ea"
      unitRef="usd">-119550302</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzctNS0xLTEtMA_e798e93c-7064-44f6-9ecc-eaac79616de6"
      unitRef="usd">-97148326</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzgtMS0xLTEtMA_d5c098df-b891-4da9-9da6-716bc9fa17a4"
      unitRef="usd">-1063757</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzgtMy0xLTEtMA_cbf95981-56e8-43c2-abeb-9787b21141e5"
      unitRef="usd">-1192558</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzgtNS0xLTEtMA_1065af87-523d-4fee-a85d-62407eb60621"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzktMS0xLTEtMA_2852ba23-d4cd-4c4f-8280-15172079ba0b"
      unitRef="usd">-167139915</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzktMy0xLTEtMA_f0eb22ba-adc4-47fc-bf11-3f25b2691e40"
      unitRef="usd">-118357744</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjQvZnJhZzpmMDU5NzFhZTkwNzU0NWJhOGRmZjFmYTc1NGEyN2ViZC90YWJsZTpjNzExZTZiMGEzOTU0NDA2YjM2YWNmMTE4NTQwOGIwMy90YWJsZXJhbmdlOmM3MTFlNmIwYTM5NTQ0MDZiMzZhY2YxMTg1NDA4YjAzXzktNS0xLTEtMA_550cdf62-ed9b-4f05-aa3f-58405976a444"
      unitRef="usd">-97148326</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i37ba42be07e34414bfad4d78f2cdd2c1_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc2LTEtMS0xLTA_9497b97c-c000-43dc-b9a0-dfb6781d3d54"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i37ba42be07e34414bfad4d78f2cdd2c1_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc2LTMtMS0xLTA_e916898c-e714-4984-91cf-92353edff5a9"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i28bc6b87217f4ff59425a80bbd1e2ad1_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc2LTUtMS0xLTA_3c487198-af22-4e2b-9d77-a07263430e87"
      unitRef="shares">90357644</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i28bc6b87217f4ff59425a80bbd1e2ad1_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc2LTctMS0xLTA_1cedefd6-14fc-43ac-ac89-abebf4ccc708"
      unitRef="usd">90358</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic2d253912b0f4408b7670b8cbf6b0149_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc2LTktMS0xLTA_b8c3703d-9ac1-4069-88d7-8b0dfe2060db"
      unitRef="usd">665775504</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic56fe18af934493fa8353bf3feefd308_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc2LTExLTEtMS0w_e2f164f7-2382-4c20-93ab-ba746db760e8"
      unitRef="usd">-523356317</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75e4a748c91441108389565fa9192239_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc2LTEzLTEtMS0w_51a740ff-5131-4faf-8292-366d9ac65353"
      unitRef="usd">-117005</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic8049e1241294c54aa32f8547e18a755_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc2LTE1LTEtMS0w_033e4444-7073-44eb-9126-952793e2d8ee"
      unitRef="usd">96269</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i098d7fa0e69c497394a273e6da442d60_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc2LTE3LTEtMS0w_a6cf37d5-8fe3-44ab-97de-7c091a9e993c"
      unitRef="usd">142488809</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib7aba2cb555e4b1ba182fde50316d33e_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTExLTEtMS0w_bdc02a01-e7e8-4a2a-9036-379da004ddf3"
      unitRef="usd">231366</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9955fcfc3e2c4e3b81ca03f6caf2daa2_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTEzLTEtMS0w_3be9cd88-22ff-4670-9e3c-923cb963bbe8"
      unitRef="usd">-231366</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb4f83564ad0407e9192905a852387c8_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTE3LTEtMS0w_cc5c860d-7f6b-4e8e-b5ce-8cd85ed11ea6"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia18d7a4702454a37944331f885cfb8b1_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc4LTUtMS0xLTA_f7de6b20-3f60-46c6-b81f-7704b3157fa1"
      unitRef="shares">5669025</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia18d7a4702454a37944331f885cfb8b1_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc4LTctMS0xLTA_21462bf7-c9ac-45cf-aa77-318fff083469"
      unitRef="usd">5669</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib44b98a091634594bb6b156389961e55_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc4LTktMS0xLTA_3e132892-b969-4204-bb29-3c47b2f1d4fe"
      unitRef="usd">29222107</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc4LTE3LTEtMS0w_de460d59-dee2-4be9-bb8f-77f24727af64"
      unitRef="usd">29227776</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ia18d7a4702454a37944331f885cfb8b1_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc5LTUtMS0xLTA_45652b8a-88b9-4d1a-b227-3c4c5df769ed"
      unitRef="shares">1199141</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia18d7a4702454a37944331f885cfb8b1_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc5LTctMS0xLTA_d95a940b-f8cc-4cf0-b1be-1f9edf5038df"
      unitRef="usd">1199</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib44b98a091634594bb6b156389961e55_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc5LTktMS0xLTA_37970517-73f5-4405-af27-7354bf034ab5"
      unitRef="usd">1808327</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc5LTE3LTEtMS0w_731a4104-feb9-4704-913d-cfb888859762"
      unitRef="usd">1809526</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib44b98a091634594bb6b156389961e55_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgwLTktMS0xLTA_5c3f51b9-1f6e-4433-9b2b-920035262f96"
      unitRef="usd">10988277</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i287bb517d7014611b68f17996d1f4e9c_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgwLTExLTEtMS0w_7f8e044d-94d1-40b1-8505-1cc170237e39"
      unitRef="usd">-333655</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgwLTE3LTEtMS0w_c893bd36-73f0-40fd-a4c2-0dfec966cfd7"
      unitRef="usd">10654622</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="i287bb517d7014611b68f17996d1f4e9c_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgxLTExLTEtMS0w_426ea1de-91ad-4526-97bc-815f858d2245"
      unitRef="usd">-96967830</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgxLTE3LTEtMS0w_5fd26aaa-96bb-4068-9478-a9d08ebf10ce"
      unitRef="usd">-96967830</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i86080f7508e64793a3517dba947f4e05_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgyLTEzLTEtMS0w_b50ce14f-c6bb-447b-b2f2-897504759a0e"
      unitRef="usd">-180496</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgyLTE3LTEtMS0w_283d5d3b-c4f3-426c-a7d7-2cb864a8a016"
      unitRef="usd">-180496</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i4f0daeaeee744d499efc2b85f77f9d54_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgzLTEtMS0xLTA_1f14bfd9-c831-4c23-a184-996bac26371e"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f0daeaeee744d499efc2b85f77f9d54_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgzLTMtMS0xLTA_efb101f4-708b-439d-a584-5412a1fb6495"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i7a3a60879f794353a9d97762ab033aa3_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgzLTUtMS0xLTA_ad591c3a-1b2d-452d-916f-928e48a62a54"
      unitRef="shares">97225810</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7a3a60879f794353a9d97762ab033aa3_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgzLTctMS0xLTA_a86f3a5c-99c1-4fe0-8d4b-82aa135075cb"
      unitRef="usd">97226</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i740feef31f3f47f0ba79a75a7d90f120_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgzLTktMS0xLTA_79135f6a-4071-4e4d-a79a-3f9a5ffc7f86"
      unitRef="usd">707794215</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67fdcc0b65fc4a0089a046845912b455_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgzLTExLTEtMS0w_f926ffdf-db0f-47ef-8c6d-f25546113cbb"
      unitRef="usd">-620426436</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife9269e896424523ab66d904e94b790c_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgzLTEzLTEtMS0w_ad0737df-42f3-4ce4-a386-3e06c4e1604a"
      unitRef="usd">-528867</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia497f4c2f35943b49482c9b5840af9b9_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgzLTE1LTEtMS0w_ca69b5db-b93f-498e-8e3f-2a6ee4cf4215"
      unitRef="usd">96269</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc185e611aa641b780dc3634c14f4ee0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzgzLTE3LTEtMS0w_74489f4d-1b6e-49a6-b25b-8371e67b55be"
      unitRef="usd">87032407</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5cbd0517be1f4ad2b1e368f3d2f228a3_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg0LTUtMS0xLTA_c7a2d6e8-bb45-445e-8dfe-cd78983dfb33"
      unitRef="shares">3340678</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5cbd0517be1f4ad2b1e368f3d2f228a3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg0LTctMS0xLTA_4901e8b8-1876-42a7-a8df-1839690bbddc"
      unitRef="usd">3340</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7825d9df4ecd47ff89c494932b5e4951_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg0LTktMS0xLTA_12047a9a-28ec-4513-876c-88d683c67480"
      unitRef="usd">9085669</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg0LTE3LTEtMS0w_0c92b50b-ba4a-41c2-ba01-faf8f8fca2db"
      unitRef="usd">9089009</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i5cbd0517be1f4ad2b1e368f3d2f228a3_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg1LTUtMS0xLTA_160ffe1e-299c-4faf-a9b7-73f7ecf9c45a"
      unitRef="shares">794546</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5cbd0517be1f4ad2b1e368f3d2f228a3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg1LTctMS0xLTA_aeeee462-f750-4ed9-80eb-da8596cb62d2"
      unitRef="usd">795</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7825d9df4ecd47ff89c494932b5e4951_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg1LTktMS0xLTA_ff51fd6d-6681-4b9e-a561-3844f35ac8fa"
      unitRef="usd">-781200</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg1LTE3LTEtMS0w_c93e16ff-ac73-40c8-b95b-bfb56146edfd"
      unitRef="usd">-780405</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i7825d9df4ecd47ff89c494932b5e4951_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg2LTktMS0xLTA_57f195e7-7a95-4644-88c0-2f3b5a514029"
      unitRef="usd">15752698</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg2LTE3LTEtMS0w_71acc1ac-af9b-40d0-8906-b880322d5651"
      unitRef="usd">15752698</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7825d9df4ecd47ff89c494932b5e4951_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg3LTktMS0xLTA_16cc3a0e-f349-4760-93ad-5dcd38bc0fdc"
      unitRef="usd">10795403</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if885952e35d34a77981589fd208c6f6e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg3LTE1LTEtMS0w_ccdf3a13-acac-486b-afad-1ef9e187882b"
      unitRef="usd">105917</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg3LTE3LTEtMS0w_4a014f47-fcfb-40b6-939e-1f07e7d474a2"
      unitRef="usd">10901320</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="if885952e35d34a77981589fd208c6f6e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg4LTE1LTEtMS0w_32e9f801-5a25-494e-9313-9778e4d8a759"
      unitRef="usd">2960131</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg4LTE3LTEtMS0w_acb75c9c-9b9b-4610-b12d-2e5bacd6b9f8"
      unitRef="usd">2960131</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:ProfitLoss
      contextRef="i4bb1fb8250b642e28bbf60ee14bb5157_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg5LTExLTEtMS0w_465071e0-6865-40b2-aad9-e5ac135c9689"
      unitRef="usd">-119359219</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if885952e35d34a77981589fd208c6f6e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg5LTE1LTEtMS0w_169c101e-606b-4d8c-94a0-74044fc07cee"
      unitRef="usd">-1192558</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzg5LTE3LTEtMS0w_dcb7861c-f9c7-4230-9114-1829f1415e6f"
      unitRef="usd">-120551777</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i87950b9f2a414087a42b5de774c7f46d_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkwLTEzLTEtMS0w_d72d9869-76bb-456c-aead-42cc58148e6a"
      unitRef="usd">1001475</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkwLTE3LTEtMS0w_750b3fa4-dcb1-451b-8dcf-25405406fe1a"
      unitRef="usd">1001475</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesIssued
      contextRef="ib2a2c6f594ba44cea4528ac7e5994bbe_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkxLTEtMS0xLTA_bed2c998-1989-4504-9fcc-4657b3fce26e"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib2a2c6f594ba44cea4528ac7e5994bbe_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkxLTMtMS0xLTA_5362f722-3891-4296-8496-f87e35d99b72"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i7e3418a8da5543a1b4777a24eeab51bd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkxLTUtMS0xLTA_4953b6ab-7f94-44d3-b264-e50534c4f5be"
      unitRef="shares">101361034</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7e3418a8da5543a1b4777a24eeab51bd_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkxLTctMS0xLTA_32c4298f-68c3-408d-87ab-868eeb511c48"
      unitRef="usd">101361</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i005f7fef38fe454d8d059b0ff21bb4cc_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkxLTktMS0xLTA_fd26b824-b350-41b8-8df6-b3a584ccb205"
      unitRef="usd">742646785</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i107de4cc8049489c90dcdc7df31185d7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkxLTExLTEtMS0w_3effe74b-4af7-41df-b0f2-244d58211bb1"
      unitRef="usd">-739785655</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3627569429294e4ca52aea6769a42428_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkxLTEzLTEtMS0w_c331bcd3-fbe6-441d-a5f9-c44e3b18e0b2"
      unitRef="usd">472608</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icf69dcb513af441394c278e7178dd8e1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkxLTE1LTEtMS0w_d42925dd-6acb-4e3a-a38c-4bf2c202e136"
      unitRef="usd">1969759</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkxLTE3LTEtMS0w_0f0b9581-e8b7-46d7-aa79-ee1e1273026a"
      unitRef="usd">5404858</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i23a4b782e98343ba867b1942902cd9c0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkyLTUtMS0xLTQyMg_ec78a746-8cac-4315-9fee-6d7739a7c8a4"
      unitRef="shares">66064886</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i23a4b782e98343ba867b1942902cd9c0_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkyLTctMS0xLTQyMg_674af010-2735-4a49-9d29-769045c1a1ca"
      unitRef="usd">66065</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia154d39818f845b8b99981331588d907_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkyLTktMS0xLTQyMg_47c61e90-4831-46eb-b08a-93b80f216c16"
      unitRef="usd">454420335</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkyLTE3LTEtMS00MjI_5796318e-0e6d-4fa8-a416-81b18014b152"
      unitRef="usd">454486400</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="iab9cb5c1258e4438bb749f1d6a97298c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkzLTEtMS0xLTQyMg_5f4205a4-914f-4b20-9fe6-9747faec8457"
      unitRef="shares">-14</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i23a4b782e98343ba867b1942902cd9c0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkzLTUtMS0xLTQyMg_29e86ff9-09b2-4a0b-98c8-53654e08b7c2"
      unitRef="shares">5147</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i23a4b782e98343ba867b1942902cd9c0_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkzLTctMS0xLTQyMg_5d140314-9286-43aa-a393-505ad9fdfe20"
      unitRef="usd">5</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ia154d39818f845b8b99981331588d907_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkzLTktMS0xLTQyMg_08802ba5-07ac-43f0-a753-54a545feaf9e"
      unitRef="usd">-5</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzkzLTE3LTEtMS00MjI_09a715e7-8893-42fd-9ec8-bc6875ffd0f6"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i7793a330338242b48cd682861d2c7f7b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk0LTUtMS0xLTQyMg_0ff6257a-5ad4-4b83-a70a-c4020d26717b"
      unitRef="shares">11535660</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i7793a330338242b48cd682861d2c7f7b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk0LTctMS0xLTQyMg_ba5f5f65-a3a2-4369-a161-50cbdd47cd0a"
      unitRef="usd">11536</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i360f12716f38470bbf4ae171a15c2372_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk0LTktMS0xLTQyMg_9312ca07-10b5-4873-b596-da66ec6d59e4"
      unitRef="usd">43682850</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="iaaf5815034574ba68cf12263477730bb_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk0LTE3LTEtMS00MjI_c6fe08f9-0d62-4d15-b557-8f898644d7fa"
      unitRef="usd">43694386</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i71043bc300f54b1da5f262214bdd0d8f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk1LTUtMS0xLTQyMg_53b012cb-d3f5-43c9-a64d-f0ceb69eb55c"
      unitRef="shares">4962364</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i71043bc300f54b1da5f262214bdd0d8f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk1LTctMS0xLTQyMg_38c4af13-50e3-45da-9220-1a7295ce2cb5"
      unitRef="usd">4961</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i2cd6d538b5cf46eea148f05fc8d3313e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk1LTktMS0xLTQyMg_e1ea6f03-1799-4156-9251-53a8116e5d70"
      unitRef="usd">102666349</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ic03220c5093b43cfac7c2b6ee8ed0184_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk1LTE3LTEtMS00MjI_8a5179f0-24b4-478f-8963-35c5a7951d34"
      unitRef="usd">102671310</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i23a4b782e98343ba867b1942902cd9c0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk2LTUtMS0xLTQyMg_0f21f805-53a4-4369-8184-24651d01b024"
      unitRef="shares">2922402</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i23a4b782e98343ba867b1942902cd9c0_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk2LTctMS0xLTQyMg_8913f0d4-d730-4898-8a59-f2c4de91f48f"
      unitRef="usd">2923</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia154d39818f845b8b99981331588d907_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk2LTktMS0xLTQyMg_b3cb408e-16a8-4717-8c35-0f84024b7c66"
      unitRef="usd">8238701</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk2LTE3LTEtMS00MjI_907e843d-7f10-44d5-af19-71396a9c98bc"
      unitRef="usd">8241624</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia154d39818f845b8b99981331588d907_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk3LTktMS0xLTQyMg_fdc7ed19-2e4d-4d48-8faa-57a83c816c48"
      unitRef="usd">15655585</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i51877c6afa3e4a95a48234a7814aa510_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk3LTE1LTEtMS00MjI_465e27a1-6fe0-4bab-a21e-e82dce549a24"
      unitRef="usd">-8062</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk3LTE3LTEtMS00MjI_cf0b7453-1cf6-4ce2-a7ba-4c795f4a17a2"
      unitRef="usd">15647523</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i51877c6afa3e4a95a48234a7814aa510_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk4LTE1LTEtMS00MjI_05b714a2-5098-4e87-a741-285359222c6f"
      unitRef="usd">2379969</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk4LTE3LTEtMS00MjI_65c21e54-7688-441c-a521-6f6190456400"
      unitRef="usd">2379969</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="i51877c6afa3e4a95a48234a7814aa510_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk5LTE1LTEtMS00MjI_b7f8c06f-7637-468b-8e72-05b972f812eb"
      unitRef="usd">3181640</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzk5LTE3LTEtMS00MjI_5bed2ade-f2e9-4801-a8f1-746fa770f6f1"
      unitRef="usd">3181640</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:ProfitLoss
      contextRef="ifa46d2918b494bf6b84cf170d1bd45b3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMC0xMS0xLTEtNDIy_eb42939a-d845-4bfe-ba74-0465367900c5"
      unitRef="usd">-166411157</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i51877c6afa3e4a95a48234a7814aa510_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMC0xNS0xLTEtNDIy_c77bd460-e924-40b9-b554-ef91212d094a"
      unitRef="usd">-1063757</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMC0xNy0xLTEtNDIy_4a2f76af-b6f3-46df-94db-62955e92286d"
      unitRef="usd">-167474914</us-gaap:ProfitLoss>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ia154d39818f845b8b99981331588d907_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMS05LTEtMS05MDYx_ee473969-8d47-48c5-923b-f615e29a10e5"
      unitRef="usd">-96269</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i51877c6afa3e4a95a48234a7814aa510_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMS0xNS0xLTEtOTA2MQ_93fc479a-7942-457c-8797-2ed14b970e6b"
      unitRef="usd">96269</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMS0xNy0xLTEtOTA2Nw_f13ae7b3-fc41-4d4c-b8db-c1bc2a696236"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib11feb96d4f04657b2246c8fc89ee878_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMS0xMy0xLTEtNDIy_ef04125c-bbd1-42e1-8422-8da83d206ce2"
      unitRef="usd">-755963</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMS0xNy0xLTEtNDIy_f8eaea1d-6a87-4ab2-b345-485161c84382"
      unitRef="usd">-755963</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib11feb96d4f04657b2246c8fc89ee878_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMi0xMy0xLTEtNDIy_106de8b2-d97b-4010-814c-2b72ada15678"
      unitRef="usd">27205</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMi0xNy0xLTEtNDIy_52909d28-596a-4e91-a073-f8de000261d4"
      unitRef="usd">27205</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i1cf0fd331c9340aab8d9ff4bdb145e55_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMy0xLTEtMS00MjI_4c6ed4b8-d27a-42e1-9b27-86e05c86333f"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1cf0fd331c9340aab8d9ff4bdb145e55_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMy0zLTEtMS00MjI_7391db9d-6ae1-46b2-b1fa-15a22dab2460"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ic4b271c4ed074580b9dd08164751212e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMy01LTEtMS00MjI_f6e55737-45bd-453e-b50f-b77457c8a197"
      unitRef="shares">186851493</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic4b271c4ed074580b9dd08164751212e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMy03LTEtMS00MjI_91e9fafc-d4e8-4a9c-a7b2-cff2a580474b"
      unitRef="usd">186851</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5cbd1b6109f04daeb2321b67b43c7080_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMy05LTEtMS00MjI_7bf1ee4f-de3d-4848-95ad-87b6a32f91d8"
      unitRef="usd">1367406869</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7451d3a8f3541b6bfb4ad50349ef17c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMy0xMS0xLTEtNDIy_8b821d70-ce30-4ed4-9d24-6cd0d701d998"
      unitRef="usd">-906196812</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f72e3ff2fe94fd3bd217b59590c7d5e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMy0xMy0xLTEtNDIy_8e0c0ddf-5872-43a9-b678-25428ceedcee"
      unitRef="usd">-256150</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe28f3a96c8b4546bb455081a9f12d46_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMy0xNS0xLTEtNDIy_d71115b0-90c1-4693-b728-dd084544c395"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzEwMy0xNy0xLTEtNDIy_05359a16-0a71-4354-aef8-8c0169c717d1"
      unitRef="usd">461140758</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib7aba2cb555e4b1ba182fde50316d33e_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90ZXh0cmVnaW9uOmRlZGFlNzNlM2MyMTRiYjJhYWY1NGIxZTdiM2FiNzMzXzg2OQ_4b00f765-c300-4d57-b01f-4b2603f7afe6"
      unitRef="usd">231000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9955fcfc3e2c4e3b81ca03f6caf2daa2_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90ZXh0cmVnaW9uOmRlZGFlNzNlM2MyMTRiYjJhYWY1NGIxZTdiM2FiNzMzXzg2OQ_abedb938-2214-484f-a63d-f5e670a01056"
      unitRef="usd">-231000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMtMS0xLTEtMA_00fa0a08-5c88-4aef-a7bb-4f9955e56edd"
      unitRef="usd">-167474914</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMtMy0xLTEtMA_954e0e77-9bde-4658-a041-d604c0431684"
      unitRef="usd">-120551777</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMtNS0xLTEtMA_7313a76d-0e0b-4f4c-a104-8fbaf69b1014"
      unitRef="usd">-96967830</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUtMS0xLTEtMA_87b6dbbf-b69f-4818-9aa9-b4ebe334d8db"
      unitRef="usd">3038996</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUtMy0xLTEtMA_3a656761-5fc7-4db9-91dd-b64967259999"
      unitRef="usd">3598388</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUtNS0xLTEtMA_69b09d97-e179-4ce1-8417-feec1a9014fc"
      unitRef="usd">3747183</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYtMS0xLTEtMA_32b84d72-d62e-4ec6-bf4d-3a7b6befb2e0"
      unitRef="usd">547081</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYtMy0xLTEtMA_dc4eb53b-8c00-45fa-a5ed-9fc8e3c0abef"
      unitRef="usd">1066294</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYtNS0xLTEtMA_77088892-43a2-47ec-9066-bddd7b1c7f66"
      unitRef="usd">1249584</us-gaap:AmortizationOfIntangibleAssets>
    <ino:AmortizationOfOperatingLeaseRightOfUseAssets
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzctMS0xLTEtMA_953685b1-9764-4baf-9988-9b0f2a12d5e5"
      unitRef="usd">1041713</ino:AmortizationOfOperatingLeaseRightOfUseAssets>
    <ino:AmortizationOfOperatingLeaseRightOfUseAssets
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzctMy0xLTEtMA_5e3b3fd9-84f6-40bc-bfef-f3e93f048a64"
      unitRef="usd">851760</ino:AmortizationOfOperatingLeaseRightOfUseAssets>
    <ino:ChangeInValueOfCommonStockWarrants
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzgtMS0xLTEtMA_d46f60cd-4faa-47c0-8b72-0bb9fbb33426"
      unitRef="usd">0</ino:ChangeInValueOfCommonStockWarrants>
    <ino:ChangeInValueOfCommonStockWarrants
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzgtMy0xLTEtMA_adf748e5-8c21-43e1-9642-427281eee549"
      unitRef="usd">0</ino:ChangeInValueOfCommonStockWarrants>
    <ino:ChangeInValueOfCommonStockWarrants
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzgtNS0xLTEtMA_101722d6-c0a9-4648-8632-60b25485dfe2"
      unitRef="usd">-360795</ino:ChangeInValueOfCommonStockWarrants>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzktMS0xLTEtMA_acdfbe9c-0a51-41a8-801c-2ce936604c78"
      unitRef="usd">75670977</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzktMy0xLTEtMA_a5161aeb-bf9b-4624-bb4c-28d4238ad3c1"
      unitRef="usd">1763652</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzktNS0xLTEtMA_30be6ed9-0bf6-4db5-a37a-e621636bcfdb"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:ShareBasedCompensation
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzExLTEtMS0xLTA_689c6c53-e9f1-45a4-a8bd-18ea029fa633"
      unitRef="usd">15647523</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzExLTMtMS0xLTA_4ca5e5f1-0f88-4c28-844c-d7281577ca75"
      unitRef="usd">10901320</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzExLTUtMS0xLTA_81f9308f-3aaf-4767-affb-6a4eaac98753"
      unitRef="usd">10654622</us-gaap:ShareBasedCompensation>
    <ino:NonCashInterestExpense
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzEyLTEtMS0xLTA_e0ffebe6-c75b-4bfb-a868-348dcf00e6d3"
      unitRef="usd">4077686</ino:NonCashInterestExpense>
    <ino:NonCashInterestExpense
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzEyLTMtMS0xLTA_1fb20137-2d8c-480f-96bc-8d99f534c8ff"
      unitRef="usd">5230954</ino:NonCashInterestExpense>
    <ino:NonCashInterestExpense
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzEyLTUtMS0xLTA_6245de95-a838-4d8c-a913-85ca3528209c"
      unitRef="usd">0</ino:NonCashInterestExpense>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzEzLTEtMS0xLTA_0f7256cc-fe39-4d38-ab31-ba6b6302ff1d"
      unitRef="usd">0</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzEzLTMtMS0xLTA_14a7372a-50a2-4de3-97ad-2cb237b283f6"
      unitRef="usd">1962</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzEzLTUtMS0xLTA_723c5c6f-5c16-41b3-9793-70317f16f1b2"
      unitRef="usd">72561</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE1LTEtMS0xLTA_380528fa-b81b-4f54-a020-e51a0f4cb0b2"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE1LTMtMS0xLTA_636ca916-587c-4dbc-a4a9-97eed3bc3adb"
      unitRef="usd">-5397</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE1LTUtMS0xLTA_5455e4b5-37a7-4714-b525-b5700fa79d07"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:GainLossOnInvestments
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE4LTEtMS0xLTA_79052109-823b-43f3-a071-91a478ce638b"
      unitRef="usd">-588270</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE4LTMtMS0xLTA_a39c77db-9fc4-44c1-bb93-c35018f3924b"
      unitRef="usd">476368</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE4LTUtMS0xLTA_96eac4ca-0ad6-4705-be81-c48bc4583f62"
      unitRef="usd">-1342005</us-gaap:GainLossOnInvestments>
    <ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE5LTEtMS0xLTQ0Njk_6198b20f-34ab-43ce-804f-d1b1515b9cce"
      unitRef="usd">1713770</ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity>
    <ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE5LTMtMS0xLTQ0Njk_f99d0ece-4759-4f30-9f91-b2d077a209ba"
      unitRef="usd">0</ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity>
    <ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE5LTUtMS0xLTQ0Njk_95426c10-b915-4405-af57-169db79dfa04"
      unitRef="usd">0</ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIwLTEtMS0xLTQ0NzU_2c45fe54-92cb-4a0e-869b-35ec240b113e"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIwLTMtMS0xLTQ0NzU_d68a5886-57b6-4e97-b75a-6ac305c09249"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIwLTUtMS0xLTQ0NzU_c5fa3899-5940-44a6-8b0f-c9ed457e0f11"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE5LTEtMS0xLTA_a1ffb1f2-47bc-4836-a12a-57cd62832f3b"
      unitRef="usd">-26913</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE5LTMtMS0xLTA_bdec8722-7922-46e2-b1a7-9d00d4122913"
      unitRef="usd">-5889</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzE5LTUtMS0xLTA_0d92c45e-7580-4a0c-9c70-79272e1eecf1"
      unitRef="usd">-14529</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIwLTEtMS0xLTA_4ca353f7-56b9-4afd-89f0-1b27c87f5ff8"
      unitRef="usd">36556658</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIwLTMtMS0xLTA_584bfc43-5205-4b84-83a1-2d23010038c3"
      unitRef="usd">-3090557</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIwLTUtMS0xLTA_ff6d28cb-0548-4519-8c82-450de89cbf76"
      unitRef="usd">-1988567</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIxLTEtMS0xLTA_10226b80-6fed-4a9f-adf6-501c2363bb35"
      unitRef="usd">-4584610</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIxLTMtMS0xLTA_79ea8cf0-b149-4ffe-b851-5fe8c0e108a6"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIxLTUtMS0xLTA_d28c98fa-15e8-4de2-8cc3-3d4073f1d96c"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic03220c5093b43cfac7c2b6ee8ed0184_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI0LTEtMS0xLTQ0ODY_4fe6a796-be4e-43cd-94b4-20d40e8af426"
      unitRef="usd">-8177043</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8b8aa89313b84034867fdb688e65bfdd_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI0LTMtMS0xLTQ0ODY_562dc32f-b3f1-4410-9d19-bea57a02ca17"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ibc5e017651494a17b39d87c26345b84c_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI0LTUtMS0xLTQ0ODY_75952463-cf58-4c96-9d26-d76bd5a26959"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="iaaf5815034574ba68cf12263477730bb_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI1LTEtMS0xLTQ0ODY_fc6d7727-e91a-434f-a0d9-37893bafc98f"
      unitRef="usd">8762030</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i3888369ceb0d47fd91589b1bd565e24b_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI1LTMtMS0xLTQ0ODY_e05fe868-7c2d-450a-af94-0c5be9b93896"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0398c951aeaa42e8a809af10d39ca6e8_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI1LTUtMS0xLTQ0ODY_63ac558f-d40c-465c-af42-44f7e2fe9b35"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI2LTEtMS0xLTQ0OTI_b4ce7fa5-ad1e-4326-8cd7-f41e41957eb2"
      unitRef="usd">1695497</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI2LTMtMS0xLTQ0OTI_f9d1d44f-ad1c-41af-8635-613a65a368a1"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI2LTUtMS0xLTQ0OTI_d4151708-b529-4dcd-961b-6961c71cc9b6"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIyLTEtMS0xLTA_d62cc118-8c93-4f0f-ad4c-2cbbd6c6985b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIyLTMtMS0xLTA_bc322159-b2ff-4344-805d-fd376c507e29"
      unitRef="usd">-266215</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIyLTUtMS0xLTA_8c9f28c9-61da-4169-acba-4afd5fb1bae8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIzLTEtMS0xLTA_a9c64b72-83d9-4564-a4f2-fe89b9eda107"
      unitRef="usd">-15902</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIzLTMtMS0xLTA_14c60c36-63b1-4359-b8dd-512cf289dbbd"
      unitRef="usd">-471172</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzIzLTUtMS0xLTA_27bc7b01-7ef2-48ae-b2cc-1471d2fdaa48"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI1LTEtMS0xLTA_12931f91-8b4f-4288-af84-f969e20f1c9d"
      unitRef="usd">17859894</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI1LTMtMS0xLTA_133bd261-b8af-462d-b093-f213f861c097"
      unitRef="usd">-2616288</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI1LTUtMS0xLTA_ccb679e7-e691-44f2-b05b-df682142c8dd"
      unitRef="usd">-2686844</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI2LTEtMS0xLTA_b61b2077-ed09-403d-912c-47e3040c5293"
      unitRef="usd">-844423</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI2LTMtMS0xLTA_78c086bf-5793-4ca7-9da2-3773d4475a2f"
      unitRef="usd">593461</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI2LTUtMS0xLTA_93a54646-3cb9-4fc6-adf5-16950cfa3bb2"
      unitRef="usd">251964</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI3LTEtMS0xLTA_6bdc8120-9f93-491e-800f-a97c25c5f946"
      unitRef="usd">38849572</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI3LTMtMS0xLTA_ae65e3a9-db5e-4fde-b12d-f76f713dcc6c"
      unitRef="usd">178008</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI3LTUtMS0xLTA_1744af7e-770b-4fd1-8d09-fd88218b5c75"
      unitRef="usd">-1194316</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI4LTEtMS0xLTA_dae67bc4-3bff-4c82-894f-ee716060fde5"
      unitRef="usd">-374107</ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI4LTMtMS0xLTA_a1f6c126-5f20-45e5-adda-dcfd9d6fd71d"
      unitRef="usd">-70665</ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzI4LTUtMS0xLTA_c3348853-1c65-4b81-bdaa-3fad4f536659"
      unitRef="usd">-725202</ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMwLTEtMS0xLTA_18294eda-d16d-4fda-9e71-1eb634240065"
      unitRef="usd">23285424</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMwLTMtMS0xLTA_544980ee-74c1-426d-9b90-3ee4e1bf69bd"
      unitRef="usd">2026</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMwLTUtMS0xLTA_e22264c1-5ad9-4100-9799-56129df2dc6c"
      unitRef="usd">30644</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMxLTEtMS0xLTA_37c15ee7-f1dd-4232-963f-3847b3412128"
      unitRef="usd">3115828</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMxLTMtMS0xLTA_7367d483-abb8-4983-97e0-aac37c16c456"
      unitRef="usd">-4337829</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMxLTUtMS0xLTA_5898065c-6ef0-404d-b043-e63c59644128"
      unitRef="usd">550407</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMyLTEtMS0xLTA_ddac1ae6-8f90-4348-baef-a37ca20a24b2"
      unitRef="usd">5962381</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMyLTMtMS0xLTA_4a0e4aac-c2e9-4275-b363-08ca811b008b"
      unitRef="usd">-1622037</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMyLTUtMS0xLTA_ee0c6311-bb74-40e4-8adc-c42fa3548727"
      unitRef="usd">-2940128</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMzLTEtMS0xLTA_a5c78e1f-8d94-4327-b81e-f713bf2974f2"
      unitRef="usd">135650</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMzLTMtMS0xLTA_913c1eef-efa8-4e51-ac43-903b1a7a7f64"
      unitRef="usd">-248063</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzMzLTUtMS0xLTA_00db7a57-f054-49da-ade8-c0c37bf53329"
      unitRef="usd">50849</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM0LTEtMS0xLTA_5602aa61-2f2a-49e8-ba3c-9cc5c3e91e0e"
      unitRef="usd">-68078</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM0LTMtMS0xLTA_ee0cee17-218f-45fa-b0b5-33d8c9184078"
      unitRef="usd">-180450</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM0LTUtMS0xLTA_00278614-8a0e-4172-a095-7ef73e1f2a47"
      unitRef="usd">-1016836</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM1LTEtMS0xLTA_9ad9bea2-5b4b-4101-892f-0f9af76e5830"
      unitRef="usd">5725</ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties>
    <ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM1LTMtMS0xLTA_bc7e414e-355d-4eda-9a58-05009c2aa610"
      unitRef="usd">-1800</ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties>
    <ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM1LTUtMS0xLTA_d1d3b453-8297-42c2-a3ef-7d97845fd509"
      unitRef="usd">-140535</ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties>
    <us-gaap:StraightLineRent
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM2LTEtMS0xLTA_3767006d-0394-4ea0-b022-a418336d882f"
      unitRef="usd">0</us-gaap:StraightLineRent>
    <us-gaap:StraightLineRent
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM2LTMtMS0xLTA_30a07016-fa40-41b4-98e8-2a731e7e8388"
      unitRef="usd">0</us-gaap:StraightLineRent>
    <us-gaap:StraightLineRent
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM2LTUtMS0xLTA_21b283a6-afab-42cc-ba0e-b4dbc0e51417"
      unitRef="usd">398357</us-gaap:StraightLineRent>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM3LTEtMS0xLTA_2115350e-c63d-40c5-b9b2-916df506dfc3"
      unitRef="usd">-2091855</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM3LTMtMS0xLTA_ec4ca243-6220-4e01-8eaa-522168cfa54a"
      unitRef="usd">-1733599</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM4LTEtMS0xLTA_0720515f-1498-4f3b-82ed-dbffaace3e5e"
      unitRef="usd">1409098</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM4LTMtMS0xLTA_481a2fbf-3107-48a1-a819-bf085991bc11"
      unitRef="usd">1899364</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM4LTUtMS0xLTA_0944dcbf-46f1-4c99-a7a3-9414d2461b3e"
      unitRef="usd">4165848</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM5LTEtMS0xLTA_552955ab-5556-4e54-a373-ee8810d41391"
      unitRef="usd">-784925</ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM5LTMtMS0xLTA_abd955f9-1dfa-4dbc-9634-ec061da9d9e1"
      unitRef="usd">816342</ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzM5LTUtMS0xLTA_33023851-0cda-41a0-84aa-bb4423d6e625"
      unitRef="usd">27083</ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQwLTEtMS0xLTA_1e0e7894-3640-473e-9abd-0d2071bcf058"
      unitRef="usd">20720</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQwLTMtMS0xLTA_36197582-7c47-47f1-86b0-f6671693e200"
      unitRef="usd">-48507</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQwLTUtMS0xLTA_224d2d1b-9c40-45e8-99d9-9430d4e34324"
      unitRef="usd">87333</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQxLTEtMS0xLTA_173cfd91-8e89-4e3d-8a9d-0b1e41866c8d"
      unitRef="usd">-177979046</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQxLTMtMS0xLTA_5f1eb86d-f284-46b2-9395-a130d8a813d8"
      unitRef="usd">-97850136</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQxLTUtMS0xLTA_d8bab279-e183-484b-9e85-5a392367bb57"
      unitRef="usd">-73550156</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQzLTEtMS0xLTA_4067e1bb-aafa-4d66-a8e2-20a5cfff2e55"
      unitRef="usd">156216677</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQzLTMtMS0xLTA_65463a0a-6094-48b7-8d4e-7cf38de71f6c"
      unitRef="usd">100950301</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQzLTUtMS0xLTA_158caa3e-94af-480a-aa10-b3b0810331e1"
      unitRef="usd">88155046</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ0LTEtMS0xLTA_bc607f1d-c13c-426e-94fb-b32bb99d2d53"
      unitRef="usd">62991023</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ0LTMtMS0xLTA_953abbdd-d9de-416a-9fda-43bde503baf1"
      unitRef="usd">92893232</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ0LTUtMS0xLTA_4ef4cf80-18ca-4e18-a15f-5dee99702555"
      unitRef="usd">132659976</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ1LTEtMS0xLTA_4d4edacd-7897-410a-a18f-ee6508e67481"
      unitRef="usd">1520665</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ1LTMtMS0xLTA_43574da4-9ae1-438b-8ebb-11b3cd758855"
      unitRef="usd">987926</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ1LTUtMS0xLTA_61d3a699-e4da-4de0-9ef0-2eff10aa1cfd"
      unitRef="usd">2085022</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <ino:ProceedsFromSaleOfEquitySecuritiesFVNI
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ2LTEtMS0xLTA_66b65ad8-de79-4f24-ad9d-64d528a26b17"
      unitRef="usd">40125418</ino:ProceedsFromSaleOfEquitySecuritiesFVNI>
    <ino:ProceedsFromSaleOfEquitySecuritiesFVNI
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ2LTMtMS0xLTA_8a494891-9268-4df0-976b-88c3627fbbca"
      unitRef="usd">0</ino:ProceedsFromSaleOfEquitySecuritiesFVNI>
    <ino:ProceedsFromSaleOfEquitySecuritiesFVNI
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ2LTUtMS0xLTA_76d50283-ba48-4ba8-ad11-abd893fd9355"
      unitRef="usd">0</ino:ProceedsFromSaleOfEquitySecuritiesFVNI>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ3LTEtMS0xLTA_a4bc1fee-060b-4720-9df7-e24d1c7900fb"
      unitRef="usd">2774851</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ3LTMtMS0xLTA_37524fac-bc1f-413f-84cd-8f246e72a675"
      unitRef="usd">0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ3LTUtMS0xLTA_c0d54c1b-af9c-483f-8c09-f9d3503d763a"
      unitRef="usd">0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ4LTEtMS0xLTA_824fa8f0-f02c-4ce2-b655-7dbfc1875e0a"
      unitRef="usd">1399999</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ4LTMtMS0xLTA_41da1a66-7200-4f0d-afa6-154b258f936f"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzQ4LTUtMS0xLTA_bfcb6a2c-df06-42cf-823d-cb2ca0d3c768"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUwLTEtMS0xLTA_f868ca9d-1c19-41fe-ae53-84db26cb6a21"
      unitRef="usd">-58795751</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUwLTMtMS0xLTA_b6cb28a7-141a-4025-a2a3-60e1edb4ff8d"
      unitRef="usd">-9044995</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUwLTUtMS0xLTA_2fa5105f-8bfd-4d4f-8dda-6b09183bc4c3"
      unitRef="usd">42419908</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUyLTEtMS0xLTA_b1be8de7-26b1-4c19-b650-b6017f983d6f"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUyLTMtMS0xLTA_27ba758d-a86d-47c6-8234-9836b80da534"
      unitRef="usd">97443617</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUyLTUtMS0xLTA_3b620de6-0fe9-4db8-adbf-cb3c5493ad33"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUzLTEtMS0xLTA_5b57e100-3bc7-483f-a60c-c2e3c179c1ff"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUzLTMtMS0xLTA_fae70432-b55d-42ae-bf43-65b5548e5f29"
      unitRef="usd">3314757</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzUzLTUtMS0xLTA_d1ba88c8-1845-430c-b7cc-af3357db629b"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU0LTEtMS0xLTA_0af2338e-279f-41e3-b14b-1fc331ac7945"
      unitRef="usd">454486400</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU0LTMtMS0xLTA_e624cd80-4413-4c90-a792-475051fae6e2"
      unitRef="usd">9089010</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU0LTUtMS0xLTA_f51f96a0-f632-4644-8318-e30eca9b2332"
      unitRef="usd">29227776</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ino:ProceedsfromStockOptionandWarrantExercises
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU1LTEtMS0xLTA_acd5fbe0-e6f5-4145-9ea3-8ae9a88924a2"
      unitRef="usd">12269801</ino:ProceedsfromStockOptionandWarrantExercises>
    <ino:ProceedsfromStockOptionandWarrantExercises
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU1LTMtMS0xLTA_caa0fcb8-19c5-444b-9c02-65dfeae87e19"
      unitRef="usd">112522</ino:ProceedsfromStockOptionandWarrantExercises>
    <ino:ProceedsfromStockOptionandWarrantExercises
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU1LTUtMS0xLTA_20510e5c-45c6-4d01-9f3b-4c7fe4f726c0"
      unitRef="usd">2421136</ino:ProceedsfromStockOptionandWarrantExercises>
    <ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU2LTEtMS0xLTA_e5cbec6e-0a8d-4e8f-be2c-c856e32e2258"
      unitRef="usd">-4028177</ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings>
    <ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU2LTMtMS0xLTA_2609591d-7b01-4a44-bee9-9d8c879d2406"
      unitRef="usd">-892928</ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings>
    <ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU2LTUtMS0xLTA_75d568de-674c-4e33-8df4-7633a79ee5b8"
      unitRef="usd">-611610</ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU3LTEtMS0xLTA_5bc14825-2c02-4df1-ab86-26ace0cb2693"
      unitRef="usd">2379969</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU3LTMtMS0xLTA_62a6bd81-3d7d-4ebc-b48b-f7f13db39f47"
      unitRef="usd">2960131</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU3LTUtMS0xLTA_9a8556d2-7b7c-438c-8433-0a280a455460"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYzLTEtMS0xLTQ1MDY_c50a3cdd-24ea-478f-ada8-406310a9f223"
      unitRef="usd">171620</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYzLTMtMS0xLTQ1MDY_8707b6b4-2b60-4446-9843-145a0db65fe0"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYzLTUtMS0xLTQ1MDY_c0d1ba7f-2c77-4942-acae-ecfcfd849112"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU4LTEtMS0xLTA_901e32ed-bf33-45f3-b695-183eef004a8c"
      unitRef="usd">465279613</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU4LTMtMS0xLTA_94471088-7998-400c-9bf8-88c40a24f635"
      unitRef="usd">105397595</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU4LTUtMS0xLTA_6ab7952a-ee9f-4dd5-8ffd-8165b25d6b03"
      unitRef="usd">31037302</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU5LTEtMS0xLTA_feedca0d-6b78-40d3-9dc4-7fa9fccff0b4"
      unitRef="usd">27205</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU5LTMtMS0xLTA_97e1e7bd-38b8-4180-91ea-7abca7eb6dd8"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzU5LTUtMS0xLTA_945005b3-b378-4bf4-9ffb-040072b35bad"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYwLTEtMS0xLTA_5abd258d-73e9-4f3e-9c51-c8b68e4fa4e6"
      unitRef="usd">228532021</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYwLTMtMS0xLTA_ac841557-9269-4009-b9bf-8a82d83ed692"
      unitRef="usd">-1497536</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYwLTUtMS0xLTA_2c2b59df-7948-4704-9d39-51be4adabd56"
      unitRef="usd">-92946</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYxLTEtMS0xLTA_fd2316f5-bd8b-4537-bafd-5830c8cfa9e4"
      unitRef="usd">22196097</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifc185e611aa641b780dc3634c14f4ee0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYxLTMtMS0xLTA_9bfb9338-cb04-49eb-93a0-a364232ded6f"
      unitRef="usd">23693633</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i098d7fa0e69c497394a273e6da442d60_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYxLTUtMS0xLTA_be305565-d325-4bb2-b9c2-c44580cdafad"
      unitRef="usd">23786579</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYyLTEtMS0xLTA_bfe81c7f-a5fa-4524-97be-742d431c7b7d"
      unitRef="usd">250728118</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYyLTMtMS0xLTA_51e4a7b5-394c-4955-8573-0c095d317a45"
      unitRef="usd">22196097</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifc185e611aa641b780dc3634c14f4ee0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzYyLTUtMS0xLTA_007bf029-713c-43d9-9cc7-2177c6b71d12"
      unitRef="usd">23693633</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY2LTEtMS0xLTA_f7be0c90-e329-4489-9d64-bdcf0ed84db1"
      unitRef="usd">136711</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY2LTMtMS0xLTA_ef60456b-f035-4a02-aa53-500d3d3bdf5d"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY2LTUtMS0xLTA_5982ad84-c574-4756-bb63-94bd68f3d56e"
      unitRef="usd">559646</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY3LTEtMS0xLTA_3a319326-3344-4e98-92c5-bca1b63b9e44"
      unitRef="usd">4624764</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY3LTMtMS0xLTA_6f1a1112-8e29-4cc7-b146-93078b28c560"
      unitRef="usd">2717585</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY3LTUtMS0xLTA_27bcaebf-daec-4d29-9b89-137475a9b50f"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <ino:EquityComponentOfConvertibleDebtIssued
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY4LTEtMS0xLTA_8c715997-de77-45e7-8035-470484d42954"
      unitRef="usd">0</ino:EquityComponentOfConvertibleDebtIssued>
    <ino:EquityComponentOfConvertibleDebtIssued
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY4LTMtMS0xLTA_38dd4647-2b2a-40fc-8a91-8d381aa3e435"
      unitRef="usd">15752698</ino:EquityComponentOfConvertibleDebtIssued>
    <ino:EquityComponentOfConvertibleDebtIssued
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY4LTUtMS0xLTA_5a7fd887-389f-4165-97d6-c4bbdc327c5d"
      unitRef="usd">0</ino:EquityComponentOfConvertibleDebtIssued>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY5LTEtMS0xLTA_781f0ce5-c656-4361-a3d0-ccca6134a205"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzMvZnJhZzpkYjk5NzI0ZTc2MzM0NWE0OTYxMzQwYWQzMTA4MDM4Mi90YWJsZTo3NWI0NjQ5MmI5NzE0YzFjOTkyY2NjYjdiZDBkOTMzZi90YWJsZXJhbmdlOjc1YjQ2NDkyYjk3MTRjMWM5OTJjY2NiN2JkMGQ5MzNmXzY5LTMtMS0xLTA_9384a0c4-b25f-428d-9d64-b6982a1fedf8"
      unitRef="usd">14634769</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMzkvZnJhZzoyZWZiZGIwNGE2MDA0MjFjYWNhYzc3MWE5YTJmMTMxMS90ZXh0cmVnaW9uOjJlZmJkYjA0YTYwMDQyMWNhY2FjNzcxYTlhMmYxMzExXzMyNTg_a0c34572-0549-421a-9a6d-e6c88855a0be">The Company&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inovio Pharmaceuticals, Inc. (the &#x201c;Company&#x201d; or &#x201c;INOVIO&#x201d;), is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus (HPV). INOVIO's DNA medicines pipeline is comprised of three types of product candidates: DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies (dMAbs&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). In clinical trials, INOVIO has demonstrated that DNA medicines can be delivered directly into cells in the body through its proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted pathogens and cancers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's novel DNA medicine candidates are made using its proprietary SynCon&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; technology that uses a computer algorithm designed to identify and optimize the DNA sequence of the target antigen (be it virus or a tumor). INOVIO then creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce antigens to help the person&#x2019;s immune system recognize and destroy cancerous or virally infected cells.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO's patented CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; smart delivery devices provide optimized uptake of its DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Human clinical trial data to date has shown a favorable safety profile of INOVIO's DNA medicines delivered directly into cells in the body using the CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; smart device in more than 7,000 administrations across more than 3,000 patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; INOVIO's corporate strategy is to advance, protect and, once approved, commercialize its novel DNA medicines to meet urgent and emerging global health needs. The Company continues to advance and clinically validate an array of DNA medicine candidates that target HPV-associated diseases, cancer, and infectious diseases, such as COVID-19 (SARS-CoV-2). The Company aims to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's partners and collaborators include ApolloBio Corporation.,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; AstraZeneca, Beijing Advaccine, The Bill &amp;amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), The U.S. Department of Defense (DoD), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#x2019;s Medical CBRN Defense Consortium (MCDC), International Vaccine Institute (IVI), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its collaborators are currently conducting or planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp;amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis (RRP); glioblastoma multiforme (GBM); prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus).  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzIw_ce16bcfc-0f0d-4e88-bd7a-ba4ffcf704aa">Summary of Significant Accounting Policies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation and Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO incurred a net loss attributable to common stockholders of $166.4 million for the year ended December&#160;31, 2020. INOVIO had working capital of $429.5 million and an accumulated deficit of $906.2 million as of December&#160;31, 2020. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash, cash equivalents and short-term investments of $411.6 million as of December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of potential future At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds under past Sales &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Agreements of $454.5&#160;million during the year ended December 31, 2020, and net proceeds of $9.1&#160;million under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of $75.7&#160;million from a private placement of 6.50% convertible senior notes due 2024 (the &#x201c;Notes&#x201d;), net proceeds of $14.5&#160;million from the private placement of 18&#160;billion Korean Won (KRW) (approximately USD $15.0&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of $4.0&#160;million from the private placement of 4.7&#160;billion KRW (approximately USD $4.1&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#x201c;Bonds&#x201d;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company&#160;may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is closely monitoring the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will impact the Company's business and operations will depend on future developments, including the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, that are highly uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. As of December 31, 2020 the Company consolidated its wholly-owned subsidiary Inovio Asia LLC.  On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority -owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions have been eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.  Refer to Footnote 19 for further discussion of Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contracts with certain of its customers that have represented more than 10% of the Company's total revenues, as discussed in Note 7.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist principally of cash equivalents, short-term investments and investments in affiliated entities. The carrying amounts of cash equivalents approximate the related fair values due to the short-term maturities of these instruments. Investments are recorded at fair value, based on current market valuations. The Company carries convertible notes and bonds at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December&#160;31, 2020 and money market accounts at December 31, 2019.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#x2019;s affiliated entity, PLS, at December 31, 2020. Investments included mutual funds and an equity investment in the Company's affiliated entities, PLS and GeneOne, at December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#x2019; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. No allowance for doubtful accounts was deemed necessary at December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fixed Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzg3MzY_3ade6400-d079-4bc2-a028-5e2e5c6e9030"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets. The Company has not recognized any losses on long-lived assets through December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%"&gt;Valuation of Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are amortized over their estimated useful lives ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzk2MDM_9dbc4512-b92b-4a6e-ae6e-052ec9675f3d"&gt;two&lt;/span&gt; to 18 years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Historically, the Company has recorded patents at cost and amortized these costs using the straight-line method over the expected useful lives of the patents or 17 years, whichever is less. Patent cost consists of the consideration paid for patents and related legal costs. New patent costs are expensed as incurred, with patent costs capitalized as of that date continuing to be amortized over the expected life of the patent. License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&#160;31, 2019 and 2018, the Company&#x2019;s intangible assets resulting from acquisitions and additional intangibles including previously capitalized patent costs and license costs, net of accumulated amortization, totaled $3.1 million and $3.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#x2019;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#x2019;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#x2019; carrying value, and accordingly, the Company has not recognized any impairment losses through December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment as of November 30, 2020, identifying no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#x2019;s results of operations. See Note&#160;10 for further discussion of the Company&#x2019;s goodwill and intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#x2019;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowances against the Company&#x2019;s deferred tax assets were $159.7 million and $137.2 million at December&#160;31, 2020 and 2019, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808:&#160;Collaborative Arrangements&#160;(&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (&#x201c;Topic 606&#x201d;). However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company's financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are remeasured at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities (VIE)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC Topic 321, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMAbs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total trial management costs, sites activated, patients enrolled, and number of patient visits. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 11) has been considered using the "if-converted" method. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2020, 2019 and 2018, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,906,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,265,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,752,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,688,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,585,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,190,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,737,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,449,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurs stock-based compensation expense related to restricted stock units and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.42%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.73%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted ASU 2018-07 on January 1, 2019, which generally aligned the accounting for stock-based compensation for non-employees with that of employees. The fair value of the stock options granted to non-employees was estimated using the Black-Scholes pricing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.71%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2019-12. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. FASB issued this Update as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 became effective as of the beginning of 2020; however, there was no cumulative effect to be recognized with the early adoption. As of December 31, 2020, there was a loss from continuing operations and a cumulative loss in other comprehensive income and there was therefore no effect on the tax provision for the period ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2016-13&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonably supportable forecast information. The Company adopted ASU 2016-13 on January 1, 2020, and there was no material impact to its consolidated financial statements. The Company will continue to monitor the impact of the coronavirus, SARS-CoV-2 (&#x201c;COVID-19&#x201d;) outbreak on expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2018-13&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In August 2018, the FASB issued ASU 2018-13, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends certain disclosure requirements over fair value measurements. Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this guidance on January 1, 2020, and there was no material impact to its consolidated financial statement disclosures (see Note 6 for more information about the Company&#x2019;s fair value classifications).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2018-18&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which clarified the interaction between Topic 808, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative &lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arrangements&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and Topic 606, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company adopted this guidance on January 1, 2020, and there was no material impact to its consolidated financial statements.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU 2017-04.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In January 2017, the FASB issued ASU 2017-04,&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#160;&lt;/span&gt;("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and there was no material impact to its consolidated financial statements.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzIx_99d50a97-b634-4278-b42a-c9916fde8791">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation and Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO incurred a net loss attributable to common stockholders of $166.4 million for the year ended December&#160;31, 2020. INOVIO had working capital of $429.5 million and an accumulated deficit of $906.2 million as of December&#160;31, 2020. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash, cash equivalents and short-term investments of $411.6 million as of December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of potential future At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds under past Sales &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Agreements of $454.5&#160;million during the year ended December 31, 2020, and net proceeds of $9.1&#160;million under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of $75.7&#160;million from a private placement of 6.50% convertible senior notes due 2024 (the &#x201c;Notes&#x201d;), net proceeds of $14.5&#160;million from the private placement of 18&#160;billion Korean Won (KRW) (approximately USD $15.0&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of $4.0&#160;million from the private placement of 4.7&#160;billion KRW (approximately USD $4.1&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#x201c;Bonds&#x201d;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company&#160;may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is closely monitoring the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will impact the Company's business and operations will depend on future developments, including the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, that are highly uncertain.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjU2MTQ_e0831233-14e5-49c7-af7a-acbed3e86cbc"
      unitRef="usd">-166400000</us-gaap:NetIncomeLoss>
    <ino:WorkingCapital
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzIwOQ_b6d73d0f-7d9e-4dbc-9035-70a4b8eef82f"
      unitRef="usd">429500000</ino:WorkingCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjU1ODE_62588a88-1264-4c7b-9b11-c11093bad219"
      unitRef="usd">-906200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MTIwMzk_49545ef8-4b5f-4031-9464-592b664b075e"
      unitRef="usd">411600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6150a0ddcd004d80a33e1a8697c53f20_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzEwOTk1MTE2MzkwMjcz_a27dacc0-061a-4eeb-b197-194fa869ee69"
      unitRef="usd">454500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if84110be1e7d414fba59970232a6a0c4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjM0Nzk_1d36c8fe-22fb-4ea2-8d38-5093908a0ee2"
      unitRef="usd">9100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ie36d4982a87c49f39d1d799e83d16f3d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjM0OTU_b11b2f37-247c-4704-bbaf-23caccded925"
      unitRef="usd">75700000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i537cf66d5bd342bc8318a0e2943c17c8_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjM1MTA_529f344f-a87c-4629-9a51-4b7ca19b8bf6"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i340206d59d1a4f37a0d265ecd256f49a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjM1MTc_4a26a7e3-0681-43b4-ba66-e0773ad0f190"
      unitRef="usd">14500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9e8658006af5464d94cdc5612be9184f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzEwOTk1MTE2MzkwMjk2_71a8fdbd-2c49-416d-9165-44e519ecbd15"
      unitRef="krw">18000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9e8658006af5464d94cdc5612be9184f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjM1MzU_34178899-83f1-4f7e-9b2e-6bd2c6265d78"
      unitRef="usd">15000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9e8658006af5464d94cdc5612be9184f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjM1NDk_e8ed2a93-a997-44ce-bab3-4d2a6659af70"
      unitRef="number">1.0</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i7b92526d2c7d46a19cf0c21a5393e2ca_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzEwOTk1MTE2MzkwMzQ2_925a6213-9f15-435a-ad47-4919b82f2654"
      unitRef="usd">4000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0b080f596f2e47f7a9e4906d33a20b22_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzEwOTk1MTE2MzkwMzYw_85020b86-4703-4160-b664-94f4231a79e8"
      unitRef="krw">4700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0b080f596f2e47f7a9e4906d33a20b22_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzEwOTk1MTE2MzkwNDQ0_f7c232c1-a2a0-4e94-aa2f-eba0bfaabef9"
      unitRef="usd">4100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0b080f596f2e47f7a9e4906d33a20b22_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjM1NTQ_1553a3b9-509c-48a8-87f4-ddc4f9ad7b44"
      unitRef="number">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzEwNDQ1MzYwNTc2MzY2_ea453cfc-0f4d-4222-8211-5e555a2984f8">ConsolidationThe consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. As of December 31, 2020 the Company consolidated its wholly-owned subsidiary Inovio Asia LLC.  On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority -owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions have been eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2Nzcx_8c6bbc91-b723-4f00-92c8-143a8a6d6053">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQ5Njc_054eaa18-1290-4394-8bdd-584fe2afc981"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzEy_19110707-d8ae-4f09-bd3a-8d98e4541c25">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzYw_06c98f11-2762-4581-a164-8a6865519f65">Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODUz_ba67406b-1744-4384-b0ae-05d20b98708d">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist principally of cash equivalents, short-term investments and investments in affiliated entities. The carrying amounts of cash equivalents approximate the related fair values due to the short-term maturities of these instruments. Investments are recorded at fair value, based on current market valuations. The Company carries convertible notes and bonds at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2Nzc3_f5733b1a-0426-4650-80b1-4d68515a6401">Cash and Cash EquivalentsCash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December&#160;31, 2020 and money market accounts at December 31, 2019.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODQ3_c8ce7c2f-4306-4d68-a3e2-19ebdafe25d9">InvestmentsThe Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#x2019;s affiliated entity, PLS, at December 31, 2020. Investments included mutual funds and an equity investment in the Company's affiliated entities, PLS and GeneOne, at December 31, 2019.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODYx_42ddcefd-943c-4251-9188-a9816b1b2248">Accounts ReceivableAccounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#x2019; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzg0OTU_208adcf7-151b-4df7-b4b6-5765112e44b7"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzg0OTU_bfdd599d-e925-401d-b091-96b9f1f5b9f0"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODgz_48894f70-de1b-4f23-8df5-e0d30917a8a7">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fixed Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzg3MzY_3ade6400-d079-4bc2-a028-5e2e5c6e9030"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1ea16c625aa4430da8652fcd9977062c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzEwOTk1MTE2MzkwNDg1_97535446-badb-41ff-9e49-da6a0133fad0">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODEx_2317c4d8-5fb4-435b-b229-d3ebb500920f">Long-Lived AssetsAll long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2Nzcy_6e948db8-86ac-4c25-b3b6-ff27bdb05811">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%"&gt;Valuation of Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are amortized over their estimated useful lives ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzk2MDM_9dbc4512-b92b-4a6e-ae6e-052ec9675f3d"&gt;two&lt;/span&gt; to 18 years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Historically, the Company has recorded patents at cost and amortized these costs using the straight-line method over the expected useful lives of the patents or 17 years, whichever is less. Patent cost consists of the consideration paid for patents and related legal costs. New patent costs are expensed as incurred, with patent costs capitalized as of that date continuing to be amortized over the expected life of the patent. License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&#160;31, 2019 and 2018, the Company&#x2019;s intangible assets resulting from acquisitions and additional intangibles including previously capitalized patent costs and license costs, net of accumulated amortization, totaled $3.1 million and $3.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#x2019;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#x2019;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#x2019; carrying value, and accordingly, the Company has not recognized any impairment losses through December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment as of November 30, 2020, identifying no impairment.&lt;/span&gt;&lt;/div&gt;Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#x2019;s results of operations.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1ea16c625aa4430da8652fcd9977062c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzk2MDk_7103a456-ab24-4a7c-87a6-c7727549d473">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if2f035d8d1f74d318e1f75455e89e2e6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzEwMTA0_5a3f8dbb-8650-4cbc-a3b0-0e2fb1db33e0">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzExMDY0_2e16879e-f8c3-422d-9b7f-9ab2826c796b"
      unitRef="usd">3100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzExMDcx_5b810b83-cb13-4ff3-afc2-a0c87fc2df78"
      unitRef="usd">3700000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2Nzky_2aec2067-b65f-4d25-92c8-01109579aaf9">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#x2019;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowances against the Company&#x2019;s deferred tax assets were $159.7 million and $137.2 million at December&#160;31, 2020 and 2019, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjU1OTU_614cb767-e9af-4800-9f81-3e96207b841f"
      unitRef="usd">159700000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzQzOTgwNDY2MjU2MDQ_b3750a5f-3b8e-4d2d-b56a-f4f5a24e1523"
      unitRef="usd">137200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODQx_3b0583c6-611f-449f-9f1d-aafeeb408867">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808:&#160;Collaborative Arrangements&#160;(&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (&#x201c;Topic 606&#x201d;). However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzY1_a1e27db2-cb80-4334-a443-8e4679cbe24a">Revenue Recognition&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <ino:GrantRevenuePolicyTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzI0_e3f246b1-0788-43d4-8b95-d91314eda863">Grants&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations.</ino:GrantRevenuePolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzU2_b302d48f-afd1-47ce-a5dd-24d8aeef3754">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company's financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzA5_c53509e8-d24e-4b33-9018-c709c67cf414">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are remeasured at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities (VIE)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC Topic 321, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement,&lt;/span&gt; to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODU2_97d169f4-2800-48af-83a2-054aec02f06d">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMAbs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total trial management costs, sites activated, patients enrolled, and number of patient visits. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2Nzk1_ec4c2717-cb83-44b5-bf2e-098b23f6b14d">Net Loss Per Share&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 11) has been considered using the "if-converted" method. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. &lt;/span&gt;For the years ended December 31, 2020, 2019 and 2018, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODA4_1c3e0292-62d2-49eb-a3ca-c6a9d290818e">&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,906,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,265,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,752,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,688,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,585,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,190,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,737,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,449,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iba72fa0012f445dd820803f63d0f038a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzItMS0xLTEtMA_6d08f939-9957-4dd9-81c1-fb19bdf5f2cf"
      unitRef="shares">8906624</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i656dfbe21acc42619acc008ddb6d5362_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzItMy0xLTEtMA_8046309c-5ff5-421e-97b3-84dc4afd2383"
      unitRef="shares">9265390</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9025cc3fe1a74a43b1903d7fbd5b140e_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzItNS0xLTEtMA_3f299963-720d-436c-bcae-37545bcf98ba"
      unitRef="shares">8752677</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9609d90a67ee46b7abceb06d1fcaa5b7_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzQtMS0xLTEtMA_910fdb40-64f4-4584-809b-90b47070a226"
      unitRef="shares">2558052</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9c0e39c482da423594a8b74a964a6471_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzQtMy0xLTEtMA_fd6e40e2-2dfc-4d72-b073-306af265a3ed"
      unitRef="shares">2069936</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie3dffc4892f444aea3b32fa15bd0cbca_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzQtNS0xLTEtMA_2d7f9e76-2606-4e43-bd42-f21a79fda647"
      unitRef="shares">1688017</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibf6b492d876f45ff96cd2a77765bdef8_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzUtMS0xLTEtMzg1Mg_847dd7f0-d3b9-4136-9dea-594266652044"
      unitRef="shares">663353</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id3e05652c96d47cbb27fabd2cf99fc32_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzUtMy0xLTEtMzg1Mg_d695bef9-d2be-4ff8-bd15-882d3fef2c7c"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2128ce96ca6b41749cc080d568dfb0af_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzUtNS0xLTEtMzg1Mg_2fcb9063-4015-449d-a6e5-f1c004ff6711"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i922f47d757b34b2d903a5c97adad9e66_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzUtMS0xLTEtMA_0942e2a3-ae81-4da0-a8d5-039fd2a6e351"
      unitRef="shares">3309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icd0b936b6baf4cd39d116548a1ec5f65_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzUtMy0xLTEtMA_09246a8d-4b75-4ec0-8fb2-f7f56dfb60e2"
      unitRef="shares">8456</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0491bd11569e4c70be12a68e3eb1cbf2_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzUtNS0xLTEtMA_c0020c05-e6f7-4f8e-93cc-e8eea2044b32"
      unitRef="shares">8456</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8f8129c3d125441a91d09e391d9c6e73_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzYtMS0xLTEtMA_ebbf078c-4fab-4bc0-be13-80935c186158"
      unitRef="shares">3049980</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i89954e650abd432f915000cefb94d545_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzYtMy0xLTEtMA_576c773d-da7e-4dc6-ae1a-e5208c5b9d8b"
      unitRef="shares">14585653</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icecba79931fe4bc5a892cd67d1db6a6c_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzYtNS0xLTEtMA_2d6ac513-15ba-475e-871e-560bceb15e0a"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i82c6c3c2c1c34abca8e04f10eaa8f2fc_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzctMS0xLTEtMA_5b71c1d6-caab-45bc-8354-c2a341870ca0"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i09fb87c71e9d48c9b0018f20e4d467a7_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzctMy0xLTEtMA_82d9c657-0bf0-422b-bdaf-2ec2574803aa"
      unitRef="shares">3799071</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1c09b6ea337f41979072422f8aba29f1_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzctNS0xLTEtMA_444ed911-fea8-45f0-929b-3b21ab5c06c7"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifdabd2e1d4a641529a738e6e5213335b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzgtMS0xLTEtMA_03e4ba74-65f9-417b-bf19-66d0a5435ad6"
      unitRef="shares">1009450</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i27178e3407dc46aeabb6e03458be5284_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzgtMy0xLTEtMA_70dbde31-0ed6-4140-b830-4f215b7d12d3"
      unitRef="shares">1009450</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i833eed11e677427591fa49c0a58a8d3f_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzgtNS0xLTEtMA_3db742ce-7029-4812-8a0b-ceeed609000b"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzktMS0xLTEtMA_227b7158-6a73-41b6-b3aa-66e2ffb8824c"
      unitRef="shares">16190768</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzktMy0xLTEtMA_2cfff47e-0aaa-4bf1-a797-916094d4ef7b"
      unitRef="shares">30737956</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTpmZTE2MmNhOTNlYTU0MjZiOWM4YzUzOTczMjI4NDYyMC90YWJsZXJhbmdlOmZlMTYyY2E5M2VhNTQyNmI5YzhjNTM5NzMyMjg0NjIwXzktNS0xLTEtMA_48894f7e-10b0-4ac7-a7fc-c653dcf1cf5d"
      unitRef="shares">10449150</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzE4_b77cd367-9893-4a92-8d63-73d8544d57eb">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODAz_eedeb390-ef79-4b08-a25d-28f07eb12511">Stock-Based CompensationThe Company incurs stock-based compensation expense related to restricted stock units and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2ODQz_90eb9462-b8ac-4070-9735-f0819e827ed7">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.42%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.73%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.71%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if1f13165d5d6482590debad2f6e92178_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzItMS0xLTEtMA_7b934863-e1d2-4ea0-9a19-e52d0da5f31c"
      unitRef="number">0.0063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="idb0e0943a16c445bbe684491faf920a8_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzItMy0xLTEtMA_60d00ac3-a339-4991-b20a-cf3f8d37250a"
      unitRef="number">0.0242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iddced08b347f44f785f1537e866c5bf5_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzItNS0xLTEtMA_95e50acf-16f9-40e3-adee-36dd3b6cb5f7"
      unitRef="number">0.0273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if1f13165d5d6482590debad2f6e92178_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzMtMS0xLTEtMA_922ead6e-6339-4e13-ac1e-e590a6dedee7"
      unitRef="number">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="idb0e0943a16c445bbe684491faf920a8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzMtMy0xLTEtMA_8a438044-df6b-46b6-bee9-c12fd23a05f6"
      unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iddced08b347f44f785f1537e866c5bf5_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzMtNS0xLTEtMA_b84d506f-4fd0-4e29-8a77-0feab0c8d4b8"
      unitRef="number">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if1f13165d5d6482590debad2f6e92178_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzQtMS0xLTEtMA_fe25a221-a815-4d30-965d-920426ba1050">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="idb0e0943a16c445bbe684491faf920a8_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzQtMy0xLTEtMA_71ddbd0c-1aaf-4e06-9e67-1e1886a726a1">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iddced08b347f44f785f1537e866c5bf5_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzQtNS0xLTEtMA_37a5ea8e-48ab-43e9-8068-c9f87dcaf05b">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if1f13165d5d6482590debad2f6e92178_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzUtMS0xLTEtMA_548504cf-f22f-43bf-bfbc-eb3bee1ad2c0"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="idb0e0943a16c445bbe684491faf920a8_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzUtMy0xLTEtMA_d43d788e-1120-4aa3-85c5-a652b7a3464e"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iddced08b347f44f785f1537e866c5bf5_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZTo4ODFjMWIyZTU1NzA0MTc0ODU3NmZiYzMwOWEzNzZjMy90YWJsZXJhbmdlOjg4MWMxYjJlNTU3MDQxNzQ4NTc2ZmJjMzA5YTM3NmMzXzUtNS0xLTEtMA_c8799c99-fdd1-4277-baae-9baefc4d3e85"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id2d6cd258bb84425bbbfe977d3faefb6_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzItMS0xLTEtMA_502999ff-025f-4983-b0cc-144e48ee2232"
      unitRef="number">0.0082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1c09bb9e28c146a2a7d84bd07c5eb551_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzItMy0xLTEtMA_f8be9a24-5e6e-4cf8-a084-6b0200880d9e"
      unitRef="number">0.0245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i020096d75bda46dcb066c2fd6645c02b_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzItNS0xLTEtMA_4e757583-133d-4c11-8249-b19efc2365f0"
      unitRef="number">0.0271</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id2d6cd258bb84425bbbfe977d3faefb6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzMtMS0xLTEtMA_db960c38-0898-4dcc-bc43-4548c6894594"
      unitRef="number">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1c09bb9e28c146a2a7d84bd07c5eb551_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzMtMy0xLTEtMA_2b57d360-2897-4890-835b-a5db405b58ec"
      unitRef="number">0.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i020096d75bda46dcb066c2fd6645c02b_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzMtNS0xLTEtMA_c5c636a6-7d76-4302-82f2-55fcb4bfb2d6"
      unitRef="number">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id2d6cd258bb84425bbbfe977d3faefb6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzQtMS0xLTEtMA_d0f35612-a4d5-4087-8ce5-d686c8ae130d">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1c09bb9e28c146a2a7d84bd07c5eb551_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzQtMy0xLTEtMA_37c07b44-bde3-4fa2-b576-1cc72bfaf39e">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i020096d75bda46dcb066c2fd6645c02b_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzQtNS0xLTEtMA_91d203fa-9e7c-4bc2-b8eb-52d7344aeb51">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id2d6cd258bb84425bbbfe977d3faefb6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzUtMS0xLTEtMA_dcde901f-bbc4-4312-8191-f172eaf92285"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1c09bb9e28c146a2a7d84bd07c5eb551_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzUtMy0xLTEtMA_b5b8cef8-4e62-4f5c-963d-62f43beda1ad"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i020096d75bda46dcb066c2fd6645c02b_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90YWJsZToxYjBjMGY2ZWZhZWY0YWI5OTAxZWYyZWI1M2RiMWE2OS90YWJsZXJhbmdlOjFiMGMwZjZlZmFlZjRhYjk5MDFlZjJlYjUzZGIxYTY5XzUtNS0xLTEtMA_6f0b33db-3f83-4862-aa6a-9e8c028239f0"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzM2NzE5_63304561-9c50-4265-b34e-dccf6ad2c51c">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements - Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2019-12. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. FASB issued this Update as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 became effective as of the beginning of 2020; however, there was no cumulative effect to be recognized with the early adoption. As of December 31, 2020, there was a loss from continuing operations and a cumulative loss in other comprehensive income and there was therefore no effect on the tax provision for the period ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2016-13&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonably supportable forecast information. The Company adopted ASU 2016-13 on January 1, 2020, and there was no material impact to its consolidated financial statements. The Company will continue to monitor the impact of the coronavirus, SARS-CoV-2 (&#x201c;COVID-19&#x201d;) outbreak on expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2018-13&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In August 2018, the FASB issued ASU 2018-13, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends certain disclosure requirements over fair value measurements. Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this guidance on January 1, 2020, and there was no material impact to its consolidated financial statement disclosures (see Note 6 for more information about the Company&#x2019;s fair value classifications).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2018-18&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which clarified the interaction between Topic 808, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative &lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arrangements&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and Topic 606, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company adopted this guidance on January 1, 2020, and there was no material impact to its consolidated financial statements.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU 2017-04.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In January 2017, the FASB issued ASU 2017-04,&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#160;&lt;/span&gt;("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and there was no material impact to its consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDgvZnJhZzplMTRlNjc3YTgzYjI0NGQ1YmJkNDE3ZGEyMDYxNDg0Zi90ZXh0cmVnaW9uOmUxNGU2NzdhODNiMjQ0ZDViYmQ0MTdkYTIwNjE0ODRmXzc3MQ_5ec11372-9d79-49e5-80cd-144fb54eb721">Revenue Recognition  During the year ended December&#160;31, 2020, the Company recognized total revenue under license and other agreements of $5.0 million from Advaccine, $1.4 million from its affiliated entity Plumbline Life Sciences, Inc. ("PLS"), and $1.0 million from various other contracts. Of the total revenue recognized during the year ended December&#160;31, 2020, $127,000 was in deferred revenue as of December 31, 2019. During the year ended December 31, 2019, the Company recognized revenue of $293,000 that was included in deferred revenue at December 31, 2018. Performance obligations are generally satisfied within 12 months of the initial contract date.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58fdd3cd014b4e69a232a56367655377_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDgvZnJhZzplMTRlNjc3YTgzYjI0NGQ1YmJkNDE3ZGEyMDYxNDg0Zi90ZXh0cmVnaW9uOmUxNGU2NzdhODNiMjQ0ZDViYmQ0MTdkYTIwNjE0ODRmXzQzOTgwNDY1MTIyNjY_b7efee4e-61ba-4381-a8d8-a753da7cd3ea"
      unitRef="usd">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59d8b0164c8b45a394697662732fe279_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDgvZnJhZzplMTRlNjc3YTgzYjI0NGQ1YmJkNDE3ZGEyMDYxNDg0Zi90ZXh0cmVnaW9uOmUxNGU2NzdhODNiMjQ0ZDViYmQ0MTdkYTIwNjE0ODRmXzQzOTgwNDY1MTIyODU_b93dd908-b469-436f-9727-d48ef0b2b6ea"
      unitRef="usd">1400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36022e8256554cf79c99deed72b40319_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDgvZnJhZzplMTRlNjc3YTgzYjI0NGQ1YmJkNDE3ZGEyMDYxNDg0Zi90ZXh0cmVnaW9uOmUxNGU2NzdhODNiMjQ0ZDViYmQ0MTdkYTIwNjE0ODRmXzQzOTgwNDY1MTIzNTE_9bde42dd-0241-4860-856a-5aa85b7c9626"
      unitRef="usd">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDgvZnJhZzplMTRlNjc3YTgzYjI0NGQ1YmJkNDE3ZGEyMDYxNDg0Zi90ZXh0cmVnaW9uOmUxNGU2NzdhODNiMjQ0ZDViYmQ0MTdkYTIwNjE0ODRmXzQ5MQ_bbb2e9ef-f2ef-4572-97d0-8ca830a44c23"
      unitRef="usd">127000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDgvZnJhZzplMTRlNjc3YTgzYjI0NGQ1YmJkNDE3ZGEyMDYxNDg0Zi90ZXh0cmVnaW9uOmUxNGU2NzdhODNiMjQ0ZDViYmQ0MTdkYTIwNjE0ODRmXzYxNA_91b3b251-f240-4d27-bf1c-f12a879a9b29"
      unitRef="usd">293000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzEwOTk1MTE2MzI1MTc2_e861d772-8e2f-4ec2-87f4-c59f92a3686d">Collaborative Agreements &lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Advaccine Biopharmaceuticals Suzhou Co., Ltd. (Advaccine)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2020, the Company entered into a Collaboration and License Agreement (the &#x201c;Agreement&#x201d;) with Advaccine. Under the terms of the Agreement, the Company has granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#x2019;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#x201c;Greater China&#x201d;). Advaccine will not have the right to grant sublicenses, other than to affiliated entities, without the Company&#x2019;s express prior written consent. As part of the collaboration, Advaccine has also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Advaccine have collaborated since January 2020 to leverage Advaccine&#x2019;s clinical development expertise to conduct an early-stage clinical trial in China in parallel with the Company&#x2019;s clinical development efforts in the United States and South Korea. In December 2020, the Company and Advaccine announced that they had dosed the first subject in a Phase 2 clinical trial of INO-4800 in China. This trial is independent of the Company&#x2019;s ongoing clinical trial of INO-4800, called INNOVATE, being conducted in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Agreement, Advaccine made an upfront payment to the Company of $3.0&#160;million subsequent to December 31, 2020. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $108.0&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China, if approved. As of December 31, 2020 the Company had earned a $2.0&#160;million milestone payment based on the enrollment of the first subject in the Phase 2 clinical trial for the product in the Advaccine territory. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within Greater China, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#x2019;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Agreement, Advaccine will be responsible for the development and commercialization of the licensed products at its own cost and expense and shall use commercially reasonable efforts to develop, obtain and maintain regulatory approval of INO-4800, as well as the Company&#x2019;s CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; device and arrays for use in connection with the administration of INO-4800, in each region in Greater China. In the event that the Company has not initiated the planned Phase 3 segment of its ongoing clinical trial of INO-4800 in the United States within one year after entering into the Agreement, Advaccine may elect to conduct a Phase 3 clinical trial outside of Greater China at its own cost and expense for the purposes of obtaining regulatory approval in China, subject to the Company&#x2019;s right to review and approve the protocols and design of such a trial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Agreement, the Company will supply Advaccine&#x2019;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#x2019;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808, and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606.  The license to INO-4800 in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the $3.0&#160;million upfront payment plus the initial $2.0&#160;million milestone payment which was achieved upon contract signing.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Agreement, subject to certain conditions. Advaccine may terminate the Agreement at any time for convenience upon nine months&#x2019; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in Greater China, or 18 months&#x2019; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, the entire transaction price of $5.0&#160;million was allocated to the license performance obligation. The Company determined that as of December 31, 2020, the transfer of technology has occurred for the use and benefit of the license and accordingly, the performance obligation was fully satisfied.  The Company accordingly has recognized $5.0&#160;million in revenue under collaborative research and development arrangements on the consolidated statement of operations during the year ended December 31, 2020. As of December&#160;31, 2020, the Company had an accounts receivable balance of $7.1 million from Advaccine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ApolloBio Corporation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the territories of China, Hong Kong, Macao, Taiwan, and may include Korea in the event that no patent covering&#160;VGX-3100&#160;is issued in China within the three years following the effective date of the ApolloBio Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the ApolloBio Agreement, the Company received proceeds of $19.4 million in March 2018, which comprised the upfront payment of $23.0 million less $2.2 million in foreign income taxes and $1.4 million in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the consolidated statement of operations. The Company also incurred advisory fees of $960,000 in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in the United States, China and Korea. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#x2019;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the terms of the ApolloBio Agreement under ASC Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the $23.0 million upfront payment.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As of December 31, 2020 there have been no significant reimbursable program costs under the ApolloBio Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning one year after the effective date for any reason upon 90 days written notice to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, the entire transaction price of $23.0 million was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. The Company has recorded the gross upfront payment received from ApolloBio of $23.0 million as license revenue on the consolidated statement of operations during the year ended December 31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AstraZeneca&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of $27.5 million to the Company in September 2015. AstraZeneca may be obligated to make potential future development and regulatory event-based payments to the Company totaling up to $125 million and potential future commercial event-based payments totaling up to $115 million, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca will fund all development costs associated with MEDI0457 immunotherapy. The Company is entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca can also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2017, the Company had recognized all of the $27.5 million upfront payment as revenue, as all identified materia&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;l performance obligations had been met with respect to that payment.&#160;In both December 2018 and March 2019, the Company recognized as revenue $2.0 million in milestone payments from AstraZeneca triggered by AstraZeneca&#x2019;s initiation of the Phase 2 portion of ongoing clinical trials in the second and third major indication, respectively, under the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Coalition for Epidemic Preparedness Innovations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April&#160;11, 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate&#160;preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of $56 million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the years ended December&#160;31, 2020 and 2019, the Company received funding of $6.4 million and $6.3 million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of December&#160;31, 2020, the Company had a grant funding liability balance related to the CEPI grant of $2.6 million recorded as grant funding liability on the consolidated balance sheet related to the CEPI grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, CEPI awarded the Company a grant of up to $9.0&#160;million to develop a vaccine against COVID-19. This initial CEPI funding is intended to support preclinical and clinical development through Phase 1 human testing in the United States of INO-4800, the Company's COVID-19 vaccine candidate against COVID-19. In April 2020, CEPI awarded the Company a grant of $6.9&#160;million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $5.0&#160;million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3&#160;million to support large-scale manufacturing of INO-4800. During the year ended December&#160;31, 2020, the Company received funding of $10.0 million from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of December&#160;31, 2020 the Company had $3.4&#160;million recorded as deferred grant funding on the consolidated balance sheet related to the CEPI grants related to INO-4800.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bill &amp;amp; Melinda Gates Foundation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Bill &amp;amp; Melinda Gates Foundation (&#x201c;Gates&#x201d;) awarded and funded the Company a grant of $2.2&#160;million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1&#160;million for the project. During the years ended December&#160;31, 2020 and 2019, the Company recorded $463,000 and $2.1 million, respectively, as contra-research and development expense related to the Gates dMAb grant. As of December&#160;31, 2020, the Company had $575,000 recorded as deferred grant funding on the consolidated balance sheet related to the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, Gates awarded and funded the Company a grant of $5.0&#160;million to accelerate the development of the CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP device for the intradermal delivery of INO-4800. During the year ended December&#160;31, 2020, the Company recorded $4.1 million as contra-research and development expense and had $884,000 recorded as deferred grant funding on the consolidated balance sheet related to this Gates grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Defense (DoD) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#x201c;OTA Agreement&#x201d;)&#160;with the DoD to fund the Company&#x2019;s efforts in developing the CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is approximately $54.5&#160;million. The Company has determined that the OTA Agreement should be considered under &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which is outside the scope of Topic 606, as the government agency granting the Company funds is not receiving reciprocal value for their contributions. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company will record contra-research development expense on the consolidated statement of operations in the same period that the underlying expenses are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#x201c;Procurement Contract&#x201d;) from the DoD for the purchase of the Company&#x2019;s intradermal CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;2000 device and accessories. The CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 2000 devices will be used to inject&#160;INO-4800&#160;in the Company&#x2019;s planned later-stage clinical trials. The total purchase price under the Procurement Contract is approximately $16.6&#160;million. The Company has determined that the Procurement Contract does not currently fall under the scope of ASC Topic 606 as contingencies remain regarding INO-4800 which does not give the Company the ability to satisfy its obligations under the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, the Company recorded $21.2 million as contra-research and development expense related to these agreements with the DoD. As of December&#160;31, 2020, the Company had an accounts receivable balance of $11.4&#160;million on the consolidated balance sheet from the DoD.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, the Company announced that the DoD has also agreed to provide funding for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Phase 2/3 clinical trial for INO-4800, called INNOVATE (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;OVIO I&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-4800 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Va&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ccine &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;T&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rial for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;E&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fficacy)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. These expenses will be paid directly by the DoD.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="ie1340701a627440abb646d47f8dd59a0_D20210301-20210301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzMyOTg1MzQ5MjgwNTc_e646af0f-9087-455a-8570-4256224eb109"
      unitRef="usd">3000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved
      contextRef="i613bf85d5ad641aeb9777c902ee5e720_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzEwOTk1MTE2MzI1MTc4_bbbdc963-c4f2-40a8-bec5-b98e769c07f3"
      unitRef="usd">108000000.0</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementPaymentEarned
      contextRef="i613bf85d5ad641aeb9777c902ee5e720_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzMyOTg1MzQ5MzM2NDA_09b95815-30e5-41a7-bb61-4210b6aca1fb"
      unitRef="usd">2000000.0</ino:CollaborationAgreementPaymentEarned>
    <ino:CollaborationAgreementRoyaltyPeriod
      contextRef="i613bf85d5ad641aeb9777c902ee5e720_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzEwOTk1MTE2MzI1MjA5_931e66a0-b54d-4aad-bbc3-215f540b8a6c">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination
      contextRef="i613bf85d5ad641aeb9777c902ee5e720_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzEwOTk1MTE2MzI1MjI3_7a582422-0197-4bf0-b456-b63f51843d03">P1Y</ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i613bf85d5ad641aeb9777c902ee5e720_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzMyOTg1MzQ5MzQyNTY_d27cc633-eec9-492d-be89-dd15cd2b4c7f"
      unitRef="usd">3000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementPaymentEarned
      contextRef="i613bf85d5ad641aeb9777c902ee5e720_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzMyOTg1MzQ5MzE5MDM_03b43e05-303b-42a3-a744-642327acbb63"
      unitRef="usd">2000000.0</ino:CollaborationAgreementPaymentEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i613bf85d5ad641aeb9777c902ee5e720_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzEwOTk1MTE2MzI1MjMz_971ecee1-e900-4a4a-b8cf-dad9ce87fb9b"
      unitRef="usd">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1629a50f2cbd40418d7f6000e5d7136c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzMyOTg1MzQ5MzQ4MzA_daee5085-b2fb-452e-ad20-1cc502f0f330"
      unitRef="usd">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNet
      contextRef="i07a67056b0694c8eb1abe2d9df8f95cc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1NzAzOTM_a4f48401-9188-4fc3-a5e2-6931ee2ec47c"
      unitRef="usd">7100000</us-gaap:AccountsReceivableNet>
    <ino:CollaborationAgreementTerritoryExpansionOptionPeriod
      contextRef="i0580e1e8b8464f7daadfc64c85589325_D20171229-20171229"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzEwOTk1MTE2MzI1MjQ2_776db8cb-d49a-4268-8708-cd7d91d70e0d">P3Y</ino:CollaborationAgreementTerritoryExpansionOptionPeriod>
    <ino:ProceedsFromCollaborativeAgreement
      contextRef="ic70aad9f1bbb46c7aef9aac80dd8d982_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzc3NQ_6758a8d1-fc85-44b8-9967-c89546d85bf4"
      unitRef="usd">19400000</ino:ProceedsFromCollaborativeAgreement>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="ic70aad9f1bbb46c7aef9aac80dd8d982_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzgzMg_f4a9e89f-0817-4173-9b1d-2d7fc1d3a484"
      unitRef="usd">23000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementCorporateIncomeTax
      contextRef="iccbc152ca5c64a51b143e8f925a6386c_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzg0MA_a6646928-6bea-4bbc-9ba6-443f50661829"
      unitRef="usd">2200000</ino:CollaborativeAgreementCorporateIncomeTax>
    <ino:CollaborativeAgreementForeignNonIncomeTaxes
      contextRef="iccbc152ca5c64a51b143e8f925a6386c_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzg3MQ_bdc8b969-62b8-48f3-817e-40a0a07ad63e"
      unitRef="usd">1400000</ino:CollaborativeAgreementForeignNonIncomeTaxes>
    <ino:CollaborativeAgreementAdvisoryFees
      contextRef="i0d23e87ce6a14739b73a33d11363becf_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzExOTg_1b9d3a17-3db3-44ec-899b-c75fb46d91fd"
      unitRef="usd">960000</ino:CollaborativeAgreementAdvisoryFees>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved
      contextRef="i198477edba824f6ea373e4e1b0ef0825_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzE3ODY_15bfc2b8-d88f-42f9-a3c4-ec305a2d708e"
      unitRef="usd">20000000.0</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementRoyaltyPeriod
      contextRef="i198477edba824f6ea373e4e1b0ef0825_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzIzMjc_b85eb3f3-b753-4a79-80b8-f07bcb7976a9">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i198477edba824f6ea373e4e1b0ef0825_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzI5NjE_1fb991c2-60db-480e-aa0f-0812d8905611"
      unitRef="usd">23000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination
      contextRef="i198477edba824f6ea373e4e1b0ef0825_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzgyNDYzMzcyNTk2ODU_8ea215b5-f304-44d1-85e7-aa62ec2e09c8">P1Y</ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination>
    <ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination
      contextRef="i198477edba824f6ea373e4e1b0ef0825_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQyNDU_f7790453-b851-47cb-890a-1f27ae9a69fe">P90D</ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i9d79fdc0914349cba02f4425251657ee_D20180401-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzMzM_11dc8e2c-c7fb-498f-8b84-d5d9a7d16c3a"
      unitRef="usd">23000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="ida214446db3b464690a216afd28cd2bd_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQ2MzY_fe513f3b-a749-447e-9f52-c7f755026d34"
      unitRef="usd">23000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i5415ff5fd21249ac9bb9bf4e91ebb967_D20150901-20150930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzUyNzQ_13aab287-e65f-44fd-864f-4661e95514c8"
      unitRef="usd">27500000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones
      contextRef="i0a96b2b8330c413eac49b9d0b68a5735_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzU0NDM_36b46dae-8442-45dd-8705-fa593b0e5e27"
      unitRef="usd">125000000</ino:CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones>
    <ino:CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones
      contextRef="i0a96b2b8330c413eac49b9d0b68a5735_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzU1MTQ_fd764019-7943-42c2-a1ca-b9f206267d26"
      unitRef="usd">115000000</ino:CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="iecbf562e66684d72bb93637a9483430f_D20171231-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzY1NDQ_3d667d7d-140e-4e89-b65d-bfc36b8c6406"
      unitRef="usd">27500000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementMilestonePaymentRevenueRecognized
      contextRef="icde7df1aa421475ebcaddca0a5faed9e_D20181201-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzY3NDE_692ed506-f721-4c89-8dd5-3318ebaedbff"
      unitRef="usd">2000000.0</ino:CollaborativeAgreementMilestonePaymentRevenueRecognized>
    <ino:CollaborativeAgreementMilestonePaymentRevenueRecognized
      contextRef="i1ba7d9f763e04c32b364239929d24393_D20190302-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzY3NDE_8bda92bb-d193-4a6b-824b-15be4a0fd2f5"
      unitRef="usd">2000000.0</ino:CollaborativeAgreementMilestonePaymentRevenueRecognized>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i9f7ef79982d84ebd9bc2953403b7e029_D20180411-20180411"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzgwODM_4f5bcb66-b821-4e95-a1dc-159d9bfb1a14"
      unitRef="usd">56000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment
      contextRef="i9f7ef79982d84ebd9bc2953403b7e029_D20180411-20180411"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzEwOTk1MTE2MzI1MjQ3_1378ae08-dcca-462e-8a2e-b3a697c6bd1d">P5Y</ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="iea76d18ca06a49d7851b0c0ff3a34c6d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjYzOTY_93ac2659-f3bc-4c1a-b13d-9c89ab9223ce"
      unitRef="usd">6400000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i85493c81c5114a8795086a2445f83c41_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzgzOTU_d51d3648-6eef-4d93-8b17-27679792d00c"
      unitRef="usd">6300000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="id233e1d41be44b12951cb39c380c2e4c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzg2MDA_dcacab4d-0e55-4bca-a68a-d23e28a5a9c2"
      unitRef="usd">2600000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i62896ff9dfdf42f19fd838c00bab3f1d_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjU0NzU_6463c653-91e7-46b9-b195-0f47f1ef2c85"
      unitRef="usd">9000000.0</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="id6e5de1ef1e64ba791fd38a6b29b9cc9_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjU0ODk_badd1abb-1afa-49f3-a212-d84b1dbe3ed6"
      unitRef="usd">6900000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i3d96c9c2aee04b989b045f3a11979c60_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjU1MTc_8300fb2d-4daf-4f98-8616-ef07cfcec9c9"
      unitRef="usd">5000000.0</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i3d1c029556354cc880be0619e862bd95_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjU1MDM_af8649d3-23e9-43cd-9b9d-b31279b1ddc2"
      unitRef="usd">1300000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i0e7308dee93f48cb8fc7b11c2b76aaad_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjYzNjM_44a47760-7200-431d-acb6-d7ceb2f85683"
      unitRef="usd">10000000.0</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="i8b4cb28aa5624d32a8dd171551850f0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzEwOTk1MTE2MzI1Mjk3_0843d7ab-c1b4-4efb-b3bf-3a6b109ed5b2"
      unitRef="usd">3400000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i56edaab4f0df412ba9168d447a83002d_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjU2ODI_afc3f59d-9a78-4e74-9e95-029131051857"
      unitRef="usd">2200000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i234be8858e5244cdbdbccb259435578a_D20190801-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjU2OTY_2ba2c3eb-deaf-419f-aa10-cfdf1dba0fb3"
      unitRef="usd">1100000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i6257d5c8c1b740bea21e2623fc3ce7b3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjY0MDU_82876a6e-5776-4ab9-ac16-17505e422c8f"
      unitRef="usd">463000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="ic708a39c59804e988fb7464a0d0169de_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjY0MTA_431a7ec0-903d-4334-8751-045e72134a2e"
      unitRef="usd">2100000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="if593976c97db405798c736bb8b0cda97_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjU5NjQ_a56f7c21-e207-425f-9099-71b429461844"
      unitRef="usd">575000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i8903d8385b2841c5b9653a466d3c1db9_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjU5OTA_b3f09032-6a43-455d-ad58-4d6596a41c7d"
      unitRef="usd">5000000.0</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i915d8cff852f486180f3c82d2ebda044_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjY0MzQ_8c2bb1a4-6e7e-4acb-bcec-b6328c1c834c"
      unitRef="usd">4100000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="ief209891b012422a8c1dc68518ef3bc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjYxMjU_48b50d90-533c-4283-991a-00c691f08eec"
      unitRef="usd">884000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i87746e71a46a454787656a4370821f51_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjYxNjk_08803adc-4269-455d-b8cb-b48dccfd7cbe"
      unitRef="usd">54500000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeArrangementFixedPriceContractAmountAwarded
      contextRef="i6ea2ecae9adf4b6a887dee064675992e_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjYyNjY_6225cd39-02fb-4a5c-a2ae-6bb8f8439916"
      unitRef="usd">16600000</ino:CollaborativeArrangementFixedPriceContractAmountAwarded>
    <ino:GrantProceedsReceived
      contextRef="i7bd9953ed4844195ad1d5a16e1dba0ee_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjY0NjI_55485df5-2bb4-4b3c-80bf-12d7908629e2"
      unitRef="usd">21200000</ino:GrantProceedsReceived>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i99bceb219d684923a420db226755fc2f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTEvZnJhZzpmM2E2MzEzMzBkMjc0OGVlOWRkYTk3MDYzYmRkZTRmMy90ZXh0cmVnaW9uOmYzYTYzMTMzMGQyNzQ4ZWU5ZGRhOTcwNjNiZGRlNGYzXzQzOTgwNDY1MjYzMzc_087073ba-e240-4988-8b64-49b45207b70c"
      unitRef="usd">11400000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90ZXh0cmVnaW9uOmRjYjdkMWIxMjQ1YTRhMWNhZDk3NjZkMmYyYzBhNTk0XzE0NTA_b84a5188-7145-4752-99e7-b9d46dc7977b">Short-term Investments&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments at December&#160;31, 2020 consisted of mutual funds, certificates of deposit and U.S. agency mortgage-backed securities. Short-term investments at December&#160;31, 2019 consisted of mutual funds. Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's debt securities are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the consolidated statements of operations and are derived using the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;specific identification method for determining the cost of the securities sold.&#160;During the years ended December&#160;31, 2020 and 2019, the Company recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;gross realized ga&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in on investments of $744,000 and $594,000, respectively, and gross realized loss on investments of $1.3 million and $118,000, respectively. During the year ended December&#160;31, 2020, the Company recorded net unrealized gain on available for sale equity securities of $1.7&#160;million. There was no material unrealized gain or loss on available-for-sale equity securities recorded during the year ended December 31, 2019. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the years ended&#160;December&#160;31, 2020,&#160;2019&#160;and&#160;2018. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2020, the Company had&#160;12&#160;available-for-sale securities in a gross unrealized loss position, of which none were in such position for longer than 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of December&#160;31, 2020 and 2019:   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,177,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,239,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,365,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(690,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,914,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,599,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,338,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2020&#160;were primarily due to changes in interest rates, including credit spreads from perceived increased credit risks as a result of the COVID-19 global pandemic, and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at December&#160;31, 2020, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90ZXh0cmVnaW9uOmRjYjdkMWIxMjQ1YTRhMWNhZDk3NjZkMmYyYzBhNTk0Xzc1OA_2d31a88b-5ec0-4581-99e4-c355293bf266"
      unitRef="usd">744000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90ZXh0cmVnaW9uOmRjYjdkMWIxMjQ1YTRhMWNhZDk3NjZkMmYyYzBhNTk0Xzc2NQ_1a0ce313-6026-41d5-bd88-b4fb744510a4"
      unitRef="usd">594000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90ZXh0cmVnaW9uOmRjYjdkMWIxMjQ1YTRhMWNhZDk3NjZkMmYyYzBhNTk0XzgyNQ_aa6b2205-801c-4d18-a2db-dae76e4eac2b"
      unitRef="usd">1300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90ZXh0cmVnaW9uOmRjYjdkMWIxMjQ1YTRhMWNhZDk3NjZkMmYyYzBhNTk0XzgzMg_53925e68-31c6-49c0-a571-78ee0104e2c6"
      unitRef="usd">118000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90ZXh0cmVnaW9uOmRjYjdkMWIxMjQ1YTRhMWNhZDk3NjZkMmYyYzBhNTk0XzQzOTgwNDY1MTMxNjQ_9ad8c252-43af-420e-802a-7f565a0a6029"
      unitRef="usd">1700000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90ZXh0cmVnaW9uOmRjYjdkMWIxMjQ1YTRhMWNhZDk3NjZkMmYyYzBhNTk0XzExODU_3f53008d-1d33-439c-87f2-f67b936b092d"
      unitRef="investment">12</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90ZXh0cmVnaW9uOmRjYjdkMWIxMjQ1YTRhMWNhZDk3NjZkMmYyYzBhNTk0XzEyNjQ_8acf375f-9785-49f3-9441-9cc3853353de"
      unitRef="investment">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90ZXh0cmVnaW9uOmRjYjdkMWIxMjQ1YTRhMWNhZDk3NjZkMmYyYzBhNTk0XzE0NTg_7043411c-164a-41a5-9578-ebdf75db7706">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of December&#160;31, 2020 and 2019:   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,177,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,239,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,365,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(690,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,914,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,599,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,338,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id0595f6d10944686ae57a515abd3ec36_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzItMy0xLTEtMA_4b702403-6dd6-4a53-90d2-0b72758baafe"
      unitRef="usd">153177675</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id0595f6d10944686ae57a515abd3ec36_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzItNS0xLTEtMA_3b7eaba8-2b4a-4ba4-bb8b-5e64bd56d963"
      unitRef="usd">2339639</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id0595f6d10944686ae57a515abd3ec36_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzItNy0xLTEtMA_8a4eccb9-241a-4ebc-b0f9-41a90380be1a"
      unitRef="usd">644140</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id0595f6d10944686ae57a515abd3ec36_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzItOS0xLTEtMA_a39fef65-33c8-419d-af05-183d1f7d8ec8"
      unitRef="usd">154873174</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="id170cedd88294bc89c6f402a37e123d7_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzQtMS0xLTEtNjY3NC90ZXh0cmVnaW9uOjU0MmI1OGNkZTc5OTQ2YjE5NDQ3MTFiZDk5MGJjZDczXzY1OTcwNjk3NjY2NzI_a40f3169-d492-416e-a9a1-fd211a61c1ba">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if06443a97a314fdb92d5c69b9c9a3577_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzQtMy0xLTEtMA_75f8e688-eadc-49c1-8f8a-536aa147ff1d"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if06443a97a314fdb92d5c69b9c9a3577_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzQtNS0xLTEtMA_9e9d7171-f3e6-4216-9cd0-e19d48aaf323"
      unitRef="usd">26260</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if06443a97a314fdb92d5c69b9c9a3577_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzQtNy0xLTEtMA_04d20363-ca2a-4b0f-a958-7a6b43f70da7"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if06443a97a314fdb92d5c69b9c9a3577_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzQtOS0xLTEtMA_3bea03e4-1d4d-4dd5-8a8c-27c807fcdfac"
      unitRef="usd">3016260</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie9de27164b224d649a37a0d1268584c1_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzUtMy0xLTEtMA_3168bcd8-d179-4948-b8dc-22c46af34f12"
      unitRef="usd">3062256</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie9de27164b224d649a37a0d1268584c1_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzUtNS0xLTEtMA_a41edef5-8435-4dde-979d-0cee14e4cefb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie9de27164b224d649a37a0d1268584c1_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzUtNy0xLTEtMA_75dc810c-7592-49f2-ba4d-c0509c071d2d"
      unitRef="usd">36755</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie9de27164b224d649a37a0d1268584c1_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzUtOS0xLTEtMA_aeb38262-e38d-4125-a71b-222f5afb0909"
      unitRef="usd">3025501</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzctMy0xLTEtMA_95e7b7bb-627a-45eb-b80f-fb4457e60dff"
      unitRef="usd">159239931</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzctNS0xLTEtMA_f7b89e13-b657-4d55-bf89-1f4ae9fa03dd"
      unitRef="usd">2365899</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzctNy0xLTEtMA_d15e458c-c0e5-457e-b768-c7d4bbf6fe7d"
      unitRef="usd">690895</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYjNlMjA2ODhiYTc0ZTFjYmQ0NDI2M2U0NzhiZTQ3Ny90YWJsZXJhbmdlOmRiM2UyMDY4OGJhNzRlMWNiZDQ0MjYzZTQ3OGJlNDc3XzctOS0xLTEtMA_b30fd314-44f5-4d48-a142-6cfeb50e8545"
      unitRef="usd">160914935</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id26a1e4045ce4ee0b3633de9cb1dac61_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYTk2NDI2NTMwYmU0MjAwYmRiOTUwY2RjODk1MDBiOC90YWJsZXJhbmdlOmRhOTY0MjY1MzBiZTQyMDBiZGI5NTBjZGM4OTUwMGI4XzItMy0xLTEtMA_7b019027-6e18-4a2b-99f6-03609c23d840"
      unitRef="usd">66599219</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id26a1e4045ce4ee0b3633de9cb1dac61_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYTk2NDI2NTMwYmU0MjAwYmRiOTUwY2RjODk1MDBiOC90YWJsZXJhbmdlOmRhOTY0MjY1MzBiZTQyMDBiZGI5NTBjZGM4OTUwMGI4XzItNS0xLTEtMA_1b4da174-65ad-438b-98ae-e479f06019ab"
      unitRef="usd">754709</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id26a1e4045ce4ee0b3633de9cb1dac61_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYTk2NDI2NTMwYmU0MjAwYmRiOTUwY2RjODk1MDBiOC90YWJsZXJhbmdlOmRhOTY0MjY1MzBiZTQyMDBiZGI5NTBjZGM4OTUwMGI4XzItNy0xLTEtMA_03f51571-1c22-4003-b7c8-fde9257760dd"
      unitRef="usd">15911</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id26a1e4045ce4ee0b3633de9cb1dac61_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNTQvZnJhZzpkY2I3ZDFiMTI0NWE0YTFjYWQ5NzY2ZDJmMmMwYTU5NC90YWJsZTpkYTk2NDI2NTMwYmU0MjAwYmRiOTUwY2RjODk1MDBiOC90YWJsZXJhbmdlOmRhOTY0MjY1MzBiZTQyMDBiZGI5NTBjZGM4OTUwMGI4XzItOS0xLTEtMA_1a38cbdf-2b8b-45f2-8e9a-991db16dbd64"
      unitRef="usd">67338017</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzU4Njg_a81503cd-cf77-4328-87b9-756f3f7b44cd">Fair Value Measurements&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level&#160;1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets are, and prior to September 30, 2020 liabilities were, classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company did not have any transfer of assets and liabilities between Level 1, Level 2 and Level 3 of the fair value hierarchy during the years ended December&#160;31, 2020 and 2019. All liabilities in the fair value hierarchy were extinguished as of September 30, 2020 as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,914,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,372,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,330,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,338,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,338,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,315,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,315,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,003,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,003,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 assets at December&#160;31, 2020 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#x2019;s investment in its affiliated entity, PLS. Level 1 assets at December&#160;31, 2019 consisted of money market funds and mutual funds held by the Company that are valued at quoted market prices, as well as the Company&#x2019;s investments in its affiliates, GeneOne and PLS. The Company accounts for its investment in 597,808 common shares of PLS as an equity investment with a fair value based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of operations as unrealized gain (loss) on available-for-sale equity securities or as a gain (loss) on investment in affiliated entities. In August 2020, the Company sold its investment in 1,644,155 common shares of its affiliated entity GeneOne for net proceeds of $40.1&#160;million, resulting in a gain on investment in affiliated entity of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$36.7&#160;million. Previously, the Company accounted for its investment in GeneOne based on the closing price of the shares on the KOSDAQ Market of the Korea Exchange (KOSDAQ) on the applicable balance sheet date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at December&#160;31, 2020 consisted of certificates of deposit and U.S. agency mortgage-backed securities. Level 2 assets held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Level 3 assets held as of December&#160;31, 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Level 3 liabilities held at December&#160;31, 2020 due to the full conversion of the August 2019 Bonds into shares of the Company's common stock. Level 3 liabilities held as of December 31, 2019 consisted of the embedded conversion option contained in the August 2019 Bonds that met the criteria to be bifurcated and accounted for separately from the August 2019 Bonds (the "derivative liability") (see Note 11 below for more information). The derivative liability was recorded at fair value of $7.1 million upon the issuance of the August 2019 Bonds, and is subsequently remeasured to fair value at each reporting period. The derivative liability was initially valued and remeasured using a "with-and-without" method. The "with-and-without" methodology involves valuing the whole instrument on an as-is basis and then valuing the instrument without the embedded conversion option. The difference between the entire instrument with the embedded conversion option compared to the instrument without the embedded conversion option is the fair value of the derivative, recorded as the derivative liability. There was no derivative liability associated with the issuance of the December 2019 Bonds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the August 2019 Bonds with the conversion option is estimated using a Monte Carlo simulation approach. The key inputs to valuing the August 2019 Bonds with the conversion option on the date of issuance and as of August 3, 2020 conversion date included the Company&#x2019;s stock price on the valuation date; the expected annual volatility of the Company&#x2019;s common stock, and the discount yield, which was derived by making the fair value of the August 2019 Bonds equal to the face value on the issuance date. Fair value measurements are highly sensitive to changes in these inputs and significant changes in these inputs could result in a significantly higher or lower fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in fair value of the derivative liability for the year ended December&#160;31, 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,670,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Derecognition of the derivative liability upon conversion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,490,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzU4NzY_2f85eb7d-e8e8-4c62-aa61-c534554b0756">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,914,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,372,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,330,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,349,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,338,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,338,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,315,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,315,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,003,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,003,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id77b897f2b2646018276c3a658805161_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzUtMS0xLTEtMA_62d3e9e1-ec00-4e65-b23b-a5eb8dac51ea"
      unitRef="usd">59996800</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i68422a65e88b40e79296e5aa6b8060db_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzUtMy0xLTEtMA_ecc07c29-5dd0-495b-b25c-4f5e06d83609"
      unitRef="usd">59996800</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic061ab952f6e49ceb26243c60817cee2_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzUtNS0xLTEtMA_4631aebd-062b-4ff3-9446-2e3dd21207c3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i17c551a0610440a7b6f0abe61e8c82f8_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzUtNy0xLTEtMA_5baba00c-0d33-477a-8945-8d7fa3570931"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iacece918c44e4d6ca768677f180897d7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzgtMS0xLTEtMA_88832884-c5e6-472a-a3ff-7aae5f77462f"
      unitRef="usd">154873174</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i94dda5a90e794d048dc952d0627fdba7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzgtMy0xLTEtMA_bef3b4ff-5e7c-465a-b6a3-75f68fcef990"
      unitRef="usd">154873174</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iddeab32014174a6eb2d035b28d1446b8_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzgtNS0xLTEtMA_256dae0a-16ea-4e33-a631-fcfeed947a1b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0ca9c371fd4d4ea3be2f6127b2b2dffa_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzgtNy0xLTEtMA_82e00c8c-feab-4e55-9c13-2151c324a196"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibbdeb8f70e6a44778a3ea02aaaeb1562_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzEwLTEtMS0xLTA_c0cf2fad-85c3-4e5f-a0c0-439265793f44"
      unitRef="usd">3016260</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9e8472dc355b42e086aa634156b612b7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzEwLTMtMS0xLTA_7e914c5c-5110-4c75-b324-c1ff80bb2090"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if851e1354ade45b6a4ac89925d9a4403_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzEwLTUtMS0xLTA_e891c5f1-2fd9-491f-bfe1-9cd7f59f4736"
      unitRef="usd">3016260</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i62adc1206c1a4893b5f3e46ab68ec7dd_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzEwLTctMS0xLTA_ba3c48ca-8b11-4704-88cb-45e6c55bea63"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ca4e3a2cfb347d1961b839895da975d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzExLTEtMS0xLTEyODQ_8bfd2679-dd29-4093-97a3-833869d2332c"
      unitRef="usd">3025501</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if81c022e21c148fcbb11892de0c3ae71_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzExLTMtMS0xLTEyODQ_83b09f99-7341-49da-8def-98ea6795e324"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i99fa94fde4e748cfab7a583ebf129abd_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzExLTUtMS0xLTEyODQ_28b14f91-8ace-40a0-95db-958e662b2daf"
      unitRef="usd">3025501</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id1a574e3690b4028a3943434014b9a30_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzExLTctMS0xLTEyODQ_a2730601-437a-48a8-a529-a00871a35561"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0710bc234ed846439f5d59a967a8aa8b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzEzLTEtMS0xLTA_be633323-219f-4cb1-9fe1-7dad7afe2eb1"
      unitRef="usd">160914935</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i76a5e1669e794e9db24a12f605d4c94b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzEzLTMtMS0xLTA_b6a2e516-a0fa-45ca-b907-3d568ac14eef"
      unitRef="usd">154873174</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1005ed8e84ab4360b9311d1c584538bd_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzEzLTUtMS0xLTA_29d72bfe-38e3-451f-85ef-7f5ef10c0f00"
      unitRef="usd">6041761</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i13d84d47d468404abefbd435934323d5_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzEzLTctMS0xLTA_ea62c138-b69f-448f-81ec-44175551879d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0710bc234ed846439f5d59a967a8aa8b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzE1LTEtMS0xLTEyOTc_8aa44efd-b2b7-47f8-970e-b1bb70cd0d79"
      unitRef="usd">4460366</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i76a5e1669e794e9db24a12f605d4c94b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzE1LTMtMS0xLTEyOTc_7b9a6adf-5fc7-4006-a8a0-9bff3937d5c8"
      unitRef="usd">4460366</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1005ed8e84ab4360b9311d1c584538bd_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzE1LTUtMS0xLTEyOTc_38af9aaa-8dc7-4e6c-9a16-adf0840f8460"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i13d84d47d468404abefbd435934323d5_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzE1LTctMS0xLTEyOTc_b74eb6dd-cc9a-4202-9d19-18b898e5bc94"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0710bc234ed846439f5d59a967a8aa8b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzE2LTEtMS0xLTYwODI_d537ea3d-7c96-416f-92b3-05bfd1049780"
      unitRef="usd">225372101</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i76a5e1669e794e9db24a12f605d4c94b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzE2LTMtMS0xLTYwODI_ee5263ba-8ce2-4786-bd2f-0ef73fb39b9a"
      unitRef="usd">219330340</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1005ed8e84ab4360b9311d1c584538bd_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzE2LTUtMS0xLTYwODI_ebe4b98f-c6dc-41d2-945c-79c16e928ae9"
      unitRef="usd">6041761</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i13d84d47d468404abefbd435934323d5_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTphZmE5ZTI0MmRmNzA0ZmU1ODM3M2ZkNGMwM2NhMjM3ZS90YWJsZXJhbmdlOmFmYTllMjQyZGY3MDRmZTU4MzczZmQ0YzAzY2EyMzdlXzE2LTctMS0xLTYwODI_cd7c8eb0-0657-4ec9-ad09-618f35389eac"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6e2afcee19774482b251567dfd704749_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzUtMS0xLTEtNDA1Mg_2c2b71b8-ba51-4e80-a4c4-da8922d516c3"
      unitRef="usd">2349729</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2913e54184ff437ea27bd0066e1dafd0_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzUtMy0xLTEtNDA1Mg_09a04f30-79ef-43e4-b2d3-b417b2ab2527"
      unitRef="usd">2349729</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia26736c769c2420f9ca66117d30c734a_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzUtNS0xLTEtNDA1Mg_2fc73a98-dda4-473e-ae91-511d4d35802a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic0ea3dd77c114edaa793e22ac478cf97_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzUtNy0xLTEtNDA1Mg_006148d5-d793-421a-99e7-b2c4a434a857"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i66b39d6da16f4eb380e2a990dfff1f36_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzUtMS0xLTEtMA_4868797a-23f9-4bf6-9fe4-fd593dcd2a2e"
      unitRef="usd">67338017</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i096fa31c0c464101ae5cf90270267cde_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzUtMy0xLTEtMA_e202f848-abdd-46db-8164-0eca8dd57cb5"
      unitRef="usd">67338017</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idce13f5e5f4c4fc5af43c4edef726f4a_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzUtNS0xLTEtMA_99005701-4b17-4c66-9e14-77685aeeea42"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icd3a02a734354ed7820d83f40571c7d6_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzUtNy0xLTEtMA_f1020094-6841-404e-9661-a0440999e717"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8add3b9ca8da438b900d8ea5ac0b076c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzgtMS0xLTEtMA_815bd8c9-ccdc-4d38-996d-8ba1d8da9d2c"
      unitRef="usd">6315356</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie64a636ae54645beb9d8ee43e42dcc10_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzgtMy0xLTEtMA_4c2f02e3-8522-49c2-84e2-0d83ab952f03"
      unitRef="usd">6315356</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i86bce27cb66c4603aa2e7c5f6f92d9d6_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzgtNS0xLTEtMA_2ddf5f58-3d7f-4bda-9fe0-b7cf6b431ea6"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7004a0f54b4e4ac8adfa3750ee6ccf4e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzgtNy0xLTEtMA_c9f90f7d-5340-4bb3-b3e5-b99c4e502c93"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8add3b9ca8da438b900d8ea5ac0b076c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEwLTEtMS0xLTA_6bf6753c-96f1-4595-8c85-c0e3c7bd2526"
      unitRef="usd">76003102</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie64a636ae54645beb9d8ee43e42dcc10_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEwLTMtMS0xLTA_00a9d344-fe67-411e-bb3c-c1eef10216b1"
      unitRef="usd">76003102</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i86bce27cb66c4603aa2e7c5f6f92d9d6_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEwLTUtMS0xLTA_5b586d7e-3ee6-4091-a857-65e787da6a0d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7004a0f54b4e4ac8adfa3750ee6ccf4e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEwLTctMS0xLTA_b5481edf-f900-4018-9984-6c5152086bd1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i8add3b9ca8da438b900d8ea5ac0b076c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEyLTEtMS0xLTA_dab05ae2-bed7-4fc4-b457-1b853e894671"
      unitRef="usd">8819023</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie64a636ae54645beb9d8ee43e42dcc10_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEyLTMtMS0xLTA_02f6f5d9-38db-413a-9355-cbb18121847d"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i86bce27cb66c4603aa2e7c5f6f92d9d6_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEyLTUtMS0xLTA_13539484-db17-4588-80ce-a31d5cb21aed"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i7004a0f54b4e4ac8adfa3750ee6ccf4e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEyLTctMS0xLTA_9a494971-34be-4e51-ada2-8b9e4aae1469"
      unitRef="usd">8819023</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8add3b9ca8da438b900d8ea5ac0b076c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEzLTEtMS0xLTA_68c70561-94c5-4052-946a-81c6810dc90c"
      unitRef="usd">8819023</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie64a636ae54645beb9d8ee43e42dcc10_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEzLTMtMS0xLTA_6c4d90ff-6341-4a98-a5d9-9416fe7d71e7"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i86bce27cb66c4603aa2e7c5f6f92d9d6_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEzLTUtMS0xLTA_7116086d-9139-4a4d-b628-58b765389641"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7004a0f54b4e4ac8adfa3750ee6ccf4e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTo3NDYzZTFlNmEyNGQ0NTU2YTk0ZTVhN2M2MzcyYzNiNC90YWJsZXJhbmdlOjc0NjNlMWU2YTI0ZDQ1NTZhOTRlNWE3YzYzNzJjM2I0XzEzLTctMS0xLTA_cae3dfed-4107-4429-b707-c5754fb116e3"
      unitRef="usd">8819023</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i7d23fef8ecff4bdebfef8e1a463d13e3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzE5MjA_e15eff0b-d87a-4e17-b372-358602ef0f91"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares
      contextRef="i221a334cfa384bf7bff65c8d98c24f2e_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzQzOTgwNDY1MTc1MDE_225c7d06-9b47-4862-baca-d9aa64e21559"
      unitRef="shares">1644155</us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares>
    <ino:ProceedsFromSaleOfEquitySecuritiesFVNI
      contextRef="i627a611d119640b18733b47fcdec6850_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzQzOTgwNDY1MjAyNTY_00650595-e1b7-49da-bb57-1fd6d1dc04e6"
      unitRef="usd">40100000</ino:ProceedsFromSaleOfEquitySecuritiesFVNI>
    <us-gaap:EquitySecuritiesFvNiRealizedGain
      contextRef="i627a611d119640b18733b47fcdec6850_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzQzOTgwNDY1MjAyNzE_cf9ce8ee-6725-447c-98f5-601c8806751b"
      unitRef="usd">36700000</us-gaap:EquitySecuritiesFvNiRealizedGain>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib52bd61505e648f7bd380109eafb2944_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzU4Nzc_b3381296-e691-4e4d-a2df-5d03db3bde3e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if7a4e61e0eaa451ca758740df043909a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzU4Nzc_cf18fb81-2dd8-4182-8c65-c4046ec233e3"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib52bd61505e648f7bd380109eafb2944_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzQzOTgwNDY1MTgxNjQ_f5fa7a95-5b89-4770-96a7-c3ffb14b0454"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i6c79379a56b342509ef8394d089e5206_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzQzMDk_b02b5e43-c8a5-4002-9ca2-f6de96def0f1"
      unitRef="usd">7100000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90ZXh0cmVnaW9uOjE0YTVjZWRiZWFlZjQ0Yzg4ZmNiNmEyZDA2NWFmNjk0XzU4NjY_16c4cbc7-87d1-4a0c-a8ee-9ce32c7e27df">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in fair value of the derivative liability for the year ended December&#160;31, 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,670,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Derecognition of the derivative liability upon conversion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,490,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTpmNTFhYWEyMTZmYzY0ODZiYjRiZTE4NzExM2Q5Nzg3My90YWJsZXJhbmdlOmY1MWFhYTIxNmZjNjQ4NmJiNGJlMTg3MTEzZDk3ODczXzAtMS0xLTEtMA_587ba43e-0f4c-4c2a-a287-e6ffceef51d0"
      unitRef="usd">8819023</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTpmNTFhYWEyMTZmYzY0ODZiYjRiZTE4NzExM2Q5Nzg3My90YWJsZXJhbmdlOmY1MWFhYTIxNmZjNjQ4NmJiNGJlMTg3MTEzZDk3ODczXzEtMS0xLTEtMA_253d894f-8e31-45bd-817a-9f1f4e561bf7"
      unitRef="usd">-75670977</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTpmNTFhYWEyMTZmYzY0ODZiYjRiZTE4NzExM2Q5Nzg3My90YWJsZXJhbmdlOmY1MWFhYTIxNmZjNjQ4NmJiNGJlMTg3MTEzZDk3ODczXzItMS0xLTEtMA_a6221f57-198c-4c63-8b69-2990307130dc"
      unitRef="usd">84490000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjAvZnJhZzoxNGE1Y2VkYmVhZWY0NGM4OGZjYjZhMmQwNjVhZjY5NC90YWJsZTpmNTFhYWEyMTZmYzY0ODZiYjRiZTE4NzExM2Q5Nzg3My90YWJsZXJhbmdlOmY1MWFhYTIxNmZjNjQ4NmJiNGJlMTg3MTEzZDk3ODczXzMtMS0xLTEtMA_630497d1-3a75-47bf-bdd0-2f082039110d"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzEzNzA_9aea6a42-c2db-4b04-9266-17c4f630544b">Major Customers and Concentration of Credit Risk&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Customer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ApolloBio&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AstraZeneca&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,194,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,850,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advaccine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plumbline Life Sciences, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other, including affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,411,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,111,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,481,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2020, 2019 and 2018, the Company recognized revenue from various license and other agreements. As of December&#160;31, 2020, $11.4 million, or 62%, and $7.1 million, or 38%, of the Company's accounts receivable was attributable to the DoD and Advaccine, respectively. As of December&#160;31, 2019, $469,000, or 67%, and $161,000, or 23%, of the Company's accounts receivable was attributable to MCDC and AstraZeneca, respectively. &lt;/span&gt;&lt;/div&gt;There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzEzNjA_a00b857a-28bd-452c-ad99-e6b8f0d05e54">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Customer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ApolloBio&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AstraZeneca&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,194,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,850,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advaccine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plumbline Life Sciences, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other, including affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,411,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,111,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,481,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib09ce28847f9441691e291976b0a485e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzEtMS0xLTEtMA_277655ee-2b65-438a-90cb-a5e98f1530bc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icc1ad91fea794c9590f178cc0037615c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzEtMy0xLTEtMA_216c93f2-a159-4736-bdc1-5908a287d6fe"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e8cb281f8e84403b97d0d2fecd0b80c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzEtNS0xLTEtMA_f87c338f-8fcd-4abd-abf2-3c737d509c1c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic4ea9cc86768413da095a70b56c90878_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzEtNy0xLTEtMA_8629fe63-44c5-43aa-bcc6-d32149e78c64"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16a1aae8996946329e172cd6fe4f18be_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzEtOS0xLTEtMA_31ec1126-a005-42de-bfef-e1ca4b9b10d0"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i71a6c7568e7c4d8d9bfa945381152967_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzEtMTEtMS0xLTA_689a58f5-f564-4cb5-8b1f-6b2b0d3b64d4"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic13e135184a4471d939ad3f817c42607_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzItMS0xLTEtMA_9d0490e2-103d-4281-b3a0-ffd46d5dc8de"
      unitRef="usd">170587</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i786830bb15014490bcfe93e2c9d6a1e0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzItMy0xLTEtMA_97d36307-f415-4e5e-937e-a20d145479de"
      unitRef="number">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86bef865624946d194ded3a39b0a65c9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzItNS0xLTEtMA_5ce3f7e4-fbf2-471c-b194-643906da1b51"
      unitRef="usd">3194877</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id292a9ccf0334d99847358e5a3ab1c42_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzItNy0xLTEtMA_5b95fbb4-fdf6-4d42-ab24-f465fdb9ec93"
      unitRef="number">0.78</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifab0a228644849cbb1110e99d5c4def2_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzItOS0xLTEtMA_ae8c808b-2a67-438a-a236-3b73a803f3c2"
      unitRef="usd">6850424</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i34104c83002345e7a7bc49036cda039d_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzItMTEtMS0xLTA_d3c6b0ac-a59c-4196-bba1-3c0c3ae5111c"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i281ff24884ff458b8adb28cb18217a61_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzMtMS0xLTEtMA_dc2cabdd-434f-451a-b54f-6392e773ab28"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1c4dc4da8dca44c2a1fe44b672260615_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzMtMy0xLTEtMA_710a9967-7fbd-4293-b73b-cee984f199a9"
      unitRef="number">0.68</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85bcd3d07a5448baa7741c3754cf1afb_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzMtNS0xLTEtMA_898ac156-8dd1-45e8-96fb-4ffe3aabad76"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic8cfb53cdc7e41538de275f318de41dc_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzMtNy0xLTEtMA_f2442823-69fc-44de-b2ca-7bec3778b43e"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60903cdb147d440493201f13edec1181_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzMtOS0xLTEtMA_5032dd66-1c94-490e-9867-53f2a90a8da7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibdff2f0208d44cfe89bc5c92c6d26e82_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzMtMTEtMS0xLTA_acba2797-59de-4b45-8047-887bbe41903a"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e37913d1c5547849d25527ab47a8354_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzQtMS0xLTEtMA_d85e71b7-711d-481f-95f5-fb9a64ed4863"
      unitRef="usd">1370396</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia92449862a9b4330882477084d9c358a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzQtMy0xLTEtMA_2b790dc4-9176-415f-ad85-18dfe641e574"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6147c70afd684bf981a1e0b1202b8058_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzQtNS0xLTEtMA_8f818790-0035-4d68-aeae-6dcb937d5a47"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ica6d55dbeb8f4cc3a279ee53cb51b7f6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzQtNy0xLTEtMA_e5f56b49-c474-4d75-9d31-011117ffd32f"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf1bd4850cb8489ea58ab4b2fda5a1a9_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzQtOS0xLTEtMA_498ddd2a-571b-4de8-831f-f0d330550924"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia1e50a9cd8294f3fa132e51c85220781_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzQtMTEtMS0xLTA_bc1b0a24-69a3-4b34-81bb-fa47b3e1548f"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06dcac265f274ebb9813e7af23d4696d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzUtMS0xLTEtMA_1a27ac02-5dad-44b4-abc1-516586013526"
      unitRef="usd">870237</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i69dd35be2ade4fb39a51b18d53c5b8ac_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzUtMy0xLTEtMA_e1cc76e1-304c-4187-9164-5f2ac22763c4"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i608cd9009af344c89aa12e0f7b311227_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzUtNS0xLTEtMA_437577f3-8426-4ed1-9aad-85d79c229315"
      unitRef="usd">917053</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i823cb278de9e47d192778260c3f6db48_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzUtNy0xLTEtMA_e0f24c01-6940-435b-83f6-11a677f97926"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc88be27567345b7a63177cf8f6f0a99_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzUtOS0xLTEtMA_22024d30-7ecd-4769-b75f-e82cc4cb1a19"
      unitRef="usd">631473</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic35720e7a755474fbed63e8de7d3a5c2_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzUtMTEtMS0xLTA_f94bd630-e5b1-4c06-88f4-2e4b6ec97a19"
      unitRef="number">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzYtMS0xLTEtMA_d3f6b9b8-19fc-46e8-b3ae-01bb79dd58ad"
      unitRef="usd">7411220</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i93819976a973446ea1061a1f37473186_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzYtMy0xLTEtMA_fcc7a3d1-8328-40ca-9556-cc1dd40f4401"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzYtNS0xLTEtMA_6d113549-29ce-4dca-9c01-3e91770ef443"
      unitRef="usd">4111930</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib4efea026d744acf8d1ff320d47ea351_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzYtNy0xLTEtMA_8414806e-86ba-4dd2-b836-e177c40c99ef"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzYtOS0xLTEtMA_536cef07-ac2a-4cb2-b4ef-303f1770b6f0"
      unitRef="usd">30481897</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i488395dd3cfd4a979f4c1b6dc93cab19_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90YWJsZTpiNzE1YTUwYWVhNGY0N2Y1YThkZWNkMTE0ZDY2MjNjMy90YWJsZXJhbmdlOmI3MTVhNTBhZWE0ZjQ3ZjVhOGRlY2QxMTRkNjYyM2MzXzYtMTEtMS0xLTA_cb360321-d9d6-4a73-9fb2-a8c8a3030e4c"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="i74e4216a6494415aa925b9f9484b6be5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzQzOTgwNDY1MTM2OTY_0de5bcf8-44af-49d4-b829-69a286ad5917"
      unitRef="usd">11400000</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia060b83189564cb68c4c124f57185051_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzQzOTgwNDY1MTM3MTA_67343eb8-1207-44f1-9e5d-ce44983e0471"
      unitRef="number">0.62</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="i07a67056b0694c8eb1abe2d9df8f95cc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzQzOTgwNDY1MTM3MTU_a4f48401-9188-4fc3-a5e2-6931ee2ec47c"
      unitRef="usd">7100000</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6d4ece7344ab45b3a9385623a0a4e13d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzQzOTgwNDY1MTM3Mjk_ef351c38-2902-46ed-9358-7b5a266db48e"
      unitRef="number">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="i8525ad5935324dd89b3d251246713420_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzQzOTgwNDY1MTMxNDk_ddc5640c-2547-4ca1-85f4-f43be471c5a2"
      unitRef="usd">469000</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic4b3aa0a98414a8abe5a915a77d31a03_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzQzOTgwNDY1MTMxNTk_6e301255-5cb1-4601-b55c-55f99563fa85"
      unitRef="number">0.67</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="ife05d4e1d47d421fb4f563cd562c6a2c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzEwNDU_03f57dd4-f5f6-4e61-a57d-02ad3617e4eb"
      unitRef="usd">161000</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3f2dd21c2fb446e1ae44bb46996bcb90_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjMvZnJhZzo4Mzc5OTY0MGFmOGI0OTQ5YjgxODlkMzRhYWQwY2UzMy90ZXh0cmVnaW9uOjgzNzk5NjQwYWY4YjQ5NDliODE4OWQzNGFhZDBjZTMzXzEwNTI_f9ae4776-0c24-451b-a2eb-50e1298d7392"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODU4L2ZyYWc6NzRjMDI1ZTNhNjg1NDQzOWI5NTVlYWE2Y2Q4NTM3ZjUvdGV4dHJlZ2lvbjo3NGMwMjVlM2E2ODU0NDM5Yjk1NWVhYTZjZDg1MzdmNV84MjQ2MzM3MjA5OTA2_55f9b5d7-42f5-4772-863b-edf8b837f775">Prepaid Expenses and Other Current Assets&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets at December&#160;31, 2020 and 2019 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing expenses (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,661,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,695,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,584,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,357,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,584,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:24.91pt"&gt;Prepaid manufacturing expenses related to deposits made to reserve capacity for the manufacturing of INO-4800 expected in 2021. In the event that the manufacturing does not occur in 2021 the deposits will be forfeited.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODU4L2ZyYWc6NzRjMDI1ZTNhNjg1NDQzOWI5NTVlYWE2Y2Q4NTM3ZjUvdGV4dHJlZ2lvbjo3NGMwMjVlM2E2ODU0NDM5Yjk1NWVhYTZjZDg1MzdmNV84MjQ2MzM3MjA5OTA3_9cec650d-2c87-4384-b23f-0a468e56362c">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets at December&#160;31, 2020 and 2019 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing expenses (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,661,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,695,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,584,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,357,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,584,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:24.91pt"&gt;Prepaid manufacturing expenses related to deposits made to reserve capacity for the manufacturing of INO-4800 expected in 2021. In the event that the manufacturing does not occur in 2021 the deposits will be forfeited.&lt;/span&gt;&lt;/div&gt;</ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <ino:PrepaidManufacturingExpensesCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODU4L2ZyYWc6NzRjMDI1ZTNhNjg1NDQzOWI5NTVlYWE2Y2Q4NTM3ZjUvdGFibGU6ODZlZjFmYmRkYTY4NDc3ZmI0OTVhZjcyNTQzZWI0ZGMvdGFibGVyYW5nZTo4NmVmMWZiZGRhNjg0NzdmYjQ5NWFmNzI1NDNlYjRkY18yLTEtMS0xLTY4Mzk_b6e37173-4d4c-4c88-976a-8b3e47d8ec7a"
      unitRef="usd">35661947</ino:PrepaidManufacturingExpensesCurrent>
    <ino:PrepaidManufacturingExpensesCurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODU4L2ZyYWc6NzRjMDI1ZTNhNjg1NDQzOWI5NTVlYWE2Y2Q4NTM3ZjUvdGFibGU6ODZlZjFmYmRkYTY4NDc3ZmI0OTVhZjcyNTQzZWI0ZGMvdGFibGVyYW5nZTo4NmVmMWZiZGRhNjg0NzdmYjQ5NWFmNzI1NDNlYjRkY18yLTMtMS0xLTY4Mzk_eaff564e-a198-4a31-ab96-91988a29c16d"
      unitRef="usd">0</ino:PrepaidManufacturingExpensesCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODU4L2ZyYWc6NzRjMDI1ZTNhNjg1NDQzOWI5NTVlYWE2Y2Q4NTM3ZjUvdGFibGU6ODZlZjFmYmRkYTY4NDc3ZmI0OTVhZjcyNTQzZWI0ZGMvdGFibGVyYW5nZTo4NmVmMWZiZGRhNjg0NzdmYjQ5NWFmNzI1NDNlYjRkY18zLTEtMS0xLTY4Mzk_77b0e3bd-895d-4fa5-aae0-b196eb9b1f49"
      unitRef="usd">4695509</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODU4L2ZyYWc6NzRjMDI1ZTNhNjg1NDQzOWI5NTVlYWE2Y2Q4NTM3ZjUvdGFibGU6ODZlZjFmYmRkYTY4NDc3ZmI0OTVhZjcyNTQzZWI0ZGMvdGFibGVyYW5nZTo4NmVmMWZiZGRhNjg0NzdmYjQ5NWFmNzI1NDNlYjRkY18zLTMtMS0xLTY4Mzk_89fa4953-65ed-4b66-a6fe-2bc80dc3db7a"
      unitRef="usd">1584598</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODU4L2ZyYWc6NzRjMDI1ZTNhNjg1NDQzOWI5NTVlYWE2Y2Q4NTM3ZjUvdGFibGU6ODZlZjFmYmRkYTY4NDc3ZmI0OTVhZjcyNTQzZWI0ZGMvdGFibGVyYW5nZTo4NmVmMWZiZGRhNjg0NzdmYjQ5NWFmNzI1NDNlYjRkY18xMS0xLTEtMS02ODM5_f106cdc6-2a9b-47c7-b31b-41b1801f1a2a"
      unitRef="usd">40357456</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODU4L2ZyYWc6NzRjMDI1ZTNhNjg1NDQzOWI5NTVlYWE2Y2Q4NTM3ZjUvdGFibGU6ODZlZjFmYmRkYTY4NDc3ZmI0OTVhZjcyNTQzZWI0ZGMvdGFibGVyYW5nZTo4NmVmMWZiZGRhNjg0NzdmYjQ5NWFmNzI1NDNlYjRkY18xMS0zLTEtMS02ODM5_82b7ada8-0bc9-422b-86d4-e6ab9f580311"
      unitRef="usd">1584598</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90ZXh0cmVnaW9uOmIyY2E1OTk3OTJjMzRlOTA5NDRlMGI1YmQxODI2OTU3XzQ2MQ_1f2c06c7-358e-460f-9041-69c08c137b3b">Fixed Assets&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets at December&#160;31, 2020 and 2019 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Depreciation&lt;br/&gt;and&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,179,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,549,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,630,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,788,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,727,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,061,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,828,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,296,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,544,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,419,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,341,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,993,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,348,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,007,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,996,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,011,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,102,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,229,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,048,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,944,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,103,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,781,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,996,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,939,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,166,458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,773,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the years ended December&#160;31, 2020, 2019 and 2018 was $3.0 million, $3.6 million and $3.7 million, respectively. The Company determined that the carrying value of these long-lived assets was not impaired during the periods presented.  During the year ended December 31, 2020 the Company disposed of fixed assets with a net book value of $227,000 and accumulated depreciation of $200,000.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90ZXh0cmVnaW9uOmIyY2E1OTk3OTJjMzRlOTA5NDRlMGI1YmQxODI2OTU3XzQ2OA_a16aea13-7b2e-4395-9f72-376c718b4adc">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets at December&#160;31, 2020 and 2019 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Depreciation&lt;br/&gt;and&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,179,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,549,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,630,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,788,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,727,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,061,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,828,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,296,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,544,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,419,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,341,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,993,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,348,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,007,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,996,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,011,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,102,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,229,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,048,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,944,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,103,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,781,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,996,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,939,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,166,458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,773,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i37c81a59aea34482aaa080e093a3867a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzItMS0xLTEtMA_854cc153-7218-4b3f-ac8b-1215783c9967"
      unitRef="usd">15179447</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i37c81a59aea34482aaa080e093a3867a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzItMy0xLTEtMA_72e117cd-c680-46e1-8451-2aa7f8f19308"
      unitRef="usd">6549418</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i37c81a59aea34482aaa080e093a3867a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzItNS0xLTEtMA_5c39a5ed-6c55-485a-91f5-67f91bbcb534"
      unitRef="usd">8630029</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id1ab2e4de0604a18954781289db76d63_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzMtMS0xLTEtMA_12e08a9f-2422-4664-b922-98062cf468ea"
      unitRef="usd">4788678</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id1ab2e4de0604a18954781289db76d63_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzMtMy0xLTEtMA_eb295e1e-e0d8-4197-a298-a36a642ae635"
      unitRef="usd">3727508</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id1ab2e4de0604a18954781289db76d63_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzMtNS0xLTEtMA_27bfa889-7ef6-4933-bf8a-e36202ea70e9"
      unitRef="usd">1061170</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5c19b53631bf4b87bd6a70572b19cb99_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzQtMS0xLTEtMA_9e07e18c-39a3-4466-878e-6139a1d519de"
      unitRef="usd">2828675</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5c19b53631bf4b87bd6a70572b19cb99_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzQtMy0xLTEtMA_e4c4fdeb-b381-4f72-b8d5-9199e3180033"
      unitRef="usd">2296942</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5c19b53631bf4b87bd6a70572b19cb99_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzQtNS0xLTEtMA_f082cfcc-74dd-48ae-a811-81d9cb37f0d9"
      unitRef="usd">531733</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i33214248981d4bc3b9306852d8766f9d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzUtMS0xLTEtMA_508de953-fdee-4123-9e04-634a9846728b"
      unitRef="usd">4544915</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i33214248981d4bc3b9306852d8766f9d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzUtMy0xLTEtMA_5919fe9c-e993-45ee-9dad-f9d99edba749"
      unitRef="usd">3419703</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i33214248981d4bc3b9306852d8766f9d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzUtNS0xLTEtMA_54b7c81b-a51c-4005-96d2-b4553b904790"
      unitRef="usd">1125212</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzYtMS0xLTEtMA_dede9fca-47f4-4f60-bd38-650c8bde4632"
      unitRef="usd">27341715</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzYtMy0xLTEtMA_907c2389-fcd3-44ac-96a4-9e2e20c5042a"
      unitRef="usd">15993571</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzYtNS0xLTEtMA_77679efe-1109-4d4e-9f98-6cb4eb606e09"
      unitRef="usd">11348144</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1a2f30004a6f4760aa2daadba4a229e7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzgtMS0xLTEtMA_9cd3a56c-7ce3-4dfb-9ef0-1e971bd21499"
      unitRef="usd">15007935</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i1a2f30004a6f4760aa2daadba4a229e7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzgtMy0xLTEtMA_c23b320b-a85c-421e-88e3-7fe9a208fb7e"
      unitRef="usd">4996777</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1a2f30004a6f4760aa2daadba4a229e7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzgtNS0xLTEtMA_c4e26af7-f491-4b66-8aa9-4ea4daf7c75b"
      unitRef="usd">10011158</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i142b64fd7b4e4c77ab64ed7e235de34e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzktMS0xLTEtMA_d874d9e1-54d1-42a1-9d21-0bab94cd5663"
      unitRef="usd">4102467</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i142b64fd7b4e4c77ab64ed7e235de34e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzktMy0xLTEtMA_8c385d46-8a0a-45d7-a1e8-78de03b36d72"
      unitRef="usd">3229357</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i142b64fd7b4e4c77ab64ed7e235de34e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzktNS0xLTEtMA_1513b2a9-4134-4a9f-b5b4-41ab52878c36"
      unitRef="usd">873110</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie5d0edfd70ad4cd9b77378f5caf6c6fb_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzEwLTEtMS0xLTA_b3d53f92-ee8f-4d83-b1f1-dc435e6b0226"
      unitRef="usd">3048053</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie5d0edfd70ad4cd9b77378f5caf6c6fb_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzEwLTMtMS0xLTA_c79582f2-7d6e-4c4e-9798-1312ed0e4d74"
      unitRef="usd">1944293</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie5d0edfd70ad4cd9b77378f5caf6c6fb_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzEwLTUtMS0xLTA_9f7c8e19-ad50-4fa5-9864-b043681fc3d9"
      unitRef="usd">1103760</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i331d2b93d53845bbbec83894edc52039_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzExLTEtMS0xLTA_011b7486-a95e-48de-9f96-8221e415bfcd"
      unitRef="usd">3781020</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i331d2b93d53845bbbec83894edc52039_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzExLTMtMS0xLTA_716447e2-8245-4778-bb04-19872441429a"
      unitRef="usd">2996031</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i331d2b93d53845bbbec83894edc52039_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzExLTUtMS0xLTA_d3d32e5b-9812-4ceb-91fa-45e653d7e169"
      unitRef="usd">784989</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzEyLTEtMS0xLTA_10093a77-d94d-45e1-a02c-4285e325f45c"
      unitRef="usd">25939475</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzEyLTMtMS0xLTA_f1b7630c-031f-45e2-ad6f-7e642d689035"
      unitRef="usd">13166458</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90YWJsZTo5YTdkZmY1NzMyOGU0NGM3YTU0YzkxNDdjMTUzMDZiMS90YWJsZXJhbmdlOjlhN2RmZjU3MzI4ZTQ0YzdhNTRjOTE0N2MxNTMwNmIxXzEyLTUtMS0xLTA_eae46eb6-6665-45e0-82dc-ae2b5842ca1a"
      unitRef="usd">12773017</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90ZXh0cmVnaW9uOmIyY2E1OTk3OTJjMzRlOTA5NDRlMGI1YmQxODI2OTU3XzQzOTgwNDY1MTE2MjI_3471d691-0576-43a5-9989-339d6b4bfe3b"
      unitRef="usd">3000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90ZXh0cmVnaW9uOmIyY2E1OTk3OTJjMzRlOTA5NDRlMGI1YmQxODI2OTU3XzQzOTgwNDY1MTE2MzA_2c5ae3b5-44cc-4bf3-877b-cd8004c2f73b"
      unitRef="usd">3600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90ZXh0cmVnaW9uOmIyY2E1OTk3OTJjMzRlOTA5NDRlMGI1YmQxODI2OTU3XzQzOTgwNDY1MTE2Mzg_a7909996-863f-45ff-9fd4-ae4f4e459529"
      unitRef="usd">3700000</us-gaap:Depreciation>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90ZXh0cmVnaW9uOmIyY2E1OTk3OTJjMzRlOTA5NDRlMGI1YmQxODI2OTU3XzQxNw_3ca257a8-3845-4a8c-bf43-e9fb983c5646"
      unitRef="usd">227000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjYvZnJhZzpiMmNhNTk5NzkyYzM0ZTkwOTQ0ZTBiNWJkMTgyNjk1Ny90ZXh0cmVnaW9uOmIyY2E1OTk3OTJjMzRlOTA5NDRlMGI1YmQxODI2OTU3XzQ1Mg_c6e213e4-206b-4675-ab3e-2d891857bd97"
      unitRef="usd">200000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90ZXh0cmVnaW9uOmNkMTQ3YTE4ZTI4ZjRhMzRiNzBlMmQxMjhlYTcyN2ZkXzEwNzU_cdd74ea1-cbdb-473b-a15d-44dc9bccf2f8">Goodwill and Intangible Assets&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following sets forth goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:53pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful&lt;br/&gt;Life&lt;br/&gt;(Yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,276,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,248,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioject (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,468,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,631,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,175,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,581,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,356,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,326,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,146,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,779,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,693,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,326,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,660,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,779,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,207,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Goodwill was recorded from the acquisition of other companies and assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Other intangible assets represent the estimated fair value of acquired intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate amortization expense on intangible assets was $547,000, $1.1 million and $1.2 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Amortization expense related to intangible assets at December&#160;31, 2020 is expected to be incurred as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,351,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,147,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no impairment or impairment indicators present and no losses were recorded during the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90ZXh0cmVnaW9uOmNkMTQ3YTE4ZTI4ZjRhMzRiNzBlMmQxMjhlYTcyN2ZkXzEwNzI_eb331e25-14d2-4ebc-b1c9-f0ccc7b4bcfb">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following sets forth goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:53pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful&lt;br/&gt;Life&lt;br/&gt;(Yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,276,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,248,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioject (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,468,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,631,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,175,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,581,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,356,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,326,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,146,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,779,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,693,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,326,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,660,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,779,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,207,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Goodwill was recorded from the acquisition of other companies and assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Other intangible assets represent the estimated fair value of acquired intellectual property.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:Goodwill
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzMtMy0xLTEtMA_ca116398-7a9f-4c94-8c83-a5a3de869c50"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzMtNy0xLTEtMA_01440f95-caf7-47df-8abc-a9d16104bf53"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzMtOS0xLTEtMA_8ae2c1ee-7c98-43b2-976a-e40064b15cb8"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzMtMTMtMS0xLTA_5a775dad-ffac-4b6c-a392-597e489d09c9"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i714873ccaa6945ed8fddc9ca8b4a2ba9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzYtMS0xLTEtMA_a957e3ef-bef3-4ba6-b1f9-6e69a53e8f8f">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i78dee1adddd343d99fde448fd85a0794_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzYtMy0xLTEtMA_e554f469-6741-476a-bb0e-c147a9ffd384"
      unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i78dee1adddd343d99fde448fd85a0794_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzYtNS0xLTEtMA_16255b62-45f8-44aa-ab6d-251b81b75bd7"
      unitRef="usd">1276852</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i78dee1adddd343d99fde448fd85a0794_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzYtNy0xLTEtMA_728fa7b8-86ee-4378-a307-c0e7727ac89e"
      unitRef="usd">46909</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i898390694847439889865bfd898b6744_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzYtOS0xLTEtMA_6bb40ddb-cc70-4759-b554-fa4bc519ae67"
      unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i898390694847439889865bfd898b6744_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzYtMTEtMS0xLTA_59dda494-683f-4c6c-98c8-5389473a76e9"
      unitRef="usd">1248104</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i898390694847439889865bfd898b6744_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzYtMTMtMS0xLTA_458980ed-ae73-47a8-bfa4-06d52b599f0b"
      unitRef="usd">75657</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i5b01ba2e220c4965b4bea51288906959_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzktMS0xLTEtMA_dd89def0-4862-4d7d-bf75-a47189273be4">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3c086571fe9d4f12adaba3aba2947770_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzktMy0xLTEtMA_449121a0-9e76-4466-a0d9-7702300944a4"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3c086571fe9d4f12adaba3aba2947770_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzktNS0xLTEtMA_0e1608cc-94d2-48e5-bb5a-882aded6d94c"
      unitRef="usd">2468889</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3c086571fe9d4f12adaba3aba2947770_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzktNy0xLTEtMA_84f77d3a-e939-4a04-b74a-f3022d845949"
      unitRef="usd">2631111</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie0d8a0c7b06b44b58e6943d769503627_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzktOS0xLTEtMA_12be2736-63c0-4b08-a644-393d25f3045a"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie0d8a0c7b06b44b58e6943d769503627_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzktMTEtMS0xLTA_25ee0b8b-4a7a-4cf5-a641-75bd507c1472"
      unitRef="usd">2175556</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie0d8a0c7b06b44b58e6943d769503627_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzktMTMtMS0xLTA_5005fdd0-4e4a-47b0-80b0-c0e8d90a3037"
      unitRef="usd">2924444</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i564bfb8806cf4e91b81d269583a69770_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEwLTEtMS0xLTA_a565dc60-8660-48d9-a477-62b1ac876b33">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3873b02397f24b078c0992e44ff9bc6b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEwLTMtMS0xLTA_41ba8905-f9d0-40e6-8962-2da3be35ad43"
      unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3873b02397f24b078c0992e44ff9bc6b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEwLTUtMS0xLTA_ebd134eb-5091-4935-8ed6-b2aaaa25a3c3"
      unitRef="usd">3581250</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3873b02397f24b078c0992e44ff9bc6b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEwLTctMS0xLTA_ceeaf2d3-d72f-4ed7-8034-9fc4fbcffb41"
      unitRef="usd">468750</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i18f5246a5fd14efc8c588f0e34623d44_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEwLTktMS0xLTA_3aa59e53-3ce4-4b93-a9a8-2b353d7afc32"
      unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i18f5246a5fd14efc8c588f0e34623d44_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEwLTExLTEtMS0w_25f563f9-b756-4ad0-881c-a8d18cd43f99"
      unitRef="usd">3356250</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i18f5246a5fd14efc8c588f0e34623d44_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEwLTEzLTEtMS0w_71df64c4-b745-4842-a678-4270ac343082"
      unitRef="usd">693750</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic368e3ff4b6c43beb3e373aaad80cfaf_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzExLTEtMS0xLTA_7891ddae-5bb6-41d1-bccf-9e5dddd8155b">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzExLTMtMS0xLTA_f7f068d5-3c35-4345-9429-4a9e25f512b0"
      unitRef="usd">10473761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzExLTUtMS0xLTA_0380b7f8-56f0-4652-995f-348ab34a42ac"
      unitRef="usd">7326991</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzExLTctMS0xLTA_95d904cd-f19b-4b8b-a98f-cbf07d294f7d"
      unitRef="usd">3146770</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzExLTktMS0xLTA_057e0d0d-f123-4c05-b300-782f7ae70f94"
      unitRef="usd">10473761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzExLTExLTEtMS0w_f6a35f6a-259e-43f5-9e76-ab7b8cd608b8"
      unitRef="usd">6779910</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzExLTEzLTEtMS0w_3b922f58-8a70-4df8-a488-69f766c37655"
      unitRef="usd">3693851</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEyLTMtMS0xLTA_2c47e214-b2c4-4986-b302-01fda4ba998c"
      unitRef="usd">20987132</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEyLTUtMS0xLTA_914e37bb-25aa-41f4-995d-6285c5c019ef"
      unitRef="usd">7326991</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ino:GoodwillAndIntangibleAssetsNet
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEyLTctMS0xLTA_5e9e3863-d581-43b3-ab24-0fb34134fc2c"
      unitRef="usd">13660141</ino:GoodwillAndIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEyLTktMS0xLTA_c4001d3e-2d1a-4d2e-a79c-f60c27e2c005"
      unitRef="usd">20987132</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEyLTExLTEtMS0w_3a1cd45c-066d-4e38-ad3e-f8ac0a636e71"
      unitRef="usd">6779910</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ino:GoodwillAndIntangibleAssetsNet
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZTplMTYyZDJlYzFkNzg0OGZmYWM1NTcxZGFlZjE2OGI5NC90YWJsZXJhbmdlOmUxNjJkMmVjMWQ3ODQ4ZmZhYzU1NzFkYWVmMTY4Yjk0XzEyLTEzLTEtMS0w_df62a5b3-7a93-4a44-97f4-e651f4c88e2a"
      unitRef="usd">14207222</ino:GoodwillAndIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90ZXh0cmVnaW9uOmNkMTQ3YTE4ZTI4ZjRhMzRiNzBlMmQxMjhlYTcyN2ZkXzQzOTgwNDY1MTI1OTU_e6a1bc48-919c-41f9-af07-77437f4548a6"
      unitRef="usd">547000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90ZXh0cmVnaW9uOmNkMTQ3YTE4ZTI4ZjRhMzRiNzBlMmQxMjhlYTcyN2ZkXzQzOTgwNDY1MTI2MDA_b7680399-38db-4231-ac44-44175faa354b"
      unitRef="usd">1100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90ZXh0cmVnaW9uOmNkMTQ3YTE4ZTI4ZjRhMzRiNzBlMmQxMjhlYTcyN2ZkXzQzOTgwNDY1MTI2MDg_4a316714-977c-4f3b-850e-ed350a034aaa"
      unitRef="usd">1200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90ZXh0cmVnaW9uOmNkMTQ3YTE4ZTI4ZjRhMzRiNzBlMmQxMjhlYTcyN2ZkXzEwNzA_6bf78696-829d-45fe-aeb5-89f82e859ee6">Amortization expense related to intangible assets at December&#160;31, 2020 is expected to be incurred as follows: &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,351,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,147,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZToxNTc1ZmI1NjlkOGI0MDM2OGMzNGJmNGQ1NDVlODkyOS90YWJsZXJhbmdlOjE1NzVmYjU2OWQ4YjQwMzY4YzM0YmY0ZDU0NWU4OTI5XzEtMS0xLTEtMA_8106ffc6-43ff-4175-ac6e-ce9a862b3895"
      unitRef="usd">521000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZToxNTc1ZmI1NjlkOGI0MDM2OGMzNGJmNGQ1NDVlODkyOS90YWJsZXJhbmdlOjE1NzVmYjU2OWQ4YjQwMzY4YzM0YmY0ZDU0NWU4OTI5XzItMS0xLTEtMA_9b1b50eb-9d9c-4224-9675-ef923bd4f611"
      unitRef="usd">493000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZToxNTc1ZmI1NjlkOGI0MDM2OGMzNGJmNGQ1NDVlODkyOS90YWJsZXJhbmdlOjE1NzVmYjU2OWQ4YjQwMzY4YzM0YmY0ZDU0NWU4OTI5XzMtMS0xLTEtMA_fb84838d-b74d-4bf4-9a30-d68dcee388c9"
      unitRef="usd">276000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZToxNTc1ZmI1NjlkOGI0MDM2OGMzNGJmNGQ1NDVlODkyOS90YWJsZXJhbmdlOjE1NzVmYjU2OWQ4YjQwMzY4YzM0YmY0ZDU0NWU4OTI5XzQtMS0xLTEtMA_7cbea71d-4c8b-4bc2-9206-f2fce0f612e0"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZToxNTc1ZmI1NjlkOGI0MDM2OGMzNGJmNGQ1NDVlODkyOS90YWJsZXJhbmdlOjE1NzVmYjU2OWQ4YjQwMzY4YzM0YmY0ZDU0NWU4OTI5XzUtMS0xLTEtMA_8abd8ac9-5d06-4b07-9dba-9def76d78be7"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZToxNTc1ZmI1NjlkOGI0MDM2OGMzNGJmNGQ1NDVlODkyOS90YWJsZXJhbmdlOjE1NzVmYjU2OWQ4YjQwMzY4YzM0YmY0ZDU0NWU4OTI5XzYtMS0xLTEtMA_aec9ef94-fcf8-4717-9291-6b43d51f2ac1"
      unitRef="usd">1351000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90YWJsZToxNTc1ZmI1NjlkOGI0MDM2OGMzNGJmNGQ1NDVlODkyOS90YWJsZXJhbmdlOjE1NzVmYjU2OWQ4YjQwMzY4YzM0YmY0ZDU0NWU4OTI5XzctMS0xLTEtMA_b5a376be-a10e-4efc-86d2-722debb64a0e"
      unitRef="usd">3147000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90ZXh0cmVnaW9uOmNkMTQ3YTE4ZTI4ZjRhMzRiNzBlMmQxMjhlYTcyN2ZkXzkyOA_3242a3fc-1a1e-41fc-aeaf-247eb8b67b12"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90ZXh0cmVnaW9uOmNkMTQ3YTE4ZTI4ZjRhMzRiNzBlMmQxMjhlYTcyN2ZkXzkyOA_6a4e7e3e-63e1-4d7c-97c1-c6eabd562991"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNjkvZnJhZzpjZDE0N2ExOGUyOGY0YTM0YjcwZTJkMTI4ZWE3MjdmZC90ZXh0cmVnaW9uOmNkMTQ3YTE4ZTI4ZjRhMzRiNzBlMmQxMjhlYTcyN2ZkXzkyOA_fa2f692c-2e8e-40cd-87a5-f5fe8bf3987e"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE1NTQw_bb99a0c7-eb7c-40e7-bd86-72567108d0d1">Convertible Debt&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#x201c;Notes&#x201d;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were approximately $75.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of 6.50% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial conversion rate will be 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.38 per share), subject to adjustment upon the occurrence of specified events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may not redeem the Notes prior to March 1, 2022. On or after March 1, 2022, the Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#x2019;s own stock and classified in stockholders&#x2019; equity in its consolidated balance sheet, and that the cash conversion guidance applies. Therefore, the Notes issuance proceeds of $78.5 million are allocated first to the liability component based on the fair value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion features. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was $62.2 million and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of $2.8 million are allocated to the liability and equity component in the same proportion as the issuance proceeds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $18.6 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is 13.1%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December 31, 2020, the Company received notices for the conversion of $62.1&#160;million of principal amount of the Notes, which were settled into an aggregate of 11,535,660 shares of the Company's common stock. The fair value of the Notes at the date of conversion was $43.7&#160;million compared to the carrying value of $52.5&#160;million, resulting in a $8.8&#160;million gain on extinguishment of debt. Thi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;s gain was recorded in the consolidated statement of operations. To measure the fair value of the converted Notes as of the conversion dates, the Company engaged a third-party valuation expert and utilized a binomial lattice model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the Notes at December&#160;31, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount converted into common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,085,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount on the liability component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,312,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(318,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,139,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2020 and 2019,&#160;the Company recognized $6.9 million and $7.0&#160;million, respectively, of interest expense related to the Notes, of which $4.1 million and $4.4&#160;million, respectively, related to the contractual interest coupon. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;August 2019 Convertible Bonds &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2019, the Company closed a private placement of the August 2019 Bonds with an aggregate principal amount of 18 billion KRW (approximately USD $15.0 million based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were approximately $14.5 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The August 2019 Bonds, which are unsecured obligations of the Company, were issued on August 1, 2019 and accrued interest at a coupon rate of 1.00% per annum, payable quarterly. The August 2019 Bonds were scheduled to mature on July 31, 2024, unless earlier converted or repurchased. On August 3, 2020 the August 2019 Bonds were converted in full into an aggregate of 4,962,364 shares of the Company's common stock, leaving no further August 2019 Bonds outstanding. The initial &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;conversion rate was 211.0595 shares per KRW1,000,000 in principal amount (equivalent to an initial conversion price of approximately USD $4.00 per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate was reset on January 2, 2020 and was subject to reset quarterly thereafter if the current market price was lower than the conversion price then in effect. The conversion rate as of the date of conversion on August 1, 2020 was 275.6873 shares per KRW1,000,000 in principal amount (equivalent to a conversion price of approximately USD $3.14 per share). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature was considered a derivative requiring bifurcation from the August 2019 Bonds as it did not meet the equity scope exception due to the fact that it was denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was $7.1 million, which was recorded as a reduction to the carrying value of the debt. This debt discount was being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option was accounted for as a derivative liability, which was revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the consolidated&#160;statements of operations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At their issuance, the Company determined that the expected life of the August 2019 Bonds was equal to the period through August 1, 2022 as this represented the point at which the August 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $7.3 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, was being amortized using the effective interest method through August 1, 2022. For the years ended December&#160;31, 2020 and 2019,&#160;the Company recognized $1.6 million and $982,000, respectively, of interest expense related to the August 2019 Bonds, of which $87,000 and $65,000, respectively, related to the contractual interest coupon. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, all outstanding August 2019 Bonds were converted into common stock. Immediately prior to the conversion, the derivative liability was revalued at $84.5&#160;million. The change in fair value of the derivative liability was an increase of $75.7&#160;million, which was recorded on the consolidated statement of operations. To measure the fair value of the derivative liability as of the conversion date, the Company engaged a third-party valuation expert.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, a loss on extinguishment of $8.2&#160;million was recorded on the consolidated statement of operations. This loss represents the difference between (a) the calculated fair value of the derivative liability immediately prior to its derecognition plus the carrying amount of the debt component including any unamortized debt discount and issuance costs and (b) the fair value of the 4,692,364 shares of the Company's common stock issued upon conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;December 2019 Convertible Bonds &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#x201c;December 2019 Bonds&#x201d;) with an aggregate principal amount of 4.7 billion KRW (approximately USD $4.1 million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were approximately $4.0 million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The December 2019 Bonds, which are unsecured obligations of the Company, were issued on December&#160;31, 2019 and will accrue interest at a coupon rate of 1.00% per annum, payable quarterly. The December 2019 Bonds will mature on December&#160;31, 2024, unless earlier converted or repurchased. The outstanding December 2019 Bonds will be repaid at maturity at a price equal to the principal of the outstanding bonds to be repaid plus a premium on such bonds to provide an internal rate of return with respect to such bonds of 6.00%. Commencing on December&#160;31, 2020, the December 2019 Bonds are convertible until the date that is one month prior to maturity date. Upon conversion, the Company will deliver shares of common stock of the Company. The initial conversion rate was 214.7766 shares per KRW1,000,000 principal amount of Bonds (equivalent to an initial conversion price of approximately USD $4.00 per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. The conversion rate was subject to reset on July&#160;2, 2020 and on each three month anniversary thereafter until the maturity date to the then current market price if the current market price is lower than the conversion price then in effect; provided that the conversion rate will not exceed 357.9611 shares per KRW1,000,000 (equivalent to a conversion price of approximately USD $2.40 per share based on the exchange rate as of December&#160;19, 2019). &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The conversion rate has not been reset as of December&#160;31, 2020 from the initial conversion rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The December 2019 Bonds will be subject to repurchase by the Company at the option of the bondholders from and including December&#160;31, 2022 up to the date that is one month prior to the maturity date at a repurchase price equal to the principal of the December 2019 Bonds to be repurchased plus a premium on the Bonds in order to ensure an internal rate of return with respect to the Bonds equal to 6.00%. In addition, upon the occurrence of a fundamental change (as defined in the Subscription Agreement) the Company will be required to offer to repurchase the Bonds at a repurchase price equal to the principal amount thereof plus accrued and unpaid interest thereon to but excluding the applicable repurchase date. If certain &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;bankruptcy and insolvency-related events of default occur, the principal of, and accrued and unpaid interest on, all of the then outstanding December 2019 Bonds shall automatically become due and payable. If any other event of default occurs and is continuing, the holders of at least 25% of the in aggregate principal amount of the December 2019 Bonds by notice to the Company may declare the principal of, and accrued and unpaid interest on, all of the then-outstanding December 2019 Bonds to be due and payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature does not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature meets the definition of a derivative, it qualifies for the equity scope exception for instruments that are both indexed to an entity&#x2019;s own stock and classified in stockholders&#x2019; equity in its consolidated balance sheet. The December 2019 Bonds are denominated in a foreign currency other than the Company&#x2019;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#x2019;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario is fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency does not impact the settlement of the conversion option. Further, as there is no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the December 2019 Bonds at December&#160;31, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,327,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of premium associated with the December 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,515,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the expected life of the December 2019 Bonds was equal to the period through December 31, 2022 as this represents the point at which the December 2019 Bonds are initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds is 6.2%. For the year ended December&#160;31, 2020,&#160;the Company recognized $253,000 of interest expense related to the December 2019 Bonds, of which $40,000 related to the contractual interest coupon. As of December&#160;31, 2020, there have not been any conversions or redemptions of the December 2019 Bonds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, future minimum payments due under the Company's convertible debt instruments are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Convertible Notes (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 2019 Bonds (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,110,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,110,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,571,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,519,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,149,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,701,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,850,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of 6.5% per year. &lt;/span&gt;&lt;/div&gt;(2) Amounts represent amounts due under the December 2019 Bonds, including interest based on the fixed rate of 1% per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of 6% at maturity.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7ab95ac0698643e2a24b4f704858ab14_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzEzOA_ccf073d8-db67-4f6b-b8b9-e27856b6e6eb"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7ab95ac0698643e2a24b4f704858ab14_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE3NQ_d7f29f48-80b9-4e26-822f-584ae6e7d84c"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="iaa895d662b3145c5a41a31d0ed8415b0_D20190219-20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQyMQ_56d1ca42-734e-4236-b43d-2d394e82360b"
      unitRef="usd">75700000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7ab95ac0698643e2a24b4f704858ab14_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzYzMA_102a9ee9-1e98-46c1-855f-3b9df1702f98"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE0MzI_7a91c3e9-5194-41d6-a367-ad7a72bc107b"
      unitRef="usdPerShare">5.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE3NDQ_24feeb97-3cef-48d7-9ccb-0dc178b7f642"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE3OTU_9dfdabb6-7bb8-47b7-8453-e30492f2cecf"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE4NTE_eb480205-4a25-4704-b085-bb707067c497"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzIxMjI_88778a6c-f03d-4d19-80a4-358bc4fccd60"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7ab95ac0698643e2a24b4f704858ab14_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzI2NTE_36bafe7f-288c-4560-bd9d-0cc4cd74228e"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtFairValue
      contextRef="i7ab95ac0698643e2a24b4f704858ab14_I20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzI5Njc_cc025620-2ea9-459f-b8d5-1422a5a02a2a"
      unitRef="usd">62200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i7ab95ac0698643e2a24b4f704858ab14_I20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzMxNzk_51bb2e85-c7ab-4cf5-abdb-714ba66eb71e"
      unitRef="usd">2800000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i7ab95ac0698643e2a24b4f704858ab14_I20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1Mjc0Mzc_b96bb55b-3be4-48e6-b3bc-60a744fef2d2"
      unitRef="usd">18600000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1Mjc2Njg_87c0b85e-33b0-446f-9e00-24be4c4a1eb5"
      unitRef="number">0.131</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzMyOTg1MzQ5MDkzNzI_0ffc4a75-32b8-401b-ac45-85ea974259b6"
      unitRef="usd">62100000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzMyOTg1MzQ5MDkzODk_ca9c0819-8cd9-431d-956b-978a26daa3f0"
      unitRef="shares">11535660</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzcxODU_ed4a3fc6-0e86-4c0f-b730-286d7acfa318"
      unitRef="usd">43700000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzczMjg_aee2a2f7-4084-4c66-8b83-bb818ab790d0"
      unitRef="usd">52500000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzcyNTQ_e1c7cdbd-6991-4ee2-b894-30ec5a78fe63"
      unitRef="usd">8800000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE1NTQx_48a5f88c-a1b8-4df2-972e-82830cb37865">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the Notes at December&#160;31, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount converted into common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,085,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount on the liability component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,312,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(318,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,139,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the December 2019 Bonds at December&#160;31, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,327,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of premium associated with the December 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,515,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4a2b66e18d454ede830f8d1d4aada02f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo0NmFjNjBkMzcwNjU0MTM2YTU4OTJlMDQxOTVlYTI2NC90YWJsZXJhbmdlOjQ2YWM2MGQzNzA2NTQxMzZhNTg5MmUwNDE5NWVhMjY0XzAtMS0xLTEtMA_d3b6757e-01ea-4643-8c49-c604b6378823"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <ino:DebtInstrumentConvertibleDebtConvertedAmount
      contextRef="i4a2b66e18d454ede830f8d1d4aada02f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo0NmFjNjBkMzcwNjU0MTM2YTU4OTJlMDQxOTVlYTI2NC90YWJsZXJhbmdlOjQ2YWM2MGQzNzA2NTQxMzZhNTg5MmUwNDE5NWVhMjY0XzEtMS0xLTEtMzY0OA_4efb5cb1-21fc-4ba3-a3fa-61ccbbe984eb"
      unitRef="usd">62085000</ino:DebtInstrumentConvertibleDebtConvertedAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i4a2b66e18d454ede830f8d1d4aada02f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo0NmFjNjBkMzcwNjU0MTM2YTU4OTJlMDQxOTVlYTI2NC90YWJsZXJhbmdlOjQ2YWM2MGQzNzA2NTQxMzZhNTg5MmUwNDE5NWVhMjY0XzEtMS0xLTEtMA_f29f4212-966a-46d2-aad5-0b3837ae8b86"
      unitRef="usd">2312404</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i4a2b66e18d454ede830f8d1d4aada02f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo0NmFjNjBkMzcwNjU0MTM2YTU4OTJlMDQxOTVlYTI2NC90YWJsZXJhbmdlOjQ2YWM2MGQzNzA2NTQxMzZhNTg5MmUwNDE5NWVhMjY0XzItMS0xLTEtMA_6c1e0f75-17f9-4311-a533-31a7d2e18a13"
      unitRef="usd">318266</us-gaap:DeferredFinanceCostsNet>
    <ino:DebtinstrumentAccruedInterest
      contextRef="i4a2b66e18d454ede830f8d1d4aada02f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo0NmFjNjBkMzcwNjU0MTM2YTU4OTJlMDQxOTVlYTI2NC90YWJsZXJhbmdlOjQ2YWM2MGQzNzA2NTQxMzZhNTg5MmUwNDE5NWVhMjY0XzMtMS0xLTEtMA_9fe3944f-8e32-495a-84f7-8d4044afc341"
      unitRef="usd">355658</ino:DebtinstrumentAccruedInterest>
    <us-gaap:LongTermDebt
      contextRef="i4a2b66e18d454ede830f8d1d4aada02f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo0NmFjNjBkMzcwNjU0MTM2YTU4OTJlMDQxOTVlYTI2NC90YWJsZXJhbmdlOjQ2YWM2MGQzNzA2NTQxMzZhNTg5MmUwNDE5NWVhMjY0XzQtMS0xLTEtMA_d1d05db1-2f2f-456a-a083-ba19c403543b"
      unitRef="usd">14139988</us-gaap:LongTermDebt>
    <us-gaap:InterestExpense
      contextRef="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQxNjM_68408ea3-3215-4ddd-9230-1fbc42c0cafe"
      unitRef="usd">6900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie36d4982a87c49f39d1d799e83d16f3d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MjkzMjM_0509dc4e-c0ca-4181-9b61-abfa161c1d2a"
      unitRef="usd">7000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="ie6d09c017e724216bcf006aa836a0724_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQyMTc_71497464-2732-469f-9c70-137722f400f7"
      unitRef="usd">4100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ie36d4982a87c49f39d1d799e83d16f3d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MjkyNjg_d1e298f3-c8aa-42df-b2fb-f5458eb13b0e"
      unitRef="usd">4400000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1ef0a0da5279497abe1189b528c9b923_I20190801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQ0OTI_7e624bab-cead-4bae-800f-6c8978398eab"
      unitRef="krw">18000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1ef0a0da5279497abe1189b528c9b923_I20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQ1MzE_e6bf8401-882f-44b8-a49b-0244e5ab7840"
      unitRef="usd">15000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ie42755ee382b4362b35b654a372750a0_D20190801-20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQ3ODI_f8057fed-f63c-46ac-8bea-ad971ea3d94e"
      unitRef="usd">14500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1ef0a0da5279497abe1189b528c9b923_I20190801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzUxNDc_790da17e-78cd-48a1-b000-d7de273e6df5"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i9081e6bad5e84753997332afda1396e2_D20200803-20200803"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzAyMzc_287ae931-d955-4f59-9323-bd562783e5bd"
      unitRef="shares">4962364</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i1b97fc9dbea24d1a8c1cc2caf0be1794_I20200803"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzYwNDY_d31cbe2b-d32d-4f0b-8b3e-28f9f0d81c06"
      unitRef="usdPerShare">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i3e5cc4151269456bb11f37ef3096b655_I20200803"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzEwMzg_26bbdeac-69f7-4fd1-97f7-f92990adca8f"
      unitRef="usdPerShare">3.14</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i1ef0a0da5279497abe1189b528c9b923_I20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzgwOTg_f3401595-98ce-4955-8c06-853d335aa683"
      unitRef="usd">7100000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i1ef0a0da5279497abe1189b528c9b923_I20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzkxNzM_67afd868-8499-4151-b372-c8eaadeeae79"
      unitRef="usd">7300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:InterestExpense
      contextRef="i4b884d1d8cee4549b13c04c430171c0d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzk0NDk_98139c41-841d-4c06-a536-6793c6a2bca4"
      unitRef="usd">1600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i340206d59d1a4f37a0d265ecd256f49a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzgyNDYzMzcyMzQ2MTI_51bbd66e-685d-410b-b0aa-41a55ed74642"
      unitRef="usd">982000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i4b884d1d8cee4549b13c04c430171c0d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzk1MTU_3bd79d22-2f78-4e59-ac1f-91ba93b5d142"
      unitRef="usd">87000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i340206d59d1a4f37a0d265ecd256f49a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzIyNzg_f133954a-e896-4c7c-8ab8-35405540294f"
      unitRef="usd">65000</us-gaap:InterestExpenseDebt>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="i68fab246bae941029c1bb3eb8d3d4400_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzQ4MDc_691612e4-033f-4508-9561-746e21685212"
      unitRef="usd">84500000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i8b9a6b9c0fba4da0a1e8ad1ae9afb802_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzQ4MjI_5f0d628b-8913-43c7-abc2-dc27ee44b68e"
      unitRef="usd">75700000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8b9a6b9c0fba4da0a1e8ad1ae9afb802_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzQ4Mzc_2d66d928-9a27-46ab-bddf-770c7329df31"
      unitRef="usd">-8200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i8b9a6b9c0fba4da0a1e8ad1ae9afb802_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzQ4NTE_0a5f61f5-5a85-4c37-aa73-5d76d12a3dcc"
      unitRef="shares">4692364</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i01aabdcf7e1946cfad86edb560658159_I20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzk5Nzk_6ecae8c1-57b9-4232-83c9-bc9ab1e4995f"
      unitRef="krw">4700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i01aabdcf7e1946cfad86edb560658159_I20191226"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzEwMDA1_bac0e217-9b9f-4b3c-a990-29fff8370b32"
      unitRef="usd">4100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="icec95e1e34f940efa96dfde18a03f4f4_D20191226-20191226"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzEwMTU4_2128c2b7-2ddc-4c9e-950d-6a046c64b679"
      unitRef="usd">4000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i01aabdcf7e1946cfad86edb560658159_I20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzEwMzE1_1cb1f8fe-d75a-41f8-9993-72ab25f31d03"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ino:DebtInstrumentConvertibleInternalRateOfReturn
      contextRef="i01aabdcf7e1946cfad86edb560658159_I20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzEwNjc5_9df13a45-16e4-4a2a-af50-5ef663040fc1"
      unitRef="number">0.0600</ino:DebtInstrumentConvertibleInternalRateOfReturn>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i700bda11831d4df3889dde4f49d91305_I20191226"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzExMTM3_fba6ae12-6ad8-4e33-816d-bdcddf5d334a"
      unitRef="usdPerShare">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i8b023471d6394305b1996c77b2d112da_I20191226"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzExNjM2_4baa958d-1de5-4001-bb99-a4ef480e974b"
      unitRef="usdPerShare">2.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <ino:DebtInstrumentConvertibleInternalRateOfReturn
      contextRef="i01aabdcf7e1946cfad86edb560658159_I20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzEyMTAw_9d1e2404-900d-48eb-a8a9-d450d0e091cf"
      unitRef="number">0.0600</ino:DebtInstrumentConvertibleInternalRateOfReturn>
    <ino:DebtInstrumentConvertibleRequiredBondholderApprovalPercentage
      contextRef="icec95e1e34f940efa96dfde18a03f4f4_D20191226-20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzEyNzEy_310a6e52-2ec5-48fe-86b5-7c2a3fb50fa4"
      unitRef="number">0.25</ino:DebtInstrumentConvertibleRequiredBondholderApprovalPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i90a70ccee3354926b91c35b43f4f36de_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo4MTFhOTFjYTliMjY0YzE5OGIwNmQ5NmIxOTU3NDVjMi90YWJsZXJhbmdlOjgxMWE5MWNhOWIyNjRjMTk4YjA2ZDk2YjE5NTc0NWMyXzAtMS0xLTEtMA_4e57cf54-a89e-435f-be1f-966e881e0500"
      unitRef="usd">4327370</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i90a70ccee3354926b91c35b43f4f36de_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo4MTFhOTFjYTliMjY0YzE5OGIwNmQ5NmIxOTU3NDVjMi90YWJsZXJhbmdlOjgxMWE5MWNhOWIyNjRjMTk4YjA2ZDk2YjE5NTc0NWMyXzItMS0xLTEtMA_db9a6d03-f6a3-4778-9916-155c42867071"
      unitRef="usd">36525</us-gaap:DeferredFinanceCostsNet>
    <ino:DebtInstrumentAccretionOfPremium
      contextRef="i90a70ccee3354926b91c35b43f4f36de_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo4MTFhOTFjYTliMjY0YzE5OGIwNmQ5NmIxOTU3NDVjMi90YWJsZXJhbmdlOjgxMWE5MWNhOWIyNjRjMTk4YjA2ZDk2YjE5NTc0NWMyXzMtMS0xLTEtMA_c9150370-f641-4de8-8185-8b4dff907a03"
      unitRef="usd">214171</ino:DebtInstrumentAccretionOfPremium>
    <ino:DebtinstrumentAccruedInterest
      contextRef="i90a70ccee3354926b91c35b43f4f36de_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo4MTFhOTFjYTliMjY0YzE5OGIwNmQ5NmIxOTU3NDVjMi90YWJsZXJhbmdlOjgxMWE5MWNhOWIyNjRjMTk4YjA2ZDk2YjE5NTc0NWMyXzQtMS0xLTEtMA_bd08af65-8c8e-41ee-ae41-1774f329d853"
      unitRef="usd">10818</ino:DebtinstrumentAccruedInterest>
    <us-gaap:LongTermDebt
      contextRef="i90a70ccee3354926b91c35b43f4f36de_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo4MTFhOTFjYTliMjY0YzE5OGIwNmQ5NmIxOTU3NDVjMi90YWJsZXJhbmdlOjgxMWE5MWNhOWIyNjRjMTk4YjA2ZDk2YjE5NTc0NWMyXzUtMS0xLTEtMA_61e68721-5dcd-4895-b975-9e03ac6765c8"
      unitRef="usd">4515834</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ifbed9e38f9f44e17bc3443f38555ff5b_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE0ODIz_1a86e559-c3af-4b69-a8e9-de12a44e7a25"
      unitRef="number">0.062</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpense
      contextRef="i4d6e94e1cacc426ebf7ec4cb5e51ff53_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzUxMDM_55b306b3-52b6-4b73-8b50-48421e28f374"
      unitRef="usd">253000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i4d6e94e1cacc426ebf7ec4cb5e51ff53_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzQzOTgwNDY1MzUxMDc_6efbf5b1-f45d-4e42-b151-dbc79e639f6b"
      unitRef="usd">40000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE1NTQ0_71041647-1fb6-419e-9efc-0c82c5d926b2">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, future minimum payments due under the Company's convertible debt instruments are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Convertible Notes (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 2019 Bonds (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,110,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,110,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,571,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,519,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,149,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,701,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,850,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of 6.5% per year. &lt;/span&gt;&lt;/div&gt;(2) Amounts represent amounts due under the December 2019 Bonds, including interest based on the fixed rate of 1% per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of 6% at maturity.</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzItMi0xLTEtMA_3756bb63-5fe2-4aca-9759-47097b3f1090"
      unitRef="usd">1067000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ifbed9e38f9f44e17bc3443f38555ff5b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzItNi0xLTEtMA_d52a5ce8-4d2b-4f75-ba9e-97bc0ffdb976"
      unitRef="usd">43000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ic594f80a76ff4858a3452511b0ae1fad_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzItOC0xLTEtMA_3b2a1343-7a33-4891-8219-6a30e14ad6e9"
      unitRef="usd">1110000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzMtMi0xLTEtMA_19856807-95df-45ab-a682-a24485fa55d1"
      unitRef="usd">1067000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ifbed9e38f9f44e17bc3443f38555ff5b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzMtNi0xLTEtMA_427b7057-2b3a-4326-822e-66162cb06fff"
      unitRef="usd">43000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ic594f80a76ff4858a3452511b0ae1fad_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzMtOC0xLTEtMA_eaf3dee7-b764-4fe8-aa48-1ff7aee8da3d"
      unitRef="usd">1110000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzQtMi0xLTEtMA_8dfdc255-5ec9-46fb-a282-b360af1e928a"
      unitRef="usd">1067000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ifbed9e38f9f44e17bc3443f38555ff5b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzQtNi0xLTEtMA_ddbb4315-0133-4790-8dfe-f92ef40d85c9"
      unitRef="usd">44000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ic594f80a76ff4858a3452511b0ae1fad_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzQtOC0xLTEtMA_ad40ff88-edb3-4815-8d53-1bf23c885e49"
      unitRef="usd">1111000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzUtMi0xLTEtMA_993e8b8a-68f4-4b8c-b132-08111946a330"
      unitRef="usd">16948000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ifbed9e38f9f44e17bc3443f38555ff5b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzUtNi0xLTEtMA_8481eeea-54ee-4d23-b6b9-dd6e15ed2597"
      unitRef="usd">5571000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ic594f80a76ff4858a3452511b0ae1fad_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzUtOC0xLTEtMA_341ed811-2912-4e45-b401-591cc7764be0"
      unitRef="usd">22519000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebt
      contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzctMi0xLTEtMA_3c1ecde7-fc42-4bf4-9c16-f36b7a1b5204"
      unitRef="usd">20149000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ifbed9e38f9f44e17bc3443f38555ff5b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzctNi0xLTEtMA_6bab3dbb-34ec-4b7c-bd40-3a67e780e5b3"
      unitRef="usd">5701000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic594f80a76ff4858a3452511b0ae1fad_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90YWJsZTo2ODk0NmM5ZTAyMDM0MGNkYjQ3YTdmNTk4YzdhZGI0NS90YWJsZXJhbmdlOjY4OTQ2YzllMDIwMzQwY2RiNDdhN2Y1OThjN2FkYjQ1XzctOC0xLTEtMA_5ce15392-0d29-4243-aebd-b37d955d8722"
      unitRef="usd">25850000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib1fd9f19434d481d9950a24dc8314104_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE1MjYy_33feab5d-442b-4681-a963-133b751b8a43"
      unitRef="number">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i450df2d2eb374134a57819c4d3d41137_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE1NDE1_876f9f3d-d3b5-493a-8370-c7922fdeb791"
      unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ino:DebtInstrumentConvertibleInternalRateOfReturn
      contextRef="i450df2d2eb374134a57819c4d3d41137_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNzUvZnJhZzplOGQ0N2RjNzc0MGQ0OGRmYTNmNjU5M2RmYTRjNjUwZC90ZXh0cmVnaW9uOmU4ZDQ3ZGM3NzQwZDQ4ZGZhM2Y2NTkzZGZhNGM2NTBkXzE1NTI0_9d03d473-537a-496b-a0bb-4a85591e403c"
      unitRef="number">0.06</ino:DebtInstrumentConvertibleInternalRateOfReturn>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90ZXh0cmVnaW9uOmZjODNiOWQ0OTgzMDRiYzRhOGRkODVlNzgyY2E4NTk1XzE1MQ_f7f84081-ef60-4c00-9a58-96485e96c298">Accounts Payable and Accrued Expenses&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses at December&#160;31, 2020 and 2019 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,919,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,127,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,967,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued subcontract costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,003,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,203,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,237,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90ZXh0cmVnaW9uOmZjODNiOWQ0OTgzMDRiYzRhOGRkODVlNzgyY2E4NTk1XzE1Mw_ed531f08-b28b-4db4-b98a-07b33417c1f3">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses at December&#160;31, 2020 and 2019 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,919,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,127,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,967,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued subcontract costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,003,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,203,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,237,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzItMS0xLTEtMA_a6a06c93-8a5c-47c1-9a5b-4ca315e1d76d"
      unitRef="usd">825516</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzItMy0xLTEtMA_a636a469-db4e-4b6c-9ef7-dfe271283e9f"
      unitRef="usd">6919081</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzMtMS0xLTEtMA_ec116b5f-a381-40ce-aba5-0481209f1fcc"
      unitRef="usd">13127257</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzMtMy0xLTEtMA_07230dfa-f450-4ff4-a491-08abec062a88"
      unitRef="usd">8967897</us-gaap:AccruedSalariesCurrent>
    <ino:AccruedSubcontractExpenses
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzQtMS0xLTEtMA_e2b4cd40-aad7-4247-a103-9b8e1e9a680e"
      unitRef="usd">247796</ino:AccruedSubcontractExpenses>
    <ino:AccruedSubcontractExpenses
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzQtMy0xLTEtMA_902b91c4-0eeb-4a41-a8b9-26c8b6717c12"
      unitRef="usd">273508</ino:AccruedSubcontractExpenses>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzYtMS0xLTEtMA_d6cd0c12-a719-4da1-bb6c-5f530836a3ab"
      unitRef="usd">7003239</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzYtMy0xLTEtMA_c27a06ab-6ed7-40da-934e-d12bb7878a80"
      unitRef="usd">2076772</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzExLTEtMS0xLTA_13152d70-fc63-40ce-b0ce-0a5d90027ce6"
      unitRef="usd">21203808</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODEvZnJhZzpmYzgzYjlkNDk4MzA0YmM0YThkZDg1ZTc4MmNhODU5NS90YWJsZToyMjRjYzM4YjM0MTU0ODAyOTg5ODZkZjQ2NDQ0ODE4YS90YWJsZXJhbmdlOjIyNGNjMzhiMzQxNTQ4MDI5ODk4NmRmNDY0NDQ4MThhXzExLTMtMS0xLTA_88df34d0-0719-475c-8369-e2c70c167c1b"
      unitRef="usd">18237258</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzNTY2_a72eff60-8af9-41c7-be19-8dac394520f9">Stockholders&#x2019; Equity&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Outstanding as of&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par $0.001&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, 14 shares of the Company&#x2019;s Series&#160;C preferred stock were converted into an aggregate of 5,147 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The holder of any share or shares of Series C Preferred Stock has the right at any time, at such holder&#x2019;s option, to convert all or any lesser portion of such holder&#x2019;s shares of the Preferred Stock into fully paid and non-assessable shares of Common Stock. As of December 31, 2020, the Conversion Value w&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;as $27.20 per share, such&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; that the outstanding shares of Series C Preferred Stock were convertible into an aggregate of 3,309 shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, the Company entered into the Sales Agreement with an outside placement agent (the &#x201c;Placement Agent&#x201d;) to sell shares of its common stock w&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ith aggregate gross proceeds of up to $100.0 million, from time to time, through an &#x201c;at-the-market&#x201d; equity offering program under which the Placement Agent will act as sales agent. During the first quarter of 2020, the Company and the Placement Agent entered into a first and second amendment to the Sales Agreement (the "Prior Sales Agreement") to increase the amount of common stock that may be sold under the Sales Agreement from $100.0&#160;million to $250.0&#160;million. As of March 31, 2020, there was no remaining capacity under the Prior Sales Agreement. On April 3, 2020, the Company and the Placement Agent entered into a new Sales Agreement (the "New Sales Agreement") to sell shares of its common stock&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 3, 2020 and May 12, 2020, the Company filed prospectus supplements pursuant to the New Sales Agreement for the offer and sale of its Common Stock for aggregate gross proceeds of up to an aggregate of $250.0&#160;million. Under the New Sales Agreement, the Company will set the parameters for the sale of shares, inclu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ding the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The New Sales Agreement provides that the Placement Agent will be entitled to compensation for its services in an amount equal to up to 3.0% of the gross proceeds from the sales of shares sold through the Placement Agent under the New Sales Agreement. The Company has no obligation to sell any shares under the New Sales Agreement, and could at any time suspend solicitation and offers under the New Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2020, the Company sold 43,148,952 shares of its common stock under the Prior Sales Agreement. The sales were made at a weighted average price of $4.92 per share, resulting in aggregate net proceeds of $208.2&#160;million. As of March 31, 2020, there was no remaining capacity under the Prior Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, the Company sold a total of 22,915,934 shares of common stock under the New&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Sales Agreement. The sales were made at a weighted average price of $10.91 per share resulting in aggregate net proceeds of $246.2 million. As of December&#160;31, 2020, t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;here was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;no&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; remaining capacity under the New Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options and Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. The maximum number of shares of the Company&#x2019;s common stock available for issuance over the term of the 2016 Incentive Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;may not exceed 18,000,000 shares, provided that commencing with the first business day of each calendar year beginning January&#160;1, 2020, such maximum number of shares shall be increased by&#160;2,000,000 shares of common stock unless the Board determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2021, the maximum number of shares to be issued increased by 2,000,000. At December&#160;31, 2020, there were&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 18,000,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares of common stock reserved for issuance upon exercise of incentive awards granted and to be granted at future dates under the 2016 Incentive Plan. At December&#160;31, 2020, the Company had 6,739,577 shares of common stock available for future grant under the 2016 Incentive Plan, 2,558,052 shares underlying outstanding but unvested restricted stock units and options outstanding to purchase 5,742,109 shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At December&#160;31, 2020, the Company had options outstanding to purchase 3,164,515 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December&#160;31, 2020, 2019 and 2018 was $14.5 million, $9.8 million and $10.2 million, respectively, of which $8.0 million, $5.9 million and $5.9 million was included in research and development expenses and $6.5 million, $3.9 million and $4.3 million was included in general and administrative expenses, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020 and 2019, there was $4.4 million and $3.4 million, respectively, of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.4 years and 1.7 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2020 and 2019, there was $10.9 million and $4.3 million, respectively, of total unrecognized compensation expense related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 1.9 years and 1.6 years, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and restricted stock units granted to non-employees for the years ended December&#160;31, 2020, 2019 and 2018 was $1.2 million, $970,000 and $302,000, respectively. As of December&#160;31, 2020, options to purchase 845,375 shares of common stock granted to non-employees remained outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total stock options outstanding at December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted    Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.48-$3.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.01-$6.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,261,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.01-$9.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,879,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,864,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9.01-$12.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$12.01-$15.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.01-$25.62&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,906,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,079,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the aggregate intrinsic value of options outstanding was $24.2 million, the aggregate intrinsic value of options exercisable was $16.8 million, and the weighted average remaining contractual term of options exercisable was 5.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2020, the aggregate intrinsic value of unvested restricted stock units was $22.6 million and the aggregate intrinsic value of restricted stock units which vested during the year ended December 31, 2020 was $13.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2020, options to purchase 8,906,624 shares of common stock and 2,558,052 restricted stock units were expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2020 was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,265,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,178,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(306,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,906,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2020 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,586,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,040,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average exercise price per share was $4.44 for the 78,750 options which expired during the year ended December&#160;31, 2020, $6.27 for the 324,502 options which expired during the year ended December&#160;31, 2019 and $5.17 for the 119,091 options which expired during the year ended December&#160;31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share was $6.87, $2.19 and $2.86 for options granted during the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value was $9.12, $3.09 and $4.31 per share for restricted stock units granted during the years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received $12.3 million, $113,000 and $1.5 million in proceeds from the exercise of stock options during the years ended December&#160;31, 2020, 2019 and 2018, respectively. The aggregate intrinsic value of options exercised was $14.2 million, $25,000 and $910,000 during the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 28, 2020, the Company granted 663,353 performance-based RSUs to key employees under the 2016 Incentive Plan. The RSUs will vest in two tranches as follows: 50% of the shares in each tranche will vest upon achievement of the predetermined performance milestones and the remaining 50% of the shares in each tranche will vest upon subsequent completion of a one-year service period. The grant date fair value of the performance-based RSUs was $8.0&#160;million based on the grant date closing price per share of $12.06. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, the underlying performance milestones of the RSUs were not probable of achievement, and no stock-based compensation expense was recognized for the performance-based RSUs for the year then ended.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzNTc5_4165421f-0750-4007-bf03-d29974c93a0c">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Outstanding as of&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par $0.001&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i43ff85947d654cd3b9d8600362c08d4e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTphMWE1NjkyZjliMDc0YzQ3YTExM2M0ZjJkNTdhMTQwNy90YWJsZXJhbmdlOmExYTU2OTJmOWIwNzRjNDdhMTEzYzRmMmQ1N2ExNDA3XzQtMC0xLTEtNjY4MC90ZXh0cmVnaW9uOmM2ZGQ5NDMzYTAzMzQ3MjFhMTk3YTE1MjhmMTlmYzVhXzY1OTcwNjk3NjY3MDI_63e5982f-e633-430e-a1da-8a4773339730"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i43ff85947d654cd3b9d8600362c08d4e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTphMWE1NjkyZjliMDc0YzQ3YTExM2M0ZjJkNTdhMTQwNy90YWJsZXJhbmdlOmExYTU2OTJmOWIwNzRjNDdhMTEzYzRmMmQ1N2ExNDA3XzQtMS0xLTEtMA_eda4772a-0b59-490e-8637-57a81601f4e6"
      unitRef="shares">1091</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i43ff85947d654cd3b9d8600362c08d4e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTphMWE1NjkyZjliMDc0YzQ3YTExM2M0ZjJkNTdhMTQwNy90YWJsZXJhbmdlOmExYTU2OTJmOWIwNzRjNDdhMTEzYzRmMmQ1N2ExNDA3XzQtMy0xLTEtMA_47ae25b1-404b-43e2-8c61-7a20d0ddba21"
      unitRef="shares">1091</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i43ff85947d654cd3b9d8600362c08d4e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTphMWE1NjkyZjliMDc0YzQ3YTExM2M0ZjJkNTdhMTQwNy90YWJsZXJhbmdlOmExYTU2OTJmOWIwNzRjNDdhMTEzYzRmMmQ1N2ExNDA3XzQtNS0xLTEtMA_873cbfaf-f8d5-4b72-82e2-b5ce23041002"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8d422727fda34bcea389c96828efbd6f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTphMWE1NjkyZjliMDc0YzQ3YTExM2M0ZjJkNTdhMTQwNy90YWJsZXJhbmdlOmExYTU2OTJmOWIwNzRjNDdhMTEzYzRmMmQ1N2ExNDA3XzQtNy0xLTEtMA_317b02f8-f9a3-44b7-8aa8-129021b29ea3"
      unitRef="shares">23</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="idf338a94fd4b4eceba8d37e44eab78f0_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1MjQ4ODU_74a362e6-ebf1-476b-8daa-fb62a10b8433"
      unitRef="shares">14</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="i9ea987ce83ae454ba3d280374d688b3a_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1MjQ4ODk_a264c4e4-6110-4268-a51d-36a687823ee6"
      unitRef="shares">5147</us-gaap:ConversionOfStockSharesIssued1>
    <ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzMyOTg1MzQ5MDk2Mzg_dbf28b6f-fb99-4b55-a76a-7a7d123bf61b"
      unitRef="usdPerShare">27.20</ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i43ff85947d654cd3b9d8600362c08d4e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzMyOTg1MzQ5MDk2NDY_54da81c4-757c-4f5b-8810-8e7ddc465e86"
      unitRef="shares">3309</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="i8846f56dce3d432d966649b28efa7c9a_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzUxNjg_abc4c7ae-048f-4cd4-9058-f0bc8e1478bb"
      unitRef="usd">100000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="i8846f56dce3d432d966649b28efa7c9a_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1MjU4NzE_15046048-4ecf-4bd3-a61b-e4325f1b0901"
      unitRef="usd">100000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="ia01d038a4d224f74b7cec88d7ab01932_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1MjU4ODc_58487ff6-eeb8-4b66-90e5-c6df83e20631"
      unitRef="usd">250000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementRemainingAuthorizedAmount
      contextRef="i02e208f208514fac82fa7b99a461039a_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzgyNDYzMzcyMzQwMjc_dbec97cd-f8f1-4899-9481-5ef5265c8d9c"
      unitRef="usd">0</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="i5ae124c42b254d14b9b5f269fd7419ce_D20200403-20200512"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzgyNDYzMzcyMzQwNDU_68f79fda-87e5-4168-8b83-130083c15d45"
      unitRef="usd">250000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementAgentFee
      contextRef="i2b37597d28484e31879b4ec99d19767b_D20180501-20180531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzU3NTY_cb5cd605-48ab-4d3f-a14d-7feaff618e98"
      unitRef="number">0.030</ino:StockSalesAgreementAgentFee>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="i64aec48d41f548978f711e0981b117a9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1Mjc3MjQ_eb73d5da-f67a-4c83-b5b6-553aba7a87da"
      unitRef="shares">43148952</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i02e208f208514fac82fa7b99a461039a_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1Mjc3MzY_48373b92-c75c-4d30-8052-2e84b3efa88d"
      unitRef="usdPerShare">4.92</us-gaap:SaleOfStockPricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock
      contextRef="i64aec48d41f548978f711e0981b117a9_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1Mjc3NDM_435d3e94-ff38-4b63-ab63-0cc463aafdb2"
      unitRef="usd">208200000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSalesAgreementRemainingAuthorizedAmount
      contextRef="i0a9f7074a224430daf98266033b9e313_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1Mjc3NTg_c4522acb-1bf7-4170-b9ba-395420b0e047"
      unitRef="usd">0</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="i00014904fa624256a7ae429094225ce3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzYwNzU_b167682e-803e-45a8-812b-7c36ae9a8759"
      unitRef="shares">22915934</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ie326789176224a66adc6eb18840f7e83_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzYxNzk_0f4afd2b-b915-4f74-8761-9539df98c6a5"
      unitRef="usdPerShare">10.91</us-gaap:SaleOfStockPricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock
      contextRef="i00014904fa624256a7ae429094225ce3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzYyMzE_1da7661c-58af-4093-b49a-e3c93dcc425e"
      unitRef="usd">246200000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSalesAgreementRemainingAuthorizedAmount
      contextRef="ie326789176224a66adc6eb18840f7e83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzY1OTcwNjk3OTI0OTQ_2bcb97c1-0b16-4746-ba2d-f51c5cf5d6be"
      unitRef="usd">0</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i868ece5d5ec040e5bc282761eb8ff2b3_I20160513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0Xzg4MDU_1430953d-48b1-4a4a-8e76-ad6e2fa3e726"
      unitRef="shares">18000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan
      contextRef="i868ece5d5ec040e5bc282761eb8ff2b3_I20160513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0Xzg5NzA_6fe8e3c1-3b45-4e16-9c16-653ea160edfc"
      unitRef="shares">2000000</ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan>
    <ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized
      contextRef="i1d250281b0084a9c9e85c87f5e174e6c_I20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzkyNzE_2538bd3d-3cbe-4361-b469-b336ac278c02"
      unitRef="shares">2000000</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="if5aa6e62b90746e2a0e7a79dcda10743_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzkyOTM_65a42dee-bf44-4358-9d0f-3ae25917612f"
      unitRef="shares">18000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="if5aa6e62b90746e2a0e7a79dcda10743_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0Xzk0NzE_e2e8d124-37e2-4588-b4d0-771e265052dd"
      unitRef="shares">6739577</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <ino:NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan
      contextRef="i336b7f2097e04fa9946695e9082976b1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0Xzk1NTU_965eb398-1de1-4cf0-8ee5-5fac02dfae29"
      unitRef="shares">2558052</ino:NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="if5aa6e62b90746e2a0e7a79dcda10743_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0Xzk2NjA_d5ac3f88-b5d3-4e7d-9571-3b73c4be67b7"
      unitRef="shares">5742109</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i336b7f2097e04fa9946695e9082976b1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzgyNDYzMzcyMzQwNzM_38d1ac9b-fc16-4f41-ae20-6d3805e1d68d">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm
      contextRef="i336b7f2097e04fa9946695e9082976b1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzgyNDYzMzcyMzQwOTU_b466a6d0-446c-46d6-b79b-b747a7ca407f">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="i7ddcf49caf034014b934f70e033c7381_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwMTU0_e4eca104-a871-4bc4-83e2-11c9ad7a216d"
      unitRef="shares">3164515</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia9a611d11b194c04a97196e8637d3ea5_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzgyNDYzMzcyMzQxMTc_8ab3b3f4-6f4d-44e6-98f1-35778a5c363c">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm
      contextRef="ia9a611d11b194c04a97196e8637d3ea5_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzgyNDYzMzcyMzQxMzk_de28ef2b-2076-4868-b30a-c7407cda9910">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:ShareBasedCompensation
      contextRef="i3d376d80def94aaeaa2d3d07b689dd72_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNTA3_ade6d6bb-3398-4610-9644-b15deea51c01"
      unitRef="usd">14500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7b2e5387ae774d5b966fe4cfedf17ca3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNTEx_2ed605ab-1d7f-4dff-b307-942847b05595"
      unitRef="usd">9800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib3f04bc964bc4062b85a1da80bfd3649_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNTE4_7bb3cc28-0495-40cf-bf41-cc30d87ff125"
      unitRef="usd">10200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i495966b5ff4e4727a8837c97fa4bd60a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNTQ1_69dc416c-6d4b-4393-93f1-f748418efc36"
      unitRef="usd">8000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i60c500e2193a495a8e8d53e8bda2c96e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNTQ5_fc0e57f6-5bdf-4894-a10f-ea1cbb4470b1"
      unitRef="usd">5900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i5686e8d556c34f1287b6ab813a0dfe50_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNTU2_743db82a-2c29-4a4b-9776-5142fc380d5d"
      unitRef="usd">5900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifcfb3bb7cf6d4f7f907cc373a9f10860_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNjIx_0e3ff4ac-8d73-4444-b44b-77a72d15ad2f"
      unitRef="usd">6500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4f0bd5564d5d480c930234de144bd099_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNjI1_0aba075b-ff82-4732-b4e1-a9fe4888e4df"
      unitRef="usd">3900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9bd082535e33430d840b84b42712a05a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNjMy_bd451fd6-ffa6-42d5-ae3f-32ff59e46acf"
      unitRef="usd">4300000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNzM5_5ab2314f-a2c1-4c56-bac4-42da23822ea5"
      unitRef="usd">4400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwNzQ2_0a816f31-77e6-4ea8-9bea-8a9c0a7c32a5"
      unitRef="usd">3400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwOTE3_b981cde1-747c-4964-b6fd-253647bfb073">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1MzY3MTA_7db0f2ea-7e67-4e80-9558-fa2d97a3930e">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ic358738bd92c4585907376620670c7fb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwOTY0_09cf1422-bf56-46f5-b1c8-362e03a914ab"
      unitRef="usd">10900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia6335ae27741400684bafee789c7d140_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEwOTc5_4402f5ed-fc9a-41aa-8e02-f6e775a03ba1"
      unitRef="usd">4300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iadcbc296b043424a97f9d0cbf4b4f313_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzExMTUz_39de6724-957d-443b-8976-72c60ca99385">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8447cd2594e94149a11ee2086d36b99a_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzExMTY2_feca6cc2-425d-4089-b2af-cf5fcb8585c0">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9d936012135e4af182293a6bbca9297d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzExNjI0_3f194134-d95b-4cbe-8682-d9c8c2372f00"
      unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia2a529a3bc394bac9063df42512b5b9c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzExNjI4_59e33c21-3f7b-4073-91ed-7a0d349b68f9"
      unitRef="usd">970000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0f5ffa0e16ec4dcca0f2275c5832f658_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzExNjM1_2aa4f4f5-aae3-4ecc-b9b7-3e20af5e4259"
      unitRef="usd">302000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6a196d09ea024f9f8f82d3947718333d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzExNjk2_2f26eaec-7d4a-496d-8aca-10009a3e2649"
      unitRef="shares">845375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzNTY4_f337bad5-9c3d-4c11-b726-08bf6e58fd39">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total stock options outstanding at December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted    Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.48-$3.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.01-$6.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,261,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.01-$9.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,879,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,864,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9.01-$12.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$12.01-$15.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.01-$25.62&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,906,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,079,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ieac0bc60961d47e7ab6e7a227877260b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzItMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTgzM2FmZjQxMTRiYjFiNTFiZmEzYjg5OTJjNzkzXzY1OTcwNjk3NjY2NzY_3831e5c4-85de-49ff-87b9-41ed04250fec"
      unitRef="usdPerShare">1.48</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ieac0bc60961d47e7ab6e7a227877260b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzItMC0xLTEtMC90ZXh0cmVnaW9uOmFlMTgzM2FmZjQxMTRiYjFiNTFiZmEzYjg5OTJjNzkzXzY1OTcwNjk3NjY2ODQ_4c185fbb-82cc-463f-855b-6af0ca31422b"
      unitRef="usdPerShare">3.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i6a4f019880eb4d7e9f92a9fef1fc03ba_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzItMi0xLTEtMA_4075d85a-4fcc-4f95-b2e1-8af20d324b73"
      unitRef="shares">452749</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ieac0bc60961d47e7ab6e7a227877260b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzItNC0xLTEtMA_c5dd7bb1-be68-4aa8-be07-ad5f5037a182">P2Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i6a4f019880eb4d7e9f92a9fef1fc03ba_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzItNi0xLTEtMA_bdbae6a2-5c0a-48e0-9c3c-faa69fcb4c32"
      unitRef="usdPerShare">2.24</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i6a4f019880eb4d7e9f92a9fef1fc03ba_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzItOC0xLTEtMA_0efdc8f2-2959-40ef-8774-f6a93fc21684"
      unitRef="shares">428231</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i6a4f019880eb4d7e9f92a9fef1fc03ba_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzItMTAtMS0xLTA_d16131f7-01ae-4d20-8e58-095284c17428"
      unitRef="usdPerShare">2.23</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ieb1a3d043e3142e993801b0549b85c79_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjQyMTlmYTQ4MmZkNTRmMDBiODNlYmU0MDJjYmQ3NjI1XzY1OTcwNjk3NjY2NzY_c521cac6-4273-4c96-9b3c-be255cc67581"
      unitRef="usdPerShare">3.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ieb1a3d043e3142e993801b0549b85c79_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjQyMTlmYTQ4MmZkNTRmMDBiODNlYmU0MDJjYmQ3NjI1XzY1OTcwNjk3NjY2ODQ_dd08c88f-c6c7-4f14-b9cd-e32cf89fe0e1"
      unitRef="usdPerShare">6.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i424ca8a2ddb04b9d9993270673bfb2b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzMtMi0xLTEtMA_ccc8efd4-b4f0-4d09-a32c-66b18e2777a2"
      unitRef="shares">3261410</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ieb1a3d043e3142e993801b0549b85c79_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzMtNC0xLTEtMA_1f6f575c-2632-4589-8236-bc3f3d241e04">P7Y4M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i424ca8a2ddb04b9d9993270673bfb2b7_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzMtNi0xLTEtMA_5827b11a-ea06-428d-817d-dab6cf97331d"
      unitRef="usdPerShare">3.85</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i424ca8a2ddb04b9d9993270673bfb2b7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzMtOC0xLTEtMA_8b989b18-2eec-4708-b4a4-882e9e903d03"
      unitRef="shares">1975426</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i424ca8a2ddb04b9d9993270673bfb2b7_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzMtMTAtMS0xLTA_ccca4ff0-7074-4555-889b-5aa44133a156"
      unitRef="usdPerShare">3.98</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i0529e897544648afb4f8c8facb9c526d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjJjNDhiMGRiYmE4YzQ5M2FiZmYzYzMyMmMyNjRiMjc3XzY1OTcwNjk3NjY2NzY_ea86f776-f6ec-4e0b-b46a-34a2d7b3ce3d"
      unitRef="usdPerShare">6.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i0529e897544648afb4f8c8facb9c526d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzQtMC0xLTEtMC90ZXh0cmVnaW9uOjJjNDhiMGRiYmE4YzQ5M2FiZmYzYzMyMmMyNjRiMjc3XzY1OTcwNjk3NjY2ODQ_fb5619b7-c8d5-49da-9703-45f871f5bbb2"
      unitRef="usdPerShare">9.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i7b636fe087494ecaa5b251e1c14a1e4b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzQtMi0xLTEtMA_fbc5c823-6021-4153-bcad-fda943e59987"
      unitRef="shares">3879209</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i0529e897544648afb4f8c8facb9c526d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzQtNC0xLTEtMA_ae951b20-6eba-4d6e-be1c-2e35ce0efcb8">P6Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i7b636fe087494ecaa5b251e1c14a1e4b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzQtNi0xLTEtMA_bad7be69-5c54-4b89-b209-312f80eb5ed8"
      unitRef="usdPerShare">7.59</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i7b636fe087494ecaa5b251e1c14a1e4b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzQtOC0xLTEtMA_ebd47740-a488-40ad-9aca-19fafab86801"
      unitRef="shares">2864794</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i7b636fe087494ecaa5b251e1c14a1e4b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzQtMTAtMS0xLTA_be19331c-d28d-4e4f-b79a-7bc366e12eb2"
      unitRef="usdPerShare">7.33</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i0898c082ec1c41a5a28d7feae8fd298d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjgxMmY2YWEwMWZhZDQzYjZhOTA3ODI3ZmY4YWIyMDY3XzY1OTcwNjk3NjY2Nzc_8cc7e58d-036c-4be0-9980-fd75859b4aa3"
      unitRef="usdPerShare">9.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i0898c082ec1c41a5a28d7feae8fd298d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzUtMC0xLTEtMC90ZXh0cmVnaW9uOjgxMmY2YWEwMWZhZDQzYjZhOTA3ODI3ZmY4YWIyMDY3XzY1OTcwNjk3NjY2ODY_f8c658e0-5cf0-4c81-a8dd-b86650243282"
      unitRef="usdPerShare">12.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ib8ba04b2fc50444a883de5f9c28c9da1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzUtMi0xLTEtMA_0f256dd2-eb09-4ca8-a737-70301d1d71c3"
      unitRef="shares">365223</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i0898c082ec1c41a5a28d7feae8fd298d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzUtNC0xLTEtMA_61856f66-9f85-4492-8bb5-d138b217f8ed">P7Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ib8ba04b2fc50444a883de5f9c28c9da1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzUtNi0xLTEtMA_d77d8820-883a-4bbc-8d95-315e37a68c6e"
      unitRef="usdPerShare">10.42</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ib8ba04b2fc50444a883de5f9c28c9da1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzUtOC0xLTEtMA_f7726354-489c-44d7-853e-e73fd3ea5850"
      unitRef="shares">233282</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ib8ba04b2fc50444a883de5f9c28c9da1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzUtMTAtMS0xLTA_e15d9151-38c6-451d-be57-f6e4b512faad"
      unitRef="usdPerShare">10.08</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i2a8b1922df074f8d881dc9835917dfc0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtMC0xLTEtMzMyMy90ZXh0cmVnaW9uOjVhZWE5NTQxNDc2ZTQ5ZDc4OGVkZjM4ZjAzZTkwMmM2XzY1OTcwNjk3NjY2Nzk_ab8f949b-93d5-4cee-a4c5-20338de00c9f"
      unitRef="usdPerShare">12.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i2a8b1922df074f8d881dc9835917dfc0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtMC0xLTEtMzMyMy90ZXh0cmVnaW9uOjVhZWE5NTQxNDc2ZTQ5ZDc4OGVkZjM4ZjAzZTkwMmM2XzY1OTcwNjk3NjY2ODg_9a982226-42ab-4d76-978a-0f211fcd795b"
      unitRef="usdPerShare">15.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i1329f8962cf44001a77927afa8dd9600_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtMi0xLTEtMzMyMw_f1ccf6d2-936d-435e-9236-227e1a81ec2b"
      unitRef="shares">833282</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i2a8b1922df074f8d881dc9835917dfc0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtNC0xLTEtMzMyMw_a2cbc8eb-1565-47d3-bdf4-420e8a178fe3">P5Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i1329f8962cf44001a77927afa8dd9600_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtNi0xLTEtMzMyMw_ff4f172f-f0c2-479e-a110-d6e1efa9c07e"
      unitRef="usdPerShare">13.46</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i1329f8962cf44001a77927afa8dd9600_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtOC0xLTEtMzMyMw_c7606a95-1730-4135-9ac8-f5ef4f5b4e69"
      unitRef="shares">546723</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i1329f8962cf44001a77927afa8dd9600_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtMTAtMS0xLTMzMjM_b5508c3e-b400-4852-a723-e8311aaab7c6"
      unitRef="usdPerShare">13.14</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i5d1018668fb54f4a8f27dc2bbbebbc43_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjY5NGU4ZTBjZjIyZjRkMDhhMjU0YjgwNjAyZWFkYjE2XzY1OTcwNjk3NjY2Nzk_1c01d9bb-0c3a-42b2-ab20-553882102110"
      unitRef="usdPerShare">15.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i5d1018668fb54f4a8f27dc2bbbebbc43_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtMC0xLTEtMC90ZXh0cmVnaW9uOjY5NGU4ZTBjZjIyZjRkMDhhMjU0YjgwNjAyZWFkYjE2XzY1OTcwNjk3NjY2ODg_fc248ff5-dcd6-4f7a-8d7a-59aff5ace278"
      unitRef="usdPerShare">25.62</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i5c519ce051934157ac2a92180ffe1298_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtMi0xLTEtMA_fc18c035-f81d-49b0-8fd2-65296d5dd489"
      unitRef="shares">114751</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i5d1018668fb54f4a8f27dc2bbbebbc43_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtNC0xLTEtMA_925818de-c82e-40a0-97ee-3b42b912a5d2">P9Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i5c519ce051934157ac2a92180ffe1298_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtNi0xLTEtMA_e467628e-439a-43e9-9e7e-59060db38ce9"
      unitRef="usdPerShare">20.57</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i5c519ce051934157ac2a92180ffe1298_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtOC0xLTEtMA_4fea72ea-91ae-41f5-978a-b4c448cf4ad4"
      unitRef="shares">31041</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i5c519ce051934157ac2a92180ffe1298_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzYtMTAtMS0xLTA_6e2f89bd-c66b-42fa-89ab-2c1684b05664"
      unitRef="usdPerShare">20.59</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzctMi0xLTEtMA_b8fcc9b7-d89f-4424-a724-45385c6ececf"
      unitRef="shares">8906624</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzctNC0xLTEtMA_f74a77d2-8af0-4c35-ad9a-1660fdd93692">P6Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzctNi0xLTEtMA_ed173937-b42a-46c1-874b-8ad7dda67fbd"
      unitRef="usdPerShare">6.78</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzctOC0xLTEtMA_4d1f17e9-dd04-43b2-bf7e-fae62acda4cf"
      unitRef="shares">6079497</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTo5ZjJiOWNkZjBjMzg0YmRhYWZlMjAwMzMwOWI4ZjdlNy90YWJsZXJhbmdlOjlmMmI5Y2RmMGMzODRiZGFhZmUyMDAzMzA5YjhmN2U3XzctMTAtMS0xLTA_82dd2c12-96ea-4c8c-bb98-26cec2634e3a"
      unitRef="usdPerShare">6.58</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzExOTM1_dc5aa4a6-dcfa-478a-81dc-5a2c8c194250"
      unitRef="usd">24200000</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzExOTk2_41baa088-56a0-4232-a6ff-ac35d0d7ae4c"
      unitRef="usd">16800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyMDc5_8e349701-309e-4176-9fa4-02ecf47b0569">P5Y8M12D</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="ic358738bd92c4585907376620670c7fb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyMTc4_d0c52796-894e-4b37-a540-d3d2f6d27bf9"
      unitRef="usd">22600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="iadcbc296b043424a97f9d0cbf4b4f313_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyMjk2_750f05a8-b87c-4976-8e0a-723c9de2f780"
      unitRef="usd">13500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyMzQ4_8bc53dd2-45a7-4488-a280-0216f3beada8"
      unitRef="shares">8906624</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber>
    <ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber
      contextRef="ic358738bd92c4585907376620670c7fb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyMzc4_3f91c480-2f8b-4db9-bef0-d0d0896a552e"
      unitRef="shares">2558052</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzNTcy_9d6c6e60-8fe2-467d-996e-3e4c2e56388c">&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2020 was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,265,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,178,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(306,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,906,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzktMS0xLTEtMA_9ad2e208-ed15-43db-8e86-f1e7d913eb7c"
      unitRef="shares">9265390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzktMy0xLTEtMA_a436f1c0-7d0b-4ca5-9938-f8ff5fe25e5d"
      unitRef="usdPerShare">5.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzEwLTEtMS0xLTA_123d7705-0b12-474d-95ef-656038221a5b"
      unitRef="shares">2126182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzEwLTMtMS0xLTA_bb44b571-d6a0-432e-9bcb-6d309fdd2a25"
      unitRef="usdPerShare">10.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzExLTEtMS0xLTA_a4e77d2e-d537-4392-a309-d37f78f74b7a"
      unitRef="shares">2178252</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzExLTMtMS0xLTA_83238fd5-09e8-4c0d-a4f0-b2bbcbf53253"
      unitRef="usdPerShare">5.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzEyLTEtMS0xLTA_7762738a-be6f-4ab2-a2e7-1984552508bb"
      unitRef="shares">306696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzEyLTMtMS0xLTA_315509ae-0170-495c-9e96-a30ede9b6db8"
      unitRef="usdPerShare">6.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzEzLTEtMS0xLTA_4d83999c-7198-4be2-b313-28c515be2f9c"
      unitRef="shares">8906624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZTpmNWM0ZGIyMmM0Mjg0Yjg0OWQxYzBlNTlmZGE4MWU3MS90YWJsZXJhbmdlOmY1YzRkYjIyYzQyODRiODQ5ZDFjMGU1OWZkYTgxZTcxXzEzLTMtMS0xLTA_368c0dda-47e8-4709-8d39-026a4274a3c9"
      unitRef="usdPerShare">6.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzNTUx_5e17779c-4b4d-4d9d-a0a3-59e86770b1a0">&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2020 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,586,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,040,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia6335ae27741400684bafee789c7d140_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZToyMzQ3ODI2YzU2NTM0ZGY1Yjc4MDFmNDQwNWYzYTdjMy90YWJsZXJhbmdlOjIzNDc4MjZjNTY1MzRkZjViNzgwMWY0NDA1ZjNhN2MzXzktMS0xLTEtMA_fccfb449-7779-47e0-95dd-365eedc38151"
      unitRef="shares">2069936</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iadcbc296b043424a97f9d0cbf4b4f313_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZToyMzQ3ODI2YzU2NTM0ZGY1Yjc4MDFmNDQwNWYzYTdjMy90YWJsZXJhbmdlOjIzNDc4MjZjNTY1MzRkZjViNzgwMWY0NDA1ZjNhN2MzXzEwLTEtMS0xLTA_bb4b99b5-2d68-4b19-95d0-09e4027a4115"
      unitRef="shares">1586280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="iadcbc296b043424a97f9d0cbf4b4f313_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZToyMzQ3ODI2YzU2NTM0ZGY1Yjc4MDFmNDQwNWYzYTdjMy90YWJsZXJhbmdlOjIzNDc4MjZjNTY1MzRkZjViNzgwMWY0NDA1ZjNhN2MzXzExLTEtMS0xLTA_9d3568d6-befe-4df9-b5a9-badc1da46e2e"
      unitRef="shares">1040628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="iadcbc296b043424a97f9d0cbf4b4f313_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZToyMzQ3ODI2YzU2NTM0ZGY1Yjc4MDFmNDQwNWYzYTdjMy90YWJsZXJhbmdlOjIzNDc4MjZjNTY1MzRkZjViNzgwMWY0NDA1ZjNhN2MzXzEyLTEtMS0xLTA_6a6a78d7-3889-429c-9112-1e3cb3513610"
      unitRef="shares">57536</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic358738bd92c4585907376620670c7fb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90YWJsZToyMzQ3ODI2YzU2NTM0ZGY1Yjc4MDFmNDQwNWYzYTdjMy90YWJsZXJhbmdlOjIzNDc4MjZjNTY1MzRkZjViNzgwMWY0NDA1ZjNhN2MzXzEzLTEtMS0xLTA_1cdf0c50-af63-41cd-8686-d9cf869453a0"
      unitRef="shares">2558052</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyNzA3_2786140f-bec5-456c-932c-ad74a14e70ed"
      unitRef="usdPerShare">4.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyNzE4_ad3829f0-cdb6-44cb-b85a-1141f5dcc026"
      unitRef="shares">78750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyNzgy_7681159a-e81c-4948-8c0c-54cddcfce58d"
      unitRef="usdPerShare">6.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyNzkz_69e1d241-6762-4c97-b9fa-c10a0020f7e3"
      unitRef="shares">324502</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyODYw_a06238f3-8daa-4c5d-a4c1-ebff485238fa"
      unitRef="usdPerShare">5.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyODcx_6d130a98-535b-4b8f-93bc-001580306a1c"
      unitRef="shares">119091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyOTky_231c439b-ce64-4ec9-a7cd-34a44fe8fd88"
      unitRef="usdPerShare">6.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEyOTk2_08c766cb-81ac-4787-8261-4eb172193f06"
      unitRef="usdPerShare">2.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzMDAz_f246fe1a-1a6c-40a5-aa63-2fdd6342832d"
      unitRef="usdPerShare">2.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iadcbc296b043424a97f9d0cbf4b4f313_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzMTM4_ae67b4b9-9a34-479e-927a-bbee9772c380"
      unitRef="usdPerShare">9.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8447cd2594e94149a11ee2086d36b99a_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzMTQy_2c533b79-926b-4976-8f42-7543fd307814"
      unitRef="usdPerShare">3.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i01d41a23f9d7414e9ca33540626eb820_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzMTQ5_5a10cc2a-d94f-4478-be1e-4fac43f7b804"
      unitRef="usdPerShare">4.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzMjg0_df4a65a1-a7e9-4a79-9428-64e3f75076bc"
      unitRef="usd">12300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzMjg4_c2a9a9d7-7225-40a8-926c-6bc57b8c9dc1"
      unitRef="usd">113000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzMjk1_db7a31db-f4b3-49ee-8c85-cb631db3c64b"
      unitRef="usd">1500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzNDY1_21323c69-49ae-4131-a3f9-b74e05e2fc8c"
      unitRef="usd">14200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzNDY5_67fecd79-4432-4857-9aea-32a0f0c026f2"
      unitRef="usd">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzEzNDc2_1cbb8920-1312-4096-ab67-d196ab0d10f0"
      unitRef="usd">910000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie3b43b488fbc4c9bb91dea3e06d1edd9_D20200828-20200828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1Mjk5ODU_041c747e-26ab-4b3e-ae12-5cbd22b70613"
      unitRef="shares">663353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i091f59652b674cbba9a610be2bac6d93_D20200828-20200828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1Mjk5OTQ_4318e85e-12b1-4151-a9a3-f0868d9847a1"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ice5bec7f1fe94cf09064dbef4b963a15_D20200828-20200828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1Mjk5OTk_cff01c79-b877-4c21-837a-733c3787512b"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ice5bec7f1fe94cf09064dbef4b963a15_D20200828-20200828"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzgyNDYzMzcyMzQwNjE_967cfbe2-5682-4093-8a00-ed2aa4e83c6d">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue
      contextRef="ie3b43b488fbc4c9bb91dea3e06d1edd9_D20200828-20200828"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1MzAwMDU_696465c3-54b8-452a-8e42-5744a135da25"
      unitRef="usd">8000000.0</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie3b43b488fbc4c9bb91dea3e06d1edd9_D20200828-20200828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQvZnJhZzpmMDlmNjk1MWIxNzM0NjRmODgyOWI2ZGE4NTU2YjMxNC90ZXh0cmVnaW9uOmYwOWY2OTUxYjE3MzQ2NGY4ODI5YjZkYTg1NTZiMzE0XzQzOTgwNDY1MzAwMTk_c4646cbc-a7aa-4d0a-96e5-9eac00af6025"
      unitRef="usdPerShare">12.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzMzMTY_893e30d4-c065-42b0-8271-18f75977bcb7">Leases &lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases approximately 82,200 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms of 2.9 years to 9.0 years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;As of December&#160;31, 2020, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,968,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,045,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,023,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,001,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,888,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,988,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,595,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,393,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,329,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,064,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs included in operating expenses in the consolidated statements of operations for the years ended December&#160;31, 2020, 2019 and 2018 were $3.4 million, $3.2 million and $3.4 million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="i1795839f068f4fc6864f4b49d44926c3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzUw_1dcb1360-9ed0-4a9d-95cf-74f3fce7a56b"
      unitRef="sqft">82200</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="id8df0be21b6144949f383e03e347241b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzE0MQ_4a509d57-2998-432e-9779-42be91e9d475"
      unitRef="sqft">57360</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i49fe24c3cf784f4aad4300bb064363bb_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzgyNDYzMzcyMTMxNTQ_64567f40-b412-4da4-a628-1651c988ca42">P2Y10M24D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i71066e05ce5044f48965c132ee5b5187_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzgyNDYzMzcyMTMxMzM_8b861751-757a-4a82-a5d0-547d09c2f787">P9Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzMzMDQ_c5b842cc-6123-49f3-958d-deb3daf434d6">&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;As of December&#160;31, 2020, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,968,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,045,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,023,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,001,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,888,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,988,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,595,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,393,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,329,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,064,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzEtMS0xLTEtMA_23490e5c-28b5-44c5-a8b0-d7a70e2fccea"
      unitRef="usd">3968000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzItMS0xLTEtMA_2245d471-7650-4e16-96d2-a06368470e15"
      unitRef="usd">4045000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzMtMS0xLTEtMA_e15a6fef-170a-4449-907f-b9a06043fa45"
      unitRef="usd">4023000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzQtMS0xLTEtMA_c71d7087-8087-4ce5-b03d-2bddbb6548a3"
      unitRef="usd">3001000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzUtMS0xLTEtMA_b69cb50f-ff40-4a1a-afb6-2c21f0172806"
      unitRef="usd">3063000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzYtMS0xLTEtMA_b225ad62-d4e0-4551-9f29-c2d0eb096566"
      unitRef="usd">9888000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzctMS0xLTEtMA_d2f33029-7457-417d-a75a-c3ac97c1fb33"
      unitRef="usd">27988000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzgtMS0xLTEtMA_fe7c8f30-8cd7-4997-8007-ab45909daf57"
      unitRef="usd">7595000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzktMS0xLTEtMA_93ceeb61-8b29-4cb4-b706-eafc8eec6ad7"
      unitRef="usd">20393000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzEwLTEtMS0xLTA_4abca6b3-affd-4e98-b9a0-b9b56db8cf0b"
      unitRef="usd">2329000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzExLTEtMS0xLTA_39313ca3-9941-4e54-ab18-836ab834ea58"
      unitRef="usd">18064000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzEzLTEtMS0xLTA_f8ec3937-d25f-49f0-a4d7-68486c17f278">P7Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90YWJsZTpjMWFhM2NkYWU4OGY0YzgyODQ2OTFjMTE3YmJjN2M1OS90YWJsZXJhbmdlOmMxYWEzY2RhZTg4ZjRjODI4NDY5MWMxMTdiYmM3YzU5XzE0LTEtMS0xLTA_57e3b5e4-6cc5-4feb-a86d-76e3577e7091"
      unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCost
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzIxMTA_1ef91bdb-07fb-4a03-92a9-46066767fce4"
      unitRef="usd">3400000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzIxMTQ_326f82b4-2feb-427f-bff8-84c9882ad527"
      unitRef="usd">3200000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzIxMjE_aa016570-2103-4382-b2d8-05c5209a0f2c"
      unitRef="usd">3400000</us-gaap:LeaseCost>
    <ino:LesseeNumberOfLeaseAgreementsEnteredInto
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzI0MDM_453733e8-dba5-42ff-8992-aa3ad61170c1"
      unitRef="lease">2</ino:LesseeNumberOfLeaseAgreementsEnteredInto>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTAvZnJhZzoxZjY5Y2E2ZDQyMzU0YjQxYTk5MjMzN2YyYjA0MDMxMS90ZXh0cmVnaW9uOjFmNjljYTZkNDIzNTRiNDFhOTkyMzM3ZjJiMDQwMzExXzI0NTQ_7ab73600-d06e-497b-b6d2-2f38824fbad3"
      unitRef="sqft">13500</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTMvZnJhZzplNDY1OWIyYmNiYzA0ODFiYjFmMzM5YmVmNWU0OTI0MS90ZXh0cmVnaW9uOmU0NjU5YjJiY2JjMDQ4MWJiMWYzMzliZWY1ZTQ5MjQxXzM2Ng_83825b46-05a3-4d19-9ce0-b313bc54c7c2">Investment in Affiliated Entity&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020 and 2019, the Company held 597,808 and 395,758 common shares in PLS, representing a 19.7% and 15.0% ownership interest, respectively. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 27, 2020, the Company sold 1,644,155 shares of common stock in GeneOne for net proceeds of approximately 47.4&#160;billion KRW (approximately USD $40.1&#160;million based on the exchange rate on the date of sale). The Company no longer holds an investment in GeneOne shares and GeneOne is no longer considered a related party to the Company under ASC Topic 850.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Please see further information as discussed in Note 2 and Note 6.&lt;/span&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="id04015c2a4c74d3f9bda78d8a29a1f31_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTMvZnJhZzplNDY1OWIyYmNiYzA0ODFiYjFmMzM5YmVmNWU0OTI0MS90ZXh0cmVnaW9uOmU0NjU5YjJiY2JjMDQ4MWJiMWYzMzliZWY1ZTQ5MjQxXzQ5NDc4MDIzMjU0ODc_8ebcd083-8956-4156-b1d2-46e4c036831a"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i5d75b37d31b1415baa94fe75e2eced26_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTMvZnJhZzplNDY1OWIyYmNiYzA0ODFiYjFmMzM5YmVmNWU0OTI0MS90ZXh0cmVnaW9uOmU0NjU5YjJiY2JjMDQ4MWJiMWYzMzliZWY1ZTQ5MjQxXzE4Mg_a35e4109-5488-48ab-bc26-934168362ac7"
      unitRef="shares">395758</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="if2747486006c46f3999136afeba9ca67_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTMvZnJhZzplNDY1OWIyYmNiYzA0ODFiYjFmMzM5YmVmNWU0OTI0MS90ZXh0cmVnaW9uOmU0NjU5YjJiY2JjMDQ4MWJiMWYzMzliZWY1ZTQ5MjQxXzIxNQ_399ba5b4-4511-4d7c-a531-4e4787b424c2"
      unitRef="number">0.197</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ie5382c3775034bdc84ed280f6032b6c1_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTMvZnJhZzplNDY1OWIyYmNiYzA0ODFiYjFmMzM5YmVmNWU0OTI0MS90ZXh0cmVnaW9uOmU0NjU5YjJiY2JjMDQ4MWJiMWYzMzliZWY1ZTQ5MjQxXzIyMg_f160cf12-5a21-4554-959d-0b1e696a0ad5"
      unitRef="number">0.150</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i2ef5e314188044e59bf80890444a8798_D20200827-20200827"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTMvZnJhZzplNDY1OWIyYmNiYzA0ODFiYjFmMzM5YmVmNWU0OTI0MS90ZXh0cmVnaW9uOmU0NjU5YjJiY2JjMDQ4MWJiMWYzMzliZWY1ZTQ5MjQxXzQ5NDc4MDIzMjYxOTI_bc1718ab-fd7e-48a9-a580-dfb38f75fce6"
      unitRef="shares">1644155</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i2ef5e314188044e59bf80890444a8798_D20200827-20200827"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTMvZnJhZzplNDY1OWIyYmNiYzA0ODFiYjFmMzM5YmVmNWU0OTI0MS90ZXh0cmVnaW9uOmU0NjU5YjJiY2JjMDQ4MWJiMWYzMzliZWY1ZTQ5MjQxXzgyNDYzMzcyMTA0MjY_0c0e7710-699e-41f3-bac5-45a56523d9d2"
      unitRef="krw">47400000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i2ef5e314188044e59bf80890444a8798_D20200827-20200827"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTMvZnJhZzplNDY1OWIyYmNiYzA0ODFiYjFmMzM5YmVmNWU0OTI0MS90ZXh0cmVnaW9uOmU0NjU5YjJiY2JjMDQ4MWJiMWYzMzliZWY1ZTQ5MjQxXzQ5NDc4MDIzMjYyMDQ_f6133456-c2d1-48f3-8b54-911857e66e31"
      unitRef="usd">40100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzQ5NTA_8fdb126d-6404-4bcc-8b21-efa4dcd3bf5f">Income Taxes &lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of pretax loss from operations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162,664,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,809,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,798,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162,890,304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,809,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,798,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the provision for (benefit from) income taxes are presented in the following table: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(257,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax expense (benefit), using a 21% statutory tax rate for December 31, 2020, 2019 and 2018, is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (benefit) taxes at statutory rates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,207,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,370,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,908,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,428,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,457,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,898,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,450,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,650,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,838,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,170,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,953,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,094,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,068,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,268,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deconsolidation of subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,176,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Limited NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(368,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(616,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,176,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(257,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax benefit recorded during the year ended December 31, 2019 of  $257,000 was principally due to a requirement under ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, that a company must consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations. As a result of the requirement under ASC 740-20-45-7, the pretax income which the Company generated from other comprehensive income was a source of income which resulted in the partial realization of the current year loss from continuing operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Adoption of ASU 2019-12&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company early adopted ASU No. 2019-12 as of January 1, 2020.  Among other provisions, ASU 2019-12 eliminated the requirement under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities as of December&#160;31, 2020 and 2019 are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,835,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,788,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,242,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,737,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,506,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,256,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,255,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,852,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,122,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,283,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,722,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,127,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,413,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,484,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,229,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159,705,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137,159,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,779,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,070,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,676,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,894,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,862,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,381,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(487,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(805,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2020, the Company had federal, California and Pennsylvania tax net operating loss (NOL) carryforwards of $566.2 million, $68.6 million and $75.3 million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. The aggregate federal net operating losses generated in 2018 and after for the amount of $270.3 million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year, subject to certain modifications made by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) enacted in 2020. The federal NOL carryforward began to expire in 2021, and the California and Pennsylvania NOL carryforwards will begin and have begun to expire in 2028 and 2020, respectively, unless previously utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, as of December 31, 2020, the Company had federal and state research and development (R&amp;amp;D) tax credit carryforwards of $19.8 million and $3.2 million, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#x2019;s NOL and R&amp;amp;D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section&#160;382/383 analysis regarding the limitation of NOL and R&amp;amp;D credit &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;carryforwards as of December&#160;31, 2020. As a result of the analysis, the Company estimates that approximately $10.2 million of tax benefits related to NOL and R&amp;amp;D carryforwards will expire unused. Accordingly, the related NOL and R&amp;amp;D credit carryforwards have been removed from deferred tax assets, accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes may further limit the ability to use the NOL and R&amp;amp;D carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Tax Cuts and Jobs Act of 2017 subjects a U.S. stockholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&amp;amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.  The Company has elected to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. For 2020, the Company did not generate any GILTI due to losses earned by its foreign subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On March 27, 2020, the CARES Act was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits federal NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows federal NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. Due to the Company's history of net operating losses, the CARES Act is not expected to have a material impact on the Company's financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the Company's unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,204,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,313,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,575,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,319,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases (decreases) related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,210,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,204,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was $10.9 million, $9.9 million and $8.3 million as of December&#160;31, 2020, 2019 and 2018, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve&#160;months of the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2017 and state and local income tax examinations before 2016. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not currently under Internal Revenue Service (&#x201c;IRS&#x201d;), state or local tax examination.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzgyNDYzMzcyMTY1MDc_834e2b7a-7a44-4c52-8ebe-d12e8670d52a">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of pretax loss from operations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162,664,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,809,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,798,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162,890,304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,809,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,798,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYzU0ZDFiNWQ3NWM0YmMwYmFjYjJmMDdhNmI5MDIzZi90YWJsZXJhbmdlOmVjNTRkMWI1ZDc1YzRiYzBiYWNiMmYwN2E2YjkwMjNmXzItMS0xLTEtNjk3Nw_11f670b4-7cb3-41e5-b279-1b2d73823267"
      unitRef="usd">-162664355</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYzU0ZDFiNWQ3NWM0YmMwYmFjYjJmMDdhNmI5MDIzZi90YWJsZXJhbmdlOmVjNTRkMWI1ZDc1YzRiYzBiYWNiMmYwN2E2YjkwMjNmXzItMy0xLTEtNjk3Nw_c21fbbc5-d319-4915-a7ac-873ac87ef0c8"
      unitRef="usd">-120809112</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYzU0ZDFiNWQ3NWM0YmMwYmFjYjJmMDdhNmI5MDIzZi90YWJsZXJhbmdlOmVjNTRkMWI1ZDc1YzRiYzBiYWNiMmYwN2E2YjkwMjNmXzItNS0xLTEtNjk3Nw_a957f7f0-5d5f-4c0e-bb49-bfe4d68aded6"
      unitRef="usd">-94798019</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYzU0ZDFiNWQ3NWM0YmMwYmFjYjJmMDdhNmI5MDIzZi90YWJsZXJhbmdlOmVjNTRkMWI1ZDc1YzRiYzBiYWNiMmYwN2E2YjkwMjNmXzMtMS0xLTEtNjk3Nw_251eadeb-032f-4abb-a14e-21822af29aaa"
      unitRef="usd">-225949</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYzU0ZDFiNWQ3NWM0YmMwYmFjYjJmMDdhNmI5MDIzZi90YWJsZXJhbmdlOmVjNTRkMWI1ZDc1YzRiYzBiYWNiMmYwN2E2YjkwMjNmXzMtMy0xLTEtNjk3Nw_edde4279-2b30-4470-a15f-466b2fc87adf"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYzU0ZDFiNWQ3NWM0YmMwYmFjYjJmMDdhNmI5MDIzZi90YWJsZXJhbmdlOmVjNTRkMWI1ZDc1YzRiYzBiYWNiMmYwN2E2YjkwMjNmXzMtNS0xLTEtNjk3Nw_b6d98754-be98-4b96-87a4-fb883e882844"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYzU0ZDFiNWQ3NWM0YmMwYmFjYjJmMDdhNmI5MDIzZi90YWJsZXJhbmdlOmVjNTRkMWI1ZDc1YzRiYzBiYWNiMmYwN2E2YjkwMjNmXzQtMS0xLTEtODg2Mg_2ad6a92f-d063-492f-9f90-3da2bdbedfa3"
      unitRef="usd">-162890304</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYzU0ZDFiNWQ3NWM0YmMwYmFjYjJmMDdhNmI5MDIzZi90YWJsZXJhbmdlOmVjNTRkMWI1ZDc1YzRiYzBiYWNiMmYwN2E2YjkwMjNmXzQtMy0xLTEtODg2Mg_1e217899-0ad7-457e-8d93-b17271bfc924"
      unitRef="usd">-120809112</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYzU0ZDFiNWQ3NWM0YmMwYmFjYjJmMDdhNmI5MDIzZi90YWJsZXJhbmdlOmVjNTRkMWI1ZDc1YzRiYzBiYWNiMmYwN2E2YjkwMjNmXzQtNS0xLTEtODg2Mg_f7b68442-f9a8-48ae-a3fc-2ec34edcdfbb"
      unitRef="usd">-94798019</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzQ5MjU_bbda0a79-0eb2-404d-8314-cb5680f3b571">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the provision for (benefit from) income taxes are presented in the following table: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(257,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzMtMS0xLTEtMA_598910a7-80e7-4ca2-8b65-dcfd87b799f8"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzMtMy0xLTEtMA_8f6d6ffc-0e03-4729-b258-dfc5e43a0a6d"
      unitRef="usd">4000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzMtNS0xLTEtMA_fe674bb5-6ed7-4ee0-b643-0cc6df7c3ade"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzQtMS0xLTEtMA_70be785d-de07-4b42-88c2-485921b3ca22"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzQtMy0xLTEtMA_95d6fa26-efc6-4a68-85e1-7df9c41b4df0"
      unitRef="usd">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzQtNS0xLTEtMA_7ae729c1-36f5-4277-8fab-81abf3b072dc"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzUtMS0xLTEtMA_2e82bc05-e140-4209-abe5-b9a45d62c8b3"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzUtMy0xLTEtMA_dc6ab88a-b3d3-40b7-a794-2869a9d65963"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzUtNS0xLTEtMA_f7f6c4b0-4ee4-4834-9937-bbcf25d60907"
      unitRef="usd">2170000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzYtMS0xLTEtMA_bc99d4fb-cc2f-437a-b2d0-1dab6215d0cf"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzYtMy0xLTEtMA_a11868d2-cd35-48ea-b56d-62e0b6934bbc"
      unitRef="usd">6000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzYtNS0xLTEtMA_e9af4849-75ed-48b4-b60c-ce682774e992"
      unitRef="usd">2170000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzgtMS0xLTEtMA_4c22de25-7d05-4774-ad18-fceaf397ffcb"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzgtMy0xLTEtMA_53325691-16ec-4606-a5dc-b120e923368e"
      unitRef="usd">-263000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzgtNS0xLTEtMA_5a051495-82a1-4377-bf14-9fc5e62fb87b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzktMS0xLTEtMA_04bbbbf1-c93e-4fa9-b9b4-1fdc381fade6"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzktMy0xLTEtMA_ebeb6785-65e7-43cb-801a-492d6ea72001"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzktNS0xLTEtMA_3069f38e-10f7-474b-a1f0-1e0faaf10045"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzEwLTEtMS0xLTA_fca881d7-a951-4158-9961-13eb884bbc34"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzEwLTMtMS0xLTA_b7b10dff-a2be-439d-8852-7c7988e20c58"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzEwLTUtMS0xLTA_eb9edcb0-30a6-495b-a40b-51d42af4083c"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzExLTEtMS0xLTA_a0b92cd4-84be-409f-9091-764cea0c8e00"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzExLTMtMS0xLTA_0dd66a15-fe62-46ad-ae0c-0bb276af259f"
      unitRef="usd">-263000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzExLTUtMS0xLTA_f3d18f52-2f06-4599-8383-2e1fc67ba1a9"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzEyLTEtMS0xLTA_1f5e1a74-f49f-4607-b45e-90642a13b4c2"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzEyLTMtMS0xLTA_5a99cf25-d0c7-44de-a682-f73c81f53858"
      unitRef="usd">-257000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTpmODkxYTA2YmQ4NTk0NmEwYjc0ODEyZGFjMjk0NjQzZC90YWJsZXJhbmdlOmY4OTFhMDZiZDg1OTQ2YTBiNzQ4MTJkYWMyOTQ2NDNkXzEyLTUtMS0xLTA_615354c9-e7a6-467d-a3f0-0413f8c343f7"
      unitRef="usd">2170000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzQ5MjY_a5a82dbe-3282-4cd9-aa28-6be8588531dd">&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax expense (benefit), using a 21% statutory tax rate for December 31, 2020, 2019 and 2018, is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (benefit) taxes at statutory rates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,207,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,370,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,908,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,428,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,457,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,898,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,450,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,650,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,838,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,170,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,953,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,094,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,068,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,268,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deconsolidation of subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,176,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Limited NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(368,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(616,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,176,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(257,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzItMS0xLTEtMA_97764c9f-d6fb-477d-a827-f52efde89a5e"
      unitRef="usd">-34207000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzItMy0xLTEtMA_c2b53651-cecc-4476-91af-6be7b61f5ad2"
      unitRef="usd">-25370000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzItNS0xLTEtMA_7e9d6c6b-30ee-487b-9150-b8cd9de1b99f"
      unitRef="usd">-19908000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzMtMS0xLTEtMA_000ee685-e169-4b75-9f40-0a80d4163da1"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzMtMy0xLTEtMA_ed82520d-bbe4-4deb-bec9-c0544c5abddb"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzMtNS0xLTEtMA_23661aef-6bab-48c2-839d-0c1d12e81e17"
      unitRef="usd">-4000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <ino:EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzQtMS0xLTEtMA_286e43c8-6283-4d43-b57c-10c717d7e18d"
      unitRef="usd">0</ino:EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount>
    <ino:EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzQtMy0xLTEtMA_35b06efd-5ac0-4104-811c-d166b6618c1c"
      unitRef="usd">0</ino:EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount>
    <ino:EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzQtNS0xLTEtMA_4acbf3d9-d342-4e5b-80a0-c95f17a94799"
      unitRef="usd">2170000</ino:EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzUtMS0xLTEtMA_a8c75a1a-e1f9-4c08-a175-a6896c2fa634"
      unitRef="usd">21428000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzUtMy0xLTEtMA_f30564d2-d731-4e37-b2d3-b7a296aa5e69"
      unitRef="usd">25457000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzUtNS0xLTEtMA_5a73c6b9-0ed9-474a-9240-5ab8832a5f54"
      unitRef="usd">20898000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzYtMS0xLTEtNjk5OQ_f5cf9688-e951-4d29-b019-f4f7b9d8e429"
      unitRef="usd">14450000</ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt>
    <ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzYtMy0xLTEtNjk5OQ_dd3ec3ec-bbf8-4805-8f6f-b10c40c8b4bd"
      unitRef="usd">0</ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt>
    <ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzYtNS0xLTEtNjk5OQ_9d821819-c926-4451-8fe1-848ad4747d6e"
      unitRef="usd">0</ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt>
    <ino:IncomeTaxReconciliationStatuteLimitations
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzYtMS0xLTEtMA_7068465a-d348-49f5-ab12-a9cc7df94fcf"
      unitRef="usd">-2650000</ino:IncomeTaxReconciliationStatuteLimitations>
    <ino:IncomeTaxReconciliationStatuteLimitations
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzYtMy0xLTEtMA_2b4b23b1-bd40-4568-a45d-a30b41632e53"
      unitRef="usd">-3838000</ino:IncomeTaxReconciliationStatuteLimitations>
    <ino:IncomeTaxReconciliationStatuteLimitations
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzYtNS0xLTEtMA_f1c4e5aa-14dc-4722-b341-928f0fe35fff"
      unitRef="usd">-3170000</ino:IncomeTaxReconciliationStatuteLimitations>
    <ino:IncomeTaxReconciliationFairValueWarrant
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzctMS0xLTEtMA_7b08b832-57b7-406b-88b4-2f61956ef70c"
      unitRef="usd">0</ino:IncomeTaxReconciliationFairValueWarrant>
    <ino:IncomeTaxReconciliationFairValueWarrant
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzctMy0xLTEtMA_92a68b0a-da81-4840-8ea3-db7ecf1a3e59"
      unitRef="usd">0</ino:IncomeTaxReconciliationFairValueWarrant>
    <ino:IncomeTaxReconciliationFairValueWarrant
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzctNS0xLTEtMA_7c4b0c01-9351-4196-a1b2-0bfad464c29b"
      unitRef="usd">-76000</ino:IncomeTaxReconciliationFairValueWarrant>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzgtMS0xLTEtMA_af4ca1f8-7ab6-4ba8-9b83-fc62611f5ea1"
      unitRef="usd">-1953000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzgtMy0xLTEtMA_92aaa5b2-257b-4142-a946-7c9e758c3f69"
      unitRef="usd">1114000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzgtNS0xLTEtMA_46700f22-3ed4-4385-870b-8622f8fb1154"
      unitRef="usd">1094000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzktMS0xLTEtMA_c3046505-3938-435c-b229-895e3e4ccd09"
      unitRef="usd">1068000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzktMy0xLTEtMA_279f74da-32a6-4457-a725-b673ffcfea1b"
      unitRef="usd">1537000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzktNS0xLTEtMA_578ace8d-af35-4803-8b79-66a1752765ad"
      unitRef="usd">1268000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzExLTEtMS0xLTcwMDM_964a60df-04d1-4e0e-b341-04c08eaea569"
      unitRef="usd">853000</ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary>
    <ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzExLTMtMS0xLTcwMDM_6ccb6702-d136-4a91-8494-7c82a9be6c46"
      unitRef="usd">0</ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary>
    <ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzExLTUtMS0xLTcwMDM_524162b3-909b-449d-b979-99d74ad93592"
      unitRef="usd">0</ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary>
    <ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzEwLTEtMS0xLTA_dba7dce6-861a-4e7e-91d7-938dee58f495"
      unitRef="usd">468000</ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzEwLTMtMS0xLTA_46dd4824-ac0a-4a53-ac78-a7eef51bf678"
      unitRef="usd">616000</ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzEwLTUtMS0xLTA_3bbb2f89-87db-4147-9ec7-f64c68db5b70"
      unitRef="usd">2176000</ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzExLTEtMS0xLTA_c431da66-b942-47ff-a79a-2e532eda49cb"
      unitRef="usd">-368000</ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzExLTMtMS0xLTA_5dc443ee-24d2-44bf-9577-94dc0a8e47fd"
      unitRef="usd">-616000</ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzExLTUtMS0xLTA_be57edff-1b93-468f-9a69-eeb4bdcde438"
      unitRef="usd">-2176000</ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzEyLTEtMS0xLTA_a68480bd-d705-4a4c-84e2-85db9a37dabb"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzEyLTMtMS0xLTA_eadd4720-3061-499c-bc36-2a1d38c891f3"
      unitRef="usd">12000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzEyLTUtMS0xLTA_11e09431-5382-4394-ba3a-94e4ec6c0b9d"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzE1LTEtMS0xLTcwMDc_5507d9bc-3eb9-4487-a87b-022eae769373"
      unitRef="usd">-9000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzE1LTMtMS0xLTcwMDc_029d2918-c0b2-4589-bb3c-0fb13194c52f"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzE1LTUtMS0xLTcwMDc_329cec0d-f6da-425f-9118-53ba58738a65"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzEzLTEtMS0xLTA_c74c41b1-bf6c-454b-bf75-19f736776b0d"
      unitRef="usd">920000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzEzLTMtMS0xLTA_c17e1c5d-620a-46a3-8202-e162fda5e0a7"
      unitRef="usd">831000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzEzLTUtMS0xLTA_70c56a8b-49fb-4c7e-84bc-70b488a4cd8e"
      unitRef="usd">-102000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <ino:ComprehensiveIncomeLossTaxExpenseBenefit
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzE0LTEtMS0xLTA_ce09bf5b-525e-49c3-9181-ee5cc005edde"
      unitRef="usd">0</ino:ComprehensiveIncomeLossTaxExpenseBenefit>
    <ino:ComprehensiveIncomeLossTaxExpenseBenefit
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzE0LTMtMS0xLTA_6579d517-4219-4177-b7f9-7ec3b744440f"
      unitRef="usd">-257000</ino:ComprehensiveIncomeLossTaxExpenseBenefit>
    <ino:ComprehensiveIncomeLossTaxExpenseBenefit
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTowZmZhOGQ0ZTA2MzI0NzE3YTY1ZDRkM2RjMmIyZDg3OS90YWJsZXJhbmdlOjBmZmE4ZDRlMDYzMjQ3MTdhNjVkNGQzZGMyYjJkODc5XzE0LTUtMS0xLTA_4d098637-09b7-436f-bf6d-7c271b4af746"
      unitRef="usd">2170000</ino:ComprehensiveIncomeLossTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzk1OA_1ca5b0fd-eb6d-46b2-9905-4422a456dd96"
      unitRef="usd">-257000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzQ5MTE_5b8f77e1-4b4f-4869-9d55-2f78e2dcee95">Significant components of the Company&#x2019;s deferred tax assets and liabilities as of December&#160;31, 2020 and 2019 are shown below:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,835,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,788,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,242,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,737,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,506,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,256,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,255,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,852,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,122,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,283,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,722,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,127,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,413,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,484,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,229,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(159,705,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137,159,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,779,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,070,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,676,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,894,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,862,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,381,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(487,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(805,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzMtMS0xLTEtMA_3499bf8b-816d-4992-966e-091406c6633a"
      unitRef="usd">5250000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzMtMy0xLTEtMA_b94dd7f2-73a1-4001-bcf5-d32a8686f822"
      unitRef="usd">6300000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzQtMS0xLTEtMA_1d212dc6-4edd-4944-af34-6d4078f39390"
      unitRef="usd">127835000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzQtMy0xLTEtMA_8ee6dee6-e3ae-41a8-ad32-e39ec63675b4"
      unitRef="usd">110788000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherTaxCarryforwards
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzUtMS0xLTEtMA_2a2d7edc-d5e7-4b3e-b6a9-e8f25d5b4305"
      unitRef="usd">13242000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherTaxCarryforwards
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzUtMy0xLTEtMA_7c329d47-b30f-4995-9094-3cdd4dd1763a"
      unitRef="usd">11737000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzYtMS0xLTEtMA_c730aa91-9207-48fa-91bd-f5763dcd4607"
      unitRef="usd">1628000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzYtMy0xLTEtMA_ad883e60-9336-4b26-aca9-4b0c3f03dd5f"
      unitRef="usd">1506000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzgtMS0xLTEtMA_22947114-d905-454d-88e5-56b1d945781e"
      unitRef="usd">3256000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzgtMy0xLTEtMA_a27d4473-4a38-4c97-a745-6a5d2eb95363"
      unitRef="usd">3255000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ino:DeferredTaxAssetsIntangibleAssets
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzktMS0xLTEtMA_b0355a5a-d1ab-4d42-afdd-7244fc3172ea"
      unitRef="usd">757000</ino:DeferredTaxAssetsIntangibleAssets>
    <ino:DeferredTaxAssetsIntangibleAssets
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzktMy0xLTEtMA_abc4739f-9282-4e7d-90b2-3a516cded5c9"
      unitRef="usd">889000</ino:DeferredTaxAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzEwLTEtMS0xLTA_0b84eae1-0e6c-4e3c-b9fa-4f2f4078375f"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzEwLTMtMS0xLTA_1bd6ccba-39a6-4e88-bf50-323c121567d2"
      unitRef="usd">1852000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <ino:DeferredTaxAssetInterestExpense
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzExLTEtMS0xLTA_9882de1d-14d7-425a-a343-c4ec6ac37c8b"
      unitRef="usd">564000</ino:DeferredTaxAssetInterestExpense>
    <ino:DeferredTaxAssetInterestExpense
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzExLTMtMS0xLTA_04e35656-0fb1-45d7-a3f9-3ca5cc0beb1c"
      unitRef="usd">1122000</ino:DeferredTaxAssetInterestExpense>
    <us-gaap:DeferredTaxAssetsInvestments
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzEyLTEtMS0xLTA_3f4ebcf4-2d01-4a4c-995f-5898cb42f3b1"
      unitRef="usd">542000</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsInvestments
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzEyLTMtMS0xLTA_bc2837b4-a347-461b-87d2-9bc25aa8af57"
      unitRef="usd">645000</us-gaap:DeferredTaxAssetsInvestments>
    <ino:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzEzLTEtMS0xLTA_39877d89-1e9a-4b8a-9698-bee9a7b14c84"
      unitRef="usd">4283000</ino:DeferredTaxAssetsOperatingLeaseLiability>
    <ino:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzEzLTMtMS0xLTA_f31d0f34-e6f7-43b6-9f57-e50f66a1943e"
      unitRef="usd">4722000</ino:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE0LTEtMS0xLTA_c3e6125d-6f22-4afd-92a3-d4619d85b392"
      unitRef="usd">6127000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE0LTMtMS0xLTA_20c52d93-8468-463e-b124-eda59665fe03"
      unitRef="usd">2413000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE1LTEtMS0xLTA_5c49a096-9c54-4876-95fb-1d3b9eaa07b2"
      unitRef="usd">163484000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE1LTMtMS0xLTA_49e3b544-e6b6-4cd8-be32-54f586692bbd"
      unitRef="usd">145229000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE2LTEtMS0xLTA_823ccf3c-3202-48c5-84e7-b9cbab3cd0bb"
      unitRef="usd">159705000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE2LTMtMS0xLTA_2dfa6d85-42ad-4531-af5f-a10a9f2396f7"
      unitRef="usd">137159000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE3LTEtMS0xLTA_27208165-48e0-48f7-a8d7-702665de6680"
      unitRef="usd">3779000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE3LTMtMS0xLTA_bd265456-73c9-40ca-a346-b01f42931f34"
      unitRef="usd">8070000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE5LTEtMS0xLTA_79a15424-d5cf-4333-9e1f-e30c3f0de107"
      unitRef="usd">179000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzE5LTMtMS0xLTA_cdcd0690-5030-404d-84e8-0861c2fd6d73"
      unitRef="usd">160000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzIxLTEtMS0xLTA_0dd9bc41-7707-4bf7-9bb4-02fc8ccd55e0"
      unitRef="usd">2676000</ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzIxLTMtMS0xLTA_8612c90f-6749-426f-887c-73e5d85a9534"
      unitRef="usd">2894000</ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <ino:DeferredTaxLiabilitiesFinancingArrangementDiscount
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzIyLTEtMS0xLTA_57584b6a-ccce-458b-ae7b-498e7b322e31"
      unitRef="usd">469000</ino:DeferredTaxLiabilitiesFinancingArrangementDiscount>
    <ino:DeferredTaxLiabilitiesFinancingArrangementDiscount
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzIyLTMtMS0xLTA_6777f354-0e3c-44e4-8549-0d2530ba2753"
      unitRef="usd">2862000</ino:DeferredTaxLiabilitiesFinancingArrangementDiscount>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzIzLTEtMS0xLTA_2508719f-0782-43ef-97e2-e9cc37db1a95"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzIzLTMtMS0xLTA_208d57ee-3a3b-41f1-b4b5-b5aee0aa1ae8"
      unitRef="usd">1381000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzI0LTEtMS0xLTA_08e23996-b693-4a5c-9cf4-66cf435320af"
      unitRef="usd">487000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzI0LTMtMS0xLTA_3de8863e-48a6-4189-b372-7affef4bda15"
      unitRef="usd">805000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzI1LTEtMS0xLTA_3c1f34e3-5db8-4546-bb23-a5c29aac698e"
      unitRef="usd">32000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTozOTQ2ZTViNWQzNjY0YWRlYTg5MDRhMDc0NjQzNDcyZC90YWJsZXJhbmdlOjM5NDZlNWI1ZDM2NjRhZGVhODkwNGEwNzQ2NDM0NzJkXzI1LTMtMS0xLTA_d5e90980-b448-4a8d-8a28-4f0e3b9907cb"
      unitRef="usd">32000</us-gaap:DeferredTaxLiabilities>
    <ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet
      contextRef="i2dcec29e7a224ece9361e16b87782889_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzE3MTY_92d92ad3-b7f4-462c-a90a-b089097044ca"
      unitRef="usd">566200000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
    <ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet
      contextRef="ib776ba015a6a43aea6946a399cff7c5d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzE3MjA_ce5cf50b-7be6-4d5b-a7cb-572d37d8a2d5"
      unitRef="usd">68600000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
    <ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet
      contextRef="if6a7c79dd6fb44fea2add2a158468fae_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzE3Mjc_74aace1a-97c9-43e8-aadf-fa4605607f5d"
      unitRef="usd">75300000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="id072f2455d4849af90468cc0d319cb25_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzE4OTE_70f7cfa9-07d9-44e8-be18-e67ff6324c4f"
      unitRef="usd">270300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i41c87ddc992c48b1acc2970661bb9d63_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzIzMTQ_f82248c7-c67c-48bf-99e0-22f322be0c67"
      unitRef="usd">19800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="id820841c83d4427ca89b1647c1b78ca7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzIzMjE_0e3d97dc-5cd1-4fca-bee3-4264b47a566c"
      unitRef="usd">3200000</us-gaap:TaxCreditCarryforwardAmount>
    <ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzQ5NDY_42413872-0b99-44d7-b6f0-25e03bca75f2">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock>
    <ino:OperatingLossCarryforwardsExpiringintheNextTwelveMonths
      contextRef="ie1a1fd05e61e4d45b37b83d2c13345a4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzItMS0xLTEtMA_5063d0f6-ec16-4dd9-b464-3fe9e97df26c"
      unitRef="usd">2300000</ino:OperatingLossCarryforwardsExpiringintheNextTwelveMonths>
    <ino:OperatingLossCarryforwardsExpiringintheNextTwelveMonths
      contextRef="i52f711d0981940219b0fb0f426d25c3d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzItMy0xLTEtMA_43bee9e5-850a-49ab-94cd-717027ccc894"
      unitRef="usd">300000</ino:OperatingLossCarryforwardsExpiringintheNextTwelveMonths>
    <ino:TaxCreditCarryforwardExpiringintheNextTwelveMonths
      contextRef="icc506eb64eb44797985abc96b9c8f82f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzItNS0xLTEtMA_56d8404e-9c0d-42a1-84e2-f3ef5bdc69cf"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringintheNextTwelveMonths>
    <ino:TaxCreditCarryforwardExpiringintheNextTwelveMonths
      contextRef="id820841c83d4427ca89b1647c1b78ca7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzItNy0xLTEtMA_3cb505b9-1aaf-4d9c-ae8f-06c9442731c8"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringintheNextTwelveMonths>
    <ino:OperatingLossCarryforwardsExpiringinTwoYears
      contextRef="ie1a1fd05e61e4d45b37b83d2c13345a4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzMtMS0xLTEtMA_7c01b23f-1fac-4cc5-b27f-f251782eb9ce"
      unitRef="usd">6100000</ino:OperatingLossCarryforwardsExpiringinTwoYears>
    <ino:OperatingLossCarryforwardsExpiringinTwoYears
      contextRef="i52f711d0981940219b0fb0f426d25c3d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzMtMy0xLTEtMA_cb372ff2-990c-43d3-894b-717b49d25e8a"
      unitRef="usd">400000</ino:OperatingLossCarryforwardsExpiringinTwoYears>
    <ino:TaxCreditCarryforwardExpiringinTwoYears
      contextRef="icc506eb64eb44797985abc96b9c8f82f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzMtNS0xLTEtMA_99a0b150-630b-485e-a68f-9168dc5ead84"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinTwoYears>
    <ino:TaxCreditCarryforwardExpiringinTwoYears
      contextRef="id820841c83d4427ca89b1647c1b78ca7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzMtNy0xLTEtMA_f311cf3c-4aba-4df8-b2fb-1af68f779123"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinTwoYears>
    <ino:OperatingLossCarryforwardsExpiringinThreeYears
      contextRef="ie1a1fd05e61e4d45b37b83d2c13345a4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzQtMS0xLTEtMA_14f09f0b-c254-4d3e-8b2f-0fe9e51397ab"
      unitRef="usd">5300000</ino:OperatingLossCarryforwardsExpiringinThreeYears>
    <ino:OperatingLossCarryforwardsExpiringinThreeYears
      contextRef="i52f711d0981940219b0fb0f426d25c3d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzQtMy0xLTEtMA_2cdf8775-9101-41b2-b127-161709f09a13"
      unitRef="usd">1200000</ino:OperatingLossCarryforwardsExpiringinThreeYears>
    <ino:TaxCreditCarryforwardExpiringinThreeMonths
      contextRef="icc506eb64eb44797985abc96b9c8f82f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzQtNS0xLTEtMA_0140f5de-af26-42a4-9f38-84c297e2faad"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinThreeMonths>
    <ino:TaxCreditCarryforwardExpiringinThreeMonths
      contextRef="id820841c83d4427ca89b1647c1b78ca7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzQtNy0xLTEtMA_86a78adc-8cbd-412e-bd72-b4c79ec4c587"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinThreeMonths>
    <ino:OperatingLossCarryforwardsExpiringinFourYears
      contextRef="ie1a1fd05e61e4d45b37b83d2c13345a4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzUtMS0xLTEtMA_eda5525e-d327-4417-9195-7173274dc07d"
      unitRef="usd">14500000</ino:OperatingLossCarryforwardsExpiringinFourYears>
    <ino:OperatingLossCarryforwardsExpiringinFourYears
      contextRef="i52f711d0981940219b0fb0f426d25c3d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzUtMy0xLTEtMA_ed84f0f5-233a-499b-8ad1-66af9116fb74"
      unitRef="usd">9100000</ino:OperatingLossCarryforwardsExpiringinFourYears>
    <ino:TaxCreditCarryforwardExpiringinFourMonths
      contextRef="icc506eb64eb44797985abc96b9c8f82f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzUtNS0xLTEtMA_85ed22f1-1683-4d66-8b8a-57067e59e619"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinFourMonths>
    <ino:TaxCreditCarryforwardExpiringinFourMonths
      contextRef="id820841c83d4427ca89b1647c1b78ca7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzUtNy0xLTEtMA_6b489e2b-f7d3-4d7d-8b99-8cb39674b22a"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinFourMonths>
    <ino:OperatingLossCarryforwardsExpiringinFiveYears
      contextRef="ie1a1fd05e61e4d45b37b83d2c13345a4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzYtMS0xLTEtMA_9ed6e2d8-e337-46ee-8f47-42cbec0a5222"
      unitRef="usd">267700000</ino:OperatingLossCarryforwardsExpiringinFiveYears>
    <ino:OperatingLossCarryforwardsExpiringinFiveYears
      contextRef="i52f711d0981940219b0fb0f426d25c3d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzYtMy0xLTEtMA_c9eaa206-5d5c-4832-b8f2-e2d3329acbac"
      unitRef="usd">132900000</ino:OperatingLossCarryforwardsExpiringinFiveYears>
    <ino:TaxCreditCarryforwardExpiringinFiveYears
      contextRef="icc506eb64eb44797985abc96b9c8f82f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzYtNS0xLTEtMA_dc67a55d-64f1-4e3d-8b40-53a4b4ffa564"
      unitRef="usd">19800000</ino:TaxCreditCarryforwardExpiringinFiveYears>
    <ino:TaxCreditCarryforwardExpiringinFiveYears
      contextRef="id820841c83d4427ca89b1647c1b78ca7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzYtNy0xLTEtMA_fda087be-4a4f-4a96-9893-49e710443a23"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinFiveYears>
    <ino:OperatingLossCarryforwardsIndefinitelyCarryforward
      contextRef="ie1a1fd05e61e4d45b37b83d2c13345a4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzctMS0xLTEtMA_a70fd64c-2d9a-43d8-994b-004d5fd3ca20"
      unitRef="usd">270300000</ino:OperatingLossCarryforwardsIndefinitelyCarryforward>
    <ino:OperatingLossCarryforwardsIndefinitelyCarryforward
      contextRef="i52f711d0981940219b0fb0f426d25c3d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzctMy0xLTEtMA_3670633f-c49c-4d4f-81af-9db1db7d2244"
      unitRef="usd">0</ino:OperatingLossCarryforwardsIndefinitelyCarryforward>
    <ino:TaxCreditCarryforwardCarryforwardIndefinitely
      contextRef="icc506eb64eb44797985abc96b9c8f82f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzctNS0xLTEtMA_caa4f817-e7a9-4e26-911c-d9514cc06019"
      unitRef="usd">0</ino:TaxCreditCarryforwardCarryforwardIndefinitely>
    <ino:TaxCreditCarryforwardCarryforwardIndefinitely
      contextRef="id820841c83d4427ca89b1647c1b78ca7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzctNy0xLTEtMA_c25c3d2c-f744-4dc6-a2f8-c20346881f71"
      unitRef="usd">3200000</ino:TaxCreditCarryforwardCarryforwardIndefinitely>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ie1a1fd05e61e4d45b37b83d2c13345a4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzgtMS0xLTEtMA_ed3fff44-6a02-4ccd-b1ca-8f99e0fc8942"
      unitRef="usd">566200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i52f711d0981940219b0fb0f426d25c3d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzgtMy0xLTEtMA_6b3a4e79-d5c0-4110-bf58-25318a87fed8"
      unitRef="usd">143900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="icc506eb64eb44797985abc96b9c8f82f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzgtNS0xLTEtMA_1a029742-8e8c-4f10-839f-0eadae286604"
      unitRef="usd">19800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="id820841c83d4427ca89b1647c1b78ca7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTo1OWIwMDY4ZjEzMTc0OWU0YjMwNTJmZjZjOGE5OTUyZi90YWJsZXJhbmdlOjU5YjAwNjhmMTMxNzQ5ZTRiMzA1MmZmNmM4YTk5NTJmXzgtNy0xLTEtMA_02adb8b9-a4f1-4efa-bd4e-698c0b21cd99"
      unitRef="usd">3200000</us-gaap:TaxCreditCarryforwardAmount>
    <ino:TaxBenefitsExpired
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzMwMjM_5b8455bb-73d0-48af-8395-8cf06c106e47"
      unitRef="usd">10200000</ino:TaxBenefitsExpired>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzQ5MTY_f1e62647-bfea-45e4-83a3-c8922f075f67">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the Company's unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,204,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,313,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,575,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,319,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases (decreases) related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,210,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,204,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzItMS0xLTEtMA_b872d82b-e153-4828-b47a-9c194026a707"
      unitRef="usd">11204000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ifc185e611aa641b780dc3634c14f4ee0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzItMy0xLTEtMA_bcf38ad3-6c00-47b7-8789-c115f7466057"
      unitRef="usd">9632000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i098d7fa0e69c497394a273e6da442d60_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzItNS0xLTEtMA_d80c5429-10d8-4aac-afa9-3deb6482d0f2"
      unitRef="usd">8313000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzMtMS0xLTEtMA_f16fa9e1-d37b-46ca-a55e-89c8a1e659cf"
      unitRef="usd">1043000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzMtMy0xLTEtMA_d1ca805b-f13c-447e-90b9-477a909e0557"
      unitRef="usd">1575000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzMtNS0xLTEtMA_47e01221-94e6-4676-a904-8036a5e16206"
      unitRef="usd">1319000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzQtMS0xLTEtMA_45c4e6cd-da22-46c4-8d06-3b106092175b"
      unitRef="usd">27000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzQtMy0xLTEtMA_364a588b-e9fb-4b63-bf3a-6a580285416a"
      unitRef="usd">3000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzQtNS0xLTEtMA_43ec8cc5-8ffc-475a-8f8e-291cf8b30b56"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzUtMS0xLTEtNzExNA_bb99866a-c2db-4a30-9bf2-8edfb33f22ad"
      unitRef="usd">-64000</ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther>
    <ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzUtMy0xLTEtNzExNA_dac36a5a-839d-4332-b962-274ed428a716"
      unitRef="usd">0</ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther>
    <ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzUtNS0xLTEtNzExNA_927fd4fa-5ecd-49d7-8fd5-6bc303f59392"
      unitRef="usd">0</ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzUtMS0xLTEtMA_7146d214-4135-4b92-bb5f-5be1576e3d17"
      unitRef="usd">12210000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzUtMy0xLTEtMA_a31a6e2b-342c-4059-abd4-9ad976abbaaa"
      unitRef="usd">11204000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ifc185e611aa641b780dc3634c14f4ee0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90YWJsZTplYTQ2Nzc0OWZhNWM0Mjc0YjYwNTU5YjdkMGM3ODAzNi90YWJsZXJhbmdlOmVhNDY3NzQ5ZmE1YzQyNzRiNjA1NTliN2QwYzc4MDM2XzUtNS0xLTEtMA_0f9ba524-98cb-406f-9559-b0c20c504621"
      unitRef="usd">9632000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i461a06745d764430b3e72d9b80f2433e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzM4MDA_e6fda5f1-b1cd-41ae-a4d2-c6c77f1b1ea2"
      unitRef="usd">10900000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="if06f128df0d4400ebe7bd1d7e8943618_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzM4MDQ_68be8aeb-0a55-4cfb-b055-684744759a1e"
      unitRef="usd">9900000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ifc185e611aa641b780dc3634c14f4ee0_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xOTkvZnJhZzo5Nzc4YWM1MDZlYWU0MmVlYTY5YzRkZDRkNmI0ZGNiMC90ZXh0cmVnaW9uOjk3NzhhYzUwNmVhZTQyZWVhNjljNGRkNGQ2YjRkY2IwXzM4MTE_fd1f04c6-6928-4dcb-8d17-113ba9c6f059"
      unitRef="usd">8300000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDIvZnJhZzo2MzYzNGQyYTQ0OTQ0Y2E2OWU4N2I4MDhjZDlmYTAxNS90ZXh0cmVnaW9uOjYzNjM0ZDJhNDQ5NDRjYTY5ZTg3YjgwOGNkOWZhMDE1XzU0NA_b8b96fea-88a1-41a5-97cb-43bae37dc27c">401(k) PlanThe Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches 50% of its employees&#x2019; contributions, up to 6% of their annual compensation. The Company&#x2019;s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled $1.1 million, $1.2 million and $1.2 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDIvZnJhZzo2MzYzNGQyYTQ0OTQ0Y2E2OWU4N2I4MDhjZDlmYTAxNS90ZXh0cmVnaW9uOjYzNjM0ZDJhNDQ5NDRjYTY5ZTg3YjgwOGNkOWZhMDE1XzI2MA_20fccc40-212e-4f8c-b555-9f7495ae49ab"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDIvZnJhZzo2MzYzNGQyYTQ0OTQ0Y2E2OWU4N2I4MDhjZDlmYTAxNS90ZXh0cmVnaW9uOjYzNjM0ZDJhNDQ5NDRjYTY5ZTg3YjgwOGNkOWZhMDE1XzMwMg_24abaa55-0e4d-4a03-8232-3ebefcc6c1a3"
      unitRef="number">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDIvZnJhZzo2MzYzNGQyYTQ0OTQ0Y2E2OWU4N2I4MDhjZDlmYTAxNS90ZXh0cmVnaW9uOjYzNjM0ZDJhNDQ5NDRjYTY5ZTg3YjgwOGNkOWZhMDE1XzQ1Nw_0455a452-ac18-4c62-a9cd-5f135b2b8d5d"
      unitRef="usd">1100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="idb7e049ad2784543b766df1154e2599c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDIvZnJhZzo2MzYzNGQyYTQ0OTQ0Y2E2OWU4N2I4MDhjZDlmYTAxNS90ZXh0cmVnaW9uOjYzNjM0ZDJhNDQ5NDRjYTY5ZTg3YjgwOGNkOWZhMDE1XzQ2MQ_79cbc12c-f9a6-4846-954b-1b7269b4ddf6"
      unitRef="usd">1200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="id6014b9675e54093ba947147d012abd7_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDIvZnJhZzo2MzYzNGQyYTQ0OTQ0Y2E2OWU4N2I4MDhjZDlmYTAxNS90ZXh0cmVnaW9uOjYzNjM0ZDJhNDQ5NDRjYTY5ZTg3YjgwOGNkOWZhMDE1XzQ3Ng_4bca90ed-d267-4c98-9b8e-b4b921c41530"
      unitRef="usd">1200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzc2ODY_7000d883-ebf4-4524-9c4f-22a4a2870c28">Related Party Transactions&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GeneOne Life Sciences &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 27, 2020, the Company sold 1,644,155 shares of common stock in GeneOne for net proceeds of approximately 47.4&#160;billion KRW (approximately USD $40.1&#160;million based on the exchange rate on the date of sale). The Company no longer holds an investment in GeneOne shares and GeneOne is no longer considered a related party to the Company under ASC 850. The Company's consolidated balance sheet as of December 31, 2020 no longer reflects GeneOne&#x2019;s portion in accounts receivable and accounts payable and accrued expenses with affiliated entities, whereas the Company&#x2019;s balance sheet as of December 31, 2019 reflects $128,000 and $511,000 in accounts receivable and accounts payable and accrued expenses with &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;affiliated entities, respectively, related to GeneOne. Revenues recognized from GeneOne will no longer be presented as revenue with affiliated entity on the consolidated statement of operations after the change in related party designation in August 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized from GeneOne for the years ended December&#160;31, 2020, 2019 and 2018 consisting of&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;patent, device maintenance and licensing fees was $125,000, $127,000 and $342,000, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses recorded from transactions with GeneOne related primarily to biologics manufacturing and were $4.7 million, $2.5 million and $7.0 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plumbline Life Sciences, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company owned 597,808 shares of common stock in Plumbline Life Sciences, Inc. ("PLS") as of December 31, 2020 and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 20, 2020, the Company entered into a Debt and Share Subscription Agreement with PLS under which the Company received 202,050 shares of PLS common stock in exchange for a portion of the outstanding accounts receivable balance due from PLS. Following the issuance of these shares and as of December 31, 2020, the Company held a 19.7% ownership interest in PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized from PLS consists of milestone, license and patent fees. For the years ended December&#160;31, 2020 and 2019, the Company recognized revenue from PLS of $1.4 million and $111,000, respectively. At December 31, 2020 and 2019, the Company had an accounts receivable balance of $67,000 and $589,000, respectively, related to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Wistar Institute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, the Company entered into collaborative &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company will reimburse Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreement. The Company will have the exclusive right to in-license new intellectual property developed in this agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, the Company rece&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ived a&#160;$6.1 million&#160;sub-grant through Wistar to develop a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;DMAb&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; against the Zika infection, with fun&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ding through December 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company received a $10.7&#160;million sub-grant through Wistar for the preclinical development and translational studies of DMAbs as countermeasures for COVID-19, with funding through September 2022. The sub-grant also includes an option for an additional $6.0&#160;million in funding through September 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended December&#160;31, 2020 and 2019, the Company recorded $1.9 million and $2.2 million, respectively, as contra-research and development expense from Wistar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 4). Research and development expenses recorded from Wistar for the years ended December&#160;31, 2020 and 2019 were $2.3 million and $1.5 million, respectively. At December&#160;31, 2020 and 2019, the Company had an accounts receivable balance of $425,000 and $616,000, respectively, and an accounts payable and accrued liability balance of $643,000 and $219,000, respectively, related to Wistar. As of December&#160;31, 2020, the Company had $96,000 recorded as grant funding liability on its consolidated balance sheet related to Wistar.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="ie9f188d112294323bf3087ef33c420b6_I20200827"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzc3_4f93d108-32b6-4c53-87f8-6713359aad63"
      unitRef="shares">1644155</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i39837d9d2abd48a3aca884118a65d728_D20200827-20200827"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzgyNDYzMzcyMjQyMTY_d6035cf3-232e-467a-9a6c-0d69abe3edae"
      unitRef="krw">47400000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i39837d9d2abd48a3aca884118a65d728_D20200827-20200827"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQ5NDc4MDIzMzM3NDg_db0679a0-14ab-4017-b114-ff16d4a65cc8"
      unitRef="usd">40100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="idbd8535467dc4b5eae52e74f3983bcef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQ5NDc4MDIzMzQ4OTc_1e4af4f2-f223-4f6d-8f5d-1f6ba1aab915"
      unitRef="usd">128000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="idbd8535467dc4b5eae52e74f3983bcef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQ5NDc4MDIzMzM4MDU_b1380b8e-13e1-440f-ab8f-7f2f1509cc4e"
      unitRef="usd">511000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RevenueFromRelatedParties
      contextRef="iec6e16acd2c14a4e90471eef35722254_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQzMjk_4010c8ea-32de-4a2f-833b-fafb3a98abc7"
      unitRef="usd">125000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i31ce6dcaa01b46eeab8e3956ce276921_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQzMzM_157d731f-b09a-476f-8ebc-d035a20a7c9c"
      unitRef="usd">127000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="if81fb01786fc4764ac42fbc00018292e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQzNDA_fbc1be5c-9336-4cb1-ac7b-fbcadeca2772"
      unitRef="usd">342000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="iec6e16acd2c14a4e90471eef35722254_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQ0NzA_6aff6026-6733-4df3-bce5-79af796834d3"
      unitRef="usd">4700000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i31ce6dcaa01b46eeab8e3956ce276921_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQ0NzQ_4ce775b2-9430-42f8-bf85-f5b78598ca8e"
      unitRef="usd">2500000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="if81fb01786fc4764ac42fbc00018292e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQ0ODE_f515f41f-7eec-48d6-935b-2525973dd5d0"
      unitRef="usd">7000000.0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i741b2d70a16540e4849e177841399ef2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQ5ODI_0cbee8b8-1c6d-4aca-9fb2-37e155a2e85d"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <ino:InvestmentOwnedAdditionalSharesAcquired
      contextRef="if9933acb5084469ba365e771ad142f6f_I20200220"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzQ5NDc4MDIzMzU1NDc_7f429409-9ee7-47ce-9ed2-40332b122e4c"
      unitRef="shares">202050</ino:InvestmentOwnedAdditionalSharesAcquired>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i741b2d70a16540e4849e177841399ef2_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzMyOTg1MzQ4OTY2MDY_9afcccb3-bc20-4739-8acc-4d97629f4467"
      unitRef="number">0.197</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i8fa046515d344201b301dfcac426f1d7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzUyOTg_14f10b0e-e684-44ff-be08-5c8bfef0c4bd"
      unitRef="usd">1400000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i12e6aa36d34c4fed9f215ef703733288_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzUzMDU_67bffadc-5c57-4407-9814-a88b6ecac207"
      unitRef="usd">111000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i741b2d70a16540e4849e177841399ef2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzU0MDA_9e3aa9aa-6c7d-4013-9a9f-d32a75885b94"
      unitRef="usd">67000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i584919522b8946388cc46b11e1b6c134_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzU0MDc_73a21572-98c0-4e78-9566-c64c4c094e8e"
      unitRef="usd">589000</us-gaap:AccountsReceivableRelatedParties>
    <ino:CollaborativeAgreementExpensesToReimburse
      contextRef="i850db8c1404e41ef8a3f4e2c5d6497c9_D20160301-20160331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzYyMDg_64efd19c-bab9-4ba7-bc35-5b47cafdd1f9"
      unitRef="usd">3100000</ino:CollaborativeAgreementExpensesToReimburse>
    <ino:CollaborativeArrangementTerm
      contextRef="i850db8c1404e41ef8a3f4e2c5d6497c9_D20160301-20160331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzgyNDYzMzcyMjQyNTg_5a99dcec-987e-4271-a122-11a061ceb50e">P5Y</ino:CollaborativeArrangementTerm>
    <ino:ProceedsFromSubGrant
      contextRef="ib07cb6287f3248b5b722d555d87a2523_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzY0MDc_6888d02e-fb95-476e-a30c-c2649d86eab5"
      unitRef="usd">6100000</ino:ProceedsFromSubGrant>
    <ino:CollaborativeAgreementAwardedAmount
      contextRef="i510403322bee48dd9b1d7fa361079cf8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzgyNDYzMzcyMjQyMzA_a18b809d-8a67-4234-862f-6362436caea1"
      unitRef="usd">10700000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAwardedOptionAmount
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzgyNDYzMzcyMjQyNDU_72ffa380-bdf3-40d4-996c-f7bf8ca44a4f"
      unitRef="usd">6000000.0</ino:CollaborativeAgreementAwardedOptionAmount>
    <ino:GrantProceedsReceived
      contextRef="i510403322bee48dd9b1d7fa361079cf8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzY5NDk_eeb9a005-3ca7-4020-b7a5-e0dfe9ce9fbc"
      unitRef="usd">1900000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="i4bc8a5ec417940d080468c000bb0c684_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzY5NTY_3bb9751e-39e9-47e5-a45b-6952b6d7d858"
      unitRef="usd">2200000</ino:GrantProceedsReceived>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i510403322bee48dd9b1d7fa361079cf8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzczMzQ_5e68a6b0-8ad5-4ff2-9f3b-594c7bfc0598"
      unitRef="usd">2300000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i4bc8a5ec417940d080468c000bb0c684_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzczNDk_da7bcc0a-b6ea-4f4b-8016-93c255b4a429"
      unitRef="usd">1500000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i329099e1a64e4114916fa70aa8f77967_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzc0Mzk_649c35bd-5c1c-43de-ba5b-76eefe8ed93b"
      unitRef="usd">425000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i1344066b478244ff886e0ea7d3f13c3c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzc0NDY_5497b022-2f85-4a6a-aebc-60e7f351b042"
      unitRef="usd">616000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i329099e1a64e4114916fa70aa8f77967_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzc1MjE_12981947-673f-48a9-9162-1e6ae17183b4"
      unitRef="usd">643000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i1344066b478244ff886e0ea7d3f13c3c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzc1Mjg_1e7ccf7a-3b2e-42e8-957e-434143cf7ff8"
      unitRef="usd">219000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <ino:DeferredGrantFundingFromAffiliate
      contextRef="i329099e1a64e4114916fa70aa8f77967_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDUvZnJhZzo0MjU3MGIyMWNmYWE0ZjZiYmU4MGNkN2QyMzc1ZGFkZC90ZXh0cmVnaW9uOjQyNTcwYjIxY2ZhYTRmNmJiZTgwY2Q3ZDIzNzVkYWRkXzc1OTE_fe6b483d-5993-4cb4-9da1-537e3c364718"
      unitRef="usd">96000</ino:DeferredGrantFundingFromAffiliate>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl84MjQ2MzM3MjIzNzg4_b593797e-df3a-40c4-a8f1-cb56139208c0">Geneos Therapeutics, Inc. &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In February 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested&#160;$1.2&#160;million&#160;in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;61%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $800,000. Following this transaction, as of March 31, 2020, the Company held&#160;52%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $800,000.  Following this transaction, the Company owned 47% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#x2019;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support.  However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#x2019; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $4.1&#160;million, of which $2.4&#160;million related to the remeasurement of the retained noncontrolling interest investment to fair value.  The gain has been recorded separately on the Company's consolidated statement of operations.  The following table shows the amounts related to the deconsolidation accounting: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Working capital (excluding cash) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note payable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets, net of accumulated depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of noncontrolling interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,181,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of investment in Geneos retained&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on deconsolidation of Geneos &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,121,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in cash resulting from the deconsolidation of Geneos&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,774,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The details of the Company&#x2019;s 47% retained equity investment in Geneos are shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Geneos Share Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,799,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Geneos Series A preferred stock was based on the per share price paid by third-party investors in connection with the most recent closing of the Series A preferred stock financing for Geneos on June 1, 2020. The fair value of Geneos common stock was determined by a third-party valuation, as there is no public market for such stock. Geneos&#x2019;s enterprise value, which was estimated using a market approach that derived an implied total equity value from a transaction involving its own securities, was allocated to all classes of equity using the option pricing method. Under the option pricing method, each equity class was modeled as having a call option with a distinct claim on the total value of Geneos. Each option&#x2019;s exercise price was based on the total value available for each participating security holder. The characteristics of each class of ownership determined the claim on the total value for that class of ownership.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated value allocated to common stock included assumptions related to the fair value of the enterprise, expected volatility, expected term, and risk-free interest rate. Expected volatility was based on historical asset volatilities derived from daily stock price changes of guideline public companies. The estimated expected term was based on a weighted average of the estimated time to Geneos's next financing and successful exit timing assumption.  The risk-free interest rate was based on the yield of U.S. Treasury with a comparable term. Geneos&#x2019;s common stock is classified as a Level 3 financial instrument. The assumptions used in the fair value calculation as of June 1, 2020 are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Geneos enterprise value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,966,531&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#x2019;s common stock.  Since the Company&#x2019;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#x2019;s common stock investment and will therefore be recorded as an equity security under ASC 321.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 1, 2020, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#x2019;s investment and the amount of underlying equity in Geneos&#x2019;s net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the Series A preferred stock financing on June 1, 2020. The Company has determined that its Series A preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#x2019;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $1.4&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The date of this transaction was determined to be a VIE reconsideration event; based on the Company&#x2019;s assessment, Geneos continues to be a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continues to not be the primary beneficiary of Geneos, as it does not have the power to direct the activities that most significantly impact Geneos&#x2019;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 36% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Geneos&#x2019;s Series A-1 preferred stock was based on the per share price paid by third-party investors in connection with the closing on November 12, 2020.  The Company has concluded that its Series A-1 preferred stock investment is not similar to its prior Series A preferred stock investment due to certain material rights held solely by Series A preferred stockholders. Therefore, the Company will continue to record its Series A preferred stock investment in Geneos at cost, as there have been no observable price changes or impairments identified since the deconsolidation date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s share of net losses of Geneos for the period from June 1, 2020 through &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; w&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as $4.6&#160;million. O&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f this amount, $819,000 has been allocated to the equity method investment, thereby reducing the balance to $0 as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The remaining &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.8&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; loss has been allocated to the Company&#x2019;s Series A and Series A-1 preferred stock investments in Geneos, on a ratable basis, thereby reducing the investment balance t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;o $434,000 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos upon deconsolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos Series A-1 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in net loss of Geneos &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,584,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to exclusively license its SynCon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;immunotherapy and CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i3278752f623242159a014d02f29d289b_D20190201-20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4ODY1_1f08473b-8f6d-43f6-bf42-fdf46bfa56e9"
      unitRef="usd">1200000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ie036575d65ff4badb43323c689c9ffe6_I20190228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4ODc5_967e47f5-4771-4d67-9e25-af361a61635c"
      unitRef="number">0.61</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment
      contextRef="i9f560f41562c4fc9a3ad15d9c446af7c_I20200101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4ODg5_7000606f-ff56-4319-a85b-fdb1552bdae6"
      unitRef="usd">800000</ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ie331329335874c70bd80518d6ff9c532_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4ODg0_4ac26abc-3f7e-4760-81de-406aeac67272"
      unitRef="number">0.52</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment
      contextRef="i5fae662cff7740e8b862767817b4873b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4ODk5_92cf8e15-6a29-44ed-a1ff-ae129fb80f4b"
      unitRef="usd">800000</ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="if720e223acd541dc9a923f12ccafdf0a_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4OTA5_fc6aa071-f012-430e-97e5-6f5c149f1d5f"
      unitRef="number">0.47</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="id6ef275f991c4ded9ea7eddc6b7b1498_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4OTE0_310d34ae-06b7-4f25-80a1-ae012a631ebb"
      unitRef="usd">4100000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
      contextRef="id6ef275f991c4ded9ea7eddc6b7b1498_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4OTI4_9be78adf-79eb-444f-8c55-eb1ae60489a8"
      unitRef="usd">2400000</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl84MjQ2MzM3MjIzNzg5_4b649067-24b6-4d5d-9dc9-fb781be0e1fb">The following table shows the amounts related to the deconsolidation accounting: &lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Working capital (excluding cash) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note payable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets, net of accumulated depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of noncontrolling interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,181,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of investment in Geneos retained&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on deconsolidation of Geneos &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,121,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in cash resulting from the deconsolidation of Geneos&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,774,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The details of the Company&#x2019;s 47% retained equity investment in Geneos are shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Geneos Share Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,799,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The remaining &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.8&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; loss has been allocated to the Company&#x2019;s Series A and Series A-1 preferred stock investments in Geneos, on a ratable basis, thereby reducing the investment balance t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;o $434,000 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as shown in the table below:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos upon deconsolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos Series A-1 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in net loss of Geneos &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,584,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <ino:WorkingCapitalExcludingCash
      contextRef="i9bc7852775b6421ca17e8e3e194bab5c_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6ZTA1ODM2NjY0Y2Q0NDgyZGFkNjg0Y2ExOTA1OTIzN2YvdGFibGVyYW5nZTplMDU4MzY2NjRjZDQ0ODJkYWQ2ODRjYTE5MDU5MjM3Zl8wLTEtMS0xLTU3Ng_6c37622b-3403-48cb-8531-7b3a14a849c3"
      unitRef="usd">59992</ino:WorkingCapitalExcludingCash>
    <us-gaap:NotesPayable
      contextRef="i9bc7852775b6421ca17e8e3e194bab5c_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6ZTA1ODM2NjY0Y2Q0NDgyZGFkNjg0Y2ExOTA1OTIzN2YvdGFibGVyYW5nZTplMDU4MzY2NjRjZDQ0ODJkYWQ2ODRjYTE5MDU5MjM3Zl8xLTEtMS0xLTU3Ng_ebd756e7-c8d8-4db2-a1a7-cdd24c59630f"
      unitRef="usd">171620</us-gaap:NotesPayable>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9bc7852775b6421ca17e8e3e194bab5c_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6ZTA1ODM2NjY0Y2Q0NDgyZGFkNjg0Y2ExOTA1OTIzN2YvdGFibGVyYW5nZTplMDU4MzY2NjRjZDQ0ODJkYWQ2ODRjYTE5MDU5MjM3Zl8yLTEtMS0xLTU3Ng_4340ce3c-3e2a-4899-902f-d8aa29f6cc70"
      unitRef="usd">16340</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:MinorityInterest
      contextRef="i9bc7852775b6421ca17e8e3e194bab5c_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6ZTA1ODM2NjY0Y2Q0NDgyZGFkNjg0Y2ExOTA1OTIzN2YvdGFibGVyYW5nZTplMDU4MzY2NjRjZDQ0ODJkYWQ2ODRjYTE5MDU5MjM3Zl8zLTEtMS0xLTU3Ng_ae37d5c5-d7af-4d62-a7c8-4012273e8fa3"
      unitRef="usd">3181640</us-gaap:MinorityInterest>
    <us-gaap:RetainedInterestFairValueDisclosure
      contextRef="i9bc7852775b6421ca17e8e3e194bab5c_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6ZTA1ODM2NjY0Y2Q0NDgyZGFkNjg0Y2ExOTA1OTIzN2YvdGFibGVyYW5nZTplMDU4MzY2NjRjZDQ0ODJkYWQ2ODRjYTE5MDU5MjM3Zl80LTEtMS0xLTU3Ng_ad1b9445-dba8-4834-bb63-714ded2697bf"
      unitRef="usd">3618998</us-gaap:RetainedInterestFairValueDisclosure>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="id6ef275f991c4ded9ea7eddc6b7b1498_D20200601-20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6ZTA1ODM2NjY0Y2Q0NDgyZGFkNjg0Y2ExOTA1OTIzN2YvdGFibGVyYW5nZTplMDU4MzY2NjRjZDQ0ODJkYWQ2ODRjYTE5MDU5MjM3Zl81LTEtMS0xLTU3Ng_6e70103d-87c1-4979-8b26-4cfad8352dde"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="id6ef275f991c4ded9ea7eddc6b7b1498_D20200601-20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6ZTA1ODM2NjY0Y2Q0NDgyZGFkNjg0Y2ExOTA1OTIzN2YvdGFibGVyYW5nZTplMDU4MzY2NjRjZDQ0ODJkYWQ2ODRjYTE5MDU5MjM3Zl82LTEtMS0xLTU3NDU_c6011bc1-c840-438d-85f9-1de7ec565122"
      unitRef="usd">2774851</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i4eaf8e38eb024ee5bd2c0e686600ecd3_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4OTQy_d3f1b1a2-12e0-4df1-b63a-01d7b4157744"
      unitRef="number">0.47</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i75e5c84b89524b7285a0f1fd58ce7d28_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6MTQ5NDhjYTNkMmJhNDdjY2I2ZjRiNTdjMDkzNDEwYWMvdGFibGVyYW5nZToxNDk0OGNhM2QyYmE0N2NjYjZmNGI1N2MwOTM0MTBhY18xLTEtMS0xLTU3Ng_2c851935-7266-4af4-be8e-12749289a807"
      unitRef="shares">3000000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="i75e5c84b89524b7285a0f1fd58ce7d28_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6MTQ5NDhjYTNkMmJhNDdjY2I2ZjRiNTdjMDkzNDEwYWMvdGFibGVyYW5nZToxNDk0OGNhM2QyYmE0N2NjYjZmNGI1N2MwOTM0MTBhY18xLTMtMS0xLTU3Ng_5a16071c-e26a-492b-9759-f2c6549c341b"
      unitRef="usdPerShare">0.273</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestments
      contextRef="i75e5c84b89524b7285a0f1fd58ce7d28_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6MTQ5NDhjYTNkMmJhNDdjY2I2ZjRiNTdjMDkzNDEwYWMvdGFibGVyYW5nZToxNDk0OGNhM2QyYmE0N2NjYjZmNGI1N2MwOTM0MTBhY18xLTUtMS0xLTU3Ng_2169165e-fc76-4e5a-b03b-d445da374e97"
      unitRef="usd">819000</us-gaap:EquityMethodInvestments>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="ica4b744c22f9404fa2cb9f77877257ff_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6MTQ5NDhjYTNkMmJhNDdjY2I2ZjRiNTdjMDkzNDEwYWMvdGFibGVyYW5nZToxNDk0OGNhM2QyYmE0N2NjYjZmNGI1N2MwOTM0MTBhY18yLTEtMS0xLTU3Ng_b635afae-9f04-4b83-9298-0085f46a63e1"
      unitRef="shares">2113206</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="ica4b744c22f9404fa2cb9f77877257ff_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6MTQ5NDhjYTNkMmJhNDdjY2I2ZjRiNTdjMDkzNDEwYWMvdGFibGVyYW5nZToxNDk0OGNhM2QyYmE0N2NjYjZmNGI1N2MwOTM0MTBhY18yLTMtMS0xLTU3Ng_ff2706ba-123c-4d83-b2ff-9af8536b2146"
      unitRef="usdPerShare">1.325</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestments
      contextRef="ica4b744c22f9404fa2cb9f77877257ff_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6MTQ5NDhjYTNkMmJhNDdjY2I2ZjRiNTdjMDkzNDEwYWMvdGFibGVyYW5nZToxNDk0OGNhM2QyYmE0N2NjYjZmNGI1N2MwOTM0MTBhY18yLTUtMS0xLTU3Ng_8a0bed50-247a-4288-b07e-fad55a7681e6"
      unitRef="usd">2799998</us-gaap:EquityMethodInvestments>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i9bc7852775b6421ca17e8e3e194bab5c_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6MTQ5NDhjYTNkMmJhNDdjY2I2ZjRiNTdjMDkzNDEwYWMvdGFibGVyYW5nZToxNDk0OGNhM2QyYmE0N2NjYjZmNGI1N2MwOTM0MTBhY18zLTEtMS0xLTU3Ng_da5f83e0-d807-47f4-b43b-ebb202f7494d"
      unitRef="shares">5113206</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:EquityMethodInvestments
      contextRef="i9bc7852775b6421ca17e8e3e194bab5c_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6MTQ5NDhjYTNkMmJhNDdjY2I2ZjRiNTdjMDkzNDEwYWMvdGFibGVyYW5nZToxNDk0OGNhM2QyYmE0N2NjYjZmNGI1N2MwOTM0MTBhY18zLTUtMS0xLTU3Ng_87e05848-105b-4018-a36d-48a54e1fbe8e"
      unitRef="usd">3618998</us-gaap:EquityMethodInvestments>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl84MjQ2MzM3MjIzNzkz_c4bcc1a3-6fe3-49d2-9dc3-da4274a9cdc9">The assumptions used in the fair value calculation as of June 1, 2020 are presented below:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Geneos enterprise value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,966,531&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <ino:AlternativeInvestmentMeasurementInputTerm
      contextRef="id3d03457e0864bfc8b1b8bfd7dfc1ec0_D20200601-20200601"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6NjU1ZDM2MjBlZThlNDEyZjgzMmM2M2UwN2E2YTAwYjgvdGFibGVyYW5nZTo2NTVkMzYyMGVlOGU0MTJmODMyYzYzZTA3YTZhMDBiOF8wLTEtMS0xLTU3Ng_b8bfd5be-f148-4e7c-b4d1-910e5a09c417">P2Y11M1D</ino:AlternativeInvestmentMeasurementInputTerm>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i3c0fc01307c94a3f818e05fa200f315f_I20200601"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6NjU1ZDM2MjBlZThlNDEyZjgzMmM2M2UwN2E2YTAwYjgvdGFibGVyYW5nZTo2NTVkMzYyMGVlOGU0MTJmODMyYzYzZTA3YTZhMDBiOF8xLTEtMS0xLTU3Ng_04cc4c88-c7a5-406a-9c8a-4cc682c4cd28"
      unitRef="number">0.70</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i9a56ec56c1704c999304cafdca127971_I20200601"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6NjU1ZDM2MjBlZThlNDEyZjgzMmM2M2UwN2E2YTAwYjgvdGFibGVyYW5nZTo2NTVkMzYyMGVlOGU0MTJmODMyYzYzZTA3YTZhMDBiOF8yLTEtMS0xLTU3Ng_84f69037-9289-4836-8b88-f4c25985e0f2"
      unitRef="number">0.0246</us-gaap:AlternativeInvestmentMeasurementInput>
    <ino:EquityMethodInvestmentEnterpriseValue
      contextRef="i9bc7852775b6421ca17e8e3e194bab5c_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6NjU1ZDM2MjBlZThlNDEyZjgzMmM2M2UwN2E2YTAwYjgvdGFibGVyYW5nZTo2NTVkMzYyMGVlOGU0MTJmODMyYzYzZTA3YTZhMDBiOF8zLTEtMS0xLTU3Ng_b6ab909d-c139-4abd-a4e5-2f29c87fc38c"
      unitRef="usd">4966531000</ino:EquityMethodInvestmentEnterpriseValue>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i1d304f7e01154532bc01359f95252e17_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl8zMjk4NTM0ODk4NTIx_3a73d42a-88d8-45aa-8b8a-91211572f5a0"
      unitRef="usd">1400000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ic121c422f0fe4bf881984c703f46d52f_I20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl8zMjk4NTM0ODk4NTM1_9780205e-f4ed-48d2-a80f-da9fab301814"
      unitRef="number">0.36</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i684fbe7297024813bfc8e35aab204865_D20200601-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE4OTU3_c03adae5-204e-42a5-b358-e4b77f9bb797"
      unitRef="usd">-4600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iefe35c0283fe4a69ae2e6dd8855e61f9_D20200601-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE5MDM4_22aa8517-7a27-48d9-9453-55df9446bd37"
      unitRef="usd">-819000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i760444398ee74fd3afd5baf01b8fc34e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE5MDQ4_765c9b95-3230-4544-8bb1-d289c145d122"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ide3b32650b4e4f67aa4cae4aa5642502_D20200601-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl80Mzk4MDQ2NTE5MDUy_0f51a11c-ec97-4b68-9b79-f339a8263690"
      unitRef="usd">-3800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i294f24f4c95d4f61a311238a03b975ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGV4dHJlZ2lvbjplYTUzN2MzNTg1NDg0MDRkYjQ4NmRmYmE2YjAwMDBmYl84MjQ2MzM3MjIzNzk1_6d73dd39-d5fc-48d2-909e-fa1a3fb6884d"
      unitRef="usd">434000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i9bc7852775b6421ca17e8e3e194bab5c_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6NGFkNTc4ZWRiNGMwNDUwZmJiMzQ1N2EzYmEyNTVjYmUvdGFibGVyYW5nZTo0YWQ1NzhlZGI0YzA0NTBmYmIzNDU3YTNiYTI1NWNiZV8xLTItMS0xLTU3Njc_620b3a42-75bb-488f-adab-3f27c7db718e"
      unitRef="usd">3618998</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i4dc3ada5f7d04ae89165c132fbfcfc62_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6NGFkNTc4ZWRiNGMwNDUwZmJiMzQ1N2EzYmEyNTVjYmUvdGFibGVyYW5nZTo0YWQ1NzhlZGI0YzA0NTBmYmIzNDU3YTNiYTI1NWNiZV8yLTItMS0xLTU3Njc_c100f066-d9f3-417c-9408-0fd25098d5fa"
      unitRef="usd">1399999</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i684fbe7297024813bfc8e35aab204865_D20200601-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6NGFkNTc4ZWRiNGMwNDUwZmJiMzQ1N2EzYmEyNTVjYmUvdGFibGVyYW5nZTo0YWQ1NzhlZGI0YzA0NTBmYmIzNDU3YTNiYTI1NWNiZV8zLTItMS0xLTU3Njc_f1bde3c6-3971-4ad1-a74e-49321b7b7a6f"
      unitRef="usd">-4584610</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ic0f4d31539a04f7f8e95ff7d666d0c49_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xODQ0L2ZyYWc6ZWE1MzdjMzU4NTQ4NDA0ZGI0ODZkZmJhNmIwMDAwZmIvdGFibGU6NGFkNTc4ZWRiNGMwNDUwZmJiMzQ1N2EzYmEyNTVjYmUvdGFibGVyYW5nZTo0YWQ1NzhlZGI0YzA0NTBmYmIzNDU3YTNiYTI1NWNiZV80LTItMS0xLTU3Njc_406b3064-f5f5-470a-bc8c-9f1d7c6aece1"
      unitRef="usd">434387</us-gaap:EquityMethodInvestments>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90ZXh0cmVnaW9uOjcxNDI2MDdjNjE1YjQ3MDE5MWViY2ZkNGMzNDAxNzQ1XzIwOQ_7c80affc-28dc-48e1-bab9-9394d5045abe">Quarterly Financial Information (Unaudited)&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the quarterly results of operations of the Company for the years ended December&#160;31, 2020 and 2019 (unaudited):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter&#160;Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter&#160;Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter&#160;Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter&#160;Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Consolidated Statements of Operations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue under collaborative research and development arrangements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,003,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue under collaborative research and development arrangements from affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue, including from affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,580,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,302,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,455,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,376,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,111,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,617,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,110,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,071,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,448,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,920,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,565,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,448,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,559,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,339,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,329,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,180,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,232,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,068,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,984,046)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,846,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,803,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,306,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97,755,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,221,977)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) on investment in affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,951,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,883,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,181,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain on available-for-sale equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,315,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,358,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,050,092)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(152,102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(425,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on deconsolidation of Geneos&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,121,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of convertible bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,177,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on extinguishment of convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,674,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,087,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) before income tax benefit and share in net loss of Geneos&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,415,201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,931,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128,270,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,135,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in net loss of Geneos&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,923,179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,759,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(901,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,338,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,171,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129,172,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,135,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) attributable to Inovio Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,338,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,171,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128,703,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,541,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter&#160;Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter&#160;Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter&#160;Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter&#160;Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Consolidated Statements of Operations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue under collaborative research and development arrangements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,770,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue under collaborative research and development arrangements from affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue, including from affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,829,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,003,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,137,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,486,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,389,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,696,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,681,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,850,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,975,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,700,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,818,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,336,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,364,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,421,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,951,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,200,694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,535,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,668,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,428,671)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,194,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(656,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,315,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,551,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from investment in affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,681,401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(485,841)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(750,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss before income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,235,146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,536,452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,685,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,351,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,147,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,536,452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,579,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,288,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;445,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss attributable to Inovio Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,662,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,090,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,387,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,219,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90ZXh0cmVnaW9uOjcxNDI2MDdjNjE1YjQ3MDE5MWViY2ZkNGMzNDAxNzQ1XzIxMw_966faa59-fa6e-44df-97aa-43eee3367cb6">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the quarterly results of operations of the Company for the years ended December&#160;31, 2020 and 2019 (unaudited):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter&#160;Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter&#160;Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter&#160;Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter&#160;Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Consolidated Statements of Operations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue under collaborative research and development arrangements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,003,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue under collaborative research and development arrangements from affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,172,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue, including from affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,580,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,302,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,455,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,376,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,111,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,617,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,110,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,071,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,448,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,920,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,565,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,448,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,559,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,339,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,329,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,180,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,232,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,068,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,984,046)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,846,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,803,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,306,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97,755,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,221,977)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) on investment in affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,951,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,883,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,181,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain on available-for-sale equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,315,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,358,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,050,092)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(152,102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(425,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on deconsolidation of Geneos&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,121,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of convertible bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,177,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on extinguishment of convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,674,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,087,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) before income tax benefit and share in net loss of Geneos&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,415,201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,931,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128,270,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,135,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in net loss of Geneos&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,923,179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,759,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(901,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,338,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,171,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129,172,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,135,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) attributable to Inovio Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,338,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,171,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128,703,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,541,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter&#160;Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter&#160;Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter&#160;Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quarter&#160;Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Consolidated Statements of Operations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue under collaborative research and development arrangements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,770,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue under collaborative research and development arrangements from affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue, including from affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,829,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,003,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,137,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,486,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,389,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,696,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,681,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,850,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,975,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,700,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,818,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,336,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,364,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,421,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,951,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,200,694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,535,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,668,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,428,671)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,194,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(656,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,315,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,551,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from investment in affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,681,401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(485,841)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(750,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss before income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,235,146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,536,452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,685,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,351,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,147,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,536,452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,579,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,288,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;445,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss attributable to Inovio Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,662,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,090,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,387,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,219,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if88d7d6e81274ed0ba37814cb46d85e5_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzQtMS0xLTEtMA_d38db849-d36c-425b-b0ae-3dd1b7b2f431"
      unitRef="usd">5003494</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i573ba12b81674a4e8f8ea7ef32efdbe8_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzQtMy0xLTEtMA_7d380d00-e9d4-476b-a7a8-21f95220ba14"
      unitRef="usd">21490</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i795cb1a151064426a4dfe996df0c38c4_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzQtNS0xLTEtMA_6792cae5-e487-4c44-a880-345eb29fae93"
      unitRef="usd">74102</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13703c117a254b43812c022797496182_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzQtNy0xLTEtMA_b72d5a4a-7a77-4370-873b-9503fd79c166"
      unitRef="usd">71500</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67fe64f9d9cc4e94987901784abf46ab_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzUtMS0xLTEtMA_7fe93294-c0c6-4777-a9f9-df178051679c"
      unitRef="usd">82774</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i070e992116654fa581ad7cf2f0c976f3_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzUtMy0xLTEtMA_8ecbd83f-9dfb-401a-bf5b-d366fb63be1c"
      unitRef="usd">103684</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife87feec4ca84488991ff60a2283130f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzUtNS0xLTEtMA_98016138-d559-4890-8ff7-955fbe3f2577"
      unitRef="usd">95146</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d9cc3f0455f498ab2daa193d5030329_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzUtNy0xLTEtMA_335c3211-4a09-4d33-8b28-ef6567ecd056"
      unitRef="usd">1172126</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6d2e46c031143829dacb9e46e09d8e3_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzYtMS0xLTEtMA_51237bc4-3fa2-4fe4-a88d-7524849b9a4e"
      unitRef="usd">494313</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i590abc5d2cd1439bb9b334157e97cf1c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzYtMy0xLTEtMA_20f37ce8-ad04-41eb-90cc-0d57e8d7bc94"
      unitRef="usd">111004</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10e7342c08644032af98955a95c3f840_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzYtNS0xLTEtMA_c23fd3c4-8466-4332-ad79-b5ba59f4be08"
      unitRef="usd">97939</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63f67afbae934928a16259c4523b7b46_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzYtNy0xLTEtMA_11df2260-093b-4d48-98be-6eee5d8b6657"
      unitRef="usd">83648</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzgtMS0xLTEtMA_83332acc-1152-41e7-8fc2-111b49c97f56"
      unitRef="usd">5580581</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzgtMy0xLTEtMA_79ff660f-8622-4c9b-b210-41bd0114ad1e"
      unitRef="usd">236178</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzgtNS0xLTEtMA_758de3ac-48f0-46c6-b3cc-4e2a90330584"
      unitRef="usd">267187</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzgtNy0xLTEtMA_73a96b0d-4a94-4bce-b591-dacbaceb6d38"
      unitRef="usd">1327274</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzEwLTEtMS0xLTA_e08837d7-a31e-420d-80c8-af5eb388dad0"
      unitRef="usd">26302561</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzEwLTMtMS0xLTA_04105173-b494-4502-be64-3fe8cc186a58"
      unitRef="usd">26455112</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzEwLTUtMS0xLTA_c4a9424c-bceb-4526-b52c-8d640ae3d8fc"
      unitRef="usd">22376575</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzEwLTctMS0xLTA_2f14955f-5e16-4eb2-9ed6-ce11c849e221"
      unitRef="usd">19111188</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzExLTEtMS0xLTA_f8aa8069-f21a-44d1-8b0c-1acc4ec98310"
      unitRef="usd">8617458</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzExLTMtMS0xLTA_cc2e6266-5375-4bb4-bdad-dd47273ecabb"
      unitRef="usd">10110506</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzExLTUtMS0xLTA_4aa8d60d-611a-4365-9618-817464236d0b"
      unitRef="usd">11071510</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzExLTctMS0xLTA_654cc10e-415e-461f-8d4b-8f6da54d992f"
      unitRef="usd">7448354</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzEzLTEtMS0xLTA_8ea16746-22a5-4076-b8f2-12443ac0aa79"
      unitRef="usd">34920019</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzEzLTMtMS0xLTA_f8211860-765c-4ea8-bc6b-4651fe73f79d"
      unitRef="usd">36565618</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzEzLTUtMS0xLTA_ff107002-387c-4b22-80e8-9571d6849725"
      unitRef="usd">33448085</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzEzLTctMS0xLTA_06185599-93a2-41c8-8793-ae1f561b345c"
      unitRef="usd">26559542</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE0LTEtMS0xLTA_a98b87c0-d05e-435f-8826-e04f7dda85a9"
      unitRef="usd">-29339438</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE0LTMtMS0xLTA_9aa64360-4953-4e38-8692-998ac1c73288"
      unitRef="usd">-36329440</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE0LTUtMS0xLTA_716f7fd4-d68f-4de9-b474-7c9d7ec54cc2"
      unitRef="usd">-33180898</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE0LTctMS0xLTA_2a735ff1-159e-4c33-84b1-e22f76266c66"
      unitRef="usd">-25232268</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE1LTEtMS0xLTA_0c0835fa-aeda-4f51-b0e7-030b64b3789e"
      unitRef="usd">931168</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE1LTMtMS0xLTA_62a2d57f-f34c-49ba-bb43-7d8c83f721f3"
      unitRef="usd">896710</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE1LTUtMS0xLTA_5bd50360-25a0-4e82-a8fb-00ac9f1d01b6"
      unitRef="usd">1067399</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE1LTctMS0xLTA_f143bb62-b0d1-49df-ae04-4fe34af1ee84"
      unitRef="usd">416569</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE2LTEtMS0xLTA_b1c13bb2-0617-4df4-8277-c222a2b44ee8"
      unitRef="usd">1068008</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE2LTMtMS0xLTA_20951723-b6b3-4e6c-8cb8-25db20485f5a"
      unitRef="usd">1984046</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE2LTUtMS0xLTA_a1c0e6f2-54a6-4c36-a155-7cf23750a28b"
      unitRef="usd">2846641</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE2LTctMS0xLTA_23e9eadf-706c-452b-a927-807afd4d5f27"
      unitRef="usd">2803755</us-gaap:InterestExpense>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE4LTEtMS0xLTA_45601d42-3835-4a11-951c-8b8678103c42"
      unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE4LTMtMS0xLTA_ed84de9a-dfc9-4d44-a785-0c35d0015a02"
      unitRef="usd">35306000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE4LTUtMS0xLTA_1188624a-0fe2-44fb-8e61-9c00b4bee37a"
      unitRef="usd">-97755000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE4LTctMS0xLTA_6516b6fe-4e4f-4ac8-be79-90b56ee38225"
      unitRef="usd">-13221977</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE5LTEtMS0xLTA_0b1efe38-2524-48cd-892e-0dbc393b9727"
      unitRef="usd">306317</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE5LTMtMS0xLTA_f2c8457f-d0ac-4077-a813-eac5251ca861"
      unitRef="usd">26951898</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE5LTUtMS0xLTA_e224f1f1-103a-4ac8-8290-f3face94a68c"
      unitRef="usd">-3883176</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE5LTctMS0xLTA_525514e5-53a0-4925-9890-836d4dd850ad"
      unitRef="usd">13181619</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE5LTEtMS0xLTEwNjk_a55772d8-4dd9-45ea-a44a-1f3c96d328ac"
      unitRef="usd">1070975</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE5LTMtMS0xLTEwNjk_9003095a-622e-4311-b579-08f528b5ed37"
      unitRef="usd">1315980</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE5LTUtMS0xLTEwNzg_6ba044c5-5dc5-4bfa-a62f-add0c7545482"
      unitRef="usd">4358634</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzE5LTctMS0xLTEwNzg_9574bc5c-869c-461c-b05b-589a9f4cf266"
      unitRef="usd">-5050092</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIwLTEtMS0xLTA_1875043a-f698-47ab-aa1d-6a4eaeb8ed8d"
      unitRef="usd">9350</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIwLTMtMS0xLTA_48216014-0d90-4be2-b5f2-734a9b369326"
      unitRef="usd">-136644</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIwLTUtMS0xLTA_63ed8856-5cb3-4b7b-ac13-56fdc16a5285"
      unitRef="usd">-152102</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIwLTctMS0xLTA_24c36919-2171-43f7-a2e6-ebaad0fb4917"
      unitRef="usd">-425500</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIxLTEtMS0xLTEwNjk_c86a62f3-549a-4f43-801e-682551e523b8"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIxLTMtMS0xLTEwNjk_5833dc7e-f2cf-48fb-9d65-2e19b22234f1"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIxLTUtMS0xLTEwNzg_0396b8b7-c0f8-4eae-b3bb-9d391cc1849e"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIxLTctMS0xLTEwNzg_b46acd9a-4d66-4bf7-97ab-14e62d430f1b"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6b066217c7b540b2bc2fabd939e07804_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIyLTEtMS0xLTEwNjk_b7f72600-e3a5-4c51-85fe-b335e84c149d"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8b1addc1c587493fa83cae1c6f2f7fc9_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIyLTMtMS0xLTEwNjk_da3b0a85-b863-4261-b8d6-13798739d67d"
      unitRef="usd">-8177043</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ica64d2e3910943c8a4e37fa1fe5e8214_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIyLTUtMS0xLTEwNzg_0ff193f9-5e84-459a-8b9c-36c2f2636a77"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6e09b6ad2e474af5bfdec3ff92271d9f_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIyLTctMS0xLTEwNzg_a6b412d7-83b7-4045-a95e-2b5c993e078c"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ifdb7d9b899e44f18bf0403f267912de3_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIzLTEtMS0xLTEwNjk_fc1b0129-fc4a-4453-996e-5dda8ea2057b"
      unitRef="usd">5674435</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ib072c12c52ab4aeda860c97446fc70b6_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIzLTMtMS0xLTEwNjk_3d74727e-2ed9-4c7a-b864-71546b111f25"
      unitRef="usd">3087595</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie49e671657294b3c8baefe0969b6bae7_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIzLTUtMS0xLTEwNzg_27bf8532-fad1-423f-b508-8476d0e39efd"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9a5a1a01c5584587899e703311afd962_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIzLTctMS0xLTEwNzg_75365766-468e-4283-86f2-ea674fd2d6d6"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIxLTEtMS0xLTA_e48e44f6-bb96-4e45-b4f5-edecd0ef6b8d"
      unitRef="usd">-22415201</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIxLTMtMS0xLTA_2418b106-2e83-4a6b-a86a-b0ebe76ff8a7"
      unitRef="usd">20931010</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIxLTUtMS0xLTA_2aa6d0a1-6b14-40ba-ac4e-e6f50d352722"
      unitRef="usd">-128270709</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIxLTctMS0xLTA_1ab44cd1-6d8f-46e2-bdd5-c70566544e6c"
      unitRef="usd">-33135404</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI2LTEtMS0xLTEwNzM_50a58d19-9ce7-4985-867d-cb022b9dddc5"
      unitRef="usd">-1923179</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI2LTMtMS0xLTEwNzM_90692c91-6aae-44a8-97f9-4b4d293964e6"
      unitRef="usd">-1759674</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI2LTUtMS0xLTEwODI_8f947552-4c9c-45a4-9fea-6ab2e8b9f1e9"
      unitRef="usd">-901757</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI2LTctMS0xLTEwODI_d5768e31-bc10-42aa-9f7c-949c705c728b"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIzLTEtMS0xLTA_dc76362f-d1a2-4b6b-9cd9-b28a85134645"
      unitRef="usd">-24338380</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIzLTMtMS0xLTA_4adc9d9a-03ff-431d-bb2d-b239a5e0a959"
      unitRef="usd">19171336</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIzLTUtMS0xLTA_a1107ab3-9a94-4de0-ad5b-e044cdd1f518"
      unitRef="usd">-129172466</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzIzLTctMS0xLTA_0d671b4a-ca9a-478b-a931-d9e00a8cdfb4"
      unitRef="usd">-33135404</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI0LTEtMS0xLTA_1b93a588-8d5c-4fc1-8047-fd69035ada67"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI0LTMtMS0xLTA_eabd6eb1-0276-4226-b447-23552c96ad2d"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI0LTUtMS0xLTA_5229cca3-68f1-43d3-91b3-4e0ab191cca8"
      unitRef="usd">-469407</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI0LTctMS0xLTA_5cb7c81c-f815-400d-a9d5-0ca8aa5b945a"
      unitRef="usd">-594350</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI1LTEtMS0xLTA_cdd952e8-39d4-4f5e-8808-2e974ab8dc95"
      unitRef="usd">-24338380</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI1LTMtMS0xLTA_8a935c5a-8bbf-4357-8e90-48f56de2b57f"
      unitRef="usd">19171336</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI1LTUtMS0xLTA_ce83103f-0831-4cf6-a60b-9f981bbb0984"
      unitRef="usd">-128703059</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI1LTctMS0xLTA_424e20d6-7b01-4a07-90a0-0e8a7aeb36f1"
      unitRef="usd">-32541054</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI3LTEtMS0xLTA_f1b0b8ea-925a-4a41-999f-1ff8a741a245"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI3LTMtMS0xLTA_8aa79df2-3983-413f-8adf-94e6efe401d6"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI3LTUtMS0xLTA_3acf9682-dd05-49bb-bf76-0d392a3fe65f"
      unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI3LTctMS0xLTA_6c427db8-cb23-46a1-8f68-5e0edf4649c0"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI4LTEtMS0xLTA_3e0fc8f6-c29b-4224-950a-564b327144ce"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i25ea18478dee4f4b8d14dbbbfc880891_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI4LTMtMS0xLTA_f43dab25-7ee8-4ecb-ad12-e929252b2c5e"
      unitRef="usdPerShare">0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i186117d1662a41d1b4aec9099b4092f3_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI4LTUtMS0xLTA_72839f37-af65-45b6-a9e3-0f71cf003d1b"
      unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i80669d4b60ce4c90bcefaf1df7b2c82e_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZToyYzA5N2FlYzAzZWM0NjY4YWJmYzMwMmJkNDU3M2U5NC90YWJsZXJhbmdlOjJjMDk3YWVjMDNlYzQ2NjhhYmZjMzAyYmQ0NTczZTk0XzI4LTctMS0xLTA_5e7d47e4-19ec-4e0a-b062-f8dc2b91d363"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1af80391a9d7498d9623d41397672588_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzQtMS0xLTEtMA_71e73d37-6bde-4759-8c56-7b487e0b9898"
      unitRef="usd">184523</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97adc1d442cd448fb9146600ab5d2804_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzQtMy0xLTEtMA_44f5165b-e73e-4c2e-aa22-378a88b550ff"
      unitRef="usd">617427</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i270677398e2d488297835140b7cd4b5e_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzQtNS0xLTEtMA_110c3c9c-5d61-4cf6-9ff1-f145ec5b9780"
      unitRef="usd">64283</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab53db1ca1924309875498ea3f081da6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzQtNy0xLTEtMA_4e6d0d6b-4f43-4b51-819f-dcc322774744"
      unitRef="usd">2770712</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if64f1e0018c643a58e89139a5f4c240e_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzUtMS0xLTEtMA_e3ca3cdb-4051-47bb-8514-ae1d60097814"
      unitRef="usd">55665</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c9ec00a3c0e4514abe1f49e7c8af240_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzUtMy0xLTEtMA_0804316c-1ed0-477c-be91-170f20f580ca"
      unitRef="usd">53014</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fdefad67e8242bda643664dba8120e2_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzUtNS0xLTEtMA_be622ce7-4607-406d-a80f-0f89a18befb8"
      unitRef="usd">71390</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb1b5faf5d454621b7facd84a26755bc_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzUtNy0xLTEtMA_1fddf463-d6ad-4d2e-a241-acd27f78b6ad"
      unitRef="usd">55579</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedf7ee151bb8419a90965b37855024f2_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzYtMS0xLTEtMA_011e707c-dd4c-41ff-9da3-33f02d8d86ec"
      unitRef="usd">39300</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie53b02189840498b87e2fd8412e3a928_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzYtMy0xLTEtMA_65091932-3e14-4c5c-94fe-d9f43757710d"
      unitRef="usd">196422</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i606478849fd3433da994e2810ba1aab2_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzYtNS0xLTEtMA_89e8369f-8050-4b94-8f3f-61ac01e90092"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie60fc32c63d143b0a967a81f8d4d95a9_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzYtNy0xLTEtMA_288157fc-65ab-468a-b37f-09c711bfa528"
      unitRef="usd">3614</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzgtMS0xLTEtMA_b40d5a47-3262-4693-b055-e07e6c3b4132"
      unitRef="usd">279488</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzgtMy0xLTEtMA_230836c9-1189-4cd8-828e-6049da390d47"
      unitRef="usd">866863</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzgtNS0xLTEtMA_4ad2a1e5-4e19-41ac-95ef-0cec3d928c61"
      unitRef="usd">135673</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzgtNy0xLTEtMA_13e808a8-9358-4329-b883-6e35f772dca4"
      unitRef="usd">2829905</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzEwLTEtMS0xLTA_f05cff3c-f59a-438e-9086-10213937fd81"
      unitRef="usd">22003955</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzEwLTMtMS0xLTA_71f38aa1-4e02-43b7-a0f0-5e7212190f98"
      unitRef="usd">19137209</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzEwLTUtMS0xLTA_92bb04bc-7a9a-4a3c-aa59-32f8ef975b07"
      unitRef="usd">22486266</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzEwLTctMS0xLTA_00bedacd-7e77-4608-9f0b-810c67fdcdcb"
      unitRef="usd">24389888</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzExLTEtMS0xLTA_b415a22c-001c-4b46-936c-97a2efb59550"
      unitRef="usd">8696586</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzExLTMtMS0xLTA_40b4e658-8d7d-4bb4-b795-8a23c190c1fe"
      unitRef="usd">5681441</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzExLTUtMS0xLTA_1a393c34-afdd-4eef-809d-e0298713a505"
      unitRef="usd">5850101</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzExLTctMS0xLTA_75db5e8f-a04d-44ba-968f-f1fca57ac333"
      unitRef="usd">6975029</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzEzLTEtMS0xLTA_cdc4ba0d-9704-402a-a4b2-1ff33ccf64db"
      unitRef="usd">30700541</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzEzLTMtMS0xLTA_88670209-4566-47db-9513-6c3c67a41ce1"
      unitRef="usd">24818650</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzEzLTUtMS0xLTA_06aaf0fe-5232-404c-b5db-0e255801e984"
      unitRef="usd">28336367</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzEzLTctMS0xLTA_f86825c8-18dc-456e-86d0-dc493bc0eeda"
      unitRef="usd">31364917</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE0LTEtMS0xLTA_3e2033c7-dda9-4a26-a260-e1b2c691d2b1"
      unitRef="usd">-30421053</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE0LTMtMS0xLTA_2f6d4dd1-c59e-448e-9e30-581fe2e2cd2b"
      unitRef="usd">-23951787</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE0LTUtMS0xLTA_dd594e6a-6ad5-4323-9630-9a50d5796e64"
      unitRef="usd">-28200694</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE0LTctMS0xLTA_3fa30ccc-3edd-42ac-89f0-c7490fd01b4e"
      unitRef="usd">-28535012</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE1LTEtMS0xLTA_575808d5-99bd-47ea-b116-cd8c4aaa5bb1"
      unitRef="usd">587679</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE1LTMtMS0xLTA_94bfb88a-ba05-4a01-b158-55ca735a0e96"
      unitRef="usd">637438</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE1LTUtMS0xLTA_112e80fa-afcb-4c75-8835-cd8a4c9a0ffb"
      unitRef="usd">755330</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE1LTctMS0xLTA_8206785e-4e00-4b51-ab7a-a8f22e3ce8f2"
      unitRef="usd">625535</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE2LTEtMS0xLTEwNTI_4bfb7b9e-070e-4d7e-b4a1-fff67b47351b"
      unitRef="usd">2668837</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE2LTMtMS0xLTEwNTI_002d1437-19d5-488d-9ec2-200e4b28ffa2"
      unitRef="usd">2428671</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE2LTUtMS0xLTEwNTI_018f76a2-fe56-4e22-9942-ba2992c3e3d1"
      unitRef="usd">2194783</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE2LTctMS0xLTEwNTI_406fd3c0-75f7-4460-b21b-16aef7787c34"
      unitRef="usd">656248</us-gaap:InterestExpense>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE2LTEtMS0xLTA_412c6d5e-ef6d-4526-a916-a9ceadcb7f5b"
      unitRef="usd">-4315105</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE2LTMtMS0xLTA_9248ed33-44c9-41fa-8c28-42d52879b1a1"
      unitRef="usd">2551453</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE2LTUtMS0xLTA_66a8eef9-7782-48f8-8009-8fc3772ffb51"
      unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE2LTctMS0xLTA_706d8203-e910-4225-a976-4938d8edf85f"
      unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE4LTEtMS0xLTEwNTI_4a7c4587-22b0-4171-8a57-fe311c01a5b4"
      unitRef="usd">-1681401</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE4LTMtMS0xLTEwNTI_5fd66cec-6b5e-4a43-b103-3661b4c5b694"
      unitRef="usd">-485841</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE4LTUtMS0xLTEwNTI_6b8b85c3-5ae1-4785-bea0-a0ac3438825f"
      unitRef="usd">-173212</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE4LTctMS0xLTEwNTI_c3b49976-a0c9-4b2c-8cf7-59395521dfef"
      unitRef="usd">-750103</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE3LTEtMS0xLTA_0280c597-23df-4e56-b066-c4fe35bfa766"
      unitRef="usd">263571</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE3LTMtMS0xLTA_9f10c5a2-41a5-48b3-aadb-5be35dc926d6"
      unitRef="usd">140956</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE3LTUtMS0xLTA_350e5b87-9fcb-462b-9777-4f45392899a7"
      unitRef="usd">127512</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE3LTctMS0xLTA_a708515d-fdfe-482a-a100-93dc8aa1b0c0"
      unitRef="usd">-35839</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE4LTEtMS0xLTA_8f2d216e-b422-469b-a562-ce2410aa8783"
      unitRef="usd">-38235146</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE4LTMtMS0xLTA_5d1bce2b-08dd-416f-8a9e-5b8f2c9c9d7f"
      unitRef="usd">-23536452</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE4LTUtMS0xLTA_5df6de44-a968-4aa4-9859-055d48f4ab0d"
      unitRef="usd">-29685847</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE4LTctMS0xLTA_0f52f81d-8d64-4f1e-af60-d2fb98282d8e"
      unitRef="usd">-29351667</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE5LTEtMS0xLTA_936db1ae-ebe4-4d69-9e8f-3de6ab8659e6"
      unitRef="usd">-87764</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE5LTMtMS0xLTA_048dd203-cb36-47f4-b1d3-1e3035abc049"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE5LTUtMS0xLTA_2f0fff01-c3d9-4862-bcb6-4f4c90500ae4"
      unitRef="usd">-106771</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzE5LTctMS0xLTA_d4ad3ed0-97e4-470d-9a26-f6923c14004b"
      unitRef="usd">-62800</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIwLTEtMS0xLTA_10470330-8046-4a70-be5a-92d13b1af901"
      unitRef="usd">-38147382</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIwLTMtMS0xLTA_b62b0425-f0bd-4aa5-9b0e-f4400d36fbb0"
      unitRef="usd">-23536452</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIwLTUtMS0xLTA_da773161-1156-46fa-88ce-61dad51117f8"
      unitRef="usd">-29579076</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIwLTctMS0xLTA_f562996e-866f-41e4-a848-0065b536c846"
      unitRef="usd">-29288867</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIxLTEtMS0xLTA_991d15df-be02-4cdc-ba25-5167137fdc74"
      unitRef="usd">-485344</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIxLTMtMS0xLTA_dba4beeb-a7d4-4878-b4a7-1231a4b13938"
      unitRef="usd">-445759</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIxLTUtMS0xLTA_108a8666-a8d5-45e3-b980-112fd18a4066"
      unitRef="usd">-191850</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIxLTctMS0xLTA_c7773e12-f895-4868-8eb3-4bd93a686c88"
      unitRef="usd">-69605</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIyLTEtMS0xLTA_c6f86a39-f9e7-433a-ba8b-6344c91f6bbe"
      unitRef="usd">-37662038</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIyLTMtMS0xLTA_c0ea27d7-d09b-4626-b822-b90f1519c3e4"
      unitRef="usd">-23090693</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIyLTUtMS0xLTA_3ae1d623-64f9-4475-81f6-26cb09aa0c55"
      unitRef="usd">-29387226</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzIyLTctMS0xLTA_301670da-0c8b-4f7f-8ffa-8a47f57afe37"
      unitRef="usd">-29219262</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzI0LTEtMS0xLTA_7974b278-eec8-48ab-b98a-735b75b3db5f"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzI0LTMtMS0xLTA_8b86d6db-2a2c-4eae-9128-8f704e71fa8e"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzI0LTUtMS0xLTA_e0940dce-08da-43f8-8862-b80afaa25de7"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzI0LTctMS0xLTA_58be537c-cb3f-4bc0-b1b2-9cf6f43444c3"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i748a768d51414cce859cb0837e99006b_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzI1LTEtMS0xLTA_c1b9f407-30f3-4694-a47c-8ddc77441e94"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icf38e2b9aa614e0ab891a192c6173df4_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzI1LTMtMS0xLTA_a3401424-2162-4b2f-8b84-5c24cee14244"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7c6db7698a064eee933877749271a1c0_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzI1LTUtMS0xLTA_ae38914d-64a0-401f-aa22-3e3f86536cb9"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idc3cef93ee01414888d89f68ab3dbe22_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMDgvZnJhZzo3MTQyNjA3YzYxNWI0NzAxOTFlYmNmZDRjMzQwMTc0NS90YWJsZTpjMzE4ZmYzOGU2N2U0ZjM2OWIzN2EyYWM4NjNmYjc5MC90YWJsZXJhbmdlOmMzMThmZjM4ZTY3ZTRmMzY5YjM3YTJhYzg2M2ZiNzkwXzI1LTctMS0xLTA_e90b1e26-e4d3-405d-8e98-0dba50fd4012"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMTEvZnJhZzo0YjQyMTlmM2QzZDU0NTkwOTc5ZjcxNGVkODNjMDgzNC90ZXh0cmVnaW9uOjRiNDIxOWYzZDNkNTQ1OTA5NzlmNzE0ZWQ4M2MwODM0XzE4NDU_a01803bf-b9df-4faf-86fb-ea86cee74bf9">Subsequent EventsOn January 25, 2021, the Company closed an underwritten public offering of 20,355,000 shares of the Company's common stock at a public offering price of $8.50 per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other estimated offering expenses, were $162.1&#160;million.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if258c2eac36b42adb8115f070d01b735_D20210125-20210125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMTEvZnJhZzo0YjQyMTlmM2QzZDU0NTkwOTc5ZjcxNGVkODNjMDgzNC90ZXh0cmVnaW9uOjRiNDIxOWYzZDNkNTQ1OTA5NzlmNzE0ZWQ4M2MwODM0XzMyOTg1MzQ4ODgzMTY_4a15f295-e485-4ab1-93e1-8191f01ffd49"
      unitRef="shares">20355000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i6888c79a29d34124835456052fe2309e_I20210125"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMTEvZnJhZzo0YjQyMTlmM2QzZDU0NTkwOTc5ZjcxNGVkODNjMDgzNC90ZXh0cmVnaW9uOjRiNDIxOWYzZDNkNTQ1OTA5NzlmNzE0ZWQ4M2MwODM0XzMyOTg1MzQ4ODgzMjg_dd05b611-1ff1-4abc-a235-b9c1f6c84321"
      unitRef="usdPerShare">8.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes
      contextRef="i6888c79a29d34124835456052fe2309e_I20210125"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8yMTEvZnJhZzo0YjQyMTlmM2QzZDU0NTkwOTc5ZjcxNGVkODNjMDgzNC90ZXh0cmVnaW9uOjRiNDIxOWYzZDNkNTQ1OTA5NzlmNzE0ZWQ4M2MwODM0XzMyOTg1MzQ4ODgzMzU_2fdf1e68-78f4-49e4-9637-5aa419200248"
      unitRef="usd">162100000</us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTE3LTEtMS0w_cc5c860d-7f6b-4e8e-b5ce-8cd85ed11ea6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTE3LTEtMS0w_cc5c860d-7f6b-4e8e-b5ce-8cd85ed11ea6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTExLTEtMS0w_bdc02a01-e7e8-4a2a-9036-379da004ddf3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTExLTEtMS0w_bdc02a01-e7e8-4a2a-9036-379da004ddf3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTEzLTEtMS0w_3be9cd88-22ff-4670-9e3c-923cb963bbe8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTEzLTEtMS0w_3be9cd88-22ff-4670-9e3c-923cb963bbe8"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90ZXh0cmVnaW9uOmRlZGFlNzNlM2MyMTRiYjJhYWY1NGIxZTdiM2FiNzMzXzExNDY_195c7e0a-b8ba-4aef-9e33-54bfb12e8a43" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90ZXh0cmVnaW9uOmRlZGFlNzNlM2MyMTRiYjJhYWY1NGIxZTdiM2FiNzMzXzExNDY_195c7e0a-b8ba-4aef-9e33-54bfb12e8a43" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Upon adoption of ASU 2016-01 on January 1, 2018, the Company began to measure and record equity investments, except those accounted for under the equity method of accounting that have a readily determinable fair value, at fair value and began to recognize the changes in fair value in its consolidated statements of operations, instead of recognizing unrealized gains and losses through accumulated other comprehensive income (loss), as done under the previous guidance. The Company recorded a $231,000 cumulative effect adjustment to reclassify the cumulative unrealized gain, net of tax effect, from its investment in an affiliated entity, PLS, from accumulated other comprehensive loss to accumulated deficit.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTE3LTEtMS0w_cc5c860d-7f6b-4e8e-b5ce-8cd85ed11ea6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90ZXh0cmVnaW9uOmRlZGFlNzNlM2MyMTRiYjJhYWY1NGIxZTdiM2FiNzMzXzExNDY_195c7e0a-b8ba-4aef-9e33-54bfb12e8a43"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTExLTEtMS0w_bdc02a01-e7e8-4a2a-9036-379da004ddf3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90ZXh0cmVnaW9uOmRlZGFlNzNlM2MyMTRiYjJhYWY1NGIxZTdiM2FiNzMzXzExNDY_195c7e0a-b8ba-4aef-9e33-54bfb12e8a43"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90YWJsZTo0ODUyZWRjZGM5MGY0YmI2YjJkNzFhNWM2ODgyNzBjMi90YWJsZXJhbmdlOjQ4NTJlZGNkYzkwZjRiYjZiMmQ3MWE1YzY4ODI3MGMyXzc3LTEzLTEtMS0w_3be9cd88-22ff-4670-9e3c-923cb963bbe8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xMjcvZnJhZzpkZWRhZTczZTNjMjE0YmIyYWFmNTRiMWU3YjNhYjczMy90ZXh0cmVnaW9uOmRlZGFlNzNlM2MyMTRiYjJhYWY1NGIxZTdiM2FiNzMzXzExNDY_195c7e0a-b8ba-4aef-9e33-54bfb12e8a43"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351126392552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 26, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOVIO PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. Germantown Pike<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Plymouth Meeting<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">COMMON STOCK, $0.001 PAR VALUE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,632,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive proxy statement to be filed with the Commission pursuant to Regulation&#160;14A in connection with the registrant&#8217;s 2021 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8217;) are incorporated by reference into Part&#160;III of this Report. Such Proxy Statement will be filed with the Commission not later than 120&#160;days after the conclusion of the registrant&#8217;s fiscal year ended December&#160;31, 2020.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351132039816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 250,728,118<span></span>
</td>
<td class="nump">$ 22,196,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">160,914,935<span></span>
</td>
<td class="nump">67,338,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">18,559,967<span></span>
</td>
<td class="nump">700,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from affiliated entities</a></td>
<td class="nump">503,782<span></span>
</td>
<td class="nump">1,332,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">40,357,456<span></span>
</td>
<td class="nump">1,584,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity', window );">Prepaid expenses and other current assets from affiliated entities</a></td>
<td class="nump">106,432<span></span>
</td>
<td class="nump">1,050,140<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">471,170,690<span></span>
</td>
<td class="nump">94,200,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">11,348,144<span></span>
</td>
<td class="nump">12,773,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entities</a></td>
<td class="nump">4,460,366<span></span>
</td>
<td class="nump">6,315,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="nump">434,387<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,146,770<span></span>
</td>
<td class="nump">3,693,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">12,741,296<span></span>
</td>
<td class="nump">13,783,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">25,957,448<span></span>
</td>
<td class="nump">2,672,024<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">539,772,472<span></span>
</td>
<td class="nump">143,951,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">21,203,808<span></span>
</td>
<td class="nump">18,237,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accounts payable and accrued expenses due to affiliated entities</a></td>
<td class="nump">642,969<span></span>
</td>
<td class="nump">729,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">9,950,345<span></span>
</td>
<td class="nump">4,049,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">46,628<span></span>
</td>
<td class="nump">92,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredRevenueFromAffiliatedEntityCurrent', window );">Deferred revenue from affiliated entities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">2,329,394<span></span>
</td>
<td class="nump">2,074,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="nump">7,474,310<span></span>
</td>
<td class="nump">6,065,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliateCurrent', window );">Grant funding liability from affiliated entities</a></td>
<td class="nump">58,500<span></span>
</td>
<td class="nump">708,425<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">41,705,954<span></span>
</td>
<td class="nump">31,989,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">79,214<span></span>
</td>
<td class="nump">101,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,819,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">18,063,515<span></span>
</td>
<td class="nump">20,409,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">32,046<span></span>
</td>
<td class="nump">32,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliateNoncurrent', window );">Grant funding liability from affiliated entity, net of current portion</a></td>
<td class="nump">37,500<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">57,663<span></span>
</td>
<td class="nump">36,943<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">78,631,714<span></span>
</td>
<td class="nump">138,546,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Inovio Pharmaceuticals, Inc. stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock&#8212;par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December&#160;31, 2020 and 23 at December&#160;31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;par value $0.001; Authorized shares: 600,000,000 at December 31, 2020 and December 31, 2019, issued and outstanding: 186,851,493 at December&#160;31, 2020 and 101,361,034 at December&#160;31, 2019</a></td>
<td class="nump">186,851<span></span>
</td>
<td class="nump">101,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,367,406,869<span></span>
</td>
<td class="nump">742,646,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(906,196,812)<span></span>
</td>
<td class="num">(739,785,655)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(256,150)<span></span>
</td>
<td class="nump">472,608<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</a></td>
<td class="nump">461,140,758<span></span>
</td>
<td class="nump">3,435,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,969,759<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">461,140,758<span></span>
</td>
<td class="nump">5,404,858<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">539,772,472<span></span>
</td>
<td class="nump">143,951,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="nump">14,139,988<span></span>
</td>
<td class="nump">64,180,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember', window );">Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="nump">$ 4,515,834<span></span>
</td>
<td class="nump">$ 12,842,592<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expense, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliateNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliateNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredRevenueFromAffiliatedEntityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable from related parties as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredRevenueFromAffiliatedEntityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351132582040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">186,851,493<span></span>
</td>
<td class="nump">101,361,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">186,851,493<span></span>
</td>
<td class="nump">101,361,034<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351131973192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 7,411,220<span></span>
</td>
<td class="nump">$ 4,111,930<span></span>
</td>
<td class="nump">$ 30,481,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">94,245,436<span></span>
</td>
<td class="nump">88,017,319<span></span>
</td>
<td class="nump">95,257,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">37,247,828<span></span>
</td>
<td class="nump">27,203,156<span></span>
</td>
<td class="nump">29,315,159<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">131,493,264<span></span>
</td>
<td class="nump">115,220,475<span></span>
</td>
<td class="nump">124,573,035<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(124,082,044)<span></span>
</td>
<td class="num">(111,108,545)<span></span>
</td>
<td class="num">(94,091,138)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">3,311,846<span></span>
</td>
<td class="nump">2,605,981<span></span>
</td>
<td class="nump">2,264,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(8,702,450)<span></span>
</td>
<td class="num">(7,948,539)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInFairValueOfCommonStockWarrants', window );">Change in fair value of common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">360,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="num">(75,670,977)<span></span>
</td>
<td class="num">(1,763,652)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Gain (loss) on investment in affiliated entities</a></td>
<td class="nump">36,556,658<span></span>
</td>
<td class="num">(3,090,557)<span></span>
</td>
<td class="num">(1,988,567)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain on available-for-sale equity securities</a></td>
<td class="nump">1,695,497<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(704,896)<span></span>
</td>
<td class="nump">496,200<span></span>
</td>
<td class="num">(1,343,856)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="nump">4,121,075<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax benefit/(provision for income tax)</a></td>
<td class="num">(162,890,304)<span></span>
</td>
<td class="num">(120,809,112)<span></span>
</td>
<td class="num">(94,798,019)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (provision for income taxes)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">257,335<span></span>
</td>
<td class="num">(2,169,811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="num">(4,584,610)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(167,474,914)<span></span>
</td>
<td class="num">(120,551,777)<span></span>
</td>
<td class="num">(96,967,830)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="nump">1,063,757<span></span>
</td>
<td class="nump">1,192,558<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="num">$ (166,411,157)<span></span>
</td>
<td class="num">$ (119,359,219)<span></span>
</td>
<td class="num">$ (96,967,830)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in USD per share)</a></td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted average number of common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in shares)</a></td>
<td class="nump">155,126,857<span></span>
</td>
<td class="nump">98,717,999<span></span>
</td>
<td class="nump">92,539,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember', window );">Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="num">$ (8,177,043)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="nump">8,762,030<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5,170,586<span></span>
</td>
<td class="nump">3,636,945<span></span>
</td>
<td class="nump">29,860,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember', window );">Revenue under collaborative research and development arrangements from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,453,730<span></span>
</td>
<td class="nump">235,649<span></span>
</td>
<td class="nump">449,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ino_OtherRevenueMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">786,904<span></span>
</td>
<td class="nump">237,536<span></span>
</td>
<td class="nump">171,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ino_OtherRevenueAffiliatedEntityMember', window );">Other revenue from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInFairValueOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of common stock warrants which are measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInFairValueOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_OtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_OtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_OtherRevenueAffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_OtherRevenueAffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351128845720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (167,474,914)<span></span>
</td>
<td class="num">$ (120,551,777)<span></span>
</td>
<td class="num">$ (96,967,830)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">27,205<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="num">(755,963)<span></span>
</td>
<td class="nump">1,001,475<span></span>
</td>
<td class="num">(180,496)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(168,203,672)<span></span>
</td>
<td class="num">(119,550,302)<span></span>
</td>
<td class="num">(97,148,326)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to non-controlling interest</a></td>
<td class="nump">1,063,757<span></span>
</td>
<td class="nump">1,192,558<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="num">$ (167,139,915)<span></span>
</td>
<td class="num">$ (118,357,744)<span></span>
</td>
<td class="num">$ (97,148,326)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351120560904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>6.50% Convertible Senior Notes Due 2024</div></th>
<th class="th"><div>August 2019 Bonds</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th">
<div>Common stock </div>
<div>6.50% Convertible Senior Notes Due 2024</div>
</th>
<th class="th">
<div>Common stock </div>
<div>August 2019 Bonds</div>
</th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>6.50% Convertible Senior Notes Due 2024</div>
</th>
<th class="th">
<div>Additional paid-in capital </div>
<div>August 2019 Bonds</div>
</th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th">
<div>Accumulated deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th">
<div>Accumulated other comprehensive income (loss) </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Non- controlling interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">90,357,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 142,488,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 90,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 665,775,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (523,356,317)<span></span>
</td>
<td colspan="2" class="nump">$ 231,366<span></span>
</td>
<td class="num">$ (117,005)<span></span>
</td>
<td colspan="2" class="num">$ (231,366)<span></span>
</td>
<td class="nump">$ 96,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,669,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash</a></td>
<td class="nump">29,227,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,222,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,199,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments</a></td>
<td class="nump">1,809,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,808,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,654,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,988,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(333,655)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(96,967,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,967,830)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="num">(180,496)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(180,496)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">97,225,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="nump">87,032,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 97,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">707,794,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(620,426,436)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(528,867)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">96,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,340,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash</a></td>
<td class="nump">9,089,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,085,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">794,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments</a></td>
<td class="num">(780,405)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(781,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of issuance of convertible notes</a></td>
<td class="nump">15,752,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,752,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,901,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,795,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">105,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Acquisition of non-controlling interest in Geneos, net</a></td>
<td class="nump">2,960,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">2,960,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(120,551,777)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119,359,219)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(1,192,558)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">1,001,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">1,001,475<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">101,361,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">5,404,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 101,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742,646,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(739,785,655)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">472,608<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">1,969,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,064,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash</a></td>
<td class="nump">454,486,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454,420,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock/senior notes to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">5,147<span></span>
</td>
<td class="nump">11,535,660<span></span>
</td>
<td class="nump">4,962,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock/senior notes to common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 43,694,386<span></span>
</td>
<td class="nump">$ 102,671,310<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 11,536<span></span>
</td>
<td class="nump">$ 4,961<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">$ 43,682,850<span></span>
</td>
<td class="nump">$ 102,666,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,922,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments</a></td>
<td class="nump">8,241,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,238,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">15,647,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,655,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(8,062)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Acquisition of non-controlling interest in Geneos, net</a></td>
<td class="nump">2,379,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">2,379,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Deconsolidation of Geneos</a></td>
<td class="num">(3,181,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(3,181,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(167,474,914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(166,411,157)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(1,063,757)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Dissolution of majority-owned subsidiary VGX Animal Health, Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(96,269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="num">(755,963)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(755,963)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">27,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">27,205<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">186,851,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 461,140,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 186,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,367,406,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (906,196,812)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">$ (256,150)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="20"></td></tr>
<tr><td colspan="20"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Upon adoption of ASU 2016-01 on January 1, 2018, the Company began to measure and record equity investments, except those accounted for under the equity method of accounting that have a readily determinable fair value, at fair value and began to recognize the changes in fair value in its consolidated statements of operations, instead of recognizing unrealized gains and losses through accumulated other comprehensive income (loss), as done under the previous guidance. The Company recorded a $231,000 cumulative effect adjustment to reclassify the cumulative unrealized gain, net of tax effect, from its investment in an affiliated entity, PLS, from accumulated other comprehensive loss to accumulated deficit.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351127095240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (167,474,914)<span></span>
</td>
<td class="num">$ (120,551,777)<span></span>
</td>
<td class="num">$ (96,967,830)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">3,038,996<span></span>
</td>
<td class="nump">3,598,388<span></span>
</td>
<td class="nump">3,747,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">547,081<span></span>
</td>
<td class="nump">1,066,294<span></span>
</td>
<td class="nump">1,249,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AmortizationOfOperatingLeaseRightOfUseAssets', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">1,041,713<span></span>
</td>
<td class="nump">851,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfCommonStockWarrants', window );">Change in fair value of common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(360,795)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value of derivative liability</a></td>
<td class="nump">75,670,977<span></span>
</td>
<td class="nump">1,763,652<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">15,647,523<span></span>
</td>
<td class="nump">10,901,320<span></span>
</td>
<td class="nump">10,654,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">4,077,686<span></span>
</td>
<td class="nump">5,230,954<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfPremium', window );">Amortization of premiums on investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,962<span></span>
</td>
<td class="nump">72,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,397<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss (gain) on short-term investments</a></td>
<td class="nump">588,270<span></span>
</td>
<td class="num">(476,368)<span></span>
</td>
<td class="nump">1,342,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity', window );">Settlement of receivable with shares of common stock from affiliated entity (PLS)</a></td>
<td class="num">(1,713,770)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="num">(4,121,075)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">26,913<span></span>
</td>
<td class="nump">5,889<span></span>
</td>
<td class="nump">14,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">(Gain) loss on equity investment in affiliated entities</a></td>
<td class="num">(36,556,658)<span></span>
</td>
<td class="nump">3,090,557<span></span>
</td>
<td class="nump">1,988,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Share of net loss in Geneos</a></td>
<td class="nump">4,584,610<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Net unrealized gain on available-for-sale equity securities</a></td>
<td class="num">(1,695,497)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Tax benefit from other unrealized gains on short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(266,215)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Unrealized transaction loss on foreign-currency denominated debt</a></td>
<td class="nump">15,902<span></span>
</td>
<td class="nump">471,172<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(17,859,894)<span></span>
</td>
<td class="nump">2,616,288<span></span>
</td>
<td class="nump">2,686,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Accounts receivable from affiliated entities</a></td>
<td class="nump">844,423<span></span>
</td>
<td class="num">(593,461)<span></span>
</td>
<td class="num">(251,964)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(38,849,572)<span></span>
</td>
<td class="num">(178,008)<span></span>
</td>
<td class="nump">1,194,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity', window );">Prepaid expenses and other current assets from affiliated entities</a></td>
<td class="nump">374,107<span></span>
</td>
<td class="nump">70,665<span></span>
</td>
<td class="nump">725,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(23,285,424)<span></span>
</td>
<td class="num">(2,026)<span></span>
</td>
<td class="num">(30,644)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">3,115,828<span></span>
</td>
<td class="num">(4,337,829)<span></span>
</td>
<td class="nump">550,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense', window );">Accrued clinical trial expenses</a></td>
<td class="nump">5,962,381<span></span>
</td>
<td class="num">(1,622,037)<span></span>
</td>
<td class="num">(2,940,128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accounts payable and accrued expenses due to affiliated entities</a></td>
<td class="nump">135,650<span></span>
</td>
<td class="num">(248,063)<span></span>
</td>
<td class="nump">50,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(68,078)<span></span>
</td>
<td class="num">(180,450)<span></span>
</td>
<td class="num">(1,016,836)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties', window );">Deferred revenue from affiliated entities</a></td>
<td class="nump">5,725<span></span>
</td>
<td class="num">(1,800)<span></span>
</td>
<td class="num">(140,535)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StraightLineRent', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(398,357)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet', window );">Operating lease right-of-use assets and liabilities, net</a></td>
<td class="num">(2,091,855)<span></span>
</td>
<td class="num">(1,733,599)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="nump">1,409,098<span></span>
</td>
<td class="nump">1,899,364<span></span>
</td>
<td class="nump">4,165,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent', window );">Grant funding liability from affiliated entities</a></td>
<td class="num">(784,925)<span></span>
</td>
<td class="nump">816,342<span></span>
</td>
<td class="nump">27,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">20,720<span></span>
</td>
<td class="num">(48,507)<span></span>
</td>
<td class="nump">87,333<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(177,979,046)<span></span>
</td>
<td class="num">(97,850,136)<span></span>
</td>
<td class="num">(73,550,156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="num">(156,216,677)<span></span>
</td>
<td class="num">(100,950,301)<span></span>
</td>
<td class="num">(88,155,046)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale of or maturity of investments</a></td>
<td class="nump">62,991,023<span></span>
</td>
<td class="nump">92,893,232<span></span>
</td>
<td class="nump">132,659,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of capital assets</a></td>
<td class="num">(1,520,665)<span></span>
</td>
<td class="num">(987,926)<span></span>
</td>
<td class="num">(2,085,022)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ProceedsFromSaleOfEquitySecuritiesFVNI', window );">Proceeds from sale of investment</a></td>
<td class="nump">40,125,418<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Decrease of cash resulting from the deconsolidation of Geneos</a></td>
<td class="num">(2,774,851)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Investment in Geneos</a></td>
<td class="num">(1,399,999)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(58,795,751)<span></span>
</td>
<td class="num">(9,044,995)<span></span>
</td>
<td class="nump">42,419,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuances of convertible senior notes and convertible bonds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">97,443,617<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Costs related to issuances of convertible senior notes and convertible bonds</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,314,757)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">454,486,400<span></span>
</td>
<td class="nump">9,089,010<span></span>
</td>
<td class="nump">29,227,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ProceedsfromStockOptionandWarrantExercises', window );">Proceeds from stock option and warrant exercises, net of tax payments</a></td>
<td class="nump">12,269,801<span></span>
</td>
<td class="nump">112,522<span></span>
</td>
<td class="nump">2,421,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings', window );">Taxes paid related to net share settlement of equity awards, net of proceeds from option exercises</a></td>
<td class="num">(4,028,177)<span></span>
</td>
<td class="num">(892,928)<span></span>
</td>
<td class="num">(611,610)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Acquisition of non-controlling interest</a></td>
<td class="nump">2,379,969<span></span>
</td>
<td class="nump">2,960,131<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Geneos issuance of note payable</a></td>
<td class="nump">171,620<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">465,279,613<span></span>
</td>
<td class="nump">105,397,595<span></span>
</td>
<td class="nump">31,037,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">27,205<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">228,532,021<span></span>
</td>
<td class="num">(1,497,536)<span></span>
</td>
<td class="num">(92,946)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">22,196,097<span></span>
</td>
<td class="nump">23,693,633<span></span>
</td>
<td class="nump">23,786,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">250,728,118<span></span>
</td>
<td class="nump">22,196,097<span></span>
</td>
<td class="nump">23,693,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts accrued for purchases of property and equipment</a></td>
<td class="nump">136,711<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">559,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">4,624,764<span></span>
</td>
<td class="nump">2,717,585<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EquityComponentOfConvertibleDebtIssued', window );">Equity component of issuance of convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,752,698<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,634,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="nump">8,177,043<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="num">$ (8,762,030)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AmortizationOfOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Operating Lease Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AmortizationOfOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period in the fair value of common stock warrants, which are revalued at each balance sheet date subsequent to initial receipt or issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EquityComponentOfConvertibleDebtIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Component Of Convertible Debt Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EquityComponentOfConvertibleDebtIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInAccruedClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromSaleOfEquitySecuritiesFVNI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Equity Securities, FV-NI</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromSaleOfEquitySecuritiesFVNI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsfromStockOptionandWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Stock Option and Warrant Exercises</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsfromStockOptionandWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Receivable With Shares Of Common Stock From Equity Security</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of purchase premium on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StraightLineRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between actual rental income due and rental income recognized on a straight-line basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StraightLineRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122271672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">The Company</a></td>
<td class="text">The Company<div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;), is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus (HPV). INOVIO's DNA medicines pipeline is comprised of three types of product candidates: DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies (dMAbs</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In clinical trials, INOVIO has demonstrated that DNA medicines can be delivered directly into cells in the body through its proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted pathogens and cancers. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's novel DNA medicine candidates are made using its proprietary SynCon</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology that uses a computer algorithm designed to identify and optimize the DNA sequence of the target antigen (be it virus or a tumor). INOVIO then creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce antigens to help the person&#8217;s immune system recognize and destroy cancerous or virally infected cells.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's patented CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery devices provide optimized uptake of its DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trial data to date has shown a favorable safety profile of INOVIO's DNA medicines delivered directly into cells in the body using the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart device in more than 7,000 administrations across more than 3,000 patients.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> INOVIO's corporate strategy is to advance, protect and, once approved, commercialize its novel DNA medicines to meet urgent and emerging global health needs. The Company continues to advance and clinically validate an array of DNA medicine candidates that target HPV-associated diseases, cancer, and infectious diseases, such as COVID-19 (SARS-CoV-2). The Company aims to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's partners and collaborators include ApolloBio Corporation.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> AstraZeneca, Beijing Advaccine, The Bill &amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), The U.S. Department of Defense (DoD), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium (MCDC), International Vaccine Institute (IVI), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators are currently conducting or planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis (RRP); glioblastoma multiforme (GBM); prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus).  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122269960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO incurred a net loss attributable to common stockholders of $166.4 million for the year ended December&#160;31, 2020. INOVIO had working capital of $429.5 million and an accumulated deficit of $906.2 million as of December&#160;31, 2020. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and short-term investments of $411.6 million as of December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of potential future At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds under past Sales </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreements of $454.5&#160;million during the year ended December 31, 2020, and net proceeds of $9.1&#160;million under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of $75.7&#160;million from a private placement of 6.50% convertible senior notes due 2024 (the &#8220;Notes&#8221;), net proceeds of $14.5&#160;million from the private placement of 18&#160;billion Korean Won (KRW) (approximately USD $15.0&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of $4.0&#160;million from the private placement of 4.7&#160;billion KRW (approximately USD $4.1&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#8220;Bonds&#8221;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company&#160;may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is closely monitoring the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will impact the Company's business and operations will depend on future developments, including the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, that are highly uncertain.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. As of December 31, 2020 the Company consolidated its wholly-owned subsidiary Inovio Asia LLC.  On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority -owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions have been eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.  Refer to Footnote 19 for further discussion of Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracts with certain of its customers that have represented more than 10% of the Company's total revenues, as discussed in Note 7.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist principally of cash equivalents, short-term investments and investments in affiliated entities. The carrying amounts of cash equivalents approximate the related fair values due to the short-term maturities of these instruments. Investments are recorded at fair value, based on current market valuations. The Company carries convertible notes and bonds at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December&#160;31, 2020 and money market accounts at December 31, 2019.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#8217;s affiliated entity, PLS, at December 31, 2020. Investments included mutual funds and an equity investment in the Company's affiliated entities, PLS and GeneOne, at December 31, 2019. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. No allowance for doubtful accounts was deemed necessary at December&#160;31, 2020 and 2019.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzg3MzY_3ade6400-d079-4bc2-a028-5e2e5c6e9030">three</span> to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets. The Company has not recognized any losses on long-lived assets through December&#160;31, 2020.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Valuation of Intangible Assets and Goodwill</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzk2MDM_9dbc4512-b92b-4a6e-ae6e-052ec9675f3d">two</span> to 18 years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the Company has recorded patents at cost and amortized these costs using the straight-line method over the expected useful lives of the patents or 17 years, whichever is less. Patent cost consists of the consideration paid for patents and related legal costs. New patent costs are expensed as incurred, with patent costs capitalized as of that date continuing to be amortized over the expected life of the patent. License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&#160;31, 2019 and 2018, the Company&#8217;s intangible assets resulting from acquisitions and additional intangibles including previously capitalized patent costs and license costs, net of accumulated amortization, totaled $3.1 million and $3.7 million, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through December&#160;31, 2020.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment as of November 30, 2020, identifying no impairment.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations. See Note&#160;10 for further discussion of the Company&#8217;s goodwill and intangible assets.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances against the Company&#8217;s deferred tax assets were $159.7 million and $137.2 million at December&#160;31, 2020 and 2019, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;Topic 606&#8221;). However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grants</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Liabilities</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company's financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are remeasured at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Investments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.&#160;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMAbs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total trial management costs, sites activated, patients enrolled, and number of patient visits. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 11) has been considered using the "if-converted" method. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2020, 2019 and 2018, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,906,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,265,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,752,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,585,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,190,768&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,737,956&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,449,150&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to restricted stock units and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes forfeitures as they occur. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.42%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.73%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU 2018-07 on January 1, 2019, which generally aligned the accounting for stock-based compensation for non-employees with that of employees. The fair value of the stock options granted to non-employees was estimated using the Black-Scholes pricing model.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.71%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Recently Adopted</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2019-12. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. FASB issued this Update as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 became effective as of the beginning of 2020; however, there was no cumulative effect to be recognized with the early adoption. As of December 31, 2020, there was a loss from continuing operations and a cumulative loss in other comprehensive income and there was therefore no effect on the tax provision for the period ended December 31, 2020. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2016-13</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonably supportable forecast information. The Company adopted ASU 2016-13 on January 1, 2020, and there was no material impact to its consolidated financial statements. The Company will continue to monitor the impact of the coronavirus, SARS-CoV-2 (&#8220;COVID-19&#8221;) outbreak on expected credit losses.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2018-13</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In August 2018, the FASB issued ASU 2018-13, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends certain disclosure requirements over fair value measurements. Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this guidance on January 1, 2020, and there was no material impact to its consolidated financial statement disclosures (see Note 6 for more information about the Company&#8217;s fair value classifications).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2018-18</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In November 2018, the FASB issued ASU 2018-18, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which clarified the interaction between Topic 808, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative </span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Topic 606, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company adopted this guidance on January 1, 2020, and there was no material impact to its consolidated financial statements.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2017-04.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In January 2017, the FASB issued ASU 2017-04,&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#160;</span>("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and there was no material impact to its consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122288408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition  During the year ended December&#160;31, 2020, the Company recognized total revenue under license and other agreements of $5.0 million from Advaccine, $1.4 million from its affiliated entity Plumbline Life Sciences, Inc. ("PLS"), and $1.0 million from various other contracts. Of the total revenue recognized during the year ended December&#160;31, 2020, $127,000 was in deferred revenue as of December 31, 2019. During the year ended December 31, 2019, the Company recognized revenue of $293,000 that was included in deferred revenue at December 31, 2018. Performance obligations are generally satisfied within 12 months of the initial contract date.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122299704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text">Collaborative Agreements <div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. (Advaccine)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a Collaboration and License Agreement (the &#8220;Agreement&#8221;) with Advaccine. Under the terms of the Agreement, the Company has granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;). Advaccine will not have the right to grant sublicenses, other than to affiliated entities, without the Company&#8217;s express prior written consent. As part of the collaboration, Advaccine has also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Advaccine have collaborated since January 2020 to leverage Advaccine&#8217;s clinical development expertise to conduct an early-stage clinical trial in China in parallel with the Company&#8217;s clinical development efforts in the United States and South Korea. In December 2020, the Company and Advaccine announced that they had dosed the first subject in a Phase 2 clinical trial of INO-4800 in China. This trial is independent of the Company&#8217;s ongoing clinical trial of INO-4800, called INNOVATE, being conducted in the United States.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Agreement, Advaccine made an upfront payment to the Company of $3.0&#160;million subsequent to December 31, 2020. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $108.0&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China, if approved. As of December 31, 2020 the Company had earned a $2.0&#160;million milestone payment based on the enrollment of the first subject in the Phase 2 clinical trial for the product in the Advaccine territory. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within Greater China, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#8217;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Agreement, Advaccine will be responsible for the development and commercialization of the licensed products at its own cost and expense and shall use commercially reasonable efforts to develop, obtain and maintain regulatory approval of INO-4800, as well as the Company&#8217;s CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> device and arrays for use in connection with the administration of INO-4800, in each region in Greater China. In the event that the Company has not initiated the planned Phase 3 segment of its ongoing clinical trial of INO-4800 in the United States within one year after entering into the Agreement, Advaccine may elect to conduct a Phase 3 clinical trial outside of Greater China at its own cost and expense for the purposes of obtaining regulatory approval in China, subject to the Company&#8217;s right to review and approve the protocols and design of such a trial.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Agreement, the Company will supply Advaccine&#8217;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#8217;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808, and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606.  The license to INO-4800 in the </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the $3.0&#160;million upfront payment plus the initial $2.0&#160;million milestone payment which was achieved upon contract signing.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Agreement, subject to certain conditions. Advaccine may terminate the Agreement at any time for convenience upon nine months&#8217; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in Greater China, or 18 months&#8217; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $5.0&#160;million was allocated to the license performance obligation. The Company determined that as of December 31, 2020, the transfer of technology has occurred for the use and benefit of the license and accordingly, the performance obligation was fully satisfied.  The Company accordingly has recognized $5.0&#160;million in revenue under collaborative research and development arrangements on the consolidated statement of operations during the year ended December 31, 2020. As of December&#160;31, 2020, the Company had an accounts receivable balance of $7.1 million from Advaccine.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the territories of China, Hong Kong, Macao, Taiwan, and may include Korea in the event that no patent covering&#160;VGX-3100&#160;is issued in China within the three years following the effective date of the ApolloBio Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ApolloBio Agreement, the Company received proceeds of $19.4 million in March 2018, which comprised the upfront payment of $23.0 million less $2.2 million in foreign income taxes and $1.4 million in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the consolidated statement of operations. The Company also incurred advisory fees of $960,000 in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in the United States, China and Korea. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the ApolloBio Agreement under ASC Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the $23.0 million upfront payment.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, 2020 there have been no significant reimbursable program costs under the ApolloBio Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning one year after the effective date for any reason upon 90 days written notice to the Company.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $23.0 million was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. The Company has recorded the gross upfront payment received from ApolloBio of $23.0 million as license revenue on the consolidated statement of operations during the year ended December 31, 2018.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of $27.5 million to the Company in September 2015. AstraZeneca may be obligated to make potential future development and regulatory event-based payments to the Company totaling up to $125 million and potential future commercial event-based payments totaling up to $115 million, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca will fund all development costs associated with MEDI0457 immunotherapy. The Company is entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca can also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2017, the Company had recognized all of the $27.5 million upfront payment as revenue, as all identified materia</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l performance obligations had been met with respect to that payment.&#160;In both December 2018 and March 2019, the Company recognized as revenue $2.0 million in milestone payments from AstraZeneca triggered by AstraZeneca&#8217;s initiation of the Phase 2 portion of ongoing clinical trials in the second and third major indication, respectively, under the agreement. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;11, 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate&#160;preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of $56 million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the years ended December&#160;31, 2020 and 2019, the Company received funding of $6.4 million and $6.3 million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of December&#160;31, 2020, the Company had a grant funding liability balance related to the CEPI grant of $2.6 million recorded as grant funding liability on the consolidated balance sheet related to the CEPI grant. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $9.0&#160;million to develop a vaccine against COVID-19. This initial CEPI funding is intended to support preclinical and clinical development through Phase 1 human testing in the United States of INO-4800, the Company's COVID-19 vaccine candidate against COVID-19. In April 2020, CEPI awarded the Company a grant of $6.9&#160;million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $5.0&#160;million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3&#160;million to support large-scale manufacturing of INO-4800. During the year ended December&#160;31, 2020, the Company received funding of $10.0 million from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of December&#160;31, 2020 the Company had $3.4&#160;million recorded as deferred grant funding on the consolidated balance sheet related to the CEPI grants related to INO-4800.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Bill &amp; Melinda Gates Foundation (&#8220;Gates&#8221;) awarded and funded the Company a grant of $2.2&#160;million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1&#160;million for the project. During the years ended December&#160;31, 2020 and 2019, the Company recorded $463,000 and $2.1 million, respectively, as contra-research and development expense related to the Gates dMAb grant. As of December&#160;31, 2020, the Company had $575,000 recorded as deferred grant funding on the consolidated balance sheet related to the grant.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Gates awarded and funded the Company a grant of $5.0&#160;million to accelerate the development of the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device for the intradermal delivery of INO-4800. During the year ended December&#160;31, 2020, the Company recorded $4.1 million as contra-research and development expense and had $884,000 recorded as deferred grant funding on the consolidated balance sheet related to this Gates grant. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Defense (DoD) </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the DoD to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is approximately $54.5&#160;million. The Company has determined that the OTA Agreement should be considered under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Not-for-Profit Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which is outside the scope of Topic 606, as the government agency granting the Company funds is not receiving reciprocal value for their contributions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company will record contra-research development expense on the consolidated statement of operations in the same period that the underlying expenses are incurred. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 device and accessories. The CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2000 devices will be used to inject&#160;INO-4800&#160;in the Company&#8217;s planned later-stage clinical trials. The total purchase price under the Procurement Contract is approximately $16.6&#160;million. The Company has determined that the Procurement Contract does not currently fall under the scope of ASC Topic 606 as contingencies remain regarding INO-4800 which does not give the Company the ability to satisfy its obligations under the arrangement. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company recorded $21.2 million as contra-research and development expense related to these agreements with the DoD. As of December&#160;31, 2020, the Company had an accounts receivable balance of $11.4&#160;million on the consolidated balance sheet from the DoD.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company announced that the DoD has also agreed to provide funding for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 2/3 clinical trial for INO-4800, called INNOVATE (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OVIO I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-4800 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Va</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ccine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rial for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fficacy)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These expenses will be paid directly by the DoD.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122342312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-term Investments</a></td>
<td class="text">Short-term Investments<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments at December&#160;31, 2020 consisted of mutual funds, certificates of deposit and U.S. agency mortgage-backed securities. Short-term investments at December&#160;31, 2019 consisted of mutual funds. Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's debt securities are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the consolidated statements of operations and are derived using the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specific identification method for determining the cost of the securities sold.&#160;During the years ended December&#160;31, 2020 and 2019, the Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross realized ga</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in on investments of $744,000 and $594,000, respectively, and gross realized loss on investments of $1.3 million and $118,000, respectively. During the year ended December&#160;31, 2020, the Company recorded net unrealized gain on available for sale equity securities of $1.7&#160;million. There was no material unrealized gain or loss on available-for-sale equity securities recorded during the year ended December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the years ended&#160;December&#160;31, 2020,&#160;2019&#160;and&#160;2018. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2020, the Company had&#160;12&#160;available-for-sale securities in a gross unrealized loss position, of which none were in such position for longer than 12 months. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December&#160;31, 2020 and 2019:   </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,177,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,140)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,239,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,365,899&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(690,895)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,914,935&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,599,219&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,911)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,338,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2020&#160;were primarily due to changes in interest rates, including credit spreads from perceived increased credit risks as a result of the COVID-19 global pandemic, and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at December&#160;31, 2020, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351124375272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level&#160;1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets are, and prior to September 30, 2020 liabilities were, classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company did not have any transfer of assets and liabilities between Level 1, Level 2 and Level 3 of the fair value hierarchy during the years ended December&#160;31, 2020 and 2019. All liabilities in the fair value hierarchy were extinguished as of September 30, 2020 as described below.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:38.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,914,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,372,101&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,330,340&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, 2019:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,338,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,338,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,315,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,315,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,003,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,003,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Derivative liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 assets at December&#160;31, 2020 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. Level 1 assets at December&#160;31, 2019 consisted of money market funds and mutual funds held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investments in its affiliates, GeneOne and PLS. The Company accounts for its investment in 597,808 common shares of PLS as an equity investment with a fair value based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of operations as unrealized gain (loss) on available-for-sale equity securities or as a gain (loss) on investment in affiliated entities. In August 2020, the Company sold its investment in 1,644,155 common shares of its affiliated entity GeneOne for net proceeds of $40.1&#160;million, resulting in a gain on investment in affiliated entity of </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$36.7&#160;million. Previously, the Company accounted for its investment in GeneOne based on the closing price of the shares on the KOSDAQ Market of the Korea Exchange (KOSDAQ) on the applicable balance sheet date. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at December&#160;31, 2020 consisted of certificates of deposit and U.S. agency mortgage-backed securities. Level 2 assets held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of December&#160;31, 2020 and 2019. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 liabilities held at December&#160;31, 2020 due to the full conversion of the August 2019 Bonds into shares of the Company's common stock. Level 3 liabilities held as of December 31, 2019 consisted of the embedded conversion option contained in the August 2019 Bonds that met the criteria to be bifurcated and accounted for separately from the August 2019 Bonds (the "derivative liability") (see Note 11 below for more information). The derivative liability was recorded at fair value of $7.1 million upon the issuance of the August 2019 Bonds, and is subsequently remeasured to fair value at each reporting period. The derivative liability was initially valued and remeasured using a "with-and-without" method. The "with-and-without" methodology involves valuing the whole instrument on an as-is basis and then valuing the instrument without the embedded conversion option. The difference between the entire instrument with the embedded conversion option compared to the instrument without the embedded conversion option is the fair value of the derivative, recorded as the derivative liability. There was no derivative liability associated with the issuance of the December 2019 Bonds.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the August 2019 Bonds with the conversion option is estimated using a Monte Carlo simulation approach. The key inputs to valuing the August 2019 Bonds with the conversion option on the date of issuance and as of August 3, 2020 conversion date included the Company&#8217;s stock price on the valuation date; the expected annual volatility of the Company&#8217;s common stock, and the discount yield, which was derived by making the fair value of the August 2019 Bonds equal to the face value on the issuance date. Fair value measurements are highly sensitive to changes in these inputs and significant changes in these inputs could result in a significantly higher or lower fair value. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair value of the derivative liability for the year ended December&#160;31, 2020: </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,670,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Derecognition of the derivative liability upon conversion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,490,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351123649800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers and Concentration of Credit Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Major Customers and Concentration of Credit Risk</a></td>
<td class="text">Major Customers and Concentration of Credit Risk<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.503%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Customer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ApolloBio</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,194,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,850,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advaccine</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plumbline Life Sciences, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other, including affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,411,220&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,111,930&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,481,897&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020, 2019 and 2018, the Company recognized revenue from various license and other agreements. As of December&#160;31, 2020, $11.4 million, or 62%, and $7.1 million, or 38%, of the Company's accounts receivable was attributable to the DoD and Advaccine, respectively. As of December&#160;31, 2019, $469,000, or 67%, and $161,000, or 23%, of the Company's accounts receivable was attributable to MCDC and AstraZeneca, respectively. </span></div>There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122384376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">Prepaid Expenses and Other Current Assets<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets at December&#160;31, 2020 and 2019 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,661,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,695,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,584,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,357,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,584,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:24.91pt">Prepaid manufacturing expenses related to deposits made to reserve capacity for the manufacturing of INO-4800 expected in 2021. In the event that the manufacturing does not occur in 2021 the deposits will be forfeited.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351124260792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets</a></td>
<td class="text">Fixed Assets<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets at December&#160;31, 2020 and 2019 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Depreciation<br/>and<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,179,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,549,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,630,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,788,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,727,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,828,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,296,942)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,544,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,419,703)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,341,715&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,993,571)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,348,144&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,007,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,996,777)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,011,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,102,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,229,357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,048,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,944,293)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,781,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,996,031)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,939,475&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,166,458)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,773,017&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2020, 2019 and 2018 was $3.0 million, $3.6 million and $3.7 million, respectively. The Company determined that the carrying value of these long-lived assets was not impaired during the periods presented.  During the year ended December 31, 2020 the Company disposed of fixed assets with a net book value of $227,000 and accumulated depreciation of $200,000.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122399704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.874%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:53pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,276,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,248,104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,468,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,175,556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (c)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,581,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,356,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,326,991)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,146,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,779,910)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,693,851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,326,991)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,660,141&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,779,910)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,207,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Goodwill was recorded from the acquisition of other companies and assets.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Other intangible assets represent the estimated fair value of acquired intellectual property.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense on intangible assets was $547,000, $1.1 million and $1.2 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Amortization expense related to intangible assets at December&#160;31, 2020 is expected to be incurred as follows: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,147,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no impairment or impairment indicators present and no losses were recorded during the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122300824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Debt</a></td>
<td class="text">Convertible Debt<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were approximately $75.7 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of 6.50% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate will be 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.38 per share), subject to adjustment upon the occurrence of specified events.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the Notes prior to March 1, 2022. On or after March 1, 2022, the Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet, and that the cash conversion guidance applies. Therefore, the Notes issuance proceeds of $78.5 million are allocated first to the liability component based on the fair value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion features. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was $62.2 million and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of $2.8 million are allocated to the liability and equity component in the same proportion as the issuance proceeds. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $18.6 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is 13.1%.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2020, the Company received notices for the conversion of $62.1&#160;million of principal amount of the Notes, which were settled into an aggregate of 11,535,660 shares of the Company's common stock. The fair value of the Notes at the date of conversion was $43.7&#160;million compared to the carrying value of $52.5&#160;million, resulting in a $8.8&#160;million gain on extinguishment of debt. Thi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">s gain was recorded in the consolidated statement of operations. To measure the fair value of the converted Notes as of the conversion dates, the Company engaged a third-party valuation expert and utilized a binomial lattice model.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at December&#160;31, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount on the liability component</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,312,404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,139,988&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020 and 2019,&#160;the Company recognized $6.9 million and $7.0&#160;million, respectively, of interest expense related to the Notes, of which $4.1 million and $4.4&#160;million, respectively, related to the contractual interest coupon. </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">August 2019 Convertible Bonds </span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2019, the Company closed a private placement of the August 2019 Bonds with an aggregate principal amount of 18 billion KRW (approximately USD $15.0 million based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were approximately $14.5 million. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2019 Bonds, which are unsecured obligations of the Company, were issued on August 1, 2019 and accrued interest at a coupon rate of 1.00% per annum, payable quarterly. The August 2019 Bonds were scheduled to mature on July 31, 2024, unless earlier converted or repurchased. On August 3, 2020 the August 2019 Bonds were converted in full into an aggregate of 4,962,364 shares of the Company's common stock, leaving no further August 2019 Bonds outstanding. The initial </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conversion rate was 211.0595 shares per KRW1,000,000 in principal amount (equivalent to an initial conversion price of approximately USD $4.00 per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate was reset on January 2, 2020 and was subject to reset quarterly thereafter if the current market price was lower than the conversion price then in effect. The conversion rate as of the date of conversion on August 1, 2020 was 275.6873 shares per KRW1,000,000 in principal amount (equivalent to a conversion price of approximately USD $3.14 per share). </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature was considered a derivative requiring bifurcation from the August 2019 Bonds as it did not meet the equity scope exception due to the fact that it was denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was $7.1 million, which was recorded as a reduction to the carrying value of the debt. This debt discount was being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option was accounted for as a derivative liability, which was revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the consolidated&#160;statements of operations.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At their issuance, the Company determined that the expected life of the August 2019 Bonds was equal to the period through August 1, 2022 as this represented the point at which the August 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $7.3 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, was being amortized using the effective interest method through August 1, 2022. For the years ended December&#160;31, 2020 and 2019,&#160;the Company recognized $1.6 million and $982,000, respectively, of interest expense related to the August 2019 Bonds, of which $87,000 and $65,000, respectively, related to the contractual interest coupon. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, all outstanding August 2019 Bonds were converted into common stock. Immediately prior to the conversion, the derivative liability was revalued at $84.5&#160;million. The change in fair value of the derivative liability was an increase of $75.7&#160;million, which was recorded on the consolidated statement of operations. To measure the fair value of the derivative liability as of the conversion date, the Company engaged a third-party valuation expert.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, a loss on extinguishment of $8.2&#160;million was recorded on the consolidated statement of operations. This loss represents the difference between (a) the calculated fair value of the derivative liability immediately prior to its derecognition plus the carrying amount of the debt component including any unamortized debt discount and issuance costs and (b) the fair value of the 4,692,364 shares of the Company's common stock issued upon conversion.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Convertible Bonds </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#8220;December 2019 Bonds&#8221;) with an aggregate principal amount of 4.7 billion KRW (approximately USD $4.1 million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were approximately $4.0 million.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Bonds, which are unsecured obligations of the Company, were issued on December&#160;31, 2019 and will accrue interest at a coupon rate of 1.00% per annum, payable quarterly. The December 2019 Bonds will mature on December&#160;31, 2024, unless earlier converted or repurchased. The outstanding December 2019 Bonds will be repaid at maturity at a price equal to the principal of the outstanding bonds to be repaid plus a premium on such bonds to provide an internal rate of return with respect to such bonds of 6.00%. Commencing on December&#160;31, 2020, the December 2019 Bonds are convertible until the date that is one month prior to maturity date. Upon conversion, the Company will deliver shares of common stock of the Company. The initial conversion rate was 214.7766 shares per KRW1,000,000 principal amount of Bonds (equivalent to an initial conversion price of approximately USD $4.00 per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. The conversion rate was subject to reset on July&#160;2, 2020 and on each three month anniversary thereafter until the maturity date to the then current market price if the current market price is lower than the conversion price then in effect; provided that the conversion rate will not exceed 357.9611 shares per KRW1,000,000 (equivalent to a conversion price of approximately USD $2.40 per share based on the exchange rate as of December&#160;19, 2019). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion rate has not been reset as of December&#160;31, 2020 from the initial conversion rate.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Bonds will be subject to repurchase by the Company at the option of the bondholders from and including December&#160;31, 2022 up to the date that is one month prior to the maturity date at a repurchase price equal to the principal of the December 2019 Bonds to be repurchased plus a premium on the Bonds in order to ensure an internal rate of return with respect to the Bonds equal to 6.00%. In addition, upon the occurrence of a fundamental change (as defined in the Subscription Agreement) the Company will be required to offer to repurchase the Bonds at a repurchase price equal to the principal amount thereof plus accrued and unpaid interest thereon to but excluding the applicable repurchase date. If certain </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bankruptcy and insolvency-related events of default occur, the principal of, and accrued and unpaid interest on, all of the then outstanding December 2019 Bonds shall automatically become due and payable. If any other event of default occurs and is continuing, the holders of at least 25% of the in aggregate principal amount of the December 2019 Bonds by notice to the Company may declare the principal of, and accrued and unpaid interest on, all of the then-outstanding December 2019 Bonds to be due and payable.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature does not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature meets the definition of a derivative, it qualifies for the equity scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet. The December 2019 Bonds are denominated in a foreign currency other than the Company&#8217;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#8217;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario is fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency does not impact the settlement of the conversion option. Further, as there is no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the December 2019 Bonds at December&#160;31, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,327,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of premium associated with the December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,515,834&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the expected life of the December 2019 Bonds was equal to the period through December 31, 2022 as this represents the point at which the December 2019 Bonds are initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds is 6.2%. For the year ended December&#160;31, 2020,&#160;the Company recognized $253,000 of interest expense related to the December 2019 Bonds, of which $40,000 related to the contractual interest coupon. As of December&#160;31, 2020, there have not been any conversions or redemptions of the December 2019 Bonds.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, future minimum payments due under the Company's convertible debt instruments are as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible Notes (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 2019 Bonds (2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,571,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,519,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,149,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,701,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,850,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of 6.5% per year. </span></div>(2) Amounts represent amounts due under the December 2019 Bonds, including interest based on the fixed rate of 1% per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of 6% at maturity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122427320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">Accounts Payable and Accrued Expenses<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses at December&#160;31, 2020 and 2019 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,919,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,127,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,967,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued subcontract costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,003,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,203,808&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,237,258&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122274216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:47.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.313%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Outstanding as of<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par $0.001</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, 14 shares of the Company&#8217;s Series&#160;C preferred stock were converted into an aggregate of 5,147 shares of the Company&#8217;s common stock.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The holder of any share or shares of Series C Preferred Stock has the right at any time, at such holder&#8217;s option, to convert all or any lesser portion of such holder&#8217;s shares of the Preferred Stock into fully paid and non-assessable shares of Common Stock. As of December 31, 2020, the Conversion Value w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as $27.20 per share, such</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> that the outstanding shares of Series C Preferred Stock were convertible into an aggregate of 3,309 shares of common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company entered into the Sales Agreement with an outside placement agent (the &#8220;Placement Agent&#8221;) to sell shares of its common stock w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ith aggregate gross proceeds of up to $100.0 million, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent will act as sales agent. During the first quarter of 2020, the Company and the Placement Agent entered into a first and second amendment to the Sales Agreement (the "Prior Sales Agreement") to increase the amount of common stock that may be sold under the Sales Agreement from $100.0&#160;million to $250.0&#160;million. As of March 31, 2020, there was no remaining capacity under the Prior Sales Agreement. On April 3, 2020, the Company and the Placement Agent entered into a new Sales Agreement (the "New Sales Agreement") to sell shares of its common stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2020 and May 12, 2020, the Company filed prospectus supplements pursuant to the New Sales Agreement for the offer and sale of its Common Stock for aggregate gross proceeds of up to an aggregate of $250.0&#160;million. Under the New Sales Agreement, the Company will set the parameters for the sale of shares, inclu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ding the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The New Sales Agreement provides that the Placement Agent will be entitled to compensation for its services in an amount equal to up to 3.0% of the gross proceeds from the sales of shares sold through the Placement Agent under the New Sales Agreement. The Company has no obligation to sell any shares under the New Sales Agreement, and could at any time suspend solicitation and offers under the New Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020, the Company sold 43,148,952 shares of its common stock under the Prior Sales Agreement. The sales were made at a weighted average price of $4.92 per share, resulting in aggregate net proceeds of $208.2&#160;million. As of March 31, 2020, there was no remaining capacity under the Prior Sales Agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company sold a total of 22,915,934 shares of common stock under the New</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement. The sales were made at a weighted average price of $10.91 per share resulting in aggregate net proceeds of $246.2 million. As of December&#160;31, 2020, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> remaining capacity under the New Sales Agreement.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. The maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the 2016 Incentive Plan </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may not exceed 18,000,000 shares, provided that commencing with the first business day of each calendar year beginning January&#160;1, 2020, such maximum number of shares shall be increased by&#160;2,000,000 shares of common stock unless the Board determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2021, the maximum number of shares to be issued increased by 2,000,000. At December&#160;31, 2020, there were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 18,000,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of common stock reserved for issuance upon exercise of incentive awards granted and to be granted at future dates under the 2016 Incentive Plan. At December&#160;31, 2020, the Company had 6,739,577 shares of common stock available for future grant under the 2016 Incentive Plan, 2,558,052 shares underlying outstanding but unvested restricted stock units and options outstanding to purchase 5,742,109 shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At December&#160;31, 2020, the Company had options outstanding to purchase 3,164,515 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December&#160;31, 2020, 2019 and 2018 was $14.5 million, $9.8 million and $10.2 million, respectively, of which $8.0 million, $5.9 million and $5.9 million was included in research and development expenses and $6.5 million, $3.9 million and $4.3 million was included in general and administrative expenses, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and 2019, there was $4.4 million and $3.4 million, respectively, of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.4 years and 1.7 years, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020 and 2019, there was $10.9 million and $4.3 million, respectively, of total unrecognized compensation expense related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 1.9 years and 1.6 years, respectively.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and restricted stock units granted to non-employees for the years ended December&#160;31, 2020, 2019 and 2018 was $1.2 million, $970,000 and $302,000, respectively. As of December&#160;31, 2020, options to purchase 845,375 shares of common stock granted to non-employees remained outstanding.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock options outstanding at December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"/><td style="width:26.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted    Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.48-$3.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.01-$6.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,261,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.01-$9.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,879,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,864,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.01-$12.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12.01-$15.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.01-$25.62</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,906,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,079,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the aggregate intrinsic value of options outstanding was $24.2 million, the aggregate intrinsic value of options exercisable was $16.8 million, and the weighted average remaining contractual term of options exercisable was 5.7 years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, the aggregate intrinsic value of unvested restricted stock units was $22.6 million and the aggregate intrinsic value of restricted stock units which vested during the year ended December 31, 2020 was $13.5 million.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, options to purchase 8,906,624 shares of common stock and 2,558,052 restricted stock units were expected to vest.</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2020 was as follows: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:70.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,265,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,178,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306,696)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,906,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2020 was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:84.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,586,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,040,628)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,536)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558,052&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price per share was $4.44 for the 78,750 options which expired during the year ended December&#160;31, 2020, $6.27 for the 324,502 options which expired during the year ended December&#160;31, 2019 and $5.17 for the 119,091 options which expired during the year ended December&#160;31, 2018.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $6.87, $2.19 and $2.86 for options granted during the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value was $9.12, $3.09 and $4.31 per share for restricted stock units granted during the years ended December&#160;31, 2020, 2019 and 2018, respectively. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received $12.3 million, $113,000 and $1.5 million in proceeds from the exercise of stock options during the years ended December&#160;31, 2020, 2019 and 2018, respectively. The aggregate intrinsic value of options exercised was $14.2 million, $25,000 and $910,000 during the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 28, 2020, the Company granted 663,353 performance-based RSUs to key employees under the 2016 Incentive Plan. The RSUs will vest in two tranches as follows: 50% of the shares in each tranche will vest upon achievement of the predetermined performance milestones and the remaining 50% of the shares in each tranche will vest upon subsequent completion of a one-year service period. The grant date fair value of the performance-based RSUs was $8.0&#160;million based on the grant date closing price per share of $12.06. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December&#160;31, 2020</span><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, the underlying performance milestones of the RSUs were not probable of achievement, and no stock-based compensation expense was recognized for the performance-based RSUs for the year then ended.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122427320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases <div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately 82,200 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms of 2.9 years to 9.0 years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of December&#160;31, 2020, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.370%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,968,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,045,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,023,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,888,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,988,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,595,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,393,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,329,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,064,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the consolidated statements of operations for the years ended December&#160;31, 2020, 2019 and 2018 were $3.4 million, $3.2 million and $3.4 million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122274216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Affiliated Entity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investment in Affiliated Entity</a></td>
<td class="text">Investment in Affiliated Entity<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, the Company held 597,808 and 395,758 common shares in PLS, representing a 19.7% and 15.0% ownership interest, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 27, 2020, the Company sold 1,644,155 shares of common stock in GeneOne for net proceeds of approximately 47.4&#160;billion KRW (approximately USD $40.1&#160;million based on the exchange rate on the date of sale). The Company no longer holds an investment in GeneOne shares and GeneOne is no longer considered a related party to the Company under ASC Topic 850.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Please see further information as discussed in Note 2 and Note 6.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122360808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of pretax loss from operations are as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,664,355)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,809,112)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,798,019)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225,949)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax loss from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,890,304)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,809,112)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,798,019)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the provision for (benefit from) income taxes are presented in the following table: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257,000)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax expense (benefit), using a 21% statutory tax rate for December 31, 2020, 2019 and 2018, is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (benefit) taxes at statutory rates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,207,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,370,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,908,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,428,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,457,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,898,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,450,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,650,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,838,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,170,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,953,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,268,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deconsolidation of subsidiary</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,176,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited NOLs and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(616,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,176,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax benefit recorded during the year ended December 31, 2019 of  $257,000 was principally due to a requirement under ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that a company must consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations. As a result of the requirement under ASC 740-20-45-7, the pretax income which the Company generated from other comprehensive income was a source of income which resulted in the partial realization of the current year loss from continuing operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adoption of ASU 2019-12</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company early adopted ASU No. 2019-12 as of January 1, 2020.  Among other provisions, ASU 2019-12 eliminated the requirement under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2020 and 2019 are shown below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,300,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,835,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,788,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,242,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,737,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,256,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,255,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,852,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,283,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,722,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,127,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,413,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,484,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,229,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,705,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,159,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,070,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,676,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,894,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,862,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,381,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(487,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(805,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2020, the Company had federal, California and Pennsylvania tax net operating loss (NOL) carryforwards of $566.2 million, $68.6 million and $75.3 million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. The aggregate federal net operating losses generated in 2018 and after for the amount of $270.3 million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year, subject to certain modifications made by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) enacted in 2020. The federal NOL carryforward began to expire in 2021, and the California and Pennsylvania NOL carryforwards will begin and have begun to expire in 2028 and 2020, respectively, unless previously utilized. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December 31, 2020, the Company had federal and state research and development (R&amp;D) tax credit carryforwards of $19.8 million and $3.2 million, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:46.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.365%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal R&amp;D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State R&amp;D</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#8217;s NOL and R&amp;D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section&#160;382/383 analysis regarding the limitation of NOL and R&amp;D credit </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carryforwards as of December&#160;31, 2020. As a result of the analysis, the Company estimates that approximately $10.2 million of tax benefits related to NOL and R&amp;D carryforwards will expire unused. Accordingly, the related NOL and R&amp;D credit carryforwards have been removed from deferred tax assets, accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes may further limit the ability to use the NOL and R&amp;D carryforwards.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act of 2017 subjects a U.S. stockholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.  The Company has elected to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. For 2020, the Company did not generate any GILTI due to losses earned by its foreign subsidiary.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On March 27, 2020, the CARES Act was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits federal NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows federal NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. Due to the Company's history of net operating losses, the CARES Act is not expected to have a material impact on the Company's financial statements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company's unrecognized tax benefits:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,632,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,313,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,575,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,210,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,632,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was $10.9 million, $9.9 million and $8.3 million as of December&#160;31, 2020, 2019 and 2018, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve&#160;months of the reporting date.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2017 and state and local income tax examinations before 2016. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not currently under Internal Revenue Service (&#8220;IRS&#8221;), state or local tax examination.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122348888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Plan</a></td>
<td class="text">401(k) PlanThe Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches 50% of its employees&#8217; contributions, up to 6% of their annual compensation. The Company&#8217;s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled $1.1 million, $1.2 million and $1.2 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351123439752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transaction, Due from (to) Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Life Sciences </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 27, 2020, the Company sold 1,644,155 shares of common stock in GeneOne for net proceeds of approximately 47.4&#160;billion KRW (approximately USD $40.1&#160;million based on the exchange rate on the date of sale). The Company no longer holds an investment in GeneOne shares and GeneOne is no longer considered a related party to the Company under ASC 850. The Company's consolidated balance sheet as of December 31, 2020 no longer reflects GeneOne&#8217;s portion in accounts receivable and accounts payable and accrued expenses with affiliated entities, whereas the Company&#8217;s balance sheet as of December 31, 2019 reflects $128,000 and $511,000 in accounts receivable and accounts payable and accrued expenses with </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">affiliated entities, respectively, related to GeneOne. Revenues recognized from GeneOne will no longer be presented as revenue with affiliated entity on the consolidated statement of operations after the change in related party designation in August 2020. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from GeneOne for the years ended December&#160;31, 2020, 2019 and 2018 consisting of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patent, device maintenance and licensing fees was $125,000, $127,000 and $342,000, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses recorded from transactions with GeneOne related primarily to biologics manufacturing and were $4.7 million, $2.5 million and $7.0 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owned 597,808 shares of common stock in Plumbline Life Sciences, Inc. ("PLS") as of December 31, 2020 and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, the Company entered into a Debt and Share Subscription Agreement with PLS under which the Company received 202,050 shares of PLS common stock in exchange for a portion of the outstanding accounts receivable balance due from PLS. Following the issuance of these shares and as of December 31, 2020, the Company held a 19.7% ownership interest in PLS.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from PLS consists of milestone, license and patent fees. For the years ended December&#160;31, 2020 and 2019, the Company recognized revenue from PLS of $1.4 million and $111,000, respectively. At December 31, 2020 and 2019, the Company had an accounts receivable balance of $67,000 and $589,000, respectively, related to PLS.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company will reimburse Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreement. The Company will have the exclusive right to in-license new intellectual property developed in this agreement.  </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company rece</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ived a&#160;$6.1 million&#160;sub-grant through Wistar to develop a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DMAb</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against the Zika infection, with fun</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ding through December 2020. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $10.7&#160;million sub-grant through Wistar for the preclinical development and translational studies of DMAbs as countermeasures for COVID-19, with funding through September 2022. The sub-grant also includes an option for an additional $6.0&#160;million in funding through September 2024. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended December&#160;31, 2020 and 2019, the Company recorded $1.9 million and $2.2 million, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 4). Research and development expenses recorded from Wistar for the years ended December&#160;31, 2020 and 2019 were $2.3 million and $1.5 million, respectively. At December&#160;31, 2020 and 2019, the Company had an accounts receivable balance of $425,000 and $616,000, respectively, and an accounts payable and accrued liability balance of $643,000 and $219,000, respectively, related to Wistar. As of December&#160;31, 2020, the Company had $96,000 recorded as grant funding liability on its consolidated balance sheet related to Wistar.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351123746104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc.<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">Geneos Therapeutics, Inc. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In February 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested&#160;$1.2&#160;million&#160;in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;61%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $800,000. Following this transaction, as of March 31, 2020, the Company held&#160;52%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $800,000.  Following this transaction, the Company owned 47% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support.  However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $4.1&#160;million, of which $2.4&#160;million related to the remeasurement of the retained noncontrolling interest investment to fair value.  The gain has been recorded separately on the Company's consolidated statement of operations.  The following table shows the amounts related to the deconsolidation accounting: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (excluding cash) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net of accumulated depreciation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of noncontrolling interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of investment in Geneos retained</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,121,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash resulting from the deconsolidation of Geneos</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,774,851&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The details of the Company&#8217;s 47% retained equity investment in Geneos are shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Geneos Share Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,799,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,113,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos Series A preferred stock was based on the per share price paid by third-party investors in connection with the most recent closing of the Series A preferred stock financing for Geneos on June 1, 2020. The fair value of Geneos common stock was determined by a third-party valuation, as there is no public market for such stock. Geneos&#8217;s enterprise value, which was estimated using a market approach that derived an implied total equity value from a transaction involving its own securities, was allocated to all classes of equity using the option pricing method. Under the option pricing method, each equity class was modeled as having a call option with a distinct claim on the total value of Geneos. Each option&#8217;s exercise price was based on the total value available for each participating security holder. The characteristics of each class of ownership determined the claim on the total value for that class of ownership.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated value allocated to common stock included assumptions related to the fair value of the enterprise, expected volatility, expected term, and risk-free interest rate. Expected volatility was based on historical asset volatilities derived from daily stock price changes of guideline public companies. The estimated expected term was based on a weighted average of the estimated time to Geneos's next financing and successful exit timing assumption.  The risk-free interest rate was based on the yield of U.S. Treasury with a comparable term. Geneos&#8217;s common stock is classified as a Level 3 financial instrument. The assumptions used in the fair value calculation as of June 1, 2020 are presented below:</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geneos enterprise value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,966,531</span></td></tr></table></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock.  Since the Company&#8217;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#8217;s common stock investment and will therefore be recorded as an equity security under ASC 321.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 1, 2020, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217;s net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the Series A preferred stock financing on June 1, 2020. The Company has determined that its Series A preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $1.4&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continues to be a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continues to not be the primary beneficiary of Geneos, as it does not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 36% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos&#8217;s Series A-1 preferred stock was based on the per share price paid by third-party investors in connection with the closing on November 12, 2020.  The Company has concluded that its Series A-1 preferred stock investment is not similar to its prior Series A preferred stock investment due to certain material rights held solely by Series A preferred stockholders. Therefore, the Company will continue to record its Series A preferred stock investment in Geneos at cost, as there have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos for the period from June 1, 2020 through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as $4.6&#160;million. O</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f this amount, $819,000 has been allocated to the equity method investment, thereby reducing the balance to $0 as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The remaining </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.8&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> loss has been allocated to the Company&#8217;s Series A and Series A-1 preferred stock investments in Geneos, on a ratable basis, thereby reducing the investment balance t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o $434,000 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as shown in the table below:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos upon deconsolidation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,584,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,387&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351124261640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information (Unaudited)</a></td>
<td class="text">Quarterly Financial Information (Unaudited)<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the quarterly results of operations of the Company for the years ended December&#160;31, 2020 and 2019 (unaudited):</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Consolidated Statements of Operations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,003,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue, including from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,580,581&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,178&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,187&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327,274&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,302,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,455,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,376,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,111,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,617,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,110,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,071,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,448,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,920,019&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,565,618&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,448,085&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,559,542&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,339,438)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,329,440)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,180,898)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,232,268)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,068,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,984,046)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,846,641)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,803,755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,306,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,755,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,221,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on investment in affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,951,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,883,176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,181,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,050,092)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152,102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,121,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,177,043)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,674,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,087,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) before income tax benefit and share in net loss of Geneos</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,415,201)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,931,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128,270,709)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,135,404)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,923,179)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,759,674)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(901,757)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,338,380)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,171,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,172,466)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,135,404)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,407&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,350&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,338,380)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,171,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128,703,059)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,541,054)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.83)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Consolidated Statements of Operations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,770,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue, including from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,488&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866,863&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,673&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,829,905&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,003,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,137,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,486,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,389,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,696,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,681,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,850,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,975,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,700,541&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,818,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,336,367&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,364,917&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,421,053)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,951,787)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,200,694)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,535,012)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,668,837)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,428,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,194,783)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(656,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,315,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,551,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from investment in affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,681,401)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(485,841)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173,212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(750,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,839)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss before income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,235,146)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,536,452)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,685,847)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,351,667)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,764&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,771&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,800&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,147,382)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,536,452)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,579,076)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,288,867)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485,344&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445,759&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,850&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,605&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,662,038)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,090,693)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,387,226)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,219,262)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351123538056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsOn January 25, 2021, the Company closed an underwritten public offering of 20,355,000 shares of the Company's common stock at a public offering price of $8.50 per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other estimated offering expenses, were $162.1&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351132395864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Liquidity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO incurred a net loss attributable to common stockholders of $166.4 million for the year ended December&#160;31, 2020. INOVIO had working capital of $429.5 million and an accumulated deficit of $906.2 million as of December&#160;31, 2020. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and short-term investments of $411.6 million as of December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of potential future At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds under past Sales </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreements of $454.5&#160;million during the year ended December 31, 2020, and net proceeds of $9.1&#160;million under a Sales Agreement during the year ended December 31, 2019. The Company also received net proceeds of $75.7&#160;million from a private placement of 6.50% convertible senior notes due 2024 (the &#8220;Notes&#8221;), net proceeds of $14.5&#160;million from the private placement of 18&#160;billion Korean Won (KRW) (approximately USD $15.0&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due August 2024 (the "August 2019 Bonds"), and net proceeds of $4.0&#160;million from the private placement of 4.7&#160;billion KRW (approximately USD $4.1&#160;million based on the exchange rate on the date of issuance) aggregate principal amount of its 1.0% convertible bonds due December 2024 (the "December 2019 Bonds" and, together with the August 2019 Bonds, the &#8220;Bonds&#8221;) during the year ended December 31, 2019. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company&#160;may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is closely monitoring the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will impact the Company's business and operations will depend on future developments, including the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, that are highly uncertain.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text">ConsolidationThe consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. As of December 31, 2020 the Company consolidated its wholly-owned subsidiary Inovio Asia LLC.  On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority -owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions have been eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist principally of cash equivalents, short-term investments and investments in affiliated entities. The carrying amounts of cash equivalents approximate the related fair values due to the short-term maturities of these instruments. Investments are recorded at fair value, based on current market valuations. The Company carries convertible notes and bonds at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsCash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December&#160;31, 2020 and money market accounts at December 31, 2019.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text">InvestmentsThe Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#8217;s affiliated entity, PLS, at December 31, 2020. Investments included mutual funds and an equity investment in the Company's affiliated entities, PLS and GeneOne, at December 31, 2019.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text">Accounts ReceivableAccounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzg3MzY_3ade6400-d079-4bc2-a028-5e2e5c6e9030">three</span> to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text">Long-Lived AssetsAll long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Valuation of Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Valuation of Intangible Assets and Goodwill</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjA2ZDA3NjY3ZDQ5NzQ3NjVhODI4MjM3NGQxMjExZTY2L3NlYzowNmQwNzY2N2Q0OTc0NzY1YTgyODIzNzRkMTIxMWU2Nl8xNDIvZnJhZzo0OTI4NzM4ZjIwNTM0MTI1YmYyYmVhNGUyZGNmMzI1MS90ZXh0cmVnaW9uOjQ5Mjg3MzhmMjA1MzQxMjViZjJiZWE0ZTJkY2YzMjUxXzk2MDM_9dbc4512-b92b-4a6e-ae6e-052ec9675f3d">two</span> to 18 years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the Company has recorded patents at cost and amortized these costs using the straight-line method over the expected useful lives of the patents or 17 years, whichever is less. Patent cost consists of the consideration paid for patents and related legal costs. New patent costs are expensed as incurred, with patent costs capitalized as of that date continuing to be amortized over the expected life of the patent. License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&#160;31, 2019 and 2018, the Company&#8217;s intangible assets resulting from acquisitions and additional intangibles including previously capitalized patent costs and license costs, net of accumulated amortization, totaled $3.1 million and $3.7 million, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through December&#160;31, 2020.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment as of November 30, 2020, identifying no impairment.</span></div>Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances against the Company&#8217;s deferred tax assets were $159.7 million and $137.2 million at December&#160;31, 2020 and 2019, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Agreements</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;Topic 606&#8221;). However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantRevenuePolicyTextBlock', window );">Grants</a></td>
<td class="text">Grants<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span>, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Liabilities</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company's financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are remeasured at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Investments</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMAbs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total trial management costs, sites activated, patients enrolled, and number of patient visits. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 11) has been considered using the "if-converted" method. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. </span>For the years ended December 31, 2020, 2019 and 2018, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based CompensationThe Company incurs stock-based compensation expense related to restricted stock units and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements - Recently Adopted</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Recently Adopted</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2019-12. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. FASB issued this Update as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12. By early adopting, ASU 2019-12 became effective as of the beginning of 2020; however, there was no cumulative effect to be recognized with the early adoption. As of December 31, 2020, there was a loss from continuing operations and a cumulative loss in other comprehensive income and there was therefore no effect on the tax provision for the period ended December 31, 2020. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2016-13</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2016, the FASB issued ASU 2016-13,&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonably supportable forecast information. The Company adopted ASU 2016-13 on January 1, 2020, and there was no material impact to its consolidated financial statements. The Company will continue to monitor the impact of the coronavirus, SARS-CoV-2 (&#8220;COVID-19&#8221;) outbreak on expected credit losses.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2018-13</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In August 2018, the FASB issued ASU 2018-13, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends certain disclosure requirements over fair value measurements. Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this guidance on January 1, 2020, and there was no material impact to its consolidated financial statement disclosures (see Note 6 for more information about the Company&#8217;s fair value classifications).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2018-18</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In November 2018, the FASB issued ASU 2018-18, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which clarified the interaction between Topic 808, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative </span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arrangements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Topic 606, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company adopted this guidance on January 1, 2020, and there was no material impact to its consolidated financial statements.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2017-04.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In January 2017, the FASB issued ASU 2017-04,&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#160;</span>("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and there was no material impact to its consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Revenue [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351123664040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,906,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,265,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,752,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,585,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,190,768&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,737,956&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,449,150&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of assumptions used to estimate the fair value of stock options</a></td>
<td class="text">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.42%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.73%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.71%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351123526840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of investments</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December&#160;31, 2020 and 2019:   </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,177,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,140)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,239,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,365,899&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(690,895)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,914,935&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,599,219&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,911)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,338,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122359112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Financial assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:38.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,914,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,372,101&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,330,340&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, 2019:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,338,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,338,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,315,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,315,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,003,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,003,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Derivative liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in fair value of the financial liabilities</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair value of the derivative liability for the year ended December&#160;31, 2020: </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,670,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Derecognition of the derivative liability upon conversion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,490,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351123585608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers and Concentration of Credit Risk (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of major customers and concentration risks</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.503%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Customer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ApolloBio</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,194,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,850,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advaccine</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plumbline Life Sciences, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other, including affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,411,220&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,111,930&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,481,897&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122314056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule Of Prepaid Expenses And Other Current Assets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets at December&#160;31, 2020 and 2019 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,661,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,695,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,584,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,357,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,584,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:24.91pt">Prepaid manufacturing expenses related to deposits made to reserve capacity for the manufacturing of INO-4800 expected in 2021. In the event that the manufacturing does not occur in 2021 the deposits will be forfeited.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Prepaid Expenses And Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351123683064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of fixed assets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets at December&#160;31, 2020 and 2019 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Depreciation<br/>and<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,179,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,549,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,630,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,788,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,727,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,828,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,296,942)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,544,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,419,703)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,341,715&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,993,571)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,348,144&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,007,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,996,777)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,011,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,102,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,229,357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,048,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,944,293)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,781,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,996,031)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,939,475&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,166,458)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,773,017&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122364696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Summary of intangible assets by major asset class</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.874%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:53pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,276,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,248,104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,468,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,175,556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (c)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,581,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,356,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,326,991)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,146,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,779,910)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,693,851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,326,991)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,660,141&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,779,910)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,207,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Goodwill was recorded from the acquisition of other companies and assets.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Other intangible assets represent the estimated fair value of acquired intellectual property.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of finite-lived intangible assets, future amortization expense</a></td>
<td class="text">Amortization expense related to intangible assets at December&#160;31, 2020 is expected to be incurred as follows: <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,147,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351123605000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of convertible debt</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at December&#160;31, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount on the liability component</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,312,404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,139,988&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the December 2019 Bonds at December&#160;31, 2020 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,327,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of premium associated with the December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,515,834&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of maturities of long-term debt</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, future minimum payments due under the Company's convertible debt instruments are as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible Notes (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 2019 Bonds (2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,571,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,519,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,149,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,701,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,850,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of 6.5% per year. </span></div>(2) Amounts represent amounts due under the December 2019 Bonds, including interest based on the fixed rate of 1% per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of 6% at maturity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351216884600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable and accrued expenses</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses at December&#160;31, 2020 and 2019 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,919,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,127,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,967,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued subcontract costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,003,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,203,808&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,237,258&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351123793016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Summary of preferred stock authorized, issued and outstanding</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:47.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.313%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Outstanding as of<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par $0.001</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of shares authorized under stock option plans, by exercise price range</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock options outstanding at December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"/><td style="width:26.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted    Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.48-$3.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.01-$6.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,261,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.01-$9.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,879,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,864,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.01-$12.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12.01-$15.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.01-$25.62</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,906,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,079,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock options, activity</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2020 was as follows: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:70.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,265,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,178,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306,696)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,906,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted stock unit activity</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2020 was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:84.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,586,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,040,628)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,536)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558,052&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122290072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of operating lease liabilities</a></td>
<td class="text"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of December&#160;31, 2020, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.370%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,968,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,045,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,023,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,888,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,988,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,595,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,393,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,329,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,064,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351127312552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of components of pretax loss from operations</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of pretax loss from operations are as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,664,355)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,809,112)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,798,019)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225,949)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax loss from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,890,304)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,809,112)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,798,019)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of income tax expense (benefit)</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the provision for (benefit from) income taxes are presented in the following table: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257,000)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax expense (benefit), using a 21% statutory tax rate for December 31, 2020, 2019 and 2018, is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (benefit) taxes at statutory rates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,207,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,370,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,908,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,428,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,457,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,898,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,450,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,650,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,838,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,170,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,953,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,268,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deconsolidation of subsidiary</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,176,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited NOLs and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(616,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,176,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2020 and 2019 are shown below:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,300,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,835,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,788,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,242,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,737,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,256,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,255,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,852,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,283,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,722,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,127,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,413,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,484,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,229,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159,705,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,159,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,070,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,676,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,894,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,862,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,381,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(487,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(805,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock', window );">Schedule of operating loss and tax credit carryforward expirations</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:46.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.365%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal R&amp;D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State R&amp;D</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of unrecognized tax benefits rollforward</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company's unrecognized tax benefits:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,632,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,313,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,575,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,210,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,632,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122272808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of equity method investments</a></td>
<td class="text">The following table shows the amounts related to the deconsolidation accounting: <div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (excluding cash) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net of accumulated depreciation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of noncontrolling interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of investment in Geneos retained</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,121,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash resulting from the deconsolidation of Geneos</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,774,851&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The details of the Company&#8217;s 47% retained equity investment in Geneos are shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Geneos Share Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,799,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,113,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The remaining <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.8&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> loss has been allocated to the Company&#8217;s Series A and Series A-1 preferred stock investments in Geneos, on a ratable basis, thereby reducing the investment balance t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o $434,000 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as shown in the table below:</span><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos upon deconsolidation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,584,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,387&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of fair value measurement inputs and valuation techniques</a></td>
<td class="text">The assumptions used in the fair value calculation as of June 1, 2020 are presented below:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geneos enterprise value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,966,531</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351123624648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of quarterly financial information (unaudited)</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the quarterly results of operations of the Company for the years ended December&#160;31, 2020 and 2019 (unaudited):</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Consolidated Statements of Operations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,003,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue, including from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,580,581&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,178&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,187&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327,274&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,302,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,455,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,376,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,111,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,617,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,110,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,071,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,448,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,920,019&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,565,618&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,448,085&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,559,542&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,339,438)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,329,440)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,180,898)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,232,268)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,068,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,984,046)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,846,641)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,803,755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,306,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,755,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,221,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on investment in affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,951,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,883,176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,181,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,050,092)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152,102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,121,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,177,043)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,674,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,087,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) before income tax benefit and share in net loss of Geneos</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,415,201)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,931,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128,270,709)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,135,404)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,923,179)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,759,674)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(901,757)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,338,380)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,171,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,172,466)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,135,404)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,407&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,350&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,338,380)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,171,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128,703,059)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,541,054)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.83)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quarter&#160;Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Consolidated Statements of Operations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,770,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue, including from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,488&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866,863&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,673&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,829,905&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,003,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,137,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,486,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,389,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,696,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,681,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,850,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,975,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,700,541&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,818,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,336,367&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,364,917&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,421,053)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,951,787)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,200,694)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,535,012)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,668,837)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,428,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,194,783)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(656,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,315,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,551,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from investment in affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,681,401)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(485,841)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173,212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(750,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,839)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss before income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,235,146)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,536,452)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,685,847)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,351,667)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,764&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,771&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,800&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,147,382)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,536,452)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,579,076)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,288,867)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485,344&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445,759&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,850&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,605&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,662,038)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,090,693)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,387,226)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,219,262)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351208524136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,338,380<span></span>
</td>
<td class="num">$ (19,171,336)<span></span>
</td>
<td class="nump">$ 128,703,059<span></span>
</td>
<td class="nump">$ 32,541,054<span></span>
</td>
<td class="nump">$ 37,662,038<span></span>
</td>
<td class="nump">$ 23,090,693<span></span>
</td>
<td class="nump">$ 29,387,226<span></span>
</td>
<td class="nump">$ 29,219,262<span></span>
</td>
<td class="nump">$ 166,411,157<span></span>
</td>
<td class="nump">$ 119,359,219<span></span>
</td>
<td class="nump">$ 96,967,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">906,196,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">739,785,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">906,196,812<span></span>
</td>
<td class="nump">739,785,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454,486,400<span></span>
</td>
<td class="nump">9,089,010<span></span>
</td>
<td class="nump">$ 29,227,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,146,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,693,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,146,770<span></span>
</td>
<td class="nump">3,693,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,705,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137,159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,705,000<span></span>
</td>
<td class="nump">137,159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,327,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,327,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | August 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454,500,000<span></span>
</td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net amount of current assets and current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351128935080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Antidilutive Securities Table (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">16,190,768<span></span>
</td>
<td class="nump">30,737,956<span></span>
</td>
<td class="nump">10,449,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">8,906,624<span></span>
</td>
<td class="nump">9,265,390<span></span>
</td>
<td class="nump">8,752,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember', window );">Service-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">2,558,052<span></span>
</td>
<td class="nump">2,069,936<span></span>
</td>
<td class="nump">1,688,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">663,353<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">3,309<span></span>
</td>
<td class="nump">8,456<span></span>
</td>
<td class="nump">8,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024 | Convertible Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">3,049,980<span></span>
</td>
<td class="nump">14,585,653<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Bonds | Convertible Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,799,071<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds | Convertible Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">1,009,450<span></span>
</td>
<td class="nump">1,009,450<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CommonStockEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CommonStockEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351127772568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract', window );"><strong>Summary of assumptions used to estimate the fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.63%<span></span>
</td>
<td class="nump">2.42%<span></span>
</td>
<td class="nump">2.73%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember', window );">Non Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract', window );"><strong>Summary of assumptions used to estimate the fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.82%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.71%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumptions used in estimation of fair value of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351132893800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 5,580,581<span></span>
</td>
<td class="nump">$ 236,178<span></span>
</td>
<td class="nump">$ 267,187<span></span>
</td>
<td class="nump">$ 1,327,274<span></span>
</td>
<td class="nump">$ 279,488<span></span>
</td>
<td class="nump">$ 866,863<span></span>
</td>
<td class="nump">$ 135,673<span></span>
</td>
<td class="nump">$ 2,829,905<span></span>
</td>
<td class="nump">$ 7,411,220<span></span>
</td>
<td class="nump">$ 4,111,930<span></span>
</td>
<td class="nump">$ 30,481,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from deferred revenue beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
<td class="nump">$ 293,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">Advaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_OtherCounterpartyMember', window );">Other Counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_AdvaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_AdvaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_OtherCounterpartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_OtherCounterpartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351113720520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="10">1 Months Ended</th>
<th class="th" colspan="9">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 01, 2021</div></th>
<th class="th"><div>Apr. 11, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Aug. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,580,581<span></span>
</td>
<td class="nump">$ 236,178<span></span>
</td>
<td class="nump">$ 267,187<span></span>
</td>
<td class="nump">$ 1,327,274<span></span>
</td>
<td class="nump">$ 279,488<span></span>
</td>
<td class="nump">$ 866,863<span></span>
</td>
<td class="nump">$ 135,673<span></span>
</td>
<td class="nump">$ 2,829,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,411,220<span></span>
</td>
<td class="nump">$ 4,111,930<span></span>
</td>
<td class="nump">$ 30,481,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,580,581<span></span>
</td>
<td class="nump">236,178<span></span>
</td>
<td class="nump">267,187<span></span>
</td>
<td class="nump">1,327,274<span></span>
</td>
<td class="nump">279,488<span></span>
</td>
<td class="nump">866,863<span></span>
</td>
<td class="nump">135,673<span></span>
</td>
<td class="nump">2,829,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,411,220<span></span>
</td>
<td class="nump">4,111,930<span></span>
</td>
<td class="nump">30,481,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,474,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,065,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,474,310<span></span>
</td>
<td class="nump">6,065,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,003,494<span></span>
</td>
<td class="nump">21,490<span></span>
</td>
<td class="nump">74,102<span></span>
</td>
<td class="nump">71,500<span></span>
</td>
<td class="nump">184,523<span></span>
</td>
<td class="nump">617,427<span></span>
</td>
<td class="nump">64,283<span></span>
</td>
<td class="nump">2,770,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,170,586<span></span>
</td>
<td class="nump">3,636,945<span></span>
</td>
<td class="nump">29,860,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,003,494<span></span>
</td>
<td class="nump">$ 21,490<span></span>
</td>
<td class="nump">$ 74,102<span></span>
</td>
<td class="nump">$ 71,500<span></span>
</td>
<td class="nump">$ 184,523<span></span>
</td>
<td class="nump">$ 617,427<span></span>
</td>
<td class="nump">$ 64,283<span></span>
</td>
<td class="nump">$ 2,770,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,170,586<span></span>
</td>
<td class="nump">3,636,945<span></span>
</td>
<td class="nump">29,860,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">Advaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">Advaccine | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementPaymentEarned', window );">Collaboration agreement, payment earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Obligation period to pay royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination', window );">Agreement period from effective date for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">Advaccine | Collaborative Arrangement | Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">Advaccine | Collaborative Arrangement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
<td class="nump">23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Obligation period to pay royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination', window );">Agreement period from effective date for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementTerritoryExpansionOptionPeriod', window );">Territory expansion option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ProceedsFromCollaborativeAgreement', window );">Proceeds from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAdvisoryFees', window );">Advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination', window );">Agreement, number of days written notice before termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio | Collaborative Arrangement | Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementCorporateIncomeTax', window );">Collaborative agreement, corporate income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementForeignNonIncomeTaxes', window );">Collaborative agreement, foreign non-income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember', window );">AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones', window );">Agreement anticipated development and regulatory event based payment receivable milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones', window );">Agreement, anticipated commercial event based payment receivable milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized', window );">Agreement, milestone payment, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment', window );">Collaborative agreement, period to receive funding for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | COVID19 Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | IN O4800</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill And Melinda Gates Foundation | Collaborative Arrangement | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">884,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">884,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill And Melinda Gates Foundation | Collaborative Arrangement | D N A Encoded Monoclonal Antibody Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department Of Defence | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Grant proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department Of Defence | Collaborative Arrangement | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded', window );">Purchase price, procurement contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Additional Revenue To Be Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAdditionalRevenueToBeAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementPaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Payment Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementPaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementRoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Royalty Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementRoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementTerritoryExpansionOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Territory Expansion Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementTerritoryExpansionOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAdvisoryFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Advisory Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAdvisoryFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementCorporateIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Corporate Income Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementCorporateIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementForeignNonIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Non-Income Taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementForeignNonIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received for Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Milestone Payment, Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementMilestonePaymentRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Number of Days Written Notice Before Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period From Effective Date For Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period to Receive Funding for Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementsUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements, Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementsUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementFixedPriceContractAmountAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaborative Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_AdvaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_AdvaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_ApolloBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_ApolloBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_SARSCoV2COVID19VaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_SARSCoV2COVID19VaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_INO4800Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_INO4800Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351128796232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Debt securities, available-for-sale, realized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 744,000<span></span>
</td>
<td class="nump">$ 594,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Debt securities, available-for-sale, realized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain on available-for-sale equity securities</a></td>
<td class="nump">$ 1,070,975<span></span>
</td>
<td class="nump">$ 1,315,980<span></span>
</td>
<td class="nump">$ 4,358,634<span></span>
</td>
<td class="num">$ (5,050,092)<span></span>
</td>
<td class="nump">$ 1,695,497<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in a gross unrealized loss position | investment</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of securities in a gross unrealized loss position for more than twelve months | investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351133001016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments - Summary of Available-for-sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 159,239,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">2,365,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(690,895)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">160,914,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">153,177,675<span></span>
</td>
<td class="nump">$ 66,599,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">2,339,639<span></span>
</td>
<td class="nump">754,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(644,140)<span></span>
</td>
<td class="num">(15,911)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">154,873,174<span></span>
</td>
<td class="nump">$ 67,338,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">26,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">3,016,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">3,062,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(36,755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 3,025,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual Maturity</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale contractual maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtSecuritiesAvailableforSaleContractualMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351209066920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">$ 160,914,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entities</a></td>
<td class="nump">4,460,366<span></span>
</td>
<td class="nump">$ 6,315,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">154,873,174<span></span>
</td>
<td class="nump">67,338,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">3,016,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">3,025,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">160,914,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entities</a></td>
<td class="nump">4,460,366<span></span>
</td>
<td class="nump">6,315,356<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">225,372,101<span></span>
</td>
<td class="nump">76,003,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,819,023<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,819,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">154,873,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entities</a></td>
<td class="nump">4,460,366<span></span>
</td>
<td class="nump">6,315,356<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">219,330,340<span></span>
</td>
<td class="nump">76,003,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">6,041,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">6,041,761<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,819,023<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,819,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">59,996,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">59,996,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,349,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,349,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">154,873,174<span></span>
</td>
<td class="nump">67,338,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">154,873,174<span></span>
</td>
<td class="nump">67,338,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">3,016,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">3,016,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">3,025,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">3,025,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351132995256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ProceedsFromSaleOfEquitySecuritiesFVNI', window );">Proceeds from sale of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,125,418<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(588,270)<span></span>
</td>
<td class="nump">476,368<span></span>
</td>
<td class="num">$ (1,342,005)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ino_GeneOneLifeSciencesMember', window );">GeneOne (affiliated entity)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ProceedsFromSaleOfEquitySecuritiesFVNI', window );">Proceeds from sale of investment</a></td>
<td class="nump">$ 40,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGain', window );">Realized gain on sale of investment</a></td>
<td class="nump">$ 36,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 | GeneOne (affiliated entity)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares', window );">Number of shares held in an affiliated entity (in shares)</a></td>
<td class="nump">1,644,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets held-in-trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember', window );">Common stock | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromSaleOfEquitySecuritiesFVNI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Equity Securities, FV-NI</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromSaleOfEquitySecuritiesFVNI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of affiliates held for management investment companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611322-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ino_GeneOneLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ino_GeneOneLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351128293656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at beginning of year</a></td>
<td class="nump">$ 8,819,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">75,670,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Derecognition of the derivative liability upon conversion</a></td>
<td class="num">(84,490,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at end of year</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351208724520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers and Concentration of Credit Risk (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 5,580,581<span></span>
</td>
<td class="nump">$ 236,178<span></span>
</td>
<td class="nump">$ 267,187<span></span>
</td>
<td class="nump">$ 1,327,274<span></span>
</td>
<td class="nump">$ 279,488<span></span>
</td>
<td class="nump">$ 866,863<span></span>
</td>
<td class="nump">$ 135,673<span></span>
</td>
<td class="nump">$ 2,829,905<span></span>
</td>
<td class="nump">$ 7,411,220<span></span>
</td>
<td class="nump">$ 4,111,930<span></span>
</td>
<td class="nump">$ 30,481,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_ApolloBioMember', window );">ApolloBio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_ApolloBioMember', window );">ApolloBio | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AstraZenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,587<span></span>
</td>
<td class="nump">$ 3,194,877<span></span>
</td>
<td class="nump">$ 6,850,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AstraZenecaMember', window );">AstraZeneca | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AstraZenecaMember', window );">AstraZeneca | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AstraZenecaMember', window );">AstraZeneca | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AdvaccineMember', window );">Advaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AdvaccineMember', window );">Advaccine | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AdvaccineMember', window );">Advaccine | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AdvaccineMember', window );">Advaccine | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember', window );">Plumbline Life Sciences, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,370,396<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember', window );">Plumbline Life Sciences, Inc. | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember', window );">All other, including affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 870,237<span></span>
</td>
<td class="nump">$ 917,053<span></span>
</td>
<td class="nump">$ 631,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember', window );">All other, including affiliated entities | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_DoDMember', window );">DoD | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">$ 11,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_DoDMember', window );">DoD | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_MCDCMember', window );">MCDC | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_MCDCMember', window );">MCDC | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_ApolloBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_ApolloBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_AdvaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_AdvaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_AllOtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_DoDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_DoDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_MCDCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_MCDCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351128255560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_PrepaidManufacturingExpensesCurrent', window );">Prepaid manufacturing expenses</a></td>
<td class="nump">$ 35,661,947<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">4,695,509<span></span>
</td>
<td class="nump">1,584,598<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 40,357,456<span></span>
</td>
<td class="nump">$ 1,584,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidManufacturingExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Manufacturing Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidManufacturingExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351132358664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 27,341,715<span></span>
</td>
<td class="nump">$ 25,939,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(15,993,571)<span></span>
</td>
<td class="num">(13,166,458)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">11,348,144<span></span>
</td>
<td class="nump">12,773,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">3,038,996<span></span>
</td>
<td class="nump">3,598,388<span></span>
</td>
<td class="nump">$ 3,747,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Property, plant and equipment disposed of</a></td>
<td class="nump">227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1', window );">Accumulated depreciation written off due to disposal of property plant and equipment</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">15,179,447<span></span>
</td>
<td class="nump">15,007,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(6,549,418)<span></span>
</td>
<td class="num">(4,996,777)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">8,630,029<span></span>
</td>
<td class="nump">10,011,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">4,788,678<span></span>
</td>
<td class="nump">4,102,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(3,727,508)<span></span>
</td>
<td class="num">(3,229,357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">1,061,170<span></span>
</td>
<td class="nump">873,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">2,828,675<span></span>
</td>
<td class="nump">3,048,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(2,296,942)<span></span>
</td>
<td class="num">(1,944,293)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">531,733<span></span>
</td>
<td class="nump">1,103,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Computer equipment and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">4,544,915<span></span>
</td>
<td class="nump">3,781,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(3,419,703)<span></span>
</td>
<td class="num">(2,996,031)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">$ 1,125,212<span></span>
</td>
<td class="nump">$ 784,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in accumulated depreciation, depletion and amortization as a result of sale or disposal of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351249634312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 10,513,371<span></span>
</td>
<td class="nump">$ 10,513,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">10,473,761<span></span>
</td>
<td class="nump">10,473,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(7,326,991)<span></span>
</td>
<td class="num">(6,779,910)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, Net Book Value</a></td>
<td class="nump">3,146,770<span></span>
</td>
<td class="nump">3,693,851<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsGross', window );">Total goodwill and intangible assets, Gross</a></td>
<td class="nump">20,987,132<span></span>
</td>
<td class="nump">20,987,132<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsNet', window );">Total goodwill and intangible assets, Net Book Value</a></td>
<td class="nump">$ 13,660,141<span></span>
</td>
<td class="nump">14,207,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Schedule of intangible assets by major asset class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">$ 1,323,761<span></span>
</td>
<td class="nump">1,323,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(1,276,852)<span></span>
</td>
<td class="num">(1,248,104)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, Net Book Value</a></td>
<td class="nump">$ 46,909<span></span>
</td>
<td class="nump">75,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Schedule of intangible assets by major asset class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember', window );">Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(2,468,889)<span></span>
</td>
<td class="num">(2,175,556)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, Net Book Value</a></td>
<td class="nump">$ 2,631,111<span></span>
</td>
<td class="nump">2,924,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember', window );">Bioject | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Schedule of intangible assets by major asset class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">$ 4,050,000<span></span>
</td>
<td class="nump">4,050,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(3,581,250)<span></span>
</td>
<td class="num">(3,356,250)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, Net Book Value</a></td>
<td class="nump">$ 468,750<span></span>
</td>
<td class="nump">$ 693,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Schedule of intangible assets by major asset class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351128349432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 547,081<span></span>
</td>
<td class="nump">$ 1,066,294<span></span>
</td>
<td class="nump">$ 1,249,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351132432904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Amortization Expense (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 521,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">493,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, Net Book Value</a></td>
<td class="nump">$ 3,146,770<span></span>
</td>
<td class="nump">$ 3,693,851<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351112445352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 03, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,068,008<span></span>
</td>
<td class="nump">$ 1,984,046<span></span>
</td>
<td class="nump">$ 2,846,641<span></span>
</td>
<td class="nump">$ 2,803,755<span></span>
</td>
<td class="nump">$ 2,668,837<span></span>
</td>
<td class="nump">$ 2,428,671<span></span>
</td>
<td class="nump">$ 2,194,783<span></span>
</td>
<td class="nump">$ 656,248<span></span>
</td>
<td class="nump">$ 8,702,450<span></span>
</td>
<td class="nump">$ 7,948,539<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,306,000<span></span>
</td>
<td class="num">(97,755,000)<span></span>
</td>
<td class="num">(13,221,977)<span></span>
</td>
<td class="num">$ (4,315,105)<span></span>
</td>
<td class="nump">$ 2,551,453<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(75,670,977)<span></span>
</td>
<td class="num">(1,763,652)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,312,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,312,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,674,435<span></span>
</td>
<td class="nump">$ 3,087,595<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,762,030<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1858045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt instrument, convertible, threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt instrument, convertible, threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,535,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of date conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Debt instrument, convertible, carrying amount of equity component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,177,043)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Bonds | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 3.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="nump">4,962,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,692,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Debt instrument, convertible, carrying amount of equity component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">982,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,000<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleInternalRateOfReturn', window );">Debt instrument, convertible, internal rate of return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Bonds | Convertible Debt | Initial Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.0002110595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Bonds | Convertible Debt | After January 2, 2020 Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.0002756873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,327,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,327,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleInternalRateOfReturn', window );">Debt instrument, convertible, internal rate of return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage', window );">Debt instrument, convertible, required bondholder approval, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds | Convertible Debt | Initial Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0002147766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds | Convertible Debt | After July 2, 2020 Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0003579611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds | Convertible Debt | After July 2, 2020 Conversion Price | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleInternalRateOfReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Internal Rate Of Return</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleInternalRateOfReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Required Bondholder Approval, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_InitialConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=ino_InitialConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJanuary22020ConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJanuary22020ConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJuly22020ConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJuly22020ConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351232743336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Balance Of Convertible Debt (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 78,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleDebtConvertedAmount', window );">Principal amount converted into common shares</a></td>
<td class="num">(62,085,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount on the liability component</a></td>
<td class="num">(2,312,404)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(318,266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtinstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">355,658<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">14,139,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">4,327,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(36,525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentAccretionOfPremium', window );">Accretion of premium associated with the bonds</a></td>
<td class="nump">214,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtinstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">10,818<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 4,515,834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentAccretionOfPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Accretion Of Premium</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentAccretionOfPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleDebtConvertedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Converted Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleDebtConvertedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtinstrumentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtinstrumentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351127968232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Schedule of Maturities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 26, 2019</div></th>
<th class="th"><div>Mar. 01, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 14,139,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">4,515,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">1,110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">1,110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">1,111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">22,519,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">25,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">1,067,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">1,067,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">1,067,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">16,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 20,149,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">5,571,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 5,701,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleInternalRateOfReturn', window );">Debt instrument, convertible, internal rate of return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleInternalRateOfReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Internal Rate Of Return</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleInternalRateOfReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351128494088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent', window );">Trade accounts payable</a></td>
<td class="nump">$ 825,516<span></span>
</td>
<td class="nump">$ 6,919,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">13,127,257<span></span>
</td>
<td class="nump">8,967,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AccruedSubcontractExpenses', window );">Accrued subcontract costs</a></td>
<td class="nump">247,796<span></span>
</td>
<td class="nump">273,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other accrued expenses</a></td>
<td class="nump">7,003,239<span></span>
</td>
<td class="nump">2,076,772<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 21,203,808<span></span>
</td>
<td class="nump">$ 18,237,258<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccruedSubcontractExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Subcontract Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccruedSubcontractExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351132031688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series&#160;C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351129278248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>May 12, 2020</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>May 13, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare', window );">Convertible preferred stock, shares issued upon conversion, conversion price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,647,523<span></span>
</td>
<td class="nump">$ 10,901,320<span></span>
</td>
<td class="nump">$ 10,654,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,906,624<span></span>
</td>
<td class="nump">9,265,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value for options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm', window );">Options exercisable, remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber', window );">Number of options expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,906,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options, expirations in period, weighted average exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.44<span></span>
</td>
<td class="nump">$ 6.27<span></span>
</td>
<td class="nump">$ 5.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, expirations in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,750<span></span>
</td>
<td class="nump">324,502<span></span>
</td>
<td class="nump">119,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options, grants in period, weighted average grant date fair value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.87<span></span>
</td>
<td class="nump">$ 2.19<span></span>
</td>
<td class="nump">$ 2.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,300,000<span></span>
</td>
<td class="nump">$ 113,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options, exercises in period, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ino_EmployeeMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,500,000<span></span>
</td>
<td class="nump">9,800,000<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000.0<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ino_NonEmployeeMember', window );">Non Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">970,000<span></span>
</td>
<td class="nump">$ 302,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,900,000<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Aggregate intrinsic value of unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate intrinsic value of vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber', window );">RSU's expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,558,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.12<span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
<td class="nump">$ 4.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,586,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Reserved number of shares under the Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan', window );">Number of potential shares authorized for issuance under a share-based compensation plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized', window );">Increase in number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grants under the Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,739,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan', window );">Number of shares of vested restricted stock outstanding under the plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,558,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Number of common stock shares outstanding under the Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,742,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Contractual year term of incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in USD per share)</a></td>
<td class="nump">$ 12.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">663,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan | Restricted Stock Units (RSUs) | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan | Restricted Stock Units (RSUs) | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of incentive plan</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember', window );">2007 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Number of common stock shares outstanding under the Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,164,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Contractual year term of incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, shares issued upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Prior Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementRemainingAuthorizedAmount', window );">Remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Stock sale agreement, aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,148,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Stock sale agreement, aggregate proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | New Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementRemainingAuthorizedAmount', window );">Remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementAgentFee', window );">Agent fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Stock sale agreement, aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,915,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Stock sale agreement, aggregate proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of potential shares authorized for issuance under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of vested restricted stock outstanding under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateNumberofSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Number of Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateNumberofSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementAgentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Agent Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementAgentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementMaximumAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Maximum Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementMaximumAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementRemainingAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Remaining Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementRemainingAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ino_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ino_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ino_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ino_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_PriorSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_PriorSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_NewSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_NewSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351127815096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Options Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">8,906,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in USD per share)</a></td>
<td class="nump">$ 6.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">6,079,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 6.58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesOneMember', window );">$1.48-$3.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in USD per share)</a></td>
<td class="nump">1.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in USD per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">452,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in USD per share)</a></td>
<td class="nump">$ 2.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">428,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 2.23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesTwoMember', window );">$1.48-$3.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in USD per share)</a></td>
<td class="nump">3.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in USD per share)</a></td>
<td class="nump">$ 6.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">3,261,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in USD per share)</a></td>
<td class="nump">$ 3.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">1,975,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 3.98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesThreeMember', window );">$6.01-$9.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in USD per share)</a></td>
<td class="nump">6.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in USD per share)</a></td>
<td class="nump">$ 9.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">3,879,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in USD per share)</a></td>
<td class="nump">$ 7.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">2,864,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 7.33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFourMember', window );">$9.01-$12.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in USD per share)</a></td>
<td class="nump">9.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in USD per share)</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">365,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in USD per share)</a></td>
<td class="nump">$ 10.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">233,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 10.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFiveMember', window );">$12.01-$15.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in USD per share)</a></td>
<td class="nump">12.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in USD per share)</a></td>
<td class="nump">$ 15.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">833,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in USD per share)</a></td>
<td class="nump">$ 13.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">546,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 13.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesSixMember', window );">$15.01-$25.62</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in USD per share)</a></td>
<td class="nump">15.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in USD per share)</a></td>
<td class="nump">$ 25.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">114,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in USD per share)</a></td>
<td class="nump">$ 20.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">31,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 20.59<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351121059864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">9,265,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">2,126,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(2,178,252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(306,696)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">8,906,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 5.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share) | $ / shares</a></td>
<td class="nump">10.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share) | $ / shares</a></td>
<td class="nump">5.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in USD per share) | $ / shares</a></td>
<td class="nump">6.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 6.78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122109864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details) - Performance-based restricted stock units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,069,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,586,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(1,040,628)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled (in shares)</a></td>
<td class="num">(57,536)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">2,558,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351127623720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>ft&#178; </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Lessee, operating lease, area of land under lease</a></td>
<td class="nump">13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeNumberOfLeaseAgreementsEnteredInto', window );">Number of lease agreements entered into | lease</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember', window );">San Diego, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Lessee, operating lease, area of land under lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember', window );">Plymouth Meeting, Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Lessee, operating lease, area of land under lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeNumberOfLeaseAgreementsEnteredInto">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Number Of Lease Agreements Entered Into</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeNumberOfLeaseAgreementsEnteredInto</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseAreaofLandUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area of Land Under Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseAreaofLandUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351128883288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Maturities of Operating Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">2021</a></td>
<td class="nump">$ 3,968,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">4,045,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">4,023,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">3,001,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">3,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">9,888,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">27,988,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(7,595,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">20,393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(2,329,394)<span></span>
</td>
<td class="num">$ (2,074,842)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 18,063,515<span></span>
</td>
<td class="nump">$ 20,409,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351124276024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Affiliated Entity (Details)<br> &#8361; in Billions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 27, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 27, 2020 </div>
<div>KRW (&#8361;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454,486,400<span></span>
</td>
<td class="nump">$ 9,089,010<span></span>
</td>
<td class="nump">$ 29,227,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.70%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="nump">395,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_GeneOneLifeSciencesMember', window );">GeneOne Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (shares)</a></td>
<td class="nump">1,644,155<span></span>
</td>
<td class="nump">1,644,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">1,644,155<span></span>
</td>
<td class="nump">1,644,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 40,100,000<span></span>
</td>
<td class="nump">&#8361; 47.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_GeneOneLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_GeneOneLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351128840152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Pretax Loss from Operations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S. Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (162,664,355)<span></span>
</td>
<td class="num">$ (120,809,112)<span></span>
</td>
<td class="num">$ (94,798,019)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225,949)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax benefit/(provision for income tax)</a></td>
<td class="num">$ (22,415,201)<span></span>
</td>
<td class="nump">$ 20,931,010<span></span>
</td>
<td class="num">$ (128,270,709)<span></span>
</td>
<td class="num">$ (33,135,404)<span></span>
</td>
<td class="num">$ (38,235,146)<span></span>
</td>
<td class="num">$ (23,536,452)<span></span>
</td>
<td class="num">$ (29,685,847)<span></span>
</td>
<td class="num">$ (29,351,667)<span></span>
</td>
<td class="num">$ (162,890,304)<span></span>
</td>
<td class="num">$ (120,809,112)<span></span>
</td>
<td class="num">$ (94,798,019)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351120313656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of the Provision for Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,170,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">2,170,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(263,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(263,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="num">$ (87,764)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (106,771)<span></span>
</td>
<td class="num">$ (62,800)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (257,335)<span></span>
</td>
<td class="nump">$ 2,169,811<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351132891064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income (benefit) taxes at statutory rates</a></td>
<td class="num">$ (34,207)<span></span>
</td>
<td class="num">$ (25,370)<span></span>
</td>
<td class="num">$ (19,908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount', window );">Foreign income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">21,428<span></span>
</td>
<td class="nump">25,457<span></span>
</td>
<td class="nump">20,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt', window );">Nondeductible loss on extinguishment of debt</a></td>
<td class="nump">14,450<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncomeTaxReconciliationStatuteLimitations', window );">Research and development tax credits</a></td>
<td class="num">(2,650)<span></span>
</td>
<td class="num">(3,838)<span></span>
</td>
<td class="num">(3,170)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncomeTaxReconciliationFairValueWarrant', window );">Change in fair value of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(1,953)<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">1,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Uncertain tax positions</a></td>
<td class="nump">1,068<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">1,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary', window );">Deconsolidation of subsidiary</a></td>
<td class="nump">853<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits', window );">Expired NOLs and credits</a></td>
<td class="nump">468<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="nump">2,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits', window );">Limited NOLs and credits</a></td>
<td class="num">(368)<span></span>
</td>
<td class="num">(616)<span></span>
</td>
<td class="num">(2,176)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in tax rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differential</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">920<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="num">(102)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ComprehensiveIncomeLossTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (257)<span></span>
</td>
<td class="nump">$ 2,170<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ComprehensiveIncomeLossTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comprehensive Income (Loss), Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ComprehensiveIncomeLossTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Deconsolidation of Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible, Loss on Extinguishment of Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Foreign Withholding Taxes, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncomeTaxReconciliationFairValueWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation, Fair Value Warrant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncomeTaxReconciliationFairValueWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncomeTaxReconciliationStatuteLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation, Statute Limitations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncomeTaxReconciliationStatuteLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351126341544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">$ (87,764)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (106,771)<span></span>
</td>
<td class="num">$ (62,800)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (257,335)<span></span>
</td>
<td class="nump">$ 2,169,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxBenefitsExpired', window );">Tax benefits expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">$ 9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900,000<span></span>
</td>
<td class="nump">$ 9,900,000<span></span>
</td>
<td class="nump">8,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=ino_CaliforniaIncomeTaxAuthorityMember', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=ino_PennsylvaniaStateIncomeTaxAuthorityMember', window );">Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxBenefitsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Benefits Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxBenefitsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=ino_CaliforniaIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=ino_CaliforniaIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=ino_PennsylvaniaStateIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=ino_PennsylvaniaStateIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351120300824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research expense</a></td>
<td class="nump">$ 5,250<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">127,835<span></span>
</td>
<td class="nump">110,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards', window );">Research and development and other tax credits</a></td>
<td class="nump">13,242<span></span>
</td>
<td class="nump">11,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">1,628<span></span>
</td>
<td class="nump">1,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">3,256<span></span>
</td>
<td class="nump">3,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredTaxAssetsIntangibleAssets', window );">Acquired intangibles</a></td>
<td class="nump">757<span></span>
</td>
<td class="nump">889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDerivativeInstruments', window );">Derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredTaxAssetInterestExpense', window );">Interest expense</a></td>
<td class="nump">564<span></span>
</td>
<td class="nump">1,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestments', window );">Investment in affiliated entity</a></td>
<td class="nump">542<span></span>
</td>
<td class="nump">645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredTaxAssetsOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">4,283<span></span>
</td>
<td class="nump">4,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">6,127<span></span>
</td>
<td class="nump">2,413<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, gross</a></td>
<td class="nump">163,484<span></span>
</td>
<td class="nump">145,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(159,705)<span></span>
</td>
<td class="num">(137,159)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">3,779<span></span>
</td>
<td class="nump">8,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Acquired intangibles</a></td>
<td class="num">(179)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(2,676)<span></span>
</td>
<td class="num">(2,894)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount', window );">Note discount</a></td>
<td class="num">(469)<span></span>
</td>
<td class="num">(2,862)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements', window );">Convertible note</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(487)<span></span>
</td>
<td class="num">(805)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">$ (32)<span></span>
</td>
<td class="num">$ (32)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxAssetInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxAssetInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Financing Arrangement, Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxLiabilitiesFinancingArrangementDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherTaxCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesFinancingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351120339640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes Expected Expirations of Federal and State Losses and Credits (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Expirations of Operating Loss Carryforwards, Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinTwoYears', window );">2022</a></td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinThreeYears', window );">2023</a></td>
<td class="nump">5.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFourYears', window );">2024</a></td>
<td class="nump">14.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFiveYears', window );">2025 and thereafter</a></td>
<td class="nump">267.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward', window );">Indefinite</a></td>
<td class="nump">270.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Total</a></td>
<td class="nump">566.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Expirations of Operating Loss Carryforwards, Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths', window );">2021</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinTwoYears', window );">2022</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinThreeYears', window );">2023</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFourYears', window );">2024</a></td>
<td class="nump">9.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFiveYears', window );">2025 and thereafter</a></td>
<td class="nump">132.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward', window );">Indefinite</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Total</a></td>
<td class="nump">143.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract', window );"><strong>Expirations of Tax Credit Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths', window );">2021</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinTwoYears', window );">2022</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinThreeMonths', window );">2023</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinFourMonths', window );">2024</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinFiveYears', window );">2025 and thereafter</a></td>
<td class="nump">19.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardCarryforwardIndefinitely', window );">Indefinite</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Total</a></td>
<td class="nump">19.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract', window );"><strong>Expirations of Tax Credit Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths', window );">2021</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinTwoYears', window );">2022</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinThreeMonths', window );">2023</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinFourMonths', window );">2024</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinFiveYears', window );">2025 and thereafter</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardCarryforwardIndefinitely', window );">Indefinite</a></td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Total</a></td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Five Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Four Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Three Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Two Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in the Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Indefinitely Carryforward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsIndefinitelyCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardCarryforwardIndefinitely">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Carryforward Indefinitely</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardCarryforwardIndefinitely</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Five Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringinFourMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Four Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringinFourMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringinThreeMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Three Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringinThreeMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Two Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in the Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351217417224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Unrecognized Tax Benefits Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of the year</a></td>
<td class="nump">$ 11,204<span></span>
</td>
<td class="nump">$ 9,632<span></span>
</td>
<td class="nump">$ 8,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">1,043<span></span>
</td>
<td class="nump">1,575<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases (decreases) related to prior year tax positions</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Increases (decreases) related to prior year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther', window );">Other</a></td>
<td class="num">(64)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of the year</a></td>
<td class="nump">$ 12,210<span></span>
</td>
<td class="nump">$ 11,204<span></span>
</td>
<td class="nump">$ 9,632<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Increase (Decrease) In Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351122197624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Maximum annual contribution per employee, percent</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Company's contribution to 401(k) plan</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351125694008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br> &#8361; in Billions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 27, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 27, 2020 </div>
<div>KRW (&#8361;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 20, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454,486,400<span></span>
</td>
<td class="nump">$ 9,089,010<span></span>
</td>
<td class="nump">$ 29,227,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedOptionAmount', window );">Awarded option amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneOneLifeSciencesMember', window );">GeneOne (affiliated entity)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 40,100,000<span></span>
</td>
<td class="nump">&#8361; 47.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_GeneOneLifeSciencesMember', window );">GeneOne (affiliated entity)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (shares) | shares</a></td>
<td class="nump">1,644,155<span></span>
</td>
<td class="nump">1,644,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 40,100,000<span></span>
</td>
<td class="nump">&#8361; 47.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
<td class="nump">342,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Operating expenses related to affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PLSaffiliatedentityMember', window );">PLS (affiliated entity)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,000<span></span>
</td>
<td class="nump">589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PLSaffiliatedentityMember', window );">PLS (affiliated entity) | Available-for-sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_InvestmentOwnedAdditionalSharesAcquired', window );">Investment owned, additional shares acquired (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember', window );">The Wistar Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425,000<span></span>
</td>
<td class="nump">616,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643,000<span></span>
</td>
<td class="nump">219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Operating expenses related to affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementExpensesToReimburse', window );">Expenses to reimburse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ProceedsFromSubGrant', window );">Proceeds from sub-grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedAmount', window );">Awarded amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Grant proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliate', window );">Deferred grant funding from affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedOptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Option Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedOptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementExpensesToReimburse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Expenses To Reimburse</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementExpensesToReimburse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_InvestmentOwnedAdditionalSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment Owned, Additional Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_InvestmentOwnedAdditionalSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromSubGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sub-Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromSubGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneOneLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneOneLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_GeneOneLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_GeneOneLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PLSaffiliatedentityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PLSaffiliatedentityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351126314696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,399,999<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,121,075<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,121,075<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,923,179<span></span>
</td>
<td class="nump">$ 1,759,674<span></span>
</td>
<td class="nump">$ 901,757<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,584,610<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember', window );">Series A-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="nump">$ 1,399,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment', window );">Stock purchase agreement, commitment of additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="nump">4,121,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount', window );">Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,584,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="nump">3,618,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,387<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="nump">$ 819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Series A-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,000<span></span>
</td>
<td class="nump">$ 434,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Commitment Of Additional Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351132653016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net of accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,348,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,348,144)<span></span>
</td>
<td class="num">$ (12,773,017)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Carrying value of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,969,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (4,121,075)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(4,121,075)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Decrease in cash resulting from the deconsolidation of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,774,851<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_WorkingCapitalExcludingCash', window );">Working capital (excluding cash)</a></td>
<td class="num">$ (59,992)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Note payable</a></td>
<td class="nump">171,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net of accumulated depreciation</a></td>
<td class="num">(16,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Carrying value of noncontrolling interest</a></td>
<td class="nump">3,181,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedInterestFairValueDisclosure', window );">Fair value of investment in Geneos retained</a></td>
<td class="nump">3,618,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="num">(4,121,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Decrease in cash resulting from the deconsolidation of Geneos</a></td>
<td class="nump">$ 2,774,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WorkingCapitalExcludingCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working Capital, Excluding Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WorkingCapitalExcludingCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedInterestFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of interest continued to be held by a transferor after transferring financial assets to a third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedInterestFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351120876392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Investment in Geneos (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Fair Value</a></td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,113,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Fair Value</a></td>
<td class="nump">434,387<span></span>
</td>
<td class="nump">$ 3,618,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Common</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per Share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,113,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per Share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,799,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351128063464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Fair Value Assumptions (Details) - Geneos Therapeutics, Inc.<br></strong></div></th>
<th class="th">
<div>Jun. 01, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EquityMethodInvestmentEnterpriseValue', window );">Geneos enterprise value</a></td>
<td class="nump">$ 4,966,531,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AlternativeInvestmentMeasurementInputTerm', window );">Equity method investment, measurement input, expected term</a></td>
<td class="text">2 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Equity method investment, measurement input</a></td>
<td class="nump">0.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Equity method investment, measurement input</a></td>
<td class="nump">0.0246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AlternativeInvestmentMeasurementInputTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Alternative Investment, Measurement Input, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AlternativeInvestmentMeasurementInputTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EquityMethodInvestmentEnterpriseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Enterprise Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EquityMethodInvestmentEnterpriseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351209146280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Preferred Stock Investment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos upon deconsolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="nump">$ 1,923,179<span></span>
</td>
<td class="nump">$ 1,759,674<span></span>
</td>
<td class="nump">$ 901,757<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,584,610<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos as of December 31, 2020</a></td>
<td class="nump">434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="nump">434,387<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,584,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos as of December 31, 2020</a></td>
<td class="nump">434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,387<span></span>
</td>
<td class="nump">434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Series A-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos as of December 31, 2020</a></td>
<td class="nump">$ 434,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,000<span></span>
</td>
<td class="nump">$ 434,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351134142248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 5,580,581<span></span>
</td>
<td class="nump">$ 236,178<span></span>
</td>
<td class="nump">$ 267,187<span></span>
</td>
<td class="nump">$ 1,327,274<span></span>
</td>
<td class="nump">$ 279,488<span></span>
</td>
<td class="nump">$ 866,863<span></span>
</td>
<td class="nump">$ 135,673<span></span>
</td>
<td class="nump">$ 2,829,905<span></span>
</td>
<td class="nump">$ 7,411,220<span></span>
</td>
<td class="nump">$ 4,111,930<span></span>
</td>
<td class="nump">$ 30,481,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">26,302,561<span></span>
</td>
<td class="nump">26,455,112<span></span>
</td>
<td class="nump">22,376,575<span></span>
</td>
<td class="nump">19,111,188<span></span>
</td>
<td class="nump">22,003,955<span></span>
</td>
<td class="nump">19,137,209<span></span>
</td>
<td class="nump">22,486,266<span></span>
</td>
<td class="nump">24,389,888<span></span>
</td>
<td class="nump">94,245,436<span></span>
</td>
<td class="nump">88,017,319<span></span>
</td>
<td class="nump">95,257,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,617,458<span></span>
</td>
<td class="nump">10,110,506<span></span>
</td>
<td class="nump">11,071,510<span></span>
</td>
<td class="nump">7,448,354<span></span>
</td>
<td class="nump">8,696,586<span></span>
</td>
<td class="nump">5,681,441<span></span>
</td>
<td class="nump">5,850,101<span></span>
</td>
<td class="nump">6,975,029<span></span>
</td>
<td class="nump">37,247,828<span></span>
</td>
<td class="nump">27,203,156<span></span>
</td>
<td class="nump">29,315,159<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">34,920,019<span></span>
</td>
<td class="nump">36,565,618<span></span>
</td>
<td class="nump">33,448,085<span></span>
</td>
<td class="nump">26,559,542<span></span>
</td>
<td class="nump">30,700,541<span></span>
</td>
<td class="nump">24,818,650<span></span>
</td>
<td class="nump">28,336,367<span></span>
</td>
<td class="nump">31,364,917<span></span>
</td>
<td class="nump">131,493,264<span></span>
</td>
<td class="nump">115,220,475<span></span>
</td>
<td class="nump">124,573,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(29,339,438)<span></span>
</td>
<td class="num">(36,329,440)<span></span>
</td>
<td class="num">(33,180,898)<span></span>
</td>
<td class="num">(25,232,268)<span></span>
</td>
<td class="num">(30,421,053)<span></span>
</td>
<td class="num">(23,951,787)<span></span>
</td>
<td class="num">(28,200,694)<span></span>
</td>
<td class="num">(28,535,012)<span></span>
</td>
<td class="num">(124,082,044)<span></span>
</td>
<td class="num">(111,108,545)<span></span>
</td>
<td class="num">(94,091,138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">931,168<span></span>
</td>
<td class="nump">896,710<span></span>
</td>
<td class="nump">1,067,399<span></span>
</td>
<td class="nump">416,569<span></span>
</td>
<td class="nump">587,679<span></span>
</td>
<td class="nump">637,438<span></span>
</td>
<td class="nump">755,330<span></span>
</td>
<td class="nump">625,535<span></span>
</td>
<td class="nump">3,311,846<span></span>
</td>
<td class="nump">2,605,981<span></span>
</td>
<td class="nump">2,264,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,068,008)<span></span>
</td>
<td class="num">(1,984,046)<span></span>
</td>
<td class="num">(2,846,641)<span></span>
</td>
<td class="num">(2,803,755)<span></span>
</td>
<td class="num">(2,668,837)<span></span>
</td>
<td class="num">(2,428,671)<span></span>
</td>
<td class="num">(2,194,783)<span></span>
</td>
<td class="num">(656,248)<span></span>
</td>
<td class="num">(8,702,450)<span></span>
</td>
<td class="num">(7,948,539)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,306,000<span></span>
</td>
<td class="num">(97,755,000)<span></span>
</td>
<td class="num">(13,221,977)<span></span>
</td>
<td class="num">(4,315,105)<span></span>
</td>
<td class="nump">2,551,453<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(75,670,977)<span></span>
</td>
<td class="num">(1,763,652)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Gain (loss) on investment in affiliated entities</a></td>
<td class="nump">306,317<span></span>
</td>
<td class="nump">26,951,898<span></span>
</td>
<td class="num">(3,883,176)<span></span>
</td>
<td class="nump">13,181,619<span></span>
</td>
<td class="num">(1,681,401)<span></span>
</td>
<td class="num">(485,841)<span></span>
</td>
<td class="num">(173,212)<span></span>
</td>
<td class="num">(750,103)<span></span>
</td>
<td class="nump">36,556,658<span></span>
</td>
<td class="num">(3,090,557)<span></span>
</td>
<td class="num">(1,988,567)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain on available-for-sale equity securities</a></td>
<td class="nump">1,070,975<span></span>
</td>
<td class="nump">1,315,980<span></span>
</td>
<td class="nump">4,358,634<span></span>
</td>
<td class="num">(5,050,092)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,695,497<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">9,350<span></span>
</td>
<td class="num">(136,644)<span></span>
</td>
<td class="num">(152,102)<span></span>
</td>
<td class="num">(425,500)<span></span>
</td>
<td class="nump">263,571<span></span>
</td>
<td class="nump">140,956<span></span>
</td>
<td class="nump">127,512<span></span>
</td>
<td class="num">(35,839)<span></span>
</td>
<td class="num">(704,896)<span></span>
</td>
<td class="nump">496,200<span></span>
</td>
<td class="num">(1,343,856)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,121,075<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,121,075<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax benefit/(provision for income tax)</a></td>
<td class="num">(22,415,201)<span></span>
</td>
<td class="nump">20,931,010<span></span>
</td>
<td class="num">(128,270,709)<span></span>
</td>
<td class="num">(33,135,404)<span></span>
</td>
<td class="num">(38,235,146)<span></span>
</td>
<td class="num">(23,536,452)<span></span>
</td>
<td class="num">(29,685,847)<span></span>
</td>
<td class="num">(29,351,667)<span></span>
</td>
<td class="num">(162,890,304)<span></span>
</td>
<td class="num">(120,809,112)<span></span>
</td>
<td class="num">(94,798,019)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,764<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">106,771<span></span>
</td>
<td class="nump">62,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">257,335<span></span>
</td>
<td class="num">(2,169,811)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="num">(1,923,179)<span></span>
</td>
<td class="num">(1,759,674)<span></span>
</td>
<td class="num">(901,757)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,584,610)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(24,338,380)<span></span>
</td>
<td class="nump">19,171,336<span></span>
</td>
<td class="num">(129,172,466)<span></span>
</td>
<td class="num">(33,135,404)<span></span>
</td>
<td class="num">(38,147,382)<span></span>
</td>
<td class="num">(23,536,452)<span></span>
</td>
<td class="num">(29,579,076)<span></span>
</td>
<td class="num">(29,288,867)<span></span>
</td>
<td class="num">(167,474,914)<span></span>
</td>
<td class="num">(120,551,777)<span></span>
</td>
<td class="num">(96,967,830)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">469,407<span></span>
</td>
<td class="nump">594,350<span></span>
</td>
<td class="nump">485,344<span></span>
</td>
<td class="nump">445,759<span></span>
</td>
<td class="nump">191,850<span></span>
</td>
<td class="nump">69,605<span></span>
</td>
<td class="nump">1,063,757<span></span>
</td>
<td class="nump">1,192,558<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="num">$ (24,338,380)<span></span>
</td>
<td class="nump">$ 19,171,336<span></span>
</td>
<td class="num">$ (128,703,059)<span></span>
</td>
<td class="num">$ (32,541,054)<span></span>
</td>
<td class="num">$ (37,662,038)<span></span>
</td>
<td class="num">$ (23,090,693)<span></span>
</td>
<td class="num">$ (29,387,226)<span></span>
</td>
<td class="num">$ (29,219,262)<span></span>
</td>
<td class="num">(166,411,157)<span></span>
</td>
<td class="num">(119,359,219)<span></span>
</td>
<td class="num">(96,967,830)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net income (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember', window );">Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (8,177,043)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,177,043)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="nump">5,674,435<span></span>
</td>
<td class="nump">3,087,595<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,762,030<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5,003,494<span></span>
</td>
<td class="nump">21,490<span></span>
</td>
<td class="nump">74,102<span></span>
</td>
<td class="nump">71,500<span></span>
</td>
<td class="nump">$ 184,523<span></span>
</td>
<td class="nump">$ 617,427<span></span>
</td>
<td class="nump">$ 64,283<span></span>
</td>
<td class="nump">$ 2,770,712<span></span>
</td>
<td class="nump">5,170,586<span></span>
</td>
<td class="nump">3,636,945<span></span>
</td>
<td class="nump">29,860,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember', window );">Revenue under collaborative research and development arrangements from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">82,774<span></span>
</td>
<td class="nump">103,684<span></span>
</td>
<td class="nump">95,146<span></span>
</td>
<td class="nump">1,172,126<span></span>
</td>
<td class="nump">55,665<span></span>
</td>
<td class="nump">53,014<span></span>
</td>
<td class="nump">71,390<span></span>
</td>
<td class="nump">55,579<span></span>
</td>
<td class="nump">1,453,730<span></span>
</td>
<td class="nump">235,649<span></span>
</td>
<td class="nump">449,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ino_OtherRevenueAffiliatedEntityMember', window );">Other revenue, including from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 494,313<span></span>
</td>
<td class="nump">$ 111,004<span></span>
</td>
<td class="nump">$ 97,939<span></span>
</td>
<td class="nump">$ 83,648<span></span>
</td>
<td class="nump">$ 39,300<span></span>
</td>
<td class="nump">$ 196,422<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,614<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_OtherRevenueAffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_OtherRevenueAffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351312576520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 25, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Underwritten public offering, common stock (in shares) | shares</a></td>
<td class="nump">20,355,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in USD per share) | $ / shares</a></td>
<td class="nump">$ 8.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes', window );">Commissions and other estimated offering expenses | $</a></td>
<td class="nump">$ 162.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount for commissions, taxes and other expenses that were incurred but unpaid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140351123721624">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
<td class="text">us-gaap:AccountingStandardsUpdate201601Member<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>109
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M6*+XB%.<*+[-/VNLN%(\R0\WC,)JUP_ _37GZGBB7U!^2KO["U!+ P04
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MO]N7?YFM0Z+?K[!5._Q%+UM;/$'%NNWL<KL8$"S+>O,_?]T&8F\!X9$%=+N
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M(R_Q4$879,7-D]Q\H;6AGN5+)=?N'VVJV%[?0^E*&UG48%!0,%$]R6N]$#N
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MY\SZ8DCCQ3"[29-_H].(/.HR!_'RB[&PMN?04Q+H[6->/#E3CA\J?T6$^LI
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MJHV -@P) 8E0Q">0W 3-;D "% D!B5#$)Y#B!,UQ0 (4"0&)4,0GD.@$S71
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M_;<'UA_*[*'Z/>.[K"RS9?7C'$ZR,E<"@-]G6;GYH!ZP_0L09_\'4$L#!!0
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M!-W+D@U+0<EH-Y;,&*R-J Q-7PPXS ,.2P/.;]Y=#^N&KMC7XIXG+W2QK>X
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MA)#XC5OSH5XQ(B&&YC+J-[0,P[DT4[/(PPL_4T!Q.P+9:E<O!U.I*CI'L$+
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MOKVWQ=*V3@!_7S4P8,8?W <<7A__\#]02P,$%     @ M'YA4O6V]=^I"
MVQ(  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6R=6&%OVS@2_2L#'["7
M $[BN-GK7IT&<)RTR:)I#:>; GNX#[1$6]Q0I):D[&I__;T9R8Z=38OB@**Q
M)'(X\^;-FY'.USX\QD+K1%]+Z^+;7I%2]>;D)&:%+E4\]I5V>++PH50)EV%Y
M$JN@52Z;2GLR' S^=5(JXWH7YW)O&B[.?9VL<7H:*-9EJ4)SJ:U?O^V=]C8W
M9F99)+YQ<G%>J:6^U^FW:AIP=;*UDIM2NVB\HZ 7;WOCTS>79[Q>%CP8O8X[
MOXDCF7O_R!>W^=O>@!W25F>)+2C\6>F)MI8-P8T_.YN][9&\<??WQOH[B1VQ
MS%74$V^_F#P5;WN_]"C7"U7;-//K&]W%\S/;R[R-\C^MN[6#'F5U3+[L-L.#
MTKCVK_K:X? C&X;=AJ'XW1XD7EZII"[.@U]3X-6PQC\D5-D-YXSCI-RG@*<&
M^]+%YT+3Q)>5<LWY28)!OGV2=9LOV\W#;VP^'=*==ZF(=.URG>\;.($G6W>&
M&W<NA]^U>*6S8WIUVJ?A8#CXCKU7V_!>B;U7W[#W*2R5,W\I9D ?@;KHK<E5
M2PB7TS3HJ%UJ;_@%O3-.N<PH2_>XJ<&^%.D_XWE, ?SY[W<\.MMZ="8>G?U_
M@/_P9KIU?F4\30L%<F:Z3B93-O9Q'Q >)*S\Z1^_#(>#4;=!KDY'Y,/FP>W'
M3P^WG[K[AWTRD13-C4\Z*YRW?ME0UAVV\."BSHDK454FMPW-@W%+_*/D0<CP
M" &!+&0&%=>@+J)9.FRX^CBF4N<F0R21ER9(1Q+LJ\ G89?VE=6T"+XDXQ92
MKG6D')90;H@H0TITZ,NFS5U2,7HD*N&,M4D%%76I'%5PSEI?JI4)L'%P,WTX
M/*8VT'_&9]Y4IM*,, ?.@08C(2XH%4%K2DV%1;B$HWD-1^%'SN31\8U86JE,
M#/7ERI1E[3QP9X#80==&KUWF41Q4>N<SZQVXI5PR<Y_SJH/\#NQ"1DY?GXV(
M?764P2E.)K R;4K%?RH44-&PPVSDP%,!*/=C@H\TUUAF(79!,V!(2D)*C /Z
M&>0OXB<Q/^!"P['Z>EF0 =$1*$#0">I,$3E-L+,RF>:\93C6Q(2"@"W14KA
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M P7;LN8_L^_"A^"%9T=[7CB6%XZ);IZ(J'R5==F+YVUSD[3X-(R&?Z&ETMM
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MBB;/6-12W%,X>@ =^PI?2G#*%A>;-Q9Q&X*^W6WDM6RS.F-<A^^!3.1&)^A
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MM7*6>>)Y<F76A&P^&0P\XN ?7%S6\G?L_I1HT4'M(JY#*+(%=FF4!L"<04+
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M=S*-47(KF->!>15I!E<^M6'W*X@PV_P0P;RP)$BN4,>C".FR8V/9&T1ML".
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M!6$@1FC[M0,>I-M+VKGI%FT1:I!!LJA$RO@ &5\KI) .3.D+48-;!IBMV4V
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MTR50S7!&[_36ARA#K@[BTH#1FVNS/Q _0::SYG!4#?VDPH L+!3\9KCKP(A
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M7S4 !.4?. %&(HF\%_\+4$L#!!0    ( +1^85+XY+W$ P,  /4&   9
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M2:@<6!" NQ1B :Q9ZKI7"V# AKBTP@IAMID,_4 ;-N(B.8:P<,$B!O4J_NU
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M'B#5%O<SX,99C/2_N&+%&%LI6E=YB:"-K:4PEZV;E(Z%17DGZ]J,CU&.GG'
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M68J.;4XZM)]V91YM/^IL6UOV>%JHK_646WZN<P)&!TX]1Z>"YS"HGL?W^,C
M1'PI\%R%'#GS<GS]\7H2=O;$8\5%O>A,39%V%C%K4236M0P3Q:E-L*W2C6ZC
MT09 MPWG[@%OLZ@C&('O-B3KG$+LP!H?[' UWI\ :@-,>W <(7$,2JD_2-Y%
MIS^ 29T,KN7Z"XQ*_B;S\JEX"T(N4BE^)4M^!:MV7U< 8WR?U,;'S"R!^[RX
M[\^\XXWPF0!OQ\@]7-@.DXZW7Z!9I#>TU'[[ 4O-;\\7EI])Z40[[5BAV%@7
M5!(TC0T!5$G!?/C0091&8KS7W?)&YRV!=XKG]N9!NF HI(0)LD85W[BG^_KJ
MLQNH;YW4?,#L.QR_;:TJ-X5),FZT V$+DU+'C<YV4-V!FW&!,DF-#SJ#@Z?:
M#9]6@NPVA7S6;0"A_6/8N6,\Y?H6AP@L*L=]6<1]?C#C:&-9>[05>[D_(QQA
M'7]P\NB8]H%0_#%OI^S''_<WN[[N\QI1,;Q7OG>L\>#T\2E1]V?89!LB^,03
M26!JO\,VMKN,$?-@+!C!>W_0\;ZH_^,X[>4>:==WR!:ODV3.SD[^),F Q;(0
MG( N,..M/0<O8 XD9/_"7#RD^ [+[G=]5060D_HUGZ*&P3G$ *;"$!.9?HV'
M"K$LNN4S*^\_G;=WNI]:P:> FI Z162T'_AHOR3AV.J%MU,=R+6WM3=W!);S
M("KS+GNMOM:!#F*YME;664MOS\\PS;\?D8/#N124'D#6GV,<CQ%X:4JLR$9H
MSP_$UW$CU^W:9*JS;R7>U..L"B=V^1\-\LH8-M<+;':>=T\!QX)\=7'>?N[E
M4Y\;M-$'ZX5A*]A](ZB[V-1)>^.1<)LJI,$6G(8O;WK(WWZ<,V[[%0U9/'I?
M?Q(W#G8]]?@MIHOS+;QD5E#-VD5:>-];,&\QXA+_C=29=/XNUIQF7+W"SJFO
M.N=F]H/3D[82.6QAC>U(Z([8'K6D31TIV3E/_[%9U-0I?')Z-GUT=#H1[TP]
M!59.P;YQ7_RE^QS/](,K(W[@XB*Q?-)N0O!GHJF@YT^&Q%MV>-/-"FL?!9=0
M5W2^AD KV';8OH(VI:VK OOME?!+X^Y9X#ENZPCHKRO&8[UH1O;"4 &+87<
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M&I,%]D7($3>7PB\-?&LL-E'PI6ZVY,8%#X;M>RN@!KSU@-=ZW18Q<4P0^9P
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MEQ;@_5)AGPXW)*#YL<J+_P!02P,$%     @ M'YA4M2Z-Y&H P  :@@  !D
M  !X;"]W;W)K<VAE971S+W-H965T,30N>&ULM591C^(V$/XKHY1M7R(2)X&$
M+2"QT.I.ZDJKW5XKM>J#209PUXFI[<!M?WW'#N2XZ[)55?5A-_;8\WW?C,<>
MID>EG\T.T<+'6C9F%NRLW=]&D2EW6',S5'ML:&6C=,TM3?4V,GN-O/).M8R2
M.!Y'-1=-,)]ZVX.>3U5KI6CP08-IZYKKESN4ZC@+6' V/(KMSCI#-)_N^1:?
MT'[8/VB:13U*)6ILC% -:-S,@@6[O<O<?K_A)X%'<S$&%\E:J6<W>5_-@M@)
M0HFE=0B</@=<HI0.B&3\<<(,>DKG>#D^HW_O8Z=8UMS@4LF?165WLZ (H,(-
M;Z5]5,=W>(IGY/!*)8W_#\=N;S8)H&R-5?7)F134HNF^_.,I#Q<.17S%(3DY
M)%YW1^15KKCE\ZE61]!N-Z&Y@0_5>Y,XT;A#>;*:5@7YV?D]_UUI6'HBU 9X
M4\%2-24V5G.?-[6!I<9*6'@4YGD:66)UOE%Y8KCK&)(K#"R!>]78G8'OF@JK
MSP$BDMMK3LZ:[Y(W$5=8#B%E(21Q$K^!E_8Y2#U>>@7/Q=5%_H$"UY9*V0HT
M\.MB;2@+I?WM#9*L)\D\2?8_)OI-!G=];\V>ES@+Z'X:U <,_C5MO]4G%Q[Q
M@$V+<..V_:@LEV1GDROVXC7[8J^D5'="P0"^_JI(6/)M_[VY8DO2,(YC]P?Y
MB"P+=PZ_8(,E!Y;'X:C((8$T9),L+/(<\@+&83&*PRS)R!D6U8&7)>4'1CW0
MN/@;U9??!]G6:Y=6^$%L$)Y*@90I$\+[ABJ.A2E1IY,QL'^&6D@)RNY0AR":
M4K:5:+; -QLA!;=8 >5?^"(K"#-)<Z!K,F%Y&(]22!(84WEG.0U/2=2GO X@
M#S/&PH3.AE%0-\#(EH6,;)/T;!M 2JDH6%A,\I-IU6JG@!3!"W(J!'27$>@J
M8;VFTSY?I[ [7U<F[D!#[[%4]9XW+Z2B5-M&_$F.9T$;K6HX<"U4:T *JBN#
MWML'#WRK$>D-I\9!A^B*XA7& 6/#C!XW*:D>0Z!Z'2<WH4<9Y$/VV4I:T K!
M7,CZAJJZ+%5+)$XAB@-?2X0C)[NU6JQ;ZPU6>:^56GGHOD9"\C)[].U!OES1
MR2:D,QM/?#EYB?E9(ANSWIJD_T7>_7*U[+1]JO<OU;WV%$47[S]=W:WO<@8\
M:=<*>FO?2!==__BTO>O"]UQO14-'B1MRC8?Y* #==;9N8M7>=Y.ULO1.^.&.
M?@R@=AMH?:.4/4\<0?_S8OX74$L#!!0    ( +1^85(460_EYP(  )0&   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;+5537/;-A#]*SMLIM/.,.*'
M2'VXDF9L.9WZX%CC3)M#IP>(7(J8@  +@);37]\%2-%R)G8NR47$ N^]?;L0
MEZNCTI],C6CAL1'2K(/:VO8BBDQ18\/,1+4HZ:12NF&60GV(3*N1E9[4B"B-
MXUG4,"Z#S<KO[?1FI3HKN,2=!M,U#=.?KU"HXSI(@M/&/3_4UFU$FU7+#O@!
M[9_M3E,4C2HE;U :KB1HK-;!97)QE3F\!_S%\6C.UN JV2OUR04WY3J(G2$4
M6%BGP.CQ@%L4P@F1C7\'S6!,Z8CGZY/Z[[YVJF7/#&Z5^,A+6Z^#10 E5JP3
M]EX=_\"AGMSI%4H8_PO''CN?!U!TQJIF().#ALO^R1Z'/IP1%O$+A'0@I-YW
MG\B[O&:6;59:'4$[-*FYA2_5L\D<E^Y2/EA-IYQX=K/3V#)>PKM'NF:#!I@L
MX<[6J&';:8W2PJ4Q:,TJLI3.D:)BD+[JI=,7I),4;I6TM8%WLL3RN4!$/D>S
MZ<GL5?JJXC46$Y@F(:1Q&K^B-QV+GWJ]Z8MZ%5*-)6R5L2:$+6NY98+_AV4(
M0V?"LX[TG8!K;@JA3*<1_K[<&ZOIK_7/*W:RT4[F[60_XBZ^D_2I;,!SI/+(
M8D"R'LDLT(5@LZ>CTZ5X=!HG2R@4O;C&4G-5!42'2@F: %P>+GJD1YVR-4QV
M%;6QTP1XROT+^Q7>P#0/9[,D7&9S"G[^:9$FZ6^#^?9+MUDX6^9A'B\A"?-%
M%N;+!9&R.)SF\S#+9Q0\'3CY;SC0*)@KPBIZUUME.!7>L!+=AD:#^@&A8"TK
MN/U,)6I?ZG,MJO_F_=W;;!''7K=P>ERZ+B03N)&>@@^NL[9F]BL*I2(G4EE0
M!=W!B>N!HZDC%P+VKLVZ0DXI)E_[1T9GDZ)!??#ST-!E==+V0V/<'4?N93]I
MGN#]O+YE^L"E 8$54>/)/ ] ]S.P#ZQJ_=S9*TM3S"]K^FR@=@ ZKY2RI\ E
M&#]$F_\!4$L#!!0    ( +1^85*]3,X)!00  *,(   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$V+GAM;)U6VV[C-A#]%<+8ARS VB0E65+@&,AE%RVPVP:[
MO3P4?: ERB96$KTD%<=_WT/*45SL)BWZDFBHF3-GCF8X7AV,_>)V2GGRV+6]
MNYKMO-]?+A:NVJE.NKG9JQYO&F,[Z6':[<+MK9)U#.K:A6!LN>BD[F?K53R[
MM^N5&7RK>W5OB1NZ3MKCC6K-X6K&9T\'G_1VY\/!8KW:RZWZK/QO^WL+:S&A
MU+I3O=.F)U8U5[-K?GF3!O_H\+M6!W?V3$(E&V.^!..G^FK& B'5JLH'!(E_
M#^I6M6T  HVO)\S9E#($GC\_H;^/M:.6C73JUK1_Z-KOKF;%C-2JD4/K/YG#
MC^I43Q;P*M.Z^)<<1M\4&:O!>=.=@F%WNA__R\>3#F<!!7LA0)P"1.0])HHL
M[Z27ZY4U!V*#-]#"0RPU1H.<[L-'^>PMWFK$^?5[_:AJ<NV<\FZU\$ ,YXOJ
M%'TS1HL7HKD@'TWO=XZ\ZVM5_Q-@ 2H3'_'$YT:\BGBGJCE)."6""?8*7C+5
MET2\Y 6\>XO^M?Y(R7TK>T]D7Y-W7P>]1V-Y\N?UQGF+SOCKE53IE"J-J=+_
M*>5_CR:C(4=#>@)55+=1=E(FUB$8+TEE,"#.P]TTQ.\4:4R+2=/]]I+<&N?)
M=54-W=#*X/(SIOP&$X(\P?U;V \*';XS;4UTM[?F0069''E#>$9Y7M(TS6%<
M+&F6PN#%6U@%72:,,E&2#W)CK/3&'HF:-$YI7L E+\A%0G.1TXPAC%.VY(!D
MY)>FT15H#[;7?K JEM;HQ_#LB*"%"-$9N1!4E$M:IN(MR4 X3Q(4V.T'CP*>
MTX5H QTL$F=I2DN>A<0I+VG.DI"8BXP*=.X; C))"B2XH"B46)8)S7(>JN(<
M[PK*T_3[8D'ZU\1B+*=E$G'! ;SS/(^P4 K0/"M>4HLS0=-E'D@+4=(D0UR1
M)Y3S?],JH0R,69:@%NB40J^Q8 ;AE^QUM>!2X*.@!R!T(,P2Z) 78%^402NH
MD^";YZ-6X+-<TC2+'< %RD-VGD,E[(9*RWCEJD?L#A=:TL;6/"II'5'AJOBV
M]TZBGAJ[( <)*9,YPZW7MD"CP5H^6=$/!_GS:TBP5_&2;X]S\BORA8)E?\0M
MC:IQ>2*MWV&< I=*6GO$E) 'V0[J-#S@VII^^T,+D&G^ I'>^/"1I;8XKP<;
M @,*[A9M:D=0M(.>JIZ3N^>WH=Z7RHT.$T'M]L:-,]R<S_Y!^QV1I,?<ALWV
M3/:-0/,R-EX$\FS$Z_,/$!T9"X[S[]UPB[/%T2F[C>O1X4X9>C_ND.ETVL#7
MX^)Y=A_7]T=IM[IWI%4-0MD\SV;$CBMQ-+S9QS6T,1Y++3[N\"M"V>" ]XTQ
M_LD(":;?)>N_ 5!+ P04    " "T?F%2=2*!)9,$  #T"@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-RYX;6RM5FUOVS80_BL'+Q@2@+!%2K+DS G@-%L7
M8-V"OJP8AGV@)=IB2XDN2<7)?OV.E*S8>2O0[HNM(^^>>^YX=^1\J\UG6PGA
MX+96C3T;5<YM3B<36U2BYG:L-Z+!G94V-7<HFO7$;HS@93"JU81%T712<]F,
MSN=A[=J<SW7KE&S$M0';UC4W=Q="Z>W9B(YV"V_ENG)^87(^W_"U>"?<A\VU
M06DRH)2R%HV5N@$C5F>C!3V]2+Q^4/A3BJW=^P8?R5+KSUZX*L]&D2<DE"B<
M1^#X=R->":4\$-+XTF..!I?></][A_Y+B!UC67(K7FGU49:N.AOE(RC%BK?*
MO=7;7T4?3^KQ"JUL^(5MIYO&(RA:ZW3=&R.#6C;=/[_M\[!GD$?/&+#>@ 7>
MG:/ \I([?CXW>@O&:R.:_PBA!FLD)QM_*.^<P5V)=N[\M=;E5BH%O"GAJG&\
M6<NE$K"P5C@[GSCTX34G18]WT>&Q9_ H@S>Z<96%GYM2E(< $R0W,&0[AA?L
M1<1+48PAI@18Q*(7\.(AXCC@Q=\4,5Q*6RAM6R/@[\72.H-U\\\+;I/!;1+<
M)O];HK\'#]Y7 E9:8<_)9@UA"3O85;#>MY/W=KRS6]YA=7W2II.A4/A_"G@&
MHEX*,YS#PQ4Z@X^A 40)BQMAL)_A@Q6K5L%KHZV%15&T=:NX5_@=@2^P3U_:
MNL+J6<E&.@$*V[8\A5W Q_P$CH!&)*4QB3.*PH\_Y(RRGQXN?UWG\H&/WV2!
M\T98U %*8A:3;$KAF!*634F>LA-(IF06S1YL)CFA47("64JF:0874G_"H0/'
MRQ/ ?DAQ,R)1%,$Q(\DT)WD^.P%&II@Z2NGA/D6,-)WZ_1E+2)(D\(>K,,_'
M!8+ED) H[95CDN;H/(T\JYQD:72X&Z?3;G<ZB\/N>^VX>N+,D0/F),GZ@#*,
M#:.<T1.("<6 LRPZ4/ K,S*CD5?PX'E*>_"O5-<1E@J9Y1FA,4-AWQ6>"X)-
M(_1('^GM>42]A+ H(XPQ\+4P-,*66[PF"FUP[L#*Z!HP<3CVO[32RG %Z!7H
MD,Q"UQO>2#QHS[,C-P[GM3N[Q]R-P%O/BL8%6&&=K$/)KK@T<,-5*SQ^*6[P
MHMO@NA-%U6BEUW>[9.#5@] MIFEC4,6X.]A6LJA@*W#:'%+G3=^!>_S'H0BZ
M<OA6?@'.B&?XC&&Q7ANQ1D/@-<X+^2\/F1.W&]\8@)^//?O$'Z5)Y@N/P!$=
M4[RIE J7+D:."VQ8P"$4^-T);BP(?T<\GB[]1/'&^)$3C,UN1+B_E>?X%#,C
MN@GB]!,,N7MBA$D;C(O>:BG0L&B-3PZW_?#$V?<7,O5$_1Q]".(K-64T=!R*
M#!+LAEZ(P0^-7DB I<-..@@XI?$EM7*(B!,E[8".0MME]PI=?308&%:M-+4_
M8TSCGB217L&=QI3NBL G#TWP*O/S[+#"RM;X:+[S')ZZ%"=[+Y%:F'5X;UGL
MM[9QW:-D6!V>=(ON)7.OWKT'WW"SEHT%)59H&HVS= 2F>V-U@M.;\*Y9:H>O
MI/!9X;-4&*^ ^RNMW4[P#H:'[OE_4$L#!!0    ( +1^85)><XQ>:Q(  'Y"
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;-U<:X_CQI7]*X7>]FXW
MP%&+U+,]#Z#'LT8FAIV!QTX0+/9#B2Q)E:%(F45VC_+K]]Q;1;(HD?UT-D&^
MS*C)>MRZ[WOJ2F_N\N*+V2I5BJ^[-#-OS[9EN?_VZLK$6[639I3O588WZ[S8
MR1)_%ILKLR^43'C2+KV*QN/YU4[J[.S=&W[VJ7CW)J_*5&?J4R%,M=O)XO!>
MI?G=V[/PK'[PL]YL2WIP]>[-7F[49U7^NO]4X*^K9I5$[U1F=)Z)0JW?GMV$
MW[Z?TG@>\&>M[HSW6=!)5GG^A?[XF+P]&Q-!*E5Q22M(_'>KOE-I2@N!C-_<
MFF?-EC31_URO_CV?'6=92:.^R]._Z*3<OCU;GHE$K665EC_G=W]0[CPS6B_.
M4\/_BCL[-EJ<B;@R9;YSDT'!3F?V?_G5\<&;L!P/3(C<A(CIMALQE1]D*=^]
M*?([4=!HK$8?^*@\&\3IC(3RN2SP5F->^>Z[/+M51:E7J1(?U*I\<U5B57IW
M%;L5WML5HH$5PDC\F&?EUHC_SA*5=!>X CD-35%-T_OHWA4_J'@D)F$@HG$T
MOF>]27/&":\W&5QO58H/VL1I;JI"B?^Y69FR@#[\[SV+3YO%I[SX] 4,O'<%
M,KMOS5[&ZNT9[,JHXE:=G2PK_ >?5:;S0OR4E\J(/V7B>[4J*IB4"*^):>&U
MD%DB?I1%O!6A?1*(<JNPR&XOLX.(\7^J2I4(*?:%OI6E$OL4),#<2I&OQ?EB
M.9I!W]*436>S*=2&!Q4ZB_5>ID+N\LJ.U:41\]%L_ V6;6DTEL:,:4PJ1<*<
MB@NBXC__8QE%X]=,/G\.7U^.Q"]X8T]TIR DDZ>)T)E'8+Y>*VR_$64N?JMD
MJM=:T1!3ZK(B$P=5J^J@"B/V56$J"?(P].<*U(33Z8VHH)\%\^&SBJM"EQJ;
MW<1\B/!Z,@F$-#B7(C4>B9_@$?=%'BN5&+$N\AW/;(A@(N4>([YJ. >5'L"T
MV6A1,\T_D"P:?E29H;U!>+Y*-7B*H88(\,5#TI-Q7(!K.BNQD0$I\B")KV!)
M+,T6Z^WT*YEE8 2V)D85<,HX.^3E),_K?%;[4NU6.'A(VRB)-P<,#,1*;726
MT5DPQ1M6*XPLP?S"<MX)>(_WM.>N(RX<&"ZI)--J-V?KG08X<*J,P;Y%JC';
MJ8A* KCT1$'AP(D"GR&R> OW"LY_*HA3$!WQA(R6*5A5!H9C^(#THOD[D3C_
M#@MI*P8848P_<*Z?\EOO3-'$&H%']4IU=!8G9AGO.6 XH6RAB(KYBK6KO=O=
M0')F+>-Z9(PU),E&%W&U,Z7,8F682Y#*&C)\T=XD"NA%B7 (AI8ZO9\U%+H3
MJ'TBX.:8$\<\6BG$<\6#67*Z/&!,J4;B5SJA)8P";]=O,.'01!)9HE+$TX*-
MAJF!\+ 8K1VPB@;";*'YIO81<#H[K(V0%G^A!20]6>E,-CPDO2:='9['6DD/
MZ[!N%5%G,&:8?TNW5=R:T>%R-EJ.I[-Z9=+C\S 8C\>]'LU*Z4+]5L'SI,KZ
M$9GU;8/I,<O@R!7,1I,E;\,[7H(7U>IO()E72OZ&P,ZNMM&G/(97*%1F%S-[
M%5OWIFXQS"I2(P5B,ORJ,R!/K_:UX?@V&(TH1!"_20V[K[K2I77=FG J <_!
MXWU>E*P)3BGM7M ?*S!MGZ;2$$4T&&0;L,WQIF'"D9?[KR.-4%^MJPTG<#1N
MZ"FC,W&A+ZT7(Z:7(E6T<33V51VRN]LJ+% (&X)H(?*[E %>(AK9,((-)F/_
M57<-Q 'K' -62JA)6M$3R[1'6%;-5[C^Q-I(H5))["$N[ZRE@SH<[#5O<:%Q
MMD<N3M;:LXNIP)F3Y:W^>(\M-VOS4!1.26_"<<O[/L-HQ8_!*]6X\ #90V5<
MS$KX+%6VESIIXU>9(^)4)8G99Z-'D_4_OJ(K6%_%#*.A6)WH(+Z0\M$C;2C,
MQZI+&VT/J=(^/-6Y5@H%"3WQM&JM.&X9L:,"R!($JR\X$;)*+N'I. ,A!3$Q
MRB%654LS#: ,I*CL!-Z,='V5ES -9!)?B03V'A@ -TL)3[AX#>]V5VL^TPO[
M,75&8Y\[Y^\FD)#(2^.M=8H9,B2=,'=6,F4N<!E@M;4Y-=NH=^)-A4DT& X+
M$;F.4:17?HAJ.-ND0*=9(25 :9K'3,-:%RQEZPRT7.F4R*5,,\_(U5'ME-01
M:BUU(4BZ++HLSU[YL3"AA/=.@X,Y&?&=1F31"?$OACI"7#IAA57%SMAQ5G+N
M>4-R2QWH<ORK5:='";K*ERA:'W'58V:7;'K22SI[]7[=O$.T/)]'HZAE8T;^
M(,X+JZS:U/9&R:C'22M5SD"-*MD,_(&\<8(BIWT$VZIL@E+G4L@1#S2Q<P1+
MF!,,Y136\]3&R LWAXES ^V#KN:Q9LXV['?+0$NBT7) 24[4@P[E!--JBJY3
MK!VKGXL_=9YQHIGWBPV;6RUJ;;TK$,KCXY3RTX.S1&15]/GHC([%6S" QR7P
M;C8*L\,0*[U&"BMK4CMNHSDP!]5^37+DL8; YV/C0ENO?!PT/<M?(WV"E\8X
MI)RE]5H/J['ZBOR"IJ.&ZM'/)AQP&  9.<TM\FJS/4FIK52@M C]5+Q:)XAI
MN28UA!EO=>PK""F$RZ/ 9"\K:DL L3ITRZ%[4N,1"CBR'>AL>G"1.2]!?M<>
M2"W#Y6A>ZV5@P[DAX=3\/Y'(/0'#%ZYLS0/+&L1%9YM0V[]C=F7J;$.A>&04
MJ@V+.Z0I][#7RK)G7EV7#7E;38G4*/QF)#ZTV0[5?8++6_$!-1)O5.,LW520
M2BCLE[C\P?2Y3>(I/%G8V#H>W)LT!$X9;'T/'Y9RM+/1L<48J!H/@]ED%LSG
M8Z\6&,X=+9=.!>@TKFP3)JHRVA.P,YY.VJ*=&2B+UE.=>LSS6=3&0"IB396R
M,V:LXGSI^;X-%83X7WVE 94VVQI>(>4DHK4P=A11T@0!Y_\ZAMZ8-TU'#E)8
MY "+Y- AR;A6OQ8W%7?-#M.37=,FIJL"*MO(#2-$L.\B>06^0,-L1J;Y5*#"
MND(DSRFKNH07S/(=^2,DNJ0Y8I>C4+0"JM.48^F<Z")IKR2=0^"X,]\2(-#5
MJG.Q6 :S\9@KN).W[8E9N6I-L8IT,8^"\7)&,R_%KUEKID<.(QLTK8LHF(11
M,!U/>Q;H!$IQ,0F7032?7Y*7XM2X,>#)#/H]6S+,U&A9<[QP&H23Z^!ZN13?
M.\L[,+HS8+TLAE.<CU1JDS%UY_/1=2?G.%^,QAT]WEL?0VZ4*N^:4)(S*J2F
M=G&6X2P:(ZU1GT\]3\#K3T?3H?6/UH+ &(^EL-/L"SGLJ;Z_J3855WCA=0<$
M?9]3O8/2U@WH!SHIF ^BG#327]XN::/]0ZAGN(2NV]/^\/-?Q$6W_O_U\P<$
MG%G+X6[ZBP)B*[.-<FX\ZSBH6H4N^9/E4A?EU. "'!_4@3PHHN4/R-ZE^,B/
M^7"?8*P9(4<7/WS\=(F20&S2'/8G"$X@7Q'+O:8P29*J>5-GR+K8.7(U 8-Y
ME09VAV>!HN&T]9?6#YRPO X,E!L\!B -[$:./?FQ"GCXJ6=P#&=:I6JB9S@:
M^ZAFT*"LR(#@0) 2#E#L8EB+L^4> OK'"N>>/(B GN">K2Y/G%4/*"BGK)Z3
M$^LJ3?LCZ32XAL.;S*>/"J0!P2FW),DLQZ(%Y\VG!.1520@G)5T/X&_PXE$(
M+L^N.]@;+(;1-_;?.CLUL)=@;VQ[TQ%A>PWT=(_UV7AH93:V"O3[P'5]S* 4
MF8/+'V7&-S:1Y[]I0"<AIK&-)M*^#DNN,3=+ Y)(67QAPV10!ZL@;/)-A\R.
M [T=@X?$49=8]I/;Y@D]F=.1S>$ +.K%;#1?+B8O$O5C)8SL=NHAK"]$CDZ5
M_.DH$O. LC:-ZH"CCE<EV#*12/ +Q<:%]NR/,K!LJLP&GW).^AB(HALV%TWI
M5L+2B_E$4J(H)\ND<Q;2Z4U\<(5QHR>M4UA76>R"33UX*,GNX0.V/O+(G&DO
MV@RA*07\O/<IH$6309NCQ(U6/*[ .( >I3,HM*PF4'GLK_J8>NW$8EQM2IL[
M9:/BG-##823 YP"?+;&XM@71B097>_L(ERLVG ,CU]\*I%#KU-;U5'>P:&%K
M^4[!QNRIX=@R0@COK3#,28GQ+'AE*&[]>T$M-VR5V*"% ,I[V#6(OO1PZP$D
MIN-_HU,<QOF^'B!F0#+_'%1F,9K\PT&9/I_P%%2FR^K1[U:2A2T@94NFZV7$
ML?+IY5A/3MV69LL%1U_>8C[KV^$I!=G'K-V-<"-V 6U&^)B$U:O*+7[SL7-_
M[U__']U$]UEZUX="\N?+DYJCUV$V7G]@34X[8R1=]IJ]T]_1&\'RWQ6YZ:5K
M$+YY#GK3<]TOD3S:3H)3V.I\Z=U;O.#@Y*=XER/0.-%42')6O5+EG4*2>B$O
M71:0QI75T4<R2O>I%%V=47+&-FAO0NGBLI-G=)%+]EC^W82[ON2K\6H0/^(;
MXZ-+$[KA75T."'L:S*\?7ZC5M6_5%=^H=4/#>$D[9/YTR,2_ZT)*O@,=>7%P
M;5Y^=U>7$-Z\[O5Z),(RA;$]!+'XH-/+$!9I(8Y7-?#1A[<\"_^8MB"0=44]
MG'DQ '(4?1P&PO?[QXUD+\%!>D@_;O\ZCH-/ 4!H"S^2#&['K0?<7R#+MH&)
M3V9+QF[BU"B7XZ*_QXI7K=L9>$W;RT!]9#M=[>A0W%71C(1X;U'BV?  [I"*
MU)PL%(C)K(:[$$M3O 6XF0[L'I$P85:QZ\ ;N)'IXX%LPRD;8ML2YKI"./O!
MH@2_9Z"D\7]/;O9R75Z>4^JV<774\C%@$*QZ,9\/(@1]CL >^O\=$FHX7W?5
M/A46JGL"'P*%3C"?&D/TP2$*R)(3^$+58H6QDG , 4D>.M2J0T?<M3DP^-,+
M'=T'*^FGHDJO:SOQFU'Z^O.HLK/-7V(R6XRNYV$XJ![/!8NBT?2%LN\7'QP7
MT[^B7,4*[VB!IAQHHL6 ?3S@8>&>GE^6D>>I>TF9CDY#VPFQ$32ZUI:'/,JI
MFMF^X9; QWCDOF,W/KD.$#V.F>;:T01Y%-S?G2/YY:SZ"?ZY7:>ATSEI5#LR
M2;3M@!PP=$EX64*=XU3C.FVZ8.1MS;6_PUL^5RL3%]J*Y@:Y#Z=5EZ=>=]7T
MH7%NPOG%D=A;BI_$;^=5V5O0??V#;7L\D,&X3O>>Q56IA2SF1,';WX:6CZW_
M6\GL2U'MR_C@] XUPBU!BJ_JLM-Z2'LSSE^HL0P.3I0EZ-SM]!',-4S:*!;[
MI(=R"C@%2I2J,H<F4X\9MUHR<D:X*M^1V82(ST5BLI@7TWU"MG'9/Y?1.JN:
M9L>FE=SO7)TU'9?ZH8QXR%)6!]>G<01A<4=OHN)4NAKSQ:Q\]1 KK=&><.U%
MV'QO"O1T=#[)E1F$$1OOW+/92-RDY9:1H(?V()C>U;)D^KIVPCY$&1 N7W^!
MI>VL&0#V_P4[3(<CE600[NBV@5I+]29[Z-:A(;OG[J$!6_(JQ6$/>V>DMSI/
MZSYHVU#$^1@G'BP7>%L&=S%?$<8FT\/?N5!S[>%'28F+FMH\DK$C\0?D1/PM
MB+UWG="4:[+V\=;^>TYF Y/O[&$^E6EN:EK:3*PRB:A+U*WU5WM?XM_0M=][
MZ:MUZZ%.HW_I-OVNTXK0/GOZK)?0QGPTQ!67QSP_!:4L,T?B>WN/7']1A.M6
MNE\^[DRN;0@*OU(9S"<^RI*: ?W5?-WXK'S4D0FV93+'2>10Y+\X 7-Y1,?)
M-<4]S^Y>3378TG.O1'J3NW_#2Q'BSE&S5Z^W>%[KUS281(M@LA@_W'TU#V;1
MS#9?J=H5U]EC7P]S'Y41]6(MPM,.KG <+,.A!JYI, MGP7(R?5XS;J^F/' A
M=)K%/[XW=\B9_ZYW0K_T7[;XK:Q]=&CZ>FGT3??:Y=%MK,UE2S2;< GYB,N4
M7H3.ZW2SM>B3FMCZB\+ .<2MO%5M'6F_H5N[/6-ALOIK,O<YDWOV65<V/X%
M=U!^)&8VG:!,K?U>;,?*N]]I\',0;NKWC/2O3B GM:2//[LOU867O4*^B"[%
M+WQ%"'I#ZH ,QG-[;05CFK@/81"&EOFLW^T8-Z+S?N*_GS;OP_K]5(3SX'JZ
MY+]GP6SAWD0PW6O^: DZQ^ @G%X[&F;!8ARZSQ%,?.:0"1SLAJW?L[>.4DCW
MMLMRUT?9%N.-[G2_,,,1W_LVKH5KR11&HN]K[%?>;P+L5+'A7SX@N8(&^_,
MS=/FQQ5N[&\*M,/M+S/\*(L-Q(^"98VIX]%B=B8*^VL']H\RW_,O#" E10G%
M'[=*XH0T ._7.0[I_J -FI^<>/=_4$L#!!0    ( +1^85*7U6ORF (  -<%
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;*U436^C,!#]*R/4HU7
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M;EG0Y$5E 72^E=(<-S;!,,L7OP%02P,$%     @ M'YA4A>(I:CQ#0  .2X
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M$@R5/4TY@&[*(N-0HX<FY*I=6=1;%KJ12U;GD/(<7?2S:J42RA2(X@:6)[>
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MWJSIAX/: >B\4J2S7[@ PR]L\1M02P,$%     @ M'YA4I#;D3^O#P  ]BH
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M4GM!%9G[<\6P*I3ZVP_7XLY/$8>S1%#:+D-FI$HA[^\+=<\=AD?EG?2;8HA
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MS)L[U^'-6H.#DZWGP;'G?F?;&@-TH"![G.PI/NIS%GJHP^B0MD"2EAE/E7R
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M"9H,ST\C,(W+-8'357"6E7;D4V%8TH\!C4^@];76K@M\@?Y7,_\-4$L#!!0
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MG#N[%8YV0QH]L*M\&L9I0T&Y"0YO-<Z%BX\JDT&EXEJZ<"\^.6F\9+S\^3!
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MTJ4ONS60/SL[Z9^.3O?P[WZ)![WK7VYZ+Y]E&++3&J;0T&&K5 /X8!T$+=Q
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M/>O%%EO_"+;@;ZU+&X+-^7&C)&81VH#W*XN,K7Z0@N;C^\5_ %!+ P04
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M9&6I+;)C6BJ?<IB=-?A>*)4QE&U"/JMR"3@KZ*^+PW\XT5$%/*RH^4%E[GW
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M4HJ8 XDH&%=A#E]@"<[BI+1 W;/&54O.5,GF]--&(?TF(_$K5[V#"R*A2))
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M9M:<9 JL*#2-7TTC,'T?Z VGFU![*^VHDL.PIM:)QCO0>J6UVQE^@Z$9+WX
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MMK;(3%;#;J\:YS+3=6VYZ#NSJ&S6-5G>;#;P/G!=_F7=5(5M:?"_S2\O9T^
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M(=BQS0WVPS(*@@,E2TS<33<@XEK6F%_B'U _KDQ+DMG;H1B+;/*0PF"/!)^
M<0D<$&>I&KO%+-W0:L-WV<SEGX+^<.2F"NHB< $WH#;+:D>1A#&!?(PCGBE'
M/#M*SD_L?KT6W\"-,<2WC4"X *.;Z"AZ[2%B%1]"A*( H=C)I]G-+/OEZNH]
M$.//O@2*Q(X"FI1 1_5JG"=/O_'6"BF>*"I!'(OLN%&IC>04\>']+%*3R'U@
MBO0M6[+JW'4'WLB\UI/0T\-\/J^,QR!KT:WIO1_DTSI1?*C5#<C)"A!E>8=>
MK'=#V)DI2HQ2^Q@<6%<!8\?XY[GRS_/[-&@.:PFDO@:_%!Q9M-#'>.FOC_9S
M) ? (.H9A41D]>1ALVAH(MJ1;*2$D9FF/#1(H"]$*K"FHCV'#Z"_<3@1E6YZ
M5#(=;VT@%G$.3<N3D$<.8@D#GV2O=2X,'R>WB/'14/)O_@D4C>+^LOJRZ\6+
MN%(OK]JEBHLR3 Y]NM*M@;=6/4AD1'@LYHH2PW=DZWN4<_8Q@"1,6J)^!V.6
MV9V%M2'3%KT%CLQAQ069@E&4E>3>5\#./RT@2?*_QSCOA7+>BZ.\\K,!D%#H
MTX8+W/$F<,<8 SY@T,]'!QWUVY>CS!FQ%:,C8JPHVSDYE.H<<@<:V<LEB!P2
M*<CR7>D3J[EIVQUER8(,V4^KAM"ZR!#.:R\5EQSR%D<O BNB/8LW9^.E8L@T
M@IMRASGF%PN4C&'X20C?4PB+@C_D&ZOZ'FPL7%?)$4"-S7.R!K'#47J: G0U
M<T.%:K6O 0_P^#\I:[\@/Y9L14:J9 8X)N7=QT1@)VG7B5CPJ-><R!T;+8O<
M[1YVQ#$HT4H)>B7;]BW("<1G71W=$//S4#=S?EQ\>I%"?[P.A!\MCOF+8UWO
M,57+N@Z=:HZG#&3O0GT_%@ )3P,:\C7Q!,D^<"!6%. ;,AS&=R7_#G@D&J=Y
M>(SQREBS3*'?VP+BO\$O[(7BH';GN3!Q*,@ 08\6Z 6*Q>8>(. W[UG]^[_-
M+\^_5]>-Q-WX@-U(&N<8U:-JJ?E12D4[;Y3.#W[[8^+V+$E5).*(L-=L['17
M@L?"%K\BA31QB#H7)8>K<#MXYXZ($3+P\=AY!8:5>@MJVD]ATTP=D"X5,$K$
M34\F#^60)@<)-B%BLY9C?BHLA17E%<-A>Q08*_A[NC#Y%_1?(XIS+= >X#Y0
MLA?''8AIT,WOW]Y,1KB RI+N6]I#Y__[_LRT?)B;AD!?]+?:CL%Q#S=>!&Z\
M.,I/5Y[A/U"V'HDXRI7?/(I^U>I7>XH&$-.4>61(4^%*(]E0TP9G.M$QXLJA
M*):D !M?P:=TFC^D\D>PF834XZ%],5M+Q^'%@LTC?1=9O,!R"$R<YR#*,(9
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M^0"%?@%K\H9FN_>X5==-O\ M(<WUL'Z)*M1M;9=EA %Y>);]C-76_,$%;;X
MH"NMV69LL84[$"5]5U:DRE4^8-B,#0N*JQFN _-5+YL%$>8A+!S[KO>]&$O'
MP,[(VR,<3[P(7*K/\9+BBC1?60*RCJJ-648T8%7YYB):W;]4^O.Y0N* 0_L7
MY^$1?3<3'I+V]?#$EP*J&9@);,X_>M?M#Q2A):X=&C'T9UA%22;"#9L(-]YH
M3.P;MK5$&!I/?5J[9)K%PD ;H>U7:GB0;"^)<N,-!!.K008Q20V-#9%#/B5*
MP268,A1>1@<2,)R_'3$VU40N?39.'O,M F!9VKR$6AJ-;JT2.RU$*E]TK62%
M87(]TOH@$SCP0IIUY="C/U:%(Z^B^N](  U[RQ6)P LYQ'1 [[WXVH28U(-S
MRW),V8^0F),+$M]^AGVAY'VZ6?:K&IKOO8EVQ40.K2^Q@92A<V8AUA7SG1LS
M5T_'M=)9*I?VT4P[Q@^W=ZI%N_)@KR++.QE DS+48"-%;@HK%PT'"X;W+910
MO;;!\@1)&,@@+&BX4&6T/5 2/=3=C*?Z@*IW= 04XT%442!RS%$#">30@#Y.
M:93N?GACTBG253'@7%%$+6JQ.180%F<G+JY"U@JQJ<CR(?%[2R6VZ5;'*8]2
M2CP6<'=!;5?BF.IPWDXG[X WSZ@52;YIHI2/&5LHD%C*<M3CD*5+"3+JRC#2
M &PDLF0(DVH"W.^P!(^^M8F'P)N-^I3(-HNZD Y5S60 US1567'7+2J<0823
MB8]TC'=5S34^7O^H">B/V(TJL[@@6]ND2$7&"']BGR=F('I_Y$PB44<*%+FU
M4)>OI_W6DX-)P;M':@%%YD\&'*R.9GI>6RK0!TDS1(V"-,L^J >,1I8YJ%W)
M,9YRXD*]YKA8840*)B6U%:I7*C#'D2:^9T?$<9$I*54=++V8N+9H,,N'Z@:\
MGK173G#CF:9#3MGG8%'E1BIQ,4ZA_.SY0F(!++0 4@I=W,/U 2[7B&U755JG
M06!&/=3"3M:O@H5X2J76K3]2[K\_XS#IWBH/%++Y.8-83DMRN1W90"H.@D)'
M ^'AJ/3\^+'F7[!7[GCF[R$OIF93G$OQW?_VFO$.!! V]";!A*?0B6[\P$V_
MZ"@)\N+I\^GE^=-)]J[IZ-#?>^I(EKV6,VS3>V/Y:<?V<&;VXO@YUU>6FI(B
MWM^&(H0Q5/VE@0[8=IRM3UO[^D/);L]=9HT5@N]H06\6MJ!CK$ECE>&35(&S
MW''XR</G2Z/Y *<8IW&H?T]Y'ZYSEEYYOH-9%&BB5E"^5.Q 71II(+^2 *#4
M5N)3%)(@[332!]L'T%I-MVNSQ%"Z)\D/6%-\DN=P'PV>7 ;%;G!LA'.>_U3R
M4V>CC1VCUAY)#T *FZ1%VG<4T$S6SX=EJ;* '1$NE(J/E(<3]PREU*>RK%Z4
MR[Z5.!>OO;42[70^)SN*[*AC05C5V)QJY1V<F>5B!,F!>48=)31FZU5%.A:8
MNJ\/O"X-#^3$<.A<,3Y7K"B]K4_600R/6Y.N7Z01V[@JB4'DK3IA[(L#67B5
M%MM2^]U97HU!EQ8^M38^!RVT2/D>6RF)CT9=J^NI_[A7V,!=K3&T/J6B;V>[
MKM*X/0X]BC ^M2HG8[PI?V>Q.L*?OU^. %;<4[AR$<ZS7QP_D0[&D 6G)KNF
MA>6[[&/4V&M4,/\+XW%QJ33*E7#K-KZW(O=OI45LWH.F\^,%JF_P:9.!"ULW
MOO$8;V0=2?Q-X]MQZNSZR-!:9;^X[+C>+DAJSWE)&^R17D21E0SV,94FCPPW
MH=X%'9U&'J_-&RQJ*:@=P"V!IP=M#,Z*'<3#P?7)N;19]MK_%E<J)H58 *AX
MBW+R"590TFT#R/G:6^FH1!\*]'?81^P>9,5HX'.'X]CY)N)]]M&--W*474VD
M[/3SF]=G1PP.[,K7NG6YG:B%T M.O)+C(?E6$C]LZMO'?0/W[12,HNF+^ Z
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MUQ\%;A(_FKGJM=  H46!O4%-Z7"'Z2T9N2.T%<7Q0#K,2 =EQ]07"/J.A!A
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M@,8[T/-6:W<^>(+QT[+\"E!+ P04    " "T?F%2X>Q6=_P"  !_!@  &0
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M:*UH-W)=(ZR,06O@[*T@RDPO9Y:,.959/@!?]\#\$>"0PTO5VLK +VV!Q7V
M&7DYNLKWKE[SDX@WF)]#%#+@ 0].X$5CZ)''B[XO]!MI\EJ93B/\O5H;JZF
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M7,9C#U0W-;J-D8WKU*TTU/=NF=.@164=Z'PGI3EN;(!A="__ 5!+ P04
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MJ\X<>\&<S^"];,Q:PTU3B.)[ U/T;7"0[1V\8J,6WXK<@\ GP"BC(_:"(>#
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M<>@6R@K@^5+BS-(O+, PQL__ 5!+ P04    " "T?F%2:;KCN]("  !7!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q]E6U/VS 0Q[_**6(:2*%)
MD_0)M94*;-HDD!"PH6G:"S>Y-AY.G-D.I=]^9R<-W8"^:7SVW>_^Y^2NTXU4
MCSI'-/!<B%+/O-R8ZBP(=)ICP71/5EC2R4JJ@ADRU3K0E4*6N:!"!%$8#H."
M\=*;3]W>C9I/96T$+_%&@:Z+@JGM.0JYF7E];[=QR]>YL1O!?%JQ-=ZA^5;=
M*+*"CI+Q DO-90D*5S-OT3\[3ZR_<_C.<:/WUF K64KY:(VOV<P+K2 4F!I+
M8/1XP@L4PH)(QI^6Z74I;>#^>D?_[&JG6I9,XX44#SPS^<P;>Y#ABM7"W,K-
M%VSK&5A>*H5VO[!I?)/(@[361A9M,"DH>-D\V7-[#WL!X_"=@*@-B)SN)I%3
M><D,FT^5W("RWD2S"U>JBR9QO+0OY<XH.N449^972"5I.+YG2X'Z9!H8@MJC
M(&T!YPT@>@?0C^!:EB;7\*G,,/L7$)":3E*TDW0>'21>8MJ#N.]#%$;A 5[<
ME1@[7GRXQ)^+I3:*OH)?!YA)QTP<,WF'><U,K;CAQ)4KH!91S/!R#<+F L'9
MD@MW_-:%'D8O')(N 8LEJNXB?# YTIO?SVMW+F11L7+[41]2 1M4"$S#2@IJ
M0WT&/Y IP#*S[O_GZL,1Q/YD./;#,+0;$21^F QV9FS-*-Z9"=AE?V<.K#EL
M3N]SRLM6AM@3?SQN@/?2,$$-;4?&B]J*;:G7C89HY$]:SRO4))6&C:83>&*B
MIB*RW]05UA6.1_Y@XE2=M-!#5T!7&$_B/6Y:*V4QE51N0!Q'?AQ-&MR5+->G
M)+LXB#R"/@D=)@[ZX 8 9J?LB2+6^*I"AQOU$MC2W>O7_AG7J:Q)$.5#&/<&
M\.&M+S78:_8"U=J-- TNM.G[;K>;FHMF6+RX-R/WFJDU+S7I6U%HV!L-/%#-
M&&L,(RLW.I;2T"!RRYPF/RKK0.<K*<W.L FZ_Y+Y7U!+ P04    " "T?F%2
MHA\X#1L(  #1%@  &0   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6RE6&UO
MXS82_BN$+]=3 -66J'=O$B")6W2![7:QV6UQ.-P'6J)C8F71):F\]-??\$6R
M;,O>H/=%(BER9CA\YIFAKIZY^";7E"KTLJD;>3U9*[6=SV:R7-,-D5.^I0U\
M67&Q(0JZXG$FMX*2RBS:U#,<!.EL0U@SN;DR8Y_$S15O5<T:^DD@V6XV1+S>
MT9H_7T_"23?PF3VNE1Z8W5QMR2-]H.KK]I. WJR74K$-;23C#1)T=3VY#>=W
MA9YO)OS.Z+,<M)'>R9+S;[KSOKJ>!-H@6M-2:0D$7D_TGM:U%@1F_.ED3GJ5
M>N&PW4G_V>P=]K(DDM[S^@]6J?7U))^@BJY(6ZO/_/D7ZO:3:'DEKZ5YHF<[
M-\TFJ&REXANW&"S8L,:^R8OSPV!!'IQ8@-T";.RVBHR5"Z+(S97@STCHV2!-
M-\Q6S6HPCC7Z4!Z4@*\,UJF;]TW)-Q1](2]4(N\+6=947E[-%(C6$V:E$W-G
MQ> 38D*,?N6-6DOT4U/1:E_ #&SJ#<.=87?XK,0%+:<H"GV$ QR<D1?U&XV,
MO.B[&T4+)LN:RU90])_;I50"H/'?,RKB7D5L5,0G5#Q Q%1M31%?(5"VY0UM
ME-0]B!<%BD&I1"O!-PB"2A -2SGFZ_-JOJSIV\4C KLD,,QKB#\Y1_^F1-A#
M0N!BNEE2T;L9'F&A'SGZ.GV8H@5X3"I6H@ODA2GVTS3VHR2Y-'T<^'E0^&&(
M3;^(_:S(?1!PB2!>(!H:Y&&<^$4,(S_\(\<A?M>_/YVQV"G+B\"/@OA[RLZ<
M6]*?6_(WSXU9T&A3Z0OPH*3(6]*&KI@:#9*S>C2_SN66E/1Z B<FJ7BBDY'3
M5#"R%?R)&>(#WNUU&E==#JRB]GR-M$;!D;+&++>GS9I'F 01_>93OV^% $%S
M]#.MX#QJ\'5W8A<H]H,@&(P\**)HW\/F:]?K$'!X[M@/LV!O9FIZN_$%75$P
MHMK9T,WT<!KI*9<'F@_?IW0?OG?R=GO<M3R<9/;KQ<"Z,VA+>[2E;T8;7:VH
M24M#I F].4%+WI2L9B8HQK!V5LMIK.T+W@>YAI-2@BU; QND.$"S4:QI-90&
M(:H!VVJ\$67P)N% 6L7%:[\!J1>?"Q\?M5)+)0B'_QP18(!_A%7?@I4TE0&L
MCYC\.^SFDD%O3+_Y@2%V%P"$*/9QT&,!<.%'%@V6F@J_"/(A+G>[]E$#916X
M>.6@W,7Q$11C*Z"#[MZ1G(ZA^S5I'K5"]$3JUAXHT9X@34G!KWZ,<QM>B1];
M."/-I(4=_<BUHUH H#YLP\4@@+[ @3^V3*ZA]C+65W2I4!B#B/W0[=Z? 5]$
ME&MS+!5]@DIO:];JLRPAEAD0FP?I(W%N\R(_C_*^'7;NW.UG19@PFS)A\DR$
M()H=C_R6I9WG>?GM1UV>50:<@#7K#B_TB\2%>0CYPY)8Z >%;7T%3PE%-&^"
ML5LNF44XS$AS-S>),M?";FRA@TCRFE5]%,EV*5G%H+!%N55X9.U/+UL&WD ?
M?_L@C:\ZW\1.;!KNV-"V/K -4V-+O"CM'.A676H7AYU#=J[<161G1SC.U7WD
M50QH2><!!I#UBGV.[-Z_0=P+5& +B1R"3+^],,!=:/P?7)KU7)J]F4LKESC,
M/HB45%F/ =,M@>X4HZ.UUG<4@&/8BI6 OI$L?0\CI'DU&\W>R;>8H-D*5A^3
MDZ.TPB1TN>;/#; %A/(<W9Y8868OCE7.T3W9,D5J]A>,BRXX.P:^0(F/721?
M0/J- ML&B*$2 NT5B!<"KH(8P!G$:6*Q'P9^EEN8GHQWW><&%\/(#R,?Q]A)
M\3,73+WA @0T$.>AG^(^X@(+_Y-A#2(3.T6WK(FWY9^MB2_6* "_)C6),D=[
M>5XXM8(]$9-RNU-YW06&GR?6T/=038'G5.^U).V8(\3=E">88/8-4496*Y-3
M0;T.'!":N#VGL37O X5M#)1"5LDM3T QZV3:H$I][7E+!'%HYX10J\2YLP$D
M8FSW\_L(\7MA4OA9D#A6",'C>L3TOG  QBA0(S_+K$PXA8-BS,P;H'@^[FPO
MS(I.:>HXW5SS-8!;2:TJDPJR'6?EA<M^'[DA'UGR%ISJQ6FQFY,Z6KGGX'9A
M,U;#!U4@$'V4ARZ-LA==F]A]>7'NR,?+.Y]\!"NJ$WLS*;\GL:YYAJSRGJSR
M-Y.5JZ6@_C%I5P?.+F3VPE CD)VY*Y[5.5X&WIEX:H',7+E#_;Y"T99(4\9H
MP^A^TM'4I .BU#"'^LZ8-KQ>(@]"8</J6EM[.;<9S\)S 3)W-;W)9[9<,LUN
M_/,/9+-]MW"?NA[07:A3QS2"9V">QR4[3,(HG88P(3ZNF0(<H016AE,\]C&&
MH)HFJ(#E(U\3>T 0FY2L@!@03K-I!L2&IP4*BVG>3WX/%=6*-9"S$<ZTI8?2
M(M /#)RFYAW&$4BXL#(NS,<S0"MZH!5O!EK;Z((?DMA?#NFN!)5(P)$YC(WA
MZJR*T]>+@YNG^]D'VJ7)F.8GG&8_06OB4#3(I/^2IPUVQ3W];G%_1VI#@U#-
M+^DC:QIS>;$9^U6+N-!Y" ?=?;;P4QODT,[]R!$N7!&$9FPY-+6T]V,KYJA@
MC*,N?64N:8*TXD":5U'7O!Q*W@H&]YT1N2X3> =759LIO#0>K\X&/J Z*>_O
M'OLX[ J $ZX8@^%L\)MQ0\6C^9FJ+X- U_:/8S_:_Z^]M;\I=]/MS]Y?B8"3
MD:BF*U@:3+-D@H3]@6H[BF_-3\LE5XIO3'--"9"$G@#?5QS(WW6T@OXO]LW_
M %!+ P04    " "T?F%26AC\%<4$  #""@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6R-5MMNXS80_96!ZQ0QH+5U\RVU#239:X%=!$FZ^U#T@9;&
M%A%*5$@JCO^^0TJ6G=0V^I!((CES9LZ9&7.VD>I)9X@&7G-1Z'DG,Z:\&@QT
MDF'.=%^66-#.2JJ<&?I4ZX$N%;+4&>5B$/K^:) S7G06,[=VIQ8S61G!"[Q3
MH*L\9VI[@T)NYIV@LUNXY^O,V(7!8E:R-3Z@^:N\4_0U:+VD/,="<UF PM6\
M<QU<W0SM>7?@)\>-/G@'F\E2RB?[\2V==WP;$ I,C/7 Z/&"MRB$=41A/#<^
M.RVD-3Q\WWG_['*G7)9,XZT4OWAJLGEGTH$45ZP2YEYNOF*3CPLPD4*[_["I
MSX[&'4@J;63>&%,$.2_J)WMM>#@PF/@G#,+&('1QUT NRH_,L,5,R0TH>YJ\
MV1>7JK.FX'AA17DPBG8YV9G%%RQ0:GC,4+$2*\,3[<&W(NG#Y2-;"M2]V< 0
MCCT]2!J?-[7/\(3/((3OLC"9AD]%BNE;!P,*L(TRW$5Y$Y[U^!$IH"CP(/1#
M_XR_J,TZ<OZB$_Y^R"*A")44M+.F? TJU ;^OEYJHZA2_CD#$K<@L0.)3X \
M4 .EE4"0*\#GBILMY&@RF0(O7@B-2MOH8^R>=6N[]$J7+,%YA]I0HWK!SH+T
M@Q5E(S<V'V.5 YW)C09#.RR7%6%1$PEF, 4CW7**1(*6@J>LZ9#$GB,/5_"+
M>LFZ2EC)#1-PB:^)J-)Z26<]Z,+E<.I-IV$/?DB#4+*M0PW&@3<*??C,7PF)
M:8V&*JJ@\4(T$$*55W40*5+X":^A+X.1%\5^#VZ94EN+\L)$Y:@KWFK%=UI%
M7C AJ)B@&%?[\WMRZ16:^E9H:$ 1:N2-@@F%/8$OM  $_9X%<M$87<9>$ :>
M/Q[V@"J09IY&Z],20!XU-;Z-:*5D?I3/O:<NA-YX''N386!;C4Y2.$+;$];P
M5N8E*[:__S8)@_$?&N+QQ3[BIG2.IL54+7-AUZRG6OFEG;4>31*3P:HE1U/@
M(FG89P[\SZH@Q>JV\NH<:-?NO,NEOT-\R"SFK2!AZW<-=XHGI#^J9M/)\=/)
M08GE1$3D^;YO_X@(OQ^.(WI.@JE;N:,IC$I12*$7!)$7^B/:#?I1.*QIFTZ=
M7(_2EN'PX,Q>RF[4G]!PI (A,"$IM(SR6R)235-/)(=%_Y[K!U2<DK@&5J3M
MQX< RC8NFL')TV'/[@7P; $Q4*SAG6FN'8\*EUN2,*T2UX\9'NJW9((51!FU
M!'3C*'8\U()0F6&^)"IWP\ZNGU+XB@;7D:*HRB-5?4C74:LSJ0=>Y$28-@*3
MD>UG1_2;;AE.8@*A+CZ*<"K#+E@.HLD8S@S=83MTA_][Z.Y+GP8OTY7")J*R
M(A&MWG:SYL=@DA7\F;KDV$0^CVD[FOJARDOKB@30F.[D.HAAUWUNU/ZG_5PO
MNX%>V&IM!/[T6M+UQ58OJAPNM\B4[D'8GX;P4UI?PLZ&L7\!]UP_?5@IQ/V$
M5+:7PWX\NMA)8'VK4G&:8W5,W=B;CD;>, J.<3\XN%?DJ-;N]D1CQ/Y*U%>,
M=K6]H%W7]Y+]\?IV]YVI-2=N!*[(U.^/B5)5WYCJ#R-+=TM92D-W'O>:T243
ME3U ^RM)OS+-AP5HKZV+?P%02P,$%     @ M'YA4O@LN2+X!P  SA,  !D
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M[53/2M3W9W5#\9V]45ISI7AA'[= 4Q#&0+_/N-:NIF$&:&\QY_\"4$L#!!0
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MR.*H4S2TR.WF_UYH/$K8RQ4>#T&:#O@\$4+O&F: ZL Y^P-02P,$%     @
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M9W)@72Z!XA*G^) KO\UE/ B@L\3IW._ZK[T;6]3O/_9S:P*@;T!'=*4'0.8
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M9>*%*:H&[OUE[KB[>U)MT]__+L/E_P!02P,$%     @ M'YA4N&2'1$,!
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M6;8@FNAS B]*?X/W3%8; &<;Q<$Z _,9K%U_]]?^D3FB .!ZF@$H Z J@+0
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MS%ZP,!'@WR^#(-X_) ;R&YOC_P%02P,$%     @ M'YA4B%9KA5N @  "P8
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M]TM#2(_%G8R@]G-5^4$3?B "GU@J=AGX-0UIV!4P9'%-A>BYPBND5;RAP3G
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MJV@3ICJ'9LI*,B]SP;H3CBT(*PI[>X4]"X639..'0M%IE*3)J1-RK;*>NK>
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M2)958D60D=Q>\5.5B(; ;^\1!)4@.%405H+0!&K)3%@3+/$HXFR%N+96WO3
MY,:H530DU[=Q)KG:)4HG1S/)XH>4T02X^(B^/I9$/J-/:&;O*F)S-%5Y!<XA
M0<8674Q 8D+%I3)[CUPD4LQ!1*Y4--JG&U<GW]B3@STG3R!NH="_0H$7>#OD
MXY/E_F!=[JH<U(D(ZD0$QE^X+Q&O$<<LR_03EB>HJ(,7)GA<RI1Q\@>2*T2$
M*-6&-E/U(:0:D'QQ "6L44*#TMZ#LI'Q*U1@CI:8EH N2([N9A-4 +>)O]R5
M>.N^;]SK.EZ.O);G^9&[;.;WF-4:>[MF;Y_(+BR[?3P:B3,QV-6=\-9_MX'E
M>_:WP7^"X5H(G3J$SIM"J.[W$?S.%M5@@WO;(@AW$W=KXNZ;B!N/Y3'L[E'L
M;8M]V+T:NW<0>P:<@/CPSN]ZG\>;[YD#==2O_??_=TD/:I3!>4MZ\"_%ZGNO
M;W_OS.5:';!>AH-]8(W/DG_&(JR<GPCU^HGP@W/7677"H4+;8;)5:6[CBZ_;
MK9^8+T@N$(6Y$GFMGGK)<-O!V(EDA6D"[IE4+849IJKK ZX-U/Z<,?DRT7U%
MW4>._@)02P,$%     @ M'YA4JKW2!KO"@  5CX  !D   !X;"]W;W)K<VAE
M971S+W-H965T-C4N>&ULS5OK;]M&$O]7%L8=F@*NQ'WQ43@&8CMVG5Q3(V[:
M#X?[L)'6$E&*5$G*CHO[XV^7I+A\+(>4$^'J#XD>,[/SVM_,+%=G3TGZ1[:6
M,D=?-E&<O3Y9Y_GVQ_D\6ZSE1F2S9"MC]<U#DFY$KMZFJWFV3:58%DR;:$X<
MQYUO1!B?G)\5G]VEYV?)+H_"6-ZE*-MM-B)]OI!1\O3Z!)_L/_@8KM:Y_F!^
M?K85*WDO\T_;NU2]F]=2EN%&QEF8Q"B5#Z]/WN ?WP=$,Q04OX7R*6N\1MJ4
MSTGRAWYSNWQ]XFB-9"07N18AU'^/\E)&D9:D]/BS$GI2KZD9FZ_WTJ\+XY4Q
MGT4F+Y/H]W"9KU^?^"=H*1_$+LH_)D\_R<H@KN4MDB@K_D5/%:US@A:[+$\V
M%;/28!/&Y?_B2^6(!@-F PRD8B!3&6C%0+L,[@ #JQC85 9>,?"I#&[%X'88
M"!]@\"H&K\LP9+1?,?A3O114#,%4!NSL(^=T6>@02QWL,NG*+"E2[$KDXOPL
M39Y0JNF5//VBR-."7V56&.LM=9^GZMM0\>7G]WFR^&.=1$N99M^AMW_NPOP9
M_8 ^B#05.MG1JRN9BS#*OE>??KJ_0J_^\?W9/%<K:_[YHEKEHER%#*SR9K>:
M(>*?(N(0Q\)^";._V\4S1)U!]BN8_6?QC# 9Y'X[SDVQYL:^A?MZC#N=5>S6
MQ6]@]BNY -E_FLR. PO[[71VF^WO1L(F5-B<8>7?3P@;+19WV]QSE>1UII,Z
MTTDAC@Z(NXQ$EJ'D 14IC_[]+_4]NLWE)OL/()W6TFDAG0U)3^)'F>;AYT@B
M5=L>9)K*)<KT4J<H6XM49BC,LIWZ<+=5I611T.O"=-IXK5C#A=IS85SLM:U,
M2U[;EKLI%0H*A73E?#PGWHR<S1\M9K#:# ::<:]7^T'7J*52:Z,*=R9TZ;.M
M7TKR&NMC[C*/$UKK4.:HA= )'$QU4C0);VV$+F<N&;"*UU9QT*JWFVV4/$N)
M,ID^:@=G V:>HEC'(LO5Y^))I,OL%.5)+J(6E7J3Y8HR1\^JYTGE(EG%X5]R
M:7,2[YG$F*/_.C[JT]$.7<MRM[;<_3M8?JI3-4R62/5X^X^'T@96&"O)(D4,
M;9(X7V>(,+04SYD-^B8)\O>",+$(:OG4JWWJ@9(_[#:?U<942))LM9$*5'9Y
MEHMX&<8KY32TW:6+M?*P=IU:O42!8E.70&#=S>6:;B,!_,!Q7<(ZB=*G"XC+
M:3"0*'YME \:]6:U2N5*Y!*%<9Z&JF5>H$<1[>2 G383_%X.$T: ) YJW8(7
MZJ;3;:^<_"+319@)A< VY8(^MK@^H!QV3 ?E@.K]TE?@5&T"/<_HA%#HGJ=J
M<MBIO93+=&-M N 5>)'+V2')C!L-(#XPG>67K1IX%!"H7-:0,):ZU0)0[K9U
M,R4;DRFN/=4JA:DHU5/*E&ASBIZ*B4E#EBJ@:@+<QT >5$@K)9J5E,U8=^-9
MJ-P9\3HES$+%9]@;<(3I+C#<7L".& T0[07(\SW>K4$6,DH8=TC7QCX=QH$3
MX $K3?.!X>ZCMG*5BCB'(UV0J%V@4.%!A&D%"!,#SBRA]+VN._I49*;;Z+8S
M;%2^.^ *T[%@N&6Y2Y.%E,L,/:3)IJH@':2S-QRXWTE@0FTMAXT2TQ[=K8V.
M0\AIFA,,U^A&5I<6M4(NAF#?:K;;S\EN\:G,[E,2;K&Z3Q9@P&C3/6"X?=BW
M9!!XFZJ-_2,,-=A47@R7WD/F@4I4.P3<&H(^9>!;"&]M(AVHI2"F:A.XIGZ4
MF:JIBS52_0RZDH\R2K8;J2#E[1=M)10>8FHKP4<(#VF,M'!]/"0\E:A6E79L
MT;$0\L 6G0F$;;M,N2-PN;N1L4+YJ(C-F^5&-5)97IU'30B/J3>$'2,\!L0)
M#.('A8?WG.E:-X^%D-K#TR=D% J/P6T"X_8'-=1,@#%B,)%XQPB$@4DR,MU$
M4;(0NGT8FG^+IK>75U5H^H,-MI:6BK"%:YXM,GV!M("U@< 8N"8P7!]G-"5]
M%/89IQZWJTL-!M-1#%:%O1@URL!_BD/5]KWZ>/^IJTE[!0/ ]!@ 3 T 4QB
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M>+F60DW!FD!]_Y D^?Z-_CEK_5/R\_\!4$L#!!0    ( +1^85(AF5D&808
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MA++4QA 2.XN2W!H/R[$G/AZRG4R3G#YQ('99%O%_;VG*#B,+6<>!YV2SE7K
M'@^+:$,75+X43US=V8V559+17"0L!YRN1]8-NGXD6E\*_DKH09Q< YW)DK%?
M^F:V&EE0!T13&DMM(5)_>SJA::H-J3#^J6U:C4L-GEX?K=^7N:M<EI&@$Y;^
M2%9R.[(""ZSH.MJE\ID='FB=CZ?MQ2P5Y2\X5%K?MT"\$Y)E-:PBR)*\^H]>
MZSJ< ,J.&< U@-N >P%P:L#I"[@UX/8%O!KP^@*D!DA?P*\!OR\0U$#0%PAK
M(&P#Y-+$P>/,P;X^4#/9;V;[(G*<;E3.MUTMK')53B,9C8><'0#7>F5/7Y1+
MN^358DQRO0D7DJNGB>+D>);'+*/@>_1*!?@()BPK6$YS*0!;@R=.9?0*'ID0
M8,U9!KX5E$=Z]PAP-57/DE1\4-3+8@JN_O@PM*6*2-NUX]K[;>4=7_#N@"\L
MEUL![O(571GX>3>/<(<!6Y6BJ0<^UN,6=UJ<TG@ '/0GP!!#0T"3;GQ!"X7#
MB_BT&Y_O\D[\KAO_$O'.X.][YXY" _ZI=^Y&_*%W[D9\UCMW(SY_W[Q_?E_I
M'OOC0<<J=II=[93VG/_=U6":B#AE8L<I^'FS%)*K]][?'2[<QH5;NG ON'@9
M+ 9@JKP(F<2F>E>X7^*Z%=B//R*""7$=SQO:^]/:FJ08!C!$")]+'PW2T/7#
MH"S[WI"/U^3C=>:CWNGJC9V;,JE <NH38R]TPU8:;W6P%7V7XBQJTD1-.J/^
MJMJT5!_/2ZH:,@J2:N+UJ;VD.5TGTKXJ.-LG9=.D)"<*XWE-WM878Q=Y:F&>
MYS)YJ\0P=!!$K:2G!I,(!]B'/FQ5\,X@=1SD>"YTSY7W)F6 '0^YY%SYR921
MXSG$]5IKZ\&D#$G@!:Y_KIP9E<HY(2WEW)0\P4$(G79*GXUU,N\"@_3"+K!/
M6H.,\DW9\ H0LUTNJ_.D&6UZZINRM6B-WZ+K&3*,SU4/7K7,O\U7#;PZD3>)
MZA12NE:NX,!7JY]737%U(UE1-B9+)E6C4UYNU7<$Y5J@GJ\9D\<;[:#Y,AG_
M!U!+ P04    " "T?F%2Z[+_894#  "]#@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970W,RYX;6RE5]N.VC 4_!4KZL-6ZFYND 0$2 66LI4JK4HOS][D %&3
MF-KFTK^O[9@L(<'0[0O$SLQXSK$='P_VA/YB:P".#GE6L*&UYGS3MVT6KR''
M[(%LH!!OEH3FF(LF7=EL0P$GBI1GMN<X@9WCM+!& ]7W3$<#LN596L S16R;
MYYC^&4-&]D/+M8X=7]/5FLL.>S38X!4L@'_?/%/1LBN5),VA8"DI$(7ET/KH
M]N>N+PD*\2.%/3MY1C*4%T)^R<93,K0<Z0@RB+F4P.)O!Q/(,JDD?/S6HE8U
MIB2>/A_59RIX$<P+9C AV<\TX>NA%5DH@27>9OPKV<]!!]25>C')F/I%^Q(;
MAA:*MXR37).%@SPMRG]\T(DX(0B==H*G"=XYH7.!X&N"?RNAHPF=6PE=3>B>
M$X(+A$ 3@EM'"#4AO)40:4*D9K><#C674\SQ:$#)'E&)%FKR02T(Q193F!9R
M[2XX%6]3P>.CIR(F.:!O^  ,W:-%N80162*^!O1,R2Y5RU3L$E3#WDV!XS1C
M[P7K^V**[MZ]']A<.)*Z=JQ''Y>C>Q=&]]$74O U0X]% DD+?V;FNYY!P!:I
MJ/+A'?,Q]HR*4X@?D.]^0)[C]EH,3<ST!6P$W;E(GYKIG[>%D?YHIG_!U&A^
M=G/LGM-"__1_J9O?3H\,,^E7*]M7>OX%O<F64BAXWR#5J:0Z2JIS06H&"5"<
MM66T)(:**,^)W4AD;G>:M":BXSAGH+E)IF:Y6UGN&BTO..;09KBD!0;#3837
M-&R2J1D.*L.!.<>$BG.F:+,<7+5\%3%O(CPW=$[CJKD.*]>AT;5>9"@M/XT<
M'Q <1%W! -V]0 '+E+=]%F?AU9":B* Y"TV0,:JHBBHR;ITI+$'$E9CV3J_2
MZKUU[_2N)J&)N/<"OYD'HP59_O79!L<PM$1]QX#NP!HA0VRN\WIZ.F_;9IIG
M"NXZ9&Z$U"V?'/CN6S>:9AI-7X7,C9"Z:>_5M&<T?5R1_[S1M*XQI":D?949
MM>J!O1Y2KF\,[.G?XAEKN=.3XCX*PZ!3]SIIP9V%,VV3<IT@#-TZ\+$-&'C1
M>7YFU\?\U";E=4/?[Y[GN@GTW* 7N>Y9QNV3VC<'NE+W((9BLBUX62Q4O=5=
MZZ.Z89SUC]W^H]O2/Y-W,U5KO\J7%SM1;JW2@J$,EF(HYR$4AR(M[TIE@Y.-
MJKQ?"!=UO'I<B_LE4 D0[Y>$\&-##E#=6$=_ 5!+ P04    " "T?F%2(97(
MB-,$   6$@  &0   'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6R-6-]OHS@0
M_E>L:!]:J2D8" FK-%);]G25=K=5N[U[.-V# TYB%>R<;9KN?W^#0TB"'=*7
MA!_?#-_'C&?&3#="OJD5I1I]E 57-X.5UNNOGJ>R%2V)NA9KRN'.0LB2:#B5
M2T^M)26Y,2H++_#]V"L)XX/9U%Q[DK.IJ'3!.'V22%5E2>3O.UJ(S<T #W87
MGMERI>L+WFRZ)DOZ0O7K^DG"F==ZR5E)N6*"(TD7-X-;_#7%26U@$'\QNE$'
MQZB6,A?BK3YYR&\&?LV(%C33M0L"?^_TGA9%[0EX_-<X';3/K T/CW?>_S#B
M0<R<*'HOBK]9KE<W@\D Y71!JD(_B\V?M!$TJOUEHE#F%VT:K#] 6:6T*!MC
M8% ROOTG'\V+.## \0F#H#$(N@;1"8.P,0@_:Q U!I%Y,ULIYCVD1)/95(H-
MDC4:O-4'YF4::Y#/>!WW%RWA+@,[/7O@F2@I^D4^J$)#]$PSP3-6,&*B(A;H
M"'"14DU8H2X!^OJ2HHLOE^@+8AS]6HE*$9ZKJ:>!5>W;RQH&=UL&P0D&.$ _
M!-<KA;[QG.;'#CR0TVH*=IKN@EZ/*<VN48BO4. 'OH/0_:?-<>(P3S]O/NE1
M$[81"HV_\&R$T+</6.Z*HHL[RNF"Z<LK= ^OCO&*\25Z7%-IPJ:N#J+6#>D_
MMW.E)2RW?WNX12VWR'"+^KE=S!L^2)LT(1HI372EA?R-@!-UIL76]=BXKLO3
M^VP81H$_GGKOA\%RP()1./:/8:D#AI/$G[2P(X&C5N"H5^ +R*"0X$8FB+M"
M'&HQ+(L%S>%M%ZA1[M*W]1P?,.IPOC^+2&W$,'(KBEM%<:\BJ)90"_F!)G=T
MXK/LSR)2&Q'@@\ =\1^W_,>]_.]7A"_KD*!W4E3;G"8%M"_",^H2,G:0B())
M1XP#-8I&G5Q,'2A_DIS(L4FK:-*KZ*>HZUX%#7!>4%0(I1!HHA^PKI<54ROH
MLB;E<CIWYMG$(H6C:-2-EHWJ1JL/<20L:84EO<*>J:)$9BL$C0'8O\.0L39B
M(.E0)FG.M#/U$COI@]@2Y$"%D[ 3U]2%.IF#V-]W3?^36;@@3)I4I'6,-D1*
MPMVR&I=]2^H\)'5 AN/XA)Z#*0"?J7,B>QO6 U2.H"[4;<8L+:<.;#/ R2CL
M:K%A&..H*\>!\I,3-0X'>SU!KYY7* 821A5N<FTM%#.-T2DG<#"(N_7!A8(N
MU%7C0 7QB?J ]Q, #GO5I'4+5Z)@>3N6J6JN6,Y@5'=J"BT>$SM -LA*MC[(
ML9C]R(#[9P888ABL??3S\;LRE:&G$C2N#I\?V:&Q03&.NTIL$/2B4^MF/Q[@
M_OG@.RN9_JP81S,/;34.E$.. ]6C9S\<X/[I8%_7ZG5S<G3#YZ<#!P0'715]
M;HX5[,<#W#\?[.:;'7^4L\6"2F@[C!1.+793'R9=,3;&6BI]D&,M^\$ ]T\&
MCWI%I9.SW:N3P(J #9J$N$O;!@VQ'YQ@ON_\N+_U/[33)0PRS:9EMTEP"DJL
M\=V28T-@(V!58!OEF#F]@PUS2>72?'A0T/DJKK?[S/9J^W'CUFSI.]?OZH\>
M9B.^=[/]8O*#R"7C"A5T 2[]ZS&L6+G]"+$]T6)MMN5SH6&3;PY7E,"NH@;
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ML1SY6HZIHL.!X!LDC+5F,Q=Y0>1HO80L,[4[4T(_91JGAC=9Q%- W^@6)/J
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M3A[^8O4#139?)@M=_46'6NM/4+;31I9U,!"47!S_T^>Z$"<!.!P(('4 ^6A
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M$G \@QF..K9PBH0+.UA@\O]E'#O28/JO4FYESU8P_,0<4W O5+Q)M[(7=J.
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M'-]>H&P ?E]):5X[=H+F-3?[ U!+ P04    " "T?F%2'\I>\)8"  #Q!@
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MR6?H^#+)M/_"MO8=1@%DE3:2-V"K@%-1CV37G,,!(!Z= 20-('D+&)P!]!M
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M0N4<[/Y:2K,W7(#VE9O\!5!+ P04    " "T?F%2E:(_\ZX%  "O&0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6RU6=MNVS@0_17">T$"M+%(W>RN
M8R"IFPNVER!IMP^+?:#EL2U4$EV2LAN@'[^D)$MV1#$.=IV'6+)FSLQP9LY0
M]&C#^#>Q!)#H1YIDXKRWE'+UIM\7T1)2*L[8"C+U9,YX2J6ZY8N^6'&@LT(I
M3?K$<8)^2N.L-QX5W]WQ\8CE,HDSN.-(Y&E*^>,E)&QSWL.][1?W\6(I]1?]
M\6A%%_  \LOJCJN[?HTRBU/(1,PRQ&%^WKO ;VY=7RL4$G_%L!$[UTB',F7L
MF[ZYG9WW'.T1)!!)#4'5QQK>0I)H).7']PJT5]O4BKO76_2K(G@5S)0*>,N2
MK_%,+L][@QZ:P9SFB;QGFQNH BH<C%@BBO]H4\H&00]%N9 LK925!VF<E9_T
M1[40.PHD[% @E0(Y5,&M%-RG"KA#P:L4O$,5_$K!/]2EH%((#K405@KAH0J#
M2F'P5,'I4!A6"L.B',K\%<F?4$G'(\XVB&MIA:8OB@HJM%7.XTP7^X/DZFFL
M].3X'A(J88;N*)>/Z#.GF:!%&0IT,@%)XT2<HM]_&;@!_@/%&;J,DT0_'?6E
MLJXQ^E%EZ;*T1#HL7>2+,T3"5X@XQ/GR,$$GOYZ*)>5@PGK[ JP_[[^BD\K%
M;L2)'?$C6Y\AU]&(.*B\,Z"\LZ-\H%RAX.=0KNPH$XBV*,^OU/7!6'C8[='-
MX2B#;I1;.\H53%76G#(N4T!]5;QU!9.Z@DF!ZKZT@M'?[Y4HNI60BG\LAMS:
MD%L8\CH,W7$6 <P$FG.6HEB(G&81(#9'$4M394\U:_3-E.X2-RQP]?19CSW?
M\P:!YSBC_GHWF6W)H3,8.OB)W$U;C@P)"<,PJ 7W8O3J&#UKC!<;RF=J,=FJ
M'$4IRS-I"JF$"78<")SBSVS?K^W[5OO7D,$GE;03.I_'25PD%C(9R\=32P:#
M&CTX;JF$M:'P.*5R&;9+165_;V%+@BP%L;<K&9YYYN4?U'X/[.F/(IUPH;8Q
M$<1K.DW 1#F#5O(Q&73F?E@;'UJ-3W) DBG399)6*DFQF?*&+?L^QIWVL=/,
M0N<(U8=W9BT^;OWAAA0QL8;R,4^GP'7%E42+V"93ED_*NU/T$W5.E,L*>B^_
M@>=AWW]2@P<([KO?4"T^$M=>8@/9FCNHDCRPA7!#H=C.H?>PADS5<N'Z\]5\
MA=M<BHG?\O?:*!>VY&X,<JY'NMNCX69L)^=/*^!4QMD"P0_ULB5 U.&IOFWU
MC#%6OYV=T)"<ZTIP-XAB3=K1MA%#VR3"S;# @;T&WS^\E F:^8##(S-!0^G8
MSNG_@0FN<)OI_6$X< 8=:]M0/;9S_6&#YJI"V4UNT*[X:VP8"&K7U%4"I!D(
MQ#X07MK*%=RNO]@SE7<EN-?+EA%&FA%#L+UH@4>J4.FB($N=:BZ6\<KHK!T)
M#\]"YS?;!GUGAVX?1AV=I$KO8JW>,'7V7\\9?RUH N@!HIS'[17>M]U,$N(>
MM]-(0_S$3ORWV1J$3%5T98^]0G0VB[4MFFR;CT;?\YCK_E,OTP>TX"UIL[E^
M??*[*J5A<V)G\\]+0%]C(2E'MYE0"<DEV):AX4URY%TV:6B4V/?9!]((,>RJ
M31.VDMM[J\%!=U<V'$SL''SPUO:*M!DW\%R#JVTY@BV4US SL3/S_S#D29N.
MB6MDP;8@]BVSVVV(V[43][NM[\6JQ^DTY\)4&N_<-F.[V.9"P\2NG3\_ T^-
M%NUJ/GH$RFW<YS:\ZS[#NWN[:)%/7R]4-YK>YR<5TMZDM:[#SJF)?2N_/5+H
M/DNH /;*P EMQAM*=NV4?*WC1:OM.I0T 3.C%X;M]=!4M97@WN$+L7G;4+)K
MI^0)S('KX5"D"<WS;*8;L<A>W7E&W]N;X*&!M_H[Y\3ZIXP/E"_B3* $YDK/
M.0L5#"]_'2AO)%L51\=3)B5+B\LET!EP+:">SQF3VQM]&EW_1C/^%U!+ P04
M    " "T?F%2&!7.,64%    &P  &0   'AL+W=O<FMS:&5E=',O<VAE970X
M,2YX;6RU66UOXC@0_BL6NI-VI2Z)G4"2%47:EKY VU6UW-Y].-T' P:B)C%K
M&]A*^^//#B$A;T[:;?G0)F&>&<]X9IYQ&.PI>^)K0@3X&081/^^LA=A\-@P^
M7Y,0\R[=D$A^LZ0LQ$+>LI7!-XS@10P* P.99M\(L1]UAH/XV2,;#NA6!'Y$
M'AG@VS#$[/F"!'1_WH&=XX-O_FHMU -C.-C@%9D2\7WSR.2=D6I9^"&)N$\C
MP,CRO/,%?GY G@+$$G_[9,]/KH%R94;ID[H9+\X[IEH1"<A<*!58_MN12Q($
M2I-<QX]$:2>UJ8"GUT?MU['STID9YN22!O_X"[$^[[@=L"!+O W$-[J_)8E#
M/:5O3@,>_P7[1-;L@/F6"QHF8+F"T(\.__'/)! G &C7 % "0&T!5@*PV@+L
M!&"W!?020*\MH)\ ^FT!3@)PV@+<!."V!7@)P&L+@.9QY\S6D'2S6^\V/&XW
M;+W?\+CA,-YQXY"+<2*/L,## :-[P)2\U*<NXFJ(\3)__4@5[E0P^:TO<6)X
M0R)".?AK31C>D*WPY_P,C*-Y%WP"7S%C6-45^# B OL!_RB??I^.P(<_/@X,
M(<TK)<8\,75Q,(5J3$VV41>8\ P@$YD5\$L]_"O==8%EUL)'>O@UF74!<A4<
M>A7P*SU\1&1(K/K%7^OA4[+1+OZF1>@T\%L]_ $S[>+'O^?[Y/?@=ZWAE1MW
MWQ[N5L ?&B*/:Y/6D*66UAM*ZPW%^JS:+([F-!*,!O*;E:PT01CA OQ[+P7!
M6)"0_Z<Q8Z5FK-B,76/F$3]+=A4<""JY\<?69P3@Q<)79(D#X!_-^I&D[!GW
M%SYF/N%5FWLPY,2&U!BP&T++4Y^!L3O=Q;*<F9>XUTGDO+13+VVMES=R, &2
M_1=$QI33P%_@>!J@2W#H:U5U;C>M\[I1XJ8L84,$3:>7E[MMU#0Y2/2;--V5
MY8K1U4GDHMM+H]O31G>ZQC)K9(0C.3\&E'-]7'LE^]!#%G0*>7+=*^>3T_/Z
MCEV(<5G.,Z6D4PAQ6:P8XO+"[)YK]V%![JXL5PRQSE8NQ/TTQ'UMB,?13E:A
MJE05Y_K8]LOY9MF66XC%N)W8I)W875FLQELG]=;1)Q11/09\^03!HQS/"6-D
M ::"SI\T'<]-E;OOV5B]U(SW%CMVX35VS9QY:&;SFJGO>74#F\8Y>#(-PO>,
M(LQH$"*M&P5#1T(Z W0?$<;7_@9L")O+.,OC(Y@]@XUL1I&H'!OUEJQ^US3_
MK!P8]< ^K '>- !MIP9XVP#LH3(P']^,_V'# ) %3W;M-*B5@Z]>4ZTWX]<"
M)Z\ YL.0#0BP84)X3;5D! E[[UHM&4U /4^\W3AW"<MM'=JF^N3;_ZA*$.4%
M\]YD-  ;>$"U?+#9LOD:<^G(BA&BW#L#<QJ&_J&[RJS->7ALNY7UZ)26ZE:X
M]- LE_<HXQ[HOOD@>I'HU,U^^>5D' 7U)#4J+&,EEW<&F PRYEM&CO%EZE ?
M20Z.BLTXY3B9;TOL,[##P994.N&5G$"V)J8H(SJD)[J7C9_C1%MNJBF,>?F%
M9)R(X)M0?J+F-!16'[J>Y^;3\"H1;!SG*A16SG/-^O*>GYQ5]7Q4_W+H%[B4
MI2I3BS>,;RAC+&2]9S-%&2<@/2>\-+'*!RL7>O4)GK$'TI^O6N=5^=A16$"2
M5HT'F'&SR$0KDO<THR^DIR]='KWJ4( RKD'.NV951@%(3P$OS:IR\[=T7(2R
MYH_>Y(1RA<I'%-DU2FDU;BDW:98[.&2<O*Q6OPT]8+;R(PX"LI1 L^O(!&2'
MGUL.-X)NXO?7,RH$#>/+-<$+PI2 _'Y)J3C>J%?BZ8]>P_\!4$L#!!0    (
M +1^85*P(;B;]0,  %P/   9    >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM
M;+57VV[;.!#]%<+8AQ1H+%%W%8Z!.FX2+W:+H-EN'Q;[P$ACFZA$>DDJ3OY^
M24F5+[I$>\F+K<N<X3FCX<QPMN?BN]P"*/2<9TQ>3;9*[3Y8EDRVD!,YY3M@
M^LV:BYPH?2LVEMP)(&D)RC/+L>W R@EED_FL?'8OYC->J(PRN!=(%GE.Q,L"
M,KZ_FN#)CP=?Z&:KS -K/MN1#3R ^KJ[%_K.:KRD- <F*6=(P/IJ\A%_6&'?
M $J+WRGLY=$U,E(>.?]N;E;IU<0VC""#1!D71/\]P35DF?&D>?Q5.YTT:QK@
M\?4/[S>E>"WFD4BXYMDWFJKMU22:H!36I,C4%[Z_@UI023#AF2Q_T;ZR#?T)
M2@JI>%Z#-8.<LNJ?/->!. )@KP?@U !G+,"M >Y8@%<#O+$ OP;X8P%!#0C&
M L(:$(X%1#4@&@N(:T!<ID/U_<J/OR2*S&>"[Y$PUMJ;N2@SJ$3K;TZ92?8'
M)?1;JG%J?@L,N$2_;4&0'12*)O(]6K%DBB[1$A+.),]H2LK$_)@DO&"*L@VZ
M6((B-)/OM-G7AR6Z^.G=S%*:C_%J)?7:BVIMIV?MGPLV139^CQS;L3O@U\-P
M36^*W'[X<AC^ #L-MWOAGT:0'X#?#,-_)6*0_.U_TWXW&H[C#OAJ/#PZA5LZ
M_YHD=)HD=$I_;H^_SYSI3%."9YE)KA53($ J],<OVA"M%.3RSX%EW&89MUS&
MZUGFACY#BHB4H'22,]U)^%I7VZ3(BXPH_2H%W3 26F9[5SY6[L/2O>DB3_-+
MC%TOPIXWLYZ.O]YHR[LN2R<,71N'C>6)6J]1ZPVJO29"O)AP/I&L ".5G8:9
MUF'N4EJY#HY8V6<*7[6X:UO@.(A#/^[6Y3>Z_$%=M[J#(UV-TK/JI 56Q:Q+
MC]^*\AG;Y:L6G]H6EQYVL!WZIX8WK[JZ]5NAZ79UUS8\<[4:6NPDOD$3WV P
MOGISZZE)@LX/E!"YU2.-U).#R9BUX#E26_A'L;\-6@QU?GN1C\^TMNW.M0Y9
MG&@-&ZWA<"[U=;^!:A,UOJ.W+&IQLTP\*.&;GB6-_X3LJ"(9NH#G)"O2ZI'<
M=K;EN)W)?AS'3G<PL7V8)>Q!+I^Y K0C+^0Q@\YQP&Z7A! '3L]7Q$=##'[3
MRKZH_9_L2!RX7A^S0V?#SIM5X47M^YB5BR,<]-(Z=$+\2BLD5!PH4?:D&>@C
MC#*;OMX4PDQX#-).8FZ;6("C.(YZB!V:%A[N6O^FNB]PN]6TZNDIGT.SP</=
MYO^NA@O<+MCGY;"B:AT-]>;<J2?&#6429;#62'MJ#FJB.LI5-XKORCG_D2M]
M:B@OM_KX"\(8Z/=KKK=G?6..#LV!>OXW4$L#!!0    ( +1^85**FL;E&0,
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M!J8,Y/L-I>)AHV:K>OB>_0=02P,$%     @ M'YA4J1D@=J[ @  ,P@  !D
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M E, ^7Y-J7@9* --1SWY'U!+ P04    " "T?F%2^;ZP\]\,  "6/0  &0
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MG#!PNB>QQ9 @SR7X 6X-%DM*0F3GN,$1\A5ED\?4!*<<(XJ$3>N2'(8T::7
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MAI11+H 5"M].75+L(>='H9!C6/" >.M1PSK@_"C4:^L9SH?&-"J<<ZGSHZ8
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ME]4'7@#-\KJ.5Z_QYSXO);L(1/9'(#^NL!>O4/<'(\=?;9;II85F3"K\YLV
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MC[#^?,FK<F)8^!/N%,5)&C8I+YJJ.O/GKM47S>?[MQ'W;U)^_ ]02P,$%
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M\(_CEV?:FW9XSL^6OY/<_ )02P$"% ,4    " "T?F%2!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M +1^85("3)0\[@   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( +1^85*97)PC$ 8  )PG   3
M  "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ M'YA4A=J
M4B$ !P  5AL  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( +1^85*EGJ5EC @  ,8E   8
M  " @4,/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "T
M?F%28;5Z*M4"  "["0  &               @($%&   >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ M'YA4F*VPU\!"   .2(  !@
M         ("!$!L  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( +1^85("]8^EC ,  *4*   8              " @4<C  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "T?F%2C-%*ZM$-   -0@
M&               @($))P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ M'YA4G^$?;AP#0  2CX  !@              ("!$#4  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( +1^85+UMO7?J0@
M -L2   8              " @;9"  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    " "T?F%2&XJ-B0HJ  !+A0  &               @(&5
M2P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ M'YA4OCD
MO<0# P  ]08  !D              ("!U74  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    " "T?F%2S\W6DTD8  ";5   &0
M    @($/>0  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M +1^85(#)WL7?0<  *43   9              " @8^1  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ M'YA4LH=0E1,"P  N"(  !D
M             ("!0YD  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    " "T?F%2U+HWD:@#  !J"   &0              @('&I   >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( +1^85(460_EYP(
M )0&   9              " @:6H  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ M'YA4KU,S@D%!   HP@  !D              ("!
MPZL  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "T?F%2
M=2*!)9,$  #T"@  &0              @('_KP  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( +1^85)><XQ>:Q(  'Y"   9
M      " @<FT  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ M'YA4I?5:_*8 @  UP4  !D              ("!:\<  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "T?F%2%XBEJ/$-   Y+@
M&0              @($ZR@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( +1^85+25E>A8@<  ,T1   9              " @6+8  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ M'YA4EO4CUHK
M P  S@8  !D              ("!^]\  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    " "T?F%2D-N1/Z\/  #V*@  &0
M@(%=XP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( +1^
M85)PWK&I\@(  '8&   9              " @4/S  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ M'YA4E<ZH9ED"   B!<  !D
M         ("!;/8  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    " "T?F%2RT<"QG$.  "0+   &0              @($'_P  >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( +1^85+=6)R^WP<  .43
M   9              " @:\- 0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ M'YA4J+ 0%F0 @  F 4  !D              ("!Q14!
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "T?F%2C@)%
M+?8L   BEP  &0              @(&,& $ >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( +1^85+CS%G#.P0  'P*   9
M  " @;E% 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
MM'YA4EST;Y]  P  Z08  !D              ("!*TH! 'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    " "T?F%2ELC96F4$  # #   &0
M            @(&B30$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( +1^85(#0]C)^0(  &8&   9              " @3Y2 0!X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ M'YA4N'L5G?\ @
M?P8  !D              ("!;E4! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    " "T?F%2#$6, V\#   F!P  &0              @(&A
M6 $ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( +1^85*5
MH[,G:P0  ($*   9              " @4=< 0!X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ M'YA4FUJII#U P  50D  !D
M     ("!Z6 ! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +1^85):&/P5Q00  ,(*   9              "
M@2UX 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ M'YA
M4O@LN2+X!P  SA,  !D              ("!*7T! 'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    " "T?F%2L&S#WZD'  #0*@  &0
M        @(%8A0$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( +1^85+,5A/\800  -$4   9              " @3B- 0!X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ M'YA4G16?U)V P  ? X
M !D              ("!T)$! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    " "T?F%2!VRK=LP#   N#P  &0              @(%]E0$
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( +1^85)7%&9Q
MQ0H  )Y$   9              " @8"9 0!X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ M'YA4@<QC3M\ P  " P  !D
M ("!?*0! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " "T
M?F%2::!#&44$  !!$0  &0              @($OJ $ >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( +1^85*93J.*!@@  *-!   9
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M970U-2YX;6Q02P$"% ,4    " "T?F%26H87NL\$   ?%   &0
M    @(&:Q0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    (
M +1^85)_WS\_Q 0  "47   9              " @:#* 0!X;"]W;W)K<VAE
M971S+W-H965T-3<N>&UL4$L! A0#%     @ M'YA4K:3 >UZ @  A08  !D
M             ("!F\\! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"
M% ,4    " "T?F%2**(BQ8\"  !(!P  &0              @(%,T@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( +1^85(1*[Z;] H
M !5$   9              " @1+5 0!X;"]W;W)K<VAE971S+W-H965T-C N
M>&UL4$L! A0#%     @ M'YA4J)A=F-. P  / H  !D              ("!
M/> ! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " "T?F%2
MB"ZOV^X#   S$@  &0              @('"XP$ >&PO=V]R:W-H965T<R]S
M:&5E=#8R+GAM;%!+ 0(4 Q0    ( +1^85+6DV9.J0(  "D'   9
M      " @>?G 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%
M  @ M'YA4HB$X3+, @  4PH  !D              ("!Q^H! 'AL+W=O<FMS
M:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " "T?F%2JO=(&N\*  !6/@
M&0              @('*[0$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+
M 0(4 Q0    ( +1^85(AF5D&808   XG   9              " @?#X 0!X
M;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ M'YA4K/-SD<<
M P  & H  !D              ("!B/\! 'AL+W=O<FMS:&5E=',O<VAE970V
M-RYX;6Q02P$"% ,4    " "T?F%2'=Q6#^4"   N!P  &0
M@('; @( >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( +1^
M85(<\F6BG ,  *4-   9              " @?<% @!X;"]W;W)K<VAE971S
M+W-H965T-CDN>&UL4$L! A0#%     @ M'YA4B((J/%4 P  TPH  !D
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M=#<T+GAM;%!+ 0(4 Q0    ( +1^85+3_YW"500  !83   9
M  " @:(= @!X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @
MM'YA4JE@PJ>;!   +A$  !D              ("!+B(" 'AL+W=O<FMS:&5E
M=',O<VAE970W-BYX;6Q02P$"% ,4    " "T?F%22,J -PD$  #D$@  &0
M            @($ )P( >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4
M Q0    ( +1^85+3") :/@,  -D)   9              " @4 K @!X;"]W
M;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ M'YA4A_*7O"6 @
M\08  !D              ("!M2X" 'AL+W=O<FMS:&5E=',O<VAE970W.2YX
M;6Q02P$"% ,4    " "T?F%2E:(_\ZX%  "O&0  &0              @(&"
M,0( >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( +1^85(8
M%<XQ904    ;   9              " @6<W @!X;"]W;W)K<VAE971S+W-H
M965T.#$N>&UL4$L! A0#%     @ M'YA4K AN)OU P  7 \  !D
M     ("! ST" 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +1^85*%WZ6H=0(  ',%   9              "
M@6]8 @!X;"]W;W)K<VAE971S+W-H965T.#<N>&UL4$L! A0#%     @ M'YA
M4A$3@F;@ 0  5 0  !D              ("!&UL" 'AL+W=O<FMS:&5E=',O
M<VAE970X."YX;6Q02P$"% ,4    " "T?F%20._'AY\"   ;$0  #0
M        @ $R70( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +1^85*7BKL<
MP    !,"   +              "  ?Q? @!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( +1^85+OAO_)?08  ,TY   /              "  >5@ @!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " "T?F%2PR792)0"  #?,P  &@
M    @ &/9P( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" "T?F%2C9S+JS0"  !6,@  $P              @ %;:@( 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     8 !@ %<:  # ; (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>438</ContextCount>
  <ElementCount>580</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>115</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/TheCompany</Role>
      <ShortName>The Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2112105 - Disclosure - Short-term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestments</Role>
      <ShortName>Short-term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121107 - Disclosure - Major Customers and Concentration of Credit Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRisk</Role>
      <ShortName>Major Customers and Concentration of Credit Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124108 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2127109 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2130110 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2135111 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2140112 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/AccountsPayableandAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2143113 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2150114 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2154115 - Disclosure - Investment in Affiliated Entity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/InvestmentinAffiliatedEntity</Role>
      <ShortName>Investment in Affiliated Entity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2156116 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2165117 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/A401kPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2167118 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2169119 - Disclosure - Geneos Therapeutics, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsInc</Role>
      <ShortName>Geneos Therapeutics, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2176120 - Disclosure - Quarterly Financial Information (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited</Role>
      <ShortName>Quarterly Financial Information (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2179121 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Short-term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsTables</Role>
      <ShortName>Short-term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestments</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/FairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Major Customers and Concentration of Credit Risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskTables</Role>
      <ShortName>Major Customers and Concentration of Credit Risk (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRisk</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2328306 - Disclosure - Fixed Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FixedAssetsTables</Role>
      <ShortName>Fixed Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/FixedAssets</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2331307 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2336308 - Disclosure - Convertible Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtTables</Role>
      <ShortName>Convertible Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ConvertibleDebt</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2341309 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/AccountsPayableandAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/AccountsPayableandAccruedExpenses</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2344310 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockholdersEquity</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2351311 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/Leases</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2357312 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/IncomeTaxes</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2370313 - Disclosure - Geneos Therapeutics, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncTables</Role>
      <ShortName>Geneos Therapeutics, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GeneosTherapeuticsInc</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2377314 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables</Role>
      <ShortName>Quarterly Financial Information (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionDetails</Role>
      <ShortName>Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RevenueRecognition</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CollaborativeAgreements</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Short-term Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails</Role>
      <ShortName>Short-term Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Short-term Investments - Summary of Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Short-term Investments - Summary of Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Major Customers and Concentration of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails</Role>
      <ShortName>Major Customers and Concentration of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2429413 - Disclosure - Fixed Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FixedAssetsDetails</Role>
      <ShortName>Fixed Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/FixedAssetsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2432414 - Disclosure - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2433415 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2434416 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2437417 - Disclosure - Convertible Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtNarrativeDetails</Role>
      <ShortName>Convertible Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2438418 - Disclosure - Convertible Debt - Balance Of Convertible Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails</Role>
      <ShortName>Convertible Debt - Balance Of Convertible Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2439419 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails</Role>
      <ShortName>Convertible Debt - Schedule of Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2442420 - Disclosure - Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/AccountsPayableandAccruedExpensesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2445421 - Disclosure - Stockholders' Equity - Summary of Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2446422 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2447423 - Disclosure - Stockholders' Equity - Summary of Stock Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2448424 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2449425 - Disclosure - Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails</Role>
      <ShortName>Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2452426 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2453427 - Disclosure - Leases - Summary of Maturities of Operating Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails</Role>
      <ShortName>Leases - Summary of Maturities of Operating Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2455428 - Disclosure - Investment in Affiliated Entity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails</Role>
      <ShortName>Investment in Affiliated Entity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/InvestmentinAffiliatedEntity</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2458429 - Disclosure - Income Taxes - Components of Pretax Loss from Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails</Role>
      <ShortName>Income Taxes - Components of Pretax Loss from Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2459430 - Disclosure - Income Taxes - Summary of the Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Summary of the Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2460431 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2461432 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2462433 - Disclosure - Income Taxes Significant Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes Significant Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2463434 - Disclosure - Income Taxes Expected Expirations of Federal and State Losses and Credits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails</Role>
      <ShortName>Income Taxes Expected Expirations of Federal and State Losses and Credits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2464435 - Disclosure - Income Taxes Unrecognized Tax Benefits Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails</Role>
      <ShortName>Income Taxes Unrecognized Tax Benefits Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2466436 - Disclosure - 401(k) Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/A401kPlanDetails</Role>
      <ShortName>401(k) Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/A401kPlan</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2468437 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2471438 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2472439 - Disclosure - Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2473440 - Disclosure - Geneos Therapeutics, Inc. - Investment in Geneos (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Investment in Geneos (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2474441 - Disclosure - Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2475442 - Disclosure - Geneos Therapeutics, Inc. - Preferred Stock Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Preferred Stock Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2478443 - Disclosure - Quarterly Financial Information (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails</Role>
      <ShortName>Quarterly Financial Information (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2480444 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SubsequentEvents</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="ino-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - ino-20201231.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - ino-20201231.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="ino-20201231.htm">ino-20201231.htm</File>
    <File>ino-12312020x10kex1014.htm</File>
    <File>ino-12312020x10kex211.htm</File>
    <File>ino-12312020x10kex231.htm</File>
    <File>ino-12312020x10kex311.htm</File>
    <File>ino-12312020x10kex312.htm</File>
    <File>ino-12312020x10kex321.htm</File>
    <File>ino-20201231.xsd</File>
    <File>ino-20201231_cal.xml</File>
    <File>ino-20201231_def.xml</File>
    <File>ino-20201231_lab.xml</File>
    <File>ino-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ino-20201231_g1.jpg</File>
    <File>ino-20201231_g2.jpg</File>
    <File>ino-20201231_g3.jpg</File>
    <File>ino-20201231_g4.jpg</File>
    <File>ino-20201231_g5.jpg</File>
    <File>ino-20201231_g6.jpg</File>
    <File>ino-20201231_g7.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>115
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ino-20201231.htm": {
   "axisCustom": 0,
   "axisStandard": 36,
   "contextCount": 438,
   "dts": {
    "calculationLink": {
     "local": [
      "ino-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ino-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ino-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ino-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 795,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 8,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 12
   },
   "keyCustom": 110,
   "keyStandard": 470,
   "memberCustom": 52,
   "memberStandard": 51,
   "nsprefix": "ino",
   "nsuri": "http://www.inovio.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.inovio.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Revenue Recognition",
     "role": "http://www.inovio.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Collaborative Agreements",
     "role": "http://www.inovio.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112105 - Disclosure - Short-term Investments",
     "role": "http://www.inovio.com/role/ShorttermInvestments",
     "shortName": "Short-term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116106 - Disclosure - Fair Value Measurements",
     "role": "http://www.inovio.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121107 - Disclosure - Major Customers and Concentration of Credit Risk",
     "role": "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRisk",
     "shortName": "Major Customers and Concentration of Credit Risk",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124108 - Disclosure - Prepaid Expenses and Other Current Assets",
     "role": "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127109 - Disclosure - Fixed Assets",
     "role": "http://www.inovio.com/role/FixedAssets",
     "shortName": "Fixed Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130110 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135111 - Disclosure - Convertible Debt",
     "role": "http://www.inovio.com/role/ConvertibleDebt",
     "shortName": "Convertible Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140112 - Disclosure - Accounts Payable and Accrued Expenses",
     "role": "http://www.inovio.com/role/AccountsPayableandAccruedExpenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.inovio.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143113 - Disclosure - Stockholders' Equity",
     "role": "http://www.inovio.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150114 - Disclosure - Leases",
     "role": "http://www.inovio.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154115 - Disclosure - Investment in Affiliated Entity",
     "role": "http://www.inovio.com/role/InvestmentinAffiliatedEntity",
     "shortName": "Investment in Affiliated Entity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156116 - Disclosure - Income Taxes",
     "role": "http://www.inovio.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2165117 - Disclosure - 401(k) Plan",
     "role": "http://www.inovio.com/role/A401kPlan",
     "shortName": "401(k) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2167118 - Disclosure - Related Party Transactions",
     "role": "http://www.inovio.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2169119 - Disclosure - Geneos Therapeutics, Inc.",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsInc",
     "shortName": "Geneos Therapeutics, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2176120 - Disclosure - Quarterly Financial Information (Unaudited)",
     "role": "http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited",
     "shortName": "Quarterly Financial Information (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2179121 - Disclosure - Subsequent Events",
     "role": "http://www.inovio.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Short-term Investments (Tables)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsTables",
     "shortName": "Short-term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.inovio.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Major Customers and Concentration of Credit Risk (Tables)",
     "role": "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskTables",
     "shortName": "Major Customers and Concentration of Credit Risk (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "role": "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328306 - Disclosure - Fixed Assets (Tables)",
     "role": "http://www.inovio.com/role/FixedAssetsTables",
     "shortName": "Fixed Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331307 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336308 - Disclosure - Convertible Debt (Tables)",
     "role": "http://www.inovio.com/role/ConvertibleDebtTables",
     "shortName": "Convertible Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341309 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "role": "http://www.inovio.com/role/AccountsPayableandAccruedExpensesTables",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344310 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.inovio.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations",
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ino:ChangeInFairValueOfCommonStockWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2351311 - Disclosure - Leases (Tables)",
     "role": "http://www.inovio.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2357312 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.inovio.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2370313 - Disclosure - Geneos Therapeutics, Inc. (Tables)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncTables",
     "shortName": "Geneos Therapeutics, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2377314 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)",
     "role": "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables",
     "shortName": "Quarterly Financial Information (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)",
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
     "shortName": "Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "if1f13165d5d6482590debad2f6e92178_D20200101-20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)",
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "if1f13165d5d6482590debad2f6e92178_D20200101-20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Revenue Recognition (Details)",
     "role": "http://www.inovio.com/role/RevenueRecognitionDetails",
     "shortName": "Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Collaborative Agreements (Details)",
     "role": "http://www.inovio.com/role/CollaborativeAgreementsDetails",
     "shortName": "Collaborative Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i613bf85d5ad641aeb9777c902ee5e720_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ino:CollaborativeAgreementsUpfrontPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Short-term Investments - Narrative (Details)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails",
     "shortName": "Short-term Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Short-term Investments - Summary of Available-for-sale Securities (Details)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails",
     "shortName": "Short-term Investments - Summary of Available-for-sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0710bc234ed846439f5d59a967a8aa8b_I20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:ProceedsFromSaleOfEquitySecuritiesFVNI",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i627a611d119640b18733b47fcdec6850_D20200801-20200831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ino:ProceedsFromSaleOfEquitySecuritiesFVNI",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "if06f128df0d4400ebe7bd1d7e8943618_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)",
     "role": "http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails",
     "shortName": "Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "if06f128df0d4400ebe7bd1d7e8943618_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Major Customers and Concentration of Credit Risk (Details)",
     "role": "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails",
     "shortName": "Major Customers and Concentration of Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i93819976a973446ea1061a1f37473186_D20200101-20201231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:PrepaidManufacturingExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:PrepaidManufacturingExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429413 - Disclosure - Fixed Assets (Details)",
     "role": "http://www.inovio.com/role/FixedAssetsDetails",
     "shortName": "Fixed Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432414 - Disclosure - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433415 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
       "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434416 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i37ba42be07e34414bfad4d78f2cdd2c1_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i37ba42be07e34414bfad4d78f2cdd2c1_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437417 - Disclosure - Convertible Debt - Narrative (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
     "shortName": "Convertible Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "ie6d09c017e724216bcf006aa836a0724_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i4a2b66e18d454ede830f8d1d4aada02f_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438418 - Disclosure - Convertible Debt - Balance Of Convertible Debt (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
     "shortName": "Convertible Debt - Balance Of Convertible Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i4a2b66e18d454ede830f8d1d4aada02f_I20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ino:DebtInstrumentConvertibleDebtConvertedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i4a2b66e18d454ede830f8d1d4aada02f_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439419 - Disclosure - Convertible Debt - Schedule of Maturities (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
     "shortName": "Convertible Debt - Schedule of Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "ic594f80a76ff4858a3452511b0ae1fad_I20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442420 - Disclosure - Accounts Payable and Accrued Expenses (Details)",
     "role": "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails",
     "shortName": "Accounts Payable and Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445421 - Disclosure - Stockholders' Equity - Summary of Preferred Stock (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails",
     "shortName": "Stockholders' Equity - Summary of Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i43ff85947d654cd3b9d8600362c08d4e_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446422 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447423 - Disclosure - Stockholders' Equity - Summary of Stock Options Outstanding (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails",
     "shortName": "Stockholders' Equity - Summary of Stock Options Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "if06f128df0d4400ebe7bd1d7e8943618_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448424 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails",
     "shortName": "Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "ia6335ae27741400684bafee789c7d140_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449425 - Disclosure - Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails",
     "shortName": "Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "ia6335ae27741400684bafee789c7d140_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:LesseeOperatingLeaseAreaofLandUnderLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452426 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.inovio.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:LesseeOperatingLeaseAreaofLandUnderLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ino:AmortizationOfOperatingLeaseRightOfUseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453427 - Disclosure - Leases - Summary of Maturities of Operating Lease Payments (Details)",
     "role": "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails",
     "shortName": "Leases - Summary of Maturities of Operating Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455428 - Disclosure - Investment in Affiliated Entity (Details)",
     "role": "http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails",
     "shortName": "Investment in Affiliated Entity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "if2747486006c46f3999136afeba9ca67_I20201231",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458429 - Disclosure - Income Taxes - Components of Pretax Loss from Operations (Details)",
     "role": "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails",
     "shortName": "Income Taxes - Components of Pretax Loss from Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459430 - Disclosure - Income Taxes - Summary of the Provision for Income Taxes (Details)",
     "role": "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Summary of the Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460431 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Details)",
     "role": "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails",
     "shortName": "Income Taxes - Reconciliation of Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i748a768d51414cce859cb0837e99006b_D20191001-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461432 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.inovio.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ino:TaxBenefitsExpired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462433 - Disclosure - Income Taxes Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "ie1a1fd05e61e4d45b37b83d2c13345a4_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ino:OperatingLossCarryforwardsExpiringintheNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463434 - Disclosure - Income Taxes Expected Expirations of Federal and State Losses and Credits (Details)",
     "role": "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
     "shortName": "Income Taxes Expected Expirations of Federal and State Losses and Credits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "ie1a1fd05e61e4d45b37b83d2c13345a4_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ino:OperatingLossCarryforwardsExpiringintheNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "if06f128df0d4400ebe7bd1d7e8943618_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464435 - Disclosure - Income Taxes Unrecognized Tax Benefits Activity (Details)",
     "role": "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails",
     "shortName": "Income Taxes Unrecognized Tax Benefits Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i098d7fa0e69c497394a273e6da442d60_I20171231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466436 - Disclosure - 401(k) Plan (Details)",
     "role": "http://www.inovio.com/role/A401kPlanDetails",
     "shortName": "401(k) Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - The Company",
     "role": "http://www.inovio.com/role/TheCompany",
     "shortName": "The Company",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468437 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ino:CollaborativeAgreementAwardedOptionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2471438 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
     "shortName": "Geneos Therapeutics, Inc. - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i4dc3ada5f7d04ae89165c132fbfcfc62_I20200601",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2472439 - Disclosure - Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
     "shortName": "Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i9bc7852775b6421ca17e8e3e194bab5c_I20200601",
      "decimals": "0",
      "lang": "en-US",
      "name": "ino:WorkingCapitalExcludingCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i461a06745d764430b3e72d9b80f2433e_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2473440 - Disclosure - Geneos Therapeutics, Inc. - Investment in Geneos (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
     "shortName": "Geneos Therapeutics, Inc. - Investment in Geneos (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i9bc7852775b6421ca17e8e3e194bab5c_I20200601",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i9bc7852775b6421ca17e8e3e194bab5c_I20200601",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:EquityMethodInvestmentEnterpriseValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474441 - Disclosure - Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
     "shortName": "Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i9bc7852775b6421ca17e8e3e194bab5c_I20200601",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:EquityMethodInvestmentEnterpriseValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "if06f128df0d4400ebe7bd1d7e8943618_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2475442 - Disclosure - Geneos Therapeutics, Inc. - Preferred Stock Investment (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails",
     "shortName": "Geneos Therapeutics, Inc. - Preferred Stock Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2478443 - Disclosure - Quarterly Financial Information (Unaudited) (Details)",
     "role": "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails",
     "shortName": "Quarterly Financial Information (Unaudited) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "ic4e2ea2f527e48bfb59b26033969baf7_D20201001-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "if258c2eac36b42adb8115f070d01b735_D20210125-20210125",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2480444 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.inovio.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "if258c2eac36b42adb8115f070d01b735_D20210125-20210125",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20201231.htm",
      "contextRef": "i0e91cfe897ce44a18aa94d71bdfa2276_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": null,
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - ino-20201231.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - ino-20201231.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 115,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r706",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r706",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ino_A2007IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2007 Incentive Plan [Member]",
        "label": "2007 Incentive Plan [Member]",
        "terseLabel": "2007 Incentive Plan"
       }
      }
     },
     "localname": "A2007IncentivePlanMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A2016IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Incentive Plan [Member]",
        "label": "2016 Incentive Plan [Member]",
        "terseLabel": "2016 Incentive Plan"
       }
      }
     },
     "localname": "A2016IncentivePlanMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A6.50ConvertibleSeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "label": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "terseLabel": "6.50% Convertible Senior Notes Due 2024"
       }
      }
     },
     "localname": "A6.50ConvertibleSeniorNotesDue2024Member",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AccruedClinicalTrialExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trial Expense, Current",
        "label": "Accrued Clinical Trial Expense, Current",
        "verboseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenseCurrent",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_AccruedSubcontractExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Subcontract Expenses",
        "label": "Accrued Subcontract Expenses",
        "terseLabel": "Accrued subcontract costs"
       }
      }
     },
     "localname": "AccruedSubcontractExpenses",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_AdvaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advaccine",
        "label": "Advaccine [Member]",
        "terseLabel": "Advaccine"
       }
      }
     },
     "localname": "AdvaccineMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AfterJanuary22020ConversionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "After January 2, 2020 Conversion Price [Member]",
        "label": "After January 2, 2020 Conversion Price [Member]",
        "terseLabel": "After January 2, 2020 Conversion Price"
       }
      }
     },
     "localname": "AfterJanuary22020ConversionPriceMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AfterJuly22020ConversionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "After July 2, 2020 Conversion Price [Member]",
        "label": "After July 2, 2020 Conversion Price [Member]",
        "terseLabel": "After July 2, 2020 Conversion Price"
       }
      }
     },
     "localname": "AfterJuly22020ConversionPriceMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AllOtherCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All Other Customers [Member]",
        "label": "All Other Customers [Member]",
        "terseLabel": "All other, including affiliated entities"
       }
      }
     },
     "localname": "AllOtherCustomersMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AlternativeInvestmentMeasurementInputTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alternative Investment, Measurement Input, Term",
        "label": "Alternative Investment, Measurement Input, Term",
        "terseLabel": "Equity method investment, measurement input, expected term"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInputTerm",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_AmortizationOfOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization Of Operating Lease Right-Of-Use Assets",
        "label": "Amortization Of Operating Lease Right-Of-Use Assets",
        "terseLabel": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "AmortizationOfOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ApolloBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ApolloBio [Member]",
        "label": "ApolloBio [Member]",
        "terseLabel": "ApolloBio"
       }
      }
     },
     "localname": "ApolloBioMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumptions used in estimation of fair value of stock options.",
        "label": "Assumptions Used In Estimation Of Fair Value Of Stock Options [Abstract]",
        "verboseLabel": "Summary of assumptions used to estimate the fair value of stock options"
       }
      }
     },
     "localname": "AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ino_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca [Member]",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_August2019ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "August 2019 Convertible Bonds [Member]",
        "label": "August 2019 Convertible Bonds [Member]",
        "terseLabel": "August 2019 Bonds"
       }
      }
     },
     "localname": "August2019ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_BillAndMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bill And Melinda Gates Foundation",
        "label": "Bill And Melinda Gates Foundation [Member]",
        "terseLabel": "Bill And Melinda Gates Foundation"
       }
      }
     },
     "localname": "BillAndMelindaGatesFoundationMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_BiojectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bioject [Member]",
        "label": "Bioject [Member]",
        "terseLabel": "Bioject"
       }
      }
     },
     "localname": "BiojectMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CELLECTRA3PSPProprietarySmartDeviceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C E L L E C T R A3 P S P Proprietary Smart Device",
        "label": "C E L L E C T R A3 P S P Proprietary Smart Device [Member]",
        "terseLabel": "CELLECTRA 3PSP Proprietary Smart Device"
       }
      }
     },
     "localname": "CELLECTRA3PSPProprietarySmartDeviceMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CaliforniaIncomeTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California Income Tax Authority [Member]",
        "label": "California Income Tax Authority [Member]",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CaliforniaIncomeTaxAuthorityMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ChangeInFairValueOfCommonStockWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of the change in fair value of common stock warrants which are measured at fair value on a recurring basis.",
        "label": "Change in Fair Value of Common Stock Warrants",
        "verboseLabel": "Change in fair value of common stock warrants"
       }
      }
     },
     "localname": "ChangeInFairValueOfCommonStockWarrants",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ChangeInValueOfCommonStockWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change during the reporting period in the fair value of common stock warrants, which are revalued at each balance sheet date subsequent to initial receipt or issuance.",
        "label": "Change in Value of Common Stock Warrants",
        "verboseLabel": "Change in fair value of common stock warrants"
       }
      }
     },
     "localname": "ChangeInValueOfCommonStockWarrants",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ChangeInValueOfInvestmentsInAffiliatedCompany": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.",
        "label": "Change in Value of Investments in Affiliated Company",
        "negatedLabel": "(Gain) loss on equity investment in affiliated entities",
        "terseLabel": "Gain (loss) on investment in affiliated entities",
        "verboseLabel": "Gain (loss) on investment in affiliated entities"
       }
      }
     },
     "localname": "ChangeInValueOfInvestmentsInAffiliatedCompany",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CoalitionforEpidemicPreparednessInnovationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coalition for Epidemic Preparedness Innovations [Member]",
        "label": "Coalition for Epidemic Preparedness Innovations [Member]",
        "terseLabel": "Coalition for Epidemic Preparedness Innovations"
       }
      }
     },
     "localname": "CoalitionforEpidemicPreparednessInnovationsMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CollaborationAgreementAdditionalRevenueToBeAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "label": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "terseLabel": "Additional revenue to be achieved"
       }
      }
     },
     "localname": "CollaborationAgreementAdditionalRevenueToBeAchieved",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones",
        "label": "Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones",
        "terseLabel": "Agreement, anticipated commercial event based payment receivable milestones"
       }
      }
     },
     "localname": "CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones",
        "label": "Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones",
        "terseLabel": "Agreement anticipated development and regulatory event based payment receivable milestones"
       }
      }
     },
     "localname": "CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementPaymentEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Payment Earned",
        "label": "Collaboration Agreement, Payment Earned",
        "terseLabel": "Collaboration agreement, payment earned"
       }
      }
     },
     "localname": "CollaborationAgreementPaymentEarned",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementRoyaltyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Royalty Period",
        "label": "Collaboration Agreement, Royalty Period",
        "terseLabel": "Obligation period to pay royalties"
       }
      }
     },
     "localname": "CollaborationAgreementRoyaltyPeriod",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborationAgreementTerritoryExpansionOptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Territory Expansion Option Period",
        "label": "Collaboration Agreement, Territory Expansion Option Period",
        "terseLabel": "Territory expansion option period"
       }
      }
     },
     "localname": "CollaborationAgreementTerritoryExpansionOptionPeriod",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementAdvisoryFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Advisory Fees",
        "label": "Collaborative Agreement, Advisory Fees",
        "terseLabel": "Advisory fees"
       }
      }
     },
     "localname": "CollaborativeAgreementAdvisoryFees",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Amount",
        "label": "Collaborative Agreement, Awarded Amount",
        "terseLabel": "Awarded amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedAmount",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedOptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Option Amount",
        "label": "Collaborative Agreement, Awarded Option Amount",
        "terseLabel": "Awarded option amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedOptionAmount",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementCorporateIncomeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Corporate Income Tax",
        "label": "Collaborative Agreement, Corporate Income Tax",
        "terseLabel": "Collaborative agreement, corporate income tax"
       }
      }
     },
     "localname": "CollaborativeAgreementCorporateIncomeTax",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementExpensesToReimburse": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Expenses To Reimburse",
        "label": "Collaborative Agreement, Expenses To Reimburse",
        "terseLabel": "Expenses to reimburse"
       }
      }
     },
     "localname": "CollaborativeAgreementExpensesToReimburse",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementForeignNonIncomeTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Non-Income Taxes",
        "label": "Collaborative Agreement, Foreign Non-Income Taxes",
        "terseLabel": "Collaborative agreement, foreign non-income Taxes"
       }
      }
     },
     "localname": "CollaborativeAgreementForeignNonIncomeTaxes",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementFundingToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Funding Received for Research and Development",
        "label": "Collaborative Agreement, Funding To Be Received",
        "terseLabel": "Collaborative agreement, funding to be received"
       }
      }
     },
     "localname": "CollaborativeAgreementFundingToBeReceived",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementMilestonePaymentRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Milestone Payment, Revenue Recognized",
        "label": "Collaborative Agreement, Milestone Payment, Revenue Recognized",
        "terseLabel": "Agreement, milestone payment, revenue recognized"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestonePaymentRevenueRecognized",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Number of Days Written Notice Before Termination",
        "label": "Collaborative Agreement, Number of Days Written Notice Before Termination",
        "terseLabel": "Agreement, number of days written notice before termination"
       }
      }
     },
     "localname": "CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Period From Effective Date For Termination",
        "label": "Collaborative Agreement, Period From Effective Date For Termination",
        "terseLabel": "Agreement period from effective date for termination"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodFromEffectiveDateForTermination",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "label": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "terseLabel": "Collaborative agreement, period to receive funding for research and development"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementsUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreements, Upfront Payment Received",
        "label": "Collaborative Agreements, Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "CollaborativeAgreementsUpfrontPaymentReceived",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementFixedPriceContractAmountAwarded": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded",
        "label": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded",
        "terseLabel": "Purchase price, procurement contract"
       }
      }
     },
     "localname": "CollaborativeArrangementFixedPriceContractAmountAwarded",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Term",
        "label": "Collaborative Arrangement, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "CollaborativeArrangementTerm",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CommonStockEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock equivalents.",
        "label": "Common Stock Equivalents [Abstract]",
        "verboseLabel": "Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect"
       }
      }
     },
     "localname": "CommonStockEquivalentsAbstract",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ino_ComprehensiveIncomeLossTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comprehensive Income (Loss), Tax Expense (Benefit)",
        "label": "Comprehensive Income (Loss), Tax Expense (Benefit)",
        "totalLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "ComprehensiveIncomeLossTaxExpenseBenefit",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Bonds [Member]",
        "label": "Convertible Bonds [Member]",
        "terseLabel": "Convertible Bonds"
       }
      }
     },
     "localname": "ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share",
        "terseLabel": "Convertible preferred stock, shares issued upon conversion, conversion price (in USD per share)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ino_DNAEncodedMonoclonalAntibodyTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "D N A Encoded Monoclonal Antibody Technology",
        "label": "D N A Encoded Monoclonal Antibody Technology [Member]",
        "terseLabel": "D N A Encoded Monoclonal Antibody Technology"
       }
      }
     },
     "localname": "DNAEncodedMonoclonalAntibodyTechnologyMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DebtInstrumentAccretionOfPremium": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Accretion Of Premium",
        "label": "Debt Instrument, Accretion Of Premium",
        "terseLabel": "Accretion of premium associated with the bonds"
       }
      }
     },
     "localname": "DebtInstrumentAccretionOfPremium",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DebtInstrumentConvertibleDebtConvertedAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Converted Amount",
        "label": "Debt Instrument, Convertible Debt, Converted Amount",
        "negatedTerseLabel": "Principal amount converted into common shares"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtConvertedAmount",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DebtInstrumentConvertibleInternalRateOfReturn": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Internal Rate Of Return",
        "label": "Debt Instrument, Convertible, Internal Rate Of Return",
        "terseLabel": "Debt instrument, convertible, internal rate of return"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleInternalRateOfReturn",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Required Bondholder Approval, Percentage",
        "label": "Debt Instrument, Convertible, Required Bondholder Approval, Percentage",
        "terseLabel": "Debt instrument, convertible, required bondholder approval, percentage"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRequiredBondholderApprovalPercentage",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ino_DebtSecuritiesAvailableforSaleContractualMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale contractual maturity.",
        "label": "Debt Securities, Available-for-Sale Contractual Maturity",
        "terseLabel": "Contractual Maturity"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforSaleContractualMaturity",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_DebtinstrumentAccruedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, Accrued Interest",
        "label": "Debt instrument, Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "DebtinstrumentAccruedInterest",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_December2019ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2019 Convertible Bonds [Member]",
        "label": "December 2019 Convertible Bonds [Member]",
        "terseLabel": "December 2019 Bonds"
       }
      }
     },
     "localname": "December2019ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, Current",
        "label": "Deferred Grant Funding, Current",
        "terseLabel": "Grant funding liability",
        "verboseLabel": "Deferred grant funding"
       }
      }
     },
     "localname": "DeferredGrantFundingCurrent",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate",
        "label": "Deferred Grant Funding, From Affiliate",
        "terseLabel": "Deferred grant funding from affiliate"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliate",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate, Current",
        "label": "Deferred Grant Funding, From Affiliate, Current",
        "terseLabel": "Grant funding liability from affiliated entities"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliateCurrent",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliateNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate, Noncurrent",
        "label": "Deferred Grant Funding, From Affiliate, Noncurrent",
        "terseLabel": "Grant funding liability from affiliated entity, net of current portion"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliateNoncurrent",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredRevenueFromAffiliatedEntityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of consideration received or receivable from related parties as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.",
        "label": "Deferred Revenue from Affiliated Entity, Current",
        "verboseLabel": "Deferred revenue from affiliated entities"
       }
      }
     },
     "localname": "DeferredRevenueFromAffiliatedEntityCurrent",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredTaxAssetInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset, Interest Expense",
        "label": "Deferred Tax Asset, Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "DeferredTaxAssetInterestExpense",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredTaxAssetsIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Intangible Assets",
        "label": "Deferred Tax Assets, Intangible Assets",
        "terseLabel": "Acquired intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsIntangibleAssets",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease Liability",
        "label": "Deferred Tax Assets, Operating Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredTaxLiabilitiesFinancingArrangementDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Financing Arrangement, Discount",
        "label": "Deferred Tax Liabilities, Financing Arrangement, Discount",
        "negatedTerseLabel": "Note discount"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFinancingArrangementDiscount",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset",
        "label": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset",
        "negatedTerseLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DepartmentOfDefenceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Department Of Defence",
        "label": "Department Of Defence [Member]",
        "terseLabel": "Department Of Defence"
       }
      }
     },
     "localname": "DepartmentOfDefenceMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DoDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DoD [Member]",
        "label": "DoD [Member]",
        "terseLabel": "DoD"
       }
      }
     },
     "localname": "DoDMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Deconsolidation of Subsidiary",
        "label": "Effective Income Tax Rate Reconciliation, Deconsolidation of Subsidiary",
        "terseLabel": "Deconsolidation of subsidiary"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible, Loss on Extinguishment of Debt",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible, Loss on Extinguishment of Debt",
        "terseLabel": "Nondeductible loss on extinguishment of debt"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits",
        "label": "Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits",
        "terseLabel": "Expired NOLs and credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Reconciliation, Foreign Withholding Taxes, Amount",
        "label": "Effective Income Tax Reconciliation, Foreign Withholding Taxes, Amount",
        "terseLabel": "Foreign income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits",
        "label": "Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits",
        "terseLabel": "Limited NOLs and credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee [Member]",
        "label": "Employee [Member]",
        "terseLabel": "Employee"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_EmployeesAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and Directors [Member]",
        "label": "Employees and Directors [Member]",
        "terseLabel": "Employees and Directors"
       }
      }
     },
     "localname": "EmployeesAndDirectorsMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_EquityComponentOfConvertibleDebtIssued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Component Of Convertible Debt Issued",
        "label": "Equity Component Of Convertible Debt Issued",
        "terseLabel": "Equity component of issuance of convertible notes"
       }
      }
     },
     "localname": "EquityComponentOfConvertibleDebtIssued",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_EquityMethodInvestmentEnterpriseValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Enterprise Value",
        "label": "Equity Method Investment, Enterprise Value",
        "terseLabel": "Geneos enterprise value"
       }
      }
     },
     "localname": "EquityMethodInvestmentEnterpriseValue",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GeneOneLifeSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GeneOne Life Sciences [Member]",
        "label": "GeneOne Life Sciences [Member]",
        "terseLabel": "GeneOne (affiliated entity)",
        "verboseLabel": "GeneOne Life Sciences"
       }
      }
     },
     "localname": "GeneOneLifeSciencesMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_GeneosTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geneos Therapeutics, Inc. [Member]",
        "label": "Geneos Therapeutics, Inc. [Member]",
        "terseLabel": "Geneos Therapeutics, Inc."
       }
      }
     },
     "localname": "GeneosTherapeuticsInc.Member",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_GoodwillAndIntangibleAssetsGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets gross.",
        "label": "Goodwill and Intangible Assets Gross",
        "totalLabel": "Total goodwill and intangible assets, Gross"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGross",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GoodwillAndIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets net.",
        "label": "Goodwill and Intangible Assets Net",
        "totalLabel": "Total goodwill and intangible assets, Net Book Value"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsNet",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GrantProceedsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Proceeds Received",
        "label": "Grant Proceeds Received",
        "terseLabel": "Grant proceeds received"
       }
      }
     },
     "localname": "GrantProceedsReceived",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GrantRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Revenue [Policy Text Block]",
        "label": "Grant Revenue [Policy Text Block]",
        "terseLabel": "Grants"
       }
      }
     },
     "localname": "GrantRevenuePolicyTextBlock",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ino_INO4800Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I N O4800",
        "label": "I N O4800 [Member]",
        "terseLabel": "IN O4800"
       }
      }
     },
     "localname": "INO4800Member",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_IncomeTaxReconciliationFairValueWarrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Reconciliation, Fair Value Warrant",
        "label": "Income Tax Reconciliation, Fair Value Warrant",
        "terseLabel": "Change in fair value of warrants"
       }
      }
     },
     "localname": "IncomeTaxReconciliationFairValueWarrant",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncomeTaxReconciliationStatuteLimitations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Reconciliation, Statute Limitations",
        "label": "Income Tax Reconciliation, Statute Limitations",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStatuteLimitations",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInAccruedClinicalTrialExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "label": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedClinicalTrialExpense",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.",
        "label": "Increase Decrease in Deferred Revenue From Related Parties",
        "verboseLabel": "Deferred revenue from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenueFromRelatedParties",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "terseLabel": "Operating lease right-of-use assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 35.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.",
        "label": "Increase Decrease in Prepaid Expenses and Other Current Assets from Affiliated Entity",
        "negatedLabel": "Prepaid expenses and other current assets from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseinDeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Grant Funding, Current",
        "label": "Increase (Decrease) in Deferred Grant Funding, Current",
        "terseLabel": "Grant funding liability"
       }
      }
     },
     "localname": "IncreaseDecreaseinDeferredGrantFundingCurrent",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current",
        "label": "Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current",
        "terseLabel": "Grant funding liability from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_InitialConversionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Conversion Price [Member]",
        "label": "Initial Conversion Price [Member]",
        "terseLabel": "Initial Conversion Price"
       }
      }
     },
     "localname": "InitialConversionPriceMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_InvestmentOwnedAdditionalSharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Owned, Additional Shares Acquired",
        "label": "Investment Owned, Additional Shares Acquired",
        "terseLabel": "Investment owned, additional shares acquired (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedAdditionalSharesAcquired",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_LesseeNumberOfLeaseAgreementsEnteredInto": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Number Of Lease Agreements Entered Into",
        "label": "Lessee, Number Of Lease Agreements Entered Into",
        "terseLabel": "Number of lease agreements entered into"
       }
      }
     },
     "localname": "LesseeNumberOfLeaseAgreementsEnteredInto",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ino_LesseeOperatingLeaseAreaofLandUnderLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area of Land Under Lease",
        "label": "Lessee, Operating Lease, Area of Land Under Lease",
        "terseLabel": "Lessee, operating lease, area of land under lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAreaofLandUnderLease",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "ino_LicensewithAffiliatedEntitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License with Affiliated Entities [Member]",
        "label": "License with Affiliated Entities [Member]",
        "terseLabel": "Revenue under collaborative research and development arrangements from affiliated entities"
       }
      }
     },
     "localname": "LicensewithAffiliatedEntitiesMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_MCDCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MCDC [Member]",
        "label": "MCDC [Member]",
        "terseLabel": "MCDC"
       }
      }
     },
     "localname": "MCDCMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_MutualFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mutual funds.",
        "label": "Mutual Funds [Member]",
        "terseLabel": "Mutual funds",
        "verboseLabel": "Mutual funds"
       }
      }
     },
     "localname": "MutualFundsMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NewSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Sales Agreement [Member]",
        "label": "New Sales Agreement [Member]",
        "terseLabel": "New Sales Agreement"
       }
      }
     },
     "localname": "NewSalesAgreementMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NonCashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Interest Expense",
        "label": "Non-Cash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpense",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_NonEmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non employee.",
        "label": "Non Employee [Member]",
        "terseLabel": "Non Employee"
       }
      }
     },
     "localname": "NonEmployeeMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of potential shares authorized for issuance under a share-based compensation plan.",
        "label": "Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan",
        "verboseLabel": "Number of potential shares authorized for issuance under a share-based compensation plan (in shares)"
       }
      }
     },
     "localname": "NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of vested restricted stock outstanding under the plan.",
        "label": "Number of Shares of Vested Restricted Stock Outstanding Under Plan",
        "verboseLabel": "Number of shares of vested restricted stock outstanding under the plan (in shares)"
       }
      }
     },
     "localname": "NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net",
        "label": "Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net",
        "terseLabel": "Net operating loss carryforwards that will expire due to IRC Section 382 limitations"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OperatingLossCarryforwardsExpiringinFiveYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiring in Five Years",
        "label": "Operating Loss Carryforwards, Expiring in Five Years",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpiringinFiveYears",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OperatingLossCarryforwardsExpiringinFourYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiring in Four Years",
        "label": "Operating Loss Carryforwards, Expiring in Four Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpiringinFourYears",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OperatingLossCarryforwardsExpiringinThreeYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiring in Three Years",
        "label": "Operating Loss Carryforwards, Expiring in Three Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpiringinThreeYears",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OperatingLossCarryforwardsExpiringinTwoYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiring in Two Years",
        "label": "Operating Loss Carryforwards, Expiring in Two Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpiringinTwoYears",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiring in the Next Twelve Months",
        "label": "Operating Loss Carryforwards, Expiring in the Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpiringintheNextTwelveMonths",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OperatingLossCarryforwardsIndefinitelyCarryforward": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Indefinitely Carryforward",
        "label": "Operating Loss Carryforwards, Indefinitely Carryforward",
        "terseLabel": "Indefinite"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsIndefinitelyCarryforward",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OtherCounterpartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Counterparty [Member]",
        "label": "Other Counterparty [Member]",
        "terseLabel": "Other Counterparty"
       }
      }
     },
     "localname": "OtherCounterpartyMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_OtherRevenueAffiliatedEntityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Revenue Affiliated Entity [Member]",
        "label": "Other Revenue Affiliated Entity [Member]",
        "terseLabel": "Other revenue from affiliated entities",
        "verboseLabel": "Other revenue, including from affiliated entities"
       }
      }
     },
     "localname": "OtherRevenueAffiliatedEntityMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_OtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Revenue [Member]",
        "label": "Other Revenue [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "OtherRevenueMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PLSaffiliatedentityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PLS (affiliated entity) [Member]",
        "label": "PLS (affiliated entity) [Member]",
        "terseLabel": "PLS (affiliated entity)"
       }
      }
     },
     "localname": "PLSaffiliatedentityMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PennsylvaniaStateIncomeTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pennsylvania State Income Tax Authority [Member]",
        "label": "Pennsylvania State Income Tax Authority [Member]",
        "terseLabel": "Pennsylvania"
       }
      }
     },
     "localname": "PennsylvaniaStateIncomeTaxAuthorityMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlumblineLifeSciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plumbline Life Sciences, Inc. [Member]",
        "label": "Plumbline Life Sciences, Inc. [Member]",
        "terseLabel": "Plumbline Life Sciences, Inc."
       }
      }
     },
     "localname": "PlumblineLifeSciencesIncMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlumblineLifeSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plumbline Life Sciences [Member]",
        "label": "Plumbline Life Sciences [Member]",
        "terseLabel": "Plumbline Life Sciences"
       }
      }
     },
     "localname": "PlumblineLifeSciencesMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlymouthMeetingPennsylvaniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plymouth Meeting, Pennsylvania [Member]",
        "label": "Plymouth Meeting, Pennsylvania [Member]",
        "terseLabel": "Plymouth Meeting, Pennsylvania"
       }
      }
     },
     "localname": "PlymouthMeetingPennsylvaniaMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.",
        "label": "Prepaid Expenses and Other Current Assets from Affiliated Entity",
        "verboseLabel": "Prepaid expenses and other current assets from affiliated entities"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_PrepaidManufacturingExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Manufacturing Expenses, Current",
        "label": "Prepaid Manufacturing Expenses, Current",
        "terseLabel": "Prepaid manufacturing expenses"
       }
      }
     },
     "localname": "PrepaidManufacturingExpensesCurrent",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_PriorSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prior Sales Agreement [Member]",
        "label": "Prior Sales Agreement [Member]",
        "terseLabel": "Prior Sales Agreement"
       }
      }
     },
     "localname": "PriorSalesAgreementMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ProceedsFromCollaborativeAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Collaborative Agreement",
        "label": "Proceeds From Collaborative Agreement",
        "terseLabel": "Proceeds from collaborative agreement"
       }
      }
     },
     "localname": "ProceedsFromCollaborativeAgreement",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings",
        "label": "Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings",
        "terseLabel": "Taxes paid related to net share settlement of equity awards, net of proceeds from option exercises"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ProceedsFromSaleOfEquitySecuritiesFVNI": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale Of Equity Securities, FV-NI",
        "label": "Proceeds From Sale Of Equity Securities, FV-NI",
        "terseLabel": "Proceeds from sale of investment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquitySecuritiesFVNI",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ProceedsFromSubGrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sub-Grant",
        "label": "Proceeds From Sub-Grant",
        "terseLabel": "Proceeds from sub-grant"
       }
      }
     },
     "localname": "ProceedsFromSubGrant",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ProceedsfromStockOptionandWarrantExercises": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Stock Option and Warrant Exercises",
        "label": "Proceeds from Stock Option and Warrant Exercises",
        "verboseLabel": "Proceeds from stock option and warrant exercises, net of tax payments"
       }
      }
     },
     "localname": "ProceedsfromStockOptionandWarrantExercises",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_RangeOfExercisePricesFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of Exercise Prices Five [Member]",
        "label": "Range of Exercise Prices Five [Member]",
        "terseLabel": "$12.01-$15.00"
       }
      }
     },
     "localname": "RangeOfExercisePricesFiveMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_RangeOfExercisePricesFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of Exercise Prices Four [Member]",
        "label": "Range of Exercise Prices Four [Member]",
        "terseLabel": "$9.01-$12.00"
       }
      }
     },
     "localname": "RangeOfExercisePricesFourMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_RangeOfExercisePricesOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of Exercise Prices One [Member]",
        "label": "Range of Exercise Prices One [Member]",
        "terseLabel": "$1.48-$3.00"
       }
      }
     },
     "localname": "RangeOfExercisePricesOneMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_RangeOfExercisePricesSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of Exercise Prices Five [Member]",
        "label": "Range of Exercise Prices Six [Member]",
        "terseLabel": "$15.01-$25.62"
       }
      }
     },
     "localname": "RangeOfExercisePricesSixMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_RangeOfExercisePricesThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of Exercise Prices Three [Member]",
        "label": "Range of Exercise Prices Three [Member]",
        "terseLabel": "$6.01-$9.00"
       }
      }
     },
     "localname": "RangeOfExercisePricesThreeMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_RangeOfExercisePricesTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of Exercise Prices Two [Member]",
        "label": "Range of Exercise Prices Two [Member]",
        "terseLabel": "$1.48-$3.00"
       }
      }
     },
     "localname": "RangeOfExercisePricesTwoMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SARSCoV2COVID19VaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "S A R S Co V2 C O V I D19 Vaccine",
        "label": "S A R S Co V2 C O V I D19 Vaccine [Member]",
        "terseLabel": "COVID19 Vaccine"
       }
      }
     },
     "localname": "SARSCoV2COVID19VaccineMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Agreement [Member]",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SanDiegoCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "San Diego, California [Member]",
        "label": "San Diego, California [Member]",
        "terseLabel": "San Diego, California"
       }
      }
     },
     "localname": "SanDiegoCaliforniaMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Prepaid Expenses And Other Current Assets",
        "label": "Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule Of Prepaid Expenses And Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]",
        "label": "Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]",
        "terseLabel": "Schedule of operating loss and tax credit carryforward expirations"
       }
      }
     },
     "localname": "ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ino_SeriesAOnePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A One Preferred Stock [Member]",
        "label": "Series A One Preferred Stock [Member]",
        "terseLabel": "Series A-1 Preferred Stock"
       }
      }
     },
     "localname": "SeriesAOnePreferredStockMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ServiceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Based Restricted Stock Units",
        "label": "Service Based Restricted Stock Units [Member]",
        "terseLabel": "Service-based restricted stock units"
       }
      }
     },
     "localname": "ServiceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 32.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Of Receivable With Shares Of Common Stock From Equity Security",
        "label": "Settlement Of Receivable With Shares Of Common Stock From Equity Security",
        "negatedTerseLabel": "Settlement of receivable with shares of common stock from affiliated entity (PLS)"
       }
      }
     },
     "localname": "SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value",
        "terseLabel": "Grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award maximum contractual term.",
        "label": "Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term",
        "verboseLabel": "Contractual year term of incentive plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, remaining contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value",
        "terseLabel": "Aggregate intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "terseLabel": "Increase in number of shares authorized (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of options expected to vest (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number",
        "terseLabel": "RSU's expected to vest (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement, Commitment Of Additional Investment",
        "label": "Stock Purchase Agreement, Commitment Of Additional Investment",
        "terseLabel": "Stock purchase agreement, commitment of additional investment"
       }
      }
     },
     "localname": "StockPurchaseAgreementCommitmentOfAdditionalInvestment",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSaleAgreementAggregateNumberofSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "label": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "terseLabel": "Stock sale agreement, aggregate number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockSaleAgreementAggregateNumberofSharesIssued",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "label": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "terseLabel": "Stock sale agreement, aggregate proceeds from issuance of stock"
       }
      }
     },
     "localname": "StockSaleAgreementAggregateProceedsFromIssuanceOfStock",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSalesAgreementAgentFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sales Agreement, Agent Fee",
        "label": "Stock Sales Agreement, Agent Fee",
        "terseLabel": "Agent fee"
       }
      }
     },
     "localname": "StockSalesAgreementAgentFee",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ino_StockSalesAgreementMaximumAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sales Agreement, Maximum Authorized Amount",
        "label": "Stock Sales Agreement, Maximum Authorized Amount",
        "terseLabel": "Authorized amount"
       }
      }
     },
     "localname": "StockSalesAgreementMaximumAuthorizedAmount",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSalesAgreementRemainingAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sales Agreement, Remaining Authorized Amount",
        "label": "Stock Sales Agreement, Remaining Authorized Amount",
        "terseLabel": "Remaining authorized amount"
       }
      }
     },
     "localname": "StockSalesAgreementRemainingAuthorizedAmount",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxBenefitsExpired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Benefits Expired",
        "label": "Tax Benefits Expired",
        "terseLabel": "Tax benefits expired"
       }
      }
     },
     "localname": "TaxBenefitsExpired",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxCreditCarryforwardCarryforwardIndefinitely": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Carryforward Indefinitely",
        "label": "Tax Credit Carryforward, Carryforward Indefinitely",
        "terseLabel": "Indefinite"
       }
      }
     },
     "localname": "TaxCreditCarryforwardCarryforwardIndefinitely",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxCreditCarryforwardExpiringinFiveYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Expiring in Five Years",
        "label": "Tax Credit Carryforward, Expiring in Five Years",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpiringinFiveYears",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxCreditCarryforwardExpiringinFourMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Expiring in Four Months",
        "label": "Tax Credit Carryforward, Expiring in Four Months",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpiringinFourMonths",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxCreditCarryforwardExpiringinThreeMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Expiring in Three Months",
        "label": "Tax Credit Carryforward, Expiring in Three Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpiringinThreeMonths",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxCreditCarryforwardExpiringinTwoYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Expiring in Two Years",
        "label": "Tax Credit Carryforward, Expiring in Two Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpiringinTwoYears",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Expiring in the Next Twelve Months",
        "label": "Tax Credit Carryforward, Expiring in the Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpiringintheNextTwelveMonths",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TheWistarInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Wistar Institute [Member]",
        "label": "The Wistar Institute [Member]",
        "terseLabel": "The Wistar Institute"
       }
      }
     },
     "localname": "TheWistarInstituteMember",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Increase (Decrease) In Other",
        "label": "Unrecognized Tax Benefits, Increase (Decrease) In Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseInOther",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_WorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net amount of current assets and current liabilities.",
        "label": "Working Capital",
        "verboseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_WorkingCapitalExcludingCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working Capital, Excluding Cash",
        "label": "Working Capital, Excluding Cash",
        "negatedTerseLabel": "Working capital (excluding cash)"
       }
      }
     },
     "localname": "WorkingCapitalExcludingCash",
     "nsuri": "http://www.inovio.com/20201231",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r56",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r130",
      "r137",
      "r237",
      "r400",
      "r401",
      "r402",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r130",
      "r137",
      "r237",
      "r400",
      "r401",
      "r402",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r130",
      "r137",
      "r237",
      "r400",
      "r401",
      "r402",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r202",
      "r324",
      "r330",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Major Customers [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r356",
      "r357",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r582",
      "r653",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/LeasesNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r356",
      "r357",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r582",
      "r653",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r202",
      "r324",
      "r330",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Name of Major Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r200",
      "r324",
      "r328",
      "r583",
      "r652",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r200",
      "r324",
      "r328",
      "r583",
      "r652",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r336",
      "r356",
      "r357",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r582",
      "r653",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/LeasesNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r336",
      "r356",
      "r357",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r582",
      "r653",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/LeasesNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r203",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "verboseLabel": "Title of Individual with Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r558",
      "r560",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r134",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r439",
      "r440",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible List]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Accounts payable and accrued liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/AccountsPayableandAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableTradeCurrentAndNoncurrent": {
     "auth_ref": [
      "r610",
      "r639"
     ],
     "calculation": {
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable, Trade",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r21",
      "r628"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r21",
      "r204",
      "r205"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedParties": {
     "auth_ref": [
      "r20",
      "r117",
      "r543",
      "r546",
      "r636"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.",
        "label": "Accounts Receivable, Related Parties",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r51",
      "r123",
      "r543",
      "r546"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Accounts receivable from affiliated entities"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes": {
     "auth_ref": [
      "r640"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount for commissions, taxes and other expenses that were incurred but unpaid as of the balance sheet date.",
        "label": "Accrued Liabilities for Commissions, Expense and Taxes",
        "terseLabel": "Commissions and other estimated offering expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesForCommissionsExpenseAndTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r41"
     ],
     "calculation": {
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r35",
      "r272"
     ],
     "calculation": {
      "http://www.inovio.com/role/FixedAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated Depreciation and Amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in accumulated depreciation, depletion and amortization as a result of sale or disposal of property, plant and equipment.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Sale or Disposal of Property, Plant and Equipment",
        "terseLabel": "Accumulated depreciation written off due to disposal of property plant and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r61",
      "r63",
      "r64",
      "r632",
      "r664",
      "r668"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r60",
      "r64",
      "r65",
      "r127",
      "r128",
      "r129",
      "r473",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r22",
      "r403"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Equity component of issuance of convertible notes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r359",
      "r361",
      "r406",
      "r407"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r361",
      "r392",
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Allocated share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r28",
      "r210",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure alternative investment.",
        "label": "Alternative Investment, Measurement Input",
        "terseLabel": "Equity method investment, measurement input"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r101",
      "r257",
      "r264"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Total antidilutive securities (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r115",
      "r182",
      "r192",
      "r198",
      "r231",
      "r466",
      "r477",
      "r510",
      "r601",
      "r630"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r53",
      "r115",
      "r231",
      "r466",
      "r477",
      "r510"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets held-in-trust",
        "totalLabel": "Assets, fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "verboseLabel": "Gross\u00a0Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r219"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross\u00a0Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r216",
      "r246"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r214",
      "r217",
      "r246",
      "r608"
     ],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair\u00a0Market\u00a0Value",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Securities [Member]",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r363",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Liquidity"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r106",
      "r107",
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Amounts accrued for purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r31",
      "r103"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r104",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r97",
      "r103",
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r97",
      "r515"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashDivestedFromDeconsolidation": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.",
        "label": "Cash Divested from Deconsolidation",
        "negatedTerseLabel": "Decrease of cash resulting from the deconsolidation of Geneos",
        "terseLabel": "Decrease in cash resulting from the deconsolidation of Geneos"
       }
      }
     },
     "localname": "CashDivestedFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r113",
      "r115",
      "r144",
      "r145",
      "r146",
      "r148",
      "r150",
      "r158",
      "r159",
      "r160",
      "r231",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r454",
      "r455",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r47",
      "r277",
      "r611",
      "r638"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock",
        "verboseLabel": "Common"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "verboseLabel": "Summary of common and preferred stock authorized, issued and outstanding"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.",
        "label": "Common Stock, Other Shares, Outstanding",
        "verboseLabel": "Number of common stock shares outstanding under the Incentive Plan (in shares)"
       }
      }
     },
     "localname": "CommonStockOtherSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock\u2014par value $0.001; Authorized shares: 600,000,000 at December 31, 2020 and December 31, 2019, issued and outstanding: 186,851,493 at December\u00a031, 2020 and 101,361,034 at December\u00a031, 2019"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r110",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r67",
      "r69",
      "r70",
      "r78",
      "r617",
      "r646"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Inovio Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r69",
      "r77",
      "r462",
      "r463",
      "r481",
      "r616",
      "r645"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Comprehensive loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r69",
      "r76",
      "r461",
      "r481",
      "r615",
      "r644"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r169",
      "r170",
      "r202",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r202",
      "r507",
      "r508",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r202",
      "r507",
      "r508",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r164",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "Major Customers and Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRisk"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r169",
      "r170",
      "r202",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r167",
      "r169",
      "r170",
      "r171",
      "r507",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r169",
      "r170",
      "r202",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r305",
      "r306",
      "r325"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r305",
      "r306",
      "r325"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "verboseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized from deferred revenue beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r106",
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of stock, shares converted (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r106",
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Conversion of stock, shares issued (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r16",
      "r603",
      "r631"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "verboseLabel": "Convertible Debt Securities"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "verboseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r17",
      "r18",
      "r295",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Convertible preferred stock, shares issued upon conversion (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r435",
      "r443"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r122",
      "r435"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r435",
      "r443",
      "r445"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current income tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r435",
      "r443"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r168",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionByUniqueDescriptionAxis": {
     "auth_ref": [
      "r106",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.",
        "label": "Debt Conversion Description [Axis]",
        "terseLabel": "Debt Conversion Description [Axis]"
       }
      }
     },
     "localname": "DebtConversionByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r106",
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt conversion, converted instrument principal amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r106",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Debt conversion, converted instrument, shares issued (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionNameDomain": {
     "auth_ref": [
      "r106",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Name [Domain]",
        "terseLabel": "Debt Conversion, Name [Domain]"
       }
      }
     },
     "localname": "DebtConversionNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r15",
      "r16",
      "r602",
      "r603",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Debt instrument, convertible, carrying amount of equity component"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt instrument, convertible, conversion price (in USD per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r44",
      "r295",
      "r298",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt instrument, convertible, conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Debt instrument, convertible, threshold percentage of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r526",
      "r528"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "netLabel": "Principal amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of date conversion"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r43",
      "r285",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument, interest rate, effective percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt instrument, redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r45",
      "r120",
      "r295",
      "r299",
      "r300",
      "r301",
      "r525",
      "r526",
      "r528",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r525",
      "r528"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Unamortized debt discount on the liability component",
        "terseLabel": "Debt instrument, unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Number of securities in a gross unrealized loss position for more than twelve months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r225"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Debt securities, available-for-sale, realized gain"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r225"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "terseLabel": "Debt securities, available-for-sale, realized gain"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleSaleAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Sale [Abstract]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleSaleAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r222",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of securities in a gross unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r475"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "negatedLabel": "Gain on deconsolidation of Geneos",
        "negatedTerseLabel": "Gain on deconsolidation of Geneos",
        "terseLabel": "Gain on deconsolidation of Geneos"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount": {
     "auth_ref": [
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.",
        "label": "Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount",
        "terseLabel": "Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value"
       }
      }
     },
     "localname": "DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r436",
      "r443"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r36",
      "r527"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized debt issuance cost",
        "terseLabel": "Debt issuance costs, net"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r436",
      "r443"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r101",
      "r116",
      "r436",
      "r443",
      "r444",
      "r445"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r413",
      "r414"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r436",
      "r443"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDerivativeInstruments": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.",
        "label": "Deferred Tax Assets, Derivative Instruments",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsDerivativeInstruments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets, gross"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).",
        "label": "Deferred Tax Assets, Investments",
        "terseLabel": "Investment in affiliated entity"
       }
      }
     },
     "localname": "DeferredTaxAssetsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r428"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "NOL carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]",
        "terseLabel": "Expirations of Operating Loss Carryforwards, Components [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOtherTaxCarryforwards": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other.",
        "label": "Deferred Tax Assets, Other Tax Carryforwards",
        "terseLabel": "Research and development and other tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsOtherTaxCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards [Abstract]",
        "terseLabel": "Expirations of Tax Credit Carryforwards [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance",
        "terseLabel": "Deferred tax assets, valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r414",
      "r428"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesFinancingArrangements": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.",
        "label": "Deferred Tax Liabilities, Financing Arrangements",
        "negatedTerseLabel": "Convertible note"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFinancingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Acquired intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Company's contribution to 401(k) plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/A401kPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Maximum annual contribution per employee, percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/A401kPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contribution, percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/A401kPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r101",
      "r270"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r54",
      "r55",
      "r504"
     ],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative liability",
        "verboseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r124",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Liabilities"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r324",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r37",
      "r123",
      "r543"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "verboseLabel": "Accounts payable and accrued expenses due to affiliated entities"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r123",
      "r543",
      "r609",
      "r641"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r79",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r143",
      "r144",
      "r148",
      "r149",
      "r150",
      "r153",
      "r154",
      "r618",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net income (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted average number of common shares outstanding"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r79",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r144",
      "r148",
      "r149",
      "r150",
      "r153",
      "r154",
      "r618",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r151",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r515"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "auth_ref": [
      "r487"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.",
        "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability",
        "terseLabel": "Fair value of derivative liability"
       }
      }
     },
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "auth_ref": [
      "r489"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "terseLabel": "Change in fair value of derivative liability",
        "verboseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r132",
      "r140",
      "r142",
      "r157",
      "r237",
      "r294",
      "r302",
      "r400",
      "r401",
      "r402",
      "r439",
      "r440",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r659",
      "r660",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Percentage of ownership"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r32",
      "r183",
      "r228"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "periodEndLabel": "Investment in Geneos as of December 31, 2020",
        "periodStartLabel": "Investment in Geneos upon deconsolidation",
        "terseLabel": "Investment in Geneos",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Investment in Affiliated Entity"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/InvestmentinAffiliatedEntity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Schedule of equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r502"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Investments in affiliated entities",
        "verboseLabel": "Investments in affiliated entities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGain": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain",
        "terseLabel": "Realized gain on sale of investment"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGain": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain",
        "negatedTerseLabel": "Net unrealized gain on available-for-sale equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r227",
      "r649"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Net unrealized gain on available-for-sale equity securities",
        "verboseLabel": "Net unrealized gain on available-for-sale equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of fair value measurement inputs and valuation techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r490",
      "r505",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r352",
      "r491",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r490",
      "r491",
      "r493",
      "r494",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r337",
      "r339",
      "r344",
      "r352",
      "r491",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1",
        "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r337",
      "r339",
      "r344",
      "r352",
      "r491",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Unobservable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r352",
      "r491",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "verboseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r495",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Changes in fair value of the financial liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedTerseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedNetLabel": "Derecognition of the derivative liability upon conversion"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r495"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r352",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r498",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]",
        "verboseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsFairValueoftheCompanysDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r111",
      "r501",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r220",
      "r221",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r251",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]",
        "verboseLabel": "Eligible Item or Group for Fair Value Option [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "verboseLabel": "Financial assets and liabilities that are measured at fair value on recurring basis"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      },
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Intangible assets, Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r258",
      "r259",
      "r263",
      "r266",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r263",
      "r585"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Intangible assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r258",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r263",
      "r584"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite lived intangible assets, net",
        "totalLabel": "Intangible assets, Net Book Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Indefinite lived:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r511",
      "r512",
      "r513",
      "r514"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Unrealized transaction loss on foreign-currency denominated debt"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Office furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "negatedLabel": "Share of net loss in Geneos"
       }
      }
     },
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r84",
      "r101",
      "r215"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedTerseLabel": "Loss (gain) on short-term investments",
        "terseLabel": "Gain on investments"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r101",
      "r287",
      "r288"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Gain (loss) on extinguishment of debt",
        "terseLabel": "Gain (loss) on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r253",
      "r254",
      "r600"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r255",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Valuation of Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r101",
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r269",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r121",
      "r446"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "U.S. Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r73",
      "r182",
      "r191",
      "r194",
      "r197",
      "r199",
      "r598",
      "r613",
      "r620",
      "r650"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income tax benefit/(provision for income tax)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r121",
      "r446"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r74",
      "r101",
      "r180",
      "r228",
      "r612",
      "r642"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Share in net loss of Geneos",
        "terseLabel": "Share in net loss of Geneos"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r417",
      "r424",
      "r430",
      "r441",
      "r447",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r141",
      "r142",
      "r181",
      "r415",
      "r442",
      "r448",
      "r651"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit",
        "negatedTerseLabel": "Income tax benefit (provision for income taxes)",
        "terseLabel": "Income tax benefit",
        "totalLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails",
      "http://www.inovio.com/role/IncomeTaxesSummaryoftheProvisionforIncomeTaxesDetails",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r71",
      "r111",
      "r411",
      "r412",
      "r424",
      "r425",
      "r429",
      "r437",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r410",
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Change in tax rates"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign tax rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income (benefit) taxes at statutory rates"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income tax, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 31.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "verboseLabel": "Accounts payable and accrued expenses due to affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 34.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Receivable, Related Parties",
        "negatedTerseLabel": "Accounts receivable from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Definite lived:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.",
        "label": "Debt Security Category [Axis]",
        "terseLabel": "Debt Security Category [Axis]"
       }
      }
     },
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r256",
      "r261"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Schedule of intangible assets by major asset class"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r72",
      "r179",
      "r524",
      "r527",
      "r619"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r85",
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense, debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r95",
      "r98",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeAmortizationOfPremium": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization of purchase premium on nonoperating securities.",
        "label": "Investment Income, Amortization of Premium",
        "terseLabel": "Amortization of premiums on investments"
       }
      }
     },
     "localname": "InvestmentIncomeAmortizationOfPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r670",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Number of shares owned (shares)",
        "verboseLabel": "Shares (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r230",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r672",
      "r673",
      "r674",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r685",
      "r686",
      "r687",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r672",
      "r673",
      "r674",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r685",
      "r686",
      "r687",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares": {
     "auth_ref": [
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of affiliates held for management investment companies.",
        "label": "Investments in and Advances to Affiliates, Balance, Shares",
        "terseLabel": "Number of shares held in an affiliated entity (in shares)"
       }
      }
     },
     "localname": "InvestmentsInAndAdvancesToAffiliatesBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r226",
      "r599",
      "r622",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r536",
      "r538"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Lease, cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total remaining lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r40",
      "r115",
      "r193",
      "r231",
      "r467",
      "r477",
      "r478",
      "r510"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r115",
      "r231",
      "r510",
      "r605",
      "r635"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r42",
      "r115",
      "r231",
      "r467",
      "r477",
      "r478",
      "r510"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities held",
        "totalLabel": "Liabilities, fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Revenue under collaborative research and development arrangements"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "verboseLabel": "Licenses"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r283",
      "r603",
      "r631"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Long-term debt, fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r125",
      "r278"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r125",
      "r278"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r125",
      "r278"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r125",
      "r278"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r45",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "verboseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r52",
      "r115",
      "r231",
      "r510",
      "r604",
      "r634"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Carrying value of noncontrolling interest",
        "verboseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r302",
      "r464",
      "r465"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedLabel": "Dissolution of majority-owned subsidiary VGX Animal Health, Inc."
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Noncontrolling interest, ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r52",
      "r82",
      "r460",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities collateralized by real estate mortgage loans (mortgages), issued by US Government Sponsored Enterprises, such as Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac).",
        "label": "Mortgage-backed Securities, Issued by US Government Sponsored Enterprises [Member]",
        "terseLabel": "U.S. agency mortgage-backed securities"
       }
      }
     },
     "localname": "MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r161",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "The Company"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/TheCompany"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r97",
      "r99",
      "r102"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r66",
      "r68",
      "r75",
      "r102",
      "r115",
      "r131",
      "r135",
      "r136",
      "r137",
      "r138",
      "r141",
      "r142",
      "r147",
      "r182",
      "r191",
      "r194",
      "r197",
      "r199",
      "r231",
      "r510",
      "r614",
      "r643"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss from operations",
        "totalLabel": "Net loss attributable to Inovio Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r66",
      "r68",
      "r141",
      "r142",
      "r470",
      "r480"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements - Recently Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": {
     "auth_ref": [
      "r303",
      "r472"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.",
        "label": "Noncontrolling Interest, Decrease from Deconsolidation",
        "negatedTerseLabel": "Deconsolidation of Geneos"
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r303",
      "r464",
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Acquisition of non-controlling interest in Geneos, net"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r302",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r16",
      "r603",
      "r631"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Note payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r182",
      "r191",
      "r194",
      "r197",
      "r199"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Less: current portion",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "netLabel": "Long-term operating lease liabilities",
        "verboseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r529"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r535",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r534",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Geneos Therapeutics, Inc."
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r610",
      "r639"
     ],
     "calculation": {
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other.",
        "label": "Other Accrued Liabilities",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": {
     "auth_ref": [
      "r58",
      "r59",
      "r62"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax",
        "terseLabel": "Tax benefit from other unrealized gains on short-term investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation",
        "verboseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r58",
      "r61"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on short-term investments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r252"
     ],
     "calculation": {
      "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.",
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Costs related to issuances of convertible senior notes and convertible bonds"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "negatedTerseLabel": "Investment in Geneos",
        "terseLabel": "Payments to acquire additional interest in subsidiaries"
       }
      }
     },
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of capital assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r336",
      "r338",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/A401kPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r363",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Preferred Class A [Member]",
        "terseLabel": "Preferred"
       }
      }
     },
     "localname": "PreferredClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)",
        "verboseLabel": "Preferred Stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock\u2014par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December\u00a031, 2020 and 23 at December\u00a031, 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r29",
      "r30"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Prepaid expenses and other current assets",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuances of convertible senior notes and convertible bonds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Acquisition of non-controlling interest"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from Geneos issuance of note payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "verboseLabel": "Proceeds from sale of or maturity of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r91",
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r66",
      "r68",
      "r96",
      "r115",
      "r131",
      "r141",
      "r142",
      "r182",
      "r191",
      "r194",
      "r197",
      "r199",
      "r231",
      "r461",
      "r469",
      "r471",
      "r480",
      "r481",
      "r510",
      "r620"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r35",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r276",
      "r691",
      "r692",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Disposals",
        "terseLabel": "Property, plant and equipment disposed of"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisposals",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r34",
      "r271"
     ],
     "calculation": {
      "http://www.inovio.com/role/FixedAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r273",
      "r637"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.inovio.com/role/FixedAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "negatedTerseLabel": "Fixed assets, net of accumulated depreciation",
        "totalLabel": "Net Book Value",
        "verboseLabel": "Fixed assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/FixedAssetsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "terseLabel": "Computer equipment and other"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r33",
      "r111",
      "r273",
      "r691",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of fixed assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant, and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]",
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Quarterly Financial Information (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r346",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Due from (to) Related Party [Abstract]",
        "terseLabel": "Related Party Transaction, Due from (to) Related Party [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedPartyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "verboseLabel": "Operating expenses related to affiliated entity"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r346",
      "r542",
      "r546",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r540",
      "r541",
      "r543",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r408",
      "r702"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r111",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Performance-based restricted stock units",
        "verboseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r302",
      "r403",
      "r633",
      "r663",
      "r668"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r132",
      "r140",
      "r142",
      "r237",
      "r400",
      "r401",
      "r402",
      "r439",
      "r440",
      "r659",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedInterestFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of interest continued to be held by a transferor after transferring financial assets to a third party.",
        "label": "Retained Interest, Fair Value Disclosure",
        "terseLabel": "Fair value of investment in Geneos retained"
       }
      }
     },
     "localname": "RetainedInterestFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r177",
      "r178",
      "r190",
      "r195",
      "r196",
      "r200",
      "r201",
      "r202",
      "r323",
      "r324",
      "r583"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Revenues",
        "terseLabel": "Total revenues",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails",
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r169",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r112",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r327",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r81",
      "r671"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "verboseLabel": "Revenue from related parties"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r533",
      "r538"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]",
        "terseLabel": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accounts payable and accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/AccountsPayableandAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "verboseLabel": "Summary of investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of income tax expense (benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective income tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Financial assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of components of pretax loss from operations"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "verboseLabel": "Summary of intangible assets by major asset class"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of maturities of long-term debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r35",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Schedule of quarterly financial information (unaudited)"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r118",
      "r544",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/InvestmentinAffiliatedEntityDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r363",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock unit activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Schedule of shares authorized under stock option plans, by exercise price range"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r368",
      "r380",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock options, activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Summary of assumptions used to estimate the fair value of stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r48",
      "r113",
      "r158",
      "r159",
      "r290",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "verboseLabel": "Summary of preferred stock authorized, issued and outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r423",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of unrecognized tax benefits rollforward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of finite-lived intangible assets, future amortization expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r167",
      "r169",
      "r170",
      "r171",
      "r507",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of major customers and concentration risks"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/MajorCustomersandConcentrationofCreditRiskTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Preferred Stock",
        "verboseLabel": "Series\u00a0C Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)",
        "verboseLabel": "Vesting period of incentive plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Reserved number of shares under the Incentive Plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Number of shares available for grants under the Incentive Plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Options, exercises in period, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "terseLabel": "Options, expirations in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options, grants in period, weighted average grant date fair value (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r370",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "verboseLabel": "Number of options outstanding to purchase common stock (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r360",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]",
        "verboseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, expirations in period, weighted average exercise price (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Exercise price, lower range limit (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Exercise price, upper range limit (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Price per Share (in USD per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Aggregate intrinsic value of unvested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Aggregate intrinsic value of vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r387",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value for options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (in USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise\u00a0price (in USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (in Years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r14",
      "r606",
      "r607",
      "r629"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r113",
      "r115",
      "r144",
      "r145",
      "r146",
      "r148",
      "r150",
      "r158",
      "r159",
      "r160",
      "r231",
      "r294",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentinGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r50",
      "r127",
      "r128",
      "r129",
      "r132",
      "r140",
      "r142",
      "r157",
      "r237",
      "r294",
      "r302",
      "r400",
      "r401",
      "r402",
      "r439",
      "r440",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r659",
      "r660",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r157",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r49",
      "r294",
      "r295",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock/senior notes to common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r294",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock for cash (in shares)",
        "verboseLabel": "Underwritten public offering, common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r294",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r294",
      "r302",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r50",
      "r294",
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock/senior notes to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r294",
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r302",
      "r362",
      "r381"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r25",
      "r26",
      "r115",
      "r212",
      "r231",
      "r510"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Inovio Pharmaceuticals, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Inovio Pharmaceuticals, Inc. stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r115",
      "r127",
      "r128",
      "r129",
      "r132",
      "r140",
      "r231",
      "r237",
      "r302",
      "r400",
      "r401",
      "r402",
      "r439",
      "r440",
      "r459",
      "r460",
      "r479",
      "r510",
      "r516",
      "r517",
      "r521",
      "r660",
      "r661"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r114",
      "r302",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StraightLineRent": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 33.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between actual rental income due and rental income recognized on a straight-line basis.",
        "label": "Straight Line Rent",
        "negatedTerseLabel": "Deferred rent"
       }
      }
     },
     "localname": "StraightLineRent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r522",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r522",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r522",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r522",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r549",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward amount",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r220",
      "r221",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]",
        "verboseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r409",
      "r419"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of the year",
        "periodStartLabel": "Balance at beginning of the year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Increases (decreases) related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases related to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases (decreases) related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r162",
      "r163",
      "r165",
      "r166",
      "r172",
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "Basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27405-111563"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6284393-111563"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32059-109318"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "http://asc.fasb.org/subtopic&trid=2229187"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14.Column B)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611322-123010"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r703": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r704": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r705": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r706": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r707": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r708": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r709": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r710": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r711": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>116
<FILENAME>0001055726-21-000018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001055726-21-000018-xbrl.zip
M4$L#!!0    ( +1^85)XK0/$B_8  )E-!P :    :6YO+3$R,S$R,#(P>#$P
M:V5X,3 Q-"YH=&WLO5MWV\BU+OI^?@5V<G:VN :DMN1[.SMCJ"6YVXEORU*G
M5Y[. (&BB#8(,+A(9G[]F;>Z@0!%V>XFS$8>TA8) H6J6;/FY9O?_.O_.G]W
M=O6O]Q?!O%YDP?N??WC]ZBSXT^%WW_WR\.R[[\ZOSH.?KMZ\#AX=/3@.KLHH
MK](Z+?(H^^Z[B[=_"OXTK^OE]]]]=WM[>W3[\*@HK[^[^O =WNK1=UE15.HH
MJ9,__>VO^ G\OXJ2O_T_?_U?AX?!>1$W"Y7705RJJ%9)T%1I?AW\DJCJ8W!X
M*%>=%<M5F5[/Z^#DP<EQ\$M1?DQO(OZ^3NM,_4W?YZ_?\=]__8X>\M=ID:S^
M]M<DO0G2Y/_^*7UT?!*KV<FSY\^G\:,X>?CLR2PZ?C2='4?/'CQZ&,W^OV,8
MY'=P.?^FJE>9^K]_6J3YX5SA\[]_>K*L7]RF23W__OC!@__])^^Z6GVJ#Z,L
MO<Z_I]'"M[,"WDV^CHNL*+__\P/ZWPO\YG 6+=)L]?W_N4H7J@K>JMO@0[&(
M\O\35C##AY4JTQE?6*7_4=\?X\/ISUL>S2.X3Y;F2H_N^ 2'=/%IGD[3.CA^
M<'3\Z*_?X0\Z7JIGL#!EY=_N^Z.O]X8/6F_XM/L-_^?B[.>K5^_>!F?OWO_+
M'^WZZD7E-2S@M*CK8L%SZ+Q&#$*C2OXDS1/XZ_L'1P^?+'_[Q>M^M;-WKU^?
M_O#NPRF]WNG;\P VXL7;RXO@],</%Q=O+MY>]:[.YC?]M:GJ=+;R7O5W>=%N
M*;V:IU6@7V4G,UUD630MR@@561#E2? Z!6FH5'!Z72I%6NGW&5_W!!W4<Q7\
MY<_/3DX>O-CE/)G9V.5DT#P<OY@$(#2T8^&H2/.Z"*(J*&;!N8K58JK*X.%Q
MB&?$@V HLW<QFZFX3F]4< [GVR"F<+HB:9^J^E:I?*=[\%5>W*1%\'X>E8LH
M5DV=QE%6A<&K/#[:Y5R%NYR4G6J=*(B+<JFU(AAR40Z_3DABU*<4CA PSQHX
M/<H =U@6W<H&A']%I:+KYM$-7A4%RPP6%;^>HEFGJBJ(ZN#)@^"7H^!'!2L.
M&_@V#]ZG'U487#9IK8+CXP=A\#Y;+8JFG@=OE,+GP2>GP?'S1T].@I\O3X.#
M 6QK%MPA;.>0IGRG!T1R$\4Q?!S\D!9+?RO#LOYG7C1@P1^%P>LZV>VN#GSI
MWBRG/QP?/GSP+ S>%D?!R?&SX'_@VGD37-9P'-:A?K&38WC621C\/8WRZZH)
MWI<@&'D, GTV3_-H$,)J%F@(\GH4!*+U46ZM[*#RJ(H%;'A\:*EFJL1#'H[X
M.9SV:0['/9BZ:=)$6;;"8S\:PO'^/BKKU0"FE283GIFQL<$S-! 3".<H5=4N
M9^E(INDS72=V$G?D$7ZX.'MU=?KZ\EMS^[K?YA?<S=%.A2'4"@A\B;@!+9/7
ML%_B(D^:F,R;4E4J*N,Y;:I$P78JEN0.P@F!>^J?HK(.8(\E:@;_1&LZ*VXG
M] N\!(X!O%O')7_Y\^/G+X)Q,;_:8MHC),5#P3= 8%D7RRA?!;<IV)/JTQ*>
MHN!XAM-$KRRN>.M'2UZ]"JX"FV%1P!4%K&H)DG$-A@,X*+C&]L%7<%:E=5&N
M^M9[7.ZOMMRTN_A$00-.P32#$QO;8 XL5HH?'+9VKMZU%9IGP=^CO(E@P3!8
M$,(/XJQ)\*>.&EB6*H81D$14-7RM8.%!,8"RJ.KH6@7FV[I,T=;%S<]RXCXZ
MPA,YI?'2N/(<SV@P/TDD'641BKZI4C"%P.Z!2V$<C:)K8B]:-2O8_3JWSPF#
M-_!*,WA:4Y)5"_<Z*Q8+5<8PN/0_XM#-?/7$VR("71='R[3&"]'H N<,#0A0
MA$MC4/AB?32JL*\GTR 7LZ9$R8ER=D2J!I?$77-7T;&,5"@DQ;2.\.=EL;!V
M-2@ZD.<*HTZ9Q#2K9OHK+"7^A/SV= &KC?>M@DK5*% @"+2T>(D6+%>HU)I(
M*4^68!2]6O&SQ8SWA#VO;],L0^F&,5[#9-4\4?HEX5/S>/AEECF1"GQ8)68R
M>!+\ZKCXQ8R/9->-'F7Z*Q[+S@JBDP?3;ZTN,JQ999-D@M\=JY)$^FV1'UHY
M7HO-AT%""4,. .,*X]^RHH,)_^)+7/2_Q  \1]ABRZ:L&MQ,L 2W\Q0VE%T\
MVF656;\@]U;%V7AZV<[?G@;ZQPOO1 *K*E95!6^ QU=3J4TJPQ$:1X^0"EDS
ML8[V8]N^+6[#X H%&.9GI[&:4"R5*@7MZ1D..++K0JRC18J+J5V>15,W;#O3
MYR'<X$;E)#TMK8N&343K1P( :MW9U:Y]%^''N-XS. F+VPH4];-OTH<_A?>)
M,Q4<;RNJ#XX&-?YSW&^\>E]QKSU^M+/L\TX#YL='QW_Y\_&3!R_6_W^7NWX(
MY^5I'!=-3N[790UJ(RJ3G=HQ.KRZ4'"3X""=T-G%!Q/KJI^/+H^":Y6#HJ3
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M_;M));T:)<6R=@(ET7();ETT!7/U=71;D2^@4KIC'%6*_8*J9O^=+E;)U_3
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M\ QT3;.D38F!R\$H=2J2"Q$[C#8)XX=Q;Y8@UQ4:,E2N3Z@V5+]80%2)9HE
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MVJL]%5-ON0I.=6A$-H-F2>F/RX:!_E(1P2'\\""=Z,1I=-_7@JMA,X)1EZS
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M2_]\*=BDE)OPL:;!N8>QRC6<_=)-^FP#E5+_R 2NG&\[GA'Z*6F.I[OMOO#
MID"[872AF :7^N7\UJZZIS!IIBFSY,%1\'Z.0;:';?153ZYZHZW1P6EK!:X'
MP-61'^^T<9SPC]M=-IFT,2>F\?PZ^*2%O_-YLES>,_A778"*U)!^S'Q8SI3.
M"8/)WYOCI3>/W]9&N[7KM[1].!SI5)2V\_:/K%K8GK74"ND!:[M?A>9)H$7V
M#"'%PG(X8:@;EVTI.4.FV+;9\=^I%(XL&)3Z!1%*+S4IV[1)KMG>\?MC=O@1
MTN;#J.C[,P#@%P-(@?39<T/(AH32^JR7*=&6]GC)8^F)XK-S6?I<T)@(R3UX
MOE-!M*6$)'^4];76@V;U"!UC/22';R4J$]GHI3V1_L)4$F+6J')];,^NL+P
M(L63/ZSTKU-C[A3OOM/6C@-2 *%.>#)9!HCE7 HJ-OJ@ALC"-J "39!0^R@W
M?4@'E(VS/&0S= #B.*0U:+5HV(9$5AO3PNT$MO^U1GW,L8*Y5>]\9V K;,>Q
MW"B7$\3@DO$.8N%.LIY>Y<7PIS%]^&5R<_)@3!^.Z<-O-GTHC!73E8 NI@J4
MVLPOC%AO3F@X&!P8RJ5E1MO$ -P%OVI3NS#)\SHES,NT0G7Y+S#6.I(CQ@"U
M]-(4<><3,6PQYH8F@S-7H)>;DFAA.J+*)L(G1BW'1#J?X1J\&YBD'AT].@JP
MQ$&#*$VI0SKC4(Q@55M,V:VG;!QX8*B@G%(3PDX[D]A5'T[QQ18]B(,J<LP(
MK_&P<U>/)DQ"3;H*9BX489O'CGV#"7:%[]N18NE/@_FL"'!(1J5-ND4K)M-;
MN9V(W8<[):R=DKLO,9E>A/@[$D=W2DZ-<3%VX/EM._"\+]6A"0,Z2[#C>?\9
M0PL^*94F0W1B .W8L-Y@2+&WEK]%P#Y%UJ2)M.1ESJ,Z$L2FEY1H*C5KLKXL
M=T?1[MU);A\@NGZ0%(LEM;LUM3+KZK4PAC_W+.AZ42<4XI\:ZQ ;#!U_504S
M3!KU 0KX*Z\&%&&K7HX:Y<N/SE?W%D7M%$9Y9XYY&U]SDS3[6T_:;!#NMBUO
M=XIQ^TWO*<$>;E:X@G()3PK[E$E]\#@Q,.W76IC=1T:@ #$X[=8369]X?4*X
M8 Q#EG..HV">5?(QWH.U<C/U-IJQPLDH^2\==D^20\-&4VET#_VPQ<-K C?=
M"K-[%?P\68=%9.A5HVZ)];CI>@5)SQAX _ \A7X BBVWVHY0$*B$-8KKP@>H
M>U2:CXZ>AV1YVH=2+62$M&P)C4J:.)K"';Q:.IT* !U,-^P#@JE-$P=["UXA
MY:Q-AW;'MG53@AIVS5:VL:Z[ZOLW;?/6EBZ:FEAN)2A,6WM?N-3Z*4//+&)A
MQXKZM'+**#HKL,3+$"U(< S:3S7RE'#8;2,<PPH(J&E_?ZZ#).Z-S[" M*+L
ML6^<C+R%KFRBR-@Z!;$W]:V/^FO,7#7[@2DU=RVR?=A JI%6&(703C"=G$3M
M2/2<3 B*&@C1,C;">Z"Y_\A:-GUNO:@Q<_>@VTL6>IM1W='+[7BQD2H7_A.V
MHS\22?[<\ ]Q8^HWY'E!>H254(GCCJ1=1CRB]*ZW1?DQ2 H)8NL&Q5$\1WI;
M(_52[:F9P=OVCC.)\ .B**RH'PV5'DE%N=M2B<T:&V;'T45$$ZC+ESI6."GB
MAA_7AK*Z3D&?0>GN:GJ7S#A=G/+4T\:A)<UKW"83<1B1[%=,AR*I!RP.+LTG
MUTV:4&:U$F&I@E=G/X7!CV?OZ>H?7[]W F&D^%I,&0[BS:A'K8)%*PM!;0#V
M0UYE GG6P*,6#Z.$\M@4@*/\FKJ/,18T  /JNHFNE6M6R\TG'4/K5,@^D-O'
M<]@0U[/P'IB?N%A*/9]9I-J=%^Y]('3XXO+",A)%@92A\8MF^N\Q-?.%J9GC
M,34SIF:^S=2,*$+/9G0,1>=<0E?,/Y9(R>!56+B>,6NP2HBBNQ-,WRH6WAM#
M\<EVAB+QL _,4/RHU%*?/8ZK8&CM(W-HP.I>EYH46IM&71V"VF:<:41]ES6G
M+^PQIAS8%8=NI$):6G9&-U&:T0%H.^N"Z3KIJS=QJDO@_!32]O4&! [=>E<F
MT+,\A)]M$ZV]%'4S1#+]#PYF0W&*Y16I4MQ'..X,,Y5N2PB-M]!K(J9.V(+<
M.WT1;0<#2QIGN9;67<TVT1)Q\756EG$"SQHVQQT\"2$%V20%R;7^A4#/YP7X
MEI%Y,\3^.Y3U[48=5?^"D'G4FG-X27E=/^&KB(6G?7/<*Q(E\T3 B0-H2UP:
M!C.\,*J1_WS7FZ5CIYMP)Z<R$SL?7<8UF=9<8UAJ2YO=!Z?A4(LN)]+]3]H5
M3_[ O!9Y=V.8,3.BZ=R[4\H;-^/:#@3_JXD,NX*?N37+)M1&/=M2P^&\'8<N
M\)[0ZSPZ>MI[HF$TX$(HDW:=4+&"U"',5BUUHM7(.YQQ]UJ1F->\MY+@'WEQ
M>_A3<>MD4'S%=G+TI,4W98/ZPF+,B03R99FIF&;..;$<K=D1X0X>HU-(1)-^
M'7"I,+:3\,!;2(FG]#S/K6PS8IFZVY[PH=$2;FL=MQW0+3=;6 I#$6X#$R%R
M0N-OG!8ZIA+210FV Q$Z4=L)$=K0]I<45%=,J!6EZ=G*IJ-"X!![33VN:FL:
M=Z3C?)+A[B:'+7#W-M5_SHQW,?'4@P-\Z]R%6?<!06S7Z;:<@VY99&@5<><>
MJE)H- NORPSGG'IKK]J5(^@X@->#.EAUR( AV$#&1@+Y%X5DA7-CD1I*G0[X
M]A6MT<G=DDY]ZMT3U4":=V.PJO>][-UV\VIK)+;[XX,^NQ,)P262J*P'P,*I
M3>@HMNUFR:QBDDK4Q;$J*7;)G)NLN$W&'.0&]#\VWF(N,%.?NJ$X1EK\Z/O2
ML66/'5-*VXZ9;[BC/-RZ-X7?EI+[C1G'U'H@<HKISF+M2=%,G;*1TG([LH,,
M'E-07L?V7Y+\=2XY&,OA+?D)N]<X(K\^P_+^"[05E/$A=1Z#G%1B)32D=JTT
MP1YMLN=]F^S212SL.,;CY-,:BZG3+,4;L75]"EWEUY@'\7 9:^ EQZKR3:96
M PZ?,^.@ZN*Y05=9"EV?3MH<,V[>"2UDC!Q0:(=W8%<R+&SO:BZ!<6L 6\4N
MFI)W+646]C#_=O2N;<T7,O,B &5:-#EM%KT6FYO.AF-^YDOS,R=C?F;,SWR;
M^1G49DVE441^''9#/OX]P1O ;&#]_!YU$*JSD!LE5K7I)])!4,T=+1@"U>IL
M3,T$6A F 8F$/C-6BFW;30B1S9#N)B.>Z[^N.+4!$A=-R?Z!N/;&:'$NQT!?
M47X,B<R<L('1DB8(?T8:'']%II^33_".#'X7[T_V+SJXO^P*3"C'OJRUH:=Q
MA!PQ?GE^:N+T%V].&5VS#;0PW0ARX9M[5$$ZO'#1X/1&.7Y;Y$(P$T_\08=K
MH3'NL88A_QLE/,7F( ZYFS'%N85)-[(]1)V&,A(1I7/R:,T/Y@C6>D4-@BV=
M@Y".44NQKMFQB;7&7W!I.N8)C5M/-55K#^L($%%0S#NP/]]P'00/Y>-OE(?2
MCR*B-.Z'^_"XGX[2>>4/;D7<SJNA]@1U'$UV&X[L=1KOS_#IYKV(#L77;G?%
M][7R<PH362=W5?F[I%\:2.8$Y+9@QZK:A*0;B-BJ>S.QW5U_Y3^<T7[2K4T7
MG%2Z01O.0V<&0R-AL?U"DWN''L$;=2=M&FCW&8[&PB[#\SNE4^PB2/U\<M0M
MPM,=9;QM T!B6Q0B.[LZW9I@!W_+.34>Y/V?]N;T\Y\F;5);\(P\6N@(XAW4
M(9Q M#$.(4.BY]R'].X^U0"?2]T:E8@Y:UB;N3 TQT9<DQ@WD\JN@;SBWAQE
MTT$>99WM,N_%4/H;EL2T21\ZSM0NA$ %8ZMFD>%^ILJX7JP36'=@9GA$U.FD
M[R1S#R*X<]>I([R@!Z<3TQW; MR*Q5(Q$I-Z6>6*H-QH+/M!3$$MD5/X:Y$*
MSZ;Y%./U2*Y9Y#-PU_3"'/PPD27$I^HZ XND@-NTH!;+HJH4GZ-BOF#[R=!P
M0E-'G*CR65][G-W.A<4U-?US4W=X[9:LF]*TO>R@VXUL8R]@FI8H:,'P9R6H
M9K(;J&[29&;P/C=%AIU^ND!A'54.#'>AK+0AAM5O,E49UJ=43N39(+9T+SKG
MCNAKE\K)4DV;$M1:52R<#!5%%K2\<-]U<[H9C @7[#K@CHXB7=TWM=@;)NO'
M_4S6CN2X=5*7\P@UT,"@OYB.Z,+,>14B>ON3(<_RA_&[L@ [F"N'R"AA/LD4
M S:5M,33E35NVI]2.4D9S4!S1?%'S"FEH*)+S*J@%49AMJMSVNK=U3^B_GWN
MNLZ*GU:ECU/<XP$18/!G<ZQ(4A/VCM8>Z13>+/BTZ-#JUGI"M*J#6$ #%DV^
MZ%[LWSUD$IC(TZ>3Y[MPMVFS5G)-5ZGRAB<P5I>T['0B0C*FGKXP]?1P3#V-
MJ:=O,_7DUH:8@A#!?!JRR1M53ADN8I$%3I@$O]!8<@\C[JE HNRXZ>X&<'\]
M9MGX(R>&!;?V\V4A6>B;JX\]8*DE<Q"F$@E.K$>,L&<?$D*8F6"[+VS_8NUM
MUFQ3BT]W&"(J9CS1N2]S#I2MN4\WOW[+("!6.*KD0OBO!O4XD&#L 3Q;68DP
MB4%] #DI(!/:0V= :&ON&J]T $<#7WKX^$=XCS.E/F$HH3))G!(1_]CPG. K
M;3\-^?>GD]"8N=ZB[V3-NQR*WW+975]]VS7W[*4-RUY]SKKOCV/0VX/@C7:Y
M-\2(!^8>9"KBL/>V,>Z['.1V?,5H?R?L;PSASRA5;)],3APDL6'1M8*$SPEI
M?MUZP<RTYI&[Z%<!R9=FY;HB#NU_/V)CU.#=.((#\LSYY:/D)JWP MM3>E.#
M&^+21YVJO9<<MMQ:S1P'(/@1E4[+=Z'+VU5@'81)SDF#5&9%D;?J&3'H1 %V
M3=]E^N+BXX6NH;XM@H.32?!#4Z&/5P7GF&<"G:=_/9%*,SN"*<PN$2C<4I2$
M5\*)*_DAM+4%D2@,W\61BQG!%C#;L%YHV!L];85,_5C<W>V4B'&"N6HUPL(=
M_?K@W?#E/:..=]^\.[2W'NKR(*&E2A=3Q/UPIU'W[4SAEA<FK-S8;YNH'%$I
M=4%U(3X-B MA;J&JN(?#JL\09:X<3S)-*6TK^'$GR0=WY4ZQRCXXT!QIW.8]
M6_D4:;"LV$R"9.%&T=9EZF!7..DL]J6S*ZHB5&_[<@CWDLXZJW>&DK)KPM,\
MHU)3$X=U.X7U)_TW8IHZ=@#LZ*:4RHB[<A'$Y\"Y2JWX)/?=FQBGT@",=ZE<
M(ZEZ?J=SB1XFP V-P0GTN<&Q/1+?7M:Q#Z0F*%VD-2KHC*Z%V;%@7]B:4U2X
MH .OR\@)2[KEI%;_P8N5[HOU2MV2ZW>ZX@@V(;&QB-1KS-;+R20I=8Y-$*:6
M1HP92;16V?59'[H0AG>4M8%#^9',POO5MW6DWMG-72\']2=?L\ESO\?6S+?I
M(3P3@M[-72;:SO7:Y^8(,;E6KZ*H<_/K+&37;>HNY(Y-]ED@B0UU&VSQP@A(
MO_-;W8% T6-SQL$>4&=GV.T 6T<[Q?V, ?PO#> _&@/X8P#_"P/XP[$N>JFJ
MWA;!3U&Y0-ZO4X[U[)K=8Q:HU#F"?)1#VXX C5NSPUIPF4F>L+T1?52F.K&#
M"L2-4'#5,3% . ?CE#K/*UUIP+4Q!,,CGH\/:?71$EKWA?%M%4M/GUAS:%-)
ML<$K"?1"[!QRM5U*">Z\*>VV.DF)- /I+*)3J_!H@(I,4Y7'R(14YEMP937L
MM;A/M!X,U0S]Y<^/G[T@=(&77_&XL/T8>7^('&8;Q_!K4Z95D@H42^BQ>V=3
MAEAAF76BJUCH-;N>$5K\ N&4V@-.%T@F#D-=RX!HFY*>XB3/TY[7OBN#@!$B
M,!&[S29M3W:SB/0)GI_2/_@=,RN_R7*W7^]+U]IO5KV^T%ZPJ;W6OVNBZO<5
MH_WVL'O)K=X6M2EJPT6ZFL,Y "L*2\1GXG <ZUZ1;1^,3JQENG)]J0+K03M<
M<N.,G692:_HFRL&F*B<V+6&A;6FMD_=N%RR\JK:3A\RA<"#3-[&N#F7OM2M_
MR;X[9?_Q1I:RPG,+;]V#2L)7/9N>=SR>K!$Q_- K]Y$XA5T,3AX1*I/\M;HV
MZ"8?[>XCJ5LQNGY.8S5ND]5KA!U4^H!T&\)<&,$VO*$0>N0T9;85I\2]FC02
MZ1=3R"49YXG?HUW<2WBC+;.+&TN[JF,MEPX7VT!8[,#P=A)6:SVTA;2&3S]L
MSZN54]2BM.C,L=[=.*BWJKAE3ZI9*K3X,P2&ZO80.B]LC'+_9VJQS(KU]"_;
MN]KL)J.TQJ^6\'8&18"6:E%K IQ;E66'4R6$-)%!&RWGX+5$,:BUZS3C3)FI
M91\,.=K:&$UT: @T:7UMIES#X#HKIJASL*LF-Y,,,>'J2"XRM<[!A-%L^O0D
MD.3C9QVB'.4ZT97 /9H<T:NHI;Y(1BD&@\Y?@3V$.*L!U_1/OGGQ7LX^J]SI
M[-6?]M^R:E5<=>EJIPN"R#FK;FN=R2'") J@=Z_E_&#"?_+#O",SE)2/\-4=
M1)V<='R >_R4S$=)A+7J&A,X*_N19CG5!Y+;+9J\1>T="L&E/V6ATS.DA',:
M5V]]KUH^3!=$I'MW]$^4TPFK'9J5N9 B#$=(0"QF339+$?64%;HWMNE-X1SP
MW2R=;)ZODUO)?D"*8O'DA3K#GLEFN&WRC5)EZ@;KU5Z=_>2\;JC]BEMJTEI%
M:>).AO3QFL% M.7P">Z* ^87ZWP76:;.*6\[1OHV'9?:)KB(#-#,91LVF0]K
M8"!"2PR1*'"*S_W<_)_T&->IE#80HA-Y8%LFH:"+AM.SU#^BKB=97NE6:MUV
M 3GMW));)78Y0TLF#&)"NC:PYIG&W[&HRWND5=4H2]!!-4%^Q9D+9.@%Z&Y=
MH^ WG+NK()9VRYBA^,(,Q>,Q0S%F*+[-$H-N]?5Y(--[*-DHJXHNM50ZSN**
M&T76*Z;=0GV/1I&K?2N7WSMA?N\OPI8Z#*$S2AF $5DYW ?=9U0GY()L$.%H
MA.&O;.<&!SBP;MZP9[;A-)>^4G%$B-WUB@D+I?-P]*UQ<"S5/GU/B/,?]S.$
M?E 4JAM*=LT1&&*1Z8D>.@'&T#CEE#XBDLI2FOY),-'6!E!=05H+UJ+R0X9Y
M0FX+>0_21E8[?$*HZ\!SN,]"3+4*8.>7(KF1B1V*B^$3V""G0/1142SQ)BWK
MAEW+%ACD(!I"=* E&4.("+3XB$E"&(O<BE'"]H5_Z>@:> 19PRO;CGTBVBAU
MB6&]EC.,*,>O4G8DA9Z(;ART)FB]-, E>W,;%-]5T'5+OJ"A,XH2L)#=KI@8
MF2)UUO8CD2&.1\UES"3Q680I:OQ7 A-5IM.&7?,JRCAPAAJSW7_0P-!;\99[
M4:I03IK(+S#M6ZK>3+=F]W/M?,XC>3-\#THE[()="84'UT?'2N??_'NZA4%E
MD05(,-A]I0#<7! 6K^5:<\5OF9[OR3=*S[<>*]N/L_M)/SW?NQLD@U:WG/<]
MUYVO=GR$?Q9]7)N/K;N-E^U[ RJMN)VL6]"F>('4#L-@'2.>Z0M7IC<#76[X
M?J+,UP)<ZH**JM)Z\*Z([#U"$N:%&9A"R!0I"#,'UR<5-W+:Q.;).C+-=H\Z
ME#^Q%(KX95DX<G5=4%I&<I*NE?&C:5V VLT+M/AMIS09GE_N8A.-[IL+^B!&
M8J#RHU2:D5]2@RJ6-^+DB2VJ32;!M"@^<APPD\/0/:>T\>Y2HFIO1G.AR[W@
MM)K#U9F)2-FE(W@$!SZKBNW _*9(8STL[%&@3 H8?2C=\9BSR#AK^C$SE^<G
M!F51+.C$(#BS>PZ9P> Q@G'+?S>PJ32GNT,6K$U%?JL9K":)NP.2N::FU?IZ
M/'.6FCFY'8)>[X>\%CYSUH?;D*VMSE?D59NJB'>2W/*>I2!<F[:VZS:VE-N2
MRNWNIO)=KK XFC0 Q#?P9+*EI^#A][P/3 (G-*C[VUNXTR7M@YX%Z)[S3G <
MTU=GJ4V!.'"YSV6_$WI.E,!-BZ*3$GG2!U)?_S7R NZ)O_VDGXJI^[UW?&3O
M"0=A-.F;]1]Y+PRLE/UN!71G8,XEEG1M!"U<:!0,!F\P/-EO!1:Z!]A*G2-:
MU>G?F2AP;=.E@;\0(X#A,$UCXXIZ]84+##>P?SXMHYQSY]UV4RB6$2CA&/O"
M<?:(OLB;Q90[+OIUMV)&T1 IB<Z6CB8=#0-5QT=("KE89LI6;M=D4E1MPY+^
MA%/;_&W4O ,X[6XO[$X.'7BP>)G@5K^LY^R8G?O"[-R3,3LW9N>^S>Q<5[_I
MC=9H'WRCC]NZUDPB7F-G5WNS0V<4MM>QRZAK%4>5!0W^RFZ-U<>A[U9K_8]:
M#IX7S_6=0&NG^5H -T!05:Y0OULGE!UB2?_90\.+K]HTH*/?*1B\O<_ADMY&
MSEE'Y@;.X-9QDDU+, .OO+@E?T;X4ISUJ#JI9]?A-#UGNB"'N&*HJ1S:#B86
M8NA5531EK/R6<I9RQ5UT)WBN(=8Y@JTLQ"I33,G#+6IL2\B> 7)K1**JII'J
MB(S#:!<YI=@\]J_I/^V63;R?T1O!QIF9HUU:C[]3]X*>>#WHC(1@B3OV:G[I
M(9EF B0$XW)A'AK2Z:?@X,DD6,!]Y]7$9XYUL;<]? /MG@.]VFF=X(KIAL2R
MI0Z3#C=TA,F=_Y^]=VUN&TG21O\*8_></5($I&WY[IDX;X1LR]W:L=U>2^XY
M\Q$DBQ+:(, !0*DYO_[DK:JR"@!)67*3XG CMD>62* N65EY>?))EJN>T]C+
M'FUGZ9O 'EI6'G@RPC")+3)C$FN_+J"K0"'4S8 L8QO_&:9U!NL2,</WSV<^
M&[L48NH$PK8 LT46B8O%7YOBB&)M,/^>F>I O-2I,G1Y-"KG\#7&\HX'HZP:
MS:?, B4X>QR1HSF35W9>! Z+Z]_%CW77 E^%<)T@^9.UWE&MCHB;IA_2:X&K
M$VENF163?&Z*D4O^SJQR]=K[4"=J;1D;!L4Z5[=_9K1^ZU".=P@-55PT&![#
M);752GBR7-B66X 1-YK%>'8P\O0/S4.G^R;&/%2)*NK3ET\:,7_@%!TQ]<Y$
M[GJY$K>I..<[. COYV[?V>1>RJSXG1W=+59;M^609L)=!&ZV)0>BZ<O!E&L\
MJ")D1#8CELP%%U(?"1DB?&:9<:5UGM)%L\G'O#XR=*<9/<:$U(+;)# ^D=V@
M(_>QCC'[G8D:K>:=SK2.AI]@8J%]%*2BI91?M'P5W52CNW&)ZY,E//HAY(3X
M^R. _)+\KB.G<YQ'?E=ZZIP?;O%Z<AIM;IW'K@Q[.>L^E8-W&4).MZKZ6#"F
MV"2T2"T.UB).&7GE[[;O16?9AA-4D*(5ZR$>;/<Y;=R(*L!!%NB'QX_@OQ\Z
MR&,2L"LB,)'_E=CB0QLK4"$!0^%<2D%3'A*^:/%7XT#*]<!NLE3<7=-(AXB<
MD^6)E?^E?%AB_L=X+K(4J\5:CX!M"&K'[[8S2R^J/V.K/*L(7#:@S['?AVJU
M0<N!RA-5)#*W7I<4;*C"6 Y8JQZ8$JLD84+!):50 U)F?"LH, ("8HHK[E<B
MA+ >;T$E.I+0#Z(5+4" JB*RMQ6+'%6+92!K<'(I""*1)L5O-IN#^H?%J09,
MEUPY\]P_%<NV&C976Y/!WK\VEPZR"BY@PQ+HPW:*DMD6W\/$W);[$2QY#SP*
MP29^W>PA\0>H54]%+V*B8_O$'B$>W%Z7FM['GT!WJ<S0V6L=QO90.RB&'),!
ME3T2E,7RYEIGF!>F9UD"UB!B*QI+N9A:L#0^M?L,RSTS+"_W&99]AN5Q9EA6
MW-B*%ZQ-^$*4HWR1L*[JH%?E+K?10R@>,N(&*9:UFV^"+HX9_#06'M_PS8.J
M%WY"+GFN 6(%)Y]@LA?^C(%K(%+! IY8WVCI&=!C,EP2=1?",.#N&9$)"$:D
M&3M[8HHYIJIW07JIH\P?5")V8RR)U'JK^EYN_/2FS,86[CDNY\,&:1TX&F9C
M7I:0"KP4VQH"X6_M1FFKV:QVQE_K)6EFE_:+[/,6%'IYM[KEM"WUU'H+_(+S
M@\H! YF6JP7[%1=PP"LTE57&[RX920J<XM<4\9OM&O&8"SY>/M*"CX^GG[Z^
M/WU[^?7+&9D1%U\_?_[PC]TXR2_[BSX<N]+%?#;+%YL]QCN2;NX'CKK5ENOU
MG4& Q89UY[LX/>CZ]@BO>K[HB!V/[%2"OEBB!%7)0#!3TGSNFZH;4C<HI'7[
M3N8()N=.O@8YY2V?'>7\L&YN!G8"94")G.:(6;<F&=;<H@@Q+1=3Q<_ $;9#
M4:V3N(+#_J%NP!XR=\DQ?.U+(,0=8$)R)QHP#L]6VIB8U79)]5-J]\DG"F3!
M_1(M32L(P-[S26T?O5BDJ;:+7,PB?OO&Z'D0*8PWTK41&NC ^UO;"G&A6**<
M5"@- @H0Z>E(]ZZHT&AG/A0YY/)"$YA652'3&9S?L4]7M ]ZW.ULV;G9$=7?
MCS2R5+3;<,_^")5OY[?7\#]<P^OEOK=^[S]YO>&CY0'3QW5@1RL/[,= !"_-
MZ+J P5TM!I?8AWUBJJUQ??LT.UAC< D$6%-T0'/"I0H2"@TVBO,03[$ORRMO
MBW %#CMLO.\X^S1P.QQ,18J@XL5'N7LAH* 5CO:@H_I:'PF-Y["G52= VI@.
M?4H[2#9#)=1X"7#C4];2-EE**T5WNXPH,GP05\.7@"O[H>I\:B7GN)N^9XH1
MR;S;/"TO)/\H]V-3@[HRYI#?YSLQ<1&J8KL6/#Y!B:2M$@R"!A<UMG1%W2NP
M.RC007M+;9K91/Q'K?BU^$<IWQ@8\[8D2H(\I'2L'<P<H7Q<B/6#18*>^)>L
M@7MAM(:0V+:!&T5H4RRQI]]'V#+#I1P4K_L^!WK?'.BK?0YTGP-]G#E0AELC
MBERE'S"Q((@;3T^A-8;Z5N:,>=<C*G8?;._"OB=P)F.4SLAJ RT563;=5IV,
M;#+)1DA;[P@CB7ZWR6K0>S]__!PXA:Z@Z[!;$:I!\4(<G!YBO&-8SKD-L:U)
MTG0]3)@VR=!GR&@(F,4KCM#09(=I.I->'C%##?/@^>PF7(XS@V5E;.A^MNPG
M"<W$XMJ%;8]>KKLMXCI]@E/#AN/[=Z>.]>OLX^EATJ*_CKB)'%.01'<\GR 9
MZS4:'J%1@BN$>'&T8)3EP=0RO#:58ZMK#)'/8/W'C*8)Z\WD';KM93T?:LF0
MY&Z)U8.XT(I.)OXXQGS*ZIML\9M#CDXIYS>L*A/2Q"NXR IE<82@:P%D,PN=
MO40KR0&'I>BX1+")B%5DJ6U/QQGX!:Y5/AC:MNC7.#\IA6.*$^42C:Y!>QC>
MTX@A*#0R%?(-DXWD6O/7!'='C"6U- AP<&BA"Z*2S@5(QQ1^0+(B^)_0NA1>
M/NXR:B$/GD6P(RX3"7[4F;-=[I,NVFEMMWUH)U9,7H7EINK4O+\\JP^7TNMX
M)J,6,R+J/6\.:Z*)(/W^\O@$?'(P]G>$;^WE.MPM6Q$4W)& SI+DFU_O+4J_
M?6<HUL_E[ODW_]T[1.A_2+!V"X*INYHNVQH1WVA9<TO';E?$2]*&H0PN&?,C
M2R/^@#SARA%F+1('R\. 8#U>GM*>_]"K 5O:L]N%PPSME;OL&'QA:HRJT"8Y
M6!Q-"%0/WR*E\>KY_WT8(#,=X8<9=VKXM6%F^(ZLI)I-6YZ(_@DQ@<((;*DB
MUG*'\5%?@()Z#A7H@/DK7+; 1=[#U=!FJY:&E9O?-P?\B!,?._&=,5CZ4\9Z
M\1B3N'DK47NE=3V?FKHO'3.-1M^=OP07S^#5BM^IROG5-4&GV9/3CP /Z_MM
MEX<9MD(^K#WJ?U<<1']:=<O3J6T.H"(HGL(2K#2'NW:\$)(/U-!I9U:PHZXW
M='-9[4K-^9^6HK22WA'J<W09!-/W_-CP^Y:#?J^HPH\.(CSA,>Y*#*&?14*5
M?6[-Q4"NZY!)T[D<)&@_A!(6E*M^+SOT/IUVSW3:ZWTZ;9].NV<Z;7N49"^[
MQ!MB&X'+88Z-TKEY(_AZ1V^Q1,]4$T/)EPVKSTMUP9,"]?X7N?M4K]YJ(N\[
M+#"E2FTGR1TQI4ML7%NH(">CDOM5* ]+5U:&Q"M,Z'0\\ FS05I1R@[^1$;N
MB+)S,@/="BVR#!I-'4:N?$HI#^D$2RD=^UO;E7LFQ>ENCA.3HI%=*RJ$__K/
M9R__.@*Y==VV>97BU*3MPF<3AVI))4]#BRT&B,SJ>).1K$==%/;JD1:%O04)
M-D6=:O/J<:O)5_VE8%]GDPI']#E=;#H^ZGD@X3^HAPZ>_G0X&*6Y097 ?=;I
M!N2L^V0B5<_OB)ZPRS/Q+2=3[.%^A-2)#!^HS 0T&#HI_.\1N"49MS"?RXK,
M>$784,6\ TPY1UWQ]?CB>/"NS/,4H;-?+_ZOIPDL#/[_X8/&IS8J,+T)S'<*
M4O\QR^'"@I6UXK,]%<%=0D#WW+IB(-M?APXQ)9CH[X)/78X)5"B/6Q%M4PP.
M3D"N29PQP#2Z1EP/K2?V-G5T+)2R4KT?IVZQ.4YQ('W4\<KR?_L$-_731/J=
M!Z%=&9D?, 4@U.L/.SM<MY?0H6+\6^U9N6V?WS<6A_%.)DQ1B"63CJ(4T;37
M]^]?T.GAS7+.'H:HC[!34SJKS5_L#W\%SW26IXN_9 6)%7WIK^'CGH,,$B\2
M*"0YM'18^<]B<+]^=?S3RQ=H<S=@:#=C^V(QQX_)'/_O9MS^V_/C)R^?]/X5
M;LC>ORU[ZHN3XZ<GKQ[\L4_ABR?]?]:/_6]:"%X,6.YZEA;_[W\\_0^W(^GH
MVQ59DT>B)H;C\0MC_BI;E9L)'.\9L1YEXX%5(O+7IIQU_'&&^)[BZB]/9G\,
M3D(UBX]K[6(Y^X_E8F0E 5^'_Y07R.">'#]_KGY).;&_/#U^^=R^6M3YT<F+
MX]?/-Z;2/\7TJG;K=G)7GCP[?MK:%/EER\Z,MNG5QO;(WZ=G-\H8^\'[Q8OS
M<-LIB]JYH9M=U<C(74M!_<D2OPG#Z218D$VOPS0;CW.SH:4X*[!,QMK]DZQ"
MPCUI1@J&#?_B,U+B#9[X>J1+8BL'.^QS=E-B/\SH+VBBZ6CWDOCV0VW%GW.H
M-[I707QW?Z:C,/_^3'_'F7YZMS.]/]+[(_WG+<[3_9%V)IUKFB6=IX6,G<%O
MT9$,4LH4O!, Y/MWI_NSN3^;#[$XS_9G\QYG4Y77[0_DGW8@;2JB;XUV^L ^
M7U_0MF"=-BIG[\E UG!W:?38.LWW,G[OM\S[\_[?E+5X9 7RYXRPUCQ=<9[+
MY]_287ECL*1#TD=($H,5$]+- 0N0ESQ(RAVX@=NJ#Q_4AY8Q!K^4YC53@<^E
M_U^ZD**2*T/ &8>C<4-;\O#E'-78IQ13>CBQSH?X"A_[KE%9"*PF7^Q."KH7
M_ZI4T2/,0&M"K@=-1MOL*_Y=2HT.GCV/,[ >0?'6(BO^=YY6#"N7O#$-\^H*
M<68-F&7PS@OJ!!QC=JD5R8H>5_XUV''7/F)45HS&DFHN^,<U/NPFS>>&NA5Q
M4Q&>&!QYCM)8B<>>F$0[EE;$"$%@-WFT[_C;RD];%/W0N!-<%ECG@2>0476Y
MZ@U9S*=#PT,F*>$68>ZA2A'M4<GWC6W\M$<E[U')ZZ*2-P+M>'G\\OEW03M>
M/#]^^>KYPX,PGAS_=++>8^\,PAB]&+^>G/P@!V?;\L.=YD28@+]+ZOTN:[=/
MO?^;QPTOU[2T5AE9S+04FEIL,E5H&\$3^[W'K8^R;6Y[]C'OO>SN97<ONWO9
M?5RRNP4A^[UL/^I(_];*_AW"_#^H<\-&@\*]];Y?RD6:4R%M67BAWV@T>$=H
M7?K)%7G-%X,OV$%QPX'W"T'T"5=7'PM@0!D"XK2J<# ,Q,>!^D'EI,X@0S)^
M,3B_H?K%QZ^C?K$NRW[P:+@X<GE6G,\7<P5CQU_S3X-A6L.<QIUTSG:'D&5R
M5^2QGSM+SW;#XNC5D<TTA$UC0?3@8.E\1$8X&-V4(I*"U4)PR#W<A<P8">"&
M\->B0,$H6=RPTX.U!'H3^\P=X'/[J;QO>8LP.FI-5LSQ=7/XB9*G@SQM*(GR
M7__Y_-5?J8^"JX%<&"RA=6.V8^L=%[=[]N.B?_/0%/FX^6.65:DFF<F1@N^W
M% V"MWF:39G8RQ[Q#]SR%6G*I5D&V *.B:C[=5O#^+DM(J_(+8/,7(8PD;LM
M/1%%A.U/5FP]Y>C#_-WM-2?FP^]AQ@Y)TO-%V$HE?F#P+7=&Q\BE-9:NX#14
MYHN]PP3#%^V*1NXG?G,6@L&EW#Q?U0,N^,E/?T:A8/=,L@VRDD2%EJ^/7[S$
M=7B3E74&+P,G\:QHJDTS5IX'\+3:-D- M>Y-,GVUK;:?D,TU)2@ :A?\JIJS
M?57(G5.V],_0T,TBP(G6!4:_:#\6X4CED.A_#_XX).H_!-FB:F+UZ(AF0^LS
MNK3(HK@I\SE,@0P&RT58>^-9&RBCPX/LA@D+Q=)=#"KNENZ7"+X3&+G+;DVG
M2BO4!ZQ+PQ'+C:W?UDU)R 94@E"I@\5^2?22#.?T%K+B1BGW]B"Q00L)UHHP
M+\1T5 [R$IM;\)7[D.*L6MOHC7E@%?SDQ>94<+9)L^^X[\+5#7>L\GI+_NOF
M%;)W&UQCDWIP *<.I![/X9CXH4%8RWE38V<],9I&Y1QLJ/R0J5DS$CS?30^D
M4E1C.LC9W*)^,<7"?K^\+:RAII>'GB:LZMCG%HRWVO[RQH3M)==T@@ZR8W/,
M!] QB<F8$B%9_4:$Y=?I#2'4TC'\ ?%Y\#N88DX_E),).R#TC!3##M@79XI]
M!,F5"]B4$SR^>_S9/?%G)WO\V1Y_]GB;S($*8S>6R2)G5593URI[5R>#VW).
ME_0$-8NP+<;ZL=6R+;S38X(H5KN"BTT#1;?:@%K=5&)L>.0N/F0M(,LV1;J:
MYT7TE;=9;32VUT=Q-6ET%(&++9RU#3>Z$F9(WCF:H\D4PZD3:H$S1;K1ON"P
M*'*'3@[B?];:TONAYZ$O%[H^1R-ZESRT7ATS"YJIQ</G=K"V >O -4'-L+N;
ME&80X>?#[4P<F[_7WG"=1__V# YL.S@.'%F;@8E0*QNOJ ^U;0X;1'49,+^B
M[5?@UZ.DJ7T9$LCC3.9Y8[L*C.TK)#(<SYY.2G;HXYIMKFUL!-CD[#.,THH[
M9]S*9.#\U4@DCV&U:#@U#8!ELVZM,M< J+?1/M+Y'!J8G'YKDWX#?UG-9=E^
MVAF1?Z(;L]!3N!%QSX-4MQ><V!%8:]A@ 01RESR*['BC?9,^E3J0N6%_ :/(
M01X"SP'5$&.Q%V<W5,PF"-0$A2Q]BM "'$AK(N:AMET??*9"!WGAM6N'>6&8
M_P.RVMA_%QBE0-$7?F+_R'':I /SQR@')^ &^8WY^@N#"9VJ3L8MT6^]!MR<
M[([A"+L,^DZ0978ABN776$?8K!VKB'7"0X; -WIX;X[7:%+E;DY76SA@)FY)
M5L7*$NRD#OU95NW?9H>'"=5-P77-"0[N\ K&X# KI'<L7V/JQN;\9#96%W)\
M&U!A?I#$1L=:':-BL89C+!]LW8OP LK8=%RH5JK8@NJT*/R=="^3CV3=S?$A
M)7*C4)GGJY(RMF223;TO!N,+FX9Q^+QY*U_N]= HS=&H:URW71RYX>N![HR6
MG/7=%+XKM\W!!Q2VO%XM'EM51 FOZ=!_;5^ >E@5(\L$O$8!YAIE]^5H!%(.
MJW:6DK'K"*O]Z7:30_=@.DN+S(;">-7PT_T00>V0)-29^70RR?*, ][< B"K
M[%G"BM.+^5!\$LZOJ&9[8P/N(ET?TO.9&GN[+C^6&1BFE(X6<=3;3HXC9JX]
ML5S5Z:'6%?#5JZJ$K:II4CC.[T)!WAV D0P.AFBQPU*9*0C^V(DJA_JY+I6P
M#L[!8/]6#_@ W8ST=W3E8:&O"%W14?I+'1(RNWANAH=AYVCW>T%(C#!7HD<5
MZME >+#<W6O4+*0^5[N@Q=\^$]4]V#6@UZ\,VP'8$7)WJM-?]&E7T:J#CP;<
MRS'K5C!F#39X/Y,%X=^^R<O1-S(:MZ-TG<%OTG'RUD1X).6EQJU)AX;.)7[^
M-D/W6#5#RT!_C5%A@$F2WH "( 6) #INZPX'I_A&HFD#&&-3PUJ1=E?\Z:Z+
M?(PP2?6PXPA*OS%0PY5RDL!_GN!_GM((@DLF$G?IUE()1LF)-J-!J-LIFUNS
M>>..A#M33,\ :@VYTV]0[S?Q"^RAL6ZY-6GBC_5,<?GV.'W -Z:Z0-'-Z;+Y
M]AF%>V84GNPS"ON,PN/,*+R]1E/7#/X!.E/2DYR])/HCUH&S.?6I,HZ][0WJ
M<=!A^.6437&K(^&W7R\&8U%@WOY5KVGA4^T5$L;(%<PS5EH^>&N5;2(<.^!@
M7W5H;I=X_A7$\%10');6=04YBC?UK6%*$&S$-[2:B2:X0MQ]BW2\_^Z']':9
M 8H6-RAON%/0EIZ"YN1^BNC9Y[FY$A9:E9"I0AN==+DL).60.<DBOZEX]O@-
M[G6?^'O4W2L=^'@P5V<-W.9AJQ-'[.+0]K.*UL!%DWQ74@MT:M.RC W=#WR9
M@GF$O4/MU2D+!5>-N4D%%M P (#>3"@''(>W5]'+&957!9GB:&C@8+("SE;#
M72B5K:$,C%VQ45_VV:CG>.L8<"]A"3Z@H&R)"7KN-F]<PH-!PG ##75-]]XM
MGO1Z/K7N24;3 .D6-C!2(W-6)>BDR%1=R V.(KGO(-75W%C%HQ[H+"H+8;=*
MR8XA;2S&'L92P!>M;HDB6!9%TNC&=[,*$83T#1>X %%%X_+O.,*+IL+6\?]3
MSJEUKNM0_4<VM6]*D>&(B9\6L3Z1WC\&WPTZ"3Z(9]^CL=QZH*F*O!7P^G^R
MCMLE\K!7O<$O@\V9)>9U"N[KQH5^1T#@Z>%FZP^ZMSNZO1(5\1M1"O'.0:T&
M[L1IFA'FHJO;]RF[L7C37/@>ET'WS>DL-XVQ3N]<= ')Y:J8F262*VWTK#-J
M%L5WHB":FV70ATN^&G$5UG%@ +]J<^1R$5N/=;D+*NZ]A&G77#AX^]<9-?-T
M3<69NQ'# EA'A$;(B-0\1YQN.-VFL@JZ&1DU7>M^ "E'NPE^T#YB008MB"XG
M4VQ$F1NTP=UCP\/7H+=YE<C^D*[JE+YP=UK&'6@K.W$KHZY3JGL:=ER]R2@8
MQ_S)DI)S30D/GK;*J%1(^GU6HPE%I=LNLP]_H PJ"C"?!QP3X1K*24.Y1++'
M85\HF*X>DG#:$A--9F9(YPQ&6#@]P; RN00CN]$I<7?F+MMI.S%2P-X=!OBP
MF34V=Z."S=80QW[B&+\!NY"N6*S-FBQ<A"42_ EL3T'1<KY;85G@&G5^BM<&
M+9R"EU@ZEH4Z+3W]<$\+04RE>(L@5-/VV<-.YZ,<!]S>VK=X;''A<)#GOLU]
M,I!^?F+.@E:GXT.H"'X<ED+%T%=>CONMA24C==$J-W,TB+I.M<S>'GP,;!<2
M">/ X;R![U$^94EV19U))[Q>>-R*\>C!.<GGM3=?#N*0N,\4O51UD&65P1T*
M:V M0O+05%O$(9T-7*XY=2^N&Y<BIWV%>9 N4;^QNXO'G)?'&H;ALDYZP4)A
MS!V'9L6=WH!GB<YYXMU. O+'OMBJP>^.=3'<2NM"2Y(V+<!4F//.-UT&1M;T
M&!H&+(-R82A9<^6N6P1X8N_M$I,NSO18;D;$T9&H%??L.@6],X+?7<']!JK^
MB"*X&!$ '7Z5L@??>;Z>'[_JO95_S&6Z-3=?*]+"X0-C=[KNO]EL-*7O6B.)
MP36@;<V\581-$931]<4WA)7V"@BSX5_BGNE[J;4!4L#:=P7YV,G#ZHV-.H*O
M>RMETC\V35JQS['<,\?R=)]CV>=8[IECV1H3IY]GAU05!BK/"TP&;#A>=<9^
M2AN2$B [7PLK.Q<NN"L([[U\,6#R=TYGV"M11W@Q4DN3IK2'3U2XZMZ,5F*0
M2J'+.(/+KK&H1_<O;QE,)N0!6?0/U@68[HC%@\9 MY,GY^]@6"#=/J[<%ER#
MFKM)"=#!^)#X0[S510:6-)]O1[[QZU.J1P #"*3'8ZP2^N>MFC5ZZU+J;,7N
M@ TL,@&I#<%1.J;*E_2/A$L[RG+,!CG,%$M5:_X;FM(EIY@8OX4OLT$$]Q8L
MI&%OW'U(W%0/^F ?N:P<]J,'ZW&0;@/U#$C.0$G2-K#/=!YH0<A+^M 6Q <1
M'@Y=6 S3VO": X^ 6XTP2BS$*"A^HU*>@]-#$5;ZC!74*"K#U6#AHONX@:_^
M\B%B%4=:=FX..& 0X8[\W%L4!9+Q]T.+1\63$; 13<?D8REE>G-(%&NI]5+B
M[ZI%I9/AVZ7$GW1SBIW==M1-/<5M>F?9U>M#?Y?("L+1Q4S?SYC.*_"K\!#G
M>^W,;='/X?/;Z>4V(1/#)"UIT+7"NF$@TI;<H"Y(G)AR.: M08.SQ9H_N@Z4
MB+)##^\@DK,1AQ8(E7C?"X/,G\/!P18H^@T+@%/N!Q3%84XQI\*2=D\?K<(/
MCSN"INN8GS#IJ(8J*-6]\UVQ@CJ/AS;)<LKNZS?C0%! *M/,*R2Q!-/%F&\"
ML#;3&8=N5,VJNRSPJ_I$D#X-E7\<#A^57)"$9=S1!>(B6U;O)A[*A>%-9J9P
M>KUCW.K]+C7I!UWIZ:@9N)>T%+$*@?4O;UL 4-M."X5=LF6%^#;E<'@<4=_.
M=0%G0Q%A?,IJ(#6%A3WZQ5Y!,VK9I99T"1ZK,MET"+MM]+3<*JI;-<]UY-8&
M?C%[4(<8',_2HIA7W*T+4Y,:$C= 4F^] Y1B\J#23(DC(7UF08IY7([F=..2
M4/C$%^[7#,6A(IB;FRB/)T:(QU<\UD!D/A-+$!@L1,LPP=ZV'2)" EE-MSH!
MI=@&>=G^X__LBBDR7A8(&;PM7<GDALV2OXO%0()#L 4E8\-#L?=1W)(@ZI#B
MJ6<(ARA;/@L(ND@+EGS\+L)3U$&U,0PZ=U3(B2H37XX QI9UK%Q<G=/)"J>P
M=*;WQ_H^SO7!*HK@6NEV[K4G'\VK]D7@EFQB"58UU9Z*+W[FV-(Z]CVC.)#T
M+U]8, =U +5*C5"MJ#C\>F$.B1 \*46Q+$)B1"#!2E2;054HG3]I3#H\H1!
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MIET0V6G^=$==_)?[ R_]AGP[MM]GH5L05MNFH"B%<8PV;4JY):81K,"\L*@
M6*69U6+2Z]E6S?QFD7-M.^5[ C4^0*- >5+C1<E\0N:%$,D'<MK\*CB_S2);
MUO?4'F)#-^=RP:X:N,H.7O_$3:A7[^K#>15K1#(# S)6'G>Q(3UB:2L-R.VL
MV'\+'G<Z++>\[JATRF'!UP/=$&@D9=-D'1MS<( /V (D B<P<?@TFVT ([2
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MB':6(PEB%58FFPYA_0,?W]9UFG$'CCV" /9[KVP&,*1^:OO;3Y&/I%9"0M#
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M7Z/B=_P\@7XY9UA+BY91$S08I1%CV0IM#/PO?;3'$.@8*RR S [3>8Z:W+*
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MZLXKR-,OYQ>H"E'#@!9RVNK#Z=])Y>"'_GZ.N@ZU$OSC##[IU36H<-"E9^]
MFZ.6? O:$50GO^W\\I=?OUZ"6( 0X2MP^^%#9S__"O]"-?SK;^>_@B#][>RB
MK=R5;O\'"C$(^B?[$%"8[[Z^O62MSD^Y/'O[RZ=?/_SZ\S^Z;Y6S2WSUY2_^
M8D%E_N$,0U/?:PYL!_W_R2.E_S\74U&\X1TQR4[Z"?ZC"7L"C8T'V<C+EZ8H
MV%!\G'A#7H"29:X=?^ZZO1HXPV!W3%NP:U3BC\X0%SS,%2';MJ\EINQ78S9K
M)]L^9N">5E-RZ\1='KLR1(KX"+0H+^L:EW:<3F%EX0=;5YC1@A.@G8!+F-(S
MKG%A+0S'=5C3H,+^3#$M'^?7P8FL"K-P;,%8.[85O>@^T")LQ:ZY.$78>,P+
ME^3*,=+H.)XI$ 'G"+E<)4I(1:'(V -#&R>J$(V=;%6<BDV;XEC*J"3N%3B3
M&)W8@AUZB]/9BAW:Y"IL-/>75EE-C!)S%+)D,*3J4TKI52)\^&?2-IC'^WZ^
MI3NWRQQ20"T@8^_M6+>TB!.3C@\W;E?9[:!%V#\4_^+#51*1B@K7[H*DC+ZZ
M-D+$EPMA\!=;UAZ,'2.E9?2F4"K>)"E\,;O*<DQW'ME&QRK$&!0?V4SH\^-7
M2_;F0$BJPLY;%&6FF!V=^0&*G066M.'JE 6I90\F:8ZIA6E68WD5I0JR(D4P
MBH1-D9$;K G#1&,NL.QS7;S6>OBZR:/'3+CMZX.]@C#$J^9WCW+<!X87&Y,B
MDWF.HW;K7@T*<P4/I33UR!->R2C]92 L[PYO8NVP)J!O]D4JF%%9="WX@1"D
M=9HS5+Q,J1E&,;LJFBPR4>E6&<,YZ9$','>?DBD0R2Q9D;5+F8%XF1N,WK($
M9+6N9P'I_AT$?Z0@'S@\>SB)Z@W7JB4]"3ZH0VG5/I\@\LP22R FBN/[ZGN_
M/)G;=QLNUY'LUD;5D6C!2CS9%8S 23]M:X</LWWU,JL]&=G.'79CV@*[#;;6
MFCX,F^^AZ=R:T)IV,QN:@PT8.QT799#-7XZR&+!US_BKCJ3ADLO6Y<O5=2Z]
M@CVV;EW[ZC!.Q 8\:Z>,,#WTEE;+$FK?MG<QACIJ&?OMH625083WR>CNUW37
M)?K@-W7'%?/@UW1[-1_-36VQ*$NOZ6YKIW53+PF9[C-CZV7&GN\S8_O,V$,2
MBV[6X.TM'8\-WL].U6Z:' =-#0KN460PO('TK>JQ-MMCF\J:&HE/;H5IRE?U
M%1I84;6&7-J\VG1CW5[#?_QRX^UF"+E9SN')6[?0"P>!WXJ5!G-E.FN(KP*-
MV]RD%>$\+4&ZV \.5,:, @02+7,/PW6&B_J2XZ&+)RXGIB5Z\@H&WYJ>+UN(
MK2^LJK&9/ :!P/EK>K[E;"S)F72"^J*IX#]Y)M[RZ96SWCFA9X2HOFR4S9B$
MGXGFR@+#EKQ>]J4TBE$YAY]S%P"[A8%>ER5Y3%(CCS! .Y.0C?('R1(]\2]9
M U?&: WIDAT$A_^ZO 7'K4HV2DG4(T@L;6'-&,&5ZWH^-9*#8V^D5S*Z=@QV
M"S15)!"M]Z(? @Y"DQMEI^/CT"MF)C1=K";P4<^)%LE9PCPY5!0V+]SQX.-R
M;?*Q Z)R=0"^6&IMD"^5?-R<#7=AE,17@90:/*X7Y2 ON?-@SV)F-;L-"$_E
M:(_%T(KW(NW(J?8LZ9Y#>V6D_@!T5"8 9J5?[KQ8@08Z[_N;)UZYBR"DM=5;
MXT$Z!+<W<:&+;IW BV1#+JZYE_-*0<$NK,\+GMZ5XR0ROI\P(^[=5L;%!VJM
MA"6)&3F7CLI,!TIZ=.>( ]NBH_U5+$FTS3(IX.,J!QAT;;'G-$/V0OOD*%#+
MCC;UD -[-K#1>ZHJ@PR> 4"Z(WX<#U]OGJM6\I@>[,46UJ'"=!JJ9<.+D$'E
M]GO:SY?&KS:-4NN*O-?'SZV90^7WL6CUA7<HNFJ+PW+J-!P7S2C&+Y-S82DL
M@A4X>X@Z'D[C+5K16]Q84"L]OKZ\;2*P?HGQV2R6%<..M_'-5:6XR8FSZC)7
MLP#_K6!>6*?C-Y19F>W+)#CI8X8D,"A@.T.E==)/9?0!7(W&Q3L_6,[J3?<M
M/#LG,",CHB]^0?#SFS-PNT_??#BS_O6OZB.$Z 9?^^+SV5MPU1,,!ER<_>]7
M#A,01)QB!OCSYZ^?R%E/&&[X[OS+V=O+P;O3CZ<_GUTX_.3[+[]^Q ]\.?MP
MRFC'7^D-;[Z<G;[]1?#? 9[]R]G/IU_>?2!T^GOZ[*=?+\_?GO%GSP:??[VX
M.&<H.O[JXBL\1MZ*4_[U$@&6%Y>GG]YU@"OAS[_@KVUHXP+&C$$/W%L,5"
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M#:KK-4WGA/C%@0*M3#8=SO%9*MG7Z)5,L&+_J)P<S<K1-X-T%#6[%Y14I2@
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M"67&X"%3_ .[-T<J='>LJW[:WA76E5?4Z&I8^TK95M;,Z3:JJ' 9C7=L/_.
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M4+T><:4)B\/W!W&O<SJ,1J?]BXO!L#<,N_VSD>KT!J..ZI_TNFKT=^_@69)
M6[DKK>Y8.+B+<V2DNR/WW=XI.,,-RG +9' 9Z,L_ZA6EHRV),&]X3U"HU0GG
M*-B @.%D7L8;E7BF'P+>L,*SC@2$K#N?B=Y3?_[3R@*6Q@&OYX O&@?<..#-
M'7#5/&YRJR"]1< ,HWE0A?0.4JQJFD67\I<KP%:.U?(R3E T\*6K8G- G/ -
M>#B':LP2BYVDQSSZB_[1R?D93$"N^YF'\F&>FR.<F^,\K#[K]8\N3NH?GQQU
M:I\]4[/'V&7JMIZ8;*J2]P?=@]*=D)>GTT50N@X2KHFLS$TZ/5BUR/T=NKQZ
M!K9U0Y_^D^^YW!67S;)(P[?]/I# A-&0O?<E;M'AMR!ZZYU?9?AG\,N1PUE9
M!T_9_PG_34WXB*4PH+:6NZIYWKO>XZD1==^2AKY]T]7_KM"&BF%YS3;C><A?
M?/ZIL2'_APU1>J7^FK\&ZR%CV?\^.S;#&@V/J< XXQA#K#5WX^MH2;,56VN1
MSNJ)5YNMV/YLQ=8_@CHW1U#;VKYMM+5[*=KB%\6;.,.DV.?%?3R(;9'9!E9K
MVUWFK@;7:(D?8:&^$43#K8+$8]WX=C6&#QN-X=<D?7CW<_JP%M7X"Q1&L[*[
M\X%/==+?Z]P;U[0_KNE%N9D=G2T]:E=W9I%6<0)5E* 20I[W,-7F2.]^QNJ-
MG7J]=JJQ19M&47L?V=1%<ELRFVN_M5LHR)^(^9O, 8LWYJ*3D* ?IF D1GA>
M]Z05A%KZ T*1>C+:P9X>XE5D=A<3+<6AP-G$539P^3Y1)!'&.S4U#]7M!\!%
MI[-(2_0\&R\M@M@E':^>$3=^L_&;6_.;QX,T7.H?]_ED_.-_4$L#!!0    (
M +1^85)OWI[S(P,  "8-   9    :6YO+3$R,S$R,#(P>#$P:V5X,C$Q+FAT
M;=5776_:,!1]WZ_P,DW=I":.0P(EI$@,D,I&H6KIJCU-#C9@-8DCQT#IKY^3
MD):60NE*U8V'*.'>>WSN9VZ\CZU^<_#KK TF,@S V>6W;J<)-!W"JU(3PM:@
M!4X&IUU@&R8" X&CA$G&(QQ V.YI0)M(&;L0SN=S8UXRN!C#P3E,H6P8<)Y0
M@TBBU;WT'W6EF-0_>!]U';3X<!K22(*AH%A2 J8)B\;@BM#D&NCZ4JO)XX5@
MXXD$EFDA<,7%-9OA7"Z9#&B]P/%@_NS![!#/YV11]PB; 4:.-4:/JLX1*ATA
MXHSLLH_\H6-7J3FR2R9U"+)^(T42*O7<)I&+@!YK(8OT"4W/=RM6+&MS1N3$
M1:;Y6<OTZMZ(1U(=)I1Q?IMCK"%)>B-U'+!QY&;^:+EI(1[R@ OWDYG]:JE$
M'^&0!0OW8,!"FH >G8-S'N+HX#!1.= 3*M@H5TS8+56<%+WL<;[DJW "%M&"
M/[)2TNV;"?.9BB8R$'A(>=5M+,;*<\ECMZI@5[@/5:2I>"?RG5[_9Z</SDX:
MYZ>-9OMRT&DVNA>'H--K&IN=^5?87TS]A!&&!5.8+V;[1(VM)\SG4O+0=12?
ME10Z&U(HL1_0 L'G@E"AJV $.$ZH6]S4"$OB "]<%F4N94:U&162#7&PA%2G
MW+>&8>;M(15?20K\I=C(1%"2=5G9,>PRVB@VC<VR;; (&952^:]@M\N<JK5_
MLA6CBBIO0M;>R1)F61.%0E' =IP.+&6HRB*)<72LE;1")\:$J,GMF@!E6L49
M_XWJTN?G;*SX)K5:;:6 CN3C7LA[4-O>GOL>017#>6X&F0]FT +T<$B_H*^/
M7ENOB')YEXCEPV=CS-XE*-^G@B6$#=.U!O 1Z(LQCM@M3I_OPK/?FEI.VW0Z
M*R.0\( 14+CZ%@57@.HI0CH3K;NW HN(2HJK5_=?EFMO1OO)!'0B/F,<-!*&
M#T&WV]Q?3;XPXOO">>?"WS'L%WPJ)^ '5_OWJ\H<9CO!RE:R;6/999M9W;AC
MGG]ON((&JB-G=&T'O\],5NSFO0GV57JF<MWDF;5]><V_(+)OF?H?4$L#!!0
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MTB9*VPK'$6<:K0)*2J,3$/C:LAT$A0!$6?#\$PO@\"BI4"P"1&D21L2U@-R
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M87V70WB$J"O=^I!';H=6G^&NJK\U>_8_4$L#!!0    ( +1^85+C9G?9=@4
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M=U2T/J9SH+-QU+6]C6/?U-JVO8/6TZAM/TBM8QQ1. .<*B&IWM0:M4J@+(3
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M8CT0),6:CZW=-%^74^'T:Q$\@9J:J761>RZGRV=Q56XN[8_^!5!+ P04
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MJ51KFQ2,#,U #*DX![%F]>RH9CB-H:C]&*;N-P^TK<VTKM8J>C!$)3.VIK%
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M;,A[L90CIAI\<Z.:%3LJBPE/:'[\B [D?EL)^?>X]A<7UY[-965TU[ZT=^.
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M]'BR[-5I[DQY\GK"1W3PGD-GG[BXIKA,YE*7L_E6NELN1@SV3K6Q H12)&:
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MH,3D-.2.-HP N\$9I'60:1A6;Y24SJ%4]FP2!=5(A2@EL-6G +59:F4$LG\
MYFA#JVRYMA)\Y9H$;/"9Q:70O-4'8'D,*Z0[<S14<[092D>C^KYRL;U<'AC
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M@ J$XDD#A!"=)T,@UH]AL6?H_+U2F:N;VM?C G% '[P#YHS%LPMJAV.R'MR
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M9B;KP;&WF0L[;-!;1QIJ-CB2"-&X$D=$Z&WAT<5YB4N;P!P KWUK64/?Q#%
M9:^".D?3*UM4DQE&,-OY:*D_O9^SVB9]OSU:SNI'%<@?Z?V0Q8T'<VDRGPNO
M#AE+Q,/@7'*I,7DH5<AGK!BSR](*QS;\#>Y#!&B-V]FY>9\)H3&4WGFI4&:?
M!$"HI-S.ZH_$LS2CZ,T.J2]5L/'S\W[BGC=K,(PHA#E5R9YZ3FHAST[#KP0<
M<RZ>M@O6&[/#P]ET:\',&6(+D:MX!N\88XR I=M02A7IM(]H..TC:L* K>E1
M64QXHE'L(SJ0<V!V =-?7+PKG[<N!34D!O7>H.&S>X/JH6M9'B!CV:B=!W8.
M6H*BIJ'FS(F*.A/O/EIF,G['H,$RZ,L6F(Q?4R*I$V=RT_^"A48U.[4]!9$@
M6N/QM&?*H(FS3@S715>-S&;S+^+LURK[<X3XFL)U)-9!!5=< +90L(3F(C9.
M8+'*J4F!L\G?8-U@F?''&-V37Z^&58'/GV@-&H"LP:JXXE/ I-H4,HBW.6&/
M0A#98HJI;(^RN1(DVHRXB4!2(3/8%B"C1JW)6C&8;;$V_:;0_,Y'#=%'#4#A
M$+9D4F^H ^ -4\/L8E2Z%%33-()68U>7/1<R=]E! C2J=J,#%R(E$G!H$)P+
M&HN/*#=OYYPVE9@GWL64T::H9H5B)*Y1BLT93$N2QV!5KBAW+F8])&:I$CA(
MU=!(0JDNNQ2ME-R:JN'5>DC48&FPF3*],=$].I0/5AW[5[ZS:D\[>2W]_0M=
M^XBKZ&,=A1LLNV"<RD1C,A!6E!QJ3BV(32"QGLYIV.$6N=HT&!_;U*_9&Q&(
MHD174#58%$=&$B7DRF3UE1$8R@& L;ZF:[&DY@PFZ?H'$6+$(&BRT[B\V!%)
MG\V@LGGAD9AK ^SULCR8/C_G>[5KT7BF)I_M2,>326,<3X04K65KBT50ST^8
M+$;)T2?V0F'LX^G"4=G\>/+L4^1L6!H"D?0.O)Y-*K%O?$\?+Z$-&4+%:G8H
M[_3UW5FE\WEDMPY?'<R.93O; !0GP6>-Y5,"#@5C; *U"3>;*OG3$J?VM,3I
M#L<_G_7%S\;QX\2EKRFT[IN!4C'J7V!4-^9 EBF;TMA'P-.E@U,<\P['SYJ]
M_UP<\]IP! PZ!$MH#0222Y2S3Q53(R@<#6V+73T[Z*$LA.;U^36]9?):#F:K
M[KZWWKS2JVVEP8VF!F/$6?2D8%.6S,%++DQ.AZ]LB\$= ,";L<0AYM@Q#;'Z
MW@0RJR:BDJTGPTV"V19+/ 2 -V*B6VW%EY)JBZPQ9$.3:NU-K[!9D^.8>A1^
M%L _RE3F=*#X7N/#R72R6,ZIAS9;;*2AF=)'L"IBAFPJ^EY"B<6">F&#N&U&
M>J,0;\9,HP*97?!!O._KVQE,R5# )>O(!-HV,[U9B#=BJ*L/.7E55N@JA!S4
M4/L4HS,QF9K:".H+7?N5YOS;;7WJ<I?S25V>[MCX:3I9+AX^^FDLLW_1^T#B
M4@(+QD0===1$4L::6%\9_B:HX<"RQJU/Q+54A[$8\.#ZG&Q#-K6TWA>R)_R,
M1]9L&I_-"Y@,D"J[@-#+IP.2M=(SUB/W,BNG>V3&(6"&!.:&I JCCSK@K(H5
MH&:S<^@IEE()':8Q=53XT[F]>[/I-D^WDZ/@D'RI'M7M5331<P,7K"NA8!W1
MN!P.E)L9E::%ULB(C5*!:R73G$NAANQ=BR%O2P!QN5!N)%"(9+$W)!4R#AJV
MW+)C': IV>R]'T&YP,TB>#$M8JF:4J/!:!F2)"I1_](AEI/>/%-&Y/4>/:>Y
M7*>%\(W980^W5^"L7EU<.UH^G\TG;X5_FK+,5V+F_JJ024\=6%P_OO5&YG6R
MD%75D@\*4W=45T_OMW.'+.Y/M])U1H*F]CMG(P4X"39TA$V:;=7X0L,?I%M
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M7<P7, 98 6#(,*B"AA]!%?A701E*OM9DU^:,LQ1W'=;3A^V(DAEUBD9J@>>
M1/P%T !=)VRT_HMR9-@TNE@NF.P\21&4T$_W+\U7<<D.\)UN-)\DB_'DFRD
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M@HQ#A1?( Z]'S.4 A>^P5Y+\M6> 1D#Z"0TQ_^8MR\I#(O  4E,,@P27##
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MA%X.)$-!()0#X2/]H*7P;V9#H/$BFVA!E-S>29@<49B;S,1(RRDYY)$6 9<
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MB.(+0#<1WBVUXT3682T5-* ^;;DP$]538!]<+*T"6[QP<4-VF76O-*+F 2R
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M948+Y2:$,%A*(]97WR6;&P./B4378QB#E':BIH4 3+>@?_.TU/ZD;"9763I
M.RA2$#I2^U[ 6\A(%JHU7Q?6,O50U16S!;"288@:4\47U6NPX,9GC29#TY)6
M>%C6@[?#L\/R](3:@$RP"-"7"4.RBS#9:_.R*0""L,-I0N&%F"M0RFX274\H
MV'B>AB"M1:&:N^<R7WP*^<O1)#9]+-*N"^+Y":HSLOKF'%DKV1]&O=$6Z9]1
MI(N %B#2S0<Z5<_T;(;E@D2X^FUEI(("I<S"TRV%7@[35@) ]\FFY:5N[8;-
M<(N/LKL]1[DA ,C%O 1@SX0+=]O.,SJ=YJ+()\7E*)G&R"J&J:AI@MTC2S(/
MTU)7[@4<@"V\YYK5_M<_#*?U0CNJJ02Q $ZL3B\#U"W#D;()C["*1,#Q(=&L
M&^1DD(9C69VX\D427J*FB!*F@!"_D,"+_%PPH\"<A#-4PQZMT&\O/7O;0\]*
M-)VC)J7UBGRCDR*#>K.$+:WIU(ZM#"-K=^H2J4*%2BO,_>!*Z:0">D6F&%KH
MJ:N+*(TMVX*H! =9ZU@IB1G0]#4O; L[3854V<3?%!7>+6HBN>J(FO-A-?P-
MQ_K0^MSAJ#*LIZ09K2N&AXVFM0CM):0-2MWCH!**<U@V+1=6ISRE\&YOOJ==
M /-1"[#1U4>/4BEJJ;1@U1 G/,DI'[/4%YHMG'^J+Q9.24_+;81AI72A:.$T
MQW:;:]+W2E:G7"<'O2G7P+_!5K/%YY]OS_E74JA;[!!V?P4>?LZ5^L_%:<S=
MK)LDSKMHJS"V+S))B F:P5%&J9N422Q4IGLJ<19Q<?B%[60UGNA6!1SV*A:;
M.]_/Z_QG8MW2TKJA/20HOGK+&5J6R!"@"ON#5I6%)?\8JG/DA*59B/0]Q&$X
MG 3;.\34=-/C:9S;O(K.MLC'=&$GS\_MYJL$?&MVO5SB-84"J-/UG(71<_A?
M6<]0]I#1=L_JCYQVG(A6? ]E)68KD?>^\A<2S:G>?J*E23G&7KA*JK1;#F,4
MUL0,$T0IHY94ENUJL2[C;;<ALKYH3^>5XR3*SFIT5%#+&9X'V9=3'D0AF2(A
M0E0#J;C0HU(<<Y!XQ-)F:3@5"2 P@OWVK&[/2MLY81#3<U.W"E0HEPZH6/Z!
MRY*!F*)+9Y-EA)&HWFJZRNI>U[63).4E9ZO:-?YY!A,7==9+U5UCF"W6[H1-
MSN-<99HZG?+OCKAW<&>K!^]N?E-8/7*EHR5=\_GNJ:,F_044.2&R_:FRMB 1
MO21+5VKL[J!+^8.,-<^XC'*JQ*^ORY5($W>!7MI2RH317),U(6H,K\N5D&_8
M4_(J)?^5=)'RW87MY"]FCOPE\K7)T+TY<"0=K!@#6"KA( _M>K D,AY%^ !%
M+KI%#^'\'36,X1)+"N= QK7)8D.9=J D1FT]RZ&( IY&?'&-MX=U7A^\U0WS
M4$4:5 /KRBF>JKA-)>U3?A^M%U0.1>5QYX)+N3_QG!7#I//GIZ'H6"7;"(#P
M(2L:13=@S(:L<!+1?",9]8A/Y4RN(M-P\3*. 6K%:N$Z[BOF?+>*.=44-B+*
M(ID^*\JVR_3B"CGMG%!"^A*A NOH3X2HE _VJE(^1W=H##(]Q3J:Y)U0')"7
MPS2P O,<3JKH$ /ZO]%JO*!X(*JN(ZK$R(!%D=XU#;TT2=(QY2/)DJ&N=*(0
M"UUYV93H"JU<PI:U)EE/9?U)XSC,%F8% X7#2%42&R]@&EA[\IK[](/Q@BJC
MLG1>S2:_%<V 1+$%T3@22&"I3 C5B%P IGR*V6'%_2+4.14!(A1:MQ#U"&4#
MPMVCHWVQD+_%@![.7*SD^",NKNA2PDZ+S7)74$I=>XUBE[!EZ%.X+&JL(JDQ
M27DAT%3%7I49P%+9_8B#U):1#+4BDA&(3L;C^ LD_@C?@N%'(.OT/+"/JCWE
M+=_8G.6?$6I9'D.!096D"J[-Q+QE*>4-%]A,!H+E![P<!T8)#L241%^&9$^7
M?X<N9=5%F>59JB4GHD*+^+YKKB]FBD=F5&*NC)A$J*.*D5$592A.O[2=HD2-
M_)F$P^XQPM<H 9DW47.GTR=8/1:*@X_<*;))QR+E"!0)3S.1+Y#,L88>!KMA
M->*L4I2SD#+%*J\N,L66%TN=+R\=$12!^:C\:DW8_7GYR^=%+G=>TNDN0W/Y
M7#0G\))QC(@I/P PC4#/2ZV*=MDE%9)X^SC%%)Y*50ADLQ*]% 6D\E)1"L80
MS6 @O_R8P"(K)2;JVD!&8*_TO"S9)TI535;!(CEH]L3S1"! "DO9/%Q5Y2)9
M*4]KA5_&:X.B)4(N<E20#[P9O$>5V2?+)T%6^!+=N=K("J./:=<)+BQBRNX2
M!2OGTKM1+I.YIJ)8A:5+%7PN,TB O6O=C+($4 &I2>/8GH+^,@5YB8RD%ULG
M*HXBBZ'X4-+7$I%K%J'34F57*8DDV4@V"8.Y8APE]N*GI=^):- 1MIP1GT![
M,+I"UZ2N83VI6%;)0@'(L<8[)V<L[+6WW^N_9K-0< "+7*.)"SL,%@%BE(V0
MAF-EBU2W9Y3(YB?PCYROH \;>$525@%$O]49PX!XZGN^>P9WM&WLF<F3$!AI
M5,#'8;BJSA[3UEE4!0@(YZ*4.V:@)506>E04@";S96%4G>=6-(H4(W.(E_A)
M+.(LL$6F[+>9E2.-,0"RICJ!()>3G^;Q!!&.KR[E%M*(,\IOR<\!?B@%[3G#
M!A 1\$0X)B\DW=\9GV*18HR%<YY"W"I&7@6@A,FIDF[/,Z77KXA-RB$23G^)
M#Y4):2:F4,K$EC@R+]53[LJ#K!Y'!"\0 Y6J@NATJK EC7["%$M.*/\ETDJ+
MF\/6O#,I/"/*$,I>.I6"==\:V+)=+*)2V)X(O=0RB?*G6&Z@!/+$-,IX7FT^
M(*I+BF3.B)<;>DK_0N6-59PGC9$R/EWD]4HS)X\!)26Q="ZA$R LLJ;("(/;
MBIGGB>CN@!U/=F\3'FAY0892&11#YY5BL\496C$WR9;.M=64L+F(=ZZMV*/*
MI=8#D;ZX$EN6=PJNGH0U#:"TBQFVD0VIC$<1;1EP"NROW2\Y?\4<H/9NY !M
M:'4*,V=$P;?A7.90EW//1=,!Q77)0DP1^O (56\1'93NEI!0VF!1%>"\'"GU
MX+,5VRU%=XKR%I)#"HNU!_)4_$ *HT^1@2@ D]N_B!^_M\?[&T,7]F[6)UW.
M(F9TE(O,GT!\?;U#3MF9^-4..81 1$.6*"'/"C!&(>ZQ ,X]M:WWI/ID$0'[
M*O)/&5[QHSH1C29ILAA/1.GMW(.EGB?%=3&;LVN^+I(C#^&A\E)%%JA1@[7"
M>J5^I8@$*4Q4ST+&1K**4HR)347&@(AOR.-("DT.QPQCS17>U7%B30JA=_IE
MST)A@4]<V"(IDJDT<]6*7RWK0]$&<-5;2@-L5BZRO)3ZZIV0I)WCS]U27;U\
MT5E>8+!:H$=6[B/K=+5D7SE*!<M:J*H60O^F<A=%>3>L@*&Z3@M/.57BJCI0
M,%=@7B2/U+57G*I J2I-Z\:M2B[!6*=PPK&Z'B:LH!)*YM=2@'/N?"UWY:.J
M4_0.62R$BM'/1:O@HJCQG3AZ52=;&C-\U:Z72@SQTFOSU)Y2BIE*CA"Y9RO6
MYAE;HO&E;&\NMU6XS]2 KBK1XQ@C'*K'3>;;R(4A2V<I>"]0YJE*6[+\#(@>
M*:4 ]B2.ENO">G;N('R0Z'VV +Z948\70":5" TL%J/", MFHOC1';*H\(M]
MJ,43>O\*^"C0W1Z /!T *0MN1G;AU9)VDO,K(:$==.'T)K):WW+&M>:A,&F7
M@T&K&[C?MB</RTTT*K"'*$B4,F5:T<E9"E.51QJN"V&0^ N'0S&IJI?SC0B[
MP=!3XO48VQVJAN\P,5_J73G"TU5=.VIS*8,V<_,*D!8V@Q:U%C![&DMU4*Y?
M3BXJ&*1*9MC[O!3VYZHX#C<JP*-PHLJP44HPY1G\!GLH+)RNQ!!AR<DG+??E
MP5+/;%4D0I8J0XM3.5,6OT!)KSS]?<HPQCXFIX&PC[*M[TUSKQ0LMP/=G]"G
M.Z&E> ,,^X#[@(0P?K-&;=GU(B=VRH&:9>BS.!/*A%'EHB63"6DMPMV&:@NF
M&&-YU%!4&B;0+5/YBNX4)0PJ_76W*Y&NXI@I5D'9XA''TF^ENA64YE'X^&IK
MDH=DQB]I4]N9VO.MALY)$HI0PY$P,LE2T7D.>&ZZV\K9/CBWBY5RSGFI1R82
M\RC-MTR;:\0[=JW>LXZ_PSI*@HI:HX4QQ205I=$C5+=J&D>;!2N:6^:J: SJ
M&>" =*YC:5LL/4[=E8$G<!;G<6WX-$_%+24_O11]B8MUU67L (I7E'+C(L55
MN?Y%46X4B]F\:#,(5Y*I"#E?4>WO#X3GR"'SJ%])@6)F>;0=H_  KZA X:5<
MC2A/-\M'X49)X@/#Y6Q:UR[HWI4T]_P9_ +520TH_!]4?@%$).];T;WSYQ7
MH0+O&?DV5>WUDB&;5'(RMB%CA >$?BVGF'>SHVX'914;?;68'J,2L-TPF4U8
M.F4>?9U2M;F?VZ2TO*LWNL<SD80$2[D_C7_C-.J%OKD2A9I4:?0VC"(1^#-%
MU"RC2[*YI)Y<#'._O,5D??6I]+0PKF$Y%<*^JX:M6BG4XKX[)#E+)<U/%V.L
M#IS$E&M.IJ^B\E^U,OGZ_%%I=LUA>#ET$MF'8!XR0*/$0\C,N^:<W=/[$T,1
M !DM,LER"&!L)UAXN#1Z44:AE)PD"HX_CNM5/%[E=@M+Q9<+I$AJCA8OIJYH
M'[(2HDR!Z7E*G2CU@$/)7RB9)/9JD'U6*+8+*S%BKXB[K2)RI%.4:;F AVLK
M?KG:ZF,B^D.:4G'DP G$\"O=6\9P*28+)&%9'\W#(NA*A6?)/!!*(!=!9.]B
M*K@G#F)-S"4LUV57U0%\'G",",BKTF+=I:)!!Y7.SDH2(!4M)12@+;I'3T'O
MA-U1EE\\$442FJHJ<,<D2Q4.2FN4[P+M$K[$14P><6$4SJO'$?!"FPQ=R[T>
M*^\O\2+UWI\CJ.#T1ZJAWS2V;99GWQIJH%I9JR)5!'S^6GNI+2G#H"J7@^@+
MPO$BE<JO=)+N\=!3&38T\8ER)8O*DHM,BFQ%K!T,3@[+#)"J/<S+Y1R*AP2[
M_#U;N-X"X#6GR"M%J0>#WF%=DJ^RM-R6:\E4=K^(S[J!946#J5^KAI^*$-.C
M14HY1,>@/)0JW*+4.2,)AI\Y\(Y/S@[SNORB6Q*5P KO210KE"$TP_IJ!:>,
MJA;B;\7@M7?UB[KV&@= H98 Y+1N5:@>O.YU#\52J>1ZZ:'=D_C3VN[NW]#=
M8Y%[@?H#!*J^2>*].+OKTW,1!!,FS@L"EMHJ>9+?54N8";6 .LJ4>7?I4*S&
MEZ]DF8C>3'Y1+)R"OX79N:YUHZA<*$FR+8IU4@-)1$<;58DN$65\E1FJE&R3
MI'Y$$4PIQ@NE8TY@68Q4B*;*!1=;YDF%2MJ^*WH(3E[BAPE(!!0,('ZNA&]H
MRJX5NY4,'+ANL(AD-\DLJ_J I"M4K-EJ\0JX,9E.$W+=%:FK(O0+RRRQ-&5+
M86C@7!@49/G[:671BOH/U7HT:.I7F?#SPE:=JPA;R;Z^\:P-<6S'!>4J+$M;
MTRM2&?:)!J5%<W8CT6"+Y.:'DBE%]'<3F0:J:D7!-P>] I_F+)A%B/CVH.SO
MV&&ML[J"YM%20&U::^E@Q= YLIC$22DHU=*FT\(?(,/4!"^L5:)=!B=%- 7:
M=<9HAN$SC)9%4;4B*O/>ADH$JL:FU&0MDQ(BV^/PO[OE*]'F.Q=2@>*?!#+E
M)DR5R";UKB=-DB-J+*F=<^43Z(HFTP<]H)M#T?MWG')!IUA34T*Y5 9+5]+U
MB$H!5?#40T?!76Z$QMJ<*C7K[.)L3YK?OJ^P>[A\>8+U/YVZ86- 5"3% $!4
MS'.$W2)FD "$G"$ QEQF=!:6T]4HCK\F\3&:L25"U:DS>)G/R: ,-V64WXH)
M:WL&\[<8S,69*MU%_CN7YT8<BI*IVESD^:KXT$K^EJ(C,A*'7M0KEOZ^C/S
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M49?J^]$!HR1%.'5(-M2K#N6DEZ2RMHPH,K,F1[N.P3W+:MEG] G+[/M)> 4
MIBCJ2A%%^2B$<"^U]U =-#! 52'RU8+]I08@>$+J&BQZ/H'R.%2E #J$E%TA
MVW"6HYM6QB)=V6H<!Y1I$%+V G5JN@8P#^^7UP]5F8*(B]&$*=U!&KN,$LAW
ML3PT&/1*Z0Q$]P/)),4Q TH0L:R5IG0SS*K(XV]!,L5 [*6V)I(Z:E2&578[
ME?&M*6D=DJ"-I@Z$#K^!E,4.2#(W555 82(**O_ .*'0K)EB.W;^+!"** EY
M6!.1O\@#J29S59 D9).@OJAU[91R_V5(6;88CS'O!><O@W@Q$J$4I!T&\M6A
M8$9,)NK%I,IA6#C_' HM*:]+>:>71:G35KX*HI4+M8+12]405W)\BCOA^Y*P
M@1'E-25@82<$($MTG^25C ]$P^G*8N2C+ _J\$Z+P0S3$.<P,TD8>55W7Z8I
M82(DEEPI=Q$K!<S+P8B <36>:KG!E:AIRDT6I1$U9+;^,S5S$2;R#":F?A)Q
M+3(TIM1#5^VC*AQ2GG@EG2%G@'GK9\7;=DY>K&R<T"\P3V6<B/2^5=XNO=G,
M1^EPPR7\I=7G:4U6X&3(6;2C[KD^JG2-0@F3&RZ4#RO/@9"FO2G,9"Y3ND3J
MFD:Q.C*R2%*+R 803I'R'M359_,1B]0QT7H1TV+8E.$NRKHF-9$,()@6\9%7
MX@.YN'H7!\0 J"&2K XCWHGQ ")!,LL23S2)($JJ -%2=CE"52Z3P4I0L$BT
MQ&@GX>K+DBCT!<&*I'2\J50CI_0%;SE/KA'.86_62L/#LC2GJ*8[R>ZYT\+G
MP QDLU ,*ZW=L\5%L41<YII&&1CKM:&:*H68%?!R5 :8; V\S-'C2L'?LABJ
M0%"BF9%J??4 %)7?4J5G%>1<250BE"DJ"0AW6R5&6.1-1:*'7:!:FN2S4#4S
MYLE*A2,L0!LMJR58:^4F\D5G/#2"8\;GA D>A8-$V;-SK&6$!OTI-@3^PDMQ
MWFFY5J:HDX1+5K6=A+%D2MJ2LU22M*0(4,\$^D\U$A!"6YR1)*C"G%HEHUT)
M8I"WL.;E [2(YW#RT%57YNS2'Z2$$9P;%JV31=)&4Q$$4L;<+?F_<[OX 0/S
M^379=\4.K:GT2_OS_+%SFZ$N&(_UB ?SYU9K9;:Z8=3-S<V7=KBU04-(=7G:
M,NYM)-C@_4VCA>U$I#,#6/WO@HLR/@\U!7NQW['OMV.]A""_SV=<V,"5P*G6
MX<XM'H_>C*UA#5NV\/C(LY==)1**:/<'!F@$=J?M?T^CYB8MJE5IN#_MW_&T
M'RO#HLP!7NTY26BE CJ*U.W1:@4/--9BL2E9:4LU015]B6 FVL%4=$Y5KS_<
M,X\G81Z29ZN.'LEG-%W%0<0 QL[+"YY10<[]HC\)QTX+_ ZGH=RS3^A2=UOV
M5:RV=WK_W0^R?\5TC\XNIGMLZ) 839A&#PN^DGT"PSW/)FA2-EU1!Q9H[_WQ
M?W0+)EQ#%.TM,M39J9.#4/_S=D5%*;W</44Q,@1/J"U.21@HHV^>L34JU3Z2
MMJO<\E]Q3]:UKH<Y</#&:%E4_2AEJ<S"&5>%,.ZO1/+59BX;#T!Y,-Q$-1LX
M*97(>U0&V!92H0".Z"7#O9X+ZBIL*:+ "7K)%YD*2I:E559KY1:QQ3,1#Y;5
MA,4*'A-QSZ*TYOK^)$&"#8:4B8W&\HU9SROL+YP"U:?>_ST+XT3'0%+#M(Q/
M8[M^-1L_P[K>]URI<F^SX\P^OY"?DXQY36@##4!<EERJY=BSS\C2OGGL]Y/%
M.DZW_<%9BH?EM<5&F(2BXCO?G+W72Q;MLY07W7;?<BSQ]-CR(%N3*'H*Q'$3
MPMN1YQ6A:8^9AK4MJ8@DG&!O1%Q'QC\OT+VKDV%^&LZIH$5)<U#F'NG<*O>W
MI]@+D!_7VL&;\T,JUX?5FV5 !2@AHJ(SNL-)I,T3%>>QR+O!:5BE4!3A!^R
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MNP7*7(KS3,F=!F_GDMO_S_G)C\]?)Z_['_K"KMI33@*DLO/?EOG$>C]'K!+
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MLUGQEIY0^]HBS<<U_= 6.BLGA0-,20NRJ51&Q2WN=%;<UO-E1<XIC=106@B
M@+RE>7E3C 5QU7E^\>K-#FU: 7>QYLNDRB?=Y&+.S(X",F!3X388,+\^W:CK
MVHNSC!_)6- BKB4;9Q0I+Y6U8RWKR,Y1'!(V3Y'CSU\[1G%YW9\&=/2'J58_
M<MJ%@NI:VZLSE -3!L.&F_85[=I&DO?3F*U#B/WN'7Q_<+SCL*7ZBB&&EW-<
M=R=JO9  V7=RZ410P60D<F%YLI>*.!<TD\MC=)?X!?T:?NQ$WC$Y,Y91V;@=
M>M+9^^VD;OX'@,P2TP6N>?/"]EEY;S'B>K%!(&<TDG%\E!RTRI^EDXO3-SO&
M:J!'2K5K HP@?E2/E>54H&9 )Y4^3H:-5Y#&"6/_ASJIG%BR>KK7!'*;/(@4
ME52E*,G@C9<S>0_+4 69AE &APUZ/WES25];L"8!;B*FN1"X,.Q\.:I!*^OU
M8J.M&Y!>);QQ;.Z8:P&P3;XTZ O5%C)EW T$9%6&EKV4FQX6+;AU>ESJ[&!:
MPQEU;L.:87N.<:QZ#'O-*L8Z=(X/G[ Q";#Q,T$FK>62:!E^R;*/R=&P@6QO
M\2*:@SHZ(M.U?_3]X2#^M='*)]=">6'IUA%5-$6Q"PA#A8WC4X697+^EX&%M
MNJ;&9<$OMY4;2%E]UZ!LJ4^M;A(OY8WQ5MRB<\?:A)E27&<,ONZ\/3\]]WS^
M#>QG\(3.Z;OS';]-74AH,9!XCX;)8#^-6T1FY60Y13L1/>'L_^WM[5+T].*G
M]WO)-+]BG9J4XI&"_(B%2C+0-]B<9=6.:@9L1 ,E'8?]"+4Y@M0P12-F VDS
MD$%,U_V!I#,[???V=$?94FD^ D2FR66:W7/OS>P_[J7Q$;QFT]AV>#8N5L5I
M63S"4KZB44*=JIJE[)C;\E)B MX;<+-DEUBL\H@AB3 DQX\8DB]-]+*@8C,I
MG]?-!#ZD(\GMGY0S"+=UX7!/2Q4EBXV&\GD+69Q<>\TB&':Y8"(<-INL2./>
M-)/M5*B]."+[=#C$^3SU=4I8M5!4P2ERYBPP@Y)K*HUG%>YULZOTQ"C3$,N(
MC+P./0TQ[!FU=(.[HLKE M*:M7:-I9H;H!D;JPQ*CT:=DKF&QPHJSG1\3:[E
MLFJ\,5-/0S-S1I<(1^7)Z8XK8XWH>Q.VV[UZ.5?@H#HNKGYA/YY"^5C^D^Z
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MX4QT]"YLV'%VZ=@Q+3Q7CI;318X:^J@L:Q6L1>E($O%BYR13\ A.#,&)P^T
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MZD#:3I?/V:5U]1AW!2.8UO9B(0*O6:9RG6A<)!>XR,52'FA?DIIK%G1W1D[
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M&_CC(<%8ZQR'U2OA=+@&\T:+*+Q!^Z).),<4SK$9CWPA7#C=$/6<+A953I&
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MT0XN50EX& )LCOM-%F@'(+^/GHA0-T *[@(G\DD>6<*(S3D:O>_0E"KXUE?
M[[<VRY<'DGF\F;!I4-'4?%S0U>& VIL++6.6OF(_3$LI(=W#W3450Z*]K;/E
MI*2M!I@Z.;=T\LI:CO[%(D7YIQRCM9S^E:Z3;=?%\BI7?/.&1YGID 1RQ<P>
MF+&*G(B:3BAH.;W01? ]IC2\0=/X%8!>9+FK?G*64D"?_)+12+AU?9:!+-!"
MGU%)5EW.>\4$M>C5*&]\ML?]Y/9-]5DVSR2Y7(J54N)1\W5:KH$[1)N!D )6
M/Z1L2C<<!P7N1'QEZ)&YY,<'K:7EB.&9J0?=70&%5< M1#1=D9=9]**_ ]66
MPC0GY'N57[<N^^R-WU>&8TWENQN1?QVH+IFJ"J3J8[ ?(<X(O3S@JDH& .*_
MY2ST YRY\DZV%+0SS=\YP ANG$@-GL\;W:2V2US]T"MZL%\O8\KYPM4J0-C4
M5_N<;"25&J40R^K.@N16^B7GOC30JO[72)S<E3A=T91-IW J)ME\6J[$*MD:
MM^6*)5'(?<^C3+08I>E262?75:NYGZ:9'35R@655+W..SP#>8( "S"+VE.RG
M &,T7E8AL2EOUI?G'Y W+0(][[SV.TH),GFG2"KCN^&>.=;R%\'.IQ&Y$H)L
M'V>;I0+&O$_RD44I_[]IQKJMM\GV;;(V"W+KH"QU&1@/F8AZ.>III"*<'_+7
M;;-A,Q@PPMR]7\/6#)\_OTSK12\59RJP0FIK_B?_F :[Q?I?)QG[P7*7;RT7
M$IF %]FH6J)]TS%I-LP '\;0X^'CV.[K*+G@YMBP&_(E2!NP=&]SW2KUQ\Q]
MK,=DO<(K*BE?=8CX0@]PS'Q\P4W#/)=:U/H!9DD@%J_@S$_2Y$<V0"_0U:5T
M6@O'S_E7=8]QX-45N:/ANK6,)_!B&2^GAG@#V1;4GG'?Y:[-L9+LE=*A)!77
M>]VUX]X+L]++#O>=7$Q =PJN,W>N1.A9Z$0O>>)*3=BB\?!D=W>(.YT. UFB
MX^'@Z%G]=2]VQH]E[GA-:^WV#Y(9^S_[^/]H]+7@4!)=0DH=R-G@3, 5]+FV
MO)*05;;Q]IVPN^R?6R*].P)_T65):)XO3MY=]$[+#[VAC_&Q^?^<8LU1__@;
M NG]_O!A!]+2G&L$,BJ'F\9)X<#_O D=4YR TS<?SL]Z@Z</O%GW)^%=[R:G
MH>GN)A?+^7PJUDP84$^@7LT\A-L7G1@D-N(F-JF(M&)3-/.\ N.RDMX ,(ND
MRN')G DN:HLCR:[2UP?_F6G>*R"[A^A ^%L(+^KEC&:-L6]DX\O;K]PM(]=_
MW-,YO>3_>W9_Z?*3B05)_S)3_+_QEI_R@L[(%,\DD8Y&Y2;A=1J?(]X">L3\
M"4HZ\!=PB0YWG[F_Y3\/GNW('G33UR<G::*)(=?:P%5/^Z*_)_AZ$*_53S]W
MO/P^GBYK&*F*"S3^YNA&C1G<.NQ YM!?#W7W&AJD3#XA7)4Z.%>8E2(O%%7>
MI_EM2O;D)0C-_EEJ&O(5G:METJDR119QP#V=2I(99J>VZ?F1:U25/,ZFJ!^\
M'L>3 -V[+F;WBG);U@!=\ J W9=MF2@>LL0(^6A<W,HT4=YUM%YX<P4U@6"'
M3/HMO=^"$8)@*UQ\-I?U%NQLO\>";>4G&0VLLU3@3,LY^6PLIK6:J9:D\#9^
MM]??C<KW_83AP9H)L_1CX_M=2Z#Q"DQE,ZC#DT".LN26]RL:UA6V'GYHL'O<
M^"EH!JTX!;><JS^NL"4KQZI'Q'"X:58ORH)%=:9&>BHX.-=%VXUXT9%9NE'2
MHO!\N"98.Q QG? =@RBRA=(;@$FZOBZG$VEM<$>+CE6T^3G9^/^S]Z[=;1Q)
MMNA?P3JGYTQ[K2);I.37]#H?:#W<ZK9LC:2VY]XO=Q6 !%A6H0I3#U+H7W\S
M=D1D1E85*$IMFL0T^D-;)(%ZY",R'COVYB>A NX%%U+4'#T^RZ))XL,N;RHN
M[IT/!BN.0)A$#H5EY#AHL'7L- Z3#:^<\P,1!Z7\U&2.@C2B01)#P3U?@=II
M:O[S65/O?-2R(_%2AK,Q:EQ"H)-EL2X@E4JQ4,YB5*P+9$:8&/4)3&9(L\:#
MJR^'NVL3F#P[DR(38W6]V;JNB.F@>>'=6S^<>>@=4XWW().BMY5\%5N@N! 6
M1;/H-U0]61#..0Q3B+%J;[[6H83@)TS&A.PLC!\5^(NJ]]X*^B&"DHX\T,E\
M=S+\'<UWH<Q&]'3T(7E._"GC:?3&CAF(K0IW(]S'O DPQOO>>6JH9Y2S\DN9
M=I[_EP]%BU(.J6T1V\K1J4P)EZX^P5]HL7;L>GDOC(&P:P +1V^'I^&_B>S
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M@L1A+H5;SY]TWKAP<;XLO37LR5$1=,90G3UR6+KTF?A-UL"XMIW1AXO5V#"
M)*<E9Z;?*_.2?H+%[*MK+E>.]JB]KS6.&=\)0]2U "TCGZFXI,LZ8HOG#L;
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M,V0+_.;A#*=C!+&2>,'%3,Q2HRD^O7Y0O:<G_NBKME+2F::A0/K!W[)5329
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M5&;),_LUWF_H3/E N6)T'?$_I>Z1S>8E%A/^$SUUSMXVQ57.K ,$;".2-_M
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MA+.0N98:<V5Q/'E[Q5A'.X F,BR<[^"#S1+EFX@G8BF"UH44/4,+JI:[<7(
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M"J/QMH%2.59B%"UEA#7\=3;(E3RM*T7FL<[9T"6)\JI]VTLV2:30C"<ST3R
M<Q'O$N@IX^=-*I-HE7O>IP%(PMD&H2Y"N<';0+\224QB1&9NLBX18D+MC&#
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MV]^\#&&/)JNH<2N5^74[X,4<^(\*LU?;Q\)Q0@3C#8U32[E:$81;=J)?_/E
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M1G#?);/JH&+E'.>C=WQX[&:B&A)J$HSYVS U<BA5!F*O_78V ;NAK-DAT4F
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M(;&6LU]TBT[':5Y3;QE!VM!\!IU2"R(>V/+#6R(_W6[$]2!JDRF2OZ6]HOC
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M?^%])I0$YVCPWQ]#ZJ@U;D[:*(N&QMXQT2[Y B)8"HC-9=UT_$L^HCX!VO6
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M[YZ6$.6M[>F"R.WY#S\\?_KNS<7LW,] /$>$MX/=+QCB">7K\&2BL#S]#NW
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M!D"1.0\]1IJ*/B"V8?X@#O-*+8B&/G1&5X)7R<TCH&SX-EB<+BA 'QT<3 ]
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MDPHIC"N*"J(U-&LNBH<DR8W EW3-2DY+T'%#1ATQA#I:YTFOQLQ>DG5)=N2
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M"8W7F#H!:584C,'STJLL;L\^^H#V?!*@A*9%,XLTC.3:^)D(?=.5:?9/TJ8
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M;_F_^ BEW*C0#SB;IM+D%E-Q6?Y91MSQA!$%MRBE^(&DW"HR7(;[3DE-4.9
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MZ8#Z"J$;X=]#E\A,%8::5'.L%F4+U<D3=Y?4#UIVED.W4:*396I8<BA$!A"
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M@Q\AKYZD6'_\\73*1'1PA=E@N!RQ9%4&5BO&M03/,K.:@B[7+GBNV2"$UXA
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MOE*/6[N9S4@#+64ZC[5RHW5E*KW462?%R#,0S%J7>!HX<_Y O+(7H8PM!+1
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M>G]&&R/BXMF0H@Y+(LI%$2",R8B(XUE[,N@^6"AG?J:%^0,WK4"3K9VWIE,
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M!W:(-9A".Y?T>:[<J*1OZ.]I59F'30Q+0(MVKUE*T(*/8D_0IB8&&'ZUZV0
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MP_YDEX"_HDD2Q#"[O?8MYU@KQWK<Y9IP(+>:]3SA=I._!3H"XV3O9NH>9LI
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M\% &UA9\$BCUE;&[!7SJS587/HGE"4J2L%1"Z$#^Q77>#O$-;4P?9!HPTS7
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MT^K_I]Q35K_AM6Q4BD-(_!S1:<Z(PN$<7+V./5-TC,(1JCYS\PT#NGNY.O*
M]B<GY7K@.LF^&G.@3(;P=MZ3C4]NU<&*5WPH#:Q?&#-\5'H,AY@A*^C-FPOB
M5O=>(N$.JI'>-)$GEB9JZFL2]IM5!L&Y^&MMBJJHZ8-U![D3:1LMG@X6AJFL
M;C-2M#;\P 1%Y\AM!6[GG-O5F6.7N'ZX2\MEZ% 1>H)R/05'82=]58D N?_;
M>5U=L1YIC^7<&FAL6Z(\P#[Q6TANE;LS]*?/B(FYI51?C*?]YH+_SYP-%-_U
MR'&)%H&N%<; [TYJG>$\P3341<AA),+O0&&%=QK;2\HN"!1@M:#_U=5""!\,
M'-0PM=/T5RRM>VHCUZ..VLDGWW-N]=Z?^ OM!@7$_^B03""N\$&&B9:/)I!<
MC^U^*S<^)>BDJ73XMMJJ'?H]X]#8+-H^^ %*?Y@LJL:B@H97U'V0J9_O3]ZR
M\^=FU36V4_-F_JK?9"?2\UTGTK]F,'69U47L7X$*-IV&=#XPE9@3*1 FZ(!&
M Z&3D1?G^(NH6J3?=)R5/IR,\9CU7SROL^6N4GEW,SLV?;,0#-HZOPTO*N_J
MP EE50P*$A:NW3&\?0,\&/-UU4E>(^W?YLW$\773K:@RM9N7.VPN6V_HQDC8
M]2C=T!4HX@5VVA&^QMU$W>E$,;.U)3T5?IZL\7=J$TIO:!Q&W1T%-NUFZ)N#
M^U,^EHV.A6I_C?@6[04TFV)13SH,=Y-YAU0D9ZTV>4ZJLX5TI#6!U*O2%@U.
M2,^"",KSR9\KDC;?3<VWZ1*8DW)3@@")'%F)UV?^#%"AMXB+ DXC9,RH'V W
M9W?(!2$H6TFZ0Z$\$#U<NJDE>/71=N&?+/-'6%UGXH0TD22J949ZJ#JN>4;%
M(4'M _3^,T>5,D:Q<'7:7FM7OKS3^2[FUOD(C?,R*\W$G)6*"YC&P#P@%>H%
M5P;<DF:K)PNWK13VU0U9T'F&+!Z1GZ$*C!QB;'**[(N@(1CTY$ZO!]1=1Q&X
M/_F^JRFW2)7#*69P/">YD0:$]B"XX-JNI@[P4 ]+GB=4.4RR-WV.CRZ(J<#/
MC8]A2>N"UH$V+NM3*)M=Z==;T[".[-)E5![Q(3_+NEQ@'(2)M*:;Y4()WC#1
M8A[4G.:VS)*0X6UC!GY43DMH%+TSFE.9IG0NUZ+FF0L"2T'PD'/+8YA/U):D
M5A'@X;$W>1OW[.9!NVF 1@9 !V?A]\E917K FWI_O1UT+'2;U966\:ZJ>I$#
M=TN$=/YY+B%3,5^H"(*_^/E:Q:[/747B?]SU#2@8_9%AX:O,AQ7^80)RF0$!
MUX'$XP$L9.E<TV,1YP8$3U(11,4SJ-HU[2A')HKMQ5G'H..H(&< NB#[H\.^
M:"Y<GMI"K>7Q(*][Y-%^H"L05%8U20'N"^.NW^(7SC_]PDAI$?OG0#BLXUHH
M;G I[%69KOB\NBK9PE4WKXV^6"BQ\KZ-]D1'C@)!E: Y:V,5E'A?9S/1)8&V
MA7RB[WG-C7C"^L2ER0F@LD2!Z;>I.^Y^9@57!DWH5)I&7!7T-:)Z1L"8;6Q'
M''FNCM)?B<1Q^)A#7W^)$O]@U2/0[5>3Q@]G,U\'\4G^?9>R?UW#*=ZK:%^Y
MJ$F;D)$MJ<,(<X@"/=8T_4<4\@4%<<7D?H#6Q'.'<BY%V_7P+T"\8^:(2M7E
MO.WIRQUA+E$<;T*1GR8@ OI1[',:;C80;:>*VNT-Z(,Y<UZ'M6TX/(4_1, @
MX&CT@QV^  ^>4K\-%!;T<RL../I='TYTE/WJ+0AQ')="NMW?$+ <*>P_W2/;
M=V9]N+@=&SMT;_P!SDTD@M1*N%9E;'E9;YQ(G2&=@&!X= [".H?)-83-?*$9
M'639N<.IN>$F^Y-7FVZ/S0-B=5I..$T$E5;5R9D#3%[N1FX\VGS"5LQ_;9'Y
MP?)?&?X.PEY]/>C;M32\$L4B'94-+Q[N!?.%(C^]I9Q=ZPC3N^10-Z'GP8E1
ME4$)K5KYH3$P?6%B)N,J,\T4SR,.>QHY^.>VQO":+7Y5GD/H.UY)9> $R6"W
M-9172LAU8V/SY?@ N<WMH#K9C$VKMD*02CGKLP2KPRL<I[Z$IC7Y9[VXLS<*
M\%84;"HAST!4S)H943PW5L:  +?-JM,:H3E47T"/V&RAE@7XT5+0NT#8RH$)
MC%K*_IFD[.*X^35*N3E"SRVR,G9P7Q6-;(2\(&P)*0/(6K((URVTV^087ML>
M)'T?_^-OV9D.CVY%__WDX&!ZP/]C>CX&*$S^\N'8=_LM(8R,)@LHRJM<I3"M
M($UP';5M!.?(.$YV?W(:\4ZHNQ=80+B-,"KC<.\62M,?-<B#CJ+8CJB!T7_)
M-#/BE^$E#2GK=@O (_G^O*^A/K9ZL[A^D^5K5^]M%R\#DC&N81/UNR43^G]:
MYD*MS[E4D0T==&O$E(O:FEMAD+?-_'RD*9K16!LG'E&O$,23Y1:A5O^?F=2Q
MLP@TI1%A=>],.<(5+;Y]9@, VO0M5(5F++\P9;7,_OBAOCRU= N6@ZQ)E:25
M,"LZ/:.YN%[\A>(-79D0!5.[N]G7HLX*;S0$T".] !'1PZTB2@2E;RP*P1TE
M+6/6PEZ[((0/K8#HY)Z^>B&WI*W@ S4N*TW3IF 1DR8O(+R9L5MQQ:'P /T(
M(PT-5R45L-0VD9O>G[77@ZV\] Y1(=+K]8K W^%'4[NJI^++62EE$N.EH)G,
M !QE@#7$721CYW]/_+;G79'CK8I&_62,EDW64W8/<T /<U;EZ +_Z PPG8UA
ME&()EG[-9M1I?\8-(Z#))E;F5-&;'6+5[/HG!UN 6+T_H\B*C$'".^07-3V-
MU%J.Y&++1<@(!\5GU*+@SU6I <1CY ^-[!OZ4MM**Q&<"'06=6Z/[\$VU$C%
M)TY/_ #AC8_I:(.$YC*<\Z)6TMM#M%MOW#Y7J(TOXF^GR4Z6_N&H'"X!,UL\
MJT%M0$7]J%Y]/^(7_5H9MWL].+_W(T19V-X <\Z-O5!N@8=V]S6==9UMG,,Y
MT*Y73BIV_FBB&;>GD[K$/*2,SH+RK?)BA-]H?A"/<8;>E9DH"4*8E)0K._H+
MI?IG:\DK2E9>H^!:C_M$$HPDJN+9'AX??339TME"O%Z*LP,JK-03>#3:]C<.
ME=\X="B)DX_[_J/S1G5.A3CF!V0I;E=?.FV3&FL;%+E6ZDYVD7!XM%>1@A4
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M"2=,LIQ..X!T:UZ0^Y,MLMA\P@P\>RQ*F8=2*L534/4LB4RP%N:VCJ9:O9W
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M ";8Z-8K4.TXJ+#!7+UK.YU.Y<U[O72'+(Y%F%J![P[\P$_])\X-WE\#J>4
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MBGUJM.AZ7P_1:,6U6GW1[=V._<2*Q32*4^",8>KZ86*-HOC!C;WC((K^ E8
MNW130<6NMN4FY X-A6?YH74CADAJ?-6-[HD5C:QT+/#S+*8(LG4R3/%3I]]L
MTK==6,@3GDVMAHK?=\Y+OG_^8SAVPSMA+-0R%ZI9MV.1"&.3%O$*&@ [RM(L
M%I:XI\^CV(JR6'T(AW##H0]6SE3$<.0)]CRK61< E6@BL N2@/,^1AG\& (-
MPA+^Z'')Y5B#1PNK@_T0P'GW:"79<(P;1<1KU#]/W$>;?G0^JX\>_""8_2P9
M1UG@S7XJ?DSAJF8_G09N./N9"]L<^E/8U.Q?!B+PX2;FEDY2?U+R^#06GE_R
MSBC%FW #]3G<JOP3(I ?9OE*",I0W!'C1MC1C> 5,2S@SS3 =^K&/+$WO[P2
MJ.* WR@,'BVY,<";I(98D0$(<PC'(LD"^!&NV_+\T0A>@:>+8<?!8^T0:/8D
M2 %'[L;6@[ D3.&FW92NFQ'%I=N!NQ@%\!O3*OYU"?+B]8*<2**08#$ ]/?@
MOHEB5&9(87&DWVD<_8-)&$CE 8DF#*/4NLL HB!0A:(U"13;"F"S08*XX,+7
M[OWTT3;)#P'H#L=X)-I5S?H6Q2("9<,&1/()81X$_(S/A8\2A6 !V#8RA22;
MT,NFL"&?DEB(8.GL[A".X0X?N<<98%T@ )-%DBBFL_AR:M:?@BX(U"5X7QA9
MT0#4!KH(9#/9U$.&0SM:M99%<I@?@@W"W^@KP(9/PA!1^9JY,8VO#O%BF&R,
M%>!/+J.]0G8\(CQ/C#)!8"/43&@=!.+?TL4&0?2 U^;YR3!+$@0!W" Q=LW1
MX>8\4@()V/J6X#' %8F_S&B!@A#MB4+@6__(0D)GZP&0C7$?GL7N@!0)S-]@
M A1>@>!DL>,!>J2"/V7TS+_D$SP9;=SI5+@Q'@0(0CS @X*I=!83:O!_%QUP
MA(%ND "^Q7?P'H0X?#3*@+'!R^]]N'?&;4!^3^+8/;PCRA*ZK2!*@!B1-7H"
MA15\_##V44BE<)8IX9SKW?L)[@20%"0#O :X,PEBA=F >E&LOPD,%N4R7-0@
M2WPD)QN^/ PR-"+H%J,,4\HF?BK)!=:8VPP<_ *VP'J 0VK$%;R6?[]80"%,
MC+C>J3NEM:4<NO:3OZPOO,^:E$6'@/]T+G7_Q/&'A,)#-TO$+$L 6$KQ-XJC
M"3P>P3-2Q5M+(# 4 5$ ?HAYR-@)CH1ZGPCF !38#'$]@"<H3)_IXP",2_P,
MQ(.7#5.YV;%[CT0R%* -(%'>87@=OPVD$$?W;O 90#H$NQ)V2!CGAT@5('>0
M-N$ZT-ZT4I3D6OK@\J"0@E")IKAM_.PN=B<%+,03%'>O,9EW!AK%L7X!D9#Z
MQ=0F<(D!XBIH'UJE40^PU"+1B>R7"%]N%9CS2*L[ZMLD,;743E+8J6 ^SE\R
M7@CL?PAT!71NB$<X=.+'PLM%JSJ)WKM:M'"@F>5!#L*U#4&D$G22;(2I#B3K
MPQA8+=TIO'4@M,C4N -JHT#9ZT<>OD2IG9[<BKH90K\HY$,^ZC>' @\%W F8
M%_%@I:K VY)LBA0.OZ!*/18%#D[7F  H S=69RQ[I8O,'S3;8.;%:X)PG$V(
MYLWU\UM$I1DP"W@22EG@M_="]DZ%NW'_$O V4 8>@<,G+,GY[@R0 UL<HIV!
MJA \6@00+JQI@18>N7Z FA2^($)-!I@V?9&@X&4D27#=F86 'H;$E%E*N<RK
M!=YU',$E2Z8LAF-IM>!S9]]/0' ,A\C/Z=[P[7@.D)D/S,$E]B7N2*3\)8&H
M@_I5&KL^\8]9K&.#P+V'Q5RIG,'I1\#'8?/RC_)S>!?<8(8DBJ>6F\'3>R2*
M2]<"35 9)W-O<0,0:"'#'#'(G6IZ$RYW<M*:HM8> '8@'81$Q$Q;D" "8&V\
M/.#$)J<QWB*9'MX>8-PD0C.4;XCD<82K).FQ( '*NR*,?93;>RQLCA=[8"2;
MVX(U!KV&.#YS0N;"QEU*KFMR2KO @5DEGH@8]13_7XP59%0=LR4P=1_YDECJ
M%K= V'\7"Y8<GT$W$$2E^!0@X#3V!5PD*"DHS%B/$:@*#051&QS4$R.D(OD;
MZ$F(SVP.!($ ;0>X1/YIJ%92_(#OTV6U#608<3S7G] 3?@BRQ0>(/G[6NIH/
M1B?[$^[0N@CICL<"X#=&G0HDV(.6,=,H >1=K$$O5AD6^3K7=.@U?UJIK[RZ
MQ[+<Z78)=X;ZYI.TJD;M+39>KD)=?+_\X^(2V:MK#?S(X'ODAPC17 2K@DU?
M9!*(> -$.^*OR)7BOP3+6="3X8_(">]0HT*F.4'/!'%-U#&0>!42I:@F3T4$
M8H#%$V S6<ZLFPOV-@W1"(Z96:M/T:R-@"R1"Y%5PI)I"IL#4VCBWOLQK''T
MV]4?'VO6)5!<<2-3?RKP'O#,>,;8I].A1@T$:Z6/4];ME3*5L]A/!3E@TV_^
M9)*%4<Y E;0 '2+R8-U)%$:@VH>D1Z7^("(-Y,C[=C+0Q20O"O<.(M-*P)?$
M$1 UCYOT[=E8!MPZ+O#3?X']T6U]?I5]KXFO'\DA.2-'R=5"^IHGX,(3$+BD
MUJ*(* (?6>( 'PO@R"BO/9#:PY28*:HE(@@2I<X!K%#VQ.1:FN7<"> ]*=K^
M4$C71 *Z/] SK$6N''2 Q!$8@8SR;)6.I#D-6[^EM]'?)&8\*D\-XM$=>I[3
M7-Z")CF.[H3T,S%=)#5K[Q@.$F0((B8H0,:@,I*&9 2C_7PW=_,WC^%I%%:T
ML_G5FUHMT49&F$9<,$,?G!O<13%PU$G.Q &UM:>?5*TIZ-?P3J(0A& B_ID)
M\E2R.X01EE :L-4Z0NLBM9@GH_9BI1GH?DC&+'G@.T#/*!F0[<K5 =T#-YGX
M'I(V^U50U??C8<9&3@Q[(2Z-6Z"S(+7$R*]=IBO8.'-PH?9",F@L@BGMDWVD
M,@:6,!\'D^P1:'B"ZF%T%^(Q2?" <1-'CY+HI+(*)T('NA1;L&/B'4]S*VZ;
M'M%*#?$,I^=?OYZ?WEZ?5.3U!/)2,H%DRZ,4#@FBX3W0D('<V91,8NFE+4HH
MU&BD $*,LBU4QX%"R9JR_A*/IN]0F_^PAK1+3,L5W4A@Q*.N$KH35,YP22(A
MWL(>RH_?2-F;,>I!<+AD[J'0';ODRWX XQ'L]/N(8VG2,(<;&?G!@KM?7RU@
MT42NUHID7H!D2(V""R:W !G^71M>;;D>(+Y/"AW'V(9QE"3&8TUZ#!B83W&I
MO4/G2_(;Q.1X$A9KKD"Z?B)C#R[Y(I6]!-((& )*6W81HV_1=%,(0NIY]8I6
MF^#P,HR4A*R1"O@:67%W030 (F)KWPJ%\#C I\+7QE8*OE,@#W(D<*@/1'3L
M/BJ97*;8L:N/]0.PSHX-.Z[<XBLU"546P2FH#V?'3M\ZNCFYOCD^C?XX;GSD
MP*0_,;><4N"\L _6Z><=/#):I$^-T=G8O<,U_-@[QL@/*>EPR\/"0MKQHP/!
M\&@(*L;8GQ8<8LJJ# #AP\3T$BWAQ>\R!ZR[. =L.^E<^\!*%-I)3#9=HBI\
M=3+%B/$O?F2= M^IV=8)<IW_%:$8NO"+)_T;-B:<6+_XH$K_FSN9?K:^H=3P
M7.M7HJ$OF"G)1'-$GWRT83TWX" S.H[/IZ#T3/RA=14+V);P*+7@(@3N).GD
MZ/3\Z@*^=T:^3D'O!H+UK&L@6#<&,K_B=(K$.@&N-7RTCLY.KJ]./O+>?J_=
MU."[>&2.RHST2D=GT1D\]2L<ZA)XT%=_)*P;#.,@,_WMX@_K#^7,OR7]X;M(
M'Z+X+YLDNER75[H=D]/J6B#5XM%X)]IN^(9\#E8X_>7ZN_[2*8;(0>AF$^OH
MV^G9*6SE(I2.<++]Y>OATR3U4R!'Z^CB#[R*[^J)4V*#^0/&G_1G9 #]1ER[
M[,_XUY,@ ";/IMM%SDW/-#>])$T1L"%!!^:0(SL"@\U_F:\GB*H]&2ZO1]NZ
M"K+)@!QJYC7#.M<"K@KLI="Z&KOQQ!V*C/00_!.8=' ?Q[^)8((O_QK=^<.$
MP!I/(NN+GZ!22TN!Y>D/)6!"U,X2&<"X$F&8/ : ,K[+?_^3H@WP7D"ADWCR
M6+P*A50L6A"!_@3%PC4.N7_:PY^B- +#UC+G**'2'X6$O>A,B=&R#D/\>2XN
M6JH3(^!GA#7Z>MG_9$JV(2&0"Q;+?090D2+<193T'K&Y=.*[GV>7*EEGC,DG
MS'* )0%-Y@OC8I@>%8(&7WS-O0OPP8 YFT/SV@6-MS2TAUBH'"[TN?DQAWVT
M#SD%>0E/P]FOKZ\^@X;D1P,X 0A3UYID 2!E%$\$/?#K+]\^HUBG3 %YH,_(
M9#Y;YX,H@#-_\ST/3(YS^#YBH7[;S6/HQ9%<YMOY]<UGZROL&JP65#L^6__K
M_^6RYR2/TVBMAS[?/XP%AJ3P;-[!3G@KS:Q8R0#VP!@)#6#?"=+SR.-+Z77(
M9PC2&+"(,4R7B43E>:#M%^BXLDK!8+QY$)87T1J<'(9*GUJ-'B=\R5>,*,P<
M" 0E)W/^2*V$M,2 H]NT,_@A5-_B;2A];R1DD #N5@ ^A4(_5Q39_OV2.S"U
MQLORJ\146EC@GQE8LA8Z\Y"/NOA=CV.YG,Q1OKX8P4G3 EG"0658WTRI**92
M<!) #:5.V99TR%8IYM%\ D%AVR4I,;"N+Y/[M/:.?DP)SD6'QM R@V].Z2>
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ME>D;,MOJ5-[1ZS1V7=>E4B3!3KVCKK1F_18]"!H=XX_(,(^8X4OA,\\W%(:
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M1-54E5ZV7M1,5B][I_:H+WPS>_.-G2QX3VEX#P,'X5T@N%$(]J@H_SICWC
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M-.%L"E2L$I7QQB=J%N8@ROC2 _\O$?CC*/*,G"UQ+\>*L6(=T[@]9(& "S.
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MKA<7E@I8#(ED6%@%+ :((LF= D;U:)C(AL_$FFD;8-B#-T%F![1X@$1&UMI
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M2HCYY\"I P@3M!5IDS8OK>'YOUMP*RI2Z^P5?O1>M_N7.N^5;V]%;75IW+W
M%Z6N7CL*VVEK]Y_]$7GM]'95I^.R]5S5C;$,9;?.^"M[1X,F?]\D>_GU>WQZ
M_8D<]O77_>O/O\NOQU]W\.>]'7+T]1/YO/<7._KYE_W][XOCO0-Z^/60'/W^
MUX_#K_L_/I]_PN_)4>O3S_S[T>5?WX]^?L)'^"]X?)Y"^SOZ=/[EQG[GY]'/
MTV^'YP<_#C]^P$<M\>/P_,/UY_:?%Y]_YN33Y2'^?+E_<W3YN77T=0<>?GSW
M]=/Y4?-H;Q]^NOSS\A/^^^+SY<'/3V<2?OKX9_?S>?[]\./1M\.]??KI_/.W
MX]__@H>_?_[ZR=W_Z]MO1Y?O+@\__D4^?WSW[7CPG7__>9%<ZI9]KA^?\%_?
M#\\O+NQZJ7VV[Y\OCYKV6?'A[W_A3Q\__?B\IUN?/O[%_OWSK][A&?SQ_GR_
M=[CSC\;(0!(G($,H!50@"(3&!F2I)=C4<!I3;943!ALQ%@V$Q/^\&J>/*4KN
MG! 7S<D7BY3E 9PV$IPRR#.$A<Z@IO9B)C%QHI&.C9"4<"0<."$9P*EVX'0S
M!*=$2,V51$#$% %*E 8B$0BPC&*&$RHE%Q:<< -)WH RKA$V;8X*/R4*=I%W
M>L"E@KBD!M/M74[2^X9/CN=[\HDPN\Y@M'Q-R1_(N3V/@]%Q!.R9"WL^5!4C
ME*1Q"I4"B'%J%2-)@<Q2"3(-42QT(E6,MMY8>&E(1!N2L*>"SV0 6*IB-*O]
M^]*Y=_FJ1.#>17#O2'.0.J$8&F65AHP#"A$#B>$Q2#.=28$85!ANO>%Q@Q#1
ML Q=(^;==*?1SJ#!2,>DQBK-2<L\2FV8U3I;9^!9OMHP.(W3X6$<F5[IGPT
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M8OVI08R78*\L7VL8'4@1#3XRO?T?Y2S W_-<?V^V6@&)YD,B/.9\('&,("8
M4J,!Q9J"!&<(8(642+2.E91;;T@#4=Z(XT6E@@3G0_V8>?G.A\#,2V'FD5IA
MB%98<P40(@)0UY)0Q-H (5,A.4Q=KH=C9BY)0S!4(V;>=&?$@+R# V)EJD1
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M5C_"L$&A;$B\1GZA#7"SE"FY/?5C4?5#&XU%SS"^KCR2@W::7YIS]:-JL)F
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MDF3: )YFW-)FJH"$/ 693*F"))8PI?>@W43Z>@+0!?K:,/JB*2%$"BL^E82
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MHV)2*ZM6-PQ,(_AM7 68E'V_#9DO^QHNS;XK@B13@!JWX*J(FD/KYK_HG[U
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M"21I!@2L 6)9R,1R(46*.4MG5PH3&,[XK\@02\\05S[SN?%!>:,YTQG*D;'
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ME!)*:;G#0N.OOUT<,8N*Q&R*!)N.$16<YIQ8(KRH@ 2*^D"<];J.DM4I9!M
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MX;ZP<#\7R;""\>"H)HQZ2<!H0;RTBD2G5 HJ2IM@915$4\B^,1*?\ L&>33
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MUW/SM*)FC$E/27F UB"Z%<1K;DAUSA>A0Q!68A =*18I]BXH%A1S5&F042L
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M+R=K5U;?[1<*=+&_?S)5;NWMNT[AM(($5KO__LOU#NI(N7%2/#--9[23.K7
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M".L[@?64"[J(27,>%0G460(*##%*<**HYQ*,C#GQE56A:*.MO$7I!/J>YV=
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M7,J<I&S\%EYKY>=\54\1Q[1I0$\P4ZWQ,X :[)VHCST 9Z*0PZ-I%VW!3R?
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M%Z&S_D^4#K:I@>%%(\C2>CB#JG;P""C]^N??C#F=.K6F,O.X.:6A2]1_HW6
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M2552IL$@[( X#FTZF&^1#\/LRM>^.%26:UF12HU/BY/$Z" "^L\UCS1$0^S
M+D"1I*$_C0">@S=7-X'N]?#%V)\_?JBE@+.$(]ZGN6(S9JV[9!*:Z[*Y=6-
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M:ER<@F75ZG=!OA+-UP2XDDM1-ZQ-3T_[WG]83:$-#77HJDX)Q?R7!590-H_
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M>LLS(GG)"1>*$Y5I2W1F>9$5F6%,/GC$=H10.YE@GROIU\N2KVH +KWRDPS
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M61$[,J/<:EF(('BF<PO&3D%YX<&P,=87V]J=>RYVNN=/2FE>@MBAF<T(-ZX
ML5,ZXJ3(O2O!ZA4>K)ULAW.]0S\_HG-GQ$YT#O\5V^XU;>:7.FU?VI/^Z[;1
M_#W,9B'\'LPLS+;MUP\_[O-C6Q3.YQ(THM)@EQO-B/*(W)Y[)3CWH@AV73_,
MKR9QXQ-_'H+G/737Z'N9-O,Z[=OO4+-.;+6+K6M'D_$)F8?IV6!RCBV,L77G
M*$YHI]=S>QK<Y&0,+_#8R'CIVD%D2S(I"3;@-$#A\]C)=LV5HZ&QP]%P?C'
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MLIA;6)=W/>[O4?*5_O-WJM_5G=;O>XN3!9 LCG.CAL<9W!M?&D\(!O&(H*?
MGS2AG<'3*>B^#Y/I._+X%,\;9K4'U[GF19)Q29BCO%G_V#NYKTL:OE:O;7"K
MEN!I=N!93[N0?6?M]$!^O(H*9[ZD RI[KS$-HF0!.36:P'I.DR,37Q$=K>K-
M(4$.GJ'R1#F3''@4I6F)0:N/9V688NAQ_B& )OP=--=H0..5Z3.K!51GP*=#
M4'Y3=WH18WGX79+Z8)2X$'4H/CW=GV^>Z;]K1^U\84=1 Z#4;&9WV9SBL54<
MY0H^'PRW&S==C"<6MC49#</Q^6)>P?;A(W&$D_.K1KI3+5P*6;J*A(?C& \%
M)D'?$2,#2>%75D1EZ?C+/;SUVBJ&;1KM_S7U52\ ^W 6 LA0L!AEW, S=#6[
M6MU84#I=(R0>216_S+HKYT9F-FL"2[.??F MI.ZDM(I:Z!"$4!W7O50/J7NC
MAQXCN*6=3%-TI7.TW;B(*E,__3QX/#+33H0W@A149_6U&&PNCXR6_I*9O)/;
M62L?%Z<UK'!FAY?-ZIYN:5^0K*2FKAQS=T1-]53.XB'@+^>3670U?HY"'9Y=
M 9U6&1R=&ROAE+6W& L2=3'??,M*>LHMG3D^)50N+5GGW]-I"^]X$DAT)4@,
M#?]L1A_,Q>S!O_K"&N3RTBHN+T":YJ/_UT[_]6C=BV\&9+L66)AZE1O!9 9O
MY<8H+6A9..6I=;Y4E"Z?EXN\X#17>>D+!'TWVNE"")W3,D@A3+GI/5>?L_??
MP[)<2.Z-X;KDN>?:"AV<+'C009>NN$N::SVU=.7E'95S/5E\;V38"PP&@5T4
MCP8>3_!L"L^[XF'#8_ $P0J<WLT5OVWCM!/ 6(66OQIL?HWUN!ZL_"H9L9R#
MDQ<V#T8 RV-%(->.41NLISX+04JVZ3U7RHBE]QC&N2M*'Z3&MB+":"9R)3/&
MK<VT-'=)IFRVAL&*+$C&=^\DA<?SEHI\<: ;#6&<POTZ<@&S%N3Y,,;JR>"W
MR<1'IQIY\WET1^MC$Y&!3;R<]G"$$*?H S8W/FN.+)8PEJ_!FG=JSS<H_$]D
MZJN9].&##@T]:,_Y\<\F"R/4&0_Q,#HYV[!39_T#,3,XJ;>C<X(48_7V8A!&
M0S#23,Q5>3D/YVWH)D7ZY\F*7O>(.6QWDO:K9PX&9'P ZH,'+MV!H8TJ\-4<
MC,083GU4T6]+8>"9&+J/F2$PR:0"HR(PTVDDO2I4E<(MU;G\K$Y%J][L3L%2
M#,T9=W6+O:B&$F/I2\_#S)'@ZR7NCN%_NJ&+G<$08V07_2U:2<4HAYCIG) 0
M-J95)"9)N154I].8T\EBA"T>\/AN-$SG=@:#9K/SZO'6S(:SNZ!VKV;JS<D#
M&Z(VZ_P"O"NR429]5DA9@%8L>"&%49CV7'!/&:7 ?\>4JP=7^A'Y-\CO7*_I
M\MW!5\ZJKLS(IV!%UD;DW\ _M05Y=[*I3ZILZO/1P=&+T>%;E\.U'U^_?9;!
ML^GKL_^\.WRRG[_Y;?_BX,EKO#Y[,US*ICY[]<_A;_"\CQ[&=3@\>/MG]N;)
M7\/79W]F!T?^W>NC9Q\.W^YGSY^\./OO1Y<?_'DL@J,T+QC1OM"$ZR"(RIQ'
MF.'2"AYLP59\PUQKE5O)"ZT-%UI;H[WRVE&O<T\E7<ZEK@WY%QTA/=A8(7N3
ME%6V>WN9R>O5VI5K\^A)>WR-DG IR:CI,]$F2C42K9-Q-9]@[MZT6MATU [F
M31C/0B=?SIQ,0WUT4@[^KXT%-HN97ZJN$:KT/G<^H]QR4-&&Y<P(F4L0,6#V
M%U?4IA+1+ZX9+\[\9%[]?D,&W?^GRJ78P^.!6?!'YI^F9D;^<%S[Y\?G1R<?
M#I^\IC"."YC7L2U"&0(/1%)K",\5)49Y14PA<F\*Y\$\>_!([&8K!3 #8(M1
MS'M#%WO/OS?. 9WOW(Q4@,!M1B5WRG)A<LVE!HW$BIR5@15Z2RIW@U2>/WEU
M;$$(>9TI8F&3@%1D273!"N*Y"F5FF95(*G277T$J: V9LAR.AM$6JDS8/T:+
M,XN"<O [@EZ]=#%I9;:#R=^[@X</_OC]Y8.?DKEU$P++P2E@03$!HH>[LL ^
MA![,TH)9GN5T2V!W@\ ^'A[M'VOK V?>$_#C*!;D940):8@P1@E;."V91 *[
M2A:]-U-,-&L.@*O@W^[@>7+,^OJOHQC]C;3K3<CPDTS1#AGF-R##=;3W^]#8
MA&&89OVBF?0=JB#]YA0HP(:UUK*@ [;VAG^X0&NV\$!YSJ@\,YP[E@/1L6('
M+,)5PD.G#Y-.0(O&7,*:JLRZY'6J=P>76W#-A1N-M_H%-[3)/"CZC&OC6:&X
MX+D%+>M+2L%*9V!INBL ";8$^#4($)Z!H$ VMTQ0($">$0X;1&Q)'2DI,ZK0
M1ENF'SQB.E]/@#$#-U%AF_JR2H[S%1)3NX,_PC1N:HQM@/(]J8LF>@F]6+0^
MBT?<5:D+99A1.3]MRD%2&=.H$;4#C'*LB6>L1B^^2) "09.6'_FM0Q'\JX<B
M>J?RG7/#-IOOSD0CCO9K1CH[8/OLX./^QX./O[X[>.NRY[_]-7K^]PM@A'<Y
M,-''UV<OWKTY>G&&[:;[C 2_';W^>'!T\/'@MS\OL-7TF[]?B3>_O3B%]P,3
M'0[A\^CPM]<?__MQ_\/SHW=@1^"[GL%_'3L.2E)?@#17@8%<#PX^%24G3NA2
M,Y-+)?UR;,(5I2Z!=0QL!5>:*EKDO%1%#LX0XU(LQR:6<E]:A_GR^,1:W__J
M=_?'6ECIK<A%5A0%EWFA,RYIIFAN07I((:_?['=='.0.'JTT'N;@U^'D_-2
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M7X$FIP!%F_R]5NSM5)K@(MV#P;6NN(R'(.5B5*$JP^WX_4JR6&A1)ZMOED.
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M*@LTX)&JY&7AC?&E0W W(93.F8@H,P5E3)/ZP^?E91_5N?W[_\"^8QO6YS$
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MY[,P:M973Z^-&JZI:=VI2PU!M+1X</V@9/]9R!@UZDQJAVVF[P*F>ZZIBML
MW%$GPU6,-VO11LQ@/HPG )>#=E01ZIA:T[DRP;JE>:91CR8?2/HTG]0'H9[,
M PC-JF_=M9 ]H@2N6K'7"!_+  @=%)-&8MX<IN-*9(U/$A]K(KBH>K:P&I<+
MA6<?X=G'5HE@<_ +;"' *#*%)BH#&5%FA76VT(4T&K&H5N*RJ17:38$T&CJZ
M/FQ&1>L][(SJ2&,)0&,]UD-%[JVXZ=#RO5/TUZV*7+5JUA4G-OWCNO6)K2Q<
M/0W:EG=]Z_*N6S"HMI'7RZ2F.'R[?TQ+JS5UC,C,6TS$#<28+$9BF5<Z$Y+2
MJT*O2P;ZCUMVLRV OJH 6MW] N@K"YJ7"J SY;+ F+-EIKDLI68Y5Y89JCGC
M2M@;%$!_LSKG'Z(\;-W9\[8\;%FRWDGPJDMQ4J<5$+P-L0XD57N60(>P0]/-
M.W I9=R_)(NC#<;QAJJXJO*MN>$ZE6]7E[JM>?\U"MY6:MT2*:="MNK^)1X8
M1KZO&D)?MR:N7H79IQ3"+=6RM5.]WC)T"ZW:+MO?(F*PQ23[O-/&BT-XUL%'
M=W%X](YAOTX5#*/""E+F&2><>TJ4" 78R9(%QT*FG;H2DFQ-RE<DRG&-Q9AT
M[+<@$&\NKB8.& '(W4GY! ROOQ.#'$;^^#76]/W(% *_ U64!4+CB)Q8)2CA
MA;,$W"5#:,D*$[21N@P/'NG5<)-'*,9+:RJ_%/+5=U% B"W12^\R37G.M;,F
M8R7G3#!!I2A"J'(Q>)V+(?-L&S;XJ@4A<-4QI=ZIP!QQ!=8Y:542=)>(%UZ;
MPE/I<G-5V."+5PEN/%W]SP*$<UXEPU]:--@4#'YV)6!WH'7Q7W-D#,8U.%++
MQ^Q-,FS_O/W&+4I!77'.I;>YY9A3E<$7TI2>*03I\17'5"U*U3;0]K4Y!M[Q
M^K@,@N9E;A$$1X,5402B2\&0@0HA,B9]?F6.HVGP ]KVM5^ZQH^J.^D+W;0>
M"YWR-V$<G+F+L[FJ"&MO<;*8S0=%W!!Q:6O";NERKP==)VX?(PL'P3_#@IN0
M'G<RFECPI>P0!1]"2UX2]3A#0NHL*=8AM7\]^*E;7]2!]>C>85QUT+Y4.#1;
MLGW^9Q81(7)*6;\^"#N[H.R)T9Z#_2?/P/@JZA3Q.6QE0(C55!8T:"N"3A>P
M'R!ASX&%8&O>#Z>+V>#AO__XZZ?!_.(<-HTF0,V8;MX@85=8'C"TMJ$@_#*9
MM0HJC7ZW-\E-';IN*, %IZ(L!0ALRK@V3ENK;<F#I@$^R2(*<)'I),#AP];D
M^:H"_!7^?DQS8RQ3!0E2E"# 2T^4Y/!)2AJT$)2C&\B*7;%9@"^U:AN.!R_#
M^;QNZD?%,CG%0&=E:20;Z<R\"ZN'@9<<8\1 #$F9&TTBQ](XYA.4JZ :4MK4
MC9)!C9:6697GF>,T#\9Q;;7/K%1&%/F5IWKR\]*D8!7<$$_/_9-V"6 %7C0+
ML(_S_Q6GWR-H#! >-.'N'YFXL\,G!\>YQ+Q1$X@"WXIPX3U6MPE0<$+G-@LB
ML.+!(\HNH6VDNQ7"[&11;"#$^T]YCYLY;FGM"EJC!T=_'I>^D."N:U)HGA/.
M'".&.D.L+EDFF2P\DT!K=#.MM?TH'$+U?VI>7FU%#&9ACK0 VK^*/E_#J.J+
MZAAU+Q?H-"X!DZ7#!S.;35SJ?)&,L?K5/1NG[S5>FMJ*^7&I?58LO9Z F5(W
MTJI2\]K,-1AV\[ZZRCKFYUW#;G.80XNU Q7.^S)H606ZU4*2U4>"2_DI\Y2,
M"^_P#=R;"Y?X\YAA/CFO')>ACVD"TX =F7%5F[. RHBLTE@N2[VY=W[ VB.P
M92@&!%GIGH2.1I^2FQ.<+85D04JIN"\8F)FYS NCN<IYGI5UO7E.2?UA:W%^
M14'YFAX^^?,X]Q*$8>$)Y5D@')&6K12>V-*!OE8.I*B\RN)<=D7:H_)X&([T
MTDF#J]CJ3IX)CS:$WV:1!^)A\%F8U^4L*/NKUBFFS4Q*V9;/Q@,+(K?;3YNJ
MJE5]57RL5\K4U^0:W*BDT(?"E]08SB@O1+#.>.],9D1I@M=5&!MF^E6"<HWU
MT;!8G,&+9EH_,J_EAT_VCZ5FP8M,DK)@E( KIPDVP"9Y3E6PL$6V+!\\NDFZ
MHS6%UV4A\Y!QES.;(_"UUDQ[QG.=QPW769XQDCYL-_R;;KBRWFA0=,13C>GB
MTA+%N"54V,!-5GI6BO7PY)=6F*Z@E<^J:'['IIJ#T7(2;31[T?VA*4.HVJ1U
M[)BZ9VN5,!0#NVO;H[59X@'18:NTZ.$49?O;6*7JX>*4TU!)2: ;/.!8D_![
M-XVF&X:"'T_@PGE=I;M_#NKN;.@&?TRQ)U'P$?_UV7@\>5]ID[LXY2OCQ6!-
MCY)RH[1[S+4^:-P87DE;/M[_X]D.MBB;+4QJ#E]%57NA*O#L?;=+Y*#&&VX
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M37CD/B:7E\!J2NCOI9JOF)K?)_[RX@:\C+\\C;)/9E:"UP1[I$1.89I$P2$
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M*_%S8?CY=1H_7>3.Z(2\#![X9Z#(<.&1,I[(:*BVT2RPLJU$SQ(]2_1\QN+
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M<+<!2F\[5R9T--@G[1";71!YD!9P:$.C.P)+;[N'E=1LGTT,SK34PH 4?O9
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MH$FCV^T/B/<UJEDM)+G1G?;<._%RM1M(_H0,@43-]=]OD<BK001XZ<1+^D7
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MJ@@XCR-"#P+*NQ+<Y0/*7YX5*5\*(/^.O5YS$,8J$?%>B/AI$A&MI)2DO,[
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M@B^GA>_HI_-.V33J?5$.#R\SK*T>QCFG?C@,1^')3ZP#I6C0O_XG4T&GC#\
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M@W4<)(V%2C&@))D'#=IZI%VTR :C")CBP?"8_6DW-#]<L7?51NH%>\M$^ZC
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MG(F$7,S-':2,6I.(!<:Y2(5156?JNFF.&SA^?2178+%Q"IWO>.5;F.W^=;Z
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M-4'G\4P$U_62>;HK8D^E)ZW$?.7N7O=OKK2=;V&RJA08.FB'/EX&9Q$Z@^S
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MK?!L)3S[.FW>&,.B=MHBJ1-'W&F/'&$480T(9KBTC.5D25DW7&^8PZ:*W;P
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MY^R%0IR%"H>Q"P3RYTK?9X2-H![@3+2+D%_YD(7;=@K?TPNU4#I/I=LU<JN
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M>H,E"PEPA5 GW"WQ@@D98$\G ^^P:B3+ &\)$QGSE""6%,@ ^*?($"""RN+
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M@O<:I4'""XZX*Z8*88,8H2F7-X@8=#Y,(-XR!:G\DE?LEU3YO$?CP40^+[K
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M(H3I09) +EX&^3^!OS.U1!,_C_KC^SD%EQ&Y?K3?D4UPNQ]LY]Q>##;^==/
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M2I96*DM?@#UZP8#!@2Q1"?Z941+IQ"E20.Q28%AIPC>VV"9>(1? )'!B*0-
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M11M&L)-;*X(+>'ATU7;:Q>%YC-T;3<.R.U"VPFW8OC\:_TELUEXK^':SR'9
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MIXG_\9^_ZM>#"S(CMPN.HT\4J #7X"5(SV5BQAC"I$W16>.M5 ],X\VWJ%D
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MFYIJ8'Z[$_F.PE*/6YKUQOLWZ,M]_#GL6]B;=M?V+SX/X\D@SY. 3_9['5B
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MTGI7$59)7/YL>W/[T$AN)0X)81YR6AP<JY!/G/-B11NMR Y0?<..1^W^?#&
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M.8@,R%*GL"!$_V_0[,;L4P51 &P6&Y_>%GN=TZ8O%,>KQ0@>#R3XY1/?-/N
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M DL6<)(H>I*WK8-!CDN.6(HF&A42S4XR.F._YW[YT9?HA$]-12^4B@1-BI"
MC2:&PQID'$[P/TYEH,*S6V)E:BIZ="HZOZ0BSEP$TA%("VP1-]8APWU BBA,
ME?=>&[ZR/FOKN::BFHJ6DXJ\AP4V.LFCXUP99;2PSAOIC-=)TW2W+<"K^58R
M0=V\*5-STX*X:6="39)!<\PC,AZ'7.:.Y$3<%"46DW#!2^/3PC*NU/Q4\],C
M\=-B0A1J?GH:?AKK3LP[@84SB%B;P(PS'MFH$\+2FSRQ#*9X&?GIQ1_L!OC0
M.AW=4SN-]LXZ^]%V:XJ9CV*V)SU%RF/B*$N().L1!\T6.:H22E00I6D$E3:N
MK,LU4B><>[F ?2S72@W8^P)VK!/XG-4E)8J,P0!8%AC2AKOL3W'<P'Q%;;,_
MA=> ?;F ?3('1(W@>R)XPNM@C,6."(PDPPYQ+2*R$K1Z0Z0.7D0;-*_SO+X"
M%#^9F5ZC^+XH'J_#B1'B4\X;;YT%VSQI4)R3 U,] 9B5RLE EA'%KR$^A;VR
M5*[+:)LWNC'6)#,_R7R8M,X)3]@DT!(\%1Q(AD6D@640SG$<@C"CK%M9GW70
M_-EO3M20?73KO(;LO2$[U@NH!U5 *0'J/":($T>1(U0A(HG*6#:6Y.*^,\XG
MUI!],9!].OL\8[C>>+L7B"=,=$PX3B* 89ZHS($!')G$--(\'^^/-%D;EG'C
MK0;RBS'1:R#?'\CCU5A+J[0-'FGO JS&-"(7%"S)W"L3/?="JV4$\FO80>?U
M#OI36^E_=@;=6N.?GV,^3QKI,5@AJ(@H,-#S.2<*='\C\HX<?,&#QPJ4!<+7
MQ!*Y 6MG_C.UTFO(WANRYQ.0U3R!AH\H8_E0@G$(M 2"I+3)$"*34WQEW=11
M+R\9L4]FI&<(UZK]O3 \8:-K$0.EB2 B-4,\2(FTTQ8)A:6*PH#N9)9Q Z[&
M\4NQT6L<WQ_'X[58.JY-I XE%3*.50 <&Y,M=F:DXHY2NXPX?@T;Z6*4V[8;
MRS30];[ZDUOLS>_U'MT]*&=_TF(W,<A(@T:1,;#898Q()PZ?J'?18RLHI2#_
M4JVI)?()UL[]YVJRUYB]+V8GXMY-M)9BB400.=4SH\CI1!'@F#%JK <A7EDG
MC*Z9&K,O%[/W-]KOKM;7<+TG7">L\^"ELD($)#F8Z#RRK-5SC 2SW/&4K)#\
MALSL-5I?#%J?SC2O,7Q?#$^$N >+M7(1<<L3_&,D,MJ C6ZB(IAS9A<8XEYO
MGM\=@5N7E7?J+?2G,<BW)FH?3?Y0T\U<=.,GK7*K< J2>T2#L?EDJT8FGVS%
MF >1 O.@_M]4IJIVY[\8X-[?*O^1SE##^>'A/)&\1BHL&4O(<P,&>P 50A.;
MD F.!*<"I;P^YOH: /W(^^R3GR=Q76-Y3BQ/6//>@@6@B4)160/6/ 5+@!"/
M@A&$>X\EKO?:7P66[V_0UZA])-1.N,Q+?8EZE!3/IT>]1)8FC3S%C$NM"2A:
MLTOE/=]=]7ES7 X+/ RKD#%H=>@,<HFQ$>SN5 'B!6?(7.  O1@6_%G?PBNH
M6?VXM'<T'8_/@(V \:3%-*>T"\@1;Y%.N39LR@G'Z<JZD')A9W 7AY$ESPA<
MLV7-EH\>9E&SY>+9<C+\DED>E4%!>(PX(1BY)#2B@A%MM4HQZ'QZB2TLKJ)F
MRYHM:[9\J "7UU!#_K'I<L(31D"G-(I3I*/VB">@2\U,0CC:8"/54N+%QK74
M;%FS9<V6#^6/K-GR =ARK%QB:H/3SB!;10$FBUS@$4FC/7:4^&#,0CR02T.6
MI?_RM[Z%E\)_0_/[^JAK.X,3@(-?_Q_X<M21$]L]:K;+YH@1737;(;;[;RA?
M4Z(DT&H(7/>W]<OA*)][G^<\(I1IAG+Q]Z#;&]AVO^AWBJU<=;J=ZUW'[[$]
MB,7;3HC%+UL?W_Y:?(KEO/<*IFEYZ(AIM@H?V@.X?M"+12?E<TAPRPETX[S<
M:E*_]W(%\?+R8>GHPI<H+ORD>5B<V//"Q:+5/&GV8RB:[?)1N1'0KH;M%[;P
M@Y-!"ZS+[['P#=L^BOFJSED[=GN-YFE^^TFG&_/5[4+@_RXZWD//BK-FOP$7
M6OBA&R,ZC[9;@)G:[(2U8F_<W*)A>T!<)Z>MF!L SX!.C_I<B3KT^S?H,_QF
M6^>]9J_HQB-H/,ACV=BR[;:D0VC+#;V>EH\L=YDLFS"&):8F)68X2YR6TO'[
M::?7S->\Z<9J%'X_:X9^8T3($S<.L87'MU@',!KT;[[E6N7Q)Q+&/Q'C5X9H
MXM_&98WQ4WL4D>M&^PV5I][>V-:9/>^M_#:-.0#<E5&\.@ W8[?Z]\H$5<N+
M#3227/6'A<BU@?4,&YZ,%300Z;A9N07Y3S2PTV@#40<1W8P^GKC8'4HW62WR
M2KQ6;, %(-N]0:L_PO1(Y%<G$5[$7A^6ZSZTLH+HZ6FW\V_Y3>N\^*\Y= 0N
M06F7BHN@).<,.Q85#<9IG"AG+-XM_J ]. F=_O#W*]N9?\1V3,U^=>0G/O^H
MH8-_&MB??&G;KV:P>_R-[5PT&OL7G^'=7QH'>Q_.#[Y^:>P<MXYWWL-][S_0
M_>./W_;IUMD_%]MGT.Y#X307PCFD6,"(:YNRD220]@E+3\"^Y0J,)#QCW2]
M/%M#ENO;?X&VJZ$M2F("[H1UY!K[38G?&3R@B.5,@%3 T@%4O.%]I^32UGDE
M9*.GW6GY:%A8%5R,;;CMI/,=;DO=S@G(2HK=;FX2M-/V>K$/$FR]+^6W"=^[
M\[RP=.":WFFG75(Y7#[P(Q;/#?EN6T/PVU:K<V;;/JX5F[ V0C_+1>K?9J\?
MX=M;;EB=6!UZN0MEU^#ML$1U\QJ7>Y@&_0&,R'A)JY8Y:'(SP04P+A,C/('#
M_P-HKARO^>'#I?-SNUQ(/_5+?)8CWN[TBR;<X>$_,%V@C>75#08NCP[<#MW:
M %1G%2L_"E;U:TTIU^DTZ.;SQE67*GIPS5:S?Y[;E16!_-6M$K!V+S6)KCT=
M?V9- 6BD>#N D<O]^D_']4!H2X8$:E)%;^".83PS=WY>^[0&#>SX;XU."Y39
M<K[@9I"(]ZV.@X$%/0O&LYGUWK\Z9PB>#'.UU0;!!&WK_=9?>UN_%J"HM(="
M NJLA7F%X8,VM?.K>LW0M-UF[%5*S)\;G_[(<YU2\:$<\(W58J]SVO2%XGBU
MV.FL%6*UQ-@@+V9'^5%W:,LJ]&*"W]L%S$.>9P\?3^RWO"Z4<!H^]!1T=0_+
M0JO2FG*WN]%WCMHPT%-8A"?F!O3CR6FG:[N@^MFL3X4FB&0W0ZF7Z0&>4LEZ
M%_3 +L@5+%OEV&09'X(EJW,@_N40P^KSO0GJ:OGH1B76^3'M7IQ$SN4C\C6E
M.CBZN)G14R(RY'?9H9YX^9!.NW6^5ES3&LO^5L]^I";\"8_/*^+T<AS 4,H8
M/P)"SG#.G#%\5:CHJM4!#NQ-2%;F@6M2=?[\X%GLMHMMV_6-@JK5R:'9^/CN
M4PG3LSQ1;>N'UD5%^+U+$G^[^V5K$Q%30.-#/&GZH7$PNA^6C9,.B'BG9+YL
M41P!+\/DG)1#& 'E *5,>B71=;+ ECQ1_IFMX5Y^52<E6(2*K'\.E\]LAN8I
MS\@OI6;X5278+L)PMS.V7,SSE+M&U@"=ERQ]M9_EDC/5H@F)@HX#5^D\0L2L
MENW+8Y5;!L97;FJY*$)K\U?1PG@.U[24UXE30'.L[)VI5L*U8YF#H4U@]N<;
MX?KOS<Z@!]K@J6V&43=+ IA:0L<+60/6T@X0 MS=AH'JC#84AZ)[M;< ERSQ
MDV11J@*VR%IHMPDC,%SQ.NTK;TK--JS,^8J2XTY AJ^N2U->@6F-%4=#?(K:
M*!\YMT1;:WA0Q(5D*57R<#,/+,X)QL>JZ[1#ZY-O@*K1BKOI<_N2)L.$KOJQ
MTVK]6:V8>WFT]^#M?[1@57EU.NL'L;VW?YA(E%1RA5R*%G$1.>BLEB&O#:4)
M*Y&D6@&CQ-O3;-)V!_$V0VQYR"L33>IDW%;0RL#J#4Z@N?"07J5@944MK[PW
M:H"#"1F:4LO?_(C,A^Z"/"373-5A8T9^A=(S!\/2LJ>]^&;TX??0[)VV[/F;
M9KOL7'G3C*-X0^/;F#4M6+:_AT&$P\</3?.UTC2_XDZL?A-FC5)ZX\]XC=SX
MVVV/)61-,G6OQ][^FV!U8R6_^>?)Q_X@JG3.@Y\/LSFB[[0W,MLO?MDG(N[2
MJ<H+]S3=4C.[E<]J@P85@%Y&CJ."D=6I?KZ:29S89)UCNV*Y)SCK*8OJ\(W'
M,U[FP!%3#]S]!D[/PQ_//V'?'[:5W8&%[4^8=D,3*]M2]]Q-?>T!%Z\IGB)A
MF0C5(>' X6'11>4""0IL4<XDT7FOA)AK>R7L#GLE(\OT!GOT<M,$/U,#M JS
M.(7?/U"X#^]^/6CL?-W&V\<>[Q_OG^WLY3"*\&W[_3;;W=RXV+D:9@&&ZL[F
M/BO#*T[>D?V+#^?0MN;.\0;9V6LUH>UG^]">[<UM^L_%UN2)!Z<5#9HZ%(E@
MB&NJD>/*(N/+B&MI%<[[+6258KX*LK;8:(N7$GE6\]PKXCE/=#Z^1:R5/,>*
MX>"99-P3GGB,N.0Y7?/<,O#<.)S,^<2T#0Q)CS'BRBFDE3;($R*2XE)B 3QG
M5B6C-<W5-%?3'#8ZJ&1QE,9SHYCAEBH69;"<TR KFE,US2T!S4WFSM38"TX-
M(CAHQ*WUR"9K$ OY7(BF 2>ZLJY7&6'/B>9>05J^''N3]\ G-E)&,3C51KS]
MMQC%3?;JW'TWTM9]]C\7RU^7<_FQ#%6$L?ZSVSEY6TWFWV78!%S]]V@N:[J;
MB^ZV)ZW71"2P6R0H,.40E]XB*T1$VGAM293"^ 36ZRKF"Z&[.KW0\@(_.!4Q
M-S90I;G@S"DI0P+MGD<JC/$9^,0,@?\P?J@:^ \,_+$Y%XBW&@N'$F$><:XB
M,M@9,.R4-=A$++(Y1U:%$C7P7SCP)2;<&:E$%!P;YF#!5X2K (N[=4&5P-<C
MX#^(8Z8&_L,"?\+  :3#O%*"#(\25GPE$0">(XV9M"(22;',P&?$+!GP7_P>
MXMB&^07@4WW\==*>.04@=!=ES;R*(@A+:\W\G:>R9K:?9+8/D[8,%QXHS0<4
M8&JS+0.D%K!$S!$LL:%$"9=SF"_0;[-$'N@7COE?GI<ELQEKT#\@Z"<SG7,K
MM'8HFN00=Y(AEYA%H,MH3+7@1-J5]=G.BU]KN"\KW)_.?+F:Z[P&^A,"?=)N
M8=%K[P72*7G$E<A)175$-"MXVC'LA*P+(CT!5'?SP;E7MI\RCS:R !.D!QV&
M3W=,BO #.V3$6%OM<N9J3IJ+DSY?6AP[%^_^W=DX=,X8+:5%G@900"S#R+B4
M<]2%Y!A+E-JPLBYGQ_[=70.I':A+K($LUMZ856VEQO3#8OI\"M/!^NP,M3ES
M2D"<Y7K'1E)$%8^!4VT569RN42-[B9']L+9%C>P'1_;.]&IMJ$J!)XM$](!L
M$Q18$4$@Z3S#+ G##%U&9+_XO8^)\U.QRC'QDR>G[I&'\A4%XO[TZ+P8BK]G
MAKHZ3/?I+*_MC4-8A&6@A"-.F$"P1(.&YD1"PD4BE(PLD!R^0E<IP8N/T_U9
M]#R/PPHU@]8,6I];?5D,.MXXLXQ8&:E#C%./.!8&@47#D;'!*&F=L]8^W+G5
MFD%K!JT9M#X1^^P8=&)'$B?CK*! F=H[8%"9D!% HPY[BKW 7%+R8"=BGXI
M[U9CX4Z%$Y:G4D+.TV?+@B/9\7!CPKTR66Z9LWGB@IQJLQMAJ."/U>*L,VC!
M=V4"YBJ']+5<S&7"TB7)H?X#=MB#_G[-/=HJ4VV^&_4%+OD(/7G-N=:!$#8.
MHTS!BD1RC=, IJB-R/) D9=>J40<B9:6N=:OE^\;Y5I?G4L4[JEJUZ+PP*+P
MX5!J%[6-#F$K!.(^.5@'X)/47'&NA+$DPF)PBR243#*7,-Q/:ZB%X6&%8>_=
M80HD8>XEDH;J7/S=(1V(0H3D'20O$UA;*^MZC=TB#+<4\JBR/ ^3/.>DSSGG
M=34#N<;",%]]/C PHV!![WIQG)QH.<]S-Y3KV7G1S/GD8J\J7G :V[;5;\)J
M.\RT?&U]O#R'D%O=;URMO%,66:D.,%PFDYZ5 KHH"[Y,IIT?)5N_<46>[DOH
MQ*HS%F[WS=/\HC*_?9F#O=.WK3NM\F5)A1QRTTR@!K7[K3P@U2Y<SD<_.IHQ
MJC_4/XNM[[&:H1/H;*,WVKWHQM-.M^Q(R#48GE\%J<G!S:*01V>R1$%ANW%2
MW,KR"*,$Y>.<X%DL8)!:^;\3W\+8G>20R=,R$7&>K.-!M]D+S:H:U5KQ%088
M'G=6Q']]/"V_G,Z+7R8)!^EI'X'<3+9CJD3&C ;%?V&XVL.Z&FEXIJ8W3L5.
M5-G?JE7Y4ZOC;WG"^#ZY5OQOYRQ7-5@=5Q'IEW5 ,@"KW/PM>[9Z61? #OJ-
M3K=9 BS7X"BSG)?2DR>BS-9>OBH.3_]490-@0!L T=DX.LN_C* 6+I/5YPSP
MPSH=58;XJM!#.![T^F62]&)P.FKT&">CDA^393Z&/T^C;YBQ?9AS 4 #M@M,
MR[7"8Y]B]WO3Q^*7O,M*\>];'S^5G\COOPZK4F2450-^9:2O0&AFD:W;38]R
M.<(R8"6E"MPHKJ2PFFK*% ^$$A*E/ 2279FXZZ'!=RV'9@D^HM:*!TY4_W=L
M]V#<-MJA#"[XN]/K=V._V2USYE]&.#=['@1KT%V6-/7GVYM;HV6=;E_L7\#S
MSL'^A_L^X'WZCNY^_<QW*+QKLW%\L-DZV=_;^'?GT]5E'>X[WL8'F_\!^Q_:
MN/GQ.*L#!WM';/_XZ&SW_<ZW[$O8WGQ'P.['.=)/.R-S@GJM+<G:OD P]F#Y
MPZ(>F0J>*K\R7N\VLH*E@K%<1]#&G.<F"A,$)TKEK$!6PE]7L]IS3'[Y]FOQ
M=\NVK]G5SV[YF%UC[8=#LGY5/[&A<UH263$:GFX')+/XU(!5"&@OCQ:,.Y!N
M_BLO4/VL 0#CGF?:S2Q6ED4Z.6UUSN-( PH@W;E82FYAM^D&90M/\Z.&E39*
M\A[=4Z:3&5T9J_(M.>^N/1I5AVIVRRJ# *FJLV61C;RN3-/DF!]!!?<->/*-
M*C^HYBZ'_"PRG'AKY\^K++!9#<3;B7'((_JNZGIW.S<3!G;J]ZKSNZG\\5+?
M1_35,<,6W=Z ]2)Y[SE&E-"(>-(>.0'&GTF*&V$C-]:MK(OK+L#_OB:;P^*:
M4U()6D^U,C]?27G-(K)]MGUT2+EU-KL&<.0!<8L9 IV#(A9!>?1>>F+9RKJ<
M+2$5NPP+LDZ2S!2U7-9EG9*=4D<?6W>]RX)3PR)5HZ)YYYD[X<[27USJC>/J
M.;D-$X7HLNY8FE-Q/H?%SYZ$F,=S<8.HO@45Y^.EW;<LCHHG$,H/9.?L$',A
M+!<464\TXE[")^,#$HDPX:C30<!R3-;(@MR7/QLH?ZUT>#W+/YAENOWA4!GO
M/*$>)6,EXII+9 1WB#A%I7$\A)0S?MQ6$'1>U^3/QDW72%^@#+"=HT/NO#4X
M!A2H5(!THY%Q.B*70^>(YT0P_ ,9&#GC*E?)=+V8.?R3:S/,]I^V;'[6W!=+
M8.[K!S?W/U:99/ZVW?[Y7A?:6DWQ4EKXGT<HP=O'G]GV^ZWS[:\[)_M?W^&#
MXX/F_LEGO@U2#L\ZW[[PY.#]G]\.KCGN/YSO[/FS_>.M?_?I06-_[^/)SLE_
MFH"2LWWZ =J=W_OEV_[7C]_^N?!T=W/_$*8&!ZT9BBYQQ,O-?<\3HM1R2[7"
MGNJK)KXUS,"LY.0C&B:&&A.9<S(QX9G47E\U\8>S4)334$S.P^T6_^R"Y3]\
M^97&Q@3&2J">P\*O:3X 0?-Q1>BV92:1IREP7C[Q31,TRJ:_@U_A?6S'W78L
M_FJF6'SRS:JN[+VKX?VX7N"-1SL>P9-"1#YCW2XV!D>#7O]J%=2A4P&4]G"S
M==AK@ W0N[)$1YAMK0,AE!K.*'.)8:UB8LQSBIVLH@JPINJ:47CGI7FK_3U6
MON7=,UBBAV<\/@V;LQR11T_!->R0)\,"P1HQZD G\P+,094TDHHP)HRU0;*<
MA4URODJ$N+XJ5W.:#3,PWTXZ652!MK-1-T)'7J_S]L!IM^-C#.6U]A3^^K>9
M2ZBVSF\6F&_=LRO2 BS#5# A:V]<6V:]U9H36(6D  K1P]4'I 7-$ANDYY":
MOX<-SHDTMGJ]09:9W?2V[.:G?KDX#47'O#K1.3K?V=R_@&>=;\-]N78JJ-I
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M1JG#%\,\H8]O;\QF]32[S,) :;?>1QZ(Z7C/$MW@VJM;1G2KQL;-][5H#)N
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MUG)O87.S0G(J,"U&60-XZO7E.YP$L20W!/$&MC0G-3)@B*'$F(&5*9DT>.^
M[=]6_F9LE#62'48!$K?ONK?&06;%ZDZZQF V]JHN/-"WX^:G68"[9?N>40RN
M=_*G)/S5K AJ>*(YZLZ( ,@FEA% K[:8.:/ GEAN160;M12\VEP= /).!L5"
M8 8%D?Q(6S;8Y'JJ,"4)@*QS34+.^')CM)&(+<;/*O1F![>V7?[Q6@V\<VS^
M.&I9+O1.OJVNPAVLE(>HJT PWL>C^.%5"RMHOD_8_;H6?ZN]L'B0]L*KE6NX
M$;A.:#UW&VO/>M^W[GSYY)?+3@ NED3 ;2+)=-6:IM]!5=)25[34%5V::/?+
MSQ^/3SQ_^_<?[>-?CCX?/W\-K__:/KKZG1S3%U=@8ET>G_SUX<W9ZYN)=OC-
MW_">J]-._HXW5X?X^ 3,L#.XQ^>OV9N3X_:;DY?D^._C]MN_<C+^RVFBW0?_
M3E+LF.44P=0YL,QT0C98AUBBRJO@%'F(PJ*ES=A]J?IV5V\3R<"W;IO?63^S
M18;CP><3(9%4P-Q&G=OV><)H<LDG+VEAN(8PW.5-AO,PUPE+B8))#'&B/#(<
M:X13H (;#2ZIW3L@%:M[>9C2R^/Q\%<W?)@D1=W(HGH(^W.5+B%;2&<_/%X@
M BZGN WANZN;?)>("Y%YB9A1!'$;"+(J!S$81HE33EF9<NT$H3E8=8MJVT)=
MP6+,/90Q-Y(0)S)>ZZ:"]Y@]YKY:ZO_V.O\[[;)O<FB:O7.LTM,.)QX8$<S8
MG$R4=#0B@54LI0S8<W-K8$8QA!]W8\ W-P:.I6-8<I1$$H@K;)'S&JSA1(+R
MT@(-D=$A#--J0V;P)K"SF=XA*]7]V73OD(;F*MZ:O!2_^,[%H/TIQZAWVKY.
M;Z\#RR^[SY8?H*]]RS*/PS?O>4EEFSS0B-6?OKD<[* NS[^7%Z_B/\TOX:<8
M\/;9V46W+GI@SR_KH_MG+_[][Q?/3OXXW-9!?<KA'$WH,!?@AV]\?]DZA]O/
M^\RT6<(X3W"N*/RDL<%Y[ ]RDE\NHU"!#]K+59_>QRX:Y:Y,IBD'[/L<^3!N
M&3(!A'W?CZ-T]?-^+Q>[&,7VG_>&L3LJ5]*[M)TAW-4X%_9&+,?D?NI4R%&2
MRDROFUQTI;ZU40H[?$6XR%5<IO5JQO>1BX)/!N!&DO HD:7G8.(FL207^<:[
M=?YAG?PX*F^14R(OQC4RTL7P(J<O7!<9F6G2LD)%JC5H\#:"K7=]#&:&DE(%
M;A174EA--66*AYP9&Z5\1['>F_G40Z],M71EYHRD!VYB\?N%[0]SNO_/DZS4
ME]V1C54WI6A$%XK+H^?O/[WM_GKZ]JK'CDY^OSS^<,C>7+WY<OSW2_C<X9=7
M)S]WWIP=G[U]_@?84+]_/LK7^]/@M_\YQ?[LKZ[]VUR\^N"_'#]_28^>AP_'
M'UZ0-Q]^9T?/7XBCO_]JOZ%O/X(-!?;/X1>X=_*?JY>?7_W^3GF-;4H>41UR
MO$DD@&EGD&$PR@)S85V\&<C(B'*44.E-3-PFK",5+/<>#\)H+=7-OA/7X]^Z
MGH#6S RT?GC=M1>A#;C[Q]<;22P-6/CVW<S?O38>WF)#=#IQJIPFEA(6@@7S
MG EIOUY$?P/+\4]_&L-%)[Y*7U^8#>J1\A2K\\O1YW=&RF2M,$ ],B+.0T)&
M68LXBS$R)I5W"U&_6OH@E'$:/L)SEP.GO?..$&,CO+2P.N]JV/*ZU-U3YIA>
M)YBW1[4:S\[&^?%Y,_J?:Y"-"K3<J']UH_33=6Y=W2"C%;LY^W-YE%1M?,%*
M-JT?+JYQ^N,=C?I-#Y=9P=I9W(+GB*44B5PH$JF;7R3RF^Q]@PVD\22:8)CF
MCC,9'14J!>V"H$R8:&\+@_LVB]P([I>..*ZIH)1P:;1Q-F#L% M,8D/D4IY9
MW@9I!)MF-2_B N;P;F%K*T7#D7W)U,9#]_"^8.5FM^MF^=UNZ!O''_>(:GSB
MLN[Z6UY2S9=C2W&TL;W(N_4=CC[*8)3!*(-Q]P88NSHJL\>FM;5UQZ/371V/
M/^/Y<#P@N P(#$A=5*6,13T61[;O3V]'RBY$FM577%:H>/F(/)NMK_WG7'WM
M5]?ZPH_K1*'=>KHY>\!YAX5V_S"W<I.-OLD="GI:CK$_\M'61;PGC.X:FUZN
MT9QK[,)&\O66C*,E/:[W6"M6 /Q1I?+</KS>9[.V''*#^][YJ")YOY]+YM4;
MS%H)8SL68+?3.7%)ZZ""C)I0Q6/ SC*E"?>.RZ!%'$=8PV5OC;"^<\3<>%'F
MJ&HP:X;YYOYN#T^?70Q@I&+_18[FR2-\.&H]$T[LEZ9$T]W[#.[-W[\.WI[T
M+M]<'8IC"N^Y.KQZ^_<1AOOD\-K9FZNCST=GOW[,D7%']+4X?C;^S']^/75G
MH?/JPZ\?CIY_9&_^_@O^S/?].SW^<'KZYNPM?,_AY9NSW_'QB;]Z>_(1_^?J
M]W$DW8OAT>&[P'1PFAL4F/2(4^&0PS8B%D(.L*:)PU0>B IC5G%S6XGNIPBS
M+GF\A;.^QEE",6<)=9I(Q2V/.NEH54R,QA1<U.,X #7F+&SFJW$7SFH89UU>
M<Y8"TL(!8Q1-X(@KZ9!55B-*<OL'"KM3KNY-"1#68DI((:Q"6,TD+&6$=\02
M0;#DG$K+0XK&R)!P[A'+QX3%)X0E"V$UF;".IT:65(;Z7($W<JT0]YPCJS5&
MC(OHJ$DV&K9WH'A%,"V$50AK2PB+,(69)T19*G+L#GB''E.JC.)&$DUO1%IB
M5KS"1A/6U,)RB@9AN47**B LF&>DP9Q&1F"6@C*>2 F$12JQI,1=*:/27,5N
MU*+!IM3NM.O3HDF?]%M5[>^^6HI4*4J>3##>\VBXT<I@HC2W+G%I7=&^MHCE
M7L]J7S"QAE'#D<=>@A\)5&=-,B@DF%XL")AM?N] TTJIM86O#992*?60-HQP
MK##X693 IB9XLD(3&Y1/%/PNHV1B12G:+H1/[1@=O0N:)61"<@@\9XM<$BZ+
MW3(YR5PD@'""625U@?@.0SQ%#6P?/?=6<ZZU,20EB2VEFA&&4]%6M@KB,]J*
MT9A(PC0*0AC$M0%7)24%KHI(+K)$A5)[!T94A-_6X*@@? <0CK-]SA+.;4?
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MO+D(ERQWU4PNQ^QP0[4ED@KCN:#,*<=OEI<J.D/#$3[=Q D)B5*)$1A>#O'
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M2:7 49 Z(1ZB08XKCI0W046?S[IIK6D0C2MMBBU06&#C>D9A@:=A@9D4%ZO
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M=P#G1XP:*)C>-*;GPP4P6%1..X4\3AIEJ1XYYC*PF2'> VGG?D.\(C0'^Y5
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M!#&>Y?0&RBIL<"7-!LKR%ZXK7->D!V]Z2%3ANO6X;J:DL(TD2,J0Y,D@SI5
M&JPY1"48Y[!_82_$J"R%5A6EWU%45.&ZPG6-$RT+UZW,=5-!DF$B%0X680^>
M*T\J(9UR&*CE*@EE4V1J% 1&X'^Y#>'?.Q0$]@TY\CSV6X-3VX^W1GG=X;'O
MI@_?>J2SB6.A<I=-O\L=DOB7[WBCLY7[_?R7';3].EWG=M0:VA6#Y[?8_S.S
M[&;%>SIC^,Q;-R]LOPOC-IA\;[V^BI6SFI6#9Y5Z911W5&D4H]<(YLWEZ R+
M%!-.B6RHYJ:Q>'\3&OT6N6N%@YKT;/?AH#5%]<)!#\U!4P5=.RV## Y12SWB
MT48$>X(&=TMA'A5)-A<[Q?NT(2UM"P<5#KJ;';2>V%TXZ*$Y:*IL1VPX#C[F
M9A 6<9: ?NI*91K;9"T5(:K:#EH,42T<U"2<%@[:J A=..BA.6BJ. OMHF#*
MYYJI"7'G,7+$461\DHDSSKEG3>*@'9*3-R]]/6]W+H8QW#,F>330RT3(-;,
MMIBO'V"$=H_N'TUZ&Z_O0OBK$3Z9"Y,ESB2.%6(XL=S/D"/+@?]U"![<!$ZB
MX6N+;YN'S1/G3!4*+12Z$\IAH=#[4NA4.[2,@U]#.:($O'7N:$+::8Z$IQPL
MW?Q23:%T,6FL4&BAT$*AVRU\%@J]+X5.I4\;&>QP/"#)+48P)PE92REBD24M
M<[DS9]:6'0J%%@HM%-I$W;90Z'TI=*K<1H,=B52BR ,X\E@$I*/1" =G!4X!
M2)7N$(5^0_@-[<%YQU[FQXQ?9]WRSOEWEH$M [M=[ZP']I]UV8^#FMOR)M;N
M7M3-HY?^)K0_'?Q?^#&YZ@SU^)@KZ8PWZ8/_Z_K_/+AFQW4_5N]I6 :LI%2!
M&\65%#:W4F:*!T()B5*^@S_V9C[UZ%D,-)L+E.RWQA;#\<497,//FP8X&N)3
MU$;YR+DEVEK#@R(N)+#;E<RF <5CTP",@UKCGS<"_KQP@_@_%S!P+S[!C\$)
M7/Q?G9[_^-2;_\F+R>:/WWSX'?[=.3NBOU^]??X:'Y]\_ R?%V\_^"_'O_SU
M\=7SXP]@+%P=PT;^]C^GV)_]U;5_FXM7'_YH'S]_^>75WV_@<\<?CT]^)Z].
M#N%>.V?'5R_PV[]_YT?TZ/.KYT<X]]T^?O[ZG<5$8^82<B8DQ)--2,OD4+1:
M^A@5=\F,##18R3$<YE0LXRR)1%%BN>2<$*>4U1R;J(DDDLJ]5@23ZCROU?X%
M &8ZYJW1H$]L@?$D+R[:NP.AW0UPQ1^IJGV41[9QZ:28URS21^OHFV-T\*K;
M^M7"9_J7+2JJ%BQ84K6&I['UK'<&CW'9\IW>((:6S58SV#6?^^WA,'9;YV#5
M #!Z*<']=M_#7UJW6MEU)M#@AH&=J-">1NN9=)S:X#0A(F&% X;;9*)&$6"(
M"C3YRZR!_?+XYQ72\OX< K9>#@:P=IY?Y/L%Z[O="[4!/H 9J%]J4+[>H\/P
MZ/+5R7L"]CQ_!=<Z.GGS#HA-)&H$V-1:(&X=0> -$:2)(0F3!%:U :[$%1.B
MPDOZQ8T2P 9Y9<RLI_\>P#(X.^ME@,"<M.RP91<6TSG ,>8/_M<]/#<)OII7
MQE(3&">4:R:XD%C0%"F#I?_NY;+U1!>6#*R$5ZE>.+_EVYE^6UDDHT7RX?V[
M$+!PDA $ZX'D1>*1I4P C7N2<IU^1F%#U_M+*DM.<P3W6R>P/KIQ"//> [8/
M@US!;&;-5"V;P,* V0H7\&%8(/G%:SJ*_<%_M\ X\N"M#0? 5*%>8NW! +YG
M].\>?* /^\$09AN<[>E*BZ/FDH.J]3GVX]?7VT;6&1(KT-:A][!UA7^WK6MW
MVL-V'/S<ZS^;/MNX->9A-YS8+S/\);_WI7GU^AU-(8%-J9'2B2-N(D=&,H6$
MM9P8L,]@QO8.8!/<OZWI+>S2'?C7_J(5W5K5&OB&#3'>R3G=5P)V^_/>H)V_
MY\=^[, 7?HH_?6Z'X>FD;.?,!\<J!)Y^Q+I!+PM*MW[D-L/]L0V6GQ''\P,R
M]]/UPB7\<3H\ZQS\?U!+ P04    " "T?F%2)RAL;<P;  !@1@$ $    &EN
M;RTR,#(P,3(S,2YX<V3M75ESXSB2?N]?P?7+]$:,RJ)$7Q5=/2%?%9[PM;:K
M:W9?.B 2DC!% 1H>MC6_?A/@*9$$ 4ENLH>*J.BV)&0"R ](9"82P"]_>Y^[
MQBOV?,+HEP/S4__ P-1F#J'3+P??7JY[IP=_^_6GGW[YKU[O'^=/M\8EL\,Y
MIH%QX6$48,=X(\',^.Y@_X<Q\=C<^,Z\'^05]7J_"J(+MEAZ9#H+C$%_8*[_
MZGVVCD[,X6!L]\XFJ-^S\/BD-SZ!C\/3D\'1V?'Q*3X[^^OT<[\_=!QL'_?Z
MR![WK.&1V1N?#@:]P<2QCX^' ]0_.Q-,W_W/OCW#<V1 QZC_^=W_<C +@L7G
MP\.WM[=/;\-/S)L>#OI]\_ ?=[?/HNA!7-8E],=*Z?>QYR;EAX?\YS'R<5*<
M4+92&CZ_$O;)9G,H/^B;@Z&9%.6,B(0UH7Z J)VRIN&\O+03>(?!<H$/H03V
MB)T2,*I PV@OI4-!X)%Q&.!KYLTO\02%;O#E(*3_"I%+)@0[,!!<S*%>*9#[
M.4#>% ?W:([]!;)QK2Q^_<DP.#YDOF!>8- "X03Y8]%BWPL$6:]O]K@0(T1O
MF8T",4SC\J*'!:)#[ 8^_]3+6'QZ]YV#0_4&A'YOBM!"OQ%YPJ@A\3?ZC<D-
M5_/L[.SPG8^_RF84QY0HW^-_]LR!7K55@U.];OC42^AVT89L[NFU(:';L@WE
M4TBE*7G*^XB0M^6,M\4\WJXMF[5CTT8(5CZV/TW9ZZ&#2>WD\*N(^!^5\P%1
MR@+!A7\3?[=8$#IAT1?P%4?U<P+M$YXD6K:@P$OFC_C?9^39'G-K)MOAPF,+
M[ 4$^WGE+QC,/#SY<@!JKI?HM]]=-/X$#4E*%/BO#D_^\R&08/<VZTA"RY'Z
M<N #%BZ.1-/B?MO(U>TWD-BA*U#^L_?>P1/=W@,)H>0_H?,+#^MV'DA\,"HV
MP9[3O\#O!G&^'%PPL%H?T12:Q[__]G1398"(:K/B"<^$:X;&KWTP"^&?T<O,
MW)XA* U.^LOA.L$:J]#'S@/]5?R]WL^8."XB(5R;&\ITJZ.JE"S^,I&C5+K4
M9RYQN(E_CER^C#_/, Y\56E7D4ND;PKI#T#DSR VG(H_8V7$O(R(V1Z/P']$
M'O1JA@,"[=P2G%5><J3XA%9'ROAYA?=_=Q2Y5%H^FSR FA5-VV!*5?"1(S;L
M]RT98AE3@TV,C.T>J\D%FT/'9ICZY!7?,G]+R(KLY,A9_?Z1.G(KW W.?H_@
MY#E@]H\9<QWL^5?_"DFPW ["$GYR#(_Z_6-U#//L_V)$%>Q1G%P@?W;MLK=M
MYU_*1H[9<;]_HC'O@*LAV'8(J9<9YOH&4<7YE"LOD?W [)MF9(<3WW:9'WH8
M/@"Q$5-W2,3/X7R.O"7H'#*E9 +V$PU&MLU"&A Z?831:(.WIB9^15YR:/B_
M=6ABQD)W9:R-C+>1,-\CMR;MCT!0"<E!?S@H3C)U),&HC__JDCVO!L +&KN[
MA33F* -TV+>&VP$:5;*'<UWX]\CCWM KOL0!(NY.@2WPED%L]8^LK2#N&6E]
MQL]QC7N\US$9P2>'N"$7TS.V0X\$R13\@!&@4)M\3!Q;VZS(4#C? B-K@B':
ML!\GE<AEI;C#=HZ@,FZ@@N\MFC_R_7"^$%&4#Q@V^I7+1]&))4)ZFX^B?&'>
MI)YHDY%OE)%K52?'U1-^Q33$3]AFTXBIVI HH9-;Z:=F$<V8B9'CTFG1:TW*
M:G+YM#JS1-RU#HA.SH8+YKIHS")[9#3U<!1.40WOE!-+YX79-XMPK' R,E9[
M)+1F2 T/Z30Q34L$N95PZ>1<>9XQ+PBP-[^AK]@/-"9**:5\EL "4D!#L.EQ
M/D:.4<<1T'+TJ^FE;KTY');8]Z5H=-*%+Q'KA@Z["B>Y&K,LL<^C E7G7?$2
M::<^S>@5Q,&'\H1Y/G)S?O'6B&K4(<?ZR!+[0VI8YYRCM-X>5-SC->=][BX.
MA6M$O-^0&^([C+@@-1:W<E+YZG9L%B<IYV,(1D:>4]=!T%G?9 SD"]S)L.BL
M5@#2Q16N5+ CW\>!CZAS2]"8N$)YQ+\[*$A)&$5/7+EXA$[/D4_T].>'U"S7
MJJ=6_U1U+/2,J"T&-,;(M28IY1@HR!.#FXV,M%&&:-5>X2;BW,QH4F,EQ_S,
MZI^I8]YMLZE4WMFDFP1IB@5,.(^\"DDE<V.Y/;3:54FA'_0MLZ\.?7XN3XP@
M2PCYBV]D34A5P;*3(^0._9-Y%Z$?L#GVN)Z^8-2&[D0)G6QR 8J1!$_$_Z$V
M##3X2>TN'GTK&,R"N9%R%YI\A;_(K1(U&+R*/8XE<M>QTK2Y2DVW <\ZV!;3
M+MITZC!HJ6Q]MG+U/+3,0KJ!/KP=5,*/'EX@XER]\[U/S)%X@.4*H/'X08C(
M;%6#5(F37/'"&ENPJ6.V1L)7P"@X&S'KV+C>@[8B:AU=J\%/KF6/AL5XO#*
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MJ0=Z]<[-JI#X,['T3'CG=?9)-Z^CI7-\=/SIJ)_;\7K&%/R0>Q9@_S+$@_[
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ML-9C3%N-U6R1OR4VC4'Q9($ QMBE_9@JQ,XD119BRC3@&M"G[1A6=9*5@HE
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M.7A!G4ZFRU7A'88:4I*G-BEV3^G5EGK=RP9NSGR+1V>!(:C6Q'DNRHV(GCC
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M#PW+%]/%<GY9SJL\]Q'0Z%^6DRM9IQ!-)*#1J94X&6(C!R*YRR%(A0%5DW8
M]P$:4M[O:!;<;1E:0?K5_+N;:'Z;^FVW\-)!;06+J^RB5HD887"]9SH2FY0A
M3&6EN;0,%_[VI-B#;!!;C8WI<:I"*O(DPWP."3W'8H!++_F5%VHA>NY+T[[D
M I&1:Q)\4 3]0,LP+E'B=AN-6NS8B^? E-E7PXG3A5^E!/0F.2]BG*^.1K[,
MK^;P87SY8>094,TIA@0*=293]"1P#$I"EH%9&7+L5 3ZV#A#2E"=K.7J@JVF
MZO$-1)>K8!'FL,"U2C #@2I"/2\V* J$$PSA 6P*5DJA7$<]WSO(D+)!U91<
M1Z0-7N9;#O7FVU492UETK$J<*8V+#L6E1CI<=#PH(,)XFR77C((Y^,5^>,P#
M<S$#M^5-)=Y?GN6ZVN,7OSSYJKX#'EX]E.P\DR9AI! B&)Y(,OB*RX@.ORL-
MKJ4/R5B-'IQO4GY>,XS<?=:U"%_#1_]EU:FV+%[C:1Q_]),7TSO5"E%QQH Y
MXG3 &(>!0'IG3IP4$=F=G8$FL>9)J(<;D![ I]O>97]ZK!:-' 1Y6ZH@3 84
M#"/9.(M1=3EUQ:4G*4H(7 H!+)V=<0.L.3D/T8[1VAGYM:I(2,Q9<*7S3%""
M2- *W75#,5#GU'M@@<4FC7Z.@SND\I(S<NQ@S9V/9:OR V6=UQ'*&;J8B90^
MDT!-)L4E36"#UJI)@X*CT XW4.^38P?KK:$_CV%G"2\6K_R7LD/GIVD3B&Y;
MM1[AQC_^S-.]]P-QG[J3]NAP1^^_=GUR#R)KL4?[Z*#'1XN=']V#Z)I>UGYS
M\(NKP7?NF-OVR>51!^$R*RG@LFGD#;K?)A)CA58L@Y!MVAX=@+%"'\;=H=[.
M?=JV"<9A?YU-XT863 <J(6622Z<9"5F1$)PFU ;IO S:B#:WO74$.*3HL17'
M]G15K*^\FBT^RYS?^(F?[TY8<E6NOR:&A4"DPL C\&P)RSSS9#Q":7)*9C^<
M(<6"/=+F5,74;1]_[S1OLEAD8!@M>$)-=,7)$Z7+F22,B8"_D(RZ)A'@ 1B'
M%/;U1:=6*JRR#[/E^F6(LW*W3UQNG8Q12MHR307)H<2F-G#BK8U$9"68E_@F
M)/:(T_3P"$.*SUJ3H:*L&\9G;Y:S^/O[V01%OUC?C7F$I[SG(:?[Q(\A.S5R
MN/O\HV.L>Q_50@HMHJB[HUPU7'DUWU2#K#YS?#1U\! M9'?(K.K+M$(!<8>'
MMI!;VS+B!_2T^M7+CV4&BY>7R\420^/Q]%T3&CXR5E,^'C+/?L1]$5'?^+O?
M<*CY^F,O5K<!(@M*$_K6*N@Z?E]J.4H>#57U^LUO9U'1 >,V5<VQ\S]5)3^#
M/RYKO?G#TX6R#T&=61WM -WX\UHS;.'HK)]<82&^YT&UYMYVP5V/<?4J76\J
MS?++CU &GKY;?>;59HOI5#D=,50M29XZRUKE6+!8 -P<]^KN["L ES 2.G*1
M-!!-)8::(!RQ*BNB0S(R)9"1-3E"W17@R;O0'<>YZOCA4C"FG'PO1TYE=.68
MBA4$OW,T):[">>5Q0 5-;Z5:+;AV9U>ZH1[KE3P< G)5F>%!4P\\$I8S8G7!
M$Z^B)%[K')6(29LFFSH'(QU2FGYXA#M8EV>AW+I0PREA.,)2,1DB?=0D1,^(
M8114XJ94!)V;<5UK:WJKWQH:X0[6Y'GX5AHJ4,'+C22<<"LLD9)%$D!EXFFB
M-/#D999GYUO'WAB]U7(-CF^':K)WOMWLXL&8%:94U#K'</5'8906ZXZ(H-!
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M?>WKCO;4O>^'1CI^F[O+4]M*J4FAP(LI?@EO_>>CJD)V_[K&Y._!4G&21Q?
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M$MSS"<W"[^ 3W@Z,_E5ZN>1"GGZ__WG^[UYX.7EY.![6B>,U_7'U@/JJN\#
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MBA.[X3M.FNSOBJN,T?LRYMT4O\ PO_SV!<<SI*7N[?PS3B^98Q!%H:G-*2;
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M#H8&+F5B,5C%N!59!,5=HTWB6W ="S?Z-'^#BLLK@Q[4IO!":4\(0F%:J<"
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MP<0LZM+H=IAD.KWT6.C1UMH-+MQLZPC[YWB*,!K^'\QK3@^RK==.C6:RU*[
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M;'(NLPGDZ!C2B\7[K)'?3MD;]2.6/SN;[M[@?&"\X,*1)6Q4P'30--DY,(Q
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M"D9K471>*I,?C%\W0#U6=>N^O-.B#3U\7U6K/DO_O1A.\</GR73^$:<G%Y4
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M]SEE)I9[)1A([VHY703-,0>==F!2K^">!.GNSYTM]IXN#.H/&F65RE[J:5>
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MY]2DE7%WB$?'GT;>:7#4?OM-;[2&4B59BX<$T)H&Q'%>(K,5&8)3&)I<$GJ
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MH=Y,X<X6GV(GO8+'PYX;A(?NESR[>*+G\OYU)=+LV9@"Q"D%BI/I^H2P6%T
MA67)>(*5 5FL$H<0DG<N*TGI4H?=_!M><5AUFZ9NF?1OTY[KN]Y,QFMD*S"(
M.22!E).@L4Q+  ;HD!7' T;G<]%=''SEP<?IUOWLUZ)*>!D*K5L>156B00K.
MHX_U4B$EG2%EP;*U4N>LO7!M2H(OHGB:0>7^#FFUIWHG0YP/8YRK3N:%@I0N
M8VHJ)=U@4/=T1>+N7-EUL^A0CKZ/$[*[C"U #!"X8L5DFO9CUBP:G1E*Q1U/
M01O71.[B\9#WM@L7#YN[N_CWH-<J5#3@4Y!,YHQDJ=I%3M:&%:"%C=QK;-/A
M_0%=J[A_AW>^BK&+MZX-U7LLD'R/7W&\H+^>)I].GW6'VL8M#]F[+/$V8!L5
MA08R)L?1!T[QL4,?C3=%%>"80!LQN!GC?B:[>U7H]<]J8, NE9DB0]&J*.FY
MU@%\(+9+*4PT/!)1RQ8[]E-;^6(X@T^?IOAI=1*V>L_Y.4$!9\':PM2R%WM1
MEOEZIPFD2S8A+RKH%O/<;<#VOQRS?-[IC<+Q\IBOYIK/%[/YY 2GIS<.A^-/
MSV8SI/^CC.+;0'NMBP7'@JH)OR6# *46E'PZ=-HH:6RC*S,[8[T'>84^F73U
M(DU;;S6HB=R&\_40XFFASJ7/^?]@'G"$Q"%RYF)=][27+/!D&:>XW+H<LI!-
MCOEW@WEDM&KHHQ8J7=M-L1)],%: @<!4$&0&5SR#4*^7J"2M$=D*WT;W[P90
MASH.;\J1WJS^$,ZOG]>K'#C] M/Y]QIT+Y.^%(3F/&26 S=D'>EKBVW)A)<I
M.D7FBKVUC]D&X+XV&OOS[*1'"_?=>@2_+*;I,V5@9ZV+-B&N,J\N('MO,],5
MW>'/H/=WY.107K@WRHCB9536L*Q551H2=4I-@244E+^H:!/TU\OF?JERPX'S
M/3%E%^/W+1>9OT)*M+RNME=R1*-3;< M0#,=:H<?Q6GNK.<O6=)Z6[KT!-AX
M[('[I;0Q_*0?J_5\?OQNM#B)] N*D0I^2$,<I[/+Q%Q7"6X,3&I5C[4K<RVO
M+7M"LJ6@$\)U<.8-KS@VQ_9ES9Z_TK?SSSB].-05))U"ED(3)%X;XWF:E4*.
MP)*4->(I%"UW*16XYO''YMP^K'CMD7"/6\K/)R/R_V0*58'@S!AWV1V][DE[
M[XUV@KBQ,^JY$UXIKU!%[:SUW-0^8DGEY"E"QT$'M#V8\>Y[S;<\L)51N^PZ
MUT:W&1(Z)8M&+%5BV,G$53 IB1"NLVT_6\^7'W[AU.C9.+^9C-,UO[[0T'5V
MGN%30&P 0V FU1L:Q3KF8RHL^UAXX2E&U>1J9)^#V*]ITU9/_?F%ILOQ?'7V
M]AX3TJ_S +*./GC)+')5"V-JVQ;ZIQ3IJRHH4U*VPPJPTTL/OW5X;P2[W-:I
ME6-Z#@DO "6GK($^RWGI)1BM=T<FO^*S]'F(%2Y-R]HKIYASP3*MO&4101%Z
MC=RI& 7O$BK>X=4_V-3$23U'H-OAKDA?M3L)GHU.&&X5*X&B9.VAL$@Q,>-*
M\H!&&I6Z1*,=7O6#,[TXH<?ZQNOAO9]\A]'\^SN<#B=Y(+13I= \B!Z(PIP#
M R C2.5LI$@PB$WYGATX<NE5/SC2BQ-ZO&E]_2)ZBJN>";^D1#K5W[V .?XV
MF=:KX</Q<C #%7,@A(:Y7-MJ.+*&1Z TL-:H9!36)GGG6*<3A!^<:NJT!E>:
M[U)NH&P$$WAD,3I)9JK'B^ SLT9)6RQFXYOH+#^*XI![)^2A/'N5C*;_Q9&^
ME.F0_J7O+[]]@>7YQ&FQXVJB!@2A%>=,.IGK:7=@WDG+A%4\9\4+I!VSN\[O
M?H+,.HB;KM+*[K7]/YTDQ#P[_0RV3=,##LXG9PPK")SI:#R+RX9%*6NOA82\
M>:=]^RG K6]ZHI3IV057">+Z#[B>3Z9?ZL_P%1GI!.O<",&)4.MIDHB>Z4"&
M *LURR'$)!U*(<*=HZNK[WNB9&GBCJN4\?U3AN(Z''X:DZ7.0.)L8*60229.
MX&RJ-V<% T[1GG4J9 \J"]Y%6W2'5_X@3J].N<J=T#]WGN6OPQDMG[\AH4,,
MR),4S&3* [1,@@5M/2-.@T[:@, N)0:WO^D'4_IPP9:-Q+YVIR_ >[.HEIV4
M%_!]]B^*M>9(I)[7SAQ8B.,7,TJC:L<]HYBIPNBZ>$-V,9JI (8#CQKRCEO5
M=\+Q@UWMW;>%>PUVL:O@?QI^@:K&1DGE:/*E_A3&^3U^6HQ@&?=_K5)<%RZ_
MG9[SU/K2/X8CI)1S3)^5DJE$3F&>*MK4,Y_:2[BNV=X[CT+7,I&['Z+TA/('
M;^_;]5M8W6#?_<+0GD].3G":AC#J.AA-"X$3+'%%24H6B8&CQ,5Q@U)*&I/<
M<87N!=</YA[>O5NXVF#__PS<&>S-"SM%:UF6(H=*FGIDH1@43DN'U%YZGBA=
M\G=>]&]]_0_F-7/6%H+=RZ:_<#YPF04E29(^"A&!^<*1\91-HE\BXL;AT@/9
M].\EMU^,ZSMJL<%9 4NQ02FK ].H*4ZSGM))<BP3SJ@"N>B=3VIO?N&/;ZQ'
MAVSYJO;:9K[I!' ^64%<@:: _SW.$&HQ[_AB6#6@O-)BIH_**5W;Y"G)@HF&
MY8(^U0+Z8.^^Q;@CF!]T.Y CMU!QKPWM%ZO6>K^37=;?R?,%_81P)2TTUNYI
M(41D&H)G/B>*PFN?SN2-E)TJD&YXQ1.E35]&WT*&'K>JST?_V_ ;Q<#38<+U
MHOKLI!;^+^5J:"X5"G@**3"?M&?:8V3>5F,DF5':F(+8?=NZ\^N?*(D.X:PM
M!-MK/WM)^/4)W]E2+!1-<GEY"QUK.^ :VQI*_K4*2E"@F'7H,L]L??@3)<?^
MAMY2S;BW],>J9>+L/(]>2IC6_'I:NW8."$&*%@0S4,5&/4U^ 33E#I8\1UD$
MA])&W_,68$^014U\MH54^\LGGLFB]F"S4XV#Z+7D6!P+4OG:.R>S*+-D(@6#
M021EVVB&]#^40RF-/!BZWC,;'JR625 QQ'KC7G@CZB HK"1;LE*D"^@QA4YZ
MH(].R^2^^7"; LHN?KDW.8LN()^Z LI.CKR3KL5=O'!OE''U9HRBZ=M8)9D6
M0;%@%6>.IG11LA,TOQ\)57950&G/E%V,WU@!!9Q"U F9*BG6]B+(H$A@ JRI
M]ZJ3%UURNT>B@+*3X6]00-G%:CU?=WWVA1;"R:_#R0J*#QJP1E\6HF*:1TTY
MHU0LH>-:F02^=-EEWGCLT3EP#ZOU_076WHS_'XXQP;J%1\F<4XK&LC$T*(T$
M)H%D5DCM?+$6.MUJO_+@HW/B7I;K_?HGC);6+)/IRR_#C"?#]&Z*-%;,8YS-
M7HW'DZ_+(H:UHHX4/!@3@1'%,M,8"TT:AA-V[4P1J++M<C-AYQ<?&PW:6K[G
M&Z"_#D<C2F#^0/IEAM]ACK/?R!P9+HB\&XS"D#%8,%5JR9C"?'"9(274,6HG
MH%-5>8=7'1L5^K9NCU<R3\^1ZD#KN-^6>J8T3NL @@),)SE!R2E3 %$OZ8$)
M%'*&8HK119;09<J_]@7'YNA^+-GC)<?U_D5M!O&V7-B/6*80NO! W,H,7/:T
M+KDJN!PBDY"3P!AJJX$6&Y1;T3SQK9W^/-6@0=958\#V\:_%VSK ;=G[:D>\
M]]/6J@=/;QZR',!-+9KS[0B;6PDR&L%X-K7S@#(,"#R+W !XF[G+37IF/ A6
MW=)OZOY)M8MW&I#INDE\37E'@720A6%PL?9E)TM %:WGVD+*7$3=18R]-R&[
M^VHNU=2K5]I ].:2!HU$/BSB#/][07B6A?KGO=J\%,5B8-;6O9>0)$5L(C+N
M*":D-5Q:WZ1CR#5X?H1'O7FKQ]SY!ECK[I =@#5M WH=LOL)>GKQW^V<V,/X
M+5IS7@LP98%0=P:C#O0I"(?,EQ"8]QZ#E]'CYK791\F*6X*6PY)B%YNW)\-J
M$8PEUNN(@LDJ8:Y!(RV"4)CPSDL=@BBJR4V7K6CNH==E/]ZZF0-W,'6/\4;=
M@7HWG>1%FK^=?L#IUV$Z9;E6*151]6B+HO^J=P!]J#KVR?$2+7++N^S"=#KC
MW@;@B4<6O?BEQQW9"WCJ^%>(9JO/H0NHOFMHKD5S^)J9_1UUU>L]6;GG&IGK
MP3FT&2#4H^"J5J6E8R +,*FMYDYZX. ?J>MOJ($YD.=W,6Z#X. U01G/UH<&
MKD!"S3-S!*OFPX5Y)31+Q9I(P\NE30IZ"<5ASVAZ\LRD+[/V7!;SX=G[#\\G
M_Y3/W_[SU0L1_GFI7"<IX[4I%-N@H!&"Y2QF 8R'%(W3.D;?1:GDIG<\9F?V
M:K^>JV5>O7FK/>?KSE->\&6K*<]5(B"<4\SJ"PM"Z1"3347G#HZ\]-#'[KF[
M6ZCOBIB7KU^_?/[Q_3/U[L,[&N>7Z1#G,/W^X02F\Q=8Q[J>)U0 F@IH83%U
MGD@UFK0VLY*3%C*C-Z'3?<2N+WSL+FYCV9XK75Z\>?:2,HJ,^8_)>))&M:U#
ME6V)D_S](Z;/X\EH\FG=A*HXRX4 R9)" JNKAFS R#0:;9Q"*T07@9-=WOG8
M2=#,O@UTR,_D&9\MYI\GT^'\^VEE=53H:(9BRG%@.CC-P 5@.?N(AH-(2;0(
MN[;#>>+I>8^^:E!7<Q75^I9%!UPMM_VO W8_N_Y]..]6/NQA^0:9W+7X./)D
M.:^;CJ;JP)K(8J#/(1E:,S+DA*5)(X/#,N*6'?]#$F(7@S<@PDH->%EI.%TO
M?!QM,1@#<U+3<F>=8;2B>N9I?D2A752NR1*S#<SA=_O[<=6D9SM?F^KWV$7T
M PUW/L?IR:OQ5YPM*T7OTO1RZV/V;G5Y.[B-!I<2;(*2("F!.F9*XT!QD7SP
M]5)#TH/;<.YKNF58T9<!5P]K8L9M0#>-J2*",U(:JS4/%@) E,6 D$+KN-V8
M5S'O:](WM0YHV3;HSBU9.SVVB9EO!K]A<*6"-$)PBV1PJ4W,WEN*2842SF;C
MMAK\IG'L:_H/BQ/*E+]/RK.O].CJV3*9SF"$'S M:)8<XAY]<O=\81-WW77
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MLF?1>,T<V5Z9.V=H96P<)_+\2Q$<0IW>M70JI0CNK+0:UK6XGY;H95PX@SQ
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M><:/']*GP+K,R&BD!X7*>*>T3A"5%(D62@_1BZ ?4*N?#+?WTPDY[/,?[R^
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M7\#E*'-/CI>+#(.D>>=H8?8Z!Q9JKU)#(XJIB[/;(Z3GS+=C:F<-RPXZZ5W
MBEOF3/QQ]ROWY\R;RS1%^N:;RX=&X;W90[(K(1O/#,A:5[74RM_9,;O(KU6Z
MN-5;M/4[;#N(SYV%IZ*]-:P\^'2XK]7\.XPO:F@93<A_T=_.1\(XRQ5W3#GI
MR @IE@7E#<-L7(C"IH1-\L-:#>@YD_BDE+V&Q0>=1C_$]J[\!\[FF#_01W*=
MYM<'Z?=BGA?[Q&)'(%D9D<E$SBAS[4&O&4@%3!JPTGF03I@=]NN= 3QG2@TG
M^35\.3CN_%X\_B+L_G%@? 9>7(+$,%5&"Y58%(X,4Z=1!HM%\#;A@D\A>\ZD
M:2/^-00YN&WTWBOEXD.="#2*]S@=3[(8%<0@,)"H?+4\T102%?&^%C,,,191
M3LQ]73.(<Z#=T92ZAJ&'G=#O.Y#KJ\37D\M%:M$57-3V#"/03I%*D1GO-*LU
M(!@)LM97!^-TTM;+3C=T_<)ZSI0[MI;6,.[P*X"UXQE9RXVLCK3-%19:9"$K
MS83CL7A=M&Z3Y+<>SG,F38^"7J/_O4__;V#]]O7;Q>0'XD><?A\G7(_RSQJA
M4LW !9-GGR9SN+C_\]>3V?S/R?R_</X!T^3SY<()#BJ417BXUS+6[C^.^41.
ML,F^&,\S>MLDW*C9B,Z!A:>A[C5$/OB"HMG(EK8!><77WZJ_)T8\VZ*R%JR8
MVO@(#;"@R5=.#I60H;ALF[05'W:8/RG?E!AK D,/#DE_=;'X'7+4UP[TNMS<
M"$&!3"$RB76Z"EY8@&B9"SFCX<ZGV.0DKQN\<^!= T6LX<OAN77[&K3OOM5?
MO._@+X^.1@JBCQS)N<\<:$31L!B=9)F'S$707@5[4I[QII&< PN/J]XUA-W[
M<N,@[^OQ:&Z#+MZ00S:^G(W3HF;'J,;O*Z$E*ZG6ZU&@&20AF#1!NDR*D(ZW
M=)L[(WW.[#Q!7:ZAZL&E=)Z\8_QEPQWC]1!_^P>G:3R#9<^\>R,3([ Q)J4D
M4U(Y1B+V+";ZP,&1Q<V+!]ZDS5"[(3UG/I^8PM=P^;#,@,.FZKU1_2>./W^I
M9O9WG,)GO(U_7ST6\^ YMS(SE6NDM V&08Z"14'&-==)Y]@IPG!HX,^9Q*>O
MZ36\[N=2:)\IN\RIOVM\,%O<>GWZ I?7DWG#KG3K:HYT2D(A1&8 )=-1.U)2
M4$S&(&6QBO/8IAC6T8;\G*?'\:6W$V'6S)6#F^0./O1E\,$H^1"$LH(!UD/R
MXA/S/&<&1JKBN-9B-0;SF4Z4__@Y2P:DRIHILO=]VD$AA;?6WS>L(3;S21W,
M8\^;/&P).45&MIYEVAEDWI;:3-/;B%[:O-I:LM^@T&XPGS-[3TV+:QAZ6+[/
MWF-;F81/#1)\<85+S62IK9]RM"R )ETHZ3F-V3JKFU)U-[POE[,-];J&O.W3
MD&9/G!K1 ,?3Q1_-WEPN;W!6/)5K'P8727HC&7+FKI8[BY9,+N4\\\X[9KP)
M 2!:W?"<9<"!/N<9\"S(L:9<Q\%W?8<>H:X9[TA(@RFF1;^^1-N34BS4O.3D
M2DB^F"1\D_IM#<;R(CC=6,5K:'OT*\=%>L*F&;KXX:_D'OP.XV49]E$J.4D3
M!>.N=@;UF3,?)#*G"@KK@HQM2A(./,Z?=&]+C353X7B96D^ZR3M+(F3G2#O,
MU%1=C8 L@K2L2"38'+F-\J0F2=\2>-'3YZAT6C.Q>NAB<E=*89F3\N"&K2:H
M!^4AH"$')M7(:R>9S[5+AA3%&MHAT35)X'@2V3D0L5_QKR'(X5U*#C:LEB.Y
MG1.+F,&5  2M(R\!(PN1>YH%9&YYVFX6-[=**9Z4/8[WV,/@SH&F)T>"-4P_
M7MK;CIO"B(-,ON:R%)MJ:?C:]"PK9 #:)(@<49U6=OB. WS1C&])AC6L/]Y=
MY?V\P _5S)G1B!+]E R=44[!QN(MPZ0-S65. ](T/O31< UHHVZ20=QD-&?#
MYZ.J>0UY&V7E[9G4&H*2RAO#E*[]2S.)-YK@F9%6H? D>#-@+E\?F<H#1:_M
MN.2M\8)$!*U,MLR7VBPE*\' %&#$'QTD:F=TTV#B@T?PG)>(9Z3[-6O(X5=E
M6UK%@8E<!9&9L%8P74Q@8).@)4%'L!I"DFTLM5-MPWC0%M23H$^_#:,*UCEK
MB<.6=*O1<>:3*4Q&R<EYUU;J-K1Y3FT8=U)YYS:,NXA^F-Y[71"][#:,.^GL
MZ29\^PA\&"IX<O$R7Y0&T[1ZVLA9%*B9ER"D5T$;;-[SZR3;,/;,@%WD/' ;
M1I<%"*$X^?>UY*&/Y&3D[%DR'JRWQB-OTDS^U-LP[J2R'=HP[B+O)HW/;HM]
M70,JP6NK=&+<>V#:2<%"=)I%C!&3L3EB$R_S$9)GK_;#9-MBWE_%V3B/8?KC
M7@W[Q?KF+61O<V&U33G3&HF/BCY(*[37HD@OVAB$FQ"=G4'8B^@;-""[!^=/
M^$J??B(/> :I"OMV#CR-L*6!^#3$(QF,_>AT<WN)/A728CEY&FFT2AC@ADG,
MM+L%VN="+1X?C74FJ%*D:;.N'(DR3QF8QV+,+GKHN8_F2KNTY48(2#9T0<&$
MB+6X#AKF PTWEFA32@)DZE+<=]VSAS<;^I;_I$?A]6@R5CSOI^/)="VHH$.(
MW&A6DC!,\V)8E$CPG"U"RJACIX9B&U]P5FKM1XP]3]0_\>_U=%,>N(N1B45A
M(W*%675-&*(O&8HH(+JT,-CP^+/2:Q\B;&#CU:K>=:B+G2:!*LXX9$G4UJ0N
M!>91!X9<DA'KL@^F256G^R#.S;K?6\ ]]GY=Q7)-Y2YH6AKO#^$<QU#?7ST;
M]'R ;!O8X2NH(,F<0U9D17KZ@ &7#9OLH@XM1&E->:Z:?L*^;J7H743:\Z[\
MBK91^^:R!K2,OV/%=;VG:!I>],71=E*!&<P,0A0,M9$R@98@?8=M>=/SA]^7
M#Y'YI&>!]6PV$R;NUF%2 1*86BN\WB9H;G-MS4)$Y:0GCED*WL5JWO3\YZS$
MPP768*E=A)1\HE]>K#!.J^)S)O?+USX8CBL&0A3&E<Q1>$C>-[DK>8#BW&RI
M_47<8QOUSJ%O&S.1[X9QF5<F19<Q-3U/;3"HXQAV!W"EMY3SGA7=XIRVQ=BB
M3$'41+!8ZO)>\\+(3>;D,?OD.!9M7).N ,^'O$_8JB?.W5WTVX"S*WW*_B*%
MS#Y\_.O&E#.6!T#-("-)BT?- EEPK(1@P:,P4C0AWU941SC).KKB)ZVTUB#4
M@<S)R5>\C?%Y6_^@BJM.OPS&DT<0&3I-T$J-\069&2:.P2I'%DN30[$MF,[-
MKNM+_(^9<7!BW09HUQ.B"[B6YMI6=,>QNWK393>.'*"(!EO3=I#"F BZ6-J^
M TT1*9'Y#(%)+2#%H#3737S"([#D"0/G."391?X]']7=-*BYWNZ2S$6H:)E
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M4A&=@LOU^L R7WAAT@GNHG&%2'>,W(+.(SAN&L%PQS5'T?BI9 <\[-5DG2;
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M?;@[C27!!E[G^_D*EQ_#CXTG)4H0BM8(5A@Z 6TD3XI)<H-9E,XJ2P=@DW2
MAR!>N[X'"[:!'?EQ,2<O>_7CXU78M!JO.2K?JOW\'E>3VO&<S!L#7-5%VI3!
M13* HK#.DE]MHVA3LO,$J',AP6B";Y <O[WB"?-D;\6D((FZ6AY-S5.K\UFL
MX2*Z['F3,<?;0,Y%^8,$W&0$[6U:]#6>/\)T\3_A:HV_39<UOVB]P$D2W#CO
M-;!,=*1%>W RUU^8*>1 !]$IU:<W!SI@.Q=:C*V&!NGIAPHW&/'8E1IS1B/(
MG;(:O"H)?,@1K6 VB":W$*^H;F8(0\84?X,$]&JV_C:MF:V8:][S%MQ)P2QR
MJHW)!!UNRKL(Y+LED+3D;&S6MK2YHWH:U[FP8TSQ-T@WWQVC8;1AJ=HX.CM3
M\U]$(7C% F<"L=09[*7)N?)"$XW'-"OZ"_C%)AI[)&?8%@&"_@/*\03.&08\
MH%3.6(GN%THT[J72@YV!>XCVV;)&NX#\U1.->RGRN,[ 1VCA^2A3,!II$H22
MZO69L'64&P>K9$"3I%%!G0E5>G<&;L^4'L(_9?Z332$43NZ3$G42M&;U>/6T
M<L8,^=C&H]JZQWSA^4^-5-(U,ZJ//)^M/=M]L=UT=OT/C!PWV_^"-@&SC@O:
MBI2)B!F#-L%@(<^P>H3&H.)>.IFEW=/I;?^[6H7(F.:ZB"# .M35NDG$*6X@
MF:","!H-ZY)]^OPALOMBX(=%X_E-N JSA)\N [UEHGB)F0PZ*$;(.C,0P96H
M((J<=93(L319[5.@7I)#W(<-CZNP1Q)\BZ3.BN+C8IIP8ERT.=@"+,L$2EH#
MP3 )C-$62HLLS+7)XKR#<"X*/U*H#0)K^XJ]9<2TZ8M%]"JT.BT@<*V@2.NL
M*<ZJTJ3[PBNHK1^B^#'$?8)(VK7[GH6T12+M/)F6IX+0X#%DL$$E'K+$*$[2
MO.Z%7'D-T?MP ;_8*R^.D0QS5L"'0F(Q=6X7DGUM LLNQQ*%/,MA62.H]-"5
M5Q_1/E^A= >0O_J55R]%'E<Q?806GH\R$IDV10):6WN7L4S6;"J 0L4B9)"B
MDR'Y&JC2]\KK!$SI(?Q37GFIR"/7=*AZ6B(H[6J3*1U!*\]%E-;G[5:Y9W/E
MU4LE7:^\^LCSI,6 EKP=&P(#Y(F!0E3@90Q :]7>I*+)E&KB1KZ.8L!C+(AQ
MA=[ P=A1*-$%T:]=#-A+9X=+P8X1^&F* 8OP@@?-H) +!8I+"RY$^@*\9\HK
M1Z=>EQ#8BZ7 T<6 (S.@CYQ/4@RHF2V!,0-:8 1EA25K1V7@7+NL>-).-[EE
M>IG%@+W4<[ 8L(]L&YS_=U5LFX5>W()"C"%H TZB)!I;#E%S1Z DL;FVTS9-
MRHIVHGGU2A\NXV<K%;S+&;Y8+M=?OVWF?(X<[7SJ%6WBG9T7M17Q=#G'&O6T
M/C#%; Y)A4@ZTT:J$(S;;>@_];96,4\;"*HG,J&@4TEQS\%%BZ!=8 19,>-?
M3UG@Q14];+89K'1_%_^?&&H">_WMN]FW]>HS+KY. GE,UM9J!W+#R4%+Y* 9
M2QNJX\%Q4I617:9O='[A2PIW]%'Y0^>TC70;G%2=@-(^'04YS@ED,;1/HR2W
M3&@%L4Y]\$9*$9KD_W9"]]KYTDX5(]]@[8[?_;ZYU%E,E[C9CR<^B"1L84"T
M=O42#PE@+!"44)I+::3KTB:RT\M>N^K;2/5D,5*>4+"4$N@Z_$7E0AX:RPE,
M*"C1&+*[?Z7^XT,^_N$"?K$Q4C+'LTB1@4BFU(EU&3PO&@0*:;3*ALM?J"R@
METH/Q4C[B/;9 EY=0/[J,=)>BCPJ\G6,%IZ-,HE)9X/U==H&>?%2(D2&&E*L
M:(54'-F94*5OC+0]4_H(_Y0Q4A:54SPD F(,':]D![E<AWZ9VB_2B)@MZV!8
MOL88:2^5=(V1]I%GBTFRV]XP_7L;AM.:H@U!D8>3>.VV4GUCXCJ/7GK%LO6Y
M24>3?8!>O_TPJLA;>!<[<-TPOPNREH'2_=">)V ZC@H[\&* _!M$SYY J!E/
M)M:I;,K1WHB>@<\F =/DCGDAC&PS!?;4S#@01STU,?J(_02$^/WO;YA6F.N=
MZLWY)KDK224#)=2&H-D6\"5GR#ZKI%4)$MMD<!^$]@S75B,I\@ _!FKA!%;&
MIN[D?^97836]VER[;4 :8]!%I8$7149UE@5"5!F<RS&5&)BSY114V8GN;-DR
M7!<GV%C^FB[_]0=9Y[=6V%]AA3=(,UHRF&N/ZE(KM&T*$&1R0/:X8MQKCFW*
MA+I#/%OJC*25O;9LZPR G]L<WU_[CYP%<.@U;3(!>BUN*QN ,1D%^3-12JNX
MBTZEX&VINHPI%[O;I3WTQE89 :0!=-Y5[ZL.,J$C#KRJ_:Y]'05G=/:IS0[0
MJ@IZ;XF>246I8B&:.@!->0$A!S(BK0@F,!6=:') OH**R#X<Z%P1V4/<#8RF
M;H.Q#>>%%65!ZVA!B5JVJ;P%%[.V+#$OVQQ_KVY&^1"&C*^*$]91>U\4"I$!
M=<R@.$J(66JP'%W1B64EFB1,=>+$6$%P4PIG&0,8LD]!&22QEZS 2&T-HX5*
MWF00^PL-@@\A^W !O]@@N# V^Q@%"</5QC[% YDX9)6*S&UPR=+V_NL$P7NI
M]% 0O(]HGRVBV07DKQX$[Z7(HT*;QVCAV2@C4:GDJOOJM*-#W?F:RB[!*9M+
MECSJU"4.]AJHTC<(WIXI?81_RB!XJ+4KK@Y74H4\ V\C1&7(N'(R699=B6:K
MR__9!,%[J:1K$+R//$]:*&RJ*6]-(F(SHGB@<S+P(("GXIAG46?5I.78*RD4
M/L:"&%?HIRD4[H+HURX4[J6SPV6BQPC\-(7",@GOT$A 5HCR21(RU!F8M4)H
MVJZ$;!+H?O&%PB,SH(^<1S[Z#\Q!U*R$DK,$*_UFTXO@?. 0LM*,8S)*=ND2
M\@H&2?;20?=!DGT$>(I.N/^U)AL'%U<__IC.PBQ-P]6[69DOOFY&0?SW+*SS
M=(5;9.L4#>KXX,'QGV,6L!7Q(85Z74R6RC%EG(FQSH44+'F-,N8PZ;^6\56P
M,3J."<OU>OR)U+%K,5M*,=)';;74F%!Y&9S)Q;(0'4^9OA_?42F/US6^:HX/
MF?9[_HF4TR5(:HI5-BF9F18UP!T+,]8$6V2.M9Z^HW;&B8[^-EV&+^2Z?=D\
M_$/Y"[_C;(WW-\+H%.=".3":15 8-/EMDH..G@1I<DJJR6"Z0\"&#V3;/*_&
M9=[.9ZM%2*M_3E>7;]?+U?PK+N[FA%XLETC_I8_A[XG(M,FIS""64)/QR-.,
MEDXA4AI]:EK$HIL,5SH"Z^GM@%&9]'AN6UMM-;@<^ N72 ^\O)C1I_H=K^:;
MV9,UQVZVQ(DJ&%DJ%JRN'K"-9,:@]9"0&REEY-HU29-_$M79D68L#31P$>N]
MUB)<$;:+_)7DO"12U^+Q6WC!%<^$C<"$5&1#FT(+5QQXCII.\JAX:=)8Z@"N
M,Z/(F%IH<*7TX1M6/+,O-WB6$R]3D)R\Y9(,><OD^8 /Y#<7[Z25G'E438Z@
M1TC.C C#)/U8]8,'QMX!NL\AF12=C3>QKJB.@E&TMNA5H ,NBU12\;)-Q?X.
M+.>J_B.E_9@ @^? WMZ87R.Z S@)F+UPO "SPM7L,CJW$OUB="B)>R6%;I*Q
ML@?/F1%A#*D_)L/@L:^WL&[/)5.*$)X.(LS.@-(UF&J8@,)4,0:MD:F)=;"%
MXTR5?XR4'RM]\#37WTD4.5=/?S']OC%+ZC3BNC=]F#W^NSK57KC T2&#Q'.-
MK',!P7 &)>A2 Z+"V"8'1&^D9T:<MIIZ3"T[)$SQ]C+,ON"[V:8UT8?R(,7R
MW>RBE.G5-*PPOYU__19F/R;H97%%1; Q2E"N)C-SQB!8] I1:KV=.[XS:M'K
MI6?"CK;"?LP*-TXF\"=,ZP7)&Y=_?'\__>_9 L/5]/]AOJ7TQ!KE2]$*7/8D
M"QD2>(('+(C,>/(BBX8#E@[!.Q/R--3)8^;XP=[*ZA(7[^>S^<]V]-U!ZD2V
M2FJ@+:$F__ (+GH+6: (*F'1ODGP^VE89\:4$76PX[YK\'WH;YCFL^7\:IHW
MBZ_,_;"HW+WX6C/&)K4MHN&B0!&U87B@WP5K/1E;.JH@@\#2A",'<)T92<;4
MP@Z6#+\6)4#+B@>KZ?1WI?%ZNKS<#)@LOV%<3;@*27*6:L],39931O!)(UBI
M?>+!9K[=T':DB]%#R,Z,*>-J8@=7!M^._EQ=5>-"T]F:8-YX[<3S-UCF"[S^
MYSZ'OW%)ZU@$ C"=A<6/C8QHPZQ5)"3VJ\V6>>T!3KA/.3IA@<5<VRLE#3ZZ
M MR%Y)(2.84FQ4\-UW1F_'PIVM_![,&7OW>8;P[O-S@C=:TFN13EO3-@"R>O
MT3H.7GI'/WI,&(35KDMGO2-9^0C/63)JF-1WL&&$F^ N5:1*D)'/O(&D5 ;%
M5+VNII.;6Z]Y+)G1?MQ^QWHQ!;TGW'O&T,@.W@R^-/ZXF!-]-^YAMBD&Y!**
M,C6.J03X; T(H9C)6EN=FM0CW$,X,P8<*=L=:AY\3?P>5_=\O%BM%M.X7M74
MO<_S/<<;TSXPE^M8IMJ0TL@,SJH(.FDI8C*1AR9C['HC/3/2M-74#FX=?4^\
M$_'$FB1%,1HP\)J K3RA21$BN856^LR5;1)U^@G%.7.BEX1WZ'OX#7!8S(A_
MRX^X^'09%O@F+*>IYD]-K]8KS!=QN<F]FTBE9:#]#HSP'I1+'&K=)I0@I!*.
M&]FIQ7/_*^!N^,Z,(RVTLH,]@V^!=^*<I&08*U:"M9XVLLAI#R-L((/3!E/R
M/#7)(-Z)YO3,:**\+@3I)?@6?66V0-TLN,)R4I-93'M=S<O5'KPC;%+Q(#@F
MR5B3U-<]>'X-1APC_ 8)C7NVR9NJ8!6LL"&!%K[>NA0%H0@#S#)D189D4Q.S
M]"E0IVK)T_;2?RRIOX0&/>1YY75:?5A\PL7W:;IN*:&9"SGY"#G3!J>*SN!5
M[:AEZE!ZEV+*72S33MTV=@%XKO+Z\30['U'"(S==N<&SI"WR!M'RKBGI85!C
M]^79B^;T?7B&*^JQUD>2\LDH(+S-P:D NJ B(R=G"%H5L"B*,RYEGKOT"7^)
MJG^BK\Z)--]'N TLR#\)RFQYVQI8:AM+X0IL8$A@M(9@:_FWT$D4;YS9KI\?
MQSSX"<5IV^N,I)GY6&(=L4RN)L?= /GW='5YGPOW^VRU272Z@9<*\L +!U$B
M&<$Z.?"%TYDFO6::1U,Z#:3L\*K7K-H6TARY.\8F/>G&/MG"=]L\7DF5R9#E
M8".Y.4H6 \XY#RA\T=IPZ;;K6W;J^O";7KNJ1Y9E"T</X^K=C!S9=;7W-\<3
M9PYE0@8YUHY=@I;M>(CDQC@5F9)>YB;)Z8^AG(VU/I*TF^O_01^X+KA:ML3:
M!^QY&F,-5=R3/!@H]08&W5Y\-CO:D)(&EED!98J$6%*!*+3 Z(6UO$GRPFG9
M<*!'UJG(T$?8(QL!;^>S[[A836G#>S.?Y5NS1++DN2D:.,<Z]4/4YI#90]*.
MLZRRR*:+D;?[Z<\0#!I%\O-1Q3:RZ7YA_D.S![ ^X6PZ7[R?K\BV62-I1MW:
M(3ZAB49!DCH21H7@O<^@.5.,[!RO?1>;KNO[SD#9342[]SL>L1_:IW5<XO^N
M:X^-[YNDKY_>W:FITZ-'#.[;]#2HK=9,B13D9$K)*:Y$4LXB_3Z[X%S)P:;)
M4_B&B.KX-EC[GC2ZX+JTMD)G5*&3*@N)-?O-2111A&CHSTW"Q_(;IXG5UE/O
M@R:UF*'.V 7C:SH%G9K@F;-0)*82A1(Z-G$Y]@$:WG"X#DA:+M>8?ULOIK,O
M'W$QG>=-A&_Y'O^]^:OE1 J?HB"W+T>#Y$JX!"%F"2H$+Z/(R8DFUE0W>*??
MHD?AQ^,^Q*/KHD6+ZG"%-\TY-P/[;N/!$U6$8MX'\$+6RV+ZG<N<W,V2HT:D
M,RLT*;?:!^A<6#&&O!MX7A<I+8BI?TY#K.,::R'I?/%V_O7K=%E]D^5-ROO%
M+&\J)28%?=SX'+G4W .-%D(Q@KCK)9/.Y:2;7+;WQ'DFK&FIG0:7.ULRN+Z_
M(MO):<8CA(2<MC?'(7*N0 L6N!%:,MZ$,;O G"IKH\T6,E2ZSYVEL6\A/VYF
M6F.P#+.UY+<86DMF'H)4'@JGU20ALPE-.ACMP?-<M\'#]7R .,?(N\'1LP/6
MC8?<!5C+N^"]R)YI2L(8^CO,B0'"/RD[A'<*%2^ 1EI0TE: 04&*Y'!F*^O,
MH#-@Q:'!"2<E11^9MR?#[4SQK I9R0@:@R 7*D?PIF2(@7%6Z#C5O$FQP4XT
MSVYQ'JNMISEPA*C[CEBX^>/Z2PQ+_+__Y_\#4$L#!!0    ( +1^85+!(%7Q
M'BD& (<%!P 3    :6YO+3(P,C Q,C,Q7V<Q+FIP9^R[!53<S9;HVXV[!'<-
MA&#!'1+<W370N#2AD<9)@KN[);@3W"&X0W!W=R<XC^]\<^><N7?>W)ESS[UO
MWKJS6:O7C]I5]=^U]Z[^[ZH%S[//JP L64D920 0"   7WX S^MHVC)B8D;*
MJDJ2,O(2?U&@2<M;@>UAL   .[ 31%5*E%);1Y<2<00  T &( #8  !CD.,G
M!35)=<"+R$B(43J^= +\"[F>_F-V &""65J9DA+P'Q-LT">(TXN!RB_,86KF
M"'IAOQ>VA3I]^J/]](5Q36S^8!BX/QCR8N +$_[!%G\RTU_Z_,GO_V!3.[#I
M"_]A\R=3.],_N.N%@UR<S5X85OZ% URLS* O//G"M+;.=E8O?//'6#LS8T<
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M%DP)3"U,.\P@S!3,*LP!S!4L !85%A^6"I89EA=6#%8)5A?6'!8"ZPT; IL
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M0; >(Z(;"RDF:XW;20U\Z ]!2S?F^,9@@@H/*2T)JVL2)1*C%!'](=UK5UC
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M@@-&1B)=/;>N*!1_GX\P0E$F+#BH88;F:"U;4F[T%U?(QMVO#.;(.XYTAF>
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M3A!>^+O<(#2T"Z'4LA(QN!B!@BWN2!/TM^4ENF=!HTQ\K0%> .<7,.CZ3O.
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MN0C12Z%,L<FT+F1K9!OB@_=I)OV94A.8DV^M";W]V;D2('RKE7==QNF)]LO
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M(.#?\TOHYDXH))<"G)?\Q7:V Y:7#<&M"S9H2Y:$QYEV1]92E5_<IN(O6/D
M)QM?C'>K^!+OL8Z,-Z/2M[3REN*A/,-.G2&F 2!;DX#,EGNLTW,\RS;6\?02
MM>U,;@T?)<TG*I1S.Y='MCHVPF?HFJ7J$M]NJN0?S>WW6"<VB<8!P>161QO
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M2\JYB8RS6INT=^K%R=NGO+LM^S-7@S-8EV@,I&Q9$^-.JN.UKAP9#>DO>+O
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M)'XB0A9L,TL.,5#,/DV/,1594YNF4D3=(+51D+:*Y1G7#?0SQZ9EG&.QYM8
M_H:HUNWSB,WCYT^!6S8T78M44K75'J-[J@JL8;AJ&4ZKU<EM/P0=&_73,C-/
MVT)9.4$T[8<0".1!_+_,7PE(F[BX^-^CT9 VD81.3AGT9L]?4$:(B_-#CH<
MUZ^\NNU'L7=\@\S:D;9%P7WDM6H6F],7BA2A"C\;+09/!.D!J^5F&9S]5'<
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M5FXLGJP\/>4B&CK,((BLUA.A]:+1/RC.?5'+_XCL@TOPLV)4-E[K1$NU7HD
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MJ^'^P)1.H%?9T1=_/W28..7YT6) ZSV.;-*F162VEO)+>TUJ[3C();!GTB&
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M^T*B,=*U-GIXX%H;>7?&^NE6^AY'..]V^89>5\N1]U(_XRXZI#O1HL/P'H?
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M($_7(JIB(G/TA?7#"O=)P?18C>-Y(WP\^]FY*"5[E0M(9]3L0 '4=#67I_0
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MF'%VB$:>'6_M<UR+IBY-2LR%?G$XF1T4NX:EE*JPLB&0A]4D@8T)L-M*GSE
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MSB)8AX^W[^QO34?W_'(>9MX??3NFD]:PJ)QT0FV9E%$8?54#"6B.^&906>Z
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M$)(3H<Z\#ZI:BLP@$&C8-I>)I[<;*/W2G,PX?,%)-#5;?+L1/[@HILPB1J;
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M\N\0AA9>S"@!OA=%]+QK3!C8Y%4RB'[Y6L5^"2Z4HN[>B>>\:7M\',3TQ!K
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MJ<<[*QST)5JAI]0F^!WH!24.(8HB3O-Z!&[H W:[KY_K936KOBW8T9XX)71
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M]NBD>=GU?@"N;[>DS8<A?)U8 ]^2/%4KIDP'JX1(?@*9N&R'+9.0(KOQ?GG
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M>NL S]!,103B]EGZHZ3OK8_8I:)YN64^=TE@:P8JG:MWS*%O:_B7:S]JZ#U
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MY3NWK$A<;<F7 XE;R).,Z\CZ">Z+"#RWXCQL0#*VHCH@&:.MI9U29C3E$EX
MARMW9M]\9.\Y?[_P57?V0#<]2IRLV]8O<NGM"Z-:_+%W_VU<V'^2[(0/5M<R
M4[#!(INIEGR[N8/;IH9C-^'YJ@V^.-I/ZK0MR#++(OJ!*3=\J$FK#]96\-?Z
M"7R*,Q#4VA-OU<X_-V%&(#?6C)0#)WATUW3&A[*ZZI[?9<0B9J YM6UX!.&I
M0-<OX-9#K5E]L<HU+T8-IS#+5#4-@W;V,RVZ<]%AXWZ_%ZGU(2?OR:,-6(I
MNH'ZET^K4;(=+;#?%DPOVC"&#JSV6.\9]"%Y4TL+X_/=&/Y563)F*Q.KD,6&
M",W&R2B!=^\]PPM"%TF*_]1&7YA?V1L]VBGO/L %6,Z<I_LQOL>ZDO!+02Q
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MO9D3L=9S^:*\64-617YF,IH+ET1]9$-&]*B)H(>$1N:D#J28.-V:'F^VDX)
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M,P]GQI%4QG_'QL?B?KFC@<;8=5S]\,X'' =?F',X.M[WC14R=AQ$IP\MRFQ
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M%+:ST>#UBKF,_[HKE8-8_W A'5[(G<=V,!<);SDR2.BCF-FR$2EY'VV4>)[
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M5?[\S>YN%'2D#6Q9-'0SKF WV.H S55&TDR$QX'L0<&[UJ659 EP--EM6_W
M<?--4K3684C/)=N,(8Y]OC=C.M.KAM3^WOX!VPGM5!#_D15J,A8._CVW?Z3
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MJ+EG9-KJMSG]@TAY3AECO(K]8\JQ-H"MY/@/:.;7'WW/_MQ<?KKW@$;3=_2
M%NU_D ^]_)XT^OT!+>D>YRS^ >W8(#+DMJWBWF9.#S?!_J^O7'VT65^H0G:>
M<XQTCL*.SJX>T'IFSG)/?<%JRY0:J5WFM22?E86Y9SGLAGHV+7R%,\O%<8AJ
M[+I.Z&1^T8]\4.S<;X6H!NGE3IH2M^0QYY#U>-:=RW%IG,NHO<J8EP,MFS6U
M#[A9X#1:+#64P<3/WJ81+\K.D^K%$QET(-Z2\&@^$FF"T1[JDN&$.(;@AX>P
M?(_U#=F!X$A)\@ 84H?]>+#W4.U;FZC[N#.;FT GAL8K]R;%7;TC>T_M?. )
M D=R;KX1AXBWAEPT;_Z8][N*@1;LAZDXPU'TNXDO\5"&),<]&;PY'O **C)1
ME-]G<C^RC1!XD&_?J]_LHU8N408Z-&PL=[N2!4?HQF^A)F;[G 727I.U-H\+
M*:[4=!$/P;K/WFXP95P*\:3L<E(+UP=SR.[DO)W#GGWZ6JV*B[#DZX6WI]@\
M%HBQH%A QCHMKM3TL""05.R]#U% .O8ZC6;O'%&<F#VV_]*YGDYA U;Q6DD<
MY<DLOJQE.G]&GT:W$;<6BOEU\EL7AX9B]:I3FUZ.SJ[G.E4]CVV'.!;1!.)X
MUG<J'=HA3?E%Y(@UKK$&QR6>*%['@3JN\:&HGPB2YL[DF280;T*,65B^/?RM
M'=N=743YL>Y[B7C/@\N!]EC90\+0B*=_/F]"(WB?1@C@<OQES?R7ELWP>GN-
M-%8:V?_]F:M5CP^8!.>U*)P?%ZZYL>9%M\1%#$$Y.<5'#E+4RH^ 5Y-N_K.F
ML/%'QCM%=M>] MP%P/0"Q'/=FR\7?B"\"27&*UNOC;>(?B7#+\:KJ=YN4B*5
M>/+\+]+PA2*<5A>N.MH9GA0M*D34<^G !6VE&8EZ*'_+/Z&L'"8;>%D59_^>
M$=B-R;@(#>.%UL?5/Y->D7CAY,R"G$ZX5(LO %*N(YZPM5G-?8CU58J-<\P<
MLZ\:&.R7]U(65B&T!U!G#YL8RO;[(4H4K"2B:D_5[EV/LNPVQF=G_-514Y4S
M#G4;?0; ;1OB:_T\DLVO4/0J*6L) :#5AU"AG=!?#<QK\P<N?-D]C)I,03^X
M[=EK2MS-UA37]C^,J*"+2+3[K][^:CRQ\3^'['LN1!FY\KPR[?[MD=(H< G@
MTOXURMO<KC<KQ!0N#-?[$YAL]G7?<8")^C^3=P:?7*B!\:(]<D.P,,OZL$+W
MW!04-7-999,V;/63B]<#9/'(LH-;LW=W(&P6P%V/WA8(^IIW$^\9%9=LO7I!
MC":HPC_LM,%1;/4I4A=;9E92MVEU4R%IS\,>;$(R+4BAVKV<1K4^V705#S9S
M-:@.,#!SU;_*AFVET8;B7SD=7/F-M/Z2.."(F6K6QB7)+_J>#<:/#;O,K T_
M^51/>*?PTNZQ!;EW"^4[[_JL1I<,>&4C389'=J7$>-*;@;O-G:@'-/TA/VV5
M RM&!%0)E(J:V(/JOUJ HJS.F9I5<O1?V0!3#]K/<P*E"?K?82KB?J"7N;=]
MM#ZT\8"FI9OD)^YNSKR@4G?&.ODMV_C, 4RX 8H]"EM(2E@',S!<T60QK\@&
M X$0[-->&?RM!);5MD^D,>V&FSZ&=P;(FYDI[7#"2SY'[5<.5[<;[/RT^''W
M9:':K0]H# )35^K:YQF'-.J(4EQ*3@E]'27W>EV[RWK$"$IO8(Y,IAFX4TTB
MN6A90JPW5O?<4"P![*'0ARRW/ %7^UE,^,D\H.&K],2J-Z5ER.+(RS''FX;3
M,4/HZ*PLQ,62U_ ]^D&+'KR'BS'.H>V$V VIG?L_^A4\5R6RH(]QE8\TOF7-
M0<3=D<O+C.G<'[WCKMY4WGD/-Y-$K=>*3C.>G&_&(P$TRQT?U_=&87UQ5P :
M:WR_O8JNN8HY0\45,MT$T="=U.D/^HZC"=2*W(5>0F-A>J5UJJX#8)_CU.K9
MPD[N\F>JF6IX;'+#K>O7+-MDMZ3G[0:9:>DO)JG/6#*"^<>*C"MVV+HBR%-T
M:C7I$#DT'X;T.RZ1K29C\L<BCLP$FKY"I*K+41,G9J#)OAF013/PU?<K1[A3
M/S>VB'<I0%_E+&7RT/).R! _HF^M.%K)VT7XC![LU=!!$*(MT1()3Q]:3N)U
MHS_/F%*]WY6-HODI***TBJOKX7A9PF>81M;N*<P?8ZY-%%1GU;6M$U_YA6:N
MND6O>%EID.ON]^B+3?_.V721*%.(3&ML*4S51R.M0+DYG6FN;W38O:6B9E7Z
M,$EIXAZL_A\DY#4L%%YR<*R?8D+"K/?Y#.R7='RE>3(1YF<*T3%PTF6!.PNW
M[1GZQ09#%G4:CX7S.;[(].AB?32A(WU V[NI0,PY7@A4Z5G)<-R>BBB,W\IU
M*;8UC4QU(KB0Y<E]FC0:-FJ$!!'.711I.$+V8I]%WF !AM85!QN%]F29G9A
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MDSZ3$5W<)WVU"41T&ZQR/XB=RGXO*D+*)U/VU!*_YPU84]:B6CM9-O-UZ_"
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M42;**1/V;D\%:!MH#@\X:QIBI[47R"@\2;.':R >YUV;IU0!WRSO%)3IW#8
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M55]/T#1T2"K1J,TGU<D/E'W#URN6CY3D(>PY.DHDBSQAC+_+X1O4H%O/OL&
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MA-4(DO?\&R[JX1MU*^?WM(H7X1V7FT]984>]KZJ&^T0_EHC:"M<3[(+BU*F
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M\14QA&3\]JPZ,U'NKKJ=7P*J7-+5])=K?D#>*R3?D2!?^]WHRJB0:9&KO__
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M>TVV8L2^9M=;8VFAE:Q]&-525.M&&Y^H-=7!)/2^+L;N%KHCU *!=[<J%IE
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MKLE?HW>9K/%-,W,U1W]"&\.S<T-=L>M?OK<H_IQ0<$EO[4R(_@!CB*Y1Z8V
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MXYU7<82/Y5@2,L?2+\M<PZO&7+R"4?*5HR?/QI;MCCB!B1^MRQ)DUT:WJ7A
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M>%=%2]B\!>,+Z"Q*XU,,3H)_+6%2>/=JLS*!/N;/I&U9OF,R<.:]8<A[P_:
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M=U$+.Z]@QOAETZQ6YE[1]K)[A.JWF2)7*K,J*EY38#J%I!)@"D=592:2LTU
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M2H \8("?ZMAXVRVR-@0JV2R^F2W%)JEKK\7FDT__3I3XV<:]<OT0_!ZO;4-
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MT(^%91I/??R=5"D\!O?WYGIW!__(9Z%LR!4?7U#U P:CT,"?VQL^7[1O?*@
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M9HR_E^:S!_ZX%2ARZIN/:'&,5/N0I7#L?PA^Z>04%J2Y#-.;^#SJ0I)">'Z
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ME_(JJK4WV9 J3%NW[AKOJG<20Q-^1PF3:I%:HRV.IGR=M.1DATL\]EFLPX;
M(HIXGM[QC I%R\"&DC\B,:AFRW,MVB^!76\0(L8;=&'*A?!^OMP)TY4'(TS=
M+RS!KNU%:!$5C9\?/R+C/K"5.5/4#&M.:8?4IVP_8'@H,R41D3T[_Z\Y1M;C
M[OP*F?^6MWYD_YQ#EP,G;]G*\7/0NKX[T<21 N;&B\%[6E=$QE!A'ZC>9]!I
MLP,W7;"C[62R"5?/83;2Z-QQ&F@3#O/_M9:%79 4Q11CT%>8S$=.@N7NXQ-"
MAOR58YI4L#&9K=@.:@WFW*/:3#$Y0RQ?L\D82ZHR4CJ-N?LY!\I72-%Z&8Y"
M UJKSZ93T,F7U1#EX,WF-E\C>+U?5Q4W==#NE1]B&PQ*><"8)0^5*I^7&H"^
M[EA:U/FZF+)0(SB-9I[(<FB<$CP1<HN!?B$:,%)\)<0R71')L2O<KSY4)\3L
M[A*?X_R9G>>70)]\7N:O5_*,7HG0/3'_0YD'C-?0O@>,IH-C_25%I'N3N$J#
M.X>>CI>O67*UZMZD=<A>8LANX:4PF)Q2M*-R"V1I+LJ=P+'\@,&FN#_,/<5K
MJG.;-Z;./3J3&YW;:OO'OCS9.$\]OG"[&$'QLVN-4E5)#/;& Q6:V76 GF;#
M]K4>@/A..<R>?)XO4:;3^&]!; EQ$0R.3;VB9]]J*!6G;"@,VI26/CU@-#Y@
MT(/[$3?9Z W$4C<7 KY7*(3%C7<V$OF H0G=OO* 2EB%'WE7VJ^MZY7JN*:K
MVGCSS16G:;IZJ)X 01#A 4[8<ET+\I1S8'-^IZZZ:7?>^<^3 +?-8AHDW \:
MP*D*J$9 :/;FL(N^64FX&VL9)[]*I_9)JK)]/Y.J9@"+@;V]Y,IL(:'"5V14
M7\B?0=^FFNP?%&$EY<-JP,:^U*%R/-9G:6-)V8N_&%=JQQ44AH?G>Z\R<CM*
MCNC2WY/BXU#I=A00KZ$ KK>AQ^8_;"OJ@/P[[6,IIW!JK=1QJMMPHEXFA0<,
MK0S3NYT/HQ+Y+:$D]BB%VZWJ*M0"0GMNQ?1Y,;A74*7G+L!+HJTTP:C3V.TG
M_$/IJ III^W]0OL#1B=1K%FN6N>"QJ'I#=**R5\],+E7*R- DZJ$X;/ZU*.-
MBN\E< QK&_Q2E'7>[;@0S1/&J 1AZUDN\CQC4*G_GD8(9[8@,SM9I?(U&VN>
M(IM-TKU.8E\^VCO#6'7Z<Y# X>=EP0<,/FW@.HV(LRSF5J6GXB]W?CZ;V<H+
M=@A4FE:P:<F^Q=TE?"L%KW3_^02Y&=7+&[?R-4M?XFS*8AYTP K.';4S:"!5
MP+%O7HP_+@I*=8*(==N](=.D.*S^1*E#=7JKUSE)H=OETPQA0T9C*RO?.JNN
M+BZH,0=QPZY1J;N&SPG*<\=2&5+.@ >IELB!)JX]IG=K0\ ?BVH]>V=!V;=+
M5]6FW_C/2R;/@U45["N'"^J0*\(6/.DUN(IP#A+-QS9//-:^ O(,KER1 +V[
M6<G-O>@QQA>E19\_&$>WQ9_7U?I/)69>>29'[-&^RIS)C,*B?GO:<$.=)*)(
MX <.XL*1U08WSU$>*MM8 C>MO?5HWWS^/"[Q6$M34;-;CZ4TD),.B](X+I\.
M*!DDV.!DXK@MG"<XHMM_3?NIV#1-"IH"$EY;T\([/ZG2K2A:.4R0T-/<[>+-
MUA+T7M:E\*[,M=4R?V.OW89@ODX\$6$H/G(@!@;V_SAC7YFE4]KN@+:2D>MT
M:U+F9T$,0;B4;T2HT[FPG^01([KC\R8HYDCX6N5E)E82B;#28<+?7VN8<#6P
M*5D#-  N*#E-1 HT&P+M6 )=/V"LF_L*I#6%3&8CJPP[ O:BJQ8@'O8<<V '
M3Q';)H?!'D^#.O$(;77^DC]B!64MMW\ +])AH=YW^YHOK#'1<:6/9>IBNL3$
M+,9,4=VOXIF^@&X9;VPWL66.U0<]O3_1KBN>T7!XJ[E6#[2"?C]VOGN^@KP;
MN49DS%V3;FUU4((F_)U\,!_%-X&&UEWT>U?K4@O]G4T[7*1CGC$\7<GL0Z0D
MSEM$"HJ4) M;)<*9V7IY/%*T@)9H-N5B"ACG7$H@4_+VW"9(SVFZ#/PBQ=6[
MWM1XR3K9K 9EP^I+9[$;?[>?SJ@4H0,OL2=<%^C49A6&TY4Z4EVF=;F=A]\#
M +AZXN\BM9)[0$]ZW^CTT_:;<I?86;BW[ J^*7K!XY<EP),Q*U!(4:']7:;=
MVWZBAO"0YY=1HU8W(<[;B(]=?T1]+0Z$M9:%^Z/@<>=C%9S9!@$F?V?;;"!6
M=J9VQ+O7NDDS<744?JUE"=%+X:P-?K!*T]Q%!9!4T,<CK-/U0H1<_N:MI$.=
M_H>JE%#CU-4[9_>8&J^L$L(%-I$#<;?UE%,CB;.S9F=V*=M2"-X#ABUR/!.J
M'L[P.G'Z_QZ=5O+[SXF!WQVQ?=(TY91O?.S,JE[7R5OF]FET9#"1'[]>CY0%
MPFYSE&<F'P5J[^I6-<[C:194\;2L>#"]8$F:SYMB^?UD4+T:#-CQKSOY>4P.
M[;67RP0J&7],KCX(Q0*,&,&V[L;AR'6G#XE;N0KN\OU!5![V-MT+M99+O\M1
M1<D)6H%% _IDQZ'T[ S_.K<&*;<'#'MSP^\_FAN8Q?Q:D,&J)1G]K<EQ94;4
M"_3HF:L*M^V%*"S0VPZ[-CG')-(8O<Z\0:HM7V?O_8RIU)S^VAEA:Z@!7C>R
M]@1:@?Z1 N8<RB+6X"'"QO5Y26F"T[UR<%4J@"?>+)FN0R-L]#VIS.R,G0?*
M,Z(W(<U/_/D!0\4](X7O"BPNQG=%+SGVGW3CU"R%+-DK]&[-LR#?U\&&E)DH
M;V\_WA(N'Z4O'"6J[-Y+!_+I;CQ:2[ZDGUGX-&^=[Y2GTB$ZQ66<]V;RC31G
MMIYMHF5XAQ\C&R#/7KV',>9U1%&RC _A(P]6@.T'HKW V>?!O^=-U2M1_D;5
M*CO=7\/U0\JG13FW6S("L+.[&,HQ 7:9V25#T5?;O'ST/%7_&M8VGYLOJ,_8
MTC:NL=ENE6@P@OI>QIF$#]4JF$<D]1%"Z_<4@#X<M2E1?>X1&K)(A-/SL9?:
MD3BD<5VK.W$F+BQQ)M[/5Q!  ;8NTN4$T DKQ1H9(ZL'+RIZ/G=!W[PEL$$_
MKV#!"4@G1[QERG^,Z=:]*FLEEAB- !U1KY;%Q;RWH'_4USTERQ\FJ/S._S_4
MH_XI,-)P^Y]JOX45,ORK%V!IH5>*.%URX0SK0$TTDQFOX]\._QW.\!.U^^M@
M_</X6YNR.F]!+(VM2DU-4*VGMOC.E=!FE*<6!'(%\0*W?C'YI<7=#M*2U \1
MDIE+28DL<O+EVC_H):>,[WIV8R*%(;S^U-7S;0,!P^ F+N/?*6>8+@58K<3M
MSKWADK"\+D]KQ8KWCZ4@L6'>V.'_,+1PK^"B1ULFN>\YG@>=Q516A[]?.;HN
M?.,\/C$?-+($PP35JPWRV5B^8G5?E<;'J?A$S_4_ AKX7]!]7I![8V0^<1%+
MD(1A$<OSK8Z8\NJ$>98R5U8[)"BS(RL?"T=,#-JWR]$]Z=)D.*)$I]%@[0/G
M8.SND-",2VTYX6+IGJT>OC,_"\TRS2Z^.J*9SXZG?K[U=_('+HB M,.Y;+"A
M62D1?*>*&:!ONY;!./(^D/[@CB/MU@!QWR^ZF79Z"+[3VV-71YVYZ-:/G-&V
M'PV,W)@^PTL MM?$E?*&0!*^>R).3$6;@UK63N2($&@X:!,Y\W\J8N]_^XG'
MQ1XP:F=]/1JK-94<8N(<*9/B<M3\J/BYY/L_](VFS2SB-*)7E:Q=65U^%%E%
M*C-RK<L]A89,Y&8)X(\[XEQ+:6'D_.8SZK6V('F9F2,WIO+B.$UT)C=2/T:I
M4G9/PCAQNGP]A$3);[_&8@Y>Y\,8X.65$;TH*II OF8Z-E/ZB*$P*"Q@VR D
MKZ'7.NOU,I10C/"T&R )J**2H+O ? ?@KW9E*^4[M>E=KT4R?T\J%L)W,XB>
MRTLAIT^GE.YR..F5QXLYEA=GTE)ZO.QV^H]U/?W@([YGD3^S9Z.ILS*LO-FG
M-3EA8-;\\FI0-I]W2K):1NR]6 ?0NX:QQLXP)Z^QV2+]A(JGW0 ON,1=M$%M
M@6HZ"&919Z;Y*HODFG)K+A84<&$_"#>;]#@OR.*E-?%C1884'4!DP>BJG(F:
MN"%UCIO0'QP*(FV#O!H&CJ[C+P(B@5IURH/T@Y2BOR.^>'QK@!,9U9@G<I7'
M;EAZ3+I.U@2D17'IM#[6<S"J>JUN-N3_TSK2CP48(V*9SDL2_XX5D]B2W"=$
M?_3_:9PQR<*_]5D^\;C_)[B&?W#B/\,QZ-+J_I-/\QL3V[\G_$+?]YNOU]CB
M'J_0X7?MR-6/KWA_HFQ#GU(7ZVTG.TND9+S+<304\F<SHA?Z[EMT6Z'NA/]!
M_ZNA,X%)_WA]V6!/W60P\3H0 JL>BUB;]1X6ZW4/9B8;71OY5<%2-NKE7Y$U
M4Z-[F&I>5' -JQYZV7^F@/7J:Y]Y#WK+H!==Y[/^/;EW/JIBKMBCM44=]W<^
M/A/38E @UW O=8][ICMED?[G [']YEY7 <9)4:O)(RI0;(G69)[",_>VDG;Z
M S)&436NHX&EWT<S>J'$V: O8JHZD9&IQBG?/ /T^9+&9V-)?;&R8!IGQQ3M
M$2$T6<G@OGMK$FG&0.\J&0]I "NE1?H[%M;V6Q*X0<"^4+:JKO44:.R(.B67
M-UAD969&;FFZCMN[4_D8X;QC^\(MK<U[I#"7Q!GI8"Q_/]C!R(ST.SA)@,R%
M(QBN^)2@]D7F$F%HP7@>3]Z0Q_*MOK[7<;<MK@=56YS )VY;2/ (>.C^&6(?
M'@SQ/H?;WE.,41*0T-AUKPSQ!,6;D'F0N=\>F>9G@</D(YOU\K_ZM)Q0Y319
MYS5.I?5?'.])RKI8C2!_H0\<('G,K+_)M^$PIPBM1QVQ,_X81\?+U$ SZB_O
MZSRZ>>2F^YP5 2\G]KOMDO"96W_U+3ICB?<2C&PN= ([&Z04Q4^0:#@_%U5_
M=L*/H?V5[,@516K]GT8:%4FZ%[\GS_I%%N1N04&,LY <O1/3YBSW9K;773#:
M2$62'NK*EQL)T=:VV"PI=?Z)59W'Q9+9%YL756!(1+Y.$^3=@8NFNX# @A;H
M^^?>$;N%;[U;MQ+4DH)Q/@QND<+;LM1@9E14"30I?6%K,#K&/<RBAD!!>=\5
M?:;?&8+>_)>>WD:LFN,7;R3IRYV8"'J( M%F :C;=?'"U6>._\IZQ@MM4^^9
M@QYBD]SKWU_Z%8)C#6&NVT0<W)MK!6U)FJ./:PJYH5?!\B=%H:''5WIZ"9?W
M6&U0S<M32:?%@]D'C%_!=]C@JP[];+C]D!"P-7,8P/%%W$<P0E,@FX_2'<6Y
M"\>5'6QV&M!"5I@PU0$,O@%1U/F[L=.^Y@< )_< 63+UN!IA>/;$1>;RS^7"
MS1W6)HM+,5\EDZ>=7&'3'6R(%\F*9BF:/CBUYR_W3W[/D48&7%+@L)5Q_R*T
M/?-1$,YG2^8!,-;HA@7P9(1E_ZBP<A1KP%'P=3)KYK9;6Y0\TL&1_5S.)6(4
M47CF5PM2N3!E36.&II&>IX4.3#>CM2+:^_I,V+N$-IH$<PWZ;Y#*P5"@@Z:+
M[R;ZG!'I@VHUH_&U])6U: X7S1HQBA._1R,>^3%3I0$EDW#^&F)V4NKKIFDO
ME>7W:?!XQXLI/EG7^<3>2=G#A=)?7MGO:]2)@$D9>GV!O3I?'JJD_W@N3E>V
MR;O;%T&Z/5\T7\PF\H"A,6[?4\X_^N29XDEJ?F4IUW'*7$5H^,S?/&.X%_^%
M"1;N':9%[IF[IK=<@+B@='8V/0?]S=FGR3BZI5C8EHGF(X/F,Z_<A1$E2GUJ
M<EF9"ZB.&1'U\E8N1_QQZT8\! \\%D$IWGR8SI&O9N"T]?9D3&&-%#<% G<?
M%D8=[@=M&Y?7?"EK');BDUEDYU1I5J1*K&$V;G21(YEJ,--;7LVBI B#S6V#
M.6Y)Q$CXFF]^FH2F?;=N19ZU@(0K*_7.XY+,0\"SY-*N_1+-C@M9[GN5[E(X
MXV7C""F/35;4?/H^Y]T,=X=)WAS<:WR'+#_8-D6:B>6CI323:S>X)7/F-C<7
M:M^3C9C?[8S(NK_$?-2_QN?^B^HPU/A'9D>U9 58Y[;Z %'V^^#U?EZ?'4-K
M!;^)WO'LJT58-&S>R9H_,<DOKR9QBRA]_;D0X_-606S60EPK6CU9P;,=MR=9
MQ9SV&FR?UA+]T/GS>\>$T)8O=[MJ^_,A#170[ASEA/P$ZG:<R33#>GNO7$]S
MAXJ* QQ&J &BS4'+A1B8:SKEYV!PT<;GOKJ!7^L1D^P>7&IROD,99(ET+DI-
M49U"[,3"1Y3?!L[EB>;?WINOFVABMAI]Q4S_GM>U[D%1.<S5X^L^\T;P.<Z'
M*IG_B[NO#FJKW?JE!FV!4J"X.RT.18.T.,6*.Q0++H$2'"JXNTMQAZ(!@A27
MX&X)18)+"1KT]CURY[S??/>[Y]R9,V?F[B0S^_EGY[&]GO5;\EM&:L/W\&H8
MGRU+KOY4[B>- 83?NON9S!J*G*>W[P+\EMG,7<$L%&(7 RZ#O J][XPH#8V/
M;"HC7T\:D25,'-F561DR&!B\7HVSJ2PI;"YL4QUKV'2?S:<+'VS%96JK(*9@
M-]0N:WQ=)D>,>83F]AD?JYJX4%1'#9T7Z\0_!W9KR(1%%X1U>^<LD,A8P[DO
M86H[2LJX J=K]3JL9RMI. FN76O3E*J?7)+4[6)!3/+%KS<_4$4Q.Z^GZV:Q
M.!5!CF%&6M_\Q86<J&4OOS"-!DF<139=?MJ#?F-,>B5T;:!;SPP@$) C>^>M
MS5(611%7=ZX?0- /TCAMZK:JF_["7,V'$U>=SE=,$RKZ= )5LP)FFNRHU%AF
M(2]F>V77?@Y-2!Y?7Y:C*B]A::$CHE:0U_+(!(JI%)$B#9/&:M1MWIY=SL0?
M"QP>U+,T3&0=NO&UKHBATO)<TQ#)8_Z/K>%/Z!1P4YO7OJK;VMYP4I&1[6:T
M/S(O0([^W"$6M>G*YUJ,HT]*?[L2CLWW^_+DXW/^(XQK"+$!! (M3PK0_C8^
MV_[)YW#%:^&N1B^@*.A[<20_9\UB^5[2E?"B^7EY^HV-8,T"CUJ8FMJ!8T5L
MNGMFO'F-4\,-PZ/V^4HV>("?FI&)3DNZTR8,Y<\UUHR.\PG?AEW2("])3(1[
M!KJEY4-" ]X\ZN\/G?NM]6:$A&0&R*0NA<ZG9BX'UDW>8= TWKR\7=X35_Y$
MOXU/P,#[ 0/?E8\/_!SCGA4#'XOI/6(7>C"QE;N.R('A0=4MT&/+7<[D/?$2
M)9R$DI,9O,M!$=A(+SUY#_NQ+7N"$L?'X/*C.OC1T2"O:@S!-F+3<6N .S@2
M7C'9<P+4RX7FGF1N_<A^SMC%2![,=Z_ZHV5HAD7/F#AC+_;E\#>[0TK-/<1@
M\<7LZD*_MO6"$70BFQFLY;+M:D3-P6NTHXJV*:JO\ 3YJ6>GOW:VPFZ><D&9
MUYTATO+;.D]J[$ZSE\*-=W9N]IN48(/T9=UQ_Y-@<TLZWC<6-+11NHV#?266
MD(BHC\J\] HCR1*TMN]=@HS:CHSKA:*I&4-,DM82YXL_S<HT+F Q%;AAVBEM
MT/_B3<')7%*^6$RFT2T0[E27/NC<?+C'(.8I!$QZ8AZ;_L6RZ\6Y^_:9/;ML
M::>CL<@SGLM<S*Y-0[*4#R-K9E9Y'R[U6FIT&SR:_#R2B56DD1\>?9/Y&UAP
M;%NOG& J;5CM#>^?\W2Y? K3JE@EX845HAXQ7A3YBRL4*\T<Y5[S/;(]Z5O@
MS/4*8T<>;.Y37YDV7[H+FO5]#AA(M8'+38\&_E+1E_\ZPPCTH_AY-3[1OMH^
M]LA3!IX;)TO+I1W^(_ZO46X @.<??)K92"LTE>?_R_'@X?Y&FL1GTT9GW,#X
MTHX&T)<Q>\;8^?4>GP+F?=)K^],BM*YE1)E98.I<*$J&]A2'H*;(-J;M^&#"
MJ<D DE6O[D]RKS#TI#=[VV4KKDU$DC)PQ<K="2WUZFPC),!\(T:=$#,!=U#L
M;W]H&"]G YB_;F-[%!ZZ.0"LT00)7>AE(@R:*-0T2BD%LQ^)_ACM&QA<LP4!
MHJ "U^-V+4D_ERME(L9^\=N;IM1V<>;#WK([C!T@IE*6])1YOJ,[W;<I(,S/
M?NC%U[8-F9\=2]M4D$3@V\[A&+X>?.LH9KLBK#M@+,'LGG0K::=CZ8>5RL*R
M3>/J+OE/@/(_F3]JI_\4R75/5OKO-3_:H?]8Z_X=A?<_-N7_2Z"1"8G-]6&G
M=WP5ZIF1JI.>K8)7D]5F1GW.9A+J!J^_X0DBN_.+C?\%2('E#H,6WWMYH!5Q
M6AEN9&&\X2KHL%RRO^'2D(DV0^Z95/.U:_#QN&R.:GA*M+;$4.K]%8;,GC__
MT.(+'UD&6=F2DS 0 FX##H'<$=T(6"V)C!Y66;%10(A>:.A%X*,/3G)W&&33
MI1#R-<@)A\37<KSI/CP!V;VB_NN6NGL=/EGVB)-'N;'_N8S0/V[?R/G/4/2,
MBSR[PLM4UG)IHLF.,>@>NI&0[ES*!('=2=RW5S+TEDM]ISC.=U<7C#)[]=;B
M2BI^74NH<C*8!1G3^U6-">I(2?2K["%NA>_G6O]E)=J%@V.8+W.5;\[ )KFT
M OA@Z]%K-H@^">/AU'E=5&;-^C7JD),YQ^5&:11VO GCN]&"PW"\H7S4K=7I
M>H+LQM0171/N^#QGU=\%A)I;5!2&P\KJ@A#=0=T@$-D#]I'_WXTA?VPS,??2
M<\^@+5,371O]V*BVR5-<Q.,\_'@MLP\/!'ODE2<VXRHV/#SS77;<XZE]'H7D
M5W$7?YI!,EH\5.O'HHR-?1C;_XBR.@40VL<([#2E)11*H>"YQQ?*!W!N#S1'
M7#@>'.(>'MR&YNT1UBWLXFGZ!61>8FM,?C)8NOZTL1H=)62?)WN]SJS5^;_[
M1'@%?X"@O_2;YBB:F5W^R7;V5(PNM=7TDAM2!':>/&-*WN))+G2YX.Z?>VF4
M/"V6-D-G.Q.'M'.^PQ"<M5I9W/V#<]@G"N& 8K,Z5W /\8&;?UB,-'?-M S(
M9P@<T./9G;KPBCWY2-:.QVQ']ABK(O:84[)*^< RBZV75N7IOV;FH_?^4Z6A
M2I-EK:,G&5=B!1+/M#3'_C8D8XKF[&V_Q>AJM'^OTF#>X)\+$24\#/QO'BP*
M8'^ZWP6'?SL?)?RY:=? HJ'Q1?Y[<Q>5,<O@V(Z5<X6S5XY]+U/!=I*295.
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MA]QF0'Q*%Q%_T.1E2[BE\OC&Z.P>)K9X@=J- D09-[MKE0+;JK;#*^P^]HD
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MZB&TK+]WZ]7+]B'W+&L,G%;// ;TZ-X^^RLJOJNOG?-T$4LC"B%@Q ]]W=<
M@:VGT9N */DM//38CPQ8-/%8Z5\WN3YPTIOC$>)9>ZXKZ]B,2IT4QW?-,^PG
M,F\KZ@0%1<I*5:(>Y*BB5<!W&H3G-C;::1HUWGT&P":[N^+,/=AP 8TJ?_\U
M8_L7U^3R)*.KQ)WP=4AT(TKOIU3MREU_\[U3$:_%(/$*-#JLP];"[&VX:)RS
MQD@?5W1BFWK*C75FF[4SC58J9D+Z\D*=E;9S<TF]Q.QTZZH]-P'I+UAL40U/
MO;7*]%0WRSJOD_QMH#'?VRF?%_DQS<2.EL4)\T5 QX&6P0W,UX^@F7,NO,4B
M&W!<DS/U15491UQJT;;251[=;Q4$?UD !R;)U77R?A3D@59T6-P_?_&6,P*D
M#/CV7_W<6/GH"CA3TPPM<,",_:EAE_V$K0WC]??]X!53RVC>Y])$)H7ALP=A
M?%BBQ0*NCR+2I_,4CMTK6(N\C4UV'M;E7WO<1I5=2?Q-5NF]N)UDOX'\(NR\
MZRR+*62&&IC2*6N*<B($,F(U?>BX$_5PMA+UR >VXH=+1P9OW6BXW:B#^!F\
MM.,6^D-24K<.^*4\9&_2P7<&C$R6NNV:H9JAZ@X%.KK0_D*LS: W A8S)3IL
M;<LU TNSS8/EIH\:==Q@HZEJ7(BP.\994-!5LY%%,[1OBP'4/?CK-K3R*R&E
M;GZIRIG?/!*[2>QW\V;5#1]T;@>IV_I\0\S,[1?LM8EVF_3*SA^TC?3;)-1A
M;E%<AL-1U%&GZ-1 ;W5#E8+Y4AMOK7URS!#Z++%B_[26Q%*D&'K1A^^6NYBX
M1O$=N%4L%T8"K&/O7.G9D\(]@9:WS&5LB0OP81+_%"V".=Y4L02#PM8A5<[H
MPCSV5R='>BV\!A[^YTD[Q1D/$;VBJ/L[<4_A8Z+Z.:?I(L:>6&5"*Z-N,@)A
MW;$?O*'9;(G151HC6K\LJRV0'_&(?*>G/M<(?BZV(A;1!KYZ8T!(S#),Z_8D
M$T=+/CLOE6B3RMH9NRB?"BA@?7)#D0H4V"R)8Q=I-B!BFHIJX]*I>><B\<RU
M^]F;K_WO.'M8W_:^,QUYVT_TXBL:Y 6($P3@WE.90/8W92X"XK1^M_/G^) C
M=@;,[8;M!E%WBZLA?"$+#WE<&=%*BX3FYUK#RE>9VUFIVLEM37R;(OYQ@;Q'
MMY_SG/Q4[869>*U<DY9+>T631WL>,:3$4UVG':/7R?.P.LNG&PWA["TE[QG^
M"MV-@XWY42_?OS(J/G-]'5@!:,J=,X:C$R=TJQUD>@$2NO7-#T@%_&/:C%+Y
MK@E!BK9TYL[LE!4Y N?K^G-?H" ^9^ZST1+ZZ3OFP98W8?P<] 8D],[#29-C
MC;+=V.+C4@94^F\(75[,^Q)9)'V!1O #WF^H%? &9DZ?H+?@L#8CIEH(GSM_
MB/H$8HG-L0D2SU6)C<Q83;*QWD^^J"'S=A#U\;14>C]64",4_@*67!D.CDT[
MKY*/<F\CWE#&'(MT:)>#%*]X3:T3^W@%_FXT)YCW E^%3N20J1_H-8@2W>F5
M';S\9*/0/PC**L/QWPJ3VIX1TW#% S:^-IS?$G=L_^ ?ZA9%[M7HS.,T.67Y
M)<Q0'T@:QO"*SYHQ+SZRA4/DT)40F$,.*J4&N?F1'P,C[+#5G68+7IZZS[D3
M?P9<>#OG<^AU#L?'Y8%'(K)#Y$::@=Z]OST"!)77<SCM+*AC=5?G4YDP[I1I
M,=>[) )U0Q8B3%(]MRVY_<765>Q?+YZZL*M5P-3J>"^#?,9>NT07WM^CENY*
MIL\T^[,,"A5TXNM(3-QN!/G2.BTEZAL?]#C2S+?NM5:Q?R[F;<2JZ/J:+YR,
MZ6A_J@W_S?_PQ-@UEPC%#Q[@CV(7O-UE119JRCD@"?)+**34=FH%%_'^H$FV
MAP]J#DXG--O<+F=JJF'="HO7.6\A_Z QSV5^KO74NUDC7T6@A(,X%DTZ<GM-
MN@QNE%2M:M9K[LF,NK?8+-B2T*$161?;P9H$7D'9"6^$WP) M<(B#I7W #,U
M'U-[XG=B^\3OYY)P=\JD!K)T1F_CG.7VVNS$)H[8Y,0Q..08!?\Z?Y$75H%0
M_%&W!>8PUJQR&:==GS%;)[+QA@"[<RD-/K-+'*/H"G"P'.X/B^8G<MR_.G]=
M=*9'#B^Z!_KS8[U?')/'0ZB0Z5\#R0>;B=U(E.@&D@*C)'JW[PS%M&W!3 PS
M/@:(?".'A3]H$5Q>*;R;NQ+.?]#H6V3].&)\7J:N#KVVK"JX&<[;1G8DL/J(
M*Q5,W6E!\5!60R#._&B5HN/O\RJZIUUWS1>]FWL[837]^EUOWL*>4KYHGN\<
M AJ/R?C7]XZ1-3UC/^,HNDRE$=2K7G=+1S9P;X)TEQIJ= (-4IT)ZA/#10)#
M!W,/&$NTUE$H8K>=]:V-]BOC (+/N>=6 J6#_F0&:A.)[*\K0"D4CHY1SB8D
ME2%7J,\&=JB<D5\4%]7'*#7;@,JA/3W)!B<]$-8Y"2Z_B+D,:/K3+^/W/I9G
M\5P97PGZK$*PA^I'+245[+M8=($_)XE5Q%,'UR!?;/IV7%JPO2NKQ<9%/)DL
M;54]G&;336)?$V]R;K<G65L0NM)[(>B&"OD+E^:YR45+?]Z?EMBV>3^8V'=D
MSTD9"H:1*QDGQ>+R"X!<<;N)%AE $'$(EE'_N,7&CE1Y[[<KW\U!]<0+Y0P8
M#=/0"/VJ8EWB3K9"Q_A ,)"EKI5)5GB9WL(#\9[Q=L+(HBX7+IJ$,O\K]5^+
MRF/M1&(L>A[!CRE6CW#T%(72 Z1D<23P2;\:3+8H?"<O<QC<Z9(6 !,X3=M1
M=KV*T=>4AW,)BU'2@/ %H/^BN7[:#?G+6L5I[G,/6/S H<8J_!;+[X5JRH><
M0(?,AZ"0N5UBWC->>94^1:4"D(IXIE^!J[4P%4;KB7X5HYK^")=NC8AT_[MQ
M971:C3ZG+0E:2_IG*]+L\&&$.A/"9U'(:00YU90A?$YV6R6H?Q0^.LCD,4@W
MRN1X.ETYR)!$UD+V9H/;71C J?1E8W-^6TE_^PI:.(;.S_%R=9N+F[T_Z2*I
M>% JP]^"W=BV8Y1G3E*^>$9 UJ$^OQ#&VRPM$R7^Z3]&G\J; M.LB[OV1V1W
M+-9<"BJZ6/E<?E%VD\N 2GJ)M\2YB-T$]#O>Q-',SMO1FE'[1'[L@HD[J<)_
M E.7[(T^2! ;-Z@?F6XGS(L:B,;MP)FUD[/TJ8319FSXZ0DKS%W$+ !X/QXR
M(1*L/W6CY%DE6.-U@S\Q;@=[*Q>D$EO0FV.9QRL*HF5$O))7R%@*P5S[^Q6[
M,+3I7E%L'MB1,ZR7GM]I;1VG8B_NU/6ASZHD[$,[?ZY2?U3;C!N>!P"J$]R-
M[M%<^=:8/)Z4]EG&0G;; FIA:32[0\ZY\F HUOA =;*F15@A-!-YR/YC2F0O
M^IKC<)!/ *-V+K)E^_%-[WO!;?9G :Y5?3A3^$PD_^E4R=39A](N:,>H01#1
M:X#[W(MCJOABZ3M$<<&_$/!H%S>:G4LNB=U" 1MO5[?>&GCVM2+7E\..#U&U
M-+)08K;[:^]; $OP[Z3RM@2+2E4]TE. /S+J454)]^ I_'RZ1MH7SFBV(:QS
M3O0W5M$KUJ[12V)PF/.BU<,_MJX$O?D:8K$OZA<_=_N"Z%2(OJ(SYH!"UDDE
MZ?D+6DQ/5_H^"U&@IC,U*2&C/.XYQ.J%J[0;D1S1NT1Y*3+7[VYN\I9=:#AG
M"4D_0?Z%R*'KY:]^_+&SA]:94P!9FO1$]!%[)H' ,G<?F\L*]301-QX:1BZ7
M>^K'&ED&>I^7DA\ @O_IK/)_1X5!>>"5$]\-?-P@>(2<<S5-;?O#'[1Z?IY&
M_%E<Q.ANH' TP@T! , T\7E7M&3]KKZ IY818EK?"P%"  IVY(J&2O3 UEK\
M[:U"7DZ]<__OCR(MU]]>EO[+NA82MC:I\P&"KC;<J-_4!G'%\ &]Q4-Y9NU#
M/BC#$2"]VF=9XDE$6"Y'K$-B:4&>&C-.WQ&''<."G WD%B6%U$'N6%L'7:HH
M_VQNF#@#V?G6UWGJX:'_%I+Q_]LL/PY:*;-K6/G6Q>6S^24%E8?)-LSGS.GQ
M+$NO!5@RM=.U=30VJ?P*WC]:FL+CM^\AUR5\G%0S,RV@ B@^6=^!=XV];QM$
M.SVR3@,PL#XZ H,87KS(_OM&P/FZG_FHJ!6?ND+:,MBD0OJ_<UX*9R.R];M&
M1)HT6Q1'NH?=CKO6#MCOG]B)AUTW.=BZSDQ5U@K*49:3!$I.XP&:< =NO.L.
M;(!D/C9G7A]-)(G".(DZ6S\^^XC1/D(]TC5Z-X+@F/D/S.S_-A+RWSS&:@E4
MVT'H<_%EGJ7F/>LR9NI5.EQ$V6WC+) T+IP*X%T2W3'RQM(!R_7#*\V(]JB&
M 0#O&Y*]:P:G<U\IX:0I_=B0YI%9ZHGI=E7K<RS,8"QJ,2+K*G-NK/WYUQ8Y
M;0E#N)/*S4(MF+XF7FW"5=\"U(OMI4E#2_9=#7[H\T\WI\L7)6%9+H6QN%P.
M\Y'8$;6ROIVDCL4.9WVWTZ"O2Y>*52!@$ZQ'E4G\\:_PG<\=JVL5G1$E2!TO
M3_O4^@.7*[V-C>4_8OA?%I@8>%B]XN7I\+G!,"MQ?EP_;,2L= _7,#0V^Y=9
M^*?-#0H?B%88XW%7]RC"6X"?CV7:I34'752)139'C=0>>QX5JLL^ =7^E-G0
MFII/7+%0PP-<9P5(F]&Z83?'XPN+OV[H*ML\"C]^&\#D6SU[H'2T:,-D23WI
M(RQ+0Y$[N)BP<*IM$Q]>@)N0U;N? 5,5.XUOP3$PR?C:8/_?(]O_E/C^YG)X
M_5[,<N];LIN]D7HQYX>-(_@&/RU<-VYP(<NJ)*26N-8-_ERE7T18 _;\\3AI
M^3$W:1!VK=UQ$5<'%W9JTGTT* [HO;RF*-X_R"OBQ5&GIQ#*3G>K R2)HT]3
M(X\L>E7L%D_,!,74G6T>ST^Z5E>#CEG6D;=1Y>L#*EXP /->()=+7J#!)YCH
MT/%&5G8&G!QA5]Y<L^O,BW)\+/B]RVW,T_T&5HL)N<Q1FX!-!^8(D>Z[H/R6
MYZSV8IZ>:\7VAIF=ZA4^20JSQATGQ'T ^*F<G1QN#PO=+N<V"FL 5<O[['"8
M9.H$V_*4/W723LR&4%5@Z368CY89%=0\<WWBH1AHI(K&*O<!,L_@<!]VC4ZS
M/EAY"<^92ED G[]^6K4LX=.9$9HO3+"$HY@'<D.JOU85(Y); 9X>W_U!([,C
M44Z<=K?/[\<0^'R+;%5W*J)34<_.JNKM54J1^W)WX6<KB&"JV-'4YDN2SO+)
M;+T>)I)+H=\<$Y04F73;35P-2%P0O?KPR/I<",IO^/5HE080=(B"&0699?S@
MCGZ?YT> NQ!+U%.4*G>7T$O4%H;B;]:;J><;:SZW.GE\ES$Q[3OT2YS^UG$T
M.D"!/*-YORSXAFLYO0WQNO,;_U-SJ>E>&JC%0H'S%T,+@N0)?0NTKJXQ=GX<
MV?8,,O_YG4;.N^FS\QV-,9[$!#]IX*,]PZQH$4]YDZZNCX^;49%-&DCSAI?^
ML&GW6)/P(6<9L+ DME-4:L\9'&#HX-YHPC.I)76MQX':TVO,3O3*U?_B/^)4
M79Q9GV,6^/!VZF8.-[F;)D?$22_=8+2K#:)R]S8BLD=1PG.UN?O+.<6[S!IM
MNRH6K.:VGY/8F;$H4Y5!%[2;5JL//K68U1<> :]"Q"8;SA@+]*YBYCB6S><B
MOU/*O5R1&3[-/M(2;>?+IP7GWV#EF2,/8Q8T]F 9O(9"_A6*01VSDMJSU_A.
ML@SY3BJI,[Y#4P"/T(KQ]=H I_Z&]ZPBG$NF06(6#<G-'&.PP>2$0S6+T:H)
M7.(])XQB+CYS3Q<8 7WE I?GYG)2/?X6Z6C&<N:8FDY#/\?0(*VZ+*3OKB,/
M-L5+!BU@OX06D00Q.VR5!;Y\D50/)YSZF:C;K'O1L*A>SCYVI\"D^P=-D'(8
M&^ RVLW? D:L,B3YI>40)NO7YKR('$(#];/L;M==,FKG;!]H[6E6$2M9+[<4
M5.FW22*2(6I<S]1EV2YD+:E76>INHYP*DYS:$XT,G.N4-OSYFW0F:'[G@T2O
MCR/G']YNZH1_TIWUD6^A_/Y%R[L.,;":)U)YQ62Z01"84^*?E"OA(4-6S<Y,
M>5T#BW.%Q+ 9P29O8D@-%WJX]<R=Y-*?!WU)D'35ZI%@$?;@'-6A>7,I$*\P
MV7>FANLM4[-O6%?Q](L66P<,<+_8GKNB7NLS%0<O+^YX#J[R_EYHRN2SX#'D
M>FS$,9KS!PUG\T@&52*0C;/WVDM9+CKUV!:GN4]@&NJHYN["DT_P\JH2BN8@
M]+Z[Z(YMWB5<72?B1;NU[;FHB$)20IYP[;)AJ".!9-$B9/;)X-V,L^[3Z&C6
MV1#:/?2UGF<'D*9/<1Q4 F=C0Z,XP\L!?0CB%7CCK'ZX>A(T[7O\@+S S?*M
ME_U->94!X6=!+\_8!@$+0J^]Y]MS^-UK^84]'S:VC$25Q1G49AZ:@MR@_E0_
M]DD\$[0I"M*,K9KO9:%FQ-7ZFE&A&EFKO!TFNEW]+U?3!C$IO3+FX#2G2IB:
M[>;FFHP55B/;?%G)/[*NM\.AKRTS R_NVZ&Y#@[7=TYE*P$I<Z=#ZNK]^[N_
M[-F37(CK&\M\O=L.E+O[HZ?+WFX[2%K^TBG5<G.]HY^W>==E3O^,_OG(1TFD
MY$=E."TMHA8+ (D$G"!1D"KS]I]K![\L,$=;AD^'A6OY>=CYJ0^[04WMV>UP
MQ/V"24EK4ST7,,[FH7;F?'##TGKJ,&04_Z3G=I0-.)LY++]^H1X*;LZHUK&X
MBJV*H-L*Z1EZ>A4USE^B,D-#"6'A9$]=K1I+B,X]&MJ_NS)J5+0^@0'\Q>DZ
MX.Y1M^X-')N,B:\BHBH2O_X7LSTP= (^5-VS"(7+.!4IZ*WU66S/+/Q M]EO
M24SU!Y*T18M_]"B?&EA@W-H>X)A*EM9+CVW]:V]3Y$5>4(( D'OE1Y?^_M=.
M9Y=I8,SI<XZ$EF'5D\/=V_J5Y8%I"B85U<:\II ?JLC#?1*G)6QL694M=24V
M)NO0I8%@LZ"TE&\I>9F'.=5I@C;QTA+M*.C/$(N[OQP2NCR,JFY568>'U2_C
MJO1N;^=.Y#D-SXT-W-W[=+ #:CO]WVD8X3&GX0OL[F?H\=7_+N\K@%Y;D7B%
MB!FVU9[3[<W5+-H(+#Q H!4-?%F3WBLU(1Y\SN0AY9(45-(^V%R=="4QJTLD
M"<2+7+N+1-DM0.TA\I9QHG:6;]U[E72Z>^8NNHO>;0&VH2'45:I/@L6\K??C
MYX5VXEL$K0"IDC3<#',/"^@NIHL!HU.DWY)_#9<Y[ VRC\Q'5&/@"Q.X-I9V
MVY/B29B2*'(O7 [\VK1.U97D3N0*+&XBZ+D><(RM/W%8&EV:$%00PCA='*KW
M_HW2.-M@;=<[-K.**P/]B$5Q7P#(QC]N_<JCM'6BU!F!8/^>U^-?L] 29JV+
M$-88:/2O.V>I&NJI*&_F%920%'-,3#V2#ETO>6L'Y!<O_E3'EF5!!%?$F<-H
MW4YN!.TD%QV5 6\U'?+IU D'.FU^6S%+!!%[%LO&Q)^R&.59DWJP8K(ONRQ4
MNTDQNL&7/UHB($TL!^4)C/6+=L4YH[P0%2\5L5%\#;NJN<_WO//4U#=B:F3L
MT<O&(WX^U1A+.K95O+D)_7E5EJ[O=MJ>=/,K"SZ/</Z( /##'3%;.@K8+V1^
M]PTW1E8P-0XY&I5\WC:<6V?DF=L:&]JGLC1D#;$A7 %$)9ML%&8&-8<^S!YQ
M+B!V(_ER:\OJM>KV/]PPT N^\C*XSU0.M">%CT."9J:;Y'/#@MZV5Y=N(JK7
M#X=Z6H8+/5*SIT_BV-]85BQ-I46"1\%#R@W\W'<$-A"B%M?IM=='?&TRM+]7
M *X4!$-"(6<?.G8LS9)@@POFYY.WLM.V=TUA^O361R,D>0S7I2NI39?;W[6:
M;CJ3A1&/ ^"IO-8E#2=X85@6.VJ+:P;SDP69]W:1\(T@-^_Z@?5VV,1<"GC!
M.[2WMS:R@4V*.ZR'C>S7 [>L^:D2*:P]EMN:,ZA2<NPRM>]]W'W-@J93PX@:
M0=7XG8,0ZDT,J#FSHQU7\VS;@.:=JTDY$(4Z:X@H/ ]R" ^T:B=<!/8.D\LI
M1Z>M-+V>(^^P!]U>H\02*!X&<O6N7+MK6]:M%I2A??QR09W"]EL.IV<9DL1<
MS<.L*&%,<9J?,-C6HW)[N[ <V_=Z_HM9=Y9@*.DY.8) ^XIZS0T%DXD.B)J*
M$U-%]HW\0>,09ROS4FLNL3U[I&TUORJ><$\"AWPYD\OL_PX;QZW8%05.]=%=
M*,_-1YB$<7F:JS>UDO="(:$T:0KV3ER5S-AG;_18]&U8#<]_-?BA)_218ON\
M"TW_-KB<96KM99;*DTOJ;2/JII=T8<,+J1!*^ZQ_H]B[L^ETLSP=ZXXBWS 2
M/=_0/8XVD9.)ZI]JG @T6FW%=8Z, 9NMI"UBR]VX=E3@:*FRIUX:Z<6%TTL_
MV?IU?=#.FN?A%Z7 KL#E?N%_#_V#YN>'J 5#&S.ACDTZ3HH- 6JA$$G6JY1!
MC/G?VWJ9_JJZ+AD1'U*A%F[J6DTC@A6IY/F>H,+([((_:%_N>8 KP1:B>C\\
M>%^ZU+[+$*BML^)Z0@2%#/.I$<PQZ<3<!*8U\+P^W.D^TGTPT/D$Z=?M\?^#
MIH@<>[31<WYXLEXEJ[5C86$&9:DCF$DIT2US:<33#)D^92 IHJ/-G95U"#QP
M']2),-0I$F>A,^%)TJBA%CGL;T2TO'57NDTR80\1M_:TT?A$458[J=K%NDO'
MX$ S1I:&)J**7 D,)"3C9T>V#H2'>_ZMAH^-#9 \.S?<QN9:6-@%^>CXJ':D
M6>>-M$H]\\0,JNAN.CC_@U87E3--HM_(H+T452,7;M]NT,-U'V;7LZBSMYYN
M+!G7$[07$;$ZNCP=/[=^BX?Y]";^TC#2W"AVKY5G:'Y05CTZF0Z#]GK9^;@X
M,Q#LJ)\[(;N2F)AS>(@X>W2'?)W5O8D>3@-1O8]F5ZGHOV!]HQ373QX,I*Q&
M4EP%L816^8C%/&]->KOHQNHG[_2Z=*G*XKN ;H<7[4R5*2\K7KH@0"2^OP09
MHN$B^\3<!?A<C]R1[S-^_RB7Q2F%].:$U>:FE=-)4G@"_^/T[^0_:(OSM8OD
ML;JG:D=#ZJBF'1,HV'F FCKLU:__":V9UV_3CP_5?51YN\C;QDK0$:Q\Z19-
M9 H2)(LA^%&ZS-HU^6[7@%EM<MDI.9 ,SF14_;G O5T38@?DF[0.B_',_61G
M\CC$&3TZDI@J@G66;+&9YMX>Z>?Z"Z>;_%=YSX:HZM?"1(Y72"1\9=?:T_CO
M@@1/V,E'LPMS98"%^IZ787'H-0Z-!&;Q=^;?A9^(W+ X'B-K%0-K0?17NJM4
M6 GB%7W,6]@&HZ17S&,8Y4D*^LMZ^1#M$=IU7C].>>Y.$=D5,U;NKPK$_./I
M(%04ZB$&*BG12NI:S!MB15FUDL][SMD_U>NX33G2HNN+>4?47@JWE=JJX>'8
M@</7+._^<S#/R?Z/A\OL(@,=X&=?[I!1>DKG/&;W-Y2?-?=%0CZII=!;>Q'Z
M^[/I$*EMF0%)3]] T-_J3358WT\OJ73,"$W.2>10$@IN5KQ]<7=EWNW;2 WR
M<$<N#"@9TE$14S _\CP21ZMR?*R\\MW1OD3DR+HUQ \LU?I>)MT)$QR.N,^G
M=\CZT,</%[6%YA;J963$4]+]@[ <[GE^MP+\FK2R9SS*UNP'B6GQA(Y^&W^L
M*7=SE.Q]U>0P]@?M@T9:Q0)5+AUA5;+:]%1G7"WQ-^DS[E8P8^U1&'*>!-NN
M=D')8Y'UJ,W^+I?:4D15X/X-8(U)89CKQ5R_TH$8]JV,#94=0E:!=D=S_#^?
M+OU374^;\E_5%[@1HB/WF+CKAKY/HR/^M2!(D!<12E'WWFN:LIUSWS*9[_K?
M=N/_G:$"13\84?XZ+/[Q9G<W\SLVU<G*V*=/,#1!OP?8ZT% T#6WAZ4'3L!M
M)O$9F,.$$7W0+MOB^Y \$KZ]/_=C8.\6??@"5\RZLN1HLQ//RYKPXV><?QF6
M\%B'BE?!O,GHSE$K59AW>&PAIR5Z')8$N95_^J@ZMKV%?'0XD7[>A],^/6Y]
M0B0R:F''8O7S9B3;AR@]?0VFB*U.^@9:RR7'",47AD#.QKIVL)_[-7CD=D,)
M&QL-[^"IX(KO26-IF%/;]"1<#'<=&$1*@P\]*_Z5._^M6J:?N8Z?S*KDK&0/
M#F!=]BWF7XEQI!5RL5%PE(R"?ZOF-4&'#^Y7KO5&1OT]6#*PY=9G\K1[A[E]
M_-[O=[F/! )'D7W/C(&CVSO(84-XD+KNB DLO>GVF,UW1V/J?&PG*R82J'N^
MWG)[T8<Z03S(?O1/_I=_U1A&U!8\XJ^R.G516'3:H:[4*F)]Z5+;= =@!J7.
M(XC;!U61:146[#OQ3$#?V)%J'M59_\:7*Q(\SS.WH:5!HY^_'H]*^_%-:K:M
MTTD11U\A0_^!S_Y?QUW^^ZPVO+J]/-LV@[PN5"BLHVD;:KC>?R3M"^,R%U77
M_F#FEOG6W'\-FW@4_[5,:"Q+.%OLW+;($T8R-[1!LJ\2M-:LIJ;*&Q__5C=&
M\HB6%MX#1QYVH1OD,X4?ZQY=B-:.4M1/)@_OH'\R,A/R^,&!K6!E0\C0#^Z?
MYMK@4.16 *7W,58HT9B;+)+(6%/\PY3D[O[R9/UK&:^(QI]Y!HZ\14=5>E'E
M*B7<GD;SEP34/_AWF'88]I)X0>'#8_G*86)\N<4&[YW5: ^K7.9Q)(+P?7/4
M"-W@PG1Q$)PAPKVA3XLEP);H>-U@]7,L&BX\FW.;S<+T4(3Q@1%"M,WV6"S5
M^PQ7/[7YE]PK(1 I\0N<7YZFX:)QH<N@:6"2L!I1+2]VME9T&Z#2_0G-[__S
M^"/'ZZ]5:H6QN.<L#3+=4+[2,>PTBN&W9NN>A!SN@IQ)$''PSZ2F\=9RWD'O
M%P7.$\+@I@-^G,L.DW,6KSLY;S?1FB4DR$-@%E%:FDOVI:EF3U1-^&V3&EOW
MIJ]TBQFP(W$K6J $U3_2YA],/7IO"+LS>AAZ\,8U]P=$P+21 [#>K06._<0/
MKT7#'QO 066&,.0&K!)B4I!7IV+#57.--\UZNK%O\2651..YIY\7XBRC"R_(
MEK9&@XS5<?-"?37=Y+>W=J,Z)0+4].0K\K:8[<81L.]WVR[%]>4+V7<Q67M>
MPUMK-^LR2<H7JX,;+JY>A._97Q;=0"K;5JBF*U>]M?QZJGP9S>FDEK:9NCS%
MLU;7E-J8PDJG3@N:]+I'TWJA 8^P$/VXM7AI&3+PF[^%(W\5B3+7^<PD2^ZF
M/0M&[>@BB!>5_4LMEAZ<P4%>,+?,*_7O/@D#YM0K0&3'!"A)D:GQ;_7\G*X4
MV*MR<0J; O".5J7C&MO<\D'^T)TK*3GO<0M(*N^L+'LM228?T1FOJH07,#=L
M)[7QW;?5<#M3J*D\93I*#I@6KK)[/+-L)+>I/2'DA9W'3/F!8#>^0<PN/%9$
M(F=&D:C9,E"H3SP8R6/8+-)(G#Z=T;V"ZW 7QUK1F</+X5P]&B0;-@;YE'F^
M2[E8G5&34>1@3&U'A'6[D )W0!E1&G!T>S\8F@QI@MCR<J>]45IZSE8<G_LU
M0EN+FWQ'>%FD1^"HK/,LU[@DX=LD]^Z3_'._^YU&?OEWEXPVAPZ&]:\E+WAB
MB(^G+<RV6\_/8QR?X&IZ6\]P\R$E_>M3^L,W"A?_H.D?9'N8G@DM:=NSJ0@F
M7/CSIC;9%P76'20S;<*U^RW6ML!1TPY:E<O 3GR?N@T7.U2 Q(Y47*JSR^E9
M0&#0N2;L]3W/1K?=OL_LEE*!AWFOND9@N;9N9>/ 'S0^'J6="*4(T7QS<(U:
MGZI12^7* JHQ1- "$[6G&QF\LO*0/3&-P::"4?(SDX7"/V*U [.T ;M)I+9'
M(\61C<'5"S_BM(7;N2!JVKF;1QOHN>90U?USM@%>#M\WQQ+1S1M:3=5_O[6;
MT]J\X](_0^_,WLS<%T#-NH5DZQ_ZU5Y9]*/?#L$GQQ_/;Q852TGNS.8KY7E&
MM#<>[/=<=72+"A]ZB\IB(EZ [QE=S!:\SXKE3@WI&_FEPE=6)Q%O"QHK=4E^
MWCN_9;9[+GJ=!Z"45^1RD^5NT'?&/AEY=_OE0;37KU&/<9@Y0.@,WF^M!3Y>
M?&W@CS<?RSKK#8DH7%?Q 52KE2OTI5?=.1.=3>'VJ00*'\D:!0A*%O!'F"("
M0_P?2Z##88]_T!ZQ]\RKVH==-W\V'^B)A,#&[<;+1.\33Y B_=J5;HHJPTVT
M$R>(6RB+E&.XJ]BR628+R:YHYIQ7?V'A5Z'Z%>RRW)SX/,69RL@XLLB[/FMK
MOK4^@=S!HB9[/DQI6_W @H(O.>@JVH%I*3]O6I.+Z\Q%<7B'N:1G@?.NP,1:
MH-TNWQT3N5R;U"%5D<6YE&H?3,@AO\YDI5Y\475@Z IF-6'\T&0T"I6Y\AT;
M<(5\'M5B@*1\"G2<ZV.3Z"NZN4U26KM_C[^PLO]P.\=!=KZW?\>"3\/%)Z6-
MB,WJP^T7>XX'1HQX1_?TB4$U*9]]'PY-XZ!#>DXCL9_WS4XFJ)57VANN%)(5
MINF5RDB1:KQRF'I[*9#C0%!(G;C:1'L.<.FBP1>GU?FXK@7J.#!H>(#_,MWD
M$[AX3*BAK1P;"_7C38"*G K[I>?$L%JV00#Q0R*WV&QJWU!ZLPT/P"P_*U6Q
M=PX=!ZZU^PN*G.7J-3E+1JGM5=E.9_"WSD=.XRL-JZ\N O"5ZQ"^12(E0A75
M]U9M2<E3N:RF>1CMKK4>(#O?NY2R0W>!=F6ZH&2D<>WE33#SZ?EERV7NTOE9
MX'OP ^'HFM^23[,^@5YKX>1=>;%;H9CS^OC,.T/YEH<7@_'=1I[/O8#%@/6L
MP:'*]I(SBMJ,*KW<A")IO87V4;K(EYH/-K]M,Y8>AP.LV%9B5->'(U;;'G-H
M?I>47^VRCE&RK[#K/,GH7.V'O7J@6[=PW+W9I] K]'I*<("?*F(X2:"#O=OO
M'!@AQ4UZ)\06O?,'[3=Y69#PFI7 TU6ZC=Z'1UM8;N;6)LJ0V.^=M.$=_=I_
MZ7UUZZ8W[\!>#%-9 U7SZ;=?5F<HRO&W%J6ZC6C&3F-Z/9W];,-0?K8AI >%
MT4$K;,UXS*# #O0#:;?;*VVDS#ZYPZ[5A_GZ" %MKWYFD,;@:6US+68@T7FG
M[4G MU09W>9+N>XT_OT13R3C^O:SD?.M4&7NQ8?MAS!8>([>5Q(I)MJDW5E:
M?K=$!;5%&NX@?AI^&H8@'W'V%N.,48G8>F[P*6,<_-9FS; M>_GF2JEDL.7:
M?8QE??I;B.$P@FWX_)(8=F7H/[A%S7^KE"-6X!]S-X)P:0UENESV]1</Z]48
MZ U-AD<>#PHTC]E _)=IP3>\1PW[K<064B:S&:%%)V,5RV-D:6ID)X<[#R*0
MM.GMELU4$WU%[^&8+23[XZ.WY_E#S?;#ML7*9L>8OIR6XVM]-I.BG_J)J08F
MN_0O .E1/D0H(6\$VXO";T<Z"9NI6.OU)PN5*K1X@MX:<IR4Y$OMR[U0G5SB
MDHE;LMFO ^ ,V1DZUJ,WRAVAA3V6E1AI(:+5Z67;O_'/$ -(A A_RB8\!52Z
M;;<PO:5^X; K-VGV/H![:T%0D7/QM^.U*F?UW!3,*"UX[ EW95\%0&4P]FJV
M\G.+CX;!T;0.WZ725&6125":?K=3<>4L"=["%@]]Z<@>]+FR&PHG/K7!CQ;!
MKS7$>JRZ!.%_=74PLK$BU2V4')!^W+<\*DCKT=!(B%[MFH_LMR=24MU'HR#R
M<?B,,I1)>$XA2],]ERE%[<-QVJ_V;(5B%^=T$H<WFDRWRD^2<$L-W:YT6U6<
M_\!?[//ZU;Q!8EC#01@<^59DZW#$P5YN>,TIE?_SFML-V5?A9\GN-Q7S?K^,
M_=T-:(SK#Z<1S3"Y9VS3[)L[C3X;+C!\B6$G\4])L9-99!9I&$TJV[@<[#5I
M@#BGQJ,8-\$LH^Y$125J7IFC_&L/I1JCI-U\YQJC#G%RD",R-\!XT!X27&S!
M%#^>(=B*\6/FLR6(= /_1'+A3JPE,N3)S8YA2K1+FE@W/@"J&)8^,U^Y+'^\
M?O:9N][Z+6/59E6G9VTDX$WSJ+$"3:#>[1V[=AMW.+%K6ZO$ZN,>?^YU-NQZ
MW8T--W.&1'9^ZXMQ&7P/:FIXLQC$X4=TQB^J1AY1KO9..X_A/+&]="?8Y$L"
M6+@.Y!V^4/)R=+?8>CF&O69P,&J@(DB&N'^X\>WM\%A:S<#JA;CMH$SYI0A/
MKLR8\:72J;WAY>@?--[9F'#;<@Q(^Q7TKR,^$:\U/U;SN_S?Z,)<*+BUY9/=
MLD>\/JV<[XK^3;3>@IB#X!]&=\DMR+B 6;B]:QB.%+O.1TO<KZEL,CK]?:_:
M^-DH;$@/>!<)V?69JF6D(_3@\GEF]$0L$?Y$&SC"/DI8V].POK7A/>S3L\18
M:>UEKQ1F<6ZG\3:5B89G;94#.GQI,ZN7:C4E &#QHV+?HW0O]?HB@\M/H=1H
M015!<(_-*032)OB*73%'([F2H[M-NW14Y/G(H\RD<_>M..[1#C-[78ND*B Z
MC[&QB)B!6*9ZKP2BXEOL')^9J '2 !D49]K51#D42+PE'+__Z_#@K3L##8CE
M:S(2"2^OIP</ZZ8,PB_2YQVV# >;?<3>EHX;G9*N<'L_2#[NZK&"9L*S T5F
MTJ\-9$ -R0M"Q3 LB3ZEZ]PP65[/WJ[%=4M*[P4B.,>IALJ[R>-VI&#A%;K"
M7GM DQ;WZ>3@_K=?UC]O6>L77CD)'%I4&Q2("?6FTP]VBZ0RD[EAM(4.O&:P
M#F-\03Y42+*DJS]F6;EU]*4>TORSCZQ9ZI5YYSO)XQVCIRL3XN366\K48Y-+
M+Q]H8_C)X4-"T ^.</V@SX<KBOR>-JZ)CPU=>X$RR[>$WI=8H.9:<84W4,Z6
M-P>E.DN_EH-8U,>U%KST$CP$6XBJ#RQW+6=<\G^7P0V&5+D&HI8;KY0\%TAW
M779>4UA6]?661\(+P=4B%:D:?J6]?K6JGU1*BY;6E()<C=VGA3\[*=S$4%:N
MC(YO]PY75=NUU:N1 @ 7+??IJV&4*0MMLR,IE>#F\]<Z?IJ''T#RCS5I0\N>
M$63+8=4YP_*J_H"+OM&'-ZATS-'EU-$4]'M%QL?,[B78[Z%;&&I6NV^S>W5@
M^('F#QKT3404-.-_\O7AV/AH;H-G347O2>5I@V<#)(_,'5Q8&EQ 9:==1;QD
MN@9= 45_+CO)A04SQ&$E9S409+%3%JQ5UM<I7V+<_$$[MUK5[^=GWSJ9"]8,
M+/-V)-7^?=R G#G7:=)J:!1[7=GW+4>)SU@@?1M27(=+IB<0'?[=,\^4V;*
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M] B9^2?\\8FL]+_>W<*@T8%TK '0?=R5= ]N15*_?]N5_W<25+CW@;\9IJ&
MYOG:YXDZ4\38)_QI;&+T?$/24F-M(>5N;,=>9\YB!*8<4BS1P8<.[PYE =I-
MSV8<I4VD6/'[U%6(@Q8$1D(Z(#]X.T!G(W_0M#)\#',-;)>$W'G3I^:$<E8P
M61*Z%J@IT@1/=>@+F$Z/-J2^C1@:]?9D]"*,LF^Z_B$4"T$H-$LE+E;.HD7[
M!P#*C]#Z=V>G(>\=+$U3;KVLT>NO-^)B10YRTX;.@>5-",)F%26#@VQN-\ZP
M'U/-B*R/QSO:7PX/N%S0SP2UX?-,6-DMMA;FYGL48(W_/G76OYK=[">CG4Z
MNB50DIT(DYK*<N]<4,KN*.>&Q?.[6#77!=#*V,Z*/S,YQ&5D5=U $Q;D)H:S
M.$*0%:6:<2E;7;8IVS^U8<'YY="R4ACD Y9+\N>H.YR$*P.1DJ\N6?\1#@S
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MI]E9<5#HQD!I>]9A@EXKG9-TT6Z]GHK=82/NMD9@74B_2>^@@M2'\[9*%A>
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MF2$U;"7NA?U"G5FNDI2?DCM4/D6T%357@QMPJC^2%J3U9T;]JQB?MF.+LT2
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MLWEC%]N&J)^X?T^5-770D/GV:3:=I<DT_\;.U7ULP(!#\ ,K")OI:+ UT*'
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M29+YSW^U5]:_)MY?$7[?K?Q-$97.%D] 5!/Y!&)]S93VH#IGJM(H34FQ*--
M;<1VC5] %/<R3LD:R"C Z,7(QLCOA;GP,@F68 _/K7&\N0U4N]F[OC"CGX^C
M"3L$G0D(" 3YM!S>U,Q<Z.0M=9#]&"T[?.U2#@_&K*\:35L:[7!6I9T:L<"F
M1[0P:J6'U6%04(G'X7J3:W:[:*N\V,XHGQ%[5;I)TR(8EBWN_!Z^H]);<BAP
M >C<#HR<W>I,GUB?/S>NV[O,=EXTBL>LM@^E26S)P)JO:CU0M@2JXWPNTS\V
MC!TZ;U+LH161Z+]^:)Y8U"X!23!"%-^0"^WFU'::]S@-WL5(F+8/?Z^JL/RX
M,IN:[LX._\ZC:V YS;*19#3HEGQF;DQ>(BI$)8<H\JMCSZG75!K4*%"Y%8XZ
M;_[E%42VY@7R<K++'7VS)BXO4=+_*9LN<W2[2K_GJ,V$R8FZ3G_RI3=VBZN(
MJTL9 @MEM_8O[O)FC,+S8Q<V KDO+&P:TT>/BK0XS[BI_XRFBX9W#<6\EYUK
M2QI0U])OM- 3H]Q159"HT!JRL!2U8@SDG:Z F,;/J#%$_IRA(2-D>A 1^E6D
M[]N.:8.J9&,R8F:3FM=J3U%2:"CIT'7@FDC6G-9\\=67\\)EZVOIE!3R,O3!
MK'[+SDDR]I!WMK#5OD#%&XV#Z6K"UB-X5="6\42Q2;.99D33\=B:Y<OCC402
M<GWK?X8Q^D1K#XI=/-)H%FKL>[K 8R:M?U E;K$GV.K$PB5TZ-CC-D9U1:#-
M[ \1U#&'\6H+$.<H4,+5U$HXUO@F#T2I[B/Q4\4$>283]+_:-2V)L$6$9$Q/
M+?,S" <%0=_C-$S YV<#_,H%39:D+L@X+9X+9+ELMT1&3[P^ZYM&Y$T<C$ZF
MR9/R/O5*NQ]$2@9Z4/#WC+1;3OV<__?X,7T3[9#4@L'?_#JN*8K0_1'#^H;X
MA\,\O3K88#K[^SR][Y4M_A;+=R7>JQ.P!0)I*H_[\726D"B:O/X/B'',],AK
M"'&&-"^]J9#MF^UAY.IHK\,(=GB[CL+O*@*FU'Y-&61_J/NF\O>ZA'2)X3LO
M8,^BR KB5VS.]4I^LF<3K2MVVN#>I668L"[Q?X('GN'-.0;$C4[A3Q0/#8\?
M>-/J7+=?!.P*N9P408!OFS,&I6E"-(G8N(I(/D.3!8[D[K=?FA3GX17MP^SC
M\J(O.[00ZU2X4Q6;UZK[[9]80)YW@)SZ=DD&"8O]Y6K<"*BL^B,[8(W'X9MM
MW2UN\U2ODYMW*9#$%+K+MB>KGD]3'\T.]12KOSE>!OTV%'GTY9M!1FO7OV::
M[1=63)&.)<?JVB[\Q"[)$V@"50,:O_>VPZI'\BP,DA;3XEDH\9$%K1X-^FL7
M&A+=X(^>OK>_[4V$"@XJ QM+76LU?9C RHWREI"DUEO987*^6J,6,!;;]0 &
MN<K[*!_ZZ]N-:&BO[?6'!T;4(?V_>E>V@YU?C\(GXJH^S=YB^1Z(=?+L#?UQ
M>ZT/4O]Y$O/_%OGCO\UUFKWY*;VA3]F/?VL'5T\D(82!'"_B6454-T/X!OW]
MNIN,V>%P^B%34;I>P+R.FH/L@DEM897[]_Q1GY<VQ:5\0!<W$CR&T.WW"7(?
MY>:A;]#>;O >2%T_SPAJK?' WI$N 0W-[L@;DM$Y]!;/P<K+D)[!W>A RLD0
M,1\J\402A1>'I/(KS.#?,KLX5/]SG.A_5>7\O#!I:[>L8"JH;&S[2-/\H=5+
M0'PT6@[AZA@_*%1:#*+\Q-@LZYO71_(\GZL'2S,CW@1Q%UPH29.AE9YVD"R@
M7 _OLB84X1E>7I0_QNM" )QWK=4^>S.2?N3-C#[XO^B\\OU;G==G-C:>'E?_
M_21U+LH]VAV:Z^&F+*VU"HVMB\ILHA+W33R(LFA,F\ [BF\&\]!DN@^.5O"!
MZ7:U[!]?(O/>Z,B)[8@IQU7,&;:R,9@7]VX\L0Y;##/NXRE"P!]""4L80._@
M'YXV!*R>8%//)2+%7=[*_(C''UY8 SGM!>5=;5_^??&:(<@$Q#J3!<1@-_).
M?G^QT;1TFM.(M8@&>(#I6WW9:$\.ULQDIN>.=5_QQ4.SMRT47O >J])#J47J
MQ*TFAC5WYH.F-T^W;1HP-*^]J6/?\I8?.4C_$C 9[C&NZ!)P&U+2>$8HF7'O
M=0OY0^;[ ?X#RO]%1_R?>N/>OSV.<)[$]_*EL,5]&U)2D,M+SZ7>C.N<'*B-
MS:&GEXT.R9[Y[L&M#;7EI*]D,F'(B.'UO'SM,_FTX>G$^=\?P?+B//(R6W"1
M%KAR#R)N?SE\S%_%NYJWRMV45W.97X1VGIU?/[M1=,.*??JQB,-X+2%IO^,J
M=A<U0-62#>IAMF)E5'T,=3=87W@P%<Y1/].R^03EI BRRNU/&5;:26F$%Q7W
MF2:&AKA^6VB*4S?(G ]ZBG588*Y[]^5?+XHM"44:]\^5)<*G<U,O*3]"E3&V
M])P4CKH)H*^]I/$/2?O8<;\ 6S+2AV4?35PUP/P^+$CP;5';OJBI<3_Y%"RE
M^L:2-@?D\I5.6H;>Y\2/^2!T(S3;UDP*;Y!Z"XHHG_Q2?X4H%;X#:%LT@M.A
M6P;9LK>"CRW6#7OEL%.%OB0B"WUX=1[2X,=)_"*1"Z*,WRQ3>,6FR1I!N0L$
M=!HZ'V/S,R++UOD>!^C69GBO/*B3#Y0')DEF/+;S#'G.Z6$5]^G<ZS6 /_*_
M1QWD[Z;94+SD'<#KSX? 0^L;QOLD,(\SL=]"".-Q&K>M-WJZ@QB+!?:0O] 9
M%SD#Q?QQ]WB_U NXH:IT0C:G4@RJ=!]D&G7IYJQ.59XF#TVC9WKPO' R2_>.
M*ES$K9D#3%Z"BG:&GY4I8_<HH@[53-7IODWUAGBR5:<O\J ,Q5Q?KP=/Z+_)
MR#16VEIG3_'ZI,)>FQKC<6[,_:L.&]R6BL%ABQ&7%Z:D$-EGB/7)= WC^:LD
M)Y2ND-J-MUB3'B'CZF?RI#H*9FCKD._ 1(%#YP(,;[ ^,HE9B4\X<W0\$9::
MB3*:9+T:P2T9'R1U<C,.U%;3+T&(>=="[@!RC[U 3E>6>SB7>P/7,>H=BLU0
M ZE&*=? ,O2>)4>3+DK/PF!X\5&@8:,'MWZ+J^=7B^<MV!_!0$*F+3VB:2J[
MF80<Z3#HC)@^;((/JAHP1VE:YCZ=[UO9:!,#];PX,>@7?933VVKU^*.DZ#/A
M(WN5?!?UO/+QM=_6>IY#/I.=W./^E=^-# AKK.9\K&Z'BUH3P'5_8<S5>E@S
M]#KE>$Y0%VG<*SPYGAH9OL53VP%21>H;,=G0!YW0]F'LM9@4 V= T+6>+1J=
MLHDGWLNU<TFYM'AZ6W)X:&)#X=_T$KGLNJ^Q,2B5*^. A&OB^;V]]IN?8HAW
M$>.12!ZCM,$,G]\!8*@+J)=1U?/0]U_5>?A-GJL4!E&<7]\!XEU?CPMF8Z.S
M367-X]'6!&.GYTJ>\YX+8KM-CM5#C4=O+MLU7WP)D=C![J_> 9KW;@\WC7=;
M&\T1G[.-4#-!P-LSV-7N':"RXU&2EY?745!Y!]?B18W$3/;ZJ.36(KIS[_BZ
MTR=[5,3R&0/HKQ(I U1%D"0LCW5UG>F$FB3Y:BYG_@YPV=$,=:-[)'T'$#1@
M/0Q\052S/LET.TD""3J;JR:QG+^Y QSS[*+/]_0*325%V!XGW 'VAKHZSZ#F
M-\61R.9/UZNGU[!.K%E&UOBA>*NHGH*EYB9ZWL1TL2L0_Q3_V7?'FW4SK;>7
M0V@^_2D52^/JH(-#2?/PVR$J(%!@&QA%'&A>*DD&;,\U]4GI[/P!'#-?QW@:
MX%6X<<O$H"^\LT5D4(>#:C]\_"MY=\1\7)'PP=K#7V(G8C"H%,_N+7AW;VWO
MQ"S7)RC5QGWK[&SQ=V?CK4FG@-^2L=I<3=(F@RN#\"WZ.EWMUNFWOQC!=6='
M!U<-/,N/%]6>,WN]L]8Q'^]U>+F=L[,PHY*54911]!2P._(1RR8*:1Y9\;+Y
M;82JEC]S&95$'XH._NJ8SS"A&)RURG_"/1LTUL%]R50:2 4ERM:MDM_9W<>J
M,E3!E9K'G/;X+QN;-33'@K)!A_>1N]1L?H#%V[@>989&]/H-AF7&S*)A3NAR
MQX)#B0:8A6*(LL'LN@)=V8(JQFI[&CHBT5,5%%8]\F/%]:X-QS(R290Q<CF5
M\H]7WU^I_VKA$[09$OG<PB!9P\$RSOLWD>'Q8WJ)'V,04PKO)L35K-&KK1RQ
M/E$A7I]!L6+T)P1/5N-F[X%$J9"<#2A3V2NT91U>3C)@=G.C%V)T6G@'D-FE
MDYA]"FF)TR805QOR4(NO)1,(\/P*_VP,;/\S(<0.=I\%!3YE:/?&!+K"@_<H
M+MSO !M.P/U;NIR-&+-^FLEF#&7ZGFIZ+%/[C.7KWQ2NM7)\5Q5S0=H9B#^5
M<TN]S7"]%I"W'KHAXF3]X\E=A0C3FJ@)A+*'/H(C/1JSU660#QA7XM2V$52#
M(Y)#,946*UB8F-33SO.V#V<E457ZICYK/-^6Z479CKR.V,Q)0)B!B!"YC+F<
MK'0#L^)]HYSB[<9LYYRMU\W&*<_-$3( Y!KJ_:#8?7SDVK%2-G4V%(19[$DN
M[AX8))!W29K1F:9@;]Q/LOW>H2[V/*XBWW)%F9!Z?&6:K5USH(E"J6,HK7<9
MO5APYMN1M6MD \D+"&OJDO U"HX+-UB16XE3S6'?MO @UQ2 D1<1PPG9F#@?
M0&)L"$6*O:>+&OIM^&N]; (G,HG</TD@7V9_7?T5;C*LEF:741F4A7>Y)BQS
M\)DJ)[12;N4#O^<^EH&K<="QQFY86'.E+)WH2TUR@X,K";VDK8^Y"PWAL$[.
MXISP-VGHQL' -U^(AH(=-HWLI89 ,,*PWZHL2T.%):[6V2 DIRV.>LDS,/C9
M[_#TJ/=L#TCO>WKSQO@3H]W(2Z*)?D$U/'/X;D_JKMGB,F.>E0@1MC?/=SOE
MIZ-;5K31H')D3/VK.\";V^;TDXK.FHQS-53@W$]A<H&:5\TF2;"M2C3[ZZM.
MLPE;CX>:VZH29)PZC"XDVZBELH9PU]?"KLDO0ZLG'C-1)I-Q]@A-.PCEGXS0
M:"U_LG&_U0JS)TBNH:L,U*:VXTP!ZR5"<3_6W:,%\>YZ6JSB9A.$]$V7QY/O
MF^87SF) /U>HA<L[:%#T.ZTW)EDLR&8]XQ2'J&UVYE\"&YFW//EZ6;$VPHM@
MJ$-EU34;P<(B:W-,!S9C\!>)W7>K_Q>@:XDF$BI"P!+9F#,V[1](1*3J6[G*
MKVM992CILTD/I6O%2-(5A@F+6O&"7K,=FA7KJ"/DB6-*1!NI9$A<4XH6!OFB
MU)H699/F.^"C0TQ44*72?@ZHLAI['T]5TR5SNNZBK!M8CW+"<!VOY)-**LK:
MY=S!05)K 3'W-5:3)XF5Z'E7/]'+"#(X,0S!1OB#^5:Y;;X4=MP[.,+TB8^)
M4RQ;K:*13DE&4CRTTL*95%P@N3.CA\>F>\/S61X%DZC\3Y\6OYKRDP6-I0"S
M/,06?CC/ 3*A5@MN$!W&OJE#^;S!PI/$)JZ2.-(]7ENL^97_[SN #5)#2'Y'
MWEXU'SON&I^1P7)4X=V?<Q7@<#W0<5S_;'F/1O":T&[_]]&NF8_*4'_T'T#3
M4 R>OZVF33*IDBL^"^I0L=]G83$!/C8R,L5QL>SO%<$*D(E!ZC"N$OQ98LZ_
MW5TF/[=F9 ?/+$L)P?T#5S&TLX^BT#-VL)/:#&EAT$:XY-!YT\CS7/;F]H7$
MX,Z\=^R.O2LW"V9#%\X="S(_>^F83L3O &9Q0>GCN@\4]K7#G1FS:Q<<H]LS
M(%Y.YV-0OM/S  U$<YW^>1:<\"4RJSH;E3_)"PU]I!)U87QQ2+8S,SY9KY*?
M?'G5O+!O'1$UL6PG L6T\B5/=L'174"-\)":.!QZW.FIT+D6< D;R".B-2_
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M%=3SEY7C]R&.)B)O@P\8X^5;OA3#I.N,"Q-9KNC0A-B$="49%ZUH,Q&$X!U
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M#VU9COR8.P7HFHTXEU%TYH$R]"6>Z[D:&V97([M2-]L!UJ.>@3KNZEWS UG
MZJ;"=_:Q7?UV7&D%XR+Z1TV6567UWRK]- =F<A=>_E43FU3Y&6T>%SFL(4J"
MX*J_A\.XLG&Z@S68.H/L9N/FSPQX/&Y%RK_[_II:S:;&M4Z%6?VM04R?_4R]
M/J<Y1[I>S,])4H0^<2$^>$\HJA4CR;M9([$ITM*:9FK,"Z&0C^*[AAI\R.;*
MRP"9@(78J-5UE7'E:0:-F/6S32D@9(^IGQG%JXMSQ-:GK$M:%5/P0I[G'CEB
M"W)W-:P[97+?,$@C,^K%ZQXI#O@;B'@>,.1M\'6F9S7_2G;[B;H1B$JH(BE\
M40*0>BN'+S/,R-@]C-PU=^(-NKBY=1KZGO2KMA\E)FU:*8L1Z#$D^=K  UIU
MZ0(X\\GV[BWUBS_!N2^I-CBXBY3(/!$^W)H2#$RAK#(DIA&=6_U%O;(O,M(1
MW&S=$Y8VMMM'^29>7\FS1Z1.X:&P@S2O-4@S/!ZDJY/P/?,CM@G17OBD>N=X
M_K9<251939X#4;2]2+P-]5VP$IR7Y$]*N2 -#^RH06=4PSH2XG;:$[^*3;:=
MO/8PUE_Q&5!\]>'@H;(6F'J@?9</A^M0<>?D$921@O(R61.9V"PQY/G<8)VG
MP$OXMU$>2&1Z_I+I\>^W-(BL;1ALY_6L^FYL!MJ;%H3O>:8"DB2J)$:DH#X>
M0(V;9 *IUZ&^.X-':LP3+%L)H1'FD9'Y-;3O0USB@9(]6?RJ6".=YNH_8 I5
MY*P^,C(G)K7&D-J^!3/;$?A:F1F6D6I%7I0/]'CO&A6(A8JR# VWMAQ)P,!7
M:=I?VUZ%)<=2E4T<LB:W]E%>GCE'^TE^N.J(<UH(C+0#N]H$L=G<6%_I5KM^
MDZ,B3U*4 0#FY4$:/R(@/C 83$# [V;(3MX(Q@E);9ER<@"C4>3JAP(&/S/M
M%+MZ_5&1?+M,H^*'IL; P7+I!3P]"["]]SX-4U.KF-KR\7B64+TOY%&L'=KF
M\*,-_L\54]$ 77%NQ@,F/!?IY=7BWTLY=0<R$\"XQP>!.7X<*Q:;T-K5>(E)
MY.C&=PD??T19F9L!R] 3>?Z4W#VP_HCFV8')B2U5/6*@J7E>SW!>'7%-:H^%
MMV&F>6.RM:,<PZ=!<%EAKF!ZF1_-4<:N/Q_ R/1B;PN=>3F =* YGXCH#HN%
MYL>L97YO6;MW97>[?XC['&KT" BXKNYBD5?JG:6%P60ZPY>&ZKG^YZ=&\06!
M@1"W=0R<I]CKHU^L@%A?\WJIT/>JX9WCC-&H_MS^E5)M*-A?X// ,X%$4T!2
MK97:M7+#UA#MGE)!G07HI*""\@[0.V?PI6 %SO2^71./M2(<QC'B&IA0_50[
M*>JL:#DS1G</[=OXW;8U_-F6HYS*QL]TH>2 EU1RQQ?L-U,*'B.73O4.I;D'
M-B[3W.\2H#$Q,FWU_OM=WRSKS'-F_/BB?=R'32?U;FP]E&]=Q3I?S_#\S(CE
M,C<>.-2/JR9B$!_I \!@B9K?OBU 77<UR" _K/< C#Z&/6*-&^6[Q?=$W24Q
M&Q*JP^KOM+4T1S8N^EG!_J\A<<'Z>A#SFZ[E=W$AD;/5BN&E*:9[>JXVMNWX
MI*B$6?PT<#;7JI>@1ZMO 4^8$]/SJ0LS=A/3I<?P\[8+<HO=N:7C/9*6(%%V
M=/F2VE!!:-/-\_[;IVVI:EF7[O%ZIT;<@BVVD_'X1NPYJ7K&G,9W /W3D ^6
M/-[-#4DFRV@SEI][!(]J#GSC$A;[#*@+#ZD+,6&^]?N]^]/AZ>Q%($]/FU-5
MDY@GH=,3,E@SNX#A::Z&UF2'O?9676;;$_IYC(-^LO*6\S/&)*1A 5B$3E9F
M=Y' 8CG.;U$LGHUB_VN;N=F.1(7 )9D4LQS!,(]%!F"U-L,NC>]T@<W+JRJI
M;SX*[WV= !G>$+Z;['6V+.M<6?#LC@U]$(4V&RWI."?QER$ML+@^<Y W+'K_
MK9D"R85HKXSLBP#-.!6]7V4=&3J).CXBS7T<>@X?ED0Z*CRNBO%>C!6<IK!0
M,P^@Q8B8% ?"Y(5BY1"EPI/ ?AT#^FQ$C4G3.79T83-G<7Z#QGZ&C'2]!'R-
M6\G>,YG[4S2+&%Y:ITYX3RCJP'_G\#PA)?/EX*_H;EQ:"R@%)_/XC,)$7< \
M.J.*(Z,0:LC $J2QA2_QN<F'5A:NN\,IZ4*H7A<L!M2GZ0HD):VQ( O2C]*/
M&Z*K@!5?';L8E7K/P^9M.7X#F?N??JO<B"&O?;/6<T#<1VNQ1,BFI:[*JM_U
M9,.*.7&19(G,GX%"X8"I2\SYI<0[I77$#Z-!K-?>ZE+QA)I#<R<]WMX=@-/8
M=ZJ8@E.I(DRDHW(K']7 %;B],[B.]NX,Z:!/4A-JNBZ'*T94'+3^$W&<Z%L2
M_[8)US3AG.PPF7E?00YIEBPO;B2=;V-%-Z$K2OPP 4ZN&2Q*G?$D6@ &XZ\(
M\F;S_ZZAF3K/ $EW6*HU4=!CJPZ3PN%,?\R&:X[F&V1A!=)Q^C'@*Q.O.A!I
MOH\K<J* GMX2_H[9<6,:Z*EBEZN18D6.D\M=CB@)KY[ZIW8I(["G\:]2"D,F
M18)I-"J&.TQ,;TTTIZ<M31/CM@LVV[(TXROFBS XS69^\N$SO$8_S!<Z()._
MZF3/GP/OE9JSO=AZ,):^9+N0'TSK>DWVA%*YUXI.39E:?FKL#A#DI[9],SW<
M86^TMK/ZQF0AC)U0>8I+%KR[0\]+SK;UDZS.A:6>FM? _#'$#A0G3!A=H?IP
M1&\KS4<5D^834YQI:\TF:IVF[260I/0D[AW;ZD!VY%Q>ZJXA8K)<0I<UCM43
MTXK(6+S=N"$)1+^!T1(L]6?E2[]Y=:EN'S=A8T*^XP3YT 6NVW9J^'@QLVF=
MYM!4W:;9"\TLRN;*JF (6(I5\>]DLX+-"K8;8DR6J'91=3)\L1GST"#,Y1]@
M:5Q?;5NX$F%P!S ^OP, %2Z?69VJ8C$5S85OO$WPHI/&R$=>(NUHVMV/3Y^*
M!N3[A^X1&JCW)M;1^9)O&T#-,R(LJ'S7<+=&);K._P*<>[FXZC*#;/AZS5]I
M10XA$*&[,P,T1.T9B\CKO"%DWFQO!ZNMKUJ'.MC!OM.:E[%UW:-.S=TM]GU>
M>JMMG^%O#&4Q^:0V3LFY)=A?=+LG)V&K;8C'0ZX#Y8BMR0*C4@4SIT\V]+H[
M&E_;@"KI XW/XU!7IMW'W#:#H"/"W,#\(WC>S<0=0+E><MF+<O-/9&,^VIKU
MYK*N7'0)A%11.\#QY$FFXNW237%KH)Q2QLGD\-UJJQ)3 (8NT=GP4PW'/1-(
M06=&Q9RWK5$>G\_EX'Y9R2R>65MZ09PN\=%TN%:9M@_4EJC_>?6K_G#'-1N<
MZLU9=JV36RIMA[5NW[A%3 <R,=IHL.EFP7I&Q9:ES:=67&=I03B:RB3]ZYB#
MACU[_2SEP=ZSQC)Y([]9CP4)W2N)=K'&XN3<=(8)KR#>LL,WRVG[3=>W7N.H
MXR+>6QO/(*\)D^0OB!6^BS;;+7W>:32O'=]0$WE!/(\@46*:@]\4-6?.MT?7
M^K^_Z;-M[!LONQW<[Y\Q@T8[GI@^HREMJ%[9PM./Z1.I6>&)-=9I/;6;^KW"
M>H'T>1CRIC")WWLU3O/%MX>?"_5W^9:Y".C0E_)Z:+R+5,_N+.ZR02D[0IU^
ML(#* L965&Z/WK%XZ&J_!.>=7KFG;1M$9P=IU/JZCFWZT&A!;+=9#3N!<IPX
ML:A3]KZ-HY;N*)-775ST7)H<Y+\#;.G&(<\(IW[G44,UB?!OF()44W*,^9R9
M/2#$QR=2*J(-"J/SX!^F,JUB6F>DNS0>0@1*?]4SH9(7Q==>S[==GP?CI8%X
M1)9RU46]P$T@S$EE$*FW)ZJN?"RO>\;UU>Q-&9KJ=FWX9.'95N/))=>,6<4K
MT.(Q5_(=H.*<8DK -#\)E3LA$7E"^3_(>\NH.+IN6Y@X! L.P8)#<'<($""X
M:R,)TKA#XY $@M.X6W!MK+%&@]-H<!IH" Z-NY.;YYSW'>-][G?N.&><*W^^
M755C[*H?);MJ[UI[KK7F'#/MUYJ9&RB72B,+P!SY!-'O^-;"AS4F_JZ1_A4A
M2>YC&ZK"LJ2B>"K@9X8087HL;?8GAA^]WS32808J/[9?KNI7^HV6_QN-J'VG
M3%B[FX[8>2"O9Y&CR,2"/L'%5U%<,"IOC6&)1T6!L<$P.X"NJV8Z<27&PE"5
M1$&/?E[%L7CPIBA]H=FF,E0KK4I3VGC_.^B)9/G)\2_W O/,$17"T_ZH"D:!
M]:_57@EP0K8)BB4L9<UA/ S2]\\X<= <*>OC#S:6MAF]J!T]Z"N'1T]DI3TC
M0QW]P.^BEX<>QB1IKP;&^OIS4@)D"1&#Q1L+#AYC20>),$OZ"P>^[ 6!=#DU
M7)7F.=:W14-OE@8]NK2" G&L&9O]!+DB9$R"0^_:R];)<XL/K!=G9%1M4TU?
M9/;""0VPC$]('76$5R)ZV.F-8(*1)M96+QSU\V)5<D(M9S3MV/3::HDDNY\$
M%OY&LTEVHWKK$K4ZM4)?2":_%)7/T&I)W*C*[J$BGHZ*L7=V4+/2"2^&JN*K
M>2#Y&SU0,1TT57+21H[^+F'4>7 MI]]HRIP/WQ"^N+DG@)RRFAM6F:=D2)7$
MB+TIESC#*OWB&&I=0",%L)&>"/&K].ED;&*%&H7%:L^#TK3%FHY; ^(MJI*G
M=HAQZI/1FXS,+:8Z<])>0<9Y!?8%'J\;APF;MPX.=<G3(P?+[U-4(>WA?JI$
M+(%[;1CT#Z8ZRDLI!V3[! EO[$C;Z+X0N%QO.NGTK6*9YG%UJH\.#TN<$(=%
MMR*^#,&!$HL^ CX15A$JYK YVS>_T<9W=J(8%L.OH6Z_UD\FUU[ KYV<<.Y5
MNF\EI><#3",R1:,:H;J]*9WJ&XF75PXQY ++JQ>FO%:]*^S2??$]#9([A+9*
M6^=@R>Y2_2$"Y^7*=A41@1,!Z62)PM9O<./TM^ZL*JZ+E:K#(Y2VG6Q]!ZK#
MPVBJ!WN+HN5##D[YA]5->A'&,L3%,Z=]>ZK"?O?#.@0T*YV#11EL[XN&3<9E
M^6'?X]K"/PDM!A?:68L*6&,_TG]K#2$OYNOAC@SRPPTO5C6WHHIG@<B35(S1
M9SOQ04?HH01Q@W(6JL<7]?MTA9,D%!3*K7#(1%)K:MU=>O+%XH/-)&["E<--
M8.@U)>7,M'8 WA+\@=RWQC0BX^XE(\CQ0&$9"?=BUY]4^\Z5()FM98P=)3L*
M)EM<F8PAV(I<0K([9J&O;Z5NT)@QUJA9=,CG6YVQSL+M8/:.E3Z"8#VL$?5^
MFP^6+U [0<K=XD6-N'IJ^L!:X0^;VP&?P"PO6]2:3[Z/,A^W&$\EEG\[_M&?
MHL:*(;(YVV6 /7C9O,. ,6O49K>0VV:SR!X> UT'C?CO^F]T#%*^:0<4S?9<
M"[$]PS(6N;JS?)N*(J(E?3N>:_@Z<5<:J^O5+,2(+H3TLT&P>=339W]!K?XF
M)(D:6 4+#@T+O@TW#<N@Y7)@WU=:SL__'>B:2/5P9&]B3MPT?#'3G9+TWO25
MV:D:A9\\56Z?'A#R<< _.8$I/%B^<(YBC(2OXH0BOJGS<?MO-(>ET5C'['E;
M8]KC/@,,5/T=87&WN/V%:(80_/WR#;D2<YOP4+)9N6W/^P>*D#%I.Z*"$ 6:
M=)X(:PLA8(242SQ+'A-8/\HXK6>-^PT-R,J,Q,K1X-'5O\<ACRWM/4Q$-P"@
M7P86L[[_V!IV[_O.F]#]];6PP<K+V2W/7Z_%'-_9SB?+@*S+HA-0:W%^C]4.
M&V>=F)QF N,>BF??V<?*4MW/(0L#TX&3'ZN,<GK'=B[\>4OT,_UD6J+0^R"S
MP+6X@375K$:)9"?]^&&V=?4TL>#_ ,^M=FM5JZLZ99^'2.5 )+]D##RQV1=8
MW9MH<&+%6GMZ[+J_OX;J=6)\>'B>T*%PC_%(S^3<9,)TA!QT<J@Z%O-YXLV-
MWLMQ^*I>;,D8R\8)WO$/L117>38U+NA5DHTF3C[IYVQ!DA/V;E[O#FK6EI:.
M6<\ 8^2#GJ=G8-*UZ<0_\'*'VUA?_N3"1<SY2QKC&-Q<5*O72:PPQKG$!S&1
M,3+)VL.H?A]DN-!%EZ_^"<E:J;21"U[L9PRROYB#7>4L[FD?2[*0B:(W#AX,
M5[D@SQ%-H$;;LZ7,;"Z*D3!J_I)UX@"+$4OCBKEO2$1F*#5F9V3XC4S96RD:
MM &K ;*R_U;,_[_ZM"K._Z8R\$XC[I^!R4X':]3A2M2.-T&7193*\2%+?]O]
M7W!FQ[>ALM),'07-.1F8J<1%RY=45()=HKM(Z1N9[FJB\9T^+26K;"334&5'
MZ+$$06/Q$NW+BSWK0$8.??-#C=:=J[;BKR[X&2F^A&]D%_##H5Y]Q%N0RO'G
MV5Q %&L=BZ@DUD?W:GPK(.CTSQ98-K8Y^OGDWZXN)NJV_K!UHD=VX+UO._\;
MS>F)DB7;.<K_"9&R]@A;A=8Z%PXN%0DMV_L3I5^]&.;L.75KXOJ%:;T',K.J
M'DEM$;>J)O,JW9VH^0V6-;E/_2@1C:.'CN*##X]BPZ20:7LSQ)AGIB5>,%T\
M6FN+Q ^8QWE7S4X:FD-K)98N#>8P,'P2$A#=I !FY=OO(F95(Q.,>UH]\)SS
M!%I[^^'_I?9 C5V#J8TMN4HC;,348574^?V4LW:A  G<ZB X"%STY$R3*U;!
M=2"TCL\6D+8H3<L]**N:?24Q^QMMY(5I<D*/_C%?95"V#S>%!<-S-8W8.F_[
MSV>GTY0DJ!X=I@#AD+WQ4Z(:VL=,O(A=&&#6-4U4<PEN 4%TQ+8(>XPY[L/!
MO>7X"?=X(WRA-+X9\2M_D0;#_\EDY@KR0?B!5W8=^/.YOP;49 _.E/+]>NH@
M0SDS8<FC6=UTMTL=@TD<WOQMW:OO52"Q?N_%X^TLZIC).3\33"*TF;Z5;9V^
M\4JL86Z=8G0I=&]>038TI.KP8@KG2=EO-$]"$.!MHAN@)NE+NE$&5<Y$GOV>
ME'1KY75K)&\CSBS[-Q\B>.L/YL53E]IA >;_0C3"O](C)?GHR%:>.L6TC=P*
MZQU1,3SZ&O9O;5V@UZRW$[D@N7_3<B4^/2B2&'&I>,_M:W7?H1?XHAGVR+/N
M/SP]GL:R[/&34HGA'<X^9=<B'MC8W\B3_B%5\:_T2(/Q@_OBX\NOTEEO:ZZ
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MC[*BWKKP/MFJ/B:A'=WHMN0>5Z#YF9FNCE=HUJ'RL44+9#0M2EY!/_DZ''S
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M9F<AF9T[?FP251$_S';,K/LWIE%GW]&?*RBDM2H1N(O-,' ZVJS':WGR,@6
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M>36BQ*"\/,J:R/Y4UVZ 8VG*_]DPT.R<MSOGU0F?BM9.LNJ0-3R%(_<%$PL
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MU4\N\?6#\8F\/<I[BV>I'0J"M1]7S0<21)[$_+MW('YTSV2!QP&G"=RNZ^J
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ML^:H3.D9EG5?P*B6RZDV6(: P-M(.7374A]+T\WWZI:_?NKL<&]S_PX5][W
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MLU&*#)V[1"/Y/7MO?*1I_+<JZE!9%_+BYY02-$SPI>[_13IB2X8_*.Y-E7M
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MQ$+[KXY-Y]&!:EMK6""8S4WPF*NGF)#$2-V[_M]6IZR-&QPYSP7#.>7R>0.
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MI)(F="Z4Q?0@_).W"]R+([BY:BO;Z6O0>XF"@ICU.AE(C!6NC[7;.M8QR0V
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MI)- B-"9$6%)N"1W=C6J@_HN%0&&#'N?ZS%CIY*9,=7(4SKU,TD3NH%_JVR
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M5LM36>78'FD^ )70VOK%S*?\O=O[A4!O8I9XG.D_9S#.O6<D>JBGZ&_K]<>
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M54[6$WD)Z))>ZS%EG[P>I3ICZ7#D@F<G6/"8\8@E032]EH8?MBE2T>S-&%Q
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M+\A6==2NJ+T(HXL2>#;9LUB36GM&B$!3R@4Y"9AR@AC[6[D_?[R;%9W]T6P
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M.C=_6!AE"X(LW0#:YT*R<X^:@0;MS9^:]MF>G2]ONUT'YQX*YB:<3 $5M&X
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M8 Q!<;TM&%@-6+8/+]<IC PK,@E1NJ\\\'@ C*SM'8/NEGZW+Q9,_(J0/T^
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MD*:Q?=;]E,TD 8IG1!,8?JG(%9YS#HK74>12L!Z7+1Q-<L!3_:ABJ6+!,Z[
M<UWP/[,^_'\F$FJYU'\ U B)7^\93@V9_)L\,EW!OZD?%\+V#X"R70.-LIR)
MLZF:0B1$<^I5YB,C&K[/&.O+SW;8N9:(M>=OY^>27-:GNLS>#H\G+_I=Y#HQ
MM6L.\R[D4EK[A\U!%6@=E@;%ML6D[=@9;=4SSTW:K>=5VZ=Z^S+G[O,A479)
MJ9J+7T(%:TH8Z^%U_0^ CS4/@,.7@@B[1/>;D:)B[F;>/6RP!*6)[QE+'2=\
M,<L.?A;%%L7.OWOWHBX@3*6++':(2@K_K:H<BS\U&>AK(UDLB?!S +H@"=Z/
M,.[F9NXWEA<?=G9<R6_+'6D=VL0IW(4UI<![T.QRU5J=LQTS8.9DVC-<35_J
MWLO8C](L&&+C/P1!D:UGHE<RC;FQLQ%9[:(VK;NIF<63]C6UR%TPT>$(:9B#
MZWIE/MJL1A53+_=FRK>^SEYGS > 74@;!7 W77=M]7ULBM&*;ES2ZWH-48\Y
MC6,O061L<4F)4JJ-UXRT8Z!F1X0&P>$ZEI(+NJV_<9:VN(.7&/KB?+M23YZ]
MXEW;Q>)&>V*6)?B RG"PZY$K.F]B)56+^X&PM&U#GN\'1%--+X,]WG<VA<-,
M"7%_NF"CTG?#30UDI:.MBKO<S9.U*)&)WF2I)-(RSWP<G7\TW"F)B[-I]@&O
M2!JN(ZX7-NQNQ5L:V>+'2,C69T"73=6ZM=SU (Q!W""6$9;C=MRNYQ[#LL\E
MM=LTP>;5+=Q=KJEBF%H"T6L%"2WYK(U[57L;AM9-CMHFNO6SG!]Q5"IP0V<<
MCST7N5QX!U8FTCRD.>"G\Z>A<CZ&85ZZW* ;+>X),F!JCT%]4A.K0?-L*"46
MD^DQ4>3S@O2]#V+G>%^6;87R')XQ6#<@+69.>&-'E'LGRN"M'B4L\=:*7BJJ
M)(#"^DF3[-O7S)U<\ $#HVUB$^IP PY W!KX,S*7%SV^ZC*4D)>P"A8]X<_4
MM3)P++]W%45.^N.2XY#EG%7^[3R-PQ +04^W'?;,DQ_>_.8_8K6;0*:U%4 J
MSV%E28-7'*>][_U[B-ZFJ02^M6!,OO=PG_[4,ZKW9MI/ZHB_NX1'3V9@%:A>
M%=O3MUBVUN161W\@'3JG< "IDX.%*:4J1PJ8![R&MNWPS.9+T\>%UV),K3.S
MRR$GT>2JY[RUI.CJ3UC"MDDNE$S%8 )>^:.GIQO\.3U7KX3=_5A'1]D,V52"
M1TR&$*NE1.GXS,)'!C^"F^/S66+-N&B^-P5F@]7/U]:TF6V;'*IA] NJ<?.W
ML?JY!-7AJN&JLC0]*\;34LH%1:\U]3Y1/S]7T6\GVIG;6=BKFS/")0H__;<J
M.G^=H]NAFX'N&<M;XQ5CA?[H.&&<./$X"*196#RN^@[WD:3!8>:P5.U->;'3
M+4>+JVY<G8LBGM<CH^IA#=JOGBDI1U-W=L3OUPYV3)BY95ZS,&G,'K0@IW2R
M[(IVRYS(W6S0OT1>O#UVW$Z/"]><@S8Z],V_T@R8GY$H-14)'A0H?O-[7:6Z
MJPK5W&2>=7A<2#*7MG?(M%K[V-8UZE'85E7L+NCD6?4(EA#7F@^/P5?B[G!]
M8_?:*% 4L*]C"U&QNL8<[X9I(FAR>$ %(=X>5/<-+\32+7M/FQ#9<1O!@U^B
M**J2+KVDV*-3U8%O_YY8"H/37T6*^$<?&2@,(/T8P?$5G2,8\I=TEV[L\_]T
MO_[W'<?_'93"MC;89FU'U->G=/2^8M92'#:+Z^T89J3GQT)>>;XF<QYXSWBU
M?BU6Z@2_^@%NH@4DK+U5-JE9-+[KG!5NJRSCR"<G ;ZVL"0#R7HHF:)EP2VO
ML)\1^6JCS/@62+S0U&]JJ$12*C*S1KWR4U*&J4(B!E1+8_KF_4OG<L'/RS_5
M/JI'Q3_;P O5@JWC$=DY'L%>L^SI(UP*('WFG+57A&,I@L_7XY1,#>2$+!W!
M+D;YKY^F8 C'7.% %@L&5WY-EOV\IR+0D9J_688WZ^VUO3M*G58PM5=K%.@0
M6<);M84(<I-CY+_/HK27RY]/)45Y?;C* DJ.QO[PAYP$7?5BBHCZ"0.51PAA
MDUEL_2^Y+\?<FY4_$PML!Y''00B4&#>#<J2=!F7O@Q4;T>IC(/6QL0I%!TT+
M>D1!A%Z'KZ9^M->YL9AJA<>@\V/0.C[E*?YM0)S)AJ9*^'#%7#EC?_A:<S[G
M<OTES !?!R*U8\T2\(O1"IM-6/ #VGS36JQ@F7%%W_.K=IQW8',@\ MT<>#M
M^6[+B(FS\!-E!)FH;-YR:IVUS6?KDQ&L!0J#5D57'T80#:5CE4"S\*C;;ROV
MQ=5W/L'M/?4PV,^I*L$W)!\K^PA!T\SSWZYL=4-*95GL8&[U*!NP U9[8KV>
M09NOC1'U=N2VX@)[J\B1CQ-V9R956BO)E",+##!6)QE7OC.+#4"?K6)A+-4V
M,(S)&?)9GF6012HI$CF,X.:^/<NXO?+A?VO(1"#$D^0U=6GBKH-(E1.AF1<Q
M<[J-P:M/2LLDI0WQKF3W.(&UTW57NWRX?IOJRP<8L:FCV/Q5$[=\AH+PP;QF
M?.$"@HM5Z&YI56)C+9CJ73TRSU.F+Q2^.Z4;9(T??06AT.-7T<C"\V;PIMS2
M1TXFW-ZV%@5!KZ[+YE?]#YIG;A2'C'N+^X1/8+/CU?U/NO!NMF;JE/:!U]AN
M4?W=*T_;:"+*E#P*S6&>_$,G&OSFWF&I=AJ:P.64Q1+5#E&PCQA)B[D+V)OD
MMA%99N>&U3T+=+V0D>T;D=EL/GAW5W>\7BFC/Q<U>CRT?).W[?3,)J=G1[\>
M; N+GIY7:$WI28'F3!'C@<R]218+3@X1%3(RM;8SVD1"-R$Y0%SOV->UTOCP
ML$A7%]**P5NWPZ\':_KDMR<>H&NOT47/!I\[XUN6\_RY#R9,9@AR(K+/B)C,
M@J[G8<(0[D;18=(A>,N]YEN73A:3QCE-\]V@$+&MO5OJB:YIAHJ?7\_$V8:@
M!L!U> :\S8 (:\ EQ-I,L1+/F>=3!A;+?6%J>?1F::20Z-NRRW#$C2*Y/(67
MK8@X &CY>A?F4G7NE0^3;4A@8'!#24W$_F1H_/H.R:76J4#T] 'P:S"/.._$
MGHN0T;9TR&4**:4)]F,NJM;SR(Q,;<,P\'18?.X>!-WST!=3N../?:R#^\X@
MYV!OSO).(6+,O8]^[0[+*.0[VZV;LVO]&K6M9\:,++P1_-*'/NH59 RUX<[$
M=^[5ZB92*7EB3#C,,\-IV^B2S0>Y\,Q6S,#S:_7L&S_+X=N[C;9>XFLAQF?8
M=QC;R]5$+'X^LW&,R?5ZT-9Y!45.\!VJF!7^6;M;Y-7F3._4\@93#Z.H\K)O
M(IE7Y;9IM@[IH[XM=T8*T;T-Q'=V;A]:@SPNK5H1WM).48<1X[>!Q'[SDW35
M.%^Q1=QBN#T2&??%[2+2QS)I@2[8"D^KZFMU(I9A<RYVK@'6:GK)$6W*GQW,
MUS-2;A,(>+T;ARU)[LR5@2<D<RS["B:\\:T)&1EW=UR+F1U1+(,(3F[[083]
M4!^!$? 8"+0K0U"Q%C>*WLQIASN&*7X^ Q;'>_MV?2KV[?VP8+,N]A&V_K01
M"-[IXFAH%_6L_QAY-W$PCVCY#L5*^&DQQ(S+'3S[ V_SF IQ169G6K*Z&M.2
M%E(T%Q7I%:F?_OD(AX2]*:/Z0E.WQJ^$=S\'^IXY2Y^C06#0L2;=.<P$A/NK
M+QPX.'A4"XSH24EWM27D?OZC'F-PZ(RDP=;;T.5J<=UP[*\MB1MS'G6S01JF
MRUT6X6QRH@E9U^1D^K(V2N.;)U 13GM?PF5$8?J*/TG&\#N@B]HJ_'U#TUYA
M:?+\8/;JBK&O3PH&2I%9/55]G3.$I'_V"Q7J<:BK?0]+'CMCZ7HV QK9<W9X
M>>1DFE\R!E9$Q_SP6H;_>N1W_F^*+]D"JZ(;:0-T"*Y;6JS4))\BD5B2PP,#
MHE$>L4[[F6?R&SM*NNH;)E29HH(?Y9X46'P8''X"EG@Q!8F5-C#''YWNC>$/
M=&;MG3?G(=6L>64B:4S582'"((X2ZC=H^>NKL04=&,B$A&[RECX;' 2S0%EZ
M!P>ED31#,UO8<B3AY1];>)FF??-UCL)Y=S6"J2J?OIVGQN?HIB4#^?$_!K#0
M+,C#%OX9#>G_U008OS.,X9#O>"V,[D=BG($3"XEW[T0598AS'CV9%&C07O>4
M[T%6K3%#/KBZ15RY813UV^"/)KB[:U72<<EBC$(Q1DEZ>+B^];"H]BJ^E&)1
MY8"2Q20WR)($)Y,*X'%#RF,^UK4>MLZ'+[0VS]+X-3>*7!]@?Q)I<A<M5U'$
M/5YS?^IHWXV((S43<B,]QB%H_%W[_NC%5W3\1T/7(^H/_PH71[:L1=;@L>:(
M0G8+&Z/@RJ1N?2P*0:G 'F&,D:7%/EW@4=%BF1Z!AWH_'>J:7 FM *P!UWL&
MSJ=FREKB6#*[5JB? .VT3S<XBJ<G3#?-^C2NP'W2E*Q-(M'?:Y\*BJ>+SWW=
M%L%SH< [SQ4IVM9<>98Y, -)Z^/-4*_/YW9O^UZN%;I/3'_R8C:UC,9&)5<\
M728)^XIO[I*==JS6E(G'5'WHIK5RZD27G>U3:+=JAXC*R-/1=+7W'!A5<OB^
MRW0.O=;+=$"VE<_6*Q+[=,/#I9-S60VEJ,4?SPO@5SL6>J<98,:Q),4/IVT?
M;?76/#U_XBE\A7 W'^$\O<R)RT]M)60RUUCL:O_R JF^8E6N;O>A2SD<7#(B
M=9HLY?7IGJ_#3<EK\U6L@[TYP:5R?<*L^T;8/(RDW5U\R_1BP["*M:"57G1,
MW<V/8Q@A?#RRAKS_;7YHPA"WE:JNJ%LYWE*7:]XJUT-GNK?(UJ$5^+QY/4D*
MSWW].)Q5, %5'(OT\ CS1T1/J*?73.A'[5?W,\)*TMU'_%H."A.##01ZTTGM
M#P 4H&5=6>BRC8;$P";!F[T*E71&HEGE=-WPG'NFFGZ74YN91+DO YBBA7IQ
M47:R4LB)I-S]-DS1\$NDRUR<GG6OX33/>E]]0/UK0G.YQ5B);M-NP]EHU%D6
M[W=!,5&TRCH& NB/@(2'"9T>5."[7\*PM^@HKJ"F4 $*O<B8 3D,MQ(OK"Z6
MVHX0/Z:WAD&D$TT_GZY8@2:2;Q]]7[?^3D1VV\Y^#TO=1NZU>#7!R<Q@/'9J
M\8S%[A$AS#KE''<8/[3\?;4B6N:*GNO#$88QC.;!M^\.DU"U59OM<LQM]M<G
MR2?36.,=F!?>3-9!E5SG\&/50%&T,0*&D0X<=4&Z7VYF3KR,CIR5*MD-FJV7
M%FYZ9.OJI'\7B]K#C!#U7/Z@:T*+HSQH7L0S-9><U/]=,2>HXUF.+P,NY= I
MXGMV$@CD<I3+XI5C[D,ZE;>VV.J!N%':$AV8"3>[(RH&P;_;6!4"JQ0%*=I4
MHS/TLB ^!%^,^M6H&;?%*1K0\>J?(M^N&[A:=0UI2J^(,FZ[[G]BN?[DL+TP
M:.&\W1K"J.L=W<0[=,W0%*O1V".@?2V6O3:;D"59V\0R2UCI4MFTV)*T^VY
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MZ9GO%KZU<B&==VN[$RE\QD% K'9M'3>_@OPI<IE3;]GM UQ1"IZDF Y(+"E
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M#GWA 9@=7B=?J0R4S(X3J(N#?E-M6?4B%[TZ4U612;?]YU*1CN.*5:M_F5L
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MX-])@ZO/OAP-!D@P?^I5A#&5K*1]7KYS ZRR.XA@(.&;^?0S5TR,>)?=-<C
M>G[G N=_G$!_8LJCFEP'<1VSBT&D?;'[/.IV84_]V9FWN;;B'?_;MJH$R?>/
ML(Y]K[_"^$0)(IQ[/MZLVSNS5#C2I-D[RR(D/W\%6"EZ2DA-[IJ,^?-]6B;W
M":I^/;C"@)J0*]"W>W4LE)O84_C>&:*ZL=9](*-/'J0WS/>NWT*.+#$9+B7+
MN?%C<_O(/7DDJ$RB^2N ,?7FQ\7L84P"R57646&)^RMLG+"N?%[WX]X"<@D&
M+$;LAGG/M8AOR?XM2,PB$ L&$9I]\)MX&RLDS5"S1Q$G@DP(+S_7]%V9VF=T
M8Q_T*DR>!,V7]P35Z>^ZOW\7$_U4LE;:QR&8F)1^?MU#H,B PH#RZ!L*3B?=
MHR4&!L[A3H:1KC]G$+\9;I='=33]07-C Y -7+J,OU*:+O-A^.<A#3)@Q<N=
M<S"3*ZO3(64C1:BG@/@M.5C9Z< -@YPF;L3*PZ>@R/V))2O[4CQ'X<\D-;MR
M55DB.2[?>19"W\A&D=*;.8T=DSLC]_@E5HRK A74Q%\H*0<'C3<NR[]0V@[I
M?Z'@)Y]"H6G2&IDKETOYTJNG=?-T+SY>:XX.Y12._+@]FJ0]OI9F1R*]SI"M
MOU "Y^4>:#G,<Q\5Y_S?):6CX)Z@;=@HJY"'RU3?W1C9O7%R;=(A53ZIA(KL
M-8LX]$C'D.E5PAY!$<PE4K3%4^='?:/A>/8WVO3@;+2-$11_U$L;Z3_@G&M*
M&BA0%;F4=UO]88VFQF0G@7H,V>ZVLW??,TZAQLY<7)U19.IH+I:8&I/8 WI!
MWG)(Y=K(/B0H3!\U_A(H6\54MQW#;,48\=(>8P[ZUUMS/CP0.5F !?N8M]RY
M=G,AB_^GDH+_L<3B[S*DS6RD=YQ![EE,;]W6W+/%K:T<[M0OWK4;B "!K&QV
M"^D5M(94S?[' M+C,/Q'%=V13RG<1;XX6XO:IKE=+A;E;(=3<[GG6Q.L0I;9
MV@B^V3)L1/>K&O9AAM[^#BUGL6X ]TLF4/+!+Y1G,=D-"[?DU!R6\URNN0=Q
M)5/TM!(^*^*)/>F=D=>--.[X<563HSIS*?(?X5@\G3-&17_><,02\><-1]KD
MC$D"]L18C,(>O/1@(B)[>WL0:'6<@AEE#A)I'JD"Z0Y']B 74D'_5N3U?/AT
MUDKW"T5)&D_T[=8=**!#O\NX"S%@+T+JRO?,ED+,GP]F!B_QMGNZI+W.;[33
MNQ13F5WPRG&SC!+9&PZ8'JPW"'_MHM[-W<TT+"O[.Z _N/P)WH=;H\N:RPXX
M1T>[/Y[.MF:(\) V-%$L?B#+(JD#0E*MJ31KIMQ%]%N$56D*XQ&,CY)Z*1F[
MC'IL,\36$C\G+3X7OK_0/'R9#\]Q.RO<V@D8"=9T6GPE]L)68P*8-39L>&*,
M:?F^*JE[.:X70(\&)URHX$"E<B.B20SWB9>;A7]J,:A"0+.]P!O)N"4.&E6"
MG,(L##AN 63'B!G?P1#W*2KR4N+Q(5S?+'GNM5-A"H$T>HGWZ!UA\C+/[.ZY
M@@O06"\5%U8Z)\L$7PS=F/Q"4477.HJ%MX<7R#A=6@+XKB=G#_Q^H7@RG_UE
MKN.H_4ST%\H1_DUYN]T_#76@69(60D["OUHZ-MT>+Z>_*C?4.YN2XJW'/A2Q
M#**<>OHI\A%GW0$?DI*C[;:@L#X/([4H;,2I ?;E8[\MAXI3M"T?13![5H7N
MG)P$40^ZHKK#^NAWDG@YA,DZHGY<TM$?WZN^3\<!JI0U2=&.#]9RBA5*@GT8
M7?4DE# X05)\F!)D&1V>E+>9DE33$3-LUC7BUD\RF>JA1[V\H'PKI(AT-N=K
M,.%@\74USCL=![[Q(["GCQJ6]= PF>9\C:A&4B3-]=FQD\> /1#E,XES=GNN
MC?>3U#LFAK_AR#@B/2*4M+0Z&X_#<I<ELR='8X\W=EGQXT"$&IG+YW>6'<OT
MI-6JBG%6<4L!O#U%5O8KH"K?U-J#GB;1UOY):G 9K[" H:,QUR<3BB[U(5XU
M9V*'&[LXR@2RNA9A^?U1H_WOO0S'6D QF<6]:.H -E#QA.G,9^^CC<,'$\[>
M].F4^1'C\([RJ6IR"9%J8_'OP+.:N68K+LY81E;QBR]\&UV?AQ@2_MIZ;0-W
M_A%E/G$+W7?O*<^8Q/^W.MG2R7\[\G'#X4*;1WP6?P _B)UZ((?C.KTU?7U/
MEI,?;-=NZY9S/-+@@'7X]XA_/<06D@C!1,%.A  P(Z,!B832.)V<HT='=P(B
M/!OM"G+M*D7M)OW(X0M'9,MB70O+N>0"(MVY /==XL"=:VN76:FK(,8XPWS;
M!G^O^^,5@9-$P48/%"G[8/S\9K< L:74 V3FN=/,&'W8+"4L-DF[CO/[#]TM
M4K<J!28M\[)^8?K6<OH3"Y7'2AK##+1//Y&W7#. &1D9DN3X&9-4<+(VDE1P
M^S>2Y,!B3/R, @R,K*S@X T4>2.%='GC=(7,""!P]<]<Q)]/L/*C0VC2G(9[
MH_'-C:&[=]QG1$;4K%K?QZF&(7)*PEZM2017EMS>W$V,^L$E/_%,,3?/C,";
M/<_;3$F:I<!YH(G)K/Z0E\S!-TTB*7_5H_E0DQZ2'*F2/"=-+BIOVUTVX/0E
M64G/4!M_I::!9ZAME4UE9Z;>5W]K+N8Z$Q'B@NJ*2?"A07CAB#W7662VG#9P
M^X3?+_/4.]KWLGQPO)?>XNM+ [;7,4_E0,QG@+K1S^^S+8/J-L2?ME10P1SN
M\>8.7Y;DQH1A[2]/IW8N9^:Y-L4PGS\UB:K5[?[Q+%.GO_=YW$'SSLV%YGSZ
M'@V'4[5X'H_A-]9IP'NM\IJ?(]C2 LEVCZOUL^V#&IUMJE.*Q3Q6IV-,"S2(
MZ$2/4B=%LYZQ53>H6P#PXT)S'D5P?W()9/-O?7AFDBCW^.U=*R%<^L6&<N2C
MXY9<M,YNS7'JD'HU'W3@HD;I>$:]Z6-6H>&VS%Z-I(2.+)EH-J$NAB/<,^F,
M!E(K%K<OI"XM\D]>WEKXTU*REW0BE!R$W$KF%SMZ'_ HZ0'.7,^]8(/J[J8L
M)WO^/.S*C*QE>RHE"B1\X6:V3*=9*5L_4(]T#S&0;6J&/O7QR7RYJP*^8&*E
M%DCK"VWL6WZ[;+8^UD+@SL7&!X!JA<YNVHPGZ9>P;=,PP[RD7H-&"Z<TC@ZW
MBO11RF?E/53GVQ$O/9+8OZ2HBMGP@8ECNL/"EZ!0*&JN1T[J9NO847#BPAX<
M86'0E7T5K!"M[K37R-5Q,!;?Z[!D24S=$H=47(V;:$IYC%G@*LC8X\H*\02R
ML7=1^0?M0KH];#0ZAYS79BA,.=X/;+R!+ +EL#*[%G.HT[KL2K7DV*/[]47B
M1JC".>BISEU?,HH.D'P>.V+9,%/Y-LI]%'0*'3WHJL0P/D2HQ!6L&(;J[QRD
M(-34G7%<^#_>M.GFZPH8#KRDC20KOW]]I42BISK1<K8%5T0@C@Z73UV;#B7A
M,^?+[^K?C%AH]^U!.1+8^J3SO;()-%@$.# #^!68@%,V-9_>J@=IPJ[J[/P8
M84\"^9VEF^MN>^KZ@))CW4<T\=D!K\C6"\J]/YJ*\OD/:4"DR]>Y0ZN[J/>6
MM+PPDGVS7=P4V09B=\= K2$B8@Q]HX-+1=YQIZX7J8L5N(DXJ9DSODW7+W0#
M&('Y26C^RSR,:,2MZH7<0VI*C-HKI:T-3/@.1LHUN/^IDDVVM,"Z%NH3M'6S
M?6+#5OOAW]T3W!<T</5YR;*QK?'.:)"+_NK?VC"EHEH,O?'S++]FWB(7W"[M
MC?>HI_-*?&Q-8D[UO;?RIE+>3$@Q&MH?"[6J5MQ3I]01/Y,P]X(4M$KKOT_I
M^89I\U2\ D83RSJI41-<?=YWG%A.0";V?Q#?!OZ1LOKO4HA+[G$>QKRZ@]&.
M@BYM[!E$,%J3%^[JC.8:=]#?2[;U&M/'+F5">$@BN#I4$$?.6"+VX[!&*GE_
M_*#WPXN)N($VN;V\5E9!D?/+V-P2B<0"$@7J1L8KV^ZG*PH$%&D!KVY$6RM
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M%OSF9MXP;P5/(^U]CP4C'.JO"_Z#8:W,Z14L;(V0*=:I9C0Q2RXE=[1"SBO
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MB+D/BB#P=$M-PWV'PY6%D>[T_01\7*?YYV9O:],._<WH'35J^G 8ZAJPKO"
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M+LZC)Q/<>@Q*." K%UI32U^2KZ&ETV =\+"WD=GH%7'HDJ!T5?TIAL67Z/@
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M \79@1F/&KVFPH**A(R7:0RS][0SQ8OG8.3%&G=E<^<BG D&@]@!76+XK1Q
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MJ;Q=4IHE/$[UW[I*SY5J[,CRBWFLZJQ>$[S-C5)/B]&LB "G9DD;YF*#?'$
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M@7=O.I_5*1TH$X*+Q9D@97(GZI3/2.-@>)>-KMZ(IWH-B-X- X395IEKX9A
MN-+J>0O#5];0$1NNV#BRB&-U>M2T0V%@@FA!^9%IFGM37JIY/)0[9A@[A28)
MDZ< \V793)PT\W0E'D>/46U("%V%H.20@SQ&8&P\!Q)7-6,LO'8/<%$]KUZL
MC=TT4ZOP/">$-V/14JTVB5>C+RMED-IIZES7U<R1WE,KZ8OT^R.N?K@@4KW-
M2^Q;84]SE4#[CJ9;.D?IUTB\JK8_CU.D/]6' PU=V$J:GR &@PR'M5PWYJON
MC@M@AMX,(WU-2ZN0P\8A!.)Z]$NQ[:OD@;6-Z%WMDD_;'-6>6GB;#7;X@C0Z
M>.@-F'%/NJ0KT\UNS6U>K8H_C<1K3"/\V&<Q:\6+_]'P2![81N:NME:GFJVN
M]*VA%ZYPQ]4TD/#_ &SY\ZD%(>+S21LLVT6W_\YYA&4)4[K-&C?R?O&VY%!J
MH\ !*>K >.=+^<I#Q6W,(X#^IU[;SLV\K,S/^ZUR;%=0Q'*D1<&!K**\E9!^
MP=XHUUQ65M84\2*Y9ED#BIV1Y17LG#+)+8I_PR/O27P7 *<\EL" +YYJ'._N
M/!UZG^@&O/MBA7OYW5<(?.!KJCOR"&#0ZKH_]5LZ#)>6^CEM6W^AMGAT&E0F
MLL+XYP+(;DTLE!2CFDTK<^I.;=\)?HW=GPK_5( !>WFW)O O'YS]YQ(Y?%[E
M BG3_!'VL2:<*?M46(>FCN=:7YD%SP4$3P,P<7$'V\CL[VZ3XF3)B^IEE/>2
MG?E8E;;""^1]2R,\TY/,5JM9%^M9A^Z<NMJF=$V+S^N<^+OGA@Y_'75-!)JG
M%5E9O16\;05(05*ET,6;AOU]GW*/G^]L]A L*_%SBI9B_9:ZNV.758F>W6<7
M,:UO9Y2XVY'I2P<CQA$)<8%Y*'04?[PD&LYPC[T)3HMVB_74:>K3^-B6#Q2T
M. #ZAE0]GZYL\(Q<JRS;"5GL&%18,_3@:'+Y+IQ*U;]I;<J))=%N?#+>/3XH
MMVN(WN//_@SU$AT3O5[8K@N3BX]M\+95[>:U$+Q<9>K6]900,=\6TZ^5=2%.
MZ3DTP[;28BF6-K4PPSS DNX*'S+C">>EC?/(IXK3Q I=\F3(CVY::&QSA8',
M -SY7!->OBI.X4J'$*.$<0NX6\"/GTJ=W3V8^]:/ %265[P175K%P ])+6*L
M20FX@XTS34=*KH5+9:Z)$%(U9]0G/63EV_O\@1!FV^P3/<G.R<JNX*[Y!(-D
MBLC(S.]EM&9,KYL_0@0NSG8C"<,FW*T5LCK&*B(Z5RMK*HDR7*1[26HX&O;'
M)O,5FM\-<73I-7/T$(7;=S(/$@+177$66D?2O2,7H W=M5BFZN?-!3)=-7.9
MLFEI[*2-BULS8* Z(@:3_9:G6!W=? S2PD\9R,4!T%A9H/B8A&ONIL[-:J3A
M73]#+,K0+3U;>6/,:).!<N_/Z^Z!QV:Z O%E!4DS"Q]A77U>H6AXV/:AW?Y!
MHN0@A@!5B[24=H[>((BJ+F>*HWTS1.]+1,Z)O<PQ;SU?-AD@2Q]=V,5ZV%HB
MB$-<+YKFR4!HE)YTOC^<KU(;%]UMRPN%"QUVP;#Q@N OWN!J^,-/,6;A!E*H
M@N9 0(#G^"Y4F$<C?V.!((DTBN-<!+)IVN6>T3+XXU\;^%/=;)EPV:"'GH4
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M;?9E)<S_7!.YMNL^WXNH]9ZM\=["!3G=?H,!?E/="%ULQN*;JEK5UR-*?G8
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M@OEXQR:]3\O"TB;QF8)85C@2D>'4[<R;L_$2%KF+VM0F4)E<(';9!$ZUBVE
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M;#%Y7#TUOGFG"_[8BJ<D=D3=5#8^M3X"Q GM(TT):=?0$]T_6XWZ$AP#<FF
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MKH09[*DRDZ@?G'Q6,.[BQGZ^-'LV)Q I)'^[?I^^%_5 \6P@I,3LQIJDC[3
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MT[26.4/"UDYG@*N.TDM9B:$%)8:%(&L?"1ZRD4R"BZ'#2I9=:CTF+AS:#$!
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M7 \I5KA5(N[;+K8R]92SX:*0J17D*WUK6Y#8VP'O$8PA28JR-4F@BI]J<8%
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MI^29)*7.HWR1GU\ZJ+ROU$\*G4*F7[VY>;< D\W,CJ6B OWZ&+_\786B H&
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MG>>)3-UP]@Z=6G$,[-[EST]_)1>88S$1''GU.7OP*T"B$'!14-7DGF%8ZI;
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M7PMB6N%F=NK%@>4"#S:.7IV(0%X%[&N5L0UI3"L=+P1KA?JU+P/"$UIF6I-
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M@[]D!*]K\,THS/E<JAR@)"[:C"T]C'96#<2.>T#1BG._<0J!^F?[]")/W2P
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M-,O%<B@@!Z2 0OE".E ?)5;+ T\B2?)W"%GZ/KI7/B<9P3W5#$#]MI\)KR6
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M4S9?N.N;.A8A;;:U(XTU/\9BC:B&=%'/1,\UQU)5U+BAPN_EI'$AO6S+,3)
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MX+.<@&I 2CY/V8PY=B<&EU1DFJ[5$A_N85[X7GJ(POC40P;+JY,+6*SHY]W
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MEI#I)O:M4/4:+_5^9,TS*^0%8*2:9I&XT!1D)YN7$\GC2V-GN4X\66BX1TG
M1 )O76!^K3Z*-Z*Z E]02X!'WS-*[E'*O-G/]PM;EZ_J"++/YV4R$(40G0B,
MTA(C!_OGD,D:KMGPA?1:^SLV3/-GCB;5"_2E<]4<()9@N5&]WG[5]T$!9R8G
MXJH2I&SCO?\</0+(?_&#;=MI&ZSJ<2U](F\%$YZSJ$G4Y+:U4_.2!$SYE2.>
M\.@?W5K-H1W (PZL7K2, I,(,EI5_1XUIF&.J,\?TH[2;PM_]>&->KY:UWKP
MQ;96$JTZIM_E+/]6 (&^&+URC](A91PCTUGGIW^F.0F(*N539O_FDC(D%=2V
M/<]X1<.0-= 5V=/E3N>G*NNK+Y;+W=YN<M/I'YY?*&.>^2Q)VA,U)Y)\?.LW
M&S)7_?+;5\/C5ZON?(:Z2U4 :7Y%F_I?0ZAEW$-3PO-*S]\$(EPZ"'1:]JI^
M2PU_H_<L:1F#0\H:ZC1(3\4=,.A0Z89#W.WWFFAVY&JSZA[%]RKMPC_K?S7^
M84\OWP]/^4T+)5V?3RQ"'X-3_J_OI+QS7AL6J&K;"APJF[TU9'MM)YOMNN81
M65(GKS;?E9&,@"45911S;RES*[T(/)57?6"RYO6QWO/Q'\$=AVS[T;GN'H7U
M4,W/60E[SEEVW(3QMQ=NZMN0&F6!B)ZA&#N>S(XF'OIVJV9%LSVO;HVGQ *%
M[>B!I.6[6#0H9$I^3".S62>;%12^@(A[E*?X ZZB-A6(Q:T$4/(82<0W'GLU
M383>S!!S:7593F^GA(;-9?F0!'I&=GS]*T9;.W.YH[FX9NT'U2ZSI4\'ESBU
M@I[DDGW>^N<9P#B[;XW (K#2_SP%T"1+Y;_9$&4R/XG6I3T.)M4H:8=AS-AH
M*D%L$DV_<W]B ]"Z%<U4S,Q-$S]1TL17E0O#LJ+XNHE4OG*9P6XEZ[I'"?K\
M;Q J//)K#/]^XE(4+NSFI:LPUN@V.^FC=6XE%[H?)?!N*[WNST/ J@/%[&'-
MVO ><PJ1W.JFT[VE?L]#'A\=DMBASZ4Q3'085%RD9=24S\@;CQI;(>564:'U
MD"MTFMQ#G9#NXC'8#'+G&F8+(BHRVI.U&)0!8@1.\.E ?XB_>;(:SN?.$*<%
M2RLR5D$MI?FWF>J3=7?C3G#W@MU@\WOK;*:6><3&-/CBHC+=QY"7)/Q6R&1U
MA&(PH7XUTV.]_MRYQO#'P^,@/5&I6P3U2$]CHH4#N_L5D>_?HM[ -H8[[=ZB
M#99:C<!0S3!RBKHLHLW:5D.#U2EU8J9PLS*U=X5-0]!CR154$*UE&D/&.'Q&
M6V!K@47X3DAR<N4F7\3:;SRSS>=BC_V&5I=U%%4J<WM1VJ'Z>==9X%S&U!1Q
M%I!]NYG&G<N424W1VL[&6X#;DXPO&2JV\\HYS2GX.T=4\<'+;%.F]]*-BI1$
MO:B8M7G_(M'P<%O'>1FS[WBBSO-\PSYWJ!-QGC2'9(B>+'=@*CEIJ>[?81$6
M3BQ(U JWS4NP$\EQDU%46$U(@]GZE*N%9"KVV[H(V83JY.CYJF5!1+9'C(3_
M'#[6Q'^1,)4_A*_/]*B#/B)6:],D2AVL;A+SQIQM!#C=72%-43<O6[F][E'4
MK1L4I1=T\0)[%9=6CQ,HJ\\XU+WL98RHK;X1(N3I?P.8I;F8&AT7+>.];:1F
M -1: 5^:)N",0B"F.+Y'-UR4<9"AT)GIVY=TS-"DY]J?+T#KDX8 TRL:GZS3
M=H,^I+W:>]L-^]$A(Z;15!_U;.G!9LG!MWY\3GL_\U=QWYTX7C:Y:9EN%<:$
M!%NN1K)ZA&'IW.8TOQ*>(L:75]N&&\3-"RHHF1L,1XU<)9IH>?6:V!#[J4UU
MIO,.:BGIG#AKZ_RLY.*Y]& @%%[8ZVTLKS%GW,.?M2DE(N4B17=YO_VQF50S
M@F(T2+NJ2,N&3(1)LYG1LQ9[8_"Z03/4_F,6W'_T$9$<]);&Y('?EQ"M^7N4
M)NA>\Q2]GPOX#EPZ>_UIIAP(T5:DSYUM;AP>,DU,'5:3MMI-7%N_REB SQQ5
M#:_M[2&9 8VMPN=::6E[4H@O7Q(VZF'[MN9?LPH'7=<M]1=S0^<?=L,=A]9[
MR!5N7#;\QVN:!+B\Y]-.;Q(7I_=>(MQVL8"7"V>[I3\\FD0"<DY]21L:%FI+
M/-C9>\?XW2HNG>O92.HQJH2%55+S@<T5T2I4')SC"1M+P9]38'F>Z' EN%/G
M\<:P__AW>M4*$5DM?_T6\41>OWT!KI*<&8-NDN8&&1QD]XQ-*?#EQFB7-WK>
MD=HR_"K92UZ(Y8W1JJ]AJ!4G]5V?X\C/C_;"<\-= $!.^,-Q$LU:#Z+B-]SX
M3EY\RN.U%!*5#R&]3JM6O;(IT$P@/0@(7#>;?:A-8,XNF5V=65.IL;!D,$8B
MFS\85/*1YN.I="GCN[<I158WE#6O!=[>N3&OG;(R,;>^")8/F,>V6V@GC\JW
M&(J&Q$QP+=GM6=1_:W.T]O'F,K,>K?[%<AVO5.DC%-]G1//WDX!-]]9?'U).
M]8J11> .&+T4_?-YNP?4U-1_/&A'_0M6PVKC,;@<!X<ZN1P7Y$_^S.7%,@^S
MI"+\:M5\SC6=3PP*844Z0/V=W=0D(F45:WT;&1X]YU<[S=]ZU;N093I!:J^6
M((R0CU$U'CE1:\FY+FY!TT)8=Q-'G2R&O,U9/5V1JSN7%7#-[5T"<H\[L](1
MTN,>UI'&A*I_?K(/=7S^>[404OD;3W=JMR!6W(2.B)I1Y;ZU>$BQP8"Q_<^"
M,XLG&_S%U6<TGCE/S"EC"D*X0,8^]A]N<92FG"1>&CZSK?=0"?H5 &=3&AH>
MAV8*&U%$>VQ&&\:X,P.=*7DB[SYP0;).1\SO;D_Y#E%%?D?)&A?JAUHCZQ(
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M.;R;30O$"'_2DA$"N6280WPK2A608C_6N&</;.S%JG@Y$JL_$O\H;P?XL"5
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MQ_&<DMKI26;ID"\ZBC1#'O@T1@83A]5F J<Z\.2^ZNJPHR?)>(>O= =<)"4
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M5K<AA0D*IFYP8_Q*+'_ -NP'P<<L!G]FK\=-L [@"<Y$R_Z<UBU@>FLX]$Z
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MH;$M*^F0$R"R^];W[=T.7:.Q%="&5NQYQ%9 UWLL@#V3[M?=_[&:FO%ZLT#
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MEK+P_-JQEMK+(O]YI#T2QS !;&MBPQ=3:]VQ9+GC8DA?[-7MW/<0;I<Y4S[
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M[</-@XD/JUM1$,MU62&ZYM0E*A]>/?0P(B=*+ET%7%V?\/[2?3MNPP>?-#O
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MS>9H.@%UZEY;'F6UG;#KB<FRW%'CD/?;B86\Z1SHIX$IJ[1W,8.3%U[!95G
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MGJ".;\L=D%P(X=T C.#ZF(YG9BA-VQU6X[^S&G>P,"A[;[]N WIY%ZX_D_K
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M<[,:LL4VXO>0EWE5FB-W(:(@-$6$<:TY57ZGDM[H+8"P/%8=M/AXK9EO5?^
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MX1=9^0YTL@5WI\5'%/LLP4T9=,VH&1\7'BI@O8<"OB%H]@S]^O1&&.$H8TB
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M53?,6":N^(*B,2C%1E)<I85@R;\H!3CP;<A#U^\!U(1@B+J)S?YVA0-#9UI
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M7E^1'U(W3\'ZR1I";# *M#F(@52*QP3#0O3"CI[J^#"\:'[9I":1)]$;+'#
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MZ/./N%_UHO@K=P?4-/S_L4+9)^?/ 5M:5V^P <;60@C9"S,5[X>ES"N:5/<
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M[J5HK+<$MX%$40U-0KEZ=+H_6<48XDLR E0F*7[ANW@7!76?O5B-NSE+A>G
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M6Y&TTUWCF88(34URK2F,B^M,K"=.)/@F@.26",\M"!'A=&6WSAH?*%:UDVP
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M!G>9?L[NWJC21,4:X!R]T#$4[G@/L(]B&>N:$SDT@#W1,WCN[;AH]T,J:B2
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M: =DG:L-@+$IH3W.!+=4[5S4NP-%.I7RXG4O65*<8>-$V71RP"%;/IL%WS2
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M=E7J#8:A,E.&\GX>]P"<(\/X3[7H?LXT9COCZ HJH?5S!"_4U @T(PN>4+2
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M9<S0>:(SD@[HYE/'.@$]XLK7L*[]O0SR>J\?;Q=,4Z\+^/?]\TVX2% FM:>
M_(SCJ4_Z@_7/M2JA@H.]"DF+L0-)'[2;4]2>O)H^<[X'/+ZCV/VGJA\%UJ7M
M2GMJZ# SQP!?KYR7DLIR(ZX7@-,O"C CP!EOY,ZI-J-7S.TG8R$;56*(8S^6
M4Y(#*&R$$3#!_RU>X<@#VO+_5RQ7S3HO$+2H*&;/>H8B\OG"763]*'A K+>X
M5/#_Z#GS_R-1C0UX8]&F$:]6MO+<R#?S4XS-8_48/RE_Y>TN'3UO@9(KUL%?
M7ALY#6E-\:F#_:PR/7.]QZ4Q4$V$VN\:<Q,Y/ZL@-:<,P^H=#L'$V*]\T1WU
M4!FGN:-$HJ\"-RWK;/D:+5-6T^5Y[SEEOT;6<*!-\:B$1.;C*./8>YZ[TO6?
M"5W1XQ/L]!SO@:TY*:A/C!HY]\SMI.DFX30JOKQ6#0;=Q[YE,BQ\$0D]'A:(
M3Q?E@5J(=*NJC"$+B*&K*\FG6:(\@->!)P,4I(?U.\;@#KVJE1US3KIIU!+O
M29I7[2Y]"IY=K+C\_0190NG-MQ7F<Y=*'VDT2"&M'*<\>NO1TNQGHB/F2ZS4
M,.%4?GC8H<#2]H0Q$O'HLTN<KV]I,8)]+"W-NFCIP\1:?-)IB;]M$NN\K,VB
MKC:'1NZC)P=>>F66&*%T@\8J7[D?PQSYD1/<;9]NH-,Y$'W6]8<0R/#?CF7+
M-/I!0WI_@83#<(KX7B?\0:[P%^S]'F99?JR-MPR?@[4FN _-(6)38TJ>BV^'
MQ:C(UN]X&C*&??"[JQSDIW'94AX4W):]F]]4^"QMCDJ;D5B5".\LWO..;$VU
M<!)>RA91J&\7>^4KRL8PT&(H/+R6N/]%Q,"MVB]XR<I+9/I;7'=)TO%),[3Y
M:&;T2A933FR$A1(VG\S93O.6&3$RYLF&M-/]!&RCD?69SST7]!P$KKG97@QY
M@[-?&2F6KCST/MU=S@Y8YF9=U#<$QV9UE3=1,;1*!^;[ZJCH_ 8&10GS@:N:
MXR<<:*Y/)0E<BH/+=MA*EJX@_& M#+.OJXJ5]*\6_W1U(";'T!V_Q+;J@T33
M"QN&0)R;?9(4+4L !Y65CF;,DPM8SE7S4TY1/YL4%$<O\$ZA#.O??64:QF0]
M<9BDH)$4U*)/L5=X>0KUOIS?ZEH83H: HX%>5(O1)#W$<.^13ABM?X=Q83]9
MGQY<PHAKIPF/+HW8;[T2)D 6<*YQGK"T?DE7!]:M26:>RMQR_Y>'>BGD_9>L
M]-V?*_:<AJ?_?\8?_;=DZT97>)=[#16P?>D?Z9K8BPU0%]!QGB/EW<W<-Y7(
MU-IHK[L'"*B<W1(=T'J5K%22-9Q"GRAX%SHV:6,5E"\C:-VEGD5L+[3'A0<+
M7RC'5%MROND;.8$N,76Z7UD\U4LYQ,-4K/H^,@GUUH[)LV""^D9P:J5]L4<G
MD4>*N<B]X%7> IN_H1 .C4X&"?L>/W+=UX([L @9.M/$116R8W?\.QIV=P[5
M7A-]<X[:CL=6Y$_6)B$\HJW,,'U_![H_QD4XR,NH]M)A4/K^A$[ES,%?@@I\
M4I\P:Q#$O5C0V_X>X.,JBH*<JD0_7OD$):@T7/RX^'R#3.:S'&BGA3!07>_O
M((W]=4Q7MH5I9_-7]-$^)\E0H5/RYN0RY0Q7_2H=MR&V$>2#:E4]YRNK44%]
M>(OY6$RU<PS.NN6XP@KOMMQ.JMSMQ1N[D:W\]<)T3*@8?VIFZSR_4K/\8O4G
M@HH!44%7C)@WB2XSEGP);4+8-?YAPF&G;Z)%PDL[),5S%6Y+A+#/'0SW7V^O
MO*&Y![P%<20 D:_7=#A4JG5-0^=4&X3/O;TISIJE"7F1;+$TC9T@AZWHMP&R
MS]5D$C5!D97'2U5*I:8D(GHW'R$?WB*$0P.Q9'>) R"1+>$HKE62>%/]@([Q
M[.!"Y0BOKW%5IC,NVZ73"27#FAX>UM5VSWKQAQ18QDR4TW2,$\<W+*?V2^N:
M*L..OE57#HZX?:,(?R4J=D9FTPZ)'9?T*5 NM/=0/??"^TKS\VIUALFMV#?)
M=V".:JO&?NM$",I5O(WZ''L/\(4"Q75_Y9P#4WI@39"=L5,4J8;I$]\?_UE(
M)./ZY$NJ81CWW^%MI!J*BI^55C\_&#."CG0Y""^_OP[OYW:)ABL\YXO=>^Q!
M<H@WW@#R"3E$K6=0Z)O'RN86]YG)OR?%8?E?UQ#^3^2ID=RU%R1_T']"]HYL
M41>/;<B#[Q[@T)H.#B916<QG$+GU8RO^B<T;C)G^Y<N):X1YG+XF]> >8#C-
MRS1QFBZ.U]#8F"K!&/I8?P%7%!>R+K@RG[K&FI^]-S_4&NT:*@A]#0+Y7%<=
M%N.J.>-\U0*7>Q+Q%^)E<(ZT=Z@:,QE4Z4I]!179.VS5USG3-3T9'T"-:<LK
MR?P0NLR\EKJ;^+)KPHE-1Z;+=*W,SX^$W;PI]RQV;>R-TW/=W^<,W:@-MGC^
M %[*R$@LX1UV_?7D/! KM1Y4C4Y8%I@X\E_CJGYN.-_-7)GZQU$VA_</X'C^
M'>4KKK(E7;CSB_YK/L]U!01Z;?(46',/"&Z0VN#[B*A>R$]*LQ!._JB2>)*[
M<%UK-O*[5Z)TSY9'VSI:6FU[Y!Y )2T#-L"(=/#2 \4S0P13J7+1,[_!NH^V
M@JV$RL84?+\7G9?<.8L15ERF;#PV B^Z;Z_C18+I, H]RY2CJ1_@&)UZ#)X\
M>G+^=%JS'V<E__)X>!HEAA.=#-?0?X>7E@%JG!)2G],U0+NA-N^*"UI"H;MH
MSP].XLACD3@:LI>=H$W,:TD[[?8V]SXQ1\[!%GZ0Z1,ASB-B3YDVOAW(KQ;^
MWS(4M=7EJEX>-A[G3PC>,O71JA!$A0QN,SUH,3S"\Y :0U@PQMS-9U)*RF4#
MR0V$?J?*A-YUPNR2\53'F)M^;Q^(_X0' %J^7Y)(3[2X6R XNUT;$"@0Y@,#
MK=U+!?H@\[4EWNX[NE$>5Z^#]/(E(4[/C,\V+QQT0O/LGQ>*GF\3KQW]]K<A
M?+DZ\J-) B/3!1%L>042;G4N7#%J)XXM^3M!\VTT<<4:%?1 MB;(:!5R'KYS
M#[!NA(7^(PALS>/!X4=-LH7&1D"-)2-.X6+@B]M8K3>SU*)C?G*B ,).2"5]
MXRIO^'/L=1?U5CQ#$%@[JS9AD_K(9-QD?'E_V_(OD?H1WF!:5!?]V9(N+N;E
M^DKGT:^KGI1\;&NWNSA1=C'A^:BQ@&4!.L/"C(3:T:QQ!3\^8HK0]#P*ZU^(
MS=5!Y[>&<CF!30L71MZ,C<T*]).R6O]20MC\>4GP^44;;6S80V\'3ZW,8W>E
MJ"M_F8N-20; /< N ;N.-&93,B6LC3S_EZ?.>38.@]J%VYT%8WTS:1XK7WHM
MK4@]4LW)1*G/5^NG2%M55\[[AD0)W=G;K4]^VI<6LHWFR;0I:\MKCK=/93@9
M"FF_(3Z!,4XC3 S+,.#AP$3ZQ#.Z[B:/;TH$?57=KQ-<S6/:T.]A>)C"3E_9
M#MT71GIRW.<Q:MHQY'$X.VW?%:Y-TWV)#,.B.7)%2A9NHHGI/BBKE>E$NPP[
MG,53S1MF&L2IVE=E9H9E^!AR'B2]@RTE0[7O.JOPN,8M)EZWQ!J62.+Y10S'
M;:GL!T7R'_1FP3Z@B9+F>R,%P]UHXO!>]OD\4O//P%LW.H_/;T8-S .%OQ@;
M(6C,C8>P&9W[)I?HD38&]._9?JDY?3>5+,EIS<1(A8^:*XL7,LHGF-FBL8*I
M,Q^F1KS@1(/PJJ5T^+_02>3K^5]Z,/[\1XI0R_S?F1S-D5%I=W&EBJI1K5+*
M]IR*_JKU4Y<]BY@*8Q/.;6_?-OEC/+*AI*\Z,I48@#-[TL84V.UM$^BZ>YI)
M,+M@5-X_I<*/FY[ZIW;QVH8AB#>BB=-J/?K97@-15NK!&;[[3^SP8A2E3V"
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MZ>H=DR.K9_QO'1R0$79OD-M1>^7^U%NEHF6720=0>&CHS0\Z2X2LA:HTTO_
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MO@>06"?RE]4CBX2&7!//C.\!S!YF%9@NW7,7 [VC4P<#*<<NXXZH6 '^<DS
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MB=;[>(4 +I*Y'Z&#57UU_>3._43]@N<WGF.:"C0,3YCY.CL?AL;QB>^W,C7
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MQ8C&RZ:ZVY1T5)Z/#VP:##E8*MZ+W.ZT8_A)_A[]]5F *S[J%O P?]_Q%O#
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M=Y,X+4]V.%BK\P\- V8@Z3[DNM_Y2SZ5#Q_$0X.SOVTF5XE/.V?N*/"PT9>
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MXTA\/FT$W[X&?KIST?,%(1=ZPST5X#$ER1'EF(UAW$;F4OV@G'BYJF9C<9.
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MB()G3;KO1:0U3;*&SL_RS.!')\XQ*9EBDR)R?_ :#X::^A46BL35$EH77KL
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MKA*=!\'568F'?DPD4K=;#NK44Q;>,=XIX!Z$4J#0)YOY?]^% 7-5Q*WTF-:
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M^P"?(FQ@O1.04QZWWBM99_AFI'"J.^OV[Z!B=,[_"A;6/U[91"H66NCOV?V
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MG<HC;?+=RM:Z?F<[(\ \\^UVT#9S:>Z6P+&?"">U5O&,6U1R2_X=**Y$@S-
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M4@1#I] V&Z:<CK!G"A#KGVU(S9'_X%@[&_S6WADODO;+6>TC1Q9)Y>N17[[
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M6RB ?$%YT3LRIHR$KM"0.*Y,]JI[>8%'E5P4P :TT+ Q]CD0#Q%M-.XO=DT
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MF<D0#[KTT]H9D)0QQ[4WZ[VPD>/<67W1\&[Z1U(<RP^YVFDZGR)I/]7PL@
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MG+5B;=.J6\EL0S/-UW;NK=!SQ >S>V#<_$*#R'+TX\:48*_.L%:1*)_[(8>
M?Q_$+8\%-VH4>\6&M2#N;<(,L6(++:9:HLJO\H3(T[4:XZX5EH'9Q7KH)@VC
M7U'WL(,311H\A!E=S );_%E>A:39/L=X.RORKR19 XP9ZK8Q^G+A\'HB()>9
M@E2QD65DL"XC6"$8B\[%*!W6T\VQ#D:SH19!LPRFNR'(JFX8V9-,CT2?QYV
M%46YHP#4^SR'S?99 =]'&3A>R'HV:73=@*"!21'#SO >V3#="L^L>IV+^XK
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MU_B:+NB1);CU!HEKB (P4GP!'\T>H0#2<6UX_X]=:E/OJVZT4(!M:9 ,"E!
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M?.^P[0MNYKH7JR0\@1.@TQWADQ3UGH6P0 7O&@-)5KAE37FUCT/QZJBW*@I
M])-1$@RY%T/B=,")=N#@8*[7M XS]N-9?G(\H%N,K<<MHP"<\UF[IEUS[P(5
M$*M[)O)Q[FK76^XD&O;@#T;<;F+GQ)I5ST0=SJZ3>/](8C'*;M-SEN"]K&SO
ML""*0 %@%8$8"-M^W=:RH_F@VHH>YMD+YMM.D\.2*A'DCBL*4"?7"4880%"
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MO,*O#?C=[@P?WCZG;Q^_H(RDGWX'=KP$1</$EA G_ =LI O6="GK0;:1+6F
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M3:_+*(<I@K6LJN[1.X<S;P&(E)BPD(WATHID5O)5//CUX4<Y6R$=B I1(31
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MAR="1U$.D=+0CVF(Q6)JG-YA (O6$W6P[FBP]T^\VI.NJR9LF<:!>3FKYB?
MQY%#("XYT+MLNV)()6/:L[$$IWGM5XPER]7O%5F8!5]>UN'HI$Z?ZHD1P<\?
MCS_N#'=WHMXZWZMQP ,?*J/V@O:X"3H4W]<TP*.P.4H-:L4./T6)T*<!/C$/
MF=Y^VS^WJ=)&397)TW60,5=.VD45)NTNL?5(F&.*8^O$*%8+0PL0"/(FYZ#
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MUZ=U1IX^>81KYP>07@J^-&^,[)4>0+ <:K_XSZ?\L8D0<L>!,?DG\%4%6T*
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M"UUK(Q(RR>].=RE0(WI6SZ"D!L.RZG1'2PV?!H?ETP!7)TMC*[6+1%S2IG9
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M:<N 3DL+1X,GTC62T_9^N%2UW@M+4ROJYX)H %:J.!2YK%YZ^SCZ\%WM]&V
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M_A]N<M?EJY^'[&__"@COGLZR@Q&(;CV7SG+W<5+.:^48LT^^%)@&-ERJK#$
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MDZ&<XLV"V2KJ'B5,DQV+(;HG*I>E2$A<.\M^(%,\I+S/+P0OE6%1D;"?9"6
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M>ABSL3N3ME&=^YMX\W5!Z0;+]T]2<C.@> 42M"0F#_VL(6^Y&VFAK)G347A
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M;V*NWGU.S'D>!P)J^EEK<_:+&N'/)UJD '@Q:HUE7KMKF7'*Q^R8TM&O.:2
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MW*=":,%K73LB5 @:H?W9)^'0[> .4(^!8J@=@CM$?\]AJVBD9Y=$)W.F3S\
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M[\<#_VVR<.O&@]5V!P+1IR=^8'%2&N?YJ+K21?&9_!!13;&*I81WLH#G@ ,
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ME<KN'8)']%=U-'=:MLJE=MW"FY?2DE(A%#/]^YG+ER4J?;!;/:6P2^55U2\
ME+F482\--4\9-$2JQKYO6V0/B/0<:"@.J^DRKO*+SA26ZT(9/,!D0T$S- 1^
M40A6]?#1O>V;^F&L67:X]S&DO&-8/;_C7>\_"J53CH_-BO3HC0Q\C>*XUNIA
M]V$[JT@SW/".<LNK7M$7RQ4O<:4A%T=.@P^>47]0>8(*-(DJ]6F 3W9X7*[*
MTEX?3?/)@4 84IGX9K>=N]7 _G<+D%I6W[\HI4($CP]?6B%S*<@/OYQ\(EXD
MRIA?2$USL=U94_L20KV^PTWUD6$U6- T,L80]G0R6R.B0C<_U?W!'80.!V3B
MGA"Z3'!0W95<_!+C%($2 \V&&U0EXHQOD'(13)#QG)1Z)CO3G/K9,)=[%SHI
M#"5,$>I4HNK7\<;G*CM:^A*#NHPIJ[GVL(O-HEJ"-\%D(WI\P_ZTQ%#TL=LS
M404CLPQ_K;OD'&&)M" D[Q480+ XM=7(+?'>O&!])40PPD"%V^3>IM2H"I-C
ME'39^&SA?8%\V-V/LIJ>5V"WR(:']L&M,;(-H^(V1.M(73*4%I4I?:H^7O_]
MW^F^6]&9NFZ> ,;Z%,Z446X=1@-PA*$A6B-76U,@/_*?3$VR.O+ =6&DYS8T
M4!_ON5^8#\N],)PZ /U@ _6)9^_)-O+?O:NY_UI+6IG4LOJ!0QI:QK<_+^8?
M 8R317R9QA&"]<5)']7_U0D3R+WT7TE:$@P@M"UYC7FAS&@E>?"%N]"'=?!=
MTYAZ&R>T.A6-\DL!Z35%EG5SUB288(F#:Q.S'\_H6>R>\8^G]R9^3]#VR'?:
M38UUL+XT5"OSEQZ"C1NH>*@;^G-EZ^CFM[AWT+R'*.VH2&OAN7*;I0=OX524
MA\H5-R=,X6L?36![Q4CZ8O( =W/^STV,G$<UF+[D!A%H<(OPD1!O](8)?X7G
MJ5O6XN3G=VK+PB7GJ^<3K:6H+?26F7 K\%KA^345QH:\=ZG@35T8K8Y4/@\_
MRBW7TF?827:4@W%E7+ 2HG%4G#',_6K[_G&AB=C7)P->5-RL4V/;^-3#/W=]
M?P;3U%W9#:*2;D67->QDD9T:[,I]MF:IKJ)@7T,#:\8*W=AVBT+G9668G_:M
MK".I-2NTA7JU<P)?MK5-W%:\^N#+[1LLNH_+ ZXWE)7WL@FI2U7U$D_!1UZ5
M[DR>[_X6,!H/^*KD+Y0*D+MN;["KSS18\$48[6-[YY/BLA^67"WFWU\>'P]K
M-JZT.1>;&/]MG])^<1"2DO_-#C<O839%L#11+-3*F:EP)R(K.B=-Q:QI=@Q
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M'\DI7?!\8 3^-"[LEA$)H'_(W+YRFGI,DSWRK&0J$\CB9AT^CCCM0EOV@7-
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M+L!1?AKLB0S,G_&+IZCHOT3^^7]_EN?_9R1FZP(;AOTM(L,X+#'%]P+.J5T
MN.(DA,:3:XT)]>3KS*"BV; +P"?S9D+%K!4M*GZ%OS[:C@30X:8^FV@5M+C6
MJSCZPQJOB.DXQ8<&^FIE*OZIBR/#N9XV,A0FXI2\WQ[5(,[6 7H$:J9%0U.O
M%-YV@[A2P_1>JE-.K1"<*%ZV?2.7S>,T<LW@ E_S+FY[_Q:.^YAIW*C8:.U(
M-ZP3@A1U$A&]YGW95TN\2RM8:U?)HYWP#B_/%SZX3*N[^%.]9H! 96<;WNT(
M[2^)]?W+5]M_$'S>!>M=Q4+"WF18*%VQ/=@!LMB$]X3SQ3%X5F_X!@?%<I$
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MV,(IH$L&K$'HI(0Z*S"+MJ=WQEMCFC 7'B>@2%DCS9LW%O9LY&KWR8<N%7>
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M4M]JQ?"]I:I4Y"K]IW,1A&=8XV[P]>.F,J),R0?NM7"O )6/0I_B,5[</4(
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M(5PR3I]ZN[GFM:4K++Z;]&[P8'+ODQ\DT1$P/;F21Z!*F&;Q#OS%T!7 R6;
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MZEXT&Y<#1S0C8EI%UKG4T=:_VGWN_V!<UX$JZ]*QT@%N:7-_Z#HY6+3K<QH
MW833$4+Q,3XB%AX.IB;7OH]KO 0$47XGWB<OOZAL#5@'TQ#O$>P""@E19A-0
M"=[G7IYV0:+2C^&C;*?S+Y@WTD:]P$8PT,R$Q#MUUFF?H!,-[Z!'^U"H8_^C
M=]0J+=Q%GU*- T^%\"M7@-0'V.S+1M1EFM[CB[+:CKNKL.L$([4(!05UEOJ)
MM6 #E:>]HKD/U:V&XD/RH("4+KOM^^0[>T+K#6$^.\=5DZJV>:X*%8LF"Y//
MPRQ8SZZ;\6=M0XY,IA%.J.@,9>N<#OQ =]MK)9:1UIRBCC#;1,W76RXC='M?
MJ$I*?F>&N]M58W.3H'0HP0X:LY0"U]3OU7(3[P#Z%OYNB6^5ST_R'(=AT]A"
M'9QZR[D69(4/$9ME'$T43_(2Y>8:)^J(K28G&FCQ-P!XWST_B"3GKML#,K>:
MDM3.N(>><:= F[%>V>VP=VAV>.ZA_Q4@-)WI$+S[C)U M9;4NPK\\2V)O5F;
M+\3X3)56D*K*Y;^@9#52UY9!Z^81<H[M5A),SID)KUOV^]H+J;-]J#SL>V"%
MJEZ)K@-1JE[H#E:VR' 2OEA)7@'*V=UW_;C!YXNL&!PJ] I@AYQ?F<3P6Z[4
MK =4;&"'VWYHN=E^++3:><>1].&'5X0YUPVEM"\#RJ :CW!(P>5"X$@VVCP5
M1/\GZ<O#P4T6VFODK-<[8AZ^NR%409:G]YO+UKE=%3L:(V>8H_ (QYSVS54^
M/Q[O:SYN)*OY0H1%Y[4YC882UQ,1WW8.[$UP9$?#WQA1P131/1\[WY\_NY[;
MC\55I4URO(?S?ABMAAEBDNC\I=Q'H^4N)+18."*$3-H25_\/]MX[J*GH^Q<-
M@@+2I'>" B)=>B<HTD1 0 &I*E(C(-*"A"Z]@X""$.E20^^]%Y$.$J0DH=>$
M$@($N/B[\_YY,V_FOC??=^?>F?O'^O><O<]:ZU/V/F>?D?G8>>^*WQ*2<=\8
MT>VUTC-%*!H*_*?AKB6Z(^"-$3?0O/^<'USF^^R'SW>?Z'/I9(LESX=*(\UT
M<R_G0+4W^W(5:MJ(,9M$+U9X*W@X(X^_'?2W_8WKRKO(38 ^NZB&WD5R_D X
MK@W-.$P%D+O6/'6[ EC\\7^<$%\&)4)Q M4FCZQO6N&[]6:4WMC8<S"G'CB!
ME5<FA=_D?RQ=?#/ZZV\,JLF:%E*BCHF-6MQN:@V+MIL@2T4;-.I AA.TGO]6
M'01\]V7##Z-)[)%7@-UM)!7X'EEM>)7-?:\8+:K<E0MFF,W+-BEKR\MI6$UJ
M!N8*H-G@BM>0(F=UV<M>U9A0&1?+Y@YBPXU6/R>=-U:Y-U$KPBKMJZSW>UO;
M0T*$P$R&820)[E+U6GY]F#6=F \UP-BU_BR'%>";'T^Y_MEEJFOZ(C&D7S#]
MUMV:\W+RY"PMMDT<8K3L'?Y. 12V:SSQ9UXM\W-5&'4W/E6N,M W^--1^[F>
M_U ;"=X$\Z9%#;G:5#%3TU@VNTNWH%B[=GJ#(]BKA&H^K*/=8XQT/@6U5$O:
MOX0WN*1X==0H-0RG^SN4V%FXJ"=;^@PH>:H:9GM3_,^[XUVSI6NLCCX&<D)O
M85*K2Y[-*GRNT*&LEA_67M7E?12YIQ5#YZ<-Y_JW- <1T\A [F6BZJM_MU/M
M*'RT/(7W-K[Z7C R[W\BW^>W0?PGP#X@^MKS,:AP;-3+?MK+*()DE\6<A>:7
MCOM4).W<PG]9O?50GO$/>(E.B0\)1MJ700K5)\2HR>K;I^X&ZWV"EG:<,![$
M?W:6L@X*J*(GJ&,6L]ZWV)0Z%CG>_W$_\>! OT*E[VW4"VCW;7F#Y_[#[57P
MSVT/H.+6K)!IT>-63;/4Y:Z^ RU"RBLVB5-#"JU7'*N1'/^D) 7[N;/A;Z$2
MQ0B775OVW'12ZCAE-6JR(MMOW)&K*3-R8TSV-H$_/FHKAT(ESV6VTF&= 8@,
M4[R1Z\^1GY"/6^"("?FXQPJ/)_-^>)C\:3;GX#A:MMG3*3&%E]G5?_/NEI!R
M:>01U" ;P!5(+L-CE]AJVX'^X]%(9PI4,-Z\,VI,C:DZ?XM(Y(44!6^24N)
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M%<?X3DV9S)R(U/D#P\5%LL,ZN2E L>0&Z:=;;'WUA1#_0;BTSKFES+@>&^K
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M,#S_ZE(8:5CM3X*ZZX.(S8^.!V6_ODW-. \R+?QJ9I<GQIM/M)KC)#%[)<B
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MRD.(4QG5V/*+7GID)[ON01B3*IY]^ [Q:P&^BH=^8EU-^KVPVY=#*G=".IG
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MMZ!=M=FO--IYU*FD 5MN-5S4I7:] 05A8=WP2!@XT GL4*V.['H2LDO=I^F
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M^_!XN"ZV_$.>A0.F/GO/@_:7*;*.V]7,[-8/\X>H!SQS2OZVQZ6F.T6L]51
M_%>:61TY[?8ZSR12K?^YH&H;:^[[;(R/L8"U""K,'P#3UE9+B!3T(HK3W&,1
M8+:UT(C-/9_1@HMY>Z3$*RR>]UFD[ST[P^K*]KY76T(JNNQ?<G&E%IO3D)UL
M5EW.0HTCCZV&OQ)FV<#&F!^4@RL376Z&,HV,MJMM[16!U(1>;17Z/;*&<AWM
MW%Y<.21ZV):Z'$>NB1&N\ 5>>J\INY"0JKKXC9,7M'AVN>D0=NWA#F!B/BIT
MAC@3(@/VYX M!GI1OL_)O#ZPFO";C\C+:AGK;?[]?ZN6ZC0%CO0@,V3E?Q/K
M3@H(GE1W+O4O-PD))/-2)I83BU&LXN\,!@M\7 07WK?_?VO;9%@=YP0(F7<2
M+]"X^&&%P>7F"DF(6XOI6^>3BE3SI1=N\UG>8_Y2"[3J'(O)2V@M3S^>UY<\
M\F;\3-5R=/)Z'U,Y'C@AONDF#+OH31P8^))]='7=?J.!>O4!Z$7GC[B'Y?@G
M8?.-QN'\(7:_ @F7+G>E<DZOYRW^4U1].T]/E*;,:<[SMLUTF^-W/(/3*?%U
MR7^9AC2&1A*6YY "H:FN\T+S?\)5A$068.])::ZZ$SMR#@^VY3:LK.LAG :>
M7WU>N':E1&N[+>85]PIKT#8[S9."D<'. A.:(.JZ)2()1*(>EYB'E#O>%+T_
MR@87-7YG++XHZ%HJ^//N&NQB8%-3V'$NK#7R*.B:=([# Q4!@AH*-1I15C:Q
M<P2?*/C+U#['T:$MF-]%E*3KD.\R=$G#?\I%J'&=P>*)R!_!7Y,W?E(WGUAY
MIOXJ6'F#&"=&CJH"J3(/Z0G/OZH<3]:#H+6-YHVO0\ 2'QZ"NO(YI(].0.A8
M35;R=VQ\I!"*%DRY4*0U&GZQDJ%)76K*DDN;WRLKF1JN>?SGTO*<^<.>8*0C
MA]F]S5-TGA,=PH/MMHS+VNS4HAK?10&WV4<AN;Z?FQ+.5.2*S7X?KECQKWCT
M=;9:XWN95# TAP;RW@0%CR<'UEA6\(XZ5IMVVWD&O_J:->V0;]HXLG/JZ $$
M;D];24'?(D7%#\&)=&\(N;DYPDO#(0B0JD@JDMV4\KETBN1GM.K8FQ&IX13^
MA ZBGN Z<$2Z_5^F7O[Y/97QZ>Z?^8*O.W[+1$4MG3+J92OB,,,OE,=4>>IP
M8Q2)SJMXVR#D87=C4^ZURXH2/UA\6 RZGK=IOG3/VP*S,&[0W/!MQU<M<0$A
MT'!WD@L/$=BD[EUQU2'_^\G(4<G!F^M&L9<AS&>*_!^*Q:?BZFV7)C>#K[7.
MU9:!S4JJ-!T_XY7"9_=M[6\.R<EFM:0=KH_LZ'!%]IWP-U#79R'GW*C8=%#0
MT'/RF3"-1]NWA@_U.(DOL#?>6N'?$E Z/(R7DYIJ9*&K[:&&\0FIZ!#?"ODO
M$4 @I"DHJ(Y5[-&V>IV-XDMIBOA^+]\*VIBVTDT4I<ZB7&(B^>F8SAY TB\]
M5439<=&/#H.%P>WFFR1MZAF-;XH:-FS.P]TZ%TZ4GM)GGHPBS/E7"?!XRDZ$
M[7KGGG-@U[5W38L*[] ?YZ4VTCE&W"7XLY6[$)+PET3HZN11$!Y0AZXP*/JN
M3"Y64#)YB%@%NK0TU,^.C&.]]$H@S+UYY54DF32U;FVVVVQZG<AK-0EVA;;W
MQ J?Q!NP&H$*Z]+] :^Q'G)!^"YGKH2N8@YOM!9ID\M)+N=3=5,9UU8(+(YL
M1[(Y'O7A$)A*%=RY^R_3)CFST<!=X/,,;UH)Q!R PR)K=RAJAJ.2B%?C\F+1
M+^5D'C2[#8O+*[WQQQ5['W]1%M)[6DQRV?,N] _-T5;#;<"T!\X8R2T\K6 3
MHXA(LU;*^IS7=ZQZ7CH@;!,<MK:S_V('WQ(V7U< )"\-:0=[$ @*H=N9+;A:
M2\+<C@8VL>AN'1VX$.'>S9]I(I>3ZXWG-+PP@+E[2:O_NO^ZHWGTB3RDTQ[?
M:.(412HC)I4![R@WH1#Q7_,^6#Q7J_Q^(67IO.#Y?K[K[E5"+MTU$<[;)'CB
MPDAC/EN83>;0))N2M>7DOMW1Z'?6YA^_.#[ZIP.7X0D8SN\XC 3D051\Y!7:
M_!MHY+A(5V@02M+T!JA)Y,[EQ^:?;GAS59RI[/5V5.&WN=G?#X3!<1,.&\$S
M>D@^9X3L0['S!P&C<KOX4DS^.@]R?)?O7R*#1@% 81;4J,Z:8BZZN7Z10UB:
MZY&EC'MAR5\F1] 7-\DGWS4WG*;:^FM0\Q0QST#PPI3FE2_FBW+@;EMHE-OS
MO;@&(]"'\"USF?,7$1C'9[^BM92V][*H^69T]S+@B0CM6L<P'Z2B*V@_F*/,
MRYYMZ"_3E,J%N8$'8\I*U0\,_MR6OGT^Y![\P2B#C2SR-A3?B>7I)O$I*!^!
MV0<^ ]6EXGD<^I6W)7H)>EVP3?%J\1_(P2Y7L>O)FT4BES#G(BCP[@IZL0-H
M8,9_L"*EIS]L8\;?SJF7Z!!6!8J8;?D3</EDPC[V(DU8R*7-_S>A(KJQ"]M<
M7VQI>Z1W!_Q>R+6G@^GY]9]Z$:-.PQG:2E$=5ZE'G<)2)[U'X+TY8C%PSP41
M$FE.\-T&3P6#AA^S'@&&3VSAM%(R<^^,B=.E?3W,A*8,\%Q<>G6T3-+M^@N#
MB>8; ]\6[O2=O6H;'D;.N,JX3P=2]SMY1-C0+NXA7]=0)FLX%T^PX),+=C;H
M>D4W@?C@4XTWQ=\9<9DPZ_]DR9:#P4>[M8\W#\[Z3BR:@0M;1626YJI41H.0
MRV'"2%JG4RNM"$GZEU7YS?DPT;9:EEM.EAH71#_E^D0KKA%=WZ;N,!5PRK X
M'M?64L)%%H[!!M36DP9?,IO=CN%8^%+\VAA%[\R5L]ROB$R_*CO/#WMM.X61
MG+,7X,G"6BA:5.<F#QW3ZS@N8#N&T+ED#.G<CU$ *P=M7S< ""JQZ_Y:/ W]
M'<6R.R=@3->X3K7Z;494S'K:BOO#O[S]QT+S,8_))XF0"WZGO26BHWW?^#_H
M)'&F($["CJ!8Q'R][71,MVO!5[A[<!D<'"*Q%Q;\ 8[2BNJ($D3PA0<&DG0$
MZ.8GEZ&F <A)T)*3L0)TN<E@YH:BM/RD<YD/Y.Q*>4C@<;6*"]UP@9;/N(?-
M(-7B93C75YYD4$1YL@8<8EY=\\D(TLFX>Z_[*;UXP=2\^R]3HV1!W?1<>7;P
MPI#)XUSKIX+MK/5-$[8^JO'M?8Z_R,U_F<XP#&C[;R-Y/")/?:.#H,:+<_(W
M&RMA\K(<>[>LGV$]@&5NED5/Y]IG[>O2^#F3"Y[E!Z%:;.WG-G\A6UN$.+M>
MW+AG56B0N=RP9(K<F%8!!H;980Z%EAMH X[CFFY02%2;-G,4OVI"O9;9H:FM
MS 6Q?RL5KQH(OK.WJ,7T\R+W=+@</;LBW)8:@6FMT-,J?YE)6/ZQ^F (Z"O
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MCKK(4&FA<:F'^S82<KY4PCZ!9% Y%\]H@I87GG'>/M4G51[IZ1)O#TA$*Y5
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M<E!32 ;OM<IZ:N#PC "*O[WJG<:!,YJ;XK"@:&ZQ<[K@EO9[RRTDRUKW(6=
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M9L;+:)<]_8E\9YSV32\%=]\*$__%P@>&#:@G$F]356=*?722S'1[??_K,M^
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MTT>W?@5=7+Z>=\YECL?1M_F;&4>XX[>[B<15S\B:<CA\P8UU@,5RMCYTYL\
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M ^.4Q9?1:QM?+[^R9JQ<&F<F&GYQ&@?IS_:%$^(C9O\JL\\ KZB%(Y^)-U3
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M]?(9G84?,L&)=OC?++5M%^.YC4SD.\62KX4S#&XHVQ._H]Y;7%K?N6/;SQS
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M55R+H,<N,3H/I1LD/==&29\ !"KC1>/LJA^MUP]:>1M(YZ&_(+USP&IK2K-
M=H<6]V!E,!OW^HZ_WV=ITK=;AJ,"0=TOZW]ZZYB23P"?7)A#(!6:S=[,K37.
M#C5&J:R)&I71$V=LN SC;I"\5VOD.6NK]9[.I<31V)(J"ZL7NJ5BRB)4S/U
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M^7']IT)3K<+=S[4>KC$L8X0C.=B!/%-CWPR.M?G@G7ZMBSP*SCPPW9#G5.T
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MF^WA:@MS\CJ7Q"7)2)3^\(PJ*=]IZ8<5GJS3;J'1#Q6[JC%HD8X:<;(4I]E
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M4DU7Q#NK&)=T/[3X56Q;*1#U>"A1C:?C(+*<M&I(NAA\$R]=?PLF-?L2>H,
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M$]?NBHZE#U>S^PI\??;QNL- ^!N0X=>J50VAU(6E;/Q&3"D&<I-\-138-*X
MYI&1(LEF$G4S@E\=N'RM8<[]M+@-42R@2:+)@YWUY-P"<D W?K!+S6OO[C.=
MP%+6*Z2XRZEUP]-2KMPCS+(#0XGRR76N+]9*F[K=N0I6D7-=V.,,<]_^>HFX
ME/>Y52 +G)%L)'AO9L=Y!"M&W56#ESPFS[VA*<RJCE?M=$V\TO0TXH,&*POI
MDB0K'/.$+UY366[2G/2US>L"7CZ1GYMQQ?$^&FL>_Y;;L?B.K%]_9'>F*^G>
M=K)=;.?G+7+^N@ZLW>]:MX,AQ,N@6-XQS-T7A2!@I'0A)N0><=A?XN* 0@('
M)-Y H^2=R>"_ <'6D 79.-Z]!D+.TTZFRC7R,SQX+7U9'/Y>S7SEJ\I4XVTU
M V&TK^'55<+*OY%:(_#:G%PS^C HU/F5A$59;!$)W/RQ=<HE0[*V%87*HB4]
MH$91SG=!>"<49H0[-1BQ%/?C1;/'VUEOG1T\RA]T9;!4GD^!/V!2$6L,#'/-
M:I4]ZP1/-(IAH)":U7Z;OJ%9TNVVE%GAPIVZ@$N?;KQQV%?I;;M^"JACK:J%
M4<#:QM#'E/1J\M"J\;(-5>&QW2Z[PBF@]\>;&!:(Y= =O5]47$HG>=.J@1Q&
M8G8_@P\<1LVQRK49_+?Y&=G8U]NK^K/.TM91D6AXC8=4"SF(TR*J\TG:K>88
M>Y/6Q53P'G; >,,YMN?E"UO#5/]G_1-V0O@P=K_*:32^M]GU["N<6MF^$IAH
M6N2U=2UR;RSJQK?1W:=EW>H54IUWF+Y8,-PY!6Q>47L#1ZE64_*BLWKMZWSA
M!>W5,W_OK'+4%S@<-WNSW%VMD7L0X<#(6>8D]6EK(/?Z-B25DMK97%Q$8']_
MQ\8U(\/G#[56I[$Y<79F!DF,SY/3 R!B6__,L^WVP-M $Y4TYR,]UX+.>Z0A
M"N1-0N$LWG7+&*KVJ$C=&/CIR]L;81_%S8+8'EFPOQSUCK6RFS/H':QODS7S
M9FO^:+Z,!]6LF]C>5\+F:>K4G0(BQO!LJ>130*<@,_E5\W)+A<L3-\O#.V,/
M[ZSNW52D*VJ"O7R@\L _I<M?I8\PB/?AN4F-/I$EC^/"D]Y)DT3'7J8O>=C-
M>M]F$ARG>_LG"ZSB>2=DVDJT9'+]/YX@-N2CGFVXE2U.X3."V970JHTSJ'-%
MO19/>-__BW%6PL!1B*6,_U!09EUKXA3@ A[$ZSRN'Y918-4S10^QIN=52'3+
M7T3T.=@\T!36%^;G3&/[DAPK'/559#JCI6@I!)8)0CT\"HRUQCSF-?7,.AL5
M4 GWJHSQ(EP_7K ;>J0%C]-O(=-.%*DP7P*0'=I@:F.[%F41N_0ETWY7>UFH
M_"7KJ*I[(:':(G4OF@)I(6[R_!7DHCJ+1XN2N]=MIZ<U:@7JS&2FR^R&4UZ]
M5OY!=QZ0SG,.DXXC;,0023H=>$@4V;G;UK\2]V&@8II:M6EN=Z]#X4;A*U\_
M;J<?!W=,O.34K-"T"T.*TL!>X'49V9WUBNN>F,>C^ '?\[H-'('ZRCWZ?#C5
MQ5?FXT61)3R@5/-Z]WVCPBS\,>+7+<ONB>SG:QJ6^P;*Y ;WY^E[JTN^S50K
MRI4!8F_G,; [* 0SD8Y__SITT(N!FB-0D,QVCS <&;R AJ4MVM>$1I52?>=E
MH_R.P:#FD4UB+JT/&LBL(\& S?F8]OQB?TURKU#X;*L_!O'0P:2.P)KJO].T
M21"_]RG(MXRB4GSL7FKZB.LW[,)5TP?_9_ K59P)Q+"X_#%S]]'-WWW?_R*G
M3P'_YO;' P"1@,1'SM1P/>, @]Q?9&:6 B#AQ="$WIO=&)F= X6C2B0I9BL'
M7&;Z73/R+I7==KOL%%"+\SOYB8:T6JV];)WTV7$V?735*O\UUPI00.,N^[O0
MZR.[Z<-.N/1]BX915F1=BZB@Q^9GAM'6R%G.^-0QJP+<N] _5KA,YPC$^< 2
M&Z624C!URC!SML_Z=F.R3;\NT[R'$$N>[7J'MJ)D#Z<5:-'+H=PDD1<F]&]D
ME\:ZR4SSFBBDOBVDZO5@+V:U-^#'K@P6_FZ.#_@V_0GGERPO4=7'%3CU8W_5
M6I/U%."*?-HKR-]"<?HZ'S&DSO$\PVG?-L/:P%8IW%];9ZE"1<4T.[PI&K @
M5H?+[.V5C8?0C4G31%%4:">6,V7A"::5PII<F^(Z*RNC<E-7]3F;D4K_PM?5
M[%- 5-ZE7=35T.X 0:;FNL9AV, /19'$N2<17V$?YD B6N-O)/@65P3XU'&%
MJR\6Z%>N9GF#K#9F^C=#^^Y[!'(@8]-TRWXU%HGE9+0Z,HN7!(@6H;::FAA)
MXE6KAY ,HB<G0@5#WG^KR/3BT<246:PK,L6)F:5VZ@*#PLN!%)[H:15QP#]J
MUD)B_:S*!$9VWO-\WX+1KTLJ<Q:-(29JUX4"K]9HQ_?/OHH(%'XCWX?*M2*D
MIQ%E6?[F\M90I8FE-'OY=O<R R+SC+$?%&:F?H 8;V:^.7\EMJ1Q(1X('O5$
MA[UIXSJY,0V!ZW5!1(<0I@'<%0YAA!GUV>:!)5(*DX7)4WI$(:UQ0PYJ^PEQ
MSS-%.;W>^.^N_:PG=-?JGX,15VP*9,0_87PQ#3\\ Z5O:-"#3K;&X?6Z42PT
M(\I*^R\;=44UM^;">R.VTS-VZF:K5W3XH;Z<V@R31O,RX.N7KH>L^2<=&<"3
MNII]J4DZ5(=2*.0B>**.-R&Q@+]AHT+VXPCR@W870]]4FS^#%Z-BGO.U1)H-
M!3Q?$DTS)706@ZY -V&L'V4HKN2^J]J3,D"I"N%;NX#L-W(74<(X]6OEUV&2
M.>*$P7CU:Y3DJL6I,,*%3 &V-9W;4_+Z(PK:2CKIC/39B[X6EZZ*C=FNSJX&
MCVS;NI<WK[OKYXIS&JL^:CT%I/\Z^G"R/K$_/-G:E%89(KH C,<C\Q*KU 7F
MVRX:+$C[]$S*[&K*/S%BAEY-/3:KJT0V39_3CE@=K%(O6-#LE@R+!5[R^VR2
MXYT/Y04E*I"4S4<\<B!&X/>?KBC?[BRCY_)N!^K8G*A0S3+9>^Q\N[#WR)[1
MZNY%U#A0]8N0^?T666B@Y[E."0-63'0WT,7Q)9M\HL9K1V-R@R4H0C*PF*:!
M(:^[A2J-HEZ,C&]L>G9GF[UP:MX6^5#AH'K>Y0F#6^EPY^B>;^+)!C;$JGO4
MOJ9>G,/^FA6^ QR,]S<BA+';:8RVSF"PR>2P[FB:#G%3$!YL-HI[V$*NI&P&
MRJAW-]:E:,JIO=VJ&GKP&J4BC 13-2F7/&-SZ49I3\52_%P4&9))[O@PQ4S
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ML_/>HA*P;J[;'7++0_'Z#?)$EM^'/P^=,F$7_W$K  ,_^0GT<?D^.<Y7!Q/
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MDR;%;--!BH+R!E KSZZ7-N(QRDG$YH+;J+IF 0LN'9WQ IQ"HZSPPD^@W"D
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ML#34^RQ0"Y:\D2#Z>SW]<XSHTZ5G"_[3Y(LH8[)S;S3&F6ATGP=Q8>$75U7
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M&OT1R5[K^/X.UELU0&7Z\_658F]/5BUM6CDN(&!J)JX&!S9 XZJSO>$9&I"
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MS;(!?N?SJ+FE& YY]&77.C0TB+[,X>G/;:E1S6(03"OPF<+T.Z!-_ V[\[;
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M"E/@_%2]8\$%2KC>5[OUOGC5W>B%W)H2+<FW*\+?\[\EIT4L7_KA E7CYHF
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MKP7PXR4BXMNVI#R(@& J5!Z!1:G'ZH2UG@AHC< :I8Y8*>XY$@&""AF7YOW
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MBK_R0NONLY"7X4-(@[,8RSGMEL:Q$ XG"GN&/%OZ4671N7WM= 9EVU[*>-6
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MVI$VEY%PX!>6^+("Y56Z<1%X'+=A3;:^N[,_9JJQ#ORXF]WC:_D+&I*GXEV
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ML3FK9VRT/5VB@!-\%59RZX%A2ZB:-J0]$4#!2: 6/;?%4&&5"1.$I8R-<R(
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M<>MN+2?NJAN 1_5AW# L/-L^ 8 W0[#N;_YK!I.GF'V;SLDZ7O8U2H9+QH!
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MJA-V-#*39A 396W71>,@^YC+SL(15&;BJ>PX(H(.V84C[5:8N^KO'48O9V\
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M*OMKV^L)1D]!1<M@DI<%&G-@&5_AJ+U6-Y&T]A2/49Y+;/4!I&.)P1XFAEK
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MATY3M0)$".G#//_=<?5:4T6U-E+;<9.WA>._56.Z@)0DB7KO[N\JORP3?^E
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MR+Q>#HUY'_EB[@(XTU)Q0W8+&.F) !\DJX+_JW%Q"Y##-4_=4$VY13%M2H
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MW>G=,Y9E/[,-\:=G9UN5+'_X&V/( 5]YI?J=4-)ZY.$K=A=F7EQ\]@[S VQ
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MH@?ZWT#5AR=)(]=X )0+?H0P7Z^(A"$#(1 ," F_ICB$(5/?%JO>%*';^0Y
M9G[F_0E_+E,OS(YY%RPR$DXBHY 5ZTF=T">0^RC9X/\T8'2Y>Z]&!4.1$=97
M("Q+G83[;'GROS^G)K]E%F$=M&J^YRX@2N:;S!8=E.Q*5&\SWP^C\S&B_&;[
M0HPZCH)'RA/L3/FI"P\ BVDUV-MPBHA\7G\.9T&WS]FCPU%D'8LJ'8:B@;[
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MF!H_+*/-J:JWY\!V#EX47VVE9-!.U_=TYK"[*;:ME_G<EZ.+=K2[D&';FW+
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MD5TUJ"@[LC>+(GER:=!$,:.WF_R=28Q=7!&K_NLU)FVMU*'1UM1R>$WI<$^
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M;N,K8F1U.LH7XY.?:<7S/MKTX^?8UEXKK&Y#W">4_*\L*S*[IB;^IN2M70;
MEX36U#PS7NM3?8A\A=LU9#!"6$V@+'C<)LEYPM8NNRGB6V!/R"*MFIS-C"A
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M7OA?U3^MM[0&ZKG(8_1)L%;ZHI^KA#1)2>2P_S. -;H/!H/N!WULU K&O^N
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M%ZR F6G0O)F),'EW.J##&/.9#OL31,H@KZ-N3EV]^2QS2PLT6=D][WXXPN>
MH?=>^&JQP;)YB^U]WUT)HH"RK/"#GF*'[U'8*+M/@-<%Q7HF&&H$V(O62N/F
MR8#(\B^^=KV-:?. Z#3_=H-1IWH3B/KP.+P@5XZC'4XA4L(J0&BZ=1G:W #]
M3X!>,RB] N%;(4OOA3@MZLPM O!D)3S?8V2K.)-Y<*9N]%R]"9;ZX#C !/G.
M,4D(2]-. 1;= UM4#BHTL@&([A\YV=$1\QPXLRT#6.3"B2WG+?X6-L 7"H=?
MIBU27PS7EHJVB-142O,A:]LA.@4 0^7AR-HJ73I%D?,W?N::(.*W<>;YJ*.>
M"9%ZWQ2NW4,<"^&H,K0#JOJ *G5:/2L:3*KXZRHI>R./&2DR-QOA)]\Y,7K@
MVQCJO;8O71#B@E#<WDAYCI# %R%9YM\SQ"\=+$M@)4QFH,NIH H0_JA6Q!.L
MC'UPXYQDB. <T7G'$Z:'%2>?S-P9=:@_#E%#.;>S[B'^Q3%*TY%C%#.05O]5
M1(\C8@8[.[V91W(C=81/8+IUAU[!E/TC?W4TQ[P@DC>]1'J(=^;)U$@EYLCV
M0.6X-+ I>LR=B7/1#^+\&D)0.R,4.<BT@\D;LS\+P^9@PP",Y8A4 Y$KI'D1
MV^_^G.OE!2AB'8TQ&5!V:BU5$U@?CW0"#?AY#6;1S/X]W1T-,1EP]HG/7V)'
MWD YXL $?,LS>+M+14ZL&HB:8Q'K+<3QT7'_PA^^]KA);F7O"'XC>*:)FW8:
M. TF6=#Z@=.*9*C3_:-4JJ8,>4>NPWD<=;BO?Z34(R<H.&<66IUQ"C/Z%M@4
MRS#%C!+G,27A[?38C@(U?:0ED$&8;S.2G6_#@0)WHL^B*A,4)@TBJ&\<:Z',
M+F2(0PS#"UN]H2K'.2B!E2@XBP4<FXOC\GT$%!LOMEK?86940X&L.[Z^#C75
M.\]N,]O?FBRKUESXICS50P\G_[!_5_8=TJ'35]3"N/@["N16\PX9& ?W8];$
M4Y$;Z%N[-*6CK?HT*!M"O9:P[-.BQS'F37++*MNB$6'7]KE'^)9"+.MB%?D
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M<Y+'!#JWUVP8%[[YOYA[SZ"FWBB,,XB*@H B2"<H*$H5$.E$1+J 2J^1)DU
M>@L$08JT" @H544%I 2DA)K0BS01I(02$IKTA!("*6S^N[,SNSO[8>OL?KA?
M[N2^\^;><Y[S_.9M>-'4V#O"#R_T'PC#.I%)U'<3,EM3B\+GF:8O+M&:U?U:
M(U_>MS2N\QZ]8VC1TC S*] <+Z%4GI!U+,(S(S:C+=)+-SRG@-=T!4;>#3WI
M,_@-=QRG"3V\CGCK/)'TAC\J;.<R]JMC-H!UCF$N$RP/"24QE4;]4D1+%W^F
M:,.>3GQ_7UY5E*<Z:/FT458[ZZT),4UY26 JB%"+*TFDR=,F3"DJ$VKV 5C@
M^:YR0=%O=32SY]?IYK:?;:1]*831/\5OA&D[#@_"(MH+Q![^49,MM=_0$&\L
M^-:FB/"2K&GG?-WT1+QJ58275]4HY+F@#5N\4$7&,\N5I_,A[XO 6J-#Y@(/
MNYW<>Q#</AX&DR%H67M5NQ-VW%':+NT6M$-E1TW_Q]U( ^)(MUW_#^ZA= 4>
M9[?V19_;MFG*_U3H.E@+:H?R18T57IDXL(7RZ&-1YSQ";BX(IHH;!=VX1%NW
MUH*4-DG.G;G+9A3A4'D*N-UB<G(4>PHP7K</H5S54  R*APQ,Q9=&6%QSCA7
M6<6T 57!IGH\KU9Z^U1?P?S;]UFA-Z6Z=X?NCE7-&B?YVH*C%MSZ3P'L"J>
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MA2H_QY&WT7VEFL+6WVH:&QI2OT9GL&@I-+*DQU*QZ?U58W2#D02M4^QA&;T
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MRY=LNP )S"!W.8C%++!S6FL22ZND+%U"WL5PI0U1JK[E*"W&]S.>;V1/!3>
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MU?S4P6\#*!.J 4*S8X$)CO@XV)L#$UXKCTUBI*JUMZ8PRV5RC!Y:^P7SW;L
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M_UYQJ]<]"'KAQ%2E)QP0(P_3I>8=\(/9*!?P4O5?Q$711FU+V =#F<)9 Z>
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M0V'8M#(\&5L_U9UJJC,6Q-58](Q0N2X5N"C/F3PT8LGHN3-**!/CY?I-<NN
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M!T"=V/3=3%FO$A"X?)G9]-A7ML[=TOX.F#1#/DI= &9W<178MKZ8#1?9I]A
M\46'L]JH7LZ5T/YNL@8:\P KS0YGY!3S$N.XM_+;45#K^)[HJ=-=U<H37,EQ
M!YW'K:>R8@9C?XIW<S@F E_9.)]FBXX:U?(]7#I;?)B@TF+,\'B4J?&\,*V7
MFUE)#$4?>76H&V? E&DQY:,Q/O>8ZBB>JFJ/8C<Q];%\/SR;2(\Y1(%"@WGP
M0S_!K%+P'TN5QPMHMLKIZ>&;YF;B<E?RW12LWJM44/;W!,VBEF]L6S(T! 11
MJTZ>&/,JYH@HS"AZ6X_RW@6< K.Y[F/BPU=WH2M(+PN@::B$R?TI%^M&0[[2
M*YUDA5=5=#%TR1A]PEK]Q_Q 6<R=C)/Z:V"]5>T@2XP9^B!2T*?E4?(G"KEK
MG^2W.$>[P'^5(3'+.)K)"\"):EL ,I(H] VO.UU9J\S5I=9@G1JI5Z=Q,U?_
MYA7=>LQ2HFWEDI/,F>%GMK;5,O,=AOEO"[IE@)='5YI"J #7L._1CT?9SO/:
M>:#JC[%\D:WBV-L_7^UPT4]_;L"=]UH*:?8>)COFV<I1'@N112J_AV<'^GTC
M*F,@L:T"WACN[H8)?#WA=31/(3H-HHQ(\LP>]NMUHZJY^;I>C=SIT,),;?)T
ME_G'U)Y+';N\>/O2 6.J3-^+\JNTMGA?U&%X*X_B2![427W\G7M$LN[W:'*>
ML<^O'L>'1O,7/?J?6*:^DOR,\[^5J.BYG^+E1O6=Y]I-_VA\PG-\N-@>$@6+
ML[R29!2_]2)MWY)K,7N$<X9'7YX$& <BO8,0E@98=IP3)K*'GMN>)#JC<[3#
M9O]1*<:!X4VS\;J$X' AI55R/(M[#\#L/"OXDI/]K, KHO9O&;=6/N["E:\\
MH1A-WGSCN>AQFP00ZB/>PU*L%N_SP/$9>I308CT,<X14^?)W?AEJ;[^[6UOW
M^BC(E!A[W>>E3RV@X*A_A3:N.P7S3TG/TVIWJS W3W$,^#*%E5!#B]YZ=)>J
M]6KR =X/=-P).>*FVFZP9#FO5Q(H= R6:\'.5-*EN>/*6[[>-&N*\+C[FF;>
MK?&M)-%[+OC7L>JWX$D@AU?V\RAOI_E^B(AU6F1 T$2U4(Y[O;$>9S7:8C0"
M9LM-AI?L:>? <D6>%Q8[^@NDA!7^1,RSJ0KNRWN]>_OLT5^M-26CAAZ]6>1/
M(+.TMHZ9OMF^F$6=1:+CG'+?[,'3V!6F3@I6.5Z;=^_9<@3Q U^AZJO,$:W,
M'@V^I@=MC9V<!8Z[5*7<4DUO7G-_";VR*H/N#?3$,6:(R'8M*6-.9QF@H7W=
MR0.^$+Y;'P38!.37X[#]P'-O="XUS(Z;,E!@ILJ[Y>&4=[:_U]&\T<R!:L_/
MTIT[X2\EQSY)QDM&%V)OX\PPOI<>!WZD.6N(E$8S.\]%O/<1*<@,47$NO^H&
MZ ?DG-"@F=<>OA?KZ<+L7&]I0B8-[==HTCC.8,2 0O5[$;U+,FM_8D;- RLQ
M0-(+X*KLN7?[!6#\$7(*3$FZ#@6M+( J\[K<W4O -UWKE)^"%7:</4/Q )KC
M$'*]AS^(0@0YO--/;DIO>&2J[UQ%LVC%1.WQJ)3:1F"/H4L%#Y7<D]C2P\=,
MP'?&2=PA*M=?LS^9Y(%TK^=.9?PM1P7%D>"82%SRC^^BDW7GDP5. W?]PCNX
M"E]'$[@[2#=K,/0?O'+IT$>CTJF9KO5C QZ#$Q+PISV/KYT#J@)0OIW9S"B1
MT:BM"5'X =BB319Y_^RY6]*M/LHZ9NICKB:5DRO'D7N[&&2?BA1>/6\);[=F
MVQM7?%]*73-,+1I<+>?9+-'[4G-@,8G\&=E2,RRT_?:X$A\VIN]LIABK&>A=
M:8;6(V]Q]3+Z\+SDK>+<X^%X0VN!.@]=/>_[S?N>.&F,3&'%DJ."X:5F5+H/
MH=N-@=#O7%VBI(<E)GZ7WWZD#( _QIM@(#^7*;SD3T;IC&NU/>8/JERYAW,V
M(MPL$LPOW0.PP0[T\VPMTY!&[5Y-;F#5.V#1?^9DXGP5?S@<403HB1N'%G P
MA,HMLW,P#%#PC5W2'[$8+F'L]%9<J_2:I+5W)=3H2%%3FE;9G?/7&K\2#4T8
MP_IU5"0@.E+_/(;(H%+JZU?@V/X 4P%RM73BI->_.5^M'&RD=C> ['T6#=7)
M: 0W)5$6$]:U7P!U[9]_PIOC?*RUJ5F<S+)PX)_ELT+7\9+"2O6. <O_6^.V
M_R^6#95&D>0P\U!?$W>VM[\\;#[@R)I)W$.,!](IJWKTG:LZHMJ:[4:$\8'X
M5RUL?UWO#\Q /FQ$8GDJ8(;'Q#WWMR4!4!/7>CG$%>)3=NO).A/WA%3V-"58
M<]\9R1O-Z<=XW%M9:+[=,#%G\7 @'_B>,TJYL_)2] 4^16#."FY= (I,Q*[R
MR=E< +P1>6MH,'V2^VL,>,_D6_!!UB+H<^J9[_+4\7<\4N^/=S/7I*K?GR@5
M'M,%>]P?!8LN=3^.G9%KY:$@BKLXGFVG*@P. 5E5EA;=_T6OR</WV74%N8TW
M7Z.([5:29BWF33::A8M)3W/5"DV6BFK4Z$;SP^VW_Y];?_[_]C]M LDZG,T'
MB3/2I];16P>DN_8^'C?F]K,'.AB>'HZNR)WE\)/E?_N>UCLGR1%408__=PAS
MZL=4I3>CB(L[QXKW[]D>@,G_CJUFYNXEQEJL:G&:W-$6^-2@Y&\R4;T.NA6E
M)!F$:DD0/1!;3/Z0[J=^Q@UVK3NLX^QI!;G52O8F/^^B2>*_2R)O!RJB6F4@
MA-_M6FV$,S@2UK_2;74/;)%^'.X,!7>G<;%.I:X*M^H<#=%!O2\ #+^1AECZ
M3G^?F.+*\Z16FHFH8<4?6:$>DOWH7>T51,2^^\:R8[^1*)NBP73;_%@ :..U
MA_ H=7H?[3-\8LVFV8-%Q,3<OG5//%NM$+^Z]]1)G J)4W^0O<5GF::\2<>X
MZ)NP(^,=P9(.0Q: 0?D9%<>@@,[BZ:E*GN5<#@/!,GA</WBT_4I]IDZ$/%&[
M0@-WYC\LD7@=,"!)OSK?])AS*!9S _X)+I4[9[2+<@JTR.U3J%70^RQV/6/G
MJ$>@@>]C>/-[IF&.M:I'3U?K82M%?SR /6*4<ZGGP_[BB:#Q#+\KP"2Q#4,4
M?H.@94*4^XZ-""^"61.5)EWR&]Y;?:]/5(J:NNM#1]/CUMIX)3@4\:0#%11/
MEZ*EQ3'IWW2ZS]B^M?DW7FQ^K5R_4N"HTSYOLC5GCF<'_'M^S:<%FXD:&8)^
MFWN./$GO:47J0#8>+#A+)%T)D74;[* )_/JGX\\.9G16$?=);XZ]T]?3<E[5
M>E7GP83(TZ5;@0TTE)HON9[6S[ H4^7\AGO"/_7U=-V6:_1P:H#@*>8W)@T?
M?5XO\T1C76!@E5BA-1B>'YF@I+T2Q-<!1XTR."YQ!Z0?7MLO7!IRMJ7ZOD];
M';%GLZ8LX;07C7<B445> .Y"(G-/L4$7@*^=%NG"KZM/IE)F$,ERGF@M5A<3
MU5GT!:"0)P[OAQ'#)>#35RR$>OSU>H9*]J3Y:3!/O%==5-_U:G0!PI_TDW#*
MNQ0_+P"UOCW+L_FK.WC?U8?E097&SX0=2DQV0.1[7XQI=&@*4G]--GJ&]5OE
MY(1A@+@3#/?E5\*6.#!MI)A5H3:0=NVC_ID9C!\=(3V"99B=(]Z'Q(BRE)J1
MO@#,@W ?XBV8U0+$?3=,U=DV>@K+;J>_"[2.K>'NH,'FP@MUZ[3JK.(*&57!
M9@_0>&X&TT*JU_:C5TQU6^K3($6(CV<IJ[ H%2:,UIQL5*MV@3VU#\M\MCY)
MR$IFP76V+6+/U7RM"+5K6$42A(KIM=;4-&.#PUQ\_=AT7*[-95'R;J_Q]Q?^
MZ'Q_C:&3O/W1!2 TQ[3'V@GS8^[Z[#6!4G6V]2Q^IA":7"OSP[UC NU2H"GF
M A"I!%M-N,,B?+ 9OT80GF-=;ZR/PX4[O A[M_&"1LA*XPPTHC_DMFP0(=H&
M8A0Z:6_P(2:45V:^);4I,7%%)\?EX,8+EC>#/RY9/BF>U_3T5O*9P<:-2OUB
MN..?!+W:%,>WNO7>>U]3:E^R-X=KRIO<)<;)H:Q3N+ F]AJ(3WX_&B^$*\..
M1L'LQ>8DD"B5<!\7*3/%WR>-^P-"MQ=H_"8'F4OTOESY_?#Q@/0D\<WE._F@
M@ZGQX!*G)18L5V%0%9H)[N=)>]1[KTFC=^OH9XG];_ZW5^P& .XS4;90?[?B
MT[+6'SFEIKAV),=QH([F]%DV%]1@O'[?IZ'ZCVM=E4,[^\365%W04Z369&6'
MI*7E\/<N%EZ R>\0^;L>_HE@>CPS;G@ZT).@/V?B%'QW4DD6<]9KMIW_RBO1
M]!>3/)/ @^PH.N-PGD]-/&1*,\5[:6L4YR6D&W@X"A)W*H3.Z7&9]K[!^\K[
M06G0H&SS=^$$)HF.I J*5QE_8U80G<KTJ[+[#\2Z]K5V7X:I:9?CK^%^J#6P
MOS&AXAR.;5(D#P:;OVW!F'A3 4V*H_%?6RP'*I'IF];'+]3NH02MI&+G)G"M
MR7APXMETP:Z_3UMA9RDZ#=<<GZEP&'TT89O*RDP8W-'@">M7+L^IQW>N*(Z\
M=$@ER6#VSA)=0G\IFY)_:2CJ^#N* C.0YG,$,E<:0HGL&-!/Y)^Q;:S#YL&1
M7R&7]_!#D/&:C^I+D$>_!AG%QEJ\'_!.\!",2@KVP=<T);)7AX[0QY3Z;G\O
MS;@FP&'1P/,)FQ!D04.PLG%];8.U2E!>A]4@SK2.S0"2.GCF&Y3PM-W;4MI6
M+4YJX99':V5EO<7HI&,?EB]6BIM\_D$OHA+=S-GZX4.:?DO\(DM\H^AC9?4M
M\$-2)XP+[IT;;BDR&:CI]^"0>/]13+]=^I#63#COVP_)O[I8.Y7)^+>%.H(O
M_04Z;U*1=<K(C3DM+]=1F1.K,P_Z'#JN!G8V&G.]_O)*C@;0*XE2OB+OL\=T
M1?7MC7#EQ8;V&9G2[-*);YBQS6RS6<N9^C_!ZFB[B$!/%()-G0</ZV:S;$X\
MQTV*63=2SV?'NEO>)KP-GKI%9, ,RZ@PM4^(!IIYNMW+6'*8,-FS%D^[]>7*
M*%"4FK;U1!Y^$W$>1>(A\N 'BG:!E-YD[D5F@GJ,I%(_CA=QC9$-G_G)507)
M-5[<Q/>J2I*H9#')6N-VD\'W>/_DSC<O3OF C$8$I<N$??!<QK_9@7?7<_Q6
M0+JWR4+/-OC+LK"I];O!$^H/)1_UG:O59HO9R;58GIFU@D^;3GSW,K$QNMCE
MGQ#J><?V1Y.G">QZC-T-/A[@[C_=']?E[<-< :)+CP#F/CU^N7L]J&56-()5
MU%4:$3?'''^RYN1&'EF,_^&B9OMVJ(X8R7+%__:\5' 7N 8649M+!358K9"=
MJX%&',V@>.O]OLF$L'*)WE%'')205! I4-#>)0/A>W()V&\(R^>T0GXO"TFS
M>P^^F2Z*'(HPV\3;KPK!O@L_]TZ>F @PE8&T!*6?W4,M1W/18B,*YH+#5A>I
MS1"O):2KLDN?N?._?"S\BB7KJKK<@1#8$LN4@K(0M= SG=H["9*Y]4U[B/ A
M],["TRJ+?C+>$(G+^9JYI)A 8@7A4 TS/ 8N7RV6*DD^J. ^[Y0L@-X]ED$*
M8(<"J!S6^4*%AQI(A0=W^M38GK)F&C137P"4\MFM*6;3OUSBN +*3ROU_@<!
M+4P)/'B1M#9A,AG!SJ!?JY_-Y^2[W7Z\IT>#;WF*+0Q;A@:83M;-\W[ZB52P
MG?)EJ BY^O+'+3+ H#ORFO^,:QO6H-.2>4JELP*/>#(A=@'8FKD &(12^O5A
M:L@6@KV/F:-/+W]YEAEW;WS?JV-&A7_ZA<^A6ZL2,TAPHG_YD->^G_YM68#G
M\06@ S%[ 4"E=</)=%:!4=Q,SE*T/B23UACFZ<K[.<+B8 GO])CJ=S0^Q()8
MCF-5CJK8-87CS-=3388I\\<GC,Y+K7QZ]+H9WAQ^A;XVK74[P;FS8+,=HVH+
M4SW&Z=KR=OD\M^T=_YM=H8+^Q)5_$;O#31L,M"1*N7C00KI,/_R1^3[J DQW
MG'S.F02]P?OV\0=WI,<9:/O<KRF"<L4I0.8@HSE8O3)U;>W+&*[4I/A=BY2J
MMS=M7&L:LZ0Z!,*6YF?[IBQ:(4D/ .+*96_GU(2*&/0M,3M]\XEB-JD7R]5I
M.<XXUIO;7=&+"5:$0G0FO<3N_-[VM\A4^N/C6WY?W8/H;)?H>51"VVE9K(1-
M2"!)_FOC0!',%BB=X0)<37+B4FKX2/F]H2EBE?JC+&"[E"TU)M3-8E37'^E*
M<26BNU?IE%O2YT>,SZD2L4NB!\4G9J?IH6IYE 0Z44?O>?".%R0V#["'# YZ
MW%"^H9(RL@V^$\BZ&C.4J<S>,\<$]W6YK:?<%E](,Z'*]HEUUO"CX;40S14;
MT @0HY/+XNA_^',$IM[>E+0SKS[%Z$Q$"K^-?SX0%W1'(HFB/ ./7+'K<E%?
M_=/KT,IM6S[R;6XGUU[GZ>8M#Y=7K;U/F]A_]&=Q28;Z@U2%<^B*[F>;IN*,
M9A:Y$(FC9DH9Q1&E:BGGE2<(0UL$W. T0 -?N@*_Z=BE/4&T^KICFB['Y..?
M=6LD<<K9B.^D(B'N L LM1R6<V7:NR5S1%Y:8]\V67?RL&J&J2WE3F 4Y0(Q
MI=_2;S^#>'!>A7CG1#];KH]INP!$G&8_W1G5/Y:17H//W<W@C'2S,611[.2P
ML<;"\]NEH:*3:WU[ 2@$)S[^Z*_W"'W7?NES%YLG',>U&IR%-!\^O7B#TCI5
MFO1S9:,+MY_R*)9UJ4,0F?.$I'M&WO)K9<29.A(6S4A7D<,Q.(7S4CLL*7_-
M;#F*)#%12V@Z$.&9%!837:V->_W1EY>AAN;HY>T!H*CF:A%^_!*7EH(G7EF@
M$>RU8C3VRX[?^7XB+84S)E9*C/\4S[YV&?["2[^Z(#G3RHZ[=YY)E,;VG)Z#
M+-JG*T6EV,O5ZRT4[!,YZG&*7;W=QRS;Z@;ZP5/+1T%,R[B;XQ> DQM"2*@I
MM7BI;EC-*U\C(U.U&26Y52R]4*'!S:JLZ5S)EAD0XB_7P 7@.C?V O"12'LI
MK(Y)# B&'1(W 81+F /^."RL/ZX_3W,]CY6U]K16EN4VQ8V&7@ 8O2S85_1"
M($2[-6IJSJ<$K6BC)F2=5+Q9!$^JB-#5ON6,OY,DJL0+@-00:15&<#!9O@Y\
MTR(6?0&@/$'<@1;W*%365Y;.":&Q9L[0RC=D-R/I*-UKR>I, ->H5E^[30Z6
M:#.(&OJ6@2!&_O0,,1'N4?%L' =#:GNIB2I_)[VUE1U[V1=5#J@) A';52(%
M)CSNDX*#&CQH?<O_6YJ&D(59<[,Z+9/#'-B7(TQ3NK2++1?-T0TRJ)CG:2\C
MA"3H9L7W1]W6E,GYSLN5?%>!<[=Q\?5X@[RENJH$A\ ,&[<:QFCM>)K)07+?
M:XHANR'I9+S(VP.VIW#KT0.SS$Q"L?_H-TSP\BR!N-"*6#K=OP#0!*$+B.88
MT;;2A]E%T,FNN?BO(]4N+M+&#S[7NX=$KV\I5UNX!%)BPTB4\X5X,51P'AQJ
MW>V?@FLI,&W;&)8=8HG8X&'/':+*RW^3%W4]E_=*G^D!S.H",*=P >B^ % K
M&13CBW8LGAYWXI:=XG>,AFM,]CSKOIS:B"<VXFQ/'GZO3--/H8CJG-K2G"VJ
M./V]G9=A%/_ RGWJ[X,'7I/-/HO<^OC,OF VC/YSTCTL7<K7"L3.O$%;]&_@
M9  -<A#<\*='1UL+PQ?JK4>&;]_YM72$\W9:IM]Q_J@0-15B^; +$+2[!0P#
MTTG#YZW7C)I*\/EFC?7U\9)^ >XL2]OA]3V0&TK\K'+]'3>@#[,O]>/("$%1
M\UMG@9/O7/&'4P?>)'ZQ+\P-C;'\+O./];4:NZYSWN )T6L(&W+[;6ZK8%#J
M'V-4630/QBK1^+A$][X1G"G6FLJ)!B&]*Q%D!]PAN4RU+MPK])<QZ+ZFR"ZB
M_:K:CMGR[O0M^:KH_F<R:+"H&H@ORP94BV[.SJDKGE]&_W$#_U[H?1"Z,Z>:
M)/ R-L)(_]E5Q6B\]BI?%P2O\Z^,,(ER>B5*)0_5XAY<^>OP;C]:(L&9T?,"
M8'X! +XX?T\2?%(6/"J;FI']:Q(E4!1OY*HUER+)PVV5?B?@@1]+*XVM5I%@
MYK1.48M3\78 E..G>Z4>I:$]NI1O636 Q#>6!KRCQ&ZW*HXB)#!MOW0:$7PL
MU23-;[3=__MWSBN7^7C4^]BL:/3NL2].?KQ*12%X^I^G1;1$<&>!-8[#51),
M#NFIURX (:'=,.0]<(%AUY>5M?=E):46L[+KR\_&!K&3PP):+7'Y/FD9%AI5
M57G5#4FKF_;[^VOZA\(5C*_4]357J-8FUWR[2L6NET$)/_>]=,>O[LKT'*,;
M@CTM'0@6E^$(Z8/0HIM=PU<S.>FU:^QR#GZ=VF@<@.-BCT2##:\T"DUMY8A?
M8D4O9'9YY;!++Z)&IYBHKV/=EXJ])\/TY]'"$_>'*YR,//KC;KK43>A1T]V.
ME4>_O_3EY&^ZSKQR72IFLDI_BTE.JREHN@_WTQ0ZXSG!R=^RG]!8M(GKL+65
MO\;U@5MK\T0L6H4&J[HQDA.WND\-:JG_6)RSU*<?X7 _3H-FKZR[+/0Q+T9"
M:#,7_W T5EK9%_4.D;]L/N#MDK]#51_LE"JN?M^FMSV:59-L>B30"2.)JL_'
M!JQ)+='_F-X<=_'6JWV8YTDI+U.R9'W//&[61I?^DEX+?4O5HS!@T*W4#A!R
M<DT ]V]5YN@8=+W.UR+-G('+?BPC2\_:"@)?8T!1TE:%Z.!'8]XB+[*H%95U
M*=_U[\@(W3X#&8!3ENN0>R-6!&E'2V8$9JFFQ,)DQ_)=;ZLWX?GM9]\/:*+S
M*: \L;'!TJ>^W? $_ZT(V-L@YMY7YE*6?#-2N]H:AW>(0THQD5]@=74V5MON
M:..90=206A%3X'C)?EE]46/@JJ,WVEK@:#"II:8->6J]= J)#J8>DX;LM1GT
MG-%EEJ[35UOLN/7(Z#VI_B*+!E.19G(9E:Q1EZCQ;5)[/-"JRJ%9*4P7:/U]
M:C-Z,6Q_P4?HNF+-*,<,WQZ<P#H;&(2YS*^Q2J"J'1F?FD7-ZQ4^#Y30V7Y^
M%NM&_0ONL38IKJI^ZMV(2/_BGY Y\LF?ICF%#ZNDAN;E]L5X?UG.IG.I4,IU
M.%O+7;LIUQ/0%$Q!'=FCF^7H.2CNJ^/OLAV(L_VR)BZGY6VGG70KJ4;/LN4L
M]WO*.G==;U,I%(+SQN84%C@RFQKE0ZX]9!\2R&#-?[AZ5ZOYD_JU>/JG3LC=
M2]1S$?LK(\8)0[9RGQDP!OI0\D47Y!Z+#1,J MP[9YS^VOZ5_ 5;R5Z2QM+'
MM7/AB[:Z37'%\(5G9<+N.F66FA[;[5K9918?R9160&-&0)96LE)'+-HH6!:S
M.%,JW/[<YY'CS*'B0);S#6YW9VSL.X1P,#=I#'D)YL'DT(3..<JD>1/D*>WQ
M<FEG0QV#X*=(PH&'Y&^RA5"5@?-PV+ML8$?PG6K\^[*Z]KQ5D;>_M=^-RR4*
M5V9YZ=/1Q-(/!P0M']JA)<W;LP4,>PP#2UM419N#;_Q]D2E9;BKE]IE94NLX
M&0U?O0!4;8C%<7%BL[?V'S N96);GF)ZXW#E5P-%O%<'*D6IPA/\@U+4%@9"
M'Y-$NI0=N?^3RTW=0$?(7Y48".&&_07@[!KC#ACS&OB7+%#I @"/.3PGIT+G
MJ0JK46>,R+7'_(7=3KMMT2H*3$+W:I>3(%WKODO\V%0$Y )P"4"1W:^<,CX'
MWU5XD%5LI-UT?0:7<W=D<\M'@_=VCH=C,?%V2V_[/6Q#U_*=!7R,Y=0I(<I;
M-5Z@3GM U()YP*!.N_JN7195\>KA7[4I;AR@^@(P$56><0$(#<0G<9,3K^-3
M5JFCANO/#(<;CM2*KZ<*O5PG.S%=3WD@3'Y_'#EG$K2]%^Z@+M'EJ:UGZ_M'
M<B_A-G2YJYTZ0C[P&1SM?T??+:%T2=VU\D2TZU);&T #>DSY8BKB-L,KC)V,
M0O9EV8(F]+B"9._=1XBT,VTWJ^^K8F6[5>[A:["WD%U&U>&?ZZ:)3!/#%IG.
M,B3WN9+W>JK.@?G<,@[><6JC.$W\:9$CD%X)XK1Z2-?<YR[T>TE=+NG6W@\S
M<S]U![<K=U>"-NZ2::Z_;/E:!G1,V8?X3FR(WL].O?\ZK=H5N6F^5 _4(_X[
M\DH#9=]#8)*@"9J8R\G9$)1+T#\3@BBZRCHO=?G(BKI/NIV6-< 8E9B+ETQF
M%Z&()_4MK7$/ZT-==*\E>;E_MM&??=,1>F,E#,P*ZWPIRM,<AO(::TP28-;W
M\MX>5,V[%LPX0AH%?E_<ZH'3XSW[2/S8)Z&_#NP/@#]&\G*T8^R7[8T^]\NX
MON[X67\GH=#SOR^!B3$8]F6<BY6Y+B=.F\GTG/M#A:499=D5E^:D,A%+P;'(
M?YW..L$QR[>5+ J7B4K8+>+]#'.F^]0QX/V8(: $1'P^^/>KS\2*?+X<(?3U
ME]&,CPW) '2AJ:U**O>-'7,F*,$CYF<<1FPLS<&#^0Y^BMS)N1QP%9E  -:V
M.++U&5;;O+6MJ5K[)/D%EO8D,6I.\^95L-7BE\SZ1^K2ATS@'VG[TK3KMW2P
M,<,?>8V\+P ?<@WD7_JQB/N#<F"=VA> ]19[,$ZD\P)0"#(\LP!;Q/6]S@_O
MFOY@[5<,\_:JQLH'F^DQQ':/9VTXNI@M!4%(3U3O@+JYOX;_+S[<^G\98R8P
MJG8^(.7]P=JQ9B]S5I &&C_SP4.XC)5%(2=<5U51W(+N6[0 S7]E.T[!NND3
MG[+U3R8@=XN.-\$/*V:XJG@B;)(T&!*GDTS,7)_&/^Y<#]OF)[M*6'T3H::Q
MUV\K=V\>&&?S;&T?Y%50A2_8]B#CFRC;>:4>%*2T P YOX]U-V[0_GCC50J'
M]U=JT]1JE3S>^ 8))GVRWJU-2[F[9X8L^;(TO6KO<*.FA<5/>.>Z-SRL&5 (
M%:&GQL,ZV_8 B"@CZC5WL70^JLV: #2*,.RGR*%3R3^J\.E.WW,4,E%JZ9_"
M/0Q1"36BRWO?SW-W8IJ6?'<_0[E@>2G6#K-V9GCVOZ6Q:<3J##M<[%><S=&"
M1F:$6Y<<L%)'E5%00&9BX6HT?QG9"APOT/?>=6GM)Y=XQ,.D >MD[:9$4-2\
M;SJ3'L$DC?3W3Q7AZ7E)._L(@><\9\W\1YAA V9V?'W,\K&HI7?]HP_&9S_$
M 0=D]A1)"J I2WY,5>*:"_FQ*M(+[ZTCN"^CX^36!.)4'PL+O;'.D B601!O
M1Z*>.>8Z,JO<UY!U)5 MJZ^O33X4P5\ WK]KSZ2/^SG=99 7T^RU.&D!LEZO
MEJ.QY;!XH4N=4A8]HI+0M(' O #2+%\ [*'+W315&5;1U'?>TLW:#BE:5PNV
M>*(WZ4W/X!W<M0U=L&@N_N2N=A8L-RZGA@,B9!84L2DL>)/E($G:DI)SMQ;C
M&R:E%TGBK!UK52Y^5N@@4UXO9/^D8V" -TG[EA]ODIZGI28F$J>$L>N$<&FO
M+MXV0+K6L=Y+)6/*<Z?NJG]*S<$KZ-G'@;RD41%]AI66E9,^&]JG"ACH"R,+
MM0BVN$+&8!_BX@E1SQL>@5@I@1V1X_TN &#FY3,:QC\B?GI]N;.(+G"M<E4<
M1=1AG1/O1 XH!.VIRFI]]^5\0^]?0AA+G__FD/C-GZLHTZ+!"T"RPK&S](MW
M5(54X-L-F^D_24,P<N*55?K9?P6UXDM7(+0[IN$]J7^K#J5B_&P3&[X/*=[C
MQ2X@VZ&PG\UB'_8SEI^/[TDY^=RM-0TJ>_PA/OT&H.(R+ZJ039)8\#P:F/HT
MZ9'>W*)GZUT/UH2TAAJSJ@U?ZBF'5"4U88T_&I7+#B^8N01MJ='3<BBSJ/8(
M\"83$L)@*Z7<QR\0!WP7@/J44XJ]A@O PT,,@=1Y\P(@6(D]Q-EA^O89S\,O
M)?0#$MSV/&'K/)<@:I^_N/DWH.$P[CA!P#W66SG -^<*QB*M"T%N3V*=M&W,
MZ=*N-S.V:;9U,'GM9EP6HC=&=2*TBGX]5(+*QZK6DUPN .F;*(QAZ68*U@//
MFP3F1?03E_'Y[F)[YP0/[547QSF[B7EC$A*D.I T%WAH@TYJR;*>%@>;$+W.
M*U4X''(II)M.((P.S0?%9<8Z3E;6UG))$(GG_&S/=UDLYN,Q39UD&:? Z.7K
M@?>PY6H)NMAW20UH2A&(6ZQUSE7WI'AYUH[^;3<)6FA1XB6YV,"_*G),7!P%
M1DEK&':Q"PUM=XN,+CZ42[S4'%='?(-\R:+C!%:;/G]-FK2S_G468166X@A5
M 5'%M4&@#8C2+1CF!2+RSTQJL# V95B,-N5W@F[-._UK+9H.QOXA/C1G!YQQ
M_ZY) 1G0P>3G]7!XJRH,DC?[K,QQ;,B]1.->/)^51,C>;^IC#L]XIY-=U7&I
M"P M6J;9,L6./+?8M/=^Z,SL576V^) K$ZW<J[ ],<S\:FX,7$G3?ZXWL61I
M8'.15G!3*MZ!'B2(;:<\;&!5.BTKS)@H!S,(JTXY"CE4-M\V>UBI3A\1P5JJ
M]1E>E39S <A="6RY %R_$P&\A>_JS)&?$.69:I4NW;X 6-4C&OY^\[N?8^0L
MV_C9&DG!6K7OE? ;J\+>M3I0VV+%\[SBC$-A<6U'2(!,_(9.!Q\%C_M/;!9R
M6IQ(AG$*?%"+=P\J;J]$91H3&_/;/[4.^DI2W*)A?&.\4O6(3L'=\A%P)3.7
MJC</E]" _]+5 K0A.*M8*DNN'_01J:4+A8=H!1_E*21'\OBX3Z9[(=*SG<L9
M.9YC;Q93$IY7%<*%*ROADV?;9G@R5&Y8NP(^8*T&$ZG6.EXPM<<[ ;$\/= ;
MQJKT#%?M)K;P6<GUC[X"2Y)^7@!NUR:$PIB4M/.A$QN!2F*5I-Y)2^+'Z\,2
ML/)/)[KP@15&KKHSZ178U6TP+5'6X2L4HA.I/5'Y_F@E4BEY.CU!N*_EEB9<
M#-]%X"+*XZ<K9*K+31;1&<-AM\'HV\(2>B$ 4583XQ"%_=%2)9 (1V^8=PER
MTVO'S.CP@4N5-W(0RV#LCP\VU,\^T1KW75J>:<G1P?;A\&!RXK/)$[%(7+->
M7$7& [/2_,3EH"YY:@Z)>W,+UI]8;"/HR<M@G1JD>6\,I.,/J#[7ME$AX[R(
M%R)^+Z5RX?,2.?V][P'[#]N<4&)[( QRY0(0=1<I13#;MS-J4*P\J$N?L2:#
M^3$R,+OM==]2?(,L)+[$FZ$.8U48&C'+'RO9=G539@S%FS3O)WK6C;<\&L!U
MW@VE?>X.%9:Y'_L=ZQ-Q6/[7CUF8"<@<#J=Y@90BL53F0Y1/E2"XA_@4E!G\
M/>D&IE;A_$,[KX;K,[2FG*Q O0-':D)97 %'#AT4G@I[H_=7@?J00+%T =AV
M %L&<I_'$*DQ>KV?\+G/VI&NI_SZ&FMLX5,N;.6E1NSZO*,43=*R/[E_'W?F
M7F_U$XOQTM&S:)ZRB3"F,0WO%J.;O2'L]JETE,/3@I[]0U&U5B9D3D2T>7%Y
MHTP^%1Q7@G&MT,?IF:FDQK7[2_[KT%202P-K:.=$<TG517K/A+OC HI>C<X6
MW;T:E/HX!(9\!I8FLEH8X+Z=YRO1TM47K4ZJ5]=J9P\;LSO)]?IRGSGPF?NF
M8>&3A^Q0H"[^/8H3W.7?+(EN+JR9&]GXQ"%$XZK_I(LLE([N!N/F\E68+9B"
M-.J?4UX"]=\U:F^=NJ?!FVR8(4!C7V%&^4.J5U<RZWQ\HI@B\VD$^6M;HJHW
MMYJ1XL/2J&$>2V"7CX?%@@_A%S.)Z@$JX) A>+3<T_:V5K-*)7F>QQV;J-:F
MMR)XUL^Y;YRVEF=A78@:WYAVEO=8.EJ@'M8UYSBHRD7;I*F6\#I@2 U;-EBF
MH7_;,6[VQ5K&.7MS72AIQLGIBW5C?3J;O%7*,YY2%L$.S)-KH;2! ZMZ>#[P
MSSB882IN\721DO=M[Z1.:\( JWS'K>YU^C?NK]X/"SRCPM39\CMYK?T%[AY)
M#4L,3HO'L*HQ9$]GV3:4D1"2*>?99C@[K%Z/D!SQ"BI(OZ_'B-PL1O/ ILUF
M+B0B.3W[ZB?H$L42&:L<_$?YKV"ZX%$2-9ZY>,$,;Z9C7R7J)@HYR!UI^D+W
M/I?CRODTP+?7:;Q\L \4[K\PM<''V"#9HIS50J\D36=:'9T\?50NAA<;)N(N
M95L:]!@<V;O$A8D%)9OAO6OKIKB6) SYLHM2Z(A!^^5L*UR9'P]?DT0=8#6^
M(:0K"Q> G^RBN:OTS(Y&XSUV;D@13Y_X8=F!^TSS5ZC8X\H\8^D\P7:![\YS
MB9S8M1=U=5C5SY72>=8N00Y\*>YT>ZY4O^^&O>^Z*@>7Q^CMT6/*.STLM%SJ
M1'Q6[7G?/Y@^N*7'XY\B')U8=@#(8J*@2!P)^.T\1$TCS:\Y*$IOR%FX$[@I
M)-C[NL>HE)%5,'I@"(H>AUG07P)]Z)L+0'_F6N[9!> R]XZ[6#XA7(4-C(%A
MOU7^7 ">:1&L5X![ ZC1V<TU$(QVYVQCW?1;+U_#-%^$QI][+E4M]Y^R;UHA
M693E&)/_$UQGHC3=:D/)3(>$%7*8I4LUC(Y]I*49C&YW"6C9AL*(C/2DQ\OT
MP-U5P@7@26@;';]-)HERU4C*@06J5$U%*<>0I#<&T!L#%07Z_=L6(#R;VQZ#
MQA.,?N@(;$#ITJ1>I4I<IVT)A.0VBL?Z5B%^PNA.<F\0E;YCS)]:/'M>6TT:
MG0\T7++W2;F'"Z>X^\GMNMNY_V<W+P&QZ%LMA'GEZVDSJ<#;)D1IGL'V]81(
MX$HV]ZU6H14+8)\,Z1[RDOK$-%7$U<HF1RT%^I4]?W.T)=PJJB<]\#_L/J"A
ML)5L!+5+ZQ.N<HCWJI [QT_[O;7VA(&G=(^O]2#(SHD$)&CM\!_(,+0+\W5S
M:AL@W\SH.SET,S7<K&S?OGJ-W93)F3,,*%LE;@G'I5+)S:Y^6T8PY60JB_SE
M N*,5(QOO-E@(23I.#7_@?\MY[K^K_7&!2##]@+@#CROA;\X_W(!<!R-',+P
M/:[!TD<[2RF#'E=K4V>:H:]Y2#R_JC8N9G+E<2L_GWS_H67:?YICN5D*_%NN
M( IA%4TU$/,*2F.='!*:10O=N?;\[P/[0!_3 JQY2U[JZLI7"4(K:,UIA47O
MU:[.-UM"CE\<EH8-\V]*5W^Q92I(J@G81CQ,2$/8<<NN<>\C@-&UC;P)VA9:
M!-/$=(^W(7]#E9<^U/0B,#SHE\17C6FXX/.F!UB9.A=)M$L%S*G\V_J BXKO
M#Z\!BU_B.U_@8]QA%P"R5AZ,[-.T%YBJG#&_/:[-(Q1Q*":"DQKQ=>\K0 (Z
M()^VVM )OA'H.)X_V6I24'GV5-ML@8=E*R3+)C]>S4U"@8,FS*QU,V$F<R-X
M*"WYU^(O[T20L503LMY@ZPAA/:2B$#R32R<U&I:Q<"8;7;OH:S M_+#N>W5U
MEJ9L^OT[M/>]8T7W^Z#F*^]'H.I[US$)KY#MW,07,P_4ZNN14EMC>S9NKS6T
M@%\ZSJZ.QZX<-_I([YZI$V^GH=32R]1]E4AWI^^!:)SA8ODW&X!>7U;5_W&1
MD_J8;PXD]@D7KS;!7[1 W;I8U>N5/Z[%2W,"R H]7O=:N34Z6&%\775DEE/[
M]XO?]ZQBW;O7*C[?UE2W^.-,G#B/"!:XY%/7@H6@">K8K+4G.D_IJ^MZQN92
M_S!H!&O28\+26)5LZ,V13R[CAPJ_@8)%(2U9,(?AIXH6[E*]&9L'9[^>\-Y;
M$*QP7-MP9?QX-W'P>*:]&(\@L!+E\"-PE8;2>;#]6??"@J7])*^(F[HO2%T?
M-C='>:#C*9N+T0.'@[A8(M5C"(XC$ROFFJ7/O%F;,ZE>\TAV#][>Y*,J3X[=
M8D2K2PQM1<<K! X&@;3GD$JEMB;92AQ'9X%5V2=!+@&_=Q&VBP^1X/.4P'M%
MEGU;)I9H"3,]5A+_8H$1=]1#A'Q?M#1B%FF$KUEAV'2=%EE^GJ0:U$BMD"C0
M]W*,-8W[Y#?W2YC.K\*5T5DP2B7.KFRGP2>'=5+K=T^ ]VUS[53AH=9G7'[R
MK-3Q*7]1V'+0Q.6\29C+F %>,]-UJ?,3<5:9&F?TJ^<W$:7*,32D"/;I2Z+0
M:LW1+?0_SH)Y"PT>.A5[V>4\T>]"H2@?F JH#05(VUT Z((2" "BS 7@ _>*
M<GVE.]/(L^[D^J\;[VGN<?,*G<P5]IU[P0L=<^(*YK;9E./3;;F3;6VO^8RI
M 2.D7I8! =?-X9]Z0-",XPK2I,HR1:3Q"R5^];UR6.YJ< "L4[O5#]ZU!J&'
MJ@D-5!(5YDQWZ"&L@LF_)K4B@U5PTW%N]#K=?\I@S%*(V98.&.  AJ)-T\-2
MQ-0)V:_6-#JE-K6HOV-?3Z1V"0FG[9V6[Z60A]>T2UZF13H\MLAT#O]MT"AC
MK+J^O39YL#'21_:Z\\TG':CW'* L/!^. F^XTB1:*#.7VN(N=>MQTLX?2K[$
M-JU458UI7X N-5E8_V9[&FVZE55$(:6\:N=.?FV;WN<>6^/!+V73]_,?O#*1
MAW JB.WF;>;^C_W2^X'_D:HY!U*<IRO)$Y06' ]1;6#SUIC7QMVXLP+, ->Z
M2!W21N-9X+#"&D7QU1_!-TE].31XD;6!0+-OCO[[,_F\$AUOIT3O07WZGUA_
M"->%KF482@HK%<<X()8>N"C>FQBL?A5!J2FV*#L"]PVBI[\$M;S+',B.VCH/
M!,.V'QDF1.<PM&'MB+<;?DH8]TYJ%LS..NJK9;]P9.6X5%%&3_MF=8+HL5LX
M" :Y3^^4_V15<=]T0*HX947!?%S-N/^.S#ZV/7BE5WRI!7@-?UL'(_;>"T$Y
MQPJ1JE09,^&;K^\_4B-_A']9S ,'!(!X)=F\OC="GYD8I"PO_1K8\!:R%I?F
M*Q!4555I^($^4E$[#_O7>>(:U XEO'0'^Q!AC=I7UVG)@/[*E^CBP"!&/_O(
M";.[S2,/UN3A6>W 0-T)D@AI*G>^F<>O^>FRR9R9^9L$>6O^HA=<CT4:$YQ!
MLTL\EV_L%\B')6][6'AKUU3*0P4W>3)?:Q:8\Y4B+EW]^QL*9\,X/=P5O)5?
ME8-"2N:NJ1C.\7FUZ6_SG@WYN*%#3U[=O6$]/M^O+#W^GSUIZN,?0DN:/'54
M,H0._*1_+,S4,^7<TE+Z[O3ZU&?^0'W">Q56GT;,9(Y'["[1GPM$M_UH@GQ<
MICM9CN&Z-MW*5S[J[5+LJ/%1JEZW7"+<V[WVQW>.DAUZ5GCBSZDXP9,=;9M)
M0CJNL=FC,K)4BWU01"P#*'D!L,N==07&<U,&!L'G%W7.$46KM((CY P;AB9F
MOAX6,!^*QV9\TH<PC"XD+LZO:(>;QOOC%XO?AZT3K4OTG_4.\[::JY<H\H&V
M\(+VZX$ S)\]0MZ. B@2(JTX'[";Z"WDF-3'$T'%3*4OQ=)Q0.N.)?5R4?[
M-ZO<1_OGM'W;?7H!(#PV,S9_7/_MV1^D]5,SZXT&T<-5N3Z6,V<C!W66\O&*
M9:&:L/H1L5VLBC9E\NHC,7K+4/.='4="T05 [TCE^7DI8OU,!+%W+_\RWF^"
M2F&=+R\ Z[288U*[&.*$16A!*8C !95<E>WY@ \K=?3?8QO4<9$+G5EE;%@$
M/ YS>CH2]MUN\[17"+8VNK>,@L]Q(=7"NGWGZI(<](0ZO)J^Q59_XG>97PL\
M[XRU;N-_9PR=_JG3X.A>,SG8\WK072(_+E3KU";+&SWBV4.TN #PSX61.IB
M9Z\8W8'?#R,/ DT(XD3PV%Z(;,:7YA\A7#DVJ6;,IU9@(T?@52E:O97H0)'4
M8WTP?666T=.-![$6SG'34P>S#?*O<I.1T0DKH YZ^N#19J[\0JC/L4%;0WL3
MLWY]J;"'W)L\MT*>)[%T*T@Q7#@_RG$RH4?@6$P[OX8@4UO]V7$(%:<"@IL!
MCX'R%P";<S[4P[S5?<\G^$[K.R*"O<*BAX?%-=%SK^UN]=U3?TSM:FF^XF?C
MGH';5UO&*59C!_%OQ>@6=Y)K/U*!'7P;D$8_-/JN,"2MU&0E#I9R8'0"_O3
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MGK'G".6FPZ KWB_%'W/UK5 OUVV;!?3<,\"'P"J]ZC8O -1U+RST'/L^YB\
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M#\V]OG_-']5U?=4J#FVE9)PNTU#;(]_@S'LX5Y@R%^0]XSA6O(.L.41)0'G
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M.U'J(K19<+.YN1LL+?%EFQPKVF?W5%BJ02E61H6Y8*=PAKS0?J)!\I'4.4Z
M50-;N; R7-*5;>QWV5'FY_0OKB[KIV](Y+=E]S@'&S5D7>SBG/\V<&[.<3F
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MA]*O .\L0]H$L>++KM0[A&>CH&I!@;\TV?2$,7+<\*O2KUW[)(_0F@[_:SI
M':=0,;DH/)"^-*;O<@4HMIRIA196BD-*%BKRD&#7=3\ME ;N>7UO#%"];01!
M/-+R+O>7[5B%6:72K6!KCY:*WR7]/UGR627%MD#H!.@4<AHY;8F.Q'HM.!_!
M5MAQKUGM0%N%0R F)"H5-%-1\?1[JIS73HENJ%WJ?/_IR410NRE_D4Y9J8)'
M: &2%W'IDK.(D-$Z-;W,X<12KYA> 5#.NCCKKHNNCC7M1@.[2!4^!24CF^CF
M^[W$GUFE#.NT%=TGX3**R@9YS?8^K&$R_$]'\N$/(2EK@L%7 +JV!WB[*7P0
M.E4=2#WM%Q9=?\$*E]!AKO(!U#R::_Q23$EZ\"A84F*1#ZN,F3O]WC9RDA-I
MXO-YV97$R)Q_??(",B Z]HS8H]DF:7/VX+;:!_JO#]IQ4E$GUAGZ,05]K%YE
M!<XP:<B^OT?_TX$,F:-UEP/QL\#3UI9RG4REZH:1'-74!9NQ_/KG<)<9GA&:
M6;VSGD7>9<OIJ65\-70D^PD=G;7>L!RKF;G)M&JGDGVB<LR=L]EJ4 WQ:<4/
MI(/@+8@9QM/1>B4NA@\B2)+&;I)L6!KRB$--QN5Q0@C5%_?Z>KF,I9JAGSC0
M!R35VO#W)JG4 G<1"R>ISP)C[M* NX!$A0\ 0';77\[:7/-W;M[\HANZZMZF
M"\C4'!$^)98UH?$*C1^CDQ?&*)OFO?+6<,(H\+;I6GT';HBB_4==V@^^4E][
M-U7J\Q)ZYWA*->%FHMAT$A)Z.>[O>TA$?=B)BNB-Y26*O1CG>_6?S3*.^+M?
M_/0!.FATW9AZ.^3F?[W4Y6H2,SI%^P5W^L6;FN9&!UD0:&JXX9R21RC<OO_,
MPO<U&C1C?QHX0:"^ G1HK&K1[C[;A8I@%'MG*V:GY/0D[3V^+;M8C0I9W98
MN E#>G_"R*%B^!O8P=69%OX5N'BW!05&H"S-E\YC49$Y0<'6AT._0(FRE#?D
MJ))#GN94GP8V*V:VJ^:HGMU76#L&-IGS$O$WIR%U*YP/RG06_3L5N""]5'Q4
MW[,T4]'C Z1-6NWM8%&:'.H:%9B[%, $]WKYA'&HGJO8$GG429JWUYAMQ;2
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MO.Y7X7@V&)?+PSN_%XJ=0Q\3:&&=,;HOHTL6JB/AZ4W^/SR^X5B5UUX L]J
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M#:??6'\>*3(.2K=N#NT45'B=]J'R,V?'611'QW_Y3PY/SW&TG(HQ!ZCLR>Z
M[4]V!X_I!WTZ?'R;;6C[)J]-RIJ10@W&/(<7C (S_HRO*47JZ/*/VS"39:\<
MZGTB5]+CT)& [;@SX>:H-?;_#8#E?[?7"%W2Q_J8 TG5]Z]K# 0RRETKGE@L
MC9U.E*%Z&9,_NO.^%>\9]SU("O^$UW]-31L:#?Y>+CCC6WN]^<3C;EUT#_F.
MW\/7N_JNWMSZN/]::UYZP;N64Q,V3\)P;W+2-)[\?-!T[=!XYP+'B<[I?EN#
M%.SIL5G1T]TI9R[4Z"4^,A4J+U(MKO8^H13>=569'CD[>MN-:^2N$/>>#8;0
MQ%<LS_B],I[+?_LZ"^WTG<U-4>,9-[ T&] 6UW^3O-;RVJ.;\<LRE;$_G6_\
ML%PF:B?AI.O_G;\&S=3F(?YT8QC>CX#7:PP?,Q?$RM@=6?>V(Z#DDNH-!@(=
MAW#J^? C,BONTOZJF.:[;QQYU;TS$OG4.EXN=0L0/J2HO\IJ7._R5MD]RQV]
MQC(<;'JO0V:XZBIC7?;4];7T6J0WGA*OXF]UZ=Y0R-_[>>2[:;:'8&N_XV*M
M&+*E):WCN]['O^6*\A@(_H>^5IZB34X.\Z4,1.V#(+[@J1["*:EM3M'7H!3O
MK;(F:LLRW95(Z' KQ)E6L'UK?M\9[[XO9W1TCB[FT>.X/'](J[33RK )"VY?
M&C:^WG?VZ2WDR#1=C%YV_5U^LL/ I?Q@WCJHP*COY@L>VR*)T$6CB-ZA0O.'
M'9\]<PS+LR2:+-XL2%HODPVRGWW'2C\7-UO<;+]F]K^(W0WDE,8@KQX!O7[:
M;39VK&"BKK38.)XS&/%^#?)>3D-]=)<BAJ>PK/=&C$AZP?-7IYY"?P]NT^"[
MZD1D()RF%W9[,Q!S"TX,1#*7MYH: _%8>Q"YQ*''0"0)!QR3G?>E?1CDY?FF
M(E6[J:'T[<R>TOYOI>VCXL]>R&]3RKGIKYWMKQ-#P80P$+SR1!S^[?2=6=U3
M?F\]9Q_WC!\**7KZ1V'[O 0^5^$EY>B@;7II9!<!+[*5+U3^;JUAL:Y6GW^W
MT<\C]=AESZKYTIDFCUKS%\A"ON!9L^D1W=TN&WWO[^O 7V]=9[4CW!)]>GX_
MX943X9@& R'E2W9;$CR GE5,X<[UB;W 0-S!JE>T'\L_JBXV'+I3T#7@EB3N
MAZAO@^4>^XM9<R=K2V^G*)H$]SH</O1YQD[9](2W1V]\!P&RG3&@/:D5;A=4
MDW:Z**4G=_Y4X@+5(3#%F'?$/TLV:M+]8.BU!O,Y=!":Q],?K=GJ=WIFH'_"
M]'K>Q];Q8C=W2OXN;M?!$R^N1;0;V\@M_- R2._HTEQD(*KR2%E_S43&2=_4
M=)VF:PN7NN9RI196)B1-;!E_H^>QSWV[>.2]BV&2SPD'=!9'166\M6C/7_>,
M365]Z7] 4\P4.9)=%/4(.> R*FZS\_*<PA1/V:W(0:28&G),^%:XTOU$G3*G
MNQ&[WST<..=D<6.W[0+TZ7KZ6)3$P\*OAE5GY2P_N;417V8[>A T>M2_X?4B
M/D,.;7/93N2'J>A@!9$XI?/%H1CSBC+KE&[J#F+ZE?<-.3*&9*7P7;0G% 9"
M:V;M7]RE 1N:L6L;:Q\P$/Z<M*V6&(I,?1@#L<&Y4E1M#[T_>+!E6CQ/7W[B
MTKV_2P0- FQY2V9) B0#OP/<9-D&V3]\MAG8M!1.]72&\O6;H"<N8=+0MW$_
MG5HB-[B?_%XSN/W/F!BU@)0GW^<;*C997EG2]/GAQ@$IE*O<V)\]GE-J&R>\
M/"1??ME_G5Z7P">O9^@-T*G7?F=H>8,,Q-8_7X)&NC[X*0/1K>*5620>;\Q
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ME&^YL5AR>2422WR5#Z*:#**:RD $S]#\&0BUF]4,1+'^;W'"8,"*K*(6T21
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M(.>[FWW!3('OA/7-=B8=:E,G0_S]A/V#BIIBA=#>GHS=-!469,'LN1@2*^K
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M!/V74,#.!,LVKQ^CQ85WV]OF6@--!%^[]JP6D2(Q[D_(=W4>&-242L6'$&Y
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MZE[@ GZ^_*>=9BF,VOVG)&V3:2C ZPOW1\<20(OV310@'+K"=*?FWYQBT1.
MHHX&_4%+ MI./2S*?A,^(0"=A*,E"2:9WP^<DF5[EOU# [M"@VRV8)C]R\/-
M;B7XQM&./BQK,9W_6&:N;\Q TL4C,NU3](!0.%NYVW5GWL89_D$9<RU%? O&
MPPZOB8&V5PT4.=639<?"3D\Z[QS(U03[JMS45;TS=)GE^Q%Z3YJV3[1'&J%L
MX,"F><E-,'J :;ZS43:F%G6L0Z8@;VI%.36V-CK%\W/UM>]U%9\W 4?7\/#;
M"VLF@A!-# 7H- J586-?I0"3'$Z96.>,^&5#WDP?OKO).Q<':548Q)93S)HM
M,?7M9-6Q&F$/R^&NP<HW \NK8U5(Z1.?)A@$\QVF&VB_NQ8O)QG[AMY3VO:H
M:'VGU57X;E*$E\!5ETP!CLEV*GU+K"=*+'2J(#K;"1ZPKPO(F<'/01^1_3"5
MUC6,B[\>WO:=L"P($PM+],IA2)"<4.ZO[Z=.]VIW0,C8.(H=Y+ =C>)26AIM
M-D0+N@R8?97.O&&B5&J4%$W,--Z<\GDP1_.*QHHLB^>=,Q$.E+V.2:I"3P5!
M5 K_J.?)\BM+M4(PE31&:&3<&M9?4%7_$+2457E4QLV/"*I\EG/.:B;Y'*F
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ME9;.ZA0X^7LI[JN,U5_A$TO4LYP9CS:C337\5/&A61P'9YYEP:A,YEMJJ%,
M1E3,8-T'"E!,D)VZY92I$70?6IW6E*0V'ZX(.8=50,,2FO4+5\PM@FLSBHOU
M)1I]K683H045>545^P2I&6V!:6Z=YMAXX9<>C0JW IOF&3I@1_$I1%" 5E7Q
M^OOVZFFG5N&ARKV7F_8>'T<*7IUXH;-;_WFJB:5>576-?-9Y]OC0?4P+(O%H
MU4REE7;>P>@V=4A./99B.^G<+[3XR:[W+(+N<W':>1'$B@1$._,AG_"O\/O6
MEWH\]O),:D2KZ;?K-V .$U/W_O"Z+(A#L6OQH SG'CO.G_4[!G&1^++"FV$L
M@:O_H"MH>(IQZ(]';::8BCY#O1M,1Z1<NBURF3!TC716F]-U/BZ3KRXI9Y_0
MET9Z!9R]GQ*=>.=QU$,9SY(2(W9ZER43=HA&$W8_&OJH%$;;)50?QHN/RCV+
M@:4EPJ?\_96]9_/LDV=M0DMX-EN=? ;7?K#%D,^/4.V@ ).\';/R(T8F<Q2
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M\/(('@K5#HWOSJD\$/C'5#K<^ IE'7Z3 +"951* 5_1(3$ZT+Z<'$O^FUI$
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MB ?"> [/Q1"$/P/%]"-GN8<(P/)-&(A)X\0QKCPWWR6#UE+C"TXP!1_\<W>
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MU 3;HL$KV8$>$=8,AB,MZ!)/89A09^PC- P'\MXV@H#*2HJVA5RTANS2ZQ,
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M?BU.-\FA6]>MYUA\_R9F+@]3M+I37X4;2 H;-_;YU+)MQ7==@=5(S"$_XFN
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M2W>8^:5;Z =H)0:4L5"5/D_Z64(N_3JZVZQ.?JJ_+CB.^[!V3^GL*19P^V7
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M:/LQ;VV4J]B@?G#%>=_^IP[]94JE88W^Y@JH)#AY_DJLIG.)I[7U]0X':6-
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MP*T\!LG&&$/H%GIE/]P/"NO#T.,J<0L\,/10D%:<^V<C_\$I$#JF$J&;$^#
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MH2A/]JZ=C_ .*<]*7 +SS?6UPPK6I8C4%>T<<K//ZJ!/N$I&-GZ[]LC\'=3
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M \JPX&<BAB:#F\C*IK0C.O!?*'43KRF/21/9\# TM.(*V#-@9_)!561R9W7
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M!+D 2PYZQ[\TG/@7WV&@^&]=82+;"V$D9?6!*K-XZAR3L/D(>2J+J=Z?I-)
MA<8'(!9)9N=?+&1*:@'^6A(TL_J/,9N^^+.I9K6N-^BC,/5=LB;MQ)7 ']S/
M:5\FH<A27F9H^/'6K DG5ZG;>JC :(NF;5(+MC+5^LX4$QZU0V/XF9%D /\.
M4BPIF6;6.ML5\NYYWFN;=SZ3HDK;A".KZZ>@98=+?!MSI.Y!CH+*D/',5C9>
M"_I:.S#4K >-^1L R66*;-$Y15N$YI0E\FLH-D)_Y:C&_'5LU"$(;F-8"!ID
M="8V U+V'Y35-=]WL01%?2?-AG\YV WI*[3B2)K)(EMX#=$61WY@@$IB]C3S
M9?S7.J"8">=W*F_]^4U*D'['5]9O%FW7QH -M4,%!<X)0M*,(SBC@)DQJ,CP
MQ4-9+:0;ESRT",8"D%?G^>0A:4=6E/;VI)J\0ZE?[,?/S8TLJ;1:P2FT9%\:
MG&_7R98NRYVUYN_J15]Z8V:"%^3B%&KD8\<X C(<,-82K739!%^3=S5!M?O/
MV<W4'?9T4%I1^Y&4K'<J"8]6A%#@L)/E/_';I'24U].J1]=Y.G5*M^P5/*9?
M6]]4>'C9F7O[7)XZG\UO=NP+U/)\?G;5Y36T\O:D\[\*:5GVU&_PKX=$9FSP
M_[-?];@^-0:'#)LE'NO920:?JMXJM1 H7:U_D=*V;/DR^)7ZYS_3A_\#OB4Q
M#Y'JR\&O1LLD(SOM[[ZT'.7?T2T1>RS\!4^V_&;Y69Y5WU98*I""4()4AC9B
MP(YE0BNSGQQ 4@!^^^# ^73-#N1?)UQ5."(1RPLTI"4!/:>P-%VW,*JC XFF
MTJ1R*4XHM^C-[=.'?7&HC>.2.3:4^ B54%[7#T/P?946APW3)-=-?D@U5.@=
MD@F?S5_FRE]R]U0"W:NVHE,D("-9+U^1OT&R@COUP^6+]U':V?;)-I:+"0\A
MN]PV@>PB#MK2=D'%<2MN>"T^BVQBH+[]251;*N"S50>S2:9,-&WW)#PE_5#1
M_L2O)YMTB%,G(S0.V?BHB>FWC&=I/7_Z)3UN*.[<<)[9Y=!Y7Y9F1Y&@/0VF
M57?N[UM?YK6%TM8T%IOHP.O"9R02< 0T:FE4[_JZYQX2Y.8P/P267P$1!)T_
M8&LRS:+/I%M>2:<!? Z^"N FLU$YRRW7-749DC1RMWWJ MQMUTX4?KEOI"-\
MT_PF+^8B4@1MUTJS)N;WGI5%5"B/Z5Z?L'J:>W)J!_;J',>\6[78-D(0J_XF
M.4ZSX3"^%G.W03?-/=<W(,\-Z%(%#M6BKD9E=K8;#?N&K)@E4+>!#4I8815^
MSTUO+SIQC6QZ_?6\>=CK;Q4='7)9 G5M:RYLO-?Q?J'SXS67_CZ9!N*78(^7
M!AE:U/25A^OMQ/\FT\:_^57:Z.'Y-$6LLW#L\4JA$Q_K(Z=O;=+7'GOY__\Q
M].]__UG;='B+>V36XBO5#A,'0]RF-5$IH\9M-XHDV,Y&&&GL/KE->$OH[=ET
MP5%?GF[S$3R/"MS=7<4M[Q5*\4:M2AV7N/I3=OG]/;!5$G$/TZ7?:3SXZIY-
MNQ<J%YI6JF_3"LXTY" #U=:2;"LYCK]7Y(O;WGR -VZZJ?WLV]9M[P(_WSG$
M(2'6*9];E/U$3<.[S3B; &<E(]Y;KF\[H(JP;'4J.FJO^NEYLW% V\Y09X4+
MNW/3[_3#/!V<,&IRJ$9R;>7KX04OHXRDUH&O[#Y)(\:GZV4*M;_MM0HZ61JS
MU1'2VE/J0"?>([ B'[$>%#+SD*]J6SS>\>7KBW@49W#&;+L61_D#O%#]5BG[
M#WWQ67$Q;;NHN_2,0S-<H8".ULV7MK#HTLTLJG\9V(KRMFL.&^(9IXC3B%H[
MN^MJ'UN,TT+AD//6T61($7V5S[M]CI??O6B]OAG\YL,S>C41D%E3M^U4PB$#
M_],:7K$#LPQ8@)@L"TT#U\8]66M!S*V,>M,9<-IOX%'?_9/[M*KJ%.^KY;8.
MFT6UQ1 X0TZ3DROXW#LGDY,Z*(9YV:RS,:?RV:?3[XI/74C[V'\?UK-AQ+7^
MKB#;/0;,%L?G$.,^/]^M6B+H&)!D+Q&$\75\(;DWW/G=P^H=[>+Q(<]$SJ;U
M7C2:5NP96).14;)V;C3VANY"OMO9?>3##ZSJ(E+B#?46D7U:YHG/6\QTDJCB
M+'U2XU/VQ*'J3M[,1S[.J1[F9XN"2S,MHI)SL?TSV\.CC@7L)K3OELMHF)!H
M(F.)3L>(^ "T5HJ'U]3I=X5$?)!UTP%E[YI+/GGC^AU#JXRT;YV-K[OQO@]F
M$M^--B92?1O5=C7F6FBW+;Q?G/OV)"WE^#51(>6WST/+;X0F7V7)K.[G2)P\
M>-YD;\F^)EGP,$VG87+.G)68'RI1],91V]1HXF*,LQ;*^>VU8Q_YG]QDV1(G
M'>N/=I=1,LCKXY6B#R2UDR,&C2<C1UU[KW4X1QEI220KL6:5-;FAJ!G3A>.1
MJ/BA6&QYEPR<(!OH.A90&%GAN[UEAP[[P:#]/O?VB"OO_5S9><:__()?=X%^
M&(+5!1>H)M0\E1-VK!<<;2+:"PX_;4E4JNH^=#.(E<U&\&B-U*ZYS&#9+1Y(
M$_JS[;C8Q299-C)W>6VSL7VK;V>>-CHJ=)+>IW6H&S;P(.YP*X*-IMWD*]9)
M'BLWJWL<[V&IO\5<RS<VPN)\582#P?Y8V?V94N&;]\MMO/GN*]LUZ;0Q@:2=
MK=EO%A*+$N<9L'SQS*=ZLFD7GMAJD 9C"ODSB68EW;19D[P 7RQ1L+ZZ$QEX
M8&H=4M>1,!8N83:^F-/XP47KDN%T47K\JM J]NWOZX\=%2O*KTQ[+G77E8<X
MU+7I3J2<:3$M>*9&H$>9]P0L3\FQ:WIHZ\&:!00[N:\,SN92*,MB(>3H6UNQ
M?RTI(,%:K&Z;J;C83IG^T"BKM1/C'\_Q2;!\\0S(?^YA\GZQ*C5A5.=Z;^JE
M1R4U:7:" T5N;\J.?*E$WRVYFAC6$]HG?'F6(&T\_^9,(>;+C$EK87%;-#@1
M-_'DX;@JJ\8F[![K^06WJ!SMF@Y5\[PG[682(8LQMU7DB0S8T89DTK'1@JKL
M#%/UU,KD$7>#CFI[QQWTT.DB0\J]GEV=O&ZA_4]"KWI8$?1OHX_VI:5Y6]A0
MC8E#-/$%P5DMISVGNX\8F/JG3^2I<^_]NI^][CA,/CBF0JF&M .QGHPYVJJ@
MT*[P=$>[=HM"UF9=%&Q&S$3]D7K'YD^AST02)+6V&MQ'%3?0[ F.;)5\X9HI
M'A=0QJ);6B^TS'$HUG5WEXV2:CT-=DXW';K7D."_N^.]3.1YU[3V,,5>O+)A
MP427CEV>5L94NS..,Z!<^XVAP;Q]=51.\4#27$F6^\YB<93]Z_X"I]MHV;XL
M-G*6 9&>F?5\5 V>=X\>>:9%K"A@D)LJLDK'(_2JTBZXA^*Z]Z,J50495KUN
MN R[?,$3$5\Z[//E-"4K2V*2.K_(E)YZ,*,2=/^M8<7-#MA,:+NT)2CZU S=
MW3C<'3S18>KJ->6&+MF=)/@DKL8A.K/&XMNLB8Z.[+[GP=*O"/_G=MDQSXT=
M1 KY2CE@.;+4A"I?F'?4E4B07./\W.=SW'8Y[9$O5/ VO=93\59*? W16ZDW
MIH)N\IX!XR[A)GM5==>9R_*-*9FYSL:LFY"X7GWQ^K478@*P+L)I][4"4C<]
MA;$3CCTL)#$\86\,(H !(^QLVE*=QR^8]" :<27?_*B3B\C0L?3GVTR/[E$<
M"/!J/]"'[\"7^6X@CQ"ES(B<Y3)"1_D*Z*36 W".X<U=GHH32=]>/NH/V)^[
M,?3FU8-?S[J*W93V<)]/)J$CR&RF;3D3? BV,5^E-C3OR_-F79^R36M%/E<(
M7HD/33KV@;BN?\_^ O7=)MOU4VE'R*GI]H!0B0A:F?B53XG?K,S28;&__7I1
M0+UVOM&Q8=[V*Q'Z>_:G*0[ U<Z2+ V@R.^Y&D]BG]>',G$_U\?2WUC.MM T
M>]DSU'3>BJZ_@*4:>X=()VU<U55T7.P5M?;6IDVH!/H#ERE>CV9#DGYE%ISL
M12T#=[5;Y33*Y#CJ;1&>5S0^>3P43HB>-']WE&5C@-CA!K;&L_\&S^I2IG"W
M3Y;"?[4DE0&+#^Y:QM%TFJT2*XKH3W7 SI750QG&]DPN5"&9]"M];@CR\SL<
M+70_O"\&?% _&OH85'_HM+C 29?DM(P2:T$U)9J13$?WC^F;76IN>W-Y_YBA
MK%F8@_J8Z<D:S'?BVA"YRP_FQDXE9YG5W*^Q;^ETO?3ID>3)7)&33$K;Z!\L
MMQO#[<=.F7FUG:K!:(<[**3RO;$YY=42)=@2%2)O-3+[T>?RIR\#$_HO9!U\
M3@19I=;J)LO8?+C4$F+0$G+Z@U4J)/6XO'!.3HB.:40-VS>%M,[[/LW:Q6F*
M1Q9OS+YHCDG2D;>*C@ZW1\EM%9M+/F.2<3C[\OZ6@1?-T?'W*YFDO!O]:CNQ
MIRQ;%C]]OF<9Y:S9DM1T0 ?U04\BX$@?OL5G71_I):JI %A%-@:XQKCVAX8(
M"*LT<956*VN^R]*7+NM]_7#T[#XMJJ8DRL4=/U#HL^F\NK;+B+:1KY#H')2X
M+8Q0-B\?23\I;WE3E^WT.<U2I 0EFM*RBX/2VMGHG___6WMR#F%Y@ _.1R'7
MX:ER[;KG?WV;YN_I<TNT&+!;08KX->03BPYR6-H=U)@#10K<(,F B>G?P8V+
MRX)W%=IZ;6^B'<AL_.48=@]DA9EN?\&]IZGFYO2W6K?F8[BK)$Y?;SRW)90!
M<\M101'9U8G-:'V^A84(S(8O(_G&)3;X[MRZ;P1ZP.1^"^!ND4^".5JK":V:
M;J'I#.7/7&234\VN.\+*V>WOV'Y\8I6@0:Y_?2"59'6NV6RLCW9Z5+%]M:.L
M>O"WA"C])Z>?.;Y5Z1/N2S).C),DG2%89/GY2IEY7"V=VIMN$_Q1(^Y$+>>A
ML_G;K,*J"HR;79!W "&5,\1%<- <L]8AN$!U-D9@3_!H&&_UB^'$"QVS:PN!
M4"0<K4_ AWA=C7F&RDLXQK=X3=F1\.#&W4%T_Y8Q?' ON,?#PG>7;^MA,,;*
MG>M-0:&I5(DFA[#BR :%ILCF#?&8MI<RE2_R>2+LDU]/8E^[ATT5R:1ZA/0,
MW97H2O/P]91X97-5\K;[I[315=NKJ7+>)FVN),WQ]GAL&#R'+Y<DM[,_E]@>
MF& A>[)F>W(7_X/']20N^*>.R;$1)*K]ZD6>-&2:%LXR><=ZG/75NX5>K#P&
MEO;=OVQXR:7:VL=)$V=C]<-HDFODSYN7STMG'5!:)7"CQVU4J[KA7J))#?:J
M_MVX585M!VK5(TW>%L6-?W@?':OJ=XSTH13YP.W]7%:K<MHYIXS^_+<!AWK"
MM8L,4ZPO>-WB7&.RWI;(3IC'7HOH(EO6;8=_N\,_'?-%L_"JZNO@.;OVLH]<
M]W9S3'>W317XIN%H0N0W28\(:6?CD*8:O"Y/+F?&9NM>Z=)5\AA^G.TM[<%/
MVY)/N)H*.9UU3&U[J^.+;$>+/AV/P9X<^\BWF\IE*$--)<4OU+F/"FH*[KG^
M;$-* FQ5PRK]S VMJCE?ZXHV<1\45MA'<A\ H16+]V[WBA.?CCDTL XP8/1K
MD5 R<L#M%[**F[O(R]@GSG7_<G9ZP]^^7#:4_#L)04D3_9D:&PK.IW+4VO-%
MMUFGY$NM+1D?T!%(%<<SEJ8,V$;'7NPBNSWV 8ZF[EL>,22P41&I'666JB7E
MFN7FN[["=)-MR&=IDWCUCS)IJLJR\N]W9@%0\:%(TJ>SYM1_1()B&+*5$P\#
MUF!^BI;$/#Z]$\37(H:F:< '"G[.ZB #]LR=##SJX3&!%"P7\D@&;W7:#LA"
MXTJ3MC\_&!B6>>%KR("1> "G >P,Q1?1#Q^MNLZ '9F"EJO_N+N=?_:&: WM
M _WP!-#VIH$E<V/S<M7@Q*KN71"4O$<4'0:LPH".BP;J!\B0&X"TK=5T%EPY
MK1[VO)@! P6Z*A&S?,V(70 Y&$$(*SH#><A1?CJ& 0M*H )[&#!L+;02;6/
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M*)J4,7YFR)4!0V-(">"6-"?*3 $#5J+YG1)JI<9+Y%,,6)FK(P.FYHY<^,"
M"2*6HUJBH&+ UK?FTRC? +PXS8X!NS/:!:(G<5/A/WBH_NGZGZZ972]_,><E
M=AF*[%P&C+?\I?T9<\D<4O9$^4$!@0L^/BFKHX9*$:SD=[VMN8Y"$U[^%9LI
MV3XO7;[E'3 H>\OBS^+7"66. =?)4&_'%D"]K\PM"M]>D9**,\**9.RO51UL
M76\D<!#FU;I<2\LKTY\XM [5W1'RRNO%?9B[^-A&H3=^XXDF,XDD:<D.!V>
M6(> QOBPY0_&56C&V3A$G ']I[Y3LD8U_IV--.?U+*#IC[C$G:K.@%VQ0<YN
M@68AEAC*DRF:?%8Y?I&? 9MV8]*G0I--N3)-%5K- 29]+((\X+*2;W2HXGNA
M"= .Z.%BP+8#2U(1M$W(06=H":B'<P8RMU!0E)DLK+L 0EP)')J66""A>R&A
M3G^'5W8<G0_ZQ3-@-S5IMZE6D(.>/8)JPQO0[,T";IUZ#Y^%YN*:VA]VH/;
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M9LW4JQYK@$]"%7 RN].2]>N8/P;]87Z;E<P/W43(IZUB_C:\&?@.@QFDO60
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ML?[W3T#G:@:L&"ID>'"*@*DU,,F#*(77L/(8G&=[L?0V5#6Q&.U*LO:5'%W
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MB=US3H6$GO'JOHGB)P!UY%I5ZMQE^_YD9S.)-R<*G/^X'!=A[)D%8D=H+ Q
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M@O";EL^ZO)3XUNZI>QQ RG'[9;V1,8($8,M^QNJENL0 [)@KH?*<;'$03!6
M_AO]VZ"V2F<Z8@?,)@%>NPM%3+W=OBX..Y1:^%SK47 <%D0].0L*AF4[R@\+
M@ <.GJ$MY PH..%W#RP:K;]$PP!242!\]+UZG8WJW(6@M1_^C8TE/F9B/_\[
M=AL9]Q>2*%/L'>0T*+CH=P^L(^TE!-B8-ZT<BE[+^*5[.&R] JP4FO!^!B]
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MJUCF=A7;_;%=;-TWQ7][M;8TZBF8WFXI+-D*YCL[BWH"=NG/83\13("&[.!
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M![T@%C[6X8(9P&ZHMI4PV3<FOZ0E@"*?,X0MH,V2J158>A<S0_OZE*\P6"2
MFF7[21SZWQ,'[[S"R-(2&?T=^?68-VV=Y@@YUU-A/!37/K+_2.3B-ROG1Q[+
MC5%GL7A'V$W$]76.L$*<-$50V*F%^/KR!B;[;8 )I:'<)$Y5_FZI#U(Z2'6*
M&1#^_?7K9F\SZ0;/>*YZ0=6B^N$U)P2'G)]B9\ *]FGS_]2'!Q6(L_\?^S1#
M04GVY,!&HXB!S:>W.4]XLYZW>:TT3ZMYE.%(L?MDB9;)<6?L)I6^_M\^;?L_
MO2Y:-,6'W2$(X05]XFM7;_INS[%^E(AQ_OA@1P>!MK7'B&B;SV^<%/(@HW*_
ML<DY^6S0@80-]UNH1PJZ:8E19*.GUI_>XY$N7+-BT]O) 'AY/M@WR?RPP4:E
M>.,0BG35?=77:X+FF]ON*\3T#2-+E),RK4%;C+%6LL>-[*FKO#*]$<+V4=IO
M3U1MO%3>IG$+#6!TT!R&7K(]86F>#G<F;[CO&3^HE6DQ3I=9R<M2\)F^,9%5
M/DD_2A&7:-US[TE:+N'<U/)&ATKMH&AT%5T?.C,@)9>%WB=T*=FL::%YW:)O
MA#W54,:DI"*VS&.WPNP%\@EJ0; LI.26SG'^4G#OG.FSI]N@4Q:=J+<QZ)TH
M%R,>2_>!Z6;B2%CEU=9C49TL?&Y+>S[J"$<Z15JR7C[,_:7Z^UB21G3(/K58
MJ_0LKE*K)L6D2JWU%U$RBV,K-2^BI(!_\LJQ'J'=A0\B,R&X]>VYI?_ZY!C%
M34;_FEO;]/=/H/]3E0*4,M:IX.M"/4I,R2BB'%*^9]N55=P[K&Y4K%IN)>%T
MYP!">.C#KJA5!'@'58=<VZ"H0&R-<!1W?PK>V#"!@_4%4(;2W*@62L^G9A/5
MQP0>3ECO;8JLCCGRS/:;WY/>\L;X@:/-UIZSND1<I)IY%G<2Z;V^#5:---QY
M((;-EV5KG)D7$"J^LISL')MLHW/'\/5"YMP/3*R(+T9J^/R$FYQ%6;[MF\G>
M2KDD[GL9EJXIC6WODZOO= ASV[A)&2?-W+5P1]2L)S<5C>(0(\-ZD[9#KM2E
MMOU?JIYFF#L$ <*2R_D?UUKLYB=[=3X??/8BZN#._\Y/H/D',/+@'0*?EZ&1
M?KCQAG@^]U/-\=""1.1<9T/F)^"A;=X%7F[$T+$W<N4:"%(K83-8KTO9FF+X
M^>GMA^QWRQ;8 Z\<Z B[L,%W$0PU[DQ\,2?C.GV;Z*BC-$IA)^/Q3P,#8M%A
M!(1N_)O25Q4$#QF#CN7^4O76#L])_@LL;M+SYZT>!6VR_T;-[<*H=]".9K@*
M!LKUS2]7#5GWR,_=GI,WM.DW[U\:;Y71Z)#V;#*[4-3$L?5#^RO,C=).+1%0
MWO3MEP-Z#N#=UZ^*A2."^0R.2X;M186O=FH=5CO=KM\&WLV<1O*5TMF:\,)D
M(J7LR;IAYGMJ\M5B(ZKZ(Y*"XI%FED,?GKU:\4RVT>#[4,"M.I"<FMO6>LZB
M;(BWRRY_!#MN<W%=;[R[<.K+N&FN*)KD/NR)]AIZW7AZBO9Y]>VQ-&3PG3X[
M5'Q=.RG:<N1"L0$!,;V9A1J@^\GVBV3:(Z4JU%"]S(YOEX*W?Z@ K>1"1]7;
M>7SB%@VY1X>U<*^F/#WP_OT9DN?.66$JQJX>O*KRZ<Z8TI1?7YT8PI@2%I:2
M, ">:]?I9,T8XXC=OVCPLNN WI4AWBH]N?ZXFERAR]YW5)4.-!F:=%&C.OA(
MW \>]C9K/]Q0M^SL$^0=Z!?T#J/L+!Q*EE3]L/;P&,NA6V%J+W-,]3T3!A_W
MNZR\[9P961LTL'EL8S5>DJ&?>[NOQ&)<WVC8VG;&>8.0O/)^;1]6@*P;EJ=A
MF'.Q.<<]91C9-><A694Z<4E<=QNK1-B1U@G]AB"^Z_.W&J^"2<2K*=%$ QSW
M4!M)%,G'9JNJE-4_?S;[0 I%X\2WS4(Q.[[ON)4:&#[*@1!R1U\FVQ5I9;X^
MX2X[6MJ[#,Z)CV<,G#J\MTTU56=K7-/@_? "_6E(178)HTF6 7.0LPLBN]^%
MEO1$>E2G ?4M\FXYN9L.7>3*J7IP93+?N[O!8&9'[#&:M55^B8>Z8OJ,_YJ-
M3<&1% 'DA6RUDI6X'+T?]!^OWJ3%SE)+UT<,M+#-(RQ>GIO=TWF^O*R$H[L-
M96OUS8"4;]D&ONE.$=H3K-+?=VRRKSG&LOM**PD;HG8G+1-\$8!HB'UCYV/G
M0NKQ^-[55FF/^RC/LA9SQ2QI?%^RZNZ[4?-*<VZ#]?C]]/12@Z;80[/+K=LG
M?+6F]PX?<Z*Q&A%-AGT\C4$'9\H]ZS[9K>]3<K3J7Y: BRL2L@/ZXGRXX=VQ
MWKSOA%0_^Q1HJ7XZ_;Q-$YVX^AXRQQN4]56]FS:0KUNZ\#V\LGIPW*[]L5:T
ME;?UP,=FL6S:]N F#_3IZ 995,QRK/R&^:J>LOHE]M>2B4*3O+R++PY?UBC,
MVL)*JD[!%_3>;GUZ=$PW%K_?0%Q#6"OVEK=SSKSXZ4$CUW%=3L\GBJ%?L^TR
M7#_P+X;Z"5_;^VJO[.>+ Z>7.TKS;L^]6I_)GG#Z:FUIM>^<!G[YH>UE7)6L
M_TQ.Q^!QV.WW:V'^XS>*= EZ(GP5?/0#NS)*6!<NN%7 ^1\[)C6P&T.>%(,E
MYY44"XBH3>.AW3<^S5_C9\^,R':"\.DL%LV#"2#%BWWUT:W1$JSLPAPL:"&N
MR:T0!+[U&]Z0/K&EL<%XJGBK;?DVK;5C;(-:4^C]- XR=Q6I0 R#J>K2VN>3
M4=L[1>&=WE_4(5N2O2<A#)>5M$?ECBF>)"3'$EH7(W5,DJ6'QK]Q#D3:@1ZO
MP.*&U-Z'H\@2S9[2MOB(4G7_6QZWW&]0W5_7%V_UTBM[0ZD=$:Z1V^K51Q#4
MX'@%9IPC]XS$:FBZDS3U)%*:==/,[LK-)RP5O0C!KW+="WXVR<8_:MU<1^#&
M'*7#UQ,G3RX7ZM5>$<.LJ -A-BV<2^_K:Z]U?M.3N+E8I2=Q5#QSH!K5Z&T=
MAR.VQP>R4XQB,4>?@>$-@9+=;_CJC_J8^#, ONF.5BF1*^OV4&?0Q;<O!B/T
M3Y<=".>\&>?",K\@BK$FJ]3;1$MIH,=0"!]S_]&F7DW/"\%M;Y3OB[;RJLW7
M.GX^&A-O[1FG==@'08RAWO=I;AH6(S_I<VOW%'^7:].O^/$EJ]0^KV^;)"1O
M?RAX6HTBP:<]S 'P'>4!QJWG]M,]-&WGS&C1>#[?&XVY4PE3'8V:U=*SK0HV
M\26/9<?DO,^IVN]-FB3LH*%?-(^AHRIEXR-N+X24E5N+I[D[OBB+6B 9\?>7
M/2)U#G\<ICRVCS"0.>[QHMB515?*85><?E! !KQ>5#H'Z/<)?Y 2>(_XRC+D
MN[O($X$0'?0E[/#A-8/[[Z:2XDKE\BD2==:(>T3*M2Q2K. Y<A[EM(;U^/!S
M3O,CNG(:65;]P?P!K27WPKXI/.EKQKV]HNPWV; 0Y!="DME(,[I;Y*O"?2IV
M)\ZM-/9C^O6::R?]@BR]]Q9"W-,IXHCPT8<1M//42J-Z'/=,NFJA6G('CZ6K
M=WSVAQ3#HWSC=?CS[\)45,V.;!&2>Q84D*_26,!B XJCA%MAD>N.3G'S-<CG
M'%>DMJYA+GHNMG]FIR]4*_1F)I'"[]F3GQ9$7:%<"TD7KA(N[TTS";$RK$<F
M>@R*ACC40GP_W+^W1^.ER>.3#49AXIID@7(BFINF5MJSTJ($GS/]./M$!*G?
MBFR:Q;[')=GH[J=0'Z60]3O68GY8OAM+PG>-]2FJ>QB61J/Y7406FNB;YV7:
MU+75[L1Z2QW.;"B3[O.6U9"7YET48%]<&_1F204VCIJ#%'+[B4Y%6PM3,)*H
MJ6[0VS-H@*_JG7L13-MS?H+-F4/*Y"-WYXT*YWPO$Y]P@W#;>Z>23(KCK2K*
M_2MN3SS=VG _0[HZ5]Q[I_GMK4$UAYZM\"]I3L94BY+3J(] PFN:9??M-M;V
M!C6=U-2MJQ'*>8+K5P\?&>H?+(XYTWI#XNC@&]MJ\'.GD$.;%F($OF#&4W1G
MUW(QAA7H35,R\/7=HO-R!47S0UE<2^IBI[N!<.:#N[M:W8)\KVD'3H7O,P0"
M8O,PMF3Y\&J47%4.V%5?Z13.-3;5Z6:1FL=CLZ_SJ$R-HS.[I+GNUNW?V._K
MLI8KHG9,X:6_S)4&<!B_[2UIK: -VLR(AJ8.>\VV[.7-PX\ID2V"Y#$J*D&W
MD<(7,:?CB3KO'"@'&BVLQ<M)LI(MF84IZZ::^=-MXWFRAS9U:!MN(6#V?"PL
M>,4 KA0(703[B&6YOC<R7-1N:I/$= :X#.IZVSPSW2.*^>@9'J(">_8Y72WT
MYIZ>%[O'<ER,K<8HII624?/0KVTX44,E;\HO<SXZSV7.BQI?:#MXMN-#F&UD
M!?^VT3ET<C,_>A3;G*\^=B LSRL\K/T$-/".@$5\-7Q]Z*'UJS0/U /Y4Z>-
M'Z@.C%]0-9;TO55AT8XK4<(3R,VD\FB:+-'^!@?&MZ2T:WDFXK(#]]-<'8=2
M_).W]+K;:UN;SJREMA5]OO65!E^K0VQ&Y9L7@E;]8H?"0S187H*>UN05?.;K
M3RF]YHNS;UUV^UJ&Z+C,C4L+Q0[;.$B>9\O&G* _4S3:.CW,55:<6&]3VJ=A
M(!]6X+F[.\%4/T7&)G+\R.CA;SCG@8ZBDU5OSS0AF(\[Z0MC $6WGSI#O%PR
M&Q(6B=M*YK3GB@+25R9W'R]LJ;H:=O+CCH/JD4*?W8GHS=/4=:AT-$"_ZY/R
M0W3)_O>*LH<\1(^(&BSFF079)]P+WC1Y7\9[M#<^QQ83T*FUW;;_(K9.A>QI
MUDW3Y?CP.,[?/81%.T1A]!'I?:588:^#:O-NI&T]Y5Z-MY:J%D<X[/P>-NUY
MC A/,B]7"W+4ED 4AR\=V2$@X<F^?<IT@':>[+$:C0C-K[9Y?M$GC1<Y:UDJ
M9;VZ>B42=5,4^_$$6]SA6^@G*H%J)3U:HIB#9I2RI(QV^[$V\45L6""RN*TY
M_ K4YUG:EOOMFYYF7ZID\OE/;5?SYD]8+.U$P+?G*U52>_JT-"^^E"KGH^EW
M;WE[=TG5QN;X,]R)I+OS 8; ;3MEL)$T@X@]C#E&QH8HVMY9J4;! MS25SD2
ML;_+X0S4>6FQ^[3C=:OB>TDEEW#G/$"5L<;\QLE(1;2XM27(TC LYF[Z^L2-
M[)>]O-I>,KK.FJ5=+^TNZT\[U.N*1FKO[UHL7BN/Q4OZ&!!Q<XU;5V,T3%^
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M 1OT+JD0DK$;\_3@>J)0OT6/4^'UJ3@E]IR,9\!M_L6LFOB!$>\Z-.<WG\X
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M]AZ>2M_Z%AMYFU8M-FU).@P(7HK*$4H_UV.<5,,2572Q_7^$\K-<QW\]!F
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M*%DPI1GBCGXJ,+;-L)QP6?*1A["^2&.=F75<Y/5ZUO=E+1/P'NX[EPT5.\D
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MK):@W-L=_O&=9*.]A(N0+F!N=ZWO7SC97[KY_^.TF6P\>/9:X_[7&Q;<3?Y
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M _%VGF4)M?F0W5@[A&4]_&^L'NK18, =[&UM.1+YTN"L98+F#8/3#+Q7%"0
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M:TI@'-G I[T3C1FZ__:]X]OKFC0"FAR+/I<>M*>T+XMZ44N^?'L]D$8 @^3
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M0,)P,]NV [X<(]E178T/*6\3\6G8_?_8^^ZPJ)9MSU941% $!22V"@*"@(*
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MS8W4$%%ZK"$ZGXB\V)"(&$N07TLBIE4-'ZEZXRM%"DGWM6@O<@IM,NTXX?L
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MYE^ZHE_D_BY6+L!+]6M8T-!6%4(6P9;.(N"DTS]TL3X9.M5&#N?II;((TTE
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MSM2N#<O7!:ORVX'L ,7,_A03H3C1(&G0GU8IKCC9!+^ZO4/TR!?;-L-ID"\
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MYM]VRR*>\!@[O1MXAE<R#@O_4F4ZSLO-;!DTS%\X.[QG97@.MB$:LWYH XL
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M!G@A4&OO?ZP.-P +\.>'JE2F.QW*IDPJL(\<7H92XZSV*')B"F'V4AQ(YT\
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MK#JZZ706,9;QA'TMG/*V!!DXRE/T%O,A\7!W^V.WQT0IM.73!A-:N@>-;4[
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M))06@3FHBE\<S*^P?4)6IP*[=8:SI"[<K=ART*OD5S2F,[Z[Z\1YZ[30@0\
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M/+QEMT?IK8>/#S)?G( -)-4:2\?CZ=;UHPLM[";.%,?'E^>9/N96+9Y2+HD
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M/;0Z-D/U03^2?=!A1C4\ZGK"Q[H5G8FS.=.P1VRX8@5Q? XF$+FS1NCY7-H
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M_1H]G'QT4YF\B?ZBMWTR_DF^OMY#VZ_-=GF%;W=EWF"%#( A75S!;*Q X:D
ME"Y1 OZ9^)^)_YC8BKV^&O:Z1ZI0NIC7,/&6T=!GHN^L57&^?6/2$BUJ<Q[;
MU$E'=+FH8OXT_FH$#:(*3<Q _\$ZW]F8-#"&W34;,2-76K2F?F%$NSU@OJAZ
MI(GC8>;Y\4=CZ]DP0A>."3M]&PIA8DE0H+R_K+#OC*Q&%8N^U!=LV^KM9Y/2
M?!F,"H-NKU+%I$?,G1!_K15#-%G*N1:[R8%>NC(!8>F&HO)E#P7$\@DJ\"6J
M$8IRF6!?*W::#T8ZA&[#SGMT@(^@('R0"O 7_,I)^6?=?D&/IU3S0M'O Q0I
M]&!DFQB0BW]\D<((VQ"TVZYS@[;ZBEMA828S(2;A\QZMX",H^_56(X>5_:Q8
MV,]*C81B40#) SUY:QLVYGODWGY9O\G\NZ3IE,)H:,JK"((L%7B.OGL/M;(/
M0=Z!^N*8]#<*R"!+"7LCIA&0H,Z_";KW/6P%RI";Y;<G66LP@/8.2!OO)\ [
M8%,;>IH+3:+#-LW^',*Z?G6=<EN2.3, B>(.A=AO"-((G R'=B+T'\\++XI
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M^BT-C7HV\1:YP&I\@QO4#\U54N,"1]?.NOA/W> ;\B]BK36R81"'WJ.&KEG
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MA2CJIX_9C9W]6/;J=F\/MD.='*DH*DC'\JA%SEA Z4NS4![@HTOBYX+^QN.
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MF2RC QL2:J$BWS<1^C>Q/D.Y753,5MR8([G2>KP30CJT<]ZOS4^< GR("*$
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MKP,TR/V(5XI1NTC.N-V3I+J5I/(-VI[:EW4;R>6OA^,DRL1BE47ZSY/;T?"
M:_@[,P-OQ8.LNJ6)YMXK=:-&;=/MR-.I@_8:AH')\.BKJ-@K3"KU^:V3JT$;
MVD@3@E16)+7=\.W'JGG2+UMMK9ZQ/ACBEWY1KC8GJ<;-?:>.1V1!*:4GC/DZ
MVE:7;ZWK*8(]8]R(Q)1P\ZMHOA!7;':9I+FQR$<5UOG+,W&G:$Z%;0NPC ?S
MMYL,UO+ ]1P>5&&^;NH>T\J=[ZTS,E45^)[->97!$2FO5$&L+Y0\@,Z^H"0\
MK"3L;HK9'">U)%EBJR*9YQ.Y<7&-W$'%7TE0"$E0?J>BLG\#5CQRH!9_?_V^
MWC/<Y2NZG!SH H22H)2MO%OL*D/ILC.WVA9^QT4RAD,8TY#JQA-$#4O+?%U1
M\N#TW>30<_3_.B]-<7LKX!P*()]^U0#6N5)9<V'@Z$LMV0$3@D,F F0NJ>84
M3U*['E@4.Q\%?6T+YD$)H_+(G8**PNI ,4>Q^[;602HQ41Q'/ZL_4N&O@-$@
M.'%RC377':\V*K/V;"@,):]9)7X>M?2X$5 <-7+*[_:!OG%D:WC7GJOSM .N
MBWPXOY',/="$>SP<P80<0X^JW?RLPGGH;N@D20XG/KD=L#DSL*%+.R]OD5]5
M.F8R<DY#SG=%/0_P,T76.UWP$R-=Y)PCTCOO"<OTDELQN-M'=M!^[ A>7J#,
MZ'!9=T2N^Q53'L4N\<\31">2PT91RS@=@A7/OS:\VLS+T>L^DF#;<;/=%XA*
MT7M\N4LEOJT':@,-XJ))<\B<'Z/N/H_.,].D;I(-17,S/>-M>:)\?/\QY070
MD?OBOGF2^\K!A.'.!C/IQ%D#YV^OZC442S^/9JW3S'0E[JEGE/AR3CD');(2
MHIP=:4.ECS!ZB]B(T\.N"!XKX!"TR6#U::P]VHT0^-"<_*/R06E<:A.GWI?^
M@VI)(4* ]_17VEC$14)*[@(%8"(YY-J?3>I *+EX/7!T3,LR>EZJ)]E4=%<6
M3%)Y2]H0G(11\9!JZJF1Q@D1R&&Q\&13>\>,'1$N<]W3U6CE&?H#D1V!,::$
MUS8U/J5/<>N-?FQ%-24];CZFW [CA)V@TSL/)@+*/1?\2C[4<O<,*#QO?G90
MX85[\5L/!DWZ(/K@_LO6@$\\@!-_ABRFR9K2921L&Z'J7\(]YJY\/5_"\:%U
M52Q5MC=._PG4K; .WS+>E"+ >;!*FWGJ*MR_JUE?4/9Q?0K!H\OH^%6Y^#S!
MK]H":DV/@+7![T&=WHZUP1G#FH(OAQJYV^A-*VY3N=ER\$-N5HU0[:48[S(_
M(2E-^BJOM%[O$7WX<&4H'GX_C#I.P&YT0:)%_D S (<V0"(,N.;\$>X"<!'M
M[E3<5@AO6O8/CUO).:.*QS7/JQ\),KBMAXY\:W4HHG\8(8H?RYC2UFHRT4ES
M_*";W9QA\EW=-W76U"/4[?Y+K43-JXE2_KE,- Z]#Q&BJ7:>[*[#=J4#:Z,M
M46;2+L"#:^;/\Q8.XJ2&4W!= 6ZZ-".=-"'IIO-1VD()_"/IHYT+R"Z6 [.P
M(PAS- SNT))XJG_)C2.])U_\O #Y<YEM&,KJ_(=/S9&?/<*8)UD[23*$K@?Y
MQH0R(K1^H)+%P(]'^['M</]=HEE^1 >'^)AN''>DD,QJ["Y/8%Y:9ZYLE+KC
MXS7%[G-/"J6BS:*^E^K8"U=+I5V=]?+VK?2*Q7;C F:?'3QDL_?N1#.P_^(2
MC**/C<A?QL[@,22!1-XR*EW3OIZEXIFRD"]U5SXG)<!WRA5M>BJA@6#F'I2!
MPS2/20X4$Y5D1?F]KFW+XMXH]UB&<,2%%/YHY'O4% T(^(OT2B.#>3F_NE75
MR.EVY^7EBM6=&!$^+4CUX51BC)\S_3P[VV#LFMW *O6TO^F;>(E2&X"Q0^&=
M\.(/8:JFAU [K;VK6TX#U=[GST_B>:,JN3L5MH.$;:@U./C,PB/"PP[J7,YO
M;4R4QZ>7X,;-^C$?\T;,/I;'G$]ZJ53L_?K6,E^#L@G_N#PP5&^V(3.F/:G-
M"U]->:5=:KOZUF)>L2#D[67@XXH:[8Q).!?F5F+?@1;$:7S_>!.:>IB0[,"7
M,;^;PYTGR7;I]=!'7OUV_\L>G ^IZN[*!YCG&?1N+#J*M1Q1N'A\N.>0$3:(
MK^36Y;J;"@QWXO\+=P?_Y6(^M%>I*)1%:-VZA_=-?W6RC-U@D7J^+%!+NJ!9
M4C& JIL*BJPP0A4Y+^OBLE<GX@)%Q1#FR01[HF;/A\*J7G>%\F6K"(T4NA&J
MJ&J>JJ=F<X]6HV!:AB'PE"T1@L@4SWU??3T<#VI$Z/Z:S/O^YF0IW@PK2?[I
M/26'VAA[G;B"/!\AMT'2B?:\*Y7HS3 %0WO0"K4_<.*!?F=Z:Q61]2HRS%P$
M&0LDPX]X!17/+*\'Q^=)1?11[WBU&"NFGQ>%$K,K, = O]S:L,?HAJ2W]?!F
M2V2:8DV%BXV/>4"ERJJ.P_.CBYH&PNW$5*VBM:8= Y+.'?7K'M-SK'+T_ :J
M<UHAXL@= C35(8[7(X6G9-W?0Z8S6>/VB7<'A[)AN _[BW,O=X+5)'4W,M#[
M#FNNP^W08JN>S0LQ]'J('G_G;E[0$/3[Q\-O,/0B<>;LA%M_^&Z8=NO.\B)2
M@3@$-4C:WZ<-+$,; G"8/2KI<1*[*ID%^=MOK/.W;_UT]S=?D^ U\8K_%?+J
M97FDU=5[F_:03[737FB2,'1_TTTI;0I0[P:;5/_#=XL85=ZQLG5,37!_)I*?
M&#6+^8.4D#])S>+C/?Z%O 7Y#_[_[^-W&48VOBE^8\ MTFMS,#R'I_J*S*WY
M)RX&%&"2&44.8(>A"8/:JO='G)9^:)ZV<H7B@KLH@,H+].!/D_B5D;L,YGZ8
M*7,9EJ"_^=^!COT9^M ]&C$,;'^"_L[^8F#W7; Z=NL#:PT*0 =&C V.RCWD
M_MS^.0KPH7EPD2S3N_^XC\2W#FKS_N+FS^L"?L4$_(?A_W\89L[A%.,.EVP:
MO[.Y&*7%W.[N?OLFK03(U&WJ:<YW,F9*Z[< *NV%J=[^AIKZ;P',9WY@LODM
M?LBO$!S2DY]<0OT*?W^]UB\(\N-#@5GDO\%W_Z/YZ3E3M2F/[N9V%4\[Z[EL
MS*;]DVSY#V.8_*IN38M?P;Y(BN_3^=2HC4O8RLI_F#G_4?S4<(KADI_=C5]D
MUMW/>+3+TR_^CX;[W\U/4Y%9L%"@-$=*\J3_9TW(U:K0N']6?_\/P_\P_'_-
M,)[,$'_M@7Q-/<.%JU8!NX.W5 &][HW5I??RW+I2G6OKZU.<;4(94X:V/S_1
M^\M+9 8=#BEVG&O@L>]I6W;:A)8(?.)TOJ'RZ%N+;/PZAN"4@]H]8$$!)D#(
M)8-5P9_6&>X(#Z1<Q_LHH/M1,J'8&SG4)D8(50<=A1RM#?51:<.&<=RH(73C
M8 V8;J,H@$,*F3M[COS$$$, !5AV[R;GS6+6Y_"1.^\PBQZ:H"(@.^<Q.R=6
MXD4FG7_/;G\?OGY7,!,7&2=Q4H"M2FA_]2 900;3C L4P+10=Y>. K0]H "?
M4&[=L"/(1G<S4.?TVQ2 !KF7'_D'8O_F&[P[&HW\JD[6$B=?(Z:'$DQ_!]#M
MCV0VG64H  H:ANR #BR](OM#UXR1:T+_4T'=D#E@*;)#LB3?(Y=9H3:.48#H
M=@H0I3R?O+\M2M!"!=A?6%?)#!2 : [Y Z4]TT[D7-<49)UYLTH0O"^2% LC
MA6QKL^+*2')WNO8 -!)G0P&&?_R)T,(86' H(SGV]Q?*&Q+:.X2<+J0 T[J5
MMNA S&1E/O('M0\%"("2!]7_2,E@';:S3F@E->XYM4%_"%" TW$4@-^W5Q4A
M^B=#_)[2;AE8$W6A6J"SD/^8]+_3I'R$6UA'=6QPT%+)LYJ*WL"^@\C3:9*.
M;0*<4[T]59$$-7?=7:;.';"0984IZ1U/D].Q[U2 1FVZ95\IN=B?OLHI.)@B
M;R^R'UQM;H,\E\9?(?&WD0U2V<BO'LYM&$)VQ]?YS'P;\K'W^N2 (C^PA&X&
M"UBZ+UF@D8<P9R@ -I,J/;D"]5M.ZB0!^8P]6FM2 @4(_< 4'PK&=<Y^Z \%
MN>EQTAT(+FP!M<&3L.9,/O?D[WD#_V']']9_R?IV2;B0?D_Q4'Y$D:*_(N+#
MQR\:/)X^7VEM5!\;F#!E>=H<FC)]?ZT@9WDG0E(JLD9__TW6_YV2_K>R+G?T
M:]7O?CC@FFMV@[/!D:&][T1B;7^JHE3V4>:MGTD>Z.TVZ_HMII3?TKQ)JZT*
MYCB_@OJ=&[K,(\/:\3M30'\C"^#69RCU!TR_%^= [ZW_6W@7R?CPZ&J5%X8M
MLA_W3=9^$G2O+*K+POLKK>L_!^/_1;P9/2VSAA<-2H6,RBWE5];E+E"A'Z[W
M%%. ?Q#&?S9OV2S+K/GM ;8YH_*7WVN_UK]QG&9Z.Y=G]Q_/^'^:M27Y6(TN
M.: 7.06V%2()>*/V:-/WD. _%X3S=7S9MOJO:F/5 GVM[J=LVG?)L2V^1#C;
MTRV27V-(Y@H2ETY7*7P6"2\IC";2C#<[N"0FWJ["O.I'$]0VQ7>9M<'Z$7_[
MJ?26?*C(&Q"&,Q@)/VR,$[;_)(2-[G]GYT=SX#V7U7%%=19G^A!*6.87!L/6
M)1GMTZ/&[:SUMBA@XB7=#_6K)E?>+2A<$<6(:KY^[>FA')Y<>Z]@KT"9<<&P
M="MVG//A;$5YU+U0F:"Y\TN7;VW[1(N,_LLA0/=QR;_.UB,+FFP:T'V6'/H^
M_^-OC9S#'_%?V(-NLP\S9=G8*,Z9OG]VJVAY)^@1F(5<YG%D?35IG%K^U=$J
M5BU6;33VL2;TTJI)WQ]7=!_ MRX?QE^=FFN@ "<=N,(>#\^/,R+JMY2NC^N6
MU,3*#%<P<VMS;WZ'=_&6+$,+5YM>1(:B&)!E8M5W'+ [)EL:VLOY;W;A+^B#
M/]LF0"]\\3RH\OT2MM88O]T H269[*76"HS;4P"6)%QL6O*8"OTP(;3GBX]K
M+2NTW'BFGLJVZ_,%D]K*/=2&*F[UB>HS/X420B"#H8Y WQ+67QAKGD-\\C$Z
MP%EH< YM<SRKE9DE>K8WK=+;89L4B:JO[&G6T:[5]HS9W:HL^[ZG>STY5*1%
M^<G^N_/_XMUS_E>O_RU;>?RTK-H1OX@U2,,-UN^Z_C#8\E0^/>B> &&>%\E<
MD<UR=;V@*WLW54K0;E;CCH;HS#*UEI6WME=9*SK(DP*<0$ RU).[')RQVK3&
M!7B:EX-?VA]N&Q0=/J0O*2+9RN\<_E;EG. G6HY3G*7*] 34! 4X3O#8&L$R
M#D9*O\U7#/>Y@6=]'YX91'-%M?EU;"Q>LE*#??OQVZLI%[[G4B4ZUU>VAF%L
M'4V;Y;\D3.7IUO$R]\@D=-)JE>'V8L+*#)<=A%XI=3:5Q6[3LW1$GW=I"0DT
M[_AB=*C;F8UD00C))NBUZN*4DW#Y#2+E:(1Z]F)9Y8-%36?>(\;&K<XR+5LQ
MM0;QMY@^-;)2?SJ"FM@3:H$5C>5@P]FU<6)I4ZNT"\.=LU5I9G#OM0;N')K*
MN"_EI>41:]C1ZR&):A$:HVT&PY\3#CQB5L*S+U/C3]0/Q%8FUF0./<6MMQXC
M.+=&S6_9\:2GI5FH'"OI:VBKU6"XOS"@%BY8Q_\P]G+)(HQ-T0M[AM"+JYI<
M?59"TSN'*4=9X!F;'JE+1&J4W$P7J#$21RE^;"V_]X2Y.&LV"\X](3I6,P$)
MV0)UF%3@:XE],-K<4F"9WM&K8NDT4#!L.J(N=8Z32Y@O[*U'NI78;8"M$&HU
M'NBG@/L.>L]0\KFK](0!4P=QAF%I.9%'P3<^OK#7X3A1_%WW='/CV6FOYW2?
MXX'U3JHIYB9='H04X3"*&V8;GQ&&@.78R>>CT[]]XPXN#2!J-#TO,FT['K5E
MI';-BT_WDN!@GNEBK2A!'9]2;\$R0#+WG<(PPGL4VAU,\ZR_]' 3&:^,L574
M^6CPA4Q$T\WLF"@MX -J I9AI[\J,Y&NX<0;H4_>XK2WRK+A"LV[I7G9\UR.
MFT_*M<" 7OQ,)URFR44":O]L0O,E!_ZEJG<*W+D%PJE\@0!MVL4$N8L'6_#@
M'&LV!EXNQ'GH+\C%Q_0Q/A2\71J+90T2%GSMOV*<>(.C(=V(:J#:*\\!O#<B
M+1/NV1A-*#,+DMC2YA(ISU/NY;O[0;KG9<&'+[-.&G<<LY<#H=)PTZWGA. ,
M<JN%$'ZE=M@B;6H1>A1FV[8%I^M=3I.O+W@>>,#\PS/Y4M,YJ\CS(R$R&\Y/
MJR$Y<$UQ]COX+Y@I_4M7N1U>VN$3'MKP*;<YT'A:V?BM5DI$N&+)5 3U*1[V
M+1O\>* 0;B78$\NC:S*8OUR,/'ZAO'?U5$6?3;STFX:Y@QKO+-\EW=68R .<
M"3 +O&XC+#R1F^"+A7*-PG<'F^*I5S(8MS(>V#EZV7G:B!9^^F#2S(*TB1%[
MG/2RLE@\[E&=4(5A!XS:C\:L$9^BB_].9AP@'4O_X<VPJ_0^(Q1QS3U/;]9X
M^NF[G7'[RB&'XRJE%TGC&.G.F71-9(8M\(<53W^Z<F$<R$\5H /8WX1^H#2'
MO06R)F9. >J@&S(?F"\-8&R[& EL>V[<1!X#AW8MN%Q-\2UI&S>-J4.?F-5X
M*OOO[.56\^])+SN025<I0*O#W&H$=.VV.W1WTH8"I+X<A#"/H9N+Q,YU?"RO
M[+,KL?VL:=>M "F_>U'K?-/=S,%X1$^8Z6".9M'B@[ULQ3-[TGLV/Q.RO[.7
MJ7A^[[Q,)'&=G0+PH%\GY> & _3#B^#+PA1@XLRK289\A;.^<WTOB%KP>Y5&
M]N/;L^+D2_KBRYR3I?.6V11@/!-#F$&T,5_','IM7MR6C^B))!]TZ0I\_&T)
M->9["E,L'LQ--BO1)6Y"P*B6Q3Y% 8(3TA(S*(!?"@68BEFO=K>6Q\8]-\82
MP=!<IW/IT8!%);1Z]["?X@]&"B#F';>W&TD!7H M$_W'U^;!%&.\G (0*G$7
M%SI\<V(M!&S:E]4IP %UZ7+/@V#+[>=D65L]R0!GOR>HZNXSM-.;?3_\1'JJ
MU;B7V!VD,MO55 QY"8I38[6VD26P7K10[TIR16E44J+L]X@:E?Q<YE#.-/KV
MQ8_AUWT?YHEX*8RLPJ2]"!&0QG*,U3#26QF57*0HEQ/N<[4(T](K[77OVX6+
M#WVLN'K1\QW*_(GGPB18WD])Q_MIF_O1SJT'9 @==BJF%TZNI/O7T_=+: CR
M$YOX[@IF]XBA!L;-5R0!OTUZ>I\"Y"^"24:)VXMM]9XG;'^WX.C?"X]0[,A/
M5U4I #IRH:374 J[ND-GB]G$[QF ><O?O0#XS77IO2E9752$7(':B]_?C\1Y
MYV0Q>G<6N64_G_D_[=;[B_M^/RN]OX. (E\=9M_SH !#L97VOXG(*<1KR'&6
M Z=9(2@(Y$*&UXLJSKFT@SRJZEO/*4 MYKWP6^X4>AKE4)MWJ+&D=-46,X:-
MV2<C+AOZB.;-U/43Q(:G9KXLXQ+(:N%U=F(?P\..XV<$)PS?DW3Q%(#$;^ _
MW&U@;C#MZ"_19K9Q'QI7D=_:--PGSQO@DWE]*&),@(^W?)FP07)HLL3%EN1(
M^YWM<^9JP2Y,&AN_UG!,%GDFR'OA,"<K_IUZ>%-OVJ89B^F[WBJ8M1(,;=E3
M?ROMDGQ,_ SL+7NCL8SO$>P-@]V<3TXR1Y"2E^=.%T4?\>9EYJ'VI3URT)>(
M7X8I.IQ83&3 ER2F9:NPY;DRJ%N:D )33EJA2Y$FF\Y4")T>Q /YD<N=SK[^
MVM6-C'5SM.786L]G^+X+B!UW>_3[KE&]<5,[O[S$"#N=-,^35PP-YJ<]66ZI
M^F4C)O3D1J'73?*RQLZ\3Q\=;4.)T24:M)J=BT;& (^@[.1+!-A$?C 8\8Y:
M.,9>5JUY;627\?!$(*RA]@@!S&.I#^*WPX3* QH/,P=*YRZOTQTWLUS\"KG7
M^2@:WK,X%;>LDFI?*^*OM7QNT4C+N: +=4[A9M/#+5I.J,E2R8O( XA;O7Y\
MMK%(YF6$>"[<0^%%I\BMGKFH6)S*F9YH$0H !]0+2.0JQB=I@:]Y^1-BEO;$
M$!X"%W)"YL(/KZW-+\!C:_#ZS<K\C?9C9_J=,Z"2U65,%2N2F>HN=7-CA9C)
M4_W+J:J1QC'7!%=NN=UD$YB=.);8&+_5R3ZY&KB*M G1<^3CQK)VYH[QE]6V
M,97BO_-[713$M9=/<3;;PSW)QS#,)%G"8SR"MQ!?FI+=+-$O<[AZ2M#*C-7L
M]92"CE?K]2UR07 &[E8-*FJF6OE<\G:VR<+<,SORA7YIGS2X3,Z/!(7NO/SW
M.LS6K>U]CQ]YN\DL\%+M%?B=A1]?G!Y,,"W67Q]:N'YR*O_ 8J2+Q5/7211
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M)!R8A'CA%5U]0(L]BV9\!""RFVL(NL)+M&J'7 M_UTC_0:'M!X\(XU7# PF
M&24!2$K8ET7W_/X._F4; :@=)H;L2$FHH15T@Q[< /I&1J]M0I'^Y_3'?ZVX
MH! 72JJU@LYCI;FW5Q$C83D3WYAND_GG;[,YWKQ!76>1"WMSEVZ^7?-4M)F[
MVY&>3>PAU:0 O%%!H KK<,80U.9D9/SY9ONT1/N[;F$6,NY%W;+KI?=??T!Z
MF/DX?%E3D!@D ,]].!OO0ZJ.'ZH.:$ZS2"/NA/Q\S-&YV,5/X[L-OINPB6/
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M%?]M^OP0UGYB[CCJ%?0["G$4"-T;+03]S"C&/PLE .-@ E"&ZGDT0[5A_(
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MG#";2Y,/%^3\1 ,>5ROYJ+;8KO@*#)1^5G]86(SHJARP.C^1WF9^O2/@G"I
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MGQ)Y^V2K74JUXC5M[^@_N._F7 LF$!<2!T73'E/;VQ5Z/SG)&#V%(R4 =XT
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M!* G8YO(.T#U3TLROU#US=2*..^=/ 7^SR=.[D_])^:4OV"U5X,!7;_&_#\
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MRJ-2HYG&/#SW58DZ2\T0JG:(VM,]+K^*A1<80Z3:KCLZYH_CREA2SW&%KQ.
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M7*,*E0]:,U-%3\VL8+W0+'NCZ^ZKJ&$IQL/0< 7KQ'L"]<<DI.@<1-$:'/L
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MF@:)@Z9%:_O+>=]G>(>D%6[X+5#/;K2FE8?4#0%G$E-&UT B[U-X?@#\28O
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MBWUIJ !0,/5*0]YW6TK_9W.&ZO"U%>C)G\57X7TL2FD^QK/$+ .%\&R<G;I
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M,JZ@(#?)IQ\%:BJ5S(QY[@NBEMSMA;5YOP&K8SHO.,G3Y9-^V_3/;W\F#)%
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M1-_ZX&RF(ZI)SK7'YX_0^H^,J[>L"*S'2J*9FUF<%R-$F49>)BSYUV1(/9%
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MO!R)$4)'!XCA'^,,%L\%(%?L3J^5+3-<L;\RN^F\D5RGD\^Y8I,P&,'_TQI
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M]Y^V"#8;*-<I5_79HBGQ4I\79LV,'WD(U(Q2!W^Y9RK!4$6>E6^9,H)U+SZ
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M[^2L>%@%PZ&&%= H(L"$=FL2D>3?F^Z%.G(9EQH2[_(PIHA:FL0^^%8WS20
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MHE -_%WE#U]=%DH]2>S+#=N)\3D22;\'5G<OTBQ1WO'U(P*6!K=>!!G6]T/
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ME&3@<,TS,B KAE[RA9**&4M-/V48?_+5:I=;[84#-6);SF.E9(!T@I6*Y+%
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M*:6]/.I->RTXU#DH86[K5AWL"\<.76::+%X=]'U^4J&5]^&6M<RW61K'=9L
MCLP&8\Z&^?](#7<A :]%_C^CSKL94H)Q@<I7U3]J>X?>]A%ENS'Z>K$A5IRM
MN_AN!GR"?W0)?P2J>+,USPE$2S_/D6V/\27\XLE2 X[".FWF-NZ0@2/P44KL
M-'Q9=:8$[$P!O6V&Q3K=K\>>[;9T%Q.TM!)(8^-<U;@^DCU ;?&0 S.9G3U"
M?_Z5KJ,"[VD5P6J3C6]:Y>G5"=F+;2?-C&@?D>PY WNF!H^_>[OOMX"3$F$9
M"$.%C0WE1<4C 5%H^#H1C)PYS>5%$)9!C[V(;Q/J#1*D5K$Y+9QR/.0P$Q7E
M&1')]8RE+TZT-B/I1Q0?9V4]XT!MF^365R:T)CO'5:&-NRUS<GTKLNLPQEK(
MZ#)S]\!2%DKB()MKU_ ![.)[T6?V2J>J)=*+A*,YY,\X#MQY?.9HU4V9A+*;
M'\7D&&^'-VXK=H\@\$*PS"E7",N)IX2KU9N;T5T:5'(Y*W!Z[-[["9G$AY3P
M*[P-#O3+C!M+58<L/BR?V;AL8&;[Q4A;I+3HE:!AMN7%E>DC;[BB3[JD2+;>
MGXX2=>M]^?"T:<#X\H'@0J2&5@=I:&WF7%B3FEF9_91SAN=CYM\4CE-.EDT=
MNYO:+ZK>,;*9);"+(W>VQE[NKLCN=.8 $;N(<J<UY_!_DYNT4L0X58*VZA_(
MMA"U%]BVD]H527SY+]%ST7!H1IF6V3.C='N$HD@(=_3M+OB>G3M]4S\DX28+
MJ3!S)4-U[VS2A8.*ZZK)/Z>,C.]31EA18#>;/#-=DY*H>E$<-.-Y<4",(J'Y
M#@AU8$F1\KO$O6_G=/T*=]V[PW\\PHT+M^*J+(KW9JW0O3Y@R/)F5!5P$EZ=
M)IS;0*W1=J.Q$(P*]&!TD6+8"&VT.RO_^$4S7\@9GJ0S(:JR?A/H47XL(Y%*
M2)5P!$DPSZ?U3_95D>6_Z=IU_RZ7J&$=."H*<?K.,Y4,>"GNM*X^'^XD/=G.
M)%' EC,-H/_F?T&LG6F'8WG@RW&DDQ@*L,WN&E0,)Y&!FB(RD+/,&C%$!O9/
M;:=#^!#YZY[Q<:13;JK;5+-HW'ZPIM3MI]%(G++[ 0A\-D-&V1>WT]_Z!S&9
M5,4M-/O_$6O(!2E%XTVPG#:EG615MP+#J2S O\$@##5R8K>3]D?*YKU[=/3P
M)\IXU1-]'ABLW&P.^'9%RA>2"?Z'3,B]9->7?A8)@5.6HH)NE#)"-PRA&R]-
MUA\L<-$377V[SX.7";2__ N%@:23K12HK<!O:-PI&*[WFI"TF)=\VC6PB#O(
M2@-!@UJ?A2=W++:BT/]*3^_0G];(P-:Z_\Z6_?T9,K ZQTA<X2$#N;P;B-XF
M\%;B$$H&2N969E">)FJ2 0"YT^Q\N#212+F.(.R#CR-D_QK'3:KL) /3/8+X
M"75B,N(SJ>S^.H]'W^K2[[X([OHB#/NV'VR#WX5LP4X27F/<8(,PNDP6B#F+
MG)>&DSP>0#6+/*P_#"\X-P7[.P:ZW9"G^UGEKD?,GWZG:X[+X&B.Q/M'C\>J
MLOMM\^)I5:$J1PN]%'R]_UCTD,79'6K&FA?2-8X=@Q">?N7L'7QV(WS4\AMZ
M=3(-,DWI3H>S;I0@8<L<CA.T6LZ\\Z,4OHE0F9.&V*Q+\RSU(^WXS 524^4F
MV%NW$L,^MH$TSS#/%@[Z7._Q3CFA@J'\LXGI PKFD7M!YIWNU$?#RXZUWPN[
MH<P:?7W6U><0!2Q&ZS1#='J!3A4M_D,F3PKW72;*7)?!SV%*=]\6FWZ\&?VP
M_'90W=OOH<XK=_4?8OT_D0[^[SU"V8I^Z$,&_ 7'K+:G::$T^FEOGNR97C@$
MCC7AWI(**W=6KM/@>[,LPJ@:9)G<_NGK1F9*]##+DN#V%*JA$+5WW5I^_%Q-
M 6:]&1ZFV&^*(%16MGLJ['1O2"8-W;';W>XK"NRB4*V*/=?ISOYA\%%_=;_6
MS ;>J:FAR;:*)R7E:5-3%9!RF,/K@#H61*ZILNH,J<;K->BTJ--TYRZDY44P
MM&A::_\:=K>31^YHD.+9SV7<SDZWEQD"/ZK$\9=L9R!3^^<8-B)NO?E0="&K
MZ;<1UN>I(DQ/*0]P^:T.(485<I>YJC6&?UDV>9(XH*,WV^\VA/-4'G7\T- S
M/&/'F^(=UJ_\9$5 H9N9*_@J"4VCW-%+*J5U&NHR,CH:'.NU)AR6@?M06QEB
M=MYU\5BR9Y0Q.ORM;^QL$R5H?Y^%8RTSVET?ZU\EH8_V=Y"+TQX8U.V;R[^,
M^]"S5N^2KCNHV\2?U@\4OY8ODCG,4W9C'G8QM8P%=\(M37>F5@V;$/'>V7-<
MNWTI@R )V:C_;)2DFUGXV SI[H$I,\,#M$T5<!274#C:=XP,9.+N%\3OK!_X
MKA,OSUA@[(V,RY:DG5O92FZY>.51GI?Q6D7PF". $B=1PB\]/1I1[M;.CJ-&
MN45^*_3A#4)=P_?9MMA=CGB\_I!242=[-./&B,9&/A9]&PM[>K]KC85%&<$V
MY!RTR&YWZG)N<RFQJ9UFD8(,:!ZMYZ;ROC#N)THJI0Q#V'W#7+1YU:!PN<N>
M546 U,<\9W @@;#/ZBBN4#A=]'IVN+GJ246^4[E?3M;'943E-5O:?:$]&]B^
M)G5Q1A_Q!4-ACJ 5&M)HU;TPI&S#<5MW6-':^&+EY.AC3TM'W7L?1)>36_6Z
M043O>EL,K7Q/B[TN%IQ^CMH^G,EV(G&3D;1%/U=4:7H=#2G#!;YVRD )H?B:
M<&I=*LVJ[U2CZJ(@E/E6.O$0E'7WT^$=EFJ7RIW+LB%]BQ]@,CZ@QH!_]R1T
M;3U#<TS$VRGCZS?,_4YTCD#:NKEN.^E5EHO9&;\6SP<4G+* VT::()VSE<ZR
M[TN(UXZVKW*/W./-7S+".<MES"E7DWA$!2-6SXRNE&C<5#$SU"H7=FQ5(/9T
M@$Y> TKCS#/(S%S)[\SPUCW F:?S78CHM#!Z\M@[NLBF0.7S(+43<J%J;:CP
MR?3TE]9A0#-U)F^E;R;/<55EX^7H4[&)-V2@4>$ND#\F"P^\8S3I]L&8GD5[
M$/6S?#QUYX?2E)(?'AT3EDWYHGP!H/"9,W@[65NH:>3VQDC@X/7U?27(ZO#/
M"-F/Y?3Y_1.AMYY<DWQ@@7'+>5?CB:PVK<5&5)&!KY^^\NKV8]+3BV13^5NF
MLK5&HD2]0-@2=3*GIX$N/H6WX76T>4L#WC.!_CZS=J'6AK3T _" NZF#UE?0
MI-9'#9I'D*(SN-Z[<2XA,R)!=]_DW+!#WC<PQ@Y<0\GCG):;E!/EXQ2%HP79
M8JCCTL0Z\RXVN!>:W!ITG5A1<6#P/-R6RRLFD&&_'CZFU1U#F#EXDTKLZ %W
MN_P>'DPQ5-/'>TC3<-_.-\SJX]ID64GI]WEO%=_7Z@3:T(1]+&(^5U!H<\8F
MB9FOZ2; EE"(P6G&LD SK X9P&R!N"+'W%$M8ZQ&^GLSC9[@],F<MEK6<<F*
MT_*\A=D%R]'$*^F<Y@\?YW=U0S,QZCK>./U]-U]U<Q?\X5-VB<5P/LOA.*D,
M"O&U_1O).3&VE0;9>(-(-ZLDG<7ST[IUK$['XMC1N-[7P^Y,7>N!=#.:11^C
M&389\L[;"2<%QRNE6Q@,N:=_H62A.FKW5.9^RWS0>'D9:TG;V[M%7>?R0O"W
MHLYS!+4Z!3,%'1I5*_82/WM!E?6FI$ELQ/UV5HWOF?/ZM=V.B#@'8+>-8E94
M;?]_WQM45'A9&"[;X!P9R+ F ]]P<XP_[Y::>[;1H)YY_O7$/^RGROC8D 3_
M<46H=-R,WF'ZP&O/&8E7DAJT/ZT)B8Y-5Z"HG=$U(;,Z>5&]FNE6=":R-CSN
M*<<.TGLEX7_[]C:JHC)8O\]RH;,]RN#1;M>G8M1NPZOFVT8LUR@1'3$U8Z#Y
M9DP(XW%AL/9# )IC^ZZ^X,A2);\-EX=(#XVLQ>2%WWJ*7G\^-,&J_HEP8D:S
M8<&-S2DG,Y\/Q'*1@;K8CU.)F[VD;3J79.(ZA(*\77H)W()0;FVC1V,O@3O;
M@VH&E)#C\H(C1F2 H/_KZA@\#!R!\%.P-&/S]Q[<U=OXN9TUQ=7,GQZ&8=^5
M0-CUB@8$X^K) *Z($G6" &',?2#AY;<*XUN''/8[#7*O1OP^'/5?&5[V71\W
MSMUM856T*N%M 4=EG6E)7NEDX EDFF5[L.(I%D:DT"4#E%P[^W#'W!57,@F'
MR< *UX>MWZ5E^T[$P($,'*'^ JX=L"(<1>UN2](Q>D&6/H+!,</) .,5NS^E
ME@RTM8UBBV_GCI6U^%4K[(N 8_11?*\W6*&4ZH3-G2;MYW1"8^/=*3]2>IP+
M:?N8)'I0SDG\</;44.#@.'V")Y>S\$LNK7R.55*"*NE<,?<#7G65VP1O;ORU
M&/L(".\+(06AF ^%@.][@U5(U)-(G)(P8IM^"8[]E;<+/FJ"$R4]W2 #FU/0
M<"1..Y8&4E@IFK@%R?PR(S-SK)BTW^T(-%^?:B0#HQS=X#?-$DA]SZ'J1E^7
MY.W62CAT8YVIC--9!A1LZ+X?T22&-#J9M]I*_7SZ_<RW1UV>(MBN4'G8P#ZA
MC*S$2'.>?4U7U,.O7%*B7,X %UQ1J\N>!SQT(M9:.?XYE\.D5EK"*J(!F0U!
M.*G>E71TCHTT&: @:D1$CJ"P(8_0:[S#X,C5G3-HYR!S7BW=T9H;IF^4#,2:
M;ZEO.(/34:0[X,,Q-Q+%NHZ!:6L^V]GNP*E(40([HY?.L*)M9:M<@8 S&Z%7
M=^=,I1K$A23TSQ=H=JHHO3V/A="X,"'9\SL7A<9^53<L'SFB0XBWSVI)G,1%
MC+GP(ZO2E7)09V;,1ZG)P.6J\$8+.I^I"Y].4,J'KS,_7NXO-532\%7)56 R
M#I0E)%<,TXN?2(+?"'6PKGE[Z_5 L6>LU0?]EKJ/AY(4C7:Z.MAVECAZ/NKM
MH%SI[_UE2G_<;F/<!<'?^\M"(,"I^'M_V0Y&_KV_[&W2D/KOC6L[$'KS>^/:
M.2C9NGUO7/O_"F$Q.!**3P:G*LQZ XP(8S4A_+2R3@;8!N!4!!4RH/>>#+0O
M=]/NP?\Y]F?AU?_8M9(G9?]U&;)D+P?I+G)/9="S#-6=?B_)P)P?R(/*:ZDE
M+=#*;[$I+<?5@T?ZQU1N2?^&4+#'S-L'9JC4]#*I<]4'QIHH?1.?NR-#\_7;
MZ<>]<^\'!K7YBBPC+^9'JE&<NEK-%(9?O$F<=^%*I'._JV^E^73\-YGCV=UK
M]">:A)ES)SLG@M0)-QPGC\12FD9W>E)]R_IV6N&C%5N@U<>L<*EZMH*BM%"O
M OT50.0 )86KX4?7K$WKSRHDWL86*&^-*V%.,%J5DX$P]*G._#\V:%=O=ORU
M+?O7;BYEQ')OU<+E46+-VP,+/EG)>HCXE=IC@?=Z+8.OIG34S<8?]V,ZJ:#Z
M3CC__I@%UYV@^G0'9?' ]12,K@*7.D?>/,7)E%,%"8>FF>AKW.5QVE15((.S
MSI*ZR[' !#D/UN[2TOF-S[^9:(7=>1.IK.!XP9AK_XGR#![\AD>Q5<!E7!2#
M]UK(<JL)H[HSC6^$V89]OJ[#<U]D '(X9?0%CUM+@G]8>JM):/7IA[Y-3Q=9
M9>6K-#(WF&\9LM1=T<=912Q1SCU[1:.7VY4NV%31LS(\7_ZK#R*[X;.+[;&D
M :7^RK95 ]KWI);-,K9<[/QI>U>1V'"-TT<U4Q]]W+\I(FIB9BPF6Q+&P2O*
M@;7FS<%=A$+^-L[-*E-7?\#,U1-EY\B9];DS_G*.DL^@44Q<(,9.Y"["13:X
MU.?BM6)[#^2U+A829SZ4%QL/[T!U7>'^_HI5%8G*H^:%$\$5*<A;JH!F(D:4
MH)P)S@VK$O?WOL -R!8N'PNU.)#MCC60LVW;FJ*55HM.?$/!X[+_#-L=S;9)
MBQ0[\R(IPMVW?IXF_;/A'=>STM?XV>6G]VMW92'QN-8A,F#^4=G4@W5,7KJT
M0>_*-"_?)2H%YGG9\DRN4MSMS$<Z[CWY.M[1O9<N%%JH!G,@-]0I\GGH'EQ2
M4*)ZY;EHWB;%'M<:7^NY>9CN).+120-B^%"^HN49[I6N$=/%B>AC6KV%AY4:
MFL]<"KC5/CCG>9H,/%2RP+8+#219"'H.P".$FU3XS/%OTR8ISTL9.;":M\N(
MZ.(JX+X1_!X9,Z(,9.#QYR9KLY":@;)NALZ"ED'*IPKBE&<<,DZ-TFXO^<#6
M\39DX(- *AJ''Z>FQ5UU8+U<W^792;\>/DUJ1M5O63XP?.GX6,J^? (KGMDZ
MA^@K%LR&$3G9:BB)PYYIT^G\A&N?KW8^BGK\:H+QVB>'!Z5?9,S*-\LS[&JC
MRK(2<0.59O%#B$]1K6J:64%#L>U3*X?SS/1^!;;><0]^<1B/[I5+Q.4U;#A;
MC/L1C5XMW!9 20AX]+T"I.M3=39?I+M?_M@,NILR!)]WT1FF>O/!2SOZ^7YO
MX*3J/9Y)SR(6^5EG0C\Z@*9XB]'@K(2=]F6=F^U*&^'=GLW,Q\LTK7U;5@\>
M.C%Q(N:=9L&7E;?. :,:'OY3/!YM7UF\-EK,(PMPD:-S+@F*73?9#3BU8N+"
MO'ZK9:'PM9E27!%0;1%+#X3IY/:FG5QI[ALU,3I[S<C>X4%&0!J%AL;^XR[[
MU;@^"SG]$<K[_^K+V/]GUP7P/S=_N@F!;#86^"$IY3^G@9^6@4S'DR&4)C^&
MV)YD)"&#4G_:H'T_SPTR_L,J4>?R)B$ "9$T)"ED[UV&U_&4@:!=,#1-!(!U
M71X)CLK$_IT.1ZYQS1<EO'S]BKX.<R5U^1<?W3:;JC$/*\B_-2MWJ&M3G'F<
MY[(V)ML396IHF.GQ9+[JR 9V?W;G5 YM%M/A^),IH>P!E@.O#FTFR4@[=U9L
MW\Q.G)&(]:<?+N1$HRR26YT?:[2+GB #L,/XIHE3N;+I2U[;I3W)[V:IG<;=
MP--2E[D1OTAZO+S.<<W8^K3JYHL% PQOT.&<*-5%3 (JILST:;_SZYPB_,8Z
M(</5\6$S)_UXK%=AG-!KM7U3 1WJ5ZBC+BO) P+0!W04B#MFFDI=1R]N=5*;
MW5"X22E2^22V>PPUP 85->_O@UAN"#+3+U[62X\IK:Z,JPN^MEA_>M&$0ND+
M:VLN%/G8;'O,-N4< @>5!GV:)FP99Z,>!9+F(KL"12)RI/!XPRK,&I\@Z0",
M=#;,(?,4[T$('NH[3Y-D('V?,'@"P;3+T)S^3B9WYP0A,0R&S1;Z@1ZBQV88
M=")0HD)I,<MB2"I<8U49/4@M2CB+,"-5QRJAQ^<S8\K$;\.L%VK?QI(!I^%B
M#(.[P3)752 C?A_B8$8HW:;(2N[ HX,J3\5#Y%:V#,4'@DIG83CM*%,BQ7HF
M 2 #\TEDP/MM E39L.OL'+,D-92XW)M3TE[5M2CBM!P*BG(PZ_!_SAHJR=3H
M\NBP-"]U#8FY<-G'Q[[.0:%C-%Q>5"S_%/4;!:<KE;:OTFOFCU_?;W\N&QQ]
M:$8&U@[WPK' SA^X RO:.B$'/)4!CE#L?)$$>%]S"S98KO&T^WIK5]EQW=G0
MZRN/LA7\';?#XFUT4_S-\R]FUXEOA5X\JF#CU73)N59[M/2 E'BBDF6V<%.G
MGHJ+C:0 YI*97O$G-4_UT"_U7RA#M4!LCA 9V-X_A\(!X,Z?:MW+ M$;,0':
MT5I0;035"ID4U."2$])>O>]8_[1Z_6R@9X6GJ32=^]!-&G,S3VZ4'EYU _1Q
MEW?:,'./+"FF7;?*U37;*EHPAK_(>!1R)R;EH5B]2K_ U.+#9I.9_@X,QJ!/
MV=@C :,]OYKN<,@]&;"^\>J2[:&#.0\#7H>-9[F^MU-X6#[M)\[ZZ#GSW[HA
M\/?>^>^Z?4:T%K[%X<D)U?$7P6^XV;W@,A=>*_C//\V1]E7%H02[?CJUH8%"
MHB>,P.UQV(IPY$_I!@O'AL")-LBMT\B<ECZP6*[=4U&HG2.ZY.$T\>/!,,/K
MJUGT\"&U\P,J+"K:%9QTQ=!O8.\O4]PSG6>540SO4P9]'O*]<^F[O233_BIN
M,)IB4=[6QMT,6XU\MA8(5CDECUY,.FR(/Q;?%\4\QJ%*<>C8=(!/B^31M73P
M!=MAQ N)HZ[\U?,;.O81ULW._$;.D[%,&/#U9_:#2#L>]R_31Q1=)X4$GV0Y
M6U5IY(?K='=%&<<,K4_FQJS6.TA(#Z64BUARV"Y$W.82ATL>>YW;N_.ENZ>K
MKS:^F8>J3 GL\NK%M+Y/@0OL)IIU- [([*-!M&^#\UGM5+&M 6N"S+4NY[Q3
M=&>S^IHLIMUL;\0_R[O.S.K"3$5UL*2B=L.Y2ZA@K5@905_+%GG4]=?2)VMM
M'8/*"6$K?1RK<,>,U(:%!X>8Q.HR.D<3*_$8BHS/^1(YHI\0>B_3YQ^GZ_1W
MU%\1/U'3(=,QL6CQ\3;<03.Z5  R(09[K<LB;H$,[)];@D_ 7,B P0KX[5Q)
M1^FE-;"J;)54.@'E A67& ^VNUC5KE4;7<4I.G5YMT0*Y3N]0L13\\_42GV:
MAEK"\\8TRL,UQ.ZH#T89;[ZP;Q8@#3<L;DBZI0:XV.2Y-%K<NLZDICMYX$7]
MB-T==^-1//JDUM>!OB%='>E28NF<=!/_+U8\LK^HT4<P\U#(A/FF.^_;K(ZJ
MCDU,-I UYRP6,F,M>:PC]KPZPMRROZD^5]?YGD02551]H;U"5@!_JB@X*H7%
MYKHA%QY*A8%\>;",CCY*9MX<AL&#@_OLGNBFE+^^]*JA\M<G=>P])2N"WDYJ
MI:4-L\L>1=0GXN.(;[9 H^,Y>AED8+W 8B [(,"0?EA+NS9A9B//AN&B[M57
MOQJ&YM[A;BT[<$<O=^IJE%\^+]<'/YZFAGS8"CV$J8G>]Z#TG-HC0^ML>JL8
M0;]EP->=5E*JQ>MR0@=U@1A%6;#X?/4I%1,399F*BWPMP;L$JO/O:\$W'FW
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M_0.2]+V(:QP&YU1.>@5WC7E^CD+=[+D4LS$2$EBQF?J!/7D;D-B!R>BN?'
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M#6C?2(EAQ/VDQ>K[XZ([ Q>5DOM8(5Z_$4\28!<_V-)GQLDM_"G!C0# 7VK
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MS&$C_$)(+%$S'X)A9(*4/!Z&\0VU?1OK=F4=@M &E1E\BS%T"?RC5U1[4:K
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MYJ&3W ]CWIJ(OW,)2<+4:S*B6GQOR#6.]TCV*[VSEX#_ +HOOP8>GNS/.!.
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M(7+I+9K6TIM'BUE>B"=1!^.63GW^(\!7D"R\T?LS@ )0L#,'(VH2 ><6FY<
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M;&2R.VIR+!'*?_(\U5-C4@)Q47S_N^;=\@R'=Y^^7:=D\^Z&7@M11K>HJTP
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MF049W.)G1:4+6% AP0QD9S!N_I9)USZE<)-\NKO[G\" A/+M9]=ILOGN#(]
MG301*N$DON:&T<()T4#.'TZ>_5(9]C(_IGRJ%9[P:QI0<J0V*D&JMK',K2U4
MQ-<3>?H3?!.5>Z)2)Z/@B-0R+2=T>+8;#^6GR U#T54O7D^JI21WS*MSL:LU
M7QM=W3::3/UCYCR5;B1?^?-Y8/IW2L<<YDA(*X"+:,]!]13Q8VP;/ [WV481
M98GWV+',73G!^\\)>9QUL9X%3L$L29N[6$I.2Y[F]!40YM-LMXVWWLTNT[Q\
M#B%'7JOM%9\&,/;B]4@@6^(R2*S3B,3>.)E0^L-3"GN-HWKVU-%#:(ZG><-
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M,MQEK%*;$;.GJ#8I[Q@S*C6.47%TB:;NA!?-Z1QH/NBG6^=A>#7#3*Y0WQ,
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M&GC>:D#.X#S0"&VSQFF>B_QW]?(_96\<HP*TY&YG(TL5J"BH2L6:GV\/RB%
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M]$/UN$QD:B?=YU_E[RZ6! 96JN_,[P<ZR@2SMKW@8<<SY/%PZ0O!SJSU;(>
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MN<?P?Z"?O,68(=98/,XX"J,O& ="TMRE]A&:K= 06:NKUPJ/<$IZ$4,ELOY
MK[5F]W[M!Z2B)#[  !_14 JUAPCJ->+2BB;F$XE\\5 06[]2K;Q6#=E[DG4F
MNQI'<HKD)\S$?N0BA2N1O-+B:H?,3,4@^X2Q8[SCR$U;O_>U\;%\M]>Z8^-[
M/)_<FOMDFG#+H>-<95-\&#9;$H51RV696#AP)HIP8OE#^WPX+"2263*H1A4^
M2S :R0'>!EM!<_-"'L\'MHA [Z7_A@)!S":C@88>9V\^_.L8_2/2594!,W/1
M&)F?N\B5W'@V$+75%JOF!Z"Z=[5-0LY?3D.8W^)ELB_"E8[V8J$EFPOVJ*29
MF3[^.6H)J=1>G]88VC+'K8%R.1N]/Z3^,RIE[BDIF&IG,,^D6EGQC+.U2T/6
MPB/A961:$5*<PN:56OP?CC2%F-#I==A,\'"9#4U445A/[F.VGB@!5)[!Q#I0
MKJC^P,;IY0=9E'C4-/L7NB5:BAZ?79 *?//ZXMLL0O2Y+<%\&1Z=^G)"A$YT
M%R0"]G:RG]C!YHZXD>G?CRZ<AVPI?Z!=?1]'K_.8)NH2P"E=L6NM4X.;#"^?
M=9(AR8P%JGACHS;";=/UO=GFVE93U_U>/DD<Z!%)_J3LLHVX!$Q/J>'6UCZ3
M6/!W6Y9-EFH08U7?Q]9"7[5$3+_N6,_\X5'%&+,?E\][XV>[-6G(G_\DVF$\
MPQI/794CT$@3G1!R:]RVT^5);]6'ML2!!]/7G/IW^H0!=EE2ZY;P,_CH): T
MKWUT8;'D-!HOV6,EB&OIVJ?<S.7\#<<8H-!<10I_CU%ZLR]'U96^F]JG&US?
M-?;F]+!FV9,4@;K [UI!P.\FC;7&>6.H[\Q:U*"2OF<1M25G@W( ?,)E'A64
MUS4&HJY.Q.&>Q3LK^)XHJ2:?Q4[T?C@2)C.*_;7P[V46O_*[778-3O[XD4O
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M&2@I)DTMT$TH/Y8-NQ_/3_ZV?H2G(=*@+F5S_SV]7XRK(?$H]HE\9=%'D[N
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M++R.-:#SMJ$#4B?>%HI4"A[]"@14 SWOO5H]9LY<SIF1,AB!RF+BA-T9!E7
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MS^:KQS,.LD@)ZI?=4S[@$ZB^G<_#]:]ESG8OK&\)%W@@IB_6UD8_PSNZM9D
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MI@FY/O[Z-J#/HC0B\>*@E-K[OP_]R6)BCR[RSQFJG)O2\@^V,Q0R'?/CO&W
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M]4WC?]*;_&8K-N -3C,3/>O:FF4=G&+DW1IDM\"A*01@\@IF+2=N7U7/L<3
MM;RC0J)K/;JJU$WWB<$[1/!;P7K5ACA!-G$-(9,>']C.Z6/?VFH4Q)T0C?.+
MEH_<K1BJ<'07G3_A*,PK''"W4T&GGSUSEJ4M'XV<3[!ECA2A8)BY'+5A;<%-
M-.''SW7 A2V)6H6M4W%RAN5R)P<WDK,=I$(>+7T\O$4AUQM,:MFW= 6@);J=
MO0HLXY8T>#9D+!'GQ;UK=K^&_LNNJ*2AZH:[1L;&M9)$FN,C.H+4VVW$\,&9
M&#9OO=WUT>#1Y>G!FHNO%JS8Q+IR2>J\U*!"^27FF\ZP7]<J^ H <$\O.I[>
M7+O(5Q5J"KZ6+$W'"P4E\W-;N,VTIF?)+E0^;J6'OX4$]V0$R86RFOW)0F3'
M("J8\)255K#9SS%7>;-0@S1=3I.,WRO5V>:K]P>X7O*P)TU^CJ73Z'XTZ,5#
M2F3G#94\%_1.WO0U_#%0;' G)T).:UQ\ UR<K)[&+\@L*L@KRR*!_6AZSHM+
MN]:T2"9X%=O\CJD,]:;#!_,MY3?5K)RK9A;N]!D[JKVLMKW,=.RUW_"65ED2
MA>OU/_!V>F.J/@[+@5@58&T:P:>N?K)HW-Y:&1S^>.?F$$3R\;?7KKV"2ICJ
M%I$S+:)BMV4LRU1<Z0S0ZK?7P\JBDJT:](Q5S'NM]AY9&EEMII190.)S.J7
M_9G0,\T551N53.OJA@.?WN/>MLF\*)\']5UKF7(M,N=ITR<AXJ]#GNLQCUA
M2>$@2HA^1SJZ;,%\,]%%83PUPLZZQX]F5)KW_K3),_^-!UC]75#5\6GJWJ'%
MK@-1D1"2@)'J-J3?M+Q36>"\/+M/M^AR=NPJK&_:0B5?.COW:$_-Z:M#2GQ+
M"9]GYH(<L;5L"\G:(K8<='-L:$7;]3FW2B<K2G1M)2/0_VTX)24?%4FGT/M?
M'ZK8NH'\2+K@FY#0=AL)W *\DC@EQ:"SC+T)HS>W[,B/>3;;#$Q-,SWD]6Y
MO.AT??DMS,:+(@KID'-S)UMZ7%7',;#263$1\@D2?< F/[!?.V]0/5E-^46'
MW78@[=5F@6>XO*7-PZ:+*\"J/AJ$,CQ44E)W<N?J6+[@[;GEA-8N699B6%S8
M"M".<:7I,([7'5M%#P@U]_=MR-=SR,<]]8\)MZ5U.7](O"B#E/885C<UC@)?
MI!CQ!#=-U3H3U&<6A>_<FE,[3M.SU'<:0?P9U5U9,Q8#MB-KYQ<C?%S)IV!,
M$OLA4,72.;"E\*<FCWA(Y1U99HL]U8YU'8:&=-M2_K/F&-?2!=6+#,/X%D7F
MUFZDJR3R(;9KKZC$Q=*\)1Q;^+%B:)HF=$"Z\]<C/UXI=WZ$@H/S10#L-_+8
MQ=?=\)IK*?(A9QCA%-SVT)"UMLK.0//)8$5X>@$:/KBV^H.]7XOQN%WLOM '
M@%"2C3KF"H!6V+'!IW=(4/QFV!Z9)88:-<>8M+A2#LM_A?,[U*7=8X>FT\$@
MG8R1I)+O:0,4X]M8%\!XHMI9QREN%*JSK,=>=[9S!JKOD%$EI[)K2 A@I?NB
M9&;,KC'\PE-5$$<&<>Q<X,"3G9ZY*,/#+JM*MU]R:C NSH-R!3^_Z.E_0OG#
M;/V!4<JW%"/X?%=!NE<@AJ*[E71Y"GZ1%.A0Z9)1-$U7ZBIG( E$ ;52!OR?
M__[ =#PL$DL"*9]_24C$*61Z.3$>_#4>7ZV'MS1.'IV)9 P8AJR2NM[YDW=A
MGGA+A^R#AFM>1C_QXY(A)S%B17:;APUUNX/%&/)BJ];%S-)V\?$0ZED7,[13
M3+1DH>B._TEJF!<%X?Z(W/"M+533(QQV\K."<M"G/DP.;5?I7"[Z";]._9?>
M[)?*HGLTE<WA2_\-WCUR/YV\KLFI@$7'N5> D #%<ZGAFU> ]G<+[/?!:E#+
M[Z,B$[#:.V=DB@6ODLD;ND>&N'U7!(5(- 15ZQ/P;7N\MYQJP>BV=-[P'%T\
M2T&QC::C$!7']*(FC2/=GPX7V? >NKD/Y#=\<G EL-'C!TCX<RDHD#[::S5H
M6%(7U'LVM]'7O4]H\K2JS#N3GM[)D")H%U7H*>0()U1N'I8K+%NG&S?K9RVE
M\;$1;OPF4WP9_[GYFJB.<@YYFP.]K]'S4L</=P7 U,?A.;8O^[MG3<:.51ZL
M9!NH6U8'JH22A7UZ6:IH/I<'" C)OT7KZ(3DJI-BU"NK3RD@IAB/'QU]*2P!
MYP[>*3C4$DD7\JVDV#=7,_L8"H\4(G$I^LT;2H7[M&WLSW-;/P8>K2[;P<-N
MP-4;U1"J,,/5VUD/07_? +QM[(4YN@8L+@_!ERA;H*]QGY+T65+=63ZS;,_;
M+#UGQ+R1VE\!93PL%A2/_QVE.H(=274KTKKF$H9E\Q9E>6"F=< 0#&L_LJB3
MKO=Y^_Y"B\T[CR^L(I)?^#\*KG/%>Z0$CZJQ&E#H(Q$UJ/UC[J?KF"%>^IDM
M8[U2\:F-BSL\]$L'-8J,GH>25'.RH;A# MB0I(?*P/#IQXBH9;P8>M-2=&M*
MM^^M:RS#XQJ%2?5 3Z$-I4'0I!KY-N%2R/ V!-R5Z'0I$&,\49D,G)?"^@ZZ
M!JV>_%2U-;F36K'BX-&1^MN8BNGHLI5U!]:\+W?9!L/1NAH20G!I*1C*H[*/
MI953]=&$*\"9@F&-<XH5F;2F'S]O4])YYXFNBE\EMI'9<H<0CRNH(LQ*9".]
M>%*+N?G7(O02"X:^BT@'Q<_'D]7L]Y"N_>Y[$QIO>T8PJVD@YBC&\H!HML>W
M65G2FSZW\>'J%!&+3B%W5Z3 ZE]R 1BA.T\?:/=9O6VZT%R6F#U_.'4N[UR\
M949? F;-R.,.U#WSR;O3-3#T)IG^/K6K),!C:4V#K>#_;D%[J%Z5<TY:Q2,:
M<<G CR$M<AF@0K#RSEP!9@XX\5> 9Y=#Y-B3%?>C]88H=:?%F[-$?WF5&*E;
MP'F%4CG97+44_HFTDQ^R^<+_9=M(LTFK>'0(>46YM]$8^N.XV[@4HZ5BUT>
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MC@>J\N4!@#\66Z%M+:S?X\24!56DP"[Q<9&9I&A]R_H=7:_A)8,*E[C)$Z.
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MPO#I ^"WZV3[\;_:X;-/^OW3,ZRN*&,2D)PVL@? K_U\O[6I>T*_;FEOG@=
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MX8"%6H*+.2!ZH[$R.L[,:SV/]T\AJ)!=7BW(:6HB=JM1[I*5BVO4_MH<A^Y
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MK!>^[<ZI#K*&/,7&,DFQFQL8>FFTWRO1U5Z5V9J[9X#7/NVM8^-9]#O-,O2
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M*CN_$+$A,UWK ]0@\;.8.BN)_&ZS%%GWNI3=KM>"V4W\8VW&"N:F)F\[J;>
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M:^*)^^FW9\$#LM\(G:.$;C6*V*20RR3OJO<F)L(@)U*5JIK)WEK.07),0E*
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M"X"_,VM60&68)AT3%D*"5 G.S[%RA-"/W?JB.'^B$W^==65 [U,8FL'WUXQ
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MDYR)+W-Q5WG6E(,CK8]6=BP-5M=T)9+#ZGMD>@>:_U3_42%R)Y4CDX39UDN
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M_W_$XT'\M\&SC9>/7T 0%D,4/J%Y!RP^+R\L-#\L,?QI OPY@D^"7U+Y@*6
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MO7,MC-[1V)C:?B_ 7H6O5^#8F_/X5NYTL0&(6O-FR6$-F"$-T+@_30MG*5
M+I,L]!A*K?Q9P: H1F_5*?BSMOQ(1.6<MY?R(;?B0WZK>Z1YUE"-@70KT);9
M!B7$,JRH<CFE,TT.^I(KA3+]GXG6G2\[[DS'#&XZV+Y6*!]4"S]TU<> %0CT
M^ #^E(_ZRVG)0""%+$K"F[0R!/L<GK2 )DR;9,5Y^7<UAF<NYTQ$++S,#QK+
M.![X57#]]H<_R7"Z?\'%@H0U45AE%^CK%H(OH1%JKL"6=%MH38<;;=ST8.;5
MD!)"8PT/"+OX%<H&+;HW3>XJX*/?/:4U8]2QA1 \Y;4BBP&=(SX>^VDW:3$7
MB\P9)L_&]:*;[(QJ=E?'S]V<OV*B)!!U%/44KP#[OY8[%%O2?+J )85S:&>@
M2769\IS25^!,"E<9&Q"&9H4<].(-CC:9.^U@L_*\X?.#7>=D^5PQ_W$)GE,
M7!B]I;2=4X(.<A3#?IGK0^VH=:)TD^S'5#N3/?(J;R%R[7=35.,:!BK\A6Q^
M'R);UKU+<!AT T O G3(N=M"#,I]K-^=53=[9,7\!(8?6_QSE"&8J:_3K-:1
MIYNMQ;PJ%%23H>(:H4P.8O<'_&C7AXZ(<IV*6+S [%$,QR)HBN=O#:.2285B
M0+]!K@2DQ.5EN&5T:4"44VU3T?JI/K))[\/<UERI<9O.0T93KM=>JAX<_#(2
MF;Y^K2Q22 [/AY\M$>VRP)UC.'8_4B7AM<'-G$[DT_,8;"M)20=DS8Y6]F,W
MA2^[GO%8I&/6)B5TJQNM?RR_>W\44N6*IK%XX6P_R@YF8; &7)$(V%M%4/UE
M_'Z</GC\NF!ZY[8(W>E0CN)Z[;K*I4Q@_KU:<&T>K2B<(6EH^RY;Y"=QUH0K
MFL+09W9#4BQ'2'^I;HT4 S8R^R!GEGGHID[+M0)C&!>2!A8#LP?##O\,>]K:
MT9[3WU&@.3I_R^I@E> WETJV]"I5[A;7%*ID7N84F>DN4;*5=$&-#XPIU/8U
M79]ATH_&@UGQ1:S5(D]'LWNWXX0-WHJ%BR1E"UJQM/\)#P34S<EO]!?+0B9+
MGK2E+00/QHB0PT6M_O7[3OZ2%BG*LYLYHX!WW7?L;?98_7?EGL&O=>Q=:>78
MZ_J0^D8VVR7 *<SS'#3S+"?@^ZN\0G/34S_&[_\XZJ9GL.AJ/A*'[%N([]M"
MB '4W_KB/6#P)UM&24I836=,8/#M@FN#I(:FXBN*Q]0KJI?1_2+R"(X") ='
M5@,G%7^$2Y:O9$NMS'DQ-%/P.L'.WIXC-()\D/B%@%>M/$]:4[WINR?BXO*.
MU4O:5(R][+&8 5B.WPH!^N% UKXAL&, 68N!\-Z1<^<)CJU'W">7\@_Y/YR/
M8\O "=?G-F)*XM/ZZ?:YA"V3Q14:7T+/.?84FW/:B'YJ;>- 4$D*1LXHE"ZY
M87V[)VI)P3,P]5*+FY-09TKB'?+I)U]42>6VWXC@,0JD;0 ;T:7+)$B>TG=*
M_%==)@:)%P\AZ_=U\ 1=3 TM?_X=[[)FA5!YKWJ[R6OG$WLYA6,&"'S%ZI'W
MN;0%E8T^I3T?PJIU='2?M'5U=3ZZF+HH[32J=JMOGTJ56OT>A+#13Q,2$=)&
M]B!O<;<S!/N!68 ZTX_*Q/.!(PO]M97+1'ZLC^SDEWP>%BV@(':_UXKO=DOC
M*Z>%=SIAZ^#@3*[!Q3-,N@'01E^Q)'73Q!A</<+-J8 *5\8SFZY?F@G]HN4[
MKI;KF])Q\-TYL,^M$>@1,$/3"&*P5HI X"/3W@/'\QO8AYHZ[A\KY8TQ-=M4
M6X:R?YQP[ KB_0@$$N;<F D<N"('?MM"!&-F]0=XE_33-!9S;6F<W(4_WUL3
MFFXO-&D(3^WWDYY3X-NQ_?-H,O?M%@+TVIBU9<[7,Y0J6%IL=:AC.:A3_:JT
MDBIW"-23?^O.ER*1;Y^7M3_S)#\?^RG18@M!)7/B^[C;8<":P\^7;.M$_$"F
MCF'K,.T.05',(+V:3GNCUQG6K"H/LF?NP,'Z[1TV9DBNT"X&@?D&TF49<S\N
M:G)R\:+?B]4?8D=/> .>)?T"[W^26JQ_\YASFNMN]S*6;HSLQ1PY^-1(V?^S
MD. O4986]P-J._$R*N4.SAT*?HR]>[*Q=4:_*9YNT-\NUAY0%A@?:&!U56QZ
M@LUH>//$]R6V3@86+Q.V7"C@BX34!W-PA\$-9C4C]558-53B4'!VLCI:47C#
M6]?)4?O=W6 %WD-7NKH\_[I-D?53HY';1P"+M JK$/*CGSZ4^VY*,20553O;
MS<S'7V=VK=C7#<&TS&TM!@9X(2B*.0REL2*YO5T6D/,22GC%^&],UR.P_:=C
M"W&J-GI.-%)25C[GQID1G8*HG;1VFX7('E&IHZARH!Y%+P<CN"(\++/O0+-@
MMU!S(TTW?&5%7&/59\+CO6==X[NQ(16;OCM)YW)Y8_<NYGTJ::IDRT8Q3W+N
M;"%",>+X?I0"[O!RC<&@CV%G8RN(LR(Q%!0O+,PG% JF,BIW/&^B*/_<)8+J
MDJT&>G8"$;-H:CGE96T68]D#<A9,,K-^NBK7A6( J3HU9.U07:?Q[J(AVS\3
MQI*J:Y<;Y"ZI9X9'2,!16X2F/G2EM JRI;XZ0T0JUFENR:1G9SC.C19FKR;A
MH'[O;(:1J*6FRX+8L4N#&I[G;^PY8,C#)-#U813U9'J X7>7"?*05+]\?TM]
MW<=O+2V+<I-+G>VLF$_?^9LL[/.\AX=5:OVV2PL$[KO1C"72'6#,(7#N$_TB
MR,@>=,/7P1(>G-4D.XRAY'"^4^+)=ZY2TN^8X' ]V>F]Y?F+M&4W@Y?9+QIN
MVZ%C\@A9L,/%MQ AHQD8T UYHP1)O.Q(.'(EBRMCG5VLF/3ADXW\8);KO'5\
M74.=<)96>:;,GQ.ON:4B>3\\ND[!NA)J.ZW\X/5'.4D1.-5R\LJ1)HN#8Q2'
MR8TZ\K3HB\2E4(/=3B?KW_C:)#R_)/'JC+W01_)1M#-;$;Y&'(I80I--24##
M3 97%.<$ IEFWI4^B] U1SFL+OVROE\3X=TC)[KWTD&5VR=]6\7?VO$D6I0P
M6,L%)&"VB%J020Q"9_VE,&-3S11*YU?^+GP\]2X?M/%.TG?+K6_>$?GN;?D=
M;1)P 9#$^4&C-((,VX;3BM_]G2O/H*1P35;W?Y??%ZKQ@W(LF]SO%Y#?*E;_
MYYGNH][;<SM.S%BSFZ]U,PB0GB=;G5.-XWD.]!BR_5B.6#=:SS2.-V'IM<]&
M'UZG:5+VQQ<51I KDIDAA3NX(K3I=/F37EX3]<1!GLW*9+8OK2Y=:?L$&Z ^
MNJCH:#O]ZXV1N IWG&0;&V88JN94MEZ=78TLD_GQ&@Y4@!DX!9M_![>[$-T[
MFC%#D67K!H3_)@K.0@'":JGS5F+<D'=ZN ?2_5=%<V[U90@(1 H.PW 4K$__
M&L6RPW<7$!L"^\0Q[QB$[AJ[8)7#_N)JY-U?;.MQ7[]('/3R],6>2]I=\M!M
M!*\!#2\[SFYRMW_BE',/8N6HMQH9VS=(%"'EKI+>+J6.5.W5*A6PZ^:/N&U.
M? V(SN,6@9HBPMU[4+7H!A1;>I1YG-."BU^B)!,%.B.JYK ;W5&&/@=!9&:3
M:(WF^8D30Y\;[2,B,[UY;U<LZSUWM]S3\)5R*5?%)M]-Y+EP@-\-P6=U_1&0
MB1O) [Z;*5=$D[',%<V-6^8HV$Z964:ATW3Q$M_E(D?BRTC[R''.*Y*=5U]L
M)(T8[_Q0GONNYEY0MM]:"728=XG8KY^, 6V0.<7ZD'5L5.BS^6 /?%Y,0H#=
M'7+OIE-S8X?O+9O5N(KLW,WC*1UG!,.H *0]L\9@S"RATRV4\(,4,;PJ+CRK
M-_;I:!]7"PHN];0O"][<<ZG;2)3UXKS>$]'4N<N3DCLE'DYS"7#$6G**V(Y4
M0F:Q"5B<LISU&=*L[(]AF-J5]$I]_WLKHUUX_5).35UGACJ6>N/MXIF8Z'P#
MB8)8)5V8& ]A';H796&(U<#)MH'FU?N,XKT]MA!N;1F(T*PO'VHG B(M?FIE
M'Q?^5K]WC3^>2*>!PSU*2IS<+400)=-#+UFFY=42)NEZ?^VK>%G+#H=3^[80
M:Y\'C[W54_->.)'B="43P8=Y:<N6+J&:P >:325C$,822I814N1[^\V_L<R6
MNJ>6E_0BRFYI*9'W?GIHYWEY_-':"SFUB#=[',)@Y40@P*2;DHYI,A_MB4C/
M+U: , DO/* NAQ&5]X>I80;ON&/8QR;QM9)(K1^,=21A(>[^(0C@BLUM(>[9
MKF"8YXU*.&J3JQ2NZFT*> *8D[F7) P1D\QO/46N"+'W\D[!=; 8 ,]MS,IQ
M1>+*L'7NG/Q.AQ?S#M1'IQ50DL&%W&RFW+4[)ZK'&X]_-=TYN"^9\^VA7^9G
M((0 Z6+6[%DJ^.EB14XZ7C5$:=]4ERKV^=?33>--@#@44UN>S_SKDDD>>:J7
M^V3M4DKF 06G)8V+O)GL,2AYZ;445P@)EQ[-%8PDSMJPW;:[CAQUO*UK:G&G
M>VE#YZ-W=_*LJ9T>=\*[=]ZB.'77.G!%*L&?_3["L+<&87PTQYUBZ)\R[C)@
MC/:;*_3[&+7FMIJWE,4OO9"3M2;F7*9/+_8K=%X[.R:XBJ:7P)9,XMP'+J S
MNH0@:Y8#%CU8Z-/,V%V-%\LZ/>;;17 JB99XW=XI)R9K][DMTU@\,9_?05DL
MP6]Y"T%W*<>/+&X;MU"&MA TN9SP,*/7L:?'K5O2_(+CS!]Q.)^,7<^<?!:5
M^&5^5-IRK#/DO<G!3U)_M&#E/($A#K<'8)[1!WZMEKJMQ+*E=R>""D>'5ADD
M6@&WTD,&<07=8L*6U61B.,GX?9 JE4C7I%*4OOOL@;+/FBD$5WX[@]$K-["7
MMN&/CT\[E^M?>.A-9+F.2+[33H[]8\K"2N$Y^11F1LS3$4/?)_6OL87GD9OG
M>]=O;B':WYFO,O2YVY/@2'C*[:8PS\ TV+'0"$]>(;_/+3W?4EF[TC+M^O9;
MSM78(P.)CWI5\B\*N#\XM_WSC=V%B"'H!<.T!\UOL1/*6I;K>Q1N;D):E!G7
M:TZ(.E.P/N?AV3?IH/R[5W5W;+\!#=7OR,N.@MQHQ!R4V.\G4YVF2R,BDVYC
M&\O?S2OZ''0<UTX<>K.&K;N-IC8>&>RAD'F[ZV$7&ENHX2<M=D/^H0Q4;^'3
MFJ4$P)MAU%+TZ>.<9H'?MJ;W'85AIQW<1;(S='^Q/KXW">C"P,7-"@BCVRYI
MKK4N(R'-M'[Q2.%.=]#4^W[02D'&H;9QO<"[GV]9!TCIR%V,67Q2=6MI7G]G
M*;*FZP#0$PE<(B2B1(R(A!+)+@7<^9>@4O(2JT[<"QKIY-\S^75*=_US4^Z%
M:[<-A[Z25(0E3DC>#-R32&8KPR%7SMX)32ZAT_"*X&@/)=,UE!%*NAL*;#<Z
M%=BS1"9YM=SJ7A%1?17<6?7ISKS@\;S;MR.O\$K\P+ 5G]$X4KUP0;!.\+0"
MU_/X\QZB=QA:R30W^4HX>-F].ZHX?$!M4ZWX]^]-MN0@J5VV%6[YB)R\W^88
MN]97;>-< :S%AD-A4+)1-9WV<<_! <<%/^F?MKGL@_O7@WB+./?A!*['-"+I
M\:P3V#FF+:1,+4'Y0#]I?:VY6(H]<:R&+G7B#OGK6J/JB.[;054X?Z[Q769U
M@6^3>AUG1;FB4BPM_!S,R;* 2Z-)A<B<NP.+VUB.;(U"3'JTT*^?Y??U+$;V
MWAVY;Y#W,/U-AE=2]\/MH3];N4(P?FK+X1>)S/W8Y"V$DY4[K*/KG$,)I!K!
MEJ-0MQ!LF632&7.8%60'LD27JEJ=5.RW68=>7Y>[%993L:0O8%]=X3</IR<Q
MAPC30$B560#"Z/GB*OABH#TMO?-LN4\(V7R]X*GG<.7KG++$\,#\J$.RJ[L+
M]MO@QE**K850JA::5"*D2UA[S5!E5C* M;,@B^;6;QZZ!-R@MI7TXV4F<>K2
M#>?[^<9(:L5!;3^>6*KW\4::\G[1VK5[YAG^[<$Y=A"#F+V%N!R8IZ>#<XXL
M1)+^Y+5JLE6O1S<\]AJPL90KN./CK9/5US+J__#/1:(L$$A1XDZ5P+T,]1-Q
MKG( 4S_:,X(:]#%MA-R73"9^F<.EOK),A67E?^?@GGM>)QJ$>N?J;]JW$0[O
M/\C#BF#IX\E$<2!D5!J[W+TH!:)S.DUJV693NCILQ\?0U]X?WV/WOWYW2D<G
M2]GB<GCF>;LGS_AVV!END#69[T"YM<\,DQZTP.^(-(LC#+<,'!#X?.&;O%LB
M^^#?+-VN1TS+&,.U74Z+1B;3;Q7?.$WPO[<3M&5Z-HRM<R6PFDL:3\9'ENHD
M<49CJ77/YD][;)S)7/QXI"GEUJ59]4]/6KU&ASZYE3K21@16^UR[=-LF]B2<
M'GB[]/X]IUS@_(5'M+C'KBLRY$4!W_F^XJ0;%L:0*8RI"YP[0)"C%(R+/6@^
MO"3N(N-T(]ANK\KXDE>.LXBK-:RTU\BY/="PGM?:<S E^[#Z=IXWHR]PMG!"
ME> '4(* WZ@(?IXBBX?K9J\YU5'ANZP<5]J$*=E2]ESAS?%IYIA[7YUAJUC.
M77DM[53=%"?;+TBV/&L+H76*TP6LE9IP2XP*OZ"I]?EWO(">872]VQIM27&?
M*2JU>%<62<YB!_C#1K9'\Z[[JY\BF@O#YA5/K..K#V1?^,'S-Y<AR!6I!PVH
MZFDI;&>6!TX+R@%C>[D'IE3JQSK]&(*6+823K'///?:&+[[_0OLU>&5GXO7;
M?G[A<TW+K= RZPK.!%)E8'H!ODG:QBV<_Q):/LBM_7V./Q4M;OPDRS<$5&N5
M.J'HEVH^L[\JX,+.-Z6[;R-'2\#(KA3:ZWBN4"YC BWUQ,>[]F[%@H?]OFU^
MKPCG&_;GF=_ODE)MS'VC)H\&PP)>+%'2B: MD(22LM!V-QI-KS%#/P_R"&B\
M_F2^*R?LQ8)UJ.R73S;UEB)5WUS5+.[QC.%@#I\$<M]0FA38Q].HA%Y,MH]6
M$<WL,3K=M5V?-%,<ICCLM=<FQY^B*A4<>6!G%*N<7E)C@82)?LF@_LUB66B6
MJE5Y]Q@C+4TGYK6L0]7)R.:*A79'X6BS<NG<R-<$&>@[3)Q*MQ!#W_[M]:#7
MJH)1?Z\RC/#YL"-WXJ18&OAA60L!L)5@B$ISQA;^&.SN$O@045?ZLFG,@R86
M\%T^X/QM=W?KJ]%5?0(LE8&#Y[?Q?,,TEM"M0 =F'5C;NHQ.]#%,]IQDFRXK
MNI'D.\> 87$'Q[8@3<)8TK$WV8>PGW/2Q'V,6%B@QP?M7P=IHOH<A7!&G*=-
M2'GR(NYHX7DSF:C'4()^Z8<O&343Y\L/#+]65%KA5[$^^8#'FU3(;H$MQ(L+
M!_794D5<47U&)5?8JA3G.]'I @XN&9?KU8/E??(1Z<I384_;,U6CMHFF/RH/
MOO0R,#7@_4FF4-M0_S44&(MA/T*OJ6XA_'F]MQ 3&^)G!.GYB<\60X^8=U56
M8?$_3Q1>6M HJ3+3-11$Q[P[:+_+G.OF.^H1F&E4-(K$XE=A_0R ZI$PV5^3
MAHU(LMYAUK.O]O*!NVD/HY<?\AK75W]74IK4F&[FN)('WL^:S'LOGJZWEOS;
M>(#']I51P T+#0[,::BO,?5$^BGP:_\6 F:Q@5N(5+@]<:9M(%XJ[2=.X! _
MNA[<BSLX)HS[OC^W Z6[^\;3UQ1F"*>#&*@_AV9>BR!',2T9ETHD.LT:.@7F
M+&]:X0H.T ]ZVO,O'_5]X/*!:7<FS]]_7M$$,$>!5A1("TU 4PM*7J+H:)85
M%,_T^H#?\YT(E@3G&ZP87W]XP".H-<ISH:*IH*I[B!EP^[F<M6J4BF+%U,P*
MABU/9(E#L<Q_J1_NB3LY;G$D6,GT[K)L&2JCHAW\=G?M2*2.:'C+"7^7W,J<
M.];W&Y3=>0@1ZYO[!5_BAU&@%W'6F3DWUFFYY#CK2).#%59PAUP_Z_[^8TC8
MAIN^T]ZHXZ_D'W!1XJ6TU,"1F;#*?WMHL$G"0IGQ8"5=IA0KNN3"*<GN4IG'
MHJS!UW6)>ML[.*V\/CK,'Q\?VB,+F*)WUB A5?66&W9L*YAF1'7MP\^@Q/YC
MU2Q>YA4(4QER7>,%RPZ'?LF@9#AF^"QN(8Y/?)U6S:11&\_;M;MED$TB#HL%
MJQH/BESE[/R.VMZU\WMAACPZ-7JJO7&F<F;;8X'XA&-?#OOE?]M^PE[EU)'\
MG?/JP(8\X@_&$K8*C3NLM)?SW*CD(X&TA1"VT%U@NX(<PIP1@=^:FF+B.A9W
MX%1G"=I7R0MLX95*4US9[*= NA%K.: ^\\0$$%:7P96"LBH@06>&]=<TS8Y7
M8.*MS9,?PFK7P]2;.AKC^$!T4?"13V5GSFRS]!?\R6)Z;2'RQKF'MQ"SZ"W$
MO%*&#TRK!6.AV&/@#%N"O#YS=.)"8^;7I2]YL6;7&"F2C@<Z[K@+*;HO/+@/
MTY5?/)M?TEB7L.@^H,$,W7*+ )(&G+$VJR3A)0=3EY?-W/&V<?*4M^[*'*?<
M]*3FE?3<PP-FU534(4X50*U%-Y:LA;(,($]F!^<QCH?!:PGJ9WUNSG*8(KZL
M6=>XY7#?)SZZ>%$[/U]*[6QCSO"/Y5!ZI.P+_.AQ)*1<ESB$_ADB'\@M/S#3
MAP)C!-EPV:KCW%*2VD),NBP@$F#4A'1CU[S!8E*WCSJG+(Q]%9PA 5*/6P ^
M:'B@&%FH*P_3>@F=L=3.5@/;RQ[&;IP_!-'\0R)],43P# :"J?L:C')\(Z -
M@>'(?#C&QJ!N_NZ8:FADH-.BU:=T9>D3M@YQ9J],!M9R&Y]=$NKV/7^[&[\?
MZ+%$!R'A3.PY;H'"P^8$CQ&5L-MGJ(4K?U')G99A#.?!(S?:&SXL<7M"0XU>
M.EPR+0QH*]S38 9\%WK9J.& FMF84X4YG#8#32M98[%DV1X@E8%.7,=A]-.,
M1,U=6NUCPI");&OY$UX7JM_ZV<M:D]0R:Y_(\"&N1V-@8.OFQ#/-TI@KD-_5
M*FB&MK:X"]BANYD2MEQ,#68,_'#4O*N6WK\DT3XD].[YMZ&7#;>-8DK(1;3-
M%"#P&3&(HA#T=SJCLI^FL"%I2Z,?FU:MGG?W(+^>3]*V>W+M#D;=)/U>@4+2
M2]<WJ$2/V#X*@0*&!0Z@LP#P)(7LYOS!S)YUF.T/XE]K]E+DS,26!M;C#RMG
MTHYE"RZ.6\9M2VS.=A/:]M#A[RQ,'1"<F\T;<R@JNB<GGJ9)BA#VP1T#BRLK
M!BNP<WW7/W!R9FXVQ5>5R3]:+V8Z*>>OJ>W_<W7X_M"N"Q_)W:A3^/=;B"83
M$D".I2%3+0QP1J_;/)$RD.=I!G]^T;.^EQ3R+.681JO)CG -E>&'D>?H8=7=
M 1V%?^2XPGXL1 BJOGFT;T.*;0\YTT11<JM=!XH<)\TB2D.OI_S>0F3@=(-D
MHA_$2,6K%5M/V(PJ]&__2+Q6= ZAO?H<L?=QYO^1::]Z*XBLY>=JX[3K_*4=
MUY.TJ:@;):!-708%/%U'-AW80NPB4@M@J^BGL0]01S/D[*.6B,G #K:61?D3
M3Z]R4[6_,2,U4U(>EW\JNAJ[RX72U6YF:U)^G1$LP"E!]HS>P7ZY$@EBT$8.
M<U'C@]ZOQDHR%$J25_V.1TV6!KKEYI/=U]5?M46FUUPU?,+O92V]S?YXB0E^
MF C:ERC^:^:Z#K M&8%LJ<:EC;2FT;02R6:9#T:8F\6F8^%Z.K^\K:UX+(KB
MPH[8BQW?;\67._3C,8_*FLRFC#0/8W,M"DZVPC$N/WYFT0*&PASN&%'&><EQ
M,"+] *?0<<=@&1#XW4?QI<2@I'OP=$#P(YF+F7NS)T[^.&*;_?1/[&;Q+DX&
MSFT)DTJ4[Q+#3Z&E.\V7"2)L_ZG?A]=_T15Z)+]+!D_/M%PA&[7=<6"5'3A^
M\^!0\T[3\&4$LBRH%)G&-8$5V'6Y,^S?L]$)N*[>1O%;'/D(:9.N<5&3OQ;\
M^F.+A<).?&$ZQ$-&PK5._%VM=I?:7F6ZX9IN"'_4$Q*WA_E0CQI>.P@%V@X!
MU#O36XCFM#3RM*/(/#8:^XV]O^2=K(&C6BU^B%.3;*Q&1HV(#ER[5M<&+UX$
M+W>/^!+()%(+T?6QJ8"?8N"R3\GRB&FO)$51P;,%S/HNU>!-F:?8:=B\?N6F
MXI#OLL]9I'S/W<(5/;@Z1>20*^FM?BS'590BSOPJS5RAI\!#((6J2CV<TI_;
MWM9:O *&H,BF'L$6PWRX.?[SRSQ'==:XX]8(/![H.0&OGEY\B-.^A0@'4K80
MK8.]$>3-4]#9953*U3D]0I0@R?9#0)?L)CHX1>\2=ZK57=5=Z>I+&Q-U4KGL
MSDJ@QX%(S=Q"R,"W*:<T$7O09,?SG'HS<YHI,2F6$2)_.B\,?!S_YK=V<WMS
M^^VW].H!5XWX<SS2X2X71>M[ZL;D]_)24=!> GO'A..< ;,:\F?A<&*<9X(]
MA!PB<E&?CMSUK4N(.Y;L<_[J)^$P#Z9D!\\=U79[LS=J^]O\7?HC("TYMH3C
ML@E;.I1Y&U)EV4'ES/?@3*H^5]BG'W@:W((2JM53GJJ372>OV-SK:JK.-2 /
M;--S/]?Z?I /GSQ^%&4 O6!:<UY$;\R9G.4TX)'<J>OB62N4[4V 6"@%^;M.
M8,0X]\7KG.FR*_HF@]A&CY/B#+O9DV7GWBCZSW?LX900J8]N0X[,*<8F6QK-
MO,%0REA"9>"/@'FM*2H-8X:NS1--8=LEL\/R N[8ZWW)6\IY4GSLU;ES=N.6
M"[\XTCS@U[6R_SSDA:W/]QYZQ!!TAC,@ENT+_H9;YW1RZ8=:KC1V"W&L[57+
M6,R>"AS=@DF.CDZY]WRG>J95R][N>V%?RSA9L /N_$6N;;!<<,?AZU/845 M
M4=+"G'W"-76S_U0I)_GDV.46V]W7CL04/-(>E!\4D]BE]N 3EGKVE8D]<6W?
M7MXAM#\QL40>+^R-_<#=APL"-[-*&6XY^LTLH5\1O,-/+![JG0#*#2S*HC7/
M"=^ CD6-5ES!\!.I]P%^="  [:TDP#*4H@6W!<U@I'%*AAORV)#%C[J=?PL7
M!M',AY=VJ[Y]?OQ%MD&BYF*LYO?,O;RW.*5=/.R]G"JN"%3 O Y]INV-&16&
M6D_<=9S^-31T5L=Q/*] ?'=FC[>BW:5H5R>19(P.=P@-.D;,17"%.:Q#\_A!
MH&&#?I5*Q_0<P<V4@'7-=>E= FWMTV;:_._JM%*X(W'2\H6#:@2U^'P*?\OM
M,_L(S=]*D7EH*IQUX E"*AH\B4KL4@4=NXGR(S40:Z"]A%F7TZ4.#9YBN0RT
M5OFGQUU(/9_96WRI0]G=9E*[/C;@XJ(_["AX)FE!'5QA]1C&OIDSG!>&Q(SK
MF#ZX9&Z>;RZA-7YWMC+4CMS?  1[J:HF//E\$B!E_QRD2)_AP>PU68/Y'?\Q
M$* 3ENJRT>*PV<H6=WVPD,,VG+N#2B7NZ-K9O,E6]3_K%I;-C&VI)>US?-^]
M8S"R@["?@[%&Q%'67K,,<6C./;P, 0X:Y,U&T9K0,]._%UQ7#-U_>[MR5QPZ
MAH>.ASR7MZ^(E#EZ[DQZZ;Z]HBQ7MB*#0!=FF4+#5+<D=OQ3* 38A?4[,ZYG
M],B1]",D-$Q\H;IE;57$V_/SS+OY@]"?*[:'E=*L$;AX6.$ 6&%/["!76)5U
MB,)]5X!JNE;$0!YO9Y@OMD9@B_GNVK6G!B^UYN06L8Y]5D0DJXI4?ET=-!-D
M2\.];@W#C?F'T]Z%Y,Z1'>DY95CC56KQ,[\JK".ID;VOR/G6EWAO:_U)NK.X
MS_R;BJ4<(>MLNGB2\/(O@4S$GZ(^3(,CO8QAL$RYT0DP,'!Z7P!-DMFVG(YJ
M+&\/1E!SHJAO9IP\)%/N@_$*=0MK$#YIL$_G@FSKT4B77:;ZLY[,&&@2=!XH
MD>R,990O%Z2QKU;AK!@ <V(^V(*_R#;!F*^II:GEI<"I8]_LQ0YXBK<).0QK
M/VS*=FR$X:&XA.<?1J*DB $42!N=0Z16H86(EVOD3C1#649O& 22D(7,,%/[
M6[BL9@E';865']">[AW7Y=Z730IVW1=M(0_T[.3J0H)<4;FE.DC[PR8]@\:Q
M<F%<NV?XVJ%'@JU5J(!=FQZ8&)(U+:&G^NYQV&M_S88_BWUCAR E^HS@5THO
M "FG5K+VP27F[+^M$_X=G$QBR$<\"HH=5";2CD"FL52-*<.14Q6FZV)1&F7A
M83^--0D2K7>5KQA(W0]=U\\B"G<IXN(@[R5DTA9"#J<55HOUZS]R\F] QQ,?
MWL\+'N]2%(7Y9 Z9';S]]NB>))[:S$P$9,+\M^WIS?U8 CIL($.V$-L /Q3Y
M:Z_/'L@VH7KT69"2#-1*+7KQVHIT\&3WT&ZY%I.7NGTG(S\KJ?T9VO,L4/>W
MY@UBX$(<5Q'[HA?=%-%O6I<>VW4D*120*FC@CDZJ-N?SAD^[&CNHI4[,#>N3
M' S?31B8O;]&_[6RE_?G)%=X%8ZZ DXSFIK7I<!PA,FP*OXCGN>#A0PVN=\@
MM-"<V$=(G8EM'TC6&;>5>CX46#5G'6U,DHT5ZO'7D3'9C[9F'^.D-^=X,D49
ML6LNX.2RY/?6+N.QF#GD#NS7/JX2=ZIXY:M[Z#,C;69KTM(XWX1CG-GSY\/2
M_DDW/Y;9CDF?$1S!-)NPI3"TK_3^JR"Z']WL6O=TU4<-TEUF 3*>*T?TT\CO
MY\[=.3274-::OQ0EWGE7_4EMJKU)0JY;^6[L*%O:C2O4RD QF9Q.KAA^7K:D
M>3&+MLM":%56GI#*-MQ"B*E/N3(]O4^8@GKAZ.:R^6J&RH[<,E[-PV8)FW#>
M_7N$^^_E/<N@$O#<1AH1N5&R;+;(!Y6 +]R/M":97:T,2OJRJ%"PWW!\*.A'
MTKA9_M@AI?!O9/7/ Y\!2Q"S1F/YLL]\P&G&L"+8T:!L8P6$/M\\?0'<0I B
M^!>^9U2'Y%.,FOO7-F-G^/JE>\)E%Z4)F^-](ZHJ]T?'F\X(=J-!%P*D4M=7
M!VD!=!.0P"1, )<54=WZ8. 9%I!J6 GYZCT/U\-_"(MJ7\+00Z\,=4WOEY'8
M+HH;W$.X $W"/IM'-6FFXP3]&%+,CZ#-(RI%A'UT''=V";T=:T4=67@TFF%3
ME""^9GQP83YT1D5(;.SX2(.*_='MG]^65%:5(N4XCX! 3 X@BC_$=H1&&<!R
M21K[(F6'D8+M9%CTZ#:'BE-E'SV.*C=/3@=.Z1T'E4,?O#JN$3\[+R.V ]=1
M!O3LL-# F<%&)(6B05=B,J;E= XMBR#%*YAIH6@)-KA?_NUIK_LX%?NYC3OC
M^E,->['MI^Q^OF^U9[O\(\:>[^7]M 'IP%'@W$_Y]V9D*'>7XVE.Z:^-M';K
M@8[ 9ROR]Q:%$BY^L6G5>YN[Q)WUXVOX=/OK9XO.ZY2U>!8:6F5Z<'+-Q%D'
M0BA2AB42BQ!OCP>0V@1(S$$^GCN?)KU]J^T9%]!L<E<6=WP7\UU9P]'9Z=<>
M</HAN<(L. '<H3S6=J#G&/< GF)":69F+<UR#4/D4V;2<?N)HI\GI]\LA&#"
MY\*N<FJ,MTGZ*2Q'V@A_VLV*9<N@N<)$D,@5*6+MG<</;R&DFMT-F[80-[-.
M?_CU.G*11XT<S?Q).%#.E]CN$/@JV?SF)V9=>56I6)THUM02%$PRI*1Q$1,U
MT37ZQR?*)G\Y[/35$#7%7I0@R9>J?K)VX;'<+7;)K1O% U S@";;M7_O@)I#
M_YZS'85B69'0D0@)G-/+KLG?&+%0%-_ZT_KFYK:VIH<Z$4K$W:G6H7LM(J_@
M@7OA"H#UWE(D#^<AT7^4[-8--+EEHH/09&?F\W&S:T9(,7*0A1A8DM*UFY@6
M/2KJ86LP?/6S6F'.ZJ@Z231A?5V(=9#G1\JYS3!7<Z<P8VR3PW!\_$!Z5O!Z
M36'0,NZ*N\Q8V^B97?:_X7X! <&]7RQL4D\H S[.<5YT'<!/.G%GCICD^$&3
M+RS*E\SY\3N'GQ8=SOD\,B;[\]_[%RGB,2JTY<BC/I:"%O]T^Q=(CFP5^'@O
M&"_."/N:\QO%@W.$_&MMJW&&T(,R#UOS]X3H.X/[W2]$OH@2?"#M%.=_.RU;
M)F8X]6\M+$,!\RU\<01W&@"=",E_3=:(+%_N9+'D>-=NC6>!"<L=F%0EB?:6
M*9Q7V!-):\&BN%B=ZS@!:_L3S[V,H<GMB*^K\'J:(+$GXJ8\NH>0**_W@%:#
M(GGHR >F7K;H^^GQ<:XW4=5*_DW.'I%R]*&+<3KV:K\-SPCV8$![#*2JWU<"
MJ5,&,=GHG;5;B- %U4&X4Y%OCD]P[B.?@?PT[C%GSHPD'%2((S9KBA35?>'W
M,'[CTJ,8^FUCQ[^.6YYMS0H-0C<U;P[J(]')G48T4SK*%N3KXGM0NZ?XAZ?;
M*R)W3#[=^;"G2XI!V,U;]M*![R(71V$H@VLHOR.LN2I$XHHHLSQQ>V&J+<>=
M9J*$<;Y@;NZO4TXS--+*C%N8S%2LZZI9FE.K\VYGG7=5JI^\WNQ\6050JTM
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MW(B2Z!;\MIE*I#X&&C#97%$VFE-FIKZ<$^L,$OIUPQ4UN]MK""1ZI.M4[>?
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MY]SW410K=L<CHBL_U.F^Y\P=R#[R]>'N5\.C3B"P,U#.+*,/]D$!8XL>J 0
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MYC_1V%,%Q%7E?0R>[SI*>=C^7;_>Z;'0-1#F(5N -TEW,?W8IM8U7#P+R38
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M=P?68[0;DWB81MN1XY<YZ83@<)R2/4./>NYEI# QH^8JD/<"%=YK65@;3O'
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M(&[M+/\M2\)3%*F)"AQ_L)C<H+66?>3Q%WX^[9]YXJA[4$9:VC6\:\4\B8C
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ML%@._#$L+$;YXHT1F0]]PZ9\Z:?:=0J=2@/%R,=R&)EC@"]]O <LQ%5&Q?-
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MGRUTVVHM+7X(@CY28&CL63EA$[Y35Q#;X\K#O&H<'R&8,--!'<C0W>S=!F7
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M#>QK2PBMS]A;;'1^S:Z^/&S9\VZX9Y+^<KUF/,K.6!IOM)&[><VGQLWWQX_
MR('*2\^\W1_UM)SY:$B[-CK1FOWE<O(3'D"ID]RN%O'_)Q+D_S?VE"#*%F&>
MHO>29BB85E (6(;J$E>Y3V<^7;[W+KY2-/?$ Y&?434O%(6BHM[]=ONP'\Z#
MU*$_I^":;M+/DT)?JL.%?M.:4Y\K7NHCEU:$I=?<#[>2!#=6N/WW3;REO>'P
M9W#Y[(F]9RP^&M^/O:*<)W4\J&&W7S&(A%WJ9F@Q)894D0:4IS04Q>AU^;X1
M9LV/U?UTBY^-[OT7QE9W/^P\_W.OWC#< "!N_F^;1 -]G6;#>HLZC7A+[R>C
MEZ:)$)'%,Q&AUL.U)YR?/;'R+D>.WG?]-G;V?"M_MG_"37X-,C0(R%_[8&=_
M.HAN3BJRJE5YG"PCY6ERN?+]O&CNS2]VJU=H?CPV0C)]FIA+#BK_SE"M?YA9
M#Y47 9L"- AAM08%]K;NM$-]=P@P1[.2*W#!4ZYQ1O<E1&Z)VKX!['ZW[06D
MGR$L7?0U_%HWR'1U)\EFN^U$XYLC<:$[<724AZ?%"JVO%5X69F*PNW_$+-Q7
MW7N\?4T\L2GH(M"Z%Z:$;KC,];R0$AQ3S)&ECH[!4U(\)'L;A%IQ'D2,H$F>
M:N3N3FMIN$O')<_9@Y=EO\MY?[\LH#%UA]O+KW$9FS)DY"&$KK1,:$U5JC_8
M];$X3S)\:NKF[<.PXY=/C,^F8B!;,F:3;+=343W\U;V.0 8812#PH=V$HW;:
MED;482((73(XG%0#$9E '&E->GP)K1GM(]D^<$)SW52\Q.O>D>#XSO#OQN92
M+Q#0HW\M:KJ/!R""FMMN#_M6(X%$#'"<#FP#BJNHTPE-4T#J_I%]]YZJ)9@F
MND3+O=-V%' TN"U_Y3W@N8W!29UKKZZ-G/O<\?G";HN>_YQJ_:]G_/P,"R8?
MUY,_1(\6<'EK*33<]T?=>2B52^G+0<)3#ZV!BT5.-15QO*=W7;S_<<M33_,L
M0@'/5R_$[H>5H9D'G6CQ0_B[,+KRUHMX<DZ#L"02PF4=06?TT!DE2?JR32*3
MBSFF$Q)7$E2>YI^J3$PBJY<I[(D]SG4-]>@R6&,@#@,KG8MA[[%%_%QLBJ?W
M-WS]%"P<]NC^NF+?U%J?O;?OX16';NEXQ)&0ZR]CA^J/T;<X@-TQK#P.P(L@
MX8$7@GCA8M@"@WJ\A0CXMR&4W+">-'%T20,B=FR?Q;#7F%R,_:BE2=R5W&;G
M%#UBQU+L&;0:0.;/@2U%E.%E73*$KH!KP0FPFPBE6\%,[P+$5F- ,"Z<A+W%
MT!^W[7YP_-U:']_+9/.:0QV'--SOWYMIMNPZ70)L =&5M)9/$6&10,K#RJ7Y
M#^QNM! <*4%* TXK40CA&ZX#=O/. RJ/-G53Y,]+P-2\7!)Q@HE''MS/#&N
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M_U7H+6 _0.]UT<)_.CO]WV/5\'"\I)XRY6NK;(%ZI5WT]*-^=0^Y=57XT?>
ML NM 27$P/>\;9C.L[<=16T+'0P$O2?K\,2*#>.'4^%W"$(AS4[*I]7OSRA^
M@0U/T1Q,EP-AO4A05C<.$7HKY.?/4:UN[\<D*_[AX<_'C(DV2<9YS(NL[*-C
M] "3;B&$=,RH[\D:D._KE9/\K%M&C+8X_6?F'I?IIF1"1$"MS 76!SV\@N2Z
M.H[_DL*B/=3P_<8[:,_3D6693V&Q'V+4!?//YF<"A*]O0PMFW]L7GS(1?H5>
M6[4=+,3/3]OU?>( YL98OY);R3C^)<8=&9/L0_G#;$^2,&7C??(ZQ/=YPD9L
M*DF8'^'Z+6 _6)J2%"N1F,#[*^+$P):+8I+3Q/MX.Q]SF%-H4T]C3_1A-?/7
M%L9R<<:/XNSD:F0DKI<KW_(]K?EKTW-A?/V>@;AU\_]W]#E LH$#"$Z7I <7
M(&TI<TTLA;;F=RM83Z="#^LDXV,M,W6U\>V"U[XA&QQG_;HM'EQ0Y#TF+PZP
M>FY_K:]\6<<3>*=?9=535>P!K?)Q8>SW^JA" =F1P0BE7<61'W_7'^T_V8O4
MS[(;N?VMYF[9ETK;C*B T[D X0^?3$C=PG<\2A 9S_>T;VH?=SL^X#BXG]IL
M=OW,VPGQ]&O\$G[_5#[_+CO]J0[WNUZRSW6X]DK^%5?71ZDY556/\S,7 FF\
M>7J":\-#[)/LWI^>2'F5N1"D:)N8QYE44/FME>/<!NW*F(M?[1@.>N^]!ZB<
M=U1#6Z<J'/<D0:5S:*(/?NV2_IQ"1H5-8@;KS %[&VE):XN;V< (N/.OKQW0
M+.LZ'QL77'2]QL-WZ7A0$^R5S@.[H5JLRN8Z=N.8DL^D,J:VZ?WQN>-;1\R2
MFT"OOL)>KCI3_<-\+_@2Q*9 .WXUR'/3D ;1C7#^&P>F1G@_4* OD:<HJQ<C
MFQR%>S.^E$6FQ4:55OKYZ94"+;L\; [Q'F^^K^;=^30E/W&Z\#AN*9<#>*GO
M#(XI3#X_G'A9I9D@EF*1;4!ZK/;X$_L4) 9-]G"CO>JOB1_@-J:=TM9_BL)_
MA,DIG6D&\,OU\-Q);EZ-<I2BNQ[5U%+KREV4S/%*^>B^6#\[C[FAQ"A(+T00
MIQ4CYI!&U-1F1YTA%XKD$L-5B#6@4FI!59_6/.S/R,GJ"U#ZOA,U'4C"-&"$
MD3IQGD_(*W_H?NV"#ON#/U1-W^HI5D5?W(]7CFC3.M2M-CIS^]X7Y2<Y[F0Y
MG)F*5QYN.U"C C/:P+3PU(;X2:. H%<%;Z=6N13=F/84?1^R?=Y>#JO6[083
M0-I0S]L$M0'+Q'NO?\:G9-,OCV[='@U0QZ]/0>_,!&SR\PZ8BZJ+M+ZT,I2X
M=9=GWL0@\#;8Z&6[^X^1*2N%59TXY* "H\/1X6215)&L>)FVVFB(+%"^VUEJ
MGOM;8A34M3"U7"%N;A#(+_#W+A^Q24!-< !K;FQ];L/9QP'\]G#$.9HSGG(
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M =X_%!F6D&OQ'^768[QC/&2;"+LUNJ47*/1IVJO!DX.K]SUI,L#*;IH?E@,
M0!:Q@ZFRK"5>V*EHLDYYB<6W!QN# 52_A-3RTU!VNBD<M.._KVN^ZSM6;8FT
M5F694:(]'Z@#OU7/Q8XF&0(A,7,\Y;<E6HQIQOHP,4H'3")@C6>NI3:?;ZO8
MNFE&'A56R^, TD.Q9I?L5NN!3$V*?].Q@VZ.!_I$Q\YQ$58WNPJ]^GTN">*8
M]EF[J,7*0"!BU\L7 **@W>^.*K]T8;'-)6<CF/A@759BM>64>F9^CK#\,Q.S
M9Z8+SE&=<X[)@[^-1GMASK[/9[<2:J<BE[+*N VJ/FJM\>\H7\&QH?),.MRP
MABH95N[A(01N'#-)75QL'U+R)!F<6;NV=#GC]"L340 @'J;R9Y8NE15V('?8
MYBL^:EE/SJ<(:%Y)C_6E<  6,.$NSWR'J3';+EKL7K</[P+W]JI^BM%]!KX<
M5_788P+]$/;B*W 9RM! < !<_:9:[?_)G0VA^&63&%W7FUB^A?Y^?1>=+U[;
M?PN\G!/2*KQ[F%C9@!_SH&$X@%?[47T!PTM_SK] 4421M^@GR*NA;"#%.12S
M87VN+0MQ7[?.9[[F5>Z3X&)? \VU+Q.&2:^_]<D)'.7=1+,%3W#O&V2]X "(
M*8[@+_3;C$OTY.9WH6'%*O>_XON0P ]'MOH\9^2NJ(PG7R.M:Y;<FGAPMZ;"
M\S2T8 %+,<>-]!NQPH;9@LJ!U!HH4.!!K^2MT!83\=?&1XQ_%2H?(*A/2',
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MGE/^XTN:TE@Y?/;A!O="C205OVK\A!;9^WZU"1OLN)_N\*DN-'B#K/!^I6Y
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ML0%YOP,CE9N(DF!G14D. #SMY<]63>  EA=_,-)N $'3H+9Z%RT4/^4]]IO
MX>*/TIO+7EDHR"HOM_I>HF00NJ2*B*_"0>K:CSX0O]]TGH6OZJ;?8<1OD"MR
M<5>429VJO"*;'>N^5)7;@VGOXP);]]JIDU@C\L]__=J\X)V2_<@4=,_L=)I\
MF6QE8?I:\OO42A,5+G7#9>A]^SO1XI_Q(O\S*X:1(2T<P&XDJ#(*$7G3'>2E
M_:7O47S7UZ].W_9*S<6WFNT)');14Z1&3F-7V2>F3$E (>,..MHLE:6YK*\J
MSP8$9M#D#@IT(8><FLO.TG->-E@BHJY/'2S_^#SM-M[OW2*N?KAA[Z. D3N?
MLNV41<+BLDVVLVFU'X_]8ND/TK*BH9*H'AT?NQ]T19)U*"A2[Z)V8"#_KK'^
MBODY1B[/TH$G9[UO;72_V"'$@,A4R#(_V;RH^\AVTI1,Z:1,JMMS3=^W&.N=
MHQ&K>B>(.$'$/D.H,!URN?)S&2;KIL(^X*J:7FE@G.E#FZ/:'F*IIM;="Z?K
MK*0F;V(\6A:MBC?UQQ<//W;IZW*_2YZ?*7F\:KYHOJ/_H3839W1*9,S.;L3>
MR-G)\^C9YI?W(^0$<S,_ ![S&1M(T$2B[L==;Y>1]:SYG!%Q*NR?03;_JX:#
M4+O;ZD#7ANR_$0YLN->:DRUC66DYG]>*H*;]/[:< )O' H^Z:LRZI+3:QY$&
M'SD;B$_&#79 L^Y)/#.#9MU/?1Y3*\,O@2EHOZSE8=,K/V7Z%Z&J*"_ZS3[:
MKS!4SC+;IWM-TF=8Z]SKJS*_AE-,J49DHU9W['6ZY">TRV]&!'1:Q7$B^!YA
MJ:?R')"6&O-A.LA:'?;2;CA:0QL)8USR:"]R,)QRS@E=ON2@^9T#J$(/53),
M-W2K-.8_-PG5*L/AHEEN'\U%'HL?>,'38],=J'J";.IQX2ZE>^E37>WP5E9Q
M;LZ8T ";I>43@-QVL:+8U3DNHU9 [?H/(1?L()-Q [_ 1Y$B%'133;A&\_JF
MZ9.YU"[T+;3FK$4 "3/A..(XTJY=W!JA//]EJ134<;9 *.A37H./2<%D?5'=
MN+_GPKAK?$0+V;L\S6[]2?P"!R _JAKN]I5/W-RA3?L?Z<3^KQPTM-KTA)GT
ME,W[/H>;O^H;VCVIT=+Y480_3_&EY87&A*.S2TE%=:(.(]/29M?5;!Z5W.$
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M9/)4'__7KVDG(S14Y.+.6MW4B8->,BZ7\/_<YSDJ_*E=[G%KO^G)C)-QG6T
MGH%X1^\B5-_A8RN9BB'U(H@GZZTZ&4>U^_>,7X,6)@NM\:R<TWU@=96N0>4G
MOR] 4]=;OMFN[$\7ZY%S*_(>V)O%6,,^(HHT+,/D;2*5R+._'Y2EG\[P>Q)9
M+H5?'7)O,ROYE&_J^W+YBD*:0/[;;8;4JFLA(4MKX\E,)/O^4!WCBOW"UZQZ
M4?HI4G6M?7ZK7Y=^Z://Y> O9BC+Q>#%[]\U#B53)&]3/V4*A^/=@.)" 60%
M@N>'L5,8TS+X@\53P"FOS%=" 3(O2<O[&L?NV"F&;$0&'KEF*%M9'G92&'F
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M$O4X,"P.LTD(&6ZQYEZ5.%W" ?1]"&+!NAQ[H'V/T0DIW-+A]L,F<X0C:%L
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MH<;ZMFX]0=O!72Z3J"X(S^KY.>39_CWHN01/(/N5@;^Z3;)]B+:'"/..A'1
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M>9DH!*D2N#UA=?NLV@PS$8<L*6\B",!!9N66&U2?7J+=?N+A0=R]@;X@1>A
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M]NX#B^6P<)W56KR$3$[*YET/XT4M1/IR,A+U\>#Y.[BIG#$F69IUZX<S$;,
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MESZV+/[Z@HVP]S_NW1A)ABKS##6SBYX29*XLO1JHG9Y_\_'O (CNV,HY=KF
M8FY\]>P_B#J$U]X'-.TSSOB54TT1X?-ZE:4HJM/UC]5#A<EO*FLL.)]YH1L:
M<GM75+_ .7!7'.PU5.4_01AT45;A]'>+A2FGEJ@2&]M( =UP/]5[HL,%=BKX
MJYS"WO9/*.AAQF17^*/!/ETP,$M-V*6FS.;%75B,G)L&#W$_7'3-]\)H)%&\
MC9OZ?^?;:YCG29I_(9(DRUNK/[4CSPS^E.[_)'74.%MO9;_.5?D!'3E/*[NM
MMT1J/@2+N.X(6'=-%B!W% K,M$?8B#]7>P"J)3<L_6W,+'O#W'F9*RLN"1NW
MY)D,W&@L^C]]2Y<I#40!ZV=<B:!T%!OQ(C_W_/:@]-;$..GO6_36)O+[J?_2
M4L8;7RW7B#51 Q>(:\LH'P6 8K.S!_43%\RF];:HG0><__J5LB_I"W<)<T H
M=^Y]8&X4._, +ASE8" ;<?4DK..>5@!@2J3G,^+! C%%(VH7:7DN3SMNEP1-
MTF[OB4%Y/N%<@Y4'09JBXQ^P,[Y$:C9T'*Z><M0YZ,!I6/:=A\$;14V&7@1&
MH:AZG&S$,3M>7K1],QO1-0Q,&C&;-H3XF-LX:#>Q=0Z@&#'%X4IK!VNOXS#!
M->[<?P4H\JSC*T> R=?<T-E*J?/;=!4(V[Y#4[^1QO5 %QS<D]+,^$#HQ X;
M;XN/P^JR7@S)U$'^^U"D/W_&$1R N44B50*Z_W^L.Y,-[J6>F^>7PQX$]74<
MDHX'^?2'3WQH,5L&G+F'<ZGA@0S-( ';0]R*#18>N$ZI9==\T11G+Q!&-7(O
M&Z$HZ61E"TD=!>B+0.MJOB6=GQ6O_"&F:SBA7C*-Z$AE'@7^9-I:*GX%ZB\
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M:\S#46Q*'/[<MJHE/U63'(L5L6\E6_2UB!RM+/48:_XSJ(,TN4RP!L-HC,G
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M&7T7L?K2:7ZJUM%%!(OTU6?WB/RM?R*DXL;S[[:T*?@RG:3@X*ZS*I\B@%(
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MW,"#9U06SP3=!7VX!8, B5D!5.RY+6Q:4,(&02#_"'^^Y:9RKBEZXID3V&P
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M1]X/P*)?1GG(#^);VXITL\\,?-H^I&Q/6*P/Q(8E,Q5>,;2Q'<AC;,0CI#!
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M"J4O?'%S$A^FB%3D*(;V9RF]K_5*OK33(?KB8;]U1W8@-)>(8330TNIK^IA
M?![,X*R<##4)*CT1SV@HHJ,WF[(_41FC%:E7-N@MR4FLR]QT]VSW,-5P:975
MFU4(Q:!'IR,5JIL$BI Z&\GQAQ]=2^A%@V?(LEXS-,7O_!(_U@%3</,9=$7E
MPJ/)Z_W,3S0CM\^=53)GDC1WOX^(:CPHPE<@=-$4*]!#%IP@$,629L3;A)]C
MT\+]J!N_#M?^\KQ65YG(.)_UX]0]U&UL1:DN/Z9!] :F7'?&"R1Q_/HGS'%U
M$N#8J<_^8JZA'>JMN0_VGFE<6ML=P^H*CD3XHF6,]L,L2=\56\ [SRY)B<6%
M[(OK=QC89D9W>]EH.)8.XH9F.;7\=+PO]R#4WNR\"6K/IDW9+AN8>'BL*7:V
M_9;O^7&1V9#T7TE&]PQI!5D9ZF,D# _YX[8%?0?Y&:I2$0H;PYW67N7M.45D
M$*.E-^]^%7X=L1J!W*X5_/\OA?Z?IM[%08$4P?;XF65!I$>HRKXW<WWJ"LM[
M#]V)BVV6W3%V,#U4Y867N7T64"KX2"K'Q58KV]*CHZKU1Y.&SR2N0]O$[**.
M.9XCKX2WYB<O%F=8K7'^63QRA6)?([A0?O^W;:TUQN !?52Z$[?XM.$!+?"<
M/)<%M#"*'O^HA)'A:5W!".8[OJ 4:-K9(.GT"R?).\U6?WAL[<##V]F@]',^
M-BU5(.8T!D-KLP$4$NU9+I'\&)EO<<.T[T5:^6(K#/?Q#1I--*FR31-VLF*!
M$5,G:="&'A[2*'^#FV\@Q^:OK(L$?B"#UB11Y5$%_HNN!:S@U79F;=48_\/8
M$/JH.*QO#OAMMQ6F_M  H,=6M;_-,5[=CD($6^S-%.J7?<K^Z$?[I&A^R:I\
MA^=(AFT1TIS<=X!)A;QHT"Y,A, )QPD5=$LL90BD+=+N&%7UB,#0':G,SZT[
MUIZ OH[6Q=&$"..ZRF4AHMAFA<ZAII!R,'H;"8K>2&X7]T<;B'+T7)&,,8_Y
M,Y@T=D(I3_9]D\;#5P3JW*FQ684Z4RI_KG_L=W]7*D^VFI'S1- -6;UJG?X^
M0MF)WE^Y&-GW.'.!<)F5<U%WR?W!7CY699X!4"Q-T4,HJ85=\P.?>K;?%&!-
ME\N9F2C&!$B"7E<,")(H4UN-)<MBEWOC>&GS(R2>;#A]38U\PWHV7FWL47GE
M;?3<551/A3?,-@J <D,N?A@E0\EJN/YX2_O S;;ZX'E. )^TN,IRMG%V_1DK
M&T!R*/GW[[N%\J@WP$RW?VT7),_PJ=TRMQ #,[ 3JS<#[E"3%:/S-@RM9+?H
M?HCN@[(,;//XU^!Q^?1\9<M>T)$4YLQU(BJ33 T%9[U@/#B/&_00A T-",2&
M>=CJ#(X^/]5C.XD>%;$7'?:U=.X@#7)%#F(%,2FP[21DP%0E>XIP0/=W7!-
MEP4ZCZ5N%B*H'S%^B5+S O%P[M[A#<V"[36<://5<)O^KVQ;8#))C;+)B(YH
MV(RM;@FEL21>>I^ >>B&2E8*Z8WH#,7-%]DXB]3G!Y1M B;M7^53 '&"/&2
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MR^RZ &,Y7&L98U;IQI!?<-*MU"M?O'&+JAX>;S8^OYRNZ6(W)BY[NW#=6@+
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MO'NA8\+"9V^6K=J+5N4ZGV?P*]C. * WN944C5D+:_A#%+)!!(]E_XID(+=
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MI2Z =@F;,@T79]D7^F8_^=&-.>!RGK P?\7BODFV9V>JY!\!,>OAR'<G/X5
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MO,00920!$"SP=O,_/ZD"67!W7G5XN-?R7'\ZV<SF4*^-_I,=9U*N<$?%<_H
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M4PM$VMP0 Q>S*<8_-X:&S0]^3;36RE;_D3DU;18V^+#*N$>8:SQ+ )H]- 7
M65$E*UAGP!3ZIA/H;B;ONPB;TM.)O0?"N@@IQ9OQ>DRY,JW8LB/3LKF]ON*#
M<N7'+,]'Z1ZNL;K(VBF==G3'Z34 #6JIQ;&4Z2,DS&H5%C6,$>-(S<V[@8X#
MT ,F-P*]JWY5TM_\I%L4#1N?#?C<QYD,/1(HM[M,T/F;YQ87I0XS+8&N"\C
MMZ ]R6H  %6^8;L4C#M=7)S "I>D/@/=9<>:.1>9_(91+:5[/9^>FY\-/]XE
M9O0O_80+Y-\ (PPL*V.I<HG"*R"0&GX)-*6LRR28\)*XV+*+D3D^LD_/3C-J
MT+3W?*R)2%O-8])]]]H=$,".A?FNBP!=9V&^.N Q4>II6@]'LI[EW=Y42P-Z
M'OVU]1]:<3/8_:JMP]^&BR>+G&Z;N5A_<_Z^@,X*@]6.K*XP[R)$.<+U3!L4
M 78 N"LJ[H,1Z=!&W#\SQCI!$4:+@X\?)MH9?>R?LM'6(DT4O3[P2<R(:A68
M[WGV%':T%?+O#T?H!5.8BY&Y%OWVB"QGT&- #/2^//VVL?4+\JQ8O;"(Y=AW
MXPI?A>M1'B?/EX/_HMHD_T7J_R,7<!' ;9COR,S4QV!0#<^2]V6>7'1&A/<1
MW 9B;X-,LH97RZB)A;>)%D]*V*&;03ZOD]H/>5[N?%]^;W(+QETU\29V63$[
M)X8+_#S(KD_"*?MRE@ 1/UGWI(AR88T(IO\3K\_^'U3?;$/*$ZA7PQYV'7(B
MB3^%FP%=%OKK:!AN<_7:DLX,QH9K@WT0#.A!D&EEY&*[-+AQE[8-B0URJEYP
ML+,4GLWT;+K]X[S6F$UNX1D/NP&(')QV&4O87,)V!A/&&1<:07%Z^N)2%U0.
MI=I'WH:(_5POGG4C+#CIMW(U1_$']+#E S6M[T8UQZYK[UOA?K]S=4.P)Z^S
MI$K) ZM)Q<@;MB-QF/T=8BL=AYJ__-7B&\5<FM!<\$!_S#N2ZO!LS4%];3B7
M:"8@_ V*0Z_R,BU92NQLP$-C?1;H-,1(_0V>U>WC*+QPIE$["D1R&?AB%]\A
MSU#]VMPIF/&FS]#!H.30W&9=_PX>[CBCD3NE_GJ0 NQF%79"$,N8Y 8E9[:]
M]3=P&4G:6*>*2!FW[$JU)1YS1'_V%B)Z-QGR*KL-JS).6.[ZC-P%<KO/BV8W
M 3Y0 IKA08-1G]"(Y#^L0V!<8-%/SJEZ\#JNLE:_/=W"GP\3>H]L\EG6/REA
M32A 6,([XN0U-M= X/ -:K'X6]AD:6+CYM,-5RP:SX/2GF/IX'%C@:JR#]]7
M++H/>'L\^7:FC?5^73/=2H#/FFH3?S3C@"M7VL? :0J>"WEIUW3F*%/3#"0=
MDQ0VA$^6#4LH0YC)N6;&+@? I<9Z-.E&P5>%+NRQR@A5MOH=G-4/HUE@T%!%
MX!:&H&H7[E!+<QR I>)E +(/XO$X=45/4;JUOC753<TVCZ(P>"1)(BA]1/&K
M<Y!3Z:O:*)+">B^:X,H1$J'I,%Z"L'*6W!1* _F0II9D8B^51(_K01UB8ZK#
M#I%S?!/5I_16,L8#G0_%)$GAFM.7$]45O6S2'K7L1./" 1]14#V8:LKD0\JQ
MWW7(@Q8H11#>8U0:Q;I%%'DV>"LX/P)=G^-<^CK/QN;W(L5&)54/IYDY5Z((
MS^=\P#3"6%*NC/BL'B(OS!<.JH5!^74:VBJ"02>\E!I],N5;RM?]UBDG?1_N
MYW^8O:IL*?B\+ZA.+^>KI_4B?-:51*2ZDK!<%4>59EX EQA7Z5)I-"(E+J;]
M1 GHT?<'1)MG(*G')OHT; /Y\C=/%*4H!Y@YGT)_%VZ#[/F^#JIU%-,UEAQ9
M\K/T\<OL4OTAN_ ^.%\'CT^'_$Z>?Y,<)]5,D1/KU=3;=RYJZ/UQMRX\4NY^
M4LS_[^)6_]"UNAR[B4I*,ZXYX6TS+N_X\K'C/1I'R4]YHD1Y9%G;$'8]_M8Z
M(8X4S)*(V]F/74"7"4NZ%!SJS8Z+&8CAZ+)4.J;NC-^E>[U\>T)R.'>"V)JZ
M=HBW9N[HC=O^^WD\)]E_NHE-HE1)>HZUK&@/= 9*<8S^RWS%PDV::5H5SRP;
MZ3V[K[D-\9Q0S:/IJ'@T6?X1$/*,/)%QYC2>8+#"2 )UZ<ID>RZ2B%Y4K@.O
M,8W!\"Y<'?(\V&905BQ7):F9GRAB:)?\B^)3Z'A$.L_:2[,L<O2Y$XA>/<?=
M$\+L<LYIECR[V@3J0<_I<5>E2W=")=U[2+!XPH\H=%;5LN7@&M7E]\<Q5[U'
MM>)',Z''#/96*RO=YMK\ ,PS&&XG%SRI!+H;\%%08P!3VQ ?X!EG/Q@86F1?
M,+OR^$;*YY0EJ=>U%!NMM6^XID>*Q+L75GHAGZ_=/H;M1GT"=N&#X%SD)HD/
MUI'A?('66V+(ZWN1#E$KO=G>B0'MWKS4PL,_LP09KG>O.W]/<YLP2>_;C4RU
MO#2I)&_U#/ %0&TB=1=W?Z731EB2>\BBU'.T]0L=7]JEPREV5N1>O BI%9"9
M<[$SR=(Q)3^0"OQV?EFRL>'L:X^KFXIWBZRV=+GO<A>Q<@,S5\'0 8.9KC^W
ME,:E!\QD8CGK%YV1?75M/ /W=[= 6HOH'Y_&\\3P/'WC^(/($DNB8*@:%")H
MN-X%J\=U!\_J],G&)2//T7Y<_](.Q=J&W\F#9AJW5%.2KC:W^J?0>B O&VH:
MW"/T-&NME!"S>'/\K9%96W-V',P#B(/5P>,:[[_K(04+SRU/RV9EU;@O0-PI
M)!V:H-JCF]J7OG3>7=+;15-C24>[T=5B 5(EE[,\">]6Y&^AJQ8'+F%E]$OB
MO"-XVW&!WWY&WQDT+O()L1DZ+O\ R[4VT8FH4\@ D$I#=P)U6.H-IKX_;!>*
M'X&A[,LU1)L9K4P_[%!*LG.R;7A8Z^HK$O+%5EE1Y<U;A1C+LW=,YSA"?4PS
MSBQ&%B 5X>NX8(6FS-"EPY/;56CBO=EKI10FV[!/4:XA_;?QMQKKL<\:[*L+
M7Q](I=J_4H:_#GE,F69)MI&G61+"'*$4IB:1TP7EY5I;.P_R]Q=+N?8[]U=M
M%,,^K#0B;,Y7ZB&N9M&+,&T]@?V1YQ41)E\.*8X\?>CEGIU4ZTVH:4R#]^H+
MVCKC$7UDM8#NVG,%M!_ R+&420LWYWWV7&GK&-?G2_O$V,2>CKE"?J:S%??P
M3WCENS/\#2"1Z<:R -%<@5?] I"RMB&0]@"DRJ- 6L</BF@O1F[.=VHSO,DH
MI#VQ?ZR[2[LP?4';,QM^XFO>T1N'SDB='&DQ\>8(/64*<+[@H+78U2JF*N<#
M=$_C>CP=*0(6DP(=+^/=PJUJU*R^:*DT/?0 (G;Y)_!GFN=[#@;4#!@#C?:K
M[YD765+<890AS;B?K9QA/+\^7,[W,:;'FR;=CXG=>L!^\WBRX\T?X5<ZE;WC
ME=(G+8X_LQ4:_M $UT$Q/"&CH"_S-FJ<N)/)L]1H@"7V@I$"%D(3E>G$'E^6
M*\V8TIL';<!-%/[^5#OOY&? &)0L^MU]._UNNGJ!@W7G@T_1WE% ESCJ,-()
M/,0\S9F"-FX.K!,J>E&JM.D> (W97\WR*/XEJY(T4M7TVL//Y6\USQWKKR?,
M$VLL'51^3]XPI\,O@:(,=S"&:0MT70]#@T=AO5P^TXI]RCK-1;UW%\7!1P6(
M=%> ZG:)\YOBK*-_] XN\T83SOH(TR34NMO1.V/VR@U#$+]Z@BF,FG27I4&I
M.P>"O]CY,.^V%&@G3*9#';'B4@.V2"=H%C>UCNFOG T.:II*^S#-1Q6JJ/M8
MVU\NI^UTK)D7G@QO0K,D,ID,<QJ6VLC41"0-+&J#<646A2LXH/X;?G4;@EJ4
MG= ;&H@I&J<V&HZ-_?@<)9B4,_[XSIM.JKSZ$>L!O"T3CG1FE^,#0/P=^Z@M
M3AFM0V<?4G4<&4@W[E6S:6R>#F/FVC3-_&RB$<_I-XB55[ZPU_QB%RFF9^'E
M#<_#WR(F<.VY&V86(%ONI!!< M.XGW]&6;;OP)/]L'V@%2,R.-ZA%O$@+/[Z
M.?^(\,#8EC==^^WG2P9+!,J'Q(.>_^),X>N]61)RC)V@^)<^&-HU^$P]Z>_
M0)5T'VQO)>L /:>S]&;3>&-$5L.QP+\(1;=::>/#'\O?'% G2+G1(>'P_<4[
M"=F6H31[T3DK\@AUTK?8CQ <AQ1<$D!)(,\U1*AC36[D=Z0@1H<B_+WCJ6N'
M_UV)3]W_-;<64D#\RH02Q#E"IYD"7$#+V\$/=)TWDT9]412OIWGW8'>!I_P
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MQ:*JR8+I :KB+Y7YY8<E([7!_*Q<X.@W]$]P_36H?P7#",;AC]\K_J=_^V\
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MB&."6)A!BG("D4@8I"3#,)$X8UF:IVF>S;JNT9/OAS_!>FQ#!N;Y5A,@6E4
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MXUF$>1#)+,NM#DE=!IT:KS42ZWUDDR6\*3Y5:2M*2ZTC')?VOC%K],\['(?
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M]3]>NM^V@=_R'-HOJ$.?0C=XMLY");!Z:)LC:=ZX#G7QO*8P@,<S:'N(O)Y
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MF!.U\_A,ROK9-)(F)F2NVB[GV[Y[-,IS'H4AE)%N=Y,A#/.$(?4J8B02P>)
MW=CI7,)A].F=5K3" R,]Z(KO]@:[3('=:SX0K -SP7$\.YN$@1HD]D#,)[FX
M##\J _7 Y25-];E%ST!_74KI#:D$?[M\U.7AC#UB?EM=K^J'95G\'\%_7:@[
MFAHLGY[TW[7;N+KY+DI65.)S63#Q13V5HDUU1U' 1(8BR!D.(4IP!C%&'":)
MR 7.<I)BXI0<X%_&J>U9UG("(R@PDO8L0S#$C-I1Z"O/T\!4VV^*W!,9A@/1
M:_+# &*.FS Q',Y[218##M6W*HPB-5'5-TU%4.U:GR$J41[A%$89SR$*N(0$
MD1CF(1<9EYD@PNE8_< 84V/=M8CKRJA7@"LI7:N^[$-I1Y<7 C0PW6VPN5EC
M\^X4-CVJNAS5WF\ME_UA1J[@<E3/_;HMQ[_JT[J[+DO-)$V!YNU7VEB]:]T?
M27NKZ^?MV5IEHGJ^/I!%0TXZM$<7G!?\X\JD+PH>!"A*<Q@*G.N\K0!2BB,8
M8R)X2".2D6#V),IBR>]J9=9>8OD-(+_+B_=2B^'>P3?BOE@L= PM)7-3_>V'
M8ETU]<\^K,(AGH2<A9FN9 OS1 J(<)A 3&4"U0/"(L2R+(I1^R3<+/@?_CE8
MZS"@X;G@?[!'X)+MPBM/ZL"KJE$(4JT1Z&H-.FKKE,/N]UK5@=']"C3:=X)7
M*M!$N]8* - B8&)>&PS41X/"T%N4 2=N^(W+$,)/8#LSX)S8;7*&%,"]@)W9
M7=V1N;B^+X41ZOI>?;HGM6CNO93-KNRVJE:"SR(9AC1+=!.)C$,D2 YSG%$3
M:9Q$,L(TL$J1ZC'VU+9*38'P2LD/R%J!*_6Q50$LC ZZ_GI;U+TP:KBO5GWF
MZ?1Z,S#Z0Z\8!G@M.KC> K^1OB5W#7RC &@T& YL^XIS X(^4G4YW^ [U9'K
M"=^)FG&N=QRM/EQ/5;NUX/K>8J!@]^Y8X2Q!,N!4;8QQ3C*U.U;[9!KR% :9
MQ'%*4Y'G3F7?W(:?VEIB%?A^=>E"TG.J[/8NPTW P,N)93B\9SJ[#+918^-W
M)9A6A/Q!=)SCY _?I:>#<44K\5\K==>;;^J?34M"(4,<AJ$VFO-(_2.XVLQ*
M#A.2DY1AG& IG(Z #X\S-6;;B@F,G/W[/AX#UM*U<CE<0YNU?9!R]U2<QL&K
M7^'(4.-Z 4[KN[=G/_/UGD&HB[I8=]ZZ$VQ5FKI)-VUKK_=*:.TA6-5M!]L;
M4FH7=_59E(V#X/GP#<SC'Z5QR'C*=;I-"A'*)"0R9\JDRC')N0@2YG1(.:"L
M4^.FKJ1@*VHO=AIRBNT8;B(3-S!+]IPS]Q#@X='T&E<\H+CC!BL/C_M>!/0(
M0_:L%JHP6RYJA9_ZTOWZ,/R=8*4N*:,E>]$(?<9SAGE .<01#=1JP$*(=>47
MM1+$)$)1&&9BMC ^ /[5?E%P%L2*,?*&,?;$&7*OMR.E=E/]+!9BZ1AK[3XO
M=A0^#,PCU0G=D1VLA==!,HWX39W6%PIXK _:%SNOY4&=A1BW.FA?C/:*@_:^
MD?L1U37_1A@K%F)3:)WF 4TUL>DJ?;IL!DXXAB3$3 9A1@B-;8^@7MQ[<@;J
M6CS[LXN7:)T_"+H @Z%MO;5DYZNCG\7!_HSF CQ&.H,Y_U@XG:H<4?C$J<G+
M*T8[%3DB:O?4X]A7^K0NGZN/2YV/^JUSAJ)/Z 5O3N*; ALS1CD*@R"!) IB
M14DI@Y0J(RSFJ4SB3*2"6)^*6X\Z.;)J1 1+(Z-3;1XWM,]3VB 8#DQV.S+O
MG*VVN#9RGRO+<P&N+LW(!\!WM+[D7G!V;%;NB-?)ON6V]QJQA;FC>KO=S%TO
M[IO@H4.FFM*K@M;7BS;,JK-A7W=UD#R*TRC&,!140!1S#G.1,1C+#!&1\AP1
MI[-I^Z&GQND=R9ML!U.)IXVWW/&^G6WX<.FDV.V@AX%Z8.KWB'*/I!-7P/SF
MHEB//G**BBLJ^YDKSG?P5.BH:>.H/\UR+A@/$($B5O"C2&V:\S#!,.*,ID*&
M,@O91=6.MF--C;EVB_DL9=O0U)3UN;#H40=@.U+R!-O@!NC+\D=77="NP.?E
MO&#/X+?VOX-44+" :M B29WA7K=2TK[>9\LE';BDKZETL'?LQ^5"F60K5A=T
M+MJ,O,,Q[F^75:T;NR8R1!D,PQ!!),(,YFE,( NS)(EUO'CLF#WK0:JIT92)
MT6RS6EA'5E<SRL>$V5I8(T_#P+1WN%VV#F5^V3-[1\5M$O#!Q*1MDH?_0KI>
M9\"O->=#L)$-/8]8[MN /F]^0;XS]51IH?V-+LO79B+]313W#[7@U]]$239?
M:"X)9R14/(^"& 98I! E<0@ISS(8HS"(11SG,7=JJ/2:RDQMY5@+"T@C+1#K
M:BQ/IAJ+C@[_]>X=>!)E$R7>)S?VM1X<NZ7HC_(X#+R"G5V &GVNP*%Z/9O?
M:L6OP.:I:I5^<8WGC-E7GCOO2;2OI<_X>;6O/','4VU?6R;W$\9UO\.?U<M:
MOU^9J@8Z>.):2F,LB!G-LC!A(H(X3C!$.960(O4I$3E%E!,<Y5:=0:Q&F]H2
MM^G7>:\E!K(1N8DC(FNA[4_"SJ-]_F31*X8#KPL;^(RPH)7V"FAYP?40^-F?
M('K%<:23PPOQ=#HQM,;GQ$GA^7N,=D)HK4[W9-#^H@O:)MZJQV9QKW=B32'D
M-ER(H3#FB!#($26Z8&<,B8QC&$<LE5)$89#'/9HG'A[-Y5D?L85BC]Z)1]"T
M,^<](30PJS:59;9BMBT5SX>H]>NG>!H/[UT5CPPW?F_%TWH?[+!XYI)^)/'R
MU.[]MX_%KXM2D+FV*'\FQ>+#LJIF"<XEIXF$7*(8(I0PB&5 88ASGI,T3>(X
M=/%TV T[-8/MHZC!:B,EN%=B AT*]HT4<VU.0[DLH:F8(IK#[6JCH!O96,X*
M(BB/LB2 <8PD1 +I%KBIHO(\IY2%*.?8L06N_WD9A]"G-C-V*X)_M(<^3'@9
MLZ&LP[_"C[=78"LVT'*#'[3DQUURSHN%&U0^UPW+D4==0MS0>+F:.%[MON_?
MM@97]WE+RO)9O7XZXJVZ^?Y4E.H/Q<(T!M<=PJM9*DD<RBB$A+(<HIB&,,_U
M<:K,,$4\P#*BMDX MZ&GML"H1S"VW[ ZPGQ^]S\<>$,;K6O!@98<[(BN/<"-
M\$#QDA$?&/D' ]K>33 <X"/Y#/P"[^1"Z(?="7^"XPU'<R[T4[3K:>AYAWX[
MB@\%H<7<+"PSDH@<I3F#,8L5LRL>AWF0(K6+D$1B'D=YG+FT)>O<VXFZ1^M-
M-M\*Z&97=E&S,QY[8C$P$W^P ,#9^#N@JD\+KWO[4<VX WJ]M-4.?<7=(/OZ
M(/Y65#4I=4VHHE[5Z[3!+(]13+@NIQ)@97K%NKH*ELK^$HPP0A -K?;UIP:9
MFI&EY 2-H& CJ;TM<!3*\^:5#X &?GT/8=,C._4H2/:FD0^P1C*"^H'F9.R<
M0^.$67/TTM$,F'/"=TV5L]\=N2W&IG/S=56M'IOC<AW3QFK!_[J<J]LH<G[6
M\90SG$8LIC2%,9>!,G:"%-* 9S"(1,!R$2#"L)LW;@2II^?*6\L)OFT$':GK
M@<-<VYEH$YN_@=<.#YT..AWO.YJ;C63S3&R5-S',$^APX#Y5D^AMX"#V'Z.K
M@?L\>.MGT&/HGEMK455";'?SNAC->H/P_.N"%Q73H?B"WWQGZJMMWGL2X$PD
M6*U&. XA"H,$XHA)F.4A$H3$DN9ICYI9O82QHJOQZV9I7?X"GM0M-1E],P1$
M^'^NF@Q'QYU\KTFRW/,/AOE(W@$COX[8W;@-M0I78*.$/DG:J@$:/;RGF%R$
MHU?70R]!QG527(+5GCOCHIOUZ/_"'@1?S<4G^;D43Z3@;3Y*=;W@)JCB[:HL
M-8^;B(JO^JAXVT8\R43(:!S! "E;'F4XAGG. LB9Y#F)4H)Y8MT,Y@)!IN9
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M3HU,M-C_-^@(#AK)@1$=*-FU98,<3$1;]"WL[@$P'9AJ+.'L8WK;XNI@? ^
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MD47*$HX#'H4",1:[[*1/C#4UVMSK#TLN:J9L@[;=EMH3A@/3ZI&.QT-$65H
MXG-/?6JX4??4%GJ_W%/;7'*)/TY'EVN;KHT\5Q9>VUY>]XT4<EF*S:Y>5#??
MU69>C5$L2/E\6XO':C?";1T#-4M"$68REY#'+(4(A1G$6%)(%2DE,J TD^FL
M7M9D[N+/&T16)Q;;2#S<:ZC]X"8]B1J-0-%XNO2Q A4+(8OZIQ^>RN6WHEJG
M+FV_X1CA-.03X.)L?/5Y'<=9^8/6\\^-*V:K*MCJNI[RK7-3-#6R#P61^O9P
M#CH)_CVDPXC["A[607$_[*$==LB1&U"T=;4[D7%_$\7]0RWX]3>EU+VX^2Y*
M5E3"U-29)7D<L3A.8,!C[20.!<24IC#&-$0)B\,X0CU+X PO_31CD@Y7U_GU
M[AU0,C2QMWUJPXSQ, 19E' :P2#/$40IB2&E40)EF.0I%APSFO2JWS/%1^%5
M2@/]$9X".U-E@O,ZM)_M\C8@FT8?'>VOP%I_T ( U@B<*80X7JN/?G,VB1X?
MCJ+_,9I[])L/;UT]>@[O*=7G>E4_+$N="CY+)<,LX 3F@1 0\3" - \C]1"%
M2<I1EG%N=2)B,=;4O'L'$WW(1ER/>3X=O/\_[MZTN7$<2Q?^*XB8&SU5$4(-
M%Q DIC\YMWHS(BO3;RXS<6]]4&"U.2U+;E%RI?O77X"+1&NA  JD^;[1T97I
M-$F<\X!\<'!P%KNEP1.* ]/YJ2P?L)=TP!R?8S@&3?%I#?>Z&3['>E],\#EQ
M2\_]%+^78KN07]1IUONJMVR:K#2%E:/_6.:;HN2ZLLMTOGG^;LI2[#W=/(OB
MA <49HG)!(@C;#JZAE $'&D+FJDH<*I-Y%F^J;%5HYY)%5CO5*G8"VRU,H#6
M>CC:Q)ZGU=+V?;W)&M'&W=FN>X-@!O:J5<P)C'(ST"@&_BQ5&Z88Q4"P>S53
M/8LXKCDZ#+Y'9N= P_1;&&[7*RZE*!V Y7BU<=N8L&).(DDC$J90HHQ"Q!&"
M&0D%#"..S0%.R+E3.OG%$:=&WHW E:N^XNQ579]!-D*[\?9EU.V8V"N6 W/K
M2Q@K]JS%W>WX/9J=UM#XY+_+@X[*:-88''*4_8V]6>=1KC?/M_H-V=PLRSZ9
MCV:%_=V49M36)0HH24)(8RD@DB2#S-B9+"(JC$B:)2ASI)R.X:;&-V]7'<=Y
M?>"TYA)/( U/)*6@,U"*6L;U[(2=@5)<KSQB 8MG$ND:<6P&L=#^!'W8W'5=
MSND'J>\Q5<3JL\DZSNM-%14Q)Y)$0::-E2!@(40)$9 %/(,T(;$(TP1GJ5/D
MF]VP4^.26MI^J:<7$+:C%?^X#4PONZ2#6N)6_$432PA^J<4^[UOLG9AJA],0
M*:H71GZ59%4[-,ZEK5K>[9ZG\'FU?/_PN%@]RR8HG*- 8)H(&#!D0MP(@PPG
M!')&XSC5NZ:46-'-R:=/C56T@*"1T#ZH_ABT;@:Y&HJ!B:*-0H\<@V,X[!,+
MKH)EI&P" X^LA3Q?*-(I<^"LVAWI L?WC)8C<%;<=F+ ^8O<:>F]4M(XB?8!
M6U_I1GXUI8!XF:*E)UR/)Z38ZLO8H@S]^K)\_W.3+^^V>7%O7HLORA2EGB=Z
M!Q8);%K>!+'>@W$!*=:LIA).4);$4F;6V58>Y9H@%>[%KB)US7O_0G+C]1=:
M=GMN\#F1ETGVE:9G8'K>:=4VX(QBX*5F94CM7K=9U0O </O1)+Y[M4FT7QI>
M:3)'6E3&GE2GY6D Z#L6-I^CC;8D#@!1>S$=XO%]PW86^L>5":-^DJTCQ.)F
M*<J(Z=.__J[_5IBSX-6R^)0O91EA/8]BDL9!R&$64ZX7Y)1"*I-4[S6BD >$
MIRSF;G$^_H2;VH+\0K<7L8G&3]C^N<IP*YO\O+SI3Z,<*+5SK+?C==;M_"NO
M-9<#K]YC36./<";_>/N-?_(HW\@!4_Z1/8ZP&F",/D6,3K;]4?NV/Z9*TI8N
M_J ;<]'SG"<$(1I@J"*L($J0*8ZF-V9IF@5,!G% [8[$>HT^/8[?B0@:&5UJ
M[+B"?WD+-2BD@SN\.]NF&07 V(B[E#<:$/G1ZAQ=;%P'>&L&'FI5/+G5>D/8
M6?K(]9DCUD#JJ>[+8DA]'W)->OXW_2:6"]*NBB-C&0\#A&"4B@2B $>0)6$,
M Q0P),(PE,1I:W!FG*FM /7N?R?GE14RCW&U,[X]H#4PN?<!JF?*^%D8_*=[
M'P_U"JG:9_4]G69]_O)^C'##]=JT79CZC555D-7#XUK>RV6Q\W_4YTJ(I#*6
M,8))0".(M,4(37<$R+E(0F[*<41.A;BM1YX::[0$!ZMRV\C;HC>E,WXQ;GS'
MM"'[V;!CED$P'IAK;KZ\_0AN-IMUSK:;,@Y^LP*WM"P@Y*\]>F^$?-*0_>"C
M$I,S)H=4Y?Z WN9,V1:M:8_V<5F7ZVI"-^I0#;TM+^6H:AW-TRAA*I4*\I3'
MFLF""!(3=$&11"(-"9)AXM:ZL9\@5A_=J)T<FVIGLEWMK.:XNH87[5'MK.<\
M65M/0V$_FG%5]6W\I5'A5],9YJ#R7*OPW(6"<WT,KRL0]&R7]9%D;+/M"K1.
M6'77/*U_Y?-=,X:Z3,_R[I,9_U-3W7LN4I*0D HH2((@DHQ $G$!TU3%D20T
MC>U"7UT&G9JI5TJWKWCN7H'[(LHV3D'_V WN"SS1BV4G-JA0_30@JNYUS7VB
M.W9=\^M0[E76W!8NB[+F%Q\U>EES6^5.E36WOM>-N8OU9OY5TL7[PNS_]6+0
M,K'?26U<\SHL0;\O7U23.?%N]4#SY1PEE,9)+& 2FU.?-$L@U6\7E&D<)$&<
M!EED=>ISC1!38W8CHXG;::0$?U9R6CK^KIJ/;LX?"^6!UP!W@*V)R ="'5:K
M?GS+8M4_'5JK5XT_"IOY0*AA-R_/ZK>__U'H)^IQ\P<]6#&7G$:9WJG#@&)B
MRBPB2%,20"H1"8B*,"%.#;U>/GYJ#*6E,]_/3CZW+?<!='9;Z?Z #$PFAUC,
MP.UJD7--*O6?@Y3*. V'S_WNP0BC[F-/:W>X/SUSE?N^4[/&>BO%MRUKSJ";
MDOIS@=-89%D&<8HY1,38)U&2PIA1FN($Q4F@;'>:YX>9VO==2PJ*O:B KPI;
MW]H%3"_O*_T@-?1A0 U22\I=*P8O.-GO%/W@-=+>L!=N3CO!RW!T[/TZ;AYM
MMW=9@?;^SN+JOHGH;/-VM7S2C%,;4?4N01!, B53R# .($J" #(5QE HE#+.
ML9 D<DL]/SW0U'BQ#&/:"SH#Y4[";7MV$5P[>\@'9(.[VGJAU2.QO!L*OZGD
M9\8:.7F\6^/C=/$+U_<]XU2K]4.Y7+QY?JN-L+O5^KE*+JDCQYYO?N;%/* Q
M41QGD&:9-J(2O4TB.) PX33$DF6$8*=J-Y;C3I(]&@%!(S?XT\CJ'-1EA[SM
M,:5W/,>@%F<H>YP^.@'C][C1;NB1SQ>=\#@^4'2[_<J^ZW5MV9UO,TNB(!.I
M@%$6$(AD'$,6A!IYS"06,=-4Y%1,^MQ 4^.=5B+I3M*>1LM9;&V)YGK$!F:6
M?F#U[[)^!HE!6JP?CO4Z_=7/:'RVN?JYZ[U4CWB1.*NW3?E:BL]RLS\A6Q5Z
M'T67XJW^1;XIYHE,D"0DA"1-3(!6Q& F>*1W0I+&,2$L1>B*JA&N\DR-:VJ1
MP><OGZH(+5[)>551 >=)NNQA&AGZ@4GK=-& @WH!NZF1F_91?*E5.55O7V.J
MKJK[,.24O6J]!]]3=VV5A[Y NU5W<![E-:LZ](7D0C6'WH_M9RQ_RKGQ%-:1
M^Q@IDJ!$&Q%(6Q)(* I)%F!(4!C*2$9!&H0N%O*+IT]MJ?HJG^1R*\%V*<H\
MB79FO1Y':BSORX]+Z L7J\<J-[^54>UF.K]$VLY>[HW?P.M-+=< .0\G-?9I
M#+\<8%0+^*1NAV;OZ8OZ1&0]ZMF^IX6\N5O+\H5]N]J:WI6/=+UY;OF;XTBI
M2#$.@RS4V^(@3"'5&V6(]7\#(1*]14[M0[ L1YT:&;2E[./5=X.\^^L?#,B!
M6:$'AHYQ58Z87!](93O@B)%3CAB\#)5RO;EG\?NJL4SQ?77#_[G5%LS9<MGS
M!+$818+ )-/8(QH)2#!6,.,A0CB-E8RP6[Z3_>!6G\ZX.4[U]!0FHHC3QWQ#
M%[VRFAQFP,X2\8SJ2'7T:Z%-EF8M-CBHK3][65S?8U5]9\"\5MBW'WW<:OO.
MJ!Q5WG=_0J_JUV]I<=^T^J[#*>91D@8X-LVS4Y9!) 6%#+,4XHPE@8PC%'.K
M[='Y(:9F%FDI(==B@KR6LTF_=*H"?0K+RRZZZQ$:F%X,.$9"T(C8A#%=#8Y3
MG>PK01JO6+8C6*Z%LSMPZ*Z>?>K&,4MH=PA^4$>[Z\I^IMKOJY7X*U\L-''J
M!^L),S5#JRRA=WG!%ZMBNVZU3\PHYBBB*8Q)2/5>,<&0F,.0)(VH-N!(PK-P
M_B37;&7K(G(3P.7%;HLQW'O=R%_:$7L-+B5"^Y@,.\MM.( 'IM=N9,%>>/#G
M("'V_8#S:<4Y2C"J)=</G4-KKN=3//=DV]7$"F.<2!0G,&0)@XA$"I*,<"A3
MS#,DPI2&3G6$+HXX-7NOL_-8[Q)DEX&WW(3ZA'/HO>>U2/KKXS9DM;++@TZC
MF]NE"F;V-_:MEFZB;\N*[+?K.A^[U0;]8U%LI?CQJ$V\79CN7 8LQ#1 4)-2
MH+>;DD(B PHCF48X3+05BYP:O/6086K\U%(!/#8Z5!UK9Z HU0!YJ0?8:D5,
M3=%:$_!+OJRO<"Q\UF?J[/ALX D9W-V_GXN=^%7;VQFH-  ?6W.Q5\)GK?+>
M"/HM2>XNQLB5QWOC=%Q@O/^CK@GH-8$/IENO8>;-\Q]R<[_2-N.3W@F7_L"Y
M#(E0@5 0L4RS)>$*9@(I*#))$2,Q[U4G]L*H4^/'<@Y,A:ZEW-2]FA3X72[E
MRKTLF@7F*HLY8]I>#KB0$)FP:A:C#,8D8HI129),-:<WWU\#^I>G-]___S<#
M=@N-]W=YX*6E#H7[Q4C\:]5.O1(:5%*#EMB^8[(M4?(?H'UIX%>(UK;$XG3H
MMNW-_1:%%P%Q;^EZ_:Q6Z[_H6A3?36'6N60JY:&(8<J2#*(TUEOY6$4P#.,T
M5"2E"7)*]K@PWM06@I=1HN"%P.#/4F3'3?PEP.V8R"., W/050@Z<X\E+CY9
MY]*0H_*-I?Z'3&-[6\_\][R@=W=K8SQH*_:+JB-&J_>=A6$@&$90I%033*8M
M3VT-(<A%2G"$4T(E<\J![QAL:NSR4E9CX33!M+VHI1-G.U[QA=[ I-(?./>L
M> M$O&;&=XTW;G:\A>9'&?(V]_1CD<K^V;=2^?#T.9^S&$>4:.(($F0Z$.,(
M4OUO,$SUC@HA@:,@<3M(/37,](Y+6P:@V211I<I<!RF _J=2;C?J. UN*J3*
M: A3GFEJ3D():40UPC$C421$E$KB0LW70CM.DN\(P-IQ\;5P#<S!]4ZRW8WJ
MPW_!SQ_]46\7 #XI]^0XHU)MEZ:'%-MYK7N,WC>Y-GVIOBP/W)!U@DT692C#
M!$$5QI$IR)A"8NK,AE&81#1.)!?6)<*[AYH:$U32@AL8'KKE[>/2+H#;S0-^
M(1N8#1JT@!;U$*_+^4VNP-D']OD#<*0 O^N = KVL\.F(^COP@-&"_ZS4Z0=
M!&AY1S]+]?_=TK5FJ,7SAWQ)ESRGBU;%EGW<F9 R9)G D JF;5?*$&229%!B
MJ1DW#J(L=-KYV@T[-9K=20UV8H.6W."7'TNZ%;FVP!S/FRUGP<X6\X_MP'Q\
M"=9A8OW<8/)IPUF./*I5YX;&H9WG>'??TI2'/0U,!QK]TPLGX)PG(D*)X#"6
MW)1\D@G,4FT*!H21#,<Q3F.KW%:W8:=&55_/9K/O6FAMZ$^W4BV.$V'IQ?,.
M[]#^O)-]3DI$S;^\$-MGP4L7F/R6O[0:>>1BF"YH')?&=+K;GPOPQW(MZ2+_
MEQ2_FY1P)C.1,LU/2<P51#S D&%M5 4AU:9KD%*:X1ZA%)='GF@<A2EUL]T)
M"NZTI$ O__2X;[BL_#G%3L?K'5T'<]/?[=4#ZM=U@LW 7F1@9![6*W8:GZ%]
M9 >COKK'[#0*-OZS,W=ZSH_X44BU77S*E9RCB#,4RA#BF&"3(1%"&E *DPPG
MC%+..':J$&0QYM2LJ7UD_^,^@UPV<L_ MI0<++3HGM(D6OC;49%G5 ?FHLY4
M"4U(%9Z?NO#TERQQC- HZ1*M8:>1,'&,@W7*Q(E;^Q'2!YJO_XLNMG*?"U;L
M4H92B1D3J8288 :1P'IKEP4)Q&D2QFD:10%RVMIU#38U"C*R@E+85AIDT3L_
MJQ-G.\;QA=[ 5-,?.&>&L4'$)[5TCC<JI]AH?D@F5O?T8Y%O_%Z*[4)^465L
M]AM:2&&ZOLME4;JDJKR%NLJPMJ1^F'J I5/]RZ/YO>&WXLWS^Y]RS?-"WJYS
M+K^:(H!5?!))(BHX99"F7$*D"-5_2Q,88$(8PR@6F5.6UK#B3HW)2FT@,TJ"
MNK0+N-G76#1-8YL2J)4^H%0(E!KUBS8;^'VPX\OIS/+0YZN#3K S*X^#NT]>
M'UCB45>&<= _7%M&&K7?ZG33.+0^K-;?Z$+N]_>MMACZIWF6*"FH$C#(D( H
MQ('^JB(,HXPFDL0BDLIIYVT[\-16#&,I_.W?M/I__X.N_R$WU=]+V\%M';!&
M/N8HB<(XA(3+6".?$<@RO> SF5(<AA$B"+G%:@Z!_3CQF]_T-[*!>IX?0&Z1
M@W4=\'9+Z1!@#GYLM&]?5/I>;X[<VOZ6/%=\?"Y>UF./N@RY(G*XH#C?[Z/]
MXIOG'\O\GWJ#) N^SLN%J6JNEF"LF2B%B4HP1#(@,.,LA"87.LQ$3)+ JB&)
MTZA36Q0.6@V"EKB]^JO906][J.T9T#'(J1^65[9NO(#-<'T<SPW\BDT=+V#1
MW>'QTLT]HJU/6LZMC=R;Y_TE]3[OQAR=5R9T;3L;SOQOF=_=;Z2XT;+2._E5
MFH+3^?+N;=V[=DL7W[5Y,4<L9"F+%$P%SR 2608)$C%4(8\#Q#C*4NO.VZ-+
M/S5^K/0H@-QK,@/K1GC ]](#8]LYQ#N/_EYTD^[D9WL,=PLH-0-M[=L^%_#F
M&;2OV[EE# :U/P:T4  -#*#& >R  "TDP/>)OSD.P?=3?H/&BN<?&P-/N0&O
M-75=Z0:CRS1>!L-KP?TB*>+5A' WI'J4S]K_K70]WLIU>>T<*Y[%01S!@! *
M4:(09"E/((FCB,4)C:FT3G'S)];43)_^)0-G[?*!C^6IA"DB^./;._ HU]6]
MEKD=GF?^L@WT.O,YL''3O^+@K+VAK0Z8M'[5/:\R@_:VR.O,Y$A&QL@SZF1)
M^ >^PT3P.-AH:[]_@-J+^@!/=U^M_WNU_H=9_JM63',2B(1%4029,.E$3##(
M,A1!$:=1C#&2@<)V)T''#Y_>64\M7].(RIXG#U"[O%KU1V+@%:>!X.V5$-C3
M?7\HQFKD(C> /IBV<663LJW^+DW,;M64H>SX7?_3(J<L7Y0'(;_Y8>33V'2P
MZL$-HS'C:4';[';F"G>&NI7+9?&\>*++G'[3<[]O)5P'-)C2BV7M <8QCEBJ
M8,+#LIQX *E2 0P)PRFEG*3$JKF!TZA3VPVT!;?_FNU!OLQU@T W, VV90:E
MT.UNY3NY>]3+L$?6GD('07@D=O6&M!.Q.B/6P;GVSQJ-CIW5:S.U^\W]3OO_
M6*TW=_1.OJ'\']K2W0415(;NF^<?WWY?:;MO:5[";]KL+5;:('Y?-F]=YX4L
MZL\D")(L3F0,0Q1K$Y6G$E)MG,)(ZHF*4JE$D+B$ _@1:VK+P(_?OOT&M%9+
M_@P>:@TA*U7LG4CJ:0+M@@K&GY:!EY@_#F:A'1U5>P#8,_CQ#>SU CO%0$NS
M 9K2^P7;9QB#)\E&C7/PB^9A((3GIU];G%Q2S67U1NCY;;4SFH=8IA(E"A))
M-4>3(($T8R$4C,HLDC$6@7(+*.T><'JNA7UQ[841>+=7?.Y;D_PDSEH*)G',
M( ^3%*)(24ABO2"BF&$5XS0- MFCIH('L,>OI_!)%L5_[O;FC_HKZ6K$TP=M
MNX7+WYLZ\(+4JO]N))V!G:PS4$L[1/GW+E2&J?Y^<L17*O[>I?WYVN^==_4Y
MHEWHOZ[6U2GRW5J69\@WRTW.\T?SO;[;EU"B2_%5WFT79GZ?WS^9L^;6(?-7
MR67^9 Z6_\@7LMBLEK*8IQ%/B @%%%E@*KVD(<QD@F$6D%#@3$D16W<1'U;4
MJ5GM.P4!W6MX5-!JO5,2F"+>&U EGSW644[KG:+@8:>IRQG@H"^'S<GN5*9\
M\-/>EJ)@I^D,M'0%[PXF?Z\N*/4]"'';JPS^F-[DNQP*3^4E&.V@^+5?!L>S
MXS'FI_,\>5 !1CQC'@/(E^?.HXSHKY9!.Z"ME;5:F)3(2@F]]7VH_JW,6-W7
MD,V" +- !9!SJ3=(B220*(0AE8)2%DM"E&,7"K\"3F_C^FW[\$ UGZR4.?)L
MI#8UGP38K(">Y?S!..TW]Q(H4VSDJ2PVHB\O(\[ JKKA^HH%5\RZW4;M]69R
M8+NB4<Q,RLGJ!$:[65VXO%9P!G8J@I:.=7T",$A-XF$F8.C2!%=(^.JE"*Y'
MUZ;T@(=1>M=,SI<F1GJY6>=LVY0V>/_PN%@]R_4?=,/OFUCGYO=2?W3+S1=5
M_G(N)!$J)1)28;:N"&60A"&&(94H3%"<Q7'D6$[Y.HFFMD-M) </M>A5:E4M
M^\S$#?,NQ]% \V;'^*/.QL D7^L"VL*6Y05G8#='C4(O+IJ!6B>S/)17>*W;
M[ =@SR6=KQ1J[&K/?C \40C:TX/]%3O<VVP4!:$0,H91EC&(TB36S!LQ&*=*
MH(#34!.PFZ7>.=[T#.]6Y;X_)#72]J@\THVQ'4MZPVU@!CQ7ZG 06]4*E*&K
M';Z2)6FENTV]PVOM/..]*.M2?5$O:E45'_(G64>78,D2K*2$1)KZS4G,(:5"
MP"#@,D2Q_E^8V1X^7!AK:K;9_PJCW_2+]+_"Y+<@L/?Y7D+TLL?>(TX#<T95
M=$\;/B^+\17 2-LCNO,2=O8.;X\8CN2QOA)+)W>S)3H=_N)+3QC-X6NI2MMC
M:WM+SP)]G)MDAZ+ES:WCZ14+LB2*89Q% J(8<T@21+1)E@A)@XC2V"G2\MQ
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MO]SDF^>O\BXWC7>7&W.6,F<QR528!C#&6$!D#CA9(C.8A#QC+(Q39-=G^]P
M4S-G*QG!7DA@I+2CD;,@=I.Q#V@&)EY'5*P_^4NJ[QUX1>/!*R3_[6[U]!_Z
MULJ!I_]RZ+L[^]A1/O5+2C6?]<7K>B:);EDA_[G5:T29DOI=/Z4^2I<12910
M&*89,3U$TPR2A(=0?^ $I6F"LMCIE/+L2%/[J/>"UIG@1E3'*(7+\-J=2GH!
M;>#/O2=>[CF.E[#PFJYX=K!Q,P\OZ7R41'CQ!A\A#0>M3TQ<NHF=^DHWLLYS
MF1,E&!.40H&$@B@F"&9IE, LE 1E&58,6?GK^PHP-59I)(:T[HLE:IF!5LLQ
M*-)Y,NS(9DB(!^:@HP)<1VW(&OF!46"7N#=4H(0]>,.%3EC(\(K!%/8(=8=7
M.#RG'_.]-=J9CDYF#_TU+_[Q:1=9%,5QD&5Q!C.F3(ISF$#*4@1#)!'3"$DE
MG:*ZSP\U-39[(2DPHEX1O]6!L!UQ^<%M<'=4/\B<F>@R&CXYIV.T4=GELM:'
M/&)Q1S_&^+CD:T--[V3UY\?EE\V]7.]Y:]_L8AZA4)&0:[M(:6Q11#C,4(QA
M$DF.F,1IK*QR['J,/35.*05M=P)Q8Q$7U.UH92 L!^:91FKP2R/WKR!?@@K=
MEIUD@;,S]?1 S"<7N0P_*CGUP.60K?H\POV0[L8XEOZ/7$I.F\PU',LL24,8
MX3""B*D8LBP0,%54!8AS@2)F&Z9P]/2I45!+0/NSH&/,+A^G787$P 32DJU'
MZ,$Q&O9'8%>A,M)9EQ,Z3J=99[7O.+8ZOF>T\ZFSXK8/HLY?U+LL5=G<[T.^
MI%K"MZMB4WR6F[FDF28J$4%!8A,=*@)(TBR!C*614C3D 7;:B9T99VI\]4ZR
M3=F0U@@)N)%R!I;2O6;425!#(3-MD0J(--=#%(<"9E1I*Y61D/)()'&:-"7Q
MAX?U91G\@8']H7]IRM[_JZP9?0BR'WCMC% /;^+ ZT7Y$GYL\'E;O82?.U["
M/K6PNC#P7.'JY%!CUZWJTO=$-:K.RWN>#%[7*+WXLMT4INBMMDT/?'0OBB]\
M72T6:K4V-\X3G')3&U#;FAA!A&4""=$&9Y!%"D<I2A-%G8X<1U=A:@O$[M2A
M<8._+##B>)@Y_AMA>4HZZ7D>^OBU59:VK3YHZ6_:8764K]T5KFT!<>((Y>6[
M _Z\8<:ZXQN?9[RO-I->#X_'UV+<4^E7FZ6CX^[7D\3=N;+WU:R*XBU=KY_K
M9Q8?E\)4E,PW<O'<_L6<R82S@ F8)/I-0T$001H@_:/*8BE1QDAFG?7F/OS4
M5K.]G/;^B!Z@7W;?# OE>&?E6GKP0OP9:"OPXG>#0F[O(QH6^I&<2+ZGP,G/
MU!_!#D=4CX>.YJGJKW#;E77%4]R7BG+18AWK&GO>7W)B73-AWEPO9IO5?\EB
MTUKE/F]+GRQ-TR24)(*$$P61X I2SD*H I)E B>I0%:%(4:0=6J+4"65J650
M]^<H,W2, J:IQY-6 ?R2+T%A5"X<4DJ&GO++J]J$)O+_0WNF]ZW9-WH?[*(J
MW:?S&MBOM!-Z'49:EJ?S6C@MZ"--5,?J/[0$HYD*(T'9MBO&&K)W1=NJ\(OI
M9?:XECPOQ=-_7\A2SJ6XJ4Y*RG\W.<-?U.UZI8VES;/IB;#15[S_YS8O>Z"%
M\R"3%"N"82;"!"+$$&0HPY!$@< DP(I1Y5@(UZ=\4S,V6NH!T=(/_+7.-QNY
MU&:( F(K#<N(O'A<%71A3)/'6D/P:%0L&QS*1DGG KQ>7P [C^XK3NO0T16M
M&6VK-@,[Y<KI:JLW*TL;Z._61+'OYKA1=U;VJJDF^?W%2>Y3.7B(J?!<<-BK
MB&/7*1X"WQ/EC0<9IN?AHNEE9LZ,M33;M5ZLJG)B99>+MZOEDZ96+<075?U]
MD[.%_":YOK(,W\P4BRD+*<1Q$D 4J1!2E5"(0IP%J0F9I<CIG/ ::::V9.P%
MKA:"^G"XZBGY'X5<FE(IR]5&%F;1X*N'!WUE^4O'T\"KIM#R8&^LB1EZOUGV
MAZP4 94F=4W$JEFDG(&7T]92".PU\GC.Y@-8KT=F5PDT[NF7#^R.#K*\/+1O
M&0=3(F+]6/<Q_J:WV7K,[7*S?GZ[$G(>QH*BC" HXD! A",$*8HXU)9\E&(E
M2$H#MZH.G>--C5#K<@8O9#8M7TWK7E/'OI(<&-%=*S]TX][-D0.@.3 +^@"R
M1[$(*WBNKAW1/<K(I22L5#ZN+&%WVW61N]_ISZH@]OGS%.,'62VUE5DT$29S
MC%!$64"@2C,)$8LR2+ (H,H$IF&HE# UP=SC>WM),SF"^OF85W-6&-NA^W!Q
MKXY- ,\ 4VEG^8TV00-S7J-'60:KTF3F=89Z!]->A>P0(;?]!'J5P-RKL#L7
MOGO=0]W/F(\SRFXX7VL#]*V^(>=T\7V=TT5=,&P>X)"+(!*0!)F"B L,:4P$
M3$E&4H9$D 56#.P\\M38MA85\%I6L#'"-F4:+9-6W?&_?'P[&*H#4^2IA-6/
M2]#@W$@/2O&;4H)#P6Q_/#H8W",==OJ%W>G LA=T'<>/;L\;[3"QEYKMH\%^
M#^AYT/=$\X7I>O>AJOQKLGKV'H:6]_CWM5Z5?BRU0 N3'F76J#=2+U!2KU_S
M1$11S)70"X34=GJ<)I"&IJ\=CA"->!9GD6/*F!>YK#Z_41/,2FG_]F\A#OZ^
ME[DT!UWK'OB9.,MCN=$F8\34M;T",[!3$&IA8:%5G('VB5VI%SB8L1E@I6[&
MQO=X[N83:Z^G;5X$&_>,S2>61R=K7A_>C[T_24T<\F5EK*_2U/UK?OHNUP]S
M' M,*0]@;*KRHBB,H?'L0AD14U<]"#.[= *W8:=FP>^WWXNJ6-RZ$;GZ!Z"%
M>' C84O\[5C6/ZH#TV@E\ N_1@7L3NKJ'\#W+F"=&=(-)Y\4:#GRJ!SGAL8A
MB3G>?6T1T4/'QJ==Q3?%.4)IP&$D8@H10A1J;E(PD'$@!)4I)3WKAIX=<[K\
M=.P>]-(F]3SZ=@3E&=.!V>EZ.*\H!GH1H&'J?YX?]I5*?E[$X7R5S\NW]B]]
MGHN<KI^K8*?R"/[F9U[,8XFB.%(($H0S4X> 08(3#$/&X@2'F1 X=BU]?G*D
MJ3%/%6:H0!6O\J<1L4?!\].@VE&+%Z@&)A0GE'J5.>]$P'>9\].#C5[FO%/G
M4V7.NV_H&PIS(X1^5XK;5;&AB_^3/U81,$F$A$@5E#&)(9(XA$0D$F8<XRR*
MTC"-K8R2[F&FQ@9UO$8MZ@Q4P@(M;:]@EY/(=K."/[P&IH2^4/4(9^E"XNHH
MEI,/'SEXI4O!XYB5SJM[=*FCBUP;&LN<5FV3S*'L=G._6NNAFHJ8)-(&0IIH
M%'$$42 RR+)$09;PD(LP" )F5:7(;KBID<)>8H=N:9=!O7R\Z1>J@?E@+VS3
M#JV,_VCD[5%7TP)#AUYS7K$<J\O<M9BZ]9:SAJBKJ]SEAXS73\Y:H1>=Y.SO
M<B?;)O+EJWR2RZTT+9=OE,H7N?&65_3^=JLO6&[F::BR-&84IM24ADN9)EW&
M8ZC".$F45#&-U/Q)KMG*AG;M!W;Y#MK#CQ!1MJZ$KQK$TYWX0!KYK<NG.\[#
M99X>!MO!#P)K4+^V0=W+#2K!9Z 6?1!L[?E[&(Q'XO'O]Q)PX] Q+CGZ4#;E
MT;MI36%Z2R?K_AAKR67^I(%?K>N_FQ.V:EK6LCJ,?:1K\YX#6H:];O1C&5V4
M14B+>RDW0)2!Y4OPN-J8;\($:=&U\6<7^F*Z 7_)M3294&: U=VR/,_5SVJ^
MJWQI9-+D]V!6E[_RS3WX_>;F=E8F6OYUG_-[0/4#VM4_F#QX5K'55YE;]<-6
M2PF>M01&)2/L4C_99'+NW)/\F9OSYER!Q6IY)]?ZKTN^V)I<;F".HO6^8I'S
MLI&JDN8G(\AZ]4P7U>$UVVZT-,T=^5*;@Z8:25X2]V]^ED7W-Z]C>71XV&C+
MI+N"[>6RQ]V>PNE-16&:A7&*96AJ^2#CIHAA)E ,4R:EX"*5(HIL.F=W#>*T
M'QFA4_9W,P80#7^;CMFTE/7*F';W"LU]41IK:6M'H&L1#6>:]+*ZPLEBL?K+
M<.> @>8#EVQ^,<[KAH5;%&L^>6T_+OA]M1)_Y8O%G 5QP 1/H8C*?F0)@8PD
M^D<9)EF 9:9B;F<D'SYZ>F9P(YG;9[Z#*@IP'(HPA;$(B-Y/! H2AE+(98()
MP7$D$J>& 7V &L-=<R5,=@S81_F!6>^BWLYT=JBD3PK;/7M4VCK4Z)"JCG[?
M\YR5WTNQ-:<TAY%R^RBY3[L(!")BD;$HA1%' B)&&<P4X9#&E(24,B52M[;3
M+J-/[>NUB$^](B#$;6+LJ& PN >WDCPA[7[>VP<QKV? 3@*,>R[<!YNCL^)>
M#^G'=1]HOBYK-E2VW<U2M/JR_2%IL=6FWY?E5S.PJ?*@+_B\6JZ;']_0(B]V
M1OEWR>^7^3^WLOANA/XN?V[>:'3^,8]I*'&:()@(%D)$ PH)Y11F<:@HQY2H
MS*H@PZA23XU;F]?"[(.4!@ \&03 0Z5N6=,Q7SYN-T7I9GG:[90V._W<V':<
M5\..I2<WX0.SN]&W*K0#_FC-[\?]_.YWPGMUP)^E0L!H!$J5/-+^J%/@<[D8
M1_!1EYE1Y^)P>1IW\)[)@?MJI$4U/MW_RW?]MX+RLOY$?1*=82%4:-P/V,1+
M<9E"PADUU3M01FE 0N2TNW8<?VI+S=O50FM3UE5YDB^*"9>5'EL_5UUZ-_=T
M"5[>].>[E0G&=[3P7>?-;O48<#8&7@?&F CW1+]^<'I-Z7,48=SDO7[X'*7I
M]7S,X.6.YBB,,1$DA6D:1! )$L$LP@PF"8XDE;&40:_FI19C3XTI/W_Y5)T-
M-P(.5IG(?QVB"?&<<]6A5RDO-,IA4,?P4RT=9'UT9/&(ONS%-A^7Q69=QH-\
MT"_931FG,><$8QRD 511D$*$&8>,H$!;=_HWB :8"R?/P[F!IL9+5:/EG: S
MH/1U=?"**T6=@19+'F<9#\TJ@""*1 094C&4D1!I$* PQ=%\*3<C +NKA+$9
M&-9;O8/A^2-=^(72EMJO?_?&\$I_;+UV1DIPTXU5#\KN!L(O/Y\9:V0R[M;X
MF'DO7.\>^ZI)_(U<2I5OBK)^HQ1S@J12E$90FF*[""$,:<(Y) E*TS"5BD36
M3;F.'S\U2C6F":M%-$%T1D;[L,H3\'5_]=>#,O"W;O!HI /O/>!A'TYZ'2YC
MA8VZX.,4TWA>_8[8Q1,WC1:C>%[@=BQBQU4]O8"ET;GS5[[+"[Y8&??D/*:F
M63N)(4YCS5PTS2!+60I#A%44(:K_#%T"#\^.Y$1B(T0?-GNK_0&2HX/N/*08
M122.0L@"@2'*5 )I:D*[N+8/>4Q31863"]4+I&/4URP%!?=R(6"^A'K-+5Q;
M%IT%U=*_Z0.J@5>+YL5KG6SMY?3HF[P$A5<OY-G!QO4W7M+YR+-X\8:K Z>6
MFUSDBZWQ0.^#%MZ7L?Y2F"AS4QEX6RW!7]3[.LWA5J[+UG'E6= \0Z&*XS"
M"4HBB)1F%,)D"K, Q4$08!)$3HSB5[RIT5 [/*"M7RM("#0: J,B:.D(OBC0
M:&D:O50=(^OSY/Y16C[> CL*?+VY'9@WG:95'4[KJM>T7A,2YA']@6+&?$CX
M6D%E'M'MB#KS.4J_E>0M+>X_+%9_?=8(Z;]^7)HVU54LP8=\29?<_)UK 4O1
M]@O8KFE#9IJL":H-46H,?!$3R)) P3B.LR 4@BOEY/>]5J#)K1;;Q\=%>9)H
MDI%VXOZG&]5?/4UVY#XF^ /3N5$%&%UFH-8&[-0IS_1W"H&]1BU+>9 .&[[P
M]4G85\LT*D7[0O"0E+T]]UJ#_J,FBN6=Z>*VB_IJLBT. CJY-M&#A'(89[&"
M"!,&*48(IB3&5&58,"+<<KIZ2.'RQ8^3_O5M^_! U\_&(LMW6M29GZ9%^P/]
MG]6Z^AGPA?ZSK]%M/U.NEO4@Z(]H/N_EKT,,2L)M5!@T>/8*$(>Q@NW%>"53
MUQFG\_:L^Z-Z&JVK94FZ_YUO[M]NB\WJ0:Z;T-A]S0PF>*R$,%Z, "(92Q.+
M$$$E4DDSC$0696[T:#/L]/CPL"J,H^%I [6E<>D9OJ$-R%K<JKY'(_ ,[$2^
M7/+%W3YT@,BK#6@S[KAVG@,21[:<R[T]#[PX-Z?\VBC\IBE/F,"J'X^FJLS[
MGQNY+ P%?LJ+S1P%:1Q(3*&2A$.$0@8SCAA4- K3-,B"R*X\J..X4]L$[\4&
M.[E!)3CX<R\Z,+*[!K);SH3E 8]_?(<^[O$"K?OQCQM07@^#+(<>]VC(#8^C
M@R+'VWON,HW7\ TMI#!^1?W<TK'8#G]_\[R_YI8^FW^[,6&C7Q[+ /C?]96;
MXN.R:D'^WS*_N]](<:,-&7JG195KGA?R=IUS.6<APHQ0"5,5Q1#%4D$2!]3L
M3J,LS5"<A<CI3&D\V:?&GJ7DVH#[)5^"']_>@4>Y!H51]5?'K>N(TV^YY9WF
MI Z]538:0694 FV]VVE&I:NB?6&M/"BU-R'[I?XS4"%@2M)5&,Q @P*H80 -
M#J $PN->>_S9\[I''U'\<??VX\_+D4_@%43HZ4NH-PAO#;9FWV"&_YH7_Z@3
M'^-4)@F/0DAH'%9>5B*4@I*8DMXQ,ZY6I_.M[O&FMO8TXH(7\@(CL*,CX0+.
MECX$?^@-[3XX#YS'>M2.N'CU&5P8<EQW@9W^1YX"R]NN.]19J0_Y,M]H"_Y)
MBD,?Z8?MQAPC/:S6F_Q?Y?AUU]Z#,P2,PXCS,(:!_J^VIT,,,Q8F,!08RY1S
M(K*T3XR6#^&F1EHO"KB4VL%%63+XZ$!H!E2IHLDRVNG8=&SO=S#D9;;=3HS&
MGL,1CY(JQ6"IV?&YT@Q4VH&V>DU'\E'.F7Q"/\0!E!?Y7N5DRB>RYXZLO([A
MGNGUQ]MW;VOS)V%A@+$@,!,J@BB5VN!$,84R8B(A08(1MPJC>OG8J1&SD<P^
M<ZD%3S<?]E=Z8"8S0O7HZ-)2W#Y5JQ\ (Z5HV0'AE)MUK&]'3E;KXM%RL8X%
M;.=@G?AMKU31MVLI\DT[Q;_]]X]+(2L+:/&L34@2A!PK&'.D( HS 1G" 8PP
M"IB*3 *_E4O6>>2IT=!>-J<T2@>H+_/58  .3&DFV;(2_$6=D-F+GT!;^*$P
M=LIB'0;K$1-</6'NFO[JCEMW9JS#\\9,FG57\R"?ML<#/-%]F<&;:\-U^5U#
M+_]8+3?WQ3R*A%()XGIKP .(>)9!&B<QC'A(N(A"FE[)]2>'G1K1ZS<POI)^
M3L/;D]^O!NVUR+T1W)PSE:*#2O9!P+V2V*\&^;59W1GLZTF]$S-71C_]L->E
M\TX%+W)Y]]W]O,.?M\;X_Z)VI;J^R;OR9&PNI$PD80DD),(0)0F#+##&>IK$
M <HHX21T<?6>'6EJ=%T):MQ^^]9G12VKFS/V/+AVGE4OD U,UGNT]O7[OEU"
MR]G1>1$)GU[+\X.-ZH*\J/.A/_'R#5?G^5<!8L4M?3;>QYNET/^RWLIV2>B#
M,P02F1CWE$,2R@0BHG?Z#"F-N4B",)4)Y6'??BG.PDR-:=I'#+36!CQ6ZI3)
M*K12J#D*ZITDU&/>W,Y^AIZ-$<]Z&D7 ;6LB:EU 2YF1$HCZXSI0/KV[/*^5
M/=\;N8Y<^?[/'"A8]EP$T_M_;O/-\[XH8%%6#/]^3Y=U;-.'U5K)?&-.G*KP
MIGD<XT@F,88LBD*(4*P@9;&$6<(3*52&.!/SI;PSO4*_>XR9]:>"%:7LJH<>
M*#)@%(YI7+E8U,&S9=!LX3MJUN-[8$G]$YO6Z43-7@B:K?1OE4TMVM7\=R&U
M.Q3V4;4C!LWZG[Q1@V8]BC^MH%G_\^(<-#N "/VK@)\H,J*8DLJTE8VHD!!)
MDL",,055G*4(14F2I9%K#?#I5W@I2S&[%0YQ =5N3;@>JH'INP=*O<I5CU,T
MY<Q(HY>JMB]P<N'JGCY,N3&%4V[7JZ=<2/'F^4=A..9$Q91YI&@@>)+ .$8$
M(HRU=8LEABH-*<4X2@-3)\J^$*S]T$Y\,4)E6--AO:Q']%C+;JP6M:M&1'>"
M.[H\[>?"T@<Z",)#.T6E.4W1X-ZVP/W%2*Z-N5]/%GWRZ"MU1LRK\]1^]'&]
MJ<ZH'+E7W9]PK;_UM"U6_FMQL]W<K];YOZ3XL=3/_K99\7]4AM:M?A>+-\\O
M\I.^&NMM[]U+E<!(1@(*$640,9%!*E.3682H2!"+4NG4TFEXD:=F;[5=AM6.
M'M"=>F!K] .%41"L2@W!HU%Q9HA -IF0CT9-4!K6?3V[@[TAKO[?*<S[B'O_
MW9Y^OR]JTF%G!ZFNH%1H)'?QT-,PC%-Y,*E?R?4\]"R<=U //G*_)>V':0B[
MNEN:P5M]'^9)A"1GIA-#&.N]>LI#4Y\ATO_!&37I91E)YX^EL^#;AJXMFTN=
M&<V%2@[''(Y5WM"%<0\#N@%,WN5+4US7+"J;>PF>)5V[K0SG@"9(ACR3$<1"
M48@"HC<^IL*Z4@@Q$H1I0'D-]/NE&!GF9L110)9+X1]>N]72 V #+W%M"4&[
MHXV_M>H""#X7F'-#C;HJ7-#WD,HO7=Z/?T_&DWW6+T+5+7B.-?5B1BD4*>)Z
M%Q &, M9!@6E>B\0TR163G5R+HPW-6/^;!"D$;EG;^M+D-M1AD<@!Z:.*S%T
MYA%+9'SRR:4A1^452_T/^<7V-C>>*=:;^5L3&2'7C]ID>C8/O/F9%W.5DA G
MF811I"%%.#/A7P3!%,<DC *2!H+8$,NY :;&)&T9ZS??B&G)'6=A["8+'^ ,
MS [.N%CSP27E.PA W]KZ^/5/AQ_^V6>/\J5?TJSYM"]>U[>^\<.#WCJ:76+9
M-VI.<8911CF,:)1")!"!&2813(7*3"GCF(>!:RWCET.XO+#CU"VN)*P\>7_[
MMRP*H[]KC*M6>N!_!;\%0?AWL-]8UZ[ _P0X"&9!]7^SZ7@G>9EE"^)P!LQ+
M5D85'OQK2&8@+PH39VA^N]IN"E.&4>\'_Q.$&9YE23A#)&X_[V__%N+@[R\>
M&@;A+,;A+(C1N2M#XEI^^>!-L+-=KIG=P>FHG-92MEG5GVX&/I;8^ZRC?%I_
MOS63#\88N3[R:0V/:R&?N<Z-F83,Y^_JM*@/><'IXG_K'?P'_2_%/"%)'(<I
M@TQ;'!"%D?F;$% DQHL4,*(OL#$T.L:8FJW1B DJ.8$1%)22VGW>77!V?^&>
M0!KX(^^!C_4W;H' _C,OFN^\D/RWN]73?^B[JT]<_^7PR^YZ\B@?MX5JS?=M
M<VD_XZ.C(LZ)6CAFU.]_K>8$Z2\]Y!2&*440\9#KW49 8$@%#9($42X<+91>
M<DS/C-'O6.2VYO>; #O#8'!0!R:6SG)@9>:LY&7IVY8RLXI^M"+^#(RK</1I
MA?039%13Y2JL#NV9ZQ[F;O2\7V[V32.^RD<S1%FD?:.7ZC"6-$PB ;D@>EN6
M(03U S(HF0HEQAE-A%71KDL#3<W\J61MVI^ G;2@$M?>!NI$][(AY NS@4FK
M+UQ.)I$-%E?819V/'\TXLE&R;2%97=\S5(R6A_YF8U4>VC=-6>=4\" ,,@QQ
MR@5$0:!)0641S"(B,RY4*NPJ^5T::&JD8.0L0[*JG7T58;5K57!]\X)S>-L9
M/CY0')@F&@!KUT@5P;3K)>TQ9.D"%%X#C<Z--6YXT 6-CX)Z+EW?LVG4$\T7
M)A1-K=:%'F+?\KDN]HA,D@Q! 4RH9@T4A1*2.,V@B"A*2$1Q(F*G;E$7!IP:
MA>SDA5I@:"1N-5]W; MU"6L[VO")X,#TT0G> "7G;:'QVOKITICC]GRR1."H
MV9/M?3T=.#1?E[[>/R0UN3[&161:X?U8KE@AUT]FY(_+Q^VF^"J-IODBK^K>
M&S%,E:,WM,B+7<.\WVF^_+0JBH_+JBW]QV73AW[.(RR04MK4";6!@Y(X@0PK
M"1/&,QS3+ EIU"-M?30%K+[>5TA:OR_#EK7!I#02U8F7HPMIM%? TNTTJ1D=
MR55EYJX^WVJI7;43;2L.*LW!2]5G8*<\*+5_T7G4( !^,1C\"AH4S O3X.#1
MTS7VU'GUCHTF_+@>M;'GY,@+-[H [L52]</66CKY3E9_?ESNJG-],C]_-2VE
MOJ@?1>4^+/]M)]%GN9E3G"81U2\5$B&!* L5S'B8P3#6V_DP)3P-K#H_^1!F
M:I;ZON+<PH@*UD9^N%)P6S2M5<J0B,6^.,\,+.7Y5LG^IZ][91I[4@9>;!I5
MP"^-,F9=:!4&+(77:THY3U\4U$I5AR9Z%2EOW"GVZPQ\'G6B[,N]CCEA(Q6!
M'6_BG(K$^D*ZHW3LU4.,5E#6%QCM,K/>GMEOC]BLKXUGZW:UR/ESJW8DEQ0E
M L%$DABB5&_O]'+(("&4!UE9GM:I=N2%\::VO)DJ L8@L7"_]H+7;M?D$;2A
M3[AJ2?=XS4 E+?BS_G.0[%M+A'QN*2X-.>I&P%+_0_/=]C9WH_M,#M4)MC,5
MJN:(I+%@.(-,I*88@HJA-JU162,FQJG^([7N>N4V]-08IQ3*WNARQ/FR+3P<
M>@-3S]F\R1DX9UL-"K6]-3L<Y"/9KKZA=[)0^Z'788\Z/G TZ[.?HFU;L^<3
M>N>N/*[EO5P6^9-^)%\]2&U-?5%ZX,J]HQ>>6Q.'L5K>;#;KG&TW9=7>U6<-
MQ6JYT;#HI]]]-#DULMC,29R&01R%D"4*0\0C"9DI,9CA**8B(A%.E4O=,,_R
M.:TC(Q07>Z$>6&@;UCGAQ.OTV5FZKS@I R]/+^>C4JUVW)?;=1/PH;6<@9V>
MH%84M#4%FQ5XJ2MHE/6:-3/$+'A.NO$JXM@Y.T/@>R+E9Y!AKBBCSBX7M66'
M16W+__R7%D#+4GI#S';%=&FG=W*>HA@SK"+(<)+H58$Q2'"H_Y-2R0C',LF<
M(F4&D7)J>XQ:3!."5TO8HQ*Z]ZFT6R%>?8(&7B<\5#<O_P#-)%>ZSL#MY<GN
M5\-\J,GP7JW<NZ#CUR4?"NN3%<@'&^S:FIPO/>2BROHH:_O-*39%- ,!91+%
M$(5I"IG &,8I82+A)%%AVJ^JYOE!IT;O[;J8!^='HCHR:CKG.-;3L9H!2QKW
MC.O0K.P!TBM*2E[&:)BBD!WCOE)9Q\M(G"_,:'%O7U?'0O^X,@]_DBV2W)=9
MWY_XA!23%&4(TH@$$&4JA9DV82&+TP@K1=/(C: <QIX:3[T0'=S<K:7LT>'1
M!7Q;)\0@D [N8'B!9LM:;#=;&.3TK0=@?GT!]L./O,]WQN5X#^_^B*MK#56U
M:JM:+/,XPRDF 8)8IMSX73&D-"$P93*3QJ BH5,:VYEQID=.^ZI#LZ:\>%T:
MJ'<+L7,86SM'KT5N>"=GJZ9/)>2@17U.X3!0;9\70[U6B9]3^G94^CEY>4]Z
MH,7]S5*8/TR7J2>Z,$OU357#4-M4554J1G'"DB""(@H51$&408*3&'*) Z79
M@DGF6I_,9ER73V"DHF6F]8@)?"T;O,B]Y(Z$886Z)7WX1G)H,FD@+/_2$GEF
MBJHU4E>9%1[)Q04EKU1C-?"XQ.."Q1$-.=WLLS6K5:G]XT+[N][=^Z)_==>\
M>13PD*B,0Q51HFV@+(%9FFF"PQ%/12!4&"CG4X;AY9Z:356+U2ZKZ+L=J_^Y
M=SB6F-:,CGA0X=R*I3$.04O%H5NK#C89P[=5]2_Z!%JJ#C8?=NU4AQN^WUKV
MTCNY"_&?DR25*8H1E)+I_7>@EQV2T PF,0TBG.&(1IE+W-.9<:86O_3=C %6
M!^EEK30RM]7B'+IV[.X!LX'9^"A/:">D/UJ]@()/&CPWU*BT=4'?0YJY='G?
M#LM*KM=EO.:G_<L_9R2*%9815-A8I!E+(4,JA6D0!RA#/, ,[RHNV)/#Z=&L
MWO.#\@@C]4\5M<!@0W_V9X<S(-N1PQ68C=5QN<;(A&9_:B?B>DD3M,/!;]/E
MDR.-W'2Y2]OCILN=5_<L(\6Y:3E@4NME7J;:FRQ:I/>BD<I"R$P92H3#$!*.
M8DAQ&,LLH($43GU%3XXRM9UE(R18[Z1T+!-U$DL[ K@:H8&__QTX>P%G@"H]
M+^!FL5C]5;9E4ZMUTSOH4U>PN'MYJ"YTO-:$.CG0N(6@NG0]JO[4>7%?:X%M
M/BZ+S;I,^_F4+^7'C7PHYD$JI0B)-A*B2$'$E8(L9:9Y2!8GC(9Z%T%=2.',
M.%.C!2,FV,L)_C22@E)4Q]"G<\#:F@A7PS6XC= #J1XF0B<.?FV$TT.-;"1T
MZGML)71?WM-);GP:]ZN%OJ,PGGB]Z^62J8 % <0RD1 EG!H;@<.48ZXM%143
M$KKX%(Z'F*8[X>-R]92OP.T]73_HZ[:;G--%E:7X6W747RM1]AE*_UX>W'5L
MH6WQMO0A7X7BT.[>EG#_#BKQCC*3;JFIK^S1D7L6$:\^U^-1QG6/GM7RR)-Y
M_LI^W/"9;K;K?6BD.>] *4]1% F89:;:56DJL#B#,@MYQ/7V02&K=H'GAYB:
ME?#]7I:I%G3I^*6?0,_N2[\.DX&_]$JX5J2S.;(;)G#P/ X^O^\3HXSZ?9_7
M\O#[[KBRW_==9?U]IS]?EM_[L%K+_&ZY_RW=R'>Y4M+0=TX7\Y2'F%!EDJUI
M"%%,8T@9RV 017K;@&C*F%,SXIYR3(TI:GE+9Z.>( E$2U@W[N@[,W8$,P+>
M [/0>RT5W[1RI8WSTLA[5!ZUF93#Z]J*S4PCH*U/T^1*A'WR6U]11B7!*_$Z
M9,IK']?3X[K0++,L8[$_+I]DL3'[M%;IT[+4Z5S&A/$@I*9P/S7DJ7=7*(X@
MI9(C(3D)F9.SQ6K4J5%EO4-XD)O[E:E(W,@]T_^TKX&<&]$=/;56<V#IN?6-
M[-">W+V\X&,+TG99Z8^=D+J[;UT@\NK.M1IX7/>N"Q9'[EZGF_LV*+L10K]P
MQ5O]UR_K[ZN_EG."" MH',,0JPPB&2601"F!2<3C,$.*\0B[]28[&F-RW%/U
MV:KEG $CJ<81&%E=>Y(= ]I-+9Y@&MJZZH-0CS9D9S&XN@/9\9-';CYV5K7C
MOF/G+^WIM5EM9'%+G\M\ZP3SB&:<0Q)0_7W'002S0.C//6)41"'#(@F=_#6M
MAT_MPS:R@<=*-D=731LR2R=-3R"&=L\8L<#M!1#<73$GM/7JA&D_?USWRPG-
MCAPOIZZYLNO.F^?=7_^?7*[U@^Z?/\DGK>O/O)C3.$U5&D40L5AO$H@T*>"$
M096E$=.?,D;2:EEV&W9J'_2^-PK8"5OF_'R^^2_PIY'8\9S6$GT[!O"/Z<#<
M< V<_1O"6*$S2#>7[I%?IQ6+%1IG^ZC8W=V/F;[J3<<Z-VVQRW.D'\M\4WS]
M]J/N@T<I2Y#0NX,T$:'>)R@,"4DDI(02_=Z1F"JGN+'.T:;&0[=RK5;K!Q,)
M5:>TK'?B5P?#8&L4<".C;L US#0.DQ!&.&,0!6$(,Y4J*,(HX/HW*0VX6ZZL
M-\C'R9'=BUMEC(-28/"+%MDU&:P;:3NV]X;>P"3?"=L _1VM</%)[]T#CLKJ
M5KH?DKG=3=?%_-:VZLU2Z']9;Z5HA177;:[G B5*88FA.;*'*,$*DEA12$08
M"!Y+'//,C6 <1I\>W>S"8.L-9&D8T4I^('^:Q##GYK(.LT&TC9\D2099.1LT
MQC#3.P!(, X5CT(>J]@EYFJ@N1@C&*MS)GHG<;A,AN7QP# 0#WU(T*![VT*W
M%OQE^D<MN_]8;P? AH@ MQG^5>+"'7 Y%RWN\HA^2\PG6112GLEFJS.]BW=;
M^;\E77_(G^0<(:QH3/3.(93FT#-)(<U8" E%3(I4_SIQ.N]T%6!JFPG]=B9N
MU.4,N1U_#0GDP"16B3X[[G_7ZGV[60$F-<OE8@:,"L#HX(_,^J+GD]&<91B5
MUOHB=,AMO9_3TT.;+_5&/Z>+?:Q]Z10,DBS#@II0UP2;DQ0.&<LHQ'%,]?QD
M),V8DTOV]#A3HZN=F"_R/_KX7L_@BG$JI!")MGSCT!0%4Y!Q1J%0<<I#I5 8
M.!8%\X#L.'N.]XO\+B];>V_D@SE@_7V]VCZ6R78M7VU50,(KYI8.[NMQ'-JC
MW>/E=/=D=\/@U75]9JAQ?=7=^AXYIR]<WH^%FU[?7Y;?J*G.?+LVQ3XTW^OY
MWYCHL4<ST%Q13#&FPD3/11!IAH:9PMK6C"6.,,ZXW!<ZL",/NX&MOH&7-0\&
MYI*R#ZFF"9$7CZO"%$=10.4_]::NZK/M1AR6\-OQB$=(QZ$5(W#=?<E ^JZ$
M-"]96*/:B ]*^<%. 7^,XP:83P*R''E4/G)#XY">'.^^N@Q+53?>K-Q54XPF
MA7Z.DRC#)(BAX!F"B-($$B6$J=0D$.>F55'DEF1]<<RIV9+OVN58*EJ:@:=&
M;$ ;N7N79SD/?A"$J4@BR"(-.<*FXD62)3!2L>0,I8%DV:X@SOAS<% =9XPF
M3V.@;K<\>'Z1!UX;7I3+N:G?X3V:-Q?1O*9RSB5\!BJC<W;8UZJI<PF'C@([
M%V_M[37(-_)3_B3%Q^5&OS!F7U>-=?-@NNC]JQSN?7609%P5W_5DR7DF4LE4
MRF&*I%X5@I1"%L8*(B1C'(M 6[?NN]\^DDQO=ZS?R]AYN]MK$JRWPT,#._QV
M66L 2Q7 7H>*QDPIUD=9!@ZTU:F=IZ4J7O?4UV#I><_=2Y2Q]^37X'5BSW[5
MX_IQ9)7T]4WR[;H\D/KP]#G_*NG"U%<U9OH\)1E+XRB&*F'&Q9HIR!#",-:&
M,R<9%XHY1;U>&G!J]G$C&[@S&U#37X163<7V"7)NA'@1<3OF\XGCP!17)Q;N
M99V!#_\%/W^<@1VX1F)_3&:+C4_*NCCFJ-QDB\ A"5G?US>>]4DNM_*#EO>M
M:5=,^>:_\\W]VVVQ63W(]>UJD?/G5N<U%!$6LQ2F*=;<0QF%&:$IE$&"19;2
MB,=.C8S<AI\>$Y72E]GT=\O2]>4:<NF$OAT/#8?IP*S4P&D^'M"(#O[2LH-&
M>/!G)3X8I)1*/^3\AFTZ23!R'&<?=(X#.WL]Q8W=BO6F)LX_RMSY*EE8RL_Z
M[7NW>BBMJ" ,1,KU;C(,8KVEU"1&0YE %J@T94D:LDC8,-GEH:;&6NVD=R,E
M^+.2T_+4U +;;I[RB]C G.0.EC7KV./0P3#Z(2UVT3\=,HO%**.PB+VV#6,X
MW-$W2(\6LKAA1<E"\XRS$$O.8<252=Y) DA2$4',$D0R)4D<.86NO'S\U%B@
MD@[\V<CG&#-Q@)V=9=(?D8&_<GLP>D3 G=+9;WS;BQ%&CEX[I=UQ;-K)J]R^
MVGRYVGFH?U_3Y>;#MNP<TX2C)S3AB!(%PX1&$!$10LIP J-8QHQA@@-A57/Q
MPCA3^XY+$8&J9-P%_EL68;R$:18F 5*<0:FY41M) 8<T81G$7$4JE"$+I*7?
MW2.JX_C5=R=8=VV _<#:S98>H1KKE*]Z"6LY+^=$.($E5KP,ERI]K6. ]F+
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MRB1,8<)3K!D<84@S$4!.XS 0@4A(XM1-Z-Q 4Z/NO9R@$M2F+8,;M);N=P^
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M:&Z&;&D+--",0,YE0CB.222=DHUZ6YK;$%Z;YWF"H!_0;EX("M/(O'"B\MI
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M$;=U/'RR**[?P79,YW#UP(,%N^]J^V&SWC2<4R5DU=4J%CDB-$LQA3)%=GM
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MWI=O;<"#O74)F%$4/)CG^6\&7=>=_20_21>-3/_/]]_M3Y4?X.A(M5D/6JZ
MTA>/R<)U?>$^:$S2)Q,-)V&^F[^%&6^N!K9C)!K^[,G&J*O=;X]>US_L2LVV
M]^L'\_3?U0^U2NNX3,>4$(T%5%%J"V9P EFB">1)REB:<H0Y]]N0ZFAM?F/4
MY^6W]5(OA57X_W.]X87:5C67*^/!+Z7Y__-_Q#CZWZEG,D(7[))@S(6*H<Q(
M9F4N,:09HS#AB&+!>"YE/$@A[SK0IYB;E;:!-!R6;NM)@1 :>5QN2]U5AMZ
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ME%*:P327!"*>I)#DDD')$Y8F2%.<"[]0L:?%^86"A\J?EJ96#BG/@X!V(ZB
MX(U,3 ?46KS4,O8&?.C0!O#F'D=<0G).7Y.3<HVC_\\YQO6V@<F9VXU02I9A
MU_NBV#/CRD=MRX0;6HD05C*"(I$Q1%0AR"(M8:*4UD(J)K57,8;+3<TMZFDL
MK28LR]I6NZDGC;6>.9>7 7:CDS"PC<PD3Q%[WT+L31=B_EF3O6 $S8N\W-JT
MF8^]7I_D-O;?,73^M#/]OK3'3(I"[2P#O?TI5GN[^?G;9B/_6JY6BYQDF:(F
M#(FR!-LT1@1I+"(HD13<!"I4I(GOD;G^9N<7E1RM!JPT>X#:CA/@KC.GL"".
MS"DM]&YK](S%5G:GMADT1@=4X/'!*.SLR*'=B:=&[DB<SHL\[O7/_'O]W285
MOE^7NWL?=4N%XA]L6YX;7G 3J5"=<IC@")DY4<XA)X:,(H$I2VB.,N&1XM??
MX/S(I[+9G@_5=H?Z1RG4<I3:J9*1_JK-=T\-<\"^FXW"XSDR#QV!_'N#85L9
M!_QC# S=\^C"8CE1PMR7[\H.A4!4V,I]*89K$^&V3>VGNIZ/Q=W^WN$EO@%_
M?5^*[X!M[6/*:R5@.Z"8^25GJS(D+;XKTZZTJV_%GA?JWWM[V&>W,>V8*15;
MF3N%6C[L#!D=(O] B7GN/=61@>?PD,E2[=P=:N?4>=PU/"G\;K.SNWYL567N
MW1Y$Q-YMMDU 7";KG=>I*'-9<RFDP9["/,DE1$F>0A+E&F8XTZGF@L;4,8P-
M;-G\!IMC NQ#XUZ3"GO4;P.Z]4W5N:^LNJP6H!%MH9KK4\E#O 3]@]D+=>S(
MHU[=HQ\U./C5))X?/;/%Y8^S_2K3O+P(O#H5'AJ6@AZB#_V3TB?NR\G3U,-^
MI8$3UP."[Y#*'J*UR9/; T)T+MT]Y.,'BF8_57.U,OT+E@J>29;#.$ERB/*(
M0AI)!),8HS2-TCA-HL5NLV,KMT6E,VUXK40?6AHQ;=#6CBC75&MY6^_-][-
M4F1FP"B#FG$.D48(4A4KR+12.28L%X1Y"6%?">04N:FC .FV[G8E/",/]!]/
M=*VM@2%%K2^['U3)^DPST\I77_;S1+.ZX]+! DUEQ<=JD;_AZ->;8E<LB,!*
MI#2&,H[-YYYQ#*VT"DREC&ED%4XCO5BK;S;'ZHN73M.E)IU>;UJ]WB<-C[B2
M8VUKYX@V84Y1K2FLS61I5RXX%VJ]-&'0VHR#E4Q1^Q_Y9BT]R:.K>QRW :]$
M>S)IIZK8;KWS=YP<E)8&57;J@R.PLM/%YJ96=NKS^XRR4^\M5V@P\^?1W_.8
ML0H4RX.2#TUT6#S1 Z@T HZG*&L)T*Y:M*_4M^5Z;:Y]5:WKQ0N&HR1CE$/)
M5 R1T (217(H<$YCD3!%D+]X\TR<FULT]8]+)=:K8Y<!ZZS/I -\)*5G8O*,
M1H6S&M-')>!&:?KFF1H+*&&X::L93%V'?69]&5S,>B[^3:^"/1?/+PS:L[31
M?SNF5/%NDI$^V9VU'THN&&-4YHI"GN4$(B4$Y#I*H>!2QX3$A&'D*G-VMH6Y
MC9>ED>"A29+;UF:ZKX:?Q[%_;^)J=$8>&2I@#MF#GP(!X[[@?S5 $RW=^P+E
MM?#>"4+'$OKY^R9;#.\TN[VLW7WA\,I@RUTYL;I=RZ<'F63&D(XT@9)0>R C
MUU:A)8*I0$0K(IA 7AH '6W-C>E:IC;K)D=C_0MU74+8+1P/A-O('/@<LM=.
MD VJG-4#1NC"6)>:F[SN58_?Y\I:]=T2M&J5K7MB#[V*[^K+7YM:)$>1E*5*
M:ZAC6R&:\@12B>TA#()SGD=*^>GJ>[0]-U:I[;.ETH-4ESJ+M\<4/SR*+ST#
M;R$\@FK1 - FJ-MTMODYU&/JPL6QSE+G(R:NN%?^897S#(M6Y9SB!8URF>8Q
M@Q(E"40Y32"C6D$B$B;B-$Y9[%D;-:1Y\TNPJ^UKDF(WVE9RMCD:/RKMR(F*
M[IWKR@P3QG3.8"1D9*)=22$QD2Y4&<4YRX@2639)U<0K.W**@:PTL90&;76F
M72A_5&P[6>G$<[UXU>@W>M],.#P.+)98]6SSF58NSJ! 8@?NLZB,>,Z^.0S!
M5R$;K!9B5QO72!<>\D]*Y;/F0/ECLU/\9J]NM:'#?QI2>F=&F(4@G! L",0V
M"1YAF9F/0$O(\TQ3Q6@>B=1?U-#3BKEQ^9?O:JN8M7"(Y*%O%[CQ\^C CDS$
MC4SB,2FM=.'F($OQ>&/S=K@R]+LTK%O"#ZPCP'H26D-Q()#AU15]#7D!W<6!
M6)U79!SZL(%JV_OM>KG;;VWIQ'?+G_:GHA';IBK5&%&("3+,9].-*9<8*L8B
M@3"/TL1+!^QR4W.CMX]:VSUXW1A<KDWJVF1/*>C+^+K16AC41N:N=T^0:LP<
M0P.Z%XV@$M"76YM6 ;K7ZQ,!Z/X[_/A"JN7B;:DE>BNE>5CQ><=VZN/V;KOY
M8:?C"Y1I$>DT,?204XCR)(.$,@1QE!-A)L*8QTX5"_L:FAM75+:"VM@;4)IK
M3] V!KOQ12^^W6P1$K61N6(X8,YLX8K&D2N*ABP*)?[V;?/C?YE'5#QA?GA.
M#[V/GX0<7)ULJ,'Y^HF72-_^>V]L>K\N=MM]E:QK2Q)^^<[6=<).57CD_;J:
M!2Z89$HF*H:&43A$!!/(M:&<*(ISBA,>F?G:@)3^J>QW^A*G/Q]0EU/R/G,\
M>?>/O%@W1F_^MUG(JYP'+>]!Z3[8&?_K3%7#V/6[8EZ5V:SU#>RV6:P#^MK^
MWV.-<&"/!%L_'-I^4&WMPZ]KB>^ZM.[M[ITRSV8K.P3OS2?Q>+S?$/XBC2*6
M1HF .D)6@9O&D"=FYLV2V-92X5$<>]5;"FK=W +PYN@FKZS_U>K@VI-K.U T
M]H.ML3N,<O? 'G4;M5ZLG\8.^1U5P&VGU3Z!@U//[YE,&?PZV"?0#Q]HX!Q4
MQJ_#UE&+_,I&AA:_L34#E'S+MO8@07$KQ/Y^7QZ[?6-:%\O=(F-,(XJXF<&H
M#**884B)0#!729II(B0ATK>^35^C\TOK:-D(9&6D;YF:7J3S1!&<\0SFPIZV
MB)6=*S().4Y3E=%8Q+EJYHJ3(OUT@O?_ Z3=!KBP[^G(HU9C+&BL!;^TD:P-
M#J@6X8Y.V,(\O:U.7'O'%873\CK.=UZIS%-NS7VRY\@^ZC^+2NEUD:J$I2CF
MD&F20T3B!-(X9C#FDN=*<JZ5EVA\9VMSB\*/N]8K:RW86G/A1L-]T2A #]2<
M.8NU&]T$0W!DICG9\O_4H&>,K12@1]"DZ0)E%'6:LPV^C$Y-E^\7%6LZ;QI:
MWX;OCFL4?YJ7Q"K _I<AK&4A["QG(0E7J4 QQ B9$":)%229D%#K2+$H8E1F
MB0^K]+8X-V8IM526!XMOP/YH,Y"UT;[%;OI0CS(3'PI#XUC; B X$H;5J802
MY0@3I%.BL5_@& ;W2>/&/]M VUYHT :;2IBXJ3;T6.HB;M8J?$>X$7W0EWID
MLJ^T@5KO<QOF-WWO\X#20X[0A"T^U-?HQ.6''#$X+4#D>N,P^O_-Q*N%E4!3
MQ<?UVY]VD-DOB^^VL:82$<)4(I+"*-4FJ(QC"9F9MD*%)6.YC%B:<1_Z[VUQ
M;O1O#0:_K*PNGZ4=]<3D876)^E&/981E'N50<)1 1,WP2[E0D$=89%QCR77L
M1_]A<)^4_E\$>3>^#_H6C\SW%8R_-S"^/8$Q;)DH9VA"\GU_HY/RO3,&S_G>
M_<;KRED^+65WM[7"K+M'*V&SNUV76Y</MLT%2D6*D2'^%$?4JM4:"E)I!JF*
M),-9CD6<#LAU\31CIBDK[Y8_K0S;@+4%WVYP#4+#HSIQ,<R3*IB-]3>EA/VN
M3.\]>!"^/J8G=&/4RW0UX47J9WKB<ZF>IN]CALK$''1C+75^8>:'+R:*>&4\
M^]<"818G0BN($BOQ$(G,'JD2$&>Q3DS$&^O<*\>AL[6Y!;6?Q7<E]ROU7'O7
M/Z+J!MF-N()!-S)-M>RL%':_EJ8":RLHC0UXTL )E+"J,5T-3JP;X^#[J7*,
MRTW^.GJVHKCAK.7N-=MN'_5F6V9W_7Q8VKI9R[4] V7/0A4+E>@TCWD,8\Y-
ML,0UAUQ*!E.6B#B2YG\C)]$8GT;G1BSFW<K*07KG>4+3"^EN6AD+OY'9Q<8^
ME<V@;;159JW,M@FOUO#RS*5'R3MG6-VE^\: =ZKR=X%@]E+Y\\6K0_C/^5&3
M:0'Z.M>6!_2^UX^_B^UN\0?[S\WV];[8;>X- =[^7!8+RF6$."(P(VENIK51
M LUM$A*4,S.OC5B42Q>F/O_XN7%R:2$XF B^6B,O1RHN '83\/6PC!W(U7;U
M0>'\C7=[W!&EF1M;$9KYV_/H[,*3)_FXN[UJ/N.>JZ[,9[_;K);B\3BC4!%3
ML:(FJB)ED(4U)'$>0RH02DWX)1*5#TI-?];0W#[B8Q+RX$3RYU"Z3<Y" #3R
MYWS$Y@945H*O]7]'F9KU03)*ZO7SMEXFB_J"QQ<3HB]=/U1!AQ5E]91%EJ!,
M(LT@21F"*-(QY)A)J'(AXYABG#'EIXI3/WENWWV=D"6,:;Y2-PU6;M_Y( 1&
M_K!KYU]W.3] 7N:9HV$E8YJ'3RP#\\RG4VF7YQ?X+X0<\] V1=&.UXLR8"_G
M;<OZ.%MUM$']OKQ?5A.ZXH/:+:QDB_ER!621BLQ7&V'(5!;#)(MEPK5.-782
MYPYBS=R^=&-24R#19K':HHFB[98]!+L#?RU7*Z"LA[9TN[**3.\_O0:?[?FF
MS1JD) &KHYONBP37=V[_HLRD738R-;529FU//?&F7DNHCI0=3BG?U$?*%&@Y
M=0,^=.36CM!+[FL\D_;61(L_D_2:U\I0,)0[EHRN;V.RM:1@<+07F<(]=%C8
M>BO^O3=\+=\MUTO[Z!_VV/?.O)=VKZ+,XBY^7Z[5^YVZ+Q:2"HIMFAW.=&9U
MC.S<EF=FR$3*#ILLXTYK4T,:G]N0V-@.*N-A:3TXFE\=32C 5^L!*%UP7-<:
MU#5N@?18@(\\H 7%VCLH'P):R+C=J_U)0_LAR#R/_@<]PW^"\/[#1T2BJ)87
MQ"+'.>8(1E2;*;I0F=4FSV!.(V;FZCAGTBG!XN3)<V.I]Q] :9U[&/<4J/[
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MU!6VS(YK/&700W2'&_-,!/+(W-0I5E(J.BEA)S=MEVY V2&EOG>I]!V.P@*
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MB?)Q@A,:FT&5.:567F'#W,:^@^4WX+ZQ'=3J^3=@6R\X;@_V>^Q-#>PDA[W
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M..-2DTCXT6MOF_,CVN,AB96U^7AV[Y!D6)L.'C9;_P*Z_;W $ZN>FN20I:F
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M1;.'(VJ$I8)&&8(JTMQJ73-(,LV@9C@6C.E41I'GV?-S[<R/V&H# 2O-]3T
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M6.G$\0_Z4H1N]4CJCNC5/=VJYVF&)5)+4*Y6H+&NA\ 948]XED$59S"<JA"
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M>!*M7R#==+UYOUQ)46W4.]<CU[GCZ94*'<P8ERG=<7I&I -NY<:S3\^;-+&
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M9&T[F&OC+76?#?$>',T[8OC",;WNL1U"(MH.J)%"_/[(4PGTCZ!A$>X?NSK
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MA!(DN(L[.BAE;O[G:TV5ORI?@6PU=7,SA\&T\RMG0S1VL%7IUUFM^:\=[87
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MOED62;V:KJ*?_6_PRTL>/+<N42=(2"")3 R(%QI(5BQ:ZX1!.SC$&7?/^KV
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M7BD9A*Y3(7<?0>-&NL<J^D'<'"CUD<^BG9:<SQ;S=.E#:4@,STU!(OZ/R,R
MN)* 9A%0)H$KN/VZ:._YL__36P+!H5I;#"K"D4%PIO^JZ X;'V$^72S?+M9X
M)&\ M2HO>+)!ZJ[0FQJ'QS/5BC@%&A4?#>#1JJDV/6#1=[UQ3YC!@5)%S V<
M/GO&?.8,U"9N2!: QS&UO/3"#"0'(616,0E7J2/-;5(:*=\[WDLY4LH-X.3"
M-;\>+"RR"E25^-P*/'Q+ WM;PO7(G3 JX ]U%>_D-B&-Y-\/5.R=Q_A'2+F)
MEX@[@YWV-:%_^?WB\5J9+8W_3^5)MY/6HR<72 Q)E;GT%DVFLD1Q$[6EVK,4
M*D+I*;2.B[;CX+$?:]4TU8#1NNKV?#$+\5IP//DDM>/$ "WET;$\\$ O3YH<
M&&,VL3HM_>ZEJ)& ?!@S-HS<&[%G*T 2OIS-TPO<,+/%UR*F"[XF-%NMK/3$
M>(W.GDJ2>(7L9"LSIR(PJ:NX2@]2-:Z-&DCW=XS54&IH E5_ASE*:59F1:?S
MZ7Q:)%0F(%PRY)+V% ,%DKK7&QQ#E8!A"J&:)>8$10E6210^0M>X1JH.LH94
M11/8NB.F"="HF) 6:7:92"%<N?DWN%&HUX8)KUV5=C-W*!DWGJN#G^/$W4"O
MA2L&KILM32"E& 3*0KB ?IYG@3BF&(DT0K22L^"KO(+90TLC.8"!':,#9=T
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M2C[">CV[J'9&N0(&5V$&_YRNOVS?G]U(#Y0W\-N'&!>O@'],O/&"BI )#:4
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M=G,PI#(:P-8;6*T ND?$=\PQ*(:Q2!2H__*&F6=)?&2!&)V%M2*D[*M<A3Y
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M6+MNV&-;MTWDT0&^GO$B+WH&S.9?ZE0J^F\=4'6BG%+%!$O7;:V^,;3/D(,
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MX]61?'.^K ([28HK#"R#]Q%!!>_ Y43>9 F2):>%&)2O^<02PR#W<T>?QI+
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M+&\"V:?)^HDJ$G<"S**9[#JXN7]?S/''Q52$.X66B6&N/;V=88QVP0IX%\C
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M;D;=W9/=JT=E=W/V4H[1^F0@L>KNJYP@>)?KO#N6BY*:HWX&GX?2\+*5XBZ
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M>C_HVDE2RTH\F3J).W#)!4B877!"6Q[N^25; QC/K3/MBW-SXV]T5O<+FWH
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M1>+T[G!;F(TFG@Z ]W&Y($[DU5OBX[O5ZCS,$WXH=;\G67.KT6H0(I)_+U0
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M^-=0$D$Q3)Y,YEQ43:XVX&KQH@B.H<\18YLNDD^3=?!SUM:O;WOJ3?2?HM
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M)6F%5H@Z;6U4#J#PX0L/]P@?(')+_KM5*+S!PEF;8<W/438,<B?P>-)&%UW
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M_J1VQH-L#MLN)_2$UC%*.MA#+\XV?P?SPW+9MO>889!!)!]!;+KE<U; AVC
M^IQ1,^M2;')K.XR\89@]@8>TAEKI &M[^_QOO]:_>/O^Y?)><"9#=)%A@IA9
M( %$#3%: 9GYS+A73OHVLX#'YF08@D_@&:T/79_NC<1]]J]3F-Y0Q#M?K.=I
M,Y%]5DN6)%<"2J(S1LF@("3.06@O;";-"7LG4ASWDF(PI<.P?0(O9!TJMA>K
M_M2C^2^//)IO)?+Z3URE^;H^%?XH"#X+)L8DI0 II 72B(.8Z \6+(4DK+C
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M#UQMY?%E?CZ+T434)D.V2.I11D#PS +W3GC.%+I&CUP-F?J)+H3V!&W3?70
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MT!8FP*M-<W"&X .%Q\%IZ3DC]UPT&8[])%6=/RDVA\VRE09/P?H^)MS?KHM
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MORXO5I>,!<^\ST&1SU(3/ ,9\*"+ !$C.IL3B=&.!+CK13MK@M8-WO;3RBG
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M'$30Q@=4-MZ=L3M2Y^%]J#U!6[@+ N_U*FZNT0Z"CF&L;9K0JZR\$RF"93D
M?:? 9V_!:AF*2TY:T21"'D[BM  ] EX&GM8'*J\S6&[;C@OE<HJ>@RVTGY5.
MY&Y@1$@R<JX84]++UO#K841$*Z4_@:T]-#!QJ>/?<(%O%_C;O."'-,=%PO6V
MPWPQ/.MD-'B7:C-'P\"93?Z:8:RHXET>4MC_Z +]@&,?K2W'%N'$.'CWVX=0
MRB91 C/);WY^-<*"HB!6(@5(@F,MJ^0"(JL-\)QG4G/GQ-VY,P_BX-$%IL['
M'@T'XXAPZM+GS_C/^?H\K-XLUL3!Q3E>#9R0A0F'"FQM6JV4D."T5Q!]3CE8
MG644 V#PV.=/G8,\&@I&$>"$(%BOSF>;&3:X^EK%42>[;<Y(GX7AO' P/BM0
M:#PX)0K086F$SBP$= /<"OK\6RX%?7?7G7B,@&GMQ/%\UE$4,#& WN/7BU7Z
M'-;XXM,*-T\+=UG:;K.4+ :F2"1U8+>*7-7VA1I20&Y%,(J+(>->!Z%J,%73
MN";C*'[96@O=.JPA.BF%"N2U*]IL.1?RNUP (XJ3O!3A[V:0G8+#VE"1@WS8
M7:3:03S\9E&6JR\;K?SR_269XT_+U?>WY17&\P^8+JX'!3(A!:)C$!-WEQ%?
MX)ZX+$QA"(FSV.3&=2!]T[I#Q[^@::&V#M"X29K\^#DL/N*7K\M56'U_\^5K
MF*\V.WC38Z2V5JUE,U>OX6\6K\.J)IZOMU*8X_IM>;/XANOS^J_6VXT>(\-B
M90#.;<VO- +JK$&0.EH;M3"6-<FZ:\;1U T1&N#O;K?E+L#0P:YX\2W,SZK)
M()FOPQEN)3R_/G.\]:AK@QTI:L:R*!&"1P<,A8Q.Q:A4DSSYYPB;>,Q:'_A9
M-E1F!^!\Y,3[[;KCM0JHM4<!(3!!_&0!,1H-AB,*PTQV;2I;GR-LVJK5;MYT
M]E-4!\"[V99O_UA@_B6<!7+#/WPF\6]"0!U"H>A/FII"PF@31>\ ><TM3H7I
M-NT%GB*JGPO\P]5_SQT=21<=X.K=:ID0\[H^_K]9KR\J)V_+R^67+\O%A_.:
MGY14\-+$ -XF1EP5"R'7QS ;,.DHC>=-?,EG*>OG:6!TA(VKE0Y@]B*E3>DL
M>1\X_U:M^RWYD3<P0\1B@HO 4290(7GR XH')GR4SF%P>LA-W^Y.W3.$]?/R
M,#K(1M5)!QA[=8$_I"\1"]LN1"\6^??E(EU^,W/,8S(R@_.6S'216*?C2,"4
MR5)KIW)ID_H_C+ZI^XLT1%P+#74 O/?X#1>7^7-W=E#P3G!,1+FN<Y)X=A"+
MDZ %9P49!M^FL.]1BJ;N!=(07.-H8<0,Z]&CS-=_UKH<W'@%MV.G?\[//]_^
M)S,K71'.%RC>D.&V@H-S4=3Y-%)Q8Q)C3:KE#Z1[ZF8@3<%Y/(U."N'Z7'0G
M/GJ1\Z:U4SB[#)%>I/^YF!--LRQMS-(A&._KY,):%>NT I&2)1>#FS H=VC@
M<M.V*&^"KE;"[N!,?4UDUPRI\\_+_".+J_7G^==M;6KXA+,8ZQ!"2:$/^044
M"84, 1T';ZR.@1D;K6]A[ 93. AX[J2 UU9+'<#OV=@H%!^LPP1)"4NQ$:/8
M2',!)BCN<I;H<Y,>S;O%J[O9[9?+,_K)LDYU_':32W!U1E7/??XE7I"(9T(P
M.HB< "T+88:.('"E6$ FZ#]%\!S< ,L]>,%AEXGLI/90.XE/G(/S(U,KDM>G
M#5L?<?5EQK(OM38<6*R=L1TAW#NO".8Z^YRDY#+OC)P?UQ@&EM.Z>AY5KE,G
MD]^ZW/QP$?]&C)S/I$ IC!60?/;;#BEU+HO6/*&D[\N@^:8/??8P/)S61?$H
M<NS*3EP9OQ>U<2)>3]1A,053(GFMKC;29P;J<S0HD[120O DALR='[#4,)2<
MUDUO"RGW#)JW7S?ZNF2*9VL56@G1ED(!3Y$D.AG 9I*BS3%*X0^%SNT%AP'H
MM"YNVTE\ZCSA:BRO#.BE+TTQ<F'6"(4*N-:UJH,7B-)YT"PYC"QI9X>,@'SP
MPX?!X[2N7L>19 ?AWM"'"<F=0!'K%/L00!56'R:X!4/FDQPM:70<4N5RG*>C
MW7;$U0R]C3Y_O5CD;9OV%U=%:S-NR8>,A(N2:C/C8BTXXACJ0[2PQF4T0PSJ
MLPL-VRFG=U,WKH3[['55*P66ZX^?<16^XL7Y/-5^ZC^2/*C]R\.?,T+3EP$$
MCM3JI6[+VMJ,CD]2])M:CX'K\^N6&D&Z:((V0$8D@4*>P&-Q8"RSCBF.TNL6
MIN1IL@Y.:5]]"HOYOS=J>;E<K)=G\WS52.[=+96]+;_.%V&1YN'L _T$+_--
M'^B.%&-66GH/L;!4NS#Y.DW3@/2"?-8H8A!-DGW'9F3:=+@1L7@O;WU*C9^0
M$=RDM.[3">NI3VME$!\B]CAF4=AB:ZTSA&P8'8'&0C#" $6H6G+A#&=-[M7;
MFL6'WTG6MQJBNVQ9X1YJP3_YRX[\Y60+H!)6<EZ2P"9=69XCK&NSM0M6AKU<
M[:F1#B*87\-\]5_A[ (O!V"3\?UM'B+YE9>U%J':V/QV\;[67ZSJ*)--W+"Z
M^O:7L)ZOZ[_?Z/8CIL^+^?]<X'IC"&[U*LS>"XL4TG,?Z^P1!\Z39+SR]!.*
MA)1NDFA^%.ZFS2=NB/7^L'%"Y_;O875Y];5_+\MAG]OJ+'^:@>.<ZN1,VH!.
M02[UWD36>1_!:_JCH.!,X[V[V%,XU?].\J^UGU>?>UFU%'4PP>0 %,LK4)%E
M"+1[P1&7BH=HA&A2 ?8@-5V?W[N@XJY-.USV/7;1D9D9FTD84DL)JE81.VT2
M9.94=)8K+H;T,6W;1:<97$;0Z7-=<G81\,ETR>&>6)"E0-HPQ3CM(R5J6P^M
M=9%"%C,D9OJIN^3LI/B]NN3LHH6I7[\>\A/^8UN1S=%H\ML4%!9J.[IBP>4@
MP:6(.J=@2WG.X7ENC5/HE;.3.I<-9#NQ^;E.XMQL'YVM2LK0IC%D#Q13""0?
M!NBSU3P4F>-HC;A^6'G:H&S<$VE_D?:"A>W>\)P;QX6 [(T&19N#$*PSH3IJ
MEGW,1@ZI+]D-#5,?*P=H[R$,["'*GD\-9W7B0FO:!,F!*K5#/)T'@-$6IFTP
M/@S)Z^SSU#A(:4//AETDV,&%X_4CSLNSL%Z_+9NR],MVV5YHKIDEHQA]'6@2
M(1HGR=42$DM0(?L\P#KL'  _2M&T-=SCG2'CBKX##-VF?[NU7,[6EUP N6+D
M(6$&;R0#'P7/SD83=9,,F_ND3#P%81P=+T<5> ^0N>F!<=5&73N96"&*#=94
ML\W+<7% ,J)CV).L9)->C?<HF7@8ZH&JO8N4@^0\L:?R 6LOLQ=O%_CN:O7;
MG AT :T+D+RB*$RA@V#KY,(8I<ZY4)@WI'KIZ54F'BLZ#AI&%F8']N/N:?S;
M=5I?0*U0L@!1Q%IA18Q$GC-8YKF+GB+^-@E9CU(T;2.0\=V6<43? 8;>A>^7
MR0++;77U3='U%6]O%A\NXGJ>YV&UJ1:UM$TXG=DY,1*;2!X\.?7DY2OG4C'<
M\"9]0':FM*\'@#T1<K>95E-U=8#'NV)[H/[ZE^_O-AJ862=%0&*->5U9"P$\
M<G(ABXB(V2NICF+EGJ"QKRN_<3#82D53.UK5$7AW_T;]RY?Y92> <GNO7659
MS8P5P29-&TIZ6XN9!41D#++CZ'(0QM[MX/NP [;7ZGW=!AP&KR/IH ,;]PK3
M[>3BOY%'^W95.QIO:\]H7S!7DJ2MXNM]+%F@P)&3)7+944PLDVURZ?0,77WY
M<./8LC%5T1^RWN.WJU2WVJWX/-09]3?[YAZW3"=)<7 &D3U)TJ B9UB06\Q-
M=IZSB*%--\&#R)ZV#]Q1<-E2D1W =GCK'5F,-*I(2#9D\F&)Q:"3@8S*92%\
M0='D2G7<!DG-^KZU 6,;]72 NS>+M/R"==_4VL5'TNAGC X!ZP1%4%5J"A-"
M3-F T()))C0*V:2>81!UTW:":X.W\=6R.];\)=86^*D6T'YL;.K6,Z%++DXQ
M,!L_%A/?I(YN7%AR01P+;;**#X%5LSYOQS1CNXG^A)+][[@0VV9K\\6GD9/_
MGUVG53' ;@P>ISC >*-K*UX(MO:<4=Q=UM.GC#(QH>I0Y)^E.( )$56=^9R=
MJ5F%HH 7Q0)G FEKI!S*D 3OOT!QP"ZH&%8<L(OL>RP.\,BEMT6 H/^!<CR!
M<X8!#RA)')8,^U^N.& GG3X[0G<' 9],<0#%#Y$"C 2AI !*D_,7$N=@E0QH
M$H4>84C)YD]='+"3XO<J#MA%"SVG>=H40N%>UTEMHDXWH@ B>I(48\9S8SS>
M'6]V0FF>C=0Y- %T%]EV<!'P>,#AE>8D(07*6@LJE<H(,M#6!1$"=\PUF1AU
M6";%D8L(]CFYQA7]Q';FG\O5O\CQ>QF^SL_#V>L_T]E%WGR__CPK9(]%[6'+
M.-;]%25$[6B[*2D,288VW)"VGT\LT9<SLZ<"E^-+LY];G]^7Y[A^%[YO=HLH
M02@2#5AA*!JP,4-@,M(?43JK;.V!T"9&O"&B+RMR&&0.%G('!]"[U?(KTKG\
M[BQL^B#6NZJO]=#^'2E\Y#H7Z0UP585B4P87D20CK+/!9!M%FXRK)XCJ-?/@
M$ "-IH1^#,]=0<V85QEC4I!$%1*/IMZ:UQ;;UG 172;O[!C^3*_)!(?@YR!A
M=V"$;AZ6+^F_[K5ST]INE@0WSI-CSS+M !*2!R=S_8.9@B4$,:BKP\[X&4!;
MKWD AT!J;)5T@++G4FX8[1E7:DDY&@H=Z:@&KTH"'W)$*Y@-HDD-S!C93Q,\
M[!^"KC%5T<^95^.$5_/ZOH>Y/B#?X7)6,(N<N*(8E8YSY5V$:$,"29+*QF9M
M2YLBJZ?IZO4E_Q" C:F*$WIZO7E=GB\N_\+(;ZZ/+]#JL74@2\=Y9?721N0A
M0-(L$&R8@&"X!)L*\RS+Z+')#I[BE34+:8M$ 25SVB)!D W&D,$&E7C($N/=
MJ3%_U5?675 Q[)5U%]GW^,K*,<J K-"!771M8ZEJ7CR""2R['$L4<D@VPD_U
MRKJ33I][9=U%P"?SRLHE,FV*!+2V)@^S#%&D BA4+$(&*=R0\H.?^I5U)\7O
MUX)M!RWT_,JJ(H]<"PH:2"2U]W1-T]01M/)<1&E]OEND]U.^LNZDSJ&OK+O(
MMH/(__$^(#;88D-@@#PQBC8IVO RTB$>B_8F%1UTDT[YA[79.?(KZSXGU[BB
M[P!##S2#*,(+'C2#8A@%J%Q:<"&2F+QGRBM'QKA)(_?3:;.SDXZ?;[.SB\![
M@,R]]B^:V1(8,Z %1E!66#J]50;.M<N*)^UTDXJ._MOL[*3:9]OL["+GO8'R
M#5=Q.=HS[';EC6A>7+&!&$,=*>0D2MHTED.L@S0XE[1W:HFH:9(#]" UW?7B
M.00RA\N[ _OR^-4ITUP7$018A[KF126(D<[N9((R@HPN2:R_Y+$C=P\\Q*T9
M1_0=8.C'LLK\2S@+BX0?/I-<US/%2\Q,D(2,D'5((P+M*HHX1<XZ2N18FL#H
M*:+ZNMK94^_WZ@Y'4D(79]F&[G>K><*9<=%F\@&!99E 26L@&":!,<\-B:6P
M03<ZNX=7UR3T%4^- Y<]!=R!M7FL$E)&3)L>/03F0M+0 @+7"HJTSIKBK"K'
MG-S6UVDU#FC&$/V(YJ7]6^CM@5T77S8CUL=^#7UJB5;OH8/9.LZ+:+*:D]=L
M02B3R8DJ ISB'$2*+!3N3'9-7(0I7D1Y0L%22J!K.QZ5BP+/<@(3"DHTAN+,
M_SN4:F=4#'L1W47V/;Z(4EB9*_<D E-J-\0,GA<- H4T6F7#Y5^N[G0GG3[W
M(KJ+@$_F130QZ6RPOG:(D-OA;HR._A0K5T(JCNRO_B*ZD^+W>A'=10L]OXBR
MJ,@*AT2$&P.*6P<NU^9<IK8?-B)FRYYQ@WZ&%]&=U#GT1707V780B&T'UE8I
MO5E\O3C_2/]NLYM(!M&&H$"6Q&OYDH$8:%_QZ*57+%N?FY3\/$907_'[_N?6
MJ(+O%$#;_:493R;6KEC*T?Y"S\!GDX#ID+,7PL@V740?)VEBYV<4E0_ T1[R
M[Q!)K__\BNDR+__+UKA*[DI2R4 )=6I&M@5\R1FRSRII58+$-JFHSY+6'[+V
M <$SV#I0(UU<2M_E:7-]^E_+,]+5V>9>;,.6,09=5!IX4>1+9ED@1)7!N1Q3
MB8$Y6XX!M >IF_@H/ [6#M=+EW![/U__ZU=R2Z\<B??A'+>\9;3D*>*F-;VH
M];T!@DP.R!%5C'O-L<W=]W 2)[X./P[P1M)0'^A[] 7!DF"BYPY0!$9ABN?@
MHD70+K 0HV+&=]A5YLB) 0?Y]Z.(?N);A!=G]#D+TL(WO'DJNK</R1N8!4XN
M[*7CRC(HDS)$8RU$QX/C,6HCAPRA&+Q@7]>8>RIWV5K2'7CU@QB;%1&%YR)1
M!&0L&7"IP0NMR)[3SO-&2A&:%/4/HJZOJX?#L-9.+1.;JH>?M5]O[OU6\S5N
MGDIG/H@D;&% 6\C5JADDAB(YD4HHS:4TTCWW #QXL;Y.M,--U/@2/J&"ZA^G
M-=ZP/W(BP7/+M$HFV(F]XR04.&M]Q-K#3P@/JB0-=,(A&(Y2F,"D&_10>A()
M!:84SC(&,!3&UFDI%ES)"HS4UC!T1?(FO?=/+Z%@%U0,2RC81?8])A0(8[./
M48!7KO8C+!ZBE!24BLQM<,GF,.2JZJ=**-A)I\\E%.PBX)-)*)"H5'+U L-I
M.J:%\[7"08)3-I<L>=1IR//>3YU0L)/B]THHV$4+/2<4A%I)50>8J#IZ27D;
M*42H"5].)LNR*]&8 6[UJ2<4[*3.H0D%N\BV@WC_\1I0HS7%!";1)JK=40)9
MYL"# )Z*8YY%G563#-&3*K'>Y^0:5_0=8.B!&C^9A'=H)" K))<DB0/4&9BU
M0FC:"4(VR24XG1+KG73\?(GU+@*?>FXRUCGC+]XN\,<P]KH&N(22LP0K_69+
M17 ^< A9:<8Q&26']/]X>I7NZJAWTM^RB3 [L"2/WX*1?M%Y5Q]S3)U%3S&D
M5Y*!]]%9;G3VJ<UKZRD]@!UR&HTC^@XP]&C!E$F%?#(+T4ARS)07M M" 6Y%
M,(&IZ$23')%#:M4F>!';2=M#:]5V$/W>"/I*EG!)QH^<_)$JK(<,%36<%U:4
MA7J<4PQ1R_#(Z0<7L[8L,2_;9(&,-^MU@I>P0S VOEKZ:43\&#?>%X5"9$ =
M*9+D*"%FJ<%RLNDZL:Q$D^R/$RNS;6&Z=A']@:;K]2*W>B/[_R_(*N+J[/NO
M\T58I'DX>[,HR]67S<?^8Q$N\IR O,>KV, /'N$=;!\61GKY>G+IF[[ZUX\>
MO([.$UH#^D0XK&7^D>! 9YZN12J*DR5JL5UWI/-0:_7D<A])]K_0W_[73'JI
MK(X*!+<(2M>9.L5*8"E:QY.@77E\:5R3-ZT;UA)9=RU< W7UF1 PS%)L(J9]
M$@%V^OBC&;Z'V)G(_&$.D@[&",7Q.@2"W*[@I("HE8]HK4]MFJT?V?Q]2)\Q
M7YSAV_+TSJJ*N=E>T83L+3. O-1T0-00:Y,@'I,S)MN4[M9RCG2KO@^UIV4<
M=\'=O;OXYLH\95NY?];4;I]_-&O9,D]J5]@2@'C6]840?7TPS*+F!F>PA">5
MT=L0FP1W1S:7](GATZ=5#9GI\]^6]_@-%Q>XO;@D5T;4.2YZ,]:%%T5.AS#
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M4$L! A0#%     @ M'YA4GBM \2+]@  F4T' !H              ( !
M &EN;RTQ,C,Q,C R,'@Q,&ME>#$P,30N:'1M4$L! A0#%     @ M'YA4F_>
MGO,C P  )@T  !D              ( !P_8  &EN;RTQ,C,Q,C R,'@Q,&ME
M>#(Q,2YH=&U02P$"% ,4    " "T?F%2GS7KQ2<$   /&0  &0
M    @ $=^@  :6YO+3$R,S$R,#(P>#$P:V5X,C,Q+FAT;5!+ 0(4 Q0    (
M +1^85+Y_A\];P@  ,8K   9              "  7O^  !I;F\M,3(S,3(P
M,C!X,3!K97@S,3$N:'1M4$L! A0#%     @ M'YA4I.9A+!5"   D"L  !D
M             ( !(0<! &EN;RTQ,C,Q,C R,'@Q,&ME>#,Q,BYH=&U02P$"
M% ,4    " "T?F%2XV9WV78%   /(   &0              @ &M#P$ :6YO
M+3$R,S$R,#(P>#$P:V5X,S(Q+FAT;5!+ 0(4 Q0    ( +1^85)P+I!0<F %
M (?G,P 0              "  5H5 0!I;F\M,C R,#$R,S$N:'1M4$L! A0#
M%     @ M'YA4B<H;&W,&P  8$8! !               ( !^G4& &EN;RTR
M,#(P,3(S,2YX<V102P$"% ,4    " "T?F%2ZXWW26XZ  #X<P( %
M        @ 'TD08 :6YO+3(P,C Q,C,Q7V-A;"YX;6Q02P$"% ,4    " "T
M?F%255@""8B\  #!% @ %               @ &4S 8 :6YO+3(P,C Q,C,Q
M7V1E9BYX;6Q02P$"% ,4    " "T?F%2P2!5\1XI!@"'!0< $P
M    @ %.B0< :6YO+3(P,C Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( +1^85+W
MUD C_),! -^C 0 3              "  9VR#0!I;F\M,C R,#$R,S%?9S(N
M:G!G4$L! A0#%     @ M'YA4ASXHX#Y?00 >]L$ !,              ( !
MRD8/ &EN;RTR,#(P,3(S,5]G,RYJ<&=02P$"% ,4    " "T?F%22;YLL4^^
M @":ZP, $P              @ 'TQ!, :6YO+3(P,C Q,C,Q7V<T+FIP9U!+
M 0(4 Q0    ( +1^85)B0HV\-%\! &&) 0 3              "  72#%@!I
M;F\M,C R,#$R,S%?9S4N:G!G4$L! A0#%     @ M'YA4M;#J58)B@  "IP
M !,              ( !V>(7 &EN;RTR,#(P,3(S,5]G-BYJ<&=02P$"% ,4
M    " "T?F%2T0V#2JZ) 0#'S0$ $P              @ $3;1@ :6YO+3(P
M,C Q,C,Q7V<W+FIP9U!+ 0(4 Q0    ( +1^85(Z<?"1X8D! %45$  4
M          "  ?+V&0!I;F\M,C R,#$R,S%?;&%B+GAM;%!+ 0(4 Q0    (
M +1^85(Q%5EBAO   *[S"@ 4              "  06!&P!I;F\M,C R,#$R
@,S%?<')E+GAM;%!+!08     $P 3 /8$  "]<1P    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
